<SEC-DOCUMENT>0000078003-17-000049.txt : 20171109
<SEC-HEADER>0000078003-17-000049.hdr.sgml : 20171109
<ACCEPTANCE-DATETIME>20171109160436
ACCESSION NUMBER:		0000078003-17-000049
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		104
CONFORMED PERIOD OF REPORT:	20171001
FILED AS OF DATE:		20171109
DATE AS OF CHANGE:		20171109

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PFIZER INC
		CENTRAL INDEX KEY:			0000078003
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				135315170
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-03619
		FILM NUMBER:		171190729

	BUSINESS ADDRESS:	
		STREET 1:		235 E 42ND ST
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10017
		BUSINESS PHONE:		2125732323

	MAIL ADDRESS:	
		STREET 1:		235 E 42ND ST
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10017

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PFIZER CHARLES & CO INC
		DATE OF NAME CHANGE:	19710908
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>pfe-10012017x10q.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!--p:3e18c5d8f90145198c6eeabecff8db9c,x:4f84b239cbc54764a8c18afef1a195ce-->
<!-- Document created using Wdesk  -->
<!-- Copyright 2017 Workiva -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2017-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:pfe="http://www.pfizer.com/20171001" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:exch="http://xbrl.sec.gov/exch/2017-01-31" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:us-types="http://fasb.org/us-types/2017-01-31" xmlns:utreg="http://www.xbrl.org/2009/utr" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:us-roles="http://fasb.org/us-roles/2017-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:currency="http://xbrl.sec.gov/currency/2017-01-31" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
	<head>
		<meta http-equiv="Content-Type" content="text/html" />
		<title>Document</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="FD2017Q3YTD" name="dei:AmendmentFlag" id="Fact-83D2860B497A5064A93AF07613474681-wk-Fact-83D2860B497A5064A93AF07613474681" format="ixt:booleanfalse">false</ix:nonNumeric><ix:nonNumeric contextRef="FD2017Q3YTD" name="dei:CurrentFiscalYearEndDate" id="Fact-091B6CEC43AC5F9B80D6BC4FEA2FAE5A-wk-Fact-091B6CEC43AC5F9B80D6BC4FEA2FAE5A">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="FD2017Q3YTD" name="dei:DocumentFiscalPeriodFocus" id="Fact-F86CC2693C62557FBB4A21129802B162-wk-Fact-F86CC2693C62557FBB4A21129802B162">Q3</ix:nonNumeric><ix:nonNumeric contextRef="FD2017Q3YTD" name="dei:DocumentFiscalYearFocus" id="Fact-51AC809EDC6C5251A846176ECEF9E7E0-wk-Fact-51AC809EDC6C5251A846176ECEF9E7E0">2017</ix:nonNumeric><ix:nonNumeric contextRef="FD2017Q3YTD" name="dei:DocumentPeriodEndDate" id="Fact-E2444EC6498C5C90B4F6554272005CF7-wk-Fact-E2444EC6498C5C90B4F6554272005CF7">2017-10-01</ix:nonNumeric><ix:nonNumeric contextRef="FD2017Q3YTD" name="dei:EntityCentralIndexKey" id="Fact-E26EE28CF2DB5C69AE66219664B5B8C7-wk-Fact-E26EE28CF2DB5C69AE66219664B5B8C7">0000078003</ix:nonNumeric><ix:nonNumeric contextRef="FD2017Q3YTD" name="dei:EntityFilerCategory" id="Fact-C4AF45A25BBA52C59CEA3C4FAEF95682-wk-Fact-C4AF45A25BBA52C59CEA3C4FAEF95682">Large Accelerated Filer</ix:nonNumeric><ix:nonNumeric contextRef="FD2017Q3YTD" name="dei:TradingSymbol" id="Fact-0D91055AAE495497A9207FE0E0A52D11-wk-Fact-0D91055AAE495497A9207FE0E0A52D11">PFE</ix:nonNumeric><ix:nonNumeric contextRef="D2017Q1Feb03-Feb03_us-gaap_CounterpartyNameAxis_pfe_ICUMedicalMember_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_HISMember" name="pfe:AdministrativeServicePeriod" id="Fact-95BD962ED6C754738A80F9397E3EBC26-wk-Fact-95BD962ED6C754738A80F9397E3EBC26">P24M</ix:nonNumeric><ix:nonNumeric contextRef="D2016Q4Dec22-Dec22_us-gaap_BusinessAcquisitionAxis_pfe_AstraZenecaMember" name="pfe:BusinessCombinationConsiderationTransferredUndiscountedRoyaltyPaymentsTerm" id="Fact-FFDCE598E8D55CB289ADEDDF07649B0C-wk-Fact-FFDCE598E8D55CB289ADEDDF07649B0C">P10Y</ix:nonNumeric><ix:nonNumeric contextRef="D2015Q3Sept3_us-gaap_BusinessAcquisitionAxis_pfe_HospiraMember" name="pfe:BusinessCombinationExpectedIntegrationRelatedCostsPeriod" id="Fact-678327A4807F5E5B81DC971F6764C18E-wk-Fact-678327A4807F5E5B81DC971F6764C18E">P3Y</ix:nonNumeric><ix:nonFraction decimals="-6" unitRef="usd" contextRef="FD2017Q3YTD_us-gaap_BusinessAcquisitionAxis_pfe_MedivationMember" name="pfe:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIncreaseDecreaseinAmortizationofIntangibleAssets" id="Fact-108ACE1BE67CD8CA124091F7C5BD2275-wk-Fact-108ACE1BE67CD8CA124091F7C5BD2275" sign="-">38000000</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="number" contextRef="FD2017Q3YTD_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredEuroDebtThreemonthEURIBORPlus0.20FloatingRateNotesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember_us-gaap_VariableRateAxis_pfe_EURIBORMember" name="pfe:DebtInstrumentFloorInterestRate" id="Fact-3CE8DD804B5255D8AD16D7F8D587D468-wk-Fact-3CE8DD804B5255D8AD16D7F8D587D468">0</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="number" contextRef="D2017Q1Feb03-Feb03_us-gaap_CounterpartyNameAxis_pfe_ICUMedicalMember_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_HISMember_us-gaap_VariableRateAxis_us-gaap_LondonInterbankOfferedRateLIBORMember" name="pfe:DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivableInterestRateYearThree" id="Fact-B9BA37C4F97E50B4801E35D36C0350DA-wk-Fact-B9BA37C4F97E50B4801E35D36C0350DA">0.025</ix:nonFraction><ix:nonNumeric contextRef="D2017Q1Feb03-Feb03_us-gaap_CounterpartyNameAxis_pfe_ICUMedicalMember_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_HISMember" name="pfe:DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivableTerm" id="Fact-9AA5438967D25A2FB18E43A9C6412819-wk-Fact-9AA5438967D25A2FB18E43A9C6412819">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="D2017Q1Feb03-Feb03_us-gaap_CounterpartyNameAxis_pfe_ICUMedicalMember_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_HISMember" name="pfe:DisposalGroupIncludingDiscontinuedOperationShareTransferRestrictionTermMinimum" id="Fact-83730CB88A1A580482A4329996C1C777-wk-Fact-83730CB88A1A580482A4329996C1C777">P18M</ix:nonNumeric><ix:nonFraction decimals="-8" unitRef="usd" contextRef="FI2017Q3_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_ProductOrServiceAxis_pfe_EucrisaMember" name="pfe:IntangibleAssetsTransfersDuringPeriod" id="Fact-1886FA38E19059AEB70E4C4D4D1E7C55-wk-Fact-1886FA38E19059AEB70E4C4D4D1E7C55">4800000000</ix:nonFraction><ix:nonNumeric contextRef="D2017Q1Feb03-Feb03_us-gaap_CounterpartyNameAxis_pfe_ICUMedicalMember_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_HISMember" name="pfe:MaximumManufacturingServicePeriod" id="Fact-4488229945EF520D93DACCB283FA6143-wk-Fact-4488229945EF520D93DACCB283FA6143">P5Y</ix:nonNumeric><ix:nonFraction decimals="-6" unitRef="usd" contextRef="FD2017Q3YTD" name="pfe:OtherNonoperatingIncomeMiscellaneous" id="Fact-2DCBC353F98C1E49878F91FA7CB70CBC-wk-Fact-2DCBC353F98C1E49878F91FA7CB70CBC">62000000</ix:nonFraction><ix:nonNumeric contextRef="D2017Q2Jun01-Jun30_us-gaap_ProductOrServiceAxis_pfe_BesponsaMember_us-gaap_StatementGeographicalAxis_us-gaap_EuropeanUnionMember" name="pfe:ResearchandDevelopmentArrangementAggregatePaymentObligationTerm" id="Fact-5AEB656A82955D31BB52F6AA233ABF00-wk-Fact-5AEB656A82955D31BB52F6AA233ABF00">P9Y</ix:nonNumeric><ix:nonNumeric contextRef="D2017Q3Aug01-Aug31_us-gaap_ProductOrServiceAxis_pfe_BesponsaMember_us-gaap_StatementGeographicalAxis_country_US" name="pfe:ResearchandDevelopmentArrangementAggregatePaymentObligationTerm" id="Fact-CBCCCCDA49BA0FF2BD5578ECBDA59B31-wk-Fact-CBCCCCDA49BA0FF2BD5578ECBDA59B31">P9Y</ix:nonNumeric><ix:nonNumeric contextRef="FD2017Q3YTD_us-gaap_ProductOrServiceAxis_pfe_MylotargMember_us-gaap_StatementScenarioAxis_us-gaap_ProFormaMember" name="pfe:ResearchandDevelopmentArrangementAggregatePaymentObligationTerm" id="Fact-157F827A2F6F6FB739A7921C1F74E307-wk-Fact-157F827A2F6F6FB739A7921C1F74E307">P10Y</ix:nonNumeric><ix:nonNumeric contextRef="FD2017Q3YTD_us-gaap_ProductOrServiceAxis_pfe_EnbrelMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementCopromotionMember" name="pfe:RoyaltyRevenueTerm" id="Fact-26CAFC13D0405FFA992D15D4B236379C-wk-Fact-26CAFC13D0405FFA992D15D4B236379C">P36M</ix:nonNumeric><ix:nonFraction decimals="-6" unitRef="usd" contextRef="FI2016Q4" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" id="Fact-E880E7106AA35CF2A064350EE9638A88-wk-Fact-E880E7106AA35CF2A064350EE9638A88">14807000000</ix:nonFraction><ix:nonFraction decimals="-6" unitRef="usd" contextRef="FI2017Q3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" id="Fact-F26558A44B7C5E24A9D0B3C320ABC3AC-wk-Fact-F26558A44B7C5E24A9D0B3C320ABC3AC">15906000000</ix:nonFraction><ix:nonNumeric contextRef="D2016Q3Sep28-Sep28_us-gaap_BusinessAcquisitionAxis_pfe_MedivationMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" id="Fact-985CE3B601BD5CEB82036E285D8B99EA-wk-Fact-985CE3B601BD5CEB82036E285D8B99EA">P12Y</ix:nonNumeric><ix:nonFraction decimals="-6" unitRef="usd" contextRef="FI2016Q4" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" id="Fact-88DE6FFC0A6C582BA8AE3854966F0852-wk-Fact-88DE6FFC0A6C582BA8AE3854966F0852">609000000</ix:nonFraction><ix:nonFraction decimals="-6" unitRef="usd" contextRef="FI2017Q3" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" id="Fact-B85FE09635045F46B656606350B6714A-wk-Fact-B85FE09635045F46B656606350B6714A">590000000</ix:nonFraction><ix:nonFraction decimals="-9" unitRef="usd" contextRef="FI2016Q4" name="us-gaap:Assets" id="Fact-4CB7130CEF915377BE0293C8FB86F1C5-wk-Fact-4CB7130CEF915377BE0293C8FB86F1C5">172000000000</ix:nonFraction><ix:nonFraction decimals="-6" unitRef="usd" contextRef="FD2016Q3QTD_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioAdjustmentMember_us-gaap_SubsegmentsAxis_pfe_PfizersWorldwideResearchandDevelopmentandPfizersGlobalProductDevelopmentMember" name="us-gaap:CostsAndExpenses" id="Fact-69DA9C8DB01F29E760CF0D1D589D302E-wk-Fact-69DA9C8DB01F29E760CF0D1D589D302E" sign="-">33000000</ix:nonFraction><ix:nonFraction decimals="-6" unitRef="usd" contextRef="FD2016Q3YTD_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioAdjustmentMember_us-gaap_SubsegmentsAxis_pfe_PfizersWorldwideResearchandDevelopmentandPfizersGlobalProductDevelopmentMember" name="us-gaap:CostsAndExpenses" id="Fact-17FB254DDBD7EBF0A4640D1CF0DFDF3C-wk-Fact-17FB254DDBD7EBF0A4640D1CF0DFDF3C" sign="-">94000000</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="number" contextRef="FD2017Q3YTD_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredEuroDebtThreemonthEURIBORPlus0.20FloatingRateNotesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember_us-gaap_VariableRateAxis_pfe_EURIBORMember" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" id="Fact-01BF741FB2755E73A886A5BE68BB5FC7-wk-Fact-01BF741FB2755E73A886A5BE68BB5FC7">0.002</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="number" contextRef="FI2017Q3_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtFourPointTwoPercentDue2047Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" id="Fact-6E82CA370AD05B74A8C040983981E3A5-wk-Fact-6E82CA370AD05B74A8C040983981E3A5">0.042</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="number" contextRef="FI2017Q3_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredEuroDebtOnePointZeroPercentDue2027Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" id="Fact-4451245F3A7F55148F3A9CF8EE4B2EA3-wk-Fact-4451245F3A7F55148F3A9CF8EE4B2EA3">0.01</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="number" contextRef="FI2017Q3_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredEuroDebtPointTwofivePercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" id="Fact-F07F689C9F345FB594015AD41DD952BD-wk-Fact-F07F689C9F345FB594015AD41DD952BD">0.0025</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="number" contextRef="FI2017Q3_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredEuroDebtZeroPercentDue2020Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" id="Fact-F8DC0CB6636E5AF6A5F71C82B82ABD2C-wk-Fact-F8DC0CB6636E5AF6A5F71C82B82ABD2C">0</ix:nonFraction><ix:nonFraction decimals="-6" unitRef="usd" contextRef="FD2016Q3QTD" name="us-gaap:GainLossOnCashFlowHedgeIneffectivenessNet" id="Fact-C7C39FB31383575CB4CACADB51F1154E-wk-Fact-C7C39FB31383575CB4CACADB51F1154E">0</ix:nonFraction><ix:nonFraction decimals="-6" unitRef="usd" contextRef="FD2016Q3YTD" name="us-gaap:GainLossOnCashFlowHedgeIneffectivenessNet" id="Fact-6DC28BDC30C1507C83C9B34C55EA3419-wk-Fact-6DC28BDC30C1507C83C9B34C55EA3419">0</ix:nonFraction><ix:nonFraction decimals="-6" unitRef="usd" contextRef="FD2017Q3QTD" name="us-gaap:GainLossOnCashFlowHedgeIneffectivenessNet" id="Fact-9851E4D7078E5D07BA0939E6014D8042-wk-Fact-9851E4D7078E5D07BA0939E6014D8042">0</ix:nonFraction><ix:nonFraction decimals="-6" unitRef="usd" contextRef="FD2017Q3YTD" name="us-gaap:GainLossOnCashFlowHedgeIneffectivenessNet" id="Fact-6021DC299F0A510793175260F54CDDC3-wk-Fact-6021DC299F0A510793175260F54CDDC3">0</ix:nonFraction><ix:nonFraction decimals="-6" unitRef="usd" contextRef="FD2017Q3QTD_us-gaap_BusinessAcquisitionAxis_pfe_HospiraMember_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" id="Fact-4E5DABE54DEE36D9155191CB96BF29E6-wk-Fact-4E5DABE54DEE36D9155191CB96BF29E6">127000000</ix:nonFraction><ix:nonFraction decimals="-6" unitRef="usd" contextRef="FD2017Q3YTD_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_LossContingenciesByNatureOfContingencyAxis_pfe_PatentMatterMember" name="us-gaap:LitigationSettlementExpense" id="Fact-036EF4E92BD4F27B29AF91FD15932060-wk-Fact-036EF4E92BD4F27B29AF91FD15932060">79000000</ix:nonFraction><ix:nonFraction decimals="-6" unitRef="usd" contextRef="FD2017Q3YTD_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_ProductOrServiceAxis_pfe_CelebrexMember" name="us-gaap:LitigationSettlementExpense" id="Fact-F4277608FF9F588BA3D091FCB8132DA4-wk-Fact-F4277608FF9F588BA3D091FCB8132DA4">94000000</ix:nonFraction><ix:nonFraction decimals="-6" unitRef="usd" contextRef="FI2016Q4" name="us-gaap:LongTermDebtCurrent" id="Fact-4C5952B687735A68B4F8FF2FF8E28F5B-wk-Fact-4C5952B687735A68B4F8FF2FF8E28F5B">4225000000</ix:nonFraction><ix:nonFraction decimals="-6" unitRef="usd" contextRef="FI2017Q3" name="us-gaap:LongTermDebtCurrent" id="Fact-438EE85774DF543BA158096F9559C174-wk-Fact-438EE85774DF543BA158096F9559C174">3072000000</ix:nonFraction><ix:nonFraction decimals="-6" unitRef="usd" contextRef="FD2016Q3YTD_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_pfe_AccountingStandardsUpdate201609StatutoryTaxWithholdingComponentMember" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" id="Fact-01726B7A2C705A62882A466A815D605B-wk-Fact-01726B7A2C705A62882A466A815D605B" sign="-">87000000</ix:nonFraction><ix:nonFraction decimals="-8" unitRef="usd" contextRef="FD2016Q3QTD_us-gaap_CurrencyAxis_currency_EUR_us-gaap_StatementGeographicalAxis_pfe_DevelopedEuropeMember" name="us-gaap:SalesRevenueGoodsNet" id="Fact-62FD8B6CE5625EEAA34044C5ED64A925-wk-Fact-62FD8B6CE5625EEAA34044C5ED64A925">1700000000</ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:href="pfe-20171001.xsd" xlink:type="simple"/></ix:references><ix:resources><xbrli:context id="FD2017Q3YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2017Q4Nov06">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-11-06</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-03</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-04</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2017Q2Jun30_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_LaboratorioTeutoBrasileroMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:LaboratorioTeutoBrasileroMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2016Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q3">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-10-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2017Q1Feb03_us-gaap_CounterpartyNameAxis_pfe_ICUMedicalMember_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_HISMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">pfe:ICUMedicalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pfe:HISMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-02-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2015Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2016Q3">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-10-02</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2016Q2AnacorAcquisition_us-gaap_BusinessAcquisitionAxis_pfe_AnacorMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:AnacorMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-06-24</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_pfe_AccountingStandardsUpdate201609StatutoryTaxWithholdingComponentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">pfe:AccountingStandardsUpdate201609StatutoryTaxWithholdingComponentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2016Q3Sep28_us-gaap_BusinessAcquisitionAxis_pfe_MedivationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:MedivationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-09-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2016Q2Jun24-Jun24_us-gaap_BusinessAcquisitionAxis_pfe_AnacorMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:AnacorMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-06-24</xbrli:startDate>
			<xbrli:endDate>2016-06-24</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2016Q3Aug01-Aug01_us-gaap_BusinessAcquisitionAxis_pfe_BambooTherapeuticsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:BambooTherapeuticsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-08-01</xbrli:startDate>
			<xbrli:endDate>2016-08-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_us-gaap_BusinessAcquisitionAxis_pfe_MedivationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:MedivationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-03</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2016Q3Aug01-Aug01_us-gaap_BusinessAcquisitionAxis_pfe_BambooTherapeuticsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:BambooTherapeuticsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-08-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2017Q1Jan05_us-gaap_CounterpartyNameAxis_pfe_ICUMedicalMember_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_HISMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">pfe:ICUMedicalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pfe:HISMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-01-05</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q2QTD_us-gaap_BusinessAcquisitionAxis_pfe_AstraZenecaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:AstraZenecaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-04-03</xbrli:startDate>
			<xbrli:endDate>2017-07-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2016Q3Sep28-Sep28_us-gaap_BusinessAcquisitionAxis_pfe_MedivationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:MedivationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-09-28</xbrli:startDate>
			<xbrli:endDate>2016-09-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2016Q4Dec22-Dec22_us-gaap_BusinessAcquisitionAxis_pfe_AstraZenecaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:AstraZenecaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-22</xbrli:startDate>
			<xbrli:endDate>2016-12-22</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2016Q4Dec22_us-gaap_BusinessAcquisitionAxis_pfe_AstraZenecaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:AstraZenecaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-22</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2017Q2Jun30_dei_LegalEntityAxis_pfe_LaboratorioTeutoBrasileroMember_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_LaboratorioTeutoBrasileroMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">pfe:LaboratorioTeutoBrasileroMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:LaboratorioTeutoBrasileroMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_us-gaap_CounterpartyNameAxis_pfe_MerckKGaAMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">pfe:MerckKGaAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2016Q4Oct06_us-gaap_CounterpartyNameAxis_pfe_ICUMedicalMember_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_HISMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">pfe:ICUMedicalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pfe:HISMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-10-06</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2016Q3Sep28_us-gaap_BusinessAcquisitionAxis_pfe_MedivationMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:MedivationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-09-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_LaboratorioTeutoBrasileroMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:LaboratorioTeutoBrasileroMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_us-gaap_CounterpartyNameAxis_pfe_ICUMedicalMember_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_HISMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">pfe:ICUMedicalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pfe:HISMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q1Feb03-Feb03_us-gaap_CounterpartyNameAxis_pfe_ICUMedicalMember_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_HISMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">pfe:ICUMedicalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pfe:HISMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-02-03</xbrli:startDate>
			<xbrli:endDate>2017-02-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q1QTD_us-gaap_CounterpartyNameAxis_pfe_MerckKGaAMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">pfe:MerckKGaAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-04-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q3_us-gaap_CounterpartyNameAxis_pfe_ICUMedicalMember_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_HISMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">pfe:ICUMedicalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pfe:HISMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-10-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_us-gaap_CounterpartyNameAxis_pfe_ICUMedicalMember_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_HISMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">pfe:ICUMedicalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pfe:HISMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-03</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3QTD_us-gaap_BusinessAcquisitionAxis_pfe_BambooTherapeuticsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:BambooTherapeuticsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-04</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q3Sep29-Oct01_us-gaap_BusinessAcquisitionAxis_pfe_MedivationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:MedivationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-09-29</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_LaboratorioTeutoBrasileroMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:LaboratorioTeutoBrasileroMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2016Q3Aug01-Aug01_us-gaap_BusinessAcquisitionAxis_pfe_BambooTherapeuticsMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:BambooTherapeuticsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-08-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q1Feb03-Feb03_us-gaap_CounterpartyNameAxis_pfe_ICUMedicalMember_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_HISMember_us-gaap_VariableRateAxis_us-gaap_LondonInterbankOfferedRateLIBORMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">pfe:ICUMedicalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pfe:HISMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-02-03</xbrli:startDate>
			<xbrli:endDate>2017-02-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2016Q4Dec22_us-gaap_BusinessAcquisitionAxis_pfe_AstraZenecaMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:AstraZenecaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-22</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2016Q4Dec22_us-gaap_BusinessAcquisitionAxis_pfe_AstraZenecaMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:AstraZenecaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-22</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q3_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_HisunPfizerPharmaceuticalsCoLtdMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:HisunPfizerPharmaceuticalsCoLtdMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-10-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q1QTD_us-gaap_BusinessAcquisitionAxis_pfe_AstraZenecaMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioForecastMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:AstraZenecaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioForecastMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-04-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2016Q3_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_HisunPfizerPharmaceuticalsCoLtdMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:HisunPfizerPharmaceuticalsCoLtdMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-10-02</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2016Q4Dec22-Dec22_us-gaap_BusinessAcquisitionAxis_pfe_AstraZenecaMember_us-gaap_RangeAxis_us-gaap_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:AstraZenecaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-22</xbrli:startDate>
			<xbrli:endDate>2016-12-22</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q1QTD_us-gaap_BusinessAcquisitionAxis_pfe_BambooTherapeuticsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:BambooTherapeuticsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-04-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_HisunPfizerPharmaceuticalsCoLtdMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:HisunPfizerPharmaceuticalsCoLtdMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2016Q3Sep28_us-gaap_BusinessAcquisitionAxis_pfe_MedivationMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:MedivationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-09-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2016Q4Dec22-Dec22_us-gaap_BusinessAcquisitionAxis_pfe_AstraZenecaMember_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:AstraZenecaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-22</xbrli:startDate>
			<xbrli:endDate>2016-12-22</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2016Q4_us-gaap_BusinessAcquisitionAxis_pfe_MedivationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:MedivationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2016Q2AnacorAcquisition_us-gaap_BusinessAcquisitionAxis_pfe_AnacorMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:AnacorMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-06-24</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_us-gaap_BusinessAcquisitionAxis_pfe_MedivationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:MedivationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2016Q3Sep28-Sep28_us-gaap_BusinessAcquisitionAxis_pfe_MedivationMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:MedivationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-09-28</xbrli:startDate>
			<xbrli:endDate>2016-09-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_us-gaap_RestructuringCostAndReserveAxis_pfe_AssetImpairmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pfe:AssetImpairmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OtherRestructuringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q3_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-10-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q3_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OtherRestructuringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-10-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2016Q4_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2016Q4_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OtherRestructuringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2016Q4_us-gaap_RestructuringCostAndReserveAxis_pfe_AssetImpairmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pfe:AssetImpairmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q3_us-gaap_RestructuringCostAndReserveAxis_pfe_AssetImpairmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pfe:AssetImpairmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-10-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q3_us-gaap_RestructuringCostAndReserveAxis_pfe_ManufacturingPlantNetworkOptimizationMember_us-gaap_RestructuringPlanAxis_pfe_EnterprisewideCostReductionProductivityPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pfe:ManufacturingPlantNetworkOptimizationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pfe:EnterprisewideCostReductionProductivityPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-10-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_us-gaap_SubsegmentsAxis_pfe_ManufacturingOperationsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">pfe:ManufacturingOperationsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_us-gaap_RestructuringPlanAxis_pfe_EnterprisewideCostReductionProductivityPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pfe:EnterprisewideCostReductionProductivityPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3QTD_us-gaap_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-04</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-03</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-10-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_us-gaap_SubsegmentsAxis_pfe_WorldwideResearchandDevelopmentandGlobalProductDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">pfe:WorldwideResearchandDevelopmentandGlobalProductDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_us-gaap_SubsegmentsAxis_pfe_ManufacturingOperationsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">pfe:ManufacturingOperationsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_us-gaap_SubsegmentsAxis_pfe_WorldwideResearchandDevelopmentandGlobalProductDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">pfe:WorldwideResearchandDevelopmentandGlobalProductDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_us-gaap_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-03</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_us-gaap_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q3_us-gaap_RestructuringCostAndReserveAxis_pfe_CentralizationofCorporateandPlatformFunctionsMember_us-gaap_RestructuringPlanAxis_pfe_EnterprisewideCostReductionProductivityPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pfe:CentralizationofCorporateandPlatformFunctionsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pfe:EnterprisewideCostReductionProductivityPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-10-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-10-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-03</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_us-gaap_BusinessAcquisitionAxis_pfe_HospiraMember_us-gaap_RestructuringCostAndReserveAxis_pfe_BusinessIntegrationCostsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:HospiraMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pfe:BusinessIntegrationCostsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q3_us-gaap_RestructuringPlanAxis_pfe_EnterprisewideCostReductionProductivityPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pfe:EnterprisewideCostReductionProductivityPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-10-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3QTD_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_us-gaap_SubsegmentsAxis_pfe_WorldwideResearchandDevelopmentandGlobalProductDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">pfe:WorldwideResearchandDevelopmentandGlobalProductDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-04</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_us-gaap_SubsegmentsAxis_pfe_WorldwideResearchandDevelopmentandGlobalProductDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">pfe:WorldwideResearchandDevelopmentandGlobalProductDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-03</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_us-gaap_RestructuringCostAndReserveAxis_pfe_BusinessIntegrationCostsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pfe:BusinessIntegrationCostsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3QTD_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-04</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_us-gaap_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3QTD_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_us-gaap_SubsegmentsAxis_pfe_ManufacturingOperationsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">pfe:ManufacturingOperationsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-04</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_us-gaap_SubsegmentsAxis_pfe_ManufacturingOperationsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">pfe:ManufacturingOperationsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-03</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q3Sept20152018_us-gaap_BusinessAcquisitionAxis_pfe_HospiraMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioForecastMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:HospiraMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioForecastMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-09-03</xbrli:startDate>
			<xbrli:endDate>2018-09-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2015Q4YTD_us-gaap_BusinessAcquisitionAxis_pfe_HospiraMember_us-gaap_RestructuringCostAndReserveAxis_pfe_ReturnofAcquiredRightsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:HospiraMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pfe:ReturnofAcquiredRightsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_us-gaap_BusinessAcquisitionAxis_pfe_HospiraMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:HospiraMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3QTD_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-04</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-03</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-04</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-03</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-03</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-04</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-04</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3QTD_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-04</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-03</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2015Q3Sept3_us-gaap_BusinessAcquisitionAxis_pfe_HospiraMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:HospiraMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-09-03</xbrli:startDate>
			<xbrli:endDate>2015-09-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-10-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-10-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-10-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q3_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-10-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2016Q3_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_LaboratorioTeutoBrasileroMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:LaboratorioTeutoBrasileroMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-10-02</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3QTD_us-gaap_BusinessAcquisitionAxis_pfe_KingMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_pfe_OtherInProcessResearchandDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:KingMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">pfe:OtherInProcessResearchandDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-04</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_us-gaap_BusinessAcquisitionAxis_pfe_HospiraMember_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:HospiraMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViivHealthcareLimitedMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:ViivHealthcareLimitedMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-03</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_us-gaap_BusinessAcquisitionAxis_pfe_InnoPharmaMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:InnoPharmaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3QTD_us-gaap_BusinessAcquisitionAxis_pfe_InnoPharmaMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:InnoPharmaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-04</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_LossContingenciesByNatureOfContingencyAxis_pfe_PatentMatterMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">pfe:PatentMatterMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-03</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DistributionRightsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DistributionRightsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_us-gaap_ProductOrServiceAxis_pfe_XtandiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:XtandiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-03</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_LaboratorioTeutoBrasileroMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:LaboratorioTeutoBrasileroMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_us-gaap_BusinessAcquisitionAxis_pfe_HospiraMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_pfe_OtherInProcessResearchandDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:HospiraMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">pfe:OtherInProcessResearchandDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_us-gaap_ProductOrServiceAxis_pfe_XtandiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:XtandiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_us-gaap_BusinessAcquisitionAxis_pfe_KingMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_pfe_OtherInProcessResearchandDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:KingMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">pfe:OtherInProcessResearchandDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_us-gaap_ProductOrServiceAxis_pfe_EnbrelMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementCopromotionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:EnbrelMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementCopromotionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-03</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViivHealthcareLimitedMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:ViivHealthcareLimitedMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DistributionRightsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DistributionRightsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-03</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_ProductOrServiceAxis_pfe_CelebrexandBextraMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:CelebrexandBextraMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_ProductOrServiceAxis_pfe_CelebrexMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:CelebrexMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-03</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_us-gaap_ProductOrServiceAxis_pfe_EnbrelMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementCopromotionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:EnbrelMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementCopromotionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_pfe_OtherInProcessResearchandDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">pfe:OtherInProcessResearchandDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DistributionRightsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DistributionRightsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_ProductOrServiceAxis_pfe_CelebrexMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:CelebrexMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_LossContingenciesByNatureOfContingencyAxis_pfe_PatentMatterMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">pfe:PatentMatterMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_us-gaap_BusinessAcquisitionAxis_pfe_HospiraMember_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:HospiraMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-03</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-10-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-10-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-10-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-10-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-10-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-10-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-10-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_USGovernmentDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-10-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_pfe_WesternEuropeanandOtherGovernmentDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">pfe:WesternEuropeanandOtherGovernmentDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-10-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_pfe_WesternEuropeanAsianandOtherGovernmentDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">pfe:WesternEuropeanAsianandOtherGovernmentDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-10-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_pfe_TimeDepositsCorporateDebtAndOtherMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">pfe:TimeDepositsCorporateDebtAndOtherMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-10-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_pfe_SupranationalDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">pfe:SupranationalDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-10-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_GovernmentNationalMortgageAssociationCertificatesAndObligationsGNMAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:GovernmentNationalMortgageAssociationCertificatesAndObligationsGNMAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-10-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_pfe_WesternEuropeanScandinaviaAndOtherGovernmentAgencyDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">pfe:WesternEuropeanScandinaviaAndOtherGovernmentAgencyDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-10-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_AssetBackedSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-10-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-04</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyShortTermBorrowingsMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_pfe_NetInvestmentHedgingNonderivativeInstrumentsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyShortTermBorrowingsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">pfe:NetInvestmentHedgingNonderivativeInstrumentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_pfe_OtherDerivativeInstrumentsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">pfe:OtherDerivativeInstrumentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyShortTermBorrowingsMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_pfe_NetInvestmentHedgingNonderivativeInstrumentsMember_us-gaap_OtherComprehensiveIncomeLocationAxis_us-gaap_OtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyShortTermBorrowingsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">pfe:NetInvestmentHedgingNonderivativeInstrumentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:OtherComprehensiveIncomeLocationAxis">us-gaap:OtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-04</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_pfe_OtherDerivativeInstrumentsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">pfe:OtherDerivativeInstrumentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3QTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_pfe_OtherDerivativeInstrumentsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">pfe:OtherDerivativeInstrumentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-04</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_pfe_OtherDerivativeInstrumentsMember_us-gaap_OtherComprehensiveIncomeLocationAxis_us-gaap_OtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">pfe:OtherDerivativeInstrumentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:OtherComprehensiveIncomeLocationAxis">us-gaap:OtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-03</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyLongTermDebtMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_pfe_NetInvestmentHedgingNonderivativeInstrumentsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyLongTermDebtMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">pfe:NetInvestmentHedgingNonderivativeInstrumentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyLongTermDebtMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_pfe_NetInvestmentHedgingNonderivativeInstrumentsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyLongTermDebtMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">pfe:NetInvestmentHedgingNonderivativeInstrumentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-03</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-03</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-04</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyShortTermBorrowingsMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_pfe_NetInvestmentHedgingNonderivativeInstrumentsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyShortTermBorrowingsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">pfe:NetInvestmentHedgingNonderivativeInstrumentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_pfe_OtherDerivativeInstrumentsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">pfe:OtherDerivativeInstrumentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-03</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-03</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember_us-gaap_OtherComprehensiveIncomeLocationAxis_us-gaap_OtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:OtherComprehensiveIncomeLocationAxis">us-gaap:OtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-03</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyLongTermDebtMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_pfe_NetInvestmentHedgingNonderivativeInstrumentsMember_us-gaap_OtherComprehensiveIncomeLocationAxis_us-gaap_OtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyLongTermDebtMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">pfe:NetInvestmentHedgingNonderivativeInstrumentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:OtherComprehensiveIncomeLocationAxis">us-gaap:OtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-03</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-03</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3QTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_pfe_OtherDerivativeInstrumentsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">pfe:OtherDerivativeInstrumentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-04</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-03</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_pfe_OtherDerivativeInstrumentsMember_us-gaap_OtherComprehensiveIncomeLocationAxis_us-gaap_OtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">pfe:OtherDerivativeInstrumentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:OtherComprehensiveIncomeLocationAxis">us-gaap:OtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_pfe_OtherDerivativeInstrumentsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">pfe:OtherDerivativeInstrumentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-03</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_OtherComprehensiveIncomeLocationAxis_us-gaap_OtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:OtherComprehensiveIncomeLocationAxis">us-gaap:OtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3QTD_us-gaap_OtherComprehensiveIncomeLocationAxis_us-gaap_OtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:OtherComprehensiveIncomeLocationAxis">us-gaap:OtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-04</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_OtherComprehensiveIncomeLocationAxis_us-gaap_OtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:OtherComprehensiveIncomeLocationAxis">us-gaap:OtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-04</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-04</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_pfe_OtherDerivativeInstrumentsMember_us-gaap_OtherComprehensiveIncomeLocationAxis_us-gaap_OtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">pfe:OtherDerivativeInstrumentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:OtherComprehensiveIncomeLocationAxis">us-gaap:OtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_OtherComprehensiveIncomeLocationAxis_us-gaap_OtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:OtherComprehensiveIncomeLocationAxis">us-gaap:OtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-03</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_OtherComprehensiveIncomeLocationAxis_us-gaap_OtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:OtherComprehensiveIncomeLocationAxis">us-gaap:OtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-03</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-04</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-03</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_OtherComprehensiveIncomeLocationAxis_us-gaap_OtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:OtherComprehensiveIncomeLocationAxis">us-gaap:OtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_OtherComprehensiveIncomeLocationAxis_us-gaap_OtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:OtherComprehensiveIncomeLocationAxis">us-gaap:OtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-04</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember_us-gaap_OtherComprehensiveIncomeLocationAxis_us-gaap_OtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:OtherComprehensiveIncomeLocationAxis">us-gaap:OtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyShortTermBorrowingsMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_pfe_NetInvestmentHedgingNonderivativeInstrumentsMember_us-gaap_OtherComprehensiveIncomeLocationAxis_us-gaap_OtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyShortTermBorrowingsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">pfe:NetInvestmentHedgingNonderivativeInstrumentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:OtherComprehensiveIncomeLocationAxis">us-gaap:OtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_OtherComprehensiveIncomeLocationAxis_us-gaap_OtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:OtherComprehensiveIncomeLocationAxis">us-gaap:OtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-03</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_OtherComprehensiveIncomeLocationAxis_us-gaap_OtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:OtherComprehensiveIncomeLocationAxis">us-gaap:OtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-04</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_OtherComprehensiveIncomeLocationAxis_us-gaap_OtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:OtherComprehensiveIncomeLocationAxis">us-gaap:OtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-03</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember_us-gaap_OtherComprehensiveIncomeLocationAxis_us-gaap_OtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:OtherComprehensiveIncomeLocationAxis">us-gaap:OtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-03</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember_us-gaap_OtherComprehensiveIncomeLocationAxis_us-gaap_OtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:OtherComprehensiveIncomeLocationAxis">us-gaap:OtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-04</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyLongTermDebtMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_pfe_NetInvestmentHedgingNonderivativeInstrumentsMember_us-gaap_OtherComprehensiveIncomeLocationAxis_us-gaap_OtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyLongTermDebtMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">pfe:NetInvestmentHedgingNonderivativeInstrumentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:OtherComprehensiveIncomeLocationAxis">us-gaap:OtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-04</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-03</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyLongTermDebtMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_pfe_NetInvestmentHedgingNonderivativeInstrumentsMember_us-gaap_OtherComprehensiveIncomeLocationAxis_us-gaap_OtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyLongTermDebtMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">pfe:NetInvestmentHedgingNonderivativeInstrumentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:OtherComprehensiveIncomeLocationAxis">us-gaap:OtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_pfe_OtherDerivativeInstrumentsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">pfe:OtherDerivativeInstrumentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-03</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-04</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-04</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-03</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember_us-gaap_OtherComprehensiveIncomeLocationAxis_us-gaap_OtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:OtherComprehensiveIncomeLocationAxis">us-gaap:OtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyShortTermBorrowingsMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_pfe_NetInvestmentHedgingNonderivativeInstrumentsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyShortTermBorrowingsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">pfe:NetInvestmentHedgingNonderivativeInstrumentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_OtherComprehensiveIncomeLocationAxis_us-gaap_OtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:OtherComprehensiveIncomeLocationAxis">us-gaap:OtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-04</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyShortTermBorrowingsMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_pfe_NetInvestmentHedgingNonderivativeInstrumentsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyShortTermBorrowingsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">pfe:NetInvestmentHedgingNonderivativeInstrumentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_OtherComprehensiveIncomeLocationAxis_us-gaap_OtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:OtherComprehensiveIncomeLocationAxis">us-gaap:OtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-04</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyLongTermDebtMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_pfe_NetInvestmentHedgingNonderivativeInstrumentsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyLongTermDebtMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">pfe:NetInvestmentHedgingNonderivativeInstrumentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3QTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_pfe_OtherDerivativeInstrumentsMember_us-gaap_OtherComprehensiveIncomeLocationAxis_us-gaap_OtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">pfe:OtherDerivativeInstrumentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:OtherComprehensiveIncomeLocationAxis">us-gaap:OtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-04</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_pfe_OtherDerivativeInstrumentsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">pfe:OtherDerivativeInstrumentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-04</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyLongTermDebtMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_pfe_NetInvestmentHedgingNonderivativeInstrumentsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyLongTermDebtMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">pfe:NetInvestmentHedgingNonderivativeInstrumentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-04</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-03</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-03</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyLongTermDebtMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_pfe_NetInvestmentHedgingNonderivativeInstrumentsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyLongTermDebtMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">pfe:NetInvestmentHedgingNonderivativeInstrumentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-04</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember_us-gaap_OtherComprehensiveIncomeLocationAxis_us-gaap_OtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:OtherComprehensiveIncomeLocationAxis">us-gaap:OtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember_us-gaap_OtherComprehensiveIncomeLocationAxis_us-gaap_OtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:OtherComprehensiveIncomeLocationAxis">us-gaap:OtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyLongTermDebtMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_pfe_NetInvestmentHedgingNonderivativeInstrumentsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyLongTermDebtMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">pfe:NetInvestmentHedgingNonderivativeInstrumentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-04</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember_us-gaap_OtherComprehensiveIncomeLocationAxis_us-gaap_OtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:OtherComprehensiveIncomeLocationAxis">us-gaap:OtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-04</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyLongTermDebtMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_pfe_NetInvestmentHedgingNonderivativeInstrumentsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyLongTermDebtMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">pfe:NetInvestmentHedgingNonderivativeInstrumentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_OtherComprehensiveIncomeLocationAxis_us-gaap_OtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:OtherComprehensiveIncomeLocationAxis">us-gaap:OtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-03</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-04</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_us-gaap_OtherComprehensiveIncomeLocationAxis_us-gaap_OtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:OtherComprehensiveIncomeLocationAxis">us-gaap:OtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyLongTermDebtMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_pfe_NetInvestmentHedgingNonderivativeInstrumentsMember_us-gaap_OtherComprehensiveIncomeLocationAxis_us-gaap_OtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyLongTermDebtMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">pfe:NetInvestmentHedgingNonderivativeInstrumentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:OtherComprehensiveIncomeLocationAxis">us-gaap:OtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_us-gaap_OtherComprehensiveIncomeLocationAxis_us-gaap_OtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:OtherComprehensiveIncomeLocationAxis">us-gaap:OtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-03</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_us-gaap_OtherComprehensiveIncomeLocationAxis_us-gaap_OtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:OtherComprehensiveIncomeLocationAxis">us-gaap:OtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyLongTermDebtMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_pfe_NetInvestmentHedgingNonderivativeInstrumentsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyLongTermDebtMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">pfe:NetInvestmentHedgingNonderivativeInstrumentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-03</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-10-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-10-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_ProductOrServiceAxis_pfe_BesponsaMember_us-gaap_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:BesponsaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-10-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_CashAndCashEquivalentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-10-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q3_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-10-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-10-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q3_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-10-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-10-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2016Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_ProductOrServiceAxis_pfe_BesponsaMember_us-gaap_StatementGeographicalAxis_us-gaap_EuropeanUnionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:BesponsaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">us-gaap:EuropeanUnionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-10-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-10-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-10-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-10-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2016Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-10-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q1_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-04-02</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q3_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_ProductOrServiceAxis_pfe_BesponsaMember_us-gaap_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:BesponsaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-10-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_LongtermDebtTypeAxis_pfe_ForeignCurrencyLongTermDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">pfe:ForeignCurrencyLongTermDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-10-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-10-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q3_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_ProductOrServiceAxis_pfe_BesponsaMember_us-gaap_StatementGeographicalAxis_us-gaap_EuropeanUnionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:BesponsaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">us-gaap:EuropeanUnionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-10-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2016Q4_us-gaap_ShortTermDebtTypeAxis_us-gaap_CommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q3_us-gaap_DebtInstrumentAxis_pfe_EuroLongtermDebtMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:EuroLongtermDebtMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-10-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_ProductOrServiceAxis_pfe_BesponsaMember_us-gaap_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:BesponsaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-10-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2016Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q3_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-10-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-10-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_VariableRateAxis_pfe_GermanGovernmentBondRateMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">pfe:GermanGovernmentBondRateMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-10-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_ProductOrServiceAxis_pfe_BesponsaMember_us-gaap_StatementGeographicalAxis_us-gaap_EuropeanUnionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:BesponsaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">us-gaap:EuropeanUnionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-10-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-10-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_us-gaap_EquitySecuritiesByIndustryAxis_us-gaap_TechnologySectorMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:EquitySecuritiesByIndustryAxis">us-gaap:TechnologySectorMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q3_us-gaap_ShortTermDebtTypeAxis_us-gaap_CommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-10-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-10-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q3_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-10-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2017Q3Aug31_us-gaap_ProductOrServiceAxis_pfe_BesponsaMember_us-gaap_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:BesponsaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-08-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2017Q2Jun30_us-gaap_ProductOrServiceAxis_pfe_BesponsaMember_us-gaap_StatementGeographicalAxis_us-gaap_EuropeanUnionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:BesponsaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">us-gaap:EuropeanUnionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q3_us-gaap_ShortTermDebtTypeAxis_us-gaap_ShortTermDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ShortTermDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-10-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q3_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-10-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_DebtSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2016Q4_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2016Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2016Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_LongTermDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2016Q4_us-gaap_ShortTermDebtTypeAxis_us-gaap_ShortTermDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ShortTermDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q3_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-10-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2016Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q3_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-10-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-10-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q3_us-gaap_LongtermDebtTypeAxis_us-gaap_LongTermDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-10-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q3_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-10-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_EquitySecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-10-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_DebtSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-10-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_EquitySecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2016Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q3_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredEuroDebtZeroPercentDue2020Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredEuroDebtZeroPercentDue2020Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-10-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q3_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredEuroDebtOnePointZeroPercentDue2027Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredEuroDebtOnePointZeroPercentDue2027Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-10-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q3_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtFourPointTwoPercentDue2047Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtFourPointTwoPercentDue2047Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-10-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q3_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredEuroDebtThreemonthEURIBORPlus0.20FloatingRateNotesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredEuroDebtThreemonthEURIBORPlus0.20FloatingRateNotesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-10-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q3_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-10-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q3_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredEuroDebtPointTwofivePercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredEuroDebtPointTwofivePercentDue2022Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-10-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q3_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-10-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-10-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-10-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_LongTermDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2016Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q3_us-gaap_BalanceSheetLocationAxis_pfe_ShortTermDebtAndCurrentPortionofLongTermDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:ShortTermDebtAndCurrentPortionofLongTermDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-10-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2016Q4_us-gaap_BalanceSheetLocationAxis_pfe_ShortTermDebtAndCurrentPortionofLongTermDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:ShortTermDebtAndCurrentPortionofLongTermDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_LongTermDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-10-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_CashAndCashEquivalentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-10-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q2Jun01-Jun30_us-gaap_ProductOrServiceAxis_pfe_BesponsaMember_us-gaap_StatementGeographicalAxis_us-gaap_EuropeanUnionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:BesponsaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">us-gaap:EuropeanUnionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-06-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q3Aug01-Aug31_us-gaap_ProductOrServiceAxis_pfe_BesponsaMember_us-gaap_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:BesponsaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-08-01</xbrli:startDate>
			<xbrli:endDate>2017-08-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredEuroDebtThreemonthEURIBORPlus0.20FloatingRateNotesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember_us-gaap_VariableRateAxis_pfe_EURIBORMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredEuroDebtThreemonthEURIBORPlus0.20FloatingRateNotesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">pfe:EURIBORMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_FiniteLivedIntangibleAssetsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:FiniteLivedIntangibleAssetsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-03</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3QTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_FiniteLivedIntangibleAssetsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:FiniteLivedIntangibleAssetsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-04</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_FiniteLivedIntangibleAssetsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:FiniteLivedIntangibleAssetsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q3_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_ProductOrServiceAxis_pfe_BesponsaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:BesponsaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-10-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_FiniteLivedIntangibleAssetsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:FiniteLivedIntangibleAssetsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q3_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember_us-gaap_ProductOrServiceAxis_pfe_EucrisaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:EucrisaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-10-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2016Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2016Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2016Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsAndOtherMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">pfe:LicensingAgreementsAndOtherMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2016Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q3_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-10-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q3_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-10-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2016Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q3_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsAndOtherMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">pfe:LicensingAgreementsAndOtherMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-10-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q3_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-10-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q3_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-10-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2016Q4_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2016Q4_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q3_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-10-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q3_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-10-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q3_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-10-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q3_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_SubsegmentsAxis_pfe_PfizersWorldwideResearchandDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">pfe:PfizersWorldwideResearchandDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-10-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q3_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember_us-gaap_SubsegmentsAxis_pfe_PfizersWorldwideResearchandDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">pfe:PfizersWorldwideResearchandDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-10-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q3_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-10-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q3_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-10-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q3_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-10-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q3_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-10-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q3_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-10-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q3_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-10-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q3_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember_us-gaap_SubsegmentsAxis_pfe_PfizersWorldwideResearchandDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">pfe:PfizersWorldwideResearchandDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-10-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q3_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember_us-gaap_SubsegmentsAxis_pfe_PfizersWorldwideResearchandDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">pfe:PfizersWorldwideResearchandDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-10-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q3_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_ProductOrServiceAxis_pfe_EucrisaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:EucrisaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-10-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:NonqualifiedPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:SupplementalEmployeeRetirementPlanDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-04</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-04</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3QTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-04</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:NonqualifiedPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:SupplementalEmployeeRetirementPlanDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-03</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-03</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3QTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-04</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-03</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-03</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:NonqualifiedPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:SupplementalEmployeeRetirementPlanDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:NonqualifiedPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:SupplementalEmployeeRetirementPlanDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q3_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-10-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q3_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-10-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q3_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-10-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q3_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:NonqualifiedPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:SupplementalEmployeeRetirementPlanDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-10-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q1Jan01-Jan31_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-01-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q2Apr01-Apr30_us-gaap_BusinessAcquisitionAxis_pfe_HospiraMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:HospiraMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-04-01</xbrli:startDate>
			<xbrli:endDate>2017-04-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-04</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-03</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q1Mar01-Mar31_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationCaseAxis_pfe_PfizerVersusZydusMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_ProductOrServiceAxis_pfe_XeljanzMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:GainContingenciesByNatureAxis">pfe:PatentInfringementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">pfe:PfizerVersusZydusMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:XeljanzMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-03-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2016Q4_us-gaap_LossContingenciesByNatureOfContingencyAxis_pfe_ViolationofAntitrustLawsMember_us-gaap_ProductOrServiceAxis_pfe_PhenytoinSodiumCapsulesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">pfe:ViolationofAntitrustLawsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:PhenytoinSodiumCapsulesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q1Mar01-Mar31_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationCaseAxis_pfe_PfizerVersusPrinstonandBreckenridgeMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_ProductOrServiceAxis_pfe_XeljanzMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:GainContingenciesByNatureAxis">pfe:PatentInfringementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">pfe:PfizerVersusPrinstonandBreckenridgeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:XeljanzMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-03-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q1Feb01-Feb28_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationCaseAxis_pfe_PfizerVersusMicroLabsMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_ProductOrServiceAxis_pfe_XeljanzMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:GainContingenciesByNatureAxis">pfe:PatentInfringementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">pfe:PfizerVersusMicroLabsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:XeljanzMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-02-01</xbrli:startDate>
			<xbrli:endDate>2017-02-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q2Feb01-Apr30_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationCaseAxis_pfe_PfizerandBMSVersusSeveralGenericManufacturersMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_ProductOrServiceAxis_pfe_EliquisMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:GainContingenciesByNatureAxis">pfe:PatentInfringementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">pfe:PfizerandBMSVersusSeveralGenericManufacturersMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:EliquisMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-02-01</xbrli:startDate>
			<xbrli:endDate>2017-04-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2017Q1Feb02_us-gaap_ShareRepurchaseProgramAxis_pfe_ShareRepurchaseAgreementwithCitibankMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">pfe:ShareRepurchaseAgreementwithCitibankMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-02-02</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q3_us-gaap_ShareRepurchaseProgramAxis_pfe_ShareRepurchaseAgreementwithCitibankMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">pfe:ShareRepurchaseAgreementwithCitibankMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-10-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q1Jan01-Jan31_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationCaseAxis_pfe_PfizerVersusMylanLaboratoriesandAccordHealthcareInc.Member_us-gaap_LitigationStatusAxis_us-gaap_JudicialRulingMember_us-gaap_ProductOrServiceAxis_pfe_ToviazMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:GainContingenciesByNatureAxis">pfe:PatentInfringementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">pfe:PfizerVersusMylanLaboratoriesandAccordHealthcareInc.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:ToviazMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-01-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q3Jul01-Jul31_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationCaseAxis_pfe_PfizerVersusMylanLaboratoriesandAccordHealthcareInc.Member_us-gaap_LitigationStatusAxis_us-gaap_JudicialRulingMember_us-gaap_ProductOrServiceAxis_pfe_ToviazMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:GainContingenciesByNatureAxis">pfe:PatentInfringementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">pfe:PfizerVersusMylanLaboratoriesandAccordHealthcareInc.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:ToviazMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-01</xbrli:startDate>
			<xbrli:endDate>2017-07-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q3_us-gaap_LitigationCaseAxis_pfe_StateofIllinoisVersusPfizerMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_LossContingenciesByNatureOfContingencyAxis_pfe_AverageWholesalePriceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">pfe:StateofIllinoisVersusPfizerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">pfe:AverageWholesalePriceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-10-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2015Q1March2015_us-gaap_LitigationCaseAxis_pfe_JanssenandNewYorkUniversityVersusHospiraCelltrionHealthcareandCelltrionInc.Member_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_ProductOrServiceAxis_pfe_InflectraMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">pfe:JanssenandNewYorkUniversityVersusHospiraCelltrionHealthcareandCelltrionInc.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:InflectraMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-03-01</xbrli:startDate>
			<xbrli:endDate>2015-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2015Q1MonthOfJanuary_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationCaseAxis_pfe_PfizerVersusMylanLaboratoriesandAccordHealthcareInc.Member_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_ProductOrServiceAxis_pfe_ToviazMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:GainContingenciesByNatureAxis">pfe:PatentInfringementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">pfe:PfizerVersusMylanLaboratoriesandAccordHealthcareInc.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:ToviazMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-01-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2015Q1SD_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationCaseAxis_pfe_PfizerVersusSeveralGenericManufacturersMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_us-gaap_ProductOrServiceAxis_pfe_ToviazMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:GainContingenciesByNatureAxis">pfe:PatentInfringementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">pfe:PfizerVersusSeveralGenericManufacturersMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:ToviazMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-06-01</xbrli:startDate>
			<xbrli:endDate>2015-07-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2016Q3Aug01-Aug31_us-gaap_LitigationCaseAxis_pfe_HospiraVersusParMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_ProductOrServiceAxis_pfe_PrecedexPremixMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">pfe:HospiraVersusParMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:PrecedexPremixMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-08-01</xbrli:startDate>
			<xbrli:endDate>2016-08-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q4Oct02-Oct31_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationCaseAxis_pfe_PfizerVersusBreckenridgeMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_ProductOrServiceAxis_pfe_XeljanzMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:GainContingenciesByNatureAxis">pfe:PatentInfringementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">pfe:PfizerVersusBreckenridgeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:XeljanzMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-10-02</xbrli:startDate>
			<xbrli:endDate>2017-10-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q1Feb06-Feb06_us-gaap_ShareRepurchaseProgramAxis_pfe_ShareRepurchaseAgreementwithCitibankMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">pfe:ShareRepurchaseAgreementwithCitibankMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-02-06</xbrli:startDate>
			<xbrli:endDate>2017-02-06</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q2Feb06-May19_us-gaap_ShareRepurchaseProgramAxis_pfe_ShareRepurchaseAgreementwithCitibankMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">pfe:ShareRepurchaseAgreementwithCitibankMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-02-06</xbrli:startDate>
			<xbrli:endDate>2017-05-19</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q1Feb02-Feb02_us-gaap_ShareRepurchaseProgramAxis_pfe_ShareRepurchaseAgreementwithCitibankMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">pfe:ShareRepurchaseAgreementwithCitibankMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-02-02</xbrli:startDate>
			<xbrli:endDate>2017-02-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q2Apr01-Apr30_us-gaap_LitigationCaseAxis_pfe_RegentsVersusMedivationMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_us-gaap_ProductOrServiceAxis_pfe_XtandiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">pfe:RegentsVersusMedivationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:XtandiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-04-01</xbrli:startDate>
			<xbrli:endDate>2017-04-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2015Q1March2015_us-gaap_LitigationCaseAxis_pfe_JanssenandNewYorkUniversityVersusHospiraCelltrionHealthcareandCelltrionInc.Member_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_us-gaap_ProductOrServiceAxis_pfe_InflectraMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">pfe:JanssenandNewYorkUniversityVersusHospiraCelltrionHealthcareandCelltrionInc.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:InflectraMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-03-01</xbrli:startDate>
			<xbrli:endDate>2015-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q3Sep01-Sep30_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationCaseAxis_pfe_WyethVersusSunMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_ProductOrServiceAxis_pfe_BosulifMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:GainContingenciesByNatureAxis">pfe:PatentInfringementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">pfe:WyethVersusSunMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:BosulifMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-09-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2016Q3Jul01-Jul31_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationCaseAxis_pfe_PfizerVersusMylanLaboratoriesandAccordHealthcareInc.Member_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_ProductOrServiceAxis_pfe_ToviazMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:GainContingenciesByNatureAxis">pfe:PatentInfringementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">pfe:PfizerVersusMylanLaboratoriesandAccordHealthcareInc.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:ToviazMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-01</xbrli:startDate>
			<xbrli:endDate>2016-07-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2015Q2June2015_us-gaap_LitigationCaseAxis_pfe_HospiraVersusAmnealPharmaceuticalsLLCMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_ProductOrServiceAxis_pfe_PrecedexPremixMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">pfe:HospiraVersusAmnealPharmaceuticalsLLCMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:PrecedexPremixMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-06-01</xbrli:startDate>
			<xbrli:endDate>2015-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2015Q3July2015_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationCaseAxis_pfe_PfizerVersusSeveralGenericManufacturersMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_ProductOrServiceAxis_pfe_ToviazMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:GainContingenciesByNatureAxis">pfe:PatentInfringementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">pfe:PfizerVersusSeveralGenericManufacturersMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:ToviazMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-07-01</xbrli:startDate>
			<xbrli:endDate>2015-07-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2015Q4_us-gaap_LitigationCaseAxis_pfe_HospiraVersusFreseniusMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_ProductOrServiceAxis_pfe_PrecedexPremixMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">pfe:HospiraVersusFreseniusMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:PrecedexPremixMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-12-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q1Feb01-Feb28_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationCaseAxis_pfe_PfizerVersusMylanLaboratoriesandAccordHealthcareInc.Member_us-gaap_LitigationStatusAxis_us-gaap_JudicialRulingMember_us-gaap_ProductOrServiceAxis_pfe_ToviazMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:GainContingenciesByNatureAxis">pfe:PatentInfringementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">pfe:PfizerVersusMylanLaboratoriesandAccordHealthcareInc.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:ToviazMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-02-01</xbrli:startDate>
			<xbrli:endDate>2017-02-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2016Q1Jan2016_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationCaseAxis_pfe_PfizerVersusMylanLaboratoriesandAccordHealthcareInc.Member_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_ProductOrServiceAxis_pfe_ToviazCompositionofmatterPatentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:GainContingenciesByNatureAxis">pfe:PatentInfringementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">pfe:PfizerVersusMylanLaboratoriesandAccordHealthcareInc.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:ToviazCompositionofmatterPatentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-01-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q3_us-gaap_ProductOrServiceAxis_pfe_MylotargMember_us-gaap_StatementScenarioAxis_us-gaap_ProFormaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:MylotargMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ProFormaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-10-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2013Q1MonthOfMarch_us-gaap_LossContingenciesByNatureOfContingencyAxis_pfe_EnvironmentalRemediationLitigationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">pfe:EnvironmentalRemediationLitigationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-03-01</xbrli:startDate>
			<xbrli:endDate>2013-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2016Q1Jan2016_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationCaseAxis_pfe_PfizerVersusMylanLaboratoriesandAccordHealthcareInc.Member_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_ProductOrServiceAxis_pfe_ToviazMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:GainContingenciesByNatureAxis">pfe:PatentInfringementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">pfe:PfizerVersusMylanLaboratoriesandAccordHealthcareInc.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:ToviazMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-01-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q4Oct02-Oct31_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_ProductOrServiceAxis_pfe_CelebrexMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:CelebrexMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-10-02</xbrli:startDate>
			<xbrli:endDate>2017-10-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2015Q1Jan1-31_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationCaseAxis_pfe_PfizerVersusMylanLaboratoriesandAccordHealthcareInc.Member_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_ProductOrServiceAxis_pfe_ToviazCompositionofmatterPatentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:GainContingenciesByNatureAxis">pfe:PatentInfringementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">pfe:PfizerVersusMylanLaboratoriesandAccordHealthcareInc.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:ToviazCompositionofmatterPatentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-01-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2015Q1March2015_us-gaap_LitigationCaseAxis_pfe_JanssenandNewYorkUniversityVersusHospiraCelltrionHealthcareandCelltrionInc.Member_us-gaap_ProductOrServiceAxis_pfe_InflectraMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">pfe:JanssenandNewYorkUniversityVersusHospiraCelltrionHealthcareandCelltrionInc.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:InflectraMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-03-01</xbrli:startDate>
			<xbrli:endDate>2015-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2013Q2MonthofJune_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationCaseAxis_pfe_PfizerVersusMylanLaboratoriesandAccordHealthcareInc.Member_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_ProductOrServiceAxis_pfe_ToviazMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:GainContingenciesByNatureAxis">pfe:PatentInfringementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">pfe:PfizerVersusMylanLaboratoriesandAccordHealthcareInc.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:ToviazMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-06-01</xbrli:startDate>
			<xbrli:endDate>2013-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q3Aug01-Aug10_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationCaseAxis_pfe_PfizerVersusMylanLaboratoriesandAccordHealthcareInc.Member_us-gaap_LitigationStatusAxis_us-gaap_JudicialRulingMember_us-gaap_ProductOrServiceAxis_pfe_ToviazMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:GainContingenciesByNatureAxis">pfe:PatentInfringementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">pfe:PfizerVersusMylanLaboratoriesandAccordHealthcareInc.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:ToviazMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-08-01</xbrli:startDate>
			<xbrli:endDate>2017-08-10</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2017Q1Feb06_us-gaap_ShareRepurchaseProgramAxis_pfe_ShareRepurchaseAgreementwithCitibankMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">pfe:ShareRepurchaseAgreementwithCitibankMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-02-06</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q3Jul01-Jul31_us-gaap_LitigationCaseAxis_pfe_PfizerVersusBMSE.R.SquibbSonsOnoPharmaceuticalandTasukuHonjoMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_LossContingenciesByNatureOfContingencyAxis_pfe_PatentInfringementMember_us-gaap_ProductOrServiceAxis_pfe_BavencioMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">pfe:PfizerVersusBMSE.R.SquibbSonsOnoPharmaceuticalandTasukuHonjoMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">pfe:PatentInfringementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:BavencioMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-01</xbrli:startDate>
			<xbrli:endDate>2017-07-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2013Q2MonthofJune_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationCaseAxis_pfe_PfizerVersusSeveralGenericManufacturersMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_ProductOrServiceAxis_pfe_ToviazCompositionofmatterPatentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:GainContingenciesByNatureAxis">pfe:PatentInfringementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">pfe:PfizerVersusSeveralGenericManufacturersMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:ToviazCompositionofmatterPatentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-06-01</xbrli:startDate>
			<xbrli:endDate>2013-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q3_us-gaap_LitigationCaseAxis_pfe_ClassActionVersusAmericanOpticalCorporationAndVariousOtherDefendantsMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_LossContingenciesByNatureOfContingencyAxis_us-gaap_DamagesFromProductDefectsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">pfe:ClassActionVersusAmericanOpticalCorporationAndVariousOtherDefendantsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:DamagesFromProductDefectsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-10-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q2May19-May19_us-gaap_ShareRepurchaseProgramAxis_pfe_ShareRepurchaseAgreementwithCitibankMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">pfe:ShareRepurchaseAgreementwithCitibankMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-05-19</xbrli:startDate>
			<xbrli:endDate>2017-05-19</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_us-gaap_ProductOrServiceAxis_pfe_MylotargMember_us-gaap_StatementScenarioAxis_us-gaap_ProFormaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:MylotargMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ProFormaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3QTD_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-04</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_us-gaap_CurrencyAxis_currency_EUR_us-gaap_StatementGeographicalAxis_pfe_DevelopedEuropeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">pfe:DevelopedEuropeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3QTD_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_HISMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pfe:HISMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-04</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_us-gaap_CurrencyAxis_currency_EUR_us-gaap_StatementGeographicalAxis_pfe_DevelopedEuropeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">pfe:DevelopedEuropeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-03</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-03</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_HISMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pfe:HISMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-03</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_us-gaap_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_HISMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pfe:HISMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_HISMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pfe:HISMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3QTD_us-gaap_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-04</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_us-gaap_CurrencyAxis_currency_EUR_us-gaap_StatementGeographicalAxis_pfe_DevelopedEuropeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">pfe:DevelopedEuropeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-03</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_CertainSignificantItemsMember_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:OtherSegmentReconcilingItemsAxis">pfe:CertainSignificantItemsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_OtherUnallocatedMember_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:OtherSegmentReconcilingItemsAxis">pfe:OtherUnallocatedMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_OtherUnallocatedMember_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:OtherSegmentReconcilingItemsAxis">pfe:OtherUnallocatedMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-03</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_PurchaseAccountingAdjustmentsMember_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:OtherSegmentReconcilingItemsAxis">pfe:PurchaseAccountingAdjustmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_PurchaseAccountingAdjustmentsMember_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:OtherSegmentReconcilingItemsAxis">pfe:PurchaseAccountingAdjustmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_CertainSignificantItemsMember_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:OtherSegmentReconcilingItemsAxis">pfe:CertainSignificantItemsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3QTD_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-04</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_PurchaseAccountingAdjustmentsMember_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:OtherSegmentReconcilingItemsAxis">pfe:PurchaseAccountingAdjustmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-03</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_BusinessCombinationsAcquisitionRelatedCostsMember_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:OtherSegmentReconcilingItemsAxis">pfe:BusinessCombinationsAcquisitionRelatedCostsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-03</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_BusinessCombinationsAcquisitionRelatedCostsMember_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:OtherSegmentReconcilingItemsAxis">pfe:BusinessCombinationsAcquisitionRelatedCostsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3QTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_PurchaseAccountingAdjustmentsMember_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:OtherSegmentReconcilingItemsAxis">pfe:PurchaseAccountingAdjustmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-04</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_OtherUnallocatedMember_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:OtherSegmentReconcilingItemsAxis">pfe:OtherUnallocatedMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_BusinessCombinationsAcquisitionRelatedCostsMember_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:OtherSegmentReconcilingItemsAxis">pfe:BusinessCombinationsAcquisitionRelatedCostsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_CertainSignificantItemsMember_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:OtherSegmentReconcilingItemsAxis">pfe:CertainSignificantItemsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-03</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3QTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_BusinessCombinationsAcquisitionRelatedCostsMember_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:OtherSegmentReconcilingItemsAxis">pfe:BusinessCombinationsAcquisitionRelatedCostsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-04</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3QTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_CertainSignificantItemsMember_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:OtherSegmentReconcilingItemsAxis">pfe:CertainSignificantItemsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-04</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3QTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_OtherUnallocatedMember_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:OtherSegmentReconcilingItemsAxis">pfe:OtherUnallocatedMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-04</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_PremarinFamilyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:LegacyEstablishedProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:PremarinFamilyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_BiosimilarsMember_us-gaap_ProductOrServiceAxis_pfe_InflectraRemsimaMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:BiosimilarsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:InflectraRemsimaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_RareDiseaseMember_us-gaap_ProductOrServiceAxis_pfe_AllOtherRareDiseaseProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:AllOtherRareDiseaseProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-03</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_us-gaap_ProductOrServiceAxis_pfe_AllianceBiopharmaceuticalsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthandEssentialHealthMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:AllianceBiopharmaceuticalsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthandEssentialHealthMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_CentreOneMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:CentreOneMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-04</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_OncologyMember_us-gaap_ProductOrServiceAxis_pfe_BosulifMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:OncologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:BosulifMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InternalMedicineMember_us-gaap_ProductOrServiceAxis_pfe_ToviazMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:ToviazMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-04</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_SterileInjectablePharmaceuticalsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:SterileInjectablePharmaceuticalsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InternalMedicineMember_us-gaap_ProductOrServiceAxis_pfe_ChantixChampixMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:ChantixChampixMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:VaccinesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InflammationandImmunologyMember_us-gaap_ProductOrServiceAxis_pfe_XeljanzMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:XeljanzMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_SterileInjectablePharmaceuticalsMember_us-gaap_ProductOrServiceAxis_pfe_SulperazonMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:SterileInjectablePharmaceuticalsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:SulperazonMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-04</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_ProductOrServiceAxis_pfe_VfendMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:PeriLOEProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:VfendMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_ProductOrServiceAxis_pfe_CelebrexMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:PeriLOEProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:CelebrexMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-03</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_PremarinFamilyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:LegacyEstablishedProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:PremarinFamilyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-04</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthandEssentialHealthMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthandEssentialHealthMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-03</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_SterileInjectablePharmaceuticalsMember_us-gaap_ProductOrServiceAxis_pfe_AllOtherSterileInjectablePharmaceuticalsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:SterileInjectablePharmaceuticalsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:AllOtherSterileInjectablePharmaceuticalsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-03</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3QTD_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthandEssentialHealthMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthandEssentialHealthMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-04</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:VaccinesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-03</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InflammationandImmunologyMember_us-gaap_ProductOrServiceAxis_pfe_EnbrelMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:EnbrelMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-03</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-04</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_HospiraInfusionSystemsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:HospiraInfusionSystemsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_RareDiseaseMember_us-gaap_ProductOrServiceAxis_pfe_SomavertMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:SomavertMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_SterileInjectablePharmaceuticalsMember_us-gaap_ProductOrServiceAxis_pfe_TygacilMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:SterileInjectablePharmaceuticalsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:TygacilMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-03</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_ProductOrServiceAxis_pfe_AllOtherPeriLOEProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:PeriLOEProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:AllOtherPeriLOEProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:LegacyEstablishedProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_SterileInjectablePharmaceuticalsMember_us-gaap_ProductOrServiceAxis_pfe_SulperazonMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:SterileInjectablePharmaceuticalsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:SulperazonMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_RareDiseaseMember_us-gaap_ProductOrServiceAxis_pfe_BeneFIXMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:BeneFIXMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-03</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_CentreOneMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:CentreOneMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_OncologyMember_us-gaap_ProductOrServiceAxis_pfe_XtandiAllianceMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:OncologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:XtandiAllianceMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-03</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InternalMedicineMember_us-gaap_ProductOrServiceAxis_pfe_ViagraMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:ViagraMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-03</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_VaccinesMember_us-gaap_ProductOrServiceAxis_pfe_FSMEIMMUNTicoVacMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:VaccinesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:FSMEIMMUNTicoVacMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InflammationandImmunologyMember_us-gaap_ProductOrServiceAxis_pfe_XeljanzMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:XeljanzMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-04</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_EffexorMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:LegacyEstablishedProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:EffexorMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_ConsumerHealthcareMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:ConsumerHealthcareMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-04</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InternalMedicineMember_us-gaap_ProductOrServiceAxis_pfe_ChantixChampixMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:ChantixChampixMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_SterileInjectablePharmaceuticalsMember_us-gaap_ProductOrServiceAxis_pfe_PrecedexMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:SterileInjectablePharmaceuticalsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:PrecedexMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-04</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_OncologyMember_us-gaap_ProductOrServiceAxis_pfe_OtherOncologyProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:OncologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:OtherOncologyProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:LegacyEstablishedProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-03</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:OncologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-04</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-04</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_LipitorMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:LegacyEstablishedProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:LipitorMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-04</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_LipitorMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:LegacyEstablishedProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:LipitorMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-03</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:PeriLOEProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_OtherLegacyEstablishedProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:LegacyEstablishedProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:OtherLegacyEstablishedProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_EffexorMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:LegacyEstablishedProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:EffexorMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-03</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_ProductOrServiceAxis_pfe_VfendMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:PeriLOEProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:VfendMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-03</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_SterileInjectablePharmaceuticalsMember_us-gaap_ProductOrServiceAxis_pfe_AllOtherSterileInjectablePharmaceuticalsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:SterileInjectablePharmaceuticalsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:AllOtherSterileInjectablePharmaceuticalsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_VaccinesMember_us-gaap_ProductOrServiceAxis_pfe_PrevnarPrevenarFamilyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:VaccinesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:PrevnarPrevenarFamilyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_OncologyMember_us-gaap_ProductOrServiceAxis_pfe_IbranceMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:OncologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:IbranceMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-03</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_ZoloftMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:LegacyEstablishedProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:ZoloftMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-04</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_VaccinesMember_us-gaap_ProductOrServiceAxis_pfe_OtherVaccinesProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:VaccinesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:OtherVaccinesProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-03</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_ProductOrServiceAxis_pfe_ViagraMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:PeriLOEProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:ViagraMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-03</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_HospiraInfusionSystemsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:HospiraInfusionSystemsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-03</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_OncologyMember_us-gaap_ProductOrServiceAxis_pfe_OtherOncologyProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:OncologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:OtherOncologyProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-04</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InflammationandImmunologyMember_us-gaap_ProductOrServiceAxis_pfe_AllOtherInflammationandImmunologyProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:AllOtherInflammationandImmunologyProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_SterileInjectablePharmaceuticalsMember_us-gaap_ProductOrServiceAxis_pfe_PrecedexMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:SterileInjectablePharmaceuticalsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:PrecedexMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-03</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_SterileInjectablePharmaceuticalsMember_us-gaap_ProductOrServiceAxis_pfe_TygacilMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:SterileInjectablePharmaceuticalsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:TygacilMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-04</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_BiosimilarsMember_us-gaap_ProductOrServiceAxis_pfe_InflectraRemsimaMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:BiosimilarsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:InflectraRemsimaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-04</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_EpiPenMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:LegacyEstablishedProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:EpiPenMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_ProductOrServiceAxis_pfe_PristiqMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:PeriLOEProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:PristiqMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-04</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_ZoloftMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:LegacyEstablishedProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:ZoloftMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InternalMedicineMember_us-gaap_ProductOrServiceAxis_pfe_LyricaMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:LyricaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-03</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_XanaxXanaxXRMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:LegacyEstablishedProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:XanaxXanaxXRMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-04</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:PeriLOEProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_SterileInjectablePharmaceuticalsMember_us-gaap_ProductOrServiceAxis_pfe_PrecedexMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:SterileInjectablePharmaceuticalsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:PrecedexMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_PremarinFamilyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:LegacyEstablishedProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:PremarinFamilyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-03</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_XanaxXanaxXRMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:LegacyEstablishedProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:XanaxXanaxXRMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-03</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_SterileInjectablePharmaceuticalsMember_us-gaap_ProductOrServiceAxis_pfe_AllOtherSterileInjectablePharmaceuticalsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:SterileInjectablePharmaceuticalsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:AllOtherSterileInjectablePharmaceuticalsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InternalMedicineMember_us-gaap_ProductOrServiceAxis_pfe_BMP2Member_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:BMP2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-04</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InternalMedicineMember_us-gaap_ProductOrServiceAxis_pfe_AllOtherInternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:AllOtherInternalMedicineMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InternalMedicineMember_us-gaap_ProductOrServiceAxis_pfe_ViagraMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:ViagraMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_BiosimilarsMember_us-gaap_ProductOrServiceAxis_pfe_InflectraRemsimaMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:BiosimilarsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:InflectraRemsimaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-03</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_VaccinesMember_us-gaap_ProductOrServiceAxis_pfe_FSMEIMMUNTicoVacMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:VaccinesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:FSMEIMMUNTicoVacMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-04</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_OncologyMember_us-gaap_ProductOrServiceAxis_pfe_OtherOncologyProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:OncologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:OtherOncologyProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-04</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_EpiPenMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:LegacyEstablishedProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:EpiPenMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-04</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_us-gaap_ProductOrServiceAxis_pfe_ViagraMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthandEssentialHealthMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:ViagraMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthandEssentialHealthMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_OncologyMember_us-gaap_ProductOrServiceAxis_pfe_BosulifMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:OncologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:BosulifMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-04</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_EpiPenMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:LegacyEstablishedProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:EpiPenMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_ProductOrServiceAxis_pfe_AllOtherPeriLOEProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:PeriLOEProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:AllOtherPeriLOEProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-03</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_SterileInjectablePharmaceuticalsMember_us-gaap_ProductOrServiceAxis_pfe_FragminMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:SterileInjectablePharmaceuticalsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:FragminMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-03</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-03</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InternalMedicineMember_us-gaap_ProductOrServiceAxis_pfe_EliquisMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:EliquisMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-03</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_ConsumerHealthcareMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:ConsumerHealthcareMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-03</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_ProductOrServiceAxis_pfe_CelebrexMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:PeriLOEProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:CelebrexMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_OncologyMember_us-gaap_ProductOrServiceAxis_pfe_XtandiAllianceMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:OncologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:XtandiAllianceMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InflammationandImmunologyMember_us-gaap_ProductOrServiceAxis_pfe_EucrisaMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:EucrisaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InternalMedicineMember_us-gaap_ProductOrServiceAxis_pfe_EliquisMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:EliquisMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-04</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InflammationandImmunologyMember_us-gaap_ProductOrServiceAxis_pfe_XeljanzMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:XeljanzMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_us-gaap_ProductOrServiceAxis_pfe_LyricaMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthandEssentialHealthMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:LyricaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthandEssentialHealthMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-03</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InflammationandImmunologyMember_us-gaap_ProductOrServiceAxis_pfe_EnbrelMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:EnbrelMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InternalMedicineMember_us-gaap_ProductOrServiceAxis_pfe_ToviazMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:ToviazMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InternalMedicineMember_us-gaap_ProductOrServiceAxis_pfe_LyricaMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:LyricaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-04</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_ProductOrServiceAxis_pfe_ViagraMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:PeriLOEProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:ViagraMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_LipitorMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:LegacyEstablishedProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:LipitorMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_RareDiseaseMember_us-gaap_ProductOrServiceAxis_pfe_AllOtherRareDiseaseProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:AllOtherRareDiseaseProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-04</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_ZithromaxZmaxMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:LegacyEstablishedProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:ZithromaxZmaxMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-03</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InflammationandImmunologyMember_us-gaap_ProductOrServiceAxis_pfe_AllOtherInflammationandImmunologyProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:AllOtherInflammationandImmunologyProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-03</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:OncologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_SterileInjectablePharmaceuticalsMember_us-gaap_ProductOrServiceAxis_pfe_AllOtherSterileInjectablePharmaceuticalsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:SterileInjectablePharmaceuticalsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:AllOtherSterileInjectablePharmaceuticalsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-04</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_ProductOrServiceAxis_pfe_ZyvoxMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:PeriLOEProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:ZyvoxMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_OtherLegacyEstablishedProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:LegacyEstablishedProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:OtherLegacyEstablishedProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-04</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_OncologyMember_us-gaap_ProductOrServiceAxis_pfe_OtherOncologyProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:OncologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:OtherOncologyProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-03</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_BiosimilarsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:BiosimilarsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_BiosimilarsMember_us-gaap_ProductOrServiceAxis_pfe_AllOtherBiosimilarsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:BiosimilarsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:AllOtherBiosimilarsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_OncologyMember_us-gaap_ProductOrServiceAxis_pfe_XtandiAllianceMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:OncologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:XtandiAllianceMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_RareDiseaseMember_us-gaap_ProductOrServiceAxis_pfe_AllOtherRareDiseaseProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:AllOtherRareDiseaseProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_BiosimilarsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:BiosimilarsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-04</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_NorvascMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:LegacyEstablishedProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:NorvascMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-03</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_BiosimilarsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:BiosimilarsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InternalMedicineMember_us-gaap_ProductOrServiceAxis_pfe_BMP2Member_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:BMP2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_HospiraInfusionSystemsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:HospiraInfusionSystemsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_ProductOrServiceAxis_pfe_ZyvoxMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:PeriLOEProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:ZyvoxMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-03</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_RareDiseaseMember_us-gaap_ProductOrServiceAxis_pfe_GenotropinMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:GenotropinMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-03</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_ProductOrServiceAxis_pfe_AllOtherPeriLOEProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:PeriLOEProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:AllOtherPeriLOEProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-04</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_OtherLegacyEstablishedProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:LegacyEstablishedProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:OtherLegacyEstablishedProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-03</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_SterileInjectablePharmaceuticalsMember_us-gaap_ProductOrServiceAxis_pfe_MedrolMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:SterileInjectablePharmaceuticalsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:MedrolMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-03</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_OncologyMember_us-gaap_ProductOrServiceAxis_pfe_BosulifMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:OncologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:BosulifMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-03</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-04</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_OncologyMember_us-gaap_ProductOrServiceAxis_pfe_InlytaMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:OncologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:InlytaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_ProductOrServiceAxis_pfe_VfendMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:PeriLOEProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:VfendMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InternalMedicineMember_us-gaap_ProductOrServiceAxis_pfe_ToviazMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:ToviazMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_SterileInjectablePharmaceuticalsMember_us-gaap_ProductOrServiceAxis_pfe_MedrolMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:SterileInjectablePharmaceuticalsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:MedrolMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-04</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_NorvascMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:LegacyEstablishedProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:NorvascMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_OncologyMember_us-gaap_ProductOrServiceAxis_pfe_SutentMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:OncologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:SutentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_us-gaap_ProductOrServiceAxis_pfe_LyricaMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthandEssentialHealthMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:LyricaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthandEssentialHealthMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_OncologyMember_us-gaap_ProductOrServiceAxis_pfe_IbranceMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:OncologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:IbranceMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-04</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_SterileInjectablePharmaceuticalsMember_us-gaap_ProductOrServiceAxis_pfe_FragminMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:SterileInjectablePharmaceuticalsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:FragminMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_CentreOneMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:CentreOneMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_VaccinesMember_us-gaap_ProductOrServiceAxis_pfe_FSMEIMMUNTicoVacMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:VaccinesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:FSMEIMMUNTicoVacMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-03</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_NorvascMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:LegacyEstablishedProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:NorvascMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_RareDiseaseMember_us-gaap_ProductOrServiceAxis_pfe_ReFactoAfXynthaMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:ReFactoAfXynthaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3QTD_us-gaap_ProductOrServiceAxis_pfe_ViagraMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthandEssentialHealthMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:ViagraMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthandEssentialHealthMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-04</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_ProductOrServiceAxis_pfe_ViagraMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:PeriLOEProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:ViagraMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-04</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_RareDiseaseMember_us-gaap_ProductOrServiceAxis_pfe_BeneFIXMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:BeneFIXMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InflammationandImmunologyMember_us-gaap_ProductOrServiceAxis_pfe_EnbrelMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:EnbrelMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-04</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_ProductOrServiceAxis_pfe_ZyvoxMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:PeriLOEProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:ZyvoxMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_BiosimilarsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:BiosimilarsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-03</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_ConsumerHealthcareMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:ConsumerHealthcareMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3QTD_us-gaap_ProductOrServiceAxis_pfe_LyricaMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthandEssentialHealthMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:LyricaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthandEssentialHealthMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-04</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InternalMedicineMember_us-gaap_ProductOrServiceAxis_pfe_AllOtherInternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:AllOtherInternalMedicineMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-04</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InternalMedicineMember_us-gaap_ProductOrServiceAxis_pfe_ViagraMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:ViagraMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:VaccinesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_us-gaap_ProductOrServiceAxis_pfe_AllianceBiopharmaceuticalsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthandEssentialHealthMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:AllianceBiopharmaceuticalsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthandEssentialHealthMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-03</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_ProductOrServiceAxis_pfe_PristiqMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:PeriLOEProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:PristiqMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:PeriLOEProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-04</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_RareDiseaseMember_us-gaap_ProductOrServiceAxis_pfe_GenotropinMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:GenotropinMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InflammationandImmunologyMember_us-gaap_ProductOrServiceAxis_pfe_EucrisaMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:EucrisaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-03</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_OncologyMember_us-gaap_ProductOrServiceAxis_pfe_SutentMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:OncologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:SutentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_XanaxXanaxXRMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:LegacyEstablishedProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:XanaxXanaxXRMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_ProductOrServiceAxis_pfe_LyricaMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:PeriLOEProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:LyricaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-03</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_ProductOrServiceAxis_pfe_AllOtherPeriLOEProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:PeriLOEProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:AllOtherPeriLOEProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_SterileInjectablePharmaceuticalsMember_us-gaap_ProductOrServiceAxis_pfe_PrecedexMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:SterileInjectablePharmaceuticalsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:PrecedexMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthandEssentialHealthMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthandEssentialHealthMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InternalMedicineMember_us-gaap_ProductOrServiceAxis_pfe_LyricaMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:LyricaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InternalMedicineMember_us-gaap_ProductOrServiceAxis_pfe_ToviazMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:ToviazMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-03</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_VaccinesMember_us-gaap_ProductOrServiceAxis_pfe_OtherVaccinesProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:VaccinesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:OtherVaccinesProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_ProductOrServiceAxis_pfe_RevatioMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:PeriLOEProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:RevatioMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_RareDiseaseMember_us-gaap_ProductOrServiceAxis_pfe_GenotropinMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:GenotropinMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_OncologyMember_us-gaap_ProductOrServiceAxis_pfe_XalkoriMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:OncologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:XalkoriMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_XalatanXalacomMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:LegacyEstablishedProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:XalatanXalacomMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-04</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_ZoloftMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:LegacyEstablishedProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:ZoloftMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_SterileInjectablePharmaceuticalsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:SterileInjectablePharmaceuticalsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-03</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_BiosimilarsMember_us-gaap_ProductOrServiceAxis_pfe_AllOtherBiosimilarsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:BiosimilarsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:AllOtherBiosimilarsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-03</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_EpiPenMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:LegacyEstablishedProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:EpiPenMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-03</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_SterileInjectablePharmaceuticalsMember_us-gaap_ProductOrServiceAxis_pfe_FragminMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:SterileInjectablePharmaceuticalsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:FragminMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-04</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_RelpaxMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:LegacyEstablishedProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:RelpaxMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InflammationandImmunologyMember_us-gaap_ProductOrServiceAxis_pfe_AllOtherInflammationandImmunologyProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:AllOtherInflammationandImmunologyProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-04</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InternalMedicineMember_us-gaap_ProductOrServiceAxis_pfe_EliquisMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:EliquisMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_ProductOrServiceAxis_pfe_VfendMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:PeriLOEProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:VfendMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-04</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_RelpaxMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:LegacyEstablishedProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:RelpaxMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-04</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_RareDiseaseMember_us-gaap_ProductOrServiceAxis_pfe_ReFactoAfXynthaMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:ReFactoAfXynthaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-04</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_RareDiseaseMember_us-gaap_ProductOrServiceAxis_pfe_ReFactoAfXynthaMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:ReFactoAfXynthaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_OncologyMember_us-gaap_ProductOrServiceAxis_pfe_XtandiAllianceMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:OncologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:XtandiAllianceMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-04</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_OncologyMember_us-gaap_ProductOrServiceAxis_pfe_SutentMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:OncologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:SutentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-03</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_ProductOrServiceAxis_pfe_RevatioMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:PeriLOEProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:RevatioMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_OncologyMember_us-gaap_ProductOrServiceAxis_pfe_SutentMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:OncologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:SutentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-04</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InflammationandImmunologyMember_us-gaap_ProductOrServiceAxis_pfe_AllOtherInflammationandImmunologyProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:AllOtherInflammationandImmunologyProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InflammationandImmunologyMember_us-gaap_ProductOrServiceAxis_pfe_EucrisaMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:EucrisaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-04</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_OncologyMember_us-gaap_ProductOrServiceAxis_pfe_XalkoriMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:OncologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:XalkoriMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-04</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-03</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_PremarinFamilyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:LegacyEstablishedProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:PremarinFamilyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InflammationandImmunologyMember_us-gaap_ProductOrServiceAxis_pfe_EnbrelMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:EnbrelMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_us-gaap_ProductOrServiceAxis_pfe_AllianceBiopharmaceuticalsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthandEssentialHealthMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:AllianceBiopharmaceuticalsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthandEssentialHealthMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_VaccinesMember_us-gaap_ProductOrServiceAxis_pfe_OtherVaccinesProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:VaccinesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:OtherVaccinesProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-04</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_SterileInjectablePharmaceuticalsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:SterileInjectablePharmaceuticalsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-04</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_SterileInjectablePharmaceuticalsMember_us-gaap_ProductOrServiceAxis_pfe_FragminMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:SterileInjectablePharmaceuticalsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:FragminMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_HospiraInfusionSystemsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:HospiraInfusionSystemsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-04</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_ZithromaxZmaxMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:LegacyEstablishedProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:ZithromaxZmaxMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-04</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_SterileInjectablePharmaceuticalsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:SterileInjectablePharmaceuticalsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_BiosimilarsMember_us-gaap_ProductOrServiceAxis_pfe_AllOtherBiosimilarsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:BiosimilarsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:AllOtherBiosimilarsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InflammationandImmunologyMember_us-gaap_ProductOrServiceAxis_pfe_XeljanzMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:XeljanzMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-03</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:OncologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_RareDiseaseMember_us-gaap_ProductOrServiceAxis_pfe_BeneFIXMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:BeneFIXMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-04</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_ProductOrServiceAxis_pfe_LyricaMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:PeriLOEProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:LyricaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-04</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InternalMedicineMember_us-gaap_ProductOrServiceAxis_pfe_ChantixChampixMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:ChantixChampixMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-03</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_RelpaxMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:LegacyEstablishedProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:RelpaxMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_BiosimilarsMember_us-gaap_ProductOrServiceAxis_pfe_AllOtherBiosimilarsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:BiosimilarsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:AllOtherBiosimilarsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-04</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_OncologyMember_us-gaap_ProductOrServiceAxis_pfe_BosulifMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:OncologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:BosulifMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_VaccinesMember_us-gaap_ProductOrServiceAxis_pfe_OtherVaccinesProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:VaccinesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:OtherVaccinesProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:PeriLOEProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-03</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_VaccinesMember_us-gaap_ProductOrServiceAxis_pfe_PrevnarPrevenarFamilyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:VaccinesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:PrevnarPrevenarFamilyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-04</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:LegacyEstablishedProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_RareDiseaseMember_us-gaap_ProductOrServiceAxis_pfe_SomavertMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:SomavertMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_ProductOrServiceAxis_pfe_LyricaMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:PeriLOEProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:LyricaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-03</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthandEssentialHealthMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthandEssentialHealthMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3QTD_us-gaap_ProductOrServiceAxis_pfe_AllianceBiopharmaceuticalsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthandEssentialHealthMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:AllianceBiopharmaceuticalsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthandEssentialHealthMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-04</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_ZithromaxZmaxMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:LegacyEstablishedProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:ZithromaxZmaxMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_OncologyMember_us-gaap_ProductOrServiceAxis_pfe_IbranceMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:OncologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:IbranceMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_XalatanXalacomMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:LegacyEstablishedProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:XalatanXalacomMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-03</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_SterileInjectablePharmaceuticalsMember_us-gaap_ProductOrServiceAxis_pfe_SulperazonMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:SterileInjectablePharmaceuticalsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:SulperazonMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_ZoloftMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:LegacyEstablishedProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:ZoloftMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-03</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_OncologyMember_us-gaap_ProductOrServiceAxis_pfe_IbranceMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:OncologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:IbranceMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InternalMedicineMember_us-gaap_ProductOrServiceAxis_pfe_AllOtherInternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:AllOtherInternalMedicineMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_EffexorMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:LegacyEstablishedProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:EffexorMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_OncologyMember_us-gaap_ProductOrServiceAxis_pfe_XalkoriMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:OncologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:XalkoriMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_ProductOrServiceAxis_pfe_RevatioMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:PeriLOEProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:RevatioMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-04</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_SterileInjectablePharmaceuticalsMember_us-gaap_ProductOrServiceAxis_pfe_MedrolMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:SterileInjectablePharmaceuticalsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:MedrolMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_RareDiseaseMember_us-gaap_ProductOrServiceAxis_pfe_SomavertMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:SomavertMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-04</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_ProductOrServiceAxis_pfe_CelebrexMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:PeriLOEProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:CelebrexMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-04</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InternalMedicineMember_us-gaap_ProductOrServiceAxis_pfe_ViagraMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:ViagraMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-04</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_OncologyMember_us-gaap_ProductOrServiceAxis_pfe_InlytaMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:OncologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:InlytaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_SterileInjectablePharmaceuticalsMember_us-gaap_ProductOrServiceAxis_pfe_MedrolMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:SterileInjectablePharmaceuticalsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:MedrolMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_RareDiseaseMember_us-gaap_ProductOrServiceAxis_pfe_GenotropinMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:GenotropinMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-04</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-03</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_OncologyMember_us-gaap_ProductOrServiceAxis_pfe_InlytaMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:OncologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:InlytaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-03</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InternalMedicineMember_us-gaap_ProductOrServiceAxis_pfe_AllOtherInternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:AllOtherInternalMedicineMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-03</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_XalatanXalacomMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:LegacyEstablishedProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:XalatanXalacomMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_OncologyMember_us-gaap_ProductOrServiceAxis_pfe_InlytaMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:OncologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:InlytaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-04</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InternalMedicineMember_us-gaap_ProductOrServiceAxis_pfe_BMP2Member_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:BMP2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_ProductOrServiceAxis_pfe_PristiqMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:PeriLOEProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:PristiqMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-03</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_BiosimilarsMember_us-gaap_ProductOrServiceAxis_pfe_InflectraRemsimaMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:BiosimilarsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:InflectraRemsimaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_us-gaap_ProductOrServiceAxis_pfe_ViagraMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthandEssentialHealthMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:ViagraMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthandEssentialHealthMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_ProductOrServiceAxis_pfe_CelebrexMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:PeriLOEProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:CelebrexMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_VaccinesMember_us-gaap_ProductOrServiceAxis_pfe_PrevnarPrevenarFamilyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:VaccinesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:PrevnarPrevenarFamilyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-03</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_ProductOrServiceAxis_pfe_ZyvoxMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:PeriLOEProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:ZyvoxMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-04</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InflammationandImmunologyMember_us-gaap_ProductOrServiceAxis_pfe_EucrisaMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:EucrisaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_NorvascMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:LegacyEstablishedProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:NorvascMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-04</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_OncologyMember_us-gaap_ProductOrServiceAxis_pfe_XalkoriMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:OncologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:XalkoriMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-03</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_SterileInjectablePharmaceuticalsMember_us-gaap_ProductOrServiceAxis_pfe_SulperazonMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:SterileInjectablePharmaceuticalsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:SulperazonMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-03</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_VaccinesMember_us-gaap_ProductOrServiceAxis_pfe_FSMEIMMUNTicoVacMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:VaccinesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:FSMEIMMUNTicoVacMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-03</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_ConsumerHealthcareMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:ConsumerHealthcareMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_RareDiseaseMember_us-gaap_ProductOrServiceAxis_pfe_SomavertMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:SomavertMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-03</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InternalMedicineMember_us-gaap_ProductOrServiceAxis_pfe_BMP2Member_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:BMP2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-03</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_RareDiseaseMember_us-gaap_ProductOrServiceAxis_pfe_AllOtherRareDiseaseProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:AllOtherRareDiseaseProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_VaccinesMember_us-gaap_ProductOrServiceAxis_pfe_PrevnarPrevenarFamilyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:VaccinesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:PrevnarPrevenarFamilyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_ProductOrServiceAxis_pfe_ViagraMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:PeriLOEProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:ViagraMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_ProductOrServiceAxis_pfe_PristiqMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:PeriLOEProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:PristiqMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_RelpaxMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:LegacyEstablishedProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:RelpaxMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-03</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_ProductOrServiceAxis_pfe_RevatioMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:PeriLOEProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:RevatioMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-03</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_SterileInjectablePharmaceuticalsMember_us-gaap_ProductOrServiceAxis_pfe_TygacilMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:SterileInjectablePharmaceuticalsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:TygacilMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:LegacyEstablishedProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-04</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_us-gaap_ProductOrServiceAxis_pfe_LyricaMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthandEssentialHealthMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:LyricaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthandEssentialHealthMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InternalMedicineMember_us-gaap_ProductOrServiceAxis_pfe_LyricaMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:LyricaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InternalMedicineMember_us-gaap_ProductOrServiceAxis_pfe_EliquisMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:EliquisMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_CentreOneMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:CentreOneMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-03</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InternalMedicineMember_us-gaap_ProductOrServiceAxis_pfe_ChantixChampixMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:ChantixChampixMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-04</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_OtherLegacyEstablishedProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:LegacyEstablishedProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:OtherLegacyEstablishedProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_XanaxXanaxXRMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:LegacyEstablishedProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:XanaxXanaxXRMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_us-gaap_ProductOrServiceAxis_pfe_ViagraMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthandEssentialHealthMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:ViagraMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthandEssentialHealthMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-03</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:OncologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-03</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:VaccinesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-04</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_XalatanXalacomMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:LegacyEstablishedProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:XalatanXalacomMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_RareDiseaseMember_us-gaap_ProductOrServiceAxis_pfe_BeneFIXMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:BeneFIXMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_ZithromaxZmaxMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:LegacyEstablishedProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:ZithromaxZmaxMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-04</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_RareDiseaseMember_us-gaap_ProductOrServiceAxis_pfe_ReFactoAfXynthaMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:ReFactoAfXynthaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-03</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_ProductOrServiceAxis_pfe_LyricaMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:PeriLOEProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:LyricaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_SterileInjectablePharmaceuticalsMember_us-gaap_ProductOrServiceAxis_pfe_TygacilMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:SterileInjectablePharmaceuticalsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:TygacilMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_LipitorMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:LegacyEstablishedProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:LipitorMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_EffexorMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:LegacyEstablishedProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:EffexorMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-04</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_us-gaap_StatementGeographicalAxis_pfe_DevelopedEuropeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">pfe:DevelopedEuropeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_us-gaap_StatementGeographicalAxis_pfe_EmergingMarketsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">pfe:EmergingMarketsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_us-gaap_StatementGeographicalAxis_pfe_DevelopedEuropeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">pfe:DevelopedEuropeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-03</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_us-gaap_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-03</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_us-gaap_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_us-gaap_StatementGeographicalAxis_pfe_EmergingMarketsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">pfe:EmergingMarketsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-03</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3QTD_us-gaap_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-04</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_us-gaap_StatementGeographicalAxis_pfe_DevelopedRestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">pfe:DevelopedRestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_us-gaap_StatementGeographicalAxis_pfe_DevelopedRestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">pfe:DevelopedRestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-03</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_us-gaap_StatementGeographicalAxis_pfe_DevelopedEuropeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">pfe:DevelopedEuropeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_us-gaap_StatementGeographicalAxis_pfe_DevelopedRestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">pfe:DevelopedRestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3QTD_us-gaap_StatementGeographicalAxis_pfe_DevelopedEuropeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">pfe:DevelopedEuropeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-04</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3QTD_us-gaap_StatementGeographicalAxis_pfe_EmergingMarketsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">pfe:EmergingMarketsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-04</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_us-gaap_StatementGeographicalAxis_pfe_EmergingMarketsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">pfe:EmergingMarketsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3QTD_us-gaap_StatementGeographicalAxis_pfe_DevelopedRestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">pfe:DevelopedRestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-04</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_us-gaap_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3QTD_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioAdjustmentMember_us-gaap_SubsegmentsAxis_pfe_PfizersWorldwideResearchandDevelopmentandPfizersGlobalProductDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioAdjustmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">pfe:PfizersWorldwideResearchandDevelopmentandPfizersGlobalProductDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-04</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3QTD_us-gaap_CurrencyAxis_currency_EUR_us-gaap_StatementGeographicalAxis_pfe_DevelopedEuropeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">pfe:DevelopedEuropeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-04</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3YTD_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioAdjustmentMember_us-gaap_SubsegmentsAxis_pfe_PfizersWorldwideResearchandDevelopmentandPfizersGlobalProductDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioAdjustmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">pfe:PfizersWorldwideResearchandDevelopmentandPfizersGlobalProductDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-10-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:unit id="shares">
		<xbrli:measure>xbrli:shares</xbrli:measure>
	</xbrli:unit><xbrli:unit id="Operating_Segment">
		<xbrli:measure>pfe:Operating_Segment</xbrli:measure>
	</xbrli:unit><xbrli:unit id="number">
		<xbrli:measure>xbrli:pure</xbrli:measure>
	</xbrli:unit><xbrli:unit id="usd">
		<xbrli:measure>iso4217:USD</xbrli:measure>
	</xbrli:unit><xbrli:unit id="usdPerShare">
		<xbrli:divide>
			<xbrli:unitNumerator>
				<xbrli:measure>iso4217:USD</xbrli:measure>
			</xbrli:unitNumerator>
			<xbrli:unitDenominator>
				<xbrli:measure>xbrli:shares</xbrli:measure>
			</xbrli:unitDenominator>
		</xbrli:divide>
	</xbrli:unit><xbrli:unit id="gbp">
		<xbrli:measure>iso4217:GBP</xbrli:measure>
	</xbrli:unit><xbrli:unit id="Claim">
		<xbrli:measure>pfe:Claim</xbrli:measure>
	</xbrli:unit><xbrli:unit id="lagoon">
		<xbrli:measure>pfe:lagoon</xbrli:measure>
	</xbrli:unit><xbrli:unit id="Patent">
		<xbrli:measure>pfe:Patents</xbrli:measure>
	</xbrli:unit><xbrli:unit id="Defendant">
		<xbrli:measure>pfe:Defendant</xbrli:measure>
	</xbrli:unit><xbrli:unit id="iso4217_EUR">
		<xbrli:measure>iso4217:EUR</xbrli:measure>
	</xbrli:unit><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43771853e11438-wk-Fact-000B2C159A9A57D09032E22544108F38" toRefs="TextSelection-DE7EF4A6663E52BF8D3620854A57A945-0-wk-Footnote-DE7EF4A6663E52BF8D3620854A57A945_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43770747e953-wk-Fact-0041457EF706567A8463582BD5F7861D" toRefs="TextSelection-8D2A93033C2E56DE9E814F0AB36328EE-0-wk-Footnote-8D2A93033C2E56DE9E814F0AB36328EE_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e953-wk-Fact-0041457EF706567A8463582BD5F7861D" toRefs="TextSelection-E96B3A139CCA56EC98329BC3717B10E3-0-wk-Footnote-E96B3A139CCA56EC98329BC3717B10E3_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e5004-wk-Fact-008DAD250F08510DA34610C6465700EC" toRefs="TextSelection-2BFD6C99096B50AD93705C5601B21F46-0-wk-Footnote-2BFD6C99096B50AD93705C5601B21F46_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e1287-wk-Fact-016B619738A05C4C98C28A747752066A" toRefs="TextSelection-E90A054BCC035ECEB6B6F2B7C947C3CE-0-wk-Footnote-E90A054BCC035ECEB6B6F2B7C947C3CE_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43770747e1287-wk-Fact-016B619738A05C4C98C28A747752066A" toRefs="TextSelection-E96B3A139CCA56EC98329BC3717B10E3-0-wk-Footnote-E96B3A139CCA56EC98329BC3717B10E3_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e9748-wk-Fact-019763780A0F5F0EB5ACCFF5ADADB2C7" toRefs="TextSelection-39CF024D03225486829869F6CA02C00E-0-wk-Footnote-39CF024D03225486829869F6CA02C00E_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d43770747e9748-wk-Fact-019763780A0F5F0EB5ACCFF5ADADB2C7" toRefs="TextSelection-53BB8CAFCA475C0C9DB2195050D36025-0-wk-Footnote-53BB8CAFCA475C0C9DB2195050D36025_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43770747e9748-wk-Fact-019763780A0F5F0EB5ACCFF5ADADB2C7" toRefs="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43690878e1706-wk-Fact-01FC3E63A2EE59F6B2846C1357AAF742" toRefs="TextSelection-792D3AB23D6354CFBB2776AE7F6407B4-0-wk-Footnote-792D3AB23D6354CFBB2776AE7F6407B4_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43687704e2506-wk-Fact-02AE17DCB8665481BC805EA0E0D7CB38" toRefs="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687704e2506-wk-Fact-02AE17DCB8665481BC805EA0E0D7CB38" toRefs="TextSelection-9231AC55B8EC5775BC4995B0797F870F-0-wk-Footnote-9231AC55B8EC5775BC4995B0797F870F_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43674379e856-wk-Fact-030CEB52DE005078B1752AD07DFF2B1C" toRefs="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43771853e5882-wk-Fact-035E25AAED92520288A7CD55C86FFB01" toRefs="TextSelection-450A7304FB7E513FB479F6D9A06EF1D3-0-wk-Footnote-450A7304FB7E513FB479F6D9A06EF1D3_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e4118-wk-Fact-04349CF31E83539A9C576802A8424538" toRefs="TextSelection-2BFD6C99096B50AD93705C5601B21F46-0-wk-Footnote-2BFD6C99096B50AD93705C5601B21F46_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687704e3095-wk-Fact-044058D73AF55D17962CBA73D63800BD d43690878e2093-wk-Fact-044058D73AF55D17962CBA73D63800BD" toRefs="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43674379e1076-wk-Fact-047944C84B99570199B5350DAC450B3B" toRefs="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e9808-wk-Fact-04C7C8ED03EF514FBDD27EE2DA62A7D5" toRefs="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43770747e9808-wk-Fact-04C7C8ED03EF514FBDD27EE2DA62A7D5" toRefs="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43681613e1719-wk-Fact-050DF5AA83565B919248F2CDC8C1441E" toRefs="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43712510e5327-wk-Fact-05422B8407F15A068C445BB5C57F5700" toRefs="TextSelection-621F9196966C550EA113DA57575C171E-0-wk-Footnote-621F9196966C550EA113DA57575C171E_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43712496e1431-wk-Fact-058D1994C3365CD1AB976A08ED207000" toRefs="TextSelection-B57619F44FCF544D96067CF4816A9082-0-wk-Footnote-B57619F44FCF544D96067CF4816A9082_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687849e1692-wk-Fact-05DE724F3E9F5A43ABA68FEBEAE4BBAF" toRefs="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687849e2376-wk-Fact-065F9DBED67053D59EE0A60E93DFDD22" toRefs="TextSelection-77536863BCE35B419E3A4119D41DB4BD-0-wk-Footnote-77536863BCE35B419E3A4119D41DB4BD_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43687849e2376-wk-Fact-065F9DBED67053D59EE0A60E93DFDD22" toRefs="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43674379e1943-wk-Fact-06E6B320DD2E5DEAAE0840FF5C32D34D" toRefs="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687849e2501-wk-Fact-075959EB0B9D5963B37F54F55082FEA0" toRefs="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43712496e2381-wk-Fact-083D0D52D0F352EBA5B14A872E1DE0C8" toRefs="TextSelection-C37CD88178CA35C475D25A62F2B54FED-0-wk-Footnote-C37CD88178CA35C475D25A62F2B54FED_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43697240e2335-wk-Fact-08713BCAEBE7560790D2B69F31D04450" toRefs="TextSelection-FF348CC7844F523299A112551B170BE6-0-wk-Footnote-FF348CC7844F523299A112551B170BE6_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e1603-wk-Fact-08EE5A3AD5B453F08A8BB6A7ACA9E8BF" toRefs="TextSelection-58096FF6357955D6B6AA25D56767CB0A-0-wk-Footnote-58096FF6357955D6B6AA25D56767CB0A_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43770747e1603-wk-Fact-08EE5A3AD5B453F08A8BB6A7ACA9E8BF" toRefs="TextSelection-8D2A93033C2E56DE9E814F0AB36328EE-0-wk-Footnote-8D2A93033C2E56DE9E814F0AB36328EE_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687704e862-wk-Fact-08F7B1DEB2E25ACA94468FF7CE567177 d43771853e2263-wk-Fact-08F7B1DEB2E25ACA94468FF7CE567177 d43771853e4920-wk-Fact-08F7B1DEB2E25ACA94468FF7CE567177" toRefs="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43770747e7432-wk-Fact-090EF04B0EE45784B7F05495ED9053FC" toRefs="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e7432-wk-Fact-090EF04B0EE45784B7F05495ED9053FC" toRefs="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43771853e8174-wk-Fact-091C801F849C5456B9FD0DC999483C5D" toRefs="TextSelection-B88EBF1DF3CD5B06AADA1AA5E249F160-0-wk-Footnote-B88EBF1DF3CD5B06AADA1AA5E249F160_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687704e1935-wk-Fact-09351BE188EA5C05843D243B15A603F5" toRefs="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43681613e2123-wk-Fact-0998A9FB896651C8813749DB0BBD1634" toRefs="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e7393-wk-Fact-09DBCF3E9CE2515B8F9E9D356B588B2E" toRefs="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43770747e7393-wk-Fact-09DBCF3E9CE2515B8F9E9D356B588B2E" toRefs="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43674379e1013-wk-Fact-09FA50EC8B6A5544A580831FEECF0695" toRefs="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e11114-wk-Fact-09FE0334A6DB46CA6D5F5A6A83AF54B0" toRefs="TextSelection-39CF024D03225486829869F6CA02C00E-0-wk-Footnote-39CF024D03225486829869F6CA02C00E_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43770747e11114-wk-Fact-09FE0334A6DB46CA6D5F5A6A83AF54B0" toRefs="TextSelection-53BB8CAFCA475C0C9DB2195050D36025-0-wk-Footnote-53BB8CAFCA475C0C9DB2195050D36025_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d43770747e11114-wk-Fact-09FE0334A6DB46CA6D5F5A6A83AF54B0" toRefs="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43674379e1677-wk-Fact-0A0DAFD467625E0D8018223CBF2CB456" toRefs="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e4137-wk-Fact-0A1FE70C55BA5D7C9D62C4839596BBE9" toRefs="TextSelection-2BFD6C99096B50AD93705C5601B21F46-0-wk-Footnote-2BFD6C99096B50AD93705C5601B21F46_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687704e1786-wk-Fact-0A252F10C1E25CFA8D6B9B5104061718 d43690878e1466-wk-Fact-0A252F10C1E25CFA8D6B9B5104061718" toRefs="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43770747e8274-wk-Fact-0A4EFE67B20358CA8861BC89A7FA3032" toRefs="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e8274-wk-Fact-0A4EFE67B20358CA8861BC89A7FA3032" toRefs="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687849e2756-wk-Fact-0A65F347C9FD5314AD71D7212990864D d43691920e2625-wk-Fact-0A65F347C9FD5314AD71D7212990864D" toRefs="TextSelection-2A0DF68DD6E953419D1E9B1C848DB228-0-wk-Footnote-2A0DF68DD6E953419D1E9B1C848DB228_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43687849e2756-wk-Fact-0A65F347C9FD5314AD71D7212990864D d43691920e2625-wk-Fact-0A65F347C9FD5314AD71D7212990864D" toRefs="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e4364-wk-Fact-0A66AB4BBDF556D9BBC2F78276184CD8" toRefs="TextSelection-2BFD6C99096B50AD93705C5601B21F46-0-wk-Footnote-2BFD6C99096B50AD93705C5601B21F46_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43674379e2006-wk-Fact-0A96E5EFE1F05A0EAA09A948F325D5CB" toRefs="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43712496e1265-wk-Fact-0ACADD6A2EFE53F1891A48EEF52A1F7C" toRefs="TextSelection-1B1FEAD5EA4E576891141CE7B2D9386E-0-wk-Footnote-1B1FEAD5EA4E576891141CE7B2D9386E_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43712496e1265-wk-Fact-0ACADD6A2EFE53F1891A48EEF52A1F7C" toRefs="TextSelection-B57619F44FCF544D96067CF4816A9082-0-wk-Footnote-B57619F44FCF544D96067CF4816A9082_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43771853e2976-wk-Fact-0B8C5DECC76C5C9E999FC0C03F083D1F" toRefs="TextSelection-78FC5AB8EFAB585E87BBCF93BE9FBF1D-0-wk-Footnote-78FC5AB8EFAB585E87BBCF93BE9FBF1D_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43681613e1582-wk-Fact-0BA196038F9B5E96BAFED82F9B4D0A80" toRefs="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687849e1864-wk-Fact-0BC6042F31745BE3B397485995AF247B" toRefs="TextSelection-77536863BCE35B419E3A4119D41DB4BD-0-wk-Footnote-77536863BCE35B419E3A4119D41DB4BD_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43687849e1864-wk-Fact-0BC6042F31745BE3B397485995AF247B" toRefs="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e4096-wk-Fact-0C018797136D5DE49DB04A0BF65EC513" toRefs="TextSelection-7EC55EFE69505245B1A079B8132EFBB7-0-wk-Footnote-7EC55EFE69505245B1A079B8132EFBB7_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43690878e2178-wk-Fact-0C0E82D74BA85110A5BDBF458FE4D314" toRefs="TextSelection-792D3AB23D6354CFBB2776AE7F6407B4-0-wk-Footnote-792D3AB23D6354CFBB2776AE7F6407B4_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43681613e2764-wk-Fact-0C14F39B228253AAB03AA6A6439EFA78" toRefs="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43681613e2764-wk-Fact-0C14F39B228253AAB03AA6A6439EFA78" toRefs="TextSelection-EB5698F25D035A90984FA270E724B7BB-0-wk-Footnote-EB5698F25D035A90984FA270E724B7BB_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43674379e1809-wk-Fact-0CD797C3DDB8580E8F7A4492293BE3C1" toRefs="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43697224e2885-wk-Fact-0D2E2A926A3F9786A8C65A1EF5DC2AD4" toRefs="TextSelection-066A0A390204B79351965A22CE69E761-0-wk-Footnote-066A0A390204B79351965A22CE69E761_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43697224e2885-wk-Fact-0D2E2A926A3F9786A8C65A1EF5DC2AD4" toRefs="TextSelection-4AF5AB391F1CD8054C065A2324C0D822-0-wk-Footnote-4AF5AB391F1CD8054C065A2324C0D822_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43681613e2838-wk-Fact-0E16C50451235A15BAA9EA1F20FC4F80" toRefs="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43674379e2699-wk-Fact-0E8B49C6C7365DEB9EDE52E9D965698D" toRefs="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43687704e2745-wk-Fact-0EF2FD50430259DC8181FE20C0F40B34" toRefs="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687704e2745-wk-Fact-0EF2FD50430259DC8181FE20C0F40B34" toRefs="TextSelection-9231AC55B8EC5775BC4995B0797F870F-0-wk-Footnote-9231AC55B8EC5775BC4995B0797F870F_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43681613e1106-wk-Fact-0F638C219E595606B659714F53B6D14B" toRefs="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e4299-wk-Fact-0F8D6EEC302657CA8AE0B3CB897EB60C" toRefs="TextSelection-2BFD6C99096B50AD93705C5601B21F46-0-wk-Footnote-2BFD6C99096B50AD93705C5601B21F46_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43690878e1196-wk-Fact-0FA2545E29EF51FFAFF4BBCC15878817" toRefs="TextSelection-792D3AB23D6354CFBB2776AE7F6407B4-0-wk-Footnote-792D3AB23D6354CFBB2776AE7F6407B4_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43771853e10054-wk-Fact-0FBFE9A681A053E09C98AD1EEF2EAB26" toRefs="TextSelection-3AE2F5A9070951C0ACDF4F146E825D8D-0-wk-Footnote-3AE2F5A9070951C0ACDF4F146E825D8D_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687704e1068-wk-Fact-0FC4340BB89A562D9A6DFA4186E041AB" toRefs="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43687704e1068-wk-Fact-0FC4340BB89A562D9A6DFA4186E041AB" toRefs="TextSelection-AE19F19C6AE65BBDA7F551089E2E7EDF-0-wk-Footnote-AE19F19C6AE65BBDA7F551089E2E7EDF_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43687704e1722-wk-Fact-1011397EB1385A98BE195F68F7FE92A7 d43690878e1072-wk-Fact-1011397EB1385A98BE195F68F7FE92A7" toRefs="TextSelection-792D3AB23D6354CFBB2776AE7F6407B4-0-wk-Footnote-792D3AB23D6354CFBB2776AE7F6407B4_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d43687704e1722-wk-Fact-1011397EB1385A98BE195F68F7FE92A7 d43690878e1072-wk-Fact-1011397EB1385A98BE195F68F7FE92A7" toRefs="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687704e1722-wk-Fact-1011397EB1385A98BE195F68F7FE92A7 d43690878e1072-wk-Fact-1011397EB1385A98BE195F68F7FE92A7" toRefs="TextSelection-9231AC55B8EC5775BC4995B0797F870F-0-wk-Footnote-9231AC55B8EC5775BC4995B0797F870F_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43687704e1684-wk-Fact-10A93FAA5CBC5B458A708E3EEBF01F13 d43690878e1033-wk-Fact-10A93FAA5CBC5B458A708E3EEBF01F13" toRefs="TextSelection-792D3AB23D6354CFBB2776AE7F6407B4-0-wk-Footnote-792D3AB23D6354CFBB2776AE7F6407B4_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d43687704e1684-wk-Fact-10A93FAA5CBC5B458A708E3EEBF01F13 d43690878e1033-wk-Fact-10A93FAA5CBC5B458A708E3EEBF01F13" toRefs="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687704e1684-wk-Fact-10A93FAA5CBC5B458A708E3EEBF01F13 d43690878e1033-wk-Fact-10A93FAA5CBC5B458A708E3EEBF01F13" toRefs="TextSelection-9231AC55B8EC5775BC4995B0797F870F-0-wk-Footnote-9231AC55B8EC5775BC4995B0797F870F_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687704e1365-wk-Fact-110B8A55AF7C5BFEAC9F11433EB9280B d43712496e1685-wk-Fact-110B8A55AF7C5BFEAC9F11433EB9280B" toRefs="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687704e1973-wk-Fact-110FAC29CE4C53DFB4DD30D11B664569" toRefs="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e5023-wk-Fact-119D2B7CC2895FCA84AA22FCC552D134" toRefs="TextSelection-2BFD6C99096B50AD93705C5601B21F46-0-wk-Footnote-2BFD6C99096B50AD93705C5601B21F46_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43690878e1874-wk-Fact-11F7A96D6D935A80A19BB49104FFB650" toRefs="TextSelection-792D3AB23D6354CFBB2776AE7F6407B4-0-wk-Footnote-792D3AB23D6354CFBB2776AE7F6407B4_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687704e1954-wk-Fact-12644093904C5936B08DC2FFA86C8E1C" toRefs="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43687849e1350-wk-Fact-130257F4983E52BEA926FB24D7677099" toRefs="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687849e1350-wk-Fact-130257F4983E52BEA926FB24D7677099" toRefs="TextSelection-F185CD45BC245C2EB8EDBFD55DB8A33F-0-wk-Footnote-F185CD45BC245C2EB8EDBFD55DB8A33F_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687849e2032-wk-Fact-13B324D73BAB58EC8AE8E3B51B6EC46D" toRefs="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43712510e4837-wk-Fact-13DD39AEEF96518F9A80C62D8E6A58EB" toRefs="TextSelection-621F9196966C550EA113DA57575C171E-0-wk-Footnote-621F9196966C550EA113DA57575C171E_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43697224e1028-wk-Fact-143C071DEB4F5718B431ADB619B90A82" toRefs="TextSelection-FE5DD06AA8B65777900C47B8AC19C4C6-0-wk-Footnote-FE5DD06AA8B65777900C47B8AC19C4C6_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43687704e2083-wk-Fact-143D73146425519EBA3BAC0B389543EF" toRefs="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687704e2083-wk-Fact-143D73146425519EBA3BAC0B389543EF" toRefs="TextSelection-9231AC55B8EC5775BC4995B0797F870F-0-wk-Footnote-9231AC55B8EC5775BC4995B0797F870F_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687704e1218-wk-Fact-1577AD25D0BD5FE9BC590CD0FFB82AC1" toRefs="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43687704e1218-wk-Fact-1577AD25D0BD5FE9BC590CD0FFB82AC1" toRefs="TextSelection-AE19F19C6AE65BBDA7F551089E2E7EDF-0-wk-Footnote-AE19F19C6AE65BBDA7F551089E2E7EDF_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43771853e11164-wk-Fact-15783BA6644A5B24968CE32B5F022A68" toRefs="TextSelection-ED6F6E1A7C41596DA6F5B1BDFBB72CB7-0-wk-Footnote-ED6F6E1A7C41596DA6F5B1BDFBB72CB7_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43771853e3323-wk-Fact-16217BBC721C5351BFA615340C8310C9" toRefs="TextSelection-13C3E50268A15908A8AC9D1B6C938D2D-0-wk-Footnote-13C3E50268A15908A8AC9D1B6C938D2D_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43771853e3323-wk-Fact-16217BBC721C5351BFA615340C8310C9" toRefs="TextSelection-78FC5AB8EFAB585E87BBCF93BE9FBF1D-0-wk-Footnote-78FC5AB8EFAB585E87BBCF93BE9FBF1D_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e10035-wk-Fact-16809863F1405611BBE44B0DB80273DE" toRefs="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43770747e10035-wk-Fact-16809863F1405611BBE44B0DB80273DE" toRefs="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43771853e4687-wk-Fact-16BC8C896FAA55B4BECE452FC941C562" toRefs="TextSelection-E9F14C2885BA59D8B6B4AD221FC38619-0-wk-Footnote-E9F14C2885BA59D8B6B4AD221FC38619_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43771853e11504-wk-Fact-16FFF27FA1865523A99E7DB32984FAAA" toRefs="TextSelection-450A7304FB7E513FB479F6D9A06EF1D3-0-wk-Footnote-450A7304FB7E513FB479F6D9A06EF1D3_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43687849e1094-wk-Fact-1745891B013F59B28C550000447D41B6" toRefs="TextSelection-36C36413532355188985D26E3B171357-0-wk-Footnote-36C36413532355188985D26E3B171357_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687849e1094-wk-Fact-1745891B013F59B28C550000447D41B6" toRefs="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43712510e4504-wk-Fact-177183957B01565CA3DE15186DC0AA3E" toRefs="TextSelection-621F9196966C550EA113DA57575C171E-0-wk-Footnote-621F9196966C550EA113DA57575C171E_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43770747e8789-wk-Fact-177D9D5D5C305B2CB2F2B8CFC0B8B38B" toRefs="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e8789-wk-Fact-177D9D5D5C305B2CB2F2B8CFC0B8B38B" toRefs="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43690878e1422-wk-Fact-18674C7559605F059F86A2A98B4C09F5" toRefs="TextSelection-792D3AB23D6354CFBB2776AE7F6407B4-0-wk-Footnote-792D3AB23D6354CFBB2776AE7F6407B4_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687704e1133-wk-Fact-191AFA552BEF51A38ED7B886728FB89F" toRefs="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43687704e1133-wk-Fact-191AFA552BEF51A38ED7B886728FB89F" toRefs="TextSelection-AE19F19C6AE65BBDA7F551089E2E7EDF-0-wk-Footnote-AE19F19C6AE65BBDA7F551089E2E7EDF_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e5740-wk-Fact-19A2A621AB2F5D67AFB144F44BDFF8C9" toRefs="TextSelection-0BDE8CEE983B5F118E2EFACDF9CC6405-0-wk-Footnote-0BDE8CEE983B5F118E2EFACDF9CC6405_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43771853e11098-wk-Fact-19D08708847D5BDEAC5A5C81A5DC8E05" toRefs="TextSelection-7266C8E6B8975A65A379AF3B415EA220-0-wk-Footnote-7266C8E6B8975A65A379AF3B415EA220_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e11010-wk-Fact-1A851ADE80F15F3490D42C3F2F83E624" toRefs="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43770747e11010-wk-Fact-1A851ADE80F15F3490D42C3F2F83E624" toRefs="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687704e1263-wk-Fact-1A88D36F44FC57EEB2947A0516F8E2FB" toRefs="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43712496e3507-wk-Fact-1AB7DD0AE8235344A53584C522F56843" toRefs="TextSelection-04B3DB4115835E2FBB99EA13FC1FD64B-0-wk-Footnote-04B3DB4115835E2FBB99EA13FC1FD64B_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43770747e8647-wk-Fact-1B18B8E0BFFA5FAB8CC46A153B1999C9" toRefs="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e8647-wk-Fact-1B18B8E0BFFA5FAB8CC46A153B1999C9" toRefs="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43697240e3223-wk-Fact-1B4BEA3CDC1756D68AA1A2E1DC80FA4D" toRefs="TextSelection-5368EA2EA2275823ADDE27DF2382EF3B-0-wk-Footnote-5368EA2EA2275823ADDE27DF2382EF3B_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43674379e2630-wk-Fact-1B54ADB976A25833A5F7A46C177A2A45" toRefs="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43681613e1200-wk-Fact-1B9FEF203B3C5505BC6C4EC5902F0BCF" toRefs="TextSelection-3DD94144621C5A68BC21C5DB64345BB9-0-wk-Footnote-3DD94144621C5A68BC21C5DB64345BB9_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43681613e1200-wk-Fact-1B9FEF203B3C5505BC6C4EC5902F0BCF" toRefs="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687849e2176-wk-Fact-1C3BC6367D20581BA4D58D85D2EF3508" toRefs="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43712510e4324-wk-Fact-1C567788B51552EC86AD93358A113C04" toRefs="TextSelection-621F9196966C550EA113DA57575C171E-0-wk-Footnote-621F9196966C550EA113DA57575C171E_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43712496e2260-wk-Fact-1D412AB78B1D52DEAA171F130190DA4E" toRefs="TextSelection-C37CD88178CA35C475D25A62F2B54FED-0-wk-Footnote-C37CD88178CA35C475D25A62F2B54FED_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43712510e4187-wk-Fact-1D5607877A1C54618597D694BA991812" toRefs="TextSelection-621F9196966C550EA113DA57575C171E-0-wk-Footnote-621F9196966C550EA113DA57575C171E_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43687704e3141-wk-Fact-1E5089DBEBB75DB7864724ADB41A8830 d43690878e2224-wk-Fact-1E5089DBEBB75DB7864724ADB41A8830" toRefs="TextSelection-792D3AB23D6354CFBB2776AE7F6407B4-0-wk-Footnote-792D3AB23D6354CFBB2776AE7F6407B4_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d43687704e3141-wk-Fact-1E5089DBEBB75DB7864724ADB41A8830 d43690878e2224-wk-Fact-1E5089DBEBB75DB7864724ADB41A8830" toRefs="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687704e3141-wk-Fact-1E5089DBEBB75DB7864724ADB41A8830 d43690878e2224-wk-Fact-1E5089DBEBB75DB7864724ADB41A8830" toRefs="TextSelection-9231AC55B8EC5775BC4995B0797F870F-0-wk-Footnote-9231AC55B8EC5775BC4995B0797F870F_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e4384-wk-Fact-1EB643CEE30E5AE0B145130CC6CEAC25" toRefs="TextSelection-2BFD6C99096B50AD93705C5601B21F46-0-wk-Footnote-2BFD6C99096B50AD93705C5601B21F46_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43771853e5863-wk-Fact-1F06BFCD01CA55BFA37745ACCFA9290A" toRefs="TextSelection-450A7304FB7E513FB479F6D9A06EF1D3-0-wk-Footnote-450A7304FB7E513FB479F6D9A06EF1D3_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687704e3268-wk-Fact-1F15569F17C85A6FB44008E62E8E62E3" toRefs="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687849e1815-wk-Fact-1F4BA95B10925AE8A489F10EF8546E3C" toRefs="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d43687704e1910-wk-Fact-1F598F7CC0A659DC8B78C122AEB4F4CE d43687849e904-wk-Fact-1F598F7CC0A659DC8B78C122AEB4F4CE d43681613e821-wk-Fact-1F598F7CC0A659DC8B78C122AEB4F4CE" toRefs="TextSelection-3DD94144621C5A68BC21C5DB64345BB9-0-wk-Footnote-3DD94144621C5A68BC21C5DB64345BB9_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="5" fromRefs="d43687704e1910-wk-Fact-1F598F7CC0A659DC8B78C122AEB4F4CE d43687849e904-wk-Fact-1F598F7CC0A659DC8B78C122AEB4F4CE d43681613e821-wk-Fact-1F598F7CC0A659DC8B78C122AEB4F4CE" toRefs="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687704e1910-wk-Fact-1F598F7CC0A659DC8B78C122AEB4F4CE d43687849e904-wk-Fact-1F598F7CC0A659DC8B78C122AEB4F4CE d43681613e821-wk-Fact-1F598F7CC0A659DC8B78C122AEB4F4CE" toRefs="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43687704e1910-wk-Fact-1F598F7CC0A659DC8B78C122AEB4F4CE d43687849e904-wk-Fact-1F598F7CC0A659DC8B78C122AEB4F4CE d43681613e821-wk-Fact-1F598F7CC0A659DC8B78C122AEB4F4CE" toRefs="TextSelection-9231AC55B8EC5775BC4995B0797F870F-0-wk-Footnote-9231AC55B8EC5775BC4995B0797F870F_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="4" fromRefs="d43687704e1910-wk-Fact-1F598F7CC0A659DC8B78C122AEB4F4CE d43687849e904-wk-Fact-1F598F7CC0A659DC8B78C122AEB4F4CE d43681613e821-wk-Fact-1F598F7CC0A659DC8B78C122AEB4F4CE" toRefs="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e10429-wk-Fact-1FF4C4C95159585A8AD2FEAE77CAC774" toRefs="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43770747e10429-wk-Fact-1FF4C4C95159585A8AD2FEAE77CAC774" toRefs="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43681613e2196-wk-Fact-202F98BA511E52368E7B8599E950975E" toRefs="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43691920e1143-wk-Fact-20A5C02D91765E01AC1BECE67B1B1069" toRefs="TextSelection-C94190737D79577A8993EFAC2CD3FC95-0-wk-Footnote-C94190737D79577A8993EFAC2CD3FC95_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43697224e1371-wk-Fact-21036AB1E903531C8D597B8E28342703" toRefs="TextSelection-6E67095C033B51BB9FABBA85E8DC4DFA-0-wk-Footnote-6E67095C033B51BB9FABBA85E8DC4DFA_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43771853e3561-wk-Fact-2131D133192A51CEA24287EC4D1DC30D" toRefs="TextSelection-78FC5AB8EFAB585E87BBCF93BE9FBF1D-0-wk-Footnote-78FC5AB8EFAB585E87BBCF93BE9FBF1D_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43678813e956-wk-Fact-2164B7E786595ADF8A2FFDAB7982BEB2" toRefs="TextSelection-E16E3AA57ADF5C6FB93B6FC578ED7F95-0-wk-Footnote-E16E3AA57ADF5C6FB93B6FC578ED7F95_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43770747e841-wk-Fact-2216EB0E4F0B50869B845DEBE01027C3" toRefs="TextSelection-0A1952177FA453EC8B5651D58249A9BA-0-wk-Footnote-0A1952177FA453EC8B5651D58249A9BA_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e841-wk-Fact-2216EB0E4F0B50869B845DEBE01027C3" toRefs="TextSelection-8D2A93033C2E56DE9E814F0AB36328EE-0-wk-Footnote-8D2A93033C2E56DE9E814F0AB36328EE_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43674379e2386-wk-Fact-22383CE0D78B56089748D1342C097ED3" toRefs="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687704e1180-wk-Fact-225BF3E60210511691B41C170582C821" toRefs="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43687704e1180-wk-Fact-225BF3E60210511691B41C170582C821" toRefs="TextSelection-AE19F19C6AE65BBDA7F551089E2E7EDF-0-wk-Footnote-AE19F19C6AE65BBDA7F551089E2E7EDF_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43712496e1943-wk-Fact-2287BD2729395E10AA7149FD8CDD1C22" toRefs="TextSelection-7160FF67E87550A19177FE255A41A2D7-0-wk-Footnote-7160FF67E87550A19177FE255A41A2D7_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43674379e1987-wk-Fact-22AAFEBAB3755B18A95911F7BF8494E3" toRefs="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43681613e1036-wk-Fact-22BDA5BA109D56B8A234197E3982FF14" toRefs="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43771853e10198-wk-Fact-232A214804B055189EC1111DA289CA2D" toRefs="TextSelection-DE7EF4A6663E52BF8D3620854A57A945-0-wk-Footnote-DE7EF4A6663E52BF8D3620854A57A945_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43690878e1254-wk-Fact-232AC2542E565EDABA540B1D57A95D2D" toRefs="TextSelection-792D3AB23D6354CFBB2776AE7F6407B4-0-wk-Footnote-792D3AB23D6354CFBB2776AE7F6407B4_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e10390-wk-Fact-238B98C4D02459528B018866A4D1E3C1" toRefs="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43770747e10390-wk-Fact-238B98C4D02459528B018866A4D1E3C1" toRefs="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43771853e2128-wk-Fact-241DA9C0A5035519B185693E59F3571D" toRefs="TextSelection-78FC5AB8EFAB585E87BBCF93BE9FBF1D-0-wk-Footnote-78FC5AB8EFAB585E87BBCF93BE9FBF1D_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43771853e2128-wk-Fact-241DA9C0A5035519B185693E59F3571D" toRefs="TextSelection-8540AADB45BE54D38C10451BF6A88AB4-0-wk-Footnote-8540AADB45BE54D38C10451BF6A88AB4_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43771853e2041-wk-Fact-2439FB836F6B538B8D7D394CD6614D2E" toRefs="TextSelection-13C3E50268A15908A8AC9D1B6C938D2D-0-wk-Footnote-13C3E50268A15908A8AC9D1B6C938D2D_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43771853e2041-wk-Fact-2439FB836F6B538B8D7D394CD6614D2E" toRefs="TextSelection-78FC5AB8EFAB585E87BBCF93BE9FBF1D-0-wk-Footnote-78FC5AB8EFAB585E87BBCF93BE9FBF1D_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e11095-wk-Fact-246EBF73EC0858A18FCF596C5A717E80" toRefs="TextSelection-39CF024D03225486829869F6CA02C00E-0-wk-Footnote-39CF024D03225486829869F6CA02C00E_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d43770747e11095-wk-Fact-246EBF73EC0858A18FCF596C5A717E80" toRefs="TextSelection-53BB8CAFCA475C0C9DB2195050D36025-0-wk-Footnote-53BB8CAFCA475C0C9DB2195050D36025_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43770747e11095-wk-Fact-246EBF73EC0858A18FCF596C5A717E80" toRefs="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43770747e8171-wk-Fact-24B21791DB6C58DCB111630D09C1ACBF" toRefs="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e8171-wk-Fact-24B21791DB6C58DCB111630D09C1ACBF" toRefs="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e1089-wk-Fact-24CD21A3984953BA839ABDB818130188" toRefs="TextSelection-8D2A93033C2E56DE9E814F0AB36328EE-0-wk-Footnote-8D2A93033C2E56DE9E814F0AB36328EE_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43770747e1089-wk-Fact-24CD21A3984953BA839ABDB818130188" toRefs="TextSelection-91730671722A5F83BA05EF347193E4CF-0-wk-Footnote-91730671722A5F83BA05EF347193E4CF_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687849e2777-wk-Fact-24F5F5FD900B538BB0C1F5C1D6714D02 d43691920e2645-wk-Fact-24F5F5FD900B538BB0C1F5C1D6714D02" toRefs="TextSelection-2A0DF68DD6E953419D1E9B1C848DB228-0-wk-Footnote-2A0DF68DD6E953419D1E9B1C848DB228_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43687849e2777-wk-Fact-24F5F5FD900B538BB0C1F5C1D6714D02 d43691920e2645-wk-Fact-24F5F5FD900B538BB0C1F5C1D6714D02" toRefs="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43697224e1778-wk-Fact-264D8D2580555027A2EF57DE7B0E9E4A" toRefs="TextSelection-ECF6A95A77365D79B2E9D472B81966D9-0-wk-Footnote-ECF6A95A77365D79B2E9D472B81966D9_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43674379e2361-wk-Fact-279845FB1E2F5BE68F8072CC3AE0313B" toRefs="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e9728-wk-Fact-283251A1FA2159899190EA9CCFA53A25" toRefs="TextSelection-39CF024D03225486829869F6CA02C00E-0-wk-Footnote-39CF024D03225486829869F6CA02C00E_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d43770747e9728-wk-Fact-283251A1FA2159899190EA9CCFA53A25" toRefs="TextSelection-53BB8CAFCA475C0C9DB2195050D36025-0-wk-Footnote-53BB8CAFCA475C0C9DB2195050D36025_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43770747e9728-wk-Fact-283251A1FA2159899190EA9CCFA53A25" toRefs="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43681613e2896-wk-Fact-2876808E5D6E5BCEA80558572E768C26" toRefs="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687704e1993-wk-Fact-288376604CC25FCA9066DC7223130DD2" toRefs="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43770747e8858-wk-Fact-288B765C343F5E4F98C92B3CC3D540BD" toRefs="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e8858-wk-Fact-288B765C343F5E4F98C92B3CC3D540BD" toRefs="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687704e1010-wk-Fact-28E7163DD278532183F033BDA283F0A1" toRefs="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43687704e1010-wk-Fact-28E7163DD278532183F033BDA283F0A1" toRefs="TextSelection-AE19F19C6AE65BBDA7F551089E2E7EDF-0-wk-Footnote-AE19F19C6AE65BBDA7F551089E2E7EDF_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687704e1321-wk-Fact-2955D213201255B6B4C71E112F5F3621" toRefs="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e4038-wk-Fact-29ACCDED11BA511481ECE7E30ABD1FFA" toRefs="TextSelection-7EC55EFE69505245B1A079B8132EFBB7-0-wk-Footnote-7EC55EFE69505245B1A079B8132EFBB7_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43712510e6050-wk-Fact-29DAA58640B95FAD926B443F7C99CB05" toRefs="TextSelection-6550A25092D55979B6A1D62BD4EDF090-0-wk-Footnote-6550A25092D55979B6A1D62BD4EDF090_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e7374-wk-Fact-2A83FB655E5C5030BB0751EC39ED3AD7" toRefs="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43770747e7374-wk-Fact-2A83FB655E5C5030BB0751EC39ED3AD7" toRefs="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e1064-wk-Fact-2A8F43C5F6985C19B50BEDA00C1E0EDB" toRefs="TextSelection-8D2A93033C2E56DE9E814F0AB36328EE-0-wk-Footnote-8D2A93033C2E56DE9E814F0AB36328EE_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43770747e1064-wk-Fact-2A8F43C5F6985C19B50BEDA00C1E0EDB" toRefs="TextSelection-91730671722A5F83BA05EF347193E4CF-0-wk-Footnote-91730671722A5F83BA05EF347193E4CF_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43690878e1234-wk-Fact-2AF1807BCF8A5ADC8187B51D6E464FFD" toRefs="TextSelection-792D3AB23D6354CFBB2776AE7F6407B4-0-wk-Footnote-792D3AB23D6354CFBB2776AE7F6407B4_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687849e1949-wk-Fact-2B43072B673F54B48A3077572AC7B122" toRefs="TextSelection-77536863BCE35B419E3A4119D41DB4BD-0-wk-Footnote-77536863BCE35B419E3A4119D41DB4BD_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43687849e1949-wk-Fact-2B43072B673F54B48A3077572AC7B122" toRefs="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e10887-wk-Fact-2B6D0F44C93359ADA6DC515DA57F73D4" toRefs="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43770747e10887-wk-Fact-2B6D0F44C93359ADA6DC515DA57F73D4" toRefs="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43687704e2706-wk-Fact-2BD65B1FAD49532F94B23261F5066D15 d43712471e5775-wk-Fact-2BD65B1FAD49532F94B23261F5066D15" toRefs="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687704e2706-wk-Fact-2BD65B1FAD49532F94B23261F5066D15 d43712471e5775-wk-Fact-2BD65B1FAD49532F94B23261F5066D15" toRefs="TextSelection-9231AC55B8EC5775BC4995B0797F870F-0-wk-Footnote-9231AC55B8EC5775BC4995B0797F870F_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43681613e2216-wk-Fact-2BEDC5A7D4A059F58F71D107B4C1CAFF" toRefs="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43771853e1525-wk-Fact-2C08174C90215980AF8C21393CA8C5DE" toRefs="TextSelection-78FC5AB8EFAB585E87BBCF93BE9FBF1D-0-wk-Footnote-78FC5AB8EFAB585E87BBCF93BE9FBF1D_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43771853e8213-wk-Fact-2C55373A40E0521188DF042ECD16B096" toRefs="TextSelection-B88EBF1DF3CD5B06AADA1AA5E249F160-0-wk-Footnote-B88EBF1DF3CD5B06AADA1AA5E249F160_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43674379e925-wk-Fact-2C8D97E870025A9E9218D1538714EA7C d43678813e910-wk-Fact-2C8D97E870025A9E9218D1538714EA7C" toRefs="TextSelection-431A3875E30657529B6519DFB33F40EB-0-wk-Footnote-431A3875E30657529B6519DFB33F40EB_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43674379e925-wk-Fact-2C8D97E870025A9E9218D1538714EA7C d43678813e910-wk-Fact-2C8D97E870025A9E9218D1538714EA7C" toRefs="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e4965-wk-Fact-2C95CA02AB4558B9A40486FF0E1ECD3D" toRefs="TextSelection-2BFD6C99096B50AD93705C5601B21F46-0-wk-Footnote-2BFD6C99096B50AD93705C5601B21F46_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43687849e1409-wk-Fact-2CCCE52F43F055888FBA5D0EB59CC576" toRefs="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687849e1409-wk-Fact-2CCCE52F43F055888FBA5D0EB59CC576" toRefs="TextSelection-F185CD45BC245C2EB8EDBFD55DB8A33F-0-wk-Footnote-F185CD45BC245C2EB8EDBFD55DB8A33F_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43690878e2120-wk-Fact-2D022CD3C3AD5211BB51112CC40FC473" toRefs="TextSelection-792D3AB23D6354CFBB2776AE7F6407B4-0-wk-Footnote-792D3AB23D6354CFBB2776AE7F6407B4_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43687704e1618-wk-Fact-2D8CDE5E04555F14B8B630B25163E15F" toRefs="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687704e1618-wk-Fact-2D8CDE5E04555F14B8B630B25163E15F" toRefs="TextSelection-9231AC55B8EC5775BC4995B0797F870F-0-wk-Footnote-9231AC55B8EC5775BC4995B0797F870F_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43674379e2674-wk-Fact-2D9C52897DAC5AD0A4FC1108BB490212" toRefs="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43771853e4803-wk-Fact-2DA3332AAA9A5E4A8EDAC00B3DB27FF9" toRefs="TextSelection-DC6DDCB74FC9523D97BA51FBA6B1C05E-0-wk-Footnote-DC6DDCB74FC9523D97BA51FBA6B1C05E_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43712496e2528-wk-Fact-2E0D7E0341AF521EB10E77F7AB951A30" toRefs="TextSelection-C37CD88178CA35C475D25A62F2B54FED-0-wk-Footnote-C37CD88178CA35C475D25A62F2B54FED_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43771853e10404-wk-Fact-2E5C7379161F5F76A0E97E4215BB339F" toRefs="TextSelection-450A7304FB7E513FB479F6D9A06EF1D3-0-wk-Footnote-450A7304FB7E513FB479F6D9A06EF1D3_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43771853e3302-wk-Fact-2E6085148E385843A6F6681DB2EA3E75" toRefs="TextSelection-13C3E50268A15908A8AC9D1B6C938D2D-0-wk-Footnote-13C3E50268A15908A8AC9D1B6C938D2D_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43771853e3302-wk-Fact-2E6085148E385843A6F6681DB2EA3E75" toRefs="TextSelection-78FC5AB8EFAB585E87BBCF93BE9FBF1D-0-wk-Footnote-78FC5AB8EFAB585E87BBCF93BE9FBF1D_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43697224e1391-wk-Fact-2E6E4BDF4E235E37AD8DFBB014690780" toRefs="TextSelection-6E67095C033B51BB9FABBA85E8DC4DFA-0-wk-Footnote-6E67095C033B51BB9FABBA85E8DC4DFA_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43771853e3389-wk-Fact-2E8BCB0198B9547BFA12E7848D133E48" toRefs="TextSelection-13C3E50268A15908A8AC9D1B6C938D2D-0-wk-Footnote-13C3E50268A15908A8AC9D1B6C938D2D_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43771853e3389-wk-Fact-2E8BCB0198B9547BFA12E7848D133E48" toRefs="TextSelection-78FC5AB8EFAB585E87BBCF93BE9FBF1D-0-wk-Footnote-78FC5AB8EFAB585E87BBCF93BE9FBF1D_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43687849e1605-wk-Fact-2EABA378D8055B138BD1C9439BF5DF77" toRefs="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687849e1605-wk-Fact-2EABA378D8055B138BD1C9439BF5DF77" toRefs="TextSelection-F185CD45BC245C2EB8EDBFD55DB8A33F-0-wk-Footnote-F185CD45BC245C2EB8EDBFD55DB8A33F_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e8692-wk-Fact-2EC8C97286795110842254B7AD03EA8C" toRefs="TextSelection-39CF024D03225486829869F6CA02C00E-0-wk-Footnote-39CF024D03225486829869F6CA02C00E_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43770747e8692-wk-Fact-2EC8C97286795110842254B7AD03EA8C" toRefs="TextSelection-53BB8CAFCA475C0C9DB2195050D36025-0-wk-Footnote-53BB8CAFCA475C0C9DB2195050D36025_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d43770747e8692-wk-Fact-2EC8C97286795110842254B7AD03EA8C" toRefs="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e9667-wk-Fact-2F4C56B8E6C658B98917D6369850F69C" toRefs="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43770747e9667-wk-Fact-2F4C56B8E6C658B98917D6369850F69C" toRefs="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43681613e2288-wk-Fact-2F51CAACA19456CCB50C8D86205439BE" toRefs="TextSelection-3DD94144621C5A68BC21C5DB64345BB9-0-wk-Footnote-3DD94144621C5A68BC21C5DB64345BB9_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43681613e2288-wk-Fact-2F51CAACA19456CCB50C8D86205439BE" toRefs="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43687704e2064-wk-Fact-2F837D3EBB765EBCB1249DE75E4FF1D1" toRefs="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687704e2064-wk-Fact-2F837D3EBB765EBCB1249DE75E4FF1D1" toRefs="TextSelection-9231AC55B8EC5775BC4995B0797F870F-0-wk-Footnote-9231AC55B8EC5775BC4995B0797F870F_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43712496e2509-wk-Fact-2F901B411CA0586B801E2011D88D1ACA" toRefs="TextSelection-C37CD88178CA35C475D25A62F2B54FED-0-wk-Footnote-C37CD88178CA35C475D25A62F2B54FED_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43712496e2065-wk-Fact-300D4D3DDB1355E8938FDCD261A66E64" toRefs="TextSelection-7160FF67E87550A19177FE255A41A2D7-0-wk-Footnote-7160FF67E87550A19177FE255A41A2D7_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43697240e1730-wk-Fact-305740AD59515768A45E4205357775C9 d43697240e2354-wk-Fact-305740AD59515768A45E4205357775C9" toRefs="TextSelection-FF348CC7844F523299A112551B170BE6-0-wk-Footnote-FF348CC7844F523299A112551B170BE6_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43712496e1621-wk-Fact-309464A163D5551F8E0560FD895331BC" toRefs="TextSelection-C882D128F7C35640B8C0E15448983D9E-0-wk-Footnote-C882D128F7C35640B8C0E15448983D9E_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43674379e1607-wk-Fact-30C18A2BCA9E5DB3B71D6CCCF9EC18D9" toRefs="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e4195-wk-Fact-30E328BC808A5B65A7A777945EE0CE96" toRefs="TextSelection-2BFD6C99096B50AD93705C5601B21F46-0-wk-Footnote-2BFD6C99096B50AD93705C5601B21F46_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687849e2737-wk-Fact-31B8668E1E1956DF8878873FF4C52DA7 d43691920e2605-wk-Fact-31B8668E1E1956DF8878873FF4C52DA7" toRefs="TextSelection-2A0DF68DD6E953419D1E9B1C848DB228-0-wk-Footnote-2A0DF68DD6E953419D1E9B1C848DB228_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43687849e2737-wk-Fact-31B8668E1E1956DF8878873FF4C52DA7 d43691920e2605-wk-Fact-31B8668E1E1956DF8878873FF4C52DA7" toRefs="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687849e2117-wk-Fact-322107AB58155A3EA1AD6413AB9D9A99" toRefs="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e8196-wk-Fact-324434DC15AC56F3976EFDF4A8E4050E" toRefs="TextSelection-39CF024D03225486829869F6CA02C00E-0-wk-Footnote-39CF024D03225486829869F6CA02C00E_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43770747e8196-wk-Fact-324434DC15AC56F3976EFDF4A8E4050E" toRefs="TextSelection-53BB8CAFCA475C0C9DB2195050D36025-0-wk-Footnote-53BB8CAFCA475C0C9DB2195050D36025_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d43770747e8196-wk-Fact-324434DC15AC56F3976EFDF4A8E4050E" toRefs="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43697240e3242-wk-Fact-32830C0722A659AF88B98C905235BC15" toRefs="TextSelection-5368EA2EA2275823ADDE27DF2382EF3B-0-wk-Footnote-5368EA2EA2275823ADDE27DF2382EF3B_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687849e3074-wk-Fact-32954ABF73B65A8C9307A33BA47D9ABB" toRefs="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43681613e1745-wk-Fact-33114474B11F56B7AE997B42206DB57C" toRefs="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687849e1178-wk-Fact-33A901EBBAEB5B7B8CD51B4273CBCE61" toRefs="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43712496e1470-wk-Fact-33C51462AA72510092370BCC6B190DCD" toRefs="TextSelection-B57619F44FCF544D96067CF4816A9082-0-wk-Footnote-B57619F44FCF544D96067CF4816A9082_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43771853e11040-wk-Fact-3478C9FA86F457899DC079177D757215" toRefs="TextSelection-7266C8E6B8975A65A379AF3B415EA220-0-wk-Footnote-7266C8E6B8975A65A379AF3B415EA220_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43687849e1133-wk-Fact-34A31155E9EC5355982021CA6EBEFB38" toRefs="TextSelection-36C36413532355188985D26E3B171357-0-wk-Footnote-36C36413532355188985D26E3B171357_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687849e1133-wk-Fact-34A31155E9EC5355982021CA6EBEFB38" toRefs="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43697224e964-wk-Fact-34F816D444055102A29F3BD0BBE0EC9E" toRefs="TextSelection-FE5DD06AA8B65777900C47B8AC19C4C6-0-wk-Footnote-FE5DD06AA8B65777900C47B8AC19C4C6_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e10991-wk-Fact-3509C7CDE8445B7B95D3CD4AB8311EBD" toRefs="TextSelection-39CF024D03225486829869F6CA02C00E-0-wk-Footnote-39CF024D03225486829869F6CA02C00E_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d43770747e10991-wk-Fact-3509C7CDE8445B7B95D3CD4AB8311EBD" toRefs="TextSelection-53BB8CAFCA475C0C9DB2195050D36025-0-wk-Footnote-53BB8CAFCA475C0C9DB2195050D36025_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43770747e10991-wk-Fact-3509C7CDE8445B7B95D3CD4AB8311EBD" toRefs="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687849e2071-wk-Fact-3584E6A95DE851E29AE8ED49EB250F3F" toRefs="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e10553-wk-Fact-367407A06D845402883E3D448F892BA4" toRefs="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43770747e10553-wk-Fact-367407A06D845402883E3D448F892BA4" toRefs="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e2871-wk-Fact-36F90A1B2B3150DD8B3EF42CE7A207C4" toRefs="TextSelection-A9B5859E968353E1AF0EF5AF16D3F7DE-0-wk-Footnote-A9B5859E968353E1AF0EF5AF16D3F7DE_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43681613e1126-wk-Fact-378721671BB456518AD2AD4867C237B9" toRefs="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43771853e4590-wk-Fact-379798FC1BCC5947B93DE423936B8B64" toRefs="TextSelection-3802305E73EB52F28FAAF4EA5481D580-0-wk-Footnote-3802305E73EB52F28FAAF4EA5481D580_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687849e3055-wk-Fact-3831F5857C7B5144886C985E77E751EE" toRefs="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43692105e1257-wk-Fact-38D6CEB8D8AD5DDC81AC2FCD8FAE9F8C" toRefs="TextSelection-2A36E737FFF05E75B357CB41AFB5B6E2-0-wk-Footnote-2A36E737FFF05E75B357CB41AFB5B6E2_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43697224e1086-wk-Fact-38D872801B2E5B2ABE4AE2E3D2CD2C57" toRefs="TextSelection-FE5DD06AA8B65777900C47B8AC19C4C6-0-wk-Footnote-FE5DD06AA8B65777900C47B8AC19C4C6_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43674379e2655-wk-Fact-394FE75EF25C5117BE8B89037EFA6718" toRefs="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43697240e3204-wk-Fact-39F7ED9F3086578FAC1610BAD7C34831" toRefs="TextSelection-5368EA2EA2275823ADDE27DF2382EF3B-0-wk-Footnote-5368EA2EA2275823ADDE27DF2382EF3B_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43674379e1568-wk-Fact-3A3BB372357A5CD2BCD070742B0C6955 d43770747e1962-wk-Fact-3A3BB372357A5CD2BCD070742B0C6955" toRefs="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43674379e1568-wk-Fact-3A3BB372357A5CD2BCD070742B0C6955 d43770747e1962-wk-Fact-3A3BB372357A5CD2BCD070742B0C6955" toRefs="TextSelection-E90A054BCC035ECEB6B6F2B7C947C3CE-0-wk-Footnote-E90A054BCC035ECEB6B6F2B7C947C3CE_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e8750-wk-Fact-3A60D355B3D65BBF94AB49C42ABD832B" toRefs="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43770747e8750-wk-Fact-3A60D355B3D65BBF94AB49C42ABD832B" toRefs="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e4345-wk-Fact-3A9320AC96A65345AF2925F4F49F63EE" toRefs="TextSelection-2BFD6C99096B50AD93705C5601B21F46-0-wk-Footnote-2BFD6C99096B50AD93705C5601B21F46_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687849e3016-wk-Fact-3AB6460969F05E5CB5282AE2FB7FB81F" toRefs="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e1564-wk-Fact-3ABBEBBC9C675BDDBFD1245A5C8DACAB" toRefs="TextSelection-58096FF6357955D6B6AA25D56767CB0A-0-wk-Footnote-58096FF6357955D6B6AA25D56767CB0A_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43770747e1564-wk-Fact-3ABBEBBC9C675BDDBFD1245A5C8DACAB" toRefs="TextSelection-8D2A93033C2E56DE9E814F0AB36328EE-0-wk-Footnote-8D2A93033C2E56DE9E814F0AB36328EE_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43712510e4997-wk-Fact-3AD287E437335513A247CED1511F52AE" toRefs="TextSelection-621F9196966C550EA113DA57575C171E-0-wk-Footnote-621F9196966C550EA113DA57575C171E_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43712496e1583-wk-Fact-3B1D1CAB9A6C50A0AFB2D0D10CB345EC" toRefs="TextSelection-C882D128F7C35640B8C0E15448983D9E-0-wk-Footnote-C882D128F7C35640B8C0E15448983D9E_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43771853e4760-wk-Fact-3C874C1F4C8853D68A9C0BEB283CEC51" toRefs="TextSelection-E9F14C2885BA59D8B6B4AD221FC38619-0-wk-Footnote-E9F14C2885BA59D8B6B4AD221FC38619_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687849e1236-wk-Fact-3C8E3740EBD853D5A2217E87A8E69C70" toRefs="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43770747e10075-wk-Fact-3D22C73D416A54A79E8C5296818B091D" toRefs="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e10075-wk-Fact-3D22C73D416A54A79E8C5296818B091D" toRefs="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687849e1067-wk-Fact-3DD9D4B9BF27581180EA172B8CC2DC14" toRefs="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e10494-wk-Fact-3DDF166872145F4BAF10CA9D1ED6DA8F" toRefs="TextSelection-39CF024D03225486829869F6CA02C00E-0-wk-Footnote-39CF024D03225486829869F6CA02C00E_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d43770747e10494-wk-Fact-3DDF166872145F4BAF10CA9D1ED6DA8F" toRefs="TextSelection-53BB8CAFCA475C0C9DB2195050D36025-0-wk-Footnote-53BB8CAFCA475C0C9DB2195050D36025_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43770747e10494-wk-Fact-3DDF166872145F4BAF10CA9D1ED6DA8F" toRefs="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43674379e2584-wk-Fact-3E322F23F0E95E659A8A7D474667DE0D" toRefs="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43771853e11079-wk-Fact-3E9CA6EB4A915AFF8A6FCEB98114AB68" toRefs="TextSelection-7266C8E6B8975A65A379AF3B415EA220-0-wk-Footnote-7266C8E6B8975A65A379AF3B415EA220_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43687704e2398-wk-Fact-3F5327605CC159E0884F58369042FADA" toRefs="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687704e2398-wk-Fact-3F5327605CC159E0884F58369042FADA" toRefs="TextSelection-9231AC55B8EC5775BC4995B0797F870F-0-wk-Footnote-9231AC55B8EC5775BC4995B0797F870F_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43674379e1253-wk-Fact-4014B8D306BF54FC8CDF5431816FAA50 d43697240e2375-wk-Fact-4014B8D306BF54FC8CDF5431816FAA50" toRefs="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43674379e1253-wk-Fact-4014B8D306BF54FC8CDF5431816FAA50 d43697240e2375-wk-Fact-4014B8D306BF54FC8CDF5431816FAA50" toRefs="TextSelection-FF348CC7844F523299A112551B170BE6-0-wk-Footnote-FF348CC7844F523299A112551B170BE6_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43687704e2025-wk-Fact-40459F40D11A5E0AA41A1F4213969546" toRefs="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687704e2025-wk-Fact-40459F40D11A5E0AA41A1F4213969546" toRefs="TextSelection-9231AC55B8EC5775BC4995B0797F870F-0-wk-Footnote-9231AC55B8EC5775BC4995B0797F870F_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43687704e3180-wk-Fact-413D25685F8F583AB53236F9F57575B9 d43690878e2263-wk-Fact-413D25685F8F583AB53236F9F57575B9" toRefs="TextSelection-792D3AB23D6354CFBB2776AE7F6407B4-0-wk-Footnote-792D3AB23D6354CFBB2776AE7F6407B4_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d43687704e3180-wk-Fact-413D25685F8F583AB53236F9F57575B9 d43690878e2263-wk-Fact-413D25685F8F583AB53236F9F57575B9" toRefs="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687704e3180-wk-Fact-413D25685F8F583AB53236F9F57575B9 d43690878e2263-wk-Fact-413D25685F8F583AB53236F9F57575B9" toRefs="TextSelection-9231AC55B8EC5775BC4995B0797F870F-0-wk-Footnote-9231AC55B8EC5775BC4995B0797F870F_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43674379e1721-wk-Fact-41E568B8775D59BFBCD7C2E611178392" toRefs="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e5759-wk-Fact-41F768EB6EEC5BBBA68D38AC1F01367F" toRefs="TextSelection-0BDE8CEE983B5F118E2EFACDF9CC6405-0-wk-Footnote-0BDE8CEE983B5F118E2EFACDF9CC6405_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43681613e1248-wk-Fact-4205D6E535945DAFBDC33902ED523920" toRefs="TextSelection-3DD94144621C5A68BC21C5DB64345BB9-0-wk-Footnote-3DD94144621C5A68BC21C5DB64345BB9_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43681613e1248-wk-Fact-4205D6E535945DAFBDC33902ED523920" toRefs="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43771853e8278-wk-Fact-4207856257675CFDB3EB4159D299660D" toRefs="TextSelection-C4FFB7FEB33B5D5EBA7924687B243323-0-wk-Footnote-C4FFB7FEB33B5D5EBA7924687B243323_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43674379e2094-wk-Fact-4207CB01CC1150BFA16DC1CBD3FDE8A0" toRefs="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43674379e2405-wk-Fact-42825AA4D3815C349BD40B420827B233" toRefs="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43681613e1382-wk-Fact-42968803AD055EFEB0C3ED702C15D6AC" toRefs="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43770747e8898-wk-Fact-42F9DF20DDCA5646904966177DFB6AA4" toRefs="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e8898-wk-Fact-42F9DF20DDCA5646904966177DFB6AA4" toRefs="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="Fact-438EE85774DF543BA158096F9559C174-wk-Fact-438EE85774DF543BA158096F9559C174" toRefs="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687849e1987-wk-Fact-439917D3DAAF58E1AD6CD991FC80DC42" toRefs="TextSelection-77536863BCE35B419E3A4119D41DB4BD-0-wk-Footnote-77536863BCE35B419E3A4119D41DB4BD_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43687849e1987-wk-Fact-439917D3DAAF58E1AD6CD991FC80DC42" toRefs="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43771853e11380-wk-Fact-442B1474BBCB5FE8A099D633CB680650" toRefs="TextSelection-DE7EF4A6663E52BF8D3620854A57A945-0-wk-Footnote-DE7EF4A6663E52BF8D3620854A57A945_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e4403-wk-Fact-44ACB44C1F6D5867A9AE1BCDA6662468" toRefs="TextSelection-2BFD6C99096B50AD93705C5601B21F46-0-wk-Footnote-2BFD6C99096B50AD93705C5601B21F46_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43681613e2059-wk-Fact-450DDE9FBB965039B395036FE74CBBB0" toRefs="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43771853e4822-wk-Fact-4589B65A44FD5257A71D6C106B182464" toRefs="TextSelection-DC6DDCB74FC9523D97BA51FBA6B1C05E-0-wk-Footnote-DC6DDCB74FC9523D97BA51FBA6B1C05E_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43674379e2031-wk-Fact-45A307B4BFCC56B2A721109AA18533BB" toRefs="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43712496e3283-wk-Fact-45F6314CE80C59AC9D1C31C3E15AFBD8" toRefs="TextSelection-02609C62928C5D1CBFB6DD071D9D7B0E-0-wk-Footnote-02609C62928C5D1CBFB6DD071D9D7B0E_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43681613e1402-wk-Fact-4638ED2A9682598F89E8D0DE8B195AA8" toRefs="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43771853e4606-wk-Fact-465B9433DD0F5F3D8D3A8DC7524E082A" toRefs="TextSelection-3802305E73EB52F28FAAF4EA5481D580-0-wk-Footnote-3802305E73EB52F28FAAF4EA5481D580_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43712496e2445-wk-Fact-466AE7233A2D57E48E9D5268F9EEEBF0" toRefs="TextSelection-C37CD88178CA35C475D25A62F2B54FED-0-wk-Footnote-C37CD88178CA35C475D25A62F2B54FED_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e1628-wk-Fact-46A836D9C25B56FF9251C6C08C3CCB44" toRefs="TextSelection-58096FF6357955D6B6AA25D56767CB0A-0-wk-Footnote-58096FF6357955D6B6AA25D56767CB0A_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43770747e1628-wk-Fact-46A836D9C25B56FF9251C6C08C3CCB44" toRefs="TextSelection-8D2A93033C2E56DE9E814F0AB36328EE-0-wk-Footnote-8D2A93033C2E56DE9E814F0AB36328EE_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687849e3113-wk-Fact-46E6ECDFD5B35112ACFA85A4DD680D69" toRefs="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e4176-wk-Fact-46FCF46F8CE857D6A45597A49A1788DE" toRefs="TextSelection-2BFD6C99096B50AD93705C5601B21F46-0-wk-Footnote-2BFD6C99096B50AD93705C5601B21F46_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687849e1968-wk-Fact-472E8E6F6DB25346B046668C52D5902F" toRefs="TextSelection-77536863BCE35B419E3A4119D41DB4BD-0-wk-Footnote-77536863BCE35B419E3A4119D41DB4BD_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43687849e1968-wk-Fact-472E8E6F6DB25346B046668C52D5902F" toRefs="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43771853e11144-wk-Fact-473A8153DB95559E92CC6D9F938E0BCE" toRefs="TextSelection-ED6F6E1A7C41596DA6F5B1BDFBB72CB7-0-wk-Footnote-ED6F6E1A7C41596DA6F5B1BDFBB72CB7_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43687704e2822-wk-Fact-473E2E1DAAB95751BEEBC640CAD75D52" toRefs="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687704e2822-wk-Fact-473E2E1DAAB95751BEEBC640CAD75D52" toRefs="TextSelection-9231AC55B8EC5775BC4995B0797F870F-0-wk-Footnote-9231AC55B8EC5775BC4995B0797F870F_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43712496e3540-wk-Fact-477878BBEDE5542C9F9E88C10D02CABE" toRefs="TextSelection-3E9076747FF25E3B8D3B9AAF71548F16-0-wk-Footnote-3E9076747FF25E3B8D3B9AAF71548F16_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43690878e1537-wk-Fact-4791EB1764F851F9BFC3743AD13BD04D" toRefs="TextSelection-792D3AB23D6354CFBB2776AE7F6407B4-0-wk-Footnote-792D3AB23D6354CFBB2776AE7F6407B4_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43771853e3215-wk-Fact-47A9B6BC4350580490BDDDA2982DE155" toRefs="TextSelection-13C3E50268A15908A8AC9D1B6C938D2D-0-wk-Footnote-13C3E50268A15908A8AC9D1B6C938D2D_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43771853e3215-wk-Fact-47A9B6BC4350580490BDDDA2982DE155" toRefs="TextSelection-78FC5AB8EFAB585E87BBCF93BE9FBF1D-0-wk-Footnote-78FC5AB8EFAB585E87BBCF93BE9FBF1D_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e4058-wk-Fact-47F85ABECEA3558FB193E486A6300E36" toRefs="TextSelection-7EC55EFE69505245B1A079B8132EFBB7-0-wk-Footnote-7EC55EFE69505245B1A079B8132EFBB7_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e10015-wk-Fact-481B3D6C84EF52CCBEBB11AB001F4356" toRefs="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43770747e10015-wk-Fact-481B3D6C84EF52CCBEBB11AB001F4356" toRefs="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43687704e2784-wk-Fact-485CB0863B5C5B9D8B2C74086517AD5B" toRefs="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687704e2784-wk-Fact-485CB0863B5C5B9D8B2C74086517AD5B" toRefs="TextSelection-9231AC55B8EC5775BC4995B0797F870F-0-wk-Footnote-9231AC55B8EC5775BC4995B0797F870F_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43770747e7739-wk-Fact-4918CC17DAC15E038DC184F1DA176587" toRefs="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e7739-wk-Fact-4918CC17DAC15E038DC184F1DA176587" toRefs="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43697224e1460-wk-Fact-4927FC00863B524C890DD332985D1F82" toRefs="TextSelection-FCAEF1B26EF652E4896D2456427B24D7-0-wk-Footnote-FCAEF1B26EF652E4896D2456427B24D7_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43771853e2795-wk-Fact-4978864FED0C5781909B06FB41801AC3" toRefs="TextSelection-78FC5AB8EFAB585E87BBCF93BE9FBF1D-0-wk-Footnote-78FC5AB8EFAB585E87BBCF93BE9FBF1D_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43697224e2924-wk-Fact-49CB6967F08724E343E55A1EFDC1A551" toRefs="TextSelection-066A0A390204B79351965A22CE69E761-0-wk-Footnote-066A0A390204B79351965A22CE69E761_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43697224e2924-wk-Fact-49CB6967F08724E343E55A1EFDC1A551" toRefs="TextSelection-4AF5AB391F1CD8054C065A2324C0D822-0-wk-Footnote-4AF5AB391F1CD8054C065A2324C0D822_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43674379e1784-wk-Fact-4A5801DF38F08BD8CEC3922878CFA84A" toRefs="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e10370-wk-Fact-4ADCC13FDAC45B6BB3630C98712932FD" toRefs="TextSelection-39CF024D03225486829869F6CA02C00E-0-wk-Footnote-39CF024D03225486829869F6CA02C00E_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d43770747e10370-wk-Fact-4ADCC13FDAC45B6BB3630C98712932FD" toRefs="TextSelection-53BB8CAFCA475C0C9DB2195050D36025-0-wk-Footnote-53BB8CAFCA475C0C9DB2195050D36025_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43770747e10370-wk-Fact-4ADCC13FDAC45B6BB3630C98712932FD" toRefs="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43771853e2192-wk-Fact-4B3A8022310558FC9B763D89CFB05272" toRefs="TextSelection-78FC5AB8EFAB585E87BBCF93BE9FBF1D-0-wk-Footnote-78FC5AB8EFAB585E87BBCF93BE9FBF1D_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43687704e2911-wk-Fact-4B8F1DBA2929519A88C07E8910A30454" toRefs="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687704e2911-wk-Fact-4B8F1DBA2929519A88C07E8910A30454" toRefs="TextSelection-9231AC55B8EC5775BC4995B0797F870F-0-wk-Footnote-9231AC55B8EC5775BC4995B0797F870F_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="Fact-4C5952B687735A68B4F8FF2FF8E28F5B-wk-Fact-4C5952B687735A68B4F8FF2FF8E28F5B" toRefs="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e7335-wk-Fact-4C647D3AD0F151A9BA9998C97C5B0A63" toRefs="TextSelection-39CF024D03225486829869F6CA02C00E-0-wk-Footnote-39CF024D03225486829869F6CA02C00E_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43770747e7335-wk-Fact-4C647D3AD0F151A9BA9998C97C5B0A63" toRefs="TextSelection-53BB8CAFCA475C0C9DB2195050D36025-0-wk-Footnote-53BB8CAFCA475C0C9DB2195050D36025_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d43770747e7335-wk-Fact-4C647D3AD0F151A9BA9998C97C5B0A63" toRefs="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687849e1301-wk-Fact-4C6BD95E3D2E5FB8B5E794AE6EE85755" toRefs="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43712510e4343-wk-Fact-4C8B761BC8A857289F300FD346EDCFF2" toRefs="TextSelection-621F9196966C550EA113DA57575C171E-0-wk-Footnote-621F9196966C550EA113DA57575C171E_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="Fact-4CB7130CEF915377BE0293C8FB86F1C5-wk-Fact-4CB7130CEF915377BE0293C8FB86F1C5" toRefs="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43681613e973-wk-Fact-4CD7C8E134F3568695AECCF94C6AF4FD d43697224e1499-wk-Fact-4CD7C8E134F3568695AECCF94C6AF4FD" toRefs="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43681613e973-wk-Fact-4CD7C8E134F3568695AECCF94C6AF4FD d43697224e1499-wk-Fact-4CD7C8E134F3568695AECCF94C6AF4FD" toRefs="TextSelection-FCAEF1B26EF652E4896D2456427B24D7-0-wk-Footnote-FCAEF1B26EF652E4896D2456427B24D7_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43712510e4818-wk-Fact-4CE5EEDBEB0E56709AF5BDD28428C8A4" toRefs="TextSelection-621F9196966C550EA113DA57575C171E-0-wk-Footnote-621F9196966C550EA113DA57575C171E_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43681613e904-wk-Fact-4D5D0B01BEBB5DEFB2827E50144E0489" toRefs="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43681613e2078-wk-Fact-4D68DAE5FD3059969FCBB65614BE4D06" toRefs="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43771853e4668-wk-Fact-4DBF4C8A615D5B5885A229550C249596" toRefs="TextSelection-E9F14C2885BA59D8B6B4AD221FC38619-0-wk-Footnote-E9F14C2885BA59D8B6B4AD221FC38619_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43712496e1841-wk-Fact-4DC7F6E7ED055FD8910B97A13EEF264E" toRefs="TextSelection-7160FF67E87550A19177FE255A41A2D7-0-wk-Footnote-7160FF67E87550A19177FE255A41A2D7_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43712496e2235-wk-Fact-4DCE62D0C18E5CD6957CFB6E8F495684" toRefs="TextSelection-C37CD88178CA35C475D25A62F2B54FED-0-wk-Footnote-C37CD88178CA35C475D25A62F2B54FED_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e11192-wk-Fact-4E50B891ECDF54F8B82E01242152C091" toRefs="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43770747e11192-wk-Fact-4E50B891ECDF54F8B82E01242152C091" toRefs="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43687704e3122-wk-Fact-4F013E58EAE3506D989984D20AC7A60B d43690878e2205-wk-Fact-4F013E58EAE3506D989984D20AC7A60B" toRefs="TextSelection-792D3AB23D6354CFBB2776AE7F6407B4-0-wk-Footnote-792D3AB23D6354CFBB2776AE7F6407B4_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d43687704e3122-wk-Fact-4F013E58EAE3506D989984D20AC7A60B d43690878e2205-wk-Fact-4F013E58EAE3506D989984D20AC7A60B" toRefs="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687704e3122-wk-Fact-4F013E58EAE3506D989984D20AC7A60B d43690878e2205-wk-Fact-4F013E58EAE3506D989984D20AC7A60B" toRefs="TextSelection-9231AC55B8EC5775BC4995B0797F870F-0-wk-Footnote-9231AC55B8EC5775BC4995B0797F870F_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43687704e1599-wk-Fact-4F4FAE747047530784054ED85551DFDC" toRefs="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687704e1599-wk-Fact-4F4FAE747047530784054ED85551DFDC" toRefs="TextSelection-9231AC55B8EC5775BC4995B0797F870F-0-wk-Footnote-9231AC55B8EC5775BC4995B0797F870F_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e3159-wk-Fact-4F630A08F3EE5D04A766A973955E5DEE" toRefs="TextSelection-DAFABE7CE058521690718900BE6137FA-0-wk-Footnote-DAFABE7CE058521690718900BE6137FA_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43687704e2418-wk-Fact-4FA35F91DEE258C694579DEDDD33A6CF" toRefs="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687704e2418-wk-Fact-4FA35F91DEE258C694579DEDDD33A6CF" toRefs="TextSelection-9231AC55B8EC5775BC4995B0797F870F-0-wk-Footnote-9231AC55B8EC5775BC4995B0797F870F_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687849e2996-wk-Fact-503B87CD9CE65FEDBBDC99370F10DF6B" toRefs="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43674379e2183-wk-Fact-50ADB7EB4847506EA08C0BF6C7E30E84" toRefs="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43770747e8151-wk-Fact-5134E9EECF3F53FC8E0FBFCC64592278" toRefs="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e8151-wk-Fact-5134E9EECF3F53FC8E0FBFCC64592278" toRefs="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43712496e1348-wk-Fact-5183BF736F1E563FA304D5EEBF7843EF" toRefs="TextSelection-B57619F44FCF544D96067CF4816A9082-0-wk-Footnote-B57619F44FCF544D96067CF4816A9082_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43687849e1666-wk-Fact-51BE1E50E018595FBB09E1CA22E07612" toRefs="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687849e1666-wk-Fact-51BE1E50E018595FBB09E1CA22E07612" toRefs="TextSelection-F185CD45BC245C2EB8EDBFD55DB8A33F-0-wk-Footnote-F185CD45BC245C2EB8EDBFD55DB8A33F_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687849e2327-wk-Fact-51ECCBCA921E59759451F63108AF904D" toRefs="TextSelection-77536863BCE35B419E3A4119D41DB4BD-0-wk-Footnote-77536863BCE35B419E3A4119D41DB4BD_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43687849e2327-wk-Fact-51ECCBCA921E59759451F63108AF904D" toRefs="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687849e1216-wk-Fact-524E646459CB5301AEC5027EA98F9741" toRefs="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687849e1902-wk-Fact-526D1E8FCDB9599FBA3FC176B4CBDF40" toRefs="TextSelection-77536863BCE35B419E3A4119D41DB4BD-0-wk-Footnote-77536863BCE35B419E3A4119D41DB4BD_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43687849e1902-wk-Fact-526D1E8FCDB9599FBA3FC176B4CBDF40" toRefs="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43697224e1304-wk-Fact-527425D761315660B95CBE4E0343A596" toRefs="TextSelection-7430C81CDF35536B95DB492D56AB6CFD-0-wk-Footnote-7430C81CDF35536B95DB492D56AB6CFD_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e2890-wk-Fact-52A1B75A34225AB0850E4467B145EE4C" toRefs="TextSelection-A9B5859E968353E1AF0EF5AF16D3F7DE-0-wk-Footnote-A9B5859E968353E1AF0EF5AF16D3F7DE_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e10868-wk-Fact-52FA3ED749A551E69FCC2DB848C60415" toRefs="TextSelection-39CF024D03225486829869F6CA02C00E-0-wk-Footnote-39CF024D03225486829869F6CA02C00E_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43770747e10868-wk-Fact-52FA3ED749A551E69FCC2DB848C60415" toRefs="TextSelection-53BB8CAFCA475C0C9DB2195050D36025-0-wk-Footnote-53BB8CAFCA475C0C9DB2195050D36025_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d43770747e10868-wk-Fact-52FA3ED749A551E69FCC2DB848C60415" toRefs="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43674379e1120-wk-Fact-5329671706335212AE3F5E2B75B7A4AB" toRefs="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43690878e2313-wk-Fact-5342CFBA0356578DAD0043F0EADED8C5" toRefs="TextSelection-0333DDFA54555789BB4E2E73E3451A69-0-wk-Footnote-0333DDFA54555789BB4E2E73E3451A69_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43690878e2313-wk-Fact-5342CFBA0356578DAD0043F0EADED8C5" toRefs="TextSelection-792D3AB23D6354CFBB2776AE7F6407B4-0-wk-Footnote-792D3AB23D6354CFBB2776AE7F6407B4_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43697224e2866-wk-Fact-53CD55B10DB9D18954E05A1EF2A58668" toRefs="TextSelection-066A0A390204B79351965A22CE69E761-0-wk-Footnote-066A0A390204B79351965A22CE69E761_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43697224e2866-wk-Fact-53CD55B10DB9D18954E05A1EF2A58668" toRefs="TextSelection-4AF5AB391F1CD8054C065A2324C0D822-0-wk-Footnote-4AF5AB391F1CD8054C065A2324C0D822_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43692105e1198-wk-Fact-53D122DE8506544FBB5C5E66B2ABDED8" toRefs="TextSelection-2A36E737FFF05E75B357CB41AFB5B6E2-0-wk-Footnote-2A36E737FFF05E75B357CB41AFB5B6E2_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43697224e1584-wk-Fact-53DF84C7A47DE18B0F1C5A2FEA57D70F" toRefs="TextSelection-8C5E9E30C7EB5291A3E0EE605FC281E8-0-wk-Footnote-8C5E9E30C7EB5291A3E0EE605FC281E8_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43697240e2085-wk-Fact-54A6BC26AA6157E19153460F2648274D d43697240e2123-wk-Fact-54A6BC26AA6157E19153460F2648274D" toRefs="TextSelection-7432EEEACAB3598FA522C1D7E1584D05-0-wk-Footnote-7432EEEACAB3598FA522C1D7E1584D05_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43697240e1363-wk-Fact-5609BB6BDB4E55C38CE62E60B3E67446" toRefs="TextSelection-7432EEEACAB3598FA522C1D7E1584D05-0-wk-Footnote-7432EEEACAB3598FA522C1D7E1584D05_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687704e1029-wk-Fact-570366E89FCD5DA8ACCEEA8270C0E4C3" toRefs="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43687704e1029-wk-Fact-570366E89FCD5DA8ACCEEA8270C0E4C3" toRefs="TextSelection-AE19F19C6AE65BBDA7F551089E2E7EDF-0-wk-Footnote-AE19F19C6AE65BBDA7F551089E2E7EDF_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e11263-wk-Fact-57780600A4525A59B0F30E20473A845F" toRefs="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43770747e11263-wk-Fact-57780600A4525A59B0F30E20473A845F" toRefs="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687849e1197-wk-Fact-579A851CE2B25899921158748034540F" toRefs="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e5647-wk-Fact-57AB6949DEF75EA6A568EF9676344801" toRefs="TextSelection-0BDE8CEE983B5F118E2EFACDF9CC6405-0-wk-Footnote-0BDE8CEE983B5F118E2EFACDF9CC6405_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43771853e1694-wk-Fact-57E8C529F5385E41A7B3E91CFC576F36" toRefs="TextSelection-13C3E50268A15908A8AC9D1B6C938D2D-0-wk-Footnote-13C3E50268A15908A8AC9D1B6C938D2D_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d43771853e1694-wk-Fact-57E8C529F5385E41A7B3E91CFC576F36" toRefs="TextSelection-78FC5AB8EFAB585E87BBCF93BE9FBF1D-0-wk-Footnote-78FC5AB8EFAB585E87BBCF93BE9FBF1D_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43771853e1694-wk-Fact-57E8C529F5385E41A7B3E91CFC576F36" toRefs="TextSelection-C2AA3A20AB3F54349FC86854E44E1000-0-wk-Footnote-C2AA3A20AB3F54349FC86854E44E1000_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43687704e2321-wk-Fact-57FC3ED392B859D78861D64EC5C88CB0" toRefs="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687704e2321-wk-Fact-57FC3ED392B859D78861D64EC5C88CB0" toRefs="TextSelection-9231AC55B8EC5775BC4995B0797F870F-0-wk-Footnote-9231AC55B8EC5775BC4995B0797F870F_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e7701-wk-Fact-581448B02BB95042932A4BD0D7479AFE" toRefs="TextSelection-39CF024D03225486829869F6CA02C00E-0-wk-Footnote-39CF024D03225486829869F6CA02C00E_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43770747e7701-wk-Fact-581448B02BB95042932A4BD0D7479AFE" toRefs="TextSelection-53BB8CAFCA475C0C9DB2195050D36025-0-wk-Footnote-53BB8CAFCA475C0C9DB2195050D36025_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d43770747e7701-wk-Fact-581448B02BB95042932A4BD0D7479AFE" toRefs="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43712496e1412-wk-Fact-5902E7F7E3325E0295E9C62DFD622D3E" toRefs="TextSelection-B57619F44FCF544D96067CF4816A9082-0-wk-Footnote-B57619F44FCF544D96067CF4816A9082_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687849e2717-wk-Fact-5950DF108F195FB594A31172740C60B3 d43691920e2585-wk-Fact-5950DF108F195FB594A31172740C60B3" toRefs="TextSelection-2A0DF68DD6E953419D1E9B1C848DB228-0-wk-Footnote-2A0DF68DD6E953419D1E9B1C848DB228_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43687849e2717-wk-Fact-5950DF108F195FB594A31172740C60B3 d43691920e2585-wk-Fact-5950DF108F195FB594A31172740C60B3" toRefs="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e4326-wk-Fact-59CF56CBCF3D5BF18E0D45DDA6F642AA" toRefs="TextSelection-2BFD6C99096B50AD93705C5601B21F46-0-wk-Footnote-2BFD6C99096B50AD93705C5601B21F46_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e11172-wk-Fact-59D88BD8C3615E16ADCBC18168C4F03C" toRefs="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43770747e11172-wk-Fact-59D88BD8C3615E16ADCBC18168C4F03C" toRefs="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43674379e1828-wk-Fact-5A2D57F680925DEC8A9CCA1553046941" toRefs="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43674379e2139-wk-Fact-5A59BE776E6E5E20B8346BDFE1D63D1D" toRefs="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e2980-wk-Fact-5AA4AF01AEF35754AABE41FB942D2F87" toRefs="TextSelection-D60DE89EECC65B759281157686B85E20-0-wk-Footnote-D60DE89EECC65B759281157686B85E20_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43681613e1653-wk-Fact-5AFE9DE44AC65078B297BF4B6B39C511" toRefs="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43697240e3270-wk-Fact-5B921CA5279853B595C111072F4FBA7F" toRefs="TextSelection-73987C5EBB9C5D43BC69B77F006C18A6-0-wk-Footnote-73987C5EBB9C5D43BC69B77F006C18A6_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43771853e4552-wk-Fact-5BB441E685D3543B8C59407802A0ACC5" toRefs="TextSelection-3802305E73EB52F28FAAF4EA5481D580-0-wk-Footnote-3802305E73EB52F28FAAF4EA5481D580_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687849e2416-wk-Fact-5BC61B13CAF15E29B03835EA44B618DD" toRefs="TextSelection-77536863BCE35B419E3A4119D41DB4BD-0-wk-Footnote-77536863BCE35B419E3A4119D41DB4BD_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43687849e2416-wk-Fact-5BC61B13CAF15E29B03835EA44B618DD" toRefs="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687849e3182-wk-Fact-5CD3245395AF57768A6DF8D7BDF6B0BB" toRefs="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43690878e1215-wk-Fact-5CD97DE05A495D5EAFB1D7B5FE4550A4" toRefs="TextSelection-792D3AB23D6354CFBB2776AE7F6407B4-0-wk-Footnote-792D3AB23D6354CFBB2776AE7F6407B4_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43681613e2150-wk-Fact-5D13F9FBBDEE52528006AA947B5F7E3A" toRefs="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43712496e1329-wk-Fact-5D501002D38D5167AA036C63DF82035D" toRefs="TextSelection-B57619F44FCF544D96067CF4816A9082-0-wk-Footnote-B57619F44FCF544D96067CF4816A9082_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43770747e10927-wk-Fact-5D5B1229DA1A57F080E4C581EAE83373" toRefs="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e10927-wk-Fact-5D5B1229DA1A57F080E4C581EAE83373" toRefs="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43712496e3341-wk-Fact-5E7B2FD2D8475DEA875CCD41E3E715EF" toRefs="TextSelection-02609C62928C5D1CBFB6DD071D9D7B0E-0-wk-Footnote-02609C62928C5D1CBFB6DD071D9D7B0E_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43712496e2484-wk-Fact-5EA1B375EFA75241A699CD076C5A9E06" toRefs="TextSelection-C37CD88178CA35C475D25A62F2B54FED-0-wk-Footnote-C37CD88178CA35C475D25A62F2B54FED_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43712496e1517-wk-Fact-5EA5FA662B4B55B598D62154953933DD" toRefs="TextSelection-6912797A078E5D59B618DFFBB81C1BB6-0-wk-Footnote-6912797A078E5D59B618DFFBB81C1BB6_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43712496e1185-wk-Fact-5EB5BCA88A6D540EBCA8B56A37E73824" toRefs="TextSelection-B57619F44FCF544D96067CF4816A9082-0-wk-Footnote-B57619F44FCF544D96067CF4816A9082_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43697224e1216-wk-Fact-5EDED3CDB1965C449739DBF427B7E981" toRefs="TextSelection-7679A63ACE625532ADFCC5B97C6C9FC6-0-wk-Footnote-7679A63ACE625532ADFCC5B97C6C9FC6_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43697224e1546-wk-Fact-5F0338CD4AAEEBC4E9D45A2FEA4E4512" toRefs="TextSelection-8C5E9E30C7EB5291A3E0EE605FC281E8-0-wk-Footnote-8C5E9E30C7EB5291A3E0EE605FC281E8_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43712496e2362-wk-Fact-5F3BEDE745975795948CDC9485283B89" toRefs="TextSelection-C37CD88178CA35C475D25A62F2B54FED-0-wk-Footnote-C37CD88178CA35C475D25A62F2B54FED_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43771853e11484-wk-Fact-5F6DD21DF11E5B29871B857CC403739A" toRefs="TextSelection-450A7304FB7E513FB479F6D9A06EF1D3-0-wk-Footnote-450A7304FB7E513FB479F6D9A06EF1D3_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687849e2807-wk-Fact-5FA838CDA13D589CA9003C05768C2A3F" toRefs="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687704e1404-wk-Fact-5FBAE33C336F53F48E8FF7CDE77BBB26 d43712496e1724-wk-Fact-5FBAE33C336F53F48E8FF7CDE77BBB26" toRefs="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43771853e2107-wk-Fact-5FBB1F07246D5AAFB10CAD5C2A396D68" toRefs="TextSelection-78FC5AB8EFAB585E87BBCF93BE9FBF1D-0-wk-Footnote-78FC5AB8EFAB585E87BBCF93BE9FBF1D_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43771853e2107-wk-Fact-5FBB1F07246D5AAFB10CAD5C2A396D68" toRefs="TextSelection-8540AADB45BE54D38C10451BF6A88AB4-0-wk-Footnote-8540AADB45BE54D38C10451BF6A88AB4_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687849e3035-wk-Fact-5FD229EF81AC578B949A3DF35BCE1FF6" toRefs="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e11070-wk-Fact-604E73BB58B354A8BE73520A47D45028" toRefs="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43770747e11070-wk-Fact-604E73BB58B354A8BE73520A47D45028" toRefs="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687704e1571-wk-Fact-6056A2295D7857F1915F488C04BDB11A d43771853e3671-wk-Fact-6056A2295D7857F1915F488C04BDB11A" toRefs="TextSelection-78FC5AB8EFAB585E87BBCF93BE9FBF1D-0-wk-Footnote-78FC5AB8EFAB585E87BBCF93BE9FBF1D_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43687704e1571-wk-Fact-6056A2295D7857F1915F488C04BDB11A d43771853e3671-wk-Fact-6056A2295D7857F1915F488C04BDB11A" toRefs="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687704e1805-wk-Fact-60867BC7B4C25795A91A0C8BA6B7BDAB d43690878e1485-wk-Fact-60867BC7B4C25795A91A0C8BA6B7BDAB" toRefs="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43770747e863-wk-Fact-60F0DB778C3D556896B02410EB2C0B1B" toRefs="TextSelection-8D2A93033C2E56DE9E814F0AB36328EE-0-wk-Footnote-8D2A93033C2E56DE9E814F0AB36328EE_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e863-wk-Fact-60F0DB778C3D556896B02410EB2C0B1B" toRefs="TextSelection-E96B3A139CCA56EC98329BC3717B10E3-0-wk-Footnote-E96B3A139CCA56EC98329BC3717B10E3_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e907-wk-Fact-6118811AB2DE5F6BA426EF1F188FBC53" toRefs="TextSelection-8D2A93033C2E56DE9E814F0AB36328EE-0-wk-Footnote-8D2A93033C2E56DE9E814F0AB36328EE_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687849e1434-wk-Fact-61418F4200B850038486B4BEDFA4FA9E" toRefs="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43771853e9297-wk-Fact-61AE31A35DC45F109F24557407C6BF9E" toRefs="TextSelection-08466783230155A08D7C13267B950D39-0-wk-Footnote-08466783230155A08D7C13267B950D39_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e8112-wk-Fact-620EDDBB2E7E58FE85B15DE61C5EDD21" toRefs="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43770747e8112-wk-Fact-620EDDBB2E7E58FE85B15DE61C5EDD21" toRefs="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687849e1538-wk-Fact-6246160B22DB5F86A702C0FDC31AEA8A" toRefs="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e4222-wk-Fact-626B15D2B1215E4FBC1B22217ABF166E" toRefs="TextSelection-2BFD6C99096B50AD93705C5601B21F46-0-wk-Footnote-2BFD6C99096B50AD93705C5601B21F46_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43687704e1657-wk-Fact-626C408AD0435F32862D27637DFEBF9C" toRefs="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687704e1657-wk-Fact-626C408AD0435F32862D27637DFEBF9C" toRefs="TextSelection-9231AC55B8EC5775BC4995B0797F870F-0-wk-Footnote-9231AC55B8EC5775BC4995B0797F870F_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687849e1775-wk-Fact-627842F5F2E15231B3D26A535F4705CA" toRefs="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43771853e11419-wk-Fact-6313B867BAC65FC1A4718632BEF06E26" toRefs="TextSelection-DE7EF4A6663E52BF8D3620854A57A945-0-wk-Footnote-DE7EF4A6663E52BF8D3620854A57A945_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43712496e1284-wk-Fact-632EFDC664F45A20BEB9A47C3FEE1B4D" toRefs="TextSelection-1B1FEAD5EA4E576891141CE7B2D9386E-0-wk-Footnote-1B1FEAD5EA4E576891141CE7B2D9386E_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43712496e1284-wk-Fact-632EFDC664F45A20BEB9A47C3FEE1B4D" toRefs="TextSelection-B57619F44FCF544D96067CF4816A9082-0-wk-Footnote-B57619F44FCF544D96067CF4816A9082_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43674379e2272-wk-Fact-63822E0DBF7E5CA2BB97325B6C3209EA" toRefs="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687704e3056-wk-Fact-63E834283E2059E3A8C189B4778885B0 d43690878e2054-wk-Fact-63E834283E2059E3A8C189B4778885B0" toRefs="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43771853e10256-wk-Fact-65EF603C04E95A788234DDAF3AC7D0D3" toRefs="TextSelection-DE7EF4A6663E52BF8D3620854A57A945-0-wk-Footnote-DE7EF4A6663E52BF8D3620854A57A945_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43697224e1324-wk-Fact-66565D977AC4509C90AB6F21D06331BE" toRefs="TextSelection-7430C81CDF35536B95DB492D56AB6CFD-0-wk-Footnote-7430C81CDF35536B95DB492D56AB6CFD_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43687704e2803-wk-Fact-669021DA4A3E525F9913592D2FD04D72" toRefs="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687704e2803-wk-Fact-669021DA4A3E525F9913592D2FD04D72" toRefs="TextSelection-9231AC55B8EC5775BC4995B0797F870F-0-wk-Footnote-9231AC55B8EC5775BC4995B0797F870F_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43697224e2943-wk-Fact-66BA540C016377984D0B5A1F012CEDE6" toRefs="TextSelection-066A0A390204B79351965A22CE69E761-0-wk-Footnote-066A0A390204B79351965A22CE69E761_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43712496e2464-wk-Fact-66E019D2BC3C5C3C98FDC370D9EE61F3" toRefs="TextSelection-C37CD88178CA35C475D25A62F2B54FED-0-wk-Footnote-C37CD88178CA35C475D25A62F2B54FED_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687849e2690-wk-Fact-672E389254015A85B0E497DA6B98ED65" toRefs="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e926-wk-Fact-672E844C4F3953138ADA20A9FE757D32" toRefs="TextSelection-8D2A93033C2E56DE9E814F0AB36328EE-0-wk-Footnote-8D2A93033C2E56DE9E814F0AB36328EE_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43771853e10236-wk-Fact-67696AFA82F051C9ADF09241496CA1F1" toRefs="TextSelection-DE7EF4A6663E52BF8D3620854A57A945-0-wk-Footnote-DE7EF4A6663E52BF8D3620854A57A945_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e10972-wk-Fact-67797DE457375667B2C84DC5692034E9" toRefs="TextSelection-39CF024D03225486829869F6CA02C00E-0-wk-Footnote-39CF024D03225486829869F6CA02C00E_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d43770747e10972-wk-Fact-67797DE457375667B2C84DC5692034E9" toRefs="TextSelection-53BB8CAFCA475C0C9DB2195050D36025-0-wk-Footnote-53BB8CAFCA475C0C9DB2195050D36025_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43770747e10972-wk-Fact-67797DE457375667B2C84DC5692034E9" toRefs="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43712510e4978-wk-Fact-680AB021A9D85E21AC0D650674666D7F" toRefs="TextSelection-621F9196966C550EA113DA57575C171E-0-wk-Footnote-621F9196966C550EA113DA57575C171E_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43674379e1032-wk-Fact-686063BE60325E2A839CE026F903431A" toRefs="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687849e2307-wk-Fact-6866C3FD323B5B328644E3617D27748F" toRefs="TextSelection-77536863BCE35B419E3A4119D41DB4BD-0-wk-Footnote-77536863BCE35B419E3A4119D41DB4BD_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43687849e2307-wk-Fact-6866C3FD323B5B328644E3617D27748F" toRefs="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43674379e1278-wk-Fact-691B87100C6755EB85765E65D5C328BA d43697240e3378-wk-Fact-691B87100C6755EB85765E65D5C328BA" toRefs="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43681613e1173-wk-Fact-6944308547D65750B49346E97B2688A0" toRefs="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43687849e1369-wk-Fact-6968FECDFB645F1C88CC9A36C37CAA90" toRefs="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687849e1369-wk-Fact-6968FECDFB645F1C88CC9A36C37CAA90" toRefs="TextSelection-F185CD45BC245C2EB8EDBFD55DB8A33F-0-wk-Footnote-F185CD45BC245C2EB8EDBFD55DB8A33F_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687849e2826-wk-Fact-69A896461F495ACBB885D53F5353F71F" toRefs="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687704e3037-wk-Fact-69E50427EE6E533896BB8B1907041230 d43690878e2035-wk-Fact-69E50427EE6E533896BB8B1907041230" toRefs="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43697224e1480-wk-Fact-69F129F21E2851A6981AF851D0C9DC3E" toRefs="TextSelection-FCAEF1B26EF652E4896D2456427B24D7-0-wk-Footnote-FCAEF1B26EF652E4896D2456427B24D7_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e1673-wk-Fact-6AAB9598D7F95613809C632062D37B56" toRefs="TextSelection-58096FF6357955D6B6AA25D56767CB0A-0-wk-Footnote-58096FF6357955D6B6AA25D56767CB0A_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43770747e1673-wk-Fact-6AAB9598D7F95613809C632062D37B56" toRefs="TextSelection-8D2A93033C2E56DE9E814F0AB36328EE-0-wk-Footnote-8D2A93033C2E56DE9E814F0AB36328EE_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43697240e3289-wk-Fact-6AC822CCA34E51E4AFF352F6B975BAEF" toRefs="TextSelection-73987C5EBB9C5D43BC69B77F006C18A6-0-wk-Footnote-73987C5EBB9C5D43BC69B77F006C18A6_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43712496e1205-wk-Fact-6AEAE394B9B450FDAF7AF8A431A29CCE" toRefs="TextSelection-B57619F44FCF544D96067CF4816A9082-0-wk-Footnote-B57619F44FCF544D96067CF4816A9082_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43712496e2298-wk-Fact-6B7573DC24D452F9A1161BC5959839D3" toRefs="TextSelection-C37CD88178CA35C475D25A62F2B54FED-0-wk-Footnote-C37CD88178CA35C475D25A62F2B54FED_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e8235-wk-Fact-6BED389587795F178A51DFB7B1F38F10" toRefs="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43770747e8235-wk-Fact-6BED389587795F178A51DFB7B1F38F10" toRefs="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687704e1551-wk-Fact-6C225350ED6F51898E27B37470C6135A d43771853e3652-wk-Fact-6C225350ED6F51898E27B37470C6135A" toRefs="TextSelection-78FC5AB8EFAB585E87BBCF93BE9FBF1D-0-wk-Footnote-78FC5AB8EFAB585E87BBCF93BE9FBF1D_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43687704e1551-wk-Fact-6C225350ED6F51898E27B37470C6135A d43771853e3652-wk-Fact-6C225350ED6F51898E27B37470C6135A" toRefs="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43771853e1954-wk-Fact-6C4D8296C83F57DC93CF1B41EF47EFF1" toRefs="TextSelection-13C3E50268A15908A8AC9D1B6C938D2D-0-wk-Footnote-13C3E50268A15908A8AC9D1B6C938D2D_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43771853e1954-wk-Fact-6C4D8296C83F57DC93CF1B41EF47EFF1" toRefs="TextSelection-78FC5AB8EFAB585E87BBCF93BE9FBF1D-0-wk-Footnote-78FC5AB8EFAB585E87BBCF93BE9FBF1D_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43674379e1765-wk-Fact-6C83895D828D8E3BC5AC922878C0762E" toRefs="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687704e3229-wk-Fact-6CE7E4C1FB715EB9A50793367CE85508" toRefs="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e4280-wk-Fact-6CF1FB1C274D54BC8DA1DED40575D72D" toRefs="TextSelection-2BFD6C99096B50AD93705C5601B21F46-0-wk-Footnote-2BFD6C99096B50AD93705C5601B21F46_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e8255-wk-Fact-6D120F6B1B935942908A657A342EF520" toRefs="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43770747e8255-wk-Fact-6D120F6B1B935942908A657A342EF520" toRefs="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43712510e5163-wk-Fact-6D35DF163ED156B392B0ABBC405525F5" toRefs="TextSelection-621F9196966C550EA113DA57575C171E-0-wk-Footnote-621F9196966C550EA113DA57575C171E_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43697240e2028-wk-Fact-6D6000856CC75C59855BFA6956D3EBE0 d43697240e2065-wk-Fact-6D6000856CC75C59855BFA6956D3EBE0" toRefs="TextSelection-7432EEEACAB3598FA522C1D7E1584D05-0-wk-Footnote-7432EEEACAB3598FA522C1D7E1584D05_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43770747e7759-wk-Fact-6E0D94B5020A54D8AA03215EBE1D7EF9" toRefs="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e7759-wk-Fact-6E0D94B5020A54D8AA03215EBE1D7EF9" toRefs="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43674379e1366-wk-Fact-6F2B43838191546AA755245948E565C5" toRefs="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43771853e2020-wk-Fact-701D108258D15E76898CF0E9F156AAB3" toRefs="TextSelection-13C3E50268A15908A8AC9D1B6C938D2D-0-wk-Footnote-13C3E50268A15908A8AC9D1B6C938D2D_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43771853e2020-wk-Fact-701D108258D15E76898CF0E9F156AAB3" toRefs="TextSelection-78FC5AB8EFAB585E87BBCF93BE9FBF1D-0-wk-Footnote-78FC5AB8EFAB585E87BBCF93BE9FBF1D_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43674379e1588-wk-Fact-708405E59C1952EAA954BB6C9B186068" toRefs="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43674379e1415-wk-Fact-70B456CF1E475D979F768DB28C19676E" toRefs="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e2961-wk-Fact-70B840CF49ED50999728E55D1211F51E" toRefs="TextSelection-D60DE89EECC65B759281157686B85E20-0-wk-Footnote-D60DE89EECC65B759281157686B85E20_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43690878e2139-wk-Fact-712D745DC4AA5C53A5626F7D089F61CB" toRefs="TextSelection-792D3AB23D6354CFBB2776AE7F6407B4-0-wk-Footnote-792D3AB23D6354CFBB2776AE7F6407B4_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687849e2437-wk-Fact-713AA3AA57EE5FBCBD96967A8F7E9885" toRefs="TextSelection-77536863BCE35B419E3A4119D41DB4BD-0-wk-Footnote-77536863BCE35B419E3A4119D41DB4BD_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43687849e2437-wk-Fact-713AA3AA57EE5FBCBD96967A8F7E9885" toRefs="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43771853e2873-wk-Fact-713D053AAB3F543EAA3B2BC05CA14525" toRefs="TextSelection-78FC5AB8EFAB585E87BBCF93BE9FBF1D-0-wk-Footnote-78FC5AB8EFAB585E87BBCF93BE9FBF1D_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43681613e1428-wk-Fact-71772D6AB77F595C866B3F8F2284E23A" toRefs="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687849e2396-wk-Fact-719A3A5AFE7E590BA2BBA17A3393549C" toRefs="TextSelection-77536863BCE35B419E3A4119D41DB4BD-0-wk-Footnote-77536863BCE35B419E3A4119D41DB4BD_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43687849e2396-wk-Fact-719A3A5AFE7E590BA2BBA17A3393549C" toRefs="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43771853e1673-wk-Fact-71E7D0DF9D86563A92C28ADB4DD1F792" toRefs="TextSelection-13C3E50268A15908A8AC9D1B6C938D2D-0-wk-Footnote-13C3E50268A15908A8AC9D1B6C938D2D_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d43771853e1673-wk-Fact-71E7D0DF9D86563A92C28ADB4DD1F792" toRefs="TextSelection-78FC5AB8EFAB585E87BBCF93BE9FBF1D-0-wk-Footnote-78FC5AB8EFAB585E87BBCF93BE9FBF1D_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43771853e1673-wk-Fact-71E7D0DF9D86563A92C28ADB4DD1F792" toRefs="TextSelection-C2AA3A20AB3F54349FC86854E44E1000-0-wk-Footnote-C2AA3A20AB3F54349FC86854E44E1000_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e9788-wk-Fact-721EE01F467C5AA2AF5D9ABD57151BB3" toRefs="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43770747e9788-wk-Fact-721EE01F467C5AA2AF5D9ABD57151BB3" toRefs="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e8569-wk-Fact-7245AD177ECF539AA450E00174CA6B5E" toRefs="TextSelection-39CF024D03225486829869F6CA02C00E-0-wk-Footnote-39CF024D03225486829869F6CA02C00E_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43770747e8569-wk-Fact-7245AD177ECF539AA450E00174CA6B5E" toRefs="TextSelection-53BB8CAFCA475C0C9DB2195050D36025-0-wk-Footnote-53BB8CAFCA475C0C9DB2195050D36025_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d43770747e8569-wk-Fact-7245AD177ECF539AA450E00174CA6B5E" toRefs="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e4551-wk-Fact-727F9AD82CCB5AC493868224E1DEDA9B" toRefs="TextSelection-5259D0A3B8885FEE951D5ABCA017CBFC-0-wk-Footnote-5259D0A3B8885FEE951D5ABCA017CBFC_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687849e1750-wk-Fact-7299B19500C65AA4886E0CA9F295C4DC" toRefs="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687849e2521-wk-Fact-72DABC7CCBA75E3598D920B948A182DB" toRefs="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687849e1028-wk-Fact-72F6CFB7B5D35966938C0A78B6424FE7" toRefs="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43681613e1608-wk-Fact-7366AB7164FB57C0B8A92433A2836E49" toRefs="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43712496e2426-wk-Fact-73777733794C543CA62126B6042D00DB" toRefs="TextSelection-C37CD88178CA35C475D25A62F2B54FED-0-wk-Footnote-C37CD88178CA35C475D25A62F2B54FED_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687704e843-wk-Fact-739EC43DD13B5516B11DE41A93EEDF71 d43771853e2244-wk-Fact-739EC43DD13B5516B11DE41A93EEDF71 d43771853e4901-wk-Fact-739EC43DD13B5516B11DE41A93EEDF71" toRefs="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43770747e822-wk-Fact-73ABA67055275455B7AA44864D34F006" toRefs="TextSelection-0A1952177FA453EC8B5651D58249A9BA-0-wk-Footnote-0A1952177FA453EC8B5651D58249A9BA_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e822-wk-Fact-73ABA67055275455B7AA44864D34F006" toRefs="TextSelection-8D2A93033C2E56DE9E814F0AB36328EE-0-wk-Footnote-8D2A93033C2E56DE9E814F0AB36328EE_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43687704e1637-wk-Fact-741D17F5FCAB522EB406F004C9FDBAA3" toRefs="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687704e1637-wk-Fact-741D17F5FCAB522EB406F004C9FDBAA3" toRefs="TextSelection-9231AC55B8EC5775BC4995B0797F870F-0-wk-Footnote-9231AC55B8EC5775BC4995B0797F870F_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43674379e1385-wk-Fact-74A94C963B005FB79E90256BEDC19745" toRefs="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43691920e1203-wk-Fact-74D925B0A9935FB7A7B9371D66730DC0" toRefs="TextSelection-C94190737D79577A8993EFAC2CD3FC95-0-wk-Footnote-C94190737D79577A8993EFAC2CD3FC95_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43697224e944-wk-Fact-74E639AFF5BE5619A8D6D94B13D9C7F4" toRefs="TextSelection-FE5DD06AA8B65777900C47B8AC19C4C6-0-wk-Footnote-FE5DD06AA8B65777900C47B8AC19C4C6_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43681613e2261-wk-Fact-74EE204494395BACA3BF106440743D87" toRefs="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687849e2220-wk-Fact-75134F72E4DA517BA3893A36B2D82E24" toRefs="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43681613e1562-wk-Fact-751B2E1EB7FE550C886A2AD44ED6CFCB" toRefs="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e1197-wk-Fact-757F830EC82D5CFD89824C319DD82983" toRefs="TextSelection-8D2A93033C2E56DE9E814F0AB36328EE-0-wk-Footnote-8D2A93033C2E56DE9E814F0AB36328EE_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43770747e1197-wk-Fact-757F830EC82D5CFD89824C319DD82983" toRefs="TextSelection-91730671722A5F83BA05EF347193E4CF-0-wk-Footnote-91730671722A5F83BA05EF347193E4CF_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43770747e7553-wk-Fact-75B9ED2C492450B59C9FBE062087C17F" toRefs="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e7553-wk-Fact-75B9ED2C492450B59C9FBE062087C17F" toRefs="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687704e901-wk-Fact-769863A67705599FBF10A0F9C982956F d43771853e3632-wk-Fact-769863A67705599FBF10A0F9C982956F d43771853e4973-wk-Fact-769863A67705599FBF10A0F9C982956F" toRefs="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d43687704e1890-wk-Fact-769C4E4C0C905BDA89016FEC60CCEAB2 d43687849e885-wk-Fact-769C4E4C0C905BDA89016FEC60CCEAB2 d43681613e802-wk-Fact-769C4E4C0C905BDA89016FEC60CCEAB2" toRefs="TextSelection-3DD94144621C5A68BC21C5DB64345BB9-0-wk-Footnote-3DD94144621C5A68BC21C5DB64345BB9_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="5" fromRefs="d43687704e1890-wk-Fact-769C4E4C0C905BDA89016FEC60CCEAB2 d43687849e885-wk-Fact-769C4E4C0C905BDA89016FEC60CCEAB2 d43681613e802-wk-Fact-769C4E4C0C905BDA89016FEC60CCEAB2" toRefs="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687704e1890-wk-Fact-769C4E4C0C905BDA89016FEC60CCEAB2 d43687849e885-wk-Fact-769C4E4C0C905BDA89016FEC60CCEAB2 d43681613e802-wk-Fact-769C4E4C0C905BDA89016FEC60CCEAB2" toRefs="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43687704e1890-wk-Fact-769C4E4C0C905BDA89016FEC60CCEAB2 d43687849e885-wk-Fact-769C4E4C0C905BDA89016FEC60CCEAB2 d43681613e802-wk-Fact-769C4E4C0C905BDA89016FEC60CCEAB2" toRefs="TextSelection-9231AC55B8EC5775BC4995B0797F870F-0-wk-Footnote-9231AC55B8EC5775BC4995B0797F870F_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="4" fromRefs="d43687704e1890-wk-Fact-769C4E4C0C905BDA89016FEC60CCEAB2 d43687849e885-wk-Fact-769C4E4C0C905BDA89016FEC60CCEAB2 d43681613e802-wk-Fact-769C4E4C0C905BDA89016FEC60CCEAB2" toRefs="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687849e1922-wk-Fact-76C4477D67B058D0ADA197C508A6BFA0" toRefs="TextSelection-77536863BCE35B419E3A4119D41DB4BD-0-wk-Footnote-77536863BCE35B419E3A4119D41DB4BD_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43687849e1922-wk-Fact-76C4477D67B058D0ADA197C508A6BFA0" toRefs="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43681613e1537-wk-Fact-7715092F4977526AA9E3733E3C9831C4" toRefs="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43771853e1845-wk-Fact-773AA58B1A2B57898FCAC12E9643C9F5" toRefs="TextSelection-13C3E50268A15908A8AC9D1B6C938D2D-0-wk-Footnote-13C3E50268A15908A8AC9D1B6C938D2D_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43771853e1845-wk-Fact-773AA58B1A2B57898FCAC12E9643C9F5" toRefs="TextSelection-78FC5AB8EFAB585E87BBCF93BE9FBF1D-0-wk-Footnote-78FC5AB8EFAB585E87BBCF93BE9FBF1D_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e9648-wk-Fact-774518EA7FE3544C826E80CBE973BB7B" toRefs="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43770747e9648-wk-Fact-774518EA7FE3544C826E80CBE973BB7B" toRefs="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e9977-wk-Fact-77E4DFB6EFD85BAB909056B138A7DECB" toRefs="TextSelection-39CF024D03225486829869F6CA02C00E-0-wk-Footnote-39CF024D03225486829869F6CA02C00E_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d43770747e9977-wk-Fact-77E4DFB6EFD85BAB909056B138A7DECB" toRefs="TextSelection-53BB8CAFCA475C0C9DB2195050D36025-0-wk-Footnote-53BB8CAFCA475C0C9DB2195050D36025_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43770747e9977-wk-Fact-77E4DFB6EFD85BAB909056B138A7DECB" toRefs="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e4590-wk-Fact-78AAF3709EB25116A215400F1CC559B2" toRefs="TextSelection-5259D0A3B8885FEE951D5ABCA017CBFC-0-wk-Footnote-5259D0A3B8885FEE951D5ABCA017CBFC_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e1152-wk-Fact-7911451CA2425E27919489254BB944BC" toRefs="TextSelection-8D2A93033C2E56DE9E814F0AB36328EE-0-wk-Footnote-8D2A93033C2E56DE9E814F0AB36328EE_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43770747e1152-wk-Fact-7911451CA2425E27919489254BB944BC" toRefs="TextSelection-91730671722A5F83BA05EF347193E4CF-0-wk-Footnote-91730671722A5F83BA05EF347193E4CF_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43692105e1276-wk-Fact-797701906D5A55A4A147956137258C89" toRefs="TextSelection-2A36E737FFF05E75B357CB41AFB5B6E2-0-wk-Footnote-2A36E737FFF05E75B357CB41AFB5B6E2_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43681613e1943-wk-Fact-79F0FD4AFB255B0196EDFCDD331CEFF0" toRefs="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43771853e10828-wk-Fact-79FA16521B14520887AA9A50CD9012A4" toRefs="TextSelection-A685A65E160C5D228F531BF7107B3DF7-0-wk-Footnote-A685A65E160C5D228F531BF7107B3DF7_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687849e2239-wk-Fact-7A7785CEBF4755FBBB7EAA2A69D0EF09" toRefs="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43712510e4484-wk-Fact-7A88DB0438DC5867A92DE1BB2A8BEC24" toRefs="TextSelection-621F9196966C550EA113DA57575C171E-0-wk-Footnote-621F9196966C550EA113DA57575C171E_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e9628-wk-Fact-7CF5E0D8BCEA5A01AC63CA0BE2F7F413" toRefs="TextSelection-39CF024D03225486829869F6CA02C00E-0-wk-Footnote-39CF024D03225486829869F6CA02C00E_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d43770747e9628-wk-Fact-7CF5E0D8BCEA5A01AC63CA0BE2F7F413" toRefs="TextSelection-53BB8CAFCA475C0C9DB2195050D36025-0-wk-Footnote-53BB8CAFCA475C0C9DB2195050D36025_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43770747e9628-wk-Fact-7CF5E0D8BCEA5A01AC63CA0BE2F7F413" toRefs="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43681613e1267-wk-Fact-7D8048FC05695215AF1AB565B8040E8E" toRefs="TextSelection-3DD94144621C5A68BC21C5DB64345BB9-0-wk-Footnote-3DD94144621C5A68BC21C5DB64345BB9_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43681613e1267-wk-Fact-7D8048FC05695215AF1AB565B8040E8E" toRefs="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e1108-wk-Fact-7DAD092F708C5E7CAC2F33934FCB84C5" toRefs="TextSelection-8D2A93033C2E56DE9E814F0AB36328EE-0-wk-Footnote-8D2A93033C2E56DE9E814F0AB36328EE_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43770747e1108-wk-Fact-7DAD092F708C5E7CAC2F33934FCB84C5" toRefs="TextSelection-91730671722A5F83BA05EF347193E4CF-0-wk-Footnote-91730671722A5F83BA05EF347193E4CF_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43712496e1304-wk-Fact-7DF3605F8BAE533CAF6B416DD2F9F2C4" toRefs="TextSelection-1B1FEAD5EA4E576891141CE7B2D9386E-0-wk-Footnote-1B1FEAD5EA4E576891141CE7B2D9386E_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43712496e1304-wk-Fact-7DF3605F8BAE533CAF6B416DD2F9F2C4" toRefs="TextSelection-B57619F44FCF544D96067CF4816A9082-0-wk-Footnote-B57619F44FCF544D96067CF4816A9082_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43674379e2120-wk-Fact-7E0D6DBF276A520C83B6B208692E17BE" toRefs="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43691920e1163-wk-Fact-7E181FF37E2A50278584695E0D09574B" toRefs="TextSelection-C94190737D79577A8993EFAC2CD3FC95-0-wk-Footnote-C94190737D79577A8993EFAC2CD3FC95_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687704e1153-wk-Fact-7E1F234CCFDF5CD5B6D2068DEF0EA230" toRefs="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43687704e1153-wk-Fact-7E1F234CCFDF5CD5B6D2068DEF0EA230" toRefs="TextSelection-AE19F19C6AE65BBDA7F551089E2E7EDF-0-wk-Footnote-AE19F19C6AE65BBDA7F551089E2E7EDF_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e4532-wk-Fact-7E56CAC1C19150F0843C9E5BCB9C0112" toRefs="TextSelection-5259D0A3B8885FEE951D5ABCA017CBFC-0-wk-Footnote-5259D0A3B8885FEE951D5ABCA017CBFC_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e8838-wk-Fact-7E69FA8360D65E76BC4DD8B549DB440D" toRefs="TextSelection-39CF024D03225486829869F6CA02C00E-0-wk-Footnote-39CF024D03225486829869F6CA02C00E_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43770747e8838-wk-Fact-7E69FA8360D65E76BC4DD8B549DB440D" toRefs="TextSelection-53BB8CAFCA475C0C9DB2195050D36025-0-wk-Footnote-53BB8CAFCA475C0C9DB2195050D36025_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d43770747e8838-wk-Fact-7E69FA8360D65E76BC4DD8B549DB440D" toRefs="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43674379e2164-wk-Fact-7EDA7F85A58A5A1F95B13001B9DBA028" toRefs="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43674379e2520-wk-Fact-7EDE13D2B0D259CBB94F5F415001BFCC" toRefs="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43681613e1627-wk-Fact-7EE55D894B2E598CB81A5AD553F1A033" toRefs="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43674379e798-wk-Fact-7EFAF7B942C85E77BB9972B343FAB410 d43681613e2521-wk-Fact-7EFAF7B942C85E77BB9972B343FAB410" toRefs="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43674379e798-wk-Fact-7EFAF7B942C85E77BB9972B343FAB410 d43681613e2521-wk-Fact-7EFAF7B942C85E77BB9972B343FAB410" toRefs="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e5934-wk-Fact-7F42A871CAE05783A75EB435EF78126F" toRefs="TextSelection-8921B51644785F769ECBA4D3CCF9CAD4-0-wk-Footnote-8921B51644785F769ECBA4D3CCF9CAD4_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43712510e5144-wk-Fact-7F7AD619600C57BDB92DA526BB9447DB" toRefs="TextSelection-621F9196966C550EA113DA57575C171E-0-wk-Footnote-621F9196966C550EA113DA57575C171E_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e7453-wk-Fact-7FF9DC0A6C7D575C9FDD24720C8D14FC" toRefs="TextSelection-39CF024D03225486829869F6CA02C00E-0-wk-Footnote-39CF024D03225486829869F6CA02C00E_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43770747e7453-wk-Fact-7FF9DC0A6C7D575C9FDD24720C8D14FC" toRefs="TextSelection-53BB8CAFCA475C0C9DB2195050D36025-0-wk-Footnote-53BB8CAFCA475C0C9DB2195050D36025_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d43770747e7453-wk-Fact-7FF9DC0A6C7D575C9FDD24720C8D14FC" toRefs="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43674379e2075-wk-Fact-808C96510A955E8CBDF7099B1662C942" toRefs="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687849e1836-wk-Fact-80B5437E8AF253159081F26E14A232D2" toRefs="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43681613e2170-wk-Fact-81C7C1D62B7555CEB86C474159F55AB9" toRefs="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43697240e1384-wk-Fact-81D16D7A3AE6589781565D5CDDE413F5" toRefs="TextSelection-7432EEEACAB3598FA522C1D7E1584D05-0-wk-Footnote-7432EEEACAB3598FA522C1D7E1584D05_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43771853e1428-wk-Fact-81F0756E8C76E147E68C5A6F0304AE04" toRefs="TextSelection-78FC5AB8EFAB585E87BBCF93BE9FBF1D-0-wk-Footnote-78FC5AB8EFAB585E87BBCF93BE9FBF1D_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43697240e1325-wk-Fact-8222C49DFF25586385357680BA3E7A37" toRefs="TextSelection-7432EEEACAB3598FA522C1D7E1584D05-0-wk-Footnote-7432EEEACAB3598FA522C1D7E1584D05_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687704e1199-wk-Fact-822E670EBB815BFB8925AC8ECADDC3AB" toRefs="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43687704e1199-wk-Fact-822E670EBB815BFB8925AC8ECADDC3AB" toRefs="TextSelection-AE19F19C6AE65BBDA7F551089E2E7EDF-0-wk-Footnote-AE19F19C6AE65BBDA7F551089E2E7EDF_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e4570-wk-Fact-823EA0B8A07A5702B678EABA58D52F52" toRefs="TextSelection-5259D0A3B8885FEE951D5ABCA017CBFC-0-wk-Footnote-5259D0A3B8885FEE951D5ABCA017CBFC_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43674379e2611-wk-Fact-82E53639BF6557F091EE46784D53AC8F" toRefs="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e11303-wk-Fact-82FB012BDAB65A2A907B1CCC2DE535AD" toRefs="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43770747e11303-wk-Fact-82FB012BDAB65A2A907B1CCC2DE535AD" toRefs="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43771853e3041-wk-Fact-8317B3014C2257C6BEBBD283124A965D" toRefs="TextSelection-13C3E50268A15908A8AC9D1B6C938D2D-0-wk-Footnote-13C3E50268A15908A8AC9D1B6C938D2D_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d43771853e3041-wk-Fact-8317B3014C2257C6BEBBD283124A965D" toRefs="TextSelection-78FC5AB8EFAB585E87BBCF93BE9FBF1D-0-wk-Footnote-78FC5AB8EFAB585E87BBCF93BE9FBF1D_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43771853e3041-wk-Fact-8317B3014C2257C6BEBBD283124A965D" toRefs="TextSelection-C2AA3A20AB3F54349FC86854E44E1000-0-wk-Footnote-C2AA3A20AB3F54349FC86854E44E1000_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e8628-wk-Fact-838AFCED268F5D33AC4D66BBF1700DBF" toRefs="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43770747e8628-wk-Fact-838AFCED268F5D33AC4D66BBF1700DBF" toRefs="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e1133-wk-Fact-83B9658BE9A85FE39B70C11E0CE57D00" toRefs="TextSelection-8D2A93033C2E56DE9E814F0AB36328EE-0-wk-Footnote-8D2A93033C2E56DE9E814F0AB36328EE_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43770747e1133-wk-Fact-83B9658BE9A85FE39B70C11E0CE57D00" toRefs="TextSelection-91730671722A5F83BA05EF347193E4CF-0-wk-Footnote-91730671722A5F83BA05EF347193E4CF_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43681613e2427-wk-Fact-8446B584F9B25BB79D2E77028163C2CB" toRefs="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687849e2547-wk-Fact-84477EEDA0FB53F1A2DF30BC45CFD227" toRefs="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43697224e1651-wk-Fact-84DD287398AF5474B3AA02B3F4BF9D06" toRefs="TextSelection-9C73CEBDEE585A83B2B18F3B38A6D8CD-0-wk-Footnote-9C73CEBDEE585A83B2B18F3B38A6D8CD_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e11283-wk-Fact-84FD9CC1745E5CF6B9EBD9E4EF9761DA" toRefs="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43770747e11283-wk-Fact-84FD9CC1745E5CF6B9EBD9E4EF9761DA" toRefs="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43771853e2213-wk-Fact-853524F647B75F4EA75709651DF1AA8F" toRefs="TextSelection-78FC5AB8EFAB585E87BBCF93BE9FBF1D-0-wk-Footnote-78FC5AB8EFAB585E87BBCF93BE9FBF1D_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43697224e1757-wk-Fact-858DAA1BAEC456F597F882E9D0741E7F" toRefs="TextSelection-ECF6A95A77365D79B2E9D472B81966D9-0-wk-Footnote-ECF6A95A77365D79B2E9D472B81966D9_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e1545-wk-Fact-86294AF06C6D55869B1ABEBE900AFFD4" toRefs="TextSelection-58096FF6357955D6B6AA25D56767CB0A-0-wk-Footnote-58096FF6357955D6B6AA25D56767CB0A_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43770747e1545-wk-Fact-86294AF06C6D55869B1ABEBE900AFFD4" toRefs="TextSelection-8D2A93033C2E56DE9E814F0AB36328EE-0-wk-Footnote-8D2A93033C2E56DE9E814F0AB36328EE_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43681613e2704-wk-Fact-8690986C383F54748BB0095D0303FF1E" toRefs="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43681613e2704-wk-Fact-8690986C383F54748BB0095D0303FF1E" toRefs="TextSelection-EB5698F25D035A90984FA270E724B7BB-0-wk-Footnote-EB5698F25D035A90984FA270E724B7BB_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43674379e2718-wk-Fact-871F7D1326F153D0A78F67C95DCE6D47" toRefs="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e7720-wk-Fact-8727D6540E165428BFB9698977FED583" toRefs="TextSelection-39CF024D03225486829869F6CA02C00E-0-wk-Footnote-39CF024D03225486829869F6CA02C00E_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43770747e7720-wk-Fact-8727D6540E165428BFB9698977FED583" toRefs="TextSelection-53BB8CAFCA475C0C9DB2195050D36025-0-wk-Footnote-53BB8CAFCA475C0C9DB2195050D36025_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d43770747e7720-wk-Fact-8727D6540E165428BFB9698977FED583" toRefs="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43697224e1565-wk-Fact-872E272F8D3F541FBE9D985BACC8A6A2" toRefs="TextSelection-8C5E9E30C7EB5291A3E0EE605FC281E8-0-wk-Footnote-8C5E9E30C7EB5291A3E0EE605FC281E8_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43681613e1808-wk-Fact-8788492837FF523EB753AAF056BFAF4A" toRefs="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e10350-wk-Fact-87C02FE05790562287F7FA992F915C2A" toRefs="TextSelection-39CF024D03225486829869F6CA02C00E-0-wk-Footnote-39CF024D03225486829869F6CA02C00E_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d43770747e10350-wk-Fact-87C02FE05790562287F7FA992F915C2A" toRefs="TextSelection-53BB8CAFCA475C0C9DB2195050D36025-0-wk-Footnote-53BB8CAFCA475C0C9DB2195050D36025_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43770747e10350-wk-Fact-87C02FE05790562287F7FA992F915C2A" toRefs="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43687704e2448-wk-Fact-8810BC1FB19F5CCBB75143FDC43F7193" toRefs="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687704e2448-wk-Fact-8810BC1FB19F5CCBB75143FDC43F7193" toRefs="TextSelection-9231AC55B8EC5775BC4995B0797F870F-0-wk-Footnote-9231AC55B8EC5775BC4995B0797F870F_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43712496e1497-wk-Fact-88427B31421C553CAC12777E36570F80" toRefs="TextSelection-6912797A078E5D59B618DFFBB81C1BB6-0-wk-Footnote-6912797A078E5D59B618DFFBB81C1BB6_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43771853e4856-wk-Fact-8896D6C24D4F5AEEABD89DD662622B8D" toRefs="TextSelection-DC6DDCB74FC9523D97BA51FBA6B1C05E-0-wk-Footnote-DC6DDCB74FC9523D97BA51FBA6B1C05E_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43681613e2941-wk-Fact-88DA733F540B50B5B2437B8FAA7A8EDF" toRefs="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="Fact-88DE6FFC0A6C582BA8AE3854966F0852-wk-Fact-88DE6FFC0A6C582BA8AE3854966F0852" toRefs="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43712510e4168-wk-Fact-88EBC3EBE111513F840C9F921A314BB9" toRefs="TextSelection-621F9196966C550EA113DA57575C171E-0-wk-Footnote-621F9196966C550EA113DA57575C171E_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687704e3075-wk-Fact-89167C4150EA5B6CB2833B441C176EB5 d43690878e2073-wk-Fact-89167C4150EA5B6CB2833B441C176EB5" toRefs="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43771853e8298-wk-Fact-89988FDDF95F52A4910F81944C0989F3" toRefs="TextSelection-C4FFB7FEB33B5D5EBA7924687B243323-0-wk-Footnote-C4FFB7FEB33B5D5EBA7924687B243323_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e1647-wk-Fact-8A158D27D5F55CB592CF35BFF232EA8E" toRefs="TextSelection-58096FF6357955D6B6AA25D56767CB0A-0-wk-Footnote-58096FF6357955D6B6AA25D56767CB0A_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43770747e1647-wk-Fact-8A158D27D5F55CB592CF35BFF232EA8E" toRefs="TextSelection-8D2A93033C2E56DE9E814F0AB36328EE-0-wk-Footnote-8D2A93033C2E56DE9E814F0AB36328EE_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43712510e5492-wk-Fact-8A4811792A515F62A3DF96296C7FF609" toRefs="TextSelection-621F9196966C550EA113DA57575C171E-0-wk-Footnote-621F9196966C550EA113DA57575C171E_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43712496e2215-wk-Fact-8A4AB1B8685C5997998FB7F7C5FFCE5D" toRefs="TextSelection-C37CD88178CA35C475D25A62F2B54FED-0-wk-Footnote-C37CD88178CA35C475D25A62F2B54FED_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43690878e1383-wk-Fact-8A7DCB81F28D538A87559BA9CEA85B1F" toRefs="TextSelection-792D3AB23D6354CFBB2776AE7F6407B4-0-wk-Footnote-792D3AB23D6354CFBB2776AE7F6407B4_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43771853e3410-wk-Fact-8AA7427BBF485EA4842503B7D6B6F5B3" toRefs="TextSelection-13C3E50268A15908A8AC9D1B6C938D2D-0-wk-Footnote-13C3E50268A15908A8AC9D1B6C938D2D_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43771853e3410-wk-Fact-8AA7427BBF485EA4842503B7D6B6F5B3" toRefs="TextSelection-78FC5AB8EFAB585E87BBCF93BE9FBF1D-0-wk-Footnote-78FC5AB8EFAB585E87BBCF93BE9FBF1D_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43681613e2308-wk-Fact-8AB5E43C2479535A8B0B89EA014F6940" toRefs="TextSelection-3DD94144621C5A68BC21C5DB64345BB9-0-wk-Footnote-3DD94144621C5A68BC21C5DB64345BB9_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43681613e2308-wk-Fact-8AB5E43C2479535A8B0B89EA014F6940" toRefs="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43687704e2487-wk-Fact-8AF2BFF4A0B050A8AEDFE6EBFEC9B378" toRefs="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687704e2487-wk-Fact-8AF2BFF4A0B050A8AEDFE6EBFEC9B378" toRefs="TextSelection-9231AC55B8EC5775BC4995B0797F870F-0-wk-Footnote-9231AC55B8EC5775BC4995B0797F870F_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e3249-wk-Fact-8AFCAB1E804757FEBFCB197A8AE4804C" toRefs="TextSelection-8C173666F61E55D5A1394009569043BA-0-wk-Footnote-8C173666F61E55D5A1394009569043BA_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43771853e1866-wk-Fact-8B6B8D08A6E0596D82BFAC1026B33906" toRefs="TextSelection-13C3E50268A15908A8AC9D1B6C938D2D-0-wk-Footnote-13C3E50268A15908A8AC9D1B6C938D2D_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43771853e1866-wk-Fact-8B6B8D08A6E0596D82BFAC1026B33906" toRefs="TextSelection-78FC5AB8EFAB585E87BBCF93BE9FBF1D-0-wk-Footnote-78FC5AB8EFAB585E87BBCF93BE9FBF1D_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687704e3210-wk-Fact-8BCC41FCBE495D779B180688D6602014" toRefs="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43697224e1196-wk-Fact-8C132ED2C80858EDAC92446BF10B1EF2" toRefs="TextSelection-7679A63ACE625532ADFCC5B97C6C9FC6-0-wk-Footnote-7679A63ACE625532ADFCC5B97C6C9FC6_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43770747e8878-wk-Fact-8C7D1064A7B350C98174EAAD041CABE0" toRefs="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e8878-wk-Fact-8C7D1064A7B350C98174EAAD041CABE0" toRefs="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43674379e1740-wk-Fact-8C84C3AC99B45AE2BA8FC636F5622DE6" toRefs="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43681613e1474-wk-Fact-8C91183376945DA18E85A8BAB3F22AAF" toRefs="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43771853e2956-wk-Fact-8CC7C9AC13B558B88EEA9469BCD245B1" toRefs="TextSelection-78FC5AB8EFAB585E87BBCF93BE9FBF1D-0-wk-Footnote-78FC5AB8EFAB585E87BBCF93BE9FBF1D_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43681613e2491-wk-Fact-8CCB92621D2F5FA2970B7C2EB7A111BE" toRefs="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43770747e7778-wk-Fact-8D17A1AAEAA359D5832C616000B8A948" toRefs="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e7778-wk-Fact-8D17A1AAEAA359D5832C616000B8A948" toRefs="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687849e1472-wk-Fact-8D699BC64D745ABCB0D7483468DED443" toRefs="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e9609-wk-Fact-8E3F5651762058A3BE3D1D3ABAC06BF2" toRefs="TextSelection-39CF024D03225486829869F6CA02C00E-0-wk-Footnote-39CF024D03225486829869F6CA02C00E_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d43770747e9609-wk-Fact-8E3F5651762058A3BE3D1D3ABAC06BF2" toRefs="TextSelection-53BB8CAFCA475C0C9DB2195050D36025-0-wk-Footnote-53BB8CAFCA475C0C9DB2195050D36025_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43770747e9609-wk-Fact-8E3F5651762058A3BE3D1D3ABAC06BF2" toRefs="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687704e1532-wk-Fact-8EACD6F676A95BF0AB83AE15D642DBEA d43771853e2301-wk-Fact-8EACD6F676A95BF0AB83AE15D642DBEA" toRefs="TextSelection-78FC5AB8EFAB585E87BBCF93BE9FBF1D-0-wk-Footnote-78FC5AB8EFAB585E87BBCF93BE9FBF1D_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43687704e1532-wk-Fact-8EACD6F676A95BF0AB83AE15D642DBEA d43771853e2301-wk-Fact-8EACD6F676A95BF0AB83AE15D642DBEA" toRefs="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43687849e1153-wk-Fact-8EF4AF6384775AC783C5F87F272BBA35" toRefs="TextSelection-36C36413532355188985D26E3B171357-0-wk-Footnote-36C36413532355188985D26E3B171357_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687849e1153-wk-Fact-8EF4AF6384775AC783C5F87F272BBA35" toRefs="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43687704e1703-wk-Fact-8F2AF78FFD8356E9921CBFEFF7E852B8 d43690878e1052-wk-Fact-8F2AF78FFD8356E9921CBFEFF7E852B8" toRefs="TextSelection-792D3AB23D6354CFBB2776AE7F6407B4-0-wk-Footnote-792D3AB23D6354CFBB2776AE7F6407B4_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d43687704e1703-wk-Fact-8F2AF78FFD8356E9921CBFEFF7E852B8 d43690878e1052-wk-Fact-8F2AF78FFD8356E9921CBFEFF7E852B8" toRefs="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687704e1703-wk-Fact-8F2AF78FFD8356E9921CBFEFF7E852B8 d43690878e1052-wk-Fact-8F2AF78FFD8356E9921CBFEFF7E852B8" toRefs="TextSelection-9231AC55B8EC5775BC4995B0797F870F-0-wk-Footnote-9231AC55B8EC5775BC4995B0797F870F_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43690878e1932-wk-Fact-8F3C8079FB235F47AFEECF5DBF3A99E7" toRefs="TextSelection-792D3AB23D6354CFBB2776AE7F6407B4-0-wk-Footnote-792D3AB23D6354CFBB2776AE7F6407B4_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43770747e7798-wk-Fact-8F4FBA0654FF59F5B667567DEC33C73B" toRefs="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e7798-wk-Fact-8F4FBA0654FF59F5B667567DEC33C73B" toRefs="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e8819-wk-Fact-8F504B317F065E6AB4D6EA024526004B" toRefs="TextSelection-39CF024D03225486829869F6CA02C00E-0-wk-Footnote-39CF024D03225486829869F6CA02C00E_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43770747e8819-wk-Fact-8F504B317F065E6AB4D6EA024526004B" toRefs="TextSelection-53BB8CAFCA475C0C9DB2195050D36025-0-wk-Footnote-53BB8CAFCA475C0C9DB2195050D36025_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d43770747e8819-wk-Fact-8F504B317F065E6AB4D6EA024526004B" toRefs="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43712496e3466-wk-Fact-8F95E4DDAC9B520C8A1E53E1D2C8CC7B" toRefs="TextSelection-04B3DB4115835E2FBB99EA13FC1FD64B-0-wk-Footnote-04B3DB4115835E2FBB99EA13FC1FD64B_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687704e1488-wk-Fact-901AC284652F5C9B93B4B3D55F3C6EAE d43697224e1868-wk-Fact-901AC284652F5C9B93B4B3D55F3C6EAE" toRefs="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43674379e1696-wk-Fact-90502764073B5E8B974A1DC7FD2018F9" toRefs="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43770747e8919-wk-Fact-905FF1755B2D5F84A3DD31F07D5EFDAF" toRefs="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e8919-wk-Fact-905FF1755B2D5F84A3DD31F07D5EFDAF" toRefs="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e9707-wk-Fact-9086EDAB64E75CD192D2A7C873603ACA" toRefs="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43770747e9707-wk-Fact-9086EDAB64E75CD192D2A7C873603ACA" toRefs="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e11153-wk-Fact-909A7518DD255E87B44DE7EF018F16C1" toRefs="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43770747e11153-wk-Fact-909A7518DD255E87B44DE7EF018F16C1" toRefs="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43690878e1764-wk-Fact-90C41519A36D526CAAA4ACCAE371F162" toRefs="TextSelection-792D3AB23D6354CFBB2776AE7F6407B4-0-wk-Footnote-792D3AB23D6354CFBB2776AE7F6407B4_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43712496e1879-wk-Fact-90E6722B594454179E2707D4EF701095" toRefs="TextSelection-7160FF67E87550A19177FE255A41A2D7-0-wk-Footnote-7160FF67E87550A19177FE255A41A2D7_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43681613e2401-wk-Fact-910C3C95984A581EB892DD60EDC26455" toRefs="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687704e1448-wk-Fact-916495EF6D70560FBFED7475E53E1BEA d43697224e1828-wk-Fact-916495EF6D70560FBFED7475E53E1BEA" toRefs="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687849e2201-wk-Fact-9172F69C54DD547D933CB7C875628316" toRefs="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43771853e5612-wk-Fact-91BE74609E00525280568DAA60F6DF3B" toRefs="TextSelection-DE7EF4A6663E52BF8D3620854A57A945-0-wk-Footnote-DE7EF4A6663E52BF8D3620854A57A945_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43712496e2318-wk-Fact-91C0C255B43A5416B3C5C28C3BD45315" toRefs="TextSelection-C37CD88178CA35C475D25A62F2B54FED-0-wk-Footnote-C37CD88178CA35C475D25A62F2B54FED_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43697224e1432-wk-Fact-92A8B07CD3785791B6C291224D7DF376" toRefs="TextSelection-6E67095C033B51BB9FABBA85E8DC4DFA-0-wk-Footnote-6E67095C033B51BB9FABBA85E8DC4DFA_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43771853e5593-wk-Fact-92C4B36CCF2B53258C24D575B5A46D08" toRefs="TextSelection-DE7EF4A6663E52BF8D3620854A57A945-0-wk-Footnote-DE7EF4A6663E52BF8D3620854A57A945_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43697224e1737-wk-Fact-92DEAC51BE5052E8AC6E2521BB717C22" toRefs="TextSelection-ECF6A95A77365D79B2E9D472B81966D9-0-wk-Footnote-ECF6A95A77365D79B2E9D472B81966D9_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e10534-wk-Fact-92E17207D19C5E5A932D3D83BCD07078" toRefs="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43770747e10534-wk-Fact-92E17207D19C5E5A932D3D83BCD07078" toRefs="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43712496e2177-wk-Fact-93040E88DF5D56A99DAE7E4CE1BBE9F2" toRefs="TextSelection-C37CD88178CA35C475D25A62F2B54FED-0-wk-Footnote-C37CD88178CA35C475D25A62F2B54FED_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43674379e1633-wk-Fact-93644FE962325258B137234D02EB03E6" toRefs="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43674379e881-wk-Fact-93CA7130473D54F2A4475CBF05C3A3EF" toRefs="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43712496e3486-wk-Fact-94001D1F99AF509E84946618AAA5FC87" toRefs="TextSelection-04B3DB4115835E2FBB99EA13FC1FD64B-0-wk-Footnote-04B3DB4115835E2FBB99EA13FC1FD64B_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43681613e2336-wk-Fact-94268C3E6B575791AF135AE3FFBDED27" toRefs="TextSelection-3DD94144621C5A68BC21C5DB64345BB9-0-wk-Footnote-3DD94144621C5A68BC21C5DB64345BB9_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43681613e2336-wk-Fact-94268C3E6B575791AF135AE3FFBDED27" toRefs="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43674379e2254-wk-Fact-949EBE5A327851FCB9BF19AA6ACC7A3A" toRefs="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43697240e3308-wk-Fact-94EEFBE86EAF5F65881310E2436550F1" toRefs="TextSelection-73987C5EBB9C5D43BC69B77F006C18A6-0-wk-Footnote-73987C5EBB9C5D43BC69B77F006C18A6_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43771853e8317-wk-Fact-9577FDA2F67253B8A7F69BB91B1286ED" toRefs="TextSelection-C4FFB7FEB33B5D5EBA7924687B243323-0-wk-Footnote-C4FFB7FEB33B5D5EBA7924687B243323_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e10849-wk-Fact-957B6D659FDB5023A7F0DBA1FC6C7332" toRefs="TextSelection-39CF024D03225486829869F6CA02C00E-0-wk-Footnote-39CF024D03225486829869F6CA02C00E_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43770747e10849-wk-Fact-957B6D659FDB5023A7F0DBA1FC6C7332" toRefs="TextSelection-53BB8CAFCA475C0C9DB2195050D36025-0-wk-Footnote-53BB8CAFCA475C0C9DB2195050D36025_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d43770747e10849-wk-Fact-957B6D659FDB5023A7F0DBA1FC6C7332" toRefs="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43674379e2430-wk-Fact-95915EECEB845388928ED9B038AC306C" toRefs="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e9996-wk-Fact-95C58C19C66A579CB912AE3B96A6747E" toRefs="TextSelection-39CF024D03225486829869F6CA02C00E-0-wk-Footnote-39CF024D03225486829869F6CA02C00E_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d43770747e9996-wk-Fact-95C58C19C66A579CB912AE3B96A6747E" toRefs="TextSelection-53BB8CAFCA475C0C9DB2195050D36025-0-wk-Footnote-53BB8CAFCA475C0C9DB2195050D36025_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43770747e9996-wk-Fact-95C58C19C66A579CB912AE3B96A6747E" toRefs="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43771853e5902-wk-Fact-96034CF0E4F8560C81E68935C2975A14" toRefs="TextSelection-450A7304FB7E513FB479F6D9A06EF1D3-0-wk-Footnote-450A7304FB7E513FB479F6D9A06EF1D3_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43681613e2857-wk-Fact-9641A5BEA98B590492283AE6831A946D" toRefs="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43687704e2340-wk-Fact-9652D747D2CD5DF5B4AE1CACCD0A7222" toRefs="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687704e2340-wk-Fact-9652D747D2CD5DF5B4AE1CACCD0A7222" toRefs="TextSelection-9231AC55B8EC5775BC4995B0797F870F-0-wk-Footnote-9231AC55B8EC5775BC4995B0797F870F_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687849e3201-wk-Fact-965936205F21501FABEFE22DBAD6AD70" toRefs="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43771853e4837-wk-Fact-970AC97D21605174BC2DCA8AD22AECDF" toRefs="TextSelection-DC6DDCB74FC9523D97BA51FBA6B1C05E-0-wk-Footnote-DC6DDCB74FC9523D97BA51FBA6B1C05E_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43687704e2872-wk-Fact-9731AEDCAB005D1FBDC36BDD20F9FFF8" toRefs="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687704e2872-wk-Fact-9731AEDCAB005D1FBDC36BDD20F9FFF8" toRefs="TextSelection-9231AC55B8EC5775BC4995B0797F870F-0-wk-Footnote-9231AC55B8EC5775BC4995B0797F870F_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687849e2287-wk-Fact-9768F9056D7E593CA8B86BE96384F1DB" toRefs="TextSelection-77536863BCE35B419E3A4119D41DB4BD-0-wk-Footnote-77536863BCE35B419E3A4119D41DB4BD_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43687849e2287-wk-Fact-9768F9056D7E593CA8B86BE96384F1DB" toRefs="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687704e1095-wk-Fact-97AEC38197D45AB8B6B38E3761427F3A" toRefs="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43687704e1095-wk-Fact-97AEC38197D45AB8B6B38E3761427F3A" toRefs="TextSelection-AE19F19C6AE65BBDA7F551089E2E7EDF-0-wk-Footnote-AE19F19C6AE65BBDA7F551089E2E7EDF_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43771853e10424-wk-Fact-9814D8F2526C58C48FBE9FC9B3F3314B" toRefs="TextSelection-450A7304FB7E513FB479F6D9A06EF1D3-0-wk-Footnote-450A7304FB7E513FB479F6D9A06EF1D3_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43692105e1217-wk-Fact-985F88532E195B47BDB854CF286F26CD" toRefs="TextSelection-2A36E737FFF05E75B357CB41AFB5B6E2-0-wk-Footnote-2A36E737FFF05E75B357CB41AFB5B6E2_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e4946-wk-Fact-9897B650EC365D66BE5F4FE1539C840D" toRefs="TextSelection-2BFD6C99096B50AD93705C5601B21F46-0-wk-Footnote-2BFD6C99096B50AD93705C5601B21F46_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43687704e2891-wk-Fact-98E7EC7835B052E592B533FDD3656AFB" toRefs="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687704e2891-wk-Fact-98E7EC7835B052E592B533FDD3656AFB" toRefs="TextSelection-9231AC55B8EC5775BC4995B0797F870F-0-wk-Footnote-9231AC55B8EC5775BC4995B0797F870F_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43681613e2540-wk-Fact-98FDF1C40AF759C4B5005A20CA031801" toRefs="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687849e2865-wk-Fact-990F7FE47CEA5D99BCE375CA7BAC5739" toRefs="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43690878e1364-wk-Fact-9943CA1B5CD35B98836DDF43C586A63B" toRefs="TextSelection-792D3AB23D6354CFBB2776AE7F6407B4-0-wk-Footnote-792D3AB23D6354CFBB2776AE7F6407B4_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43697224e1257-wk-Fact-994608FEC5B95CBF9C3D06616F806463" toRefs="TextSelection-7679A63ACE625532ADFCC5B97C6C9FC6-0-wk-Footnote-7679A63ACE625532ADFCC5B97C6C9FC6_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43712496e1450-wk-Fact-9947697CFC005CC4B553C619A29CF327 d43712496e3419-wk-Fact-9947697CFC005CC4B553C619A29CF327" toRefs="TextSelection-B57619F44FCF544D96067CF4816A9082-0-wk-Footnote-B57619F44FCF544D96067CF4816A9082_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43678813e975-wk-Fact-9A5C2CB5B6525CAF82F961091ABF22D5" toRefs="TextSelection-E16E3AA57ADF5C6FB93B6FC578ED7F95-0-wk-Footnote-E16E3AA57ADF5C6FB93B6FC578ED7F95_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43687849e1625-wk-Fact-9A9E5B540C0052C7BE5FB833D0FCA0E3" toRefs="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687849e1625-wk-Fact-9A9E5B540C0052C7BE5FB833D0FCA0E3" toRefs="TextSelection-F185CD45BC245C2EB8EDBFD55DB8A33F-0-wk-Footnote-F185CD45BC245C2EB8EDBFD55DB8A33F_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e11222-wk-Fact-9ABA0C515EA950C6981FD708D959A2E8" toRefs="TextSelection-39CF024D03225486829869F6CA02C00E-0-wk-Footnote-39CF024D03225486829869F6CA02C00E_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d43770747e11222-wk-Fact-9ABA0C515EA950C6981FD708D959A2E8" toRefs="TextSelection-53BB8CAFCA475C0C9DB2195050D36025-0-wk-Footnote-53BB8CAFCA475C0C9DB2195050D36025_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43770747e11222-wk-Fact-9ABA0C515EA950C6981FD708D959A2E8" toRefs="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e9767-wk-Fact-9AFC9FBE04FB5689977BCF73503C994B" toRefs="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43770747e9767-wk-Fact-9AFC9FBE04FB5689977BCF73503C994B" toRefs="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43697224e1344-wk-Fact-9B9CE720BFE65909A3F34FE77F5D328D" toRefs="TextSelection-7430C81CDF35536B95DB492D56AB6CFD-0-wk-Footnote-7430C81CDF35536B95DB492D56AB6CFD_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e5703-wk-Fact-9BD0B9C42899598DB27286851288BA9C" toRefs="TextSelection-0BDE8CEE983B5F118E2EFACDF9CC6405-0-wk-Footnote-0BDE8CEE983B5F118E2EFACDF9CC6405_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43681613e2446-wk-Fact-9C5F9B5D363652D592CA2481C87B9506" toRefs="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e8093-wk-Fact-9CA0877B96475CE6BFD987BA91892F67" toRefs="TextSelection-39CF024D03225486829869F6CA02C00E-0-wk-Footnote-39CF024D03225486829869F6CA02C00E_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43770747e8093-wk-Fact-9CA0877B96475CE6BFD987BA91892F67" toRefs="TextSelection-53BB8CAFCA475C0C9DB2195050D36025-0-wk-Footnote-53BB8CAFCA475C0C9DB2195050D36025_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d43770747e8093-wk-Fact-9CA0877B96475CE6BFD987BA91892F67" toRefs="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43687704e1742-wk-Fact-9CDAD2B93E775B8EA25F98BBA2F83485 d43690878e1091-wk-Fact-9CDAD2B93E775B8EA25F98BBA2F83485" toRefs="TextSelection-792D3AB23D6354CFBB2776AE7F6407B4-0-wk-Footnote-792D3AB23D6354CFBB2776AE7F6407B4_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d43687704e1742-wk-Fact-9CDAD2B93E775B8EA25F98BBA2F83485 d43690878e1091-wk-Fact-9CDAD2B93E775B8EA25F98BBA2F83485" toRefs="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687704e1742-wk-Fact-9CDAD2B93E775B8EA25F98BBA2F83485 d43690878e1091-wk-Fact-9CDAD2B93E775B8EA25F98BBA2F83485" toRefs="TextSelection-9231AC55B8EC5775BC4995B0797F870F-0-wk-Footnote-9231AC55B8EC5775BC4995B0797F870F_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43771853e5631-wk-Fact-9D09FA5E842755B1A0C73898B8865ED0" toRefs="TextSelection-DE7EF4A6663E52BF8D3620854A57A945-0-wk-Footnote-DE7EF4A6663E52BF8D3620854A57A945_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43712496e1602-wk-Fact-9DB7D15107575A4E87DEBC34B67A7866" toRefs="TextSelection-C882D128F7C35640B8C0E15448983D9E-0-wk-Footnote-C882D128F7C35640B8C0E15448983D9E_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687849e1322-wk-Fact-9DF54FB1EA595037ACB26A2654176B64" toRefs="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43691920e1183-wk-Fact-9E3C8C139B5F5A29BA180FCB89C053CB" toRefs="TextSelection-C94190737D79577A8993EFAC2CD3FC95-0-wk-Footnote-C94190737D79577A8993EFAC2CD3FC95_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43771853e10035-wk-Fact-9E503F48EBD8524C93A07C83B1436882" toRefs="TextSelection-3AE2F5A9070951C0ACDF4F146E825D8D-0-wk-Footnote-3AE2F5A9070951C0ACDF4F146E825D8D_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43771853e1608-wk-Fact-9F0EA4485B0153C7823866D0926BA03D" toRefs="TextSelection-78FC5AB8EFAB585E87BBCF93BE9FBF1D-0-wk-Footnote-78FC5AB8EFAB585E87BBCF93BE9FBF1D_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687849e2607-wk-Fact-9F76A95D96735FEB9B3AA6495B54B6C9" toRefs="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43674379e2767-wk-Fact-A00F92664332571D9A768489A67E66E0" toRefs="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687849e2567-wk-Fact-A0788365B82455288EB3A6C6558EC05A" toRefs="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43674379e2564-wk-Fact-A0D16119E38D5A9FAB554486905A9CCC" toRefs="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43681613e1673-wk-Fact-A0FAAC12696C59849AE70392155E65FF" toRefs="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43674379e1165-wk-Fact-A14EC3C3E45252D8988217A4980EB580" toRefs="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43697224e1047-wk-Fact-A15E72E726725EF2BD9FCCCC3A222E16" toRefs="TextSelection-FE5DD06AA8B65777900C47B8AC19C4C6-0-wk-Footnote-FE5DD06AA8B65777900C47B8AC19C4C6_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43771853e10385-wk-Fact-A18BC4FC7BA15BDA9B32041CAF276842" toRefs="TextSelection-450A7304FB7E513FB479F6D9A06EF1D3-0-wk-Footnote-450A7304FB7E513FB479F6D9A06EF1D3_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43771853e1588-wk-Fact-A18F9A2CB32656BA9AA6CDE701027F25" toRefs="TextSelection-78FC5AB8EFAB585E87BBCF93BE9FBF1D-0-wk-Footnote-78FC5AB8EFAB585E87BBCF93BE9FBF1D_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43697240e1285-wk-Fact-A1B9EBB00CA357B685505D97968F301E" toRefs="TextSelection-7432EEEACAB3598FA522C1D7E1584D05-0-wk-Footnote-7432EEEACAB3598FA522C1D7E1584D05_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43681613e1493-wk-Fact-A1C1CAB3E9EF556989E8998B597D9BF9" toRefs="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43690878e1725-wk-Fact-A1F4A6FC924452F79F29E27B44D8E522" toRefs="TextSelection-792D3AB23D6354CFBB2776AE7F6407B4-0-wk-Footnote-792D3AB23D6354CFBB2776AE7F6407B4_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43697224e1604-wk-Fact-A203EA72411358678C6144B3CC9481A2" toRefs="TextSelection-8C5E9E30C7EB5291A3E0EE605FC281E8-0-wk-Footnote-8C5E9E30C7EB5291A3E0EE605FC281E8_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43771853e4722-wk-Fact-A244DBBB4D375344919B8BE000C88D5E" toRefs="TextSelection-E9F14C2885BA59D8B6B4AD221FC38619-0-wk-Footnote-E9F14C2885BA59D8B6B4AD221FC38619_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43692105e1237-wk-Fact-A34EE90663FB5081B9E32DEADBF0E652" toRefs="TextSelection-2A36E737FFF05E75B357CB41AFB5B6E2-0-wk-Footnote-2A36E737FFF05E75B357CB41AFB5B6E2_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43674379e1899-wk-Fact-A38618717132561C9E1931D14EDF6B51 d43770747e2170-wk-Fact-A38618717132561C9E1931D14EDF6B51" toRefs="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43674379e1899-wk-Fact-A38618717132561C9E1931D14EDF6B51 d43770747e2170-wk-Fact-A38618717132561C9E1931D14EDF6B51" toRefs="TextSelection-CBF70F977965537BB382CD083809AA0A-0-wk-Footnote-CBF70F977965537BB382CD083809AA0A_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43771853e10093-wk-Fact-A3F1EC328F9650DFB210D8224644F83E" toRefs="TextSelection-3AE2F5A9070951C0ACDF4F146E825D8D-0-wk-Footnote-3AE2F5A9070951C0ACDF4F146E825D8D_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687849e2052-wk-Fact-A4006F8721A75370B615CE7A639018C5" toRefs="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43697224e1690-wk-Fact-A40CCA358E885B1BBACDE3FEAE88386D" toRefs="TextSelection-9C73CEBDEE585A83B2B18F3B38A6D8CD-0-wk-Footnote-9C73CEBDEE585A83B2B18F3B38A6D8CD_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43674379e1234-wk-Fact-A41E764041225C8DBE154ADB89FBF66C d43697240e2316-wk-Fact-A41E764041225C8DBE154ADB89FBF66C" toRefs="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43674379e1234-wk-Fact-A41E764041225C8DBE154ADB89FBF66C d43697240e2316-wk-Fact-A41E764041225C8DBE154ADB89FBF66C" toRefs="TextSelection-FF348CC7844F523299A112551B170BE6-0-wk-Footnote-FF348CC7844F523299A112551B170BE6_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43712496e2007-wk-Fact-A453B8F62ABE5E21AF62323699CCC8B0" toRefs="TextSelection-7160FF67E87550A19177FE255A41A2D7-0-wk-Footnote-7160FF67E87550A19177FE255A41A2D7_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43697224e1005-wk-Fact-A5329E1466235B2299472011E1D4E1D3" toRefs="TextSelection-FE5DD06AA8B65777900C47B8AC19C4C6-0-wk-Footnote-FE5DD06AA8B65777900C47B8AC19C4C6_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43674379e1962-wk-Fact-A538FCC6CCC752E695D754993DC8690B" toRefs="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43697240e2276-wk-Fact-A5D936B4270856D1A914ABA7E1D66F0A" toRefs="TextSelection-FF348CC7844F523299A112551B170BE6-0-wk-Footnote-FF348CC7844F523299A112551B170BE6_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43681613e1699-wk-Fact-A6186BEADB90579F8CFC02466DEAFB87" toRefs="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43697224e1285-wk-Fact-A648DF513A135C13B3F96F3C76C2A737" toRefs="TextSelection-7430C81CDF35536B95DB492D56AB6CFD-0-wk-Footnote-7430C81CDF35536B95DB492D56AB6CFD_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e4984-wk-Fact-A6A09D6704F35EF6866E3822B7B2DC81" toRefs="TextSelection-2BFD6C99096B50AD93705C5601B21F46-0-wk-Footnote-2BFD6C99096B50AD93705C5601B21F46_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687849e2482-wk-Fact-A6BAD49A94C058098F01D059FDF7D0BF" toRefs="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e11242-wk-Fact-A6EB4F0FD63E5855AF650D3234A6748E" toRefs="TextSelection-39CF024D03225486829869F6CA02C00E-0-wk-Footnote-39CF024D03225486829869F6CA02C00E_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d43770747e11242-wk-Fact-A6EB4F0FD63E5855AF650D3234A6748E" toRefs="TextSelection-53BB8CAFCA475C0C9DB2195050D36025-0-wk-Footnote-53BB8CAFCA475C0C9DB2195050D36025_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43770747e11242-wk-Fact-A6EB4F0FD63E5855AF650D3234A6748E" toRefs="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e5801-wk-Fact-A6F46F05463058AFAEAF923B7651C709" toRefs="TextSelection-A42108BE06A7587BABD0C4A820609CE4-0-wk-Footnote-A42108BE06A7587BABD0C4A820609CE4_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43771853e11523-wk-Fact-A70792548E685ABAA23DB0FA57120893" toRefs="TextSelection-450A7304FB7E513FB479F6D9A06EF1D3-0-wk-Footnote-450A7304FB7E513FB479F6D9A06EF1D3_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e4077-wk-Fact-A7D161E015BF50168317EC6EF30D2E9C" toRefs="TextSelection-7EC55EFE69505245B1A079B8132EFBB7-0-wk-Footnote-7EC55EFE69505245B1A079B8132EFBB7_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43674379e2748-wk-Fact-A7FCAA4C427E5D3F9EA836ACF3C4D395" toRefs="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43771853e2814-wk-Fact-A84CE5053CF85BC4965B4D4988840327" toRefs="TextSelection-78FC5AB8EFAB585E87BBCF93BE9FBF1D-0-wk-Footnote-78FC5AB8EFAB585E87BBCF93BE9FBF1D_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43771853e3476-wk-Fact-A872003B0DA95195BC5493ACF35066FF" toRefs="TextSelection-78FC5AB8EFAB585E87BBCF93BE9FBF1D-0-wk-Footnote-78FC5AB8EFAB585E87BBCF93BE9FBF1D_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43771853e3476-wk-Fact-A872003B0DA95195BC5493ACF35066FF" toRefs="TextSelection-8540AADB45BE54D38C10451BF6A88AB4-0-wk-Footnote-8540AADB45BE54D38C10451BF6A88AB4_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43697240e1304-wk-Fact-A8BCB7724076572A894D8BDFC6785A6A" toRefs="TextSelection-7432EEEACAB3598FA522C1D7E1584D05-0-wk-Footnote-7432EEEACAB3598FA522C1D7E1584D05_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43771853e11465-wk-Fact-A8CAE70BC2A35982B714238C0AC51A79" toRefs="TextSelection-450A7304FB7E513FB479F6D9A06EF1D3-0-wk-Footnote-450A7304FB7E513FB479F6D9A06EF1D3_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43771853e4644-wk-Fact-A8E12836BA70521E8E7886584342E2F2" toRefs="TextSelection-3802305E73EB52F28FAAF4EA5481D580-0-wk-Footnote-3802305E73EB52F28FAAF4EA5481D580_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e1314-wk-Fact-A8F0564C8A745E648231F57D9FCE7C93" toRefs="TextSelection-E90A054BCC035ECEB6B6F2B7C947C3CE-0-wk-Footnote-E90A054BCC035ECEB6B6F2B7C947C3CE_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43712496e1962-wk-Fact-A8F5B5BE613E55E4B3F2C69F2B5B38E3" toRefs="TextSelection-7160FF67E87550A19177FE255A41A2D7-0-wk-Footnote-7160FF67E87550A19177FE255A41A2D7_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43771853e11183-wk-Fact-A931585378205E5DA65545918DAAB331" toRefs="TextSelection-ED6F6E1A7C41596DA6F5B1BDFBB72CB7-0-wk-Footnote-ED6F6E1A7C41596DA6F5B1BDFBB72CB7_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e3230-wk-Fact-A940673F4FF9572DA53F97129770EE39" toRefs="TextSelection-8C173666F61E55D5A1394009569043BA-0-wk-Footnote-8C173666F61E55D5A1394009569043BA_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43712496e1641-wk-Fact-A94165CF2AD857B7B67158131637F55C" toRefs="TextSelection-C882D128F7C35640B8C0E15448983D9E-0-wk-Footnote-C882D128F7C35640B8C0E15448983D9E_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43771853e5469-wk-Fact-A95EC0EF20D05434AF953959C36E2AA3" toRefs="TextSelection-84795AFB20AD54C48C963C7C52B00178-0-wk-Footnote-84795AFB20AD54C48C963C7C52B00178_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43771853e4706-wk-Fact-A9623F46D9315CFAA20B6FD10082039D" toRefs="TextSelection-E9F14C2885BA59D8B6B4AD221FC38619-0-wk-Footnote-E9F14C2885BA59D8B6B4AD221FC38619_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43690878e1576-wk-Fact-A97BF6B8A8BF52F4857350DD1D9E29F5" toRefs="TextSelection-792D3AB23D6354CFBB2776AE7F6407B4-0-wk-Footnote-792D3AB23D6354CFBB2776AE7F6407B4_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687849e3143-wk-Fact-A98E6DC1451C5074AFA6C1769B31F168" toRefs="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43771853e10074-wk-Fact-A9C11CFF51AD52A5B91FCAB3F6F3901C" toRefs="TextSelection-3AE2F5A9070951C0ACDF4F146E825D8D-0-wk-Footnote-3AE2F5A9070951C0ACDF4F146E825D8D_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43770747e7532-wk-Fact-A9CF26AC98115AE2816DE97864E7E9E1" toRefs="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e7532-wk-Fact-A9CF26AC98115AE2816DE97864E7E9E1" toRefs="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43681613e2033-wk-Fact-A9D9504EBEC15503A956269CA3DEC025" toRefs="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43712496e3579-wk-Fact-AA3098CB34F551A2922049EA2BBBF5A3" toRefs="TextSelection-3E9076747FF25E3B8D3B9AAF71548F16-0-wk-Footnote-3E9076747FF25E3B8D3B9AAF71548F16_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43681613e2014-wk-Fact-AA4DB1C4ACF95301B1C9DD8DFCDA37CF" toRefs="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43674379e1434-wk-Fact-AB8C3651E3FA5E0381978C95D5308515" toRefs="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687704e3249-wk-Fact-ABA682EB80515D309B605AA81450C85B" toRefs="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43681613e885-wk-Fact-ACB630B60395539B8BEB3946C0CF2A75" toRefs="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687704e1282-wk-Fact-AD0FEF5202405A048EC52168262886B2" toRefs="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43771853e9277-wk-Fact-AD73F3732CE450B3B05C9A766AE2063A" toRefs="TextSelection-08466783230155A08D7C13267B950D39-0-wk-Footnote-08466783230155A08D7C13267B950D39_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43690878e1893-wk-Fact-AD762188EABB599D9776791285E37CB9" toRefs="TextSelection-792D3AB23D6354CFBB2776AE7F6407B4-0-wk-Footnote-792D3AB23D6354CFBB2776AE7F6407B4_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687849e2651-wk-Fact-AE655F3ED75A586981476B9D274B0149" toRefs="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43674379e837-wk-Fact-AE85FABD864252F78E2399FA5C6D7DCA" toRefs="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687849e1493-wk-Fact-AF1D710099FA5129924DD7852F2F28B0" toRefs="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43674379e1057-wk-Fact-AF72E85346065C12B27811C0B8AD4C52" toRefs="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43687704e2360-wk-Fact-AF9D3709DF59553C9EBCFCBC41F64F99" toRefs="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687704e2360-wk-Fact-AF9D3709DF59553C9EBCFCBC41F64F99" toRefs="TextSelection-9231AC55B8EC5775BC4995B0797F870F-0-wk-Footnote-9231AC55B8EC5775BC4995B0797F870F_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43712510e6011-wk-Fact-AFBA8CD89F4951449553D70FD3AC0D6E" toRefs="TextSelection-6550A25092D55979B6A1D62BD4EDF090-0-wk-Footnote-6550A25092D55979B6A1D62BD4EDF090_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687849e2092-wk-Fact-B02BB9D940C0596C9C0D21CC1C19783E" toRefs="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e5628-wk-Fact-B09CC79A60405874AF13D1064AECD5EB" toRefs="TextSelection-0BDE8CEE983B5F118E2EFACDF9CC6405-0-wk-Footnote-0BDE8CEE983B5F118E2EFACDF9CC6405_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43771853e1505-wk-Fact-B11B8159E0957CFF66445A6F02FE77F4" toRefs="TextSelection-78FC5AB8EFAB585E87BBCF93BE9FBF1D-0-wk-Footnote-78FC5AB8EFAB585E87BBCF93BE9FBF1D_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687704e1238-wk-Fact-B14EB26D36A55E6D996F420A2D075893" toRefs="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43687704e1238-wk-Fact-B14EB26D36A55E6D996F420A2D075893" toRefs="TextSelection-AE19F19C6AE65BBDA7F551089E2E7EDF-0-wk-Footnote-AE19F19C6AE65BBDA7F551089E2E7EDF_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43771853e4741-wk-Fact-B1B730E391FC52EF8914EC8E437455FB" toRefs="TextSelection-E9F14C2885BA59D8B6B4AD221FC38619-0-wk-Footnote-E9F14C2885BA59D8B6B4AD221FC38619_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43770747e8294-wk-Fact-B1F75F6B4A5C5BA399EFD6D1A9FEA6DE" toRefs="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e8294-wk-Fact-B1F75F6B4A5C5BA399EFD6D1A9FEA6DE" toRefs="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43687704e2930-wk-Fact-B227984E1B50586585A129EB332CFD86" toRefs="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687704e2930-wk-Fact-B227984E1B50586585A129EB332CFD86" toRefs="TextSelection-9231AC55B8EC5775BC4995B0797F870F-0-wk-Footnote-9231AC55B8EC5775BC4995B0797F870F_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43690878e2332-wk-Fact-B239C8DE6B03518BA7F0284DE06E3F57" toRefs="TextSelection-0333DDFA54555789BB4E2E73E3451A69-0-wk-Footnote-0333DDFA54555789BB4E2E73E3451A69_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43690878e2332-wk-Fact-B239C8DE6B03518BA7F0284DE06E3F57" toRefs="TextSelection-792D3AB23D6354CFBB2776AE7F6407B4-0-wk-Footnote-792D3AB23D6354CFBB2776AE7F6407B4_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43771853e5651-wk-Fact-B2EC756D8A9E5AF6969297EE142A38CF" toRefs="TextSelection-DE7EF4A6663E52BF8D3620854A57A945-0-wk-Footnote-DE7EF4A6663E52BF8D3620854A57A945_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43712496e1924-wk-Fact-B30550C60EA75004A2CBFC5FF95F87DF" toRefs="TextSelection-7160FF67E87550A19177FE255A41A2D7-0-wk-Footnote-7160FF67E87550A19177FE255A41A2D7_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43771853e4784-wk-Fact-B332B03EB88A57C19CFEC6C041626341" toRefs="TextSelection-DC6DDCB74FC9523D97BA51FBA6B1C05E-0-wk-Footnote-DC6DDCB74FC9523D97BA51FBA6B1C05E_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43681613e1081-wk-Fact-B3E1F1C6FF4D55E59E6FE1D02902C8D3" toRefs="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43687704e2379-wk-Fact-B4B59AB6237151588AD0DCDB47024876" toRefs="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687704e2379-wk-Fact-B4B59AB6237151588AD0DCDB47024876" toRefs="TextSelection-9231AC55B8EC5775BC4995B0797F870F-0-wk-Footnote-9231AC55B8EC5775BC4995B0797F870F_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43712496e1982-wk-Fact-B4ED4EC770E85596B83EF4F1E598DF88" toRefs="TextSelection-7160FF67E87550A19177FE255A41A2D7-0-wk-Footnote-7160FF67E87550A19177FE255A41A2D7_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43674379e944-wk-Fact-B57DF7F90CE856C48797E9E94456B6CD d43678813e929-wk-Fact-B57DF7F90CE856C48797E9E94456B6CD" toRefs="TextSelection-431A3875E30657529B6519DFB33F40EB-0-wk-Footnote-431A3875E30657529B6519DFB33F40EB_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43674379e944-wk-Fact-B57DF7F90CE856C48797E9E94456B6CD d43678813e929-wk-Fact-B57DF7F90CE856C48797E9E94456B6CD" toRefs="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43681613e1968-wk-Fact-B6676B9BE7E95127A4888156B2CAD1CD" toRefs="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43690878e2294-wk-Fact-B667DEF994C657D2B861FFE60640D001" toRefs="TextSelection-0333DDFA54555789BB4E2E73E3451A69-0-wk-Footnote-0333DDFA54555789BB4E2E73E3451A69_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43690878e2294-wk-Fact-B667DEF994C657D2B861FFE60640D001" toRefs="TextSelection-792D3AB23D6354CFBB2776AE7F6407B4-0-wk-Footnote-792D3AB23D6354CFBB2776AE7F6407B4_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43674379e1101-wk-Fact-B684218F9F965A0685489FB9D98355FE" toRefs="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43771853e11399-wk-Fact-B6E115CC3E7858DCA9A85E0C1738396B" toRefs="TextSelection-DE7EF4A6663E52BF8D3620854A57A945-0-wk-Footnote-DE7EF4A6663E52BF8D3620854A57A945_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687704e1346-wk-Fact-B73545D07B565820AFF53EEAE1860800 d43712496e1666-wk-Fact-B73545D07B565820AFF53EEAE1860800" toRefs="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43681613e1017-wk-Fact-B740A96BCFB152CEB2E4602B18EBD8F1" toRefs="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43697224e1632-wk-Fact-B77CD495CEF453F5A40BDFFD319AC5F2" toRefs="TextSelection-9C73CEBDEE585A83B2B18F3B38A6D8CD-0-wk-Footnote-9C73CEBDEE585A83B2B18F3B38A6D8CD_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43674379e1341-wk-Fact-B7825C6743265E60AFD787E20D13F87D" toRefs="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43681613e2921-wk-Fact-B7E0E2374E7052E886F3C5A3DD803575" toRefs="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43681613e948-wk-Fact-B7F6677B323F523BBF06F63407F96342" toRefs="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="Fact-B85FE09635045F46B656606350B6714A-wk-Fact-B85FE09635045F46B656606350B6714A" toRefs="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e7472-wk-Fact-B8850FDF106C528A9CBED9CA08F2B4C9" toRefs="TextSelection-39CF024D03225486829869F6CA02C00E-0-wk-Footnote-39CF024D03225486829869F6CA02C00E_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43770747e7472-wk-Fact-B8850FDF106C528A9CBED9CA08F2B4C9" toRefs="TextSelection-53BB8CAFCA475C0C9DB2195050D36025-0-wk-Footnote-53BB8CAFCA475C0C9DB2195050D36025_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d43770747e7472-wk-Fact-B8850FDF106C528A9CBED9CA08F2B4C9" toRefs="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687849e2586-wk-Fact-B8A367981AE35AEF8C0BF4154D63FC01" toRefs="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e9687-wk-Fact-B91047810A4357EFB8BEA4691EF47E86" toRefs="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43770747e9687-wk-Fact-B91047810A4357EFB8BEA4691EF47E86" toRefs="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43712496e3322-wk-Fact-B933A905F21B5DBCAF9108FCBC88194E" toRefs="TextSelection-02609C62928C5D1CBFB6DD071D9D7B0E-0-wk-Footnote-02609C62928C5D1CBFB6DD071D9D7B0E_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43771853e4571-wk-Fact-B972D2BE08BE594FA3E2081E6C7190CF" toRefs="TextSelection-3802305E73EB52F28FAAF4EA5481D580-0-wk-Footnote-3802305E73EB52F28FAAF4EA5481D580_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43674379e2539-wk-Fact-B9792AE277D55415BD4430CE375AB579" toRefs="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43712496e1899-wk-Fact-B97AEA2C854B5AABB4BE5CE4AE4372B1" toRefs="TextSelection-7160FF67E87550A19177FE255A41A2D7-0-wk-Footnote-7160FF67E87550A19177FE255A41A2D7_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43681613e1062-wk-Fact-BA0D6BC1C45C599C91DF29089DAC818D" toRefs="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43771853e2893-wk-Fact-BAF1C761A7AF5C7CBFD0E58295157553" toRefs="TextSelection-78FC5AB8EFAB585E87BBCF93BE9FBF1D-0-wk-Footnote-78FC5AB8EFAB585E87BBCF93BE9FBF1D_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43690878e1402-wk-Fact-BB81900A80EC510B82BA9955D28FB794" toRefs="TextSelection-792D3AB23D6354CFBB2776AE7F6407B4-0-wk-Footnote-792D3AB23D6354CFBB2776AE7F6407B4_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687849e1557-wk-Fact-BBA831FA48DE546FAD427528571D0824" toRefs="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43674379e2474-wk-Fact-BBB0550BDE1259DD997B8244242E79AE" toRefs="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43681613e2723-wk-Fact-BC18C3B80FE15D95A67ED86E9A5C11B9" toRefs="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43681613e2723-wk-Fact-BC18C3B80FE15D95A67ED86E9A5C11B9" toRefs="TextSelection-EB5698F25D035A90984FA270E724B7BB-0-wk-Footnote-EB5698F25D035A90984FA270E724B7BB_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e1584-wk-Fact-BC41639F074B5D2EB9452A1CA1147B95" toRefs="TextSelection-58096FF6357955D6B6AA25D56767CB0A-0-wk-Footnote-58096FF6357955D6B6AA25D56767CB0A_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43770747e1584-wk-Fact-BC41639F074B5D2EB9452A1CA1147B95" toRefs="TextSelection-8D2A93033C2E56DE9E814F0AB36328EE-0-wk-Footnote-8D2A93033C2E56DE9E814F0AB36328EE_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43771853e9316-wk-Fact-BD8207C538F258AB9385CEC1E820D409" toRefs="TextSelection-08466783230155A08D7C13267B950D39-0-wk-Footnote-08466783230155A08D7C13267B950D39_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e10514-wk-Fact-BF8085F8D70957BA81DB64AF93C77FDE" toRefs="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43770747e10514-wk-Fact-BF8085F8D70957BA81DB64AF93C77FDE" toRefs="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43712510e6069-wk-Fact-BF9FCFC1FC645049A852329D7379350D" toRefs="TextSelection-6550A25092D55979B6A1D62BD4EDF090-0-wk-Footnote-6550A25092D55979B6A1D62BD4EDF090_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43712496e1246-wk-Fact-BFEE13E8CEC95576907CDF47D40BBF3C" toRefs="TextSelection-1B1FEAD5EA4E576891141CE7B2D9386E-0-wk-Footnote-1B1FEAD5EA4E576891141CE7B2D9386E_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43712496e1246-wk-Fact-BFEE13E8CEC95576907CDF47D40BBF3C" toRefs="TextSelection-B57619F44FCF544D96067CF4816A9082-0-wk-Footnote-B57619F44FCF544D96067CF4816A9082_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43771853e10789-wk-Fact-C004A733FEAB52B8AE0B44F23C300539" toRefs="TextSelection-A685A65E160C5D228F531BF7107B3DF7-0-wk-Footnote-A685A65E160C5D228F531BF7107B3DF7_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43687704e3160-wk-Fact-C0D5F9589E725D14B3DE492AFAAAEA7D d43690878e2243-wk-Fact-C0D5F9589E725D14B3DE492AFAAAEA7D" toRefs="TextSelection-792D3AB23D6354CFBB2776AE7F6407B4-0-wk-Footnote-792D3AB23D6354CFBB2776AE7F6407B4_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d43687704e3160-wk-Fact-C0D5F9589E725D14B3DE492AFAAAEA7D d43690878e2243-wk-Fact-C0D5F9589E725D14B3DE492AFAAAEA7D" toRefs="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687704e3160-wk-Fact-C0D5F9589E725D14B3DE492AFAAAEA7D d43690878e2243-wk-Fact-C0D5F9589E725D14B3DE492AFAAAEA7D" toRefs="TextSelection-9231AC55B8EC5775BC4995B0797F870F-0-wk-Footnote-9231AC55B8EC5775BC4995B0797F870F_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687704e1301-wk-Fact-C0E90259FF035CD683F5D973FC82FD05" toRefs="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43697224e2905-wk-Fact-C12B4B795167254CFB615A1EFA195FC4" toRefs="TextSelection-066A0A390204B79351965A22CE69E761-0-wk-Footnote-066A0A390204B79351965A22CE69E761_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43697224e2905-wk-Fact-C12B4B795167254CFB615A1EFA195FC4" toRefs="TextSelection-4AF5AB391F1CD8054C065A2324C0D822-0-wk-Footnote-4AF5AB391F1CD8054C065A2324C0D822_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e4019-wk-Fact-C140E7BD63345101B2DD7451627EE662" toRefs="TextSelection-7EC55EFE69505245B1A079B8132EFBB7-0-wk-Footnote-7EC55EFE69505245B1A079B8132EFBB7_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43674379e1652-wk-Fact-C14BB34AB5A85079B41CF0775AFE681D" toRefs="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687849e1047-wk-Fact-C15E30483A415EE0AF567E4AAFB1965C" toRefs="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43681613e1988-wk-Fact-C220C3FE427351839AD8B1F16EE921CE" toRefs="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e3140-wk-Fact-C233B7CC79495307BFD442EFB72D3A1B" toRefs="TextSelection-DAFABE7CE058521690718900BE6137FA-0-wk-Footnote-DAFABE7CE058521690718900BE6137FA_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43770747e882-wk-Fact-C249892FF0905C07897B0E4EF86B976C" toRefs="TextSelection-8D2A93033C2E56DE9E814F0AB36328EE-0-wk-Footnote-8D2A93033C2E56DE9E814F0AB36328EE_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e882-wk-Fact-C249892FF0905C07897B0E4EF86B976C" toRefs="TextSelection-E96B3A139CCA56EC98329BC3717B10E3-0-wk-Footnote-E96B3A139CCA56EC98329BC3717B10E3_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e8711-wk-Fact-C2B11447AB985916A925693B614D1F62" toRefs="TextSelection-39CF024D03225486829869F6CA02C00E-0-wk-Footnote-39CF024D03225486829869F6CA02C00E_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43770747e8711-wk-Fact-C2B11447AB985916A925693B614D1F62" toRefs="TextSelection-53BB8CAFCA475C0C9DB2195050D36025-0-wk-Footnote-53BB8CAFCA475C0C9DB2195050D36025_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d43770747e8711-wk-Fact-C2B11447AB985916A925693B614D1F62" toRefs="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e8215-wk-Fact-C2CABED6EA545FADA2D30E685CF99102" toRefs="TextSelection-39CF024D03225486829869F6CA02C00E-0-wk-Footnote-39CF024D03225486829869F6CA02C00E_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43770747e8215-wk-Fact-C2CABED6EA545FADA2D30E685CF99102" toRefs="TextSelection-53BB8CAFCA475C0C9DB2195050D36025-0-wk-Footnote-53BB8CAFCA475C0C9DB2195050D36025_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d43770747e8215-wk-Fact-C2CABED6EA545FADA2D30E685CF99102" toRefs="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687849e1261-wk-Fact-C2DBD9F4462053918846BC5A4E78FE6B" toRefs="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e7354-wk-Fact-C2FB4FD03BD15A7097477EAB914C3310" toRefs="TextSelection-39CF024D03225486829869F6CA02C00E-0-wk-Footnote-39CF024D03225486829869F6CA02C00E_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43770747e7354-wk-Fact-C2FB4FD03BD15A7097477EAB914C3310" toRefs="TextSelection-53BB8CAFCA475C0C9DB2195050D36025-0-wk-Footnote-53BB8CAFCA475C0C9DB2195050D36025_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d43770747e7354-wk-Fact-C2FB4FD03BD15A7097477EAB914C3310" toRefs="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43712496e2196-wk-Fact-C2FE704D6A285AB89F6177A77115F69D" toRefs="TextSelection-C37CD88178CA35C475D25A62F2B54FED-0-wk-Footnote-C37CD88178CA35C475D25A62F2B54FED_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e4609-wk-Fact-C34B3FEB300256D1ADBB0C35ECBFED0F" toRefs="TextSelection-5259D0A3B8885FEE951D5ABCA017CBFC-0-wk-Footnote-5259D0A3B8885FEE951D5ABCA017CBFC_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43690878e2158-wk-Fact-C43E96FF08B6534FA41614FCABAEB299" toRefs="TextSelection-792D3AB23D6354CFBB2776AE7F6407B4-0-wk-Footnote-792D3AB23D6354CFBB2776AE7F6407B4_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43712496e1556-wk-Fact-C44B0511B35651E0887481BA20948E7C" toRefs="TextSelection-6912797A078E5D59B618DFFBB81C1BB6-0-wk-Footnote-6912797A078E5D59B618DFFBB81C1BB6_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43771853e5844-wk-Fact-C4B5621B0E4A59B3974A957DE7295490" toRefs="TextSelection-450A7304FB7E513FB479F6D9A06EF1D3-0-wk-Footnote-450A7304FB7E513FB479F6D9A06EF1D3_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43712496e1387-wk-Fact-C4C06BF1A8B6557EBFE62654491DA179" toRefs="TextSelection-B57619F44FCF544D96067CF4816A9082-0-wk-Footnote-B57619F44FCF544D96067CF4816A9082_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43681613e1448-wk-Fact-C5C375E41B7D5A61A86D9015B4AC1F9C" toRefs="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687704e1513-wk-Fact-C6627323E3A7545BB805B65F89BE7911 d43771853e2282-wk-Fact-C6627323E3A7545BB805B65F89BE7911" toRefs="TextSelection-78FC5AB8EFAB585E87BBCF93BE9FBF1D-0-wk-Footnote-78FC5AB8EFAB585E87BBCF93BE9FBF1D_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43687704e1513-wk-Fact-C6627323E3A7545BB805B65F89BE7911 d43771853e2282-wk-Fact-C6627323E3A7545BB805B65F89BE7911" toRefs="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687849e1577-wk-Fact-C66A904313F45C85A833A23046CD2774" toRefs="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43697224e1066-wk-Fact-C68BCBB68BF9565C8536418482AA80FC" toRefs="TextSelection-FE5DD06AA8B65777900C47B8AC19C4C6-0-wk-Footnote-FE5DD06AA8B65777900C47B8AC19C4C6_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687849e2156-wk-Fact-C6B1A7221C9D543BAFE59A9C9ECA2DF2" toRefs="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="4" fromRefs="d43687704e1852-wk-Fact-C6BAFD428E8D5DBBB9FC324DE0B23F01 d43687849e846-wk-Fact-C6BAFD428E8D5DBBB9FC324DE0B23F01" toRefs="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43687704e1852-wk-Fact-C6BAFD428E8D5DBBB9FC324DE0B23F01 d43687849e846-wk-Fact-C6BAFD428E8D5DBBB9FC324DE0B23F01" toRefs="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d43687704e1852-wk-Fact-C6BAFD428E8D5DBBB9FC324DE0B23F01 d43687849e846-wk-Fact-C6BAFD428E8D5DBBB9FC324DE0B23F01" toRefs="TextSelection-9231AC55B8EC5775BC4995B0797F870F-0-wk-Footnote-9231AC55B8EC5775BC4995B0797F870F_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687704e1852-wk-Fact-C6BAFD428E8D5DBBB9FC324DE0B23F01 d43687849e846-wk-Fact-C6BAFD428E8D5DBBB9FC324DE0B23F01" toRefs="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687849e2007-wk-Fact-C6D0FE3E8F7154EE8F40BBCDB7B4F991" toRefs="TextSelection-77536863BCE35B419E3A4119D41DB4BD-0-wk-Footnote-77536863BCE35B419E3A4119D41DB4BD_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43687849e2007-wk-Fact-C6D0FE3E8F7154EE8F40BBCDB7B4F991" toRefs="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687849e3093-wk-Fact-C761BA8C214D5A2D83B627623D2F876D" toRefs="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43687704e2842-wk-Fact-C799B208E12551D9925550E1584374F0" toRefs="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687704e2842-wk-Fact-C799B208E12551D9925550E1584374F0" toRefs="TextSelection-9231AC55B8EC5775BC4995B0797F870F-0-wk-Footnote-9231AC55B8EC5775BC4995B0797F870F_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43681613e1153-wk-Fact-C84FD7E0084E53B295E4FBE883879711" toRefs="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43771853e8232-wk-Fact-C8F31244A5485CAB8850FBA2D1B3FB16" toRefs="TextSelection-B88EBF1DF3CD5B06AADA1AA5E249F160-0-wk-Footnote-B88EBF1DF3CD5B06AADA1AA5E249F160_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43771853e5430-wk-Fact-C92E4F643F355942826164E220B2CDBA" toRefs="TextSelection-84795AFB20AD54C48C963C7C52B00178-0-wk-Footnote-84795AFB20AD54C48C963C7C52B00178_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43674379e969-wk-Fact-C9379BA9136D5BBB8F3432FB4D96CBD5" toRefs="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43771853e10366-wk-Fact-C9F9F4BF1A82536D95AD4E1D85276729" toRefs="TextSelection-450A7304FB7E513FB479F6D9A06EF1D3-0-wk-Footnote-450A7304FB7E513FB479F6D9A06EF1D3_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43712496e3302-wk-Fact-CA0E038FD7FB54A5AFFBA924D7EA3A6D" toRefs="TextSelection-02609C62928C5D1CBFB6DD071D9D7B0E-0-wk-Footnote-02609C62928C5D1CBFB6DD071D9D7B0E_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43771853e8193-wk-Fact-CA9E5961B1D758D2820894BDF915B4EC" toRefs="TextSelection-B88EBF1DF3CD5B06AADA1AA5E249F160-0-wk-Footnote-B88EBF1DF3CD5B06AADA1AA5E249F160_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43770747e7412-wk-Fact-CADEEEB82C0B519FB5E1247FA7EE8C72" toRefs="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e7412-wk-Fact-CADEEEB82C0B519FB5E1247FA7EE8C72" toRefs="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43690878e1556-wk-Fact-CB2E688471765831ADC0A8CA1A4F8DFD" toRefs="TextSelection-792D3AB23D6354CFBB2776AE7F6407B4-0-wk-Footnote-792D3AB23D6354CFBB2776AE7F6407B4_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43712510e5473-wk-Fact-CB88AB971B745EBB96F422CEAFCAA461" toRefs="TextSelection-621F9196966C550EA113DA57575C171E-0-wk-Footnote-621F9196966C550EA113DA57575C171E_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43771853e5449-wk-Fact-CB8A98F9684B5E90A54FF33CE216657C" toRefs="TextSelection-84795AFB20AD54C48C963C7C52B00178-0-wk-Footnote-84795AFB20AD54C48C963C7C52B00178_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43674379e2494-wk-Fact-CCCD07BEDF4C5FF9AF3BA300510C89D4" toRefs="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43771853e10217-wk-Fact-CD0D167B7BFA55D3B52DA395AB1BD7B8" toRefs="TextSelection-DE7EF4A6663E52BF8D3620854A57A945-0-wk-Footnote-DE7EF4A6663E52BF8D3620854A57A945_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43674379e1322-wk-Fact-CD12C4F0CCE4505FAD338F25A39BF391" toRefs="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43771853e9258-wk-Fact-CD1BFB65FFF5532B973C2FBCB7BE8C3E" toRefs="TextSelection-08466783230155A08D7C13267B950D39-0-wk-Footnote-08466783230155A08D7C13267B950D39_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43674379e1549-wk-Fact-CDA40E6949B85E61B9C8AF985182E3E5 d43770747e1943-wk-Fact-CDA40E6949B85E61B9C8AF985182E3E5" toRefs="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43674379e1549-wk-Fact-CDA40E6949B85E61B9C8AF985182E3E5 d43770747e1943-wk-Fact-CDA40E6949B85E61B9C8AF985182E3E5" toRefs="TextSelection-E90A054BCC035ECEB6B6F2B7C947C3CE-0-wk-Footnote-E90A054BCC035ECEB6B6F2B7C947C3CE_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43771853e10847-wk-Fact-CDE473F11CA35CD29DE23110EB7E3FEF" toRefs="TextSelection-A685A65E160C5D228F531BF7107B3DF7-0-wk-Footnote-A685A65E160C5D228F531BF7107B3DF7_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43712496e2547-wk-Fact-CE0D12184A835989A295DE71DFF72EF8" toRefs="TextSelection-C37CD88178CA35C475D25A62F2B54FED-0-wk-Footnote-C37CD88178CA35C475D25A62F2B54FED_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687849e2846-wk-Fact-CE6465895C815C29B1431FBD3ED3B46B" toRefs="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43712496e2045-wk-Fact-CE9A93EF950C573BB8A81EBFDFFAF1D6" toRefs="TextSelection-7160FF67E87550A19177FE255A41A2D7-0-wk-Footnote-7160FF67E87550A19177FE255A41A2D7_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687849e1519-wk-Fact-CF85F87F0E845EA3BF827845F15B8168" toRefs="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43697240e1671-wk-Fact-CFD4991422BB5F588B49A4956375B606 d43697240e2295-wk-Fact-CFD4991422BB5F588B49A4956375B606" toRefs="TextSelection-FF348CC7844F523299A112551B170BE6-0-wk-Footnote-FF348CC7844F523299A112551B170BE6_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43770747e8667-wk-Fact-CFF329117B805CE791A8F04DB947E1BC" toRefs="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e8667-wk-Fact-CFF329117B805CE791A8F04DB947E1BC" toRefs="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43770747e10947-wk-Fact-CFFE4951A2DE534ABE61BA03B8048EA4" toRefs="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e10947-wk-Fact-CFFE4951A2DE534ABE61BA03B8048EA4" toRefs="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43712496e1224-wk-Fact-D042F83875705E98AC1B9D757B41F8B1" toRefs="TextSelection-B57619F44FCF544D96067CF4816A9082-0-wk-Footnote-B57619F44FCF544D96067CF4816A9082_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43674379e988-wk-Fact-D05030AC7D8B5906A350262C6079BD92" toRefs="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43771853e888-wk-Fact-D074F89DB2815EDFA2146FB266FB023F" toRefs="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43690878e2352-wk-Fact-D0EF06948F015270863207632A10DE91" toRefs="TextSelection-0333DDFA54555789BB4E2E73E3451A69-0-wk-Footnote-0333DDFA54555789BB4E2E73E3451A69_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43690878e2352-wk-Fact-D0EF06948F015270863207632A10DE91" toRefs="TextSelection-792D3AB23D6354CFBB2776AE7F6407B4-0-wk-Footnote-792D3AB23D6354CFBB2776AE7F6407B4_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43674379e817-wk-Fact-D156C275113454EF9843F3D3060B56DB d43681613e2472-wk-Fact-D156C275113454EF9843F3D3060B56DB" toRefs="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43674379e817-wk-Fact-D156C275113454EF9843F3D3060B56DB d43681613e2472-wk-Fact-D156C275113454EF9843F3D3060B56DB" toRefs="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43681613e1924-wk-Fact-D165564A6DBB5ECA8030FB998D5E7FE7" toRefs="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687704e882-wk-Fact-D1ABF3DF10655F18B16D5BEDE8158D66 d43771853e3613-wk-Fact-D1ABF3DF10655F18B16D5BEDE8158D66 d43771853e4954-wk-Fact-D1ABF3DF10655F18B16D5BEDE8158D66" toRefs="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e4260-wk-Fact-D1DB098BFAA05A5582E3C54C39A219DE" toRefs="TextSelection-2BFD6C99096B50AD93705C5601B21F46-0-wk-Footnote-2BFD6C99096B50AD93705C5601B21F46_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43697224e985-wk-Fact-D20C669A561D58BF9A9C9AC47CBBACC7" toRefs="TextSelection-FE5DD06AA8B65777900C47B8AC19C4C6-0-wk-Footnote-FE5DD06AA8B65777900C47B8AC19C4C6_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687704e1114-wk-Fact-D23657D890AE5F088F89E76D78FD1EB7" toRefs="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43687704e1114-wk-Fact-D23657D890AE5F088F89E76D78FD1EB7" toRefs="TextSelection-AE19F19C6AE65BBDA7F551089E2E7EDF-0-wk-Footnote-AE19F19C6AE65BBDA7F551089E2E7EDF_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43690878e1745-wk-Fact-D295627FDF4F561AB6C6612120051877" toRefs="TextSelection-792D3AB23D6354CFBB2776AE7F6407B4-0-wk-Footnote-792D3AB23D6354CFBB2776AE7F6407B4_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43770747e972-wk-Fact-D2E616C04C74565E87B5EFE91C979223" toRefs="TextSelection-8D2A93033C2E56DE9E814F0AB36328EE-0-wk-Footnote-8D2A93033C2E56DE9E814F0AB36328EE_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e972-wk-Fact-D2E616C04C74565E87B5EFE91C979223" toRefs="TextSelection-E96B3A139CCA56EC98329BC3717B10E3-0-wk-Footnote-E96B3A139CCA56EC98329BC3717B10E3_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43712496e3446-wk-Fact-D319BAF88B8B545CA48395F0788E8501" toRefs="TextSelection-04B3DB4115835E2FBB99EA13FC1FD64B-0-wk-Footnote-04B3DB4115835E2FBB99EA13FC1FD64B_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687704e1048-wk-Fact-D3650EE23D875F2485C04773B26C6EBF" toRefs="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43687704e1048-wk-Fact-D3650EE23D875F2485C04773B26C6EBF" toRefs="TextSelection-AE19F19C6AE65BBDA7F551089E2E7EDF-0-wk-Footnote-AE19F19C6AE65BBDA7F551089E2E7EDF_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e4156-wk-Fact-D3AD03E39A685B5F98D9E5A6DA5939DF" toRefs="TextSelection-2BFD6C99096B50AD93705C5601B21F46-0-wk-Footnote-2BFD6C99096B50AD93705C5601B21F46_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687849e1730-wk-Fact-D4592919CCA35BD2BDC493D03993CB8A" toRefs="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e1045-wk-Fact-D53A0B9A3EDB5C82AE283FE0420CAB5D" toRefs="TextSelection-8D2A93033C2E56DE9E814F0AB36328EE-0-wk-Footnote-8D2A93033C2E56DE9E814F0AB36328EE_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43770747e1045-wk-Fact-D53A0B9A3EDB5C82AE283FE0420CAB5D" toRefs="TextSelection-91730671722A5F83BA05EF347193E4CF-0-wk-Footnote-91730671722A5F83BA05EF347193E4CF_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687704e1825-wk-Fact-D5E632B5D4A85473B7FDB1B2EC3EF703 d43690878e1505-wk-Fact-D5E632B5D4A85473B7FDB1B2EC3EF703" toRefs="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687849e2977-wk-Fact-D64522201D7F5BB5BA48471538CE6CB8" toRefs="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43771853e3062-wk-Fact-D653E73218645753AB0757271374CCA1" toRefs="TextSelection-13C3E50268A15908A8AC9D1B6C938D2D-0-wk-Footnote-13C3E50268A15908A8AC9D1B6C938D2D_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d43771853e3062-wk-Fact-D653E73218645753AB0757271374CCA1" toRefs="TextSelection-78FC5AB8EFAB585E87BBCF93BE9FBF1D-0-wk-Footnote-78FC5AB8EFAB585E87BBCF93BE9FBF1D_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43771853e3062-wk-Fact-D653E73218645753AB0757271374CCA1" toRefs="TextSelection-C2AA3A20AB3F54349FC86854E44E1000-0-wk-Footnote-C2AA3A20AB3F54349FC86854E44E1000_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43687849e1114-wk-Fact-D6817414FA765B068A1698A96A9159E8" toRefs="TextSelection-36C36413532355188985D26E3B171357-0-wk-Footnote-36C36413532355188985D26E3B171357_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687849e1114-wk-Fact-D6817414FA765B068A1698A96A9159E8" toRefs="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43771853e3582-wk-Fact-D6C99180CE0A52CAAA4028B1B586C207" toRefs="TextSelection-78FC5AB8EFAB585E87BBCF93BE9FBF1D-0-wk-Footnote-78FC5AB8EFAB585E87BBCF93BE9FBF1D_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e10449-wk-Fact-D729388174C854FE8C4CEFABB9A6A065" toRefs="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43770747e10449-wk-Fact-D729388174C854FE8C4CEFABB9A6A065" toRefs="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43697224e1236-wk-Fact-D7C62060D2E154C4AFD979CF86960190" toRefs="TextSelection-7679A63ACE625532ADFCC5B97C6C9FC6-0-wk-Footnote-7679A63ACE625532ADFCC5B97C6C9FC6_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687849e3162-wk-Fact-D87820179CF453388B904F407941F962" toRefs="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687849e2670-wk-Fact-D8BF89A982EE5516AF5D38868D45AC49" toRefs="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e1333-wk-Fact-D91DA66DDA5D533D8090F62E9D24777E" toRefs="TextSelection-E90A054BCC035ECEB6B6F2B7C947C3CE-0-wk-Footnote-E90A054BCC035ECEB6B6F2B7C947C3CE_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43681613e2242-wk-Fact-DA0EC5A432335C1691A8266D92801437" toRefs="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e10474-wk-Fact-DA9B023396AA59FCAFC767A3F15E2AAA" toRefs="TextSelection-39CF024D03225486829869F6CA02C00E-0-wk-Footnote-39CF024D03225486829869F6CA02C00E_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d43770747e10474-wk-Fact-DA9B023396AA59FCAFC767A3F15E2AAA" toRefs="TextSelection-53BB8CAFCA475C0C9DB2195050D36025-0-wk-Footnote-53BB8CAFCA475C0C9DB2195050D36025_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43770747e10474-wk-Fact-DA9B023396AA59FCAFC767A3F15E2AAA" toRefs="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43712510e6030-wk-Fact-DACE24AFDEBA5A45B37C21CDA9314DB0" toRefs="TextSelection-6550A25092D55979B6A1D62BD4EDF090-0-wk-Footnote-6550A25092D55979B6A1D62BD4EDF090_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43681613e2356-wk-Fact-DB025A970D1451AEACFC8A982A850506" toRefs="TextSelection-3DD94144621C5A68BC21C5DB64345BB9-0-wk-Footnote-3DD94144621C5A68BC21C5DB64345BB9_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43681613e2356-wk-Fact-DB025A970D1451AEACFC8A982A850506" toRefs="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43687704e2725-wk-Fact-DB504CC293605BAF9CADCD1A8D93F11A d43712471e5794-wk-Fact-DB504CC293605BAF9CADCD1A8D93F11A" toRefs="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687704e2725-wk-Fact-DB504CC293605BAF9CADCD1A8D93F11A d43712471e5794-wk-Fact-DB504CC293605BAF9CADCD1A8D93F11A" toRefs="TextSelection-9231AC55B8EC5775BC4995B0797F870F-0-wk-Footnote-9231AC55B8EC5775BC4995B0797F870F_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43687849e1388-wk-Fact-DC0B04CD35255AAE8DB2F2B96794D8DC" toRefs="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687849e1388-wk-Fact-DC0B04CD35255AAE8DB2F2B96794D8DC" toRefs="TextSelection-F185CD45BC245C2EB8EDBFD55DB8A33F-0-wk-Footnote-F185CD45BC245C2EB8EDBFD55DB8A33F_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687849e1883-wk-Fact-DC5034ABC2EA5C18880A9E00522D29F5" toRefs="TextSelection-77536863BCE35B419E3A4119D41DB4BD-0-wk-Footnote-77536863BCE35B419E3A4119D41DB4BD_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43687849e1883-wk-Fact-DC5034ABC2EA5C18880A9E00522D29F5" toRefs="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43697240e1344-wk-Fact-DC886DFF855F55D5A5C4FBBBA585838D" toRefs="TextSelection-7432EEEACAB3598FA522C1D7E1584D05-0-wk-Footnote-7432EEEACAB3598FA522C1D7E1584D05_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43681613e1220-wk-Fact-DED2BD217A165276A7FC6775BFD357E2" toRefs="TextSelection-3DD94144621C5A68BC21C5DB64345BB9-0-wk-Footnote-3DD94144621C5A68BC21C5DB64345BB9_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43681613e1220-wk-Fact-DED2BD217A165276A7FC6775BFD357E2" toRefs="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43681613e2745-wk-Fact-DEFAF9D423795479839BFC83C7E9408A" toRefs="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43681613e2745-wk-Fact-DEFAF9D423795479839BFC83C7E9408A" toRefs="TextSelection-EB5698F25D035A90984FA270E724B7BB-0-wk-Footnote-EB5698F25D035A90984FA270E724B7BB_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43712496e3598-wk-Fact-DFB58A1FD36B53C88918A31FB32F3CE9" toRefs="TextSelection-3E9076747FF25E3B8D3B9AAF71548F16-0-wk-Footnote-3E9076747FF25E3B8D3B9AAF71548F16_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43712496e2343-wk-Fact-E0337FF965B85F19893F5C95D32AAD5B" toRefs="TextSelection-C37CD88178CA35C475D25A62F2B54FED-0-wk-Footnote-C37CD88178CA35C475D25A62F2B54FED_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43770747e8769-wk-Fact-E158F0F72B4F5E699400B1D0DF2B49F9" toRefs="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e8769-wk-Fact-E158F0F72B4F5E699400B1D0DF2B49F9" toRefs="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43771853e4875-wk-Fact-E1E962311928538DB01EDDF50F83A4A9" toRefs="TextSelection-DC6DDCB74FC9523D97BA51FBA6B1C05E-0-wk-Footnote-DC6DDCB74FC9523D97BA51FBA6B1C05E_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e11323-wk-Fact-E257ACF9822153C0B4489B4BD0381028" toRefs="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43770747e11323-wk-Fact-E257ACF9822153C0B4489B4BD0381028" toRefs="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43687704e2282-wk-Fact-E36AD239D16459E1808D418ACCF15849" toRefs="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687704e2282-wk-Fact-E36AD239D16459E1808D418ACCF15849" toRefs="TextSelection-9231AC55B8EC5775BC4995B0797F870F-0-wk-Footnote-9231AC55B8EC5775BC4995B0797F870F_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43674379e2342-wk-Fact-E3E870C4333E5DBA8986F6E17DA1CE7C" toRefs="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43697224e1670-wk-Fact-E3EB811EAA2157F1B8A0AC676941AA20" toRefs="TextSelection-9C73CEBDEE585A83B2B18F3B38A6D8CD-0-wk-Footnote-9C73CEBDEE585A83B2B18F3B38A6D8CD_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687849e2463-wk-Fact-E42F286486CD5834BD8EB16236B31FEA" toRefs="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43697224e1411-wk-Fact-E45333DA3C1351558E633F4210434F91" toRefs="TextSelection-6E67095C033B51BB9FABBA85E8DC4DFA-0-wk-Footnote-6E67095C033B51BB9FABBA85E8DC4DFA_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e11050-wk-Fact-E5A70858CAFC5770B3F632E0F9C47F2B" toRefs="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43770747e11050-wk-Fact-E5A70858CAFC5770B3F632E0F9C47F2B" toRefs="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43681613e2382-wk-Fact-E5CA2563496958358157EDDBD9180C21" toRefs="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43771853e11125-wk-Fact-E5DEE2763FF15719B07579F02111EFC3" toRefs="TextSelection-ED6F6E1A7C41596DA6F5B1BDFBB72CB7-0-wk-Footnote-ED6F6E1A7C41596DA6F5B1BDFBB72CB7_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43712496e2567-wk-Fact-E6280093B5CF57199192AD6A1C984105" toRefs="TextSelection-C37CD88178CA35C475D25A62F2B54FED-0-wk-Footnote-C37CD88178CA35C475D25A62F2B54FED_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43687704e2301-wk-Fact-E6450DE123AB5BECA240B4DA5F938164" toRefs="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687704e2301-wk-Fact-E6450DE123AB5BECA240B4DA5F938164" toRefs="TextSelection-9231AC55B8EC5775BC4995B0797F870F-0-wk-Footnote-9231AC55B8EC5775BC4995B0797F870F_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43712496e2026-wk-Fact-E6F32BC6EC2E5D5AB12A3A9ECA0A4CEF" toRefs="TextSelection-7160FF67E87550A19177FE255A41A2D7-0-wk-Footnote-7160FF67E87550A19177FE255A41A2D7_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43771853e11059-wk-Fact-E71ECFC84ED058A1982578968151CD88" toRefs="TextSelection-7266C8E6B8975A65A379AF3B415EA220-0-wk-Footnote-7266C8E6B8975A65A379AF3B415EA220_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43681613e929-wk-Fact-E753F2020B8F56CEBAE560B3B8BB9086" toRefs="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43771853e1447-wk-Fact-E7A96C031340595C8C21FFE23138776B" toRefs="TextSelection-78FC5AB8EFAB585E87BBCF93BE9FBF1D-0-wk-Footnote-78FC5AB8EFAB585E87BBCF93BE9FBF1D_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43771853e3236-wk-Fact-E7E6EB83A98259609D63524CCF7C1687" toRefs="TextSelection-13C3E50268A15908A8AC9D1B6C938D2D-0-wk-Footnote-13C3E50268A15908A8AC9D1B6C938D2D_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43771853e3236-wk-Fact-E7E6EB83A98259609D63524CCF7C1687" toRefs="TextSelection-78FC5AB8EFAB585E87BBCF93BE9FBF1D-0-wk-Footnote-78FC5AB8EFAB585E87BBCF93BE9FBF1D_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e8074-wk-Fact-E84743BA7BEB5C538A4DCD2F234366E5" toRefs="TextSelection-39CF024D03225486829869F6CA02C00E-0-wk-Footnote-39CF024D03225486829869F6CA02C00E_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43770747e8074-wk-Fact-E84743BA7BEB5C538A4DCD2F234366E5" toRefs="TextSelection-53BB8CAFCA475C0C9DB2195050D36025-0-wk-Footnote-53BB8CAFCA475C0C9DB2195050D36025_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d43770747e8074-wk-Fact-E84743BA7BEB5C538A4DCD2F234366E5" toRefs="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="Fact-E880E7106AA35CF2A064350EE9638A88-wk-Fact-E880E7106AA35CF2A064350EE9638A88" toRefs="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43712496e3559-wk-Fact-E88E61DCD79054CAB129EA8C07D5A4E5" toRefs="TextSelection-3E9076747FF25E3B8D3B9AAF71548F16-0-wk-Footnote-3E9076747FF25E3B8D3B9AAF71548F16_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43674379e1209-wk-Fact-E8F1DC92BC58566FACDD0804C8857081" toRefs="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e11133-wk-Fact-E9261ECFF1BF56E48D687B9EB690D501" toRefs="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43770747e11133-wk-Fact-E9261ECFF1BF56E48D687B9EB690D501" toRefs="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43681613e992-wk-Fact-E944F13BD8105FBDB6ACB7D264796FD0 d43697224e1519-wk-Fact-E944F13BD8105FBDB6ACB7D264796FD0" toRefs="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43681613e992-wk-Fact-E944F13BD8105FBDB6ACB7D264796FD0 d43697224e1519-wk-Fact-E944F13BD8105FBDB6ACB7D264796FD0" toRefs="TextSelection-FCAEF1B26EF652E4896D2456427B24D7-0-wk-Footnote-FCAEF1B26EF652E4896D2456427B24D7_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687849e2260-wk-Fact-E969B5F6A0FD5E7199F96415161E24EE" toRefs="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e8607-wk-Fact-E989403B19655D56902F363195B8FB79" toRefs="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43770747e8607-wk-Fact-E989403B19655D56902F363195B8FB79" toRefs="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687849e2137-wk-Fact-E9A491CA05515608A24040D57754A17D" toRefs="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43674379e900-wk-Fact-EA1D3C7D16595854B5CD606B1A735B28" toRefs="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43681613e1518-wk-Fact-EA51BB96305D596BBCDA3AF91C4A5606" toRefs="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43712496e2401-wk-Fact-EADD6730C9975145BE6C22C98A531D3E" toRefs="TextSelection-C37CD88178CA35C475D25A62F2B54FED-0-wk-Footnote-C37CD88178CA35C475D25A62F2B54FED_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43687704e2044-wk-Fact-EBA23CAAE8065687AE88E6554D498B60" toRefs="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687704e2044-wk-Fact-EBA23CAAE8065687AE88E6554D498B60" toRefs="TextSelection-9231AC55B8EC5775BC4995B0797F870F-0-wk-Footnote-9231AC55B8EC5775BC4995B0797F870F_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e10055-wk-Fact-EBE9947C4118517F84796F369756CEED" toRefs="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43770747e10055-wk-Fact-EBE9947C4118517F84796F369756CEED" toRefs="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e8132-wk-Fact-ED0DC050AE3557C5AA59EE876A9CCB85" toRefs="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43770747e8132-wk-Fact-ED0DC050AE3557C5AA59EE876A9CCB85" toRefs="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687849e2348-wk-Fact-ED18C0861D3E5C15B3C0A349152628B0" toRefs="TextSelection-77536863BCE35B419E3A4119D41DB4BD-0-wk-Footnote-77536863BCE35B419E3A4119D41DB4BD_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43687849e2348-wk-Fact-ED18C0861D3E5C15B3C0A349152628B0" toRefs="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e5872-wk-Fact-ED395CB21D4254C59230DB3A66452C47" toRefs="TextSelection-10C1964C9B955D8AB1D255A5330FE0A9-0-wk-Footnote-10C1964C9B955D8AB1D255A5330FE0A9_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43712496e1536-wk-Fact-ED45326FD065577BB318715037A629A6" toRefs="TextSelection-6912797A078E5D59B618DFFBB81C1BB6-0-wk-Footnote-6912797A078E5D59B618DFFBB81C1BB6_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e9829-wk-Fact-ED75BB4B1C585EB9A02A2357479F8D29" toRefs="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43770747e9829-wk-Fact-ED75BB4B1C585EB9A02A2357479F8D29" toRefs="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43697224e1717-wk-Fact-EE1FD7EDFFF655E3BCB6C13905C55C31" toRefs="TextSelection-ECF6A95A77365D79B2E9D472B81966D9-0-wk-Footnote-ECF6A95A77365D79B2E9D472B81966D9_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43771853e8259-wk-Fact-EE748539AE775F7AB4E662FB43CE60E4" toRefs="TextSelection-C4FFB7FEB33B5D5EBA7924687B243323-0-wk-Footnote-C4FFB7FEB33B5D5EBA7924687B243323_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687704e1467-wk-Fact-EE9718ED59B15329A11D4FE12F405FEA d43697224e1848-wk-Fact-EE9718ED59B15329A11D4FE12F405FEA" toRefs="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43674379e2050-wk-Fact-EECAD1E5742D526A902588518CB825FF" toRefs="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43690878e1595-wk-Fact-EECF50AEC9F85FECBE21642BE05B9B94" toRefs="TextSelection-792D3AB23D6354CFBB2776AE7F6407B4-0-wk-Footnote-792D3AB23D6354CFBB2776AE7F6407B4_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687704e1429-wk-Fact-EEFC92F1B5E55E77955910BC4C0F4CE1 d43697224e1809-wk-Fact-EEFC92F1B5E55E77955910BC4C0F4CE1" toRefs="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e1268-wk-Fact-EF31EB7FE14056148C1A008C93495CEB" toRefs="TextSelection-E90A054BCC035ECEB6B6F2B7C947C3CE-0-wk-Footnote-E90A054BCC035ECEB6B6F2B7C947C3CE_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43770747e1268-wk-Fact-EF31EB7FE14056148C1A008C93495CEB" toRefs="TextSelection-E96B3A139CCA56EC98329BC3717B10E3-0-wk-Footnote-E96B3A139CCA56EC98329BC3717B10E3_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43681613e2103-wk-Fact-EF326C0BF8D95F73A75E0D09B3DC12A4" toRefs="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e11031-wk-Fact-EF8FCCDF207A5213AA733CAB56F33EB4" toRefs="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43770747e11031-wk-Fact-EF8FCCDF207A5213AA733CAB56F33EB4" toRefs="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43770747e7491-wk-Fact-EFD127551F54519E94393635FCB3FC4A" toRefs="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e7491-wk-Fact-EFD127551F54519E94393635FCB3FC4A" toRefs="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43674379e1918-wk-Fact-F0B612439D18585FBB73EEB374B11207 d43770747e2189-wk-Fact-F0B612439D18585FBB73EEB374B11207" toRefs="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43674379e1918-wk-Fact-F0B612439D18585FBB73EEB374B11207 d43770747e2189-wk-Fact-F0B612439D18585FBB73EEB374B11207" toRefs="TextSelection-CBF70F977965537BB382CD083809AA0A-0-wk-Footnote-CBF70F977965537BB382CD083809AA0A_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e10907-wk-Fact-F135E5CEAB8E5D4EB7575AEBFF4DF757" toRefs="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43770747e10907-wk-Fact-F135E5CEAB8E5D4EB7575AEBFF4DF757" toRefs="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43771853e10808-wk-Fact-F17AE8BADCC4517B9C333EAD88E5DA8B" toRefs="TextSelection-A685A65E160C5D228F531BF7107B3DF7-0-wk-Footnote-A685A65E160C5D228F531BF7107B3DF7_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e10573-wk-Fact-F18080A5F5AD57518995089379096CF8" toRefs="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43770747e10573-wk-Fact-F18080A5F5AD57518995089379096CF8" toRefs="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43712496e2279-wk-Fact-F1C2E56FFF6857968C5DF6D28AD574C9" toRefs="TextSelection-C37CD88178CA35C475D25A62F2B54FED-0-wk-Footnote-C37CD88178CA35C475D25A62F2B54FED_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="Fact-F26558A44B7C5E24A9D0B3C320ABC3AC-wk-Fact-F26558A44B7C5E24A9D0B3C320ABC3AC" toRefs="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43712496e1165-wk-Fact-F2A2071B8FC55425A60551104D415290" toRefs="TextSelection-B57619F44FCF544D96067CF4816A9082-0-wk-Footnote-B57619F44FCF544D96067CF4816A9082_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43687704e2467-wk-Fact-F337EEA9B15A530CA79C01F287A6870F" toRefs="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687704e2467-wk-Fact-F337EEA9B15A530CA79C01F287A6870F" toRefs="TextSelection-9231AC55B8EC5775BC4995B0797F870F-0-wk-Footnote-9231AC55B8EC5775BC4995B0797F870F_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687849e1795-wk-Fact-F368335D74285386B4B988BC23C52314" toRefs="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687704e1384-wk-Fact-F3D7E2873AD65FA18989892A60F6626A d43712496e1704-wk-Fact-F3D7E2873AD65FA18989892A60F6626A" toRefs="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43771853e3497-wk-Fact-F4E33C840C7351EB83A44DAB9FB01B6C" toRefs="TextSelection-78FC5AB8EFAB585E87BBCF93BE9FBF1D-0-wk-Footnote-78FC5AB8EFAB585E87BBCF93BE9FBF1D_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43771853e3497-wk-Fact-F4E33C840C7351EB83A44DAB9FB01B6C" toRefs="TextSelection-8540AADB45BE54D38C10451BF6A88AB4-0-wk-Footnote-8540AADB45BE54D38C10451BF6A88AB4_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43674379e1190-wk-Fact-F52CA4E0D2C151988CD5EF5FA00DEAFE" toRefs="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43687704e2764-wk-Fact-F53A90EB6B0F5931A598FD416D03851F" toRefs="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687704e2764-wk-Fact-F53A90EB6B0F5931A598FD416D03851F" toRefs="TextSelection-9231AC55B8EC5775BC4995B0797F870F-0-wk-Footnote-9231AC55B8EC5775BC4995B0797F870F_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43674379e1146-wk-Fact-F5595E1E6E5C5AB79FC9578F6E9622FC" toRefs="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43687849e1645-wk-Fact-F567CC4505EC55EF951CC1C3D6B62769" toRefs="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687849e1645-wk-Fact-F567CC4505EC55EF951CC1C3D6B62769" toRefs="TextSelection-F185CD45BC245C2EB8EDBFD55DB8A33F-0-wk-Footnote-F185CD45BC245C2EB8EDBFD55DB8A33F_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43681613e1764-wk-Fact-F59987278FE651D99A4A03B22559E7CB" toRefs="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687849e1711-wk-Fact-F6B16FF2F2E15556BF6FA7B44550EBC3" toRefs="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687849e1009-wk-Fact-F703FF2FF1295F3C9A1F766CB8844DF9" toRefs="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43681613e2877-wk-Fact-F79EE7D9A58D5B3AA60618D470617657" toRefs="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43771853e4625-wk-Fact-F7E35E4375AD52538A3022CD6B0C19EC" toRefs="TextSelection-3802305E73EB52F28FAAF4EA5481D580-0-wk-Footnote-3802305E73EB52F28FAAF4EA5481D580_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e1178-wk-Fact-F7F348B359C05BD59C8DCACAAC15C4ED" toRefs="TextSelection-8D2A93033C2E56DE9E814F0AB36328EE-0-wk-Footnote-8D2A93033C2E56DE9E814F0AB36328EE_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43770747e1178-wk-Fact-F7F348B359C05BD59C8DCACAAC15C4ED" toRefs="TextSelection-91730671722A5F83BA05EF347193E4CF-0-wk-Footnote-91730671722A5F83BA05EF347193E4CF_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43771853e5488-wk-Fact-F89CB7AD3161526488B19688958B0E65" toRefs="TextSelection-84795AFB20AD54C48C963C7C52B00178-0-wk-Footnote-84795AFB20AD54C48C963C7C52B00178_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687704e1767-wk-Fact-F8A88E3727775446BECFB5D7B19FFE9A d43690878e1447-wk-Fact-F8A88E3727775446BECFB5D7B19FFE9A" toRefs="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43674379e1297-wk-Fact-F8F5DF7C12C25020B65DFF915C2D461A d43697240e3182-wk-Fact-F8F5DF7C12C25020B65DFF915C2D461A" toRefs="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="4" fromRefs="d43687704e1871-wk-Fact-F91674DC2E49576AB1FD6B5399D570DE d43687849e865-wk-Fact-F91674DC2E49576AB1FD6B5399D570DE" toRefs="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43687704e1871-wk-Fact-F91674DC2E49576AB1FD6B5399D570DE d43687849e865-wk-Fact-F91674DC2E49576AB1FD6B5399D570DE" toRefs="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d43687704e1871-wk-Fact-F91674DC2E49576AB1FD6B5399D570DE d43687849e865-wk-Fact-F91674DC2E49576AB1FD6B5399D570DE" toRefs="TextSelection-9231AC55B8EC5775BC4995B0797F870F-0-wk-Footnote-9231AC55B8EC5775BC4995B0797F870F_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687704e1871-wk-Fact-F91674DC2E49576AB1FD6B5399D570DE d43687849e865-wk-Fact-F91674DC2E49576AB1FD6B5399D570DE" toRefs="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43712510e5308-wk-Fact-F91DB48F665752F183FB6249B5C47098" toRefs="TextSelection-621F9196966C550EA113DA57575C171E-0-wk-Footnote-621F9196966C550EA113DA57575C171E_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e1692-wk-Fact-F94A368CB7E95851A8FE7949FC3E83F4" toRefs="TextSelection-58096FF6357955D6B6AA25D56767CB0A-0-wk-Footnote-58096FF6357955D6B6AA25D56767CB0A_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43770747e1692-wk-Fact-F94A368CB7E95851A8FE7949FC3E83F4" toRefs="TextSelection-8D2A93033C2E56DE9E814F0AB36328EE-0-wk-Footnote-8D2A93033C2E56DE9E814F0AB36328EE_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43674379e2449-wk-Fact-F986BFF5DEDA51E58393FB9819F5F489" toRefs="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43712496e1860-wk-Fact-FA60C203F66751A591C313394A513BBD" toRefs="TextSelection-7160FF67E87550A19177FE255A41A2D7-0-wk-Footnote-7160FF67E87550A19177FE255A41A2D7_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43692105e1297-wk-Fact-FAF3334C03BB50B5921AB864A8788C26" toRefs="TextSelection-2A36E737FFF05E75B357CB41AFB5B6E2-0-wk-Footnote-2A36E737FFF05E75B357CB41AFB5B6E2_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43681613e1789-wk-Fact-FB31F2DD4E78576D86B0CBE5A30FD593" toRefs="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e5820-wk-Fact-FB5D18E9A92E5D758C68B08090472348" toRefs="TextSelection-A42108BE06A7587BABD0C4A820609CE4-0-wk-Footnote-A42108BE06A7587BABD0C4A820609CE4_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e8730-wk-Fact-FC17783C6AF95B6BA110F4B016C6E9A6" toRefs="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43770747e8730-wk-Fact-FC17783C6AF95B6BA110F4B016C6E9A6" toRefs="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e10410-wk-Fact-FD239FB115D9532BB0AC86A94B61DFC0" toRefs="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43770747e10410-wk-Fact-FD239FB115D9532BB0AC86A94B61DFC0" toRefs="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e5684-wk-Fact-FD39AA4E611853FFB3347204D8FFAE7B" toRefs="TextSelection-0BDE8CEE983B5F118E2EFACDF9CC6405-0-wk-Footnote-0BDE8CEE983B5F118E2EFACDF9CC6405_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687849e1281-wk-Fact-FDB2255DA9ED588F82220AD2BD357172" toRefs="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43770747e7512-wk-Fact-FDC488BF6B135DEAA89A53C4766192EC" toRefs="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e7512-wk-Fact-FDC488BF6B135DEAA89A53C4766192EC" toRefs="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687849e2632-wk-Fact-FDE8C1D4A9445B5EB201CF6786FF4FCA" toRefs="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43690878e1913-wk-Fact-FF15C80FFD7658F196DE22E2327F4EF5" toRefs="TextSelection-792D3AB23D6354CFBB2776AE7F6407B4-0-wk-Footnote-792D3AB23D6354CFBB2776AE7F6407B4_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43771853e1933-wk-Fact-FF681D2F4C60530BA4FA7ECF6068D66E" toRefs="TextSelection-13C3E50268A15908A8AC9D1B6C938D2D-0-wk-Footnote-13C3E50268A15908A8AC9D1B6C938D2D_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43771853e1933-wk-Fact-FF681D2F4C60530BA4FA7ECF6068D66E" toRefs="TextSelection-78FC5AB8EFAB585E87BBCF93BE9FBF1D-0-wk-Footnote-78FC5AB8EFAB585E87BBCF93BE9FBF1D_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43687849e1453-wk-Fact-FF71A5EF104C5E84BB31EB85E1C2233A" toRefs="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e8588-wk-Fact-FF816B32EE915991B09BB0A4C759A044" toRefs="TextSelection-39CF024D03225486829869F6CA02C00E-0-wk-Footnote-39CF024D03225486829869F6CA02C00E_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d43770747e8588-wk-Fact-FF816B32EE915991B09BB0A4C759A044" toRefs="TextSelection-53BB8CAFCA475C0C9DB2195050D36025-0-wk-Footnote-53BB8CAFCA475C0C9DB2195050D36025_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d43770747e8588-wk-Fact-FF816B32EE915991B09BB0A4C759A044" toRefs="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43770747e4241-wk-Fact-FF82CF35A3B95DE7946765F53E9FCC87" toRefs="TextSelection-2BFD6C99096B50AD93705C5601B21F46-0-wk-Footnote-2BFD6C99096B50AD93705C5601B21F46_lbl"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d43712496e1367-wk-Fact-FF8ADB2E22EA5E31A89D8C1DB543B9B8" toRefs="TextSelection-B57619F44FCF544D96067CF4816A9082-0-wk-Footnote-B57619F44FCF544D96067CF4816A9082_lbl"/></ix:resources></ix:header></div><div><a id="sD4914A539B9E5A3FAAE181C905169F74"></a></div><div style="line-height:120%;text-align:center;font-size:15pt;"><span style="font-family:inherit;font-size:15pt;">UNITED STATES</span></div><div style="line-height:120%;text-align:center;font-size:15pt;"><span style="font-family:inherit;font-size:15pt;">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">WASHINGTON, D.C. 20549</span></div><div style="line-height:120%;text-align:center;font-size:15pt;"><span style="font-family:inherit;font-size:15pt;">FORM </span><span><ix:nonNumeric id="d43681101e634-wk-Fact-6A04E86595C5527C8B9067516347E6DE" name="dei:DocumentType" contextRef="FD2017Q3YTD"><span style="font-size:15pt;font-weight:normal;">10-Q</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:15pt;"> </span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:center;text-indent:12px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">X&#160;&#160;&#160;</span><span style="font-family:inherit;font-size:9.5pt;">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)</span></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-weight:bold;">For the quarterly period ended </span><span style="font-family:inherit;font-size:9.5pt;font-weight:bold;">October&#160;1, 2017</span><span style="font-family:inherit;font-size:9.5pt;font-weight:bold;"> </span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">OR</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">TRANSITION REPORT PURSUANT TO SECTION 13</span></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">For the transition period from _______ to _______</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">COMMISSION FILE NUMBER 1-3619</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">----</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:15pt;"><span><ix:nonNumeric id="d43681101e690-wk-Fact-539A3BE729915709A0D0D8552C5387E9" name="dei:EntityRegistrantName" contextRef="FD2017Q3YTD"><span style="font-size:15pt;font-weight:bold;">PFIZER INC</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:15pt;">.</span><span style="font-family:inherit;font-size:15pt;font-weight:bold;"> </span></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(Exact name of registrant as specified in its charter)</span></div><div style="line-height:120%;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:9.5pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:50%;"></td><td style="width:50%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">DELAWARE</span></div><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(State of Incorporation)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">13-5315170</span></div><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(I.R.S. Employer Identification No.)</span></div></td></tr></table></div></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">235 East 42</span><span style="font-family:inherit;font-size:9.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">nd</sup></span><span style="font-family:inherit;font-size:9.5pt;"> Street, New York, New York&#160;&#160;10017</span></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(Address of principal executive offices)&#160;&#160;(zip code)</span></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(212) 733-2323</span></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(Registrant&#8217;s telephone number)</span></div><div style="line-height:120%;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days.</span></div><div style="line-height:120%;font-size:9.5pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:11%;"></td><td style="width:89%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">YES &#160;</span><span style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">&#160;X&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">NO ___</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).</span></div><div style="line-height:120%;text-align:justify;font-size:9.5pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:11%;"></td><td style="width:89%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">YES &#160;</span><span style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">&#160;X&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">NO ___</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act (check one):</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Large Accelerated filer&#160;</span><span style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">&#160;X&#160;&#160;</span><span style="font-family:inherit;font-size:9.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Accelerated filer&#160;&#160;___&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Non-accelerated filer&#160;&#160;___&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Smaller reporting company&#160;&#160;___&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Emerging growth company&#160;&#160;___</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;___</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).</span></div><div style="line-height:120%;font-size:9.5pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:11%;"></td><td style="width:89%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">YES ____</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">NO&#160;&#160;</span><span style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">&#160;X&#160;</span></div></td></tr></table></div></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">At </span><span style="font-family:inherit;font-size:9.5pt;text-align:center;">November&#160;6, 2017</span><span style="font-family:inherit;font-size:9.5pt;">,&#160;</span><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d43681101e861-wk-Fact-F8AEF1028ECC5329874FFD2B3F3B9399" name="dei:EntityCommonStockSharesOutstanding" contextRef="I2017Q4Nov06" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">5,960,707,317</ix:nonFraction></span></span><span style="font-family:inherit;font-size:9.5pt;"> shares of the issuer&#8217;s voting common stock were outstanding.</span></div><div><br/></div><hr style="page-break-after:always"></hr><div><a id="sDB806224029C5004A93B4D67571B0176"></a></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:94%;"></td><td style="width:6%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;font-weight:bold;color:#000000;text-decoration:none;" href="#sFF78EC98C44C5100B62EF5D5344976B4"><span style="font-family:inherit;font-size:9pt;font-weight:bold;color:#000000;text-decoration:none;">PART I.&#160;&#160;FINANCIAL INFORMATION</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Page</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;" href="#sCC6FD7D0A7B45B2DA4CA9FB067EAB1E2"><span style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;">Item 1.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;" href="#sCC6FD7D0A7B45B2DA4CA9FB067EAB1E2"><span style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;">Financial Statements</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Condensed Consolidated Statements of Income for the three and nine months ended October 1, 2017 and October 2, 2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#s4A04175926325219A03BC334EDA70F9D">5</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Condensed Consolidated Statements of Comprehensive Income for the three and nine months ended October 1, 2017 and October 2, 2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#sDC91D064BC6F54109F4C2EA47B3B87D7">6</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Condensed Consolidated Balance Sheets as of October 1, 2017 and December 31, 2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#sD50F955FEFA5593F96F72CAB6E6E6BD0">7</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Condensed Consolidated Statements of Cash Flows for the nine months ended October 1, 2017 and October 2, 2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#s83F8F5C0D7C15C23B59FDB6FD34A8B2C">8</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;" href="#s52BF2A1953FC5CA5A656FB054EAF3EDE"><span style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;">Notes to Condensed Consolidated Financial Statements</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#s52BF2A1953FC5CA5A656FB054EAF3EDE">9</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;" href="#sBB668BD2FD6757FAB81DE0B6ECF0E369"><span style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;">Review Report of Independent Registered Public Accounting Firm</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#sBB668BD2FD6757FAB81DE0B6ECF0E369">45</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;" href="#sC32211D037205AB89BC9D50A97C6A004"><span style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;">Item 2.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;" href="#sC32211D037205AB89BC9D50A97C6A004"><span style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;">Management</span></a><span style="font-family:inherit;font-size:9pt;">&#8217;</span><a style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;" href="#sC32211D037205AB89BC9D50A97C6A004"><span style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;">s Discussion and Analysis of Financial Condition and Results of Operations</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#s2926C9EA133E5195B31D60243BE7C0E8">46</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;" href="#s8F22DA2CBD7352A69CCB49539CAA6159"><span style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;">Item 3.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;" href="#s8F22DA2CBD7352A69CCB49539CAA6159"><span style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;">Quantitative and Qualitative Disclosures About Market Risk</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#s8F22DA2CBD7352A69CCB49539CAA6159">106</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;" href="#sD57E469ACE1751329298989E953E1D78"><span style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;">Item 4.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;" href="#sD57E469ACE1751329298989E953E1D78"><span style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;">Controls and Procedures</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#sD57E469ACE1751329298989E953E1D78">106</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;font-weight:bold;color:#000000;text-decoration:none;" href="#s3E17EA6CCF6D5C8599D35A23A2E42CF0"><span style="font-family:inherit;font-size:9pt;font-weight:bold;color:#000000;text-decoration:none;">PART II.&#160;&#160;OTHER INFORMATION</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;" href="#s7D8D764240E153EABA1C0A53152A2988"><span style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;">Item 1.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;" href="#s7D8D764240E153EABA1C0A53152A2988"><span style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;">Legal Proceedings</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#s7D8D764240E153EABA1C0A53152A2988">107</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;" href="#s7F59FFC53D9E574E98AFB09E1B19A9A1"><span style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;">Item 1A.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;" href="#s7F59FFC53D9E574E98AFB09E1B19A9A1"><span style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;">Risk Factors</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#s7F59FFC53D9E574E98AFB09E1B19A9A1">107</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;" href="#s4C54D740F2515D01973B8D0F0C2D288C"><span style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;">Item 2.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;" href="#s4C54D740F2515D01973B8D0F0C2D288C"><span style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;">Unregistered Sales of Equity Securities and Use of Proceeds</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#s4C54D740F2515D01973B8D0F0C2D288C">109</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;" href="#s9ACC93F8BE425B2691CA44B4708B566D"><span style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;">Item 3.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;" href="#s9ACC93F8BE425B2691CA44B4708B566D"><span style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;">Defaults Upon Senior Securities</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#s9ACC93F8BE425B2691CA44B4708B566D">109</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;" href="#s8590669D342655F38A3D40B8C29F8684"><span style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;">Item 4.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;" href="#s8590669D342655F38A3D40B8C29F8684"><span style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;">Mine Safety Disclosures</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#s8590669D342655F38A3D40B8C29F8684">109</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;" href="#s944496463A7A5DB293865996B693472F"><span style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;">Item 5.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;" href="#s944496463A7A5DB293865996B693472F"><span style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;">Other Information</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#s944496463A7A5DB293865996B693472F">109</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;" href="#sEECE8FA2C6E45735BCCB066FA94102FF"><span style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;">Item 6.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;" href="#sEECE8FA2C6E45735BCCB066FA94102FF"><span style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;">Exhibits</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#sEECE8FA2C6E45735BCCB066FA94102FF">110</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;" href="#sAFDA09B40DEA565995605E22D7135077"><span style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;">Signature</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#sAFDA09B40DEA565995605E22D7135077">111</a></div></td></tr></table></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2</span></div></div><hr style="page-break-after:always"></hr><div><a id="s4494D8EA92E05BD0B8597E152320CD10"></a></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">GLOSSARY OF DEFINED TERMS</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unless the context requires otherwise, references to &#8220;Pfizer,&#8221; &#8220;the Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; or &#8220;our&#8221; in this Quarterly Report on Form 10-Q (defined below) refer to Pfizer Inc. and its subsidiaries. We also have used several other terms in this Quarterly Report on Form 10-Q, most of which are explained or defined below:</span></div><div style="line-height:120%;text-align:center;padding-left:0px;text-indent:0px;font-size:9pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.22027290448344%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:25%;"></td><td style="width:75%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">2016 Financial Report</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Financial Report for the fiscal year ended December 31, 2016, which was filed as Exhibit 13 to the Annual Report on Form 10-K for the fiscal year ended December 31, 2016</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">2016 Form 10-K</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Annual Report on Form 10-K for the fiscal year ended December 31, 2016</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">AAV</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Adeno-Associated Virus </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">ACA (Also referred to as U.S. Healthcare Legislation)</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">U.S. Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">ACIP</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Advisory Committee on Immunization Practices</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">ALK</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">anaplastic lymphoma kinase</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">Allergan</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Allergan plc</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">Alliance revenues</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Revenues from alliance agreements under which we co-promote products discovered or developed by other companies or us</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">Anacor</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Anacor Pharmaceuticals, Inc.</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">Astellas</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Astellas Pharma U.S., Inc.</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">ASU</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Accounting Standards Update</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">ATM-AVI</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">aztreonam-avibactam</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">Avillion</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Avillion LLP</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">Bamboo</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-top:10px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Bamboo Therapeutics, Inc.</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">BMS</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Bristol-Myers Squibb Company</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">CDC</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">U.S. Centers for Disease Control and Prevention</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">Cellectis</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Cellectis SA</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">Citibank</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Citibank N.A.</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">cGMPs</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">current Good Manufacturing Practices</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">Developed Markets</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">U.S., Western Europe, Japan, Canada, Australia, South Korea, Scandinavian countries, Finland and New Zealand</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">EEA</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">European Economic Area</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">EH</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Essential Health</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">EMA</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">European Medicines Agency</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">Emerging Markets</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Africa, Eastern Europe, Central Europe, the Middle East and Turkey</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">EPS</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">earnings per share</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">EU</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">European Union</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">EURIBOR</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Euro Interbank Offered Rate</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">Exchange Act</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Securities Exchange Act of 1934, as amended</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">FASB</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Financial Accounting Standards Board</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">FDA</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">U.S. Food and Drug Administration</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">GAAP</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Generally Accepted Accounting Principles</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">GIST</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">gastrointestinal stromal tumors</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">GPD</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Global Product Development</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">HER2-</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">human epidermal growth factor receptor 2-negative</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">HIS</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Hospira Infusion Systems </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">Hisun</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Zhejiang Hisun Pharmaceuticals Co., Ltd.</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">Hisun Pfizer</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Hisun Pfizer Pharmaceuticals Company Limited</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">Hospira</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Hospira, Inc.</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">HR+</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">hormone receptor-positive</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">ICU Medical</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">ICU Medical, Inc.</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">IH</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Innovative Health</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">InnoPharma</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">InnoPharma, Inc.</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">IPR&amp;D</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">in-process research and development</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">IRS</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">U.S. Internal Revenue Service</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">IV</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">intravenous</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">Janssen</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Janssen Biotech Inc.</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">King</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">King Pharmaceuticals, Inc.</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">LDL</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">low density lipoprotein</span></div></td></tr></table></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;text-align:center;padding-left:0px;font-size:9pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.22027290448344%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:25%;"></td><td style="width:75%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">LEP</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Legacy Established Products</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">LIBOR</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">London Interbank Offered Rate</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">Lilly</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Eli Lilly &amp; Company</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">LOE</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">loss of exclusivity</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">MCO</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Managed Care Organization</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">MD&amp;A</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">Medivation</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Medivation, Inc.</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">Merck</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Merck &amp; Co., Inc.</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">Meridian</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Meridian Medical Technologies, Inc.</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">Moody&#8217;s</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Moody&#8217;s Investors Service</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">NDA</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">new drug application</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">NovaQuest</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">NovaQuest Co-Investment Fund V, L.P.</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">NSCLC</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">non-small cell lung cancer</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">NYSE</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">New York Stock Exchange</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">OPKO</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">OPKO Health, Inc.</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">OTC</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">over-the-counter</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">PBM</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Pharmacy Benefit Manager</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">Pharmacia</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Pharmacia Corporation</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">PP&amp;E</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Property, plant &amp; equipment</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">Quarterly Report on Form 10-Q</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Quarterly Report on Form 10-Q for the quarterly period ended October 1, 2017</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">RCC</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">renal cell carcinoma</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">R&amp;D</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">research and development</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">RPI</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">RPI Finance Trust</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">Sandoz</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Sandoz, Inc., a division of Novartis AG</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">Sangamo</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Sangamo Therapeutics, Inc.</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">SEC</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">U.S. Securities and Exchange Commission</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">SFJ</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">SFJ Pharmaceuticals Group</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">SIP</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Sterile Injectable Pharmaceuticals</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">S&amp;P</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Standard and Poor&#8217;s</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">Teuto</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Laborat&#243;rio Teuto Brasileiro S.A.</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">U.K.</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">United Kingdom</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">U.S.</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">United States</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">ViiV</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">ViiV Healthcare Limited</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">WRD</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Worldwide Research and Development</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">Zoetis</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Zoetis Inc.</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">4</span></div></div><hr style="page-break-after:always"></hr><div><a id="sFF78EC98C44C5100B62EF5D5344976B4"></a></div><div><br/></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">PART I&#160;- FINANCIAL INFORMATION</span></div><div><a id="sCC6FD7D0A7B45B2DA4CA9FB067EAB1E2"></a></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 1. Financial Statements</span></div><div><a id="s4A04175926325219A03BC334EDA70F9D"></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">CONDENSED CONSOLIDATED STATEMENTS OF INCOME</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(UNAUDITED)</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"></td></tr><tr><td style="width:44%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nine Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS, EXCEPT PER COMMON SHARE DATA)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">October&#160;1, <br/>2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">October&#160;2, <br/>2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">October&#160;1, <br/>2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">October&#160;2, <br/>2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687704e843-wk-Fact-739EC43DD13B5516B11DE41A93EEDF71" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">13,168</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687704e862-wk-Fact-08F7B1DEB2E25ACA94468FF7CE567177" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">13,045</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687704e882-wk-Fact-D1ABF3DF10655F18B16D5BEDE8158D66" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">38,843</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687704e901-wk-Fact-769863A67705599FBF10A0F9C982956F" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">39,196</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Costs and expenses:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of sales</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687704e1010-wk-Fact-28E7163DD278532183F033BDA283F0A1" name="us-gaap:CostOfGoodsSold" contextRef="FD2017Q3QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,847</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687704e1029-wk-Fact-570366E89FCD5DA8ACCEEA8270C0E4C3" name="us-gaap:CostOfGoodsSold" contextRef="FD2016Q3QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,085</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687704e1048-wk-Fact-D3650EE23D875F2485C04773B26C6EBF" name="us-gaap:CostOfGoodsSold" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">7,980</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687704e1068-wk-Fact-0FC4340BB89A562D9A6DFA4186E041AB" name="us-gaap:CostOfGoodsSold" contextRef="FD2016Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">9,111</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Selling, informational and administrative expenses</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687704e1095-wk-Fact-97AEC38197D45AB8B6B38E3761427F3A" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="FD2017Q3QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,500</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687704e1114-wk-Fact-D23657D890AE5F088F89E76D78FD1EB7" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="FD2016Q3QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,559</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687704e1133-wk-Fact-191AFA552BEF51A38ED7B886728FB89F" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">10,233</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687704e1153-wk-Fact-7E1F234CCFDF5CD5B6D2068DEF0EA230" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="FD2016Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">10,414</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development expenses</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687704e1180-wk-Fact-225BF3E60210511691B41C170582C821" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="FD2017Q3QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,859</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687704e1199-wk-Fact-822E670EBB815BFB8925AC8ECADDC3AB" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="FD2016Q3QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,881</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687704e1218-wk-Fact-1577AD25D0BD5FE9BC590CD0FFB82AC1" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">5,346</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687704e1238-wk-Fact-B14EB26D36A55E6D996F420A2D075893" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="FD2016Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">5,360</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization of intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687704e1263-wk-Fact-1A88D36F44FC57EEB2947A0516F8E2FB" name="pfe:AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction" contextRef="FD2017Q3QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,177</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687704e1282-wk-Fact-AD0FEF5202405A048EC52168262886B2" name="pfe:AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction" contextRef="FD2016Q3QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">968</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687704e1301-wk-Fact-C0E90259FF035CD683F5D973FC82FD05" name="pfe:AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,571</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687704e1321-wk-Fact-2955D213201255B6B4C71E112F5F3621" name="pfe:AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction" contextRef="FD2016Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,934</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Restructuring charges and certain acquisition-related costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687704e1346-wk-Fact-B73545D07B565820AFF53EEAE1860800" name="pfe:RestructuringChargesAndAcquisitionRelatedCosts" contextRef="FD2017Q3QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">149</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687704e1365-wk-Fact-110B8A55AF7C5BFEAC9F11433EB9280B" name="pfe:RestructuringChargesAndAcquisitionRelatedCosts" contextRef="FD2016Q3QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">531</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687704e1384-wk-Fact-F3D7E2873AD65FA18989892A60F6626A" name="pfe:RestructuringChargesAndAcquisitionRelatedCosts" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">377</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687704e1404-wk-Fact-5FBAE33C336F53F48E8FF7CDE77BBB26" name="pfe:RestructuringChargesAndAcquisitionRelatedCosts" contextRef="FD2016Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">988</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other (income)/deductions&#8211;&#8211;net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687704e1429-wk-Fact-EEFC92F1B5E55E77955910BC4C0F4CE1" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="FD2017Q3QTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">51</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687704e1448-wk-Fact-916495EF6D70560FBFED7475E53E1BEA" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="FD2016Q3QTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1,417</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d43687704e1467-wk-Fact-EE9718ED59B15329A11D4FE12F405FEA" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">16</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687704e1488-wk-Fact-901AC284652F5C9B93B4B3D55F3C6EAE" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="FD2016Q3YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">2,815</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;text-indent:-18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income from continuing operations before provision for taxes on income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687704e1513-wk-Fact-C6627323E3A7545BB805B65F89BE7911" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2017Q3QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,585</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687704e1532-wk-Fact-8EACD6F676A95BF0AB83AE15D642DBEA" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2016Q3QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,604</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687704e1551-wk-Fact-6C225350ED6F51898E27B37470C6135A" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">11,351</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687704e1571-wk-Fact-6056A2295D7857F1915F488C04BDB11A" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2016Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">7,575</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Provision for taxes on income</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687704e1599-wk-Fact-4F4FAE747047530784054ED85551DFDC" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2017Q3QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">727</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687704e1618-wk-Fact-2D8CDE5E04555F14B8B630B25163E15F" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2016Q3QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">249</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687704e1637-wk-Fact-741D17F5FCAB522EB406F004C9FDBAA3" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,287</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687704e1657-wk-Fact-626C408AD0435F32862D27637DFEBF9C" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2016Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,109</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income from continuing operations</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687704e1684-wk-Fact-10A93FAA5CBC5B458A708E3EEBF01F13" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" contextRef="FD2017Q3QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,858</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687704e1703-wk-Fact-8F2AF78FFD8356E9921CBFEFF7E852B8" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" contextRef="FD2016Q3QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,355</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687704e1722-wk-Fact-1011397EB1385A98BE195F68F7FE92A7" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">9,064</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687704e1742-wk-Fact-9CDAD2B93E775B8EA25F98BBA2F83485" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" contextRef="FD2016Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6,465</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Discontinued operations&#8211;&#8211;net of tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687704e1767-wk-Fact-F8A88E3727775446BECFB5D7B19FFE9A" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" contextRef="FD2017Q3QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687704e1786-wk-Fact-0A252F10C1E25CFA8D6B9B5104061718" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" contextRef="FD2016Q3QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687704e1805-wk-Fact-60867BC7B4C25795A91A0C8BA6B7BDAB" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687704e1825-wk-Fact-D5E632B5D4A85473B7FDB1B2EC3EF703" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" contextRef="FD2016Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income before allocation to noncontrolling interests</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687704e1852-wk-Fact-C6BAFD428E8D5DBBB9FC324DE0B23F01" name="us-gaap:ProfitLoss" contextRef="FD2017Q3QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,858</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687704e1871-wk-Fact-F91674DC2E49576AB1FD6B5399D570DE" name="us-gaap:ProfitLoss" contextRef="FD2016Q3QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,355</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687704e1890-wk-Fact-769C4E4C0C905BDA89016FEC60CCEAB2" name="us-gaap:ProfitLoss" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">9,066</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687704e1910-wk-Fact-1F598F7CC0A659DC8B78C122AEB4F4CE" name="us-gaap:ProfitLoss" contextRef="FD2016Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6,465</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: Net income attributable to noncontrolling interests</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687704e1935-wk-Fact-09351BE188EA5C05843D243B15A603F5" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="FD2017Q3QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">18</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687704e1954-wk-Fact-12644093904C5936B08DC2FFA86C8E1C" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="FD2016Q3QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687704e1973-wk-Fact-110FAC29CE4C53DFB4DD30D11B664569" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">32</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687704e1993-wk-Fact-288376604CC25FCA9066DC7223130DD2" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="FD2016Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">25</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income attributable to Pfizer Inc.</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687704e2025-wk-Fact-40459F40D11A5E0AA41A1F4213969546" name="us-gaap:NetIncomeLoss" contextRef="FD2017Q3QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,840</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687704e2044-wk-Fact-EBA23CAAE8065687AE88E6554D498B60" name="us-gaap:NetIncomeLoss" contextRef="FD2016Q3QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,355</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687704e2064-wk-Fact-2F837D3EBB765EBCB1249DE75E4FF1D1" name="us-gaap:NetIncomeLoss" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">9,034</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687704e2083-wk-Fact-143D73146425519EBA3BAC0B389543EF" name="us-gaap:NetIncomeLoss" contextRef="FD2016Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6,440</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Earnings per common share&#8211;&#8211;basic</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(b)</sup></span><span style="font-family:inherit;font-size:10pt;">:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income from continuing operations attributable to Pfizer Inc. common shareholders</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687704e2282-wk-Fact-E36AD239D16459E1808D418ACCF15849" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" contextRef="FD2017Q3QTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">0.48</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687704e2301-wk-Fact-E6450DE123AB5BECA240B4DA5F938164" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" contextRef="FD2016Q3QTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">0.22</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687704e2321-wk-Fact-57FC3ED392B859D78861D64EC5C88CB0" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" contextRef="FD2017Q3YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">1.51</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687704e2340-wk-Fact-9652D747D2CD5DF5B4AE1CACCD0A7222" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" contextRef="FD2016Q3YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">1.06</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Discontinued operations&#8211;&#8211;net of tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687704e2360-wk-Fact-AF9D3709DF59553C9EBCFCBC41F64F99" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" contextRef="FD2017Q3QTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687704e2379-wk-Fact-B4B59AB6237151588AD0DCDB47024876" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" contextRef="FD2016Q3QTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687704e2398-wk-Fact-3F5327605CC159E0884F58369042FADA" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" contextRef="FD2017Q3YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687704e2418-wk-Fact-4FA35F91DEE258C694579DEDDD33A6CF" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" contextRef="FD2016Q3YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income attributable to Pfizer Inc. common shareholders</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687704e2448-wk-Fact-8810BC1FB19F5CCBB75143FDC43F7193" name="us-gaap:EarningsPerShareBasic" contextRef="FD2017Q3QTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">0.48</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687704e2467-wk-Fact-F337EEA9B15A530CA79C01F287A6870F" name="us-gaap:EarningsPerShareBasic" contextRef="FD2016Q3QTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">0.22</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687704e2487-wk-Fact-8AF2BFF4A0B050A8AEDFE6EBFEC9B378" name="us-gaap:EarningsPerShareBasic" contextRef="FD2017Q3YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">1.51</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687704e2506-wk-Fact-02AE17DCB8665481BC805EA0E0D7CB38" name="us-gaap:EarningsPerShareBasic" contextRef="FD2016Q3YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">1.06</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Earnings per common share&#8211;&#8211;diluted</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(b)</sup></span><span style="font-family:inherit;font-size:10pt;">:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income from continuing operations attributable to Pfizer Inc. common shareholders</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687704e2706-wk-Fact-2BD65B1FAD49532F94B23261F5066D15" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" contextRef="FD2017Q3QTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">0.47</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687704e2725-wk-Fact-DB504CC293605BAF9CADCD1A8D93F11A" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" contextRef="FD2016Q3QTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">0.22</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687704e2745-wk-Fact-0EF2FD50430259DC8181FE20C0F40B34" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" contextRef="FD2017Q3YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">1.49</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687704e2764-wk-Fact-F53A90EB6B0F5931A598FD416D03851F" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" contextRef="FD2016Q3YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">1.04</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Discontinued operations&#8211;&#8211;net of tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687704e2784-wk-Fact-485CB0863B5C5B9D8B2C74086517AD5B" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" contextRef="FD2017Q3QTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687704e2803-wk-Fact-669021DA4A3E525F9913592D2FD04D72" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" contextRef="FD2016Q3QTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687704e2822-wk-Fact-473E2E1DAAB95751BEEBC640CAD75D52" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" contextRef="FD2017Q3YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687704e2842-wk-Fact-C799B208E12551D9925550E1584374F0" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" contextRef="FD2016Q3YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income attributable to Pfizer Inc. common shareholders</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687704e2872-wk-Fact-9731AEDCAB005D1FBDC36BDD20F9FFF8" name="us-gaap:EarningsPerShareDiluted" contextRef="FD2017Q3QTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">0.47</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687704e2891-wk-Fact-98E7EC7835B052E592B533FDD3656AFB" name="us-gaap:EarningsPerShareDiluted" contextRef="FD2016Q3QTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">0.22</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687704e2911-wk-Fact-4B8F1DBA2929519A88C07E8910A30454" name="us-gaap:EarningsPerShareDiluted" contextRef="FD2017Q3YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">1.49</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687704e2930-wk-Fact-B227984E1B50586585A129EB332CFD86" name="us-gaap:EarningsPerShareDiluted" contextRef="FD2016Q3YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">1.04</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted-average shares&#8211;&#8211;basic</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687704e3037-wk-Fact-69E50427EE6E533896BB8B1907041230" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="FD2017Q3QTD" unitRef="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">5,951</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687704e3056-wk-Fact-63E834283E2059E3A8C189B4778885B0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="FD2016Q3QTD" unitRef="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">6,066</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687704e3075-wk-Fact-89167C4150EA5B6CB2833B441C176EB5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="FD2017Q3YTD" unitRef="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">5,972</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687704e3095-wk-Fact-044058D73AF55D17962CBA73D63800BD" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="FD2016Q3YTD" unitRef="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">6,095</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted-average shares&#8211;&#8211;diluted</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687704e3122-wk-Fact-4F013E58EAE3506D989984D20AC7A60B" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="FD2017Q3QTD" unitRef="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">6,041</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687704e3141-wk-Fact-1E5089DBEBB75DB7864724ADB41A8830" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="FD2016Q3QTD" unitRef="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">6,150</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687704e3160-wk-Fact-C0D5F9589E725D14B3DE492AFAAAEA7D" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="FD2017Q3YTD" unitRef="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">6,057</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687704e3180-wk-Fact-413D25685F8F583AB53236F9F57575B9" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="FD2016Q3YTD" unitRef="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">6,175</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash dividends paid per common share</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687704e3210-wk-Fact-8BCC41FCBE495D779B180688D6602014" name="us-gaap:CommonStockDividendsPerShareCashPaid" contextRef="FD2017Q3QTD" unitRef="usdPerShare" decimals="INF" scale="0" format="ixt:numdotdecimal">0.32</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687704e3229-wk-Fact-6CE7E4C1FB715EB9A50793367CE85508" name="us-gaap:CommonStockDividendsPerShareCashPaid" contextRef="FD2016Q3QTD" unitRef="usdPerShare" decimals="INF" scale="0" format="ixt:numdotdecimal">0.30</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687704e3249-wk-Fact-ABA682EB80515D309B605AA81450C85B" name="us-gaap:CommonStockDividendsPerShareCashPaid" contextRef="FD2017Q3YTD" unitRef="usdPerShare" decimals="INF" scale="0" format="ixt:numdotdecimal">0.96</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687704e3268-wk-Fact-1F15569F17C85A6FB44008E62E8E62E3" name="us-gaap:CommonStockDividendsPerShareCashPaid" contextRef="FD2016Q3YTD" unitRef="usdPerShare" decimals="INF" scale="0" format="ixt:numdotdecimal">0.90</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><ix:footnote id="TextSelection-AE19F19C6AE65BBDA7F551089E2E7EDF-0-wk-Footnote-AE19F19C6AE65BBDA7F551089E2E7EDF_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" continuedAt="TextSelection-AE19F19C6AE65BBDA7F551089E2E7EDF-1">Excludes amortization of intangible assets, except as disclosed in </ix:footnote></span><span style="font-family:inherit;font-size:9pt;font-style:italic;"><ix:continuation id="TextSelection-AE19F19C6AE65BBDA7F551089E2E7EDF-1">Note 9A. Identifiable Intangible Assets and Goodwill: Identifiable Intangible Assets.</ix:continuation></span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><ix:footnote id="TextSelection-9231AC55B8EC5775BC4995B0797F870F-0-wk-Footnote-9231AC55B8EC5775BC4995B0797F870F_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" continuedAt="TextSelection-9231AC55B8EC5775BC4995B0797F870F-1">Amounts for the </ix:footnote></span><ix:continuation id="TextSelection-9231AC55B8EC5775BC4995B0797F870F-1" continuedAt="TextSelection-9231AC55B8EC5775BC4995B0797F870F-2"><span style="font-family:inherit;font-size:9pt;">three and nine months ended October 2, 2016</span><span style="font-family:inherit;font-size:9pt;"> have been revised from previously reported amounts to reflect the adoption of a new accounting standard in the fourth quarter of 2016, as of January 1, 2016. For additional information, see </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Note 1B</span><span style="font-family:inherit;font-size:9pt;">. </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Basis of Presentation and Significant Accounting Policies&#8211;&#8211;Adoption of New Accounting Standards</span></ix:continuation><span style="font-family:inherit;font-size:9pt;"><ix:continuation id="TextSelection-9231AC55B8EC5775BC4995B0797F870F-2">.</ix:continuation></span></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><ix:footnote id="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US">Amounts may not add due to rounding.</ix:footnote></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">See Notes to Condensed Consolidated Financial Statements.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">5</span></div></div><hr style="page-break-after:always"></hr><div><a id="sDC91D064BC6F54109F4C2EA47B3B87D7"></a></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">PFIZER&#160;INC. AND SUBSIDIARY COMPANIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(UNAUDITED)</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"></td></tr><tr><td style="width:44%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nine Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">October&#160;1, <br/>2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">October&#160;2, <br/>2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">October&#160;1, <br/>2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">October&#160;2, <br/>2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income before allocation to noncontrolling interests</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687849e846-wk-Fact-C6BAFD428E8D5DBBB9FC324DE0B23F01" name="us-gaap:ProfitLoss" contextRef="FD2017Q3QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,858</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687849e865-wk-Fact-F91674DC2E49576AB1FD6B5399D570DE" name="us-gaap:ProfitLoss" contextRef="FD2016Q3QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,355</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687849e885-wk-Fact-769C4E4C0C905BDA89016FEC60CCEAB2" name="us-gaap:ProfitLoss" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">9,066</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687849e904-wk-Fact-1F598F7CC0A659DC8B78C122AEB4F4CE" name="us-gaap:ProfitLoss" contextRef="FD2016Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6,465</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign currency translation adjustments, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687849e1009-wk-Fact-F703FF2FF1295F3C9A1F766CB8844DF9" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" contextRef="FD2017Q3QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">878</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687849e1028-wk-Fact-72F6CFB7B5D35966938C0A78B6424FE7" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" contextRef="FD2016Q3QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">417</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687849e1047-wk-Fact-C15E30483A415EE0AF567E4AAFB1965C" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,352</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687849e1067-wk-Fact-3DD9D4B9BF27581180EA172B8CC2DC14" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" contextRef="FD2016Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">998</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Reclassification adjustments</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d43687849e1094-wk-Fact-1745891B013F59B28C550000447D41B6" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax" contextRef="FD2017Q3QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687849e1114-wk-Fact-D6817414FA765B068A1698A96A9159E8" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax" contextRef="FD2016Q3QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687849e1133-wk-Fact-34A31155E9EC5355982021CA6EBEFB38" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">110</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687849e1153-wk-Fact-8EF4AF6384775AC783C5F87F272BBA35" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax" contextRef="FD2016Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687849e1178-wk-Fact-33A901EBBAEB5B7B8CD51B4273CBCE61" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" contextRef="FD2017Q3QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">875</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687849e1197-wk-Fact-579A851CE2B25899921158748034540F" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" contextRef="FD2016Q3QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">417</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687849e1216-wk-Fact-524E646459CB5301AEC5027EA98F9741" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,461</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687849e1236-wk-Fact-3C8E3740EBD853D5A2217E87A8E69C70" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" contextRef="FD2016Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">998</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unrealized holding losses on derivative financial instruments, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d43687849e1261-wk-Fact-C2DBD9F4462053918846BC5A4E78FE6B" name="us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax" contextRef="FD2017Q3QTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">50</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d43687849e1281-wk-Fact-FDB2255DA9ED588F82220AD2BD357172" name="us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax" contextRef="FD2016Q3QTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">126</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d43687849e1301-wk-Fact-4C6BD95E3D2E5FB8B5E794AE6EE85755" name="us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">149</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d43687849e1322-wk-Fact-9DF54FB1EA595037ACB26A2654176B64" name="us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax" contextRef="FD2016Q3YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">970</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Reclassification adjustments for realized (gains)/losses</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687849e1350-wk-Fact-130257F4983E52BEA926FB24D7677099" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesBeforeTax" contextRef="FD2017Q3QTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">56</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687849e1369-wk-Fact-6968FECDFB645F1C88CC9A36C37CAA90" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesBeforeTax" contextRef="FD2016Q3QTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">150</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d43687849e1388-wk-Fact-DC0B04CD35255AAE8DB2F2B96794D8DC" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesBeforeTax" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">393</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687849e1409-wk-Fact-2CCCE52F43F055888FBA5D0EB59CC576" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesBeforeTax" contextRef="FD2016Q3YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">280</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687849e1434-wk-Fact-61418F4200B850038486B4BEDFA4FA9E" name="us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesBeforeTax" contextRef="FD2017Q3QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687849e1453-wk-Fact-FF71A5EF104C5E84BB31EB85E1C2233A" name="us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesBeforeTax" contextRef="FD2016Q3QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">24</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d43687849e1472-wk-Fact-8D699BC64D745ABCB0D7483468DED443" name="us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesBeforeTax" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">542</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d43687849e1493-wk-Fact-AF1D710099FA5129924DD7852F2F28B0" name="us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesBeforeTax" contextRef="FD2016Q3YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">690</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unrealized holding gains on available-for-sale securities, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687849e1519-wk-Fact-CF85F87F0E845EA3BF827845F15B8168" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" contextRef="FD2017Q3QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">384</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687849e1538-wk-Fact-6246160B22DB5F86A702C0FDC31AEA8A" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" contextRef="FD2016Q3QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">261</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687849e1557-wk-Fact-BBA831FA48DE546FAD427528571D0824" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">698</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687849e1577-wk-Fact-C66A904313F45C85A833A23046CD2774" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" contextRef="FD2016Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">740</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Reclassification adjustments for realized gains</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d43687849e1605-wk-Fact-2EABA378D8055B138BD1C9439BF5DF77" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax" contextRef="FD2017Q3QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">278</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d43687849e1625-wk-Fact-9A9E5B540C0052C7BE5FB833D0FCA0E3" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax" contextRef="FD2016Q3QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">112</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d43687849e1645-wk-Fact-F567CC4505EC55EF951CC1C3D6B62769" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">181</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d43687849e1666-wk-Fact-51BE1E50E018595FBB09E1CA22E07612" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax" contextRef="FD2016Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">129</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687849e1692-wk-Fact-05DE724F3E9F5A43ABA68FEBEAE4BBAF" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax" contextRef="FD2017Q3QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">106</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687849e1711-wk-Fact-F6B16FF2F2E15556BF6FA7B44550EBC3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax" contextRef="FD2016Q3QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">149</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687849e1730-wk-Fact-D4592919CCA35BD2BDC493D03993CB8A" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">518</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687849e1750-wk-Fact-7299B19500C65AA4886E0CA9F295C4DC" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax" contextRef="FD2016Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">611</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Benefit plans: actuarial losses, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d43687849e1775-wk-Fact-627842F5F2E15231B3D26A535F4705CA" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" contextRef="FD2017Q3QTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">103</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d43687849e1795-wk-Fact-F368335D74285386B4B988BC23C52314" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" contextRef="FD2016Q3QTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">82</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d43687849e1815-wk-Fact-1F4BA95B10925AE8A489F10EF8546E3C" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">41</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d43687849e1836-wk-Fact-80B5437E8AF253159081F26E14A232D2" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" contextRef="FD2016Q3YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">101</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Reclassification adjustments related to amortization</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687849e1864-wk-Fact-0BC6042F31745BE3B397485995AF247B" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" contextRef="FD2017Q3QTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">140</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687849e1883-wk-Fact-DC5034ABC2EA5C18880A9E00522D29F5" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" contextRef="FD2016Q3QTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">140</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687849e1902-wk-Fact-526D1E8FCDB9599FBA3FC176B4CBDF40" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">448</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687849e1922-wk-Fact-76C4477D67B058D0ADA197C508A6BFA0" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" contextRef="FD2016Q3YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">418</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Reclassification adjustments related to settlements, net</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687849e1949-wk-Fact-2B43072B673F54B48A3077572AC7B122" name="pfe:OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax" contextRef="FD2017Q3QTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">38</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687849e1968-wk-Fact-472E8E6F6DB25346B046668C52D5902F" name="pfe:OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax" contextRef="FD2016Q3QTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">28</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687849e1987-wk-Fact-439917D3DAAF58E1AD6CD991FC80DC42" name="pfe:OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">89</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687849e2007-wk-Fact-C6D0FE3E8F7154EE8F40BBCDB7B4F991" name="pfe:OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax" contextRef="FD2016Q3YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">76</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d43687849e2032-wk-Fact-13B324D73BAB58EC8AE8E3B51B6EC46D" name="pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax" contextRef="FD2017Q3QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">76</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687849e2052-wk-Fact-A4006F8721A75370B615CE7A639018C5" name="pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax" contextRef="FD2016Q3QTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">69</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d43687849e2071-wk-Fact-3584E6A95DE851E29AE8ED49EB250F3F" name="pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">111</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687849e2092-wk-Fact-B02BB9D940C0596C9C0D21CC1C19783E" name="pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax" contextRef="FD2016Q3YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">51</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d43687849e2117-wk-Fact-322107AB58155A3EA1AD6413AB9D9A99" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax" contextRef="FD2017Q3QTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687849e2137-wk-Fact-E9A491CA05515608A24040D57754A17D" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax" contextRef="FD2016Q3QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">155</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687849e2156-wk-Fact-C6B1A7221C9D543BAFE59A9C9ECA2DF2" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">384</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687849e2176-wk-Fact-1C3BC6367D20581BA4D58D85D2EF3508" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax" contextRef="FD2016Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">444</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Benefit plans: prior service (costs)/credits and other, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687849e2201-wk-Fact-9172F69C54DD547D933CB7C875628316" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" contextRef="FD2017Q3QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687849e2220-wk-Fact-75134F72E4DA517BA3893A36B2D82E24" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" contextRef="FD2016Q3QTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">95</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d43687849e2239-wk-Fact-7A7785CEBF4755FBBB7EAA2A69D0EF09" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687849e2260-wk-Fact-E969B5F6A0FD5E7199F96415161E24EE" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" contextRef="FD2016Q3YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">182</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Reclassification adjustments related to amortization</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d43687849e2287-wk-Fact-9768F9056D7E593CA8B86BE96384F1DB" name="us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" contextRef="FD2017Q3QTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">46</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d43687849e2307-wk-Fact-6866C3FD323B5B328644E3617D27748F" name="us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" contextRef="FD2016Q3QTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">45</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d43687849e2327-wk-Fact-51ECCBCA921E59759451F63108AF904D" name="us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">138</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d43687849e2348-wk-Fact-ED18C0861D3E5C15B3C0A349152628B0" name="us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" contextRef="FD2016Q3YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">127</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Reclassification adjustments related to curtailments, net</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d43687849e2376-wk-Fact-065F9DBED67053D59EE0A60E93DFDD22" name="pfe:OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax" contextRef="FD2017Q3QTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d43687849e2396-wk-Fact-719A3A5AFE7E590BA2BBA17A3393549C" name="pfe:OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax" contextRef="FD2016Q3QTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d43687849e2416-wk-Fact-5BC61B13CAF15E29B03835EA44B618DD" name="pfe:OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">14</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d43687849e2437-wk-Fact-713AA3AA57EE5FBCBD96967A8F7E9885" name="pfe:OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax" contextRef="FD2016Q3YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">14</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687849e2463-wk-Fact-E42F286486CD5834BD8EB16236B31FEA" name="pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax" contextRef="FD2017Q3QTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687849e2482-wk-Fact-A6BAD49A94C058098F01D059FDF7D0BF" name="pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax" contextRef="FD2016Q3QTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687849e2501-wk-Fact-075959EB0B9D5963B37F54F55082FEA0" name="pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687849e2521-wk-Fact-72DABC7CCBA75E3598D920B948A182DB" name="pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax" contextRef="FD2016Q3YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">12</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d43687849e2547-wk-Fact-84477EEDA0FB53F1A2DF30BC45CFD227" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" contextRef="FD2017Q3QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">48</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687849e2567-wk-Fact-A0788365B82455288EB3A6C6558EC05A" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" contextRef="FD2016Q3QTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">48</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d43687849e2586-wk-Fact-B8A367981AE35AEF8C0BF4154D63FC01" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">151</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687849e2607-wk-Fact-9F76A95D96735FEB9B3AA6495B54B6C9" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" contextRef="FD2016Q3YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">54</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other comprehensive income, before tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687849e2632-wk-Fact-FDE8C1D4A9445B5EB201CF6786FF4FCA" name="us-gaap:OtherComprehensiveIncomeLossBeforeTax" contextRef="FD2017Q3QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">938</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687849e2651-wk-Fact-AE655F3ED75A586981476B9D274B0149" name="us-gaap:OtherComprehensiveIncomeLossBeforeTax" contextRef="FD2016Q3QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">793</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687849e2670-wk-Fact-D8BF89A982EE5516AF5D38868D45AC49" name="us-gaap:OtherComprehensiveIncomeLossBeforeTax" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,669</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687849e2690-wk-Fact-672E389254015A85B0E497DA6B98ED65" name="us-gaap:OtherComprehensiveIncomeLossBeforeTax" contextRef="FD2016Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,417</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Tax provision/(benefit) on other comprehensive income</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(d)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d43687849e2717-wk-Fact-5950DF108F195FB594A31172740C60B3" name="us-gaap:OtherComprehensiveIncomeLossTax" contextRef="FD2017Q3QTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">80</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687849e2737-wk-Fact-31B8668E1E1956DF8878873FF4C52DA7" name="us-gaap:OtherComprehensiveIncomeLossTax" contextRef="FD2016Q3QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">116</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d43687849e2756-wk-Fact-0A65F347C9FD5314AD71D7212990864D" name="us-gaap:OtherComprehensiveIncomeLossTax" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">218</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687849e2777-wk-Fact-24F5F5FD900B538BB0C1F5C1D6714D02" name="us-gaap:OtherComprehensiveIncomeLossTax" contextRef="FD2016Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">111</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other comprehensive income before allocation to noncontrolling interests</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687849e2807-wk-Fact-5FA838CDA13D589CA9003C05768C2A3F" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2017Q3QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,018</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687849e2826-wk-Fact-69A896461F495ACBB885D53F5353F71F" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2016Q3QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">677</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687849e2846-wk-Fact-CE6465895C815C29B1431FBD3ED3B46B" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,888</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687849e2865-wk-Fact-990F7FE47CEA5D99BCE375CA7BAC5739" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2016Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,306</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Comprehensive income before allocation to noncontrolling interests</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687849e2977-wk-Fact-D64522201D7F5BB5BA48471538CE6CB8" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" contextRef="FD2017Q3QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,876</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687849e2996-wk-Fact-503B87CD9CE65FEDBBDC99370F10DF6B" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" contextRef="FD2016Q3QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,031</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687849e3016-wk-Fact-3AB6460969F05E5CB5282AE2FB7FB81F" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">10,953</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687849e3035-wk-Fact-5FD229EF81AC578B949A3DF35BCE1FF6" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" contextRef="FD2016Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">7,771</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: Comprehensive income attributable to noncontrolling interests</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687849e3055-wk-Fact-3831F5857C7B5144886C985E77E751EE" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" contextRef="FD2017Q3QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">19</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687849e3074-wk-Fact-32954ABF73B65A8C9307A33BA47D9ABB" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" contextRef="FD2016Q3QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687849e3093-wk-Fact-C761BA8C214D5A2D83B627623D2F876D" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">48</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687849e3113-wk-Fact-46E6ECDFD5B35112ACFA85A4DD680D69" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" contextRef="FD2016Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">24</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Comprehensive income attributable to Pfizer Inc.</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687849e3143-wk-Fact-A98E6DC1451C5074AFA6C1769B31F168" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="FD2017Q3QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,857</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687849e3162-wk-Fact-D87820179CF453388B904F407941F962" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="FD2016Q3QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,032</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687849e3182-wk-Fact-5CD3245395AF57768A6DF8D7BDF6B0BB" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">10,906</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687849e3201-wk-Fact-965936205F21501FABEFE22DBAD6AD70" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="FD2016Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">7,747</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><ix:footnote id="TextSelection-36C36413532355188985D26E3B171357-0-wk-Footnote-36C36413532355188985D26E3B171357_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" continuedAt="TextSelection-36C36413532355188985D26E3B171357-1">The foreign currency translation adjustments reclassified into </ix:footnote></span><ix:continuation id="TextSelection-36C36413532355188985D26E3B171357-1" continuedAt="TextSelection-36C36413532355188985D26E3B171357-2"><span style="font-family:inherit;font-size:9pt;font-style:italic;">Other (income)/deductions&#8212;net </span><span style="font-family:inherit;font-size:9pt;">in the condensed consolidated statements of income primarily result from sale of our </span><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43687849e3224-wk-Fact-7A20B5BEC3C75D16BFE5A86C05D26ABA" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="I2017Q2Jun30_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_LaboratorioTeutoBrasileroMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">40</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:9pt;"> ownership investment in Teuto. See </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Note 2D. </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Acquisitions, Sale of Hospira Infusion Systems Net Assets, Collaborative Arrangement and Equity-Method Investments</span></ix:continuation><span style="font-family:inherit;font-size:9pt;font-style:italic;"><ix:continuation id="TextSelection-36C36413532355188985D26E3B171357-2">: Equity-Method Investments.</ix:continuation></span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><ix:footnote id="TextSelection-F185CD45BC245C2EB8EDBFD55DB8A33F-0-wk-Footnote-F185CD45BC245C2EB8EDBFD55DB8A33F_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" continuedAt="TextSelection-F185CD45BC245C2EB8EDBFD55DB8A33F-1">Reclassified into </ix:footnote></span><ix:continuation id="TextSelection-F185CD45BC245C2EB8EDBFD55DB8A33F-1" continuedAt="TextSelection-F185CD45BC245C2EB8EDBFD55DB8A33F-2"><span style="font-family:inherit;font-size:9pt;font-style:italic;">Other (income)/deductions&#8212;net </span><span style="font-family:inherit;font-size:9pt;">and </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Cost of sales</span><span style="font-family:inherit;font-size:9pt;"> in the condensed consolidated statements of income. For additional information on amounts reclassified into </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Cost of sales,</span><span style="font-family:inherit;font-size:9pt;"> see </span></ix:continuation><span style="font-family:inherit;font-size:9pt;font-style:italic;"><ix:continuation id="TextSelection-F185CD45BC245C2EB8EDBFD55DB8A33F-2">Note 7F. Financial Instruments: Derivative Financial Instruments and Hedging Activities.</ix:continuation></span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(c)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><ix:footnote id="TextSelection-77536863BCE35B419E3A4119D41DB4BD-0-wk-Footnote-77536863BCE35B419E3A4119D41DB4BD_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" continuedAt="TextSelection-77536863BCE35B419E3A4119D41DB4BD-1">Generally reclassified, as part of net periodic pension cost, into </ix:footnote></span><ix:continuation id="TextSelection-77536863BCE35B419E3A4119D41DB4BD-1" continuedAt="TextSelection-77536863BCE35B419E3A4119D41DB4BD-2"><span style="font-family:inherit;font-size:9pt;font-style:italic;">Cost of sales, Selling, informational and administrative expenses,</span><span style="font-family:inherit;font-size:9pt;"> and/or </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Research and development expenses</span><span style="font-family:inherit;font-size:9pt;">, as appropriate, in the condensed consolidated statements of income. For additional information, see </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Note 10. </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Pension and Postretirement Benefit Plans</span></ix:continuation><span style="font-family:inherit;font-size:9pt;font-style:italic;"><ix:continuation id="TextSelection-77536863BCE35B419E3A4119D41DB4BD-2">.</ix:continuation></span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(d)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><ix:footnote id="TextSelection-2A0DF68DD6E953419D1E9B1C848DB228-0-wk-Footnote-2A0DF68DD6E953419D1E9B1C848DB228_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" continuedAt="TextSelection-2A0DF68DD6E953419D1E9B1C848DB228-1">See </ix:footnote></span><span style="font-family:inherit;font-size:9pt;font-style:italic;"><ix:continuation id="TextSelection-2A0DF68DD6E953419D1E9B1C848DB228-1">Note 5C. Tax Matters: Tax Provision/(Benefit) on Other Comprehensive Income.</ix:continuation></span></div></td></tr></table><div style="line-height:120%;padding-top:1px;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><ix:footnote id="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US">Amounts may not add due to rounding.</ix:footnote></span></div><div style="line-height:120%;text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">See Notes to Condensed Consolidated Financial Statements.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">6</span></div></div><hr style="page-break-after:always"></hr><div><a id="sD50F955FEFA5593F96F72CAB6E6E6BD0"></a></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">CONDENSED CONSOLIDATED BALANCE SHEETS</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:74%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">October&#160;1, <br/>2017</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">December&#160;31, <br/>2016</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(Unaudited)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;text-decoration:underline;">Assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43674379e798-wk-Fact-7EFAF7B942C85E77BB9972B343FAB410" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2017Q3" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,779</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43674379e817-wk-Fact-D156C275113454EF9843F3D3060B56DB" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2016Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,595</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Short-term investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43674379e837-wk-Fact-AE85FABD864252F78E2399FA5C6D7DCA" name="us-gaap:ShortTermInvestments" contextRef="FI2017Q3" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">14,146</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43674379e856-wk-Fact-030CEB52DE005078B1752AD07DFF2B1C" name="us-gaap:ShortTermInvestments" contextRef="FI2016Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">15,255</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Trade accounts receivable, less allowance for doubtful accounts: 2017&#8212;$590; 2016&#8212;$609</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43674379e881-wk-Fact-93CA7130473D54F2A4475CBF05C3A3EF" name="us-gaap:AccountsReceivableNetCurrent" contextRef="FI2017Q3" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">10,002</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43674379e900-wk-Fact-EA1D3C7D16595854B5CD606B1A735B28" name="us-gaap:AccountsReceivableNetCurrent" contextRef="FI2016Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">8,225</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Inventories</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43674379e925-wk-Fact-2C8D97E870025A9E9218D1538714EA7C" name="us-gaap:InventoryNet" contextRef="FI2017Q3" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">7,925</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43674379e944-wk-Fact-B57DF7F90CE856C48797E9E94456B6CD" name="us-gaap:InventoryNet" contextRef="FI2016Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6,783</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Current tax assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43674379e969-wk-Fact-C9379BA9136D5BBB8F3432FB4D96CBD5" name="pfe:OtherTaxAssetsCurrent" contextRef="FI2017Q3" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,263</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43674379e988-wk-Fact-D05030AC7D8B5906A350262C6079BD92" name="pfe:OtherTaxAssetsCurrent" contextRef="FI2016Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,041</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43674379e1013-wk-Fact-09FA50EC8B6A5544A580831FEECF0695" name="us-gaap:OtherAssetsCurrent" contextRef="FI2017Q3" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,158</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43674379e1032-wk-Fact-686063BE60325E2A839CE026F903431A" name="us-gaap:OtherAssetsCurrent" contextRef="FI2016Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,249</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Assets held for sale</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43674379e1057-wk-Fact-AF72E85346065C12B27811C0B8AD4C52" name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" contextRef="FI2017Q3" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">16</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43674379e1076-wk-Fact-047944C84B99570199B5350DAC450B3B" name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" contextRef="FI2016Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">801</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43674379e1101-wk-Fact-B684218F9F965A0685489FB9D98355FE" name="us-gaap:AssetsCurrent" contextRef="FI2017Q3" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">40,291</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43674379e1120-wk-Fact-5329671706335212AE3F5E2B75B7A4AB" name="us-gaap:AssetsCurrent" contextRef="FI2016Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">38,949</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Long-term investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43674379e1146-wk-Fact-F5595E1E6E5C5AB79FC9578F6E9622FC" name="us-gaap:LongTermInvestments" contextRef="FI2017Q3" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">7,311</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43674379e1165-wk-Fact-A14EC3C3E45252D8988217A4980EB580" name="us-gaap:LongTermInvestments" contextRef="FI2016Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">7,116</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Property, plant and equipment, less accumulated depreciation: 2017&#8212;$15,906; 2016&#8212;$14,807</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43674379e1190-wk-Fact-F52CA4E0D2C151988CD5EF5FA00DEAFE" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="FI2017Q3" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">13,505</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43674379e1209-wk-Fact-E8F1DC92BC58566FACDD0804C8857081" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="FI2016Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">13,318</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Identifiable intangible assets, less accumulated amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43674379e1234-wk-Fact-A41E764041225C8DBE154ADB89FBF66C" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="FI2017Q3" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">49,721</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43674379e1253-wk-Fact-4014B8D306BF54FC8CDF5431816FAA50" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="FI2016Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">52,648</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Goodwill</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43674379e1278-wk-Fact-691B87100C6755EB85765E65D5C328BA" name="us-gaap:Goodwill" contextRef="FI2017Q3" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">56,078</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43674379e1297-wk-Fact-F8F5DF7C12C25020B65DFF915C2D461A" name="us-gaap:Goodwill" contextRef="FI2016Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">54,449</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Noncurrent deferred tax assets and other noncurrent tax assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43674379e1322-wk-Fact-CD12C4F0CCE4505FAD338F25A39BF391" name="pfe:DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent" contextRef="FI2017Q3" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,858</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43674379e1341-wk-Fact-B7825C6743265E60AFD787E20D13F87D" name="pfe:DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent" contextRef="FI2016Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,812</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other noncurrent assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43674379e1366-wk-Fact-6F2B43838191546AA755245948E565C5" name="us-gaap:OtherAssetsNoncurrent" contextRef="FI2017Q3" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,388</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43674379e1385-wk-Fact-74A94C963B005FB79E90256BEDC19745" name="us-gaap:OtherAssetsNoncurrent" contextRef="FI2016Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,323</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:3px double #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-bottom:3px double #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43674379e1415-wk-Fact-70B456CF1E475D979F768DB28C19676E" name="us-gaap:Assets" contextRef="FI2017Q3" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">172,151</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:3px double #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-bottom:3px double #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43674379e1434-wk-Fact-AB8C3651E3FA5E0381978C95D5308515" name="us-gaap:Assets" contextRef="FI2016Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">171,615</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;text-decoration:underline;">Liabilities and Equity</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Short-term borrowings, including current portion of long-term debt: 2017&#8212;$3,072; 2016&#8212;$4,225</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43674379e1549-wk-Fact-CDA40E6949B85E61B9C8AF985182E3E5" name="us-gaap:DebtCurrent" contextRef="FI2017Q3" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">9,448</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43674379e1568-wk-Fact-3A3BB372357A5CD2BCD070742B0C6955" name="us-gaap:DebtCurrent" contextRef="FI2016Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">10,688</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Trade accounts payable</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43674379e1588-wk-Fact-708405E59C1952EAA954BB6C9B186068" name="us-gaap:AccountsPayableCurrent" contextRef="FI2017Q3" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,480</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43674379e1607-wk-Fact-30C18A2BCA9E5DB3B71D6CCCF9EC18D9" name="us-gaap:AccountsPayableCurrent" contextRef="FI2016Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4,536</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Dividends payable</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43674379e1633-wk-Fact-93644FE962325258B137234D02EB03E6" name="us-gaap:DividendsPayableCurrent" contextRef="FI2017Q3" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,909</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43674379e1652-wk-Fact-C14BB34AB5A85079B41CF0775AFE681D" name="us-gaap:DividendsPayableCurrent" contextRef="FI2016Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,944</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Income taxes payable</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43674379e1677-wk-Fact-0A0DAFD467625E0D8018223CBF2CB456" name="us-gaap:TaxesPayableCurrent" contextRef="FI2017Q3" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,003</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43674379e1696-wk-Fact-90502764073B5E8B974A1DC7FD2018F9" name="us-gaap:TaxesPayableCurrent" contextRef="FI2016Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">437</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Accrued compensation and related items</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43674379e1721-wk-Fact-41E568B8775D59BFBCD7C2E611178392" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="FI2017Q3" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,932</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43674379e1740-wk-Fact-8C84C3AC99B45AE2BA8FC636F5622DE6" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="FI2016Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,487</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other current liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43674379e1765-wk-Fact-6C83895D828D8E3BC5AC922878C0762E" name="us-gaap:OtherLiabilitiesCurrent" contextRef="FI2017Q3" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">10,446</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43674379e1784-wk-Fact-4A5801DF38F08BD8CEC3922878CFA84A" name="us-gaap:OtherLiabilitiesCurrent" contextRef="FI2016Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">11,023</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total current liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43674379e1809-wk-Fact-0CD797C3DDB8580E8F7A4492293BE3C1" name="us-gaap:LiabilitiesCurrent" contextRef="FI2017Q3" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">28,217</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43674379e1828-wk-Fact-5A2D57F680925DEC8A9CCA1553046941" name="us-gaap:LiabilitiesCurrent" contextRef="FI2016Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">31,115</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Long-term debt</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43674379e1899-wk-Fact-A38618717132561C9E1931D14EDF6B51" name="us-gaap:LongTermDebtNoncurrent" contextRef="FI2017Q3" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">34,503</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43674379e1918-wk-Fact-F0B612439D18585FBB73EEB374B11207" name="us-gaap:LongTermDebtNoncurrent" contextRef="FI2016Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">31,398</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Pension benefit obligations, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43674379e1943-wk-Fact-06E6B320DD2E5DEAAE0840FF5C32D34D" name="us-gaap:DefinedBenefitPensionPlanLiabilitiesNoncurrent" contextRef="FI2017Q3" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">5,531</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43674379e1962-wk-Fact-A538FCC6CCC752E695D754993DC8690B" name="us-gaap:DefinedBenefitPensionPlanLiabilitiesNoncurrent" contextRef="FI2016Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6,406</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Postretirement benefit obligations, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43674379e1987-wk-Fact-22AAFEBAB3755B18A95911F7BF8494E3" name="us-gaap:OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent" contextRef="FI2017Q3" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,687</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43674379e2006-wk-Fact-0A96E5EFE1F05A0EAA09A948F325D5CB" name="us-gaap:OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent" contextRef="FI2016Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,766</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Noncurrent deferred tax liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43674379e2031-wk-Fact-45A307B4BFCC56B2A721109AA18533BB" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" contextRef="FI2017Q3" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">30,411</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43674379e2050-wk-Fact-EECAD1E5742D526A902588518CB825FF" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" contextRef="FI2016Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">30,753</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other taxes payable</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43674379e2075-wk-Fact-808C96510A955E8CBDF7099B1662C942" name="us-gaap:LiabilityForUncertainTaxPositionsNoncurrent" contextRef="FI2017Q3" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4,304</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43674379e2094-wk-Fact-4207CB01CC1150BFA16DC1CBD3FDE8A0" name="us-gaap:LiabilityForUncertainTaxPositionsNoncurrent" contextRef="FI2016Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other noncurrent liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43674379e2120-wk-Fact-7E0D6DBF276A520C83B6B208692E17BE" name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="FI2017Q3" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6,388</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43674379e2139-wk-Fact-5A59BE776E6E5E20B8346BDFE1D63D1D" name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="FI2016Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6,337</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43674379e2164-wk-Fact-7EDA7F85A58A5A1F95B13001B9DBA028" name="us-gaap:Liabilities" contextRef="FI2017Q3" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">111,041</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43674379e2183-wk-Fact-50ADB7EB4847506EA08C0BF6C7E30E84" name="us-gaap:Liabilities" contextRef="FI2016Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">111,776</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Commitments and Contingencies</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43674379e2254-wk-Fact-949EBE5A327851FCB9BF19AA6ACC7A3A" name="us-gaap:CommitmentsAndContingencies" contextRef="FI2017Q3" unitRef="usd" xsi:nil="true" scale="0" format="ixt:nocontent"></ix:nonFraction></span><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43674379e2272-wk-Fact-63822E0DBF7E5CA2BB97325B6C3209EA" name="us-gaap:CommitmentsAndContingencies" contextRef="FI2016Q4" unitRef="usd" xsi:nil="true" scale="0" format="ixt:nocontent"></ix:nonFraction></span><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Preferred stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43674379e2342-wk-Fact-E3E870C4333E5DBA8986F6E17DA1CE7C" name="us-gaap:PreferredStockValue" contextRef="FI2017Q3" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">22</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43674379e2361-wk-Fact-279845FB1E2F5BE68F8072CC3AE0313B" name="us-gaap:PreferredStockValue" contextRef="FI2016Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">24</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Common stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43674379e2386-wk-Fact-22383CE0D78B56089748D1342C097ED3" name="us-gaap:CommonStockValue" contextRef="FI2017Q3" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">463</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43674379e2405-wk-Fact-42825AA4D3815C349BD40B420827B233" name="us-gaap:CommonStockValue" contextRef="FI2016Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">461</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Additional paid-in capital</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43674379e2430-wk-Fact-95915EECEB845388928ED9B038AC306C" name="us-gaap:AdditionalPaidInCapital" contextRef="FI2017Q3" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">83,827</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43674379e2449-wk-Fact-F986BFF5DEDA51E58393FB9819F5F489" name="us-gaap:AdditionalPaidInCapital" contextRef="FI2016Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">82,685</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Treasury stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d43674379e2474-wk-Fact-BBB0550BDE1259DD997B8244242E79AE" name="us-gaap:TreasuryStockValue" contextRef="FI2017Q3" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">89,421</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d43674379e2494-wk-Fact-CCCD07BEDF4C5FF9AF3BA300510C89D4" name="us-gaap:TreasuryStockValue" contextRef="FI2016Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">84,364</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Retained earnings</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43674379e2520-wk-Fact-7EDE13D2B0D259CBB94F5F415001BFCC" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="FI2017Q3" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">75,043</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43674379e2539-wk-Fact-B9792AE277D55415BD4430CE375AB579" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="FI2016Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">71,774</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Accumulated other comprehensive loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d43674379e2564-wk-Fact-A0D16119E38D5A9FAB554486905A9CCC" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2017Q3" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">9,164</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d43674379e2584-wk-Fact-3E322F23F0E95E659A8A7D474667DE0D" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2016Q4" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">11,036</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total Pfizer Inc. shareholders&#8217; equity</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43674379e2611-wk-Fact-82E53639BF6557F091EE46784D53AC8F" name="us-gaap:StockholdersEquity" contextRef="FI2017Q3" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">60,770</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43674379e2630-wk-Fact-1B54ADB976A25833A5F7A46C177A2A45" name="us-gaap:StockholdersEquity" contextRef="FI2016Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">59,544</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Equity attributable to noncontrolling interests</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43674379e2655-wk-Fact-394FE75EF25C5117BE8B89037EFA6718" name="us-gaap:MinorityInterest" contextRef="FI2017Q3" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">340</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43674379e2674-wk-Fact-2D9C52897DAC5AD0A4FC1108BB490212" name="us-gaap:MinorityInterest" contextRef="FI2016Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">296</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total equity</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43674379e2699-wk-Fact-0E8B49C6C7365DEB9EDE52E9D965698D" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2017Q3" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">61,110</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43674379e2718-wk-Fact-871F7D1326F153D0A78F67C95DCE6D47" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2016Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">59,840</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:3px double #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total liabilities and equity</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:3px double #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-bottom:3px double #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43674379e2748-wk-Fact-A7FCAA4C427E5D3F9EA836ACF3C4D395" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="FI2017Q3" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">172,151</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:3px double #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-bottom:3px double #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43674379e2767-wk-Fact-A00F92664332571D9A768489A67E66E0" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="FI2016Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">171,615</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><ix:footnote id="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" continuedAt="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-1">Amounts may not add due to rounding.</ix:footnote></span></div><div style="line-height:120%;padding-top:10px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><ix:continuation id="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-1"></ix:continuation>See Notes to Condensed Consolidated Financial Statements.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">7</span></div></div><hr style="page-break-after:always"></hr><div><a id="s83F8F5C0D7C15C23B59FDB6FD34A8B2C"></a></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(UNAUDITED)</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:76%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Nine Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">October&#160;1, <br/>2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">October&#160;2, <br/>2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;text-decoration:underline;">Operating Activities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Net income before allocation to noncontrolling interests</span><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d43681613e802-wk-Fact-769C4E4C0C905BDA89016FEC60CCEAB2" name="us-gaap:ProfitLoss" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">9,066</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d43681613e821-wk-Fact-1F598F7CC0A659DC8B78C122AEB4F4CE" name="us-gaap:ProfitLoss" contextRef="FD2016Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6,465</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Adjustments to reconcile net income before allocation to noncontrolling interests to net cash provided by operating activities:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Depreciation and amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d43681613e885-wk-Fact-ACB630B60395539B8BEB3946C0CF2A75" name="pfe:DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4,695</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d43681613e904-wk-Fact-4D5D0B01BEBB5DEFB2827E50144E0489" name="pfe:DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization" contextRef="FD2016Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4,208</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Asset write-offs and impairments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d43681613e929-wk-Fact-E753F2020B8F56CEBAE560B3B8BB9086" name="pfe:AssetWriteOffsAndAssetImpairmentCharges" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">326</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d43681613e948-wk-Fact-B7F6677B323F523BBF06F63407F96342" name="pfe:AssetWriteOffsAndAssetImpairmentCharges" contextRef="FD2016Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,146</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Loss on sale of HIS net assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d43681613e973-wk-Fact-4CD7C8E134F3568695AECCF94C6AF4FD" name="us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">52</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d43681613e992-wk-Fact-E944F13BD8105FBDB6ACB7D264796FD0" name="us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" contextRef="FD2016Q3YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1,422</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Deferred taxes from continuing operations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d43681613e1017-wk-Fact-B740A96BCFB152CEB2E4602B18EBD8F1" name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">241</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(<ix:nonFraction id="d43681613e1036-wk-Fact-22BDA5BA109D56B8A234197E3982FF14" name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="FD2016Q3YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1,335</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Share-based compensation expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d43681613e1062-wk-Fact-BA0D6BC1C45C599C91DF29089DAC818D" name="us-gaap:ShareBasedCompensation" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">595</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d43681613e1081-wk-Fact-B3E1F1C6FF4D55E59E6FE1D02902C8D3" name="us-gaap:ShareBasedCompensation" contextRef="FD2016Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">532</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Benefit plan contributions in excess of expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(<ix:nonFraction id="d43681613e1106-wk-Fact-0F638C219E595606B659714F53B6D14B" name="pfe:PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,042</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(<ix:nonFraction id="d43681613e1126-wk-Fact-378721671BB456518AD2AD4867C237B9" name="pfe:PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense" contextRef="FD2016Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">775</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Other adjustments, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(<ix:nonFraction id="d43681613e1153-wk-Fact-C84FD7E0084E53B295E4FBE883879711" name="us-gaap:OtherNoncashIncomeExpense" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">561</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d43681613e1173-wk-Fact-6944308547D65750B49346E97B2688A0" name="us-gaap:OtherNoncashIncomeExpense" contextRef="FD2016Q3YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">68</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Other changes in assets and liabilities, net of acquisitions and divestitures</span><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(<ix:nonFraction id="d43681613e1200-wk-Fact-1B9FEF203B3C5505BC6C4EC5902F0BCF" name="us-gaap:IncreaseDecreaseInOperatingCapital" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,644</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(<ix:nonFraction id="d43681613e1220-wk-Fact-DED2BD217A165276A7FC6775BFD357E2" name="us-gaap:IncreaseDecreaseInOperatingCapital" contextRef="FD2016Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,582</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Net cash provided by operating activities</span><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d43681613e1248-wk-Fact-4205D6E535945DAFBDC33902ED523920" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">9,728</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d43681613e1267-wk-Fact-7D8048FC05695215AF1AB565B8040E8E" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="FD2016Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">10,151</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;text-decoration:underline;">Investing Activities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Purchases of property, plant and equipment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(<ix:nonFraction id="d43681613e1382-wk-Fact-42968803AD055EFEB0C3ED702C15D6AC" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,256</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(<ix:nonFraction id="d43681613e1402-wk-Fact-4638ED2A9682598F89E8D0DE8B195AA8" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="FD2016Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,134</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Purchases of short-term investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(<ix:nonFraction id="d43681613e1428-wk-Fact-71772D6AB77F595C866B3F8F2284E23A" name="us-gaap:PaymentsToAcquireShortTermInvestments" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6,469</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(<ix:nonFraction id="d43681613e1448-wk-Fact-C5C375E41B7D5A61A86D9015B4AC1F9C" name="us-gaap:PaymentsToAcquireShortTermInvestments" contextRef="FD2016Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">15,170</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Proceeds from redemptions/sales of short-term investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d43681613e1474-wk-Fact-8C91183376945DA18E85A8BAB3F22AAF" name="us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">5,783</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d43681613e1493-wk-Fact-A1C1CAB3E9EF556989E8998B597D9BF9" name="us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" contextRef="FD2016Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">20,685</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Net proceeds from redemptions/sales of short-term investments with original maturities of three months or less</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d43681613e1518-wk-Fact-EA51BB96305D596BBCDA3AF91C4A5606" name="us-gaap:PaymentsForProceedsFromShortTermInvestments" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">2,758</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d43681613e1537-wk-Fact-7715092F4977526AA9E3733E3C9831C4" name="us-gaap:PaymentsForProceedsFromShortTermInvestments" contextRef="FD2016Q3YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">6,485</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Purchases of long-term investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(<ix:nonFraction id="d43681613e1562-wk-Fact-751B2E1EB7FE550C886A2AD44ED6CFCB" name="us-gaap:PaymentsToAcquireMarketableSecurities" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,526</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(<ix:nonFraction id="d43681613e1582-wk-Fact-0BA196038F9B5E96BAFED82F9B4D0A80" name="us-gaap:PaymentsToAcquireMarketableSecurities" contextRef="FD2016Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4,771</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Proceeds from redemptions/sales of long-term investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d43681613e1608-wk-Fact-7366AB7164FB57C0B8A92433A2836E49" name="us-gaap:ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,417</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d43681613e1627-wk-Fact-7EE55D894B2E598CB81A5AD553F1A033" name="us-gaap:ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments" contextRef="FD2016Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6,915</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Acquisitions of businesses, net of cash acquired</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(<ix:nonFraction id="d43681613e1653-wk-Fact-5AFE9DE44AC65078B297BF4B6B39C511" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(<ix:nonFraction id="d43681613e1673-wk-Fact-A0FAAC12696C59849AE70392155E65FF" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" contextRef="FD2016Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">17,679</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Acquisitions of intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(<ix:nonFraction id="d43681613e1699-wk-Fact-A6186BEADB90579F8CFC02466DEAFB87" name="us-gaap:PaymentsToAcquireIntangibleAssets" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">188</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(<ix:nonFraction id="d43681613e1719-wk-Fact-050DF5AA83565B919248F2CDC8C1441E" name="us-gaap:PaymentsToAcquireIntangibleAssets" contextRef="FD2016Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">96</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Other investing activities, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d43681613e1745-wk-Fact-33114474B11F56B7AE997B42206DB57C" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">519</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d43681613e1764-wk-Fact-F59987278FE651D99A4A03B22559E7CB" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" contextRef="FD2016Q3YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">60</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Net cash provided by/(used in) investing activities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d43681613e1789-wk-Fact-FB31F2DD4E78576D86B0CBE5A30FD593" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">38</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(<ix:nonFraction id="d43681613e1808-wk-Fact-8788492837FF523EB753AAF056BFAF4A" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="FD2016Q3YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">4,704</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;text-decoration:underline;">Financing Activities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Proceeds from short-term borrowings</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d43681613e1924-wk-Fact-D165564A6DBB5ECA8030FB998D5E7FE7" name="us-gaap:ProceedsFromShortTermDebt" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">7,003</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d43681613e1943-wk-Fact-79F0FD4AFB255B0196EDFCDD331CEFF0" name="us-gaap:ProceedsFromShortTermDebt" contextRef="FD2016Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6,397</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Principal payments on short-term borrowings</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(<ix:nonFraction id="d43681613e1968-wk-Fact-B6676B9BE7E95127A4888156B2CAD1CD" name="us-gaap:RepaymentsOfShortTermDebt" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">7,691</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(<ix:nonFraction id="d43681613e1988-wk-Fact-C220C3FE427351839AD8B1F16EE921CE" name="us-gaap:RepaymentsOfShortTermDebt" contextRef="FD2016Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,321</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Net proceeds from/(payments on) short-term borrowings with original maturities of three months or less</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d43681613e2014-wk-Fact-AA4DB1C4ACF95301B1C9DD8DFCDA37CF" name="us-gaap:ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">555</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(<ix:nonFraction id="d43681613e2033-wk-Fact-A9D9504EBEC15503A956269CA3DEC025" name="us-gaap:ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess" contextRef="FD2016Q3YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">963</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Proceeds from issuance of long-term debt</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d43681613e2059-wk-Fact-450DDE9FBB965039B395036FE74CBBB0" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">5,273</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d43681613e2078-wk-Fact-4D68DAE5FD3059969FCBB65614BE4D06" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" contextRef="FD2016Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">5,031</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Principal payments on long-term debt</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(<ix:nonFraction id="d43681613e2103-wk-Fact-EF326C0BF8D95F73A75E0D09B3DC12A4" name="us-gaap:RepaymentsOfLongTermDebt" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4,474</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(<ix:nonFraction id="d43681613e2123-wk-Fact-0998A9FB896651C8813749DB0BBD1634" name="us-gaap:RepaymentsOfLongTermDebt" contextRef="FD2016Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4,317</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Purchases of common stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(<ix:nonFraction id="d43681613e2150-wk-Fact-5D13F9FBBDEE52528006AA947B5F7E3A" name="us-gaap:PaymentsForRepurchaseOfCommonStock" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">5,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(<ix:nonFraction id="d43681613e2170-wk-Fact-81C7C1D62B7555CEB86C474159F55AB9" name="us-gaap:PaymentsForRepurchaseOfCommonStock" contextRef="FD2016Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">5,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Cash dividends paid</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(<ix:nonFraction id="d43681613e2196-wk-Fact-202F98BA511E52368E7B8599E950975E" name="us-gaap:PaymentsOfOrdinaryDividends" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">5,750</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(<ix:nonFraction id="d43681613e2216-wk-Fact-2BEDC5A7D4A059F58F71D107B4C1CAFF" name="us-gaap:PaymentsOfOrdinaryDividends" contextRef="FD2016Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">5,496</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Proceeds from exercise of stock options</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d43681613e2242-wk-Fact-DA0EC5A432335C1691A8266D92801437" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">656</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d43681613e2261-wk-Fact-74EE204494395BACA3BF106440743D87" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="FD2016Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">946</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Other financing activities, net</span><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(<ix:nonFraction id="d43681613e2288-wk-Fact-2F51CAACA19456CCB50C8D86205439BE" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">223</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(<ix:nonFraction id="d43681613e2308-wk-Fact-8AB5E43C2479535A8B0B89EA014F6940" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" contextRef="FD2016Q3YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">192</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Net cash used in financing activities</span><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(<ix:nonFraction id="d43681613e2336-wk-Fact-94268C3E6B575791AF135AE3FFBDED27" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">9,650</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(<ix:nonFraction id="d43681613e2356-wk-Fact-DB025A970D1451AEACFC8A982A850506" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="FD2016Q3YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">6,915</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Effect of exchange-rate changes on cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d43681613e2382-wk-Fact-E5CA2563496958358157EDDBD9180C21" name="us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">67</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(<ix:nonFraction id="d43681613e2401-wk-Fact-910C3C95984A581EB892DD60EDC26455" name="us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents" contextRef="FD2016Q3YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">79</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Net increase/(decrease) in cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d43681613e2427-wk-Fact-8446B584F9B25BB79D2E77028163C2CB" name="us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">184</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(<ix:nonFraction id="d43681613e2446-wk-Fact-9C5F9B5D363652D592CA2481C87B9506" name="us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease" contextRef="FD2016Q3YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1,547</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Cash and cash equivalents, beginning</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d43681613e2472-wk-Fact-D156C275113454EF9843F3D3060B56DB" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2016Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,595</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d43681613e2491-wk-Fact-8CCB92621D2F5FA2970B7C2EB7A111BE" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2015Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,641</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Cash and cash equivalents, end</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d43681613e2521-wk-Fact-7EFAF7B942C85E77BB9972B343FAB410" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2017Q3" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,779</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d43681613e2540-wk-Fact-98FDF1C40AF759C4B5005A20CA031801" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2016Q3" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,094</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;text-decoration:underline;">Supplemental Cash Flow Information</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Non-cash transactions:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-12px;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Receipt of ICU Medical common stock</span><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d43681613e2704-wk-Fact-8690986C383F54748BB0095D0303FF1E" name="pfe:NoncashorPartNoncashDivestitureAmountofConsiderationReceivedCommonStock" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">428</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d43681613e2723-wk-Fact-BC18C3B80FE15D95A67ED86E9A5C11B9" name="pfe:NoncashorPartNoncashDivestitureAmountofConsiderationReceivedCommonStock" contextRef="FD2016Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-12px;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Promissory note from ICU Medical</span><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d43681613e2745-wk-Fact-DEFAF9D423795479839BFC83C7E9408A" name="pfe:NoncashorPartNoncashDivestitureAmountofConsiderationReceivedNoteReceivable" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">75</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d43681613e2764-wk-Fact-0C14F39B228253AAB03AA6A6439EFA78" name="pfe:NoncashorPartNoncashDivestitureAmountofConsiderationReceivedNoteReceivable" contextRef="FD2016Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Cash paid (received) during the period for:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Income taxes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d43681613e2838-wk-Fact-0E16C50451235A15BAA9EA1F20FC4F80" name="us-gaap:IncomeTaxesPaidNet" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,424</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d43681613e2857-wk-Fact-9641A5BEA98B590492283AE6831A946D" name="us-gaap:IncomeTaxesPaidNet" contextRef="FD2016Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,430</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Interest</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d43681613e2877-wk-Fact-F79EE7D9A58D5B3AA60618D470617657" name="us-gaap:InterestPaidNet" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,101</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d43681613e2896-wk-Fact-2876808E5D6E5BCEA80558572E768C26" name="us-gaap:InterestPaidNet" contextRef="FD2016Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,177</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:3px double #000000;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Interest rate hedges</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:3px double #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(<ix:nonFraction id="d43681613e2921-wk-Fact-B7E0E2374E7052E886F3C5A3DD803575" name="pfe:InterestPaidInterestRateHedges" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">183</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-bottom:3px double #000000;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:3px double #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(<ix:nonFraction id="d43681613e2941-wk-Fact-88DA733F540B50B5B2437B8FAA7A8EDF" name="pfe:InterestPaidInterestRateHedges" contextRef="FD2016Q3YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">356</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-bottom:3px double #000000;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><ix:footnote id="TextSelection-3DD94144621C5A68BC21C5DB64345BB9-0-wk-Footnote-3DD94144621C5A68BC21C5DB64345BB9_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" continuedAt="TextSelection-3DD94144621C5A68BC21C5DB64345BB9-1">Amounts for the </ix:footnote></span><ix:continuation id="TextSelection-3DD94144621C5A68BC21C5DB64345BB9-1" continuedAt="TextSelection-3DD94144621C5A68BC21C5DB64345BB9-2"><span style="font-family:inherit;font-size:7.5pt;">three and nine months ended October 2, 2016</span><span style="font-family:inherit;font-size:7.5pt;"> have been revised from previously reported amounts to reflect the adoption of a new accounting standard in the fourth quarter of 2016, as of January 1, 2016. For additional information, see </span><span style="font-family:inherit;font-size:7.5pt;font-style:italic;">Note 1B</span><span style="font-family:inherit;font-size:7.5pt;">. </span><span style="font-family:inherit;font-size:7.5pt;font-style:italic;">Basis of Presentation and Significant Accounting Policies</span></ix:continuation><span style="font-family:inherit;font-size:7.5pt;font-style:italic;"><ix:continuation id="TextSelection-3DD94144621C5A68BC21C5DB64345BB9-2">: Adoption of New Accounting Standards.</ix:continuation></span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><ix:footnote id="TextSelection-EB5698F25D035A90984FA270E724B7BB-0-wk-Footnote-EB5698F25D035A90984FA270E724B7BB_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" continuedAt="TextSelection-EB5698F25D035A90984FA270E724B7BB-1">In connection with the sale of HIS net assets to ICU Medical, on February 3, 2017, Pfizer received </ix:footnote></span><ix:continuation id="TextSelection-EB5698F25D035A90984FA270E724B7BB-1" continuedAt="TextSelection-EB5698F25D035A90984FA270E724B7BB-2"><span style="font-family:inherit;font-size:7.5pt;"><span><ix:nonFraction id="d43681613e3005-wk-Fact-911EB761D3C6590EA6CD704F46034785" name="pfe:DisposalGroupIncludingDiscontinuedOperationConsiderationTransferredEquityInterestsShares" contextRef="I2017Q1Feb03_us-gaap_CounterpartyNameAxis_pfe_ICUMedicalMember_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_HISMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">3.2</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:7.5pt;"> newly issued shares of ICU Medical common stock initially valued at </span><span style="font-family:inherit;font-size:7.5pt;"><span>$<ix:nonFraction id="d43681613e3009-wk-Fact-88E2E31CC1495183A0F02B04F4BB0670" name="pfe:DisposalGroupIncludingDiscontinuedOperationConsiderationTransferredEquityInterests" contextRef="I2017Q1Feb03_us-gaap_CounterpartyNameAxis_pfe_ICUMedicalMember_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_HISMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">428</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:7.5pt;"> and a promissory note in the amount of </span><span style="font-family:inherit;font-size:7.5pt;"><span>$<ix:nonFraction id="d43681613e3013-wk-Fact-C837741F7E265EA590514DA12CED34D8" name="pfe:DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivable" contextRef="I2017Q1Feb03_us-gaap_CounterpartyNameAxis_pfe_ICUMedicalMember_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_HISMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">75</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:7.5pt;">. For additional information, see </span><span style="font-family:inherit;font-size:7.5pt;font-style:italic;">Note 2B</span><span style="font-family:inherit;font-size:7.5pt;">.</span><span style="font-family:inherit;font-size:7.5pt;font-style:italic;"> </span><span style="font-family:inherit;font-size:7.5pt;font-style:italic;">Acquisitions, Sale of Hospira Infusion Systems Net Assets, Collaborative Arrangement and Equity-Method Investments</span></ix:continuation><span style="font-family:inherit;font-size:7.5pt;font-style:italic;"><ix:continuation id="TextSelection-EB5698F25D035A90984FA270E724B7BB-2">: Sale of Hospira Infusion Systems Net Assets.</ix:continuation></span></div></td></tr></table><div style="line-height:120%;padding-bottom:1px;text-align:left;padding-left:12px;text-indent:-12px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><br/></span></div><div style="line-height:120%;padding-bottom:2px;padding-left:12px;text-indent:-12px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><ix:footnote id="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US">Amounts may not add due to rounding.</ix:footnote></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">See Notes to Condensed Consolidated Financial Statements.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">8</span></div></div><hr style="page-break-after:always"></hr><div><a id="s52BF2A1953FC5CA5A656FB054EAF3EDE"></a></div><div><div style="line-height:120%;text-align:center;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(UNAUDITED)</span></div></div><div><br/></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="s11D410A9026C5806B392723E69155965"></a></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Note 1. </span><ix:nonNumeric contextRef="FD2017Q3YTD" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="TextSelection-169F7BFE968C5905A80BDF1DF1E87FD4-0-wk-Fact-37D24C33276B5176885EF5BD72149E0D" continuedAt="TextSelection-169F7BFE968C5905A80BDF1DF1E87FD4-1" escape="true"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Basis of Presentation and Significant Accounting Policies</span></ix:nonNumeric></div><ix:continuation id="TextSelection-169F7BFE968C5905A80BDF1DF1E87FD4-1" continuedAt="TextSelection-169F7BFE968C5905A80BDF1DF1E87FD4-2"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">A. <ix:nonNumeric contextRef="FD2017Q3YTD" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="TextSelection-D30F8380EB1F5730961C36AF92547674-0-wk-Fact-ACB8EFA199AF54EC8B6A628FCE5B2652" continuedAt="TextSelection-D30F8380EB1F5730961C36AF92547674-1" escape="true">Basis of Presentation</ix:nonNumeric></span></div><ix:continuation id="TextSelection-D30F8380EB1F5730961C36AF92547674-1" continuedAt="TextSelection-D30F8380EB1F5730961C36AF92547674-2"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">See the Glossary of Defined Terms at the beginning of this Quarterly Report on Form 10-Q for terms used throughout the condensed consolidated financial statements and related notes of this Quarterly Report on Form 10-Q.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We prepared the condensed consolidated financial statements following the requirements of the SEC for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP can be condensed or omitted.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The financial information included in our condensed consolidated financial statements for subsidiaries operating outside the U.S. is as of and for the three and </span><span style="font-family:inherit;font-size:10pt;">nine months</span><span style="font-family:inherit;font-size:10pt;"> ended </span><span style="font-family:inherit;font-size:10pt;">August&#160;27, 2017</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">August&#160;28, 2016</span><span style="font-family:inherit;font-size:10pt;">. The financial information included in our condensed consolidated financial statements for U.S. subsidiaries is as of and for the three and </span><span style="font-family:inherit;font-size:10pt;">nine months</span><span style="font-family:inherit;font-size:10pt;"> ended </span><span style="font-family:inherit;font-size:10pt;text-align:center;">October&#160;1, 2017</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;text-align:center;">October&#160;2, 2016</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenues, expenses, assets and liabilities can vary during each quarter of the year. Therefore, the results and trends in these interim financial statements may not be representative of those for the full year.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></ix:continuation><div style="line-height:120%;text-align:left;font-size:10pt;"><ix:continuation id="TextSelection-D30F8380EB1F5730961C36AF92547674-2" continuedAt="TextSelection-D30F8380EB1F5730961C36AF92547674-3"><span style="font-family:inherit;font-size:10pt;">We are responsible for the unaudited financial statements included in this Quarterly Report on Form 10-Q. The interim financial statements include all normal and recurring adjustments that are considered necessary for the fair statement of our condensed consolidated balance sheets and condensed consolidated statements of income. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the consolidated financial statements and accompanying notes included in our </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span></ix:continuation><span style="font-family:inherit;font-size:10pt;"><ix:continuation id="TextSelection-D30F8380EB1F5730961C36AF92547674-3"> Form 10-K.</ix:continuation> </span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We manage our commercial operations through </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43675583e708-wk-Fact-7FDCD3767D7C5A07BAB773B71A23B8A3" name="us-gaap:NumberOfOperatingSegments" contextRef="FD2017Q3YTD" unitRef="Operating_Segment" decimals="INF" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> distinct business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). For additional information, see </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 13</span><span style="font-family:inherit;font-size:10pt;"> and Notes to Consolidated Financial Statements&#8211;&#8211;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 18. Segment, Geographic and Other Revenue Information </span><span style="font-family:inherit;font-size:10pt;">in Pfizer&#8217;s </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;"> Financial Report.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certain amounts in the condensed consolidated financial statements and associated notes may not add due to rounding. All percentages have been calculated using unrounded amounts.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our recent significant business development activities include:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On February 3, 2017, we completed the sale of our global infusion therapy net assets, HIS, to ICU Medical. The operating results of HIS are included in our condensed consolidated statement of income and EH&#8217;s operating results through February 2, 2017 and, therefore, our financial results, and EH&#8217;s operating results, for the </span><span style="font-family:inherit;font-size:10pt;">third quarter</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;"> do not reflect any contribution from HIS global operations, while our financial results, and EH&#8217;s operating results, for the </span><span style="font-family:inherit;font-size:10pt;">third quarter</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;"> reflect three months of HIS global operations. Our financial results, and EH&#8217;s operating results, for the </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;"> reflect approximately one month of HIS domestic operations and approximately two months of HIS international operations, while our financial results, and EH&#8217;s operating results, for the </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;text-align:left;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;"> reflect nine months of HIS global operations. Assets and liabilities associated with HIS are presented as held for sale in the condensed consolidated balance sheet as of December 31, 2016. The HIS assets held for sale are reported in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Assets held for sale </span><span style="font-family:inherit;font-size:10pt;">and HIS liabilities held for sale are reported in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other current liabilities.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On December 22, 2016, which falls in the first fiscal quarter of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;"> for our international operations, we acquired the development and commercialization rights to AstraZeneca&#8217;s small molecule anti-infectives business, primarily outside the U.S. Commencing from the acquisition date, our financial statements reflect the assets, liabilities, operating results and cash flows of this business, and, in accordance with our international reporting period, our financial results, EH&#8217;s operating results, and cash flows for the </span><span style="font-family:inherit;font-size:10pt;">third quarter</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;"> reflect approximately three months and eight months, respectively, of the small molecule anti-infectives business acquired from AstraZeneca.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On September 28, 2016, we acquired Medivation for </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d43675583e810-wk-Fact-BFC7B9276178582B99CC000090BE3B00" name="us-gaap:BusinessAcquisitionSharePrice" contextRef="I2016Q3Sep28_us-gaap_BusinessAcquisitionAxis_pfe_MedivationMember" unitRef="usdPerShare" decimals="INF" scale="0" format="ixt:numdotdecimal">81.50</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> per share. Commencing from the acquisition date, our financial statements reflect the assets, liabilities, operating results and cash flows of Medivation. Therefore, Medivation operations are reflected in our financial results, IH&#8217;s operating results, and cash flows for the </span><span style="font-family:inherit;font-size:10pt;">third quarter</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;">. In accordance with our domestic and international reporting periods, our consolidated financial statements for the </span><span style="font-family:inherit;font-size:10pt;">third quarter</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;"> reflect three business days of Medivation operations, which were immaterial.</span></div></td></tr></table></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">9</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:center;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(UNAUDITED)</span></div></div><div><br/></div><ix:continuation id="TextSelection-169F7BFE968C5905A80BDF1DF1E87FD4-2" continuedAt="TextSelection-169F7BFE968C5905A80BDF1DF1E87FD4-3"><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On June 24, 2016, we acquired Anacor for </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d43675583e847-wk-Fact-A4CCFEF743375CD1801D535634B4A8AA" name="us-gaap:BusinessAcquisitionSharePrice" contextRef="I2016Q2AnacorAcquisition_us-gaap_BusinessAcquisitionAxis_pfe_AnacorMember" unitRef="usdPerShare" decimals="INF" scale="0" format="ixt:numdotdecimal">99.25</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> per share. Commencing from the acquisition date, our financial statements reflect the assets, liabilities, operating results and cash flows of Anacor. Therefore, Anacor operations are reflected in our financial results, IH&#8217;s operating results, and cash flows for the </span><span style="font-family:inherit;font-size:10pt;">third quarter</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;">. In accordance with our domestic and international reporting periods, our consolidated financial statements for the </span><span style="font-family:inherit;font-size:10pt;">third quarter</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;"> reflect approximately three months of Anacor operations.</span></div></td></tr></table><div style="line-height:120%;padding-top:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For additional information, see </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 2</span><span style="font-family:inherit;font-size:10pt;"> and Notes to Consolidated Financial Statements&#8211;&#8211;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 2. </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Acquisitions, Sale of Hospira Infusion Systems Net Assets, Collaborative Arrangement and Equity-Method Investments</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span><span style="font-family:inherit;font-size:10pt;">in</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span><span style="font-family:inherit;font-size:10pt;">Pfizer&#8217;s </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;"> Financial Report.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">B. <ix:nonNumeric contextRef="FD2017Q3YTD" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="TextSelection-3C50557390AC558DAE6FA5320BB98977-0-wk-Fact-57CAE0F791BB55BD9EC544EEB0C72C2E" continuedAt="TextSelection-3C50557390AC558DAE6FA5320BB98977-1" escape="true">Adoption of New Accounting Standards</ix:nonNumeric></span></div><ix:continuation id="TextSelection-3C50557390AC558DAE6FA5320BB98977-1" continuedAt="TextSelection-3C50557390AC558DAE6FA5320BB98977-2"><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the fourth quarter of 2016, we adopted a new accounting standard for certain elements of the accounting for share-based payments as of January 1, 2016. Specifically, the new standard requires excess tax benefits or deficiencies (including tax benefits of dividend equivalents) of share-based compensation to be recognized as a component of the </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Provision for taxes on income</span><span style="font-family:inherit;font-size:10pt;">, whereas excess tax benefits or deficiencies previously were recognized in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Additional paid-in capital</span><span style="font-family:inherit;font-size:10pt;">. The net tax benefit for the Company was </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d43675583e924-wk-Fact-422175329FA65A29A0B38D483AE5E18B" name="pfe:EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTaxBenefitAmount" contextRef="FD2016Q3QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">35</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">third quarter</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d43675583e937-wk-Fact-BD1046B7AB30529C847A0D7B4EE7F8B3" name="pfe:EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTaxBenefitAmount" contextRef="FD2016Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">85</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;">. Also, in the diluted net earnings per share calculation, when applying the treasury stock method for shares that could be repurchased, the assumed proceeds no longer include the amount of excess tax benefit.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Another element of the new accounting standard requires that we now present excess tax benefits as operating activities in our consolidated statement of cash flows. We elected to adopt this presentation on a prospective basis as of January 1, 2016. Additionally, cash paid by us when directly withholding shares for tax-withholding purposes is now a cash outflow from financing activities. This reclassification was required to be adopted retrospectively. As a result, </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d43675583e952-wk-Fact-28CA698CD3A7539CA4CD81846D893B45" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="FD2016Q3YTD_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_pfe_AccountingStandardsUpdate201609StatutoryTaxWithholdingComponentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">87</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> of cash outflows for the first nine months of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;"> was reclassified from operating activities to financing activities in the condensed consolidated statement of cash flows. For additional information, see Notes to Consolidated Financial Statements&#8211;&#8211;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 1B. </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Basis of Presentation and Significant Accounting Policies</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">:</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Adoption of New Accounting Standards</span><span style="font-family:inherit;font-size:10pt;"> included in our </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;"> Financial Report.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We adopted a new standard as of January 1, 2017 that amended guidance on the assessment of whether an entity is the primary beneficiary of a variable interest entity. Under this new guidance, when evaluating whether an entity is the primary beneficiary, a single decision maker must consider its indirect interest held through related parties under common control proportionately. There was no material impact to our condensed consolidated financial statements from adopting this standard.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></ix:continuation></ix:continuation><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><ix:continuation id="TextSelection-3C50557390AC558DAE6FA5320BB98977-2"><ix:continuation id="TextSelection-169F7BFE968C5905A80BDF1DF1E87FD4-3">We adopted a new standard as of January 1, 2017 related to inventory. The new guidance requires that inventory be measured at the lower of cost or net realizable value, which is defined as the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. There was no material impact to our condensed consolidated financial statements from adopting this standard.</ix:continuation></ix:continuation></span></div><div><a id="s59FEEF43C745568B94D7106E6AB608B1"></a></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Note 2. </span><ix:nonNumeric contextRef="FD2017Q3YTD" name="pfe:BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsCollaborativeArrangementsEquityandCostMethodInvestmentsDisclosureTextBlock" id="TextSelection-D7B224EB00D154EB858CCD0ACC390AA6-0-wk-Fact-5E34F88968B15798B1D8F595279797A6" continuedAt="TextSelection-D7B224EB00D154EB858CCD0ACC390AA6-1" escape="true"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Acquisitions, Sale of Hospira Infusion Systems Net Assets, Collaborative Arrangement and Equity-Method Investments</span></ix:nonNumeric></div><ix:continuation id="TextSelection-D7B224EB00D154EB858CCD0ACC390AA6-1" continuedAt="TextSelection-D7B224EB00D154EB858CCD0ACC390AA6-2"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">A. Acquisitions</span></div><div style="line-height:120%;padding-bottom:6px;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">AstraZeneca&#8217;s Small Molecule Anti-Infectives Business (EH)</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On December 22, 2016, which falls in the first fiscal quarter of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;"> for our international operations, we acquired the development and commercialization rights to AstraZeneca&#8217;s small molecule anti-infectives business, primarily outside the U.S., including the commercialization and development rights to the newly approved EU drug Zavicefta&#8482; (ceftazidime-avibactam), the marketed agents Merrem&#8482;/Meronem&#8482; (meropenem) and Zinforo&#8482;&#160;(ceftaroline fosamil), and the clinical development assets ATM-AVI and CXL (ceftaroline fosamil-AVI). Under the terms of the agreement, we made an upfront payment of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d43687567e648-wk-Fact-657BE69A39C55387B9A8101A49B75190" name="pfe:PaymentstoAcquireBusinessesGrossInitialPayment" contextRef="D2016Q4Dec22-Dec22_us-gaap_BusinessAcquisitionAxis_pfe_AstraZenecaMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">552</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> to AstraZeneca upon the close of the transaction and an additional </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d43687567e652-wk-Fact-D9B9F1DEBE75560B8933A4AC4B9C5CBB" name="pfe:PaymentstoAcquireBusinessesGrossPurchasePriceAdjustment" contextRef="FD2017Q2QTD_us-gaap_BusinessAcquisitionAxis_pfe_AstraZenecaMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> payment for a contractual purchase price adjustment in the second quarter of 2017. We also made a </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d43687567e656-wk-Fact-FD35C9C066AA554EA5D1807C52E5D2F8" name="us-gaap:PaymentForContingentConsiderationLiabilityInvestingActivities" contextRef="FD2017Q2QTD_us-gaap_BusinessAcquisitionAxis_pfe_AstraZenecaMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">50</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> milestone payment in the second quarter of 2017, we expect to make an additional milestone payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d43687567e660-wk-Fact-7BE54186E055C9129E079229C2143B9E" name="us-gaap:PaymentForContingentConsiderationLiabilityInvestingActivities" contextRef="FD2018Q1QTD_us-gaap_BusinessAcquisitionAxis_pfe_AstraZenecaMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioForecastMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">125</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> in our first fiscal quarter of 2018 and we will make a deferred payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d43687567e665-wk-Fact-0D1D72A9F6215AEF9F76B0E41D313DD7" name="pfe:BusinessCombinationConsiderationTransferredDeferredPayment" contextRef="D2016Q4Dec22-Dec22_us-gaap_BusinessAcquisitionAxis_pfe_AstraZenecaMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">175</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> to AstraZeneca in January 2019. In addition, AstraZeneca may be eligible to receive an additional milestone payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d43687567e669-wk-Fact-893E7328A6E2587F87C7C738D3872CF6" name="pfe:BusinessCombinationConsiderationTransferredMilestonePaymentsMaximum" contextRef="D2016Q4Dec22-Dec22_us-gaap_BusinessAcquisitionAxis_pfe_AstraZenecaMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">75</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> if the related milestone is achieved prior to December 31, 2021, and up to </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d43687567e673-wk-Fact-2B31A81FDEC654199C1610C986A617BC" name="pfe:BusinessCombinationConsiderationTransferredSalesrelatedPaymentsMaximum" contextRef="D2016Q4Dec22-Dec22_us-gaap_BusinessAcquisitionAxis_pfe_AstraZenecaMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">600</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> if sales of Zavicefta&#8482; exceed certain thresholds prior to January 1, 2026, as well as tiered royalties on sales of Zavicefta&#8482; and ATM-AVI in certain markets for a period ending on the later of ten years from first commercial sale or the loss of patent protection or loss of regulatory exclusivity. The total royalty payments are unlimited during the royalty term and the undiscounted payments are expected to be in the range of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d43687567e677-wk-Fact-F615B8561B78574CBB8752367FD1DA20" name="pfe:BusinessCombinationConsiderationTransferredUndiscountedRoyaltyPayments" contextRef="D2016Q4Dec22-Dec22_us-gaap_BusinessAcquisitionAxis_pfe_AstraZenecaMember_us-gaap_RangeAxis_us-gaap_MinimumMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">250</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d43687567e681-wk-Fact-F63FF6A144A654A5B853607E09594E11" name="pfe:BusinessCombinationConsiderationTransferredUndiscountedRoyaltyPayments" contextRef="D2016Q4Dec22-Dec22_us-gaap_BusinessAcquisitionAxis_pfe_AstraZenecaMember_us-gaap_RangeAxis_us-gaap_MaximumMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">425</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">. The total fair value </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:center;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(UNAUDITED)</span></div></div><div><br/></div><ix:continuation id="TextSelection-D7B224EB00D154EB858CCD0ACC390AA6-2" continuedAt="TextSelection-D7B224EB00D154EB858CCD0ACC390AA6-3"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">of consideration transferred for AstraZeneca&#8217;s small molecule anti-infectives business was approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d43687567e688-wk-Fact-7EB40678643F5B9A8D29CAC721DDC2D1" name="us-gaap:BusinessCombinationConsiderationTransferred1" contextRef="D2016Q4Dec22-Dec22_us-gaap_BusinessAcquisitionAxis_pfe_AstraZenecaMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,045</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, which includes </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d43687567e692-wk-Fact-5F34E1E596905AD79AC3A31E592AD8AA" name="us-gaap:PaymentsToAcquireBusinessesGross" contextRef="D2016Q4Dec22-Dec22_us-gaap_BusinessAcquisitionAxis_pfe_AstraZenecaMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">555</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> in cash, plus the fair value of contingent consideration of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d43687567e696-wk-Fact-156CCDE95FE75A349CB4A7879A148ECE" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="I2016Q4Dec22_us-gaap_BusinessAcquisitionAxis_pfe_AstraZenecaMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">490</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> (which is composed of the deferred payment, the </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d43687567e700-wk-Fact-FD35C9C066AA554EA5D1807C52E5D2F8" name="us-gaap:PaymentForContingentConsiderationLiabilityInvestingActivities" contextRef="FD2017Q2QTD_us-gaap_BusinessAcquisitionAxis_pfe_AstraZenecaMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">50</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> milestone payment made in the second quarter of 2017 and the future expected milestone and royalty payments). In connection with this acquisition, we provisionally recorded </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d43687567e704-wk-Fact-69D18BDF56E3520398AFFB46BD54FB80" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" contextRef="I2016Q4Dec22_us-gaap_BusinessAcquisitionAxis_pfe_AstraZenecaMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">879</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;">in</span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;"> </span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;font-style:italic;">Identifiable intangible assets</span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;">, primarily consisting</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d43687567e721-wk-Fact-E043D3E1364156A38BA50F1A95C5FDE6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" contextRef="I2016Q4Dec22_us-gaap_BusinessAcquisitionAxis_pfe_AstraZenecaMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">660</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> in</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> Developed technology rights</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d43687567e729-wk-Fact-98DF5EAD37225F94AEF79B530F2A918E" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" contextRef="I2016Q4Dec22_us-gaap_BusinessAcquisitionAxis_pfe_AstraZenecaMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">219</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">IPR&amp;D</span><span style="font-family:inherit;font-size:10pt;">. We also recorded </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d43687567e738-wk-Fact-EFFCA6422CE7572E8AFA6946EA58D495" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" contextRef="I2016Q4Dec22_us-gaap_BusinessAcquisitionAxis_pfe_AstraZenecaMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">92</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other current assets</span><span style="font-family:inherit;font-size:10pt;"> related to the economic value of inventory which was retained by AstraZeneca for sale on our behalf, </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d43687567e746-wk-Fact-69E147FB5625509A914677905319EACB" name="us-gaap:Goodwill" contextRef="I2016Q4Dec22_us-gaap_BusinessAcquisitionAxis_pfe_AstraZenecaMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">92</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Goodwill</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d43687567e755-wk-Fact-BA47BF334B625B08B7BA3C98253886F4" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" contextRef="I2016Q4Dec22_us-gaap_BusinessAcquisitionAxis_pfe_AstraZenecaMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">17</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> of net deferred tax liabilities. The allocation of the consideration transferred to the assets and the</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;">liabilities assumed has not yet been finalized.</span></div><div style="line-height:120%;padding-bottom:6px;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Medivation, Inc. (IH)</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On September 28, 2016, we acquired Medivation for </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d43687567e769-wk-Fact-BFC7B9276178582B99CC000090BE3B00" name="us-gaap:BusinessAcquisitionSharePrice" contextRef="I2016Q3Sep28_us-gaap_BusinessAcquisitionAxis_pfe_MedivationMember" unitRef="usdPerShare" decimals="INF" scale="0" format="ixt:numdotdecimal">81.50</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> per share. The total fair value of consideration transferred for Medivation was approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d43687567e773-wk-Fact-E1AAD35F4B8F510FBE6343C41BBB3E35" name="us-gaap:BusinessCombinationConsiderationTransferred1" contextRef="D2016Q3Sep28-Sep28_us-gaap_BusinessAcquisitionAxis_pfe_MedivationMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">14.3</ix:nonFraction> billion</span></span><span style="font-family:inherit;font-size:10pt;"> in cash (</span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d43687567e777-wk-Fact-C75AE989F4BA5F97B616D203FD1E39E8" name="pfe:BusinessCombinationConsiderationTransferredNetofCashAcquired" contextRef="D2016Q3Sep28-Sep28_us-gaap_BusinessAcquisitionAxis_pfe_MedivationMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">13.9</ix:nonFraction> billion</span></span><span style="font-family:inherit;font-size:10pt;">, net of cash acquired). Of this consideration, approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d43687567e781-wk-Fact-17EF679F2F5A56B38C3FEBA1811ABAC3" name="pfe:BusinessCombinationConsiderationTransferredAmountPayable" contextRef="FI2016Q4_us-gaap_BusinessAcquisitionAxis_pfe_MedivationMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">365</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> was not paid as of December 31, 2016, and was recorded in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other current liabilities. </span><span style="font-family:inherit;font-size:10pt;">Substantially all of the remaining consideration was paid as of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">October&#160;1, 2017</span><span style="font-family:inherit;font-size:10pt;">. Medivation is now a wholly-owned subsidiary of Pfizer. Medivation is a biopharmaceutical company focused on developing and commercializing small molecules for oncology. Medivation&#8217;s portfolio includes Xtandi (enzalutamide), an androgen receptor inhibitor that blocks multiple steps in the androgen receptor signaling pathway within tumor cells. Xtandi is being developed and commercialized through a collaboration with Astellas. Astellas has exclusive commercialization rights for Xtandi outside the U.S. In addition, Medivation has a development-stage oncology asset in its pipeline, talazoparib, which is currently in a Phase 3 study for the treatment of BRCA-mutated breast cancer. In connection with this acquisition, we recorded </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d43687567e794-wk-Fact-3492BBB2373A5647895A246D631BFA67" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" contextRef="I2016Q3Sep28_us-gaap_BusinessAcquisitionAxis_pfe_MedivationMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">12.2</ix:nonFraction> billion</span></span><span style="font-family:inherit;font-size:10pt;"> in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Identifiable intangible assets</span><span style="font-family:inherit;font-size:10pt;">, primarily consisting of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d43687567e802-wk-Fact-8565C203A73153AA923606D5F1BC085C" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" contextRef="I2016Q3Sep28_us-gaap_BusinessAcquisitionAxis_pfe_MedivationMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">8.1</ix:nonFraction> billion</span></span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Developed technology rights</span><span style="font-family:inherit;font-size:10pt;"> with an average useful life of approximately 12 years and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d43687567e810-wk-Fact-6F53AB2DFB3A5A6FAD6BC73529189371" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" contextRef="I2016Q3Sep28_us-gaap_BusinessAcquisitionAxis_pfe_MedivationMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">4.1</ix:nonFraction> billion</span></span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">IPR&amp;D, </span><span style="font-family:inherit;font-size:10pt;">and recorded </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d43687567e819-wk-Fact-6FEAC14518C35EF6BE23028F34113E5D" name="us-gaap:Goodwill" contextRef="I2016Q3Sep28_us-gaap_BusinessAcquisitionAxis_pfe_MedivationMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">6.1</ix:nonFraction> billion</span></span><span style="font-family:inherit;font-size:10pt;"> of</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> Goodwill,</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d43687567e827-wk-Fact-261798DC42D55FF282CBDF428112CF2B" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" contextRef="I2016Q3Sep28_us-gaap_BusinessAcquisitionAxis_pfe_MedivationMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">4.0</ix:nonFraction> billion</span></span><span style="font-family:inherit;font-size:10pt;"> of net income tax liabilities, and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d43687567e831-wk-Fact-EE3442C5D0BD5184AE06BF9DD04A7205" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="I2016Q3Sep28_us-gaap_BusinessAcquisitionAxis_pfe_MedivationMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">259</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> of assumed contingent consideration. In 2017 and 2016, we recorded measurement period adjustments to the estimated fair values initially recorded in 2016, which resulted in a reduction in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Identifiable intangible assets</span><span style="font-family:inherit;font-size:10pt;"> of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d43687567e840-wk-Fact-329FA1C56A20EBBA37677DED51F2DC7C" name="us-gaap:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles" contextRef="D2017Q3Sep29-Oct01_us-gaap_BusinessAcquisitionAxis_pfe_MedivationMember" unitRef="usd" decimals="-8" scale="9" sign="-" format="ixt:numdotdecimal">1.0</ix:nonFraction> billion</span></span><span style="font-family:inherit;font-size:10pt;"> with a corresponding change to </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Goodwill</span><span style="font-family:inherit;font-size:10pt;"> and net income tax liabilities. The measurement period adjustments were recorded to better reflect market participant assumptions about facts and circumstances existing as of the acquisition date. The third quarter and first nine months of 2017 results include a decrease of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d43687567e848-wk-Fact-9D3A35DE9ECE7C4558687DF9A2AF61E6" name="pfe:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIncreaseDecreaseinAmortizationofIntangibleAssets" contextRef="FD2017Q3QTD_us-gaap_BusinessAcquisitionAxis_pfe_MedivationMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">38</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Amortization of intangible assets</span><span style="font-family:inherit;font-size:10pt;"> which reflects the cumulative pre-tax impact of the measurement period adjustments to </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Identifiable intangible assets</span><span style="font-family:inherit;font-size:10pt;"> that were amortized to the income statement since the acquisition date. The measurement period adjustments did not result from intervening events subsequent to the acquisition date. The final allocation of the consideration transferred to the assets acquired and the liabilities assumed has been completed.</span></div><div style="line-height:120%;padding-bottom:6px;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Bamboo Therapeutics, Inc. (IH)</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On August 1, 2016, we acquired all the remaining equity in Bamboo, a privately-held biotechnology company focused on developing gene therapies for the potential treatment of patients with certain rare diseases relating to neuromuscular conditions and those affecting the central nervous system, for </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d43687567e867-wk-Fact-F7D5BB52F6405772A445C2B27AC9F26D" name="us-gaap:BusinessCombinationConsiderationTransferred1" contextRef="D2016Q3Aug01-Aug01_us-gaap_BusinessAcquisitionAxis_pfe_BambooTherapeuticsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">150</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, plus potential milestone payments of up to </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d43687567e871-wk-Fact-D3A3EBBC5160517E94ADBCA595690003" name="pfe:BusinessCombinationConsiderationTransferredMilestonePaymentsMaximum" contextRef="D2016Q3Aug01-Aug01_us-gaap_BusinessAcquisitionAxis_pfe_BambooTherapeuticsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">495</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> contingent upon the progression of key assets through development, regulatory approval and commercialization. The total fair value of the consideration transferred for Bamboo was approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d43687567e875-wk-Fact-1633E5F799E5581EBA3C932D6D8CE3A2" name="us-gaap:BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1" contextRef="D2016Q3Aug01-Aug01_us-gaap_BusinessAcquisitionAxis_pfe_BambooTherapeuticsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">343</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, including cash of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d43687567e879-wk-Fact-EA29606A0E2B511E89A653AE9E0999B1" name="us-gaap:PaymentsToAcquireBusinessesGross" contextRef="D2016Q3Aug01-Aug01_us-gaap_BusinessAcquisitionAxis_pfe_BambooTherapeuticsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">130</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> (</span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d43687567e883-wk-Fact-E0AC0361D7DA522494AE56B75ACFC3EA" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" contextRef="D2016Q3Aug01-Aug01_us-gaap_BusinessAcquisitionAxis_pfe_BambooTherapeuticsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">101</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, net of cash acquired), contingent consideration of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d43687567e888-wk-Fact-45683FBF65C355B489C4D3A3D4143E54" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="I2016Q3Aug01-Aug01_us-gaap_BusinessAcquisitionAxis_pfe_BambooTherapeuticsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">167</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, consisting of milestone payments, and the fair value of Pfizer&#8217;s previously held equity interest in Bamboo of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d43687567e892-wk-Fact-37CCCB24ADAA5E6D84A8C5A4C4A879E2" name="us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" contextRef="D2016Q3Aug01-Aug01_us-gaap_BusinessAcquisitionAxis_pfe_BambooTherapeuticsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">45</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">. We previously purchased a minority stake in Bamboo in the first quarter of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;"> for a payment of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d43687567e900-wk-Fact-96260D53526D568284DF6AC40BF5FEA9" name="us-gaap:PaymentsToAcquireBusinessesGross" contextRef="FD2016Q1QTD_us-gaap_BusinessAcquisitionAxis_pfe_BambooTherapeuticsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">43</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">. Upon acquiring the remaining interest in Bamboo in the third quarter of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;">, we recognized a gain of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d43687567e908-wk-Fact-CAEE4F1B76BC58C4A8827053DF7A7864" name="us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain" contextRef="FD2016Q3QTD_us-gaap_BusinessAcquisitionAxis_pfe_BambooTherapeuticsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> on our existing investment in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net</span><span style="font-family:inherit;font-size:10pt;"> over the one- year allocation period</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">.</span><span style="font-family:inherit;font-size:10pt;"> This acquisition provides us with several clinical and pre-clinical assets that complement our rare disease portfolio, an advanced recombinant AAV vector design and production technology, and a fully functional Phase I/II gene therapy manufacturing facility. Bamboo is now a wholly-owned subsidiary of Pfizer. In connection with this acquisition, we recorded </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d43687567e921-wk-Fact-468408BA9A31556A863846D8FA8DCE6A" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" contextRef="I2016Q3Aug01-Aug01_us-gaap_BusinessAcquisitionAxis_pfe_BambooTherapeuticsMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">330</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Identifiable intangible assets, </span><span style="font-family:inherit;font-size:10pt;">consisting entirely of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">IPR&amp;D. </span><span style="font-family:inherit;font-size:10pt;">We also recorded </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d43687567e934-wk-Fact-11F70F11F63A531383B5426456C060D9" name="us-gaap:Goodwill" contextRef="I2016Q3Aug01-Aug01_us-gaap_BusinessAcquisitionAxis_pfe_BambooTherapeuticsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">142</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Goodwill </span><span style="font-family:inherit;font-size:10pt;">and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d43687567e942-wk-Fact-BB08A3DC05B553B9AC750857EF6E41A6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" contextRef="I2016Q3Aug01-Aug01_us-gaap_BusinessAcquisitionAxis_pfe_BambooTherapeuticsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">94</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> of net deferred tax liabilities. The final allocation of the consideration transferred to the assets acquired and the liabilities assumed has been completed.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;padding-bottom:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Anacor Pharmaceuticals, Inc. (IH)</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On June 24, 2016, we acquired Anacor for </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d43687567e955-wk-Fact-A4CCFEF743375CD1801D535634B4A8AA" name="us-gaap:BusinessAcquisitionSharePrice" contextRef="I2016Q2AnacorAcquisition_us-gaap_BusinessAcquisitionAxis_pfe_AnacorMember" unitRef="usdPerShare" decimals="INF" scale="0" format="ixt:numdotdecimal">99.25</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> per share. The total fair value of consideration transferred for Anacor was approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d43687567e959-wk-Fact-95C29614540351DE9037594EC3C94315" name="us-gaap:PaymentsToAcquireBusinessesGross" contextRef="D2016Q2Jun24-Jun24_us-gaap_BusinessAcquisitionAxis_pfe_AnacorMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">4.9</ix:nonFraction> billion</span></span><span style="font-family:inherit;font-size:10pt;"> in cash (</span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d43687567e963-wk-Fact-7F7DF1BB1F03504B8A8B5D2E9C815949" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" contextRef="D2016Q2Jun24-Jun24_us-gaap_BusinessAcquisitionAxis_pfe_AnacorMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">4.5</ix:nonFraction> billion</span></span><span style="font-family:inherit;font-size:10pt;"> net of cash acquired), plus </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d43687567e967-wk-Fact-F1D518BE01C15066AFE97B15088EC11E" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" contextRef="I2016Q2AnacorAcquisition_us-gaap_BusinessAcquisitionAxis_pfe_AnacorMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">698</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> debt assumed. Anacor is now a wholly-owned subsidiary of Pfizer. Anacor is a biopharmaceutical company focused on novel small-molecule therapeutics derived from its boron chemistry platform. Anacor&#8217;s crisaborole, a non-steroidal topical PDE-4 inhibitor with anti-inflammatory properties, was approved by the FDA on December 14, 2016 under the trade name, Eucrisa. In connection with this acquisition, we recorded </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d43687567e971-wk-Fact-F1D518BE01C15066AFE97B15088EC11E" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" contextRef="I2016Q2AnacorAcquisition_us-gaap_BusinessAcquisitionAxis_pfe_AnacorMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">698</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> as the fair value of notes payable in cash, and recorded </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d43687567e976-wk-Fact-30109A63BBBB5D869A8C0F101C3C0957" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" contextRef="I2016Q2AnacorAcquisition_us-gaap_BusinessAcquisitionAxis_pfe_AnacorMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">4.9</ix:nonFraction> billion</span></span><span style="font-family:inherit;font-size:10pt;"> in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Identifiable intangible assets</span><span style="font-family:inherit;font-size:10pt;">, </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">11</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:center;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(UNAUDITED)</span></div></div><div><br/></div><ix:continuation id="TextSelection-D7B224EB00D154EB858CCD0ACC390AA6-3" continuedAt="TextSelection-D7B224EB00D154EB858CCD0ACC390AA6-4"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">primarily consisting of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d43687567e987-wk-Fact-68E476566B0850718997E601135758C9" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" contextRef="I2016Q2AnacorAcquisition_us-gaap_BusinessAcquisitionAxis_pfe_AnacorMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">4.8</ix:nonFraction> billion</span></span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">IPR&amp;D</span><span style="font-family:inherit;font-size:10pt;">, and recorded </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d43687567e995-wk-Fact-11AD8C3FBDFD5610B463B5D5299551B3" name="us-gaap:Goodwill" contextRef="I2016Q2AnacorAcquisition_us-gaap_BusinessAcquisitionAxis_pfe_AnacorMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">646</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Goodwill </span><span style="font-family:inherit;font-size:10pt;">and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d43687567e1003-wk-Fact-654A611F62EB5266A240D2727045C86A" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" contextRef="I2016Q2AnacorAcquisition_us-gaap_BusinessAcquisitionAxis_pfe_AnacorMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">346</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> of net income tax liabilities. The final allocation of the consideration transferred to the assets acquired and the liabilities assumed has been completed.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">B. </span><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Sale of Hospira Infusion Systems Net Assets to ICU Medical, Inc. (EH)</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"> </span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On October 6, 2016, we announced that we entered into a definitive agreement under which ICU Medical would acquire all of our global infusion therapy net assets, HIS, for approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d43687567e1045-wk-Fact-BE2F6AB244E55D7A8640979329D166AC" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration" contextRef="I2016Q4Oct06_us-gaap_CounterpartyNameAxis_pfe_ICUMedicalMember_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_HISMember" unitRef="usd" decimals="-9" scale="9" format="ixt:numdotdecimal">1</ix:nonFraction> billion</span></span><span style="font-family:inherit;font-size:10pt;"> in cash and ICU Medical common stock</span><span style="font-family:Arial;font-size:8pt;">.</span><span style="font-family:inherit;font-size:10pt;"> HIS includes IV pumps, solutions, and devices.</span><span style="font-family:Arial;font-size:8pt;"> </span><span style="font-family:inherit;font-size:10pt;">As a result of the performance of HIS relative to ICU Medical&#8217;s expectations, on January 5, 2017, we entered into a revised agreement with ICU Medical under which ICU Medical would acquire HIS for up to approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d43687567e1057-wk-Fact-422B7533CB3952A4836B385CAF9FF170" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration" contextRef="I2017Q1Jan05_us-gaap_CounterpartyNameAxis_pfe_ICUMedicalMember_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_HISMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">900</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, composed of cash and contingent cash consideration, ICU Medical common stock and seller financing.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The revised transaction closed on February 3, 2017. At closing, under the terms of the revised agreement, we received </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687567e1064-wk-Fact-911EB761D3C6590EA6CD704F46034785" name="pfe:DisposalGroupIncludingDiscontinuedOperationConsiderationTransferredEquityInterestsShares" contextRef="I2017Q1Feb03_us-gaap_CounterpartyNameAxis_pfe_ICUMedicalMember_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_HISMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">3.2</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> newly issued shares of ICU Medical common stock (as originally agreed), which we initially valued at approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d43687567e1068-wk-Fact-88E2E31CC1495183A0F02B04F4BB0670" name="pfe:DisposalGroupIncludingDiscontinuedOperationConsiderationTransferredEquityInterests" contextRef="I2017Q1Feb03_us-gaap_CounterpartyNameAxis_pfe_ICUMedicalMember_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_HISMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">428</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> (based upon the closing price of ICU Medical common stock on the closing date less a discount for lack of marketability) and which are reported as available-for-sale equity securities at fair value in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Long-term investments</span><span style="font-family:inherit;font-size:10pt;"> on the condensed consolidated balance sheet as of </span><span style="font-family:inherit;font-size:10pt;">October&#160;1, 2017</span><span style="font-family:inherit;font-size:10pt;">, a promissory note in the amount of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d43687567e1080-wk-Fact-C837741F7E265EA590514DA12CED34D8" name="pfe:DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivable" contextRef="I2017Q1Feb03_us-gaap_CounterpartyNameAxis_pfe_ICUMedicalMember_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_HISMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">75</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, which is reported in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other noncurrent assets</span><span style="font-family:inherit;font-size:10pt;"> on the condensed consolidated balance sheet as of </span><span style="font-family:inherit;font-size:10pt;">October&#160;1, 2017</span><span style="font-family:inherit;font-size:10pt;">, and net cash of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d43687567e1093-wk-Fact-DB17DE17C6F85F4CAB63402F954B36A7" name="us-gaap:ProceedsFromDivestitureOfBusinesses" contextRef="D2017Q1Feb03-Feb03_us-gaap_CounterpartyNameAxis_pfe_ICUMedicalMember_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_HISMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">200</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> before customary adjustments for net working capital, which is reported in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other investing activities, net</span><span style="font-family:inherit;font-size:10pt;"> on the condensed consolidated statement of cash flows for the </span><span style="font-family:inherit;font-size:10pt;">nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">October&#160;1, 2017</span><span style="font-family:inherit;font-size:10pt;">. In addition, we are entitled to receive a contingent amount of up to an additional </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d43687567e1110-wk-Fact-CCE861B5954250CAA7F6496324EC1015" name="pfe:DisposalGroupIncludingDiscontinuedOperationContingentConsideration" contextRef="I2017Q1Feb03_us-gaap_CounterpartyNameAxis_pfe_ICUMedicalMember_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_HISMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">225</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> in cash based on ICU Medical&#8217;s achievement of certain cumulative performance targets for the combined company through December 31, 2019. After receipt of the ICU Medical shares, we own approximately </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687567e1114-wk-Fact-89A1AEFA59C55B02AF326045F1AD9175" name="us-gaap:MinorityInterestOwnershipPercentageByParent" contextRef="FI2017Q3_us-gaap_CounterpartyNameAxis_pfe_ICUMedicalMember_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_HISMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">16</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> of ICU Medical. We have agreed to certain restrictions on transfer of our ICU Medical shares for 18 months after the closing date. The promissory note from ICU Medical has a term of </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> years and bears interest at LIBOR plus </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687567e1122-wk-Fact-22A4660F38F150D2A1EE54C402FB0060" name="pfe:DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivableInterestRate" contextRef="D2017Q1Feb03-Feb03_us-gaap_CounterpartyNameAxis_pfe_ICUMedicalMember_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_HISMember_us-gaap_VariableRateAxis_us-gaap_LondonInterbankOfferedRateLIBORMember" unitRef="number" decimals="4" scale="-2" format="ixt:numdotdecimal">2.25</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> for the first year and LIBOR plus </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687567e1126-wk-Fact-058D7A80D5A055368745AF7482558CB0" name="pfe:DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivableInterestRateYearTwo" contextRef="D2017Q1Feb03-Feb03_us-gaap_CounterpartyNameAxis_pfe_ICUMedicalMember_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_HISMember_us-gaap_VariableRateAxis_us-gaap_LondonInterbankOfferedRateLIBORMember" unitRef="number" decimals="4" scale="-2" format="ixt:numdotdecimal">2.50</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> for the second and third years. We recognized pre-tax income of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d43687567e1131-wk-Fact-9D15F4421F756404E8579242D4ADE49A" name="us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" contextRef="FD2017Q3QTD_us-gaap_CounterpartyNameAxis_pfe_ICUMedicalMember_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_HISMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">12</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> in the </span><span style="font-family:inherit;font-size:10pt;">third</span><span style="font-family:inherit;font-size:10pt;"> quarter of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;"> and pre-tax losses of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d43687567e1143-wk-Fact-E5CB1F203E7813A248DE9242F0D38585" name="us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" contextRef="FD2017Q3YTD_us-gaap_CounterpartyNameAxis_pfe_ICUMedicalMember_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_HISMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">52</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> in the first </span><span style="font-family:inherit;font-size:10pt;">nine</span><span style="font-family:inherit;font-size:10pt;"> months of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;"> in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net, </span><span style="font-family:inherit;font-size:10pt;">representing adjustments to amounts previously recorded to write down the HIS net assets to fair value less costs to sell. For additional information, see </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 4</span><span style="font-family:inherit;font-size:10pt;"> and Notes to Consolidated Financial Statements&#8211;&#8211;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 2. </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Acquisitions, Sale of Hospira Infusion Systems Net Assets, Collaborative Arrangement and Equity-Method Investments</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span><span style="font-family:inherit;font-size:10pt;">in</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span><span style="font-family:inherit;font-size:10pt;">Pfizer&#8217;s </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;"> Financial Report.</span></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">While we have received the full purchase price excluding the contingent amount as of the February 3, 2017 closing, the sale of the HIS net assets was not completed in certain non-U.S. jurisdictions due to temporary regulatory or operational constraints. In these jurisdictions, which represent a relatively small portion of the HIS net assets, we have continued to operate the net assets for the net economic benefit of ICU Medical, and we are indemnified by ICU Medical against risks associated with such operations during the interim period, subject to our obligations under the definitive transaction agreements. Sales of the HIS net assets have occurred in certain of these jurisdictions as of October 1, 2017 and we expect the sale of the HIS net assets in the remaining jurisdictions to be fully completed by the first quarter of 2018. As such, and as we have already received all of the non-contingent proceeds from the sale and ICU Medical is contractually obligated to complete the transaction, we have treated these jurisdictions as sold for accounting purposes.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In connection with the sale transaction, we entered into certain transitional agreements designed to facilitate the orderly transition of the HIS net assets to ICU Medical. These agreements primarily relate to administrative services, which are generally to be provided for a period of up to 24 months after the closing date. We will also manufacture and supply certain HIS products for ICU Medical and ICU Medical will manufacture and supply certain retained Pfizer products for us after closing, generally for a term of five years. These agreements are not material to Pfizer and none confers upon us the ability to influence the operating and/or financial policies of ICU Medical subsequent to the sale.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">C. Collaboration Arrangement</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;padding-bottom:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Collaboration with Merck &amp; Co., Inc.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In 2013, we entered into a worldwide, except for Japan, collaboration agreement with Merck for the development and commercialization of ertugliflozin (PF-04971729), our oral sodium glucose cotransporter (SGLT2) inhibitor for the treatment of type 2 diabetes currently under regulatory review. Under the agreement, we are collaborating with Merck on the clinical development of ertugliflozin, and ertugliflozin-containing fixed-dose combinations with metformin and Januvia (sitagliptin) tablets.</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">12</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:center;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(UNAUDITED)</span></div></div><div><br/></div><ix:continuation id="TextSelection-D7B224EB00D154EB858CCD0ACC390AA6-4" continuedAt="TextSelection-D7B224EB00D154EB858CCD0ACC390AA6-5"><div style="line-height:120%;padding-top:6px;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:10pt;">In the first quarter of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:10pt;">we received a </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d43687567e1238-wk-Fact-B002A9FE8D3757229766F6559419D0FF" name="us-gaap:ProceedsFromCollaborators" contextRef="FD2017Q1QTD_us-gaap_CounterpartyNameAxis_pfe_MerckKGaAMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">90</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> milestone payment from Merck upon the FDA&#8217;s acceptance for review of the NDAs for ertugliflozin and two fixed-dose combinations (ertugliflozin plus Januvia (sitagliptin) and ertugliflozin plus metformin), which has been deferred and primarily reported in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other noncurrent liabilities </span><span style="font-family:inherit;font-size:10pt;">and is being recognized in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net</span><span style="font-family:inherit;font-size:10pt;"> over a multi-year period. We are eligible for additional payments associated with the achievement of future clinical, regulatory and commercial milestones. We share potential revenues and certain costs with Merck on a </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687567e1250-wk-Fact-8CFF4D7FC68454FCB7F23231E8D396E7" name="pfe:CollaborativeArrangementCollaboratorsRevenueandExpenseOwnershipPercentage" contextRef="FD2017Q3YTD_us-gaap_CounterpartyNameAxis_pfe_MerckKGaAMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">60</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;">/</span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687567e1255-wk-Fact-0FA05C8A024E5017BC626808F9824970" name="pfe:CollaborativeArrangementCompanysRevenueandExpenseOwnershipPercentage" contextRef="FD2017Q3YTD_us-gaap_CounterpartyNameAxis_pfe_MerckKGaAMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">40</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> basis, with Pfizer having the </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687567e1259-wk-Fact-0FA05C8A024E5017BC626808F9824970" name="pfe:CollaborativeArrangementCompanysRevenueandExpenseOwnershipPercentage" contextRef="FD2017Q3YTD_us-gaap_CounterpartyNameAxis_pfe_MerckKGaAMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">40</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> share. </span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">D. Equity-Method Investments</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;padding-bottom:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Investment in Hisun Pfizer Pharmaceuticals Company Limited</span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:10pt;">In </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;">,</span><span style="font-family:inherit;font-size:11pt;"> </span><span style="font-family:inherit;font-size:10pt;">we determined that we had other-than-temporary declines in the value of Hisun Pfizer, our </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687567e1282-wk-Fact-E0E2AB1F4EEE53C6B6DCA69B4759EC8D" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="FI2016Q3_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_HisunPfizerPharmaceuticalsCoLtdMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">49</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;">-owned equity-method investment in China, and, therefore, we recognized a loss of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d43687567e1286-wk-Fact-B851DA622DEF69DCB2D83E8DBA5E58C7" name="us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment" contextRef="FD2016Q3YTD_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_HisunPfizerPharmaceuticalsCoLtdMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">211</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> for the first </span><span style="font-family:inherit;font-size:10pt;">nine</span><span style="font-family:inherit;font-size:10pt;"> months of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;"> in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net </span><span style="font-family:inherit;font-size:10pt;">(see </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 4</span><span style="font-family:inherit;font-size:10pt;">)</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">. </span><span style="font-family:inherit;font-size:10pt;">The declines in value resulted from lower expectations as to the future cash flows to be generated by Hisun Pfizer, primarily as a result of an increase in risk due to the continued slowdown in the Chinese economy and changes in the expected timing and number of new product introductions by Hisun Pfizer. As of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">October&#160;1, 2017</span><span style="font-family:inherit;font-size:10pt;">, the carrying value of our investment in Hisun Pfizer is </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d43687567e1315-wk-Fact-EA898D13F5055FB9AF4A0540A1775D85" name="us-gaap:EquityMethodInvestments" contextRef="FI2017Q3_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_HisunPfizerPharmaceuticalsCoLtdMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">270</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, which is included in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Long-term investments</span><span style="font-family:inherit;font-size:10pt;">. We are continuing to evaluate strategic alternatives with Hisun. These strategic alternatives could impact the value of our investment in Hisun Pfizer in future periods.</span></div><div style="line-height:120%;text-align:left;font-size:5pt;"><span style="font-family:inherit;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In valuing our investment in Hisun Pfizer, we used discounted cash flow techniques, reflecting our best estimate of the various risks inherent in the projected cash flows, and a nominal terminal year growth factor. Some of the more significant estimates and assumptions inherent in this approach include: the amount and timing of the projected net cash flows, which include the expected impact of competitive, legal, economic and/or regulatory forces on the products; the long-term growth rate, which seeks to project the sustainable growth rate over the long-term; and the discount rate, which seeks to reflect the various risks inherent in the projected cash flows, including country risk. </span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;padding-bottom:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Investment in Laborat&#243;rio Teuto Brasileiro S.A.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We entered into an agreement on June 30, 2017 to exit our investment in Teuto, a </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687567e1338-wk-Fact-7A20B5BEC3C75D16BFE5A86C05D26ABA" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="I2017Q2Jun30_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_LaboratorioTeutoBrasileroMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">40</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;">-owned generics company in Brazil, and sell our </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687567e1342-wk-Fact-7A20B5BEC3C75D16BFE5A86C05D26ABA" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="I2017Q2Jun30_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_LaboratorioTeutoBrasileroMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">40</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> interest in Teuto to the majority shareholders. As part of the agreement, we have waived our option to acquire the remaining </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687567e1346-wk-Fact-E514899ACB1955ECA8A28246180FA71D" name="us-gaap:MinorityInterestOwnershipPercentageByParent" contextRef="I2017Q2Jun30_dei_LegalEntityAxis_pfe_LaboratorioTeutoBrasileroMember_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_LaboratorioTeutoBrasileroMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">60</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> of Teuto, and Teuto&#8217;s other shareholders have waived their option to sell their </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687567e1350-wk-Fact-E514899ACB1955ECA8A28246180FA71D" name="us-gaap:MinorityInterestOwnershipPercentageByParent" contextRef="I2017Q2Jun30_dei_LegalEntityAxis_pfe_LaboratorioTeutoBrasileroMember_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_LaboratorioTeutoBrasileroMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">60</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> stake in the company to us. As a result, in the second quarter of 2017, we recognized a net loss of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d43687567e1354-wk-Fact-3E108918AAAA5512B11A290783D5B15E" name="us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal" contextRef="FD2017Q3YTD_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_LaboratorioTeutoBrasileroMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">30</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net </span><span style="font-family:inherit;font-size:10pt;">(see </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 4</span><span style="font-family:inherit;font-size:10pt;">), which included the impairment of our equity-method investment in Teuto, the reversal of a contingent liability associated with the majority shareholders&#8217; option to sell their </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43687567e1367-wk-Fact-E514899ACB1955ECA8A28246180FA71D" name="us-gaap:MinorityInterestOwnershipPercentageByParent" contextRef="I2017Q2Jun30_dei_LegalEntityAxis_pfe_LaboratorioTeutoBrasileroMember_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_LaboratorioTeutoBrasileroMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">60</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> stake in the company to us, and the recognition in earnings of the currency translation adjustment associated with the Teuto investment. The transaction closed on August 16, 2017. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:10pt;">In </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:10pt;">we determined that we had an other-than-temporary decline in the value of Teuto, and, therefore, we recognized a loss of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d43687567e1380-wk-Fact-6870F39A774D54ABA3E37823BC3AAA03" name="us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment" contextRef="FD2016Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_LaboratorioTeutoBrasileroMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">50</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> for the first </span><span style="font-family:inherit;font-size:10pt;">nine</span><span style="font-family:inherit;font-size:10pt;"> months of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;"> in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net</span><span style="font-family:inherit;font-size:10pt;"> (see </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 4</span><span style="font-family:inherit;font-size:10pt;">) related to our equity-method investment. The decline in value resulted from lower expectations as to the future cash flows to be generated by Teuto, primarily due to a slowdown in Brazilian economic conditions, which have been impacted by political risk, higher inflation, and the depreciation of the Brazilian real.</span></div></ix:continuation><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><ix:continuation id="TextSelection-D7B224EB00D154EB858CCD0ACC390AA6-5">In valuing our investment in Teuto, we used discounted cash flow techniques, reflecting our best estimate of the various risks inherent in the projected cash flows, and a nominal terminal year growth factor. Some of the more significant estimates and assumptions inherent in this approach include: the amount and timing of the projected net cash flows, which include the expected impact of competitive, legal, economic and/or regulatory forces on the products; the long-term growth rate, which seeks to project the sustainable growth rate over the long-term; and the discount rate, which seeks to reflect the various risks inherent in the projected cash flows, including country risk.</ix:continuation></span></div><div><a id="s61D37D5D9A4C51669C93FC2FF5882391"></a></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Note 3. </span><ix:nonNumeric contextRef="FD2017Q3YTD" name="us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock" id="TextSelection-618AF0F88D785702B89176A8C50F5054-0-wk-Fact-3E4D502FB086570FBDDEE5A68B121067" continuedAt="TextSelection-618AF0F88D785702B89176A8C50F5054-1" escape="true"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives</span></ix:nonNumeric></div><ix:continuation id="TextSelection-618AF0F88D785702B89176A8C50F5054-1" continuedAt="TextSelection-618AF0F88D785702B89176A8C50F5054-2"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We incur significant costs in connection with acquiring, integrating and restructuring businesses and in connection with our global cost-reduction/productivity initiatives. For example: </span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In connection with acquisition activity, we typically incur costs associated with executing the transactions, integrating the acquired operations (which may include expenditures for consulting and the integration of systems and processes), and restructuring the combined company (which may include charges related to employees, assets and activities that will not continue in the combined company); and</span></div></td></tr></table></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">13</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:center;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(UNAUDITED)</span></div></div><div><br/></div><ix:continuation id="TextSelection-618AF0F88D785702B89176A8C50F5054-2" continuedAt="TextSelection-618AF0F88D785702B89176A8C50F5054-3"><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In connection with our cost-reduction/productivity initiatives, we typically incur costs and charges associated with site closings and other facility rationalization actions, workforce reductions and the expansion of shared services, including the development of global systems.</span></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:5pt;"><span style="font-family:inherit;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">All of our businesses and functions may be impacted by these actions, including sales and marketing, manufacturing and R&amp;D, as well as groups such as information technology, shared services and corporate operations. </span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In connection with our acquisition of Hospira, we are focusing our efforts on achieving an appropriate cost structure for the combined company. For up to a three-year period post-acquisition, we expect to incur costs of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d43712496e662-wk-Fact-0A980F0F2A3F5178AC7FC8E4FEA5946D" name="us-gaap:BusinessCombinationIntegrationRelatedCosts" contextRef="D2018Q3Sept20152018_us-gaap_BusinessAcquisitionAxis_pfe_HospiraMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioForecastMember" unitRef="usd" decimals="-9" scale="9" format="ixt:numdotdecimal">1</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:8pt;"> </span><span style="font-family:inherit;font-size:10pt;">(not including costs of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d43712496e668-wk-Fact-630CDB7F3DE05425814E7E7D20334106" name="us-gaap:RestructuringAndRelatedCostIncurredCost" contextRef="FD2015Q4YTD_us-gaap_BusinessAcquisitionAxis_pfe_HospiraMember_us-gaap_RestructuringCostAndReserveAxis_pfe_ReturnofAcquiredRightsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">215</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> for full-year 2015 associated with the return of acquired IPR&amp;D rights as described in the </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Current-Period Key Activities </span><span style="font-family:inherit;font-size:10pt;">section of Notes to Consolidated Financial Statements&#8211;&#8211;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 3</span><span style="font-family:inherit;font-size:10pt;">. </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives </span><span style="font-family:inherit;font-size:10pt;">in our 2016 Financial Report) associated with the integration of Hospira.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In 2016, we substantially completed previously disclosed cost-reduction initiatives begun in 2014 associated with our global commercial structure reorganization, manufacturing plant network rationalization and optimization initiatives, and additional cost-reduction/productivity initiatives across the enterprise.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As a result of the evaluation performed in connection with our decision in September 2016 to not pursue, at that time, splitting IH and EH into two separate publicly-traded companies, we identified new opportunities to potentially achieve greater optimization and efficiency to become more competitive in our business. Therefore, in early </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;">, we initiated new enterprise-wide cost reduction/productivity initiatives, which we expect to substantially complete by the end of 2019. These initiatives will encompass all areas of our cost base and will include:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Optimization of our manufacturing plant network to support IH and EH products and pipelines. During 2017-2019, we expect to incur costs of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d43712496e703-wk-Fact-A6DA652414025530B36D028F2F20662D" name="us-gaap:RestructuringAndRelatedCostExpectedCost1" contextRef="FI2017Q3_us-gaap_RestructuringCostAndReserveAxis_pfe_ManufacturingPlantNetworkOptimizationMember_us-gaap_RestructuringPlanAxis_pfe_EnterprisewideCostReductionProductivityPlanMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">800</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> related to this initiative. Through </span><span style="font-family:inherit;font-size:10pt;">October&#160;1, 2017</span><span style="font-family:inherit;font-size:10pt;">, we incurred approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d43712496e711-wk-Fact-A696CF153A785389AB4F20EB35681CCB" name="us-gaap:RestructuringAndRelatedCostCostIncurredToDate1" contextRef="FI2017Q3_us-gaap_RestructuringCostAndReserveAxis_pfe_ManufacturingPlantNetworkOptimizationMember_us-gaap_RestructuringPlanAxis_pfe_EnterprisewideCostReductionProductivityPlanMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">122</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> associated with this initiative.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Activities in non-manufacturing related areas, which include further centralization of our corporate and platform functions, as well as other activities where opportunities are identified. During 2017-2019, we expect to incur costs of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d43712496e722-wk-Fact-543739C1FDA4541AA1CFC40F4AFD1D54" name="us-gaap:RestructuringAndRelatedCostExpectedCost1" contextRef="FI2017Q3_us-gaap_RestructuringCostAndReserveAxis_pfe_CentralizationofCorporateandPlatformFunctionsMember_us-gaap_RestructuringPlanAxis_pfe_EnterprisewideCostReductionProductivityPlanMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">200</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> related to this initiative. Through </span><span style="font-family:inherit;font-size:10pt;">October&#160;1, 2017</span><span style="font-family:inherit;font-size:10pt;">, we incurred approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d43712496e730-wk-Fact-B94BA700C26A571D85A5F6298779F4E4" name="us-gaap:RestructuringAndRelatedCostCostIncurredToDate1" contextRef="FI2017Q3_us-gaap_RestructuringCostAndReserveAxis_pfe_CentralizationofCorporateandPlatformFunctionsMember_us-gaap_RestructuringPlanAxis_pfe_EnterprisewideCostReductionProductivityPlanMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">131</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> associated with this initiative. </span></div></td></tr></table><div style="line-height:120%;padding-top:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The costs expected to be incurred during 2017-2019, of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d43712496e737-wk-Fact-0655BCC984EC5E32A4901E8943054DB2" name="us-gaap:RestructuringAndRelatedCostExpectedCost1" contextRef="FI2017Q3_us-gaap_RestructuringPlanAxis_pfe_EnterprisewideCostReductionProductivityPlanMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">1.0</ix:nonFraction> billion</span></span><span style="font-family:inherit;font-size:10pt;"> for the above-mentioned programs (but not including expected costs associated with the Hospira integration), include restructuring charges, implementation costs and additional depreciation&#8211;&#8211;asset restructuring. Of this amount, we expect that about </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43712496e741-wk-Fact-D1F0EB11DD424B38B635920E6B1F138B" name="pfe:RestructuringandRelatedCostNoncashChargesPercentage" contextRef="FD2017Q3YTD_us-gaap_RestructuringPlanAxis_pfe_EnterprisewideCostReductionProductivityPlanMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">20</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> of the total charges will be non-cash.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Current-Period Key Activities</span></div><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For the </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;">, we incurred costs of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d43712496e761-wk-Fact-6DC8F760B64658B29976EADDD8399D10" name="us-gaap:RestructuringAndRelatedCostIncurredCost" contextRef="FD2017Q3YTD_us-gaap_RestructuringPlanAxis_pfe_EnterprisewideCostReductionProductivityPlanMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">253</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> associated with the 2017-2019 program, </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d43712496e765-wk-Fact-8EA6CC21C47A56CEA78505DBDA24C339" name="us-gaap:RestructuringAndRelatedCostIncurredCost" contextRef="FD2017Q3YTD_us-gaap_BusinessAcquisitionAxis_pfe_HospiraMember_us-gaap_RestructuringCostAndReserveAxis_pfe_BusinessIntegrationCostsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">238</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> associated with the integration of Hospira and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d43712496e769-wk-Fact-2E6527B47EEF5D9FAF41B981229A8F2A" name="us-gaap:RestructuringAndRelatedCostIncurredCost" contextRef="FD2017Q3YTD_us-gaap_RestructuringCostAndReserveAxis_pfe_BusinessIntegrationCostsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">110</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> associated with all other acquisition-related initiatives.</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">14</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:center;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(UNAUDITED)</span></div></div><div><br/></div><ix:continuation id="TextSelection-618AF0F88D785702B89176A8C50F5054-3" continuedAt="TextSelection-618AF0F88D785702B89176A8C50F5054-4"><div style="line-height:120%;font-size:10pt;"><ix:nonNumeric contextRef="FD2017Q3YTD" name="us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock" id="TextSelection-257BED4D93EB563FAF639E7FF8921EF6-0-wk-Fact-E4BF1BE3099C5848BEFF399D6802A679" continuedAt="TextSelection-257BED4D93EB563FAF639E7FF8921EF6-1" escape="true"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"></td></tr><tr><td style="width:48%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td colspan="17" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides the components of costs associated with acquisitions and cost-reduction/productivity initiatives:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Arial;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nine Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">October&#160;1, <br/>2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">October&#160;2, <br/>2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">October&#160;1, <br/>2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">October&#160;2, <br/>2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Restructuring charges</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(a)</sup></span><span style="font-family:inherit;font-size:10pt;">:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Employee terminations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d43712496e1165-wk-Fact-F2A2071B8FC55425A60551104D415290" name="us-gaap:SeveranceCosts1" contextRef="FD2017Q3QTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">20</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43712496e1185-wk-Fact-5EB5BCA88A6D540EBCA8B56A37E73824" name="us-gaap:SeveranceCosts1" contextRef="FD2016Q3QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">347</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43712496e1205-wk-Fact-6AEAE394B9B450FDAF7AF8A431A29CCE" name="us-gaap:SeveranceCosts1" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43712496e1224-wk-Fact-D042F83875705E98AC1B9D757B41F8B1" name="us-gaap:SeveranceCosts1" contextRef="FD2016Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">464</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Asset impairments</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43712496e1246-wk-Fact-BFEE13E8CEC95576907CDF47D40BBF3C" name="pfe:RestructuringAssetImpairmentCharges" contextRef="FD2017Q3QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">101</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43712496e1265-wk-Fact-0ACADD6A2EFE53F1891A48EEF52A1F7C" name="pfe:RestructuringAssetImpairmentCharges" contextRef="FD2016Q3QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">27</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43712496e1284-wk-Fact-632EFDC664F45A20BEB9A47C3FEE1B4D" name="pfe:RestructuringAssetImpairmentCharges" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">126</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43712496e1304-wk-Fact-7DF3605F8BAE533CAF6B416DD2F9F2C4" name="pfe:RestructuringAssetImpairmentCharges" contextRef="FD2016Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">45</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exit costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43712496e1329-wk-Fact-5D501002D38D5167AA036C63DF82035D" name="us-gaap:BusinessExitCosts1" contextRef="FD2017Q3QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">10</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43712496e1348-wk-Fact-5183BF736F1E563FA304D5EEBF7843EF" name="us-gaap:BusinessExitCosts1" contextRef="FD2016Q3QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">29</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43712496e1367-wk-Fact-FF8ADB2E22EA5E31A89D8C1DB543B9B8" name="us-gaap:BusinessExitCosts1" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">16</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43712496e1387-wk-Fact-C4C06BF1A8B6557EBFE62654491DA179" name="us-gaap:BusinessExitCosts1" contextRef="FD2016Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">64</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total restructuring charges</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43712496e1412-wk-Fact-5902E7F7E3325E0295E9C62DFD622D3E" name="us-gaap:RestructuringCharges" contextRef="FD2017Q3QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">91</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43712496e1431-wk-Fact-058D1994C3365CD1AB976A08ED207000" name="us-gaap:RestructuringCharges" contextRef="FD2016Q3QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">404</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43712496e1450-wk-Fact-9947697CFC005CC4B553C619A29CF327" name="us-gaap:RestructuringCharges" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">150</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43712496e1470-wk-Fact-33C51462AA72510092370BCC6B190DCD" name="us-gaap:RestructuringCharges" contextRef="FD2016Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">574</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Transaction costs</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d43712496e1497-wk-Fact-88427B31421C553CAC12777E36570F80" name="pfe:BusinessCombinationAcquisitionRelatedCostsTransactionCosts" contextRef="FD2017Q3QTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">14</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43712496e1517-wk-Fact-5EA5FA662B4B55B598D62154953933DD" name="pfe:BusinessCombinationAcquisitionRelatedCostsTransactionCosts" contextRef="FD2016Q3QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">54</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43712496e1536-wk-Fact-ED45326FD065577BB318715037A629A6" name="pfe:BusinessCombinationAcquisitionRelatedCostsTransactionCosts" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43712496e1556-wk-Fact-C44B0511B35651E0887481BA20948E7C" name="pfe:BusinessCombinationAcquisitionRelatedCostsTransactionCosts" contextRef="FD2016Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">114</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Integration costs</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(d)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43712496e1583-wk-Fact-3B1D1CAB9A6C50A0AFB2D0D10CB345EC" name="us-gaap:BusinessCombinationIntegrationRelatedCosts" contextRef="FD2017Q3QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">73</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43712496e1602-wk-Fact-9DB7D15107575A4E87DEBC34B67A7866" name="us-gaap:BusinessCombinationIntegrationRelatedCosts" contextRef="FD2016Q3QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">74</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43712496e1621-wk-Fact-309464A163D5551F8E0560FD895331BC" name="us-gaap:BusinessCombinationIntegrationRelatedCosts" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">224</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43712496e1641-wk-Fact-A94165CF2AD857B7B67158131637F55C" name="us-gaap:BusinessCombinationIntegrationRelatedCosts" contextRef="FD2016Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">300</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:36px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Restructuring charges and certain acquisition-related costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43712496e1666-wk-Fact-B73545D07B565820AFF53EEAE1860800" name="pfe:RestructuringChargesAndAcquisitionRelatedCosts" contextRef="FD2017Q3QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">149</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43712496e1685-wk-Fact-110B8A55AF7C5BFEAC9F11433EB9280B" name="pfe:RestructuringChargesAndAcquisitionRelatedCosts" contextRef="FD2016Q3QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">531</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43712496e1704-wk-Fact-F3D7E2873AD65FA18989892A60F6626A" name="pfe:RestructuringChargesAndAcquisitionRelatedCosts" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">377</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43712496e1724-wk-Fact-5FBAE33C336F53F48E8FF7CDE77BBB26" name="pfe:RestructuringChargesAndAcquisitionRelatedCosts" contextRef="FD2016Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">988</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Additional depreciation&#8211;&#8211;asset restructuring</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#160;</sup></span><span style="font-family:inherit;font-size:10pt;">recorded in our condensed consolidated statements of income as follows</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(e)</sup></span><span style="font-family:inherit;font-size:10pt;">:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Cost of sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43712496e1841-wk-Fact-4DC7F6E7ED055FD8910B97A13EEF264E" name="us-gaap:RestructuringReserveAcceleratedDepreciation" contextRef="FD2017Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">39</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43712496e1860-wk-Fact-FA60C203F66751A591C313394A513BBD" name="us-gaap:RestructuringReserveAcceleratedDepreciation" contextRef="FD2016Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">46</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43712496e1879-wk-Fact-90E6722B594454179E2707D4EF701095" name="us-gaap:RestructuringReserveAcceleratedDepreciation" contextRef="FD2017Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">74</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43712496e1899-wk-Fact-B97AEA2C854B5AABB4BE5CE4AE4372B1" name="us-gaap:RestructuringReserveAcceleratedDepreciation" contextRef="FD2016Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">145</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Research and development expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43712496e1924-wk-Fact-B30550C60EA75004A2CBFC5FF95F87DF" name="us-gaap:RestructuringReserveAcceleratedDepreciation" contextRef="FD2017Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43712496e1943-wk-Fact-2287BD2729395E10AA7149FD8CDD1C22" name="us-gaap:RestructuringReserveAcceleratedDepreciation" contextRef="FD2016Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43712496e1962-wk-Fact-A8F5B5BE613E55E4B3F2C69F2B5B38E3" name="us-gaap:RestructuringReserveAcceleratedDepreciation" contextRef="FD2017Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43712496e1982-wk-Fact-B4ED4EC770E85596B83EF4F1E598DF88" name="us-gaap:RestructuringReserveAcceleratedDepreciation" contextRef="FD2016Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total additional depreciation&#8211;&#8211;asset restructuring</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43712496e2007-wk-Fact-A453B8F62ABE5E21AF62323699CCC8B0" name="us-gaap:RestructuringReserveAcceleratedDepreciation" contextRef="FD2017Q3QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">39</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43712496e2026-wk-Fact-E6F32BC6EC2E5D5AB12A3A9ECA0A4CEF" name="us-gaap:RestructuringReserveAcceleratedDepreciation" contextRef="FD2016Q3QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">47</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43712496e2045-wk-Fact-CE9A93EF950C573BB8A81EBFDFFAF1D6" name="us-gaap:RestructuringReserveAcceleratedDepreciation" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">74</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43712496e2065-wk-Fact-300D4D3DDB1355E8938FDCD261A66E64" name="us-gaap:RestructuringReserveAcceleratedDepreciation" contextRef="FD2016Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">151</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Implementation costs recorded in our condensed consolidated statements of income as follows</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(f)</sup></span><span style="font-family:inherit;font-size:10pt;">:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Cost of sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43712496e2177-wk-Fact-93040E88DF5D56A99DAE7E4CE1BBE9F2" name="pfe:ImplementationCosts" contextRef="FD2017Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">26</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43712496e2196-wk-Fact-C2FE704D6A285AB89F6177A77115F69D" name="pfe:ImplementationCosts" contextRef="FD2016Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">46</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43712496e2215-wk-Fact-8A4AB1B8685C5997998FB7F7C5FFCE5D" name="pfe:ImplementationCosts" contextRef="FD2017Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">77</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43712496e2235-wk-Fact-4DCE62D0C18E5CD6957CFB6E8F495684" name="pfe:ImplementationCosts" contextRef="FD2016Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">127</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Selling, informational and administrative expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43712496e2260-wk-Fact-1D412AB78B1D52DEAA171F130190DA4E" name="pfe:ImplementationCosts" contextRef="FD2017Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">22</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43712496e2279-wk-Fact-F1C2E56FFF6857968C5DF6D28AD574C9" name="pfe:ImplementationCosts" contextRef="FD2016Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">23</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43712496e2298-wk-Fact-6B7573DC24D452F9A1161BC5959839D3" name="pfe:ImplementationCosts" contextRef="FD2017Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">46</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43712496e2318-wk-Fact-91C0C255B43A5416B3C5C28C3BD45315" name="pfe:ImplementationCosts" contextRef="FD2016Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">56</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Research and development expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43712496e2343-wk-Fact-E0337FF965B85F19893F5C95D32AAD5B" name="pfe:ImplementationCosts" contextRef="FD2017Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43712496e2362-wk-Fact-5F3BEDE745975795948CDC9485283B89" name="pfe:ImplementationCosts" contextRef="FD2016Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43712496e2381-wk-Fact-083D0D52D0F352EBA5B14A872E1DE0C8" name="pfe:ImplementationCosts" contextRef="FD2017Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">26</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43712496e2401-wk-Fact-EADD6730C9975145BE6C22C98A531D3E" name="pfe:ImplementationCosts" contextRef="FD2016Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">17</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43712496e2426-wk-Fact-73777733794C543CA62126B6042D00DB" name="pfe:ImplementationCosts" contextRef="FD2017Q3QTD_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeExpenseMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43712496e2445-wk-Fact-466AE7233A2D57E48E9D5268F9EEEBF0" name="pfe:ImplementationCosts" contextRef="FD2016Q3QTD_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeExpenseMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43712496e2464-wk-Fact-66E019D2BC3C5C3C98FDC370D9EE61F3" name="pfe:ImplementationCosts" contextRef="FD2017Q3YTD_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeExpenseMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43712496e2484-wk-Fact-5EA1B375EFA75241A699CD076C5A9E06" name="pfe:ImplementationCosts" contextRef="FD2016Q3YTD_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeExpenseMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total implementation costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43712496e2509-wk-Fact-2F901B411CA0586B801E2011D88D1ACA" name="pfe:ImplementationCosts" contextRef="FD2017Q3QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">57</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43712496e2528-wk-Fact-2E0D7E0341AF521EB10E77F7AB951A30" name="pfe:ImplementationCosts" contextRef="FD2016Q3QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">78</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43712496e2547-wk-Fact-CE0D12184A835989A295DE71DFF72EF8" name="pfe:ImplementationCosts" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">150</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43712496e2567-wk-Fact-E6280093B5CF57199192AD6A1C984105" name="pfe:ImplementationCosts" contextRef="FD2016Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">202</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total costs associated with acquisitions and cost-reduction/productivity initiatives</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43712496e2597-wk-Fact-92DAC8013B8C556790B4A17D538A564B" name="pfe:RestructuringChargesAcquisitionRelatedCostsandImplementationCosts" contextRef="FD2017Q3QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">245</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43712496e2616-wk-Fact-7CECCC8EC894510AB4D2C56B832BE7E6" name="pfe:RestructuringChargesAcquisitionRelatedCostsandImplementationCosts" contextRef="FD2016Q3QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">655</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43712496e2636-wk-Fact-8E185443D65254359F4DF6FCBC0332AD" name="pfe:RestructuringChargesAcquisitionRelatedCostsandImplementationCosts" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">601</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43712496e2655-wk-Fact-FB4F3567F2715719817872203ABF0B67" name="pfe:RestructuringChargesAcquisitionRelatedCostsandImplementationCosts" contextRef="FD2016Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,341</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></ix:nonNumeric></div><ix:continuation id="TextSelection-257BED4D93EB563FAF639E7FF8921EF6-1" continuedAt="TextSelection-257BED4D93EB563FAF639E7FF8921EF6-2"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><ix:footnote id="TextSelection-B57619F44FCF544D96067CF4816A9082-0-wk-Footnote-B57619F44FCF544D96067CF4816A9082_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" continuedAt="TextSelection-B57619F44FCF544D96067CF4816A9082-1">In the </ix:footnote></span><ix:continuation id="TextSelection-B57619F44FCF544D96067CF4816A9082-1" continuedAt="TextSelection-B57619F44FCF544D96067CF4816A9082-2"><span style="font-family:inherit;font-size:9pt;">third quarter</span><span style="font-family:inherit;font-size:9pt;"> and </span><span style="font-family:inherit;font-size:9pt;">first nine months of</span><span style="font-family:inherit;font-size:9pt;"> </span><span style="font-family:inherit;font-size:9pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:9pt;">, restructuring charges are primarily associated with our acquisitions of Hospira and Medivation, as well as cost-reduction and productivity initiatives not associated with acquisitions. In the </span><span style="font-family:inherit;font-size:9pt;">third quarter</span><span style="font-family:inherit;font-size:9pt;"> and </span><span style="font-family:inherit;font-size:9pt;">first nine months of</span><span style="font-family:inherit;font-size:9pt;"> </span><span style="font-family:inherit;font-size:9pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:9pt;">, restructuring charges are largely associated with cost-reduction and productivity initiatives not associated with acquisitions, as well as our acquisitions of Hospira and Medivation. In the third quarter and first </span><span style="font-family:inherit;font-size:9pt;">nine</span><span style="font-family:inherit;font-size:9pt;"> months ended </span><span style="font-family:inherit;font-size:9pt;">October&#160;1, 2017</span><span style="font-family:inherit;font-size:9pt;">, </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Employee terminations</span><span style="font-family:inherit;font-size:9pt;"> primarily include revisions of our estimates of severance benefits. Employee termination costs are generally recorded when the actions are probable and estimable and include accrued severance benefits, pension and postretirement benefits, many of which may be paid out during periods after termination.</span></ix:continuation></div></td></tr></table><ix:continuation id="TextSelection-B57619F44FCF544D96067CF4816A9082-2" continuedAt="TextSelection-B57619F44FCF544D96067CF4816A9082-3"><div style="line-height:120%;padding-top:4px;padding-left:24px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">The restructuring activities for </span><span style="font-family:inherit;font-size:9pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:9pt;"> are associated with the following:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:12px;"><span style="font-family:inherit;font-size:9pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">For the </span><span style="font-family:inherit;font-size:9pt;">third quarter</span><span style="font-family:inherit;font-size:9pt;"> of </span><span style="font-family:inherit;font-size:9pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:9pt;">, IH (</span><span style="font-family:inherit;font-size:9pt;"><span>$<ix:nonFraction id="d43712496e2737-wk-Fact-66B95E1A6D7B599799C4A84EB9110D19" name="us-gaap:RestructuringCharges" contextRef="FD2017Q3QTD_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:9pt;">); EH (</span><span style="font-family:inherit;font-size:9pt;"><span>$<ix:nonFraction id="d43712496e2741-wk-Fact-5A0E5A3357A95DB4B2FD2A6FDF59334A" name="us-gaap:RestructuringCharges" contextRef="FD2017Q3QTD_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:9pt;">); WRD/GPD (</span><span style="font-family:inherit;font-size:9pt;"><span>$<ix:nonFraction id="d43712496e2745-wk-Fact-B782EBE01C7659F081B7CA147E96F107" name="us-gaap:RestructuringCharges" contextRef="FD2017Q3QTD_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_us-gaap_SubsegmentsAxis_pfe_WorldwideResearchandDevelopmentandGlobalProductDevelopmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">15</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:9pt;">); manufacturing operations (</span><span style="font-family:inherit;font-size:9pt;"><span>$<ix:nonFraction id="d43712496e2750-wk-Fact-6A98F19D2E4051A39A53CE6AAF3875FA" name="us-gaap:RestructuringCharges" contextRef="FD2017Q3QTD_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_us-gaap_SubsegmentsAxis_pfe_ManufacturingOperationsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">47</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:9pt;">); and Corporate (</span><span style="font-family:inherit;font-size:9pt;"><span>$<ix:nonFraction id="d43712496e2754-wk-Fact-04706406A17B5F69814D3B93EE94C5D6" name="us-gaap:RestructuringCharges" contextRef="FD2017Q3QTD_us-gaap_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">25</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:9pt;">).</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:12px;"><span style="font-family:inherit;font-size:9pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">For the </span><span style="font-family:inherit;font-size:9pt;">first nine months of</span><span style="font-family:inherit;font-size:9pt;"> </span><span style="font-family:inherit;font-size:9pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:9pt;">, IH (</span><span style="font-family:inherit;font-size:9pt;"><span>$<ix:nonFraction id="d43712496e2773-wk-Fact-B291069689DF5433B74923044CD3EE55" name="us-gaap:RestructuringCharges" contextRef="FD2017Q3YTD_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">10</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:9pt;">); EH (</span><span style="font-family:inherit;font-size:9pt;"><span>$<ix:nonFraction id="d43712496e2777-wk-Fact-EFE605EAE655557BA8F4271E31854382" name="us-gaap:RestructuringCharges" contextRef="FD2017Q3YTD_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">9</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:9pt;"> income); WRD/GPD (</span><span style="font-family:inherit;font-size:9pt;"><span>$<ix:nonFraction id="d43712496e2781-wk-Fact-B706C7115BAD564CA000F2546D6F7E7E" name="us-gaap:RestructuringCharges" contextRef="FD2017Q3YTD_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_us-gaap_SubsegmentsAxis_pfe_WorldwideResearchandDevelopmentandGlobalProductDevelopmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">29</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:9pt;">); manufacturing operations (</span><span style="font-family:inherit;font-size:9pt;"><span>$<ix:nonFraction id="d43712496e2786-wk-Fact-7C9AE0C695D15F888B7BE9D8D97A7118" name="us-gaap:RestructuringCharges" contextRef="FD2017Q3YTD_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_us-gaap_SubsegmentsAxis_pfe_ManufacturingOperationsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">70</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:9pt;">); and Corporate (</span><span style="font-family:inherit;font-size:9pt;"><span>$<ix:nonFraction id="d43712496e2790-wk-Fact-64F34CC93DDC542DA48141B016E34A41" name="us-gaap:RestructuringCharges" contextRef="FD2017Q3YTD_us-gaap_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">51</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:9pt;">).</span></div></td></tr></table><div style="line-height:120%;padding-top:4px;text-align:left;padding-left:24px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">The restructuring activities for </span><span style="font-family:inherit;font-size:9pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:9pt;"> are associated with the following:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:12px;"><span style="font-family:inherit;font-size:9pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">For the </span><span style="font-family:inherit;font-size:9pt;">third quarter</span><span style="font-family:inherit;font-size:9pt;"> of </span><span style="font-family:inherit;font-size:9pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:9pt;">, IH (</span><span style="font-family:inherit;font-size:9pt;"><span>$<ix:nonFraction id="d43712496e2817-wk-Fact-1322E18998D05D589F0B8442817BA831" name="us-gaap:RestructuringCharges" contextRef="FD2016Q3QTD_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">148</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:9pt;">); EH (</span><span style="font-family:inherit;font-size:9pt;"><span>$<ix:nonFraction id="d43712496e2821-wk-Fact-1239F4C8E82550F1B133AC9C07C7D4DE" name="us-gaap:RestructuringCharges" contextRef="FD2016Q3QTD_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">28</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:9pt;">); WRD/GPD (</span><span style="font-family:inherit;font-size:9pt;"><span>$<ix:nonFraction id="d43712496e2825-wk-Fact-A51B360ED17555C7AB63195A3314FF36" name="us-gaap:RestructuringCharges" contextRef="FD2016Q3QTD_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_us-gaap_SubsegmentsAxis_pfe_WorldwideResearchandDevelopmentandGlobalProductDevelopmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">52</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:9pt;">); manufacturing operations (</span><span style="font-family:inherit;font-size:9pt;"><span>$<ix:nonFraction id="d43712496e2830-wk-Fact-27E8D93198C95467A56674B994E4A8C3" name="us-gaap:RestructuringCharges" contextRef="FD2016Q3QTD_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_us-gaap_SubsegmentsAxis_pfe_ManufacturingOperationsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">108</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:9pt;">); and Corporate (</span><span style="font-family:inherit;font-size:9pt;"><span>$<ix:nonFraction id="d43712496e2834-wk-Fact-47F671A9BF6B5E0381241BBFBE7146B2" name="us-gaap:RestructuringCharges" contextRef="FD2016Q3QTD_us-gaap_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">67</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:9pt;">).</span></div></td></tr></table></ix:continuation><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><ix:continuation id="TextSelection-B57619F44FCF544D96067CF4816A9082-3" continuedAt="TextSelection-B57619F44FCF544D96067CF4816A9082-4"><div style="line-height:120%;font-size:9pt;padding-left:12px;"><span style="font-family:inherit;font-size:9pt;">&#8226;</span></div></ix:continuation></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9pt;"><ix:continuation id="TextSelection-B57619F44FCF544D96067CF4816A9082-4" continuedAt="TextSelection-B57619F44FCF544D96067CF4816A9082-5"><span style="font-family:inherit;font-size:9pt;">For the </span><span style="font-family:inherit;font-size:9pt;">first nine months of</span><span style="font-family:inherit;font-size:9pt;"> </span><span style="font-family:inherit;font-size:9pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:9pt;">, IH (</span><span style="font-family:inherit;font-size:9pt;"><span>$<ix:nonFraction id="d43712496e2858-wk-Fact-CFCB464692345B42BEEB0DF525BA5F59" name="us-gaap:RestructuringCharges" contextRef="FD2016Q3YTD_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">162</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:9pt;">); EH (</span><span style="font-family:inherit;font-size:9pt;"><span>$<ix:nonFraction id="d43712496e2862-wk-Fact-3CF994FD24A55EA68571449794C7E0C6" name="us-gaap:RestructuringCharges" contextRef="FD2016Q3YTD_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">19</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:9pt;">); WRD/GPD (</span><span style="font-family:inherit;font-size:9pt;"><span>$<ix:nonFraction id="d43712496e2866-wk-Fact-A6F759F161E6564FB7A0CAD14447043E" name="us-gaap:RestructuringCharges" contextRef="FD2016Q3YTD_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_us-gaap_SubsegmentsAxis_pfe_WorldwideResearchandDevelopmentandGlobalProductDevelopmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">104</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:9pt;">); manufacturing operations (</span><span style="font-family:inherit;font-size:9pt;"><span>$<ix:nonFraction id="d43712496e2871-wk-Fact-8F5857168E9254F7AD67D9E467C9964C" name="us-gaap:RestructuringCharges" contextRef="FD2016Q3YTD_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_us-gaap_SubsegmentsAxis_pfe_ManufacturingOperationsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">181</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:9pt;">); and Corporate (</span><span style="font-family:inherit;font-size:9pt;"><span>$<ix:nonFraction id="d43712496e2875-wk-Fact-6112838DAC895E1FB980F1B2C5F1C930" name="us-gaap:RestructuringCharges" contextRef="FD2016Q3YTD_us-gaap_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">107</ix:nonFraction> million</span></span></ix:continuation><span style="font-family:inherit;font-size:9pt;"><ix:continuation id="TextSelection-B57619F44FCF544D96067CF4816A9082-5">).</ix:continuation></span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><ix:footnote id="TextSelection-1B1FEAD5EA4E576891141CE7B2D9386E-0-wk-Footnote-1B1FEAD5EA4E576891141CE7B2D9386E_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" continuedAt="TextSelection-1B1FEAD5EA4E576891141CE7B2D9386E-1">The asset impairment charges for the </ix:footnote></span><ix:continuation id="TextSelection-1B1FEAD5EA4E576891141CE7B2D9386E-1" continuedAt="TextSelection-1B1FEAD5EA4E576891141CE7B2D9386E-2"><span style="font-family:inherit;font-size:9pt;">third</span><span style="font-family:inherit;font-size:9pt;"> quarter and the </span><span style="font-family:inherit;font-size:9pt;">first nine months of</span><span style="font-family:inherit;font-size:9pt;"> </span><span style="font-family:inherit;font-size:9pt;text-align:center;">2017</span></ix:continuation><span style="font-family:inherit;font-size:9pt;"><ix:continuation id="TextSelection-1B1FEAD5EA4E576891141CE7B2D9386E-2"> are largely associated with our acquisitions of Hospira and Medivation.</ix:continuation></span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(c)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><ix:footnote id="TextSelection-6912797A078E5D59B618DFFBB81C1BB6-0-wk-Footnote-6912797A078E5D59B618DFFBB81C1BB6_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" continuedAt="TextSelection-6912797A078E5D59B618DFFBB81C1BB6-1">Transaction costs represent external costs for banking, legal, accounting and other similar services, which in the </ix:footnote></span><ix:continuation id="TextSelection-6912797A078E5D59B618DFFBB81C1BB6-1" continuedAt="TextSelection-6912797A078E5D59B618DFFBB81C1BB6-2"><span style="font-family:inherit;font-size:9pt;">third quarter</span><span style="font-family:inherit;font-size:9pt;"> of 2017 reflect the reversal of an accrual related to the acquisition of Medivation. Transaction costs for the </span><span style="font-family:inherit;font-size:9pt;">first nine months of</span><span style="font-family:inherit;font-size:9pt;"> </span><span style="font-family:inherit;font-size:9pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:9pt;"> are directly related to our acquisitions of Hospira, Anacor and Medivation. Transaction costs in the </span><span style="font-family:inherit;font-size:9pt;">third quarter</span><span style="font-family:inherit;font-size:9pt;"> of </span><span style="font-family:inherit;font-size:9pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:9pt;"> were mostly related to the Medivation acquisition, and in the </span><span style="font-family:inherit;font-size:9pt;">first nine months of</span><span style="font-family:inherit;font-size:9pt;"> </span><span style="font-family:inherit;font-size:9pt;text-align:center;">2016</span></ix:continuation><span style="font-family:inherit;font-size:9pt;"><ix:continuation id="TextSelection-6912797A078E5D59B618DFFBB81C1BB6-2">, were mostly related to the Medivation and Anacor acquisitions, and our terminated transaction with Allergan.</ix:continuation></span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(d)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><ix:footnote id="TextSelection-C882D128F7C35640B8C0E15448983D9E-0-wk-Footnote-C882D128F7C35640B8C0E15448983D9E_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" continuedAt="TextSelection-C882D128F7C35640B8C0E15448983D9E-1">Integration costs represent external, incremental costs directly related to integrating acquired businesses, and primarily include expenditures for consulting and the integration of systems and processes. In the </ix:footnote></span><ix:continuation id="TextSelection-C882D128F7C35640B8C0E15448983D9E-1" continuedAt="TextSelection-C882D128F7C35640B8C0E15448983D9E-2"><span style="font-family:inherit;font-size:9pt;">third</span><span style="font-family:inherit;font-size:9pt;"> quarter and </span><span style="font-family:inherit;font-size:9pt;">first nine months of</span><span style="font-family:inherit;font-size:9pt;"> </span><span style="font-family:inherit;font-size:9pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:9pt;">, integration costs primarily relate to our acquisitions of Hospira and Medivation. The </span><span style="font-family:inherit;font-size:9pt;">first nine months of</span><span style="font-family:inherit;font-size:9pt;"> </span><span style="font-family:inherit;font-size:9pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:9pt;"> also include a net gain of </span><span style="font-family:inherit;font-size:9pt;"><span>$<ix:nonFraction id="d43712496e2982-wk-Fact-D2D1CF92DB215E23CC515B653B45E8EE" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" contextRef="FD2017Q3YTD_us-gaap_BusinessAcquisitionAxis_pfe_HospiraMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">12</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:9pt;"> related to the settlement of the Hospira U.S. qualified defined benefit pension plan (see </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Note 10</span><span style="font-family:inherit;font-size:9pt;">). In the </span><span style="font-family:inherit;font-size:9pt;">third quarter</span><span style="font-family:inherit;font-size:9pt;"> of </span><span style="font-family:inherit;font-size:9pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:9pt;">, integration </span></ix:continuation></div></td></tr></table></ix:continuation></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">15</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:center;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(UNAUDITED)</span></div></div><div><br/></div><ix:continuation id="TextSelection-618AF0F88D785702B89176A8C50F5054-4" continuedAt="TextSelection-618AF0F88D785702B89176A8C50F5054-5"><ix:continuation id="TextSelection-257BED4D93EB563FAF639E7FF8921EF6-2" continuedAt="TextSelection-257BED4D93EB563FAF639E7FF8921EF6-3"><div style="line-height:120%;padding-left:12px;text-align:left;"><ix:continuation id="TextSelection-C882D128F7C35640B8C0E15448983D9E-2" continuedAt="TextSelection-C882D128F7C35640B8C0E15448983D9E-3"><span style="font-family:inherit;font-size:9pt;">costs were mostly related to our acquisition of Hospira, and in the </span><span style="font-family:inherit;font-size:9pt;">first nine months of</span><span style="font-family:inherit;font-size:9pt;"> </span><span style="font-family:inherit;font-size:9pt;text-align:center;">2016</span></ix:continuation><span style="font-family:inherit;font-size:9pt;"><ix:continuation id="TextSelection-C882D128F7C35640B8C0E15448983D9E-3">, integration costs were mostly related to our acquisition of Hospira and our terminated transaction with Allergan.</ix:continuation></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(e)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><ix:footnote id="TextSelection-7160FF67E87550A19177FE255A41A2D7-0-wk-Footnote-7160FF67E87550A19177FE255A41A2D7_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US">Additional depreciation&#8211;&#8211;asset restructuring represents the impact of changes in the estimated useful lives of assets involved in restructuring actions.</ix:footnote></span></div></td></tr></table></ix:continuation><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><ix:continuation id="TextSelection-257BED4D93EB563FAF639E7FF8921EF6-3" continuedAt="TextSelection-257BED4D93EB563FAF639E7FF8921EF6-4"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(f)</sup>&#160;</span></div></ix:continuation></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><ix:continuation id="TextSelection-257BED4D93EB563FAF639E7FF8921EF6-4"><ix:footnote id="TextSelection-C37CD88178CA35C475D25A62F2B54FED-0-wk-Footnote-C37CD88178CA35C475D25A62F2B54FED_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US">Implementation costs represent external, incremental costs directly related to implementing our non-acquisition-related cost-reduction/productivity initiatives.</ix:footnote></ix:continuation></span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><ix:nonNumeric contextRef="FD2017Q3YTD" name="us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock" id="TextSelection-C02E54F660E853B6825EE03D4882D043-0-wk-Fact-1B0704622B8656D297CF2DFF4C48C616" continuedAt="TextSelection-C02E54F660E853B6825EE03D4882D043-1" escape="true"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.05068226120858%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"></td></tr><tr><td style="width:41%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td colspan="17" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides the components of and changes in our restructuring accruals:</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Employee</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Termination Costs</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Asset</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Impairment Charges</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exit Costs</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrual</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance, December 31, 2016</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43712496e3283-wk-Fact-45F6314CE80C59AC9D1C31C3E15AFBD8" name="us-gaap:RestructuringReserve" contextRef="FI2016Q4_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,547</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43712496e3302-wk-Fact-CA0E038FD7FB54A5AFFBA924D7EA3A6D" name="us-gaap:RestructuringReserve" contextRef="FI2016Q4_us-gaap_RestructuringCostAndReserveAxis_pfe_AssetImpairmentsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43712496e3322-wk-Fact-B933A905F21B5DBCAF9108FCBC88194E" name="us-gaap:RestructuringReserve" contextRef="FI2016Q4_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OtherRestructuringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">36</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43712496e3341-wk-Fact-5E7B2FD2D8475DEA875CCD41E3E715EF" name="us-gaap:RestructuringReserve" contextRef="FI2016Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,583</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Provision</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43712496e3361-wk-Fact-E2B8E755EC4E512694F08689178F25FB" name="us-gaap:RestructuringCharges" contextRef="FD2017Q3YTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43712496e3380-wk-Fact-CFEA8FFE79D85111A3CD5895E62603FD" name="us-gaap:RestructuringCharges" contextRef="FD2017Q3YTD_us-gaap_RestructuringCostAndReserveAxis_pfe_AssetImpairmentsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">126</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43712496e3399-wk-Fact-C4388648F0E6529DA69A86993AA93AE7" name="us-gaap:RestructuringCharges" contextRef="FD2017Q3YTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OtherRestructuringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">16</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43712496e3419-wk-Fact-9947697CFC005CC4B553C619A29CF327" name="us-gaap:RestructuringCharges" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">150</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Utilization and other</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d43712496e3446-wk-Fact-D319BAF88B8B545CA48395F0788E8501" name="pfe:PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment" contextRef="FD2017Q3YTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">401</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d43712496e3466-wk-Fact-8F95E4DDAC9B520C8A1E53E1D2C8CC7B" name="pfe:PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment" contextRef="FD2017Q3YTD_us-gaap_RestructuringCostAndReserveAxis_pfe_AssetImpairmentsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">126</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d43712496e3486-wk-Fact-94001D1F99AF509E84946618AAA5FC87" name="pfe:PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment" contextRef="FD2017Q3YTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OtherRestructuringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">24</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d43712496e3507-wk-Fact-1AB7DD0AE8235344A53584C522F56843" name="pfe:PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">551</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance, October 1, 2017</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(c)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43712496e3540-wk-Fact-477878BBEDE5542C9F9E88C10D02CABE" name="us-gaap:RestructuringReserve" contextRef="FI2017Q3_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,154</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43712496e3559-wk-Fact-E88E61DCD79054CAB129EA8C07D5A4E5" name="us-gaap:RestructuringReserve" contextRef="FI2017Q3_us-gaap_RestructuringCostAndReserveAxis_pfe_AssetImpairmentsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43712496e3579-wk-Fact-AA3098CB34F551A2922049EA2BBBF5A3" name="us-gaap:RestructuringReserve" contextRef="FI2017Q3_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OtherRestructuringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">28</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43712496e3598-wk-Fact-DFB58A1FD36B53C88918A31FB32F3CE9" name="us-gaap:RestructuringReserve" contextRef="FI2017Q3" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,182</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></ix:nonNumeric></div><ix:continuation id="TextSelection-C02E54F660E853B6825EE03D4882D043-1" continuedAt="TextSelection-C02E54F660E853B6825EE03D4882D043-2"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><ix:footnote id="TextSelection-02609C62928C5D1CBFB6DD071D9D7B0E-0-wk-Footnote-02609C62928C5D1CBFB6DD071D9D7B0E_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" continuedAt="TextSelection-02609C62928C5D1CBFB6DD071D9D7B0E-1">Included in </ix:footnote></span><ix:continuation id="TextSelection-02609C62928C5D1CBFB6DD071D9D7B0E-1" continuedAt="TextSelection-02609C62928C5D1CBFB6DD071D9D7B0E-2"><span style="font-family:inherit;font-size:9pt;font-style:italic;">Other current liabilities</span><span style="font-family:inherit;font-size:9pt;"> (</span><span style="font-family:inherit;font-size:9pt;"><span>$<ix:nonFraction id="d43712496e3632-wk-Fact-390AAFCB20395D8BB52C559F36D58DEA" name="us-gaap:RestructuringReserve" contextRef="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">863</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:9pt;">) and </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Other noncurrent liabilities</span><span style="font-family:inherit;font-size:9pt;"> (</span><span style="font-family:inherit;font-size:9pt;"><span>$<ix:nonFraction id="d43712496e3640-wk-Fact-8CD99659D08F5B5C8736AD83CC9D34B9" name="us-gaap:RestructuringReserve" contextRef="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">720</ix:nonFraction> million</span></span></ix:continuation><span style="font-family:inherit;font-size:9pt;"><ix:continuation id="TextSelection-02609C62928C5D1CBFB6DD071D9D7B0E-2">).</ix:continuation></span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><ix:footnote id="TextSelection-04B3DB4115835E2FBB99EA13FC1FD64B-0-wk-Footnote-04B3DB4115835E2FBB99EA13FC1FD64B_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US">Includes adjustments for foreign currency translation.</ix:footnote></span></div></td></tr></table></ix:continuation></ix:continuation><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><ix:continuation id="TextSelection-C02E54F660E853B6825EE03D4882D043-2" continuedAt="TextSelection-C02E54F660E853B6825EE03D4882D043-3"><ix:continuation id="TextSelection-618AF0F88D785702B89176A8C50F5054-5" continuedAt="TextSelection-618AF0F88D785702B89176A8C50F5054-6"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(c)</sup>&#160;</span></div></ix:continuation></ix:continuation></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9pt;"><ix:continuation id="TextSelection-C02E54F660E853B6825EE03D4882D043-3" continuedAt="TextSelection-C02E54F660E853B6825EE03D4882D043-4"><ix:continuation id="TextSelection-618AF0F88D785702B89176A8C50F5054-6" continuedAt="TextSelection-618AF0F88D785702B89176A8C50F5054-7"><span style="font-family:inherit;font-size:9pt;"><ix:footnote id="TextSelection-3E9076747FF25E3B8D3B9AAF71548F16-0-wk-Footnote-3E9076747FF25E3B8D3B9AAF71548F16_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" continuedAt="TextSelection-3E9076747FF25E3B8D3B9AAF71548F16-1">Included in </ix:footnote></span><ix:continuation id="TextSelection-3E9076747FF25E3B8D3B9AAF71548F16-1" continuedAt="TextSelection-3E9076747FF25E3B8D3B9AAF71548F16-2"><span style="font-family:inherit;font-size:9pt;font-style:italic;">Other current liabilities </span><span style="font-family:inherit;font-size:9pt;">(</span><span style="font-family:inherit;font-size:9pt;"><span>$<ix:nonFraction id="d43712496e3696-wk-Fact-BC33EB2BDFDA5634AC2BD66608C560BF" name="us-gaap:RestructuringReserve" contextRef="FI2017Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">533</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:9pt;">) and </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Other noncurrent liabilities </span><span style="font-family:inherit;font-size:9pt;">(</span><span style="font-family:inherit;font-size:9pt;"><span>$<ix:nonFraction id="d43712496e3704-wk-Fact-EFB40B30DEDD59D39687610C2E350851" name="us-gaap:RestructuringReserve" contextRef="FI2017Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">650</ix:nonFraction> million</span></span></ix:continuation></ix:continuation></ix:continuation><span style="font-family:inherit;font-size:9pt;"><ix:continuation id="TextSelection-C02E54F660E853B6825EE03D4882D043-4"><ix:continuation id="TextSelection-618AF0F88D785702B89176A8C50F5054-7"><ix:continuation id="TextSelection-3E9076747FF25E3B8D3B9AAF71548F16-2">).</ix:continuation></ix:continuation></ix:continuation></span></div></td></tr></table><div><a id="s4362FAD4F64C5B1BB3ADA5E1B5FE357D"></a></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Note 4. </span><ix:nonNumeric contextRef="FD2017Q3YTD" name="us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock" id="TextSelection-C533AB02168D52D5BD955FB100D4D7A8-0-wk-Fact-8EE905C2CEF35A019008C9C7BCEB5544" continuedAt="TextSelection-C533AB02168D52D5BD955FB100D4D7A8-1" escape="true"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Other (Income)/Deductions&#8212;Net</span></ix:nonNumeric></div><ix:continuation id="TextSelection-C533AB02168D52D5BD955FB100D4D7A8-1" continuedAt="TextSelection-C533AB02168D52D5BD955FB100D4D7A8-2"><div style="line-height:120%;font-size:10pt;"><ix:nonNumeric contextRef="FD2017Q3YTD" name="us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" id="TextSelection-1D3ED85953925617BCBDD47BED8C2E25-0-wk-Fact-4C516EECB4E65E809D86019A1208131E" continuedAt="TextSelection-1D3ED85953925617BCBDD47BED8C2E25-1" escape="true"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"></td></tr><tr><td style="width:44%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td colspan="17" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides components of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net</span><span style="font-family:inherit;font-size:10pt;">:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nine Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">October&#160;1, <br/>2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">October&#160;2, <br/>2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">October&#160;1, <br/>2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">October&#160;2, <br/>2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest income</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d43697224e944-wk-Fact-74E639AFF5BE5619A8D6D94B13D9C7F4" name="us-gaap:InvestmentIncomeInterest" contextRef="FD2017Q3QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">99</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d43697224e964-wk-Fact-34F816D444055102A29F3BD0BBE0EC9E" name="us-gaap:InvestmentIncomeInterest" contextRef="FD2016Q3QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">123</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d43697224e985-wk-Fact-D20C669A561D58BF9A9C9AC47CBBACC7" name="us-gaap:InvestmentIncomeInterest" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">275</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d43697224e1005-wk-Fact-A5329E1466235B2299472011E1D4E1D3" name="us-gaap:InvestmentIncomeInterest" contextRef="FD2016Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">357</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest expense</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43697224e1028-wk-Fact-143C071DEB4F5718B431ADB619B90A82" name="us-gaap:InterestExpense" contextRef="FD2017Q3QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">320</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43697224e1047-wk-Fact-A15E72E726725EF2BD9FCCCC3A222E16" name="us-gaap:InterestExpense" contextRef="FD2016Q3QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">291</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43697224e1066-wk-Fact-C68BCBB68BF9565C8536418482AA80FC" name="us-gaap:InterestExpense" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">940</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43697224e1086-wk-Fact-38D872801B2E5B2ABE4AE2E3D2CD2C57" name="us-gaap:InterestExpense" contextRef="FD2016Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">889</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net interest expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43697224e1111-wk-Fact-D14F3295B62D504D84DB0D76858E4471" name="us-gaap:InterestRevenueExpenseNet" contextRef="FD2017Q3QTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">220</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43697224e1130-wk-Fact-6E5ABDB000475A2E8AFE3E4F8D393B0C" name="us-gaap:InterestRevenueExpenseNet" contextRef="FD2016Q3QTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">168</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43697224e1149-wk-Fact-EBD7B6F7EC2A575BA2553AE5B835F7B7" name="us-gaap:InterestRevenueExpenseNet" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">666</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43697224e1169-wk-Fact-84432CAA802B54E295166E8D67B869DA" name="us-gaap:InterestRevenueExpenseNet" contextRef="FD2016Q3YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">532</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Royalty-related income</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d43697224e1196-wk-Fact-8C132ED2C80858EDAC92446BF10B1EF2" name="us-gaap:RoyaltyRevenue" contextRef="FD2017Q3QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">140</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d43697224e1216-wk-Fact-5EDED3CDB1965C449739DBF427B7E981" name="us-gaap:RoyaltyRevenue" contextRef="FD2016Q3QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">233</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d43697224e1236-wk-Fact-D7C62060D2E154C4AFD979CF86960190" name="us-gaap:RoyaltyRevenue" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">331</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d43697224e1257-wk-Fact-994608FEC5B95CBF9C3D06616F806463" name="us-gaap:RoyaltyRevenue" contextRef="FD2016Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">695</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certain legal matters, net</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43697224e1285-wk-Fact-A648DF513A135C13B3F96F3C76C2A737" name="us-gaap:GainLossRelatedToLitigationSettlement" contextRef="FD2017Q3QTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">183</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d43697224e1304-wk-Fact-527425D761315660B95CBE4E0343A596" name="us-gaap:GainLossRelatedToLitigationSettlement" contextRef="FD2016Q3QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">40</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43697224e1324-wk-Fact-66565D977AC4509C90AB6F21D06331BE" name="us-gaap:GainLossRelatedToLitigationSettlement" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">194</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43697224e1344-wk-Fact-9B9CE720BFE65909A3F34FE77F5D328D" name="us-gaap:GainLossRelatedToLitigationSettlement" contextRef="FD2016Q3YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">494</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net gains on asset disposals</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(d)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d43697224e1371-wk-Fact-21036AB1E903531C8D597B8E28342703" name="pfe:GainLossOnDispositionOfAssetsAndEquitySecurities" contextRef="FD2017Q3QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">155</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d43697224e1391-wk-Fact-2E6E4BDF4E235E37AD8DFBB014690780" name="pfe:GainLossOnDispositionOfAssetsAndEquitySecurities" contextRef="FD2016Q3QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">47</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d43697224e1411-wk-Fact-E45333DA3C1351558E633F4210434F91" name="pfe:GainLossOnDispositionOfAssetsAndEquitySecurities" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">349</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d43697224e1432-wk-Fact-92A8B07CD3785791B6C291224D7DF376" name="pfe:GainLossOnDispositionOfAssetsAndEquitySecurities" contextRef="FD2016Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">81</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:18px;text-indent:-18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Loss on sale and impairment on remeasurement of HIS net assets</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(e)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d43697224e1460-wk-Fact-4927FC00863B524C890DD332985D1F82" name="us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" contextRef="FD2017Q3QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">12</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43697224e1480-wk-Fact-69F129F21E2851A6981AF851D0C9DC3E" name="us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" contextRef="FD2016Q3QTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1,422</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43697224e1499-wk-Fact-4CD7C8E134F3568695AECCF94C6AF4FD" name="us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">52</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43697224e1519-wk-Fact-E944F13BD8105FBDB6ACB7D264796FD0" name="us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" contextRef="FD2016Q3YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1,422</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certain asset impairments</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(f)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43697224e1546-wk-Fact-5F0338CD4AAEEBC4E9D45A2FEA4E4512" name="us-gaap:AssetImpairmentCharges" contextRef="FD2017Q3QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">130</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43697224e1565-wk-Fact-872E272F8D3F541FBE9D985BACC8A6A2" name="us-gaap:AssetImpairmentCharges" contextRef="FD2016Q3QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">133</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43697224e1584-wk-Fact-53DF84C7A47DE18B0F1C5A2FEA57D70F" name="us-gaap:AssetImpairmentCharges" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">143</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43697224e1604-wk-Fact-A203EA72411358678C6144B3CC9481A2" name="us-gaap:AssetImpairmentCharges" contextRef="FD2016Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,080</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Business and legal entity alignment costs</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(g)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43697224e1632-wk-Fact-B77CD495CEF453F5A40BDFFD319AC5F2" name="pfe:BusinessInfrastructureAlignmentCosts" contextRef="FD2017Q3QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">16</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43697224e1651-wk-Fact-84DD287398AF5474B3AA02B3F4BF9D06" name="pfe:BusinessInfrastructureAlignmentCosts" contextRef="FD2016Q3QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">69</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43697224e1670-wk-Fact-E3EB811EAA2157F1B8A0AC676941AA20" name="pfe:BusinessInfrastructureAlignmentCosts" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">54</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43697224e1690-wk-Fact-A40CCA358E885B1BBACDE3FEAE88386D" name="pfe:BusinessInfrastructureAlignmentCosts" contextRef="FD2016Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">180</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other, net</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(h)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d43697224e1717-wk-Fact-EE1FD7EDFFF655E3BCB6C13905C55C31" name="pfe:OtherNonoperatingIncomeExpenseNet" contextRef="FD2017Q3QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">191</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d43697224e1737-wk-Fact-92DEAC51BE5052E8AC6E2521BB717C22" name="pfe:OtherNonoperatingIncomeExpenseNet" contextRef="FD2016Q3QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">55</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d43697224e1757-wk-Fact-858DAA1BAEC456F597F882E9D0741E7F" name="pfe:OtherNonoperatingIncomeExpenseNet" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">445</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d43697224e1778-wk-Fact-264D8D2580555027A2EF57DE7B0E9E4A" name="pfe:OtherNonoperatingIncomeExpenseNet" contextRef="FD2016Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">117</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43697224e1809-wk-Fact-EEFC92F1B5E55E77955910BC4C0F4CE1" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="FD2017Q3QTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">51</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43697224e1828-wk-Fact-916495EF6D70560FBFED7475E53E1BEA" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="FD2016Q3QTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1,417</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d43697224e1848-wk-Fact-EE9718ED59B15329A11D4FE12F405FEA" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">16</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43697224e1868-wk-Fact-901AC284652F5C9B93B4B3D55F3C6EAE" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="FD2016Q3YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">2,815</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></ix:nonNumeric></div><ix:continuation id="TextSelection-1D3ED85953925617BCBDD47BED8C2E25-1" continuedAt="TextSelection-1D3ED85953925617BCBDD47BED8C2E25-2"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><ix:footnote id="TextSelection-FE5DD06AA8B65777900C47B8AC19C4C6-0-wk-Footnote-FE5DD06AA8B65777900C47B8AC19C4C6_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" continuedAt="TextSelection-FE5DD06AA8B65777900C47B8AC19C4C6-1">Interest income decreased in the </ix:footnote></span><ix:continuation id="TextSelection-FE5DD06AA8B65777900C47B8AC19C4C6-1" continuedAt="TextSelection-FE5DD06AA8B65777900C47B8AC19C4C6-2"><span style="font-family:inherit;font-size:8.5pt;">third</span><span style="font-family:inherit;font-size:8.5pt;"> quarter and </span><span style="font-family:inherit;font-size:8.5pt;">first nine months of</span><span style="font-family:inherit;font-size:8.5pt;"> </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:8.5pt;">, primarily driven by a lower investment balance. Interest expense increased in the </span><span style="font-family:inherit;font-size:8.5pt;">third</span><span style="font-family:inherit;font-size:8.5pt;"> quarter and </span><span style="font-family:inherit;font-size:8.5pt;">first nine months of</span><span style="font-family:inherit;font-size:8.5pt;"> </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:8.5pt;">, </span><span style="font-size:8.5pt;">primarily as a result of higher short-term interest rates, offset, in part, by the retirement of high-coupon debt and the issuance of new low-coupon debt</span></ix:continuation><span style="font-family:inherit;font-size:8.5pt;"><ix:continuation id="TextSelection-FE5DD06AA8B65777900C47B8AC19C4C6-2">.</ix:continuation></span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><ix:footnote id="TextSelection-7679A63ACE625532ADFCC5B97C6C9FC6-0-wk-Footnote-7679A63ACE625532ADFCC5B97C6C9FC6_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" continuedAt="TextSelection-7679A63ACE625532ADFCC5B97C6C9FC6-1">Royalty-related income </ix:footnote></span><ix:continuation id="TextSelection-7679A63ACE625532ADFCC5B97C6C9FC6-1" continuedAt="TextSelection-7679A63ACE625532ADFCC5B97C6C9FC6-2"><span style="font-family:inherit;font-size:8.5pt;">decreased</span><span style="font-family:inherit;font-size:8.5pt;"> in the </span><span style="font-family:inherit;font-size:8.5pt;">third</span><span style="font-family:inherit;font-size:8.5pt;"> quarter and </span><span style="font-family:inherit;font-size:8.5pt;">first nine months of</span><span style="font-family:inherit;font-size:8.5pt;"> </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:8.5pt;">, primarily due to lower royalty income for Enbrel of </span><span style="font-family:inherit;font-size:8.5pt;"><span>$<ix:nonFraction id="d43697224e1960-wk-Fact-DDDA2865DA8E5B27856F2501BDE0E579" name="pfe:DecreaseinRoyaltyRevenue" contextRef="FD2017Q3QTD_us-gaap_ProductOrServiceAxis_pfe_EnbrelMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementCopromotionMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">139</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:8.5pt;"> and </span><span style="font-family:inherit;font-size:8.5pt;"><span>$<ix:nonFraction id="d43697224e1965-wk-Fact-664B8E36A01C508E890ED26FD1160970" name="pfe:DecreaseinRoyaltyRevenue" contextRef="FD2017Q3YTD_us-gaap_ProductOrServiceAxis_pfe_EnbrelMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementCopromotionMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">414</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:8.5pt;">, respectively, resulting from the expiration on October 31, 2016 of the </span><span style="font-family:inherit;font-size:8.5pt;">36</span><span style="font-family:inherit;font-size:8.5pt;">-month royalty period under the collaboration agreement for Enbrel in the U.S. and Canada (the collaboration period under the agreement expired on October 31, 2013), partially offset by the addition of Xtandi royalty-related income of </span><span style="font-family:inherit;font-size:8.5pt;"><span>$<ix:nonFraction id="d43697224e1973-wk-Fact-3E9482897F2659E587019ECDD5CFA627" name="us-gaap:RoyaltyRevenue" contextRef="FD2017Q3QTD_us-gaap_ProductOrServiceAxis_pfe_XtandiMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">73</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:8.5pt;"> and </span><span style="font-family:inherit;font-size:8.5pt;"><span>$<ix:nonFraction id="d43697224e1977-wk-Fact-3594D9BE74BB506C9B63A7F9083C250F" name="us-gaap:RoyaltyRevenue" contextRef="FD2017Q3YTD_us-gaap_ProductOrServiceAxis_pfe_XtandiMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">160</ix:nonFraction> million</span></span></ix:continuation><span style="font-family:inherit;font-size:8.5pt;"><ix:continuation id="TextSelection-7679A63ACE625532ADFCC5B97C6C9FC6-2">, respectively.</ix:continuation> </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(c)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><ix:footnote id="TextSelection-7430C81CDF35536B95DB492D56AB6CFD-0-wk-Footnote-7430C81CDF35536B95DB492D56AB6CFD_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" continuedAt="TextSelection-7430C81CDF35536B95DB492D56AB6CFD-1">In the </ix:footnote></span><ix:continuation id="TextSelection-7430C81CDF35536B95DB492D56AB6CFD-1" continuedAt="TextSelection-7430C81CDF35536B95DB492D56AB6CFD-2"><span style="font-family:inherit;font-size:8.5pt;">third quarter</span><span style="font-family:inherit;font-size:8.5pt;"> and </span><span style="font-family:inherit;font-size:8.5pt;">first nine months of</span><span style="font-family:inherit;font-size:8.5pt;"> </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:8.5pt;">, primarily includes a </span><span style="font-family:inherit;font-size:8.5pt;"><span>$<ix:nonFraction id="d43697224e2004-wk-Fact-CD48A7567A23874149CC5923C0F05394" name="us-gaap:LitigationSettlementExpense" contextRef="FD2017Q3QTD_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_ProductOrServiceAxis_pfe_CelebrexMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">94</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:8.5pt;"> charge to resolve a class action lawsuit filed by direct purchasers relating to Celebrex, which is subject to the negotiation of a final settlement agreement and court approval, and a </span><span style="font-family:inherit;font-size:8.5pt;"><span>$<ix:nonFraction id="d43697224e2008-wk-Fact-3231336CCB0FB42B1C815926376CD5FE" name="us-gaap:LitigationSettlementExpense" contextRef="FD2017Q3QTD_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_LossContingenciesByNatureOfContingencyAxis_pfe_PatentMatterMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">79</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:8.5pt;"> charge to reflect damages awarded by a jury in a patent matter. In the </span><span style="font-family:inherit;font-size:8.5pt;">first nine months of</span><span style="font-family:inherit;font-size:8.5pt;"> </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:8.5pt;">, primarily includes amounts to resolve a Multi-District Litigation relating to Celebrex and Bextra that was pending against the Company in New York federal court for </span><span style="font-family:inherit;font-size:8.5pt;"><span>$<ix:nonFraction id="d43697224e2021-wk-Fact-90148B681841572FA508B7090BDF2831" name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" contextRef="FD2016Q3YTD_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_ProductOrServiceAxis_pfe_CelebrexandBextraMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">486</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:8.5pt;">, partially offset by the reversal of a legal accrual where a loss was no longer deemed probable. In addition, the </span><span style="font-family:inherit;font-size:8.5pt;">first nine months of</span><span style="font-family:inherit;font-size:8.5pt;"> </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">2016</span></ix:continuation><span style="font-family:inherit;font-size:8.5pt;"><ix:continuation id="TextSelection-7430C81CDF35536B95DB492D56AB6CFD-2"> includes a settlement related to a patent matter.</ix:continuation></span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(d)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><ix:footnote id="TextSelection-6E67095C033B51BB9FABBA85E8DC4DFA-0-wk-Footnote-6E67095C033B51BB9FABBA85E8DC4DFA_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" continuedAt="TextSelection-6E67095C033B51BB9FABBA85E8DC4DFA-1">In the </ix:footnote></span><ix:continuation id="TextSelection-6E67095C033B51BB9FABBA85E8DC4DFA-1" continuedAt="TextSelection-6E67095C033B51BB9FABBA85E8DC4DFA-2"><span style="font-family:inherit;font-size:8.5pt;">third</span><span style="font-family:inherit;font-size:8.5pt;"> quarter of </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:8.5pt;">, primarily includes gains on sales/out-licensing of product and compound rights (approximately </span><span style="font-family:inherit;font-size:8.5pt;"><span>$<ix:nonFraction id="d43697224e2066-wk-Fact-27FF63E43EB45961B411225F2EF045B3" name="us-gaap:GainLossOnDispositionOfIntangibleAssets" contextRef="FD2017Q3QTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DistributionRightsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">71</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:8.5pt;">) and gains on sales and redemptions of investments in equity and debt securities (approximately </span><span style="font-family:inherit;font-size:8.5pt;"><span>$<ix:nonFraction id="d43697224e2070-wk-Fact-C4F53EFB305756E29F326D614DED4225" name="us-gaap:GainOnSaleOfInvestments" contextRef="FD2017Q3QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">66</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:8.5pt;">). In the </span><span style="font-family:inherit;font-size:8.5pt;">first nine months of</span><span style="font-family:inherit;font-size:8.5pt;"> </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:8.5pt;">, primarily includes gains on sales and redemptions of investments in equity and debt securities (approximately </span><span style="font-family:inherit;font-size:8.5pt;"><span>$<ix:nonFraction id="d43697224e2087-wk-Fact-9AB5CF5D0B945844958CC736E8E4BBA4" name="us-gaap:GainOnSaleOfInvestments" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">183</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:8.5pt;">), gains on sales/out-licensing of product and compound rights (approximately </span><span style="font-family:inherit;font-size:8.5pt;"><span>$<ix:nonFraction id="d43697224e2091-wk-Fact-F7F8AF6D3AE054A8B25643416253F993" name="us-gaap:GainLossOnDispositionOfIntangibleAssets" contextRef="FD2017Q3YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DistributionRightsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">141</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:8.5pt;">) and a gain on sale of property (approximately </span><span style="font-family:inherit;font-size:8.5pt;"><span>$<ix:nonFraction id="d43697224e2095-wk-Fact-72BA63D2163F5848A6F0FD4B745778C3" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">52</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:8.5pt;">), partially offset by a net loss related to the sale of our </span><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d43697224e2099-wk-Fact-7A20B5BEC3C75D16BFE5A86C05D26ABA" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="I2017Q2Jun30_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_LaboratorioTeutoBrasileroMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">40</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:8.5pt;"> ownership investment in Teuto, including the extinguishment of a put option for the remaining </span><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d43697224e2104-wk-Fact-E514899ACB1955ECA8A28246180FA71D" name="us-gaap:MinorityInterestOwnershipPercentageByParent" contextRef="I2017Q2Jun30_dei_LegalEntityAxis_pfe_LaboratorioTeutoBrasileroMember_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_LaboratorioTeutoBrasileroMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">60</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:8.5pt;"> ownership interest (approximately </span><span style="font-family:inherit;font-size:8.5pt;"><span>$<ix:nonFraction id="d43697224e2108-wk-Fact-3E108918AAAA5512B11A290783D5B15E" name="us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal" contextRef="FD2017Q3YTD_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_LaboratorioTeutoBrasileroMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">30</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:8.5pt;">). In the </span><span style="font-family:inherit;font-size:8.5pt;">first nine months of</span><span style="font-family:inherit;font-size:8.5pt;"> </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:8.5pt;">, includes gains on sales/out-licensing of product and compound rights (approximately </span><span style="font-family:inherit;font-size:8.5pt;"><span>$<ix:nonFraction id="d43697224e2123-wk-Fact-9B06F8DFF7275943B32FBE5BEF80BAD9" name="us-gaap:GainLossOnDispositionOfIntangibleAssets" contextRef="FD2016Q3YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DistributionRightsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">49</ix:nonFraction> million</span></span></ix:continuation><span style="font-family:inherit;font-size:8.5pt;"><ix:continuation id="TextSelection-6E67095C033B51BB9FABBA85E8DC4DFA-2">).</ix:continuation></span></div></td></tr></table></ix:continuation></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">16</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:center;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(UNAUDITED)</span></div></div><div><br/></div><ix:continuation id="TextSelection-C533AB02168D52D5BD955FB100D4D7A8-2" continuedAt="TextSelection-C533AB02168D52D5BD955FB100D4D7A8-3"><ix:continuation id="TextSelection-1D3ED85953925617BCBDD47BED8C2E25-2" continuedAt="TextSelection-1D3ED85953925617BCBDD47BED8C2E25-3"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(e)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><ix:footnote id="TextSelection-FCAEF1B26EF652E4896D2456427B24D7-0-wk-Footnote-FCAEF1B26EF652E4896D2456427B24D7_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" continuedAt="TextSelection-FCAEF1B26EF652E4896D2456427B24D7-1">In the </ix:footnote></span><ix:continuation id="TextSelection-FCAEF1B26EF652E4896D2456427B24D7-1" continuedAt="TextSelection-FCAEF1B26EF652E4896D2456427B24D7-2"><span style="font-family:inherit;font-size:8.5pt;">third</span><span style="font-family:inherit;font-size:8.5pt;"> quarter and </span><span style="font-family:inherit;font-size:8.5pt;">first nine months of</span><span style="font-family:inherit;font-size:8.5pt;"> </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:8.5pt;">, represents adjustments to amounts previously recorded to write down the HIS net assets to fair value less costs to sell related to the sale of HIS net assets to ICU Medical. In the </span><span style="font-family:inherit;font-size:8.5pt;">third</span><span style="font-family:inherit;font-size:8.5pt;"> quarter and </span><span style="font-family:inherit;font-size:8.5pt;">first nine months of</span><span style="font-family:inherit;font-size:8.5pt;"> </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:8.5pt;">, represents a charge related to the write-down of the HIS net assets to fair value less estimated costs to sell.</span></ix:continuation></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt"><ix:continuation id="TextSelection-FCAEF1B26EF652E4896D2456427B24D7-2"></ix:continuation>(f)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><ix:footnote id="TextSelection-8C5E9E30C7EB5291A3E0EE605FC281E8-0-wk-Footnote-8C5E9E30C7EB5291A3E0EE605FC281E8_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" continuedAt="TextSelection-8C5E9E30C7EB5291A3E0EE605FC281E8-1">In the </ix:footnote></span><ix:continuation id="TextSelection-8C5E9E30C7EB5291A3E0EE605FC281E8-1" continuedAt="TextSelection-8C5E9E30C7EB5291A3E0EE605FC281E8-2"><span style="font-family:inherit;font-size:8.5pt;">third quarter</span><span style="font-family:inherit;font-size:8.5pt;"> and </span><span style="font-family:inherit;font-size:8.5pt;">first nine months of</span><span style="font-family:inherit;font-size:8.5pt;"> </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:8.5pt;">, primarily includes an intangible asset impairment charge of </span><span style="font-family:inherit;font-size:8.5pt;"><span>$<ix:nonFraction id="d43697224e2190-wk-Fact-72EE4791596BA158F53D5A37348ABBAB" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="FD2017Q3YTD_us-gaap_BusinessAcquisitionAxis_pfe_HospiraMember_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">127</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:8.5pt;"> related to developed technology rights, acquired in connection with our acquisition of Hospira, for a generic sterile injectable product for the treatment of edema associated with certain conditions. The intangible asset impairment charge for the </span><span style="font-family:inherit;font-size:8.5pt;">third</span><span style="font-family:inherit;font-size:8.5pt;"> quarter and </span><span style="font-family:inherit;font-size:8.5pt;">first nine months of</span><span style="font-family:inherit;font-size:8.5pt;"> </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:8.5pt;"> is associated with EH and reflects, among other things, updated commercial forecasts and an increased competitive environment. In the </span><span style="font-family:inherit;font-size:8.5pt;">third</span><span style="font-family:inherit;font-size:8.5pt;"> quarter of </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:8.5pt;">, primarily includes intangible asset impairment charges of </span><span style="font-family:inherit;font-size:8.5pt;"><span>$<ix:nonFraction id="d43697224e2218-wk-Fact-1A9B5AD0645B5DC4A49B41F2929A74ED" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="FD2016Q3QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">126</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:8.5pt;">, reflecting </span><span style="font-family:inherit;font-size:8.5pt;"><span>$<ix:nonFraction id="d43697224e2223-wk-Fact-DC8284A6DB6FB24085565A29C02C07A0" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="FD2016Q3QTD_us-gaap_BusinessAcquisitionAxis_pfe_InnoPharmaMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">97</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:8.5pt;"> of sterile injectable IPR&amp;D compounds acquired in connection with our acquisition of InnoPharma and </span><span style="font-family:inherit;font-size:8.5pt;"><span>$<ix:nonFraction id="d43697224e2227-wk-Fact-5968F9546C62F64E1D0C5A2A3BCBA564" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="FD2016Q3QTD_us-gaap_BusinessAcquisitionAxis_pfe_KingMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_pfe_OtherInProcessResearchandDevelopmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">29</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:8.5pt;"> of other IPR&amp;D assets acquired in connection with our acquisition of King in 2011. The intangible asset impairment charges for the </span><span style="font-family:inherit;font-size:8.5pt;">third quarter</span><span style="font-family:inherit;font-size:8.5pt;"> of </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:8.5pt;"> are associated with the following: EH (</span><span style="font-family:inherit;font-size:8.5pt;"><span>$<ix:nonFraction id="d43697224e2239-wk-Fact-D8C2AD7A7C3E87ED1F515A2AAF093A04" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="FD2016Q3QTD_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">97</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:8.5pt;">) and IH (</span><span style="font-family:inherit;font-size:8.5pt;"><span>$<ix:nonFraction id="d43697224e2243-wk-Fact-D2E5FB58422E0FB3AB815A2AEB5C5F61" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="FD2016Q3QTD_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">29</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:8.5pt;">). In the </span><span style="font-family:inherit;font-size:8.5pt;">first nine months of</span><span style="font-family:inherit;font-size:8.5pt;"> </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:8.5pt;">, primarily includes intangible asset impairment charges of </span><span style="font-family:inherit;font-size:8.5pt;"><span>$<ix:nonFraction id="d43697224e2256-wk-Fact-80C134FABADABFC450303B686A461AFA" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="FD2016Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">767</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:8.5pt;">, reflecting (i) </span><span style="font-family:inherit;font-size:8.5pt;"><span>$<ix:nonFraction id="d43697224e2260-wk-Fact-D58EC54B3CD75170A967113B6B0E9D54" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="FD2016Q3YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">331</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:8.5pt;"> related to developed technology rights for a generic injectable antibiotic product for the treatment of bacterial infections; and (ii) </span><span style="font-family:inherit;font-size:8.5pt;"><span>$<ix:nonFraction id="d43697224e2264-wk-Fact-BC61E6765AC157DC9B8F172FD69DC7DB" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="FD2016Q3YTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">265</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:8.5pt;"> related to an IPR&amp;D compound for the treatment of anemia, both acquired in connection with our acquisition of Hospira; (iii) </span><span style="font-family:inherit;font-size:8.5pt;"><span>$<ix:nonFraction id="d43697224e2269-wk-Fact-A5F6440492279866164E5A2B67C301AC" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="FD2016Q3YTD_us-gaap_BusinessAcquisitionAxis_pfe_InnoPharmaMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">97</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:8.5pt;"> of sterile injectable IPR&amp;D compounds acquired in connection with our acquisition of InnoPharma; and (iv) </span><span style="font-family:inherit;font-size:8.5pt;"><span>$<ix:nonFraction id="d43697224e2273-wk-Fact-EE3C7374F9AE43FFF5EA5A2BB1168494" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="FD2016Q3YTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_pfe_OtherInProcessResearchandDevelopmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">74</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:8.5pt;"> of other IPR&amp;D assets, </span><span style="font-family:inherit;font-size:8.5pt;"><span>$<ix:nonFraction id="d43697224e2277-wk-Fact-2CDCE282EB5B536395E3B5210D3F57CB" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="FD2016Q3YTD_us-gaap_BusinessAcquisitionAxis_pfe_HospiraMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_pfe_OtherInProcessResearchandDevelopmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">45</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:8.5pt;"> of which were acquired in connection with our acquisition of Hospira and </span><span style="font-family:inherit;font-size:8.5pt;"><span>$<ix:nonFraction id="d43697224e2281-wk-Fact-A81F037EFFDE1ABBAF665A2C35DD472A" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="FD2016Q3YTD_us-gaap_BusinessAcquisitionAxis_pfe_KingMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_pfe_OtherInProcessResearchandDevelopmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">29</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:8.5pt;"> of which were acquired in connection with our acquisition of King in 2011. The intangible asset impairment charges for the </span><span style="font-family:inherit;font-size:8.5pt;">first nine months of</span><span style="font-family:inherit;font-size:8.5pt;"> </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:8.5pt;"> are associated with the following: EH (</span><span style="font-family:inherit;font-size:8.5pt;"><span>$<ix:nonFraction id="d43697224e2294-wk-Fact-480BE219F98A3D26E5055A2C79EA0B25" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="FD2016Q3YTD_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">738</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:8.5pt;">) and IH (</span><span style="font-family:inherit;font-size:8.5pt;"><span>$<ix:nonFraction id="d43697224e2298-wk-Fact-ED3014D19D3478D49D105A2C9375E6EF" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="FD2016Q3YTD_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">29</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:8.5pt;">). In addition, the </span><span style="font-family:inherit;font-size:8.5pt;">first nine months of</span><span style="font-family:inherit;font-size:8.5pt;"> </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:8.5pt;"> includes an impairment loss of </span><span style="font-family:inherit;font-size:8.5pt;"><span>$<ix:nonFraction id="d43697224e2310-wk-Fact-B851DA622DEF69DCB2D83E8DBA5E58C7" name="us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment" contextRef="FD2016Q3YTD_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_HisunPfizerPharmaceuticalsCoLtdMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">211</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:8.5pt;"> related to Pfizer&#8217;s </span><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d43697224e2315-wk-Fact-E0E2AB1F4EEE53C6B6DCA69B4759EC8D" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="FI2016Q3_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_HisunPfizerPharmaceuticalsCoLtdMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">49</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:8.5pt;">-owned equity-method investment with Hisun in China, Hisun Pfizer, and an impairment loss of </span><span style="font-family:inherit;font-size:8.5pt;"><span>$<ix:nonFraction id="d43697224e2319-wk-Fact-96654A18A70557C4A91408A50BAC15DE" name="us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment" contextRef="FD2016Q3YTD_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_LaboratorioTeutoBrasileroMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">50</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:8.5pt;"> related to Pfizer&#8217;s </span><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d43697224e2323-wk-Fact-31F8A4E3497D5CFFB700513EEC18625D" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="FI2016Q3_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_LaboratorioTeutoBrasileroMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">40</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:8.5pt;">-owned equity-method investment in Teuto. For additional information concerning Hisun Pfizer and Teuto, see </span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Note 2D. </span></ix:continuation></div></td></tr></table><div style="line-height:120%;padding-bottom:1px;padding-top:1px;padding-left:12px;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><ix:continuation id="TextSelection-8C5E9E30C7EB5291A3E0EE605FC281E8-2">The intangible asset impairment charge for 2016 for the IPR&amp;D compound for the treatment of anemia acquired in connection with our acquisition of Hospira reflects, among other things, the impact of regulatory delays, including delays resulting from a court ruling, which required a 180-day waiting period after approval before a biosimilar product can be launched. The intangible asset impairment charges for 2016 for the sterile injectable IPR&amp;D compounds acquired in connection with our acquisition of InnoPharma reflect, among other things, the impact of portfolio prioritization decisions and decreased commercial profiles of certain compounds. The intangible asset impairment charges for 2016 for developed technology rights and other IPR&amp;D assets acquired in connection with our acquisition of Hospira reflect, among other things, the impact of new scientific findings, updated commercial forecasts, changes in pricing, and an increased competitive environment. The intangible asset impairment charges for 2016 for other IPR&amp;D assets acquired in connection with our acquisition of King reflect changes in the competitive environment.</ix:continuation></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(g)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><ix:footnote id="TextSelection-9C73CEBDEE585A83B2B18F3B38A6D8CD-0-wk-Footnote-9C73CEBDEE585A83B2B18F3B38A6D8CD_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" continuedAt="TextSelection-9C73CEBDEE585A83B2B18F3B38A6D8CD-1">In the </ix:footnote></span><ix:continuation id="TextSelection-9C73CEBDEE585A83B2B18F3B38A6D8CD-1" continuedAt="TextSelection-9C73CEBDEE585A83B2B18F3B38A6D8CD-2"><span style="font-family:inherit;font-size:8.5pt;">third</span><span style="font-family:inherit;font-size:8.5pt;"> quarter and </span><span style="font-family:inherit;font-size:8.5pt;">first nine months of</span><span style="font-family:inherit;font-size:8.5pt;"> </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:8.5pt;"> and </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">2016</span></ix:continuation><span style="font-family:inherit;font-size:8.5pt;"><ix:continuation id="TextSelection-9C73CEBDEE585A83B2B18F3B38A6D8CD-2">, represents expenses for changes to our infrastructure to align our commercial operations, including costs to internally separate our businesses into distinct legal entities, as well as to streamline our intercompany supply operations to better support each business. </ix:continuation></span></div></td></tr></table></ix:continuation><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><ix:continuation id="TextSelection-1D3ED85953925617BCBDD47BED8C2E25-3" continuedAt="TextSelection-1D3ED85953925617BCBDD47BED8C2E25-4"><div style="line-height:120%;font-size:8.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(h)</sup>&#160;</span></div></ix:continuation></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8.5pt;"><ix:continuation id="TextSelection-1D3ED85953925617BCBDD47BED8C2E25-4" continuedAt="TextSelection-1D3ED85953925617BCBDD47BED8C2E25-5"><span style="font-family:inherit;font-size:8.5pt;"><ix:footnote id="TextSelection-ECF6A95A77365D79B2E9D472B81966D9-0-wk-Footnote-ECF6A95A77365D79B2E9D472B81966D9_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" continuedAt="TextSelection-ECF6A95A77365D79B2E9D472B81966D9-1">In the </ix:footnote></span><ix:continuation id="TextSelection-ECF6A95A77365D79B2E9D472B81966D9-1" continuedAt="TextSelection-ECF6A95A77365D79B2E9D472B81966D9-2"><span style="font-family:inherit;font-size:8.5pt;">third quarter</span><span style="font-family:inherit;font-size:8.5pt;"> and </span><span style="font-family:inherit;font-size:8.5pt;">first nine months of</span><span style="font-family:inherit;font-size:8.5pt;"> </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:8.5pt;">, includes, among other things, dividend income of </span><span style="font-family:inherit;font-size:8.5pt;"><span>$<ix:nonFraction id="d43697224e2432-wk-Fact-4F0D695F67305B7684A19B343AB32C0C" name="us-gaap:InvestmentIncomeDividend" contextRef="FD2017Q3QTD_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViivHealthcareLimitedMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">54</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:8.5pt;"> and </span><span style="font-family:inherit;font-size:8.5pt;"><span>$<ix:nonFraction id="d43697224e2436-wk-Fact-A4D794D7B0F25073BE267F34843F9BB3" name="us-gaap:InvestmentIncomeDividend" contextRef="FD2017Q3YTD_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViivHealthcareLimitedMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">211</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:8.5pt;">, respectively, from our investment in ViiV, and income of </span><span style="font-family:inherit;font-size:8.5pt;"><span>$<ix:nonFraction id="d43697224e2441-wk-Fact-9562A60DEB5731FADACA592BE4044B46" name="pfe:OtherNonoperatingIncomeMiscellaneous" contextRef="FD2017Q3QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">62</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:8.5pt;"> from resolution of a contract disagreement. In the </span><span style="font-family:inherit;font-size:8.5pt;">first nine months of</span><span style="font-family:inherit;font-size:8.5pt;"> </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:8.5pt;">, includes, among other things, </span><span style="font-family:inherit;font-size:8.5pt;"><span>$<ix:nonFraction id="d43697224e2459-wk-Fact-EF1D4381DCB852C2BC671DE2544FB0BF" name="pfe:PaymentsforMergerTerminationCosts" contextRef="FD2016Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">150</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:8.5pt;"> paid to Allergan for reimbursement of Allergan&#8217;s expenses associated with the terminated transaction and income of </span><span style="font-family:inherit;font-size:8.5pt;"><span>$<ix:nonFraction id="d43697224e2471-wk-Fact-D1FAB14020F3553CBF8E62EB164D279F" name="pfe:OtherNonoperatingIncomeMiscellaneous" contextRef="FD2016Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">116</ix:nonFraction> million</span></span></ix:continuation></ix:continuation><span style="font-family:inherit;font-size:8.5pt;"><ix:continuation id="TextSelection-1D3ED85953925617BCBDD47BED8C2E25-5"><ix:continuation id="TextSelection-ECF6A95A77365D79B2E9D472B81966D9-2"> from resolution of a contract disagreement.</ix:continuation></ix:continuation></span></div></td></tr></table><div style="line-height:120%;padding-left:4px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><ix:nonNumeric contextRef="FD2017Q3YTD" name="us-gaap:ScheduleOfImpairedIntangibleAssetsTextBlock" id="TextSelection-20B5D661C20C7C1C5B7F5A1C1412998A-0-wk-Fact-210637473B50FE09AFA05A1C328C470F" continuedAt="TextSelection-20B5D661C20C7C1C5B7F5A1C1412998A-1" escape="true"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="21"></td></tr><tr><td style="width:38%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td></tr><tr><td colspan="21" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides additional information about the intangible assets that were impaired during 2017 in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net</span><span style="font-family:inherit;font-size:10pt;">:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Fair Value</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Nine Months Ended</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">October 1, 2017</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Level 3</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Impairment</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Intangible assets</span><span style="font-family:inherit;font-size:9pt;font-style:italic;">&#8211;&#8211;</span><span style="font-family:inherit;font-size:9pt;">Developed technology rights</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(b)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43697224e2866-wk-Fact-53CD55B10DB9D18954E05A1EF2A58668" name="us-gaap:FiniteLivedIntangibleAssetsFairValueDisclosure" contextRef="FI2017Q3_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">50</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43697224e2885-wk-Fact-0D2E2A926A3F9786A8C65A1EF5DC2AD4" name="us-gaap:FiniteLivedIntangibleAssetsFairValueDisclosure" contextRef="FI2017Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43697224e2905-wk-Fact-C12B4B795167254CFB615A1EFA195FC4" name="us-gaap:FiniteLivedIntangibleAssetsFairValueDisclosure" contextRef="FI2017Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43697224e2924-wk-Fact-49CB6967F08724E343E55A1EFDC1A551" name="us-gaap:FiniteLivedIntangibleAssetsFairValueDisclosure" contextRef="FI2017Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">50</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43697224e2943-wk-Fact-66BA540C016377984D0B5A1F012CEDE6" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" contextRef="FD2017Q3YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">127</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></ix:nonNumeric></div><ix:continuation id="TextSelection-20B5D661C20C7C1C5B7F5A1C1412998A-1" continuedAt="TextSelection-20B5D661C20C7C1C5B7F5A1C1412998A-2"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><ix:footnote id="TextSelection-4AF5AB391F1CD8054C065A2324C0D822-0-wk-Footnote-4AF5AB391F1CD8054C065A2324C0D822_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US">The fair value amount is presented as of the date of impairment, as these assets are not measured at fair value on a recurring basis.</ix:footnote></span></div></td></tr></table></ix:continuation></ix:continuation><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><ix:continuation id="TextSelection-20B5D661C20C7C1C5B7F5A1C1412998A-2" continuedAt="TextSelection-20B5D661C20C7C1C5B7F5A1C1412998A-3"><ix:continuation id="TextSelection-C533AB02168D52D5BD955FB100D4D7A8-3" continuedAt="TextSelection-C533AB02168D52D5BD955FB100D4D7A8-4"><div style="line-height:120%;font-size:8.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(b)</sup>&#160;</span></div></ix:continuation></ix:continuation></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8.5pt;"><ix:continuation id="TextSelection-20B5D661C20C7C1C5B7F5A1C1412998A-3" continuedAt="TextSelection-20B5D661C20C7C1C5B7F5A1C1412998A-4"><ix:continuation id="TextSelection-C533AB02168D52D5BD955FB100D4D7A8-4" continuedAt="TextSelection-C533AB02168D52D5BD955FB100D4D7A8-5"><span style="font-family:inherit;font-size:8.5pt;"><ix:footnote id="TextSelection-066A0A390204B79351965A22CE69E761-0-wk-Footnote-066A0A390204B79351965A22CE69E761_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" continuedAt="TextSelection-066A0A390204B79351965A22CE69E761-1">Reflects intangible assets written down to fair value in the </ix:footnote></span><ix:continuation id="TextSelection-066A0A390204B79351965A22CE69E761-1" continuedAt="TextSelection-066A0A390204B79351965A22CE69E761-2"><span style="font-family:inherit;font-size:8.5pt;">third quarter</span><span style="font-family:inherit;font-size:8.5pt;"> of </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">2017</span></ix:continuation></ix:continuation></ix:continuation><span style="font-family:inherit;font-size:8.5pt;"><ix:continuation id="TextSelection-C533AB02168D52D5BD955FB100D4D7A8-5"><ix:continuation id="TextSelection-20B5D661C20C7C1C5B7F5A1C1412998A-4"><ix:continuation id="TextSelection-066A0A390204B79351965A22CE69E761-2">. Fair value was determined using the income approach, specifically the multi-period excess earnings method, also known as the discounted cash flow method. We started with a forecast of all the expected net cash flows associated with the asset and then applied an asset-specific discount rate to arrive at a net present value amount. Some of the more significant estimates and assumptions inherent in this approach include: the amount and timing of the projected net cash flows, which includes the expected impact of competitive, legal and/or regulatory forces on the product; the discount rate, which seeks to reflect the various risks inherent in the projected cash flows; and the tax rate, which seeks to incorporate the geographic diversity of the projected cash flows.</ix:continuation></ix:continuation></ix:continuation></span></div></td></tr></table><div style="line-height:120%;padding-left:4px;text-align:left;padding-left:12px;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">17</span></div></div><hr style="page-break-after:always"></hr><div><a id="s53D6DF219A3F56C7AB941AE17CF69E51"></a></div><div><div style="line-height:120%;text-align:center;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(UNAUDITED)</span></div></div><div><br/></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Note 5. </span><ix:nonNumeric contextRef="FD2017Q3YTD" name="us-gaap:IncomeTaxDisclosureTextBlock" id="TextSelection-207F451CB634542BA031A4F17BD64BDC-0-wk-Fact-2ACE6A4FFC3A542DB9475C1606F2AD4D" continuedAt="TextSelection-207F451CB634542BA031A4F17BD64BDC-1" escape="true"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Tax Matters</span></ix:nonNumeric></div><ix:continuation id="TextSelection-207F451CB634542BA031A4F17BD64BDC-1" continuedAt="TextSelection-207F451CB634542BA031A4F17BD64BDC-2"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">A. Taxes on Income from Continuing Operations</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our effective tax rate for continuing operations was </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43691920e643-wk-Fact-B28AC12352F15ADEB0DE5D42E6FDA384" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="FD2017Q3QTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">20.3</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">third</span><span style="font-family:inherit;font-size:10pt;"> quarter of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;">, compared to </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43691920e655-wk-Fact-1695D7752478550AA5BC3FD108067073" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="FD2016Q3QTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">15.5</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">third</span><span style="font-family:inherit;font-size:10pt;"> quarter of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;"> and was </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43691920e668-wk-Fact-4F62F6352743557B99817F09BD80BFD2" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="FD2017Q3YTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">20.1</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;">, compared to </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43691920e680-wk-Fact-5A6FB2B5BFF655129456447A1D77D3A6" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="FD2016Q3YTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">14.6</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The </span><span style="font-family:inherit;font-size:10pt;">higher</span><span style="font-family:inherit;font-size:10pt;"> effective tax rate for the </span><span style="font-family:inherit;font-size:10pt;">third</span><span style="font-family:inherit;font-size:10pt;"> quarter of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;"> in comparison with the same period in </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;"> was primarily due to: </span></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">an unfavorable change in the jurisdictional mix of earnings as a result of operating fluctuations in the normal course of business,</span></div></td></tr></table><div style="line-height:120%;padding-top:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">partially offset by:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the non-recurrence of the unfavorable tax effects of an impairment charge related to the write-down of the HIS net assets to fair value less estimated costs to sell, mainly related to goodwill, which is not deductible for tax purposes, and the jurisdictional mix of intangible assets.</span></div></td></tr></table><div style="line-height:120%;padding-top:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The </span><span style="font-family:inherit;font-size:10pt;">higher</span><span style="font-family:inherit;font-size:10pt;"> effective tax rate for the </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;"> in comparison with the same period in </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;"> was primarily due to:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the non-recurrence of benefits related to the final resolution of an agreement in principle reached in February 2016 and finalized in April 2016 to resolve certain claims related to Protonix, which resulted in the receipt of information that raised our initial assessment in 2015 of the likelihood of prevailing on the technical merits of our tax position; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the non-recurrence of benefits associated with our Venezuela operations; as well as </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">a decrease in benefits associated with the resolution of certain tax positions pertaining to prior years primarily with various foreign tax authorities, and the expiration of certain statutes of limitations,</span></div></td></tr></table><div style="line-height:120%;padding-top:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">partially offset by:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the change in the jurisdictional mix of earnings as a result of operating fluctuations in the normal course of business; as well as</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the non-recurrence of the unfavorable tax effects of an impairment charge related to the write-down of HIS net assets to fair value less estimated costs to sell, mainly related to goodwill, which is not deductible for tax purposes, and the jurisdictional mix of intangible assets.</span></div></td></tr></table><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">B. Tax Contingencies</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are subject to income tax in many jurisdictions, and a certain degree of estimation is required in recording the assets and liabilities related to income taxes. All of our tax positions are subject to audit by the local taxing authorities in each tax jurisdiction. These tax audits can involve complex issues, interpretations and judgments and the resolution of matters may span multiple years, particularly if subject to negotiation or litigation. Our assessments are based on estimates and assumptions that have been deemed reasonable by management, but our estimates of unrecognized tax benefits and potential tax benefits may not be representative of actual outcomes, and variation from such estimates could materially affect our financial statements in the period of settlement or when the statutes of limitations expire, as we treat these events as discrete items in the period of resolution.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The U.S. is one of our major tax jurisdictions, and we are regularly audited by the IRS:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">With respect to Pfizer, the IRS has issued a Revenue Agent&#8217;s Report (RAR) for tax years 2009-2010. We are not in agreement with the RAR and are currently appealing certain disputed issues. Tax years 2011-2013 are currently under audit. Tax years 2014-2017 are open, but not under audit. All other tax years are closed.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">With respect to Hospira, the federal income tax audit for tax years 2012-2013 was effectively settled in the third quarter of 2017. The IRS is currently auditing tax year 2014 through short-year 2015. All other tax years are closed. The tax years under audit for Hospira are not considered material to Pfizer.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">With respect to Anacor and Medivation, the open tax years are not considered material to Pfizer.</span></div></td></tr></table><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition to the open audit years in the U.S., we have open audit years in other major tax jurisdictions, such as Canada (2010-2017), Japan (2015-2017), Europe (2011-2017, primarily reflecting Ireland, the United Kingdom, France, Italy, Spain and Germany), Latin America (1998-2017, primarily reflecting Brazil) and Puerto Rico (2010-2017).</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">18</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:center;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(UNAUDITED)</span></div></div><div><br/></div><ix:continuation id="TextSelection-207F451CB634542BA031A4F17BD64BDC-2" continuedAt="TextSelection-207F451CB634542BA031A4F17BD64BDC-3"><div style="line-height:120%;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">C. Tax Provision/(Benefit) on Other Comprehensive Income</span></div><div style="line-height:120%;font-size:10pt;"><ix:nonNumeric contextRef="FD2017Q3YTD" name="pfe:ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock" id="TextSelection-5FC0C4FA21D6594890557187529CE237-0-wk-Fact-80CB44040EA9534CAEFC9288DA01ED37" continuedAt="TextSelection-5FC0C4FA21D6594890557187529CE237-1" escape="true"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90167158308752%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"></td></tr><tr><td style="width:56%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td colspan="17" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides the components of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Tax provision/(benefit) on</span><span style="font-family:inherit;font-size:10pt;">&#160;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">other comprehensive income:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Nine Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">October&#160;1, <br/>2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">October&#160;2, <br/>2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">October&#160;1, <br/>2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">October&#160;2, <br/>2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Foreign currency translation adjustments, net</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d43691920e1143-wk-Fact-20A5C02D91765E01AC1BECE67B1B1069" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" contextRef="FD2017Q3QTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">62</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43691920e1163-wk-Fact-7E181FF37E2A50278584695E0D09574B" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" contextRef="FD2016Q3QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d43691920e1183-wk-Fact-9E3C8C139B5F5A29BA180FCB89C053CB" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">192</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d43691920e1203-wk-Fact-74D925B0A9935FB7A7B9371D66730DC0" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" contextRef="FD2016Q3YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">15</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Unrealized holding losses on derivative financial instruments, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43691920e1224-wk-Fact-7D25F7010081517DA252227101C919B5" name="us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax" contextRef="FD2017Q3QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">28</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43691920e1243-wk-Fact-0B09CD0C5C875357BE7DB79124A4E04C" name="us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax" contextRef="FD2016Q3QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43691920e1262-wk-Fact-722BD08C0AD55CC19AEF3680CB2D5D3D" name="us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">30</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d43691920e1282-wk-Fact-F256DC9852A85B949366691563740C3F" name="us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax" contextRef="FD2016Q3YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">192</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Reclassification adjustments for realized (gains)/losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d43691920e1308-wk-Fact-3001F1013C895E04954075538DBEE734" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesTax" contextRef="FD2017Q3QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">29</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43691920e1328-wk-Fact-6BF3EA8F2B6E5F4A85E0DC70502C1FF0" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesTax" contextRef="FD2016Q3QTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">32</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d43691920e1347-wk-Fact-BF5C82D2F0C159A9A419B6DD8D19C3DD" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesTax" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">169</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43691920e1368-wk-Fact-3C0F36FE7BE25F00AA19BC7299034AA1" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesTax" contextRef="FD2016Q3YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">81</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d43691920e1393-wk-Fact-AD1F5A27320B58F18350611619CB4C2D" name="us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesTax" contextRef="FD2017Q3QTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43691920e1413-wk-Fact-1839ACB9C53D55CEBD85396C29D84D4B" name="us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesTax" contextRef="FD2016Q3QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">32</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d43691920e1432-wk-Fact-12958CC2E3FF51A3ADB14C7CA9457E07" name="us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesTax" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">139</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d43691920e1453-wk-Fact-17B8EE1FBF5052AC902A168CF6CC3D75" name="us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesTax" contextRef="FD2016Q3YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">112</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Unrealized holding gains on available-for-sale securities, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43691920e1479-wk-Fact-B4261AE3D0AD53E7A8C763DE827437AD" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" contextRef="FD2017Q3QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">37</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43691920e1498-wk-Fact-0254BA20C96B5206AB66C400FD6835C8" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" contextRef="FD2016Q3QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">40</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43691920e1517-wk-Fact-28D2206529865A97837AAF55B33A5622" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">93</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43691920e1537-wk-Fact-A2AB1B08748952748A1F3C1E2F170710" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" contextRef="FD2016Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">106</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Reclassification adjustments for realized gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d43691920e1562-wk-Fact-030C80E057F5593F9D68A9372EB2A16A" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax" contextRef="FD2017Q3QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">49</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d43691920e1582-wk-Fact-D14F73654E0F5DF990DC7EC1EF852DF3" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax" contextRef="FD2016Q3QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">14</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d43691920e1602-wk-Fact-22D264995729522A81CA77400001843C" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">45</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d43691920e1623-wk-Fact-1947B284C39954C0AF1BB2E06C63F0ED" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax" contextRef="FD2016Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">16</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d43691920e1649-wk-Fact-AFA051D845ED5A11AED1963B8C1115D7" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" contextRef="FD2017Q3QTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">12</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43691920e1669-wk-Fact-36B9CCE20B0B58E3A6D7C635D646A4A9" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" contextRef="FD2016Q3QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">26</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43691920e1688-wk-Fact-7E914933941352F582E1401C1CA8F6F9" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">47</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43691920e1708-wk-Fact-D44BF12F799052A8A971DB3069E83535" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" contextRef="FD2016Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">90</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Benefit plans: actuarial losses, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d43691920e1733-wk-Fact-C88E0803B3405BB08C35BC886D3586A7" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodTax" contextRef="FD2017Q3QTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">37</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d43691920e1753-wk-Fact-8EAA48BFD1E753AD9286C15FFA84D853" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodTax" contextRef="FD2016Q3QTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">31</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d43691920e1773-wk-Fact-A25C48C507965910871A9543E7003F58" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodTax" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">15</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d43691920e1794-wk-Fact-24AE98869F0F535BB9A91ABD483DF3F1" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodTax" contextRef="FD2016Q3YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">39</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Reclassification adjustments related to amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43691920e1821-wk-Fact-0081DB29634057AD9D9EBDB3B979B8A3" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossTax" contextRef="FD2017Q3QTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">60</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43691920e1840-wk-Fact-B416F2387D03519F9E13415DD2D9E08F" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossTax" contextRef="FD2016Q3QTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">47</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43691920e1859-wk-Fact-87EAA8D878E75CC79AF824C14B894450" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossTax" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">152</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43691920e1879-wk-Fact-B0A199C2320F541BB1BE527BA011F035" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossTax" contextRef="FD2016Q3YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">140</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Reclassification adjustments related to settlements, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43691920e1904-wk-Fact-BF40EC18B19B5E49AFE8135277A519A5" name="pfe:OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossTax" contextRef="FD2017Q3QTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">22</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43691920e1923-wk-Fact-FCB00CA73E71550D82239494B41AFEDB" name="pfe:OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossTax" contextRef="FD2016Q3QTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">10</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43691920e1942-wk-Fact-FE1D94521C65567088D5F749B74F3A38" name="pfe:OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossTax" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">30</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43691920e1962-wk-Fact-27A911109D0B54CAB683C3341D54C568" name="pfe:OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossTax" contextRef="FD2016Q3YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">27</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d43691920e1987-wk-Fact-2D02134C06C45FB8B14D2201C3D7093F" name="pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodTax" contextRef="FD2017Q3QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">33</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43691920e2007-wk-Fact-994151A2479E5461AE616130A49BB496" name="pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodTax" contextRef="FD2016Q3QTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">14</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d43691920e2026-wk-Fact-7ABB5D061EE55B3D89537240DDD85EB4" name="pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodTax" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">46</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43691920e2047-wk-Fact-DCFF9A51C6D65F0AB9013F20E74CE188" name="pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodTax" contextRef="FD2016Q3YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43691920e2072-wk-Fact-0EA8A7BD6AB55E229C923B6D7DBA89B3" name="pfe:DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetActuarialGainLossTax" contextRef="FD2017Q3QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">11</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43691920e2091-wk-Fact-0F7E9B3406F4555D90C0A9337371F4C1" name="pfe:DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetActuarialGainLossTax" contextRef="FD2016Q3QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">40</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43691920e2110-wk-Fact-2C7DDB814E8E5E38A07A56B0E4904F50" name="pfe:DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetActuarialGainLossTax" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">121</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43691920e2130-wk-Fact-586CB94688A0590FAA31205761B7DECB" name="pfe:DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetActuarialGainLossTax" contextRef="FD2016Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">133</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Benefit plans: prior service (costs)/credits and other, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43691920e2155-wk-Fact-F15B315AAC995FCC90DC58635B7F0703" name="pfe:DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetPriorServiceCostCreditAndOtherTax" contextRef="FD2017Q3QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43691920e2174-wk-Fact-E3120D61B45B5500A79741CA03EE6AEA" name="pfe:DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetPriorServiceCostCreditAndOtherTax" contextRef="FD2016Q3QTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">35</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43691920e2193-wk-Fact-DF1241B013185B9CB0A7B8208F03EA3E" name="pfe:DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetPriorServiceCostCreditAndOtherTax" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43691920e2213-wk-Fact-0C91880B29B654E2A2262315B815355C" name="pfe:DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetPriorServiceCostCreditAndOtherTax" contextRef="FD2016Q3YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">66</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Reclassification adjustments related to amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d43691920e2238-wk-Fact-1D4D11ACEF6A550F9C379446440A583F" name="us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax" contextRef="FD2017Q3QTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">17</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d43691920e2258-wk-Fact-A92831B4D5F55E66A0BB6737C4474926" name="us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax" contextRef="FD2016Q3QTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">17</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d43691920e2278-wk-Fact-9CEBD2DC02AF5056BDB9E0D45DD7DDCB" name="us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">50</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d43691920e2299-wk-Fact-199FC1BC8DC55D4E9C754C068F72C6C5" name="us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax" contextRef="FD2016Q3YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">47</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Reclassification adjustments related to curtailments, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d43691920e2325-wk-Fact-02B298FD4505502FAA9DBE3E2F9216CC" name="pfe:OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditTax" contextRef="FD2017Q3QTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d43691920e2345-wk-Fact-B3F52E0194FF566A92AB7966FD65A1B8" name="pfe:OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditTax" contextRef="FD2016Q3QTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d43691920e2365-wk-Fact-3107C1C590B45D1CA7422E04631E2C81" name="pfe:OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditTax" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d43691920e2386-wk-Fact-3A8DE8AE66985B7A9FD65B5E72C64243" name="pfe:OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditTax" contextRef="FD2016Q3YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43691920e2412-wk-Fact-0441EF2C04495634A674F15BDFDA7D0E" name="pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax" contextRef="FD2017Q3QTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43691920e2431-wk-Fact-6240EFE702B958268B507CF7BA87B7F2" name="pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax" contextRef="FD2016Q3QTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43691920e2450-wk-Fact-DBA0FEB188FE5A5FADB65B9196841736" name="pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43691920e2470-wk-Fact-EB1E29CA46EA5B0A9E10C8FD860FDB64" name="pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax" contextRef="FD2016Q3YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d43691920e2495-wk-Fact-7F10800AE77A5C41AA5BF5E4A13A33D8" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect" contextRef="FD2017Q3QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">17</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43691920e2515-wk-Fact-ED107C23D8D75E359B0CB95276C3F32C" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect" contextRef="FD2016Q3QTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">18</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d43691920e2534-wk-Fact-B86D23F2CD3E58FFACC67A9E65457798" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">55</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43691920e2555-wk-Fact-17AA06FDF341543CB908A3C9DE8AA4ED" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect" contextRef="FD2016Q3YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">15</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">Tax provision/(benefit) on other comprehensive income</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d43691920e2585-wk-Fact-5950DF108F195FB594A31172740C60B3" name="us-gaap:OtherComprehensiveIncomeLossTax" contextRef="FD2017Q3QTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">80</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43691920e2605-wk-Fact-31B8668E1E1956DF8878873FF4C52DA7" name="us-gaap:OtherComprehensiveIncomeLossTax" contextRef="FD2016Q3QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">116</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d43691920e2625-wk-Fact-0A65F347C9FD5314AD71D7212990864D" name="us-gaap:OtherComprehensiveIncomeLossTax" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">218</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43691920e2645-wk-Fact-24F5F5FD900B538BB0C1F5C1D6714D02" name="us-gaap:OtherComprehensiveIncomeLossTax" contextRef="FD2016Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">111</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></ix:nonNumeric></div></ix:continuation><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><ix:continuation id="TextSelection-5FC0C4FA21D6594890557187529CE237-1" continuedAt="TextSelection-5FC0C4FA21D6594890557187529CE237-2"><ix:continuation id="TextSelection-207F451CB634542BA031A4F17BD64BDC-3" continuedAt="TextSelection-207F451CB634542BA031A4F17BD64BDC-4"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup>&#160;</span></div></ix:continuation></ix:continuation></td><td style="vertical-align:top;padding-left:6px;"><div style="line-height:120%;text-align:left;font-size:9pt;text-indent:-6px;"><span style="font-family:inherit;font-size:9pt;"><ix:continuation id="TextSelection-5FC0C4FA21D6594890557187529CE237-2"><ix:continuation id="TextSelection-207F451CB634542BA031A4F17BD64BDC-4"><ix:footnote id="TextSelection-C94190737D79577A8993EFAC2CD3FC95-0-wk-Footnote-C94190737D79577A8993EFAC2CD3FC95_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US">Taxes are not provided for foreign currency translation adjustments relating to investments in international subsidiaries that will be held indefinitely.</ix:footnote></ix:continuation></ix:continuation></span></div></td></tr></table><div><a id="sCE2ECB787E575BBEA9852D435A835B32"></a></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Note 6. </span><ix:nonNumeric contextRef="FD2017Q3YTD" name="us-gaap:ComprehensiveIncomeNoteTextBlock" id="TextSelection-2D11F2BB40C25512A3FC80946791DD6A-0-wk-Fact-724F5C5042095114BD75F8686409A36D" continuedAt="TextSelection-2D11F2BB40C25512A3FC80946791DD6A-1" escape="true"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"> </span></ix:nonNumeric></div><ix:continuation id="TextSelection-2D11F2BB40C25512A3FC80946791DD6A-1" continuedAt="TextSelection-2D11F2BB40C25512A3FC80946791DD6A-2"><div style="line-height:120%;font-size:10pt;"><ix:nonNumeric contextRef="FD2017Q3YTD" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="TextSelection-5DA93522D4A15C9A955CD584AA15E736-0-wk-Fact-EC3A117A8FF55DE3869BE8DD815E9ECC" continuedAt="TextSelection-5DA93522D4A15C9A955CD584AA15E736-1" escape="true"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"></td></tr><tr><td style="width:23%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td colspan="25" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides the changes, net of tax, in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Accumulated other comprehensive loss</span><span style="font-family:inherit;font-size:10pt;">:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net Unrealized Gains/(Losses)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Benefit Plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign Currency Translation Adjustments </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Derivative Financial Instruments</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Available-For-Sale Securities</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Actuarial Gains/(Losses)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prior Service (Costs)/Credits and Other</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accumulated Other Comprehensive Income/(Loss)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance, December&#160;31, 2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d43692105e1075-wk-Fact-A26834331A4E566C86D979822918457B" name="us-gaap:StockholdersEquity" contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">6,659</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43692105e1095-wk-Fact-221959FA9D815244845776458CA6E530" name="us-gaap:StockholdersEquity" contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">348</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d43692105e1115-wk-Fact-AD346E1FD4E35AD3868EB429B3A1BE5D" name="us-gaap:StockholdersEquity" contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">131</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d43692105e1135-wk-Fact-66FDB0064EDD5661A645D17405DAAE1E" name="us-gaap:StockholdersEquity" contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">5,473</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43692105e1155-wk-Fact-AE6E0103E5DC57999D8419D17047E55D" name="us-gaap:StockholdersEquity" contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">879</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d43692105e1175-wk-Fact-1C5D2C0F26F45CC297A9902A74F9EEC2" name="us-gaap:StockholdersEquity" contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">11,036</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other comprehensive income/(loss)</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43692105e1198-wk-Fact-53D122DE8506544FBB5C5E66B2ABDED8" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2017Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,638</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d43692105e1217-wk-Fact-985F88532E195B47BDB854CF286F26CD" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2017Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">403</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43692105e1237-wk-Fact-A34EE90663FB5081B9E32DEADBF0E652" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2017Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">470</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43692105e1257-wk-Fact-38D6CEB8D8AD5DDC81AC2FCD8FAE9F8C" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2017Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">263</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d43692105e1276-wk-Fact-797701906D5A55A4A147956137258C89" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2017Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">96</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43692105e1297-wk-Fact-FAF3334C03BB50B5921AB864A8788C26" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2017Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,872</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance, October&#160;1, 2017</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d43692105e1327-wk-Fact-9BD14851B5AF511ABBBC5C7674FAA3EF" name="us-gaap:StockholdersEquity" contextRef="FI2017Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">5,021</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d43692105e1347-wk-Fact-F15CE6FEF57E50C49CDB01BFBFF360E0" name="us-gaap:StockholdersEquity" contextRef="FI2017Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">55</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43692105e1368-wk-Fact-24EDD802F3BA5DF78DE63E6A9EF3C0F4" name="us-gaap:StockholdersEquity" contextRef="FI2017Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">339</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d43692105e1387-wk-Fact-A7149C565C45560B9178A58A4E3356E5" name="us-gaap:StockholdersEquity" contextRef="FI2017Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">5,210</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43692105e1407-wk-Fact-526D747181715C33A9D32427AAD93214" name="us-gaap:StockholdersEquity" contextRef="FI2017Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">783</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d43692105e1427-wk-Fact-7AA58A1D40FB550292F1257410C0514E" name="us-gaap:StockholdersEquity" contextRef="FI2017Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">9,164</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div></ix:nonNumeric></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><ix:continuation id="TextSelection-5DA93522D4A15C9A955CD584AA15E736-1" continuedAt="TextSelection-5DA93522D4A15C9A955CD584AA15E736-2"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup>&#160;</span></div></ix:continuation></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:9pt;"><ix:continuation id="TextSelection-5DA93522D4A15C9A955CD584AA15E736-2" continuedAt="TextSelection-5DA93522D4A15C9A955CD584AA15E736-3"><span style="font-family:inherit;font-size:9pt;"><ix:footnote id="TextSelection-2A36E737FFF05E75B357CB41AFB5B6E2-0-wk-Footnote-2A36E737FFF05E75B357CB41AFB5B6E2_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" continuedAt="TextSelection-2A36E737FFF05E75B357CB41AFB5B6E2-1">Amounts do not include foreign currency translation adjustments attributable to noncontrolling interests of </ix:footnote></span><ix:continuation id="TextSelection-2A36E737FFF05E75B357CB41AFB5B6E2-1" continuedAt="TextSelection-2A36E737FFF05E75B357CB41AFB5B6E2-2"><span style="font-family:inherit;font-size:9pt;"><span>$<ix:nonFraction id="d43692105e1447-wk-Fact-85FFE2528F0255C4AF78F51D7D6CA92E" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToNoncontrollingInterest" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">16</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:9pt;"> income for the </span><span style="font-family:inherit;font-size:9pt;">first nine months of</span><span style="font-family:inherit;font-size:9pt;"> </span><span style="font-family:inherit;font-size:9pt;text-align:center;">2017</span></ix:continuation></ix:continuation><span style="font-family:inherit;font-size:9pt;"><ix:continuation id="TextSelection-5DA93522D4A15C9A955CD584AA15E736-3"><ix:continuation id="TextSelection-2A36E737FFF05E75B357CB41AFB5B6E2-2">.</ix:continuation></ix:continuation></span></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></ix:continuation><div style="line-height:120%;text-align:left;font-size:10pt;"><ix:continuation id="TextSelection-2D11F2BB40C25512A3FC80946791DD6A-2" continuedAt="TextSelection-2D11F2BB40C25512A3FC80946791DD6A-3"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">October&#160;1, 2017</span><span style="font-family:inherit;font-size:10pt;">, with respect to derivative financial instruments, the amount of unrealized pre-tax net losses on derivative financial instruments estimated to be reclassified into income within the next 12 months is approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d43692105e1481-wk-Fact-053DA37D6DF35D4488C445B5609AC8D8" name="us-gaap:CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths" contextRef="FD2017Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">154</ix:nonFraction> million</span></span></ix:continuation><span style="font-family:inherit;font-size:10pt;"><ix:continuation id="TextSelection-2D11F2BB40C25512A3FC80946791DD6A-3">, which is expected to be offset primarily by gains related to available-for-sale securities and gains resulting from reclassification adjustments related to foreign currency exchange-denominated forecasted intercompany inventory sales.</ix:continuation></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">19</span></div></div><hr style="page-break-after:always"></hr><div><a id="s6990B20761A85206BACCE7ACEC9BFBFE"></a></div><div><div style="line-height:120%;text-align:center;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(UNAUDITED)</span></div></div><div><br/></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Note 7. </span><ix:nonNumeric contextRef="FD2017Q3YTD" name="us-gaap:FinancialInstrumentsDisclosureTextBlock" id="TextSelection-1EE0D555564D5ACA882C4EC0D6E9B51D-0-wk-Fact-B3A5822AA2D35F53AB503C921439D025" continuedAt="TextSelection-1EE0D555564D5ACA882C4EC0D6E9B51D-1" escape="true"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Financial Instruments</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"> </span></ix:nonNumeric></div><ix:continuation id="TextSelection-1EE0D555564D5ACA882C4EC0D6E9B51D-1" continuedAt="TextSelection-1EE0D555564D5ACA882C4EC0D6E9B51D-2"><div style="line-height:120%;font-size:6pt;"><span style="font-family:inherit;font-size:6pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">A. Selected Financial Assets and Liabilities</span></div><div style="line-height:120%;font-size:10pt;"><ix:nonNumeric contextRef="FD2017Q3YTD" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" id="TextSelection-068F0051446755189ABCE40C311C2AE8-0-wk-Fact-250357A851405B8BA77916238965B5B8" continuedAt="TextSelection-068F0051446755189ABCE40C311C2AE8-1" escape="true"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:74%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides additional information about certain of our financial assets and liabilities:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">October&#160;1, <br/>2017</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">December&#160;31, <br/>2016</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:justify;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;text-decoration:underline;">Selected financial assets measured at fair value on a recurring basis</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Trading funds and securities</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43770747e822-wk-Fact-73ABA67055275455B7AA44864D34F006" name="us-gaap:TradingSecurities" contextRef="FI2017Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">347</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43770747e841-wk-Fact-2216EB0E4F0B50869B845DEBE01027C3" name="us-gaap:TradingSecurities" contextRef="FI2016Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">325</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Available-for-sale debt securities</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43770747e863-wk-Fact-60F0DB778C3D556896B02410EB2C0B1B" name="us-gaap:AvailableForSaleSecurities" contextRef="FI2017Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_DebtSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">16,598</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43770747e882-wk-Fact-C249892FF0905C07897B0E4EF86B976C" name="us-gaap:AvailableForSaleSecurities" contextRef="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_DebtSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">18,632</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Money market funds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43770747e907-wk-Fact-6118811AB2DE5F6BA426EF1F188FBC53" name="us-gaap:AvailableForSaleSecurities" contextRef="FI2017Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,824</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43770747e926-wk-Fact-672E844C4F3953138ADA20A9FE757D32" name="us-gaap:AvailableForSaleSecurities" contextRef="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,445</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Available-for-sale equity securities</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43770747e953-wk-Fact-0041457EF706567A8463582BD5F7861D" name="us-gaap:AvailableForSaleSecurities" contextRef="FI2017Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_EquitySecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,032</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43770747e972-wk-Fact-D2E616C04C74565E87B5EFE91C979223" name="us-gaap:AvailableForSaleSecurities" contextRef="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_EquitySecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">540</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Derivative financial instruments in a receivable position</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(d)</sup></span><span style="font-family:inherit;font-size:9pt;">:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Interest rate swaps</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43770747e1045-wk-Fact-D53A0B9A3EDB5C82AE283FE0420CAB5D" name="us-gaap:DerivativeAssets" contextRef="FI2017Q3_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">630</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43770747e1064-wk-Fact-2A8F43C5F6985C19B50BEDA00C1E0EDB" name="us-gaap:DerivativeAssets" contextRef="FI2016Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">625</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Foreign currency swaps</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43770747e1089-wk-Fact-24CD21A3984953BA839ABDB818130188" name="us-gaap:DerivativeAssets" contextRef="FI2017Q3_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">92</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43770747e1108-wk-Fact-7DAD092F708C5E7CAC2F33934FCB84C5" name="us-gaap:DerivativeAssets" contextRef="FI2016Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">79</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Foreign currency forward-exchange contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43770747e1133-wk-Fact-83B9658BE9A85FE39B70C11E0CE57D00" name="us-gaap:DerivativeAssets" contextRef="FI2017Q3_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">110</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43770747e1152-wk-Fact-7911451CA2425E27919489254BB944BC" name="us-gaap:DerivativeAssets" contextRef="FI2016Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">551</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43770747e1178-wk-Fact-F7F348B359C05BD59C8DCACAAC15C4ED" name="us-gaap:InvestmentsFairValueDisclosure" contextRef="FI2017Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">20,631</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43770747e1197-wk-Fact-757F830EC82D5CFD89824C319DD82983" name="us-gaap:InvestmentsFairValueDisclosure" contextRef="FI2016Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">22,198</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;text-decoration:underline;">Other selected financial assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Held-to-maturity debt securities, carried at amortized cost</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(c), (e)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43770747e1268-wk-Fact-EF31EB7FE14056148C1A008C93495CEB" name="us-gaap:HeldToMaturitySecuritiesAmortizedCostBeforeOtherThanTemporaryImpairment" contextRef="FI2017Q3_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,464</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43770747e1287-wk-Fact-016B619738A05C4C98C28A747752066A" name="us-gaap:HeldToMaturitySecuritiesAmortizedCostBeforeOtherThanTemporaryImpairment" contextRef="FI2016Q4_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,242</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Restricted stock and private equity securities, carried at cost or at equity-method</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(e)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43770747e1314-wk-Fact-A8F0564C8A745E648231F57D9FCE7C93" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" contextRef="FI2017Q3_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">719</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43770747e1333-wk-Fact-D91DA66DDA5D533D8090F62E9D24777E" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" contextRef="FI2016Q4_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">735</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43770747e1358-wk-Fact-A0182ACA4F165CCB82F049A8ABDC4DBF" name="pfe:OtherSelectedFinancialAssets" contextRef="FI2017Q3_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,183</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43770747e1377-wk-Fact-CA4FA1C7373451C8A831BCB0B87C840F" name="pfe:OtherSelectedFinancialAssets" contextRef="FI2016Q4_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,977</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total selected financial assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43770747e1407-wk-Fact-E6CB94780D3353F3BA7F2B694D175111" name="pfe:SelectedFinancialAssets" contextRef="FI2017Q3" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">22,815</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43770747e1426-wk-Fact-5C1AA03131755C62809F1FFA81347761" name="pfe:SelectedFinancialAssets" contextRef="FI2016Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">24,175</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;text-decoration:underline;">Selected financial liabilities measured at fair value on a recurring basis</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Derivative financial instruments in a liability position</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(f)</sup></span><span style="font-family:inherit;font-size:9pt;">:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Interest rate swaps</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43770747e1545-wk-Fact-86294AF06C6D55869B1ABEBE900AFFD4" name="us-gaap:DerivativeLiabilities" contextRef="FI2017Q3_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">154</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43770747e1564-wk-Fact-3ABBEBBC9C675BDDBFD1245A5C8DACAB" name="us-gaap:DerivativeLiabilities" contextRef="FI2016Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">148</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Foreign currency swaps</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43770747e1584-wk-Fact-BC41639F074B5D2EB9452A1CA1147B95" name="us-gaap:DerivativeLiabilities" contextRef="FI2017Q3_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">710</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43770747e1603-wk-Fact-08EE5A3AD5B453F08A8BB6A7ACA9E8BF" name="us-gaap:DerivativeLiabilities" contextRef="FI2016Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,374</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Foreign currency forward-exchange contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43770747e1628-wk-Fact-46A836D9C25B56FF9251C6C08C3CCB44" name="us-gaap:DerivativeLiabilities" contextRef="FI2017Q3_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">309</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43770747e1647-wk-Fact-8A158D27D5F55CB592CF35BFF232EA8E" name="us-gaap:DerivativeLiabilities" contextRef="FI2016Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">143</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43770747e1673-wk-Fact-6AAB9598D7F95613809C632062D37B56" name="us-gaap:DerivativeLiabilities" contextRef="FI2017Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,173</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43770747e1692-wk-Fact-F94A368CB7E95851A8FE7949FC3E83F4" name="us-gaap:DerivativeLiabilities" contextRef="FI2016Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,665</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;text-decoration:underline;">Other selected financial liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Short-term borrowings:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Principal amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43770747e1807-wk-Fact-3F79F79E695F5CE4B962B63AAED2DE8F" name="pfe:ShorttermDebtGross" contextRef="FI2017Q3_us-gaap_ShortTermDebtTypeAxis_us-gaap_ShortTermDebtMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">9,460</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43770747e1826-wk-Fact-027F10FE60DD52F486596E63C347B317" name="pfe:ShorttermDebtGross" contextRef="FI2016Q4_us-gaap_ShortTermDebtTypeAxis_us-gaap_ShortTermDebtMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">10,674</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net fair value adjustments related to hedging and purchase accounting</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43770747e1851-wk-Fact-E40F35B62CBF5523AF38617867D4C7F7" name="pfe:DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting" contextRef="FI2017Q3_us-gaap_ShortTermDebtTypeAxis_us-gaap_ShortTermDebtMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43770747e1870-wk-Fact-D952476EAD965FD6B32296538DBBE2EC" name="pfe:DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting" contextRef="FI2016Q4_us-gaap_ShortTermDebtTypeAxis_us-gaap_ShortTermDebtMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">24</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net unamortized discounts, premiums and debt issuance costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d43770747e1895-wk-Fact-682AE28CCF9C5CFD92DE68FAEA990C8A" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" contextRef="FI2017Q3_us-gaap_ShortTermDebtTypeAxis_us-gaap_ShortTermDebtMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">15</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d43770747e1915-wk-Fact-FA96EB5CF9675E82B84293BDCF862686" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" contextRef="FI2016Q4_us-gaap_ShortTermDebtTypeAxis_us-gaap_ShortTermDebtMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">11</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:30px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total short-term borrowings, carried at historical proceeds, as adjusted</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(e)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43770747e1943-wk-Fact-CDA40E6949B85E61B9C8AF985182E3E5" name="us-gaap:DebtCurrent" contextRef="FI2017Q3" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">9,448</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43770747e1962-wk-Fact-3A3BB372357A5CD2BCD070742B0C6955" name="us-gaap:DebtCurrent" contextRef="FI2016Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">10,688</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Long-term debt:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Principal amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43770747e2033-wk-Fact-62D4603F2920566D82D47397DAD177D8" name="us-gaap:DebtInstrumentCarryingAmount" contextRef="FI2017Q3_us-gaap_LongtermDebtTypeAxis_us-gaap_LongTermDebtMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">33,671</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43770747e2052-wk-Fact-60A8300F8F915FE4A2791C932D3F675C" name="us-gaap:DebtInstrumentCarryingAmount" contextRef="FI2016Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_LongTermDebtMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">30,529</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net fair value adjustments related to hedging and purchase accounting</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43770747e2077-wk-Fact-7E1D2ADE8CC85A6A93BF9005DA5868E8" name="pfe:DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting" contextRef="FI2017Q3_us-gaap_LongtermDebtTypeAxis_us-gaap_LongTermDebtMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">981</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43770747e2096-wk-Fact-614F307EF6C9513B9C3CFB3B7890CA2B" name="pfe:DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting" contextRef="FI2016Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_LongTermDebtMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">998</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net unamortized discounts, premiums and debt issuance costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d43770747e2121-wk-Fact-50C16A695EC55BD7BE645A931F2CD3FB" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" contextRef="FI2017Q3_us-gaap_LongtermDebtTypeAxis_us-gaap_LongTermDebtMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">149</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d43770747e2141-wk-Fact-6D30546FE1C55A63A405488535B42F5C" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" contextRef="FI2016Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_LongTermDebtMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">130</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:30px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total long-term debt, carried at historical proceeds, as adjusted</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(g)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43770747e2170-wk-Fact-A38618717132561C9E1931D14EDF6B51" name="us-gaap:LongTermDebtNoncurrent" contextRef="FI2017Q3" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">34,503</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43770747e2189-wk-Fact-F0B612439D18585FBB73EEB374B11207" name="us-gaap:LongTermDebtNoncurrent" contextRef="FI2016Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">31,398</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43770747e2214-wk-Fact-2C3C2A2FBC5A5C7782D4EC059C66B0D8" name="pfe:OtherFinancialLiabilities" contextRef="FI2017Q3" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">43,951</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43770747e2233-wk-Fact-46F3B1E000295AB899BE7E92E41A5B2F" name="pfe:OtherFinancialLiabilities" contextRef="FI2016Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">42,085</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total selected financial liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43770747e2263-wk-Fact-8DCAFAA7B56457C6BEF555E12EFD7591" name="pfe:SelectedFinancialLiabilities" contextRef="FI2017Q3" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">45,124</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43770747e2282-wk-Fact-5E2BE4A63E3B578A867B078295A4C781" name="pfe:SelectedFinancialLiabilities" contextRef="FI2016Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">43,750</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></ix:nonNumeric></div><ix:continuation id="TextSelection-068F0051446755189ABCE40C311C2AE8-1" continuedAt="TextSelection-068F0051446755189ABCE40C311C2AE8-2"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><ix:footnote id="TextSelection-8D2A93033C2E56DE9E814F0AB36328EE-0-wk-Footnote-8D2A93033C2E56DE9E814F0AB36328EE_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" continuedAt="TextSelection-8D2A93033C2E56DE9E814F0AB36328EE-1">We use a market approach in valuing financial instruments on a recurring basis. All of our financial assets and liabilities measured at fair value on a recurring basis use Level 2 inputs in the calculation of fair value, except </ix:footnote></span><ix:continuation id="TextSelection-8D2A93033C2E56DE9E814F0AB36328EE-1" continuedAt="TextSelection-8D2A93033C2E56DE9E814F0AB36328EE-2"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d43770747e2301-wk-Fact-EB14449D25875188A6C1A2FB87CDCC9E" name="pfe:FinancialAssetsAndLiabilitiesMeasuredAtFairValuePercentage" contextRef="FI2017Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">5</ix:nonFraction>%</span></span></ix:continuation><span style="font-family:inherit;font-size:8.5pt;"><ix:continuation id="TextSelection-8D2A93033C2E56DE9E814F0AB36328EE-2"> that use Level 1 inputs.</ix:continuation></span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><ix:footnote id="TextSelection-0A1952177FA453EC8B5651D58249A9BA-0-wk-Footnote-0A1952177FA453EC8B5651D58249A9BA_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" continuedAt="TextSelection-0A1952177FA453EC8B5651D58249A9BA-1">As of </ix:footnote></span><ix:continuation id="TextSelection-0A1952177FA453EC8B5651D58249A9BA-1" continuedAt="TextSelection-0A1952177FA453EC8B5651D58249A9BA-2"><span style="font-family:inherit;font-size:8.5pt;">October&#160;1, 2017</span><span style="font-family:inherit;font-size:8.5pt;">, trading funds and securities are composed of </span><span style="font-family:inherit;font-size:8.5pt;"><span>$<ix:nonFraction id="d43770747e2325-wk-Fact-F2BAAC1F8C0155D4BF7BAE62787DC4B4" name="us-gaap:TradingSecuritiesEquity" contextRef="FI2017Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">274</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:8.5pt;"> of trading equity funds and </span><span style="font-family:inherit;font-size:8.5pt;"><span>$<ix:nonFraction id="d43770747e2329-wk-Fact-6B300406E4D055CAA310A2CA99305580" name="us-gaap:TradingSecuritiesDebt" contextRef="FI2017Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">74</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:8.5pt;"> of trading debt funds. As of </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">December&#160;31, 2016</span><span style="font-family:inherit;font-size:8.5pt;">, trading funds and securities are composed of </span><span style="font-family:inherit;font-size:8.5pt;"><span>$<ix:nonFraction id="d43770747e2341-wk-Fact-B377D7EDA5A55915B767CED9AB9A0251" name="us-gaap:TradingSecuritiesEquity" contextRef="FI2016Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">236</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:8.5pt;"> of trading equity funds and </span><span style="font-family:inherit;font-size:8.5pt;"><span>$<ix:nonFraction id="d43770747e2346-wk-Fact-5673CD6101B3593E8580BF751D06B905" name="us-gaap:TradingSecuritiesDebt" contextRef="FI2016Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">89</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:8.5pt;"> of trading debt funds. As of </span><span style="font-family:inherit;font-size:8.5pt;">October&#160;1, 2017</span><span style="font-family:inherit;font-size:8.5pt;"> and </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">December&#160;31, 2016</span><span style="font-family:inherit;font-size:8.5pt;">, trading equity funds of </span><span style="font-family:inherit;font-size:8.5pt;"><span>$<ix:nonFraction id="d43770747e2358-wk-Fact-3773CDF02A2C540293D7C2DE790FCA07" name="us-gaap:TradingSecuritiesRestricted" contextRef="FI2017Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">63</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:8.5pt;"> and </span><span style="font-family:inherit;font-size:8.5pt;"><span>$<ix:nonFraction id="d43770747e2362-wk-Fact-DFF536411EC059C38BB823809C4C34CE" name="us-gaap:TradingSecuritiesRestricted" contextRef="FI2016Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">71</ix:nonFraction> million</span></span></ix:continuation><span style="font-family:inherit;font-size:8.5pt;"><ix:continuation id="TextSelection-0A1952177FA453EC8B5651D58249A9BA-2">, respectively, are held in trust for benefits attributable to the former Pharmacia Savings Plus Plan.</ix:continuation></span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(c)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><ix:footnote id="TextSelection-E96B3A139CCA56EC98329BC3717B10E3-0-wk-Footnote-E96B3A139CCA56EC98329BC3717B10E3_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" continuedAt="TextSelection-E96B3A139CCA56EC98329BC3717B10E3-1">Gross unrealized gains and losses are not significant, except as of </ix:footnote></span><ix:continuation id="TextSelection-E96B3A139CCA56EC98329BC3717B10E3-1" continuedAt="TextSelection-E96B3A139CCA56EC98329BC3717B10E3-2"><span style="font-family:inherit;font-size:8.5pt;">October&#160;1, 2017</span><span style="font-family:inherit;font-size:8.5pt;">, available-for-sale equity securities&#8217; unrealized gains are </span><span style="font-family:inherit;font-size:8.5pt;"><span>$<ix:nonFraction id="d43770747e2386-wk-Fact-1FF87B2336F9B8E1315B831E8E8ED77B" name="us-gaap:AvailableForSaleEquitySecuritiesGrossUnrealizedGain" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">406</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:8.5pt;"> and unrealized losses are </span><span style="font-family:inherit;font-size:8.5pt;"><span>$<ix:nonFraction id="d43770747e2390-wk-Fact-FFD37754D254246CC994831E8E9A1E3D" name="us-gaap:AvailableForSaleEquitySecuritiesGrossUnrealizedLoss" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">119</ix:nonFraction> million</span></span></ix:continuation><span style="font-family:inherit;font-size:8.5pt;"><ix:continuation id="TextSelection-E96B3A139CCA56EC98329BC3717B10E3-2">.</ix:continuation></span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(d)</sup><ix:footnote id="TextSelection-91730671722A5F83BA05EF347193E4CF-0-wk-Footnote-91730671722A5F83BA05EF347193E4CF_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" continuedAt="TextSelection-91730671722A5F83BA05EF347193E4CF-1">&#160;</ix:footnote></span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8.5pt;"><ix:continuation id="TextSelection-91730671722A5F83BA05EF347193E4CF-1" continuedAt="TextSelection-91730671722A5F83BA05EF347193E4CF-2"><span style="font-family:inherit;font-size:8.5pt;">Designated as hedging instruments, except for certain contracts used as offsets; namely, foreign currency forward-exchange contracts with fair values of </span><span style="font-family:inherit;font-size:8.5pt;"><span>$<ix:nonFraction id="d43770747e2419-wk-Fact-FFB9B4A0936651119FB54BF7F4D85632" name="us-gaap:DerivativeFairValueOfDerivativeAsset" contextRef="FI2017Q3_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">40</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:8.5pt;"> as of </span><span style="font-family:inherit;font-size:8.5pt;">October&#160;1, 2017</span><span style="font-family:inherit;font-size:8.5pt;">; and foreign currency forward-exchange contracts with fair values of </span><span style="font-family:inherit;font-size:8.5pt;"><span>$<ix:nonFraction id="d43770747e2427-wk-Fact-672D98C873A75FBD8A51318589146FD5" name="us-gaap:DerivativeFairValueOfDerivativeAsset" contextRef="FI2016Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">162</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:8.5pt;"> as of </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">December&#160;31, 2016</span></ix:continuation><span style="font-family:inherit;font-size:8.5pt;"><ix:continuation id="TextSelection-91730671722A5F83BA05EF347193E4CF-2">.</ix:continuation></span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(e)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><ix:footnote id="TextSelection-E90A054BCC035ECEB6B6F2B7C947C3CE-0-wk-Footnote-E90A054BCC035ECEB6B6F2B7C947C3CE_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" continuedAt="TextSelection-E90A054BCC035ECEB6B6F2B7C947C3CE-1">The differences between the estimated fair values and carrying values of held-to-maturity debt securities, restricted stock and private equity securities at cost, and short-term borrowings not measured at fair value on a recurring basis were not significant as of </ix:footnote></span><ix:continuation id="TextSelection-E90A054BCC035ECEB6B6F2B7C947C3CE-1" continuedAt="TextSelection-E90A054BCC035ECEB6B6F2B7C947C3CE-2"><span style="font-family:inherit;font-size:8.5pt;">October&#160;1, 2017</span><span style="font-family:inherit;font-size:8.5pt;"> or </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">December&#160;31, 2016</span><span style="font-family:inherit;font-size:8.5pt;">. The fair value measurements of our held-to-maturity debt securities and our short-term borrowings are based on Level 2 inputs, using a market approach. The fair value measurements of our </span><span style="font-family:inherit;font-size:8.5pt;background-color:#ffffff;">priv</span></ix:continuation><span style="font-family:inherit;font-size:8.5pt;"><ix:continuation id="TextSelection-E90A054BCC035ECEB6B6F2B7C947C3CE-2">ate equity securities carried at cost are based on Level 3 inputs.</ix:continuation></span></div></td></tr></table><div style="line-height:120%;padding-left:4px;text-align:left;padding-left:12px;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><br/></span></div></ix:continuation></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">20</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:center;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(UNAUDITED)</span></div></div><div><br/></div><ix:continuation id="TextSelection-1EE0D555564D5ACA882C4EC0D6E9B51D-2" continuedAt="TextSelection-1EE0D555564D5ACA882C4EC0D6E9B51D-3"><ix:continuation id="TextSelection-068F0051446755189ABCE40C311C2AE8-2" continuedAt="TextSelection-068F0051446755189ABCE40C311C2AE8-3"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(f)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><ix:footnote id="TextSelection-58096FF6357955D6B6AA25D56767CB0A-0-wk-Footnote-58096FF6357955D6B6AA25D56767CB0A_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" continuedAt="TextSelection-58096FF6357955D6B6AA25D56767CB0A-1">Designated as hedging instruments, except for certain contracts used as offsets; namely, foreign currency forward-exchange contracts with fair values of </ix:footnote></span><ix:continuation id="TextSelection-58096FF6357955D6B6AA25D56767CB0A-1" continuedAt="TextSelection-58096FF6357955D6B6AA25D56767CB0A-2"><span style="font-family:inherit;font-size:8.5pt;"><span>$<ix:nonFraction id="d43770747e2499-wk-Fact-3C97612091CC5A7080F96C66E1F8AF67" name="us-gaap:DerivativeFairValueOfDerivativeLiability" contextRef="FI2017Q3_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">60</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:8.5pt;"> as of </span><span style="font-family:inherit;font-size:8.5pt;">October&#160;1, 2017</span><span style="font-family:inherit;font-size:8.5pt;">; and foreign currency swaps with fair values of </span><span style="font-family:inherit;font-size:8.5pt;"><span>$<ix:nonFraction id="d43770747e2507-wk-Fact-F650193C390E5EA5A151907EB06BF4AE" name="us-gaap:DerivativeFairValueOfDerivativeLiability" contextRef="FI2016Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">269</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:8.5pt;"> and foreign currency forward-exchange contracts with fair values of </span><span style="font-family:inherit;font-size:8.5pt;"><span>$<ix:nonFraction id="d43770747e2516-wk-Fact-116969AF25A05CA8857AA9F6980B5573" name="us-gaap:DerivativeFairValueOfDerivativeLiability" contextRef="FI2016Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">113</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:8.5pt;"> as of </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">December&#160;31, 2016</span></ix:continuation><span style="font-family:inherit;font-size:8.5pt;"><ix:continuation id="TextSelection-58096FF6357955D6B6AA25D56767CB0A-2">.</ix:continuation></span></div></td></tr></table></ix:continuation><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><ix:continuation id="TextSelection-068F0051446755189ABCE40C311C2AE8-3" continuedAt="TextSelection-068F0051446755189ABCE40C311C2AE8-4"><div style="line-height:120%;font-size:8.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(g)</sup>&#160;</span></div></ix:continuation></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8.5pt;"><ix:continuation id="TextSelection-068F0051446755189ABCE40C311C2AE8-4" continuedAt="TextSelection-068F0051446755189ABCE40C311C2AE8-5"><span style="font-family:inherit;font-size:8.5pt;"><ix:footnote id="TextSelection-CBF70F977965537BB382CD083809AA0A-0-wk-Footnote-CBF70F977965537BB382CD083809AA0A_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" continuedAt="TextSelection-CBF70F977965537BB382CD083809AA0A-1">The fair value of our long-term debt (not including the current portion of long-term debt) was </ix:footnote></span><ix:continuation id="TextSelection-CBF70F977965537BB382CD083809AA0A-1" continuedAt="TextSelection-CBF70F977965537BB382CD083809AA0A-2"><span style="font-family:inherit;font-size:8.5pt;"><span>$<ix:nonFraction id="d43770747e2562-wk-Fact-45C5834678DB58BDAA717AECB3594675" name="us-gaap:LongTermDebtFairValue" contextRef="FI2017Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">39.0</ix:nonFraction> billion</span></span><span style="font-family:inherit;font-size:8.5pt;"> as of </span><span style="font-family:inherit;font-size:8.5pt;">October&#160;1, 2017</span><span style="font-family:inherit;font-size:8.5pt;"> and </span><span style="font-family:inherit;font-size:8.5pt;"><span>$<ix:nonFraction id="d43770747e2570-wk-Fact-0EA04BF7E19453C7A25ACCB13F4B457B" name="us-gaap:LongTermDebtFairValue" contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">34.9</ix:nonFraction> billion</span></span><span style="font-family:inherit;font-size:8.5pt;"> as of </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">December&#160;31, 2016</span><span style="font-family:inherit;font-size:8.5pt;">. The fair value measurements for our long-term debt are based on Level 2 inputs, using a market approach. Long-term debt includes foreign currency long-term borrowings with fair values of </span><span style="font-family:inherit;font-size:8.5pt;"><span>$<ix:nonFraction id="d43770747e2582-wk-Fact-BC78E42FE17E5426A74B537FA7D7F232" name="us-gaap:LongTermDebtFairValue" contextRef="FI2017Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_LongtermDebtTypeAxis_pfe_ForeignCurrencyLongTermDebtMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">4.7</ix:nonFraction> billion</span></span><span style="font-family:inherit;font-size:8.5pt;"> as of </span><span style="font-family:inherit;font-size:8.5pt;">October&#160;1, 2017</span></ix:continuation></ix:continuation><span style="font-family:inherit;font-size:8.5pt;"><ix:continuation id="TextSelection-CBF70F977965537BB382CD083809AA0A-2"><ix:continuation id="TextSelection-068F0051446755189ABCE40C311C2AE8-5">, which are used as hedging instruments.</ix:continuation></ix:continuation></span></div></td></tr></table><div style="line-height:120%;padding-left:4px;text-align:left;font-size:10pt;"><ix:nonNumeric contextRef="FD2017Q3YTD" name="us-gaap:FairValueByBalanceSheetGroupingTextBlock" id="TextSelection-6E798238F9AC5935959E73C61E57387F-0-wk-Fact-B6875F7E94B654F18BD6C2CB1C5F7563" continuedAt="TextSelection-6E798238F9AC5935959E73C61E57387F-1" escape="true"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:72%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides the classification of these selected financial assets and liabilities in our condensed consolidated balance sheets:</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">October&#160;1, <br/>2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December&#160;31, <br/>2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43770747e2786-wk-Fact-C14CB8A835A056749D89EDF60990A9AA" name="pfe:SelectedFinancialAssets" contextRef="FI2017Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_CashAndCashEquivalentsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">526</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43770747e2805-wk-Fact-874EB63A337F5B4FA4242E746F192A96" name="pfe:SelectedFinancialAssets" contextRef="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_CashAndCashEquivalentsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">547</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Short-term investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43770747e2825-wk-Fact-1581DCE37F87517D9ECBF9C086D87E06" name="pfe:SelectedFinancialAssets" contextRef="FI2017Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">14,146</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43770747e2844-wk-Fact-032D3B270315597495D82B755AC4482E" name="pfe:SelectedFinancialAssets" contextRef="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">15,255</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other current assets</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43770747e2871-wk-Fact-36F90A1B2B3150DD8B3EF42CE7A207C4" name="pfe:SelectedFinancialAssets" contextRef="FI2017Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">288</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43770747e2890-wk-Fact-52A1B75A34225AB0850E4467B145EE4C" name="pfe:SelectedFinancialAssets" contextRef="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">567</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Long-term investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43770747e2915-wk-Fact-350A83F5C4215640814818A652039736" name="pfe:SelectedFinancialAssets" contextRef="FI2017Q3_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">7,311</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43770747e2934-wk-Fact-97A4038FB64E5728860321AE65BCAB42" name="pfe:SelectedFinancialAssets" contextRef="FI2016Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">7,116</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other noncurrent assets</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43770747e2961-wk-Fact-70B840CF49ED50999728E55D1211F51E" name="pfe:SelectedFinancialAssets" contextRef="FI2017Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">543</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43770747e2980-wk-Fact-5AA4AF01AEF35754AABE41FB942D2F87" name="pfe:SelectedFinancialAssets" contextRef="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">689</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43770747e3010-wk-Fact-E6CB94780D3353F3BA7F2B694D175111" name="pfe:SelectedFinancialAssets" contextRef="FI2017Q3" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">22,815</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43770747e3029-wk-Fact-5C1AA03131755C62809F1FFA81347761" name="pfe:SelectedFinancialAssets" contextRef="FI2016Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">24,175</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Short-term borrowings, including current portion of long-term debt</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43770747e3098-wk-Fact-1D82794B618257F78F598CF9F73E8258" name="pfe:SelectedFinancialLiabilities" contextRef="FI2017Q3_us-gaap_BalanceSheetLocationAxis_pfe_ShortTermDebtAndCurrentPortionofLongTermDebtMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">9,448</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43770747e3117-wk-Fact-87FE279043415B0A8BAD4E7A3A89CFD4" name="pfe:SelectedFinancialLiabilities" contextRef="FI2016Q4_us-gaap_BalanceSheetLocationAxis_pfe_ShortTermDebtAndCurrentPortionofLongTermDebtMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">10,688</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other current liabilities</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43770747e3140-wk-Fact-C233B7CC79495307BFD442EFB72D3A1B" name="pfe:SelectedFinancialLiabilities" contextRef="FI2017Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">277</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43770747e3159-wk-Fact-4F630A08F3EE5D04A766A973955E5DEE" name="pfe:SelectedFinancialLiabilities" contextRef="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">443</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Long-term debt</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43770747e3184-wk-Fact-591249F3A3B953A590882A39D1A9DD7A" name="pfe:SelectedFinancialLiabilities" contextRef="FI2017Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_LongTermDebtMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">34,503</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43770747e3203-wk-Fact-5936AEBB2929595EAF13054CFE38FD5D" name="pfe:SelectedFinancialLiabilities" contextRef="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_LongTermDebtMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">31,398</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other noncurrent liabilities</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(d)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43770747e3230-wk-Fact-A940673F4FF9572DA53F97129770EE39" name="pfe:SelectedFinancialLiabilities" contextRef="FI2017Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">896</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43770747e3249-wk-Fact-8AFCAB1E804757FEBFCB197A8AE4804C" name="pfe:SelectedFinancialLiabilities" contextRef="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,222</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43770747e3279-wk-Fact-8DCAFAA7B56457C6BEF555E12EFD7591" name="pfe:SelectedFinancialLiabilities" contextRef="FI2017Q3" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">45,124</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43770747e3298-wk-Fact-5E2BE4A63E3B578A867B078295A4C781" name="pfe:SelectedFinancialLiabilities" contextRef="FI2016Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">43,750</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></ix:nonNumeric></div><ix:continuation id="TextSelection-6E798238F9AC5935959E73C61E57387F-1" continuedAt="TextSelection-6E798238F9AC5935959E73C61E57387F-2"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><ix:footnote id="TextSelection-A9B5859E968353E1AF0EF5AF16D3F7DE-0-wk-Footnote-A9B5859E968353E1AF0EF5AF16D3F7DE_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" continuedAt="TextSelection-A9B5859E968353E1AF0EF5AF16D3F7DE-1">As of </ix:footnote></span><ix:continuation id="TextSelection-A9B5859E968353E1AF0EF5AF16D3F7DE-1" continuedAt="TextSelection-A9B5859E968353E1AF0EF5AF16D3F7DE-2"><span style="font-family:inherit;font-size:9pt;">October&#160;1, 2017</span><span style="font-family:inherit;font-size:9pt;">, derivative instruments at fair value include interest rate swaps (</span><span style="font-family:inherit;font-size:9pt;"><span>$<ix:nonFraction id="d43770747e3321-wk-Fact-D9382D2EDCC659CA849F7D7BEE1A33C7" name="pfe:SelectedFinancialAssets" contextRef="FI2017Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">97</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:9pt;">), foreign currency swaps (</span><span style="font-family:inherit;font-size:9pt;"><span>$<ix:nonFraction id="d43770747e3325-wk-Fact-5F43619CCE5E5C3C9F78C006EA857643" name="pfe:SelectedFinancialAssets" contextRef="FI2017Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">86</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:9pt;">) and foreign currency forward-exchange contracts (</span><span style="font-family:inherit;font-size:9pt;"><span>$<ix:nonFraction id="d43770747e3329-wk-Fact-5250A6954FA55E1C99886991BB3C2CF2" name="pfe:SelectedFinancialAssets" contextRef="FI2017Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">105</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:9pt;">) and, as of </span><span style="font-family:inherit;font-size:9pt;text-align:center;">December&#160;31, 2016</span><span style="font-family:inherit;font-size:9pt;">, include interest rate swaps (</span><span style="font-family:inherit;font-size:9pt;"><span>$<ix:nonFraction id="d43770747e3338-wk-Fact-9A136F3603FE563FA0181F7FB96BD1CC" name="pfe:SelectedFinancialAssets" contextRef="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">26</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:9pt;">), foreign currency swaps (</span><span style="font-family:inherit;font-size:9pt;"><span>$<ix:nonFraction id="d43770747e3342-wk-Fact-3F3E30F15064545B802AD046C9E17B4C" name="pfe:SelectedFinancialAssets" contextRef="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">43</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:9pt;">) and foreign currency forward-exchange contracts (</span><span style="font-family:inherit;font-size:9pt;"><span>$<ix:nonFraction id="d43770747e3355-wk-Fact-E01C9BFB927A5CA488365B65EC8BD6C8" name="pfe:SelectedFinancialAssets" contextRef="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">497</ix:nonFraction> million</span></span></ix:continuation><span style="font-family:inherit;font-size:9pt;"><ix:continuation id="TextSelection-A9B5859E968353E1AF0EF5AF16D3F7DE-2">).</ix:continuation></span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><ix:footnote id="TextSelection-D60DE89EECC65B759281157686B85E20-0-wk-Footnote-D60DE89EECC65B759281157686B85E20_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" continuedAt="TextSelection-D60DE89EECC65B759281157686B85E20-1">As of </ix:footnote></span><ix:continuation id="TextSelection-D60DE89EECC65B759281157686B85E20-1" continuedAt="TextSelection-D60DE89EECC65B759281157686B85E20-2"><span style="font-family:inherit;font-size:9pt;">October&#160;1, 2017</span><span style="font-family:inherit;font-size:9pt;">, derivative instruments at fair value include interest rate swaps (</span><span style="font-family:inherit;font-size:9pt;"><span>$<ix:nonFraction id="d43770747e3374-wk-Fact-E6D90BEAB70E5F0E9E0D711DE2D3B265" name="pfe:SelectedFinancialAssets" contextRef="FI2017Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">532</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:9pt;">), foreign currency swaps (</span><span style="font-family:inherit;font-size:9pt;"><span>$<ix:nonFraction id="d43770747e3378-wk-Fact-C04D58B8AC0D5303B3B2068EAD424F6A" name="pfe:SelectedFinancialAssets" contextRef="FI2017Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:9pt;">) and foreign currency forward-exchange contracts (</span><span style="font-family:inherit;font-size:9pt;"><span>$<ix:nonFraction id="d43770747e3382-wk-Fact-AF1808DC6D2A57B3B1C44677F5112896" name="pfe:SelectedFinancialAssets" contextRef="FI2017Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">5</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:9pt;">) and, as of </span><span style="font-family:inherit;font-size:9pt;text-align:center;">December&#160;31, 2016</span><span style="font-family:inherit;font-size:9pt;">, include interest rate swaps (</span><span style="font-family:inherit;font-size:9pt;"><span>$<ix:nonFraction id="d43770747e3391-wk-Fact-EC83A458C6B35CFC979AC747D965A4D6" name="pfe:SelectedFinancialAssets" contextRef="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">599</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:9pt;">), foreign currency swaps (</span><span style="font-family:inherit;font-size:9pt;"><span>$<ix:nonFraction id="d43770747e3395-wk-Fact-DC926B2EDC6654C18AE6604914AD72A0" name="pfe:SelectedFinancialAssets" contextRef="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">36</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:9pt;">) and foreign currency forward-exchange contracts (</span><span style="font-family:inherit;font-size:9pt;"><span>$<ix:nonFraction id="d43770747e3404-wk-Fact-93B2D486DC1755F597BE0363A34BF0D1" name="pfe:SelectedFinancialAssets" contextRef="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">54</ix:nonFraction> million</span></span></ix:continuation><span style="font-family:inherit;font-size:9pt;"><ix:continuation id="TextSelection-D60DE89EECC65B759281157686B85E20-2">).</ix:continuation></span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(c)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><ix:footnote id="TextSelection-DAFABE7CE058521690718900BE6137FA-0-wk-Footnote-DAFABE7CE058521690718900BE6137FA_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" continuedAt="TextSelection-DAFABE7CE058521690718900BE6137FA-1">As of </ix:footnote></span><ix:continuation id="TextSelection-DAFABE7CE058521690718900BE6137FA-1" continuedAt="TextSelection-DAFABE7CE058521690718900BE6137FA-2"><span style="font-family:inherit;font-size:9pt;">October&#160;1, 2017</span><span style="font-family:inherit;font-size:9pt;">, derivative instruments at fair value include foreign currency forward-exchange contracts (</span><span style="font-family:inherit;font-size:9pt;"><span>$<ix:nonFraction id="d43770747e3427-wk-Fact-D0C449F0E4795BCF86CF0547BDDD9858" name="pfe:SelectedFinancialLiabilities" contextRef="FI2017Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">276</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:9pt;">) and interest rate swaps (</span><span style="font-family:inherit;font-size:9pt;"><span>$<ix:nonFraction id="d43770747e3431-wk-Fact-631131C929F031BC3E295A684B82600F" name="pfe:SelectedFinancialLiabilities" contextRef="FI2017Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:9pt;">) and, as of </span><span style="font-family:inherit;font-size:9pt;text-align:center;">December&#160;31, 2016</span><span style="font-family:inherit;font-size:9pt;">, include interest rate swaps (</span><span style="font-family:inherit;font-size:9pt;"><span>$<ix:nonFraction id="d43770747e3439-wk-Fact-1A0D40EA51075595ABAC8E4790EF7080" name="pfe:SelectedFinancialLiabilities" contextRef="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:9pt;">), foreign currency swaps (</span><span style="font-family:inherit;font-size:9pt;"><span>$<ix:nonFraction id="d43770747e3444-wk-Fact-08852AFF5F88570697995A5B34C82D12" name="pfe:SelectedFinancialLiabilities" contextRef="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">300</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:9pt;">) and foreign currency forward-exchange contracts (</span><span style="font-family:inherit;font-size:9pt;"><span>$<ix:nonFraction id="d43770747e3458-wk-Fact-A944C0B6E0975A6385CE0A94B72B97BA" name="pfe:SelectedFinancialLiabilities" contextRef="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">143</ix:nonFraction> million</span></span></ix:continuation><span style="font-family:inherit;font-size:9pt;"><ix:continuation id="TextSelection-DAFABE7CE058521690718900BE6137FA-2">).</ix:continuation></span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(d)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><ix:footnote id="TextSelection-8C173666F61E55D5A1394009569043BA-0-wk-Footnote-8C173666F61E55D5A1394009569043BA_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" continuedAt="TextSelection-8C173666F61E55D5A1394009569043BA-1">As of </ix:footnote></span><ix:continuation id="TextSelection-8C173666F61E55D5A1394009569043BA-1" continuedAt="TextSelection-8C173666F61E55D5A1394009569043BA-2"><span style="font-family:inherit;font-size:9pt;">October&#160;1, 2017</span><span style="font-family:inherit;font-size:9pt;">, derivative instruments at fair value include interest rate swaps (</span><span style="font-family:inherit;font-size:9pt;"><span>$<ix:nonFraction id="d43770747e3478-wk-Fact-705FB2500D595ABA8C549B72A96B54CB" name="pfe:SelectedFinancialLiabilities" contextRef="FI2017Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">153</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:9pt;">), foreign currency swaps (</span><span style="font-family:inherit;font-size:9pt;"><span>$<ix:nonFraction id="d43770747e3482-wk-Fact-D4436A20E8AA5B2E942797768A9AA765" name="pfe:SelectedFinancialLiabilities" contextRef="FI2017Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">710</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:9pt;">) and foreign currency forward-exchange contracts (</span><span style="font-family:inherit;font-size:9pt;"><span>$<ix:nonFraction id="d43770747e3486-wk-Fact-63C7D318AB085F0ABAA4D7A8C1586D44" name="pfe:SelectedFinancialLiabilities" contextRef="FI2017Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">33</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:9pt;">) and, as of </span><span style="font-family:inherit;font-size:9pt;text-align:center;">December&#160;31, 2016</span><span style="font-family:inherit;font-size:9pt;">, include interest rate swaps (</span><span style="font-family:inherit;font-size:9pt;"><span>$<ix:nonFraction id="d43770747e3495-wk-Fact-1F8D622FE8D553B8ACC42D6FC66AB8F1" name="pfe:SelectedFinancialLiabilities" contextRef="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">147</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:9pt;">) and foreign currency swaps (</span><span style="font-family:inherit;font-size:9pt;"><span>$<ix:nonFraction id="d43770747e3499-wk-Fact-E6713FC610C95165BD885FB1D579C44E" name="pfe:SelectedFinancialLiabilities" contextRef="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">1.1</ix:nonFraction> billion</span></span></ix:continuation><span style="font-family:inherit;font-size:9pt;"><ix:continuation id="TextSelection-8C173666F61E55D5A1394009569043BA-2">).</ix:continuation></span></div></td></tr></table></ix:continuation><div style="line-height:120%;padding-left:4px;text-align:left;font-size:5pt;"><span style="font-family:inherit;font-size:5pt;"><ix:continuation id="TextSelection-6E798238F9AC5935959E73C61E57387F-2"><br/></ix:continuation></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">There were no significant impairments of financial assets recognized in any period presented.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">21</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:center;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(UNAUDITED)</span></div></div><div><br/></div><ix:continuation id="TextSelection-1EE0D555564D5ACA882C4EC0D6E9B51D-3" continuedAt="TextSelection-1EE0D555564D5ACA882C4EC0D6E9B51D-4"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">B. Investments in Debt Securities</span></div><div style="line-height:120%;font-size:10pt;"><ix:nonNumeric contextRef="FD2017Q3YTD" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" id="TextSelection-9688601E187958D5B11F4E2C12289E3E-0-wk-Fact-2EBB3A03ADF55C91AC6582A974E1EC8C" continuedAt="TextSelection-9688601E187958D5B11F4E2C12289E3E-1" escape="true"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.41520467836257%;border-collapse:collapse;text-align:left;"><tr><td colspan="21"></td></tr><tr><td style="width:47%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td colspan="21" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides the contractual maturities, or as necessary, the estimated maturities, of the available-for-sale and held-to-maturity debt securities:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Years</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">October&#160;1, <br/>2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Within 1</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Over 1</span></div><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">to 5</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Over 5</span></div><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">to 10</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Over 10</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">Available-for-sale debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Corporate debt</span><span style="font-family:inherit;font-size:9.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d43770747e4019-wk-Fact-C140E7BD63345101B2DD7451627EE662" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue" contextRef="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,741</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d43770747e4038-wk-Fact-29ACCDED11BA511481ECE7E30ABD1FFA" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue" contextRef="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,591</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d43770747e4058-wk-Fact-47F85ABECEA3558FB193E486A6300E36" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearSixThroughTenFairValue" contextRef="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,525</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d43770747e4077-wk-Fact-A7D161E015BF50168317EC6EF30D2E9C" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingAfterYearTenFairValue" contextRef="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">17</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d43770747e4096-wk-Fact-0C018797136D5DE49DB04A0BF65EC513" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6,874</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Western European, Asian, and other government debt</span><span style="font-family:inherit;font-size:9.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d43770747e4118-wk-Fact-04349CF31E83539A9C576802A8424538" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue" contextRef="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_pfe_WesternEuropeanAsianandOtherGovernmentDebtMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6,071</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d43770747e4137-wk-Fact-0A1FE70C55BA5D7C9D62C4839596BBE9" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue" contextRef="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_pfe_WesternEuropeanAsianandOtherGovernmentDebtMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">268</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d43770747e4156-wk-Fact-D3AD03E39A685B5F98D9E5A6DA5939DF" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearSixThroughTenFairValue" contextRef="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_pfe_WesternEuropeanAsianandOtherGovernmentDebtMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d43770747e4176-wk-Fact-46FCF46F8CE857D6A45597A49A1788DE" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingAfterYearTenFairValue" contextRef="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_pfe_WesternEuropeanAsianandOtherGovernmentDebtMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d43770747e4195-wk-Fact-30E328BC808A5B65A7A777945EE0CE96" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_pfe_WesternEuropeanAsianandOtherGovernmentDebtMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6,339</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Western European, Scandinavian and other government agency debt</span><span style="font-family:inherit;font-size:9.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d43770747e4222-wk-Fact-626B15D2B1215E4FBC1B22217ABF166E" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue" contextRef="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_pfe_WesternEuropeanScandinaviaAndOtherGovernmentAgencyDebtMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,955</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d43770747e4241-wk-Fact-FF82CF35A3B95DE7946765F53E9FCC87" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue" contextRef="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_pfe_WesternEuropeanScandinaviaAndOtherGovernmentAgencyDebtMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">42</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d43770747e4260-wk-Fact-D1DB098BFAA05A5582E3C54C39A219DE" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearSixThroughTenFairValue" contextRef="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_pfe_WesternEuropeanScandinaviaAndOtherGovernmentAgencyDebtMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d43770747e4280-wk-Fact-6CF1FB1C274D54BC8DA1DED40575D72D" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingAfterYearTenFairValue" contextRef="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_pfe_WesternEuropeanScandinaviaAndOtherGovernmentAgencyDebtMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d43770747e4299-wk-Fact-0F8D6EEC302657CA8AE0B3CB897EB60C" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_pfe_WesternEuropeanScandinaviaAndOtherGovernmentAgencyDebtMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,998</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Supranational debt</span><span style="font-family:inherit;font-size:9.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d43770747e4326-wk-Fact-59CF56CBCF3D5BF18E0D45DDA6F642AA" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue" contextRef="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_pfe_SupranationalDebtMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">387</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d43770747e4345-wk-Fact-3A9320AC96A65345AF2925F4F49F63EE" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue" contextRef="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_pfe_SupranationalDebtMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">195</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d43770747e4364-wk-Fact-0A66AB4BBDF556D9BBC2F78276184CD8" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearSixThroughTenFairValue" contextRef="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_pfe_SupranationalDebtMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d43770747e4384-wk-Fact-1EB643CEE30E5AE0B145130CC6CEAC25" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingAfterYearTenFairValue" contextRef="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_pfe_SupranationalDebtMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d43770747e4403-wk-Fact-44ACB44C1F6D5867A9AE1BCDA6662468" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_pfe_SupranationalDebtMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">582</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Government National Mortgage Association and other U.S. government guaranteed asset-backed securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d43770747e4428-wk-Fact-739D85C3F5BC57A3959777FF1E874E02" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue" contextRef="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_GovernmentNationalMortgageAssociationCertificatesAndObligationsGNMAMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">42</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d43770747e4447-wk-Fact-624B0C7232B950EF913C61FB2CEC9FD5" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue" contextRef="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_GovernmentNationalMortgageAssociationCertificatesAndObligationsGNMAMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">424</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d43770747e4466-wk-Fact-295DB833412051558996F47F668BDCCE" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearSixThroughTenFairValue" contextRef="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_GovernmentNationalMortgageAssociationCertificatesAndObligationsGNMAMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d43770747e4486-wk-Fact-830495F390625246A197A34AEB1BE01A" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingAfterYearTenFairValue" contextRef="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_GovernmentNationalMortgageAssociationCertificatesAndObligationsGNMAMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d43770747e4505-wk-Fact-A08E288683A85FB986B3A2F6B65016A4" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_GovernmentNationalMortgageAssociationCertificatesAndObligationsGNMAMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">466</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Other asset-backed debt</span><span style="font-family:inherit;font-size:9.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d43770747e4532-wk-Fact-7E56CAC1C19150F0843C9E5BCB9C0112" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue" contextRef="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_AssetBackedSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">161</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d43770747e4551-wk-Fact-727F9AD82CCB5AC493868224E1DEDA9B" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue" contextRef="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_AssetBackedSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">61</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d43770747e4570-wk-Fact-823EA0B8A07A5702B678EABA58D52F52" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearSixThroughTenFairValue" contextRef="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_AssetBackedSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d43770747e4590-wk-Fact-78AAF3709EB25116A215400F1CC559B2" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingAfterYearTenFairValue" contextRef="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_AssetBackedSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d43770747e4609-wk-Fact-C34B3FEB300256D1ADBB0C35ECBFED0F" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_AssetBackedSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">226</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">U.S. government debt</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d43770747e4634-wk-Fact-052C6D67631B5167B39C1C450918ED2D" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue" contextRef="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_USGovernmentDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d43770747e4653-wk-Fact-84EFA802CC125F46BD1B6F80D744CBF8" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue" contextRef="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_USGovernmentDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">112</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d43770747e4672-wk-Fact-81044F82060A5A71A3C4DC16A4BFA596" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearSixThroughTenFairValue" contextRef="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_USGovernmentDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d43770747e4692-wk-Fact-AA25A0077BA151A5B93F70D9F8C32C8B" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingAfterYearTenFairValue" contextRef="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_USGovernmentDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d43770747e4711-wk-Fact-781AE6F13E6558D6B180FCE59E8AA6FE" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_USGovernmentDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">112</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">Held-to-maturity debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Time deposits and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d43770747e4842-wk-Fact-9497D2B99E8F532ABA9BF8778499740F" name="us-gaap:HeldToMaturitySecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue" contextRef="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_pfe_TimeDepositsCorporateDebtAndOtherMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,133</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d43770747e4861-wk-Fact-C26A172AA2015DDC96937A8A949851FD" name="us-gaap:HeldToMaturitySecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue" contextRef="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_pfe_TimeDepositsCorporateDebtAndOtherMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d43770747e4880-wk-Fact-56B56E04C41758EEBF969C401CFB67CD" name="us-gaap:HeldToMaturitySecuritiesDebtMaturitiesRollingYearSixThroughTenFairValue" contextRef="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_pfe_TimeDepositsCorporateDebtAndOtherMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d43770747e4900-wk-Fact-10F216CEA33854B1988BA3D20D83EF34" name="us-gaap:HeldToMaturitySecuritiesDebtMaturitiesRollingAfterTenYearsFairValue" contextRef="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_pfe_TimeDepositsCorporateDebtAndOtherMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d43770747e4919-wk-Fact-05FAE8BC65185C4A8E628507C0468351" name="us-gaap:HeldToMaturitySecurities" contextRef="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_pfe_TimeDepositsCorporateDebtAndOtherMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,137</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Western European government debt</span><span style="font-family:inherit;font-size:9.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d43770747e4946-wk-Fact-9897B650EC365D66BE5F4FE1539C840D" name="us-gaap:HeldToMaturitySecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue" contextRef="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_pfe_WesternEuropeanandOtherGovernmentDebtMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">326</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d43770747e4965-wk-Fact-2C95CA02AB4558B9A40486FF0E1ECD3D" name="us-gaap:HeldToMaturitySecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue" contextRef="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_pfe_WesternEuropeanandOtherGovernmentDebtMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d43770747e4984-wk-Fact-A6A09D6704F35EF6866E3822B7B2DC81" name="us-gaap:HeldToMaturitySecuritiesDebtMaturitiesRollingYearSixThroughTenFairValue" contextRef="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_pfe_WesternEuropeanandOtherGovernmentDebtMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d43770747e5004-wk-Fact-008DAD250F08510DA34610C6465700EC" name="us-gaap:HeldToMaturitySecuritiesDebtMaturitiesRollingAfterTenYearsFairValue" contextRef="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_pfe_WesternEuropeanandOtherGovernmentDebtMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d43770747e5023-wk-Fact-119D2B7CC2895FCA84AA22FCC552D134" name="us-gaap:HeldToMaturitySecurities" contextRef="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_pfe_WesternEuropeanandOtherGovernmentDebtMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">326</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Total debt securities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d43770747e5053-wk-Fact-C4BCB339A5495A399358BD6AA2AE0DE2" name="pfe:DebtSecuritiesMaturitiesWithinOneYear" contextRef="FI2017Q3" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">12,818</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d43770747e5072-wk-Fact-4959CD52B8E35EA2BCB1FB75C3A00877" name="pfe:DebtSecuritiesMaturitiesOverOneToFiveYears" contextRef="FI2017Q3" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,694</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d43770747e5092-wk-Fact-ACB94031FC6F50A4B5DB7E9A583E4985" name="pfe:DebtSecuritiesMaturitiesOverFiveToTenYears" contextRef="FI2017Q3" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,532</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d43770747e5111-wk-Fact-51B7B970C0FF534DBE86CE70940B8755" name="pfe:DebtSecuritiesMaturitiesAfterTenYears" contextRef="FI2017Q3" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">18</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d43770747e5130-wk-Fact-EEC42F263F2C58FC8D358F86963173E5" name="pfe:DebtSecurities" contextRef="FI2017Q3" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">18,061</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></ix:nonNumeric></div><ix:continuation id="TextSelection-9688601E187958D5B11F4E2C12289E3E-1" continuedAt="TextSelection-9688601E187958D5B11F4E2C12289E3E-2"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><ix:footnote id="TextSelection-7EC55EFE69505245B1A079B8132EFBB7-0-wk-Footnote-7EC55EFE69505245B1A079B8132EFBB7_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US">Issued by a diverse group of corporations, with a significant concentration in the technology sector, virtually all of which are investment-grade.</ix:footnote></span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><ix:footnote id="TextSelection-2BFD6C99096B50AD93705C5601B21F46-0-wk-Footnote-2BFD6C99096B50AD93705C5601B21F46_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US">Issued by governments, government agencies or supranational entities, as applicable, all of which are high quality.</ix:footnote></span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(c)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><ix:footnote id="TextSelection-5259D0A3B8885FEE951D5ABCA017CBFC-0-wk-Footnote-5259D0A3B8885FEE951D5ABCA017CBFC_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" continuedAt="TextSelection-5259D0A3B8885FEE951D5ABCA017CBFC-1">Includes receivable-backed, loan-backed, and mortgage-backed securities, all of which are high quality and in senior positions in the capital structure of the security. Receivable-backed securities are collateralized by credit cards receivables, loan-backed securities are collateralized by senior secured obligations of a diverse pool of companies or student loans, and mortgage-backed securities are collateralized by diversified pools of residential and commercial mortgages.</ix:footnote></span></div></td></tr></table></ix:continuation><div style="line-height:120%;padding-left:4px;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><ix:continuation id="TextSelection-5259D0A3B8885FEE951D5ABCA017CBFC-1"><ix:continuation id="TextSelection-9688601E187958D5B11F4E2C12289E3E-2"><br/></ix:continuation></ix:continuation></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">C. Short-Term Borrowings</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Short-term borrowings include amounts for commercial paper of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d43770747e5219-wk-Fact-12FEA2C55DBB5A1AB1A5BC0F06793EC2" name="us-gaap:CommercialPaper" contextRef="FI2017Q3_us-gaap_ShortTermDebtTypeAxis_us-gaap_CommercialPaperMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">6.1</ix:nonFraction> billion</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">October&#160;1, 2017</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d43770747e5243-wk-Fact-1CDCA4D062395A1E9FFCACCF22AEE7E3" name="us-gaap:CommercialPaper" contextRef="FI2016Q4_us-gaap_ShortTermDebtTypeAxis_us-gaap_CommercialPaperMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">5.8</ix:nonFraction> billion</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">December&#160;31, 2016</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">D. Long-Term Debt</span></div><div style="line-height:120%;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><ix:nonNumeric contextRef="FD2017Q3YTD" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" id="TextSelection-B4278B0788455C229D5F562E48108B1B-0-wk-Fact-DB729713D79F5291A2ADD6D80FCE7B7E" continuedAt="TextSelection-B4278B0788455C229D5F562E48108B1B-1" escape="true"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"></td></tr><tr><td style="width:58%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides the amounts of senior unsecured long-term debt issued in the first quarter of 2017:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Principal</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">As of October&#160;1, 2017</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Maturity Date</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Euro</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">U.S. Dollar</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">3-month EURIBOR + 0.20% floating rate notes (0% floor)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">March&#160;6, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8364;</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43770747e5577-wk-Fact-6EDCC77F5B3B5A5898F08B197A517306" name="us-gaap:LongTermDebt" contextRef="FI2017Q3_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredEuroDebtThreemonthEURIBORPlus0.20FloatingRateNotesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" unitRef="iso4217_EUR" decimals="-6" scale="6" format="ixt:numdotdecimal">1,250</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43770747e5596-wk-Fact-70DFF9D31E2B55829E5F491E31F31C7A" name="us-gaap:LongTermDebt" contextRef="FI2017Q3_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredEuroDebtThreemonthEURIBORPlus0.20FloatingRateNotesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,479</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">0.00% euro notes</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">March&#160;6, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43770747e5628-wk-Fact-B09CC79A60405874AF13D1064AECD5EB" name="us-gaap:LongTermDebt" contextRef="FI2017Q3_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredEuroDebtZeroPercentDue2020Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" unitRef="iso4217_EUR" decimals="-6" scale="6" format="ixt:numdotdecimal">1,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43770747e5647-wk-Fact-57AB6949DEF75EA6A568EF9676344801" name="us-gaap:LongTermDebt" contextRef="FI2017Q3_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredEuroDebtZeroPercentDue2020Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,183</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">0.25% euro notes</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">March&#160;6, 2022</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43770747e5684-wk-Fact-FD39AA4E611853FFB3347204D8FFAE7B" name="us-gaap:LongTermDebt" contextRef="FI2017Q3_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredEuroDebtPointTwofivePercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" unitRef="iso4217_EUR" decimals="-6" scale="6" format="ixt:numdotdecimal">1,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43770747e5703-wk-Fact-9BD0B9C42899598DB27286851288BA9C" name="us-gaap:LongTermDebt" contextRef="FI2017Q3_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredEuroDebtPointTwofivePercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,183</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1.00% euro notes</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">March&#160;6, 2027</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43770747e5740-wk-Fact-19A2A621AB2F5D67AFB144F44BDFF8C9" name="us-gaap:LongTermDebt" contextRef="FI2017Q3_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredEuroDebtOnePointZeroPercentDue2027Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" unitRef="iso4217_EUR" decimals="-6" scale="6" format="ixt:numdotdecimal">750</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43770747e5759-wk-Fact-41F768EB6EEC5BBBA68D38AC1F01367F" name="us-gaap:LongTermDebt" contextRef="FI2017Q3_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredEuroDebtOnePointZeroPercentDue2027Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">887</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total euro long-term debt issued in the first quarter of 2017</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8364;</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43770747e5801-wk-Fact-A6F46F05463058AFAEAF923B7651C709" name="us-gaap:LongTermDebt" contextRef="FI2017Q3_us-gaap_DebtInstrumentAxis_pfe_EuroLongtermDebtMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" unitRef="iso4217_EUR" decimals="-6" scale="6" format="ixt:numdotdecimal">4,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43770747e5820-wk-Fact-FB5D18E9A92E5D758C68B08090472348" name="us-gaap:LongTermDebt" contextRef="FI2017Q3_us-gaap_DebtInstrumentAxis_pfe_EuroLongtermDebtMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4,732</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">4.20% notes</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">March 17, 2047</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43770747e5872-wk-Fact-ED395CB21D4254C59230DB3A66452C47" name="us-gaap:LongTermDebt" contextRef="FI2017Q3_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtFourPointTwoPercentDue2047Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,065</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total long-term debt issued in the first quarter of 2017</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(d)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43770747e5934-wk-Fact-7F42A871CAE05783A75EB435EF78126F" name="us-gaap:LongTermDebt" contextRef="FI2017Q3_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">5,797</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></ix:nonNumeric></div><ix:continuation id="TextSelection-B4278B0788455C229D5F562E48108B1B-1" continuedAt="TextSelection-B4278B0788455C229D5F562E48108B1B-2"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><ix:footnote id="TextSelection-0BDE8CEE983B5F118E2EFACDF9CC6405-0-wk-Footnote-0BDE8CEE983B5F118E2EFACDF9CC6405_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" continuedAt="TextSelection-0BDE8CEE983B5F118E2EFACDF9CC6405-1">Redeemable at any time, in whole, or in part, at our option prior to 30 to 90 days of maturity date at the comparable German government bond rate, plus </ix:footnote></span><ix:continuation id="TextSelection-0BDE8CEE983B5F118E2EFACDF9CC6405-1" continuedAt="TextSelection-0BDE8CEE983B5F118E2EFACDF9CC6405-2"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d43770747e5949-wk-Fact-B55CD3A73A0154D1B36B441E7005C424" name="pfe:DebtInstrumentRedemptionRuleRedemptionPricePercentageBasisSpread" contextRef="FD2017Q3YTD_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_VariableRateAxis_pfe_GermanGovernmentBondRateMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">0.15</ix:nonFraction>%</span></span></ix:continuation><span style="font-family:inherit;font-size:8.5pt;"><ix:continuation id="TextSelection-0BDE8CEE983B5F118E2EFACDF9CC6405-2">; plus, in each case, accrued and unpaid interest. The fixed rate euro notes are also redeemable at our option, in whole, or in part, within 30 to 90 days of maturity date.</ix:continuation></span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><ix:footnote id="TextSelection-A42108BE06A7587BABD0C4A820609CE4-0-wk-Footnote-A42108BE06A7587BABD0C4A820609CE4_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" continuedAt="TextSelection-A42108BE06A7587BABD0C4A820609CE4-1">The weighted-average effective interest rate for the euro notes at issuance was </ix:footnote></span><ix:continuation id="TextSelection-A42108BE06A7587BABD0C4A820609CE4-1" continuedAt="TextSelection-A42108BE06A7587BABD0C4A820609CE4-2"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d43770747e5965-wk-Fact-BC3DC25DC81C5DFB9A13CECE763F92E4" name="us-gaap:DebtWeightedAverageInterestRate" contextRef="FI2017Q3_us-gaap_DebtInstrumentAxis_pfe_EuroLongtermDebtMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" unitRef="number" decimals="4" scale="-2" format="ixt:numdotdecimal">0.23</ix:nonFraction>%</span></span></ix:continuation><span style="font-family:inherit;font-size:8.5pt;"><ix:continuation id="TextSelection-A42108BE06A7587BABD0C4A820609CE4-2">.</ix:continuation></span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(c)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><ix:footnote id="TextSelection-10C1964C9B955D8AB1D255A5330FE0A9-0-wk-Footnote-10C1964C9B955D8AB1D255A5330FE0A9_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US">The notes, issued in U.S. dollars in Taiwan, are redeemable, at our option, in whole but not in part, on each March 17 on or after March 17, 2020.</ix:footnote></span></div></td></tr></table></ix:continuation><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><ix:continuation id="TextSelection-B4278B0788455C229D5F562E48108B1B-2" continuedAt="TextSelection-B4278B0788455C229D5F562E48108B1B-3"><div style="line-height:120%;font-size:8.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(d)</sup>&#160;</span></div></ix:continuation></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8.5pt;"><ix:continuation id="TextSelection-B4278B0788455C229D5F562E48108B1B-3" continuedAt="TextSelection-B4278B0788455C229D5F562E48108B1B-4"><span style="font-family:inherit;font-size:8.5pt;"><ix:footnote id="TextSelection-8921B51644785F769ECBA4D3CCF9CAD4-0-wk-Footnote-8921B51644785F769ECBA4D3CCF9CAD4_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" continuedAt="TextSelection-8921B51644785F769ECBA4D3CCF9CAD4-1">The aggregate amount at issuance date was </ix:footnote></span><ix:continuation id="TextSelection-8921B51644785F769ECBA4D3CCF9CAD4-1" continuedAt="TextSelection-8921B51644785F769ECBA4D3CCF9CAD4-2"><span style="font-family:inherit;font-size:8.5pt;"><span>$<ix:nonFraction id="d43770747e5993-wk-Fact-49AA33C66F135204B829109228125B2B" name="us-gaap:DebtInstrumentFaceAmount" contextRef="FI2017Q1_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">5,279</ix:nonFraction> million</span></span></ix:continuation></ix:continuation><span style="font-family:inherit;font-size:8.5pt;"><ix:continuation id="TextSelection-8921B51644785F769ECBA4D3CCF9CAD4-2"><ix:continuation id="TextSelection-B4278B0788455C229D5F562E48108B1B-4">. The increase in the amount since the date of issuance is due to foreign currency exchange.</ix:continuation></ix:continuation></span></div></td></tr></table></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">22</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:center;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(UNAUDITED)</span></div></div><div><br/></div><ix:continuation id="TextSelection-1EE0D555564D5ACA882C4EC0D6E9B51D-4" continuedAt="TextSelection-1EE0D555564D5ACA882C4EC0D6E9B51D-5"><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><ix:nonNumeric contextRef="FD2017Q3YTD" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="TextSelection-3A1839DF39625590BB411A26F8418C46-0-wk-Fact-9BDDE0BC5BA952228898A0108A538356" escape="true"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"></td></tr><tr><td style="width:28%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td colspan="25" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides the maturity schedule of our </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Long-term debt</span><span style="font-family:inherit;font-size:10pt;">&#160;outstanding as of October 1, 2017:</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">After 2021</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Maturities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43770747e6318-wk-Fact-AC7D38B45888587EA0DC514DE87C4C97" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" contextRef="FI2017Q3" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">481</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43770747e6337-wk-Fact-A9A80232BFEB5330A2ADCA7EE13D5D57" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" contextRef="FI2017Q3" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4,825</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43770747e6357-wk-Fact-36938B2094D55254A9001E639027E169" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" contextRef="FI2017Q3" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,534</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43770747e6376-wk-Fact-CB25656B01C05BE88A63637C25270DD7" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" contextRef="FI2017Q3" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4,502</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43770747e6395-wk-Fact-700581DDEEF45B26A99FBE4F4D6DEC2C" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" contextRef="FI2017Q3" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">23,162</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43770747e6415-wk-Fact-5683EE7588BA524A9C12A9E4B64A122D" name="us-gaap:LongTermDebt" contextRef="FI2017Q3" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">34,503</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></ix:nonNumeric><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">E. Other Noncurrent Liabilities</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In August 2017, the U.S. approved Besponsa (inotuzumab ozogamicin) and in June 2017, the EU approved Besponsa as monotherapy for the treatment of adults with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia. In connection with the U.S. approval, we incurred an obligation to make guaranteed fixed annual payments over a nine-year period aggregating </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d43770747e6437-wk-Fact-E3FE77994DEE098DC89774653986FAA8" name="pfe:ResearchandDevelopmentArrangementAggregatePaymentObligation" contextRef="I2017Q3Aug31_us-gaap_ProductOrServiceAxis_pfe_BesponsaMember_us-gaap_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">296</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> related to a research and development arrangement. As a result, we have recorded the estimated net present value of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d43770747e6441-wk-Fact-B0A1A71383936103AC777468C4C42FA8" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="FI2017Q3_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_ProductOrServiceAxis_pfe_BesponsaMember_us-gaap_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">248</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> as an intangible asset in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Developed technology rights</span><span style="font-family:inherit;font-size:10pt;">, and we have recorded </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d43770747e6449-wk-Fact-C1A1C96BF7D0B1F0211D7468F3C017EF" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="FI2017Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_ProductOrServiceAxis_pfe_BesponsaMember_us-gaap_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">233</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other noncurrent liabilities </span><span style="font-family:inherit;font-size:10pt;">and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d43770747e6458-wk-Fact-9B810526969AEFFC8BD17469215CA157" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="FI2017Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_ProductOrServiceAxis_pfe_BesponsaMember_us-gaap_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">15</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span><span style="font-family:inherit;font-size:10pt;">in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other current liabilities</span><span style="font-family:inherit;font-size:10pt;"> as of October 1, 2017. In connection with the EU approval, we incurred an obligation to make guaranteed fixed annual payments over a nine-year period aggregating </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d43770747e6468-wk-Fact-990703736CF35318A941AB8393055A5E" name="pfe:ResearchandDevelopmentArrangementAggregatePaymentObligation" contextRef="I2017Q2Jun30_us-gaap_ProductOrServiceAxis_pfe_BesponsaMember_us-gaap_StatementGeographicalAxis_us-gaap_EuropeanUnionMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">148</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> related to a research and development arrangement. As a result, we recorded the estimated net present value of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d43770747e6472-wk-Fact-8D4BE048DA1152D883E89F25779C82AE" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="FI2017Q3_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_ProductOrServiceAxis_pfe_BesponsaMember_us-gaap_StatementGeographicalAxis_us-gaap_EuropeanUnionMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">123</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> as an intangible asset in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Developed technology rights</span><span style="font-family:inherit;font-size:10pt;">, and we have recorded </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d43770747e6481-wk-Fact-E05D9022639A54EF825FBE13B1CA8085" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="FI2017Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_ProductOrServiceAxis_pfe_BesponsaMember_us-gaap_StatementGeographicalAxis_us-gaap_EuropeanUnionMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">117</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other noncurrent liabilities </span><span style="font-family:inherit;font-size:10pt;">and</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d43770747e6491-wk-Fact-5A71AD33CDFC59868F473BBF286D1856" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="FI2017Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_ProductOrServiceAxis_pfe_BesponsaMember_us-gaap_StatementGeographicalAxis_us-gaap_EuropeanUnionMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other current liabilities</span><span style="font-family:inherit;font-size:10pt;"> as of October 1, 2017.&#160;</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">F. </span><span style="font-weight:bold;text-decoration:underline;">Derivative Financial Instruments and Hedging Activities</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"> </span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Foreign Exchange Risk</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">October&#160;1, 2017</span><span style="font-family:inherit;font-size:10pt;">, the aggregate notional amount of foreign exchange derivative financial instruments hedging or offsetting foreign currency exposures was </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d43770747e6524-wk-Fact-AD2AC7E53C405A0FB0D82BBA282C9FE6" name="us-gaap:DerivativeAssetNotionalAmount" contextRef="FI2017Q3_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">31.5</ix:nonFraction> billion</span></span><span style="font-family:inherit;font-size:10pt;">. The derivative financial instruments primarily hedge or offset exposures in the euro, Japanese yen and U.K. pound. The maximum length of time over which we are hedging future foreign exchange cash flow relates to our </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d43770747e6528-wk-Fact-E69F0F7513A15BC1875F9D0AEECF77B3" name="us-gaap:LongTermDebt" contextRef="FI2017Q3_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">2.0</ix:nonFraction> billion</span></span><span style="font-family:inherit;font-size:10pt;"> U.K. pound debt maturing in 2038.</span></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We designate foreign currency forward-exchange contracts as cash flow hedges of a portion of our forecasted euro, Japanese yen, U.K. pound, Canadian dollar, and Australian dollar-denominated intercompany inventory sales expected to occur no more than two years from the date of each hedge. As of </span><span style="font-family:inherit;font-size:10pt;">October&#160;1, 2017</span><span style="font-family:inherit;font-size:10pt;">, the notional amount of outstanding foreign currency forward-exchange contracts hedging our intercompany forecasted sales was </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d43770747e6539-wk-Fact-C45BE8C73AE5550A968D05EA296EDAD6" name="invest:DerivativeNotionalAmount" contextRef="FI2017Q3_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">3.9</ix:nonFraction> billion</span></span><span style="font-family:inherit;font-size:10pt;">, with a pre-tax loss of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d43770747e6543-wk-Fact-4575500D957C58BEB126E33983329C3A" name="us-gaap:UnrealizedLossOnForeignCurrencyDerivativesBeforeTax" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">97</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> deferred in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Accumulated other comprehensive loss. </span><span style="font-family:inherit;font-size:10pt;">Based on quarter-end foreign exchange rates that are subject to change, we expect to reclassify a pre-tax loss of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d43770747e6551-wk-Fact-17E80A40DA32526383413D538658EA88" name="us-gaap:ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months" contextRef="FI2017Q3" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">63</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> within the next 12 months into </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Cost of sales. </span><span style="font-family:inherit;font-size:10pt;">We recognized a </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d43770747e6560-wk-Fact-0F9F8FB289DF58579790250AC327F0EA" name="us-gaap:ForeignCurrencyCashFlowHedgeGainLossReclassifiedToEarningsNet" contextRef="FD2017Q3QTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">4</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> loss in the </span><span style="font-family:inherit;font-size:10pt;">third quarter</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;"> and a </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d43770747e6572-wk-Fact-9EE7295EEEA651DCA19E75A1C6B523E6" name="us-gaap:ForeignCurrencyCashFlowHedgeGainLossReclassifiedToEarningsNet" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">67</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> gain in the </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;"> as an offset to </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Cost of sales</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Interest Rate Risk</span></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">October&#160;1, 2017</span><span style="font-family:inherit;font-size:10pt;">, the aggregate notional amount of interest rate derivative financial instruments designated as fair value hedges was </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d43770747e6603-wk-Fact-022B25CABD9B5182A55A3669BB8FBECC" name="us-gaap:DerivativeAssetNotionalAmount" contextRef="FI2017Q3_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">12.4</ix:nonFraction> billion</span></span><span style="font-family:inherit;font-size:10pt;">. The derivative financial instruments primarily hedge U.S. dollar fixed-rate debt.</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">23</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:center;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(UNAUDITED)</span></div></div><div><br/></div><ix:continuation id="TextSelection-1EE0D555564D5ACA882C4EC0D6E9B51D-5" continuedAt="TextSelection-1EE0D555564D5ACA882C4EC0D6E9B51D-6"><div style="line-height:120%;font-size:10pt;"><ix:nonNumeric contextRef="FD2017Q3YTD" name="us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" id="TextSelection-45DB9A78706E5101A711A3F227E5B726-0-wk-Fact-6356769EA8525FE3B5A340D09DCB1D06" continuedAt="TextSelection-45DB9A78706E5101A711A3F227E5B726-1" escape="true"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"></td></tr><tr><td style="width:28%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td colspan="25" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides information about the gains/(losses) incurred to hedge or offset operational foreign exchange or interest rate risk:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Three Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Amount of</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Gains/(Losses)</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Recognized in OID</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a), (b), (c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Amount of</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Gains/(Losses)</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Recognized in OCI</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(Effective Portion)</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a), (d)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Amount of</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Gains/(Losses)</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Reclassified from</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">OCI into OID and COS</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(Effective Portion)</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a), (d)</sup></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">October&#160;1, <br/>2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">October&#160;2, <br/>2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">October&#160;1, <br/>2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">October&#160;2, <br/>2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">October&#160;1, <br/>2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">October&#160;2, <br/>2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Derivative Financial Instruments in Cash Flow Hedge Relationships:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Foreign currency swaps</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43770747e7335-wk-Fact-4C647D3AD0F151A9BA9998C97C5B0A63" name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="FD2017Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43770747e7354-wk-Fact-C2FB4FD03BD15A7097477EAB914C3310" name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="FD2016Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43770747e7374-wk-Fact-2A83FB655E5C5030BB0751EC39ED3AD7" name="us-gaap:DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet" contextRef="FD2017Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_OtherComprehensiveIncomeLocationAxis_us-gaap_OtherComprehensiveIncomeMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">218</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43770747e7393-wk-Fact-09DBCF3E9CE2515B8F9E9D356B588B2E" name="us-gaap:DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet" contextRef="FD2016Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_OtherComprehensiveIncomeLocationAxis_us-gaap_OtherComprehensiveIncomeMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">87</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43770747e7412-wk-Fact-CADEEEB82C0B519FB5E1247FA7EE8C72" name="us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" contextRef="FD2017Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">148</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d43770747e7432-wk-Fact-090EF04B0EE45784B7F05495ED9053FC" name="us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" contextRef="FD2016Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">39</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Foreign currency forward-exchange contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43770747e7453-wk-Fact-7FF9DC0A6C7D575C9FDD24720C8D14FC" name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="FD2017Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43770747e7472-wk-Fact-B8850FDF106C528A9CBED9CA08F2B4C9" name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="FD2016Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d43770747e7491-wk-Fact-EFD127551F54519E94393635FCB3FC4A" name="us-gaap:DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet" contextRef="FD2017Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_OtherComprehensiveIncomeLocationAxis_us-gaap_OtherComprehensiveIncomeMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">269</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d43770747e7512-wk-Fact-FDC488BF6B135DEAA89A53C4766192EC" name="us-gaap:DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet" contextRef="FD2016Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_OtherComprehensiveIncomeLocationAxis_us-gaap_OtherComprehensiveIncomeMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">212</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d43770747e7532-wk-Fact-A9CF26AC98115AE2816DE97864E7E9E1" name="us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" contextRef="FD2017Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">204</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d43770747e7553-wk-Fact-75B9ED2C492450B59C9FBE062087C17F" name="us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" contextRef="FD2016Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">111</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Derivative Financial Instruments in Net Investment Hedge Relationships:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Foreign currency forward-exchange contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43770747e7701-wk-Fact-581448B02BB95042932A4BD0D7479AFE" name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="FD2017Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43770747e7720-wk-Fact-8727D6540E165428BFB9698977FED583" name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="FD2016Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43770747e7739-wk-Fact-4918CC17DAC15E038DC184F1DA176587" name="us-gaap:DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet" contextRef="FD2017Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_OtherComprehensiveIncomeLocationAxis_us-gaap_OtherComprehensiveIncomeMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43770747e7759-wk-Fact-6E0D94B5020A54D8AA03215EBE1D7EF9" name="us-gaap:DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet" contextRef="FD2016Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_OtherComprehensiveIncomeLocationAxis_us-gaap_OtherComprehensiveIncomeMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43770747e7778-wk-Fact-8D17A1AAEAA359D5832C616000B8A948" name="us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" contextRef="FD2017Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43770747e7798-wk-Fact-8F4FBA0654FF59F5B667567DEC33C73B" name="us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" contextRef="FD2016Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Derivative Financial Instruments Not Designated as Hedges:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Foreign currency forward-exchange contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43770747e8074-wk-Fact-E84743BA7BEB5C538A4DCD2F234366E5" name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="FD2017Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">33</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43770747e8093-wk-Fact-9CA0877B96475CE6BFD987BA91892F67" name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="FD2016Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">20</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43770747e8112-wk-Fact-620EDDBB2E7E58FE85B15DE61C5EDD21" name="us-gaap:DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet" contextRef="FD2017Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember_us-gaap_OtherComprehensiveIncomeLocationAxis_us-gaap_OtherComprehensiveIncomeMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43770747e8132-wk-Fact-ED0DC050AE3557C5AA59EE876A9CCB85" name="us-gaap:DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet" contextRef="FD2016Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember_us-gaap_OtherComprehensiveIncomeLocationAxis_us-gaap_OtherComprehensiveIncomeMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43770747e8151-wk-Fact-5134E9EECF3F53FC8E0FBFCC64592278" name="us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" contextRef="FD2017Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43770747e8171-wk-Fact-24B21791DB6C58DCB111630D09C1ACBF" name="us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" contextRef="FD2016Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Foreign currency swaps</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43770747e8196-wk-Fact-324434DC15AC56F3976EFDF4A8E4050E" name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="FD2017Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d43770747e8215-wk-Fact-C2CABED6EA545FADA2D30E685CF99102" name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="FD2016Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43770747e8235-wk-Fact-6BED389587795F178A51DFB7B1F38F10" name="us-gaap:DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet" contextRef="FD2017Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember_us-gaap_OtherComprehensiveIncomeLocationAxis_us-gaap_OtherComprehensiveIncomeMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43770747e8255-wk-Fact-6D120F6B1B935942908A657A342EF520" name="us-gaap:DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet" contextRef="FD2016Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember_us-gaap_OtherComprehensiveIncomeLocationAxis_us-gaap_OtherComprehensiveIncomeMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43770747e8274-wk-Fact-0A4EFE67B20358CA8861BC89A7FA3032" name="us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" contextRef="FD2017Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43770747e8294-wk-Fact-B1F75F6B4A5C5BA399EFD6D1A9FEA6DE" name="us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" contextRef="FD2016Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Non-Derivative Financial Instruments in Net Investment Hedge Relationships:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Foreign currency long-term debt</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43770747e8569-wk-Fact-7245AD177ECF539AA450E00174CA6B5E" name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="FD2017Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyLongTermDebtMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_pfe_NetInvestmentHedgingNonderivativeInstrumentsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43770747e8588-wk-Fact-FF816B32EE915991B09BB0A4C759A044" name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="FD2016Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyLongTermDebtMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_pfe_NetInvestmentHedgingNonderivativeInstrumentsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d43770747e8607-wk-Fact-E989403B19655D56902F363195B8FB79" name="us-gaap:DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet" contextRef="FD2017Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyLongTermDebtMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_pfe_NetInvestmentHedgingNonderivativeInstrumentsMember_us-gaap_OtherComprehensiveIncomeLocationAxis_us-gaap_OtherComprehensiveIncomeMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">166</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43770747e8628-wk-Fact-838AFCED268F5D33AC4D66BBF1700DBF" name="us-gaap:DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet" contextRef="FD2016Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyLongTermDebtMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_pfe_NetInvestmentHedgingNonderivativeInstrumentsMember_us-gaap_OtherComprehensiveIncomeLocationAxis_us-gaap_OtherComprehensiveIncomeMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43770747e8647-wk-Fact-1B18B8E0BFFA5FAB8CC46A153B1999C9" name="us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" contextRef="FD2017Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyLongTermDebtMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_pfe_NetInvestmentHedgingNonderivativeInstrumentsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43770747e8667-wk-Fact-CFF329117B805CE791A8F04DB947E1BC" name="us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" contextRef="FD2016Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyLongTermDebtMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_pfe_NetInvestmentHedgingNonderivativeInstrumentsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">All other net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43770747e8692-wk-Fact-2EC8C97286795110842254B7AD03EA8C" name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="FD2017Q3QTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_pfe_OtherDerivativeInstrumentsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43770747e8711-wk-Fact-C2B11447AB985916A925693B614D1F62" name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="FD2016Q3QTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_pfe_OtherDerivativeInstrumentsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43770747e8730-wk-Fact-FC17783C6AF95B6BA110F4B016C6E9A6" name="us-gaap:DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet" contextRef="FD2017Q3QTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_pfe_OtherDerivativeInstrumentsMember_us-gaap_OtherComprehensiveIncomeLocationAxis_us-gaap_OtherComprehensiveIncomeMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43770747e8750-wk-Fact-3A60D355B3D65BBF94AB49C42ABD832B" name="us-gaap:DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet" contextRef="FD2016Q3QTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_pfe_OtherDerivativeInstrumentsMember_us-gaap_OtherComprehensiveIncomeLocationAxis_us-gaap_OtherComprehensiveIncomeMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43770747e8769-wk-Fact-E158F0F72B4F5E699400B1D0DF2B49F9" name="us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" contextRef="FD2017Q3QTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_pfe_OtherDerivativeInstrumentsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43770747e8789-wk-Fact-177D9D5D5C305B2CB2F2B8CFC0B8B38B" name="us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" contextRef="FD2016Q3QTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_pfe_OtherDerivativeInstrumentsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43770747e8819-wk-Fact-8F504B317F065E6AB4D6EA024526004B" name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="FD2017Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">34</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43770747e8838-wk-Fact-7E69FA8360D65E76BC4DD8B549DB440D" name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="FD2016Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">18</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d43770747e8858-wk-Fact-288B765C343F5E4F98C92B3CC3D540BD" name="us-gaap:DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet" contextRef="FD2017Q3QTD_us-gaap_OtherComprehensiveIncomeLocationAxis_us-gaap_OtherComprehensiveIncomeMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">216</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d43770747e8878-wk-Fact-8C7D1064A7B350C98174EAAD041CABE0" name="us-gaap:DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet" contextRef="FD2016Q3QTD_us-gaap_OtherComprehensiveIncomeLocationAxis_us-gaap_OtherComprehensiveIncomeMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">126</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d43770747e8898-wk-Fact-42F9DF20DDCA5646904966177DFB6AA4" name="us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" contextRef="FD2017Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">55</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d43770747e8919-wk-Fact-905FF1755B2D5F84A3DD31F07D5EFDAF" name="us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" contextRef="FD2016Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">150</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Nine Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Amount of</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Gains/(Losses)</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Recognized in OID</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a), (b), (c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Amount of</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Gains/(Losses)</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Recognized in OCI</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(Effective Portion)</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a), (d)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Amount of</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Gains/(Losses)</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Reclassified from</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">OCI into OID and COS</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(Effective Portion)</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a), (d)</sup></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">October&#160;1, <br/>2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">October&#160;2, <br/>2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">October&#160;1, <br/>2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">October&#160;2, <br/>2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">October&#160;1, <br/>2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">October&#160;2, <br/>2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Derivative Financial Instruments in Cash Flow Hedge Relationships:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Foreign currency swaps</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43770747e9609-wk-Fact-8E3F5651762058A3BE3D1D3ABAC06BF2" name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="FD2017Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43770747e9628-wk-Fact-7CF5E0D8BCEA5A01AC63CA0BE2F7F413" name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="FD2016Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43770747e9648-wk-Fact-774518EA7FE3544C826E80CBE973BB7B" name="us-gaap:DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet" contextRef="FD2017Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_OtherComprehensiveIncomeLocationAxis_us-gaap_OtherComprehensiveIncomeMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">455</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d43770747e9667-wk-Fact-2F4C56B8E6C658B98917D6369850F69C" name="us-gaap:DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet" contextRef="FD2016Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_OtherComprehensiveIncomeLocationAxis_us-gaap_OtherComprehensiveIncomeMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">204</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43770747e9687-wk-Fact-B91047810A4357EFB8BEA4691EF47E86" name="us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" contextRef="FD2017Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">419</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d43770747e9707-wk-Fact-9086EDAB64E75CD192D2A7C873603ACA" name="us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" contextRef="FD2016Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">165</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Foreign currency forward-exchange contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d43770747e9728-wk-Fact-283251A1FA2159899190EA9CCFA53A25" name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="FD2017Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43770747e9748-wk-Fact-019763780A0F5F0EB5ACCFF5ADADB2C7" name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="FD2016Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d43770747e9767-wk-Fact-9AFC9FBE04FB5689977BCF73503C994B" name="us-gaap:DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet" contextRef="FD2017Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_OtherComprehensiveIncomeLocationAxis_us-gaap_OtherComprehensiveIncomeMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">604</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d43770747e9788-wk-Fact-721EE01F467C5AA2AF5D9ABD57151BB3" name="us-gaap:DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet" contextRef="FD2016Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_OtherComprehensiveIncomeLocationAxis_us-gaap_OtherComprehensiveIncomeMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">770</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d43770747e9808-wk-Fact-04C7C8ED03EF514FBDD27EE2DA62A7D5" name="us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" contextRef="FD2017Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">26</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d43770747e9829-wk-Fact-ED75BB4B1C585EB9A02A2357479F8D29" name="us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" contextRef="FD2016Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">118</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Derivative Financial Instruments in Net Investment Hedge Relationships:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Foreign currency forward-exchange contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43770747e9977-wk-Fact-77E4DFB6EFD85BAB909056B138A7DECB" name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="FD2017Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43770747e9996-wk-Fact-95C58C19C66A579CB912AE3B96A6747E" name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="FD2016Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43770747e10015-wk-Fact-481B3D6C84EF52CCBEBB11AB001F4356" name="us-gaap:DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet" contextRef="FD2017Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_OtherComprehensiveIncomeLocationAxis_us-gaap_OtherComprehensiveIncomeMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d43770747e10035-wk-Fact-16809863F1405611BBE44B0DB80273DE" name="us-gaap:DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet" contextRef="FD2016Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_OtherComprehensiveIncomeLocationAxis_us-gaap_OtherComprehensiveIncomeMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">15</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43770747e10055-wk-Fact-EBE9947C4118517F84796F369756CEED" name="us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" contextRef="FD2017Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43770747e10075-wk-Fact-3D22C73D416A54A79E8C5296818B091D" name="us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" contextRef="FD2016Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Derivative Financial Instruments Not Designated as Hedges:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Foreign currency forward-exchange contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d43770747e10350-wk-Fact-87C02FE05790562287F7FA992F915C2A" name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="FD2017Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">111</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d43770747e10370-wk-Fact-4ADCC13FDAC45B6BB3630C98712932FD" name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="FD2016Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">49</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43770747e10390-wk-Fact-238B98C4D02459528B018866A4D1E3C1" name="us-gaap:DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet" contextRef="FD2017Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember_us-gaap_OtherComprehensiveIncomeLocationAxis_us-gaap_OtherComprehensiveIncomeMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43770747e10410-wk-Fact-FD239FB115D9532BB0AC86A94B61DFC0" name="us-gaap:DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet" contextRef="FD2016Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember_us-gaap_OtherComprehensiveIncomeLocationAxis_us-gaap_OtherComprehensiveIncomeMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43770747e10429-wk-Fact-1FF4C4C95159585A8AD2FEAE77CAC774" name="us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" contextRef="FD2017Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43770747e10449-wk-Fact-D729388174C854FE8C4CEFABB9A6A065" name="us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" contextRef="FD2016Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Foreign currency swaps</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d43770747e10474-wk-Fact-DA9B023396AA59FCAFC767A3F15E2AAA" name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="FD2017Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d43770747e10494-wk-Fact-3DDF166872145F4BAF10CA9D1ED6DA8F" name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="FD2016Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43770747e10514-wk-Fact-BF8085F8D70957BA81DB64AF93C77FDE" name="us-gaap:DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet" contextRef="FD2017Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember_us-gaap_OtherComprehensiveIncomeLocationAxis_us-gaap_OtherComprehensiveIncomeMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43770747e10534-wk-Fact-92E17207D19C5E5A932D3D83BCD07078" name="us-gaap:DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet" contextRef="FD2016Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember_us-gaap_OtherComprehensiveIncomeLocationAxis_us-gaap_OtherComprehensiveIncomeMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43770747e10553-wk-Fact-367407A06D845402883E3D448F892BA4" name="us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" contextRef="FD2017Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43770747e10573-wk-Fact-F18080A5F5AD57518995089379096CF8" name="us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" contextRef="FD2016Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Non-Derivative Financial Instruments in Net Investment Hedge Relationships:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Foreign currency short-term borrowings</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43770747e10849-wk-Fact-957B6D659FDB5023A7F0DBA1FC6C7332" name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="FD2017Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyShortTermBorrowingsMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_pfe_NetInvestmentHedgingNonderivativeInstrumentsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43770747e10868-wk-Fact-52FA3ED749A551E69FCC2DB848C60415" name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="FD2016Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyShortTermBorrowingsMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_pfe_NetInvestmentHedgingNonderivativeInstrumentsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43770747e10887-wk-Fact-2B6D0F44C93359ADA6DC515DA57F73D4" name="us-gaap:DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet" contextRef="FD2017Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyShortTermBorrowingsMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_pfe_NetInvestmentHedgingNonderivativeInstrumentsMember_us-gaap_OtherComprehensiveIncomeLocationAxis_us-gaap_OtherComprehensiveIncomeMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d43770747e10907-wk-Fact-F135E5CEAB8E5D4EB7575AEBFF4DF757" name="us-gaap:DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet" contextRef="FD2016Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyShortTermBorrowingsMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_pfe_NetInvestmentHedgingNonderivativeInstrumentsMember_us-gaap_OtherComprehensiveIncomeLocationAxis_us-gaap_OtherComprehensiveIncomeMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">26</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43770747e10927-wk-Fact-5D5B1229DA1A57F080E4C581EAE83373" name="us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" contextRef="FD2017Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyShortTermBorrowingsMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_pfe_NetInvestmentHedgingNonderivativeInstrumentsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43770747e10947-wk-Fact-CFFE4951A2DE534ABE61BA03B8048EA4" name="us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" contextRef="FD2016Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyShortTermBorrowingsMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_pfe_NetInvestmentHedgingNonderivativeInstrumentsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Foreign currency long-term debt</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43770747e10972-wk-Fact-67797DE457375667B2C84DC5692034E9" name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="FD2017Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyLongTermDebtMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_pfe_NetInvestmentHedgingNonderivativeInstrumentsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43770747e10991-wk-Fact-3509C7CDE8445B7B95D3CD4AB8311EBD" name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="FD2016Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyLongTermDebtMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_pfe_NetInvestmentHedgingNonderivativeInstrumentsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d43770747e11010-wk-Fact-1A851ADE80F15F3490D42C3F2F83E624" name="us-gaap:DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet" contextRef="FD2017Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyLongTermDebtMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_pfe_NetInvestmentHedgingNonderivativeInstrumentsMember_us-gaap_OtherComprehensiveIncomeLocationAxis_us-gaap_OtherComprehensiveIncomeMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">518</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43770747e11031-wk-Fact-EF8FCCDF207A5213AA733CAB56F33EB4" name="us-gaap:DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet" contextRef="FD2016Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyLongTermDebtMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_pfe_NetInvestmentHedgingNonderivativeInstrumentsMember_us-gaap_OtherComprehensiveIncomeLocationAxis_us-gaap_OtherComprehensiveIncomeMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43770747e11050-wk-Fact-E5A70858CAFC5770B3F632E0F9C47F2B" name="us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" contextRef="FD2017Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyLongTermDebtMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_pfe_NetInvestmentHedgingNonderivativeInstrumentsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43770747e11070-wk-Fact-604E73BB58B354A8BE73520A47D45028" name="us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" contextRef="FD2016Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyLongTermDebtMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_pfe_NetInvestmentHedgingNonderivativeInstrumentsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">All other net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43770747e11095-wk-Fact-246EBF73EC0858A18FCF596C5A717E80" name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="FD2017Q3YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_pfe_OtherDerivativeInstrumentsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43770747e11114-wk-Fact-09FE0334A6DB46CA6D5F5A6A83AF54B0" name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="FD2016Q3YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_pfe_OtherDerivativeInstrumentsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43770747e11133-wk-Fact-E9261ECFF1BF56E48D687B9EB690D501" name="us-gaap:DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet" contextRef="FD2017Q3YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_pfe_OtherDerivativeInstrumentsMember_us-gaap_OtherComprehensiveIncomeLocationAxis_us-gaap_OtherComprehensiveIncomeMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43770747e11153-wk-Fact-909A7518DD255E87B44DE7EF018F16C1" name="us-gaap:DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet" contextRef="FD2016Q3YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_pfe_OtherDerivativeInstrumentsMember_us-gaap_OtherComprehensiveIncomeLocationAxis_us-gaap_OtherComprehensiveIncomeMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43770747e11172-wk-Fact-59D88BD8C3615E16ADCBC18168C4F03C" name="us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" contextRef="FD2017Q3YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_pfe_OtherDerivativeInstrumentsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43770747e11192-wk-Fact-4E50B891ECDF54F8B82E01242152C091" name="us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" contextRef="FD2016Q3YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_pfe_OtherDerivativeInstrumentsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d43770747e11222-wk-Fact-9ABA0C515EA950C6981FD708D959A2E8" name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="FD2017Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">117</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d43770747e11242-wk-Fact-A6EB4F0FD63E5855AF650D3234A6748E" name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="FD2016Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">56</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d43770747e11263-wk-Fact-57780600A4525A59B0F30E20473A845F" name="us-gaap:DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet" contextRef="FD2017Q3YTD_us-gaap_OtherComprehensiveIncomeLocationAxis_us-gaap_OtherComprehensiveIncomeMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">666</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d43770747e11283-wk-Fact-84FD9CC1745E5CF6B9EBD9E4EF9761DA" name="us-gaap:DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet" contextRef="FD2016Q3YTD_us-gaap_OtherComprehensiveIncomeLocationAxis_us-gaap_OtherComprehensiveIncomeMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1,014</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43770747e11303-wk-Fact-82FB012BDAB65A2A907B1CCC2DE535AD" name="us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" contextRef="FD2017Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">394</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d43770747e11323-wk-Fact-E257ACF9822153C0B4489B4BD0381028" name="us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" contextRef="FD2016Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">283</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr></table></div></ix:nonNumeric></div><ix:continuation id="TextSelection-45DB9A78706E5101A711A3F227E5B726-1" continuedAt="TextSelection-45DB9A78706E5101A711A3F227E5B726-2"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><ix:footnote id="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" continuedAt="TextSelection-65D371B3E1255C359F57BC7540F815ED-1">OID = Other (income)/deductions&#8212;net, included in </ix:footnote></span><ix:continuation id="TextSelection-65D371B3E1255C359F57BC7540F815ED-1" continuedAt="TextSelection-65D371B3E1255C359F57BC7540F815ED-2"><span style="font-family:inherit;font-size:9pt;font-style:italic;">Other (income)/deductions&#8212;net</span><span style="font-family:inherit;font-size:9pt;"> in the condensed consolidated statements of income. COS = Cost of sales, included in </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Cost of sales</span><span style="font-family:inherit;font-size:9pt;"> in the condensed consolidated statements of income.</span></ix:continuation></div></td></tr></table><div style="line-height:120%;padding-left:12px;font-size:9pt;"><ix:continuation id="TextSelection-65D371B3E1255C359F57BC7540F815ED-2" continuedAt="TextSelection-65D371B3E1255C359F57BC7540F815ED-3"><span style="font-family:inherit;font-size:9pt;">OCI = Other comprehensive income/(loss), included in the</span><span style="font-family:inherit;font-size:9pt;font-style:italic;"> </span><span style="font-family:inherit;font-size:9pt;">condensed consolidated statements of comprehensive income</span></ix:continuation><span style="font-family:inherit;font-size:9pt;font-style:italic;"><ix:continuation id="TextSelection-65D371B3E1255C359F57BC7540F815ED-3">.</ix:continuation></span></div></ix:continuation></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">24</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:center;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(UNAUDITED)</span></div></div><div><br/></div><ix:continuation id="TextSelection-1EE0D555564D5ACA882C4EC0D6E9B51D-6" continuedAt="TextSelection-1EE0D555564D5ACA882C4EC0D6E9B51D-7"><ix:continuation id="TextSelection-45DB9A78706E5101A711A3F227E5B726-2" continuedAt="TextSelection-45DB9A78706E5101A711A3F227E5B726-3"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><ix:footnote id="TextSelection-39CF024D03225486829869F6CA02C00E-0-wk-Footnote-39CF024D03225486829869F6CA02C00E_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US">Includes gains and losses attributable to derivative instruments designated and qualifying as fair value hedges (primarily interest rate swaps), as well as the offsetting gains and losses attributable to the hedged items in such hedging relationships.</ix:footnote></span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(c)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><ix:footnote id="TextSelection-53BB8CAFCA475C0C9DB2195050D36025-0-wk-Footnote-53BB8CAFCA475C0C9DB2195050D36025_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US">There was no significant ineffectiveness for any period presented.</ix:footnote></span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(d)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><ix:footnote id="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" continuedAt="TextSelection-C789897C877D591AA18C91398D33C66E-1">For derivative financial instruments in cash flow hedge relationships, the effective portion is included in </ix:footnote></span><ix:continuation id="TextSelection-C789897C877D591AA18C91398D33C66E-1" continuedAt="TextSelection-C789897C877D591AA18C91398D33C66E-2"><span style="font-family:inherit;font-size:9pt;font-style:italic;">Other comprehensive income&#8211;&#8211;Unrealized holding losses on derivative financial instruments, net</span><span style="font-family:inherit;font-size:9pt;">. For derivative financial instruments in net investment hedge relationships and for foreign currency debt designated as hedging instruments, the effective portion is included in </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Other comprehensive income&#8211;&#8211;Foreign currency translation adjustments, net.</span></ix:continuation></div></td></tr></table></ix:continuation><div style="line-height:120%;text-align:left;font-size:5pt;"><span style="font-family:inherit;font-size:5pt;"><ix:continuation id="TextSelection-C789897C877D591AA18C91398D33C66E-2"><ix:continuation id="TextSelection-45DB9A78706E5101A711A3F227E5B726-3"><br/></ix:continuation></ix:continuation></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For information about the fair value of our derivative financial instruments, and the impact on our condensed consolidated balance sheets, see </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 7A</span><span style="font-family:inherit;font-size:10pt;"> above</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">.</span><span style="font-family:inherit;font-size:10pt;"> Certain of our derivative instruments are covered by associated credit-support agreements that have credit-risk-related contingent features designed to reduce our counterparties&#8217; exposure to our risk of defaulting on amounts owed. As of </span><span style="font-family:inherit;font-size:10pt;">October&#160;1, 2017</span><span style="font-family:inherit;font-size:10pt;">, the aggregate fair value of these derivative instruments that are in a net liability position was </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d43770747e11462-wk-Fact-9AF94E1718055B36AF1473DD6FA8AC28" name="us-gaap:DerivativeNetLiabilityPositionAggregateFairValue" contextRef="FI2017Q3" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">491</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, for which we have posted collateral of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d43770747e11466-wk-Fact-83676F6D04CF55E6BF4F2F7A93F749A2" name="us-gaap:CollateralAlreadyPostedAggregateFairValue" contextRef="FI2017Q3" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">505</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> in the normal course of business. If there had been a ratings downgrade, we would not have been required to post any additional collateral to our counterparties</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">.</span></div><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">G. Credit Risk</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On an ongoing basis, we review the creditworthiness of counterparties to our foreign exchange and interest rate agreements and do not expect to incur a significant loss from failure of any counterparties to perform under the agreements. There are no significant concentrations of credit risk related to our financial instruments with any individual counterparty, except for certain significant customers. As of </span><span style="font-family:inherit;font-size:10pt;">October&#160;1, 2017</span><span style="font-family:inherit;font-size:10pt;">, we had </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d43770747e11487-wk-Fact-D427E787F5E953CC87B4E77E1029EE0B" name="us-gaap:ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure" contextRef="FD2017Q3YTD_us-gaap_EquitySecuritiesByIndustryAxis_us-gaap_TechnologySectorMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">946</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> due from a well-diversified, high quality group of technology companies around the world. For details about our investments, see </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 7B </span><span style="font-family:inherit;font-size:10pt;">above.</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><br/></span></div></ix:continuation><div style="line-height:120%;font-size:10pt;"><ix:continuation id="TextSelection-1EE0D555564D5ACA882C4EC0D6E9B51D-7" continuedAt="TextSelection-1EE0D555564D5ACA882C4EC0D6E9B51D-8"><span style="font-family:inherit;font-size:10pt;">In general, there is no requirement for collateral from customers. However, derivative financial instruments are executed under credit-support agreements that provide for the ability to request collateral payments depending on levels of exposure, our credit rating and the credit rating of the counterparty. As of </span><span style="font-family:inherit;font-size:10pt;">October&#160;1, 2017</span><span style="font-family:inherit;font-size:10pt;">, we received cash collateral of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d43770747e11504-wk-Fact-36E81E11E9DD5BCF926972893DB780F4" name="us-gaap:SecuritiesReceivedAsCollateral" contextRef="FI2017Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_CashAndCashEquivalentsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">232</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> from various counterparties. The collateral primarily supports the approximate fair value of our derivative contracts. With respect to the collateral received, the obligations are reported in </span></ix:continuation><span style="font-family:inherit;font-size:10pt;font-style:italic;"><ix:continuation id="TextSelection-1EE0D555564D5ACA882C4EC0D6E9B51D-8">Short-term borrowings, including current portion of long-term debt.</ix:continuation></span></div><div><a id="s27E63E3E483C5B758B387DC4E1C22B7C"></a></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Note 8. </span><ix:nonNumeric contextRef="FD2017Q3YTD" name="us-gaap:InventoryDisclosureTextBlock" id="TextSelection-4167516592215B518BC81B6C6A71159D-0-wk-Fact-45AE462D8C1754ABB1595A3DC2F1F0B0" continuedAt="TextSelection-4167516592215B518BC81B6C6A71159D-1" escape="true"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Inventories</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"> </span></ix:nonNumeric></div><ix:continuation id="TextSelection-4167516592215B518BC81B6C6A71159D-1" continuedAt="TextSelection-4167516592215B518BC81B6C6A71159D-2"><div style="line-height:120%;font-size:10pt;"><ix:nonNumeric contextRef="FD2017Q3YTD" name="us-gaap:ScheduleOfInventoryNoncurrentTableTextBlock" id="TextSelection-73D671FE70D05EE080AADF16162F8780-0-wk-Fact-2869BD6C4F9556D5BA49E16C10F6DFB7" continuedAt="TextSelection-73D671FE70D05EE080AADF16162F8780-1" escape="true"><ix:nonNumeric contextRef="FD2017Q3YTD" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="TextSelection-BBF61FA9F0F75655BF81552E4FA32995-0-wk-Fact-95EC3C3E941157058D2F4623F88F3D8D" continuedAt="TextSelection-BBF61FA9F0F75655BF81552E4FA32995-1" escape="true"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides the components of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Inventories</span><span style="font-family:inherit;font-size:10pt;">:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">October&#160;1, <br/>2017</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December&#160;31, <br/>2016</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finished goods</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43678813e776-wk-Fact-1439518851A955238034978DD7259990" name="us-gaap:InventoryFinishedGoodsNetOfReserves" contextRef="FI2017Q3" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,977</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43678813e795-wk-Fact-12C6819137C35A228B5BD0A728DC7674" name="us-gaap:InventoryFinishedGoodsNetOfReserves" contextRef="FI2016Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,293</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Work-in-process</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43678813e815-wk-Fact-F5CC53D4DCC551978E43CE6D859A7D31" name="us-gaap:InventoryWorkInProcessNetOfReserves" contextRef="FI2017Q3" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4,070</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43678813e834-wk-Fact-9AB42259ABDF5A918AF352862AB84CA0" name="us-gaap:InventoryWorkInProcessNetOfReserves" contextRef="FI2016Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,696</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Raw materials and supplies</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43678813e859-wk-Fact-8C25BE4FBE9C55FEBCD93C67D6DF1CD5" name="us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves" contextRef="FI2017Q3" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">879</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43678813e878-wk-Fact-0DF17399CAC556DF9137FEB380FD9334" name="us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves" contextRef="FI2016Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">793</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Inventories</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43678813e910-wk-Fact-2C8D97E870025A9E9218D1538714EA7C" name="us-gaap:InventoryNet" contextRef="FI2017Q3" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">7,925</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43678813e929-wk-Fact-B57DF7F90CE856C48797E9E94456B6CD" name="us-gaap:InventoryNet" contextRef="FI2016Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6,783</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Noncurrent inventories not included above</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(b)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43678813e956-wk-Fact-2164B7E786595ADF8A2FFDAB7982BEB2" name="us-gaap:InventoryNoncurrent" contextRef="FI2017Q3" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">669</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43678813e975-wk-Fact-9A5C2CB5B6525CAF82F961091ABF22D5" name="us-gaap:InventoryNoncurrent" contextRef="FI2016Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">683</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></ix:nonNumeric></ix:nonNumeric></div><ix:continuation id="TextSelection-BBF61FA9F0F75655BF81552E4FA32995-1" continuedAt="TextSelection-BBF61FA9F0F75655BF81552E4FA32995-2"><ix:continuation id="TextSelection-73D671FE70D05EE080AADF16162F8780-1" continuedAt="TextSelection-73D671FE70D05EE080AADF16162F8780-2"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><ix:footnote id="TextSelection-431A3875E30657529B6519DFB33F40EB-0-wk-Footnote-431A3875E30657529B6519DFB33F40EB_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" continuedAt="TextSelection-431A3875E30657529B6519DFB33F40EB-1">The change from </ix:footnote></span><ix:continuation id="TextSelection-431A3875E30657529B6519DFB33F40EB-1" continuedAt="TextSelection-431A3875E30657529B6519DFB33F40EB-2"><span style="font-family:inherit;font-size:9pt;text-align:center;">December&#160;31, 2016</span></ix:continuation><span style="font-family:inherit;font-size:9pt;"><ix:continuation id="TextSelection-431A3875E30657529B6519DFB33F40EB-2"> reflects the build of inventory primarily for and in advance of new or potential product launches and increases to meet targeted levels for certain products in the normal course of business, including those related to demand.</ix:continuation></span></div></td></tr></table></ix:continuation></ix:continuation></ix:continuation><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><ix:continuation id="TextSelection-BBF61FA9F0F75655BF81552E4FA32995-2" continuedAt="TextSelection-BBF61FA9F0F75655BF81552E4FA32995-3"><ix:continuation id="TextSelection-73D671FE70D05EE080AADF16162F8780-2" continuedAt="TextSelection-73D671FE70D05EE080AADF16162F8780-3"><ix:continuation id="TextSelection-4167516592215B518BC81B6C6A71159D-2" continuedAt="TextSelection-4167516592215B518BC81B6C6A71159D-3"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(b)</sup>&#160;</span></div></ix:continuation></ix:continuation></ix:continuation></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9pt;"><ix:continuation id="TextSelection-BBF61FA9F0F75655BF81552E4FA32995-3" continuedAt="TextSelection-BBF61FA9F0F75655BF81552E4FA32995-4"><ix:continuation id="TextSelection-73D671FE70D05EE080AADF16162F8780-3" continuedAt="TextSelection-73D671FE70D05EE080AADF16162F8780-4"><ix:continuation id="TextSelection-4167516592215B518BC81B6C6A71159D-3" continuedAt="TextSelection-4167516592215B518BC81B6C6A71159D-4"><span style="font-family:inherit;font-size:9pt;"><ix:footnote id="TextSelection-E16E3AA57ADF5C6FB93B6FC578ED7F95-0-wk-Footnote-E16E3AA57ADF5C6FB93B6FC578ED7F95_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" continuedAt="TextSelection-E16E3AA57ADF5C6FB93B6FC578ED7F95-1">Included in </ix:footnote></span><ix:continuation id="TextSelection-E16E3AA57ADF5C6FB93B6FC578ED7F95-1" continuedAt="TextSelection-E16E3AA57ADF5C6FB93B6FC578ED7F95-2"><span style="font-family:inherit;font-size:9pt;font-style:italic;">Other noncurrent assets</span></ix:continuation></ix:continuation></ix:continuation></ix:continuation><span style="font-family:inherit;font-size:9pt;"><ix:continuation id="TextSelection-4167516592215B518BC81B6C6A71159D-4"><ix:continuation id="TextSelection-73D671FE70D05EE080AADF16162F8780-4"><ix:continuation id="TextSelection-BBF61FA9F0F75655BF81552E4FA32995-4"><ix:continuation id="TextSelection-E16E3AA57ADF5C6FB93B6FC578ED7F95-2">. There are no recoverability issues associated with these amounts.</ix:continuation></ix:continuation></ix:continuation></ix:continuation></span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">25</span></div></div><hr style="page-break-after:always"></hr><div><a id="s24CB35D15CA8530AA334C8398B21FE57"></a></div><div><div style="line-height:120%;text-align:center;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(UNAUDITED)</span></div></div><div><br/></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Note 9.<ix:nonNumeric contextRef="FD2017Q3YTD" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="TextSelection-6062CC2978B259FEA1842F0E419EF5CF-0-wk-Fact-97F204FAA2BE518098817396FD8D037F" continuedAt="TextSelection-6062CC2978B259FEA1842F0E419EF5CF-1" escape="true"> </ix:nonNumeric></span><ix:continuation id="TextSelection-6062CC2978B259FEA1842F0E419EF5CF-1" continuedAt="TextSelection-6062CC2978B259FEA1842F0E419EF5CF-2"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Identifiable Intangible Assets and Goodwill</span></ix:continuation></div><ix:continuation id="TextSelection-6062CC2978B259FEA1842F0E419EF5CF-2" continuedAt="TextSelection-6062CC2978B259FEA1842F0E419EF5CF-3"><div style="line-height:120%;text-align:left;font-size:5pt;"><span style="font-family:inherit;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">A. Identifiable Intangible Assets</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:inherit;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Balance Sheet Information</span></div><div style="line-height:120%;font-size:10pt;"><ix:nonNumeric contextRef="FD2017Q3YTD" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="TextSelection-63DEC5623E5C5D73892FB2BAD239D760-0-wk-Fact-F090FF4A59965434BD425415F879FB2F" continuedAt="TextSelection-63DEC5623E5C5D73892FB2BAD239D760-1" escape="true"><ix:nonNumeric contextRef="FD2017Q3YTD" name="us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" id="TextSelection-6DFE3044CA0A5B71B9481DF8583265EB-0-wk-Fact-9F6AD4A71A38593CA1E839E2272D1DA6" continuedAt="TextSelection-6DFE3044CA0A5B71B9481DF8583265EB-1" escape="true"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"></td></tr><tr><td style="width:28%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td colspan="25" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides the components of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Identifiable intangible assets</span><span style="font-family:inherit;font-size:10pt;">:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">October&#160;1, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Carrying</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amount</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accumulated</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Identifiable</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Intangible</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Assets, less</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accumulated</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Carrying</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amount</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accumulated</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Identifiable</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Intangible</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Assets, less</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accumulated</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Finite-lived intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Developed technology rights</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43697240e1285-wk-Fact-A1B9EBB00CA357B685505D97968F301E" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="FI2017Q3_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">89,585</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d43697240e1304-wk-Fact-A8BCB7724076572A894D8BDFC6785A6A" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="FI2017Q3_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">53,960</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43697240e1325-wk-Fact-8222C49DFF25586385357680BA3E7A37" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="FI2017Q3_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">35,625</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43697240e1344-wk-Fact-DC886DFF855F55D5A5C4FBBBA585838D" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="FI2016Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">83,390</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d43697240e1363-wk-Fact-5609BB6BDB4E55C38CE62E60B3E67446" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="FI2016Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">49,650</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43697240e1384-wk-Fact-81D16D7A3AE6589781565D5CDDE413F5" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="FI2016Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">33,740</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Brands</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43697240e1404-wk-Fact-0673EBFC50BF5790974811704635181B" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="FI2017Q3_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,135</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d43697240e1423-wk-Fact-303BAFA42E765D29869BBFF7735E1676" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="FI2017Q3_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,127</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43697240e1443-wk-Fact-4E7F9773EC505514835D19BCB42DBF5B" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="FI2017Q3_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,008</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43697240e1463-wk-Fact-6FCE50ADA4D65905979B13CF8B17B7F6" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="FI2016Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,092</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d43697240e1482-wk-Fact-2F7AA2C07FD35E5A832FBA6A253A51D2" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="FI2016Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,032</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43697240e1503-wk-Fact-E2B9EAB1D5515A3EA298E93E09D3B133" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="FI2016Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,060</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Licensing agreements and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43697240e1528-wk-Fact-6E3E89D2AC2C5E169FB88F87EBFE2A6E" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="FI2017Q3_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsAndOtherMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,930</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d43697240e1547-wk-Fact-78BB584B72D15F48A47507C651101086" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="FI2017Q3_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsAndOtherMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,071</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43697240e1567-wk-Fact-AFBAD8CE22005F63BAA4AEBF86677C90" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="FI2017Q3_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsAndOtherMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">859</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43697240e1587-wk-Fact-161ED29469D05B7E84E0C6CDEA89F9D1" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="FI2016Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsAndOtherMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,869</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d43697240e1606-wk-Fact-FEFD4CD4E3FF538EB7329A3C9FF600DB" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="FI2016Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsAndOtherMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,005</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43697240e1627-wk-Fact-61A4C5F0781A594684642F5BB201E729" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="FI2016Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsAndOtherMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">864</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43697240e1652-wk-Fact-BF285486F7F35B8DB44772EFB8690A73" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="FI2017Q3" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">93,650</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d43697240e1671-wk-Fact-CFD4991422BB5F588B49A4956375B606" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="FI2017Q3" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">56,158</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43697240e1691-wk-Fact-D3CF77A5EC1B5110ADD0AEEFD5A42263" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="FI2017Q3" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">37,492</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43697240e1711-wk-Fact-1CE3CA7DC39F5EA6AD800051DB3360BD" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="FI2016Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">87,351</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d43697240e1730-wk-Fact-305740AD59515768A45E4205357775C9" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="FI2016Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">51,687</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43697240e1751-wk-Fact-F980A62CD1E6505DB9CEEDF97CA54153" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="FI2016Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">35,664</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Indefinite-lived intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Brands and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43697240e1904-wk-Fact-3360B614FDB7584BB5E86371BB13C45A" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" contextRef="FI2017Q3_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6,937</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43697240e1941-wk-Fact-3360B614FDB7584BB5E86371BB13C45A" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" contextRef="FI2017Q3_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6,937</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43697240e1961-wk-Fact-E25686C1008150CFA2AE2C8C99CD41BE" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" contextRef="FI2016Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6,883</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43697240e1999-wk-Fact-E25686C1008150CFA2AE2C8C99CD41BE" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" contextRef="FI2016Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6,883</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">IPR&amp;D</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(a)</sup></span><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43697240e2028-wk-Fact-6D6000856CC75C59855BFA6956D3EBE0" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" contextRef="FI2017Q3_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">5,292</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43697240e2065-wk-Fact-6D6000856CC75C59855BFA6956D3EBE0" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" contextRef="FI2017Q3_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">5,292</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43697240e2085-wk-Fact-54A6BC26AA6157E19153460F2648274D" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" contextRef="FI2016Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">10,101</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43697240e2123-wk-Fact-54A6BC26AA6157E19153460F2648274D" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" contextRef="FI2016Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">10,101</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43697240e2149-wk-Fact-EFB5E853E99F51BDAD4EE953AE648F4E" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" contextRef="FI2017Q3" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">12,229</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43697240e2186-wk-Fact-EFB5E853E99F51BDAD4EE953AE648F4E" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" contextRef="FI2017Q3" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">12,229</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43697240e2206-wk-Fact-4A3790AC3D755608AA6E025EF63F2CE7" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" contextRef="FI2016Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">16,984</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43697240e2244-wk-Fact-4A3790AC3D755608AA6E025EF63F2CE7" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" contextRef="FI2016Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">16,984</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Identifiable intangible assets</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(b)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43697240e2276-wk-Fact-A5D936B4270856D1A914ABA7E1D66F0A" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" contextRef="FI2017Q3" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">105,879</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d43697240e2295-wk-Fact-CFD4991422BB5F588B49A4956375B606" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="FI2017Q3" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">56,158</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43697240e2316-wk-Fact-A41E764041225C8DBE154ADB89FBF66C" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="FI2017Q3" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">49,721</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43697240e2335-wk-Fact-08713BCAEBE7560790D2B69F31D04450" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" contextRef="FI2016Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">104,335</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d43697240e2354-wk-Fact-305740AD59515768A45E4205357775C9" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="FI2016Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">51,687</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43697240e2375-wk-Fact-4014B8D306BF54FC8CDF5431816FAA50" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="FI2016Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">52,648</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></ix:nonNumeric></ix:nonNumeric></div><ix:continuation id="TextSelection-6DFE3044CA0A5B71B9481DF8583265EB-1" continuedAt="TextSelection-6DFE3044CA0A5B71B9481DF8583265EB-2"><ix:continuation id="TextSelection-63DEC5623E5C5D73892FB2BAD239D760-1" continuedAt="TextSelection-63DEC5623E5C5D73892FB2BAD239D760-2"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><ix:footnote id="TextSelection-7432EEEACAB3598FA522C1D7E1584D05-0-wk-Footnote-7432EEEACAB3598FA522C1D7E1584D05_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" continuedAt="TextSelection-7432EEEACAB3598FA522C1D7E1584D05-1">The changes in the gross carrying amount of </ix:footnote></span><ix:continuation id="TextSelection-7432EEEACAB3598FA522C1D7E1584D05-1" continuedAt="TextSelection-7432EEEACAB3598FA522C1D7E1584D05-2"><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Developed technology rights </span><span style="font-family:inherit;font-size:8.5pt;">and </span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">IPR&amp;D</span><span style="font-family:inherit;font-size:8.5pt;"> primarily reflect (i) the transfer of </span><span style="font-family:inherit;font-size:8.5pt;"><span>$<ix:nonFraction id="d43697240e2411-wk-Fact-35AD5C012C5D53ED891D36C19D6C896E" name="pfe:IntangibleAssetsTransfersDuringPeriod" contextRef="FI2017Q3_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember_us-gaap_ProductOrServiceAxis_pfe_EucrisaMember" unitRef="usd" decimals="-8" scale="9" sign="-" format="ixt:numdotdecimal">4.8</ix:nonFraction> billion</span></span><span style="font-family:inherit;font-size:8.5pt;"> from </span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">IPR&amp;D</span><span style="font-family:inherit;font-size:8.5pt;"> to </span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Developed technology rights</span><span style="font-family:inherit;font-size:8.5pt;"> to reflect the approval of Eucrisa, (ii) the </span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Developed technology rights</span><span style="font-family:inherit;font-size:8.5pt;"> and </span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">IPR&amp;D</span><span style="font-family:inherit;font-size:8.5pt;"> acquired as part of the acquisition of AstraZeneca&#8217;s small molecule anti-infectives business (see </span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Note 2A</span><span style="font-family:inherit;font-size:8.5pt;">), (iii) the </span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Developed technology rights</span><span style="font-family:inherit;font-size:8.5pt;"> of </span><span style="font-family:inherit;font-size:8.5pt;"><span>$<ix:nonFraction id="d43697240e2440-wk-Fact-406170E8DCB75316BF73021292411F88" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="FI2017Q3_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_ProductOrServiceAxis_pfe_BesponsaMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">371</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:8.5pt;"> recorded in connection with the EU and U.S. approvals of Besponsa (see </span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Note 7E</span><span style="font-family:inherit;font-size:8.5pt;">), partially offset by (iv) measurement period adjustments related to Medivation (see </span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Note 2A</span><span style="font-family:inherit;font-size:8.5pt;">) and (v) impairments of </span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Developed technology rights</span><span style="font-family:inherit;font-size:8.5pt;"> (see </span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Note 4)</span></ix:continuation><span style="font-family:inherit;font-size:8.5pt;"><ix:continuation id="TextSelection-7432EEEACAB3598FA522C1D7E1584D05-2">.</ix:continuation></span></div></td></tr></table></ix:continuation></ix:continuation><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><ix:continuation id="TextSelection-6DFE3044CA0A5B71B9481DF8583265EB-2" continuedAt="TextSelection-6DFE3044CA0A5B71B9481DF8583265EB-3"><ix:continuation id="TextSelection-63DEC5623E5C5D73892FB2BAD239D760-2" continuedAt="TextSelection-63DEC5623E5C5D73892FB2BAD239D760-3"><div style="line-height:120%;font-size:8.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(b)</sup>&#160;</span></div></ix:continuation></ix:continuation></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8.5pt;"><ix:continuation id="TextSelection-6DFE3044CA0A5B71B9481DF8583265EB-3" continuedAt="TextSelection-6DFE3044CA0A5B71B9481DF8583265EB-4"><ix:continuation id="TextSelection-63DEC5623E5C5D73892FB2BAD239D760-3" continuedAt="TextSelection-63DEC5623E5C5D73892FB2BAD239D760-4"><span style="font-family:inherit;font-size:8.5pt;"><ix:footnote id="TextSelection-FF348CC7844F523299A112551B170BE6-0-wk-Footnote-FF348CC7844F523299A112551B170BE6_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" continuedAt="TextSelection-FF348CC7844F523299A112551B170BE6-1">The decrease in </ix:footnote></span><ix:continuation id="TextSelection-FF348CC7844F523299A112551B170BE6-1" continuedAt="TextSelection-FF348CC7844F523299A112551B170BE6-2"><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">I</span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;text-align:right;">dentifiable intangible assets, less accumulated amortization</span><span style="font-family:inherit;font-size:8.5pt;text-align:right;">, </span><span style="font-family:inherit;font-size:8.5pt;">is primarily due to amortization, measurement period adjustments related to Medivation (see </span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Note 2A</span><span style="font-family:inherit;font-size:8.5pt;">), as well as impairments of </span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Developed technology rights</span><span style="font-family:inherit;font-size:8.5pt;"> (see </span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Note 4)</span><span style="font-family:inherit;font-size:8.5pt;">, partially offset by assets acquired as part of the acquisition of AstraZeneca&#8217;s small molecule anti-infectives business (see </span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Note 2A</span><span style="font-family:inherit;font-size:8.5pt;">) and the assets recorded in connection with the EU and U.S. approvals of Besponsa (see </span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Note 7E</span></ix:continuation></ix:continuation></ix:continuation><span style="font-family:inherit;font-size:8.5pt;"><ix:continuation id="TextSelection-63DEC5623E5C5D73892FB2BAD239D760-4"><ix:continuation id="TextSelection-6DFE3044CA0A5B71B9481DF8583265EB-4"><ix:continuation id="TextSelection-FF348CC7844F523299A112551B170BE6-2">).</ix:continuation></ix:continuation></ix:continuation></span></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><ix:nonNumeric contextRef="FD2017Q3YTD" name="pfe:IdentifiableintangibleassetsasapercentageoftotalidentifiableintangibleassetslessaccumulatedamortizationbysegmentTableTextBlock" id="TextSelection-40578DE379BE5EACAEB3ED0AC4AEE674-0-wk-Fact-AD4E8626E6685A29AE7C19E7BCFF3A7A" escape="true"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"></td></tr><tr><td style="width:55%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our identifiable intangible assets are associated with the following, as a percentage of total identifiable intangible assets, less accumulated amortization:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">October&#160;1, 2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">IH</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">EH</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">WRD</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Developed technology rights</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43697240e2697-wk-Fact-311A195A53525918B720FC57C17CC107" name="pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet" contextRef="FI2017Q3_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">68</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43697240e2712-wk-Fact-93D4315B06AC5101B88D1B4E2A1DCBCB" name="pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet" contextRef="FI2017Q3_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">32</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43697240e2727-wk-Fact-5C360B5BF9885FF7A6CB9E2EAFC8FE97" name="pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet" contextRef="FI2017Q3_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_SubsegmentsAxis_pfe_PfizersWorldwideResearchandDevelopmentMember" unitRef="number" decimals="2" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Brands, finite-lived</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43697240e2748-wk-Fact-E2E06C1C6FA1525C91AA7A739339ABBC" name="pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet" contextRef="FI2017Q3_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">75</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43697240e2763-wk-Fact-4BFEDB0028C65FF4A59FA4C74032F0E6" name="pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet" contextRef="FI2017Q3_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">25</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43697240e2778-wk-Fact-D6AD9D102B0C5CF4BBCA3D48DA9CFAA9" name="pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet" contextRef="FI2017Q3_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember_us-gaap_SubsegmentsAxis_pfe_PfizersWorldwideResearchandDevelopmentMember" unitRef="number" decimals="2" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Brands, indefinite-lived</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43697240e2799-wk-Fact-E4AEE7EACC2E5C89B1CEE64FC524586A" name="pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet" contextRef="FI2017Q3_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">71</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43697240e2814-wk-Fact-0EFE0CC1FA4651CE9B9C2A50ACFB7D9A" name="pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet" contextRef="FI2017Q3_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">29</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43697240e2829-wk-Fact-28BA78A4F479559F980AF3252ED9CCB1" name="pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet" contextRef="FI2017Q3_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember_us-gaap_SubsegmentsAxis_pfe_PfizersWorldwideResearchandDevelopmentMember" unitRef="number" decimals="2" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">IPR&amp;D </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43697240e2850-wk-Fact-5843645CD86D5318971467CD0235EF5F" name="pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet" contextRef="FI2017Q3_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">80</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43697240e2865-wk-Fact-96A880B4097256C9BA83AAF51DE43150" name="pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet" contextRef="FI2017Q3_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">13</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43697240e2880-wk-Fact-74D65A8327F95BD5B29F8FA42A695DBB" name="pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet" contextRef="FI2017Q3_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember_us-gaap_SubsegmentsAxis_pfe_PfizersWorldwideResearchandDevelopmentMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr></table></div></ix:nonNumeric><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:5pt;"><span style="font-family:inherit;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Amortization</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:inherit;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total amortization expense for finite-lived intangible assets was </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d43697240e2907-wk-Fact-B26040C54F96504998E917E2A1EF109A" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="FD2017Q3QTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_FiniteLivedIntangibleAssetsMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">1.2</ix:nonFraction> billion</span></span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">third</span><span style="font-family:inherit;font-size:10pt;"> quarter of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d43697240e2919-wk-Fact-698B176643E457EBA1FEFFCA8ECF5C73" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="FD2016Q3QTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_FiniteLivedIntangibleAssetsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">988</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">third</span><span style="font-family:inherit;font-size:10pt;"> quarter of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d43697240e2932-wk-Fact-ACF2B879159B582D8139C91E8A10C009" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="FD2017Q3YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_FiniteLivedIntangibleAssetsMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">3.6</ix:nonFraction> billion</span></span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d43697240e2944-wk-Fact-C99DDFFBDCE059D4A7F2304F704FEFEE" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="FD2016Q3YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_FiniteLivedIntangibleAssetsMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">3.0</ix:nonFraction> billion</span></span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;">.</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">26</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:center;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(UNAUDITED)</span></div></div><div><br/></div><ix:continuation id="TextSelection-6062CC2978B259FEA1842F0E419EF5CF-3" continuedAt="TextSelection-6062CC2978B259FEA1842F0E419EF5CF-4"><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">B. Goodwill</span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><ix:nonNumeric contextRef="FD2017Q3YTD" name="us-gaap:ScheduleOfGoodwillTextBlock" id="TextSelection-0F79EE6E5A2C58CB80DE00324DD8E137-0-wk-Fact-8D8A604DA01059F18645787F45FBA6DA" continuedAt="TextSelection-0F79EE6E5A2C58CB80DE00324DD8E137-1" escape="true"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:55%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides the components of and changes in the carrying amount of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Goodwill</span><span style="font-family:inherit;font-size:10pt;">:</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">IH</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">EH</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance, December&#160;31, 2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43697240e3143-wk-Fact-8B858EB96E0B54168AAD76F7E31A02A1" name="us-gaap:Goodwill" contextRef="FI2016Q4_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">30,134</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43697240e3162-wk-Fact-ECD85C16469253E8ACB3C5F1B3BBE6EF" name="us-gaap:Goodwill" contextRef="FI2016Q4_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">24,315</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43697240e3182-wk-Fact-F8F5DF7C12C25020B65DFF915C2D461A" name="us-gaap:Goodwill" contextRef="FI2016Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">54,449</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Additions</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43697240e3204-wk-Fact-39F7ED9F3086578FAC1610BAD7C34831" name="us-gaap:GoodwillAcquiredDuringPeriod" contextRef="FD2017Q3YTD_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">572</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43697240e3223-wk-Fact-1B4BEA3CDC1756D68AA1A2E1DC80FA4D" name="us-gaap:GoodwillAcquiredDuringPeriod" contextRef="FD2017Q3YTD_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">92</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43697240e3242-wk-Fact-32830C0722A659AF88B98C905235BC15" name="us-gaap:GoodwillAcquiredDuringPeriod" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">664</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43697240e3270-wk-Fact-5B921CA5279853B595C111072F4FBA7F" name="us-gaap:GoodwillOtherIncreaseDecrease" contextRef="FD2017Q3YTD_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">491</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43697240e3289-wk-Fact-6AC822CCA34E51E4AFF352F6B975BAEF" name="us-gaap:GoodwillOtherIncreaseDecrease" contextRef="FD2017Q3YTD_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">475</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43697240e3308-wk-Fact-94EEFBE86EAF5F65881310E2436550F1" name="us-gaap:GoodwillOtherIncreaseDecrease" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">966</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance, October&#160;1, 2017</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43697240e3339-wk-Fact-3B12F4B948D05D978CB909A2F4520D86" name="us-gaap:Goodwill" contextRef="FI2017Q3_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">31,197</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43697240e3358-wk-Fact-81A851BFCD2955758BC03DB834D3D37E" name="us-gaap:Goodwill" contextRef="FI2017Q3_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">24,882</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43697240e3378-wk-Fact-691B87100C6755EB85765E65D5C328BA" name="us-gaap:Goodwill" contextRef="FI2017Q3" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">56,078</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></ix:nonNumeric></div><ix:continuation id="TextSelection-0F79EE6E5A2C58CB80DE00324DD8E137-1" continuedAt="TextSelection-0F79EE6E5A2C58CB80DE00324DD8E137-2"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><ix:footnote id="TextSelection-5368EA2EA2275823ADDE27DF2382EF3B-0-wk-Footnote-5368EA2EA2275823ADDE27DF2382EF3B_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" continuedAt="TextSelection-5368EA2EA2275823ADDE27DF2382EF3B-1">IH additions primarily represent measurement period adjustments related to our Medivation acquisition, and EH additions relate to our acquisition of AstraZeneca&#8217;s small molecule anti-infectives business, which are subject to change until we complete the valuation of assets acquired and liabilities assumed (see </ix:footnote></span><ix:continuation id="TextSelection-5368EA2EA2275823ADDE27DF2382EF3B-1" continuedAt="TextSelection-5368EA2EA2275823ADDE27DF2382EF3B-2"><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Note 2A</span></ix:continuation><span style="font-family:inherit;font-size:8.5pt;"><ix:continuation id="TextSelection-5368EA2EA2275823ADDE27DF2382EF3B-2">).</ix:continuation></span></div></td></tr></table></ix:continuation></ix:continuation><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><ix:continuation id="TextSelection-0F79EE6E5A2C58CB80DE00324DD8E137-2" continuedAt="TextSelection-0F79EE6E5A2C58CB80DE00324DD8E137-3"><ix:continuation id="TextSelection-6062CC2978B259FEA1842F0E419EF5CF-4" continuedAt="TextSelection-6062CC2978B259FEA1842F0E419EF5CF-5"><div style="line-height:120%;font-size:8.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(b)</sup>&#160;</span></div></ix:continuation></ix:continuation></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><ix:continuation id="TextSelection-6062CC2978B259FEA1842F0E419EF5CF-5"><ix:continuation id="TextSelection-0F79EE6E5A2C58CB80DE00324DD8E137-3"><ix:footnote id="TextSelection-73987C5EBB9C5D43BC69B77F006C18A6-0-wk-Footnote-73987C5EBB9C5D43BC69B77F006C18A6_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US">Primarily reflects the impact of foreign exchange and an adjustment of our estimate of goodwill associated with the HIS net assets sold.</ix:footnote></ix:continuation></ix:continuation></span></div></td></tr></table><div><a id="sD3BE543B41135907884E64983C5A3A92"></a></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Note 10. </span><ix:nonNumeric contextRef="FD2017Q3YTD" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="TextSelection-108DD3F434485B42AD3B4CE4A038BDC6-0-wk-Fact-EFF2005AFB805E22A95DB5A897950074" continuedAt="TextSelection-108DD3F434485B42AD3B4CE4A038BDC6-1" escape="true"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Pension and Postretirement Benefit Plans</span></ix:nonNumeric></div><ix:continuation id="TextSelection-108DD3F434485B42AD3B4CE4A038BDC6-1" continuedAt="TextSelection-108DD3F434485B42AD3B4CE4A038BDC6-2"><div style="line-height:120%;font-size:10pt;"><ix:nonNumeric contextRef="FD2017Q3YTD" name="us-gaap:ScheduleOfNetBenefitCostsTableTextBlock" id="TextSelection-3F349BD1197C5BBA9A1BB21C88406E1E-0-wk-Fact-500E0CC9ACEE5A4690191FBC1A04F684" continuedAt="TextSelection-3F349BD1197C5BBA9A1BB21C88406E1E-1" escape="true"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="33"></td></tr><tr><td style="width:27%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td></tr><tr><td colspan="33" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides the components of net periodic benefit cost/(income):</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="31" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Three Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Arial;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Pension Plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Arial;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">U.S.</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Qualified</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">U.S.</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Supplemental</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(Non-Qualified)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">International</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Postretirement</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Plans</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Oct&#160;1, 2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Oct&#160;2, 2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Oct&#160;1, 2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Oct&#160;2, 2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Oct&#160;1, 2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Oct&#160;2, 2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Oct&#160;1, 2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Oct&#160;2, 2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net periodic benefit cost/(credit):</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Service cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43712510e1704-wk-Fact-9E9209F9A748579AAF874A87DF78C03D" name="us-gaap:DefinedBenefitPlanServiceCost" contextRef="FD2017Q3QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">67</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43712510e1723-wk-Fact-8714D4A622405CD6AB9185ACD20BD070" name="us-gaap:DefinedBenefitPlanServiceCost" contextRef="FD2016Q3QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">69</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43712510e1743-wk-Fact-1E3A1193A3EF5D5FA90C719E1E1C2A1D" name="us-gaap:DefinedBenefitPlanServiceCost" contextRef="FD2017Q3QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43712510e1762-wk-Fact-0C863B6EEB905815B1F70A90BE67A0A2" name="us-gaap:DefinedBenefitPlanServiceCost" contextRef="FD2016Q3QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43712510e1781-wk-Fact-481449526D1057088ED9870C387494AE" name="us-gaap:DefinedBenefitPlanServiceCost" contextRef="FD2017Q3QTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">44</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43712510e1801-wk-Fact-41EDF11A6AEB5CC0A903B82579EABF9A" name="us-gaap:DefinedBenefitPlanServiceCost" contextRef="FD2016Q3QTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">41</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43712510e1820-wk-Fact-C814785A192A52CCAF640691C51A3304" name="us-gaap:DefinedBenefitPlanServiceCost" contextRef="FD2017Q3QTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">10</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43712510e1839-wk-Fact-135852348E555F4AB8AB8330D1762860" name="us-gaap:DefinedBenefitPlanServiceCost" contextRef="FD2016Q3QTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">11</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Interest cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43712510e1859-wk-Fact-8C938F85BB8A51A08B716303B9D043F4" name="us-gaap:DefinedBenefitPlanInterestCost" contextRef="FD2017Q3QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">157</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43712510e1878-wk-Fact-D181F1F1F0F9549AB0AAD66667DA5D73" name="us-gaap:DefinedBenefitPlanInterestCost" contextRef="FD2016Q3QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">218</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43712510e1897-wk-Fact-21AD6A14FD6E5AF1B3B95C4CB9BEB6F8" name="us-gaap:DefinedBenefitPlanInterestCost" contextRef="FD2017Q3QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">13</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43712510e1917-wk-Fact-F0C627D912BB5038A7441B4C323F14CB" name="us-gaap:DefinedBenefitPlanInterestCost" contextRef="FD2016Q3QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">18</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43712510e1936-wk-Fact-2419217873095BD3AB73F321E36C47D2" name="us-gaap:DefinedBenefitPlanInterestCost" contextRef="FD2017Q3QTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">52</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43712510e1956-wk-Fact-6EF224137E2A543BBAD79C942899C04D" name="us-gaap:DefinedBenefitPlanInterestCost" contextRef="FD2016Q3QTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">58</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43712510e1975-wk-Fact-F16069631AEA55FFBFBAEA5F47EFA30B" name="us-gaap:DefinedBenefitPlanInterestCost" contextRef="FD2017Q3QTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">23</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43712510e1994-wk-Fact-7EADE07DC1C65F9A8D9D917A78C49E82" name="us-gaap:DefinedBenefitPlanInterestCost" contextRef="FD2016Q3QTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">33</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Expected return on plan assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d43712510e2019-wk-Fact-9A7B6E07A41152D8AE4FAE1762D02940" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" contextRef="FD2017Q3QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">248</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d43712510e2039-wk-Fact-918079B890DC59749E32C36C8E843601" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" contextRef="FD2016Q3QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">239</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43712510e2059-wk-Fact-6F2C0A4B5D0752368E32A74CDBD0FD9C" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" contextRef="FD2017Q3QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43712510e2079-wk-Fact-A936B10CF3A85F05AFE634207AC14544" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" contextRef="FD2016Q3QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d43712510e2098-wk-Fact-B594018F3E2657488F25A3772003918D" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" contextRef="FD2017Q3QTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">87</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d43712510e2119-wk-Fact-BF0D1AA9D89854BFA0ED402AB6E63FBD" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" contextRef="FD2016Q3QTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">95</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d43712510e2139-wk-Fact-22489E2609795BD3B1FDE0B8D17DDD91" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" contextRef="FD2017Q3QTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d43712510e2159-wk-Fact-C59043F87A1658239E9BA9697B357B75" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" contextRef="FD2016Q3QTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Amortization of:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Actuarial losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43712510e2346-wk-Fact-41E8CD7A36715DECB7404562BAE76D26" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" contextRef="FD2017Q3QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">91</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43712510e2365-wk-Fact-88B688C938EB55DDB880C46047CEE537" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" contextRef="FD2016Q3QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">99</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43712510e2384-wk-Fact-A879C840BBEB52A3AE989EEACE5274E6" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" contextRef="FD2017Q3QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">12</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43712510e2404-wk-Fact-70B67E696D2C5B60BE542F2FB05F382E" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" contextRef="FD2016Q3QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43712510e2423-wk-Fact-36D28693F6A356BABCAE6F5DF3DA79F4" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" contextRef="FD2017Q3QTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">29</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43712510e2443-wk-Fact-5FE299955AD05A708EF81988B211C3E7" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" contextRef="FD2016Q3QTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">23</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43712510e2462-wk-Fact-C12C1826A6CA57A2B6B4C9FD4D3B59B1" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" contextRef="FD2017Q3QTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43712510e2481-wk-Fact-0688D85081B75BDCA7C39E89C4BAD62C" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" contextRef="FD2016Q3QTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Prior service costs (credits)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43712510e2507-wk-Fact-F63613D6C4635A1085DB928EB41688A4" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" contextRef="FD2017Q3QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43712510e2526-wk-Fact-6C3AED6081D956DB9A88358A6DBC4860" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" contextRef="FD2016Q3QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43712510e2545-wk-Fact-172B7D1439E957C5909E9CA529B344CD" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" contextRef="FD2017Q3QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43712510e2565-wk-Fact-64992226CD4A56A18E318C5D80777974" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" contextRef="FD2016Q3QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d43712510e2584-wk-Fact-A51AFD1ABFE35B3A9834A6482D23F893" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" contextRef="FD2017Q3QTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d43712510e2605-wk-Fact-3131B0A0FE0C54FABB189CDAB6310BFF" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" contextRef="FD2016Q3QTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d43712510e2625-wk-Fact-316E2928EA2D58D0AB005A0221B707BB" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" contextRef="FD2017Q3QTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">45</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d43712510e2645-wk-Fact-FE9EDE18655A5BDA9B23C201A401F1C4" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" contextRef="FD2016Q3QTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">45</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Curtailments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43712510e2671-wk-Fact-3E4B2138956458C0A87D14CCDFFFE310" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" contextRef="FD2017Q3QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43712510e2690-wk-Fact-119B0C3F842254FBB549178DD2B0B03F" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" contextRef="FD2016Q3QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43712510e2709-wk-Fact-73AE6CA28F0956EEA08FFF8B0864B697" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" contextRef="FD2017Q3QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43712510e2729-wk-Fact-94F622C3D10457ACA9281668326FF033" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" contextRef="FD2016Q3QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d43712510e2748-wk-Fact-D47337A92FE05C088F99D88647D3AAE0" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" contextRef="FD2017Q3QTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43712510e2769-wk-Fact-5ACE4653B79D513195DB093FC19BC1FD" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" contextRef="FD2016Q3QTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d43712510e2788-wk-Fact-0AB1E7D5BDA3559BAF29906AD572874D" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" contextRef="FD2017Q3QTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d43712510e2808-wk-Fact-8F56DA0D0D69553292F1071E7183FC7E" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" contextRef="FD2016Q3QTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Settlements</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43712510e2834-wk-Fact-E67F7356BDB85C86BFA985D27BB3661C" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" contextRef="FD2017Q3QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">30</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43712510e2853-wk-Fact-790FED1A1448526D93D700D9E0FAFC88" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" contextRef="FD2016Q3QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">21</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43712510e2872-wk-Fact-F88E8EB3200C59CC9B23BEBA7578EEDC" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" contextRef="FD2017Q3QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43712510e2892-wk-Fact-4ED9BB0264BB502CAA444ECC25BDC794" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" contextRef="FD2016Q3QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43712510e2911-wk-Fact-2C23635A95855B45B523793ED15431B6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" contextRef="FD2017Q3QTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43712510e2931-wk-Fact-A7CE8DD917725CFE8CC3ECDA78AEB77E" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" contextRef="FD2016Q3QTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43712510e2950-wk-Fact-083C294BF26A544786E00C3E7C12EFAD" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" contextRef="FD2017Q3QTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43712510e2969-wk-Fact-95F4A2EA070D5BBDB6B1B498E2F481B5" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" contextRef="FD2016Q3QTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43712510e2999-wk-Fact-0634C6E9A2985833989CFF0FED04324E" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" contextRef="FD2017Q3QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">99</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43712510e3018-wk-Fact-EB2CC601202B5F75A3AFB7E3C7411A43" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" contextRef="FD2016Q3QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">170</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43712510e3038-wk-Fact-88E8BFE6441E54D3BC4F7503E3CFA476" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" contextRef="FD2017Q3QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">39</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43712510e3057-wk-Fact-594C4C2B50DC5FBA9CDCFEABA069BD95" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" contextRef="FD2016Q3QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">39</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43712510e3076-wk-Fact-E90EB1307D4C58DD8577753F88B5C776" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" contextRef="FD2017Q3QTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">35</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43712510e3096-wk-Fact-541D0ABF1C47588090B21F7F496B7A53" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" contextRef="FD2016Q3QTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">27</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d43712510e3115-wk-Fact-E7BD283525F35A9A93A3A517FDA649FE" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" contextRef="FD2017Q3QTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">17</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d43712510e3135-wk-Fact-F82AC1F26D5556AEBEC85DA302886F9E" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" contextRef="FD2016Q3QTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="31" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Nine Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Arial;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Pension Plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Arial;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">U.S.</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Qualified</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">U.S.</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Supplemental</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(Non-Qualified)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">International</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Postretirement</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Plans</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Oct&#160;1, 2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Oct&#160;2, 2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Oct&#160;1, 2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Oct&#160;2, 2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Oct&#160;1, 2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Oct&#160;2, 2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Oct&#160;1, 2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Oct&#160;2, 2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net periodic benefit cost/(credit):</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Service cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43712510e4168-wk-Fact-88EBC3EBE111513F840C9F921A314BB9" name="us-gaap:DefinedBenefitPlanServiceCost" contextRef="FD2017Q3YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">202</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43712510e4187-wk-Fact-1D5607877A1C54618597D694BA991812" name="us-gaap:DefinedBenefitPlanServiceCost" contextRef="FD2016Q3YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">193</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43712510e4207-wk-Fact-1F98BD9FFCED5901924B791569BE79B4" name="us-gaap:DefinedBenefitPlanServiceCost" contextRef="FD2017Q3YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">18</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43712510e4226-wk-Fact-20C79A8F2E045982B15335AA71808AF1" name="us-gaap:DefinedBenefitPlanServiceCost" contextRef="FD2016Q3YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">14</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43712510e4245-wk-Fact-EE795E72CF0B586D8271826487C38254" name="us-gaap:DefinedBenefitPlanServiceCost" contextRef="FD2017Q3YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">127</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43712510e4265-wk-Fact-F77ADF5E7EA55CCFA751E84649076560" name="us-gaap:DefinedBenefitPlanServiceCost" contextRef="FD2016Q3YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">126</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43712510e4284-wk-Fact-18BEBD46DF265C0B8B7DABE4F2F2509A" name="us-gaap:DefinedBenefitPlanServiceCost" contextRef="FD2017Q3YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">32</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43712510e4303-wk-Fact-8EE5C13B7DBD5E0BA3AC6121F7EA5D8E" name="us-gaap:DefinedBenefitPlanServiceCost" contextRef="FD2016Q3YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">31</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Interest cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43712510e4324-wk-Fact-1C567788B51552EC86AD93358A113C04" name="us-gaap:DefinedBenefitPlanInterestCost" contextRef="FD2017Q3YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">478</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43712510e4343-wk-Fact-4C8B761BC8A857289F300FD346EDCFF2" name="us-gaap:DefinedBenefitPlanInterestCost" contextRef="FD2016Q3YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">486</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43712510e4362-wk-Fact-E5565536FF3D5DE48C3815BCC3BC3B2E" name="us-gaap:DefinedBenefitPlanInterestCost" contextRef="FD2017Q3YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">41</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43712510e4382-wk-Fact-F4590E0D775A5327AF25D5B8F905A8A3" name="us-gaap:DefinedBenefitPlanInterestCost" contextRef="FD2016Q3YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">40</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43712510e4401-wk-Fact-6C5FEC04B2785666ACABA4F3B96A4636" name="us-gaap:DefinedBenefitPlanInterestCost" contextRef="FD2017Q3YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">152</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43712510e4421-wk-Fact-21739BA9BEF15C0B855BD7CD56E00260" name="us-gaap:DefinedBenefitPlanInterestCost" contextRef="FD2016Q3YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">178</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43712510e4440-wk-Fact-90D3C8712DB157458E1E52CF9BCEB9A1" name="us-gaap:DefinedBenefitPlanInterestCost" contextRef="FD2017Q3YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">68</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43712510e4459-wk-Fact-4F487D83D43E56229435DA9286E5F40D" name="us-gaap:DefinedBenefitPlanInterestCost" contextRef="FD2016Q3YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">77</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Expected return on plan assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d43712510e4484-wk-Fact-7A88DB0438DC5867A92DE1BB2A8BEC24" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" contextRef="FD2017Q3YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">759</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d43712510e4504-wk-Fact-177183957B01565CA3DE15186DC0AA3E" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" contextRef="FD2016Q3YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">721</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43712510e4524-wk-Fact-C9BCC376A186520AB1BD957F9FBA6A2D" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" contextRef="FD2017Q3YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43712510e4544-wk-Fact-D5A99F0316C251ED852805136939B6CE" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" contextRef="FD2016Q3YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d43712510e4563-wk-Fact-601051399A3C5E888AD42B1761966C5D" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" contextRef="FD2017Q3YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">256</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d43712510e4584-wk-Fact-20AB6A6441BE569B81A0C2BF9DCCC1BE" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" contextRef="FD2016Q3YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">291</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d43712510e4604-wk-Fact-7651EF7DB7CA52F4B5FE5AF758BEA23A" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" contextRef="FD2017Q3YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">27</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d43712510e4624-wk-Fact-AE490A2A12DA5DD28FC1E4707DB5823B" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" contextRef="FD2016Q3YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">25</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Amortization of:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Actuarial losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43712510e4818-wk-Fact-4CE5EEDBEB0E56709AF5BDD28428C8A4" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" contextRef="FD2017Q3YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">302</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43712510e4837-wk-Fact-13DD39AEEF96518F9A80C62D8E6A58EB" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" contextRef="FD2016Q3YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">297</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43712510e4856-wk-Fact-AC375B6DCF765DE5837DCC465AE925C9" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" contextRef="FD2017Q3YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">37</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43712510e4876-wk-Fact-8BA6DCC82B4D537780288614EE9E590B" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" contextRef="FD2016Q3YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">27</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43712510e4895-wk-Fact-AF6BCFE35F745884842E47484E2EDC8F" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" contextRef="FD2017Q3YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">86</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43712510e4915-wk-Fact-F76768D39E9F5FAF81B70BAE938B8DF9" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" contextRef="FD2016Q3YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">70</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43712510e4934-wk-Fact-E316611573F4511EBAAEEDFD17698D80" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" contextRef="FD2017Q3YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">23</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43712510e4953-wk-Fact-5D88572993275A159D7362B763962F8B" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" contextRef="FD2016Q3YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">23</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Prior service costs (credits)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43712510e4978-wk-Fact-680AB021A9D85E21AC0D650674666D7F" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" contextRef="FD2017Q3YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43712510e4997-wk-Fact-3AD287E437335513A247CED1511F52AE" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" contextRef="FD2016Q3YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d43712510e5016-wk-Fact-FB7369F024D05E75AA6DF22182703DA6" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" contextRef="FD2017Q3YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d43712510e5037-wk-Fact-406C36C728985B18AAA8178B23CAEF0A" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" contextRef="FD2016Q3YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d43712510e5057-wk-Fact-B9E908A6A00C5A63B03CB653A7DEFA9B" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" contextRef="FD2017Q3YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d43712510e5078-wk-Fact-DEC9B7A087E352FF8CF2B700A565E84A" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" contextRef="FD2016Q3YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d43712510e5098-wk-Fact-4CB08463D31A5ECFA7D302165110B765" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" contextRef="FD2017Q3YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">137</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d43712510e5118-wk-Fact-EFF3ACA2894F5594939E61D017667DE7" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" contextRef="FD2016Q3YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">127</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Curtailments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43712510e5144-wk-Fact-7F7AD619600C57BDB92DA526BB9447DB" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" contextRef="FD2017Q3YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">10</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43712510e5163-wk-Fact-6D35DF163ED156B392B0ABBC405525F5" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" contextRef="FD2016Q3YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43712510e5182-wk-Fact-FBDDF40EF6005914A87FF3F8C1B40371" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" contextRef="FD2017Q3YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43712510e5202-wk-Fact-CE2594AB59715893B8873903D64990F3" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" contextRef="FD2016Q3YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d43712510e5221-wk-Fact-924C12340C895DA4AC7B5C27331978CF" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" contextRef="FD2017Q3YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d43712510e5242-wk-Fact-280C02B056E55C4E88BBC63F93B62E90" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" contextRef="FD2016Q3YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d43712510e5262-wk-Fact-5647AD9D2EB55C4682FEA8EADC4277DC" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" contextRef="FD2017Q3YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">15</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d43712510e5282-wk-Fact-2289F00C7F9B56E1934620C34080192A" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" contextRef="FD2016Q3YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">14</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Settlements</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43712510e5308-wk-Fact-F91DB48F665752F183FB6249B5C47098" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" contextRef="FD2017Q3YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">54</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43712510e5327-wk-Fact-05422B8407F15A068C445BB5C57F5700" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" contextRef="FD2016Q3YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">52</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43712510e5346-wk-Fact-99BCC57499EC5443A21A15A4EE3D4D19" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" contextRef="FD2017Q3YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">32</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43712510e5366-wk-Fact-262F9FFDE5945D0895DA507FF57BEBFB" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" contextRef="FD2016Q3YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">23</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43712510e5385-wk-Fact-6A451675830B5BCB88F49C7A376DD060" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" contextRef="FD2017Q3YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43712510e5405-wk-Fact-50EB5D2681BA55DCA92E02E4FA9A5A65" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" contextRef="FD2016Q3YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43712510e5424-wk-Fact-BB811267500F56E5A4A56D25EA764A32" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" contextRef="FD2017Q3YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43712510e5443-wk-Fact-0890865A19355663B5E6B53DEB1C67B3" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" contextRef="FD2016Q3YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43712510e5473-wk-Fact-CB88AB971B745EBB96F422CEAFCAA461" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" contextRef="FD2017Q3YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">292</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43712510e5492-wk-Fact-8A4811792A515F62A3DF96296C7FF609" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" contextRef="FD2016Q3YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">316</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43712510e5512-wk-Fact-1D9D70789485540EB39A4C803F82D501" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" contextRef="FD2017Q3YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">127</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43712510e5531-wk-Fact-CE0AE7E1EADD53ED9A9021F576D1E9F0" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" contextRef="FD2016Q3YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">105</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43712510e5550-wk-Fact-7490A5856338531D86C5ACC2B1999B22" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" contextRef="FD2017Q3YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">106</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43712510e5570-wk-Fact-B98CEE082A4B567DAE5062D3C0B469C1" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" contextRef="FD2016Q3YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">81</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d43712510e5589-wk-Fact-D1A4B22C7EEF52E39B7E2BE8A00171F5" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" contextRef="FD2017Q3YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">57</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d43712510e5609-wk-Fact-3D45E9B89C2855B19D16F17D9B8411B1" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" contextRef="FD2016Q3YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">36</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></ix:nonNumeric></div><table cellpadding="0" cellspacing="0" style="padding-bottom:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><ix:continuation id="TextSelection-3F349BD1197C5BBA9A1BB21C88406E1E-1" continuedAt="TextSelection-3F349BD1197C5BBA9A1BB21C88406E1E-2"><div style="line-height:120%;font-size:8.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup>&#160;</span></div></ix:continuation></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8.5pt;"><ix:continuation id="TextSelection-3F349BD1197C5BBA9A1BB21C88406E1E-2" continuedAt="TextSelection-3F349BD1197C5BBA9A1BB21C88406E1E-3"><span style="font-family:inherit;font-size:8.5pt;"><ix:footnote id="TextSelection-621F9196966C550EA113DA57575C171E-0-wk-Footnote-621F9196966C550EA113DA57575C171E_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" continuedAt="TextSelection-621F9196966C550EA113DA57575C171E-1">In April 2017, we settled the remaining obligation associated with the Hospira U.S. qualified defined benefit pension plan. We purchased a group annuity contract on behalf of the remaining plan participants with a third-party insurance provider. As a result, we were relieved of the </ix:footnote></span><ix:continuation id="TextSelection-621F9196966C550EA113DA57575C171E-1" continuedAt="TextSelection-621F9196966C550EA113DA57575C171E-2"><span style="font-family:inherit;font-size:8.5pt;"><span>$<ix:nonFraction id="d43712510e5669-wk-Fact-B14683B4545D5992A77B1DC1D5223C72" name="us-gaap:DefinedBenefitPlanSettlementsBenefitObligation" contextRef="D2017Q2Apr01-Apr30_us-gaap_BusinessAcquisitionAxis_pfe_HospiraMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">156</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:8.5pt;"> net pension benefit obligation and recorded a pretax settlement gain of </span><span style="font-family:inherit;font-size:8.5pt;"><span>$<ix:nonFraction id="d43712510e5673-wk-Fact-9A6D679CCC3853AFBA200EBFC12C2334" name="pfe:DefinedBenefitPlanNetPeriodicBenefitCostCreditGainLossDuetoSettlementPretax" contextRef="D2017Q2Apr01-Apr30_us-gaap_BusinessAcquisitionAxis_pfe_HospiraMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">41</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:8.5pt;">, partially offset by the recognition of actuarial losses and prior service costs upon plan settlement of approximately </span><span style="font-family:inherit;font-size:8.5pt;"><span>$<ix:nonFraction id="d43712510e5677-wk-Fact-CB6FAB81ED7E509598517EA9999DEB3C" name="pfe:DefinedBenefitPlanActuarialLossandPriorServiceCostsImmediateRecognitionasComponentinNetPeriodicBenefitCost" contextRef="D2017Q2Apr01-Apr30_us-gaap_BusinessAcquisitionAxis_pfe_HospiraMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">30</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:8.5pt;"> in</span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;"> Restructuring charges and certain acquisition-related costs</span><span style="font-family:inherit;font-size:8.5pt;"> during the second quarter of 2017 (see </span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Note 3</span></ix:continuation></ix:continuation><span style="font-family:inherit;font-size:8.5pt;"><ix:continuation id="TextSelection-3F349BD1197C5BBA9A1BB21C88406E1E-3"><ix:continuation id="TextSelection-621F9196966C550EA113DA57575C171E-2">).</ix:continuation></ix:continuation></span></div></td></tr></table></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">27</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:center;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(UNAUDITED)</span></div></div><div><br/></div><ix:continuation id="TextSelection-108DD3F434485B42AD3B4CE4A038BDC6-2" continuedAt="TextSelection-108DD3F434485B42AD3B4CE4A038BDC6-3"><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><ix:nonNumeric contextRef="FD2017Q3YTD" name="pfe:ScheduleofEmployerContributionstoPensionandPostretirementPlansTableTextBlock" id="TextSelection-D638BF741BE55958808C4743FE3F2B96-0-wk-Fact-A2DFD1479CC65E73A35055DEEBBA4D38" continuedAt="TextSelection-D638BF741BE55958808C4743FE3F2B96-1" escape="true">As of and for the </ix:nonNumeric></span><ix:continuation id="TextSelection-D638BF741BE55958808C4743FE3F2B96-1" continuedAt="TextSelection-D638BF741BE55958808C4743FE3F2B96-2"><span style="font-family:inherit;font-size:10pt;">nine months</span><span style="font-family:inherit;font-size:10pt;"> ended </span><span style="font-family:inherit;font-size:10pt;">October&#160;1, 2017</span><span style="font-family:inherit;font-size:10pt;">, we contributed and expect to contribute in 2017 from our general assets as follows: </span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.41520467836257%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"></td></tr><tr><td style="width:47%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Pension Plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">U.S. Qualified</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">U.S. Supplemental (Non-Qualified)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">International</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Postretirement Plans</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Contributions from our general assets for the nine months ended October 1, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43712510e5926-wk-Fact-A5FB7ACA0EB850FFB76E01E8A4C4AB78" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" contextRef="FD2017Q3YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,095</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43712510e5945-wk-Fact-C675961749D85280943790477D62B603" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" contextRef="FD2017Q3YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">121</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43712510e5965-wk-Fact-983F4374652F5EC897A4DFC34EA7D1C6" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" contextRef="FD2017Q3YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">134</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43712510e5984-wk-Fact-D8D35E279DF7560C9A1471CA970C8FA7" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" contextRef="FD2017Q3YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">158</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Expected contributions from our general assets during 2017</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43712510e6011-wk-Fact-AFBA8CD89F4951449553D70FD3AC0D6E" name="us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsRemainderOfFiscalYear" contextRef="FI2017Q3_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,095</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43712510e6030-wk-Fact-DACE24AFDEBA5A45B37C21CDA9314DB0" name="us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsRemainderOfFiscalYear" contextRef="FI2017Q3_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">146</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43712510e6050-wk-Fact-29DAA58640B95FAD926B443F7C99CB05" name="us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsRemainderOfFiscalYear" contextRef="FI2017Q3_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">170</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43712510e6069-wk-Fact-BF9FCFC1FC645049A852329D7379350D" name="us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsRemainderOfFiscalYear" contextRef="FI2017Q3_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">204</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></ix:continuation></div></ix:continuation><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><ix:continuation id="TextSelection-D638BF741BE55958808C4743FE3F2B96-2" continuedAt="TextSelection-D638BF741BE55958808C4743FE3F2B96-3"><ix:continuation id="TextSelection-108DD3F434485B42AD3B4CE4A038BDC6-3" continuedAt="TextSelection-108DD3F434485B42AD3B4CE4A038BDC6-4"><div style="line-height:120%;font-size:8.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup>&#160;</span></div></ix:continuation></ix:continuation></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8.5pt;"><ix:continuation id="TextSelection-D638BF741BE55958808C4743FE3F2B96-3" continuedAt="TextSelection-D638BF741BE55958808C4743FE3F2B96-4"><ix:continuation id="TextSelection-108DD3F434485B42AD3B4CE4A038BDC6-4" continuedAt="TextSelection-108DD3F434485B42AD3B4CE4A038BDC6-5"><span style="font-family:inherit;font-size:8.5pt;"><ix:footnote id="TextSelection-6550A25092D55979B6A1D62BD4EDF090-0-wk-Footnote-6550A25092D55979B6A1D62BD4EDF090_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" continuedAt="TextSelection-6550A25092D55979B6A1D62BD4EDF090-1">Contributions expected to be made for </ix:footnote></span><ix:continuation id="TextSelection-6550A25092D55979B6A1D62BD4EDF090-1" continuedAt="TextSelection-6550A25092D55979B6A1D62BD4EDF090-2"><span style="font-family:inherit;font-size:8.5pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:8.5pt;"> are inclusive of amounts contributed during the </span><span style="font-family:inherit;font-size:8.5pt;">nine months ended October 1, 2017</span><span style="font-family:inherit;font-size:8.5pt;">, including the </span><span style="font-family:inherit;font-size:8.5pt;"><span>$<ix:nonFraction id="d43712510e6099-wk-Fact-885470E609A55770B3A25C242F4D7451" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" contextRef="D2017Q1Jan01-Jan31_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">1.0</ix:nonFraction> billion</span></span></ix:continuation></ix:continuation></ix:continuation><span style="font-family:inherit;font-size:8.5pt;"><ix:continuation id="TextSelection-108DD3F434485B42AD3B4CE4A038BDC6-5"><ix:continuation id="TextSelection-D638BF741BE55958808C4743FE3F2B96-4"><ix:continuation id="TextSelection-6550A25092D55979B6A1D62BD4EDF090-2"> voluntary contribution that was made in January 2017 for the U.S. qualified plans, which was considered pre-funding for future anticipated mandatory contributions and is also expected to reduce Pension Benefit Guaranty Corporation variable rate premiums. The U.S. supplemental (non-qualified) pension plan, international pension plan and the postretirement plan contributions from our general assets include direct employer benefit payments.</ix:continuation></ix:continuation></ix:continuation></span></div></td></tr></table><div><a id="sFF3E27BA178E51DABA68666E051AAE84"></a></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Note 11. </span><ix:nonNumeric contextRef="FD2017Q3YTD" name="us-gaap:EarningsPerShareTextBlock" id="TextSelection-BEB713F2A6E555C48CDD0BE6F45CF73D-0-wk-Fact-F19F42D3ED1153DA88341D380D30F862" continuedAt="TextSelection-BEB713F2A6E555C48CDD0BE6F45CF73D-1" escape="true"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Earnings Per Common Share Attributable to Common Shareholders</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"> </span></ix:nonNumeric></div><ix:continuation id="TextSelection-BEB713F2A6E555C48CDD0BE6F45CF73D-1" continuedAt="TextSelection-BEB713F2A6E555C48CDD0BE6F45CF73D-2"><div style="line-height:120%;font-size:10pt;"><ix:nonNumeric contextRef="FD2017Q3YTD" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="TextSelection-68F99197870A50E0AF5421E0F000D153-0-wk-Fact-2CC1123C7E005A5A8A2A842C08052D73" continuedAt="TextSelection-68F99197870A50E0AF5421E0F000D153-1" escape="true"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.22027290448344%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"></td></tr><tr><td style="width:52%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td colspan="17" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides the detailed calculation of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Earnings per common share (EPS)</span><span style="font-family:inherit;font-size:10pt;">:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nine Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(IN MILLIONS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">October&#160;1, <br/>2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">October&#160;2, <br/>2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">October&#160;1, <br/>2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">October&#160;2, <br/>2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">EPS Numerator&#8211;&#8211;Basic</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income from continuing operations</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43690878e1033-wk-Fact-10A93FAA5CBC5B458A708E3EEBF01F13" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" contextRef="FD2017Q3QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,858</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43690878e1052-wk-Fact-8F2AF78FFD8356E9921CBFEFF7E852B8" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" contextRef="FD2016Q3QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,355</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43690878e1072-wk-Fact-1011397EB1385A98BE195F68F7FE92A7" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">9,064</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43690878e1091-wk-Fact-9CDAD2B93E775B8EA25F98BBA2F83485" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" contextRef="FD2016Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6,465</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: Net income attributable to noncontrolling interests</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43690878e1111-wk-Fact-FEC1F9E3E96D52E58D0D70628A483E1B" name="us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" contextRef="FD2017Q3QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">18</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43690878e1130-wk-Fact-9392927738705D6E92D72F8BB15FA833" name="us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" contextRef="FD2016Q3QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43690878e1149-wk-Fact-DC80DEB9EB6D52B8B5265B5AD1E69FF0" name="us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">32</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43690878e1169-wk-Fact-62865A98C4E75066B568D0761F489763" name="us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" contextRef="FD2016Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">25</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income from continuing operations attributable to Pfizer Inc.</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43690878e1196-wk-Fact-0FA2545E29EF51FFAFF4BBCC15878817" name="us-gaap:IncomeLossFromContinuingOperations" contextRef="FD2017Q3QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,840</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43690878e1215-wk-Fact-5CD97DE05A495D5EAFB1D7B5FE4550A4" name="us-gaap:IncomeLossFromContinuingOperations" contextRef="FD2016Q3QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,355</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43690878e1234-wk-Fact-2AF1807BCF8A5ADC8187B51D6E464FFD" name="us-gaap:IncomeLossFromContinuingOperations" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">9,032</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43690878e1254-wk-Fact-232AC2542E565EDABA540B1D57A95D2D" name="us-gaap:IncomeLossFromContinuingOperations" contextRef="FD2016Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6,440</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: Preferred stock dividends&#8211;&#8211;net of tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43690878e1279-wk-Fact-C8EBDE48436B51B9A53BB91E8B6C411C" name="us-gaap:PreferredStockDividendsIncomeStatementImpact" contextRef="FD2017Q3QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43690878e1298-wk-Fact-5EDA51D3C057538A9FF8CF7C050DFAD3" name="us-gaap:PreferredStockDividendsIncomeStatementImpact" contextRef="FD2016Q3QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43690878e1317-wk-Fact-CB617A7FF9EA50C6B252DA9FB0F9022D" name="us-gaap:PreferredStockDividendsIncomeStatementImpact" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43690878e1337-wk-Fact-535C623BC356553C9A7C1964DD4187DA" name="us-gaap:PreferredStockDividendsIncomeStatementImpact" contextRef="FD2016Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income from continuing operations attributable to Pfizer Inc. common shareholders</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43690878e1364-wk-Fact-9943CA1B5CD35B98836DDF43C586A63B" name="pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic" contextRef="FD2017Q3QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,839</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43690878e1383-wk-Fact-8A7DCB81F28D538A87559BA9CEA85B1F" name="pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic" contextRef="FD2016Q3QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,355</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43690878e1402-wk-Fact-BB81900A80EC510B82BA9955D28FB794" name="pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">9,032</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43690878e1422-wk-Fact-18674C7559605F059F86A2A98B4C09F5" name="pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic" contextRef="FD2016Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6,439</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Discontinued operations&#8211;&#8211;net of tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43690878e1447-wk-Fact-F8A88E3727775446BECFB5D7B19FFE9A" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" contextRef="FD2017Q3QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43690878e1466-wk-Fact-0A252F10C1E25CFA8D6B9B5104061718" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" contextRef="FD2016Q3QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43690878e1485-wk-Fact-60867BC7B4C25795A91A0C8BA6B7BDAB" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43690878e1505-wk-Fact-D5E632B5D4A85473B7FDB1B2EC3EF703" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" contextRef="FD2016Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income attributable to Pfizer Inc. common shareholders</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43690878e1537-wk-Fact-4791EB1764F851F9BFC3743AD13BD04D" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="FD2017Q3QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,839</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43690878e1556-wk-Fact-CB2E688471765831ADC0A8CA1A4F8DFD" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="FD2016Q3QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,355</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43690878e1576-wk-Fact-A97BF6B8A8BF52F4857350DD1D9E29F5" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">9,033</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43690878e1595-wk-Fact-EECF50AEC9F85FECBE21642BE05B9B94" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="FD2016Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6,439</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">EPS Numerator&#8211;&#8211;Diluted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income from continuing operations attributable to Pfizer Inc. common shareholders and assumed conversions</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43690878e1706-wk-Fact-01FC3E63A2EE59F6B2846C1357AAF742" name="pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted" contextRef="FD2017Q3QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,840</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43690878e1725-wk-Fact-A1F4A6FC924452F79F29E27B44D8E522" name="pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted" contextRef="FD2016Q3QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,355</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43690878e1745-wk-Fact-D295627FDF4F561AB6C6612120051877" name="pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">9,032</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43690878e1764-wk-Fact-90C41519A36D526CAAA4ACCAE371F162" name="pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted" contextRef="FD2016Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6,440</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Discontinued operations&#8211;&#8211;net of tax, attributable to Pfizer Inc. common shareholders and assumed conversions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43690878e1784-wk-Fact-4942B8D2D5425A1694B0B637E62DB5A3" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" contextRef="FD2017Q3QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43690878e1803-wk-Fact-BFBAA1FFB04554EE8A5DE945E2215A8B" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" contextRef="FD2016Q3QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43690878e1822-wk-Fact-C7BE3A035DD15D11B5F1395D4A05620F" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43690878e1842-wk-Fact-46BFB691D89B5BA0A334C6AE54B4AB42" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" contextRef="FD2016Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income attributable to Pfizer Inc. common shareholders and assumed conversions</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43690878e1874-wk-Fact-11F7A96D6D935A80A19BB49104FFB650" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" contextRef="FD2017Q3QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,840</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43690878e1893-wk-Fact-AD762188EABB599D9776791285E37CB9" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" contextRef="FD2016Q3QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,355</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43690878e1913-wk-Fact-FF15C80FFD7658F196DE22E2327F4EF5" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">9,034</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43690878e1932-wk-Fact-8F3C8079FB235F47AFEECF5DBF3A99E7" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" contextRef="FD2016Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6,440</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">EPS Denominator</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted-average number of common shares outstanding&#8211;&#8211;Basic</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43690878e2035-wk-Fact-69E50427EE6E533896BB8B1907041230" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="FD2017Q3QTD" unitRef="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">5,951</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43690878e2054-wk-Fact-63E834283E2059E3A8C189B4778885B0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="FD2016Q3QTD" unitRef="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">6,066</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43690878e2073-wk-Fact-89167C4150EA5B6CB2833B441C176EB5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="FD2017Q3YTD" unitRef="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">5,972</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43690878e2093-wk-Fact-044058D73AF55D17962CBA73D63800BD" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="FD2016Q3YTD" unitRef="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">6,095</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Common-share equivalents: stock options, stock issuable under employee compensation plans, convertible preferred stock and accelerated share repurchase agreements</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43690878e2120-wk-Fact-2D022CD3C3AD5211BB51112CC40FC473" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" contextRef="FD2017Q3QTD" unitRef="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">89</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43690878e2139-wk-Fact-712D745DC4AA5C53A5626F7D089F61CB" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" contextRef="FD2016Q3QTD" unitRef="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">84</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43690878e2158-wk-Fact-C43E96FF08B6534FA41614FCABAEB299" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" contextRef="FD2017Q3YTD" unitRef="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">85</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43690878e2178-wk-Fact-0C0E82D74BA85110A5BDBF458FE4D314" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" contextRef="FD2016Q3YTD" unitRef="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">80</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted-average number of common shares outstanding&#8211;&#8211;Diluted</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43690878e2205-wk-Fact-4F013E58EAE3506D989984D20AC7A60B" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="FD2017Q3QTD" unitRef="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">6,041</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43690878e2224-wk-Fact-1E5089DBEBB75DB7864724ADB41A8830" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="FD2016Q3QTD" unitRef="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">6,150</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43690878e2243-wk-Fact-C0D5F9589E725D14B3DE492AFAAAEA7D" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="FD2017Q3YTD" unitRef="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">6,057</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43690878e2263-wk-Fact-413D25685F8F583AB53236F9F57575B9" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="FD2016Q3YTD" unitRef="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">6,175</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock options that had exercise prices greater than the average market price of our common stock issuable under employee compensation plans</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a),</sup></span><span style="font-family:inherit;font-size:9pt;">&#160;</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(b)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43690878e2294-wk-Fact-B667DEF994C657D2B861FFE60640D001" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2017Q3QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockOptionMember" unitRef="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">47</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43690878e2313-wk-Fact-5342CFBA0356578DAD0043F0EADED8C5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2016Q3QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockOptionMember" unitRef="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">38</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43690878e2332-wk-Fact-B239C8DE6B03518BA7F0284DE06E3F57" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2017Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockOptionMember" unitRef="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">47</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43690878e2352-wk-Fact-D0EF06948F015270863207632A10DE91" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2016Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockOptionMember" unitRef="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">60</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></ix:nonNumeric></div><ix:continuation id="TextSelection-68F99197870A50E0AF5421E0F000D153-1" continuedAt="TextSelection-68F99197870A50E0AF5421E0F000D153-2"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><ix:footnote id="TextSelection-792D3AB23D6354CFBB2776AE7F6407B4-0-wk-Footnote-792D3AB23D6354CFBB2776AE7F6407B4_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" continuedAt="TextSelection-792D3AB23D6354CFBB2776AE7F6407B4-1">Amounts for the </ix:footnote></span><ix:continuation id="TextSelection-792D3AB23D6354CFBB2776AE7F6407B4-1" continuedAt="TextSelection-792D3AB23D6354CFBB2776AE7F6407B4-2"><span style="font-family:inherit;font-size:8.5pt;">third quarter</span><span style="font-family:inherit;font-size:8.5pt;"> and first </span><span style="font-family:inherit;font-size:8.5pt;">nine months</span><span style="font-family:inherit;font-size:8.5pt;"> ended </span><span style="font-family:inherit;font-size:8.5pt;">October&#160;2, 2016</span><span style="font-family:inherit;font-size:8.5pt;"> have been revised from previously reported amounts to reflect the adoption of a new accounting standard in the fourth quarter of </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:8.5pt;">, as of January 1, 2016, that requires, when applying the treasury stock method for shares that could be repurchased, that the assumed proceeds no longer include the amount of excess tax benefit (see </span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Note 1B</span></ix:continuation><span style="font-family:inherit;font-size:8.5pt;"><ix:continuation id="TextSelection-792D3AB23D6354CFBB2776AE7F6407B4-2">).</ix:continuation></span></div></td></tr></table></ix:continuation></ix:continuation><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><ix:continuation id="TextSelection-68F99197870A50E0AF5421E0F000D153-2" continuedAt="TextSelection-68F99197870A50E0AF5421E0F000D153-3"><ix:continuation id="TextSelection-BEB713F2A6E555C48CDD0BE6F45CF73D-2" continuedAt="TextSelection-BEB713F2A6E555C48CDD0BE6F45CF73D-3"><div style="line-height:120%;font-size:8.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(b)</sup>&#160;</span></div></ix:continuation></ix:continuation></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><ix:continuation id="TextSelection-BEB713F2A6E555C48CDD0BE6F45CF73D-3"><ix:continuation id="TextSelection-68F99197870A50E0AF5421E0F000D153-3"><ix:footnote id="TextSelection-0333DDFA54555789BB4E2E73E3451A69-0-wk-Footnote-0333DDFA54555789BB4E2E73E3451A69_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US">These common stock equivalents were outstanding for the periods presented, but were not included in the computation of diluted EPS for those periods because their inclusion would have had an anti-dilutive effect.</ix:footnote></ix:continuation></ix:continuation></span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">28</span></div></div><hr style="page-break-after:always"></hr><div><a id="s24D5E2940F07543985402858595FF397"></a></div><div><div style="line-height:120%;text-align:center;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(UNAUDITED)</span></div></div><div><br/></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Note 12. </span><ix:nonNumeric contextRef="FD2017Q3YTD" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="TextSelection-66B8C111E79C55E1A7A77357A28182A8-0-wk-Fact-27B9A092A14E5E03A0C1180A2C115DE3" continuedAt="TextSelection-66B8C111E79C55E1A7A77357A28182A8-1" escape="true"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Commitments and Contingencies</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"> </span></ix:nonNumeric></div><ix:continuation id="TextSelection-66B8C111E79C55E1A7A77357A28182A8-1" continuedAt="TextSelection-66B8C111E79C55E1A7A77357A28182A8-2"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We and certain of our subsidiaries are subject to numerous contingencies arising in the ordinary course of business. For a discussion of our tax contingencies, see </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 5B.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accelerated share repurchase agreement&#8211;&#8211;On February 2, 2017, we entered into an accelerated share repurchase agreement with Citibank to repurchase </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d43707686e645-wk-Fact-BE13D7C1D60C5FF79A853FF26CFA4638" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" contextRef="I2017Q1Feb02_us-gaap_ShareRepurchaseProgramAxis_pfe_ShareRepurchaseAgreementwithCitibankMember" unitRef="usd" decimals="INF" scale="9" format="ixt:numdotdecimal">5</ix:nonFraction> billion</span></span><span style="font-family:inherit;font-size:10pt;"> of our common stock. Pursuant to the terms of the agreement, on February 6, 2017, we paid </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d43707686e649-wk-Fact-A3F5302D1FAA5AB49D1B490F7BEB5AB9" name="us-gaap:AcceleratedShareRepurchasesSettlementPaymentOrReceipt" contextRef="I2017Q1Feb06_us-gaap_ShareRepurchaseProgramAxis_pfe_ShareRepurchaseAgreementwithCitibankMember" unitRef="usd" decimals="-9" scale="9" sign="-" format="ixt:numdotdecimal">5</ix:nonFraction> billion</span></span><span style="font-family:inherit;font-size:10pt;"> to Citibank and received an initial delivery of approximately </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43707686e653-wk-Fact-8AD53DD45A3D5D6AA1B2FEA1E2C8CA7E" name="us-gaap:TreasuryStockSharesAcquired" contextRef="D2017Q1Feb06-Feb06_us-gaap_ShareRepurchaseProgramAxis_pfe_ShareRepurchaseAgreementwithCitibankMember" unitRef="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">126</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> shares of our common stock from Citibank at a price of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d43707686e657-wk-Fact-21884CAAD38C5940A008A86452D48031" name="us-gaap:AcceleratedShareRepurchasesInitialPricePaidPerShare" contextRef="D2017Q1Feb06-Feb06_us-gaap_ShareRepurchaseProgramAxis_pfe_ShareRepurchaseAgreementwithCitibankMember" unitRef="usdPerShare" decimals="INF" scale="0" format="ixt:numdotdecimal">31.73</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> per share, which represented, based on the closing price of our common stock on the NYSE on February 2, 2017, approximately </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43707686e661-wk-Fact-E11E162A07C854CFBC7C05056862D8CC" name="pfe:AcceleratedShareRepurchasesSharesRepurchasedDuringPeriodPercentageofAgreementAmount" contextRef="D2017Q1Feb02-Feb02_us-gaap_ShareRepurchaseProgramAxis_pfe_ShareRepurchaseAgreementwithCitibankMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">80</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> of the notional amount of the accelerated share repurchase agreement. On May 16, 2017, the accelerated share repurchase agreement with Citibank was completed, which, per the terms of the agreement, resulted in Citibank owing us a certain number of shares of Pfizer common stock. Pursuant to the agreement&#8217;s settlement terms, we received an additional </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43707686e666-wk-Fact-D750C4F2B63E590F8E54F970CFCFD791" name="us-gaap:TreasuryStockSharesAcquired" contextRef="D2017Q2May19-May19_us-gaap_ShareRepurchaseProgramAxis_pfe_ShareRepurchaseAgreementwithCitibankMember" unitRef="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">24</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> shares of our common stock from Citibank on May 19, 2017. The average price paid for all of the shares delivered under the accelerated share repurchase agreement was </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d43707686e670-wk-Fact-8E42571D5CEA5C2399EC72D3C489EEF3" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" contextRef="D2017Q2Feb06-May19_us-gaap_ShareRepurchaseProgramAxis_pfe_ShareRepurchaseAgreementwithCitibankMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">33.31</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> per share. The common stock received is included in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Treasury Stock</span><span style="font-family:inherit;font-size:10pt;">. This agreement was entered into pursuant to our previously announced share repurchase authorization. At </span><span style="font-family:inherit;font-size:10pt;">October&#160;1, 2017</span><span style="font-family:inherit;font-size:10pt;">, our remaining share-purchase authorization was approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d43707686e682-wk-Fact-A96737DE25D05E9E9E87B3E1D0D83CE0" name="us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" contextRef="FI2017Q3_us-gaap_ShareRepurchaseProgramAxis_pfe_ShareRepurchaseAgreementwithCitibankMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">6.4</ix:nonFraction> billion</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pending approval in the EU of Mylotarg&#8211;&#8211;Mylotarg was developed, in part, through a research arrangement with a third party. If Mylotarg is approved in the EU in 2018 for the treatment of acute myeloid leukemia, we will incur an obligation for additional fixed payments over a 10-year period aggregating </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d43707686e689-wk-Fact-8BBD252B838276FE62847E0EE6C2B52D" name="pfe:ResearchandDevelopmentArrangementAggregatePaymentObligation" contextRef="FI2017Q3_us-gaap_ProductOrServiceAxis_pfe_MylotargMember_us-gaap_StatementScenarioAxis_us-gaap_ProFormaMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">310</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">A. Legal Proceedings</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our non-tax contingencies include, but are not limited to, the following:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Patent litigation, which typically involves challenges to the coverage and/or validity of patents on various products, processes or dosage forms. We are the plaintiff in the vast majority of these actions. An adverse outcome in actions in which we are the plaintiff could result in loss of patent protection for a drug, a significant loss of revenues from that drug or impairment of the value of associated assets.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Product liability and other product-related litigation, which can include personal injury, consumer, off-label promotion, securities, antitrust and breach of contract claims, among others, often involves highly complex issues relating to medical causation, label warnings and reliance on those warnings, scientific evidence and findings, actual, provable injury and other matters.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Commercial and other matters, which can include merger-related and product-pricing claims and environmental claims and proceedings, can involve complexities that will vary from matter to matter.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Government investigations, which often are related to the extensive regulation of pharmaceutical companies by national, state and local government agencies in the U.S. and in other countries.&#160;</span></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certain of these contingencies could result in losses, including damages, fines and/or civil penalties, and/or criminal charges, which could be substantial.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We believe that our claims and defenses in these matters are substantial, but litigation is inherently unpredictable and excessive verdicts do occur. We do not believe that any of these matters will have a material adverse effect on our financial position. However, we could incur judgments, enter into settlements or revise our expectations regarding the outcome of certain matters, and such developments could have a material adverse effect on our results of operations in the period in which the amounts are accrued and/or our cash flows in the period in which the amounts are paid.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have accrued for losses that are both probable and reasonably estimable. Substantially all of our contingencies are subject to significant uncertainties and, therefore, determining the likelihood of a loss and/or the measurement of any loss can be complex. Consequently, we are unable to estimate the range of reasonably possible loss in excess of amounts accrued. Our assessments are based on estimates and assumptions that have been deemed reasonable by management, but the assessment process relies heavily on estimates and assumptions that may prove to be incomplete or inaccurate, and unanticipated events and circumstances may occur that might cause us to change those estimates and assumptions.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amounts recorded for legal and environmental contingencies can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The principal pending matters to which we are a party are discussed below. In determining whether a pending matter is a principal matter, we consider both quantitative and qualitative factors in order to assess materiality, such as, among other things, </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">29</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:center;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(UNAUDITED)</span></div></div><div><br/></div><ix:continuation id="TextSelection-66B8C111E79C55E1A7A77357A28182A8-2" continuedAt="TextSelection-66B8C111E79C55E1A7A77357A28182A8-3"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the amount of damages and the nature of any other relief sought in the proceeding, if such damages and other relief are specified; our view of the merits of the claims and of the strength of our defenses; whether the action purports to be, or is, a class action and, if not certified, our view of the likelihood that a class will be certified by the court; the jurisdiction in which the proceeding is pending; any experience that we or, to our knowledge, other companies have had in similar proceedings; whether disclosure of the action would be important to a reader of our financial statements, including whether disclosure might change a reader&#8217;s judgment about our financial statements in light of all of the information that is available to the reader; the potential impact of the proceeding on our reputation; and the extent of public interest in the matter. In addition, with respect to patent matters in which we are the plaintiff, we consider, among other things, the financial significance of the product protected by the patent. As a result of considering qualitative factors in our determination of principal matters, there are some matters discussed below with respect to which management believes that the likelihood of possible loss in excess of amounts accrued is remote.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">A1. Legal Proceedings&#8211;&#8211;Patent Litigation</span></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Like other pharmaceutical companies, we are involved in numerous suits relating to our patents, including but not limited to, those discussed below. Most of the suits involve claims by generic drug manufacturers that patents covering our products, processes or dosage forms are invalid and/or do not cover the product of the generic drug manufacturer. Also, counterclaims, as well as various independent actions, have been filed alleging that our assertions of, or attempts to enforce, patent rights with respect to certain products constitute unfair competition and/or violations of antitrust laws. In addition to the challenges to the U.S. patents on a number of our products that are discussed below, patent rights to certain of our products are being challenged in various other countries. We are also party to other patent damages suits in various jurisdictions pursuant to which generic drug manufacturers, payers, governments or other parties are seeking damages from us for alleged delay of generic entry. Additionally, our licensing and collaboration partners face challenges by generic drug manufacturers to patents covering several of their products that may impact our licenses or co-promotion rights to such products. We also are often involved in other proceedings, such as inter partes review, post-grant review, re-examination or opposition proceedings, before the U.S. Patent and Trademark Office, the European Patent Office, or other foreign counterparts relating to our intellectual property or the intellectual property rights of others. Also, if one of our patents is found to be invalid by such proceedings, generic or competitive products could be introduced into the market resulting in the erosion of sales of our existing products. For example, several of the patents in our pneumococcal vaccine portfolio have been challenged in inter partes review and post-grant review proceedings in the United States. The invalidation of these patents could potentially allow a competitor pneumococcal vaccine into the marketplace. We are also subject to patent litigation pursuant to which one or more third parties seeks damages and/or injunctive relief to compensate for alleged infringement of its patents by our commercial or other activities. For example, our subsidiary, Hospira, is involved in patent and patent-related disputes over its attempts to bring generic pharmaceutical and biosimilar products to market. If one of our marketed products is found to infringe valid patent rights of a third party, such third party may be awarded significant damages, or we may be prevented from further sales of that product. Such damages may be enhanced as much as three-fold in the event that we or one of our subsidiaries, like Hospira, is found to have willfully infringed valid patent rights of a third party.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Actions In Which We Are The Plaintiff</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Bosulif (bosutinib)</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In December 2016, Wyeth LLC, Wyeth Pharmaceuticals Inc., and PF Prism C.V. (collectively, Wyeth) brought a patent-infringement action against Alembic Pharmaceuticals, Ltd, Alembic Pharmaceuticals, Inc. (collectively, Alembic), Sun Pharmaceutical Industries, Inc., and Sun Pharmaceutical Industries Limited (collectively, Sun), in the U.S. District Court for the District of Delaware in connection with abbreviated new drug applications respectively filed with the FDA by Alembic and Sun, each seeking approval to market generic versions of bosutinib. Alembic is challenging patents, which expire in 2026, covering polymorphic forms of bosutinib and methods of treating chronic myelogenous leukemia. Sun is challenging the patent covering polymorphic forms of bosutinib that expires in 2026. In March 2017, Wyeth brought a patent-infringement action against MSN Laboratories Private Limited and MSN Pharmaceuticals, Inc. (collectively, MSN), in the U.S. District Court for the District of Delaware in connection with an abbreviated new drug application filed with the FDA by MSN, seeking approval to market a generic version of bosutinib, and challenging a patent expiring in 2026 covering polymorphic forms of bosutinib. In September 2017, the case against MSN was dismissed. Also, in September 2017, Wyeth brought an additional patent-infringement action against Sun in the U.S. District Court for the District of Delaware asserting the infringement and validity of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43707686e782-wk-Fact-C8E2AFCA1B38D14844F19D7928EB1D5D" name="us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber" contextRef="D2017Q3Sep01-Sep30_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationCaseAxis_pfe_WyethVersusSunMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_ProductOrServiceAxis_pfe_BosulifMember" unitRef="Patent" decimals="INF" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> other patents challenged by Sun, which expire in 2025 and 2026 respectively, covering compositions of bosutinib and methods of treating chronic myelogenous leukemia. </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">30</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:center;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(UNAUDITED)</span></div></div><div><br/></div><ix:continuation id="TextSelection-66B8C111E79C55E1A7A77357A28182A8-3" continuedAt="TextSelection-66B8C111E79C55E1A7A77357A28182A8-4"><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">EpiPen</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In July 2010, King, which we acquired in 2011 and is a wholly-owned subsidiary, brought a patent-infringement action against Sandoz in the U.S. District Court for the District of New Jersey in connection with Sandoz&#8217;s abbreviated new drug application filed with the FDA seeking approval to market an epinephrine injectable product. Sandoz is challenging patents, which expire in 2025, covering the next-generation autoinjector for use with epinephrine that is sold under the EpiPen brand name.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Flector Patch (diclofenac)</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In October 2015, the owners (Teikoku Seiyaku Co., Ltd. and Altergon SA) of a patent covering Pfizer&#8217;s Flector Patch product, along with the New Drug Application holder (IBSA Institut Biochemique SA), brought a patent-infringement action against Actavis Laboratories UT, Inc. in the U.S. District Court for the District of Delaware in connection with an abbreviated new drug application filed by Actavis Laboratories UT, Inc. with the FDA requesting approval to launch a generic version of Flector Patch prior to the 2019 expiration of the patent. In August 2016, Pfizer subsidiary Alpharma Pharmaceuticals LLC was added as a plaintiff to the lawsuit. In August 2017, this case was settled on terms not material to Pfizer. </span></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Precedex Premix</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In June 2014,</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span><span style="font-family:inherit;font-size:10pt;">Ben Venue Laboratories, Inc. (Ben Venue)</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span><span style="font-family:inherit;font-size:10pt;">notified our subsidiary, Hospira, that it had filed an abbreviated new drug application with the FDA seeking approval to market a generic version of Hospira&#8217;s premix version of Precedex and containing allegations that a patent relating to the use of Precedex in an intensive care unit setting, which expires in March 2019, was invalid or not infringed. In August 2014, Hospira and Orion Corporation (co-owner of the patent that is the subject of the lawsuit) filed suit against Ben Venue, Hikma Pharmaceuticals PLC (Hikma), and West-Ward Pharmaceutical Corp. in the U.S. District Court for the District of Delaware asserting the validity and infringement of the patent that is the subject of the lawsuit. In October 2014, Eurohealth International Sarl was substituted for Ben Venue and Hikma. In June 2016, this case was settled on terms not material to Pfizer.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In June 2015, Amneal Pharmaceuticals LLC (Amneal) notified Hospira that it had filed an abbreviated new drug application with the FDA seeking approval to market a generic version of Hospira&#8217;s premix version of Precedex and containing allegations that </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43707686e816-wk-Fact-F836B59EF1E6523A93483B8C479F540F" name="us-gaap:GainContingencyPatentsFoundNotInfringedUponNumber" contextRef="D2015Q2June2015_us-gaap_LitigationCaseAxis_pfe_HospiraVersusAmnealPharmaceuticalsLLCMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_ProductOrServiceAxis_pfe_PrecedexPremixMember" unitRef="Patent" decimals="INF" scale="0" format="ixt-sec:numwordsen">four</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> patents relating to the Precedex premix formulations and their use, all of which expire in 2032, were invalid or not infringed. In August 2015, Hospira filed suit against Amneal in the U.S. District Court for the District of Delaware asserting the validity and infringement of the patents that are the subject of the lawsuit.</span></div><div style="line-height:120%;text-align:left;font-size:5pt;"><span style="font-family:inherit;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In December 2015, Fresenius Kabi USA LLC (Fresenius) notified Hospira that it had filed an abbreviated new drug application with the FDA seeking approval to market a generic version of Hospira&#8217;s premix version of Precedex and containing allegations that </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43707686e825-wk-Fact-9B87954E679D58C79D73CE7D945E50CC" name="us-gaap:GainContingencyPatentsFoundNotInfringedUponNumber" contextRef="D2015Q4_us-gaap_LitigationCaseAxis_pfe_HospiraVersusFreseniusMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_ProductOrServiceAxis_pfe_PrecedexPremixMember" unitRef="Patent" decimals="INF" scale="0" format="ixt-sec:numwordsen">four</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> patents relating to the Precedex premix formulations and their use, all of which expire in 2032, were invalid or not infringed. In January 2016, Hospira filed suit against Fresenius in the U.S. District Court for the Northern District of Illinois asserting the validity and infringement of the patents that are the subject of the lawsuit.</span></div><div style="line-height:120%;text-align:justify;font-size:5pt;"><span style="font-family:inherit;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In August 2016, Par Sterile Products, LLC (Par) notified Hospira that it had filed an abbreviated new drug application with the FDA seeking approval to market a generic version of Hospira&#8217;s premix version of Precedex and containing allegations that </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43707686e834-wk-Fact-6510AC1D5754580B84274EACDF64E139" name="us-gaap:GainContingencyPatentsFoundNotInfringedUponNumber" contextRef="D2016Q3Aug01-Aug31_us-gaap_LitigationCaseAxis_pfe_HospiraVersusParMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_ProductOrServiceAxis_pfe_PrecedexPremixMember" unitRef="Patent" decimals="INF" scale="0" format="ixt-sec:numwordsen">four</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> patents relating to the Precedex premix formulations and their use, all of which expire in 2032, were invalid or not infringed. In September 2016, Hospira filed suit against Par in the U.S. District Court for the District of Delaware asserting the validity and infringement of the patents that are the subject of the lawsuit. In December 2016, the case was stayed pending the outcome of Hospira&#8217;s suit against Amneal (including all appeals).</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Toviaz (fesoterodine)</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have an exclusive, worldwide license to market Toviaz from UCB Pharma GmbH (UCB), which owns the patents relating to Toviaz.</span></div><div style="line-height:120%;text-align:left;font-size:5pt;"><span style="font-family:inherit;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Beginning in May 2013, several generic drug manufacturers notified us that they had filed abbreviated new drug applications with the FDA seeking approval to market generic versions of Toviaz and asserting the invalidity, unenforceability and/or non-infringement of all of our patents for Toviaz that are listed in the FDA&#8217;s list of Approved Drug Products with Therapeutic Equivalence Evaluations, commonly referred to as the &#8220;Orange Book&#8221;. Beginning in June 2013, we filed actions against all of those generic drug manufacturers in the U.S. District Court for the District of Delaware, asserting the infringement of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43707686e850-wk-Fact-3E0BD8FE7B39597EA628675F2C76844D" name="us-gaap:GainContingencyPatentsFoundInfringedUponNumber" contextRef="D2013Q2MonthofJune_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationCaseAxis_pfe_PfizerVersusMylanLaboratoriesandAccordHealthcareInc.Member_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_ProductOrServiceAxis_pfe_ToviazMember" unitRef="Patent" decimals="INF" scale="0" format="ixt-sec:numwordsen">five</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> of the patents for Toviaz: </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43707686e854-wk-Fact-3224E869B20A571898DF7DD0FB349424" name="us-gaap:GainContingencyPatentsFoundInfringedUponNumber" contextRef="D2013Q2MonthofJune_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationCaseAxis_pfe_PfizerVersusSeveralGenericManufacturersMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_ProductOrServiceAxis_pfe_ToviazCompositionofmatterPatentsMember" unitRef="Patent" decimals="INF" scale="0" format="ixt-sec:numwordsen">three</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> composition-of-matter patents and a method-of-use patent that expire in 2019 and a patent covering salts of fesoterodine that expires in 2022. In June and July 2015, we settled with </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43707686e858-wk-Fact-E42DF851A7915AAC8FEEC578D4CA849C" name="pfe:GainContingencyNumberofDefendants" contextRef="D2015Q1SD_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationCaseAxis_pfe_PfizerVersusSeveralGenericManufacturersMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_us-gaap_ProductOrServiceAxis_pfe_ToviazMember" unitRef="Defendant" decimals="INF" scale="0" format="ixt-sec:numwordsen">four</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> of the generic defendants. The trial relating to the </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43707686e862-wk-Fact-47B6716DC5EE5CDE99EFE7EAD7231169" name="pfe:GainContingencyNumberofDefendants" contextRef="D2015Q3July2015_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationCaseAxis_pfe_PfizerVersusSeveralGenericManufacturersMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_ProductOrServiceAxis_pfe_ToviazMember" unitRef="Defendant" decimals="INF" scale="0" format="ixt-sec:numwordsen">four</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> remaining defendants occurred in July 2015. In April 2016, the District Court held that the patents that were the subject of the lawsuit were valid and infringed. The defendants&#8217; deadline to appeal this decision expired in June 2016. </span></div><div style="line-height:120%;text-align:left;font-size:5pt;"><span style="font-family:inherit;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In December 2014, Mylan Pharmaceuticals, Inc. (Mylan Pharmaceuticals) notified us that it had filed an</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span><span style="font-family:inherit;font-size:10pt;">abbreviated new drug application with the FDA seeking approval to market a generic version of Toviaz and asserting the invalidity, unenforceability and/or non-infringement of all of our patents for Toviaz that are listed in the Orange Book. In January 2015, we filed an action against Mylan Pharmaceuticals in the U.S. District Court for the District of Delaware, asserting the infringement of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43707686e875-wk-Fact-CD087C72236253F0BE5CB2C866CC4CC9" name="us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber" contextRef="D2015Q1MonthOfJanuary_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationCaseAxis_pfe_PfizerVersusMylanLaboratoriesandAccordHealthcareInc.Member_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_ProductOrServiceAxis_pfe_ToviazMember" unitRef="Patent" decimals="INF" scale="0" format="ixt-sec:numwordsen">five</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> of the </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">31</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:center;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(UNAUDITED)</span></div></div><div><br/></div><ix:continuation id="TextSelection-66B8C111E79C55E1A7A77357A28182A8-4" continuedAt="TextSelection-66B8C111E79C55E1A7A77357A28182A8-5"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">patents for Toviaz: </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43707686e882-wk-Fact-9B9FE860AB7B50C49B571A07FD7E0DDF" name="us-gaap:GainContingencyPatentsFoundInfringedUponNumber" contextRef="D2015Q1Jan1-31_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationCaseAxis_pfe_PfizerVersusMylanLaboratoriesandAccordHealthcareInc.Member_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_ProductOrServiceAxis_pfe_ToviazCompositionofmatterPatentsMember" unitRef="Patent" decimals="INF" scale="0" format="ixt-sec:numwordsen">three</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> composition-of-matter patents and a method-of-use patent that expire in 2019 and a patent covering salts of fesoterodine that expires in 2022. In January 2017, the District Court issued a verdict finding that the </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43707686e886-wk-Fact-F05CEC43CAA05EBB93B0C39B4E9A2F6C" name="us-gaap:GainContingencyPatentsFoundInfringedUponNumber" contextRef="D2017Q1Jan01-Jan31_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationCaseAxis_pfe_PfizerVersusMylanLaboratoriesandAccordHealthcareInc.Member_us-gaap_LitigationStatusAxis_us-gaap_JudicialRulingMember_us-gaap_ProductOrServiceAxis_pfe_ToviazMember" unitRef="Patent" decimals="INF" scale="0" format="ixt-sec:numwordsen">five</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> patents that are the subject of the lawsuit are valid and infringed. In August 2017, the District Court issued a written decision consistent with the verdict, finding the </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43707686e890-wk-Fact-82C1AE73C31F5512A6DC0E04B6CBFDF0" name="us-gaap:GainContingencyPatentsFoundInfringedUponNumber" contextRef="D2017Q3Aug01-Aug10_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationCaseAxis_pfe_PfizerVersusMylanLaboratoriesandAccordHealthcareInc.Member_us-gaap_LitigationStatusAxis_us-gaap_JudicialRulingMember_us-gaap_ProductOrServiceAxis_pfe_ToviazMember" unitRef="Patent" decimals="INF" scale="0" format="ixt-sec:numwordsen">five</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> patents valid and infringed. In September 2017, Mylan Pharmaceuticals appealed the District Court&#8217;s decision to the U.S. Court of Appeals for the Federal Circuit.</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span></div><div style="line-height:120%;text-align:left;font-size:5pt;"><span style="font-family:inherit;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In December 2016, Torrent Pharmaceuticals, Ltd. (Torrent) notified us that it had filed an</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span><span style="font-family:inherit;font-size:10pt;">abbreviated new drug application with the FDA seeking approval to market a generic version of Toviaz and asserting the invalidity, unenforceability and/or non-infringement of all of our patents for Toviaz that are listed in the Orange Book. In February 2017, we filed an action against Torrent in the U.S. District Court for the District of Delaware, asserting the infringement of the same </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43707686e905-wk-Fact-DCE6E43BA9085B46AAF7CA7AEB3D8E0A" name="us-gaap:GainContingencyPatentsFoundInfringedUponNumber" contextRef="D2017Q1Feb01-Feb28_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationCaseAxis_pfe_PfizerVersusMylanLaboratoriesandAccordHealthcareInc.Member_us-gaap_LitigationStatusAxis_us-gaap_JudicialRulingMember_us-gaap_ProductOrServiceAxis_pfe_ToviazMember" unitRef="Patent" decimals="INF" scale="0" format="ixt-sec:numwordsen">five</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> patents that are the subject of the action against Mylan Pharmaceuticals. In September 2017, this case was dismissed.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Xeljanz (tofacitinib)</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2017, we brought a patent-infringement action against MicroLabs USA Inc. and MicroLabs Ltd. (collectively, MicroLabs) in the U.S. District Court for the District of Delaware asserting the infringement and validity of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43707686e915-wk-Fact-3B7C7BE1ED075C00B0637749F3A5B24F" name="us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber" contextRef="D2017Q1Feb01-Feb28_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationCaseAxis_pfe_PfizerVersusMicroLabsMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_ProductOrServiceAxis_pfe_XeljanzMember" unitRef="Patent" decimals="INF" scale="0" format="ixt-sec:numwordsen">three</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> patents challenged by MicroLabs in its abbreviated new drug application seeking approval to market a generic version of tofacitinib 5 mg tablets. Of the </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43707686e919-wk-Fact-3B7C7BE1ED075C00B0637749F3A5B24F" name="us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber" contextRef="D2017Q1Feb01-Feb28_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationCaseAxis_pfe_PfizerVersusMicroLabsMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_ProductOrServiceAxis_pfe_XeljanzMember" unitRef="Patent" decimals="INF" scale="0" format="ixt-sec:numwordsen">three</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> patents that are the subject of the lawsuit, one covers the active ingredient and expires in December 2025, the second covers an enantiomer of tofacitinib and expires in 2022, and the third covers a polymorphic form of tofacitinib and expires in 2023. </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43707686e923-wk-Fact-3B7C7BE1ED075C00B0637749F3A5B24F" name="us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber" contextRef="D2017Q1Feb01-Feb28_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationCaseAxis_pfe_PfizerVersusMicroLabsMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_ProductOrServiceAxis_pfe_XeljanzMember" unitRef="Patent" decimals="INF" scale="0" format="ixt-sec:numwordsen">Three</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> other patents for Xeljanz expiring in December 2020 have not been challenged by MicroLabs.</span></div><div style="line-height:120%;text-align:left;font-size:5pt;"><span style="font-family:inherit;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Separately, also in February 2017, we brought a patent-infringement action against Sun Pharmaceutical Industries Ltd. in the U.S. District Court for the District of Delaware asserting the infringement and validity of our patent covering a polymorphic form of tofacitinib, expiring in 2023, that was challenged by Sun Pharmaceutical Industries Ltd. in its abbreviated new drug application seeking approval to market a generic version of tofacitinib 11 mg extended release tablets. In November 2017, we brought an additional patent-infringement action against Sun Pharmaceuticals Industries Ltd. in the U.S. District Court for the District of Delaware asserting the infringement and validity of another patent challenged by Sun Pharmaceuticals Industries Ltd, which covers the active ingredient and expires in December 2025.</span></div><div style="line-height:120%;text-align:left;font-size:5pt;"><span style="font-family:inherit;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In March 2017, we brought a patent-infringement action against Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Ltd. (collectively, Zydus) in the U.S. District Court for the District of Delaware asserting the infringement and validity of the same </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43707686e938-wk-Fact-CFDD2F198A3450C8A311ED1ADA364BFB" name="us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber" contextRef="D2017Q1Mar01-Mar31_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationCaseAxis_pfe_PfizerVersusZydusMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_ProductOrServiceAxis_pfe_XeljanzMember" unitRef="Patent" decimals="INF" scale="0" format="ixt-sec:numwordsen">three</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> patents that are the subject of the action against MicroLabs, which Zydus challenged in its abbreviated new drug application seeking approval to market a generic version of tofacitinib 5 mg tablets.</span></div><div style="line-height:120%;text-align:left;font-size:5pt;"><span style="font-family:inherit;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Also in March 2017, we brought separate actions in the U.S. District Court for the District of Delaware against Prinston Pharmaceutical Inc., Zhejiang Huahai Pharmaceutical Co., Ltd., Huahai US Inc. and Solco Healthcare US, LLC (collectively Prinston) and against Breckenridge Pharmaceutical Inc., Pensa Pharma S.A. and Laboratorios Del Dr. Esteve, S.A. (collectively Breckenridge) on the </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43707686e947-wk-Fact-0AB4EFF384BE569F8B6BB4992C90BFCB" name="us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber" contextRef="D2017Q1Mar01-Mar31_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationCaseAxis_pfe_PfizerVersusPrinstonandBreckenridgeMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_ProductOrServiceAxis_pfe_XeljanzMember" unitRef="Patent" decimals="INF" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> patents expiring in 2022 and 2023, respectively, that were challenged by Prinston and Breckenridge in their respective abbreviated new drug applications seeking approval to market generic versions of tofacitinib 5 mg tablets. In October 2017, we brought an additional patent-infringement action against Breckenridge in the U.S. District Court for the District of Delaware asserting the infringement and validity of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43707686e951-wk-Fact-A56B4A8FF13A028962D79CFB52106DA8" name="us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber" contextRef="D2017Q4Oct02-Oct31_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationCaseAxis_pfe_PfizerVersusBreckenridgeMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_ProductOrServiceAxis_pfe_XeljanzMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" unitRef="Patent" decimals="INF" scale="0" format="ixt-sec:numwordsen">four</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> additional patents challenged by Breckenridge, </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43707686e955-wk-Fact-2297A230035623E28B6C9D07DFC63B22" name="pfe:GainContingencyPatentsAllegedlyInfringeduponNumberDuetoExpireinDecember2020" contextRef="D2017Q4Oct02-Oct31_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationCaseAxis_pfe_PfizerVersusBreckenridgeMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_ProductOrServiceAxis_pfe_XeljanzMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" unitRef="Patent" decimals="INF" scale="0" format="ixt-sec:numwordsen">three</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> of which expire in December 2020 and </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43707686e959-wk-Fact-1FC6E796980ABAC596759D09C650A691" name="pfe:GainContingencyPatentsAllegedlyInfringeduponNumberDuetoExpireinDecember2025" contextRef="D2017Q4Oct02-Oct31_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationCaseAxis_pfe_PfizerVersusBreckenridgeMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_ProductOrServiceAxis_pfe_XeljanzMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" unitRef="Patent" decimals="INF" scale="0" format="ixt-sec:numwordsen">one</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> of which expires in December 2025.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Xtandi (enzalutamide)</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In December 2016, Medivation and Medivation Prostate Therapeutics, Inc. (collectively, the Medivation Group); Astellas Pharma Inc., Astellas US LLC and Astellas Pharma US, Inc. (collectively, Astellas); and The Regents of the University of California filed patent-infringement suits in the U.S. District Court for the District of Delaware against Actavis Laboratories FL, Inc. and Actavis LLC (collectively, Actavis); Zydus; and Apotex Inc. and Apotex Corp. (collectively, Apotex) in connection with those companies&#8217; respective abbreviated new drug applications filed with the FDA for approval to market generic versions of enzalutamide. The generic manufacturers are challenging patents, which expire as early as 2026, covering enzalutamide and treatments for prostate cancer. In May 2017, the Medivation Group filed a patent-infringement suit against Roxane Laboratories Inc. (Roxane) in the same court in connection with Roxane&#8217;s abbreviated new drug application with the FDA for approval to market a generic version of enzalutamide. </span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">32</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:center;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(UNAUDITED)</span></div></div><div><br/></div><ix:continuation id="TextSelection-66B8C111E79C55E1A7A77357A28182A8-5" continuedAt="TextSelection-66B8C111E79C55E1A7A77357A28182A8-6"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Matters Involving Our Collaboration/Licensing Partners</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Nexium 24HR (esomeprazole)</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have an exclusive license from AstraZeneca PLC (AstraZeneca) to market in the U.S. the OTC version of Nexium (Nexium 24HR). Between October 2014 and November 2016, Actavis Laboratories FL, Inc. (Actavis), Andrx Labs, LLC (Andrx), Perrigo Company plc (Perrigo), Lupin Limited, Dr. Reddy&#8217;s Laboratories, Inc. &amp; Ltd. (Dr. Reddy&#8217;s), Hetero USA Inc. (Hetero), Aurobindo Pharma USA Inc. (Aurobindo) and Cipla Limited (Cipla) notified us that they had filed abbreviated new drug applications with the FDA seeking approval to market generic versions of Nexium 24HR prior to the expiration of one or more of AstraZeneca&#8217;s patents listed in the Orange Book for Nexium 24HR. AstraZeneca filed actions against each of these companies in the U.S. District Court for the District of New Jersey asserting infringement of the challenged patents. In March 2017, the cases against Actavis and Andrx were settled on terms not material to Pfizer. In June 2017, the cases against Perrigo, Dr. Reddy&#8217;s and Lupin Limited were settled on terms not material to Pfizer. In August 2017, the cases against Hetero and Aurobindo were settled on terms not material to Pfizer. In October 2017, AstraZeneca&#8217;s action against Cipla was settled on terms not material to Pfizer. We were not a party to AstraZeneca&#8217;s patent-infringement actions.</span></div><div style="line-height:120%;text-align:left;font-size:5pt;"><span style="font-family:inherit;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Toviaz (fesoterodine)&#8211;&#8211;Inter-Partes Reviews</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In January 2016, Mylan Pharmaceuticals and Mylan Laboratories (collectively, Mylan) filed petitions with the U.S. Patent and Trademark Office requesting inter partes reviews of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43707686e989-wk-Fact-B827DE4CAA695625A887B42190536432" name="us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber" contextRef="D2016Q1Jan2016_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationCaseAxis_pfe_PfizerVersusMylanLaboratoriesandAccordHealthcareInc.Member_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_ProductOrServiceAxis_pfe_ToviazMember" unitRef="Patent" decimals="INF" scale="0" format="ixt-sec:numwordsen">five</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> of the patents covering fesoterodine, the active ingredient in Toviaz: </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43707686e993-wk-Fact-1CC84571D7CF59F08C207EDB52CE8144" name="us-gaap:GainContingencyPatentsFoundInfringedUponNumber" contextRef="D2016Q1Jan2016_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationCaseAxis_pfe_PfizerVersusMylanLaboratoriesandAccordHealthcareInc.Member_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_ProductOrServiceAxis_pfe_ToviazCompositionofmatterPatentsMember" unitRef="Patent" decimals="INF" scale="0" format="ixt-sec:numwordsen">three</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> composition-of-matter patents and a method-of-use patent that expire in 2019 and a patent covering salts of fesoterodine that expires in 2022. The patents are owned by UCB, and we have an exclusive, worldwide license to market Toviaz from UCB. In July 2016, the Patent Trial and Appeal Board agreed to institute inter partes reviews of all </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43707686e997-wk-Fact-C2AAE9F2BCE35DBCAADE3B01CFAF2055" name="us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber" contextRef="D2016Q3Jul01-Jul31_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationCaseAxis_pfe_PfizerVersusMylanLaboratoriesandAccordHealthcareInc.Member_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_ProductOrServiceAxis_pfe_ToviazMember" unitRef="Patent" decimals="INF" scale="0" format="ixt-sec:numwordsen">five</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> patents. Amerigen Pharmaceuticals Limited (Amerigen), Alembic Pharmaceuticals Limited and Torrent Pharmaceuticals Limited have joined the inter partes reviews. In July 2017, the U.S. Patent and Trademark Office issued decisions upholding all </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43707686e1001-wk-Fact-ECE922F44A5155208854AB6F559ACD87" name="us-gaap:GainContingencyPatentsFoundNotInfringedUponNumber" contextRef="D2017Q3Jul01-Jul31_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationCaseAxis_pfe_PfizerVersusMylanLaboratoriesandAccordHealthcareInc.Member_us-gaap_LitigationStatusAxis_us-gaap_JudicialRulingMember_us-gaap_ProductOrServiceAxis_pfe_ToviazMember" unitRef="Patent" decimals="INF" scale="0" format="ixt-sec:numwordsen">five</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> patents. In September 2017, Mylan and Amerigen appealed the U.S. Patent and Trademark Office decisions to the U.S. Court of Appeals for the Federal Circuit</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">.</span></div><div style="line-height:120%;text-align:left;font-size:5pt;"><span style="font-family:inherit;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Eliquis</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February, March, and April 2017, </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43707686e1015-wk-Fact-750640771EAF58C694292FC06FD2EE09" name="pfe:GainContingencyNumberofDefendants" contextRef="D2017Q2Feb01-Apr30_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationCaseAxis_pfe_PfizerandBMSVersusSeveralGenericManufacturersMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_ProductOrServiceAxis_pfe_EliquisMember" unitRef="Defendant" decimals="INF" scale="0" format="ixt-sec:numwordsen">twenty-five</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> generic companies sent BMS Paragraph-IV certification letters informing BMS that they had filed abbreviated new drug applications seeking approval of generic versions of Eliquis, challenging the validity and infringement of one or more of the </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43707686e1019-wk-Fact-BC63078738B9511EA742B4F671C18334" name="us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber" contextRef="D2017Q2Feb01-Apr30_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationCaseAxis_pfe_PfizerandBMSVersusSeveralGenericManufacturersMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_ProductOrServiceAxis_pfe_EliquisMember" unitRef="Patent" decimals="INF" scale="0" format="ixt-sec:numwordsen">three</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> patents listed in the Orange Book for Eliquis. The patents currently are set to expire in 2019, 2026, and 2031. Eliquis has been jointly developed and is being commercialized by BMS and Pfizer. In April 2017, BMS and Pfizer filed patent-infringement actions against all generic filers in the U.S. District Court for the District of Delaware and the U.S. District Court for the District of West Virginia, asserting that each of the generic companies&#8217; proposed products would infringe each of the patent(s) that each generic filer challenged. Some generic filers challenged only the 2031 patent, some challenged both the 2031 and 2026 patent, and one generic company challenged all </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43707686e1023-wk-Fact-BC63078738B9511EA742B4F671C18334" name="us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber" contextRef="D2017Q2Feb01-Apr30_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationCaseAxis_pfe_PfizerandBMSVersusSeveralGenericManufacturersMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_ProductOrServiceAxis_pfe_EliquisMember" unitRef="Patent" decimals="INF" scale="0" format="ixt-sec:numwordsen">three</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> patents.</span></div><div style="line-height:120%;text-align:left;font-size:5pt;"><span style="font-family:inherit;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Bavencio (avelumab)</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In July 2017, BMS, E.R. Squibb &amp; Sons LLC, Ono Pharmaceutical Co. Ltd., and Tasuku Honjo brought a patent-infringement action in the U.S. District Court for the District of Delaware against Pfizer, Merck KGaA, and EMD Serono, alleging that Bavencio (avelumab) infringes </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43707686e1035-wk-Fact-41E085AAF2D45D2FA0940954E181FA2B" name="us-gaap:LossContingencyPatentsAllegedlyInfringedNumber" contextRef="D2017Q3Jul01-Jul31_us-gaap_LitigationCaseAxis_pfe_PfizerVersusBMSE.R.SquibbSonsOnoPharmaceuticalandTasukuHonjoMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_LossContingenciesByNatureOfContingencyAxis_pfe_PatentInfringementMember_us-gaap_ProductOrServiceAxis_pfe_BavencioMember" unitRef="Patent" decimals="INF" scale="0" format="ixt-sec:numwordsen">one</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> patent relating to methods for treating tumors with anti-PD-L1 antibodies, which expires in 2023.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Actions In Which We Are The Defendant</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Inflectra (infliximab-dyyb)</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In March 2015, Janssen and New York University, together, brought a patent-infringement action in the U.S. District Court for the District of Massachusetts against Hospira, Celltrion Healthcare Co. Ltd. and Celltrion Inc. alleging that infliximab-dyyb, to be marketed by Hospira in the U.S. under the brand name Inflectra, would infringe </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43707686e1049-wk-Fact-83F6C3F97F875EAB83365A740872B386" name="us-gaap:LossContingencyPatentsAllegedlyInfringedNumber" contextRef="D2015Q1March2015_us-gaap_LitigationCaseAxis_pfe_JanssenandNewYorkUniversityVersusHospiraCelltrionHealthcareandCelltrionInc.Member_us-gaap_ProductOrServiceAxis_pfe_InflectraMember" unitRef="Patent" decimals="INF" scale="0" format="ixt-sec:numwordsen">six</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> patents relating to infliximab, its manufacture and use. Claims with respect to </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43707686e1053-wk-Fact-195837297ED85FA8AF050C77B7803645" name="us-gaap:LossContingencyClaimsDismissedNumber" contextRef="D2015Q1March2015_us-gaap_LitigationCaseAxis_pfe_JanssenandNewYorkUniversityVersusHospiraCelltrionHealthcareandCelltrionInc.Member_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_us-gaap_ProductOrServiceAxis_pfe_InflectraMember" unitRef="Patent" decimals="INF" scale="0" format="ixt-sec:numwordsen">four</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> of the patents have since been dismissed by the plaintiffs, leaving </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43707686e1057-wk-Fact-08744C5FDA975D9FAD7578D35D75C22D" name="us-gaap:LossContingencyPatentsAllegedlyInfringedNumber" contextRef="D2015Q1March2015_us-gaap_LitigationCaseAxis_pfe_JanssenandNewYorkUniversityVersusHospiraCelltrionHealthcareandCelltrionInc.Member_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_ProductOrServiceAxis_pfe_InflectraMember" unitRef="Patent" decimals="INF" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> patents at issue in the ongoing action: the infliximab antibody patent and a patent relating to cell culture media. In August 2016, the U.S. District Court for the District of Massachusetts ruled that the antibody patent was invalid, and Janssen has appealed that ruling to the Court of Appeals for the Federal Circuit. </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">33</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:center;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(UNAUDITED)</span></div></div><div><br/></div><ix:continuation id="TextSelection-66B8C111E79C55E1A7A77357A28182A8-6" continuedAt="TextSelection-66B8C111E79C55E1A7A77357A28182A8-7"><div style="line-height:120%;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">A2. Legal Proceedings&#8211;&#8211;Product Litigation</span></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Like other pharmaceutical companies, we are defendants in numerous cases, including but not limited to those discussed below, related to our pharmaceutical and other products. Plaintiffs in these cases seek damages and other relief on various grounds for alleged personal injury and economic loss.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Asbestos</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Between 1967 and 1982, Warner-Lambert owned American Optical Corporation, which manufactured and sold respiratory protective devices and asbestos safety clothing. In connection with the sale of American Optical in 1982, Warner-Lambert agreed to indemnify the purchaser for certain liabilities, including certain asbestos-related and other claims. As of </span><span style="font-family:inherit;font-size:10pt;">October&#160;1, 2017</span><span style="font-family:inherit;font-size:10pt;">, approximately </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43707686e1079-wk-Fact-37310CB06F485061B349B80A64A17695" name="us-gaap:LossContingencyPendingClaimsNumber" contextRef="FI2017Q3_us-gaap_LitigationCaseAxis_pfe_ClassActionVersusAmericanOpticalCorporationAndVariousOtherDefendantsMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_LossContingenciesByNatureOfContingencyAxis_us-gaap_DamagesFromProductDefectsMember" unitRef="Claim" decimals="0" scale="0" format="ixt:numdotdecimal">56,500</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> claims naming American Optical and numerous other defendants were pending in various federal and state courts seeking damages for alleged personal injury from exposure to asbestos and other allegedly hazardous materials. Warner-Lambert was acquired by Pfizer in 2000 and is a wholly-owned subsidiary of Pfizer. Warner-Lambert is actively engaged in the defense of, and will continue to explore various means of resolving, these claims.</span></div><div style="line-height:120%;text-align:left;font-size:5pt;"><span style="font-family:inherit;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Numerous lawsuits are pending against Pfizer in various federal and state courts seeking damages for alleged personal injury from exposure to products allegedly containing asbestos and other allegedly hazardous materials sold by Pfizer and certain of its previously owned subsidiaries.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">There also are a small number of lawsuits pending in various federal and state courts seeking damages for alleged exposure to asbestos in facilities owned or formerly owned by Pfizer or its subsidiaries.</span></div><div style="line-height:120%;text-align:left;font-size:5pt;"><span style="font-family:inherit;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Effexor</span></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Personal Injury Actions</span></div></td></tr></table><div style="line-height:120%;padding-top:4px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A number of individual lawsuits and multi-plaintiff lawsuits have been filed against us and/or our subsidiaries in various federal and state courts alleging personal injury as a result of the purported ingestion of Effexor. Among other types of actions, the Effexor personal injury litigation includes actions alleging a variety of birth defects as a result of the purported ingestion of Effexor by women during pregnancy. Plaintiffs in these birth-defect actions seek compensatory and punitive damages. In August 2013, the federal birth-defect cases were transferred for consolidated pre-trial proceedings to a Multi-District Litigation (</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">In re Effexor</span><span style="font-family:inherit;font-size:10pt;"> (</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Venlafaxine Hydrochloride) Products Liability Litigation MDL-2458</span><span style="font-family:inherit;font-size:10pt;">) in the U.S. District Court for the Eastern District of Pennsylvania. Almost all plaintiffs have voluntarily dismissed their actions. The Multi-District Litigation, as well as the coordinated state court proceedings in California, has been administratively stayed. </span></div><div style="line-height:120%;text-align:left;font-size:5pt;"><span style="font-family:inherit;font-size:5pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Antitrust Actions</span></div></td></tr></table><div style="line-height:120%;padding-top:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Beginning in May 2011, actions, including purported class actions, were filed in various federal courts against Wyeth and, in certain of the actions, affiliates of Wyeth and certain other defendants relating to Effexor XR, which is the extended-release formulation of Effexor. The plaintiffs in each of the class actions seek to represent a class consisting of all persons in the U.S. and its territories who directly purchased, indirectly purchased or reimbursed patients for the purchase of Effexor XR or generic Effexor XR from any of the defendants from June 14, 2008 until the time the defendants&#8217; allegedly unlawful conduct ceased. The plaintiffs in all of the actions allege delay in the launch of generic Effexor XR in the U.S. and its territories, in violation of federal antitrust laws and, in certain of the actions, the antitrust, consumer protection and various other laws of certain states, as the result of Wyeth fraudulently obtaining and improperly listing certain patents for Effexor XR in the Orange Book, enforcing certain patents for Effexor XR and entering into a litigation settlement agreement with a generic drug manufacturer with respect to Effexor XR. Each of the plaintiffs seeks treble damages (for itself in the individual actions or on behalf of the putative class in the purported class actions) for alleged price overcharges for Effexor XR or generic Effexor XR in the U.S. and its territories since June 14, 2008. All of these actions have been consolidated in the U.S. District Court for the District of New Jersey. </span></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In October 2014, the District Court dismissed the direct purchaser plaintiffs&#8217; claims based on the litigation settlement agreement but declined to dismiss the other direct purchaser plaintiff claims. In January 2015, the District Court entered partial final judgments as to all settlement agreement claims, including those asserted by direct purchasers and end-payer plaintiffs, which plaintiffs appealed to the U.S. Court of Appeals for the Third Circuit. In August 2017, the U.S. Court of Appeals for the Third Circuit reversed the District Court&#8217;s decisions and remanded the claims to the District Court. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Zoloft</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A number of individual lawsuits and multi-plaintiff lawsuits have been filed against us and/or our subsidiaries in various federal and state courts alleging personal injury as a result of the purported ingestion of Zoloft. Among other types of actions, the Zoloft personal injury litigation includes actions alleging a variety of birth defects as a result of the purported ingestion of Zoloft by women during pregnancy. Plaintiffs in these birth-defect actions seek compensatory and punitive damages and the disgorgement of profits resulting from the sale of Zoloft. In April 2012, the federal birth-defect cases were transferred for consolidated pre-trial proceedings to a Multi-District Litigation (</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">In re Zoloft Products Liability Litigation MDL-2342</span><span style="font-family:inherit;font-size:10pt;">) in the </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">34</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:center;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(UNAUDITED)</span></div></div><div><br/></div><ix:continuation id="TextSelection-66B8C111E79C55E1A7A77357A28182A8-7" continuedAt="TextSelection-66B8C111E79C55E1A7A77357A28182A8-8"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. District Court for the Eastern District of Pennsylvania. A number of plaintiffs have voluntarily dismissed their actions. In April 2016, the District Court granted our motion for summary judgment, dismissing the claims of almost all of the remaining plaintiffs. In May 2016, the plaintiffs appealed the District Court&#8217;s decision to the U.S. Court of Appeals for the Third Circuit. In June 2017, the U.S. Court of Appeals for the Third Circuit affirmed the District Court&#8217;s decision.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Lipitor</span></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Antitrust Actions</span></div></td></tr></table><div style="line-height:120%;padding-top:4px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Beginning in November 2011, purported class actions relating to Lipitor were filed in various federal courts against, among others, Pfizer, certain affiliates of Pfizer, and, in most of the actions, Ranbaxy, Inc. (Ranbaxy) and certain affiliates of Ranbaxy. The plaintiffs in these various actions seek to represent nationwide, multi-state or statewide classes consisting of persons or entities who directly purchased, indirectly purchased or reimbursed patients for the purchase of Lipitor (or, in certain of the actions, generic Lipitor) from any of the defendants from March 2010 until the cessation of the defendants&#8217; allegedly unlawful conduct (the Class Period). The plaintiffs allege delay in the launch of generic Lipitor, in violation of federal antitrust laws and/or state antitrust, consumer protection and various other laws, resulting from (i) the 2008 agreement pursuant to which Pfizer and Ranbaxy settled certain patent litigation involving Lipitor, and Pfizer granted Ranbaxy a license to sell a generic version of Lipitor in various markets beginning on varying dates, and (ii) in certain of the actions, the procurement and/or enforcement of certain patents for Lipitor. Each of the actions seeks, among other things, treble damages on behalf of the putative class for alleged price overcharges for Lipitor (or, in certain of the actions, generic Lipitor) during the Class Period. In addition, individual actions have been filed against Pfizer, Ranbaxy and certain of their affiliates, among others, that assert claims and seek relief for the plaintiffs that are substantially similar to the claims asserted and the relief sought in the purported class actions described above. These various actions have been consolidated for pre-trial proceedings in a Multi-District Litigation (</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">In re Lipitor Antitrust Litigation MDL-2332</span><span style="font-family:inherit;font-size:10pt;">) in the U.S. District</span><span style="font-family:inherit;font-size:10pt;color:#0000ff;"> </span><span style="font-family:inherit;font-size:10pt;">Court for the District of New Jersey. </span></div><div style="line-height:120%;padding-top:4px;font-size:5pt;"><span style="font-family:inherit;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In September 2013 and 2014, the District Court dismissed with prejudice the claims by direct purchasers. In October and November 2014, the District Court dismissed with prejudice the claims of all other Multi-District Litigation plaintiffs. All plaintiffs have appealed the District Court&#8217;s orders dismissing their claims with prejudice to the U.S. Court of Appeals for the Third Circuit. In addition, the direct purchaser class plaintiffs appealed the order denying their motion to amend the judgment and for leave to amend their complaint to the U.S. Court of Appeals for the Third Circuit. In August 2017, the U.S. Court of Appeals for the Third Circuit reversed the District Court&#8217;s decisions and remanded substantially all of the claims to the District Court.</span></div><div style="line-height:120%;text-align:left;font-size:5pt;"><span style="font-family:inherit;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Also, in January 2013, the State of West Virginia filed an action in West Virginia state court against Pfizer and Ranbaxy, among others, that asserts claims and seeks relief on behalf of the State of West Virginia and residents of that state that are substantially similar to the claims asserted and the relief sought in the purported class actions described above.</span></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Personal Injury Actions</span></div></td></tr></table><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A number of individual and multi-plaintiff lawsuits have been filed against us in various federal and state courts alleging that the plaintiffs developed type 2 diabetes as a result of the purported ingestion of Lipitor. Plaintiffs seek compensatory and punitive damages. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2014, the federal actions were transferred for consolidated pre-trial proceedings to a Multi-District Litigation (</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">In re Lipitor (Atorvastatin Calcium) Marketing, Sales Practices and Products Liability Litigation (No. II) MDL-2502</span><span style="font-family:inherit;font-size:10pt;">) in the U.S. District Court for the District of South Carolina. Since 2016, certain cases in the Multi-District Litigation were remanded to certain state courts. In January 2017, the District Court granted our motion for summary judgment, dismissing substantially all of the remaining cases pending in the Multi-District Litigation. In January 2017, the plaintiffs appealed the District Court&#8217;s decision to the U.S. Court of Appeals for the Fourth Circuit.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Viagra</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A number of individual and multi-plaintiff lawsuits have been filed against us in various federal and state courts alleging that the plaintiffs developed melanoma and/or the exacerbation of melanoma as a result of the purported ingestion of Viagra. Plaintiffs seek compensatory and punitive damages. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In April 2016, the federal actions were transferred for coordinated pre-trial proceedings to a Multi-District Litigation (</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">In Re: Viagra (Sildenafil Citrate) Products Liability Litigation, MDL-2691</span><span style="font-family:inherit;font-size:10pt;">) in the U.S. District Court for the Northern District of California. In December 2016, federal actions filed against Lilly and filed against both us and Lilly, were transferred for coordinated pre-trial proceedings to the Multi-District Litigation (</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">In re: Viagra (Sildenafil Citrate) and Cialis (Tadalafil) Products Liability Litigation, MDL-2691</span><span style="font-family:inherit;font-size:10pt;">).</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">35</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:center;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(UNAUDITED)</span></div></div><div><br/></div><ix:continuation id="TextSelection-66B8C111E79C55E1A7A77357A28182A8-8" continuedAt="TextSelection-66B8C111E79C55E1A7A77357A28182A8-9"><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Celebrex</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Beginning in July 2014, purported class actions were filed in the U.S. District Court for the Eastern District of Virginia against Pfizer and certain subsidiaries of Pfizer relating to Celebrex. The plaintiffs seek to represent U.S. nationwide or multi-state classes consisting of persons or entities who directly purchased from the defendants, or indirectly purchased or reimbursed patients for some or all of the purchase price of, Celebrex or generic Celebrex from May 31, 2014 until the cessation of the defendants&#8217; allegedly unlawful conduct. The plaintiffs allege delay in the launch of generic Celebrex in violation of federal antitrust laws or certain state antitrust, consumer protection and various other laws as a result of Pfizer fraudulently obtaining and improperly listing a patent on Celebrex, engaging in sham litigation and prolonging the impact of sham litigation through settlement activity that further delayed generic entry. Each of the actions seeks treble damages on behalf of the putative class for alleged price overcharges for Celebrex since May 31, 2014. In December 2014, the District Court granted the parties&#8217; joint motions to consolidate the direct purchaser and end-payer cases, and all such cases were consolidated as of March 2015. In October 2014 and March 2015, we filed motions to dismiss the direct purchasers&#8217; and end-payers&#8217; amended complaints, respectively. In November 2015, the District Court denied in part and granted in part our motion to dismiss the direct purchasers&#8217; amended complaint. In February 2016, the District Court denied in part and granted in part our motion to dismiss the end-payers&#8217; amended complaint, and in August 2016, the District Court dismissed substantially all of the end-payer&#8217;s remaining claims. In February 2017, the District Court dismissed with prejudice all of the end-payers&#8217; claims. In March 2017, the end-payers appealed the District Court&#8217;s order dismissing their claims with prejudice to the U.S. Court of Appeals for the Fourth Circuit. In August 2017, the District Court granted the direct purchasers&#8217; motion for class certification. In October 2017, Pfizer and the direct purchasers entered into an agreement-in-principle, which is subject to the negotiation of a final settlement agreement and court approval, to resolve the direct purchasers&#8217; class action for </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d43707686e1216-wk-Fact-ECDDC95F6CDDCC54760F9203E934A283" name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" contextRef="D2017Q4Oct02-Oct31_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_ProductOrServiceAxis_pfe_CelebrexMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">94</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Intravenous Solutions</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Beginning in November 2016, purported class actions were filed in the U.S. District Court for the Northern District of Illinois against Hospira, Hospira Worldwide, Inc. and certain other defendants relating to intravenous saline solution. Plaintiffs seek to represent classes consisting of all persons and entities in the U.S. who directly purchased intravenous saline solution sold by any of the defendants from January 1, 2013 until the time the defendants&#8217; allegedly unlawful conduct ceases. Plaintiffs allege that the defendants&#8217; conduct restricts output and artificially fixes, raises, maintains and/or stabilizes the prices of intravenous saline solution sold throughout the U.S. in violation of federal antitrust laws. Plaintiffs seek treble damages (for themselves and on behalf of the putative classes) and an injunction against defendants for alleged price overcharges for intravenous saline solution in the U.S. since January 1, 2013. On February 3, 2017, we completed the sale of our global infusion therapy net assets, HIS, which includes intravenous saline solution, to ICU Medical. The litigation is the subject of cross-claims for indemnification by both Pfizer and ICU Medical under the purchase agreement.</span></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Separately, in April 2017, Pfizer, Hospira and </span><span style="font-family:inherit;font-size:10pt;">two</span><span style="font-family:inherit;font-size:10pt;"> employees of Pfizer received grand jury subpoenas issued by the United States District Court for the Eastern District of Pennsylvania, in connection with an investigation by the U.S. Department of Justice, Antitrust Division. The subpoenas seek documents related to the sale, manufacture, pricing and shortages of intravenous solutions, including saline, as well as communications among market participants regarding these issues. The Department of Justice investigation is also the subject of cross-claims for indemnification by both Pfizer and ICU Medical under the purchase agreement. In addition, in August 2015, the New York Attorney General issued a subpoena to Hospira for similar information. Hospira has produced records to the New York Attorney General and will coordinate with ICU Medical to produce records to the New York Attorney General as appropriate going forward, and Hospira and Pfizer will coordinate with ICU Medical to produce records to the Department of Justice.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Hormone Therapy Consumer Class Action</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A certified consumer class action is pending against Wyeth in the U.S. District Court for the Southern District of California based on the alleged off-label marketing of its hormone therapy products. The case was originally filed in December 2003. The class consists of California consumers who purchased Wyeth&#8217;s hormone-replacement products between January 1995 and January 2003 and who do not seek personal injury damages therefrom. The class seeks compensatory and punitive damages, including a full refund of the purchase price.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Eliquis</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A number of individual and multi-plaintiff lawsuits have been filed against us and Bristol-Myers Squibb Company in various federal and state courts pursuant to which plaintiffs seek to recover for personal injuries, including wrongful death, due to bleeding as a result of the alleged ingestion of Eliquis. Plaintiffs seek compensatory and punitive damages.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2017, the federal actions were transferred for coordinated pre-trial proceedings to a Multi-District Litigation (</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">In Re: Eliquis (Apixaban) Products Liability Litigation MDL-2754</span><span style="font-family:inherit;font-size:10pt;">) in the U.S. District Court for the Southern District of New York. In July 2017, the District Court dismissed substantially all of the actions that were pending in the Multi-District Litigation. In </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">36</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:center;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(UNAUDITED)</span></div></div><div><br/></div><ix:continuation id="TextSelection-66B8C111E79C55E1A7A77357A28182A8-9" continuedAt="TextSelection-66B8C111E79C55E1A7A77357A28182A8-10"><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">August 2017, certain plaintiffs appealed the District Court&#8217;s dismissal to the U.S. Court of Appeals for the Second Circuit. Additional cases continue to be transferred to the Multi-District Litigation.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">EpiPen</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Beginning in February 2017, purported class actions were filed in various federal courts by indirect purchasers of EpiPen against Pfizer, and/or its affiliates King and Meridian, and/or various entities affiliated with Mylan N.V., and Mylan N.V. Chief Executive Officer, Heather Bresch. The plaintiffs in these actions seek to represent U.S. nationwide classes comprising persons or entities who paid for any portion of the end-user purchase price of an EpiPen between 2009 until the cessation of the defendants&#8217; allegedly unlawful conduct. In August 2017, a similar lawsuit brought on behalf of a purported class of direct purchaser plaintiffs against Pfizer, King, Meridian and Mylan was voluntarily dismissed without prejudice. Against Pfizer and/or its affiliates, plaintiffs generally allege that Pfizer&#8217;s and/or its affiliates&#8217; settlement of patent litigation regarding EpiPen delayed market entry of generic EpiPen in violation of federal antitrust laws and various state antitrust or consumer protection laws. At least one lawsuit also alleges that Pfizer and/or Mylan N.V. violated the federal Racketeer Influenced and Corrupt Organizations Act. Plaintiffs also filed various consumer protection and unjust enrichment claims against, and relating to conduct attributable solely to, Mylan Pharmaceuticals regarding EpiPen. Plaintiffs seek treble damages for alleged overcharges for EpiPen since 2009. In August 2017, the actions were consolidated for coordinated pre-trial proceedings in a Multi-District Litigation (</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">In re: EpiPen (Epinephrine Injection, USP) Marketing, Sales Practices and Antitrust Litigation</span><span style="font-family:inherit;font-size:10pt;">, MDL-2785) in the U.S. District Court for the District of Kansas with other EpiPen-related actions against Mylan N.V. and/or its affiliates to which Pfizer, King and Meridian are not parties.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Nexium 24HR and Protonix</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A number of individual and multi-plaintiff lawsuits have been filed against Pfizer, certain of its subsidiaries and/or other pharmaceutical manufacturers in various federal and state courts alleging that the plaintiffs developed kidney-related injuries as a result of the purported ingestion of certain proton pump inhibitors. The cases against us involve Nexium 24HR and/or Protonix and seek compensatory and punitive damages and, in some cases, treble damages, restitution or disgorgement. In August 2017, the federal actions were ordered transferred for coordinated pre-trial proceedings to a Multi-District Litigation (</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">In re: Proton-Pump Inhibitor Products Liability Litigation</span><span style="font-family:inherit;font-size:10pt;"> (No. II)) in the U.S. District Court for the District of New Jersey.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Docetaxel&#160;</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A number of lawsuits have been filed against Hospira and Pfizer in various federal and state courts alleging that plaintiffs who were treated with Docetaxel developed permanent hair loss. The significant majority of the cases also name other defendants, including the manufacturer of the branded product, Taxotere. Plaintiffs seek compensatory and punitive damages.</span></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In October 2016, the federal cases were transferred for coordinated pre-trial proceedings to a Multi-District Litigation (</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">In re Taxotere (Docetaxel) Products Liability Litigation</span><span style="font-family:inherit;font-size:10pt;">, MDL-2740) in the U.S. District Court for the Eastern District of Louisiana.</span></div><div style="line-height:120%;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">A3. Legal Proceedings&#8211;&#8211;Commercial and Other Matters</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Average Wholesale Price Litigation</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pfizer, certain of its subsidiaries and other pharmaceutical manufacturers were sued in various state courts by a number of states alleging that the defendants provided average wholesale price (AWP) information for certain of their products that was higher than the actual average prices at which those products were sold. The AWP is used to determine reimbursement levels under Medicare Part B and Medicaid and in many private-sector insurance policies and medical plans. All but </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43707686e1298-wk-Fact-D5208D6686935FF38064D253ECACA456" name="us-gaap:LossContingencyPendingClaimsNumber" contextRef="FI2017Q3_us-gaap_LitigationCaseAxis_pfe_StateofIllinoisVersusPfizerMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_LossContingenciesByNatureOfContingencyAxis_pfe_AverageWholesalePriceMember" unitRef="Claim" decimals="INF" scale="0" format="ixt-sec:numwordsen">one</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> of those actions have been resolved through settlement, dismissal or final judgment. The plaintiff state, Illinois,</span><span style="font-family:inherit;font-size:10pt;color:#ff0000;"> </span><span style="font-family:inherit;font-size:10pt;">in the </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43707686e1306-wk-Fact-D5208D6686935FF38064D253ECACA456" name="us-gaap:LossContingencyPendingClaimsNumber" contextRef="FI2017Q3_us-gaap_LitigationCaseAxis_pfe_StateofIllinoisVersusPfizerMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_LossContingenciesByNatureOfContingencyAxis_pfe_AverageWholesalePriceMember" unitRef="Claim" decimals="INF" scale="0" format="ixt-sec:numwordsen">one</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> remaining action claims that the alleged spread between the AWPs at which purchasers were reimbursed and the actual sale prices was promoted by the defendants as an incentive to purchase certain of their products. The action</span><span style="font-family:inherit;font-size:10pt;color:#ff0000;"> </span><span style="font-family:inherit;font-size:10pt;">alleges, among other things, fraud</span><span style="font-family:inherit;font-size:10pt;color:#ff0000;"> </span><span style="font-family:inherit;font-size:10pt;">and violation of the state&#8217;s unfair trade practices and</span><span style="font-family:inherit;font-size:10pt;color:#ff0000;"> </span><span style="font-family:inherit;font-size:10pt;">consumer protection statutes and seeks monetary and other relief, including civil penalties and treble damages.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Monsanto-Related Matters</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In 1997, Monsanto Company (Former Monsanto) contributed certain chemical manufacturing operations and facilities to a newly formed corporation, Solutia Inc. (Solutia), and spun off the shares of Solutia. In 2000, Former Monsanto merged with Pharmacia &amp; Upjohn Company to form Pharmacia. Pharmacia then transferred its agricultural operations to a newly created subsidiary, named Monsanto Company (New Monsanto), which it spun off in a two-stage process that was completed in 2002. Pharmacia was acquired by Pfizer in 2003 and is a wholly-owned subsidiary of Pfizer.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In connection with its spin-off that was completed in 2002, New Monsanto assumed, and agreed to indemnify Pharmacia for, any liabilities related to Pharmacia&#8217;s former agricultural business. New Monsanto has defended and/or is defending Pharmacia in connection with various claims and litigation arising out of, or related to, the agricultural business, and has been indemnifying Pharmacia when liability has been imposed or settlement has been reached regarding such claims and litigation.</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">37</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:center;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(UNAUDITED)</span></div></div><div><br/></div><ix:continuation id="TextSelection-66B8C111E79C55E1A7A77357A28182A8-10" continuedAt="TextSelection-66B8C111E79C55E1A7A77357A28182A8-11"><div style="line-height:120%;padding-top:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In connection with its spin-off in 1997, Solutia assumed, and agreed to indemnify Pharmacia for, liabilities related to Former Monsanto&#8217;s chemical businesses. As the result of its reorganization under Chapter 11 of the U.S. Bankruptcy Code, Solutia&#8217;s indemnification obligations relating to Former Monsanto&#8217;s chemical businesses are primarily limited to sites that Solutia has owned or operated. In addition, in connection with its spinoff that was completed in 2002, New Monsanto assumed, and agreed to indemnify Pharmacia for, any liabilities primarily related to Former Monsanto&#8217;s chemical businesses, including, but not limited to, any such liabilities that Solutia assumed. Solutia&#8217;s and New Monsanto&#8217;s assumption of, and agreement to, indemnify Pharmacia for these liabilities apply to pending actions and any future actions related to Former Monsanto&#8217;s chemical businesses in which Pharmacia is named as a defendant, including, without limitation, actions asserting environmental claims, including alleged exposure to polychlorinated biphenyls. Solutia and/or New Monsanto are defending Pharmacia in connection with various claims and litigation arising out of, or related to, Former Monsanto&#8217;s chemical businesses, and have been indemnifying Pharmacia when liability has been imposed or settlement has been reached regarding such claims and litigation.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Environmental Matters</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In 2009, we submitted to the U.S. Environmental Protection Agency (EPA) a corrective measures study report with regard to Pharmacia&#8217;s discontinued industrial chemical facility in North Haven, Connecticut and a revised site-wide feasibility study with regard to Wyeth Holdings Corporation&#8217;s discontinued industrial chemical facility in Bound Brook, New Jersey. In September 2010, our corrective measures study report with regard to the North Haven facility was approved by the EPA, and we commenced construction of the site remedy in late 2011 under an Updated Administrative Order on Consent with the EPA. In July 2011, Wyeth Holdings Corporation finalized an Administrative Settlement Agreement and Order on Consent for Removal Action (the 2011 Administrative Settlement Agreement) with the EPA with regard to the Bound Brook facility. In May 2012, we completed construction of an interim remedy to address the discharge of impacted groundwater from that facility to the Raritan River. In September 2012, the EPA issued a final remediation plan for the Bound Brook facility&#8217;s main plant area, which is generally in accordance with one of the remedies evaluated in our revised site-wide feasibility study. In March 2013, Wyeth Holdings Corporation (now Wyeth Holdings LLC) entered into an Administrative Settlement Agreement and Order on Consent with the EPA to allow us to undertake detailed engineering design of the remedy for the main plant area and to perform a focused feasibility study for </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43707686e1344-wk-Fact-36FD01124C8551AD9F189087D936C419" name="pfe:FeasibilityStudyNumberOfLagoons" contextRef="D2013Q1MonthOfMarch_us-gaap_LossContingenciesByNatureOfContingencyAxis_pfe_EnvironmentalRemediationLitigationMember" unitRef="lagoon" decimals="INF" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> adjacent lagoons. In September 2015, the U.S., on behalf of the EPA, lodged a complaint and consent decree with the federal District Court for the District of New Jersey that will allow Wyeth Holdings LLC to complete the design and to implement the remedy for the main plant area. In December 2015, the consent decree (which supersedes the 2011 Administrative Settlement Agreement) was entered by the District Court. We have accrued for the estimated costs of the site remedy for the North Haven facility and the site remediation for the Bound Brook facility.</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:inherit;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are a party to a number of other proceedings brought under the Comprehensive Environmental Response, Compensation, and Liability Act of 1980, as amended, and other state, local or foreign laws in which the primary relief sought is the cost of past and/or future remediation.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Contracts with Iraqi Ministry of Health</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In October 2017, a number of United States service members, civilians, and their families brought a complaint against a number of pharmaceutical and medical devices companies, including Pfizer and certain of its subsidiaries, alleging that the defendants violated the United States Anti-Terrorism Act. The complaint alleges that the defendants provided funding for terrorist organizations through their sales practices pursuant to pharmaceutical and medical device contracts with the Iraqi Ministry of Health.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">A4. Legal Proceedings&#8211;&#8211;Government Investigations</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Like other pharmaceutical companies, we are subject to investigations and extensive regulation by government agencies in the U.S., other developed markets and multiple emerging markets in which we operate. As a result, we have interactions with government agencies on an ongoing basis. Criminal charges, and substantial fines and/or civil penalties, as well as limitations on our ability to conduct business in applicable jurisdictions, could result from government investigations. Among the investigations by government agencies are the matters discussed below.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Phenytoin Sodium Capsules</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In 2012, Pfizer sold the U.K. Marketing Authorisation for phenytoin sodium capsules to a third party, but retained the right to supply the finished product to that third party. In May 2013, the U.K. Competition &amp; Markets Authority (CMA) informed us that it had launched an investigation into the supply of phenytoin sodium capsules in the U.K. market. In August 2015, the CMA issued a Statement of Objections alleging that Pfizer and Pfizer Limited, a U.K. subsidiary, engaged in conduct that violates U.K. and EU antitrust laws. In December 2016, the CMA imposed a </span><span style="font-family:inherit;font-size:10pt;color:#0b0c0c;">&#163;</span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43707686e1376-wk-Fact-8925E94D49E25FBFAFA3C8122B68CDD4" name="us-gaap:LossContingencyEstimateOfPossibleLoss" contextRef="FI2016Q4_us-gaap_LossContingenciesByNatureOfContingencyAxis_pfe_ViolationofAntitrustLawsMember_us-gaap_ProductOrServiceAxis_pfe_PhenytoinSodiumCapsulesMember" unitRef="gbp" decimals="-5" scale="6" format="ixt:numdotdecimal">84.2</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> fine on Pfizer and Pfizer Limited. Pfizer appealed the CMA Decision to The Competition Appeal Tribunal in February 2017</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">.</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">38</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:center;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(UNAUDITED)</span></div></div><div><br/></div><ix:continuation id="TextSelection-66B8C111E79C55E1A7A77357A28182A8-11" continuedAt="TextSelection-66B8C111E79C55E1A7A77357A28182A8-12"><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Civil Investigative Demand relating to Pharmacy Benefit Managers</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In March 2016, Pfizer received a Civil Investigative Demand from the U.S. Attorney&#8217;s Office for the Southern District of New York related to Pfizer&#8217;s contractual relationships with pharmacy benefit managers with respect to certain pharmaceutical products over the period from January 1, 2006 to the present. We have provided information to the government in response to this Civil Investigative Demand.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Subpoenas relating to Copayment Assistance Organizations</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In December 2015 and July 2016, Pfizer received subpoenas from the U.S. Attorney&#8217;s Office for the District of Massachusetts requesting documents related to the Patient Access Network Foundation and other 501(c)(3) organizations that provide financial assistance to Medicare patients. We have been providing information to the government in response to these subpoenas.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">U.S. Department of Justice Investigation relating to Greenstone</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of July 2017, the U.S. Department of Justice&#8217;s Antitrust Division is investigating our Greenstone generics business. We believe this is related to an ongoing antitrust investigation of the generic pharmaceutical industry. The government has been obtaining information from Greenstone.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Intravenous Solutions</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">See </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 12A2. Legal Proceedings</span><span style="font-family:inherit;font-size:10pt;">&#8211;&#8211;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Product Litigation</span><span style="font-family:inherit;font-size:10pt;">&#8211;&#8211;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Intravenous Solutions</span><span style="font-family:inherit;font-size:10pt;"> above for information regarding government investigations related to sales of intravenous solution products.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">A5. Legal Proceedings&#8211;&#8211;Matters Resolved During the First </span><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Nine Months</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"> of 2017</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During 2017, certain matters, including the matter discussed below, were resolved or were the subject of definitive settlement agreements or settlement agreements-in-principle.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Xtandi</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In April 2014, the Regents of the University of California (the Regents) filed a complaint against the Medivation Group in California Superior Court in San Francisco. Medivation was acquired by Pfizer in September 2016 and is now a wholly-owned subsidiary of Pfizer. The Regents&#8217; complaint sought a </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43707686e1435-wk-Fact-F5F570175048519D98A990604BA2E267" name="pfe:LossContingencyCollaborationArrangementPercentageofPaymentsSoughtbyPlaintiff" contextRef="D2017Q2Apr01-Apr30_us-gaap_LitigationCaseAxis_pfe_RegentsVersusMedivationMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_us-gaap_ProductOrServiceAxis_pfe_XtandiMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">10</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> share, under a license agreement between the Medivation Group and the Regents, of certain payments the Medivation Group receives with respect to Xtandi under the Medivation Group&#8217;s sub-licensing and collaboration agreement with Astellas. Trial was scheduled to commence in May 2017. In July 2017, the parties resolved the matter through a settlement on terms not material to Pfizer, which was recorded in the second quarter of 2017 as a measurement period adjustment related to the Medivation acquisition.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">B. Guarantees and Indemnifications</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the ordinary course of business and in connection with the sale of assets and businesses, we often indemnify our counterparties against certain liabilities that may arise in connection with the transaction or related to activities prior to the transaction. These indemnifications typically pertain to environmental, tax, employee and/or product-related matters and patent-infringement claims. If the indemnified party were to make a successful claim pursuant to the terms of the indemnification, we would be required to reimburse the loss. These indemnifications are generally subject to threshold amounts, specified claim periods and other restrictions and limitations. Historically, we have not paid significant amounts under these provisions and, as of </span><span style="font-family:inherit;font-size:10pt;">October&#160;1, 2017</span><span style="font-family:inherit;font-size:10pt;">, recorded amounts for the estimated fair value of these indemnifications were not significant. </span></div></ix:continuation><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><ix:continuation id="TextSelection-66B8C111E79C55E1A7A77357A28182A8-12">Pfizer Inc. has also guaranteed the long-term debt of certain companies that it acquired and that now are subsidiaries of Pfizer.</ix:continuation> </span></div><div><a id="s11089EB88F875EEAA58BF4E77845BEAC"></a></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">N</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">ote 13.</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span><ix:nonNumeric contextRef="FD2017Q3YTD" name="us-gaap:SegmentReportingDisclosureTextBlock" id="TextSelection-B389BD5A47A85F2CB2DBBB9DF9010D7E-0-wk-Fact-DD4ABF30826E58CF8AF9DE1186C26B83" continuedAt="TextSelection-B389BD5A47A85F2CB2DBBB9DF9010D7E-1" escape="true"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Segment, Geographic and Other Revenue Information</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span></ix:nonNumeric></div><ix:continuation id="TextSelection-B389BD5A47A85F2CB2DBBB9DF9010D7E-1" continuedAt="TextSelection-B389BD5A47A85F2CB2DBBB9DF9010D7E-2"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">A. Segment Information</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We manage our commercial operations through </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43771853e654-wk-Fact-7FDCD3767D7C5A07BAB773B71A23B8A3" name="us-gaap:NumberOfOperatingSegments" contextRef="FD2017Q3YTD" unitRef="Operating_Segment" decimals="INF" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> distinct business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH and EH segments are each led by a single manager. Each operating segment has responsibility for its commercial activities and for certain IPR&amp;D projects for new investigational products and additional indications for in-line products that generally have achieved proof-of-concept. Each business has a geographic footprint across developed and emerging markets. Our chief operating decision maker uses the revenues and earnings of the </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43771853e658-wk-Fact-7FDCD3767D7C5A07BAB773B71A23B8A3" name="us-gaap:NumberOfOperatingSegments" contextRef="FD2017Q3YTD" unitRef="Operating_Segment" decimals="INF" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> operating segments, among other factors, for performance evaluation and resource allocation.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We regularly review our segments and the approach used by management for performance evaluation and resource allocation.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As described in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 1A</span><span style="font-family:inherit;font-size:10pt;">, acquisitions and divestitures have impacted our results of operations in 2017 and 2016.</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">39</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:center;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(UNAUDITED)</span></div></div><div><br/></div><ix:continuation id="TextSelection-B389BD5A47A85F2CB2DBBB9DF9010D7E-2" continuedAt="TextSelection-B389BD5A47A85F2CB2DBBB9DF9010D7E-3"><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Operating Segments</span></div><div style="line-height:120%;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:50%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Some additional information about our business segments follows:</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-style:italic;font-weight:bold;">IH Segment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-style:italic;font-weight:bold;">EH Segment</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:4px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">IH focuses on developing and commercializing novel, value-creating medicines and vaccines that significantly improve patients&#8217; lives, as well as products for consumer healthcare.<br/>Key therapeutic areas include internal medicine, vaccines, oncology, inflammation &amp; immunology, rare diseases and consumer healthcare.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:5px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">EH includes legacy brands that have lost or will soon lose market exclusivity in both developed and emerging markets, branded generics, generic sterile injectable products, biosimilars, select branded products including anti-infectives and, through February 2, 2017, HIS. EH also includes an R&amp;D organization, as well as our contract manufacturing business.</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #000000;"><div style="font-size:9.5pt;"><span style="font-family:inherit;font-size:3pt;font-weight:bold;"><br/></span><span style="font-family:inherit;font-size:9.5pt;font-weight:bold;">Leading brands include:<br/></span><span style="font-family:inherit;font-size:9.5pt;">- </span><span style="font-family:inherit;font-size:9.5pt;font-style:italic;">Prevnar 13/Prevenar 13<br/></span><span style="font-family:inherit;font-size:9.5pt;">- </span><span style="font-family:inherit;font-size:9.5pt;font-style:italic;">Xeljanz<br/></span><span style="font-family:inherit;font-size:9.5pt;">- </span><span style="font-family:inherit;font-size:9.5pt;font-style:italic;">Eliquis<br/></span><span style="font-family:inherit;font-size:9.5pt;">- </span><span style="font-family:inherit;font-size:9.5pt;font-style:italic;">Lyrica</span><span style="font-family:inherit;font-size:9.5pt;">&#160;(U.S., Japan and certain other markets)<br/>- </span><span style="font-family:inherit;font-size:9.5pt;font-style:italic;">Enbrel </span><span style="font-family:inherit;font-size:9.5pt;">(outside the U.S. and Canada)<br/>- </span><span style="font-family:inherit;font-size:9.5pt;font-style:italic;">Viagra</span><span style="font-family:inherit;font-size:9.5pt;">&#160;(U.S. and Canada)<br/>- </span><span style="font-family:inherit;font-size:9.5pt;font-style:italic;">Ibrance<br/></span><span style="font-family:inherit;font-size:9.5pt;">- </span><span style="font-family:inherit;font-size:9.5pt;font-style:italic;">Xtandi<br/></span><span style="font-family:inherit;font-size:9.5pt;">- Several OTC consumer healthcare products (e.g., </span><span style="font-family:inherit;font-size:9.5pt;font-style:italic;">Advil</span><span style="font-family:inherit;font-size:9.5pt;">&#160;and<br/></span><span style="font-family:inherit;font-size:9.5pt;font-style:italic;">&#160;&#160;Centrum</span><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #000000;"><div style="font-size:3pt;"><span style="font-family:inherit;font-size:3pt;"><br/></span></div><div style="font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-weight:bold;">Leading brands include:</span></div><div style="font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">- </span><span style="font-family:inherit;font-size:9.5pt;font-style:italic;">Lipitor</span></div><div style="font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-style:italic;">- Premarin </span><span style="font-family:inherit;font-size:9.5pt;">family</span></div><div style="font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-style:italic;">- Norvasc</span></div><div style="padding-left:6px;text-indent:-6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-style:italic;">- Lyrica </span><span style="font-family:inherit;font-size:9.5pt;">(Europe, Russia, Turkey, Israel and Central Asia countries)</span></div><div style="font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">- </span><span style="font-family:inherit;font-size:9.5pt;font-style:italic;">Celebrex</span></div><div style="font-size:10pt;"><span style="font-family:inherit;font-size:9.5pt;">- </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Inflectra/Remsima</span></div><div style="font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-style:italic;">- </span><span style="font-family:inherit;font-size:9.5pt;">Several sterile injectable products</span></div><div style="padding-left:5px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Other Costs and Business Activities</span></div><div style="line-height:120%;text-align:justify;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certain pre-tax costs are not allocated to our operating segment results, such as costs associated with the following:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">WRD, which is generally responsible for research projects for our IH business until proof-of-concept is achieved and then for transitioning those projects to the IH segment via the GPD organization for possible clinical and commercial development. R&amp;D spending may include upfront and milestone payments for intellectual property rights. The WRD organization also has responsibility for certain science-based and other platform-services organizations, which provide technical expertise and other services to the various R&amp;D projects, including EH R&amp;D projects. WRD is also responsible for facilitating all regulatory submissions and interactions with regulatory agencies, including all safety-event activities.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">GPD, which is generally responsible for the clinical development of assets that are in clinical trials for our WRD and Innovative portfolios. GPD also provides technical support and other services to Pfizer R&amp;D projects.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate, representing platform functions (such as worldwide technology, global real estate operations, legal, finance, human resources, worldwide public affairs, compliance and worldwide procurement) and certain compensation and other corporate costs, such as interest income and expense, and gains and losses on investments. Effective in the first quarter of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;">, Corporate also includes the costs associated with our Pfizer Medical organization (Medical), previously reported as part of Other Business Activities. Medical is responsible for the provision of medical information to healthcare providers, patients and other parties, transparency and disclosure activities, clinical trial results publication, grants for healthcare quality improvement and medical education, and partnerships with global public health and medical associations. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other unallocated costs, representing overhead expenses associated with our manufacturing and commercial operations that are not directly assessed to an operating segment, as business unit (segment) management does not manage these costs (which include manufacturing variances associated with production).</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certain transactions and events such as (i) purchase accounting adjustments, where we incur expenses associated with the amortization of fair value adjustments to inventory, intangible assets and PP&amp;E; (ii) acquisition-related costs, where we incur costs for executing the transaction, integrating the acquired operations and restructuring the combined company; and (iii) certain significant items, representing substantive and/or unusual, and in some cases recurring, items (such as restructuring or legal charges) that are evaluated on an individual basis by management and that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis. Such items can include, but are not limited to, non-acquisition-related restructuring costs, as well as costs incurred for legal settlements, asset impairments and disposals of assets or businesses, including, as applicable, any associated transition activities.</span></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Segment Assets</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We manage our assets on a total company basis, not by operating segment, as many of our operating assets are shared (such as our plant network assets) or commingled (such as accounts receivable, as many of our customers are served by both operating segments). Therefore, our chief operating decision maker does not regularly review any asset information by operating segment and, accordingly, we do not report asset information by operating segment. Total assets were approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d43771853e888-wk-Fact-D074F89DB2815EDFA2146FB266FB023F" name="us-gaap:Assets" contextRef="FI2017Q3" unitRef="usd" decimals="-9" scale="9" format="ixt:numdotdecimal">172</ix:nonFraction> billion</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">October&#160;1, 2017</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;text-align:center;">December&#160;31, 2016</span><span style="font-family:inherit;font-size:10pt;">.</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">40</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:center;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(UNAUDITED)</span></div></div><div><br/></div><ix:continuation id="TextSelection-B389BD5A47A85F2CB2DBBB9DF9010D7E-3" continuedAt="TextSelection-B389BD5A47A85F2CB2DBBB9DF9010D7E-4"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Selected Income Statement Information</span></div><div style="line-height:120%;font-size:10pt;"><ix:nonNumeric contextRef="FD2017Q3YTD" name="us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock" id="TextSelection-39C150A185E756079931FFB72A73329E-0-wk-Fact-969D3CD924E057A9B1F62A878378C5A0" continuedAt="TextSelection-39C150A185E756079931FFB72A73329E-1" escape="true"><ix:nonNumeric contextRef="FD2017Q3YTD" name="us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" id="TextSelection-3A70334D7C5D5252B1EF2B0781B55137-0-wk-Fact-2A0AF4F3CF765E09ADA3E806BBB2BCEB" continuedAt="TextSelection-3A70334D7C5D5252B1EF2B0781B55137-1" escape="true"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td colspan="17" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides selected income statement information by reportable segment:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Three Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Earnings</span><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">October&#160;1, <br/>2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">October&#160;2, <br/>2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">October&#160;1, <br/>2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">October&#160;2, <br/>2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Reportable Segments:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:6px;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">IH</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d43771853e1389-wk-Fact-32744FC079E6516B83654D2F854DDC81" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3QTD_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">8,118</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d43771853e1408-wk-Fact-CD5A7DF5427B5D659DC40A0EF86911E6" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3QTD_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">7,332</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d43771853e1428-wk-Fact-81F0756E8C76E147E68C5A6F0304AE04" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2017Q3QTD_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4,875</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d43771853e1447-wk-Fact-E7A96C031340595C8C21FFE23138776B" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2016Q3QTD_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4,187</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:6px;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">EH</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d43771853e1467-wk-Fact-1893B9D2D478593B987C2D75B2840206" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3QTD_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">5,050</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d43771853e1486-wk-Fact-8E0B859C556B55518AC4A34726DE143E" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3QTD_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">5,712</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d43771853e1505-wk-Fact-B11B8159E0957CFF66445A6F02FE77F4" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2017Q3QTD_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,765</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d43771853e1525-wk-Fact-2C08174C90215980AF8C21393CA8C5DE" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2016Q3QTD_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,128</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Total reportable segments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d43771853e1550-wk-Fact-BF46CA4FE42754B5B32511A01C0C8DE0" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3QTD_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">13,168</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d43771853e1569-wk-Fact-DB74B53DC930574FB35809CDD61DBAF0" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3QTD_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">13,045</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d43771853e1588-wk-Fact-A18F9A2CB32656BA9AA6CDE701027F25" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2017Q3QTD_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">7,640</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d43771853e1608-wk-Fact-9F0EA4485B0153C7823866D0926BA03D" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2016Q3QTD_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">7,315</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-12px;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Other business activities</span><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(b), (c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(<ix:nonFraction id="d43771853e1673-wk-Fact-71E7D0DF9D86563A92C28ADB4DD1F792" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2017Q3QTD_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">759</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(<ix:nonFraction id="d43771853e1694-wk-Fact-57E8C529F5385E41A7B3E91CFC576F36" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2016Q3QTD_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">753</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Reconciling Items:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Corporate</span><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(<ix:nonFraction id="d43771853e1845-wk-Fact-773AA58B1A2B57898FCAC12E9643C9F5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2017Q3QTD_us-gaap_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1,382</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(<ix:nonFraction id="d43771853e1866-wk-Fact-8B6B8D08A6E0596D82BFAC1026B33906" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2016Q3QTD_us-gaap_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1,537</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Purchase accounting adjustments</span><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(<ix:nonFraction id="d43771853e1933-wk-Fact-FF681D2F4C60530BA4FA7ECF6068D66E" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2017Q3QTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_PurchaseAccountingAdjustmentsMember_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1,154</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(<ix:nonFraction id="d43771853e1954-wk-Fact-6C4D8296C83F57DC93CF1B41EF47EFF1" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2016Q3QTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_PurchaseAccountingAdjustmentsMember_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">966</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Acquisition-related costs</span><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(<ix:nonFraction id="d43771853e2020-wk-Fact-701D108258D15E76898CF0E9F156AAB3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2017Q3QTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_BusinessCombinationsAcquisitionRelatedCostsMember_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">155</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(<ix:nonFraction id="d43771853e2041-wk-Fact-2439FB836F6B538B8D7D394CD6614D2E" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2016Q3QTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_BusinessCombinationsAcquisitionRelatedCostsMember_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">280</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Certain significant items</span><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(d)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(<ix:nonFraction id="d43771853e2107-wk-Fact-5FBB1F07246D5AAFB10CAD5C2A396D68" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2017Q3QTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_CertainSignificantItemsMember_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">449</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(<ix:nonFraction id="d43771853e2128-wk-Fact-241DA9C0A5035519B185693E59F3571D" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2016Q3QTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_CertainSignificantItemsMember_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1,969</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Other unallocated</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(<ix:nonFraction id="d43771853e2192-wk-Fact-4B3A8022310558FC9B763D89CFB05272" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2017Q3QTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_OtherUnallocatedMember_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">156</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(<ix:nonFraction id="d43771853e2213-wk-Fact-853524F647B75F4EA75709651DF1AA8F" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2016Q3QTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_OtherUnallocatedMember_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">206</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d43771853e2244-wk-Fact-739EC43DD13B5516B11DE41A93EEDF71" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">13,168</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d43771853e2263-wk-Fact-08F7B1DEB2E25ACA94468FF7CE567177" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">13,045</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d43771853e2282-wk-Fact-C6627323E3A7545BB805B65F89BE7911" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2017Q3QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,585</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d43771853e2301-wk-Fact-8EACD6F676A95BF0AB83AE15D642DBEA" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2016Q3QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,604</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="17" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Nine Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Earnings</span><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">October&#160;1, <br/>2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">October&#160;2, <br/>2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">October&#160;1, <br/>2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">October&#160;2, <br/>2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Reportable Segments:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">IH</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d43771853e2756-wk-Fact-ADD1149F121F5FEDB87B00FCFF919B53" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3YTD_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">23,204</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d43771853e2775-wk-Fact-8161BA8BA7C8570786334FD60871F61F" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3YTD_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">21,471</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d43771853e2795-wk-Fact-4978864FED0C5781909B06FB41801AC3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2017Q3YTD_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">14,190</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d43771853e2814-wk-Fact-A84CE5053CF85BC4965B4D4988840327" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2016Q3YTD_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">12,470</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">EH</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d43771853e2835-wk-Fact-A017B762D4F6541E8D5C4026A635906A" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3YTD_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">15,639</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d43771853e2854-wk-Fact-4A86BFAF3887566093AD955E2EF858FC" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3YTD_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">17,725</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d43771853e2873-wk-Fact-713D053AAB3F543EAA3B2BC05CA14525" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2017Q3YTD_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">8,558</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d43771853e2893-wk-Fact-BAF1C761A7AF5C7CBFD0E58295157553" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2016Q3YTD_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">9,985</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Total reportable segments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d43771853e2918-wk-Fact-FBE7252DC35752CABDE9FD8E2DACE551" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3YTD_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">38,843</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d43771853e2937-wk-Fact-0F4B985F368C5B5DBE7D51634A6C7FAD" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3YTD_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">39,196</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d43771853e2956-wk-Fact-8CC7C9AC13B558B88EEA9469BCD245B1" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2017Q3YTD_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">22,748</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d43771853e2976-wk-Fact-0B8C5DECC76C5C9E999FC0C03F083D1F" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2016Q3YTD_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">22,454</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Other business activities</span><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(b), (c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(<ix:nonFraction id="d43771853e3041-wk-Fact-8317B3014C2257C6BEBBD283124A965D" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2017Q3YTD_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">2,205</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(<ix:nonFraction id="d43771853e3062-wk-Fact-D653E73218645753AB0757271374CCA1" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2016Q3YTD_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">2,096</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Reconciling Items:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Corporate</span><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(<ix:nonFraction id="d43771853e3215-wk-Fact-47A9B6BC4350580490BDDDA2982DE155" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2017Q3YTD_us-gaap_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">3,948</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(<ix:nonFraction id="d43771853e3236-wk-Fact-E7E6EB83A98259609D63524CCF7C1687" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2016Q3YTD_us-gaap_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">4,217</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Purchase accounting adjustments</span><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(<ix:nonFraction id="d43771853e3302-wk-Fact-2E6085148E385843A6F6681DB2EA3E75" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2017Q3YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_PurchaseAccountingAdjustmentsMember_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">3,527</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(<ix:nonFraction id="d43771853e3323-wk-Fact-16217BBC721C5351BFA615340C8310C9" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2016Q3YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_PurchaseAccountingAdjustmentsMember_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">3,103</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Acquisition-related costs</span><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(<ix:nonFraction id="d43771853e3389-wk-Fact-2E8BCB0198B9547BFA12E7848D133E48" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2017Q3YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_BusinessCombinationsAcquisitionRelatedCostsMember_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">347</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(<ix:nonFraction id="d43771853e3410-wk-Fact-8AA7427BBF485EA4842503B7D6B6F5B3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2016Q3YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_BusinessCombinationsAcquisitionRelatedCostsMember_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">598</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Certain significant items</span><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(d)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(<ix:nonFraction id="d43771853e3476-wk-Fact-A872003B0DA95195BC5493ACF35066FF" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2017Q3YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_CertainSignificantItemsMember_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">797</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(<ix:nonFraction id="d43771853e3497-wk-Fact-F4E33C840C7351EB83A44DAB9FB01B6C" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2016Q3YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_CertainSignificantItemsMember_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">4,112</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Other unallocated</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(<ix:nonFraction id="d43771853e3561-wk-Fact-2131D133192A51CEA24287EC4D1DC30D" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2017Q3YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_OtherUnallocatedMember_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">573</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(<ix:nonFraction id="d43771853e3582-wk-Fact-D6C99180CE0A52CAAA4028B1B586C207" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2016Q3YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_OtherUnallocatedMember_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">753</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d43771853e3613-wk-Fact-D1ABF3DF10655F18B16D5BEDE8158D66" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">38,843</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d43771853e3632-wk-Fact-769863A67705599FBF10A0F9C982956F" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">39,196</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d43771853e3652-wk-Fact-6C225350ED6F51898E27B37470C6135A" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">11,351</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d43771853e3671-wk-Fact-6056A2295D7857F1915F488C04BDB11A" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2016Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">7,575</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></ix:nonNumeric></ix:nonNumeric></div><ix:continuation id="TextSelection-3A70334D7C5D5252B1EF2B0781B55137-1" continuedAt="TextSelection-3A70334D7C5D5252B1EF2B0781B55137-2"><ix:continuation id="TextSelection-39C150A185E756079931FFB72A73329E-1" continuedAt="TextSelection-39C150A185E756079931FFB72A73329E-2"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><ix:footnote id="TextSelection-78FC5AB8EFAB585E87BBCF93BE9FBF1D-0-wk-Footnote-78FC5AB8EFAB585E87BBCF93BE9FBF1D_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" continuedAt="TextSelection-78FC5AB8EFAB585E87BBCF93BE9FBF1D-1">Income from continuing operations before provision for taxes on income. IH&#8217;s earnings in the </ix:footnote></span><ix:continuation id="TextSelection-78FC5AB8EFAB585E87BBCF93BE9FBF1D-1" continuedAt="TextSelection-78FC5AB8EFAB585E87BBCF93BE9FBF1D-2"><span style="font-family:inherit;font-size:8pt;">third quarter</span><span style="font-family:inherit;font-size:8pt;"> and </span><span style="font-family:inherit;font-size:8pt;">first nine months of</span><span style="font-family:inherit;font-size:8pt;"> </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:8pt;text-align:center;"> include d</span><span style="font-family:inherit;font-size:8pt;">ividend income of </span><span style="font-family:inherit;font-size:8pt;"><span>$<ix:nonFraction id="d43771853e3708-wk-Fact-4F0D695F67305B7684A19B343AB32C0C" name="us-gaap:InvestmentIncomeDividend" contextRef="FD2017Q3QTD_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViivHealthcareLimitedMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">54</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:8pt;"> and </span><span style="font-family:inherit;font-size:8pt;"><span>$<ix:nonFraction id="d43771853e3713-wk-Fact-A4D794D7B0F25073BE267F34843F9BB3" name="us-gaap:InvestmentIncomeDividend" contextRef="FD2017Q3YTD_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViivHealthcareLimitedMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">211</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:8pt;">, respectively, from our investment in ViiV. For additional information, see </span></ix:continuation><span style="font-family:inherit;font-size:8pt;font-style:italic;"><ix:continuation id="TextSelection-78FC5AB8EFAB585E87BBCF93BE9FBF1D-2">Note 4.</ix:continuation></span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><ix:footnote id="TextSelection-C2AA3A20AB3F54349FC86854E44E1000-0-wk-Footnote-C2AA3A20AB3F54349FC86854E44E1000_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" continuedAt="TextSelection-C2AA3A20AB3F54349FC86854E44E1000-1">Other business activities includes the costs managed by our WRD and GPD organizations. Effective in the first quarter of </ix:footnote></span><ix:continuation id="TextSelection-C2AA3A20AB3F54349FC86854E44E1000-1" continuedAt="TextSelection-C2AA3A20AB3F54349FC86854E44E1000-2"><span style="font-family:inherit;font-size:8pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:8pt;">, Medical, previously reported as part of Other Business Activities, was reclassified to Corporate. We have reclassified approximately </span><span style="font-family:inherit;font-size:8pt;"><span>$<ix:nonFraction id="d43771853e3755-wk-Fact-5905DF29CEB855E3B862AF54314416A8" name="us-gaap:CostsAndExpenses" contextRef="FD2016Q3QTD_us-gaap_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioAdjustmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">33</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:8pt;"> and </span><span style="font-family:inherit;font-size:8pt;"><span>$<ix:nonFraction id="d43771853e3759-wk-Fact-B705E9A7D8C95A719E9D8EBCD91F3B0F" name="us-gaap:CostsAndExpenses" contextRef="FD2016Q3YTD_us-gaap_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioAdjustmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">94</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:8pt;"> of costs from Other Business Activities to Corporate in the </span><span style="font-family:inherit;font-size:8pt;">third quarter</span><span style="font-family:inherit;font-size:8pt;"> and </span><span style="font-family:inherit;font-size:8pt;">first nine months of</span><span style="font-family:inherit;font-size:8pt;"> </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2016</span></ix:continuation><span style="font-family:inherit;font-size:8pt;"><ix:continuation id="TextSelection-C2AA3A20AB3F54349FC86854E44E1000-2">, respectively, to conform to the current period presentation.</ix:continuation></span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><ix:footnote id="TextSelection-13C3E50268A15908A8AC9D1B6C938D2D-0-wk-Footnote-13C3E50268A15908A8AC9D1B6C938D2D_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US">For a description, see the &#8220;Other Costs and Business Activities&#8221; section above.</ix:footnote></span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(d)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><ix:footnote id="TextSelection-8540AADB45BE54D38C10451BF6A88AB4-0-wk-Footnote-8540AADB45BE54D38C10451BF6A88AB4_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" continuedAt="TextSelection-8540AADB45BE54D38C10451BF6A88AB4-1">Certain significant items are substantive and/or unusual, and in some cases recurring, items (such as restructuring or legal charges) that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis.</ix:footnote></span></div></td></tr></table><ix:continuation id="TextSelection-8540AADB45BE54D38C10451BF6A88AB4-1" continuedAt="TextSelection-8540AADB45BE54D38C10451BF6A88AB4-2"><div style="line-height:120%;padding-bottom:1px;padding-top:1px;padding-left:12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">For Earnings in the </span><span style="font-family:inherit;font-size:8pt;">third quarter</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:8pt;">, certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of </span><span style="font-family:inherit;font-size:8pt;"><span>$<ix:nonFraction id="d43771853e3827-wk-Fact-37BD8A19727152D698DBC1686715DAF3" name="pfe:RestructuringChargesandImplementationCosts" contextRef="FD2017Q3QTD_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">90</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:8pt;">, (ii) charges for certain legal matters of </span><span style="font-family:inherit;font-size:8pt;"><span>$<ix:nonFraction id="d43771853e3831-wk-Fact-28221068F090B979068691C4E99F537C" name="us-gaap:GainLossRelatedToLitigationSettlement" contextRef="FD2017Q3QTD_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">183</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:8pt;">, (iii) income of </span><span style="font-family:inherit;font-size:8pt;"><span>$<ix:nonFraction id="d43771853e3835-wk-Fact-3611B2339C325915870B95AB1F744E4A" name="us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" contextRef="FD2017Q3QTD_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_HISMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">12</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:8pt;">, representing an adjustment to amounts previously recorded to write down the HIS net assets to fair value less costs to sell, (iv) certain asset impairment charges of </span><span style="font-family:inherit;font-size:8pt;"><span>$<ix:nonFraction id="d43771853e3840-wk-Fact-6DDBD1867C46495FB2EB91F4D044DCDC" name="us-gaap:AssetImpairmentCharges" contextRef="FD2017Q3QTD_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">127</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:8pt;">, (v) charges for business and legal entity alignment of </span><span style="font-family:inherit;font-size:8pt;"><span>$<ix:nonFraction id="d43771853e3844-wk-Fact-0B9DB54EC1E25EAA89596B22BF341CCB" name="pfe:BusinessInfrastructureAlignmentCosts" contextRef="FD2017Q3QTD_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">16</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:8pt;"> and (vi) other charges of </span><span style="font-family:inherit;font-size:8pt;"><span>$<ix:nonFraction id="d43771853e3848-wk-Fact-20AD4F5DADC053D79D3489491D0428DC" name="us-gaap:OtherOperatingIncomeExpenseNet" contextRef="FD2017Q3QTD_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">45</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:8pt;">. For additional information, see </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Note 2B, Note 3</span><span style="font-family:inherit;font-size:8pt;"> and </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Note 4.</span></div><div style="line-height:120%;padding-bottom:1px;text-align:left;padding-left:12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">For Earnings in the </span><span style="font-family:inherit;font-size:8pt;">third quarter</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:8pt;">, certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of </span><span style="font-family:inherit;font-size:8pt;"><span>$<ix:nonFraction id="d43771853e3869-wk-Fact-872681DE787E5F8C88A4C6B4EFA47198" name="pfe:RestructuringChargesandImplementationCosts" contextRef="FD2016Q3QTD_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">375</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:8pt;">, (ii) income for certain legal matters of </span><span style="font-family:inherit;font-size:8pt;"><span>$<ix:nonFraction id="d43771853e3873-wk-Fact-1AFA07536C255929A6B61B3652BEC04C" name="us-gaap:GainLossRelatedToLitigationSettlement" contextRef="FD2016Q3QTD_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">40</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:8pt;">, (iii) an impairment charge related to the write-down of the HIS net assets to fair value less estimated costs to sell of </span><span style="font-family:inherit;font-size:8pt;"><span>$<ix:nonFraction id="d43771853e3877-wk-Fact-A6569EB0674CCF1D6CFF06D996CFFC1E" name="us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" contextRef="FD2016Q3QTD_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_HISMember" unitRef="usd" decimals="-8" scale="9" sign="-" format="ixt:numdotdecimal">1.4</ix:nonFraction> billion</span></span><span style="font-family:inherit;font-size:8pt;">, (iv) certain asset impairment charges of </span><span style="font-family:inherit;font-size:8pt;"><span>$<ix:nonFraction id="d43771853e3882-wk-Fact-3C16F4BA6F45515DA360E5DB15216695" name="us-gaap:AssetImpairmentCharges" contextRef="FD2016Q3QTD_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">126</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:8pt;">, (v) charges for business and legal entity alignment of </span><span style="font-family:inherit;font-size:8pt;"><span>$<ix:nonFraction id="d43771853e3886-wk-Fact-214FDB7F2FDD54F1A5930E33E66DEDA7" name="pfe:BusinessInfrastructureAlignmentCosts" contextRef="FD2016Q3QTD_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">69</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:8pt;"> and (vi) other charges of </span><span style="font-family:inherit;font-size:8pt;"><span>$<ix:nonFraction id="d43771853e3890-wk-Fact-A6DE9F337DBA5C059E43788A35061556" name="us-gaap:OtherOperatingIncomeExpenseNet" contextRef="FD2016Q3QTD_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">17</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:8pt;">. For additional information, see </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Note 3 </span><span style="font-family:inherit;font-size:8pt;">and</span><span style="font-family:inherit;font-size:8pt;font-style:italic;"> Note 4</span><span style="font-family:inherit;font-size:8pt;">.</span></div><div style="line-height:120%;padding-bottom:1px;text-align:left;padding-left:12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">For Earnings in the </span><span style="font-family:inherit;font-size:8pt;">first nine months of</span><span style="font-family:inherit;font-size:8pt;"> </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:8pt;">, certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of </span><span style="font-family:inherit;font-size:8pt;"><span>$<ix:nonFraction id="d43771853e3931-wk-Fact-566A8C7FB2E9567F8627369F2F7110E1" name="pfe:RestructuringChargesandImplementationCosts" contextRef="FD2017Q3YTD_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">253</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:8pt;">, (ii) charges for certain legal matters of </span><span style="font-family:inherit;font-size:8pt;"><span>$<ix:nonFraction id="d43771853e3935-wk-Fact-1CAE3E85970E5125B600FBCDDDEB3CF3" name="us-gaap:GainLossRelatedToLitigationSettlement" contextRef="FD2017Q3YTD_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">191</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:8pt;">, (iii) incremental charges to amounts previously recorded to write down the HIS net assets to fair value less costs to sell of </span><span style="font-family:inherit;font-size:8pt;"><span>$<ix:nonFraction id="d43771853e3939-wk-Fact-871B8C7C6D2657B0A7A3802199B06C67" name="us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" contextRef="FD2017Q3YTD_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_HISMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">52</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:8pt;">, (iv) certain asset impairment charges of </span><span style="font-family:inherit;font-size:8pt;"><span>$<ix:nonFraction id="d43771853e3944-wk-Fact-0FF0873A3B7C8B24FE3C91C31F8FEECB" name="us-gaap:AssetImpairmentCharges" contextRef="FD2017Q3YTD_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">127</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:8pt;">, (v) charges for business and legal entity alignment of </span><span style="font-family:inherit;font-size:8pt;"><span>$<ix:nonFraction id="d43771853e3948-wk-Fact-47D7D731E2AA51849CDAC797D0EC8C44" name="pfe:BusinessInfrastructureAlignmentCosts" contextRef="FD2017Q3YTD_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">54</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:8pt;"> and (vi) other charges of </span><span style="font-family:inherit;font-size:8pt;"><span>$<ix:nonFraction id="d43771853e3952-wk-Fact-7AB7F74380385861BC9DE7E304F1441B" name="us-gaap:OtherOperatingIncomeExpenseNet" contextRef="FD2017Q3YTD_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">119</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:8pt;">. For additional information, see </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Note 2B</span><span style="font-family:inherit;font-size:8pt;">, </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Note 3</span><span style="font-family:inherit;font-size:8pt;"> and </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Note 4</span><span style="font-family:inherit;font-size:8pt;">.</span></div></ix:continuation></ix:continuation></ix:continuation><div style="line-height:120%;padding-bottom:4px;text-align:left;padding-left:12px;font-size:8pt;"><ix:continuation id="TextSelection-8540AADB45BE54D38C10451BF6A88AB4-2" continuedAt="TextSelection-8540AADB45BE54D38C10451BF6A88AB4-3"><ix:continuation id="TextSelection-3A70334D7C5D5252B1EF2B0781B55137-2" continuedAt="TextSelection-3A70334D7C5D5252B1EF2B0781B55137-3"><ix:continuation id="TextSelection-39C150A185E756079931FFB72A73329E-2" continuedAt="TextSelection-39C150A185E756079931FFB72A73329E-3"><span style="font-family:inherit;font-size:8pt;">For Earnings in the </span><span style="font-family:inherit;font-size:8pt;">first nine months of</span><span style="font-family:inherit;font-size:8pt;"> </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:8pt;">, certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of </span><span style="font-family:inherit;font-size:8pt;"><span>$<ix:nonFraction id="d43771853e3980-wk-Fact-DA4CD3647EB85DAD999F46FDE8BCC875" name="pfe:RestructuringChargesandImplementationCosts" contextRef="FD2016Q3YTD_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">743</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:8pt;">, (ii) charges for certain legal matters of </span><span style="font-family:inherit;font-size:8pt;"><span>$<ix:nonFraction id="d43771853e3984-wk-Fact-6E5F463B046E559FB6203DF71B997D6C" name="us-gaap:GainLossRelatedToLitigationSettlement" contextRef="FD2016Q3YTD_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">506</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:8pt;">, (iii) an impairment charge related to the write-down of the HIS net assets to fair value less estimated costs to sell of </span><span style="font-family:inherit;font-size:8pt;"><span>$<ix:nonFraction id="d43771853e3988-wk-Fact-2934EDB57FC9F122D58206DC8FEEF818" name="us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" contextRef="FD2016Q3YTD_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_HISMember" unitRef="usd" decimals="-8" scale="9" sign="-" format="ixt:numdotdecimal">1.4</ix:nonFraction> billion</span></span><span style="font-family:inherit;font-size:8pt;">, (iv) certain asset impairment charges of </span><span style="font-family:inherit;font-size:8pt;"><span>$<ix:nonFraction id="d43771853e3993-wk-Fact-2B16F76028F051AB9F14E509E904CEDE" name="us-gaap:AssetImpairmentCharges" contextRef="FD2016Q3YTD_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">1.1</ix:nonFraction> billion</span></span><span style="font-family:inherit;font-size:8pt;">, (v) charges for business and legal entity alignment of </span><span style="font-family:inherit;font-size:8pt;"><span>$<ix:nonFraction id="d43771853e3997-wk-Fact-51707D511E915781B85A68A1F96A23C3" name="pfe:BusinessInfrastructureAlignmentCosts" contextRef="FD2016Q3YTD_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">180</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:8pt;"> and (vi) other charges of </span><span style="font-family:inherit;font-size:8pt;"><span>$<ix:nonFraction id="d43771853e4001-wk-Fact-A953722E279E5F628E0F1194A6AD4CD0" name="us-gaap:OtherOperatingIncomeExpenseNet" contextRef="FD2016Q3YTD_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">189</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:8pt;">. For additional information, see </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Note 3</span><span style="font-family:inherit;font-size:8pt;"> and </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Note 4</span></ix:continuation></ix:continuation></ix:continuation><span style="font-family:inherit;font-size:8pt;"><ix:continuation id="TextSelection-39C150A185E756079931FFB72A73329E-3"><ix:continuation id="TextSelection-3A70334D7C5D5252B1EF2B0781B55137-3"><ix:continuation id="TextSelection-8540AADB45BE54D38C10451BF6A88AB4-3">.</ix:continuation></ix:continuation></ix:continuation></span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">41</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:center;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(UNAUDITED)</span></div></div><div><br/></div><ix:continuation id="TextSelection-B389BD5A47A85F2CB2DBBB9DF9010D7E-4" continuedAt="TextSelection-B389BD5A47A85F2CB2DBBB9DF9010D7E-5"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Equity in the net income of investees accounted for by the equity method is not significant for any of our operating segments. </span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The operating segment information does not purport to represent the revenues, costs and income from continuing operations before provision for taxes on income that each of our operating segments would have recorded had each segment operated as a standalone company during the periods presented.</span></div><div style="line-height:120%;padding-top:9px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">B. Geographic Information</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As described in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 1A</span><span style="font-family:inherit;font-size:10pt;">, acquisitions and divestitures have impacted our results of operations in 2017 and 2016.</span></div><div style="line-height:120%;font-size:10pt;"><ix:nonNumeric contextRef="FD2017Q3YTD" name="us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock" id="TextSelection-B3DC163610C85BDB8A33634D6C9634CD-0-wk-Fact-A284F798559C51C390060107A40A445E" continuedAt="TextSelection-B3DC163610C85BDB8A33634D6C9634CD-1" escape="true"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.41520467836257%;border-collapse:collapse;text-align:left;"><tr><td colspan="23"></td></tr><tr><td style="width:28%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td></tr><tr><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides revenues by geographic area:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nine Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">October&#160;1, <br/>2017</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">October&#160;2, <br/>2016</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Change</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">October&#160;1, <br/>2017</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">October&#160;2, <br/>2016</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Change</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43771853e4443-wk-Fact-0EA10CF754CD5C9DB01D72A4A1556529" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3QTD_us-gaap_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6,534</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43771853e4462-wk-Fact-F97ABA1D718F526BA78D768C9F338C6C" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3QTD_us-gaap_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6,530</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43771853e4476-wk-Fact-196BFDB75FA651D398D5C064BC502C40" name="pfe:PercentageChangeInRevenue" contextRef="FD2017Q3QTD_us-gaap_StatementGeographicalAxis_country_US" unitRef="number" decimals="2" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43771853e4496-wk-Fact-17C8CEFC90255E2E8A36C1F2C89B8B7A" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3YTD_us-gaap_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">19,516</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43771853e4515-wk-Fact-9F3DFC9719AA53928C17946C2F27D2D5" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3YTD_us-gaap_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">19,561</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43771853e4529-wk-Fact-B6F9B0C09A965788BE5881BC84869216" name="pfe:PercentageChangeInRevenue" contextRef="FD2017Q3YTD_us-gaap_StatementGeographicalAxis_country_US" unitRef="number" decimals="2" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Developed Europe</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43771853e4552-wk-Fact-5BB441E685D3543B8C59407802A0ACC5" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3QTD_us-gaap_StatementGeographicalAxis_pfe_DevelopedEuropeMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,163</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43771853e4571-wk-Fact-B972D2BE08BE594FA3E2081E6C7190CF" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3QTD_us-gaap_StatementGeographicalAxis_pfe_DevelopedEuropeMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,218</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d43771853e4590-wk-Fact-379798FC1BCC5947B93DE423936B8B64" name="pfe:PercentageChangeInRevenue" contextRef="FD2017Q3QTD_us-gaap_StatementGeographicalAxis_pfe_DevelopedEuropeMember" unitRef="number" decimals="2" scale="-2" sign="-" format="ixt:numdotdecimal">2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43771853e4606-wk-Fact-465B9433DD0F5F3D8D3A8DC7524E082A" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3YTD_us-gaap_StatementGeographicalAxis_pfe_DevelopedEuropeMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6,309</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43771853e4625-wk-Fact-F7E35E4375AD52538A3022CD6B0C19EC" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3YTD_us-gaap_StatementGeographicalAxis_pfe_DevelopedEuropeMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6,982</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d43771853e4644-wk-Fact-A8E12836BA70521E8E7886584342E2F2" name="pfe:PercentageChangeInRevenue" contextRef="FD2017Q3YTD_us-gaap_StatementGeographicalAxis_pfe_DevelopedEuropeMember" unitRef="number" decimals="2" scale="-2" sign="-" format="ixt:numdotdecimal">10</ix:nonFraction></span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Developed Rest of World</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43771853e4668-wk-Fact-4DBF4C8A615D5B5885A229550C249596" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3QTD_us-gaap_StatementGeographicalAxis_pfe_DevelopedRestOfWorldMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,632</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43771853e4687-wk-Fact-16BC8C896FAA55B4BECE452FC941C562" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3QTD_us-gaap_StatementGeographicalAxis_pfe_DevelopedRestOfWorldMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,711</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d43771853e4706-wk-Fact-A9623F46D9315CFAA20B6FD10082039D" name="pfe:PercentageChangeInRevenue" contextRef="FD2017Q3QTD_us-gaap_StatementGeographicalAxis_pfe_DevelopedRestOfWorldMember" unitRef="number" decimals="2" scale="-2" sign="-" format="ixt:numdotdecimal">5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43771853e4722-wk-Fact-A244DBBB4D375344919B8BE000C88D5E" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3YTD_us-gaap_StatementGeographicalAxis_pfe_DevelopedRestOfWorldMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4,797</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43771853e4741-wk-Fact-B1B730E391FC52EF8914EC8E437455FB" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3YTD_us-gaap_StatementGeographicalAxis_pfe_DevelopedRestOfWorldMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4,940</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d43771853e4760-wk-Fact-3C874C1F4C8853D68A9C0BEB283CEC51" name="pfe:PercentageChangeInRevenue" contextRef="FD2017Q3YTD_us-gaap_StatementGeographicalAxis_pfe_DevelopedRestOfWorldMember" unitRef="number" decimals="2" scale="-2" sign="-" format="ixt:numdotdecimal">3</ix:nonFraction></span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Emerging Markets</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43771853e4784-wk-Fact-B332B03EB88A57C19CFEC6C041626341" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3QTD_us-gaap_StatementGeographicalAxis_pfe_EmergingMarketsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,839</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43771853e4803-wk-Fact-2DA3332AAA9A5E4A8EDAC00B3DB27FF9" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3QTD_us-gaap_StatementGeographicalAxis_pfe_EmergingMarketsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,586</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43771853e4822-wk-Fact-4589B65A44FD5257A71D6C106B182464" name="pfe:PercentageChangeInRevenue" contextRef="FD2017Q3QTD_us-gaap_StatementGeographicalAxis_pfe_EmergingMarketsMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">10</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43771853e4837-wk-Fact-970AC97D21605174BC2DCA8AD22AECDF" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3YTD_us-gaap_StatementGeographicalAxis_pfe_EmergingMarketsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">8,222</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43771853e4856-wk-Fact-8896D6C24D4F5AEEABD89DD662622B8D" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3YTD_us-gaap_StatementGeographicalAxis_pfe_EmergingMarketsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">7,714</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43771853e4875-wk-Fact-E1E962311928538DB01EDDF50F83A4A9" name="pfe:PercentageChangeInRevenue" contextRef="FD2017Q3YTD_us-gaap_StatementGeographicalAxis_pfe_EmergingMarketsMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43771853e4901-wk-Fact-739EC43DD13B5516B11DE41A93EEDF71" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">13,168</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43771853e4920-wk-Fact-08F7B1DEB2E25ACA94468FF7CE567177" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">13,045</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43771853e4934-wk-Fact-BD82079C9FF65D939C396D0EB390E35A" name="pfe:PercentageChangeInRevenue" contextRef="FD2017Q3QTD" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43771853e4954-wk-Fact-D1ABF3DF10655F18B16D5BEDE8158D66" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">38,843</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d43771853e4973-wk-Fact-769863A67705599FBF10A0F9C982956F" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">39,196</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d43771853e4987-wk-Fact-EA554CAB523557448216CC9E6AB99B0C" name="pfe:PercentageChangeInRevenue" contextRef="FD2017Q3YTD" unitRef="number" decimals="2" scale="-2" sign="-" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div></ix:nonNumeric></div><ix:continuation id="TextSelection-B3DC163610C85BDB8A33634D6C9634CD-1" continuedAt="TextSelection-B3DC163610C85BDB8A33634D6C9634CD-2"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><ix:footnote id="TextSelection-3802305E73EB52F28FAAF4EA5481D580-0-wk-Footnote-3802305E73EB52F28FAAF4EA5481D580_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" continuedAt="TextSelection-3802305E73EB52F28FAAF4EA5481D580-1"><span style="font-family:inherit;font-size:8pt;">Developed Europe region includes the following markets: Western Europe, Scandinavian countries and Finland.</span><span style="font-family:inherit;font-size:8pt;"> Revenues denominated in euros were </span><span style="font-family:inherit;font-size:8pt;"><span>$<ix:nonFraction id="d43771853e5015-wk-Fact-8E8904BDAA9F5324B35C02BAA84B3364" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3QTD_us-gaap_CurrencyAxis_currency_EUR_us-gaap_StatementGeographicalAxis_pfe_DevelopedEuropeMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">1.7</ix:nonFraction> billion</span></span><span style="font-family:inherit;font-size:8pt;"> in both the </span><span style="font-family:inherit;font-size:8pt;">third quarter</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:8pt;"> and </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:8pt;">, and </span><span style="font-family:inherit;font-size:8pt;"><span>$<ix:nonFraction id="d43771853e5037-wk-Fact-C846B4E888C353E9A2E2C25B78175769" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3YTD_us-gaap_CurrencyAxis_currency_EUR_us-gaap_StatementGeographicalAxis_pfe_DevelopedEuropeMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">5.0</ix:nonFraction> billion</span></span><span style="font-family:inherit;font-size:8pt;"> and </span><span style="font-family:inherit;font-size:8pt;"><span>$<ix:nonFraction id="d43771853e5041-wk-Fact-FCA4A3158A0758C4A9695F4278E7B491" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3YTD_us-gaap_CurrencyAxis_currency_EUR_us-gaap_StatementGeographicalAxis_pfe_DevelopedEuropeMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">5.3</ix:nonFraction> billion</span></span><span style="font-family:inherit;font-size:8pt;"> in the </span><span style="font-family:inherit;font-size:8pt;">first nine months of</span><span style="font-family:inherit;font-size:8pt;"> </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:8pt;"> and </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2016</span></ix:footnote><span style="font-family:inherit;font-size:8pt;"><ix:continuation id="TextSelection-3802305E73EB52F28FAAF4EA5481D580-1">, respectively.</ix:continuation></span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><ix:footnote id="TextSelection-E9F14C2885BA59D8B6B4AD221FC38619-0-wk-Footnote-E9F14C2885BA59D8B6B4AD221FC38619_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><span style="font-family:inherit;font-size:8pt;">Developed Rest of World region includes the following markets: Japan, Canada, Australia, South Korea and New Zealand.</span></ix:footnote></div></td></tr></table></ix:continuation><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><ix:continuation id="TextSelection-B3DC163610C85BDB8A33634D6C9634CD-2" continuedAt="TextSelection-B3DC163610C85BDB8A33634D6C9634CD-3"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup>&#160;</span></div></ix:continuation></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><ix:continuation id="TextSelection-B3DC163610C85BDB8A33634D6C9634CD-3"><ix:footnote id="TextSelection-DC6DDCB74FC9523D97BA51FBA6B1C05E-0-wk-Footnote-DC6DDCB74FC9523D97BA51FBA6B1C05E_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><span style="font-family:inherit;font-size:8pt;">Emerging Markets region includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Africa, Eastern Europe, Central Europe, the Middle East and Turkey.</span></ix:footnote></ix:continuation></div></td></tr></table></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">42</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:center;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(UNAUDITED)</span></div></div><div><br/></div><ix:continuation id="TextSelection-B389BD5A47A85F2CB2DBBB9DF9010D7E-5" continuedAt="TextSelection-B389BD5A47A85F2CB2DBBB9DF9010D7E-6"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">C. Other Revenue Information</span></div><div style="line-height:120%;padding-top:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Significant Product Revenues</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As described in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 1A</span><span style="font-family:inherit;font-size:10pt;">, acquisitions and divestitures have impacted our results of operations in 2017 and 2016.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">43</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:center;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(UNAUDITED)</span></div></div><div><br/></div><ix:continuation id="TextSelection-B389BD5A47A85F2CB2DBBB9DF9010D7E-6" continuedAt="TextSelection-B389BD5A47A85F2CB2DBBB9DF9010D7E-7"><div style="line-height:120%;text-align:left;font-size:10pt;"><ix:nonNumeric contextRef="FD2017Q3YTD" name="us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" id="TextSelection-49D25731B86F528799C83F48EBAD14A9-0-wk-Fact-F6E10F5E7CA055A1A83EB344BF04FB11" continuedAt="TextSelection-49D25731B86F528799C83F48EBAD14A9-1" escape="true"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"></td></tr><tr><td style="width:48%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td colspan="17" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides detailed revenue information:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Nine Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">October&#160;1, <br/>2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">October&#160;2, <br/>2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">October&#160;1, <br/>2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">October&#160;2, <br/>2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">PFIZER INNOVATIVE HEALTH (IH)</span><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d43771853e5430-wk-Fact-C92E4F643F355942826164E220B2CDBA" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">8,118</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d43771853e5449-wk-Fact-CB8A98F9684B5E90A54FF33CE216657C" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">7,332</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d43771853e5469-wk-Fact-A95EC0EF20D05434AF953959C36E2AA3" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">23,204</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d43771853e5488-wk-Fact-F89CB7AD3161526488B19688958B0E65" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">21,471</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Internal Medicine</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d43771853e5513-wk-Fact-CA16524707115418ACA6F55DC07EDB91" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,455</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d43771853e5532-wk-Fact-3706400825245EE59A5F3CE23F7A4638" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,243</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d43771853e5552-wk-Fact-41748AC25A5956969664BB602450202F" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">7,245</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d43771853e5571-wk-Fact-A566B5CCA725505FBE0CCBD0E5B0D9C3" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6,557</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Lyrica IH</span><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e5593-wk-Fact-92C4B36CCF2B53258C24D575B5A46D08" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InternalMedicineMember_us-gaap_ProductOrServiceAxis_pfe_LyricaMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,150</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e5612-wk-Fact-91BE74609E00525280568DAA60F6DF3B" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InternalMedicineMember_us-gaap_ProductOrServiceAxis_pfe_LyricaMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,049</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e5631-wk-Fact-9D09FA5E842755B1A0C73898B8865ED0" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InternalMedicineMember_us-gaap_ProductOrServiceAxis_pfe_LyricaMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,382</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e5651-wk-Fact-B2EC756D8A9E5AF6969297EE142A38CF" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InternalMedicineMember_us-gaap_ProductOrServiceAxis_pfe_LyricaMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,107</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Eliquis alliance revenues and direct sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e5676-wk-Fact-D171327093C15ED48BD61C1B80CD56A4" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InternalMedicineMember_us-gaap_ProductOrServiceAxis_pfe_EliquisMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">644</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e5695-wk-Fact-B53E687002905A7CB9CDCE789BE5C230" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InternalMedicineMember_us-gaap_ProductOrServiceAxis_pfe_EliquisMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">449</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e5714-wk-Fact-5A8BA30C5E2052EEBE7C6776D447D8DE" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InternalMedicineMember_us-gaap_ProductOrServiceAxis_pfe_EliquisMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,813</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e5734-wk-Fact-036B59F8F72459729D84552CABD6D290" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InternalMedicineMember_us-gaap_ProductOrServiceAxis_pfe_EliquisMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,225</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Chantix/Champix</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e5759-wk-Fact-4657C468E2C65C92BD2ABB46F6BA77BA" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InternalMedicineMember_us-gaap_ProductOrServiceAxis_pfe_ChantixChampixMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">240</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e5778-wk-Fact-A1D511A04C5C55CBB466AD3F603D2DF6" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InternalMedicineMember_us-gaap_ProductOrServiceAxis_pfe_ChantixChampixMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">198</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e5797-wk-Fact-3F08840BF0F755898FB0502206E7BA27" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InternalMedicineMember_us-gaap_ProductOrServiceAxis_pfe_ChantixChampixMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">727</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e5817-wk-Fact-D2F37A473E40522EBE11CEC55D7345CF" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InternalMedicineMember_us-gaap_ProductOrServiceAxis_pfe_ChantixChampixMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">631</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Viagra IH</span><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e5844-wk-Fact-C4B5621B0E4A59B3974A957DE7295490" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InternalMedicineMember_us-gaap_ProductOrServiceAxis_pfe_ViagraMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">206</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e5863-wk-Fact-1F06BFCD01CA55BFA37745ACCFA9290A" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InternalMedicineMember_us-gaap_ProductOrServiceAxis_pfe_ViagraMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">297</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e5882-wk-Fact-035E25AAED92520288A7CD55C86FFB01" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InternalMedicineMember_us-gaap_ProductOrServiceAxis_pfe_ViagraMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">711</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e5902-wk-Fact-96034CF0E4F8560C81E68935C2975A14" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InternalMedicineMember_us-gaap_ProductOrServiceAxis_pfe_ViagraMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">897</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">BMP2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e5927-wk-Fact-142E65278AE6532AA590EBBCD717A2B8" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InternalMedicineMember_us-gaap_ProductOrServiceAxis_pfe_BMP2Member_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">79</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e5946-wk-Fact-A61A879115A4506186E498490D97E0AF" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InternalMedicineMember_us-gaap_ProductOrServiceAxis_pfe_BMP2Member_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">63</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e5965-wk-Fact-4AB54F2A88CE587296961BC5EDD7B4F1" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InternalMedicineMember_us-gaap_ProductOrServiceAxis_pfe_BMP2Member_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">198</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e5985-wk-Fact-25A4B09EEA225883A45F9F720B0255C7" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InternalMedicineMember_us-gaap_ProductOrServiceAxis_pfe_BMP2Member_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">175</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Toviaz</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e6010-wk-Fact-DFBC44A3B2F256D89E8352F65BCD80AA" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InternalMedicineMember_us-gaap_ProductOrServiceAxis_pfe_ToviazMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">62</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e6029-wk-Fact-ABE7D0EA841056008FD6062A7C39DCF7" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InternalMedicineMember_us-gaap_ProductOrServiceAxis_pfe_ToviazMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">60</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e6048-wk-Fact-4650451D4A7751FA869FFA12F7003E58" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InternalMedicineMember_us-gaap_ProductOrServiceAxis_pfe_ToviazMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">187</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e6068-wk-Fact-6C13C40E22545F58BD2C66B07FFBA38B" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InternalMedicineMember_us-gaap_ProductOrServiceAxis_pfe_ToviazMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">191</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">All other Internal Medicine</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e6094-wk-Fact-0C7EC998FC4E50E2B902BE677AA9DC99" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InternalMedicineMember_us-gaap_ProductOrServiceAxis_pfe_AllOtherInternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">75</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e6113-wk-Fact-015CDB41359B586F89ED430E8B803A71" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InternalMedicineMember_us-gaap_ProductOrServiceAxis_pfe_AllOtherInternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">128</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e6132-wk-Fact-694A0FD2AEB153E58CB6BF3309DCBAF7" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InternalMedicineMember_us-gaap_ProductOrServiceAxis_pfe_AllOtherInternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">228</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e6152-wk-Fact-F216298EC60A5A65B68CF963E1BE237E" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InternalMedicineMember_us-gaap_ProductOrServiceAxis_pfe_AllOtherInternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">330</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Vaccines</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d43771853e6182-wk-Fact-F3FCBA95731F52C08EA41369F2E81D7F" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,649</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d43771853e6201-wk-Fact-5BD3996759ED5CA9B9F1B5C5097FD0B6" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,641</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d43771853e6221-wk-Fact-8975CADB3E155E6382572B4E39D69060" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4,385</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d43771853e6240-wk-Fact-E2D42F0B08935EDDBA04010AD3D25E86" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4,576</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Prevnar 13/Prevenar 13</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e6260-wk-Fact-F1D03E298AFE5BB49EE38507362DFDFA" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_VaccinesMember_us-gaap_ProductOrServiceAxis_pfe_PrevnarPrevenarFamilyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,522</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e6279-wk-Fact-AE220AEF612A5565B70C949960E90FD0" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_VaccinesMember_us-gaap_ProductOrServiceAxis_pfe_PrevnarPrevenarFamilyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,536</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e6298-wk-Fact-B83EE0EEEF5650C9915D3EEEA2C9E44F" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_VaccinesMember_us-gaap_ProductOrServiceAxis_pfe_PrevnarPrevenarFamilyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4,069</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e6318-wk-Fact-8EE9C2E338FC5C3F94F62D1D10A9FABD" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_VaccinesMember_us-gaap_ProductOrServiceAxis_pfe_PrevnarPrevenarFamilyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4,302</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">FSME/IMMUN-TicoVac</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e6343-wk-Fact-C1B77BB95D575829AE48D0BE96B7A983" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_VaccinesMember_us-gaap_ProductOrServiceAxis_pfe_FSMEIMMUNTicoVacMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">43</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e6362-wk-Fact-8D880736DA155DB5BC71B0FC575FA9C9" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_VaccinesMember_us-gaap_ProductOrServiceAxis_pfe_FSMEIMMUNTicoVacMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">33</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e6381-wk-Fact-6FFF21C6992C51A48DBA39AC95ABE556" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_VaccinesMember_us-gaap_ProductOrServiceAxis_pfe_FSMEIMMUNTicoVacMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">119</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e6401-wk-Fact-82EC0B3C97A65D948782FCC8492DC0CB" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_VaccinesMember_us-gaap_ProductOrServiceAxis_pfe_FSMEIMMUNTicoVacMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">102</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">All other Vaccines</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e6426-wk-Fact-6073CDC8548A501C818D6BA5BB71754B" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_VaccinesMember_us-gaap_ProductOrServiceAxis_pfe_OtherVaccinesProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">85</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e6445-wk-Fact-EA0282B4215E5EB59B0A858B7C943CFA" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_VaccinesMember_us-gaap_ProductOrServiceAxis_pfe_OtherVaccinesProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">72</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e6464-wk-Fact-92A1955541685690B9D2FD5CB311B9BA" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_VaccinesMember_us-gaap_ProductOrServiceAxis_pfe_OtherVaccinesProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">197</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e6484-wk-Fact-836A46AAB359562B9EA24D489A3362EA" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_VaccinesMember_us-gaap_ProductOrServiceAxis_pfe_OtherVaccinesProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">172</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Oncology</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d43771853e6514-wk-Fact-08860EE288125986894C909F92BCF2A4" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,616</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d43771853e6533-wk-Fact-DE27B499390D577195E3B6FF88C2FD46" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,104</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d43771853e6553-wk-Fact-E911DF3381F35F38A1DF45AEDBD73FD9" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4,551</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d43771853e6572-wk-Fact-B94E4881267C5825B4EE800ADAA6D64A" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,206</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Ibrance</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e6592-wk-Fact-0DF89FAF74285087B3DBDCB2D3E032A8" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_OncologyMember_us-gaap_ProductOrServiceAxis_pfe_IbranceMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">878</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e6611-wk-Fact-C34E6A4C5B355A8BB64F366F84AF85A6" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_OncologyMember_us-gaap_ProductOrServiceAxis_pfe_IbranceMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">550</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e6630-wk-Fact-43AC460D5B15527C8C4DB286489E2C2F" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_OncologyMember_us-gaap_ProductOrServiceAxis_pfe_IbranceMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,410</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e6650-wk-Fact-7EEC7835C987598BA91D539D1D33741E" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_OncologyMember_us-gaap_ProductOrServiceAxis_pfe_IbranceMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,492</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Sutent</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e6675-wk-Fact-AAD30F67E3565D6297813A2C98D4C6B5" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_OncologyMember_us-gaap_ProductOrServiceAxis_pfe_SutentMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">276</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e6694-wk-Fact-55173256EA9450E094C7CA17D252112E" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_OncologyMember_us-gaap_ProductOrServiceAxis_pfe_SutentMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">260</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e6713-wk-Fact-9087A7F6DD65523D888D34042DDFA88C" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_OncologyMember_us-gaap_ProductOrServiceAxis_pfe_SutentMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">805</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e6733-wk-Fact-92E0FA0AFEFD567C8DCA6935C8539F56" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_OncologyMember_us-gaap_ProductOrServiceAxis_pfe_SutentMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">823</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Xalkori</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e6758-wk-Fact-A465E9D72ACB547BA03784F4DEABD170" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_OncologyMember_us-gaap_ProductOrServiceAxis_pfe_XalkoriMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">146</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e6777-wk-Fact-1EF2AA07098B51BCABA26C08A4E2EE29" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_OncologyMember_us-gaap_ProductOrServiceAxis_pfe_XalkoriMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">140</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e6796-wk-Fact-DA08E1D6E8AE59B9A96BDAA0DB9F50C2" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_OncologyMember_us-gaap_ProductOrServiceAxis_pfe_XalkoriMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">442</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e6816-wk-Fact-71C4FA44FB4D5F10B54E6BA126566708" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_OncologyMember_us-gaap_ProductOrServiceAxis_pfe_XalkoriMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">415</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Xtandi alliance revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e6841-wk-Fact-C277EBD5B6E55350B5ABE43DCB81B2E3" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_OncologyMember_us-gaap_ProductOrServiceAxis_pfe_XtandiAllianceMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">150</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e6860-wk-Fact-633D0A720D6F0F6B11CA06EB48CFC067" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_OncologyMember_us-gaap_ProductOrServiceAxis_pfe_XtandiAllianceMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e6879-wk-Fact-10637337C98A5CF2AEA82F99FC8BF786" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_OncologyMember_us-gaap_ProductOrServiceAxis_pfe_XtandiAllianceMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">422</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e6899-wk-Fact-EA16560E96B45E27A58E57CB2F6D89A4" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_OncologyMember_us-gaap_ProductOrServiceAxis_pfe_XtandiAllianceMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Inlyta</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e6924-wk-Fact-B5D93F1F50C05633A02F37D05FCD4FEB" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_OncologyMember_us-gaap_ProductOrServiceAxis_pfe_InlytaMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">84</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e6943-wk-Fact-D43C6DB9B5CF57AABD4144362BC80D42" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_OncologyMember_us-gaap_ProductOrServiceAxis_pfe_InlytaMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">95</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e6962-wk-Fact-2FCF41B5C7CA5DF9BA0C83AD4F9E3868" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_OncologyMember_us-gaap_ProductOrServiceAxis_pfe_InlytaMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">256</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e6982-wk-Fact-266FE0D041AD51B3BADFC22625A61E51" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_OncologyMember_us-gaap_ProductOrServiceAxis_pfe_InlytaMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">304</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Bosulif</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e7008-wk-Fact-73EFEC7C5B0F5FB8AAB73A81AFA6625D" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_OncologyMember_us-gaap_ProductOrServiceAxis_pfe_BosulifMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">57</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e7027-wk-Fact-B8081C8455885B62AE392826639A12E7" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_OncologyMember_us-gaap_ProductOrServiceAxis_pfe_BosulifMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">43</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e7046-wk-Fact-10E6CE67EF6B54B3A47135CE5B66BF47" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_OncologyMember_us-gaap_ProductOrServiceAxis_pfe_BosulifMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">163</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e7066-wk-Fact-131F3EDDFD7D52FB952EED7E29955E92" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_OncologyMember_us-gaap_ProductOrServiceAxis_pfe_BosulifMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">121</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">All other Oncology</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e7091-wk-Fact-8FB7D77D7D87509EA2042D6B3FCB31C0" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_OncologyMember_us-gaap_ProductOrServiceAxis_pfe_OtherOncologyProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">26</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e7110-wk-Fact-A9C00ABE4C095675BFE21B9753F37E1B" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_OncologyMember_us-gaap_ProductOrServiceAxis_pfe_OtherOncologyProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">15</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e7129-wk-Fact-5427E2C43C7A5EA0940BC3C4BAFBE114" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_OncologyMember_us-gaap_ProductOrServiceAxis_pfe_OtherOncologyProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">54</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e7149-wk-Fact-EFDF08F413325FA994B39D089AB63398" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_OncologyMember_us-gaap_ProductOrServiceAxis_pfe_OtherOncologyProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">49</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Inflammation &amp; Immunology (I&amp;I)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d43771853e7179-wk-Fact-219B87F1F5BD586DBB8F06C00D233740" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d43771853e7198-wk-Fact-673C6E5A33FC51C68F9F0B9685E1C2F1" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">960</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d43771853e7218-wk-Fact-4A560A4F38C95E0BA9F9573B86D87D80" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,863</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d43771853e7237-wk-Fact-B886B803C4265A719A50FB648A126929" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,907</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Enbrel (Outside the U.S. and Canada)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e7257-wk-Fact-8B74C3380E3C501091B8DDE55E031995" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InflammationandImmunologyMember_us-gaap_ProductOrServiceAxis_pfe_EnbrelMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">613</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e7276-wk-Fact-BBBA91223D865B01A9D02A82ED5D5112" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InflammationandImmunologyMember_us-gaap_ProductOrServiceAxis_pfe_EnbrelMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">701</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e7295-wk-Fact-8E787801D82452BD87435D5EDD146AE4" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InflammationandImmunologyMember_us-gaap_ProductOrServiceAxis_pfe_EnbrelMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,818</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e7315-wk-Fact-16957E3FC1865EC5818D304B896D3077" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InflammationandImmunologyMember_us-gaap_ProductOrServiceAxis_pfe_EnbrelMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,201</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Xeljanz</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e7340-wk-Fact-1F22161872CA5538800B3F0F624588F0" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InflammationandImmunologyMember_us-gaap_ProductOrServiceAxis_pfe_XeljanzMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">348</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e7359-wk-Fact-D74A347EE03055F49E204091A2441955" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InflammationandImmunologyMember_us-gaap_ProductOrServiceAxis_pfe_XeljanzMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">235</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e7378-wk-Fact-C9F8A169F48D520FB7B2A38A107244B2" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InflammationandImmunologyMember_us-gaap_ProductOrServiceAxis_pfe_XeljanzMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">935</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e7398-wk-Fact-E2EB24E2CBDD5235A20D3C6FA6BA3A47" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InflammationandImmunologyMember_us-gaap_ProductOrServiceAxis_pfe_XeljanzMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">649</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Eucrisa</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e7422-wk-Fact-7953D783030F592BA8412FAEC83B50B7" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InflammationandImmunologyMember_us-gaap_ProductOrServiceAxis_pfe_EucrisaMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">15</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e7440-wk-Fact-95D977890609508D8D97487E681DD7A8" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InflammationandImmunologyMember_us-gaap_ProductOrServiceAxis_pfe_EucrisaMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e7458-wk-Fact-08EB232BAC905890B3444837B08BD4C3" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InflammationandImmunologyMember_us-gaap_ProductOrServiceAxis_pfe_EucrisaMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">33</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e7477-wk-Fact-D36D0948952453FF8454EDED26949131" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InflammationandImmunologyMember_us-gaap_ProductOrServiceAxis_pfe_EucrisaMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">All other I&amp;I</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e7502-wk-Fact-675636511AB75FC68785AE8E8FA5510C" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InflammationandImmunologyMember_us-gaap_ProductOrServiceAxis_pfe_AllOtherInflammationandImmunologyProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">23</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e7521-wk-Fact-C3C364E503C85480A039A92DB5ECB885" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InflammationandImmunologyMember_us-gaap_ProductOrServiceAxis_pfe_AllOtherInflammationandImmunologyProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">24</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e7540-wk-Fact-58090A45EE23591F9421C0676B410E6F" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InflammationandImmunologyMember_us-gaap_ProductOrServiceAxis_pfe_AllOtherInflammationandImmunologyProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">78</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e7560-wk-Fact-5F26EACB136F5EF28A856B0B174BF7DF" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InflammationandImmunologyMember_us-gaap_ProductOrServiceAxis_pfe_AllOtherInflammationandImmunologyProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">57</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Rare Disease</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d43771853e7590-wk-Fact-428E1568A6BF5B8E9B628219F6E50B5B" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">569</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d43771853e7609-wk-Fact-C67E33A41E0A5A08866F36100455BF9C" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">585</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d43771853e7629-wk-Fact-F92AA48F92C0526287A732ACF00839D0" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,637</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d43771853e7648-wk-Fact-78634444335D5A7985E0115A4F94838B" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,768</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">BeneFIX</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e7668-wk-Fact-3A4992B73D7D515A9630C09A8E8D7022" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_RareDiseaseMember_us-gaap_ProductOrServiceAxis_pfe_BeneFIXMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">151</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e7687-wk-Fact-0C7378A7F4CF53A4BA6A80E65A0D72DF" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_RareDiseaseMember_us-gaap_ProductOrServiceAxis_pfe_BeneFIXMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">176</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e7706-wk-Fact-9CD99F7F9EC85E0B9C70AB6E20622F25" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_RareDiseaseMember_us-gaap_ProductOrServiceAxis_pfe_BeneFIXMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">453</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e7726-wk-Fact-06B14C244D6F5C4CBA25CA4E62AC7B0A" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_RareDiseaseMember_us-gaap_ProductOrServiceAxis_pfe_BeneFIXMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">543</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Refacto AF/Xyntha</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e7751-wk-Fact-1732BED87F0656A9B0353C1C87A48553" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_RareDiseaseMember_us-gaap_ProductOrServiceAxis_pfe_ReFactoAfXynthaMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">140</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e7770-wk-Fact-F71BABD18CD45261A41A611A3AECACAB" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_RareDiseaseMember_us-gaap_ProductOrServiceAxis_pfe_ReFactoAfXynthaMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">140</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e7789-wk-Fact-72A7D9EBF47B57CDA0B3DE510E431909" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_RareDiseaseMember_us-gaap_ProductOrServiceAxis_pfe_ReFactoAfXynthaMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">409</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e7809-wk-Fact-FACE6D4B059252CEA63781A89FB54BDA" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_RareDiseaseMember_us-gaap_ProductOrServiceAxis_pfe_ReFactoAfXynthaMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">408</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Genotropin</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e7834-wk-Fact-B3E9FD5A43325ECFA22B3F96FF93DA60" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_RareDiseaseMember_us-gaap_ProductOrServiceAxis_pfe_GenotropinMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">136</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e7853-wk-Fact-56994BBD5BA05DACB90C9F5407ADC80A" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_RareDiseaseMember_us-gaap_ProductOrServiceAxis_pfe_GenotropinMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">147</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e7872-wk-Fact-80643250DAFE53DCA821C8AA917098E3" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_RareDiseaseMember_us-gaap_ProductOrServiceAxis_pfe_GenotropinMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">375</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e7892-wk-Fact-AF731B3F4A5555AABD62FFB6A2BF12F1" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_RareDiseaseMember_us-gaap_ProductOrServiceAxis_pfe_GenotropinMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">425</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Somavert</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e7918-wk-Fact-72B961E07B085F2F93A837DE59686CF5" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_RareDiseaseMember_us-gaap_ProductOrServiceAxis_pfe_SomavertMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">65</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e7937-wk-Fact-94F261CAD03B54B283A6FFDC0C8B3267" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_RareDiseaseMember_us-gaap_ProductOrServiceAxis_pfe_SomavertMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">59</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e7956-wk-Fact-AA4E8389AB1457D5B2A64893F6FED20E" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_RareDiseaseMember_us-gaap_ProductOrServiceAxis_pfe_SomavertMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">182</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e7976-wk-Fact-4C3732254DAD546F823FD75D885F90F6" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_RareDiseaseMember_us-gaap_ProductOrServiceAxis_pfe_SomavertMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">173</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">All other Rare Disease</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e8001-wk-Fact-7CCD756011875D60BF26983F931E3C30" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_RareDiseaseMember_us-gaap_ProductOrServiceAxis_pfe_AllOtherRareDiseaseProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">77</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e8020-wk-Fact-C8F59D52403859FDAE25CE4B2D75B61F" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_RareDiseaseMember_us-gaap_ProductOrServiceAxis_pfe_AllOtherRareDiseaseProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">64</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e8039-wk-Fact-32B6C9E3886F5235AEFB1DB4E626DEF5" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_RareDiseaseMember_us-gaap_ProductOrServiceAxis_pfe_AllOtherRareDiseaseProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">218</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e8059-wk-Fact-01C7C71AE4C65077B69A2A356736E709" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_RareDiseaseMember_us-gaap_ProductOrServiceAxis_pfe_AllOtherRareDiseaseProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">219</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Consumer Healthcare</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d43771853e8089-wk-Fact-876FA36A390750B09C5C3A6768A26CAE" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_ConsumerHealthcareMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">829</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d43771853e8108-wk-Fact-2B7A9FB3F508549A8C434D1BC267C9DF" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_ConsumerHealthcareMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">798</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d43771853e8128-wk-Fact-800805A59D7956DD8B18DC38E202BCFA" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_ConsumerHealthcareMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,522</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d43771853e8147-wk-Fact-E5DAD62FA91F5B43957002F62E3B847B" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_ConsumerHealthcareMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,457</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">PFIZER ESSENTIAL HEALTH (EH)</span><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(d)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d43771853e8174-wk-Fact-091C801F849C5456B9FD0DC999483C5D" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">5,050</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d43771853e8193-wk-Fact-CA9E5961B1D758D2820894BDF915B4EC" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">5,712</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d43771853e8213-wk-Fact-2C55373A40E0521188DF042ECD16B096" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">15,639</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d43771853e8232-wk-Fact-C8F31244A5485CAB8850FBA2D1B3FB16" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">17,725</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Legacy Established Products (LEP)</span><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(e)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d43771853e8259-wk-Fact-EE748539AE775F7AB4E662FB43CE60E4" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,681</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d43771853e8278-wk-Fact-4207856257675CFDB3EB4159D299660D" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,708</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d43771853e8298-wk-Fact-89988FDDF95F52A4910F81944C0989F3" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">7,995</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d43771853e8317-wk-Fact-9577FDA2F67253B8A7F69BB91B1286ED" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">8,373</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Lipitor</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e8337-wk-Fact-4F7D0A0BF0B3547696F65B90925A51C6" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_LipitorMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">491</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e8356-wk-Fact-C5E580417C255B5A9496B3FDC6855AA2" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_LipitorMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">422</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e8375-wk-Fact-C58A86525FE35C3081B70829D7BE6C7F" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_LipitorMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,341</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e8395-wk-Fact-8D063B8E215F521BA88075E95FC81EF0" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_LipitorMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,294</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Premarin family</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e8420-wk-Fact-14843DFEC83A5E1FA820F208F5B581A0" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_PremarinFamilyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">238</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e8439-wk-Fact-EF1D7C93406B59DAB08DBBCDA794B94C" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_PremarinFamilyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">244</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e8458-wk-Fact-9A540CD7E91C53D98C0A6FA10FC45B37" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_PremarinFamilyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">711</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e8478-wk-Fact-5B0A95DDA6D55C2B93F040732E862770" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_PremarinFamilyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">751</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Norvasc</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e8503-wk-Fact-0329EED4FEA551388AB212092162364A" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_NorvascMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">226</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e8522-wk-Fact-A7080FE1586B5C65A5EAF5CFE4E627BD" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_NorvascMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">238</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e8541-wk-Fact-47FF728D9FBA58A983AF4392C02B9ACA" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_NorvascMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">684</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e8561-wk-Fact-EFEBBDE9757A5676A83DAD10B3D86F3C" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_NorvascMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">714</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">EpiPen</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e8586-wk-Fact-472F881EBECC59D28306B926958946F7" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_EpiPenMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">82</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e8605-wk-Fact-AF2DC9ED10685A39963CB757C976F5D5" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_EpiPenMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">110</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e8624-wk-Fact-2D58F17354D35378BFCD3AD0420F7078" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_EpiPenMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">253</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e8644-wk-Fact-1852BFDBB2515865AE0923F4F1AE42A1" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_EpiPenMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">300</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Xalatan/Xalacom</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e8669-wk-Fact-08437CD1F5145373A32D15ECA655D8F8" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_XalatanXalacomMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">83</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e8688-wk-Fact-7AC6C61132045FAB988619467004F635" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_XalatanXalacomMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">91</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e8707-wk-Fact-99C5FED6B8365B31B1D529DDF43CAD1A" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_XalatanXalacomMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">241</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e8727-wk-Fact-CDBECF1B07C6582DA036B977F1BEA0A8" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_XalatanXalacomMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">273</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Effexor</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e8752-wk-Fact-46F602264FBF5C009D3E0D19A2ADF39E" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_EffexorMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">76</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e8771-wk-Fact-B89A0271EA4B5EC2B44DC1EFA92C2A64" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_EffexorMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">70</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e8790-wk-Fact-F46C5E0C8CB7528B873CE42E32D3A924" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_EffexorMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">215</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e8810-wk-Fact-CDE83E5A2B5253EEBF9FE8AD4E19EFAE" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_EffexorMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">207</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Zoloft</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e8836-wk-Fact-51894A4611925F1481FB10D8D30710CD" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_ZoloftMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">78</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e8855-wk-Fact-1FB983165CB755E4BAA54DA34AA453E4" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_ZoloftMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">72</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e8874-wk-Fact-4E9DE66D1EB65A6DB7D6835507CA8456" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_ZoloftMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">215</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e8894-wk-Fact-B1FF7EE0D7EA5813A45C9F669E2AA9E9" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_ZoloftMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">228</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Zithromax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e8919-wk-Fact-7C63A1EB803858EEB8F3D2778FF33364" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_ZithromaxZmaxMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">61</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e8938-wk-Fact-AF25C8D0B0ED5632AB6C04C50AA8AA34" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_ZithromaxZmaxMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">56</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e8957-wk-Fact-B483F4B999D95F64B9375C52EF0577E9" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_ZithromaxZmaxMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">202</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e8977-wk-Fact-DC5E960BEB09595E8E440E43508EB16C" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_ZithromaxZmaxMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">203</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Relpax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e9002-wk-Fact-83792D6D5C2E51E9A6E69BCF9587E366" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_RelpaxMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">50</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e9021-wk-Fact-6316D660281758D5AB86C9A110286AB6" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_RelpaxMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">83</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e9040-wk-Fact-1AE5F92DFF9551489544871F0B38FF8E" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_RelpaxMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">193</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e9060-wk-Fact-D50DD10668A95FA2969BB39F2080B0CD" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_RelpaxMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">248</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Xanax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e9085-wk-Fact-2EAD78360E6D57E599307914B8AF4D6B" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_XanaxXanaxXRMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">58</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e9104-wk-Fact-75B41DCF45805CAFAD944707054CC12E" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_XanaxXanaxXRMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">55</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e9123-wk-Fact-EF12303BC8E9530A8CF9F8DDCD1E93B7" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_XanaxXanaxXRMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">164</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e9143-wk-Fact-575289DA5DFE59458CF75A39F1D0183F" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_XanaxXanaxXRMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">163</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">All other LEP</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e9168-wk-Fact-067FA3EE0C9C5D5B8E26BE6B521AC0C8" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_OtherLegacyEstablishedProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,237</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e9187-wk-Fact-C237E2DC723D59E1968237F06BF3B3F7" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_OtherLegacyEstablishedProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,268</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e9206-wk-Fact-8964D9DAE58D5D5493AE61BE40FF32D1" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_OtherLegacyEstablishedProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,776</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e9226-wk-Fact-5A218722537F5902999ED660D7E8DC78" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_OtherLegacyEstablishedProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,992</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Sterile Injectable Pharmaceuticals (SIP)</span><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(f)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d43771853e9258-wk-Fact-CD1BFB65FFF5532B973C2FBCB7BE8C3E" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_SterileInjectablePharmaceuticalsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,273</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d43771853e9277-wk-Fact-AD73F3732CE450B3B05C9A766AE2063A" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_SterileInjectablePharmaceuticalsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,461</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d43771853e9297-wk-Fact-61AE31A35DC45F109F24557407C6BF9E" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_SterileInjectablePharmaceuticalsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4,270</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d43771853e9316-wk-Fact-BD8207C538F258AB9385CEC1E820D409" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_SterileInjectablePharmaceuticalsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4,481</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Medrol</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e9336-wk-Fact-BEB835E7E1605E8FADA0A2A97E3A6888" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_SterileInjectablePharmaceuticalsMember_us-gaap_ProductOrServiceAxis_pfe_MedrolMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">109</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e9355-wk-Fact-673B8C7C812E5410B44343DF17426FF6" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_SterileInjectablePharmaceuticalsMember_us-gaap_ProductOrServiceAxis_pfe_MedrolMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">102</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e9374-wk-Fact-954F0556430B59A3BD2C5F259E64EA5E" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_SterileInjectablePharmaceuticalsMember_us-gaap_ProductOrServiceAxis_pfe_MedrolMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">352</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e9394-wk-Fact-69D44FAD9EB45BA48306018AA309F457" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_SterileInjectablePharmaceuticalsMember_us-gaap_ProductOrServiceAxis_pfe_MedrolMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">330</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Sulperazon</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e9419-wk-Fact-3408B775D7DC5296953F514B51FF23A8" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_SterileInjectablePharmaceuticalsMember_us-gaap_ProductOrServiceAxis_pfe_SulperazonMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">114</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e9438-wk-Fact-78DF62543AFC55BB97CA930C8853E5B5" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_SterileInjectablePharmaceuticalsMember_us-gaap_ProductOrServiceAxis_pfe_SulperazonMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">102</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e9457-wk-Fact-43E76B4E175C5BBCAE82C132443F1E2F" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_SterileInjectablePharmaceuticalsMember_us-gaap_ProductOrServiceAxis_pfe_SulperazonMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">345</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e9477-wk-Fact-1986CF96884B543DB3761C2BDAA8CFE5" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_SterileInjectablePharmaceuticalsMember_us-gaap_ProductOrServiceAxis_pfe_SulperazonMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">304</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Fragmin</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e9502-wk-Fact-403E9BF3AE335295948677D8AA616270" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_SterileInjectablePharmaceuticalsMember_us-gaap_ProductOrServiceAxis_pfe_FragminMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">79</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e9521-wk-Fact-4E72A888DC875E13A10C3DCAD6E412A8" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_SterileInjectablePharmaceuticalsMember_us-gaap_ProductOrServiceAxis_pfe_FragminMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">80</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e9540-wk-Fact-74390EB852125F548009578A70D131E9" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_SterileInjectablePharmaceuticalsMember_us-gaap_ProductOrServiceAxis_pfe_FragminMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">221</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e9560-wk-Fact-622A4C714FC9589A8791D825723DCF5F" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_SterileInjectablePharmaceuticalsMember_us-gaap_ProductOrServiceAxis_pfe_FragminMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">240</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Tygacil</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e9585-wk-Fact-859AF1BEC09351F687B1AC1130ACF600" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_SterileInjectablePharmaceuticalsMember_us-gaap_ProductOrServiceAxis_pfe_TygacilMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">60</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e9604-wk-Fact-D75DA6B18B2450C5B56DFECFB5E6CC70" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_SterileInjectablePharmaceuticalsMember_us-gaap_ProductOrServiceAxis_pfe_TygacilMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">69</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e9623-wk-Fact-152A91A936FD53EB814D9C05B28228DF" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_SterileInjectablePharmaceuticalsMember_us-gaap_ProductOrServiceAxis_pfe_TygacilMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">192</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e9643-wk-Fact-8E39861200715A3B876182637BDF6124" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_SterileInjectablePharmaceuticalsMember_us-gaap_ProductOrServiceAxis_pfe_TygacilMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">203</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Precedex</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e9668-wk-Fact-5C552D20D9EC501BA74A6B22B7F14C7F" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_SterileInjectablePharmaceuticalsMember_us-gaap_ProductOrServiceAxis_pfe_PrecedexMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">51</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e9687-wk-Fact-5FF89D5E27D551B98A5B9037DCB462D8" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_SterileInjectablePharmaceuticalsMember_us-gaap_ProductOrServiceAxis_pfe_PrecedexMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">64</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e9706-wk-Fact-9F35AC92683F55728D31E5B3DDD103DA" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_SterileInjectablePharmaceuticalsMember_us-gaap_ProductOrServiceAxis_pfe_PrecedexMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">182</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e9726-wk-Fact-125AA1D3DEF35DC883411C795FBF77FB" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_SterileInjectablePharmaceuticalsMember_us-gaap_ProductOrServiceAxis_pfe_PrecedexMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">199</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">All other SIP</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e9752-wk-Fact-714ED3F1767956A495B34EBF44362035" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_SterileInjectablePharmaceuticalsMember_us-gaap_ProductOrServiceAxis_pfe_AllOtherSterileInjectablePharmaceuticalsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">860</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e9771-wk-Fact-15D8B9658D3D54ACA6557E0E44C871AF" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_SterileInjectablePharmaceuticalsMember_us-gaap_ProductOrServiceAxis_pfe_AllOtherSterileInjectablePharmaceuticalsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,044</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e9790-wk-Fact-222AA9D4DB3258FE856F943CB208455D" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_SterileInjectablePharmaceuticalsMember_us-gaap_ProductOrServiceAxis_pfe_AllOtherSterileInjectablePharmaceuticalsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,977</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e9810-wk-Fact-88105E4607635686BD1EA55E2ADC180D" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_SterileInjectablePharmaceuticalsMember_us-gaap_ProductOrServiceAxis_pfe_AllOtherSterileInjectablePharmaceuticalsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,206</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"></td></tr><tr><td style="width:48%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Nine Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">October&#160;1, <br/>2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">October&#160;2, <br/>2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">October&#160;1, <br/>2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">October&#160;2, <br/>2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Peri-LOE Products</span><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(g)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d43771853e10035-wk-Fact-9E503F48EBD8524C93A07C83B1436882" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">794</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d43771853e10054-wk-Fact-0FBFE9A681A053E09C98AD1EEF2EAB26" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,023</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d43771853e10074-wk-Fact-A9C11CFF51AD52A5B91FCAB3F6F3901C" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,398</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d43771853e10093-wk-Fact-A3F1EC328F9650DFB210D8224644F83E" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,224</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Celebrex</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e10113-wk-Fact-128EA3181C745B7C8B9F3EC94CB87020" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_ProductOrServiceAxis_pfe_CelebrexMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">212</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e10132-wk-Fact-76A22FA87A9C500D8F6C27B6C096BCF0" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_ProductOrServiceAxis_pfe_CelebrexMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">194</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e10151-wk-Fact-BC3627280B1A54C895E1CCB4F8E7B930" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_ProductOrServiceAxis_pfe_CelebrexMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">564</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e10171-wk-Fact-CE2EF9820ED6573A94D07A737EFDBC56" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_ProductOrServiceAxis_pfe_CelebrexMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">550</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Lyrica EH</span><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e10198-wk-Fact-232A214804B055189EC1111DA289CA2D" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_ProductOrServiceAxis_pfe_LyricaMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">134</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e10217-wk-Fact-CD0D167B7BFA55D3B52DA395AB1BD7B8" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_ProductOrServiceAxis_pfe_LyricaMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">191</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e10236-wk-Fact-67696AFA82F051C9ADF09241496CA1F1" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_ProductOrServiceAxis_pfe_LyricaMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">428</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e10256-wk-Fact-65EF603C04E95A788234DDAF3AC7D0D3" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_ProductOrServiceAxis_pfe_LyricaMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">623</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Vfend</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e10281-wk-Fact-6C9EAD1F0865512985D7C5705407E063" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_ProductOrServiceAxis_pfe_VfendMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">97</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e10300-wk-Fact-AEAD728E1868528B913D4433CA55D5AE" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_ProductOrServiceAxis_pfe_VfendMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">140</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e10319-wk-Fact-5A0A99EB245E547A975A8CBE45563188" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_ProductOrServiceAxis_pfe_VfendMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">305</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e10339-wk-Fact-0CF2265B71BC58559A7EB169A8902FD7" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_ProductOrServiceAxis_pfe_VfendMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">459</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Viagra EH</span><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e10366-wk-Fact-C9F9F4BF1A82536D95AD4E1D85276729" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_ProductOrServiceAxis_pfe_ViagraMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">102</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e10385-wk-Fact-A18BC4FC7BA15BDA9B32041CAF276842" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_ProductOrServiceAxis_pfe_ViagraMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">89</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e10404-wk-Fact-2E5C7379161F5F76A0E97E4215BB339F" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_ProductOrServiceAxis_pfe_ViagraMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">285</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e10424-wk-Fact-9814D8F2526C58C48FBE9FC9B3F3314B" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_ProductOrServiceAxis_pfe_ViagraMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">286</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Pristiq</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e10449-wk-Fact-CDC4B9988F0A5B9ABCDFB0E4C7C96002" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_ProductOrServiceAxis_pfe_PristiqMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">69</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e10468-wk-Fact-37776A41FA8E5495A56B3404B197B61E" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_ProductOrServiceAxis_pfe_PristiqMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">174</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e10487-wk-Fact-0AAF81ED405D54CB9351BC4158188A30" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_ProductOrServiceAxis_pfe_PristiqMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">230</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e10507-wk-Fact-697283B80FF25DA8A92A5D902E7974C8" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_ProductOrServiceAxis_pfe_PristiqMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">546</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Zyvox</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e10532-wk-Fact-93B0D8808B855B85B6799ED23B3D6A0C" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_ProductOrServiceAxis_pfe_ZyvoxMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">68</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e10551-wk-Fact-97EFE3A796625669A1D8CCFBFD64954D" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_ProductOrServiceAxis_pfe_ZyvoxMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">94</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e10570-wk-Fact-3DFE2FB0892756F5AFED545B4B3F952D" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_ProductOrServiceAxis_pfe_ZyvoxMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">220</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e10590-wk-Fact-3C1421C03069507CA00F4331282370F7" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_ProductOrServiceAxis_pfe_ZyvoxMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">334</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Revatio</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e10615-wk-Fact-8007345A7AB456A7B0B97A5A65AB7E48" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_ProductOrServiceAxis_pfe_RevatioMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">58</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e10634-wk-Fact-E272C0172CA95773BCC48C38040FBE95" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_ProductOrServiceAxis_pfe_RevatioMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">73</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e10653-wk-Fact-C29FBDB6D43757AABB17FED9EE891C54" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_ProductOrServiceAxis_pfe_RevatioMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">189</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e10673-wk-Fact-FC0215B9880A51BFBED6DCD05771EFAD" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_ProductOrServiceAxis_pfe_RevatioMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">213</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">All other Peri-LOE Products</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e10698-wk-Fact-A4F065E7CDE652B48F4562665548B6C6" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_ProductOrServiceAxis_pfe_AllOtherPeriLOEProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">55</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e10717-wk-Fact-7351A8567C2250DDBB54A13E3D7EEC46" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_ProductOrServiceAxis_pfe_AllOtherPeriLOEProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">68</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e10736-wk-Fact-B7F63A35B709523BAEB3AA24F46E256E" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_ProductOrServiceAxis_pfe_AllOtherPeriLOEProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">176</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e10756-wk-Fact-BCC18CBF49805065B56F06ED03FED531" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_ProductOrServiceAxis_pfe_AllOtherPeriLOEProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">214</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Biosimilars</span><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(h)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d43771853e10789-wk-Fact-C004A733FEAB52B8AE0B44F23C300539" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_BiosimilarsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">141</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d43771853e10808-wk-Fact-F17AE8BADCC4517B9C333EAD88E5DA8B" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_BiosimilarsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">83</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d43771853e10828-wk-Fact-79FA16521B14520887AA9A50CD9012A4" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_BiosimilarsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">367</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d43771853e10847-wk-Fact-CDE473F11CA35CD29DE23110EB7E3FEF" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_BiosimilarsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">228</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Inflectra/Remsima</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e10867-wk-Fact-269C5F3BDCF15ACE94261F539A3FF18E" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_BiosimilarsMember_us-gaap_ProductOrServiceAxis_pfe_InflectraRemsimaMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">112</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e10886-wk-Fact-A083D570556F5EF4A97874779BE8F39E" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_BiosimilarsMember_us-gaap_ProductOrServiceAxis_pfe_InflectraRemsimaMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">49</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e10905-wk-Fact-996D10C069CD5795A87BD6E87F80A5B8" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_BiosimilarsMember_us-gaap_ProductOrServiceAxis_pfe_InflectraRemsimaMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">284</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e10925-wk-Fact-55A6F1204F945EF892559AE70BC96F62" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_BiosimilarsMember_us-gaap_ProductOrServiceAxis_pfe_InflectraRemsimaMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">130</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">All other Biosimilars</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e10950-wk-Fact-6CD3D18717EA5328937165998A7EF664" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_BiosimilarsMember_us-gaap_ProductOrServiceAxis_pfe_AllOtherBiosimilarsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">28</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e10969-wk-Fact-C37C5D32B0CF5A9EBB9E3E5724373EEA" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_BiosimilarsMember_us-gaap_ProductOrServiceAxis_pfe_AllOtherBiosimilarsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">34</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e10988-wk-Fact-2F825759B42459E4904B3140974BF299" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_BiosimilarsMember_us-gaap_ProductOrServiceAxis_pfe_AllOtherBiosimilarsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">82</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d43771853e11008-wk-Fact-22DE19FCF9B952DFA1EEF3D418C48472" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_BiosimilarsMember_us-gaap_ProductOrServiceAxis_pfe_AllOtherBiosimilarsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">97</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Pfizer CentreOne</span><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(i)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d43771853e11040-wk-Fact-3478C9FA86F457899DC079177D757215" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_CentreOneMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">161</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d43771853e11059-wk-Fact-E71ECFC84ED058A1982578968151CD88" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_CentreOneMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">156</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d43771853e11079-wk-Fact-3E9CA6EB4A915AFF8A6FCEB98114AB68" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_CentreOneMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">514</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d43771853e11098-wk-Fact-19D08708847D5BDEAC5A5C81A5DC8E05" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_CentreOneMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">540</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Hospira Infusion Systems (HIS)</span><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(j)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d43771853e11125-wk-Fact-E5DEE2763FF15719B07579F02111EFC3" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_HospiraInfusionSystemsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d43771853e11144-wk-Fact-473A8153DB95559E92CC6D9F938E0BCE" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_HospiraInfusionSystemsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">281</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d43771853e11164-wk-Fact-15783BA6644A5B24968CE32B5F022A68" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_HospiraInfusionSystemsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">97</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d43771853e11183-wk-Fact-A931585378205E5DA65545918DAAB331" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_HospiraInfusionSystemsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">879</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d43771853e11208-wk-Fact-9C752BB75A1455A0AF6ABEFA57EBB1AF" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3QTD_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthandEssentialHealthMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">13,168</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d43771853e11227-wk-Fact-6B7BF854C7B35BE4A47B37F76C73D8AC" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3QTD_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthandEssentialHealthMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">13,045</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d43771853e11247-wk-Fact-5F4B94C0B26E57A2859AEDD6C1C81FB5" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3YTD_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthandEssentialHealthMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">38,843</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d43771853e11266-wk-Fact-DA5D9362F04050B1B725050577F60279" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3YTD_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthandEssentialHealthMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">39,196</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total Lyrica</span><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d43771853e11380-wk-Fact-442B1474BBCB5FE8A099D633CB680650" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3QTD_us-gaap_ProductOrServiceAxis_pfe_LyricaMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthandEssentialHealthMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,285</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d43771853e11399-wk-Fact-B6E115CC3E7858DCA9A85E0C1738396B" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3QTD_us-gaap_ProductOrServiceAxis_pfe_LyricaMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthandEssentialHealthMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,240</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d43771853e11419-wk-Fact-6313B867BAC65FC1A4718632BEF06E26" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3YTD_us-gaap_ProductOrServiceAxis_pfe_LyricaMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthandEssentialHealthMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,810</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d43771853e11438-wk-Fact-000B2C159A9A57D09032E22544108F38" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3YTD_us-gaap_ProductOrServiceAxis_pfe_LyricaMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthandEssentialHealthMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,730</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total Viagra</span><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d43771853e11465-wk-Fact-A8CAE70BC2A35982B714238C0AC51A79" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3QTD_us-gaap_ProductOrServiceAxis_pfe_ViagraMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthandEssentialHealthMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">308</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d43771853e11484-wk-Fact-5F6DD21DF11E5B29871B857CC403739A" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3QTD_us-gaap_ProductOrServiceAxis_pfe_ViagraMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthandEssentialHealthMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">387</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d43771853e11504-wk-Fact-16FFF27FA1865523A99E7DB32984FAAA" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3YTD_us-gaap_ProductOrServiceAxis_pfe_ViagraMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthandEssentialHealthMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">996</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d43771853e11523-wk-Fact-A70792548E685ABAA23DB0FA57120893" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3YTD_us-gaap_ProductOrServiceAxis_pfe_ViagraMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthandEssentialHealthMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,183</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total Alliance revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d43771853e11548-wk-Fact-6D99D5C969795D1F87806F4E86EF0727" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3QTD_us-gaap_ProductOrServiceAxis_pfe_AllianceBiopharmaceuticalsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthandEssentialHealthMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">741</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d43771853e11567-wk-Fact-6BEE3DC90D785FB89CD0E73CF1AA35E3" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3QTD_us-gaap_ProductOrServiceAxis_pfe_AllianceBiopharmaceuticalsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthandEssentialHealthMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">419</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d43771853e11587-wk-Fact-A5238AF29D395849A330587872DA06CE" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q3YTD_us-gaap_ProductOrServiceAxis_pfe_AllianceBiopharmaceuticalsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthandEssentialHealthMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,112</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d43771853e11606-wk-Fact-8F4D63311073516AAC8FFE78BBAC2211" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q3YTD_us-gaap_ProductOrServiceAxis_pfe_AllianceBiopharmaceuticalsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthandEssentialHealthMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,155</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></ix:nonNumeric></div><ix:continuation id="TextSelection-49D25731B86F528799C83F48EBAD14A9-1" continuedAt="TextSelection-49D25731B86F528799C83F48EBAD14A9-2"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><ix:footnote id="TextSelection-84795AFB20AD54C48C963C7C52B00178-0-wk-Footnote-84795AFB20AD54C48C963C7C52B00178_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US">The IH business encompasses Internal Medicine, Vaccines, Oncology, Inflammation &amp; Immunology, Rare Disease and Consumer Healthcare. Through December 31, 2016, includes Duavive/Duavee and Viviant (recorded in All other Internal Medicine in 2016), which were transferred from Innovative Health to Essential Health effective January 1, 2017 (recorded in All other LEP (EH) beginning January 1, 2017), in order to align these products with our management of the women&#8217;s health portfolio within EH. </ix:footnote></span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><ix:footnote id="TextSelection-DE7EF4A6663E52BF8D3620854A57A945-0-wk-Footnote-DE7EF4A6663E52BF8D3620854A57A945_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US">Lyrica revenues from all of Europe, Russia, Turkey, Israel and Central Asia countries are included in Lyrica EH. All other Lyrica revenues are included in Lyrica IH. Total Lyrica revenues represent the aggregate of worldwide revenues from Lyrica IH and Lyrica EH. </ix:footnote></span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><ix:footnote id="TextSelection-450A7304FB7E513FB479F6D9A06EF1D3-0-wk-Footnote-450A7304FB7E513FB479F6D9A06EF1D3_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US">Viagra revenues from the U.S. and Canada are included in Viagra IH. All other Viagra revenues are included in Viagra EH. Total Viagra revenues represent the aggregate of worldwide revenues from Viagra IH and Viagra EH. </ix:footnote></span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(d)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><ix:footnote id="TextSelection-B88EBF1DF3CD5B06AADA1AA5E249F160-0-wk-Footnote-B88EBF1DF3CD5B06AADA1AA5E249F160_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US">The EH business encompasses Legacy Established Products, Sterile Injectable Pharmaceuticals, Peri-LOE Products, Biosimilars, Pfizer CentreOne and HIS (through February 2, 2017) and includes all legacy Hospira commercial operations.</ix:footnote></span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(e)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><ix:footnote id="TextSelection-C4FFB7FEB33B5D5EBA7924687B243323-0-wk-Footnote-C4FFB7FEB33B5D5EBA7924687B243323_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" continuedAt="TextSelection-C4FFB7FEB33B5D5EBA7924687B243323-1">Legacy Established Products primarily include products that have lost patent protection (excluding Sterile Injectable Pharmaceuticals and Peri-LOE Products). Effective January 1, 2017, All other LEP includes Duavive/Duavee and Viviant, which were transferred from Innovative Health (recorded in All other Internal Medicine (IH) in 2016), in order to align these products with our management of the women&#8217;s health portfolio within EH.</ix:footnote></span><ix:continuation id="TextSelection-C4FFB7FEB33B5D5EBA7924687B243323-1" continuedAt="TextSelection-C4FFB7FEB33B5D5EBA7924687B243323-2"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt"> </sup></span></ix:continuation><span style="font-family:inherit;font-size:8pt;"><ix:continuation id="TextSelection-C4FFB7FEB33B5D5EBA7924687B243323-2">See note (a) above.</ix:continuation></span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(f) </sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><ix:footnote id="TextSelection-08466783230155A08D7C13267B950D39-0-wk-Footnote-08466783230155A08D7C13267B950D39_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US">Sterile Injectable Pharmaceuticals include generic injectables and proprietary specialty injectables (excluding Peri-LOE Products). </ix:footnote></span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(g)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><ix:footnote id="TextSelection-3AE2F5A9070951C0ACDF4F146E825D8D-0-wk-Footnote-3AE2F5A9070951C0ACDF4F146E825D8D_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US">Peri-LOE Products include products that have recently lost or are anticipated to soon lose patent protection. These products include: Lyrica in Europe, Russia, Turkey, Israel and Central Asia; Viagra in all countries (excluding the U.S. and Canada); and worldwide revenues for Celebrex, Pristiq, Zyvox, Vfend, Revatio and Inspra. </ix:footnote></span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(h)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><ix:footnote id="TextSelection-A685A65E160C5D228F531BF7107B3DF7-0-wk-Footnote-A685A65E160C5D228F531BF7107B3DF7_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US">Biosimilars include Inflectra/Remsima (biosimilar infliximab) in the U.S. and certain international markets, Nivestim (biosimilar filgrastim) in certain European, Asian and Africa/Middle Eastern markets and Retacrit (biosimilar epoetin zeta) in certain European and Africa/Middle Eastern markets. </ix:footnote></span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(i)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><ix:footnote id="TextSelection-7266C8E6B8975A65A379AF3B415EA220-0-wk-Footnote-7266C8E6B8975A65A379AF3B415EA220_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US">Pfizer CentreOne includes revenues from our contract manufacturing and active pharmaceutical ingredient sales operation, including sterile injectables contract manufacturing, and revenues related to our manufacturing and supply agreements, including with Zoetis. </ix:footnote></span></div></td></tr></table></ix:continuation></ix:continuation><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><ix:continuation id="TextSelection-49D25731B86F528799C83F48EBAD14A9-2" continuedAt="TextSelection-49D25731B86F528799C83F48EBAD14A9-3"><ix:continuation id="TextSelection-B389BD5A47A85F2CB2DBBB9DF9010D7E-7" continuedAt="TextSelection-B389BD5A47A85F2CB2DBBB9DF9010D7E-8"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(j)</sup>&#160;</span></div></ix:continuation></ix:continuation></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><ix:continuation id="TextSelection-49D25731B86F528799C83F48EBAD14A9-3" continuedAt="TextSelection-49D25731B86F528799C83F48EBAD14A9-4"><span style="font-family:inherit;font-size:8pt;"><ix:continuation id="TextSelection-B389BD5A47A85F2CB2DBBB9DF9010D7E-8"><ix:footnote id="TextSelection-ED6F6E1A7C41596DA6F5B1BDFBB72CB7-0-wk-Footnote-ED6F6E1A7C41596DA6F5B1BDFBB72CB7_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" continuedAt="TextSelection-ED6F6E1A7C41596DA6F5B1BDFBB72CB7-1">HIS (through February 2, 2017) includes Medication Management Systems products composed of infusion pumps and related software and services, as well as IV Infusion Products, including large volume IV solutions and their associated administration sets.</ix:footnote></ix:continuation></span></ix:continuation><ix:continuation id="TextSelection-ED6F6E1A7C41596DA6F5B1BDFBB72CB7-1" continuedAt="TextSelection-ED6F6E1A7C41596DA6F5B1BDFBB72CB7-2"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt"><ix:continuation id="TextSelection-49D25731B86F528799C83F48EBAD14A9-4"> </ix:continuation></sup>&#160;</span></ix:continuation></div></td></tr></table><div style="line-height:120%;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><ix:continuation id="TextSelection-ED6F6E1A7C41596DA6F5B1BDFBB72CB7-2"><br/></ix:continuation></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">44</span></div></div><hr style="page-break-after:always"></hr><div><a id="sBB668BD2FD6757FAB81DE0B6ECF0E369"></a></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">REVIEW REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">To the Board of Directors and Shareholders of Pfizer Inc.:</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have reviewed the condensed consolidated balance sheet of Pfizer Inc. and Subsidiary Companies as of </span><span style="font-family:inherit;font-size:10pt;">October&#160;1, 2017</span><span style="font-family:inherit;font-size:10pt;">, the related condensed consolidated statements of income and comprehensive income for the </span><span style="font-family:inherit;font-size:10pt;">three-month and nine-month</span><span style="font-family:inherit;font-size:10pt;"> periods ended </span><span style="font-family:inherit;font-size:10pt;">October&#160;1, 2017</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">October&#160;2, 2016</span><span style="font-family:inherit;font-size:10pt;">, and the related condensed consolidated statements of cash flows for the </span><span style="font-family:inherit;font-size:10pt;">nine</span><span style="font-family:inherit;font-size:10pt;">-month periods ended </span><span style="font-family:inherit;font-size:10pt;">October&#160;1, 2017</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">October&#160;2, 2016</span><span style="font-family:inherit;font-size:10pt;">. These condensed consolidated financial statements are the responsibility of the Company&#8217;s management.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We conducted our reviews in accordance with the standards of the Public Company Accounting Oversight Board (United States). A review of interim financial information consists principally of applying analytical procedures and making inquiries of persons responsible for financial and accounting matters. It is substantially less in scope than an audit conducted in accordance with the standards of the Public Company Accounting Oversight Board (United States), the objective of which is the expression of an opinion regarding the financial statements taken as a whole. Accordingly, we do not express such an opinion.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Based on our reviews, we are not aware of any material modifications that should be made to the condensed consolidated financial statements referred to above for them to be in conformity with U.S. generally accepted accounting principles.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have previously audited, in accordance with standards of the Public Company Accounting Oversight Board (United States), the consolidated balance sheet of Pfizer Inc. and Subsidiary Companies as of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">December&#160;31, 2016</span><span style="font-family:inherit;font-size:10pt;">, and the related consolidated statements of income, comprehensive income, equity, and cash flows for the year then ended (not presented herein); and in our report dated February 23, 2017, we expressed an unqualified opinion on those consolidated financial statements. In our opinion, the information set forth in the accompanying condensed consolidated balance sheet as of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">December&#160;31, 2016</span><span style="font-family:inherit;font-size:10pt;">, is fairly stated, in all material respects, in relation to the consolidated balance sheet from which it has been derived.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">/s/ KPMG LLP</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">New York, New York</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">November&#160;9, 2017</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">45</span></div></div><hr style="page-break-after:always"></hr><div><a id="s2926C9EA133E5195B31D60243BE7C0E8"></a></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:inherit;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Introduction</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:inherit;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">See the Glossary of Defined Terms at the beginning of this Quarterly Report on Form 10-Q for terms used throughout this MD&amp;A. Our MD&amp;A is provided in addition to the accompanying condensed consolidated financial statements and footnotes to assist readers in understanding Pfizer&#8217;s results of operations, financial condition and cash flows. The MD&amp;A is organized as follows:</span></div><div style="line-height:100%;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:91.61793372319687%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:3%;"></td><td style="width:19%;"></td><td style="width:19%;"></td><td style="width:19%;"></td><td style="width:20%;"></td><td style="width:20%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">&#9679;</span></div></td><td colspan="4" style="vertical-align:top;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-style:italic;" href="#sF029A89915B4508184BCC9C90C1844D4"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Overview of Our Performance, Operating Environment, Strategy and Outlook</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:6px;text-align:left;padding-left:20px;text-indent:-18px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Beginning on page </span><a style="font-family:inherit;font-size:9pt;" href="#sF029A89915B4508184BCC9C90C1844D4">48</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="4" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:6px;text-align:left;padding-left:6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">This section provides information about the following: Our Business; our performance during the third quarter and first nine months of 2017 and 2016; Our Operating Environment; the Global Economic Environment; Our Strategy; Our Business Development Initiatives, such as acquisitions, dispositions, licensing and collaborations; and Our Financial Guidance for 2017.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">&#9679;</span></div></td><td colspan="4" style="vertical-align:top;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-style:italic;" href="#s45751624BA2157C6BBB36A7582911BD4"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Analysis of the Condensed Consolidated Statements of Income</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:6px;text-align:left;padding-left:20px;text-indent:-18px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Beginning on page </span><a style="font-family:inherit;font-size:9pt;" href="#s45751624BA2157C6BBB36A7582911BD4">61</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="4" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:2px;text-align:left;padding-left:6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">This section includes a Revenues Overview section as well as the following sub-sections:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="4" style="vertical-align:top;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">&#9675;  </span><a style="font-family:inherit;font-size:9pt;font-style:italic;" href="#sD97A667603A15DFDA860B7B812AE9A1F"><span style="font-family:inherit;font-size:9pt;font-style:italic;">Revenues - Major Products</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:6px;text-align:left;padding-left:20px;text-indent:-18px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Beginning on page </span><a style="font-family:inherit;font-size:9pt;" href="#sD97A667603A15DFDA860B7B812AE9A1F">65</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="4" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">This sub-section provides revenue information for several of our major biopharmaceutical products.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="4" style="vertical-align:top;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">&#9675;  </span><a style="font-family:inherit;font-size:9pt;font-style:italic;" href="#s6B8DFD9149F05D9CA471F47B21AD6A0E"><span style="font-family:inherit;font-size:9pt;font-style:italic;">Revenues - Selected Product Discussion</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:6px;text-align:left;padding-left:20px;text-indent:-18px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Beginning on page </span><a style="font-family:inherit;font-size:9pt;" href="#s6B8DFD9149F05D9CA471F47B21AD6A0E">66</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="4" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:2px;text-align:left;padding-left:18px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">This sub-section provides an overview of several of our biopharmaceutical products.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="4" style="vertical-align:top;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">&#9675;  </span><a style="font-family:inherit;font-size:9pt;font-style:italic;" href="#s2BFD6D3D3CD754148223A9AB3679D20C"><span style="font-family:inherit;font-size:9pt;font-style:italic;">Product Developments - Biopharmaceutical</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:6px;text-align:left;padding-left:20px;text-indent:-18px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Beginning on page </span><a style="font-family:inherit;font-size:9pt;" href="#s2BFD6D3D3CD754148223A9AB3679D20C">70</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="4" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:2px;text-align:left;padding-left:18px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">This sub-section provides an overview of important biopharmaceutical product developments.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="4" style="vertical-align:top;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">&#9675;  </span><a style="font-family:inherit;font-size:9pt;font-style:italic;" href="#s2179814CB9C85A8B94FB08DE76D4759A"><span style="font-family:inherit;font-size:9pt;font-style:italic;">Costs and Expenses</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:6px;text-align:left;padding-left:20px;text-indent:-18px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Beginning on page </span><a style="font-family:inherit;font-size:9pt;" href="#s2179814CB9C85A8B94FB08DE76D4759A">74</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="4" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:2px;text-align:left;padding-left:18px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">This sub-section provides a discussion about our costs and expenses.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="4" style="vertical-align:top;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">&#9675;  </span><a style="font-family:inherit;font-size:9pt;font-style:italic;" href="#sA8822C064F8F5AE195BA202652A841BF"><span style="font-family:inherit;font-size:9pt;font-style:italic;">Provision for Taxes on Income</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:6px;text-align:left;padding-left:20px;text-indent:-18px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Beginning on page </span><a style="font-family:inherit;font-size:9pt;" href="#sA8822C064F8F5AE195BA202652A841BF">77</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="4" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:2px;text-align:left;padding-left:18px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">This sub-section provides a discussion of items impacting our tax provisions.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="4" style="vertical-align:top;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">&#9675;  </span><a style="font-family:inherit;font-size:9pt;font-style:italic;" href="#s3C0BFA4C74CE550E91A50ED257324087"><span style="font-family:inherit;font-size:9pt;font-style:italic;">Non-GAAP Financial Measure (Adjusted Income)</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:6px;text-align:left;padding-left:20px;text-indent:-18px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Beginning on page </span><a style="font-family:inherit;font-size:9pt;" href="#s3C0BFA4C74CE550E91A50ED257324087">77</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="4" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">This sub-section provides a discussion of an alternative view of performance used by management.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">&#9679;</span></div></td><td colspan="4" style="vertical-align:top;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-style:italic;" href="#s15F891AFE08253819D038C61D95785A8"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Analysis of Operating Segment Information</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:6px;text-align:left;padding-left:20px;text-indent:-18px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Beginning on page </span><a style="font-family:inherit;font-size:9pt;" href="#s15F891AFE08253819D038C61D95785A8">83</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="4" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:2px;text-align:left;padding-left:6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">This section provides a discussion of the performance of each of our operating segments.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">&#9679;</span></div></td><td colspan="4" style="vertical-align:top;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-style:italic;" href="#s2FF4E53953D350ADB2D08E40585E2272"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Analysis of the Condensed Consolidated Statements of Comprehensive Income</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:6px;text-align:left;padding-left:20px;text-indent:-18px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Beginning on page </span><a style="font-family:inherit;font-size:9pt;" href="#s2FF4E53953D350ADB2D08E40585E2272">91</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="4" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:6px;text-align:left;padding-left:6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">This section provides a discussion of changes in certain components of other comprehensive income.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">&#9679;</span></div></td><td colspan="4" style="vertical-align:top;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-style:italic;" href="#s5154C7B97FDA5D58928BFB0822485FAE"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Analysis of the Condensed Consolidated Balance Sheets</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:6px;text-align:left;padding-left:20px;text-indent:-18px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Beginning on page </span><a style="font-family:inherit;font-size:9pt;" href="#s5154C7B97FDA5D58928BFB0822485FAE">91</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="4" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">This section provides a discussion of changes in certain balance sheet accounts.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">&#9679;</span></div></td><td colspan="4" style="vertical-align:top;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-style:italic;" href="#s0917392EAE535D7886A17489CA4C92F0"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Analysis of the Condensed Consolidated Statements of Cash Flows</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:6px;text-align:left;padding-left:20px;text-indent:-18px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Beginning on page </span><a style="font-family:inherit;font-size:9pt;" href="#s0917392EAE535D7886A17489CA4C92F0">93</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="4" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:6px;text-align:left;padding-left:6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">This section provides an analysis of our cash flows for the first nine months of 2017 and 2016.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">&#9679;</span></div></td><td colspan="4" style="vertical-align:top;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-style:italic;" href="#s159FC01B225C5423B0D3AED815336F77"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Analysis of Financial Condition, Liquidity and Capital Resources</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:6px;text-align:left;padding-left:20px;text-indent:-18px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Beginning on page </span><a style="font-family:inherit;font-size:9pt;" href="#s159FC01B225C5423B0D3AED815336F77">94</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="4" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:6px;text-align:left;padding-left:6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">This section provides an analysis of selected measures of our liquidity and of our capital resources as of October 1, 2017 and December 31, 2016, as well as a discussion of our outstanding debt and other commitments that existed as of October 1, 2017 and December 31, 2016. Included in the discussion of outstanding debt is a discussion of the amount of financial capacity available to help fund Pfizer&#8217;s future activities.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">&#9679;</span></div></td><td colspan="4" style="vertical-align:top;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-style:italic;" href="#sA4DEFCE48A195AF1AD518A8476FA723F"><span style="font-family:inherit;font-size:10pt;font-style:italic;">New Accounting Standards</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:6px;text-align:left;padding-left:20px;text-indent:-18px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Beginning on page </span><a style="font-family:inherit;font-size:9pt;" href="#sA4DEFCE48A195AF1AD518A8476FA723F">98</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="4" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">This section discusses accounting standards that we have recently adopted, as well as those that recently have been issued, but not yet adopted.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">&#9679;</span></div></td><td colspan="4" style="vertical-align:top;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-style:italic;" href="#s4FE0014CA34F51B9AA531DBEE26FF435"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Forward-Looking Information and Factors That May Affect Future Results</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:6px;text-align:left;padding-left:20px;text-indent:-18px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Beginning on page </span><a style="font-family:inherit;font-size:9pt;" href="#s4FE0014CA34F51B9AA531DBEE26FF435">102</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="4" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:6px;text-align:left;padding-left:6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">This section provides a description of the risks and uncertainties that could cause actual results to differ materially from those discussed in forward-looking statements presented in this MD&amp;A, relating to, among other things, our anticipated operating and financial performance, business plans and prospects, in-line products and product candidates, including anticipated regulatory submissions, data read-outs, approvals, performance, timing of exclusivity and potential benefits of Pfizer&#8217;s products and product candidates, strategic reviews, capital allocation, business-development plans, manufacturing and products supply and plans relating to share repurchases and dividends. Also included in this section is a discussion of legal proceedings and contingencies.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;padding-left:30px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Certain amounts in our MD&amp;A may not add due to rounding. All percentages have been calculated using unrounded amounts.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">46</span></div></div><hr style="page-break-after:always"></hr><div><a id="sC32211D037205AB89BC9D50A97C6A004"></a></div><div><br/></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.24561403508771%;border-collapse:collapse;text-align:left;"><tr><td colspan="23"></td></tr><tr><td style="width:44%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td></tr><tr><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides the components of the condensed consolidated statements of income:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Nine Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS, EXCEPT PER COMMON SHARE DATA)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">October&#160;1, <br/>2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">October&#160;2, <br/>2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Change</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">October&#160;1, <br/>2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">October&#160;2, <br/>2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Change</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">13,168</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">13,045</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">38,843</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">39,196</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(1</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Cost of sales</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">2,847</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">3,085</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(8</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">7,980</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">9,111</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(12</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">% of revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">21.6</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">23.6</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">20.5</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">23.2</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Selling, informational and administrative expenses</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">3,500</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">3,559</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(2</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">10,233</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">10,414</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(2</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">% of revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">26.6</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">27.3</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">26.3</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">26.6</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Research and development expenses</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1,859</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1,881</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(1</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">5,346</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">5,360</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">% of revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">14.1</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">14.4</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">13.8</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">13.7</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Amortization of intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1,177</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">968</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">22</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">3,571</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">2,934</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">22</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">% of revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">8.9</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">7.4</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">9.2</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">7.5</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Restructuring charges and certain acquisition-related costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">149</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">531</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(72</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">377</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">988</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(62</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">% of revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1.1</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">4.1</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1.0</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">2.5</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other (income)/deductions&#8211;&#8211;net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">51</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1,417</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(96</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(16</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">2,815</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">*</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Income from continuing operations before provision for taxes on income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">3,585</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1,604</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">*</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">11,351</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">7,575</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">50</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">% of revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">27.2</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">12.3</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">29.2</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">19.3</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Provision for taxes on income</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">727</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">249</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">*</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">2,287</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1,109</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">*</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Effective tax rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">20.3</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">15.5</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">20.1</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">14.6</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Income from continuing operations</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">2,858</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1,355</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">*</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">9,064</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">6,465</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">40</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">% of revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">21.7</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">10.4</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">23.3</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">16.5</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Discontinued operations&#8211;&#8211;net of tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">*</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net income before allocation to noncontrolling interests</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">2,858</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1,355</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">*</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">9,066</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">6,465</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">40</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">% of revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">21.7</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">10.4</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">23.3</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">16.5</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Less: Net income attributable to noncontrolling interests</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">18</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">*</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">32</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">25</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">27</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net income attributable to Pfizer Inc.</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">2,840</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1,355</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">*</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">9,034</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">6,440</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">40</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">% of revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">21.6</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">10.4</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">23.3</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">16.4</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;text-decoration:underline;">Earnings per common share&#8211;&#8211;basic</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(b)</sup></span><span style="font-family:inherit;font-size:9pt;">:</span></div><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Income from continuing operations attributable to Pfizer Inc. common shareholders</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">0.48</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">0.22</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">*</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1.51</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1.06</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">43</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net income attributable to Pfizer Inc. common shareholders</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">0.48</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">0.22</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">*</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1.51</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1.06</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">43</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;text-decoration:underline;">Earnings per common share&#8211;&#8211;diluted</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(b)</sup></span><span style="font-family:inherit;font-size:9pt;">:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Income from continuing operations attributable to Pfizer Inc. common shareholders</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43712471e5775-wk-Fact-2BD65B1FAD49532F94B23261F5066D15" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" contextRef="FD2017Q3QTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">0.47</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d43712471e5794-wk-Fact-DB504CC293605BAF9CADCD1A8D93F11A" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" contextRef="FD2016Q3QTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">0.22</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">*</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1.49</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1.04</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">43</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net income attributable to Pfizer Inc. common shareholders</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">0.47</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">0.22</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">*</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1.49</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1.04</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">43</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Cash dividends paid per common share</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">0.32</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">0.30</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">7</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">0.96</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">0.90</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">7</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">* Calculation not meaningful.</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Excludes amortization of intangible assets, except as disclosed in Notes to Condensed Consolidated Financial Statements&#8211;&#8211;</span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Note 9A. Identifiable Intangible Assets and Goodwill:Identifiable Intangible Assets.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Amounts for the </span><span style="font-family:inherit;font-size:9pt;">three and nine months ended October 2, 2016</span><span style="font-family:inherit;font-size:9pt;"> have been revised from previously reported amounts to reflect the adoption of a new accounting standard in the fourth quarter of 2016, as of January 1, 2016. For additional information, see Notes to Condensed Consolidated Financial Statements&#8211;&#8211;</span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Note 1B</span><span style="font-family:inherit;font-size:9pt;">. </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Basis of Presentation and Significant Accounting Policies&#8211;&#8211;Adoption of New Accounting Standards</span><span style="font-family:inherit;font-size:9pt;">.</span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">47</span></div></div><hr style="page-break-after:always"></hr><div><a id="sF029A89915B4508184BCC9C90C1844D4"></a></div><div><br/></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">OVERVIEW OF OUR PERFORMANCE, OPERATING ENVIRONMENT, STRATEGY AND OUTLOOK</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Our Business</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We apply science and our global resources to bring therapies to people that extend and significantly improve their lives through the discovery, development and manufacture of healthcare products. Our global portfolio includes medicines and vaccines, as well as many of the world&#8217;s best-known consumer healthcare products. We work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. We collaborate with healthcare providers, governments and local communities to support and expand access to reliable, affordable healthcare around the world. Our revenues are derived from the sale of our products and, to a much lesser extent, from alliance agreements, under which we co-promote products discovered or developed by other companies or us (Alliance revenues).</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We manage our commercial operations through two distinct business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). For additional information, see Notes to Condensed Consolidated Financial Statements&#8211;&#8211;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 13A. </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Segment, Geographic and Other Revenue Information</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">: Segment Information</span><span style="font-family:inherit;font-size:10pt;"> and the &#8220;Our Strategy</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">&#8211;&#8211;</span><span style="font-family:inherit;font-size:10pt;">Commercial Operations&#8221; section of this MD&amp;A below.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The majority of our revenues come from the manufacture and sale of biopharmaceutical products. As explained more fully in our </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;"> Form 10-K, the biopharmaceutical industry is highly competitive and highly regulated. As a result, we face a number of industry-specific factors and challenges, which can significantly impact our results. These factors include, among others: the loss or expiration of intellectual property rights and the expiration of co-promotion and licensing rights, the ability to replenish innovative biopharmaceutical products, healthcare legislation, pipeline productivity, the regulatory environment, pricing and access pressures and competition. We also face challenges as a result of the global economic environment. For additional information about these factors and challenges, see the &#8220;Our Operating Environment&#8221; and &#8220;The Global Economic Environment&#8221; sections of this MD&amp;A and of our </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;"> Financial Report and Part I, Item 1A, &#8220;Risk Factors&#8221; of our </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;"> Form 10-K and Part II, Item 1A, &#8220;Risk Factors&#8221; of this Quarterly Report on Form 10-Q.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The financial information included in our condensed consolidated financial statements for our subsidiaries operating outside the U.S. is as of and for the </span><span style="font-family:inherit;font-size:10pt;">three and nine months</span><span style="font-family:inherit;font-size:10pt;"> ended </span><span style="font-family:inherit;font-size:10pt;">August&#160;27, 2017</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">August&#160;28, 2016</span><span style="font-family:inherit;font-size:10pt;">. The financial information included in our condensed consolidated financial statements for U.S. subsidiaries is as of and for the </span><span style="font-family:inherit;font-size:10pt;">three and nine months</span><span style="font-family:inherit;font-size:10pt;"> ended </span><span style="font-family:inherit;font-size:10pt;text-align:center;">October&#160;1, 2017</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;text-align:center;">October&#160;2, 2016</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:50%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">References to developed and emerging markets in this MD&amp;A include:</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Developed markets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S., Western Europe, Japan, Canada, Australia, South Korea, Scandinavian countries, Finland and New Zealand</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Emerging markets (includes, but is not limited to)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Asia (excluding Japan and South Korea), Latin America, Africa, Eastern Europe, Central Europe, the Middle East and Turkey</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">References to operational variances in this MD&amp;A pertain to period-over-period growth rates that exclude the impact of foreign exchange. The operational variances are determined by multiplying or dividing, as appropriate, our current period U.S. dollar results by the current period average foreign exchange rates and then multiplying or dividing, as appropriate, those amounts by the prior-year period average foreign exchange rates. Although exchange rate changes are part of our business, they are not within our control. Exchange rate changes, however, can mask positive or negative trends in the business; therefore, we believe presenting operational variances provides useful information in evaluating the results of our business.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In October 2017, we announced that we are reviewing strategic alternatives for our Consumer Healthcare business. A range of options will be considered, including a full or partial separation of the Consumer Healthcare business from Pfizer through a spin-off, sale or other transaction, and we may ultimately determine to retain the business. Our other significant business development activities include:</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On February 3, 2017, we completed the sale of Pfizer&#8217;s global infusion therapy net assets, HIS, to ICU Medical for up to approximately $900 million, composed of cash and contingent cash consideration, ICU Medical common stock and seller financing.</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span><span style="font-family:inherit;font-size:10pt;">At closing, we received 3.2 million newly issued shares of ICU Medical common stock, which we initially valued at approximately </span><span style="font-family:inherit;font-size:10pt;">$428 million</span><span style="font-family:inherit;font-size:10pt;">, a promissory note in the amount of </span><span style="font-family:inherit;font-size:10pt;">$75 million</span><span style="font-family:inherit;font-size:10pt;"> and net cash of approximately </span><span style="font-family:inherit;font-size:10pt;">$200 million</span><span style="font-family:inherit;font-size:10pt;"> before customary adjustments for net working capital. In addition, we are entitled to receive a contingent amount of up to an additional </span><span style="font-family:inherit;font-size:10pt;">$225 million</span><span style="font-family:inherit;font-size:10pt;"> in cash based on ICU Medical&#8217;s achievement of certain cumulative performance targets for the combined company through December 31, 2019. The operating results of HIS are included in our condensed consolidated statement of income and EH&#8217;s operating results through February 2, 2017 and, therefore, our financial results, and EH&#8217;s </span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">48</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;padding-left:18px;"><span style="font-family:inherit;font-size:10pt;">operating results, for the </span><span style="font-family:inherit;font-size:10pt;">third quarter</span><span style="font-family:inherit;font-size:10pt;"> of 2017 do not reflect any contribution from HIS global operations, while our financial results, and EH&#8217;s operating results, for the </span><span style="font-family:inherit;font-size:10pt;">third quarter</span><span style="font-family:inherit;font-size:10pt;"> of 2016 reflect three months of HIS global operations. Our financial results, and EH&#8217;s operating results, for the </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;"> reflect approximately one month of HIS domestic operations and approximately two months of HIS international operations, while our financial results, and EH&#8217;s operating results, for the </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;"> reflect nine months of HIS global operations. Assets and liabilities associated with HIS are presented as held for sale in the condensed consolidated balance sheet as of December 31, 2016. The HIS assets held for sale are reported in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Assets held for sale </span><span style="font-family:inherit;font-size:10pt;">and HIS liabilities held for sale are reported in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other current liabilities.</span></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On December 22, 2016, which falls in the first fiscal quarter of 2017 for our international operations, we acquired the development and commercialization rights to AstraZeneca&#8217;s small molecule anti-infectives business, primarily outside the U.S. The total fair value of the consideration transferred for this business was approximately </span><span style="font-family:inherit;font-size:10pt;">$555 million</span><span style="font-family:inherit;font-size:10pt;"> in cash plus contingent consideration of </span><span style="font-family:inherit;font-size:10pt;">$490 million</span><span style="font-family:inherit;font-size:10pt;">. Commencing from the acquisition date, our financial statements reflect the assets, liabilities, operating results and cash flows of this business, and, in accordance with our international reporting period, our financial results, EH&#8217;s operating results, and cash flows for the </span><span style="font-family:inherit;font-size:10pt;">third quarter</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> 2017 reflect approximately three months and eight months, respectively, of the small molecule anti-infectives business acquired from AstraZeneca.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On September 28, 2016, we acquired Medivation for </span><span style="font-family:inherit;font-size:10pt;">$81.50</span><span style="font-family:inherit;font-size:10pt;"> per share. The total fair value of consideration transferred for Medivation was approximately </span><span style="font-family:inherit;font-size:10pt;">$14.3 billion</span><span style="font-family:inherit;font-size:10pt;"> in cash (</span><span style="font-family:inherit;font-size:10pt;">$13.9 billion</span><span style="font-family:inherit;font-size:10pt;">, net of cash acquired). Of this consideration, approximately </span><span style="font-family:inherit;font-size:10pt;">$365 million</span><span style="font-family:inherit;font-size:10pt;"> was not paid as of December 31, 2016, and was recorded in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other current liabilities. </span><span style="font-family:inherit;font-size:10pt;">Substantially all of the remaining consideration was paid as of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">October&#160;1, 2017</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">. </span><span style="font-family:inherit;font-size:10pt;">Commencing from the acquisition date, our financial statements reflect the assets, liabilities, operating results and cash flows of Medivation. Therefore, Medivation operations are reflected in our financial results, IH&#8217;s operating results, and cash flows for the </span><span style="font-family:inherit;font-size:10pt;">third quarter</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;">. In accordance with our domestic and international reporting periods, our consolidated financial statements for the </span><span style="font-family:inherit;font-size:10pt;">third quarter</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;"> reflect three business days of Medivation operations, which were immaterial.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On June 24, 2016, we acquired Anacor for </span><span style="font-family:inherit;font-size:10pt;">$99.25</span><span style="font-family:inherit;font-size:10pt;"> per share. The total fair value of consideration transferred for Anacor was approximately </span><span style="font-family:inherit;font-size:10pt;">$4.9 billion</span><span style="font-family:inherit;font-size:10pt;"> in cash (</span><span style="font-family:inherit;font-size:10pt;">$4.5 billion</span><span style="font-family:inherit;font-size:10pt;">, net of cash acquired), plus </span><span style="font-family:inherit;font-size:10pt;">$698 million</span><span style="font-family:inherit;font-size:10pt;"> debt assumed. Commencing from the acquisition date, our financial statements reflect the assets, liabilities, operating results and cash flows of Anacor. Therefore, Anacor operations are reflected in our financial results, IH&#8217;s operating results, and cash flows for the </span><span style="font-family:inherit;font-size:10pt;">third quarter</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;">. In accordance with our domestic and international reporting periods, our consolidated financial statements for the </span><span style="font-family:inherit;font-size:10pt;">third quarter</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;"> reflect approximately three months of Anacor operations.</span></div></td></tr></table><div style="line-height:120%;padding-left:18px;text-indent:-18px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For additional information, see Notes to Condensed Consolidated Financial Statements&#8211;&#8211;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 2. </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Acquisitions, Sale of Hospira Infusion Systems Net Assets, Collaborative Arrangement and Equity-Method Investments</span><span style="font-family:inherit;font-size:10pt;"> and the &#8220;Our Strategy&#8221; and &#8220;Our Business Development Initiatives&#8221; sections of this MD&amp;A below.</span></div><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Impact of Recent Hurricanes in Puerto Rico</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have manufacturing and commercial operations in Puerto Rico, which were impacted by the recent hurricanes toward the end of the third quarter in 2017. While our three manufacturing sites sustained some damage and became inoperable due to issues impacting Puerto Rico overall, we have made significant progress in repairing our facilities in anticipation of ramping up to full operations over the coming months. As of the date of this Form 10-Q filing, some packaging production has begun at our facilities. We expect our facilities to reach full capacity in early 2018, but there could be certain product shortages in the coming months. Our commercial sales offices in Puerto Rico have been operational since October 9, 2017. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the third quarter of 2017, we recorded $55 million in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Cost of sales</span><span style="font-family:inherit;font-size:10pt;"> for inventory losses, overhead costs related to the period in which the plants could not operate, and incremental costs to date resulting from the hurricanes in Puerto Rico. We may record additional losses in future periods but we are unable to predict them with certainty at this time. As a result of dual source supply options and sufficient pre-hurricane inventory levels, we currently expect the impact on future revenues to be insignificant. We will continue to monitor the situation closely and make any updates to our outlook if warranted. </span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Product Manufacturing</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We periodically encounter difficulties or delays in manufacturing, including due to legal or regulatory actions, such as warning letters, suspension of manufacturing or voluntary recall of a product. Within our Essential Health portfolio, we have been experiencing product shortages with some products. The product shortages are primarily for products from the legacy Hospira portfolio and are largely driven by capacity constraints and technical issues. In February 2017, for example, we received a </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">49</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">warning letter from the FDA communicating the FDA&#8217;s view that certain violations of cGMP regulations exist at Hospira&#8217;s manufacturing facility in McPherson, Kansas. We are undertaking corrective actions to address the concerns raised by the FDA. Communication with the FDA is ongoing. Until the violations are corrected, the FDA may refuse to grant premarket approval applications and/or the FDA may refuse to grant export certificates related to products manufactured at McPherson, Kansas. Any continued product shortage interruption at this manufacturing facility could negatively impact our financial results, specifically in our Sterile Injectable Pharmaceuticals portfolio. In addition to the McPherson facility, we continue to remediate issues at other legacy Hospira facilities manufacturing sterile injectables within our Essential Health portfolio. We expect to make substantial progress on our remediation efforts during 2018.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Our </span><span style="font-family:inherit;font-size:11pt;font-weight:bold;text-align:center;text-decoration:underline;">2017</span><span style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;"> Performance</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Revenues</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revenues</span><span style="font-family:inherit;font-size:10pt;"> in the </span><span style="font-family:inherit;font-size:10pt;">third</span><span style="font-family:inherit;font-size:10pt;"> quarter of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">increase</span><span style="font-family:inherit;font-size:10pt;">d </span><span style="font-family:inherit;font-size:10pt;">1%</span><span style="font-family:inherit;font-size:10pt;"> compared to the same period in </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;">, which reflects an operational </span><span style="font-family:inherit;font-size:10pt;">increase</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;">$178 million</span><span style="font-family:inherit;font-size:10pt;">, or </span><span style="font-family:inherit;font-size:10pt;">1%</span><span style="font-family:inherit;font-size:10pt;">, slightly offset by the unfavorable impact of foreign exchange.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revenues</span><span style="font-family:inherit;font-size:10pt;"> in the </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">decrease</span><span style="font-family:inherit;font-size:10pt;">d </span><span style="font-family:inherit;font-size:10pt;">1%</span><span style="font-family:inherit;font-size:10pt;"> compared to the same period in </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;">, which reflects an operational </span><span style="font-family:inherit;font-size:10pt;">increase</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;">$19 million</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">an unfavorable</span><span style="font-family:inherit;font-size:10pt;"> impact of foreign exchange of </span><span style="font-family:inherit;font-size:10pt;">1%</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following provides an analysis of the changes in revenues for the </span><span style="font-family:inherit;font-size:10pt;">third</span><span style="font-family:inherit;font-size:10pt;"> quarter and </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.02534113060429%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:64%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Three Months</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nine Months</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revenues, </span><span style="font-family:inherit;font-size:10pt;">for the three months and nine months ended October 2, 2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">13,045</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">39,196</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Disposition-related operational impact</span><span style="font-family:inherit;font-size:10pt;">&#8211;&#8211;February 2017 sale of HIS</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(280</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(783</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Other operational growth/(decline)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Continued growth from key brands</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(b)</sup></span><span style="font-family:inherit;font-size:10pt;">&#160;and growth from Biosimilars</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">806</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2,245</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Growth in Xtandi alliance revenues in the U.S. (September 2016 acquisition of Medivation) </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">148</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">420</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Declines from Peri-LOE Products, Enbrel (driven by declines in most developed Europe markets), Prevnar 13/Prevenar 13 (driven by declines in the U.S.), and Viagra (IH) (primarily in the U.S.), as well as a decline in our SIP portfolio, and for the first nine months of 2017, also includes a decline in the LEP portfolio</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(598</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(1,951</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other operational factors, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">102</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">87</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operational growth, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">178</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">19</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operational revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">13,222</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">39,215</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unfavorable impact of foreign exchange</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(54</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(372</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revenues, </span><span style="font-family:inherit;font-size:10pt;">for the three months and nine months ended October 1, 2017</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">13,168</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">38,843</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">In the </span><span style="font-family:inherit;font-size:8.5pt;">third</span><span style="font-family:inherit;font-size:8.5pt;"> quarter of </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">, f</span><span style="font-family:inherit;font-size:8.5pt;">inancial results do not reflect any contribution from HIS global operations, compared to the inclusion of three months of HIS global operations in the same period in 2016. In the </span><span style="font-family:inherit;font-size:8.5pt;">first nine months of</span><span style="font-family:inherit;font-size:8.5pt;"> </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:8.5pt;">, financial results include approximately one month of HIS domestic operations and approximately two months of HIS international operations, compared to nine months of HIS global operations in the same period in 2016.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">K</span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">ey brands </span><span style="font-family:inherit;font-size:8.5pt;">include Ibrance and Eliquis (globally) as well as Lyrica (IH) and Xeljanz (both primarily in the U.S.).</span></div></td></tr></table><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">See the &#8220;Analysis of the Condensed Consolidated Statements of Income&#8211;&#8211;Revenues and Product Developments&#8211;&#8211;Revenues&#8211;&#8211;Overview&#8221; section below for more information, including a discussion of key drivers of our revenue performance.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">50</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Income from Continuing Operations Before Provision for Taxes on Income</span></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following provides an analysis of the </span><span style="font-family:inherit;font-size:10pt;">increase</span><span style="font-family:inherit;font-size:10pt;">s in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Income from continuing operations before provision for taxes on income</span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">third</span><span style="font-family:inherit;font-size:10pt;"> quarter and </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;">:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.02534113060429%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:64%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Three Months</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Nine Months</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-style:italic;">Income from continuing operations before provision for taxes on income, </span><span style="font-family:inherit;font-size:9.5pt;">for the three months and nine months ended October 2, 2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">1,604</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">7,575</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">Favorable/(Unfavorable) change in revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">123</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(353</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">Favorable/(Unfavorable) changes:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Nonrecurrence of 2016 impairment on remeasurement of HIS net assets and lower loss on sale of HIS</span><span style="font-family:inherit;font-size:9.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">1,434</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">1,369</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Lower</span><span style="font-family:inherit;font-size:9.5pt;font-style:italic;">&#160;Cost of sales</span><span style="font-family:inherit;font-size:9.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">238</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">1,130</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Lower certain asset impairments</span><span style="font-family:inherit;font-size:9.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">3</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">937</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Lower </span><span style="font-family:inherit;font-size:9.5pt;font-style:italic;">Restructuring charges and certain acquisition-related costs</span><span style="font-family:inherit;font-size:9.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">381</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">611</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(Higher)/lower certain legal matters, net</span><span style="font-family:inherit;font-size:9.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(223</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">300</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Higher net gains on asset disposals</span><span style="font-family:inherit;font-size:9.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">108</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">268</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Higher dividend income</span><span style="font-family:inherit;font-size:9.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">54</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">204</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Lower </span><span style="font-family:inherit;font-size:9.5pt;font-style:italic;">Selling, information and administrative expenses</span><span style="font-family:inherit;font-size:9.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(d)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">59</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">181</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Lower business and legal entity alignment costs</span><span style="font-family:inherit;font-size:9.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup></span><span style="font-family:inherit;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">53</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">126</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Higher </span><span style="font-family:inherit;font-size:9.5pt;font-style:italic;">Amortization of intangible assets</span><span style="font-family:inherit;font-size:9.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(e)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(209</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(637</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Lower royalty-related income</span><span style="font-family:inherit;font-size:9.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(93</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(363</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">All other items, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">52</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">4</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-style:italic;">Income from continuing operations before provision for taxes on income, </span><span style="font-family:inherit;font-size:9.5pt;">for the three months and nine months ended October 1, 2017</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3,585</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">11,351</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">See the Notes to Condensed Consolidated Financial Statements&#8211;&#8211;</span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Note 4. </span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Other (Income)/Deductions&#8212;Net</span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">See the &#8220;Costs and Expenses&#8211;&#8211;Cost of Sales&#8221; section of this MD&amp;A.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(c)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">See the &#8220;Costs and Expenses&#8211;&#8211;Restructuring Charges and Certain Acquisition-Related Costs and Cost-Reduction/Productivity Initiatives&#8221; section of this MD&amp;A.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(d)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">See the &#8220;Costs and Expenses&#8211;&#8211;Selling, Informational and Administrative Expenses&#8221; section of this MD&amp;A.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(e)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">See the &#8220;Costs and Expenses&#8211;&#8211;Amortization of Intangible Assets&#8221; section of this MD&amp;A.</span></div></td></tr></table><div style="line-height:120%;padding-top:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For information on our tax provision and effective tax rate see the &#8220;Provision for Taxes on Income&#8221; section of this MD&amp;A and Notes to Condensed Consolidated Financial Statements&#8211;&#8211;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 5</span><span style="font-family:inherit;font-size:10pt;">.</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Tax Matters</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Our Operating Environment</span></div><div style="line-height:120%;padding-top:9px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Industry-Specific Challenges</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Intellectual Property Rights and Collaboration/Licensing Rights</span></div><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The loss, expiration or invalidation of intellectual property rights, patent litigation settlements with generic manufacturers and the expiration of co-promotion and licensing rights can have a significant adverse effect on our revenues. We have lost exclusivity for a number of our products in certain markets and we have lost collaboration rights with respect to a number of our alliance products in certain markets, and we expect certain products to face significantly increased generic competition over the next few years. Also, if one of our patents is found to be invalid by judicial, court or administrative proceedings, such as inter partes</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span><span style="font-family:inherit;font-size:10pt;">review, post-grant review, re-examination or opposition proceedings, before the U.S. Patent and Trademark Office, the European Patent Office, or other foreign counterparts, generic or competitive products could be introduced into the market resulting in the erosion of sales of our existing products. For example, several of the patents in our pneumococcal vaccine portfolio have been challenged in inter partes review and post-grant review proceedings in the U.S. The invalidation of these patents could potentially allow a competitor pneumococcal vaccine into the marketplace.</span></div><div style="line-height:120%;padding-top:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As a result of a patent litigation settlement with several generic manufacturers, generic versions of Pristiq launched in the U.S. in March 2017. See the &#8220;Intellectual Property Rights and Collaboration/Licensing Rights&#8221; section of our </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;"> Financial Report for additional information about (i) recent losses and expected losses of product exclusivity in the U.S., Europe and/or Japan impacting product revenues and (ii) recent losses of collaboration rights impacting alliance revenues. </span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We expect to lose exclusivity for various other products in various markets over the next few years, including, among others, Viagra in the U.S. in December 2017 and the expiration of the basic product patent for Lyrica in the U.S. in December 2018. </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">51</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For additional information, see the &#8220;Patents and Other Intellectual Property Rights&#8221; section in Part I, Item 1, &#8220;Business&#8221; of our </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;"> Form 10-K.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We will continue to aggressively defend our patent rights whenever we deem appropriate. For more detailed information about our significant products, see the discussion in the &#8220;Revenues&#8211;&#8211;Major Products&#8221; and &#8220;Revenues&#8211;&#8211;Selected Product Discussion&#8221; sections of this MD&amp;A. For a discussion of certain recent developments with respect to patent litigation, see Notes to Condensed Consolidated Financial Statements&#8211;&#8211;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 12A1. Commitments and Contingencies: Legal Proceedings</span><span style="font-family:inherit;font-size:10pt;">&#8211;&#8211;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Patent Litigation</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Regulatory Environment/Pricing and Access&#8211;&#8211;U.S. Healthcare Legislation</span></div><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In March 2010, the ACA was enacted in the U.S. For additional information, see the &#8220;Government Regulation and Price Constraints&#8221; section in Part I, Item 1, &#8220;Business&#8221; of our </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;"> Form 10-K. </span></div><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We recorded the following amounts as a result of the U.S. Healthcare Legislation:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$157 million</span><span style="font-family:inherit;font-size:10pt;"> in the </span><span style="font-family:inherit;font-size:10pt;">third</span><span style="font-family:inherit;font-size:10pt;"> quarter of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">$143 million</span><span style="font-family:inherit;font-size:10pt;"> in the </span><span style="font-family:inherit;font-size:10pt;">third</span><span style="font-family:inherit;font-size:10pt;"> quarter of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;">$296 million</span><span style="font-family:inherit;font-size:10pt;"> in the </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">$302 million</span><span style="font-family:inherit;font-size:10pt;"> in the </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;">, recorded as a reduction to </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revenues</span><span style="font-family:inherit;font-size:10pt;"> related to the Medicare &#8220;coverage gap&#8221; discount provision; and </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$87 million</span><span style="font-family:inherit;font-size:10pt;"> in the </span><span style="font-family:inherit;font-size:10pt;">third</span><span style="font-family:inherit;font-size:10pt;"> quarter of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">$95 million</span><span style="font-family:inherit;font-size:10pt;"> in the </span><span style="font-family:inherit;font-size:10pt;">third</span><span style="font-family:inherit;font-size:10pt;"> quarter of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;">$218 million</span><span style="font-family:inherit;font-size:10pt;"> in the </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">$219 million</span><span style="font-family:inherit;font-size:10pt;"> in the </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;">, recorded in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Selling, informational and administrative expenses</span><span style="font-family:inherit;font-size:10pt;">, related to the fee payable to the federal government (which is not deductible for U.S. income tax purposes) based on our prior-calendar-year share relative to other companies of branded prescription drug sales to specified government programs.</span></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Regulatory Environment/Pricing and Access&#8211;&#8211;Government and Other Payer Group Pressures</span></div><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Governments, MCOs and other payer groups continue to seek increasing discounts on our products through a variety of means, such as leveraging their purchasing power, implementing price controls, and demanding price cuts (directly or by rebate actions). In Europe, Japan, China, Canada, South Korea and some other international markets, governments provide healthcare at low direct cost to patients and regulate pharmaceutical prices or patient reimbursement levels to control costs for the government-sponsored healthcare system, particularly under recent global economic pressures. In the U.S., a primary government activity with implications for pharmaceutical pricing is deficit reduction. Any significant spending reductions affecting Medicare, Medicaid or other publicly funded or subsidized health programs that may be implemented, and/or any significant additional taxes or fees that may be imposed on us, as part of any broad deficit-reduction effort could have an adverse impact on our results of operations. Significant Medicare reductions could also result if Congress proceeds with certain proposals to convert the Medicare fee-for-service program into a premium support program, or if it chooses to implement the recommendations made annually by the Medicare Payment Advisory Commission, which are primarily intended to extend the fiscal solvency of the Medicare program. Similar reductions to Medicare spending could result if the threshold for action by the Independent Payment Advisory Board (IPAB) is reached, and the Secretary of the Department of Health and Human Services (to whom responsibility for developing savings proposals specified in the ACA is likely to default in the absence of a seated IPAB) is required to identify savings. Current projections by the Centers for Medicare and Medicaid Services Office of the Actuary indicate that the IPAB threshold will not be reached before 2021.</span></div><div style="line-height:120%;padding-top:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Consolidation among MCOs has increased the negotiating power of MCOs and other private insurers. Private third-party insurers, as well as governments, increasingly employ formularies to control costs by negotiating discounted prices in exchange for formulary inclusion. Failure to obtain or maintain timely or adequate pricing or formulary placement for our products or obtaining such pricing or placement at unfavorable pricing could adversely impact revenue.</span></div><div style="line-height:120%;padding-top:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Additionally, efforts by government officials or legislators to implement measures to regulate prices or payment for pharmaceutical products, including legislation on drug importation, could adversely affect our business if implemented. There has recently been considerable public and government scrutiny of pharmaceutical pricing and proposals to address the perceived high cost of pharmaceuticals, and there are indications that there could be a Presidential Executive Order that would focus on pharmaceuticals. We believe medicines are the most efficient and effective use of healthcare dollars based on the value they deliver to the overall healthcare system. We continue to work with stakeholders to ensure access to medicines within an efficient and affordable healthcare system.</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Adoption of other new legislation at the federal or state level could further affect demand for, or pricing of, our products. We face uncertainties due to federal legislative and administrative efforts to repeal, substantially modify or invalidate some or all of the provisions of the ACA, though the likelihood of repeal of the ACA is now low given the recent failure of the Senate&#8217;s multiple attempts to repeal various combinations of ACA provisions. In October 2017, the President signed an Executive Order directing federal agencies to modify how the ACA is implemented and announced that his administration will withhold the cost-</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">52</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">sharing subsidies paid to health insurance exchange plans serving low-income enrollees. The revenues generated for Pfizer by the health insurance exchanges under the ACA are minor, so the impact of the recent administration actions is expected to be limited. There is no assurance that any replacement, modification or repeal of the ACA will not adversely affect our business and financial results, particularly if the legislation reduces incentives for employer-sponsored insurance coverage. We also may face uncertainties if our industry is looked to for savings to fund certain legislation, such as reauthorization of the Children&#8217;s Health Insurance Program, or lifting the debt ceiling. There have also been recent state legislative efforts to address drug costs, which have generally focused on increasing transparency around drug costs or limiting drug prices. Recent legislation enacted includes, for example, a 2017 Maryland law that prohibits a generic drug manufacturer or wholesale distributor from engaging in price gouging in the sale of certain off-patent or generic drugs, and a 2017 California law that requires manufacturers to provide advanced notification of price increases to certain purchasers and report specified drug pricing information to the state. We cannot predict the success of current or future federal or state legislative efforts. We will continue to work with law makers and advocate for solutions that effectively improve patient health outcomes and lower costs to the healthcare system.</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The potential for additional pricing and access pressures in the commercial sector continues to be significant. Some employers, seeking to avoid the tax on high-cost health insurance in the ACA to be imposed in 2020, are already scaling back healthcare benefits and an increasing number are implementing high deductible benefit designs. This is a trend that is likely to continue, especially if proposals to limit the tax exclusion for employer sponsored health insurance ultimately become law. Private third-party payers, such as health plans, increasingly challenge pharmaceutical product pricing, which could result in lower prices, lower reimbursement rates and a reduction in demand for our products. Pricing pressures for our products may occur as a result of highly competitive insurance markets. Healthcare provider purchasers, directly or through group purchasing organizations, are seeking enhanced discounts or implementing more rigorous bidding or purchasing review processes.</span></div><div style="line-height:120%;padding-top:9px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Overall, there is increasing pressure on U.S. providers to deliver healthcare at a lower cost and to ensure that those expenditures deliver demonstrated value in terms of health outcomes. Longer term, we are seeing a shift in focus away from fee-for-service payments towards outcomes-based payments and risk-sharing arrangements that reward providers for cost reductions. These new payment models can, at times, lead to lower prices for, and restricted access to, new medicines. At the same time, these models can also expand utilization by encouraging physicians to screen, diagnose and focus on outcomes. </span></div><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outside the U.S., governments, including the different EU Member States, may use a variety of cost-containment measures for our pharmaceutical products, including price cuts, mandatory rebates, value-based pricing, and international reference pricing (i.e., the practice of a country linking its regulated medicine prices to those of other countries). This international patchwork of price regulation and differing economic conditions and assessments of value across countries has led to different prices in different countries and some third-party trade in our products between countries.</span></div><div style="line-height:120%;padding-top:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In particular, international reference pricing adds to the regional impact of price cuts in individual countries and hinders patient access and innovation. Price variations, exacerbated by international reference pricing systems, also have resulted from exchange rate fluctuations. The downward pricing pressure resulting from this dynamic can be expected to continue as a result of reforms to international reference pricing policies and measures targeting pharmaceuticals in some European countries. </span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, several important multilateral organizations, such as the United Nations (UN) and the Organization for Economic Cooperation and Development (OECD), are increasing policy pressures and scrutiny of international pharmaceutical pricing through issuing reports and policy recommendations (e.g., </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">2016 UN High Level Panel Report on Access to Medicines </span><span style="font-family:inherit;font-size:10pt;">and</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> 2017 OECD Report on New Health Technologies&#8211;&#8211;Managing Access, Value and Sustainability</span><span style="font-family:inherit;font-size:10pt;">). Government adoption of these recommendations may lead to additional pricing pressures.</span></div><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In response to the evolving U.S. and global healthcare spending landscape, we are continuing to work with health authorities, health technology assessment and quality measurement bodies and major U.S. payers throughout the product-development process to better understand how these entities value our compounds and products. Further, we are seeking to develop stronger internal capabilities focused on demonstrating the value of the medicines that we discover or develop, register and manufacture, by recognizing patterns of usage of our medicines and competitor medicines along with patterns of healthcare costs. </span></div><div style="line-height:120%;padding-top:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For additional information, see the &#8220;Regulatory Environment&#8211;&#8211;Pipeline Productivity&#8221; and &#8220;Competition&#8221; sections of our </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;"> Financial Report.</span></div><div style="line-height:120%;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">The Global Economic Environment</span></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition to the industry-specific factors discussed above, we, like other businesses, are exposed to the economic cycle, which impacts our biopharmaceutical operations globally. </span></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Governments, corporations, and insurance companies, which provide insurance benefits to patients, have implemented increases in cost-sharing and restrictions on access to medicines, potentially causing patients to switch to generic products, delay treatments, skip doses or use less effective treatments. Government financing pressures can lead to negative pricing </span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">53</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;padding-left:18px;padding-top:6px;"><span style="font-family:inherit;font-size:10pt;">pressure in various markets where governments take an active role in setting prices, access criteria (e.g., through public or private health technology assessments), or other means of cost control. Examples include Europe, Japan, China, Canada, South Korea and a number of other international markets. The U.S. continues to maintain competitive insurance markets, but has also seen significant increases in patient cost-sharing and growing government influence as government programs continue to grow as a source of coverage.</span></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We continue to monitor developments regarding government and government agency receivables in several European markets, including Greece, where economic conditions remain challenging and uncertain. For further information about our </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Accounts Receivable</span><span style="font-family:inherit;font-size:10pt;">, see the &#8220;Analysis of Financial Condition, Liquidity and Capital Resources&#8221; section of this MD&amp;A.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Significant portions of our revenues and earnings, as well as our substantial international net assets, are exposed to changes in foreign exchange rates. We seek to manage our foreign exchange risk in part through operational means, including managing same-currency revenues in relation to same-currency costs and same-currency assets in relation to same-currency liabilities. Depending on market conditions, foreign exchange risk also is managed through the use of derivative financial instruments and foreign currency debt. As we operate in multiple foreign currencies, including the euro, the Japanese yen, the Chinese renminbi, the U.K. pound, the Canadian dollar and approximately 100 other currencies, changes in those currencies relative to the U.S. dollar will impact our revenues and expenses. If the U.S. dollar were to weaken against another currency, assuming all other variables remained constant, our revenues would increase, having a positive impact on earnings, and our overall expenses would increase, having a negative impact on earnings. Conversely, if the U.S. dollar were to strengthen against another currency, assuming all other variables remained constant, our revenues would decrease, having a negative impact on earnings, and our overall expenses would decrease, having a positive impact on earnings. Therefore, significant changes in foreign exchange rates, including those changes resulting from the volatility following the U.K. referendum in which voters approved the exit from the EU, can impact our results and our financial guidance.</span></div></td></tr></table><div style="line-height:120%;padding-top:6px;text-align:left;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The impact of possible currency devaluations in countries experiencing high inflation rates or significant exchange fluctuations, including Venezuela, can impact our results and financial guidance. For further information about our exposure to foreign currency risk, see the &#8220;Analysis of Financial Condition, Liquidity and Capital Resources&#8221; and the &#8220;Our Financial Guidance for </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;">&#8221; sections of this MD&amp;A. </span></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In June 2016, the U.K. electorate voted in a referendum to leave the EU, which is commonly referred to as &#8220;Brexit&#8221;. In January 2017, the U.K. Prime Minister announced a 12-point plan of negotiating objectives and confirmed that the U.K. government will not seek continued membership in the EU single market. In March 2017, the U.K. government formally notified the European Council of its intention to leave the EU after it triggered Article 50 of the Lisbon Treaty to begin the two-year negotiation process establishing the terms of the exit and outlining the future relationship between the U.K. and the EU. This process continues to be highly complex and the end result of these negotiations may pose certain implications to our research, commercial and general business operations in the U.K. and the EU, including the approval of our products.</span></div></td></tr></table><div style="line-height:120%;padding-top:6px;text-align:left;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We generated approximately </span><span style="font-family:inherit;font-size:10pt;">2%</span><span style="font-family:inherit;font-size:10pt;"> of our worldwide revenues from the U.K. in the </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;">. However, except for the foreign currency exchange impact from the weakening U.K. pound relative to the U.S. dollar to date, there are no other immediate-term impacts to our business as there has not yet been a formal change in the relationship between the U.K. and the EU. In addition, because of the significant uncertainties associated with the negotiation process, any potential long-term impacts are not currently determinable.</span></div><div style="line-height:120%;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pfizer maintains a strong financial position while operating in a complex global environment. Due to our significant operating cash flows, financial assets, access to capital markets and available lines of credit and revolving credit agreements, we continue to believe that we have, and will maintain, the ability to meet our liquidity needs for the foreseeable future. Our long-term debt is rated high quality by both S&amp;P and Moody&#8217;s. As market conditions change, we continue to monitor our liquidity position. We have taken and will continue to take a conservative approach to our financial investments. Both short-term and long-term investments consist primarily of high-quality, highly liquid, well-diversified, available-for-sale debt securities. For further discussion of our financial condition and credit ratings, see the &#8220;Analysis of Financial Condition, Liquidity and Capital Resources&#8221; section of this MD&amp;A.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">These and other industry-wide factors that may affect our businesses should be considered along with information presented in the &#8220;Forward-Looking Information and Factors That May Affect Future Results&#8221; section of this MD&amp;A and in Part I, Item 1A, &#8220;Risk Factors&#8221; of our </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;"> Form 10-K and Part II, Item 1A, "Risk Factors," of this Quarterly Report on Form 10-Q.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Our Strategy</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We believe that our medicines provide significant value for both healthcare providers and patients, not only from the improved treatment of diseases but also from a reduction in other healthcare costs, such as emergency room or hospitalization costs, as well as improvements in health, wellness and productivity. We continue to actively engage in dialogues about the value of our medicines and how we can best work with patients, physicians and payers to prevent and treat disease and improve outcomes. </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">54</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We continue to work within the current legal and pricing structures, as well as continue to review our pricing arrangements and contracting methods with payers, to maximize patient access and minimize any adverse impact on our revenues. We remain firmly committed to fulfilling our company</span><span style="font-family:inherit;font-size:9pt;">&#8217;</span><span style="font-family:inherit;font-size:10pt;">s purpose of innovating to bring therapies to patients that extend and significantly improve their lives. By doing so, we expect to create value for the patients we serve and for our shareholders. </span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Commercial Operations</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We manage our commercial operations through two distinct business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH and EH operating segments are each led by a single manager. Each operating segment has responsibility for its commercial activities and for certain IPR&amp;D projects for new investigational products and additional indications for in-line products that generally have achieved proof-of-concept. Each business has a geographic footprint across developed and emerging markets.</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:2%;"></td><td style="width:48%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:48%;"></td></tr><tr><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Some additional information about our business segments follows:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">IH Segment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">EH Segment</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">&#9679;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">IH focuses on developing and commercializing novel, value-creating medicines and vaccines that significantly improve patients&#8217; lives, as well as products for consumer healthcare.</span></div><div style="padding-top:4px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Key therapeutic areas include internal medicine, vaccines, oncology, inflammation &amp; immunology, rare diseases and consumer healthcare.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">&#9679;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">EH includes legacy brands that have lost or will soon lose market exclusivity in both developed and emerging markets, branded generics, generic sterile injectable products, biosimilars, select branded products including anti-infectives and, through February 2, 2017, HIS. EH also includes an R&amp;D organization, as well as our contract manufacturing business.</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">&#9679;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">We expect that the IH biopharmaceutical portfolio of innovative, largely patent-protected, in-line and newly launched products will be sustained by ongoing investments to develop promising assets and targeted business development in areas of focus to help ensure a pipeline of highly-differentiated product candidates in areas of unmet medical need. The assets managed by IH are science-driven, highly differentiated and generally require a high-level of engagement with healthcare providers and consumers.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">&#9679;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">EH is expected to generate strong consistent cash flow by providing patients around the world with access to effective, lower-cost, high-value treatments. EH leverages our biologic development, regulatory and manufacturing expertise to seek to advance its biosimilar development portfolio. Additionally, EH leverages capabilities in formulation development and manufacturing expertise to help advance its generic sterile injectables portfolio. EH may also engage in targeted business development to further enable its commercial strategies.</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">&#9679;</span></div></td><td style="vertical-align:top;border-bottom:1px dotted #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">IH will have continued focus on R&amp;D productivity and pipeline strength while maximizing the value of our recently launched brands and in-line portfolio. Our acquisitions of Anacor and Medivation expanded our pipeline in the high priority therapeutic areas of inflammation and immunology and oncology.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">&#9679;</span></div></td><td style="vertical-align:top;border-bottom:1px dotted #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">For EH, we continue to invest in growth drivers and manage the portfolio to extract additional value while seeking opportunities for operating efficiencies. This strategy includes active management of our portfolio; maximizing growth of core product segments; acquisitions to strengthen core areas of our portfolio further, such as our recent acquisition of AstraZeneca&#8217;s small molecule anti-infectives business; and divestitures to increase focus on our core strengths. In line with this strategy, on February 3, 2017, we completed the sale of Pfizer&#8217;s global infusion therapy net assets, representing the infusion systems net assets that we acquired as part of the Hospira transaction, HIS, to ICU Medical.</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #000000;"><div style="font-size:9.5pt;"><span style="font-family:inherit;font-size:5pt;"><br/></span><span style="font-family:inherit;font-size:9.5pt;font-weight:bold;">Leading brands include:<br/></span><span style="font-family:inherit;font-size:9.5pt;">- </span><span style="font-family:inherit;font-size:9.5pt;font-style:italic;">Prevnar 13/Prevenar 13</span><span style="font-family:inherit;font-size:9.5pt;"><br/>- </span><span style="font-family:inherit;font-size:9.5pt;font-style:italic;">Xeljanz</span><span style="font-family:inherit;font-size:9.5pt;"><br/>- </span><span style="font-family:inherit;font-size:9.5pt;font-style:italic;">Eliquis<br/></span><span style="font-family:inherit;font-size:9.5pt;">- </span><span style="font-family:inherit;font-size:9.5pt;font-style:italic;">Lyrica</span><span style="font-family:inherit;font-size:9.5pt;">&#160;(U.S., Japan and certain other markets)<br/>- </span><span style="font-family:inherit;font-size:9.5pt;font-style:italic;">Enbrel</span><span style="font-family:inherit;font-size:9.5pt;">&#160;(outside the U.S. and Canada)<br/>- </span><span style="font-family:inherit;font-size:9.5pt;font-style:italic;">Viagra</span><span style="font-family:inherit;font-size:9.5pt;">&#160;(U.S. and Canada)<br/>- </span><span style="font-family:inherit;font-size:9.5pt;font-style:italic;">Ibrance</span><span style="font-family:inherit;font-size:9.5pt;"><br/>- </span><span style="font-family:inherit;font-size:9.5pt;font-style:italic;">Xtandi</span><span style="font-family:inherit;font-size:9.5pt;"><br/>- Several OTC consumer healthcare products (e.g., </span><span style="font-family:inherit;font-size:9.5pt;font-style:italic;">Advil</span><span style="font-family:inherit;font-size:9.5pt;">&#160;and</span></div><div style="font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#160;&#160;</span><span style="font-family:inherit;font-size:9.5pt;font-style:italic;">Centrum</span><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #000000;"><div style="font-size:9.5pt;"><span style="font-family:inherit;font-size:5pt;"><br/></span><span style="font-family:inherit;font-size:9.5pt;font-weight:bold;">Leading brands include:<br/></span><span style="font-family:inherit;font-size:9.5pt;">- </span><span style="font-family:inherit;font-size:9.5pt;font-style:italic;">Lipitor<br/></span><span style="font-family:inherit;font-size:9.5pt;">- </span><span style="font-family:inherit;font-size:9.5pt;font-style:italic;">Premarin</span><span style="font-family:inherit;font-size:9.5pt;">&#160;family<br/>- </span><span style="font-family:inherit;font-size:9.5pt;font-style:italic;">Norvasc</span><span style="font-family:inherit;font-size:9.5pt;"><br/>- </span><span style="font-family:inherit;font-size:9.5pt;font-style:italic;">Lyrica</span><span style="font-family:inherit;font-size:9.5pt;">&#160;(Europe, Russia, Turkey, Israel and Central Asia</span></div><div style="text-indent:6px;font-size:10pt;"><span style="font-family:inherit;font-size:9.5pt;">countries)<br/>- </span><span style="font-family:inherit;font-size:9.5pt;font-style:italic;">Celebrex<br/></span><span style="font-family:inherit;font-size:9.5pt;">- </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Inflectra/Remsima</span><span style="font-family:inherit;font-size:9.5pt;"><br/>- Several sterile injectable products</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:9px;padding-top:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For additional information about the </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;"> performance for each of our operating segments, see the &#8220;Analysis of Operating Segment Information&#8221; section of this MD&amp;A.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">55</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Description of Research and Development Operations</span></div><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Innovation is critical to the success of our company, and drug discovery and development is time-consuming, expensive and unpredictable. Our R&amp;D priorities include delivering a pipeline of differentiated therapies and vaccines with the greatest medical and commercial promise, innovating new capabilities that can position Pfizer for long-term leadership and creating new models for biomedical collaboration that will expedite the pace of innovation and productivity. To that end, our research primarily focuses on:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Biosimilars; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inflammation and Immunology;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Metabolic Disease and Cardiovascular Risks;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Neuroscience; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Oncology;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Rare Diseases; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vaccines.</span></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We continue to strengthen our global R&amp;D organization and pursue strategies intended to improve innovation and overall productivity in R&amp;D to achieve a sustainable pipeline that will deliver value in the near term and over time. Our R&amp;D spending is conducted through a number of matrix organizations: </span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research Units within our WRD organization are generally responsible for research assets for our IH business (assets that have not yet achieved proof-of-concept). Our Research Units are organized in a variety of ways (by therapeutic area or combinations of therapeutic areas, by discipline, by location, etc.) to enhance flexibility, cohesiveness and focus. Because of our structure, we can rapidly redeploy resources within a Research Unit between various projects as necessary because the workforce shares similar skills, expertise and/or focus. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;color:#0000ff;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our R&amp;D organization within the EH business supports the large base of EH products and is expected to develop potential new sterile injectable drugs and therapeutic solutions, as well as biosimilars. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our GPD organization is a unified center for late-stage development for our innovative products and is generally responsible for the clinical development of assets that are in clinical trials for our WRD and Innovative portfolios. GPD is expected to enable more efficient and effective development and enhance our ability to accelerate and progress assets through our pipeline. GPD combines certain previously separate development-related functions from the IH business and the WRD organization to achieve a development capability that is expected to deliver high-quality, efficient, and well-executed clinical programs by enabling greater speed, greater cost efficiencies, and reduced complexity across our development portfolio. GPD also provides technical support and other services to Pfizer R&amp;D projects. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our science-based and other platform-services organizations, where a significant portion of our R&amp;D spending occurs, provide technical expertise and other services to the various R&amp;D projects, and are organized into science-based functions (which are part of our WRD organization), such as Pharmaceutical Sciences, Medicinal Chemistry, Regulatory and Drug Safety, and non-science-based functions, such as Facilities, Business Technology and Finance. As a result, within each of these functions, we are able to migrate resources among projects, candidates and/or targets in any therapeutic area and in most phases of development, allowing us to react quickly in response to evolving needs.</span></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We manage R&amp;D operations on a total-company basis through our matrix organizations described above. Specifically, a single committee with representation from the R&amp;D groups and the IH commercial organization is accountable for aligning resources among all of our WRD, GPD and IH R&amp;D projects and for seeking to ensure optimal capital allocation across the Innovative R&amp;D portfolio. We believe that this approach also serves to maximize accountability and flexibility. Our EH R&amp;D organization manages its resources separately from the WRD and GPD organizations.</span></div><div style="line-height:120%;padding-top:9px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Generally, we do not disaggregate total R&amp;D expense by development phase or by therapeutic area since, as described above, we do not manage a significant portion of our R&amp;D operations by development phase or by therapeutic area. Further, as we are able to adjust a significant portion of our spending quickly, as conditions change, we believe that any prior-period information about R&amp;D expense by development phase or by therapeutic area would not necessarily be representative of future spending.</span></div><div style="line-height:120%;padding-top:9px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">While a significant portion of R&amp;D is done internally, we continue to seek out promising chemical and biological lead molecules and innovative technologies developed by third parties to incorporate into our discovery and development processes or projects, as well as our product lines, by entering into collaborations, alliances and license agreements with other companies, as well as leveraging acquisitions and equity- or debt-based investments. These agreements enable us to co-develop, license or acquire promising compounds, technologies or capabilities. We also enter into agreements pursuant to which a third party agrees to fund a portion of the development costs of one of our pipeline products in exchange for rights to receive potential milestone payments, revenue sharing payments, profit sharing payments and/or royalties. Collaboration, alliance, license and </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">56</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;padding-top:9px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">funding agreements and equity- or debt-based investments allow us to share risk and cost and to access external scientific and technological expertise, and enable us to advance our own products as well as in-licensed or acquired products.</span></div><div style="line-height:120%;padding-top:9px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For additional information about R&amp;D by operating segment, see the &#8220;Analysis of Operating Segment Information&#8221; section of this MD&amp;A. For additional information about our pending new drug applications and supplemental filings, see the &#8220;Analysis of the Condensed Consolidated Statements of Income&#8211;&#8211;Product Developments&#8211;&#8211;Biopharmaceutical&#8221; section of this MD&amp;A. For additional information about recent transactions and strategic investments that we believe have the potential to advance our pipeline, see the &#8220;Our Strategy&#8211;&#8211;Our Business Development Initiatives&#8221; section of this MD&amp;A.</span></div><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Intellectual Property Rights</span></div><div style="line-height:120%;padding-top:9px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We continue to aggressively defend our patent rights against increasingly aggressive infringement whenever appropriate, and we will continue to support efforts that strengthen worldwide recognition of patent rights while taking necessary steps to ensure appropriate patient access. In addition, we will continue to employ innovative approaches designed to prevent counterfeit pharmaceuticals from entering the supply chain and to achieve greater control over the distribution of our products, and we will continue to participate in the generics market for our products, whenever appropriate, once they lose exclusivity. Also, the pursuit of valid business opportunities may require us to challenge intellectual property rights held by other companies that we believe were improperly granted. Such challenges may include negotiation and litigation, which may not be successful. For additional information about our current efforts to enforce our intellectual property rights and certain other patent proceedings, see Notes to Condensed Consolidated Financial Statements</span><span style="font-family:Arial;font-size:8pt;">&#8211;&#8211;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 12A1. Commitments and Contingencies: Legal Proceedings</span><span style="font-family:inherit;font-size:10pt;">&#8211;&#8211;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Patent Litigation. </span><span style="font-family:inherit;font-size:10pt;">For information on risks related to patent protection and intellectual property claims by third parties, see &#8220;Risks Related to Intellectual Property&#8221; in Part I, Item 1A, &#8220;Risk Factors&#8221; of our </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;"> Form 10-K.</span></div><div style="line-height:120%;padding-top:9px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Capital Allocation and Expense Management</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We seek to maintain a strong balance sheet and robust liquidity so that we continue to have the financial resources necessary to take advantage of prudent commercial, research and business development opportunities and to directly enhance shareholder value through share repurchases and dividends. For additional information about our financial condition, liquidity, capital resources, share repurchases (including accelerated share repurchases) and dividends, see the &#8220;Analysis of Financial Condition, Liquidity and Capital Resources&#8221; section of this MD&amp;A. For additional information about our recent business development activities, see the &#8220;Our Strategy&#8211;&#8211;Our Business Development Initiatives&#8221; section of this MD&amp;A.</span></div><div style="line-height:120%;padding-top:9px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We remain focused on achieving an appropriate cost structure for the Company. For additional information about our cost-reduction and productivity initiatives, see the &#8220;Costs and Expenses&#8211;&#8211;Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives&#8221; section of this MD&amp;A and Notes to Condensed Consolidated Financial Statements&#8211;&#8211;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 3</span><span style="font-family:inherit;font-size:10pt;">.</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">.</span></div><div style="line-height:120%;padding-top:9px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Our Business Development Initiatives</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are committed to capitalizing on growth opportunities by advancing our own pipeline and maximizing the value of our in-line products, as well as through various forms of business development, which can include alliances, licenses, joint ventures, collaborations, equity- or debt-based investments, dispositions, mergers and acquisitions. We view our business development activity as an enabler of our strategies, and we seek to generate earnings growth and enhance shareholder value by pursuing a disciplined, strategic and financial approach to evaluating business development opportunities. We continue to evaluate business development transactions that have the potential to strengthen one or both of our businesses and their capabilities, such as our acquisitions of Hospira, Medivation, Anacor, and AstraZeneca&#8217;s small molecule anti-infectives business, as well as collaborations, and alliance and license agreements with other companies, including our collaborations with Cellectis, OPKO and Merck KGaA. We assess our businesses, assets and scientific capabilities/portfolio as part of our regular, ongoing portfolio review process and also continue to consider business development activities that will advance our businesses. In October 2017, we announced that we are reviewing strategic alternatives for our Consumer Healthcare business. A range of options will be considered, including a full or partial separation of the Consumer Healthcare business from Pfizer through a spin-off, sale or other transaction, and we may ultimately determine to retain the business. We expect that any decision regarding strategic alternatives for Consumer Healthcare would be made during 2018. For additional information on our business development activities, see Notes to Condensed Consolidated Financial Statements&#8211;&#8211;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 2. </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Acquisitions, Sale of Hospira Infusion Systems Net Assets, Collaborative Arrangement and Equity-Method Investments</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">.</span></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The more significant recent transactions and events are described below:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Sale of Hospira Infusion Systems Net Assets to ICU Medical, Inc. (EH)</span><span style="font-family:inherit;font-size:10pt;">&#8211;&#8211;On February 3, 2017, we completed the sale of our global infusion therapy net assets, HIS, to ICU Medical. In connection with this transaction, we recognized pre-tax income of approximately </span><span style="font-family:inherit;font-size:10pt;">$12 million</span><span style="font-family:inherit;font-size:10pt;"> in the third quarter of 2017 and pre-tax losses of approximately </span><span style="font-family:inherit;font-size:10pt;">$52 million</span><span style="font-family:inherit;font-size:10pt;"> in the first </span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">57</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;padding-left:18px;padding-top:6px;text-align:left;"><span style="font-family:inherit;font-size:10pt;">nine months of 2017 in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net</span><span style="font-family:inherit;font-size:10pt;">, representing adjustments to amounts previously recorded to write down the HIS net assets to fair value less costs to sell. We may record additional adjustments to the loss on the sale of HIS net assets in future periods, pending final working capital adjustments and local market closes, among other agreement provisions, which we do not expect to have a material impact on our consolidated financial statements.</span></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Acquisition of AstraZeneca&#8217;s Small Molecule Anti-Infectives Business (EH)</span><span style="font-family:inherit;font-size:10pt;">&#8211;&#8211;On December 22, 2016, which falls in the first fiscal quarter of 2017 for our international operations, we acquired the development and commercialization rights to AstraZeneca&#8217;s small molecule anti-infectives business, primarily outside the U.S. The total fair value of the consideration transferred for this business was approximately </span><span style="font-family:inherit;font-size:10pt;">$555 million</span><span style="font-family:inherit;font-size:10pt;"> in cash plus the fair value of contingent consideration of </span><span style="font-family:inherit;font-size:10pt;">$490 million</span><span style="font-family:inherit;font-size:10pt;">.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Acquisition of Medivation, Inc. (IH)</span><span style="font-family:inherit;font-size:10pt;">&#8211;&#8211;On September 28, 2016, we acquired Medivation for </span><span style="font-family:inherit;font-size:10pt;">$81.50</span><span style="font-family:inherit;font-size:10pt;"> per share. The total fair value of consideration transferred for Medivation was approximately </span><span style="font-family:inherit;font-size:10pt;">$14.3 billion</span><span style="font-family:inherit;font-size:10pt;"> in cash (</span><span style="font-family:inherit;font-size:10pt;">$13.9 billion</span><span style="font-family:inherit;font-size:10pt;">, net of cash acquired). Medivation&#8217;s portfolio includes Xtandi (enzalutamide), an androgen receptor inhibitor that blocks multiple steps in the androgen receptor signaling pathway within tumor cells. Xtandi is being developed and commercialized through a collaboration with Astellas. Astellas has exclusive commercialization rights for Xtandi outside the U.S. In addition, Medivation has a development-stage oncology asset in its pipeline, talazoparib, which is currently in a Phase 3 study for the treatment of BRCA-mutated breast cancer.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Acquisition of Bamboo Therapeutics, Inc. (R&amp;D)</span><span style="font-family:inherit;font-size:10pt;">&#8211;&#8211;On August 1, 2016, we acquired all the remaining equity in Bamboo, a privately-held biotechnology company, focused on developing gene therapies for the potential treatment of patients with certain rare diseases relating to neuromuscular conditions and those affecting the central nervous system, for </span><span style="font-family:inherit;font-size:10pt;">$150 million</span><span style="font-family:inherit;font-size:10pt;">, plus potential milestone payments of up to </span><span style="font-family:inherit;font-size:10pt;">$495 million</span><span style="font-family:inherit;font-size:10pt;"> contingent upon the progression of key assets through development, regulatory approval and commercialization. We previously purchased a minority stake in Bamboo in the first quarter of 2016 for a payment of approximately </span><span style="font-family:inherit;font-size:10pt;">$43 million</span><span style="font-family:inherit;font-size:10pt;">. This acquisition provides us with several clinical and pre-clinical assets that complement our rare disease portfolio, an advanced recombinant AAV vector design and production technology, and a fully functional Phase I/II gene therapy manufacturing facility. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Acquisition of Anacor Pharmaceuticals, Inc. (IH)</span><span style="font-family:inherit;font-size:10pt;">&#8211;&#8211;On June 24, 2016, we acquired Anacor for </span><span style="font-family:inherit;font-size:10pt;">$99.25</span><span style="font-family:inherit;font-size:10pt;"> per share. The total fair value of consideration transferred for Anacor was approximately </span><span style="font-family:inherit;font-size:10pt;">$4.9 billion</span><span style="font-family:inherit;font-size:10pt;"> in cash (</span><span style="font-family:inherit;font-size:10pt;">$4.5 billion</span><span style="font-family:inherit;font-size:10pt;"> net of cash acquired) plus </span><span style="font-family:inherit;font-size:10pt;">$698 million</span><span style="font-family:inherit;font-size:10pt;"> debt assumed. Anacor&#8217;s crisaborole, a non-steroidal topical PDE-4 inhibitor with anti-inflammatory properties, was approved by the FDA on December 14, 2016 under the trade name Eucrisa, for the treatment of mild-to-moderate atopic dermatitis in patients two years of age and older, commonly referred to as a type of eczema. Anacor also holds the rights to Kerydin, a topical treatment for onychomycosis (toenail fungus) that is distributed and commercialized by Sandoz</span><span style="font-family:inherit;font-size:10pt;color:#444444;"> in the U.S.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Research and Development Arrangement with NovaQuest Co-Investment Fund V, L.P.</span><span style="font-family:inherit;font-size:10pt;">&#8211;&#8211;In April 2016, Pfizer entered into an agreement with NovaQuest under which NovaQuest will fund up to $200 million in development costs related to certain Phase III clinical trials of Pfizer&#8217;s rivipansel compound and Pfizer will use commercially reasonable efforts to develop and obtain regulatory approvals for such compound. NovaQuest&#8217;s development funding is expected to cover up to 100% of the development costs and will be received over approximately twelve quarters from 2016 to 2019. As there is a substantive and genuine transfer of risk to NovaQuest, the development funding is recognized by us as an obligation to perform contractual services and therefore is a reduction of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Research and development expenses</span><span style="font-family:inherit;font-size:10pt;"> as incurred. The reduction to </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Research and development expenses</span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">third</span><span style="font-family:inherit;font-size:10pt;"> quarter of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span><span style="font-family:inherit;font-size:10pt;">totaled </span><span style="font-family:inherit;font-size:10pt;">$16.8 million</span><span style="font-family:inherit;font-size:10pt;"> and for the </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;"> totaled </span><span style="font-family:inherit;font-size:10pt;">$48.8 million</span><span style="font-family:inherit;font-size:10pt;">. The reduction to </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Research and development expenses</span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">third quarter</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;"> totaled </span><span style="font-family:inherit;font-size:10pt;">$14.5 million</span><span style="font-family:inherit;font-size:10pt;"> and for the </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;"> totaled </span><span style="font-family:inherit;font-size:10pt;">$29.5 million</span><span style="font-family:inherit;font-size:10pt;">. Following potential regulatory approval, NovaQuest will be eligible to receive a combination of fixed milestone payments of up to approximately </span><span style="font-family:inherit;font-size:10pt;">$267 million</span><span style="font-family:inherit;font-size:10pt;"> in total, based on achievement of first commercial sale and certain levels of cumulative net sales as well as royalties on rivipansel net sales over approximately eight years. Fixed sales-based milestone payments will be recorded as intangible assets and amortized to </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Amortization of intangible assets</span><span style="font-family:inherit;font-size:10pt;"> over the estimated commercial life of the rivipansel product and royalties on net sales will be recorded as </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Cost of sales</span><span style="font-family:inherit;font-size:10pt;"> when incurred.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Research and Development Arrangement with RPI Finance Trust</span><span style="font-family:inherit;font-size:10pt;">&#8211;&#8211;In January 2016, Pfizer entered into an agreement with RPI, a subsidiary of Royalty Pharma, under which RPI will fund up to </span><span style="font-family:inherit;font-size:10pt;">$300 million</span><span style="font-family:inherit;font-size:10pt;"> in development costs related to certain Phase III clinical trials of Pfizer&#8217;s Ibrance (palbociclib) product primarily for adjuvant treatment of hormone receptor positive early breast cancer (the Indication). RPI&#8217;s development funding is expected to cover up to 100% of the costs primarily for the applicable clinical trials through 2021. As there is a substantive and genuine transfer of risk to RPI, the development funding is recognized by us as an obligation to perform contractual services and therefore is a reduction of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Research and development expenses</span><span style="font-family:inherit;font-size:10pt;"> as incurred. The reduction to </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Research and development expenses</span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">third</span><span style="font-family:inherit;font-size:10pt;"> quarter of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;"> totaled </span><span style="font-family:inherit;font-size:10pt;">$27.6 million</span><span style="font-family:inherit;font-size:10pt;"> and for the </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;"> totaled </span><span style="font-family:inherit;font-size:10pt;">$54.4 million</span><span style="font-family:inherit;font-size:10pt;">. The reduction to </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Research and development expenses</span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">third</span><span style="font-family:inherit;font-size:10pt;"> quarter of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;"> totaled </span><span style="font-family:inherit;font-size:10pt;">$11.0 million</span><span style="font-family:inherit;font-size:10pt;"> and for the </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;"> totaled </span><span style="font-family:inherit;font-size:10pt;">$32.7 million</span><span style="font-family:inherit;font-size:10pt;">. If successful and upon approval of Ibrance in the U.S. or certain major markets in the EU for the Indication based </span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">58</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;padding-left:18px;padding-top:6px;text-align:left;"><span style="font-family:inherit;font-size:10pt;">on the applicable clinical trials, RPI will be eligible to receive a combination of approval-based fixed milestone payments of up to $250 million dependent upon results of the clinical trials and royalties on certain Ibrance sales over approximately seven years. Fixed milestone payments due upon approval will be recorded as intangible assets and amortized to </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Amortization of intangible assets</span><span style="font-family:inherit;font-size:10pt;"> over the estimated commercial life of the Ibrance product and sales-based royalties will be recorded as </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Cost of sales</span><span style="font-family:inherit;font-size:10pt;"> when incurred.</span></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Approval of Besponsa</span><span style="font-family:inherit;font-size:10pt;">&#8211;&#8211;In August 2017, the U.S. approved Besponsa (inotuzumab ozogamicin) and in June 2017, the EU approved Besponsa as monotherapy for the treatment of adults with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia. In connection with the U.S. approval, we incurred an obligation to make guaranteed fixed annual payments over a nine-year period aggregating </span><span style="font-family:inherit;font-size:10pt;">$296 million</span><span style="font-family:inherit;font-size:10pt;"> related to a research and development arrangement. As a result, we have recorded the estimated net present value of </span><span style="font-family:inherit;font-size:10pt;">$248 million</span><span style="font-family:inherit;font-size:10pt;"> as an intangible asset in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Developed technology rights</span><span style="font-family:inherit;font-size:10pt;">, and we have recorded </span><span style="font-family:inherit;font-size:10pt;">$233 million</span><span style="font-family:inherit;font-size:10pt;"> in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other noncurrent liabilities </span><span style="font-family:inherit;font-size:10pt;">and </span><span style="font-family:inherit;font-size:10pt;">$15 million</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span><span style="font-family:inherit;font-size:10pt;">in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other current liabilities</span><span style="font-family:inherit;font-size:10pt;"> as of October 1, 2017. In connection with the EU approval, we incurred an obligation to make guaranteed fixed annual payments over a nine-year period aggregating </span><span style="font-family:inherit;font-size:10pt;">$148 million</span><span style="font-family:inherit;font-size:10pt;"> related to a research and development arrangement. As a result, we have recorded the estimated net present value of </span><span style="font-family:inherit;font-size:10pt;">$123 million</span><span style="font-family:inherit;font-size:10pt;"> as an intangible asset in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Developed technology rights</span><span style="font-family:inherit;font-size:10pt;">, and we have recorded </span><span style="font-family:inherit;font-size:10pt;">$117 million</span><span style="font-family:inherit;font-size:10pt;"> in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other noncurrent liabilities </span><span style="font-family:inherit;font-size:10pt;">and</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span><span style="font-family:inherit;font-size:10pt;">$6 million</span><span style="font-family:inherit;font-size:10pt;"> in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other current liabilities</span><span style="font-family:inherit;font-size:10pt;"> as of October 1, 2017.</span></div></td></tr></table><div style="line-height:120%;padding-left:4px;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For a description of the more significant recent transactions through February 23, </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;">, the filing date of our </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;"> Form 10-K, see the &#8220;Our Business Development Initiatives&#8221; section of our </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;"> Financial Report.</span></div><div style="line-height:120%;padding-left:4px;text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Our Financial Guidance for </span><span style="font-family:inherit;font-size:11pt;font-weight:bold;text-align:center;text-decoration:underline;">2017</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On October 31, 2017, we updated our </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;"> financial guidance. Specifically, we narrowed the ranges for certain 2017 financial guidance components, including a $0.03 increase to the midpoint of our range for adjusted diluted EPS guidance to a range of </span><span style="font-family:inherit;font-size:10pt;">$2.58 to $2.62</span><span style="font-family:inherit;font-size:10pt;">. The midpoint of our new guidance range for adjusted diluted EPS implies 8% growth compared with last year.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.02534113060429%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:50%;"></td><td style="width:50%;"></td></tr><tr><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pfizer&#8217;s updated 2017 financial guidance is presented below</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a),</sup></span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#160;</sup></span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(b)</sup></span><span style="font-family:inherit;font-size:9pt;">:</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$52.4 to $53.1 billion</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-style:italic;">(previously $52.0 to $54.0 billion)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Adjusted cost of sales as a percentage of revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">20.0% to 20.5%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-style:italic;">(previously 20.0% to 21.0%)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Adjusted selling, informational and administrative expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$14.0 to $14.5 billion</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-style:italic;">(previously $13.7 to $14.7 billion)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Adjusted research and development expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$7.5 to $7.8 billion</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-style:italic;">(previously $7.5 to $8.0 billion)</span></div></td></tr><tr><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Adjusted other (income)/deductions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Approximately $500 million of income</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-style:italic;">(previously approximately $200 million of income)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Effective tax rate on adjusted income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Approximately 23.0%</span></div></td></tr><tr><td rowspan="2" style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Adjusted diluted EPS</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$2.58 to $2.62</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-style:italic;">(previously $2.54 to $2.60)</span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">T</span><span style="font-family:inherit;font-size:8pt;">he </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:8pt;"> financial guidance reflects the following:</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:1px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:12px;"><span style="font-family:inherit;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Does not assume the completion of any business development transactions&#160;not completed as of </span><span style="font-family:inherit;font-size:8pt;text-align:center;">October&#160;1, 2017</span><span style="font-family:inherit;font-size:8pt;">, including any one-time upfront payments associated with such transactions.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:1px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:12px;"><span style="font-family:inherit;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Exchange rates assumed are a blend of the actual exchange rates in effect through September 2017 and mid-October 2017 exchange rates for the remainder of the year.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:1px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:12px;"><span style="font-family:inherit;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Reflects an anticipated negative revenue impact of </span><span style="font-family:inherit;font-size:8pt;">$2.3 billion</span><span style="font-family:inherit;font-size:8pt;"> </span><span style="font-family:inherit;font-size:8pt;">due to recent and expected generic and biosimilar competition for certain products that have recently lost or are anticipated to soon lose patent protection.</span><span style="font-family:inherit;font-size:8pt;"> </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:1px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:12px;"><span style="font-family:inherit;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Reflects the anticipated negative impact of </span><span style="font-family:inherit;font-size:8pt;">$0.1 billion</span><span style="font-family:inherit;font-size:8pt;"> on revenues and </span><span style="font-family:inherit;font-size:8pt;">$0.01</span><span style="font-family:inherit;font-size:8pt;"> on adjusted diluted EPS as a result of unfavorable changes in foreign exchange rates relative to the U.S. dollar compared to foreign exchange rates from </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:8pt;">.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:12px;"><span style="font-family:inherit;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Guidance for adjusted diluted EPS assumes diluted weighted-average shares outstanding of between </span><span style="font-family:inherit;font-size:8pt;">6.0 and 6.1</span><span style="font-family:inherit;font-size:8pt;"> billion shares, which reflects the impact of our $5.0 billion accelerated share repurchase agreement executed in February 2017 and completed in May 2017.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:8pt;">For an understanding of Adjusted income and its components and Adjusted diluted EPS (all of which are non-GAAP financial measures), see the &#8220;Non-GAAP Financial Measure (Adjusted Income)&#8221; section of this MD&amp;A.</span></div></td></tr></table><div style="line-height:120%;padding-top:1px;text-align:left;padding-left:12px;font-size:9pt;"><span style="font-family:inherit;font-size:8pt;">Pfizer does not provide guidance for GAAP Reported financial measures (other than Revenues) or a reconciliation of forward-looking non-GAAP financial measures to the most directly comparable GAAP Reported financial measures on a forward-looking basis because it is unable to predict with reasonable certainty the ultimate outcome of pending litigation, unusual gains and losses, acquisition-related expenses and potential future asset impairments without unreasonable effort. These items are uncertain, depend on various factors, and could have a material impact on GAAP Reported results for the guidance period.</span><span style="font-family:inherit;font-size:9pt;"> </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">59</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For information about our actual costs and anticipated costs and cost savings associated with our three-year cost-reduction initiative entered into in the fourth quarter of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;">, the Hospira acquisition, our recent business development activities, and global commercial structure, see the &#8220;Costs and Expenses&#8211;&#8211;Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives&#8221; section of this MD&amp;A and Notes to Condensed Consolidated Financial Statements&#8211;&#8211;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 3</span><span style="font-family:inherit;font-size:10pt;">.</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">.</span></div><div style="line-height:120%;text-align:left;font-size:5pt;"><span style="font-family:inherit;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;"> financial guidance is subject to a number of factors and uncertainties as described in the &#8220;Our Operating Environment&#8221;, &#8220;The Global Economic Environment&#8221;, &#8220;Our Strategy&#8221; and &#8220;Forward-Looking Information and Factors That May Affect Future Results&#8221; sections of this MD&amp;A; in Part II, Item 1A, &#8220;Risk Factors&#8221;, of this Quarterly Report on Form 10-Q; and Part I, Item 1A, &#8220;Risk Factors&#8221; of our </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;"> Form 10-K.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">SIGNIFICANT ACCOUNTING POLICIES AND APPLICATION OF CRITICAL ACCOUNTING ESTIMATES AND ASSUMPTIONS</span></div><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For a description of our significant accounting policies, see Notes to Consolidated Financial Statements&#8211;&#8211;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 1. Basis of Presentation and Significant Accounting Policies </span><span style="font-family:inherit;font-size:10pt;">in our </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;"> Form 10-K. Of these policies, the following are considered critical to an understanding of our consolidated financial statements as they require the application of the most subjective and the most complex judgments: (i) Acquisitions (Note 1D); (ii) Fair Value (Note 1E); (iii) Revenues (Note 1G); (iv) Asset Impairments (Note 1K); (v) Income Tax Contingencies (Note 1O); (vi) Pension and Postretirement Benefit Plans (Note 1P); and Legal and Environmental Contingencies (Note 1Q). </span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:inherit;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For a discussion about the critical accounting estimates and assumptions impacting our consolidated financial statements, see the &#8220;Significant Accounting Policies and Application of Critical Accounting Estimates and Assumptions&#8221; section of our </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;"> Financial Report. See also Notes to Consolidated Financial Statements&#8211;&#8211;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 1C. Basis of Presentation and Significant Accounting Policies: Estimates and Assumptions</span><span style="font-family:inherit;font-size:10pt;"> for a discussion about the risks associated with estimates and assumptions in our </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;"> Form 10-K.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For a discussion of recently adopted accounting standards, see Notes to Condensed Consolidated Financial Statements&#8211;&#8211;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 1B. </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Basis of Presentation and Significant Accounting Policies</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">: Adoption of New Accounting Standards.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">60</span></div></div><hr style="page-break-after:always"></hr><div><a id="s45751624BA2157C6BBB36A7582911BD4"></a></div><div><br/></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">ANALYSIS OF THE CONDENSED CONSOLIDATED STATEMENTS OF INCOME</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:inherit;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">REVENUES AND PRODUCT DEVELOPMENTS</span></div><div style="line-height:120%;text-align:left;font-size:5pt;"><span style="font-family:inherit;font-size:5pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Revenues</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">&#8211;&#8211;</span><span style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Overview</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following graphs show revenues by geography (dollars in billions):</span></div><div style="line-height:120%;text-align:left;"><img src="pfe-3q17qtdrevbygeo.jpg" alt="pfe-3q17qtdrevbygeo.jpg" style="height:310px;width:341px;"></img><img src="pfe-3q17ytdrevbygeo.jpg" alt="pfe-3q17ytdrevbygeo.jpg" style="height:310px;width:342px;"></img></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.05068226120858%;border-collapse:collapse;text-align:left;"><tr><td colspan="34"></td></tr><tr><td style="width:17%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td></tr><tr><td colspan="34" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following tables provide worldwide revenues by operating segment and by geography:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="32" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Three Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Worldwide</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">International</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">World-wide</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Inter-national</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Oct&#160;1, <br/>2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Oct&#160;2, 2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Oct&#160;1, 2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Oct&#160;2, 2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Oct&#160;1, 2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Oct&#160;2, 2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">% Change in Revenues</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Operating Segments</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span><span style="font-family:inherit;font-size:9pt;">:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">IH</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">8,118</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">7,332</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">4,777</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">4,244</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">3,341</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">3,088</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">11</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">13</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">8</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">EH</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">5,050</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">5,712</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1,756</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">2,286</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">3,294</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">3,426</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(12</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(23</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(4</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">13,168</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">13,045</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">6,534</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">6,530</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">6,634</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">6,515</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">2</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="34" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="32" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Nine Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Worldwide</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">International</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">World-wide</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Inter-national</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Oct&#160;1, 2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Oct&#160;2, 2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Oct&#160;1, 2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Oct&#160;2, 2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Oct&#160;1, 2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Oct&#160;2, 2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">% Change in Revenues</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Operating Segments</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span><span style="font-family:inherit;font-size:9pt;">:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">IH</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">23,204</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">21,471</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">13,708</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">12,308</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">9,496</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">9,163</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">8</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">11</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">4</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">EH</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">15,639</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">17,725</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">5,808</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">7,253</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">9,831</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">10,472</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(12</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(20</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(6</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">38,843</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">39,196</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">19,516</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">19,561</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">19,327</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">19,636</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(1</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(2</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">IH = the Innovative Health segment; and EH = the Essential Health segment. For additional information about each operating segment, see the &#8220;Our Strategy&#8211;&#8211;Commercial Operations&#8221; and &#8220;Analysis of Operating Segment Information&#8221; sections of this MD&amp;A and Notes to Condensed Consolidated Financial Statements&#8211;&#8211;</span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Note 13A. </span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Segment, Geographic and Other Revenue Information</span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">: Segment Information.</span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">61</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Revenues&#8211;&#8211;</span><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Third Quarter</span><span style="font-family:inherit;font-size:10pt;text-decoration:underline;"> of </span><span style="font-family:inherit;font-size:10pt;text-align:center;text-decoration:underline;">2017</span><span style="font-family:inherit;font-size:10pt;text-decoration:underline;"> vs. </span><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Third Quarter</span><span style="font-family:inherit;font-size:10pt;text-decoration:underline;"> of </span><span style="font-family:inherit;font-size:10pt;text-align:center;text-decoration:underline;">2016</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:66%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td colspan="13" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following provides an analysis of the change in revenues by geographic areas in the third quarter of 2017:</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Three Months Ended October&#160;1, 2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Worldwide</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">International</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:4px;text-align:left;padding-left:18px;text-indent:-18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;text-decoration:underline;">Disposition-related operational impact:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:4px;text-align:left;padding-left:18px;text-indent:-18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Financial results in the third quarter of 2017 do not reflect any contribution from HIS global operations, compared to the inclusion of three months of HIS global operations in the same period in 2016 (February 2017 sale) </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:4px;text-align:left;padding-left:18px;text-indent:-18px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="padding-top:4px;text-align:right;padding-left:18px;text-indent:-18px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(280</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:4px;text-align:left;padding-left:18px;text-indent:-18px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:4px;text-align:left;padding-left:18px;text-indent:-18px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="padding-top:4px;text-align:right;padding-left:18px;text-indent:-18px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(220</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:4px;text-align:left;padding-left:18px;text-indent:-18px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:4px;text-align:left;padding-left:18px;text-indent:-18px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="padding-top:4px;text-align:right;padding-left:18px;text-indent:-18px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(60</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:4px;text-align:left;padding-left:18px;text-indent:-18px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:4px;text-align:left;padding-left:18px;text-indent:-18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;text-decoration:underline;">Other operational growth/(decline):</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Continued growth from key brands including Ibrance and Eliquis globally, as well as Lyrica (IH) and Xeljanz, both primarily in the U.S. </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:4px;text-align:right;padding-left:18px;text-indent:-18px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">751</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:4px;text-align:right;padding-left:18px;text-indent:-18px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">460</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:4px;text-align:right;padding-left:18px;text-indent:-18px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">291</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Growth in Xtandi alliance revenues in the U.S. (September 2016 acquisition of Medivation) </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:4px;text-align:right;padding-left:18px;text-indent:-18px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">148</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:4px;text-align:right;padding-left:18px;text-indent:-18px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">148</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:4px;text-align:right;padding-left:18px;text-indent:-18px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Growth from Biosimilars</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:4px;text-align:right;padding-left:18px;text-indent:-18px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">55</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:4px;text-align:right;padding-left:18px;text-indent:-18px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">34</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:4px;text-align:right;padding-left:18px;text-indent:-18px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">21</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Decline from Peri-LOE Products, including declines in Pristiq in the U.S., which lost marketing exclusivity in the U.S. in March 2017, as well as Lyrica (EH) and Vfend, both primarily in developed Europe markets </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(220</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(103</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(117</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Decline from the Sterile Injectable Pharmaceuticals portfolio, primarily due to legacy Hospira product shortages in the U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(182</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(196</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">14</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Lower revenues for Viagra (IH) in the U.S. primarily due to wholesaler destocking in advance of anticipated generic competition beginning in December 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(91</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(91</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Lower revenues for Enbrel, primarily in most developed Europe markets due to continued biosimilar competition </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(89</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(89</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Decline in Prevnar 13/Prevenar 13 revenues. U.S. revenues decreased primarily due to the continued decline in revenues for the Adult indication due to a smaller remaining &#8220;catch up&#8221; opportunity compared to the prior-year quarter, partially offset by growth from the pediatric indication. International revenues increased primarily due to the favorable overall impact of timing of government purchases in certain emerging markets and the launch of Prevenar 13 in China for the pediatric indication.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(16</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(40</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:4px;text-align:right;padding-left:18px;text-indent:-18px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">24</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other operational factors, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">102</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">12</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">89</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Operational growth, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">178</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">4</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">174</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Unfavorable impact of foreign exchange</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(54</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(54</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">Revenues</span><span style="font-family:inherit;font-size:9pt;">&#160;increase</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">123</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">4</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">120</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Emerging markets revenues </span><span style="font-family:inherit;font-size:10pt;">increase</span><span style="font-family:inherit;font-size:10pt;">d </span><span style="font-family:inherit;font-size:10pt;">$254 million</span><span style="font-family:inherit;font-size:10pt;">, or </span><span style="font-family:inherit;font-size:10pt;">10%</span><span style="font-family:inherit;font-size:10pt;">, in the </span><span style="font-family:inherit;font-size:10pt;">third</span><span style="font-family:inherit;font-size:10pt;"> quarter of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;">$2.8 billion</span><span style="font-family:inherit;font-size:10pt;">, reflecting an operational </span><span style="font-family:inherit;font-size:10pt;">increase</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;">$280 million</span><span style="font-family:inherit;font-size:10pt;">, or </span><span style="font-family:inherit;font-size:10pt;">11%</span><span style="font-family:inherit;font-size:10pt;">. Foreign exchange had </span><span style="font-family:inherit;font-size:10pt;">an unfavorable</span><span style="font-family:inherit;font-size:10pt;"> impact of approximately </span><span style="font-family:inherit;font-size:10pt;">1%</span><span style="font-family:inherit;font-size:10pt;"> on emerging markets revenues. The operational </span><span style="font-family:inherit;font-size:10pt;">increase</span><span style="font-family:inherit;font-size:10pt;"> in emerging markets was primarily driven by our IH segment as well as our Legacy Established Products and Sterile Injectable Pharmaceuticals portfolios.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">62</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Revenues&#8211;&#8211;First </span><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Nine Months</span><span style="font-family:inherit;font-size:10pt;text-decoration:underline;"> of </span><span style="font-family:inherit;font-size:10pt;text-align:center;text-decoration:underline;">2017</span><span style="font-family:inherit;font-size:10pt;text-decoration:underline;"> vs. First </span><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Nine Months</span><span style="font-family:inherit;font-size:10pt;text-decoration:underline;"> of </span><span style="font-family:inherit;font-size:10pt;text-align:center;text-decoration:underline;">2016</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.41520467836257%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:66%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td colspan="13" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following provides an analysis of the change in revenues by geographic areas in the first nine months of 2017:</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Nine Months Ended October 1, 2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Worldwide</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">International</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;text-decoration:underline;">Disposition-related operational impact:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Approximately one month of HIS domestic operations and approximately two months of HIS international operations in the first nine months of 2017, compared to nine months of HIS global operations in the same period in 2016 (February 2017 sale) </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:4px;text-align:left;padding-left:18px;text-indent:-18px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="padding-top:4px;text-align:right;padding-left:18px;text-indent:-18px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(783</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:4px;text-align:left;padding-left:18px;text-indent:-18px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:4px;text-align:left;padding-left:18px;text-indent:-18px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="padding-top:4px;text-align:right;padding-left:18px;text-indent:-18px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(626</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:4px;text-align:left;padding-left:18px;text-indent:-18px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:4px;text-align:left;padding-left:18px;text-indent:-18px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="padding-top:4px;text-align:right;padding-left:18px;text-indent:-18px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(158</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:4px;text-align:left;padding-left:18px;text-indent:-18px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;text-decoration:underline;">Other operational growth/(decline):</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Continued growth from key brands including Ibrance and Eliquis globally, as well as Lyrica (IH) and Xeljanz, both primarily in the U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:4px;text-align:right;padding-left:18px;text-indent:-18px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">2,102</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:4px;text-align:right;padding-left:18px;text-indent:-18px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1,404</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:4px;text-align:right;padding-left:18px;text-indent:-18px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">698</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Growth in Xtandi alliance revenues in the U.S. (September 2016 acquisition of Medivation) </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:4px;text-align:right;padding-left:18px;text-indent:-18px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">420</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:4px;text-align:right;padding-left:18px;text-indent:-18px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">420</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:4px;text-align:right;padding-left:18px;text-indent:-18px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Growth from Biosimilars</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:4px;text-align:right;padding-left:18px;text-indent:-18px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">143</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:4px;text-align:right;padding-left:18px;text-indent:-18px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">74</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:4px;text-align:right;padding-left:18px;text-indent:-18px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">69</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Decline from Peri-LOE Products, including declines in Pristiq in the U.S., which lost marketing exclusivity in the U.S. in March 2017, as well as Lyrica (EH) and Vfend, both primarily in developed Europe markets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(779</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(342</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(437</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Lower revenues for Enbrel, primarily in most developed Europe markets due to continued biosimilar competition </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(353</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(353</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Decline in the Legacy Established Products portfolio</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(250</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(314</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:4px;text-align:right;padding-left:18px;text-indent:-18px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">64</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Decline in Prevnar 13/Prevenar 13 revenues. U.S. revenues decreased primarily due to the continued decline in revenues for the Adult indication due to a smaller remaining &#8220;catch up&#8221; opportunity compared to the first nine months of 2016, partially offset by growth from the pediatric indication. International revenues increased primarily due to the favorable overall impact of timing of government purchases in certain emerging markets and the launch of Prevenar 13 in China for the pediatric indication.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(213</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(256</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:4px;text-align:right;padding-left:18px;text-indent:-18px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">44</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Decline in Viagra (IH) revenues mainly in the U.S. primarily due to lower market growth</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(186</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(186</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(1</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Decline from the Sterile Injectable Pharmaceuticals portfolio, primarily due to legacy Hospira product shortages in the U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(169</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(253</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">84</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other operational factors, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">87</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">33</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">54</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Operational growth (decline), net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">19</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(45</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">64</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Unfavorable impact of foreign exchange</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(372</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(372</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Revenues decrease</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(353</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(45</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(308</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Emerging markets revenues </span><span style="font-family:inherit;font-size:10pt;">increase</span><span style="font-family:inherit;font-size:10pt;">d </span><span style="font-family:inherit;font-size:10pt;">$508 million</span><span style="font-family:inherit;font-size:10pt;">, or </span><span style="font-family:inherit;font-size:10pt;">7%</span><span style="font-family:inherit;font-size:10pt;">, in the </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;">$8.2 billion</span><span style="font-family:inherit;font-size:10pt;">, reflecting an operational </span><span style="font-family:inherit;font-size:10pt;">increase</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;">$684 million</span><span style="font-family:inherit;font-size:10pt;">, or </span><span style="font-family:inherit;font-size:10pt;">9%</span><span style="font-family:inherit;font-size:10pt;">. Foreign exchange had an </span><span style="font-family:inherit;font-size:10pt;">unfavorable</span><span style="font-family:inherit;font-size:10pt;"> impact of approximately </span><span style="font-family:inherit;font-size:10pt;">2%</span><span style="font-family:inherit;font-size:10pt;"> on emerging markets revenues. The operational </span><span style="font-family:inherit;font-size:10pt;">increase</span><span style="font-family:inherit;font-size:10pt;"> in emerging markets was primarily driven by our IH segment as well as our Legacy Established Products and Sterile Injectable Pharmaceuticals portfolios.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Revenue Deductions</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our gross product revenues are subject to a variety of deductions that are generally estimated and recorded in the same period that the revenues are recognized, and primarily represent chargebacks, rebates and sales allowances to wholesalers, and, to a lesser extent, distributors like MCOs, retailers and government agencies with respect to our pharmaceutical products. Those deductions represent estimates of rebates and discounts related to gross sales for the reporting period and, as such, knowledge and judgment of market conditions and practice are required when estimating the impact of these revenue deductions on gross sales for a reporting period. </span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Historically, our adjustments of estimates, to reflect actual results or updated expectations, have not been material to our overall business. On a quarterly basis, our adjustments of estimates to reflect actual results generally have been less than 1% of revenues, and have resulted in either a net increase or a net decrease in revenues. Product-specific rebates, however, can have a significant impact on year-over-year individual product growth trends.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">63</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.83040935672514%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"></td></tr><tr><td style="width:44%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td colspan="17" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides information about revenue deductions:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Nine Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">October&#160;1, <br/>2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">October&#160;2, <br/>2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">October&#160;1, <br/>2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">October&#160;2, <br/>2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Medicare rebates</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">355</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">285</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">931</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">777</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Medicaid and related state program rebates</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">439</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">338</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1,335</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1,073</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Performance-based contract rebates</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a), (b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">773</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">629</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">2,321</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1,854</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Chargebacks</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1,608</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1,465</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">4,585</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">4,318</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Sales allowances</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(d)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1,419</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1,177</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">3,718</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">3,268</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Sales returns and cash discounts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">329</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">356</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1,025</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1,044</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(e)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">4,923</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">4,251</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">13,916</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">12,334</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:8.5pt;">Rebates are product-specific and, therefore, for any given year are impacted by the mix of products sold.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:8.5pt;">Performance-based contract rebates include contract rebates with MCOs within the U.S., including health maintenance organizations and PBMs, who receive rebates based on the achievement of contracted performance terms and claims under these contracts. Outside the U.S., performance-based contract rebates include rebates to wholesalers/distributors based on achievement of contracted performance for specific products or sales milestones.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(c)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:8.5pt;">Chargebacks primarily represent reimbursements to U.S. wholesalers for honoring contracted prices to third parties.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(d)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:8.5pt;">Sales allowances primarily represent price reductions that are contractual or legislatively mandated outside the U.S., discounts and distribution fees.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(e)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:8.5pt;">For the three months ended </span><span style="font-family:inherit;font-size:8.5pt;">October&#160;1, 2017</span><span style="font-family:inherit;font-size:8.5pt;">, associated with the following segments: IH (</span><span style="font-family:inherit;font-size:8.5pt;">$2.4 billion</span><span style="font-family:inherit;font-size:8.5pt;">) and EH (</span><span style="font-family:inherit;font-size:8.5pt;">$2.5 billion</span><span style="font-family:inherit;font-size:8.5pt;">). For the three months ended </span><span style="font-family:inherit;font-size:8.5pt;">October&#160;2, 2016</span><span style="font-family:inherit;font-size:8.5pt;">, associated with the following segments: IH (</span><span style="font-family:inherit;font-size:8.5pt;">$1.8 billion</span><span style="font-family:inherit;font-size:8.5pt;">); and EH (</span><span style="font-family:inherit;font-size:8.5pt;">$2.4 billion</span><span style="font-family:inherit;font-size:8.5pt;">). For the </span><span style="font-family:inherit;font-size:8.5pt;">nine</span><span style="font-family:inherit;font-size:8.5pt;"> months ended </span><span style="font-family:inherit;font-size:8.5pt;">October&#160;1, 2017</span><span style="font-family:inherit;font-size:8.5pt;">, associated with the following segments: IH (</span><span style="font-family:inherit;font-size:8.5pt;">$6.4 billion</span><span style="font-family:inherit;font-size:8.5pt;">) and EH (</span><span style="font-family:inherit;font-size:8.5pt;">$7.5 billion</span><span style="font-family:inherit;font-size:8.5pt;">). For the </span><span style="font-family:inherit;font-size:8.5pt;">nine</span><span style="font-family:inherit;font-size:8.5pt;"> months ended </span><span style="font-family:inherit;font-size:8.5pt;">October&#160;2, 2016</span><span style="font-family:inherit;font-size:8.5pt;">, associated with the following segments: IH (</span><span style="font-family:inherit;font-size:8.5pt;">$5.1 billion</span><span style="font-family:inherit;font-size:8.5pt;">) and EH (</span><span style="font-family:inherit;font-size:8.5pt;">$7.2 billion</span><span style="font-family:inherit;font-size:8.5pt;">).</span></div></td></tr></table><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total revenue deductions for the </span><span style="font-family:inherit;font-size:10pt;">third quarter</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">increase</span><span style="font-family:inherit;font-size:10pt;">d </span><span style="font-family:inherit;font-size:10pt;">16%</span><span style="font-family:inherit;font-size:10pt;"> compared to the </span><span style="font-family:inherit;font-size:10pt;">third quarter</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;">, and total revenue deductions for the </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">increase</span><span style="font-family:inherit;font-size:10pt;">d </span><span style="font-family:inherit;font-size:10pt;">13%</span><span style="font-family:inherit;font-size:10pt;"> compared to the </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;">, primarily as a result of:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:17px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:-2px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">an increase in performance-based contract rebates primarily due to sales to managed care customers in the U.S., as well as higher rebates in certain markets outside the U.S.;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:17px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:-2px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">an increase in sales allowances primarily in markets outside the U.S.;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:17px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:-2px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">an increase in chargebacks from certain IH products, partially offset by decreases across several EH products; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:17px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:-2px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">an increase in Medicaid and related state program rebates, primarily as a result of updated estimates of sales related to these programs.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our accruals for Medicare rebates, Medicaid and related state program rebates, performance-based contract rebates, chargebacks, sales allowances and sales returns and cash discounts totaled </span><span style="font-family:inherit;font-size:10pt;">$4.6 billion</span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">October&#160;1, 2017</span><span style="font-family:inherit;font-size:10pt;">, of which (i) approximately </span><span style="font-family:inherit;font-size:10pt;">$2.5 billion</span><span style="font-family:inherit;font-size:10pt;"> represents accrued rebates included in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other current liabilities,</span><span style="font-family:inherit;font-size:10pt;"> and (ii) approximately </span><span style="font-family:inherit;font-size:10pt;">$2.1 billion</span><span style="font-family:inherit;font-size:10pt;"> represents other accruals included in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other current liabilities </span><span style="font-family:inherit;font-size:10pt;">(</span><span style="font-family:inherit;font-size:10pt;">$472 million</span><span style="font-family:inherit;font-size:10pt;">), </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other noncurrent liabilities </span><span style="font-family:inherit;font-size:10pt;">(</span><span style="font-family:inherit;font-size:10pt;">$344 million</span><span style="font-family:inherit;font-size:10pt;">)</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span><span style="font-family:inherit;font-size:10pt;">and against </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Trade accounts receivable, less allowance for doubtful accounts </span><span style="font-family:inherit;font-size:10pt;">(</span><span style="font-family:inherit;font-size:10pt;">$1.3 billion</span><span style="font-family:inherit;font-size:10pt;">), in our condensed consolidated balance sheet.</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span><span style="font-family:inherit;font-size:10pt;">Our accruals for Medicare rebates, Medicaid and related state program rebates, performance-based contract rebates, chargebacks, sales allowances and sales returns and cash discounts totaled</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span><span style="font-family:inherit;font-size:10pt;">$4.3 billion</span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">December&#160;31, 2016</span><span style="font-family:inherit;font-size:10pt;">, of which (i) approximately </span><span style="font-family:inherit;font-size:10pt;">$2.3 billion</span><span style="font-family:inherit;font-size:10pt;"> represents accrued rebates included in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other current liabilities</span><span style="font-family:inherit;font-size:10pt;">, and (ii) approximately </span><span style="font-family:inherit;font-size:10pt;">$2.0 billion</span><span style="font-family:inherit;font-size:10pt;"> represents other accruals included in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other current liabilities </span><span style="font-family:inherit;font-size:10pt;">(</span><span style="font-family:inherit;font-size:10pt;">$509 million</span><span style="font-family:inherit;font-size:10pt;">), </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other noncurrent liabilities </span><span style="font-family:inherit;font-size:10pt;">(</span><span style="font-family:inherit;font-size:10pt;">$357 million</span><span style="font-family:inherit;font-size:10pt;">) and against </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Trade accounts receivable, less allowance for doubtful accounts</span><span style="font-family:inherit;font-size:10pt;"> (</span><span style="font-family:inherit;font-size:10pt;">$1.2 billion</span><span style="font-family:inherit;font-size:10pt;">), in our condensed consolidated balance sheet. </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">64</span></div></div><hr style="page-break-after:always"></hr><div><a id="sD97A667603A15DFDA860B7B812AE9A1F"></a></div><div><br/></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Revenues&#8212;Major Products</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="23"></td></tr><tr><td style="width:20%;"></td><td style="width:1%;"></td><td style="width:37%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td></tr><tr><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides revenue information for several of our major products. As described in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 1A</span><span style="font-family:inherit;font-size:10pt;">, acquisitions and divestitures have impacted our results of operations in 2017 and 2016.</span></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Nine Months Ended</span></div></td></tr><tr><td colspan="3" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">% Change</span><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup></span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">% Change</span><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">PRODUCT</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">PRIMARY INDICATIONS OR CLASS</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Oct&#160;1, <br/>2017</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Total</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Oper.</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Oct&#160;1, <br/>2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Oper.</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">TOTAL REVENUES</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">13,168</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">1</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">1</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">38,843</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">(1</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">PFIZER INNOVATIVE HEALTH (IH)</span><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">8,118</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">11</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">11</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">23,204</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">8</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">9</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">Internal Medicine</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">2,455</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">9</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">10</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">7,245</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">10</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">11</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Lyrica IH</span><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Epilepsy, post-herpetic neuralgia and diabetic peripheral neuropathy, fibromyalgia, neuropathic pain due to spinal cord injury</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">1,150</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">10</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">11</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">3,382</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">9</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">9</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Eliquis alliance revenues and direct sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Atrial fibrillation, deep vein thrombosis, pulmonary embolism</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">644</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">43</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">43</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">1,813</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">48</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">49</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Chantix/Champix</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">An aid to smoking cessation treatment in adults 18 years of age or older</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">240</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">21</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">22</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">727</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">15</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">15</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Viagra IH</span><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(d)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Erectile dysfunction</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">206</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">(31</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">(31</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">711</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">(21</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">(21</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">BMP2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Development of bone and cartilage</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">79</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">24</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">24</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">198</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">13</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">13</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Toviaz</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Overactive bladder</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">62</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">4</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">5</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">187</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">(2</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">All other Internal Medicine</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Various</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">75</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">(41</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">(41</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">228</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">(31</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">(31</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td></tr><tr><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">Vaccines</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">1,649</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">1</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">4,385</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">(4</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">(4</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Prevnar 13/Prevenar 13</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Vaccines for prevention of pneumococcal disease</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">1,522</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">(1</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">(1</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">4,069</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">(5</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">(5</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">FSME/IMMUN-TicoVac</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Tick-borne encephalitis vaccine</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">43</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">31</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">29</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">119</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">17</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">19</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">All other Vaccines</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Various</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">85</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">17</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">16</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">197</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">14</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">17</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">Oncology</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">1,616</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">46</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">46</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">4,551</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">42</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">43</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Ibrance</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Advanced breast cancer</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">878</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">60</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">59</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">2,410</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">61</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">62</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Sutent</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Advanced and/or metastatic RCC, refractory GIST (after disease progression on, or intolerance to, imatinib mesylate) and advanced pancreatic neuroendocrine tumor</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">276</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">6</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">6</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">805</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">(2</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">(1</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Xalkori</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">ALK-positive and ROS1-positive advanced NSCLC</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">146</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">4</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">4</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">442</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">6</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">8</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Xtandi alliance revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Advanced prostate cancer</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">150</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">*</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">*</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">422</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">*</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">*</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Inlyta</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Advanced RCC</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">84</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">(12</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">(10</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">256</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">(16</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">(14</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Bosulif</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Philadelphia&#160;chromosome&#8211;positive&#160;chronic myelogenous leukemia</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">57</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><br/></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">34</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><br/></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">35</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">163</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">35</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">36</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">All other Oncology</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Various</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">26</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">74</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">76</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">54</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">10</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">11</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">Inflammation &amp; Immunology (I&amp;I)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">1,000</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">4</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">4</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">2,863</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">(1</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Enbrel (Outside the U.S. and Canada)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:13px;text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, plaque psoriasis, pediatric plaque psoriasis, ankylosing spondylitis and nonradiographic axial spondyloarthritis</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">613</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">(13</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">(13</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">1,818</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">(17</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">(16</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Xeljanz</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Rheumatoid arthritis</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">348</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">48</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">49</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">935</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">44</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">44</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Eucrisa</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Mild to moderate atopic dermatitis (eczema)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">15</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">*</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">*</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">33</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">*</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">*</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">All other I&amp;I</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Various</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">23</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">(3</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">1</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">78</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">35</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">36</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">Rare Disease</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">569</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">(3</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">(3</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">1,637</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">(7</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">(6</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">BeneFIX</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Hemophilia</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">151</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">(14</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">(14</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">453</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">(17</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">(16</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Refacto AF/Xyntha</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Hemophilia</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">140</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">(1</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">409</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">3</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Genotropin</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Replacement of human growth hormone</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">136</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">(7</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">(6</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">375</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">(12</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">(10</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Somavert</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Acromegaly</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">65</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">11</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">10</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">182</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">6</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">7</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">All other Rare Disease</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Various</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">77</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">21</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">21</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">218</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">(1</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">1</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">Consumer Healthcare</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">829</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">4</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">4</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">2,522</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">3</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">3</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">PFIZER ESSENTIAL HEALTH (EH)</span><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(e)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">5,050</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">(12</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">(11</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">15,639</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">(12</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">(11</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">)</span></div></td></tr><tr><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">Legacy Established Products (LEP)</span><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(f)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">2,681</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">(1</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">7,995</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">(5</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">(3</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Lipitor</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Reduction of LDL cholesterol</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">491</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">16</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">18</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">1,341</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">4</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">6</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Premarin family</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Symptoms of menopause</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">238</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">(2</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">(2</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">711</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">(5</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">(5</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Norvasc</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Hypertension</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">226</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">(5</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">(3</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">684</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">(4</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">(1</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">EpiPen</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Epinephrine injection used in treatment of life-threatening allergic reactions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">82</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">(25</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">(25</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">253</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">(16</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">(15</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Xalatan/Xalacom</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Glaucoma and ocular hypertension</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">83</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">(9</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">(8</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">241</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">(12</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">(12</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Effexor</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Depression and certain anxiety disorders</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">76</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">8</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">9</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">215</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">4</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">5</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Zoloft</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Depression and certain anxiety disorders</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">78</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">9</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">11</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">215</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">(6</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">(4</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Zithromax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Bacterial infections</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">61</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">10</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">11</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">202</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">(1</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">3</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Relpax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Symptoms of migraine headache</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">50</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">(39</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">(39</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">193</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">(22</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">(22</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Xanax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Anxiety disorders</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">58</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">5</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">4</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">164</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">1</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">2</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">All other LEP</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Various</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">1,237</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">(2</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">(1</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">3,776</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">(5</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">(4</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td></tr><tr><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">Sterile Injectable Pharmaceuticals (SIP)</span><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(g)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">1,273</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">(13</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">(12</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">4,270</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">(5</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">(4</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Medrol</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Steroid anti-inflammatory</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">109</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">7</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">7</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">352</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">7</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">7</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Sulperazon</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Treatment of infections</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">114</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">11</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">13</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">345</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">14</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">18</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Fragmin</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Slows blood clotting</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">79</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">(1</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">(1</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">221</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">(8</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">(6</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Tygacil</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Tetracycline class antibiotic</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">60</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">(12</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">(12</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">192</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">(5</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">(5</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Precedex</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Sedation agent in surgery or intensive care</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">51</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">(21</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">(20</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">182</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">(8</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">(9</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">All other SIP</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Various</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">860</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">(18</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">(17</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">2,977</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">(7</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">(6</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td></tr></table></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">65</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="23"></td></tr><tr><td style="width:20%;"></td><td style="width:1%;"></td><td style="width:37%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Nine Months Ended</span></div></td></tr><tr><td colspan="3" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">% Change</span><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup></span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">% Change</span><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">PRODUCT</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">PRIMARY INDICATIONS OR CLASS</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Oct&#160;1, <br/>2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Oper.</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Oct&#160;1, <br/>2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Oper.</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">Peri-LOE Products</span><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(h)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">794</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">(22</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">(22</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">2,398</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">(26</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">(24</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Celebrex</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Arthritis pain and inflammation, acute pain</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">212</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">9</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">11</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">564</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">3</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">4</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Lyrica EH</span><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Epilepsy, neuropathic pain and generalized anxiety disorder</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">134</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">(30</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">(31</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">428</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">(31</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">(29</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Vfend</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Fungal infections</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">97</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">(31</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">(29</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">305</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">(33</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">(32</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Viagra EH</span><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(d)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Erectile dysfunction</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">102</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">14</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">16</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">285</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">3</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Pristiq</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Depression</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">69</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">(61</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">(61</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">230</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">(58</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">(58</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Zyvox</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Bacterial infections</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">68</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">(28</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">(27</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">220</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">(34</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">(33</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Revatio</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Pulmonary arterial hypertension</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">58</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">(20</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">(20</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">189</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">(11</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">(11</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">All other Peri-LOE Products</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Various</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">55</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">(19</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">(17</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">176</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">(17</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">(15</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">Biosimilars</span><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(i)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Various</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">141</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">70</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">67</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">367</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">61</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">63</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Inflectra/Remsima</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Inflammatory diseases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">112</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">*</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">*</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">284</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">*</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">*</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">All other Biosimilars</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Various</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">28</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">(16</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">(18</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">82</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">(15</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">(14</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">Pfizer CentreOne</span><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(j)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">161</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">3</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">3</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">514</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">(5</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">(5</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">Hospira Infusion Systems (HIS)</span><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(k)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Various</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">*</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">*</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">97</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">(89</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">(89</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">Total Lyrica</span><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Epilepsy, post-herpetic neuralgia and diabetic peripheral neuropathy, fibromyalgia, neuropathic pain due to spinal cord injury</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">1,285</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">4</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">5</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">3,810</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">2</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">3</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">Total Viagra</span><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(d)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Erectile dysfunction</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">308</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">(20</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">(20</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">996</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">(16</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">(15</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">Total Alliance revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Various</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">741</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">77</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">78</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">2,112</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">83</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">84</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">As compared to the three and </span><span style="font-family:inherit;font-size:7.5pt;">nine months</span><span style="font-family:inherit;font-size:7.5pt;"> ended </span><span style="font-family:inherit;font-size:7.5pt;text-align:center;">October&#160;2, 2016</span><span style="font-family:inherit;font-size:7.5pt;">.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">The IH business encompasses Internal Medicine, Vaccines, Oncology, Inflammation &amp; Immunology, Rare Disease and Consumer Healthcare. Through December 31, 2016, includes Duavive/Duavee and Viviant (recorded in All other Internal Medicine in 2016), which were transferred from Innovative Health to Essential Health effective January 1, 2017 (recorded in All other LEP (EH) beginning January 1, 2017), in order to align these products with our management of the women&#8217;s health portfolio within EH. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(c)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Lyrica revenues from all of Europe, Russia, Turkey, Israel and Central Asia countries are included in Lyrica EH. All other Lyrica revenues are included in Lyrica IH. Total Lyrica revenues represent the aggregate of worldwide revenues from Lyrica IH and Lyrica EH.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(d)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Viagra revenues from the U.S. and Canada are included in Viagra IH. All other Viagra revenues are included in Viagra EH. Total Viagra revenues represent the aggregate of worldwide revenues from Viagra IH and Viagra EH.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(e)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">The EH business encompasses Legacy Established Products, Sterile Injectable Pharmaceuticals, Peri-LOE Products, Biosimilars, Pfizer CentreOne and HIS (through February 2, 2017) and includes all legacy Hospira commercial operations.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(f)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Legacy Established Products primarily include products that have lost patent protection (excluding Sterile Injectable Pharmaceuticals and Peri-LOE Products). Effective January 1, 2017, All other LEP includes Duavive/Duavee and Viviant, which were transferred from Innovative Health (recorded in All other Internal Medicine (IH) in 2016), in order to align these products with our management of the women&#8217;s health portfolio within EH. See note (b) above.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(g)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Sterile Injectable Pharmaceuticals include generic injectables and proprietary specialty injectables (excluding Peri-LOE Products).</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(h)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Peri-LOE Products include products that have recently lost or are anticipated to soon lose patent protection. These products include: Lyrica in Europe, Russia, Turkey, Israel and Central Asia; Viagra in all countries (excluding the U.S. and Canada); and worldwide revenues for Celebrex, Pristiq, Zyvox, Vfend, Revatio and Inspra.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(i)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Biosimilars include Inflectra/Remsima (biosimilar infliximab) in the U.S. and certain international markets, Nivestim (biosimilar filgrastim) in certain European, Asian and Africa/Middle Eastern markets and Retacrit (biosimilar epoetin zeta) in certain European and Africa/Middle Eastern markets.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(j)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Pfizer CentreOne includes revenues from our contract manufacturing and active pharmaceutical ingredient sales operation, including sterile injectables contract manufacturing, and revenues related to our manufacturing and supply agreements, including with Zoetis.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(k)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">HIS (through February 2, 2017) includes Medication Management Systems products composed of infusion pumps and related software and services, as well as IV Infusion Products, including large volume IV solutions and their associated administration sets.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:1px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:7.5pt;">*</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Indicates calculation not meaningful.</span></div></td></tr></table><div style="line-height:120%;padding-left:4px;text-align:left;padding-left:12px;text-indent:-12px;font-size:3pt;"><span style="font-family:inherit;font-size:3pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Amounts may not add due to rounding. All percentages have been calculated using unrounded amounts.</span></div><div><a id="s6B8DFD9149F05D9CA471F47B21AD6A0E"></a></div><div style="line-height:120%;padding-top:9px;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Revenues&#8211;&#8211;Selected Product Discussion</span></div><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The information included in &#8220;Revenues&#8212;Selected Product Discussion&#8221; below should be read in conjunction with the revenue information included in the &#8220;Revenues&#8212;Major Products&#8221; section.</span></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Prevnar 13/Prevenar 13</span><span style="font-family:inherit;font-size:10pt;"> (IH) worldwide revenues </span><span style="font-family:inherit;font-size:10pt;">decrease</span><span style="font-family:inherit;font-size:10pt;">d operationally in the </span><span style="font-family:inherit;font-size:10pt;">third quarter</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;">, compared to the same periods in </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;">. Foreign exchange had </span><span style="font-family:inherit;font-size:10pt;">a de minimis</span><span style="font-family:inherit;font-size:10pt;"> impact on worldwide revenues in the </span><span style="font-family:inherit;font-size:10pt;">third quarter</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;">, compared to the same periods in </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;">.</span></div></td></tr></table><div style="line-height:120%;padding-top:4px;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the U.S., revenues for Prevnar 13 </span><span style="font-family:inherit;font-size:10pt;">decrease</span><span style="font-family:inherit;font-size:10pt;">d </span><span style="font-family:inherit;font-size:10pt;">4%</span><span style="font-family:inherit;font-size:10pt;"> in the </span><span style="font-family:inherit;font-size:10pt;">third quarter</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">9%</span><span style="font-family:inherit;font-size:10pt;"> in the </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;">, compared to the same periods in </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;">, primarily due to the continued decline in revenues for the Adult indication in the U.S. due to a high initial capture rate of the eligible population following its successful fourth-quarter 2014 launch, which resulted in a smaller remaining &#8220;catch up&#8221; opportunity (i.e., the opportunity to reach adults age 65 and older who have not been previously vaccinated with Prevnar 13) compared to the prior-year period, partially offset by growth from the pediatric indication. Given the success since the launch of the Adult indication, approximately 53% of the eligible patient pool 65 years and above in the U.S. has already been vaccinated. While the remaining eligible population is large, this cohort is much more difficult to capture.</span></div><div style="line-height:120%;padding-top:4px;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Internationally, revenues for Prevenar 13 </span><span style="font-family:inherit;font-size:10pt;">increase</span><span style="font-family:inherit;font-size:10pt;">d </span><span style="font-family:inherit;font-size:10pt;">5%</span><span style="font-family:inherit;font-size:10pt;"> operationally in the </span><span style="font-family:inherit;font-size:10pt;">third quarter</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">3%</span><span style="font-family:inherit;font-size:10pt;"> operationally in the </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;">, compared to the same periods in </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;">, primarily due to the favorable overall impact of timing of government purchases in certain emerging markets and the launch of Prevenar 13 in China for the pediatric indication. Foreign exchange had </span><span style="font-family:inherit;font-size:10pt;">a de minimis</span><span style="font-family:inherit;font-size:10pt;"> impact on international revenues in the </span><span style="font-family:inherit;font-size:10pt;">third quarter</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">an unfavorable</span><span style="font-family:inherit;font-size:10pt;"> impact in the </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;">, compared to the same periods in </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;">. </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">66</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;padding-top:5px;text-align:left;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In 2014, the ACIP voted to recommend Prevnar 13 for routine use to help protect adults aged 65 years and older against pneumococcal disease, which for adults includes pneumonia caused by the 13 pneumococcal serotypes included in the vaccine. These ACIP recommendations were subsequently approved by the directors at the CDC and U.S. Department of Health and Human Services, and were published in the Morbidity and Mortality Weekly Report in September 2014 by the CDC. As with other vaccines, the CDC regularly monitors the impact of vaccination and reviews the recommendations; in this case, however, the CDC announced formally that it will conduct this review in 2018. A potential adverse change in the ACIP recommendation could negatively impact future Prevnar 13 revenues. Currently, we are working with a number of U.S. investigators to monitor the proportion of community-acquired pneumonia caused by the serotypes included in Prevnar 13 and continue to observe trends.</span></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Lyrica</span><span style="font-family:inherit;font-size:10pt;"> (EH (revenues from all of Europe, Russia, Turkey, Israel and Central Asia)/IH (revenues from all other geographies)) worldwide revenues </span><span style="font-family:inherit;font-size:10pt;">increase</span><span style="font-family:inherit;font-size:10pt;">d operationally in the </span><span style="font-family:inherit;font-size:10pt;">third quarter</span><span style="font-family:inherit;font-size:10pt;"> and the </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;">, compared to the same periods in </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;">. Foreign exchange had </span><span style="font-family:inherit;font-size:10pt;">an unfavorable</span><span style="font-family:inherit;font-size:10pt;"> impact on worldwide revenues in the </span><span style="font-family:inherit;font-size:10pt;">third quarter</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;">, compared to the same periods in </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;">.</span></div></td></tr></table><div style="line-height:120%;padding-top:4px;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the U.S., Lyrica revenues </span><span style="font-family:inherit;font-size:10pt;">increase</span><span style="font-family:inherit;font-size:10pt;">d </span><span style="font-family:inherit;font-size:10pt;">12%</span><span style="font-family:inherit;font-size:10pt;"> in the </span><span style="font-family:inherit;font-size:10pt;">third quarter</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">10%</span><span style="font-family:inherit;font-size:10pt;"> in the </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;">, compared to the same periods in </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;">, driven by sustained demand and positive price impact.</span></div><div style="line-height:120%;padding-top:4px;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Internationally, Lyrica revenues </span><span style="font-family:inherit;font-size:10pt;">decrease</span><span style="font-family:inherit;font-size:10pt;">d </span><span style="font-family:inherit;font-size:10pt;">8%</span><span style="font-family:inherit;font-size:10pt;"> operationally in the </span><span style="font-family:inherit;font-size:10pt;">third quarter</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">10%</span><span style="font-family:inherit;font-size:10pt;"> operationally in the </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;">, compared to the same periods in </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;">, primarily due to losses of exclusivity in developed Europe markets. Foreign exchange had </span><span style="font-family:inherit;font-size:10pt;">an unfavorable</span><span style="font-family:inherit;font-size:10pt;"> impact on international revenues in the </span><span style="font-family:inherit;font-size:10pt;">third quarter</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;">, compared to the same periods in </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:4px;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Lyrica revenues in our IH segment </span><span style="font-family:inherit;font-size:10pt;">increase</span><span style="font-family:inherit;font-size:10pt;">d operationally in the </span><span style="font-family:inherit;font-size:10pt;">third quarter</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;">, compared to the same periods in </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;">, primarily driven by sustained demand and positive price impact in the U.S. Foreign exchange had </span><span style="font-family:inherit;font-size:10pt;">an unfavorable</span><span style="font-family:inherit;font-size:10pt;"> impact on Lyrica IH revenues in the </span><span style="font-family:inherit;font-size:10pt;">third quarter</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">a de minimis</span><span style="font-family:inherit;font-size:10pt;"> impact in the </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;">, compared to the same periods in </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:4px;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In our EH segment, worldwide revenues from Lyrica </span><span style="font-family:inherit;font-size:10pt;">decrease</span><span style="font-family:inherit;font-size:10pt;">d operationally in the </span><span style="font-family:inherit;font-size:10pt;">third quarter</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;">, compared to the same periods in </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;">, due to losses of exclusivity in developed Europe markets. Foreign exchange had </span><span style="font-family:inherit;font-size:10pt;">a favorable</span><span style="font-family:inherit;font-size:10pt;"> impact on Lyrica EH worldwide revenues in the </span><span style="font-family:inherit;font-size:10pt;">third quarter</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">an unfavorable</span><span style="font-family:inherit;font-size:10pt;"> impact in the </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;">, compared to the same periods in </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;">.</span></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Ibrance</span><span style="font-family:inherit;font-size:10pt;"> (IH) worldwide revenues, most of which were recorded in the U.S., </span><span style="font-family:inherit;font-size:10pt;">increase</span><span style="font-family:inherit;font-size:10pt;">d operationally in the </span><span style="font-family:inherit;font-size:10pt;">third quarter</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;">, compared to the same periods in </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;">. The significant revenue growth reflects our scientific/clinical data, continued positive patient experience as well as Ibrance being the class leader among cyclin-dependent kinase inhibitors in major markets. Foreign exchange had </span><span style="font-family:inherit;font-size:10pt;">a favorable</span><span style="font-family:inherit;font-size:10pt;"> impact on worldwide revenues in the </span><span style="font-family:inherit;font-size:10pt;">third quarter</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;"> and had </span><span style="font-family:inherit;font-size:10pt;">an unfavorable</span><span style="font-family:inherit;font-size:10pt;"> impact in the </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;">, compared to the same periods in </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;">.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Enbrel </span><span style="font-family:inherit;font-size:10pt;">(IH, outside the U.S. and Canada) worldwide revenues, excluding the U.S. and Canada, </span><span style="font-family:inherit;font-size:10pt;">decrease</span><span style="font-family:inherit;font-size:10pt;">d operationally in the </span><span style="font-family:inherit;font-size:10pt;">third quarter</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;">, compared to the same periods in </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;">, primarily due to on-going biosimilar competition in most developed Europe markets, which is expected to continue. Foreign exchange had </span><span style="font-family:inherit;font-size:10pt;">a de minimis</span><span style="font-family:inherit;font-size:10pt;"> impact on worldwide revenues in the </span><span style="font-family:inherit;font-size:10pt;">third quarter</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">an unfavorable</span><span style="font-family:inherit;font-size:10pt;"> impact in the </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;">, compared to the same periods in </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;">.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Lipitor </span><span style="font-family:inherit;font-size:10pt;">(EH) worldwide revenues </span><span style="font-family:inherit;font-size:10pt;">increase</span><span style="font-family:inherit;font-size:10pt;">d operationally in the </span><span style="font-family:inherit;font-size:10pt;">third quarter</span><span style="font-family:inherit;font-size:10pt;"> and the </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;">, compared to the same periods in </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;">. Foreign exchange had </span><span style="font-family:inherit;font-size:10pt;">an unfavorable</span><span style="font-family:inherit;font-size:10pt;"> impact on worldwide revenues in the </span><span style="font-family:inherit;font-size:10pt;">third quarter</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;">, compared to the same periods in </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;">. In the U.S., revenues </span><span style="font-family:inherit;font-size:10pt;">increase</span><span style="font-family:inherit;font-size:10pt;">d more than 100% in the </span><span style="font-family:inherit;font-size:10pt;">third quarter</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">11%</span><span style="font-family:inherit;font-size:10pt;"> in the </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;">, compared to the same periods in </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;">, primarily due to favorable rebates.</span></div></td></tr></table><div style="line-height:120%;padding-top:4px;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In our international markets, revenues </span><span style="font-family:inherit;font-size:10pt;">increase</span><span style="font-family:inherit;font-size:10pt;">d </span><span style="font-family:inherit;font-size:10pt;">11%</span><span style="font-family:inherit;font-size:10pt;"> operationally in the </span><span style="font-family:inherit;font-size:10pt;">third quarter</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;">, compared to the same period in </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;">, driven by increased demand in China and certain Middle Eastern markets, partially offset by lower volumes in Japan and pricing pressures in China. International revenues </span><span style="font-family:inherit;font-size:10pt;">increase</span><span style="font-family:inherit;font-size:10pt;">d </span><span style="font-family:inherit;font-size:10pt;">6%</span><span style="font-family:inherit;font-size:10pt;"> operationally in the </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;">, compared to the same period in </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;">, driven by increased demand in China, partially offset by lower volumes in Japan and certain Middle Eastern markets, as well as pricing pressures in China. Foreign exchange had </span><span style="font-family:inherit;font-size:10pt;">an unfavorable</span><span style="font-family:inherit;font-size:10pt;"> impact on international revenues in the </span><span style="font-family:inherit;font-size:10pt;">third quarter</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;">, compared to the same periods in </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;">.</span></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Viagra </span><span style="font-family:inherit;font-size:10pt;">(IH (U.S. and Canada revenues)/EH (all other revenues excluding U.S. and Canada)) worldwide revenues </span><span style="font-family:inherit;font-size:10pt;">decrease</span><span style="font-family:inherit;font-size:10pt;">d operationally in the </span><span style="font-family:inherit;font-size:10pt;">third quarter</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;">, compared to the same periods in </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;">. The </span><span style="font-family:inherit;font-size:10pt;">decrease</span><span style="font-family:inherit;font-size:10pt;"> in the </span><span style="font-family:inherit;font-size:10pt;">third quarter</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;">, compared to the same period in </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;">, was primarily due to wholesaler destocking in advance of anticipated generic competition in the U.S. beginning in December 2017. The </span><span style="font-family:inherit;font-size:10pt;">decrease</span><span style="font-family:inherit;font-size:10pt;"> in the </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;">, compared to the same period in </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;">, was primarily due to lower market growth. Foreign exchange had </span><span style="font-family:inherit;font-size:10pt;">a de minimis</span><span style="font-family:inherit;font-size:10pt;"> impact on worldwide revenues in the </span><span style="font-family:inherit;font-size:10pt;">third quarter</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">an unfavorable</span><span style="font-family:inherit;font-size:10pt;"> impact in the </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;">, compared to the same periods in </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;">.</span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">67</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;padding-top:4px;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenues in the U.S. </span><span style="font-family:inherit;font-size:10pt;">decrease</span><span style="font-family:inherit;font-size:10pt;">d </span><span style="font-family:inherit;font-size:10pt;">32%</span><span style="font-family:inherit;font-size:10pt;"> in the </span><span style="font-family:inherit;font-size:10pt;">third quarter</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;">, compared to the same period in </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;">, primarily due to wholesaler destocking in advance of anticipated generic competition beginning in December 2017. Revenues in the U.S. </span><span style="font-family:inherit;font-size:10pt;">decrease</span><span style="font-family:inherit;font-size:10pt;">d </span><span style="font-family:inherit;font-size:10pt;">21%</span><span style="font-family:inherit;font-size:10pt;"> in the </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;">, compared to the same period in </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;">, primarily due to lower market growth. International revenues </span><span style="font-family:inherit;font-size:10pt;">increase</span><span style="font-family:inherit;font-size:10pt;">d </span><span style="font-family:inherit;font-size:10pt;">15%</span><span style="font-family:inherit;font-size:10pt;"> operationally in the </span><span style="font-family:inherit;font-size:10pt;">third quarter</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;">, compared to the same period in </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;">, primarily from demand in emerging markets, primarily in China. International revenues </span><span style="font-family:inherit;font-size:10pt;">increase</span><span style="font-family:inherit;font-size:10pt;">d </span><span style="font-family:inherit;font-size:10pt;">3%</span><span style="font-family:inherit;font-size:10pt;"> operationally in the </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;">, compared to the same period in </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;">, primarily from increased demand in emerging markets, mainly China and certain Middle Eastern markets, partially offset by price reductions in China. Foreign exchange had </span><span style="font-family:inherit;font-size:10pt;">an unfavorable</span><span style="font-family:inherit;font-size:10pt;"> impact on international revenues in the </span><span style="font-family:inherit;font-size:10pt;">third quarter</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;">, compared to the same periods in </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;">. </span></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Xeljanz </span><span style="font-family:inherit;font-size:10pt;">(IH) worldwide revenues </span><span style="font-family:inherit;font-size:10pt;">increase</span><span style="font-family:inherit;font-size:10pt;">d operationally in the </span><span style="font-family:inherit;font-size:10pt;">third quarter</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;">, compared to the same periods in </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;">. In the U.S., Xeljanz revenues </span><span style="font-family:inherit;font-size:10pt;">increase</span><span style="font-family:inherit;font-size:10pt;">d </span><span style="font-family:inherit;font-size:10pt;">44%</span><span style="font-family:inherit;font-size:10pt;"> in the </span><span style="font-family:inherit;font-size:10pt;">third quarter</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">40%</span><span style="font-family:inherit;font-size:10pt;"> in the </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;">, compared to the same periods in </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;">, primarily driven by increased adoption among rheumatologists, growing awareness among patients and improvements in payer access. Foreign exchange had </span><span style="font-family:inherit;font-size:10pt;">an unfavorable</span><span style="font-family:inherit;font-size:10pt;"> impact on worldwide revenues in the </span><span style="font-family:inherit;font-size:10pt;">third quarter</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;"> and had </span><span style="font-family:inherit;font-size:10pt;">a de minimis</span><span style="font-family:inherit;font-size:10pt;"> impact in the </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;">, compared to the same periods in </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;">.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">BeneFIX and ReFacto AF/Xyntha</span><span style="font-family:inherit;font-size:10pt;"> (IH)&#8211;&#8211;BeneFIX worldwide revenues </span><span style="font-family:inherit;font-size:10pt;">decrease</span><span style="font-family:inherit;font-size:10pt;">d operationally in the </span><span style="font-family:inherit;font-size:10pt;">third quarter</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;">, compared to the same periods in </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;">, primarily as a result of erosion of market share in the U.S. and European countries due to increasing adoption of extended half-life treatment options as well as a price decrease in the U.K. Foreign exchange had </span><span style="font-family:inherit;font-size:10pt;">a de minimis</span><span style="font-family:inherit;font-size:10pt;"> impact on worldwide revenues in the </span><span style="font-family:inherit;font-size:10pt;">third quarter</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">an unfavorable</span><span style="font-family:inherit;font-size:10pt;"> impact in the </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;">, compared to the same periods in </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;">. </span></div></td></tr></table><div style="line-height:120%;padding-top:4px;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ReFacto AF/Xyntha worldwide revenues </span><span style="font-family:inherit;font-size:10pt;">decrease</span><span style="font-family:inherit;font-size:10pt;">d operationally in the </span><span style="font-family:inherit;font-size:10pt;">third quarter</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">increase</span><span style="font-family:inherit;font-size:10pt;">d operationally in the </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;">, compared to the same periods in </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;">. The </span><span style="font-family:inherit;font-size:10pt;">increase</span><span style="font-family:inherit;font-size:10pt;"> in the </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;"> was largely due to increased product demand in certain emerging markets, partially offset by declines in developed markets in Europe and the U.S., primarily driven by increasing adoption of extended half-life treatment options. Foreign exchange had </span><span style="font-family:inherit;font-size:10pt;">a favorable</span><span style="font-family:inherit;font-size:10pt;"> impact on worldwide revenues in the </span><span style="font-family:inherit;font-size:10pt;">third quarter</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">an unfavorable</span><span style="font-family:inherit;font-size:10pt;"> impact in the </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;">, compared to the same periods in </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;">.</span></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Sutent</span><span style="font-family:inherit;font-size:10pt;"> (IH) worldwide revenues </span><span style="font-family:inherit;font-size:10pt;">increase</span><span style="font-family:inherit;font-size:10pt;">d operationally in the </span><span style="font-family:inherit;font-size:10pt;">third quarter</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">decrease</span><span style="font-family:inherit;font-size:10pt;">d operationally in the </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;">, compared to the same periods in </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;">. The </span><span style="font-family:inherit;font-size:10pt;">increase</span><span style="font-family:inherit;font-size:10pt;"> in the </span><span style="font-family:inherit;font-size:10pt;">third quarter</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;"> was primarily driven by increased performance in certain emerging markets. The </span><span style="font-family:inherit;font-size:10pt;">decrease</span><span style="font-family:inherit;font-size:10pt;"> in the </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;"> was primarily due to competitive pressure in the U.S. and Europe and cost containment measures in certain developed international markets, partially offset by increased performance in certain emerging markets. Foreign exchange had </span><span style="font-family:inherit;font-size:10pt;">a de minimis</span><span style="font-family:inherit;font-size:10pt;"> impact on worldwide revenues in the </span><span style="font-family:inherit;font-size:10pt;">third quarter</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">an unfavorable</span><span style="font-family:inherit;font-size:10pt;"> impact in the </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;">, compared to the same periods in </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;">.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Chantix/Champix</span><span style="font-family:inherit;font-size:10pt;"> (IH) worldwide revenues </span><span style="font-family:inherit;font-size:10pt;">increase</span><span style="font-family:inherit;font-size:10pt;">d operationally in the </span><span style="font-family:inherit;font-size:10pt;">third quarter</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;">, compared to the same periods in </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;">. Foreign exchange had </span><span style="font-family:inherit;font-size:10pt;">an unfavorable</span><span style="font-family:inherit;font-size:10pt;"> impact on worldwide revenues in the </span><span style="font-family:inherit;font-size:10pt;">third quarter</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">a de minimis</span><span style="font-family:inherit;font-size:10pt;"> impact in the </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;">, compared to the same periods in </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;">. </span></div></td></tr></table><div style="line-height:120%;padding-top:4px;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the U.S., Chantix revenues </span><span style="font-family:inherit;font-size:10pt;">increase</span><span style="font-family:inherit;font-size:10pt;">d </span><span style="font-family:inherit;font-size:10pt;">27%</span><span style="font-family:inherit;font-size:10pt;"> in the </span><span style="font-family:inherit;font-size:10pt;">third quarter</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">21%</span><span style="font-family:inherit;font-size:10pt;"> in the </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;">, compared to the same periods in </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;text-align:center;">, primarily due to increased promotional activities</span><span style="font-family:inherit;font-size:10pt;">, educating healthcare providers on updates to the Chantix label, including removal of the boxed warning, the addition of EAGLES safety and efficacy data, improved patient access and positive price impact.</span></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The </span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Premarin</span><span style="font-family:inherit;font-size:10pt;"> family of products (EH) worldwide revenues </span><span style="font-family:inherit;font-size:10pt;">decrease</span><span style="font-family:inherit;font-size:10pt;">d operationally in the </span><span style="font-family:inherit;font-size:10pt;">third quarter</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;">, compared to the same periods in </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;">. Revenues in the U.S. </span><span style="font-family:inherit;font-size:10pt;">decrease</span><span style="font-family:inherit;font-size:10pt;">d </span><span style="font-family:inherit;font-size:10pt;">2%</span><span style="font-family:inherit;font-size:10pt;"> in the </span><span style="font-family:inherit;font-size:10pt;">third quarter</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">5%</span><span style="font-family:inherit;font-size:10pt;"> in the </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;">, compared to the same periods in </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;">, primarily driven by lower volume, partially offset by a positive price impact. </span></div></td></tr></table><div style="line-height:120%;padding-top:4px;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Internationally, Premarin revenues </span><span style="font-family:inherit;font-size:10pt;">decrease</span><span style="font-family:inherit;font-size:10pt;">d </span><span style="font-family:inherit;font-size:10pt;">8%</span><span style="font-family:inherit;font-size:10pt;"> operationally in the </span><span style="font-family:inherit;font-size:10pt;">third quarter</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;">, compared to the same periods in </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;">, primarily due to lower volumes in certain emerging markets and, with respect to the first nine months of 2017, the U.K., partially offset by price increases. Foreign exchange had </span><span style="font-family:inherit;font-size:10pt;">a favorable</span><span style="font-family:inherit;font-size:10pt;"> impact on international revenues in the </span><span style="font-family:inherit;font-size:10pt;">third quarter</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;">, compared to the same periods in </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;">.</span></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Norvasc </span><span style="font-family:inherit;font-size:10pt;">(EH) worldwide revenues </span><span style="font-family:inherit;font-size:10pt;">decrease</span><span style="font-family:inherit;font-size:10pt;">d operationally in the </span><span style="font-family:inherit;font-size:10pt;">third quarter</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;">, compared to the same periods in </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;">. Results for the </span><span style="font-family:inherit;font-size:10pt;">third quarter</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;"> were impacted by generic competition in Japan, lower volumes in certain Middle Eastern markets and pricing pressures in China, partially offset by demand in China. Foreign exchange had </span><span style="font-family:inherit;font-size:10pt;">an unfavorable</span><span style="font-family:inherit;font-size:10pt;"> impact on worldwide revenues in the </span><span style="font-family:inherit;font-size:10pt;">third quarter</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;">, compared to the same periods in </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;">.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Celebrex </span><span style="font-family:inherit;font-size:10pt;">(EH) worldwide revenues </span><span style="font-family:inherit;font-size:10pt;">increase</span><span style="font-family:inherit;font-size:10pt;">d operationally in the </span><span style="font-family:inherit;font-size:10pt;">third quarter</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;">, compared to the same periods in </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;">. The </span><span style="font-family:inherit;font-size:10pt;">increase</span><span style="font-family:inherit;font-size:10pt;"> in the </span><span style="font-family:inherit;font-size:10pt;">third quarter</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;">, compared to the same period in </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;">, was primarily </span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">68</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;padding-left:18px;padding-top:6px;"><span style="font-family:inherit;font-size:10pt;">driven by favorable rebates in the U.S. and increased demand in China, partially offset by generic competition in the U.S., lower volumes in certain Middle Eastern markets and pricing pressures in China and Mexico. The </span><span style="font-family:inherit;font-size:10pt;">increase</span><span style="font-family:inherit;font-size:10pt;"> in the </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;">, compared to the same period in </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;">, was primarily driven by favorable rebates in the U.S. and volume growth in emerging markets, primarily China, partially offset by generic competition in the U.S. and most developed international markets and pricing pressures in China and Mexico. Foreign exchange had </span><span style="font-family:inherit;font-size:10pt;">an unfavorable</span><span style="font-family:inherit;font-size:10pt;"> impact on worldwide revenues in the </span><span style="font-family:inherit;font-size:10pt;">third quarter</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;">, compared to the same periods in </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;">.</span></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Xalkori </span><span style="font-family:inherit;font-size:10pt;">(IH) worldwide revenues </span><span style="font-family:inherit;font-size:10pt;">increase</span><span style="font-family:inherit;font-size:10pt;">d operationally in the </span><span style="font-family:inherit;font-size:10pt;">third quarter</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;">, compared to the same periods in </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;">, as a result of a steady increase in diagnostic rates for the ALK gene mutation across key markets outside the U.S., which has led to more patients being treated. This increase was partially offset by volume declines in the U.S. and Japan due to competitive pressure, partially mitigated by the March 2016 FDA approval of the supplemental NDA to treat patients with metastatic NSCLC whose tumors are ROS1-positive as detected by an FDA-approved test. Foreign exchange had </span><span style="font-family:inherit;font-size:10pt;">a de minimis</span><span style="font-family:inherit;font-size:10pt;"> impact on worldwide revenues in the </span><span style="font-family:inherit;font-size:10pt;">third quarter</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">an unfavorable</span><span style="font-family:inherit;font-size:10pt;"> impact in the </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;">, compared to the same periods in </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;">.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Inflectra/Remsima </span><span style="font-family:inherit;font-size:10pt;">(EH) worldwide revenues </span><span style="font-family:inherit;font-size:10pt;">increase</span><span style="font-family:inherit;font-size:10pt;">d operationally in the </span><span style="font-family:inherit;font-size:10pt;">third quarter</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;">, compared to the same periods in </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;">, due to continued uptake in developed markets in Europe, and the U.S. launch in the fourth quarter of 2016, partially offset by pricing pressures in Europe. Foreign exchange had </span><span style="font-family:inherit;font-size:10pt;">a favorable</span><span style="font-family:inherit;font-size:10pt;"> impact on worldwide revenues in the </span><span style="font-family:inherit;font-size:10pt;">third quarter</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">an unfavorable</span><span style="font-family:inherit;font-size:10pt;"> impact in the </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;">, compared to the same periods in </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;">.</span></div></td></tr></table><div style="line-height:120%;padding-top:4px;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inflectra uptake in the U.S. is being driven by a number of factors including Inflectra&#8217;s clinical data package, patient support programs, price and the access/reimbursement environment. To date, reimbursement coverage has been mixed.&#160;While we achieved 100% Medicare coverage, we have experienced access challenges among commercial payers where our lower priced product has not received access at parity to the innovator product and remains in a disadvantaged position despite recent price increases taken by the innovator product. We will look at all relevant factors impacting reimbursement given our extensive experience working with commercial payers to enable greater access for Inflectra. Additionally, in September 2017, Pfizer filed suit in the U.S. District Court for the Eastern District of Pennsylvania against Johnson &amp; Johnson (J&amp;J) alleging that J&amp;J&#8217;s exclusionary contracts and other anticompetitive practices concerning Remicade&#174; (infliximab) violate federal antitrust laws. </span></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Inlyta</span><span style="font-family:inherit;font-size:10pt;"> (IH) worldwide revenues </span><span style="font-family:inherit;font-size:10pt;">decrease</span><span style="font-family:inherit;font-size:10pt;">d operationally in the </span><span style="font-family:inherit;font-size:10pt;">third quarter</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;">, compared to the same periods in </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;">, primarily due to increased competition in the U.S. and Europe, partially offset by performance in key emerging markets. Foreign exchange had </span><span style="font-family:inherit;font-size:10pt;">an unfavorable</span><span style="font-family:inherit;font-size:10pt;"> impact on worldwide revenues in the </span><span style="font-family:inherit;font-size:10pt;">third quarter</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;">, compared to the same periods in </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;">.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Pristiq</span><span style="font-family:inherit;font-size:10pt;"> (EH) worldwide revenues </span><span style="font-family:inherit;font-size:10pt;">decrease</span><span style="font-family:inherit;font-size:10pt;">d operationally in the </span><span style="font-family:inherit;font-size:10pt;">third quarter</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;">, compared to the same periods in </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;">, primarily due to loss of exclusivity in the U.S. in March 2017. Foreign exchange had </span><span style="font-family:inherit;font-size:10pt;">a de minimis</span><span style="font-family:inherit;font-size:10pt;"> impact on worldwide revenues in the </span><span style="font-family:inherit;font-size:10pt;">third quarter</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;">, compared to the same periods in </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;">.</span></div></td></tr></table><div style="line-height:120%;padding-top:6px;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Zyvox </span><span style="font-family:inherit;font-size:10pt;">(EH) worldwide revenues </span><span style="font-family:inherit;font-size:10pt;">decrease</span><span style="font-family:inherit;font-size:10pt;">d operationally in the </span><span style="font-family:inherit;font-size:10pt;">third quarter</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;">, compared to the same periods in </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;">, due to generic competition in developed international markets and the U.S. and corresponding pricing pressures, partially offset by volume growth in China. Foreign exchange had </span><span style="font-family:inherit;font-size:10pt;">an unfavorable</span><span style="font-family:inherit;font-size:10pt;"> impact on worldwide revenues in the </span><span style="font-family:inherit;font-size:10pt;">third quarter</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;">, compared to the same periods in </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;">.</span></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Eucrisa </span><span style="font-family:inherit;font-size:10pt;">(IH) is approved in the U.S. for the treatment of mild to moderate atopic dermatitis for patients two years of age and older. The FDA approved Eucrisa on December 14, 2016, and Eucrisa was launched in the U.S. late in the first quarter of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;">. Eucrisa is a novel non-steroidal topical ointment and is the first topical prescription treatment for atopic dermatitis approved in over 10 years. Prescription volume continued to strengthen through the third quarter of 2017 supported by the launch of our direct-to-consumer campaign.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Alliance revenues</span><span style="font-family:inherit;font-size:10pt;"> (IH/EH) </span><span style="font-family:inherit;font-size:10pt;">increase</span><span style="font-family:inherit;font-size:10pt;">d operationally in the </span><span style="font-family:inherit;font-size:10pt;">third quarter</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;">, compared to the same periods in </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;">, mainly due to:</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:18px;"><span style="font-family:inherit;font-size:10pt;">&#9702;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">an increase in Eliquis alliance revenues due to higher demand resulting from increased market penetration of novel oral anticoagulants and market share gains; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:18px;"><span style="font-family:inherit;font-size:10pt;">&#9702;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the inclusion of Xtandi alliance revenues of </span><span style="font-family:inherit;font-size:10pt;">$150 million</span><span style="font-family:inherit;font-size:10pt;"> in the </span><span style="font-family:inherit;font-size:10pt;">third quarter</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">$422 million</span><span style="font-family:inherit;font-size:10pt;"> in the </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;"> in the U.S. resulting from the September 2016 acquisition of Medivation. We expect patient assistance program (which provides free medicines to patients) utilization as a percentage of total demand to normalize as we move into next year.</span></div></td></tr></table><div style="line-height:120%;padding-top:4px;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign exchange had </span><span style="font-family:inherit;font-size:10pt;">an unfavorable</span><span style="font-family:inherit;font-size:10pt;"> impact on alliance revenues in the </span><span style="font-family:inherit;font-size:10pt;">third quarter</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;">, compared to the same periods in </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">69</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:18px;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#9702;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Eliquis</span><span style="font-family:inherit;font-size:10pt;"> (IH) has been jointly developed and is commercialized by Pfizer and BMS. Pfizer funds between 50% and 60% of all development costs depending on the study. Profits and losses are shared equally on a global basis, except in certain countries where Pfizer commercializes Eliquis and pays BMS compensation based on a percentage of net sales. We have full commercialization rights in certain smaller markets. BMS supplies the product to us at cost plus a percentage of the net sales to end-customers in these markets. Eliquis is part of the Novel Oral Anticoagulant (NOAC) market; the agents in this class were developed as alternative treatment options to warfarin in appropriate patients.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:18px;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#9702;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Xtandi</span><span style="font-family:inherit;font-size:10pt;"> (IH) is being developed and commercialized through a collaboration with Astellas. The two companies share equally in the gross profits (losses) related to U.S. net sales of Xtandi. Subject to certain exceptions, Pfizer and Astellas also share equally all Xtandi commercialization costs attributable to the U.S. market. Pfizer and Astellas also share certain development and other collaboration expenses and Pfizer receives tiered royalties as a percentage of international Xtandi net sales (recorded in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other (income)/deductions&#8212;net</span><span style="font-family:inherit;font-size:10pt;">).</span></div></td></tr></table><div style="line-height:120%;padding-top:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">See the &#8220;Analysis of the Consolidated Statements of Income&#8212;Revenues&#8212;Selected Product Descriptions&#8221; section of our </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;"> Financial Report for additional information regarding the primary indications or class of the selected products discussed above.</span></div><div style="line-height:120%;padding-top:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">See Notes to Condensed Consolidated Financial Statements&#8212;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 12.</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Commitments and Contingencies</span><span style="font-family:inherit;font-size:10pt;"> for a discussion of recent developments concerning patent and product litigation relating to certain of the products discussed above.</span></div><div><a id="s2BFD6D3D3CD754148223A9AB3679D20C"></a></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Product Developments&#8212;Biopharmaceutical</span></div><div style="line-height:120%;text-align:justify;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">We continue to invest in R&amp;D to provide potential future sources of revenues through the development of new products, as well as through additional uses for in-line and alliance products. Notwithstanding our efforts, there are no assurances as to when, or if, we will receive regulatory approval for additional indications for existing products or any of our other products in development.</span></div><div style="line-height:120%;text-align:left;font-size:5pt;"><span style="font-family:inherit;font-size:5pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">We continue to strengthen our global R&amp;D organization and pursue strategies intended to improve innovation and overall productivity in R&amp;D to achieve a sustainable pipeline that will deliver value in the near term and over time. Our R&amp;D priorities include:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:9.5pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">delivering a pipeline of differentiated therapies with the greatest scientific and commercial promise; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:9.5pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">innovating new capabilities that can position Pfizer for long-term leadership; and </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:9.5pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">creating new models for biomedical collaboration that will expedite the pace of innovation and productivity. </span></div></td></tr></table><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Our R&amp;D primarily focuses on:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:9.5pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Biosimilars; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:9.5pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Inflammation and Immunology;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:9.5pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Metabolic Disease and Cardiovascular Risks;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:9.5pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Neuroscience; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:9.5pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Oncology</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:9.5pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Rare Diseases; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:9.5pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Vaccines.</span></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">For additional information about our R&amp;D organization, including the EH R&amp;D organization, see the &#8220;Overview of Our Performance, Operating Environment, Strategy and Outlook&#8212;Our Strategy&#8212;Description of Research and Development Operations&#8221; section of this MD&amp;A. </span></div><div style="line-height:120%;padding-top:4px;text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">A comprehensive update of Pfizer&#8217;s development pipeline was published on </span><span style="font-family:inherit;font-size:9.5pt;text-align:center;">October&#160;31, 2017</span><span style="font-family:inherit;font-size:9.5pt;"> and is available at www.pfizer.com/science/drug-product-pipeline. It includes an overview of our research and a list of compounds in development with targeted indication and phase of development, as well as mechanism of action for some candidates in Phase 1 and all candidates from Phase 2 through registration.</span></div><div style="line-height:120%;padding-top:4px;text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">The following series of tables provides information about significant regulatory actions by, and filings pending with, the FDA and regulatory authorities in the EU and Japan, as well as additional indications and new drug candidates in late-stage development.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">70</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.41520467836257%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:26%;"></td><td style="width:57%;"></td><td style="width:17%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;font-weight:bold;">RECENT FDA APPROVALS</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;font-weight:bold;">PRODUCT</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;font-weight:bold;">INDICATION</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;font-weight:bold;">DATE APPROVED</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Lyrica (pregabalin)</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Extended-release tablets CV as once-daily therapy for the management of neuropathic pain associated with diabetic peripheral neuropathy and the management of post-herpetic neuralgia</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">October 2017</span></div><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Mylotarg (gemtuzumab ozogamicin)</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Treatment of adults with newly diagnosed CD33-positive acute myeloid leukemia (AML), and adults and children 2 years and older with relapsed or refractory CD33-positive AML</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">September 2017</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Besponsa (inotuzumab ozogamicin)</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">August 2017</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Bavencio (avelumab)</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="padding-top:0px;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Treatment for patients with locally advanced or metastatic urothelial carcinoma with disease progression on or after platinum-based therapy, which is being developed in collaboration with Merck KGaA, Germany </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">May 2017</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Bavencio (avelumab)</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="padding-top:0px;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Treatment of adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma, which is being developed in collaboration with Merck KGaA, Germany</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">March 2017</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Eucrisa (crisaborole)</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">A non-steroidal topical anti-inflammatory PDE-4 inhibitor for the treatment of mild-to-moderate atopic dermatitis</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-top:0px;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">December 2016</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.41520467836257%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:26%;"></td><td style="width:57%;"></td><td style="width:17%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;font-weight:bold;">PENDING U.S. NDAs AND SUPPLEMENTAL FILINGS</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;font-weight:bold;">PRODUCT</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;font-weight:bold;">PROPOSED INDICATION</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;font-weight:bold;">DATE FILED</span><span style="font-family:inherit;font-size:8.5pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:pt">*</sup></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">PF-05280014</span><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">A potential biosimilar to Herceptin</span><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">&#174;</sup></span><span style="font-family:inherit;font-size:5pt;">&#160;</span><span style="font-family:inherit;font-size:8pt;">(trastuzumab)</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">August 2017</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Bosulif (bosutinib)</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Treatment of patients with newly diagnosed chronic phase Philadelphia chromosome-positive chronic myeloid leukemia, which is being developed in collaboration with Avillion</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">August 2017</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Xeljanz (tofacitinib)</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Treatment of adult patients with moderately to severely active ulcerative colitis</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">July 2017</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Sutent (sunitinib)</span><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Adjuvant treatment in adult patients at high risk of recurrent renal cell carcinoma following nephrectomy</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">May 2017</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Xeljanz (tofacitinib)</span><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Treatment of adult patients with active psoriatic arthritis</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">May 2017</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">PF-06438179</span><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(d)</sup></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">A potential biosimilar to Remicade</span><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">&#174;</sup></span><span style="font-family:inherit;font-size:8pt;">&#160;(infliximab)</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">April 2017</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">ertugliflozin</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="padding-top:0px;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Treatment of type 2 diabetes, which is being developed in collaboration with Merck</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">March 2017</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Retacrit</span><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(e)</sup></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">A potential biosimilar to Epogen</span><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">&#174;</sup></span><span style="font-family:inherit;font-size:8pt;">&#160;and Procrit</span><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">&#174;</sup></span><span style="font-family:inherit;font-size:8pt;">&#160;(epotein alfa)</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">February 2015</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:1px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">tafamidis meglumine</span><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(f)</sup></span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Treatment of transthyretin familial amyloid polyneuropathy</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">February 2012</span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:7.5pt;">*</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">The dates set forth in this column are the dates on which the FDA accepted our submissions.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Herceptin</span><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></span><span style="font-family:inherit;font-size:7.5pt;"> is a registered trademark of Genentech, Inc.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">In September 2017, the FDA&#8217;s Oncologic Drug Advisory Committee (ODAC) voted six in favor and six against the benefit-risk profile for Sutent as adjuvant treatment of adult patients at high risk of recurrent renal cell carcinoma after nephrectomy (surgical removal of the cancer-containing kidney).</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(c)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">In August 2017, the FDA&#8217;s Arthritis Advisory Committee voted ten to one to recommend approval of the proposed dose of tofacitinib for the treatment of adult patients with active psoriatic arthritis.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(d)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Remicade</span><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></span><span style="font-family:inherit;font-size:7.5pt;"> is a registered trademark of Janssen. In February 2016, we divested the rights for development and commercialization of PF-06438179, a potential biosimilar to Remicade</span><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></span><span style="font-family:inherit;font-size:7.5pt;"> (infliximab) in the 28 countries that form the EEA to Sandoz, which was a condition to the European Commission&#8217;s approval of the Hospira transaction. We retain commercialization rights to PF-06438179 in all countries outside of the EEA.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(e)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Epogen</span><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></span><span style="font-family:inherit;font-size:7.5pt;"> is a registered U.S. trademark of Amgen Inc.; Procrit</span><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></span><span style="font-family:inherit;font-size:7.5pt;"> is a registered U.S. trademark of Johnson &amp; Johnson. In October 2015, we received a &#8220;complete response&#8221; letter from the FDA with respect to our biologics license application (BLA) for Retacrit, our proposed biosimilar to epoetin alfa, which was submitted for all indications of the reference product. In December 2016, we completed the resubmission of the BLA to the FDA for Retacrit in response to the &#8220;complete response&#8221; letter. In May 2017, the FDA&#8217;s ODAC voted to recommend Retacrit for approval. In June 2017, we received a &#8220;complete response&#8221; letter from the FDA, relating to matters noted in a Warning Letter issued in February 2017 following a routine inspection of the company&#8217;s facility in McPherson, Kansas in 2016. This facility was listed as the potential manufacturing site in the BLA for the proposed epoetin alfa biosimilar. The issues noted in the Warning Letter do not relate specifically to the manufacture of epoetin alfa. No additional clinical data was requested at this time and we continue to work closely with the FDA on next steps. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(f)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">In May 2012, the FDA&#8217;s Peripheral and Central Nervous System Drugs Advisory Committee voted that the tafamidis meglumine data provide substantial evidence of efficacy for a surrogate endpoint that is reasonably likely to predict a clinical benefit. In June 2012, the FDA issued a &#8220;complete response&#8221; letter with respect to the tafamidis NDA. The FDA has requested the completion of a second efficacy study, and also has asked for additional information on the data within the current tafamidis NDA. Pfizer initiated study B3461028 in December 2013, a global Phase 3 study to support a potential new indication in transthyretin cardiomyopathy, which includes transthyretin familial amyloid cardiomyopathy (TTR-FAC) and wild-type cardiomyopathy (WT-CM). We anticipate results from this study in 2018, and continue to work with the FDA to identify next steps.</span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">71</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.02534113060429%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:23%;"></td><td style="width:46%;"></td><td style="width:15%;"></td><td style="width:16%;"></td></tr><tr><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;font-weight:bold;">REGULATORY APPROVALS AND FILINGS IN THE EU AND JAPAN</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;font-weight:bold;">PRODUCT</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;font-weight:bold;">DESCRIPTION OF EVENT</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;font-weight:bold;">DATE APPROVED</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;font-weight:bold;">DATE FILED</span><span style="font-family:inherit;font-size:8.5pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:pt">*</sup></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Xeljanz (tofacitinib)</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Application filed in the EU for treatment of psoriatic arthritis</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">September 2017</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Ibrance (palbociclib)</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Approval in Japan for Ibrance in combination with endocrine therapy for the treatment of HR+, HER2- inoperable or recurrent breast cancer</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">September 2017</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Bavencio (avelumab)</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Approval in Japan for the treatment of curatively unresectable Merkel cell carcinoma, which is being developed in collaboration with Merck KGaA, Germany</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">September 2017</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Bavencio (avelumab)</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Approval in the EU for the treatment of adult patients with metastatic Merkel cell carcinoma, which is being developed in collaboration with Merck KGaA, Germany</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">September 2017</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Xeljanz (tofacitinib)</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Application filed in the EU for the treatment of ulcerative colitis</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">August 2017</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Bosulif (bosutinib)</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Application filed in the EU for the treatment of patients with newly diagnosed chronic phase Philadelphia chromosome-positive chronic myeloid leukemia, which is being developed in collaboration with Avillion</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">August 2017</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">PF-06438179</span><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Application filed in Japan for a potential biosimilar to Remicade</span><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">&#174;</sup></span><span style="font-family:inherit;font-size:8pt;">&#160;(infliximab)</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">August 2017</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">PF-05280014</span><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup></span></div><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Application filed in the EU for a potential biosimilar to Herceptin</span><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">&#174;</sup></span><span style="font-family:inherit;font-size:8pt;">&#160;(trastuzumab)</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">July 2017</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Besponsa (inotuzumab ozogamicin)</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Approval in the EU for the treatment of a</span><span style="font-family:inherit;font-size:8pt;color:#333333;">dult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">June 2017</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Trumenba</span></div><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Approval in the EU for a prophylactic vaccine for active immunization to prevent invasive disease caused by </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Neisseria meningtidis</span><span style="font-family:inherit;font-size:8pt;">&#160;serogroup B in individuals 10 years of age and older</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">May 2017</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Xalkori (crizotinib)</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Approval in Japan for the treatment of ROS1-positive non-small cell lung cancer</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">May 2017</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Xeljanz (tofacitinib)</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Application filed in Japan for the treatment of ulcerative colitis</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">May 2017</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Sutent (sunitinib)</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Application filed in the EU for the adjuvant treatment in adult patients at high risk of recurrent renal cell carcinoma following nephrectomy</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">April 2017</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">inotuzumab ozogamicin</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Application filed in Japan for the treatment of acute lymphoblastic leukemia</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">April 2017</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Xeljanz (tofacitinib)</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Approval in the EU for Xeljanz in combination with methotrexate for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drugs. Xeljanz can be given as monotherapy in case of intolerance to methotrexate or when treatment with methotrexate is inappropriate</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">March 2017</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">ertugliflozin</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Application filed in the EU for the treatment of type 2 diabetes, which is being developed in collaboration with Merck</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">February 2017</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Mylotarg (gemtuzumab ozogamicin)</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Application filed in the EU for the treatment of acute myeloid leukemia</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">December 2016</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Ibrance (palbociclib)</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="padding-top:0px;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Approval in the EU for palbociclib in combination with</span></div><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">endocrine therapy for the treatment of HR+, HER2- advanced or</span></div><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">metastatic breast cancer, as well as for the treatment of recurrent</span></div><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">advanced breast cancer</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">November 2016</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:7.5pt;">*</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">For applications in the EU, the dates set forth in this column are the dates on which the EMA validated our submissions.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup></span><span style="font-family:inherit;font-size:7.5pt;"> </span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Remicade</span><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></span><span style="font-family:inherit;font-size:7.5pt;"> is a registered trademark of Janssen. In February 2016, we divested the rights for development and commercialization of PF-06438179, a potential biosimilar to Remicade</span><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></span><span style="font-family:inherit;font-size:7.5pt;"> (infliximab) in the 28 countries that form the EEA to Sandoz, which was a condition to the European Commission&#8217;s approval of the Hospira transaction. We retain commercialization rights to PF-06438179 in all countries outside of the EEA.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Herceptin</span><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></span><span style="font-family:inherit;font-size:7.5pt;"> is a registered trademark of Genentech, Inc.</span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:12px;text-indent:-12px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">72</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.02534113060429%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:22%;"></td><td style="width:78%;"></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;font-weight:bold;">LATE-STAGE CLINICAL PROGRAMS FOR ADDITIONAL USES AND DOSAGE FORMS</span></div><div style="padding-bottom:1px;text-align:center;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;font-weight:bold;">FOR IN-LINE AND IN-REGISTRATION PRODUCTS</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;font-weight:bold;">PRODUCT</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;font-weight:bold;">PROPOSED INDICATION</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Bavencio (avelumab)</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">A monoclonal antibody that inhibits PD-L1, in combination with Inlyta (axitinib), a tyrosine kinase inhibitor,</span></div><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">for the first-line treatment of advanced renal cell carcinoma, which is being developed in collaboration with</span></div><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Merck KGaA, Germany</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Bavencio (avelumab)</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">A monoclonal antibody that inhibits PD-L1 for the first-line treatment of stage IIIb/IV non-small cell lung</span></div><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">cancer, which is being developed in collaboration with Merck KGaA, Germany</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Bavencio (avelumab)</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">A monoclonal antibody that inhibits PD-L1 for treatment of stage IIIb/IV non-small cell lung cancer that has progressed after a platinum-containing doublet, which is being developed in collaboration with Merck KGaA, Germany</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Bavencio (avelumab)</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">A monoclonal antibody that inhibits PD-L1 for treatment of platinum-resistant/refractory ovarian cancer,</span></div><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">which is being developed in collaboration with Merck KGaA, Germany</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Bavencio (avelumab)</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">A monoclonal antibody that inhibits PD-L1 for the first-line treatment of ovarian cancer, which is being</span></div><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">developed in collaboration with Merck KGaA, Germany</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Bavencio (avelumab)</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">A monoclonal antibody that inhibits PD-L1 for maintenance treatment, in the first-line setting, for patients</span></div><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">with urothelial cancer, which is being developed in collaboration with Merck KGaA, Germany</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Bavencio (avelumab)</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">A monoclonal antibody that inhibits PD-L1 for maintenance treatment of advanced or metastatic gastric/</span></div><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">gastro-esophageal junction cancers, which is being developed in collaboration with Merck KGaA, Germany</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Bavencio (avelumab)</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">A monoclonal antibody that inhibits PD-L1 for the third-line treatment of advanced or metastatic gastric/</span></div><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">gastro-esophageal junction cancers, which is being developed in collaboration with Merck KGaA, Germany</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Bavencio (avelumab)</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">A monoclonal antibody that inhibits PD-L1 for treatment of locally advanced squamous cell carcinoma of the</span></div><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">head and neck, which is being developed in collaboration with Merck KGaA, Germany</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Inlyta (axitinib)</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Adjuvant treatment of renal cell carcinoma, which is being developed in collaboration with SFJ</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Ibrance (palbociclib)</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Treatment of HER2+ advanced breast cancer, in collaboration with the Alliance Foundation Trials, LLC</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Ibrance (palbociclib)</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Treatment of high-risk early breast cancer, in collaboration with the German Breast Group</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Ibrance (palbociclib)</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Treatment of HR+ early breast cancer, in collaboration with the Alliance Foundation Trials, LLC, and the Austrian Breast Colorectal Cancer Study Group</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Xtandi (enzalutamide)</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Treatment of non-metastatic castration resistant prostate cancer</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Xtandi (enzalutamide)</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Treatment of non-metastatic high risk hormone-sensitive prostate cancer</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Xtandi (enzalutamide)</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Treatment of metastatic hormone-sensitive prostate cancer</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Vyndaqel (tafamidis meglumine)</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Adult symptomatic transthyretin cardiomyopathy</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.02534113060429%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:22%;"></td><td style="width:78%;"></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;font-weight:bold;">NEW DRUG CANDIDATES IN LATE-STAGE DEVELOPMENT</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;font-weight:bold;">CANDIDATE</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;font-weight:bold;">PROPOSED INDICATION</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">dacomitinib</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">A pan-human epidermal growth factor receptor (HER) tyrosine kinase inhibitor for the first-line treatment of patients with advanced non-small cell lung cancer with estimated glomerular filtration rate (eGFR) activating mutations, which is being developed in collaboration with SFJ</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">lorlatinib (PF-06463922)</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">A next generation ALK/ROS1 tyrosine kinase inhibitor for the treatment of patients with ALK-positive metastatic non-small cell lung cancer, previously treated with one or more ALK inhibitors</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">PF-06425090</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">A prophylactic vaccine for active immunization to prevent clostridium difficile colitis</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">PF-05280586</span><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">A potential biosimilar to Rituxan</span><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">&#174; </sup></span><span style="font-family:inherit;font-size:8pt;">(rituximab)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:1px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">PF-06439535</span><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">A potential biosimilar to Avastin</span><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">&#174;</sup></span><span style="font-family:inherit;font-size:8pt;">&#160;(bevacizumab)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">PF-06410293</span><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">A potential biosimilar to Humira</span><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">&#174;</sup></span><span style="font-family:inherit;font-size:8pt;">&#160;(adalimumab)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">rivipansel (GMI-1070)</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">A pan-selectin inhibitor for the treatment of vaso-occlusive crisis in hospitalized individuals with sickle cell disease, which was licensed from GlycoMimetics Inc.</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">somatrogon (PF-06836922)</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">A long-acting hGH-CTP for the treatment of growth hormone deficiency in children, which is being developed in collaboration with OPKO</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">somatrogon (PF-06836922)</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-top:0px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">A long-acting hGH-CTP for the treatment of growth hormone deficiency in adults, which is being developed</span></div><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">in collaboration with OPKO</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">talazoparib (MDV3800)</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">An oral PARP inhibitor for the treatment of patients with germline breast cancer susceptibility gene BRCA mutated advanced breast cancer</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">tanezumab</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">An anti-nerve growth factor monoclonal antibody for the treatment of pain, which is being developed in collaboration with Lilly</span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Rituxan</span><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></span><span style="font-family:inherit;font-size:7.5pt;"> is a registered trademark of Biogen MA Inc.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Avastin</span><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></span><span style="font-family:inherit;font-size:7.5pt;"> is a registered trademark of Genentech, Inc.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(c)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Humira</span><span style="font-family:inherit;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></span><span style="font-family:inherit;font-size:7.5pt;"> is a registered trademark of AbbVie Biotechnology Ltd.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:10px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Additional product-related programs are in various stages of discovery and development. Also, see the discussion in the &#8220;Our Strategy&#8211;&#8211;Our Business Development Initiatives&#8221; section of this MD&amp;A.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">73</span></div></div><hr style="page-break-after:always"></hr><div><a id="s2179814CB9C85A8B94FB08DE76D4759A"></a></div><div><br/></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">COSTS AND EXPENSES</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;padding-bottom:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The changes in expenses below reflect, among other things, the favorable impact of the February 2017 sale of HIS. The operating results of HIS are included in our operating results through February 2, 2017 and, therefore, operating results for the </span><span style="font-family:inherit;font-size:10pt;">third quarter</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> do not reflect HIS global operations, while operating results for the </span><span style="font-family:inherit;font-size:10pt;">third quarter</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;"> reflect three months of HIS global operations. Operating results for the </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;"> include approximately one month of HIS domestic operations and approximately two months of HIS international operations, while operating results for the </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;"> reflect nine months of HIS global operations.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Cost of Sales</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="23"></td></tr><tr><td style="width:24%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Nine Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">October&#160;1, <br/>2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">October&#160;2, <br/>2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;Change</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">October&#160;1, <br/>2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">October&#160;2, <br/>2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;Change</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">Cost of sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">2,847</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">3,085</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(8</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">7,980</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">9,111</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(12</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">As a percentage of </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">21.6</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">23.6</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">20.5</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">23.2</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Cost of sales</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">decrease</span><span style="font-family:inherit;font-size:10pt;">d </span><span style="font-family:inherit;font-size:10pt;">8%</span><span style="font-family:inherit;font-size:10pt;"> in the </span><span style="font-family:inherit;font-size:10pt;">third</span><span style="font-family:inherit;font-size:10pt;"> quarter of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;">12%</span><span style="font-family:inherit;font-size:10pt;"> in the </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;">, compared to the same periods in </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;">, primarily due to:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the favorable impact of the sale of HIS global operations (which carried a higher cost of sales than other products) of $152 million in the </span><span style="font-family:inherit;font-size:10pt;">third</span><span style="font-family:inherit;font-size:10pt;"> quarter of 2017, and $433 million in the </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;">; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the favorable impact of foreign exchange of $223 million and the favorable offset of hedging gains of $66 million, both in the </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;">;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the nonrecurring unfavorable impact of $4 million in the </span><span style="font-family:inherit;font-size:10pt;">third</span><span style="font-family:inherit;font-size:10pt;"> quarter of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;"> and $216 million in the </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;"> of acquired Hospira inventory, which is measured at fair value on the acquisition date and was amortized over the turn of the related inventory;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">recognition of synergies related to our cost-reduction/productivity initiatives; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">a favorable change in product mix, including an operational decline in the SIP portfolio and the favorability attributed to products that have lost exclusivity,</span></div></td></tr></table><div style="line-height:120%;padding-top:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">partially offset by:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$55 million in inventory losses, overhead costs related to the period in which our Puerto Rico plants were not operational, and incremental costs to date, all of which resulted from the recent hurricanes in Puerto Rico.</span></div></td></tr></table><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The </span><span style="font-family:inherit;font-size:10pt;">decrease</span><span style="font-family:inherit;font-size:10pt;"> in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Cost of sales</span><span style="font-family:inherit;font-size:10pt;"> as a percentage of revenues in the </span><span style="font-family:inherit;font-size:10pt;">third</span><span style="font-family:inherit;font-size:10pt;"> quarter of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;"> and the </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;">, compared to the same periods in </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;">, was primarily due to all of the factors discussed above, as well as an increase in alliance revenues, which have no associated cost of sales.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Selling, Informational and Administrative (SI&amp;A) Expenses</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="23"></td></tr><tr><td style="width:24%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Nine Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">October&#160;1, <br/>2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">October&#160;2, <br/>2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%<br/>&#160;Change</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">October&#160;1, <br/>2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">October&#160;2, <br/>2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%<br/>&#160;Change</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">Selling, informational and administrative expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">3,500</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">3,559</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(2</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">10,233</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">10,414</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(2</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">As a percentage of </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">26.6</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">27.3</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">26.3</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">26.6</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:4px;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">SI&amp;A expenses </span><span style="font-family:inherit;font-size:10pt;">decrease</span><span style="font-family:inherit;font-size:10pt;">d </span><span style="font-family:inherit;font-size:10pt;">2%</span><span style="font-family:inherit;font-size:10pt;"> in the </span><span style="font-family:inherit;font-size:10pt;">third</span><span style="font-family:inherit;font-size:10pt;"> quarter of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;">, compared to the same period in </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;">, primarily due to:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">lower advertising, promotional and field force expenses, reflecting the benefits of cost-reduction and productivity initiatives, and lower expenses associated wi</span><span style="font-family:inherit;font-size:10pt;color:#2c2c2c;">th products that recently lost marketing exclusivity</span><span style="font-family:inherit;font-size:10pt;">;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the favorable impact of the sale of HIS global operations of $39 million;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">lower spending for certain products, primarily Prevnar 13/Prevenar 13; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the favorable impact of foreign exchange of $11 million,</span></div></td></tr></table><div style="line-height:120%;padding-bottom:4px;padding-top:4px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">partially offset by:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">additional investment across several of our key products, primarily Eucrisa, Ibrance and Xtandi; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">increased spending for biosimilars, primarily related to the U.S. launch of Inflectra.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:4px;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">SI&amp;A expenses </span><span style="font-family:inherit;font-size:10pt;">decreased</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">2%</span><span style="font-family:inherit;font-size:10pt;"> in the first </span><span style="font-family:inherit;font-size:10pt;">nine</span><span style="font-family:inherit;font-size:10pt;"> months of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;">, compared to the same period in </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;">, primarily due to:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the non-recurrence of an allowance for doubtful trade accounts receivable of approximately $265 million, resulting from unfavorable developments with a distributor that was recorded in the first quarter of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;">; </span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">74</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">lower advertising, promotional and field force expenses </span><span style="font-family:inherit;font-size:10pt;color:#2c2c2c;">associated with products that recently lost marketing exclusivity</span><span style="font-family:inherit;font-size:10pt;"> and certain other expenses related to disputes in the ordinary course of business;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">lower spending for certain products, primarily Prevnar 13/Prevenar 13;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the favorable impact of the sale of HIS global operations of $95 million; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the favorable impact of foreign exchange of $78 million,</span></div></td></tr></table><div style="line-height:120%;padding-bottom:4px;padding-top:4px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">partially offset by:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">additional investment across several of our key products, primarily Eucrisa, Ibrance, Xtandi and Xeljanz;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">increased spending for biosimilars, primarily related to the U.S. launch of Inflectra; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">an increase in charitable contributions.</span></div></td></tr></table><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Research and Development (R&amp;D) Expenses</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="23"></td></tr><tr><td style="width:24%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Nine Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">October&#160;1, <br/>2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">October&#160;2, <br/>2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">%<br/>Change</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">October&#160;1, <br/>2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">October&#160;2, <br/>2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">%<br/>Change</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-style:italic;">Research and development expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">1,859</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">1,881</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(1</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">5,346</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">5,360</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">As a percentage of </span><span style="font-family:inherit;font-size:9.5pt;font-style:italic;">Revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">14.1</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">%</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">14.4</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">%</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">13.8</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">%</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">13.7</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">%</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:4px;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">R&amp;D expenses </span><span style="font-family:inherit;font-size:10pt;">decrease</span><span style="font-family:inherit;font-size:10pt;">d </span><span style="font-family:inherit;font-size:10pt;">1%</span><span style="font-family:inherit;font-size:10pt;"> in the </span><span style="font-family:inherit;font-size:10pt;">third</span><span style="font-family:inherit;font-size:10pt;"> quarter of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;"> and were relatively flat in the first </span><span style="font-family:inherit;font-size:10pt;">nine</span><span style="font-family:inherit;font-size:10pt;"> months of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;">, compared to the same periods in </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;">, primarily due to:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">lower expenses due to the discontinuation of the global clinical development program for bococizumab in the fourth quarter of 2016; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the close-out of certain post-marketing clinical trials; and </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the favorable impact of the sale of HIS global operations,</span></div></td></tr></table><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">partially offset by:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">increased costs associated with our oncology programs, primarily clinical trial spend on Medivation assets, as well as, in the </span><span style="font-family:inherit;font-size:10pt;">third</span><span style="font-family:inherit;font-size:10pt;"> quarter of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;">, increased costs associated with our immuno-oncology development programs;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">lower development funding credits primarily related to the discontinuation of the global clinical development program for bococizumab in the fourth quarter of 2016;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">an expense of $75 million resulting from our May 2017 agreement with Sangamo to develop and commercialize gene therapy programs for Hemophilia A;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">increased costs associated with our</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> C. difficile</span><span style="font-family:inherit;font-size:10pt;"> vaccine program, which initiated a Phase 3 clinical study in March 2017; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">increased costs associated with our tanezumab development program.</span></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For additional information on Cost of sales, SI&amp;A and R&amp;D expenses by operating segment, see the &#8220;Analysis of Operating Segment Information&#8221; section of this MD&amp;A.</span></div><div style="line-height:120%;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Amortization of Intangible Assets</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="21"></td></tr><tr><td style="width:24%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nine Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">October&#160;1, <br/>2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">October&#160;2, <br/>2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">%<br/>Change</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">October&#160;1, <br/>2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">October&#160;2, <br/>2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">%<br/>Change</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-style:italic;">Amortization of intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">1,177</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">968</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">22</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">3,571</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">2,934</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">22</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">As a percentage of </span><span style="font-family:inherit;font-size:9.5pt;font-style:italic;">Revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">8.9</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">%</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">7.4</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">%</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">9.2</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">%</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">7.5</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">%</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization of intangible assets </span><span style="font-family:inherit;font-size:10pt;">increase</span><span style="font-family:inherit;font-size:10pt;">d </span><span style="font-family:inherit;font-size:10pt;">22%</span><span style="font-family:inherit;font-size:10pt;"> in the </span><span style="font-family:inherit;font-size:10pt;">third quarter</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">22%</span><span style="font-family:inherit;font-size:10pt;"> in the </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;">, compared to the same periods in </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;">, primarily due to the inclusion of amortization expense of approximately </span><span style="font-family:inherit;font-size:10pt;">$221 million</span><span style="font-family:inherit;font-size:10pt;"> (pre-tax) in the </span><span style="font-family:inherit;font-size:10pt;">third quarter</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;"> and approximately </span><span style="font-family:inherit;font-size:10pt;">$751 million</span><span style="font-family:inherit;font-size:10pt;"> (pre-tax) in the </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;"> related to the identifiable intangible assets acquired from Medivation and Anacor, partially offset by assets that became fully amortized at the end of their estimated useful lives. </span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">See also Notes to Condensed Consolidated Financial Statements&#8212;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 9A. Identifiable Intangible Assets and Goodwill: Identifiable Intangible Assets.</span></div><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">75</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="23"></td></tr><tr><td style="width:38%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Nine Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">October&#160;1, <br/>2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">October&#160;2, <br/>2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">%<br/>Change</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">October&#160;1, <br/>2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">October&#160;2, <br/>2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">%<br/>Change</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Restructuring charges</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">91</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">404</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(77</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">150</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">574</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(74</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Transaction costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(14</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">54</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">*</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">4</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">114</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(97</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Integration costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">73</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">74</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(1</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">224</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">300</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(26</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-style:italic;">Restructuring charges and certain acquisition-related costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">149</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">531</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(72</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">377</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">988</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(62</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Total additional depreciation&#8212;asset restructuring</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">39</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">47</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(17</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">74</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">151</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(51</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;text-indent:-18px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Total implementation costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">57</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">78</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(27</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">150</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">202</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(26</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;text-indent:-6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Costs associated with acquisitions and cost-reduction/productivity initiatives</span><span style="font-family:inherit;font-size:9.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">245</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">655</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(63</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">601</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">1,341</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(55</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Comprises </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Restructuring charges and certain acquisition-related costs</span><span style="font-family:inherit;font-size:9pt;"> as well as costs associated with our cost-reduction/productivity initiatives included in </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Cost of sales</span><span style="font-family:inherit;font-size:9pt;">, </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Research and development expenses</span><span style="font-family:inherit;font-size:9pt;"> and/or </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Selling, informational and administrative expenses</span><span style="font-family:inherit;font-size:9pt;">, as appropriate. For additional information, see Notes to Condensed Consolidated Financial Statements&#8212;</span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Note 3. </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives</span><span style="font-family:inherit;font-size:9pt;">.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:6px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In connection with our acquisition of Hospira, we are focusing our efforts on achieving an appropriate cost structure for the combined company. We expect to achieve $1 billion of annual cost savings by 2018 in connection with the Hospira acquisition, 25% more than our initial cost savings target of $800 million, and have achieved approximately </span><span style="font-family:inherit;font-size:10pt;">$700 million</span><span style="font-family:inherit;font-size:10pt;"> of cost savings through </span><span style="font-family:inherit;font-size:10pt;text-align:center;">October&#160;1, 2017</span><span style="font-family:inherit;font-size:10pt;">. The one-time costs to generate the savings are expected to be approximately </span><span style="font-family:inherit;font-size:10pt;">$1 billion</span><span style="font-family:inherit;font-size:10pt;"> (not including costs of </span><span style="font-family:inherit;font-size:10pt;">$215 million</span><span style="font-family:inherit;font-size:10pt;"> for full-year 2015 associated with the return of acquired IPR&amp;D rights), incurred for up to a three-year period post-acquisition.</span></div><div style="line-height:120%;padding-bottom:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In 2016, we substantially completed previously disclosed cost-reduction initiatives begun in 2014 associated with our global commercial structure reorganization, manufacturing plant network rationalization and optimization initiatives, and additional cost-reduction/productivity initiatives across the enterprise. Through December 31, 2016, we incurred </span><span style="font-family:inherit;font-size:10pt;">$3.1 billion</span><span style="font-family:inherit;font-size:10pt;"> (pre-tax) in total costs for the 2014-2016 program. The cumulative ongoing annual cost savings associated with the 2014-2016 program (but not including expected cost savings associated with the Hospira acquisition), are approximately $3.1 billion. These savings were recognized, for the most part, through the end of 2016. However, savings from costs incurred in the last half of 2016 are expected to largely occur in 2017 and are reflected in our 2017 financial guidance.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">New Cost-Reduction/Productivity Initiatives</span><span style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;">&#8212;</span><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">2017 through 2019 Activities</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As a result of the evaluation performed in connection with our decision in September 2016 to not pursue, at that time, splitting IH and EH into two separate publicly-traded companies, we have identified new opportunities to potentially achieve greater optimization and efficiency to become more competitive in our business. Therefore, we have initiated new enterprise-wide cost-reduction/productivity initiatives, which we expect to complete by the end of 2019. These initiatives will encompass all areas of our cost base and will include further centralization of our corporate and platform functions and optimization of our manufacturing plant network to support IH and EH products and pipelines, as well as activities in other areas where opportunities are identified. The action plans related to these new initiatives are underway and, in order to achieve targeted savings of approximately </span><span style="font-family:inherit;font-size:10pt;">$1.3 billion</span><span style="font-family:inherit;font-size:10pt;"> by 2020, we expect to incur total costs of approximately </span><span style="font-family:inherit;font-size:10pt;">$1.0 billion</span><span style="font-family:inherit;font-size:10pt;"> over the next three years. Of this amount, we expect about </span><span style="font-family:inherit;font-size:10pt;">80%</span><span style="font-family:inherit;font-size:10pt;"> to be manufacturing operations related and we expect about </span><span style="font-family:inherit;font-size:10pt;">20%</span><span style="font-family:inherit;font-size:10pt;"> of the total charges will be non-cash. For additional information about these programs and expected and actual total costs, see Notes to Condensed Consolidated Financial Statements&#8212;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 3. </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives</span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The expected cost savings in </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;"> associated with these activities are reflected in our </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;"> financial guidance.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition to these major initiatives, we continuously monitor our operations for cost reduction and/or productivity opportunities, especially in light of the losses of exclusivity and the expiration of collaborative arrangements for various products.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Other (Income)/Deductions&#8212;Net</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="22"></td></tr><tr><td style="width:24%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nine Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">October&#160;1, <br/>2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">October&#160;2, <br/>2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%<br/>Change</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">October&#160;1, <br/>2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">October&#160;2, <br/>2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%<br/>Change</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">51</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1,417</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(96</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(16</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2,815</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">*</span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-bottom:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;">*</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Calculation not meaningful.</span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">76</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For information about the components of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other (income)/deductions&#8212;net</span><span style="font-family:inherit;font-size:10pt;">, see Notes to Condensed Consolidated Financial Statements&#8212;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 4. </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other (Income)/Deductions&#8212;Net</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:inherit;font-size:5pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">See also the &#8220;Analysis of Operating Segment Information&#8221; section of this MD&amp;A.</span></div><div><a id="sA8822C064F8F5AE195BA202652A841BF"></a></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">PROVISION FOR TAXES ON INCOME</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="21"></td></tr><tr><td style="width:28%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Nine Months Ended</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">October&#160;1, <br/>2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">October&#160;2, <br/>2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">%<br/>Change</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">October&#160;1, <br/>2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">October&#160;2, <br/>2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">%<br/>Change</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-style:italic;">Provision for taxes on income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">727</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">249</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">*</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">2,287</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">1,109</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">*</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-18px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Effective tax rate on continuing operations</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">20.3</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">%</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">15.5</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">%</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">20.1</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">%</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">14.6</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">%</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#160;</span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;">*</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Calculation not meaningful.</span></div></td></tr></table><div style="line-height:120%;padding-top:4px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For information about our effective tax rate and the events and circumstances contributing to the changes between periods, see Notes to Condensed Consolidated Financial Statements&#8212;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 5. </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Tax Matters</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div><a id="s3C0BFA4C74CE550E91A50ED257324087"></a></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">NON-GAAP FINANCIAL MEASURE (ADJUSTED INCOME)</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">General Description of Non-GAAP Financial Measure (Adjusted Income)</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Adjusted income is an alternative view of performance used by management. We measure the performance of the overall Company on this basis in conjunction with other performance metrics. Because Adjusted income is an important internal measurement for Pfizer, we believe that investors&#8217; understanding of our performance is enhanced by disclosing this performance measure. We report Adjusted income, certain components of Adjusted income, and Adjusted diluted earnings per share in order to portray the results of our major operations&#8211;&#8211;the discovery, development, manufacture, marketing and sale of prescription medicines, vaccines and consumer healthcare (OTC) products&#8211;&#8211;prior to considering certain income statement elements. We have defined Adjusted income as </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Net income attributable to Pfizer Inc.</span><span style="font-family:inherit;font-size:10pt;"> before the impact of purchase accounting for acquisitions, acquisition-related costs, discontinued operations and certain significant items, which are described below. Also, see the &#8220;Non-GAAP Financial Measure (Adjusted Income)&#8211;&#8211;General Description of Non-GAAP Financial Measure (Adjusted Income)&#8221; section of our </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:9.75pt;"> Financial Report for additional information. </span><span style="font-family:inherit;font-size:10pt;">Similarly, we have defined the Adjusted income components as </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Cost of sales, Selling, informational and administrative expenses, Research and development expenses, Amortization of intangible assets </span><span style="font-family:inherit;font-size:10pt;">and</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> Other (income)/deductions&#8211;&#8211;net</span><span style="font-family:inherit;font-size:10pt;">, each before the impact of purchase accounting for acquisitions, acquisition-related costs and certain significant items. We have defined Adjusted diluted earnings per share as </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Earnings per common share attributable to Pfizer Inc.&#8211;&#8211;diluted</span><span style="font-family:inherit;font-size:9pt;font-style:italic;"> </span><span style="font-family:inherit;font-size:10pt;">before the impact of purchase accounting for acquisitions, acquisition-related costs, discontinued operations and certain significant items. The Adjusted income measure, the Adjusted income component measures and the Adjusted diluted earnings per share measure are not, and should not be viewed as, substitutes for U.S. GAAP net income, U.S. GAAP net income components or U.S. GAAP diluted earnings per share. </span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following are examples of how the Adjusted income and Adjusted diluted earnings per share measures are utilized:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">senior management receives a monthly analysis of our operating results that is prepared on an Adjusted income and Adjusted diluted earnings per share basis;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our annual budgets are prepared on an Adjusted income and Adjusted diluted earnings per share basis; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">senior management&#8217;s annual compensation is derived, in part, using Adjusted income and Adjusted diluted earnings per share measures. See the &#8220;Non-GAAP Financial Measure (Adjusted Income)&#8211;&#8211;General Description of Non-GAAP Financial Measure (Adjusted Income)&#8221; section of our </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:9.75pt;"> Financial Report for additional information.</span></div></td></tr></table><div style="line-height:120%;padding-top:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Adjusted income and its components and Adjusted diluted earnings per share are non-GAAP financial measures that have no standardized meaning prescribed by U.S. GAAP and, therefore, are limited in their usefulness to investors. Because of their non-standardized definitions, Adjusted income and its components (unlike U.S. GAAP net income and its components) and Adjusted diluted earnings per share (unlike U.S. GAAP diluted earnings per share) may not be comparable to the calculation of similar measures of other companies. Adjusted income and its components and Adjusted diluted earnings per share are presented solely to permit investors to more fully understand how management assesses performance.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We also recognize that, as internal measures of performance, the Adjusted income and its components and Adjusted diluted earnings per share measures have limitations, and we do not restrict our performance-management process solely to these metrics. A limitation of these measures is that they provide a view of our operations without including all events during a period, such as the effects of an acquisition or amortization of purchased intangibles, and do not provide a comparable view of our performance to other companies in the biopharmaceutical industry. We also use other specifically tailored tools designed to achieve the highest levels of performance. For example, our R&amp;D organization has productivity targets, upon which its </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">77</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">effectiveness is measured. In addition, total shareholder return, both on an absolute basis and relative to a publicly-traded pharmaceutical index, plays a significant role in determining payouts under certain of Pfizer&#8217;s long-term incentive compensation plans.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">See the accompanying reconciliations of certain GAAP reported to non-GAAP adjusted information for the </span><span style="font-family:inherit;font-size:10pt;">third quarter</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;"> below.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Purchase Accounting Adjustments</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Adjusted income is calculated prior to considering certain significant purchase accounting impacts resulting from business combinations and net asset acquisitions. These impacts, primarily associated with Wyeth (acquired in 2009), Hospira (acquired in 2015), Anacor (acquired in June 2016) and Medivation (acquired in September 2016), can include the incremental charge to cost of sales from the sale of acquired inventory that was written up to fair value, amortization related to the increase in fair value of the acquired finite-lived intangible assets, and to a much lesser extent, depreciation related to the increase/decrease in fair value of the acquired fixed assets (primarily manufacturing facilities), amortization related to the increase in fair value of acquired debt, and the fair value changes associated with contingent consideration. Therefore, the Adjusted income measure includes the revenues earned upon the sale of the acquired products without considering the acquisition cost of those products.</span></div><div style="line-height:120%;padding-top:10px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Acquisition-Related Costs</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Adjusted income is calculated prior to considering transaction, integration, restructuring and additional depreciation costs associated with business combinations because these costs are unique to each transaction and represent costs that were incurred to restructure and integrate two businesses as a result of the acquisition decision. For additional clarity, only transaction costs, additional depreciation and restructuring and integration activities that are associated with a business combination or a net-asset acquisition are included in acquisition-related costs. We have made no adjustments for the resulting synergies.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Discontinued Operations</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Adjusted income is calculated prior to considering the results of operations included in discontinued operations, as well as any related gains or losses on the disposal of such operations. </span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Certain Significant Items</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Adjusted income is calculated prior to considering certain significant items. Certain significant items represent substantive and/or unusual items that are evaluated on an individual basis. Such evaluation considers both the quantitative and the qualitative aspects of their nature. Certain significant items may be highly variable and difficult to predict. Furthermore, in some cases it is reasonably possible that they could reoccur in future periods. For example, major non-acquisition-related cost-reduction programs stand on their own as they are specific to an event or goal with a defined term, but we may have subsequent programs based on reorganizations of the business, cost productivity or in response to loss of exclusivity or economic conditions. Legal charges to resolve litigation are also related to specific cases, which are facts and circumstances specific and, in some cases, may also be the result of litigation matters at acquired companies that were inestimable, not probable or unresolved at the date of acquisition. Unusual items may represent items that are not part of our ongoing business; items that, either as a result of their nature or size, we would not expect to occur as part of our normal business on a regular basis; items that would be non-recurring; or items that relate to products we no longer sell. While not all-inclusive, examples of items that could be included as certain significant items would be a major non-acquisition-related restructuring charge and associated implementation costs; amounts related to certain disposals of businesses, products or facilities that do not qualify as discontinued operations under U.S. GAAP; certain intangible asset impairments; adjustments related to the resolution of certain tax positions; the impact of adopting certain significant, event-driven tax legislation; or charges related to certain legal matters, such as certain of those discussed in Notes to Condensed Consolidated Financial Statements&#8212;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 12A. Commitments and Contingencies: Legal Proceedings,</span><span style="font-family:inherit;font-size:10pt;"> included in Part I, Item 1 of this Quarterly Report on Form 10-Q. Normal, ongoing defense costs of the Company or settlements of and accruals for legal matters made in the normal course of our business would not be considered certain significant items.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">78</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Reconciliations of GAAP Reported to Non-GAAP Adjusted Information&#8211;&#8211;Certain Line Items</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"></td></tr><tr><td style="width:28%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="23" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Three Months Ended October&#160;1, 2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">IN MILLIONS, EXCEPT PER COMMON SHARE DATA</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">GAAP Reported</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Purchase Accounting Adjustments</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Acquisition-Related Costs</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Discontinued Operations</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Certain Significant Items</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Non-GAAP Adjusted</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">13,168</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">13,168</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Cost of sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2,847</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(28</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(26</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(92</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">2,699</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Selling, informational and administrative expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">3,500</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(22</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">3,478</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Research and development expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">1,859</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(9</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1,851</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Amortization of intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">1,177</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(1,120</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">57</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Restructuring charges and certain acquisition-related costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">149</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(129</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(21</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other (income)/deductions&#8211;&#8211;net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">51</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(7</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(305</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(261</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Income from continuing operations before provision for taxes on income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">3,585</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1,154</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">155</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">449</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">5,343</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Provision for taxes on income</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">727</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">306</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">72</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">161</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1,267</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Income from continuing operations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2,858</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">848</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">83</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">288</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">4,077</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Discontinued operations&#8211;&#8211;net of tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net income attributable to noncontrolling interests</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">18</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">18</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net income attributable to Pfizer Inc.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2,840</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">848</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">83</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">288</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">4,059</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Earnings per common share attributable to Pfizer Inc.&#8211;&#8211;diluted</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">0.47</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">0.14</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">0.01</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">0.05</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">0.67</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"></td></tr><tr><td style="width:28%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Nine Months Ended October 1, 2017</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">IN MILLIONS, EXCEPT PER COMMON SHARE DATA</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">GAAP Reported</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Purchase Accounting Adjustments</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Acquisition-Related Costs</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Discontinued Operations</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Certain Significant Items</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Non-GAAP Adjusted</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">38,843</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">38,843</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Cost of sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">7,980</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(45</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(38</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(168</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">7,729</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Selling, informational and administrative expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">10,233</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(15</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(67</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">10,151</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Research and development expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">5,346</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">7</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(26</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">5,326</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Amortization of intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">3,571</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(3,438</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">133</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Restructuring charges and certain acquisition-related costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">377</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(309</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(68</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other (income)/deductions&#8211;&#8211;net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(16</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(35</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(468</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(519</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Income from continuing operations before provision for taxes on income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">11,351</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">3,527</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">347</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">797</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">16,023</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Provision for taxes on income</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2,287</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">990</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">137</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">263</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">3,677</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Income from continuing operations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">9,064</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">2,537</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">211</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">534</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">12,345</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Discontinued operations&#8211;&#8211;net of tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">1</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(1</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net income attributable to noncontrolling interests</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">32</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">32</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net income attributable to Pfizer Inc.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">9,034</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">2,537</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">211</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(1</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">534</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">12,313</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Earnings per common share attributable to Pfizer Inc.&#8211;&#8211;diluted</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">1.49</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">0.42</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">0.03</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">0.09</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">2.03</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">See end of tables for notes </span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(a)</sup></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(b)</sup></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">79</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"></td></tr><tr><td style="width:28%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Three Months Ended October&#160;2, 2016</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">IN MILLIONS, EXCEPT PER COMMON SHARE DATA</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">GAAP Reported</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Purchase Accounting Adjustments</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Acquisition-Related Costs</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Discontinued Operations</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Certain Significant Items</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Non-GAAP Adjusted</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">13,045</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">13,045</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Cost of sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">3,085</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(32</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(3</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(93</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">2,957</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Selling, informational and administrative expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">3,559</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(5</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(23</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">3,531</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Research and development expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">1,881</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(8</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1,873</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Amortization of intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">968</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(936</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">32</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Restructuring charges and certain acquisition-related costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">531</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(277</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(254</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other (income)/deductions&#8211;&#8211;net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">1,417</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">6</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(1,590</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(168</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Income from continuing operations before provision for taxes on income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">1,604</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">966</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">280</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1,969</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">4,819</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Provision for taxes on income</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(b), (c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">249</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">366</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">73</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">370</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1,058</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Income from continuing operations</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">1,355</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">600</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">207</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1,599</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">3,761</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Discontinued operations&#8211;&#8211;net of tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net income attributable to noncontrolling interests</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net income attributable to Pfizer Inc.</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">1,355</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">600</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">207</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1,599</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">3,761</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Earnings per common share attributable to Pfizer Inc.&#8211;&#8211;diluted</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(c)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">0.22</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">0.10</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">0.03</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">0.26</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">0.61</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"></td></tr><tr><td style="width:28%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Nine Months Ended October 2, 2016</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">IN MILLIONS, EXCEPT PER COMMON SHARE DATA</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">GAAP Reported</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Purchase Accounting Adjustments</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Acquisition-Related Costs</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Discontinued Operations</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Certain Significant Items</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Non-GAAP Adjusted</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">39,196</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">39,196</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Cost of sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">9,111</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(284</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(3</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(240</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">8,584</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Selling, informational and administrative expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">10,414</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(13</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(59</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">10,342</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Research and development expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">5,360</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(24</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">5,336</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Amortization of intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2,934</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(2,841</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">94</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Restructuring charges and certain acquisition-related costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">988</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(595</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(393</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other (income)/deductions&#8211;&#8211;net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2,815</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">33</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(3,395</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(547</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Income from continuing operations before provision for taxes on income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">7,575</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">3,103</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">598</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">4,112</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">15,388</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Provision for taxes on income</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(b), (c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">1,109</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">962</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">47</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1,377</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">3,496</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Income from continuing operations</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">6,465</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">2,141</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">550</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">2,735</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">11,892</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Discontinued operations&#8211;&#8211;net of tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net income attributable to noncontrolling interests</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">25</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">25</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net income attributable to Pfizer Inc.</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">6,440</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">2,141</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">550</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">2,735</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">11,867</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Earnings per common share attributable to Pfizer Inc.&#8211;&#8211;diluted</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(c)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">1.04</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">0.35</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">0.09</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">0.44</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1.92</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">For details of adjustments, see &#8220;Details of Income Statement Items Included in GAAP Reported but Excluded from Non-GAAP Adjusted Income&#8221; below.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">The effective tax rate on Non-GAAP Adjusted income was </span><span style="font-family:inherit;font-size:8pt;">23.7%</span><span style="font-family:inherit;font-size:8pt;"> in the </span><span style="font-family:inherit;font-size:8pt;">third quarter</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:8pt;">, compared with </span><span style="font-family:inherit;font-size:8pt;">22.0%</span><span style="font-family:inherit;font-size:8pt;"> in the </span><span style="font-family:inherit;font-size:8pt;">third quarter</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:8pt;">. The increase was primarily due to an unfavorable change in the jurisdictional mix of earnings as a result of operating fluctuations in the normal course of business. The effective tax rate on Non-GAAP Adjusted income was </span><span style="font-family:inherit;font-size:8pt;">22.9%</span><span style="font-family:inherit;font-size:8pt;"> in the </span><span style="font-family:inherit;font-size:8pt;">first nine months of</span><span style="font-family:inherit;font-size:8pt;"> </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:8pt;">, compared with </span><span style="font-family:inherit;font-size:8pt;">22.7%</span><span style="font-family:inherit;font-size:8pt;"> in the </span><span style="font-family:inherit;font-size:8pt;">first nine months of</span><span style="font-family:inherit;font-size:8pt;"> </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:8pt;">. The increase was primarily due to a decrease in benefits associated with the resolution of certain tax positions pertaining to prior years primarily with various foreign tax authorities, and the expiration of certain statutes of limitations, partially offset by a favorable change in the jurisdictional mix of earnings as a result of operating fluctuations in the normal course of business.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">GAAP Reported and Non-GAAP Adjusted amounts for the </span><span style="font-family:inherit;font-size:8pt;">three and nine months</span><span style="font-family:inherit;font-size:8pt;"> ended </span><span style="font-family:inherit;font-size:8pt;">October&#160;2, 2016</span><span style="font-family:inherit;font-size:8pt;"> have been revised from previously reported amounts to reflect the adoption of a new accounting standard in the fourth quarter of 2016, as of January 1, 2016, requiring: (i) excess tax benefits or deficiencies (including tax benefits of dividend equivalents) of share-based compensation to be recognized as a component of the </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Provision for taxes on income</span><span style="font-family:inherit;font-size:8pt;"> (the net tax benefit was </span><span style="font-family:inherit;font-size:8pt;">$35 million</span><span style="font-family:inherit;font-size:8pt;"> in the third quarter of 2016 and </span><span style="font-family:inherit;font-size:8pt;">$85 million</span><span style="font-family:inherit;font-size:8pt;"> in the </span><span style="font-family:inherit;font-size:8pt;">first nine months of</span><span style="font-family:inherit;font-size:8pt;"> 2016) and (ii) in the diluted net earnings per share calculation, when applying the treasury stock method for shares that could be repurchased, the assumed proceeds no longer include the amount of excess tax benefit. For additional information, see Notes to Consolidated Financial Statements&#8211;&#8211;</span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Note 1B. Adoption of New Accounting Standards </span><span style="font-family:inherit;font-size:8pt;">in Pfizer&#8217;s </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:8pt;"> Financial Report.</span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">80</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Details of Income Statement Items Included in GAAP Reported but Excluded from Non-GAAP Adjusted Income</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"></td></tr><tr><td style="width:56%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Nine Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">October&#160;1, <br/>2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">October&#160;2, <br/>2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">October&#160;1, <br/>2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">October&#160;2, <br/>2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;text-decoration:underline;">Purchase accounting adjustments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Amortization, depreciation and other</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1,126</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">934</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">3,482</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">2,819</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Cost of sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">28</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">32</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">45</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">284</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total purchase accounting adjustments&#8211;&#8211;pre-tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1,154</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">966</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">3,527</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">3,103</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Income taxes</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(306</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(366</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(990</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(962</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total purchase accounting adjustments&#8211;&#8211;net of tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">848</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">600</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">2,537</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">2,141</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;text-decoration:underline;">Acquisition-related costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Restructuring charges</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">70</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">150</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">82</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">181</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Transaction costs</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(14</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">54</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">4</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">114</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Integration costs</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">73</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">73</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">224</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">300</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Additional depreciation&#8211;&#8211;asset restructuring</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(d)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">26</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">3</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">38</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">3</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total acquisition-related costs&#8211;&#8211;pre-tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">155</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">280</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">347</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">598</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Income taxes</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(e)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(72</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(73</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(137</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(47</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total acquisition-related costs&#8211;&#8211;net of tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">83</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">207</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">211</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">550</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;text-decoration:underline;">Discontinued operations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total discontinued operations&#8211;&#8211;net of tax, attributable to Pfizer Inc.</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(f)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(1</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;text-decoration:underline;">Certain significant items</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Restructuring charges</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(g)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">21</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">254</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">68</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">393</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Implementation costs and additional depreciation&#8211;&#8211;asset restructuring</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(h)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">69</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">122</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">185</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">350</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Certain legal matters, net</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(i)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">183</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(40</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">191</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">506</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Loss on sale and impairment on remeasurement of HIS net assets</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(i)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(12</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1,422</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">52</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1,422</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Certain asset impairments</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(i)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">127</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">126</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">127</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1,073</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Business and legal entity alignment costs</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(i)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">16</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">69</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">54</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">180</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(j)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">45</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">17</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">119</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">189</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total certain significant items&#8211;&#8211;pre-tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">449</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1,969</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">797</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">4,112</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Income taxes</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(k)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(161</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(370</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(263</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(1,377</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total certain significant items&#8211;&#8211;net of tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">288</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1,599</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">534</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">2,735</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total purchase accounting adjustments, acquisition-related costs, discontinued operations and certain significant items&#8211;&#8211;net of tax, attributable to Pfizer Inc.</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1,219</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">2,406</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">3,280</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">5,426</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Included primarily in </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Amortization of intangible assets.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Included in </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Provision for taxes on income. </span><span style="font-family:inherit;font-size:9pt;">Income taxes includes the tax effect of the associated pre-tax amounts, calculated by determining the jurisdictional location of the pre-tax amounts and applying that jurisdiction&#8217;s applicable tax rate. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(c)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Included in </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Restructuring charges and certain acquisition-related costs</span><span style="font-family:inherit;font-size:9pt;">. Restructuring charges include employee termination costs, asset impairments and other exit costs associated with business combinations. Transaction costs represent external costs for banking, legal, accounting and other similar services. Integration costs represent external, incremental costs directly related to integrating acquired businesses, and primarily include expenditures for consulting and the integration of systems and processes. For additional information, see Notes to Condensed Consolidated Financial Statements&#8212;</span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Note 3. </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives</span><span style="font-family:inherit;font-size:9pt;font-style:italic;">.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(d)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Included in </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Cost of sales. </span><span style="font-family:inherit;font-size:9pt;">Represents the impact of changes in estimated useful lives of assets involved in restructuring actions related to acquisitions.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(e)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Included in </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Provision for taxes on income</span><span style="font-family:inherit;font-size:9pt;">. Income taxes includes the tax effect of the associated pre-tax amounts, calculated by determining the jurisdictional location of the pre-tax amounts and applying that jurisdiction&#8217;s applicable tax rate. The </span><span style="font-family:inherit;font-size:9pt;">nine months</span><span style="font-family:inherit;font-size:9pt;"> ended </span><span style="font-family:inherit;font-size:9pt;">October&#160;2, 2016</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:9pt;">were unfavorably impacted by the remeasurement of certain deferred tax liabilities resulting from plant network restructuring activities.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(f)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Included in </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Discontinued operations&#8211;&#8211;net of tax.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(g)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Amounts relate to our cost-reduction/productivity initiatives not related to acquisitions. Included in </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Restructuring charges and certain acquisition-related costs </span><span style="font-family:inherit;font-size:9pt;">(see Notes to Condensed Consolidated Financial Statements&#8212;</span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Note 3. </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives</span><span style="font-family:inherit;font-size:9pt;">). </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(h)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Amounts relate to our cost-reduction/productivity initiatives not related to acquisitions (see Notes to Condensed Consolidated Financial Statements&#8212;</span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Note 3. </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives</span><span style="font-family:inherit;font-size:9pt;">). For the three months ended </span><span style="font-family:inherit;font-size:9pt;">October&#160;1, 2017</span><span style="font-family:inherit;font-size:9pt;">, included in </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Cost of sales</span><span style="font-family:inherit;font-size:9pt;"> (</span><span style="font-family:inherit;font-size:9pt;">$38 million</span><span style="font-family:inherit;font-size:9pt;">), </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Selling, informational and administrative expenses</span><span style="font-family:inherit;font-size:9pt;"> (</span><span style="font-family:inherit;font-size:9pt;">$22 million</span><span style="font-family:inherit;font-size:9pt;">) and </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Research and development expenses</span><span style="font-family:inherit;font-size:9pt;"> (</span><span style="font-family:inherit;font-size:9pt;">$9 million</span><span style="font-family:inherit;font-size:9pt;">). For the three months ended </span><span style="font-family:inherit;font-size:9pt;">October&#160;2, 2016</span><span style="font-family:inherit;font-size:9pt;">, virtually all included in </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Cost of sales</span><span style="font-family:inherit;font-size:9pt;"> (</span><span style="font-family:inherit;font-size:9pt;">$89 million</span><span style="font-family:inherit;font-size:9pt;">), </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Selling, informational and administrative expenses</span><span style="font-family:inherit;font-size:9pt;"> (</span><span style="font-family:inherit;font-size:9pt;">$23 million</span><span style="font-family:inherit;font-size:9pt;">) and </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Research and development expenses</span><span style="font-family:inherit;font-size:9pt;"> (</span><span style="font-family:inherit;font-size:9pt;">$8 million</span><span style="font-family:inherit;font-size:9pt;">). For the </span><span style="font-family:inherit;font-size:9pt;">nine months</span><span style="font-family:inherit;font-size:9pt;"> ended </span><span style="font-family:inherit;font-size:9pt;text-align:center;">October&#160;1, 2017</span><span style="font-family:inherit;font-size:9pt;">, included in </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Cost of sales</span><span style="font-family:inherit;font-size:9pt;"> (</span><span style="font-family:inherit;font-size:9pt;">$113 million</span><span style="font-family:inherit;font-size:9pt;">), </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Selling, informational and administrative </span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">81</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;padding-left:12px;text-align:left;"><span style="font-family:inherit;font-size:9pt;">expenses (</span><span style="font-family:inherit;font-size:9pt;">$46 million</span><span style="font-family:inherit;font-size:9pt;">) and </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Research and development</span><span style="font-family:inherit;font-size:9pt;"> </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">expenses</span><span style="font-family:inherit;font-size:9pt;"> (</span><span style="font-family:inherit;font-size:9pt;">$26 million</span><span style="font-family:inherit;font-size:9pt;">). For the </span><span style="font-family:inherit;font-size:9pt;">nine months</span><span style="font-family:inherit;font-size:9pt;text-align:center;"> ended </span><span style="font-family:inherit;font-size:9pt;">October&#160;2, 2016</span><span style="font-family:inherit;font-size:9pt;">, virtually all included in </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Cost of sales</span><span style="font-family:inherit;font-size:9pt;"> (</span><span style="font-family:inherit;font-size:9pt;">$269 million</span><span style="font-family:inherit;font-size:9pt;">), </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Selling, informational and administrative</span><span style="font-family:inherit;font-size:9pt;"> </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">expenses</span><span style="font-family:inherit;font-size:9pt;"> (</span><span style="font-family:inherit;font-size:9pt;">$56 million</span><span style="font-family:inherit;font-size:9pt;">) and </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Research and development</span><span style="font-family:inherit;font-size:9pt;"> </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">expenses</span><span style="font-family:inherit;font-size:9pt;"> (</span><span style="font-family:inherit;font-size:9pt;">$22 million</span><span style="font-family:inherit;font-size:9pt;">).</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(i)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Included in </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Other (income)/deductions</span><span style="font-family:inherit;font-size:9pt;">&#8212;</span><span style="font-family:inherit;font-size:9pt;font-style:italic;">net </span><span style="font-family:inherit;font-size:9pt;">(see Notes to Condensed Consolidated Financial Statements&#8212;</span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Note 4. </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Other (Income)/Deductions&#8212;Net</span><span style="font-family:inherit;font-size:9pt;">)</span><span style="font-family:inherit;font-size:9pt;font-style:italic;">.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(j)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">For the three months ended </span><span style="font-family:inherit;font-size:9pt;">October&#160;1, 2017</span><span style="font-family:inherit;font-size:9pt;">, included in</span><span style="font-family:inherit;font-size:9pt;font-style:italic;"> Cost of sales </span><span style="font-family:inherit;font-size:9pt;">(</span><span style="font-family:inherit;font-size:9pt;">$54 million</span><span style="font-family:inherit;font-size:9pt;">) and </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net </span><span style="font-family:inherit;font-size:9pt;">(</span><span style="font-family:inherit;font-size:9pt;">$9 million</span><span style="font-family:inherit;font-size:9pt;"> income. For the three months ended </span><span style="font-family:inherit;font-size:9pt;">October&#160;2, 2016</span><span style="font-family:inherit;font-size:9pt;">, included in </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Cost of sales</span><span style="font-family:inherit;font-size:9pt;"> (</span><span style="font-family:inherit;font-size:9pt;">$4 million</span><span style="font-family:inherit;font-size:9pt;">) and </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net</span><span style="font-family:inherit;font-size:9pt;"> (</span><span style="font-family:inherit;font-size:9pt;">$13 million</span><span style="font-family:inherit;font-size:9pt;">). For the </span><span style="font-family:inherit;font-size:9pt;">nine months</span><span style="font-family:inherit;font-size:9pt;"> ended </span><span style="font-family:inherit;font-size:9pt;">October&#160;1, 2017</span><span style="font-family:inherit;font-size:9pt;">, included in </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Cost of sales </span><span style="font-family:inherit;font-size:9pt;">(</span><span style="font-family:inherit;font-size:9pt;">$55 million</span><span style="font-family:inherit;font-size:9pt;">)</span><span style="font-family:inherit;font-size:9pt;font-style:italic;">, Selling, informational and administrative</span><span style="font-family:inherit;font-size:9pt;"> expenses (</span><span style="font-family:inherit;font-size:9pt;">$21 million</span><span style="font-family:inherit;font-size:9pt;">) and </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net</span><span style="font-family:inherit;font-size:9pt;"> (</span><span style="font-family:inherit;font-size:9pt;">$43 million</span><span style="font-family:inherit;font-size:9pt;">). For the </span><span style="font-family:inherit;font-size:9pt;">nine months</span><span style="font-family:inherit;font-size:9pt;"> ended </span><span style="font-family:inherit;font-size:9pt;">October&#160;2, 2016</span><span style="font-family:inherit;font-size:9pt;">, included in </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Cost of sales </span><span style="font-family:inherit;font-size:9pt;">(</span><span style="font-family:inherit;font-size:9pt;">$29 million</span><span style="font-family:inherit;font-size:9pt;"> income), </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Selling, informational and administrative</span><span style="font-family:inherit;font-size:9pt;"> expenses (</span><span style="font-family:inherit;font-size:9pt;">$3 million</span><span style="font-family:inherit;font-size:9pt;">), </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Research and development</span><span style="font-family:inherit;font-size:9pt;"> </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">expenses </span><span style="font-family:inherit;font-size:9pt;">(</span><span style="font-family:inherit;font-size:9pt;">$2 million</span><span style="font-family:inherit;font-size:9pt;">) and </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net </span><span style="font-family:inherit;font-size:9pt;">(</span><span style="font-family:inherit;font-size:9pt;">$213 million</span><span style="font-family:inherit;font-size:9pt;">)</span><span style="font-family:inherit;font-size:9pt;font-style:italic;">.</span><span style="font-family:inherit;font-size:9pt;"> In the three months and </span><span style="font-family:inherit;font-size:9pt;">nine months</span><span style="font-family:inherit;font-size:9pt;"> ended </span><span style="font-family:inherit;font-size:9pt;">October&#160;1, 2017</span><span style="font-family:inherit;font-size:9pt;">, includes </span><span style="font-family:inherit;font-size:9pt;">$55 million</span><span style="font-family:inherit;font-size:9pt;"> in inventory losses, overhead costs related to the period in which our Puerto Rico plants were not operational, and incremental costs to date, all of which resulted from the recent hurricanes in Puerto Rico and are included in </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Cost of sales</span><span style="font-family:inherit;font-size:9pt;">. For the </span><span style="font-family:inherit;font-size:9pt;">nine months</span><span style="font-family:inherit;font-size:9pt;"> ended </span><span style="font-family:inherit;font-size:9pt;">October&#160;1, 2017</span><span style="font-family:inherit;font-size:9pt;">, includes a net loss of </span><span style="font-family:inherit;font-size:9pt;">$30 million</span><span style="font-family:inherit;font-size:9pt;"> related to the sale of our 40% ownership investment in Teuto, including the extinguishment of a put option for the remaining 60% ownership interest. For the </span><span style="font-family:inherit;font-size:9pt;">nine months</span><span style="font-family:inherit;font-size:9pt;"> ended </span><span style="font-family:inherit;font-size:9pt;">October&#160;2, 2016</span><span style="font-family:inherit;font-size:9pt;">, primarily includes </span><span style="font-family:inherit;font-size:9pt;">$150 million</span><span style="font-family:inherit;font-size:9pt;"> paid to Allergan for reimbursement of Allergan&#8217;s expenses associated with the terminated transaction.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(k)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Included in </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Provision for taxes on income</span><span style="font-family:inherit;font-size:9pt;">. Income taxes includes the tax effect of the associated pre-tax amounts, calculated by determining the jurisdictional location of the pre-tax amounts and applying that jurisdiction&#8217;s applicable tax rate. The third quarter of 2016 was unfavorably impacted by the tax effects of an impairment charge related to the write-down of the HIS net assets to fair value less estimated costs to sell, mainly related to goodwill, which is not deductible for tax purposes, and the jurisdictional mix of intangible assets. The first </span><span style="font-family:inherit;font-size:9pt;">nine months</span><span style="font-family:inherit;font-size:9pt;"> of </span><span style="font-family:inherit;font-size:9pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:9pt;"> were favorably impacted by benefits related to the final resolution of an agreement in principle reached in February 2016 and finalized in April 2016 to resolve certain claims related to Protonix, which resulted in the receipt of information that raised our initial assessment in 2015 of the likelihood of prevailing on the technical merits of our tax position, as well as benefits associated with our Venezuela operations, partially offset by the unfavorable tax effects of the impairment charge related to the write-down of the HIS net assets to fair value less estimated costs to sell, mainly related to goodwill, which is not deductible for tax purposes, and the jurisdictional mix of intangible assets.</span></div></td></tr></table><div style="line-height:120%;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">82</span></div></div><hr style="page-break-after:always"></hr><div><a id="s15F891AFE08253819D038C61D95785A8"></a></div><div><br/></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">ANALYSIS OF OPERATING SEGMENT INFORMATION</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following tables and associated notes provide additional information about the performance of our two operating segments&#8212;the IH segment and the EH segment. For additional information about each operating segment, see the &#8220;Our Strategy</span><span style="font-family:inherit;font-size:9pt;">&#8211;&#8211;</span><span style="font-family:inherit;font-size:10pt;">Commercial Operations&#8221; section of this MD&amp;A and Notes to Condensed Consolidated Financial Statements&#8212;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 13. </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Segment, Geographic and Other Revenue Information</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">, </span><span style="font-family:inherit;font-size:10pt;">as well as the &#8220;Selected Balance Sheet Information by Operating Segment&#8221; section of the MD&amp;A in our Form 10-Q for the quarter ended April&#160;2, </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As described in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 1A</span><span style="font-family:inherit;font-size:10pt;">, acquisitions and divestitures have impacted our results of operations in 2017 and 2016.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:96.74329501915709%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"></td></tr><tr><td style="width:33%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td></tr><tr><td colspan="25" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following tables provide revenue and cost information by reportable operating segment and a reconciliation of that information to our condensed consolidated statements of income:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Third Quarter of 2017</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Innovative Health (IH)</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Essential Health (EH)</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(b)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Non-GAAP</span></div><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Adjusted</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(c)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Reconciling Items</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(d)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">GAAP Reported</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">8,118</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">5,050</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">13,168</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">13,168</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Cost of sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1,082</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1,448</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">170</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">2,699</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">147</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2,847</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">% of revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">13.3</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">28.7</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">*</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">20.5</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">*</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">21.6</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Selling, informational and administrative expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1,736</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">727</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1,016</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">3,478</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">22</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">3,500</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Research and development expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">639</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">249</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">964</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1,851</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">8</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">1,859</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Amortization of intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">40</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">17</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">57</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1,120</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">1,177</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Restructuring charges and certain acquisition-related costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">149</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">149</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other (income)/deductions&#8211;&#8211;net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(253</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(155</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">147</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(261</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">312</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">51</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Income/(loss) from continuing operations before provision for taxes on income</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">4,875</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">2,765</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(2,297</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">5,343</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(1,759</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">3,585</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:96.74329501915709%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"></td></tr><tr><td style="width:33%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Nine Months Ended October 1, 2017</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Innovative Health (IH)</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Essential Health (EH)</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(b)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Non-GAAP<br/>Adjusted</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(c)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Reconciling Items</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(d)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">GAAP Reported</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">23,204</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">15,639</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">38,843</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">38,843</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Cost of sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">2,912</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">4,319</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">497</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">7,729</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">252</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">7,980</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">% of revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">12.6</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">27.6</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">*</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">19.9</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">*</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">20.5</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Selling, informational and administrative expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">4,914</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">2,212</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">3,026</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">10,151</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">82</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">10,233</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Research and development expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1,709</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">755</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">2,862</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">5,326</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">20</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">5,346</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Amortization of intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">90</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">43</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">133</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">3,438</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">3,571</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Restructuring charges and certain acquisition-related costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">377</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">377</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other (income)/deductions&#8211;&#8211;net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(611</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(248</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">341</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(519</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">503</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(16</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Income/(loss) from continuing operations before provision for taxes on income</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">14,190</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">8,558</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(6,725</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">16,023</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(4,671</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">11,351</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:96.74329501915709%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"></td></tr><tr><td style="width:33%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Third Quarter of 2016</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Innovative Health (IH)</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Essential Health (EH)</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(b)</sup></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Non-GAAP<br/>Adjusted</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(c)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Reconciling Items</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(d)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">GAAP Reported</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">7,332</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">5,712</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">13,045</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">13,045</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Cost of sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1,039</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1,546</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">372</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">2,957</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">128</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">3,085</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">% of revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">14.2</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">27.1</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">*</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">22.7</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">*</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">23.6</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Selling, informational and administrative expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1,647</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">813</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1,071</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">3,531</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">28</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">3,559</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Research and development expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">671</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">292</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">911</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1,873</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">8</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">1,881</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Amortization of intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">25</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">7</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">32</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">936</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">968</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Restructuring charges and certain acquisition-related costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">531</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">531</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other (income)/deductions&#8211;&#8211;net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(237</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(73</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">142</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(168</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1,584</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">1,417</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Income/(loss) from continuing operations before provision for taxes on income</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">4,187</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">3,128</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(2,496</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">4,819</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(3,215</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">1,604</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">See end of tables for notes (a) through (d).</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">83</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:96.74329501915709%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"></td></tr><tr><td style="width:33%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Nine Months Ended October 2, 2016</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Innovative Health (IH)</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Essential Health (EH)</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(b)</sup></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Non-GAAP<br/>Adjusted</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(c)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Reconciling Items</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(d)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">GAAP Reported</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">21,471</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">17,725</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">39,196</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">39,196</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Cost of sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">2,930</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">4,677</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">977</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">8,584</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">527</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">9,111</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">% of revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">13.6</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">26.4</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">*</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">21.9</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">*</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">23.2</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Selling, informational and administrative expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">4,947</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">2,435</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">2,960</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">10,342</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">72</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">10,414</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Research and development expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1,815</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">876</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">2,645</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">5,336</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">23</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">5,360</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Amortization of intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">74</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">20</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">94</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">2,841</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2,934</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Restructuring charges and certain acquisition-related costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">988</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">988</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other (income)/deductions&#8211;&#8211;net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(764</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(267</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">484</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(547</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">3,362</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2,815</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Income/(loss) from continuing operations before provision for taxes on income</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">12,470</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">9,985</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(7,066</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">15,388</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(7,813</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">7,575</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-bottom:1px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Amounts represent the revenues and costs managed by each of our operating segments. The expenses generally include only those costs directly attributable to the operating segment.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other comprises the costs included in our Adjusted income components (see footnote (c) below) that are managed outside of our two operating segments</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt"> </sup></span><span style="font-family:inherit;font-size:9pt;">and includes the following:</span></div></td></tr></table><div style="line-height:120%;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:96.16858237547893%;border-collapse:collapse;text-align:left;"><tr><td colspan="21"></td></tr><tr><td style="width:44%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Third Quarter of 2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other Business Activities</span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">WRD</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(i)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">GPD</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(ii)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Corporate</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(iii)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other Unallocated</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(iv)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Cost of sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">28</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">142</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">170</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Selling, informational and administrative expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">993</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">23</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1,016</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Research and development expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">568</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">193</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">194</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">8</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">964</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Amortization of intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Restructuring charges and certain acquisition-related costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other (income)/deductions&#8211;&#8211;net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(2</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">167</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(18</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">147</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Loss from continuing operations before provision for taxes on income</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(566</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(193</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(1,382</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(156</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(2,297</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:96.16858237547893%;border-collapse:collapse;text-align:left;"><tr><td colspan="21"></td></tr><tr><td style="width:44%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Nine Months Ended October 1, 2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other Business Activities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">WRD</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(i)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">GPD</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(ii)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Corporate</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(iii)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other Unallocated</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(iv)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Cost of sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(3</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">500</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">497</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Selling, informational and administrative expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(1</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">2,995</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">31</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">3,026</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Research and development expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1,674</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">560</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">616</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">12</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">2,862</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Amortization of intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Restructuring charges and certain acquisition-related costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other (income)/deductions&#8211;&#8211;net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(29</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">339</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">31</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">341</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Loss from continuing operations before provision for taxes on income</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(1,645</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(559</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(3,948</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(573</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(6,725</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr></table></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">84</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:96.16858237547893%;border-collapse:collapse;text-align:left;"><tr><td colspan="21"></td></tr><tr><td style="width:44%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Third Quarter of 2016</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other Business Activities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">WRD</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(i)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">GPD</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(ii)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Corporate</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(iii)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other Unallocated</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(iv)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Cost of sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">104</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">268</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">372</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Selling, informational and administrative expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1,073</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(3</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1,071</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Research and development expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">575</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">172</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">169</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(5</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">911</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Amortization of intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Restructuring charges and certain acquisition-related costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other (income)/deductions&#8211;&#8211;net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">5</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">191</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(54</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">142</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Loss from continuing operations before provision for taxes on income</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(580</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(173</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(1,537</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(206</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(2,496</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;padding-left:12px;text-indent:-12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:96.16858237547893%;border-collapse:collapse;text-align:left;"><tr><td colspan="21"></td></tr><tr><td style="width:44%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Nine Months Ended October 2, 2016</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other Business Activities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">WRD</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(i)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">GPD</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(ii)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Corporate</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(iii)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other Unallocated</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(iv)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Cost of sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">194</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">783</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">977</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Selling, informational and administrative expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">2,910</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">48</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">2,960</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Research and development expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1,629</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">487</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">523</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">6</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">2,645</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Amortization of intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Restructuring charges and certain acquisition-related costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other (income)/deductions&#8211;&#8211;net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(22</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">590</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(83</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">484</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Loss from continuing operations before provision for taxes on income</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(1,608</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(488</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(4,217</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(753</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(7,066</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:12px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(i)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">WRD&#8212;the R&amp;D expenses managed by our WRD organization, which is generally responsible for research projects for our IH business until proof-of-concept is achieved and then for transitioning those projects to the IH segment via the GPD organization for possible clinical and commercial development. R&amp;D spending may include upfront and milestone payments for intellectual property rights. The WRD organization also has responsibility for certain science-based and other platform-services organizations, which provide technical expertise and other services to the various R&amp;D projects, including EH R&amp;D projects. WRD is also responsible for facilitating all regulatory submissions and interactions with regulatory agencies, including all safety-event activities.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:12px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(ii)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">GPD</span><span style="font-family:inherit;font-size:8pt;font-style:italic;">&#8211;&#8211;</span><span style="font-family:inherit;font-size:8pt;">the costs associated with our GPD organization, which is generally responsible for the clinical development of assets that are in clinical trials for our WRD and Innovative portfolios. GPD also provides technical support and other services to Pfizer R&amp;D projects.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:12px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(iii)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Corporate&#8212;the costs associated with Corporate, representing platform functions (such as worldwide technology, global real estate operations, legal, finance, human resources, worldwide public affairs, compliance and worldwide procurement) and certain compensation and other corporate costs, such as interest income and expense, and gains and losses on investments. Effective in the first quarter of 2017, Corporate also includes the costs associated with our Pfizer Medical organization (Medical), previously reported as part of Other Business Activities. Medical is responsible for the provision of medical information to healthcare providers, patients and other parties, transparency and disclosure activities, clinical trial results publication, grants for healthcare quality improvement and medical education, and partnerships with global public health and medical associations. We have reclassified approximately </span><span style="font-family:inherit;font-size:8pt;">$33 million</span><span style="font-family:inherit;font-size:8pt;"> and </span><span style="font-family:inherit;font-size:8pt;">$94 million</span><span style="font-family:inherit;font-size:8pt;"> of Medical costs from Other Business Activities to Corporate in the </span><span style="font-family:inherit;font-size:8pt;">third quarter</span><span style="font-family:inherit;font-size:8pt;"> and </span><span style="font-family:inherit;font-size:8pt;">first nine months of</span><span style="font-family:inherit;font-size:8pt;"> </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:8pt;">, respectively, to conform to the current period presentation.</span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:24px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">We recognized a </span><span style="font-family:inherit;font-size:8pt;">$4 million</span><span style="font-family:inherit;font-size:8pt;"> loss in the </span><span style="font-family:inherit;font-size:8pt;">third quarter</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:8pt;"> and a </span><span style="font-family:inherit;font-size:8pt;">$67 million</span><span style="font-family:inherit;font-size:8pt;"> gain in the </span><span style="font-family:inherit;font-size:8pt;">first nine months of</span><span style="font-family:inherit;font-size:8pt;"> </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:8pt;"> as an offset to </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Cost of sales</span><span style="font-family:inherit;font-size:8pt;"> related to foreign currency forward-exchange contracts designated as cash flow hedges of a portion of our foreign exchange-denominated forecasted intercompany inventory sales. For additional information, see Notes to Condensed Consolidated Financial Statements&#8211;&#8211;</span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Note 7F</span><span style="font-family:inherit;font-size:8pt;">. </span><span style="font-size:8pt;font-style:italic;font-weight:normal;text-decoration:none;">Derivative Financial Instruments and Hedging Activities</span><span style="font-family:inherit;font-size:8pt;">.</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:12px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(iv)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Other Unallocated&#8212;other unallocated costs, representing overhead expenses associated with our manufacturing and commercial operations that are not directly assessed to an operating segment, as business unit (segment) management does not manage these costs (which include manufacturing variances associated with production).</span></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For information purposes only, the following tables present reconciliations of our segment operating results to segment operating results including estimated Other costs generally associated with each segment. While we do not manage our segments or have performance goals under such an allocated manner, we believe that some investors may find this information useful in their analyses. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The estimated Other costs generally associated with our operating segments do not purport to reflect the additional amounts that each of our operating segments would have incurred had each segment operated as a standalone company during the period presented. </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">85</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For information purposes only, for the </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;">, we estimate that Other costs, as described above, for combined WRD and GPD costs of </span><span style="font-family:inherit;font-size:10pt;">$2.2 billion</span><span style="font-family:inherit;font-size:10pt;">, and combined Corporate and Other Unallocated costs of </span><span style="font-family:inherit;font-size:10pt;">$4.0 billion</span><span style="font-family:inherit;font-size:10pt;"> after excluding (i) net interest-related expense not attributable to an operating segment included in Corporate (approximately </span><span style="font-family:inherit;font-size:10pt;">$704 million</span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;"> in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net</span><span style="font-family:inherit;font-size:10pt;">); and (ii) net income from investments and other assets not attributable to an operating segment included in Corporate (approximately </span><span style="font-family:inherit;font-size:10pt;">$146 million</span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;"> in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">(income)/deductions&#8211;&#8211;net</span><span style="font-family:inherit;font-size:10pt;">), are generally associated with our operating segments, as follows:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"></td></tr><tr><td style="width:34%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Nine Months Ended October 1, 2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Estimated Other Costs Associated with IH</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(ii)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Innovative Health Non-GAAP Adjusted</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(i), (iii)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Estimated WRD/GPD</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(ii)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Estimated Corporate/Other Unallocated</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(ii)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Innovative Health with Estimated Other Costs Associated with<br/>Innovative Health<br/>Non-GAAP Adjusted</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(ii),</sup></span><span style="font-family:inherit;font-size:9pt;">&#160;</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(iii)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">23,204</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">23,204</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Cost of sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">2,912</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">68</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">2,980</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Selling, informational and administrative expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">4,914</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(1</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1,688</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">6,601</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Research and development expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1,709</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">2,220</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">575</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">4,504</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Amortization of intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">90</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">90</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Restructuring charges and certain acquisition-related costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other (income)/deductions&#8211;&#8211;net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(611</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(29</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(84</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(725</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Income from continuing operations before provision for taxes on income</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">14,190</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(2,190</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(2,246</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">9,754</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"></td></tr><tr><td style="width:34%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Nine Months Ended October 1, 2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Estimated Other Costs Associated with EH</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(ii)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Essential Health<br/>Non-GAAP Adjusted</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(i), (iii)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Estimated WRD/GPD</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(ii)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Estimated Corporate/Other Unallocated</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(ii)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Essential Health with Estimated Other Costs Associated with<br/>Essential Health<br/>Non-GAAP Adjusted</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(ii), (iii)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">15,639</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">15,639</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Cost of sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">4,319</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">429</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">4,749</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Selling, informational and administrative expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">2,212</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1,338</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">3,550</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Research and development expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">755</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">15</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">53</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">823</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Amortization of intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">43</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">43</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Restructuring charges and certain acquisition-related costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other (income)/deductions&#8211;&#8211;net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(248</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(104</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(353</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Income from continuing operations before provision for taxes on income</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">8,558</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(15</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(1,716</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">6,827</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:6px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(i)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Amount represents the revenues and costs managed by each of our operating segments. The expenses generally include only those costs directly attributable to the operating segment. See note (a) above for more information.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:6px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(ii)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Represents costs not assessed to an operating segment, as business unit (segment) management does not manage these costs. For a description of these other costs and business activities, see note (b) above.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:1px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:18px;"><span style="font-family:inherit;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">WRD/GPD</span><span style="font-family:inherit;font-size:8pt;font-style:italic;">&#8211;&#8211;</span><span style="font-family:inherit;font-size:8pt;">The information provided for WRD and GPD was substantially all derived from our estimates of the costs incurred in connection with the R&amp;D projects associated with each operating segment. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:1px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:18px;"><span style="font-family:inherit;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Corporate/Other Unallocated</span><span style="font-family:inherit;font-size:8pt;font-style:italic;">&#8211;&#8211;</span><span style="font-family:inherit;font-size:8pt;">The information provided for Corporate and Other Unallocated was derived mainly using proportional allocation methods based on global, regional or country revenues or global, regional or country headcount, as well as certain cost metrics, as appropriate, such as those derived from research and development and manufacturing costs, and, to a lesser extent, specific identification and estimates. Management believes that the allocations of Corporate and Other Unallocated costs are reasonable.</span></div></td></tr></table><div style="line-height:120%;padding-top:1px;text-align:left;padding-left:30px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">The estimated Other costs generally associated with our operating segments do not purport to reflect the additional amounts that each of our operating segments would have incurred had each segment operated as a standalone company during the period presented.</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:6px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(iii)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">See note (c) below for an explanation of our Non-GAAP Adjusted financial measure.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:1px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(c)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:8pt;">See the &#8220;Non-GAAP Financial Measure (Adjusted Income)&#8221; section of this MD&amp;A for a definition of these &#8220;Adjusted Income&#8221; components.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(d)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:8pt;">Includes costs associated with (i) purchase accounting adjustments; (ii) acquisition-related costs; and (iii) certain significant items, which are substantive and/or unusual, and in some cases recurring, items (such as restructuring or legal charges), that are evaluated on an individual basis by management. For additional information about these reconciling items and/or our Non-GAAP adjusted measure of performance, see the &#8220;Non-GAAP Financial Measure (Adjusted Income)&#8221; section of this MD&amp;A.</span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">86</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:underline;">Third Quarter</span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:underline;"> of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;text-align:center;text-decoration:underline;">2017</span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:underline;"> vs. </span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:underline;">Third Quarter</span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:underline;"> of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;text-align:center;text-decoration:underline;">2016</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Innovative Health Operating Segment</span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Revenues</span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">IH </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revenues</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">increase</span><span style="font-family:inherit;font-size:10pt;">d </span><span style="font-family:inherit;font-size:10pt;">$786 million</span><span style="font-family:inherit;font-size:10pt;">, or </span><span style="font-family:inherit;font-size:10pt;">11%</span><span style="font-family:inherit;font-size:10pt;">, to </span><span style="font-family:inherit;font-size:10pt;">$8.1 billion</span><span style="font-family:inherit;font-size:10pt;">, reflecting an </span><span style="font-family:inherit;font-size:10pt;">11%</span><span style="font-family:inherit;font-size:10pt;"> operational </span><span style="font-family:inherit;font-size:10pt;">increase</span><span style="font-family:inherit;font-size:10pt;">. Foreign exchange had </span><span style="font-family:inherit;font-size:10pt;">a de minimis</span><span style="font-family:inherit;font-size:10pt;"> impact on IH </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revenues</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following provides an analysis of the </span><span style="font-family:inherit;font-size:10pt;">increase</span><span style="font-family:inherit;font-size:10pt;"> in IH </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revenues</span><span style="font-family:inherit;font-size:10pt;">:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:81%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:16%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">IH </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Revenues</span><span style="font-family:inherit;font-size:9pt;">, for the three months ended October 2, 2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">7,332</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;text-decoration:underline;">Operational growth/(decline):</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Continued growth from key brands including Ibrance and Eliquis globally, as well as Lyrica and Xeljanz, both primarily in the U.S. </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">751</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Growth in Xtandi alliance revenues in the U.S. (September 2016 acquisition of Medivation) </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">148</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Lower revenues for Viagra in the U.S. primarily due to wholesaler destocking in advance of anticipated generic competition beginning in December 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(91</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Lower revenues for Enbrel, primarily in most developed Europe markets due to continued biosimilar competition </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(89</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Decline in Prevnar 13/Prevenar 13 revenues. U.S. revenues decreased primarily due to the continued decline in revenues for the Adult indication due to a smaller remaining &#8220;catch up&#8221; opportunity compared to the prior-year quarter, partially offset by growth from the pediatric indication. International revenues increased primarily due to the favorable overall impact of timing of government purchases in certain emerging markets and the launch of Prevenar 13 in China for the pediatric indication.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(16</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other operational factors, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">95</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Operational growth, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">799</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Unfavorable impact of foreign exchange</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(13</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">IH</span><span style="font-family:inherit;font-size:9pt;font-style:italic;">&#160;Revenues </span><span style="font-family:inherit;font-size:9pt;">increase</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">786</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">IH </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Revenues</span><span style="font-family:inherit;font-size:9pt;">, for the three months ended October 1, 2017</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">8,118</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total IH revenues from emerging markets </span><span style="font-family:inherit;font-size:10pt;">increase</span><span style="font-family:inherit;font-size:10pt;">d </span><span style="font-family:inherit;font-size:10pt;">$167 million</span><span style="font-family:inherit;font-size:10pt;">, or </span><span style="font-family:inherit;font-size:10pt;">18%</span><span style="font-family:inherit;font-size:10pt;">, to </span><span style="font-family:inherit;font-size:10pt;">$1.1 billion</span><span style="font-family:inherit;font-size:10pt;"> on both a reported and operational basis. Foreign exchange had </span><span style="font-family:inherit;font-size:10pt;">a de minimis</span><span style="font-family:inherit;font-size:10pt;"> impact on total IH revenues from emerging markets.</span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Costs and Expenses</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">&#8226;</span><span style="font-family:inherit;font-size:10pt;"></span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Cost of sales </span><span style="font-family:inherit;font-size:10pt;">as a percentage of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revenues </span><span style="font-family:inherit;font-size:10pt;">decrease</span><span style="font-family:inherit;font-size:10pt;">d </span><span style="font-family:inherit;font-size:10pt;">0.8</span><span style="font-family:inherit;font-size:10pt;"> percentage points, </span><span style="font-family:inherit;font-size:10pt;">primarily driven by a favorable change in product mix, including an increase in alliance revenue, which have no associated cost of sales, partially offset by an increase in royalty expense, mostly related to Ibrance, and the unfavorable impact of foreign exchange.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The </span><span style="font-family:inherit;font-size:10pt;">increase</span><span style="font-family:inherit;font-size:10pt;"> in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Cost of sales </span><span style="font-family:inherit;font-size:10pt;">of </span><span style="font-family:inherit;font-size:10pt;">4%</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">was primarily driven by an increase in royalty expense, mostly related to Ibrance, and the unfavorable impact of foreign exchange, partially offset by a favorable change in product mix.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The </span><span style="font-family:inherit;font-size:10pt;">increase</span><span style="font-family:inherit;font-size:10pt;"> in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Selling, informational and administrative</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">expenses</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;">5%</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">was primarily driven by additional investment across several of our key products, primarily Eucrisa, Ibrance and Xtandi.</span><span style="font-family:inherit;font-size:10pt;"> The </span><span style="font-family:inherit;font-size:10pt;">increase</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-size:10pt;">was partially offset by lower spending for certain other products, primarily Prevnar 13/Prevenar 13, and the favorable impact of foreign exchange.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"></span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The </span><span style="font-family:inherit;font-size:10pt;">decrease</span><span style="font-family:inherit;font-size:10pt;"> in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Research and development</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">expenses</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;">5%</span><span style="font-family:inherit;font-size:10pt;"> primarily reflects:</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:18px;"><span style="font-family:inherit;font-size:10pt;">&#9702;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-size:10pt;">the discontinuation of the global clinical development program for bococizumab in the fourth quarter of 2016, </span></div></td></tr></table><div style="line-height:120%;padding-bottom:4px;text-align:left;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">partially offset by increased costs associated with:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:18px;"><span style="font-family:inherit;font-size:10pt;">&#9702;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-size:10pt;">our oncology programs, primarily clinical trial spend on legacy Medivation assets and our immuno-oncology development programs;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:18px;"><span style="font-family:inherit;font-size:10pt;">&#9702;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-size:10pt;">our </span><span style="font-size:10pt;font-style:italic;">C. difficile</span><span style="font-size:10pt;"> vaccine program, which initiated a Phase 3 clinical study in March 2017; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:18px;"><span style="font-family:inherit;font-size:10pt;">&#9702;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-size:10pt;">our tanezumab development program.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><span style="font-family:inherit;font-size:11pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:10pt;">The </span><span style="font-family:inherit;font-size:10pt;">favorable</span><span style="font-family:inherit;font-size:10pt;"> change in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net </span><span style="font-family:inherit;font-size:10pt;">primarily reflects: </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:18px;"><span style="font-family:inherit;font-size:10pt;">&#9702;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the addition of </span><span style="font-family:inherit;font-size:10pt;">$73 million</span><span style="font-family:inherit;font-size:10pt;"> in Xtandi royalty income;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:18px;"><span style="font-family:inherit;font-size:10pt;">&#9702;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">a </span><span style="font-family:inherit;font-size:10pt;">$54 million</span><span style="font-family:inherit;font-size:10pt;"> increase in dividend income from our investment in ViiV; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:18px;"><span style="font-family:inherit;font-size:10pt;">&#9702;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">a </span><span style="font-family:inherit;font-size:10pt;">$50 million</span><span style="font-family:inherit;font-size:10pt;"> milestone payment received for an out-licensed product,</span></div></td></tr></table><div style="line-height:120%;padding-bottom:4px;text-align:left;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">partially offset by:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:18px;"><span style="font-family:inherit;font-size:10pt;">&#9702;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">lower royalty income for Enbrel of </span><span style="font-family:inherit;font-size:10pt;">$139 million</span><span style="font-family:inherit;font-size:10pt;">, resulting from the expiration on October 31, 2016 of the 36-month royalty period under the collaboration agreement for Enbrel in the U.S. and Canada (the collaboration period under the agreement expired on October 31, 2013).</span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">87</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;padding-bottom:4px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Essential Health Operating Segment</span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Revenues</span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">EH </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revenues</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">decrease</span><span style="font-family:inherit;font-size:10pt;">d </span><span style="font-family:inherit;font-size:10pt;">$662 million</span><span style="font-family:inherit;font-size:10pt;">, or </span><span style="font-family:inherit;font-size:10pt;">12%</span><span style="font-family:inherit;font-size:10pt;">, to </span><span style="font-family:inherit;font-size:10pt;">$5.0 billion</span><span style="font-family:inherit;font-size:10pt;">, reflecting an </span><span style="font-family:inherit;font-size:10pt;">11%</span><span style="font-family:inherit;font-size:10pt;"> operational </span><span style="font-family:inherit;font-size:10pt;">decrease</span><span style="font-family:inherit;font-size:10pt;">, of which </span><span style="font-family:inherit;font-size:10pt;">5%</span><span style="font-family:inherit;font-size:10pt;"> operationally was due to the sale of HIS. Foreign exchange had </span><span style="font-family:inherit;font-size:10pt;">an unfavorable</span><span style="font-family:inherit;font-size:10pt;"> impact of </span><span style="font-family:inherit;font-size:10pt;">1%</span><span style="font-family:inherit;font-size:10pt;"> on EH </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revenues</span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following provides an analysis of the </span><span style="font-family:inherit;font-size:10pt;">decrease</span><span style="font-family:inherit;font-size:10pt;"> in EH </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revenues</span><span style="font-family:inherit;font-size:10pt;">:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:81%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:16%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">EH </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Revenues</span><span style="font-family:inherit;font-size:9pt;">, for the three months ended October 2, 2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">5,712</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;text-decoration:underline;">Disposition-related operational impact:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Financial results in the third quarter of 2017 do not reflect any contribution from HIS global operations, compared to the inclusion of three months of HIS global operations in the same period in 2016 (February 2017 sale) </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(280</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;text-decoration:underline;">Other operational growth/(decline):</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Decline from Peri-LOE Products, including declines in Pristiq in the U.S., which lost marketing exclusivity in the U.S. in March 2017, as well as Lyrica and Vfend, both primarily in developed Europe</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(220</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Decline from the Sterile Injectable Pharmaceuticals portfolio, primarily due to legacy Hospira product shortages in the U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(182</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Growth from Biosimilars</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">55</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other operational factors, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">6</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Operational decline, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(621</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Unfavorable impact of foreign exchange</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(41</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">EH </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Revenues</span><span style="font-family:inherit;font-size:9pt;">&#160;decrease</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(662</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">EH </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Revenues</span><span style="font-family:inherit;font-size:9pt;">, for the three months ended October 1, 2017</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">5,050</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:4px;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total EH revenues in developed markets </span><span style="font-family:inherit;font-size:10pt;">decrease</span><span style="font-family:inherit;font-size:10pt;">d </span><span style="font-family:inherit;font-size:10pt;">$749 million</span><span style="font-family:inherit;font-size:10pt;">, or </span><span style="font-family:inherit;font-size:10pt;">18%</span><span style="font-family:inherit;font-size:10pt;">, to </span><span style="font-family:inherit;font-size:10pt;">$3.3 billion</span><span style="font-family:inherit;font-size:10pt;">, reflecting an </span><span style="font-family:inherit;font-size:10pt;">18%</span><span style="font-family:inherit;font-size:10pt;"> operational </span><span style="font-family:inherit;font-size:10pt;">decline</span><span style="font-family:inherit;font-size:10pt;">, of which </span><span style="font-family:inherit;font-size:10pt;">6%</span><span style="font-family:inherit;font-size:10pt;"> operationally was due to the unfavorable impact of the sale of HIS. Total EH revenues in developed markets were also negatively impacted by a </span><span style="font-family:inherit;font-size:10pt;">33%</span><span style="font-family:inherit;font-size:10pt;"> operational decline from Peri-LOE Products and a </span><span style="font-family:inherit;font-size:10pt;">20%</span><span style="font-family:inherit;font-size:10pt;"> operational decline from the Sterile Injectable Pharmaceuticals portfolio primarily due to legacy Hospira product supply shortages in the U.S., partially offset by </span><span style="font-family:inherit;font-size:10pt;">65%</span><span style="font-family:inherit;font-size:10pt;"> operational growth from Biosimilars. Foreign exchange had </span><span style="font-family:inherit;font-size:10pt;">a de minimis</span><span style="font-family:inherit;font-size:10pt;"> impact on total EH revenues in developed markets.</span></div><div style="line-height:120%;padding-bottom:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total EH revenues from emerging markets </span><span style="font-family:inherit;font-size:10pt;">increase</span><span style="font-family:inherit;font-size:10pt;">d </span><span style="font-family:inherit;font-size:10pt;">$87 million</span><span style="font-family:inherit;font-size:10pt;">, or </span><span style="font-family:inherit;font-size:10pt;">5%</span><span style="font-family:inherit;font-size:10pt;">, to </span><span style="font-family:inherit;font-size:10pt;">$1.7 billion</span><span style="font-family:inherit;font-size:10pt;">, reflecting </span><span style="font-family:inherit;font-size:10pt;">7%</span><span style="font-family:inherit;font-size:10pt;"> operational growth, primarily driven by </span><span style="font-family:inherit;font-size:10pt;">6%</span><span style="font-family:inherit;font-size:10pt;"> operational growth from the Legacy Established Products portfolio and </span><span style="font-family:inherit;font-size:10pt;">14%</span><span style="font-family:inherit;font-size:10pt;"> operational growth from the Sterile Injectable Pharmaceuticals portfolio. Foreign exchange had </span><span style="font-family:inherit;font-size:10pt;">an unfavorable</span><span style="font-family:inherit;font-size:10pt;"> impact of </span><span style="font-family:inherit;font-size:10pt;">1%</span><span style="font-family:inherit;font-size:10pt;">. Excluding HIS from both periods, EH revenues in emerging markets grew </span><span style="font-family:inherit;font-size:10pt;">8%</span><span style="font-family:inherit;font-size:10pt;"> operationally.</span></div><div style="line-height:120%;padding-bottom:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Costs and Expenses</span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The changes in EH expenses below reflect, among other things, the favorable impact of the February 2017 sale of HIS. The operating results of HIS are included in EH&#8217;s operating results through February 2, 2017 and, therefore, operating results for EH for the </span><span style="font-family:inherit;font-size:10pt;">third quarter</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> do not reflect HIS global operations, while operating results for EH for the </span><span style="font-family:inherit;font-size:10pt;">third quarter</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;"> reflect three months of HIS global operations.</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Cost of sales </span><span style="font-family:inherit;font-size:10pt;">as a percentage of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revenues</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">increase</span><span style="font-family:inherit;font-size:10pt;">d </span><span style="font-family:inherit;font-size:10pt;">1.6</span><span style="font-family:inherit;font-size:10pt;"> percentage points </span><span style="font-size:10pt;">primarily due to cost increases reflecting the shift to EH of certain legacy Hospira costs that were previously unallocated to EH as a result of harmonizing the Hospira cost policy, and the impact of product losses of exclusivity, partially offset by the favorable impact of the sale of HIS, which had a higher cost of sales than the other EH products.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The </span><span style="font-family:inherit;font-size:10pt;">decrease</span><span style="font-family:inherit;font-size:10pt;"> in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Cost of sales</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;">6%</span><span style="font-family:inherit;font-size:10pt;"> was primarily due to:</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:18px;"><span style="font-family:inherit;font-size:10pt;">&#9702;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the favorable impact of the sale of HIS, which had a higher cost of sales than the other EH products;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:18px;"><span style="font-family:inherit;font-size:10pt;">&#9702;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">a net decrease in royalty expense and, to a lesser extent,</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:18px;"><span style="font-family:inherit;font-size:10pt;">&#9702;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">lower volumes driven by, among other things, the Sterile Injectable Pharmaceuticals (SIP) portfolio, primarily due to legacy Hospira product shortages in the U.S.,</span></div></td></tr></table><div style="line-height:120%;padding-bottom:4px;text-align:left;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">partially offset by:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:18px;"><span style="font-family:inherit;font-size:10pt;">&#9702;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">cost increases reflecting the shift to EH of certain legacy Hospira costs that were previously unallocated to EH as a result of harmonizing the Hospira cost policy.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Selling, informational and administrative</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">expenses</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">decrease</span><span style="font-family:inherit;font-size:10pt;">d </span><span style="font-family:inherit;font-size:10pt;">11%</span><span style="font-family:inherit;font-size:10pt;">, mainly due to lower advertising, promotional and field force expenses, reflecting the benefits of cost-reduction and productivity initiatives, and lower expenses associated wi</span><span style="font-family:inherit;font-size:10pt;color:#2c2c2c;">th products that recently lost marketing exclusivity, a</span><span style="font-family:inherit;font-size:10pt;">s well as the favorable impact of the sale of HIS, partially offset by increased spending for biosimilars, primarily related to the U.S. launch of Inflectra. </span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">88</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Research and development</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">expenses</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">decrease</span><span style="font-family:inherit;font-size:10pt;">d </span><span style="font-family:inherit;font-size:10pt;">15%</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="color:#2c2c2c;font-size:10pt;">primarily due to the close-out of certain post-marketing clinical trials and the favorable impact of the sale of HIS.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;color:#2c2c2c;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;color:#2c2c2c;">The </span><span style="font-family:inherit;font-size:10pt;color:#2c2c2c;">favorable</span><span style="font-family:inherit;font-size:10pt;color:#2c2c2c;"> change in </span><span style="font-family:inherit;font-size:10pt;color:#2c2c2c;font-style:italic;">Other (income)/deductions&#8211;&#8211;net</span><span style="font-family:inherit;font-size:10pt;color:#2c2c2c;"> </span><span style="font-size:10pt;">primarily reflects income from resolution of a contract disagreement and the favorable impact of foreign exchange.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:underline;">First </span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:underline;">Nine Months</span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:underline;"> of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;text-align:center;text-decoration:underline;">2017</span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:underline;"> vs. First </span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:underline;">Nine Months</span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:underline;"> of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;text-align:center;text-decoration:underline;">2016</span></div><div style="line-height:120%;padding-bottom:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Innovative Health Operating Segment</span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Revenues</span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">IH </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revenues</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">increase</span><span style="font-family:inherit;font-size:10pt;">d </span><span style="font-family:inherit;font-size:10pt;">$1,733 million</span><span style="font-family:inherit;font-size:10pt;">, or </span><span style="font-family:inherit;font-size:10pt;">8%</span><span style="font-family:inherit;font-size:10pt;">, to </span><span style="font-family:inherit;font-size:10pt;">$23.2 billion</span><span style="font-family:inherit;font-size:10pt;">, reflecting a </span><span style="font-family:inherit;font-size:10pt;">9%</span><span style="font-family:inherit;font-size:10pt;"> operational </span><span style="font-family:inherit;font-size:10pt;">increase</span><span style="font-family:inherit;font-size:10pt;">. Foreign exchange had </span><span style="font-family:inherit;font-size:10pt;">an unfavorable</span><span style="font-family:inherit;font-size:10pt;"> impact of </span><span style="font-family:inherit;font-size:10pt;">1%</span><span style="font-family:inherit;font-size:10pt;"> on IH </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revenues</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following provides an analysis of the </span><span style="font-family:inherit;font-size:10pt;">increase</span><span style="font-family:inherit;font-size:10pt;"> in IH </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revenues</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:81%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:16%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">IH </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Revenues</span><span style="font-family:inherit;font-size:9pt;">, for the nine months ended October 2, 2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">21,471</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;text-decoration:underline;">Operational growth/(decline):</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Continued growth from key brands including Ibrance and Eliquis globally, as well as Lyrica and Xeljanz, both primarily in the U.S. </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">2,102</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Growth in Xtandi alliance revenues in the U.S. (September 2016 acquisition of Medivation) </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">420</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Lower revenues for Enbrel, primarily in most developed Europe markets due to continued biosimilar competition </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(353</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Decline in Prevnar 13/Prevenar 13 revenues. U.S. revenues decreased primarily due to the continued decline in revenues for the Adult indication due to a smaller remaining &#8220;catch up&#8221; opportunity compared to the first nine months of 2016, partially offset by growth from the pediatric indication. International revenues increased primarily due to the favorable overall impact of timing of government purchases in certain emerging markets and the launch of Prevenar 13 in China for the pediatric indication.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(213</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Lower revenues for Viagra in the U.S. primarily due to lower market growth</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(186</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other operational factors, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">113</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Operational growth, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1,883</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Unfavorable impact of foreign exchange</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(150</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">IH</span><span style="font-family:inherit;font-size:9pt;font-style:italic;">&#160;Revenues </span><span style="font-family:inherit;font-size:9pt;">increase</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1,733</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">IH </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Revenues</span><span style="font-family:inherit;font-size:9pt;">, for the nine months ended October 1, 2017</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">23,204</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total IH revenues from emerging markets </span><span style="font-family:inherit;font-size:10pt;">increase</span><span style="font-family:inherit;font-size:10pt;">d </span><span style="font-family:inherit;font-size:10pt;">$377 million</span><span style="font-family:inherit;font-size:10pt;">, or </span><span style="font-family:inherit;font-size:10pt;">14%</span><span style="font-family:inherit;font-size:10pt;">, to </span><span style="font-family:inherit;font-size:10pt;">$3.1 billion</span><span style="font-family:inherit;font-size:10pt;">, reflecting a </span><span style="font-family:inherit;font-size:10pt;">15%</span><span style="font-family:inherit;font-size:10pt;"> operational </span><span style="font-family:inherit;font-size:10pt;">increase</span><span style="font-family:inherit;font-size:10pt;">. Foreign exchange had </span><span style="font-family:inherit;font-size:10pt;">an unfavorable</span><span style="font-family:inherit;font-size:10pt;"> impact of </span><span style="font-family:inherit;font-size:10pt;">1%</span><span style="font-family:inherit;font-size:10pt;"> on Total IH revenues from emerging markets.</span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Costs and Expenses</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Cost of sales </span><span style="font-family:inherit;font-size:10pt;">as a percentage of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revenues </span><span style="font-family:inherit;font-size:10pt;">decrease</span><span style="font-family:inherit;font-size:10pt;">d </span><span style="font-family:inherit;font-size:10pt;">1.1</span><span style="font-family:inherit;font-size:10pt;"> percentage points </span><span style="font-family:inherit;font-size:10pt;">primarily driven by a favorable change in product mix, including an increase in alliance revenue, which have no associated cost of sales, partially offset by an increase in royalty expense, mostly related to Ibrance.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The </span><span style="font-family:inherit;font-size:10pt;">decrease</span><span style="font-family:inherit;font-size:10pt;"> in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Cost of sales </span><span style="font-family:inherit;font-size:10pt;">of </span><span style="font-family:inherit;font-size:10pt;">1%</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">was primarily driven by favorable product mix and the favorable impact of foreign exchange, partially offset by an increase in royalty expense, mostly related to Ibrance.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The </span><span style="font-family:inherit;font-size:10pt;">decrease</span><span style="font-family:inherit;font-size:10pt;"> in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Selling, informational and administrative</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">expenses</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;">1%</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-size:10pt;">was primarily driven by the non-recurrence of an allowance for doubtful trade accounts receivable, resulting from unfavorable developments with a distributor that was recorded in the first quarter of 2016, lower spending for certain products, primarily Prevnar 13/Prevenar 13, and the favorable impact of foreign exchange, partially offset by additional investment across several of our key products, primarily Eucrisa, Ibrance, Xtandi and Xeljanz.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The </span><span style="font-family:inherit;font-size:10pt;">decrease</span><span style="font-family:inherit;font-size:10pt;"> in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Research and development</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">expenses</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;">6%</span><span style="font-family:inherit;font-size:10pt;"> primarily reflects:</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:18px;"><span style="font-family:inherit;font-size:10pt;">&#9702;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-size:10pt;">the discontinuation of the global clinical development program for bococizumab in the fourth quarter of 2016, </span></div></td></tr></table><div style="line-height:120%;padding-bottom:4px;text-align:left;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">partially offset by:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:18px;"><span style="font-family:inherit;font-size:10pt;">&#9702;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">increased costs associated with:</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#9642;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-size:10pt;">our oncology programs, including clinical trial spend on legacy Medivation assets;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#9642;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our C. difficile vaccine program, which initiated a Phase 3 clinical study in March 2017; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#9642;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-size:10pt;">our tanezumab development program; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:18px;"><span style="font-family:inherit;font-size:10pt;">&#9702;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">an expense of </span><span style="font-family:inherit;font-size:10pt;">$28 million</span><span style="font-family:inherit;font-size:10pt;">, representing IH&#8217;s portion of the </span><span style="font-family:inherit;font-size:10pt;">$75 million</span><span style="font-family:inherit;font-size:10pt;"> expense resulting from our May 2017 agreement with Sangamo to develop and commercialize gene therapy programs for Hemophilia A.</span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">89</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><span style="font-family:inherit;font-size:11pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:10pt;">The </span><span style="font-family:inherit;font-size:10pt;">unfavorable</span><span style="font-family:inherit;font-size:10pt;"> change in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net </span><span style="font-family:inherit;font-size:10pt;">primarily reflects:</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:18px;"><span style="font-family:inherit;font-size:10pt;">&#9702;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">lower royalty income for Enbrel of </span><span style="font-family:inherit;font-size:10pt;">$414 million</span><span style="font-family:inherit;font-size:10pt;">, resulting from the expiration on October 31, 2016 of the 36-month royalty period under the collaboration agreement for Enbrel in the U.S. and Canada (the collaboration period under the agreement expired on October 31, 2013),</span></div></td></tr></table><div style="line-height:120%;padding-bottom:4px;text-align:left;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">partially offset by:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:18px;"><span style="font-family:inherit;font-size:10pt;">&#9702;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">an increase of </span><span style="font-family:inherit;font-size:10pt;">$204 million</span><span style="font-family:inherit;font-size:10pt;"> in dividend income from our investment in ViiV;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:18px;"><span style="font-family:inherit;font-size:10pt;">&#9702;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the addition of </span><span style="font-family:inherit;font-size:10pt;">$160 million</span><span style="font-family:inherit;font-size:10pt;"> of Xtandi royalty income; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:18px;"><span style="font-family:inherit;font-size:10pt;">&#9702;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">a </span><span style="font-family:inherit;font-size:10pt;">$50 million</span><span style="font-family:inherit;font-size:10pt;"> milestone payment received for an out-licensed product.</span></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Essential Health Operating Segment</span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Revenues</span></div><div style="line-height:120%;padding-bottom:4px;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">EH </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revenues</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">decrease</span><span style="font-family:inherit;font-size:10pt;">d </span><span style="font-family:inherit;font-size:10pt;">$2.1 billion</span><span style="font-family:inherit;font-size:10pt;">, or </span><span style="font-family:inherit;font-size:10pt;">12%</span><span style="font-family:inherit;font-size:10pt;">, to </span><span style="font-family:inherit;font-size:10pt;">$15.6 billion</span><span style="font-family:inherit;font-size:10pt;">, reflecting a </span><span style="font-family:inherit;font-size:10pt;">11%</span><span style="font-family:inherit;font-size:10pt;"> operational </span><span style="font-family:inherit;font-size:10pt;">decrease</span><span style="font-family:inherit;font-size:10pt;">, of which </span><span style="font-family:inherit;font-size:10pt;">4%</span><span style="font-family:inherit;font-size:10pt;"> operationally was due to the sale of HIS. Foreign exchange had </span><span style="font-family:inherit;font-size:10pt;">an unfavorable</span><span style="font-family:inherit;font-size:10pt;"> impact of </span><span style="font-family:inherit;font-size:10pt;">1%</span><span style="font-family:inherit;font-size:10pt;"> on EH </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revenues</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following provides an analysis of the </span><span style="font-family:inherit;font-size:10pt;">decrease</span><span style="font-family:inherit;font-size:10pt;"> in EH </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revenues</span><span style="font-family:inherit;font-size:10pt;">:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:81%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:16%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">EH </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Revenues</span><span style="font-family:inherit;font-size:9pt;">, for the nine months ended October 2, 2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">17,725</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;text-decoration:underline;">Disposition-related operational impact:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Approximately one month of HIS domestic operations and approximately two months of HIS international operations in the first nine months of 2017, compared to nine months of HIS global operations in the same period in 2016 (February 2017 sale) </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(783</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;text-decoration:underline;">Other operational growth/(decline):</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Decline from Peri-LOE Products, including declines in Pristiq in the U.S., which lost marketing exclusivity in the U.S. in March 2017, as well as Lyrica and Vfend, both primarily in developed Europe</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(779</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Decline in the Legacy Established Products portfolio</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(250</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Decline from the Sterile Injectable Pharmaceuticals portfolio, primarily due to legacy Hospira product shortages in the U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(169</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Growth from Biosimilars</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">143</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other operational factors, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(26</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Operational decline, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(1,864</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Unfavorable impact of foreign exchange</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(222</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">EH </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Revenues </span><span style="font-family:inherit;font-size:9pt;">decrease</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(2,086</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">EH </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Revenues</span><span style="font-family:inherit;font-size:9pt;">, for the nine months ended October 1, 2017</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">15,639</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total EH revenues in developed markets </span><span style="font-family:inherit;font-size:10pt;">decrease</span><span style="font-family:inherit;font-size:10pt;">d </span><span style="font-family:inherit;font-size:10pt;">$2.2 billion</span><span style="font-family:inherit;font-size:10pt;">, or </span><span style="font-family:inherit;font-size:10pt;">17%</span><span style="font-family:inherit;font-size:10pt;">, to </span><span style="font-family:inherit;font-size:10pt;">$10.5 billion</span><span style="font-family:inherit;font-size:10pt;">, reflecting a </span><span style="font-family:inherit;font-size:10pt;">17%</span><span style="font-family:inherit;font-size:10pt;"> operational </span><span style="font-family:inherit;font-size:10pt;">decline</span><span style="font-family:inherit;font-size:10pt;">, of which </span><span style="font-family:inherit;font-size:10pt;">5%</span><span style="font-family:inherit;font-size:10pt;"> operationally was due to the unfavorable impact of the sale of HIS. Total EH revenues in developed markets were also negatively impacted by a </span><span style="font-family:inherit;font-size:10pt;">36%</span><span style="font-family:inherit;font-size:10pt;"> operational decline from Peri-LOE Products, a </span><span style="font-family:inherit;font-size:10pt;">7%</span><span style="font-family:inherit;font-size:10pt;"> operational decline in the Legacy Established Products portfolio and a </span><span style="font-family:inherit;font-size:10pt;">9%</span><span style="font-family:inherit;font-size:10pt;"> operational decline from the Sterile Injectable Pharmaceuticals portfolio, partially offset by </span><span style="font-family:inherit;font-size:10pt;">64%</span><span style="font-family:inherit;font-size:10pt;"> operational growth from Biosimilars. Foreign exchange had </span><span style="font-family:inherit;font-size:10pt;">an unfavorable</span><span style="font-family:inherit;font-size:10pt;"> impact of </span><span style="font-family:inherit;font-size:10pt;">1%</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total EH revenues from emerging markets </span><span style="font-family:inherit;font-size:10pt;">increase</span><span style="font-family:inherit;font-size:10pt;">d </span><span style="font-family:inherit;font-size:10pt;">$131 million</span><span style="font-family:inherit;font-size:10pt;">, or </span><span style="font-family:inherit;font-size:10pt;">3%</span><span style="font-family:inherit;font-size:10pt;">, to </span><span style="font-family:inherit;font-size:10pt;">$5.1 billion</span><span style="font-family:inherit;font-size:10pt;">, reflecting </span><span style="font-family:inherit;font-size:10pt;">6%</span><span style="font-family:inherit;font-size:10pt;"> operational growth, primarily driven by </span><span style="font-family:inherit;font-size:10pt;">5%</span><span style="font-family:inherit;font-size:10pt;"> operational growth from the Legacy Established Products portfolio and </span><span style="font-family:inherit;font-size:10pt;">15%</span><span style="font-family:inherit;font-size:10pt;"> operational growth from the Sterile Injectable Pharmaceuticals portfolio. Foreign exchange had </span><span style="font-family:inherit;font-size:10pt;">an unfavorable</span><span style="font-family:inherit;font-size:10pt;"> impact of </span><span style="font-family:inherit;font-size:10pt;">3%</span><span style="font-family:inherit;font-size:10pt;">. Excluding HIS in both periods, EH revenues in emerging markets </span><span style="font-family:inherit;font-size:10pt;">grew</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">7%</span><span style="font-family:inherit;font-size:10pt;"> operationally.</span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Costs and Expenses</span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The changes in EH expenses below reflect, among other things, the favorable impact of the February 2017 sale of HIS. The operating results of HIS are included in EH&#8217;s operating results through February 2, 2017 and, therefore, operating results for EH for the </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;"> include approximately one month of HIS domestic operations and approximately two months of HIS international operations, while operating results for EH for the </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;"> reflect nine months of HIS global operations.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">90</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Cost of sales </span><span style="font-family:inherit;font-size:10pt;">as a percentage of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revenues</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">increase</span><span style="font-family:inherit;font-size:10pt;">d </span><span style="font-family:inherit;font-size:10pt;">1.2</span><span style="font-family:inherit;font-size:10pt;"> percentage points, </span><span style="font-size:10pt;">primarily due to cost increases reflecting the shift to EH of certain legacy Hospira costs that were previously unallocated to EH as a result of harmonizing the Hospira cost policy, and the impact of product losses of exclusivity, partially offset by the favorable impact of the sale of HIS, which had a higher cost of sales than the other EH products, and the favorable impact of foreign exchange.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The </span><span style="font-family:inherit;font-size:10pt;">decrease</span><span style="font-family:inherit;font-size:10pt;"> in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Cost of sales</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;">8%</span><span style="font-family:inherit;font-size:10pt;"> primarily reflects;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:18px;"><span style="font-family:inherit;font-size:10pt;">&#9702;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the favorable impact of the sale of HIS, which had a higher cost of sales than the other EH products;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:18px;"><span style="font-family:inherit;font-size:10pt;">&#9702;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the favorable impact of foreign exchange;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:18px;"><span style="font-family:inherit;font-size:10pt;">&#9702;</span></div></td><td style="vertical-align:top;padding-left:6px;"><div style="line-height:120%;text-align:left;font-size:10pt;text-indent:-6px;"><span style="font-family:inherit;font-size:10pt;">a net decrease in royalty expense and, to a lesser extent,</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:18px;"><span style="font-family:inherit;font-size:10pt;">&#9702;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">lower volumes driven by, among other things, the SIP portfolio, primarily due to legacy Hospira product shortages in the U.S., </span></div></td></tr></table><div style="line-height:120%;padding-bottom:4px;text-align:left;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">partially offset by:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:18px;"><span style="font-family:inherit;font-size:10pt;">&#9702;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">cost increases reflecting the shift to EH of certain legacy Hospira costs that were previously unallocated to EH as a result of harmonizing the Hospira cost policy. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Selling, informational and administrative</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">expenses</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">decrease</span><span style="font-family:inherit;font-size:10pt;">d </span><span style="font-family:inherit;font-size:10pt;">9%</span><span style="font-family:inherit;font-size:10pt;"> primarily due to lower advertising, promotional, and field force expenses </span><span style="font-family:inherit;font-size:10pt;color:#2c2c2c;">associated with products that recently lost marketing exclusivity </span><span style="font-family:inherit;font-size:10pt;">and certain other expenses related to disputes in the ordinary course of business, as well as the favorable impact of the sale of HIS and the favorable impact of foreign exchange, partially offset by increased spending for biosimilars, primarily related to the U.S. launch of Inflectra. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Research and development</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">expenses</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">decrease</span><span style="font-family:inherit;font-size:10pt;">d </span><span style="font-family:inherit;font-size:10pt;">14%</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">primarily due to the close-out of certain post-marketing clinical trials and the favorable impact of the sale of HIS.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The </span><span style="font-family:inherit;font-size:10pt;">unfavorable</span><span style="font-family:inherit;font-size:10pt;"> change in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net </span><span style="font-family:inherit;font-size:10pt;">primarily reflects the non-recurrence of a resolution of a contract disagreement in the first quarter of 2016, partially offset by a gain on the redemption of an acquired bond.</span></div></td></tr></table><div><a id="s2FF4E53953D350ADB2D08E40585E2272"></a></div><div style="line-height:120%;padding-top:10px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">ANALYSIS OF THE CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Changes in the components of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Accumulated other comprehensive loss</span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">third quarter</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:9.5pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;"> reflect the following: </span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Foreign currency translation adjustments, net,</span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">third quarter</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;">, primarily reflects the weakening of the U.S. dollar against the euro, Canadian dollar and Australian dollar; for the </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;">, primarily reflects the weakening of the U.S. dollar against the euro, Canadian dollar, Swedish krona and the Australian dollar. For the </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;">, also includes the reclassification of amounts related to the agreement to sell our 40% ownership investment in Teuto. For additional information, see Notes to Condensed Consolidated Financial Statements&#8212;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 2D. </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Acquisitions, Sale of Hospira Infusion Systems Net Assets, Collaborative Arrangement and Equity-Method Investments</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">: Equity-Method Investments.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> Unrealized holding losses on derivative financial instruments, net </span><span style="font-family:inherit;font-size:10pt;">and </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Unrealized holding gains on available-for-sale securities, net, </span><span style="font-family:inherit;font-size:10pt;">reflect the impact of fair value remeasurements and the reclassification of realized amounts into income. For additional information, see Notes to Condensed Consolidated Financial Statements&#8212;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 7. </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments</span><span style="font-family:inherit;font-size:10pt;">.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Benefit plans: actuarial losses, net,</span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">third quarter</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;">, primarily reflects (i) the amortization of changes in the pension benefit obligation previously recognized in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other comprehensive income</span><span style="font-family:inherit;font-size:10pt;">; (ii) the unfavorable impact of foreign exchange; and (iii) an increase in actuarial losses due to an interim remeasurement. The first nine months of 2017 also reflects the remeasurement gain due to the settlement of the Hospira U.S. qualified defined benefit plan. For additional information, see Notes to Condensed Consolidated Financial Statements&#8212;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 10. </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Pension and Postretirement Benefit Plans</span><span style="font-family:inherit;font-size:10pt;">.</span></div></td></tr></table><div><a id="s5154C7B97FDA5D58928BFB0822485FAE"></a></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">ANALYSIS OF THE CONDENSED CONSOLIDATED BALANCE SHEETS</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For information about certain of our financial assets and liabilities, including </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Cash and cash equivalents, Short-term investments, Long-term investments, Short-term borrowings, including current portion of long-term debt</span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Long-term debt</span><span style="font-family:inherit;font-size:10pt;">, see the &#8220;Analysis of the Condensed Consolidated Statements of Cash Flows&#8221; section of this MD&amp;A, the &#8220;Analysis of Financial Condition, Liquidity and Capital Resources: Selected Measures of Liquidity and Capital Resources&#8221; section of this MD&amp;A and Notes to Condensed Consolidated Financial Statements&#8212;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 7. </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For information about certain balances in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Trade accounts receivable, less allowance for doubtful accounts, </span><span style="font-family:inherit;font-size:10pt;">see also the &#8220;Analysis of Financial Condition, Liquidity and Capital Resources: Selected Measures of Liquidity and Capital Resources: Accounts Receivable&#8221; section of this MD&amp;A.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For information about events and circumstances impacting our tax-related accounts, see Notes to Condensed Consolidated Financial Statements&#8212;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 5. </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Tax Matters</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">91</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For information related to changes in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Accumulated other comprehensive loss</span><span style="font-family:inherit;font-size:10pt;">, see the &#8220;Analysis of the Condensed Consolidated Statements of Comprehensive Income&#8221; section of this MD&amp;A and Notes to Condensed Consolidated Financial Statements&#8212;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 6. </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests</span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The changes in our asset and liability accounts as of </span><span style="font-family:inherit;font-size:10pt;">October&#160;1, 2017</span><span style="font-family:inherit;font-size:10pt;">, compared to </span><span style="font-family:inherit;font-size:10pt;text-align:center;">December&#160;31, 2016</span><span style="font-family:inherit;font-size:10pt;">, generally reflect, among other things, the impact of assets acquired and liabilities assumed as part of the acquisition of AstraZeneca&#8217;s small molecule anti-infectives business, measurement period adjustments related to the acquisition of Medivation, and fluctuations in foreign currency exchange rates</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">.</span><span style="font-family:inherit;font-size:10pt;"> The following explanations exclude the impact of the acquisition of AstraZeneca&#8217;s small molecule anti-infectives business, measurement period adjustments related to the acquisition of Medivation, as well as the sale of HIS to ICU Medical and foreign exchange (see Notes to Condensed Consolidated Financial Statements&#8211;&#8211;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 2. </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Acquisitions, Sale of Hospira Infusion Systems Net Assets, Collaborative Arrangement and Equity-Method Investments</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span><span style="font-family:inherit;font-size:10pt;">and </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 9. </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Identifiable Intangible Assets and Goodwill</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span><span style="font-family:inherit;font-size:10pt;">for additional information).</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Trade accounts receivable, less allowance for doubtful accounts, </span><span style="font-family:inherit;font-size:10pt;">the change reflects the timing of sales and collections in the normal course of business.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Inventories, </span><span style="font-family:inherit;font-size:10pt;">the change reflects the build of inventory primarily for and in advance of new or potential product launches and increases to meet targeted levels for certain products in the normal course of business, including those related to demand.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other current assets, </span><span style="font-family:inherit;font-size:10pt;">the change reflects a decrease in receivables associated with our derivative financial instruments, as well as the timing of receipt and payments in the normal course of business, partially offset by an increase in VAT receivable balances due to a change in our supply chain.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For PP&amp;E,</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span><span style="font-family:inherit;font-size:10pt;">the change primarily reflects depreciation during the period and reductions due to restructuring efforts, partially offset by capital additions in the normal course of business.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Identifiable intangible assets, less accumulated amortization</span><span style="font-family:inherit;font-size:10pt;">, the change primarily reflects amortization for the period, partially offset by intangible assets recorded in connection with the EU and U.S. approvals of Besponsa.</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span><span style="font-family:inherit;font-size:10pt;">For additional information, see Notes to Condensed Consolidated Financial Statements&#8212;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 7E. Financial Instruments: Other Noncurrent Liabilities</span><span style="font-family:inherit;font-size:10pt;">.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other noncurrent assets, </span><span style="font-family:inherit;font-size:10pt;">the change reflects a decrease in receivables associated with our derivative financial instruments, partially offset by net increases in the normal course of business.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Trade accounts payable,</span><span style="font-family:inherit;font-size:10pt;"> the change reflects the timing of purchases and payments in the normal course of business, including the impact of efforts to improve working capital efficiencies.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Accrued compensation and related items, </span><span style="font-family:inherit;font-size:10pt;">the decrease reflects normal bonus payments made to employees and a reduction related to the termination of a Hospira U.S. qualified defined benefit pension plan, partially offset by current year&#8217;s accruals. For additional information, see Notes to Condensed Consolidated Financial Statements&#8212;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 10. </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Pension and Postretirement Benefit Plans</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other current liabilities</span><span style="font-family:inherit;font-size:10pt;">, the change reflects a decrease in liabilities associated with:</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:18px;"><span style="font-family:inherit;font-size:10pt;">&#9702;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">payment for consideration transferred for Medivation;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:18px;"><span style="font-family:inherit;font-size:10pt;">&#9702;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">payments for restructuring activities and payments for liabilities related to the closeout of bococizumab clinical studies; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:18px;"><span style="font-family:inherit;font-size:10pt;">&#9702;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our derivative financial instruments, </span></div></td></tr></table><div style="line-height:120%;padding-top:4px;text-align:left;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">partially offset by:</span></div><div style="line-height:120%;padding-left:18px;padding-top:4px;text-align:left;"><span style="padding-top:4px;text-align:left;font-family:inherit;font-size:10pt;padding-right:18px;">&#9702;</span><span style="font-family:inherit;font-size:10pt;">an increase related to accrued healthcare fees;</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:18px;"><span style="font-family:inherit;font-size:10pt;">&#9702;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">an accrual for net funds due to ICU Medical for net economic benefit payments (see Notes to Condensed Consolidated Financial Statements&#8211;&#8211;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 2B. </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Acquisitions, Sale of Hospira Infusion Systems Net Assets, Collaborative Arrangement and Equity-Method Investments</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">: </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Sale of Hospira Infusion Systems Net Assets to ICU Medical, Inc. (EH)</span><span style="font-family:inherit;font-size:10pt;">); and </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:18px;"><span style="font-family:inherit;font-size:10pt;">&#9702;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the impact of timing of payments in the normal course of business.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Pension benefit obligations, net</span><span style="font-family:inherit;font-size:10pt;">, the decrease primarily reflects the $1.0 billion voluntary pension contribution in January 2017 and payments to plan participants</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other noncurrent liabilities</span><span style="font-family:inherit;font-size:10pt;">, the change reflects a decrease in liabilities associated with:</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:18px;"><span style="font-family:inherit;font-size:10pt;">&#9702;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">an increase in reclassification of short-term liabilities;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:18px;"><span style="font-family:inherit;font-size:10pt;">&#9702;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our derivative financial instruments; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:18px;"><span style="font-family:inherit;font-size:10pt;">&#9702;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the reversal of a contingent liability as a result of exiting our investment in Teuto (see Notes to Condensed Consolidated Financial Statements&#8211;&#8211;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 2D. </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Acquisitions, Sale of Hospira Infusion Systems Net Assets, Collaborative Arrangement and Equity-Method Investments</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">: Equity Method Investments</span><span style="font-family:inherit;font-size:10pt;">), </span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">92</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;padding-top:4px;text-align:left;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">partially offset by:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:18px;"><span style="font-family:inherit;font-size:10pt;">&#9702;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">an increase of </span><span style="font-family:inherit;font-size:10pt;">$351 million</span><span style="font-family:inherit;font-size:10pt;"> to record obligations in connection with the EU and U.S. approvals of Besponsa</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt"> </sup></span><span style="font-family:inherit;font-size:10pt;">(see Notes to Condensed Consolidated Financial Statements&#8212;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 7E. Financial Instruments: Other Noncurrent Liabilities</span><span style="font-family:inherit;font-size:10pt;">); </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:18px;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">&#9702;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">an increase in deferred revenue from a milestone payment received from Merck for the ertugliflozin collaboration agreement (see Notes to Condensed Consolidated Financial Statements&#8211;&#8211;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 2C. </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Acquisitions, Sale of Hospira Infusion Systems Net Assets, Collaborative Arrangement and Equity-Method Investments</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">: Collaboration Arrangement</span><span style="font-family:inherit;font-size:10pt;">); and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:18px;"><span style="font-family:inherit;font-size:10pt;">&#9702;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">accruals in the normal course of business.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Treasury stock,</span><span style="font-family:inherit;font-size:10pt;"> the change reflects $5 billion paid to Citibank in February 2017 pursuant to the terms of an accelerated share repurchase agreement. See Notes to Condensed Consolidated Financial Statements&#8212;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 12. </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Commitments and Contingencies</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span><span style="font-family:inherit;font-size:10pt;">for additional information.</span></div></td></tr></table><div><a id="s0917392EAE535D7886A17489CA4C92F0"></a></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">ANALYSIS OF THE CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span><span style="font-family:inherit;font-size:11pt;font-weight:bold;"> </span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.02534113060429%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:61%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nine Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">October&#160;1, <br/>2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">October&#160;2, <br/>2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%<br/>Change</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash provided by/(used in):</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating activities</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">9,728</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10,151</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(4</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Investing activities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">38</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(4,704</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">*</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Financing activities</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(9,650</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(6,915</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">40</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Effect of exchange-rate changes on cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">67</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(79</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">*</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net increase/(decrease) in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">184</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(1,547</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">*</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;">*</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Calculation not meaningful.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:1px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:9pt;">Amounts for the </span><span style="font-family:inherit;font-size:9pt;">nine months</span><span style="font-family:inherit;font-size:9pt;"> ended </span><span style="font-family:inherit;font-size:9pt;">October&#160;2, 2016</span><span style="font-family:inherit;font-size:9pt;"> have been revised from previously reported amounts to reflect the adoption of a new accounting standard in the fourth quarter of 2016, as of January 1, 2016, that requires that cash flows present (i) excess tax benefits as </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Other tax accounts, net </span><span style="font-family:inherit;font-size:9pt;">as part of operating activities, rather than financing activities on a prospective basis beginning in the year of adoption, and (ii) cash paid by us when directly withholding shares for tax-withholding purposes as a cash outflow from financing activities, rather than operating activities and is reflected in the year of adoption. The year-to-date excess tax benefit was </span><span style="font-family:inherit;font-size:9pt;">$87 million</span><span style="font-family:inherit;font-size:9pt;"> in the </span><span style="font-family:inherit;font-size:9pt;">first nine months of</span><span style="font-family:inherit;font-size:9pt;"> 2016. For cash paid by us for withholding purposes, </span><span style="font-family:inherit;font-size:9pt;">$134 million</span><span style="font-family:inherit;font-size:9pt;"> for the </span><span style="font-family:inherit;font-size:9pt;">first nine months of</span><span style="font-family:inherit;font-size:9pt;"> 2016 is presented as financing activities</span><span style="font-family:inherit;font-size:9pt;font-style:italic;"> </span><span style="font-family:inherit;font-size:9pt;">in the condensed consolidated statement of cash flows (see Notes to Consolidated Financial Statements&#8212;</span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Note 1B. Basis of Presentation and Significant Accounting Policies: Adoption of New Accounting Standards</span><span style="font-family:inherit;font-size:9pt;">).</span></div></td></tr></table><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the condensed consolidated statements of cash flows, the line item </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other changes in assets and liabilities, net of acquisitions and divestitures</span><span style="font-family:inherit;font-size:10pt;"> is presented excluding the effects of changes in foreign currency exchange rates, as these changes do not reflect actual cash inflows or outflows, and excluding any other significant non-cash movements. Accordingly, the amounts shown will not necessarily agree with the changes in the assets and liabilities that are presented in our condensed consolidated balance sheets.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Operating Activities</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our net cash provided by operating activities was </span><span style="font-family:inherit;font-size:10pt;">$9.7 billion</span><span style="font-family:inherit;font-size:10pt;"> in the </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;">, compared to </span><span style="font-family:inherit;font-size:10pt;">$10.2 billion</span><span style="font-family:inherit;font-size:10pt;"> in the same period in </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;">. The </span><span style="font-family:inherit;font-size:10pt;">decrease</span><span style="font-family:inherit;font-size:10pt;"> in net cash provided by operating activities reflects the timing of receipts from customers and payments to vendors in the ordinary course of business, as well as an increase in benefit plan contributions.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;">, the line item </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other adjustments, net</span><span style="font-family:inherit;font-size:10pt;"> primarily reflects, among other items, the decrease in the provision for bad debt expense, an increase in dividends from an equity-method investment reclassified to investing activities in 2017 and an increase in net gains on sales of </span><span style="font-family:inherit;font-size:9pt;color:#2c2c2c;">PP&amp;E</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;">, the line item </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other changes in assets and liabilities, net of acquisitions and divestitures,</span><span style="font-family:inherit;font-size:10pt;"> primarily reflects changes, in the normal course of business, in trade accounts receivable, inventories, other current assets, other noncurrent assets, trade accounts payable, accrued compensation and other current and noncurrent liabilities. For the </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;">, this line item also includes the adjustments necessary to reflect the payments of certain legal claims accrued in prior periods, including for Protonix-related matters. For additional information about accounts receivable, see also the &#8220;Selected Measures of Liquidity and Capital Resources: Accounts Receivable&#8221; section of this MD&amp;A. </span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For additional information about changes in other assets and liabilities account balances, see also &#8220;Analysis of the Condensed Consolidated Balance Sheets&#8221; in this MD&amp;A. </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">93</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Investing Activities</span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our net cash provided by investing activities was </span><span style="font-family:inherit;font-size:10pt;">$38 million</span><span style="font-family:inherit;font-size:10pt;"> in the </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;">, compared to net cash used in investing activities of </span><span style="font-family:inherit;font-size:10pt;">$4.7 billion</span><span style="font-family:inherit;font-size:10pt;"> in the same period in </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;">. The change in net cash provided by investing activities was primarily attributable to:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">a decrease in cash used for acquisitions</span><span style="font-family:inherit;font-size:9pt;">&#8212;</span><span style="font-family:inherit;font-size:10pt;">cash paid of $1.0 billion, net of cash acquired, primarily for the acquisition of AstraZeneca&#8217;s small molecule anti-infectives business in </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;"> and substantially all of the remaining consideration for the Medivation acquisition, compared to cash paid of </span><span style="font-family:inherit;font-size:10pt;">$17.7 billion</span><span style="font-family:inherit;font-size:10pt;">, net of cash acquired, primarily for the acquisitions of Medivation, Bamboo and Anacor in </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;"> (see Notes to Condensed Consolidated Financial Statements&#8212;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 2A. </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Acquisitions, Sale of Hospira Infusion Systems Net Assets, Collaborative Arrangement and Equity-Method Investments</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">: Acquisitions</span><span style="font-family:inherit;font-size:10pt;">); and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">an increase in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other investing activities, net,</span><span style="font-family:inherit;font-size:10pt;"> including dividends received from an equity-method investment,</span></div></td></tr></table><div style="line-height:120%;padding-bottom:4px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">partially offset by:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">less net proceeds generated from the sale of investments of </span><span style="font-family:inherit;font-size:10pt;">$12.2 billion</span><span style="font-family:inherit;font-size:10pt;"> in </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;"> for cash needs.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Financing Activities</span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our net cash used in financing activities was </span><span style="font-family:inherit;font-size:10pt;">$9.6 billion</span><span style="font-family:inherit;font-size:10pt;"> in </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;">, compared to </span><span style="font-family:inherit;font-size:10pt;">$6.9 billion</span><span style="font-family:inherit;font-size:10pt;"> in the same period in </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;">. The change in net cash used in financing activities was primarily attributable to:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$2.2 billion</span><span style="font-family:inherit;font-size:10pt;"> less proceeds raised from net short-term borrowings in the </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;">, compared to the </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;text-align:center;">; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-transform:default;">$5.8 billion</span><span style="font-family:inherit;font-size:10pt;"> cash dividends paid in the first nine months of 2017, compared to </span><span style="font-family:inherit;font-size:10pt;text-transform:default;">$5.5 billion</span><span style="font-family:inherit;font-size:10pt;"> in the same period in 2016,</span></div></td></tr></table><div style="line-height:120%;padding-bottom:4px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">partially offset by:</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the issuance of long-term debt of </span><span style="font-family:inherit;font-size:10pt;">$5.3 billion</span><span style="font-family:inherit;font-size:10pt;"> in the </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;">, compared to </span><span style="font-family:inherit;font-size:10pt;">$5.0 billion</span><span style="font-family:inherit;font-size:10pt;"> in the same period in </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;"> (see Notes to Condensed Consolidated Financial Statements&#8211;&#8211;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 7D. Financial Instruments: Long-Term Debt</span><span style="font-family:inherit;font-size:10pt;">).</span></div></td></tr></table><div><a id="s159FC01B225C5423B0D3AED815336F77"></a></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">ANALYSIS OF FINANCIAL CONDITION, LIQUIDITY AND CAPITAL RESOURCES</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We rely largely on operating cash flows, short-term investments, short-term commercial paper borrowings and long-term debt to provide for our liquidity requirements. We continue our efforts to improve cash inflows through working capital efficiencies. We target specific areas of focus including accounts receivable, inventories, accounts payable, and other working capital, which allows us to optimize our operating cash flows. Due to our significant operating cash flows as well as our financial assets, access to capital markets and available lines of credit and revolving credit agreements, we believe that we have, and will maintain, the ability to meet our liquidity needs for the foreseeable future, which include:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the working capital requirements of our operations, including our R&amp;D activities;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">investments in our business;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">dividend payments and potential increases in the dividend rate;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">share repurchases;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the cash requirements associated with our cost-reduction/productivity initiatives;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">paying down outstanding debt;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">contributions to our pension and postretirement plans; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">business-development activities.</span></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our long-term debt is rated high-quality by both S&amp;P and Moody&#8217;s. See the &#8220;Credit Ratings&#8221; section below. As market conditions change, we continue to monitor our liquidity position. We have taken and will continue to take a conservative approach to our financial investments. Both short-term and long-term investments consist primarily of high-quality, highly liquid, well-diversified available-for-sale debt securities.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">94</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Selected Measures of Liquidity and Capital Resources</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.635477582846%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">The following table provides certain relevant measures of our liquidity and capital resources:</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS, EXCEPT RATIOS AND PER COMMON SHARE DATA)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">October&#160;1, <br/>2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">December&#160;31, <br/>2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Selected financial assets:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-style:italic;">Cash and cash equivalents</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">2,779</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">2,595</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-style:italic;">Short-term investments</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">14,146</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">15,255</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-style:italic;">Long-term investments</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">7,311</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">7,116</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">24,236</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">24,967</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Debt:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-style:italic;">Short-term borrowings, including current portion of long-term debt</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">9,448</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">10,688</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-style:italic;">Long-term debt</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">34,503</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">31,398</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">43,951</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">42,085</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Selected net financial liabilities</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(19,714</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">(17,118</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Working capital</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">12,074</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">7,834</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Ratio of current assets to current liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">1.43:1</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">1.25:1</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Total Pfizer Inc. shareholders&#8217; equity per common share</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(d)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">10.20</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">9.81</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">See Notes to Condensed Consolidated Financial Statements&#8211;&#8211;</span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Note 7. </span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Financial Instruments</span><span style="font-family:inherit;font-size:8.5pt;"> for a description of certain assets held and for a description of credit risk related to our financial instruments held.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">The increase in selected net financial liabilities is primarily driven by (i) our decrease in short-term investments, the proceeds of which were used for various cash needs and (ii) the net increase in long-term debt. We retain a strong financial liquidity position as a result of our net cash provided by operating activities, our high-quality financial asset portfolio and access to capital markets. Both Moody&#8217;s and S&amp;P rating agencies maintained our strong investment-grade corporate debt rating subsequent to the acquisitions of Medivation and Anacor. For additional information, see the &#8220;Credit Ratings&#8221; section of this MD&amp;A.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(c)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">The increase in working capital is primarily due to the timing of accruals, cash receipts and payments in the ordinary course of business, a decline in short-term borrowings and an increase in inventory related to new or potential products, partially offset by a decline in short-term investments used for various cash needs and the sale of HIS assets to ICU Medical.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(d)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Represents total Pfizer Inc. shareholders&#8217; equity divided by the actual number of common shares outstanding (which excludes treasury stock).</span></div></td></tr></table><div style="line-height:120%;font-size:5pt;"><span style="font-family:inherit;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For additional information about the sources and uses of our funds, see the &#8220;Analysis of the Condensed Consolidated Balance Sheets&#8221; and the &#8220;Analysis of the Condensed Consolidated Statements of Cash Flows&#8221; sections of this MD&amp;A.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On March 17, 2017, we completed a public offering of </span><span style="font-family:inherit;font-size:10pt;">$1.065 billion</span><span style="font-family:inherit;font-size:10pt;"> principal amount of senior unsecured notes due 2047 with an interest rate of </span><span style="font-family:inherit;font-size:10pt;">4.20%</span><span style="font-family:inherit;font-size:10pt;">, and on March 6, 2017, we completed a public offering of &#8364;</span><span style="font-family:inherit;font-size:10pt;">4.0 billion</span><span style="font-family:inherit;font-size:10pt;"> principal amount of senior unsecured notes with a weighted-average effective interest rate of </span><span style="font-family:inherit;font-size:10pt;">0.23%</span><span style="font-family:inherit;font-size:10pt;"> (see Notes to Condensed Consolidated Financial Statements&#8211;&#8211;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 7D. Financial Instruments: Long-Term Debt</span><span style="font-family:inherit;font-size:10pt;">).</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Domestic and International Short-Term Funds</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Many of our operations are conducted outside the U.S., and significant portions of our cash, cash equivalents and short-term investments are held internationally. We generally hold up to $10 billion of these short-term funds in U.S. tax jurisdictions. The amount of funds held in U.S. tax jurisdictions can fluctuate due to the timing of receipts and payments in the ordinary course of business and due to other reasons, such as business-development activities. As part of our ongoing liquidity assessments, we regularly monitor the mix of domestic and international cash flows (both inflows and outflows). Repatriation of overseas funds can result in additional U.S. federal, state and local income tax payments. We record U.S. deferred tax liabilities for certain unremitted earnings, but when amounts earned overseas are expected to be indefinitely reinvested outside the U.S., no accrual for U.S. taxes is provided.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Accounts Receivable</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We continue to monitor developments regarding government and government agency receivables in several European markets where economic conditions remain challenging and uncertain. Historically, payments from a number of these European governments and government agencies extend beyond the contractual terms of sale. Specifically, we received delayed payments for 2016 revenues from the Greek government; virtually all Greece government receivables pertain to 2017 revenues. Also, the Greek government restructured its debt to other third parties in the third quarter of 2016. We determined our allowance for doubtful accounts to reflect these events, and have </span><span style="font-family:inherit;font-size:10pt;">$35 million</span><span style="font-family:inherit;font-size:10pt;"> in net receivables from the Greek government as of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">October&#160;1, 2017</span><span style="font-family:inherit;font-size:10pt;">. Reported revenues from all customers in Greece for the </span><span style="font-family:inherit;font-size:10pt;">nine months</span><span style="font-family:inherit;font-size:10pt;"> ended </span><span style="font-family:inherit;font-size:10pt;text-align:center;">October&#160;1, 2017</span><span style="font-family:inherit;font-size:10pt;"> were </span><span style="font-family:inherit;font-size:10pt;">$180 million</span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">95</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We believe that our allowance for doubtful accounts is appropriate. Our assessment is based on an analysis of the following: (i) payments received to date; (ii) the consistency of payments from customers; (iii) direct and observed interactions with the governments (including court petitions) and with market participants (for example, the factoring industry); and (iv) various third-party assessments of repayment risk (for example, rating agency publications and the movement of rates for credit default swap instruments).</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">October&#160;1, 2017</span><span style="font-family:inherit;font-size:10pt;">, we had about </span><span style="font-family:inherit;font-size:10pt;">$533 million</span><span style="font-family:inherit;font-size:10pt;"> in aggregate gross accounts receivable from governments and/or government agencies in Italy, Spain, Greece and Portugal where economic conditions remain challenging and uncertain. Such receivables in excess of one year from the invoice date, totaling </span><span style="font-family:inherit;font-size:10pt;">$65 million</span><span style="font-family:inherit;font-size:10pt;">, were as follows: </span><span style="font-family:inherit;font-size:10pt;">$40 million</span><span style="font-family:inherit;font-size:10pt;"> in Italy; </span><span style="font-family:inherit;font-size:10pt;">$18 million</span><span style="font-family:inherit;font-size:10pt;"> in Portugal; </span><span style="font-family:inherit;font-size:10pt;">$4 million</span><span style="font-family:inherit;font-size:10pt;"> in Greece; and </span><span style="font-family:inherit;font-size:10pt;">$3 million</span><span style="font-family:inherit;font-size:10pt;"> in Spain.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Although certain European governments and government agencies sometimes delay payments beyond the contractual terms of sale, we seek to appropriately balance repayment risk with the desire to maintain good relationships with our customers and to ensure a humanitarian approach to local patient needs.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We will continue to closely monitor repayment risk and, when necessary, we will continue to adjust our allowance for doubtful accounts.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our assessments about the recoverability of accounts receivables can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions. For information about the risks associated with estimates and assumptions, see Notes to Consolidated Financial Statements&#8211;&#8211;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 1C. Basis of Presentation and Significant Accounting Policies:</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Estimates and Assumptions</span><span style="font-family:inherit;font-size:10pt;"> included in our </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;"> Financial Report.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Credit Ratings</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Two major corporate debt-rating organizations, Moody&#8217;s and S&amp;P, assign ratings to our short-term and long-term debt. A security rating is not a recommendation to buy, sell or hold securities and the rating is subject to revision or withdrawal at any time by the rating organization. Each rating should be evaluated independently of any other rating.</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.83040935672514%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:33%;"></td><td style="width:1%;"></td><td style="width:20%;"></td><td style="width:1%;"></td><td style="width:20%;"></td><td style="width:1%;"></td><td style="width:24%;"></td></tr><tr><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides the current ratings assigned by these rating agencies to our commercial paper and senior unsecured long-term debt:</span></div></td></tr><tr><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">NAME OF RATING AGENCY</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pfizer </span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Commercial Paper </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pfizer</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Long-Term Debt</span></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Date of Last Rating Change</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Rating</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Rating</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Moody&#8217;s</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">P-1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">October 2009</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">S&amp;P</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(b)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A-1+</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">AA</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">October 2009</span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">In September 2016, Moody&#8217;s updated their credit outlook from negative outlook to stable.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">In April 2016, S&amp;P updated their credit outlook from negative watch to stable.</span></div></td></tr></table><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Debt Capacity</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have available lines of credit and revolving credit agreements with a group of banks and other financial intermediaries. We maintain cash and cash equivalent balances and short-term investments in excess of our commercial paper and other short-term borrowings. As of </span><span style="font-family:inherit;font-size:10pt;">October&#160;1, 2017</span><span style="font-family:inherit;font-size:10pt;">, we had access to </span><span style="font-family:inherit;font-size:10pt;">$7.8 billion</span><span style="font-family:inherit;font-size:10pt;"> of lines of credit, of which </span><span style="font-family:inherit;font-size:10pt;">$689 million</span><span style="font-family:inherit;font-size:10pt;"> expire within one year. Of these lines of credit, </span><span style="font-family:inherit;font-size:10pt;">$7.7 billion</span><span style="font-family:inherit;font-size:10pt;"> were unused, of which our lenders have committed to loan us </span><span style="font-family:inherit;font-size:10pt;">$7.0 billion</span><span style="font-family:inherit;font-size:10pt;"> at our request. Also, </span><span style="font-family:inherit;font-size:10pt;">$7.0 billion</span><span style="font-family:inherit;font-size:10pt;"> of our unused lines of credit, all of which expire in 2021, may be used to support our commercial paper borrowings.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Global Economic Conditions&#8211;&#8211;General</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The global economic environment has not had, nor do we anticipate it will have, a material impact on our liquidity or capital resources. Due to our significant operating cash flows, financial assets, access to capital markets and available lines of credit and revolving credit agreements, we continue to believe that we have, and will maintain, the ability to meet our liquidity needs for the foreseeable future. We monitor our liquidity position continuously in the face of evolving economic conditions. </span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Global Economic Conditions&#8211;&#8211;U.K.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In June 2016, the U.K. electorate voted in a referendum to leave the EU, which is commonly referred to as &#8220;Brexit&#8221;. In January 2017, the U.K. Prime Minister announced a 12-point plan of negotiating objectives and confirmed that the U.K. government will not seek continued membership in the EU single market. In March 2017, the U.K. government formally notified the </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">96</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">European Council of its intention to leave the EU after it triggered Article 50 of the Lisbon Treaty to begin the two-year negotiation process establishing the terms of the exit and outlining the future relationship between the U.K. and the EU. This process continues to be highly complex and the end result of these negotiations may pose certain implications to our research, commercial and general business operations in the U.K. and the EU, including the approval of our products.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We generated approximately </span><span style="font-family:inherit;font-size:10pt;">2%</span><span style="font-family:inherit;font-size:10pt;"> of our worldwide revenues from the U.K. in the </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;">. However, except for the foreign currency exchange impact from the weakening U.K. pound relative to the U.S. dollar to date, there are no other immediate-term impacts to our business as there has not yet been a formal change in the relationship between the U.K. and the EU. In addition, because of the significant uncertainties associated with the negotiation process, any potential long-term impacts are not currently determinable.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Global Economic Conditions&#8211;&#8211;Venezuela Operations</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our Venezuela operations continue to operate with the U.S. dollar as the functional currency due to the hyperinflationary status of the Venezuelan economy. </span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the second quarter of 2015, the Venezuelan government identified three official rates of exchange. These were the CENCOEX rate of 6.3; the SICAD rate of 13.5 (as of November 2017); and the SIMADI rate of </span><span style="font-family:inherit;font-size:10pt;">3,345</span><span style="font-family:inherit;font-size:10pt;"> (as of November 2017). Effective in March 2016, the CENCOEX rate was replaced by the DIPRO rate of </span><span style="font-family:inherit;font-size:10pt;">10</span><span style="font-family:inherit;font-size:10pt;"> (as of February 2017); the SICAD rate ceased to be offered; and the SIMADI rate was planned to be replaced by the DICOM rate. The Venezuelan government continued to publish the SIMADI rate, which was commonly referred to as the DICOM rate, and then began to publish the DICOM rate beginning in August 2017. That SIMADI, now DICOM, rate has grown from 206 in March 2016 to about </span><span style="font-family:inherit;font-size:10pt;">3,345</span><span style="font-family:inherit;font-size:10pt;"> (as of November 2017). Based on conditions in Venezuela, we resolved that our Venezuelan bolivar-denominated net monetary assets that are subject to revaluation are no longer expected to be substantially settled at the Venezuelan government CENCOEX official rate of </span><span style="font-family:inherit;font-size:10pt;">6.3</span><span style="font-family:inherit;font-size:10pt;"> or the DIPRO official rate of </span><span style="font-family:inherit;font-size:10pt;">10</span><span style="font-family:inherit;font-size:10pt;">, but at a rate of </span><span style="font-family:inherit;font-size:10pt;">500</span><span style="font-family:inherit;font-size:10pt;"> at the end of the second quarter and third quarter of 2016, and </span><span style="font-family:inherit;font-size:10pt;">670</span><span style="font-family:inherit;font-size:10pt;"> at the end of the fourth quarter of 2016, and at the end of the first and second quarters of 2017, and </span><span style="font-family:inherit;font-size:10pt;">2,640</span><span style="font-family:inherit;font-size:10pt;"> at the end of the third quarter of 2017.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We cannot predict whether there will be further devaluations of the Venezuelan currency or whether our use of the DICOM rate will continue to be supported by evolving facts and circumstances. Further, other potential actions by the Venezuelan government in response to economic uncertainties could impact the recoverability of our investment in Venezuela, which could result in an impairment charge and, under extreme circumstances, could impact our ability to continue to operate in the country in the same manner as we have historically.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On July 11, 2016, the Venezuelan government administration announced a new program under a State of Emergency decree that is intended to control the use of raw materials, production and distribution of products, specifically for medicines and foods. It is uncertain how this program will be applied to Pfizer in Venezuela. We continue to operate under adverse conditions in Venezuela and have </span><span style="font-family:inherit;font-size:10pt;">$6 million</span><span style="font-family:inherit;font-size:10pt;"> of net monetary assets and </span><span style="font-family:inherit;font-size:10pt;">$40 million</span><span style="font-family:inherit;font-size:10pt;"> of non-monetary assets, excluding inventory carried at lower of cost or market, in Venezuela at </span><span style="font-family:inherit;font-size:10pt;">August&#160;27, 2017</span><span style="font-family:inherit;font-size:10pt;">, our international quarter-end.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Off-Balance Sheet Arrangements</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the ordinary course of business and in connection with the sale of assets and businesses, we often indemnify our counterparties against certain liabilities that may arise in connection with a transaction or that are related to activities prior to a transaction. These indemnifications typically pertain to environmental, tax, employee and/or product-related matters, and patent-infringement claims. If the indemnified party were to make a successful claim pursuant to the terms of the indemnification, we would be required to reimburse the loss. These indemnifications generally are subject to threshold amounts, specified claim periods and other restrictions and limitations. Historically, we have not paid significant amounts under these provisions and, as of </span><span style="font-family:inherit;font-size:10pt;">October&#160;1, 2017</span><span style="font-family:inherit;font-size:10pt;">, recorded amounts for the estimated fair value of these indemnifications were not significant.</span></div><div style="line-height:120%;text-align:left;font-size:5pt;"><span style="font-family:inherit;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certain of our co-promotion or license agreements give our licensors or partners the rights to negotiate for, or in some cases to obtain under certain financial conditions, co-promotion or other rights in specified countries with respect to certain of our products.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Share-Purchase Plans and Accelerated Share Repurchase Agreements</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our October 2014 $11 billion share-purchase plan was exhausted in the first quarter of 2017. In December 2015, the Board of Directors authorized an $11 billion share repurchase program, and share repurchases commenced thereunder in the first quarter of 2017.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">97</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On February 2, 2017, we entered into an accelerated share repurchase agreement with Citibank to repurchase </span><span style="font-family:inherit;font-size:10pt;">$5 billion</span><span style="font-family:inherit;font-size:10pt;"> of our common stock. For additional information, see Notes to Condensed Consolidated Financial Statements&#8211;&#8211;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 12</span><span style="font-family:inherit;font-size:10pt;">. </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Commitments and Contingencies</span><span style="font-family:inherit;font-size:10pt;"> and &#8220;Unregistered Sales of Equity Securities and Use of Proceeds&#8211;&#8211;Issuer Purchases of Equity Securities&#8221; in Part II, Item 2 of this Quarterly Report on Form 10-Q. </span></div><div style="line-height:120%;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"></td></tr><tr><td style="width:48%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td colspan="17" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides the number of shares of our common stock purchased and the cost of purchases under our publicly announced accelerated share repurchase agreements:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nine Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(SHARES IN MILLIONS, DOLLARS IN BILLIONS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">October 1,</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">October 2,</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">October 1,<br/>2017</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">October 2,<br/>2016</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(b)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares of common stock purchased</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">150</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">154</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of purchase</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">5.0</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">5.0</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;background-color:#ffffff;"><sup style="vertical-align:top;line-height:120%;background-color:#ffffff; font-size:6pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;background-color:#ffffff;">Represents shares purchased pursuant to an accelerated share repurchase agreement with Citibank. For additional information, see </span><span style="font-family:inherit;font-size:9pt;">Notes to Condensed Consolidated Financial Statements&#8211;&#8211;</span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Note 12</span><span style="font-family:inherit;font-size:9pt;">. </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Commitments and Contingencies</span><span style="font-family:inherit;font-size:9pt;"> and &#8220;Unregistered Sales of Equity Securities and Use of Proceeds&#8211;&#8211;Issuer Purchases of Equity Securities&#8221; in Part II, Item 2 of this Quarterly Report on Form 10-Q.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;background-color:#ffffff;"><sup style="vertical-align:top;line-height:120%;background-color:#ffffff; font-size:6pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:9pt;background-color:#ffffff;">Represents shares purchased pursuant to an accelerated share repurchase agreement entered into on March 8, 2016. For additional information, see</span><span style="font-family:inherit;font-size:9pt;"> </span><span style="font-family:inherit;font-size:9pt;">Notes to Consolidated Financial Statements&#8211;&#8211;</span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Note 12</span><span style="font-family:inherit;font-size:9pt;">. </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Equity</span><span style="font-family:inherit;font-size:9pt;"> in our </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:9pt;"> Financial Report.</span></div></td></tr></table><div style="line-height:120%;font-size:5pt;"><span style="font-family:inherit;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">At </span><span style="font-family:inherit;font-size:10pt;">October&#160;1, 2017</span><span style="font-family:inherit;font-size:10pt;">, our remaining share-purchase authorization was approximately </span><span style="font-family:inherit;font-size:10pt;">$6.4 billion</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Dividends on Common Stock</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In September 2017, our Board of Directors declared a dividend of $0.32 per share, payable on December 1, </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;">, to shareholders of record at the close of business on November 10, </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div><a id="sA4DEFCE48A195AF1AD518A8476FA723F"></a></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">NEW ACCOUNTING STANDARDS</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Recently Adopted Accounting Standards</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;padding-bottom:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">See Notes to Condensed Consolidated Financial Statements&#8211;&#8211;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 1B. Basis of Presentation and Significant Accounting</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Policies: Adoption of New Accounting Standards.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Recently Issued Accounting Standards, Not Adopted as of </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:underline;">October&#160;1, 2017</span></div><div style="line-height:120%;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:38%;"></td><td style="width:1%;"></td><td style="width:19%;"></td><td style="width:1%;"></td><td style="width:41%;"></td></tr><tr><td colspan="5" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">The following table provides a brief description of recently issued accounting standards, not yet adopted:</span><span style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Standard/Description</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Effective Date </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Effect on the Financial Statements or Other Significant Matters</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">In May 2014, the FASB issued amended guidance related to </span><span style="font-family:inherit;font-size:8pt;font-weight:bold;">revenue from contracts with customers</span><span style="font-family:inherit;font-size:8pt;">. The new guidance introduces a new principles-based framework for revenue recognition and disclosure. Since its issuance the FASB has issued six ASUs, amending the guidance and effective date, and the SEC has rescinded certain related SEC guidance; the most recent of these changes was issued in December 2016.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">January 1, 2018. </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="padding-top:1px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">We have made substantial progress in completing our review of the impact of this guidance across our various business arrangements and revenue-related activities, and do not expect the adoption of this standard to have a material impact on our reported </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Revenues</span><span style="font-family:inherit;font-size:8pt;">&#160;in our consolidated financial statements, revenue recognition processes, or our internal controls. We are reviewing our disclosures for revenue recognition and do not anticipate significant changes will be needed to conform with the disclosure requirements of the new guidance.</span></div><div style="padding-top:1px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">The interpretation and applicability of the new revenue recognition standard to collaboration arrangements in certain industries is still being assessed. We expect that milestone payments received in our collaboration agreements, which are recorded in </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Other </span><span style="font-family:inherit;font-size:8pt;">(</span><span style="font-family:inherit;font-size:8pt;font-style:italic;">income</span><span style="font-family:inherit;font-size:8pt;">)</span><span style="font-family:inherit;font-size:8pt;font-style:italic;">/deductions</span><span style="font-family:inherit;font-size:8pt;">&#8211;&#8211;</span><span style="font-family:inherit;font-size:8pt;font-style:italic;">net</span><span style="font-family:inherit;font-size:8pt;">, and currently amortized over the life of the agreement, will, for many arrangements, be amortized over the remaining development period or sooner, if there is a distinct and separable licensing component. We are required to apply the new rules to existing contracts as if the new principles had always existed, and therefore, upon adoption, we expect to record a cumulative effect adjustment to </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Retained earnings</span><span style="font-family:inherit;font-size:8pt;">&#160;as of the adoption date in the range of $350 million to $550 million to accelerate what would have been future income under the current rules into prior periods. The financial statement impact on pre-tax income is expected to be less than $100 million in any future annual period.</span></div><div style="padding-top:1px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">We continue to monitor additional changes, modifications, clarifications or interpretations undertaken by the FASB, which may impact our current conclusions. In addition, we continue to monitor other changes, such as changes in our business, new collaboration arrangements, business combinations, etc., which may impact our current conclusions prior to the adoption date.</span></div></td></tr></table></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">98</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;text-align:center;padding-left:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:38%;"></td><td style="width:1%;"></td><td style="width:19%;"></td><td style="width:1%;"></td><td style="width:41%;"></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Standard/Description</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Effective Date </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Effect on the Financial Statements or Other Significant Matters</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">In January 2016, the FASB issued an update to its guidance on recognition and measurement of </span><span style="font-family:inherit;font-size:8pt;font-weight:bold;">financial assets and liabilities</span><span style="font-family:inherit;font-size:8pt;">.</span></div><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Among other things, the new guidance makes the following targeted changes to existing guidance:</span></div><div style="padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">1. Requires certain equity investments to be measured at fair value with changes in fair value recognized in net income. However, an entity may choose to measure equity investments that do not have readily determinable fair values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment of the same issuer.</span></div><div style="padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2. Requires a qualitative assessment of equity investments without readily determinable fair values to identify impairment.</span></div><div style="padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">3. Requires separate presentation of financial assets and financial liabilities by measurement category and form of financial asset on the balance sheet or in the accompanying notes to the financial statements.</span></div><div style="padding-top:1px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">In September 2017, the FASB issued a proposed amendment to this new standard which is intended to clarify certain aspects of the guidance.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">January 1, 2018.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">We have substantially completed our review of the impact of this new guidance on our consolidated financial statements, and will continue to assess events which may occur prior to adoption. As of October 1, 2017, we have $1.0 billion in available-for-sale equity securities and approximately $273 million of restricted stock and private equity securities which will be subject to the new rules. Further, for the nine months ended October 1, 2017, we recognized $406 million of previously unrealized holding gains and $119 million of previously unrealized losses on available-for-sale equity securities in </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Other comprehensive income</span><span style="font-family:inherit;font-size:8pt;">, which would have been recorded to </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Other (income)/ deductions</span><span style="font-family:inherit;font-size:8pt;">&#8211;&#8211;</span><span style="font-family:inherit;font-size:8pt;font-style:italic;">net </span><span style="font-family:inherit;font-size:8pt;">under the new rules. The impact of adoption will be recorded as a cumulative effect adjustment to </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Retained earnings. </span><span style="font-family:inherit;font-size:8pt;">We expect the adoption of this new accounting standard may increase the volatility of our income in future periods due to changes in the fair value of equity investments. We do not expect that the proposed amendment, as currently drafted, will have any substantive impact to our assessment discussed above. We continue to monitor changes, modifications, clarifications or interpretations undertaken by the FASB, which may impact our current conclusions.</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">In August 2016, the FASB issued new guidance on the </span><span style="font-family:inherit;font-size:8pt;font-weight:bold;">classification of certain transactions in the Statement of Cash Flows.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">January 1, 2018. Earlier application is permitted.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">We have substantially completed our review and will continue to assess events which may occur prior to adoption. Retrospective application is required. Upon adoption, we expect to reclassify approximately $362 million of cash outflows related to debt redemption in 2016 from operating activities to financing activities. We also expect to reclassify approximately $32 million of cash inflows from trust-owned life insurance contracts in 2016 from operating activities to investing activities. Cash outflows from trust-owned life insurance contracts represent benefit payments and are classified as operating activities. In addition, although there is no impact on the presented historical comparative financial statements, the new guidance may impact the classification of certain cash flows related to contingent consideration in a business acquisition, depending on the ultimate settlement amount of the reported contingency liability.</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">In October 2016, the FASB issued new guidance on the presentation of </span><span style="font-family:inherit;font-size:8pt;font-weight:bold;">restricted cash in the Statement of Cash Flows.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">January 1, 2018. Earlier application is permitted.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">We have substantially completed our review and will continue to assess events which may occur prior to adoption. Retrospective application is required. Our restricted cash balances as of the end of 2016 were approximately $18.1 million of short-term restricted cash and $45.3 million of long-term restricted cash. Our restricted cash balances as of October 1, 2017 were approximately $6.4 million of short-term restricted cash and $68.7 million of long-term restricted cash.</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">In October 2016, the FASB issued an update to its guidance on </span><span style="font-family:inherit;font-size:8pt;font-weight:bold;">income tax</span><span style="font-family:inherit;font-size:8pt;">&#160;accounting. The new guidance replaces the prohibition against recognizing current and deferred income taxes for an intra-entity asset transfer until the asset has been sold to an outside party with a requirement to do so, unless the asset transferred is inventory. </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">January 1, 2018. </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">We have substantially completed our review and will continue to assess events which may occur prior to adoption. Our analysis of the standard indicates that our estimate of the impact to our consolidated financial statements, using current assumptions, is not material. However, while we currently do not have any specific plans, we cannot predict intercompany asset transfers other than inventory that may occur in the future, as they are dependent on economic and operational factors that may change over time.</span></div><div style="padding-top:1px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">For example, an acquisition might cause us to realign legal entities and to transfer assets between entities as we integrate an acquired company into Pfizer. We anticipate that after adoption, our effective tax rate could be impacted by the immediate recognition of the tax consequences of intercompany asset transfers other than inventory. The impact of adoption will be recorded as a cumulative effect adjustment to </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Retained Earnings</span><span style="font-family:inherit;font-size:8pt;">.</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">In January 2017, the FASB issued new guidance to clarify the </span><span style="font-family:inherit;font-size:8pt;font-weight:bold;">definition of a business</span><span style="font-family:inherit;font-size:8pt;">. The new guidance provides a new framework for determining whether business development transactions should be accounted for as acquisitions (or disposals) of assets or businesses. If the fair value of the gross assets acquired is concentrated in a single identifiable asset, the transaction will not qualify for treatment as a business. The new guidance also requires that to be considered a business, a set of integrated activities and assets must include, at a minimum, an input and a substantive process that together significantly contribute to the ability to create outputs, without regard as to whether a market participant could replace missing elements. In addition, the new guidance narrows the definition of the term &#8220;output&#8221; to make it consistent with how outputs are described in the updated revenue recognition guidance.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">January 1, 2018. Earlier application is permitted.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">We have substantially completed our review and will continue to assess events which may occur prior to adoption. The new accounting standard is applicable on a prospective basis upon adoption and therefore has no impact on completed transactions. We expect that subsequent to our anticipated adoption date of January 1, 2018, fewer transactions will be accounted for as business acquisitions (decreasing the amount of goodwill incurred and potentially increasing IPR&amp;D expense) or disposals of a business. We will continue to monitor for changes in our business, and business combination or other transactions which might close after adoption and be impacted by these new standards.</span></div></td></tr></table></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">99</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;text-align:center;padding-left:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:38%;"></td><td style="width:1%;"></td><td style="width:19%;"></td><td style="width:1%;"></td><td style="width:41%;"></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Standard/Description</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Effective Date </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Effect on the Financial Statements or Other Significant Matters</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">In February 2017, the FASB issued amended guidance related to the </span><span style="font-family:inherit;font-size:8pt;font-weight:bold;">derecognition of nonfinancial assets. </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">January 1, 2018. Earlier application is permitted.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">We have substantially completed our review and will continue to assess events which may occur prior to adoption. The new guidance applies to the full or partial sale or transfer of nonfinancial assets, including intangible assets, real estate and inventory, under which the gain or loss is the difference between the consideration received and the carrying value of the asset. The new guidance does not impact out-licensing arrangements. We are not expecting a material impact on existing transactions. We will continue to monitor for changes in our business and transactions which might be impacted by these new standards. The impact of adoption, if any, will be recorded as a cumulative effect adjustment to </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Retained Earnings</span><span style="font-family:inherit;font-size:8pt;">.</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">In March 2017, the FASB issued guidance on the presentation of </span><span style="font-family:inherit;font-size:8pt;font-weight:bold;">net periodic pension and postretirement benefit cost. </span><span style="font-family:inherit;font-size:8pt;">Under the new rules, entities that sponsor defined benefit plans will present net benefit cost as follows:</span></div><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">1. Service cost will be included in the same income statement line items where other employee compensation costs are reported.</span></div><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2. The other components of net benefit cost will be presented outside of income from operations, if such a subtotal is presented.</span></div><div style="padding-bottom:1px;text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">3. Only the service cost component will be capitalized, when applicable (for example, as a cost of inventory, internal-use software, or a self-constructed fixed asset).</span></div><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">If a separate line item is used to present the other components of net benefit cost, it should have an appropriate description. If a separate line item or items is not used, the line item or items in the income statement where the other components of net benefit cost are included must be disclosed.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">January 1, 2018.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">We have made substantial progress in completing our review of the impact of this new guidance. We anticipate that upon adoption, the net benefit costs other than service costs will be reclassified to </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Other </span><span style="font-family:inherit;font-size:8pt;">(</span><span style="font-family:inherit;font-size:8pt;font-style:italic;">income</span><span style="font-family:inherit;font-size:8pt;">)</span><span style="font-family:inherit;font-size:8pt;font-style:italic;">/deductions</span><span style="font-family:inherit;font-size:8pt;">-</span><span style="font-family:inherit;font-size:8pt;font-style:italic;">net </span><span style="font-family:inherit;font-size:8pt;">from their current classification within </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Cost of sales, Selling, informational and administrative expenses, </span><span style="font-family:inherit;font-size:8pt;">and </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Research and development expenses. </span><span style="font-family:inherit;font-size:8pt;">We expect to adopt the practical expedient which allows us to ignore capitalized pension expense in the retrospective adjustments in our Statements of Income. Net benefit cost/(income) other than service costs was $154 million for the year ended December 31, 2016 and $89 million for the nine months ended October 1, 2017 (see Notes to Condensed Consolidated Financial Statements&#8211;&#8211;</span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Note 10.</span><span style="font-family:inherit;font-size:8pt;">&#160;</span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Pension and Postretirement Benefits</span><span style="font-family:inherit;font-size:8pt;">&#160;for further details). We are still assessing the impact on our results of operations for business segment reporting, changes in accounting processes, such as inventory standard costing methodologies, and policies. </span></div><div style="padding-top:1px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Effective January 1, 2018, future accruals under the Pfizer Consolidated Pension Plan (our largest U.S. defined benefit plan), will freeze, and the Pfizer defined contribution savings plan will provide additional annual contributions to those previously accruing benefits under the Pfizer Consolidated Pension Plan. This change will result in elimination of future service costs for the plan.</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">In May 2017, the FASB issued new guidance on the accounting for </span><span style="font-family:inherit;font-size:8pt;font-weight:bold;">modifications of share-based payment awards</span><span style="font-family:inherit;font-size:8pt;">. The new guidance clarifies that changes in the terms or conditions of a share-based payment award be accounted for as a modification unless all the following conditions are met:</span></div><div><div style="float:left; width:12px; padding-left:0px;"><span style="font-family:inherit;font-size:8pt;">1.</span></div><span style=""><span style="font-family:inherit;font-size:8pt;">The fair value of the modified award is the same as the fair value of the original award immediately before the original award is modified.</span></span></div><div><div style="float:left; width:12px; padding-left:0px;"><span style="font-family:inherit;font-size:8pt;">2.</span></div><span style=""><span style="font-family:inherit;font-size:8pt;">The vesting conditions of the modified award are the same as the vesting conditions of the original award immediately before the original award is modified.</span></span></div><div><div style="float:left; width:12px; padding-left:0px;"><span style="font-family:inherit;font-size:8pt;">3.</span></div><span style=""><span style="font-family:inherit;font-size:8pt;">The modification does not change the classification of the award as an equity instrument or a liability instrument.</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">January 1, 2018. Early application is permitted, including in interim periods.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">We have substantially completed our review and will continue to assess events that may occur prior to adoption. The new accounting standard is applicable on a prospective basis upon adoption and therefore has no impact on completed transactions. The impact of adopting this guidance will be dependent upon whether we make any future modifications of share-based payment awards, and we have no plans to modify share-based payment awards at this time. </span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">In February 2016, the FASB issued an update to its guidance on </span><span style="font-family:inherit;font-size:8pt;font-weight:bold;">leases</span><span style="font-family:inherit;font-size:8pt;">. The new ASU provides guidance for both lessee and lessor accounting models. Among other things, the new guidance requires that a right of use asset and a lease liability be recognized for leases with a duration of greater than one year.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">January 1, 2019. Earlier application is permitted.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">We have made substantial progress in completing our review of the impact of this new guidance. We anticipate recognition of at least $2 billion of additional assets and corresponding liabilities on our balance sheet. We are currently assessing the potential impact of embedded leases on our consolidated financial statements, given our manufacturing outsourcing, service arrangements and other agreements. In connection with this guidance we will need to design new global processes and technological solutions to provide the appropriate financial accounting and disclosure data. We continue to monitor changes, modifications, clarifications or interpretations undertaken by the FASB, which may impact our conclusions.</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">In March 2017, the FASB issued new guidance that shortens the </span><span style="font-family:inherit;font-size:8pt;font-weight:bold;">amortization period for certain callable debt securities held at a premium</span><span style="font-family:inherit;font-size:8pt;">. The new guidance requires the premium to be amortized to the earliest call date.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">January 1, 2019. Early application is permitted, including in interim periods, so long as any adjustments are reflected as of the beginning of the fiscal year that includes the interim period in which the guidance is applied.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">We are assessing the impact of the provisions of this new guidance on our consolidated financial statements.</span></div></td></tr></table></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">100</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;text-align:center;padding-left:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:38%;"></td><td style="width:1%;"></td><td style="width:19%;"></td><td style="width:1%;"></td><td style="width:41%;"></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Standard/Description</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Effective Date </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Effect on the Financial Statements or Other Significant Matters</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">In July 2017, the FASB issued new guidance on accounting for </span><span style="font-family:inherit;font-size:8pt;font-weight:bold;">certain financial instruments with characteristics of liabilities and equity,</span><span style="font-family:inherit;font-size:8pt;">&#160;and accounting for certain financial instruments with </span><span style="font-family:inherit;font-size:8pt;font-weight:bold;">down round features </span><span style="font-family:inherit;font-size:8pt;">(a feature in a financial instrument that reduces the strike price of an issued financial instrument if the issuer sells shares of its stock for an amount less than the currently stated strike price of the issued financial instrument or issues an equity-linked financial instrument with a strike price below the currently stated strike price of the issued financial instrument).</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">January 1, 2019. Earlier application is permitted.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">We are assessing the impact of the provisions of this new guidance on our consolidated financial statements.</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">In August 2017, the FASB issued new guidance making targeted improvements to </span><span style="font-family:inherit;font-size:8pt;font-weight:bold;">accounting for hedging activities</span><span style="font-family:inherit;font-size:8pt;">. The objective of this amendment is to improve financial reporting of hedging relationships to better portray the economic results of an entity&#8217;s risk management activities in its financial statements, and also to simplify the application of hedge accounting guidance.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">January 1, 2019. Early adoption is permitted, including in interim periods.</span></div><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">We are assessing the impact of the provisions of this new guidance on our consolidated financial statements and, pending our final review, we may consider early adoption.</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">In June 2016, the FASB issued new guidance on accounting for </span><span style="font-family:inherit;font-size:8pt;font-weight:bold;">credit losses of financial instruments</span><span style="font-family:inherit;font-size:8pt;">. The new guidance replaces the probable initial recognition threshold for incurred loss estimates in current GAAP with a methodology that reflects expected credit loss estimates.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">January 1, 2020. Earlier application is permitted as of fiscal years beginning after December 15, 2018, including interim periods within that fiscal year.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">We are assessing the impact of the provisions of this new guidance on our consolidated financial statements. Previously, when credit losses were measured under GAAP, an entity generally only considered past events and current conditions in measuring the incurred loss. The new guidance requires us to identify, analyze, document and support new methodologies for quantifying expected credit loss estimates for our financial instruments, using information such as historical estimates and current economic environmental conditions, plus the use of reasonable supportable forecast information.</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">In January 2017, the FASB issued new guidance for </span><span style="font-family:inherit;font-size:8pt;font-weight:bold;">goodwill impairment testing</span><span style="font-family:inherit;font-size:8pt;">. The new guidance eliminates the requirement to perform a hypothetical purchase price allocation to measure goodwill impairment. Under the new guidance the goodwill impairment test is performed by comparing the fair value of a reporting unit with its carrying amount, and recognizing an impairment charge for the amount by which the carrying amount of the reporting unit exceeds its fair value, although it cannot exceed the total amount of goodwill allocated to that reporting unit. </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">January 1, 2020. Earlier application is permitted.</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">We have not yet completed our review of the impact of this new guidance on our consolidated financial statements. However, we do not expect this new guidance to have a material impact on our consolidated financial statements.</span></div></td></tr></table></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">101</span></div></div><hr style="page-break-after:always"></hr><div><a id="s4FE0014CA34F51B9AA531DBEE26FF435"></a></div><div><br/></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">FORWARD-LOOKING INFORMATION AND FACTORS THAT MAY AFFECT FUTURE RESULTS</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">This report and other written or oral statements that we make from time to time contain forward-looking statements. Such forward-looking statements involve substantial risks and uncertainties. We have tried, wherever possible, to identify such statements by using words such as &#8220;will,&#8221; &#8220;may,&#8221; &#8220;could,&#8221; &#8220;likely,&#8221; &#8220;ongoing,&#8221; &#8220;anticipate,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;project,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;believe,&#8221; &#8220;target,&#8221; &#8220;forecast,&#8221; &#8220;goal,&#8221; &#8220;objective,&#8221; &#8220;aim&#8221; and other words and terms of similar meaning or by using future dates in connection with any discussion of, among other things, our anticipated operating and financial performance, business plans and prospects, in-line products and product candidates, including anticipated regulatory submissions, data read-outs, approvals, performance, timing of exclusivity and potential benefits of Pfizer&#8217;s products and product candidates, strategic reviews, capital allocation, business-development plans, manufacturing and product supply and plans relating to share repurchases and dividends. In particular, these include statements relating to future actions, business plans and prospects, our acquisitions and other business development activities, the disposition of the HIS net assets, prospective products or product approvals, future performance or results of current and anticipated products, sales efforts, expenses, interest rates, foreign exchange rates, the outcome of contingencies, such as legal proceedings, plans relating to share repurchases and dividends, government regulation and financial results, including, in particular, the expected impact of the recent hurricanes in Puerto Rico set forth in the &#8220;Overview of Our Performance, Operating Environment, Strategy and Outlook&#8211;&#8211;Our Business&#8211;&#8211;Impact of Recent Hurricanes in Puerto Rico&#8221; section of this MD&amp;A, the anticipated progress in remediation efforts at certain of our Hospira manufacturing facilities set forth in the &#8220;Overview of Our Performance, Operating Environment, Strategy and Outlook&#8211;&#8211;Our Business&#8211;&#8211;Product Manufacturing&#8221; section of this MD&amp;A, the anticipated timeframe for any decision regarding strategic alternatives for Pfizer Consumer Healthcare set forth in the &#8220;Overview of Our Performance, Operating Environment, Strategy and Outlook&#8211;&#8211;Our Strategy&#8211;&#8211;Our Business Development Initiatives&#8221; section of this MD&amp;A, our anticipated liquidity position set forth in the &#8220;Overview of Our Performance, Operating Environment, Strategy and Outlook&#8211;&#8211;The Global Economic Environment&#8221; and the &#8220;Analysis of Financial Condition, Liquidity and Capital Resources&#8221; sections of this MD&amp;A, the financial guidance set forth in the &#8220;Our Financial Guidance for </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;">&#8221; section of this MD&amp;A, the anticipated costs and cost savings, including from our acquisition of Hospira and our cost-reduction/productivity initiatives set forth in the &#8220;Costs and Expenses&#8211;&#8211;Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives&#8221; section of this MD&amp;A and in Notes to Condensed Consolidated Financial Statements&#8211;&#8211;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 3. </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">, </span><span style="font-family:inherit;font-size:10pt;">the benefits expected from our business development transactions, the anticipated product performance set forth in &#8220;Revenues and Product Developments</span><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span><span style="font-family:inherit;font-size:10pt;">Revenues</span><span style="font-family:inherit;font-size:9.5pt;">&#8212;</span><span style="font-family:inherit;font-size:10pt;">Selected Product Discussion&#8221; of this MD&amp;A and the contributions that we expect to make from our general assets to our pension and postretirement plans during </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;"> set forth in Notes to Condensed Consolidated Financial Statements&#8211;&#8211;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 10. </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Pension and Postretirement Benefit Plans</span><span style="font-family:inherit;font-size:10pt;">. Among the factors that could cause actual results to differ materially from past results and future plans and projected future results are the following:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the outcome of research and development activities including, without limitation, the ability to meet anticipated pre-clinical and clinical trial commencement and completion dates, regulatory submission and approval dates, and launch dates for product candidates, as well as the possibility of unfavorable pre-clinical and clinical trial results, including unfavorable new clinical data and additional analyses of existing clinical data;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">decisions by regulatory authorities regarding whether and when to approve our drug applications, which will depend on the assessment by such regulatory authorities of the benefit-risk profile suggested by the totality of the efficacy and safety information submitted; decisions by regulatory authorities regarding labeling, ingredients and other matters that could affect the availability or commercial potential of our products; and uncertainties regarding our ability to address the comments in complete response letters received by us with respect to certain of our drug applications to the satisfaction of the FDA;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the speed with which regulatory authorizations, pricing approvals and product launches may be achieved;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the outcome of post-approval clinical trials, which could result in the loss of marketing approval for a product or changes in the labeling for, and/or increased or new concerns about the safety or efficacy of, a product that could affect its availability or commercial potential;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">risks associated with preliminary, early stage or interim data, including the risk that final results of studies for which preliminary, early stage or interim data have been provided and/or additional clinical trials may be different from (including less favorable than) the preliminary, early stage or interim data results and may not support further clinical development of the applicable product candidate or indication;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the success of external business-development activities, including the ability to satisfy the conditions to closing of announced transactions in the anticipated time frame or at all or to realize the anticipated benefits of such transactions;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">competitive developments, including the impact on our competitive position of new product entrants, in-line branded products, generic products, private label products, biosimilars and product candidates that treat diseases and conditions similar to those treated by our in-line drugs and drug candidates;</span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">102</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the implementation by the FDA and regulatory authorities in certain other countries of an abbreviated legal pathway to approve biosimilar products, which could subject our biologic products to competition from biosimilar products, with attendant competitive pressures, after the expiration of any applicable exclusivity period and patent rights;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">risks related to our ability to develop and launch biosimilars, including risks associated with &#8220;at risk&#8221; launches, defined as the marketing of a product by Pfizer before the final resolution of litigation (including any appeals) brought by a third party alleging that such marketing would infringe one or more patents owned or controlled by the third party;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the ability to meet competition from generic, branded and biosimilar products after the loss or expiration of patent protection for our products or competitor products;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the ability to successfully market both new and existing products domestically and internationally;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">difficulties or delays in manufacturing, including delays caused by natural events, such as hurricanes; supply shortages at our facilities; and legal or regulatory actions, such as warning letters, suspension of manufacturing, seizure of product, injunctions or voluntary recall of a product;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">trade buying patterns;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the impact of existing and future legislation and regulatory provisions on product exclusivity;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">trends toward managed care and healthcare cost containment, and our ability to obtain or maintain timely or adequate pricing or formulary placement for our products;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the impact of any significant spending reductions or cost controls affecting Medicare, Medicaid or other publicly funded or subsidized health programs or changes in the tax treatment of employer-sponsored health insurance that may be implemented, and/or any significant additional taxes or fees that may be imposed on the pharmaceutical industry as part of any broad deficit-reduction effort;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><span style="font-family:inherit;font-size:10pt;">&#8226; </span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the impact of any U.S. healthcare reform or legislation, including any repeal, substantial modification or invalidation of any or all of the provisions of the U.S. Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><span style="font-family:inherit;font-size:10pt;">&#8226; </span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. federal or state legislation or regulatory action and/or policy efforts affecting, among other things, pharmaceutical product pricing, reimbursement or access, including under Medicaid, Medicare and other publicly funded or subsidized health programs; patient out-of-pocket costs for medicines, manufacturer prices and/or price increases that could result in new mandatory rebates and discounts or other pricing restrictions; the importation of prescription drugs from outside the U.S. at prices that are regulated by governments of various foreign countries; restrictions on direct-to-consumer advertising; limitations on interactions with healthcare professionals; or the use of comparative effectiveness methodologies that could be implemented in a manner that focuses primarily on the cost differences and minimizes the therapeutic differences among pharmaceutical products and restricts access to innovative medicines; as well as pricing pressures for our products as a result of highly competitive insurance markets;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">legislation or regulatory action in markets outside the U.S. affecting pharmaceutical product pricing, reimbursement or access, including, in particular, continued government-mandated reductions in prices and access restrictions for certain biopharmaceutical products to control costs in those markets;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the exposure of our operations outside the U.S. to possible capital and exchange controls, expropriation and other restrictive government actions, changes in intellectual property legal protections and remedies, as well as political unrest, unstable governments and legal systems and inter-governmental disputes;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">contingencies related to actual or alleged environmental contamination;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">claims and concerns that may arise regarding the safety or efficacy of in-line products and product candidates;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">any significant breakdown, infiltration or interruption of our information technology systems and infrastructure;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">legal defense costs, insurance expenses and settlement costs;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the risk of an adverse decision or settlement and the adequacy of reserves related to legal proceedings, including patent litigation, product liability and other product-related litigation, including personal injury, consumer, off-label promotion, securities, antitrust and breach of contract claims, commercial, environmental, government investigations, employment and other legal proceedings, including various means for resolving asbestos litigation, as well as tax issues;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our ability to protect our patents and other intellectual property, both domestically and internationally;</span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">103</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">interest rate and foreign currency exchange rate fluctuations, including the impact of possible currency devaluations in countries experiencing high inflation rates and the volatility following the U.K. referendum in which voters approved the exit from the EU;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">governmental laws and regulations affecting domestic and foreign operations, including, without limitation, tax obligations and changes affecting the tax treatment by the U.S. of income earned outside the U.S. that may result from pending and possible future proposals;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">any significant issues involving our largest wholesale distributors, which account for a substantial portion of our revenues;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the possible impact of the increased presence of counterfeit medicines in the pharmaceutical supply chain on our revenues and on patient confidence in the integrity of our medicines;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the end result of any negotiations between the U.K. government and the EU regarding the terms of the U.K.&#8217;s exit from the EU, which could have implications on our research, commercial and general business operations in the U.K. and the EU;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">any significant issues that may arise related to the outsourcing of certain operational and staff functions to third parties, including with regard to quality, timeliness and compliance with applicable legal requirements and industry standards;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">any significant issues that may arise related to our joint ventures and other third-party business arrangements;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">changes in U.S. generally accepted accounting principles;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">changes in interpretations of existing laws and regulations, or changes in laws and regulations, in the U.S. and other countries;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">uncertainties related to general economic, political, business, industry, regulatory and market conditions including, without limitation, uncertainties related to the impact on us, our customers, suppliers and lenders and counterparties to our foreign-exchange and interest-rate agreements of challenging global economic conditions and recent and possible future changes in global financial markets; and the related risk that our allowance for doubtful accounts may not be adequate;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">any changes in business, political and economic conditions due to actual or threatened terrorist activity in the U.S. and other parts of the world, and related U.S. military action overseas;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">growth in costs and expenses;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">changes in our product, segment and geographic mix; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the impact of purchase accounting adjustments, acquisition-related costs, discontinued operations and certain significant items;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the impact of acquisitions, divestitures, restructurings, internal reorganizations, product recalls, withdrawals and other unusual items, including our ability to realize the projected benefits of our cost-reduction and productivity initiatives and of the internal separation of our commercial operations into our current operating structure;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the risk of an impairment charge related to our intangible assets, goodwill or equity-method investments; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">risks related to internal control over financial reporting; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">risks and uncertainties related to our acquisitions of Hospira, Anacor, Medivation and AstraZeneca&#8217;s small molecule anti-infectives business, including, among other things, the ability to realize the anticipated benefits of those acquisitions, including the possibility that expected cost savings related to the acquisition of Hospira and accretion related to the acquisitions of Hospira, Anacor and Medivation will not be realized or will not be realized within the expected time frame; the risk that the businesses will not be integrated successfully; disruption from the transactions making it more difficult to maintain business and operational relationships; risks related to our ability to grow revenues for Xtandi and expand Xtandi into the non-metastatic castration-resistant prostate cancer setting; significant transaction costs; and unknown liabilities; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">risks and uncertainties related to our evaluation of strategic alternatives for our Consumer Healthcare business, including, among other things, the ability to realize the anticipated benefits of any strategic alternatives we may pursue for our Consumer Healthcare business, including the potential for disruption to our business resulting from the evaluation of strategic alternatives for&#160;Pfizer Consumer Healthcare; the possibility that we may not be able to realize a higher value for Pfizer Consumer Healthcare through strategic alternatives; and unknown liabilities.</span></div></td></tr></table><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We cannot guarantee that any forward-looking statement will be realized. Achievement of anticipated results is subject to substantial risks, uncertainties and inaccurate assumptions. Should known or unknown risks or uncertainties materialize or should underlying assumptions prove inaccurate, actual results could vary materially from past results </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">104</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">and those anticipated, estimated or projected. Investors should bear this in mind as they consider forward-looking statements, and are cautioned not to put undue reliance on forward-looking statements.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We undertake no obligation to publicly update forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law or by the rules and regulations of the SEC. You are advised, however, to consult any further disclosures we make on related subjects.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;"> Form 10-K listed various important factors that could cause actual results to differ materially from past and projected future results. We note these factors for investors as permitted by the Private Securities Litigation Reform Act of 1995. Readers can find them in Part I, Item 1A, of that filing under the heading &#8220;Risk Factors.&#8221; We incorporate that section of that Form 10-K in this filing and investors should refer to it. Reference is also made to Part II, Item 1A, &#8220;Risk Factors,&#8221; of this Quarterly Report on Form 10-Q. You should understand that it is not possible to predict or identify all such factors. Consequently, you should not consider any such list to be a complete set of all potential risks or uncertainties.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The operating segment information provided in this report does not purport to represent the revenues, costs and income from continuing operations before provision for taxes on income that each of our operating segments would have recorded had each segment operated as a standalone company during the periods presented.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">This report includes discussion of certain clinical studies relating to various in-line products and/or product candidates. These studies typically are part of a larger body of clinical data relating to such products or product candidates, and the discussion herein should be considered in the context of the larger body of data. In addition, clinical trial data are subject to differing interpretations, and, even when we view data as sufficient to support the safety and/or effectiveness of a product candidate or a new indication for an in-line product, regulatory authorities may not share our views and may require additional data or may deny approval altogether.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Legal Proceedings and Contingencies</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Information with respect to legal proceedings and contingencies required by this Item is incorporated herein by reference to Notes to Condensed Consolidated Financial Statements&#8211;&#8211;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 12A. Commitments and Contingencies: Legal Proceedings</span><span style="font-family:inherit;font-size:10pt;"> in Part I, Item 1, of this Quarterly Report on Form 10-Q.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">105</span></div></div><hr style="page-break-after:always"></hr><div><a id="s8F22DA2CBD7352A69CCB49539CAA6159"></a></div><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 3. Quantitative and Qualitative Disclosures About Market Risk</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Information required by this item is incorporated by reference from the discussion under the heading </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Risk Management</span><span style="font-family:inherit;font-size:10pt;"> in our </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;"> Financial Report.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div><a id="sD57E469ACE1751329298989E953E1D78"></a></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 4. Controls and Procedures</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of the end of the period covered by this report, we carried out an evaluation, under the supervision and with the participation of our principal executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act). Based on this evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures are effective in alerting them in a timely manner to material information required to be disclosed in our periodic reports filed with the SEC.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During our most recent fiscal quarter, there has not been any change in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">106</span></div></div><hr style="page-break-after:always"></hr><div><a id="s3E17EA6CCF6D5C8599D35A23A2E42CF0"></a></div><div><br/></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">PART II - OTHER INFORMATION</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div><a id="s7D8D764240E153EABA1C0A53152A2988"></a></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 1. Legal Proceedings</span></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The information required by this Item is incorporated herein by reference to Notes to Condensed Consolidated Financial Statements&#8211;&#8211;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 12A. Commitments and Contingencies: Legal Proceedings</span><span style="font-family:inherit;font-size:10pt;"> in Part I, Item 1, of this Quarterly Report on Form 10-Q.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Tax Matters</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Additional information with respect to tax matters required by this Item is incorporated herein by reference to Notes to Condensed Consolidated Financial Statements&#8211;&#8211;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 5B. Tax Matters: Tax Contingencies</span><span style="font-family:inherit;font-size:10pt;"> in Part I, Item 1, of this Quarterly Report on Form 10-Q.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We account for income tax contingencies using a benefit recognition model. If our initial assessment fails to result in the recognition of a tax benefit, we regularly monitor our position and subsequently recognize the tax benefit: (i) if there are changes in tax law, analogous case law or there is new information that sufficiently raise the likelihood of prevailing on the technical merits of the position to &#8220;more likely than not&#8221;; (ii) if the statute of limitations expires; or (iii) if there is a completion of an audit resulting in a favorable settlement of that tax year with the appropriate agency. We regularly re-evaluate our tax positions based on the results of audits of federal, state and foreign income tax filings, statute of limitations expirations, changes in tax law or receipt of new information that would either increase or decrease the technical merits of a position relative to the &#8220;more-likely-than-not&#8221; standard.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our assessments are based on estimates and assumptions that have been deemed reasonable by management, but our estimates of unrecognized tax benefits and potential tax benefits may not be representative of actual outcomes, and variation from such estimates could materially affect our financial statements in the period of settlement or when the statutes of limitations expire, as we treat these events as discrete items in the period of resolution. Finalizing audits with the relevant taxing authorities can include formal administrative and legal proceedings, and, as a result, it is difficult to estimate the timing and range of possible changes related to our uncertain tax positions, and such changes could be significant.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div><a id="s7F59FFC53D9E574E98AFB09E1B19A9A1"></a></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 1A. Risk Factors</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The &#8220;Our Operating Environment&#8221; and &#8220;Forward-Looking Information and Factors That May Affect Future Results&#8221; sections of the MD&amp;A of this Quarterly Report on Form 10-Q and Part I, Item 1A, &#8220;Risk Factors&#8221; of our </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;"> Form 10-K are incorporated by reference herein. We are including the following revised risk factor, which updates and supersedes the corresponding risk factor disclosed in our 2016 Form 10-K, and should be read in conjunction with our description of&#160;risk factors&#160;in Part I, Item 1A, &#8220;Risk Factors&#8221; of our 2016 Form 10-K:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">PRODUCT MANUFACTURING AND MARKETING RISKS</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Difficulties or delays in product manufacturing or marketing could affect future results through regulatory actions, shut-downs, approval delays, withdrawals, recalls, penalties, supply disruptions or shortages, reputational harm, product liability, unanticipated costs or otherwise. Examples of such difficulties or delays include, but are not limited to, the inability to increase production capacity commensurate with demand; the failure to predict market demand for, or to gain market acceptance of, approved products; the possibility that the supply of incoming materials may be delayed or become unavailable and that the quality of incoming materials may be substandard and not detected; the possibility that we may fail to maintain appropriate quality standards throughout the internal and external supply network and/or comply with cGMPs and other applicable regulations such as serialization (which allows for track and trace of products in the supply chain to enhance patient safety); risks to supply chain continuity as a result of natural or man-made disasters at our facilities or at a supplier or vendor, including those that may be related to climate change; or failure to maintain the integrity of our supply chains against intentional and criminal acts such as economic adulteration, product diversion, product theft, and counterfeit goods.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Regulatory agencies periodically inspect our drug manufacturing facilities to ensure compliance with applicable cGMP requirements. Failure to comply with these requirements may subject us to possible legal or regulatory actions, such as warning letters, suspension of manufacturing, seizure of product, injunctions or voluntary recall of a product, any of which could have a material adverse effect on our business, financial condition and results of operations. In February 2017, we received a warning letter from the FDA communicating the FDA&#8217;s view that certain violations of cGMP regulations exist at Hospira&#8217;s manufacturing facility in McPherson, Kansas. We are undertaking corrective actions to address the concerns raised by the FDA. Communication with the FDA is ongoing. Until the violations are corrected and confirmed by the FDA, the FDA may refuse to </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">107</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">grant premarket approval applications and/or the FDA may refuse to grant export certificates related to products manufactured at McPherson, Kansas. In addition, in September 2017, Meridian, a subsidiary of Pfizer Inc., received a warning letter from the FDA asserting the FDA&#8217;s view that certain violations of cGMP and Quality System Regulations exist at Meridian&#8217;s manufacturing sites in St. Louis, Missouri. We are undertaking corrective actions to address the concerns raised by the FDA, and communication with the FDA is ongoing. Until the violations are corrected and confirmed by the FDA, the FDA may refuse to grant premarket approval of applications and/or the FDA may refuse to grant export certificates related to products manufactured at St. Louis, Missouri.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">108</span></div></div><hr style="page-break-after:always"></hr><div><a id="s4C54D740F2515D01973B8D0F0C2D288C"></a></div><div><br/></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides certain information with respect to our purchases of shares of the Company&#8217;s common stock during the </span><span style="font-family:inherit;font-size:10pt;">third</span><span style="font-family:inherit;font-size:10pt;"> fiscal quarter of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Issuer Purchases of Equity Securities</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup>&#160;</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"></td></tr><tr><td style="width:28%;"></td><td style="width:1%;"></td><td style="width:17%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Total Number of</span></div><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Shares Purchased</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(b)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Average Price</span></div><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Paid per Share</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(b)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Total Number of Shares Purchased as Part of Publicly Announced Plan</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Approximate Dollar Value of Shares That May Yet Be Purchased Under the Plan</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">July 3, 2017 through July 30, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">12,102</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">33.46</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">6,355,862,076</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">July 31, 2017 through August 27, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">51,568</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">33.03</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">6,355,862,076</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">August 28, 2017 through October 1, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">33,579</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">34.06</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">6,355,862,076</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">97,249</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">33.44</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Our October 2014 $11 billion share-purchase plan was exhausted in the first quarter of </span><span style="font-family:inherit;font-size:9pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:9pt;">. In December 2015, the Board of Directors authorized an $11 billion share repurchase program, and share repurchases commenced thereunder in the first quarter of </span><span style="font-family:inherit;font-size:9pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:9pt;">. On February 2, 2017, we entered into an accelerated share repurchase agreement with Citibank to repurchase </span><span style="font-family:inherit;font-size:9pt;">$5 billion</span><span style="font-family:inherit;font-size:9pt;"> of our common stock. Pursuant to the terms of the agreement, on February 6, 2017, we paid </span><span style="font-family:inherit;font-size:9pt;">$5 billion</span><span style="font-family:inherit;font-size:9pt;"> to Citibank and received an initial delivery of approximately </span><span style="font-family:inherit;font-size:9pt;">126 million</span><span style="font-family:inherit;font-size:9pt;"> shares of our common stock from Citibank at a price of </span><span style="font-family:inherit;font-size:9pt;">$31.73</span><span style="font-family:inherit;font-size:9pt;"> per share, which represented, based on the closing price of our common stock on the NYSE on February 2, 2017, approximately </span><span style="font-family:inherit;font-size:9pt;">80%</span><span style="font-family:inherit;font-size:9pt;"> of the notional amount of the accelerated share repurchase agreement. On May 16, 2017, the accelerated share repurchase agreement with Citibank was completed, which, per the terms of the agreement, resulted in Citibank owing us a certain number of shares of Pfizer common stock. Pursuant to the agreement&#8217;s settlement terms, we received an additional </span><span style="font-family:inherit;font-size:9pt;">24 million</span><span style="font-family:inherit;font-size:9pt;"> shares of our common stock from Citibank on May 19, 2017. The average price paid for all of the shares delivered under the accelerated share repurchase agreement was </span><span style="font-family:inherit;font-size:9pt;">$33.31</span><span style="font-family:inherit;font-size:9pt;"> per share. The common stock received is included in </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Treasury Stock</span><span style="font-family:inherit;font-size:9pt;">. This agreement was entered into pursuant to our previously announced share repurchase authorization. At </span><span style="font-family:inherit;font-size:9pt;">October&#160;1, 2017</span><span style="font-family:inherit;font-size:9pt;">, our remaining share-purchase authorization was approximately </span><span style="font-family:inherit;font-size:9pt;">$6.4 billion</span><span style="font-family:inherit;font-size:9pt;">. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">These columns reflect the following transactions during the </span><span style="font-family:inherit;font-size:9pt;">third</span><span style="font-family:inherit;font-size:9pt;"> fiscal quarter of </span><span style="font-family:inherit;font-size:9pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:9pt;">: (i) the surrender to Pfizer of </span><span style="font-family:inherit;font-size:9pt;">91,487</span><span style="font-family:inherit;font-size:9pt;"> shares of common stock to satisfy tax withholding obligations in connection with the vesting of restricted stock units issued to employees; (ii) the surrender to Pfizer of </span><span style="font-family:inherit;font-size:9pt;">100</span><span style="font-family:inherit;font-size:9pt;"> shares of common stock to satisfy tax withholding obligations in connection with the vesting of performance share awards issued to employees; (iii) the surrender of </span><span style="font-family:inherit;font-size:9pt;">16</span><span style="font-family:inherit;font-size:9pt;"> shares of common stock to satisfy withholding obligations in connection with the settlement of total shareholder return units; and (iv) the open market purchase by the trustee of </span><span style="font-family:inherit;font-size:9pt;">5,646</span><span style="font-family:inherit;font-size:9pt;"> shares of common stock in connection with the reinvestment of dividends paid on common stock held in trust for employees who were granted performance share awards and who deferred receipt of such awards.</span></div></td></tr></table><div><a id="s9ACC93F8BE425B2691CA44B4708B566D"></a></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 3. Defaults Upon Senior Securities</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">None.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div><a id="s8590669D342655F38A3D40B8C29F8684"></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 4. Mine Safety Disclosures</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Not applicable.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div><a id="s944496463A7A5DB293865996B693472F"></a></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 5. Other Information</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">None.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">109</span></div></div><hr style="page-break-after:always"></hr><div><a id="sEECE8FA2C6E45735BCCB066FA94102FF"></a></div><div><br/></div><div style="line-height:120%;text-align:left;-sec-extract:summary;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 6. Exhibits</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:3%;"></td><td style="width:16%;"></td><td style="width:4%;"></td><td style="width:77%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="pfe-10012017x10qexhibit101.htm"><span style="font-family:inherit;font-size:10pt;">Exhibit 10.1</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amendment No. 1 to the Pfizer Supplemental Savings Plan</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="pfe-10012017x10qexhibit102.htm"><span style="font-family:inherit;font-size:10pt;">Exhibit 10.2</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pfizer Inc. Global Performance Plan</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="pfe-10012017x10qexhibit12.htm"><span style="font-family:inherit;font-size:10pt;">Exhibit 12</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Computation of Ratio of Earnings to Fixed Charges.</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="pfe-10012017x10qexhibit15.htm"><span style="font-family:inherit;font-size:10pt;">Exhibit 15</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accountants&#8217; Acknowledgment.</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="pfe-10012017x10qexhibit311.htm"><span style="font-family:inherit;font-size:10pt;">Exhibit 31.1</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certification by the Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="pfe-10012017x10qexhibit312.htm"><span style="font-family:inherit;font-size:10pt;">Exhibit 31.2</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certification by the Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="pfe-10012017x10qexhibit321.htm"><span style="font-family:inherit;font-size:10pt;">Exhibit 32.1</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certification by the Chief Executive Officer Pursuant to 18 U.S.C. Section</span></div><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="pfe-10012017x10qexhibit322.htm"><span style="font-family:inherit;font-size:10pt;">Exhibit 32.2</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certification by the Chief Financial Officer Pursuant to 18 U.S.C. Section</span></div><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exhibit 101:</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">EX-101.INS</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">EX-101.SCH</span></div><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">EX-101.CAL</span></div><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">EX-101.LAB</span></div><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">EX-101.PRE</span></div><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">EX-101.DEF</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">XBRL Taxonomy Extension Schema</span></div><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">XBRL Taxonomy Extension Calculation Linkbase</span></div><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">XBRL Taxonomy Extension Label Linkbase</span></div><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">XBRL Taxonomy Extension Presentation Linkbase</span></div><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">XBRL Taxonomy Extension Definition Document</span></div></td></tr></table></div></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">110</span></div></div><hr style="page-break-after:always"></hr><div><a id="sAFDA09B40DEA565995605E22D7135077"></a></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">SIGNATURE</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. </span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:6%;"></td><td style="width:42%;"></td><td style="width:52%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pfizer Inc.</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Registrant)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Dated:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">November&#160;9, 2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">/s/ Loretta V. Cangialosi</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Loretta V. Cangialosi, Senior Vice President and</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Controller</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Principal Accounting Officer and</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Duly Authorized Officer)</span></div></td></tr></table></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">111</span></div></div>	</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>pfe-10012017x10qexhibit101.htm
<DESCRIPTION>AMENDMENT NO. 1 TO THE PFIZER SUPPLEMENTAL SAVINGS PLAN
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s7217621858ED402A1469553C14BA067F"></a></div><div></div><div><br></div><div style="line-height:144%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXHIBIT 10.1</font></div><div style="line-height:138%;padding-bottom:13px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Amendment No. 1 to the</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Pfizer Supplemental Savings Plan (the &#8220;PSSP&#8221;)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Amended and Restated as of January 1, 2016)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">*     *     *</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;">(New material underlined twice; deletions crossed out)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Section 6.6 is amended to read as follows:</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.6&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Distributions upon Death</font><font style="font-family:inherit;font-size:10pt;">. Notwithstanding any elected Payment Option or deemed elected Payment Option made (or deemed made) by the Member, if a Member dies before distribution of his or her Account balance has begun, any remaining balance shall be distributed in a lump sum payment to the Member&#8217;s Beneficiary the January following the calendar year in which the Member&#8217;s death occurs. The immediately preceding sentence also applies with respect to amounts accrued under the Pharmacia Savings Plus Plan (as adjusted for earnings and losses) other than Grandfathered Amounts under that plan. </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">In addition, any Active Death Benefit SERP Transfer shall be distributed in a lump sum payment to the Member&#8217;s Beneficiary the January following the calendar year in which the Member&#8217;s death occurs; provided, however, that if the Active Death Benefit SERP Transfer to the Plan occurs after the January following the calendar year in which the Member&#8217;s death occurs, such amount shall be distributed immediately. Notwithstanding any of the foregoing, the entire Account balance shall be distributed no later than the December 31 of the year following the Member&#8217;s date of death.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">New Appendix D is added to read as follows:</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">APPENDIX D</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">SPECIAL PROVISIONS APPLICABLE TO ANACOR PHARMACEUTICALS, INC., LEGACY EMPLOYEES</font></div><div style="line-height:120%;text-align:justify;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Effective as of the &#8220;Closing Date&#8221; as defined pursuant to the certain Agreement and Plan of Merger, dated May 14, 2016, by and between Anacor Pharmaceuticals, Inc., Pfizer Inc., and Quattro Merger Sub, Inc., a wholly-owned subsidiary of Pfizer, (the &#8220;Merger Agreement&#8221;), providing for a tender offer by the Merger Sub followed by which the Merger Sub was merged with and into the Company with the Company remaining as the surviving corporation (the &#8220;Merger&#8221;) on the &#8220;Closing Date&#8221; as defined in the Merger Agreement, Anacor Pharmaceuticals, Inc. was acquired by Pfizer. This Article XXIX sets out the additional provisions that apply to certain participants in the PSP who were employees employed by Anacor in the United States immediately prior to the Closing Date (the &#8220;Legacy Anacor Employees&#8221;):</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Legacy Anacor Employees active on September 1, 2017 shall be eligible to participate in the Plan on and after September 1, 2017.  Rules for the crediting of years of service for Legacy Anacor Employees are set forth in the Qualified Plan in Article XXIX. </font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">The definition of Regular Earnings under the Plan shall have the meaning as set forth in the Qualified Plan, except that for clarification purposes, with respect to Legacy Anacor Employees who are eligible to defer their bonus under the Pfizer Deferred Compensation Plan, the limitations on the definition of Regular Earnings for any Legacy Anacor Employee set forth in Article XXIX of the Qualified Plan shall also include any deferred bonuses.</font></div></td></tr></table><div><br></div><div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>pfe-10012017x10qexhibit102.htm
<DESCRIPTION>PFIZER INC. GLOBAL PERFORMANCE PLAN
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sC28A46114686B94CF6A75A48450B1B10"></a></div><div></div><div><br></div><div style="line-height:144%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXHIBIT 10.2</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Pfizer Inc. Global Performance Plan</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">SECTION 1. PURPOSE </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The purpose of the Pfizer Inc. Global Performance Plan (the &#8220;GPP&#8221; or the &#8220;Plan&#8221;) is to foster a culture where colleagues are committed to, and focused on, high performance. The GPP is designed to attract, motivate, and engage a high-performing, committed workforce that contributes to the achievement of the Company&#8217;s annual financial and strategic and operational goals. The Plan is restated effective April 1, 2017. Awards under this GPP made to certain eligible employees who are otherwise eligible for awards under the Company&#8217;s Executive Annual Incentive Plan (&#8220;EAIP&#8221;) shall be subject to additional terms and conditions as set forth in the EAIP to ensure such awards are considered &#8220;performance-based&#8221; under Section 162(m) of the Internal Revenue Code of 1986, as amended.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">SECTION 2. DEFINITIONS </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As used in the Plan, the following terms shall have the meanings set forth below: </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:17px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8220;Affiliate&#8221; shall mean (i) any Person that directly, or through one or more intermediaries, controls, or is controlled by, or is under common control with, the Company or (ii) any entity in which the Company has a significant equity interest, as determined by the Committee, and (iii) the employees of such entity or Person are eligible to participate in the Plan, as determined by the Committee.   </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:17px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8220;Award&#8221; shall mean any cash incentive award granted pursuant to the provisions of the Plan.   </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:17px;"><font style="font-family:inherit;font-size:10pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8220;Board&#8221; shall mean the Board of Directors of the Company.   </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:17px;"><font style="font-family:inherit;font-size:10pt;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8220;Cause&#8221; shall include, but not be limited to, a termination of employment for significant breach of Company policy, inadequate work performance due to intentional or deliberate misconduct or intentional or deliberate failure to act, destruction of Company property, commission of unlawful acts against or reflecting on the Company, or similar occurrences. The Committee, or its designee, the Executive Vice President of Worldwide Human Resources or the Senior Vice President, Total Rewards, or its or his or her respective successors, in its or his or her sole and absolute discretion, shall determine whether a termination of employment is for &#8220;Cause.&#8221;  </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:17px;"><font style="font-family:inherit;font-size:10pt;">(e)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8220;CEO&#8221; shall mean the Chief Executive Officer of the Company.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:17px;"><font style="font-family:inherit;font-size:10pt;">(f)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8220;Code&#8221; shall mean the Internal Revenue Code of 1986, as amended from time to time.   </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:17px;"><font style="font-family:inherit;font-size:10pt;">(g)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8220;Committee&#8221; shall mean the Compensation Committee of the Board or such other persons or committee to whom it has delegated any authority, as may be appropriate.   </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:17px;"><font style="font-family:inherit;font-size:10pt;">(h)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8220;Company&#8221; shall mean Pfizer Inc., a Delaware corporation.   </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:17px;"><font style="font-family:inherit;font-size:10pt;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8220;EAIP&#8221; shall mean the Pfizer Inc. Executive Annual Incentive Plan. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:17px;"><font style="font-family:inherit;font-size:10pt;">(j)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8220;Eligible Earnings&#8221; shall mean:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">1)</font></div></td><td style="vertical-align:top;padding-left:48px;"><div style="line-height:120%;text-align:justify;font-size:10pt;text-indent:-48px;"><font style="font-family:inherit;font-size:10pt;">For Group 1 Countries: a Participant&#8217;s daily earnings (as well as any lump-sum payment made in lieu of a merit increase) adjusted for any portion of the year in which the Participant was not eligible for the Plan. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">2)</font></div></td><td style="vertical-align:top;padding-left:48px;"><div style="line-height:120%;text-align:justify;font-size:10pt;text-indent:-48px;"><font style="font-family:inherit;font-size:10pt;">For Group 2 Countries: a Participant&#8217;s base salary as of the immediately preceding December 31</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">st</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;unless there is a change in status as a full-time or part-time Employee.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">3)</font></div></td><td style="vertical-align:top;padding-left:48px;"><div style="line-height:120%;text-align:justify;font-size:10pt;text-indent:-48px;"><font style="font-family:inherit;font-size:10pt;">For Participants in the ELTI Program: a Participant&#8217;s local base salary midpoint for each month over the course of the Performance Period adjusted for any portion of the year in which the Participant was not eligible under the Plan, or to reflect a change in salary grade.  </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For Participants located in the United States, &#8220;Eligible Earnings&#8221; shall not include the following: incentive payments or other special payments (e.g., special recognition awards, discretionary awards, etc.), imputed income for life insurance and other Company-paid or subsidized benefits and perquisites, income from long-term incentive awards, reimbursed relocation expenses, relocation allowances, COLA payments or any allowance related to a global assignment, reimbursements or payments that are not pay for services (e.g., automobile and other forms of allowances), separation payments, short-term disability payments in excess of 90 days of each unrelated disability, payments in excess of the first 90 days of a continuous approved paid leave, long-term disability payments, workers&#8217; compensation payments and/or any similar payments that are generally not deemed base salary.</font></div><div style="line-height:120%;text-align:justify;padding-left:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For Participants outside the United States, Eligible Earnings will be determined based on the local competitive practices and/or regulatory requirements of the Participant&#8217;s location, but are generally limited to regular base salary.</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:17px;"><font style="font-family:inherit;font-size:10pt;">(k)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8220;ELTI Program&#8221; shall mean the Company&#8217;s Executive Long-Term Incentive Program.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:17px;"><font style="font-family:inherit;font-size:10pt;">(l)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8220;Employee&#8221; shall mean any employee of the Company or any Affiliate. For any and all purposes under this Plan, the term &#8220;Employee&#8221; shall not include a person hired as an independent contractor, leased employee, consultant or a person otherwise </font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-left:48px;text-align:justify;"><font style="font-family:inherit;font-size:10pt;">designated by the Committee, the Company or an Affiliate at the time of hire as not eligible to participate in or receive benefits under the Plan or not on the payroll, even if such ineligible person is subsequently determined to be a common law employee of the Company or an Affiliate or otherwise an employee by any governmental or judicial authority. Unless otherwise determined by the Committee in its sole discretion, for purposes of the Plan, an Employee shall be considered to have terminated employment or services and to have ceased to be an Employee if his or her employer ceases to be an Affiliate, even if he or she continues to be employed by such employer.   </font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:17px;"><font style="font-family:inherit;font-size:10pt;">(m)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8220;Exchange Act&#8221; shall mean the Securities Exchange Act of 1934, as amended.   </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:17px;"><font style="font-family:inherit;font-size:10pt;">(n)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8220;Executive Leadership Team&#8221; shall mean the team of executives of the Company reporting directly to the CEO of the Company, and including the CEO.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:17px;"><font style="font-family:inherit;font-size:10pt;">(o)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8220;Group 1 and Group 2 Countries&#8221; shall mean the countries as set forth in Appendix A hereto.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:17px;"><font style="font-family:inherit;font-size:10pt;">(p)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8220;IFW&#8221; shall mean an Incident Final Warning issued by the Company or an Affiliate to the Employee.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:17px;"><font style="font-family:inherit;font-size:10pt;">(q)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8220;Incentive Pool&#8221; shall mean the fund underlying the Plan from which payment of Awards are made.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:17px;"><font style="font-family:inherit;font-size:10pt;">(r)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8220;Incentive Award Opportunity&#8221; shall mean the total potential cash compensation opportunity underlying an Award for a Performance Period ranging from zero to two times (0%-200%) a Participant&#8217;s Incentive Target Percentage. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:17px;"><font style="font-family:inherit;font-size:10pt;">(s)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8220;Incentive Target Percentage&#8221; shall mean the targeted level of compensation underlying an Award granted to a Participant for a Performance Period, expressed as a percentage of the Participant&#8217;s Eligible Earnings (for Participants in the ELTI Program, the local base salary midpoint earned during the Performance Period). </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:17px;"><font style="font-family:inherit;font-size:10pt;">(t)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8220;Incentive Target Amount&#8221; shall mean the targeted level of compensation underlying an Award granted to a Participant for a Performance Period, expressed as a fixed value.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:17px;"><font style="font-family:inherit;font-size:10pt;">(u)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8220;Involuntary Termination&#8221; shall mean a termination of an Employee&#8217;s employment with the Company or an Affiliate by the Company or Affiliate. For purposes of this Plan only, an Involuntary Termination shall include &#8220;Terminations Due to Curtailments or Cessations of Operations, Reorganizations, Position Eliminations, or Job Restructurings Due to a Change in Required Competencies or Qualification for Position&#8221; and terminations due to failure to return to work following the expiration of short-term disability benefits because either the employee remains physically or mentally unable to return to work or because his or her position is filled while he or she is on an approved disability leave of absence. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:17px;"><font style="font-family:inherit;font-size:10pt;">(v)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8220;Key Employee&#8221; means an Employee treated as a &#8220;specified employee&#8221; as of his or her Separation from Service under Code Section 409A(a)(2)(B)(i), i.e., a key employee (as defined in Code Section 416(i) without regard to paragraph (5) thereof) of the Company or its Affiliates if the Company&#8217;s stock is publicly traded on an established securities market or otherwise. Key Employees shall be determined under rules adopted by the Company in accordance with Section 409A. Notwithstanding the foregoing, the Executive Vice President, Worldwide Human Resources or the Senior Vice President, Total Rewards, or the successor or the designee of either, may, under the alternative permissible methods allowable under Section 409A, adopt an alternative identification and effective date for purposes of determining which employees are Key Employees. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:17px;"><font style="font-family:inherit;font-size:10pt;">(w)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8220;Participant&#8221; shall mean an Employee who is selected by the Committee or the Board from time to time in their sole discretion to receive an Award under the Plan.   </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:17px;"><font style="font-family:inherit;font-size:10pt;">(x)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8220;Performance Period&#8221; shall mean one calendar year during which any performance goals specified by the Committee with respect to any Awards to be granted under the Plan are to be measured.   </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:17px;"><font style="font-family:inherit;font-size:10pt;">(y)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8220;Performance-Related Termination&#8221; shall mean an involuntary termination of employment because the Employee does not meet the performance or other essential requirements of his or her job. The determination of whether the Employee&#8217;s termination is a Performance-Related Termination shall be made by the Executive Vice President, Worldwide Human Resources, or the Senior Vice President, Total Rewards, or his or her respective successors or the designee of either, in his or her sole and absolute discretion. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:17px;"><font style="font-family:inherit;font-size:10pt;">(z)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8220;Person&#8221; shall mean any individual, corporation, partnership, association, limited liability company, joint-stock company, trust, unincorporated organization or government or political subdivision thereof.   </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:17px;"><font style="font-family:inherit;font-size:10pt;">(aa)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8220;Retirement&#8221; shall mean having attained a minimum age of 55 and a minimum of 10 years of service at the time of a Participant&#8217;s separation from the Company, unless determined otherwise, and which shall also constitute a Separation from Service for United States Participants, or as determined under local law for all other Participants.  </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:18px;"><font style="font-family:inherit;font-size:10pt;">(bb)</font></div></td><td style="vertical-align:top;padding-left:30px;"><div style="line-height:120%;text-align:justify;font-size:10pt;text-indent:-30px;"><font style="font-family:inherit;font-size:10pt;">&#8220;Section 409A&#8221; shall mean Section 409A of the Code and the regulations and other guidance issued thereunder by the U.S. Treasury or Internal Revenue Service.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:18px;"><font style="font-family:inherit;font-size:10pt;">(cc)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8220;Senior Leadership Council&#8221; shall mean that group of executives designated by the Company as members of the Senior Leadership Council.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(dd)&#160;&#160;&#160;&#160; &#8220;Separation from Service&#8221; means a &#8220;separation from service&#8221; within the meaning of Section 409A. </font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:18px;"><font style="font-family:inherit;font-size:10pt;">(ee)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8220;Target Incentive Award&#8221; shall mean the targeted level of cash compensation underlying an Award granted to a Participant for a Performance Period, calculated in accordance with Section 5 of the Plan. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:18px;"><font style="font-family:inherit;font-size:10pt;">(ff)</font></div></td><td style="vertical-align:top;padding-left:36px;"><div style="line-height:120%;text-align:justify;font-size:10pt;text-indent:-36px;"><font style="font-family:inherit;font-size:10pt;">&#8220;Termination Due to Curtailments or Cessations of Operations, Reorganizations, Position Eliminations, or Job Restructurings Due to a Change in Required Competencies or Qualification for Position&#8221; shall mean an involuntary termination as the direct result of curtailment or cessation of operations, reorganization or position elimination, or job restructuring due to a change in required competencies or qualification for the position. The determination of whether a curtailment or cessation of operations, reorganization or position elimination, job restructuring or change in competencies or qualifications has occurred </font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">2</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-left:48px;text-align:justify;"><font style="font-family:inherit;font-size:10pt;">is the sole determination of the Executive Vice President, Worldwide Human Resources, or the Senior Vice President, Total Rewards, or his or her respective successors or the designee of either, in his or her sole and absolute discretion.</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:18px;"><font style="font-family:inherit;font-size:10pt;">(gg)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8220;Compliance Written Warning&#8221; shall mean a Written Warning Letter resulting from a Compliance investigation issued by the Company or an Affiliate to an Employee.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">SECTION 3. ADMINISTRATION </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Plan shall be administered by the Committee. The Committee shall have full power and authority (i) to establish the rules and regulations relating to the Plan and the terms and conditions and amounts of any individual Award, (ii) to interpret the Plan and those rules and regulations, (iii) to select Participants for the Plan, (iv) to determine each Participant&#8217;s Incentive Target Percentage or Incentive Target Amount, Target Incentive Award and Incentive Award Opportunity, performance goals and Awards, (v) to make all factual and other determinations in connection with the Plan, and (vi) to take all other actions necessary, advisable or appropriate for the proper administration of the Plan, including the delegation of such authority or power, where appropriate. The Committee may, in its sole and absolute discretion, and subject to the provisions of the Plan, from time to time delegate any or all of its authority to administer the Plan to any other persons or committee as it deems necessary or appropriate for the proper administration of the Plan, except that no such delegation shall be made in the case of Awards intended to be qualified under Section 162(m) of the Code.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All powers of the Committee or its delegate shall be executed in their sole and absolute discretion, in the best interest of the Company, not as a fiduciary, and in keeping with the objectives of the Plan and need not be uniform as to similarly-situated individuals. The decisions of the Committee or its delegate with respect to the administration of the Plan, including all such rules and regulations, interpretations, selections, determinations, approvals, decisions, delegations, amendments, terminations and other actions, shall be final and binding on the Company and all employees of the Company, including all Participants and their respective beneficiaries, except as otherwise provided by law.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Except as may be limited by the application of Section 162(m) of the Code to Awards granted to Employees eligible to participate in the EAIP in accordance with Section 4(b) of this Plan, the Committee shall be authorized to make adjustments in Awards and or the funding of the Incentive Pool in recognition of unusual or nonrecurring events affecting the Company or its financial statements including, but not limited to, acquisitions, divestitures or similar extraordinary events or changes in applicable laws, regulations, court rulings or accounting principles. The Committee may correct any defect, supply any omission or reconcile any inconsistency in the Plan or any Award in the manner and to the extent it shall deem desirable to carry it into effect. In the event that the Company shall assume outstanding employee benefit awards or the right or obligation to make future such awards in connection with the acquisition of or combination with another corporation or business entity, the Committee may, in its discretion, make such adjustments in the Awards or the Incentive Pool in accordance with the Plan as it shall deem appropriate. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">SECTION 4. ELIGIBILITY </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;padding-left:24px;"><div style="line-height:120%;text-align:justify;font-size:10pt;text-indent:-24px;"><font style="font-family:inherit;font-size:10pt;">Any Employee shall be eligible to be selected as a Participant; however, only those Employees identified as Participants by the Committee or its designee, with respect to a Performance Period shall participate in the Plan for such Performance Period. Any Employee newly hired by the Company after October 1 shall not become eligible to participate in the Plan until the January 1 immediately following his or her hire date, except as waived by the Committee or their designee in its or their sole and absolute discretion. An Employee may only participate in one annual cash incentive plan sponsored by the Company or any Affiliate with respect to a Performance Period. As such, any Employee who is a participant in a sales incentive program or another cash incentive plan with respect to a Performance Period is not eligible to participate in the Plan.  </font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;padding-left:24px;"><div style="line-height:120%;text-align:justify;font-size:10pt;text-indent:-24px;"><font style="font-family:inherit;font-size:10pt;">Any Employee that is eligible to receive an award under the EAIP for any Performance Period shall (i) participate in this Plan with respect to the determination and funding of the Incentive Pool, and (ii) for the avoidance of doubt, shall only receive one cash incentive award during a Performance Period which shall be subject to the additional terms and conditions set forth in the EAIP plan document and related materials so that such awards remain &#8220;performance-based&#8221; compensation in accordance with Section 162(m) of the Code. To the extent that there are any conflicts between this Plan and the terms of the EAIP, the EAIP will prevail.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(c)</font></div></td><td style="vertical-align:top;padding-left:24px;"><div style="line-height:120%;text-align:justify;font-size:10pt;text-indent:-24px;"><font style="font-family:inherit;font-size:10pt;">Effective as of January 1, 2016, any Employee who is performing services in the U.S. or Puerto Rico and is eligible to receive an award for a Performance Period who is issued a Compliance Written Warning during such Performance Period, may not receive an Award in excess of the lesser of (i) Ninety percent (90%) of his or her Target Incentive Award, or (ii) Ninety percent (90%) of his or her award prior to consideration of the Participant&#8217;s performance as set forth in Section 5(a)(4). Effective as of January 1, 2016, any Employee who is performing services in the U.S. or Puerto Rico and is eligible to receive an award for a Performance Period who is issued an IFW during such Performance Period, may not receive an Award in </font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">3</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-left:48px;text-align:justify;"><font style="font-family:inherit;font-size:10pt;">excess of the lesser of (i) Seventy-Five percent (75%) of his or her Target Incentive Award, or (ii) Seventy-Five percent (75%) of his or her award prior to consideration of the Participant&#8217;s performance as set forth in Section 5(a)(4).</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">SECTION 5. AWARDS</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:justify;text-indent:0px;"><font style="text-align:justify;font-family:inherit;font-size:10pt;padding-right:24px;">(a)</font><font style="font-family:inherit;font-size:10pt;">Under the Plan, the Committee may grant Awards to Participants from time to time with respect to a Performance Period based upon the achievement of performance objectives over the Performance Period. Award payments are earned based upon the following:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:90px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:66px;"><font style="font-family:inherit;font-size:10pt;">1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The initial funding of the Incentive Pool is equal to the sum of the Target Incentive Awards for all Participants for the Performance Period.  </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:90px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:66px;"><font style="font-family:inherit;font-size:10pt;">2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The final funding of the Incentive Pool is determined by the Committee, in its discretion, based on the Company&#8217;s performance against pre-set annual goals for the following financial measures (i) revenue, (ii) adjusted diluted earnings per share (EPS), and (iii) cash flow from operations. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:90px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:66px;"><font style="font-family:inherit;font-size:10pt;">3)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Once the final pool funding is determined, Incentive Pool dollars are allocated to the business unit, division or function in which a Participant worked during the Performance Period based on the achievement of pre-set annual goals for the business unit, division or function, and as determined by the CEO. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:90px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:66px;"><font style="font-family:inherit;font-size:10pt;">4)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A Participant&#8217;s actual Award is determined based on his or her Target Incentive Award, adjusted by the funding factors stated above and further adjusted to reflect the specific business unit, division or country performance, as well as the Participant&#8217;s performance against objectives for the Performance Period, as assessed by the Participant&#8217;s manager in accordance with procedures, guidelines and/or metrics established by the Committee, or its designee, from time to time. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:90px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:66px;"><font style="font-family:inherit;font-size:10pt;">5)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A Participant&#8217;s Target Incentive Award is calculated as set forth below:</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:90px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(A) Where a Participant&#8217;s Target Incentive Award is based on the Incentive Target Percentage, the Target Incentive Award is calculated as:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:145px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:133px;"><font style="font-family:inherit;font-size:12pt;">i.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">Group 1 Countries: the sum of the product of a Participant&#8217;s Eligible Earnings for each month during the calendar year that the Participant is eligible to participate in the Plan, multiplied by the Incentive Target Percentage for the Participant&#8217;s salary grade in the respective month.  </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:145px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:133px;"><font style="font-family:inherit;font-size:12pt;">ii.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">Group 2 Countries: the product of a Participant&#8217;s Eligible Earnings as of the immediately preceding December 31</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">st</sup></font><font style="font-family:inherit;font-size:10pt;">, multiplied by the Incentive Target Percentage in effect on December 31</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">st</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;for the Participant&#8217;s salary grade, pro-rated for the number of months during the calendar year in which he or she is eligible to participate in the Plan.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:145px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:133px;"><font style="font-family:inherit;font-size:12pt;">iii.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">For Participants in the ELTI Program: the product of the local base salary midpoint for the portion of each month during the Performance Period in which he or she is eligible to participate in the Plan (adjusted for changes in grades, Incentive Target Percentages or eligibility, as applicable), multiplied by the Incentive Target Percentage for the Participant&#8217;s salary grade in the respective month.  </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:144px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(B) Where a Participant&#8217;s Target Incentive Award is based on the Incentive Target Amount, the Target Incentive Award is calculated as 1/365</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">th</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;of the annual fixed Incentive Target Amount for each day within a month the Participant is eligible to participate in the Plan.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:justify;text-indent:0px;"><font style="text-align:justify;font-family:inherit;font-size:10pt;padding-right:24px;">(b)</font><font style="font-family:inherit;font-size:10pt;">A Participant&#8217;s final Award shall be capped at 200% of the Target Incentive Award which is the maximum Incentive Award Opportunity.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:justify;text-indent:0px;"><font style="text-align:justify;font-family:inherit;font-size:10pt;padding-right:24px;">(c)</font><font style="font-family:inherit;font-size:10pt;">Notwithstanding the foregoing, any Award  may also be subject to such other terms and conditions as the Committee shall deem advisable or appropriate from time to time, consistent with the provisions of the Plan as herein set forth, including but not limited to, the pro-ration or adjustment of Target Incentive Awards, Incentive Target Percentages and/or Incentive Award Opportunities, and Incentive Target Amounts, based upon a Participant&#8217;s date of hire, re-hire, change in position and/or salary grade (including a change in position or other similar change that causes the Participant to no longer be eligible for the Plan), change in local base salary midpoint, or transfer to a different business unit or division during a Performance Period. In addition, any Awards granted to Participants may </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">4</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-left:0px;text-align:justify;"><font style="font-family:inherit;font-size:10pt;">contain such other provisions as may be necessary to meet the requirements of the Code and/or related regulations issued thereunder in order to satisfy or comply with relevant law.   </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">SECTION 6. PAYMENT OF AWARDS</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unless otherwise required by local law or local payroll schedules for Participants located outside of the United States, Awards will be paid in a lump sum on or prior to the 15</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">th</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;day of the third month of the year immediately following the year in which the close of the Performance Period occurs in accordance with the applicable short-term deferral exception provisions of Section 409A, or, in accordance with procedures established by the Committee and the applicable provisions of Section 409A, on a deferred basis pursuant to Section 9 hereof, if applicable. However, any payment may be delayed or deferred upon the reasonable anticipation of (i) the loss of the Company&#8217;s deduction with respect to such payment by application of Section 162(m) of the Code; or (ii) the making of the payment would violate Federal securities laws or other applicable law such as Section 409A.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">SECTION 7. SPECIAL PAYMENT EVENTS </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:4px;padding-top:4px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Notwithstanding anything to the contrary in Section 6 of the Plan, the following payment terms shall apply to Awards in the following events:</font></div><div style="line-height:120%;padding-bottom:4px;padding-top:4px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:0px;padding-bottom:4px;padding-top:4px;text-align:justify;text-indent:0px;"><font style="padding-bottom:4px;padding-top:4px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:24px;">(a)</font><font style="font-family:inherit;font-size:10pt;">Voluntary Termination - If a Participant voluntarily terminates his or her employment (not for Retirement) prior to the end of the Performance Period, he or she is ineligible for an Award or any payment with respect to an Award for such Performance Period. If a Participant voluntarily terminates his or her employment after the end of the Performance Period, he or she is eligible for an Award or any payment with respect to an Award for such Performance Period under the applicable provisions of this Plan at the Committee&#8217;s discretion. </font></div><div style="line-height:120%;padding-bottom:4px;padding-top:4px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:0px;padding-bottom:4px;padding-top:4px;text-align:justify;text-indent:0px;"><font style="padding-bottom:4px;padding-top:4px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:24px;">(b)</font><font style="font-family:inherit;font-size:10pt;">Involuntary Termination - If a Participant&#8217;s employment is terminated as the result of an Involuntary Termination, prior to the end of the Performance Period, his or her Target Incentive Award will be pro-rated based on actual days of eligibility, his or her Eligible Earnings and his or her Incentive Target Percentage or Incentive Target Award during the Performance Period, as well as the overall funding percentage of the business unit, division or function where the Participant is working, in the Company&#8217;s discretion. The proration factor is the number of days in the Performance Period up to the termination date divided by 365 days. If eligible, such pro-rated Target Incentive Award will be the lesser of the Participant&#8217;s (i) pro-rated Target Incentive Award or (ii) pro-rated Target Incentive Award based on the performance of the Company, the Participant&#8217;s business unit, division or function and the Participant&#8217;s individual performance. Such Award will be paid as soon as administratively practicable after the Committee&#8217;s certification as to the achievement of the performance criteria for the Performance Period but not later than March 15</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">th</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;of the year following termination. Payments to members of the Senior Leadership Council, Executive Leadership Team or to Participants who were grade 20 or above as of the beginning of the Performance Period will be made in accordance with Section 6. If a Participant is involuntarily terminated after the end of the Performance Period, he or she is eligible for an Award or any payment with respect to an Award for such Performance Period under the applicable provisions of this Plan. If a Participant&#8217;s employment is terminated as the result of an Involuntary Termination and such Participant is also eligible for Retirement, such Award will be paid in accordance with this Section 7(b).</font></div><div style="line-height:120%;padding-bottom:4px;padding-top:4px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:0px;padding-bottom:4px;padding-top:4px;text-align:justify;text-indent:0px;"><font style="padding-bottom:4px;padding-top:4px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:24px;">(c)</font><font style="font-family:inherit;font-size:10pt;">Terminations for Cause or Performance-Related Terminations - If a Participant&#8217;s employment is terminated for Cause or constitutes a Performance-Related Termination, he or she is ineligible for an Award in the year of termination, unless otherwise required by local law.   </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:0px;padding-bottom:4px;padding-top:4px;text-align:justify;text-indent:0px;"><font style="padding-bottom:4px;padding-top:4px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:24px;">(d)</font><font style="font-family:inherit;font-size:10pt;">Retirement - If a Participant retires during the Performance Period, he or she will be eligible for a prorated Target Incentive Award using the calculation in Section 7(b) above, unless the retirement occurs on or after October 1st of the Performance Period. Such Award will be paid as soon as administratively practicable after the performance criteria has been met but not later than March 15</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">th</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;of the year following termination and in accordance with the applicable funding of the Participant&#8217;s business unit or division. Payments to members of the Senior Leadership Council or Executive Leadership Team, or to Participants who were grade 20 or above as of the beginning of the Performance Period, will be made in accordance with Section 6. If a Participant retires after October 1st of the Performance Period, he or she is eligible for a prorated Award based on the applicable funding of his or her business unit or division which shall be paid as soon as practicable after the performance criteria has been met but not later than March 15</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">th</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;of the year following retirement. If a Participant retires after the end of the Performance Period, he or she is eligible for an Award or any payment with respect to an Award for such Performance Period under the applicable provisions of this Plan for an active Participant. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-left:0px;padding-bottom:4px;padding-top:4px;text-align:justify;text-indent:0px;"><font style="padding-bottom:4px;padding-top:4px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:24px;">(e)</font><font style="font-family:inherit;font-size:10pt;">Short-Term Disability or Leave of Absence - If a Participant is on short-term disability (STD) or an approved paid leave of absence under the Family &amp; Medical Leave Act (or other similar law) during a Performance Period and has at least 90 days of Eligible Earnings within the Performance Period, he or she is eligible for a Target Incentive Award for such Performance Period. Such Award will be pro-rated to exclude the time the Participant is considered on STD or paid leave, as determined by the Committee or its designee, and will be based on the actual days of eligibility for the Plan. A Participant shall be considered eligible for the Plan during the first 90 days of STD or paid leave. If eligible, such pro-rated Target Incentive Award will be the lesser of the Participant&#8217;s (i) pro-rated Target Incentive Award or (ii) pro-rated Target Incentive Award based on the performance of the Company, the Participant&#8217;s business unit, division or function and the Participant&#8217;s individual performance, within the Company&#8217;s discretion. Such Award will be paid as soon as practicable after the performance criteria have been met but not later than March 15</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">th</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;of the year following termination. Payments to members of the Senior Leadership Council or Executive Leadership Team, or to Participants who were grade 20 or above as of the beginning of the Performance Period will be made in accordance with Section 6. If Participant is not terminated, the Award shall be paid in accordance with Section 6. If a Participant is on an approved Military leave of absence under the Company&#8217;s Military Leave Policy and is eligible for differential pay, the calculation of the differential pay shall include the payment of an Award as if such Participant were actively employed.</font></div><div style="line-height:120%;padding-bottom:4px;padding-top:4px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:0px;padding-bottom:4px;padding-top:4px;text-align:justify;text-indent:0px;"><font style="padding-bottom:4px;padding-top:4px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:24px;">(f)</font><font style="font-family:inherit;font-size:10pt;">Death - If a Participant dies during a Performance Period, in the Committee&#8217;s discretion, the pro-rated Target Incentive Award will be paid to the Participant&#8217;s estate as soon as administratively possible following the Participant&#8217;s death.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">SECTION 8. AMENDMENT AND TERMINATION </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company reserves the right in its sole and absolute discretion to amend or terminate the Plan, at any time, including after the end of the calendar year and prior to payment of the Award, with or without notice, by action of the Executive Leadership Team or the Committee, as applicable. This right includes, but is not limited to, eligibility for an Award, determination of Incentive Pool funding, the modification of incentive measures, performance targets and/or performance results. This right also includes the modification of the terms of the Plan, as may be necessary or desirable, to comply with applicable laws and local customs of countries in which the Company operates or has employees. The Company&#8217;s obligation to pay compensation as herein provided is subject to any applicable orders, rules or regulations of any government agency or office having authority to regulate the payment of wages, salaries and other forms of compensation.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Committee may delegate to another committee or person, as it may appoint, the authority to take any action consistent with the terms of the Plan, either before or after an Award has been granted, which such other committee or person deems necessary or advisable to comply with any government laws or regulatory requirements of a foreign country, including but not limited to, modifying or amending the terms and conditions governing any Awards, or establishing any local country plans as sub-plans to this Plan. In addition, under all circumstances, the Committee or its delegate which for this purpose includes the Executive Vice President, Worldwide Human Resources and the Senior Vice President, Total Rewards, may make non-substantive administrative changes to the Plan as to conform with or take advantage of governmental requirements, statutes or regulations.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Notwithstanding the foregoing, the Committee or its designee may amend the terms of any Award heretofore granted, prospectively or retroactively, in order to cure any potential defects under Section 409A, in a manner deemed appropriate by the Committee in its sole discretion and absolute discretion, without the consent of the Participant.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">SECTION 9. DEFERRAL OF AWARDS UNDER THE COMPANY&#8217;S DEFERRED COMPENSATION PLAN</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Except as otherwise provided in this Plan, the Committee may provide upon the granting of an Award hereunder, that it is eligible to be deferred under, and pursuant to the terms and conditions of, the Pfizer Inc Deferred Compensation Plan, as such plan may be amended from time to time. Any such deferral shall be in accordance with the terms of such plan and in compliance with the applicable provisions of Section 409A.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">6</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">SECTION 10. TAX CONSIDERATIONS </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:justify;text-indent:0px;"><font style="text-align:justify;font-family:inherit;font-size:10pt;padding-right:24px;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#32;For Participants in the United States</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">,</font><font style="font-family:inherit;font-size:10pt;">&#32;Award payments under the Plan will be treated as taxable income for the year in which the Participant receives the payment. The Company and its Affiliates shall be authorized to withhold appropriate amounts from such payments to satisfy all federal, state and local tax withholding requirements and any other authorized deductions due in respect of an Award payment hereunder and to take such other action as may be deemed necessary in the opinion of the Company or Affiliate to satisfy all obligations for the payment of such taxes.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Notwithstanding anything herein to the contrary, the terms of the Plan are intended to, and shall be interpreted and applied so as to, comply in all respects with Section 409A. The Committee may amend the terms of any Award heretofore granted, prospectively or retroactively, in order to cure any potential defects under Section 409A, in a manner deemed appropriate by the Committee in its sole and absolute discretion, without the consent of the Participant. Nothing in this Section 10 shall be construed as an admission that any of the compensation and/or benefits payable under this Plan constitutes &#8220;deferred compensation&#8221; subject to Section 409A. Furthermore, the Company does not represent, covenant or guarantee that any particular Award made under the Plan will be exempt from Section 409A and/or will avoid unfavorable tax consequences to the Participant (e.g., Section 409A penalties).  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:justify;text-indent:0px;"><font style="text-align:justify;font-family:inherit;font-size:10pt;padding-right:24px;">(b)</font><font style="font-family:inherit;font-size:10pt;">For Participants located outside of the United States, local country rules on taxation and withholding treatment will apply.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:justify;text-indent:0px;"><font style="text-align:justify;font-family:inherit;font-size:10pt;padding-right:24px;">(c)</font><font style="font-family:inherit;font-size:10pt;">Awards made to Participants eligible under the EAIP are intended to qualify as &#8220;performance based compensation&#8221; under Section 162(m) of the Code so that they are deductible for United States tax purposes by the Company. Awards made to Participants eligible for the EAIP will be governed by the additional terms and conditions included in that plan. With respect to all Awards to Participants eligible under the EAIP, to the extent that there are any conflicts between this Plan and the terms of the EAIP, the EAIP will prevail.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">SECTION 11. RECOUPMENT </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the event of a significant restatement of the Company&#8217;s consolidated financial statements (other than a restatement resulting from a change in accounting principles), the Committee will review Awards made under the Plan for performance for the fiscal periods affected by the restatement. If the Committee determines that an Award would have been lower (or would not have been made) if it had been based on the restated results, the Committee</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:10pt;">may, to the extent permitted by applicable law, seek recoupment of all or any portion of such Award as it deems appropriate, in its sole and absolute discretion, after a review of all relevant facts and circumstances. Any recoupment may be in addition to any other remedies that may be available to the Company under applicable law. Nothing contained in this paragraph will limit the Company&#8217;s ability to seek recoupment, in appropriate circumstances and as permitted or required by applicable law (including Section 10D of the Securities Exchange Act of 1934, as amended), of any amounts from any Employee, whether or not the Employee is a senior executive. If a Participant owes any outstanding debt, including but not limited to loans, vacation and salary and expense advances, to the Company or any Affiliates, any Award payable to the Participant under this Plan, to the extent such amount is exempt from Section 409A, shall be reduced by the full amount of such debt, as permitted by law.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">SECTION 12. GENERAL PROVISIONS </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:justify;text-indent:0px;"><font style="text-align:justify;font-family:inherit;font-size:10pt;padding-right:24px;">(a)</font><font style="font-family:inherit;font-size:10pt;">Awards under this Plan are considered variable compensation and as such are not guaranteed.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:justify;text-indent:0px;"><font style="text-align:justify;font-family:inherit;font-size:10pt;padding-right:24px;">(b)</font><font style="font-family:inherit;font-size:10pt;">No Employee shall have the right to be selected to receive an Award under this Plan or, having been so selected, to be selected to receive a future Award. Neither the Award nor any benefits arising out of this Plan shall constitute part of a Participant&#8217;s employment or service contract with the Company or any Affiliate and, accordingly, this Plan and the benefits hereunder may be terminated at any time in the sole and exclusive discretion of the Company without giving rise to liability on the part of the Company or any Affiliate for severance payments. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:justify;text-indent:0px;"><font style="text-align:justify;font-family:inherit;font-size:10pt;padding-right:24px;">(c)</font><font style="font-family:inherit;font-size:10pt;">No Employee shall have any claim to be granted any Award under the Plan, and there is no obligation for uniformity of treatment of Employees or Participants under the Plan.   </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(d) Nothing in the Plan or any Award granted under the Plan shall be deemed to constitute an employment or service contract or confer or be deemed to confer on any Employee or Participant any right to continue in the employ or service of, or to continue any other relationship with, the Company or any Affiliate or limit in any way the right of the Company or any Affiliate to terminate an Employee&#8217;s employment or Participant&#8217;s service at any time, with or without Cause.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">7</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(e) Except as otherwise required by the terms of the Plan, recipients of Awards under the Plan shall not be required to make any payment or provide consideration other than the rendering of services. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(f) If any provision of the Plan is or becomes or is deemed invalid, illegal or unenforceable in any jurisdiction, or would disqualify the Plan or any Award under any law deemed applicable by the Committee, such provision shall be construed or deemed amended to conform to applicable laws or if it cannot be construed or deemed amended without, in the determination of the Committee, materially altering the intent of the Plan, it shall be stricken and the remainder of the Plan shall remain in full force and effect.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(g) Awards may be granted and paid to Participants who are foreign nationals or employed outside the United States, or both, on such terms and conditions different from those applicable to Awards to Participants employed in the United States as may, in the judgment of the Committee, be necessary or desirable in order to recognize differences in local law or tax policy. The Committee also may impose conditions on the payment of Awards in order to minimize the Company&#8217;s obligation with respect to tax equalization for Employees on assignments outside their home country.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(h) If approved by the Committee in its sole discretion, an Employee&#8217;s absence or leave because of military or governmental service, disability or other reason shall not be considered an interruption of employment for any purpose under the Plan; provided, however, that to the extent an Award under this Plan is subject to Section 409A, such absence or leave shall be considered a Separation from Service to the extent provided by Section 409A.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">SECTION 13. GOVERNING LAW</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The provisions of the Plan shall be construed, regulated and administered according to the laws of the State of New York without giving effect to principles of conflicts of law, except to the extent superseded by any controlling Federal statute.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">8</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:138%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;color:#548dd4;font-weight:bold;">APPENDIX A</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:92.01520912547528%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:11%;"></td><td style="width:33%;"></td><td style="width:3%;"></td><td style="width:10%;"></td><td style="width:43%;"></td></tr><tr><td colspan="5" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#548dd4;font-weight:bold;">Group 1 Countries</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#548dd4;font-weight:bold;">&#160;</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#548dd4;font-weight:bold;">(Accumulation Of Monthly Daily Earnings and Targets)</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#548dd4;font-weight:bold;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">AUS</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">AUSTRALIA</font></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">KAZ</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">KAZAKHSTAN</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">AUT</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">AUSTRIA</font></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">KOR</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">KOREA, REPUBLIC OF</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ZAE</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">AZERBAIJAN</font></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">LVA</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">LATVIA</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">BLR</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">BELARUS</font></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">LTU</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">LITHUANIA</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">BEL</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">BELGIUM</font></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">LUX</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">LUXEMBOURG</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">BIH</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">BOSNIA &amp; HERZEGOVINA</font></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">MYS</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">MALAYSIA</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">BOL</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">BOLIVIA</font></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">MEX</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">MEXICO</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">BRA</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">BRAZIL</font></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">NLD</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">NETHERLANDS</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">BGR</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">BULGARIA</font></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">NZL</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">NEW ZEALAND</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">CAN</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">CANADA</font></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">NIC</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">NICARAGUA</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">CHL</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">CHILE</font></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">NOR</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">NORWAY</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">CHN</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">CHINA</font></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">PAK</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">PAKISTAN</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">COL</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">COLOMBIA</font></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">PHL</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">PHILIPPINES</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">CYP</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">CYPRUS</font></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">POL</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">POLAND</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">HRV</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">CROATIA</font></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">PRT</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">PORTUGAL</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">CZE</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">CZECH REPUBLIC</font></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ROU</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ROMANIA</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">DNK</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">DENMARK</font></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">RUS</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">RUSSIAN FEDERATION</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">DOM</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">DOMINICAN REPUBLIC</font></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">SRB</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">SERBIA</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">SLV</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">EL SALVADOR</font></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">SGP</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">SINGAPORE</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">EST</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ESTONIA</font></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">SVK</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">SLOVAKIA</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">FIN</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">FINLAND</font></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">SVN</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">SLOVENIA</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">FRA</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">FRANCE</font></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ESP</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">SPAIN</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">GEO</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">GEORGIA</font></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">SWE</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">SWEDEN</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">DEU</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">GERMANY</font></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">CHE</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">SWITZERLAND</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">GRC</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">GREECE</font></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">TWN</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">TAIWAN</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">HND</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">HONDURAS</font></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">THA</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">THAILAND</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">HKG</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">HONG KONG</font></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">TUR</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">TURKEY</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">HUN</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">HUNGARY</font></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">UKR</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">UKRAINE</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">IND</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">INDIA</font></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">GBR</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">UNITED KINGDOM</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">IDN</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">INDONESIA</font></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">USA</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">UNITED STATES</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">IRL</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">IRELAND</font></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">VEN</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">VENEZUELA</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ISR</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ISRAEL</font></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">VNM</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">VIET NAM</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ITA</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ITALY</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">JPN</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">JAPAN</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:138%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:81.36882129277566%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:29%;"></td><td style="width:71%;"></td></tr><tr><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#548dd4;font-weight:bold;">Group 2 Countries</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#548dd4;font-weight:bold;">&#160;</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#548dd4;font-weight:bold;">(December 31 Salary and Target)</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#548dd4;font-weight:bold;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">DZA</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ALGERIA</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ARG</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ARGENTINA</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">BHR</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">BAHRAIN</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">CMR</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">CAMEROON</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">CRI</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">COSTA RICA</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">IVC</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">COTE D'IVOIRE (IVORY COAST)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ECU</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ECUADOR</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">EGY</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">EGYPT</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">GHA</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">GHANA</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">GTM</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">GUATEMALA</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">IRN</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">IRAN (ISLAMIC REPUBLIC OF)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">IRQ</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">IRAQ</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">JOR</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">JORDAN</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">KEN</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">KENYA</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">KWT</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">KUWAIT</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">LBN</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">LEBANON</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">LBY</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">LIBYAN ARAB JAMAHIRIYA</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">MAR</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">MOROCCO</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">NGA</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">NIGERIA</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">OMN</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">OMAN</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">PAN</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">PANAMA</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">PRY</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">PARAGUAY</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">PER</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">PERU</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">QAT</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">QATAR</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">SAU</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">SAUDI ARABIA</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">SEN</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">SENEGAL</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ZAF</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">SOUTH AFRICA</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">SDN</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">SUDAN</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">SYR</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">SYRIAN ARAB REPUBLIC</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">TUN</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">TUNISIA</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ARE</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">UNITED ARAB EMIRATES</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">URY</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">URUGUAY</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">YEM</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">YEMEN</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">10</font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12
<SEQUENCE>4
<FILENAME>pfe-10012017x10qexhibit12.htm
<DESCRIPTION>COMPUTATION OF RATIO OF EARNINGS TO FIXED CHARGES
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s0B361E7E04D15B61B2F9E6C04A49B3FE"></a></div><div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:144%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXHIBIT 12</font></div><div style="line-height:144%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Pfizer Inc. and Subsidiary Companies</font></div><div style="line-height:144%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Computation of Ratio of Earnings to Fixed Charges</font></div><div style="line-height:120%;padding-bottom:9px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:center;padding-left:12px;text-indent:-12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"></td></tr><tr><td style="width:43%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Nine Months Ended</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS, EXCEPT RATIOS)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">October&#160;1, <br>2017</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2016</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2015</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2014</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2013</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2012</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;text-decoration:underline;">Determination of earnings:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Income from continuing operations before provision for taxes on income, noncontrolling interests and cumulative effect of a change in accounting principles</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">11,351</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">8,351</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">8,965</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">12,240</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">15,716</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">11,242</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Less:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Noncontrolling interests</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">43</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">44</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">39</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">47</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">43</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">47</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Income attributable to Pfizer Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">11,308</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">8,307</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">8,925</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">12,192</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">15,673</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">11,195</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Add (deduct):</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Capitalized interest</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(55</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(61</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(32</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(41</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(32</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(41</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Amortization of capitalized interest</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">40</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">59</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">25</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">31</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">34</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">36</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Equity (income)/loss from equity-method investments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(214</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(49</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">191</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(24</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(67</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(105</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Distributed income of equity method investments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">211</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">119</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">161</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">136</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">162</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">85</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Fixed charges</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,015</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,285</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,282</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,435</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,495</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,627</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total earnings as defined</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">12,305</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">9,661</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">10,554</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">13,729</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">17,265</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">12,796</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;text-decoration:underline;">Fixed charges:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Interest expense</font><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">940</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,186</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,199</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,360</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,414</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,522</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Preferred stock dividends</font><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(b)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Rents</font><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(c)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">73</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">97</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">81</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">72</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">78</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">101</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Fixed charges</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,015</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,285</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,282</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,435</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,495</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,627</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Capitalized interest</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">55</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">61</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">32</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">41</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">32</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">41</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total fixed charges</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,070</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,346</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,314</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,476</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,527</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,668</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Ratio of earnings to fixed charges</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">11.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">8.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">9.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">11.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup>&#160;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Interest expense includes amortization of debt premium, discount and other debt costs. Interest expense does not include interest related to tax matters (primarily uncertain tax positions) of </font><font style="font-family:inherit;font-size:9pt;">$196 million</font><font style="font-family:inherit;font-size:9pt;">&#32;for the </font><font style="font-family:inherit;font-size:9pt;">first nine months of</font><font style="font-family:inherit;font-size:9pt;">&#32;</font><font style="font-family:inherit;font-size:9pt;text-align:center;">2017</font><font style="font-family:inherit;font-size:9pt;">; </font><font style="font-family:inherit;font-size:9pt;">$242 million</font><font style="font-family:inherit;font-size:9pt;">&#32;for </font><font style="font-family:inherit;font-size:9pt;text-align:center;">2016</font><font style="font-family:inherit;font-size:9pt;">; </font><font style="font-family:inherit;font-size:9pt;">$246 million</font><font style="font-family:inherit;font-size:9pt;">&#32;for </font><font style="font-family:inherit;font-size:9pt;text-align:center;">2015</font><font style="font-family:inherit;font-size:9pt;">; </font><font style="font-family:inherit;font-size:9pt;">$182 million</font><font style="font-family:inherit;font-size:9pt;">&#32;for </font><font style="font-family:inherit;font-size:9pt;text-align:center;">2014</font><font style="font-family:inherit;font-size:9pt;">; </font><font style="font-family:inherit;font-size:9pt;">$222 million</font><font style="font-family:inherit;font-size:9pt;">&#32;for </font><font style="font-family:inherit;font-size:9pt;text-align:center;">2013</font><font style="font-family:inherit;font-size:9pt;">; and </font><font style="font-family:inherit;font-size:9pt;">$265 million</font><font style="font-family:inherit;font-size:9pt;">&#32;for 2012.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(b)</sup>&#160;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Preferred stock dividends related to our Series A convertible perpetual preferred stock held by an employee stock ownership plan trust.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(c)</sup>&#160;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Rents included in the computation consist of one-third of rental expense, which we believe to be a conservative estimate of an interest factor in our leases, which are not material.</font></div></td></tr></table><div style="line-height:120%;padding-top:1px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Amounts may not add due to rounding. Percentages have been calculated using unrounded amounts. </font></div><div style="line-height:120%;padding-top:1px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:144%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-15
<SEQUENCE>5
<FILENAME>pfe-10012017x10qexhibit15.htm
<DESCRIPTION>ACCOUNTANTS' ACKNOWLEDGEMENT
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s07FDC4E4214853C0AA710CBAA599B32C"></a></div><div style="line-height:144%;text-align:right;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXHIBIT 15</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Accountants' Acknowledgment</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To the Board of Directors and the Shareholders of Pfizer Inc.:</font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We hereby acknowledge our awareness of the use therein of our report dated </font><font style="font-family:inherit;font-size:10pt;">November&#160;9, 2017</font><font style="font-family:inherit;font-size:10pt;">, included within the Quarterly Report on Form 10-Q of Pfizer Inc. for the quarter ended </font><font style="font-family:inherit;font-size:10pt;">October&#160;1, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;in the following Registration Statements:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-Form S-8 dated October 27, 1983 (File No. 2-87473),</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-Form S-8 dated March 22, 1990 (File No. 33-34139),</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-Form S-8 dated January 24, 1991 (File No. 33-38708),</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-Form S-8 dated November 18, 1991 (File No. 33-44053),</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-Form S-8 dated May 27, 1993 (File No. 33-49631),</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-Form S-8 dated May 19, 1994 (File No. 33-53713),</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-Form S-8 dated October 5, 1994 (File No. 33-55771),</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-Form S-8 dated December 20, 1994 (File No. 33-56979),</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-Form S-8 dated March 29, 1996 (File No. 333-02061),</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-Form S-8 dated September 25, 1997 (File No. 333-36371),</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-Form S-8 dated June 19, 2000 (File No. 333-39610),</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-Form S-8 dated June 19, 2000 (File No. 333-39606),</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-Form S-8 dated April 27, 2001 (File No. 333-59660),</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-Form S-8 dated April 16, 2003 (File No. 333-104581),</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-Form S-8 dated April 16, 2003 (File No. 333-104582),</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-Form S-8 dated November 18, 2003 (File No. 333-110571),</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-Form S-8 dated December 18, 2003 (File No. 333-111333),</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-Form S-8 dated April 26, 2004 (File No. 333-114852),</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-Form S-8 dated March 1, 2007 (File No. 333-140987),</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-Form S-4 dated March 27, 2009 (File No. 333-158237),</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-Form S-8 dated October 16, 2009 (File No. 333-162519),</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-Form S-8 dated October 16, 2009 (File No. 333-162520),</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-Form S-8 dated October 16, 2009 (File No. 333-162521),</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-Form S-8 dated March 1, 2010 (File No. 333-165121),</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-Form S-3ASR dated March 2, 2015 (File No. 333-202430),</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-Form S-8 dated March 2, 2015 (File No. 333-202437), and</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-Form S-4 dated September 3, 2015 (File No. 333-206758).</font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div><div style="line-height:125%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to Rule 436 under the Securities Act of 1933 (the Act), such report is not considered a part of a registration statement prepared or certified by an independent registered public accounting firm, or a report prepared or certified by an independent registered public accounting firm within the meaning of Sections 7 and 11 of the Act.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ KPMG LLP</font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">New York, New York </font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">November&#160;9, 2017</font></div><div><br></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>6
<FILENAME>pfe-10012017x10qexhibit311.htm
<DESCRIPTION>CERTIFICATION BY THE CEO - SECTION 302
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s4B696CD91E465DF2B14ED0068FC4A4F4"></a></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXHIBIT 31.1</font></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Certification by the Chief Executive Officer Pursuant to </font></div><div style="line-height:120%;padding-bottom:6px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Section 302 of the Sarbanes-Oxley Act of 2002</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I, Ian C. Read, certify that:</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:24px;"><font style="padding-bottom:6px;padding-top:6px;text-align:left;font-family:inherit;font-size:10pt;padding-right:24px;">1.</font><font style="font-family:inherit;font-size:10pt;">I have reviewed this Quarterly Report on Form 10-Q of Pfizer Inc.;</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:24px;"><font style="padding-bottom:6px;padding-top:6px;text-align:left;font-family:inherit;font-size:10pt;padding-right:24px;">2.</font><font style="font-family:inherit;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:24px;"><font style="padding-bottom:6px;padding-top:6px;text-align:left;font-family:inherit;font-size:10pt;padding-right:24px;">3.</font><font style="font-family:inherit;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:24px;"><font style="padding-bottom:6px;padding-top:6px;text-align:left;font-family:inherit;font-size:10pt;padding-right:24px;">4.</font><font style="font-family:inherit;font-size:10pt;">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;padding-left:24px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;padding-left:24px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;padding-left:24px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;padding-left:24px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.&#160;&#160;&#160;&#160;The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;padding-left:24px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;padding-left:24px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date:&#160;</font><font style="font-family:inherit;font-size:10pt;">November&#160;9, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:26%;"></td><td style="width:37%;"></td><td style="width:37%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ IAN C. READ</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Ian C. Read</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Chairman and Chief Executive Officer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>7
<FILENAME>pfe-10012017x10qexhibit312.htm
<DESCRIPTION>CERTIFICATION BY THE CFO - SECTION 302
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s803D15A7691E56A79F7874904B3C015B"></a></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXHIBIT 31.2</font></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Certification by the Chief Financial Officer Pursuant to </font></div><div style="line-height:120%;padding-bottom:6px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Section 302 of the Sarbanes-Oxley Act of 2002</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I, Frank A. D'Amelio, certify that:</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:24px;"><font style="padding-bottom:6px;padding-top:6px;text-align:left;font-family:inherit;font-size:10pt;padding-right:24px;">1.</font><font style="font-family:inherit;font-size:10pt;">I have reviewed this Quarterly Report on Form 10-Q of Pfizer Inc.;</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:24px;"><font style="padding-bottom:6px;padding-top:6px;text-align:left;font-family:inherit;font-size:10pt;padding-right:24px;">2.</font><font style="font-family:inherit;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:24px;"><font style="padding-bottom:6px;padding-top:6px;text-align:left;font-family:inherit;font-size:10pt;padding-right:24px;">3.</font><font style="font-family:inherit;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:24px;"><font style="padding-bottom:6px;padding-top:6px;text-align:left;font-family:inherit;font-size:10pt;padding-right:24px;">4.</font><font style="font-family:inherit;font-size:10pt;">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;padding-left:24px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;padding-left:24px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;padding-left:24px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;padding-left:24px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:24px;"><font style="padding-bottom:6px;padding-top:6px;text-align:left;font-family:inherit;font-size:10pt;padding-right:24px;">5.</font><font style="font-family:inherit;font-size:10pt;">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;padding-left:24px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;padding-left:24px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date:&#160;</font><font style="font-family:inherit;font-size:10pt;">November&#160;9, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:26%;"></td><td style="width:37%;"></td><td style="width:37%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ FRANK A. D'AMELIO</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Frank A. D'Amelio</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Executive Vice President, Business Operations and Chief Financial Officer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div><br></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>8
<FILENAME>pfe-10012017x10qexhibit321.htm
<DESCRIPTION>CERTIFICATION BY THE CEO - SECTION 1350
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s4D214AE70D1C572F9F22DB28A9D7BE33"></a></div><div style="line-height:120%;padding-bottom:10px;padding-top:6px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXHIBIT 32.1</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Certification by the Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Section 906 of the Sarbanes-Oxley Act of 2002</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to 18 U.S.C. Section 1350, I, Ian C. Read, hereby certify that, to the best of my knowledge, the Quarterly Report on Form 10-Q of Pfizer Inc. for the fiscal quarter ended </font><font style="font-family:inherit;font-size:10pt;text-align:center;">October&#160;1, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;(the &#8220;Report&#8221;) fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934, and that the information contained in that Report fairly presents, in all material respects, the financial condition and results of operations of Pfizer Inc.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:26%;"></td><td style="width:37%;"></td><td style="width:37%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ IAN C. READ</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Ian C. Read</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Chairman and Chief Executive Officer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">November&#160;9, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">This certification accompanies this Quarterly Report on Form 10-Q pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by such Act, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent that the Company specifically incorporates it by reference.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>9
<FILENAME>pfe-10012017x10qexhibit322.htm
<DESCRIPTION>CERTIFICATION BY THE CFO - SECTION 1350
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s99B8536607FB5C168ACA31F49CEDB814"></a></div><div style="line-height:120%;padding-bottom:10px;padding-top:6px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXHIBIT 32.2</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Certification by the Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Section 906 of the Sarbanes-Oxley Act of 2002</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to 18 U.S.C. Section 1350, I, Frank A. D'Amelio, hereby certify that, to the best of my knowledge, the Quarterly Report on Form 10-Q of Pfizer Inc. for the fiscal quarter ended </font><font style="font-family:inherit;font-size:10pt;text-align:center;">October&#160;1, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;(the &#8220;Report&#8221;) fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934, and that the information contained in that Report fairly presents, in all material respects, the financial condition and results of operations of Pfizer Inc.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:26%;"></td><td style="width:37%;"></td><td style="width:37%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ FRANK A. D'AMELIO</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Frank A. D'Amelio</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Executive Vice President, Business Operations and</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Chief Financial Officer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">November&#160;9, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">This certification accompanies this Quarterly Report on Form 10-Q pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by such Act, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent that the Company specifically incorporates it by reference.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>10
<FILENAME>pfe-20171001.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<xsd:schema attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.pfizer.com/20171001" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:pfe="http://www.pfizer.com/20171001" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import namespace="http://fasb.org/us-gaap/2017-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2017-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2017/elts/us-roles-2017-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-types/2017-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2017/elts/us-types-2017-01-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/currency/2017-01-31" schemaLocation="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/exch/2017-01-31" schemaLocation="http://xbrl.sec.gov/exch/2017/exch-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/naics/2017-01-31" schemaLocation="http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pfe-20171001_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pfe-20171001_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pfe-20171001_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pfe-20171001_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple" />
      <link:roleType id="AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterests" roleURI="http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterests">
        <link:definition>2109100 - Disclosure - Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetail" roleURI="http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetail">
        <link:definition>2409402 - Disclosure - Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsTables" roleURI="http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsTables">
        <link:definition>2309301 - Disclosure - Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestments" roleURI="http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestments">
        <link:definition>2103100 - Disclosure - Acquisitions, Sale of Hospira Infusion Systems Net Assets, Collaborative Arrangement and Equity-Method Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsAnacorPharmaceuticalsIncDetails" roleURI="http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsAnacorPharmaceuticalsIncDetails">
        <link:definition>2403404 - Disclosure - Acquisitions, Sale of Hospira Infusion Systems Net Assets, Collaborative Arrangement and Equity-Method Investments - Anacor Pharmaceuticals, Inc. (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsAstrazenecaDetails" roleURI="http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsAstrazenecaDetails">
        <link:definition>2403401 - Disclosure - Acquisitions, Sale of Hospira Infusion Systems Net Assets, Collaborative Arrangement and Equity-Method Investments - AstraZeneca (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsBambooTherapeuticsDetails" roleURI="http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsBambooTherapeuticsDetails">
        <link:definition>2403403 - Disclosure - Acquisitions, Sale of Hospira Infusion Systems Net Assets, Collaborative Arrangement and Equity-Method Investments - Bamboo Therapeutics (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsCollaborationArrangementDetails" roleURI="http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsCollaborationArrangementDetails">
        <link:definition>2403406 - Disclosure - Acquisitions, Sale of Hospira Infusion Systems Net Assets, Collaborative Arrangement and Equity-Method Investments - Collaboration Arrangement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsEquityMethodInvestmentsDetails" roleURI="http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsEquityMethodInvestmentsDetails">
        <link:definition>2403407 - Disclosure - Acquisitions, Sale of Hospira Infusion Systems Net Assets, Collaborative Arrangement and Equity-Method Investments - Equity-Method Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsMedivationDetails" roleURI="http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsMedivationDetails">
        <link:definition>2403402 - Disclosure - Acquisitions, Sale of Hospira Infusion Systems Net Assets, Collaborative Arrangement and Equity-Method Investments - Medivation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsSaleOfHospiraInfusionSystemsNetAssetsToIcuMedicalIncEhDetails" roleURI="http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsSaleOfHospiraInfusionSystemsNetAssetsToIcuMedicalIncEhDetails">
        <link:definition>2403405 - Disclosure - Acquisitions, Sale of Hospira Infusion Systems Net Assets, Collaborative Arrangement and Equity-Method Investments - Sale of Hospira Infusion Systems Net Assets to ICU Medical, Inc. (EH) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisOfPresentationAndSignificantAccountingPolicies" roleURI="http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPolicies">
        <link:definition>2101100 - Disclosure - Basis of Presentation and Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisOfPresentationAndSignificantAccountingPoliciesDetails" roleURI="http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetails">
        <link:definition>2401402 - Disclosure - Basis of Presentation and Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisOfPresentationAndSignificantAccountingPoliciesPolicies" roleURI="http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies">
        <link:definition>2201201 - Disclosure - Basis of Presentation and Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingencies" roleURI="http://www.pfizer.com/role/CommitmentsAndContingencies">
        <link:definition>2115100 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingenciesActionsInWhichWeAreDefendantDetail" roleURI="http://www.pfizer.com/role/CommitmentsAndContingenciesActionsInWhichWeAreDefendantDetail">
        <link:definition>2415403 - Disclosure - Commitments and Contingencies (Actions In Which We Are The Defendant) (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingenciesActionsInWhichWeArePlaintiffDetails" roleURI="http://www.pfizer.com/role/CommitmentsAndContingenciesActionsInWhichWeArePlaintiffDetails">
        <link:definition>2415402 - Disclosure - Commitments and Contingencies (Actions In Which We Are The Plaintiff) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingenciesDetails" roleURI="http://www.pfizer.com/role/CommitmentsAndContingenciesDetails">
        <link:definition>2415401 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>1003000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://www.pfizer.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>1003001 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (PARENTHETICAL)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlows">
        <link:definition>1004000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsOfCashFlowsParenthetical" roleURI="http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlowsParenthetical">
        <link:definition>1004501 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (PARENTHETICAL)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsOfComprehensiveIncome" roleURI="http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome">
        <link:definition>1002000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsOfComprehensiveIncomeParenthetical" roleURI="http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeParenthetical">
        <link:definition>1002501 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (PARENTHETICAL)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsOfIncome" roleURI="http://www.pfizer.com/role/CondensedConsolidatedStatementsOfIncome">
        <link:definition>1001000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF INCOME</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DocumentAndEntityInformation" roleURI="http://www.pfizer.com/role/DocumentAndEntityInformation">
        <link:definition>0001000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerCommonShareAttributableToCommonShareholders" roleURI="http://www.pfizer.com/role/EarningsPerCommonShareAttributableToCommonShareholders">
        <link:definition>2114100 - Disclosure - Earnings Per Common Share Attributable to Common Shareholders</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerCommonShareAttributableToCommonShareholdersDetails" roleURI="http://www.pfizer.com/role/EarningsPerCommonShareAttributableToCommonShareholdersDetails">
        <link:definition>2414402 - Disclosure - Earnings Per Common Share Attributable to Common Shareholders (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerCommonShareAttributableToCommonShareholdersTables" roleURI="http://www.pfizer.com/role/EarningsPerCommonShareAttributableToCommonShareholdersTables">
        <link:definition>2314301 - Disclosure - Earnings Per Common Share Attributable to Common Shareholders (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstruments" roleURI="http://www.pfizer.com/role/FinancialInstruments">
        <link:definition>2110100 - Disclosure - Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail" roleURI="http://www.pfizer.com/role/FinancialInstrumentsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail">
        <link:definition>2410402 - Disclosure - Financial Instruments - Assets and Liabilities Measured on Recurring Basis (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsAssetsAndLiabilitiesMeasuredOnRecurringBasisFootnotesDetail" roleURI="http://www.pfizer.com/role/FinancialInstrumentsAssetsAndLiabilitiesMeasuredOnRecurringBasisFootnotesDetail">
        <link:definition>2410403 - Disclosure - Financial Instruments - Assets and Liabilities Measured on Recurring Basis - Footnotes (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsBalanceSheetGroupingDetail" roleURI="http://www.pfizer.com/role/FinancialInstrumentsBalanceSheetGroupingDetail">
        <link:definition>2410404 - Disclosure - Financial Instruments - Balance Sheet Grouping (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsBalanceSheetGroupingFootnotesDetail" roleURI="http://www.pfizer.com/role/FinancialInstrumentsBalanceSheetGroupingFootnotesDetail">
        <link:definition>2410405 - Disclosure - Financial Instruments - Balance Sheet Grouping - Footnotes (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetail" roleURI="http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetail">
        <link:definition>2410411 - Disclosure - Financial Instruments - Derivative Financial Instruments and Hedging Activities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsInvestmentsInDebtSecuritiesDetail" roleURI="http://www.pfizer.com/role/FinancialInstrumentsInvestmentsInDebtSecuritiesDetail">
        <link:definition>2410406 - Disclosure - Financial Instruments - Investments in Debt Securities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsInvestmentsInDebtSecuritiesDetailCalc2" roleURI="http://www.pfizer.com/role/FinancialInstrumentsInvestmentsInDebtSecuritiesDetailCalc2">
        <link:definition>2410406 - Disclosure - Financial Instruments - Investments in Debt Securities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsLongTermDebtDetails" roleURI="http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails">
        <link:definition>2410408 - Disclosure - Financial Instruments - Long-Term Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsLongTermDebtMaturitiesDetails" roleURI="http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtMaturitiesDetails">
        <link:definition>2410409 - Disclosure - Financial Instruments - Long-Term Debt - Maturities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsNarrativeDetail" roleURI="http://www.pfizer.com/role/FinancialInstrumentsNarrativeDetail">
        <link:definition>2410412 - Disclosure - Financial Instruments - Narrative (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsOtherNoncurrentLiabilitiesDetail" roleURI="http://www.pfizer.com/role/FinancialInstrumentsOtherNoncurrentLiabilitiesDetail">
        <link:definition>2410410 - Disclosure - Financial Instruments - Other Noncurrent Liabilities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsShortTermBorrowingsDetails" roleURI="http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails">
        <link:definition>2410407 - Disclosure - Financial Instruments - Short-Term Borrowings (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsTables" roleURI="http://www.pfizer.com/role/FinancialInstrumentsTables">
        <link:definition>2310301 - Disclosure - Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IdentifiableIntangibleAssetsAndGoodwill" roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwill">
        <link:definition>2112100 - Disclosure - Identifiable Intangible Assets and Goodwill</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsDetail" roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsDetail">
        <link:definition>2412402 - Disclosure - Identifiable Intangible Assets and Goodwill - Finite-lived and Indefinite-lived Intangible Assets (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsFootnotesDetails" roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsFootnotesDetails">
        <link:definition>2412403 - Disclosure - Identifiable Intangible Assets and Goodwill - Finite-lived and Indefinite-lived Intangible Assets - Footnotes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IdentifiableIntangibleAssetsAndGoodwillFiniteLivedIntangibleAssetsPercentageOfTotalIntangiblesDetails" roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedIntangibleAssetsPercentageOfTotalIntangiblesDetails">
        <link:definition>2412404 - Disclosure - Identifiable Intangible Assets and Goodwill - Finite-lived Intangible Assets Percentage of Total Intangibles (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IdentifiableIntangibleAssetsAndGoodwillGoodwillDetail" roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillGoodwillDetail">
        <link:definition>2412407 - Disclosure - Identifiable Intangible Assets and Goodwill - Goodwill (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IdentifiableIntangibleAssetsAndGoodwillIndefiniteLivedIntangibleAssetsPercentageOfTotalIntangiblesDetails" roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillIndefiniteLivedIntangibleAssetsPercentageOfTotalIntangiblesDetails">
        <link:definition>2412405 - Disclosure - Identifiable Intangible Assets and Goodwill - Indefinite-lived Intangible Assets Percentage of Total Intangibles (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IdentifiableIntangibleAssetsAndGoodwillNarrativeDetail" roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillNarrativeDetail">
        <link:definition>2412406 - Disclosure - Identifiable Intangible Assets and Goodwill - Narrative (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IdentifiableIntangibleAssetsAndGoodwillTables" roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillTables">
        <link:definition>2312301 - Disclosure - Identifiable Intangible Assets and Goodwill (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventories" roleURI="http://www.pfizer.com/role/Inventories">
        <link:definition>2111100 - Disclosure - Inventories</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesDetail" roleURI="http://www.pfizer.com/role/InventoriesDetail">
        <link:definition>2411402 - Disclosure - Inventories (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesTables" roleURI="http://www.pfizer.com/role/InventoriesTables">
        <link:definition>2311301 - Disclosure - Inventories (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherIncomeDeductionsNet" roleURI="http://www.pfizer.com/role/OtherIncomeDeductionsNet">
        <link:definition>2107100 - Disclosure - Other (Income)/Deductions - Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherIncomeDeductionsNetDetail" roleURI="http://www.pfizer.com/role/OtherIncomeDeductionsNetDetail">
        <link:definition>2407402 - Disclosure - Other (Income)/Deductions - Net (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherIncomeDeductionsNetFootnotesDetail" roleURI="http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail">
        <link:definition>2407403 - Disclosure - Other (Income)/Deductions - Net (Footnotes) (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherIncomeDeductionsNetImpairedIntangibleAssetsDetail" roleURI="http://www.pfizer.com/role/OtherIncomeDeductionsNetImpairedIntangibleAssetsDetail">
        <link:definition>2407404 - Disclosure - Other (Income)/Deductions - Net - Impaired Intangible Assets (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherIncomeDeductionsNetTables" roleURI="http://www.pfizer.com/role/OtherIncomeDeductionsNetTables">
        <link:definition>2307301 - Disclosure - Other (Income)/Deductions - Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionAndPostretirementBenefitPlans" roleURI="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlans">
        <link:definition>2113100 - Disclosure - Pension and Postretirement Benefit Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionAndPostretirementBenefitPlansDetail" roleURI="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansDetail">
        <link:definition>2413404 - Disclosure - Pension and Postretirement Benefit Plans (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionAndPostretirementBenefitPlansNetPeriodicBenefitCostDetail" roleURI="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansNetPeriodicBenefitCostDetail">
        <link:definition>2413402 - Disclosure - Pension and Postretirement Benefit Plans - Net Periodic Benefit Cost (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionAndPostretirementBenefitPlansNetPeriodicBenefitCostFootnotesDetails" roleURI="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansNetPeriodicBenefitCostFootnotesDetails">
        <link:definition>2413403 - Disclosure - Pension and Postretirement Benefit Plans - Net Periodic Benefit Cost - Footnotes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionAndPostretirementBenefitPlansTables" roleURI="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansTables">
        <link:definition>2313301 - Disclosure - Pension and Postretirement Benefit Plans (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiatives" roleURI="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiatives">
        <link:definition>2104100 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesDetail" roleURI="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesDetail">
        <link:definition>2404402 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesFootnotesDetails" roleURI="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesFootnotesDetails">
        <link:definition>2404403 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Footnotes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesRestructuringAccrualsDetail" roleURI="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesRestructuringAccrualsDetail">
        <link:definition>2404404 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Restructuring Accruals (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesRestructuringAccrualsFootnotesDetail" roleURI="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesRestructuringAccrualsFootnotesDetail">
        <link:definition>2404405 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Restructuring Accruals - Footnotes (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesTables" roleURI="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesTables">
        <link:definition>2304301 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentGeographicAndOtherRevenueInformation" roleURI="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformation">
        <link:definition>2116100 - Disclosure - Segment, Geographic and Other Revenue Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentGeographicAndOtherRevenueInformationDetail" roleURI="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationDetail">
        <link:definition>2416403 - Disclosure - Segment, Geographic and Other Revenue Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentGeographicAndOtherRevenueInformationFootnotesDetail" roleURI="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationFootnotesDetail">
        <link:definition>2416404 - Disclosure - Segment, Geographic and Other Revenue Information - Footnotes (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentGeographicAndOtherRevenueInformationNarrativeDetail" roleURI="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationNarrativeDetail">
        <link:definition>2416402 - Disclosure - Segment, Geographic and Other Revenue Information - Narrative (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentGeographicAndOtherRevenueInformationRevenuesByGeographicAreaDetail" roleURI="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByGeographicAreaDetail">
        <link:definition>2416405 - Disclosure - Segment, Geographic and Other Revenue Information - Revenues By Geographic Area (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentGeographicAndOtherRevenueInformationRevenuesByGeographicAreaFootnotesDetail" roleURI="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByGeographicAreaFootnotesDetail">
        <link:definition>2416406 - Disclosure - Segment, Geographic and Other Revenue Information - Revenues By Geographic Area - Footnotes (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail" roleURI="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail">
        <link:definition>2416407 - Disclosure - Segment, Geographic and Other Revenue Information - Revenues By Products (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentGeographicAndOtherRevenueInformationTables" roleURI="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationTables">
        <link:definition>2316301 - Disclosure - Segment, Geographic and Other Revenue Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TaxMatters" roleURI="http://www.pfizer.com/role/TaxMatters">
        <link:definition>2108100 - Disclosure - Tax Matters</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TaxMattersDetail" roleURI="http://www.pfizer.com/role/TaxMattersDetail">
        <link:definition>2408403 - Disclosure - Tax Matters (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TaxMattersNarrativeDetail" roleURI="http://www.pfizer.com/role/TaxMattersNarrativeDetail">
        <link:definition>2408402 - Disclosure - Tax Matters - Narrative (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TaxMattersTables" roleURI="http://www.pfizer.com/role/TaxMattersTables">
        <link:definition>2308301 - Disclosure - Tax Matters (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="pfe_AcceleratedShareRepurchasesSharesRepurchasedDuringPeriodPercentageofAgreementAmount" name="AcceleratedShareRepurchasesSharesRepurchasedDuringPeriodPercentageofAgreementAmount" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_AccountingStandardsUpdate201609StatutoryTaxWithholdingComponentMember" name="AccountingStandardsUpdate201609StatutoryTaxWithholdingComponentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_AdministrativeServicePeriod" name="AdministrativeServicePeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_AllOtherBiosimilarsMember" name="AllOtherBiosimilarsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_AllOtherInflammationandImmunologyProductsMember" name="AllOtherInflammationandImmunologyProductsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_AllOtherInternalMedicineMember" name="AllOtherInternalMedicineMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_AllOtherPeriLOEProductsMember" name="AllOtherPeriLOEProductsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_AllOtherRareDiseaseProductsMember" name="AllOtherRareDiseaseProductsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_AllOtherSterileInjectablePharmaceuticalsMember" name="AllOtherSterileInjectablePharmaceuticalsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_AllianceBiopharmaceuticalsMember" name="AllianceBiopharmaceuticalsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction" name="AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_AnacorMember" name="AnacorMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_AssetImpairmentsMember" name="AssetImpairmentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_AssetWriteOffsAndAssetImpairmentCharges" name="AssetWriteOffsAndAssetImpairmentCharges" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_AstraZenecaMember" name="AstraZenecaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_AverageWholesalePriceMember" name="AverageWholesalePriceMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_BMP2Member" name="BMP2Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_BambooTherapeuticsMember" name="BambooTherapeuticsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_BavencioMember" name="BavencioMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_BeneFIXMember" name="BeneFIXMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_BesponsaMember" name="BesponsaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_BiosimilarsMember" name="BiosimilarsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_BosulifMember" name="BosulifMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts" name="BusinessCombinationAcquisitionRelatedCostsTransactionCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="pfe_BusinessCombinationConsiderationTransferredAmountPayable" name="BusinessCombinationConsiderationTransferredAmountPayable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="pfe_BusinessCombinationConsiderationTransferredDeferredPayment" name="BusinessCombinationConsiderationTransferredDeferredPayment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="pfe_BusinessCombinationConsiderationTransferredMilestonePaymentsMaximum" name="BusinessCombinationConsiderationTransferredMilestonePaymentsMaximum" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="pfe_BusinessCombinationConsiderationTransferredNetofCashAcquired" name="BusinessCombinationConsiderationTransferredNetofCashAcquired" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="pfe_BusinessCombinationConsiderationTransferredSalesrelatedPaymentsMaximum" name="BusinessCombinationConsiderationTransferredSalesrelatedPaymentsMaximum" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="pfe_BusinessCombinationConsiderationTransferredUndiscountedRoyaltyPayments" name="BusinessCombinationConsiderationTransferredUndiscountedRoyaltyPayments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="pfe_BusinessCombinationConsiderationTransferredUndiscountedRoyaltyPaymentsTerm" name="BusinessCombinationConsiderationTransferredUndiscountedRoyaltyPaymentsTerm" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_BusinessCombinationExpectedIntegrationRelatedCostsPeriod" name="BusinessCombinationExpectedIntegrationRelatedCostsPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIncreaseDecreaseinAmortizationofIntangibleAssets" name="BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIncreaseDecreaseinAmortizationofIntangibleAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_BusinessCombinationsAcquisitionRelatedCostsMember" name="BusinessCombinationsAcquisitionRelatedCostsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract" name="BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsCollaborativeArrangementsEquityandCostMethodInvestmentsDisclosureTextBlock" name="BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsCollaborativeArrangementsEquityandCostMethodInvestmentsDisclosureTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_BusinessInfrastructureAlignmentCosts" name="BusinessInfrastructureAlignmentCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_BusinessIntegrationCostsMember" name="BusinessIntegrationCostsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_CelebrexMember" name="CelebrexMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_CelebrexandBextraMember" name="CelebrexandBextraMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_CentralizationofCorporateandPlatformFunctionsMember" name="CentralizationofCorporateandPlatformFunctionsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_CentreOneMember" name="CentreOneMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_CertainSignificantItemsMember" name="CertainSignificantItemsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_ChantixChampixMember" name="ChantixChampixMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_ClassActionVersusAmericanOpticalCorporationAndVariousOtherDefendantsMember" name="ClassActionVersusAmericanOpticalCorporationAndVariousOtherDefendantsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_CollaborativeArrangementCollaboratorsRevenueandExpenseOwnershipPercentage" name="CollaborativeArrangementCollaboratorsRevenueandExpenseOwnershipPercentage" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_CollaborativeArrangementCompanysRevenueandExpenseOwnershipPercentage" name="CollaborativeArrangementCompanysRevenueandExpenseOwnershipPercentage" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_ConsumerHealthcareMember" name="ConsumerHealthcareMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting" name="DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="pfe_DebtInstrumentFloorInterestRate" name="DebtInstrumentFloorInterestRate" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_DebtInstrumentRedemptionRuleRedemptionPricePercentageBasisSpread" name="DebtInstrumentRedemptionRuleRedemptionPricePercentageBasisSpread" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_DebtSecurities" name="DebtSecurities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="pfe_DebtSecuritiesMaturitiesAfterTenYears" name="DebtSecuritiesMaturitiesAfterTenYears" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="pfe_DebtSecuritiesMaturitiesOverFiveToTenYears" name="DebtSecuritiesMaturitiesOverFiveToTenYears" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="pfe_DebtSecuritiesMaturitiesOverOneToFiveYears" name="DebtSecuritiesMaturitiesOverOneToFiveYears" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="pfe_DebtSecuritiesMaturitiesWithinOneYear" name="DebtSecuritiesMaturitiesWithinOneYear" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="pfe_DecreaseinRoyaltyRevenue" name="DecreaseinRoyaltyRevenue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent" name="DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="pfe_DefinedBenefitPlanActuarialLossandPriorServiceCostsImmediateRecognitionasComponentinNetPeriodicBenefitCost" name="DefinedBenefitPlanActuarialLossandPriorServiceCostsImmediateRecognitionasComponentinNetPeriodicBenefitCost" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetActuarialGainLossTax" name="DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetActuarialGainLossTax" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetPriorServiceCostCreditAndOtherTax" name="DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetPriorServiceCostCreditAndOtherTax" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="pfe_DefinedBenefitPlanNetPeriodicBenefitCostCreditGainLossDuetoSettlementPretax" name="DefinedBenefitPlanNetPeriodicBenefitCostCreditGainLossDuetoSettlementPretax" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="pfe_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization" name="DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_DevelopedEuropeMember" name="DevelopedEuropeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_DevelopedRestOfWorldMember" name="DevelopedRestOfWorldMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivable" name="DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivableInterestRate" name="DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivableInterestRate" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivableInterestRateYearThree" name="DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivableInterestRateYearThree" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivableInterestRateYearTwo" name="DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivableInterestRateYearTwo" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivableTerm" name="DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivableTerm" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationTransferredEquityInterests" name="DisposalGroupIncludingDiscontinuedOperationConsiderationTransferredEquityInterests" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationTransferredEquityInterestsShares" name="DisposalGroupIncludingDiscontinuedOperationConsiderationTransferredEquityInterestsShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element id="pfe_DisposalGroupIncludingDiscontinuedOperationContingentConsideration" name="DisposalGroupIncludingDiscontinuedOperationContingentConsideration" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="pfe_DisposalGroupIncludingDiscontinuedOperationShareTransferRestrictionTermMinimum" name="DisposalGroupIncludingDiscontinuedOperationShareTransferRestrictionTermMinimum" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_DistinctBusinessAxis" name="DistinctBusinessAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_DistinctBusinessDomain" name="DistinctBusinessDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_DocumentandEntityInformationAbstract" name="DocumentandEntityInformationAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_EURIBORMember" name="EURIBORMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTaxBenefitAmount" name="EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTaxBenefitAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_EffexorMember" name="EffexorMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_EliquisMember" name="EliquisMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_EmergingMarketsMember" name="EmergingMarketsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_EnbrelMember" name="EnbrelMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_EnterprisewideCostReductionProductivityPlanMember" name="EnterprisewideCostReductionProductivityPlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_EnvironmentalRemediationLitigationMember" name="EnvironmentalRemediationLitigationMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_EpiPenMember" name="EpiPenMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_EssentialHealthBusinessMember" name="EssentialHealthBusinessMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_EssentialHealthProductCategoryAxis" name="EssentialHealthProductCategoryAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_EssentialHealthProductCategoryDomain" name="EssentialHealthProductCategoryDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_EssentialHealthSegmentMember" name="EssentialHealthSegmentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_EucrisaMember" name="EucrisaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_EuroLongtermDebtMember" name="EuroLongtermDebtMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_FSMEIMMUNTicoVacMember" name="FSMEIMMUNTicoVacMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_FeasibilityStudyNumberOfLagoons" name="FeasibilityStudyNumberOfLagoons" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_FinancialAssetsAndLiabilitiesMeasuredAtFairValuePercentage" name="FinancialAssetsAndLiabilitiesMeasuredAtFairValuePercentage" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="pfe_FinancialInstrumentsAbstract" name="FinancialInstrumentsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_FootnotesToSelectedFinancialAssetsAndLiabilitiesAbstract" name="FootnotesToSelectedFinancialAssetsAndLiabilitiesAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_ForeignCurrencyLongTermDebtMember" name="ForeignCurrencyLongTermDebtMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_ForeignCurrencyShortTermBorrowingsMember" name="ForeignCurrencyShortTermBorrowingsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_FragminMember" name="FragminMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_GainContingencyNumberofDefendants" name="GainContingencyNumberofDefendants" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_GainContingencyPatentsAllegedlyInfringeduponNumberDuetoExpireinDecember2020" name="GainContingencyPatentsAllegedlyInfringeduponNumberDuetoExpireinDecember2020" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_GainContingencyPatentsAllegedlyInfringeduponNumberDuetoExpireinDecember2025" name="GainContingencyPatentsAllegedlyInfringeduponNumberDuetoExpireinDecember2025" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_GainLossOnDispositionOfAssetsAndEquitySecurities" name="GainLossOnDispositionOfAssetsAndEquitySecurities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_GenotropinMember" name="GenotropinMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_GermanGovernmentBondRateMember" name="GermanGovernmentBondRateMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_HISMember" name="HISMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_HisunPfizerPharmaceuticalsCoLtdMember" name="HisunPfizerPharmaceuticalsCoLtdMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_HospiraInfusionSystemsMember" name="HospiraInfusionSystemsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_HospiraMember" name="HospiraMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_HospiraVersusAmnealPharmaceuticalsLLCMember" name="HospiraVersusAmnealPharmaceuticalsLLCMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_HospiraVersusFreseniusMember" name="HospiraVersusFreseniusMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_HospiraVersusParMember" name="HospiraVersusParMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_ICUMedicalMember" name="ICUMedicalMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_IbranceMember" name="IbranceMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_IdentifiableintangibleassetsasapercentageoftotalidentifiableintangibleassetslessaccumulatedamortizationbysegmentTableTextBlock" name="IdentifiableintangibleassetsasapercentageoftotalidentifiableintangibleassetslessaccumulatedamortizationbysegmentTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_ImplementationCostAbstract" name="ImplementationCostAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_ImplementationCosts" name="ImplementationCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic" name="IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted" name="IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_InflammationandImmunologyMember" name="InflammationandImmunologyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_InflectraMember" name="InflectraMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_InflectraRemsimaMember" name="InflectraRemsimaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_InlytaMember" name="InlytaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_InnoPharmaMember" name="InnoPharmaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_InnovativeHealthBusinessMember" name="InnovativeHealthBusinessMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_InnovativeHealthSegmentMember" name="InnovativeHealthSegmentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_InnovativeHealthandEssentialHealthMember" name="InnovativeHealthandEssentialHealthMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_InnovativeProductsCategoryAxis" name="InnovativeProductsCategoryAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_InnovativeProductsCategoryDomain" name="InnovativeProductsCategoryDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet" name="IntangibleAssetsNetPercentageofIntangibleAssetsNet" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="pfe_IntangibleAssetsTransfersDuringPeriod" name="IntangibleAssetsTransfersDuringPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="pfe_InterestPaidInterestRateHedges" name="InterestPaidInterestRateHedges" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_InternalMedicineMember" name="InternalMedicineMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_JanssenandNewYorkUniversityVersusHospiraCelltrionHealthcareandCelltrionInc.Member" name="JanssenandNewYorkUniversityVersusHospiraCelltrionHealthcareandCelltrionInc.Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_KingMember" name="KingMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_LaboratorioTeutoBrasileroMember" name="LaboratorioTeutoBrasileroMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_LegacyEstablishedProductsMember" name="LegacyEstablishedProductsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_LicensingAgreementsAndOtherMember" name="LicensingAgreementsAndOtherMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_LipitorMember" name="LipitorMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_LongtermInvestmentsMember" name="LongtermInvestmentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_LossContingencyCollaborationArrangementPercentageofPaymentsSoughtbyPlaintiff" name="LossContingencyCollaborationArrangementPercentageofPaymentsSoughtbyPlaintiff" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_LyricaMember" name="LyricaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_ManufacturingOperationsMember" name="ManufacturingOperationsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_ManufacturingPlantNetworkOptimizationMember" name="ManufacturingPlantNetworkOptimizationMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_MaximumManufacturingServicePeriod" name="MaximumManufacturingServicePeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_MedivationMember" name="MedivationMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_MedrolMember" name="MedrolMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_MerckKGaAMember" name="MerckKGaAMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_MylotargMember" name="MylotargMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_NetInvestmentHedgingNonderivativeInstrumentsMember" name="NetInvestmentHedgingNonderivativeInstrumentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_NoncashorPartNoncashDivestitureAmountofConsiderationReceivedCommonStock" name="NoncashorPartNoncashDivestitureAmountofConsiderationReceivedCommonStock" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="pfe_NoncashorPartNoncashDivestitureAmountofConsiderationReceivedNoteReceivable" name="NoncashorPartNoncashDivestitureAmountofConsiderationReceivedNoteReceivable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_NorvascMember" name="NorvascMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_OncologyMember" name="OncologyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditTax" name="OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditTax" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax" name="OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax" name="OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax" name="OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodTax" name="OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodTax" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax" name="OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax" name="OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossTax" name="OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossTax" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_OtherDerivativeInstrumentsMember" name="OtherDerivativeInstrumentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_OtherFinancialLiabilities" name="OtherFinancialLiabilities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="pfe_OtherInProcessResearchandDevelopmentMember" name="OtherInProcessResearchandDevelopmentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_OtherIncomeExpenseMember" name="OtherIncomeExpenseMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_OtherLegacyEstablishedProductsMember" name="OtherLegacyEstablishedProductsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_OtherNonoperatingIncomeExpenseNet" name="OtherNonoperatingIncomeExpenseNet" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="pfe_OtherNonoperatingIncomeMiscellaneous" name="OtherNonoperatingIncomeMiscellaneous" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_OtherOncologyProductsMember" name="OtherOncologyProductsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_OtherSegmentReconcilingItemsAxis" name="OtherSegmentReconcilingItemsAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_OtherSegmentReconcilingItemsDomain" name="OtherSegmentReconcilingItemsDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_OtherSelectedFinancialAssets" name="OtherSelectedFinancialAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="pfe_OtherSelectedFinancialAssetsAbstract" name="OtherSelectedFinancialAssetsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_OtherSelectedFinancialLiabilitiesAbstract" name="OtherSelectedFinancialLiabilitiesAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_OtherTaxAssetsCurrent" name="OtherTaxAssetsCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="pfe_OtherUnallocatedMember" name="OtherUnallocatedMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_OtherVaccinesProductsMember" name="OtherVaccinesProductsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_PatentInfringementMember" name="PatentInfringementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_PatentMatterMember" name="PatentMatterMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_PaymentsforMergerTerminationCosts" name="PaymentsforMergerTerminationCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment" name="PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="pfe_PaymentstoAcquireBusinessesGrossInitialPayment" name="PaymentstoAcquireBusinessesGrossInitialPayment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="pfe_PaymentstoAcquireBusinessesGrossPurchasePriceAdjustment" name="PaymentstoAcquireBusinessesGrossPurchasePriceAdjustment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense" name="PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="pfe_PercentageChangeInRevenue" name="PercentageChangeInRevenue" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_PeriLOEProductsMember" name="PeriLOEProductsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_PfizerVersusBMSE.R.SquibbSonsOnoPharmaceuticalandTasukuHonjoMember" name="PfizerVersusBMSE.R.SquibbSonsOnoPharmaceuticalandTasukuHonjoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_PfizerVersusBreckenridgeMember" name="PfizerVersusBreckenridgeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_PfizerVersusMicroLabsMember" name="PfizerVersusMicroLabsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_PfizerVersusMylanLaboratoriesandAccordHealthcareInc.Member" name="PfizerVersusMylanLaboratoriesandAccordHealthcareInc.Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_PfizerVersusPrinstonandBreckenridgeMember" name="PfizerVersusPrinstonandBreckenridgeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_PfizerVersusSeveralGenericManufacturersMember" name="PfizerVersusSeveralGenericManufacturersMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_PfizerVersusZydusMember" name="PfizerVersusZydusMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_PfizerandBMSVersusSeveralGenericManufacturersMember" name="PfizerandBMSVersusSeveralGenericManufacturersMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_PfizersWorldwideResearchandDevelopmentMember" name="PfizersWorldwideResearchandDevelopmentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_PfizersWorldwideResearchandDevelopmentandPfizersGlobalProductDevelopmentMember" name="PfizersWorldwideResearchandDevelopmentandPfizersGlobalProductDevelopmentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_PhenytoinSodiumCapsulesMember" name="PhenytoinSodiumCapsulesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_PrecedexMember" name="PrecedexMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_PrecedexPremixMember" name="PrecedexPremixMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_PremarinFamilyMember" name="PremarinFamilyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_PrevnarPrevenarFamilyMember" name="PrevnarPrevenarFamilyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_PristiqMember" name="PristiqMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_PurchaseAccountingAdjustmentsMember" name="PurchaseAccountingAdjustmentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_RareDiseaseMember" name="RareDiseaseMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_ReFactoAfXynthaMember" name="ReFactoAfXynthaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_RegentsVersusMedivationMember" name="RegentsVersusMedivationMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_RelpaxMember" name="RelpaxMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_ResearchandDevelopmentArrangementAggregatePaymentObligation" name="ResearchandDevelopmentArrangementAggregatePaymentObligation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="pfe_ResearchandDevelopmentArrangementAggregatePaymentObligationTerm" name="ResearchandDevelopmentArrangementAggregatePaymentObligationTerm" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_RestructuringAssetImpairmentCharges" name="RestructuringAssetImpairmentCharges" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts" name="RestructuringChargesAcquisitionRelatedCostsandImplementationCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="pfe_RestructuringChargesAndAcquisitionRelatedCosts" name="RestructuringChargesAndAcquisitionRelatedCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="pfe_RestructuringChargesandImplementationCosts" name="RestructuringChargesandImplementationCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="pfe_RestructuringandRelatedCostNoncashChargesPercentage" name="RestructuringandRelatedCostNoncashChargesPercentage" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_ReturnofAcquiredRightsMember" name="ReturnofAcquiredRightsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_RevatioMember" name="RevatioMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_RoyaltyRevenueTerm" name="RoyaltyRevenueTerm" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_ScheduleofEmployerContributionstoPensionandPostretirementPlansTableTextBlock" name="ScheduleofEmployerContributionstoPensionandPostretirementPlansTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock" name="ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_SelectedFinancialAssets" name="SelectedFinancialAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="pfe_SelectedFinancialLiabilities" name="SelectedFinancialLiabilities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="pfe_SeniorUnsecuredDebtFourPointTwoPercentDue2047Member" name="SeniorUnsecuredDebtFourPointTwoPercentDue2047Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_SeniorUnsecuredEuroDebtOnePointZeroPercentDue2027Member" name="SeniorUnsecuredEuroDebtOnePointZeroPercentDue2027Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_SeniorUnsecuredEuroDebtPointTwofivePercentDue2022Member" name="SeniorUnsecuredEuroDebtPointTwofivePercentDue2022Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_SeniorUnsecuredEuroDebtThreemonthEURIBORPlus0.20FloatingRateNotesMember" name="SeniorUnsecuredEuroDebtThreemonthEURIBORPlus0.20FloatingRateNotesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_SeniorUnsecuredEuroDebtZeroPercentDue2020Member" name="SeniorUnsecuredEuroDebtZeroPercentDue2020Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_ShareRepurchaseAgreementwithCitibankMember" name="ShareRepurchaseAgreementwithCitibankMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_ShortTermDebtAndCurrentPortionofLongTermDebtMember" name="ShortTermDebtAndCurrentPortionofLongTermDebtMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_ShorttermDebtGross" name="ShorttermDebtGross" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="pfe_SomavertMember" name="SomavertMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_StateofIllinoisVersusPfizerMember" name="StateofIllinoisVersusPfizerMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_SterileInjectablePharmaceuticalsMember" name="SterileInjectablePharmaceuticalsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_SulperazonMember" name="SulperazonMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_SupranationalDebtMember" name="SupranationalDebtMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_SutentMember" name="SutentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_TimeDepositsCorporateDebtAndOtherMember" name="TimeDepositsCorporateDebtAndOtherMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_ToviazCompositionofmatterPatentsMember" name="ToviazCompositionofmatterPatentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_ToviazMember" name="ToviazMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_TygacilMember" name="TygacilMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_VaccinesMember" name="VaccinesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_VfendMember" name="VfendMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_ViagraMember" name="ViagraMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_ViivHealthcareLimitedMember" name="ViivHealthcareLimitedMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_ViolationofAntitrustLawsMember" name="ViolationofAntitrustLawsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_WesternEuropeanAsianandOtherGovernmentDebtMember" name="WesternEuropeanAsianandOtherGovernmentDebtMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_WesternEuropeanScandinaviaAndOtherGovernmentAgencyDebtMember" name="WesternEuropeanScandinaviaAndOtherGovernmentAgencyDebtMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_WesternEuropeanandOtherGovernmentDebtMember" name="WesternEuropeanandOtherGovernmentDebtMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_WorldwideResearchandDevelopmentandGlobalProductDevelopmentMember" name="WorldwideResearchandDevelopmentandGlobalProductDevelopmentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_WyethVersusSunMember" name="WyethVersusSunMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_XalatanXalacomMember" name="XalatanXalacomMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_XalkoriMember" name="XalkoriMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_XanaxXanaxXRMember" name="XanaxXanaxXRMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_XeljanzMember" name="XeljanzMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_XtandiAllianceMember" name="XtandiAllianceMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_XtandiMember" name="XtandiMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_ZithromaxZmaxMember" name="ZithromaxZmaxMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_ZoloftMember" name="ZoloftMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_ZyvoxMember" name="ZyvoxMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>11
<FILENAME>pfe-20171001_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterests" xlink:href="pfe-20171001.xsd#AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterests" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetail" xlink:href="pfe-20171001.xsd#AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsTables" xlink:href="pfe-20171001.xsd#AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestments" xlink:href="pfe-20171001.xsd#AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsAnacorPharmaceuticalsIncDetails" xlink:href="pfe-20171001.xsd#AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsAnacorPharmaceuticalsIncDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsAstrazenecaDetails" xlink:href="pfe-20171001.xsd#AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsAstrazenecaDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsBambooTherapeuticsDetails" xlink:href="pfe-20171001.xsd#AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsBambooTherapeuticsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsCollaborationArrangementDetails" xlink:href="pfe-20171001.xsd#AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsCollaborationArrangementDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsEquityMethodInvestmentsDetails" xlink:href="pfe-20171001.xsd#AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsEquityMethodInvestmentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsMedivationDetails" xlink:href="pfe-20171001.xsd#AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsMedivationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsSaleOfHospiraInfusionSystemsNetAssetsToIcuMedicalIncEhDetails" xlink:href="pfe-20171001.xsd#AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsSaleOfHospiraInfusionSystemsNetAssetsToIcuMedicalIncEhDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPolicies" xlink:href="pfe-20171001.xsd#BasisOfPresentationAndSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetails" xlink:href="pfe-20171001.xsd#BasisOfPresentationAndSignificantAccountingPoliciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies" xlink:href="pfe-20171001.xsd#BasisOfPresentationAndSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/CommitmentsAndContingencies" xlink:href="pfe-20171001.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/CommitmentsAndContingenciesActionsInWhichWeAreDefendantDetail" xlink:href="pfe-20171001.xsd#CommitmentsAndContingenciesActionsInWhichWeAreDefendantDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/CommitmentsAndContingenciesActionsInWhichWeArePlaintiffDetails" xlink:href="pfe-20171001.xsd#CommitmentsAndContingenciesActionsInWhichWeArePlaintiffDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/CommitmentsAndContingenciesDetails" xlink:href="pfe-20171001.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets" xlink:href="pfe-20171001.xsd#CondensedConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:href="pfe-20171001.xsd#CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:href="pfe-20171001.xsd#CondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlowsParenthetical" xlink:href="pfe-20171001.xsd#CondensedConsolidatedStatementsOfCashFlowsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome" xlink:href="pfe-20171001.xsd#CondensedConsolidatedStatementsOfComprehensiveIncome" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeParenthetical" xlink:href="pfe-20171001.xsd#CondensedConsolidatedStatementsOfComprehensiveIncomeParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/CondensedConsolidatedStatementsOfIncome" xlink:href="pfe-20171001.xsd#CondensedConsolidatedStatementsOfIncome" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/DocumentAndEntityInformation" xlink:href="pfe-20171001.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/EarningsPerCommonShareAttributableToCommonShareholders" xlink:href="pfe-20171001.xsd#EarningsPerCommonShareAttributableToCommonShareholders" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/EarningsPerCommonShareAttributableToCommonShareholdersDetails" xlink:href="pfe-20171001.xsd#EarningsPerCommonShareAttributableToCommonShareholdersDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/EarningsPerCommonShareAttributableToCommonShareholdersTables" xlink:href="pfe-20171001.xsd#EarningsPerCommonShareAttributableToCommonShareholdersTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstruments" xlink:href="pfe-20171001.xsd#FinancialInstruments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail" xlink:href="pfe-20171001.xsd#FinancialInstrumentsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsAssetsAndLiabilitiesMeasuredOnRecurringBasisFootnotesDetail" xlink:href="pfe-20171001.xsd#FinancialInstrumentsAssetsAndLiabilitiesMeasuredOnRecurringBasisFootnotesDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsBalanceSheetGroupingDetail" xlink:href="pfe-20171001.xsd#FinancialInstrumentsBalanceSheetGroupingDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsBalanceSheetGroupingFootnotesDetail" xlink:href="pfe-20171001.xsd#FinancialInstrumentsBalanceSheetGroupingFootnotesDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetail" xlink:href="pfe-20171001.xsd#FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsInvestmentsInDebtSecuritiesDetail" xlink:href="pfe-20171001.xsd#FinancialInstrumentsInvestmentsInDebtSecuritiesDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsInvestmentsInDebtSecuritiesDetailCalc2" xlink:href="pfe-20171001.xsd#FinancialInstrumentsInvestmentsInDebtSecuritiesDetailCalc2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails" xlink:href="pfe-20171001.xsd#FinancialInstrumentsLongTermDebtDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtMaturitiesDetails" xlink:href="pfe-20171001.xsd#FinancialInstrumentsLongTermDebtMaturitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsNarrativeDetail" xlink:href="pfe-20171001.xsd#FinancialInstrumentsNarrativeDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsOtherNoncurrentLiabilitiesDetail" xlink:href="pfe-20171001.xsd#FinancialInstrumentsOtherNoncurrentLiabilitiesDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails" xlink:href="pfe-20171001.xsd#FinancialInstrumentsShortTermBorrowingsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsTables" xlink:href="pfe-20171001.xsd#FinancialInstrumentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwill" xlink:href="pfe-20171001.xsd#IdentifiableIntangibleAssetsAndGoodwill" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsDetail" xlink:href="pfe-20171001.xsd#IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsFootnotesDetails" xlink:href="pfe-20171001.xsd#IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsFootnotesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedIntangibleAssetsPercentageOfTotalIntangiblesDetails" xlink:href="pfe-20171001.xsd#IdentifiableIntangibleAssetsAndGoodwillFiniteLivedIntangibleAssetsPercentageOfTotalIntangiblesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillGoodwillDetail" xlink:href="pfe-20171001.xsd#IdentifiableIntangibleAssetsAndGoodwillGoodwillDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillIndefiniteLivedIntangibleAssetsPercentageOfTotalIntangiblesDetails" xlink:href="pfe-20171001.xsd#IdentifiableIntangibleAssetsAndGoodwillIndefiniteLivedIntangibleAssetsPercentageOfTotalIntangiblesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillNarrativeDetail" xlink:href="pfe-20171001.xsd#IdentifiableIntangibleAssetsAndGoodwillNarrativeDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillTables" xlink:href="pfe-20171001.xsd#IdentifiableIntangibleAssetsAndGoodwillTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/Inventories" xlink:href="pfe-20171001.xsd#Inventories" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/InventoriesDetail" xlink:href="pfe-20171001.xsd#InventoriesDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/InventoriesTables" xlink:href="pfe-20171001.xsd#InventoriesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/OtherIncomeDeductionsNet" xlink:href="pfe-20171001.xsd#OtherIncomeDeductionsNet" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/OtherIncomeDeductionsNetDetail" xlink:href="pfe-20171001.xsd#OtherIncomeDeductionsNetDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail" xlink:href="pfe-20171001.xsd#OtherIncomeDeductionsNetFootnotesDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/OtherIncomeDeductionsNetImpairedIntangibleAssetsDetail" xlink:href="pfe-20171001.xsd#OtherIncomeDeductionsNetImpairedIntangibleAssetsDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/OtherIncomeDeductionsNetTables" xlink:href="pfe-20171001.xsd#OtherIncomeDeductionsNetTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlans" xlink:href="pfe-20171001.xsd#PensionAndPostretirementBenefitPlans" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansDetail" xlink:href="pfe-20171001.xsd#PensionAndPostretirementBenefitPlansDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansNetPeriodicBenefitCostDetail" xlink:href="pfe-20171001.xsd#PensionAndPostretirementBenefitPlansNetPeriodicBenefitCostDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansNetPeriodicBenefitCostFootnotesDetails" xlink:href="pfe-20171001.xsd#PensionAndPostretirementBenefitPlansNetPeriodicBenefitCostFootnotesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansTables" xlink:href="pfe-20171001.xsd#PensionAndPostretirementBenefitPlansTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiatives" xlink:href="pfe-20171001.xsd#RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiatives" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesDetail" xlink:href="pfe-20171001.xsd#RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesFootnotesDetails" xlink:href="pfe-20171001.xsd#RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesFootnotesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesRestructuringAccrualsDetail" xlink:href="pfe-20171001.xsd#RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesRestructuringAccrualsDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesRestructuringAccrualsFootnotesDetail" xlink:href="pfe-20171001.xsd#RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesRestructuringAccrualsFootnotesDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesTables" xlink:href="pfe-20171001.xsd#RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformation" xlink:href="pfe-20171001.xsd#SegmentGeographicAndOtherRevenueInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationDetail" xlink:href="pfe-20171001.xsd#SegmentGeographicAndOtherRevenueInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationFootnotesDetail" xlink:href="pfe-20171001.xsd#SegmentGeographicAndOtherRevenueInformationFootnotesDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationNarrativeDetail" xlink:href="pfe-20171001.xsd#SegmentGeographicAndOtherRevenueInformationNarrativeDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByGeographicAreaDetail" xlink:href="pfe-20171001.xsd#SegmentGeographicAndOtherRevenueInformationRevenuesByGeographicAreaDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByGeographicAreaFootnotesDetail" xlink:href="pfe-20171001.xsd#SegmentGeographicAndOtherRevenueInformationRevenuesByGeographicAreaFootnotesDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail" xlink:href="pfe-20171001.xsd#SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationTables" xlink:href="pfe-20171001.xsd#SegmentGeographicAndOtherRevenueInformationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/TaxMatters" xlink:href="pfe-20171001.xsd#TaxMatters" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/TaxMattersDetail" xlink:href="pfe-20171001.xsd#TaxMattersDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/TaxMattersNarrativeDetail" xlink:href="pfe-20171001.xsd#TaxMattersNarrativeDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/TaxMattersTables" xlink:href="pfe-20171001.xsd#TaxMattersTables" xlink:type="simple" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterests" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestments" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsAnacorPharmaceuticalsIncDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsAstrazenecaDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsBambooTherapeuticsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsCollaborationArrangementDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsEquityMethodInvestmentsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsMedivationDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsSaleOfHospiraInfusionSystemsNetAssetsToIcuMedicalIncEhDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPolicies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/CommitmentsAndContingencies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/CommitmentsAndContingenciesActionsInWhichWeAreDefendantDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/CommitmentsAndContingenciesActionsInWhichWeArePlaintiffDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/CommitmentsAndContingenciesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_159dcb00-b17e-17db-7098-be4159799459" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_d8bb821f-d155-9d4e-1738-736b4bf4cb19" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_159dcb00-b17e-17db-7098-be4159799459" xlink:to="loc_us-gaap_Liabilities_d8bb821f-d155-9d4e-1738-736b4bf4cb19" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_f5e246cf-e80f-d00b-c8ed-4796aa2df4b4" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d8bb821f-d155-9d4e-1738-736b4bf4cb19" xlink:to="loc_us-gaap_LiabilitiesCurrent_f5e246cf-e80f-d00b-c8ed-4796aa2df4b4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtCurrent" xlink:label="loc_us-gaap_DebtCurrent_f84a497d-68eb-d3d3-1597-16bfb6772366" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f5e246cf-e80f-d00b-c8ed-4796aa2df4b4" xlink:to="loc_us-gaap_DebtCurrent_f84a497d-68eb-d3d3-1597-16bfb6772366" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_7a72b51a-735c-1ad4-bd3f-d9bcf2d6a26d" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f5e246cf-e80f-d00b-c8ed-4796aa2df4b4" xlink:to="loc_us-gaap_AccountsPayableCurrent_7a72b51a-735c-1ad4-bd3f-d9bcf2d6a26d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DividendsPayableCurrent" xlink:label="loc_us-gaap_DividendsPayableCurrent_5de08225-2a59-df57-5770-2abc56efe41b" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f5e246cf-e80f-d00b-c8ed-4796aa2df4b4" xlink:to="loc_us-gaap_DividendsPayableCurrent_5de08225-2a59-df57-5770-2abc56efe41b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TaxesPayableCurrent" xlink:label="loc_us-gaap_TaxesPayableCurrent_8544ed0a-bea0-b1fa-ce65-66a1927d2672" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f5e246cf-e80f-d00b-c8ed-4796aa2df4b4" xlink:to="loc_us-gaap_TaxesPayableCurrent_8544ed0a-bea0-b1fa-ce65-66a1927d2672" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_cf9ed09f-3dd1-4a4b-d3fc-3b0db18c1b40" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f5e246cf-e80f-d00b-c8ed-4796aa2df4b4" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_cf9ed09f-3dd1-4a4b-d3fc-3b0db18c1b40" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_b4e6cca3-6c62-3e0a-6782-510b974f1199" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f5e246cf-e80f-d00b-c8ed-4796aa2df4b4" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_b4e6cca3-6c62-3e0a-6782-510b974f1199" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_822b66ff-44a1-e66b-5e0c-09356970a23d" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d8bb821f-d155-9d4e-1738-736b4bf4cb19" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_822b66ff-44a1-e66b-5e0c-09356970a23d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent_047fbbde-4aa8-869d-d78f-3a4cdb9536c5" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d8bb821f-d155-9d4e-1738-736b4bf4cb19" xlink:to="loc_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent_047fbbde-4aa8-869d-d78f-3a4cdb9536c5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent_7befc5cf-839d-5f10-9adb-3081595dab8a" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d8bb821f-d155-9d4e-1738-736b4bf4cb19" xlink:to="loc_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent_7befc5cf-839d-5f10-9adb-3081595dab8a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_9a73c768-7e07-f56f-7aba-2b93110d3715" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d8bb821f-d155-9d4e-1738-736b4bf4cb19" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_9a73c768-7e07-f56f-7aba-2b93110d3715" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_f234998c-5e05-09d0-d53e-5c44423c97c0" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d8bb821f-d155-9d4e-1738-736b4bf4cb19" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_f234998c-5e05-09d0-d53e-5c44423c97c0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilityForUncertainTaxPositionsNoncurrent" xlink:label="loc_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent_bda61526-afae-4edf-1e19-ab8c94a352d1" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d8bb821f-d155-9d4e-1738-736b4bf4cb19" xlink:to="loc_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent_bda61526-afae-4edf-1e19-ab8c94a352d1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_058e01e4-b9a1-623e-29f5-1b5c79bf095a" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_159dcb00-b17e-17db-7098-be4159799459" xlink:to="loc_us-gaap_CommitmentsAndContingencies_058e01e4-b9a1-623e-29f5-1b5c79bf095a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_00443492-92dd-7fc1-13b6-792f3e163e73" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_159dcb00-b17e-17db-7098-be4159799459" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_00443492-92dd-7fc1-13b6-792f3e163e73" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_4b158f76-5f04-5e4d-ead3-d80e1f9943db" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_00443492-92dd-7fc1-13b6-792f3e163e73" xlink:to="loc_us-gaap_StockholdersEquity_4b158f76-5f04-5e4d-ead3-d80e1f9943db" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_4fb6195d-d905-dac7-e5a0-79f324993f79" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b158f76-5f04-5e4d-ead3-d80e1f9943db" xlink:to="loc_us-gaap_PreferredStockValue_4fb6195d-d905-dac7-e5a0-79f324993f79" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_c3f7606a-e7e9-61d5-b60b-b4b059f68b26" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b158f76-5f04-5e4d-ead3-d80e1f9943db" xlink:to="loc_us-gaap_CommonStockValue_c3f7606a-e7e9-61d5-b60b-b4b059f68b26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_2d1b9d27-8b19-82d9-2843-5b3d292b7fbb" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b158f76-5f04-5e4d-ead3-d80e1f9943db" xlink:to="loc_us-gaap_AdditionalPaidInCapital_2d1b9d27-8b19-82d9-2843-5b3d292b7fbb" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue_40678492-c421-af67-b276-f663f9ff2f98" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b158f76-5f04-5e4d-ead3-d80e1f9943db" xlink:to="loc_us-gaap_TreasuryStockValue_40678492-c421-af67-b276-f663f9ff2f98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_065cb284-7fca-cc9b-5752-2feaf74d0011" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b158f76-5f04-5e4d-ead3-d80e1f9943db" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_065cb284-7fca-cc9b-5752-2feaf74d0011" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_04f0961a-a0bc-88cf-6658-3f950da4a458" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b158f76-5f04-5e4d-ead3-d80e1f9943db" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_04f0961a-a0bc-88cf-6658-3f950da4a458" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_cb565c4d-35c2-d825-4672-f1619e51c133" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_00443492-92dd-7fc1-13b6-792f3e163e73" xlink:to="loc_us-gaap_MinorityInterest_cb565c4d-35c2-d825-4672-f1619e51c133" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_c6057b1d-6685-8249-2051-6c57f3a16a9e" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_8a47066b-3628-88d1-49db-ed09aecc7fc7" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c6057b1d-6685-8249-2051-6c57f3a16a9e" xlink:to="loc_us-gaap_AssetsCurrent_8a47066b-3628-88d1-49db-ed09aecc7fc7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_07da1db4-2708-4446-4250-1fdd5956185e" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8a47066b-3628-88d1-49db-ed09aecc7fc7" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_07da1db4-2708-4446-4250-1fdd5956185e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaap_ShortTermInvestments_d585eba8-c5c0-6186-d29a-3180d2b06f0a" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8a47066b-3628-88d1-49db-ed09aecc7fc7" xlink:to="loc_us-gaap_ShortTermInvestments_d585eba8-c5c0-6186-d29a-3180d2b06f0a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_dd7775cd-f4ab-5607-9b31-1ee98f605818" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8a47066b-3628-88d1-49db-ed09aecc7fc7" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_dd7775cd-f4ab-5607-9b31-1ee98f605818" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_7eab44cf-1ea1-ca2a-420f-21f7b5343fc3" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8a47066b-3628-88d1-49db-ed09aecc7fc7" xlink:to="loc_us-gaap_InventoryNet_7eab44cf-1ea1-ca2a-420f-21f7b5343fc3" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_OtherTaxAssetsCurrent" xlink:label="loc_pfe_OtherTaxAssetsCurrent_546ce482-ec61-91b6-cad8-2177fd9bbb48" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8a47066b-3628-88d1-49db-ed09aecc7fc7" xlink:to="loc_pfe_OtherTaxAssetsCurrent_546ce482-ec61-91b6-cad8-2177fd9bbb48" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_1cb4a384-e314-2300-ad55-c1ed289c8f7a" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8a47066b-3628-88d1-49db-ed09aecc7fc7" xlink:to="loc_us-gaap_OtherAssetsCurrent_1cb4a384-e314-2300-ad55-c1ed289c8f7a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_7ccd4058-c821-b334-f2ba-45d4b5754cc1" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8a47066b-3628-88d1-49db-ed09aecc7fc7" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_7ccd4058-c821-b334-f2ba-45d4b5754cc1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermInvestments" xlink:label="loc_us-gaap_LongTermInvestments_c62504ca-c588-7676-b66d-68002db39ddb" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c6057b1d-6685-8249-2051-6c57f3a16a9e" xlink:to="loc_us-gaap_LongTermInvestments_c62504ca-c588-7676-b66d-68002db39ddb" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_1944a381-5c4e-ce3c-9111-13ccd1c639db" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c6057b1d-6685-8249-2051-6c57f3a16a9e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_1944a381-5c4e-ce3c-9111-13ccd1c639db" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_1fe06082-076b-052d-6e2e-930afe9d6b2d" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c6057b1d-6685-8249-2051-6c57f3a16a9e" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_1fe06082-076b-052d-6e2e-930afe9d6b2d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_93a64cae-271a-5e6b-8c83-5adf9f941142" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c6057b1d-6685-8249-2051-6c57f3a16a9e" xlink:to="loc_us-gaap_Goodwill_93a64cae-271a-5e6b-8c83-5adf9f941142" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent" xlink:label="loc_pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent_82e43fc9-87c0-0333-771d-2177fdb8d34d" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c6057b1d-6685-8249-2051-6c57f3a16a9e" xlink:to="loc_pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent_82e43fc9-87c0-0333-771d-2177fdb8d34d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_9b27fab9-d497-627b-4cfb-6b585220b978" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c6057b1d-6685-8249-2051-6c57f3a16a9e" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_9b27fab9-d497-627b-4cfb-6b585220b978" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_dd2e9db6-10f9-d78a-ba84-b18268245a83" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_dd2e9db6-10f9-d78a-ba84-b18268245a83" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_adacf05e-7e15-bd60-3e53-87432885dc29" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_ProfitLoss_adacf05e-7e15-bd60-3e53-87432885dc29" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization" xlink:label="loc_pfe_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization_4417beaf-3d45-7630-2dcc-2177fd626ab8" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_pfe_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization_4417beaf-3d45-7630-2dcc-2177fd626ab8" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_AssetWriteOffsAndAssetImpairmentCharges" xlink:label="loc_pfe_AssetWriteOffsAndAssetImpairmentCharges_6f7b0cfa-e2fe-7d77-15ea-2177fd34dfd6" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_pfe_AssetWriteOffsAndAssetImpairmentCharges_6f7b0cfa-e2fe-7d77-15ea-2177fd34dfd6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_03e83c30-c623-f96c-29f8-521a710884ee" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_03e83c30-c623-f96c-29f8-521a710884ee" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_f75d01b7-d271-b07d-c4a7-6ae60293303d" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_f75d01b7-d271-b07d-c4a7-6ae60293303d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_e3eecf87-b290-4567-8a59-5b0a8e27c85b" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_ShareBasedCompensation_e3eecf87-b290-4567-8a59-5b0a8e27c85b" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense" xlink:label="loc_pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense_d2c6ba62-f0db-2ebe-7aed-2177fcec75b3" xlink:type="locator" />
    <link:calculationArc order="7" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense_d2c6ba62-f0db-2ebe-7aed-2177fcec75b3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_371a4d3e-148a-313f-f556-b3ca6797139e" xlink:type="locator" />
    <link:calculationArc order="8" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_371a4d3e-148a-313f-f556-b3ca6797139e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapital" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapital_6c5ef6ac-0d12-b149-6c27-b013e773a274" xlink:type="locator" />
    <link:calculationArc order="9" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapital_6c5ef6ac-0d12-b149-6c27-b013e773a274" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_70319186-e7bd-7189-88d2-eba26fb93350" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_dd2e9db6-10f9-d78a-ba84-b18268245a83" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_70319186-e7bd-7189-88d2-eba26fb93350" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_fee12b15-6b42-6245-2e2f-ff030b98332c" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_70319186-e7bd-7189-88d2-eba26fb93350" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_fee12b15-6b42-6245-2e2f-ff030b98332c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments_e9694662-6637-d237-1a9d-f800fe1b0696" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_70319186-e7bd-7189-88d2-eba26fb93350" xlink:to="loc_us-gaap_PaymentsToAcquireShortTermInvestments_e9694662-6637-d237-1a9d-f800fe1b0696" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_e1dbb58a-fc75-dcc8-8b0d-72713275b7a5" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_70319186-e7bd-7189-88d2-eba26fb93350" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_e1dbb58a-fc75-dcc8-8b0d-72713275b7a5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsForProceedsFromShortTermInvestments" xlink:label="loc_us-gaap_PaymentsForProceedsFromShortTermInvestments_b1bbf188-6bb5-a3d9-0e3b-94b8cbfb59cd" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_70319186-e7bd-7189-88d2-eba26fb93350" xlink:to="loc_us-gaap_PaymentsForProceedsFromShortTermInvestments_b1bbf188-6bb5-a3d9-0e3b-94b8cbfb59cd" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_5151f7e0-f557-cbe6-275f-5bec3a3b329f" xlink:type="locator" />
    <link:calculationArc order="5" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_70319186-e7bd-7189-88d2-eba26fb93350" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_5151f7e0-f557-cbe6-275f-5bec3a3b329f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments_6eb7cb4b-e1c0-9572-e48d-1841dafd058e" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_70319186-e7bd-7189-88d2-eba26fb93350" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments_6eb7cb4b-e1c0-9572-e48d-1841dafd058e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_9d35c912-5b2d-89f7-eeb3-812a0511db5e" xlink:type="locator" />
    <link:calculationArc order="7" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_70319186-e7bd-7189-88d2-eba26fb93350" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_9d35c912-5b2d-89f7-eeb3-812a0511db5e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_3be9d1aa-8098-ddda-91ce-5e44ee6678ae" xlink:type="locator" />
    <link:calculationArc order="8" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_70319186-e7bd-7189-88d2-eba26fb93350" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_3be9d1aa-8098-ddda-91ce-5e44ee6678ae" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_5eaab9ea-3795-2871-0d80-72b9662e37e6" xlink:type="locator" />
    <link:calculationArc order="9" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_70319186-e7bd-7189-88d2-eba26fb93350" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_5eaab9ea-3795-2871-0d80-72b9662e37e6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_deb49b68-c030-7624-a39d-ea301caa5dbf" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_dd2e9db6-10f9-d78a-ba84-b18268245a83" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_deb49b68-c030-7624-a39d-ea301caa5dbf" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromShortTermDebt" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt_033e0a63-d437-58f7-120c-37d4556f8eed" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_deb49b68-c030-7624-a39d-ea301caa5dbf" xlink:to="loc_us-gaap_ProceedsFromShortTermDebt_033e0a63-d437-58f7-120c-37d4556f8eed" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepaymentsOfShortTermDebt" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt_918f2c1d-af03-b66f-ca7f-78d3e9bffdf3" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_deb49b68-c030-7624-a39d-ea301caa5dbf" xlink:to="loc_us-gaap_RepaymentsOfShortTermDebt_918f2c1d-af03-b66f-ca7f-78d3e9bffdf3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess_7d7c25f1-5bd5-158c-2590-7fec3e2c0c75" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_deb49b68-c030-7624-a39d-ea301caa5dbf" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess_7d7c25f1-5bd5-158c-2590-7fec3e2c0c75" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_e5f1c7a4-b42a-8461-2001-b1f20e51b257" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_deb49b68-c030-7624-a39d-ea301caa5dbf" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_e5f1c7a4-b42a-8461-2001-b1f20e51b257" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_2b72fe5f-3c0e-d5e0-8e5c-ad01818e58e5" xlink:type="locator" />
    <link:calculationArc order="5" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_deb49b68-c030-7624-a39d-ea301caa5dbf" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_2b72fe5f-3c0e-d5e0-8e5c-ad01818e58e5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_8a1490c4-32d9-5132-1fe2-2675a45abdae" xlink:type="locator" />
    <link:calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_deb49b68-c030-7624-a39d-ea301caa5dbf" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_8a1490c4-32d9-5132-1fe2-2675a45abdae" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfOrdinaryDividends" xlink:label="loc_us-gaap_PaymentsOfOrdinaryDividends_fccb4e5f-f3d2-b2b9-c659-8971e47ca85a" xlink:type="locator" />
    <link:calculationArc order="7" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_deb49b68-c030-7624-a39d-ea301caa5dbf" xlink:to="loc_us-gaap_PaymentsOfOrdinaryDividends_fccb4e5f-f3d2-b2b9-c659-8971e47ca85a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_d04df344-47da-0222-79d0-99b7d739fd60" xlink:type="locator" />
    <link:calculationArc order="8" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_deb49b68-c030-7624-a39d-ea301caa5dbf" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_d04df344-47da-0222-79d0-99b7d739fd60" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_9c4e2a5c-e841-39a2-fcf8-f80cfa44af11" xlink:type="locator" />
    <link:calculationArc order="9" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_deb49b68-c030-7624-a39d-ea301caa5dbf" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_9c4e2a5c-e841-39a2-fcf8-f80cfa44af11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_8629a772-7004-5d77-9980-0f501e29c5c8" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_dd2e9db6-10f9-d78a-ba84-b18268245a83" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_8629a772-7004-5d77-9980-0f501e29c5c8" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlowsParenthetical" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_499015ce-2160-aed2-85a3-080e8c4c6cdf" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_dd69e307-3cf6-284a-5315-8fa7ac464283" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_499015ce-2160-aed2-85a3-080e8c4c6cdf" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_dd69e307-3cf6-284a-5315-8fa7ac464283" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_adacf05e-7e15-bd60-3e53-87432885dc29" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_dd69e307-3cf6-284a-5315-8fa7ac464283" xlink:to="loc_us-gaap_ProfitLoss_adacf05e-7e15-bd60-3e53-87432885dc29" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_2a6e77d2-a694-61f8-1c68-085fd849c780" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_dd69e307-3cf6-284a-5315-8fa7ac464283" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_2a6e77d2-a694-61f8-1c68-085fd849c780" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax_27a35677-5e4b-23be-d135-9b2a303ead30" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_2a6e77d2-a694-61f8-1c68-085fd849c780" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax_27a35677-5e4b-23be-d135-9b2a303ead30" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesBeforeTax_b8ea9417-a946-591f-f885-7e7887367db9" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax_27a35677-5e4b-23be-d135-9b2a303ead30" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesBeforeTax_b8ea9417-a946-591f-f885-7e7887367db9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax_02278c77-83e2-e592-cc7e-098b64f44f6f" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesBeforeTax_b8ea9417-a946-591f-f885-7e7887367db9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax_02278c77-83e2-e592-cc7e-098b64f44f6f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesBeforeTax_87718395-99ac-d6a3-868b-78e339bbb8c9" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesBeforeTax_b8ea9417-a946-591f-f885-7e7887367db9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesBeforeTax_87718395-99ac-d6a3-868b-78e339bbb8c9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax_0634f537-fc07-8954-34de-cde2f21c405f" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax_27a35677-5e4b-23be-d135-9b2a303ead30" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax_0634f537-fc07-8954-34de-cde2f21c405f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_d58ac57b-2e86-36b4-7645-929f4187851d" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax_0634f537-fc07-8954-34de-cde2f21c405f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_d58ac57b-2e86-36b4-7645-929f4187851d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax_7fd05530-dcef-3f65-247b-6b26d31a1b75" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax_0634f537-fc07-8954-34de-cde2f21c405f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax_7fd05530-dcef-3f65-247b-6b26d31a1b75" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax_ce709758-44fa-3829-d9ec-d3fbd4cf49f2" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax_27a35677-5e4b-23be-d135-9b2a303ead30" xlink:to="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax_ce709758-44fa-3829-d9ec-d3fbd4cf49f2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_086c0c4e-b462-2c01-0468-31b739642a85" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax_ce709758-44fa-3829-d9ec-d3fbd4cf49f2" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_086c0c4e-b462-2c01-0468-31b739642a85" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax_bb969882-fed8-578a-3817-8df19729cd79" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax_ce709758-44fa-3829-d9ec-d3fbd4cf49f2" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax_bb969882-fed8-578a-3817-8df19729cd79" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax" xlink:label="loc_pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax_d40f9c1b-afb6-4a8d-561a-2177fc7b5245" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax_ce709758-44fa-3829-d9ec-d3fbd4cf49f2" xlink:to="loc_pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax_d40f9c1b-afb6-4a8d-561a-2177fc7b5245" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax" xlink:label="loc_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax_a5ddb8ff-a062-e9f5-6581-2177fe024f95" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax_ce709758-44fa-3829-d9ec-d3fbd4cf49f2" xlink:to="loc_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax_a5ddb8ff-a062-e9f5-6581-2177fe024f95" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_1284142c-4c9d-c050-5cf9-a9e4bc79fd86" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax_27a35677-5e4b-23be-d135-9b2a303ead30" xlink:to="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_1284142c-4c9d-c050-5cf9-a9e4bc79fd86" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax_e487ccf0-91a2-e047-f02b-f411eb8e7710" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_1284142c-4c9d-c050-5cf9-a9e4bc79fd86" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax_e487ccf0-91a2-e047-f02b-f411eb8e7710" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_703f5953-48e4-9c78-d820-a439b06ab316" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_1284142c-4c9d-c050-5cf9-a9e4bc79fd86" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_703f5953-48e4-9c78-d820-a439b06ab316" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax" xlink:label="loc_pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax_a1e8c8dd-9033-d974-0dad-2177fc9f04b8" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_1284142c-4c9d-c050-5cf9-a9e4bc79fd86" xlink:to="loc_pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax_a1e8c8dd-9033-d974-0dad-2177fc9f04b8" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax" xlink:label="loc_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax_38820070-5d45-f2ae-1a3f-2177fca80cf1" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_1284142c-4c9d-c050-5cf9-a9e4bc79fd86" xlink:to="loc_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax_38820070-5d45-f2ae-1a3f-2177fca80cf1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_9cffdcf3-2206-8087-bfa6-e205fe38a792" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax_27a35677-5e4b-23be-d135-9b2a303ead30" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_9cffdcf3-2206-8087-bfa6-e205fe38a792" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_718d5fea-c5af-042f-efd5-5fcfba2b2f17" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_9cffdcf3-2206-8087-bfa6-e205fe38a792" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_718d5fea-c5af-042f-efd5-5fcfba2b2f17" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax_8228ad10-a8ae-c457-8c0a-d513efcfc5b0" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_9cffdcf3-2206-8087-bfa6-e205fe38a792" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax_8228ad10-a8ae-c457-8c0a-d513efcfc5b0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTax_fd5fd01d-ccd5-2fe2-e9ee-a9a84a842378" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_2a6e77d2-a694-61f8-1c68-085fd849c780" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTax_fd5fd01d-ccd5-2fe2-e9ee-a9a84a842378" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_7908f590-67cb-1122-d422-880e24cad7ce" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_499015ce-2160-aed2-85a3-080e8c4c6cdf" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_7908f590-67cb-1122-d422-880e24cad7ce" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeParenthetical" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/CondensedConsolidatedStatementsOfIncome" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_641b1cab-a2b3-2e0e-8389-1455ff3f8581" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_adacf05e-7e15-bd60-3e53-87432885dc29" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_641b1cab-a2b3-2e0e-8389-1455ff3f8581" xlink:to="loc_us-gaap_ProfitLoss_adacf05e-7e15-bd60-3e53-87432885dc29" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_33076493-4882-6413-5de3-7bb85b9df3b7" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_adacf05e-7e15-bd60-3e53-87432885dc29" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_33076493-4882-6413-5de3-7bb85b9df3b7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a53f52a4-7a54-3283-f734-95683c76ebff" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_33076493-4882-6413-5de3-7bb85b9df3b7" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a53f52a4-7a54-3283-f734-95683c76ebff" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_318cebec-2b05-42bf-a988-02b2e99cecfb" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a53f52a4-7a54-3283-f734-95683c76ebff" xlink:to="loc_us-gaap_SalesRevenueGoodsNet_318cebec-2b05-42bf-a988-02b2e99cecfb" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="loc_us-gaap_CostOfGoodsSold_23c68b7c-81fb-cba2-1814-b7ab4991d5d0" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a53f52a4-7a54-3283-f734-95683c76ebff" xlink:to="loc_us-gaap_CostOfGoodsSold_23c68b7c-81fb-cba2-1814-b7ab4991d5d0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_29ad42f4-24c5-90ea-4492-fdb757d66249" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a53f52a4-7a54-3283-f734-95683c76ebff" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_29ad42f4-24c5-90ea-4492-fdb757d66249" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_9f968bdd-178b-453d-dcf7-ca4f511341b3" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a53f52a4-7a54-3283-f734-95683c76ebff" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_9f968bdd-178b-453d-dcf7-ca4f511341b3" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction" xlink:label="loc_pfe_AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction_c6b0d001-5d46-d1c1-e9c0-2177fd647324" xlink:type="locator" />
    <link:calculationArc order="5" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a53f52a4-7a54-3283-f734-95683c76ebff" xlink:to="loc_pfe_AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction_c6b0d001-5d46-d1c1-e9c0-2177fd647324" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_RestructuringChargesAndAcquisitionRelatedCosts" xlink:label="loc_pfe_RestructuringChargesAndAcquisitionRelatedCosts_8f293d69-554b-fce5-cf3a-2177fcd940ab" xlink:type="locator" />
    <link:calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a53f52a4-7a54-3283-f734-95683c76ebff" xlink:to="loc_pfe_RestructuringChargesAndAcquisitionRelatedCosts_8f293d69-554b-fce5-cf3a-2177fcd940ab" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_250c3b2f-7db5-7088-68cc-1dd831a2c2d7" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a53f52a4-7a54-3283-f734-95683c76ebff" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_250c3b2f-7db5-7088-68cc-1dd831a2c2d7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_78b7d85e-8366-fe6d-cb1f-faac5a041b79" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_33076493-4882-6413-5de3-7bb85b9df3b7" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_78b7d85e-8366-fe6d-cb1f-faac5a041b79" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_3499d6fa-02b9-de09-04ba-5055e28f27a0" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_adacf05e-7e15-bd60-3e53-87432885dc29" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_3499d6fa-02b9-de09-04ba-5055e28f27a0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_baabbf0a-644b-708a-c310-1211f9af2775" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_641b1cab-a2b3-2e0e-8389-1455ff3f8581" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_baabbf0a-644b-708a-c310-1211f9af2775" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_220f7108-2ee6-8535-1bca-b062759c7beb" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_f309c50c-2dc0-f2fb-e4a2-9d61bc04812a" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareDiluted_220f7108-2ee6-8535-1bca-b062759c7beb" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_f309c50c-2dc0-f2fb-e4a2-9d61bc04812a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_35443bfe-146b-7ba7-b1f8-4daa6ea7427c" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareDiluted_220f7108-2ee6-8535-1bca-b062759c7beb" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_35443bfe-146b-7ba7-b1f8-4daa6ea7427c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_fe6ff5e7-33ad-d0eb-3545-2854577c8d1d" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_e4763c0c-8fb9-af76-cf2b-4d5847742ea9" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareBasic_fe6ff5e7-33ad-d0eb-3545-2854577c8d1d" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_e4763c0c-8fb9-af76-cf2b-4d5847742ea9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_3fe2b3b7-b213-d182-04b7-224fb5b2cf36" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareBasic_fe6ff5e7-33ad-d0eb-3545-2854577c8d1d" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_3fe2b3b7-b213-d182-04b7-224fb5b2cf36" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/DocumentAndEntityInformation" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/EarningsPerCommonShareAttributableToCommonShareholders" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/EarningsPerCommonShareAttributableToCommonShareholdersDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_ba98cf3d-8c3a-45da-49f9-ba76e12862c3" xlink:type="locator" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted" xlink:label="loc_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted_9bf55d13-10e1-09dd-c001-2177fdf7769c" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_ba98cf3d-8c3a-45da-49f9-ba76e12862c3" xlink:to="loc_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted_9bf55d13-10e1-09dd-c001-2177fdf7769c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_b9914cca-4860-d701-8b49-ae2910ad372f" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_ba98cf3d-8c3a-45da-49f9-ba76e12862c3" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_b9914cca-4860-d701-8b49-ae2910ad372f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_223fd9c8-68e8-e433-7c40-f98b238e79de" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_86e61cf2-b7b2-e230-65f1-5a2b152f3a30" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_223fd9c8-68e8-e433-7c40-f98b238e79de" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_86e61cf2-b7b2-e230-65f1-5a2b152f3a30" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_7b1369dd-f813-fe00-b292-96e275568f1b" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_223fd9c8-68e8-e433-7c40-f98b238e79de" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_7b1369dd-f813-fe00-b292-96e275568f1b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_3d9b4bd2-957e-ddb5-7841-6a572de70646" xlink:type="locator" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic" xlink:label="loc_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic_a80ee04e-1f1e-9064-3bf8-2177fd54830d" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_3d9b4bd2-957e-ddb5-7841-6a572de70646" xlink:to="loc_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic_a80ee04e-1f1e-9064-3bf8-2177fd54830d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_29cb4575-1df0-23a0-aea0-70de299da05c" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic_a80ee04e-1f1e-9064-3bf8-2177fd54830d" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_29cb4575-1df0-23a0-aea0-70de299da05c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_33076493-4882-6413-5de3-7bb85b9df3b7" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperations_29cb4575-1df0-23a0-aea0-70de299da05c" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_33076493-4882-6413-5de3-7bb85b9df3b7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_ae72e235-8429-5ff5-7f64-578d4c768f1a" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperations_29cb4575-1df0-23a0-aea0-70de299da05c" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_ae72e235-8429-5ff5-7f64-578d4c768f1a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:label="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_2fdfbb07-51bb-6537-46a9-0bef59200e0c" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic_a80ee04e-1f1e-9064-3bf8-2177fd54830d" xlink:to="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_2fdfbb07-51bb-6537-46a9-0bef59200e0c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_3499d6fa-02b9-de09-04ba-5055e28f27a0" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_3d9b4bd2-957e-ddb5-7841-6a572de70646" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_3499d6fa-02b9-de09-04ba-5055e28f27a0" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/EarningsPerCommonShareAttributableToCommonShareholdersTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/FinancialInstruments" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail" xlink:type="extended">
    <link:loc xlink:href="pfe-20171001.xsd#pfe_SelectedFinancialLiabilities" xlink:label="loc_pfe_SelectedFinancialLiabilities_e178af4d-9d18-bbde-e061-2177fddfe6bc" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities_a3ccd28b-d904-f2d6-d218-02006f748e50" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_SelectedFinancialLiabilities_e178af4d-9d18-bbde-e061-2177fddfe6bc" xlink:to="loc_us-gaap_DerivativeLiabilities_a3ccd28b-d904-f2d6-d218-02006f748e50" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_OtherFinancialLiabilities" xlink:label="loc_pfe_OtherFinancialLiabilities_06fbc2a4-fbc2-8a36-7e04-2177fd9fbe11" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_SelectedFinancialLiabilities_e178af4d-9d18-bbde-e061-2177fddfe6bc" xlink:to="loc_pfe_OtherFinancialLiabilities_06fbc2a4-fbc2-8a36-7e04-2177fd9fbe11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtCurrent" xlink:label="loc_us-gaap_DebtCurrent_f84a497d-68eb-d3d3-1597-16bfb6772366" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_OtherFinancialLiabilities_06fbc2a4-fbc2-8a36-7e04-2177fd9fbe11" xlink:to="loc_us-gaap_DebtCurrent_f84a497d-68eb-d3d3-1597-16bfb6772366" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_ShorttermDebtGross" xlink:label="loc_pfe_ShorttermDebtGross_84d0a40a-e687-77db-4e50-2177fd36b978" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtCurrent_f84a497d-68eb-d3d3-1597-16bfb6772366" xlink:to="loc_pfe_ShorttermDebtGross_84d0a40a-e687-77db-4e50-2177fd36b978" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting" xlink:label="loc_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting_07d3b483-7a92-abc8-d92a-2177fd315eea" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtCurrent_f84a497d-68eb-d3d3-1597-16bfb6772366" xlink:to="loc_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting_07d3b483-7a92-abc8-d92a-2177fd315eea" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_2a27283b-1aea-485a-d3ce-961b25dfc734" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtCurrent_f84a497d-68eb-d3d3-1597-16bfb6772366" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_2a27283b-1aea-485a-d3ce-961b25dfc734" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_822b66ff-44a1-e66b-5e0c-09356970a23d" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_OtherFinancialLiabilities_06fbc2a4-fbc2-8a36-7e04-2177fd9fbe11" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_822b66ff-44a1-e66b-5e0c-09356970a23d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_885301e5-debb-a378-50ee-e1d9b92a7437" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtNoncurrent_822b66ff-44a1-e66b-5e0c-09356970a23d" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_885301e5-debb-a378-50ee-e1d9b92a7437" xlink:type="arc" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtNoncurrent_822b66ff-44a1-e66b-5e0c-09356970a23d" xlink:to="loc_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting_07d3b483-7a92-abc8-d92a-2177fd315eea" xlink:type="arc" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtNoncurrent_822b66ff-44a1-e66b-5e0c-09356970a23d" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_2a27283b-1aea-485a-d3ce-961b25dfc734" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_SelectedFinancialAssets" xlink:label="loc_pfe_SelectedFinancialAssets_284d6835-6855-717c-7064-2177ffffd7ad" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_b851ddfc-ce9b-3407-931e-669b0dd9719b" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_SelectedFinancialAssets_284d6835-6855-717c-7064-2177ffffd7ad" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_b851ddfc-ce9b-3407-931e-669b0dd9719b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TradingSecurities" xlink:label="loc_us-gaap_TradingSecurities_e8e5bcd2-8443-72c2-637c-8d2ab1152c82" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InvestmentsFairValueDisclosure_b851ddfc-ce9b-3407-931e-669b0dd9719b" xlink:to="loc_us-gaap_TradingSecurities_e8e5bcd2-8443-72c2-637c-8d2ab1152c82" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_d444402b-921b-e0fa-119c-908ab66850af" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InvestmentsFairValueDisclosure_b851ddfc-ce9b-3407-931e-669b0dd9719b" xlink:to="loc_us-gaap_AvailableForSaleSecurities_d444402b-921b-e0fa-119c-908ab66850af" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeAssets" xlink:label="loc_us-gaap_DerivativeAssets_990d24f7-bf09-089d-4b5d-4490e079db44" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InvestmentsFairValueDisclosure_b851ddfc-ce9b-3407-931e-669b0dd9719b" xlink:to="loc_us-gaap_DerivativeAssets_990d24f7-bf09-089d-4b5d-4490e079db44" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_OtherSelectedFinancialAssets" xlink:label="loc_pfe_OtherSelectedFinancialAssets_bc4bce99-1b6b-f76c-0ee9-2177ffc9a1f3" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_SelectedFinancialAssets_284d6835-6855-717c-7064-2177ffffd7ad" xlink:to="loc_pfe_OtherSelectedFinancialAssets_bc4bce99-1b6b-f76c-0ee9-2177ffc9a1f3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_42d61097-0951-9fd0-ccda-87d8624a6e85" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_OtherSelectedFinancialAssets_bc4bce99-1b6b-f76c-0ee9-2177ffc9a1f3" xlink:to="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_42d61097-0951-9fd0-ccda-87d8624a6e85" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HeldToMaturitySecuritiesAmortizedCostBeforeOtherThanTemporaryImpairment" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesAmortizedCostBeforeOtherThanTemporaryImpairment_46f75f3f-4ced-36de-04ea-a031e3d4605c" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_OtherSelectedFinancialAssets_bc4bce99-1b6b-f76c-0ee9-2177ffc9a1f3" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesAmortizedCostBeforeOtherThanTemporaryImpairment_46f75f3f-4ced-36de-04ea-a031e3d4605c" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsAssetsAndLiabilitiesMeasuredOnRecurringBasisFootnotesDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsBalanceSheetGroupingDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsBalanceSheetGroupingFootnotesDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsInvestmentsInDebtSecuritiesDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HeldToMaturitySecurities" xlink:label="loc_us-gaap_HeldToMaturitySecurities_3bb8bc81-af51-9945-0a22-cc4527e07a17" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue_11845fde-86d7-5d4f-f95f-2ff0c69033cf" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_HeldToMaturitySecurities_3bb8bc81-af51-9945-0a22-cc4527e07a17" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue_11845fde-86d7-5d4f-f95f-2ff0c69033cf" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue_bb8c0b1e-fd9f-a5c4-e603-c98e3365d87d" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_HeldToMaturitySecurities_3bb8bc81-af51-9945-0a22-cc4527e07a17" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue_bb8c0b1e-fd9f-a5c4-e603-c98e3365d87d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesRollingYearSixThroughTenFairValue" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesRollingYearSixThroughTenFairValue_00f917b5-f7f5-5ac4-6c9e-e7da92e61db9" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_HeldToMaturitySecurities_3bb8bc81-af51-9945-0a22-cc4527e07a17" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesRollingYearSixThroughTenFairValue_00f917b5-f7f5-5ac4-6c9e-e7da92e61db9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesRollingAfterTenYearsFairValue" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesRollingAfterTenYearsFairValue_fb085eea-83ea-9ce6-514c-2e80a091553a" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_HeldToMaturitySecurities_3bb8bc81-af51-9945-0a22-cc4527e07a17" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesRollingAfterTenYearsFairValue_fb085eea-83ea-9ce6-514c-2e80a091553a" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_DebtSecurities" xlink:label="loc_pfe_DebtSecurities_2bef87e8-a944-ecdd-923b-2177fcee076f" xlink:type="locator" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_DebtSecuritiesMaturitiesWithinOneYear" xlink:label="loc_pfe_DebtSecuritiesMaturitiesWithinOneYear_5c140f46-451f-7bfb-523b-2177fcb0d261" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_DebtSecurities_2bef87e8-a944-ecdd-923b-2177fcee076f" xlink:to="loc_pfe_DebtSecuritiesMaturitiesWithinOneYear_5c140f46-451f-7bfb-523b-2177fcb0d261" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue_764bcdd4-873e-b243-70d2-5e6b13e98cf7" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_DebtSecuritiesMaturitiesWithinOneYear_5c140f46-451f-7bfb-523b-2177fcb0d261" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue_764bcdd4-873e-b243-70d2-5e6b13e98cf7" xlink:type="arc" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_DebtSecuritiesMaturitiesWithinOneYear_5c140f46-451f-7bfb-523b-2177fcb0d261" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue_11845fde-86d7-5d4f-f95f-2ff0c69033cf" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_DebtSecuritiesMaturitiesOverOneToFiveYears" xlink:label="loc_pfe_DebtSecuritiesMaturitiesOverOneToFiveYears_d9589146-ec7e-6621-033b-2177fc9c1110" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_DebtSecurities_2bef87e8-a944-ecdd-923b-2177fcee076f" xlink:to="loc_pfe_DebtSecuritiesMaturitiesOverOneToFiveYears_d9589146-ec7e-6621-033b-2177fc9c1110" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue_e43ecc2e-e30d-adce-13de-ad342aacc705" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_DebtSecuritiesMaturitiesOverOneToFiveYears_d9589146-ec7e-6621-033b-2177fc9c1110" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue_e43ecc2e-e30d-adce-13de-ad342aacc705" xlink:type="arc" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_DebtSecuritiesMaturitiesOverOneToFiveYears_d9589146-ec7e-6621-033b-2177fc9c1110" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue_bb8c0b1e-fd9f-a5c4-e603-c98e3365d87d" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_DebtSecuritiesMaturitiesOverFiveToTenYears" xlink:label="loc_pfe_DebtSecuritiesMaturitiesOverFiveToTenYears_860c6855-4920-c79e-caad-2177fc8de135" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_DebtSecurities_2bef87e8-a944-ecdd-923b-2177fcee076f" xlink:to="loc_pfe_DebtSecuritiesMaturitiesOverFiveToTenYears_860c6855-4920-c79e-caad-2177fc8de135" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearSixThroughTenFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearSixThroughTenFairValue_32a10326-5fac-2d4e-ebe4-d0b3d261f0aa" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_DebtSecuritiesMaturitiesOverFiveToTenYears_860c6855-4920-c79e-caad-2177fc8de135" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearSixThroughTenFairValue_32a10326-5fac-2d4e-ebe4-d0b3d261f0aa" xlink:type="arc" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_DebtSecuritiesMaturitiesOverFiveToTenYears_860c6855-4920-c79e-caad-2177fc8de135" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesRollingYearSixThroughTenFairValue_00f917b5-f7f5-5ac4-6c9e-e7da92e61db9" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_DebtSecuritiesMaturitiesAfterTenYears" xlink:label="loc_pfe_DebtSecuritiesMaturitiesAfterTenYears_3b93c338-d163-b048-e00f-2177fd3d6df3" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_DebtSecurities_2bef87e8-a944-ecdd-923b-2177fcee076f" xlink:to="loc_pfe_DebtSecuritiesMaturitiesAfterTenYears_3b93c338-d163-b048-e00f-2177fd3d6df3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingAfterYearTenFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingAfterYearTenFairValue_35f8f7f2-8f7e-5afd-f112-d64048dc0db3" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_DebtSecuritiesMaturitiesAfterTenYears_3b93c338-d163-b048-e00f-2177fd3d6df3" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingAfterYearTenFairValue_35f8f7f2-8f7e-5afd-f112-d64048dc0db3" xlink:type="arc" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_DebtSecuritiesMaturitiesAfterTenYears_3b93c338-d163-b048-e00f-2177fd3d6df3" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesRollingAfterTenYearsFairValue_fb085eea-83ea-9ce6-514c-2e80a091553a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2c867d9b-5594-18ef-c82a-679b606d1bd3" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2c867d9b-5594-18ef-c82a-679b606d1bd3" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue_764bcdd4-873e-b243-70d2-5e6b13e98cf7" xlink:type="arc" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2c867d9b-5594-18ef-c82a-679b606d1bd3" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue_e43ecc2e-e30d-adce-13de-ad342aacc705" xlink:type="arc" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2c867d9b-5594-18ef-c82a-679b606d1bd3" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearSixThroughTenFairValue_32a10326-5fac-2d4e-ebe4-d0b3d261f0aa" xlink:type="arc" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2c867d9b-5594-18ef-c82a-679b606d1bd3" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingAfterYearTenFairValue_35f8f7f2-8f7e-5afd-f112-d64048dc0db3" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsInvestmentsInDebtSecuritiesDetailCalc2" xlink:type="extended">
    <link:loc xlink:href="pfe-20171001.xsd#pfe_DebtSecurities" xlink:label="loc_pfe_DebtSecurities_BEBE07181F4BAFDA80517887463FE2D3_2bef87e8-a944-ecdd-923b-2177fcee076f" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_BEBE07181F4BAFDA80517887463FE2D3_2c867d9b-5594-18ef-c82a-679b606d1bd3" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_DebtSecurities_BEBE07181F4BAFDA80517887463FE2D3_2bef87e8-a944-ecdd-923b-2177fcee076f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_BEBE07181F4BAFDA80517887463FE2D3_2c867d9b-5594-18ef-c82a-679b606d1bd3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HeldToMaturitySecurities" xlink:label="loc_us-gaap_HeldToMaturitySecurities_BEBE07181F4BAFDA80517887463FE2D3_3bb8bc81-af51-9945-0a22-cc4527e07a17" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_DebtSecurities_BEBE07181F4BAFDA80517887463FE2D3_2bef87e8-a944-ecdd-923b-2177fcee076f" xlink:to="loc_us-gaap_HeldToMaturitySecurities_BEBE07181F4BAFDA80517887463FE2D3_3bb8bc81-af51-9945-0a22-cc4527e07a17" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_7e14882f-7ab9-8302-20ff-24c510ab8806" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_fd0898b3-8ac6-af74-6eb0-16df5479b1d8" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_7e14882f-7ab9-8302-20ff-24c510ab8806" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_fd0898b3-8ac6-af74-6eb0-16df5479b1d8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_afae3a47-9c39-3601-518d-0d7ae5a5a6c2" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_7e14882f-7ab9-8302-20ff-24c510ab8806" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_afae3a47-9c39-3601-518d-0d7ae5a5a6c2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_9f5eb2fc-430b-08e9-97ff-7ba73d819a2f" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_7e14882f-7ab9-8302-20ff-24c510ab8806" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_9f5eb2fc-430b-08e9-97ff-7ba73d819a2f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_82b54d4e-a983-1385-5e08-b1962e49d9a0" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_7e14882f-7ab9-8302-20ff-24c510ab8806" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_82b54d4e-a983-1385-5e08-b1962e49d9a0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_ba31165f-5220-17cb-3dfa-506eec2ab044" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_7e14882f-7ab9-8302-20ff-24c510ab8806" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_ba31165f-5220-17cb-3dfa-506eec2ab044" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsNarrativeDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsOtherNoncurrentLiabilitiesDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwill" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_1fe06082-076b-052d-6e2e-930afe9d6b2d" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_49187b45-82fd-7060-b114-79ff249a4331" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_1fe06082-076b-052d-6e2e-930afe9d6b2d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_49187b45-82fd-7060-b114-79ff249a4331" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_5d62e128-f1a1-954f-82e2-1936cb67d793" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_49187b45-82fd-7060-b114-79ff249a4331" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_5d62e128-f1a1-954f-82e2-1936cb67d793" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_c3ed8a56-abe0-6418-c541-e6b647d6318a" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_49187b45-82fd-7060-b114-79ff249a4331" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_c3ed8a56-abe0-6418-c541-e6b647d6318a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_76e8d839-867c-df13-a643-4da04e725367" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_1fe06082-076b-052d-6e2e-930afe9d6b2d" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_76e8d839-867c-df13-a643-4da04e725367" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_a6de665e-02e5-e3e1-f0df-a5f7155acc66" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_a6de665e-02e5-e3e1-f0df-a5f7155acc66" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_5d62e128-f1a1-954f-82e2-1936cb67d793" xlink:type="arc" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_a6de665e-02e5-e3e1-f0df-a5f7155acc66" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_76e8d839-867c-df13-a643-4da04e725367" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsFootnotesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedIntangibleAssetsPercentageOfTotalIntangiblesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillGoodwillDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillIndefiniteLivedIntangibleAssetsPercentageOfTotalIntangiblesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillNarrativeDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/Inventories" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/InventoriesDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_7eab44cf-1ea1-ca2a-420f-21f7b5343fc3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_b077ba6e-d590-fd28-6cc4-ab52e924ed70" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_7eab44cf-1ea1-ca2a-420f-21f7b5343fc3" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_b077ba6e-d590-fd28-6cc4-ab52e924ed70" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_a3451b87-a72a-9fff-128b-969b95aecb3a" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_7eab44cf-1ea1-ca2a-420f-21f7b5343fc3" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_a3451b87-a72a-9fff-128b-969b95aecb3a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" xlink:label="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_e852558b-d314-cf3d-b3e3-95a7fffa96fa" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_7eab44cf-1ea1-ca2a-420f-21f7b5343fc3" xlink:to="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_e852558b-d314-cf3d-b3e3-95a7fffa96fa" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/InventoriesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/OtherIncomeDeductionsNet" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/OtherIncomeDeductionsNetDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_250c3b2f-7db5-7088-68cc-1dd831a2c2d7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestRevenueExpenseNet" xlink:label="loc_us-gaap_InterestRevenueExpenseNet_506186a8-7ac9-45e0-4545-c1a4f5377951" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_250c3b2f-7db5-7088-68cc-1dd831a2c2d7" xlink:to="loc_us-gaap_InterestRevenueExpenseNet_506186a8-7ac9-45e0-4545-c1a4f5377951" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_27459a92-428a-e415-bdb1-176ed2662e11" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestRevenueExpenseNet_506186a8-7ac9-45e0-4545-c1a4f5377951" xlink:to="loc_us-gaap_InvestmentIncomeInterest_27459a92-428a-e415-bdb1-176ed2662e11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_7c9599ab-2a77-022c-c720-63fecff6a62c" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestRevenueExpenseNet_506186a8-7ac9-45e0-4545-c1a4f5377951" xlink:to="loc_us-gaap_InterestExpense_7c9599ab-2a77-022c-c720-63fecff6a62c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:label="loc_us-gaap_RoyaltyRevenue_dffd4b04-634b-3a6d-2c65-52b2bf4bbf15" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_250c3b2f-7db5-7088-68cc-1dd831a2c2d7" xlink:to="loc_us-gaap_RoyaltyRevenue_dffd4b04-634b-3a6d-2c65-52b2bf4bbf15" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_71426e29-337e-291e-f9d3-40031a50cd68" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_250c3b2f-7db5-7088-68cc-1dd831a2c2d7" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_71426e29-337e-291e-f9d3-40031a50cd68" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_GainLossOnDispositionOfAssetsAndEquitySecurities" xlink:label="loc_pfe_GainLossOnDispositionOfAssetsAndEquitySecurities_b9394279-33dc-93e0-8b2a-2177fd5e0eab" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_250c3b2f-7db5-7088-68cc-1dd831a2c2d7" xlink:to="loc_pfe_GainLossOnDispositionOfAssetsAndEquitySecurities_b9394279-33dc-93e0-8b2a-2177fd5e0eab" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_03e83c30-c623-f96c-29f8-521a710884ee" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_250c3b2f-7db5-7088-68cc-1dd831a2c2d7" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_03e83c30-c623-f96c-29f8-521a710884ee" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges_922befcd-b5b1-7112-2dca-80fbde69a2fe" xlink:type="locator" />
    <link:calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_250c3b2f-7db5-7088-68cc-1dd831a2c2d7" xlink:to="loc_us-gaap_AssetImpairmentCharges_922befcd-b5b1-7112-2dca-80fbde69a2fe" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_BusinessInfrastructureAlignmentCosts" xlink:label="loc_pfe_BusinessInfrastructureAlignmentCosts_ef666f54-c05b-5790-3a20-2177fd02528f" xlink:type="locator" />
    <link:calculationArc order="7" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_250c3b2f-7db5-7088-68cc-1dd831a2c2d7" xlink:to="loc_pfe_BusinessInfrastructureAlignmentCosts_ef666f54-c05b-5790-3a20-2177fd02528f" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_OtherNonoperatingIncomeExpenseNet" xlink:label="loc_pfe_OtherNonoperatingIncomeExpenseNet_202d5301-b0ee-2fe8-c560-2177fcb1fa44" xlink:type="locator" />
    <link:calculationArc order="8" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_250c3b2f-7db5-7088-68cc-1dd831a2c2d7" xlink:to="loc_pfe_OtherNonoperatingIncomeExpenseNet_202d5301-b0ee-2fe8-c560-2177fcb1fa44" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/OtherIncomeDeductionsNetImpairedIntangibleAssetsDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/OtherIncomeDeductionsNetTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlans" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansNetPeriodicBenefitCostDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_bae25320-9d69-b27b-4684-0b60368d617f" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedBenefitPlanServiceCost" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_89ad3af5-a7a9-a0b6-3ed0-1824210c7a90" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_bae25320-9d69-b27b-4684-0b60368d617f" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_89ad3af5-a7a9-a0b6-3ed0-1824210c7a90" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedBenefitPlanInterestCost" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_50406d00-3746-2e05-3a50-4b2bf529ff14" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_bae25320-9d69-b27b-4684-0b60368d617f" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_50406d00-3746-2e05-3a50-4b2bf529ff14" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_053c4475-6836-cf00-1abe-b15f58110eab" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_bae25320-9d69-b27b-4684-0b60368d617f" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_053c4475-6836-cf00-1abe-b15f58110eab" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_b2e93b1c-a313-bd95-39dd-1f9d9938b2e9" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_bae25320-9d69-b27b-4684-0b60368d617f" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_b2e93b1c-a313-bd95-39dd-1f9d9938b2e9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_ab621a8a-0d01-618c-dbe1-c25fa3bace61" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_bae25320-9d69-b27b-4684-0b60368d617f" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_ab621a8a-0d01-618c-dbe1-c25fa3bace61" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments_a2b01ebf-3bb0-69b6-bb1a-f9cc09a597fb" xlink:type="locator" />
    <link:calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_bae25320-9d69-b27b-4684-0b60368d617f" xlink:to="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments_a2b01ebf-3bb0-69b6-bb1a-f9cc09a597fb" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_747869e7-4e1c-6de6-fa9c-d8cc9c90ed9d" xlink:type="locator" />
    <link:calculationArc order="7" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_bae25320-9d69-b27b-4684-0b60368d617f" xlink:to="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_747869e7-4e1c-6de6-fa9c-d8cc9c90ed9d" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansNetPeriodicBenefitCostFootnotesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiatives" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesDetail" xlink:type="extended">
    <link:loc xlink:href="pfe-20171001.xsd#pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts" xlink:label="loc_pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts_0034f2e3-1ba1-074d-c52d-2177fcfc9477" xlink:type="locator" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_RestructuringChargesAndAcquisitionRelatedCosts" xlink:label="loc_pfe_RestructuringChargesAndAcquisitionRelatedCosts_8f293d69-554b-fce5-cf3a-2177fcd940ab" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts_0034f2e3-1ba1-074d-c52d-2177fcfc9477" xlink:to="loc_pfe_RestructuringChargesAndAcquisitionRelatedCosts_8f293d69-554b-fce5-cf3a-2177fcd940ab" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_78594f6e-0c1a-d6f6-6a22-c95b7bf56846" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_RestructuringChargesAndAcquisitionRelatedCosts_8f293d69-554b-fce5-cf3a-2177fcd940ab" xlink:to="loc_us-gaap_RestructuringCharges_78594f6e-0c1a-d6f6-6a22-c95b7bf56846" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeveranceCosts1" xlink:label="loc_us-gaap_SeveranceCosts1_e0e093aa-0075-43de-2f65-66924da64b1f" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RestructuringCharges_78594f6e-0c1a-d6f6-6a22-c95b7bf56846" xlink:to="loc_us-gaap_SeveranceCosts1_e0e093aa-0075-43de-2f65-66924da64b1f" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_RestructuringAssetImpairmentCharges" xlink:label="loc_pfe_RestructuringAssetImpairmentCharges_f53442d4-8dfb-7bda-aa7b-2177fd1766c6" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RestructuringCharges_78594f6e-0c1a-d6f6-6a22-c95b7bf56846" xlink:to="loc_pfe_RestructuringAssetImpairmentCharges_f53442d4-8dfb-7bda-aa7b-2177fd1766c6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessExitCosts1" xlink:label="loc_us-gaap_BusinessExitCosts1_c6ba31ec-beb4-a555-9447-bf07868b9ce4" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RestructuringCharges_78594f6e-0c1a-d6f6-6a22-c95b7bf56846" xlink:to="loc_us-gaap_BusinessExitCosts1_c6ba31ec-beb4-a555-9447-bf07868b9ce4" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts" xlink:label="loc_pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts_5c3790fb-0f91-bc9b-98ba-2177fd38a11a" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_RestructuringChargesAndAcquisitionRelatedCosts_8f293d69-554b-fce5-cf3a-2177fcd940ab" xlink:to="loc_pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts_5c3790fb-0f91-bc9b-98ba-2177fd38a11a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationIntegrationRelatedCosts" xlink:label="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_6bb31a22-5d72-9721-76bb-72efc45096a2" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_RestructuringChargesAndAcquisitionRelatedCosts_8f293d69-554b-fce5-cf3a-2177fcd940ab" xlink:to="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_6bb31a22-5d72-9721-76bb-72efc45096a2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringReserveAcceleratedDepreciation" xlink:label="loc_us-gaap_RestructuringReserveAcceleratedDepreciation_1db848a1-40a6-5738-7efa-130ab3cc68c9" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts_0034f2e3-1ba1-074d-c52d-2177fcfc9477" xlink:to="loc_us-gaap_RestructuringReserveAcceleratedDepreciation_1db848a1-40a6-5738-7efa-130ab3cc68c9" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_ImplementationCosts" xlink:label="loc_pfe_ImplementationCosts_cf479fb8-71a7-0d12-9330-2177fcead793" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts_0034f2e3-1ba1-074d-c52d-2177fcfc9477" xlink:to="loc_pfe_ImplementationCosts_cf479fb8-71a7-0d12-9330-2177fcead793" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesFootnotesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesRestructuringAccrualsDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesRestructuringAccrualsFootnotesDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformation" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationFootnotesDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationNarrativeDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByGeographicAreaDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByGeographicAreaFootnotesDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/TaxMatters" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/TaxMattersDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTax_fd5fd01d-ccd5-2fe2-e9ee-a9a84a842378" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_cd0919d8-d8eb-cfe6-40c8-c0526b4fbf3d" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTax_fd5fd01d-ccd5-2fe2-e9ee-a9a84a842378" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_cd0919d8-d8eb-cfe6-40c8-c0526b4fbf3d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesTax_a48f57db-d47c-8b55-9bd3-4d80419acc33" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTax_fd5fd01d-ccd5-2fe2-e9ee-a9a84a842378" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesTax_a48f57db-d47c-8b55-9bd3-4d80419acc33" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax_4f22ab7c-17d1-8713-b2ed-ce75602eceb9" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesTax_a48f57db-d47c-8b55-9bd3-4d80419acc33" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax_4f22ab7c-17d1-8713-b2ed-ce75602eceb9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesTax_e2465e14-ad8d-68a8-770d-97a2e3fa6e69" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesTax_a48f57db-d47c-8b55-9bd3-4d80419acc33" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesTax_e2465e14-ad8d-68a8-770d-97a2e3fa6e69" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_0912789e-2c22-7b28-14c9-a39fc69ed3f4" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTax_fd5fd01d-ccd5-2fe2-e9ee-a9a84a842378" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_0912789e-2c22-7b28-14c9-a39fc69ed3f4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_fce92d33-1a6b-eabb-7aec-b7f763849491" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_0912789e-2c22-7b28-14c9-a39fc69ed3f4" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_fce92d33-1a6b-eabb-7aec-b7f763849491" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax_b3c38565-0d02-8626-9105-f3d50d05e2e9" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_0912789e-2c22-7b28-14c9-a39fc69ed3f4" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax_b3c38565-0d02-8626-9105-f3d50d05e2e9" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetActuarialGainLossTax" xlink:label="loc_pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetActuarialGainLossTax_e62160f0-ab3b-d806-d5f6-2177fc8351d3" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTax_fd5fd01d-ccd5-2fe2-e9ee-a9a84a842378" xlink:to="loc_pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetActuarialGainLossTax_e62160f0-ab3b-d806-d5f6-2177fc8351d3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodTax_90cadbef-4c1f-dc53-0481-4d312c2e0e3a" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetActuarialGainLossTax_e62160f0-ab3b-d806-d5f6-2177fc8351d3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodTax_90cadbef-4c1f-dc53-0481-4d312c2e0e3a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossTax_77604071-df5d-a7e7-ce4f-537a6c3c6fbd" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetActuarialGainLossTax_e62160f0-ab3b-d806-d5f6-2177fc8351d3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossTax_77604071-df5d-a7e7-ce4f-537a6c3c6fbd" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossTax" xlink:label="loc_pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossTax_ea93726a-daf8-307c-a267-2178000c188c" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetActuarialGainLossTax_e62160f0-ab3b-d806-d5f6-2177fc8351d3" xlink:to="loc_pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossTax_ea93726a-daf8-307c-a267-2178000c188c" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodTax" xlink:label="loc_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodTax_0a2283e0-514d-5a01-117d-2177fdd41610" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetActuarialGainLossTax_e62160f0-ab3b-d806-d5f6-2177fc8351d3" xlink:to="loc_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodTax_0a2283e0-514d-5a01-117d-2177fdd41610" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect_c26b4b65-cc7d-75f5-11cf-0cf5f6a1de54" xlink:type="locator" />
    <link:calculationArc order="5" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTax_fd5fd01d-ccd5-2fe2-e9ee-a9a84a842378" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect_c26b4b65-cc7d-75f5-11cf-0cf5f6a1de54" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetPriorServiceCostCreditAndOtherTax" xlink:label="loc_pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetPriorServiceCostCreditAndOtherTax_ec724e6d-4a60-1683-3295-2177ff2e4471" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect_c26b4b65-cc7d-75f5-11cf-0cf5f6a1de54" xlink:to="loc_pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetPriorServiceCostCreditAndOtherTax_ec724e6d-4a60-1683-3295-2177ff2e4471" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax_92500d4b-a22c-9691-8d53-fd8414bb722b" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect_c26b4b65-cc7d-75f5-11cf-0cf5f6a1de54" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax_92500d4b-a22c-9691-8d53-fd8414bb722b" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditTax" xlink:label="loc_pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditTax_760ba2ba-5523-20e9-b26a-2177fd9d22fd" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect_c26b4b65-cc7d-75f5-11cf-0cf5f6a1de54" xlink:to="loc_pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditTax_760ba2ba-5523-20e9-b26a-2177fd9d22fd" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax" xlink:label="loc_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax_c954b5fc-ea03-0e0e-9385-2177fc92acba" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect_c26b4b65-cc7d-75f5-11cf-0cf5f6a1de54" xlink:to="loc_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax_c954b5fc-ea03-0e0e-9385-2177fc92acba" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/TaxMattersNarrativeDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/TaxMattersTables" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>12
<FILENAME>pfe-20171001_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterests" xlink:href="pfe-20171001.xsd#AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterests" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetail" xlink:href="pfe-20171001.xsd#AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsTables" xlink:href="pfe-20171001.xsd#AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestments" xlink:href="pfe-20171001.xsd#AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsAnacorPharmaceuticalsIncDetails" xlink:href="pfe-20171001.xsd#AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsAnacorPharmaceuticalsIncDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsAstrazenecaDetails" xlink:href="pfe-20171001.xsd#AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsAstrazenecaDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsBambooTherapeuticsDetails" xlink:href="pfe-20171001.xsd#AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsBambooTherapeuticsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsCollaborationArrangementDetails" xlink:href="pfe-20171001.xsd#AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsCollaborationArrangementDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsEquityMethodInvestmentsDetails" xlink:href="pfe-20171001.xsd#AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsEquityMethodInvestmentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsMedivationDetails" xlink:href="pfe-20171001.xsd#AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsMedivationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsSaleOfHospiraInfusionSystemsNetAssetsToIcuMedicalIncEhDetails" xlink:href="pfe-20171001.xsd#AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsSaleOfHospiraInfusionSystemsNetAssetsToIcuMedicalIncEhDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPolicies" xlink:href="pfe-20171001.xsd#BasisOfPresentationAndSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetails" xlink:href="pfe-20171001.xsd#BasisOfPresentationAndSignificantAccountingPoliciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies" xlink:href="pfe-20171001.xsd#BasisOfPresentationAndSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/CommitmentsAndContingencies" xlink:href="pfe-20171001.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/CommitmentsAndContingenciesActionsInWhichWeAreDefendantDetail" xlink:href="pfe-20171001.xsd#CommitmentsAndContingenciesActionsInWhichWeAreDefendantDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/CommitmentsAndContingenciesActionsInWhichWeArePlaintiffDetails" xlink:href="pfe-20171001.xsd#CommitmentsAndContingenciesActionsInWhichWeArePlaintiffDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/CommitmentsAndContingenciesDetails" xlink:href="pfe-20171001.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets" xlink:href="pfe-20171001.xsd#CondensedConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:href="pfe-20171001.xsd#CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:href="pfe-20171001.xsd#CondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlowsParenthetical" xlink:href="pfe-20171001.xsd#CondensedConsolidatedStatementsOfCashFlowsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome" xlink:href="pfe-20171001.xsd#CondensedConsolidatedStatementsOfComprehensiveIncome" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeParenthetical" xlink:href="pfe-20171001.xsd#CondensedConsolidatedStatementsOfComprehensiveIncomeParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/CondensedConsolidatedStatementsOfIncome" xlink:href="pfe-20171001.xsd#CondensedConsolidatedStatementsOfIncome" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/DocumentAndEntityInformation" xlink:href="pfe-20171001.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/EarningsPerCommonShareAttributableToCommonShareholders" xlink:href="pfe-20171001.xsd#EarningsPerCommonShareAttributableToCommonShareholders" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/EarningsPerCommonShareAttributableToCommonShareholdersDetails" xlink:href="pfe-20171001.xsd#EarningsPerCommonShareAttributableToCommonShareholdersDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/EarningsPerCommonShareAttributableToCommonShareholdersTables" xlink:href="pfe-20171001.xsd#EarningsPerCommonShareAttributableToCommonShareholdersTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstruments" xlink:href="pfe-20171001.xsd#FinancialInstruments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail" xlink:href="pfe-20171001.xsd#FinancialInstrumentsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsAssetsAndLiabilitiesMeasuredOnRecurringBasisFootnotesDetail" xlink:href="pfe-20171001.xsd#FinancialInstrumentsAssetsAndLiabilitiesMeasuredOnRecurringBasisFootnotesDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsBalanceSheetGroupingDetail" xlink:href="pfe-20171001.xsd#FinancialInstrumentsBalanceSheetGroupingDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsBalanceSheetGroupingFootnotesDetail" xlink:href="pfe-20171001.xsd#FinancialInstrumentsBalanceSheetGroupingFootnotesDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetail" xlink:href="pfe-20171001.xsd#FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsInvestmentsInDebtSecuritiesDetail" xlink:href="pfe-20171001.xsd#FinancialInstrumentsInvestmentsInDebtSecuritiesDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails" xlink:href="pfe-20171001.xsd#FinancialInstrumentsLongTermDebtDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtMaturitiesDetails" xlink:href="pfe-20171001.xsd#FinancialInstrumentsLongTermDebtMaturitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsNarrativeDetail" xlink:href="pfe-20171001.xsd#FinancialInstrumentsNarrativeDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsOtherNoncurrentLiabilitiesDetail" xlink:href="pfe-20171001.xsd#FinancialInstrumentsOtherNoncurrentLiabilitiesDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails" xlink:href="pfe-20171001.xsd#FinancialInstrumentsShortTermBorrowingsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsTables" xlink:href="pfe-20171001.xsd#FinancialInstrumentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwill" xlink:href="pfe-20171001.xsd#IdentifiableIntangibleAssetsAndGoodwill" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsDetail" xlink:href="pfe-20171001.xsd#IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsFootnotesDetails" xlink:href="pfe-20171001.xsd#IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsFootnotesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedIntangibleAssetsPercentageOfTotalIntangiblesDetails" xlink:href="pfe-20171001.xsd#IdentifiableIntangibleAssetsAndGoodwillFiniteLivedIntangibleAssetsPercentageOfTotalIntangiblesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillGoodwillDetail" xlink:href="pfe-20171001.xsd#IdentifiableIntangibleAssetsAndGoodwillGoodwillDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillIndefiniteLivedIntangibleAssetsPercentageOfTotalIntangiblesDetails" xlink:href="pfe-20171001.xsd#IdentifiableIntangibleAssetsAndGoodwillIndefiniteLivedIntangibleAssetsPercentageOfTotalIntangiblesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillNarrativeDetail" xlink:href="pfe-20171001.xsd#IdentifiableIntangibleAssetsAndGoodwillNarrativeDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillTables" xlink:href="pfe-20171001.xsd#IdentifiableIntangibleAssetsAndGoodwillTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/Inventories" xlink:href="pfe-20171001.xsd#Inventories" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/InventoriesDetail" xlink:href="pfe-20171001.xsd#InventoriesDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/InventoriesTables" xlink:href="pfe-20171001.xsd#InventoriesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/OtherIncomeDeductionsNet" xlink:href="pfe-20171001.xsd#OtherIncomeDeductionsNet" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/OtherIncomeDeductionsNetDetail" xlink:href="pfe-20171001.xsd#OtherIncomeDeductionsNetDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail" xlink:href="pfe-20171001.xsd#OtherIncomeDeductionsNetFootnotesDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/OtherIncomeDeductionsNetImpairedIntangibleAssetsDetail" xlink:href="pfe-20171001.xsd#OtherIncomeDeductionsNetImpairedIntangibleAssetsDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/OtherIncomeDeductionsNetTables" xlink:href="pfe-20171001.xsd#OtherIncomeDeductionsNetTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlans" xlink:href="pfe-20171001.xsd#PensionAndPostretirementBenefitPlans" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansDetail" xlink:href="pfe-20171001.xsd#PensionAndPostretirementBenefitPlansDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansNetPeriodicBenefitCostDetail" xlink:href="pfe-20171001.xsd#PensionAndPostretirementBenefitPlansNetPeriodicBenefitCostDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansNetPeriodicBenefitCostFootnotesDetails" xlink:href="pfe-20171001.xsd#PensionAndPostretirementBenefitPlansNetPeriodicBenefitCostFootnotesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansTables" xlink:href="pfe-20171001.xsd#PensionAndPostretirementBenefitPlansTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiatives" xlink:href="pfe-20171001.xsd#RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiatives" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesDetail" xlink:href="pfe-20171001.xsd#RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesFootnotesDetails" xlink:href="pfe-20171001.xsd#RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesFootnotesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesRestructuringAccrualsDetail" xlink:href="pfe-20171001.xsd#RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesRestructuringAccrualsDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesRestructuringAccrualsFootnotesDetail" xlink:href="pfe-20171001.xsd#RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesRestructuringAccrualsFootnotesDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesTables" xlink:href="pfe-20171001.xsd#RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformation" xlink:href="pfe-20171001.xsd#SegmentGeographicAndOtherRevenueInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationDetail" xlink:href="pfe-20171001.xsd#SegmentGeographicAndOtherRevenueInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationFootnotesDetail" xlink:href="pfe-20171001.xsd#SegmentGeographicAndOtherRevenueInformationFootnotesDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationNarrativeDetail" xlink:href="pfe-20171001.xsd#SegmentGeographicAndOtherRevenueInformationNarrativeDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByGeographicAreaDetail" xlink:href="pfe-20171001.xsd#SegmentGeographicAndOtherRevenueInformationRevenuesByGeographicAreaDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByGeographicAreaFootnotesDetail" xlink:href="pfe-20171001.xsd#SegmentGeographicAndOtherRevenueInformationRevenuesByGeographicAreaFootnotesDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail" xlink:href="pfe-20171001.xsd#SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationTables" xlink:href="pfe-20171001.xsd#SegmentGeographicAndOtherRevenueInformationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/TaxMatters" xlink:href="pfe-20171001.xsd#TaxMatters" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/TaxMattersDetail" xlink:href="pfe-20171001.xsd#TaxMattersDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/TaxMattersNarrativeDetail" xlink:href="pfe-20171001.xsd#TaxMattersNarrativeDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/TaxMattersTables" xlink:href="pfe-20171001.xsd#TaxMattersTables" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple" />
  <link:definitionLink xlink:role="http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterests" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_61F6C75527919523A7F47446A197C3CA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_D98A3BC99F189331103B7446A1940881" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_61F6C75527919523A7F47446A197C3CA" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_D98A3BC99F189331103B7446A1940881" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_15D38E7BD92704AE7C437446A19536D1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_D98A3BC99F189331103B7446A1940881" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_15D38E7BD92704AE7C437446A19536D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_B30B78A65E407728C5897446A195B4C5_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_15D38E7BD92704AE7C437446A19536D1" xlink:to="loc_us-gaap_EquityComponentDomain_B30B78A65E407728C5897446A195B4C5_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_B30B78A65E407728C5897446A195B4C5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_15D38E7BD92704AE7C437446A19536D1" xlink:to="loc_us-gaap_EquityComponentDomain_B30B78A65E407728C5897446A195B4C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_244C01AC044E0C65C6417446A1964989" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_B30B78A65E407728C5897446A195B4C5" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_244C01AC044E0C65C6417446A1964989" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_68298F86A77E69BA3A157446A196F407" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_244C01AC044E0C65C6417446A1964989" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_68298F86A77E69BA3A157446A196F407" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" xlink:label="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_9A40968A55C8B973A7CD7446A19614BD" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_244C01AC044E0C65C6417446A1964989" xlink:to="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_9A40968A55C8B973A7CD7446A19614BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_32BF5C20461D335F5D387446A196D3F1" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_244C01AC044E0C65C6417446A1964989" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_32BF5C20461D335F5D387446A196D3F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember_46183F99B4CE69FF3C7C7446A1966499" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_244C01AC044E0C65C6417446A1964989" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember_46183F99B4CE69FF3C7C7446A1966499" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember_8F3AD7B28F179F726DEA7446A196DED9" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_244C01AC044E0C65C6417446A1964989" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember_8F3AD7B28F179F726DEA7446A196DED9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:label="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_2D5308AC1E300A59F7A77446A1979E15" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_61F6C75527919523A7F47446A197C3CA" xlink:to="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_2D5308AC1E300A59F7A77446A1979E15" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_8C616BCBB3D4FF09F1497446A1973693" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_2D5308AC1E300A59F7A77446A1979E15" xlink:to="loc_us-gaap_StockholdersEquity_8C616BCBB3D4FF09F1497446A1973693" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_1A4BF9F0FFC5C577DB6A7446A1977450" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_2D5308AC1E300A59F7A77446A1979E15" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_1A4BF9F0FFC5C577DB6A7446A1977450" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToNoncontrollingInterest_D91DB8C069C4B1865E367446A1972A4C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_61F6C75527919523A7F47446A197C3CA" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToNoncontrollingInterest_D91DB8C069C4B1865E367446A1972A4C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths" xlink:label="loc_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths_74EDC3A7DF1D9815AD147446A1979B07" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_61F6C75527919523A7F47446A197C3CA" xlink:to="loc_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths_74EDC3A7DF1D9815AD147446A1979B07" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestments" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsAnacorPharmaceuticalsIncDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_1F98119F340F50028EB96C87310341C4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_F3D34B5FD15C513A8DA749041A49D470" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1F98119F340F50028EB96C87310341C4" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_F3D34B5FD15C513A8DA749041A49D470" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_12B0D8D151C55A838BF715A6254A0C7A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_F3D34B5FD15C513A8DA749041A49D470" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_12B0D8D151C55A838BF715A6254A0C7A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_F0D88DD1A36EA51850C9C2F7BCAD7A01_0B82B7E4F07153C98FA18A29315D4D23" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_12B0D8D151C55A838BF715A6254A0C7A" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_F0D88DD1A36EA51850C9C2F7BCAD7A01_0B82B7E4F07153C98FA18A29315D4D23" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_537E7C2E29EE5023B93E63CEDBD01877" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_12B0D8D151C55A838BF715A6254A0C7A" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_537E7C2E29EE5023B93E63CEDBD01877" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_AnacorMember" xlink:label="loc_pfe_AnacorMember_31ED3D13BB6C530386BB6CEA31CC95CB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_537E7C2E29EE5023B93E63CEDBD01877" xlink:to="loc_pfe_AnacorMember_31ED3D13BB6C530386BB6CEA31CC95CB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_52D01AB8EBAF579E92CBB030216C21A9" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_F3D34B5FD15C513A8DA749041A49D470" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_52D01AB8EBAF579E92CBB030216C21A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_C825513925211D33AC30C2F7BCAD70E8_0B82B7E4F07153C98FA18A29315D4D23" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_52D01AB8EBAF579E92CBB030216C21A9" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_C825513925211D33AC30C2F7BCAD70E8_0B82B7E4F07153C98FA18A29315D4D23" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_578AE2F0084957D29EFF355DBF2BA981" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_52D01AB8EBAF579E92CBB030216C21A9" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_578AE2F0084957D29EFF355DBF2BA981" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_9AEB86AF48FC56E6AC99C2D23C4F19F9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_578AE2F0084957D29EFF355DBF2BA981" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_9AEB86AF48FC56E6AC99C2D23C4F19F9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_7D0718E45EE15B60A55649A6EC0131F9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1F98119F340F50028EB96C87310341C4" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_7D0718E45EE15B60A55649A6EC0131F9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_530CF42E5251557BBEB51D0F59601D95" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1F98119F340F50028EB96C87310341C4" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_530CF42E5251557BBEB51D0F59601D95" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_67275C04C8CF595BBFDAF9C71B077DDC" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1F98119F340F50028EB96C87310341C4" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_67275C04C8CF595BBFDAF9C71B077DDC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_503CB5B33AEF5300914E6A2669BA891F" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1F98119F340F50028EB96C87310341C4" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_503CB5B33AEF5300914E6A2669BA891F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_C3AA5110EEA45F82A408215AEB065640" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1F98119F340F50028EB96C87310341C4" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_C3AA5110EEA45F82A408215AEB065640" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_E8386BEFA9FA553AB8044BE4E66FD881" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1F98119F340F50028EB96C87310341C4" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_E8386BEFA9FA553AB8044BE4E66FD881" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_812B52E212BC5EC79F5C6B5BD4050E5E" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1F98119F340F50028EB96C87310341C4" xlink:to="loc_us-gaap_Goodwill_812B52E212BC5EC79F5C6B5BD4050E5E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_1067EF6A4A4B58E4A71623EC5EFBF08F" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1F98119F340F50028EB96C87310341C4" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_1067EF6A4A4B58E4A71623EC5EFBF08F" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsAstrazenecaDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_7163E1E0A807AA91B9E59C26438DEE2B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0F047C68B12BD1879CA79C26438C31C7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7163E1E0A807AA91B9E59C26438DEE2B" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0F047C68B12BD1879CA79C26438C31C7" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_D837182BDAE52C1633EE9C26438CF9EA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0F047C68B12BD1879CA79C26438C31C7" xlink:to="loc_us-gaap_StatementScenarioAxis_D837182BDAE52C1633EE9C26438CF9EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_391F33FA0B28885AA9439C26438DEB35_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementScenarioAxis_D837182BDAE52C1633EE9C26438CF9EA" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_391F33FA0B28885AA9439C26438DEB35_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_391F33FA0B28885AA9439C26438DEB35" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementScenarioAxis_D837182BDAE52C1633EE9C26438CF9EA" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_391F33FA0B28885AA9439C26438DEB35" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioForecastMember" xlink:label="loc_us-gaap_ScenarioForecastMember_9A0C8FB1E272A7BF7E019C26438D6335" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_391F33FA0B28885AA9439C26438DEB35" xlink:to="loc_us-gaap_ScenarioForecastMember_9A0C8FB1E272A7BF7E019C26438D6335" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_778C197B2D2C3F2BBA2C9C26438D34F1" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0F047C68B12BD1879CA79C26438C31C7" xlink:to="loc_us-gaap_RangeAxis_778C197B2D2C3F2BBA2C9C26438D34F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_9C6FE024805EC22A90A89C26438DDBE3_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_778C197B2D2C3F2BBA2C9C26438D34F1" xlink:to="loc_us-gaap_RangeMember_9C6FE024805EC22A90A89C26438DDBE3_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_9C6FE024805EC22A90A89C26438DDBE3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_778C197B2D2C3F2BBA2C9C26438D34F1" xlink:to="loc_us-gaap_RangeMember_9C6FE024805EC22A90A89C26438DDBE3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_FFE6EAA4C9A94E283E659C26438DAC25" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_9C6FE024805EC22A90A89C26438DDBE3" xlink:to="loc_us-gaap_MinimumMember_FFE6EAA4C9A94E283E659C26438DAC25" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_1519684DFD1B6D7A664A9C26438D793B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_9C6FE024805EC22A90A89C26438DDBE3" xlink:to="loc_us-gaap_MaximumMember_1519684DFD1B6D7A664A9C26438D793B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6E3AA90739EB1F172E419C26438D48E4" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0F047C68B12BD1879CA79C26438C31C7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6E3AA90739EB1F172E419C26438D48E4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_62B60025539B43A4698A9C26438DDCAA_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6E3AA90739EB1F172E419C26438D48E4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_62B60025539B43A4698A9C26438DDCAA_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_62B60025539B43A4698A9C26438DDCAA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6E3AA90739EB1F172E419C26438D48E4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_62B60025539B43A4698A9C26438DDCAA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_720D8DE4795A03A9269B9C26438D5B1C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_62B60025539B43A4698A9C26438DDCAA" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_720D8DE4795A03A9269B9C26438D5B1C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_CD056FE46311189717289C26438DD314" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0F047C68B12BD1879CA79C26438C31C7" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_CD056FE46311189717289C26438DD314" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_6EC2EC19F57021A4D0B69C26438DE24D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_CD056FE46311189717289C26438DD314" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_6EC2EC19F57021A4D0B69C26438DE24D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_6EC2EC19F57021A4D0B69C26438DE24D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_CD056FE46311189717289C26438DD314" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_6EC2EC19F57021A4D0B69C26438DE24D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_7E80A0C5AA7B1F9B9CAA9C26438DD5A6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_6EC2EC19F57021A4D0B69C26438DE24D" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_7E80A0C5AA7B1F9B9CAA9C26438DD5A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_75D9F0FDF04DB4C8FA069C26438D0D44" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0F047C68B12BD1879CA79C26438C31C7" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_75D9F0FDF04DB4C8FA069C26438D0D44" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7910038FD8FF3B1760D99C26438D5F3C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_75D9F0FDF04DB4C8FA069C26438D0D44" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7910038FD8FF3B1760D99C26438D5F3C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7910038FD8FF3B1760D99C26438D5F3C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_75D9F0FDF04DB4C8FA069C26438D0D44" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7910038FD8FF3B1760D99C26438D5F3C" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_AstraZenecaMember" xlink:label="loc_pfe_AstraZenecaMember_18C9839497F71223222B9C26438D2C8F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7910038FD8FF3B1760D99C26438D5F3C" xlink:to="loc_pfe_AstraZenecaMember_18C9839497F71223222B9C26438D2C8F" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_PaymentstoAcquireBusinessesGrossInitialPayment" xlink:label="loc_pfe_PaymentstoAcquireBusinessesGrossInitialPayment_31C15AA6EC50462279CC9C26438E796F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7163E1E0A807AA91B9E59C26438DEE2B" xlink:to="loc_pfe_PaymentstoAcquireBusinessesGrossInitialPayment_31C15AA6EC50462279CC9C26438E796F" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_PaymentstoAcquireBusinessesGrossPurchasePriceAdjustment" xlink:label="loc_pfe_PaymentstoAcquireBusinessesGrossPurchasePriceAdjustment_8FD878AEBAEE909C72C19C26438E1AC9" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7163E1E0A807AA91B9E59C26438DEE2B" xlink:to="loc_pfe_PaymentstoAcquireBusinessesGrossPurchasePriceAdjustment_8FD878AEBAEE909C72C19C26438E1AC9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities_854B8F1CED12D0FAF8719C26438ECDA9" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7163E1E0A807AA91B9E59C26438DEE2B" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities_854B8F1CED12D0FAF8719C26438ECDA9" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_BusinessCombinationConsiderationTransferredDeferredPayment" xlink:label="loc_pfe_BusinessCombinationConsiderationTransferredDeferredPayment_302719788EFA43C18D8D9C26438E5745" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7163E1E0A807AA91B9E59C26438DEE2B" xlink:to="loc_pfe_BusinessCombinationConsiderationTransferredDeferredPayment_302719788EFA43C18D8D9C26438E5745" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_BusinessCombinationConsiderationTransferredMilestonePaymentsMaximum" xlink:label="loc_pfe_BusinessCombinationConsiderationTransferredMilestonePaymentsMaximum_98799FF8F157810099439C26438E622F" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7163E1E0A807AA91B9E59C26438DEE2B" xlink:to="loc_pfe_BusinessCombinationConsiderationTransferredMilestonePaymentsMaximum_98799FF8F157810099439C26438E622F" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_BusinessCombinationConsiderationTransferredSalesrelatedPaymentsMaximum" xlink:label="loc_pfe_BusinessCombinationConsiderationTransferredSalesrelatedPaymentsMaximum_4F00A539CF613684EB529C26438EA50D" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7163E1E0A807AA91B9E59C26438DEE2B" xlink:to="loc_pfe_BusinessCombinationConsiderationTransferredSalesrelatedPaymentsMaximum_4F00A539CF613684EB529C26438EA50D" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_BusinessCombinationConsiderationTransferredUndiscountedRoyaltyPaymentsTerm" xlink:label="loc_pfe_BusinessCombinationConsiderationTransferredUndiscountedRoyaltyPaymentsTerm_1010B88A0E62C1A4F0FF9C26438E9C0D" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7163E1E0A807AA91B9E59C26438DEE2B" xlink:to="loc_pfe_BusinessCombinationConsiderationTransferredUndiscountedRoyaltyPaymentsTerm_1010B88A0E62C1A4F0FF9C26438E9C0D" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_BusinessCombinationConsiderationTransferredUndiscountedRoyaltyPayments" xlink:label="loc_pfe_BusinessCombinationConsiderationTransferredUndiscountedRoyaltyPayments_2C907DDC618C4151095F9C26438E178F" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7163E1E0A807AA91B9E59C26438DEE2B" xlink:to="loc_pfe_BusinessCombinationConsiderationTransferredUndiscountedRoyaltyPayments_2C907DDC618C4151095F9C26438E178F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_854ED5294AE38DC5D9389C26438E3009" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7163E1E0A807AA91B9E59C26438DEE2B" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_854ED5294AE38DC5D9389C26438E3009" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_0EDC9679A0BFC6EFA90B9C26438ED136" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7163E1E0A807AA91B9E59C26438DEE2B" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_0EDC9679A0BFC6EFA90B9C26438ED136" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_6BA14089CB685427E1879C26438E9D8B" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7163E1E0A807AA91B9E59C26438DEE2B" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_6BA14089CB685427E1879C26438E9D8B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_DA5F83D33317A66259D99C26438E7E37" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7163E1E0A807AA91B9E59C26438DEE2B" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_DA5F83D33317A66259D99C26438E7E37" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_989E8D34C59E3D90DFF39C26438EAF30" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7163E1E0A807AA91B9E59C26438DEE2B" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_989E8D34C59E3D90DFF39C26438EAF30" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_F2536360DE835DB18D349C26438EED82" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7163E1E0A807AA91B9E59C26438DEE2B" xlink:to="loc_us-gaap_Goodwill_F2536360DE835DB18D349C26438EED82" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_F338CA99301B7198479E9C26438E3D99" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7163E1E0A807AA91B9E59C26438DEE2B" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_F338CA99301B7198479E9C26438E3D99" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsBambooTherapeuticsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_836BF1F01B7F112700755A4F9EC3F7C0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0916E06DFE4E727C23A85A4F9EC379BA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_836BF1F01B7F112700755A4F9EC3F7C0" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0916E06DFE4E727C23A85A4F9EC379BA" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_8774CB76A362549C82795A4F9EC3E078" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0916E06DFE4E727C23A85A4F9EC379BA" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_8774CB76A362549C82795A4F9EC3E078" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_4DF437891E5D59D482DB5A4F9EC3F440_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_8774CB76A362549C82795A4F9EC3E078" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_4DF437891E5D59D482DB5A4F9EC3F440_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_4DF437891E5D59D482DB5A4F9EC3F440" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_8774CB76A362549C82795A4F9EC3E078" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_4DF437891E5D59D482DB5A4F9EC3F440" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_9E84B8A4DDEE201F16DC5A4F9EC3CF03" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_4DF437891E5D59D482DB5A4F9EC3F440" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_9E84B8A4DDEE201F16DC5A4F9EC3CF03" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_3EA5C04CC58AEA01A5845A4F9EC30C9A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0916E06DFE4E727C23A85A4F9EC379BA" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_3EA5C04CC58AEA01A5845A4F9EC30C9A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_4B3FA1EB632BEAD704B15A4F9EC389B4_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_3EA5C04CC58AEA01A5845A4F9EC30C9A" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_4B3FA1EB632BEAD704B15A4F9EC389B4_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_4B3FA1EB632BEAD704B15A4F9EC389B4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_3EA5C04CC58AEA01A5845A4F9EC30C9A" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_4B3FA1EB632BEAD704B15A4F9EC389B4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_6E76FDC5D44182494AC25A4F9EC3B1CB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_4B3FA1EB632BEAD704B15A4F9EC389B4" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_6E76FDC5D44182494AC25A4F9EC3B1CB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_A8113B07B6D11911BCF15A4F9EC3CE93" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0916E06DFE4E727C23A85A4F9EC379BA" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_A8113B07B6D11911BCF15A4F9EC3CE93" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_C108FB0D01672E725D725A4F9EC320A2_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_A8113B07B6D11911BCF15A4F9EC3CE93" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_C108FB0D01672E725D725A4F9EC320A2_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_C108FB0D01672E725D725A4F9EC320A2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_A8113B07B6D11911BCF15A4F9EC3CE93" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_C108FB0D01672E725D725A4F9EC320A2" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_BambooTherapeuticsMember" xlink:label="loc_pfe_BambooTherapeuticsMember_86FF1FE02743DD78F6255A4F9EC3D861" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_C108FB0D01672E725D725A4F9EC320A2" xlink:to="loc_pfe_BambooTherapeuticsMember_86FF1FE02743DD78F6255A4F9EC3D861" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_40A6071BDE7D9D991DC85A4F9EC430BC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_836BF1F01B7F112700755A4F9EC3F7C0" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_40A6071BDE7D9D991DC85A4F9EC430BC" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_BusinessCombinationConsiderationTransferredMilestonePaymentsMaximum" xlink:label="loc_pfe_BusinessCombinationConsiderationTransferredMilestonePaymentsMaximum_DA5F81EFDCF50B9331BF5A4F9EC4EE03" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_836BF1F01B7F112700755A4F9EC3F7C0" xlink:to="loc_pfe_BusinessCombinationConsiderationTransferredMilestonePaymentsMaximum_DA5F81EFDCF50B9331BF5A4F9EC4EE03" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1_901FE66BCF82197792D75A4F9EC43936" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_836BF1F01B7F112700755A4F9EC3F7C0" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1_901FE66BCF82197792D75A4F9EC43936" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_C8249169E4D4BABE7A6F5A4F9EC4EE70" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_836BF1F01B7F112700755A4F9EC3F7C0" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_C8249169E4D4BABE7A6F5A4F9EC4EE70" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_2C448FE2FB6ABBB5D9665A4F9EC4F04C" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_836BF1F01B7F112700755A4F9EC3F7C0" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_2C448FE2FB6ABBB5D9665A4F9EC4F04C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_7E9A807808AE9DEF0DDB5A4F9EC4E913" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_836BF1F01B7F112700755A4F9EC3F7C0" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_7E9A807808AE9DEF0DDB5A4F9EC4E913" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_2D521555D25F2E09BFA05A4F9EC42AE4" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_836BF1F01B7F112700755A4F9EC3F7C0" xlink:to="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_2D521555D25F2E09BFA05A4F9EC42AE4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain_EC32B307C5744C3295805A4F9EC47108" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_836BF1F01B7F112700755A4F9EC3F7C0" xlink:to="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain_EC32B307C5744C3295805A4F9EC47108" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_9906617BB94929A4C1EE5A4F9EC42451" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_836BF1F01B7F112700755A4F9EC3F7C0" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_9906617BB94929A4C1EE5A4F9EC42451" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_B766946BF592CD04F37E5A4F9EC4B099" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_836BF1F01B7F112700755A4F9EC3F7C0" xlink:to="loc_us-gaap_Goodwill_B766946BF592CD04F37E5A4F9EC4B099" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_38D1EE8E07E7AE32FD1D5A4F9EC47F16" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_836BF1F01B7F112700755A4F9EC3F7C0" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_38D1EE8E07E7AE32FD1D5A4F9EC47F16" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsCollaborationArrangementDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_10B877F410CE54A19F50694268EBEE36" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_EC89331E05695A38973ED4022AB2196A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_10B877F410CE54A19F50694268EBEE36" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_EC89331E05695A38973ED4022AB2196A" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_B0A69C44D49D5AB4B42211CD22C75E44" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_EC89331E05695A38973ED4022AB2196A" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_B0A69C44D49D5AB4B42211CD22C75E44" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_DE50FE3A57AB5A8C4CACC9B1C2BF1CE1_0B82B7E4F07153C98FA18A29315D4D23" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_B0A69C44D49D5AB4B42211CD22C75E44" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_DE50FE3A57AB5A8C4CACC9B1C2BF1CE1_0B82B7E4F07153C98FA18A29315D4D23" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_883E9CBCAD6C51968B046D153B80E3B8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_B0A69C44D49D5AB4B42211CD22C75E44" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_883E9CBCAD6C51968B046D153B80E3B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_7810ADBEECFC5A8C936DE51C87F68A6F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_883E9CBCAD6C51968B046D153B80E3B8" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_7810ADBEECFC5A8C936DE51C87F68A6F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="loc_us-gaap_CounterpartyNameAxis_E55C9EAE15B45F32A99049FF3CB3645E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_EC89331E05695A38973ED4022AB2196A" xlink:to="loc_us-gaap_CounterpartyNameAxis_E55C9EAE15B45F32A99049FF3CB3645E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_28C08DB74573A4C71693C9B1C2BF3355_0B82B7E4F07153C98FA18A29315D4D23" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CounterpartyNameAxis_E55C9EAE15B45F32A99049FF3CB3645E" xlink:to="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_28C08DB74573A4C71693C9B1C2BF3355_0B82B7E4F07153C98FA18A29315D4D23" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_87E445B19A5C5A938FCF7D2FDAD4CAFF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CounterpartyNameAxis_E55C9EAE15B45F32A99049FF3CB3645E" xlink:to="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_87E445B19A5C5A938FCF7D2FDAD4CAFF" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_MerckKGaAMember" xlink:label="loc_pfe_MerckKGaAMember_E51F38A986FA5F51BCA366F221D83905" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_87E445B19A5C5A938FCF7D2FDAD4CAFF" xlink:to="loc_pfe_MerckKGaAMember_E51F38A986FA5F51BCA366F221D83905" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_A002382DF0945C958DF2EF3AA6BF1041" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_EC89331E05695A38973ED4022AB2196A" xlink:to="loc_us-gaap_TypeOfArrangementAxis_A002382DF0945C958DF2EF3AA6BF1041" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_44A34BBA544F7DAECD4AC9B1C2C4F515_0B82B7E4F07153C98FA18A29315D4D23" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_A002382DF0945C958DF2EF3AA6BF1041" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_44A34BBA544F7DAECD4AC9B1C2C4F515_0B82B7E4F07153C98FA18A29315D4D23" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6362259A964D5829BDD1004C6A05C81D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_A002382DF0945C958DF2EF3AA6BF1041" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6362259A964D5829BDD1004C6A05C81D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="loc_us-gaap_CollaborativeArrangementMember_4AEA76069BEE562EB977746F9C1E22DB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6362259A964D5829BDD1004C6A05C81D" xlink:to="loc_us-gaap_CollaborativeArrangementMember_4AEA76069BEE562EB977746F9C1E22DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromCollaborators" xlink:label="loc_us-gaap_ProceedsFromCollaborators_C0B071DD1B8B5DF584A61B4CA682BEF1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_10B877F410CE54A19F50694268EBEE36" xlink:to="loc_us-gaap_ProceedsFromCollaborators_C0B071DD1B8B5DF584A61B4CA682BEF1" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_CollaborativeArrangementCollaboratorsRevenueandExpenseOwnershipPercentage" xlink:label="loc_pfe_CollaborativeArrangementCollaboratorsRevenueandExpenseOwnershipPercentage_AD6C963FD5DC5C179BF61145AFC1C305" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_10B877F410CE54A19F50694268EBEE36" xlink:to="loc_pfe_CollaborativeArrangementCollaboratorsRevenueandExpenseOwnershipPercentage_AD6C963FD5DC5C179BF61145AFC1C305" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_CollaborativeArrangementCompanysRevenueandExpenseOwnershipPercentage" xlink:label="loc_pfe_CollaborativeArrangementCompanysRevenueandExpenseOwnershipPercentage_2323A02A058E5BACB0EC0C8ACBB2F7D4" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_10B877F410CE54A19F50694268EBEE36" xlink:to="loc_pfe_CollaborativeArrangementCompanysRevenueandExpenseOwnershipPercentage_2323A02A058E5BACB0EC0C8ACBB2F7D4" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsEquityMethodInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_D7C47CB5089866E156A450828D6B08BF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_592CD31D09785B96B30450828D6A104B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_D7C47CB5089866E156A450828D6B08BF" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_592CD31D09785B96B30450828D6A104B" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_C7CDF88D8045CD6AA76950828D6AFFE1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_592CD31D09785B96B30450828D6A104B" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_C7CDF88D8045CD6AA76950828D6AFFE1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvesteeNameDomain" xlink:label="loc_us-gaap_EquityMethodInvesteeNameDomain_A0E07FB95D458FE2D72E50828D6AC26E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_C7CDF88D8045CD6AA76950828D6AFFE1" xlink:to="loc_us-gaap_EquityMethodInvesteeNameDomain_A0E07FB95D458FE2D72E50828D6AC26E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvesteeNameDomain" xlink:label="loc_us-gaap_EquityMethodInvesteeNameDomain_A0E07FB95D458FE2D72E50828D6AC26E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_C7CDF88D8045CD6AA76950828D6AFFE1" xlink:to="loc_us-gaap_EquityMethodInvesteeNameDomain_A0E07FB95D458FE2D72E50828D6AC26E" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_HisunPfizerPharmaceuticalsCoLtdMember" xlink:label="loc_pfe_HisunPfizerPharmaceuticalsCoLtdMember_FD66367D1E1AF8FC8E5650828D6A5825" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityMethodInvesteeNameDomain_A0E07FB95D458FE2D72E50828D6AC26E" xlink:to="loc_pfe_HisunPfizerPharmaceuticalsCoLtdMember_FD66367D1E1AF8FC8E5650828D6A5825" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_LaboratorioTeutoBrasileroMember" xlink:label="loc_pfe_LaboratorioTeutoBrasileroMember_CEF44FE47CD3EA662A6150828D6BBDD0" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityMethodInvesteeNameDomain_A0E07FB95D458FE2D72E50828D6AC26E" xlink:to="loc_pfe_LaboratorioTeutoBrasileroMember_CEF44FE47CD3EA662A6150828D6BBDD0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_BEB99CB0A0549BEFC9EE50828D6B6ECF" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_592CD31D09785B96B30450828D6A104B" xlink:to="loc_dei_LegalEntityAxis_BEB99CB0A0549BEFC9EE50828D6B6ECF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_29D0FA5E31B3100960E650828D6B84B0_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_BEB99CB0A0549BEFC9EE50828D6B6ECF" xlink:to="loc_dei_EntityDomain_29D0FA5E31B3100960E650828D6B84B0_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_29D0FA5E31B3100960E650828D6B84B0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_BEB99CB0A0549BEFC9EE50828D6B6ECF" xlink:to="loc_dei_EntityDomain_29D0FA5E31B3100960E650828D6B84B0" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_LaboratorioTeutoBrasileroMember" xlink:label="loc_pfe_LaboratorioTeutoBrasileroMember_58A7519531D049A5CB4B50828D6BB32A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_29D0FA5E31B3100960E650828D6B84B0" xlink:to="loc_pfe_LaboratorioTeutoBrasileroMember_58A7519531D049A5CB4B50828D6BB32A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_7D4D0695C7AE526E491A50828D6B8718" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_592CD31D09785B96B30450828D6A104B" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_7D4D0695C7AE526E491A50828D6B8718" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_A665EAE9A1079FBA2BDE50828D6B75F3_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_7D4D0695C7AE526E491A50828D6B8718" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_A665EAE9A1079FBA2BDE50828D6B75F3_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_A665EAE9A1079FBA2BDE50828D6B75F3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_7D4D0695C7AE526E491A50828D6B8718" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_A665EAE9A1079FBA2BDE50828D6B75F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_E012D118276871E039B550828D6BDA0F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_A665EAE9A1079FBA2BDE50828D6B75F3" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_E012D118276871E039B550828D6BDA0F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_DE5BB3EB45BFBCA3EFED50828D6B800F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_D7C47CB5089866E156A450828D6B08BF" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_DE5BB3EB45BFBCA3EFED50828D6B800F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment" xlink:label="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_C924361E59A4E4218F6350828D6CC5C4" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_D7C47CB5089866E156A450828D6B08BF" xlink:to="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_C924361E59A4E4218F6350828D6CC5C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:label="loc_us-gaap_EquityMethodInvestments_BC1259064AA82F921CE850828D6C694F" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_D7C47CB5089866E156A450828D6B08BF" xlink:to="loc_us-gaap_EquityMethodInvestments_BC1259064AA82F921CE850828D6C694F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_C54AE19C698E666403AB50828D6C83A0" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_D7C47CB5089866E156A450828D6B08BF" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_C54AE19C698E666403AB50828D6C83A0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal" xlink:label="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_346FE7B391A5044F414950828D6C0207" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_D7C47CB5089866E156A450828D6B08BF" xlink:to="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_346FE7B391A5044F414950828D6C0207" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsMedivationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_D31B05A8BBB414F4A55D91EBE157106D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_237D460DAD574C1EECFD91EBE155C1A9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_D31B05A8BBB414F4A55D91EBE157106D" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_237D460DAD574C1EECFD91EBE155C1A9" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_04052F71CF663ADC607091EBE155CFB2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_237D460DAD574C1EECFD91EBE155C1A9" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_04052F71CF663ADC607091EBE155CFB2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_A55D274BC0F8DD79E70E91EBE1556401_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_04052F71CF663ADC607091EBE155CFB2" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_A55D274BC0F8DD79E70E91EBE1556401_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_A55D274BC0F8DD79E70E91EBE1556401" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_04052F71CF663ADC607091EBE155CFB2" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_A55D274BC0F8DD79E70E91EBE1556401" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_MedivationMember" xlink:label="loc_pfe_MedivationMember_9C3E86480097C6D9EFB791EBE156AAE6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_A55D274BC0F8DD79E70E91EBE1556401" xlink:to="loc_pfe_MedivationMember_9C3E86480097C6D9EFB791EBE156AAE6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_084A605F3340A0EF534291EBE156DE44" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_237D460DAD574C1EECFD91EBE155C1A9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_084A605F3340A0EF534291EBE156DE44" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_13C9D543E3EF79D8D15E91EBE156BC41_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_084A605F3340A0EF534291EBE156DE44" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_13C9D543E3EF79D8D15E91EBE156BC41_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_13C9D543E3EF79D8D15E91EBE156BC41" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_084A605F3340A0EF534291EBE156DE44" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_13C9D543E3EF79D8D15E91EBE156BC41" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_BD1FB8B55C172387B01A91EBE156DE7F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_13C9D543E3EF79D8D15E91EBE156BC41" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_BD1FB8B55C172387B01A91EBE156DE7F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_85B6EEF5A1C1691A286391EBE156C3A6" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_237D460DAD574C1EECFD91EBE155C1A9" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_85B6EEF5A1C1691A286391EBE156C3A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_0A8E9DFFC379C4E7B48F91EBE1575359_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_85B6EEF5A1C1691A286391EBE156C3A6" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_0A8E9DFFC379C4E7B48F91EBE1575359_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_0A8E9DFFC379C4E7B48F91EBE1575359" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_85B6EEF5A1C1691A286391EBE156C3A6" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_0A8E9DFFC379C4E7B48F91EBE1575359" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_159F313A568C6BB1AC1391EBE157BF69" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_0A8E9DFFC379C4E7B48F91EBE1575359" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_159F313A568C6BB1AC1391EBE157BF69" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_3FE543426C5156B53CD291EBE1578F40" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_D31B05A8BBB414F4A55D91EBE157106D" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_3FE543426C5156B53CD291EBE1578F40" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_B4CEF0692237DD8CAC8F91EBE1577894" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_D31B05A8BBB414F4A55D91EBE157106D" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_B4CEF0692237DD8CAC8F91EBE1577894" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_BusinessCombinationConsiderationTransferredNetofCashAcquired" xlink:label="loc_pfe_BusinessCombinationConsiderationTransferredNetofCashAcquired_9059B1BB75588548758E91EBE158E326" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_D31B05A8BBB414F4A55D91EBE157106D" xlink:to="loc_pfe_BusinessCombinationConsiderationTransferredNetofCashAcquired_9059B1BB75588548758E91EBE158E326" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_BusinessCombinationConsiderationTransferredAmountPayable" xlink:label="loc_pfe_BusinessCombinationConsiderationTransferredAmountPayable_160FB04D50237C5B28F791EBE158C168" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_D31B05A8BBB414F4A55D91EBE157106D" xlink:to="loc_pfe_BusinessCombinationConsiderationTransferredAmountPayable_160FB04D50237C5B28F791EBE158C168" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_B705294105545A8BB7C791EBE1584757" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_D31B05A8BBB414F4A55D91EBE157106D" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_B705294105545A8BB7C791EBE1584757" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_20D8491483ADAE1CD65291EBE158E989" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_D31B05A8BBB414F4A55D91EBE157106D" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_20D8491483ADAE1CD65291EBE158E989" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_E15390B7E7F614B4BA8A91EBE158F034" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_D31B05A8BBB414F4A55D91EBE157106D" xlink:to="loc_us-gaap_Goodwill_E15390B7E7F614B4BA8A91EBE158F034" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_17555EFBCB4BB15CB14991EBE158C8FE" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_D31B05A8BBB414F4A55D91EBE157106D" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_17555EFBCB4BB15CB14991EBE158C8FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_9846125E47FEA7AFF61291EBE158DCB9" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_D31B05A8BBB414F4A55D91EBE157106D" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_9846125E47FEA7AFF61291EBE158DCB9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles" xlink:label="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles_313884EB97AC930DA83091EBE1591060" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_D31B05A8BBB414F4A55D91EBE157106D" xlink:to="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles_313884EB97AC930DA83091EBE1591060" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIncreaseDecreaseinAmortizationofIntangibleAssets" xlink:label="loc_pfe_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIncreaseDecreaseinAmortizationofIntangibleAssets_E3EDB9081DDD762CC33D91EBE15962B9" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_D31B05A8BBB414F4A55D91EBE157106D" xlink:to="loc_pfe_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIncreaseDecreaseinAmortizationofIntangibleAssets_E3EDB9081DDD762CC33D91EBE15962B9" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsSaleOfHospiraInfusionSystemsNetAssetsToIcuMedicalIncEhDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_A5D63ACA983B2026A7459C89048D58E8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5A8E4144DD81D17333969C89048BF582" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_A5D63ACA983B2026A7459C89048D58E8" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5A8E4144DD81D17333969C89048BF582" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaap_VariableRateAxis_63203E0DF31EEE0A25BC9C89048BBA75" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5A8E4144DD81D17333969C89048BF582" xlink:to="loc_us-gaap_VariableRateAxis_63203E0DF31EEE0A25BC9C89048BBA75" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_1927AB3144C1477F92119C89048B0235_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_63203E0DF31EEE0A25BC9C89048BBA75" xlink:to="loc_us-gaap_VariableRateDomain_1927AB3144C1477F92119C89048B0235_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_1927AB3144C1477F92119C89048B0235" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_63203E0DF31EEE0A25BC9C89048BBA75" xlink:to="loc_us-gaap_VariableRateDomain_1927AB3144C1477F92119C89048B0235" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_4377669E37C05573A56C9C89048BDDC5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_1927AB3144C1477F92119C89048B0235" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_4377669E37C05573A56C9C89048BDDC5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_D98266D382CE60CC9E899C89048B3D8A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5A8E4144DD81D17333969C89048BF582" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_D98266D382CE60CC9E899C89048B3D8A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_78712D984847674C928F9C89048BEEFE_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_D98266D382CE60CC9E899C89048B3D8A" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_78712D984847674C928F9C89048BEEFE_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_78712D984847674C928F9C89048BEEFE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_D98266D382CE60CC9E899C89048B3D8A" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_78712D984847674C928F9C89048BEEFE" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_HISMember" xlink:label="loc_pfe_HISMember_30293864854FE82E9ED59C89048C0869" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_78712D984847674C928F9C89048BEEFE" xlink:to="loc_pfe_HISMember_30293864854FE82E9ED59C89048C0869" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupClassificationAxis" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_63A5825036C27A4B5C799C89048C9158" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5A8E4144DD81D17333969C89048BF582" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_63A5825036C27A4B5C799C89048C9158" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_0124E2B1DB01A121B1D69C89048C9EBC_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_63A5825036C27A4B5C799C89048C9158" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_0124E2B1DB01A121B1D69C89048C9EBC_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_0124E2B1DB01A121B1D69C89048C9EBC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_63A5825036C27A4B5C799C89048C9158" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_0124E2B1DB01A121B1D69C89048C9EBC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_33082C7AE080085A39679C89048CE7B0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_0124E2B1DB01A121B1D69C89048C9EBC" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_33082C7AE080085A39679C89048CE7B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="loc_us-gaap_CounterpartyNameAxis_C8C480856DC659AEA4B49C89048C77F3" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5A8E4144DD81D17333969C89048BF582" xlink:to="loc_us-gaap_CounterpartyNameAxis_C8C480856DC659AEA4B49C89048C77F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_81D1DABD1DF6F5798BCE9C89048CDCC8_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CounterpartyNameAxis_C8C480856DC659AEA4B49C89048C77F3" xlink:to="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_81D1DABD1DF6F5798BCE9C89048CDCC8_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_81D1DABD1DF6F5798BCE9C89048CDCC8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CounterpartyNameAxis_C8C480856DC659AEA4B49C89048C77F3" xlink:to="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_81D1DABD1DF6F5798BCE9C89048CDCC8" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_ICUMedicalMember" xlink:label="loc_pfe_ICUMedicalMember_83C66512139F3A5207539C89048C2457" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_81D1DABD1DF6F5798BCE9C89048CDCC8" xlink:to="loc_pfe_ICUMedicalMember_83C66512139F3A5207539C89048C2457" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_4543AF01DA18FC5C60599C89048DA29A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_A5D63ACA983B2026A7459C89048D58E8" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_4543AF01DA18FC5C60599C89048DA29A" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationTransferredEquityInterestsShares" xlink:label="loc_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationTransferredEquityInterestsShares_58DF15E051EE10570EC59C89048D52A8" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_A5D63ACA983B2026A7459C89048D58E8" xlink:to="loc_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationTransferredEquityInterestsShares_58DF15E051EE10570EC59C89048D52A8" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationTransferredEquityInterests" xlink:label="loc_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationTransferredEquityInterests_5F4463E417C690CD78609C89048D7A74" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_A5D63ACA983B2026A7459C89048D58E8" xlink:to="loc_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationTransferredEquityInterests_5F4463E417C690CD78609C89048D7A74" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivable" xlink:label="loc_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivable_D5DB28561CBA5B20EB979C89048D72D1" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_A5D63ACA983B2026A7459C89048D58E8" xlink:to="loc_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivable_D5DB28561CBA5B20EB979C89048D72D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_547579B034460F5B020B9C89048DC29E" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_A5D63ACA983B2026A7459C89048D58E8" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_547579B034460F5B020B9C89048DC29E" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_DisposalGroupIncludingDiscontinuedOperationContingentConsideration" xlink:label="loc_pfe_DisposalGroupIncludingDiscontinuedOperationContingentConsideration_7BBADF9184B0B2EAA8E59C89048E799C" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_A5D63ACA983B2026A7459C89048D58E8" xlink:to="loc_pfe_DisposalGroupIncludingDiscontinuedOperationContingentConsideration_7BBADF9184B0B2EAA8E59C89048E799C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_A8F969C39F5B237D2E189C89048E0927" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_A5D63ACA983B2026A7459C89048D58E8" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_A8F969C39F5B237D2E189C89048E0927" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_DisposalGroupIncludingDiscontinuedOperationShareTransferRestrictionTermMinimum" xlink:label="loc_pfe_DisposalGroupIncludingDiscontinuedOperationShareTransferRestrictionTermMinimum_4CC56E67984B173790829C89048E341A" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_A5D63ACA983B2026A7459C89048D58E8" xlink:to="loc_pfe_DisposalGroupIncludingDiscontinuedOperationShareTransferRestrictionTermMinimum_4CC56E67984B173790829C89048E341A" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivableTerm" xlink:label="loc_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivableTerm_F8B51D72DDE2111E041F9C89048F30A7" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_A5D63ACA983B2026A7459C89048D58E8" xlink:to="loc_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivableTerm_F8B51D72DDE2111E041F9C89048F30A7" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivableInterestRate" xlink:label="loc_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivableInterestRate_BE00E016104D79B7F63B9C89048FEA99" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_A5D63ACA983B2026A7459C89048D58E8" xlink:to="loc_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivableInterestRate_BE00E016104D79B7F63B9C89048FEA99" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivableInterestRateYearTwo" xlink:label="loc_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivableInterestRateYearTwo_FC67E5E2885156B124969C89048F3EC9" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_A5D63ACA983B2026A7459C89048D58E8" xlink:to="loc_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivableInterestRateYearTwo_FC67E5E2885156B124969C89048F3EC9" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivableInterestRateYearThree" xlink:label="loc_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivableInterestRateYearThree_56BD7F650FAE5DAF269F9C89048F2495" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_A5D63ACA983B2026A7459C89048D58E8" xlink:to="loc_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivableInterestRateYearThree_56BD7F650FAE5DAF269F9C89048F2495" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_B64DBAC9E0FCA3A725D39C89048F52CD" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_A5D63ACA983B2026A7459C89048D58E8" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_B64DBAC9E0FCA3A725D39C89048F52CD" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_AdministrativeServicePeriod" xlink:label="loc_pfe_AdministrativeServicePeriod_DEFE91415D66C1C85B869C89048FF8A3" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_A5D63ACA983B2026A7459C89048D58E8" xlink:to="loc_pfe_AdministrativeServicePeriod_DEFE91415D66C1C85B869C89048FF8A3" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_MaximumManufacturingServicePeriod" xlink:label="loc_pfe_MaximumManufacturingServicePeriod_09C4A207E2869BF7574E9C89049074BE" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_A5D63ACA983B2026A7459C89048D58E8" xlink:to="loc_pfe_MaximumManufacturingServicePeriod_09C4A207E2869BF7574E9C89049074BE" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPolicies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_40CBB00E5D1C59BB97925CFE5747E432" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_27391B8E11945EDC9D3D36DC96F5777A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_40CBB00E5D1C59BB97925CFE5747E432" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_27391B8E11945EDC9D3D36DC96F5777A" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_B8BB46B7F4E35266BA3DAE32F071AB36" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_27391B8E11945EDC9D3D36DC96F5777A" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_B8BB46B7F4E35266BA3DAE32F071AB36" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_B7ED9F57CDA22D01C290C7A3536A53B9_0B82B7E4F07153C98FA18A29315D4D23" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_B8BB46B7F4E35266BA3DAE32F071AB36" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_B7ED9F57CDA22D01C290C7A3536A53B9_0B82B7E4F07153C98FA18A29315D4D23" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_D71E9079E36C545C9025B802638E4D82" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_B8BB46B7F4E35266BA3DAE32F071AB36" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_D71E9079E36C545C9025B802638E4D82" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_MedivationMember" xlink:label="loc_pfe_MedivationMember_5067282CB4485FF9999DD12D22A5C969" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_D71E9079E36C545C9025B802638E4D82" xlink:to="loc_pfe_MedivationMember_5067282CB4485FF9999DD12D22A5C969" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_AnacorMember" xlink:label="loc_pfe_AnacorMember_0B0566CF4E1F5D1DB17502E864058AE4" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_D71E9079E36C545C9025B802638E4D82" xlink:to="loc_pfe_AnacorMember_0B0566CF4E1F5D1DB17502E864058AE4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_0C0DD4007AE45F2C84E64CFCC1CAE1E8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_40CBB00E5D1C59BB97925CFE5747E432" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_0C0DD4007AE45F2C84E64CFCC1CAE1E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_0D161D2EA75B5BDBAC387C1C2A50BD7E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_BCD95F8D804750DF92D232BE0755A18F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_0D161D2EA75B5BDBAC387C1C2A50BD7E" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_BCD95F8D804750DF92D232BE0755A18F" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_F7106A59F68C56DBAB850ACFDF669E0E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_BCD95F8D804750DF92D232BE0755A18F" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_F7106A59F68C56DBAB850ACFDF669E0E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_DD614B8320546A494F2FC7A3536BB001_0B82B7E4F07153C98FA18A29315D4D23" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_F7106A59F68C56DBAB850ACFDF669E0E" xlink:to="loc_us-gaap_TypeOfAdoptionMember_DD614B8320546A494F2FC7A3536BB001_0B82B7E4F07153C98FA18A29315D4D23" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_A0D84E4FD93A54969239964A215A9845" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_F7106A59F68C56DBAB850ACFDF669E0E" xlink:to="loc_us-gaap_TypeOfAdoptionMember_A0D84E4FD93A54969239964A215A9845" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_AccountingStandardsUpdate201609StatutoryTaxWithholdingComponentMember" xlink:label="loc_pfe_AccountingStandardsUpdate201609StatutoryTaxWithholdingComponentMember_10626B4C8FDC57C6895DD7093B45EC2A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_A0D84E4FD93A54969239964A215A9845" xlink:to="loc_pfe_AccountingStandardsUpdate201609StatutoryTaxWithholdingComponentMember_10626B4C8FDC57C6895DD7093B45EC2A" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTaxBenefitAmount" xlink:label="loc_pfe_EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTaxBenefitAmount_928CEB226603580D91B813C675370772" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_0D161D2EA75B5BDBAC387C1C2A50BD7E" xlink:to="loc_pfe_EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTaxBenefitAmount_928CEB226603580D91B813C675370772" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_885850DC1E2A5C6982B1B611039834AF" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_0D161D2EA75B5BDBAC387C1C2A50BD7E" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_885850DC1E2A5C6982B1B611039834AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_CC6E2694C04D53F0B28BBF293E6E5E59" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_0D161D2EA75B5BDBAC387C1C2A50BD7E" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_CC6E2694C04D53F0B28BBF293E6E5E59" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pfizer.com/role/CommitmentsAndContingencies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pfizer.com/role/CommitmentsAndContingenciesActionsInWhichWeAreDefendantDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaap_LossContingenciesLineItems_708B596EA28799D6E6699C26413A7FEB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaap_LossContingenciesTable_25832DF0933F602C66939C264138C0B6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_708B596EA28799D6E6699C26413A7FEB" xlink:to="loc_us-gaap_LossContingenciesTable_25832DF0933F602C66939C264138C0B6" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_FE34E1FA3DFD842BDFBE9C2641382B63" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_25832DF0933F602C66939C264138C0B6" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_FE34E1FA3DFD842BDFBE9C2641382B63" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_6B8FD34ECD54E1EA85769C2641380155_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_FE34E1FA3DFD842BDFBE9C2641382B63" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_6B8FD34ECD54E1EA85769C2641380155_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_6B8FD34ECD54E1EA85769C2641380155" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_FE34E1FA3DFD842BDFBE9C2641382B63" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_6B8FD34ECD54E1EA85769C2641380155" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_BF17C980A9DC259519489C2641380109" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_6B8FD34ECD54E1EA85769C2641380155" xlink:to="loc_us-gaap_SubsequentEventMember_BF17C980A9DC259519489C2641380109" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_DFB3AAB8BA03A997287B9C2641398ECF" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_25832DF0933F602C66939C264138C0B6" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_DFB3AAB8BA03A997287B9C2641398ECF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="loc_us-gaap_LossContingencyNatureDomain_7A8252A5818F167A28E79C264139B539_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_DFB3AAB8BA03A997287B9C2641398ECF" xlink:to="loc_us-gaap_LossContingencyNatureDomain_7A8252A5818F167A28E79C264139B539_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="loc_us-gaap_LossContingencyNatureDomain_7A8252A5818F167A28E79C264139B539" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_DFB3AAB8BA03A997287B9C2641398ECF" xlink:to="loc_us-gaap_LossContingencyNatureDomain_7A8252A5818F167A28E79C264139B539" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DamagesFromProductDefectsMember" xlink:label="loc_us-gaap_DamagesFromProductDefectsMember_53446B40B4E52C01C4739C2641394A09" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_7A8252A5818F167A28E79C264139B539" xlink:to="loc_us-gaap_DamagesFromProductDefectsMember_53446B40B4E52C01C4739C2641394A09" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_AverageWholesalePriceMember" xlink:label="loc_pfe_AverageWholesalePriceMember_ACBF6A5C7D1CDB486CF29C264139034D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_7A8252A5818F167A28E79C264139B539" xlink:to="loc_pfe_AverageWholesalePriceMember_ACBF6A5C7D1CDB486CF29C264139034D" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_EnvironmentalRemediationLitigationMember" xlink:label="loc_pfe_EnvironmentalRemediationLitigationMember_E720F0C45D11A386F7669C2641391C70" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_7A8252A5818F167A28E79C264139B539" xlink:to="loc_pfe_EnvironmentalRemediationLitigationMember_E720F0C45D11A386F7669C2641391C70" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_ViolationofAntitrustLawsMember" xlink:label="loc_pfe_ViolationofAntitrustLawsMember_E4C61D560B4C2A67D33E9C264139C7AE" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_7A8252A5818F167A28E79C264139B539" xlink:to="loc_pfe_ViolationofAntitrustLawsMember_E4C61D560B4C2A67D33E9C264139C7AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_8B033566066B67E1113C9C2641390E3A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_25832DF0933F602C66939C264138C0B6" xlink:to="loc_us-gaap_ProductOrServiceAxis_8B033566066B67E1113C9C2641390E3A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_615F4976089CE192DE3F9C2641396E06_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ProductOrServiceAxis_8B033566066B67E1113C9C2641390E3A" xlink:to="loc_us-gaap_ProductsAndServicesDomain_615F4976089CE192DE3F9C2641396E06_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_615F4976089CE192DE3F9C2641396E06" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ProductOrServiceAxis_8B033566066B67E1113C9C2641390E3A" xlink:to="loc_us-gaap_ProductsAndServicesDomain_615F4976089CE192DE3F9C2641396E06" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_InflectraMember" xlink:label="loc_pfe_InflectraMember_E7B862046E7E38AFCC889C2641399C79" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_615F4976089CE192DE3F9C2641396E06" xlink:to="loc_pfe_InflectraMember_E7B862046E7E38AFCC889C2641399C79" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_CelebrexMember" xlink:label="loc_pfe_CelebrexMember_FAF313B87916A7BA3F6D9C264139A114" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_615F4976089CE192DE3F9C2641396E06" xlink:to="loc_pfe_CelebrexMember_FAF313B87916A7BA3F6D9C264139A114" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_PhenytoinSodiumCapsulesMember" xlink:label="loc_pfe_PhenytoinSodiumCapsulesMember_26F0F18F2C0E74D1AFCA9C2641396BA1" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_615F4976089CE192DE3F9C2641396E06" xlink:to="loc_pfe_PhenytoinSodiumCapsulesMember_26F0F18F2C0E74D1AFCA9C2641396BA1" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_XtandiMember" xlink:label="loc_pfe_XtandiMember_6A04313798EF26EEA4419C2641396204" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_615F4976089CE192DE3F9C2641396E06" xlink:to="loc_pfe_XtandiMember_6A04313798EF26EEA4419C2641396204" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationCaseAxis" xlink:label="loc_us-gaap_LitigationCaseAxis_4BD10A0FD6BD580FB45F9C264139CD48" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_25832DF0933F602C66939C264138C0B6" xlink:to="loc_us-gaap_LitigationCaseAxis_4BD10A0FD6BD580FB45F9C264139CD48" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationCaseTypeDomain" xlink:label="loc_us-gaap_LitigationCaseTypeDomain_9C8D5E1FE20637C34F4E9C2641397ED3_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LitigationCaseAxis_4BD10A0FD6BD580FB45F9C264139CD48" xlink:to="loc_us-gaap_LitigationCaseTypeDomain_9C8D5E1FE20637C34F4E9C2641397ED3_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationCaseTypeDomain" xlink:label="loc_us-gaap_LitigationCaseTypeDomain_9C8D5E1FE20637C34F4E9C2641397ED3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LitigationCaseAxis_4BD10A0FD6BD580FB45F9C264139CD48" xlink:to="loc_us-gaap_LitigationCaseTypeDomain_9C8D5E1FE20637C34F4E9C2641397ED3" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_JanssenandNewYorkUniversityVersusHospiraCelltrionHealthcareandCelltrionInc.Member" xlink:label="loc_pfe_JanssenandNewYorkUniversityVersusHospiraCelltrionHealthcareandCelltrionInc.Member_F43CE92616C5364FDD379C264139F984" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationCaseTypeDomain_9C8D5E1FE20637C34F4E9C2641397ED3" xlink:to="loc_pfe_JanssenandNewYorkUniversityVersusHospiraCelltrionHealthcareandCelltrionInc.Member_F43CE92616C5364FDD379C264139F984" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_ClassActionVersusAmericanOpticalCorporationAndVariousOtherDefendantsMember" xlink:label="loc_pfe_ClassActionVersusAmericanOpticalCorporationAndVariousOtherDefendantsMember_26B8E4869F899706A8259C2641393BDD" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationCaseTypeDomain_9C8D5E1FE20637C34F4E9C2641397ED3" xlink:to="loc_pfe_ClassActionVersusAmericanOpticalCorporationAndVariousOtherDefendantsMember_26B8E4869F899706A8259C2641393BDD" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_StateofIllinoisVersusPfizerMember" xlink:label="loc_pfe_StateofIllinoisVersusPfizerMember_3131A2B719E7D7FA1E339C26413A7D3C" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationCaseTypeDomain_9C8D5E1FE20637C34F4E9C2641397ED3" xlink:to="loc_pfe_StateofIllinoisVersusPfizerMember_3131A2B719E7D7FA1E339C26413A7D3C" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_RegentsVersusMedivationMember" xlink:label="loc_pfe_RegentsVersusMedivationMember_8D83BD4A67936EA98D019C26413A8C7D" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationCaseTypeDomain_9C8D5E1FE20637C34F4E9C2641397ED3" xlink:to="loc_pfe_RegentsVersusMedivationMember_8D83BD4A67936EA98D019C26413A8C7D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationStatusAxis" xlink:label="loc_us-gaap_LitigationStatusAxis_2357D2B8E4DFF4457B739C26413A4BEE" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_25832DF0933F602C66939C264138C0B6" xlink:to="loc_us-gaap_LitigationStatusAxis_2357D2B8E4DFF4457B739C26413A4BEE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationStatusDomain" xlink:label="loc_us-gaap_LitigationStatusDomain_74008D3A99DEA864E3CF9C26413AB77F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LitigationStatusAxis_2357D2B8E4DFF4457B739C26413A4BEE" xlink:to="loc_us-gaap_LitigationStatusDomain_74008D3A99DEA864E3CF9C26413AB77F_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationStatusDomain" xlink:label="loc_us-gaap_LitigationStatusDomain_74008D3A99DEA864E3CF9C26413AB77F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LitigationStatusAxis_2357D2B8E4DFF4457B739C26413A4BEE" xlink:to="loc_us-gaap_LitigationStatusDomain_74008D3A99DEA864E3CF9C26413AB77F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SettledLitigationMember" xlink:label="loc_us-gaap_SettledLitigationMember_5162DAD41C31B3FF6D409C26413A91B9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_74008D3A99DEA864E3CF9C26413AB77F" xlink:to="loc_us-gaap_SettledLitigationMember_5162DAD41C31B3FF6D409C26413A91B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PendingLitigationMember" xlink:label="loc_us-gaap_PendingLitigationMember_006736D35DFF4FF6A3E59C26413A8E1D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_74008D3A99DEA864E3CF9C26413AB77F" xlink:to="loc_us-gaap_PendingLitigationMember_006736D35DFF4FF6A3E59C26413A8E1D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LossContingencyPatentsAllegedlyInfringedNumber" xlink:label="loc_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber_EB72EE4C83D07664297C9C26413AEDB4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_708B596EA28799D6E6699C26413A7FEB" xlink:to="loc_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber_EB72EE4C83D07664297C9C26413AEDB4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LossContingencyClaimsDismissedNumber" xlink:label="loc_us-gaap_LossContingencyClaimsDismissedNumber_538F102A97B7626498C49C26413A577A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_708B596EA28799D6E6699C26413A7FEB" xlink:to="loc_us-gaap_LossContingencyClaimsDismissedNumber_538F102A97B7626498C49C26413A577A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LossContingencyPendingClaimsNumber" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber_F368F6717B9D7719D8139C26413A3421" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_708B596EA28799D6E6699C26413A7FEB" xlink:to="loc_us-gaap_LossContingencyPendingClaimsNumber_F368F6717B9D7719D8139C26413A3421" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_FeasibilityStudyNumberOfLagoons" xlink:label="loc_pfe_FeasibilityStudyNumberOfLagoons_A87C24D0E15B0353317F9C26413A262B" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_708B596EA28799D6E6699C26413A7FEB" xlink:to="loc_pfe_FeasibilityStudyNumberOfLagoons_A87C24D0E15B0353317F9C26413A262B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_55CE6AD169D633CBF8C29C3641629B07" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_708B596EA28799D6E6699C26413A7FEB" xlink:to="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_55CE6AD169D633CBF8C29C3641629B07" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_08D01608ABC38FD7BC789C26413A135A" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_708B596EA28799D6E6699C26413A7FEB" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_08D01608ABC38FD7BC789C26413A135A" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_LossContingencyCollaborationArrangementPercentageofPaymentsSoughtbyPlaintiff" xlink:label="loc_pfe_LossContingencyCollaborationArrangementPercentageofPaymentsSoughtbyPlaintiff_25ECCDBE199B0490CE469C26413A1295" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_708B596EA28799D6E6699C26413A7FEB" xlink:to="loc_pfe_LossContingencyCollaborationArrangementPercentageofPaymentsSoughtbyPlaintiff_25ECCDBE199B0490CE469C26413A1295" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/CommitmentsAndContingenciesActionsInWhichWeArePlaintiffDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainContingenciesLineItems" xlink:label="loc_us-gaap_GainContingenciesLineItems_6660F8B8F6DEE34F584E9D7882941EE9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainContingenciesTable" xlink:label="loc_us-gaap_GainContingenciesTable_0B11AB7C32B1849BD2579D7882865CBA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GainContingenciesLineItems_6660F8B8F6DEE34F584E9D7882941EE9" xlink:to="loc_us-gaap_GainContingenciesTable_0B11AB7C32B1849BD2579D7882865CBA" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_3C433EBADDE6B2A3CB7E9D788287016D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_GainContingenciesTable_0B11AB7C32B1849BD2579D7882865CBA" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_3C433EBADDE6B2A3CB7E9D788287016D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_8B733AA18E370FDB09C99D7882870AD8_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_3C433EBADDE6B2A3CB7E9D788287016D" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_8B733AA18E370FDB09C99D7882870AD8_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_8B733AA18E370FDB09C99D7882870AD8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_3C433EBADDE6B2A3CB7E9D788287016D" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_8B733AA18E370FDB09C99D7882870AD8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_F33D8693CD0E95DB0DA89D78828782E6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_8B733AA18E370FDB09C99D7882870AD8" xlink:to="loc_us-gaap_SubsequentEventMember_F33D8693CD0E95DB0DA89D78828782E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_1EF6C649BAF87D989D869D7882873E22" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_GainContingenciesTable_0B11AB7C32B1849BD2579D7882865CBA" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_1EF6C649BAF87D989D869D7882873E22" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="loc_us-gaap_LossContingencyNatureDomain_BD93AE6C2922F62D1C629D7882874DBB_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_1EF6C649BAF87D989D869D7882873E22" xlink:to="loc_us-gaap_LossContingencyNatureDomain_BD93AE6C2922F62D1C629D7882874DBB_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="loc_us-gaap_LossContingencyNatureDomain_BD93AE6C2922F62D1C629D7882874DBB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_1EF6C649BAF87D989D869D7882873E22" xlink:to="loc_us-gaap_LossContingencyNatureDomain_BD93AE6C2922F62D1C629D7882874DBB" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_PatentInfringementMember" xlink:label="loc_pfe_PatentInfringementMember_141380A0570DA2E87F0A9D78828709B8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_BD93AE6C2922F62D1C629D7882874DBB" xlink:to="loc_pfe_PatentInfringementMember_141380A0570DA2E87F0A9D78828709B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainContingenciesByNatureAxis" xlink:label="loc_us-gaap_GainContingenciesByNatureAxis_C2E41C793FD8069315969D788287DCD7" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_GainContingenciesTable_0B11AB7C32B1849BD2579D7882865CBA" xlink:to="loc_us-gaap_GainContingenciesByNatureAxis_C2E41C793FD8069315969D788287DCD7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainContingencyNatureDomain" xlink:label="loc_us-gaap_GainContingencyNatureDomain_8D4C6E6F34B51A60A23D9D7882873A40_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_GainContingenciesByNatureAxis_C2E41C793FD8069315969D788287DCD7" xlink:to="loc_us-gaap_GainContingencyNatureDomain_8D4C6E6F34B51A60A23D9D7882873A40_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainContingencyNatureDomain" xlink:label="loc_us-gaap_GainContingencyNatureDomain_8D4C6E6F34B51A60A23D9D7882873A40" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_GainContingenciesByNatureAxis_C2E41C793FD8069315969D788287DCD7" xlink:to="loc_us-gaap_GainContingencyNatureDomain_8D4C6E6F34B51A60A23D9D7882873A40" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_PatentInfringementMember" xlink:label="loc_pfe_PatentInfringementMember_3E654FE1010989BC85119D7882888F35" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GainContingencyNatureDomain_8D4C6E6F34B51A60A23D9D7882873A40" xlink:to="loc_pfe_PatentInfringementMember_3E654FE1010989BC85119D7882888F35" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_94E2BD6873957AE8B0769D788288CAAB" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_GainContingenciesTable_0B11AB7C32B1849BD2579D7882865CBA" xlink:to="loc_us-gaap_ProductOrServiceAxis_94E2BD6873957AE8B0769D788288CAAB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_F8D1D166D44B7E3A24659D7882888B49_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ProductOrServiceAxis_94E2BD6873957AE8B0769D788288CAAB" xlink:to="loc_us-gaap_ProductsAndServicesDomain_F8D1D166D44B7E3A24659D7882888B49_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_F8D1D166D44B7E3A24659D7882888B49" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ProductOrServiceAxis_94E2BD6873957AE8B0769D788288CAAB" xlink:to="loc_us-gaap_ProductsAndServicesDomain_F8D1D166D44B7E3A24659D7882888B49" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_BosulifMember" xlink:label="loc_pfe_BosulifMember_8BA8420A02DB0ED147339D79B77F1B3B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_F8D1D166D44B7E3A24659D7882888B49" xlink:to="loc_pfe_BosulifMember_8BA8420A02DB0ED147339D79B77F1B3B" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_PrecedexPremixMember" xlink:label="loc_pfe_PrecedexPremixMember_511397B87A39C4C509AF9D78828DC65E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_F8D1D166D44B7E3A24659D7882888B49" xlink:to="loc_pfe_PrecedexPremixMember_511397B87A39C4C509AF9D78828DC65E" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_ToviazMember" xlink:label="loc_pfe_ToviazMember_5D10F9B4CB554C4BCBD79D78828DEC07" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_F8D1D166D44B7E3A24659D7882888B49" xlink:to="loc_pfe_ToviazMember_5D10F9B4CB554C4BCBD79D78828DEC07" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_ToviazCompositionofmatterPatentsMember" xlink:label="loc_pfe_ToviazCompositionofmatterPatentsMember_EE1049E1D16984A8EC009D78828D0D4E" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_F8D1D166D44B7E3A24659D7882888B49" xlink:to="loc_pfe_ToviazCompositionofmatterPatentsMember_EE1049E1D16984A8EC009D78828D0D4E" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_XeljanzMember" xlink:label="loc_pfe_XeljanzMember_B119D7CB340A9EE832B29D78828D5B1C" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_F8D1D166D44B7E3A24659D7882888B49" xlink:to="loc_pfe_XeljanzMember_B119D7CB340A9EE832B29D78828D5B1C" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_EliquisMember" xlink:label="loc_pfe_EliquisMember_3C0CA17E8912055C50219D78828D4F18" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_F8D1D166D44B7E3A24659D7882888B49" xlink:to="loc_pfe_EliquisMember_3C0CA17E8912055C50219D78828D4F18" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_BavencioMember" xlink:label="loc_pfe_BavencioMember_5D8AB799F79AF5BEC1C69D78828D60E1" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_F8D1D166D44B7E3A24659D7882888B49" xlink:to="loc_pfe_BavencioMember_5D8AB799F79AF5BEC1C69D78828D60E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationCaseAxis" xlink:label="loc_us-gaap_LitigationCaseAxis_2100543976034476FBB69D78828D81C4" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_GainContingenciesTable_0B11AB7C32B1849BD2579D7882865CBA" xlink:to="loc_us-gaap_LitigationCaseAxis_2100543976034476FBB69D78828D81C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationCaseTypeDomain" xlink:label="loc_us-gaap_LitigationCaseTypeDomain_395BA0AFF7ADC24D8E8B9D78828E436E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LitigationCaseAxis_2100543976034476FBB69D78828D81C4" xlink:to="loc_us-gaap_LitigationCaseTypeDomain_395BA0AFF7ADC24D8E8B9D78828E436E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationCaseTypeDomain" xlink:label="loc_us-gaap_LitigationCaseTypeDomain_395BA0AFF7ADC24D8E8B9D78828E436E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LitigationCaseAxis_2100543976034476FBB69D78828D81C4" xlink:to="loc_us-gaap_LitigationCaseTypeDomain_395BA0AFF7ADC24D8E8B9D78828E436E" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_WyethVersusSunMember" xlink:label="loc_pfe_WyethVersusSunMember_E0D63AE17834610086739D7A3D6C16A0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationCaseTypeDomain_395BA0AFF7ADC24D8E8B9D78828E436E" xlink:to="loc_pfe_WyethVersusSunMember_E0D63AE17834610086739D7A3D6C16A0" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_HospiraVersusAmnealPharmaceuticalsLLCMember" xlink:label="loc_pfe_HospiraVersusAmnealPharmaceuticalsLLCMember_6DB834501C30D34EBCFE9D78828E9C47" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationCaseTypeDomain_395BA0AFF7ADC24D8E8B9D78828E436E" xlink:to="loc_pfe_HospiraVersusAmnealPharmaceuticalsLLCMember_6DB834501C30D34EBCFE9D78828E9C47" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_HospiraVersusFreseniusMember" xlink:label="loc_pfe_HospiraVersusFreseniusMember_47F5FE036AFCEAC745779D78828ECDFF" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationCaseTypeDomain_395BA0AFF7ADC24D8E8B9D78828E436E" xlink:to="loc_pfe_HospiraVersusFreseniusMember_47F5FE036AFCEAC745779D78828ECDFF" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_HospiraVersusParMember" xlink:label="loc_pfe_HospiraVersusParMember_C59735FFE9A96304A7F79D78828EC83E" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationCaseTypeDomain_395BA0AFF7ADC24D8E8B9D78828E436E" xlink:to="loc_pfe_HospiraVersusParMember_C59735FFE9A96304A7F79D78828EC83E" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_PfizerVersusMylanLaboratoriesandAccordHealthcareInc.Member" xlink:label="loc_pfe_PfizerVersusMylanLaboratoriesandAccordHealthcareInc.Member_72FBBF92812A13652E769D78828E7787" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationCaseTypeDomain_395BA0AFF7ADC24D8E8B9D78828E436E" xlink:to="loc_pfe_PfizerVersusMylanLaboratoriesandAccordHealthcareInc.Member_72FBBF92812A13652E769D78828E7787" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_PfizerVersusSeveralGenericManufacturersMember" xlink:label="loc_pfe_PfizerVersusSeveralGenericManufacturersMember_7CFA7D7E0CF6BAC8D2A49D78828EDB34" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationCaseTypeDomain_395BA0AFF7ADC24D8E8B9D78828E436E" xlink:to="loc_pfe_PfizerVersusSeveralGenericManufacturersMember_7CFA7D7E0CF6BAC8D2A49D78828EDB34" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_PfizerVersusMicroLabsMember" xlink:label="loc_pfe_PfizerVersusMicroLabsMember_CA8C0CF09D69846AEB419D78828E5710" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationCaseTypeDomain_395BA0AFF7ADC24D8E8B9D78828E436E" xlink:to="loc_pfe_PfizerVersusMicroLabsMember_CA8C0CF09D69846AEB419D78828E5710" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_PfizerVersusZydusMember" xlink:label="loc_pfe_PfizerVersusZydusMember_C0C413A44D85F5F2B49C9D78828ED067" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationCaseTypeDomain_395BA0AFF7ADC24D8E8B9D78828E436E" xlink:to="loc_pfe_PfizerVersusZydusMember_C0C413A44D85F5F2B49C9D78828ED067" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_PfizerVersusPrinstonandBreckenridgeMember" xlink:label="loc_pfe_PfizerVersusPrinstonandBreckenridgeMember_22EC7458E71D2C03D6209D78828EC414" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationCaseTypeDomain_395BA0AFF7ADC24D8E8B9D78828E436E" xlink:to="loc_pfe_PfizerVersusPrinstonandBreckenridgeMember_22EC7458E71D2C03D6209D78828EC414" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_PfizerVersusBreckenridgeMember" xlink:label="loc_pfe_PfizerVersusBreckenridgeMember_1D870EC79D91DCF699E09D78828E634C" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationCaseTypeDomain_395BA0AFF7ADC24D8E8B9D78828E436E" xlink:to="loc_pfe_PfizerVersusBreckenridgeMember_1D870EC79D91DCF699E09D78828E634C" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_PfizerandBMSVersusSeveralGenericManufacturersMember" xlink:label="loc_pfe_PfizerandBMSVersusSeveralGenericManufacturersMember_8E95607C6FDACAA666269D7882939D26" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationCaseTypeDomain_395BA0AFF7ADC24D8E8B9D78828E436E" xlink:to="loc_pfe_PfizerandBMSVersusSeveralGenericManufacturersMember_8E95607C6FDACAA666269D7882939D26" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_PfizerVersusBMSE.R.SquibbSonsOnoPharmaceuticalandTasukuHonjoMember" xlink:label="loc_pfe_PfizerVersusBMSE.R.SquibbSonsOnoPharmaceuticalandTasukuHonjoMember_924DA4E88E0762E397349D788293AD70" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationCaseTypeDomain_395BA0AFF7ADC24D8E8B9D78828E436E" xlink:to="loc_pfe_PfizerVersusBMSE.R.SquibbSonsOnoPharmaceuticalandTasukuHonjoMember_924DA4E88E0762E397349D788293AD70" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationStatusAxis" xlink:label="loc_us-gaap_LitigationStatusAxis_1CC9C75D8510465085939D7882946028" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_GainContingenciesTable_0B11AB7C32B1849BD2579D7882865CBA" xlink:to="loc_us-gaap_LitigationStatusAxis_1CC9C75D8510465085939D7882946028" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationStatusDomain" xlink:label="loc_us-gaap_LitigationStatusDomain_23B1B5937CC5CC78B53F9D7882947AE1_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LitigationStatusAxis_1CC9C75D8510465085939D7882946028" xlink:to="loc_us-gaap_LitigationStatusDomain_23B1B5937CC5CC78B53F9D7882947AE1_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationStatusDomain" xlink:label="loc_us-gaap_LitigationStatusDomain_23B1B5937CC5CC78B53F9D7882947AE1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LitigationStatusAxis_1CC9C75D8510465085939D7882946028" xlink:to="loc_us-gaap_LitigationStatusDomain_23B1B5937CC5CC78B53F9D7882947AE1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PendingLitigationMember" xlink:label="loc_us-gaap_PendingLitigationMember_E3F73B40EBF48DC7DFA59D7882949983" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_23B1B5937CC5CC78B53F9D7882947AE1" xlink:to="loc_us-gaap_PendingLitigationMember_E3F73B40EBF48DC7DFA59D7882949983" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SettledLitigationMember" xlink:label="loc_us-gaap_SettledLitigationMember_7A9CE589765D726A004A9D788294EF64" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_23B1B5937CC5CC78B53F9D7882947AE1" xlink:to="loc_us-gaap_SettledLitigationMember_7A9CE589765D726A004A9D788294EF64" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_JudicialRulingMember" xlink:label="loc_us-gaap_JudicialRulingMember_BF337A6F5F424A04C8369D788294EB44" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_23B1B5937CC5CC78B53F9D7882947AE1" xlink:to="loc_us-gaap_JudicialRulingMember_BF337A6F5F424A04C8369D788294EB44" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber" xlink:label="loc_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_4612A4966F3380997A9E9D788294532C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GainContingenciesLineItems_6660F8B8F6DEE34F584E9D7882941EE9" xlink:to="loc_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_4612A4966F3380997A9E9D788294532C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainContingencyPatentsFoundNotInfringedUponNumber" xlink:label="loc_us-gaap_GainContingencyPatentsFoundNotInfringedUponNumber_EB8437E073F4D3AA05F49D7882946457" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GainContingenciesLineItems_6660F8B8F6DEE34F584E9D7882941EE9" xlink:to="loc_us-gaap_GainContingencyPatentsFoundNotInfringedUponNumber_EB8437E073F4D3AA05F49D7882946457" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainContingencyPatentsFoundInfringedUponNumber" xlink:label="loc_us-gaap_GainContingencyPatentsFoundInfringedUponNumber_7DFC846B9209D81E69EC9D78829465BE" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GainContingenciesLineItems_6660F8B8F6DEE34F584E9D7882941EE9" xlink:to="loc_us-gaap_GainContingencyPatentsFoundInfringedUponNumber_7DFC846B9209D81E69EC9D78829465BE" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_GainContingencyNumberofDefendants" xlink:label="loc_pfe_GainContingencyNumberofDefendants_6D38BB06D773D68CADD69D788294A402" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GainContingenciesLineItems_6660F8B8F6DEE34F584E9D7882941EE9" xlink:to="loc_pfe_GainContingencyNumberofDefendants_6D38BB06D773D68CADD69D788294A402" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_GainContingencyPatentsAllegedlyInfringeduponNumberDuetoExpireinDecember2020" xlink:label="loc_pfe_GainContingencyPatentsAllegedlyInfringeduponNumberDuetoExpireinDecember2020_3F1C698956071047B90B9D78829406A6" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GainContingenciesLineItems_6660F8B8F6DEE34F584E9D7882941EE9" xlink:to="loc_pfe_GainContingencyPatentsAllegedlyInfringeduponNumberDuetoExpireinDecember2020_3F1C698956071047B90B9D78829406A6" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_GainContingencyPatentsAllegedlyInfringeduponNumberDuetoExpireinDecember2025" xlink:label="loc_pfe_GainContingencyPatentsAllegedlyInfringeduponNumberDuetoExpireinDecember2025_0B96A89B6ACEAB111FEF9D7882957B89" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GainContingenciesLineItems_6660F8B8F6DEE34F584E9D7882941EE9" xlink:to="loc_pfe_GainContingencyPatentsAllegedlyInfringeduponNumberDuetoExpireinDecember2025_0B96A89B6ACEAB111FEF9D7882957B89" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LossContingencyPatentsAllegedlyInfringedNumber" xlink:label="loc_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber_9FE15AC4E49F9D100D8E9D78829564EE" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GainContingenciesLineItems_6660F8B8F6DEE34F584E9D7882941EE9" xlink:to="loc_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber_9FE15AC4E49F9D100D8E9D78829564EE" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/CommitmentsAndContingenciesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AcceleratedShareRepurchasesLineItems" xlink:label="loc_us-gaap_AcceleratedShareRepurchasesLineItems_C95954F5BFA0E3906192921D09D9D7C0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AcceleratedShareRepurchasesTable" xlink:label="loc_us-gaap_AcceleratedShareRepurchasesTable_3056D4ED28B8EA6C6A9B921D09D7F143" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesLineItems_C95954F5BFA0E3906192921D09D9D7C0" xlink:to="loc_us-gaap_AcceleratedShareRepurchasesTable_3056D4ED28B8EA6C6A9B921D09D7F143" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_A228E606A0CE55574D25921D09D78BDB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesTable_3056D4ED28B8EA6C6A9B921D09D7F143" xlink:to="loc_us-gaap_StatementScenarioAxis_A228E606A0CE55574D25921D09D78BDB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_2ABC3B181E139BA20DE2921D09D725BF_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementScenarioAxis_A228E606A0CE55574D25921D09D78BDB" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_2ABC3B181E139BA20DE2921D09D725BF_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_2ABC3B181E139BA20DE2921D09D725BF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementScenarioAxis_A228E606A0CE55574D25921D09D78BDB" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_2ABC3B181E139BA20DE2921D09D725BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProFormaMember" xlink:label="loc_us-gaap_ProFormaMember_DAFA70A739700CFC1679921D09D89319" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_2ABC3B181E139BA20DE2921D09D725BF" xlink:to="loc_us-gaap_ProFormaMember_DAFA70A739700CFC1679921D09D89319" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_09E6EB5D26C0B6510422921D09D8D62F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesTable_3056D4ED28B8EA6C6A9B921D09D7F143" xlink:to="loc_us-gaap_ProductOrServiceAxis_09E6EB5D26C0B6510422921D09D8D62F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_4E1F224DFFD62259162D921D09D8A903_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ProductOrServiceAxis_09E6EB5D26C0B6510422921D09D8D62F" xlink:to="loc_us-gaap_ProductsAndServicesDomain_4E1F224DFFD62259162D921D09D8A903_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_4E1F224DFFD62259162D921D09D8A903" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ProductOrServiceAxis_09E6EB5D26C0B6510422921D09D8D62F" xlink:to="loc_us-gaap_ProductsAndServicesDomain_4E1F224DFFD62259162D921D09D8A903" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_MylotargMember" xlink:label="loc_pfe_MylotargMember_8C172B1B8BE8902987BE921D09D864EB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_4E1F224DFFD62259162D921D09D8A903" xlink:to="loc_pfe_MylotargMember_8C172B1B8BE8902987BE921D09D864EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_83A3DB50A991F330FA64921D09D81AE3" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesTable_3056D4ED28B8EA6C6A9B921D09D7F143" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_83A3DB50A991F330FA64921D09D81AE3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_9027777ED142B7A23E04921D09D892BD_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_83A3DB50A991F330FA64921D09D81AE3" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_9027777ED142B7A23E04921D09D892BD_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_9027777ED142B7A23E04921D09D892BD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_83A3DB50A991F330FA64921D09D81AE3" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_9027777ED142B7A23E04921D09D892BD" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_ShareRepurchaseAgreementwithCitibankMember" xlink:label="loc_pfe_ShareRepurchaseAgreementwithCitibankMember_C2A8F71CFCA543DA86E3921D09D9940A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_9027777ED142B7A23E04921D09D892BD" xlink:to="loc_pfe_ShareRepurchaseAgreementwithCitibankMember_C2A8F71CFCA543DA86E3921D09D9940A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_A685F6BD24A207A158D1921D09D9D31F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesLineItems_C95954F5BFA0E3906192921D09D9D7C0" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_A685F6BD24A207A158D1921D09D9D31F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt" xlink:label="loc_us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt_59992A404830AAEFBA76921D09D98A8A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesLineItems_C95954F5BFA0E3906192921D09D9D7C0" xlink:to="loc_us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt_59992A404830AAEFBA76921D09D98A8A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_F1230CAE177EE8066457921D09D91C51" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesLineItems_C95954F5BFA0E3906192921D09D9D7C0" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_F1230CAE177EE8066457921D09D91C51" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AcceleratedShareRepurchasesInitialPricePaidPerShare" xlink:label="loc_us-gaap_AcceleratedShareRepurchasesInitialPricePaidPerShare_FDB2AE370B97627EBE57921D09D950A6" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesLineItems_C95954F5BFA0E3906192921D09D9D7C0" xlink:to="loc_us-gaap_AcceleratedShareRepurchasesInitialPricePaidPerShare_FDB2AE370B97627EBE57921D09D950A6" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_AcceleratedShareRepurchasesSharesRepurchasedDuringPeriodPercentageofAgreementAmount" xlink:label="loc_pfe_AcceleratedShareRepurchasesSharesRepurchasedDuringPeriodPercentageofAgreementAmount_BAD406876B61F5808BFB921D09DA9E7E" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesLineItems_C95954F5BFA0E3906192921D09D9D7C0" xlink:to="loc_pfe_AcceleratedShareRepurchasesSharesRepurchasedDuringPeriodPercentageofAgreementAmount_BAD406876B61F5808BFB921D09DA9E7E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_7B16CC35C5484DE1E5B3921D09DA5008" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesLineItems_C95954F5BFA0E3906192921D09D9D7C0" xlink:to="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_7B16CC35C5484DE1E5B3921D09DA5008" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_74FF5D80B90DAA88CA40921D09DA107A" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesLineItems_C95954F5BFA0E3906192921D09D9D7C0" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_74FF5D80B90DAA88CA40921D09DA107A" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_ResearchandDevelopmentArrangementAggregatePaymentObligation" xlink:label="loc_pfe_ResearchandDevelopmentArrangementAggregatePaymentObligation_174C301B5B439354EB35921D09DAA635" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesLineItems_C95954F5BFA0E3906192921D09D9D7C0" xlink:to="loc_pfe_ResearchandDevelopmentArrangementAggregatePaymentObligation_174C301B5B439354EB35921D09DAA635" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_ResearchandDevelopmentArrangementAggregatePaymentObligationTerm" xlink:label="loc_pfe_ResearchandDevelopmentArrangementAggregatePaymentObligationTerm_13B172CEFAD1A71DE87E921D1B122958" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesLineItems_C95954F5BFA0E3906192921D09D9D7C0" xlink:to="loc_pfe_ResearchandDevelopmentArrangementAggregatePaymentObligationTerm_13B172CEFAD1A71DE87E921D1B122958" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pfizer.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlowsParenthetical" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_6060E590E46B57269153434F0B52CF4B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_9DAA17AEDC18518F93417AC216A15639" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_6060E590E46B57269153434F0B52CF4B" xlink:to="loc_us-gaap_StatementTable_9DAA17AEDC18518F93417AC216A15639" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_B602757FAD72594FAF04FDDBAD349E7C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_9DAA17AEDC18518F93417AC216A15639" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_B602757FAD72594FAF04FDDBAD349E7C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_3240B02C48E362C82CAAAE9F932B97F4_0B82B7E4F07153C98FA18A29315D4D23" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_B602757FAD72594FAF04FDDBAD349E7C" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_3240B02C48E362C82CAAAE9F932B97F4_0B82B7E4F07153C98FA18A29315D4D23" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_50FFE29006525594AEA95079A199BE30" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_B602757FAD72594FAF04FDDBAD349E7C" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_50FFE29006525594AEA95079A199BE30" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_HISMember" xlink:label="loc_pfe_HISMember_51E2FA4E6F655681AB28225BE9453C8D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_50FFE29006525594AEA95079A199BE30" xlink:to="loc_pfe_HISMember_51E2FA4E6F655681AB28225BE9453C8D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupClassificationAxis" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_769627F58DC55CF489F3172C3F275FF1" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_9DAA17AEDC18518F93417AC216A15639" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_769627F58DC55CF489F3172C3F275FF1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_56B865D63C7A24C302A1AE9F932BC003_0B82B7E4F07153C98FA18A29315D4D23" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_769627F58DC55CF489F3172C3F275FF1" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_56B865D63C7A24C302A1AE9F932BC003_0B82B7E4F07153C98FA18A29315D4D23" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_52B39804D5D054BEB732B84338005E73" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_769627F58DC55CF489F3172C3F275FF1" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_52B39804D5D054BEB732B84338005E73" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_9443657AD3535CB580C3CD157A57631E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_52B39804D5D054BEB732B84338005E73" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_9443657AD3535CB580C3CD157A57631E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="loc_us-gaap_CounterpartyNameAxis_C6B1741913875E608A4A63D764520BD5" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_9DAA17AEDC18518F93417AC216A15639" xlink:to="loc_us-gaap_CounterpartyNameAxis_C6B1741913875E608A4A63D764520BD5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_43E6ABB50F05F5E9FA2AAE9F932B22E8_0B82B7E4F07153C98FA18A29315D4D23" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CounterpartyNameAxis_C6B1741913875E608A4A63D764520BD5" xlink:to="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_43E6ABB50F05F5E9FA2AAE9F932B22E8_0B82B7E4F07153C98FA18A29315D4D23" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_6B7A2EE67C42592AAFE0270BDE988DE1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CounterpartyNameAxis_C6B1741913875E608A4A63D764520BD5" xlink:to="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_6B7A2EE67C42592AAFE0270BDE988DE1" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_ICUMedicalMember" xlink:label="loc_pfe_ICUMedicalMember_B3650B3A5BF1558A908A1FA489EC7306" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_6B7A2EE67C42592AAFE0270BDE988DE1" xlink:to="loc_pfe_ICUMedicalMember_B3650B3A5BF1558A908A1FA489EC7306" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationTransferredEquityInterestsShares" xlink:label="loc_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationTransferredEquityInterestsShares_B66755258E6953EFA9A8877E1083750C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6060E590E46B57269153434F0B52CF4B" xlink:to="loc_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationTransferredEquityInterestsShares_B66755258E6953EFA9A8877E1083750C" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationTransferredEquityInterests" xlink:label="loc_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationTransferredEquityInterests_1B160950912C5BA2BC740FD614313460" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6060E590E46B57269153434F0B52CF4B" xlink:to="loc_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationTransferredEquityInterests_1B160950912C5BA2BC740FD614313460" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivable" xlink:label="loc_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivable_75D9027D2C805ED4AE39641C1F40447E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6060E590E46B57269153434F0B52CF4B" xlink:to="loc_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivable_75D9027D2C805ED4AE39641C1F40447E" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeParenthetical" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_827A234471C250428B9E4F46165140FE" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_9115A4395B1F54869ADF1E0FB0F96F05" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_827A234471C250428B9E4F46165140FE" xlink:to="loc_us-gaap_StatementTable_9115A4395B1F54869ADF1E0FB0F96F05" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_7562AF4A91A05C3DB25A6B1D01EAB64A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_9115A4395B1F54869ADF1E0FB0F96F05" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_7562AF4A91A05C3DB25A6B1D01EAB64A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvesteeNameDomain" xlink:label="loc_us-gaap_EquityMethodInvesteeNameDomain_4153C2092D30331EC8D0C2022417E4A7_0B82B7E4F07153C98FA18A29315D4D23" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_7562AF4A91A05C3DB25A6B1D01EAB64A" xlink:to="loc_us-gaap_EquityMethodInvesteeNameDomain_4153C2092D30331EC8D0C2022417E4A7_0B82B7E4F07153C98FA18A29315D4D23" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvesteeNameDomain" xlink:label="loc_us-gaap_EquityMethodInvesteeNameDomain_7D123A8C8C675C38B52B7D17C8E42E30" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_7562AF4A91A05C3DB25A6B1D01EAB64A" xlink:to="loc_us-gaap_EquityMethodInvesteeNameDomain_7D123A8C8C675C38B52B7D17C8E42E30" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_LaboratorioTeutoBrasileroMember" xlink:label="loc_pfe_LaboratorioTeutoBrasileroMember_915688D5ED455C7E947109498C2DE751" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityMethodInvesteeNameDomain_7D123A8C8C675C38B52B7D17C8E42E30" xlink:to="loc_pfe_LaboratorioTeutoBrasileroMember_915688D5ED455C7E947109498C2DE751" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_171F9C09396358B9B4BC48B1025A3AB2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_827A234471C250428B9E4F46165140FE" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_171F9C09396358B9B4BC48B1025A3AB2" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/CondensedConsolidatedStatementsOfIncome" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pfizer.com/role/DocumentAndEntityInformation" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pfizer.com/role/EarningsPerCommonShareAttributableToCommonShareholders" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pfizer.com/role/EarningsPerCommonShareAttributableToCommonShareholdersDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1F7F5F50CDD9366C0DF002A6B8620604" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_22D9C89968C0D9CEF77602A6B8617B05" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1F7F5F50CDD9366C0DF002A6B8620604" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_22D9C89968C0D9CEF77602A6B8617B05" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_489AE300F49771E002EB02A6B8617D16" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_22D9C89968C0D9CEF77602A6B8617B05" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_489AE300F49771E002EB02A6B8617D16" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_588EB517129D3C1A670102A6B861C1AB_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_489AE300F49771E002EB02A6B8617D16" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_588EB517129D3C1A670102A6B861C1AB_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_588EB517129D3C1A670102A6B861C1AB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_489AE300F49771E002EB02A6B8617D16" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_588EB517129D3C1A670102A6B861C1AB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaap_StockOptionMember_503125AB61B0643FC01702A6B861CE06" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_588EB517129D3C1A670102A6B861C1AB" xlink:to="loc_us-gaap_StockOptionMember_503125AB61B0643FC01702A6B861CE06" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_A2BA5982DD04E5AE83D902A6B8620C3C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1F7F5F50CDD9366C0DF002A6B8620604" xlink:to="loc_us-gaap_EarningsPerShareBasicAbstract_A2BA5982DD04E5AE83D902A6B8620C3C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_D08D65B5B9BB717A138202A6B8624F8B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_A2BA5982DD04E5AE83D902A6B8620C3C" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_D08D65B5B9BB717A138202A6B8624F8B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_9588C5AA962822119D8102A6B8637D72" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_A2BA5982DD04E5AE83D902A6B8620C3C" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_9588C5AA962822119D8102A6B8637D72" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_4D55C0F333B0632BE31602A6B8631385" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_A2BA5982DD04E5AE83D902A6B8620C3C" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_4D55C0F333B0632BE31602A6B8631385" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:label="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_4C813C19B36FD90C4E0D02A6B863978E" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_A2BA5982DD04E5AE83D902A6B8620C3C" xlink:to="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_4C813C19B36FD90C4E0D02A6B863978E" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic" xlink:label="loc_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic_DBB6E306430A25B2719402A6B863F524" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_A2BA5982DD04E5AE83D902A6B8620C3C" xlink:to="loc_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic_DBB6E306430A25B2719402A6B863F524" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_7E615AD050103C1F0AE602A6B864C758" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_A2BA5982DD04E5AE83D902A6B8620C3C" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_7E615AD050103C1F0AE602A6B864C758" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_EB930E4E68C35C69D2A802A6B8645574" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_A2BA5982DD04E5AE83D902A6B8620C3C" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_EB930E4E68C35C69D2A802A6B8645574" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DilutiveSecuritiesAbstract" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract_00C94EC5F5F0AC140FDA02A6B864236C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1F7F5F50CDD9366C0DF002A6B8620604" xlink:to="loc_us-gaap_DilutiveSecuritiesAbstract_00C94EC5F5F0AC140FDA02A6B864236C" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted" xlink:label="loc_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted_94530A6877C815A229F702A6B8646F92" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_00C94EC5F5F0AC140FDA02A6B864236C" xlink:to="loc_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted_94530A6877C815A229F702A6B8646F92" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_EFBB950EA99D751BFD3602A6B864CDE7" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_00C94EC5F5F0AC140FDA02A6B864236C" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_EFBB950EA99D751BFD3602A6B864CDE7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_6BC97F5EACD1031E7B9402A6B865E16D" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_00C94EC5F5F0AC140FDA02A6B864236C" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_6BC97F5EACD1031E7B9402A6B865E16D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_C443601E108786ABDAE202A6B865F980" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1F7F5F50CDD9366C0DF002A6B8620604" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_C443601E108786ABDAE202A6B865F980" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_D744C8BD7F635C8662C702A6B865ABA2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_C443601E108786ABDAE202A6B865F980" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_D744C8BD7F635C8662C702A6B865ABA2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_4DEB466CE0B924CF77BB02A6B86625BA" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_C443601E108786ABDAE202A6B865F980" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_4DEB466CE0B924CF77BB02A6B86625BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_6D44E51893C215ADD81E02A6B86690EA" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_C443601E108786ABDAE202A6B865F980" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_6D44E51893C215ADD81E02A6B86690EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_DD3A1E3A2D538683DA2802A6B866006C" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_C443601E108786ABDAE202A6B865F980" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_DD3A1E3A2D538683DA2802A6B866006C" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/EarningsPerCommonShareAttributableToCommonShareholdersTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pfizer.com/role/FinancialInstruments" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_D09A33EFC8BA5D7C89FC6DC5981EF384" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_82A5AE74CCCA55A0AE1D2595FF718979" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_D09A33EFC8BA5D7C89FC6DC5981EF384" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_82A5AE74CCCA55A0AE1D2595FF718979" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_A315B5958242507ABDC1D6244F3ED121" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_82A5AE74CCCA55A0AE1D2595FF718979" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_A315B5958242507ABDC1D6244F3ED121" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_422238C4CB7A6E88D9F7CCD9F68F0741_0B82B7E4F07153C98FA18A29315D4D23" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_A315B5958242507ABDC1D6244F3ED121" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_422238C4CB7A6E88D9F7CCD9F68F0741_0B82B7E4F07153C98FA18A29315D4D23" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_A3E6D8E48C8D5F7F9168903EBC833057" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_A315B5958242507ABDC1D6244F3ED121" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_A3E6D8E48C8D5F7F9168903EBC833057" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_92D8F6AA069E5FBF8FCD17ABF99AA752" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_A3E6D8E48C8D5F7F9168903EBC833057" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_92D8F6AA069E5FBF8FCD17ABF99AA752" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_815E5B9027BE5DD3BD981C571DF3210D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_82A5AE74CCCA55A0AE1D2595FF718979" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_815E5B9027BE5DD3BD981C571DF3210D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_85C37F0D045F022BEDA9CCD9F68F17F4_0B82B7E4F07153C98FA18A29315D4D23" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_815E5B9027BE5DD3BD981C571DF3210D" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_85C37F0D045F022BEDA9CCD9F68F17F4_0B82B7E4F07153C98FA18A29315D4D23" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_D73ADD1F369F5A60AF4CC6118B273877" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_815E5B9027BE5DD3BD981C571DF3210D" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_D73ADD1F369F5A60AF4CC6118B273877" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtMember" xlink:label="loc_us-gaap_ShortTermDebtMember_95668803968B553A85AE557232D1CFAA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_D73ADD1F369F5A60AF4CC6118B273877" xlink:to="loc_us-gaap_ShortTermDebtMember_95668803968B553A85AE557232D1CFAA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_AA5DEF9F20F55DDCAE11A3371FCA525F" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_82A5AE74CCCA55A0AE1D2595FF718979" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_AA5DEF9F20F55DDCAE11A3371FCA525F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_D4916AC82873812EF382CCD9F68FA69A_0B82B7E4F07153C98FA18A29315D4D23" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_AA5DEF9F20F55DDCAE11A3371FCA525F" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_D4916AC82873812EF382CCD9F68FA69A_0B82B7E4F07153C98FA18A29315D4D23" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_CE1C50779225516C80668B556C2F65BF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_AA5DEF9F20F55DDCAE11A3371FCA525F" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_CE1C50779225516C80668B556C2F65BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtMember" xlink:label="loc_us-gaap_LongTermDebtMember_CB213CE7B27A585FBFA574AD5361BB97" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_CE1C50779225516C80668B556C2F65BF" xlink:to="loc_us-gaap_LongTermDebtMember_CB213CE7B27A585FBFA574AD5361BB97" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_67056AA7DFAC52F2AFF902D45531EF38" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_82A5AE74CCCA55A0AE1D2595FF718979" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_67056AA7DFAC52F2AFF902D45531EF38" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_65CECCFEFCA6532041E2CCD9F690FC9E_0B82B7E4F07153C98FA18A29315D4D23" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_67056AA7DFAC52F2AFF902D45531EF38" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_65CECCFEFCA6532041E2CCD9F690FC9E_0B82B7E4F07153C98FA18A29315D4D23" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_E6F7BDCB0B915802A089BB544237852A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_67056AA7DFAC52F2AFF902D45531EF38" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_E6F7BDCB0B915802A089BB544237852A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_B121D11620F05480923621A2BB5CB9DF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_E6F7BDCB0B915802A089BB544237852A" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_B121D11620F05480923621A2BB5CB9DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_771B641CCC625D02B5DC0D164D99D72D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_E6F7BDCB0B915802A089BB544237852A" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_771B641CCC625D02B5DC0D164D99D72D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_6D53D367502959E693ADBA258307970F" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_82A5AE74CCCA55A0AE1D2595FF718979" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_6D53D367502959E693ADBA258307970F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_BF920E20AD12BF75ED1ACCD9F690BB9D_0B82B7E4F07153C98FA18A29315D4D23" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_6D53D367502959E693ADBA258307970F" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_BF920E20AD12BF75ED1ACCD9F690BB9D_0B82B7E4F07153C98FA18A29315D4D23" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_B4CB6A5E8A765731A8877EE68CB5615A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_6D53D367502959E693ADBA258307970F" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_B4CB6A5E8A765731A8877EE68CB5615A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtSecuritiesMember" xlink:label="loc_us-gaap_DebtSecuritiesMember_1FCBA41C77C45892BAC20E318CE16DE1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_B4CB6A5E8A765731A8877EE68CB5615A" xlink:to="loc_us-gaap_DebtSecuritiesMember_1FCBA41C77C45892BAC20E318CE16DE1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_C802839F21555A069DC0A2D071158A14" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_B4CB6A5E8A765731A8877EE68CB5615A" xlink:to="loc_us-gaap_MoneyMarketFundsMember_C802839F21555A069DC0A2D071158A14" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquitySecuritiesMember" xlink:label="loc_us-gaap_EquitySecuritiesMember_EEAC019B38EB5DA9AB6D94DC640FDB13" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_B4CB6A5E8A765731A8877EE68CB5615A" xlink:to="loc_us-gaap_EquitySecuritiesMember_EEAC019B38EB5DA9AB6D94DC640FDB13" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_AC834DA6A7445646971E2713E6F7A27F" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_82A5AE74CCCA55A0AE1D2595FF718979" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_AC834DA6A7445646971E2713E6F7A27F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_CCE0FC6AB5E0020C6872CCD9F690E71C_0B82B7E4F07153C98FA18A29315D4D23" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_AC834DA6A7445646971E2713E6F7A27F" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_CCE0FC6AB5E0020C6872CCD9F690E71C_0B82B7E4F07153C98FA18A29315D4D23" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_16A4394594335F6F8B75CD13EB49ACCB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_AC834DA6A7445646971E2713E6F7A27F" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_16A4394594335F6F8B75CD13EB49ACCB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestRateSwapMember" xlink:label="loc_us-gaap_InterestRateSwapMember_B6D8AE62BBDC578FB79A8A571A519D3D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_16A4394594335F6F8B75CD13EB49ACCB" xlink:to="loc_us-gaap_InterestRateSwapMember_B6D8AE62BBDC578FB79A8A571A519D3D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CurrencySwapMember" xlink:label="loc_us-gaap_CurrencySwapMember_2054C324BF7D571FBAEFE4BFA3D75BB0" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_16A4394594335F6F8B75CD13EB49ACCB" xlink:to="loc_us-gaap_CurrencySwapMember_2054C324BF7D571FBAEFE4BFA3D75BB0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ForeignExchangeForwardMember" xlink:label="loc_us-gaap_ForeignExchangeForwardMember_5A3FECD316B2595F963A61C5C8C3A570" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_16A4394594335F6F8B75CD13EB49ACCB" xlink:to="loc_us-gaap_ForeignExchangeForwardMember_5A3FECD316B2595F963A61C5C8C3A570" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_3A0DEE1C00B359B897C49F0910C8325E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_D09A33EFC8BA5D7C89FC6DC5981EF384" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_3A0DEE1C00B359B897C49F0910C8325E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TradingSecurities" xlink:label="loc_us-gaap_TradingSecurities_2602A84370AF587B9C0DFDE8C39550AF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_3A0DEE1C00B359B897C49F0910C8325E" xlink:to="loc_us-gaap_TradingSecurities_2602A84370AF587B9C0DFDE8C39550AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_365DD3AE4179535AA5E19545912E64A4" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_3A0DEE1C00B359B897C49F0910C8325E" xlink:to="loc_us-gaap_AvailableForSaleSecurities_365DD3AE4179535AA5E19545912E64A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeAssets" xlink:label="loc_us-gaap_DerivativeAssets_0E984B72214D53D480A114C7B1535ECF" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_3A0DEE1C00B359B897C49F0910C8325E" xlink:to="loc_us-gaap_DerivativeAssets_0E984B72214D53D480A114C7B1535ECF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_3C54C80A45BC5A3D9FECB354356F334C" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_3A0DEE1C00B359B897C49F0910C8325E" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_3C54C80A45BC5A3D9FECB354356F334C" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_OtherSelectedFinancialAssetsAbstract" xlink:label="loc_pfe_OtherSelectedFinancialAssetsAbstract_F1112C10A70E5067893D9ED2271C9085" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_3A0DEE1C00B359B897C49F0910C8325E" xlink:to="loc_pfe_OtherSelectedFinancialAssetsAbstract_F1112C10A70E5067893D9ED2271C9085" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HeldToMaturitySecuritiesAmortizedCostBeforeOtherThanTemporaryImpairment" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesAmortizedCostBeforeOtherThanTemporaryImpairment_AA79B274BB565339A6C2C5761961CFC6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_OtherSelectedFinancialAssetsAbstract_F1112C10A70E5067893D9ED2271C9085" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesAmortizedCostBeforeOtherThanTemporaryImpairment_AA79B274BB565339A6C2C5761961CFC6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_6B61AE09F9AA5EE2A21E466AE1C0E52A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_OtherSelectedFinancialAssetsAbstract_F1112C10A70E5067893D9ED2271C9085" xlink:to="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_6B61AE09F9AA5EE2A21E466AE1C0E52A" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_OtherSelectedFinancialAssets" xlink:label="loc_pfe_OtherSelectedFinancialAssets_C99451FEF3805145BE686459062E56B6" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_OtherSelectedFinancialAssetsAbstract_F1112C10A70E5067893D9ED2271C9085" xlink:to="loc_pfe_OtherSelectedFinancialAssets_C99451FEF3805145BE686459062E56B6" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_SelectedFinancialAssets" xlink:label="loc_pfe_SelectedFinancialAssets_5D2522FA4C2A5707B70C468084D3E203" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_3A0DEE1C00B359B897C49F0910C8325E" xlink:to="loc_pfe_SelectedFinancialAssets_5D2522FA4C2A5707B70C468084D3E203" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_A5B06994B824579E8F8506B1CB505171" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_D09A33EFC8BA5D7C89FC6DC5981EF384" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_A5B06994B824579E8F8506B1CB505171" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_DF914707FD7952A0A8CD4E65ACC29C72" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_A5B06994B824579E8F8506B1CB505171" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_DF914707FD7952A0A8CD4E65ACC29C72" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities_08980192D7CA53DA8A1F3A4352A79649" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_DF914707FD7952A0A8CD4E65ACC29C72" xlink:to="loc_us-gaap_DerivativeLiabilities_08980192D7CA53DA8A1F3A4352A79649" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_OtherSelectedFinancialLiabilitiesAbstract" xlink:label="loc_pfe_OtherSelectedFinancialLiabilitiesAbstract_983B0751E3D15BDA88A08E34B8934C8E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_A5B06994B824579E8F8506B1CB505171" xlink:to="loc_pfe_OtherSelectedFinancialLiabilitiesAbstract_983B0751E3D15BDA88A08E34B8934C8E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermBorrowingsAbstract" xlink:label="loc_us-gaap_ShortTermBorrowingsAbstract_5A3658C5658D5B2AB754D9F4A22E8A82" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_OtherSelectedFinancialLiabilitiesAbstract_983B0751E3D15BDA88A08E34B8934C8E" xlink:to="loc_us-gaap_ShortTermBorrowingsAbstract_5A3658C5658D5B2AB754D9F4A22E8A82" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_ShorttermDebtGross" xlink:label="loc_pfe_ShorttermDebtGross_4007320707415A9BBB0601DC8F4118A4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermBorrowingsAbstract_5A3658C5658D5B2AB754D9F4A22E8A82" xlink:to="loc_pfe_ShorttermDebtGross_4007320707415A9BBB0601DC8F4118A4" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting" xlink:label="loc_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting_A021C0E9ADB65466A7B60BA335A32C56" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermBorrowingsAbstract_5A3658C5658D5B2AB754D9F4A22E8A82" xlink:to="loc_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting_A021C0E9ADB65466A7B60BA335A32C56" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_653AAE9BD3DD571DB32C5142465DEC19" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermBorrowingsAbstract_5A3658C5658D5B2AB754D9F4A22E8A82" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_653AAE9BD3DD571DB32C5142465DEC19" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtCurrent" xlink:label="loc_us-gaap_DebtCurrent_06FC4301F4415B64AEADF3A063C4913B" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermBorrowingsAbstract_5A3658C5658D5B2AB754D9F4A22E8A82" xlink:to="loc_us-gaap_DebtCurrent_06FC4301F4415B64AEADF3A063C4913B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtNoncurrentAbstract" xlink:label="loc_us-gaap_LongTermDebtNoncurrentAbstract_416F19A4639A530E96694ABA89DAFD7D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_OtherSelectedFinancialLiabilitiesAbstract_983B0751E3D15BDA88A08E34B8934C8E" xlink:to="loc_us-gaap_LongTermDebtNoncurrentAbstract_416F19A4639A530E96694ABA89DAFD7D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_D068782291165E76816DF7D94AA64026" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtNoncurrentAbstract_416F19A4639A530E96694ABA89DAFD7D" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_D068782291165E76816DF7D94AA64026" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_F868B271D2835272B876A4AE168AF71C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtNoncurrentAbstract_416F19A4639A530E96694ABA89DAFD7D" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_F868B271D2835272B876A4AE168AF71C" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_OtherFinancialLiabilities" xlink:label="loc_pfe_OtherFinancialLiabilities_36E1F154592E58059EEA3103D2D7FCD4" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtNoncurrentAbstract_416F19A4639A530E96694ABA89DAFD7D" xlink:to="loc_pfe_OtherFinancialLiabilities_36E1F154592E58059EEA3103D2D7FCD4" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_SelectedFinancialLiabilities" xlink:label="loc_pfe_SelectedFinancialLiabilities_A028B2177B545D258BEAF0423003B1C1" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_A5B06994B824579E8F8506B1CB505171" xlink:to="loc_pfe_SelectedFinancialLiabilities_A028B2177B545D258BEAF0423003B1C1" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsAssetsAndLiabilitiesMeasuredOnRecurringBasisFootnotesDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1CD67510301DF2EAD6AD83C06F95E921" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_A4AE6D7FC6AEC33A451483C06F8FDCA8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1CD67510301DF2EAD6AD83C06F95E921" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_A4AE6D7FC6AEC33A451483C06F8FDCA8" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_1F245BE68FF4A0B47C2383C06F8F26AB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_A4AE6D7FC6AEC33A451483C06F8FDCA8" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_1F245BE68FF4A0B47C2383C06F8F26AB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_244D52B2E81BF623D4E783C06F8F983D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1F245BE68FF4A0B47C2383C06F8F26AB" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_244D52B2E81BF623D4E783C06F8F983D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_244D52B2E81BF623D4E783C06F8F983D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1F245BE68FF4A0B47C2383C06F8F26AB" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_244D52B2E81BF623D4E783C06F8F983D" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_ForeignCurrencyLongTermDebtMember" xlink:label="loc_pfe_ForeignCurrencyLongTermDebtMember_4A41975D81F9C955C72A83C06F8F2E5D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_244D52B2E81BF623D4E783C06F8F983D" xlink:to="loc_pfe_ForeignCurrencyLongTermDebtMember_4A41975D81F9C955C72A83C06F8F2E5D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1FEA307C61087941203583C06F8FED0A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_A4AE6D7FC6AEC33A451483C06F8FDCA8" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1FEA307C61087941203583C06F8FED0A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_AAAB1E8F0CECBC2F4EA683C06F8F9BC4_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1FEA307C61087941203583C06F8FED0A" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_AAAB1E8F0CECBC2F4EA683C06F8F9BC4_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_AAAB1E8F0CECBC2F4EA683C06F8F9BC4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1FEA307C61087941203583C06F8FED0A" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_AAAB1E8F0CECBC2F4EA683C06F8F9BC4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_C93D7B408724595C813583C06F94CCD6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_AAAB1E8F0CECBC2F4EA683C06F8F9BC4" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_C93D7B408724595C813583C06F94CCD6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="loc_us-gaap_HedgingDesignationAxis_4B0343557998B88C478283C06F95148F" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_A4AE6D7FC6AEC33A451483C06F8FDCA8" xlink:to="loc_us-gaap_HedgingDesignationAxis_4B0343557998B88C478283C06F95148F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_7CC8A40ED56D8592BFF483C06F95413E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_4B0343557998B88C478283C06F95148F" xlink:to="loc_us-gaap_HedgingDesignationDomain_7CC8A40ED56D8592BFF483C06F95413E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_7CC8A40ED56D8592BFF483C06F95413E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_4B0343557998B88C478283C06F95148F" xlink:to="loc_us-gaap_HedgingDesignationDomain_7CC8A40ED56D8592BFF483C06F95413E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="loc_us-gaap_NondesignatedMember_4E4929FA563EEB33FE7383C06F9565E0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_7CC8A40ED56D8592BFF483C06F95413E" xlink:to="loc_us-gaap_NondesignatedMember_4E4929FA563EEB33FE7383C06F9565E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_CEB3296B166509527C6283C06F9515CB" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_A4AE6D7FC6AEC33A451483C06F8FDCA8" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_CEB3296B166509527C6283C06F9515CB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_C8FF6EDA2FE92089BFA583C06F95AA9C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_CEB3296B166509527C6283C06F9515CB" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_C8FF6EDA2FE92089BFA583C06F95AA9C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_C8FF6EDA2FE92089BFA583C06F95AA9C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_CEB3296B166509527C6283C06F9515CB" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_C8FF6EDA2FE92089BFA583C06F95AA9C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ForeignExchangeForwardMember" xlink:label="loc_us-gaap_ForeignExchangeForwardMember_328FFD76C3BE75228D4B83C06F958EE1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_C8FF6EDA2FE92089BFA583C06F95AA9C" xlink:to="loc_us-gaap_ForeignExchangeForwardMember_328FFD76C3BE75228D4B83C06F958EE1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CurrencySwapMember" xlink:label="loc_us-gaap_CurrencySwapMember_88F285A0671EE32E943E83C06F9588B5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_C8FF6EDA2FE92089BFA583C06F95AA9C" xlink:to="loc_us-gaap_CurrencySwapMember_88F285A0671EE32E943E83C06F9588B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_4D72FB2E33761506BAAE83C06F9568FF" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_A4AE6D7FC6AEC33A451483C06F8FDCA8" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_4D72FB2E33761506BAAE83C06F9568FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_3E8E008349FD4001FE8483C06F956A9C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_4D72FB2E33761506BAAE83C06F9568FF" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_3E8E008349FD4001FE8483C06F956A9C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_3E8E008349FD4001FE8483C06F956A9C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_4D72FB2E33761506BAAE83C06F9568FF" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_3E8E008349FD4001FE8483C06F956A9C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_E2A9923B9CA59CC7CCF383C06F95AEC8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_3E8E008349FD4001FE8483C06F956A9C" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_E2A9923B9CA59CC7CCF383C06F95AEC8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_16D79AF9254B2BA65ED383C06F9591C2" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_A4AE6D7FC6AEC33A451483C06F8FDCA8" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_16D79AF9254B2BA65ED383C06F9591C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_CED491933FFCD21929B283C06F9583AE_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_16D79AF9254B2BA65ED383C06F9591C2" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_CED491933FFCD21929B283C06F9583AE_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_26361C6280493481B9F383C06F95ACB3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_16D79AF9254B2BA65ED383C06F9591C2" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_26361C6280493481B9F383C06F95ACB3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_CED491933FFCD21929B283C06F9583AE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_26361C6280493481B9F383C06F95ACB3" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_CED491933FFCD21929B283C06F9583AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_2F465C3BD268775757BB83C06F957AA5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_26361C6280493481B9F383C06F95ACB3" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_2F465C3BD268775757BB83C06F957AA5" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_FootnotesToSelectedFinancialAssetsAndLiabilitiesAbstract" xlink:label="loc_pfe_FootnotesToSelectedFinancialAssetsAndLiabilitiesAbstract_47737018BB84937F2CB083C06F969081" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1CD67510301DF2EAD6AD83C06F95E921" xlink:to="loc_pfe_FootnotesToSelectedFinancialAssetsAndLiabilitiesAbstract_47737018BB84937F2CB083C06F969081" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_FinancialAssetsAndLiabilitiesMeasuredAtFairValuePercentage" xlink:label="loc_pfe_FinancialAssetsAndLiabilitiesMeasuredAtFairValuePercentage_FAFE5F2A581C842C8DDB83C06F965418" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_FootnotesToSelectedFinancialAssetsAndLiabilitiesAbstract_47737018BB84937F2CB083C06F969081" xlink:to="loc_pfe_FinancialAssetsAndLiabilitiesMeasuredAtFairValuePercentage_FAFE5F2A581C842C8DDB83C06F965418" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TradingSecuritiesEquity" xlink:label="loc_us-gaap_TradingSecuritiesEquity_17550727984FD2E15D9B83C06F96B03A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_FootnotesToSelectedFinancialAssetsAndLiabilitiesAbstract_47737018BB84937F2CB083C06F969081" xlink:to="loc_us-gaap_TradingSecuritiesEquity_17550727984FD2E15D9B83C06F96B03A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TradingSecuritiesDebt" xlink:label="loc_us-gaap_TradingSecuritiesDebt_C1D3E3C5DD0B2D28137483C06F96161D" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_FootnotesToSelectedFinancialAssetsAndLiabilitiesAbstract_47737018BB84937F2CB083C06F969081" xlink:to="loc_us-gaap_TradingSecuritiesDebt_C1D3E3C5DD0B2D28137483C06F96161D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TradingSecuritiesRestricted" xlink:label="loc_us-gaap_TradingSecuritiesRestricted_F273278ECB9D2A003ED983C06F9BCD03" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_FootnotesToSelectedFinancialAssetsAndLiabilitiesAbstract_47737018BB84937F2CB083C06F969081" xlink:to="loc_us-gaap_TradingSecuritiesRestricted_F273278ECB9D2A003ED983C06F9BCD03" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleEquitySecuritiesGrossUnrealizedGain" xlink:label="loc_us-gaap_AvailableForSaleEquitySecuritiesGrossUnrealizedGain_018B8867E1C6BEDC056583C06F9B518A" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_FootnotesToSelectedFinancialAssetsAndLiabilitiesAbstract_47737018BB84937F2CB083C06F969081" xlink:to="loc_us-gaap_AvailableForSaleEquitySecuritiesGrossUnrealizedGain_018B8867E1C6BEDC056583C06F9B518A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleEquitySecuritiesGrossUnrealizedLoss" xlink:label="loc_us-gaap_AvailableForSaleEquitySecuritiesGrossUnrealizedLoss_292E722B66CBD96B1C8B83C06F9BF32D" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_FootnotesToSelectedFinancialAssetsAndLiabilitiesAbstract_47737018BB84937F2CB083C06F969081" xlink:to="loc_us-gaap_AvailableForSaleEquitySecuritiesGrossUnrealizedLoss_292E722B66CBD96B1C8B83C06F9BF32D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_8B4684F6A889AD23A6B183C06F9B105D" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_FootnotesToSelectedFinancialAssetsAndLiabilitiesAbstract_47737018BB84937F2CB083C06F969081" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_8B4684F6A889AD23A6B183C06F9B105D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_BEA2FACC412603EC2E9C83C06F9CDE02" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_FootnotesToSelectedFinancialAssetsAndLiabilitiesAbstract_47737018BB84937F2CB083C06F969081" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_BEA2FACC412603EC2E9C83C06F9CDE02" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtFairValue" xlink:label="loc_us-gaap_LongTermDebtFairValue_682A819E7E6ECBFB4D5783C06F9C4D9F" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_FootnotesToSelectedFinancialAssetsAndLiabilitiesAbstract_47737018BB84937F2CB083C06F969081" xlink:to="loc_us-gaap_LongTermDebtFairValue_682A819E7E6ECBFB4D5783C06F9C4D9F" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsBalanceSheetGroupingDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_54E53BF25E635777A26D9863423332BE" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_C3257AD4017C59A68CB4B966050AB1C2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_54E53BF25E635777A26D9863423332BE" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_C3257AD4017C59A68CB4B966050AB1C2" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_6A3523DDB03557DE9D273D3755032668" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_C3257AD4017C59A68CB4B966050AB1C2" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_6A3523DDB03557DE9D273D3755032668" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_A5BB94C427C39AFAD03FAE9F9298A3CC_0B82B7E4F07153C98FA18A29315D4D23" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_6A3523DDB03557DE9D273D3755032668" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_A5BB94C427C39AFAD03FAE9F9298A3CC_0B82B7E4F07153C98FA18A29315D4D23" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_4BDF5E046AB95466A095F3ADAE5C803C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_6A3523DDB03557DE9D273D3755032668" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_4BDF5E046AB95466A095F3ADAE5C803C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsMember" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember_540B2769F98F562BA5A4CBA5C6E64BD1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_4BDF5E046AB95466A095F3ADAE5C803C" xlink:to="loc_us-gaap_CashAndCashEquivalentsMember_540B2769F98F562BA5A4CBA5C6E64BD1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermInvestmentsMember" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_DB0DDEC60A6D54DF88CBB2F83C60C9C3" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_4BDF5E046AB95466A095F3ADAE5C803C" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_DB0DDEC60A6D54DF88CBB2F83C60C9C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherCurrentAssetsMember" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_9953FA6D110A533EBF4B7F78FDF39C63" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_4BDF5E046AB95466A095F3ADAE5C803C" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_9953FA6D110A533EBF4B7F78FDF39C63" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_LongtermInvestmentsMember" xlink:label="loc_pfe_LongtermInvestmentsMember_02A50238EE485DF7908769971C65B6FD" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_4BDF5E046AB95466A095F3ADAE5C803C" xlink:to="loc_pfe_LongtermInvestmentsMember_02A50238EE485DF7908769971C65B6FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_2474887ED15958C68C50F7EC35A4F24C" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_4BDF5E046AB95466A095F3ADAE5C803C" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_2474887ED15958C68C50F7EC35A4F24C" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_ShortTermDebtAndCurrentPortionofLongTermDebtMember" xlink:label="loc_pfe_ShortTermDebtAndCurrentPortionofLongTermDebtMember_B3DE2C6533265F19BB471811F695A7C1" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_4BDF5E046AB95466A095F3ADAE5C803C" xlink:to="loc_pfe_ShortTermDebtAndCurrentPortionofLongTermDebtMember_B3DE2C6533265F19BB471811F695A7C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_1C5D57B745B75C3785CA83CA3FFD90B5" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_4BDF5E046AB95466A095F3ADAE5C803C" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_1C5D57B745B75C3785CA83CA3FFD90B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtMember" xlink:label="loc_us-gaap_LongTermDebtMember_85E6279587DC5AA4B63517E2E8C434EA" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_4BDF5E046AB95466A095F3ADAE5C803C" xlink:to="loc_us-gaap_LongTermDebtMember_85E6279587DC5AA4B63517E2E8C434EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_9F799E46A82E534BB634EC1D8986FCD6" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_4BDF5E046AB95466A095F3ADAE5C803C" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_9F799E46A82E534BB634EC1D8986FCD6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_DFF744CF05D955CB905DC112328A5256" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_54E53BF25E635777A26D9863423332BE" xlink:to="loc_us-gaap_AssetsAbstract_DFF744CF05D955CB905DC112328A5256" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_SelectedFinancialAssets" xlink:label="loc_pfe_SelectedFinancialAssets_6D8A63016BA9577DA31990E75282FBD7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_DFF744CF05D955CB905DC112328A5256" xlink:to="loc_pfe_SelectedFinancialAssets_6D8A63016BA9577DA31990E75282FBD7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAbstract" xlink:label="loc_us-gaap_LiabilitiesAbstract_BD52E99619F559A28785225F8CDE01A6" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_54E53BF25E635777A26D9863423332BE" xlink:to="loc_us-gaap_LiabilitiesAbstract_BD52E99619F559A28785225F8CDE01A6" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_SelectedFinancialLiabilities" xlink:label="loc_pfe_SelectedFinancialLiabilities_C1B2775507145CF084B6B3F239A46DAA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_BD52E99619F559A28785225F8CDE01A6" xlink:to="loc_pfe_SelectedFinancialLiabilities_C1B2775507145CF084B6B3F239A46DAA" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsBalanceSheetGroupingFootnotesDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_47D3223EC1E7FE607A0C5A4F9E5E389F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_3F32F9245C50F47D8E7F5A4F9E5E0D30" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_47D3223EC1E7FE607A0C5A4F9E5E389F" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_3F32F9245C50F47D8E7F5A4F9E5E0D30" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_18FB3598D46AA930EBC15A4F9E5E8FAE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_3F32F9245C50F47D8E7F5A4F9E5E0D30" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_18FB3598D46AA930EBC15A4F9E5E8FAE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_9A281FBF209F172DE3B25A4F9E5ED590_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_18FB3598D46AA930EBC15A4F9E5E8FAE" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_9A281FBF209F172DE3B25A4F9E5ED590_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_9A281FBF209F172DE3B25A4F9E5ED590" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_18FB3598D46AA930EBC15A4F9E5E8FAE" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_9A281FBF209F172DE3B25A4F9E5ED590" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherCurrentAssetsMember" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_5E3318AAC5C1471BD4C55A4F9E5EE154" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_9A281FBF209F172DE3B25A4F9E5ED590" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_5E3318AAC5C1471BD4C55A4F9E5EE154" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_9C4FC3F5220E9A520C165A4F9E5E6886" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_9A281FBF209F172DE3B25A4F9E5ED590" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_9C4FC3F5220E9A520C165A4F9E5E6886" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_D74EB8AE6C4EDDB1ED415A4F9E5E041A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_9A281FBF209F172DE3B25A4F9E5ED590" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_D74EB8AE6C4EDDB1ED415A4F9E5E041A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_C4C6FDA73863633169CB5A4F9E5E3820" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_9A281FBF209F172DE3B25A4F9E5ED590" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_C4C6FDA73863633169CB5A4F9E5E3820" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_8A5AC61C8E3FC92DCA525A4F9E5E92CC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_3F32F9245C50F47D8E7F5A4F9E5E0D30" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_8A5AC61C8E3FC92DCA525A4F9E5E92CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_9E06B97A4BC0B87408445A4F9E5EF6E6_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_8A5AC61C8E3FC92DCA525A4F9E5E92CC" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_9E06B97A4BC0B87408445A4F9E5EF6E6_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_9E06B97A4BC0B87408445A4F9E5EF6E6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_8A5AC61C8E3FC92DCA525A4F9E5E92CC" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_9E06B97A4BC0B87408445A4F9E5EF6E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestRateSwapMember" xlink:label="loc_us-gaap_InterestRateSwapMember_466BD5A865D714EB4AC25A4F9E5E945D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_9E06B97A4BC0B87408445A4F9E5EF6E6" xlink:to="loc_us-gaap_InterestRateSwapMember_466BD5A865D714EB4AC25A4F9E5E945D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CurrencySwapMember" xlink:label="loc_us-gaap_CurrencySwapMember_3F620A0F27C328909AB05A4F9E5E65C2" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_9E06B97A4BC0B87408445A4F9E5EF6E6" xlink:to="loc_us-gaap_CurrencySwapMember_3F620A0F27C328909AB05A4F9E5E65C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ForeignExchangeForwardMember" xlink:label="loc_us-gaap_ForeignExchangeForwardMember_DD98A5D86855814D6E8B5A4F9E5EC550" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_9E06B97A4BC0B87408445A4F9E5EF6E6" xlink:to="loc_us-gaap_ForeignExchangeForwardMember_DD98A5D86855814D6E8B5A4F9E5EC550" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_SelectedFinancialAssets" xlink:label="loc_pfe_SelectedFinancialAssets_A414F4973077E27BDF6F5A4F9E5E2D66" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_47D3223EC1E7FE607A0C5A4F9E5E389F" xlink:to="loc_pfe_SelectedFinancialAssets_A414F4973077E27BDF6F5A4F9E5E2D66" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_SelectedFinancialLiabilities" xlink:label="loc_pfe_SelectedFinancialLiabilities_5D91E24654C3B7C739095A4F9E5E0D7E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_47D3223EC1E7FE607A0C5A4F9E5E389F" xlink:to="loc_pfe_SelectedFinancialLiabilities_5D91E24654C3B7C739095A4F9E5E0D7E" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_20882AED6FCB469992E978AA4E209725" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_CF27A3AAD79239BF848878AA4E1C48CD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_20882AED6FCB469992E978AA4E209725" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_CF27A3AAD79239BF848878AA4E1C48CD" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_48ED47ACDE4C298930AB78AA4E1C5915" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_CF27A3AAD79239BF848878AA4E1C48CD" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_48ED47ACDE4C298930AB78AA4E1C5915" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_75F9AB8FDFC21345FC8F78AA4E1C2245_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_48ED47ACDE4C298930AB78AA4E1C5915" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_75F9AB8FDFC21345FC8F78AA4E1C2245_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_75F9AB8FDFC21345FC8F78AA4E1C2245" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_48ED47ACDE4C298930AB78AA4E1C5915" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_75F9AB8FDFC21345FC8F78AA4E1C2245" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnsecuredDebtMember" xlink:label="loc_us-gaap_UnsecuredDebtMember_6266BD9FDC1A16C982D478AA4E1CE17C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_75F9AB8FDFC21345FC8F78AA4E1C2245" xlink:to="loc_us-gaap_UnsecuredDebtMember_6266BD9FDC1A16C982D478AA4E1CE17C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_5EF685C7B1E308E6555278AA4E1D71FA" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_CF27A3AAD79239BF848878AA4E1C48CD" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_5EF685C7B1E308E6555278AA4E1D71FA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_4DA99CE97749FD2391A778AA4E1D742B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_5EF685C7B1E308E6555278AA4E1D71FA" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_4DA99CE97749FD2391A778AA4E1D742B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_4DA99CE97749FD2391A778AA4E1D742B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_5EF685C7B1E308E6555278AA4E1D71FA" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_4DA99CE97749FD2391A778AA4E1D742B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestRateContractMember" xlink:label="loc_us-gaap_InterestRateContractMember_DBA1E6354F5DE5B35CBF78AA4E1D4AE0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_4DA99CE97749FD2391A778AA4E1D742B" xlink:to="loc_us-gaap_InterestRateContractMember_DBA1E6354F5DE5B35CBF78AA4E1D4AE0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CurrencySwapMember" xlink:label="loc_us-gaap_CurrencySwapMember_82F87E83423B484497A378AA4E1DF576" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_4DA99CE97749FD2391A778AA4E1D742B" xlink:to="loc_us-gaap_CurrencySwapMember_82F87E83423B484497A378AA4E1DF576" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ForeignExchangeForwardMember" xlink:label="loc_us-gaap_ForeignExchangeForwardMember_4644AD243DB3EB919CA178AA4E1D98D4" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_4DA99CE97749FD2391A778AA4E1D742B" xlink:to="loc_us-gaap_ForeignExchangeForwardMember_4644AD243DB3EB919CA178AA4E1D98D4" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_ForeignCurrencyShortTermBorrowingsMember" xlink:label="loc_pfe_ForeignCurrencyShortTermBorrowingsMember_BB6F2AD2ED115650B75978AA4E1E2B9A" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_4DA99CE97749FD2391A778AA4E1D742B" xlink:to="loc_pfe_ForeignCurrencyShortTermBorrowingsMember_BB6F2AD2ED115650B75978AA4E1E2B9A" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_ForeignCurrencyLongTermDebtMember" xlink:label="loc_pfe_ForeignCurrencyLongTermDebtMember_499472B953FCD72A002878AA4E1E64D9" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_4DA99CE97749FD2391A778AA4E1D742B" xlink:to="loc_pfe_ForeignCurrencyLongTermDebtMember_499472B953FCD72A002878AA4E1E64D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="loc_us-gaap_HedgingDesignationAxis_45000618DCD62BD2202878AA4E1E7570" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_CF27A3AAD79239BF848878AA4E1C48CD" xlink:to="loc_us-gaap_HedgingDesignationAxis_45000618DCD62BD2202878AA4E1E7570" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_B1BE836C2F0D66D9036D78AA4E1EA68B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_45000618DCD62BD2202878AA4E1E7570" xlink:to="loc_us-gaap_HedgingDesignationDomain_B1BE836C2F0D66D9036D78AA4E1EA68B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_B1BE836C2F0D66D9036D78AA4E1EA68B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_45000618DCD62BD2202878AA4E1E7570" xlink:to="loc_us-gaap_HedgingDesignationDomain_B1BE836C2F0D66D9036D78AA4E1EA68B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_87EC418DEA5503470C9078AA4E1EF79A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_B1BE836C2F0D66D9036D78AA4E1EA68B" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_87EC418DEA5503470C9078AA4E1EF79A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="loc_us-gaap_NondesignatedMember_FF324CEEE2823836B39178AA4E1E519B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_B1BE836C2F0D66D9036D78AA4E1EA68B" xlink:to="loc_us-gaap_NondesignatedMember_FF324CEEE2823836B39178AA4E1E519B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_6FDD586F015E8F73B85878AA4E1E073B" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_CF27A3AAD79239BF848878AA4E1C48CD" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_6FDD586F015E8F73B85878AA4E1E073B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HedgingRelationshipDomain" xlink:label="loc_us-gaap_HedgingRelationshipDomain_255FF6B0A7AD4429902578AA4E1E7418_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_6FDD586F015E8F73B85878AA4E1E073B" xlink:to="loc_us-gaap_HedgingRelationshipDomain_255FF6B0A7AD4429902578AA4E1E7418_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HedgingRelationshipDomain" xlink:label="loc_us-gaap_HedgingRelationshipDomain_255FF6B0A7AD4429902578AA4E1E7418" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_6FDD586F015E8F73B85878AA4E1E073B" xlink:to="loc_us-gaap_HedgingRelationshipDomain_255FF6B0A7AD4429902578AA4E1E7418" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashFlowHedgingMember" xlink:label="loc_us-gaap_CashFlowHedgingMember_F281A920718EFF75ED8778AA4E1E2383" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_255FF6B0A7AD4429902578AA4E1E7418" xlink:to="loc_us-gaap_CashFlowHedgingMember_F281A920718EFF75ED8778AA4E1E2383" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetInvestmentHedgingMember" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_B613AD93F10553CAB19B78AA4E1E3F41" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_255FF6B0A7AD4429902578AA4E1E7418" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_B613AD93F10553CAB19B78AA4E1E3F41" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_NetInvestmentHedgingNonderivativeInstrumentsMember" xlink:label="loc_pfe_NetInvestmentHedgingNonderivativeInstrumentsMember_147B9FA1FEC67868DF0078AA4E1FCC8B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_255FF6B0A7AD4429902578AA4E1E7418" xlink:to="loc_pfe_NetInvestmentHedgingNonderivativeInstrumentsMember_147B9FA1FEC67868DF0078AA4E1FCC8B" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_OtherDerivativeInstrumentsMember" xlink:label="loc_pfe_OtherDerivativeInstrumentsMember_18FE7887BD8CF7C341E378AA4E1F933B" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_255FF6B0A7AD4429902578AA4E1E7418" xlink:to="loc_pfe_OtherDerivativeInstrumentsMember_18FE7887BD8CF7C341E378AA4E1F933B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_9C71DF60AC5223DB5CC178AA4E1F0ABF" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_CF27A3AAD79239BF848878AA4E1C48CD" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_9C71DF60AC5223DB5CC178AA4E1F0ABF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_A44E817CE9C065926F2C78AA4E1F6FFB_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_9C71DF60AC5223DB5CC178AA4E1F0ABF" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_A44E817CE9C065926F2C78AA4E1F6FFB_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_A44E817CE9C065926F2C78AA4E1F6FFB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_9C71DF60AC5223DB5CC178AA4E1F0ABF" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_A44E817CE9C065926F2C78AA4E1F6FFB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_696E486E8C8B4961607D78AA4E1F275F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_A44E817CE9C065926F2C78AA4E1F6FFB" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_696E486E8C8B4961607D78AA4E1F275F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_B3C007565DFD9CF164A978AA4E1F4320" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_CF27A3AAD79239BF848878AA4E1C48CD" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_B3C007565DFD9CF164A978AA4E1F4320" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_77FECC347A2998D162B978AA4E1FEEDB_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_B3C007565DFD9CF164A978AA4E1F4320" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_77FECC347A2998D162B978AA4E1FEEDB_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_77FECC347A2998D162B978AA4E1FEEDB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_B3C007565DFD9CF164A978AA4E1F4320" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_77FECC347A2998D162B978AA4E1FEEDB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_61AB97485D607DA6180578AA4E20C1E5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_77FECC347A2998D162B978AA4E1FEEDB" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_61AB97485D607DA6180578AA4E20C1E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLocationAxis" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLocationAxis_D25A26AF52D62E47EEFA78AA4E203AF9" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_CF27A3AAD79239BF848878AA4E1C48CD" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLocationAxis_D25A26AF52D62E47EEFA78AA4E203AF9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLocationDomain" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLocationDomain_9F753970A4E05FA5ED0B78AA4E207D75_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLocationAxis_D25A26AF52D62E47EEFA78AA4E203AF9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLocationDomain_9F753970A4E05FA5ED0B78AA4E207D75_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLocationDomain" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLocationDomain_9F753970A4E05FA5ED0B78AA4E207D75" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLocationAxis_D25A26AF52D62E47EEFA78AA4E203AF9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLocationDomain_9F753970A4E05FA5ED0B78AA4E207D75" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_OtherComprehensiveIncomeMember_E374EA4569F6FC572E8D78AA4E20E5D6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLocationDomain_9F753970A4E05FA5ED0B78AA4E207D75" xlink:to="loc_us-gaap_OtherComprehensiveIncomeMember_E374EA4569F6FC572E8D78AA4E20E5D6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeAssetNotionalAmount" xlink:label="loc_us-gaap_DerivativeAssetNotionalAmount_A9DB330FD322608D665778AA4E20BD2C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_20882AED6FCB469992E978AA4E209725" xlink:to="loc_us-gaap_DerivativeAssetNotionalAmount_A9DB330FD322608D665778AA4E20BD2C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_31FC9AA89B9F1381E10A78AA4E204CB8" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_20882AED6FCB469992E978AA4E209725" xlink:to="loc_us-gaap_LongTermDebt_31FC9AA89B9F1381E10A78AA4E204CB8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_DerivativeNotionalAmount" xlink:label="loc_invest_DerivativeNotionalAmount_E07148EA7884960A7D4178AA4E219F5A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_20882AED6FCB469992E978AA4E209725" xlink:to="loc_invest_DerivativeNotionalAmount_E07148EA7884960A7D4178AA4E219F5A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrealizedLossOnForeignCurrencyDerivativesBeforeTax" xlink:label="loc_us-gaap_UnrealizedLossOnForeignCurrencyDerivativesBeforeTax_A15B0D932880BD01634878AA4E211F6B" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_20882AED6FCB469992E978AA4E209725" xlink:to="loc_us-gaap_UnrealizedLossOnForeignCurrencyDerivativesBeforeTax_A15B0D932880BD01634878AA4E211F6B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months" xlink:label="loc_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months_D44E3E36195FDE0E15DC78AA4E21307B" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_20882AED6FCB469992E978AA4E209725" xlink:to="loc_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months_D44E3E36195FDE0E15DC78AA4E21307B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ForeignCurrencyCashFlowHedgeGainLossReclassifiedToEarningsNet" xlink:label="loc_us-gaap_ForeignCurrencyCashFlowHedgeGainLossReclassifiedToEarningsNet_A9DFDC02E420F85C5EDC78AA4E21C144" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_20882AED6FCB469992E978AA4E209725" xlink:to="loc_us-gaap_ForeignCurrencyCashFlowHedgeGainLossReclassifiedToEarningsNet_A9DFDC02E420F85C5EDC78AA4E21C144" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_3B083D80AD6CAE23B85D78AA4E21FBAF" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_20882AED6FCB469992E978AA4E209725" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_3B083D80AD6CAE23B85D78AA4E21FBAF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet_14F201A640AEF7BB85DB78AA4E2111C9" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_20882AED6FCB469992E978AA4E209725" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet_14F201A640AEF7BB85DB78AA4E2111C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_5ACCD336FC896737348278AA4E21C2BB" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_20882AED6FCB469992E978AA4E209725" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_5ACCD336FC896737348278AA4E21C2BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossOnCashFlowHedgeIneffectivenessNet" xlink:label="loc_us-gaap_GainLossOnCashFlowHedgeIneffectivenessNet_FF4E452EE8E099C6002C78AA4E218395" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_20882AED6FCB469992E978AA4E209725" xlink:to="loc_us-gaap_GainLossOnCashFlowHedgeIneffectivenessNet_FF4E452EE8E099C6002C78AA4E218395" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsInvestmentsInDebtSecuritiesDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfInvestmentsLineItems" xlink:label="loc_us-gaap_ScheduleOfInvestmentsLineItems_A64830A5E08CAF95AC4678AA92B7E9C1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfInvestmentsTable" xlink:label="loc_us-gaap_ScheduleOfInvestmentsTable_1B122C04A037CB87665A78AA92B62F4B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_A64830A5E08CAF95AC4678AA92B7E9C1" xlink:to="loc_us-gaap_ScheduleOfInvestmentsTable_1B122C04A037CB87665A78AA92B62F4B" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_49AA14A49822CBB003FD78AA92B6ECE2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_1B122C04A037CB87665A78AA92B62F4B" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_49AA14A49822CBB003FD78AA92B6ECE2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_05F10A8052398DBB54ED78AA92B6B489_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_49AA14A49822CBB003FD78AA92B6ECE2" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_05F10A8052398DBB54ED78AA92B6B489_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_05F10A8052398DBB54ED78AA92B6B489" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_49AA14A49822CBB003FD78AA92B6ECE2" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_05F10A8052398DBB54ED78AA92B6B489" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_8D8EB9EE3F06820F3E5D78AA92B67537" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_05F10A8052398DBB54ED78AA92B6B489" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_8D8EB9EE3F06820F3E5D78AA92B67537" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_WesternEuropeanAsianandOtherGovernmentDebtMember" xlink:label="loc_pfe_WesternEuropeanAsianandOtherGovernmentDebtMember_EA72CD8D8A6F7FFE3EF278AA92B6C281" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_05F10A8052398DBB54ED78AA92B6B489" xlink:to="loc_pfe_WesternEuropeanAsianandOtherGovernmentDebtMember_EA72CD8D8A6F7FFE3EF278AA92B6C281" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_WesternEuropeanScandinaviaAndOtherGovernmentAgencyDebtMember" xlink:label="loc_pfe_WesternEuropeanScandinaviaAndOtherGovernmentAgencyDebtMember_CB30E57D4BF3F4C8799878AA92B6A970" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_05F10A8052398DBB54ED78AA92B6B489" xlink:to="loc_pfe_WesternEuropeanScandinaviaAndOtherGovernmentAgencyDebtMember_CB30E57D4BF3F4C8799878AA92B6A970" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_SupranationalDebtMember" xlink:label="loc_pfe_SupranationalDebtMember_1AD4FDACD3130EB6815178AA92B6F261" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_05F10A8052398DBB54ED78AA92B6B489" xlink:to="loc_pfe_SupranationalDebtMember_1AD4FDACD3130EB6815178AA92B6F261" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GovernmentNationalMortgageAssociationCertificatesAndObligationsGNMAMember" xlink:label="loc_us-gaap_GovernmentNationalMortgageAssociationCertificatesAndObligationsGNMAMember_89EF659F315C9297769378AA92B6FE38" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_05F10A8052398DBB54ED78AA92B6B489" xlink:to="loc_us-gaap_GovernmentNationalMortgageAssociationCertificatesAndObligationsGNMAMember_89EF659F315C9297769378AA92B6FE38" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_A4DA7F9D7B2D4F3B043778AA92B65309" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_05F10A8052398DBB54ED78AA92B6B489" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_A4DA7F9D7B2D4F3B043778AA92B65309" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_USGovernmentDebtSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentDebtSecuritiesMember_3DBEE0FBEA65A8E0E64778AA92B61D9A" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_05F10A8052398DBB54ED78AA92B6B489" xlink:to="loc_us-gaap_USGovernmentDebtSecuritiesMember_3DBEE0FBEA65A8E0E64778AA92B61D9A" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_TimeDepositsCorporateDebtAndOtherMember" xlink:label="loc_pfe_TimeDepositsCorporateDebtAndOtherMember_4E27277A92FBD0C3817D78AA92B7E012" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_05F10A8052398DBB54ED78AA92B6B489" xlink:to="loc_pfe_TimeDepositsCorporateDebtAndOtherMember_4E27277A92FBD0C3817D78AA92B7E012" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_WesternEuropeanandOtherGovernmentDebtMember" xlink:label="loc_pfe_WesternEuropeanandOtherGovernmentDebtMember_DC371F58241A67D2293C78AA92B7DF8A" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_05F10A8052398DBB54ED78AA92B6B489" xlink:to="loc_pfe_WesternEuropeanandOtherGovernmentDebtMember_DC371F58241A67D2293C78AA92B7DF8A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue_7F3DAEF96C226F9CCA9B78AA92B7DCD8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_A64830A5E08CAF95AC4678AA92B7E9C1" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue_7F3DAEF96C226F9CCA9B78AA92B7DCD8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue_C9752945532AD01CEBD678AA92B7E208" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_A64830A5E08CAF95AC4678AA92B7E9C1" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue_C9752945532AD01CEBD678AA92B7E208" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearSixThroughTenFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearSixThroughTenFairValue_670BA5D746D5AE0E305C78AA92B76099" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_A64830A5E08CAF95AC4678AA92B7E9C1" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearSixThroughTenFairValue_670BA5D746D5AE0E305C78AA92B76099" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingAfterYearTenFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingAfterYearTenFairValue_B83630CFB8696D07E88578AA92B7DE4B" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_A64830A5E08CAF95AC4678AA92B7E9C1" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingAfterYearTenFairValue_B83630CFB8696D07E88578AA92B7DE4B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_C4367B456D1BDD012F1A78AA92B86676" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_A64830A5E08CAF95AC4678AA92B7E9C1" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_C4367B456D1BDD012F1A78AA92B86676" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue_9A9BBB1EA0953898D71978AA92B8BDAC" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_A64830A5E08CAF95AC4678AA92B7E9C1" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue_9A9BBB1EA0953898D71978AA92B8BDAC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue_A21CAE365F9B6009B17878AA92B86B69" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_A64830A5E08CAF95AC4678AA92B7E9C1" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue_A21CAE365F9B6009B17878AA92B86B69" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesRollingYearSixThroughTenFairValue" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesRollingYearSixThroughTenFairValue_D1831CABE6685FFFB00A78AA92B8F1C8" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_A64830A5E08CAF95AC4678AA92B7E9C1" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesRollingYearSixThroughTenFairValue_D1831CABE6685FFFB00A78AA92B8F1C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesRollingAfterTenYearsFairValue" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesRollingAfterTenYearsFairValue_7AF9BDB355A73F8DE7B078AA92B8AA34" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_A64830A5E08CAF95AC4678AA92B7E9C1" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesRollingAfterTenYearsFairValue_7AF9BDB355A73F8DE7B078AA92B8AA34" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HeldToMaturitySecurities" xlink:label="loc_us-gaap_HeldToMaturitySecurities_9A0F3DF4B3089CB57A8F78AA92B8A7D9" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_A64830A5E08CAF95AC4678AA92B7E9C1" xlink:to="loc_us-gaap_HeldToMaturitySecurities_9A0F3DF4B3089CB57A8F78AA92B8A7D9" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_DebtSecuritiesMaturitiesWithinOneYear" xlink:label="loc_pfe_DebtSecuritiesMaturitiesWithinOneYear_22A320D28C9E0CB0554A78AA92B8D19C" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_A64830A5E08CAF95AC4678AA92B7E9C1" xlink:to="loc_pfe_DebtSecuritiesMaturitiesWithinOneYear_22A320D28C9E0CB0554A78AA92B8D19C" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_DebtSecuritiesMaturitiesOverOneToFiveYears" xlink:label="loc_pfe_DebtSecuritiesMaturitiesOverOneToFiveYears_D8703D4D586E410647AC78AA92B9700D" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_A64830A5E08CAF95AC4678AA92B7E9C1" xlink:to="loc_pfe_DebtSecuritiesMaturitiesOverOneToFiveYears_D8703D4D586E410647AC78AA92B9700D" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_DebtSecuritiesMaturitiesOverFiveToTenYears" xlink:label="loc_pfe_DebtSecuritiesMaturitiesOverFiveToTenYears_DF1DBDFC358B17AF3EB478AA92B9CCEA" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_A64830A5E08CAF95AC4678AA92B7E9C1" xlink:to="loc_pfe_DebtSecuritiesMaturitiesOverFiveToTenYears_DF1DBDFC358B17AF3EB478AA92B9CCEA" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_DebtSecuritiesMaturitiesAfterTenYears" xlink:label="loc_pfe_DebtSecuritiesMaturitiesAfterTenYears_D62A663ECCA81C74435078AA92B9D1B3" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_A64830A5E08CAF95AC4678AA92B7E9C1" xlink:to="loc_pfe_DebtSecuritiesMaturitiesAfterTenYears_D62A663ECCA81C74435078AA92B9D1B3" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_DebtSecurities" xlink:label="loc_pfe_DebtSecurities_07220525955D29F6F70E78AA92B90D05" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_A64830A5E08CAF95AC4678AA92B7E9C1" xlink:to="loc_pfe_DebtSecurities_07220525955D29F6F70E78AA92B90D05" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_EA31DB6B63CF54EAA7D8BD4798333EE2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_51E56C85CE6A5ED89D2E0F3C6EA52B30" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_EA31DB6B63CF54EAA7D8BD4798333EE2" xlink:to="loc_us-gaap_DebtInstrumentTable_51E56C85CE6A5ED89D2E0F3C6EA52B30" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_CEF67C86DB7A53D29722F4B974084B7E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_51E56C85CE6A5ED89D2E0F3C6EA52B30" xlink:to="loc_us-gaap_RangeAxis_CEF67C86DB7A53D29722F4B974084B7E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_912B8DF6D3D2B165C51EC82649197DDD_0B82B7E4F07153C98FA18A29315D4D23" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_CEF67C86DB7A53D29722F4B974084B7E" xlink:to="loc_us-gaap_RangeMember_912B8DF6D3D2B165C51EC82649197DDD_0B82B7E4F07153C98FA18A29315D4D23" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_1101F102B98457D1BB25D3E98AA75AB1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_CEF67C86DB7A53D29722F4B974084B7E" xlink:to="loc_us-gaap_RangeMember_1101F102B98457D1BB25D3E98AA75AB1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_377AD433D2E252BB917DA3960A7A9F7A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_1101F102B98457D1BB25D3E98AA75AB1" xlink:to="loc_us-gaap_MaximumMember_377AD433D2E252BB917DA3960A7A9F7A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaap_VariableRateAxis_EFB6E8A6A0EF5EE883EFD8800C086C92" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_51E56C85CE6A5ED89D2E0F3C6EA52B30" xlink:to="loc_us-gaap_VariableRateAxis_EFB6E8A6A0EF5EE883EFD8800C086C92" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_5C14604D5E8263A0D7ADC82649198B48_0B82B7E4F07153C98FA18A29315D4D23" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_EFB6E8A6A0EF5EE883EFD8800C086C92" xlink:to="loc_us-gaap_VariableRateDomain_5C14604D5E8263A0D7ADC82649198B48_0B82B7E4F07153C98FA18A29315D4D23" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_667EED42CD205DB381E9B8E5B9E25E43" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_EFB6E8A6A0EF5EE883EFD8800C086C92" xlink:to="loc_us-gaap_VariableRateDomain_667EED42CD205DB381E9B8E5B9E25E43" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_EURIBORMember" xlink:label="loc_pfe_EURIBORMember_5854D078EE9C53919750C41FDCCE1904" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_667EED42CD205DB381E9B8E5B9E25E43" xlink:to="loc_pfe_EURIBORMember_5854D078EE9C53919750C41FDCCE1904" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_GermanGovernmentBondRateMember" xlink:label="loc_pfe_GermanGovernmentBondRateMember_BD811ADB34CE560A873B6BA0F0151B30" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_667EED42CD205DB381E9B8E5B9E25E43" xlink:to="loc_pfe_GermanGovernmentBondRateMember_BD811ADB34CE560A873B6BA0F0151B30" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_503290E72B645D9095F581B9EA510429" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_51E56C85CE6A5ED89D2E0F3C6EA52B30" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_503290E72B645D9095F581B9EA510429" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_6D17E4605FC9B74BCE7AC82649191952_0B82B7E4F07153C98FA18A29315D4D23" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_503290E72B645D9095F581B9EA510429" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_6D17E4605FC9B74BCE7AC82649191952_0B82B7E4F07153C98FA18A29315D4D23" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_79F4ACBA125C563CBA786742CCD4750B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_503290E72B645D9095F581B9EA510429" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_79F4ACBA125C563CBA786742CCD4750B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeniorNotesMember" xlink:label="loc_us-gaap_SeniorNotesMember_F3CDF6FC53045E819F699426907CBB73" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_79F4ACBA125C563CBA786742CCD4750B" xlink:to="loc_us-gaap_SeniorNotesMember_F3CDF6FC53045E819F699426907CBB73" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_B50E534C25C75D0883963661B805C526" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_51E56C85CE6A5ED89D2E0F3C6EA52B30" xlink:to="loc_us-gaap_DebtInstrumentAxis_B50E534C25C75D0883963661B805C526" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_FC6690859C6432494789C826491AB5DE_0B82B7E4F07153C98FA18A29315D4D23" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_B50E534C25C75D0883963661B805C526" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_FC6690859C6432494789C826491AB5DE_0B82B7E4F07153C98FA18A29315D4D23" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_B64CA27D9B5457B2A34CDBCC063EF114" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_B50E534C25C75D0883963661B805C526" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_B64CA27D9B5457B2A34CDBCC063EF114" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_SeniorUnsecuredEuroDebtThreemonthEURIBORPlus0.20FloatingRateNotesMember" xlink:label="loc_pfe_SeniorUnsecuredEuroDebtThreemonthEURIBORPlus0.20FloatingRateNotesMember_F4149BA6D6C15943AADBE6CA9F846679" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_B64CA27D9B5457B2A34CDBCC063EF114" xlink:to="loc_pfe_SeniorUnsecuredEuroDebtThreemonthEURIBORPlus0.20FloatingRateNotesMember_F4149BA6D6C15943AADBE6CA9F846679" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_SeniorUnsecuredEuroDebtZeroPercentDue2020Member" xlink:label="loc_pfe_SeniorUnsecuredEuroDebtZeroPercentDue2020Member_2E9473B14C455B688AE3AC9FEB73C6EA" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_B64CA27D9B5457B2A34CDBCC063EF114" xlink:to="loc_pfe_SeniorUnsecuredEuroDebtZeroPercentDue2020Member_2E9473B14C455B688AE3AC9FEB73C6EA" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_SeniorUnsecuredEuroDebtPointTwofivePercentDue2022Member" xlink:label="loc_pfe_SeniorUnsecuredEuroDebtPointTwofivePercentDue2022Member_ECEDA866B0755EDD93216096CF4FC691" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_B64CA27D9B5457B2A34CDBCC063EF114" xlink:to="loc_pfe_SeniorUnsecuredEuroDebtPointTwofivePercentDue2022Member_ECEDA866B0755EDD93216096CF4FC691" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_SeniorUnsecuredEuroDebtOnePointZeroPercentDue2027Member" xlink:label="loc_pfe_SeniorUnsecuredEuroDebtOnePointZeroPercentDue2027Member_FF8440BBD346526FA5C94784631E22D4" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_B64CA27D9B5457B2A34CDBCC063EF114" xlink:to="loc_pfe_SeniorUnsecuredEuroDebtOnePointZeroPercentDue2027Member_FF8440BBD346526FA5C94784631E22D4" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_EuroLongtermDebtMember" xlink:label="loc_pfe_EuroLongtermDebtMember_AED48123C30353279CCE218F7D0385D2" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_B64CA27D9B5457B2A34CDBCC063EF114" xlink:to="loc_pfe_EuroLongtermDebtMember_AED48123C30353279CCE218F7D0385D2" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_SeniorUnsecuredDebtFourPointTwoPercentDue2047Member" xlink:label="loc_pfe_SeniorUnsecuredDebtFourPointTwoPercentDue2047Member_496301FF359753DEAB925646D12549D9" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_B64CA27D9B5457B2A34CDBCC063EF114" xlink:to="loc_pfe_SeniorUnsecuredDebtFourPointTwoPercentDue2047Member_496301FF359753DEAB925646D12549D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_314DB1A4337159798BCCFAADEB6D89E4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_EA31DB6B63CF54EAA7D8BD4798333EE2" xlink:to="loc_us-gaap_LongTermDebt_314DB1A4337159798BCCFAADEB6D89E4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_6F981CF6220250F9887BDFB936055FF5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_EA31DB6B63CF54EAA7D8BD4798333EE2" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_6F981CF6220250F9887BDFB936055FF5" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_DebtInstrumentFloorInterestRate" xlink:label="loc_pfe_DebtInstrumentFloorInterestRate_164AC0EA45DC5FFBA8681FF0FC7C3420" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_EA31DB6B63CF54EAA7D8BD4798333EE2" xlink:to="loc_pfe_DebtInstrumentFloorInterestRate_164AC0EA45DC5FFBA8681FF0FC7C3420" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_38ED33A0BC6656999757EE2BAD65366A" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_EA31DB6B63CF54EAA7D8BD4798333EE2" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_38ED33A0BC6656999757EE2BAD65366A" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_DebtInstrumentRedemptionRuleRedemptionPricePercentageBasisSpread" xlink:label="loc_pfe_DebtInstrumentRedemptionRuleRedemptionPricePercentageBasisSpread_F900FB0968FC5B9EBE02F79057C91D68" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_EA31DB6B63CF54EAA7D8BD4798333EE2" xlink:to="loc_pfe_DebtInstrumentRedemptionRuleRedemptionPricePercentageBasisSpread_F900FB0968FC5B9EBE02F79057C91D68" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtWeightedAverageInterestRate" xlink:label="loc_us-gaap_DebtWeightedAverageInterestRate_AFD67E26F98A50AA837B5E1276BEAB98" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_EA31DB6B63CF54EAA7D8BD4798333EE2" xlink:to="loc_us-gaap_DebtWeightedAverageInterestRate_AFD67E26F98A50AA837B5E1276BEAB98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_22D7B7FE951A5A8C84C2185B11E3BE78" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_EA31DB6B63CF54EAA7D8BD4798333EE2" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_22D7B7FE951A5A8C84C2185B11E3BE78" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtMaturitiesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsNarrativeDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_0757E12B39E0E3ABD64F78AA47308503" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaap_ConcentrationRiskTable_CBEB5574A214DC6EF8F278AA472EDEC9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_0757E12B39E0E3ABD64F78AA47308503" xlink:to="loc_us-gaap_ConcentrationRiskTable_CBEB5574A214DC6EF8F278AA472EDEC9" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_F11B5C9D792B53A1A30E78AA472F71C7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_CBEB5574A214DC6EF8F278AA472EDEC9" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_F11B5C9D792B53A1A30E78AA472F71C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_20D16A5BA7EA8F7D077B78AA472F7167_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_F11B5C9D792B53A1A30E78AA472F71C7" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_20D16A5BA7EA8F7D077B78AA472F7167_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_20D16A5BA7EA8F7D077B78AA472F7167" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_F11B5C9D792B53A1A30E78AA472F71C7" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_20D16A5BA7EA8F7D077B78AA472F7167" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsMember" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember_4569343500F1CC89B04C78AA472F52E4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_20D16A5BA7EA8F7D077B78AA472F7167" xlink:to="loc_us-gaap_CashAndCashEquivalentsMember_4569343500F1CC89B04C78AA472F52E4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquitySecuritiesByIndustryAxis" xlink:label="loc_us-gaap_EquitySecuritiesByIndustryAxis_9E9C5EA8E5642C4521A478AA47304E13" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_CBEB5574A214DC6EF8F278AA472EDEC9" xlink:to="loc_us-gaap_EquitySecuritiesByIndustryAxis_9E9C5EA8E5642C4521A478AA47304E13" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquitySecuritiesIndustryMember" xlink:label="loc_us-gaap_EquitySecuritiesIndustryMember_CB3727F93C4DD7330C2C78AA473067E8_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_EquitySecuritiesByIndustryAxis_9E9C5EA8E5642C4521A478AA47304E13" xlink:to="loc_us-gaap_EquitySecuritiesIndustryMember_CB3727F93C4DD7330C2C78AA473067E8_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquitySecuritiesIndustryMember" xlink:label="loc_us-gaap_EquitySecuritiesIndustryMember_CB3727F93C4DD7330C2C78AA473067E8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_EquitySecuritiesByIndustryAxis_9E9C5EA8E5642C4521A478AA47304E13" xlink:to="loc_us-gaap_EquitySecuritiesIndustryMember_CB3727F93C4DD7330C2C78AA473067E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TechnologySectorMember" xlink:label="loc_us-gaap_TechnologySectorMember_6D75CFCEC3D8C53C57B378AA4730164D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquitySecuritiesIndustryMember_CB3727F93C4DD7330C2C78AA473067E8" xlink:to="loc_us-gaap_TechnologySectorMember_6D75CFCEC3D8C53C57B378AA4730164D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeNetLiabilityPositionAggregateFairValue" xlink:label="loc_us-gaap_DerivativeNetLiabilityPositionAggregateFairValue_22115CBE1C94C4CAAE2278AA473001A4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_0757E12B39E0E3ABD64F78AA47308503" xlink:to="loc_us-gaap_DerivativeNetLiabilityPositionAggregateFairValue_22115CBE1C94C4CAAE2278AA473001A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollateralAlreadyPostedAggregateFairValue" xlink:label="loc_us-gaap_CollateralAlreadyPostedAggregateFairValue_B341494865806406B56278AA47300A3B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_0757E12B39E0E3ABD64F78AA47308503" xlink:to="loc_us-gaap_CollateralAlreadyPostedAggregateFairValue_B341494865806406B56278AA47300A3B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure" xlink:label="loc_us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure_5BE33E2303446C911DD878AA47303821" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_0757E12B39E0E3ABD64F78AA47308503" xlink:to="loc_us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure_5BE33E2303446C911DD878AA47303821" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SecuritiesReceivedAsCollateral" xlink:label="loc_us-gaap_SecuritiesReceivedAsCollateral_4F30184BA1AF218D8E6F78AA4731F219" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_0757E12B39E0E3ABD64F78AA47308503" xlink:to="loc_us-gaap_SecuritiesReceivedAsCollateral_4F30184BA1AF218D8E6F78AA4731F219" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsOtherNoncurrentLiabilitiesDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6189A6256DB10ECD8A9B9C8902FA10F2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_C24D65E3CCC9F29D2F7E9C8902F7D722" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6189A6256DB10ECD8A9B9C8902FA10F2" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_C24D65E3CCC9F29D2F7E9C8902F7D722" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis_88149657AECBEF1122D89C8902F76B22" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_C24D65E3CCC9F29D2F7E9C8902F7D722" xlink:to="loc_us-gaap_StatementGeographicalAxis_88149657AECBEF1122D89C8902F76B22" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_1AB33F44F76B1BA64A619C8902F70365_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementGeographicalAxis_88149657AECBEF1122D89C8902F76B22" xlink:to="loc_us-gaap_SegmentGeographicalDomain_1AB33F44F76B1BA64A619C8902F70365_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_1AB33F44F76B1BA64A619C8902F70365" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementGeographicalAxis_88149657AECBEF1122D89C8902F76B22" xlink:to="loc_us-gaap_SegmentGeographicalDomain_1AB33F44F76B1BA64A619C8902F70365" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_FC27A23B3FA223BBA5979C8902F8BECB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentGeographicalDomain_1AB33F44F76B1BA64A619C8902F70365" xlink:to="loc_country_US_FC27A23B3FA223BBA5979C8902F8BECB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EuropeanUnionMember" xlink:label="loc_us-gaap_EuropeanUnionMember_67E5005DF02F0F96D6A29C8902F81649" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentGeographicalDomain_1AB33F44F76B1BA64A619C8902F70365" xlink:to="loc_us-gaap_EuropeanUnionMember_67E5005DF02F0F96D6A29C8902F81649" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_BCAF785B94CE881D37F99C8902F87707" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_C24D65E3CCC9F29D2F7E9C8902F7D722" xlink:to="loc_us-gaap_ProductOrServiceAxis_BCAF785B94CE881D37F99C8902F87707" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_D7BFC1AC761F2CE959BB9C8902F8947A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ProductOrServiceAxis_BCAF785B94CE881D37F99C8902F87707" xlink:to="loc_us-gaap_ProductsAndServicesDomain_D7BFC1AC761F2CE959BB9C8902F8947A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_D7BFC1AC761F2CE959BB9C8902F8947A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ProductOrServiceAxis_BCAF785B94CE881D37F99C8902F87707" xlink:to="loc_us-gaap_ProductsAndServicesDomain_D7BFC1AC761F2CE959BB9C8902F8947A" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_BesponsaMember" xlink:label="loc_pfe_BesponsaMember_A841B484277CADCB2EF89C8902F824FB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_D7BFC1AC761F2CE959BB9C8902F8947A" xlink:to="loc_pfe_BesponsaMember_A841B484277CADCB2EF89C8902F824FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_E1EAAB124FE6F314CAE89C8902F8F9BA" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_C24D65E3CCC9F29D2F7E9C8902F7D722" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_E1EAAB124FE6F314CAE89C8902F8F9BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_66DAD47E4DEB57A1FACE9C8902F91EE8_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_E1EAAB124FE6F314CAE89C8902F8F9BA" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_66DAD47E4DEB57A1FACE9C8902F91EE8_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_66DAD47E4DEB57A1FACE9C8902F91EE8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_E1EAAB124FE6F314CAE89C8902F8F9BA" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_66DAD47E4DEB57A1FACE9C8902F91EE8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_EB7C3E124740139AD72E9C8902F9B41E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_66DAD47E4DEB57A1FACE9C8902F91EE8" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_EB7C3E124740139AD72E9C8902F9B41E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_1F22C08B844E03AB5C479C8902F95016" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_C24D65E3CCC9F29D2F7E9C8902F7D722" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_1F22C08B844E03AB5C479C8902F95016" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_7134D53BAEC64641E6929C8902F9B790_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_1F22C08B844E03AB5C479C8902F95016" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_7134D53BAEC64641E6929C8902F9B790_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_7134D53BAEC64641E6929C8902F9B790" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_1F22C08B844E03AB5C479C8902F95016" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_7134D53BAEC64641E6929C8902F9B790" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_386C2752E3CB56B176539C8902F9EF17" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_7134D53BAEC64641E6929C8902F9B790" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_386C2752E3CB56B176539C8902F9EF17" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_0BD3177B09D091CD1BA09C8902F97D68" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_7134D53BAEC64641E6929C8902F9B790" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_0BD3177B09D091CD1BA09C8902F97D68" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_ResearchandDevelopmentArrangementAggregatePaymentObligationTerm" xlink:label="loc_pfe_ResearchandDevelopmentArrangementAggregatePaymentObligationTerm_FA2281E8EDA4527C632C9C8902FA7A6A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6189A6256DB10ECD8A9B9C8902FA10F2" xlink:to="loc_pfe_ResearchandDevelopmentArrangementAggregatePaymentObligationTerm_FA2281E8EDA4527C632C9C8902FA7A6A" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_ResearchandDevelopmentArrangementAggregatePaymentObligation" xlink:label="loc_pfe_ResearchandDevelopmentArrangementAggregatePaymentObligation_4A3C3814B325E0AD89129C8902FAFE86" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6189A6256DB10ECD8A9B9C8902FA10F2" xlink:to="loc_pfe_ResearchandDevelopmentArrangementAggregatePaymentObligation_4A3C3814B325E0AD89129C8902FAFE86" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_6E92C8BE9CE5CC09D30C9C8902FA9FD6" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6189A6256DB10ECD8A9B9C8902FA10F2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_6E92C8BE9CE5CC09D30C9C8902FA9FD6" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaap_ShortTermDebtLineItems_CD77D0CF1291589FA9B487EF6A62990B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTable_8F50BC16DCE6553EB1C336B431638DD5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShortTermDebtLineItems_CD77D0CF1291589FA9B487EF6A62990B" xlink:to="loc_us-gaap_ScheduleOfShortTermDebtTable_8F50BC16DCE6553EB1C336B431638DD5" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_0D94F7C67CFD5E0F9D2C98FDCF278A90" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_8F50BC16DCE6553EB1C336B431638DD5" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_0D94F7C67CFD5E0F9D2C98FDCF278A90" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_6B20550B2AADE4ED8F0FAE9F928958E0_0B82B7E4F07153C98FA18A29315D4D23" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_0D94F7C67CFD5E0F9D2C98FDCF278A90" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_6B20550B2AADE4ED8F0FAE9F928958E0_0B82B7E4F07153C98FA18A29315D4D23" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_13D069D1897C5677B6EC78BF0EC9B981" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_0D94F7C67CFD5E0F9D2C98FDCF278A90" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_13D069D1897C5677B6EC78BF0EC9B981" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_53F349890F1D5FC28196F318FBF0BD4A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_13D069D1897C5677B6EC78BF0EC9B981" xlink:to="loc_us-gaap_CommercialPaperMember_53F349890F1D5FC28196F318FBF0BD4A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommercialPaper" xlink:label="loc_us-gaap_CommercialPaper_A5E16A737045501E963CFD73CCBFE3EB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_CD77D0CF1291589FA9B487EF6A62990B" xlink:to="loc_us-gaap_CommercialPaper_A5E16A737045501E963CFD73CCBFE3EB" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwill" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_ECA9B8E0411B3B738C73831F4DF72137" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_90566B8A7E9CCB789766831F4DF748BC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_ECA9B8E0411B3B738C73831F4DF72137" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_90566B8A7E9CCB789766831F4DF748BC" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_A42CB56934C171E3E6CF831F4DF7D133" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_90566B8A7E9CCB789766831F4DF748BC" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_A42CB56934C171E3E6CF831F4DF7D133" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_1784978FCF4D701C507B831F4DF79C5C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_A42CB56934C171E3E6CF831F4DF7D133" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_1784978FCF4D701C507B831F4DF79C5C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_1784978FCF4D701C507B831F4DF79C5C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_A42CB56934C171E3E6CF831F4DF7D133" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_1784978FCF4D701C507B831F4DF79C5C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TradeNamesMember" xlink:label="loc_us-gaap_TradeNamesMember_B54943A4A64DDA9E5740831F4DF782D3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_1784978FCF4D701C507B831F4DF79C5C" xlink:to="loc_us-gaap_TradeNamesMember_B54943A4A64DDA9E5740831F4DF782D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_75F198E5BA07142C6B7A831F4DF75B2A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_1784978FCF4D701C507B831F4DF79C5C" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_75F198E5BA07142C6B7A831F4DF75B2A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_A5A06B69F2A0E8885368831F4DF761FC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_ECA9B8E0411B3B738C73831F4DF72137" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_A5A06B69F2A0E8885368831F4DF761FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_3187CD8EAA6A3B2DC4A5831F4DF8074E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_54376F526D9101D1C755831F4DF74845" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_3187CD8EAA6A3B2DC4A5831F4DF8074E" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_54376F526D9101D1C755831F4DF74845" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_4FCEFE7A9998B6B42ED2831F4DF70CDB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_54376F526D9101D1C755831F4DF74845" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_4FCEFE7A9998B6B42ED2831F4DF70CDB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9446760460D29BC869C4831F4DF7F300_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_4FCEFE7A9998B6B42ED2831F4DF70CDB" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9446760460D29BC869C4831F4DF7F300_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9446760460D29BC869C4831F4DF7F300" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_4FCEFE7A9998B6B42ED2831F4DF70CDB" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9446760460D29BC869C4831F4DF7F300" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_D3BEBC2A564CF777AF48831F4DF80008" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9446760460D29BC869C4831F4DF7F300" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_D3BEBC2A564CF777AF48831F4DF80008" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TradeNamesMember" xlink:label="loc_us-gaap_TradeNamesMember_755E30E1EB2E88D90E3B831F4DF87394" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9446760460D29BC869C4831F4DF7F300" xlink:to="loc_us-gaap_TradeNamesMember_755E30E1EB2E88D90E3B831F4DF87394" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_LicensingAgreementsAndOtherMember" xlink:label="loc_pfe_LicensingAgreementsAndOtherMember_51D7B1A8D94C158BAC3D831F4DF807AF" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9446760460D29BC869C4831F4DF7F300" xlink:to="loc_pfe_LicensingAgreementsAndOtherMember_51D7B1A8D94C158BAC3D831F4DF807AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_F59D3CC10B6649DFBE8B831F4DF86F54" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_3187CD8EAA6A3B2DC4A5831F4DF8074E" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_F59D3CC10B6649DFBE8B831F4DF86F54" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_6735039BE1644746F4B8831F4DF81CA5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_3187CD8EAA6A3B2DC4A5831F4DF8074E" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_6735039BE1644746F4B8831F4DF81CA5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_78E190F8687D3D6AE7CC831F4DF8A84E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_3187CD8EAA6A3B2DC4A5831F4DF8074E" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_78E190F8687D3D6AE7CC831F4DF8A84E" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsFootnotesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_F6696849D7519334CC62831F4DF31B96" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_E6EECFFADB9C046D0704831F4DF23591" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_F6696849D7519334CC62831F4DF31B96" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_E6EECFFADB9C046D0704831F4DF23591" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_445EED84B0015F7064FE831F4DF27AE3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_E6EECFFADB9C046D0704831F4DF23591" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_445EED84B0015F7064FE831F4DF27AE3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_97546729E982B1580CC1831F4DF28263_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_445EED84B0015F7064FE831F4DF27AE3" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_97546729E982B1580CC1831F4DF28263_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_97546729E982B1580CC1831F4DF28263" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_445EED84B0015F7064FE831F4DF27AE3" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_97546729E982B1580CC1831F4DF28263" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_B61E3B4BF959AAE96FC7831F4DF2F9D8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_97546729E982B1580CC1831F4DF28263" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_B61E3B4BF959AAE96FC7831F4DF2F9D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_10B54043915404AD185B831F4DF218C6" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_E6EECFFADB9C046D0704831F4DF23591" xlink:to="loc_us-gaap_ProductOrServiceAxis_10B54043915404AD185B831F4DF218C6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_3603130DA02E32A9EE8E831F4DF262B0_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ProductOrServiceAxis_10B54043915404AD185B831F4DF218C6" xlink:to="loc_us-gaap_ProductsAndServicesDomain_3603130DA02E32A9EE8E831F4DF262B0_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_3603130DA02E32A9EE8E831F4DF262B0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ProductOrServiceAxis_10B54043915404AD185B831F4DF218C6" xlink:to="loc_us-gaap_ProductsAndServicesDomain_3603130DA02E32A9EE8E831F4DF262B0" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_EucrisaMember" xlink:label="loc_pfe_EucrisaMember_26914EE32CE5AFDF51F9831F4DF2E794" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_3603130DA02E32A9EE8E831F4DF262B0" xlink:to="loc_pfe_EucrisaMember_26914EE32CE5AFDF51F9831F4DF2E794" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_BesponsaMember" xlink:label="loc_pfe_BesponsaMember_6D60C35F87FABAB6D1EA831F4DF3DDC4" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_3603130DA02E32A9EE8E831F4DF262B0" xlink:to="loc_pfe_BesponsaMember_6D60C35F87FABAB6D1EA831F4DF3DDC4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_8C226E01BCD4C5756B13831F4DF3AE75" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_E6EECFFADB9C046D0704831F4DF23591" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_8C226E01BCD4C5756B13831F4DF3AE75" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_946798C5470F86DC4EDC831F4DF3E93D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_8C226E01BCD4C5756B13831F4DF3AE75" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_946798C5470F86DC4EDC831F4DF3E93D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_946798C5470F86DC4EDC831F4DF3E93D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_8C226E01BCD4C5756B13831F4DF3AE75" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_946798C5470F86DC4EDC831F4DF3E93D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_81D95332F077A1C3CD4C831F4DF39F3C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_946798C5470F86DC4EDC831F4DF3E93D" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_81D95332F077A1C3CD4C831F4DF39F3C" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_IntangibleAssetsTransfersDuringPeriod" xlink:label="loc_pfe_IntangibleAssetsTransfersDuringPeriod_988F44A098D76E58DBD6831F4DF37EBC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_F6696849D7519334CC62831F4DF31B96" xlink:to="loc_pfe_IntangibleAssetsTransfersDuringPeriod_988F44A098D76E58DBD6831F4DF37EBC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_349DD2C7AB98C46186EE831F4DF39D1C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_F6696849D7519334CC62831F4DF31B96" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_349DD2C7AB98C46186EE831F4DF39D1C" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedIntangibleAssetsPercentageOfTotalIntangiblesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_5B7C62FC74B45E6BBBE0D1B4F0EB089C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_0E162BE702945F148E96B135BE75CCA3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_5B7C62FC74B45E6BBBE0D1B4F0EB089C" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_0E162BE702945F148E96B135BE75CCA3" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsegmentsAxis" xlink:label="loc_us-gaap_SubsegmentsAxis_A38AEA57FE4650199E95DEA89A81D3D6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_0E162BE702945F148E96B135BE75CCA3" xlink:to="loc_us-gaap_SubsegmentsAxis_A38AEA57FE4650199E95DEA89A81D3D6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsegmentsDomain" xlink:label="loc_us-gaap_SubsegmentsDomain_2EDB2FA71179AD160891AE9F925BC1B4_0B82B7E4F07153C98FA18A29315D4D23" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsegmentsAxis_A38AEA57FE4650199E95DEA89A81D3D6" xlink:to="loc_us-gaap_SubsegmentsDomain_2EDB2FA71179AD160891AE9F925BC1B4_0B82B7E4F07153C98FA18A29315D4D23" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsegmentsDomain" xlink:label="loc_us-gaap_SubsegmentsDomain_21157A2CC7055DD3865AAA552EFF13A3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsegmentsAxis_A38AEA57FE4650199E95DEA89A81D3D6" xlink:to="loc_us-gaap_SubsegmentsDomain_21157A2CC7055DD3865AAA552EFF13A3" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_PfizersWorldwideResearchandDevelopmentMember" xlink:label="loc_pfe_PfizersWorldwideResearchandDevelopmentMember_D981B410F9845E55A31B6C49D5E5BD46" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_21157A2CC7055DD3865AAA552EFF13A3" xlink:to="loc_pfe_PfizersWorldwideResearchandDevelopmentMember_D981B410F9845E55A31B6C49D5E5BD46" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidationItemsAxis" xlink:label="loc_us-gaap_ConsolidationItemsAxis_218E4D00F9AE5E7388F05949EC7BC6B1" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_0E162BE702945F148E96B135BE75CCA3" xlink:to="loc_us-gaap_ConsolidationItemsAxis_218E4D00F9AE5E7388F05949EC7BC6B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidationItemsDomain" xlink:label="loc_us-gaap_ConsolidationItemsDomain_3391A73413076DBA8C9EAE9F925B6082_0B82B7E4F07153C98FA18A29315D4D23" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConsolidationItemsAxis_218E4D00F9AE5E7388F05949EC7BC6B1" xlink:to="loc_us-gaap_ConsolidationItemsDomain_3391A73413076DBA8C9EAE9F925B6082_0B82B7E4F07153C98FA18A29315D4D23" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidationItemsDomain" xlink:label="loc_us-gaap_ConsolidationItemsDomain_2B22A735E8ED50F59811B0DD9CAED414" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConsolidationItemsAxis_218E4D00F9AE5E7388F05949EC7BC6B1" xlink:to="loc_us-gaap_ConsolidationItemsDomain_2B22A735E8ED50F59811B0DD9CAED414" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingSegmentsMember" xlink:label="loc_us-gaap_OperatingSegmentsMember_589FC7283A575183A10440790726B9A5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConsolidationItemsDomain_2B22A735E8ED50F59811B0DD9CAED414" xlink:to="loc_us-gaap_OperatingSegmentsMember_589FC7283A575183A10440790726B9A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaterialReconcilingItemsMember" xlink:label="loc_us-gaap_MaterialReconcilingItemsMember_144BA6D222BF5522AD0DD379CAC1B07A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConsolidationItemsDomain_2B22A735E8ED50F59811B0DD9CAED414" xlink:to="loc_us-gaap_MaterialReconcilingItemsMember_144BA6D222BF5522AD0DD379CAC1B07A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_DDC77182EE7F5B16B8AFC995D063E6C7" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_0E162BE702945F148E96B135BE75CCA3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_DDC77182EE7F5B16B8AFC995D063E6C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1BCC2B456383D80ACF68AE9F925C4298_0B82B7E4F07153C98FA18A29315D4D23" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_DDC77182EE7F5B16B8AFC995D063E6C7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1BCC2B456383D80ACF68AE9F925C4298_0B82B7E4F07153C98FA18A29315D4D23" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_F210AF62B1BF5E23ADF77D46891C1104" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_DDC77182EE7F5B16B8AFC995D063E6C7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_F210AF62B1BF5E23ADF77D46891C1104" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_B64EE51D62BA54A5A0E6FAE4B98D8B4C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_F210AF62B1BF5E23ADF77D46891C1104" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_B64EE51D62BA54A5A0E6FAE4B98D8B4C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TradeNamesMember" xlink:label="loc_us-gaap_TradeNamesMember_C0CA494F691C5DDDA3F5AFD2DA581205" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_F210AF62B1BF5E23ADF77D46891C1104" xlink:to="loc_us-gaap_TradeNamesMember_C0CA494F691C5DDDA3F5AFD2DA581205" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_05FAE0B8FC7F5FE6B5F19F11BED2F5F5" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_0E162BE702945F148E96B135BE75CCA3" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_05FAE0B8FC7F5FE6B5F19F11BED2F5F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_D7417C2E29A71455999BAE9F925C3C2E_0B82B7E4F07153C98FA18A29315D4D23" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_05FAE0B8FC7F5FE6B5F19F11BED2F5F5" xlink:to="loc_us-gaap_SegmentDomain_D7417C2E29A71455999BAE9F925C3C2E_0B82B7E4F07153C98FA18A29315D4D23" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_809E24EC080A5788A78531773EFD4438" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_05FAE0B8FC7F5FE6B5F19F11BED2F5F5" xlink:to="loc_us-gaap_SegmentDomain_809E24EC080A5788A78531773EFD4438" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_InnovativeHealthSegmentMember" xlink:label="loc_pfe_InnovativeHealthSegmentMember_EAAA02CB13AA5FECB279956095A36DB2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_809E24EC080A5788A78531773EFD4438" xlink:to="loc_pfe_InnovativeHealthSegmentMember_EAAA02CB13AA5FECB279956095A36DB2" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_EssentialHealthSegmentMember" xlink:label="loc_pfe_EssentialHealthSegmentMember_E5C2A7C425ED5EA1A69D30EBD7D3BD2F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_809E24EC080A5788A78531773EFD4438" xlink:to="loc_pfe_EssentialHealthSegmentMember_E5C2A7C425ED5EA1A69D30EBD7D3BD2F" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet" xlink:label="loc_pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet_3C22A21358D9547291B7EEA98FDEAE93" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_5B7C62FC74B45E6BBBE0D1B4F0EB089C" xlink:to="loc_pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet_3C22A21358D9547291B7EEA98FDEAE93" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillGoodwillDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillLineItems" xlink:label="loc_us-gaap_GoodwillLineItems_7A07D8AF3A49752DF80B74487D3B596F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfGoodwillTable" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_04EA4343A0C97033104374487D3A60B8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_7A07D8AF3A49752DF80B74487D3B596F" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_04EA4343A0C97033104374487D3A60B8" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_2FC73F76BE892ABEE49E74487D3B9AA0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_04EA4343A0C97033104374487D3A60B8" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_2FC73F76BE892ABEE49E74487D3B9AA0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_8202DB036C4A2E1E58B574487D3BE9BA_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_2FC73F76BE892ABEE49E74487D3B9AA0" xlink:to="loc_us-gaap_SegmentDomain_8202DB036C4A2E1E58B574487D3BE9BA_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_8202DB036C4A2E1E58B574487D3BE9BA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_2FC73F76BE892ABEE49E74487D3B9AA0" xlink:to="loc_us-gaap_SegmentDomain_8202DB036C4A2E1E58B574487D3BE9BA" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_InnovativeHealthSegmentMember" xlink:label="loc_pfe_InnovativeHealthSegmentMember_B171016C9E0B2313ED3774487D3BE85C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_8202DB036C4A2E1E58B574487D3BE9BA" xlink:to="loc_pfe_InnovativeHealthSegmentMember_B171016C9E0B2313ED3774487D3BE85C" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_EssentialHealthSegmentMember" xlink:label="loc_pfe_EssentialHealthSegmentMember_D94B32983C35F9D8BF6A74487D3BA1B9" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_8202DB036C4A2E1E58B574487D3BE9BA" xlink:to="loc_pfe_EssentialHealthSegmentMember_D94B32983C35F9D8BF6A74487D3BA1B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillRollForward" xlink:label="loc_us-gaap_GoodwillRollForward_BE5204FF1CB245D3299574487D3B5DF8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_7A07D8AF3A49752DF80B74487D3B596F" xlink:to="loc_us-gaap_GoodwillRollForward_BE5204FF1CB245D3299574487D3B5DF8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_332FDC0453C655F3B75174487D3BD214" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_BE5204FF1CB245D3299574487D3B5DF8" xlink:to="loc_us-gaap_Goodwill_332FDC0453C655F3B75174487D3BD214" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_6C0FBE01AFE058A8873F74487D3B4955" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_BE5204FF1CB245D3299574487D3B5DF8" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_6C0FBE01AFE058A8873F74487D3B4955" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillOtherIncreaseDecrease" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease_E072660759D500C413B174487D3BA5F0" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_BE5204FF1CB245D3299574487D3B5DF8" xlink:to="loc_us-gaap_GoodwillOtherIncreaseDecrease_E072660759D500C413B174487D3BA5F0" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillIndefiniteLivedIntangibleAssetsPercentageOfTotalIntangiblesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_2686E928DA335271AE0436BED1028B1D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_5BC3655DF7285E38BBEAA26FA3B61CFF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_2686E928DA335271AE0436BED1028B1D" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_5BC3655DF7285E38BBEAA26FA3B61CFF" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsegmentsAxis" xlink:label="loc_us-gaap_SubsegmentsAxis_F81489EAEDE45A4DBEA2F56039DBB42F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_5BC3655DF7285E38BBEAA26FA3B61CFF" xlink:to="loc_us-gaap_SubsegmentsAxis_F81489EAEDE45A4DBEA2F56039DBB42F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsegmentsDomain" xlink:label="loc_us-gaap_SubsegmentsDomain_92FBC704EE97B42A5230AE9F925660B3_0B82B7E4F07153C98FA18A29315D4D23" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsegmentsAxis_F81489EAEDE45A4DBEA2F56039DBB42F" xlink:to="loc_us-gaap_SubsegmentsDomain_92FBC704EE97B42A5230AE9F925660B3_0B82B7E4F07153C98FA18A29315D4D23" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsegmentsDomain" xlink:label="loc_us-gaap_SubsegmentsDomain_7B8FD2B625D351818026A06A747D5E27" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsegmentsAxis_F81489EAEDE45A4DBEA2F56039DBB42F" xlink:to="loc_us-gaap_SubsegmentsDomain_7B8FD2B625D351818026A06A747D5E27" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_PfizersWorldwideResearchandDevelopmentMember" xlink:label="loc_pfe_PfizersWorldwideResearchandDevelopmentMember_FE77081B14DE5E099708308981CBAFA6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_7B8FD2B625D351818026A06A747D5E27" xlink:to="loc_pfe_PfizersWorldwideResearchandDevelopmentMember_FE77081B14DE5E099708308981CBAFA6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_5306EAE2932E517DA6A801AFEE2B9FCF" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_5BC3655DF7285E38BBEAA26FA3B61CFF" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_5306EAE2932E517DA6A801AFEE2B9FCF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_B322A597476194A1DBBDAE9F9256370A_0B82B7E4F07153C98FA18A29315D4D23" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_5306EAE2932E517DA6A801AFEE2B9FCF" xlink:to="loc_us-gaap_SegmentDomain_B322A597476194A1DBBDAE9F9256370A_0B82B7E4F07153C98FA18A29315D4D23" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_358AEFC5DB945FCCBEE4B0519B57AA8D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_5306EAE2932E517DA6A801AFEE2B9FCF" xlink:to="loc_us-gaap_SegmentDomain_358AEFC5DB945FCCBEE4B0519B57AA8D" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_InnovativeHealthSegmentMember" xlink:label="loc_pfe_InnovativeHealthSegmentMember_644D9046537B5D059685547DDC316445" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_358AEFC5DB945FCCBEE4B0519B57AA8D" xlink:to="loc_pfe_InnovativeHealthSegmentMember_644D9046537B5D059685547DDC316445" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_EssentialHealthSegmentMember" xlink:label="loc_pfe_EssentialHealthSegmentMember_8BB667DE477D5A5D8C735D1C78856A04" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_358AEFC5DB945FCCBEE4B0519B57AA8D" xlink:to="loc_pfe_EssentialHealthSegmentMember_8BB667DE477D5A5D8C735D1C78856A04" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidationItemsAxis" xlink:label="loc_us-gaap_ConsolidationItemsAxis_DC642E6E5004572EB99FB7B133A2334D" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_5BC3655DF7285E38BBEAA26FA3B61CFF" xlink:to="loc_us-gaap_ConsolidationItemsAxis_DC642E6E5004572EB99FB7B133A2334D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidationItemsDomain" xlink:label="loc_us-gaap_ConsolidationItemsDomain_026F60FEAB4ED761BFF7AE9F92562401_0B82B7E4F07153C98FA18A29315D4D23" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConsolidationItemsAxis_DC642E6E5004572EB99FB7B133A2334D" xlink:to="loc_us-gaap_ConsolidationItemsDomain_026F60FEAB4ED761BFF7AE9F92562401_0B82B7E4F07153C98FA18A29315D4D23" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidationItemsDomain" xlink:label="loc_us-gaap_ConsolidationItemsDomain_9AC0563D3DA452B7978ED66F5F4C2E05" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConsolidationItemsAxis_DC642E6E5004572EB99FB7B133A2334D" xlink:to="loc_us-gaap_ConsolidationItemsDomain_9AC0563D3DA452B7978ED66F5F4C2E05" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingSegmentsMember" xlink:label="loc_us-gaap_OperatingSegmentsMember_257CBC9F7D715EC1A759B8EBC09FA4FD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConsolidationItemsDomain_9AC0563D3DA452B7978ED66F5F4C2E05" xlink:to="loc_us-gaap_OperatingSegmentsMember_257CBC9F7D715EC1A759B8EBC09FA4FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaterialReconcilingItemsMember" xlink:label="loc_us-gaap_MaterialReconcilingItemsMember_3CA2DFB7300B582BA36D774BF032908E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConsolidationItemsDomain_9AC0563D3DA452B7978ED66F5F4C2E05" xlink:to="loc_us-gaap_MaterialReconcilingItemsMember_3CA2DFB7300B582BA36D774BF032908E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_194BFC11DBF75C56A37EB07F81DCDFD4" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_5BC3655DF7285E38BBEAA26FA3B61CFF" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_194BFC11DBF75C56A37EB07F81DCDFD4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_52AFC6FAE99944C28C59AE9F9257E03D_0B82B7E4F07153C98FA18A29315D4D23" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_194BFC11DBF75C56A37EB07F81DCDFD4" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_52AFC6FAE99944C28C59AE9F9257E03D_0B82B7E4F07153C98FA18A29315D4D23" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_370DD81339515994AA53F5E702341EAF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_194BFC11DBF75C56A37EB07F81DCDFD4" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_370DD81339515994AA53F5E702341EAF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TradeNamesMember" xlink:label="loc_us-gaap_TradeNamesMember_ADB979B4DA1A5DFE8F0F7BE353795C94" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_370DD81339515994AA53F5E702341EAF" xlink:to="loc_us-gaap_TradeNamesMember_ADB979B4DA1A5DFE8F0F7BE353795C94" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_38A6F73BE13F55D2BD12D9F1E98FB113" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_370DD81339515994AA53F5E702341EAF" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_38A6F73BE13F55D2BD12D9F1E98FB113" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet" xlink:label="loc_pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet_9DE84574D1FD5FBCB9219FEB6426C264" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_2686E928DA335271AE0436BED1028B1D" xlink:to="loc_pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet_9DE84574D1FD5FBCB9219FEB6426C264" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillNarrativeDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_5673DBE52289573C8E30136427C582D3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_A75EF4138E575029A1E5E742823A1A8D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_5673DBE52289573C8E30136427C582D3" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_A75EF4138E575029A1E5E742823A1A8D" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9DDB03CEED8C5FE697A64B213BDDA920" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_A75EF4138E575029A1E5E742823A1A8D" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9DDB03CEED8C5FE697A64B213BDDA920" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3E2F20B2F9A623BC7825C353E5D3179E_0B82B7E4F07153C98FA18A29315D4D23" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9DDB03CEED8C5FE697A64B213BDDA920" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3E2F20B2F9A623BC7825C353E5D3179E_0B82B7E4F07153C98FA18A29315D4D23" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_399D077872C45D3FBDFCDEE25C699D96" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9DDB03CEED8C5FE697A64B213BDDA920" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_399D077872C45D3FBDFCDEE25C699D96" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMember" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMember_70D5586D519056C2970E8B0081F42002" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_399D077872C45D3FBDFCDEE25C699D96" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMember_70D5586D519056C2970E8B0081F42002" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_9D81C837E0B85203B907F1D08F8CE081" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_5673DBE52289573C8E30136427C582D3" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_9D81C837E0B85203B907F1D08F8CE081" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pfizer.com/role/Inventories" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pfizer.com/role/InventoriesDetail" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pfizer.com/role/InventoriesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pfizer.com/role/OtherIncomeDeductionsNet" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pfizer.com/role/OtherIncomeDeductionsNetDetail" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaap_LossContingenciesLineItems_190165E2439EFA6C88F09C471658495A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaap_LossContingenciesTable_95A1ADCBE302F1B121559C471651BBAD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_190165E2439EFA6C88F09C471658495A" xlink:to="loc_us-gaap_LossContingenciesTable_95A1ADCBE302F1B121559C471651BBAD" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_709F9B95DC810227F9AD9C471651E6FC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_95A1ADCBE302F1B121559C471651BBAD" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_709F9B95DC810227F9AD9C471651E6FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="loc_us-gaap_LossContingencyNatureDomain_1A1C148E0BD54D4F878D9C4716512890_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_709F9B95DC810227F9AD9C471651E6FC" xlink:to="loc_us-gaap_LossContingencyNatureDomain_1A1C148E0BD54D4F878D9C4716512890_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="loc_us-gaap_LossContingencyNatureDomain_1A1C148E0BD54D4F878D9C4716512890" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_709F9B95DC810227F9AD9C471651E6FC" xlink:to="loc_us-gaap_LossContingencyNatureDomain_1A1C148E0BD54D4F878D9C4716512890" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_PatentMatterMember" xlink:label="loc_pfe_PatentMatterMember_854AC88B33C3596A32F39C471652D425" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_1A1C148E0BD54D4F878D9C4716512890" xlink:to="loc_pfe_PatentMatterMember_854AC88B33C3596A32F39C471652D425" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_95B7C524AFAE525B86779C4716524935" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_95A1ADCBE302F1B121559C471651BBAD" xlink:to="loc_dei_LegalEntityAxis_95B7C524AFAE525B86779C4716524935" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_4248376941AB31BDA5449C471652D4FF_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_95B7C524AFAE525B86779C4716524935" xlink:to="loc_dei_EntityDomain_4248376941AB31BDA5449C471652D4FF_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_4248376941AB31BDA5449C471652D4FF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_95B7C524AFAE525B86779C4716524935" xlink:to="loc_dei_EntityDomain_4248376941AB31BDA5449C471652D4FF" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_LaboratorioTeutoBrasileroMember" xlink:label="loc_pfe_LaboratorioTeutoBrasileroMember_7AEEED5A12921B85F5379C4716525A4C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_4248376941AB31BDA5449C471652D4FF" xlink:to="loc_pfe_LaboratorioTeutoBrasileroMember_7AEEED5A12921B85F5379C4716525A4C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidationItemsAxis" xlink:label="loc_us-gaap_ConsolidationItemsAxis_F9D03C181D949B79955B9C4716528D7C" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_95A1ADCBE302F1B121559C471651BBAD" xlink:to="loc_us-gaap_ConsolidationItemsAxis_F9D03C181D949B79955B9C4716528D7C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidationItemsDomain" xlink:label="loc_us-gaap_ConsolidationItemsDomain_0B704730A752E5308FB69C4716523C80_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConsolidationItemsAxis_F9D03C181D949B79955B9C4716528D7C" xlink:to="loc_us-gaap_ConsolidationItemsDomain_0B704730A752E5308FB69C4716523C80_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidationItemsDomain" xlink:label="loc_us-gaap_ConsolidationItemsDomain_0B704730A752E5308FB69C4716523C80" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConsolidationItemsAxis_F9D03C181D949B79955B9C4716528D7C" xlink:to="loc_us-gaap_ConsolidationItemsDomain_0B704730A752E5308FB69C4716523C80" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingSegmentsMember" xlink:label="loc_us-gaap_OperatingSegmentsMember_C3DE14DD4931B85510DC9C471652F135" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConsolidationItemsDomain_0B704730A752E5308FB69C4716523C80" xlink:to="loc_us-gaap_OperatingSegmentsMember_C3DE14DD4931B85510DC9C471652F135" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_91E2A4E09B7B7FD76DE99C4716525571" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_95A1ADCBE302F1B121559C471651BBAD" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_91E2A4E09B7B7FD76DE99C4716525571" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_15DB0057F151FA9854A29C471653466D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_91E2A4E09B7B7FD76DE99C4716525571" xlink:to="loc_us-gaap_SegmentDomain_15DB0057F151FA9854A29C471653466D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_15DB0057F151FA9854A29C471653466D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_91E2A4E09B7B7FD76DE99C4716525571" xlink:to="loc_us-gaap_SegmentDomain_15DB0057F151FA9854A29C471653466D" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_EssentialHealthSegmentMember" xlink:label="loc_pfe_EssentialHealthSegmentMember_D95D2E295FD4390ADADA9C471653CC12" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_15DB0057F151FA9854A29C471653466D" xlink:to="loc_pfe_EssentialHealthSegmentMember_D95D2E295FD4390ADADA9C471653CC12" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_InnovativeHealthSegmentMember" xlink:label="loc_pfe_InnovativeHealthSegmentMember_F24057BAC55EFE88EC629C4716534727" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_15DB0057F151FA9854A29C471653466D" xlink:to="loc_pfe_InnovativeHealthSegmentMember_F24057BAC55EFE88EC629C4716534727" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_674BB4A1E66C60867F5B9C471653E3A8" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_95A1ADCBE302F1B121559C471651BBAD" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_674BB4A1E66C60867F5B9C471653E3A8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4655C8DBD7B143FD17EB9C471653D803_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_674BB4A1E66C60867F5B9C471653E3A8" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4655C8DBD7B143FD17EB9C471653D803_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4655C8DBD7B143FD17EB9C471653D803" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_674BB4A1E66C60867F5B9C471653E3A8" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4655C8DBD7B143FD17EB9C471653D803" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_HospiraMember" xlink:label="loc_pfe_HospiraMember_00BEBE1779DE28A3200B9C471653AC08" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4655C8DBD7B143FD17EB9C471653D803" xlink:to="loc_pfe_HospiraMember_00BEBE1779DE28A3200B9C471653AC08" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_InnoPharmaMember" xlink:label="loc_pfe_InnoPharmaMember_F52F1246B3DDCBC7493B9C471653B739" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4655C8DBD7B143FD17EB9C471653D803" xlink:to="loc_pfe_InnoPharmaMember_F52F1246B3DDCBC7493B9C471653B739" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_KingMember" xlink:label="loc_pfe_KingMember_C8543860A5CCFF0B525B9C4716540F94" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4655C8DBD7B143FD17EB9C471653D803" xlink:to="loc_pfe_KingMember_C8543860A5CCFF0B525B9C4716540F94" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_DAE4D35468B8FE97F2E39C471654220B" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_95A1ADCBE302F1B121559C471651BBAD" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_DAE4D35468B8FE97F2E39C471654220B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_DA1E1A15D3E802A4DB0A9C471654F385_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_DAE4D35468B8FE97F2E39C471654220B" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_DA1E1A15D3E802A4DB0A9C471654F385_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_DA1E1A15D3E802A4DB0A9C471654F385" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_DAE4D35468B8FE97F2E39C471654220B" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_DA1E1A15D3E802A4DB0A9C471654F385" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_48A1C58AE61CE0275E7B9C47165431A2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_DA1E1A15D3E802A4DB0A9C471654F385" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_48A1C58AE61CE0275E7B9C47165431A2" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_OtherInProcessResearchandDevelopmentMember" xlink:label="loc_pfe_OtherInProcessResearchandDevelopmentMember_E43E5CA632F39E1D719A9C47165466C3" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_DA1E1A15D3E802A4DB0A9C471654F385" xlink:to="loc_pfe_OtherInProcessResearchandDevelopmentMember_E43E5CA632F39E1D719A9C47165466C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationStatusAxis" xlink:label="loc_us-gaap_LitigationStatusAxis_2DCBF3D5007F128FC6779C471654ECDB" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_95A1ADCBE302F1B121559C471651BBAD" xlink:to="loc_us-gaap_LitigationStatusAxis_2DCBF3D5007F128FC6779C471654ECDB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationStatusDomain" xlink:label="loc_us-gaap_LitigationStatusDomain_686497904DD6AF2454AD9C471654BE2E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LitigationStatusAxis_2DCBF3D5007F128FC6779C471654ECDB" xlink:to="loc_us-gaap_LitigationStatusDomain_686497904DD6AF2454AD9C471654BE2E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationStatusDomain" xlink:label="loc_us-gaap_LitigationStatusDomain_686497904DD6AF2454AD9C471654BE2E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LitigationStatusAxis_2DCBF3D5007F128FC6779C471654ECDB" xlink:to="loc_us-gaap_LitigationStatusDomain_686497904DD6AF2454AD9C471654BE2E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PendingLitigationMember" xlink:label="loc_us-gaap_PendingLitigationMember_927004CA1DF7839C21079C471654EF7A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_686497904DD6AF2454AD9C471654BE2E" xlink:to="loc_us-gaap_PendingLitigationMember_927004CA1DF7839C21079C471654EF7A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_3CCA51C50DD9DAF0904C9C471655B0EB" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_95A1ADCBE302F1B121559C471651BBAD" xlink:to="loc_us-gaap_TypeOfArrangementAxis_3CCA51C50DD9DAF0904C9C471655B0EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_B81D011929653F84FB989C471655FEEB_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_3CCA51C50DD9DAF0904C9C471655B0EB" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_B81D011929653F84FB989C471655FEEB_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_B81D011929653F84FB989C471655FEEB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_3CCA51C50DD9DAF0904C9C471655B0EB" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_B81D011929653F84FB989C471655FEEB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementCopromotionMember" xlink:label="loc_us-gaap_CollaborativeArrangementCopromotionMember_E9DA8B9E4D9D0E0776E09C471655BFD1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_B81D011929653F84FB989C471655FEEB" xlink:to="loc_us-gaap_CollaborativeArrangementCopromotionMember_E9DA8B9E4D9D0E0776E09C471655BFD1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_B467D00D2AC96D1223749C471655DF31" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_95A1ADCBE302F1B121559C471651BBAD" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_B467D00D2AC96D1223749C471655DF31" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0D3CA108D2EEF9C26C3A9C4716556636_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_B467D00D2AC96D1223749C471655DF31" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0D3CA108D2EEF9C26C3A9C4716556636_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0D3CA108D2EEF9C26C3A9C4716556636" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_B467D00D2AC96D1223749C471655DF31" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0D3CA108D2EEF9C26C3A9C4716556636" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DistributionRightsMember" xlink:label="loc_us-gaap_DistributionRightsMember_D8BB07B591FAF7725E1B9C4716551DE6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0D3CA108D2EEF9C26C3A9C4716556636" xlink:to="loc_us-gaap_DistributionRightsMember_D8BB07B591FAF7725E1B9C4716551DE6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_AAF10B0BE3DA18360C439C471655A98A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0D3CA108D2EEF9C26C3A9C4716556636" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_AAF10B0BE3DA18360C439C471655A98A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_24AA36B064BAF3A02C869C471656EBD8" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_95A1ADCBE302F1B121559C471651BBAD" xlink:to="loc_us-gaap_ProductOrServiceAxis_24AA36B064BAF3A02C869C471656EBD8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_274168A1D41E4248631B9C47165624B2_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ProductOrServiceAxis_24AA36B064BAF3A02C869C471656EBD8" xlink:to="loc_us-gaap_ProductsAndServicesDomain_274168A1D41E4248631B9C47165624B2_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_274168A1D41E4248631B9C47165624B2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ProductOrServiceAxis_24AA36B064BAF3A02C869C471656EBD8" xlink:to="loc_us-gaap_ProductsAndServicesDomain_274168A1D41E4248631B9C47165624B2" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_EnbrelMember" xlink:label="loc_pfe_EnbrelMember_BA9498AB00CCC38840E39C471656E6A4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_274168A1D41E4248631B9C47165624B2" xlink:to="loc_pfe_EnbrelMember_BA9498AB00CCC38840E39C471656E6A4" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_XtandiMember" xlink:label="loc_pfe_XtandiMember_005A5310349C9D29CCAA9C471656FB57" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_274168A1D41E4248631B9C47165624B2" xlink:to="loc_pfe_XtandiMember_005A5310349C9D29CCAA9C471656FB57" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_CelebrexMember" xlink:label="loc_pfe_CelebrexMember_00CDD5B3C06D78AC5E139C4716563B98" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_274168A1D41E4248631B9C47165624B2" xlink:to="loc_pfe_CelebrexMember_00CDD5B3C06D78AC5E139C4716563B98" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_CelebrexandBextraMember" xlink:label="loc_pfe_CelebrexandBextraMember_5F13FF9444B2387028A29C471656CFA3" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_274168A1D41E4248631B9C47165624B2" xlink:to="loc_pfe_CelebrexandBextraMember_5F13FF9444B2387028A29C471656CFA3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ADCF77D77E653BCA2B369C4716573F4F" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_95A1ADCBE302F1B121559C471651BBAD" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ADCF77D77E653BCA2B369C4716573F4F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvesteeNameDomain" xlink:label="loc_us-gaap_EquityMethodInvesteeNameDomain_D51FB0AB68E0EA95AD4F9C471657753C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ADCF77D77E653BCA2B369C4716573F4F" xlink:to="loc_us-gaap_EquityMethodInvesteeNameDomain_D51FB0AB68E0EA95AD4F9C471657753C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvesteeNameDomain" xlink:label="loc_us-gaap_EquityMethodInvesteeNameDomain_D51FB0AB68E0EA95AD4F9C471657753C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ADCF77D77E653BCA2B369C4716573F4F" xlink:to="loc_us-gaap_EquityMethodInvesteeNameDomain_D51FB0AB68E0EA95AD4F9C471657753C" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_LaboratorioTeutoBrasileroMember" xlink:label="loc_pfe_LaboratorioTeutoBrasileroMember_4F2E723B564D840AEA519C471657B39E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityMethodInvesteeNameDomain_D51FB0AB68E0EA95AD4F9C471657753C" xlink:to="loc_pfe_LaboratorioTeutoBrasileroMember_4F2E723B564D840AEA519C471657B39E" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_HisunPfizerPharmaceuticalsCoLtdMember" xlink:label="loc_pfe_HisunPfizerPharmaceuticalsCoLtdMember_17436B9DD03E74EC83369C4716574415" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityMethodInvesteeNameDomain_D51FB0AB68E0EA95AD4F9C471657753C" xlink:to="loc_pfe_HisunPfizerPharmaceuticalsCoLtdMember_17436B9DD03E74EC83369C4716574415" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_ViivHealthcareLimitedMember" xlink:label="loc_pfe_ViivHealthcareLimitedMember_AD7335B3FA93CC96B4B29C471658E596" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityMethodInvesteeNameDomain_D51FB0AB68E0EA95AD4F9C471657753C" xlink:to="loc_pfe_ViivHealthcareLimitedMember_AD7335B3FA93CC96B4B29C471658E596" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_DecreaseinRoyaltyRevenue" xlink:label="loc_pfe_DecreaseinRoyaltyRevenue_DAC0D36C09A2A04546649C471658C5B4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_190165E2439EFA6C88F09C471658495A" xlink:to="loc_pfe_DecreaseinRoyaltyRevenue_DAC0D36C09A2A04546649C471658C5B4" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_RoyaltyRevenueTerm" xlink:label="loc_pfe_RoyaltyRevenueTerm_997316D9F18789639AD09C471658DE0A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_190165E2439EFA6C88F09C471658495A" xlink:to="loc_pfe_RoyaltyRevenueTerm_997316D9F18789639AD09C471658DE0A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:label="loc_us-gaap_RoyaltyRevenue_5875B80643E2F7FD923D9C4716583F48" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_190165E2439EFA6C88F09C471658495A" xlink:to="loc_us-gaap_RoyaltyRevenue_5875B80643E2F7FD923D9C4716583F48" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationSettlementExpense" xlink:label="loc_us-gaap_LitigationSettlementExpense_0D0A20883E0F6A98B2409C471658693A" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_190165E2439EFA6C88F09C471658495A" xlink:to="loc_us-gaap_LitigationSettlementExpense_0D0A20883E0F6A98B2409C471658693A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_EEFC245F4CCA145AEF219C4716592E00" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_190165E2439EFA6C88F09C471658495A" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_EEFC245F4CCA145AEF219C4716592E00" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossOnDispositionOfIntangibleAssets" xlink:label="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_C4249E220EF8BB211A0F9C471659FC43" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_190165E2439EFA6C88F09C471658495A" xlink:to="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_C4249E220EF8BB211A0F9C471659FC43" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainOnSaleOfInvestments" xlink:label="loc_us-gaap_GainOnSaleOfInvestments_97BE826112523B53E56D9C4716592D6C" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_190165E2439EFA6C88F09C471658495A" xlink:to="loc_us-gaap_GainOnSaleOfInvestments_97BE826112523B53E56D9C4716592D6C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_4C699B9A4944A9D597A89C47165AD4BF" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_190165E2439EFA6C88F09C471658495A" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_4C699B9A4944A9D597A89C47165AD4BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_C0757627A7CC8D088D939C47165A4117" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_190165E2439EFA6C88F09C471658495A" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_C0757627A7CC8D088D939C47165A4117" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_B0D8DE3E83A9F7CCC40E9C47165A1990" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_190165E2439EFA6C88F09C471658495A" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_B0D8DE3E83A9F7CCC40E9C47165A1990" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal" xlink:label="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_AC3B6A2758DF4355B9C69C47165A45C8" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_190165E2439EFA6C88F09C471658495A" xlink:to="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_AC3B6A2758DF4355B9C69C47165A45C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_B8ADDD70296F19B54FB69C47165A97AF" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_190165E2439EFA6C88F09C471658495A" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_B8ADDD70296F19B54FB69C47165A97AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment" xlink:label="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_24F2E5BB9C009165AEF19C47165A2884" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_190165E2439EFA6C88F09C471658495A" xlink:to="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_24F2E5BB9C009165AEF19C47165A2884" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentIncomeDividend" xlink:label="loc_us-gaap_InvestmentIncomeDividend_793E89681EAA70594FD09C47165A2BB4" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_190165E2439EFA6C88F09C471658495A" xlink:to="loc_us-gaap_InvestmentIncomeDividend_793E89681EAA70594FD09C47165A2BB4" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_OtherNonoperatingIncomeMiscellaneous" xlink:label="loc_pfe_OtherNonoperatingIncomeMiscellaneous_2249A417ED8EC98A8CE29C47165A986A" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_190165E2439EFA6C88F09C471658495A" xlink:to="loc_pfe_OtherNonoperatingIncomeMiscellaneous_2249A417ED8EC98A8CE29C47165A986A" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_PaymentsforMergerTerminationCosts" xlink:label="loc_pfe_PaymentsforMergerTerminationCosts_7D8CFD62A7144EA1679F9C47165AB0AD" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_190165E2439EFA6C88F09C471658495A" xlink:to="loc_pfe_PaymentsforMergerTerminationCosts_7D8CFD62A7144EA1679F9C47165AB0AD" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/OtherIncomeDeductionsNetImpairedIntangibleAssetsDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_5B2E9FD338207E47C1A891BE7BEE2344" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_098A9308C34D5D9FAD6291BE7BEC4169" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_5B2E9FD338207E47C1A891BE7BEE2344" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_098A9308C34D5D9FAD6291BE7BEC4169" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_18F268A3766C0679E3A491BE7BEDC241" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_098A9308C34D5D9FAD6291BE7BEC4169" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_18F268A3766C0679E3A491BE7BEDC241" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5C3B9269350C0958113A91BE7BEDB95E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_18F268A3766C0679E3A491BE7BEDC241" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5C3B9269350C0958113A91BE7BEDB95E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5C3B9269350C0958113A91BE7BEDB95E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_18F268A3766C0679E3A491BE7BEDC241" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5C3B9269350C0958113A91BE7BEDB95E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_4A0A986E30EEF78A537C91BE7BED15EE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5C3B9269350C0958113A91BE7BEDB95E" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_4A0A986E30EEF78A537C91BE7BED15EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_BFDF8AEA48384BFF16C291BE7BED3045" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_098A9308C34D5D9FAD6291BE7BEC4169" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_BFDF8AEA48384BFF16C291BE7BED3045" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_EA7160890314A6422B0F91BE7BED1149_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_BFDF8AEA48384BFF16C291BE7BED3045" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_EA7160890314A6422B0F91BE7BED1149_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_EA7160890314A6422B0F91BE7BED1149" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_BFDF8AEA48384BFF16C291BE7BED3045" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_EA7160890314A6422B0F91BE7BED1149" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_B77969D8CC7738F4267E91BE7BED05C0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_EA7160890314A6422B0F91BE7BED1149" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_B77969D8CC7738F4267E91BE7BED05C0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_DC2843CE2407EBEB7AF291BE7BEEB3E9" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_EA7160890314A6422B0F91BE7BED1149" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_DC2843CE2407EBEB7AF291BE7BEEB3E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_E49B3D40A47CED32C7A491BE7BEEB7C8" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_EA7160890314A6422B0F91BE7BED1149" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_E49B3D40A47CED32C7A491BE7BEEB7C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure_F1E9C2521982018511B291BE7BEECF7E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_5B2E9FD338207E47C1A891BE7BEE2344" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure_F1E9C2521982018511B291BE7BEECF7E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_A4E1817BB7886893854791BE7BEE1500" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_5B2E9FD338207E47C1A891BE7BEE2344" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_A4E1817BB7886893854791BE7BEE1500" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/OtherIncomeDeductionsNetTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlans" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_0655BCA3A48F386F7BB69C26003B0E64" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_58F943B65501197DC9DB9C260035C20A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_0655BCA3A48F386F7BB69C26003B0E64" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_58F943B65501197DC9DB9C260035C20A" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_9DDE60E9AF724D3EBC0A9C2600350B6C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_58F943B65501197DC9DB9C260035C20A" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_9DDE60E9AF724D3EBC0A9C2600350B6C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_06107B8D81988B97DFEB9C260035C7DE_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_9DDE60E9AF724D3EBC0A9C2600350B6C" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_06107B8D81988B97DFEB9C260035C7DE_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_06107B8D81988B97DFEB9C260035C7DE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_9DDE60E9AF724D3EBC0A9C2600350B6C" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_06107B8D81988B97DFEB9C260035C7DE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_248C21407034A7E0BA549C260035688F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_06107B8D81988B97DFEB9C260035C7DE" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_248C21407034A7E0BA549C260035688F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" xlink:label="loc_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember_1B64F4669BA2AE0B576A9C260035C031" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_06107B8D81988B97DFEB9C260035C7DE" xlink:to="loc_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember_1B64F4669BA2AE0B576A9C260035C031" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_1307BA41747480D8F2539C260035CC50" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_06107B8D81988B97DFEB9C260035C7DE" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_1307BA41747480D8F2539C260035CC50" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_1565ED786730FA4615959C2600358A98" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_58F943B65501197DC9DB9C260035C20A" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_1565ED786730FA4615959C2600358A98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_57C8C8363D5ADF3AA5FB9C260035B747_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_1565ED786730FA4615959C2600358A98" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_57C8C8363D5ADF3AA5FB9C260035B747_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_57C8C8363D5ADF3AA5FB9C260035B747" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_1565ED786730FA4615959C2600358A98" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_57C8C8363D5ADF3AA5FB9C260035B747" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DomesticPlanMember" xlink:label="loc_us-gaap_DomesticPlanMember_F5447EB850F5B34DE8C29C26003AB905" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_57C8C8363D5ADF3AA5FB9C260035B747" xlink:to="loc_us-gaap_DomesticPlanMember_F5447EB850F5B34DE8C29C26003AB905" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_0B0CCE0A7C5D9058C7D39C26003ABCF6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DomesticPlanMember_F5447EB850F5B34DE8C29C26003AB905" xlink:to="loc_country_US_0B0CCE0A7C5D9058C7D39C26003ABCF6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ForeignPlanMember" xlink:label="loc_us-gaap_ForeignPlanMember_3393F3E6D6A820AB4B129C26003A09D8" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_57C8C8363D5ADF3AA5FB9C260035B747" xlink:to="loc_us-gaap_ForeignPlanMember_3393F3E6D6A820AB4B129C26003A09D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetirementPlanTaxStatusAxis" xlink:label="loc_us-gaap_RetirementPlanTaxStatusAxis_EE9B36554A064C65D1C49C26003B609C" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_58F943B65501197DC9DB9C260035C20A" xlink:to="loc_us-gaap_RetirementPlanTaxStatusAxis_EE9B36554A064C65D1C49C26003B609C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetirementPlanTaxStatusDomain" xlink:label="loc_us-gaap_RetirementPlanTaxStatusDomain_323362365401814229A49C26003BD62B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTaxStatusAxis_EE9B36554A064C65D1C49C26003B609C" xlink:to="loc_us-gaap_RetirementPlanTaxStatusDomain_323362365401814229A49C26003BD62B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetirementPlanTaxStatusDomain" xlink:label="loc_us-gaap_RetirementPlanTaxStatusDomain_323362365401814229A49C26003BD62B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTaxStatusAxis_EE9B36554A064C65D1C49C26003B609C" xlink:to="loc_us-gaap_RetirementPlanTaxStatusDomain_323362365401814229A49C26003BD62B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_QualifiedPlanMember" xlink:label="loc_us-gaap_QualifiedPlanMember_ADC75BD412157F4427729C26003BFEAD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTaxStatusDomain_323362365401814229A49C26003BD62B" xlink:to="loc_us-gaap_QualifiedPlanMember_ADC75BD412157F4427729C26003BFEAD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonqualifiedPlanMember" xlink:label="loc_us-gaap_NonqualifiedPlanMember_F7873889745A1D4F86169C26003B2B66" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTaxStatusDomain_323362365401814229A49C26003BD62B" xlink:to="loc_us-gaap_NonqualifiedPlanMember_F7873889745A1D4F86169C26003B2B66" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:label="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_83C75D167FE2921611F99C26003B923B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_0655BCA3A48F386F7BB69C26003B0E64" xlink:to="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_83C75D167FE2921611F99C26003B923B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsRemainderOfFiscalYear" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsRemainderOfFiscalYear_8B1881E5D9A67DFC93959C26003B464D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_0655BCA3A48F386F7BB69C26003B0E64" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsRemainderOfFiscalYear_8B1881E5D9A67DFC93959C26003B464D" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansNetPeriodicBenefitCostDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_CDBB8AF2C084C26F167E58E0C4A24AAC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_B1E6D9DEB85CD33D790258E0C4A11A00" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_CDBB8AF2C084C26F167E58E0C4A24AAC" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_B1E6D9DEB85CD33D790258E0C4A11A00" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_8C1D741929AEB2306A9758E0C4A12E54" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_B1E6D9DEB85CD33D790258E0C4A11A00" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_8C1D741929AEB2306A9758E0C4A12E54" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_E1DD6B6C6E060F2986AA58E0C4A1BDAC_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_8C1D741929AEB2306A9758E0C4A12E54" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_E1DD6B6C6E060F2986AA58E0C4A1BDAC_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_E1DD6B6C6E060F2986AA58E0C4A1BDAC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_8C1D741929AEB2306A9758E0C4A12E54" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_E1DD6B6C6E060F2986AA58E0C4A1BDAC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_CA24403FE5E80C8FDE5A58E0C4A1ED31" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_E1DD6B6C6E060F2986AA58E0C4A1BDAC" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_CA24403FE5E80C8FDE5A58E0C4A1ED31" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" xlink:label="loc_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember_22F13CC34B8F768DBF1058E0C4A13981" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_E1DD6B6C6E060F2986AA58E0C4A1BDAC" xlink:to="loc_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember_22F13CC34B8F768DBF1058E0C4A13981" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_8589B5192333D3A2674158E0C4A11B46" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_E1DD6B6C6E060F2986AA58E0C4A1BDAC" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_8589B5192333D3A2674158E0C4A11B46" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_68A521F7AD3147B74C7158E0C4A147CE" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_B1E6D9DEB85CD33D790258E0C4A11A00" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_68A521F7AD3147B74C7158E0C4A147CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_A92C468E784C95F59A8A58E0C4A1C07D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_68A521F7AD3147B74C7158E0C4A147CE" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_A92C468E784C95F59A8A58E0C4A1C07D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_A92C468E784C95F59A8A58E0C4A1C07D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_68A521F7AD3147B74C7158E0C4A147CE" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_A92C468E784C95F59A8A58E0C4A1C07D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DomesticPlanMember" xlink:label="loc_us-gaap_DomesticPlanMember_3F87AF0DF8AE9391A31D58E0C4A25178" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_A92C468E784C95F59A8A58E0C4A1C07D" xlink:to="loc_us-gaap_DomesticPlanMember_3F87AF0DF8AE9391A31D58E0C4A25178" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_764039C20B1AD4AF6E7B58E0C4A2B6E5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DomesticPlanMember_3F87AF0DF8AE9391A31D58E0C4A25178" xlink:to="loc_country_US_764039C20B1AD4AF6E7B58E0C4A2B6E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ForeignPlanMember" xlink:label="loc_us-gaap_ForeignPlanMember_9E5EFD1E7A6C75A973F958E0C4A29670" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_A92C468E784C95F59A8A58E0C4A1C07D" xlink:to="loc_us-gaap_ForeignPlanMember_9E5EFD1E7A6C75A973F958E0C4A29670" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetirementPlanTaxStatusAxis" xlink:label="loc_us-gaap_RetirementPlanTaxStatusAxis_B3CC59DA1369AACDA88458E0C4A28212" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_B1E6D9DEB85CD33D790258E0C4A11A00" xlink:to="loc_us-gaap_RetirementPlanTaxStatusAxis_B3CC59DA1369AACDA88458E0C4A28212" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetirementPlanTaxStatusDomain" xlink:label="loc_us-gaap_RetirementPlanTaxStatusDomain_38CD8A3CF34EF52A2E4C58E0C4A2F80D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTaxStatusAxis_B3CC59DA1369AACDA88458E0C4A28212" xlink:to="loc_us-gaap_RetirementPlanTaxStatusDomain_38CD8A3CF34EF52A2E4C58E0C4A2F80D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetirementPlanTaxStatusDomain" xlink:label="loc_us-gaap_RetirementPlanTaxStatusDomain_38CD8A3CF34EF52A2E4C58E0C4A2F80D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTaxStatusAxis_B3CC59DA1369AACDA88458E0C4A28212" xlink:to="loc_us-gaap_RetirementPlanTaxStatusDomain_38CD8A3CF34EF52A2E4C58E0C4A2F80D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_QualifiedPlanMember" xlink:label="loc_us-gaap_QualifiedPlanMember_1EBEB72E59C504F19D9258E0C4A2EC55" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTaxStatusDomain_38CD8A3CF34EF52A2E4C58E0C4A2F80D" xlink:to="loc_us-gaap_QualifiedPlanMember_1EBEB72E59C504F19D9258E0C4A2EC55" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonqualifiedPlanMember" xlink:label="loc_us-gaap_NonqualifiedPlanMember_63B6E5D47646B0658AC658E0C4A225E4" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTaxStatusDomain_38CD8A3CF34EF52A2E4C58E0C4A2F80D" xlink:to="loc_us-gaap_NonqualifiedPlanMember_63B6E5D47646B0658AC658E0C4A225E4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedBenefitPlanServiceCost" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_148CAA7E3A877C3E6F5A58E0C4A25CA4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_CDBB8AF2C084C26F167E58E0C4A24AAC" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_148CAA7E3A877C3E6F5A58E0C4A25CA4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedBenefitPlanInterestCost" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_C63935ADD22A0933A76658E0C4A26A28" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_CDBB8AF2C084C26F167E58E0C4A24AAC" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_C63935ADD22A0933A76658E0C4A26A28" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_A82F4BFA8169C436411858E0C4A204BE" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_CDBB8AF2C084C26F167E58E0C4A24AAC" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_A82F4BFA8169C436411858E0C4A204BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_3CEC019DC12674A85AF558E0C4A2B5F6" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_CDBB8AF2C084C26F167E58E0C4A24AAC" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_3CEC019DC12674A85AF558E0C4A2B5F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_5CEE52BAFEE1A45F164658E0C4A257B2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_3CEC019DC12674A85AF558E0C4A2B5F6" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_5CEE52BAFEE1A45F164658E0C4A257B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_EB003D082E3D8B77235658E0C4A242EF" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_3CEC019DC12674A85AF558E0C4A2B5F6" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_EB003D082E3D8B77235658E0C4A242EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments_00B33F4458EA06BCFC7A58E0C4A351CC" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_CDBB8AF2C084C26F167E58E0C4A24AAC" xlink:to="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments_00B33F4458EA06BCFC7A58E0C4A351CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_5A948B9C366415A04F5F58E0C4A3CB04" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_CDBB8AF2C084C26F167E58E0C4A24AAC" xlink:to="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_5A948B9C366415A04F5F58E0C4A3CB04" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_ACEDA0A695614709E61158E0C4A3EF28" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_CDBB8AF2C084C26F167E58E0C4A24AAC" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_ACEDA0A695614709E61158E0C4A3EF28" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansNetPeriodicBenefitCostFootnotesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_C94B763BAB585F6D9D2646362354FD13" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_D0E4EA682CE85E7583739D01C7DA6D04" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_C94B763BAB585F6D9D2646362354FD13" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_D0E4EA682CE85E7583739D01C7DA6D04" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_9A816E6E2C8E5FBDB0D00CB0AE558AAB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_D0E4EA682CE85E7583739D01C7DA6D04" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_9A816E6E2C8E5FBDB0D00CB0AE558AAB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_019C94C208E04CEF8B15BE65690E4A76_0B82B7E4F07153C98FA18A29315D4D23" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_9A816E6E2C8E5FBDB0D00CB0AE558AAB" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_019C94C208E04CEF8B15BE65690E4A76_0B82B7E4F07153C98FA18A29315D4D23" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_104C7B3624B45E08B38ABF7EBFBAD857" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_9A816E6E2C8E5FBDB0D00CB0AE558AAB" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_104C7B3624B45E08B38ABF7EBFBAD857" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_HospiraMember" xlink:label="loc_pfe_HospiraMember_31E812AD04A3597285CC63EF569B521A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_104C7B3624B45E08B38ABF7EBFBAD857" xlink:to="loc_pfe_HospiraMember_31E812AD04A3597285CC63EF569B521A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_82071F938F835596819F4BCCE1D982B8" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_D0E4EA682CE85E7583739D01C7DA6D04" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_82071F938F835596819F4BCCE1D982B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_30B08B83C89AC9D0DD00BE4DA371E6D3_0B82B7E4F07153C98FA18A29315D4D23" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_82071F938F835596819F4BCCE1D982B8" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_30B08B83C89AC9D0DD00BE4DA371E6D3_0B82B7E4F07153C98FA18A29315D4D23" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_F2B8AB55FA2555C180C83366EA91D6CD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_82071F938F835596819F4BCCE1D982B8" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_F2B8AB55FA2555C180C83366EA91D6CD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_CDB8E7311EB25DA7ADE0506EB11388DE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_F2B8AB55FA2555C180C83366EA91D6CD" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_CDB8E7311EB25DA7ADE0506EB11388DE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_55484D933A7C5E3CAB8AE4A168A66F9F" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_D0E4EA682CE85E7583739D01C7DA6D04" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_55484D933A7C5E3CAB8AE4A168A66F9F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_9340A9F11390F290DF3BBE4DA371FA42_0B82B7E4F07153C98FA18A29315D4D23" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_55484D933A7C5E3CAB8AE4A168A66F9F" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_9340A9F11390F290DF3BBE4DA371FA42_0B82B7E4F07153C98FA18A29315D4D23" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_A0992C1AAC355AF4959E3215F4541E92" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_55484D933A7C5E3CAB8AE4A168A66F9F" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_A0992C1AAC355AF4959E3215F4541E92" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DomesticPlanMember" xlink:label="loc_us-gaap_DomesticPlanMember_168396ECD88153AF9930F95EA7B6BBA1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_A0992C1AAC355AF4959E3215F4541E92" xlink:to="loc_us-gaap_DomesticPlanMember_168396ECD88153AF9930F95EA7B6BBA1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_70C652CD6AC059EEBD955CE6ADDB5D7A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DomesticPlanMember_168396ECD88153AF9930F95EA7B6BBA1" xlink:to="loc_country_US_70C652CD6AC059EEBD955CE6ADDB5D7A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetirementPlanTaxStatusAxis" xlink:label="loc_us-gaap_RetirementPlanTaxStatusAxis_60FABF4A4FAD5627A7081CC65D5235AC" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_D0E4EA682CE85E7583739D01C7DA6D04" xlink:to="loc_us-gaap_RetirementPlanTaxStatusAxis_60FABF4A4FAD5627A7081CC65D5235AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetirementPlanTaxStatusDomain" xlink:label="loc_us-gaap_RetirementPlanTaxStatusDomain_106FF99707C33B28B8C4BE4DA3715EC9_0B82B7E4F07153C98FA18A29315D4D23" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTaxStatusAxis_60FABF4A4FAD5627A7081CC65D5235AC" xlink:to="loc_us-gaap_RetirementPlanTaxStatusDomain_106FF99707C33B28B8C4BE4DA3715EC9_0B82B7E4F07153C98FA18A29315D4D23" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetirementPlanTaxStatusDomain" xlink:label="loc_us-gaap_RetirementPlanTaxStatusDomain_1262126FE93B5006B7BDE401A606DA4F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTaxStatusAxis_60FABF4A4FAD5627A7081CC65D5235AC" xlink:to="loc_us-gaap_RetirementPlanTaxStatusDomain_1262126FE93B5006B7BDE401A606DA4F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_QualifiedPlanMember" xlink:label="loc_us-gaap_QualifiedPlanMember_2617FF9D9494576B8FA119416318DCB9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTaxStatusDomain_1262126FE93B5006B7BDE401A606DA4F" xlink:to="loc_us-gaap_QualifiedPlanMember_2617FF9D9494576B8FA119416318DCB9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedBenefitPlanSettlementsBenefitObligation" xlink:label="loc_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation_01D2742C605E58C79DD00E8D81F54B5A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_C94B763BAB585F6D9D2646362354FD13" xlink:to="loc_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation_01D2742C605E58C79DD00E8D81F54B5A" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_DefinedBenefitPlanNetPeriodicBenefitCostCreditGainLossDuetoSettlementPretax" xlink:label="loc_pfe_DefinedBenefitPlanNetPeriodicBenefitCostCreditGainLossDuetoSettlementPretax_759A631484EC5D9E81525B53E0BA088A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_C94B763BAB585F6D9D2646362354FD13" xlink:to="loc_pfe_DefinedBenefitPlanNetPeriodicBenefitCostCreditGainLossDuetoSettlementPretax_759A631484EC5D9E81525B53E0BA088A" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_DefinedBenefitPlanActuarialLossandPriorServiceCostsImmediateRecognitionasComponentinNetPeriodicBenefitCost" xlink:label="loc_pfe_DefinedBenefitPlanActuarialLossandPriorServiceCostsImmediateRecognitionasComponentinNetPeriodicBenefitCost_29CEBA4F376F53C48547A40435E9CCAF" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_C94B763BAB585F6D9D2646362354FD13" xlink:to="loc_pfe_DefinedBenefitPlanActuarialLossandPriorServiceCostsImmediateRecognitionasComponentinNetPeriodicBenefitCost_29CEBA4F376F53C48547A40435E9CCAF" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiatives" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_4CF542CCAD53A25C870A9C26431D90E8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_497351AF5A683035FED29C2643172B4F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_4CF542CCAD53A25C870A9C26431D90E8" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_497351AF5A683035FED29C2643172B4F" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_E027C3E6826D643AAFD99C2643171D8D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_497351AF5A683035FED29C2643172B4F" xlink:to="loc_us-gaap_StatementScenarioAxis_E027C3E6826D643AAFD99C2643171D8D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_A9CB31473C7744EA3C8D9C2643174C96_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementScenarioAxis_E027C3E6826D643AAFD99C2643171D8D" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_A9CB31473C7744EA3C8D9C2643174C96_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_A9CB31473C7744EA3C8D9C2643174C96" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementScenarioAxis_E027C3E6826D643AAFD99C2643171D8D" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_A9CB31473C7744EA3C8D9C2643174C96" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioForecastMember" xlink:label="loc_us-gaap_ScenarioForecastMember_99A0014D84F70574C4A19C264317A5BC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_A9CB31473C7744EA3C8D9C2643174C96" xlink:to="loc_us-gaap_ScenarioForecastMember_99A0014D84F70574C4A19C264317A5BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_471964441D0F0D8F67619C264317ACEA" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_497351AF5A683035FED29C2643172B4F" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_471964441D0F0D8F67619C264317ACEA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9DF3FBD198B5098963419C264317B346_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_471964441D0F0D8F67619C264317ACEA" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9DF3FBD198B5098963419C264317B346_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9DF3FBD198B5098963419C264317B346" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_471964441D0F0D8F67619C264317ACEA" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9DF3FBD198B5098963419C264317B346" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_HospiraMember" xlink:label="loc_pfe_HospiraMember_CDFFBE04AF0AB75D94979C26431790C7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9DF3FBD198B5098963419C264317B346" xlink:to="loc_pfe_HospiraMember_CDFFBE04AF0AB75D94979C26431790C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_61533D8AB24ABEB493D49C264317E67C" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_497351AF5A683035FED29C2643172B4F" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_61533D8AB24ABEB493D49C264317E67C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_1F166A59D29A3789F4489C2643174E41_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_61533D8AB24ABEB493D49C264317E67C" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_1F166A59D29A3789F4489C2643174E41_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_1F166A59D29A3789F4489C2643174E41" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_61533D8AB24ABEB493D49C264317E67C" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_1F166A59D29A3789F4489C2643174E41" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_ReturnofAcquiredRightsMember" xlink:label="loc_pfe_ReturnofAcquiredRightsMember_E9C90B5409D9135B8FAA9C264318609A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_1F166A59D29A3789F4489C2643174E41" xlink:to="loc_pfe_ReturnofAcquiredRightsMember_E9C90B5409D9135B8FAA9C264318609A" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_ManufacturingPlantNetworkOptimizationMember" xlink:label="loc_pfe_ManufacturingPlantNetworkOptimizationMember_3B6ED7C95EE5E79B83899C26431846EF" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_1F166A59D29A3789F4489C2643174E41" xlink:to="loc_pfe_ManufacturingPlantNetworkOptimizationMember_3B6ED7C95EE5E79B83899C26431846EF" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_CentralizationofCorporateandPlatformFunctionsMember" xlink:label="loc_pfe_CentralizationofCorporateandPlatformFunctionsMember_D99C8B77D06D90D7393E9C26431878E1" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_1F166A59D29A3789F4489C2643174E41" xlink:to="loc_pfe_CentralizationofCorporateandPlatformFunctionsMember_D99C8B77D06D90D7393E9C26431878E1" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_BusinessIntegrationCostsMember" xlink:label="loc_pfe_BusinessIntegrationCostsMember_BA7DCFDB755847A59BFD9C264318BE89" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_1F166A59D29A3789F4489C2643174E41" xlink:to="loc_pfe_BusinessIntegrationCostsMember_BA7DCFDB755847A59BFD9C264318BE89" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringPlanAxis" xlink:label="loc_us-gaap_RestructuringPlanAxis_AC4C67B9CBC15C5E701A9C2643185AAF" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_497351AF5A683035FED29C2643172B4F" xlink:to="loc_us-gaap_RestructuringPlanAxis_AC4C67B9CBC15C5E701A9C2643185AAF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringPlanDomain" xlink:label="loc_us-gaap_RestructuringPlanDomain_644CBB9D270F40ACE5F59C264318D79A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringPlanAxis_AC4C67B9CBC15C5E701A9C2643185AAF" xlink:to="loc_us-gaap_RestructuringPlanDomain_644CBB9D270F40ACE5F59C264318D79A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringPlanDomain" xlink:label="loc_us-gaap_RestructuringPlanDomain_644CBB9D270F40ACE5F59C264318D79A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringPlanAxis_AC4C67B9CBC15C5E701A9C2643185AAF" xlink:to="loc_us-gaap_RestructuringPlanDomain_644CBB9D270F40ACE5F59C264318D79A" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_EnterprisewideCostReductionProductivityPlanMember" xlink:label="loc_pfe_EnterprisewideCostReductionProductivityPlanMember_49CAB6C335E6D2D669239C264318A44C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_644CBB9D270F40ACE5F59C264318D79A" xlink:to="loc_pfe_EnterprisewideCostReductionProductivityPlanMember_49CAB6C335E6D2D669239C264318A44C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_5A226EFB35573897CA7D9C2643185847" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_497351AF5A683035FED29C2643172B4F" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_5A226EFB35573897CA7D9C2643185847" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_9690C7DEDF5E0FBDA7CA9C2643180956_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_5A226EFB35573897CA7D9C2643185847" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_9690C7DEDF5E0FBDA7CA9C2643180956_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_9690C7DEDF5E0FBDA7CA9C2643180956" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_5A226EFB35573897CA7D9C2643185847" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_9690C7DEDF5E0FBDA7CA9C2643180956" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostOfSalesMember" xlink:label="loc_us-gaap_CostOfSalesMember_1299E222993D193C2A299C26431808F3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9690C7DEDF5E0FBDA7CA9C2643180956" xlink:to="loc_us-gaap_CostOfSalesMember_1299E222993D193C2A299C26431808F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_D5FD1FF344784AC23F7F9C26431852B8" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9690C7DEDF5E0FBDA7CA9C2643180956" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_D5FD1FF344784AC23F7F9C26431852B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_F73112636689AE0FBFF99C26431879D4" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9690C7DEDF5E0FBDA7CA9C2643180956" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_F73112636689AE0FBFF99C26431879D4" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_OtherIncomeExpenseMember" xlink:label="loc_pfe_OtherIncomeExpenseMember_5900C7FA344D739757019C264318BD38" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9690C7DEDF5E0FBDA7CA9C2643180956" xlink:to="loc_pfe_OtherIncomeExpenseMember_5900C7FA344D739757019C264318BD38" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_BusinessCombinationExpectedIntegrationRelatedCostsPeriod" xlink:label="loc_pfe_BusinessCombinationExpectedIntegrationRelatedCostsPeriod_8437AE6B72C69EF70B0C9C26431D54C6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_4CF542CCAD53A25C870A9C26431D90E8" xlink:to="loc_pfe_BusinessCombinationExpectedIntegrationRelatedCostsPeriod_8437AE6B72C69EF70B0C9C26431D54C6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationIntegrationRelatedCosts" xlink:label="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_47A79B3D765841FBA50C9C26431ECA01" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_4CF542CCAD53A25C870A9C26431D90E8" xlink:to="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_47A79B3D765841FBA50C9C26431ECA01" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:label="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_6D52639CE0ADD899E0509C26431E2D77" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_4CF542CCAD53A25C870A9C26431D90E8" xlink:to="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_6D52639CE0ADD899E0509C26431E2D77" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_14778AEDD61BA7FFA4889C26431EAF83" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_4CF542CCAD53A25C870A9C26431D90E8" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_14778AEDD61BA7FFA4889C26431EAF83" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_RestructuringandRelatedCostNoncashChargesPercentage" xlink:label="loc_pfe_RestructuringandRelatedCostNoncashChargesPercentage_752ABE2FF7427400E15B9C30B8575657" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_4CF542CCAD53A25C870A9C26431D90E8" xlink:to="loc_pfe_RestructuringandRelatedCostNoncashChargesPercentage_752ABE2FF7427400E15B9C30B8575657" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:label="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_ED29960F846FAF1B7BAB9C26431E0F7E" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_4CF542CCAD53A25C870A9C26431D90E8" xlink:to="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_ED29960F846FAF1B7BAB9C26431E0F7E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringChargesAbstract" xlink:label="loc_us-gaap_RestructuringChargesAbstract_DEE58F2CAEA7EC41E4439C26431E515F" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_4CF542CCAD53A25C870A9C26431D90E8" xlink:to="loc_us-gaap_RestructuringChargesAbstract_DEE58F2CAEA7EC41E4439C26431E515F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeveranceCosts1" xlink:label="loc_us-gaap_SeveranceCosts1_259673FFB6E4DD36956C9C26431EB9E2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringChargesAbstract_DEE58F2CAEA7EC41E4439C26431E515F" xlink:to="loc_us-gaap_SeveranceCosts1_259673FFB6E4DD36956C9C26431EB9E2" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_RestructuringAssetImpairmentCharges" xlink:label="loc_pfe_RestructuringAssetImpairmentCharges_EA945165FB56660778959C26431E820B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringChargesAbstract_DEE58F2CAEA7EC41E4439C26431E515F" xlink:to="loc_pfe_RestructuringAssetImpairmentCharges_EA945165FB56660778959C26431E820B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessExitCosts1" xlink:label="loc_us-gaap_BusinessExitCosts1_A7F92F68BE4AA42A04839C26431E57B5" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringChargesAbstract_DEE58F2CAEA7EC41E4439C26431E515F" xlink:to="loc_us-gaap_BusinessExitCosts1_A7F92F68BE4AA42A04839C26431E57B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_75F0F00A91F7F2B7A5519C26431EE306" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringChargesAbstract_DEE58F2CAEA7EC41E4439C26431E515F" xlink:to="loc_us-gaap_RestructuringCharges_75F0F00A91F7F2B7A5519C26431EE306" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts" xlink:label="loc_pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts_D2189C6236BE7605CB839C26431ED851" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_4CF542CCAD53A25C870A9C26431D90E8" xlink:to="loc_pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts_D2189C6236BE7605CB839C26431ED851" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_RestructuringChargesAndAcquisitionRelatedCosts" xlink:label="loc_pfe_RestructuringChargesAndAcquisitionRelatedCosts_BFB0FF6A296F75005B149C26431E157B" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_4CF542CCAD53A25C870A9C26431D90E8" xlink:to="loc_pfe_RestructuringChargesAndAcquisitionRelatedCosts_BFB0FF6A296F75005B149C26431E157B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringReserveAcceleratedDepreciation" xlink:label="loc_us-gaap_RestructuringReserveAcceleratedDepreciation_9F7C0E2FA20C7A8CA3069C26431EF616" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_4CF542CCAD53A25C870A9C26431D90E8" xlink:to="loc_us-gaap_RestructuringReserveAcceleratedDepreciation_9F7C0E2FA20C7A8CA3069C26431EF616" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_ImplementationCostAbstract" xlink:label="loc_pfe_ImplementationCostAbstract_2D129AC7E2F938D05CC99C26431EF49E" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_4CF542CCAD53A25C870A9C26431D90E8" xlink:to="loc_pfe_ImplementationCostAbstract_2D129AC7E2F938D05CC99C26431EF49E" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_ImplementationCosts" xlink:label="loc_pfe_ImplementationCosts_448A4FBE347219FC098C9C26431ECBDC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_ImplementationCostAbstract_2D129AC7E2F938D05CC99C26431EF49E" xlink:to="loc_pfe_ImplementationCosts_448A4FBE347219FC098C9C26431ECBDC" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts" xlink:label="loc_pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts_2AF4FC65BD5170C491E09C26431FE1B1" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_4CF542CCAD53A25C870A9C26431D90E8" xlink:to="loc_pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts_2AF4FC65BD5170C491E09C26431FE1B1" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesFootnotesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_29D2347E7D0BC5E811C47DDD5D08AB9B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_9631D0D57299A46AF5D47DDD5D04A73E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_29D2347E7D0BC5E811C47DDD5D08AB9B" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_9631D0D57299A46AF5D47DDD5D04A73E" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_06D5DEBC654A9FAE092F7DDD5D0510C9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_9631D0D57299A46AF5D47DDD5D04A73E" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_06D5DEBC654A9FAE092F7DDD5D0510C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_A28D86BB9346D92416B47DDD5D059AC1_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_06D5DEBC654A9FAE092F7DDD5D0510C9" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_A28D86BB9346D92416B47DDD5D059AC1_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_A28D86BB9346D92416B47DDD5D059AC1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_06D5DEBC654A9FAE092F7DDD5D0510C9" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_A28D86BB9346D92416B47DDD5D059AC1" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_HospiraMember" xlink:label="loc_pfe_HospiraMember_D9AEF4CFF6E47B2BB7C07DDD5D05B94A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_A28D86BB9346D92416B47DDD5D059AC1" xlink:to="loc_pfe_HospiraMember_D9AEF4CFF6E47B2BB7C07DDD5D05B94A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_4F5A2A0ABF10D1E6DFD07DDD5D059F24" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_9631D0D57299A46AF5D47DDD5D04A73E" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_4F5A2A0ABF10D1E6DFD07DDD5D059F24" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_C1EB874C58B1D6B659307DDD5D05BDEA_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_4F5A2A0ABF10D1E6DFD07DDD5D059F24" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_C1EB874C58B1D6B659307DDD5D05BDEA_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_C1EB874C58B1D6B659307DDD5D05BDEA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_4F5A2A0ABF10D1E6DFD07DDD5D059F24" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_C1EB874C58B1D6B659307DDD5D05BDEA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_07D73B34FB02B04768747DDD5D0542CE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_C1EB874C58B1D6B659307DDD5D05BDEA" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_07D73B34FB02B04768747DDD5D0542CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_C9F1E53DD8D65803DCF87DDD5D05EDC2" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_9631D0D57299A46AF5D47DDD5D04A73E" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_C9F1E53DD8D65803DCF87DDD5D05EDC2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_D80A5143471C4330EFA07DDD5D06DD67_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_C9F1E53DD8D65803DCF87DDD5D05EDC2" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_D80A5143471C4330EFA07DDD5D06DD67_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_D80A5143471C4330EFA07DDD5D06DD67" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_C9F1E53DD8D65803DCF87DDD5D05EDC2" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_D80A5143471C4330EFA07DDD5D06DD67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_749F3CC186D1C03051D47DDD5D06294D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_D80A5143471C4330EFA07DDD5D06DD67" xlink:to="loc_country_US_749F3CC186D1C03051D47DDD5D06294D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetirementPlanTaxStatusAxis" xlink:label="loc_us-gaap_RetirementPlanTaxStatusAxis_464CF2868CBC8C2BBED87DDD5D062191" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_9631D0D57299A46AF5D47DDD5D04A73E" xlink:to="loc_us-gaap_RetirementPlanTaxStatusAxis_464CF2868CBC8C2BBED87DDD5D062191" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetirementPlanTaxStatusDomain" xlink:label="loc_us-gaap_RetirementPlanTaxStatusDomain_49CFC114BC3DDED41A487DDD5D06D4CE_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTaxStatusAxis_464CF2868CBC8C2BBED87DDD5D062191" xlink:to="loc_us-gaap_RetirementPlanTaxStatusDomain_49CFC114BC3DDED41A487DDD5D06D4CE_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetirementPlanTaxStatusDomain" xlink:label="loc_us-gaap_RetirementPlanTaxStatusDomain_49CFC114BC3DDED41A487DDD5D06D4CE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTaxStatusAxis_464CF2868CBC8C2BBED87DDD5D062191" xlink:to="loc_us-gaap_RetirementPlanTaxStatusDomain_49CFC114BC3DDED41A487DDD5D06D4CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_QualifiedPlanMember" xlink:label="loc_us-gaap_QualifiedPlanMember_FDA0A7D67149851DB6CB7DDD5D06B3A7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTaxStatusDomain_49CFC114BC3DDED41A487DDD5D06D4CE" xlink:to="loc_us-gaap_QualifiedPlanMember_FDA0A7D67149851DB6CB7DDD5D06B3A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsegmentsAxis" xlink:label="loc_us-gaap_SubsegmentsAxis_FB9E55F6F3449132336E7DDD5D0689CA" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_9631D0D57299A46AF5D47DDD5D04A73E" xlink:to="loc_us-gaap_SubsegmentsAxis_FB9E55F6F3449132336E7DDD5D0689CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsegmentsDomain" xlink:label="loc_us-gaap_SubsegmentsDomain_DDD398F1D891F48B15A27DDD5D06C2A7_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsegmentsAxis_FB9E55F6F3449132336E7DDD5D0689CA" xlink:to="loc_us-gaap_SubsegmentsDomain_DDD398F1D891F48B15A27DDD5D06C2A7_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsegmentsDomain" xlink:label="loc_us-gaap_SubsegmentsDomain_DDD398F1D891F48B15A27DDD5D06C2A7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsegmentsAxis_FB9E55F6F3449132336E7DDD5D0689CA" xlink:to="loc_us-gaap_SubsegmentsDomain_DDD398F1D891F48B15A27DDD5D06C2A7" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_WorldwideResearchandDevelopmentandGlobalProductDevelopmentMember" xlink:label="loc_pfe_WorldwideResearchandDevelopmentandGlobalProductDevelopmentMember_E5DD8003D74855C6FB1F7DDD5D0757E7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_DDD398F1D891F48B15A27DDD5D06C2A7" xlink:to="loc_pfe_WorldwideResearchandDevelopmentandGlobalProductDevelopmentMember_E5DD8003D74855C6FB1F7DDD5D0757E7" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_ManufacturingOperationsMember" xlink:label="loc_pfe_ManufacturingOperationsMember_DF0BEAD0C01492941C0D7DDD5D07014E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_DDD398F1D891F48B15A27DDD5D06C2A7" xlink:to="loc_pfe_ManufacturingOperationsMember_DF0BEAD0C01492941C0D7DDD5D07014E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_AD28D44D9FC7E7F50AAA7DDD5D07B259" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_9631D0D57299A46AF5D47DDD5D04A73E" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_AD28D44D9FC7E7F50AAA7DDD5D07B259" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_897520F535ECD42276957DDD5D0797EE_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_AD28D44D9FC7E7F50AAA7DDD5D07B259" xlink:to="loc_us-gaap_SegmentDomain_897520F535ECD42276957DDD5D0797EE_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_897520F535ECD42276957DDD5D0797EE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_AD28D44D9FC7E7F50AAA7DDD5D07B259" xlink:to="loc_us-gaap_SegmentDomain_897520F535ECD42276957DDD5D0797EE" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_InnovativeHealthSegmentMember" xlink:label="loc_pfe_InnovativeHealthSegmentMember_53A8158B44B09E6874737DDD5D075FD6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_897520F535ECD42276957DDD5D0797EE" xlink:to="loc_pfe_InnovativeHealthSegmentMember_53A8158B44B09E6874737DDD5D075FD6" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_EssentialHealthSegmentMember" xlink:label="loc_pfe_EssentialHealthSegmentMember_91E48AAB9A7C4DBBFA847DDD5D0708A3" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_897520F535ECD42276957DDD5D0797EE" xlink:to="loc_pfe_EssentialHealthSegmentMember_91E48AAB9A7C4DBBFA847DDD5D0708A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidationItemsAxis" xlink:label="loc_us-gaap_ConsolidationItemsAxis_5AF6EC0A09A04FB26A217DDD5D07EC87" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_9631D0D57299A46AF5D47DDD5D04A73E" xlink:to="loc_us-gaap_ConsolidationItemsAxis_5AF6EC0A09A04FB26A217DDD5D07EC87" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidationItemsDomain" xlink:label="loc_us-gaap_ConsolidationItemsDomain_E36FDA73467B4909EA377DDD5D08ECB8_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConsolidationItemsAxis_5AF6EC0A09A04FB26A217DDD5D07EC87" xlink:to="loc_us-gaap_ConsolidationItemsDomain_E36FDA73467B4909EA377DDD5D08ECB8_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidationItemsDomain" xlink:label="loc_us-gaap_ConsolidationItemsDomain_E36FDA73467B4909EA377DDD5D08ECB8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConsolidationItemsAxis_5AF6EC0A09A04FB26A217DDD5D07EC87" xlink:to="loc_us-gaap_ConsolidationItemsDomain_E36FDA73467B4909EA377DDD5D08ECB8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingSegmentsMember" xlink:label="loc_us-gaap_OperatingSegmentsMember_646F29094B0140E8AA267DDD5D084D3C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConsolidationItemsDomain_E36FDA73467B4909EA377DDD5D08ECB8" xlink:to="loc_us-gaap_OperatingSegmentsMember_646F29094B0140E8AA267DDD5D084D3C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaterialReconcilingItemsMember" xlink:label="loc_us-gaap_MaterialReconcilingItemsMember_5859EB1FE839235DD5B17DDD5D0841EB" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConsolidationItemsDomain_E36FDA73467B4909EA377DDD5D08ECB8" xlink:to="loc_us-gaap_MaterialReconcilingItemsMember_5859EB1FE839235DD5B17DDD5D0841EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CorporateNonSegmentMember" xlink:label="loc_us-gaap_CorporateNonSegmentMember_22E904595CD76FBE96F67DDD5D083A2B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConsolidationItemsDomain_E36FDA73467B4909EA377DDD5D08ECB8" xlink:to="loc_us-gaap_CorporateNonSegmentMember_22E904595CD76FBE96F67DDD5D083A2B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_AAABDCC8BBF7FDB61BBF7DDD5D0833EB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_29D2347E7D0BC5E811C47DDD5D08AB9B" xlink:to="loc_us-gaap_RestructuringCharges_AAABDCC8BBF7FDB61BBF7DDD5D0833EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_D148E70718E29B8A361F7DDD5D0D484F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_29D2347E7D0BC5E811C47DDD5D08AB9B" xlink:to="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_D148E70718E29B8A361F7DDD5D0D484F" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesRestructuringAccrualsDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_EAAC2EE9C6A02C55A0194A426E1E3ECC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_6173B35D92A51E8ED0E64A426E1BAB28" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_EAAC2EE9C6A02C55A0194A426E1E3ECC" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_6173B35D92A51E8ED0E64A426E1BAB28" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_37CFB68F5D37CD88C20F4A426E1B8FF5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_6173B35D92A51E8ED0E64A426E1BAB28" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_37CFB68F5D37CD88C20F4A426E1B8FF5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_F73A814D2C04B260E1844A426E1C15EF_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_37CFB68F5D37CD88C20F4A426E1B8FF5" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_F73A814D2C04B260E1844A426E1C15EF_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_F73A814D2C04B260E1844A426E1C15EF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_37CFB68F5D37CD88C20F4A426E1B8FF5" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_F73A814D2C04B260E1844A426E1C15EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeSeveranceMember" xlink:label="loc_us-gaap_EmployeeSeveranceMember_CC5D64EB666B8B8ECD1B4A426E1D70DA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_F73A814D2C04B260E1844A426E1C15EF" xlink:to="loc_us-gaap_EmployeeSeveranceMember_CC5D64EB666B8B8ECD1B4A426E1D70DA" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_AssetImpairmentsMember" xlink:label="loc_pfe_AssetImpairmentsMember_4746D4CFC20870F6680F4A426E1D96E1" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_F73A814D2C04B260E1844A426E1C15EF" xlink:to="loc_pfe_AssetImpairmentsMember_4746D4CFC20870F6680F4A426E1D96E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherRestructuringMember" xlink:label="loc_us-gaap_OtherRestructuringMember_7118E1EA81FC2AAE30A44A426E1D2633" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_F73A814D2C04B260E1844A426E1C15EF" xlink:to="loc_us-gaap_OtherRestructuringMember_7118E1EA81FC2AAE30A44A426E1D2633" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringReserveRollForward" xlink:label="loc_us-gaap_RestructuringReserveRollForward_898A147C082D5F653B734A426E1EB103" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_EAAC2EE9C6A02C55A0194A426E1E3ECC" xlink:to="loc_us-gaap_RestructuringReserveRollForward_898A147C082D5F653B734A426E1EB103" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringReserve" xlink:label="loc_us-gaap_RestructuringReserve_E68FA26099F7BAB5A4D34A426E1E457A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_898A147C082D5F653B734A426E1EB103" xlink:to="loc_us-gaap_RestructuringReserve_E68FA26099F7BAB5A4D34A426E1E457A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_3E36A5FC78680B9C5E874A426E1E2886" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_898A147C082D5F653B734A426E1EB103" xlink:to="loc_us-gaap_RestructuringCharges_3E36A5FC78680B9C5E874A426E1E2886" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment" xlink:label="loc_pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment_97C105F1B08E1E964AEB4A426E1FBF98" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_898A147C082D5F653B734A426E1EB103" xlink:to="loc_pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment_97C105F1B08E1E964AEB4A426E1FBF98" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesRestructuringAccrualsFootnotesDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_679FD60BC0485791AEA222D56A33AEB6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_D46A5BADDBD85DF59713C3158C7F47C4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_679FD60BC0485791AEA222D56A33AEB6" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_D46A5BADDBD85DF59713C3158C7F47C4" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_21BBB950A1875DC6A16C489D1109346B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_D46A5BADDBD85DF59713C3158C7F47C4" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_21BBB950A1875DC6A16C489D1109346B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_F1EFDE05133ED3D36599AE9F92DFFB4E_0B82B7E4F07153C98FA18A29315D4D23" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_21BBB950A1875DC6A16C489D1109346B" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_F1EFDE05133ED3D36599AE9F92DFFB4E_0B82B7E4F07153C98FA18A29315D4D23" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_C02975828E5B59F89DA02A2D8BA8D641" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_21BBB950A1875DC6A16C489D1109346B" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_C02975828E5B59F89DA02A2D8BA8D641" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_5C99509F109D5675AD0F1CE11172838F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_C02975828E5B59F89DA02A2D8BA8D641" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_5C99509F109D5675AD0F1CE11172838F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_DB9A9F85B2AD5CEE908FF0D336AD1C75" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_C02975828E5B59F89DA02A2D8BA8D641" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_DB9A9F85B2AD5CEE908FF0D336AD1C75" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringReserve" xlink:label="loc_us-gaap_RestructuringReserve_605DA31464FA56E0ABE89E8904FE141A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_679FD60BC0485791AEA222D56A33AEB6" xlink:to="loc_us-gaap_RestructuringReserve_605DA31464FA56E0ABE89E8904FE141A" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformation" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_5A3ECCB2C41EEF923E9C837D95F7CB13" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_4550F6E1C8A918855DDE837D95F523C0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_5A3ECCB2C41EEF923E9C837D95F7CB13" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_4550F6E1C8A918855DDE837D95F523C0" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_886D4B59B55BCC45D756837D95F68E61" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_4550F6E1C8A918855DDE837D95F523C0" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_886D4B59B55BCC45D756837D95F68E61" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_62C6471C4A5759B51990837D95F67BA8_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_886D4B59B55BCC45D756837D95F68E61" xlink:to="loc_us-gaap_SegmentDomain_62C6471C4A5759B51990837D95F67BA8_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_62C6471C4A5759B51990837D95F67BA8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_886D4B59B55BCC45D756837D95F68E61" xlink:to="loc_us-gaap_SegmentDomain_62C6471C4A5759B51990837D95F67BA8" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_InnovativeHealthSegmentMember" xlink:label="loc_pfe_InnovativeHealthSegmentMember_C42732A02B36568BC558837D95F6A34A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_62C6471C4A5759B51990837D95F67BA8" xlink:to="loc_pfe_InnovativeHealthSegmentMember_C42732A02B36568BC558837D95F6A34A" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_EssentialHealthSegmentMember" xlink:label="loc_pfe_EssentialHealthSegmentMember_ED9A7CDFCD7C9D6F7B05837D95F613D2" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_62C6471C4A5759B51990837D95F67BA8" xlink:to="loc_pfe_EssentialHealthSegmentMember_ED9A7CDFCD7C9D6F7B05837D95F613D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidationItemsAxis" xlink:label="loc_us-gaap_ConsolidationItemsAxis_612C7C13611324BEE095837D95F6133E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_4550F6E1C8A918855DDE837D95F523C0" xlink:to="loc_us-gaap_ConsolidationItemsAxis_612C7C13611324BEE095837D95F6133E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidationItemsDomain" xlink:label="loc_us-gaap_ConsolidationItemsDomain_12E75D91DB4CCEADC82F837D95F6E816_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConsolidationItemsAxis_612C7C13611324BEE095837D95F6133E" xlink:to="loc_us-gaap_ConsolidationItemsDomain_12E75D91DB4CCEADC82F837D95F6E816_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidationItemsDomain" xlink:label="loc_us-gaap_ConsolidationItemsDomain_12E75D91DB4CCEADC82F837D95F6E816" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConsolidationItemsAxis_612C7C13611324BEE095837D95F6133E" xlink:to="loc_us-gaap_ConsolidationItemsDomain_12E75D91DB4CCEADC82F837D95F6E816" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingSegmentsMember" xlink:label="loc_us-gaap_OperatingSegmentsMember_6A139F9D81CB1435078D837D95F6EC82" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConsolidationItemsDomain_12E75D91DB4CCEADC82F837D95F6E816" xlink:to="loc_us-gaap_OperatingSegmentsMember_6A139F9D81CB1435078D837D95F6EC82" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaterialReconcilingItemsMember" xlink:label="loc_us-gaap_MaterialReconcilingItemsMember_2680F3EFCF884E206E70837D95F6E505" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConsolidationItemsDomain_12E75D91DB4CCEADC82F837D95F6E816" xlink:to="loc_us-gaap_MaterialReconcilingItemsMember_2680F3EFCF884E206E70837D95F6E505" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CorporateNonSegmentMember" xlink:label="loc_us-gaap_CorporateNonSegmentMember_A3ECBA604D59C5B1FE3E837D95F7F373" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConsolidationItemsDomain_12E75D91DB4CCEADC82F837D95F6E816" xlink:to="loc_us-gaap_CorporateNonSegmentMember_A3ECBA604D59C5B1FE3E837D95F7F373" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_OtherSegmentReconcilingItemsAxis" xlink:label="loc_pfe_OtherSegmentReconcilingItemsAxis_6C866FB4E2F69A665454837D95F7FA37" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_4550F6E1C8A918855DDE837D95F523C0" xlink:to="loc_pfe_OtherSegmentReconcilingItemsAxis_6C866FB4E2F69A665454837D95F7FA37" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_OtherSegmentReconcilingItemsDomain" xlink:label="loc_pfe_OtherSegmentReconcilingItemsDomain_245781E5DB152A52AB7B837D95F7728D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_pfe_OtherSegmentReconcilingItemsAxis_6C866FB4E2F69A665454837D95F7FA37" xlink:to="loc_pfe_OtherSegmentReconcilingItemsDomain_245781E5DB152A52AB7B837D95F7728D_default" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_OtherSegmentReconcilingItemsDomain" xlink:label="loc_pfe_OtherSegmentReconcilingItemsDomain_245781E5DB152A52AB7B837D95F7728D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_pfe_OtherSegmentReconcilingItemsAxis_6C866FB4E2F69A665454837D95F7FA37" xlink:to="loc_pfe_OtherSegmentReconcilingItemsDomain_245781E5DB152A52AB7B837D95F7728D" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_PurchaseAccountingAdjustmentsMember" xlink:label="loc_pfe_PurchaseAccountingAdjustmentsMember_D47244C480BA4A0D3040837D95F71919" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_OtherSegmentReconcilingItemsDomain_245781E5DB152A52AB7B837D95F7728D" xlink:to="loc_pfe_PurchaseAccountingAdjustmentsMember_D47244C480BA4A0D3040837D95F71919" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_BusinessCombinationsAcquisitionRelatedCostsMember" xlink:label="loc_pfe_BusinessCombinationsAcquisitionRelatedCostsMember_F90D5E8B2CDBC159B5A4837D95F74CB2" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_OtherSegmentReconcilingItemsDomain_245781E5DB152A52AB7B837D95F7728D" xlink:to="loc_pfe_BusinessCombinationsAcquisitionRelatedCostsMember_F90D5E8B2CDBC159B5A4837D95F74CB2" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_CertainSignificantItemsMember" xlink:label="loc_pfe_CertainSignificantItemsMember_223422F094598AFBD2F2837D95F71B0C" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_OtherSegmentReconcilingItemsDomain_245781E5DB152A52AB7B837D95F7728D" xlink:to="loc_pfe_CertainSignificantItemsMember_223422F094598AFBD2F2837D95F71B0C" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_OtherUnallocatedMember" xlink:label="loc_pfe_OtherUnallocatedMember_A02E22599C4F7ACA4BD5837D95F7C9EF" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_OtherSegmentReconcilingItemsDomain_245781E5DB152A52AB7B837D95F7728D" xlink:to="loc_pfe_OtherUnallocatedMember_A02E22599C4F7ACA4BD5837D95F7C9EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_AB51C9E3A6FE440106EF837D95F7B820" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_5A3ECCB2C41EEF923E9C837D95F7CB13" xlink:to="loc_us-gaap_SalesRevenueGoodsNet_AB51C9E3A6FE440106EF837D95F7B820" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_AC3251273AE8953EDCA0837D95F7F0F3" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_5A3ECCB2C41EEF923E9C837D95F7CB13" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_AC3251273AE8953EDCA0837D95F7F0F3" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationFootnotesDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_5039E8C561C92273647791EBDDA35D1B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_F6982A4AE60A4DDED4C591EBDD9E3B81" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_5039E8C561C92273647791EBDDA35D1B" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_F6982A4AE60A4DDED4C591EBDD9E3B81" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsegmentsAxis" xlink:label="loc_us-gaap_SubsegmentsAxis_D06344289680A49104F591EBDD9E3610" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_F6982A4AE60A4DDED4C591EBDD9E3B81" xlink:to="loc_us-gaap_SubsegmentsAxis_D06344289680A49104F591EBDD9E3610" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsegmentsDomain" xlink:label="loc_us-gaap_SubsegmentsDomain_C7D9F5C70F3534A7F33D91EBDD9EB1BE_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsegmentsAxis_D06344289680A49104F591EBDD9E3610" xlink:to="loc_us-gaap_SubsegmentsDomain_C7D9F5C70F3534A7F33D91EBDD9EB1BE_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsegmentsDomain" xlink:label="loc_us-gaap_SubsegmentsDomain_C7D9F5C70F3534A7F33D91EBDD9EB1BE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsegmentsAxis_D06344289680A49104F591EBDD9E3610" xlink:to="loc_us-gaap_SubsegmentsDomain_C7D9F5C70F3534A7F33D91EBDD9EB1BE" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_PfizersWorldwideResearchandDevelopmentandPfizersGlobalProductDevelopmentMember" xlink:label="loc_pfe_PfizersWorldwideResearchandDevelopmentandPfizersGlobalProductDevelopmentMember_C595D4B4BC0C1691148591EBDD9EEF58" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_C7D9F5C70F3534A7F33D91EBDD9EB1BE" xlink:to="loc_pfe_PfizersWorldwideResearchandDevelopmentandPfizersGlobalProductDevelopmentMember_C595D4B4BC0C1691148591EBDD9EEF58" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_5455568EDB91E9961B6B91EBDD9F4714" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_F6982A4AE60A4DDED4C591EBDD9E3B81" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_5455568EDB91E9961B6B91EBDD9F4714" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvesteeNameDomain" xlink:label="loc_us-gaap_EquityMethodInvesteeNameDomain_C1AFB2B7F868416D5EBB91EBDD9FF18C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_5455568EDB91E9961B6B91EBDD9F4714" xlink:to="loc_us-gaap_EquityMethodInvesteeNameDomain_C1AFB2B7F868416D5EBB91EBDD9FF18C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvesteeNameDomain" xlink:label="loc_us-gaap_EquityMethodInvesteeNameDomain_C1AFB2B7F868416D5EBB91EBDD9FF18C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_5455568EDB91E9961B6B91EBDD9F4714" xlink:to="loc_us-gaap_EquityMethodInvesteeNameDomain_C1AFB2B7F868416D5EBB91EBDD9FF18C" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_ViivHealthcareLimitedMember" xlink:label="loc_pfe_ViivHealthcareLimitedMember_E37E02CE0382405082AC91EBDD9FE67D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityMethodInvesteeNameDomain_C1AFB2B7F868416D5EBB91EBDD9FF18C" xlink:to="loc_pfe_ViivHealthcareLimitedMember_E37E02CE0382405082AC91EBDD9FE67D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_28B101B8259E953AECA091EBDD9FAB7D" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_F6982A4AE60A4DDED4C591EBDD9E3B81" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_28B101B8259E953AECA091EBDD9FAB7D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_B55B978517F83577CEA791EBDDA04985_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_28B101B8259E953AECA091EBDD9FAB7D" xlink:to="loc_us-gaap_SegmentDomain_B55B978517F83577CEA791EBDDA04985_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_B55B978517F83577CEA791EBDDA04985" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_28B101B8259E953AECA091EBDD9FAB7D" xlink:to="loc_us-gaap_SegmentDomain_B55B978517F83577CEA791EBDDA04985" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_InnovativeHealthSegmentMember" xlink:label="loc_pfe_InnovativeHealthSegmentMember_06927BE4F9C7AE1E9DE091EBDDA07CC7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_B55B978517F83577CEA791EBDDA04985" xlink:to="loc_pfe_InnovativeHealthSegmentMember_06927BE4F9C7AE1E9DE091EBDDA07CC7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_1B3F3634C9A44B9A323091EBDDA12723" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_F6982A4AE60A4DDED4C591EBDD9E3B81" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_1B3F3634C9A44B9A323091EBDDA12723" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_CECA39F4B7252C4CEE6891EBDDA1005B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_1B3F3634C9A44B9A323091EBDDA12723" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_CECA39F4B7252C4CEE6891EBDDA1005B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_CECA39F4B7252C4CEE6891EBDDA1005B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_1B3F3634C9A44B9A323091EBDDA12723" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_CECA39F4B7252C4CEE6891EBDDA1005B" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_HISMember" xlink:label="loc_pfe_HISMember_B97836FCABDF92599D8891EBDDA107C5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_CECA39F4B7252C4CEE6891EBDDA1005B" xlink:to="loc_pfe_HISMember_B97836FCABDF92599D8891EBDDA107C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_D5B7DEC46D51FF71DB5891EBDDA15C23" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_F6982A4AE60A4DDED4C591EBDD9E3B81" xlink:to="loc_us-gaap_StatementScenarioAxis_D5B7DEC46D51FF71DB5891EBDDA15C23" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_019378D76254E2B8B72C91EBDDA10BDF_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementScenarioAxis_D5B7DEC46D51FF71DB5891EBDDA15C23" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_019378D76254E2B8B72C91EBDDA10BDF_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_019378D76254E2B8B72C91EBDDA10BDF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementScenarioAxis_D5B7DEC46D51FF71DB5891EBDDA15C23" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_019378D76254E2B8B72C91EBDDA10BDF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioAdjustmentMember" xlink:label="loc_us-gaap_ScenarioAdjustmentMember_6ABA85151FAF9BDCCEA091EBDDA223D8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_019378D76254E2B8B72C91EBDDA10BDF" xlink:to="loc_us-gaap_ScenarioAdjustmentMember_6ABA85151FAF9BDCCEA091EBDDA223D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidationItemsAxis" xlink:label="loc_us-gaap_ConsolidationItemsAxis_240CDD347BA5F62A33C591EBDDA2B0A7" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_F6982A4AE60A4DDED4C591EBDD9E3B81" xlink:to="loc_us-gaap_ConsolidationItemsAxis_240CDD347BA5F62A33C591EBDDA2B0A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidationItemsDomain" xlink:label="loc_us-gaap_ConsolidationItemsDomain_832455364EDCED859E9291EBDDA27C02_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConsolidationItemsAxis_240CDD347BA5F62A33C591EBDDA2B0A7" xlink:to="loc_us-gaap_ConsolidationItemsDomain_832455364EDCED859E9291EBDDA27C02_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidationItemsDomain" xlink:label="loc_us-gaap_ConsolidationItemsDomain_832455364EDCED859E9291EBDDA27C02" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConsolidationItemsAxis_240CDD347BA5F62A33C591EBDDA2B0A7" xlink:to="loc_us-gaap_ConsolidationItemsDomain_832455364EDCED859E9291EBDDA27C02" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingSegmentsMember" xlink:label="loc_us-gaap_OperatingSegmentsMember_044FCB88726B484EB45491EBDDA20CA5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConsolidationItemsDomain_832455364EDCED859E9291EBDDA27C02" xlink:to="loc_us-gaap_OperatingSegmentsMember_044FCB88726B484EB45491EBDDA20CA5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CorporateNonSegmentMember" xlink:label="loc_us-gaap_CorporateNonSegmentMember_F7C7A79B33BAC7C5763A91EBDDA256DB" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConsolidationItemsDomain_832455364EDCED859E9291EBDDA27C02" xlink:to="loc_us-gaap_CorporateNonSegmentMember_F7C7A79B33BAC7C5763A91EBDDA256DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaterialReconcilingItemsMember" xlink:label="loc_us-gaap_MaterialReconcilingItemsMember_AD847E0385208CB7739D91EBDDA34D41" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConsolidationItemsDomain_832455364EDCED859E9291EBDDA27C02" xlink:to="loc_us-gaap_MaterialReconcilingItemsMember_AD847E0385208CB7739D91EBDDA34D41" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentIncomeDividend" xlink:label="loc_us-gaap_InvestmentIncomeDividend_9FFFCC883FE3F097D6CE91EBDDA318D9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_5039E8C561C92273647791EBDDA35D1B" xlink:to="loc_us-gaap_InvestmentIncomeDividend_9FFFCC883FE3F097D6CE91EBDDA318D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses_1E348DABEC76A044BEBB91EBDDA35AAC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_5039E8C561C92273647791EBDDA35D1B" xlink:to="loc_us-gaap_CostsAndExpenses_1E348DABEC76A044BEBB91EBDDA35AAC" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_RestructuringChargesandImplementationCosts" xlink:label="loc_pfe_RestructuringChargesandImplementationCosts_CC3D003862CD9B3F1BCE91EBDDA33A69" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_5039E8C561C92273647791EBDDA35D1B" xlink:to="loc_pfe_RestructuringChargesandImplementationCosts_CC3D003862CD9B3F1BCE91EBDDA33A69" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_668FBA7D1C8EAC04002991EBDDA34616" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_5039E8C561C92273647791EBDDA35D1B" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_668FBA7D1C8EAC04002991EBDDA34616" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_BusinessInfrastructureAlignmentCosts" xlink:label="loc_pfe_BusinessInfrastructureAlignmentCosts_0F9B5246D7B3D5A0F4B091EBDDA4D1A9" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_5039E8C561C92273647791EBDDA35D1B" xlink:to="loc_pfe_BusinessInfrastructureAlignmentCosts_0F9B5246D7B3D5A0F4B091EBDDA4D1A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_E4C2B282ACC4A9D1217491EBDDA445A1" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_5039E8C561C92273647791EBDDA35D1B" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_E4C2B282ACC4A9D1217491EBDDA445A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_BF1C5CD6553202146F4A91EBDDA49EB6" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_5039E8C561C92273647791EBDDA35D1B" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_BF1C5CD6553202146F4A91EBDDA49EB6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges_836B26AEF0B0CCA6EF1191EBDDA43345" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_5039E8C561C92273647791EBDDA35D1B" xlink:to="loc_us-gaap_AssetImpairmentCharges_836B26AEF0B0CCA6EF1191EBDDA43345" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationNarrativeDetail" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByGeographicAreaDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_4F7730562B05905E74767E0DD699C891" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_F04B81BB400E0D16DE967E0DD6982159" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_4F7730562B05905E74767E0DD699C891" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_F04B81BB400E0D16DE967E0DD6982159" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis_633581BD1BE27FC896037E0DD698F80C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_F04B81BB400E0D16DE967E0DD6982159" xlink:to="loc_us-gaap_StatementGeographicalAxis_633581BD1BE27FC896037E0DD698F80C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_781204E11D09B517B79F7E0DD699C22A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementGeographicalAxis_633581BD1BE27FC896037E0DD698F80C" xlink:to="loc_us-gaap_SegmentGeographicalDomain_781204E11D09B517B79F7E0DD699C22A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_781204E11D09B517B79F7E0DD699C22A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementGeographicalAxis_633581BD1BE27FC896037E0DD698F80C" xlink:to="loc_us-gaap_SegmentGeographicalDomain_781204E11D09B517B79F7E0DD699C22A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_D2D57405C9D8C1D0201B7E0DD6992523" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentGeographicalDomain_781204E11D09B517B79F7E0DD699C22A" xlink:to="loc_country_US_D2D57405C9D8C1D0201B7E0DD6992523" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_DevelopedEuropeMember" xlink:label="loc_pfe_DevelopedEuropeMember_2CFA9C32F71E493EE6807E0DD6990842" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentGeographicalDomain_781204E11D09B517B79F7E0DD699C22A" xlink:to="loc_pfe_DevelopedEuropeMember_2CFA9C32F71E493EE6807E0DD6990842" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_DevelopedRestOfWorldMember" xlink:label="loc_pfe_DevelopedRestOfWorldMember_D3AEC74BFE02BBEE1BB87E0DD69942F4" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentGeographicalDomain_781204E11D09B517B79F7E0DD699C22A" xlink:to="loc_pfe_DevelopedRestOfWorldMember_D3AEC74BFE02BBEE1BB87E0DD69942F4" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_EmergingMarketsMember" xlink:label="loc_pfe_EmergingMarketsMember_BFEC4AFDB9DD7DD602B27E0DD6994010" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentGeographicalDomain_781204E11D09B517B79F7E0DD699C22A" xlink:to="loc_pfe_EmergingMarketsMember_BFEC4AFDB9DD7DD602B27E0DD6994010" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_9B9B5BD7E9DF0C5B81697E0DD6999DFF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_4F7730562B05905E74767E0DD699C891" xlink:to="loc_us-gaap_SalesRevenueGoodsNet_9B9B5BD7E9DF0C5B81697E0DD6999DFF" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_PercentageChangeInRevenue" xlink:label="loc_pfe_PercentageChangeInRevenue_BBBEFD3949BB55481CA37E0DD6999C0D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_4F7730562B05905E74767E0DD699C891" xlink:to="loc_pfe_PercentageChangeInRevenue_BBBEFD3949BB55481CA37E0DD6999C0D" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByGeographicAreaFootnotesDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_579FFA2F08D0C4CD4E86837D970E6205" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_CF00AF0396992AAEADBE837D970D72EE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_579FFA2F08D0C4CD4E86837D970E6205" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_CF00AF0396992AAEADBE837D970D72EE" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CurrencyAxis" xlink:label="loc_us-gaap_CurrencyAxis_59DFEB074CB136288389837D970D8D06" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_CF00AF0396992AAEADBE837D970D72EE" xlink:to="loc_us-gaap_CurrencyAxis_59DFEB074CB136288389837D970D8D06" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_687EBC63D5D8A6D0D262837D970D2E56_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CurrencyAxis_59DFEB074CB136288389837D970D8D06" xlink:to="loc_currency_AllCurrenciesDomain_687EBC63D5D8A6D0D262837D970D2E56_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_687EBC63D5D8A6D0D262837D970D2E56" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CurrencyAxis_59DFEB074CB136288389837D970D8D06" xlink:to="loc_currency_AllCurrenciesDomain_687EBC63D5D8A6D0D262837D970D2E56" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_EUR" xlink:label="loc_currency_EUR_E0794DE1546099E7E15D837D970DC3A8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_687EBC63D5D8A6D0D262837D970D2E56" xlink:to="loc_currency_EUR_E0794DE1546099E7E15D837D970DC3A8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis_D9C8D74E23DCF9CF0A3D837D970E48D8" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_CF00AF0396992AAEADBE837D970D72EE" xlink:to="loc_us-gaap_StatementGeographicalAxis_D9C8D74E23DCF9CF0A3D837D970E48D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_CB7F983773C111D2736D837D970E0F4E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementGeographicalAxis_D9C8D74E23DCF9CF0A3D837D970E48D8" xlink:to="loc_us-gaap_SegmentGeographicalDomain_CB7F983773C111D2736D837D970E0F4E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_CB7F983773C111D2736D837D970E0F4E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementGeographicalAxis_D9C8D74E23DCF9CF0A3D837D970E48D8" xlink:to="loc_us-gaap_SegmentGeographicalDomain_CB7F983773C111D2736D837D970E0F4E" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_DevelopedEuropeMember" xlink:label="loc_pfe_DevelopedEuropeMember_6D0D472F6ABB78C450D9837D970E5D18" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentGeographicalDomain_CB7F983773C111D2736D837D970E0F4E" xlink:to="loc_pfe_DevelopedEuropeMember_6D0D472F6ABB78C450D9837D970E5D18" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_898997B91FC9F949B200837D970E8E87" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_579FFA2F08D0C4CD4E86837D970E6205" xlink:to="loc_us-gaap_SalesRevenueGoodsNet_898997B91FC9F949B200837D970E8E87" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_0F3D0AD13C53A00665E9837D97A16C10" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_E3EE6BE707967467633D837D979D4D7E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_0F3D0AD13C53A00665E9837D97A16C10" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_E3EE6BE707967467633D837D979D4D7E" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_InnovativeProductsCategoryAxis" xlink:label="loc_pfe_InnovativeProductsCategoryAxis_52FA49BA4DE59A8C4A57837D979D10F5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_E3EE6BE707967467633D837D979D4D7E" xlink:to="loc_pfe_InnovativeProductsCategoryAxis_52FA49BA4DE59A8C4A57837D979D10F5" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_InnovativeProductsCategoryDomain" xlink:label="loc_pfe_InnovativeProductsCategoryDomain_D0D0115D946D04174F3D837D979DA855_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_pfe_InnovativeProductsCategoryAxis_52FA49BA4DE59A8C4A57837D979D10F5" xlink:to="loc_pfe_InnovativeProductsCategoryDomain_D0D0115D946D04174F3D837D979DA855_default" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_InnovativeProductsCategoryDomain" xlink:label="loc_pfe_InnovativeProductsCategoryDomain_D0D0115D946D04174F3D837D979DA855" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_pfe_InnovativeProductsCategoryAxis_52FA49BA4DE59A8C4A57837D979D10F5" xlink:to="loc_pfe_InnovativeProductsCategoryDomain_D0D0115D946D04174F3D837D979DA855" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_InternalMedicineMember" xlink:label="loc_pfe_InternalMedicineMember_D6FB61B88B0F74866E5A837D979ED4CB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_InnovativeProductsCategoryDomain_D0D0115D946D04174F3D837D979DA855" xlink:to="loc_pfe_InternalMedicineMember_D6FB61B88B0F74866E5A837D979ED4CB" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_VaccinesMember" xlink:label="loc_pfe_VaccinesMember_34FDFBF768EF05945F11837D979EEB5E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_InnovativeProductsCategoryDomain_D0D0115D946D04174F3D837D979DA855" xlink:to="loc_pfe_VaccinesMember_34FDFBF768EF05945F11837D979EEB5E" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_OncologyMember" xlink:label="loc_pfe_OncologyMember_93FAF31B2880AAD022A5837D979E42D7" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_InnovativeProductsCategoryDomain_D0D0115D946D04174F3D837D979DA855" xlink:to="loc_pfe_OncologyMember_93FAF31B2880AAD022A5837D979E42D7" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_InflammationandImmunologyMember" xlink:label="loc_pfe_InflammationandImmunologyMember_9722DB42B891AC4D3D0D837D979EDA1D" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_InnovativeProductsCategoryDomain_D0D0115D946D04174F3D837D979DA855" xlink:to="loc_pfe_InflammationandImmunologyMember_9722DB42B891AC4D3D0D837D979EDA1D" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_RareDiseaseMember" xlink:label="loc_pfe_RareDiseaseMember_EA92F4BD3F3C4967A97F837D979E4462" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_InnovativeProductsCategoryDomain_D0D0115D946D04174F3D837D979DA855" xlink:to="loc_pfe_RareDiseaseMember_EA92F4BD3F3C4967A97F837D979E4462" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_ConsumerHealthcareMember" xlink:label="loc_pfe_ConsumerHealthcareMember_8CF5C28F6D005CD18348837D979EC785" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_InnovativeProductsCategoryDomain_D0D0115D946D04174F3D837D979DA855" xlink:to="loc_pfe_ConsumerHealthcareMember_8CF5C28F6D005CD18348837D979EC785" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_EssentialHealthProductCategoryAxis" xlink:label="loc_pfe_EssentialHealthProductCategoryAxis_99AAE0FF10784A8F437D837D979EF396" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_E3EE6BE707967467633D837D979D4D7E" xlink:to="loc_pfe_EssentialHealthProductCategoryAxis_99AAE0FF10784A8F437D837D979EF396" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_EssentialHealthProductCategoryDomain" xlink:label="loc_pfe_EssentialHealthProductCategoryDomain_5DCDEFF8A9AF1727C906837D979E0765_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_pfe_EssentialHealthProductCategoryAxis_99AAE0FF10784A8F437D837D979EF396" xlink:to="loc_pfe_EssentialHealthProductCategoryDomain_5DCDEFF8A9AF1727C906837D979E0765_default" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_EssentialHealthProductCategoryDomain" xlink:label="loc_pfe_EssentialHealthProductCategoryDomain_5DCDEFF8A9AF1727C906837D979E0765" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_pfe_EssentialHealthProductCategoryAxis_99AAE0FF10784A8F437D837D979EF396" xlink:to="loc_pfe_EssentialHealthProductCategoryDomain_5DCDEFF8A9AF1727C906837D979E0765" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_LegacyEstablishedProductsMember" xlink:label="loc_pfe_LegacyEstablishedProductsMember_1400758F8D6D372C6365837D979E5E20" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_EssentialHealthProductCategoryDomain_5DCDEFF8A9AF1727C906837D979E0765" xlink:to="loc_pfe_LegacyEstablishedProductsMember_1400758F8D6D372C6365837D979E5E20" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_SterileInjectablePharmaceuticalsMember" xlink:label="loc_pfe_SterileInjectablePharmaceuticalsMember_636802574FC93027119D837D979E4E91" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_EssentialHealthProductCategoryDomain_5DCDEFF8A9AF1727C906837D979E0765" xlink:to="loc_pfe_SterileInjectablePharmaceuticalsMember_636802574FC93027119D837D979E4E91" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_PeriLOEProductsMember" xlink:label="loc_pfe_PeriLOEProductsMember_3428E82FEB4C7931EA2E837D979E8954" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_EssentialHealthProductCategoryDomain_5DCDEFF8A9AF1727C906837D979E0765" xlink:to="loc_pfe_PeriLOEProductsMember_3428E82FEB4C7931EA2E837D979E8954" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_BiosimilarsMember" xlink:label="loc_pfe_BiosimilarsMember_678FD5D22799BD321F49837D979E1588" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_EssentialHealthProductCategoryDomain_5DCDEFF8A9AF1727C906837D979E0765" xlink:to="loc_pfe_BiosimilarsMember_678FD5D22799BD321F49837D979E1588" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_CentreOneMember" xlink:label="loc_pfe_CentreOneMember_9E3014BDCE242D46ED94837D979E250C" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_EssentialHealthProductCategoryDomain_5DCDEFF8A9AF1727C906837D979E0765" xlink:to="loc_pfe_CentreOneMember_9E3014BDCE242D46ED94837D979E250C" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_HospiraInfusionSystemsMember" xlink:label="loc_pfe_HospiraInfusionSystemsMember_A94B6464CE6C8A440DD7837D979EF1D8" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_EssentialHealthProductCategoryDomain_5DCDEFF8A9AF1727C906837D979E0765" xlink:to="loc_pfe_HospiraInfusionSystemsMember_A94B6464CE6C8A440DD7837D979EF1D8" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_DistinctBusinessAxis" xlink:label="loc_pfe_DistinctBusinessAxis_830BC2ACF2D8F49898E6837D979E7D04" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_E3EE6BE707967467633D837D979D4D7E" xlink:to="loc_pfe_DistinctBusinessAxis_830BC2ACF2D8F49898E6837D979E7D04" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_DistinctBusinessDomain" xlink:label="loc_pfe_DistinctBusinessDomain_3DCBFF55E5B51536689B837D979EC700_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_pfe_DistinctBusinessAxis_830BC2ACF2D8F49898E6837D979E7D04" xlink:to="loc_pfe_DistinctBusinessDomain_3DCBFF55E5B51536689B837D979EC700_default" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_DistinctBusinessDomain" xlink:label="loc_pfe_DistinctBusinessDomain_3DCBFF55E5B51536689B837D979EC700" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_pfe_DistinctBusinessAxis_830BC2ACF2D8F49898E6837D979E7D04" xlink:to="loc_pfe_DistinctBusinessDomain_3DCBFF55E5B51536689B837D979EC700" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_InnovativeHealthBusinessMember" xlink:label="loc_pfe_InnovativeHealthBusinessMember_AE5C91574ACFF5123399837D979E8268" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_DistinctBusinessDomain_3DCBFF55E5B51536689B837D979EC700" xlink:to="loc_pfe_InnovativeHealthBusinessMember_AE5C91574ACFF5123399837D979E8268" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_EssentialHealthBusinessMember" xlink:label="loc_pfe_EssentialHealthBusinessMember_D2EDB3E9B57286ECF857837D979EDD1B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_DistinctBusinessDomain_3DCBFF55E5B51536689B837D979EC700" xlink:to="loc_pfe_EssentialHealthBusinessMember_D2EDB3E9B57286ECF857837D979EDD1B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_87433A8CDAD0CFD3DE7B837D979E2C9D" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_E3EE6BE707967467633D837D979D4D7E" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_87433A8CDAD0CFD3DE7B837D979E2C9D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_F49C6E1162911A0B5024837D979F4B0D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_87433A8CDAD0CFD3DE7B837D979E2C9D" xlink:to="loc_us-gaap_SegmentDomain_F49C6E1162911A0B5024837D979F4B0D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_F49C6E1162911A0B5024837D979F4B0D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_87433A8CDAD0CFD3DE7B837D979E2C9D" xlink:to="loc_us-gaap_SegmentDomain_F49C6E1162911A0B5024837D979F4B0D" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_InnovativeHealthSegmentMember" xlink:label="loc_pfe_InnovativeHealthSegmentMember_4F844E53BFC21A3FBFA3837D979F5869" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_F49C6E1162911A0B5024837D979F4B0D" xlink:to="loc_pfe_InnovativeHealthSegmentMember_4F844E53BFC21A3FBFA3837D979F5869" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_EssentialHealthSegmentMember" xlink:label="loc_pfe_EssentialHealthSegmentMember_0FB0CFA49DA3789688F2837D979F84B0" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_F49C6E1162911A0B5024837D979F4B0D" xlink:to="loc_pfe_EssentialHealthSegmentMember_0FB0CFA49DA3789688F2837D979F84B0" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_InnovativeHealthandEssentialHealthMember" xlink:label="loc_pfe_InnovativeHealthandEssentialHealthMember_4625026C6F2577C06CB4837D979FB6C1" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_F49C6E1162911A0B5024837D979F4B0D" xlink:to="loc_pfe_InnovativeHealthandEssentialHealthMember_4625026C6F2577C06CB4837D979FB6C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_97AEAE1B21383D1AFD19837D979F9753" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_E3EE6BE707967467633D837D979D4D7E" xlink:to="loc_us-gaap_ProductOrServiceAxis_97AEAE1B21383D1AFD19837D979F9753" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_945515D087BA9E03A59B837D979FEC85_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ProductOrServiceAxis_97AEAE1B21383D1AFD19837D979F9753" xlink:to="loc_us-gaap_ProductsAndServicesDomain_945515D087BA9E03A59B837D979FEC85_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_945515D087BA9E03A59B837D979FEC85" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ProductOrServiceAxis_97AEAE1B21383D1AFD19837D979F9753" xlink:to="loc_us-gaap_ProductsAndServicesDomain_945515D087BA9E03A59B837D979FEC85" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_LyricaMember" xlink:label="loc_pfe_LyricaMember_3F80DA0DEEB015126090837D979F96FD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_945515D087BA9E03A59B837D979FEC85" xlink:to="loc_pfe_LyricaMember_3F80DA0DEEB015126090837D979F96FD" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_EliquisMember" xlink:label="loc_pfe_EliquisMember_C2D2CDB8DFE95A7C7EE0837D979F26E5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_945515D087BA9E03A59B837D979FEC85" xlink:to="loc_pfe_EliquisMember_C2D2CDB8DFE95A7C7EE0837D979F26E5" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_ChantixChampixMember" xlink:label="loc_pfe_ChantixChampixMember_76314B1F59C73D27CC7A837D979FEF43" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_945515D087BA9E03A59B837D979FEC85" xlink:to="loc_pfe_ChantixChampixMember_76314B1F59C73D27CC7A837D979FEF43" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_ViagraMember" xlink:label="loc_pfe_ViagraMember_80E53BBAC83FE9EFF2BB837D979F22A8" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_945515D087BA9E03A59B837D979FEC85" xlink:to="loc_pfe_ViagraMember_80E53BBAC83FE9EFF2BB837D979F22A8" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_BMP2Member" xlink:label="loc_pfe_BMP2Member_5C217DA55C12A1F0659E837D979FAA91" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_945515D087BA9E03A59B837D979FEC85" xlink:to="loc_pfe_BMP2Member_5C217DA55C12A1F0659E837D979FAA91" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_ToviazMember" xlink:label="loc_pfe_ToviazMember_94181AA5AA9B4F568C89837D979F2E7C" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_945515D087BA9E03A59B837D979FEC85" xlink:to="loc_pfe_ToviazMember_94181AA5AA9B4F568C89837D979F2E7C" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_AllOtherInternalMedicineMember" xlink:label="loc_pfe_AllOtherInternalMedicineMember_95ED1FE94C32163CB3FA837D979FB284" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_945515D087BA9E03A59B837D979FEC85" xlink:to="loc_pfe_AllOtherInternalMedicineMember_95ED1FE94C32163CB3FA837D979FB284" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_PrevnarPrevenarFamilyMember" xlink:label="loc_pfe_PrevnarPrevenarFamilyMember_A8707CF8A10065A53BBA837D979F3540" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_945515D087BA9E03A59B837D979FEC85" xlink:to="loc_pfe_PrevnarPrevenarFamilyMember_A8707CF8A10065A53BBA837D979F3540" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_FSMEIMMUNTicoVacMember" xlink:label="loc_pfe_FSMEIMMUNTicoVacMember_CCE4686B46E6F4D8433F837D979F96C8" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_945515D087BA9E03A59B837D979FEC85" xlink:to="loc_pfe_FSMEIMMUNTicoVacMember_CCE4686B46E6F4D8433F837D979F96C8" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_OtherVaccinesProductsMember" xlink:label="loc_pfe_OtherVaccinesProductsMember_365902889FCB939503D1837D979FFA35" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_945515D087BA9E03A59B837D979FEC85" xlink:to="loc_pfe_OtherVaccinesProductsMember_365902889FCB939503D1837D979FFA35" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_IbranceMember" xlink:label="loc_pfe_IbranceMember_D15486EA1C1C081FA981837D979FFE36" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_945515D087BA9E03A59B837D979FEC85" xlink:to="loc_pfe_IbranceMember_D15486EA1C1C081FA981837D979FFE36" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_SutentMember" xlink:label="loc_pfe_SutentMember_5A74E63E49E4A1937E86837D979F1679" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_945515D087BA9E03A59B837D979FEC85" xlink:to="loc_pfe_SutentMember_5A74E63E49E4A1937E86837D979F1679" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_XalkoriMember" xlink:label="loc_pfe_XalkoriMember_837266581BACED4AE126837D979F058B" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_945515D087BA9E03A59B837D979FEC85" xlink:to="loc_pfe_XalkoriMember_837266581BACED4AE126837D979F058B" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_XtandiAllianceMember" xlink:label="loc_pfe_XtandiAllianceMember_9A86FE90CC1B6E14008C837D979F6125" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_945515D087BA9E03A59B837D979FEC85" xlink:to="loc_pfe_XtandiAllianceMember_9A86FE90CC1B6E14008C837D979F6125" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_InlytaMember" xlink:label="loc_pfe_InlytaMember_54B81A946661C3B03897837D97A0045A" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_945515D087BA9E03A59B837D979FEC85" xlink:to="loc_pfe_InlytaMember_54B81A946661C3B03897837D97A0045A" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_BosulifMember" xlink:label="loc_pfe_BosulifMember_F7CFDA2A9F669B0C8426837D97A0AB36" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_945515D087BA9E03A59B837D979FEC85" xlink:to="loc_pfe_BosulifMember_F7CFDA2A9F669B0C8426837D97A0AB36" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_OtherOncologyProductsMember" xlink:label="loc_pfe_OtherOncologyProductsMember_C1AA8C32D33C1E4B220D837D97A0D8D0" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_945515D087BA9E03A59B837D979FEC85" xlink:to="loc_pfe_OtherOncologyProductsMember_C1AA8C32D33C1E4B220D837D97A0D8D0" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_EnbrelMember" xlink:label="loc_pfe_EnbrelMember_BCEEA70944AB1CAE1374837D97A0B06A" xlink:type="locator" />
    <link:definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_945515D087BA9E03A59B837D979FEC85" xlink:to="loc_pfe_EnbrelMember_BCEEA70944AB1CAE1374837D97A0B06A" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_XeljanzMember" xlink:label="loc_pfe_XeljanzMember_874B10609F58DB3CDFCF837D97A0E399" xlink:type="locator" />
    <link:definitionArc order="19" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_945515D087BA9E03A59B837D979FEC85" xlink:to="loc_pfe_XeljanzMember_874B10609F58DB3CDFCF837D97A0E399" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_EucrisaMember" xlink:label="loc_pfe_EucrisaMember_EE95A03D351953062449837D97A05B28" xlink:type="locator" />
    <link:definitionArc order="20" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_945515D087BA9E03A59B837D979FEC85" xlink:to="loc_pfe_EucrisaMember_EE95A03D351953062449837D97A05B28" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_AllOtherInflammationandImmunologyProductsMember" xlink:label="loc_pfe_AllOtherInflammationandImmunologyProductsMember_6A672BB7C274B8EF6913837D97A06AB2" xlink:type="locator" />
    <link:definitionArc order="21" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_945515D087BA9E03A59B837D979FEC85" xlink:to="loc_pfe_AllOtherInflammationandImmunologyProductsMember_6A672BB7C274B8EF6913837D97A06AB2" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_BeneFIXMember" xlink:label="loc_pfe_BeneFIXMember_E1B4E04FBF37C003B41A837D97A02E88" xlink:type="locator" />
    <link:definitionArc order="22" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_945515D087BA9E03A59B837D979FEC85" xlink:to="loc_pfe_BeneFIXMember_E1B4E04FBF37C003B41A837D97A02E88" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_ReFactoAfXynthaMember" xlink:label="loc_pfe_ReFactoAfXynthaMember_244A3A71BCF63ED47516837D97A0A8F1" xlink:type="locator" />
    <link:definitionArc order="23" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_945515D087BA9E03A59B837D979FEC85" xlink:to="loc_pfe_ReFactoAfXynthaMember_244A3A71BCF63ED47516837D97A0A8F1" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_GenotropinMember" xlink:label="loc_pfe_GenotropinMember_D94E0CCBA5F81F6A8F61837D97A07451" xlink:type="locator" />
    <link:definitionArc order="24" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_945515D087BA9E03A59B837D979FEC85" xlink:to="loc_pfe_GenotropinMember_D94E0CCBA5F81F6A8F61837D97A07451" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_SomavertMember" xlink:label="loc_pfe_SomavertMember_E951959359591F94F838837D97A03160" xlink:type="locator" />
    <link:definitionArc order="25" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_945515D087BA9E03A59B837D979FEC85" xlink:to="loc_pfe_SomavertMember_E951959359591F94F838837D97A03160" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_AllOtherRareDiseaseProductsMember" xlink:label="loc_pfe_AllOtherRareDiseaseProductsMember_E7A878EBE7353C6E9618837D97A0BB57" xlink:type="locator" />
    <link:definitionArc order="26" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_945515D087BA9E03A59B837D979FEC85" xlink:to="loc_pfe_AllOtherRareDiseaseProductsMember_E7A878EBE7353C6E9618837D97A0BB57" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_ConsumerHealthcareMember" xlink:label="loc_pfe_ConsumerHealthcareMember_2BB2EAC426FAC50BA3BE837D97A07E35" xlink:type="locator" />
    <link:definitionArc order="27" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_945515D087BA9E03A59B837D979FEC85" xlink:to="loc_pfe_ConsumerHealthcareMember_2BB2EAC426FAC50BA3BE837D97A07E35" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_LipitorMember" xlink:label="loc_pfe_LipitorMember_D8EE59AFB7A555241C09837D97A0B15B" xlink:type="locator" />
    <link:definitionArc order="28" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_945515D087BA9E03A59B837D979FEC85" xlink:to="loc_pfe_LipitorMember_D8EE59AFB7A555241C09837D97A0B15B" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_PremarinFamilyMember" xlink:label="loc_pfe_PremarinFamilyMember_40EDC1EE16377D9FFFF5837D97A061C5" xlink:type="locator" />
    <link:definitionArc order="29" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_945515D087BA9E03A59B837D979FEC85" xlink:to="loc_pfe_PremarinFamilyMember_40EDC1EE16377D9FFFF5837D97A061C5" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_NorvascMember" xlink:label="loc_pfe_NorvascMember_48FF3A77E5B788749795837D97A00113" xlink:type="locator" />
    <link:definitionArc order="30" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_945515D087BA9E03A59B837D979FEC85" xlink:to="loc_pfe_NorvascMember_48FF3A77E5B788749795837D97A00113" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_EpiPenMember" xlink:label="loc_pfe_EpiPenMember_F5484E79173EB98F61A6837D97A0D5AB" xlink:type="locator" />
    <link:definitionArc order="31" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_945515D087BA9E03A59B837D979FEC85" xlink:to="loc_pfe_EpiPenMember_F5484E79173EB98F61A6837D97A0D5AB" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_XalatanXalacomMember" xlink:label="loc_pfe_XalatanXalacomMember_9FAEFBA906BF2C1ED9EA837D97A08EC3" xlink:type="locator" />
    <link:definitionArc order="32" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_945515D087BA9E03A59B837D979FEC85" xlink:to="loc_pfe_XalatanXalacomMember_9FAEFBA906BF2C1ED9EA837D97A08EC3" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_EffexorMember" xlink:label="loc_pfe_EffexorMember_7F98611C4B69CDCD93CF837D97A03FD4" xlink:type="locator" />
    <link:definitionArc order="33" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_945515D087BA9E03A59B837D979FEC85" xlink:to="loc_pfe_EffexorMember_7F98611C4B69CDCD93CF837D97A03FD4" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_ZoloftMember" xlink:label="loc_pfe_ZoloftMember_C12E2871AAE7F73591F8837D97A0C951" xlink:type="locator" />
    <link:definitionArc order="34" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_945515D087BA9E03A59B837D979FEC85" xlink:to="loc_pfe_ZoloftMember_C12E2871AAE7F73591F8837D97A0C951" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_ZithromaxZmaxMember" xlink:label="loc_pfe_ZithromaxZmaxMember_DA58EE86AC212CACCBA8837D97A151CC" xlink:type="locator" />
    <link:definitionArc order="35" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_945515D087BA9E03A59B837D979FEC85" xlink:to="loc_pfe_ZithromaxZmaxMember_DA58EE86AC212CACCBA8837D97A151CC" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_RelpaxMember" xlink:label="loc_pfe_RelpaxMember_A6F54A09A1103ADEB812837D97A1B798" xlink:type="locator" />
    <link:definitionArc order="36" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_945515D087BA9E03A59B837D979FEC85" xlink:to="loc_pfe_RelpaxMember_A6F54A09A1103ADEB812837D97A1B798" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_XanaxXanaxXRMember" xlink:label="loc_pfe_XanaxXanaxXRMember_9E84C1A6482C6DF9244B837D97A16BDC" xlink:type="locator" />
    <link:definitionArc order="37" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_945515D087BA9E03A59B837D979FEC85" xlink:to="loc_pfe_XanaxXanaxXRMember_9E84C1A6482C6DF9244B837D97A16BDC" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_OtherLegacyEstablishedProductsMember" xlink:label="loc_pfe_OtherLegacyEstablishedProductsMember_9AAF444891F90574244F837D97A1C02D" xlink:type="locator" />
    <link:definitionArc order="38" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_945515D087BA9E03A59B837D979FEC85" xlink:to="loc_pfe_OtherLegacyEstablishedProductsMember_9AAF444891F90574244F837D97A1C02D" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_MedrolMember" xlink:label="loc_pfe_MedrolMember_5FFBA03F600BCC2B01EF837D97A196A7" xlink:type="locator" />
    <link:definitionArc order="39" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_945515D087BA9E03A59B837D979FEC85" xlink:to="loc_pfe_MedrolMember_5FFBA03F600BCC2B01EF837D97A196A7" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_SulperazonMember" xlink:label="loc_pfe_SulperazonMember_927E5CD5F2990CB86D18837D97A1289B" xlink:type="locator" />
    <link:definitionArc order="40" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_945515D087BA9E03A59B837D979FEC85" xlink:to="loc_pfe_SulperazonMember_927E5CD5F2990CB86D18837D97A1289B" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_FragminMember" xlink:label="loc_pfe_FragminMember_CB9632849D1DDFFB016C837D97A1F6D3" xlink:type="locator" />
    <link:definitionArc order="41" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_945515D087BA9E03A59B837D979FEC85" xlink:to="loc_pfe_FragminMember_CB9632849D1DDFFB016C837D97A1F6D3" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_TygacilMember" xlink:label="loc_pfe_TygacilMember_D0F5315005B6A9E10B12837D97A1AECC" xlink:type="locator" />
    <link:definitionArc order="42" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_945515D087BA9E03A59B837D979FEC85" xlink:to="loc_pfe_TygacilMember_D0F5315005B6A9E10B12837D97A1AECC" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_PrecedexMember" xlink:label="loc_pfe_PrecedexMember_AA105921ECAAE35E1F4D837D97A11113" xlink:type="locator" />
    <link:definitionArc order="43" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_945515D087BA9E03A59B837D979FEC85" xlink:to="loc_pfe_PrecedexMember_AA105921ECAAE35E1F4D837D97A11113" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_AllOtherSterileInjectablePharmaceuticalsMember" xlink:label="loc_pfe_AllOtherSterileInjectablePharmaceuticalsMember_C406531A02D06DC0ABBC837D97A10C4F" xlink:type="locator" />
    <link:definitionArc order="44" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_945515D087BA9E03A59B837D979FEC85" xlink:to="loc_pfe_AllOtherSterileInjectablePharmaceuticalsMember_C406531A02D06DC0ABBC837D97A10C4F" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_CelebrexMember" xlink:label="loc_pfe_CelebrexMember_C8F332A299C4CB789935837D97A16599" xlink:type="locator" />
    <link:definitionArc order="45" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_945515D087BA9E03A59B837D979FEC85" xlink:to="loc_pfe_CelebrexMember_C8F332A299C4CB789935837D97A16599" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_VfendMember" xlink:label="loc_pfe_VfendMember_C5F8951550C576722852837D97A1696A" xlink:type="locator" />
    <link:definitionArc order="46" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_945515D087BA9E03A59B837D979FEC85" xlink:to="loc_pfe_VfendMember_C5F8951550C576722852837D97A1696A" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_PristiqMember" xlink:label="loc_pfe_PristiqMember_F57EC818FA6316CFBA45837D97A1165F" xlink:type="locator" />
    <link:definitionArc order="47" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_945515D087BA9E03A59B837D979FEC85" xlink:to="loc_pfe_PristiqMember_F57EC818FA6316CFBA45837D97A1165F" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_ZyvoxMember" xlink:label="loc_pfe_ZyvoxMember_749DC17FB837B8D3C345837D97A149E4" xlink:type="locator" />
    <link:definitionArc order="48" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_945515D087BA9E03A59B837D979FEC85" xlink:to="loc_pfe_ZyvoxMember_749DC17FB837B8D3C345837D97A149E4" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_RevatioMember" xlink:label="loc_pfe_RevatioMember_524240D949B70F8352BB837D97A1E575" xlink:type="locator" />
    <link:definitionArc order="49" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_945515D087BA9E03A59B837D979FEC85" xlink:to="loc_pfe_RevatioMember_524240D949B70F8352BB837D97A1E575" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_AllOtherPeriLOEProductsMember" xlink:label="loc_pfe_AllOtherPeriLOEProductsMember_96D370902ACD5EA1C0DB837D97A1D5E0" xlink:type="locator" />
    <link:definitionArc order="50" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_945515D087BA9E03A59B837D979FEC85" xlink:to="loc_pfe_AllOtherPeriLOEProductsMember_96D370902ACD5EA1C0DB837D97A1D5E0" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_InflectraRemsimaMember" xlink:label="loc_pfe_InflectraRemsimaMember_2558284452DA5EF8F5F9837D97A12801" xlink:type="locator" />
    <link:definitionArc order="51" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_945515D087BA9E03A59B837D979FEC85" xlink:to="loc_pfe_InflectraRemsimaMember_2558284452DA5EF8F5F9837D97A12801" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_AllOtherBiosimilarsMember" xlink:label="loc_pfe_AllOtherBiosimilarsMember_71B9936599D0A87A381D837D97A1883B" xlink:type="locator" />
    <link:definitionArc order="52" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_945515D087BA9E03A59B837D979FEC85" xlink:to="loc_pfe_AllOtherBiosimilarsMember_71B9936599D0A87A381D837D97A1883B" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_AllianceBiopharmaceuticalsMember" xlink:label="loc_pfe_AllianceBiopharmaceuticalsMember_0E998CAF50744740BDAF837D97A1F40F" xlink:type="locator" />
    <link:definitionArc order="53" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_945515D087BA9E03A59B837D979FEC85" xlink:to="loc_pfe_AllianceBiopharmaceuticalsMember_0E998CAF50744740BDAF837D97A1F40F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_1A20D25CAA640CEC8E1D837D97A292CB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_0F3D0AD13C53A00665E9837D97A16C10" xlink:to="loc_us-gaap_SalesRevenueGoodsNet_1A20D25CAA640CEC8E1D837D97A292CB" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pfizer.com/role/TaxMatters" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pfizer.com/role/TaxMattersDetail" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pfizer.com/role/TaxMattersNarrativeDetail" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pfizer.com/role/TaxMattersTables" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>13
<FILENAME>pfe-20171001_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_5724A8DFEFEA254F48ADAE9F926B53E8_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_D22D602201A850188680FCCBA32DE848" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_D22D602201A850188680FCCBA32DE848" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_D22D602201A850188680FCCBA32DE848" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_D22D602201A850188680FCCBA32DE848" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_6F06A704B44B51596893AE9F926B8F1A_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_D43AFB0B2FA653B48D3396133C0817F6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Identifiable Intangible Assets and Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_6F06A704B44B51596893AE9F926B8F1A_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_D43AFB0B2FA653B48D3396133C0817F6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_D43AFB0B2FA653B48D3396133C0817F6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_D43AFB0B2FA653B48D3396133C0817F6" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_D43AFB0B2FA653B48D3396133C0817F6" xlink:type="arc" />
    <link:label id="lab_us-gaap_SegmentReportingAbstract_8A175570E1A337941BB1837D970D02E8_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract_8A175570E1A337941BB1837D970D02E8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_8A175570E1A337941BB1837D970D02E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract_8A175570E1A337941BB1837D970D02E8" xlink:to="lab_us-gaap_SegmentReportingAbstract_8A175570E1A337941BB1837D970D02E8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_CF00AF0396992AAEADBE837D970D72EE_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_CF00AF0396992AAEADBE837D970D72EE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Revenues from External Customers and Long-Lived Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_CF00AF0396992AAEADBE837D970D72EE_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_CF00AF0396992AAEADBE837D970D72EE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Revenues from External Customers and Long-Lived Assets [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_CF00AF0396992AAEADBE837D970D72EE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_CF00AF0396992AAEADBE837D970D72EE" xlink:to="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_CF00AF0396992AAEADBE837D970D72EE" xlink:type="arc" />
    <link:label id="lab_us-gaap_CurrencyAxis_59DFEB074CB136288389837D970D8D06_terseLabel_en-US" xlink:label="lab_us-gaap_CurrencyAxis_59DFEB074CB136288389837D970D8D06" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency [Axis]</link:label>
    <link:label id="lab_us-gaap_CurrencyAxis_59DFEB074CB136288389837D970D8D06_label_en-US" xlink:label="lab_us-gaap_CurrencyAxis_59DFEB074CB136288389837D970D8D06" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Currency [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CurrencyAxis" xlink:label="loc_us-gaap_CurrencyAxis_59DFEB074CB136288389837D970D8D06" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrencyAxis_59DFEB074CB136288389837D970D8D06" xlink:to="lab_us-gaap_CurrencyAxis_59DFEB074CB136288389837D970D8D06" xlink:type="arc" />
    <link:label id="lab_currency_AllCurrenciesDomain_687EBC63D5D8A6D0D262837D970D2E56_terseLabel_en-US" xlink:label="lab_currency_AllCurrenciesDomain_687EBC63D5D8A6D0D262837D970D2E56" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Currencies [Domain]</link:label>
    <link:label id="lab_currency_AllCurrenciesDomain_687EBC63D5D8A6D0D262837D970D2E56_label_en-US" xlink:label="lab_currency_AllCurrenciesDomain_687EBC63D5D8A6D0D262837D970D2E56" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Currencies [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_687EBC63D5D8A6D0D262837D970D2E56" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_AllCurrenciesDomain_687EBC63D5D8A6D0D262837D970D2E56" xlink:to="lab_currency_AllCurrenciesDomain_687EBC63D5D8A6D0D262837D970D2E56" xlink:type="arc" />
    <link:label id="lab_currency_EUR_E0794DE1546099E7E15D837D970DC3A8_terseLabel_en-US" xlink:label="lab_currency_EUR_E0794DE1546099E7E15D837D970DC3A8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Euro Member Countries, Euro [Member]</link:label>
    <link:label id="lab_currency_EUR_E0794DE1546099E7E15D837D970DC3A8_label_en-US" xlink:label="lab_currency_EUR_E0794DE1546099E7E15D837D970DC3A8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Euro Member Countries, Euro</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_EUR" xlink:label="loc_currency_EUR_E0794DE1546099E7E15D837D970DC3A8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_EUR_E0794DE1546099E7E15D837D970DC3A8" xlink:to="lab_currency_EUR_E0794DE1546099E7E15D837D970DC3A8" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementGeographicalAxis_D9C8D74E23DCF9CF0A3D837D970E48D8_terseLabel_en-US" xlink:label="lab_us-gaap_StatementGeographicalAxis_D9C8D74E23DCF9CF0A3D837D970E48D8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementGeographicalAxis_D9C8D74E23DCF9CF0A3D837D970E48D8_label_en-US" xlink:label="lab_us-gaap_StatementGeographicalAxis_D9C8D74E23DCF9CF0A3D837D970E48D8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis_D9C8D74E23DCF9CF0A3D837D970E48D8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementGeographicalAxis_D9C8D74E23DCF9CF0A3D837D970E48D8" xlink:to="lab_us-gaap_StatementGeographicalAxis_D9C8D74E23DCF9CF0A3D837D970E48D8" xlink:type="arc" />
    <link:label id="lab_us-gaap_SegmentGeographicalDomain_CB7F983773C111D2736D837D970E0F4E_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentGeographicalDomain_CB7F983773C111D2736D837D970E0F4E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentGeographicalDomain_CB7F983773C111D2736D837D970E0F4E_label_en-US" xlink:label="lab_us-gaap_SegmentGeographicalDomain_CB7F983773C111D2736D837D970E0F4E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_CB7F983773C111D2736D837D970E0F4E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentGeographicalDomain_CB7F983773C111D2736D837D970E0F4E" xlink:to="lab_us-gaap_SegmentGeographicalDomain_CB7F983773C111D2736D837D970E0F4E" xlink:type="arc" />
    <link:label id="lab_pfe_DevelopedEuropeMember_6D0D472F6ABB78C450D9837D970E5D18_terseLabel_en-US" xlink:label="lab_pfe_DevelopedEuropeMember_6D0D472F6ABB78C450D9837D970E5D18" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Developed Europe [Member]</link:label>
    <link:label id="lab_pfe_DevelopedEuropeMember_6D0D472F6ABB78C450D9837D970E5D18_label_en-US" xlink:label="lab_pfe_DevelopedEuropeMember_6D0D472F6ABB78C450D9837D970E5D18" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Developed Europe [Member]</link:label>
    <link:label id="lab_pfe_DevelopedEuropeMember_6D0D472F6ABB78C450D9837D970E5D18_documentation_en-US" xlink:label="lab_pfe_DevelopedEuropeMember_6D0D472F6ABB78C450D9837D970E5D18" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Developed Europe [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_DevelopedEuropeMember" xlink:label="loc_pfe_DevelopedEuropeMember_6D0D472F6ABB78C450D9837D970E5D18" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DevelopedEuropeMember_6D0D472F6ABB78C450D9837D970E5D18" xlink:to="lab_pfe_DevelopedEuropeMember_6D0D472F6ABB78C450D9837D970E5D18" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_579FFA2F08D0C4CD4E86837D970E6205_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_579FFA2F08D0C4CD4E86837D970E6205" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues from External Customers and Long-Lived Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_579FFA2F08D0C4CD4E86837D970E6205_label_en-US" xlink:label="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_579FFA2F08D0C4CD4E86837D970E6205" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues from External Customers and Long-Lived Assets [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_579FFA2F08D0C4CD4E86837D970E6205" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_579FFA2F08D0C4CD4E86837D970E6205" xlink:to="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_579FFA2F08D0C4CD4E86837D970E6205" xlink:type="arc" />
    <link:label id="lab_us-gaap_SalesRevenueGoodsNet_898997B91FC9F949B200837D970E8E87_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueGoodsNet_898997B91FC9F949B200837D970E8E87" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_SalesRevenueGoodsNet_898997B91FC9F949B200837D970E8E87_label_en-US" xlink:label="lab_us-gaap_SalesRevenueGoodsNet_898997B91FC9F949B200837D970E8E87" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Revenue, Goods, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_898997B91FC9F949B200837D970E8E87" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueGoodsNet_898997B91FC9F949B200837D970E8E87" xlink:to="lab_us-gaap_SalesRevenueGoodsNet_898997B91FC9F949B200837D970E8E87" xlink:type="arc" />
    <link:label id="lab_pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract_1E313A5BEE629C8E11AB5A4F9EC35F27_label_en-US" xlink:label="lab_pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract_1E313A5BEE629C8E11AB5A4F9EC35F27" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combinations, Discontinued Operations And Disposal Groups, Collaborative Arrangements And Equity Method Investments [Abstract]</link:label>
    <link:label id="lab_pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract_1E313A5BEE629C8E11AB5A4F9EC35F27_documentation_en-US" xlink:label="lab_pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract_1E313A5BEE629C8E11AB5A4F9EC35F27" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combinations, Discontinued Operations And Disposal Groups, Collaborative Arrangements And Equity Method Investments [Abstract]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract" xlink:label="loc_pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract_1E313A5BEE629C8E11AB5A4F9EC35F27" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract_1E313A5BEE629C8E11AB5A4F9EC35F27" xlink:to="lab_pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract_1E313A5BEE629C8E11AB5A4F9EC35F27" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0916E06DFE4E727C23A85A4F9EC379BA_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0916E06DFE4E727C23A85A4F9EC379BA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0916E06DFE4E727C23A85A4F9EC379BA_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0916E06DFE4E727C23A85A4F9EC379BA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0916E06DFE4E727C23A85A4F9EC379BA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0916E06DFE4E727C23A85A4F9EC379BA" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0916E06DFE4E727C23A85A4F9EC379BA" xlink:type="arc" />
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_8774CB76A362549C82795A4F9EC3E078_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_8774CB76A362549C82795A4F9EC3E078" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_8774CB76A362549C82795A4F9EC3E078_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_8774CB76A362549C82795A4F9EC3E078" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_8774CB76A362549C82795A4F9EC3E078" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_8774CB76A362549C82795A4F9EC3E078" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_8774CB76A362549C82795A4F9EC3E078" xlink:type="arc" />
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_4DF437891E5D59D482DB5A4F9EC3F440_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_4DF437891E5D59D482DB5A4F9EC3F440" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_4DF437891E5D59D482DB5A4F9EC3F440_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_4DF437891E5D59D482DB5A4F9EC3F440" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_4DF437891E5D59D482DB5A4F9EC3F440" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_4DF437891E5D59D482DB5A4F9EC3F440" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_4DF437891E5D59D482DB5A4F9EC3F440" xlink:type="arc" />
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_9E84B8A4DDEE201F16DC5A4F9EC3CF03_terseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember_9E84B8A4DDEE201F16DC5A4F9EC3CF03" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">In Process Research and Development [Member]</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_9E84B8A4DDEE201F16DC5A4F9EC3CF03_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember_9E84B8A4DDEE201F16DC5A4F9EC3CF03" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">In Process Research and Development [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_9E84B8A4DDEE201F16DC5A4F9EC3CF03" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentMember_9E84B8A4DDEE201F16DC5A4F9EC3CF03" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentMember_9E84B8A4DDEE201F16DC5A4F9EC3CF03" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_3EA5C04CC58AEA01A5845A4F9EC30C9A_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_3EA5C04CC58AEA01A5845A4F9EC30C9A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_3EA5C04CC58AEA01A5845A4F9EC30C9A_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_3EA5C04CC58AEA01A5845A4F9EC30C9A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_3EA5C04CC58AEA01A5845A4F9EC30C9A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_3EA5C04CC58AEA01A5845A4F9EC30C9A" xlink:to="lab_us-gaap_IncomeStatementLocationAxis_3EA5C04CC58AEA01A5845A4F9EC30C9A" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_4B3FA1EB632BEAD704B15A4F9EC389B4_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_4B3FA1EB632BEAD704B15A4F9EC389B4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_4B3FA1EB632BEAD704B15A4F9EC389B4_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_4B3FA1EB632BEAD704B15A4F9EC389B4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_4B3FA1EB632BEAD704B15A4F9EC389B4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_4B3FA1EB632BEAD704B15A4F9EC389B4" xlink:to="lab_us-gaap_IncomeStatementLocationDomain_4B3FA1EB632BEAD704B15A4F9EC389B4" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_6E76FDC5D44182494AC25A4F9EC3B1CB_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_6E76FDC5D44182494AC25A4F9EC3B1CB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other (Income)/Deductions, Net [Member]</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_6E76FDC5D44182494AC25A4F9EC3B1CB_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_6E76FDC5D44182494AC25A4F9EC3B1CB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense) [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_6E76FDC5D44182494AC25A4F9EC3B1CB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_6E76FDC5D44182494AC25A4F9EC3B1CB" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_6E76FDC5D44182494AC25A4F9EC3B1CB" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_A8113B07B6D11911BCF15A4F9EC3CE93_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis_A8113B07B6D11911BCF15A4F9EC3CE93" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_A8113B07B6D11911BCF15A4F9EC3CE93_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis_A8113B07B6D11911BCF15A4F9EC3CE93" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_A8113B07B6D11911BCF15A4F9EC3CE93" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_A8113B07B6D11911BCF15A4F9EC3CE93" xlink:to="lab_us-gaap_BusinessAcquisitionAxis_A8113B07B6D11911BCF15A4F9EC3CE93" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_C108FB0D01672E725D725A4F9EC320A2_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain_C108FB0D01672E725D725A4F9EC320A2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_C108FB0D01672E725D725A4F9EC320A2_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain_C108FB0D01672E725D725A4F9EC320A2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_C108FB0D01672E725D725A4F9EC320A2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_C108FB0D01672E725D725A4F9EC320A2" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain_C108FB0D01672E725D725A4F9EC320A2" xlink:type="arc" />
    <link:label id="lab_pfe_BambooTherapeuticsMember_86FF1FE02743DD78F6255A4F9EC3D861_terseLabel_en-US" xlink:label="lab_pfe_BambooTherapeuticsMember_86FF1FE02743DD78F6255A4F9EC3D861" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Bamboo Therapeutics [Member]</link:label>
    <link:label id="lab_pfe_BambooTherapeuticsMember_86FF1FE02743DD78F6255A4F9EC3D861_label_en-US" xlink:label="lab_pfe_BambooTherapeuticsMember_86FF1FE02743DD78F6255A4F9EC3D861" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bamboo Therapeutics [Member]</link:label>
    <link:label id="lab_pfe_BambooTherapeuticsMember_86FF1FE02743DD78F6255A4F9EC3D861_documentation_en-US" xlink:label="lab_pfe_BambooTherapeuticsMember_86FF1FE02743DD78F6255A4F9EC3D861" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Bamboo Therapeutics [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_BambooTherapeuticsMember" xlink:label="loc_pfe_BambooTherapeuticsMember_86FF1FE02743DD78F6255A4F9EC3D861" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_BambooTherapeuticsMember_86FF1FE02743DD78F6255A4F9EC3D861" xlink:to="lab_pfe_BambooTherapeuticsMember_86FF1FE02743DD78F6255A4F9EC3D861" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_836BF1F01B7F112700755A4F9EC3F7C0_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems_836BF1F01B7F112700755A4F9EC3F7C0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_836BF1F01B7F112700755A4F9EC3F7C0_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems_836BF1F01B7F112700755A4F9EC3F7C0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_836BF1F01B7F112700755A4F9EC3F7C0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_836BF1F01B7F112700755A4F9EC3F7C0" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems_836BF1F01B7F112700755A4F9EC3F7C0" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_40A6071BDE7D9D991DC85A4F9EC430BC_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1_40A6071BDE7D9D991DC85A4F9EC430BC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payment to acquire the remaining equity</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_40A6071BDE7D9D991DC85A4F9EC430BC_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1_40A6071BDE7D9D991DC85A4F9EC430BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_40A6071BDE7D9D991DC85A4F9EC430BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1_40A6071BDE7D9D991DC85A4F9EC430BC" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1_40A6071BDE7D9D991DC85A4F9EC430BC" xlink:type="arc" />
    <link:label id="lab_pfe_BusinessCombinationConsiderationTransferredMilestonePaymentsMaximum_DA5F81EFDCF50B9331BF5A4F9EC4EE03_terseLabel_en-US" xlink:label="lab_pfe_BusinessCombinationConsiderationTransferredMilestonePaymentsMaximum_DA5F81EFDCF50B9331BF5A4F9EC4EE03" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum amount of potential milestone payments</link:label>
    <link:label id="lab_pfe_BusinessCombinationConsiderationTransferredMilestonePaymentsMaximum_DA5F81EFDCF50B9331BF5A4F9EC4EE03_label_en-US" xlink:label="lab_pfe_BusinessCombinationConsiderationTransferredMilestonePaymentsMaximum_DA5F81EFDCF50B9331BF5A4F9EC4EE03" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Consideration Transferred, Milestone Payments, Maximum</link:label>
    <link:label id="lab_pfe_BusinessCombinationConsiderationTransferredMilestonePaymentsMaximum_DA5F81EFDCF50B9331BF5A4F9EC4EE03_documentation_en-US" xlink:label="lab_pfe_BusinessCombinationConsiderationTransferredMilestonePaymentsMaximum_DA5F81EFDCF50B9331BF5A4F9EC4EE03" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Consideration Transferred, Milestone Payments, Maximum</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_BusinessCombinationConsiderationTransferredMilestonePaymentsMaximum" xlink:label="loc_pfe_BusinessCombinationConsiderationTransferredMilestonePaymentsMaximum_DA5F81EFDCF50B9331BF5A4F9EC4EE03" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_BusinessCombinationConsiderationTransferredMilestonePaymentsMaximum_DA5F81EFDCF50B9331BF5A4F9EC4EE03" xlink:to="lab_pfe_BusinessCombinationConsiderationTransferredMilestonePaymentsMaximum_DA5F81EFDCF50B9331BF5A4F9EC4EE03" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1_901FE66BCF82197792D75A4F9EC43936_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1_901FE66BCF82197792D75A4F9EC43936" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total fair value of consideration transferred</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1_901FE66BCF82197792D75A4F9EC43936_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1_901FE66BCF82197792D75A4F9EC43936" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Consideration Transferred, Including Equity Interest in Acquiree Held Prior to Combination</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1_901FE66BCF82197792D75A4F9EC43936" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1_901FE66BCF82197792D75A4F9EC43936" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1_901FE66BCF82197792D75A4F9EC43936" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_C8249169E4D4BABE7A6F5A4F9EC4EE70_verboseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross_C8249169E4D4BABE7A6F5A4F9EC4EE70" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Payments for acquisitions, cash portion</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_C8249169E4D4BABE7A6F5A4F9EC4EE70_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross_C8249169E4D4BABE7A6F5A4F9EC4EE70" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_C8249169E4D4BABE7A6F5A4F9EC4EE70" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross_C8249169E4D4BABE7A6F5A4F9EC4EE70" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross_C8249169E4D4BABE7A6F5A4F9EC4EE70" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_2C448FE2FB6ABBB5D9665A4F9EC4F04C_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_2C448FE2FB6ABBB5D9665A4F9EC4F04C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash payments for acquisition, net of cash acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_2C448FE2FB6ABBB5D9665A4F9EC4F04C_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_2C448FE2FB6ABBB5D9665A4F9EC4F04C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_2C448FE2FB6ABBB5D9665A4F9EC4F04C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_2C448FE2FB6ABBB5D9665A4F9EC4F04C" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_2C448FE2FB6ABBB5D9665A4F9EC4F04C" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_7E9A807808AE9DEF0DDB5A4F9EC4E913_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_7E9A807808AE9DEF0DDB5A4F9EC4E913" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration incurred</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_7E9A807808AE9DEF0DDB5A4F9EC4E913_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_7E9A807808AE9DEF0DDB5A4F9EC4E913" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_7E9A807808AE9DEF0DDB5A4F9EC4E913" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_7E9A807808AE9DEF0DDB5A4F9EC4E913" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_7E9A807808AE9DEF0DDB5A4F9EC4E913" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_2D521555D25F2E09BFA05A4F9EC42AE4_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_2D521555D25F2E09BFA05A4F9EC42AE4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of previously held equity interest</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_2D521555D25F2E09BFA05A4F9EC42AE4_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_2D521555D25F2E09BFA05A4F9EC42AE4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_2D521555D25F2E09BFA05A4F9EC42AE4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_2D521555D25F2E09BFA05A4F9EC42AE4" xlink:to="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_2D521555D25F2E09BFA05A4F9EC42AE4" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain_EC32B307C5744C3295805A4F9EC47108_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain_EC32B307C5744C3295805A4F9EC47108" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain recognized upon acquisition of remaining interest in acquiree</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain_EC32B307C5744C3295805A4F9EC47108_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain_EC32B307C5744C3295805A4F9EC47108" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain_EC32B307C5744C3295805A4F9EC47108" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain_EC32B307C5744C3295805A4F9EC47108" xlink:to="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain_EC32B307C5744C3295805A4F9EC47108" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_9906617BB94929A4C1EE5A4F9EC42451_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_9906617BB94929A4C1EE5A4F9EC42451" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Identifiable intangible assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_9906617BB94929A4C1EE5A4F9EC42451_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_9906617BB94929A4C1EE5A4F9EC42451" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_9906617BB94929A4C1EE5A4F9EC42451" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_9906617BB94929A4C1EE5A4F9EC42451" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_9906617BB94929A4C1EE5A4F9EC42451" xlink:type="arc" />
    <link:label id="lab_us-gaap_Goodwill_B766946BF592CD04F37E5A4F9EC4B099_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill_B766946BF592CD04F37E5A4F9EC4B099" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_B766946BF592CD04F37E5A4F9EC4B099_label_en-US" xlink:label="lab_us-gaap_Goodwill_B766946BF592CD04F37E5A4F9EC4B099" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_B766946BF592CD04F37E5A4F9EC4B099" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill_B766946BF592CD04F37E5A4F9EC4B099" xlink:to="lab_us-gaap_Goodwill_B766946BF592CD04F37E5A4F9EC4B099" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_38D1EE8E07E7AE32FD1D5A4F9EC47F16_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_38D1EE8E07E7AE32FD1D5A4F9EC47F16" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_38D1EE8E07E7AE32FD1D5A4F9EC47F16_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_38D1EE8E07E7AE32FD1D5A4F9EC47F16" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_38D1EE8E07E7AE32FD1D5A4F9EC47F16" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_38D1EE8E07E7AE32FD1D5A4F9EC47F16" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_38D1EE8E07E7AE32FD1D5A4F9EC47F16" xlink:type="arc" />
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_B7189941FFD0F4966B2791BE77DE5A69_verboseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments_B7189941FFD0F4966B2791BE77DE5A69" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Number of business segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_B7189941FFD0F4966B2791BE77DE5A69_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments_B7189941FFD0F4966B2791BE77DE5A69" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments_B7189941FFD0F4966B2791BE77DE5A69" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments_B7189941FFD0F4966B2791BE77DE5A69" xlink:to="lab_us-gaap_NumberOfOperatingSegments_B7189941FFD0F4966B2791BE77DE5A69" xlink:type="arc" />
    <link:label id="lab_us-gaap_Assets_2117ECD6AFEF6230AC4E91BE77DEFDB3_terseLabel_en-US" xlink:label="lab_us-gaap_Assets_2117ECD6AFEF6230AC4E91BE77DEFDB3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_Assets_2117ECD6AFEF6230AC4E91BE77DEFDB3_label_en-US" xlink:label="lab_us-gaap_Assets_2117ECD6AFEF6230AC4E91BE77DEFDB3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_2117ECD6AFEF6230AC4E91BE77DEFDB3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_2117ECD6AFEF6230AC4E91BE77DEFDB3" xlink:to="lab_us-gaap_Assets_2117ECD6AFEF6230AC4E91BE77DEFDB3" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityAbstract_1FBDC05A22A4534FF254AE9F92BB5C3A_label_en-US" xlink:label="lab_us-gaap_EquityAbstract_255CE2A4DF9F58F88E4E5771CB165BA0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_255CE2A4DF9F58F88E4E5771CB165BA0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract_255CE2A4DF9F58F88E4E5771CB165BA0" xlink:to="lab_us-gaap_EquityAbstract_255CE2A4DF9F58F88E4E5771CB165BA0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_6E1E5194439C991AB0AAAE9F92BB1670_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_11FF3BE2048E5C799A05FA7760FA3807" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_6E1E5194439C991AB0AAAE9F92BB1670_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_11FF3BE2048E5C799A05FA7760FA3807" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss) Note [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_11FF3BE2048E5C799A05FA7760FA3807" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_11FF3BE2048E5C799A05FA7760FA3807" xlink:to="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_11FF3BE2048E5C799A05FA7760FA3807" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_FADA6A04CE71AE475EECAE9F92690DD9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_522E886DF18E5E16A38D1CF845FE4787" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_FADA6A04CE71AE475EECAE9F92690DD9_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_522E886DF18E5E16A38D1CF845FE4787" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_522E886DF18E5E16A38D1CF845FE4787" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_522E886DF18E5E16A38D1CF845FE4787" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_522E886DF18E5E16A38D1CF845FE4787" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_B31A17B79E2CF130BCE8AE9F9269D927_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_B42A9C82AA485E578A6AACC2F2559319" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Indefinite Lived Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_B31A17B79E2CF130BCE8AE9F9269D927_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_B42A9C82AA485E578A6AACC2F2559319" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_B42A9C82AA485E578A6AACC2F2559319" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_B42A9C82AA485E578A6AACC2F2559319" xlink:to="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_B42A9C82AA485E578A6AACC2F2559319" xlink:type="arc" />
    <link:label id="lab_pfe_IdentifiableintangibleassetsasapercentageoftotalidentifiableintangibleassetslessaccumulatedamortizationbysegmentTableTextBlock_100D7C370EA264F59920AE9F9269F747_terseLabel_en-US" xlink:label="lab_pfe_IdentifiableintangibleassetsasapercentageoftotalidentifiableintangibleassetslessaccumulatedamortizationbysegmentTableTextBlock_746080F1E22D50C7971746ED83D08F67" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Identifiable Intangible Assets as a Percentage of Total Identifiable Intangible Assets Less Accumulated Amortization, By Segment</link:label>
    <link:label id="lab_pfe_IdentifiableintangibleassetsasapercentageoftotalidentifiableintangibleassetslessaccumulatedamortizationbysegmentTableTextBlock_100D7C370EA264F59920AE9F9269F747_label_en-US" xlink:label="lab_pfe_IdentifiableintangibleassetsasapercentageoftotalidentifiableintangibleassetslessaccumulatedamortizationbysegmentTableTextBlock_746080F1E22D50C7971746ED83D08F67" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Identifiable intangible assets as a percentage of total identifiable intangible assets less accumulated amortization, by segment [Table Text Block]</link:label>
    <link:label id="lab_pfe_IdentifiableintangibleassetsasapercentageoftotalidentifiableintangibleassetslessaccumulatedamortizationbysegmentTableTextBlock_100D7C370EA264F59920AE9F9269F747_documentation_en-US" xlink:label="lab_pfe_IdentifiableintangibleassetsasapercentageoftotalidentifiableintangibleassetslessaccumulatedamortizationbysegmentTableTextBlock_746080F1E22D50C7971746ED83D08F67" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Table Text Block] for Identifiable intangible assets as a percentage of total identifiable intangible assets less accumulated amortization, by segment [Table]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_IdentifiableintangibleassetsasapercentageoftotalidentifiableintangibleassetslessaccumulatedamortizationbysegmentTableTextBlock" xlink:label="loc_pfe_IdentifiableintangibleassetsasapercentageoftotalidentifiableintangibleassetslessaccumulatedamortizationbysegmentTableTextBlock_746080F1E22D50C7971746ED83D08F67" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_IdentifiableintangibleassetsasapercentageoftotalidentifiableintangibleassetslessaccumulatedamortizationbysegmentTableTextBlock_746080F1E22D50C7971746ED83D08F67" xlink:to="lab_pfe_IdentifiableintangibleassetsasapercentageoftotalidentifiableintangibleassetslessaccumulatedamortizationbysegmentTableTextBlock_746080F1E22D50C7971746ED83D08F67" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_5A67F1471B461A90F0FBAE9F926AF9E1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock_188DF3902572562B82D58C26C37138D6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_5A67F1471B461A90F0FBAE9F926AF9E1_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock_188DF3902572562B82D58C26C37138D6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_188DF3902572562B82D58C26C37138D6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock_188DF3902572562B82D58C26C37138D6" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock_188DF3902572562B82D58C26C37138D6" xlink:type="arc" />
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_C35D0A8E35182FCC2F0BAE9F9211531C_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock_A9E5D049048859F4824D19EA600EA061" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment, Geographic and Other Revenue Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_C35D0A8E35182FCC2F0BAE9F9211531C_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock_A9E5D049048859F4824D19EA600EA061" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_A9E5D049048859F4824D19EA600EA061" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock_A9E5D049048859F4824D19EA600EA061" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock_A9E5D049048859F4824D19EA600EA061" xlink:type="arc" />
    <link:label id="lab_pfe_FinancialInstrumentsAbstract_14455B4B3B9E0F678331AE9F9288D4CB_label_en-US" xlink:label="lab_pfe_FinancialInstrumentsAbstract_905125034F495B7DBBB5578A5B45DD3D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments [Abstract]</link:label>
    <link:label id="lab_pfe_FinancialInstrumentsAbstract_14455B4B3B9E0F678331AE9F9288D4CB_documentation_en-US" xlink:label="lab_pfe_FinancialInstrumentsAbstract_905125034F495B7DBBB5578A5B45DD3D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Financial Instruments [Abstract]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_FinancialInstrumentsAbstract" xlink:label="loc_pfe_FinancialInstrumentsAbstract_905125034F495B7DBBB5578A5B45DD3D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_FinancialInstrumentsAbstract_905125034F495B7DBBB5578A5B45DD3D" xlink:to="lab_pfe_FinancialInstrumentsAbstract_905125034F495B7DBBB5578A5B45DD3D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShortTermDebtTable_7790DC46327004F27AACAE9F9288274A_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShortTermDebtTable_8F50BC16DCE6553EB1C336B431638DD5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Short-term Debt [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShortTermDebtTable_7790DC46327004F27AACAE9F9288274A_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShortTermDebtTable_8F50BC16DCE6553EB1C336B431638DD5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Short-term Debt [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTable_8F50BC16DCE6553EB1C336B431638DD5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_8F50BC16DCE6553EB1C336B431638DD5" xlink:to="lab_us-gaap_ScheduleOfShortTermDebtTable_8F50BC16DCE6553EB1C336B431638DD5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShortTermDebtTypeAxis_B237B948A4A3BF0B9811AE9F9289E3D4_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeAxis_0D94F7C67CFD5E0F9D2C98FDCF278A90" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ShortTermDebtTypeAxis_B237B948A4A3BF0B9811AE9F9289E3D4_label_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeAxis_0D94F7C67CFD5E0F9D2C98FDCF278A90" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-term Debt, Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_0D94F7C67CFD5E0F9D2C98FDCF278A90" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_0D94F7C67CFD5E0F9D2C98FDCF278A90" xlink:to="lab_us-gaap_ShortTermDebtTypeAxis_0D94F7C67CFD5E0F9D2C98FDCF278A90" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShortTermDebtTypeDomain_6B20550B2AADE4ED8F0FAE9F928958E0_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeDomain_13D069D1897C5677B6EC78BF0EC9B981" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShortTermDebtTypeDomain_6B20550B2AADE4ED8F0FAE9F928958E0_label_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeDomain_13D069D1897C5677B6EC78BF0EC9B981" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-term Debt, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_13D069D1897C5677B6EC78BF0EC9B981" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_13D069D1897C5677B6EC78BF0EC9B981" xlink:to="lab_us-gaap_ShortTermDebtTypeDomain_13D069D1897C5677B6EC78BF0EC9B981" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommercialPaperMember_91DE98C778FFCA2F9EE2AE9F9289A99B_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember_53F349890F1D5FC28196F318FBF0BD4A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_91DE98C778FFCA2F9EE2AE9F9289A99B_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember_53F349890F1D5FC28196F318FBF0BD4A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_53F349890F1D5FC28196F318FBF0BD4A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember_53F349890F1D5FC28196F318FBF0BD4A" xlink:to="lab_us-gaap_CommercialPaperMember_53F349890F1D5FC28196F318FBF0BD4A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShortTermDebtLineItems_5CE26C8077C4BB65E3ACAE9F9289AE9D_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermDebtLineItems_CD77D0CF1291589FA9B487EF6A62990B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term Debt [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShortTermDebtLineItems_5CE26C8077C4BB65E3ACAE9F9289AE9D_label_en-US" xlink:label="lab_us-gaap_ShortTermDebtLineItems_CD77D0CF1291589FA9B487EF6A62990B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-term Debt [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaap_ShortTermDebtLineItems_CD77D0CF1291589FA9B487EF6A62990B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtLineItems_CD77D0CF1291589FA9B487EF6A62990B" xlink:to="lab_us-gaap_ShortTermDebtLineItems_CD77D0CF1291589FA9B487EF6A62990B" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommercialPaper_67F15264A1D73FF6BC4DAE9F92892C91_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaper_A5E16A737045501E963CFD73CCBFE3EB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaper_67F15264A1D73FF6BC4DAE9F92892C91_label_en-US" xlink:label="lab_us-gaap_CommercialPaper_A5E16A737045501E963CFD73CCBFE3EB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial Paper</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommercialPaper" xlink:label="loc_us-gaap_CommercialPaper_A5E16A737045501E963CFD73CCBFE3EB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaper_A5E16A737045501E963CFD73CCBFE3EB" xlink:to="lab_us-gaap_CommercialPaper_A5E16A737045501E963CFD73CCBFE3EB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfInvestmentsTable_1B122C04A037CB87665A78AA92B62F4B_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentsTable_1B122C04A037CB87665A78AA92B62F4B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Investments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentsTable_1B122C04A037CB87665A78AA92B62F4B_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentsTable_1B122C04A037CB87665A78AA92B62F4B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Investments [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfInvestmentsTable" xlink:label="loc_us-gaap_ScheduleOfInvestmentsTable_1B122C04A037CB87665A78AA92B62F4B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_1B122C04A037CB87665A78AA92B62F4B" xlink:to="lab_us-gaap_ScheduleOfInvestmentsTable_1B122C04A037CB87665A78AA92B62F4B" xlink:type="arc" />
    <link:label id="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_49AA14A49822CBB003FD78AA92B6ECE2_terseLabel_en-US" xlink:label="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_49AA14A49822CBB003FD78AA92B6ECE2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Major Types of Debt and Equity Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_49AA14A49822CBB003FD78AA92B6ECE2_label_en-US" xlink:label="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_49AA14A49822CBB003FD78AA92B6ECE2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Major Types of Debt and Equity Securities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_49AA14A49822CBB003FD78AA92B6ECE2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_49AA14A49822CBB003FD78AA92B6ECE2" xlink:to="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_49AA14A49822CBB003FD78AA92B6ECE2" xlink:type="arc" />
    <link:label id="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_05F10A8052398DBB54ED78AA92B6B489_terseLabel_en-US" xlink:label="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_05F10A8052398DBB54ED78AA92B6B489" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Major Types of Debt and Equity Securities [Domain]</link:label>
    <link:label id="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_05F10A8052398DBB54ED78AA92B6B489_label_en-US" xlink:label="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_05F10A8052398DBB54ED78AA92B6B489" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Major Types of Debt and Equity Securities [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_05F10A8052398DBB54ED78AA92B6B489" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_05F10A8052398DBB54ED78AA92B6B489" xlink:to="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_05F10A8052398DBB54ED78AA92B6B489" xlink:type="arc" />
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_8D8EB9EE3F06820F3E5D78AA92B67537_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember_8D8EB9EE3F06820F3E5D78AA92B67537" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Corporate debt [Member]</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_8D8EB9EE3F06820F3E5D78AA92B67537_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember_8D8EB9EE3F06820F3E5D78AA92B67537" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_8D8EB9EE3F06820F3E5D78AA92B67537" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember_8D8EB9EE3F06820F3E5D78AA92B67537" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember_8D8EB9EE3F06820F3E5D78AA92B67537" xlink:type="arc" />
    <link:label id="lab_pfe_WesternEuropeanAsianandOtherGovernmentDebtMember_EA72CD8D8A6F7FFE3EF278AA92B6C281_terseLabel_en-US" xlink:label="lab_pfe_WesternEuropeanAsianandOtherGovernmentDebtMember_EA72CD8D8A6F7FFE3EF278AA92B6C281" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Western European, Asian and other government debt [Member]</link:label>
    <link:label id="lab_pfe_WesternEuropeanAsianandOtherGovernmentDebtMember_EA72CD8D8A6F7FFE3EF278AA92B6C281_label_en-US" xlink:label="lab_pfe_WesternEuropeanAsianandOtherGovernmentDebtMember_EA72CD8D8A6F7FFE3EF278AA92B6C281" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Western European, Asian and Other Government Debt [Member]</link:label>
    <link:label id="lab_pfe_WesternEuropeanAsianandOtherGovernmentDebtMember_EA72CD8D8A6F7FFE3EF278AA92B6C281_documentation_en-US" xlink:label="lab_pfe_WesternEuropeanAsianandOtherGovernmentDebtMember_EA72CD8D8A6F7FFE3EF278AA92B6C281" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Western European, Asian and Other Government Debt [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_WesternEuropeanAsianandOtherGovernmentDebtMember" xlink:label="loc_pfe_WesternEuropeanAsianandOtherGovernmentDebtMember_EA72CD8D8A6F7FFE3EF278AA92B6C281" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_WesternEuropeanAsianandOtherGovernmentDebtMember_EA72CD8D8A6F7FFE3EF278AA92B6C281" xlink:to="lab_pfe_WesternEuropeanAsianandOtherGovernmentDebtMember_EA72CD8D8A6F7FFE3EF278AA92B6C281" xlink:type="arc" />
    <link:label id="lab_pfe_WesternEuropeanScandinaviaAndOtherGovernmentAgencyDebtMember_CB30E57D4BF3F4C8799878AA92B6A970_terseLabel_en-US" xlink:label="lab_pfe_WesternEuropeanScandinaviaAndOtherGovernmentAgencyDebtMember_CB30E57D4BF3F4C8799878AA92B6A970" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Western European, Scandinavia and other government agency debt [Member]</link:label>
    <link:label id="lab_pfe_WesternEuropeanScandinaviaAndOtherGovernmentAgencyDebtMember_CB30E57D4BF3F4C8799878AA92B6A970_label_en-US" xlink:label="lab_pfe_WesternEuropeanScandinaviaAndOtherGovernmentAgencyDebtMember_CB30E57D4BF3F4C8799878AA92B6A970" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Western European, Scandinavia And Other Government Agency Debt [Member]</link:label>
    <link:label id="lab_pfe_WesternEuropeanScandinaviaAndOtherGovernmentAgencyDebtMember_CB30E57D4BF3F4C8799878AA92B6A970_documentation_en-US" xlink:label="lab_pfe_WesternEuropeanScandinaviaAndOtherGovernmentAgencyDebtMember_CB30E57D4BF3F4C8799878AA92B6A970" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Western European, Scandinavia And Other Government Agency Debt [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_WesternEuropeanScandinaviaAndOtherGovernmentAgencyDebtMember" xlink:label="loc_pfe_WesternEuropeanScandinaviaAndOtherGovernmentAgencyDebtMember_CB30E57D4BF3F4C8799878AA92B6A970" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_WesternEuropeanScandinaviaAndOtherGovernmentAgencyDebtMember_CB30E57D4BF3F4C8799878AA92B6A970" xlink:to="lab_pfe_WesternEuropeanScandinaviaAndOtherGovernmentAgencyDebtMember_CB30E57D4BF3F4C8799878AA92B6A970" xlink:type="arc" />
    <link:label id="lab_pfe_SupranationalDebtMember_1AD4FDACD3130EB6815178AA92B6F261_terseLabel_en-US" xlink:label="lab_pfe_SupranationalDebtMember_1AD4FDACD3130EB6815178AA92B6F261" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supranational debt [Member]</link:label>
    <link:label id="lab_pfe_SupranationalDebtMember_1AD4FDACD3130EB6815178AA92B6F261_label_en-US" xlink:label="lab_pfe_SupranationalDebtMember_1AD4FDACD3130EB6815178AA92B6F261" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supranational Debt [Member]</link:label>
    <link:label id="lab_pfe_SupranationalDebtMember_1AD4FDACD3130EB6815178AA92B6F261_documentation_en-US" xlink:label="lab_pfe_SupranationalDebtMember_1AD4FDACD3130EB6815178AA92B6F261" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the debt of international organizations such as the World Bank, the International Monetary Fund, regional multilateral development banks, multilateral financial institutions, and other similar organizations.</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_SupranationalDebtMember" xlink:label="loc_pfe_SupranationalDebtMember_1AD4FDACD3130EB6815178AA92B6F261" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SupranationalDebtMember_1AD4FDACD3130EB6815178AA92B6F261" xlink:to="lab_pfe_SupranationalDebtMember_1AD4FDACD3130EB6815178AA92B6F261" xlink:type="arc" />
    <link:label id="lab_us-gaap_GovernmentNationalMortgageAssociationCertificatesAndObligationsGNMAMember_89EF659F315C9297769378AA92B6FE38_terseLabel_en-US" xlink:label="lab_us-gaap_GovernmentNationalMortgageAssociationCertificatesAndObligationsGNMAMember_89EF659F315C9297769378AA92B6FE38" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Government National Mortgage Association and other U.S. government guaranteed asset-back securities [Member]</link:label>
    <link:label id="lab_us-gaap_GovernmentNationalMortgageAssociationCertificatesAndObligationsGNMAMember_89EF659F315C9297769378AA92B6FE38_label_en-US" xlink:label="lab_us-gaap_GovernmentNationalMortgageAssociationCertificatesAndObligationsGNMAMember_89EF659F315C9297769378AA92B6FE38" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Government National Mortgage Association Certificates and Obligations (GNMA) [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GovernmentNationalMortgageAssociationCertificatesAndObligationsGNMAMember" xlink:label="loc_us-gaap_GovernmentNationalMortgageAssociationCertificatesAndObligationsGNMAMember_89EF659F315C9297769378AA92B6FE38" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GovernmentNationalMortgageAssociationCertificatesAndObligationsGNMAMember_89EF659F315C9297769378AA92B6FE38" xlink:to="lab_us-gaap_GovernmentNationalMortgageAssociationCertificatesAndObligationsGNMAMember_89EF659F315C9297769378AA92B6FE38" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_A4DA7F9D7B2D4F3B043778AA92B65309_terseLabel_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember_A4DA7F9D7B2D4F3B043778AA92B65309" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other asset-backed debt [Member]</link:label>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_A4DA7F9D7B2D4F3B043778AA92B65309_label_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember_A4DA7F9D7B2D4F3B043778AA92B65309" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset-backed Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_A4DA7F9D7B2D4F3B043778AA92B65309" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetBackedSecuritiesMember_A4DA7F9D7B2D4F3B043778AA92B65309" xlink:to="lab_us-gaap_AssetBackedSecuritiesMember_A4DA7F9D7B2D4F3B043778AA92B65309" xlink:type="arc" />
    <link:label id="lab_us-gaap_USGovernmentDebtSecuritiesMember_3DBEE0FBEA65A8E0E64778AA92B61D9A_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentDebtSecuritiesMember_3DBEE0FBEA65A8E0E64778AA92B61D9A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. government debt [Member]</link:label>
    <link:label id="lab_us-gaap_USGovernmentDebtSecuritiesMember_3DBEE0FBEA65A8E0E64778AA92B61D9A_label_en-US" xlink:label="lab_us-gaap_USGovernmentDebtSecuritiesMember_3DBEE0FBEA65A8E0E64778AA92B61D9A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Government Debt Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_USGovernmentDebtSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentDebtSecuritiesMember_3DBEE0FBEA65A8E0E64778AA92B61D9A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentDebtSecuritiesMember_3DBEE0FBEA65A8E0E64778AA92B61D9A" xlink:to="lab_us-gaap_USGovernmentDebtSecuritiesMember_3DBEE0FBEA65A8E0E64778AA92B61D9A" xlink:type="arc" />
    <link:label id="lab_pfe_TimeDepositsCorporateDebtAndOtherMember_4E27277A92FBD0C3817D78AA92B7E012_terseLabel_en-US" xlink:label="lab_pfe_TimeDepositsCorporateDebtAndOtherMember_4E27277A92FBD0C3817D78AA92B7E012" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Time deposits and other [Member]</link:label>
    <link:label id="lab_pfe_TimeDepositsCorporateDebtAndOtherMember_4E27277A92FBD0C3817D78AA92B7E012_label_en-US" xlink:label="lab_pfe_TimeDepositsCorporateDebtAndOtherMember_4E27277A92FBD0C3817D78AA92B7E012" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Time Deposits, Corporate Debt And Other [Member]</link:label>
    <link:label id="lab_pfe_TimeDepositsCorporateDebtAndOtherMember_4E27277A92FBD0C3817D78AA92B7E012_documentation_en-US" xlink:label="lab_pfe_TimeDepositsCorporateDebtAndOtherMember_4E27277A92FBD0C3817D78AA92B7E012" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Time Deposits, Corporate Debt And Other [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_TimeDepositsCorporateDebtAndOtherMember" xlink:label="loc_pfe_TimeDepositsCorporateDebtAndOtherMember_4E27277A92FBD0C3817D78AA92B7E012" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_TimeDepositsCorporateDebtAndOtherMember_4E27277A92FBD0C3817D78AA92B7E012" xlink:to="lab_pfe_TimeDepositsCorporateDebtAndOtherMember_4E27277A92FBD0C3817D78AA92B7E012" xlink:type="arc" />
    <link:label id="lab_pfe_WesternEuropeanandOtherGovernmentDebtMember_DC371F58241A67D2293C78AA92B7DF8A_terseLabel_en-US" xlink:label="lab_pfe_WesternEuropeanandOtherGovernmentDebtMember_DC371F58241A67D2293C78AA92B7DF8A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Western European government debt [Member]</link:label>
    <link:label id="lab_pfe_WesternEuropeanandOtherGovernmentDebtMember_DC371F58241A67D2293C78AA92B7DF8A_label_en-US" xlink:label="lab_pfe_WesternEuropeanandOtherGovernmentDebtMember_DC371F58241A67D2293C78AA92B7DF8A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Western European and Other Government Debt [Member]</link:label>
    <link:label id="lab_pfe_WesternEuropeanandOtherGovernmentDebtMember_DC371F58241A67D2293C78AA92B7DF8A_documentation_en-US" xlink:label="lab_pfe_WesternEuropeanandOtherGovernmentDebtMember_DC371F58241A67D2293C78AA92B7DF8A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Western European and Other Government Debt [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_WesternEuropeanandOtherGovernmentDebtMember" xlink:label="loc_pfe_WesternEuropeanandOtherGovernmentDebtMember_DC371F58241A67D2293C78AA92B7DF8A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_WesternEuropeanandOtherGovernmentDebtMember_DC371F58241A67D2293C78AA92B7DF8A" xlink:to="lab_pfe_WesternEuropeanandOtherGovernmentDebtMember_DC371F58241A67D2293C78AA92B7DF8A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfInvestmentsLineItems_A64830A5E08CAF95AC4678AA92B7E9C1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentsLineItems_A64830A5E08CAF95AC4678AA92B7E9C1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Debt Securities [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentsLineItems_A64830A5E08CAF95AC4678AA92B7E9C1_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentsLineItems_A64830A5E08CAF95AC4678AA92B7E9C1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Investments [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfInvestmentsLineItems" xlink:label="loc_us-gaap_ScheduleOfInvestmentsLineItems_A64830A5E08CAF95AC4678AA92B7E9C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_A64830A5E08CAF95AC4678AA92B7E9C1" xlink:to="lab_us-gaap_ScheduleOfInvestmentsLineItems_A64830A5E08CAF95AC4678AA92B7E9C1" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue_7F3DAEF96C226F9CCA9B78AA92B7DCD8_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue_7F3DAEF96C226F9CCA9B78AA92B7DCD8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Available-for-sale debt securities maturities within 1 year</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue_7F3DAEF96C226F9CCA9B78AA92B7DCD8_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue_7F3DAEF96C226F9CCA9B78AA92B7DCD8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Debt Maturities, Next Rolling Twelve Months, Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue_7F3DAEF96C226F9CCA9B78AA92B7DCD8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue_7F3DAEF96C226F9CCA9B78AA92B7DCD8" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue_7F3DAEF96C226F9CCA9B78AA92B7DCD8" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue_C9752945532AD01CEBD678AA92B7E208_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue_C9752945532AD01CEBD678AA92B7E208" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Available-for-sale debt securities maturities over 1 to 5 years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue_C9752945532AD01CEBD678AA92B7E208_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue_C9752945532AD01CEBD678AA92B7E208" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Debt Maturities, Rolling Year Two Through Five, Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue_C9752945532AD01CEBD678AA92B7E208" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue_C9752945532AD01CEBD678AA92B7E208" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue_C9752945532AD01CEBD678AA92B7E208" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearSixThroughTenFairValue_670BA5D746D5AE0E305C78AA92B76099_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearSixThroughTenFairValue_670BA5D746D5AE0E305C78AA92B76099" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Available-for-sale debt securities maturities over 5 to 10 years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearSixThroughTenFairValue_670BA5D746D5AE0E305C78AA92B76099_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearSixThroughTenFairValue_670BA5D746D5AE0E305C78AA92B76099" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Debt Maturities, Rolling Year Six Through Ten, Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearSixThroughTenFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearSixThroughTenFairValue_670BA5D746D5AE0E305C78AA92B76099" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearSixThroughTenFairValue_670BA5D746D5AE0E305C78AA92B76099" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearSixThroughTenFairValue_670BA5D746D5AE0E305C78AA92B76099" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingAfterYearTenFairValue_B83630CFB8696D07E88578AA92B7DE4B_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingAfterYearTenFairValue_B83630CFB8696D07E88578AA92B7DE4B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Available-for-sale debt securities maturities over 10 years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingAfterYearTenFairValue_B83630CFB8696D07E88578AA92B7DE4B_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingAfterYearTenFairValue_B83630CFB8696D07E88578AA92B7DE4B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Debt Maturities, Rolling after Year Ten, Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingAfterYearTenFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingAfterYearTenFairValue_B83630CFB8696D07E88578AA92B7DE4B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingAfterYearTenFairValue_B83630CFB8696D07E88578AA92B7DE4B" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingAfterYearTenFairValue_B83630CFB8696D07E88578AA92B7DE4B" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_C4367B456D1BDD012F1A78AA92B86676_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_C4367B456D1BDD012F1A78AA92B86676" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Available-for-sale debt securities maturities total</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_C4367B456D1BDD012F1A78AA92B86676_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_C4367B456D1BDD012F1A78AA92B86676" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Debt Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_C4367B456D1BDD012F1A78AA92B86676" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_C4367B456D1BDD012F1A78AA92B86676" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_C4367B456D1BDD012F1A78AA92B86676" xlink:type="arc" />
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue_9A9BBB1EA0953898D71978AA92B8BDAC_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue_9A9BBB1EA0953898D71978AA92B8BDAC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Held-to-maturity debt securities maturities within 1 year</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue_9A9BBB1EA0953898D71978AA92B8BDAC_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue_9A9BBB1EA0953898D71978AA92B8BDAC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Held-to-maturity Securities, Debt Maturities, Next Rolling Twelve Months, Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue_9A9BBB1EA0953898D71978AA92B8BDAC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue_9A9BBB1EA0953898D71978AA92B8BDAC" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue_9A9BBB1EA0953898D71978AA92B8BDAC" xlink:type="arc" />
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue_A21CAE365F9B6009B17878AA92B86B69_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue_A21CAE365F9B6009B17878AA92B86B69" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Held-to-maturity debt securities with maturities over 1 to 5 years</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue_A21CAE365F9B6009B17878AA92B86B69_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue_A21CAE365F9B6009B17878AA92B86B69" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Held-to-maturity Securities, Debt Maturities, Rolling Year Two Through Five, Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue_A21CAE365F9B6009B17878AA92B86B69" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue_A21CAE365F9B6009B17878AA92B86B69" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue_A21CAE365F9B6009B17878AA92B86B69" xlink:type="arc" />
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesRollingYearSixThroughTenFairValue_D1831CABE6685FFFB00A78AA92B8F1C8_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesRollingYearSixThroughTenFairValue_D1831CABE6685FFFB00A78AA92B8F1C8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Held-to-maturity debt securities maturities over 5 to 10 years</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesRollingYearSixThroughTenFairValue_D1831CABE6685FFFB00A78AA92B8F1C8_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesRollingYearSixThroughTenFairValue_D1831CABE6685FFFB00A78AA92B8F1C8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Held-to-maturity Securities, Debt Maturities, Rolling Year Six Through Ten, Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesRollingYearSixThroughTenFairValue" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesRollingYearSixThroughTenFairValue_D1831CABE6685FFFB00A78AA92B8F1C8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesRollingYearSixThroughTenFairValue_D1831CABE6685FFFB00A78AA92B8F1C8" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesRollingYearSixThroughTenFairValue_D1831CABE6685FFFB00A78AA92B8F1C8" xlink:type="arc" />
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesRollingAfterTenYearsFairValue_7AF9BDB355A73F8DE7B078AA92B8AA34_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesRollingAfterTenYearsFairValue_7AF9BDB355A73F8DE7B078AA92B8AA34" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Held-to-maturity debt securities maturities over 10 years</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesRollingAfterTenYearsFairValue_7AF9BDB355A73F8DE7B078AA92B8AA34_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesRollingAfterTenYearsFairValue_7AF9BDB355A73F8DE7B078AA92B8AA34" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Held-to-maturity Securities, Debt Maturities, Rolling after Ten Years, Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesRollingAfterTenYearsFairValue" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesRollingAfterTenYearsFairValue_7AF9BDB355A73F8DE7B078AA92B8AA34" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesRollingAfterTenYearsFairValue_7AF9BDB355A73F8DE7B078AA92B8AA34" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesRollingAfterTenYearsFairValue_7AF9BDB355A73F8DE7B078AA92B8AA34" xlink:type="arc" />
    <link:label id="lab_us-gaap_HeldToMaturitySecurities_9A0F3DF4B3089CB57A8F78AA92B8A7D9_totalLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecurities_9A0F3DF4B3089CB57A8F78AA92B8A7D9" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Held-to-maturity debt securities maturities total</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecurities_9A0F3DF4B3089CB57A8F78AA92B8A7D9_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecurities_9A0F3DF4B3089CB57A8F78AA92B8A7D9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Held-to-maturity Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HeldToMaturitySecurities" xlink:label="loc_us-gaap_HeldToMaturitySecurities_9A0F3DF4B3089CB57A8F78AA92B8A7D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecurities_9A0F3DF4B3089CB57A8F78AA92B8A7D9" xlink:to="lab_us-gaap_HeldToMaturitySecurities_9A0F3DF4B3089CB57A8F78AA92B8A7D9" xlink:type="arc" />
    <link:label id="lab_pfe_DebtSecuritiesMaturitiesWithinOneYear_22A320D28C9E0CB0554A78AA92B8D19C_totalLabel_en-US" xlink:label="lab_pfe_DebtSecuritiesMaturitiesWithinOneYear_22A320D28C9E0CB0554A78AA92B8D19C" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Debt securities maturities within one year</link:label>
    <link:label id="lab_pfe_DebtSecuritiesMaturitiesWithinOneYear_22A320D28C9E0CB0554A78AA92B8D19C_label_en-US" xlink:label="lab_pfe_DebtSecuritiesMaturitiesWithinOneYear_22A320D28C9E0CB0554A78AA92B8D19C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities Maturities Within One Year</link:label>
    <link:label id="lab_pfe_DebtSecuritiesMaturitiesWithinOneYear_22A320D28C9E0CB0554A78AA92B8D19C_documentation_en-US" xlink:label="lab_pfe_DebtSecuritiesMaturitiesWithinOneYear_22A320D28C9E0CB0554A78AA92B8D19C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This item represents debt securities which are expected to mature within one year of the balance sheet date.</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_DebtSecuritiesMaturitiesWithinOneYear" xlink:label="loc_pfe_DebtSecuritiesMaturitiesWithinOneYear_22A320D28C9E0CB0554A78AA92B8D19C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DebtSecuritiesMaturitiesWithinOneYear_22A320D28C9E0CB0554A78AA92B8D19C" xlink:to="lab_pfe_DebtSecuritiesMaturitiesWithinOneYear_22A320D28C9E0CB0554A78AA92B8D19C" xlink:type="arc" />
    <link:label id="lab_pfe_DebtSecuritiesMaturitiesOverOneToFiveYears_D8703D4D586E410647AC78AA92B9700D_totalLabel_en-US" xlink:label="lab_pfe_DebtSecuritiesMaturitiesOverOneToFiveYears_D8703D4D586E410647AC78AA92B9700D" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Debt securities maturities over 1 to 5 years</link:label>
    <link:label id="lab_pfe_DebtSecuritiesMaturitiesOverOneToFiveYears_D8703D4D586E410647AC78AA92B9700D_label_en-US" xlink:label="lab_pfe_DebtSecuritiesMaturitiesOverOneToFiveYears_D8703D4D586E410647AC78AA92B9700D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities Maturities Over One To Five Years</link:label>
    <link:label id="lab_pfe_DebtSecuritiesMaturitiesOverOneToFiveYears_D8703D4D586E410647AC78AA92B9700D_documentation_en-US" xlink:label="lab_pfe_DebtSecuritiesMaturitiesOverOneToFiveYears_D8703D4D586E410647AC78AA92B9700D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This item represents debt securities which are expected to mature after one year and through five years from the balance sheet date.</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_DebtSecuritiesMaturitiesOverOneToFiveYears" xlink:label="loc_pfe_DebtSecuritiesMaturitiesOverOneToFiveYears_D8703D4D586E410647AC78AA92B9700D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DebtSecuritiesMaturitiesOverOneToFiveYears_D8703D4D586E410647AC78AA92B9700D" xlink:to="lab_pfe_DebtSecuritiesMaturitiesOverOneToFiveYears_D8703D4D586E410647AC78AA92B9700D" xlink:type="arc" />
    <link:label id="lab_pfe_DebtSecuritiesMaturitiesOverFiveToTenYears_DF1DBDFC358B17AF3EB478AA92B9CCEA_totalLabel_en-US" xlink:label="lab_pfe_DebtSecuritiesMaturitiesOverFiveToTenYears_DF1DBDFC358B17AF3EB478AA92B9CCEA" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Debt securities maturities over 5 to 10 years</link:label>
    <link:label id="lab_pfe_DebtSecuritiesMaturitiesOverFiveToTenYears_DF1DBDFC358B17AF3EB478AA92B9CCEA_label_en-US" xlink:label="lab_pfe_DebtSecuritiesMaturitiesOverFiveToTenYears_DF1DBDFC358B17AF3EB478AA92B9CCEA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities Maturities Over Five To Ten Years</link:label>
    <link:label id="lab_pfe_DebtSecuritiesMaturitiesOverFiveToTenYears_DF1DBDFC358B17AF3EB478AA92B9CCEA_documentation_en-US" xlink:label="lab_pfe_DebtSecuritiesMaturitiesOverFiveToTenYears_DF1DBDFC358B17AF3EB478AA92B9CCEA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This item represents debt securities which are expected to mature after five and through ten years from the balance sheet date.</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_DebtSecuritiesMaturitiesOverFiveToTenYears" xlink:label="loc_pfe_DebtSecuritiesMaturitiesOverFiveToTenYears_DF1DBDFC358B17AF3EB478AA92B9CCEA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DebtSecuritiesMaturitiesOverFiveToTenYears_DF1DBDFC358B17AF3EB478AA92B9CCEA" xlink:to="lab_pfe_DebtSecuritiesMaturitiesOverFiveToTenYears_DF1DBDFC358B17AF3EB478AA92B9CCEA" xlink:type="arc" />
    <link:label id="lab_pfe_DebtSecuritiesMaturitiesAfterTenYears_D62A663ECCA81C74435078AA92B9D1B3_totalLabel_en-US" xlink:label="lab_pfe_DebtSecuritiesMaturitiesAfterTenYears_D62A663ECCA81C74435078AA92B9D1B3" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Debt securities maturities over 10 years</link:label>
    <link:label id="lab_pfe_DebtSecuritiesMaturitiesAfterTenYears_D62A663ECCA81C74435078AA92B9D1B3_label_en-US" xlink:label="lab_pfe_DebtSecuritiesMaturitiesAfterTenYears_D62A663ECCA81C74435078AA92B9D1B3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities Maturities After Ten Years</link:label>
    <link:label id="lab_pfe_DebtSecuritiesMaturitiesAfterTenYears_D62A663ECCA81C74435078AA92B9D1B3_documentation_en-US" xlink:label="lab_pfe_DebtSecuritiesMaturitiesAfterTenYears_D62A663ECCA81C74435078AA92B9D1B3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Securities Maturities After Ten Years</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_DebtSecuritiesMaturitiesAfterTenYears" xlink:label="loc_pfe_DebtSecuritiesMaturitiesAfterTenYears_D62A663ECCA81C74435078AA92B9D1B3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DebtSecuritiesMaturitiesAfterTenYears_D62A663ECCA81C74435078AA92B9D1B3" xlink:to="lab_pfe_DebtSecuritiesMaturitiesAfterTenYears_D62A663ECCA81C74435078AA92B9D1B3" xlink:type="arc" />
    <link:label id="lab_pfe_DebtSecurities_07220525955D29F6F70E78AA92B90D05_totalLabel_en-US" xlink:label="lab_pfe_DebtSecurities_07220525955D29F6F70E78AA92B90D05" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total debt securities</link:label>
    <link:label id="lab_pfe_DebtSecurities_07220525955D29F6F70E78AA92B90D05_label_en-US" xlink:label="lab_pfe_DebtSecurities_07220525955D29F6F70E78AA92B90D05" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities</link:label>
    <link:label id="lab_pfe_DebtSecurities_07220525955D29F6F70E78AA92B90D05_documentation_en-US" xlink:label="lab_pfe_DebtSecurities_07220525955D29F6F70E78AA92B90D05" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This item represents the total of all debt securities grouped by maturity dates.</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_DebtSecurities" xlink:label="loc_pfe_DebtSecurities_07220525955D29F6F70E78AA92B90D05" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DebtSecurities_07220525955D29F6F70E78AA92B90D05" xlink:to="lab_pfe_DebtSecurities_07220525955D29F6F70E78AA92B90D05" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementAbstract_64685388D78491E2F65A7EA6FEE4D4AA_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract_64685388D78491E2F65A7EA6FEE4D4AA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_64685388D78491E2F65A7EA6FEE4D4AA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract_64685388D78491E2F65A7EA6FEE4D4AA" xlink:to="lab_us-gaap_IncomeStatementAbstract_64685388D78491E2F65A7EA6FEE4D4AA" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_273F730C1F44F27684027EA6FEE5E533_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract_273F730C1F44F27684027EA6FEE5E533" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Costs and expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_273F730C1F44F27684027EA6FEE5E533_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract_273F730C1F44F27684027EA6FEE5E533" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_273F730C1F44F27684027EA6FEE5E533" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_273F730C1F44F27684027EA6FEE5E533" xlink:to="lab_us-gaap_CostsAndExpensesAbstract_273F730C1F44F27684027EA6FEE5E533" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostOfGoodsSold_A2D72BFF1DC38A805E947EA6FEE5F36B_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsSold_A2D72BFF1DC38A805E947EA6FEE5F36B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of sales</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsSold_A2D72BFF1DC38A805E947EA6FEE5F36B_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsSold_A2D72BFF1DC38A805E947EA6FEE5F36B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Goods Sold</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="loc_us-gaap_CostOfGoodsSold_A2D72BFF1DC38A805E947EA6FEE5F36B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsSold_A2D72BFF1DC38A805E947EA6FEE5F36B" xlink:to="lab_us-gaap_CostOfGoodsSold_A2D72BFF1DC38A805E947EA6FEE5F36B" xlink:type="arc" />
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_576359943B3F25CFB0807EA6FEE5242F_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense_576359943B3F25CFB0807EA6FEE5242F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, informational and administrative expenses</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_576359943B3F25CFB0807EA6FEE5242F_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense_576359943B3F25CFB0807EA6FEE5242F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_576359943B3F25CFB0807EA6FEE5242F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense_576359943B3F25CFB0807EA6FEE5242F" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense_576359943B3F25CFB0807EA6FEE5242F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_2540AC7243661946F52A7EA6FEE507E1_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_2540AC7243661946F52A7EA6FEE507E1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Research and development expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_2540AC7243661946F52A7EA6FEE507E1_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_2540AC7243661946F52A7EA6FEE507E1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_2540AC7243661946F52A7EA6FEE507E1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_2540AC7243661946F52A7EA6FEE507E1" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_2540AC7243661946F52A7EA6FEE507E1" xlink:type="arc" />
    <link:label id="lab_pfe_AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction_22E9F8BB6DA3E845A7737EA6FEE5A01F_terseLabel_en-US" xlink:label="lab_pfe_AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction_22E9F8BB6DA3E845A7737EA6FEE5A01F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_pfe_AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction_22E9F8BB6DA3E845A7737EA6FEE5A01F_label_en-US" xlink:label="lab_pfe_AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction_22E9F8BB6DA3E845A7737EA6FEE5A01F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization Of Intangible Assets Not Associated With Single Function</link:label>
    <link:label id="lab_pfe_AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction_22E9F8BB6DA3E845A7737EA6FEE5A01F_documentation_en-US" xlink:label="lab_pfe_AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction_22E9F8BB6DA3E845A7737EA6FEE5A01F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of amortization that is not associated with a single function. Amounts associated in a single function are included in Cost of sales, Selling, information and administrative expenses and Research and development expenses.</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction" xlink:label="loc_pfe_AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction_22E9F8BB6DA3E845A7737EA6FEE5A01F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction_22E9F8BB6DA3E845A7737EA6FEE5A01F" xlink:to="lab_pfe_AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction_22E9F8BB6DA3E845A7737EA6FEE5A01F" xlink:type="arc" />
    <link:label id="lab_pfe_RestructuringChargesAndAcquisitionRelatedCosts_A5166CE0FAB9F492BF0F7EA6FEE592DD_terseLabel_en-US" xlink:label="lab_pfe_RestructuringChargesAndAcquisitionRelatedCosts_A5166CE0FAB9F492BF0F7EA6FEE592DD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring charges and certain acquisition-related costs</link:label>
    <link:label id="lab_pfe_RestructuringChargesAndAcquisitionRelatedCosts_A5166CE0FAB9F492BF0F7EA6FEE592DD_label_en-US" xlink:label="lab_pfe_RestructuringChargesAndAcquisitionRelatedCosts_A5166CE0FAB9F492BF0F7EA6FEE592DD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Charges And Acquisition Related Costs</link:label>
    <link:label id="lab_pfe_RestructuringChargesAndAcquisitionRelatedCosts_A5166CE0FAB9F492BF0F7EA6FEE592DD_documentation_en-US" xlink:label="lab_pfe_RestructuringChargesAndAcquisitionRelatedCosts_A5166CE0FAB9F492BF0F7EA6FEE592DD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This element represents (i) restructuring charges, which are amounts charged against earnings in the period for incurred and estimated costs associated with exit from or disposal of business activities or restructurings pursuant to a program that is planned and controlled by management, and materially changes either the scope of a business undertaken by an entity, or the manner in which that business is conducted; and (ii) acquisition-related costs, which are costs incurred to effect a business combination which costs have been expensed during the period. Such costs can include transaction costs such as banking, legal, accounting and other costs directly related to effect a business combination as well as external, incremental costs of integration planning that are directly related to a business combination, including costs associated with preparing for systems and other integration activities.</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_RestructuringChargesAndAcquisitionRelatedCosts" xlink:label="loc_pfe_RestructuringChargesAndAcquisitionRelatedCosts_A5166CE0FAB9F492BF0F7EA6FEE592DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_RestructuringChargesAndAcquisitionRelatedCosts_A5166CE0FAB9F492BF0F7EA6FEE592DD" xlink:to="lab_pfe_RestructuringChargesAndAcquisitionRelatedCosts_A5166CE0FAB9F492BF0F7EA6FEE592DD" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_DAAC7B846FED6527811D7EA6FEE5900B_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_DAAC7B846FED6527811D7EA6FEE5900B" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other (income)/deductions&#8211;&#8211;net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_DAAC7B846FED6527811D7EA6FEE5900B_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_DAAC7B846FED6527811D7EA6FEE5900B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_DAAC7B846FED6527811D7EA6FEE5900B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_DAAC7B846FED6527811D7EA6FEE5900B" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense_DAAC7B846FED6527811D7EA6FEE5900B" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1335AEBA2296382B8EEE7EA6FEE58734_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1335AEBA2296382B8EEE7EA6FEE58734" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income from continuing operations before provision for taxes on income</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1335AEBA2296382B8EEE7EA6FEE58734_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1335AEBA2296382B8EEE7EA6FEE58734" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1335AEBA2296382B8EEE7EA6FEE58734" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1335AEBA2296382B8EEE7EA6FEE58734" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1335AEBA2296382B8EEE7EA6FEE58734" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_4E478D07E0472B967CAB7EA6FEE5DC0A_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_4E478D07E0472B967CAB7EA6FEE5DC0A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provision for taxes on income</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_4E478D07E0472B967CAB7EA6FEE5DC0A_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_4E478D07E0472B967CAB7EA6FEE5DC0A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_4E478D07E0472B967CAB7EA6FEE5DC0A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_4E478D07E0472B967CAB7EA6FEE5DC0A" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_4E478D07E0472B967CAB7EA6FEE5DC0A" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_9E0296CF45D128E2DE907EA6FEE5931F_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_9E0296CF45D128E2DE907EA6FEE5931F" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income from continuing operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_9E0296CF45D128E2DE907EA6FEE5931F_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_9E0296CF45D128E2DE907EA6FEE5931F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_9E0296CF45D128E2DE907EA6FEE5931F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_9E0296CF45D128E2DE907EA6FEE5931F" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_9E0296CF45D128E2DE907EA6FEE5931F" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_01E03CA8AE2486BA08B37EA6FEE598F4_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_01E03CA8AE2486BA08B37EA6FEE598F4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Discontinued operations&#8211;&#8211;net of tax</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_01E03CA8AE2486BA08B37EA6FEE598F4_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_01E03CA8AE2486BA08B37EA6FEE598F4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_01E03CA8AE2486BA08B37EA6FEE598F4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_01E03CA8AE2486BA08B37EA6FEE598F4" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_01E03CA8AE2486BA08B37EA6FEE598F4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProfitLoss_C0BCF592ADDB4A91DA5F7EA6FEE583DE_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss_C0BCF592ADDB4A91DA5F7EA6FEE583DE" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net income before allocation to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_C0BCF592ADDB4A91DA5F7EA6FEE583DE_label_en-US" xlink:label="lab_us-gaap_ProfitLoss_C0BCF592ADDB4A91DA5F7EA6FEE583DE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_C0BCF592ADDB4A91DA5F7EA6FEE583DE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss_C0BCF592ADDB4A91DA5F7EA6FEE583DE" xlink:to="lab_us-gaap_ProfitLoss_C0BCF592ADDB4A91DA5F7EA6FEE583DE" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_617CD10DE1F4DAE60DB27EA6FEE573D0_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_617CD10DE1F4DAE60DB27EA6FEE573D0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Less: Net income attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_617CD10DE1F4DAE60DB27EA6FEE573D0_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_617CD10DE1F4DAE60DB27EA6FEE573D0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_617CD10DE1F4DAE60DB27EA6FEE573D0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_617CD10DE1F4DAE60DB27EA6FEE573D0" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_617CD10DE1F4DAE60DB27EA6FEE573D0" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_071F67558CE4E1386E747EA6FEE5A8D6_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_071F67558CE4E1386E747EA6FEE5A8D6" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net income attributable to Pfizer Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_071F67558CE4E1386E747EA6FEE5A8D6_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_071F67558CE4E1386E747EA6FEE5A8D6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_071F67558CE4E1386E747EA6FEE5A8D6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_071F67558CE4E1386E747EA6FEE5A8D6" xlink:to="lab_us-gaap_NetIncomeLoss_071F67558CE4E1386E747EA6FEE5A8D6" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_11D201C9CCD19F67E3267EA6FEE584E2_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract_11D201C9CCD19F67E3267EA6FEE584E2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings per common share&#8211;&#8211;basic:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_11D201C9CCD19F67E3267EA6FEE584E2_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract_11D201C9CCD19F67E3267EA6FEE584E2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_11D201C9CCD19F67E3267EA6FEE584E2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_11D201C9CCD19F67E3267EA6FEE584E2" xlink:to="lab_us-gaap_EarningsPerShareBasicAbstract_11D201C9CCD19F67E3267EA6FEE584E2" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_B87B48F51839C7139F5C7EA6FEE52FEC_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_B87B48F51839C7139F5C7EA6FEE52FEC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_B87B48F51839C7139F5C7EA6FEE52FEC_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_B87B48F51839C7139F5C7EA6FEE52FEC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Basic Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_B87B48F51839C7139F5C7EA6FEE52FEC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_B87B48F51839C7139F5C7EA6FEE52FEC" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_B87B48F51839C7139F5C7EA6FEE52FEC" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_579D580453E97E052ABE7EA6FEE6ACA0_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_579D580453E97E052ABE7EA6FEE6ACA0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discontinued operations&#8211;&#8211;net of tax (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_579D580453E97E052ABE7EA6FEE6ACA0_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_579D580453E97E052ABE7EA6FEE6ACA0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_579D580453E97E052ABE7EA6FEE6ACA0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_579D580453E97E052ABE7EA6FEE6ACA0" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_579D580453E97E052ABE7EA6FEE6ACA0" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasic_0048B25B9B539096D6E27EA6FEE66857_totalLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic_0048B25B9B539096D6E27EA6FEE66857" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net income attributable to Pfizer Inc. common shareholders (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_0048B25B9B539096D6E27EA6FEE66857_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic_0048B25B9B539096D6E27EA6FEE66857" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_0048B25B9B539096D6E27EA6FEE66857" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic_0048B25B9B539096D6E27EA6FEE66857" xlink:to="lab_us-gaap_EarningsPerShareBasic_0048B25B9B539096D6E27EA6FEE66857" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareDilutedAbstract_246EA5AF43EB7DA3B0157EA6FEE68796_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedAbstract_246EA5AF43EB7DA3B0157EA6FEE68796" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings per common share&#8211;&#8211;diluted:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedAbstract_246EA5AF43EB7DA3B0157EA6FEE68796_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedAbstract_246EA5AF43EB7DA3B0157EA6FEE68796" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareDilutedAbstract" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract_246EA5AF43EB7DA3B0157EA6FEE68796" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_246EA5AF43EB7DA3B0157EA6FEE68796" xlink:to="lab_us-gaap_EarningsPerShareDilutedAbstract_246EA5AF43EB7DA3B0157EA6FEE68796" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_E106F9E8241B4FBA95A37EA6FEE6D0E3_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_E106F9E8241B4FBA95A37EA6FEE6D0E3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_E106F9E8241B4FBA95A37EA6FEE6D0E3_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_E106F9E8241B4FBA95A37EA6FEE6D0E3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Diluted Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_E106F9E8241B4FBA95A37EA6FEE6D0E3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_E106F9E8241B4FBA95A37EA6FEE6D0E3" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_E106F9E8241B4FBA95A37EA6FEE6D0E3" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_E1D17E8DB3820F172EC97EA6FEE60544_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_E1D17E8DB3820F172EC97EA6FEE60544" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discontinued operations&#8211;&#8211;net of tax (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_E1D17E8DB3820F172EC97EA6FEE60544_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_E1D17E8DB3820F172EC97EA6FEE60544" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_E1D17E8DB3820F172EC97EA6FEE60544" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_E1D17E8DB3820F172EC97EA6FEE60544" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_E1D17E8DB3820F172EC97EA6FEE60544" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_2036C56CF2FED965FB8B7EA6FEE6DA9D_totalLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted_2036C56CF2FED965FB8B7EA6FEE6DA9D" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net income attributable to Pfizer Inc. common shareholders (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_2036C56CF2FED965FB8B7EA6FEE6DA9D_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted_2036C56CF2FED965FB8B7EA6FEE6DA9D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_2036C56CF2FED965FB8B7EA6FEE6DA9D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted_2036C56CF2FED965FB8B7EA6FEE6DA9D" xlink:to="lab_us-gaap_EarningsPerShareDiluted_2036C56CF2FED965FB8B7EA6FEE6DA9D" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_071324D69DDB53E348D37EA6FEE68F9C_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_071324D69DDB53E348D37EA6FEE68F9C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average shares&#8211;&#8211;basic</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_071324D69DDB53E348D37EA6FEE68F9C_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_071324D69DDB53E348D37EA6FEE68F9C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_071324D69DDB53E348D37EA6FEE68F9C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_071324D69DDB53E348D37EA6FEE68F9C" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_071324D69DDB53E348D37EA6FEE68F9C" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_846440AEE28A9EEA93497EA6FEE60350_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_846440AEE28A9EEA93497EA6FEE60350" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average shares&#8211;&#8211;diluted</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_846440AEE28A9EEA93497EA6FEE60350_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_846440AEE28A9EEA93497EA6FEE60350" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_846440AEE28A9EEA93497EA6FEE60350" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_846440AEE28A9EEA93497EA6FEE60350" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_846440AEE28A9EEA93497EA6FEE60350" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareCashPaid_4118EEF8CE9F6D7365D67EA6FEE690EE_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareCashPaid_4118EEF8CE9F6D7365D67EA6FEE690EE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash dividends paid per common share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareCashPaid_4118EEF8CE9F6D7365D67EA6FEE690EE_label_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareCashPaid_4118EEF8CE9F6D7365D67EA6FEE690EE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Dividends, Per Share, Cash Paid</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockDividendsPerShareCashPaid" xlink:label="loc_us-gaap_CommonStockDividendsPerShareCashPaid_4118EEF8CE9F6D7365D67EA6FEE690EE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockDividendsPerShareCashPaid_4118EEF8CE9F6D7365D67EA6FEE690EE" xlink:to="lab_us-gaap_CommonStockDividendsPerShareCashPaid_4118EEF8CE9F6D7365D67EA6FEE690EE" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_BF7373C36DEB50014C12AE9F92801938_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_66B485098B1F55F98C4CF427C00262A7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2018</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_BF7373C36DEB50014C12AE9F92801938_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_66B485098B1F55F98C4CF427C00262A7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Year Two</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_66B485098B1F55F98C4CF427C00262A7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_66B485098B1F55F98C4CF427C00262A7" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_66B485098B1F55F98C4CF427C00262A7" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_EE7C76837F04698BEE85AE9F9280341D_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_EBDD7A410767558EA65B40FDFF9173E2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2019</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_EE7C76837F04698BEE85AE9F9280341D_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_EBDD7A410767558EA65B40FDFF9173E2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Year Three</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_EBDD7A410767558EA65B40FDFF9173E2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_EBDD7A410767558EA65B40FDFF9173E2" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_EBDD7A410767558EA65B40FDFF9173E2" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_5B706DE34AF971B9A2E2AE9F928091B3_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_C5FAE6EB88385F5BAF10CE2B740982B3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2020</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_5B706DE34AF971B9A2E2AE9F928091B3_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_C5FAE6EB88385F5BAF10CE2B740982B3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Year Four</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_C5FAE6EB88385F5BAF10CE2B740982B3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_C5FAE6EB88385F5BAF10CE2B740982B3" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_C5FAE6EB88385F5BAF10CE2B740982B3" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_E58BF44B749B708EDBB1AE9F928072F9_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_F5ABF413955D54ACAF80E019FF6678E0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_E58BF44B749B708EDBB1AE9F928072F9_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_F5ABF413955D54ACAF80E019FF6678E0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_F5ABF413955D54ACAF80E019FF6678E0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_F5ABF413955D54ACAF80E019FF6678E0" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_F5ABF413955D54ACAF80E019FF6678E0" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_495998F65C465E8CFB35AE9F9280DB03_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_28E0AB16E9BA51FF94800FA138FABCD8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">After 2021</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_495998F65C465E8CFB35AE9F9280DB03_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_28E0AB16E9BA51FF94800FA138FABCD8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal after Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_28E0AB16E9BA51FF94800FA138FABCD8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_28E0AB16E9BA51FF94800FA138FABCD8" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_28E0AB16E9BA51FF94800FA138FABCD8" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebt_2F3E07902ECF7D601BF0AE9F9280BB42_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt_81FE1D1A8AD45D21AC3C067857E67765" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_2F3E07902ECF7D601BF0AE9F9280BB42_label_en-US" xlink:label="lab_us-gaap_LongTermDebt_81FE1D1A8AD45D21AC3C067857E67765" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_81FE1D1A8AD45D21AC3C067857E67765" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt_81FE1D1A8AD45D21AC3C067857E67765" xlink:to="lab_us-gaap_LongTermDebt_81FE1D1A8AD45D21AC3C067857E67765" xlink:type="arc" />
    <link:label id="lab_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsCollaborativeArrangementsEquityandCostMethodInvestmentsDisclosureTextBlock_37FA271FB7E954FCCE0BC2F7BBFB62B0_terseLabel_en-US" xlink:label="lab_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsCollaborativeArrangementsEquityandCostMethodInvestmentsDisclosureTextBlock_5BA7420DC8D15D10BECC32BC82E2E943" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisitions, Sale of Hospira Infusion Systems Net Assets, Collaborative Arrangement and Equity-Method Investments</link:label>
    <link:label id="lab_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsCollaborativeArrangementsEquityandCostMethodInvestmentsDisclosureTextBlock_37FA271FB7E954FCCE0BC2F7BBFB62B0_label_en-US" xlink:label="lab_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsCollaborativeArrangementsEquityandCostMethodInvestmentsDisclosureTextBlock_5BA7420DC8D15D10BECC32BC82E2E943" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combinations, Disposal Groups, Including Discontinued Operations, Collaborative Arrangements, Equity and Cost Method Investments Disclosure [Text Block]</link:label>
    <link:label id="lab_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsCollaborativeArrangementsEquityandCostMethodInvestmentsDisclosureTextBlock_37FA271FB7E954FCCE0BC2F7BBFB62B0_documentation_en-US" xlink:label="lab_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsCollaborativeArrangementsEquityandCostMethodInvestmentsDisclosureTextBlock_5BA7420DC8D15D10BECC32BC82E2E943" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combinations, Disposal Groups, Including Discontinued Operations, Collaborative Arrangements, Equity and Cost Method Investments Disclosure [Text Block]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsCollaborativeArrangementsEquityandCostMethodInvestmentsDisclosureTextBlock" xlink:label="loc_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsCollaborativeArrangementsEquityandCostMethodInvestmentsDisclosureTextBlock_5BA7420DC8D15D10BECC32BC82E2E943" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsCollaborativeArrangementsEquityandCostMethodInvestmentsDisclosureTextBlock_5BA7420DC8D15D10BECC32BC82E2E943" xlink:to="lab_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsCollaborativeArrangementsEquityandCostMethodInvestmentsDisclosureTextBlock_5BA7420DC8D15D10BECC32BC82E2E943" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_F0DCFFB8106035028DCFAE9F92F642F2_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_BF836A74013A577F9CA0357F94CB4D06" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_BF836A74013A577F9CA0357F94CB4D06" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_BF836A74013A577F9CA0357F94CB4D06" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_BF836A74013A577F9CA0357F94CB4D06" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_0DE892755BD967D71AFFAE9F92F6BFB8_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_0A5B3CE2DFDA5A80B36CF5FA7761D854" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_0DE892755BD967D71AFFAE9F92F6BFB8_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_0A5B3CE2DFDA5A80B36CF5FA7761D854" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_0A5B3CE2DFDA5A80B36CF5FA7761D854" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_0A5B3CE2DFDA5A80B36CF5FA7761D854" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_0A5B3CE2DFDA5A80B36CF5FA7761D854" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_8015E95264017F34BE56AE9F92DFFA8B_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_D46A5BADDBD85DF59713C3158C7F47C4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_8015E95264017F34BE56AE9F92DFFA8B_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_D46A5BADDBD85DF59713C3158C7F47C4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_D46A5BADDBD85DF59713C3158C7F47C4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_D46A5BADDBD85DF59713C3158C7F47C4" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_D46A5BADDBD85DF59713C3158C7F47C4" xlink:type="arc" />
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_7DF642D9FBD018F41E6AAE9F92DF8655_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis_21BBB950A1875DC6A16C489D1109346B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_7DF642D9FBD018F41E6AAE9F92DF8655_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis_21BBB950A1875DC6A16C489D1109346B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_21BBB950A1875DC6A16C489D1109346B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_21BBB950A1875DC6A16C489D1109346B" xlink:to="lab_us-gaap_BalanceSheetLocationAxis_21BBB950A1875DC6A16C489D1109346B" xlink:type="arc" />
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_F1EFDE05133ED3D36599AE9F92DFFB4E_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain_C02975828E5B59F89DA02A2D8BA8D641" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_F1EFDE05133ED3D36599AE9F92DFFB4E_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain_C02975828E5B59F89DA02A2D8BA8D641" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_C02975828E5B59F89DA02A2D8BA8D641" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_C02975828E5B59F89DA02A2D8BA8D641" xlink:to="lab_us-gaap_BalanceSheetLocationDomain_C02975828E5B59F89DA02A2D8BA8D641" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_CF3D2230897EB5F17F08AE9F92DFA014_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember_5C99509F109D5675AD0F1CE11172838F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Current Liabilities [Member]</link:label>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_CF3D2230897EB5F17F08AE9F92DFA014_label_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember_5C99509F109D5675AD0F1CE11172838F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Current Liabilities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_5C99509F109D5675AD0F1CE11172838F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentLiabilitiesMember_5C99509F109D5675AD0F1CE11172838F" xlink:to="lab_us-gaap_OtherCurrentLiabilitiesMember_5C99509F109D5675AD0F1CE11172838F" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_A6F2188B967D71FE9C5BAE9F92DF0B80_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember_DB9A9F85B2AD5CEE908FF0D336AD1C75" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Noncurrent Liabilities [Member]</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_A6F2188B967D71FE9C5BAE9F92DF0B80_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember_DB9A9F85B2AD5CEE908FF0D336AD1C75" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Noncurrent Liabilities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_DB9A9F85B2AD5CEE908FF0D336AD1C75" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentLiabilitiesMember_DB9A9F85B2AD5CEE908FF0D336AD1C75" xlink:to="lab_us-gaap_OtherNoncurrentLiabilitiesMember_DB9A9F85B2AD5CEE908FF0D336AD1C75" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_D4F1677393863DEF0DE6AE9F92DF480C_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems_679FD60BC0485791AEA222D56A33AEB6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_D4F1677393863DEF0DE6AE9F92DF480C_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems_679FD60BC0485791AEA222D56A33AEB6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_679FD60BC0485791AEA222D56A33AEB6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_679FD60BC0485791AEA222D56A33AEB6" xlink:to="lab_us-gaap_RestructuringCostAndReserveLineItems_679FD60BC0485791AEA222D56A33AEB6" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringReserve_CC8457ADF181FF4348A4AE9F92DFE672_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve_605DA31464FA56E0ABE89E8904FE141A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring reserve</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_CC8457ADF181FF4348A4AE9F92DFE672_label_en-US" xlink:label="lab_us-gaap_RestructuringReserve_605DA31464FA56E0ABE89E8904FE141A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Reserve</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringReserve" xlink:label="loc_us-gaap_RestructuringReserve_605DA31464FA56E0ABE89E8904FE141A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserve_605DA31464FA56E0ABE89E8904FE141A" xlink:to="lab_us-gaap_RestructuringReserve_605DA31464FA56E0ABE89E8904FE141A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_90566B8A7E9CCB789766831F4DF748BC_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_90566B8A7E9CCB789766831F4DF748BC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_90566B8A7E9CCB789766831F4DF748BC_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_90566B8A7E9CCB789766831F4DF748BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_90566B8A7E9CCB789766831F4DF748BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_90566B8A7E9CCB789766831F4DF748BC" xlink:to="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_90566B8A7E9CCB789766831F4DF748BC" xlink:type="arc" />
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_A42CB56934C171E3E6CF831F4DF7D133_verboseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_A42CB56934C171E3E6CF831F4DF7D133" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_A42CB56934C171E3E6CF831F4DF7D133" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_A42CB56934C171E3E6CF831F4DF7D133" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_A42CB56934C171E3E6CF831F4DF7D133" xlink:type="arc" />
    <link:label id="lab_us-gaap_TradeNamesMember_B54943A4A64DDA9E5740831F4DF782D3_verboseLabel_en-US" xlink:label="lab_us-gaap_TradeNamesMember_B54943A4A64DDA9E5740831F4DF782D3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Brands [Member]</link:label>
    <link:label id="lab_us-gaap_TradeNamesMember_B54943A4A64DDA9E5740831F4DF782D3_label_en-US" xlink:label="lab_us-gaap_TradeNamesMember_B54943A4A64DDA9E5740831F4DF782D3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade Names [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TradeNamesMember" xlink:label="loc_us-gaap_TradeNamesMember_B54943A4A64DDA9E5740831F4DF782D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeNamesMember_B54943A4A64DDA9E5740831F4DF782D3" xlink:to="lab_us-gaap_TradeNamesMember_B54943A4A64DDA9E5740831F4DF782D3" xlink:type="arc" />
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_ECA9B8E0411B3B738C73831F4DF72137_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_ECA9B8E0411B3B738C73831F4DF72137" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_ECA9B8E0411B3B738C73831F4DF72137_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_ECA9B8E0411B3B738C73831F4DF72137" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_ECA9B8E0411B3B738C73831F4DF72137" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_ECA9B8E0411B3B738C73831F4DF72137" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_ECA9B8E0411B3B738C73831F4DF72137" xlink:type="arc" />
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_A5A06B69F2A0E8885368831F4DF761FC_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_A5A06B69F2A0E8885368831F4DF761FC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_A5A06B69F2A0E8885368831F4DF761FC_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_A5A06B69F2A0E8885368831F4DF761FC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-Lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_A5A06B69F2A0E8885368831F4DF761FC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_A5A06B69F2A0E8885368831F4DF761FC" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_A5A06B69F2A0E8885368831F4DF761FC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_54376F526D9101D1C755831F4DF74845_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_54376F526D9101D1C755831F4DF74845" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_54376F526D9101D1C755831F4DF74845_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_54376F526D9101D1C755831F4DF74845" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_54376F526D9101D1C755831F4DF74845" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_54376F526D9101D1C755831F4DF74845" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_54376F526D9101D1C755831F4DF74845" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_4FCEFE7A9998B6B42ED2831F4DF70CDB_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_4FCEFE7A9998B6B42ED2831F4DF70CDB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_4FCEFE7A9998B6B42ED2831F4DF70CDB_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_4FCEFE7A9998B6B42ED2831F4DF70CDB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_4FCEFE7A9998B6B42ED2831F4DF70CDB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_4FCEFE7A9998B6B42ED2831F4DF70CDB" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_4FCEFE7A9998B6B42ED2831F4DF70CDB" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9446760460D29BC869C4831F4DF7F300_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9446760460D29BC869C4831F4DF7F300" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9446760460D29BC869C4831F4DF7F300_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9446760460D29BC869C4831F4DF7F300" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9446760460D29BC869C4831F4DF7F300" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9446760460D29BC869C4831F4DF7F300" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9446760460D29BC869C4831F4DF7F300" xlink:type="arc" />
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_D3BEBC2A564CF777AF48831F4DF80008_terseLabel_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember_D3BEBC2A564CF777AF48831F4DF80008" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Developed Technology Rights [Member]</link:label>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_D3BEBC2A564CF777AF48831F4DF80008_label_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember_D3BEBC2A564CF777AF48831F4DF80008" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Developed Technology Rights [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_D3BEBC2A564CF777AF48831F4DF80008" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DevelopedTechnologyRightsMember_D3BEBC2A564CF777AF48831F4DF80008" xlink:to="lab_us-gaap_DevelopedTechnologyRightsMember_D3BEBC2A564CF777AF48831F4DF80008" xlink:type="arc" />
    <link:label id="lab_pfe_LicensingAgreementsAndOtherMember_51D7B1A8D94C158BAC3D831F4DF807AF_terseLabel_en-US" xlink:label="lab_pfe_LicensingAgreementsAndOtherMember_51D7B1A8D94C158BAC3D831F4DF807AF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License Agreements and Other [Member]</link:label>
    <link:label id="lab_pfe_LicensingAgreementsAndOtherMember_51D7B1A8D94C158BAC3D831F4DF807AF_label_en-US" xlink:label="lab_pfe_LicensingAgreementsAndOtherMember_51D7B1A8D94C158BAC3D831F4DF807AF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Licensing Agreements And Other [Member]</link:label>
    <link:label id="lab_pfe_LicensingAgreementsAndOtherMember_51D7B1A8D94C158BAC3D831F4DF807AF_documentation_en-US" xlink:label="lab_pfe_LicensingAgreementsAndOtherMember_51D7B1A8D94C158BAC3D831F4DF807AF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Licensing Agreements And Other [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_LicensingAgreementsAndOtherMember" xlink:label="loc_pfe_LicensingAgreementsAndOtherMember_51D7B1A8D94C158BAC3D831F4DF807AF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_LicensingAgreementsAndOtherMember_51D7B1A8D94C158BAC3D831F4DF807AF" xlink:to="lab_pfe_LicensingAgreementsAndOtherMember_51D7B1A8D94C158BAC3D831F4DF807AF" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_3187CD8EAA6A3B2DC4A5831F4DF8074E_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_3187CD8EAA6A3B2DC4A5831F4DF8074E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_3187CD8EAA6A3B2DC4A5831F4DF8074E_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_3187CD8EAA6A3B2DC4A5831F4DF8074E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_3187CD8EAA6A3B2DC4A5831F4DF8074E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_3187CD8EAA6A3B2DC4A5831F4DF8074E" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_3187CD8EAA6A3B2DC4A5831F4DF8074E" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_F59D3CC10B6649DFBE8B831F4DF86F54_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross_F59D3CC10B6649DFBE8B831F4DF86F54" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-lived intangible assets, gross carrying amount</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_F59D3CC10B6649DFBE8B831F4DF86F54_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross_F59D3CC10B6649DFBE8B831F4DF86F54" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_F59D3CC10B6649DFBE8B831F4DF86F54" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross_F59D3CC10B6649DFBE8B831F4DF86F54" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross_F59D3CC10B6649DFBE8B831F4DF86F54" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_6735039BE1644746F4B8831F4DF81CA5_negatedLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_6735039BE1644746F4B8831F4DF81CA5" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Finite-lived intangible assets, accumulated amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_6735039BE1644746F4B8831F4DF81CA5_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_6735039BE1644746F4B8831F4DF81CA5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_6735039BE1644746F4B8831F4DF81CA5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_6735039BE1644746F4B8831F4DF81CA5" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_6735039BE1644746F4B8831F4DF81CA5" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_78E190F8687D3D6AE7CC831F4DF8A84E_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet_78E190F8687D3D6AE7CC831F4DF8A84E" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Finite-lived Intangible Assets, less Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_78E190F8687D3D6AE7CC831F4DF8A84E_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet_78E190F8687D3D6AE7CC831F4DF8A84E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_78E190F8687D3D6AE7CC831F4DF8A84E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_78E190F8687D3D6AE7CC831F4DF8A84E" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet_78E190F8687D3D6AE7CC831F4DF8A84E" xlink:type="arc" />
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_F416B6ABCA68D67F0991831F4DF88328_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_F416B6ABCA68D67F0991831F4DF88328" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Intangible assets, gross carrying amount</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_F416B6ABCA68D67F0991831F4DF88328_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_F416B6ABCA68D67F0991831F4DF88328" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Gross (Excluding Goodwill)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_F416B6ABCA68D67F0991831F4DF88328" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_F416B6ABCA68D67F0991831F4DF88328" xlink:to="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_F416B6ABCA68D67F0991831F4DF88328" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_4C729B36282CAFE0DA6F833BDF8A3B35_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_4C729B36282CAFE0DA6F833BDF8A3B35" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Finite-lived intangible assets, accumulated amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_4C729B36282CAFE0DA6F833BDF8A3B35" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_4C729B36282CAFE0DA6F833BDF8A3B35" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_4C729B36282CAFE0DA6F833BDF8A3B35" xlink:type="arc" />
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_4066F0C09C0A8669D359831F4DF8F372_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_4066F0C09C0A8669D359831F4DF8F372" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Identifiable Intangible Assets, less Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_4066F0C09C0A8669D359831F4DF8F372_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_4066F0C09C0A8669D359831F4DF8F372" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_4066F0C09C0A8669D359831F4DF8F372" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_4066F0C09C0A8669D359831F4DF8F372" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_4066F0C09C0A8669D359831F4DF8F372" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMember_DEE11DFCF47690CC02CAC353E5D335E8_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMember_70D5586D519056C2970E8B0081F42002" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Member]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMember_DEE11DFCF47690CC02CAC353E5D335E8_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMember_70D5586D519056C2970E8B0081F42002" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMember" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMember_70D5586D519056C2970E8B0081F42002" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMember_70D5586D519056C2970E8B0081F42002" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMember_70D5586D519056C2970E8B0081F42002" xlink:type="arc" />
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_CCF1269619F72F06CEB2C353E5D46E79_verboseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets_9D81C837E0B85203B907F1D08F8CE081" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Amortization expense for finite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_CCF1269619F72F06CEB2C353E5D46E79_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets_9D81C837E0B85203B907F1D08F8CE081" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_9D81C837E0B85203B907F1D08F8CE081" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets_9D81C837E0B85203B907F1D08F8CE081" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets_9D81C837E0B85203B907F1D08F8CE081" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_10B327E73E831EE5D3A702A6B8601A61_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract_10B327E73E831EE5D3A702A6B8601A61" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_10B327E73E831EE5D3A702A6B8601A61" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract_10B327E73E831EE5D3A702A6B8601A61" xlink:to="lab_us-gaap_EarningsPerShareAbstract_10B327E73E831EE5D3A702A6B8601A61" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_22D9C89968C0D9CEF77602A6B8617B05_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_22D9C89968C0D9CEF77602A6B8617B05" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_22D9C89968C0D9CEF77602A6B8617B05_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_22D9C89968C0D9CEF77602A6B8617B05" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_22D9C89968C0D9CEF77602A6B8617B05" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_22D9C89968C0D9CEF77602A6B8617B05" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_22D9C89968C0D9CEF77602A6B8617B05" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_489AE300F49771E002EB02A6B8617D16_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_489AE300F49771E002EB02A6B8617D16" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_489AE300F49771E002EB02A6B8617D16_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_489AE300F49771E002EB02A6B8617D16" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_489AE300F49771E002EB02A6B8617D16" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_489AE300F49771E002EB02A6B8617D16" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_489AE300F49771E002EB02A6B8617D16" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_588EB517129D3C1A670102A6B861C1AB_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_588EB517129D3C1A670102A6B861C1AB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_588EB517129D3C1A670102A6B861C1AB_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_588EB517129D3C1A670102A6B861C1AB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_588EB517129D3C1A670102A6B861C1AB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_588EB517129D3C1A670102A6B861C1AB" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain_588EB517129D3C1A670102A6B861C1AB" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockOptionMember_503125AB61B0643FC01702A6B861CE06_terseLabel_en-US" xlink:label="lab_us-gaap_StockOptionMember_503125AB61B0643FC01702A6B861CE06" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Option [Member]</link:label>
    <link:label id="lab_us-gaap_StockOptionMember_503125AB61B0643FC01702A6B861CE06_label_en-US" xlink:label="lab_us-gaap_StockOptionMember_503125AB61B0643FC01702A6B861CE06" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Option [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaap_StockOptionMember_503125AB61B0643FC01702A6B861CE06" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockOptionMember_503125AB61B0643FC01702A6B861CE06" xlink:to="lab_us-gaap_StockOptionMember_503125AB61B0643FC01702A6B861CE06" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1F7F5F50CDD9366C0DF002A6B8620604_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1F7F5F50CDD9366C0DF002A6B8620604" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1F7F5F50CDD9366C0DF002A6B8620604_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1F7F5F50CDD9366C0DF002A6B8620604" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1F7F5F50CDD9366C0DF002A6B8620604" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1F7F5F50CDD9366C0DF002A6B8620604" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1F7F5F50CDD9366C0DF002A6B8620604" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_A2BA5982DD04E5AE83D902A6B8620C3C_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract_A2BA5982DD04E5AE83D902A6B8620C3C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">EPS Numerator&#8211;&#8211;Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_A2BA5982DD04E5AE83D902A6B8620C3C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_A2BA5982DD04E5AE83D902A6B8620C3C" xlink:to="lab_us-gaap_EarningsPerShareBasicAbstract_A2BA5982DD04E5AE83D902A6B8620C3C" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_D08D65B5B9BB717A138202A6B8624F8B_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_D08D65B5B9BB717A138202A6B8624F8B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income from continuing operations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_D08D65B5B9BB717A138202A6B8624F8B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_D08D65B5B9BB717A138202A6B8624F8B" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_D08D65B5B9BB717A138202A6B8624F8B" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_9588C5AA962822119D8102A6B8637D72_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_9588C5AA962822119D8102A6B8637D72" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Less: Net income attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_9588C5AA962822119D8102A6B8637D72_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_9588C5AA962822119D8102A6B8637D72" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_9588C5AA962822119D8102A6B8637D72" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_9588C5AA962822119D8102A6B8637D72" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_9588C5AA962822119D8102A6B8637D72" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperations_4D55C0F333B0632BE31602A6B8631385_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperations_4D55C0F333B0632BE31602A6B8631385" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income from continuing operations attributable to Pfizer Inc.</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperations_4D55C0F333B0632BE31602A6B8631385_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperations_4D55C0F333B0632BE31602A6B8631385" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_4D55C0F333B0632BE31602A6B8631385" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperations_4D55C0F333B0632BE31602A6B8631385" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperations_4D55C0F333B0632BE31602A6B8631385" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockDividendsIncomeStatementImpact_4C813C19B36FD90C4E0D02A6B863978E_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockDividendsIncomeStatementImpact_4C813C19B36FD90C4E0D02A6B863978E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Less: Preferred stock dividends&#8211;&#8211;net of tax</link:label>
    <link:label id="lab_us-gaap_PreferredStockDividendsIncomeStatementImpact_4C813C19B36FD90C4E0D02A6B863978E_label_en-US" xlink:label="lab_us-gaap_PreferredStockDividendsIncomeStatementImpact_4C813C19B36FD90C4E0D02A6B863978E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock Dividends, Income Statement Impact</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:label="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_4C813C19B36FD90C4E0D02A6B863978E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_4C813C19B36FD90C4E0D02A6B863978E" xlink:to="lab_us-gaap_PreferredStockDividendsIncomeStatementImpact_4C813C19B36FD90C4E0D02A6B863978E" xlink:type="arc" />
    <link:label id="lab_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic_DBB6E306430A25B2719402A6B863F524_totalLabel_en-US" xlink:label="lab_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic_DBB6E306430A25B2719402A6B863F524" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income from continuing operations attributable to Pfizer Inc. common shareholders</link:label>
    <link:label id="lab_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic_DBB6E306430A25B2719402A6B863F524_label_en-US" xlink:label="lab_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic_DBB6E306430A25B2719402A6B863F524" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Loss From Continuing Operations Available To Common Stockholders Basic</link:label>
    <link:label id="lab_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic_DBB6E306430A25B2719402A6B863F524_documentation_en-US" xlink:label="lab_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic_DBB6E306430A25B2719402A6B863F524" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This element represents the income or loss from continuing operations available to common stockholders which may also be defined as revenue less expenses and taxes from ongoing operations before extraordinary items and cumulative effects of changes in accounting principles, but after deduction of those portions of income or loss from continuing operations that are allocable to noncontrolling interests and preferred stock dividends declared or paid in the period, if any.</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic" xlink:label="loc_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic_DBB6E306430A25B2719402A6B863F524" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic_DBB6E306430A25B2719402A6B863F524" xlink:to="lab_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic_DBB6E306430A25B2719402A6B863F524" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_7E615AD050103C1F0AE602A6B864C758_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_7E615AD050103C1F0AE602A6B864C758" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discontinued operations&#8211;&#8211;net of tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_7E615AD050103C1F0AE602A6B864C758" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_7E615AD050103C1F0AE602A6B864C758" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_7E615AD050103C1F0AE602A6B864C758" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_EB930E4E68C35C69D2A802A6B8645574_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_EB930E4E68C35C69D2A802A6B8645574" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net income attributable to Pfizer Inc. common shareholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_EB930E4E68C35C69D2A802A6B8645574_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_EB930E4E68C35C69D2A802A6B8645574" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_EB930E4E68C35C69D2A802A6B8645574" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_EB930E4E68C35C69D2A802A6B8645574" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_EB930E4E68C35C69D2A802A6B8645574" xlink:type="arc" />
    <link:label id="lab_us-gaap_DilutiveSecuritiesAbstract_00C94EC5F5F0AC140FDA02A6B864236C_terseLabel_en-US" xlink:label="lab_us-gaap_DilutiveSecuritiesAbstract_00C94EC5F5F0AC140FDA02A6B864236C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">EPS Numerator&#8211;&#8211;Diluted</link:label>
    <link:label id="lab_us-gaap_DilutiveSecuritiesAbstract_00C94EC5F5F0AC140FDA02A6B864236C_label_en-US" xlink:label="lab_us-gaap_DilutiveSecuritiesAbstract_00C94EC5F5F0AC140FDA02A6B864236C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DilutiveSecuritiesAbstract" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract_00C94EC5F5F0AC140FDA02A6B864236C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_00C94EC5F5F0AC140FDA02A6B864236C" xlink:to="lab_us-gaap_DilutiveSecuritiesAbstract_00C94EC5F5F0AC140FDA02A6B864236C" xlink:type="arc" />
    <link:label id="lab_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted_94530A6877C815A229F702A6B8646F92_terseLabel_en-US" xlink:label="lab_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted_94530A6877C815A229F702A6B8646F92" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income from continuing operations attributable to Pfizer Inc. common shareholders and assumed conversions</link:label>
    <link:label id="lab_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted_94530A6877C815A229F702A6B8646F92_label_en-US" xlink:label="lab_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted_94530A6877C815A229F702A6B8646F92" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Loss From Continuing Operations Available To Common Stockholders diluted</link:label>
    <link:label id="lab_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted_94530A6877C815A229F702A6B8646F92_documentation_en-US" xlink:label="lab_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted_94530A6877C815A229F702A6B8646F92" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This element represents the income or loss from continuing operations available to common stockholders which may also be defined as revenue less expenses and taxes from ongoing operations before extraordinary items and cumulative effects of changes in accounting principles, but after deduction of those portions of income or loss from continuing operations that are allocable to noncontrolling interests and preferred stock dividends declared or paid in the period, if any.</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted" xlink:label="loc_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted_94530A6877C815A229F702A6B8646F92" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted_94530A6877C815A229F702A6B8646F92" xlink:to="lab_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted_94530A6877C815A229F702A6B8646F92" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_EFBB950EA99D751BFD3602A6B864CDE7_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_EFBB950EA99D751BFD3602A6B864CDE7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Discontinued operations&#8211;&#8211;net of tax, attributable to Pfizer Inc. common shareholders and assumed conversions</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_EFBB950EA99D751BFD3602A6B864CDE7_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_EFBB950EA99D751BFD3602A6B864CDE7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_EFBB950EA99D751BFD3602A6B864CDE7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_EFBB950EA99D751BFD3602A6B864CDE7" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_EFBB950EA99D751BFD3602A6B864CDE7" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_6BC97F5EACD1031E7B9402A6B865E16D_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_6BC97F5EACD1031E7B9402A6B865E16D" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net income attributable to Pfizer Inc. common shareholders and assumed conversions</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_6BC97F5EACD1031E7B9402A6B865E16D_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_6BC97F5EACD1031E7B9402A6B865E16D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_6BC97F5EACD1031E7B9402A6B865E16D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_6BC97F5EACD1031E7B9402A6B865E16D" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_6BC97F5EACD1031E7B9402A6B865E16D" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_C443601E108786ABDAE202A6B865F980_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_C443601E108786ABDAE202A6B865F980" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">EPS Denominator</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_C443601E108786ABDAE202A6B865F980_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_C443601E108786ABDAE202A6B865F980" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_C443601E108786ABDAE202A6B865F980" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_C443601E108786ABDAE202A6B865F980" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_C443601E108786ABDAE202A6B865F980" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_D744C8BD7F635C8662C702A6B865ABA2_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_D744C8BD7F635C8662C702A6B865ABA2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average number of common shares outstanding&#8211;&#8211;Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_D744C8BD7F635C8662C702A6B865ABA2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_D744C8BD7F635C8662C702A6B865ABA2" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_D744C8BD7F635C8662C702A6B865ABA2" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_4DEB466CE0B924CF77BB02A6B86625BA_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_4DEB466CE0B924CF77BB02A6B86625BA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common-share equivalents: stock options, stock issuable under employee compensation plans, convertible preferred stock and accelerated share repurchase agreements (shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_4DEB466CE0B924CF77BB02A6B86625BA_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_4DEB466CE0B924CF77BB02A6B86625BA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number Diluted Shares Outstanding Adjustment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_4DEB466CE0B924CF77BB02A6B86625BA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_4DEB466CE0B924CF77BB02A6B86625BA" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_4DEB466CE0B924CF77BB02A6B86625BA" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_6D44E51893C215ADD81E02A6B86690EA_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_6D44E51893C215ADD81E02A6B86690EA" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Weighted-average number of common shares outstanding&#8211;&#8211;Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_6D44E51893C215ADD81E02A6B86690EA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_6D44E51893C215ADD81E02A6B86690EA" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_6D44E51893C215ADD81E02A6B86690EA" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_DD3A1E3A2D538683DA2802A6B866006C_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_DD3A1E3A2D538683DA2802A6B866006C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options that had exercise prices greater than the average market price of our common stock issuable under employee compensation plans (shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_DD3A1E3A2D538683DA2802A6B866006C_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_DD3A1E3A2D538683DA2802A6B866006C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_DD3A1E3A2D538683DA2802A6B866006C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_DD3A1E3A2D538683DA2802A6B866006C" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_DD3A1E3A2D538683DA2802A6B866006C" xlink:type="arc" />
    <link:label id="lab_pfe_MedivationMember_9C3E86480097C6D9EFB791EBE156AAE6_terseLabel_en-US" xlink:label="lab_pfe_MedivationMember_9C3E86480097C6D9EFB791EBE156AAE6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Medivation [Member]</link:label>
    <link:label id="lab_pfe_MedivationMember_9C3E86480097C6D9EFB791EBE156AAE6_label_en-US" xlink:label="lab_pfe_MedivationMember_9C3E86480097C6D9EFB791EBE156AAE6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Medivation [Member]</link:label>
    <link:label id="lab_pfe_MedivationMember_9C3E86480097C6D9EFB791EBE156AAE6_documentation_en-US" xlink:label="lab_pfe_MedivationMember_9C3E86480097C6D9EFB791EBE156AAE6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Medivation [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_MedivationMember" xlink:label="loc_pfe_MedivationMember_9C3E86480097C6D9EFB791EBE156AAE6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_MedivationMember_9C3E86480097C6D9EFB791EBE156AAE6" xlink:to="lab_pfe_MedivationMember_9C3E86480097C6D9EFB791EBE156AAE6" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionSharePrice_3FE543426C5156B53CD291EBE1578F40_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionSharePrice_3FE543426C5156B53CD291EBE1578F40" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business acquisition, per share in cash (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionSharePrice_3FE543426C5156B53CD291EBE1578F40_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionSharePrice_3FE543426C5156B53CD291EBE1578F40" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Share Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_3FE543426C5156B53CD291EBE1578F40" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionSharePrice_3FE543426C5156B53CD291EBE1578F40" xlink:to="lab_us-gaap_BusinessAcquisitionSharePrice_3FE543426C5156B53CD291EBE1578F40" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_B4CEF0692237DD8CAC8F91EBE1577894_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1_B4CEF0692237DD8CAC8F91EBE1577894" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Consideration transferred in business acquisition</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_B4CEF0692237DD8CAC8F91EBE1577894" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1_B4CEF0692237DD8CAC8F91EBE1577894" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1_B4CEF0692237DD8CAC8F91EBE1577894" xlink:type="arc" />
    <link:label id="lab_pfe_BusinessCombinationConsiderationTransferredNetofCashAcquired_9059B1BB75588548758E91EBE158E326_terseLabel_en-US" xlink:label="lab_pfe_BusinessCombinationConsiderationTransferredNetofCashAcquired_9059B1BB75588548758E91EBE158E326" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consideration transferred in business acquisition, net of cash acquired</link:label>
    <link:label id="lab_pfe_BusinessCombinationConsiderationTransferredNetofCashAcquired_9059B1BB75588548758E91EBE158E326_label_en-US" xlink:label="lab_pfe_BusinessCombinationConsiderationTransferredNetofCashAcquired_9059B1BB75588548758E91EBE158E326" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Consideration Transferred, Net of Cash Acquired</link:label>
    <link:label id="lab_pfe_BusinessCombinationConsiderationTransferredNetofCashAcquired_9059B1BB75588548758E91EBE158E326_documentation_en-US" xlink:label="lab_pfe_BusinessCombinationConsiderationTransferredNetofCashAcquired_9059B1BB75588548758E91EBE158E326" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Consideration Transferred, Net of Cash Acquired</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_BusinessCombinationConsiderationTransferredNetofCashAcquired" xlink:label="loc_pfe_BusinessCombinationConsiderationTransferredNetofCashAcquired_9059B1BB75588548758E91EBE158E326" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_BusinessCombinationConsiderationTransferredNetofCashAcquired_9059B1BB75588548758E91EBE158E326" xlink:to="lab_pfe_BusinessCombinationConsiderationTransferredNetofCashAcquired_9059B1BB75588548758E91EBE158E326" xlink:type="arc" />
    <link:label id="lab_pfe_BusinessCombinationConsiderationTransferredAmountPayable_160FB04D50237C5B28F791EBE158C168_terseLabel_en-US" xlink:label="lab_pfe_BusinessCombinationConsiderationTransferredAmountPayable_160FB04D50237C5B28F791EBE158C168" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount payable</link:label>
    <link:label id="lab_pfe_BusinessCombinationConsiderationTransferredAmountPayable_160FB04D50237C5B28F791EBE158C168_label_en-US" xlink:label="lab_pfe_BusinessCombinationConsiderationTransferredAmountPayable_160FB04D50237C5B28F791EBE158C168" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Consideration Transferred, Amount Payable</link:label>
    <link:label id="lab_pfe_BusinessCombinationConsiderationTransferredAmountPayable_160FB04D50237C5B28F791EBE158C168_documentation_en-US" xlink:label="lab_pfe_BusinessCombinationConsiderationTransferredAmountPayable_160FB04D50237C5B28F791EBE158C168" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Consideration Transferred, Amount Payable</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_BusinessCombinationConsiderationTransferredAmountPayable" xlink:label="loc_pfe_BusinessCombinationConsiderationTransferredAmountPayable_160FB04D50237C5B28F791EBE158C168" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_BusinessCombinationConsiderationTransferredAmountPayable_160FB04D50237C5B28F791EBE158C168" xlink:to="lab_pfe_BusinessCombinationConsiderationTransferredAmountPayable_160FB04D50237C5B28F791EBE158C168" xlink:type="arc" />
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_20D8491483ADAE1CD65291EBE158E989_terseLabel_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_20D8491483ADAE1CD65291EBE158E989" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquired intangible assets, average useful life</link:label>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_20D8491483ADAE1CD65291EBE158E989_label_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_20D8491483ADAE1CD65291EBE158E989" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acquired Finite-lived Intangible Assets, Weighted Average Useful Life</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_20D8491483ADAE1CD65291EBE158E989" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_20D8491483ADAE1CD65291EBE158E989" xlink:to="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_20D8491483ADAE1CD65291EBE158E989" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_9846125E47FEA7AFF61291EBE158DCB9_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_9846125E47FEA7AFF61291EBE158DCB9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration assumed</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_9846125E47FEA7AFF61291EBE158DCB9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_9846125E47FEA7AFF61291EBE158DCB9" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_9846125E47FEA7AFF61291EBE158DCB9" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles_313884EB97AC930DA83091EBE1591060_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles_313884EB97AC930DA83091EBE1591060" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Reduction in intangible assets due to measurement period adjustments</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles_313884EB97AC930DA83091EBE1591060_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles_313884EB97AC930DA83091EBE1591060" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Intangibles</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles" xlink:label="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles_313884EB97AC930DA83091EBE1591060" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles_313884EB97AC930DA83091EBE1591060" xlink:to="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles_313884EB97AC930DA83091EBE1591060" xlink:type="arc" />
    <link:label id="lab_pfe_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIncreaseDecreaseinAmortizationofIntangibleAssets_E3EDB9081DDD762CC33D91EBE15962B9_negatedTerseLabel_en-US" xlink:label="lab_pfe_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIncreaseDecreaseinAmortizationofIntangibleAssets_E3EDB9081DDD762CC33D91EBE15962B9" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Decrease in amortization of intangible assets due to measurement period adjustments</link:label>
    <link:label id="lab_pfe_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIncreaseDecreaseinAmortizationofIntangibleAssets_E3EDB9081DDD762CC33D91EBE15962B9_label_en-US" xlink:label="lab_pfe_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIncreaseDecreaseinAmortizationofIntangibleAssets_E3EDB9081DDD762CC33D91EBE15962B9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Increase (Decrease) in Amortization of Intangible Assets</link:label>
    <link:label id="lab_pfe_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIncreaseDecreaseinAmortizationofIntangibleAssets_E3EDB9081DDD762CC33D91EBE15962B9_documentation_en-US" xlink:label="lab_pfe_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIncreaseDecreaseinAmortizationofIntangibleAssets_E3EDB9081DDD762CC33D91EBE15962B9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Increase (Decrease) in Amortization of Intangible Assets</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIncreaseDecreaseinAmortizationofIntangibleAssets" xlink:label="loc_pfe_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIncreaseDecreaseinAmortizationofIntangibleAssets_E3EDB9081DDD762CC33D91EBE15962B9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIncreaseDecreaseinAmortizationofIntangibleAssets_E3EDB9081DDD762CC33D91EBE15962B9" xlink:to="lab_pfe_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIncreaseDecreaseinAmortizationofIntangibleAssets_E3EDB9081DDD762CC33D91EBE15962B9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_F090E48937CED23885AEAE9F92B97BA7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_DF44E3A1D73F52039D1E12FC094C257F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Changes in Accumulated Other Comprehensive Loss, Net of Tax</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_F090E48937CED23885AEAE9F92B97BA7_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_DF44E3A1D73F52039D1E12FC094C257F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_DF44E3A1D73F52039D1E12FC094C257F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_DF44E3A1D73F52039D1E12FC094C257F" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_DF44E3A1D73F52039D1E12FC094C257F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_F6982A4AE60A4DDED4C591EBDD9E3B81_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_F6982A4AE60A4DDED4C591EBDD9E3B81" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_F6982A4AE60A4DDED4C591EBDD9E3B81_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_F6982A4AE60A4DDED4C591EBDD9E3B81" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_F6982A4AE60A4DDED4C591EBDD9E3B81" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_F6982A4AE60A4DDED4C591EBDD9E3B81" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_F6982A4AE60A4DDED4C591EBDD9E3B81" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsegmentsAxis_D06344289680A49104F591EBDD9E3610_terseLabel_en-US" xlink:label="lab_us-gaap_SubsegmentsAxis_D06344289680A49104F591EBDD9E3610" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsegments [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsegmentsAxis_D06344289680A49104F591EBDD9E3610_label_en-US" xlink:label="lab_us-gaap_SubsegmentsAxis_D06344289680A49104F591EBDD9E3610" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsegments [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsegmentsAxis" xlink:label="loc_us-gaap_SubsegmentsAxis_D06344289680A49104F591EBDD9E3610" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsegmentsAxis_D06344289680A49104F591EBDD9E3610" xlink:to="lab_us-gaap_SubsegmentsAxis_D06344289680A49104F591EBDD9E3610" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsegmentsDomain_C7D9F5C70F3534A7F33D91EBDD9EB1BE_terseLabel_en-US" xlink:label="lab_us-gaap_SubsegmentsDomain_C7D9F5C70F3534A7F33D91EBDD9EB1BE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsegments [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsegmentsDomain_C7D9F5C70F3534A7F33D91EBDD9EB1BE_label_en-US" xlink:label="lab_us-gaap_SubsegmentsDomain_C7D9F5C70F3534A7F33D91EBDD9EB1BE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsegments [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsegmentsDomain" xlink:label="loc_us-gaap_SubsegmentsDomain_C7D9F5C70F3534A7F33D91EBDD9EB1BE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsegmentsDomain_C7D9F5C70F3534A7F33D91EBDD9EB1BE" xlink:to="lab_us-gaap_SubsegmentsDomain_C7D9F5C70F3534A7F33D91EBDD9EB1BE" xlink:type="arc" />
    <link:label id="lab_pfe_PfizersWorldwideResearchandDevelopmentandPfizersGlobalProductDevelopmentMember_C595D4B4BC0C1691148591EBDD9EEF58_terseLabel_en-US" xlink:label="lab_pfe_PfizersWorldwideResearchandDevelopmentandPfizersGlobalProductDevelopmentMember_C595D4B4BC0C1691148591EBDD9EEF58" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pfizer's Worldwide Research and Development and Pfizer's Global Product Development [Member]</link:label>
    <link:label id="lab_pfe_PfizersWorldwideResearchandDevelopmentandPfizersGlobalProductDevelopmentMember_C595D4B4BC0C1691148591EBDD9EEF58_label_en-US" xlink:label="lab_pfe_PfizersWorldwideResearchandDevelopmentandPfizersGlobalProductDevelopmentMember_C595D4B4BC0C1691148591EBDD9EEF58" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pfizer's Worldwide Research and Development and Pfizer's Global Product Development [Member]</link:label>
    <link:label id="lab_pfe_PfizersWorldwideResearchandDevelopmentandPfizersGlobalProductDevelopmentMember_C595D4B4BC0C1691148591EBDD9EEF58_documentation_en-US" xlink:label="lab_pfe_PfizersWorldwideResearchandDevelopmentandPfizersGlobalProductDevelopmentMember_C595D4B4BC0C1691148591EBDD9EEF58" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pfizer's Worldwide Research and Development and Pfizer's Global Product Development [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_PfizersWorldwideResearchandDevelopmentandPfizersGlobalProductDevelopmentMember" xlink:label="loc_pfe_PfizersWorldwideResearchandDevelopmentandPfizersGlobalProductDevelopmentMember_C595D4B4BC0C1691148591EBDD9EEF58" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_PfizersWorldwideResearchandDevelopmentandPfizersGlobalProductDevelopmentMember_C595D4B4BC0C1691148591EBDD9EEF58" xlink:to="lab_pfe_PfizersWorldwideResearchandDevelopmentandPfizersGlobalProductDevelopmentMember_C595D4B4BC0C1691148591EBDD9EEF58" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_5455568EDB91E9961B6B91EBDD9F4714_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_5455568EDB91E9961B6B91EBDD9F4714" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_5455568EDB91E9961B6B91EBDD9F4714_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_5455568EDB91E9961B6B91EBDD9F4714" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_5455568EDB91E9961B6B91EBDD9F4714" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_5455568EDB91E9961B6B91EBDD9F4714" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_5455568EDB91E9961B6B91EBDD9F4714" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityMethodInvesteeNameDomain_C1AFB2B7F868416D5EBB91EBDD9FF18C_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvesteeNameDomain_C1AFB2B7F868416D5EBB91EBDD9FF18C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvesteeNameDomain_C1AFB2B7F868416D5EBB91EBDD9FF18C_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvesteeNameDomain_C1AFB2B7F868416D5EBB91EBDD9FF18C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvesteeNameDomain" xlink:label="loc_us-gaap_EquityMethodInvesteeNameDomain_C1AFB2B7F868416D5EBB91EBDD9FF18C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvesteeNameDomain_C1AFB2B7F868416D5EBB91EBDD9FF18C" xlink:to="lab_us-gaap_EquityMethodInvesteeNameDomain_C1AFB2B7F868416D5EBB91EBDD9FF18C" xlink:type="arc" />
    <link:label id="lab_pfe_ViivHealthcareLimitedMember_E37E02CE0382405082AC91EBDD9FE67D_terseLabel_en-US" xlink:label="lab_pfe_ViivHealthcareLimitedMember_E37E02CE0382405082AC91EBDD9FE67D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ViiV Healthcare Limited [Member]</link:label>
    <link:label id="lab_pfe_ViivHealthcareLimitedMember_E37E02CE0382405082AC91EBDD9FE67D_label_en-US" xlink:label="lab_pfe_ViivHealthcareLimitedMember_E37E02CE0382405082AC91EBDD9FE67D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ViiV Healthcare Limited [Member]</link:label>
    <link:label id="lab_pfe_ViivHealthcareLimitedMember_E37E02CE0382405082AC91EBDD9FE67D_documentation_en-US" xlink:label="lab_pfe_ViivHealthcareLimitedMember_E37E02CE0382405082AC91EBDD9FE67D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">ViiV Healthcare Limited [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_ViivHealthcareLimitedMember" xlink:label="loc_pfe_ViivHealthcareLimitedMember_E37E02CE0382405082AC91EBDD9FE67D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ViivHealthcareLimitedMember_E37E02CE0382405082AC91EBDD9FE67D" xlink:to="lab_pfe_ViivHealthcareLimitedMember_E37E02CE0382405082AC91EBDD9FE67D" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_28B101B8259E953AECA091EBDD9FAB7D_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis_28B101B8259E953AECA091EBDD9FAB7D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_28B101B8259E953AECA091EBDD9FAB7D_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis_28B101B8259E953AECA091EBDD9FAB7D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_28B101B8259E953AECA091EBDD9FAB7D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_28B101B8259E953AECA091EBDD9FAB7D" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis_28B101B8259E953AECA091EBDD9FAB7D" xlink:type="arc" />
    <link:label id="lab_us-gaap_SegmentDomain_B55B978517F83577CEA791EBDDA04985_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain_B55B978517F83577CEA791EBDDA04985" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_B55B978517F83577CEA791EBDDA04985_label_en-US" xlink:label="lab_us-gaap_SegmentDomain_B55B978517F83577CEA791EBDDA04985" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_B55B978517F83577CEA791EBDDA04985" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain_B55B978517F83577CEA791EBDDA04985" xlink:to="lab_us-gaap_SegmentDomain_B55B978517F83577CEA791EBDDA04985" xlink:type="arc" />
    <link:label id="lab_pfe_InnovativeHealthSegmentMember_06927BE4F9C7AE1E9DE091EBDDA07CC7_terseLabel_en-US" xlink:label="lab_pfe_InnovativeHealthSegmentMember_06927BE4F9C7AE1E9DE091EBDDA07CC7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Innovative Health Segment [Member]</link:label>
    <link:label id="lab_pfe_InnovativeHealthSegmentMember_06927BE4F9C7AE1E9DE091EBDDA07CC7_label_en-US" xlink:label="lab_pfe_InnovativeHealthSegmentMember_06927BE4F9C7AE1E9DE091EBDDA07CC7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Innovative Health Segment [Member]</link:label>
    <link:label id="lab_pfe_InnovativeHealthSegmentMember_06927BE4F9C7AE1E9DE091EBDDA07CC7_documentation_en-US" xlink:label="lab_pfe_InnovativeHealthSegmentMember_06927BE4F9C7AE1E9DE091EBDDA07CC7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Innovative Health Segment [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_InnovativeHealthSegmentMember" xlink:label="loc_pfe_InnovativeHealthSegmentMember_06927BE4F9C7AE1E9DE091EBDDA07CC7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_InnovativeHealthSegmentMember_06927BE4F9C7AE1E9DE091EBDDA07CC7" xlink:to="lab_pfe_InnovativeHealthSegmentMember_06927BE4F9C7AE1E9DE091EBDDA07CC7" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_1B3F3634C9A44B9A323091EBDDA12723_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_1B3F3634C9A44B9A323091EBDDA12723" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_1B3F3634C9A44B9A323091EBDDA12723_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_1B3F3634C9A44B9A323091EBDDA12723" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_1B3F3634C9A44B9A323091EBDDA12723" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_1B3F3634C9A44B9A323091EBDDA12723" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_1B3F3634C9A44B9A323091EBDDA12723" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_CECA39F4B7252C4CEE6891EBDDA1005B_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_CECA39F4B7252C4CEE6891EBDDA1005B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_CECA39F4B7252C4CEE6891EBDDA1005B_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_CECA39F4B7252C4CEE6891EBDDA1005B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_CECA39F4B7252C4CEE6891EBDDA1005B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_CECA39F4B7252C4CEE6891EBDDA1005B" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_CECA39F4B7252C4CEE6891EBDDA1005B" xlink:type="arc" />
    <link:label id="lab_pfe_HISMember_B97836FCABDF92599D8891EBDDA107C5_terseLabel_en-US" xlink:label="lab_pfe_HISMember_B97836FCABDF92599D8891EBDDA107C5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">HIS [Member]</link:label>
    <link:label id="lab_pfe_HISMember_B97836FCABDF92599D8891EBDDA107C5_label_en-US" xlink:label="lab_pfe_HISMember_B97836FCABDF92599D8891EBDDA107C5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">HIS [Member]</link:label>
    <link:label id="lab_pfe_HISMember_B97836FCABDF92599D8891EBDDA107C5_documentation_en-US" xlink:label="lab_pfe_HISMember_B97836FCABDF92599D8891EBDDA107C5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">HIS [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_HISMember" xlink:label="loc_pfe_HISMember_B97836FCABDF92599D8891EBDDA107C5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_HISMember_B97836FCABDF92599D8891EBDDA107C5" xlink:to="lab_pfe_HISMember_B97836FCABDF92599D8891EBDDA107C5" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementScenarioAxis_D5B7DEC46D51FF71DB5891EBDDA15C23_terseLabel_en-US" xlink:label="lab_us-gaap_StatementScenarioAxis_D5B7DEC46D51FF71DB5891EBDDA15C23" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementScenarioAxis_D5B7DEC46D51FF71DB5891EBDDA15C23_label_en-US" xlink:label="lab_us-gaap_StatementScenarioAxis_D5B7DEC46D51FF71DB5891EBDDA15C23" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_D5B7DEC46D51FF71DB5891EBDDA15C23" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementScenarioAxis_D5B7DEC46D51FF71DB5891EBDDA15C23" xlink:to="lab_us-gaap_StatementScenarioAxis_D5B7DEC46D51FF71DB5891EBDDA15C23" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScenarioUnspecifiedDomain_019378D76254E2B8B72C91EBDDA10BDF_terseLabel_en-US" xlink:label="lab_us-gaap_ScenarioUnspecifiedDomain_019378D76254E2B8B72C91EBDDA10BDF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Scenario, Unspecified [Domain]</link:label>
    <link:label id="lab_us-gaap_ScenarioUnspecifiedDomain_019378D76254E2B8B72C91EBDDA10BDF_label_en-US" xlink:label="lab_us-gaap_ScenarioUnspecifiedDomain_019378D76254E2B8B72C91EBDDA10BDF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario, Unspecified [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_019378D76254E2B8B72C91EBDDA10BDF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_019378D76254E2B8B72C91EBDDA10BDF" xlink:to="lab_us-gaap_ScenarioUnspecifiedDomain_019378D76254E2B8B72C91EBDDA10BDF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScenarioAdjustmentMember_6ABA85151FAF9BDCCEA091EBDDA223D8_terseLabel_en-US" xlink:label="lab_us-gaap_ScenarioAdjustmentMember_6ABA85151FAF9BDCCEA091EBDDA223D8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment [Member]</link:label>
    <link:label id="lab_us-gaap_ScenarioAdjustmentMember_6ABA85151FAF9BDCCEA091EBDDA223D8_label_en-US" xlink:label="lab_us-gaap_ScenarioAdjustmentMember_6ABA85151FAF9BDCCEA091EBDDA223D8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario, Adjustment [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioAdjustmentMember" xlink:label="loc_us-gaap_ScenarioAdjustmentMember_6ABA85151FAF9BDCCEA091EBDDA223D8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScenarioAdjustmentMember_6ABA85151FAF9BDCCEA091EBDDA223D8" xlink:to="lab_us-gaap_ScenarioAdjustmentMember_6ABA85151FAF9BDCCEA091EBDDA223D8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConsolidationItemsAxis_240CDD347BA5F62A33C591EBDDA2B0A7_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationItemsAxis_240CDD347BA5F62A33C591EBDDA2B0A7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:label id="lab_us-gaap_ConsolidationItemsAxis_240CDD347BA5F62A33C591EBDDA2B0A7_label_en-US" xlink:label="lab_us-gaap_ConsolidationItemsAxis_240CDD347BA5F62A33C591EBDDA2B0A7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidationItemsAxis" xlink:label="loc_us-gaap_ConsolidationItemsAxis_240CDD347BA5F62A33C591EBDDA2B0A7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationItemsAxis_240CDD347BA5F62A33C591EBDDA2B0A7" xlink:to="lab_us-gaap_ConsolidationItemsAxis_240CDD347BA5F62A33C591EBDDA2B0A7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConsolidationItemsDomain_832455364EDCED859E9291EBDDA27C02_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationItemsDomain_832455364EDCED859E9291EBDDA27C02" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:label id="lab_us-gaap_ConsolidationItemsDomain_832455364EDCED859E9291EBDDA27C02_label_en-US" xlink:label="lab_us-gaap_ConsolidationItemsDomain_832455364EDCED859E9291EBDDA27C02" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidationItemsDomain" xlink:label="loc_us-gaap_ConsolidationItemsDomain_832455364EDCED859E9291EBDDA27C02" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationItemsDomain_832455364EDCED859E9291EBDDA27C02" xlink:to="lab_us-gaap_ConsolidationItemsDomain_832455364EDCED859E9291EBDDA27C02" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingSegmentsMember_044FCB88726B484EB45491EBDDA20CA5_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember_044FCB88726B484EB45491EBDDA20CA5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Segments [Member]</link:label>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_044FCB88726B484EB45491EBDDA20CA5_label_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember_044FCB88726B484EB45491EBDDA20CA5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Segments [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingSegmentsMember" xlink:label="loc_us-gaap_OperatingSegmentsMember_044FCB88726B484EB45491EBDDA20CA5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingSegmentsMember_044FCB88726B484EB45491EBDDA20CA5" xlink:to="lab_us-gaap_OperatingSegmentsMember_044FCB88726B484EB45491EBDDA20CA5" xlink:type="arc" />
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_F7C7A79B33BAC7C5763A91EBDDA256DB_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember_F7C7A79B33BAC7C5763A91EBDDA256DB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Corporate [Member]</link:label>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_F7C7A79B33BAC7C5763A91EBDDA256DB_label_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember_F7C7A79B33BAC7C5763A91EBDDA256DB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate, Non-Segment [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CorporateNonSegmentMember" xlink:label="loc_us-gaap_CorporateNonSegmentMember_F7C7A79B33BAC7C5763A91EBDDA256DB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateNonSegmentMember_F7C7A79B33BAC7C5763A91EBDDA256DB" xlink:to="lab_us-gaap_CorporateNonSegmentMember_F7C7A79B33BAC7C5763A91EBDDA256DB" xlink:type="arc" />
    <link:label id="lab_us-gaap_MaterialReconcilingItemsMember_AD847E0385208CB7739D91EBDDA34D41_terseLabel_en-US" xlink:label="lab_us-gaap_MaterialReconcilingItemsMember_AD847E0385208CB7739D91EBDDA34D41" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Reconciling Items [Member]</link:label>
    <link:label id="lab_us-gaap_MaterialReconcilingItemsMember_AD847E0385208CB7739D91EBDDA34D41_label_en-US" xlink:label="lab_us-gaap_MaterialReconcilingItemsMember_AD847E0385208CB7739D91EBDDA34D41" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reconciling Items [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaterialReconcilingItemsMember" xlink:label="loc_us-gaap_MaterialReconcilingItemsMember_AD847E0385208CB7739D91EBDDA34D41" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MaterialReconcilingItemsMember_AD847E0385208CB7739D91EBDDA34D41" xlink:to="lab_us-gaap_MaterialReconcilingItemsMember_AD847E0385208CB7739D91EBDDA34D41" xlink:type="arc" />
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_5039E8C561C92273647791EBDDA35D1B_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems_5039E8C561C92273647791EBDDA35D1B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_5039E8C561C92273647791EBDDA35D1B_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems_5039E8C561C92273647791EBDDA35D1B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_5039E8C561C92273647791EBDDA35D1B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_5039E8C561C92273647791EBDDA35D1B" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems_5039E8C561C92273647791EBDDA35D1B" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentIncomeDividend_9FFFCC883FE3F097D6CE91EBDDA318D9_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeDividend_9FFFCC883FE3F097D6CE91EBDDA318D9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividend income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeDividend_9FFFCC883FE3F097D6CE91EBDDA318D9_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeDividend_9FFFCC883FE3F097D6CE91EBDDA318D9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Income, Dividend</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentIncomeDividend" xlink:label="loc_us-gaap_InvestmentIncomeDividend_9FFFCC883FE3F097D6CE91EBDDA318D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeDividend_9FFFCC883FE3F097D6CE91EBDDA318D9" xlink:to="lab_us-gaap_InvestmentIncomeDividend_9FFFCC883FE3F097D6CE91EBDDA318D9" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostsAndExpenses_1E348DABEC76A044BEBB91EBDDA35AAC_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses_1E348DABEC76A044BEBB91EBDDA35AAC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Costs and expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_1E348DABEC76A044BEBB91EBDDA35AAC_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses_1E348DABEC76A044BEBB91EBDDA35AAC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses_1E348DABEC76A044BEBB91EBDDA35AAC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses_1E348DABEC76A044BEBB91EBDDA35AAC" xlink:to="lab_us-gaap_CostsAndExpenses_1E348DABEC76A044BEBB91EBDDA35AAC" xlink:type="arc" />
    <link:label id="lab_pfe_RestructuringChargesandImplementationCosts_CC3D003862CD9B3F1BCE91EBDDA33A69_terseLabel_en-US" xlink:label="lab_pfe_RestructuringChargesandImplementationCosts_CC3D003862CD9B3F1BCE91EBDDA33A69" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost reduction and productivity initiatives excluding acquisition related costs</link:label>
    <link:label id="lab_pfe_RestructuringChargesandImplementationCosts_CC3D003862CD9B3F1BCE91EBDDA33A69_label_en-US" xlink:label="lab_pfe_RestructuringChargesandImplementationCosts_CC3D003862CD9B3F1BCE91EBDDA33A69" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Charges and Implementation Costs</link:label>
    <link:label id="lab_pfe_RestructuringChargesandImplementationCosts_CC3D003862CD9B3F1BCE91EBDDA33A69_documentation_en-US" xlink:label="lab_pfe_RestructuringChargesandImplementationCosts_CC3D003862CD9B3F1BCE91EBDDA33A69" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restructuring Charges and Implementation Costs</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_RestructuringChargesandImplementationCosts" xlink:label="loc_pfe_RestructuringChargesandImplementationCosts_CC3D003862CD9B3F1BCE91EBDDA33A69" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_RestructuringChargesandImplementationCosts_CC3D003862CD9B3F1BCE91EBDDA33A69" xlink:to="lab_pfe_RestructuringChargesandImplementationCosts_CC3D003862CD9B3F1BCE91EBDDA33A69" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_668FBA7D1C8EAC04002991EBDDA34616_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_668FBA7D1C8EAC04002991EBDDA34616" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain (loss) on sale of HIS net assets</link:label>
    <link:label id="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_668FBA7D1C8EAC04002991EBDDA34616_label_en-US" xlink:label="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_668FBA7D1C8EAC04002991EBDDA34616" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_668FBA7D1C8EAC04002991EBDDA34616" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_668FBA7D1C8EAC04002991EBDDA34616" xlink:to="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_668FBA7D1C8EAC04002991EBDDA34616" xlink:type="arc" />
    <link:label id="lab_pfe_BusinessInfrastructureAlignmentCosts_0F9B5246D7B3D5A0F4B091EBDDA4D1A9_terseLabel_en-US" xlink:label="lab_pfe_BusinessInfrastructureAlignmentCosts_0F9B5246D7B3D5A0F4B091EBDDA4D1A9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business and legal entity alignment costs</link:label>
    <link:label id="lab_pfe_BusinessInfrastructureAlignmentCosts_0F9B5246D7B3D5A0F4B091EBDDA4D1A9_label_en-US" xlink:label="lab_pfe_BusinessInfrastructureAlignmentCosts_0F9B5246D7B3D5A0F4B091EBDDA4D1A9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Infrastructure Alignment Costs</link:label>
    <link:label id="lab_pfe_BusinessInfrastructureAlignmentCosts_0F9B5246D7B3D5A0F4B091EBDDA4D1A9_documentation_en-US" xlink:label="lab_pfe_BusinessInfrastructureAlignmentCosts_0F9B5246D7B3D5A0F4B091EBDDA4D1A9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Infrastructure Alignment Costs</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_BusinessInfrastructureAlignmentCosts" xlink:label="loc_pfe_BusinessInfrastructureAlignmentCosts_0F9B5246D7B3D5A0F4B091EBDDA4D1A9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_BusinessInfrastructureAlignmentCosts_0F9B5246D7B3D5A0F4B091EBDDA4D1A9" xlink:to="lab_pfe_BusinessInfrastructureAlignmentCosts_0F9B5246D7B3D5A0F4B091EBDDA4D1A9" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_E4C2B282ACC4A9D1217491EBDDA445A1_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet_E4C2B282ACC4A9D1217491EBDDA445A1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other charges</link:label>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_E4C2B282ACC4A9D1217491EBDDA445A1_label_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet_E4C2B282ACC4A9D1217491EBDDA445A1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Operating Income (Expense), Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_E4C2B282ACC4A9D1217491EBDDA445A1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseNet_E4C2B282ACC4A9D1217491EBDDA445A1" xlink:to="lab_us-gaap_OtherOperatingIncomeExpenseNet_E4C2B282ACC4A9D1217491EBDDA445A1" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainLossRelatedToLitigationSettlement_BF1C5CD6553202146F4A91EBDDA49EB6_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossRelatedToLitigationSettlement_BF1C5CD6553202146F4A91EBDDA49EB6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income (charges) for certain legal matters</link:label>
    <link:label id="lab_us-gaap_GainLossRelatedToLitigationSettlement_BF1C5CD6553202146F4A91EBDDA49EB6_label_en-US" xlink:label="lab_us-gaap_GainLossRelatedToLitigationSettlement_BF1C5CD6553202146F4A91EBDDA49EB6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) Related to Litigation Settlement</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_BF1C5CD6553202146F4A91EBDDA49EB6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossRelatedToLitigationSettlement_BF1C5CD6553202146F4A91EBDDA49EB6" xlink:to="lab_us-gaap_GainLossRelatedToLitigationSettlement_BF1C5CD6553202146F4A91EBDDA49EB6" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetImpairmentCharges_836B26AEF0B0CCA6EF1191EBDDA43345_terseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges_836B26AEF0B0CCA6EF1191EBDDA43345" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Certain asset impairments</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_836B26AEF0B0CCA6EF1191EBDDA43345_label_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges_836B26AEF0B0CCA6EF1191EBDDA43345" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges_836B26AEF0B0CCA6EF1191EBDDA43345" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges_836B26AEF0B0CCA6EF1191EBDDA43345" xlink:to="lab_us-gaap_AssetImpairmentCharges_836B26AEF0B0CCA6EF1191EBDDA43345" xlink:type="arc" />
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_C679AE7E0076F7FC34969C2600344F03_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_C679AE7E0076F7FC34969C2600344F03" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_C679AE7E0076F7FC34969C2600344F03" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_C679AE7E0076F7FC34969C2600344F03" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_C679AE7E0076F7FC34969C2600344F03" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_58F943B65501197DC9DB9C260035C20A_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_58F943B65501197DC9DB9C260035C20A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_58F943B65501197DC9DB9C260035C20A_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_58F943B65501197DC9DB9C260035C20A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_58F943B65501197DC9DB9C260035C20A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_58F943B65501197DC9DB9C260035C20A" xlink:to="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_58F943B65501197DC9DB9C260035C20A" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetirementPlanTypeAxis_9DDE60E9AF724D3EBC0A9C2600350B6C_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeAxis_9DDE60E9AF724D3EBC0A9C2600350B6C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retirement Plan Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanTypeAxis_9DDE60E9AF724D3EBC0A9C2600350B6C_label_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeAxis_9DDE60E9AF724D3EBC0A9C2600350B6C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retirement Plan Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_9DDE60E9AF724D3EBC0A9C2600350B6C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_9DDE60E9AF724D3EBC0A9C2600350B6C" xlink:to="lab_us-gaap_RetirementPlanTypeAxis_9DDE60E9AF724D3EBC0A9C2600350B6C" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetirementPlanTypeDomain_06107B8D81988B97DFEB9C260035C7DE_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeDomain_06107B8D81988B97DFEB9C260035C7DE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retirement Plan Type [Domain]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanTypeDomain_06107B8D81988B97DFEB9C260035C7DE_label_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeDomain_06107B8D81988B97DFEB9C260035C7DE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retirement Plan Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_06107B8D81988B97DFEB9C260035C7DE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_06107B8D81988B97DFEB9C260035C7DE" xlink:to="lab_us-gaap_RetirementPlanTypeDomain_06107B8D81988B97DFEB9C260035C7DE" xlink:type="arc" />
    <link:label id="lab_us-gaap_PensionPlansDefinedBenefitMember_248C21407034A7E0BA549C260035688F_terseLabel_en-US" xlink:label="lab_us-gaap_PensionPlansDefinedBenefitMember_248C21407034A7E0BA549C260035688F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Plan [Member]</link:label>
    <link:label id="lab_us-gaap_PensionPlansDefinedBenefitMember_248C21407034A7E0BA549C260035688F_label_en-US" xlink:label="lab_us-gaap_PensionPlansDefinedBenefitMember_248C21407034A7E0BA549C260035688F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Plan [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_248C21407034A7E0BA549C260035688F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionPlansDefinedBenefitMember_248C21407034A7E0BA549C260035688F" xlink:to="lab_us-gaap_PensionPlansDefinedBenefitMember_248C21407034A7E0BA549C260035688F" xlink:type="arc" />
    <link:label id="lab_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember_1B64F4669BA2AE0B576A9C260035C031_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember_1B64F4669BA2AE0B576A9C260035C031" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental Employee Retirement Plan [Member]</link:label>
    <link:label id="lab_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember_1B64F4669BA2AE0B576A9C260035C031_label_en-US" xlink:label="lab_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember_1B64F4669BA2AE0B576A9C260035C031" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Employee Retirement Plan [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" xlink:label="loc_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember_1B64F4669BA2AE0B576A9C260035C031" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember_1B64F4669BA2AE0B576A9C260035C031" xlink:to="lab_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember_1B64F4669BA2AE0B576A9C260035C031" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_1307BA41747480D8F2539C260035CC50_terseLabel_en-US" xlink:label="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_1307BA41747480D8F2539C260035CC50" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Postretirement Plans [Member]</link:label>
    <link:label id="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_1307BA41747480D8F2539C260035CC50_label_en-US" xlink:label="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_1307BA41747480D8F2539C260035CC50" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Postretirement Benefits Plan [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_1307BA41747480D8F2539C260035CC50" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_1307BA41747480D8F2539C260035CC50" xlink:to="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_1307BA41747480D8F2539C260035CC50" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationAxis_1565ED786730FA4615959C2600358A98_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationAxis_1565ED786730FA4615959C2600358A98" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retirement Plan Sponsor Location [Axis]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationAxis_1565ED786730FA4615959C2600358A98_label_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationAxis_1565ED786730FA4615959C2600358A98" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retirement Plan Sponsor Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_1565ED786730FA4615959C2600358A98" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_1565ED786730FA4615959C2600358A98" xlink:to="lab_us-gaap_RetirementPlanSponsorLocationAxis_1565ED786730FA4615959C2600358A98" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationDomain_57C8C8363D5ADF3AA5FB9C260035B747_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationDomain_57C8C8363D5ADF3AA5FB9C260035B747" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retirement Plan Sponsor Location [Domain]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationDomain_57C8C8363D5ADF3AA5FB9C260035B747_label_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationDomain_57C8C8363D5ADF3AA5FB9C260035B747" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retirement Plan Sponsor Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_57C8C8363D5ADF3AA5FB9C260035B747" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_57C8C8363D5ADF3AA5FB9C260035B747" xlink:to="lab_us-gaap_RetirementPlanSponsorLocationDomain_57C8C8363D5ADF3AA5FB9C260035B747" xlink:type="arc" />
    <link:label id="lab_us-gaap_DomesticPlanMember_F5447EB850F5B34DE8C29C26003AB905_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticPlanMember_F5447EB850F5B34DE8C29C26003AB905" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Domestic Plan [Member]</link:label>
    <link:label id="lab_us-gaap_DomesticPlanMember_F5447EB850F5B34DE8C29C26003AB905_label_en-US" xlink:label="lab_us-gaap_DomesticPlanMember_F5447EB850F5B34DE8C29C26003AB905" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Domestic Plan [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DomesticPlanMember" xlink:label="loc_us-gaap_DomesticPlanMember_F5447EB850F5B34DE8C29C26003AB905" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticPlanMember_F5447EB850F5B34DE8C29C26003AB905" xlink:to="lab_us-gaap_DomesticPlanMember_F5447EB850F5B34DE8C29C26003AB905" xlink:type="arc" />
    <link:label id="lab_country_US_0B0CCE0A7C5D9058C7D39C26003ABCF6_terseLabel_en-US" xlink:label="lab_country_US_0B0CCE0A7C5D9058C7D39C26003ABCF6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. [Member]</link:label>
    <link:label id="lab_country_US_0B0CCE0A7C5D9058C7D39C26003ABCF6_label_en-US" xlink:label="lab_country_US_0B0CCE0A7C5D9058C7D39C26003ABCF6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_0B0CCE0A7C5D9058C7D39C26003ABCF6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US_0B0CCE0A7C5D9058C7D39C26003ABCF6" xlink:to="lab_country_US_0B0CCE0A7C5D9058C7D39C26003ABCF6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ForeignPlanMember_3393F3E6D6A820AB4B129C26003A09D8_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignPlanMember_3393F3E6D6A820AB4B129C26003A09D8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">International [Member]</link:label>
    <link:label id="lab_us-gaap_ForeignPlanMember_3393F3E6D6A820AB4B129C26003A09D8_label_en-US" xlink:label="lab_us-gaap_ForeignPlanMember_3393F3E6D6A820AB4B129C26003A09D8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Plan [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ForeignPlanMember" xlink:label="loc_us-gaap_ForeignPlanMember_3393F3E6D6A820AB4B129C26003A09D8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignPlanMember_3393F3E6D6A820AB4B129C26003A09D8" xlink:to="lab_us-gaap_ForeignPlanMember_3393F3E6D6A820AB4B129C26003A09D8" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetirementPlanTaxStatusAxis_EE9B36554A064C65D1C49C26003B609C_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanTaxStatusAxis_EE9B36554A064C65D1C49C26003B609C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retirement Plan Tax Status [Axis]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanTaxStatusAxis_EE9B36554A064C65D1C49C26003B609C_label_en-US" xlink:label="lab_us-gaap_RetirementPlanTaxStatusAxis_EE9B36554A064C65D1C49C26003B609C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retirement Plan Tax Status [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetirementPlanTaxStatusAxis" xlink:label="loc_us-gaap_RetirementPlanTaxStatusAxis_EE9B36554A064C65D1C49C26003B609C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTaxStatusAxis_EE9B36554A064C65D1C49C26003B609C" xlink:to="lab_us-gaap_RetirementPlanTaxStatusAxis_EE9B36554A064C65D1C49C26003B609C" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetirementPlanTaxStatusDomain_323362365401814229A49C26003BD62B_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanTaxStatusDomain_323362365401814229A49C26003BD62B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retirement Plan Tax Status [Domain]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanTaxStatusDomain_323362365401814229A49C26003BD62B_label_en-US" xlink:label="lab_us-gaap_RetirementPlanTaxStatusDomain_323362365401814229A49C26003BD62B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retirement Plan Tax Status [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetirementPlanTaxStatusDomain" xlink:label="loc_us-gaap_RetirementPlanTaxStatusDomain_323362365401814229A49C26003BD62B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTaxStatusDomain_323362365401814229A49C26003BD62B" xlink:to="lab_us-gaap_RetirementPlanTaxStatusDomain_323362365401814229A49C26003BD62B" xlink:type="arc" />
    <link:label id="lab_us-gaap_QualifiedPlanMember_ADC75BD412157F4427729C26003BFEAD_terseLabel_en-US" xlink:label="lab_us-gaap_QualifiedPlanMember_ADC75BD412157F4427729C26003BFEAD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Qualified [Member]</link:label>
    <link:label id="lab_us-gaap_QualifiedPlanMember_ADC75BD412157F4427729C26003BFEAD_label_en-US" xlink:label="lab_us-gaap_QualifiedPlanMember_ADC75BD412157F4427729C26003BFEAD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Qualified Plan [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_QualifiedPlanMember" xlink:label="loc_us-gaap_QualifiedPlanMember_ADC75BD412157F4427729C26003BFEAD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_QualifiedPlanMember_ADC75BD412157F4427729C26003BFEAD" xlink:to="lab_us-gaap_QualifiedPlanMember_ADC75BD412157F4427729C26003BFEAD" xlink:type="arc" />
    <link:label id="lab_us-gaap_NonqualifiedPlanMember_F7873889745A1D4F86169C26003B2B66_terseLabel_en-US" xlink:label="lab_us-gaap_NonqualifiedPlanMember_F7873889745A1D4F86169C26003B2B66" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Qualified [Member]</link:label>
    <link:label id="lab_us-gaap_NonqualifiedPlanMember_F7873889745A1D4F86169C26003B2B66_label_en-US" xlink:label="lab_us-gaap_NonqualifiedPlanMember_F7873889745A1D4F86169C26003B2B66" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonqualified Plan [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonqualifiedPlanMember" xlink:label="loc_us-gaap_NonqualifiedPlanMember_F7873889745A1D4F86169C26003B2B66" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonqualifiedPlanMember_F7873889745A1D4F86169C26003B2B66" xlink:to="lab_us-gaap_NonqualifiedPlanMember_F7873889745A1D4F86169C26003B2B66" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_0655BCA3A48F386F7BB69C26003B0E64_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_0655BCA3A48F386F7BB69C26003B0E64" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_0655BCA3A48F386F7BB69C26003B0E64_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_0655BCA3A48F386F7BB69C26003B0E64" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_0655BCA3A48F386F7BB69C26003B0E64" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_0655BCA3A48F386F7BB69C26003B0E64" xlink:to="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_0655BCA3A48F386F7BB69C26003B0E64" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer_83C75D167FE2921611F99C26003B923B_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer_83C75D167FE2921611F99C26003B923B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contributions from our general assets for the nine months ended October 1, 2017</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer_83C75D167FE2921611F99C26003B923B_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer_83C75D167FE2921611F99C26003B923B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Contributions by Employer</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:label="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_83C75D167FE2921611F99C26003B923B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_83C75D167FE2921611F99C26003B923B" xlink:to="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer_83C75D167FE2921611F99C26003B923B" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsRemainderOfFiscalYear_8B1881E5D9A67DFC93959C26003B464D_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsRemainderOfFiscalYear_8B1881E5D9A67DFC93959C26003B464D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected contributions from our general assets during 2017</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsRemainderOfFiscalYear_8B1881E5D9A67DFC93959C26003B464D_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsRemainderOfFiscalYear_8B1881E5D9A67DFC93959C26003B464D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Expected Future Employer Contributions, Remainder of Fiscal Year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsRemainderOfFiscalYear" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsRemainderOfFiscalYear_8B1881E5D9A67DFC93959C26003B464D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsRemainderOfFiscalYear_8B1881E5D9A67DFC93959C26003B464D" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsRemainderOfFiscalYear_8B1881E5D9A67DFC93959C26003B464D" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_E24DF26F86CC969DA243AE9F9297F7D2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable_C3257AD4017C59A68CB4B966050AB1C2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_E24DF26F86CC969DA243AE9F9297F7D2_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable_C3257AD4017C59A68CB4B966050AB1C2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_C3257AD4017C59A68CB4B966050AB1C2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_C3257AD4017C59A68CB4B966050AB1C2" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTable_C3257AD4017C59A68CB4B966050AB1C2" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsMember_13689E340523514DB82BAE9F9298B3FD_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsMember_540B2769F98F562BA5A4CBA5C6E64BD1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Member]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsMember_13689E340523514DB82BAE9F9298B3FD_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsMember_540B2769F98F562BA5A4CBA5C6E64BD1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsMember" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember_540B2769F98F562BA5A4CBA5C6E64BD1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsMember_540B2769F98F562BA5A4CBA5C6E64BD1" xlink:to="lab_us-gaap_CashAndCashEquivalentsMember_540B2769F98F562BA5A4CBA5C6E64BD1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShortTermInvestmentsMember_40EF4D411384DD4F4A5EAE9F92980FEE_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsMember_DB0DDEC60A6D54DF88CBB2F83C60C9C3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term Investments [Member]</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestmentsMember_40EF4D411384DD4F4A5EAE9F92980FEE_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsMember_DB0DDEC60A6D54DF88CBB2F83C60C9C3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-term Investments [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermInvestmentsMember" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_DB0DDEC60A6D54DF88CBB2F83C60C9C3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestmentsMember_DB0DDEC60A6D54DF88CBB2F83C60C9C3" xlink:to="lab_us-gaap_ShortTermInvestmentsMember_DB0DDEC60A6D54DF88CBB2F83C60C9C3" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherCurrentAssetsMember_16143C52E916CAF5EB12AE9F9298C50B_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsMember_9953FA6D110A533EBF4B7F78FDF39C63" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Current Assets [Member]</link:label>
    <link:label id="lab_us-gaap_OtherCurrentAssetsMember_16143C52E916CAF5EB12AE9F9298C50B_label_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsMember_9953FA6D110A533EBF4B7F78FDF39C63" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Current Assets [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherCurrentAssetsMember" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_9953FA6D110A533EBF4B7F78FDF39C63" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentAssetsMember_9953FA6D110A533EBF4B7F78FDF39C63" xlink:to="lab_us-gaap_OtherCurrentAssetsMember_9953FA6D110A533EBF4B7F78FDF39C63" xlink:type="arc" />
    <link:label id="lab_pfe_LongtermInvestmentsMember_B82125E1A81C38833B2AAE9F92986214_terseLabel_en-US" xlink:label="lab_pfe_LongtermInvestmentsMember_02A50238EE485DF7908769971C65B6FD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Investments [Member]</link:label>
    <link:label id="lab_pfe_LongtermInvestmentsMember_B82125E1A81C38833B2AAE9F92986214_label_en-US" xlink:label="lab_pfe_LongtermInvestmentsMember_02A50238EE485DF7908769971C65B6FD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Investments [Member]</link:label>
    <link:label id="lab_pfe_LongtermInvestmentsMember_B82125E1A81C38833B2AAE9F92986214_documentation_en-US" xlink:label="lab_pfe_LongtermInvestmentsMember_02A50238EE485DF7908769971C65B6FD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Long-term Investments [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_LongtermInvestmentsMember" xlink:label="loc_pfe_LongtermInvestmentsMember_02A50238EE485DF7908769971C65B6FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_LongtermInvestmentsMember_02A50238EE485DF7908769971C65B6FD" xlink:to="lab_pfe_LongtermInvestmentsMember_02A50238EE485DF7908769971C65B6FD" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNoncurrentAssetsMember_8EDD92FE849CE948CA38AE9F9298EF14_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentAssetsMember_2474887ED15958C68C50F7EC35A4F24C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Noncurrent Assets [Member]</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentAssetsMember_8EDD92FE849CE948CA38AE9F9298EF14_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentAssetsMember_2474887ED15958C68C50F7EC35A4F24C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Noncurrent Assets [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_2474887ED15958C68C50F7EC35A4F24C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentAssetsMember_2474887ED15958C68C50F7EC35A4F24C" xlink:to="lab_us-gaap_OtherNoncurrentAssetsMember_2474887ED15958C68C50F7EC35A4F24C" xlink:type="arc" />
    <link:label id="lab_pfe_ShortTermDebtAndCurrentPortionofLongTermDebtMember_7BB24B88BC5C1FDD1375AE9F92986952_terseLabel_en-US" xlink:label="lab_pfe_ShortTermDebtAndCurrentPortionofLongTermDebtMember_B3DE2C6533265F19BB471811F695A7C1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-Term Borrowings, Including Current Portion of Long-Term Debt [Member]</link:label>
    <link:label id="lab_pfe_ShortTermDebtAndCurrentPortionofLongTermDebtMember_7BB24B88BC5C1FDD1375AE9F92986952_label_en-US" xlink:label="lab_pfe_ShortTermDebtAndCurrentPortionofLongTermDebtMember_B3DE2C6533265F19BB471811F695A7C1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-Term Debt And Current Portion of Long-Term Debt [Member]</link:label>
    <link:label id="lab_pfe_ShortTermDebtAndCurrentPortionofLongTermDebtMember_7BB24B88BC5C1FDD1375AE9F92986952_documentation_en-US" xlink:label="lab_pfe_ShortTermDebtAndCurrentPortionofLongTermDebtMember_B3DE2C6533265F19BB471811F695A7C1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Short-Term Debt And Current Portion of Long-Term Debt [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_ShortTermDebtAndCurrentPortionofLongTermDebtMember" xlink:label="loc_pfe_ShortTermDebtAndCurrentPortionofLongTermDebtMember_B3DE2C6533265F19BB471811F695A7C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ShortTermDebtAndCurrentPortionofLongTermDebtMember_B3DE2C6533265F19BB471811F695A7C1" xlink:to="lab_pfe_ShortTermDebtAndCurrentPortionofLongTermDebtMember_B3DE2C6533265F19BB471811F695A7C1" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtMember_3CEEACC798F323AD86B9AE9F9298FEA6_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMember_85E6279587DC5AA4B63517E2E8C434EA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term debt [Member]</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMember_3CEEACC798F323AD86B9AE9F9298FEA6_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMember_85E6279587DC5AA4B63517E2E8C434EA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtMember" xlink:label="loc_us-gaap_LongTermDebtMember_85E6279587DC5AA4B63517E2E8C434EA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMember_85E6279587DC5AA4B63517E2E8C434EA" xlink:to="lab_us-gaap_LongTermDebtMember_85E6279587DC5AA4B63517E2E8C434EA" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_632C1E2DB4FC574C5E3CAE9F9298DAC1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_54E53BF25E635777A26D9863423332BE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_632C1E2DB4FC574C5E3CAE9F9298DAC1_label_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_54E53BF25E635777A26D9863423332BE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_54E53BF25E635777A26D9863423332BE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_54E53BF25E635777A26D9863423332BE" xlink:to="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_54E53BF25E635777A26D9863423332BE" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsAbstract_F9313A40457CF06CABDEAE9F9298D3DF_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract_DFF744CF05D955CB905DC112328A5256" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_F9313A40457CF06CABDEAE9F9298D3DF_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract_DFF744CF05D955CB905DC112328A5256" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_DFF744CF05D955CB905DC112328A5256" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract_DFF744CF05D955CB905DC112328A5256" xlink:to="lab_us-gaap_AssetsAbstract_DFF744CF05D955CB905DC112328A5256" xlink:type="arc" />
    <link:label id="lab_pfe_SelectedFinancialAssets_BC34DB05B79C4D549577AE9F92984E4E_verboseLabel_en-US" xlink:label="lab_pfe_SelectedFinancialAssets_6D8A63016BA9577DA31990E75282FBD7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Selected financial assets</link:label>
    <link:label id="lab_pfe_SelectedFinancialAssets_BC34DB05B79C4D549577AE9F92984E4E_label_en-US" xlink:label="lab_pfe_SelectedFinancialAssets_6D8A63016BA9577DA31990E75282FBD7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selected Financial Assets</link:label>
    <link:label id="lab_pfe_SelectedFinancialAssets_BC34DB05B79C4D549577AE9F92984E4E_documentation_en-US" xlink:label="lab_pfe_SelectedFinancialAssets_6D8A63016BA9577DA31990E75282FBD7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Total selected financial assets at the balance sheet date.</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_SelectedFinancialAssets" xlink:label="loc_pfe_SelectedFinancialAssets_6D8A63016BA9577DA31990E75282FBD7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SelectedFinancialAssets_6D8A63016BA9577DA31990E75282FBD7" xlink:to="lab_pfe_SelectedFinancialAssets_6D8A63016BA9577DA31990E75282FBD7" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAbstract_CA509ADF401954213F5DAE9F9299FA89_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract_BD52E99619F559A28785225F8CDE01A6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_CA509ADF401954213F5DAE9F9299FA89_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract_BD52E99619F559A28785225F8CDE01A6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAbstract" xlink:label="loc_us-gaap_LiabilitiesAbstract_BD52E99619F559A28785225F8CDE01A6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAbstract_BD52E99619F559A28785225F8CDE01A6" xlink:to="lab_us-gaap_LiabilitiesAbstract_BD52E99619F559A28785225F8CDE01A6" xlink:type="arc" />
    <link:label id="lab_pfe_SelectedFinancialLiabilities_4CDD75A6AD347F6724BFAE9F92997E26_terseLabel_en-US" xlink:label="lab_pfe_SelectedFinancialLiabilities_C1B2775507145CF084B6B3F239A46DAA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selected financial liabilities</link:label>
    <link:label id="lab_pfe_SelectedFinancialLiabilities_4CDD75A6AD347F6724BFAE9F92997E26_label_en-US" xlink:label="lab_pfe_SelectedFinancialLiabilities_C1B2775507145CF084B6B3F239A46DAA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selected Financial Liabilities</link:label>
    <link:label id="lab_pfe_SelectedFinancialLiabilities_4CDD75A6AD347F6724BFAE9F92997E26_documentation_en-US" xlink:label="lab_pfe_SelectedFinancialLiabilities_C1B2775507145CF084B6B3F239A46DAA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Total selected financial liabilities.</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_SelectedFinancialLiabilities" xlink:label="loc_pfe_SelectedFinancialLiabilities_C1B2775507145CF084B6B3F239A46DAA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SelectedFinancialLiabilities_C1B2775507145CF084B6B3F239A46DAA" xlink:to="lab_pfe_SelectedFinancialLiabilities_C1B2775507145CF084B6B3F239A46DAA" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_8648DF28F5FEAD64430EC20224172044_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_CA915345884B557CBED467AA541C40D0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_CA915345884B557CBED467AA541C40D0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_CA915345884B557CBED467AA541C40D0" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_CA915345884B557CBED467AA541C40D0" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementTable_C3171989AF26BC7ACD17C2022417AFDE_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable_9115A4395B1F54869ADF1E0FB0F96F05" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_C3171989AF26BC7ACD17C2022417AFDE_label_en-US" xlink:label="lab_us-gaap_StatementTable_9115A4395B1F54869ADF1E0FB0F96F05" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_9115A4395B1F54869ADF1E0FB0F96F05" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable_9115A4395B1F54869ADF1E0FB0F96F05" xlink:to="lab_us-gaap_StatementTable_9115A4395B1F54869ADF1E0FB0F96F05" xlink:type="arc" />
    <link:label id="lab_pfe_LaboratorioTeutoBrasileroMember_3BA054B48C2A346E27FEC20224176A22_terseLabel_en-US" xlink:label="lab_pfe_LaboratorioTeutoBrasileroMember_915688D5ED455C7E947109498C2DE751" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Laboratorio Teuto Brasilero [Member]</link:label>
    <link:label id="lab_pfe_LaboratorioTeutoBrasileroMember_3BA054B48C2A346E27FEC20224176A22_label_en-US" xlink:label="lab_pfe_LaboratorioTeutoBrasileroMember_915688D5ED455C7E947109498C2DE751" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Laboratorio Teuto Brasilero [Member]</link:label>
    <link:label id="lab_pfe_LaboratorioTeutoBrasileroMember_3BA054B48C2A346E27FEC20224176A22_documentation_en-US" xlink:label="lab_pfe_LaboratorioTeutoBrasileroMember_915688D5ED455C7E947109498C2DE751" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Laboratorio Teuto Brasilero [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_LaboratorioTeutoBrasileroMember" xlink:label="loc_pfe_LaboratorioTeutoBrasileroMember_915688D5ED455C7E947109498C2DE751" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_LaboratorioTeutoBrasileroMember_915688D5ED455C7E947109498C2DE751" xlink:to="lab_pfe_LaboratorioTeutoBrasileroMember_915688D5ED455C7E947109498C2DE751" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementLineItems_2F5C5FB29A890FFFBC93C2022417696D_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems_827A234471C250428B9E4F46165140FE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_2F5C5FB29A890FFFBC93C2022417696D_label_en-US" xlink:label="lab_us-gaap_StatementLineItems_827A234471C250428B9E4F46165140FE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_827A234471C250428B9E4F46165140FE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems_827A234471C250428B9E4F46165140FE" xlink:to="lab_us-gaap_StatementLineItems_827A234471C250428B9E4F46165140FE" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_CCD834F4511D7C56A0CFC20224171A33_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_171F9C09396358B9B4BC48B1025A3AB2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity method investment, ownership percentage</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_CCD834F4511D7C56A0CFC20224171A33_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_171F9C09396358B9B4BC48B1025A3AB2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Ownership Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_171F9C09396358B9B4BC48B1025A3AB2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_171F9C09396358B9B4BC48B1025A3AB2" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_171F9C09396358B9B4BC48B1025A3AB2" xlink:type="arc" />
    <link:label id="lab_pfe_HospiraMember_02B64979E9B5686641C8BE65833609B0_terseLabel_en-US" xlink:label="lab_pfe_HospiraMember_31E812AD04A3597285CC63EF569B521A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hospira [Member]</link:label>
    <link:label id="lab_pfe_HospiraMember_02B64979E9B5686641C8BE65833609B0_label_en-US" xlink:label="lab_pfe_HospiraMember_31E812AD04A3597285CC63EF569B521A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hospira [Member]</link:label>
    <link:label id="lab_pfe_HospiraMember_02B64979E9B5686641C8BE65833609B0_documentation_en-US" xlink:label="lab_pfe_HospiraMember_31E812AD04A3597285CC63EF569B521A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Hospira [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_HospiraMember" xlink:label="loc_pfe_HospiraMember_31E812AD04A3597285CC63EF569B521A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_HospiraMember_31E812AD04A3597285CC63EF569B521A" xlink:to="lab_pfe_HospiraMember_31E812AD04A3597285CC63EF569B521A" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation_AF5CAB8EE8934C412D9ABE4DA3720606_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation_01D2742C605E58C79DD00E8D81F54B5A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Decrease in pension benefit obligation in connection with Hospira pension plan</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation_AF5CAB8EE8934C412D9ABE4DA3720606_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation_01D2742C605E58C79DD00E8D81F54B5A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, (Increase) Decrease for Settlement</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedBenefitPlanSettlementsBenefitObligation" xlink:label="loc_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation_01D2742C605E58C79DD00E8D81F54B5A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation_01D2742C605E58C79DD00E8D81F54B5A" xlink:to="lab_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation_01D2742C605E58C79DD00E8D81F54B5A" xlink:type="arc" />
    <link:label id="lab_pfe_DefinedBenefitPlanNetPeriodicBenefitCostCreditGainLossDuetoSettlementPretax_E655703539536636E949BE4DA372176E_terseLabel_en-US" xlink:label="lab_pfe_DefinedBenefitPlanNetPeriodicBenefitCostCreditGainLossDuetoSettlementPretax_759A631484EC5D9E81525B53E0BA088A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pretax settlement gain</link:label>
    <link:label id="lab_pfe_DefinedBenefitPlanNetPeriodicBenefitCostCreditGainLossDuetoSettlementPretax_E655703539536636E949BE4DA372176E_label_en-US" xlink:label="lab_pfe_DefinedBenefitPlanNetPeriodicBenefitCostCreditGainLossDuetoSettlementPretax_759A631484EC5D9E81525B53E0BA088A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement, Pretax</link:label>
    <link:label id="lab_pfe_DefinedBenefitPlanNetPeriodicBenefitCostCreditGainLossDuetoSettlementPretax_E655703539536636E949BE4DA372176E_documentation_en-US" xlink:label="lab_pfe_DefinedBenefitPlanNetPeriodicBenefitCostCreditGainLossDuetoSettlementPretax_759A631484EC5D9E81525B53E0BA088A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement, Pretax</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_DefinedBenefitPlanNetPeriodicBenefitCostCreditGainLossDuetoSettlementPretax" xlink:label="loc_pfe_DefinedBenefitPlanNetPeriodicBenefitCostCreditGainLossDuetoSettlementPretax_759A631484EC5D9E81525B53E0BA088A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DefinedBenefitPlanNetPeriodicBenefitCostCreditGainLossDuetoSettlementPretax_759A631484EC5D9E81525B53E0BA088A" xlink:to="lab_pfe_DefinedBenefitPlanNetPeriodicBenefitCostCreditGainLossDuetoSettlementPretax_759A631484EC5D9E81525B53E0BA088A" xlink:type="arc" />
    <link:label id="lab_pfe_DefinedBenefitPlanActuarialLossandPriorServiceCostsImmediateRecognitionasComponentinNetPeriodicBenefitCost_169B29557E3A93328892BE4DA3726288_terseLabel_en-US" xlink:label="lab_pfe_DefinedBenefitPlanActuarialLossandPriorServiceCostsImmediateRecognitionasComponentinNetPeriodicBenefitCost_29CEBA4F376F53C48547A40435E9CCAF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Actuarial losses and prior service costs recognized upon plan settlement</link:label>
    <link:label id="lab_pfe_DefinedBenefitPlanActuarialLossandPriorServiceCostsImmediateRecognitionasComponentinNetPeriodicBenefitCost_169B29557E3A93328892BE4DA3726288_label_en-US" xlink:label="lab_pfe_DefinedBenefitPlanActuarialLossandPriorServiceCostsImmediateRecognitionasComponentinNetPeriodicBenefitCost_29CEBA4F376F53C48547A40435E9CCAF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Actuarial Loss and Prior Service Costs, Immediate Recognition as Component in Net Periodic Benefit Cost</link:label>
    <link:label id="lab_pfe_DefinedBenefitPlanActuarialLossandPriorServiceCostsImmediateRecognitionasComponentinNetPeriodicBenefitCost_169B29557E3A93328892BE4DA3726288_documentation_en-US" xlink:label="lab_pfe_DefinedBenefitPlanActuarialLossandPriorServiceCostsImmediateRecognitionasComponentinNetPeriodicBenefitCost_29CEBA4F376F53C48547A40435E9CCAF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Actuarial Loss and Prior Service Costs, Immediate Recognition as Component in Net Periodic Benefit Cost</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_DefinedBenefitPlanActuarialLossandPriorServiceCostsImmediateRecognitionasComponentinNetPeriodicBenefitCost" xlink:label="loc_pfe_DefinedBenefitPlanActuarialLossandPriorServiceCostsImmediateRecognitionasComponentinNetPeriodicBenefitCost_29CEBA4F376F53C48547A40435E9CCAF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DefinedBenefitPlanActuarialLossandPriorServiceCostsImmediateRecognitionasComponentinNetPeriodicBenefitCost_29CEBA4F376F53C48547A40435E9CCAF" xlink:to="lab_pfe_DefinedBenefitPlanActuarialLossandPriorServiceCostsImmediateRecognitionasComponentinNetPeriodicBenefitCost_29CEBA4F376F53C48547A40435E9CCAF" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_DF98991961E9C22630CEAE9F9270ECFB_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract_6DF70F13C35354498FE36682D0518DE2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_6DF70F13C35354498FE36682D0518DE2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_6DF70F13C35354498FE36682D0518DE2" xlink:to="lab_us-gaap_InventoryDisclosureAbstract_6DF70F13C35354498FE36682D0518DE2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_DD4DBF2B7A326CD71B0BAE9F92707CC5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_13A6807F77195E68BAE7BBB8258EBA98" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Components of Inventories, Current</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_DD4DBF2B7A326CD71B0BAE9F92707CC5_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_13A6807F77195E68BAE7BBB8258EBA98" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_13A6807F77195E68BAE7BBB8258EBA98" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_13A6807F77195E68BAE7BBB8258EBA98" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_13A6807F77195E68BAE7BBB8258EBA98" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock_3B07E46BF0FDC70BA99FAE9F92708941_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock_BFF30696A3835837BCDC17A11823C319" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Components of Inventories, Noncurrent</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock_3B07E46BF0FDC70BA99FAE9F92708941_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock_BFF30696A3835837BCDC17A11823C319" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Inventory, Noncurrent [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock_BFF30696A3835837BCDC17A11823C319" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock_BFF30696A3835837BCDC17A11823C319" xlink:to="lab_us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock_BFF30696A3835837BCDC17A11823C319" xlink:type="arc" />
    <link:label id="lab_pfe_WorldwideResearchandDevelopmentandGlobalProductDevelopmentMember_E5DD8003D74855C6FB1F7DDD5D0757E7_terseLabel_en-US" xlink:label="lab_pfe_WorldwideResearchandDevelopmentandGlobalProductDevelopmentMember_E5DD8003D74855C6FB1F7DDD5D0757E7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">WRD &amp; GPD [Member]</link:label>
    <link:label id="lab_pfe_WorldwideResearchandDevelopmentandGlobalProductDevelopmentMember_E5DD8003D74855C6FB1F7DDD5D0757E7_label_en-US" xlink:label="lab_pfe_WorldwideResearchandDevelopmentandGlobalProductDevelopmentMember_E5DD8003D74855C6FB1F7DDD5D0757E7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Worldwide Research and Development and Global Product Development [Member]</link:label>
    <link:label id="lab_pfe_WorldwideResearchandDevelopmentandGlobalProductDevelopmentMember_E5DD8003D74855C6FB1F7DDD5D0757E7_documentation_en-US" xlink:label="lab_pfe_WorldwideResearchandDevelopmentandGlobalProductDevelopmentMember_E5DD8003D74855C6FB1F7DDD5D0757E7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Worldwide Research and Development and Global Product Development [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_WorldwideResearchandDevelopmentandGlobalProductDevelopmentMember" xlink:label="loc_pfe_WorldwideResearchandDevelopmentandGlobalProductDevelopmentMember_E5DD8003D74855C6FB1F7DDD5D0757E7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_WorldwideResearchandDevelopmentandGlobalProductDevelopmentMember_E5DD8003D74855C6FB1F7DDD5D0757E7" xlink:to="lab_pfe_WorldwideResearchandDevelopmentandGlobalProductDevelopmentMember_E5DD8003D74855C6FB1F7DDD5D0757E7" xlink:type="arc" />
    <link:label id="lab_pfe_ManufacturingOperationsMember_DF0BEAD0C01492941C0D7DDD5D07014E_terseLabel_en-US" xlink:label="lab_pfe_ManufacturingOperationsMember_DF0BEAD0C01492941C0D7DDD5D07014E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Manufacturing operations [Member]</link:label>
    <link:label id="lab_pfe_ManufacturingOperationsMember_DF0BEAD0C01492941C0D7DDD5D07014E_label_en-US" xlink:label="lab_pfe_ManufacturingOperationsMember_DF0BEAD0C01492941C0D7DDD5D07014E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Manufacturing Operations [Member]</link:label>
    <link:label id="lab_pfe_ManufacturingOperationsMember_DF0BEAD0C01492941C0D7DDD5D07014E_documentation_en-US" xlink:label="lab_pfe_ManufacturingOperationsMember_DF0BEAD0C01492941C0D7DDD5D07014E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Manufacturing Operations [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_ManufacturingOperationsMember" xlink:label="loc_pfe_ManufacturingOperationsMember_DF0BEAD0C01492941C0D7DDD5D07014E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ManufacturingOperationsMember_DF0BEAD0C01492941C0D7DDD5D07014E" xlink:to="lab_pfe_ManufacturingOperationsMember_DF0BEAD0C01492941C0D7DDD5D07014E" xlink:type="arc" />
    <link:label id="lab_pfe_InnovativeHealthSegmentMember_53A8158B44B09E6874737DDD5D075FD6_verboseLabel_en-US" xlink:label="lab_pfe_InnovativeHealthSegmentMember_53A8158B44B09E6874737DDD5D075FD6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">IH [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_InnovativeHealthSegmentMember" xlink:label="loc_pfe_InnovativeHealthSegmentMember_53A8158B44B09E6874737DDD5D075FD6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_InnovativeHealthSegmentMember_53A8158B44B09E6874737DDD5D075FD6" xlink:to="lab_pfe_InnovativeHealthSegmentMember_53A8158B44B09E6874737DDD5D075FD6" xlink:type="arc" />
    <link:label id="lab_pfe_EssentialHealthSegmentMember_91E48AAB9A7C4DBBFA847DDD5D0708A3_verboseLabel_en-US" xlink:label="lab_pfe_EssentialHealthSegmentMember_91E48AAB9A7C4DBBFA847DDD5D0708A3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">EH [Member]</link:label>
    <link:label id="lab_pfe_EssentialHealthSegmentMember_91E48AAB9A7C4DBBFA847DDD5D0708A3_label_en-US" xlink:label="lab_pfe_EssentialHealthSegmentMember_91E48AAB9A7C4DBBFA847DDD5D0708A3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Essential Health Segment [Member]</link:label>
    <link:label id="lab_pfe_EssentialHealthSegmentMember_91E48AAB9A7C4DBBFA847DDD5D0708A3_documentation_en-US" xlink:label="lab_pfe_EssentialHealthSegmentMember_91E48AAB9A7C4DBBFA847DDD5D0708A3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Essential Health Segment [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_EssentialHealthSegmentMember" xlink:label="loc_pfe_EssentialHealthSegmentMember_91E48AAB9A7C4DBBFA847DDD5D0708A3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_EssentialHealthSegmentMember_91E48AAB9A7C4DBBFA847DDD5D0708A3" xlink:to="lab_pfe_EssentialHealthSegmentMember_91E48AAB9A7C4DBBFA847DDD5D0708A3" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringCharges_AAABDCC8BBF7FDB61BBF7DDD5D0833EB_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges_AAABDCC8BBF7FDB61BBF7DDD5D0833EB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provision</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_AAABDCC8BBF7FDB61BBF7DDD5D0833EB_label_en-US" xlink:label="lab_us-gaap_RestructuringCharges_AAABDCC8BBF7FDB61BBF7DDD5D0833EB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Charges</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_AAABDCC8BBF7FDB61BBF7DDD5D0833EB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges_AAABDCC8BBF7FDB61BBF7DDD5D0833EB" xlink:to="lab_us-gaap_RestructuringCharges_AAABDCC8BBF7FDB61BBF7DDD5D0833EB" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_D148E70718E29B8A361F7DDD5D0D484F_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_D148E70718E29B8A361F7DDD5D0D484F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net gain related to the settlement</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_D148E70718E29B8A361F7DDD5D0D484F_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_D148E70718E29B8A361F7DDD5D0D484F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_D148E70718E29B8A361F7DDD5D0D484F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_D148E70718E29B8A361F7DDD5D0D484F" xlink:to="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_D148E70718E29B8A361F7DDD5D0D484F" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_0162D4217BF08A128E3F7DDD5E1518AD_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract_0162D4217BF08A128E3F7DDD5E1518AD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_0162D4217BF08A128E3F7DDD5E1518AD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0162D4217BF08A128E3F7DDD5E1518AD" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract_0162D4217BF08A128E3F7DDD5E1518AD" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2670F50E1159B58C55577DDD5E151C1D_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2670F50E1159B58C55577DDD5E151C1D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2670F50E1159B58C55577DDD5E151C1D_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2670F50E1159B58C55577DDD5E151C1D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2670F50E1159B58C55577DDD5E151C1D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2670F50E1159B58C55577DDD5E151C1D" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2670F50E1159B58C55577DDD5E151C1D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProfitLoss_CB3C0B8B4EC1914A73D07DDD5E15DEF3_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss_CB3C0B8B4EC1914A73D07DDD5E15DEF3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income before allocation to noncontrolling interests</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_CB3C0B8B4EC1914A73D07DDD5E15DEF3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss_CB3C0B8B4EC1914A73D07DDD5E15DEF3" xlink:to="lab_us-gaap_ProfitLoss_CB3C0B8B4EC1914A73D07DDD5E15DEF3" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1B9B9E5EDF4ACD7AF6DB7DDD5E16F963_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1B9B9E5EDF4ACD7AF6DB7DDD5E16F963" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net income before allocation to noncontrolling interests to net cash provided by operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1B9B9E5EDF4ACD7AF6DB7DDD5E16F963_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1B9B9E5EDF4ACD7AF6DB7DDD5E16F963" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1B9B9E5EDF4ACD7AF6DB7DDD5E16F963" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1B9B9E5EDF4ACD7AF6DB7DDD5E16F963" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1B9B9E5EDF4ACD7AF6DB7DDD5E16F963" xlink:type="arc" />
    <link:label id="lab_pfe_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization_6CFED759CF1B051C0C2E7DDD5E163591_terseLabel_en-US" xlink:label="lab_pfe_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization_6CFED759CF1B051C0C2E7DDD5E163591" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_pfe_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization_6CFED759CF1B051C0C2E7DDD5E163591_label_en-US" xlink:label="lab_pfe_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization_6CFED759CF1B051C0C2E7DDD5E163591" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion And Amortization, Including Discontinued Operation, Depreciation and Amortization</link:label>
    <link:label id="lab_pfe_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization_6CFED759CF1B051C0C2E7DDD5E163591_documentation_en-US" xlink:label="lab_pfe_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization_6CFED759CF1B051C0C2E7DDD5E163591" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets. Includes the amount of expense from discontinued operations, that reflects the allocation of the cost of tangible and intangible assets over the assets' useful lives.</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization" xlink:label="loc_pfe_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization_6CFED759CF1B051C0C2E7DDD5E163591" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization_6CFED759CF1B051C0C2E7DDD5E163591" xlink:to="lab_pfe_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization_6CFED759CF1B051C0C2E7DDD5E163591" xlink:type="arc" />
    <link:label id="lab_pfe_AssetWriteOffsAndAssetImpairmentCharges_3FFA79E484BF33A2C4307DDD5E164406_verboseLabel_en-US" xlink:label="lab_pfe_AssetWriteOffsAndAssetImpairmentCharges_3FFA79E484BF33A2C4307DDD5E164406" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Asset write-offs and impairments</link:label>
    <link:label id="lab_pfe_AssetWriteOffsAndAssetImpairmentCharges_3FFA79E484BF33A2C4307DDD5E164406_label_en-US" xlink:label="lab_pfe_AssetWriteOffsAndAssetImpairmentCharges_3FFA79E484BF33A2C4307DDD5E164406" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Write-Offs And Asset Impairment Charges</link:label>
    <link:label id="lab_pfe_AssetWriteOffsAndAssetImpairmentCharges_3FFA79E484BF33A2C4307DDD5E164406_documentation_en-US" xlink:label="lab_pfe_AssetWriteOffsAndAssetImpairmentCharges_3FFA79E484BF33A2C4307DDD5E164406" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Asset Write-Offs And Asset Impairment Charges</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_AssetWriteOffsAndAssetImpairmentCharges" xlink:label="loc_pfe_AssetWriteOffsAndAssetImpairmentCharges_3FFA79E484BF33A2C4307DDD5E164406" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_AssetWriteOffsAndAssetImpairmentCharges_3FFA79E484BF33A2C4307DDD5E164406" xlink:to="lab_pfe_AssetWriteOffsAndAssetImpairmentCharges_3FFA79E484BF33A2C4307DDD5E164406" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_0D52202D3EFD165A689A7DDD5E16304F_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_0D52202D3EFD165A689A7DDD5E16304F" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Loss on sale of HIS net assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_0D52202D3EFD165A689A7DDD5E16304F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_0D52202D3EFD165A689A7DDD5E16304F" xlink:to="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_0D52202D3EFD165A689A7DDD5E16304F" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_20AAA73AA3465C2620CD7DDD5E1617C5_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_20AAA73AA3465C2620CD7DDD5E1617C5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred taxes from continuing operations</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_20AAA73AA3465C2620CD7DDD5E1617C5_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_20AAA73AA3465C2620CD7DDD5E1617C5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_20AAA73AA3465C2620CD7DDD5E1617C5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_20AAA73AA3465C2620CD7DDD5E1617C5" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_20AAA73AA3465C2620CD7DDD5E1617C5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensation_7F512FB452EF02DB1FBE7DDD5E163CA2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_7F512FB452EF02DB1FBE7DDD5E163CA2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_7F512FB452EF02DB1FBE7DDD5E163CA2_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_7F512FB452EF02DB1FBE7DDD5E163CA2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_7F512FB452EF02DB1FBE7DDD5E163CA2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_7F512FB452EF02DB1FBE7DDD5E163CA2" xlink:to="lab_us-gaap_ShareBasedCompensation_7F512FB452EF02DB1FBE7DDD5E163CA2" xlink:type="arc" />
    <link:label id="lab_pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense_FCABA2092F24933911837DDD5E177732_negatedTerseLabel_en-US" xlink:label="lab_pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense_FCABA2092F24933911837DDD5E177732" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Benefit plan contributions in excess of expense</link:label>
    <link:label id="lab_pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense_FCABA2092F24933911837DDD5E177732_label_en-US" xlink:label="lab_pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense_FCABA2092F24933911837DDD5E177732" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension And Other Postretirement Benefit Contributions, Net Of Pension And Other Postretirement Benefit (Expense)</link:label>
    <link:label id="lab_pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense_FCABA2092F24933911837DDD5E177732_documentation_en-US" xlink:label="lab_pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense_FCABA2092F24933911837DDD5E177732" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of cash or cash equivalents contributed during the reporting period by the entity to fund its pension plans and its non-pension postretirement benefit plans less the amount of pension and other postretirement benefit costs recognized during the period for defined benefit plans (periodic benefit costs include the following components: service cost, interest cost, expected return on plan assets, gain or loss on assets, prior service cost or credit, transition asset or obligation, and gain or loss due to settlements or curtailments).</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense" xlink:label="loc_pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense_FCABA2092F24933911837DDD5E177732" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense_FCABA2092F24933911837DDD5E177732" xlink:to="lab_pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense_FCABA2092F24933911837DDD5E177732" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_EED424E935CD5157E7797DDD5E176D04_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense_EED424E935CD5157E7797DDD5E176D04" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other adjustments, net</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_EED424E935CD5157E7797DDD5E176D04_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense_EED424E935CD5157E7797DDD5E176D04" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_EED424E935CD5157E7797DDD5E176D04" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense_EED424E935CD5157E7797DDD5E176D04" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense_EED424E935CD5157E7797DDD5E176D04" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapital_1CBBC0D3E250F4E427BC7DDD5E171720_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapital_1CBBC0D3E250F4E427BC7DDD5E171720" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other changes in assets and liabilities, net of acquisitions and divestitures</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapital_1CBBC0D3E250F4E427BC7DDD5E171720_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapital_1CBBC0D3E250F4E427BC7DDD5E171720" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapital" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapital_1CBBC0D3E250F4E427BC7DDD5E171720" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapital_1CBBC0D3E250F4E427BC7DDD5E171720" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapital_1CBBC0D3E250F4E427BC7DDD5E171720" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_F0581A12C5A6BD7E2F057DDD5E172D04_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_F0581A12C5A6BD7E2F057DDD5E172D04" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_F0581A12C5A6BD7E2F057DDD5E172D04_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_F0581A12C5A6BD7E2F057DDD5E172D04" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_F0581A12C5A6BD7E2F057DDD5E172D04" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_F0581A12C5A6BD7E2F057DDD5E172D04" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_F0581A12C5A6BD7E2F057DDD5E172D04" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5A0BFDA0D914E176B5317DDD5E17E518_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5A0BFDA0D914E176B5317DDD5E17E518" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investing Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5A0BFDA0D914E176B5317DDD5E17E518_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5A0BFDA0D914E176B5317DDD5E17E518" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5A0BFDA0D914E176B5317DDD5E17E518" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5A0BFDA0D914E176B5317DDD5E17E518" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5A0BFDA0D914E176B5317DDD5E17E518" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_36858490CC357470760D7DDD5E17324C_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_36858490CC357470760D7DDD5E17324C" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_36858490CC357470760D7DDD5E17324C_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_36858490CC357470760D7DDD5E17324C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_36858490CC357470760D7DDD5E17324C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_36858490CC357470760D7DDD5E17324C" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_36858490CC357470760D7DDD5E17324C" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireShortTermInvestments_9FBB402B7A4B1A446CE77DDD5E17A31D_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireShortTermInvestments_9FBB402B7A4B1A446CE77DDD5E17A31D" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of short-term investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireShortTermInvestments_9FBB402B7A4B1A446CE77DDD5E17A31D_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireShortTermInvestments_9FBB402B7A4B1A446CE77DDD5E17A31D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Short-term Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments_9FBB402B7A4B1A446CE77DDD5E17A31D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireShortTermInvestments_9FBB402B7A4B1A446CE77DDD5E17A31D" xlink:to="lab_us-gaap_PaymentsToAcquireShortTermInvestments_9FBB402B7A4B1A446CE77DDD5E17A31D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_3BE04FFD29F4D0A6C2F77DDD5E17EB1F_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_3BE04FFD29F4D0A6C2F77DDD5E17EB1F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from redemptions/sales of short-term investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_3BE04FFD29F4D0A6C2F77DDD5E17EB1F_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_3BE04FFD29F4D0A6C2F77DDD5E17EB1F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale, Maturity and Collection of Short-term Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_3BE04FFD29F4D0A6C2F77DDD5E17EB1F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_3BE04FFD29F4D0A6C2F77DDD5E17EB1F" xlink:to="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_3BE04FFD29F4D0A6C2F77DDD5E17EB1F" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsForProceedsFromShortTermInvestments_9100CEA09C9000175DD37DDD5E1724AA_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromShortTermInvestments_9100CEA09C9000175DD37DDD5E1724AA" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Net proceeds from redemptions/sales of short-term investments with original maturities of three months or less</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromShortTermInvestments_9100CEA09C9000175DD37DDD5E1724AA_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromShortTermInvestments_9100CEA09C9000175DD37DDD5E1724AA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for (Proceeds from) Short-term Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsForProceedsFromShortTermInvestments" xlink:label="loc_us-gaap_PaymentsForProceedsFromShortTermInvestments_9100CEA09C9000175DD37DDD5E1724AA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromShortTermInvestments_9100CEA09C9000175DD37DDD5E1724AA" xlink:to="lab_us-gaap_PaymentsForProceedsFromShortTermInvestments_9100CEA09C9000175DD37DDD5E1724AA" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_027B7A058CA5EA39D0037DDD5E186595_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities_027B7A058CA5EA39D0037DDD5E186595" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of long-term investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_027B7A058CA5EA39D0037DDD5E186595_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities_027B7A058CA5EA39D0037DDD5E186595" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_027B7A058CA5EA39D0037DDD5E186595" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities_027B7A058CA5EA39D0037DDD5E186595" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities_027B7A058CA5EA39D0037DDD5E186595" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments_1EE02F5084341C96E6697DDD5E1805BB_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments_1EE02F5084341C96E6697DDD5E1805BB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from redemptions/sales of long-term investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments_1EE02F5084341C96E6697DDD5E1805BB_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments_1EE02F5084341C96E6697DDD5E1805BB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale, Maturity and Collection of Long-term Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments_1EE02F5084341C96E6697DDD5E1805BB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments_1EE02F5084341C96E6697DDD5E1805BB" xlink:to="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments_1EE02F5084341C96E6697DDD5E1805BB" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_F8353380BF664162B9887DDD5E18241A_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_F8353380BF664162B9887DDD5E18241A" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Acquisitions of businesses, net of cash acquired</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_F8353380BF664162B9887DDD5E18241A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_F8353380BF664162B9887DDD5E18241A" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_F8353380BF664162B9887DDD5E18241A" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_0795380BB8548B3F3D517DDD5E18E76C_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets_0795380BB8548B3F3D517DDD5E18E76C" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Acquisitions of intangible assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_0795380BB8548B3F3D517DDD5E18E76C_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets_0795380BB8548B3F3D517DDD5E18E76C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_0795380BB8548B3F3D517DDD5E18E76C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireIntangibleAssets_0795380BB8548B3F3D517DDD5E18E76C" xlink:to="lab_us-gaap_PaymentsToAcquireIntangibleAssets_0795380BB8548B3F3D517DDD5E18E76C" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_C531859D4FDEB5B6D29D7DDD5E180413_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_C531859D4FDEB5B6D29D7DDD5E180413" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other investing activities, net</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_C531859D4FDEB5B6D29D7DDD5E180413_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_C531859D4FDEB5B6D29D7DDD5E180413" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_C531859D4FDEB5B6D29D7DDD5E180413" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_C531859D4FDEB5B6D29D7DDD5E180413" xlink:to="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_C531859D4FDEB5B6D29D7DDD5E180413" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_A1A36DE8210E39F72FC47DDD5E18A348_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_A1A36DE8210E39F72FC47DDD5E18A348" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by/(used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_A1A36DE8210E39F72FC47DDD5E18A348_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_A1A36DE8210E39F72FC47DDD5E18A348" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_A1A36DE8210E39F72FC47DDD5E18A348" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_A1A36DE8210E39F72FC47DDD5E18A348" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_A1A36DE8210E39F72FC47DDD5E18A348" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_943AD77F36B9090FDC007DDD5E193DF4_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_943AD77F36B9090FDC007DDD5E193DF4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financing Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_943AD77F36B9090FDC007DDD5E193DF4_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_943AD77F36B9090FDC007DDD5E193DF4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_943AD77F36B9090FDC007DDD5E193DF4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_943AD77F36B9090FDC007DDD5E193DF4" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_943AD77F36B9090FDC007DDD5E193DF4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromShortTermDebt_E97D1818499D585082AD7DDD5E19494B_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromShortTermDebt_E97D1818499D585082AD7DDD5E19494B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from short-term borrowings</link:label>
    <link:label id="lab_us-gaap_ProceedsFromShortTermDebt_E97D1818499D585082AD7DDD5E19494B_label_en-US" xlink:label="lab_us-gaap_ProceedsFromShortTermDebt_E97D1818499D585082AD7DDD5E19494B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Short-term Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromShortTermDebt" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt_E97D1818499D585082AD7DDD5E19494B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromShortTermDebt_E97D1818499D585082AD7DDD5E19494B" xlink:to="lab_us-gaap_ProceedsFromShortTermDebt_E97D1818499D585082AD7DDD5E19494B" xlink:type="arc" />
    <link:label id="lab_us-gaap_RepaymentsOfShortTermDebt_BC86C1AA5C07B5FCEB167DDD5E19197F_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfShortTermDebt_BC86C1AA5C07B5FCEB167DDD5E19197F" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Principal payments on short-term borrowings</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfShortTermDebt_BC86C1AA5C07B5FCEB167DDD5E19197F_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfShortTermDebt_BC86C1AA5C07B5FCEB167DDD5E19197F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Short-term Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepaymentsOfShortTermDebt" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt_BC86C1AA5C07B5FCEB167DDD5E19197F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfShortTermDebt_BC86C1AA5C07B5FCEB167DDD5E19197F" xlink:to="lab_us-gaap_RepaymentsOfShortTermDebt_BC86C1AA5C07B5FCEB167DDD5E19197F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess_83A9948B09E6334E16897DDD5E198C3C_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess_83A9948B09E6334E16897DDD5E198C3C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net proceeds from/(payments on) short-term borrowings with original maturities of three months or less</link:label>
    <link:label id="lab_us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess_83A9948B09E6334E16897DDD5E198C3C_label_en-US" xlink:label="lab_us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess_83A9948B09E6334E16897DDD5E198C3C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from (Repayments of) Short-term Debt, Maturing in Three Months or Less</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess_83A9948B09E6334E16897DDD5E198C3C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess_83A9948B09E6334E16897DDD5E198C3C" xlink:to="lab_us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess_83A9948B09E6334E16897DDD5E198C3C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_8EF598E46AD53F54036B7DDD5E1910A9_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_8EF598E46AD53F54036B7DDD5E1910A9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of long-term debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_8EF598E46AD53F54036B7DDD5E1910A9_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_8EF598E46AD53F54036B7DDD5E1910A9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Long-term Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_8EF598E46AD53F54036B7DDD5E1910A9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_8EF598E46AD53F54036B7DDD5E1910A9" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_8EF598E46AD53F54036B7DDD5E1910A9" xlink:type="arc" />
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_4696ACE5F34A30D7DFB17DDD5E19F667_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt_4696ACE5F34A30D7DFB17DDD5E19F667" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Principal payments on long-term debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_4696ACE5F34A30D7DFB17DDD5E19F667_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt_4696ACE5F34A30D7DFB17DDD5E19F667" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Long-term Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_4696ACE5F34A30D7DFB17DDD5E19F667" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt_4696ACE5F34A30D7DFB17DDD5E19F667" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt_4696ACE5F34A30D7DFB17DDD5E19F667" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_24AC6F1CC2D4DD9356DA7DDD5E190147_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_24AC6F1CC2D4DD9356DA7DDD5E190147" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of common stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_24AC6F1CC2D4DD9356DA7DDD5E190147_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_24AC6F1CC2D4DD9356DA7DDD5E190147" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_24AC6F1CC2D4DD9356DA7DDD5E190147" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_24AC6F1CC2D4DD9356DA7DDD5E190147" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_24AC6F1CC2D4DD9356DA7DDD5E190147" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsOfOrdinaryDividends_F7D5921BF65E342244657DDD5E19E6F4_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfOrdinaryDividends_F7D5921BF65E342244657DDD5E19E6F4" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Cash dividends paid</link:label>
    <link:label id="lab_us-gaap_PaymentsOfOrdinaryDividends_F7D5921BF65E342244657DDD5E19E6F4_label_en-US" xlink:label="lab_us-gaap_PaymentsOfOrdinaryDividends_F7D5921BF65E342244657DDD5E19E6F4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Ordinary Dividends</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfOrdinaryDividends" xlink:label="loc_us-gaap_PaymentsOfOrdinaryDividends_F7D5921BF65E342244657DDD5E19E6F4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfOrdinaryDividends_F7D5921BF65E342244657DDD5E19E6F4" xlink:to="lab_us-gaap_PaymentsOfOrdinaryDividends_F7D5921BF65E342244657DDD5E19E6F4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_0408F9110B05C32A251C7DDD5E19BB47_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised_0408F9110B05C32A251C7DDD5E19BB47" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_0408F9110B05C32A251C7DDD5E19BB47_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised_0408F9110B05C32A251C7DDD5E19BB47" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_0408F9110B05C32A251C7DDD5E19BB47" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised_0408F9110B05C32A251C7DDD5E19BB47" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised_0408F9110B05C32A251C7DDD5E19BB47" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_E678D8FD62605E1FAFA27DDD5E1976E9_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_E678D8FD62605E1FAFA27DDD5E1976E9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other financing activities, net</link:label>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_E678D8FD62605E1FAFA27DDD5E1976E9_label_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_E678D8FD62605E1FAFA27DDD5E1976E9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from (Payments for) Other Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_E678D8FD62605E1FAFA27DDD5E1976E9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_E678D8FD62605E1FAFA27DDD5E1976E9" xlink:to="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_E678D8FD62605E1FAFA27DDD5E1976E9" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_74E7BB756C5099E598E47DDD5E190797_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_74E7BB756C5099E598E47DDD5E190797" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_74E7BB756C5099E598E47DDD5E190797_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_74E7BB756C5099E598E47DDD5E190797" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_74E7BB756C5099E598E47DDD5E190797" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_74E7BB756C5099E598E47DDD5E190797" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_74E7BB756C5099E598E47DDD5E190797" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_EC893957C534375371077DDD5E192BB3_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_EC893957C534375371077DDD5E192BB3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of exchange-rate changes on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_EC893957C534375371077DDD5E192BB3_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_EC893957C534375371077DDD5E192BB3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of Exchange Rate on Cash and Cash Equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_EC893957C534375371077DDD5E192BB3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_EC893957C534375371077DDD5E192BB3" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_EC893957C534375371077DDD5E192BB3" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_56226AFBB2D407A71A3C7DDD5E19E14D_totalLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_56226AFBB2D407A71A3C7DDD5E19E14D" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net increase/(decrease) in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_56226AFBB2D407A71A3C7DDD5E19E14D_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_56226AFBB2D407A71A3C7DDD5E19E14D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_56226AFBB2D407A71A3C7DDD5E19E14D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_56226AFBB2D407A71A3C7DDD5E19E14D" xlink:to="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_56226AFBB2D407A71A3C7DDD5E19E14D" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_C396345B492E39A7BB157DDD5E19F407_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_C396345B492E39A7BB157DDD5E19F407" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, beginning</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_C396345B492E39A7BB157DDD5E19F407_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_C396345B492E39A7BB157DDD5E19F407" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_C396345B492E39A7BB157DDD5E19F407" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_C396345B492E39A7BB157DDD5E19F407" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_C396345B492E39A7BB157DDD5E19F407" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_CD2F1FFBC8BC252963567DDD5E1A028A_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_CD2F1FFBC8BC252963567DDD5E1A028A" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, end</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_CD2F1FFBC8BC252963567DDD5E1A028A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_CD2F1FFBC8BC252963567DDD5E1A028A" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_CD2F1FFBC8BC252963567DDD5E1A028A" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_562CE419A7C40AF4F30A7DDD5E1AFA84_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_562CE419A7C40AF4F30A7DDD5E1AFA84" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information</link:label>
    <link:label id="lab_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_562CE419A7C40AF4F30A7DDD5E1AFA84_label_en-US" xlink:label="lab_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_562CE419A7C40AF4F30A7DDD5E1AFA84" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Cash Flow Elements and Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_562CE419A7C40AF4F30A7DDD5E1AFA84" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_562CE419A7C40AF4F30A7DDD5E1AFA84" xlink:to="lab_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_562CE419A7C40AF4F30A7DDD5E1AFA84" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_81002851DA16F70A91887DDD5E1A20C9_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_81002851DA16F70A91887DDD5E1A20C9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash transactions:</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_81002851DA16F70A91887DDD5E1A20C9_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_81002851DA16F70A91887DDD5E1A20C9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_81002851DA16F70A91887DDD5E1A20C9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_81002851DA16F70A91887DDD5E1A20C9" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_81002851DA16F70A91887DDD5E1A20C9" xlink:type="arc" />
    <link:label id="lab_pfe_NoncashorPartNoncashDivestitureAmountofConsiderationReceivedCommonStock_564CDE91A176459F69867DDD5E1AEAAB_terseLabel_en-US" xlink:label="lab_pfe_NoncashorPartNoncashDivestitureAmountofConsiderationReceivedCommonStock_564CDE91A176459F69867DDD5E1AEAAB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Receipt of ICU Medical common stock</link:label>
    <link:label id="lab_pfe_NoncashorPartNoncashDivestitureAmountofConsiderationReceivedCommonStock_564CDE91A176459F69867DDD5E1AEAAB_label_en-US" xlink:label="lab_pfe_NoncashorPartNoncashDivestitureAmountofConsiderationReceivedCommonStock_564CDE91A176459F69867DDD5E1AEAAB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncash or Part Noncash Divestiture, Amount of Consideration Received, Common Stock</link:label>
    <link:label id="lab_pfe_NoncashorPartNoncashDivestitureAmountofConsiderationReceivedCommonStock_564CDE91A176459F69867DDD5E1AEAAB_documentation_en-US" xlink:label="lab_pfe_NoncashorPartNoncashDivestitureAmountofConsiderationReceivedCommonStock_564CDE91A176459F69867DDD5E1AEAAB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Noncash or Part Noncash Divestiture, Amount of Consideration Received, Common Stock</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_NoncashorPartNoncashDivestitureAmountofConsiderationReceivedCommonStock" xlink:label="loc_pfe_NoncashorPartNoncashDivestitureAmountofConsiderationReceivedCommonStock_564CDE91A176459F69867DDD5E1AEAAB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_NoncashorPartNoncashDivestitureAmountofConsiderationReceivedCommonStock_564CDE91A176459F69867DDD5E1AEAAB" xlink:to="lab_pfe_NoncashorPartNoncashDivestitureAmountofConsiderationReceivedCommonStock_564CDE91A176459F69867DDD5E1AEAAB" xlink:type="arc" />
    <link:label id="lab_pfe_NoncashorPartNoncashDivestitureAmountofConsiderationReceivedNoteReceivable_511AF19B0F591B3D7F367DDD5E1A8FA6_terseLabel_en-US" xlink:label="lab_pfe_NoncashorPartNoncashDivestitureAmountofConsiderationReceivedNoteReceivable_511AF19B0F591B3D7F367DDD5E1A8FA6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Promissory note from ICU Medical</link:label>
    <link:label id="lab_pfe_NoncashorPartNoncashDivestitureAmountofConsiderationReceivedNoteReceivable_511AF19B0F591B3D7F367DDD5E1A8FA6_label_en-US" xlink:label="lab_pfe_NoncashorPartNoncashDivestitureAmountofConsiderationReceivedNoteReceivable_511AF19B0F591B3D7F367DDD5E1A8FA6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncash or Part Noncash Divestiture, Amount of Consideration Received, Note Receivable</link:label>
    <link:label id="lab_pfe_NoncashorPartNoncashDivestitureAmountofConsiderationReceivedNoteReceivable_511AF19B0F591B3D7F367DDD5E1A8FA6_documentation_en-US" xlink:label="lab_pfe_NoncashorPartNoncashDivestitureAmountofConsiderationReceivedNoteReceivable_511AF19B0F591B3D7F367DDD5E1A8FA6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Noncash or Part Noncash Divestiture, Amount of Consideration Received, Note Receivable</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_NoncashorPartNoncashDivestitureAmountofConsiderationReceivedNoteReceivable" xlink:label="loc_pfe_NoncashorPartNoncashDivestitureAmountofConsiderationReceivedNoteReceivable_511AF19B0F591B3D7F367DDD5E1A8FA6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_NoncashorPartNoncashDivestitureAmountofConsiderationReceivedNoteReceivable_511AF19B0F591B3D7F367DDD5E1A8FA6" xlink:to="lab_pfe_NoncashorPartNoncashDivestitureAmountofConsiderationReceivedNoteReceivable_511AF19B0F591B3D7F367DDD5E1A8FA6" xlink:type="arc" />
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_647E67767F5BC570B80F7DDD5E1A2BB3_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract_647E67767F5BC570B80F7DDD5E1A2BB3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid (received) during the period for:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_647E67767F5BC570B80F7DDD5E1A2BB3_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract_647E67767F5BC570B80F7DDD5E1A2BB3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_647E67767F5BC570B80F7DDD5E1A2BB3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_647E67767F5BC570B80F7DDD5E1A2BB3" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract_647E67767F5BC570B80F7DDD5E1A2BB3" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_920E3FCE80D618EC68697DDD5E1AE196_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet_920E3FCE80D618EC68697DDD5E1AE196" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_920E3FCE80D618EC68697DDD5E1AE196_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet_920E3FCE80D618EC68697DDD5E1AE196" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes Paid, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_920E3FCE80D618EC68697DDD5E1AE196" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet_920E3FCE80D618EC68697DDD5E1AE196" xlink:to="lab_us-gaap_IncomeTaxesPaidNet_920E3FCE80D618EC68697DDD5E1AE196" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestPaidNet_A902F2169FF65DB6091D7DDD5E1A7A96_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet_A902F2169FF65DB6091D7DDD5E1A7A96" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_A902F2169FF65DB6091D7DDD5E1A7A96_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet_A902F2169FF65DB6091D7DDD5E1A7A96" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Paid, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet_A902F2169FF65DB6091D7DDD5E1A7A96" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet_A902F2169FF65DB6091D7DDD5E1A7A96" xlink:to="lab_us-gaap_InterestPaidNet_A902F2169FF65DB6091D7DDD5E1A7A96" xlink:type="arc" />
    <link:label id="lab_pfe_InterestPaidInterestRateHedges_782A6BA5F83067D5E4F67DDD5E1BB221_terseLabel_en-US" xlink:label="lab_pfe_InterestPaidInterestRateHedges_782A6BA5F83067D5E4F67DDD5E1BB221" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest rate hedges</link:label>
    <link:label id="lab_pfe_InterestPaidInterestRateHedges_782A6BA5F83067D5E4F67DDD5E1BB221_label_en-US" xlink:label="lab_pfe_InterestPaidInterestRateHedges_782A6BA5F83067D5E4F67DDD5E1BB221" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Paid, Interest Rate Hedges</link:label>
    <link:label id="lab_pfe_InterestPaidInterestRateHedges_782A6BA5F83067D5E4F67DDD5E1BB221_documentation_en-US" xlink:label="lab_pfe_InterestPaidInterestRateHedges_782A6BA5F83067D5E4F67DDD5E1BB221" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Interest Paid, Interest Rate Hedges</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_InterestPaidInterestRateHedges" xlink:label="loc_pfe_InterestPaidInterestRateHedges_782A6BA5F83067D5E4F67DDD5E1BB221" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_InterestPaidInterestRateHedges_782A6BA5F83067D5E4F67DDD5E1BB221" xlink:to="lab_pfe_InterestPaidInterestRateHedges_782A6BA5F83067D5E4F67DDD5E1BB221" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_869437CC269989DB4FCCAE9F92C5DC75_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract_1E708AFEB2FB54B1B3270AB8F40A6FEC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_1E708AFEB2FB54B1B3270AB8F40A6FEC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1E708AFEB2FB54B1B3270AB8F40A6FEC" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract_1E708AFEB2FB54B1B3270AB8F40A6FEC" xlink:type="arc" />
    <link:label id="lab_pfe_ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock_CF067C71CB4F93784EA0AE9F92C5798B_terseLabel_en-US" xlink:label="lab_pfe_ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock_3AF7A07E8DF552AF823AFAB3AD53B176" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Tax Provision (Benefit) on Other Comprehensive Income/(Loss)</link:label>
    <link:label id="lab_pfe_ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock_CF067C71CB4F93784EA0AE9F92C5798B_label_en-US" xlink:label="lab_pfe_ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock_3AF7A07E8DF552AF823AFAB3AD53B176" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Other Comprehensive Income (Loss), Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:label id="lab_pfe_ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock_CF067C71CB4F93784EA0AE9F92C5798B_documentation_en-US" xlink:label="lab_pfe_ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock_3AF7A07E8DF552AF823AFAB3AD53B176" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule of Other Comprehensive Income (Loss), Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_pfe_ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock_3AF7A07E8DF552AF823AFAB3AD53B176" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock_3AF7A07E8DF552AF823AFAB3AD53B176" xlink:to="lab_pfe_ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock_3AF7A07E8DF552AF823AFAB3AD53B176" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_CF27A3AAD79239BF848878AA4E1C48CD_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_CF27A3AAD79239BF848878AA4E1C48CD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_CF27A3AAD79239BF848878AA4E1C48CD_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_CF27A3AAD79239BF848878AA4E1C48CD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_CF27A3AAD79239BF848878AA4E1C48CD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_CF27A3AAD79239BF848878AA4E1C48CD" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_CF27A3AAD79239BF848878AA4E1C48CD" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_48ED47ACDE4C298930AB78AA4E1C5915_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis_48ED47ACDE4C298930AB78AA4E1C5915" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_48ED47ACDE4C298930AB78AA4E1C5915_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis_48ED47ACDE4C298930AB78AA4E1C5915" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_48ED47ACDE4C298930AB78AA4E1C5915" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_48ED47ACDE4C298930AB78AA4E1C5915" xlink:to="lab_us-gaap_LongtermDebtTypeAxis_48ED47ACDE4C298930AB78AA4E1C5915" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_75F9AB8FDFC21345FC8F78AA4E1C2245_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain_75F9AB8FDFC21345FC8F78AA4E1C2245" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_75F9AB8FDFC21345FC8F78AA4E1C2245_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain_75F9AB8FDFC21345FC8F78AA4E1C2245" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_75F9AB8FDFC21345FC8F78AA4E1C2245" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_75F9AB8FDFC21345FC8F78AA4E1C2245" xlink:to="lab_us-gaap_LongtermDebtTypeDomain_75F9AB8FDFC21345FC8F78AA4E1C2245" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnsecuredDebtMember_6266BD9FDC1A16C982D478AA4E1CE17C_terseLabel_en-US" xlink:label="lab_us-gaap_UnsecuredDebtMember_6266BD9FDC1A16C982D478AA4E1CE17C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unsecured Debt [Member]</link:label>
    <link:label id="lab_us-gaap_UnsecuredDebtMember_6266BD9FDC1A16C982D478AA4E1CE17C_label_en-US" xlink:label="lab_us-gaap_UnsecuredDebtMember_6266BD9FDC1A16C982D478AA4E1CE17C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unsecured Debt [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnsecuredDebtMember" xlink:label="loc_us-gaap_UnsecuredDebtMember_6266BD9FDC1A16C982D478AA4E1CE17C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnsecuredDebtMember_6266BD9FDC1A16C982D478AA4E1CE17C" xlink:to="lab_us-gaap_UnsecuredDebtMember_6266BD9FDC1A16C982D478AA4E1CE17C" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_5EF685C7B1E308E6555278AA4E1D71FA_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis_5EF685C7B1E308E6555278AA4E1D71FA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Instrument Risk [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_5EF685C7B1E308E6555278AA4E1D71FA_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis_5EF685C7B1E308E6555278AA4E1D71FA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_5EF685C7B1E308E6555278AA4E1D71FA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_5EF685C7B1E308E6555278AA4E1D71FA" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis_5EF685C7B1E308E6555278AA4E1D71FA" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_4DA99CE97749FD2391A778AA4E1D742B_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain_4DA99CE97749FD2391A778AA4E1D742B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Contract Type [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_4DA99CE97749FD2391A778AA4E1D742B_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain_4DA99CE97749FD2391A778AA4E1D742B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_4DA99CE97749FD2391A778AA4E1D742B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_4DA99CE97749FD2391A778AA4E1D742B" xlink:to="lab_us-gaap_DerivativeContractTypeDomain_4DA99CE97749FD2391A778AA4E1D742B" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestRateContractMember_DBA1E6354F5DE5B35CBF78AA4E1D4AE0_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateContractMember_DBA1E6354F5DE5B35CBF78AA4E1D4AE0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest Rate Contract [Member]</link:label>
    <link:label id="lab_us-gaap_InterestRateContractMember_DBA1E6354F5DE5B35CBF78AA4E1D4AE0_label_en-US" xlink:label="lab_us-gaap_InterestRateContractMember_DBA1E6354F5DE5B35CBF78AA4E1D4AE0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Rate Contract [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestRateContractMember" xlink:label="loc_us-gaap_InterestRateContractMember_DBA1E6354F5DE5B35CBF78AA4E1D4AE0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateContractMember_DBA1E6354F5DE5B35CBF78AA4E1D4AE0" xlink:to="lab_us-gaap_InterestRateContractMember_DBA1E6354F5DE5B35CBF78AA4E1D4AE0" xlink:type="arc" />
    <link:label id="lab_us-gaap_CurrencySwapMember_82F87E83423B484497A378AA4E1DF576_verboseLabel_en-US" xlink:label="lab_us-gaap_CurrencySwapMember_82F87E83423B484497A378AA4E1DF576" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Foreign Currency Swap [Member]</link:label>
    <link:label id="lab_us-gaap_CurrencySwapMember_82F87E83423B484497A378AA4E1DF576_label_en-US" xlink:label="lab_us-gaap_CurrencySwapMember_82F87E83423B484497A378AA4E1DF576" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Currency Swap [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CurrencySwapMember" xlink:label="loc_us-gaap_CurrencySwapMember_82F87E83423B484497A378AA4E1DF576" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrencySwapMember_82F87E83423B484497A378AA4E1DF576" xlink:to="lab_us-gaap_CurrencySwapMember_82F87E83423B484497A378AA4E1DF576" xlink:type="arc" />
    <link:label id="lab_us-gaap_ForeignExchangeForwardMember_4644AD243DB3EB919CA178AA4E1D98D4_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignExchangeForwardMember_4644AD243DB3EB919CA178AA4E1D98D4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign Currency Forward-Exchange Contracts [Member]</link:label>
    <link:label id="lab_us-gaap_ForeignExchangeForwardMember_4644AD243DB3EB919CA178AA4E1D98D4_label_en-US" xlink:label="lab_us-gaap_ForeignExchangeForwardMember_4644AD243DB3EB919CA178AA4E1D98D4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Exchange Forward [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ForeignExchangeForwardMember" xlink:label="loc_us-gaap_ForeignExchangeForwardMember_4644AD243DB3EB919CA178AA4E1D98D4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignExchangeForwardMember_4644AD243DB3EB919CA178AA4E1D98D4" xlink:to="lab_us-gaap_ForeignExchangeForwardMember_4644AD243DB3EB919CA178AA4E1D98D4" xlink:type="arc" />
    <link:label id="lab_pfe_ForeignCurrencyShortTermBorrowingsMember_BB6F2AD2ED115650B75978AA4E1E2B9A_terseLabel_en-US" xlink:label="lab_pfe_ForeignCurrencyShortTermBorrowingsMember_BB6F2AD2ED115650B75978AA4E1E2B9A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign Currency Short Term Borrowings [Member]</link:label>
    <link:label id="lab_pfe_ForeignCurrencyShortTermBorrowingsMember_BB6F2AD2ED115650B75978AA4E1E2B9A_label_en-US" xlink:label="lab_pfe_ForeignCurrencyShortTermBorrowingsMember_BB6F2AD2ED115650B75978AA4E1E2B9A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Short Term Borrowings [Member]</link:label>
    <link:label id="lab_pfe_ForeignCurrencyShortTermBorrowingsMember_BB6F2AD2ED115650B75978AA4E1E2B9A_documentation_en-US" xlink:label="lab_pfe_ForeignCurrencyShortTermBorrowingsMember_BB6F2AD2ED115650B75978AA4E1E2B9A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Foreign currency short - term borrowings [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_ForeignCurrencyShortTermBorrowingsMember" xlink:label="loc_pfe_ForeignCurrencyShortTermBorrowingsMember_BB6F2AD2ED115650B75978AA4E1E2B9A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ForeignCurrencyShortTermBorrowingsMember_BB6F2AD2ED115650B75978AA4E1E2B9A" xlink:to="lab_pfe_ForeignCurrencyShortTermBorrowingsMember_BB6F2AD2ED115650B75978AA4E1E2B9A" xlink:type="arc" />
    <link:label id="lab_pfe_ForeignCurrencyLongTermDebtMember_499472B953FCD72A002878AA4E1E64D9_terseLabel_en-US" xlink:label="lab_pfe_ForeignCurrencyLongTermDebtMember_499472B953FCD72A002878AA4E1E64D9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign Currency Long Term Debt [Member]</link:label>
    <link:label id="lab_pfe_ForeignCurrencyLongTermDebtMember_499472B953FCD72A002878AA4E1E64D9_label_en-US" xlink:label="lab_pfe_ForeignCurrencyLongTermDebtMember_499472B953FCD72A002878AA4E1E64D9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Long Term Debt [Member]</link:label>
    <link:label id="lab_pfe_ForeignCurrencyLongTermDebtMember_499472B953FCD72A002878AA4E1E64D9_documentation_en-US" xlink:label="lab_pfe_ForeignCurrencyLongTermDebtMember_499472B953FCD72A002878AA4E1E64D9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Foreign currency long - term debt [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_ForeignCurrencyLongTermDebtMember" xlink:label="loc_pfe_ForeignCurrencyLongTermDebtMember_499472B953FCD72A002878AA4E1E64D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ForeignCurrencyLongTermDebtMember_499472B953FCD72A002878AA4E1E64D9" xlink:to="lab_pfe_ForeignCurrencyLongTermDebtMember_499472B953FCD72A002878AA4E1E64D9" xlink:type="arc" />
    <link:label id="lab_us-gaap_HedgingDesignationAxis_45000618DCD62BD2202878AA4E1E7570_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis_45000618DCD62BD2202878AA4E1E7570" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_45000618DCD62BD2202878AA4E1E7570_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis_45000618DCD62BD2202878AA4E1E7570" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="loc_us-gaap_HedgingDesignationAxis_45000618DCD62BD2202878AA4E1E7570" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationAxis_45000618DCD62BD2202878AA4E1E7570" xlink:to="lab_us-gaap_HedgingDesignationAxis_45000618DCD62BD2202878AA4E1E7570" xlink:type="arc" />
    <link:label id="lab_us-gaap_HedgingDesignationDomain_B1BE836C2F0D66D9036D78AA4E1EA68B_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain_B1BE836C2F0D66D9036D78AA4E1EA68B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_B1BE836C2F0D66D9036D78AA4E1EA68B_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain_B1BE836C2F0D66D9036D78AA4E1EA68B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_B1BE836C2F0D66D9036D78AA4E1EA68B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationDomain_B1BE836C2F0D66D9036D78AA4E1EA68B" xlink:to="lab_us-gaap_HedgingDesignationDomain_B1BE836C2F0D66D9036D78AA4E1EA68B" xlink:type="arc" />
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_87EC418DEA5503470C9078AA4E1EF79A_terseLabel_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember_87EC418DEA5503470C9078AA4E1EF79A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Designated as Hedging Instrument [Member]</link:label>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_87EC418DEA5503470C9078AA4E1EF79A_label_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember_87EC418DEA5503470C9078AA4E1EF79A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_87EC418DEA5503470C9078AA4E1EF79A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DesignatedAsHedgingInstrumentMember_87EC418DEA5503470C9078AA4E1EF79A" xlink:to="lab_us-gaap_DesignatedAsHedgingInstrumentMember_87EC418DEA5503470C9078AA4E1EF79A" xlink:type="arc" />
    <link:label id="lab_us-gaap_NondesignatedMember_FF324CEEE2823836B39178AA4E1E519B_terseLabel_en-US" xlink:label="lab_us-gaap_NondesignatedMember_FF324CEEE2823836B39178AA4E1E519B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Not Designated as Hedging Instrument [Member]</link:label>
    <link:label id="lab_us-gaap_NondesignatedMember_FF324CEEE2823836B39178AA4E1E519B_label_en-US" xlink:label="lab_us-gaap_NondesignatedMember_FF324CEEE2823836B39178AA4E1E519B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Not Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="loc_us-gaap_NondesignatedMember_FF324CEEE2823836B39178AA4E1E519B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NondesignatedMember_FF324CEEE2823836B39178AA4E1E519B" xlink:to="lab_us-gaap_NondesignatedMember_FF324CEEE2823836B39178AA4E1E519B" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_6FDD586F015E8F73B85878AA4E1E073B_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_6FDD586F015E8F73B85878AA4E1E073B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_6FDD586F015E8F73B85878AA4E1E073B_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_6FDD586F015E8F73B85878AA4E1E073B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_6FDD586F015E8F73B85878AA4E1E073B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_6FDD586F015E8F73B85878AA4E1E073B" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_6FDD586F015E8F73B85878AA4E1E073B" xlink:type="arc" />
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_255FF6B0A7AD4429902578AA4E1E7418_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain_255FF6B0A7AD4429902578AA4E1E7418" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_255FF6B0A7AD4429902578AA4E1E7418_label_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain_255FF6B0A7AD4429902578AA4E1E7418" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HedgingRelationshipDomain" xlink:label="loc_us-gaap_HedgingRelationshipDomain_255FF6B0A7AD4429902578AA4E1E7418" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingRelationshipDomain_255FF6B0A7AD4429902578AA4E1E7418" xlink:to="lab_us-gaap_HedgingRelationshipDomain_255FF6B0A7AD4429902578AA4E1E7418" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashFlowHedgingMember_F281A920718EFF75ED8778AA4E1E2383_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember_F281A920718EFF75ED8778AA4E1E2383" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash Flow Hedging [Member]</link:label>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_F281A920718EFF75ED8778AA4E1E2383_label_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember_F281A920718EFF75ED8778AA4E1E2383" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Flow Hedging [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashFlowHedgingMember" xlink:label="loc_us-gaap_CashFlowHedgingMember_F281A920718EFF75ED8778AA4E1E2383" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowHedgingMember_F281A920718EFF75ED8778AA4E1E2383" xlink:to="lab_us-gaap_CashFlowHedgingMember_F281A920718EFF75ED8778AA4E1E2383" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetInvestmentHedgingMember_B613AD93F10553CAB19B78AA4E1E3F41_terseLabel_en-US" xlink:label="lab_us-gaap_NetInvestmentHedgingMember_B613AD93F10553CAB19B78AA4E1E3F41" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Investment Hedging [Member]</link:label>
    <link:label id="lab_us-gaap_NetInvestmentHedgingMember_B613AD93F10553CAB19B78AA4E1E3F41_label_en-US" xlink:label="lab_us-gaap_NetInvestmentHedgingMember_B613AD93F10553CAB19B78AA4E1E3F41" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Investment Hedging [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetInvestmentHedgingMember" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_B613AD93F10553CAB19B78AA4E1E3F41" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetInvestmentHedgingMember_B613AD93F10553CAB19B78AA4E1E3F41" xlink:to="lab_us-gaap_NetInvestmentHedgingMember_B613AD93F10553CAB19B78AA4E1E3F41" xlink:type="arc" />
    <link:label id="lab_pfe_NetInvestmentHedgingNonderivativeInstrumentsMember_147B9FA1FEC67868DF0078AA4E1FCC8B_terseLabel_en-US" xlink:label="lab_pfe_NetInvestmentHedgingNonderivativeInstrumentsMember_147B9FA1FEC67868DF0078AA4E1FCC8B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Investment Hedging, Nonderivative Instruments [Member]</link:label>
    <link:label id="lab_pfe_NetInvestmentHedgingNonderivativeInstrumentsMember_147B9FA1FEC67868DF0078AA4E1FCC8B_label_en-US" xlink:label="lab_pfe_NetInvestmentHedgingNonderivativeInstrumentsMember_147B9FA1FEC67868DF0078AA4E1FCC8B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Investment Hedging, Nonderivative Instruments [Member]</link:label>
    <link:label id="lab_pfe_NetInvestmentHedgingNonderivativeInstrumentsMember_147B9FA1FEC67868DF0078AA4E1FCC8B_documentation_en-US" xlink:label="lab_pfe_NetInvestmentHedgingNonderivativeInstrumentsMember_147B9FA1FEC67868DF0078AA4E1FCC8B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net Investment Hedging, Nonderivative Instruments [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_NetInvestmentHedgingNonderivativeInstrumentsMember" xlink:label="loc_pfe_NetInvestmentHedgingNonderivativeInstrumentsMember_147B9FA1FEC67868DF0078AA4E1FCC8B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_NetInvestmentHedgingNonderivativeInstrumentsMember_147B9FA1FEC67868DF0078AA4E1FCC8B" xlink:to="lab_pfe_NetInvestmentHedgingNonderivativeInstrumentsMember_147B9FA1FEC67868DF0078AA4E1FCC8B" xlink:type="arc" />
    <link:label id="lab_pfe_OtherDerivativeInstrumentsMember_18FE7887BD8CF7C341E378AA4E1F933B_terseLabel_en-US" xlink:label="lab_pfe_OtherDerivativeInstrumentsMember_18FE7887BD8CF7C341E378AA4E1F933B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Derivative Instruments [Member]</link:label>
    <link:label id="lab_pfe_OtherDerivativeInstrumentsMember_18FE7887BD8CF7C341E378AA4E1F933B_label_en-US" xlink:label="lab_pfe_OtherDerivativeInstrumentsMember_18FE7887BD8CF7C341E378AA4E1F933B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Derivative Instruments [Member]</link:label>
    <link:label id="lab_pfe_OtherDerivativeInstrumentsMember_18FE7887BD8CF7C341E378AA4E1F933B_documentation_en-US" xlink:label="lab_pfe_OtherDerivativeInstrumentsMember_18FE7887BD8CF7C341E378AA4E1F933B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Derivative Instruments [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_OtherDerivativeInstrumentsMember" xlink:label="loc_pfe_OtherDerivativeInstrumentsMember_18FE7887BD8CF7C341E378AA4E1F933B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherDerivativeInstrumentsMember_18FE7887BD8CF7C341E378AA4E1F933B" xlink:to="lab_pfe_OtherDerivativeInstrumentsMember_18FE7887BD8CF7C341E378AA4E1F933B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_9C71DF60AC5223DB5CC178AA4E1F0ABF_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_9C71DF60AC5223DB5CC178AA4E1F0ABF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Axis]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_9C71DF60AC5223DB5CC178AA4E1F0ABF_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_9C71DF60AC5223DB5CC178AA4E1F0ABF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_9C71DF60AC5223DB5CC178AA4E1F0ABF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_9C71DF60AC5223DB5CC178AA4E1F0ABF" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_9C71DF60AC5223DB5CC178AA4E1F0ABF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_A44E817CE9C065926F2C78AA4E1F6FFB_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_A44E817CE9C065926F2C78AA4E1F6FFB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Domain]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_A44E817CE9C065926F2C78AA4E1F6FFB_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_A44E817CE9C065926F2C78AA4E1F6FFB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_A44E817CE9C065926F2C78AA4E1F6FFB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_A44E817CE9C065926F2C78AA4E1F6FFB" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_A44E817CE9C065926F2C78AA4E1F6FFB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_696E486E8C8B4961607D78AA4E1F275F_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_696E486E8C8B4961607D78AA4E1F275F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Member]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_696E486E8C8B4961607D78AA4E1F275F_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_696E486E8C8B4961607D78AA4E1F275F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_696E486E8C8B4961607D78AA4E1F275F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_696E486E8C8B4961607D78AA4E1F275F" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_696E486E8C8B4961607D78AA4E1F275F" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLocationAxis_D25A26AF52D62E47EEFA78AA4E203AF9_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLocationAxis_D25A26AF52D62E47EEFA78AA4E203AF9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income Location [Axis]</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLocationAxis_D25A26AF52D62E47EEFA78AA4E203AF9_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLocationAxis_D25A26AF52D62E47EEFA78AA4E203AF9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLocationAxis" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLocationAxis_D25A26AF52D62E47EEFA78AA4E203AF9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLocationAxis_D25A26AF52D62E47EEFA78AA4E203AF9" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLocationAxis_D25A26AF52D62E47EEFA78AA4E203AF9" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLocationDomain_9F753970A4E05FA5ED0B78AA4E207D75_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLocationDomain_9F753970A4E05FA5ED0B78AA4E207D75" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income Location [Domain]</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLocationDomain_9F753970A4E05FA5ED0B78AA4E207D75_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLocationDomain_9F753970A4E05FA5ED0B78AA4E207D75" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLocationDomain" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLocationDomain_9F753970A4E05FA5ED0B78AA4E207D75" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLocationDomain_9F753970A4E05FA5ED0B78AA4E207D75" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLocationDomain_9F753970A4E05FA5ED0B78AA4E207D75" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeMember_E374EA4569F6FC572E8D78AA4E20E5D6_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeMember_E374EA4569F6FC572E8D78AA4E20E5D6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss) [Member]</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeMember_E374EA4569F6FC572E8D78AA4E20E5D6_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeMember_E374EA4569F6FC572E8D78AA4E20E5D6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss) [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_OtherComprehensiveIncomeMember_E374EA4569F6FC572E8D78AA4E20E5D6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeMember_E374EA4569F6FC572E8D78AA4E20E5D6" xlink:to="lab_us-gaap_OtherComprehensiveIncomeMember_E374EA4569F6FC572E8D78AA4E20E5D6" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossLineItems_20882AED6FCB469992E978AA4E209725_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossLineItems_20882AED6FCB469992E978AA4E209725" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossLineItems_20882AED6FCB469992E978AA4E209725_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossLineItems_20882AED6FCB469992E978AA4E209725" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_20882AED6FCB469992E978AA4E209725" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_20882AED6FCB469992E978AA4E209725" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossLineItems_20882AED6FCB469992E978AA4E209725" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeAssetNotionalAmount_A9DB330FD322608D665778AA4E20BD2C_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetNotionalAmount_A9DB330FD322608D665778AA4E20BD2C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative asset, notional amount</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetNotionalAmount_A9DB330FD322608D665778AA4E20BD2C_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetNotionalAmount_A9DB330FD322608D665778AA4E20BD2C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Asset, Notional Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeAssetNotionalAmount" xlink:label="loc_us-gaap_DerivativeAssetNotionalAmount_A9DB330FD322608D665778AA4E20BD2C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetNotionalAmount_A9DB330FD322608D665778AA4E20BD2C" xlink:to="lab_us-gaap_DerivativeAssetNotionalAmount_A9DB330FD322608D665778AA4E20BD2C" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebt_31FC9AA89B9F1381E10A78AA4E204CB8_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt_31FC9AA89B9F1381E10A78AA4E204CB8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Long-term debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_31FC9AA89B9F1381E10A78AA4E204CB8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt_31FC9AA89B9F1381E10A78AA4E204CB8" xlink:to="lab_us-gaap_LongTermDebt_31FC9AA89B9F1381E10A78AA4E204CB8" xlink:type="arc" />
    <link:label id="lab_invest_DerivativeNotionalAmount_E07148EA7884960A7D4178AA4E219F5A_terseLabel_en-US" xlink:label="lab_invest_DerivativeNotionalAmount_E07148EA7884960A7D4178AA4E219F5A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notional amount</link:label>
    <link:label id="lab_invest_DerivativeNotionalAmount_E07148EA7884960A7D4178AA4E219F5A_label_en-US" xlink:label="lab_invest_DerivativeNotionalAmount_E07148EA7884960A7D4178AA4E219F5A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_DerivativeNotionalAmount" xlink:label="loc_invest_DerivativeNotionalAmount_E07148EA7884960A7D4178AA4E219F5A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_invest_DerivativeNotionalAmount_E07148EA7884960A7D4178AA4E219F5A" xlink:to="lab_invest_DerivativeNotionalAmount_E07148EA7884960A7D4178AA4E219F5A" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrealizedLossOnForeignCurrencyDerivativesBeforeTax_A15B0D932880BD01634878AA4E211F6B_terseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedLossOnForeignCurrencyDerivativesBeforeTax_A15B0D932880BD01634878AA4E211F6B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-tax loss on foreign currency forward exchange contracts</link:label>
    <link:label id="lab_us-gaap_UnrealizedLossOnForeignCurrencyDerivativesBeforeTax_A15B0D932880BD01634878AA4E211F6B_label_en-US" xlink:label="lab_us-gaap_UnrealizedLossOnForeignCurrencyDerivativesBeforeTax_A15B0D932880BD01634878AA4E211F6B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrealized Loss on Foreign Currency Derivatives, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrealizedLossOnForeignCurrencyDerivativesBeforeTax" xlink:label="loc_us-gaap_UnrealizedLossOnForeignCurrencyDerivativesBeforeTax_A15B0D932880BD01634878AA4E211F6B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedLossOnForeignCurrencyDerivativesBeforeTax_A15B0D932880BD01634878AA4E211F6B" xlink:to="lab_us-gaap_UnrealizedLossOnForeignCurrencyDerivativesBeforeTax_A15B0D932880BD01634878AA4E211F6B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months_D44E3E36195FDE0E15DC78AA4E21307B_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months_D44E3E36195FDE0E15DC78AA4E21307B" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Pre-tax loss to be reclassified</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months_D44E3E36195FDE0E15DC78AA4E21307B_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months_D44E3E36195FDE0E15DC78AA4E21307B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months" xlink:label="loc_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months_D44E3E36195FDE0E15DC78AA4E21307B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months_D44E3E36195FDE0E15DC78AA4E21307B" xlink:to="lab_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months_D44E3E36195FDE0E15DC78AA4E21307B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ForeignCurrencyCashFlowHedgeGainLossReclassifiedToEarningsNet_A9DFDC02E420F85C5EDC78AA4E21C144_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyCashFlowHedgeGainLossReclassifiedToEarningsNet_A9DFDC02E420F85C5EDC78AA4E21C144" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain (loss) recognized as an offset</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyCashFlowHedgeGainLossReclassifiedToEarningsNet_A9DFDC02E420F85C5EDC78AA4E21C144_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyCashFlowHedgeGainLossReclassifiedToEarningsNet_A9DFDC02E420F85C5EDC78AA4E21C144" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Cash Flow Hedge Gain (Loss) Reclassified to Earnings, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ForeignCurrencyCashFlowHedgeGainLossReclassifiedToEarningsNet" xlink:label="loc_us-gaap_ForeignCurrencyCashFlowHedgeGainLossReclassifiedToEarningsNet_A9DFDC02E420F85C5EDC78AA4E21C144" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyCashFlowHedgeGainLossReclassifiedToEarningsNet_A9DFDC02E420F85C5EDC78AA4E21C144" xlink:to="lab_us-gaap_ForeignCurrencyCashFlowHedgeGainLossReclassifiedToEarningsNet_A9DFDC02E420F85C5EDC78AA4E21C144" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeGainLossOnDerivativeNet_3B083D80AD6CAE23B85D78AA4E21FBAF_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet_3B083D80AD6CAE23B85D78AA4E21FBAF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount of Gains/(Losses) Recognized in OID</link:label>
    <link:label id="lab_us-gaap_DerivativeGainLossOnDerivativeNet_3B083D80AD6CAE23B85D78AA4E21FBAF_label_en-US" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet_3B083D80AD6CAE23B85D78AA4E21FBAF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative, Gain (Loss) on Derivative, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_3B083D80AD6CAE23B85D78AA4E21FBAF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeGainLossOnDerivativeNet_3B083D80AD6CAE23B85D78AA4E21FBAF" xlink:to="lab_us-gaap_DerivativeGainLossOnDerivativeNet_3B083D80AD6CAE23B85D78AA4E21FBAF" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet_14F201A640AEF7BB85DB78AA4E2111C9_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet_14F201A640AEF7BB85DB78AA4E2111C9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount of Gains/(Losses) Recognized in OCI (Effective Portion)</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet_14F201A640AEF7BB85DB78AA4E2111C9_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet_14F201A640AEF7BB85DB78AA4E2111C9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments, Gain (Loss) Recognized in Other Comprehensive Income (Loss), Effective Portion, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet_14F201A640AEF7BB85DB78AA4E2111C9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet_14F201A640AEF7BB85DB78AA4E2111C9" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet_14F201A640AEF7BB85DB78AA4E2111C9" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_5ACCD336FC896737348278AA4E21C2BB_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_5ACCD336FC896737348278AA4E21C2BB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount of Gains/(Losses) Reclassified from OCI into OID and COS (Effective Portion)</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_5ACCD336FC896737348278AA4E21C2BB_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_5ACCD336FC896737348278AA4E21C2BB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_5ACCD336FC896737348278AA4E21C2BB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_5ACCD336FC896737348278AA4E21C2BB" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_5ACCD336FC896737348278AA4E21C2BB" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainLossOnCashFlowHedgeIneffectivenessNet_FF4E452EE8E099C6002C78AA4E218395_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnCashFlowHedgeIneffectivenessNet_FF4E452EE8E099C6002C78AA4E218395" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain (loss) on cash flow hedge ineffectiveness</link:label>
    <link:label id="lab_us-gaap_GainLossOnCashFlowHedgeIneffectivenessNet_FF4E452EE8E099C6002C78AA4E218395_label_en-US" xlink:label="lab_us-gaap_GainLossOnCashFlowHedgeIneffectivenessNet_FF4E452EE8E099C6002C78AA4E218395" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Cash Flow Hedge Ineffectiveness, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossOnCashFlowHedgeIneffectivenessNet" xlink:label="loc_us-gaap_GainLossOnCashFlowHedgeIneffectivenessNet_FF4E452EE8E099C6002C78AA4E218395" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnCashFlowHedgeIneffectivenessNet_FF4E452EE8E099C6002C78AA4E218395" xlink:to="lab_us-gaap_GainLossOnCashFlowHedgeIneffectivenessNet_FF4E452EE8E099C6002C78AA4E218395" xlink:type="arc" />
    <link:label id="lab_us-gaap_VariableRateAxis_63203E0DF31EEE0A25BC9C89048BBA75_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis_63203E0DF31EEE0A25BC9C89048BBA75" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_63203E0DF31EEE0A25BC9C89048BBA75_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis_63203E0DF31EEE0A25BC9C89048BBA75" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaap_VariableRateAxis_63203E0DF31EEE0A25BC9C89048BBA75" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis_63203E0DF31EEE0A25BC9C89048BBA75" xlink:to="lab_us-gaap_VariableRateAxis_63203E0DF31EEE0A25BC9C89048BBA75" xlink:type="arc" />
    <link:label id="lab_us-gaap_VariableRateDomain_1927AB3144C1477F92119C89048B0235_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain_1927AB3144C1477F92119C89048B0235" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_1927AB3144C1477F92119C89048B0235_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain_1927AB3144C1477F92119C89048B0235" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_1927AB3144C1477F92119C89048B0235" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain_1927AB3144C1477F92119C89048B0235" xlink:to="lab_us-gaap_VariableRateDomain_1927AB3144C1477F92119C89048B0235" xlink:type="arc" />
    <link:label id="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_4377669E37C05573A56C9C89048BDDC5_terseLabel_en-US" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_4377669E37C05573A56C9C89048BDDC5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">London Interbank Offered Rate (LIBOR) [Member]</link:label>
    <link:label id="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_4377669E37C05573A56C9C89048BDDC5_label_en-US" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_4377669E37C05573A56C9C89048BDDC5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">London Interbank Offered Rate (LIBOR) [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_4377669E37C05573A56C9C89048BDDC5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_4377669E37C05573A56C9C89048BDDC5" xlink:to="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_4377669E37C05573A56C9C89048BDDC5" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_63A5825036C27A4B5C799C89048C9158_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis_63A5825036C27A4B5C799C89048C9158" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_63A5825036C27A4B5C799C89048C9158_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis_63A5825036C27A4B5C799C89048C9158" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupClassificationAxis" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_63A5825036C27A4B5C799C89048C9158" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_63A5825036C27A4B5C799C89048C9158" xlink:to="lab_us-gaap_DisposalGroupClassificationAxis_63A5825036C27A4B5C799C89048C9158" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_0124E2B1DB01A121B1D69C89048C9EBC_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain_0124E2B1DB01A121B1D69C89048C9EBC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_0124E2B1DB01A121B1D69C89048C9EBC_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain_0124E2B1DB01A121B1D69C89048C9EBC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_0124E2B1DB01A121B1D69C89048C9EBC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_0124E2B1DB01A121B1D69C89048C9EBC" xlink:to="lab_us-gaap_DisposalGroupClassificationDomain_0124E2B1DB01A121B1D69C89048C9EBC" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_33082C7AE080085A39679C89048CE7B0_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_33082C7AE080085A39679C89048CE7B0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposed of by Sale [Member]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_33082C7AE080085A39679C89048CE7B0_label_en-US" xlink:label="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_33082C7AE080085A39679C89048CE7B0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_33082C7AE080085A39679C89048CE7B0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_33082C7AE080085A39679C89048CE7B0" xlink:to="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_33082C7AE080085A39679C89048CE7B0" xlink:type="arc" />
    <link:label id="lab_us-gaap_CounterpartyNameAxis_C8C480856DC659AEA4B49C89048C77F3_terseLabel_en-US" xlink:label="lab_us-gaap_CounterpartyNameAxis_C8C480856DC659AEA4B49C89048C77F3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_us-gaap_CounterpartyNameAxis_C8C480856DC659AEA4B49C89048C77F3_label_en-US" xlink:label="lab_us-gaap_CounterpartyNameAxis_C8C480856DC659AEA4B49C89048C77F3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="loc_us-gaap_CounterpartyNameAxis_C8C480856DC659AEA4B49C89048C77F3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CounterpartyNameAxis_C8C480856DC659AEA4B49C89048C77F3" xlink:to="lab_us-gaap_CounterpartyNameAxis_C8C480856DC659AEA4B49C89048C77F3" xlink:type="arc" />
    <link:label id="lab_us-gaap_RepurchaseAgreementCounterpartyNameDomain_81D1DABD1DF6F5798BCE9C89048CDCC8_terseLabel_en-US" xlink:label="lab_us-gaap_RepurchaseAgreementCounterpartyNameDomain_81D1DABD1DF6F5798BCE9C89048CDCC8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_us-gaap_RepurchaseAgreementCounterpartyNameDomain_81D1DABD1DF6F5798BCE9C89048CDCC8_label_en-US" xlink:label="lab_us-gaap_RepurchaseAgreementCounterpartyNameDomain_81D1DABD1DF6F5798BCE9C89048CDCC8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_81D1DABD1DF6F5798BCE9C89048CDCC8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_81D1DABD1DF6F5798BCE9C89048CDCC8" xlink:to="lab_us-gaap_RepurchaseAgreementCounterpartyNameDomain_81D1DABD1DF6F5798BCE9C89048CDCC8" xlink:type="arc" />
    <link:label id="lab_pfe_ICUMedicalMember_83C66512139F3A5207539C89048C2457_terseLabel_en-US" xlink:label="lab_pfe_ICUMedicalMember_83C66512139F3A5207539C89048C2457" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ICU Medical [Member]</link:label>
    <link:label id="lab_pfe_ICUMedicalMember_83C66512139F3A5207539C89048C2457_label_en-US" xlink:label="lab_pfe_ICUMedicalMember_83C66512139F3A5207539C89048C2457" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ICU Medical [Member]</link:label>
    <link:label id="lab_pfe_ICUMedicalMember_83C66512139F3A5207539C89048C2457_documentation_en-US" xlink:label="lab_pfe_ICUMedicalMember_83C66512139F3A5207539C89048C2457" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">ICU Medical [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_ICUMedicalMember" xlink:label="loc_pfe_ICUMedicalMember_83C66512139F3A5207539C89048C2457" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ICUMedicalMember_83C66512139F3A5207539C89048C2457" xlink:to="lab_pfe_ICUMedicalMember_83C66512139F3A5207539C89048C2457" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_4543AF01DA18FC5C60599C89048DA29A_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_4543AF01DA18FC5C60599C89048DA29A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consideration transferred</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_4543AF01DA18FC5C60599C89048DA29A_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_4543AF01DA18FC5C60599C89048DA29A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Consideration</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_4543AF01DA18FC5C60599C89048DA29A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_4543AF01DA18FC5C60599C89048DA29A" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_4543AF01DA18FC5C60599C89048DA29A" xlink:type="arc" />
    <link:label id="lab_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationTransferredEquityInterestsShares_58DF15E051EE10570EC59C89048D52A8_terseLabel_en-US" xlink:label="lab_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationTransferredEquityInterestsShares_58DF15E051EE10570EC59C89048D52A8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares received in disposition</link:label>
    <link:label id="lab_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationTransferredEquityInterestsShares_58DF15E051EE10570EC59C89048D52A8_label_en-US" xlink:label="lab_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationTransferredEquityInterestsShares_58DF15E051EE10570EC59C89048D52A8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Consideration Transferred, Equity Interests, Shares</link:label>
    <link:label id="lab_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationTransferredEquityInterestsShares_58DF15E051EE10570EC59C89048D52A8_documentation_en-US" xlink:label="lab_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationTransferredEquityInterestsShares_58DF15E051EE10570EC59C89048D52A8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Consideration Transferred, Equity Interests, Shares</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationTransferredEquityInterestsShares" xlink:label="loc_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationTransferredEquityInterestsShares_58DF15E051EE10570EC59C89048D52A8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationTransferredEquityInterestsShares_58DF15E051EE10570EC59C89048D52A8" xlink:to="lab_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationTransferredEquityInterestsShares_58DF15E051EE10570EC59C89048D52A8" xlink:type="arc" />
    <link:label id="lab_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationTransferredEquityInterests_5F4463E417C690CD78609C89048D7A74_terseLabel_en-US" xlink:label="lab_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationTransferredEquityInterests_5F4463E417C690CD78609C89048D7A74" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Value of shares received from disposition</link:label>
    <link:label id="lab_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationTransferredEquityInterests_5F4463E417C690CD78609C89048D7A74_label_en-US" xlink:label="lab_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationTransferredEquityInterests_5F4463E417C690CD78609C89048D7A74" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Consideration Transferred, Equity Interests</link:label>
    <link:label id="lab_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationTransferredEquityInterests_5F4463E417C690CD78609C89048D7A74_documentation_en-US" xlink:label="lab_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationTransferredEquityInterests_5F4463E417C690CD78609C89048D7A74" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Consideration Transferred, Equity Interests</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationTransferredEquityInterests" xlink:label="loc_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationTransferredEquityInterests_5F4463E417C690CD78609C89048D7A74" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationTransferredEquityInterests_5F4463E417C690CD78609C89048D7A74" xlink:to="lab_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationTransferredEquityInterests_5F4463E417C690CD78609C89048D7A74" xlink:type="arc" />
    <link:label id="lab_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivable_D5DB28561CBA5B20EB979C89048D72D1_terseLabel_en-US" xlink:label="lab_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivable_D5DB28561CBA5B20EB979C89048D72D1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Promissory note</link:label>
    <link:label id="lab_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivable_D5DB28561CBA5B20EB979C89048D72D1_label_en-US" xlink:label="lab_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivable_D5DB28561CBA5B20EB979C89048D72D1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Consideration, Note Receivable</link:label>
    <link:label id="lab_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivable_D5DB28561CBA5B20EB979C89048D72D1_documentation_en-US" xlink:label="lab_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivable_D5DB28561CBA5B20EB979C89048D72D1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Consideration, Note Receivable</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivable" xlink:label="loc_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivable_D5DB28561CBA5B20EB979C89048D72D1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivable_D5DB28561CBA5B20EB979C89048D72D1" xlink:to="lab_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivable_D5DB28561CBA5B20EB979C89048D72D1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfBusinesses_547579B034460F5B020B9C89048DC29E_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinesses_547579B034460F5B020B9C89048DC29E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash received from disposition</link:label>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfBusinesses_547579B034460F5B020B9C89048DC29E_label_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinesses_547579B034460F5B020B9C89048DC29E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Divestiture of Businesses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_547579B034460F5B020B9C89048DC29E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_547579B034460F5B020B9C89048DC29E" xlink:to="lab_us-gaap_ProceedsFromDivestitureOfBusinesses_547579B034460F5B020B9C89048DC29E" xlink:type="arc" />
    <link:label id="lab_pfe_DisposalGroupIncludingDiscontinuedOperationContingentConsideration_7BBADF9184B0B2EAA8E59C89048E799C_terseLabel_en-US" xlink:label="lab_pfe_DisposalGroupIncludingDiscontinuedOperationContingentConsideration_7BBADF9184B0B2EAA8E59C89048E799C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_pfe_DisposalGroupIncludingDiscontinuedOperationContingentConsideration_7BBADF9184B0B2EAA8E59C89048E799C_label_en-US" xlink:label="lab_pfe_DisposalGroupIncludingDiscontinuedOperationContingentConsideration_7BBADF9184B0B2EAA8E59C89048E799C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Contingent Consideration</link:label>
    <link:label id="lab_pfe_DisposalGroupIncludingDiscontinuedOperationContingentConsideration_7BBADF9184B0B2EAA8E59C89048E799C_documentation_en-US" xlink:label="lab_pfe_DisposalGroupIncludingDiscontinuedOperationContingentConsideration_7BBADF9184B0B2EAA8E59C89048E799C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Contingent Consideration</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_DisposalGroupIncludingDiscontinuedOperationContingentConsideration" xlink:label="loc_pfe_DisposalGroupIncludingDiscontinuedOperationContingentConsideration_7BBADF9184B0B2EAA8E59C89048E799C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DisposalGroupIncludingDiscontinuedOperationContingentConsideration_7BBADF9184B0B2EAA8E59C89048E799C" xlink:to="lab_pfe_DisposalGroupIncludingDiscontinuedOperationContingentConsideration_7BBADF9184B0B2EAA8E59C89048E799C" xlink:type="arc" />
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_A8F969C39F5B237D2E189C89048E0927_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_A8F969C39F5B237D2E189C89048E0927" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ownership percentage</link:label>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_A8F969C39F5B237D2E189C89048E0927_label_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_A8F969C39F5B237D2E189C89048E0927" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest, Ownership Percentage by Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_A8F969C39F5B237D2E189C89048E0927" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_A8F969C39F5B237D2E189C89048E0927" xlink:to="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_A8F969C39F5B237D2E189C89048E0927" xlink:type="arc" />
    <link:label id="lab_pfe_DisposalGroupIncludingDiscontinuedOperationShareTransferRestrictionTermMinimum_4CC56E67984B173790829C89048E341A_terseLabel_en-US" xlink:label="lab_pfe_DisposalGroupIncludingDiscontinuedOperationShareTransferRestrictionTermMinimum_4CC56E67984B173790829C89048E341A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum share transfer restriction term</link:label>
    <link:label id="lab_pfe_DisposalGroupIncludingDiscontinuedOperationShareTransferRestrictionTermMinimum_4CC56E67984B173790829C89048E341A_label_en-US" xlink:label="lab_pfe_DisposalGroupIncludingDiscontinuedOperationShareTransferRestrictionTermMinimum_4CC56E67984B173790829C89048E341A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Share Transfer Restriction Term, Minimum</link:label>
    <link:label id="lab_pfe_DisposalGroupIncludingDiscontinuedOperationShareTransferRestrictionTermMinimum_4CC56E67984B173790829C89048E341A_documentation_en-US" xlink:label="lab_pfe_DisposalGroupIncludingDiscontinuedOperationShareTransferRestrictionTermMinimum_4CC56E67984B173790829C89048E341A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Share Transfer Restriction Term, Minimum</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_DisposalGroupIncludingDiscontinuedOperationShareTransferRestrictionTermMinimum" xlink:label="loc_pfe_DisposalGroupIncludingDiscontinuedOperationShareTransferRestrictionTermMinimum_4CC56E67984B173790829C89048E341A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DisposalGroupIncludingDiscontinuedOperationShareTransferRestrictionTermMinimum_4CC56E67984B173790829C89048E341A" xlink:to="lab_pfe_DisposalGroupIncludingDiscontinuedOperationShareTransferRestrictionTermMinimum_4CC56E67984B173790829C89048E341A" xlink:type="arc" />
    <link:label id="lab_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivableTerm_F8B51D72DDE2111E041F9C89048F30A7_terseLabel_en-US" xlink:label="lab_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivableTerm_F8B51D72DDE2111E041F9C89048F30A7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term of promissory note</link:label>
    <link:label id="lab_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivableTerm_F8B51D72DDE2111E041F9C89048F30A7_label_en-US" xlink:label="lab_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivableTerm_F8B51D72DDE2111E041F9C89048F30A7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Consideration, Note Receivable, Term</link:label>
    <link:label id="lab_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivableTerm_F8B51D72DDE2111E041F9C89048F30A7_documentation_en-US" xlink:label="lab_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivableTerm_F8B51D72DDE2111E041F9C89048F30A7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Consideration, Note Receivable, Term</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivableTerm" xlink:label="loc_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivableTerm_F8B51D72DDE2111E041F9C89048F30A7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivableTerm_F8B51D72DDE2111E041F9C89048F30A7" xlink:to="lab_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivableTerm_F8B51D72DDE2111E041F9C89048F30A7" xlink:type="arc" />
    <link:label id="lab_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivableInterestRate_BE00E016104D79B7F63B9C89048FEA99_terseLabel_en-US" xlink:label="lab_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivableInterestRate_BE00E016104D79B7F63B9C89048FEA99" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest rate of promissory note in year one</link:label>
    <link:label id="lab_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivableInterestRate_BE00E016104D79B7F63B9C89048FEA99_label_en-US" xlink:label="lab_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivableInterestRate_BE00E016104D79B7F63B9C89048FEA99" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Consideration, Note Receivable, Interest Rate</link:label>
    <link:label id="lab_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivableInterestRate_BE00E016104D79B7F63B9C89048FEA99_documentation_en-US" xlink:label="lab_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivableInterestRate_BE00E016104D79B7F63B9C89048FEA99" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Consideration, Note Receivable, Interest Rate</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivableInterestRate" xlink:label="loc_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivableInterestRate_BE00E016104D79B7F63B9C89048FEA99" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivableInterestRate_BE00E016104D79B7F63B9C89048FEA99" xlink:to="lab_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivableInterestRate_BE00E016104D79B7F63B9C89048FEA99" xlink:type="arc" />
    <link:label id="lab_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivableInterestRateYearTwo_FC67E5E2885156B124969C89048F3EC9_terseLabel_en-US" xlink:label="lab_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivableInterestRateYearTwo_FC67E5E2885156B124969C89048F3EC9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest rate of promissory note in year two</link:label>
    <link:label id="lab_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivableInterestRateYearTwo_FC67E5E2885156B124969C89048F3EC9_label_en-US" xlink:label="lab_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivableInterestRateYearTwo_FC67E5E2885156B124969C89048F3EC9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Consideration, Note Receivable, Interest Rate, Year Two</link:label>
    <link:label id="lab_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivableInterestRateYearTwo_FC67E5E2885156B124969C89048F3EC9_documentation_en-US" xlink:label="lab_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivableInterestRateYearTwo_FC67E5E2885156B124969C89048F3EC9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Consideration, Note Receivable, Interest Rate, Year Two</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivableInterestRateYearTwo" xlink:label="loc_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivableInterestRateYearTwo_FC67E5E2885156B124969C89048F3EC9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivableInterestRateYearTwo_FC67E5E2885156B124969C89048F3EC9" xlink:to="lab_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivableInterestRateYearTwo_FC67E5E2885156B124969C89048F3EC9" xlink:type="arc" />
    <link:label id="lab_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivableInterestRateYearThree_56BD7F650FAE5DAF269F9C89048F2495_terseLabel_en-US" xlink:label="lab_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivableInterestRateYearThree_56BD7F650FAE5DAF269F9C89048F2495" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest rate of promissory note in year three</link:label>
    <link:label id="lab_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivableInterestRateYearThree_56BD7F650FAE5DAF269F9C89048F2495_label_en-US" xlink:label="lab_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivableInterestRateYearThree_56BD7F650FAE5DAF269F9C89048F2495" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Consideration, Note Receivable, Interest Rate, Year Three</link:label>
    <link:label id="lab_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivableInterestRateYearThree_56BD7F650FAE5DAF269F9C89048F2495_documentation_en-US" xlink:label="lab_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivableInterestRateYearThree_56BD7F650FAE5DAF269F9C89048F2495" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Consideration, Note Receivable, Interest Rate, Year Three</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivableInterestRateYearThree" xlink:label="loc_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivableInterestRateYearThree_56BD7F650FAE5DAF269F9C89048F2495" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivableInterestRateYearThree_56BD7F650FAE5DAF269F9C89048F2495" xlink:to="lab_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivableInterestRateYearThree_56BD7F650FAE5DAF269F9C89048F2495" xlink:type="arc" />
    <link:label id="lab_pfe_AdministrativeServicePeriod_DEFE91415D66C1C85B869C89048FF8A3_terseLabel_en-US" xlink:label="lab_pfe_AdministrativeServicePeriod_DEFE91415D66C1C85B869C89048FF8A3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Administrative service period</link:label>
    <link:label id="lab_pfe_AdministrativeServicePeriod_DEFE91415D66C1C85B869C89048FF8A3_label_en-US" xlink:label="lab_pfe_AdministrativeServicePeriod_DEFE91415D66C1C85B869C89048FF8A3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Administrative Service Period</link:label>
    <link:label id="lab_pfe_AdministrativeServicePeriod_DEFE91415D66C1C85B869C89048FF8A3_documentation_en-US" xlink:label="lab_pfe_AdministrativeServicePeriod_DEFE91415D66C1C85B869C89048FF8A3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Administrative Service Period</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_AdministrativeServicePeriod" xlink:label="loc_pfe_AdministrativeServicePeriod_DEFE91415D66C1C85B869C89048FF8A3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_AdministrativeServicePeriod_DEFE91415D66C1C85B869C89048FF8A3" xlink:to="lab_pfe_AdministrativeServicePeriod_DEFE91415D66C1C85B869C89048FF8A3" xlink:type="arc" />
    <link:label id="lab_pfe_MaximumManufacturingServicePeriod_09C4A207E2869BF7574E9C89049074BE_terseLabel_en-US" xlink:label="lab_pfe_MaximumManufacturingServicePeriod_09C4A207E2869BF7574E9C89049074BE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum manufacturing service period</link:label>
    <link:label id="lab_pfe_MaximumManufacturingServicePeriod_09C4A207E2869BF7574E9C89049074BE_label_en-US" xlink:label="lab_pfe_MaximumManufacturingServicePeriod_09C4A207E2869BF7574E9C89049074BE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum Manufacturing Service Period</link:label>
    <link:label id="lab_pfe_MaximumManufacturingServicePeriod_09C4A207E2869BF7574E9C89049074BE_documentation_en-US" xlink:label="lab_pfe_MaximumManufacturingServicePeriod_09C4A207E2869BF7574E9C89049074BE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Maximum manufacturing service period provided as a transition services to disposal group.</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_MaximumManufacturingServicePeriod" xlink:label="loc_pfe_MaximumManufacturingServicePeriod_09C4A207E2869BF7574E9C89049074BE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_MaximumManufacturingServicePeriod_09C4A207E2869BF7574E9C89049074BE" xlink:to="lab_pfe_MaximumManufacturingServicePeriod_09C4A207E2869BF7574E9C89049074BE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_04EA4343A0C97033104374487D3A60B8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable_04EA4343A0C97033104374487D3A60B8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_04EA4343A0C97033104374487D3A60B8_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable_04EA4343A0C97033104374487D3A60B8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfGoodwillTable" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_04EA4343A0C97033104374487D3A60B8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_04EA4343A0C97033104374487D3A60B8" xlink:to="lab_us-gaap_ScheduleOfGoodwillTable_04EA4343A0C97033104374487D3A60B8" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillLineItems_7A07D8AF3A49752DF80B74487D3B596F_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillLineItems_7A07D8AF3A49752DF80B74487D3B596F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:label id="lab_us-gaap_GoodwillLineItems_7A07D8AF3A49752DF80B74487D3B596F_label_en-US" xlink:label="lab_us-gaap_GoodwillLineItems_7A07D8AF3A49752DF80B74487D3B596F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillLineItems" xlink:label="loc_us-gaap_GoodwillLineItems_7A07D8AF3A49752DF80B74487D3B596F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillLineItems_7A07D8AF3A49752DF80B74487D3B596F" xlink:to="lab_us-gaap_GoodwillLineItems_7A07D8AF3A49752DF80B74487D3B596F" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillRollForward_BE5204FF1CB245D3299574487D3B5DF8_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward_BE5204FF1CB245D3299574487D3B5DF8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_BE5204FF1CB245D3299574487D3B5DF8_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward_BE5204FF1CB245D3299574487D3B5DF8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillRollForward" xlink:label="loc_us-gaap_GoodwillRollForward_BE5204FF1CB245D3299574487D3B5DF8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward_BE5204FF1CB245D3299574487D3B5DF8" xlink:to="lab_us-gaap_GoodwillRollForward_BE5204FF1CB245D3299574487D3B5DF8" xlink:type="arc" />
    <link:label id="lab_us-gaap_Goodwill_332FDC0453C655F3B75174487D3BD214_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill_332FDC0453C655F3B75174487D3BD214" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance, December 31, 2016</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_332FDC0453C655F3B75174487D3BD214" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill_332FDC0453C655F3B75174487D3BD214" xlink:to="lab_us-gaap_Goodwill_332FDC0453C655F3B75174487D3BD214" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_6C0FBE01AFE058A8873F74487D3B4955_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod_6C0FBE01AFE058A8873F74487D3B4955" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_6C0FBE01AFE058A8873F74487D3B4955_label_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod_6C0FBE01AFE058A8873F74487D3B4955" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Acquired During Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_6C0FBE01AFE058A8873F74487D3B4955" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAcquiredDuringPeriod_6C0FBE01AFE058A8873F74487D3B4955" xlink:to="lab_us-gaap_GoodwillAcquiredDuringPeriod_6C0FBE01AFE058A8873F74487D3B4955" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillOtherIncreaseDecrease_E072660759D500C413B174487D3BA5F0_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillOtherIncreaseDecrease_E072660759D500C413B174487D3BA5F0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_GoodwillOtherIncreaseDecrease_E072660759D500C413B174487D3BA5F0_label_en-US" xlink:label="lab_us-gaap_GoodwillOtherIncreaseDecrease_E072660759D500C413B174487D3BA5F0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Other Increase (Decrease)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillOtherIncreaseDecrease" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease_E072660759D500C413B174487D3BA5F0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillOtherIncreaseDecrease_E072660759D500C413B174487D3BA5F0" xlink:to="lab_us-gaap_GoodwillOtherIncreaseDecrease_E072660759D500C413B174487D3BA5F0" xlink:type="arc" />
    <link:label id="lab_us-gaap_Goodwill_C135527467B2A6C6E32474487D3B5419_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill_C135527467B2A6C6E32474487D3B5419" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance, October 1, 2017</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_C135527467B2A6C6E32474487D3B5419" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill_C135527467B2A6C6E32474487D3B5419" xlink:to="lab_us-gaap_Goodwill_C135527467B2A6C6E32474487D3B5419" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlanServiceCost_148CAA7E3A877C3E6F5A58E0C4A25CA4_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanServiceCost_148CAA7E3A877C3E6F5A58E0C4A25CA4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Service cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanServiceCost_148CAA7E3A877C3E6F5A58E0C4A25CA4_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanServiceCost_148CAA7E3A877C3E6F5A58E0C4A25CA4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Service Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedBenefitPlanServiceCost" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_148CAA7E3A877C3E6F5A58E0C4A25CA4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanServiceCost_148CAA7E3A877C3E6F5A58E0C4A25CA4" xlink:to="lab_us-gaap_DefinedBenefitPlanServiceCost_148CAA7E3A877C3E6F5A58E0C4A25CA4" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlanInterestCost_C63935ADD22A0933A76658E0C4A26A28_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanInterestCost_C63935ADD22A0933A76658E0C4A26A28" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanInterestCost_C63935ADD22A0933A76658E0C4A26A28_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanInterestCost_C63935ADD22A0933A76658E0C4A26A28" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Interest Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedBenefitPlanInterestCost" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_C63935ADD22A0933A76658E0C4A26A28" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanInterestCost_C63935ADD22A0933A76658E0C4A26A28" xlink:to="lab_us-gaap_DefinedBenefitPlanInterestCost_C63935ADD22A0933A76658E0C4A26A28" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_A82F4BFA8169C436411858E0C4A204BE_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_A82F4BFA8169C436411858E0C4A204BE" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Expected return on plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_A82F4BFA8169C436411858E0C4A204BE_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_A82F4BFA8169C436411858E0C4A204BE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Expected Return (Loss) on Plan Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_A82F4BFA8169C436411858E0C4A204BE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_A82F4BFA8169C436411858E0C4A204BE" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_A82F4BFA8169C436411858E0C4A204BE" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_3CEC019DC12674A85AF558E0C4A2B5F6_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_3CEC019DC12674A85AF558E0C4A2B5F6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of:</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_3CEC019DC12674A85AF558E0C4A2B5F6_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_3CEC019DC12674A85AF558E0C4A2B5F6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Net Periodic Benefit Cost (Credit) [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_3CEC019DC12674A85AF558E0C4A2B5F6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_3CEC019DC12674A85AF558E0C4A2B5F6" xlink:to="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_3CEC019DC12674A85AF558E0C4A2B5F6" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_5CEE52BAFEE1A45F164658E0C4A257B2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_5CEE52BAFEE1A45F164658E0C4A257B2" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Actuarial losses</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_5CEE52BAFEE1A45F164658E0C4A257B2_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_5CEE52BAFEE1A45F164658E0C4A257B2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Amortization of Gain (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_5CEE52BAFEE1A45F164658E0C4A257B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_5CEE52BAFEE1A45F164658E0C4A257B2" xlink:to="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_5CEE52BAFEE1A45F164658E0C4A257B2" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_EB003D082E3D8B77235658E0C4A242EF_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_EB003D082E3D8B77235658E0C4A242EF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prior service costs (credits)</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_EB003D082E3D8B77235658E0C4A242EF_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_EB003D082E3D8B77235658E0C4A242EF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Amortization of Prior Service Cost (Credit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_EB003D082E3D8B77235658E0C4A242EF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_EB003D082E3D8B77235658E0C4A242EF" xlink:to="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_EB003D082E3D8B77235658E0C4A242EF" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments_00B33F4458EA06BCFC7A58E0C4A351CC_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments_00B33F4458EA06BCFC7A58E0C4A351CC" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Curtailments</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments_00B33F4458EA06BCFC7A58E0C4A351CC_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments_00B33F4458EA06BCFC7A58E0C4A351CC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Curtailment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments_00B33F4458EA06BCFC7A58E0C4A351CC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments_00B33F4458EA06BCFC7A58E0C4A351CC" xlink:to="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments_00B33F4458EA06BCFC7A58E0C4A351CC" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_5A948B9C366415A04F5F58E0C4A3CB04_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_5A948B9C366415A04F5F58E0C4A3CB04" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Settlements</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_5A948B9C366415A04F5F58E0C4A3CB04" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_5A948B9C366415A04F5F58E0C4A3CB04" xlink:to="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_5A948B9C366415A04F5F58E0C4A3CB04" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_ACEDA0A695614709E61158E0C4A3EF28_totalLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_ACEDA0A695614709E61158E0C4A3EF28" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Defined benefit plan, net periodic benefit cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_ACEDA0A695614709E61158E0C4A3EF28_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_ACEDA0A695614709E61158E0C4A3EF28" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Net Periodic Benefit Cost (Credit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_ACEDA0A695614709E61158E0C4A3EF28" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_ACEDA0A695614709E61158E0C4A3EF28" xlink:to="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_ACEDA0A695614709E61158E0C4A3EF28" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_D98A3BC99F189331103B7446A1940881_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_D98A3BC99F189331103B7446A1940881" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_D98A3BC99F189331103B7446A1940881_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_D98A3BC99F189331103B7446A1940881" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_D98A3BC99F189331103B7446A1940881" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_D98A3BC99F189331103B7446A1940881" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_D98A3BC99F189331103B7446A1940881" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_15D38E7BD92704AE7C437446A19536D1_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_15D38E7BD92704AE7C437446A19536D1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_15D38E7BD92704AE7C437446A19536D1_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_15D38E7BD92704AE7C437446A19536D1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_15D38E7BD92704AE7C437446A19536D1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_15D38E7BD92704AE7C437446A19536D1" xlink:to="lab_us-gaap_StatementEquityComponentsAxis_15D38E7BD92704AE7C437446A19536D1" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityComponentDomain_B30B78A65E407728C5897446A195B4C5_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_B30B78A65E407728C5897446A195B4C5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_B30B78A65E407728C5897446A195B4C5_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_B30B78A65E407728C5897446A195B4C5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_B30B78A65E407728C5897446A195B4C5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain_B30B78A65E407728C5897446A195B4C5" xlink:to="lab_us-gaap_EquityComponentDomain_B30B78A65E407728C5897446A195B4C5" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_244C01AC044E0C65C6417446A1964989_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_244C01AC044E0C65C6417446A1964989" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Member]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_244C01AC044E0C65C6417446A1964989_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_244C01AC044E0C65C6417446A1964989" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_244C01AC044E0C65C6417446A1964989" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_244C01AC044E0C65C6417446A1964989" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_244C01AC044E0C65C6417446A1964989" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_68298F86A77E69BA3A157446A196F407_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember_68298F86A77E69BA3A157446A196F407" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign Currency Translation Adjustment [Member]</link:label>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_68298F86A77E69BA3A157446A196F407_label_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember_68298F86A77E69BA3A157446A196F407" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Foreign Currency Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_68298F86A77E69BA3A157446A196F407" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedTranslationAdjustmentMember_68298F86A77E69BA3A157446A196F407" xlink:to="lab_us-gaap_AccumulatedTranslationAdjustmentMember_68298F86A77E69BA3A157446A196F407" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_9A40968A55C8B973A7CD7446A19614BD_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_9A40968A55C8B973A7CD7446A19614BD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Financial Instruments [Member]</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_9A40968A55C8B973A7CD7446A19614BD_label_en-US" xlink:label="lab_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_9A40968A55C8B973A7CD7446A19614BD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Net Gain (Loss) from Cash Flow Hedges Attributable to Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" xlink:label="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_9A40968A55C8B973A7CD7446A19614BD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_9A40968A55C8B973A7CD7446A19614BD" xlink:to="lab_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_9A40968A55C8B973A7CD7446A19614BD" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_32BF5C20461D335F5D387446A196D3F1_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_32BF5C20461D335F5D387446A196D3F1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Available-For-Sale Securities [Member]</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_32BF5C20461D335F5D387446A196D3F1_label_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_32BF5C20461D335F5D387446A196D3F1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Net Investment Gain (Loss) Attributable to Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_32BF5C20461D335F5D387446A196D3F1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_32BF5C20461D335F5D387446A196D3F1" xlink:to="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_32BF5C20461D335F5D387446A196D3F1" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember_46183F99B4CE69FF3C7C7446A1966499_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember_46183F99B4CE69FF3C7C7446A1966499" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Actuarial Gains/(Losses) [Member]</link:label>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember_46183F99B4CE69FF3C7C7446A1966499_label_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember_46183F99B4CE69FF3C7C7446A1966499" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Defined Benefit Plans Adjustment, Net Gain (Loss) Attributable to Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember_46183F99B4CE69FF3C7C7446A1966499" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember_46183F99B4CE69FF3C7C7446A1966499" xlink:to="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember_46183F99B4CE69FF3C7C7446A1966499" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember_8F3AD7B28F179F726DEA7446A196DED9_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember_8F3AD7B28F179F726DEA7446A196DED9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prior Service (Costs)/Credits and Other [Member]</link:label>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember_8F3AD7B28F179F726DEA7446A196DED9_label_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember_8F3AD7B28F179F726DEA7446A196DED9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Defined Benefit Plans Adjustment, Net Prior Service Attributable to Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember_8F3AD7B28F179F726DEA7446A196DED9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember_8F3AD7B28F179F726DEA7446A196DED9" xlink:to="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember_8F3AD7B28F179F726DEA7446A196DED9" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_61F6C75527919523A7F47446A197C3CA_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_61F6C75527919523A7F47446A197C3CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_61F6C75527919523A7F47446A197C3CA_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_61F6C75527919523A7F47446A197C3CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_61F6C75527919523A7F47446A197C3CA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_61F6C75527919523A7F47446A197C3CA" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_61F6C75527919523A7F47446A197C3CA" xlink:type="arc" />
    <link:label id="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_2D5308AC1E300A59F7A77446A1979E15_terseLabel_en-US" xlink:label="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_2D5308AC1E300A59F7A77446A1979E15" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent, Net of Tax [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_2D5308AC1E300A59F7A77446A1979E15_label_en-US" xlink:label="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_2D5308AC1E300A59F7A77446A1979E15" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent, Net of Tax [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:label="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_2D5308AC1E300A59F7A77446A1979E15" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_2D5308AC1E300A59F7A77446A1979E15" xlink:to="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_2D5308AC1E300A59F7A77446A1979E15" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_8C616BCBB3D4FF09F1497446A1973693_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_8C616BCBB3D4FF09F1497446A1973693" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance, December 31, 2016</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_8C616BCBB3D4FF09F1497446A1973693_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity_8C616BCBB3D4FF09F1497446A1973693" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_8C616BCBB3D4FF09F1497446A1973693" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_8C616BCBB3D4FF09F1497446A1973693" xlink:to="lab_us-gaap_StockholdersEquity_8C616BCBB3D4FF09F1497446A1973693" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_1A4BF9F0FFC5C577DB6A7446A1977450_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_1A4BF9F0FFC5C577DB6A7446A1977450" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income/(loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_1A4BF9F0FFC5C577DB6A7446A1977450_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_1A4BF9F0FFC5C577DB6A7446A1977450" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_1A4BF9F0FFC5C577DB6A7446A1977450" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_1A4BF9F0FFC5C577DB6A7446A1977450" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_1A4BF9F0FFC5C577DB6A7446A1977450" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_BEBB901AAEC7E178B0D27446A19747EA_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_BEBB901AAEC7E178B0D27446A19747EA" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance, October 1, 2017</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_BEBB901AAEC7E178B0D27446A19747EA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_BEBB901AAEC7E178B0D27446A19747EA" xlink:to="lab_us-gaap_StockholdersEquity_BEBB901AAEC7E178B0D27446A19747EA" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToNoncontrollingInterest_D91DB8C069C4B1865E367446A1972A4C_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToNoncontrollingInterest_D91DB8C069C4B1865E367446A1972A4C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency translation adjustments attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToNoncontrollingInterest_D91DB8C069C4B1865E367446A1972A4C_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToNoncontrollingInterest_D91DB8C069C4B1865E367446A1972A4C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, before Tax, Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToNoncontrollingInterest_D91DB8C069C4B1865E367446A1972A4C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToNoncontrollingInterest_D91DB8C069C4B1865E367446A1972A4C" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToNoncontrollingInterest_D91DB8C069C4B1865E367446A1972A4C" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths_74EDC3A7DF1D9815AD147446A1979B07_negatedLabel_en-US" xlink:label="lab_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths_74EDC3A7DF1D9815AD147446A1979B07" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Cash flow hedge loss to be reclassified within twelve months</link:label>
    <link:label id="lab_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths_74EDC3A7DF1D9815AD147446A1979B07_label_en-US" xlink:label="lab_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths_74EDC3A7DF1D9815AD147446A1979B07" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Flow Hedge Gain (Loss) to be Reclassified within Twelve Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths" xlink:label="loc_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths_74EDC3A7DF1D9815AD147446A1979B07" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths_74EDC3A7DF1D9815AD147446A1979B07" xlink:to="lab_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths_74EDC3A7DF1D9815AD147446A1979B07" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock_B7DB8751A45701750B9DAE9F920E3F61_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock_F167DC7757355C9483DB431852D9E57B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of Revenue from Segments to Consolidated</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock_B7DB8751A45701750B9DAE9F920E3F61_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock_F167DC7757355C9483DB431852D9E57B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reconciliation of Revenue from Segments to Consolidated [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock" xlink:label="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock_F167DC7757355C9483DB431852D9E57B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock_F167DC7757355C9483DB431852D9E57B" xlink:to="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock_F167DC7757355C9483DB431852D9E57B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_CF0561BB21BBC276D1A8AE9F920F9D6E_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_04CEC220EF6A580B84830CED0072ADBE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of Operating Profit (Loss) from Segments to Consolidated</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_CF0561BB21BBC276D1A8AE9F920F9D6E_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_04CEC220EF6A580B84830CED0072ADBE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_04CEC220EF6A580B84830CED0072ADBE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_04CEC220EF6A580B84830CED0072ADBE" xlink:to="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_04CEC220EF6A580B84830CED0072ADBE" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_508FC1BA229DCB613890AE9F920F635D_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_A9676030138C50C4A508E00BA4C8187C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Revenues by Geographic Region</link:label>
    <link:label id="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_508FC1BA229DCB613890AE9F920F635D_label_en-US" xlink:label="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_A9676030138C50C4A508E00BA4C8187C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from External Customers by Geographic Areas [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_A9676030138C50C4A508E00BA4C8187C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_A9676030138C50C4A508E00BA4C8187C" xlink:to="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_A9676030138C50C4A508E00BA4C8187C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_E26018D779FE2CF9316DAE9F920FB419_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_DDE87AB6A4BE53E5B612C1BB7921796D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Significant Product Revenues</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_E26018D779FE2CF9316DAE9F920FB419_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_DDE87AB6A4BE53E5B612C1BB7921796D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from External Customers by Products and Services [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_DDE87AB6A4BE53E5B612C1BB7921796D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_DDE87AB6A4BE53E5B612C1BB7921796D" xlink:to="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_DDE87AB6A4BE53E5B612C1BB7921796D" xlink:type="arc" />
    <link:label id="lab_pfe_AnacorMember_FBA72242775051B38CF6C2F7BCADFBAE_terseLabel_en-US" xlink:label="lab_pfe_AnacorMember_31ED3D13BB6C530386BB6CEA31CC95CB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Anacor [Member]</link:label>
    <link:label id="lab_pfe_AnacorMember_FBA72242775051B38CF6C2F7BCADFBAE_label_en-US" xlink:label="lab_pfe_AnacorMember_31ED3D13BB6C530386BB6CEA31CC95CB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Anacor [Member]</link:label>
    <link:label id="lab_pfe_AnacorMember_FBA72242775051B38CF6C2F7BCADFBAE_documentation_en-US" xlink:label="lab_pfe_AnacorMember_31ED3D13BB6C530386BB6CEA31CC95CB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Anacor [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_AnacorMember" xlink:label="loc_pfe_AnacorMember_31ED3D13BB6C530386BB6CEA31CC95CB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_AnacorMember_31ED3D13BB6C530386BB6CEA31CC95CB" xlink:to="lab_pfe_AnacorMember_31ED3D13BB6C530386BB6CEA31CC95CB" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_928D42339236E422AE60C2F7BCADEE07_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_503CB5B33AEF5300914E6A2669BA891F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Debt assumed</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_928D42339236E422AE60C2F7BCADEE07_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_503CB5B33AEF5300914E6A2669BA891F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-term Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_503CB5B33AEF5300914E6A2669BA891F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_503CB5B33AEF5300914E6A2669BA891F" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_503CB5B33AEF5300914E6A2669BA891F" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_5C722851743B4379A1D2C2F7BCADC099_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_C3AA5110EEA45F82A408215AEB065640" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">IPR&amp;D</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_5C722851743B4379A1D2C2F7BCADC099_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_C3AA5110EEA45F82A408215AEB065640" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_C3AA5110EEA45F82A408215AEB065640" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_C3AA5110EEA45F82A408215AEB065640" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_C3AA5110EEA45F82A408215AEB065640" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_E576BBE6E575646A4892AE9F9236992B_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_4212A0810BDA57F9B7FF27C52C0BED30" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings Per Common Share Attributable to Common Shareholders</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_E576BBE6E575646A4892AE9F9236992B_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_4212A0810BDA57F9B7FF27C52C0BED30" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_4212A0810BDA57F9B7FF27C52C0BED30" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock_4212A0810BDA57F9B7FF27C52C0BED30" xlink:to="lab_us-gaap_EarningsPerShareTextBlock_4212A0810BDA57F9B7FF27C52C0BED30" xlink:type="arc" />
    <link:label id="lab_us-gaap_EuropeanUnionMember_67E5005DF02F0F96D6A29C8902F81649_terseLabel_en-US" xlink:label="lab_us-gaap_EuropeanUnionMember_67E5005DF02F0F96D6A29C8902F81649" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">EU [Member]</link:label>
    <link:label id="lab_us-gaap_EuropeanUnionMember_67E5005DF02F0F96D6A29C8902F81649_label_en-US" xlink:label="lab_us-gaap_EuropeanUnionMember_67E5005DF02F0F96D6A29C8902F81649" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">European Union [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EuropeanUnionMember" xlink:label="loc_us-gaap_EuropeanUnionMember_67E5005DF02F0F96D6A29C8902F81649" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EuropeanUnionMember_67E5005DF02F0F96D6A29C8902F81649" xlink:to="lab_us-gaap_EuropeanUnionMember_67E5005DF02F0F96D6A29C8902F81649" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProductOrServiceAxis_BCAF785B94CE881D37F99C8902F87707_terseLabel_en-US" xlink:label="lab_us-gaap_ProductOrServiceAxis_BCAF785B94CE881D37F99C8902F87707" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Products and Services [Axis]</link:label>
    <link:label id="lab_us-gaap_ProductOrServiceAxis_BCAF785B94CE881D37F99C8902F87707_label_en-US" xlink:label="lab_us-gaap_ProductOrServiceAxis_BCAF785B94CE881D37F99C8902F87707" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Products and Services [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_BCAF785B94CE881D37F99C8902F87707" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductOrServiceAxis_BCAF785B94CE881D37F99C8902F87707" xlink:to="lab_us-gaap_ProductOrServiceAxis_BCAF785B94CE881D37F99C8902F87707" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProductsAndServicesDomain_D7BFC1AC761F2CE959BB9C8902F8947A_terseLabel_en-US" xlink:label="lab_us-gaap_ProductsAndServicesDomain_D7BFC1AC761F2CE959BB9C8902F8947A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Products and Services [Domain]</link:label>
    <link:label id="lab_us-gaap_ProductsAndServicesDomain_D7BFC1AC761F2CE959BB9C8902F8947A_label_en-US" xlink:label="lab_us-gaap_ProductsAndServicesDomain_D7BFC1AC761F2CE959BB9C8902F8947A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Products and Services [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_D7BFC1AC761F2CE959BB9C8902F8947A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductsAndServicesDomain_D7BFC1AC761F2CE959BB9C8902F8947A" xlink:to="lab_us-gaap_ProductsAndServicesDomain_D7BFC1AC761F2CE959BB9C8902F8947A" xlink:type="arc" />
    <link:label id="lab_pfe_BesponsaMember_A841B484277CADCB2EF89C8902F824FB_terseLabel_en-US" xlink:label="lab_pfe_BesponsaMember_A841B484277CADCB2EF89C8902F824FB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Besponsa [Member]</link:label>
    <link:label id="lab_pfe_BesponsaMember_A841B484277CADCB2EF89C8902F824FB_label_en-US" xlink:label="lab_pfe_BesponsaMember_A841B484277CADCB2EF89C8902F824FB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Besponsa [Member]</link:label>
    <link:label id="lab_pfe_BesponsaMember_A841B484277CADCB2EF89C8902F824FB_documentation_en-US" xlink:label="lab_pfe_BesponsaMember_A841B484277CADCB2EF89C8902F824FB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Besponsa [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_BesponsaMember" xlink:label="loc_pfe_BesponsaMember_A841B484277CADCB2EF89C8902F824FB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_BesponsaMember_A841B484277CADCB2EF89C8902F824FB" xlink:to="lab_pfe_BesponsaMember_A841B484277CADCB2EF89C8902F824FB" xlink:type="arc" />
    <link:label id="lab_pfe_ResearchandDevelopmentArrangementAggregatePaymentObligationTerm_FA2281E8EDA4527C632C9C8902FA7A6A_terseLabel_en-US" xlink:label="lab_pfe_ResearchandDevelopmentArrangementAggregatePaymentObligationTerm_FA2281E8EDA4527C632C9C8902FA7A6A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term over which fixed annual payments are to be made</link:label>
    <link:label id="lab_pfe_ResearchandDevelopmentArrangementAggregatePaymentObligationTerm_FA2281E8EDA4527C632C9C8902FA7A6A_label_en-US" xlink:label="lab_pfe_ResearchandDevelopmentArrangementAggregatePaymentObligationTerm_FA2281E8EDA4527C632C9C8902FA7A6A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Aggregate Payment Obligation, Term</link:label>
    <link:label id="lab_pfe_ResearchandDevelopmentArrangementAggregatePaymentObligationTerm_FA2281E8EDA4527C632C9C8902FA7A6A_documentation_en-US" xlink:label="lab_pfe_ResearchandDevelopmentArrangementAggregatePaymentObligationTerm_FA2281E8EDA4527C632C9C8902FA7A6A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Aggregate Payment Obligation, Term</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_ResearchandDevelopmentArrangementAggregatePaymentObligationTerm" xlink:label="loc_pfe_ResearchandDevelopmentArrangementAggregatePaymentObligationTerm_FA2281E8EDA4527C632C9C8902FA7A6A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ResearchandDevelopmentArrangementAggregatePaymentObligationTerm_FA2281E8EDA4527C632C9C8902FA7A6A" xlink:to="lab_pfe_ResearchandDevelopmentArrangementAggregatePaymentObligationTerm_FA2281E8EDA4527C632C9C8902FA7A6A" xlink:type="arc" />
    <link:label id="lab_pfe_ResearchandDevelopmentArrangementAggregatePaymentObligation_4A3C3814B325E0AD89129C8902FAFE86_terseLabel_en-US" xlink:label="lab_pfe_ResearchandDevelopmentArrangementAggregatePaymentObligation_4A3C3814B325E0AD89129C8902FAFE86" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate amount of guaranteed fixed annual payments to be made in connection with research and development arrangement</link:label>
    <link:label id="lab_pfe_ResearchandDevelopmentArrangementAggregatePaymentObligation_4A3C3814B325E0AD89129C8902FAFE86_label_en-US" xlink:label="lab_pfe_ResearchandDevelopmentArrangementAggregatePaymentObligation_4A3C3814B325E0AD89129C8902FAFE86" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Aggregate Payment Obligation</link:label>
    <link:label id="lab_pfe_ResearchandDevelopmentArrangementAggregatePaymentObligation_4A3C3814B325E0AD89129C8902FAFE86_documentation_en-US" xlink:label="lab_pfe_ResearchandDevelopmentArrangementAggregatePaymentObligation_4A3C3814B325E0AD89129C8902FAFE86" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Aggregate Payment Obligation</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_ResearchandDevelopmentArrangementAggregatePaymentObligation" xlink:label="loc_pfe_ResearchandDevelopmentArrangementAggregatePaymentObligation_4A3C3814B325E0AD89129C8902FAFE86" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ResearchandDevelopmentArrangementAggregatePaymentObligation_4A3C3814B325E0AD89129C8902FAFE86" xlink:to="lab_pfe_ResearchandDevelopmentArrangementAggregatePaymentObligation_4A3C3814B325E0AD89129C8902FAFE86" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_6E92C8BE9CE5CC09D30C9C8902FA9FD6_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet_6E92C8BE9CE5CC09D30C9C8902FA9FD6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-lived intangible assets, net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_6E92C8BE9CE5CC09D30C9C8902FA9FD6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_6E92C8BE9CE5CC09D30C9C8902FA9FD6" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet_6E92C8BE9CE5CC09D30C9C8902FA9FD6" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_B1FE438AD8254A5599989D7882868F73_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_B1FE438AD8254A5599989D7882868F73" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_B1FE438AD8254A5599989D7882868F73" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_B1FE438AD8254A5599989D7882868F73" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_B1FE438AD8254A5599989D7882868F73" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainContingenciesTable_0B11AB7C32B1849BD2579D7882865CBA_terseLabel_en-US" xlink:label="lab_us-gaap_GainContingenciesTable_0B11AB7C32B1849BD2579D7882865CBA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_GainContingenciesTable_0B11AB7C32B1849BD2579D7882865CBA_label_en-US" xlink:label="lab_us-gaap_GainContingenciesTable_0B11AB7C32B1849BD2579D7882865CBA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain Contingencies [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainContingenciesTable" xlink:label="loc_us-gaap_GainContingenciesTable_0B11AB7C32B1849BD2579D7882865CBA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainContingenciesTable_0B11AB7C32B1849BD2579D7882865CBA" xlink:to="lab_us-gaap_GainContingenciesTable_0B11AB7C32B1849BD2579D7882865CBA" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_3C433EBADDE6B2A3CB7E9D788287016D_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis_3C433EBADDE6B2A3CB7E9D788287016D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_3C433EBADDE6B2A3CB7E9D788287016D_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis_3C433EBADDE6B2A3CB7E9D788287016D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_3C433EBADDE6B2A3CB7E9D788287016D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_3C433EBADDE6B2A3CB7E9D788287016D" xlink:to="lab_us-gaap_SubsequentEventTypeAxis_3C433EBADDE6B2A3CB7E9D788287016D" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_8B733AA18E370FDB09C99D7882870AD8_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain_8B733AA18E370FDB09C99D7882870AD8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_8B733AA18E370FDB09C99D7882870AD8_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain_8B733AA18E370FDB09C99D7882870AD8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_8B733AA18E370FDB09C99D7882870AD8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_8B733AA18E370FDB09C99D7882870AD8" xlink:to="lab_us-gaap_SubsequentEventTypeDomain_8B733AA18E370FDB09C99D7882870AD8" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventMember_F33D8693CD0E95DB0DA89D78828782E6_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember_F33D8693CD0E95DB0DA89D78828782E6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_F33D8693CD0E95DB0DA89D78828782E6_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember_F33D8693CD0E95DB0DA89D78828782E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_F33D8693CD0E95DB0DA89D78828782E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember_F33D8693CD0E95DB0DA89D78828782E6" xlink:to="lab_us-gaap_SubsequentEventMember_F33D8693CD0E95DB0DA89D78828782E6" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_1EF6C649BAF87D989D869D7882873E22_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_1EF6C649BAF87D989D869D7882873E22" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_1EF6C649BAF87D989D869D7882873E22_label_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_1EF6C649BAF87D989D869D7882873E22" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_1EF6C649BAF87D989D869D7882873E22" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_1EF6C649BAF87D989D869D7882873E22" xlink:to="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_1EF6C649BAF87D989D869D7882873E22" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_BD93AE6C2922F62D1C629D7882874DBB_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain_BD93AE6C2922F62D1C629D7882874DBB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_BD93AE6C2922F62D1C629D7882874DBB_label_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain_BD93AE6C2922F62D1C629D7882874DBB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="loc_us-gaap_LossContingencyNatureDomain_BD93AE6C2922F62D1C629D7882874DBB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNatureDomain_BD93AE6C2922F62D1C629D7882874DBB" xlink:to="lab_us-gaap_LossContingencyNatureDomain_BD93AE6C2922F62D1C629D7882874DBB" xlink:type="arc" />
    <link:label id="lab_pfe_PatentInfringementMember_141380A0570DA2E87F0A9D78828709B8_terseLabel_en-US" xlink:label="lab_pfe_PatentInfringementMember_141380A0570DA2E87F0A9D78828709B8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Patent Infringement [Member]</link:label>
    <link:label id="lab_pfe_PatentInfringementMember_141380A0570DA2E87F0A9D78828709B8_label_en-US" xlink:label="lab_pfe_PatentInfringementMember_141380A0570DA2E87F0A9D78828709B8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Patent Infringement [Member]</link:label>
    <link:label id="lab_pfe_PatentInfringementMember_141380A0570DA2E87F0A9D78828709B8_documentation_en-US" xlink:label="lab_pfe_PatentInfringementMember_141380A0570DA2E87F0A9D78828709B8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Patent Infringement [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_PatentInfringementMember" xlink:label="loc_pfe_PatentInfringementMember_141380A0570DA2E87F0A9D78828709B8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_PatentInfringementMember_141380A0570DA2E87F0A9D78828709B8" xlink:to="lab_pfe_PatentInfringementMember_141380A0570DA2E87F0A9D78828709B8" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainContingenciesByNatureAxis_C2E41C793FD8069315969D788287DCD7_terseLabel_en-US" xlink:label="lab_us-gaap_GainContingenciesByNatureAxis_C2E41C793FD8069315969D788287DCD7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain Contingencies, Nature [Axis]</link:label>
    <link:label id="lab_us-gaap_GainContingenciesByNatureAxis_C2E41C793FD8069315969D788287DCD7_label_en-US" xlink:label="lab_us-gaap_GainContingenciesByNatureAxis_C2E41C793FD8069315969D788287DCD7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain Contingencies, Nature [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainContingenciesByNatureAxis" xlink:label="loc_us-gaap_GainContingenciesByNatureAxis_C2E41C793FD8069315969D788287DCD7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainContingenciesByNatureAxis_C2E41C793FD8069315969D788287DCD7" xlink:to="lab_us-gaap_GainContingenciesByNatureAxis_C2E41C793FD8069315969D788287DCD7" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainContingencyNatureDomain_8D4C6E6F34B51A60A23D9D7882873A40_terseLabel_en-US" xlink:label="lab_us-gaap_GainContingencyNatureDomain_8D4C6E6F34B51A60A23D9D7882873A40" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain Contingency, Nature [Domain]</link:label>
    <link:label id="lab_us-gaap_GainContingencyNatureDomain_8D4C6E6F34B51A60A23D9D7882873A40_label_en-US" xlink:label="lab_us-gaap_GainContingencyNatureDomain_8D4C6E6F34B51A60A23D9D7882873A40" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain Contingency, Nature [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainContingencyNatureDomain" xlink:label="loc_us-gaap_GainContingencyNatureDomain_8D4C6E6F34B51A60A23D9D7882873A40" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainContingencyNatureDomain_8D4C6E6F34B51A60A23D9D7882873A40" xlink:to="lab_us-gaap_GainContingencyNatureDomain_8D4C6E6F34B51A60A23D9D7882873A40" xlink:type="arc" />
    <link:label id="lab_pfe_BosulifMember_8BA8420A02DB0ED147339D79B77F1B3B_terseLabel_en-US" xlink:label="lab_pfe_BosulifMember_8BA8420A02DB0ED147339D79B77F1B3B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Bosulif [Member]</link:label>
    <link:label id="lab_pfe_BosulifMember_8BA8420A02DB0ED147339D79B77F1B3B_label_en-US" xlink:label="lab_pfe_BosulifMember_8BA8420A02DB0ED147339D79B77F1B3B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bosulif [Member]</link:label>
    <link:label id="lab_pfe_BosulifMember_8BA8420A02DB0ED147339D79B77F1B3B_documentation_en-US" xlink:label="lab_pfe_BosulifMember_8BA8420A02DB0ED147339D79B77F1B3B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Bosulif [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_BosulifMember" xlink:label="loc_pfe_BosulifMember_8BA8420A02DB0ED147339D79B77F1B3B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_BosulifMember_8BA8420A02DB0ED147339D79B77F1B3B" xlink:to="lab_pfe_BosulifMember_8BA8420A02DB0ED147339D79B77F1B3B" xlink:type="arc" />
    <link:label id="lab_pfe_PrecedexPremixMember_511397B87A39C4C509AF9D78828DC65E_terseLabel_en-US" xlink:label="lab_pfe_PrecedexPremixMember_511397B87A39C4C509AF9D78828DC65E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Precedex Premix [Member]</link:label>
    <link:label id="lab_pfe_PrecedexPremixMember_511397B87A39C4C509AF9D78828DC65E_label_en-US" xlink:label="lab_pfe_PrecedexPremixMember_511397B87A39C4C509AF9D78828DC65E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Precedex Premix [Member]</link:label>
    <link:label id="lab_pfe_PrecedexPremixMember_511397B87A39C4C509AF9D78828DC65E_documentation_en-US" xlink:label="lab_pfe_PrecedexPremixMember_511397B87A39C4C509AF9D78828DC65E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Precedex Premix [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_PrecedexPremixMember" xlink:label="loc_pfe_PrecedexPremixMember_511397B87A39C4C509AF9D78828DC65E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_PrecedexPremixMember_511397B87A39C4C509AF9D78828DC65E" xlink:to="lab_pfe_PrecedexPremixMember_511397B87A39C4C509AF9D78828DC65E" xlink:type="arc" />
    <link:label id="lab_pfe_ToviazMember_5D10F9B4CB554C4BCBD79D78828DEC07_terseLabel_en-US" xlink:label="lab_pfe_ToviazMember_5D10F9B4CB554C4BCBD79D78828DEC07" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Toviaz [Member]</link:label>
    <link:label id="lab_pfe_ToviazMember_5D10F9B4CB554C4BCBD79D78828DEC07_label_en-US" xlink:label="lab_pfe_ToviazMember_5D10F9B4CB554C4BCBD79D78828DEC07" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Toviaz [Member]</link:label>
    <link:label id="lab_pfe_ToviazMember_5D10F9B4CB554C4BCBD79D78828DEC07_documentation_en-US" xlink:label="lab_pfe_ToviazMember_5D10F9B4CB554C4BCBD79D78828DEC07" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Toviaz [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_ToviazMember" xlink:label="loc_pfe_ToviazMember_5D10F9B4CB554C4BCBD79D78828DEC07" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ToviazMember_5D10F9B4CB554C4BCBD79D78828DEC07" xlink:to="lab_pfe_ToviazMember_5D10F9B4CB554C4BCBD79D78828DEC07" xlink:type="arc" />
    <link:label id="lab_pfe_ToviazCompositionofmatterPatentsMember_EE1049E1D16984A8EC009D78828D0D4E_terseLabel_en-US" xlink:label="lab_pfe_ToviazCompositionofmatterPatentsMember_EE1049E1D16984A8EC009D78828D0D4E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Toviaz Composition-of-matter Patents [Member]</link:label>
    <link:label id="lab_pfe_ToviazCompositionofmatterPatentsMember_EE1049E1D16984A8EC009D78828D0D4E_label_en-US" xlink:label="lab_pfe_ToviazCompositionofmatterPatentsMember_EE1049E1D16984A8EC009D78828D0D4E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Toviaz Composition-of-matter Patents [Member]</link:label>
    <link:label id="lab_pfe_ToviazCompositionofmatterPatentsMember_EE1049E1D16984A8EC009D78828D0D4E_documentation_en-US" xlink:label="lab_pfe_ToviazCompositionofmatterPatentsMember_EE1049E1D16984A8EC009D78828D0D4E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Toviaz Composition-of-matter Patents [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_ToviazCompositionofmatterPatentsMember" xlink:label="loc_pfe_ToviazCompositionofmatterPatentsMember_EE1049E1D16984A8EC009D78828D0D4E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ToviazCompositionofmatterPatentsMember_EE1049E1D16984A8EC009D78828D0D4E" xlink:to="lab_pfe_ToviazCompositionofmatterPatentsMember_EE1049E1D16984A8EC009D78828D0D4E" xlink:type="arc" />
    <link:label id="lab_pfe_XeljanzMember_B119D7CB340A9EE832B29D78828D5B1C_terseLabel_en-US" xlink:label="lab_pfe_XeljanzMember_B119D7CB340A9EE832B29D78828D5B1C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Xeljanz [Member]</link:label>
    <link:label id="lab_pfe_XeljanzMember_B119D7CB340A9EE832B29D78828D5B1C_label_en-US" xlink:label="lab_pfe_XeljanzMember_B119D7CB340A9EE832B29D78828D5B1C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Xeljanz [Member]</link:label>
    <link:label id="lab_pfe_XeljanzMember_B119D7CB340A9EE832B29D78828D5B1C_documentation_en-US" xlink:label="lab_pfe_XeljanzMember_B119D7CB340A9EE832B29D78828D5B1C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Xeljanz [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_XeljanzMember" xlink:label="loc_pfe_XeljanzMember_B119D7CB340A9EE832B29D78828D5B1C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_XeljanzMember_B119D7CB340A9EE832B29D78828D5B1C" xlink:to="lab_pfe_XeljanzMember_B119D7CB340A9EE832B29D78828D5B1C" xlink:type="arc" />
    <link:label id="lab_pfe_EliquisMember_3C0CA17E8912055C50219D78828D4F18_terseLabel_en-US" xlink:label="lab_pfe_EliquisMember_3C0CA17E8912055C50219D78828D4F18" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Eliquis [Member]</link:label>
    <link:label id="lab_pfe_EliquisMember_3C0CA17E8912055C50219D78828D4F18_label_en-US" xlink:label="lab_pfe_EliquisMember_3C0CA17E8912055C50219D78828D4F18" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Eliquis [Member]</link:label>
    <link:label id="lab_pfe_EliquisMember_3C0CA17E8912055C50219D78828D4F18_documentation_en-US" xlink:label="lab_pfe_EliquisMember_3C0CA17E8912055C50219D78828D4F18" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Eliquis [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_EliquisMember" xlink:label="loc_pfe_EliquisMember_3C0CA17E8912055C50219D78828D4F18" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_EliquisMember_3C0CA17E8912055C50219D78828D4F18" xlink:to="lab_pfe_EliquisMember_3C0CA17E8912055C50219D78828D4F18" xlink:type="arc" />
    <link:label id="lab_pfe_BavencioMember_5D8AB799F79AF5BEC1C69D78828D60E1_terseLabel_en-US" xlink:label="lab_pfe_BavencioMember_5D8AB799F79AF5BEC1C69D78828D60E1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Bavencio [Member]</link:label>
    <link:label id="lab_pfe_BavencioMember_5D8AB799F79AF5BEC1C69D78828D60E1_label_en-US" xlink:label="lab_pfe_BavencioMember_5D8AB799F79AF5BEC1C69D78828D60E1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bavencio [Member]</link:label>
    <link:label id="lab_pfe_BavencioMember_5D8AB799F79AF5BEC1C69D78828D60E1_documentation_en-US" xlink:label="lab_pfe_BavencioMember_5D8AB799F79AF5BEC1C69D78828D60E1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Bavencio [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_BavencioMember" xlink:label="loc_pfe_BavencioMember_5D8AB799F79AF5BEC1C69D78828D60E1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_BavencioMember_5D8AB799F79AF5BEC1C69D78828D60E1" xlink:to="lab_pfe_BavencioMember_5D8AB799F79AF5BEC1C69D78828D60E1" xlink:type="arc" />
    <link:label id="lab_us-gaap_LitigationCaseAxis_2100543976034476FBB69D78828D81C4_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationCaseAxis_2100543976034476FBB69D78828D81C4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_us-gaap_LitigationCaseAxis_2100543976034476FBB69D78828D81C4_label_en-US" xlink:label="lab_us-gaap_LitigationCaseAxis_2100543976034476FBB69D78828D81C4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationCaseAxis" xlink:label="loc_us-gaap_LitigationCaseAxis_2100543976034476FBB69D78828D81C4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationCaseAxis_2100543976034476FBB69D78828D81C4" xlink:to="lab_us-gaap_LitigationCaseAxis_2100543976034476FBB69D78828D81C4" xlink:type="arc" />
    <link:label id="lab_us-gaap_LitigationCaseTypeDomain_395BA0AFF7ADC24D8E8B9D78828E436E_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationCaseTypeDomain_395BA0AFF7ADC24D8E8B9D78828E436E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:label id="lab_us-gaap_LitigationCaseTypeDomain_395BA0AFF7ADC24D8E8B9D78828E436E_label_en-US" xlink:label="lab_us-gaap_LitigationCaseTypeDomain_395BA0AFF7ADC24D8E8B9D78828E436E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationCaseTypeDomain" xlink:label="loc_us-gaap_LitigationCaseTypeDomain_395BA0AFF7ADC24D8E8B9D78828E436E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationCaseTypeDomain_395BA0AFF7ADC24D8E8B9D78828E436E" xlink:to="lab_us-gaap_LitigationCaseTypeDomain_395BA0AFF7ADC24D8E8B9D78828E436E" xlink:type="arc" />
    <link:label id="lab_pfe_WyethVersusSunMember_E0D63AE17834610086739D7A3D6C16A0_terseLabel_en-US" xlink:label="lab_pfe_WyethVersusSunMember_E0D63AE17834610086739D7A3D6C16A0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Wyeth Versus Sun [Member]</link:label>
    <link:label id="lab_pfe_WyethVersusSunMember_E0D63AE17834610086739D7A3D6C16A0_label_en-US" xlink:label="lab_pfe_WyethVersusSunMember_E0D63AE17834610086739D7A3D6C16A0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Wyeth Versus Sun [Member]</link:label>
    <link:label id="lab_pfe_WyethVersusSunMember_E0D63AE17834610086739D7A3D6C16A0_documentation_en-US" xlink:label="lab_pfe_WyethVersusSunMember_E0D63AE17834610086739D7A3D6C16A0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Wyeth Versus Sun [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_WyethVersusSunMember" xlink:label="loc_pfe_WyethVersusSunMember_E0D63AE17834610086739D7A3D6C16A0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_WyethVersusSunMember_E0D63AE17834610086739D7A3D6C16A0" xlink:to="lab_pfe_WyethVersusSunMember_E0D63AE17834610086739D7A3D6C16A0" xlink:type="arc" />
    <link:label id="lab_pfe_HospiraVersusAmnealPharmaceuticalsLLCMember_6DB834501C30D34EBCFE9D78828E9C47_terseLabel_en-US" xlink:label="lab_pfe_HospiraVersusAmnealPharmaceuticalsLLCMember_6DB834501C30D34EBCFE9D78828E9C47" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hospira Versus Amneal Pharmaceuticals LLC [Member]</link:label>
    <link:label id="lab_pfe_HospiraVersusAmnealPharmaceuticalsLLCMember_6DB834501C30D34EBCFE9D78828E9C47_label_en-US" xlink:label="lab_pfe_HospiraVersusAmnealPharmaceuticalsLLCMember_6DB834501C30D34EBCFE9D78828E9C47" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hospira Versus Amneal Pharmaceuticals LLC [Member]</link:label>
    <link:label id="lab_pfe_HospiraVersusAmnealPharmaceuticalsLLCMember_6DB834501C30D34EBCFE9D78828E9C47_documentation_en-US" xlink:label="lab_pfe_HospiraVersusAmnealPharmaceuticalsLLCMember_6DB834501C30D34EBCFE9D78828E9C47" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Hospira Versus Amneal Pharmaceuticals LLC [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_HospiraVersusAmnealPharmaceuticalsLLCMember" xlink:label="loc_pfe_HospiraVersusAmnealPharmaceuticalsLLCMember_6DB834501C30D34EBCFE9D78828E9C47" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_HospiraVersusAmnealPharmaceuticalsLLCMember_6DB834501C30D34EBCFE9D78828E9C47" xlink:to="lab_pfe_HospiraVersusAmnealPharmaceuticalsLLCMember_6DB834501C30D34EBCFE9D78828E9C47" xlink:type="arc" />
    <link:label id="lab_pfe_HospiraVersusFreseniusMember_47F5FE036AFCEAC745779D78828ECDFF_terseLabel_en-US" xlink:label="lab_pfe_HospiraVersusFreseniusMember_47F5FE036AFCEAC745779D78828ECDFF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hospira Versus Fresenius [Member]</link:label>
    <link:label id="lab_pfe_HospiraVersusFreseniusMember_47F5FE036AFCEAC745779D78828ECDFF_label_en-US" xlink:label="lab_pfe_HospiraVersusFreseniusMember_47F5FE036AFCEAC745779D78828ECDFF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hospira Versus Fresenius [Member]</link:label>
    <link:label id="lab_pfe_HospiraVersusFreseniusMember_47F5FE036AFCEAC745779D78828ECDFF_documentation_en-US" xlink:label="lab_pfe_HospiraVersusFreseniusMember_47F5FE036AFCEAC745779D78828ECDFF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Hospira Versus Fresenius [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_HospiraVersusFreseniusMember" xlink:label="loc_pfe_HospiraVersusFreseniusMember_47F5FE036AFCEAC745779D78828ECDFF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_HospiraVersusFreseniusMember_47F5FE036AFCEAC745779D78828ECDFF" xlink:to="lab_pfe_HospiraVersusFreseniusMember_47F5FE036AFCEAC745779D78828ECDFF" xlink:type="arc" />
    <link:label id="lab_pfe_HospiraVersusParMember_C59735FFE9A96304A7F79D78828EC83E_terseLabel_en-US" xlink:label="lab_pfe_HospiraVersusParMember_C59735FFE9A96304A7F79D78828EC83E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hospira Versus Par [Member]</link:label>
    <link:label id="lab_pfe_HospiraVersusParMember_C59735FFE9A96304A7F79D78828EC83E_label_en-US" xlink:label="lab_pfe_HospiraVersusParMember_C59735FFE9A96304A7F79D78828EC83E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hospira Versus Par [Member]</link:label>
    <link:label id="lab_pfe_HospiraVersusParMember_C59735FFE9A96304A7F79D78828EC83E_documentation_en-US" xlink:label="lab_pfe_HospiraVersusParMember_C59735FFE9A96304A7F79D78828EC83E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Hospira Versus Par [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_HospiraVersusParMember" xlink:label="loc_pfe_HospiraVersusParMember_C59735FFE9A96304A7F79D78828EC83E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_HospiraVersusParMember_C59735FFE9A96304A7F79D78828EC83E" xlink:to="lab_pfe_HospiraVersusParMember_C59735FFE9A96304A7F79D78828EC83E" xlink:type="arc" />
    <link:label id="lab_pfe_PfizerVersusMylanLaboratoriesandAccordHealthcareInc.Member_72FBBF92812A13652E769D78828E7787_terseLabel_en-US" xlink:label="lab_pfe_PfizerVersusMylanLaboratoriesandAccordHealthcareInc.Member_72FBBF92812A13652E769D78828E7787" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pfizer Versus Mylan Laboratories Limited [Member]</link:label>
    <link:label id="lab_pfe_PfizerVersusMylanLaboratoriesandAccordHealthcareInc.Member_72FBBF92812A13652E769D78828E7787_label_en-US" xlink:label="lab_pfe_PfizerVersusMylanLaboratoriesandAccordHealthcareInc.Member_72FBBF92812A13652E769D78828E7787" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pfizer Versus Mylan Laboratories and Accord Healthcare Inc. [Member]</link:label>
    <link:label id="lab_pfe_PfizerVersusMylanLaboratoriesandAccordHealthcareInc.Member_72FBBF92812A13652E769D78828E7787_documentation_en-US" xlink:label="lab_pfe_PfizerVersusMylanLaboratoriesandAccordHealthcareInc.Member_72FBBF92812A13652E769D78828E7787" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pfizer Versus Mylan Laboratories and Accord Healthcare Inc. [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_PfizerVersusMylanLaboratoriesandAccordHealthcareInc.Member" xlink:label="loc_pfe_PfizerVersusMylanLaboratoriesandAccordHealthcareInc.Member_72FBBF92812A13652E769D78828E7787" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_PfizerVersusMylanLaboratoriesandAccordHealthcareInc.Member_72FBBF92812A13652E769D78828E7787" xlink:to="lab_pfe_PfizerVersusMylanLaboratoriesandAccordHealthcareInc.Member_72FBBF92812A13652E769D78828E7787" xlink:type="arc" />
    <link:label id="lab_pfe_PfizerVersusSeveralGenericManufacturersMember_7CFA7D7E0CF6BAC8D2A49D78828EDB34_terseLabel_en-US" xlink:label="lab_pfe_PfizerVersusSeveralGenericManufacturersMember_7CFA7D7E0CF6BAC8D2A49D78828EDB34" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pfizer Versus Several Generic Manufacturers [Member]</link:label>
    <link:label id="lab_pfe_PfizerVersusSeveralGenericManufacturersMember_7CFA7D7E0CF6BAC8D2A49D78828EDB34_label_en-US" xlink:label="lab_pfe_PfizerVersusSeveralGenericManufacturersMember_7CFA7D7E0CF6BAC8D2A49D78828EDB34" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pfizer Versus Several Generic Manufacturers [Member]</link:label>
    <link:label id="lab_pfe_PfizerVersusSeveralGenericManufacturersMember_7CFA7D7E0CF6BAC8D2A49D78828EDB34_documentation_en-US" xlink:label="lab_pfe_PfizerVersusSeveralGenericManufacturersMember_7CFA7D7E0CF6BAC8D2A49D78828EDB34" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pfizer Versus Several Generic Manufacturers [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_PfizerVersusSeveralGenericManufacturersMember" xlink:label="loc_pfe_PfizerVersusSeveralGenericManufacturersMember_7CFA7D7E0CF6BAC8D2A49D78828EDB34" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_PfizerVersusSeveralGenericManufacturersMember_7CFA7D7E0CF6BAC8D2A49D78828EDB34" xlink:to="lab_pfe_PfizerVersusSeveralGenericManufacturersMember_7CFA7D7E0CF6BAC8D2A49D78828EDB34" xlink:type="arc" />
    <link:label id="lab_pfe_PfizerVersusMicroLabsMember_CA8C0CF09D69846AEB419D78828E5710_terseLabel_en-US" xlink:label="lab_pfe_PfizerVersusMicroLabsMember_CA8C0CF09D69846AEB419D78828E5710" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pfizer Versus MicroLabs [Member]</link:label>
    <link:label id="lab_pfe_PfizerVersusMicroLabsMember_CA8C0CF09D69846AEB419D78828E5710_label_en-US" xlink:label="lab_pfe_PfizerVersusMicroLabsMember_CA8C0CF09D69846AEB419D78828E5710" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pfizer Versus MicroLabs [Member]</link:label>
    <link:label id="lab_pfe_PfizerVersusMicroLabsMember_CA8C0CF09D69846AEB419D78828E5710_documentation_en-US" xlink:label="lab_pfe_PfizerVersusMicroLabsMember_CA8C0CF09D69846AEB419D78828E5710" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pfizer Versus MicroLabs [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_PfizerVersusMicroLabsMember" xlink:label="loc_pfe_PfizerVersusMicroLabsMember_CA8C0CF09D69846AEB419D78828E5710" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_PfizerVersusMicroLabsMember_CA8C0CF09D69846AEB419D78828E5710" xlink:to="lab_pfe_PfizerVersusMicroLabsMember_CA8C0CF09D69846AEB419D78828E5710" xlink:type="arc" />
    <link:label id="lab_pfe_PfizerVersusZydusMember_C0C413A44D85F5F2B49C9D78828ED067_terseLabel_en-US" xlink:label="lab_pfe_PfizerVersusZydusMember_C0C413A44D85F5F2B49C9D78828ED067" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pfizer Versus Zydus [Member]</link:label>
    <link:label id="lab_pfe_PfizerVersusZydusMember_C0C413A44D85F5F2B49C9D78828ED067_label_en-US" xlink:label="lab_pfe_PfizerVersusZydusMember_C0C413A44D85F5F2B49C9D78828ED067" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pfizer Versus Zydus [Member]</link:label>
    <link:label id="lab_pfe_PfizerVersusZydusMember_C0C413A44D85F5F2B49C9D78828ED067_documentation_en-US" xlink:label="lab_pfe_PfizerVersusZydusMember_C0C413A44D85F5F2B49C9D78828ED067" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pfizer Versus Zydus [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_PfizerVersusZydusMember" xlink:label="loc_pfe_PfizerVersusZydusMember_C0C413A44D85F5F2B49C9D78828ED067" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_PfizerVersusZydusMember_C0C413A44D85F5F2B49C9D78828ED067" xlink:to="lab_pfe_PfizerVersusZydusMember_C0C413A44D85F5F2B49C9D78828ED067" xlink:type="arc" />
    <link:label id="lab_pfe_PfizerVersusPrinstonandBreckenridgeMember_22EC7458E71D2C03D6209D78828EC414_terseLabel_en-US" xlink:label="lab_pfe_PfizerVersusPrinstonandBreckenridgeMember_22EC7458E71D2C03D6209D78828EC414" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pfizer Versus Prinston and Breckenridge [Member]</link:label>
    <link:label id="lab_pfe_PfizerVersusPrinstonandBreckenridgeMember_22EC7458E71D2C03D6209D78828EC414_label_en-US" xlink:label="lab_pfe_PfizerVersusPrinstonandBreckenridgeMember_22EC7458E71D2C03D6209D78828EC414" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pfizer Versus Prinston and Breckenridge [Member]</link:label>
    <link:label id="lab_pfe_PfizerVersusPrinstonandBreckenridgeMember_22EC7458E71D2C03D6209D78828EC414_documentation_en-US" xlink:label="lab_pfe_PfizerVersusPrinstonandBreckenridgeMember_22EC7458E71D2C03D6209D78828EC414" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pfizer Versus Prinston and Breckenridge [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_PfizerVersusPrinstonandBreckenridgeMember" xlink:label="loc_pfe_PfizerVersusPrinstonandBreckenridgeMember_22EC7458E71D2C03D6209D78828EC414" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_PfizerVersusPrinstonandBreckenridgeMember_22EC7458E71D2C03D6209D78828EC414" xlink:to="lab_pfe_PfizerVersusPrinstonandBreckenridgeMember_22EC7458E71D2C03D6209D78828EC414" xlink:type="arc" />
    <link:label id="lab_pfe_PfizerVersusBreckenridgeMember_1D870EC79D91DCF699E09D78828E634C_terseLabel_en-US" xlink:label="lab_pfe_PfizerVersusBreckenridgeMember_1D870EC79D91DCF699E09D78828E634C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pfizer Versus Breckenridge [Member]</link:label>
    <link:label id="lab_pfe_PfizerVersusBreckenridgeMember_1D870EC79D91DCF699E09D78828E634C_label_en-US" xlink:label="lab_pfe_PfizerVersusBreckenridgeMember_1D870EC79D91DCF699E09D78828E634C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pfizer Versus Breckenridge [Member]</link:label>
    <link:label id="lab_pfe_PfizerVersusBreckenridgeMember_1D870EC79D91DCF699E09D78828E634C_documentation_en-US" xlink:label="lab_pfe_PfizerVersusBreckenridgeMember_1D870EC79D91DCF699E09D78828E634C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pfizer Versus Breckenridge [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_PfizerVersusBreckenridgeMember" xlink:label="loc_pfe_PfizerVersusBreckenridgeMember_1D870EC79D91DCF699E09D78828E634C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_PfizerVersusBreckenridgeMember_1D870EC79D91DCF699E09D78828E634C" xlink:to="lab_pfe_PfizerVersusBreckenridgeMember_1D870EC79D91DCF699E09D78828E634C" xlink:type="arc" />
    <link:label id="lab_pfe_PfizerandBMSVersusSeveralGenericManufacturersMember_8E95607C6FDACAA666269D7882939D26_terseLabel_en-US" xlink:label="lab_pfe_PfizerandBMSVersusSeveralGenericManufacturersMember_8E95607C6FDACAA666269D7882939D26" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pfizer and BMS Versus Several Generic Manufacturers [Member]</link:label>
    <link:label id="lab_pfe_PfizerandBMSVersusSeveralGenericManufacturersMember_8E95607C6FDACAA666269D7882939D26_label_en-US" xlink:label="lab_pfe_PfizerandBMSVersusSeveralGenericManufacturersMember_8E95607C6FDACAA666269D7882939D26" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pfizer and BMS Versus Several Generic Manufacturers [Member]</link:label>
    <link:label id="lab_pfe_PfizerandBMSVersusSeveralGenericManufacturersMember_8E95607C6FDACAA666269D7882939D26_documentation_en-US" xlink:label="lab_pfe_PfizerandBMSVersusSeveralGenericManufacturersMember_8E95607C6FDACAA666269D7882939D26" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pfizer and BMS Versus Several Generic Manufacturers [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_PfizerandBMSVersusSeveralGenericManufacturersMember" xlink:label="loc_pfe_PfizerandBMSVersusSeveralGenericManufacturersMember_8E95607C6FDACAA666269D7882939D26" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_PfizerandBMSVersusSeveralGenericManufacturersMember_8E95607C6FDACAA666269D7882939D26" xlink:to="lab_pfe_PfizerandBMSVersusSeveralGenericManufacturersMember_8E95607C6FDACAA666269D7882939D26" xlink:type="arc" />
    <link:label id="lab_pfe_PfizerVersusBMSE.R.SquibbSonsOnoPharmaceuticalandTasukuHonjoMember_924DA4E88E0762E397349D788293AD70_terseLabel_en-US" xlink:label="lab_pfe_PfizerVersusBMSE.R.SquibbSonsOnoPharmaceuticalandTasukuHonjoMember_924DA4E88E0762E397349D788293AD70" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pfizer Versus BMS, E.R. Squibb &amp; Sons, Ono Pharmaceutical and Tasuku Honjo [Member]</link:label>
    <link:label id="lab_pfe_PfizerVersusBMSE.R.SquibbSonsOnoPharmaceuticalandTasukuHonjoMember_924DA4E88E0762E397349D788293AD70_label_en-US" xlink:label="lab_pfe_PfizerVersusBMSE.R.SquibbSonsOnoPharmaceuticalandTasukuHonjoMember_924DA4E88E0762E397349D788293AD70" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pfizer Versus BMS, E.R. Squibb &amp; Sons, Ono Pharmaceutical and Tasuku Honjo [Member]</link:label>
    <link:label id="lab_pfe_PfizerVersusBMSE.R.SquibbSonsOnoPharmaceuticalandTasukuHonjoMember_924DA4E88E0762E397349D788293AD70_documentation_en-US" xlink:label="lab_pfe_PfizerVersusBMSE.R.SquibbSonsOnoPharmaceuticalandTasukuHonjoMember_924DA4E88E0762E397349D788293AD70" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pfizer Versus BMS, E.R. Squibb &amp; Sons, Ono Pharmaceutical and Tasuku Honjo [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_PfizerVersusBMSE.R.SquibbSonsOnoPharmaceuticalandTasukuHonjoMember" xlink:label="loc_pfe_PfizerVersusBMSE.R.SquibbSonsOnoPharmaceuticalandTasukuHonjoMember_924DA4E88E0762E397349D788293AD70" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_PfizerVersusBMSE.R.SquibbSonsOnoPharmaceuticalandTasukuHonjoMember_924DA4E88E0762E397349D788293AD70" xlink:to="lab_pfe_PfizerVersusBMSE.R.SquibbSonsOnoPharmaceuticalandTasukuHonjoMember_924DA4E88E0762E397349D788293AD70" xlink:type="arc" />
    <link:label id="lab_us-gaap_LitigationStatusAxis_1CC9C75D8510465085939D7882946028_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationStatusAxis_1CC9C75D8510465085939D7882946028" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation Status [Axis]</link:label>
    <link:label id="lab_us-gaap_LitigationStatusAxis_1CC9C75D8510465085939D7882946028_label_en-US" xlink:label="lab_us-gaap_LitigationStatusAxis_1CC9C75D8510465085939D7882946028" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Status [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationStatusAxis" xlink:label="loc_us-gaap_LitigationStatusAxis_1CC9C75D8510465085939D7882946028" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationStatusAxis_1CC9C75D8510465085939D7882946028" xlink:to="lab_us-gaap_LitigationStatusAxis_1CC9C75D8510465085939D7882946028" xlink:type="arc" />
    <link:label id="lab_us-gaap_LitigationStatusDomain_23B1B5937CC5CC78B53F9D7882947AE1_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationStatusDomain_23B1B5937CC5CC78B53F9D7882947AE1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation Status [Domain]</link:label>
    <link:label id="lab_us-gaap_LitigationStatusDomain_23B1B5937CC5CC78B53F9D7882947AE1_label_en-US" xlink:label="lab_us-gaap_LitigationStatusDomain_23B1B5937CC5CC78B53F9D7882947AE1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Status [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationStatusDomain" xlink:label="loc_us-gaap_LitigationStatusDomain_23B1B5937CC5CC78B53F9D7882947AE1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationStatusDomain_23B1B5937CC5CC78B53F9D7882947AE1" xlink:to="lab_us-gaap_LitigationStatusDomain_23B1B5937CC5CC78B53F9D7882947AE1" xlink:type="arc" />
    <link:label id="lab_us-gaap_PendingLitigationMember_E3F73B40EBF48DC7DFA59D7882949983_terseLabel_en-US" xlink:label="lab_us-gaap_PendingLitigationMember_E3F73B40EBF48DC7DFA59D7882949983" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pending Litigation [Member]</link:label>
    <link:label id="lab_us-gaap_PendingLitigationMember_E3F73B40EBF48DC7DFA59D7882949983_label_en-US" xlink:label="lab_us-gaap_PendingLitigationMember_E3F73B40EBF48DC7DFA59D7882949983" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pending Litigation [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PendingLitigationMember" xlink:label="loc_us-gaap_PendingLitigationMember_E3F73B40EBF48DC7DFA59D7882949983" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PendingLitigationMember_E3F73B40EBF48DC7DFA59D7882949983" xlink:to="lab_us-gaap_PendingLitigationMember_E3F73B40EBF48DC7DFA59D7882949983" xlink:type="arc" />
    <link:label id="lab_us-gaap_SettledLitigationMember_7A9CE589765D726A004A9D788294EF64_terseLabel_en-US" xlink:label="lab_us-gaap_SettledLitigationMember_7A9CE589765D726A004A9D788294EF64" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Settled Litigation [Member]</link:label>
    <link:label id="lab_us-gaap_SettledLitigationMember_7A9CE589765D726A004A9D788294EF64_label_en-US" xlink:label="lab_us-gaap_SettledLitigationMember_7A9CE589765D726A004A9D788294EF64" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Settled Litigation [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SettledLitigationMember" xlink:label="loc_us-gaap_SettledLitigationMember_7A9CE589765D726A004A9D788294EF64" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SettledLitigationMember_7A9CE589765D726A004A9D788294EF64" xlink:to="lab_us-gaap_SettledLitigationMember_7A9CE589765D726A004A9D788294EF64" xlink:type="arc" />
    <link:label id="lab_us-gaap_JudicialRulingMember_BF337A6F5F424A04C8369D788294EB44_terseLabel_en-US" xlink:label="lab_us-gaap_JudicialRulingMember_BF337A6F5F424A04C8369D788294EB44" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Judicial Ruling [Member]</link:label>
    <link:label id="lab_us-gaap_JudicialRulingMember_BF337A6F5F424A04C8369D788294EB44_label_en-US" xlink:label="lab_us-gaap_JudicialRulingMember_BF337A6F5F424A04C8369D788294EB44" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Judicial Ruling [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_JudicialRulingMember" xlink:label="loc_us-gaap_JudicialRulingMember_BF337A6F5F424A04C8369D788294EB44" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_JudicialRulingMember_BF337A6F5F424A04C8369D788294EB44" xlink:to="lab_us-gaap_JudicialRulingMember_BF337A6F5F424A04C8369D788294EB44" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainContingenciesLineItems_6660F8B8F6DEE34F584E9D7882941EE9_terseLabel_en-US" xlink:label="lab_us-gaap_GainContingenciesLineItems_6660F8B8F6DEE34F584E9D7882941EE9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_GainContingenciesLineItems_6660F8B8F6DEE34F584E9D7882941EE9_label_en-US" xlink:label="lab_us-gaap_GainContingenciesLineItems_6660F8B8F6DEE34F584E9D7882941EE9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain Contingencies [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainContingenciesLineItems" xlink:label="loc_us-gaap_GainContingenciesLineItems_6660F8B8F6DEE34F584E9D7882941EE9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainContingenciesLineItems_6660F8B8F6DEE34F584E9D7882941EE9" xlink:to="lab_us-gaap_GainContingenciesLineItems_6660F8B8F6DEE34F584E9D7882941EE9" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_4612A4966F3380997A9E9D788294532C_terseLabel_en-US" xlink:label="lab_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_4612A4966F3380997A9E9D788294532C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of patents allegedly infringed upon</link:label>
    <link:label id="lab_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_4612A4966F3380997A9E9D788294532C_label_en-US" xlink:label="lab_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_4612A4966F3380997A9E9D788294532C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain Contingency, Patents Allegedly Infringed upon, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber" xlink:label="loc_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_4612A4966F3380997A9E9D788294532C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_4612A4966F3380997A9E9D788294532C" xlink:to="lab_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_4612A4966F3380997A9E9D788294532C" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainContingencyPatentsFoundNotInfringedUponNumber_EB8437E073F4D3AA05F49D7882946457_terseLabel_en-US" xlink:label="lab_us-gaap_GainContingencyPatentsFoundNotInfringedUponNumber_EB8437E073F4D3AA05F49D7882946457" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of patents not infringed upon</link:label>
    <link:label id="lab_us-gaap_GainContingencyPatentsFoundNotInfringedUponNumber_EB8437E073F4D3AA05F49D7882946457_label_en-US" xlink:label="lab_us-gaap_GainContingencyPatentsFoundNotInfringedUponNumber_EB8437E073F4D3AA05F49D7882946457" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain Contingency, Patents Found Not Infringed upon, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainContingencyPatentsFoundNotInfringedUponNumber" xlink:label="loc_us-gaap_GainContingencyPatentsFoundNotInfringedUponNumber_EB8437E073F4D3AA05F49D7882946457" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainContingencyPatentsFoundNotInfringedUponNumber_EB8437E073F4D3AA05F49D7882946457" xlink:to="lab_us-gaap_GainContingencyPatentsFoundNotInfringedUponNumber_EB8437E073F4D3AA05F49D7882946457" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainContingencyPatentsFoundInfringedUponNumber_7DFC846B9209D81E69EC9D78829465BE_terseLabel_en-US" xlink:label="lab_us-gaap_GainContingencyPatentsFoundInfringedUponNumber_7DFC846B9209D81E69EC9D78829465BE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of patents infringed upon</link:label>
    <link:label id="lab_us-gaap_GainContingencyPatentsFoundInfringedUponNumber_7DFC846B9209D81E69EC9D78829465BE_label_en-US" xlink:label="lab_us-gaap_GainContingencyPatentsFoundInfringedUponNumber_7DFC846B9209D81E69EC9D78829465BE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain Contingency, Patents Found Infringed upon, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainContingencyPatentsFoundInfringedUponNumber" xlink:label="loc_us-gaap_GainContingencyPatentsFoundInfringedUponNumber_7DFC846B9209D81E69EC9D78829465BE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainContingencyPatentsFoundInfringedUponNumber_7DFC846B9209D81E69EC9D78829465BE" xlink:to="lab_us-gaap_GainContingencyPatentsFoundInfringedUponNumber_7DFC846B9209D81E69EC9D78829465BE" xlink:type="arc" />
    <link:label id="lab_pfe_GainContingencyNumberofDefendants_6D38BB06D773D68CADD69D788294A402_terseLabel_en-US" xlink:label="lab_pfe_GainContingencyNumberofDefendants_6D38BB06D773D68CADD69D788294A402" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of defendants</link:label>
    <link:label id="lab_pfe_GainContingencyNumberofDefendants_6D38BB06D773D68CADD69D788294A402_label_en-US" xlink:label="lab_pfe_GainContingencyNumberofDefendants_6D38BB06D773D68CADD69D788294A402" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain Contingency, Number of Defendants</link:label>
    <link:label id="lab_pfe_GainContingencyNumberofDefendants_6D38BB06D773D68CADD69D788294A402_documentation_en-US" xlink:label="lab_pfe_GainContingencyNumberofDefendants_6D38BB06D773D68CADD69D788294A402" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Gain Contingency, Number of Defendants</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_GainContingencyNumberofDefendants" xlink:label="loc_pfe_GainContingencyNumberofDefendants_6D38BB06D773D68CADD69D788294A402" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_GainContingencyNumberofDefendants_6D38BB06D773D68CADD69D788294A402" xlink:to="lab_pfe_GainContingencyNumberofDefendants_6D38BB06D773D68CADD69D788294A402" xlink:type="arc" />
    <link:label id="lab_pfe_GainContingencyPatentsAllegedlyInfringeduponNumberDuetoExpireinDecember2020_3F1C698956071047B90B9D78829406A6_terseLabel_en-US" xlink:label="lab_pfe_GainContingencyPatentsAllegedlyInfringeduponNumberDuetoExpireinDecember2020_3F1C698956071047B90B9D78829406A6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of patents due to expire in December 2020</link:label>
    <link:label id="lab_pfe_GainContingencyPatentsAllegedlyInfringeduponNumberDuetoExpireinDecember2020_3F1C698956071047B90B9D78829406A6_label_en-US" xlink:label="lab_pfe_GainContingencyPatentsAllegedlyInfringeduponNumberDuetoExpireinDecember2020_3F1C698956071047B90B9D78829406A6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain Contingency, Patents Allegedly Infringed upon, Number Due to Expire in December 2020</link:label>
    <link:label id="lab_pfe_GainContingencyPatentsAllegedlyInfringeduponNumberDuetoExpireinDecember2020_3F1C698956071047B90B9D78829406A6_documentation_en-US" xlink:label="lab_pfe_GainContingencyPatentsAllegedlyInfringeduponNumberDuetoExpireinDecember2020_3F1C698956071047B90B9D78829406A6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Gain Contingency, Patents Allegedly Infringed upon, Number Due to Expire in December 2020</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_GainContingencyPatentsAllegedlyInfringeduponNumberDuetoExpireinDecember2020" xlink:label="loc_pfe_GainContingencyPatentsAllegedlyInfringeduponNumberDuetoExpireinDecember2020_3F1C698956071047B90B9D78829406A6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_GainContingencyPatentsAllegedlyInfringeduponNumberDuetoExpireinDecember2020_3F1C698956071047B90B9D78829406A6" xlink:to="lab_pfe_GainContingencyPatentsAllegedlyInfringeduponNumberDuetoExpireinDecember2020_3F1C698956071047B90B9D78829406A6" xlink:type="arc" />
    <link:label id="lab_pfe_GainContingencyPatentsAllegedlyInfringeduponNumberDuetoExpireinDecember2025_0B96A89B6ACEAB111FEF9D7882957B89_terseLabel_en-US" xlink:label="lab_pfe_GainContingencyPatentsAllegedlyInfringeduponNumberDuetoExpireinDecember2025_0B96A89B6ACEAB111FEF9D7882957B89" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number or patents due to expire in December 2025</link:label>
    <link:label id="lab_pfe_GainContingencyPatentsAllegedlyInfringeduponNumberDuetoExpireinDecember2025_0B96A89B6ACEAB111FEF9D7882957B89_label_en-US" xlink:label="lab_pfe_GainContingencyPatentsAllegedlyInfringeduponNumberDuetoExpireinDecember2025_0B96A89B6ACEAB111FEF9D7882957B89" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain Contingency, Patents Allegedly Infringed upon, Number Due to Expire in December 2025</link:label>
    <link:label id="lab_pfe_GainContingencyPatentsAllegedlyInfringeduponNumberDuetoExpireinDecember2025_0B96A89B6ACEAB111FEF9D7882957B89_documentation_en-US" xlink:label="lab_pfe_GainContingencyPatentsAllegedlyInfringeduponNumberDuetoExpireinDecember2025_0B96A89B6ACEAB111FEF9D7882957B89" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Gain Contingency, Patents Allegedly Infringed upon, Number Due to Expire in December 2025</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_GainContingencyPatentsAllegedlyInfringeduponNumberDuetoExpireinDecember2025" xlink:label="loc_pfe_GainContingencyPatentsAllegedlyInfringeduponNumberDuetoExpireinDecember2025_0B96A89B6ACEAB111FEF9D7882957B89" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_GainContingencyPatentsAllegedlyInfringeduponNumberDuetoExpireinDecember2025_0B96A89B6ACEAB111FEF9D7882957B89" xlink:to="lab_pfe_GainContingencyPatentsAllegedlyInfringeduponNumberDuetoExpireinDecember2025_0B96A89B6ACEAB111FEF9D7882957B89" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber_9FE15AC4E49F9D100D8E9D78829564EE_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber_9FE15AC4E49F9D100D8E9D78829564EE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of patents</link:label>
    <link:label id="lab_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber_9FE15AC4E49F9D100D8E9D78829564EE_label_en-US" xlink:label="lab_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber_9FE15AC4E49F9D100D8E9D78829564EE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Patents Allegedly Infringed, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LossContingencyPatentsAllegedlyInfringedNumber" xlink:label="loc_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber_9FE15AC4E49F9D100D8E9D78829564EE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber_9FE15AC4E49F9D100D8E9D78829564EE" xlink:to="lab_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber_9FE15AC4E49F9D100D8E9D78829564EE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_E3EE6BE707967467633D837D979D4D7E_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_E3EE6BE707967467633D837D979D4D7E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from External Customers by Products and Services [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_E3EE6BE707967467633D837D979D4D7E_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_E3EE6BE707967467633D837D979D4D7E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from External Customers by Products and Services [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_E3EE6BE707967467633D837D979D4D7E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_E3EE6BE707967467633D837D979D4D7E" xlink:to="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_E3EE6BE707967467633D837D979D4D7E" xlink:type="arc" />
    <link:label id="lab_pfe_InnovativeProductsCategoryAxis_52FA49BA4DE59A8C4A57837D979D10F5_terseLabel_en-US" xlink:label="lab_pfe_InnovativeProductsCategoryAxis_52FA49BA4DE59A8C4A57837D979D10F5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Innovative Products Category [Axis]</link:label>
    <link:label id="lab_pfe_InnovativeProductsCategoryAxis_52FA49BA4DE59A8C4A57837D979D10F5_label_en-US" xlink:label="lab_pfe_InnovativeProductsCategoryAxis_52FA49BA4DE59A8C4A57837D979D10F5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Innovative Products Category [Axis]</link:label>
    <link:label id="lab_pfe_InnovativeProductsCategoryAxis_52FA49BA4DE59A8C4A57837D979D10F5_documentation_en-US" xlink:label="lab_pfe_InnovativeProductsCategoryAxis_52FA49BA4DE59A8C4A57837D979D10F5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Innovative Products Category [Axis]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_InnovativeProductsCategoryAxis" xlink:label="loc_pfe_InnovativeProductsCategoryAxis_52FA49BA4DE59A8C4A57837D979D10F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_InnovativeProductsCategoryAxis_52FA49BA4DE59A8C4A57837D979D10F5" xlink:to="lab_pfe_InnovativeProductsCategoryAxis_52FA49BA4DE59A8C4A57837D979D10F5" xlink:type="arc" />
    <link:label id="lab_pfe_InnovativeProductsCategoryDomain_D0D0115D946D04174F3D837D979DA855_terseLabel_en-US" xlink:label="lab_pfe_InnovativeProductsCategoryDomain_D0D0115D946D04174F3D837D979DA855" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Innovative Products Category [Domain]</link:label>
    <link:label id="lab_pfe_InnovativeProductsCategoryDomain_D0D0115D946D04174F3D837D979DA855_label_en-US" xlink:label="lab_pfe_InnovativeProductsCategoryDomain_D0D0115D946D04174F3D837D979DA855" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Innovative Products Category [Domain]</link:label>
    <link:label id="lab_pfe_InnovativeProductsCategoryDomain_D0D0115D946D04174F3D837D979DA855_documentation_en-US" xlink:label="lab_pfe_InnovativeProductsCategoryDomain_D0D0115D946D04174F3D837D979DA855" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Domain] for Innovative Products Category [Axis]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_InnovativeProductsCategoryDomain" xlink:label="loc_pfe_InnovativeProductsCategoryDomain_D0D0115D946D04174F3D837D979DA855" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_InnovativeProductsCategoryDomain_D0D0115D946D04174F3D837D979DA855" xlink:to="lab_pfe_InnovativeProductsCategoryDomain_D0D0115D946D04174F3D837D979DA855" xlink:type="arc" />
    <link:label id="lab_pfe_InternalMedicineMember_D6FB61B88B0F74866E5A837D979ED4CB_terseLabel_en-US" xlink:label="lab_pfe_InternalMedicineMember_D6FB61B88B0F74866E5A837D979ED4CB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Internal Medicine [Member]</link:label>
    <link:label id="lab_pfe_InternalMedicineMember_D6FB61B88B0F74866E5A837D979ED4CB_label_en-US" xlink:label="lab_pfe_InternalMedicineMember_D6FB61B88B0F74866E5A837D979ED4CB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Internal Medicine [Member]</link:label>
    <link:label id="lab_pfe_InternalMedicineMember_D6FB61B88B0F74866E5A837D979ED4CB_documentation_en-US" xlink:label="lab_pfe_InternalMedicineMember_D6FB61B88B0F74866E5A837D979ED4CB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Internal Medicine [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_InternalMedicineMember" xlink:label="loc_pfe_InternalMedicineMember_D6FB61B88B0F74866E5A837D979ED4CB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_InternalMedicineMember_D6FB61B88B0F74866E5A837D979ED4CB" xlink:to="lab_pfe_InternalMedicineMember_D6FB61B88B0F74866E5A837D979ED4CB" xlink:type="arc" />
    <link:label id="lab_pfe_VaccinesMember_34FDFBF768EF05945F11837D979EEB5E_terseLabel_en-US" xlink:label="lab_pfe_VaccinesMember_34FDFBF768EF05945F11837D979EEB5E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vaccines [Member]</link:label>
    <link:label id="lab_pfe_VaccinesMember_34FDFBF768EF05945F11837D979EEB5E_label_en-US" xlink:label="lab_pfe_VaccinesMember_34FDFBF768EF05945F11837D979EEB5E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vaccines [Member]</link:label>
    <link:label id="lab_pfe_VaccinesMember_34FDFBF768EF05945F11837D979EEB5E_documentation_en-US" xlink:label="lab_pfe_VaccinesMember_34FDFBF768EF05945F11837D979EEB5E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Vaccines [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_VaccinesMember" xlink:label="loc_pfe_VaccinesMember_34FDFBF768EF05945F11837D979EEB5E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_VaccinesMember_34FDFBF768EF05945F11837D979EEB5E" xlink:to="lab_pfe_VaccinesMember_34FDFBF768EF05945F11837D979EEB5E" xlink:type="arc" />
    <link:label id="lab_pfe_OncologyMember_93FAF31B2880AAD022A5837D979E42D7_terseLabel_en-US" xlink:label="lab_pfe_OncologyMember_93FAF31B2880AAD022A5837D979E42D7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Oncology [Member]</link:label>
    <link:label id="lab_pfe_OncologyMember_93FAF31B2880AAD022A5837D979E42D7_label_en-US" xlink:label="lab_pfe_OncologyMember_93FAF31B2880AAD022A5837D979E42D7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Oncology [Member]</link:label>
    <link:label id="lab_pfe_OncologyMember_93FAF31B2880AAD022A5837D979E42D7_documentation_en-US" xlink:label="lab_pfe_OncologyMember_93FAF31B2880AAD022A5837D979E42D7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Oncology [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_OncologyMember" xlink:label="loc_pfe_OncologyMember_93FAF31B2880AAD022A5837D979E42D7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OncologyMember_93FAF31B2880AAD022A5837D979E42D7" xlink:to="lab_pfe_OncologyMember_93FAF31B2880AAD022A5837D979E42D7" xlink:type="arc" />
    <link:label id="lab_pfe_InflammationandImmunologyMember_9722DB42B891AC4D3D0D837D979EDA1D_terseLabel_en-US" xlink:label="lab_pfe_InflammationandImmunologyMember_9722DB42B891AC4D3D0D837D979EDA1D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inflammation and Immunology (I&amp;I) [Member]</link:label>
    <link:label id="lab_pfe_InflammationandImmunologyMember_9722DB42B891AC4D3D0D837D979EDA1D_label_en-US" xlink:label="lab_pfe_InflammationandImmunologyMember_9722DB42B891AC4D3D0D837D979EDA1D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inflammation and Immunology [Member]</link:label>
    <link:label id="lab_pfe_InflammationandImmunologyMember_9722DB42B891AC4D3D0D837D979EDA1D_documentation_en-US" xlink:label="lab_pfe_InflammationandImmunologyMember_9722DB42B891AC4D3D0D837D979EDA1D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Inflammation and Immunology [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_InflammationandImmunologyMember" xlink:label="loc_pfe_InflammationandImmunologyMember_9722DB42B891AC4D3D0D837D979EDA1D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_InflammationandImmunologyMember_9722DB42B891AC4D3D0D837D979EDA1D" xlink:to="lab_pfe_InflammationandImmunologyMember_9722DB42B891AC4D3D0D837D979EDA1D" xlink:type="arc" />
    <link:label id="lab_pfe_RareDiseaseMember_EA92F4BD3F3C4967A97F837D979E4462_terseLabel_en-US" xlink:label="lab_pfe_RareDiseaseMember_EA92F4BD3F3C4967A97F837D979E4462" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rare Disease [Member]</link:label>
    <link:label id="lab_pfe_RareDiseaseMember_EA92F4BD3F3C4967A97F837D979E4462_label_en-US" xlink:label="lab_pfe_RareDiseaseMember_EA92F4BD3F3C4967A97F837D979E4462" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rare Disease [Member]</link:label>
    <link:label id="lab_pfe_RareDiseaseMember_EA92F4BD3F3C4967A97F837D979E4462_documentation_en-US" xlink:label="lab_pfe_RareDiseaseMember_EA92F4BD3F3C4967A97F837D979E4462" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Rare Disease [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_RareDiseaseMember" xlink:label="loc_pfe_RareDiseaseMember_EA92F4BD3F3C4967A97F837D979E4462" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_RareDiseaseMember_EA92F4BD3F3C4967A97F837D979E4462" xlink:to="lab_pfe_RareDiseaseMember_EA92F4BD3F3C4967A97F837D979E4462" xlink:type="arc" />
    <link:label id="lab_pfe_ConsumerHealthcareMember_8CF5C28F6D005CD18348837D979EC785_terseLabel_en-US" xlink:label="lab_pfe_ConsumerHealthcareMember_8CF5C28F6D005CD18348837D979EC785" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consumer Healthcare [Member]</link:label>
    <link:label id="lab_pfe_ConsumerHealthcareMember_8CF5C28F6D005CD18348837D979EC785_label_en-US" xlink:label="lab_pfe_ConsumerHealthcareMember_8CF5C28F6D005CD18348837D979EC785" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consumer Healthcare [Member]</link:label>
    <link:label id="lab_pfe_ConsumerHealthcareMember_8CF5C28F6D005CD18348837D979EC785_documentation_en-US" xlink:label="lab_pfe_ConsumerHealthcareMember_8CF5C28F6D005CD18348837D979EC785" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Consumer Healthcare [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_ConsumerHealthcareMember" xlink:label="loc_pfe_ConsumerHealthcareMember_8CF5C28F6D005CD18348837D979EC785" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ConsumerHealthcareMember_8CF5C28F6D005CD18348837D979EC785" xlink:to="lab_pfe_ConsumerHealthcareMember_8CF5C28F6D005CD18348837D979EC785" xlink:type="arc" />
    <link:label id="lab_pfe_EssentialHealthProductCategoryAxis_99AAE0FF10784A8F437D837D979EF396_terseLabel_en-US" xlink:label="lab_pfe_EssentialHealthProductCategoryAxis_99AAE0FF10784A8F437D837D979EF396" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Essential Health Product Category [Axis]</link:label>
    <link:label id="lab_pfe_EssentialHealthProductCategoryAxis_99AAE0FF10784A8F437D837D979EF396_label_en-US" xlink:label="lab_pfe_EssentialHealthProductCategoryAxis_99AAE0FF10784A8F437D837D979EF396" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Essential Health Product Category [Axis]</link:label>
    <link:label id="lab_pfe_EssentialHealthProductCategoryAxis_99AAE0FF10784A8F437D837D979EF396_documentation_en-US" xlink:label="lab_pfe_EssentialHealthProductCategoryAxis_99AAE0FF10784A8F437D837D979EF396" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Essential Health Product Category [Axis]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_EssentialHealthProductCategoryAxis" xlink:label="loc_pfe_EssentialHealthProductCategoryAxis_99AAE0FF10784A8F437D837D979EF396" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_EssentialHealthProductCategoryAxis_99AAE0FF10784A8F437D837D979EF396" xlink:to="lab_pfe_EssentialHealthProductCategoryAxis_99AAE0FF10784A8F437D837D979EF396" xlink:type="arc" />
    <link:label id="lab_pfe_EssentialHealthProductCategoryDomain_5DCDEFF8A9AF1727C906837D979E0765_terseLabel_en-US" xlink:label="lab_pfe_EssentialHealthProductCategoryDomain_5DCDEFF8A9AF1727C906837D979E0765" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Essential Health Product Category [Domain]</link:label>
    <link:label id="lab_pfe_EssentialHealthProductCategoryDomain_5DCDEFF8A9AF1727C906837D979E0765_label_en-US" xlink:label="lab_pfe_EssentialHealthProductCategoryDomain_5DCDEFF8A9AF1727C906837D979E0765" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Essential Health Product Category [Domain]</link:label>
    <link:label id="lab_pfe_EssentialHealthProductCategoryDomain_5DCDEFF8A9AF1727C906837D979E0765_documentation_en-US" xlink:label="lab_pfe_EssentialHealthProductCategoryDomain_5DCDEFF8A9AF1727C906837D979E0765" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Domain] for Essential Health Product Category [Axis]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_EssentialHealthProductCategoryDomain" xlink:label="loc_pfe_EssentialHealthProductCategoryDomain_5DCDEFF8A9AF1727C906837D979E0765" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_EssentialHealthProductCategoryDomain_5DCDEFF8A9AF1727C906837D979E0765" xlink:to="lab_pfe_EssentialHealthProductCategoryDomain_5DCDEFF8A9AF1727C906837D979E0765" xlink:type="arc" />
    <link:label id="lab_pfe_LegacyEstablishedProductsMember_1400758F8D6D372C6365837D979E5E20_terseLabel_en-US" xlink:label="lab_pfe_LegacyEstablishedProductsMember_1400758F8D6D372C6365837D979E5E20" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legacy Established Products (LEP) [Member]</link:label>
    <link:label id="lab_pfe_LegacyEstablishedProductsMember_1400758F8D6D372C6365837D979E5E20_label_en-US" xlink:label="lab_pfe_LegacyEstablishedProductsMember_1400758F8D6D372C6365837D979E5E20" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legacy Established Products [Member]</link:label>
    <link:label id="lab_pfe_LegacyEstablishedProductsMember_1400758F8D6D372C6365837D979E5E20_documentation_en-US" xlink:label="lab_pfe_LegacyEstablishedProductsMember_1400758F8D6D372C6365837D979E5E20" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Legacy Established Products</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_LegacyEstablishedProductsMember" xlink:label="loc_pfe_LegacyEstablishedProductsMember_1400758F8D6D372C6365837D979E5E20" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_LegacyEstablishedProductsMember_1400758F8D6D372C6365837D979E5E20" xlink:to="lab_pfe_LegacyEstablishedProductsMember_1400758F8D6D372C6365837D979E5E20" xlink:type="arc" />
    <link:label id="lab_pfe_SterileInjectablePharmaceuticalsMember_636802574FC93027119D837D979E4E91_terseLabel_en-US" xlink:label="lab_pfe_SterileInjectablePharmaceuticalsMember_636802574FC93027119D837D979E4E91" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sterile Injectable Pharmaceuticals [Member]</link:label>
    <link:label id="lab_pfe_SterileInjectablePharmaceuticalsMember_636802574FC93027119D837D979E4E91_label_en-US" xlink:label="lab_pfe_SterileInjectablePharmaceuticalsMember_636802574FC93027119D837D979E4E91" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sterile Injectable Pharmaceuticals [Member]</link:label>
    <link:label id="lab_pfe_SterileInjectablePharmaceuticalsMember_636802574FC93027119D837D979E4E91_documentation_en-US" xlink:label="lab_pfe_SterileInjectablePharmaceuticalsMember_636802574FC93027119D837D979E4E91" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sterile Injectable Pharmaceuticals [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_SterileInjectablePharmaceuticalsMember" xlink:label="loc_pfe_SterileInjectablePharmaceuticalsMember_636802574FC93027119D837D979E4E91" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SterileInjectablePharmaceuticalsMember_636802574FC93027119D837D979E4E91" xlink:to="lab_pfe_SterileInjectablePharmaceuticalsMember_636802574FC93027119D837D979E4E91" xlink:type="arc" />
    <link:label id="lab_pfe_PeriLOEProductsMember_3428E82FEB4C7931EA2E837D979E8954_terseLabel_en-US" xlink:label="lab_pfe_PeriLOEProductsMember_3428E82FEB4C7931EA2E837D979E8954" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peri-LOE Products [Member]</link:label>
    <link:label id="lab_pfe_PeriLOEProductsMember_3428E82FEB4C7931EA2E837D979E8954_label_en-US" xlink:label="lab_pfe_PeriLOEProductsMember_3428E82FEB4C7931EA2E837D979E8954" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peri-LOE Products [Member]</link:label>
    <link:label id="lab_pfe_PeriLOEProductsMember_3428E82FEB4C7931EA2E837D979E8954_documentation_en-US" xlink:label="lab_pfe_PeriLOEProductsMember_3428E82FEB4C7931EA2E837D979E8954" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Peri-LOE Products</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_PeriLOEProductsMember" xlink:label="loc_pfe_PeriLOEProductsMember_3428E82FEB4C7931EA2E837D979E8954" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_PeriLOEProductsMember_3428E82FEB4C7931EA2E837D979E8954" xlink:to="lab_pfe_PeriLOEProductsMember_3428E82FEB4C7931EA2E837D979E8954" xlink:type="arc" />
    <link:label id="lab_pfe_BiosimilarsMember_678FD5D22799BD321F49837D979E1588_terseLabel_en-US" xlink:label="lab_pfe_BiosimilarsMember_678FD5D22799BD321F49837D979E1588" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Biosimilars [Member]</link:label>
    <link:label id="lab_pfe_BiosimilarsMember_678FD5D22799BD321F49837D979E1588_label_en-US" xlink:label="lab_pfe_BiosimilarsMember_678FD5D22799BD321F49837D979E1588" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Biosimilars [Member]</link:label>
    <link:label id="lab_pfe_BiosimilarsMember_678FD5D22799BD321F49837D979E1588_documentation_en-US" xlink:label="lab_pfe_BiosimilarsMember_678FD5D22799BD321F49837D979E1588" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Biosimilars [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_BiosimilarsMember" xlink:label="loc_pfe_BiosimilarsMember_678FD5D22799BD321F49837D979E1588" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_BiosimilarsMember_678FD5D22799BD321F49837D979E1588" xlink:to="lab_pfe_BiosimilarsMember_678FD5D22799BD321F49837D979E1588" xlink:type="arc" />
    <link:label id="lab_pfe_CentreOneMember_9E3014BDCE242D46ED94837D979E250C_terseLabel_en-US" xlink:label="lab_pfe_CentreOneMember_9E3014BDCE242D46ED94837D979E250C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CentreOne [Member]</link:label>
    <link:label id="lab_pfe_CentreOneMember_9E3014BDCE242D46ED94837D979E250C_label_en-US" xlink:label="lab_pfe_CentreOneMember_9E3014BDCE242D46ED94837D979E250C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CentreOne [Member]</link:label>
    <link:label id="lab_pfe_CentreOneMember_9E3014BDCE242D46ED94837D979E250C_documentation_en-US" xlink:label="lab_pfe_CentreOneMember_9E3014BDCE242D46ED94837D979E250C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">CentreOne [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_CentreOneMember" xlink:label="loc_pfe_CentreOneMember_9E3014BDCE242D46ED94837D979E250C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_CentreOneMember_9E3014BDCE242D46ED94837D979E250C" xlink:to="lab_pfe_CentreOneMember_9E3014BDCE242D46ED94837D979E250C" xlink:type="arc" />
    <link:label id="lab_pfe_HospiraInfusionSystemsMember_A94B6464CE6C8A440DD7837D979EF1D8_terseLabel_en-US" xlink:label="lab_pfe_HospiraInfusionSystemsMember_A94B6464CE6C8A440DD7837D979EF1D8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hospira Infusion Systems (HIS) [Member]</link:label>
    <link:label id="lab_pfe_HospiraInfusionSystemsMember_A94B6464CE6C8A440DD7837D979EF1D8_label_en-US" xlink:label="lab_pfe_HospiraInfusionSystemsMember_A94B6464CE6C8A440DD7837D979EF1D8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hospira Infusion Systems [Member]</link:label>
    <link:label id="lab_pfe_HospiraInfusionSystemsMember_A94B6464CE6C8A440DD7837D979EF1D8_documentation_en-US" xlink:label="lab_pfe_HospiraInfusionSystemsMember_A94B6464CE6C8A440DD7837D979EF1D8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Hospira Infusion Systems [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_HospiraInfusionSystemsMember" xlink:label="loc_pfe_HospiraInfusionSystemsMember_A94B6464CE6C8A440DD7837D979EF1D8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_HospiraInfusionSystemsMember_A94B6464CE6C8A440DD7837D979EF1D8" xlink:to="lab_pfe_HospiraInfusionSystemsMember_A94B6464CE6C8A440DD7837D979EF1D8" xlink:type="arc" />
    <link:label id="lab_pfe_DistinctBusinessAxis_830BC2ACF2D8F49898E6837D979E7D04_terseLabel_en-US" xlink:label="lab_pfe_DistinctBusinessAxis_830BC2ACF2D8F49898E6837D979E7D04" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Distinct Business [Axis]</link:label>
    <link:label id="lab_pfe_DistinctBusinessAxis_830BC2ACF2D8F49898E6837D979E7D04_label_en-US" xlink:label="lab_pfe_DistinctBusinessAxis_830BC2ACF2D8F49898E6837D979E7D04" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Distinct Business [Axis]</link:label>
    <link:label id="lab_pfe_DistinctBusinessAxis_830BC2ACF2D8F49898E6837D979E7D04_documentation_en-US" xlink:label="lab_pfe_DistinctBusinessAxis_830BC2ACF2D8F49898E6837D979E7D04" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Distinct Business [Axis]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_DistinctBusinessAxis" xlink:label="loc_pfe_DistinctBusinessAxis_830BC2ACF2D8F49898E6837D979E7D04" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DistinctBusinessAxis_830BC2ACF2D8F49898E6837D979E7D04" xlink:to="lab_pfe_DistinctBusinessAxis_830BC2ACF2D8F49898E6837D979E7D04" xlink:type="arc" />
    <link:label id="lab_pfe_DistinctBusinessDomain_3DCBFF55E5B51536689B837D979EC700_terseLabel_en-US" xlink:label="lab_pfe_DistinctBusinessDomain_3DCBFF55E5B51536689B837D979EC700" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Distinct Business [Domain]</link:label>
    <link:label id="lab_pfe_DistinctBusinessDomain_3DCBFF55E5B51536689B837D979EC700_label_en-US" xlink:label="lab_pfe_DistinctBusinessDomain_3DCBFF55E5B51536689B837D979EC700" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Distinct Business [Domain]</link:label>
    <link:label id="lab_pfe_DistinctBusinessDomain_3DCBFF55E5B51536689B837D979EC700_documentation_en-US" xlink:label="lab_pfe_DistinctBusinessDomain_3DCBFF55E5B51536689B837D979EC700" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Domain] for Distinct Business [Axis]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_DistinctBusinessDomain" xlink:label="loc_pfe_DistinctBusinessDomain_3DCBFF55E5B51536689B837D979EC700" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DistinctBusinessDomain_3DCBFF55E5B51536689B837D979EC700" xlink:to="lab_pfe_DistinctBusinessDomain_3DCBFF55E5B51536689B837D979EC700" xlink:type="arc" />
    <link:label id="lab_pfe_InnovativeHealthBusinessMember_AE5C91574ACFF5123399837D979E8268_terseLabel_en-US" xlink:label="lab_pfe_InnovativeHealthBusinessMember_AE5C91574ACFF5123399837D979E8268" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Innovative Health Business [Member]</link:label>
    <link:label id="lab_pfe_InnovativeHealthBusinessMember_AE5C91574ACFF5123399837D979E8268_label_en-US" xlink:label="lab_pfe_InnovativeHealthBusinessMember_AE5C91574ACFF5123399837D979E8268" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Innovative Health Business [Member]</link:label>
    <link:label id="lab_pfe_InnovativeHealthBusinessMember_AE5C91574ACFF5123399837D979E8268_documentation_en-US" xlink:label="lab_pfe_InnovativeHealthBusinessMember_AE5C91574ACFF5123399837D979E8268" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Innovative Health Business [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_InnovativeHealthBusinessMember" xlink:label="loc_pfe_InnovativeHealthBusinessMember_AE5C91574ACFF5123399837D979E8268" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_InnovativeHealthBusinessMember_AE5C91574ACFF5123399837D979E8268" xlink:to="lab_pfe_InnovativeHealthBusinessMember_AE5C91574ACFF5123399837D979E8268" xlink:type="arc" />
    <link:label id="lab_pfe_EssentialHealthBusinessMember_D2EDB3E9B57286ECF857837D979EDD1B_terseLabel_en-US" xlink:label="lab_pfe_EssentialHealthBusinessMember_D2EDB3E9B57286ECF857837D979EDD1B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Essential Health Business [Member]</link:label>
    <link:label id="lab_pfe_EssentialHealthBusinessMember_D2EDB3E9B57286ECF857837D979EDD1B_label_en-US" xlink:label="lab_pfe_EssentialHealthBusinessMember_D2EDB3E9B57286ECF857837D979EDD1B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Essential Health Business [Member]</link:label>
    <link:label id="lab_pfe_EssentialHealthBusinessMember_D2EDB3E9B57286ECF857837D979EDD1B_documentation_en-US" xlink:label="lab_pfe_EssentialHealthBusinessMember_D2EDB3E9B57286ECF857837D979EDD1B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Essential Health Business [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_EssentialHealthBusinessMember" xlink:label="loc_pfe_EssentialHealthBusinessMember_D2EDB3E9B57286ECF857837D979EDD1B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_EssentialHealthBusinessMember_D2EDB3E9B57286ECF857837D979EDD1B" xlink:to="lab_pfe_EssentialHealthBusinessMember_D2EDB3E9B57286ECF857837D979EDD1B" xlink:type="arc" />
    <link:label id="lab_pfe_InnovativeHealthandEssentialHealthMember_4625026C6F2577C06CB4837D979FB6C1_terseLabel_en-US" xlink:label="lab_pfe_InnovativeHealthandEssentialHealthMember_4625026C6F2577C06CB4837D979FB6C1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Innovative Health and Essential Health [Member]</link:label>
    <link:label id="lab_pfe_InnovativeHealthandEssentialHealthMember_4625026C6F2577C06CB4837D979FB6C1_label_en-US" xlink:label="lab_pfe_InnovativeHealthandEssentialHealthMember_4625026C6F2577C06CB4837D979FB6C1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Innovative Health and Essential Health [Member]</link:label>
    <link:label id="lab_pfe_InnovativeHealthandEssentialHealthMember_4625026C6F2577C06CB4837D979FB6C1_documentation_en-US" xlink:label="lab_pfe_InnovativeHealthandEssentialHealthMember_4625026C6F2577C06CB4837D979FB6C1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Innovative Health and Essential Health [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_InnovativeHealthandEssentialHealthMember" xlink:label="loc_pfe_InnovativeHealthandEssentialHealthMember_4625026C6F2577C06CB4837D979FB6C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_InnovativeHealthandEssentialHealthMember_4625026C6F2577C06CB4837D979FB6C1" xlink:to="lab_pfe_InnovativeHealthandEssentialHealthMember_4625026C6F2577C06CB4837D979FB6C1" xlink:type="arc" />
    <link:label id="lab_pfe_LyricaMember_3F80DA0DEEB015126090837D979F96FD_terseLabel_en-US" xlink:label="lab_pfe_LyricaMember_3F80DA0DEEB015126090837D979F96FD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lyrica [Member]</link:label>
    <link:label id="lab_pfe_LyricaMember_3F80DA0DEEB015126090837D979F96FD_label_en-US" xlink:label="lab_pfe_LyricaMember_3F80DA0DEEB015126090837D979F96FD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lyrica [Member]</link:label>
    <link:label id="lab_pfe_LyricaMember_3F80DA0DEEB015126090837D979F96FD_documentation_en-US" xlink:label="lab_pfe_LyricaMember_3F80DA0DEEB015126090837D979F96FD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lyrica [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_LyricaMember" xlink:label="loc_pfe_LyricaMember_3F80DA0DEEB015126090837D979F96FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_LyricaMember_3F80DA0DEEB015126090837D979F96FD" xlink:to="lab_pfe_LyricaMember_3F80DA0DEEB015126090837D979F96FD" xlink:type="arc" />
    <link:label id="lab_pfe_ChantixChampixMember_76314B1F59C73D27CC7A837D979FEF43_terseLabel_en-US" xlink:label="lab_pfe_ChantixChampixMember_76314B1F59C73D27CC7A837D979FEF43" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Chantix / Champix [Member]</link:label>
    <link:label id="lab_pfe_ChantixChampixMember_76314B1F59C73D27CC7A837D979FEF43_label_en-US" xlink:label="lab_pfe_ChantixChampixMember_76314B1F59C73D27CC7A837D979FEF43" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Chantix Champix [Member]</link:label>
    <link:label id="lab_pfe_ChantixChampixMember_76314B1F59C73D27CC7A837D979FEF43_documentation_en-US" xlink:label="lab_pfe_ChantixChampixMember_76314B1F59C73D27CC7A837D979FEF43" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Chantix / Champix [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_ChantixChampixMember" xlink:label="loc_pfe_ChantixChampixMember_76314B1F59C73D27CC7A837D979FEF43" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ChantixChampixMember_76314B1F59C73D27CC7A837D979FEF43" xlink:to="lab_pfe_ChantixChampixMember_76314B1F59C73D27CC7A837D979FEF43" xlink:type="arc" />
    <link:label id="lab_pfe_ViagraMember_80E53BBAC83FE9EFF2BB837D979F22A8_terseLabel_en-US" xlink:label="lab_pfe_ViagraMember_80E53BBAC83FE9EFF2BB837D979F22A8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Viagra [Member]</link:label>
    <link:label id="lab_pfe_ViagraMember_80E53BBAC83FE9EFF2BB837D979F22A8_label_en-US" xlink:label="lab_pfe_ViagraMember_80E53BBAC83FE9EFF2BB837D979F22A8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Viagra [Member]</link:label>
    <link:label id="lab_pfe_ViagraMember_80E53BBAC83FE9EFF2BB837D979F22A8_documentation_en-US" xlink:label="lab_pfe_ViagraMember_80E53BBAC83FE9EFF2BB837D979F22A8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Viagra [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_ViagraMember" xlink:label="loc_pfe_ViagraMember_80E53BBAC83FE9EFF2BB837D979F22A8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ViagraMember_80E53BBAC83FE9EFF2BB837D979F22A8" xlink:to="lab_pfe_ViagraMember_80E53BBAC83FE9EFF2BB837D979F22A8" xlink:type="arc" />
    <link:label id="lab_pfe_BMP2Member_5C217DA55C12A1F0659E837D979FAA91_terseLabel_en-US" xlink:label="lab_pfe_BMP2Member_5C217DA55C12A1F0659E837D979FAA91" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">B M P 2 [Member]</link:label>
    <link:label id="lab_pfe_BMP2Member_5C217DA55C12A1F0659E837D979FAA91_label_en-US" xlink:label="lab_pfe_BMP2Member_5C217DA55C12A1F0659E837D979FAA91" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">B M P 2 [Member]</link:label>
    <link:label id="lab_pfe_BMP2Member_5C217DA55C12A1F0659E837D979FAA91_documentation_en-US" xlink:label="lab_pfe_BMP2Member_5C217DA55C12A1F0659E837D979FAA91" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">B M P 2 [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_BMP2Member" xlink:label="loc_pfe_BMP2Member_5C217DA55C12A1F0659E837D979FAA91" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_BMP2Member_5C217DA55C12A1F0659E837D979FAA91" xlink:to="lab_pfe_BMP2Member_5C217DA55C12A1F0659E837D979FAA91" xlink:type="arc" />
    <link:label id="lab_pfe_AllOtherInternalMedicineMember_95ED1FE94C32163CB3FA837D979FB284_terseLabel_en-US" xlink:label="lab_pfe_AllOtherInternalMedicineMember_95ED1FE94C32163CB3FA837D979FB284" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Other Internal Medicine [Member]</link:label>
    <link:label id="lab_pfe_AllOtherInternalMedicineMember_95ED1FE94C32163CB3FA837D979FB284_label_en-US" xlink:label="lab_pfe_AllOtherInternalMedicineMember_95ED1FE94C32163CB3FA837D979FB284" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Other Internal Medicine [Member]</link:label>
    <link:label id="lab_pfe_AllOtherInternalMedicineMember_95ED1FE94C32163CB3FA837D979FB284_documentation_en-US" xlink:label="lab_pfe_AllOtherInternalMedicineMember_95ED1FE94C32163CB3FA837D979FB284" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">All Other Internal Medicine [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_AllOtherInternalMedicineMember" xlink:label="loc_pfe_AllOtherInternalMedicineMember_95ED1FE94C32163CB3FA837D979FB284" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_AllOtherInternalMedicineMember_95ED1FE94C32163CB3FA837D979FB284" xlink:to="lab_pfe_AllOtherInternalMedicineMember_95ED1FE94C32163CB3FA837D979FB284" xlink:type="arc" />
    <link:label id="lab_pfe_PrevnarPrevenarFamilyMember_A8707CF8A10065A53BBA837D979F3540_terseLabel_en-US" xlink:label="lab_pfe_PrevnarPrevenarFamilyMember_A8707CF8A10065A53BBA837D979F3540" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prevnar 13/Prevenar 13 [Member]</link:label>
    <link:label id="lab_pfe_PrevnarPrevenarFamilyMember_A8707CF8A10065A53BBA837D979F3540_label_en-US" xlink:label="lab_pfe_PrevnarPrevenarFamilyMember_A8707CF8A10065A53BBA837D979F3540" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prevnar Prevenar Family [Member]</link:label>
    <link:label id="lab_pfe_PrevnarPrevenarFamilyMember_A8707CF8A10065A53BBA837D979F3540_documentation_en-US" xlink:label="lab_pfe_PrevnarPrevenarFamilyMember_A8707CF8A10065A53BBA837D979F3540" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Prevnar/Prevenar Family 13 [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_PrevnarPrevenarFamilyMember" xlink:label="loc_pfe_PrevnarPrevenarFamilyMember_A8707CF8A10065A53BBA837D979F3540" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_PrevnarPrevenarFamilyMember_A8707CF8A10065A53BBA837D979F3540" xlink:to="lab_pfe_PrevnarPrevenarFamilyMember_A8707CF8A10065A53BBA837D979F3540" xlink:type="arc" />
    <link:label id="lab_pfe_FSMEIMMUNTicoVacMember_CCE4686B46E6F4D8433F837D979F96C8_terseLabel_en-US" xlink:label="lab_pfe_FSMEIMMUNTicoVacMember_CCE4686B46E6F4D8433F837D979F96C8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">FSME-IMMUN/TicoVac [Member]</link:label>
    <link:label id="lab_pfe_FSMEIMMUNTicoVacMember_CCE4686B46E6F4D8433F837D979F96C8_label_en-US" xlink:label="lab_pfe_FSMEIMMUNTicoVacMember_CCE4686B46E6F4D8433F837D979F96C8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">FSME-IMMUN/TicoVac [Member]</link:label>
    <link:label id="lab_pfe_FSMEIMMUNTicoVacMember_CCE4686B46E6F4D8433F837D979F96C8_documentation_en-US" xlink:label="lab_pfe_FSMEIMMUNTicoVacMember_CCE4686B46E6F4D8433F837D979F96C8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">FSME-IMMUN/TicoVac [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_FSMEIMMUNTicoVacMember" xlink:label="loc_pfe_FSMEIMMUNTicoVacMember_CCE4686B46E6F4D8433F837D979F96C8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_FSMEIMMUNTicoVacMember_CCE4686B46E6F4D8433F837D979F96C8" xlink:to="lab_pfe_FSMEIMMUNTicoVacMember_CCE4686B46E6F4D8433F837D979F96C8" xlink:type="arc" />
    <link:label id="lab_pfe_OtherVaccinesProductsMember_365902889FCB939503D1837D979FFA35_terseLabel_en-US" xlink:label="lab_pfe_OtherVaccinesProductsMember_365902889FCB939503D1837D979FFA35" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All other Vaccines [Member]</link:label>
    <link:label id="lab_pfe_OtherVaccinesProductsMember_365902889FCB939503D1837D979FFA35_label_en-US" xlink:label="lab_pfe_OtherVaccinesProductsMember_365902889FCB939503D1837D979FFA35" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Vaccines Products [Member]</link:label>
    <link:label id="lab_pfe_OtherVaccinesProductsMember_365902889FCB939503D1837D979FFA35_documentation_en-US" xlink:label="lab_pfe_OtherVaccinesProductsMember_365902889FCB939503D1837D979FFA35" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Vaccines Products [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_OtherVaccinesProductsMember" xlink:label="loc_pfe_OtherVaccinesProductsMember_365902889FCB939503D1837D979FFA35" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherVaccinesProductsMember_365902889FCB939503D1837D979FFA35" xlink:to="lab_pfe_OtherVaccinesProductsMember_365902889FCB939503D1837D979FFA35" xlink:type="arc" />
    <link:label id="lab_pfe_IbranceMember_D15486EA1C1C081FA981837D979FFE36_terseLabel_en-US" xlink:label="lab_pfe_IbranceMember_D15486EA1C1C081FA981837D979FFE36" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ibrance [Member]</link:label>
    <link:label id="lab_pfe_IbranceMember_D15486EA1C1C081FA981837D979FFE36_label_en-US" xlink:label="lab_pfe_IbranceMember_D15486EA1C1C081FA981837D979FFE36" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ibrance [Member]</link:label>
    <link:label id="lab_pfe_IbranceMember_D15486EA1C1C081FA981837D979FFE36_documentation_en-US" xlink:label="lab_pfe_IbranceMember_D15486EA1C1C081FA981837D979FFE36" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Ibrance [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_IbranceMember" xlink:label="loc_pfe_IbranceMember_D15486EA1C1C081FA981837D979FFE36" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_IbranceMember_D15486EA1C1C081FA981837D979FFE36" xlink:to="lab_pfe_IbranceMember_D15486EA1C1C081FA981837D979FFE36" xlink:type="arc" />
    <link:label id="lab_pfe_SutentMember_5A74E63E49E4A1937E86837D979F1679_terseLabel_en-US" xlink:label="lab_pfe_SutentMember_5A74E63E49E4A1937E86837D979F1679" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sutent [Member]</link:label>
    <link:label id="lab_pfe_SutentMember_5A74E63E49E4A1937E86837D979F1679_label_en-US" xlink:label="lab_pfe_SutentMember_5A74E63E49E4A1937E86837D979F1679" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sutent [Member]</link:label>
    <link:label id="lab_pfe_SutentMember_5A74E63E49E4A1937E86837D979F1679_documentation_en-US" xlink:label="lab_pfe_SutentMember_5A74E63E49E4A1937E86837D979F1679" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sutent [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_SutentMember" xlink:label="loc_pfe_SutentMember_5A74E63E49E4A1937E86837D979F1679" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SutentMember_5A74E63E49E4A1937E86837D979F1679" xlink:to="lab_pfe_SutentMember_5A74E63E49E4A1937E86837D979F1679" xlink:type="arc" />
    <link:label id="lab_pfe_XalkoriMember_837266581BACED4AE126837D979F058B_terseLabel_en-US" xlink:label="lab_pfe_XalkoriMember_837266581BACED4AE126837D979F058B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Xalkori [Member]</link:label>
    <link:label id="lab_pfe_XalkoriMember_837266581BACED4AE126837D979F058B_label_en-US" xlink:label="lab_pfe_XalkoriMember_837266581BACED4AE126837D979F058B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Xalkori [Member]</link:label>
    <link:label id="lab_pfe_XalkoriMember_837266581BACED4AE126837D979F058B_documentation_en-US" xlink:label="lab_pfe_XalkoriMember_837266581BACED4AE126837D979F058B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Xalkori [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_XalkoriMember" xlink:label="loc_pfe_XalkoriMember_837266581BACED4AE126837D979F058B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_XalkoriMember_837266581BACED4AE126837D979F058B" xlink:to="lab_pfe_XalkoriMember_837266581BACED4AE126837D979F058B" xlink:type="arc" />
    <link:label id="lab_pfe_XtandiAllianceMember_9A86FE90CC1B6E14008C837D979F6125_terseLabel_en-US" xlink:label="lab_pfe_XtandiAllianceMember_9A86FE90CC1B6E14008C837D979F6125" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Xtandi Alliance [Member]</link:label>
    <link:label id="lab_pfe_XtandiAllianceMember_9A86FE90CC1B6E14008C837D979F6125_label_en-US" xlink:label="lab_pfe_XtandiAllianceMember_9A86FE90CC1B6E14008C837D979F6125" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Xtandi Alliance [Member]</link:label>
    <link:label id="lab_pfe_XtandiAllianceMember_9A86FE90CC1B6E14008C837D979F6125_documentation_en-US" xlink:label="lab_pfe_XtandiAllianceMember_9A86FE90CC1B6E14008C837D979F6125" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Xtandi Alliance [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_XtandiAllianceMember" xlink:label="loc_pfe_XtandiAllianceMember_9A86FE90CC1B6E14008C837D979F6125" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_XtandiAllianceMember_9A86FE90CC1B6E14008C837D979F6125" xlink:to="lab_pfe_XtandiAllianceMember_9A86FE90CC1B6E14008C837D979F6125" xlink:type="arc" />
    <link:label id="lab_pfe_InlytaMember_54B81A946661C3B03897837D97A0045A_terseLabel_en-US" xlink:label="lab_pfe_InlytaMember_54B81A946661C3B03897837D97A0045A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inlyta [Member]</link:label>
    <link:label id="lab_pfe_InlytaMember_54B81A946661C3B03897837D97A0045A_label_en-US" xlink:label="lab_pfe_InlytaMember_54B81A946661C3B03897837D97A0045A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inlyta [Member]</link:label>
    <link:label id="lab_pfe_InlytaMember_54B81A946661C3B03897837D97A0045A_documentation_en-US" xlink:label="lab_pfe_InlytaMember_54B81A946661C3B03897837D97A0045A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Inlyta [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_InlytaMember" xlink:label="loc_pfe_InlytaMember_54B81A946661C3B03897837D97A0045A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_InlytaMember_54B81A946661C3B03897837D97A0045A" xlink:to="lab_pfe_InlytaMember_54B81A946661C3B03897837D97A0045A" xlink:type="arc" />
    <link:label id="lab_pfe_OtherOncologyProductsMember_C1AA8C32D33C1E4B220D837D97A0D8D0_terseLabel_en-US" xlink:label="lab_pfe_OtherOncologyProductsMember_C1AA8C32D33C1E4B220D837D97A0D8D0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All other Oncology [Member]</link:label>
    <link:label id="lab_pfe_OtherOncologyProductsMember_C1AA8C32D33C1E4B220D837D97A0D8D0_label_en-US" xlink:label="lab_pfe_OtherOncologyProductsMember_C1AA8C32D33C1E4B220D837D97A0D8D0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Oncology Products [Member]</link:label>
    <link:label id="lab_pfe_OtherOncologyProductsMember_C1AA8C32D33C1E4B220D837D97A0D8D0_documentation_en-US" xlink:label="lab_pfe_OtherOncologyProductsMember_C1AA8C32D33C1E4B220D837D97A0D8D0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Oncology Products [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_OtherOncologyProductsMember" xlink:label="loc_pfe_OtherOncologyProductsMember_C1AA8C32D33C1E4B220D837D97A0D8D0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherOncologyProductsMember_C1AA8C32D33C1E4B220D837D97A0D8D0" xlink:to="lab_pfe_OtherOncologyProductsMember_C1AA8C32D33C1E4B220D837D97A0D8D0" xlink:type="arc" />
    <link:label id="lab_pfe_EnbrelMember_BCEEA70944AB1CAE1374837D97A0B06A_verboseLabel_en-US" xlink:label="lab_pfe_EnbrelMember_BCEEA70944AB1CAE1374837D97A0B06A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Enbrel (Outside the U.S. and Canada) [Member]</link:label>
    <link:label id="lab_pfe_EnbrelMember_BCEEA70944AB1CAE1374837D97A0B06A_label_en-US" xlink:label="lab_pfe_EnbrelMember_BCEEA70944AB1CAE1374837D97A0B06A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Enbrel [Member]</link:label>
    <link:label id="lab_pfe_EnbrelMember_BCEEA70944AB1CAE1374837D97A0B06A_documentation_en-US" xlink:label="lab_pfe_EnbrelMember_BCEEA70944AB1CAE1374837D97A0B06A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Enbrel [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_EnbrelMember" xlink:label="loc_pfe_EnbrelMember_BCEEA70944AB1CAE1374837D97A0B06A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_EnbrelMember_BCEEA70944AB1CAE1374837D97A0B06A" xlink:to="lab_pfe_EnbrelMember_BCEEA70944AB1CAE1374837D97A0B06A" xlink:type="arc" />
    <link:label id="lab_pfe_EucrisaMember_EE95A03D351953062449837D97A05B28_terseLabel_en-US" xlink:label="lab_pfe_EucrisaMember_EE95A03D351953062449837D97A05B28" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Eucrisa [Member]</link:label>
    <link:label id="lab_pfe_EucrisaMember_EE95A03D351953062449837D97A05B28_label_en-US" xlink:label="lab_pfe_EucrisaMember_EE95A03D351953062449837D97A05B28" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Eucrisa [Member]</link:label>
    <link:label id="lab_pfe_EucrisaMember_EE95A03D351953062449837D97A05B28_documentation_en-US" xlink:label="lab_pfe_EucrisaMember_EE95A03D351953062449837D97A05B28" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Eucrisa [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_EucrisaMember" xlink:label="loc_pfe_EucrisaMember_EE95A03D351953062449837D97A05B28" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_EucrisaMember_EE95A03D351953062449837D97A05B28" xlink:to="lab_pfe_EucrisaMember_EE95A03D351953062449837D97A05B28" xlink:type="arc" />
    <link:label id="lab_pfe_AllOtherInflammationandImmunologyProductsMember_6A672BB7C274B8EF6913837D97A06AB2_terseLabel_en-US" xlink:label="lab_pfe_AllOtherInflammationandImmunologyProductsMember_6A672BB7C274B8EF6913837D97A06AB2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Other Inflammation and Immunology Products [Member]</link:label>
    <link:label id="lab_pfe_AllOtherInflammationandImmunologyProductsMember_6A672BB7C274B8EF6913837D97A06AB2_label_en-US" xlink:label="lab_pfe_AllOtherInflammationandImmunologyProductsMember_6A672BB7C274B8EF6913837D97A06AB2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Other Inflammation and Immunology Products [Member]</link:label>
    <link:label id="lab_pfe_AllOtherInflammationandImmunologyProductsMember_6A672BB7C274B8EF6913837D97A06AB2_documentation_en-US" xlink:label="lab_pfe_AllOtherInflammationandImmunologyProductsMember_6A672BB7C274B8EF6913837D97A06AB2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">All Other Inflammation and Immunology Products [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_AllOtherInflammationandImmunologyProductsMember" xlink:label="loc_pfe_AllOtherInflammationandImmunologyProductsMember_6A672BB7C274B8EF6913837D97A06AB2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_AllOtherInflammationandImmunologyProductsMember_6A672BB7C274B8EF6913837D97A06AB2" xlink:to="lab_pfe_AllOtherInflammationandImmunologyProductsMember_6A672BB7C274B8EF6913837D97A06AB2" xlink:type="arc" />
    <link:label id="lab_pfe_BeneFIXMember_E1B4E04FBF37C003B41A837D97A02E88_terseLabel_en-US" xlink:label="lab_pfe_BeneFIXMember_E1B4E04FBF37C003B41A837D97A02E88" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BeneFIX [Member]</link:label>
    <link:label id="lab_pfe_BeneFIXMember_E1B4E04FBF37C003B41A837D97A02E88_label_en-US" xlink:label="lab_pfe_BeneFIXMember_E1B4E04FBF37C003B41A837D97A02E88" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bene F I X [Member]</link:label>
    <link:label id="lab_pfe_BeneFIXMember_E1B4E04FBF37C003B41A837D97A02E88_documentation_en-US" xlink:label="lab_pfe_BeneFIXMember_E1B4E04FBF37C003B41A837D97A02E88" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Bene F I X [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_BeneFIXMember" xlink:label="loc_pfe_BeneFIXMember_E1B4E04FBF37C003B41A837D97A02E88" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_BeneFIXMember_E1B4E04FBF37C003B41A837D97A02E88" xlink:to="lab_pfe_BeneFIXMember_E1B4E04FBF37C003B41A837D97A02E88" xlink:type="arc" />
    <link:label id="lab_pfe_ReFactoAfXynthaMember_244A3A71BCF63ED47516837D97A0A8F1_terseLabel_en-US" xlink:label="lab_pfe_ReFactoAfXynthaMember_244A3A71BCF63ED47516837D97A0A8F1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ReFacto AF/ Xyntha [Member]</link:label>
    <link:label id="lab_pfe_ReFactoAfXynthaMember_244A3A71BCF63ED47516837D97A0A8F1_label_en-US" xlink:label="lab_pfe_ReFactoAfXynthaMember_244A3A71BCF63ED47516837D97A0A8F1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Re Facto AF Xyntha [Member]</link:label>
    <link:label id="lab_pfe_ReFactoAfXynthaMember_244A3A71BCF63ED47516837D97A0A8F1_documentation_en-US" xlink:label="lab_pfe_ReFactoAfXynthaMember_244A3A71BCF63ED47516837D97A0A8F1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Re Facto AF Xyntha [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_ReFactoAfXynthaMember" xlink:label="loc_pfe_ReFactoAfXynthaMember_244A3A71BCF63ED47516837D97A0A8F1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ReFactoAfXynthaMember_244A3A71BCF63ED47516837D97A0A8F1" xlink:to="lab_pfe_ReFactoAfXynthaMember_244A3A71BCF63ED47516837D97A0A8F1" xlink:type="arc" />
    <link:label id="lab_pfe_GenotropinMember_D94E0CCBA5F81F6A8F61837D97A07451_terseLabel_en-US" xlink:label="lab_pfe_GenotropinMember_D94E0CCBA5F81F6A8F61837D97A07451" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Genotropin [Member]</link:label>
    <link:label id="lab_pfe_GenotropinMember_D94E0CCBA5F81F6A8F61837D97A07451_label_en-US" xlink:label="lab_pfe_GenotropinMember_D94E0CCBA5F81F6A8F61837D97A07451" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Genotropin [Member]</link:label>
    <link:label id="lab_pfe_GenotropinMember_D94E0CCBA5F81F6A8F61837D97A07451_documentation_en-US" xlink:label="lab_pfe_GenotropinMember_D94E0CCBA5F81F6A8F61837D97A07451" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Genotropin [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_GenotropinMember" xlink:label="loc_pfe_GenotropinMember_D94E0CCBA5F81F6A8F61837D97A07451" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_GenotropinMember_D94E0CCBA5F81F6A8F61837D97A07451" xlink:to="lab_pfe_GenotropinMember_D94E0CCBA5F81F6A8F61837D97A07451" xlink:type="arc" />
    <link:label id="lab_pfe_SomavertMember_E951959359591F94F838837D97A03160_terseLabel_en-US" xlink:label="lab_pfe_SomavertMember_E951959359591F94F838837D97A03160" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Somavert [Member]</link:label>
    <link:label id="lab_pfe_SomavertMember_E951959359591F94F838837D97A03160_label_en-US" xlink:label="lab_pfe_SomavertMember_E951959359591F94F838837D97A03160" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Somavert [Member]</link:label>
    <link:label id="lab_pfe_SomavertMember_E951959359591F94F838837D97A03160_documentation_en-US" xlink:label="lab_pfe_SomavertMember_E951959359591F94F838837D97A03160" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Somavert [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_SomavertMember" xlink:label="loc_pfe_SomavertMember_E951959359591F94F838837D97A03160" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SomavertMember_E951959359591F94F838837D97A03160" xlink:to="lab_pfe_SomavertMember_E951959359591F94F838837D97A03160" xlink:type="arc" />
    <link:label id="lab_pfe_AllOtherRareDiseaseProductsMember_E7A878EBE7353C6E9618837D97A0BB57_terseLabel_en-US" xlink:label="lab_pfe_AllOtherRareDiseaseProductsMember_E7A878EBE7353C6E9618837D97A0BB57" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Other Rare Disease [Member]</link:label>
    <link:label id="lab_pfe_AllOtherRareDiseaseProductsMember_E7A878EBE7353C6E9618837D97A0BB57_label_en-US" xlink:label="lab_pfe_AllOtherRareDiseaseProductsMember_E7A878EBE7353C6E9618837D97A0BB57" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Other Rare Disease Products [Member]</link:label>
    <link:label id="lab_pfe_AllOtherRareDiseaseProductsMember_E7A878EBE7353C6E9618837D97A0BB57_documentation_en-US" xlink:label="lab_pfe_AllOtherRareDiseaseProductsMember_E7A878EBE7353C6E9618837D97A0BB57" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">All Other Rare Disease Products [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_AllOtherRareDiseaseProductsMember" xlink:label="loc_pfe_AllOtherRareDiseaseProductsMember_E7A878EBE7353C6E9618837D97A0BB57" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_AllOtherRareDiseaseProductsMember_E7A878EBE7353C6E9618837D97A0BB57" xlink:to="lab_pfe_AllOtherRareDiseaseProductsMember_E7A878EBE7353C6E9618837D97A0BB57" xlink:type="arc" />
    <link:label id="lab_pfe_LipitorMember_D8EE59AFB7A555241C09837D97A0B15B_terseLabel_en-US" xlink:label="lab_pfe_LipitorMember_D8EE59AFB7A555241C09837D97A0B15B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lipitor [Member]</link:label>
    <link:label id="lab_pfe_LipitorMember_D8EE59AFB7A555241C09837D97A0B15B_label_en-US" xlink:label="lab_pfe_LipitorMember_D8EE59AFB7A555241C09837D97A0B15B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lipitor [Member]</link:label>
    <link:label id="lab_pfe_LipitorMember_D8EE59AFB7A555241C09837D97A0B15B_documentation_en-US" xlink:label="lab_pfe_LipitorMember_D8EE59AFB7A555241C09837D97A0B15B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lipitor [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_LipitorMember" xlink:label="loc_pfe_LipitorMember_D8EE59AFB7A555241C09837D97A0B15B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_LipitorMember_D8EE59AFB7A555241C09837D97A0B15B" xlink:to="lab_pfe_LipitorMember_D8EE59AFB7A555241C09837D97A0B15B" xlink:type="arc" />
    <link:label id="lab_pfe_PremarinFamilyMember_40EDC1EE16377D9FFFF5837D97A061C5_terseLabel_en-US" xlink:label="lab_pfe_PremarinFamilyMember_40EDC1EE16377D9FFFF5837D97A061C5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Premarin family [Member]</link:label>
    <link:label id="lab_pfe_PremarinFamilyMember_40EDC1EE16377D9FFFF5837D97A061C5_label_en-US" xlink:label="lab_pfe_PremarinFamilyMember_40EDC1EE16377D9FFFF5837D97A061C5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Premarin Family [Member]</link:label>
    <link:label id="lab_pfe_PremarinFamilyMember_40EDC1EE16377D9FFFF5837D97A061C5_documentation_en-US" xlink:label="lab_pfe_PremarinFamilyMember_40EDC1EE16377D9FFFF5837D97A061C5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Premarin family [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_PremarinFamilyMember" xlink:label="loc_pfe_PremarinFamilyMember_40EDC1EE16377D9FFFF5837D97A061C5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_PremarinFamilyMember_40EDC1EE16377D9FFFF5837D97A061C5" xlink:to="lab_pfe_PremarinFamilyMember_40EDC1EE16377D9FFFF5837D97A061C5" xlink:type="arc" />
    <link:label id="lab_pfe_NorvascMember_48FF3A77E5B788749795837D97A00113_terseLabel_en-US" xlink:label="lab_pfe_NorvascMember_48FF3A77E5B788749795837D97A00113" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Norvasc [Member]</link:label>
    <link:label id="lab_pfe_NorvascMember_48FF3A77E5B788749795837D97A00113_label_en-US" xlink:label="lab_pfe_NorvascMember_48FF3A77E5B788749795837D97A00113" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Norvasc [Member]</link:label>
    <link:label id="lab_pfe_NorvascMember_48FF3A77E5B788749795837D97A00113_documentation_en-US" xlink:label="lab_pfe_NorvascMember_48FF3A77E5B788749795837D97A00113" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Norvasc [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_NorvascMember" xlink:label="loc_pfe_NorvascMember_48FF3A77E5B788749795837D97A00113" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_NorvascMember_48FF3A77E5B788749795837D97A00113" xlink:to="lab_pfe_NorvascMember_48FF3A77E5B788749795837D97A00113" xlink:type="arc" />
    <link:label id="lab_pfe_EpiPenMember_F5484E79173EB98F61A6837D97A0D5AB_terseLabel_en-US" xlink:label="lab_pfe_EpiPenMember_F5484E79173EB98F61A6837D97A0D5AB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">EpiPen [Member]</link:label>
    <link:label id="lab_pfe_EpiPenMember_F5484E79173EB98F61A6837D97A0D5AB_label_en-US" xlink:label="lab_pfe_EpiPenMember_F5484E79173EB98F61A6837D97A0D5AB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Epi Pen [Member]</link:label>
    <link:label id="lab_pfe_EpiPenMember_F5484E79173EB98F61A6837D97A0D5AB_documentation_en-US" xlink:label="lab_pfe_EpiPenMember_F5484E79173EB98F61A6837D97A0D5AB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">EpiPen [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_EpiPenMember" xlink:label="loc_pfe_EpiPenMember_F5484E79173EB98F61A6837D97A0D5AB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_EpiPenMember_F5484E79173EB98F61A6837D97A0D5AB" xlink:to="lab_pfe_EpiPenMember_F5484E79173EB98F61A6837D97A0D5AB" xlink:type="arc" />
    <link:label id="lab_pfe_XalatanXalacomMember_9FAEFBA906BF2C1ED9EA837D97A08EC3_terseLabel_en-US" xlink:label="lab_pfe_XalatanXalacomMember_9FAEFBA906BF2C1ED9EA837D97A08EC3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Xalatan/Xalacom [Member]</link:label>
    <link:label id="lab_pfe_XalatanXalacomMember_9FAEFBA906BF2C1ED9EA837D97A08EC3_label_en-US" xlink:label="lab_pfe_XalatanXalacomMember_9FAEFBA906BF2C1ED9EA837D97A08EC3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Xalatan Xalacom [Member]</link:label>
    <link:label id="lab_pfe_XalatanXalacomMember_9FAEFBA906BF2C1ED9EA837D97A08EC3_documentation_en-US" xlink:label="lab_pfe_XalatanXalacomMember_9FAEFBA906BF2C1ED9EA837D97A08EC3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Xalatan / Xalacom [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_XalatanXalacomMember" xlink:label="loc_pfe_XalatanXalacomMember_9FAEFBA906BF2C1ED9EA837D97A08EC3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_XalatanXalacomMember_9FAEFBA906BF2C1ED9EA837D97A08EC3" xlink:to="lab_pfe_XalatanXalacomMember_9FAEFBA906BF2C1ED9EA837D97A08EC3" xlink:type="arc" />
    <link:label id="lab_pfe_EffexorMember_7F98611C4B69CDCD93CF837D97A03FD4_terseLabel_en-US" xlink:label="lab_pfe_EffexorMember_7F98611C4B69CDCD93CF837D97A03FD4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effexor [Member]</link:label>
    <link:label id="lab_pfe_EffexorMember_7F98611C4B69CDCD93CF837D97A03FD4_label_en-US" xlink:label="lab_pfe_EffexorMember_7F98611C4B69CDCD93CF837D97A03FD4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effexor [Member]</link:label>
    <link:label id="lab_pfe_EffexorMember_7F98611C4B69CDCD93CF837D97A03FD4_documentation_en-US" xlink:label="lab_pfe_EffexorMember_7F98611C4B69CDCD93CF837D97A03FD4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effexor [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_EffexorMember" xlink:label="loc_pfe_EffexorMember_7F98611C4B69CDCD93CF837D97A03FD4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_EffexorMember_7F98611C4B69CDCD93CF837D97A03FD4" xlink:to="lab_pfe_EffexorMember_7F98611C4B69CDCD93CF837D97A03FD4" xlink:type="arc" />
    <link:label id="lab_pfe_ZoloftMember_C12E2871AAE7F73591F8837D97A0C951_terseLabel_en-US" xlink:label="lab_pfe_ZoloftMember_C12E2871AAE7F73591F8837D97A0C951" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Zoloft [Member]</link:label>
    <link:label id="lab_pfe_ZoloftMember_C12E2871AAE7F73591F8837D97A0C951_label_en-US" xlink:label="lab_pfe_ZoloftMember_C12E2871AAE7F73591F8837D97A0C951" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Zoloft [Member]</link:label>
    <link:label id="lab_pfe_ZoloftMember_C12E2871AAE7F73591F8837D97A0C951_documentation_en-US" xlink:label="lab_pfe_ZoloftMember_C12E2871AAE7F73591F8837D97A0C951" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Zoloft [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_ZoloftMember" xlink:label="loc_pfe_ZoloftMember_C12E2871AAE7F73591F8837D97A0C951" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ZoloftMember_C12E2871AAE7F73591F8837D97A0C951" xlink:to="lab_pfe_ZoloftMember_C12E2871AAE7F73591F8837D97A0C951" xlink:type="arc" />
    <link:label id="lab_pfe_ZithromaxZmaxMember_DA58EE86AC212CACCBA8837D97A151CC_terseLabel_en-US" xlink:label="lab_pfe_ZithromaxZmaxMember_DA58EE86AC212CACCBA8837D97A151CC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Zithromax [Member]</link:label>
    <link:label id="lab_pfe_ZithromaxZmaxMember_DA58EE86AC212CACCBA8837D97A151CC_label_en-US" xlink:label="lab_pfe_ZithromaxZmaxMember_DA58EE86AC212CACCBA8837D97A151CC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Zithromax Zmax [Member]</link:label>
    <link:label id="lab_pfe_ZithromaxZmaxMember_DA58EE86AC212CACCBA8837D97A151CC_documentation_en-US" xlink:label="lab_pfe_ZithromaxZmaxMember_DA58EE86AC212CACCBA8837D97A151CC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Zithromax / Zmax [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_ZithromaxZmaxMember" xlink:label="loc_pfe_ZithromaxZmaxMember_DA58EE86AC212CACCBA8837D97A151CC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ZithromaxZmaxMember_DA58EE86AC212CACCBA8837D97A151CC" xlink:to="lab_pfe_ZithromaxZmaxMember_DA58EE86AC212CACCBA8837D97A151CC" xlink:type="arc" />
    <link:label id="lab_pfe_RelpaxMember_A6F54A09A1103ADEB812837D97A1B798_terseLabel_en-US" xlink:label="lab_pfe_RelpaxMember_A6F54A09A1103ADEB812837D97A1B798" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Relpax [Member]</link:label>
    <link:label id="lab_pfe_RelpaxMember_A6F54A09A1103ADEB812837D97A1B798_label_en-US" xlink:label="lab_pfe_RelpaxMember_A6F54A09A1103ADEB812837D97A1B798" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Relpax [Member]</link:label>
    <link:label id="lab_pfe_RelpaxMember_A6F54A09A1103ADEB812837D97A1B798_documentation_en-US" xlink:label="lab_pfe_RelpaxMember_A6F54A09A1103ADEB812837D97A1B798" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Relpax [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_RelpaxMember" xlink:label="loc_pfe_RelpaxMember_A6F54A09A1103ADEB812837D97A1B798" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_RelpaxMember_A6F54A09A1103ADEB812837D97A1B798" xlink:to="lab_pfe_RelpaxMember_A6F54A09A1103ADEB812837D97A1B798" xlink:type="arc" />
    <link:label id="lab_pfe_XanaxXanaxXRMember_9E84C1A6482C6DF9244B837D97A16BDC_terseLabel_en-US" xlink:label="lab_pfe_XanaxXanaxXRMember_9E84C1A6482C6DF9244B837D97A16BDC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Xanax [Member]</link:label>
    <link:label id="lab_pfe_XanaxXanaxXRMember_9E84C1A6482C6DF9244B837D97A16BDC_label_en-US" xlink:label="lab_pfe_XanaxXanaxXRMember_9E84C1A6482C6DF9244B837D97A16BDC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Xanax/Xanax XR [Member]</link:label>
    <link:label id="lab_pfe_XanaxXanaxXRMember_9E84C1A6482C6DF9244B837D97A16BDC_documentation_en-US" xlink:label="lab_pfe_XanaxXanaxXRMember_9E84C1A6482C6DF9244B837D97A16BDC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Xanax/Xanax XR [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_XanaxXanaxXRMember" xlink:label="loc_pfe_XanaxXanaxXRMember_9E84C1A6482C6DF9244B837D97A16BDC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_XanaxXanaxXRMember_9E84C1A6482C6DF9244B837D97A16BDC" xlink:to="lab_pfe_XanaxXanaxXRMember_9E84C1A6482C6DF9244B837D97A16BDC" xlink:type="arc" />
    <link:label id="lab_pfe_OtherLegacyEstablishedProductsMember_9AAF444891F90574244F837D97A1C02D_terseLabel_en-US" xlink:label="lab_pfe_OtherLegacyEstablishedProductsMember_9AAF444891F90574244F837D97A1C02D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Legacy Established Products [Member]</link:label>
    <link:label id="lab_pfe_OtherLegacyEstablishedProductsMember_9AAF444891F90574244F837D97A1C02D_label_en-US" xlink:label="lab_pfe_OtherLegacyEstablishedProductsMember_9AAF444891F90574244F837D97A1C02D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Legacy Established Products [Member]</link:label>
    <link:label id="lab_pfe_OtherLegacyEstablishedProductsMember_9AAF444891F90574244F837D97A1C02D_documentation_en-US" xlink:label="lab_pfe_OtherLegacyEstablishedProductsMember_9AAF444891F90574244F837D97A1C02D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Legacy Established Products [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_OtherLegacyEstablishedProductsMember" xlink:label="loc_pfe_OtherLegacyEstablishedProductsMember_9AAF444891F90574244F837D97A1C02D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherLegacyEstablishedProductsMember_9AAF444891F90574244F837D97A1C02D" xlink:to="lab_pfe_OtherLegacyEstablishedProductsMember_9AAF444891F90574244F837D97A1C02D" xlink:type="arc" />
    <link:label id="lab_pfe_MedrolMember_5FFBA03F600BCC2B01EF837D97A196A7_terseLabel_en-US" xlink:label="lab_pfe_MedrolMember_5FFBA03F600BCC2B01EF837D97A196A7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Medrol [Member]</link:label>
    <link:label id="lab_pfe_MedrolMember_5FFBA03F600BCC2B01EF837D97A196A7_label_en-US" xlink:label="lab_pfe_MedrolMember_5FFBA03F600BCC2B01EF837D97A196A7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Medrol [Member]</link:label>
    <link:label id="lab_pfe_MedrolMember_5FFBA03F600BCC2B01EF837D97A196A7_documentation_en-US" xlink:label="lab_pfe_MedrolMember_5FFBA03F600BCC2B01EF837D97A196A7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Medrol [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_MedrolMember" xlink:label="loc_pfe_MedrolMember_5FFBA03F600BCC2B01EF837D97A196A7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_MedrolMember_5FFBA03F600BCC2B01EF837D97A196A7" xlink:to="lab_pfe_MedrolMember_5FFBA03F600BCC2B01EF837D97A196A7" xlink:type="arc" />
    <link:label id="lab_pfe_SulperazonMember_927E5CD5F2990CB86D18837D97A1289B_terseLabel_en-US" xlink:label="lab_pfe_SulperazonMember_927E5CD5F2990CB86D18837D97A1289B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sulperazon [Member]</link:label>
    <link:label id="lab_pfe_SulperazonMember_927E5CD5F2990CB86D18837D97A1289B_label_en-US" xlink:label="lab_pfe_SulperazonMember_927E5CD5F2990CB86D18837D97A1289B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sulperazon [Member]</link:label>
    <link:label id="lab_pfe_SulperazonMember_927E5CD5F2990CB86D18837D97A1289B_documentation_en-US" xlink:label="lab_pfe_SulperazonMember_927E5CD5F2990CB86D18837D97A1289B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sulperazon [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_SulperazonMember" xlink:label="loc_pfe_SulperazonMember_927E5CD5F2990CB86D18837D97A1289B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SulperazonMember_927E5CD5F2990CB86D18837D97A1289B" xlink:to="lab_pfe_SulperazonMember_927E5CD5F2990CB86D18837D97A1289B" xlink:type="arc" />
    <link:label id="lab_pfe_FragminMember_CB9632849D1DDFFB016C837D97A1F6D3_terseLabel_en-US" xlink:label="lab_pfe_FragminMember_CB9632849D1DDFFB016C837D97A1F6D3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fragmin [Member]</link:label>
    <link:label id="lab_pfe_FragminMember_CB9632849D1DDFFB016C837D97A1F6D3_label_en-US" xlink:label="lab_pfe_FragminMember_CB9632849D1DDFFB016C837D97A1F6D3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fragmin [Member]</link:label>
    <link:label id="lab_pfe_FragminMember_CB9632849D1DDFFB016C837D97A1F6D3_documentation_en-US" xlink:label="lab_pfe_FragminMember_CB9632849D1DDFFB016C837D97A1F6D3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fragmin [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_FragminMember" xlink:label="loc_pfe_FragminMember_CB9632849D1DDFFB016C837D97A1F6D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_FragminMember_CB9632849D1DDFFB016C837D97A1F6D3" xlink:to="lab_pfe_FragminMember_CB9632849D1DDFFB016C837D97A1F6D3" xlink:type="arc" />
    <link:label id="lab_pfe_TygacilMember_D0F5315005B6A9E10B12837D97A1AECC_terseLabel_en-US" xlink:label="lab_pfe_TygacilMember_D0F5315005B6A9E10B12837D97A1AECC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tygacil [Member]</link:label>
    <link:label id="lab_pfe_TygacilMember_D0F5315005B6A9E10B12837D97A1AECC_label_en-US" xlink:label="lab_pfe_TygacilMember_D0F5315005B6A9E10B12837D97A1AECC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tygacil [Member]</link:label>
    <link:label id="lab_pfe_TygacilMember_D0F5315005B6A9E10B12837D97A1AECC_documentation_en-US" xlink:label="lab_pfe_TygacilMember_D0F5315005B6A9E10B12837D97A1AECC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tygacil [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_TygacilMember" xlink:label="loc_pfe_TygacilMember_D0F5315005B6A9E10B12837D97A1AECC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_TygacilMember_D0F5315005B6A9E10B12837D97A1AECC" xlink:to="lab_pfe_TygacilMember_D0F5315005B6A9E10B12837D97A1AECC" xlink:type="arc" />
    <link:label id="lab_pfe_PrecedexMember_AA105921ECAAE35E1F4D837D97A11113_terseLabel_en-US" xlink:label="lab_pfe_PrecedexMember_AA105921ECAAE35E1F4D837D97A11113" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Precedex [Member]</link:label>
    <link:label id="lab_pfe_PrecedexMember_AA105921ECAAE35E1F4D837D97A11113_label_en-US" xlink:label="lab_pfe_PrecedexMember_AA105921ECAAE35E1F4D837D97A11113" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Precedex [Member]</link:label>
    <link:label id="lab_pfe_PrecedexMember_AA105921ECAAE35E1F4D837D97A11113_documentation_en-US" xlink:label="lab_pfe_PrecedexMember_AA105921ECAAE35E1F4D837D97A11113" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Precedex [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_PrecedexMember" xlink:label="loc_pfe_PrecedexMember_AA105921ECAAE35E1F4D837D97A11113" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_PrecedexMember_AA105921ECAAE35E1F4D837D97A11113" xlink:to="lab_pfe_PrecedexMember_AA105921ECAAE35E1F4D837D97A11113" xlink:type="arc" />
    <link:label id="lab_pfe_AllOtherSterileInjectablePharmaceuticalsMember_C406531A02D06DC0ABBC837D97A10C4F_terseLabel_en-US" xlink:label="lab_pfe_AllOtherSterileInjectablePharmaceuticalsMember_C406531A02D06DC0ABBC837D97A10C4F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Other Sterile Injectable Pharmaceuticals [Member]</link:label>
    <link:label id="lab_pfe_AllOtherSterileInjectablePharmaceuticalsMember_C406531A02D06DC0ABBC837D97A10C4F_label_en-US" xlink:label="lab_pfe_AllOtherSterileInjectablePharmaceuticalsMember_C406531A02D06DC0ABBC837D97A10C4F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Other Sterile Injectable Pharmaceuticals [Member]</link:label>
    <link:label id="lab_pfe_AllOtherSterileInjectablePharmaceuticalsMember_C406531A02D06DC0ABBC837D97A10C4F_documentation_en-US" xlink:label="lab_pfe_AllOtherSterileInjectablePharmaceuticalsMember_C406531A02D06DC0ABBC837D97A10C4F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">All Other Sterile Injectable Pharmaceuticals [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_AllOtherSterileInjectablePharmaceuticalsMember" xlink:label="loc_pfe_AllOtherSterileInjectablePharmaceuticalsMember_C406531A02D06DC0ABBC837D97A10C4F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_AllOtherSterileInjectablePharmaceuticalsMember_C406531A02D06DC0ABBC837D97A10C4F" xlink:to="lab_pfe_AllOtherSterileInjectablePharmaceuticalsMember_C406531A02D06DC0ABBC837D97A10C4F" xlink:type="arc" />
    <link:label id="lab_pfe_CelebrexMember_C8F332A299C4CB789935837D97A16599_terseLabel_en-US" xlink:label="lab_pfe_CelebrexMember_C8F332A299C4CB789935837D97A16599" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Celebrex [Member]</link:label>
    <link:label id="lab_pfe_CelebrexMember_C8F332A299C4CB789935837D97A16599_label_en-US" xlink:label="lab_pfe_CelebrexMember_C8F332A299C4CB789935837D97A16599" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Celebrex [Member]</link:label>
    <link:label id="lab_pfe_CelebrexMember_C8F332A299C4CB789935837D97A16599_documentation_en-US" xlink:label="lab_pfe_CelebrexMember_C8F332A299C4CB789935837D97A16599" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Celebrex [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_CelebrexMember" xlink:label="loc_pfe_CelebrexMember_C8F332A299C4CB789935837D97A16599" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_CelebrexMember_C8F332A299C4CB789935837D97A16599" xlink:to="lab_pfe_CelebrexMember_C8F332A299C4CB789935837D97A16599" xlink:type="arc" />
    <link:label id="lab_pfe_VfendMember_C5F8951550C576722852837D97A1696A_terseLabel_en-US" xlink:label="lab_pfe_VfendMember_C5F8951550C576722852837D97A1696A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vfend [Member]</link:label>
    <link:label id="lab_pfe_VfendMember_C5F8951550C576722852837D97A1696A_label_en-US" xlink:label="lab_pfe_VfendMember_C5F8951550C576722852837D97A1696A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vfend [Member]</link:label>
    <link:label id="lab_pfe_VfendMember_C5F8951550C576722852837D97A1696A_documentation_en-US" xlink:label="lab_pfe_VfendMember_C5F8951550C576722852837D97A1696A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Vfend [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_VfendMember" xlink:label="loc_pfe_VfendMember_C5F8951550C576722852837D97A1696A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_VfendMember_C5F8951550C576722852837D97A1696A" xlink:to="lab_pfe_VfendMember_C5F8951550C576722852837D97A1696A" xlink:type="arc" />
    <link:label id="lab_pfe_PristiqMember_F57EC818FA6316CFBA45837D97A1165F_terseLabel_en-US" xlink:label="lab_pfe_PristiqMember_F57EC818FA6316CFBA45837D97A1165F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pristiq [Member]</link:label>
    <link:label id="lab_pfe_PristiqMember_F57EC818FA6316CFBA45837D97A1165F_label_en-US" xlink:label="lab_pfe_PristiqMember_F57EC818FA6316CFBA45837D97A1165F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pristiq [Member]</link:label>
    <link:label id="lab_pfe_PristiqMember_F57EC818FA6316CFBA45837D97A1165F_documentation_en-US" xlink:label="lab_pfe_PristiqMember_F57EC818FA6316CFBA45837D97A1165F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pristiq [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_PristiqMember" xlink:label="loc_pfe_PristiqMember_F57EC818FA6316CFBA45837D97A1165F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_PristiqMember_F57EC818FA6316CFBA45837D97A1165F" xlink:to="lab_pfe_PristiqMember_F57EC818FA6316CFBA45837D97A1165F" xlink:type="arc" />
    <link:label id="lab_pfe_ZyvoxMember_749DC17FB837B8D3C345837D97A149E4_terseLabel_en-US" xlink:label="lab_pfe_ZyvoxMember_749DC17FB837B8D3C345837D97A149E4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Zyvox [Member]</link:label>
    <link:label id="lab_pfe_ZyvoxMember_749DC17FB837B8D3C345837D97A149E4_label_en-US" xlink:label="lab_pfe_ZyvoxMember_749DC17FB837B8D3C345837D97A149E4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Zyvox [Member]</link:label>
    <link:label id="lab_pfe_ZyvoxMember_749DC17FB837B8D3C345837D97A149E4_documentation_en-US" xlink:label="lab_pfe_ZyvoxMember_749DC17FB837B8D3C345837D97A149E4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Zyvox [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_ZyvoxMember" xlink:label="loc_pfe_ZyvoxMember_749DC17FB837B8D3C345837D97A149E4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ZyvoxMember_749DC17FB837B8D3C345837D97A149E4" xlink:to="lab_pfe_ZyvoxMember_749DC17FB837B8D3C345837D97A149E4" xlink:type="arc" />
    <link:label id="lab_pfe_RevatioMember_524240D949B70F8352BB837D97A1E575_terseLabel_en-US" xlink:label="lab_pfe_RevatioMember_524240D949B70F8352BB837D97A1E575" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revatio [Member]</link:label>
    <link:label id="lab_pfe_RevatioMember_524240D949B70F8352BB837D97A1E575_label_en-US" xlink:label="lab_pfe_RevatioMember_524240D949B70F8352BB837D97A1E575" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revatio [Member]</link:label>
    <link:label id="lab_pfe_RevatioMember_524240D949B70F8352BB837D97A1E575_documentation_en-US" xlink:label="lab_pfe_RevatioMember_524240D949B70F8352BB837D97A1E575" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revatio [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_RevatioMember" xlink:label="loc_pfe_RevatioMember_524240D949B70F8352BB837D97A1E575" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_RevatioMember_524240D949B70F8352BB837D97A1E575" xlink:to="lab_pfe_RevatioMember_524240D949B70F8352BB837D97A1E575" xlink:type="arc" />
    <link:label id="lab_pfe_AllOtherPeriLOEProductsMember_96D370902ACD5EA1C0DB837D97A1D5E0_terseLabel_en-US" xlink:label="lab_pfe_AllOtherPeriLOEProductsMember_96D370902ACD5EA1C0DB837D97A1D5E0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Other Peri-LOE Products [Member]</link:label>
    <link:label id="lab_pfe_AllOtherPeriLOEProductsMember_96D370902ACD5EA1C0DB837D97A1D5E0_label_en-US" xlink:label="lab_pfe_AllOtherPeriLOEProductsMember_96D370902ACD5EA1C0DB837D97A1D5E0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Other Peri-LOE Products [Member]</link:label>
    <link:label id="lab_pfe_AllOtherPeriLOEProductsMember_96D370902ACD5EA1C0DB837D97A1D5E0_documentation_en-US" xlink:label="lab_pfe_AllOtherPeriLOEProductsMember_96D370902ACD5EA1C0DB837D97A1D5E0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">All Other Peri-LOE Products [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_AllOtherPeriLOEProductsMember" xlink:label="loc_pfe_AllOtherPeriLOEProductsMember_96D370902ACD5EA1C0DB837D97A1D5E0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_AllOtherPeriLOEProductsMember_96D370902ACD5EA1C0DB837D97A1D5E0" xlink:to="lab_pfe_AllOtherPeriLOEProductsMember_96D370902ACD5EA1C0DB837D97A1D5E0" xlink:type="arc" />
    <link:label id="lab_pfe_InflectraRemsimaMember_2558284452DA5EF8F5F9837D97A12801_terseLabel_en-US" xlink:label="lab_pfe_InflectraRemsimaMember_2558284452DA5EF8F5F9837D97A12801" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inflectra/Remsima [Member]</link:label>
    <link:label id="lab_pfe_InflectraRemsimaMember_2558284452DA5EF8F5F9837D97A12801_label_en-US" xlink:label="lab_pfe_InflectraRemsimaMember_2558284452DA5EF8F5F9837D97A12801" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inflectra/Remsima [Member]</link:label>
    <link:label id="lab_pfe_InflectraRemsimaMember_2558284452DA5EF8F5F9837D97A12801_documentation_en-US" xlink:label="lab_pfe_InflectraRemsimaMember_2558284452DA5EF8F5F9837D97A12801" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Inflectra/Remsima [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_InflectraRemsimaMember" xlink:label="loc_pfe_InflectraRemsimaMember_2558284452DA5EF8F5F9837D97A12801" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_InflectraRemsimaMember_2558284452DA5EF8F5F9837D97A12801" xlink:to="lab_pfe_InflectraRemsimaMember_2558284452DA5EF8F5F9837D97A12801" xlink:type="arc" />
    <link:label id="lab_pfe_AllOtherBiosimilarsMember_71B9936599D0A87A381D837D97A1883B_terseLabel_en-US" xlink:label="lab_pfe_AllOtherBiosimilarsMember_71B9936599D0A87A381D837D97A1883B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Other Biosimilars [Member]</link:label>
    <link:label id="lab_pfe_AllOtherBiosimilarsMember_71B9936599D0A87A381D837D97A1883B_label_en-US" xlink:label="lab_pfe_AllOtherBiosimilarsMember_71B9936599D0A87A381D837D97A1883B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Other Biosimilars [Member]</link:label>
    <link:label id="lab_pfe_AllOtherBiosimilarsMember_71B9936599D0A87A381D837D97A1883B_documentation_en-US" xlink:label="lab_pfe_AllOtherBiosimilarsMember_71B9936599D0A87A381D837D97A1883B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">All Other Biosimilars [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_AllOtherBiosimilarsMember" xlink:label="loc_pfe_AllOtherBiosimilarsMember_71B9936599D0A87A381D837D97A1883B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_AllOtherBiosimilarsMember_71B9936599D0A87A381D837D97A1883B" xlink:to="lab_pfe_AllOtherBiosimilarsMember_71B9936599D0A87A381D837D97A1883B" xlink:type="arc" />
    <link:label id="lab_pfe_AllianceBiopharmaceuticalsMember_0E998CAF50744740BDAF837D97A1F40F_terseLabel_en-US" xlink:label="lab_pfe_AllianceBiopharmaceuticalsMember_0E998CAF50744740BDAF837D97A1F40F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Alliance revenues [Member]</link:label>
    <link:label id="lab_pfe_AllianceBiopharmaceuticalsMember_0E998CAF50744740BDAF837D97A1F40F_label_en-US" xlink:label="lab_pfe_AllianceBiopharmaceuticalsMember_0E998CAF50744740BDAF837D97A1F40F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alliance Biopharmaceuticals [Member]</link:label>
    <link:label id="lab_pfe_AllianceBiopharmaceuticalsMember_0E998CAF50744740BDAF837D97A1F40F_documentation_en-US" xlink:label="lab_pfe_AllianceBiopharmaceuticalsMember_0E998CAF50744740BDAF837D97A1F40F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Alliance Biopharmaceuticals [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_AllianceBiopharmaceuticalsMember" xlink:label="loc_pfe_AllianceBiopharmaceuticalsMember_0E998CAF50744740BDAF837D97A1F40F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_AllianceBiopharmaceuticalsMember_0E998CAF50744740BDAF837D97A1F40F" xlink:to="lab_pfe_AllianceBiopharmaceuticalsMember_0E998CAF50744740BDAF837D97A1F40F" xlink:type="arc" />
    <link:label id="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_0F3D0AD13C53A00665E9837D97A16C10_terseLabel_en-US" xlink:label="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_0F3D0AD13C53A00665E9837D97A16C10" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from External Customer [Line Items]</link:label>
    <link:label id="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_0F3D0AD13C53A00665E9837D97A16C10_label_en-US" xlink:label="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_0F3D0AD13C53A00665E9837D97A16C10" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from External Customer [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_0F3D0AD13C53A00665E9837D97A16C10" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_0F3D0AD13C53A00665E9837D97A16C10" xlink:to="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_0F3D0AD13C53A00665E9837D97A16C10" xlink:type="arc" />
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_943E8BA73B41C534B8F1C7A353643115_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_26A4BCB00EB8562680A61958ED3B7CB3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_26A4BCB00EB8562680A61958ED3B7CB3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_26A4BCB00EB8562680A61958ED3B7CB3" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_26A4BCB00EB8562680A61958ED3B7CB3" xlink:type="arc" />
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_8294A183B72990EC0FC1C7A3536B55C8_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_BCD95F8D804750DF92D232BE0755A18F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Table]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_8294A183B72990EC0FC1C7A3536B55C8_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_BCD95F8D804750DF92D232BE0755A18F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_BCD95F8D804750DF92D232BE0755A18F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_BCD95F8D804750DF92D232BE0755A18F" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_BCD95F8D804750DF92D232BE0755A18F" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_33EEB1D74AC24E34BBE9C7A3536B9EF7_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_F7106A59F68C56DBAB850ACFDF669E0E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</link:label>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_33EEB1D74AC24E34BBE9C7A3536B9EF7_label_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_F7106A59F68C56DBAB850ACFDF669E0E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_F7106A59F68C56DBAB850ACFDF669E0E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_F7106A59F68C56DBAB850ACFDF669E0E" xlink:to="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_F7106A59F68C56DBAB850ACFDF669E0E" xlink:type="arc" />
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_DD614B8320546A494F2FC7A3536BB001_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember_A0D84E4FD93A54969239964A215A9845" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Type of Adoption [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_DD614B8320546A494F2FC7A3536BB001_label_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember_A0D84E4FD93A54969239964A215A9845" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Type of Adoption [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_A0D84E4FD93A54969239964A215A9845" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfAdoptionMember_A0D84E4FD93A54969239964A215A9845" xlink:to="lab_us-gaap_TypeOfAdoptionMember_A0D84E4FD93A54969239964A215A9845" xlink:type="arc" />
    <link:label id="lab_pfe_AccountingStandardsUpdate201609StatutoryTaxWithholdingComponentMember_3539A530EA09A4C82542C7A3536B1363_terseLabel_en-US" xlink:label="lab_pfe_AccountingStandardsUpdate201609StatutoryTaxWithholdingComponentMember_10626B4C8FDC57C6895DD7093B45EC2A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Standards Update 2016-09, Statutory Tax Withholding Component [Member]</link:label>
    <link:label id="lab_pfe_AccountingStandardsUpdate201609StatutoryTaxWithholdingComponentMember_3539A530EA09A4C82542C7A3536B1363_label_en-US" xlink:label="lab_pfe_AccountingStandardsUpdate201609StatutoryTaxWithholdingComponentMember_10626B4C8FDC57C6895DD7093B45EC2A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Standards Update 2016-09, Statutory Tax Withholding Component [Member]</link:label>
    <link:label id="lab_pfe_AccountingStandardsUpdate201609StatutoryTaxWithholdingComponentMember_3539A530EA09A4C82542C7A3536B1363_documentation_en-US" xlink:label="lab_pfe_AccountingStandardsUpdate201609StatutoryTaxWithholdingComponentMember_10626B4C8FDC57C6895DD7093B45EC2A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accounting Standards Update 2016-09, Statutory Tax Withholding Component [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_AccountingStandardsUpdate201609StatutoryTaxWithholdingComponentMember" xlink:label="loc_pfe_AccountingStandardsUpdate201609StatutoryTaxWithholdingComponentMember_10626B4C8FDC57C6895DD7093B45EC2A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_AccountingStandardsUpdate201609StatutoryTaxWithholdingComponentMember_10626B4C8FDC57C6895DD7093B45EC2A" xlink:to="lab_pfe_AccountingStandardsUpdate201609StatutoryTaxWithholdingComponentMember_10626B4C8FDC57C6895DD7093B45EC2A" xlink:type="arc" />
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_31EA92D54CE713D11865C7A3536C1DB0_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_0D161D2EA75B5BDBAC387C1C2A50BD7E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_31EA92D54CE713D11865C7A3536C1DB0_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_0D161D2EA75B5BDBAC387C1C2A50BD7E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_0D161D2EA75B5BDBAC387C1C2A50BD7E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_0D161D2EA75B5BDBAC387C1C2A50BD7E" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_0D161D2EA75B5BDBAC387C1C2A50BD7E" xlink:type="arc" />
    <link:label id="lab_pfe_EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTaxBenefitAmount_D85E52580386578904D4C7A3536CB47D_terseLabel_en-US" xlink:label="lab_pfe_EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTaxBenefitAmount_928CEB226603580D91B813C675370772" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net tax benefit</link:label>
    <link:label id="lab_pfe_EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTaxBenefitAmount_D85E52580386578904D4C7A3536CB47D_label_en-US" xlink:label="lab_pfe_EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTaxBenefitAmount_928CEB226603580D91B813C675370772" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Share-based Compensation, Excess Tax Benefit, Amount</link:label>
    <link:label id="lab_pfe_EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTaxBenefitAmount_D85E52580386578904D4C7A3536CB47D_documentation_en-US" xlink:label="lab_pfe_EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTaxBenefitAmount_928CEB226603580D91B813C675370772" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Share-based Compensation, Excess Tax Benefit, Amount</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTaxBenefitAmount" xlink:label="loc_pfe_EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTaxBenefitAmount_928CEB226603580D91B813C675370772" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTaxBenefitAmount_928CEB226603580D91B813C675370772" xlink:to="lab_pfe_EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTaxBenefitAmount_928CEB226603580D91B813C675370772" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_8240DC12E458C9590A1CC7A3536C89FC_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_885850DC1E2A5C6982B1B611039834AF" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Amount reclassified from operating activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_885850DC1E2A5C6982B1B611039834AF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_885850DC1E2A5C6982B1B611039834AF" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_885850DC1E2A5C6982B1B611039834AF" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_4D685DCA92817BE0BC95C7A3536C5CD4_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_CC6E2694C04D53F0B28BBF293E6E5E59" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount reclassified to financing activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_CC6E2694C04D53F0B28BBF293E6E5E59" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_CC6E2694C04D53F0B28BBF293E6E5E59" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_CC6E2694C04D53F0B28BBF293E6E5E59" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_90F22FC242BFC6E5D7D5AE9F92C7D2A0_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_E228CB304B6D5D63BBDB4D00DEF868BE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Matters</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_90F22FC242BFC6E5D7D5AE9F92C7D2A0_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_E228CB304B6D5D63BBDB4D00DEF868BE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_E228CB304B6D5D63BBDB4D00DEF868BE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock_E228CB304B6D5D63BBDB4D00DEF868BE" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock_E228CB304B6D5D63BBDB4D00DEF868BE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScenarioForecastMember_99A0014D84F70574C4A19C264317A5BC_terseLabel_en-US" xlink:label="lab_us-gaap_ScenarioForecastMember_99A0014D84F70574C4A19C264317A5BC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forecast [Member]</link:label>
    <link:label id="lab_us-gaap_ScenarioForecastMember_99A0014D84F70574C4A19C264317A5BC_label_en-US" xlink:label="lab_us-gaap_ScenarioForecastMember_99A0014D84F70574C4A19C264317A5BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario, Forecast [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioForecastMember" xlink:label="loc_us-gaap_ScenarioForecastMember_99A0014D84F70574C4A19C264317A5BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScenarioForecastMember_99A0014D84F70574C4A19C264317A5BC" xlink:to="lab_us-gaap_ScenarioForecastMember_99A0014D84F70574C4A19C264317A5BC" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_61533D8AB24ABEB493D49C264317E67C_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis_61533D8AB24ABEB493D49C264317E67C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_61533D8AB24ABEB493D49C264317E67C_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis_61533D8AB24ABEB493D49C264317E67C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_61533D8AB24ABEB493D49C264317E67C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_61533D8AB24ABEB493D49C264317E67C" xlink:to="lab_us-gaap_RestructuringCostAndReserveAxis_61533D8AB24ABEB493D49C264317E67C" xlink:type="arc" />
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_1F166A59D29A3789F4489C2643174E41_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain_1F166A59D29A3789F4489C2643174E41" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_1F166A59D29A3789F4489C2643174E41_label_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain_1F166A59D29A3789F4489C2643174E41" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_1F166A59D29A3789F4489C2643174E41" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_1F166A59D29A3789F4489C2643174E41" xlink:to="lab_us-gaap_TypeOfRestructuringDomain_1F166A59D29A3789F4489C2643174E41" xlink:type="arc" />
    <link:label id="lab_pfe_ReturnofAcquiredRightsMember_E9C90B5409D9135B8FAA9C264318609A_terseLabel_en-US" xlink:label="lab_pfe_ReturnofAcquiredRightsMember_E9C90B5409D9135B8FAA9C264318609A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Return of Acquired Rights [Member]</link:label>
    <link:label id="lab_pfe_ReturnofAcquiredRightsMember_E9C90B5409D9135B8FAA9C264318609A_label_en-US" xlink:label="lab_pfe_ReturnofAcquiredRightsMember_E9C90B5409D9135B8FAA9C264318609A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Return of Acquired Rights [Member]</link:label>
    <link:label id="lab_pfe_ReturnofAcquiredRightsMember_E9C90B5409D9135B8FAA9C264318609A_documentation_en-US" xlink:label="lab_pfe_ReturnofAcquiredRightsMember_E9C90B5409D9135B8FAA9C264318609A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Return of Acquired Rights [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_ReturnofAcquiredRightsMember" xlink:label="loc_pfe_ReturnofAcquiredRightsMember_E9C90B5409D9135B8FAA9C264318609A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ReturnofAcquiredRightsMember_E9C90B5409D9135B8FAA9C264318609A" xlink:to="lab_pfe_ReturnofAcquiredRightsMember_E9C90B5409D9135B8FAA9C264318609A" xlink:type="arc" />
    <link:label id="lab_pfe_ManufacturingPlantNetworkOptimizationMember_3B6ED7C95EE5E79B83899C26431846EF_terseLabel_en-US" xlink:label="lab_pfe_ManufacturingPlantNetworkOptimizationMember_3B6ED7C95EE5E79B83899C26431846EF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Manufacturing Plant Network Optimization [Member]</link:label>
    <link:label id="lab_pfe_ManufacturingPlantNetworkOptimizationMember_3B6ED7C95EE5E79B83899C26431846EF_label_en-US" xlink:label="lab_pfe_ManufacturingPlantNetworkOptimizationMember_3B6ED7C95EE5E79B83899C26431846EF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Manufacturing Plant Network Optimization [Member]</link:label>
    <link:label id="lab_pfe_ManufacturingPlantNetworkOptimizationMember_3B6ED7C95EE5E79B83899C26431846EF_documentation_en-US" xlink:label="lab_pfe_ManufacturingPlantNetworkOptimizationMember_3B6ED7C95EE5E79B83899C26431846EF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Manufacturing Plant Network Optimization [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_ManufacturingPlantNetworkOptimizationMember" xlink:label="loc_pfe_ManufacturingPlantNetworkOptimizationMember_3B6ED7C95EE5E79B83899C26431846EF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ManufacturingPlantNetworkOptimizationMember_3B6ED7C95EE5E79B83899C26431846EF" xlink:to="lab_pfe_ManufacturingPlantNetworkOptimizationMember_3B6ED7C95EE5E79B83899C26431846EF" xlink:type="arc" />
    <link:label id="lab_pfe_CentralizationofCorporateandPlatformFunctionsMember_D99C8B77D06D90D7393E9C26431878E1_terseLabel_en-US" xlink:label="lab_pfe_CentralizationofCorporateandPlatformFunctionsMember_D99C8B77D06D90D7393E9C26431878E1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Centralization of Corporate and Platform Functions [Member]</link:label>
    <link:label id="lab_pfe_CentralizationofCorporateandPlatformFunctionsMember_D99C8B77D06D90D7393E9C26431878E1_label_en-US" xlink:label="lab_pfe_CentralizationofCorporateandPlatformFunctionsMember_D99C8B77D06D90D7393E9C26431878E1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Centralization of Corporate and Platform Functions [Member]</link:label>
    <link:label id="lab_pfe_CentralizationofCorporateandPlatformFunctionsMember_D99C8B77D06D90D7393E9C26431878E1_documentation_en-US" xlink:label="lab_pfe_CentralizationofCorporateandPlatformFunctionsMember_D99C8B77D06D90D7393E9C26431878E1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Centralization of Corporate and Platform Functions [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_CentralizationofCorporateandPlatformFunctionsMember" xlink:label="loc_pfe_CentralizationofCorporateandPlatformFunctionsMember_D99C8B77D06D90D7393E9C26431878E1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_CentralizationofCorporateandPlatformFunctionsMember_D99C8B77D06D90D7393E9C26431878E1" xlink:to="lab_pfe_CentralizationofCorporateandPlatformFunctionsMember_D99C8B77D06D90D7393E9C26431878E1" xlink:type="arc" />
    <link:label id="lab_pfe_BusinessIntegrationCostsMember_BA7DCFDB755847A59BFD9C264318BE89_terseLabel_en-US" xlink:label="lab_pfe_BusinessIntegrationCostsMember_BA7DCFDB755847A59BFD9C264318BE89" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Integration Costs [Member]</link:label>
    <link:label id="lab_pfe_BusinessIntegrationCostsMember_BA7DCFDB755847A59BFD9C264318BE89_label_en-US" xlink:label="lab_pfe_BusinessIntegrationCostsMember_BA7DCFDB755847A59BFD9C264318BE89" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Integration Costs [Member]</link:label>
    <link:label id="lab_pfe_BusinessIntegrationCostsMember_BA7DCFDB755847A59BFD9C264318BE89_documentation_en-US" xlink:label="lab_pfe_BusinessIntegrationCostsMember_BA7DCFDB755847A59BFD9C264318BE89" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Integration Costs [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_BusinessIntegrationCostsMember" xlink:label="loc_pfe_BusinessIntegrationCostsMember_BA7DCFDB755847A59BFD9C264318BE89" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_BusinessIntegrationCostsMember_BA7DCFDB755847A59BFD9C264318BE89" xlink:to="lab_pfe_BusinessIntegrationCostsMember_BA7DCFDB755847A59BFD9C264318BE89" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringPlanAxis_AC4C67B9CBC15C5E701A9C2643185AAF_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringPlanAxis_AC4C67B9CBC15C5E701A9C2643185AAF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Plan [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringPlanAxis_AC4C67B9CBC15C5E701A9C2643185AAF_label_en-US" xlink:label="lab_us-gaap_RestructuringPlanAxis_AC4C67B9CBC15C5E701A9C2643185AAF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Plan [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringPlanAxis" xlink:label="loc_us-gaap_RestructuringPlanAxis_AC4C67B9CBC15C5E701A9C2643185AAF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanAxis_AC4C67B9CBC15C5E701A9C2643185AAF" xlink:to="lab_us-gaap_RestructuringPlanAxis_AC4C67B9CBC15C5E701A9C2643185AAF" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringPlanDomain_644CBB9D270F40ACE5F59C264318D79A_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringPlanDomain_644CBB9D270F40ACE5F59C264318D79A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Plan [Domain]</link:label>
    <link:label id="lab_us-gaap_RestructuringPlanDomain_644CBB9D270F40ACE5F59C264318D79A_label_en-US" xlink:label="lab_us-gaap_RestructuringPlanDomain_644CBB9D270F40ACE5F59C264318D79A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Plan [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringPlanDomain" xlink:label="loc_us-gaap_RestructuringPlanDomain_644CBB9D270F40ACE5F59C264318D79A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanDomain_644CBB9D270F40ACE5F59C264318D79A" xlink:to="lab_us-gaap_RestructuringPlanDomain_644CBB9D270F40ACE5F59C264318D79A" xlink:type="arc" />
    <link:label id="lab_pfe_EnterprisewideCostReductionProductivityPlanMember_49CAB6C335E6D2D669239C264318A44C_terseLabel_en-US" xlink:label="lab_pfe_EnterprisewideCostReductionProductivityPlanMember_49CAB6C335E6D2D669239C264318A44C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Enterprise-wide Cost Reduction/Productivity Plan [Member]</link:label>
    <link:label id="lab_pfe_EnterprisewideCostReductionProductivityPlanMember_49CAB6C335E6D2D669239C264318A44C_label_en-US" xlink:label="lab_pfe_EnterprisewideCostReductionProductivityPlanMember_49CAB6C335E6D2D669239C264318A44C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Enterprise-wide Cost Reduction/Productivity Plan [Member]</link:label>
    <link:label id="lab_pfe_EnterprisewideCostReductionProductivityPlanMember_49CAB6C335E6D2D669239C264318A44C_documentation_en-US" xlink:label="lab_pfe_EnterprisewideCostReductionProductivityPlanMember_49CAB6C335E6D2D669239C264318A44C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Enterprise-wide Cost Reduction/Productivity Plan [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_EnterprisewideCostReductionProductivityPlanMember" xlink:label="loc_pfe_EnterprisewideCostReductionProductivityPlanMember_49CAB6C335E6D2D669239C264318A44C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_EnterprisewideCostReductionProductivityPlanMember_49CAB6C335E6D2D669239C264318A44C" xlink:to="lab_pfe_EnterprisewideCostReductionProductivityPlanMember_49CAB6C335E6D2D669239C264318A44C" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostOfSalesMember_1299E222993D193C2A299C26431808F3_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesMember_1299E222993D193C2A299C26431808F3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of Sales [Member]</link:label>
    <link:label id="lab_us-gaap_CostOfSalesMember_1299E222993D193C2A299C26431808F3_label_en-US" xlink:label="lab_us-gaap_CostOfSalesMember_1299E222993D193C2A299C26431808F3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Sales [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostOfSalesMember" xlink:label="loc_us-gaap_CostOfSalesMember_1299E222993D193C2A299C26431808F3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesMember_1299E222993D193C2A299C26431808F3" xlink:to="lab_us-gaap_CostOfSalesMember_1299E222993D193C2A299C26431808F3" xlink:type="arc" />
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_D5FD1FF344784AC23F7F9C26431852B8_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_D5FD1FF344784AC23F7F9C26431852B8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, Informational and Administrative Expenses [Member]</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_D5FD1FF344784AC23F7F9C26431852B8_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_D5FD1FF344784AC23F7F9C26431852B8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_D5FD1FF344784AC23F7F9C26431852B8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_D5FD1FF344784AC23F7F9C26431852B8" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_D5FD1FF344784AC23F7F9C26431852B8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_F73112636689AE0FBFF99C26431879D4_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_F73112636689AE0FBFF99C26431879D4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_F73112636689AE0FBFF99C26431879D4_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_F73112636689AE0FBFF99C26431879D4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_F73112636689AE0FBFF99C26431879D4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember_F73112636689AE0FBFF99C26431879D4" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember_F73112636689AE0FBFF99C26431879D4" xlink:type="arc" />
    <link:label id="lab_pfe_OtherIncomeExpenseMember_5900C7FA344D739757019C264318BD38_terseLabel_en-US" xlink:label="lab_pfe_OtherIncomeExpenseMember_5900C7FA344D739757019C264318BD38" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other (Income)/Deductions - Net [Member]</link:label>
    <link:label id="lab_pfe_OtherIncomeExpenseMember_5900C7FA344D739757019C264318BD38_label_en-US" xlink:label="lab_pfe_OtherIncomeExpenseMember_5900C7FA344D739757019C264318BD38" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Income (Expense) [Member]</link:label>
    <link:label id="lab_pfe_OtherIncomeExpenseMember_5900C7FA344D739757019C264318BD38_documentation_en-US" xlink:label="lab_pfe_OtherIncomeExpenseMember_5900C7FA344D739757019C264318BD38" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Income (Expense) [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_OtherIncomeExpenseMember" xlink:label="loc_pfe_OtherIncomeExpenseMember_5900C7FA344D739757019C264318BD38" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherIncomeExpenseMember_5900C7FA344D739757019C264318BD38" xlink:to="lab_pfe_OtherIncomeExpenseMember_5900C7FA344D739757019C264318BD38" xlink:type="arc" />
    <link:label id="lab_pfe_BusinessCombinationExpectedIntegrationRelatedCostsPeriod_8437AE6B72C69EF70B0C9C26431D54C6_terseLabel_en-US" xlink:label="lab_pfe_BusinessCombinationExpectedIntegrationRelatedCostsPeriod_8437AE6B72C69EF70B0C9C26431D54C6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected integration related costs, period</link:label>
    <link:label id="lab_pfe_BusinessCombinationExpectedIntegrationRelatedCostsPeriod_8437AE6B72C69EF70B0C9C26431D54C6_label_en-US" xlink:label="lab_pfe_BusinessCombinationExpectedIntegrationRelatedCostsPeriod_8437AE6B72C69EF70B0C9C26431D54C6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Expected Integration Related Costs, Period</link:label>
    <link:label id="lab_pfe_BusinessCombinationExpectedIntegrationRelatedCostsPeriod_8437AE6B72C69EF70B0C9C26431D54C6_documentation_en-US" xlink:label="lab_pfe_BusinessCombinationExpectedIntegrationRelatedCostsPeriod_8437AE6B72C69EF70B0C9C26431D54C6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Expected Integration Related Costs, Period</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_BusinessCombinationExpectedIntegrationRelatedCostsPeriod" xlink:label="loc_pfe_BusinessCombinationExpectedIntegrationRelatedCostsPeriod_8437AE6B72C69EF70B0C9C26431D54C6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_BusinessCombinationExpectedIntegrationRelatedCostsPeriod_8437AE6B72C69EF70B0C9C26431D54C6" xlink:to="lab_pfe_BusinessCombinationExpectedIntegrationRelatedCostsPeriod_8437AE6B72C69EF70B0C9C26431D54C6" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationIntegrationRelatedCosts_47A79B3D765841FBA50C9C26431ECA01_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationIntegrationRelatedCosts_47A79B3D765841FBA50C9C26431ECA01" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Integration costs</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationIntegrationRelatedCosts_47A79B3D765841FBA50C9C26431ECA01_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationIntegrationRelatedCosts_47A79B3D765841FBA50C9C26431ECA01" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Integration Related Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationIntegrationRelatedCosts" xlink:label="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_47A79B3D765841FBA50C9C26431ECA01" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_47A79B3D765841FBA50C9C26431ECA01" xlink:to="lab_us-gaap_BusinessCombinationIntegrationRelatedCosts_47A79B3D765841FBA50C9C26431ECA01" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostIncurredCost_6D52639CE0ADD899E0509C26431E2D77_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostIncurredCost_6D52639CE0ADD899E0509C26431E2D77" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring cost incurred associated with the return of acquired in-process research and development rights</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostIncurredCost_6D52639CE0ADD899E0509C26431E2D77_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostIncurredCost_6D52639CE0ADD899E0509C26431E2D77" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Cost, Incurred Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:label="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_6D52639CE0ADD899E0509C26431E2D77" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_6D52639CE0ADD899E0509C26431E2D77" xlink:to="lab_us-gaap_RestructuringAndRelatedCostIncurredCost_6D52639CE0ADD899E0509C26431E2D77" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_14778AEDD61BA7FFA4889C26431EAF83_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_14778AEDD61BA7FFA4889C26431EAF83" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected restructuring cost</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_14778AEDD61BA7FFA4889C26431EAF83_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_14778AEDD61BA7FFA4889C26431EAF83" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Cost, Expected Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_14778AEDD61BA7FFA4889C26431EAF83" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_14778AEDD61BA7FFA4889C26431EAF83" xlink:to="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_14778AEDD61BA7FFA4889C26431EAF83" xlink:type="arc" />
    <link:label id="lab_pfe_RestructuringandRelatedCostNoncashChargesPercentage_752ABE2FF7427400E15B9C30B8575657_terseLabel_en-US" xlink:label="lab_pfe_RestructuringandRelatedCostNoncashChargesPercentage_752ABE2FF7427400E15B9C30B8575657" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of expected costs to be non-cash</link:label>
    <link:label id="lab_pfe_RestructuringandRelatedCostNoncashChargesPercentage_752ABE2FF7427400E15B9C30B8575657_label_en-US" xlink:label="lab_pfe_RestructuringandRelatedCostNoncashChargesPercentage_752ABE2FF7427400E15B9C30B8575657" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Cost, Noncash Charges, Percentage</link:label>
    <link:label id="lab_pfe_RestructuringandRelatedCostNoncashChargesPercentage_752ABE2FF7427400E15B9C30B8575657_documentation_en-US" xlink:label="lab_pfe_RestructuringandRelatedCostNoncashChargesPercentage_752ABE2FF7427400E15B9C30B8575657" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restructuring and Related Cost, Noncash Charges, Percentage</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_RestructuringandRelatedCostNoncashChargesPercentage" xlink:label="loc_pfe_RestructuringandRelatedCostNoncashChargesPercentage_752ABE2FF7427400E15B9C30B8575657" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_RestructuringandRelatedCostNoncashChargesPercentage_752ABE2FF7427400E15B9C30B8575657" xlink:to="lab_pfe_RestructuringandRelatedCostNoncashChargesPercentage_752ABE2FF7427400E15B9C30B8575657" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_ED29960F846FAF1B7BAB9C26431E0F7E_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_ED29960F846FAF1B7BAB9C26431E0F7E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring costs incurred</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_ED29960F846FAF1B7BAB9C26431E0F7E_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_ED29960F846FAF1B7BAB9C26431E0F7E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Cost, Cost Incurred to Date</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:label="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_ED29960F846FAF1B7BAB9C26431E0F7E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_ED29960F846FAF1B7BAB9C26431E0F7E" xlink:to="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_ED29960F846FAF1B7BAB9C26431E0F7E" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringChargesAbstract_DEE58F2CAEA7EC41E4439C26431E515F_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringChargesAbstract_DEE58F2CAEA7EC41E4439C26431E515F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring charges:</link:label>
    <link:label id="lab_us-gaap_RestructuringChargesAbstract_DEE58F2CAEA7EC41E4439C26431E515F_label_en-US" xlink:label="lab_us-gaap_RestructuringChargesAbstract_DEE58F2CAEA7EC41E4439C26431E515F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Charges [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringChargesAbstract" xlink:label="loc_us-gaap_RestructuringChargesAbstract_DEE58F2CAEA7EC41E4439C26431E515F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringChargesAbstract_DEE58F2CAEA7EC41E4439C26431E515F" xlink:to="lab_us-gaap_RestructuringChargesAbstract_DEE58F2CAEA7EC41E4439C26431E515F" xlink:type="arc" />
    <link:label id="lab_us-gaap_SeveranceCosts1_259673FFB6E4DD36956C9C26431EB9E2_terseLabel_en-US" xlink:label="lab_us-gaap_SeveranceCosts1_259673FFB6E4DD36956C9C26431EB9E2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee terminations</link:label>
    <link:label id="lab_us-gaap_SeveranceCosts1_259673FFB6E4DD36956C9C26431EB9E2_label_en-US" xlink:label="lab_us-gaap_SeveranceCosts1_259673FFB6E4DD36956C9C26431EB9E2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Severance Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeveranceCosts1" xlink:label="loc_us-gaap_SeveranceCosts1_259673FFB6E4DD36956C9C26431EB9E2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeveranceCosts1_259673FFB6E4DD36956C9C26431EB9E2" xlink:to="lab_us-gaap_SeveranceCosts1_259673FFB6E4DD36956C9C26431EB9E2" xlink:type="arc" />
    <link:label id="lab_pfe_RestructuringAssetImpairmentCharges_EA945165FB56660778959C26431E820B_netLabel_en-US" xlink:label="lab_pfe_RestructuringAssetImpairmentCharges_EA945165FB56660778959C26431E820B" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Asset impairments</link:label>
    <link:label id="lab_pfe_RestructuringAssetImpairmentCharges_EA945165FB56660778959C26431E820B_label_en-US" xlink:label="lab_pfe_RestructuringAssetImpairmentCharges_EA945165FB56660778959C26431E820B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring, Asset Impairment Charges</link:label>
    <link:label id="lab_pfe_RestructuringAssetImpairmentCharges_EA945165FB56660778959C26431E820B_documentation_en-US" xlink:label="lab_pfe_RestructuringAssetImpairmentCharges_EA945165FB56660778959C26431E820B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restructuring, Asset Impairment Charges</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_RestructuringAssetImpairmentCharges" xlink:label="loc_pfe_RestructuringAssetImpairmentCharges_EA945165FB56660778959C26431E820B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_RestructuringAssetImpairmentCharges_EA945165FB56660778959C26431E820B" xlink:to="lab_pfe_RestructuringAssetImpairmentCharges_EA945165FB56660778959C26431E820B" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessExitCosts1_A7F92F68BE4AA42A04839C26431E57B5_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessExitCosts1_A7F92F68BE4AA42A04839C26431E57B5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exit costs</link:label>
    <link:label id="lab_us-gaap_BusinessExitCosts1_A7F92F68BE4AA42A04839C26431E57B5_label_en-US" xlink:label="lab_us-gaap_BusinessExitCosts1_A7F92F68BE4AA42A04839C26431E57B5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Exit Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessExitCosts1" xlink:label="loc_us-gaap_BusinessExitCosts1_A7F92F68BE4AA42A04839C26431E57B5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessExitCosts1_A7F92F68BE4AA42A04839C26431E57B5" xlink:to="lab_us-gaap_BusinessExitCosts1_A7F92F68BE4AA42A04839C26431E57B5" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringCharges_75F0F00A91F7F2B7A5519C26431EE306_totalLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges_75F0F00A91F7F2B7A5519C26431EE306" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total restructuring charges</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_75F0F00A91F7F2B7A5519C26431EE306" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges_75F0F00A91F7F2B7A5519C26431EE306" xlink:to="lab_us-gaap_RestructuringCharges_75F0F00A91F7F2B7A5519C26431EE306" xlink:type="arc" />
    <link:label id="lab_pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts_D2189C6236BE7605CB839C26431ED851_terseLabel_en-US" xlink:label="lab_pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts_D2189C6236BE7605CB839C26431ED851" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transaction costs</link:label>
    <link:label id="lab_pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts_D2189C6236BE7605CB839C26431ED851_label_en-US" xlink:label="lab_pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts_D2189C6236BE7605CB839C26431ED851" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Acquisition Related Costs, Transaction Costs</link:label>
    <link:label id="lab_pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts_D2189C6236BE7605CB839C26431ED851_documentation_en-US" xlink:label="lab_pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts_D2189C6236BE7605CB839C26431ED851" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This element represents external costs directly related to effecting a business combination which costs have been expensed during the period. Such costs include advisory, legal, accounting, valuation, and other similar services.</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts" xlink:label="loc_pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts_D2189C6236BE7605CB839C26431ED851" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts_D2189C6236BE7605CB839C26431ED851" xlink:to="lab_pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts_D2189C6236BE7605CB839C26431ED851" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationIntegrationRelatedCosts_2B6031F007B8ECB2ECB29C26431E1F01_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationIntegrationRelatedCosts_2B6031F007B8ECB2ECB29C26431E1F01" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Integration costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationIntegrationRelatedCosts" xlink:label="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_2B6031F007B8ECB2ECB29C26431E1F01" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_2B6031F007B8ECB2ECB29C26431E1F01" xlink:to="lab_us-gaap_BusinessCombinationIntegrationRelatedCosts_2B6031F007B8ECB2ECB29C26431E1F01" xlink:type="arc" />
    <link:label id="lab_pfe_RestructuringChargesAndAcquisitionRelatedCosts_BFB0FF6A296F75005B149C26431E157B_totalLabel_en-US" xlink:label="lab_pfe_RestructuringChargesAndAcquisitionRelatedCosts_BFB0FF6A296F75005B149C26431E157B" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Restructuring charges and certain acquisition-related costs</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_RestructuringChargesAndAcquisitionRelatedCosts" xlink:label="loc_pfe_RestructuringChargesAndAcquisitionRelatedCosts_BFB0FF6A296F75005B149C26431E157B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_RestructuringChargesAndAcquisitionRelatedCosts_BFB0FF6A296F75005B149C26431E157B" xlink:to="lab_pfe_RestructuringChargesAndAcquisitionRelatedCosts_BFB0FF6A296F75005B149C26431E157B" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringReserveAcceleratedDepreciation_9F7C0E2FA20C7A8CA3069C26431EF616_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveAcceleratedDepreciation_9F7C0E2FA20C7A8CA3069C26431EF616" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total additional depreciation&#8211;&#8211;asset restructuring</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveAcceleratedDepreciation_9F7C0E2FA20C7A8CA3069C26431EF616_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveAcceleratedDepreciation_9F7C0E2FA20C7A8CA3069C26431EF616" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Cost, Accelerated Depreciation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringReserveAcceleratedDepreciation" xlink:label="loc_us-gaap_RestructuringReserveAcceleratedDepreciation_9F7C0E2FA20C7A8CA3069C26431EF616" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveAcceleratedDepreciation_9F7C0E2FA20C7A8CA3069C26431EF616" xlink:to="lab_us-gaap_RestructuringReserveAcceleratedDepreciation_9F7C0E2FA20C7A8CA3069C26431EF616" xlink:type="arc" />
    <link:label id="lab_pfe_ImplementationCostAbstract_2D129AC7E2F938D05CC99C26431EF49E_terseLabel_en-US" xlink:label="lab_pfe_ImplementationCostAbstract_2D129AC7E2F938D05CC99C26431EF49E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Implementation costs recorded in our condensed consolidated statements of income as follows:</link:label>
    <link:label id="lab_pfe_ImplementationCostAbstract_2D129AC7E2F938D05CC99C26431EF49E_label_en-US" xlink:label="lab_pfe_ImplementationCostAbstract_2D129AC7E2F938D05CC99C26431EF49E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Implementation Cost [Abstract]</link:label>
    <link:label id="lab_pfe_ImplementationCostAbstract_2D129AC7E2F938D05CC99C26431EF49E_documentation_en-US" xlink:label="lab_pfe_ImplementationCostAbstract_2D129AC7E2F938D05CC99C26431EF49E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Implementation Cost [Abstract]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_ImplementationCostAbstract" xlink:label="loc_pfe_ImplementationCostAbstract_2D129AC7E2F938D05CC99C26431EF49E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ImplementationCostAbstract_2D129AC7E2F938D05CC99C26431EF49E" xlink:to="lab_pfe_ImplementationCostAbstract_2D129AC7E2F938D05CC99C26431EF49E" xlink:type="arc" />
    <link:label id="lab_pfe_ImplementationCosts_448A4FBE347219FC098C9C26431ECBDC_terseLabel_en-US" xlink:label="lab_pfe_ImplementationCosts_448A4FBE347219FC098C9C26431ECBDC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total implementation costs</link:label>
    <link:label id="lab_pfe_ImplementationCosts_448A4FBE347219FC098C9C26431ECBDC_label_en-US" xlink:label="lab_pfe_ImplementationCosts_448A4FBE347219FC098C9C26431ECBDC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Implementation Costs</link:label>
    <link:label id="lab_pfe_ImplementationCosts_448A4FBE347219FC098C9C26431ECBDC_documentation_en-US" xlink:label="lab_pfe_ImplementationCosts_448A4FBE347219FC098C9C26431ECBDC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Implementation costs represent external, incremental costs directly related to Implementing cost-reduction initiatives, and primarily include expenditures related to system and process standardization and the expansion of shared services.</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_ImplementationCosts" xlink:label="loc_pfe_ImplementationCosts_448A4FBE347219FC098C9C26431ECBDC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ImplementationCosts_448A4FBE347219FC098C9C26431ECBDC" xlink:to="lab_pfe_ImplementationCosts_448A4FBE347219FC098C9C26431ECBDC" xlink:type="arc" />
    <link:label id="lab_pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts_2AF4FC65BD5170C491E09C26431FE1B1_totalLabel_en-US" xlink:label="lab_pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts_2AF4FC65BD5170C491E09C26431FE1B1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total costs associated with acquisitions and cost-reduction/productivity initiatives</link:label>
    <link:label id="lab_pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts_2AF4FC65BD5170C491E09C26431FE1B1_label_en-US" xlink:label="lab_pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts_2AF4FC65BD5170C491E09C26431FE1B1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Charges, Acquisition Related Costs and Implementation Costs</link:label>
    <link:label id="lab_pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts_2AF4FC65BD5170C491E09C26431FE1B1_documentation_en-US" xlink:label="lab_pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts_2AF4FC65BD5170C491E09C26431FE1B1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restructuring Charges, Acquisition Related Costs and Implementation Costs</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts" xlink:label="loc_pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts_2AF4FC65BD5170C491E09C26431FE1B1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts_2AF4FC65BD5170C491E09C26431FE1B1" xlink:to="lab_pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts_2AF4FC65BD5170C491E09C26431FE1B1" xlink:type="arc" />
    <link:label id="lab_pfe_DocumentandEntityInformationAbstract_42D3E5D6634DB04FF870983AF789FA65_label_en-US" xlink:label="lab_pfe_DocumentandEntityInformationAbstract_42D3E5D6634DB04FF870983AF789FA65" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document and Entity Information [Abstract]</link:label>
    <link:label id="lab_pfe_DocumentandEntityInformationAbstract_42D3E5D6634DB04FF870983AF789FA65_documentation_en-US" xlink:label="lab_pfe_DocumentandEntityInformationAbstract_42D3E5D6634DB04FF870983AF789FA65" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Document and Entity Information [Abstract]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_DocumentandEntityInformationAbstract" xlink:label="loc_pfe_DocumentandEntityInformationAbstract_42D3E5D6634DB04FF870983AF789FA65" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DocumentandEntityInformationAbstract_42D3E5D6634DB04FF870983AF789FA65" xlink:to="lab_pfe_DocumentandEntityInformationAbstract_42D3E5D6634DB04FF870983AF789FA65" xlink:type="arc" />
    <link:label id="lab_dei_EntityRegistrantName_A2CD80B2C6B27A8BD21C983AF793AB52_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName_A2CD80B2C6B27A8BD21C983AF793AB52" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_A2CD80B2C6B27A8BD21C983AF793AB52_label_en-US" xlink:label="lab_dei_EntityRegistrantName_A2CD80B2C6B27A8BD21C983AF793AB52" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_A2CD80B2C6B27A8BD21C983AF793AB52" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName_A2CD80B2C6B27A8BD21C983AF793AB52" xlink:to="lab_dei_EntityRegistrantName_A2CD80B2C6B27A8BD21C983AF793AB52" xlink:type="arc" />
    <link:label id="lab_dei_EntityCentralIndexKey_4B28099BAB4ED65CE40B983AF794AE41_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey_4B28099BAB4ED65CE40B983AF794AE41" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_4B28099BAB4ED65CE40B983AF794AE41_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey_4B28099BAB4ED65CE40B983AF794AE41" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_4B28099BAB4ED65CE40B983AF794AE41" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey_4B28099BAB4ED65CE40B983AF794AE41" xlink:to="lab_dei_EntityCentralIndexKey_4B28099BAB4ED65CE40B983AF794AE41" xlink:type="arc" />
    <link:label id="lab_dei_CurrentFiscalYearEndDate_6059370256CC9525769A983AF795F298_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_6059370256CC9525769A983AF795F298" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_6059370256CC9525769A983AF795F298_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_6059370256CC9525769A983AF795F298" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_6059370256CC9525769A983AF795F298" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate_6059370256CC9525769A983AF795F298" xlink:to="lab_dei_CurrentFiscalYearEndDate_6059370256CC9525769A983AF795F298" xlink:type="arc" />
    <link:label id="lab_dei_EntityFilerCategory_B8F4E202020BAD4AE042983AF7956E5B_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory_B8F4E202020BAD4AE042983AF7956E5B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_B8F4E202020BAD4AE042983AF7956E5B_label_en-US" xlink:label="lab_dei_EntityFilerCategory_B8F4E202020BAD4AE042983AF7956E5B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_B8F4E202020BAD4AE042983AF7956E5B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory_B8F4E202020BAD4AE042983AF7956E5B" xlink:to="lab_dei_EntityFilerCategory_B8F4E202020BAD4AE042983AF7956E5B" xlink:type="arc" />
    <link:label id="lab_dei_DocumentType_90DDD565A7E3B54845D6983AF795614D_terseLabel_en-US" xlink:label="lab_dei_DocumentType_90DDD565A7E3B54845D6983AF795614D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_90DDD565A7E3B54845D6983AF795614D_label_en-US" xlink:label="lab_dei_DocumentType_90DDD565A7E3B54845D6983AF795614D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_90DDD565A7E3B54845D6983AF795614D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType_90DDD565A7E3B54845D6983AF795614D" xlink:to="lab_dei_DocumentType_90DDD565A7E3B54845D6983AF795614D" xlink:type="arc" />
    <link:label id="lab_dei_DocumentPeriodEndDate_6FAD49566DBB549309E8983AF795E884_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_6FAD49566DBB549309E8983AF795E884" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_6FAD49566DBB549309E8983AF795E884_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_6FAD49566DBB549309E8983AF795E884" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_6FAD49566DBB549309E8983AF795E884" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate_6FAD49566DBB549309E8983AF795E884" xlink:to="lab_dei_DocumentPeriodEndDate_6FAD49566DBB549309E8983AF795E884" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalYearFocus_F76C9D1658BDFCD8FAB4983AF795A32A_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_F76C9D1658BDFCD8FAB4983AF795A32A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_F76C9D1658BDFCD8FAB4983AF795A32A_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_F76C9D1658BDFCD8FAB4983AF795A32A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_F76C9D1658BDFCD8FAB4983AF795A32A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus_F76C9D1658BDFCD8FAB4983AF795A32A" xlink:to="lab_dei_DocumentFiscalYearFocus_F76C9D1658BDFCD8FAB4983AF795A32A" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_A5128C513A7D59418918983AF7951A67_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_A5128C513A7D59418918983AF7951A67" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_A5128C513A7D59418918983AF7951A67_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_A5128C513A7D59418918983AF7951A67" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_A5128C513A7D59418918983AF7951A67" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus_A5128C513A7D59418918983AF7951A67" xlink:to="lab_dei_DocumentFiscalPeriodFocus_A5128C513A7D59418918983AF7951A67" xlink:type="arc" />
    <link:label id="lab_dei_AmendmentFlag_5863FF50D1ABF837F8A2983AF795DE4A_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag_5863FF50D1ABF837F8A2983AF795DE4A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_5863FF50D1ABF837F8A2983AF795DE4A_label_en-US" xlink:label="lab_dei_AmendmentFlag_5863FF50D1ABF837F8A2983AF795DE4A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_5863FF50D1ABF837F8A2983AF795DE4A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag_5863FF50D1ABF837F8A2983AF795DE4A" xlink:to="lab_dei_AmendmentFlag_5863FF50D1ABF837F8A2983AF795DE4A" xlink:type="arc" />
    <link:label id="lab_dei_TradingSymbol_F66B89D653C9A717BA12983AF7958104_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol_F66B89D653C9A717BA12983AF7958104" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_F66B89D653C9A717BA12983AF7958104_label_en-US" xlink:label="lab_dei_TradingSymbol_F66B89D653C9A717BA12983AF7958104" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_F66B89D653C9A717BA12983AF7958104" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol_F66B89D653C9A717BA12983AF7958104" xlink:to="lab_dei_TradingSymbol_F66B89D653C9A717BA12983AF7958104" xlink:type="arc" />
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_A0D5D1A02BDC6BAEBA4D983AF7967C4D_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_A0D5D1A02BDC6BAEBA4D983AF7967C4D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_A0D5D1A02BDC6BAEBA4D983AF7967C4D_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_A0D5D1A02BDC6BAEBA4D983AF7967C4D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_A0D5D1A02BDC6BAEBA4D983AF7967C4D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding_A0D5D1A02BDC6BAEBA4D983AF7967C4D" xlink:to="lab_dei_EntityCommonStockSharesOutstanding_A0D5D1A02BDC6BAEBA4D983AF7967C4D" xlink:type="arc" />
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_7F3BD5F71D5FF0A4FD2BAE9F924BA2FB_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_5ED0B1634B0F5BAD901D0C8CE8AEB8FE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension and Postretirement Benefit Plans</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_7F3BD5F71D5FF0A4FD2BAE9F924BA2FB_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_5ED0B1634B0F5BAD901D0C8CE8AEB8FE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension and Other Postretirement Benefits Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_5ED0B1634B0F5BAD901D0C8CE8AEB8FE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_5ED0B1634B0F5BAD901D0C8CE8AEB8FE" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_5ED0B1634B0F5BAD901D0C8CE8AEB8FE" xlink:type="arc" />
    <link:label id="lab_pfe_IntangibleAssetsTransfersDuringPeriod_988F44A098D76E58DBD6831F4DF37EBC_terseLabel_en-US" xlink:label="lab_pfe_IntangibleAssetsTransfersDuringPeriod_988F44A098D76E58DBD6831F4DF37EBC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transfer of intangible assets during period</link:label>
    <link:label id="lab_pfe_IntangibleAssetsTransfersDuringPeriod_988F44A098D76E58DBD6831F4DF37EBC_label_en-US" xlink:label="lab_pfe_IntangibleAssetsTransfersDuringPeriod_988F44A098D76E58DBD6831F4DF37EBC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Transfers During Period</link:label>
    <link:label id="lab_pfe_IntangibleAssetsTransfersDuringPeriod_988F44A098D76E58DBD6831F4DF37EBC_documentation_en-US" xlink:label="lab_pfe_IntangibleAssetsTransfersDuringPeriod_988F44A098D76E58DBD6831F4DF37EBC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Intangible Assets, Transfers During Period</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_IntangibleAssetsTransfersDuringPeriod" xlink:label="loc_pfe_IntangibleAssetsTransfersDuringPeriod_988F44A098D76E58DBD6831F4DF37EBC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_IntangibleAssetsTransfersDuringPeriod_988F44A098D76E58DBD6831F4DF37EBC" xlink:to="lab_pfe_IntangibleAssetsTransfersDuringPeriod_988F44A098D76E58DBD6831F4DF37EBC" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_349DD2C7AB98C46186EE831F4DF39D1C_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet_349DD2C7AB98C46186EE831F4DF39D1C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Increase in finite-lived intangible assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_349DD2C7AB98C46186EE831F4DF39D1C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_349DD2C7AB98C46186EE831F4DF39D1C" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet_349DD2C7AB98C46186EE831F4DF39D1C" xlink:type="arc" />
    <link:label id="lab_pfe_PfizersWorldwideResearchandDevelopmentMember_C4DA8B9013AA27A20071AE9F9256FD21_terseLabel_en-US" xlink:label="lab_pfe_PfizersWorldwideResearchandDevelopmentMember_FE77081B14DE5E099708308981CBAFA6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pfizer's Worldwide Research and Development [Member]</link:label>
    <link:label id="lab_pfe_PfizersWorldwideResearchandDevelopmentMember_C4DA8B9013AA27A20071AE9F9256FD21_label_en-US" xlink:label="lab_pfe_PfizersWorldwideResearchandDevelopmentMember_FE77081B14DE5E099708308981CBAFA6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pfizer's Worldwide Research and Development [Member]</link:label>
    <link:label id="lab_pfe_PfizersWorldwideResearchandDevelopmentMember_C4DA8B9013AA27A20071AE9F9256FD21_documentation_en-US" xlink:label="lab_pfe_PfizersWorldwideResearchandDevelopmentMember_FE77081B14DE5E099708308981CBAFA6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pfizer's Worldwide Research and Development [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_PfizersWorldwideResearchandDevelopmentMember" xlink:label="loc_pfe_PfizersWorldwideResearchandDevelopmentMember_FE77081B14DE5E099708308981CBAFA6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_PfizersWorldwideResearchandDevelopmentMember_FE77081B14DE5E099708308981CBAFA6" xlink:to="lab_pfe_PfizersWorldwideResearchandDevelopmentMember_FE77081B14DE5E099708308981CBAFA6" xlink:type="arc" />
    <link:label id="lab_pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet_E349EB5D26FFF88FA320AE9F92575723_terseLabel_en-US" xlink:label="lab_pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet_9DE84574D1FD5FBCB9219FEB6426C264" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of total identifiable intangible assets, less accumulated amortization</link:label>
    <link:label id="lab_pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet_E349EB5D26FFF88FA320AE9F92575723_label_en-US" xlink:label="lab_pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet_9DE84574D1FD5FBCB9219FEB6426C264" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net, Percentage of Intangible Assets, Net</link:label>
    <link:label id="lab_pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet_E349EB5D26FFF88FA320AE9F92575723_documentation_en-US" xlink:label="lab_pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet_9DE84574D1FD5FBCB9219FEB6426C264" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net, Percentage of Intangible Assets, Net</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet" xlink:label="loc_pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet_9DE84574D1FD5FBCB9219FEB6426C264" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet_9DE84574D1FD5FBCB9219FEB6426C264" xlink:to="lab_pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet_9DE84574D1FD5FBCB9219FEB6426C264" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_A4AE6D7FC6AEC33A451483C06F8FDCA8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_A4AE6D7FC6AEC33A451483C06F8FDCA8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_A4AE6D7FC6AEC33A451483C06F8FDCA8_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_A4AE6D7FC6AEC33A451483C06F8FDCA8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_A4AE6D7FC6AEC33A451483C06F8FDCA8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_A4AE6D7FC6AEC33A451483C06F8FDCA8" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_A4AE6D7FC6AEC33A451483C06F8FDCA8" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_1FEA307C61087941203583C06F8FED0A_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_1FEA307C61087941203583C06F8FED0A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Hierarchy [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_1FEA307C61087941203583C06F8FED0A_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_1FEA307C61087941203583C06F8FED0A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Hierarchy [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1FEA307C61087941203583C06F8FED0A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1FEA307C61087941203583C06F8FED0A" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_1FEA307C61087941203583C06F8FED0A" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_AAAB1E8F0CECBC2F4EA683C06F8F9BC4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_AAAB1E8F0CECBC2F4EA683C06F8F9BC4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_AAAB1E8F0CECBC2F4EA683C06F8F9BC4_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_AAAB1E8F0CECBC2F4EA683C06F8F9BC4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_AAAB1E8F0CECBC2F4EA683C06F8F9BC4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_AAAB1E8F0CECBC2F4EA683C06F8F9BC4" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_AAAB1E8F0CECBC2F4EA683C06F8F9BC4" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_C93D7B408724595C813583C06F94CCD6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_C93D7B408724595C813583C06F94CCD6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 2 [Member]</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_C93D7B408724595C813583C06F94CCD6_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_C93D7B408724595C813583C06F94CCD6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_C93D7B408724595C813583C06F94CCD6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member_C93D7B408724595C813583C06F94CCD6" xlink:to="lab_us-gaap_FairValueInputsLevel2Member_C93D7B408724595C813583C06F94CCD6" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_4D72FB2E33761506BAAE83C06F9568FF_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis_4D72FB2E33761506BAAE83C06F9568FF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_4D72FB2E33761506BAAE83C06F9568FF_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis_4D72FB2E33761506BAAE83C06F9568FF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_4D72FB2E33761506BAAE83C06F9568FF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_4D72FB2E33761506BAAE83C06F9568FF" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis_4D72FB2E33761506BAAE83C06F9568FF" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_3E8E008349FD4001FE8483C06F956A9C_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain_3E8E008349FD4001FE8483C06F956A9C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_3E8E008349FD4001FE8483C06F956A9C_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain_3E8E008349FD4001FE8483C06F956A9C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement Frequency [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_3E8E008349FD4001FE8483C06F956A9C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_3E8E008349FD4001FE8483C06F956A9C" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain_3E8E008349FD4001FE8483C06F956A9C" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_E2A9923B9CA59CC7CCF383C06F95AEC8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember_E2A9923B9CA59CC7CCF383C06F95AEC8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurements, Recurring [Member]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_E2A9923B9CA59CC7CCF383C06F95AEC8_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember_E2A9923B9CA59CC7CCF383C06F95AEC8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurements, Recurring [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_E2A9923B9CA59CC7CCF383C06F95AEC8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember_E2A9923B9CA59CC7CCF383C06F95AEC8" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember_E2A9923B9CA59CC7CCF383C06F95AEC8" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_16D79AF9254B2BA65ED383C06F9591C2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis_16D79AF9254B2BA65ED383C06F9591C2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_16D79AF9254B2BA65ED383C06F9591C2_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis_16D79AF9254B2BA65ED383C06F9591C2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_16D79AF9254B2BA65ED383C06F9591C2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_16D79AF9254B2BA65ED383C06F9591C2" xlink:to="lab_us-gaap_FairValueByMeasurementBasisAxis_16D79AF9254B2BA65ED383C06F9591C2" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_26361C6280493481B9F383C06F95ACB3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain_26361C6280493481B9F383C06F95ACB3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_26361C6280493481B9F383C06F95ACB3_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain_26361C6280493481B9F383C06F95ACB3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_26361C6280493481B9F383C06F95ACB3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_26361C6280493481B9F383C06F95ACB3" xlink:to="lab_us-gaap_FairValueDisclosureItemAmountsDomain_26361C6280493481B9F383C06F95ACB3" xlink:type="arc" />
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_CED491933FFCD21929B283C06F9583AE_terseLabel_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_CED491933FFCD21929B283C06F9583AE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Portion at Fair Value Measurement [Member]</link:label>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_CED491933FFCD21929B283C06F9583AE_label_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_CED491933FFCD21929B283C06F9583AE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Portion at Fair Value Measurement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_CED491933FFCD21929B283C06F9583AE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_CED491933FFCD21929B283C06F9583AE" xlink:to="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_CED491933FFCD21929B283C06F9583AE" xlink:type="arc" />
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_2F465C3BD268775757BB83C06F957AA5_terseLabel_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_2F465C3BD268775757BB83C06F957AA5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimate of Fair Value Measurement [Member]</link:label>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_2F465C3BD268775757BB83C06F957AA5_label_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_2F465C3BD268775757BB83C06F957AA5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Estimate of Fair Value Measurement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_2F465C3BD268775757BB83C06F957AA5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_2F465C3BD268775757BB83C06F957AA5" xlink:to="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_2F465C3BD268775757BB83C06F957AA5" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1CD67510301DF2EAD6AD83C06F95E921_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1CD67510301DF2EAD6AD83C06F95E921" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1CD67510301DF2EAD6AD83C06F95E921_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1CD67510301DF2EAD6AD83C06F95E921" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1CD67510301DF2EAD6AD83C06F95E921" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1CD67510301DF2EAD6AD83C06F95E921" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1CD67510301DF2EAD6AD83C06F95E921" xlink:type="arc" />
    <link:label id="lab_pfe_FootnotesToSelectedFinancialAssetsAndLiabilitiesAbstract_47737018BB84937F2CB083C06F969081_terseLabel_en-US" xlink:label="lab_pfe_FootnotesToSelectedFinancialAssetsAndLiabilitiesAbstract_47737018BB84937F2CB083C06F969081" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Footnotes to selected financial assets and liabilities:</link:label>
    <link:label id="lab_pfe_FootnotesToSelectedFinancialAssetsAndLiabilitiesAbstract_47737018BB84937F2CB083C06F969081_label_en-US" xlink:label="lab_pfe_FootnotesToSelectedFinancialAssetsAndLiabilitiesAbstract_47737018BB84937F2CB083C06F969081" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Footnotes To Selected Financial Assets And Liabilities [Abstract]</link:label>
    <link:label id="lab_pfe_FootnotesToSelectedFinancialAssetsAndLiabilitiesAbstract_47737018BB84937F2CB083C06F969081_documentation_en-US" xlink:label="lab_pfe_FootnotesToSelectedFinancialAssetsAndLiabilitiesAbstract_47737018BB84937F2CB083C06F969081" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Footnotes to selected financial assets and liabilities [Abstract]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_FootnotesToSelectedFinancialAssetsAndLiabilitiesAbstract" xlink:label="loc_pfe_FootnotesToSelectedFinancialAssetsAndLiabilitiesAbstract_47737018BB84937F2CB083C06F969081" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_FootnotesToSelectedFinancialAssetsAndLiabilitiesAbstract_47737018BB84937F2CB083C06F969081" xlink:to="lab_pfe_FootnotesToSelectedFinancialAssetsAndLiabilitiesAbstract_47737018BB84937F2CB083C06F969081" xlink:type="arc" />
    <link:label id="lab_pfe_FinancialAssetsAndLiabilitiesMeasuredAtFairValuePercentage_FAFE5F2A581C842C8DDB83C06F965418_terseLabel_en-US" xlink:label="lab_pfe_FinancialAssetsAndLiabilitiesMeasuredAtFairValuePercentage_FAFE5F2A581C842C8DDB83C06F965418" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of financial assets and liabilities measured at fair value inputs Level 1 and Level 3 inputs (less than)</link:label>
    <link:label id="lab_pfe_FinancialAssetsAndLiabilitiesMeasuredAtFairValuePercentage_FAFE5F2A581C842C8DDB83C06F965418_label_en-US" xlink:label="lab_pfe_FinancialAssetsAndLiabilitiesMeasuredAtFairValuePercentage_FAFE5F2A581C842C8DDB83C06F965418" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Assets And Liabilities Measured At Fair Value, Percentage</link:label>
    <link:label id="lab_pfe_FinancialAssetsAndLiabilitiesMeasuredAtFairValuePercentage_FAFE5F2A581C842C8DDB83C06F965418_documentation_en-US" xlink:label="lab_pfe_FinancialAssetsAndLiabilitiesMeasuredAtFairValuePercentage_FAFE5F2A581C842C8DDB83C06F965418" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Financial Assets And Liabilities Measured At Fair Value, Percentage</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_FinancialAssetsAndLiabilitiesMeasuredAtFairValuePercentage" xlink:label="loc_pfe_FinancialAssetsAndLiabilitiesMeasuredAtFairValuePercentage_FAFE5F2A581C842C8DDB83C06F965418" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_FinancialAssetsAndLiabilitiesMeasuredAtFairValuePercentage_FAFE5F2A581C842C8DDB83C06F965418" xlink:to="lab_pfe_FinancialAssetsAndLiabilitiesMeasuredAtFairValuePercentage_FAFE5F2A581C842C8DDB83C06F965418" xlink:type="arc" />
    <link:label id="lab_us-gaap_TradingSecuritiesEquity_17550727984FD2E15D9B83C06F96B03A_verboseLabel_en-US" xlink:label="lab_us-gaap_TradingSecuritiesEquity_17550727984FD2E15D9B83C06F96B03A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Trading equity funds</link:label>
    <link:label id="lab_us-gaap_TradingSecuritiesEquity_17550727984FD2E15D9B83C06F96B03A_label_en-US" xlink:label="lab_us-gaap_TradingSecuritiesEquity_17550727984FD2E15D9B83C06F96B03A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Securities, Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TradingSecuritiesEquity" xlink:label="loc_us-gaap_TradingSecuritiesEquity_17550727984FD2E15D9B83C06F96B03A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradingSecuritiesEquity_17550727984FD2E15D9B83C06F96B03A" xlink:to="lab_us-gaap_TradingSecuritiesEquity_17550727984FD2E15D9B83C06F96B03A" xlink:type="arc" />
    <link:label id="lab_us-gaap_TradingSecuritiesDebt_C1D3E3C5DD0B2D28137483C06F96161D_verboseLabel_en-US" xlink:label="lab_us-gaap_TradingSecuritiesDebt_C1D3E3C5DD0B2D28137483C06F96161D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Trading debt funds</link:label>
    <link:label id="lab_us-gaap_TradingSecuritiesDebt_C1D3E3C5DD0B2D28137483C06F96161D_label_en-US" xlink:label="lab_us-gaap_TradingSecuritiesDebt_C1D3E3C5DD0B2D28137483C06F96161D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Securities, Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TradingSecuritiesDebt" xlink:label="loc_us-gaap_TradingSecuritiesDebt_C1D3E3C5DD0B2D28137483C06F96161D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradingSecuritiesDebt_C1D3E3C5DD0B2D28137483C06F96161D" xlink:to="lab_us-gaap_TradingSecuritiesDebt_C1D3E3C5DD0B2D28137483C06F96161D" xlink:type="arc" />
    <link:label id="lab_us-gaap_TradingSecuritiesRestricted_F273278ECB9D2A003ED983C06F9BCD03_terseLabel_en-US" xlink:label="lab_us-gaap_TradingSecuritiesRestricted_F273278ECB9D2A003ED983C06F9BCD03" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading securities held in trust</link:label>
    <link:label id="lab_us-gaap_TradingSecuritiesRestricted_F273278ECB9D2A003ED983C06F9BCD03_label_en-US" xlink:label="lab_us-gaap_TradingSecuritiesRestricted_F273278ECB9D2A003ED983C06F9BCD03" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Securities, Restricted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TradingSecuritiesRestricted" xlink:label="loc_us-gaap_TradingSecuritiesRestricted_F273278ECB9D2A003ED983C06F9BCD03" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradingSecuritiesRestricted_F273278ECB9D2A003ED983C06F9BCD03" xlink:to="lab_us-gaap_TradingSecuritiesRestricted_F273278ECB9D2A003ED983C06F9BCD03" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleEquitySecuritiesGrossUnrealizedGain_018B8867E1C6BEDC056583C06F9B518A_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleEquitySecuritiesGrossUnrealizedGain_018B8867E1C6BEDC056583C06F9B518A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross unrealized gain</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleEquitySecuritiesGrossUnrealizedGain_018B8867E1C6BEDC056583C06F9B518A_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleEquitySecuritiesGrossUnrealizedGain_018B8867E1C6BEDC056583C06F9B518A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Equity Securities, Gross Unrealized Gain</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleEquitySecuritiesGrossUnrealizedGain" xlink:label="loc_us-gaap_AvailableForSaleEquitySecuritiesGrossUnrealizedGain_018B8867E1C6BEDC056583C06F9B518A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleEquitySecuritiesGrossUnrealizedGain_018B8867E1C6BEDC056583C06F9B518A" xlink:to="lab_us-gaap_AvailableForSaleEquitySecuritiesGrossUnrealizedGain_018B8867E1C6BEDC056583C06F9B518A" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleEquitySecuritiesGrossUnrealizedLoss_292E722B66CBD96B1C8B83C06F9BF32D_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleEquitySecuritiesGrossUnrealizedLoss_292E722B66CBD96B1C8B83C06F9BF32D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross unrealized loss</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleEquitySecuritiesGrossUnrealizedLoss_292E722B66CBD96B1C8B83C06F9BF32D_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleEquitySecuritiesGrossUnrealizedLoss_292E722B66CBD96B1C8B83C06F9BF32D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Equity Securities, Gross Unrealized Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleEquitySecuritiesGrossUnrealizedLoss" xlink:label="loc_us-gaap_AvailableForSaleEquitySecuritiesGrossUnrealizedLoss_292E722B66CBD96B1C8B83C06F9BF32D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleEquitySecuritiesGrossUnrealizedLoss_292E722B66CBD96B1C8B83C06F9BF32D" xlink:to="lab_us-gaap_AvailableForSaleEquitySecuritiesGrossUnrealizedLoss_292E722B66CBD96B1C8B83C06F9BF32D" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_8B4684F6A889AD23A6B183C06F9B105D_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_8B4684F6A889AD23A6B183C06F9B105D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Instruments used as offsets (assets)</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_8B4684F6A889AD23A6B183C06F9B105D_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_8B4684F6A889AD23A6B183C06F9B105D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Asset, Fair Value, Gross Asset</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_8B4684F6A889AD23A6B183C06F9B105D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_8B4684F6A889AD23A6B183C06F9B105D" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_8B4684F6A889AD23A6B183C06F9B105D" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_BEA2FACC412603EC2E9C83C06F9CDE02_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_BEA2FACC412603EC2E9C83C06F9CDE02" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Instruments used as offsets (liabilities)</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_BEA2FACC412603EC2E9C83C06F9CDE02_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_BEA2FACC412603EC2E9C83C06F9CDE02" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Liability, Fair Value, Gross Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_BEA2FACC412603EC2E9C83C06F9CDE02" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_BEA2FACC412603EC2E9C83C06F9CDE02" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_BEA2FACC412603EC2E9C83C06F9CDE02" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtFairValue_682A819E7E6ECBFB4D5783C06F9C4D9F_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue_682A819E7E6ECBFB4D5783C06F9C4D9F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_682A819E7E6ECBFB4D5783C06F9C4D9F_label_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue_682A819E7E6ECBFB4D5783C06F9C4D9F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtFairValue" xlink:label="loc_us-gaap_LongTermDebtFairValue_682A819E7E6ECBFB4D5783C06F9C4D9F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtFairValue_682A819E7E6ECBFB4D5783C06F9C4D9F" xlink:to="lab_us-gaap_LongTermDebtFairValue_682A819E7E6ECBFB4D5783C06F9C4D9F" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_F94C2249B5D7BD6A5A59922806190712_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract_F94C2249B5D7BD6A5A59922806190712" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_F94C2249B5D7BD6A5A59922806190712" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_F94C2249B5D7BD6A5A59922806190712" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract_F94C2249B5D7BD6A5A59922806190712" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_1711DF4DF5E61D767ACB92280624F1DB_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_1711DF4DF5E61D767ACB92280624F1DB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1711DF4DF5E61D767ACB92280624F1DB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1711DF4DF5E61D767ACB92280624F1DB" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_1711DF4DF5E61D767ACB92280624F1DB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShortTermInvestments_A686AA9DA2F1D4186F6A9228062B4990_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestments_A686AA9DA2F1D4186F6A9228062B4990" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestments_A686AA9DA2F1D4186F6A9228062B4990_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestments_A686AA9DA2F1D4186F6A9228062B4990" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-term Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaap_ShortTermInvestments_A686AA9DA2F1D4186F6A9228062B4990" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestments_A686AA9DA2F1D4186F6A9228062B4990" xlink:to="lab_us-gaap_ShortTermInvestments_A686AA9DA2F1D4186F6A9228062B4990" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_C13FD68362E825C322059228062B005D_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_C13FD68362E825C322059228062B005D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trade accounts receivable, less allowance for doubtful accounts: 2017&#8212;$590; 2016&#8212;$609</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_C13FD68362E825C322059228062B005D_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_C13FD68362E825C322059228062B005D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Net, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_C13FD68362E825C322059228062B005D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_C13FD68362E825C322059228062B005D" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent_C13FD68362E825C322059228062B005D" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryNet_5A761FB27869C6AEBC149228062B55D2_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet_5A761FB27869C6AEBC149228062B55D2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_5A761FB27869C6AEBC149228062B55D2_label_en-US" xlink:label="lab_us-gaap_InventoryNet_5A761FB27869C6AEBC149228062B55D2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_5A761FB27869C6AEBC149228062B55D2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet_5A761FB27869C6AEBC149228062B55D2" xlink:to="lab_us-gaap_InventoryNet_5A761FB27869C6AEBC149228062B55D2" xlink:type="arc" />
    <link:label id="lab_pfe_OtherTaxAssetsCurrent_0C80B6B41F2551E8EBB59228062CF695_terseLabel_en-US" xlink:label="lab_pfe_OtherTaxAssetsCurrent_0C80B6B41F2551E8EBB59228062CF695" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current tax assets</link:label>
    <link:label id="lab_pfe_OtherTaxAssetsCurrent_0C80B6B41F2551E8EBB59228062CF695_label_en-US" xlink:label="lab_pfe_OtherTaxAssetsCurrent_0C80B6B41F2551E8EBB59228062CF695" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Tax Assets, Current</link:label>
    <link:label id="lab_pfe_OtherTaxAssetsCurrent_0C80B6B41F2551E8EBB59228062CF695_documentation_en-US" xlink:label="lab_pfe_OtherTaxAssetsCurrent_0C80B6B41F2551E8EBB59228062CF695" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Tax Assets, Current</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_OtherTaxAssetsCurrent" xlink:label="loc_pfe_OtherTaxAssetsCurrent_0C80B6B41F2551E8EBB59228062CF695" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherTaxAssetsCurrent_0C80B6B41F2551E8EBB59228062CF695" xlink:to="lab_pfe_OtherTaxAssetsCurrent_0C80B6B41F2551E8EBB59228062CF695" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAssetsCurrent_AC7CC689A43B2FF3916D9228062C6F3A_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent_AC7CC689A43B2FF3916D9228062C6F3A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_AC7CC689A43B2FF3916D9228062C6F3A_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent_AC7CC689A43B2FF3916D9228062C6F3A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_AC7CC689A43B2FF3916D9228062C6F3A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent_AC7CC689A43B2FF3916D9228062C6F3A" xlink:to="lab_us-gaap_OtherAssetsCurrent_AC7CC689A43B2FF3916D9228062C6F3A" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_F560940D16CF0D868CAC9228062C5BE3_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_F560940D16CF0D868CAC9228062C5BE3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets held for sale</link:label>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_F560940D16CF0D868CAC9228062C5BE3_label_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_F560940D16CF0D868CAC9228062C5BE3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_F560940D16CF0D868CAC9228062C5BE3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_F560940D16CF0D868CAC9228062C5BE3" xlink:to="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_F560940D16CF0D868CAC9228062C5BE3" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrent_4D0BA2E7EE60A497C2329228062D249C_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent_4D0BA2E7EE60A497C2329228062D249C" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_4D0BA2E7EE60A497C2329228062D249C_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent_4D0BA2E7EE60A497C2329228062D249C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_4D0BA2E7EE60A497C2329228062D249C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent_4D0BA2E7EE60A497C2329228062D249C" xlink:to="lab_us-gaap_AssetsCurrent_4D0BA2E7EE60A497C2329228062D249C" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermInvestments_9CE3E7907D81D933B7889228062DA806_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermInvestments_9CE3E7907D81D933B7889228062DA806" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term investments</link:label>
    <link:label id="lab_us-gaap_LongTermInvestments_9CE3E7907D81D933B7889228062DA806_label_en-US" xlink:label="lab_us-gaap_LongTermInvestments_9CE3E7907D81D933B7889228062DA806" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermInvestments" xlink:label="loc_us-gaap_LongTermInvestments_9CE3E7907D81D933B7889228062DA806" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermInvestments_9CE3E7907D81D933B7889228062DA806" xlink:to="lab_us-gaap_LongTermInvestments_9CE3E7907D81D933B7889228062DA806" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_D63E215E68A5617D4B2E9228062D5DCD_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_D63E215E68A5617D4B2E9228062D5DCD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment, less accumulated depreciation: 2017&#8212;$15,906; 2016&#8212;$14,807</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_D63E215E68A5617D4B2E9228062D5DCD_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_D63E215E68A5617D4B2E9228062D5DCD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_D63E215E68A5617D4B2E9228062D5DCD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_D63E215E68A5617D4B2E9228062D5DCD" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_D63E215E68A5617D4B2E9228062D5DCD" xlink:type="arc" />
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_A23CE82BC5FDAD1B7B079228062D56E1_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_A23CE82BC5FDAD1B7B079228062D56E1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Identifiable intangible assets, less accumulated amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_A23CE82BC5FDAD1B7B079228062D56E1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_A23CE82BC5FDAD1B7B079228062D56E1" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_A23CE82BC5FDAD1B7B079228062D56E1" xlink:type="arc" />
    <link:label id="lab_us-gaap_Goodwill_BD1B928176E001F17F829228062D54D8_verboseLabel_en-US" xlink:label="lab_us-gaap_Goodwill_BD1B928176E001F17F829228062D54D8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_BD1B928176E001F17F829228062D54D8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill_BD1B928176E001F17F829228062D54D8" xlink:to="lab_us-gaap_Goodwill_BD1B928176E001F17F829228062D54D8" xlink:type="arc" />
    <link:label id="lab_pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent_66A882FEB1C8D75108FD9228062E4A19_terseLabel_en-US" xlink:label="lab_pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent_66A882FEB1C8D75108FD9228062E4A19" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncurrent deferred tax assets and other noncurrent tax assets</link:label>
    <link:label id="lab_pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent_66A882FEB1C8D75108FD9228062E4A19_label_en-US" xlink:label="lab_pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent_66A882FEB1C8D75108FD9228062E4A19" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net, And Other Tax Assets, Noncurrent</link:label>
    <link:label id="lab_pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent_66A882FEB1C8D75108FD9228062E4A19_documentation_en-US" xlink:label="lab_pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent_66A882FEB1C8D75108FD9228062E4A19" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net, And Other Tax Assets, Noncurrent</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent" xlink:label="loc_pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent_66A882FEB1C8D75108FD9228062E4A19" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent_66A882FEB1C8D75108FD9228062E4A19" xlink:to="lab_pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent_66A882FEB1C8D75108FD9228062E4A19" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_33C432905F731DAA1DAE9228062E22FB_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_33C432905F731DAA1DAE9228062E22FB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other noncurrent assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_33C432905F731DAA1DAE9228062E22FB_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_33C432905F731DAA1DAE9228062E22FB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_33C432905F731DAA1DAE9228062E22FB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_33C432905F731DAA1DAE9228062E22FB" xlink:to="lab_us-gaap_OtherAssetsNoncurrent_33C432905F731DAA1DAE9228062E22FB" xlink:type="arc" />
    <link:label id="lab_us-gaap_Assets_F950CCDC3D300C67B55C9228062FF610_totalLabel_en-US" xlink:label="lab_us-gaap_Assets_F950CCDC3D300C67B55C9228062FF610" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_F950CCDC3D300C67B55C9228062FF610" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_F950CCDC3D300C67B55C9228062FF610" xlink:to="lab_us-gaap_Assets_F950CCDC3D300C67B55C9228062FF610" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1B68E913F0337C850ADD9228062F34A3_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1B68E913F0337C850ADD9228062F34A3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1B68E913F0337C850ADD9228062F34A3_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1B68E913F0337C850ADD9228062F34A3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1B68E913F0337C850ADD9228062F34A3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1B68E913F0337C850ADD9228062F34A3" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1B68E913F0337C850ADD9228062F34A3" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtCurrent_E9840FCCE81C534FD0E59228062FE7A0_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtCurrent_E9840FCCE81C534FD0E59228062FE7A0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Short-term borrowings, including current portion of long-term debt: 2017&#8212;$3,072; 2016&#8212;$4,225</link:label>
    <link:label id="lab_us-gaap_DebtCurrent_E9840FCCE81C534FD0E59228062FE7A0_label_en-US" xlink:label="lab_us-gaap_DebtCurrent_E9840FCCE81C534FD0E59228062FE7A0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtCurrent" xlink:label="loc_us-gaap_DebtCurrent_E9840FCCE81C534FD0E59228062FE7A0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtCurrent_E9840FCCE81C534FD0E59228062FE7A0" xlink:to="lab_us-gaap_DebtCurrent_E9840FCCE81C534FD0E59228062FE7A0" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsPayableCurrent_BE6CD6D4F2557C01C83E9228062F557D_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_BE6CD6D4F2557C01C83E9228062F557D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trade accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_BE6CD6D4F2557C01C83E9228062F557D_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_BE6CD6D4F2557C01C83E9228062F557D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_BE6CD6D4F2557C01C83E9228062F557D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent_BE6CD6D4F2557C01C83E9228062F557D" xlink:to="lab_us-gaap_AccountsPayableCurrent_BE6CD6D4F2557C01C83E9228062F557D" xlink:type="arc" />
    <link:label id="lab_us-gaap_DividendsPayableCurrent_A8E8A4EEFAE5E71B1704922806301DD7_terseLabel_en-US" xlink:label="lab_us-gaap_DividendsPayableCurrent_A8E8A4EEFAE5E71B1704922806301DD7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividends payable</link:label>
    <link:label id="lab_us-gaap_DividendsPayableCurrent_A8E8A4EEFAE5E71B1704922806301DD7_label_en-US" xlink:label="lab_us-gaap_DividendsPayableCurrent_A8E8A4EEFAE5E71B1704922806301DD7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DividendsPayableCurrent" xlink:label="loc_us-gaap_DividendsPayableCurrent_A8E8A4EEFAE5E71B1704922806301DD7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsPayableCurrent_A8E8A4EEFAE5E71B1704922806301DD7" xlink:to="lab_us-gaap_DividendsPayableCurrent_A8E8A4EEFAE5E71B1704922806301DD7" xlink:type="arc" />
    <link:label id="lab_us-gaap_TaxesPayableCurrent_1E226FD90490FB45AEB1922806308EC7_terseLabel_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent_1E226FD90490FB45AEB1922806308EC7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income taxes payable</link:label>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_1E226FD90490FB45AEB1922806308EC7_label_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent_1E226FD90490FB45AEB1922806308EC7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Taxes Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TaxesPayableCurrent" xlink:label="loc_us-gaap_TaxesPayableCurrent_1E226FD90490FB45AEB1922806308EC7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxesPayableCurrent_1E226FD90490FB45AEB1922806308EC7" xlink:to="lab_us-gaap_TaxesPayableCurrent_1E226FD90490FB45AEB1922806308EC7" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_87B80030823CEFBFDBB8922806306845_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_87B80030823CEFBFDBB8922806306845" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued compensation and related items</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_87B80030823CEFBFDBB8922806306845_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_87B80030823CEFBFDBB8922806306845" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_87B80030823CEFBFDBB8922806306845" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_87B80030823CEFBFDBB8922806306845" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_87B80030823CEFBFDBB8922806306845" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_3C18E15CD39F76307AAC92280631C985_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent_3C18E15CD39F76307AAC92280631C985" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_3C18E15CD39F76307AAC92280631C985_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent_3C18E15CD39F76307AAC92280631C985" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_3C18E15CD39F76307AAC92280631C985" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_3C18E15CD39F76307AAC92280631C985" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent_3C18E15CD39F76307AAC92280631C985" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrent_89D755F03D23B3C3F81D922806328E57_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_89D755F03D23B3C3F81D922806328E57" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_89D755F03D23B3C3F81D922806328E57_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_89D755F03D23B3C3F81D922806328E57" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_89D755F03D23B3C3F81D922806328E57" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent_89D755F03D23B3C3F81D922806328E57" xlink:to="lab_us-gaap_LiabilitiesCurrent_89D755F03D23B3C3F81D922806328E57" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_66CBA391C6CEFF78646B92280632D38E_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent_66CBA391C6CEFF78646B92280632D38E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_66CBA391C6CEFF78646B92280632D38E_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent_66CBA391C6CEFF78646B92280632D38E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_66CBA391C6CEFF78646B92280632D38E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent_66CBA391C6CEFF78646B92280632D38E" xlink:to="lab_us-gaap_LongTermDebtNoncurrent_66CBA391C6CEFF78646B92280632D38E" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent_276A31E2379B3A5A5152922806327BEC_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent_276A31E2379B3A5A5152922806327BEC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension benefit obligations, net</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent_276A31E2379B3A5A5152922806327BEC_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent_276A31E2379B3A5A5152922806327BEC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability, Defined Benefit Pension Plan, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent_276A31E2379B3A5A5152922806327BEC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent_276A31E2379B3A5A5152922806327BEC" xlink:to="lab_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent_276A31E2379B3A5A5152922806327BEC" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent_CD2322A05C7C36C01B97922806327D6F_terseLabel_en-US" xlink:label="lab_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent_CD2322A05C7C36C01B97922806327D6F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Postretirement benefit obligations, net</link:label>
    <link:label id="lab_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent_CD2322A05C7C36C01B97922806327D6F_label_en-US" xlink:label="lab_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent_CD2322A05C7C36C01B97922806327D6F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability, Other Postretirement Defined Benefit Plan, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent_CD2322A05C7C36C01B97922806327D6F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent_CD2322A05C7C36C01B97922806327D6F" xlink:to="lab_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent_CD2322A05C7C36C01B97922806327D6F" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_6381CDCC9AD3038DF6B0922806328AF6_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_6381CDCC9AD3038DF6B0922806328AF6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncurrent deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_6381CDCC9AD3038DF6B0922806328AF6_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_6381CDCC9AD3038DF6B0922806328AF6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_6381CDCC9AD3038DF6B0922806328AF6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_6381CDCC9AD3038DF6B0922806328AF6" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_6381CDCC9AD3038DF6B0922806328AF6" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent_E97D6FC393A4F580AAFC922806333917_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent_E97D6FC393A4F580AAFC922806333917" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other taxes payable</link:label>
    <link:label id="lab_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent_E97D6FC393A4F580AAFC922806333917_label_en-US" xlink:label="lab_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent_E97D6FC393A4F580AAFC922806333917" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability for Uncertainty in Income Taxes, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilityForUncertainTaxPositionsNoncurrent" xlink:label="loc_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent_E97D6FC393A4F580AAFC922806333917" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent_E97D6FC393A4F580AAFC922806333917" xlink:to="lab_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent_E97D6FC393A4F580AAFC922806333917" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_73C358FBFD46733E147192280633A622_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent_73C358FBFD46733E147192280633A622" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other noncurrent liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_73C358FBFD46733E147192280633A622_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent_73C358FBFD46733E147192280633A622" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_73C358FBFD46733E147192280633A622" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_73C358FBFD46733E147192280633A622" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent_73C358FBFD46733E147192280633A622" xlink:type="arc" />
    <link:label id="lab_us-gaap_Liabilities_860238CB62F6138103AB9228063366CB_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities_860238CB62F6138103AB9228063366CB" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_860238CB62F6138103AB9228063366CB_label_en-US" xlink:label="lab_us-gaap_Liabilities_860238CB62F6138103AB9228063366CB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_860238CB62F6138103AB9228063366CB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities_860238CB62F6138103AB9228063366CB" xlink:to="lab_us-gaap_Liabilities_860238CB62F6138103AB9228063366CB" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_6037E0D678ADA81283F392280633EB69_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_6037E0D678ADA81283F392280633EB69" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_6037E0D678ADA81283F392280633EB69_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_6037E0D678ADA81283F392280633EB69" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_6037E0D678ADA81283F392280633EB69" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies_6037E0D678ADA81283F392280633EB69" xlink:to="lab_us-gaap_CommitmentsAndContingencies_6037E0D678ADA81283F392280633EB69" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockValue_4771A160FB2D31AFFBB5922806349857_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue_4771A160FB2D31AFFBB5922806349857" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_4771A160FB2D31AFFBB5922806349857_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue_4771A160FB2D31AFFBB5922806349857" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_4771A160FB2D31AFFBB5922806349857" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue_4771A160FB2D31AFFBB5922806349857" xlink:to="lab_us-gaap_PreferredStockValue_4771A160FB2D31AFFBB5922806349857" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockValue_BCDC5AD6017902A36D719228063455B6_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue_BCDC5AD6017902A36D719228063455B6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_BCDC5AD6017902A36D719228063455B6_label_en-US" xlink:label="lab_us-gaap_CommonStockValue_BCDC5AD6017902A36D719228063455B6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_BCDC5AD6017902A36D719228063455B6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue_BCDC5AD6017902A36D719228063455B6" xlink:to="lab_us-gaap_CommonStockValue_BCDC5AD6017902A36D719228063455B6" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_B62178FE23A58553DAE792280635CCC7_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital_B62178FE23A58553DAE792280635CCC7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_B62178FE23A58553DAE792280635CCC7_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital_B62178FE23A58553DAE792280635CCC7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_B62178FE23A58553DAE792280635CCC7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital_B62178FE23A58553DAE792280635CCC7" xlink:to="lab_us-gaap_AdditionalPaidInCapital_B62178FE23A58553DAE792280635CCC7" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockValue_90B1A31FAD11873FCCD2922806350871_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue_90B1A31FAD11873FCCD2922806350871" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Treasury stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_90B1A31FAD11873FCCD2922806350871_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue_90B1A31FAD11873FCCD2922806350871" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue_90B1A31FAD11873FCCD2922806350871" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue_90B1A31FAD11873FCCD2922806350871" xlink:to="lab_us-gaap_TreasuryStockValue_90B1A31FAD11873FCCD2922806350871" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_76373F2281C6AC95284C9228063609B8_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_76373F2281C6AC95284C9228063609B8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_76373F2281C6AC95284C9228063609B8_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_76373F2281C6AC95284C9228063609B8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_76373F2281C6AC95284C9228063609B8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_76373F2281C6AC95284C9228063609B8" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_76373F2281C6AC95284C9228063609B8" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_B404E3979C4E498ABFF392280637E30E_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_B404E3979C4E498ABFF392280637E30E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_B404E3979C4E498ABFF392280637E30E_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_B404E3979C4E498ABFF392280637E30E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_B404E3979C4E498ABFF392280637E30E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_B404E3979C4E498ABFF392280637E30E" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_B404E3979C4E498ABFF392280637E30E" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_EB3D9A07B11B65DE54E792280637748D_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_EB3D9A07B11B65DE54E792280637748D" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Pfizer Inc. shareholders&#8217; equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_EB3D9A07B11B65DE54E792280637748D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_EB3D9A07B11B65DE54E792280637748D" xlink:to="lab_us-gaap_StockholdersEquity_EB3D9A07B11B65DE54E792280637748D" xlink:type="arc" />
    <link:label id="lab_us-gaap_MinorityInterest_D58A9B88052434E2BAC5922806379A68_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest_D58A9B88052434E2BAC5922806379A68" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_D58A9B88052434E2BAC5922806379A68_label_en-US" xlink:label="lab_us-gaap_MinorityInterest_D58A9B88052434E2BAC5922806379A68" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_D58A9B88052434E2BAC5922806379A68" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest_D58A9B88052434E2BAC5922806379A68" xlink:to="lab_us-gaap_MinorityInterest_D58A9B88052434E2BAC5922806379A68" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_FADEB8BB9689C117DB22922806374193_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_FADEB8BB9689C117DB22922806374193" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_FADEB8BB9689C117DB22922806374193_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_FADEB8BB9689C117DB22922806374193" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_FADEB8BB9689C117DB22922806374193" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_FADEB8BB9689C117DB22922806374193" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_FADEB8BB9689C117DB22922806374193" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_18A77A5777F4BE6C9ABA922806375EBE_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_18A77A5777F4BE6C9ABA922806375EBE" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_18A77A5777F4BE6C9ABA922806375EBE_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_18A77A5777F4BE6C9ABA922806375EBE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_18A77A5777F4BE6C9ABA922806375EBE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_18A77A5777F4BE6C9ABA922806375EBE" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity_18A77A5777F4BE6C9ABA922806375EBE" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherIncomeAndExpensesAbstract_49A9F4688CD7523610CEAE9F92DD9674_label_en-US" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract_C227D7A3E4D5597EBAFFDE1EA714B641" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Income and Expenses [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_C227D7A3E4D5597EBAFFDE1EA714B641" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_C227D7A3E4D5597EBAFFDE1EA714B641" xlink:to="lab_us-gaap_OtherIncomeAndExpensesAbstract_C227D7A3E4D5597EBAFFDE1EA714B641" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_B38B230B263AF4A45994AE9F92DD7658_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_E6816120C90B5C099513BE2277E0A478" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other (Income)/Deductions - Net</link:label>
    <link:label id="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_B38B230B263AF4A45994AE9F92DD7658_label_en-US" xlink:label="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_E6816120C90B5C099513BE2277E0A478" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Income and Other Expense Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:label="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_E6816120C90B5C099513BE2277E0A478" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_E6816120C90B5C099513BE2277E0A478" xlink:to="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_E6816120C90B5C099513BE2277E0A478" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingenciesTable_95A1ADCBE302F1B121559C471651BBAD_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable_95A1ADCBE302F1B121559C471651BBAD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_95A1ADCBE302F1B121559C471651BBAD_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable_95A1ADCBE302F1B121559C471651BBAD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaap_LossContingenciesTable_95A1ADCBE302F1B121559C471651BBAD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable_95A1ADCBE302F1B121559C471651BBAD" xlink:to="lab_us-gaap_LossContingenciesTable_95A1ADCBE302F1B121559C471651BBAD" xlink:type="arc" />
    <link:label id="lab_pfe_PatentMatterMember_854AC88B33C3596A32F39C471652D425_terseLabel_en-US" xlink:label="lab_pfe_PatentMatterMember_854AC88B33C3596A32F39C471652D425" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Patent Matter [Member]</link:label>
    <link:label id="lab_pfe_PatentMatterMember_854AC88B33C3596A32F39C471652D425_label_en-US" xlink:label="lab_pfe_PatentMatterMember_854AC88B33C3596A32F39C471652D425" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Patent Matter [Member]</link:label>
    <link:label id="lab_pfe_PatentMatterMember_854AC88B33C3596A32F39C471652D425_documentation_en-US" xlink:label="lab_pfe_PatentMatterMember_854AC88B33C3596A32F39C471652D425" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Patent Matter [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_PatentMatterMember" xlink:label="loc_pfe_PatentMatterMember_854AC88B33C3596A32F39C471652D425" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_PatentMatterMember_854AC88B33C3596A32F39C471652D425" xlink:to="lab_pfe_PatentMatterMember_854AC88B33C3596A32F39C471652D425" xlink:type="arc" />
    <link:label id="lab_dei_LegalEntityAxis_95B7C524AFAE525B86779C4716524935_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis_95B7C524AFAE525B86779C4716524935" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_95B7C524AFAE525B86779C4716524935_label_en-US" xlink:label="lab_dei_LegalEntityAxis_95B7C524AFAE525B86779C4716524935" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_95B7C524AFAE525B86779C4716524935" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis_95B7C524AFAE525B86779C4716524935" xlink:to="lab_dei_LegalEntityAxis_95B7C524AFAE525B86779C4716524935" xlink:type="arc" />
    <link:label id="lab_dei_EntityDomain_4248376941AB31BDA5449C471652D4FF_terseLabel_en-US" xlink:label="lab_dei_EntityDomain_4248376941AB31BDA5449C471652D4FF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_4248376941AB31BDA5449C471652D4FF_label_en-US" xlink:label="lab_dei_EntityDomain_4248376941AB31BDA5449C471652D4FF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_4248376941AB31BDA5449C471652D4FF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain_4248376941AB31BDA5449C471652D4FF" xlink:to="lab_dei_EntityDomain_4248376941AB31BDA5449C471652D4FF" xlink:type="arc" />
    <link:label id="lab_pfe_InnoPharmaMember_F52F1246B3DDCBC7493B9C471653B739_terseLabel_en-US" xlink:label="lab_pfe_InnoPharmaMember_F52F1246B3DDCBC7493B9C471653B739" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">InnoPharma [Member]</link:label>
    <link:label id="lab_pfe_InnoPharmaMember_F52F1246B3DDCBC7493B9C471653B739_label_en-US" xlink:label="lab_pfe_InnoPharmaMember_F52F1246B3DDCBC7493B9C471653B739" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">InnoPharma [Member]</link:label>
    <link:label id="lab_pfe_InnoPharmaMember_F52F1246B3DDCBC7493B9C471653B739_documentation_en-US" xlink:label="lab_pfe_InnoPharmaMember_F52F1246B3DDCBC7493B9C471653B739" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">InnoPharma [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_InnoPharmaMember" xlink:label="loc_pfe_InnoPharmaMember_F52F1246B3DDCBC7493B9C471653B739" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_InnoPharmaMember_F52F1246B3DDCBC7493B9C471653B739" xlink:to="lab_pfe_InnoPharmaMember_F52F1246B3DDCBC7493B9C471653B739" xlink:type="arc" />
    <link:label id="lab_pfe_KingMember_C8543860A5CCFF0B525B9C4716540F94_terseLabel_en-US" xlink:label="lab_pfe_KingMember_C8543860A5CCFF0B525B9C4716540F94" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">King [Member]</link:label>
    <link:label id="lab_pfe_KingMember_C8543860A5CCFF0B525B9C4716540F94_label_en-US" xlink:label="lab_pfe_KingMember_C8543860A5CCFF0B525B9C4716540F94" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">King [Member]</link:label>
    <link:label id="lab_pfe_KingMember_C8543860A5CCFF0B525B9C4716540F94_documentation_en-US" xlink:label="lab_pfe_KingMember_C8543860A5CCFF0B525B9C4716540F94" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">King [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_KingMember" xlink:label="loc_pfe_KingMember_C8543860A5CCFF0B525B9C4716540F94" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_KingMember_C8543860A5CCFF0B525B9C4716540F94" xlink:to="lab_pfe_KingMember_C8543860A5CCFF0B525B9C4716540F94" xlink:type="arc" />
    <link:label id="lab_pfe_OtherInProcessResearchandDevelopmentMember_E43E5CA632F39E1D719A9C47165466C3_terseLabel_en-US" xlink:label="lab_pfe_OtherInProcessResearchandDevelopmentMember_E43E5CA632F39E1D719A9C47165466C3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other In Process Research and Development [Member]</link:label>
    <link:label id="lab_pfe_OtherInProcessResearchandDevelopmentMember_E43E5CA632F39E1D719A9C47165466C3_label_en-US" xlink:label="lab_pfe_OtherInProcessResearchandDevelopmentMember_E43E5CA632F39E1D719A9C47165466C3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other In Process Research and Development [Member]</link:label>
    <link:label id="lab_pfe_OtherInProcessResearchandDevelopmentMember_E43E5CA632F39E1D719A9C47165466C3_documentation_en-US" xlink:label="lab_pfe_OtherInProcessResearchandDevelopmentMember_E43E5CA632F39E1D719A9C47165466C3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other In Process Research and Development [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_OtherInProcessResearchandDevelopmentMember" xlink:label="loc_pfe_OtherInProcessResearchandDevelopmentMember_E43E5CA632F39E1D719A9C47165466C3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherInProcessResearchandDevelopmentMember_E43E5CA632F39E1D719A9C47165466C3" xlink:to="lab_pfe_OtherInProcessResearchandDevelopmentMember_E43E5CA632F39E1D719A9C47165466C3" xlink:type="arc" />
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_3CCA51C50DD9DAF0904C9C471655B0EB_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis_3CCA51C50DD9DAF0904C9C471655B0EB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_3CCA51C50DD9DAF0904C9C471655B0EB_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis_3CCA51C50DD9DAF0904C9C471655B0EB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_3CCA51C50DD9DAF0904C9C471655B0EB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis_3CCA51C50DD9DAF0904C9C471655B0EB" xlink:to="lab_us-gaap_TypeOfArrangementAxis_3CCA51C50DD9DAF0904C9C471655B0EB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_B81D011929653F84FB989C471655FEEB_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_B81D011929653F84FB989C471655FEEB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_B81D011929653F84FB989C471655FEEB_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_B81D011929653F84FB989C471655FEEB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_B81D011929653F84FB989C471655FEEB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_B81D011929653F84FB989C471655FEEB" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_B81D011929653F84FB989C471655FEEB" xlink:type="arc" />
    <link:label id="lab_us-gaap_CollaborativeArrangementCopromotionMember_E9DA8B9E4D9D0E0776E09C471655BFD1_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementCopromotionMember_E9DA8B9E4D9D0E0776E09C471655BFD1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Co-promotion [Member]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementCopromotionMember_E9DA8B9E4D9D0E0776E09C471655BFD1_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementCopromotionMember_E9DA8B9E4D9D0E0776E09C471655BFD1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Co-promotion [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementCopromotionMember" xlink:label="loc_us-gaap_CollaborativeArrangementCopromotionMember_E9DA8B9E4D9D0E0776E09C471655BFD1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementCopromotionMember_E9DA8B9E4D9D0E0776E09C471655BFD1" xlink:to="lab_us-gaap_CollaborativeArrangementCopromotionMember_E9DA8B9E4D9D0E0776E09C471655BFD1" xlink:type="arc" />
    <link:label id="lab_us-gaap_DistributionRightsMember_D8BB07B591FAF7725E1B9C4716551DE6_terseLabel_en-US" xlink:label="lab_us-gaap_DistributionRightsMember_D8BB07B591FAF7725E1B9C4716551DE6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Distribution Rights [Member]</link:label>
    <link:label id="lab_us-gaap_DistributionRightsMember_D8BB07B591FAF7725E1B9C4716551DE6_label_en-US" xlink:label="lab_us-gaap_DistributionRightsMember_D8BB07B591FAF7725E1B9C4716551DE6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Distribution Rights [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DistributionRightsMember" xlink:label="loc_us-gaap_DistributionRightsMember_D8BB07B591FAF7725E1B9C4716551DE6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DistributionRightsMember_D8BB07B591FAF7725E1B9C4716551DE6" xlink:to="lab_us-gaap_DistributionRightsMember_D8BB07B591FAF7725E1B9C4716551DE6" xlink:type="arc" />
    <link:label id="lab_pfe_EnbrelMember_BA9498AB00CCC38840E39C471656E6A4_terseLabel_en-US" xlink:label="lab_pfe_EnbrelMember_BA9498AB00CCC38840E39C471656E6A4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Enbrel [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_EnbrelMember" xlink:label="loc_pfe_EnbrelMember_BA9498AB00CCC38840E39C471656E6A4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_EnbrelMember_BA9498AB00CCC38840E39C471656E6A4" xlink:to="lab_pfe_EnbrelMember_BA9498AB00CCC38840E39C471656E6A4" xlink:type="arc" />
    <link:label id="lab_pfe_XtandiMember_005A5310349C9D29CCAA9C471656FB57_terseLabel_en-US" xlink:label="lab_pfe_XtandiMember_005A5310349C9D29CCAA9C471656FB57" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Xtandi [Member]</link:label>
    <link:label id="lab_pfe_XtandiMember_005A5310349C9D29CCAA9C471656FB57_label_en-US" xlink:label="lab_pfe_XtandiMember_005A5310349C9D29CCAA9C471656FB57" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Xtandi [Member]</link:label>
    <link:label id="lab_pfe_XtandiMember_005A5310349C9D29CCAA9C471656FB57_documentation_en-US" xlink:label="lab_pfe_XtandiMember_005A5310349C9D29CCAA9C471656FB57" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Xtandi [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_XtandiMember" xlink:label="loc_pfe_XtandiMember_005A5310349C9D29CCAA9C471656FB57" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_XtandiMember_005A5310349C9D29CCAA9C471656FB57" xlink:to="lab_pfe_XtandiMember_005A5310349C9D29CCAA9C471656FB57" xlink:type="arc" />
    <link:label id="lab_pfe_CelebrexandBextraMember_5F13FF9444B2387028A29C471656CFA3_terseLabel_en-US" xlink:label="lab_pfe_CelebrexandBextraMember_5F13FF9444B2387028A29C471656CFA3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Celebrex and Bextra [Member]</link:label>
    <link:label id="lab_pfe_CelebrexandBextraMember_5F13FF9444B2387028A29C471656CFA3_label_en-US" xlink:label="lab_pfe_CelebrexandBextraMember_5F13FF9444B2387028A29C471656CFA3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Celebrex and Bextra [Member]</link:label>
    <link:label id="lab_pfe_CelebrexandBextraMember_5F13FF9444B2387028A29C471656CFA3_documentation_en-US" xlink:label="lab_pfe_CelebrexandBextraMember_5F13FF9444B2387028A29C471656CFA3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Celebrex and Bextra [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_CelebrexandBextraMember" xlink:label="loc_pfe_CelebrexandBextraMember_5F13FF9444B2387028A29C471656CFA3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_CelebrexandBextraMember_5F13FF9444B2387028A29C471656CFA3" xlink:to="lab_pfe_CelebrexandBextraMember_5F13FF9444B2387028A29C471656CFA3" xlink:type="arc" />
    <link:label id="lab_pfe_HisunPfizerPharmaceuticalsCoLtdMember_17436B9DD03E74EC83369C4716574415_terseLabel_en-US" xlink:label="lab_pfe_HisunPfizerPharmaceuticalsCoLtdMember_17436B9DD03E74EC83369C4716574415" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hisun Pfizer Pharmaceuticals Co. Ltd [Member]</link:label>
    <link:label id="lab_pfe_HisunPfizerPharmaceuticalsCoLtdMember_17436B9DD03E74EC83369C4716574415_label_en-US" xlink:label="lab_pfe_HisunPfizerPharmaceuticalsCoLtdMember_17436B9DD03E74EC83369C4716574415" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hisun Pfizer Pharmaceuticals Co. Ltd [Member]</link:label>
    <link:label id="lab_pfe_HisunPfizerPharmaceuticalsCoLtdMember_17436B9DD03E74EC83369C4716574415_documentation_en-US" xlink:label="lab_pfe_HisunPfizerPharmaceuticalsCoLtdMember_17436B9DD03E74EC83369C4716574415" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Hisun Pfizer Pharmaceuticals Co. Ltd [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_HisunPfizerPharmaceuticalsCoLtdMember" xlink:label="loc_pfe_HisunPfizerPharmaceuticalsCoLtdMember_17436B9DD03E74EC83369C4716574415" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_HisunPfizerPharmaceuticalsCoLtdMember_17436B9DD03E74EC83369C4716574415" xlink:to="lab_pfe_HisunPfizerPharmaceuticalsCoLtdMember_17436B9DD03E74EC83369C4716574415" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingenciesLineItems_190165E2439EFA6C88F09C471658495A_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems_190165E2439EFA6C88F09C471658495A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_190165E2439EFA6C88F09C471658495A_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems_190165E2439EFA6C88F09C471658495A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaap_LossContingenciesLineItems_190165E2439EFA6C88F09C471658495A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems_190165E2439EFA6C88F09C471658495A" xlink:to="lab_us-gaap_LossContingenciesLineItems_190165E2439EFA6C88F09C471658495A" xlink:type="arc" />
    <link:label id="lab_pfe_DecreaseinRoyaltyRevenue_DAC0D36C09A2A04546649C471658C5B4_terseLabel_en-US" xlink:label="lab_pfe_DecreaseinRoyaltyRevenue_DAC0D36C09A2A04546649C471658C5B4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Decrease in royalty revenue</link:label>
    <link:label id="lab_pfe_DecreaseinRoyaltyRevenue_DAC0D36C09A2A04546649C471658C5B4_label_en-US" xlink:label="lab_pfe_DecreaseinRoyaltyRevenue_DAC0D36C09A2A04546649C471658C5B4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Decrease in Royalty Revenue</link:label>
    <link:label id="lab_pfe_DecreaseinRoyaltyRevenue_DAC0D36C09A2A04546649C471658C5B4_documentation_en-US" xlink:label="lab_pfe_DecreaseinRoyaltyRevenue_DAC0D36C09A2A04546649C471658C5B4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Decrease in Royalty Revenue</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_DecreaseinRoyaltyRevenue" xlink:label="loc_pfe_DecreaseinRoyaltyRevenue_DAC0D36C09A2A04546649C471658C5B4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DecreaseinRoyaltyRevenue_DAC0D36C09A2A04546649C471658C5B4" xlink:to="lab_pfe_DecreaseinRoyaltyRevenue_DAC0D36C09A2A04546649C471658C5B4" xlink:type="arc" />
    <link:label id="lab_pfe_RoyaltyRevenueTerm_997316D9F18789639AD09C471658DE0A_terseLabel_en-US" xlink:label="lab_pfe_RoyaltyRevenueTerm_997316D9F18789639AD09C471658DE0A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty period</link:label>
    <link:label id="lab_pfe_RoyaltyRevenueTerm_997316D9F18789639AD09C471658DE0A_label_en-US" xlink:label="lab_pfe_RoyaltyRevenueTerm_997316D9F18789639AD09C471658DE0A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Revenue, Term</link:label>
    <link:label id="lab_pfe_RoyaltyRevenueTerm_997316D9F18789639AD09C471658DE0A_documentation_en-US" xlink:label="lab_pfe_RoyaltyRevenueTerm_997316D9F18789639AD09C471658DE0A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Royalty Revenue, Term</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_RoyaltyRevenueTerm" xlink:label="loc_pfe_RoyaltyRevenueTerm_997316D9F18789639AD09C471658DE0A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_RoyaltyRevenueTerm_997316D9F18789639AD09C471658DE0A" xlink:to="lab_pfe_RoyaltyRevenueTerm_997316D9F18789639AD09C471658DE0A" xlink:type="arc" />
    <link:label id="lab_us-gaap_RoyaltyRevenue_5875B80643E2F7FD923D9C4716583F48_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyRevenue_5875B80643E2F7FD923D9C4716583F48" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty revenue</link:label>
    <link:label id="lab_us-gaap_RoyaltyRevenue_5875B80643E2F7FD923D9C4716583F48_label_en-US" xlink:label="lab_us-gaap_RoyaltyRevenue_5875B80643E2F7FD923D9C4716583F48" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Revenue</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:label="loc_us-gaap_RoyaltyRevenue_5875B80643E2F7FD923D9C4716583F48" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyRevenue_5875B80643E2F7FD923D9C4716583F48" xlink:to="lab_us-gaap_RoyaltyRevenue_5875B80643E2F7FD923D9C4716583F48" xlink:type="arc" />
    <link:label id="lab_us-gaap_LitigationSettlementExpense_0D0A20883E0F6A98B2409C471658693A_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementExpense_0D0A20883E0F6A98B2409C471658693A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation settlement expense</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementExpense_0D0A20883E0F6A98B2409C471658693A_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementExpense_0D0A20883E0F6A98B2409C471658693A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Settlement, Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationSettlementExpense" xlink:label="loc_us-gaap_LitigationSettlementExpense_0D0A20883E0F6A98B2409C471658693A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementExpense_0D0A20883E0F6A98B2409C471658693A" xlink:to="lab_us-gaap_LitigationSettlementExpense_0D0A20883E0F6A98B2409C471658693A" xlink:type="arc" />
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_EEFC245F4CCA145AEF219C4716592E00_verboseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_EEFC245F4CCA145AEF219C4716592E00" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Amount awarded to other party</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_EEFC245F4CCA145AEF219C4716592E00_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_EEFC245F4CCA145AEF219C4716592E00" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Settlement, Amount Awarded to Other Party</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_EEFC245F4CCA145AEF219C4716592E00" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_EEFC245F4CCA145AEF219C4716592E00" xlink:to="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_EEFC245F4CCA145AEF219C4716592E00" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainLossOnDispositionOfIntangibleAssets_C4249E220EF8BB211A0F9C471659FC43_verboseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfIntangibleAssets_C4249E220EF8BB211A0F9C471659FC43" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Gain on disposition of intangible assets</link:label>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfIntangibleAssets_C4249E220EF8BB211A0F9C471659FC43_label_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfIntangibleAssets_C4249E220EF8BB211A0F9C471659FC43" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Disposition of Intangible Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossOnDispositionOfIntangibleAssets" xlink:label="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_C4249E220EF8BB211A0F9C471659FC43" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_C4249E220EF8BB211A0F9C471659FC43" xlink:to="lab_us-gaap_GainLossOnDispositionOfIntangibleAssets_C4249E220EF8BB211A0F9C471659FC43" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainOnSaleOfInvestments_97BE826112523B53E56D9C4716592D6C_terseLabel_en-US" xlink:label="lab_us-gaap_GainOnSaleOfInvestments_97BE826112523B53E56D9C4716592D6C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain on sale of investments</link:label>
    <link:label id="lab_us-gaap_GainOnSaleOfInvestments_97BE826112523B53E56D9C4716592D6C_label_en-US" xlink:label="lab_us-gaap_GainOnSaleOfInvestments_97BE826112523B53E56D9C4716592D6C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain on Sale of Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainOnSaleOfInvestments" xlink:label="loc_us-gaap_GainOnSaleOfInvestments_97BE826112523B53E56D9C4716592D6C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainOnSaleOfInvestments_97BE826112523B53E56D9C4716592D6C" xlink:to="lab_us-gaap_GainOnSaleOfInvestments_97BE826112523B53E56D9C4716592D6C" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_4C699B9A4944A9D597A89C47165AD4BF_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_4C699B9A4944A9D597A89C47165AD4BF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain on sale of property</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_4C699B9A4944A9D597A89C47165AD4BF_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_4C699B9A4944A9D597A89C47165AD4BF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_4C699B9A4944A9D597A89C47165AD4BF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_4C699B9A4944A9D597A89C47165AD4BF" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_4C699B9A4944A9D597A89C47165AD4BF" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_AC3B6A2758DF4355B9C69C47165A45C8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_AC3B6A2758DF4355B9C69C47165A45C8" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Loss on disposal of equity method investment</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_AC3B6A2758DF4355B9C69C47165A45C8_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_AC3B6A2758DF4355B9C69C47165A45C8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Realized Gain (Loss) on Disposal</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal" xlink:label="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_AC3B6A2758DF4355B9C69C47165A45C8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_AC3B6A2758DF4355B9C69C47165A45C8" xlink:to="lab_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_AC3B6A2758DF4355B9C69C47165A45C8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_B8ADDD70296F19B54FB69C47165A97AF_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_B8ADDD70296F19B54FB69C47165A97AF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible asset impairment charges</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_B8ADDD70296F19B54FB69C47165A97AF_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_B8ADDD70296F19B54FB69C47165A97AF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment of Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_B8ADDD70296F19B54FB69C47165A97AF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_B8ADDD70296F19B54FB69C47165A97AF" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_B8ADDD70296F19B54FB69C47165A97AF" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_24F2E5BB9C009165AEF19C47165A2884_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_24F2E5BB9C009165AEF19C47165A2884" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity method investment, impairment</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_24F2E5BB9C009165AEF19C47165A2884_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_24F2E5BB9C009165AEF19C47165A2884" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Other than Temporary Impairment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment" xlink:label="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_24F2E5BB9C009165AEF19C47165A2884" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_24F2E5BB9C009165AEF19C47165A2884" xlink:to="lab_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_24F2E5BB9C009165AEF19C47165A2884" xlink:type="arc" />
    <link:label id="lab_pfe_OtherNonoperatingIncomeMiscellaneous_2249A417ED8EC98A8CE29C47165A986A_terseLabel_en-US" xlink:label="lab_pfe_OtherNonoperatingIncomeMiscellaneous_2249A417ED8EC98A8CE29C47165A986A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income from contract resolution</link:label>
    <link:label id="lab_pfe_OtherNonoperatingIncomeMiscellaneous_2249A417ED8EC98A8CE29C47165A986A_label_en-US" xlink:label="lab_pfe_OtherNonoperatingIncomeMiscellaneous_2249A417ED8EC98A8CE29C47165A986A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income, Miscellaneous</link:label>
    <link:label id="lab_pfe_OtherNonoperatingIncomeMiscellaneous_2249A417ED8EC98A8CE29C47165A986A_documentation_en-US" xlink:label="lab_pfe_OtherNonoperatingIncomeMiscellaneous_2249A417ED8EC98A8CE29C47165A986A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income, Miscellaneous</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_OtherNonoperatingIncomeMiscellaneous" xlink:label="loc_pfe_OtherNonoperatingIncomeMiscellaneous_2249A417ED8EC98A8CE29C47165A986A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherNonoperatingIncomeMiscellaneous_2249A417ED8EC98A8CE29C47165A986A" xlink:to="lab_pfe_OtherNonoperatingIncomeMiscellaneous_2249A417ED8EC98A8CE29C47165A986A" xlink:type="arc" />
    <link:label id="lab_pfe_PaymentsforMergerTerminationCosts_7D8CFD62A7144EA1679F9C47165AB0AD_terseLabel_en-US" xlink:label="lab_pfe_PaymentsforMergerTerminationCosts_7D8CFD62A7144EA1679F9C47165AB0AD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments for merger termination costs</link:label>
    <link:label id="lab_pfe_PaymentsforMergerTerminationCosts_7D8CFD62A7144EA1679F9C47165AB0AD_label_en-US" xlink:label="lab_pfe_PaymentsforMergerTerminationCosts_7D8CFD62A7144EA1679F9C47165AB0AD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Merger Termination Costs</link:label>
    <link:label id="lab_pfe_PaymentsforMergerTerminationCosts_7D8CFD62A7144EA1679F9C47165AB0AD_documentation_en-US" xlink:label="lab_pfe_PaymentsforMergerTerminationCosts_7D8CFD62A7144EA1679F9C47165AB0AD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments for Merger Termination Costs</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_PaymentsforMergerTerminationCosts" xlink:label="loc_pfe_PaymentsforMergerTerminationCosts_7D8CFD62A7144EA1679F9C47165AB0AD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_PaymentsforMergerTerminationCosts_7D8CFD62A7144EA1679F9C47165AB0AD" xlink:to="lab_pfe_PaymentsforMergerTerminationCosts_7D8CFD62A7144EA1679F9C47165AB0AD" xlink:type="arc" />
    <link:label id="lab_us-gaap_AcceleratedShareRepurchasesTable_3056D4ED28B8EA6C6A9B921D09D7F143_terseLabel_en-US" xlink:label="lab_us-gaap_AcceleratedShareRepurchasesTable_3056D4ED28B8EA6C6A9B921D09D7F143" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accelerated Share Repurchases [Table]</link:label>
    <link:label id="lab_us-gaap_AcceleratedShareRepurchasesTable_3056D4ED28B8EA6C6A9B921D09D7F143_label_en-US" xlink:label="lab_us-gaap_AcceleratedShareRepurchasesTable_3056D4ED28B8EA6C6A9B921D09D7F143" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accelerated Share Repurchases [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AcceleratedShareRepurchasesTable" xlink:label="loc_us-gaap_AcceleratedShareRepurchasesTable_3056D4ED28B8EA6C6A9B921D09D7F143" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesTable_3056D4ED28B8EA6C6A9B921D09D7F143" xlink:to="lab_us-gaap_AcceleratedShareRepurchasesTable_3056D4ED28B8EA6C6A9B921D09D7F143" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProFormaMember_DAFA70A739700CFC1679921D09D89319_terseLabel_en-US" xlink:label="lab_us-gaap_ProFormaMember_DAFA70A739700CFC1679921D09D89319" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pro Forma [Member]</link:label>
    <link:label id="lab_us-gaap_ProFormaMember_DAFA70A739700CFC1679921D09D89319_label_en-US" xlink:label="lab_us-gaap_ProFormaMember_DAFA70A739700CFC1679921D09D89319" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pro Forma [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProFormaMember" xlink:label="loc_us-gaap_ProFormaMember_DAFA70A739700CFC1679921D09D89319" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProFormaMember_DAFA70A739700CFC1679921D09D89319" xlink:to="lab_us-gaap_ProFormaMember_DAFA70A739700CFC1679921D09D89319" xlink:type="arc" />
    <link:label id="lab_pfe_MylotargMember_8C172B1B8BE8902987BE921D09D864EB_terseLabel_en-US" xlink:label="lab_pfe_MylotargMember_8C172B1B8BE8902987BE921D09D864EB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Mylotarg [Member]</link:label>
    <link:label id="lab_pfe_MylotargMember_8C172B1B8BE8902987BE921D09D864EB_label_en-US" xlink:label="lab_pfe_MylotargMember_8C172B1B8BE8902987BE921D09D864EB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Mylotarg [Member]</link:label>
    <link:label id="lab_pfe_MylotargMember_8C172B1B8BE8902987BE921D09D864EB_documentation_en-US" xlink:label="lab_pfe_MylotargMember_8C172B1B8BE8902987BE921D09D864EB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Mylotarg [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_MylotargMember" xlink:label="loc_pfe_MylotargMember_8C172B1B8BE8902987BE921D09D864EB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_MylotargMember_8C172B1B8BE8902987BE921D09D864EB" xlink:to="lab_pfe_MylotargMember_8C172B1B8BE8902987BE921D09D864EB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_83A3DB50A991F330FA64921D09D81AE3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis_83A3DB50A991F330FA64921D09D81AE3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_83A3DB50A991F330FA64921D09D81AE3_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis_83A3DB50A991F330FA64921D09D81AE3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_83A3DB50A991F330FA64921D09D81AE3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_83A3DB50A991F330FA64921D09D81AE3" xlink:to="lab_us-gaap_ShareRepurchaseProgramAxis_83A3DB50A991F330FA64921D09D81AE3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_9027777ED142B7A23E04921D09D892BD_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain_9027777ED142B7A23E04921D09D892BD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_9027777ED142B7A23E04921D09D892BD_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain_9027777ED142B7A23E04921D09D892BD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_9027777ED142B7A23E04921D09D892BD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_9027777ED142B7A23E04921D09D892BD" xlink:to="lab_us-gaap_ShareRepurchaseProgramDomain_9027777ED142B7A23E04921D09D892BD" xlink:type="arc" />
    <link:label id="lab_pfe_ShareRepurchaseAgreementwithCitibankMember_C2A8F71CFCA543DA86E3921D09D9940A_terseLabel_en-US" xlink:label="lab_pfe_ShareRepurchaseAgreementwithCitibankMember_C2A8F71CFCA543DA86E3921D09D9940A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Repurchase Agreement with Citibank [Member]</link:label>
    <link:label id="lab_pfe_ShareRepurchaseAgreementwithCitibankMember_C2A8F71CFCA543DA86E3921D09D9940A_label_en-US" xlink:label="lab_pfe_ShareRepurchaseAgreementwithCitibankMember_C2A8F71CFCA543DA86E3921D09D9940A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Repurchase Agreement with Citibank [Member]</link:label>
    <link:label id="lab_pfe_ShareRepurchaseAgreementwithCitibankMember_C2A8F71CFCA543DA86E3921D09D9940A_documentation_en-US" xlink:label="lab_pfe_ShareRepurchaseAgreementwithCitibankMember_C2A8F71CFCA543DA86E3921D09D9940A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Repurchase Agreement with Citibank [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_ShareRepurchaseAgreementwithCitibankMember" xlink:label="loc_pfe_ShareRepurchaseAgreementwithCitibankMember_C2A8F71CFCA543DA86E3921D09D9940A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ShareRepurchaseAgreementwithCitibankMember_C2A8F71CFCA543DA86E3921D09D9940A" xlink:to="lab_pfe_ShareRepurchaseAgreementwithCitibankMember_C2A8F71CFCA543DA86E3921D09D9940A" xlink:type="arc" />
    <link:label id="lab_us-gaap_AcceleratedShareRepurchasesLineItems_C95954F5BFA0E3906192921D09D9D7C0_terseLabel_en-US" xlink:label="lab_us-gaap_AcceleratedShareRepurchasesLineItems_C95954F5BFA0E3906192921D09D9D7C0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accelerated Share Repurchases [Line Items]</link:label>
    <link:label id="lab_us-gaap_AcceleratedShareRepurchasesLineItems_C95954F5BFA0E3906192921D09D9D7C0_label_en-US" xlink:label="lab_us-gaap_AcceleratedShareRepurchasesLineItems_C95954F5BFA0E3906192921D09D9D7C0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accelerated Share Repurchases [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AcceleratedShareRepurchasesLineItems" xlink:label="loc_us-gaap_AcceleratedShareRepurchasesLineItems_C95954F5BFA0E3906192921D09D9D7C0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesLineItems_C95954F5BFA0E3906192921D09D9D7C0" xlink:to="lab_us-gaap_AcceleratedShareRepurchasesLineItems_C95954F5BFA0E3906192921D09D9D7C0" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_A685F6BD24A207A158D1921D09D9D31F_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_A685F6BD24A207A158D1921D09D9D31F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share repurchase agreement, amount</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_A685F6BD24A207A158D1921D09D9D31F_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_A685F6BD24A207A158D1921D09D9D31F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_A685F6BD24A207A158D1921D09D9D31F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_A685F6BD24A207A158D1921D09D9D31F" xlink:to="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_A685F6BD24A207A158D1921D09D9D31F" xlink:type="arc" />
    <link:label id="lab_us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt_59992A404830AAEFBA76921D09D98A8A_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt_59992A404830AAEFBA76921D09D98A8A" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Accelerated share repurchases, cash paid</link:label>
    <link:label id="lab_us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt_59992A404830AAEFBA76921D09D98A8A_label_en-US" xlink:label="lab_us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt_59992A404830AAEFBA76921D09D98A8A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accelerated Share Repurchases, Settlement (Payment) or Receipt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt" xlink:label="loc_us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt_59992A404830AAEFBA76921D09D98A8A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt_59992A404830AAEFBA76921D09D98A8A" xlink:to="lab_us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt_59992A404830AAEFBA76921D09D98A8A" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_F1230CAE177EE8066457921D09D91C51_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired_F1230CAE177EE8066457921D09D91C51" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares repurchased</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_F1230CAE177EE8066457921D09D91C51_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired_F1230CAE177EE8066457921D09D91C51" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Shares, Acquired</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_F1230CAE177EE8066457921D09D91C51" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesAcquired_F1230CAE177EE8066457921D09D91C51" xlink:to="lab_us-gaap_TreasuryStockSharesAcquired_F1230CAE177EE8066457921D09D91C51" xlink:type="arc" />
    <link:label id="lab_us-gaap_AcceleratedShareRepurchasesInitialPricePaidPerShare_FDB2AE370B97627EBE57921D09D950A6_terseLabel_en-US" xlink:label="lab_us-gaap_AcceleratedShareRepurchasesInitialPricePaidPerShare_FDB2AE370B97627EBE57921D09D950A6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares repurchased, price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_AcceleratedShareRepurchasesInitialPricePaidPerShare_FDB2AE370B97627EBE57921D09D950A6_label_en-US" xlink:label="lab_us-gaap_AcceleratedShareRepurchasesInitialPricePaidPerShare_FDB2AE370B97627EBE57921D09D950A6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accelerated Share Repurchases, Initial Price Paid Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AcceleratedShareRepurchasesInitialPricePaidPerShare" xlink:label="loc_us-gaap_AcceleratedShareRepurchasesInitialPricePaidPerShare_FDB2AE370B97627EBE57921D09D950A6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesInitialPricePaidPerShare_FDB2AE370B97627EBE57921D09D950A6" xlink:to="lab_us-gaap_AcceleratedShareRepurchasesInitialPricePaidPerShare_FDB2AE370B97627EBE57921D09D950A6" xlink:type="arc" />
    <link:label id="lab_pfe_AcceleratedShareRepurchasesSharesRepurchasedDuringPeriodPercentageofAgreementAmount_BAD406876B61F5808BFB921D09DA9E7E_terseLabel_en-US" xlink:label="lab_pfe_AcceleratedShareRepurchasesSharesRepurchasedDuringPeriodPercentageofAgreementAmount_BAD406876B61F5808BFB921D09DA9E7E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares received in initial delivery, percentage of agreement amount</link:label>
    <link:label id="lab_pfe_AcceleratedShareRepurchasesSharesRepurchasedDuringPeriodPercentageofAgreementAmount_BAD406876B61F5808BFB921D09DA9E7E_label_en-US" xlink:label="lab_pfe_AcceleratedShareRepurchasesSharesRepurchasedDuringPeriodPercentageofAgreementAmount_BAD406876B61F5808BFB921D09DA9E7E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accelerated Share Repurchases, Shares Repurchased During Period, Percentage of Agreement Amount</link:label>
    <link:label id="lab_pfe_AcceleratedShareRepurchasesSharesRepurchasedDuringPeriodPercentageofAgreementAmount_BAD406876B61F5808BFB921D09DA9E7E_documentation_en-US" xlink:label="lab_pfe_AcceleratedShareRepurchasesSharesRepurchasedDuringPeriodPercentageofAgreementAmount_BAD406876B61F5808BFB921D09DA9E7E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accelerated Share Repurchases, Shares Repurchased During Period, Percentage of Agreement Amount</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_AcceleratedShareRepurchasesSharesRepurchasedDuringPeriodPercentageofAgreementAmount" xlink:label="loc_pfe_AcceleratedShareRepurchasesSharesRepurchasedDuringPeriodPercentageofAgreementAmount_BAD406876B61F5808BFB921D09DA9E7E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_AcceleratedShareRepurchasesSharesRepurchasedDuringPeriodPercentageofAgreementAmount_BAD406876B61F5808BFB921D09DA9E7E" xlink:to="lab_pfe_AcceleratedShareRepurchasesSharesRepurchasedDuringPeriodPercentageofAgreementAmount_BAD406876B61F5808BFB921D09DA9E7E" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare_7B16CC35C5484DE1E5B3921D09DA5008_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare_7B16CC35C5484DE1E5B3921D09DA5008" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Average price paid for shares delivered under agreement (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare_7B16CC35C5484DE1E5B3921D09DA5008_label_en-US" xlink:label="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare_7B16CC35C5484DE1E5B3921D09DA5008" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock Acquired, Average Cost Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_7B16CC35C5484DE1E5B3921D09DA5008" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_7B16CC35C5484DE1E5B3921D09DA5008" xlink:to="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare_7B16CC35C5484DE1E5B3921D09DA5008" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_74FF5D80B90DAA88CA40921D09DA107A_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_74FF5D80B90DAA88CA40921D09DA107A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remaining authorized repurchase amount</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_74FF5D80B90DAA88CA40921D09DA107A_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_74FF5D80B90DAA88CA40921D09DA107A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Repurchase Program, Remaining Authorized Repurchase Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_74FF5D80B90DAA88CA40921D09DA107A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_74FF5D80B90DAA88CA40921D09DA107A" xlink:to="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_74FF5D80B90DAA88CA40921D09DA107A" xlink:type="arc" />
    <link:label id="lab_pfe_ResearchandDevelopmentArrangementAggregatePaymentObligation_174C301B5B439354EB35921D09DAA635_verboseLabel_en-US" xlink:label="lab_pfe_ResearchandDevelopmentArrangementAggregatePaymentObligation_174C301B5B439354EB35921D09DAA635" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Research arrangement, fixed payment obligation</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_ResearchandDevelopmentArrangementAggregatePaymentObligation" xlink:label="loc_pfe_ResearchandDevelopmentArrangementAggregatePaymentObligation_174C301B5B439354EB35921D09DAA635" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ResearchandDevelopmentArrangementAggregatePaymentObligation_174C301B5B439354EB35921D09DAA635" xlink:to="lab_pfe_ResearchandDevelopmentArrangementAggregatePaymentObligation_174C301B5B439354EB35921D09DAA635" xlink:type="arc" />
    <link:label id="lab_pfe_ResearchandDevelopmentArrangementAggregatePaymentObligationTerm_13B172CEFAD1A71DE87E921D1B122958_verboseLabel_en-US" xlink:label="lab_pfe_ResearchandDevelopmentArrangementAggregatePaymentObligationTerm_13B172CEFAD1A71DE87E921D1B122958" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Term over which additional fixed payments are to be made</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_ResearchandDevelopmentArrangementAggregatePaymentObligationTerm" xlink:label="loc_pfe_ResearchandDevelopmentArrangementAggregatePaymentObligationTerm_13B172CEFAD1A71DE87E921D1B122958" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ResearchandDevelopmentArrangementAggregatePaymentObligationTerm_13B172CEFAD1A71DE87E921D1B122958" xlink:to="lab_pfe_ResearchandDevelopmentArrangementAggregatePaymentObligationTerm_13B172CEFAD1A71DE87E921D1B122958" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_F75A3FE82D69A52A39F4AE9F92F4D9DD_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_5D822B869F105875B8EC689244D06C94" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Components of Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_F75A3FE82D69A52A39F4AE9F92F4D9DD_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_5D822B869F105875B8EC689244D06C94" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Costs [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_5D822B869F105875B8EC689244D06C94" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_5D822B869F105875B8EC689244D06C94" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_5D822B869F105875B8EC689244D06C94" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_0EFD96ABE0BEBD7CE5A2AE9F92F472CA_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_5EF30186E3725633AE2330071E7D96EB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Components of and Changes in Restructuring Accruals</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_0EFD96ABE0BEBD7CE5A2AE9F92F472CA_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_5EF30186E3725633AE2330071E7D96EB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Restructuring Reserve by Type of Cost [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_5EF30186E3725633AE2330071E7D96EB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_5EF30186E3725633AE2330071E7D96EB" xlink:to="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_5EF30186E3725633AE2330071E7D96EB" xlink:type="arc" />
    <link:label id="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_29B3790C63F0A5FDBFB1AE9F92B12321_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_27355AD1DEC2579D9EBB5D4850F90931" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_29B3790C63F0A5FDBFB1AE9F92B12321_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_27355AD1DEC2579D9EBB5D4850F90931" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:label="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_27355AD1DEC2579D9EBB5D4850F90931" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_27355AD1DEC2579D9EBB5D4850F90931" xlink:to="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_27355AD1DEC2579D9EBB5D4850F90931" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_1A264B0E75955700FC0BAE9F92344529_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_A1A573287B32581E85DF75A5794F3179" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Basic and Diluted Earning Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_1A264B0E75955700FC0BAE9F92344529_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_A1A573287B32581E85DF75A5794F3179" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_A1A573287B32581E85DF75A5794F3179" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_A1A573287B32581E85DF75A5794F3179" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_A1A573287B32581E85DF75A5794F3179" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_E85A3FDA4D8922AB0F16C9B1C2BFE6CD_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_EC89331E05695A38973ED4022AB2196A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_E85A3FDA4D8922AB0F16C9B1C2BFE6CD_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_EC89331E05695A38973ED4022AB2196A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_EC89331E05695A38973ED4022AB2196A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_EC89331E05695A38973ED4022AB2196A" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_EC89331E05695A38973ED4022AB2196A" xlink:type="arc" />
    <link:label id="lab_pfe_MerckKGaAMember_6139D5C5F7E158DDAB89C9B1C2BF50F9_terseLabel_en-US" xlink:label="lab_pfe_MerckKGaAMember_E51F38A986FA5F51BCA366F221D83905" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Merck KGaA [Member]</link:label>
    <link:label id="lab_pfe_MerckKGaAMember_6139D5C5F7E158DDAB89C9B1C2BF50F9_label_en-US" xlink:label="lab_pfe_MerckKGaAMember_E51F38A986FA5F51BCA366F221D83905" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Merck KGaA [Member]</link:label>
    <link:label id="lab_pfe_MerckKGaAMember_6139D5C5F7E158DDAB89C9B1C2BF50F9_documentation_en-US" xlink:label="lab_pfe_MerckKGaAMember_E51F38A986FA5F51BCA366F221D83905" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Merck KGaA [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_MerckKGaAMember" xlink:label="loc_pfe_MerckKGaAMember_E51F38A986FA5F51BCA366F221D83905" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_MerckKGaAMember_E51F38A986FA5F51BCA366F221D83905" xlink:to="lab_pfe_MerckKGaAMember_E51F38A986FA5F51BCA366F221D83905" xlink:type="arc" />
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_85710FCD6F128E39E25DC9B1C2C5C67B_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember_4AEA76069BEE562EB977746F9C1E22DB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement [Member]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_85710FCD6F128E39E25DC9B1C2C5C67B_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember_4AEA76069BEE562EB977746F9C1E22DB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="loc_us-gaap_CollaborativeArrangementMember_4AEA76069BEE562EB977746F9C1E22DB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementMember_4AEA76069BEE562EB977746F9C1E22DB" xlink:to="lab_us-gaap_CollaborativeArrangementMember_4AEA76069BEE562EB977746F9C1E22DB" xlink:type="arc" />
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CA7C68864FDD74FA2CD0C9B1C2C56321_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_10B877F410CE54A19F50694268EBEE36" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CA7C68864FDD74FA2CD0C9B1C2C56321_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_10B877F410CE54A19F50694268EBEE36" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_10B877F410CE54A19F50694268EBEE36" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_10B877F410CE54A19F50694268EBEE36" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_10B877F410CE54A19F50694268EBEE36" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromCollaborators_0FA7568ECD4AAEA18C9BC9B1C2C5BE84_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromCollaborators_C0B071DD1B8B5DF584A61B4CA682BEF1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Upfront payments received</link:label>
    <link:label id="lab_us-gaap_ProceedsFromCollaborators_0FA7568ECD4AAEA18C9BC9B1C2C5BE84_label_en-US" xlink:label="lab_us-gaap_ProceedsFromCollaborators_C0B071DD1B8B5DF584A61B4CA682BEF1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Collaborators</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromCollaborators" xlink:label="loc_us-gaap_ProceedsFromCollaborators_C0B071DD1B8B5DF584A61B4CA682BEF1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromCollaborators_C0B071DD1B8B5DF584A61B4CA682BEF1" xlink:to="lab_us-gaap_ProceedsFromCollaborators_C0B071DD1B8B5DF584A61B4CA682BEF1" xlink:type="arc" />
    <link:label id="lab_pfe_CollaborativeArrangementCollaboratorsRevenueandExpenseOwnershipPercentage_65F4B866DC857C06686BC9B1C2C515B0_terseLabel_en-US" xlink:label="lab_pfe_CollaborativeArrangementCollaboratorsRevenueandExpenseOwnershipPercentage_AD6C963FD5DC5C179BF61145AFC1C305" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborator's revenue and expense ownership percentage</link:label>
    <link:label id="lab_pfe_CollaborativeArrangementCollaboratorsRevenueandExpenseOwnershipPercentage_65F4B866DC857C06686BC9B1C2C515B0_label_en-US" xlink:label="lab_pfe_CollaborativeArrangementCollaboratorsRevenueandExpenseOwnershipPercentage_AD6C963FD5DC5C179BF61145AFC1C305" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Collaborator's Revenue and Expense Ownership Percentage</link:label>
    <link:label id="lab_pfe_CollaborativeArrangementCollaboratorsRevenueandExpenseOwnershipPercentage_65F4B866DC857C06686BC9B1C2C515B0_documentation_en-US" xlink:label="lab_pfe_CollaborativeArrangementCollaboratorsRevenueandExpenseOwnershipPercentage_AD6C963FD5DC5C179BF61145AFC1C305" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Collaborator's Revenue and Expense Ownership Percentage</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_CollaborativeArrangementCollaboratorsRevenueandExpenseOwnershipPercentage" xlink:label="loc_pfe_CollaborativeArrangementCollaboratorsRevenueandExpenseOwnershipPercentage_AD6C963FD5DC5C179BF61145AFC1C305" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_CollaborativeArrangementCollaboratorsRevenueandExpenseOwnershipPercentage_AD6C963FD5DC5C179BF61145AFC1C305" xlink:to="lab_pfe_CollaborativeArrangementCollaboratorsRevenueandExpenseOwnershipPercentage_AD6C963FD5DC5C179BF61145AFC1C305" xlink:type="arc" />
    <link:label id="lab_pfe_CollaborativeArrangementCompanysRevenueandExpenseOwnershipPercentage_18F1FA3FE0EBCE764392C9B1C2C59F1F_terseLabel_en-US" xlink:label="lab_pfe_CollaborativeArrangementCompanysRevenueandExpenseOwnershipPercentage_2323A02A058E5BACB0EC0C8ACBB2F7D4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company's revenue and expense ownership percentage</link:label>
    <link:label id="lab_pfe_CollaborativeArrangementCompanysRevenueandExpenseOwnershipPercentage_18F1FA3FE0EBCE764392C9B1C2C59F1F_label_en-US" xlink:label="lab_pfe_CollaborativeArrangementCompanysRevenueandExpenseOwnershipPercentage_2323A02A058E5BACB0EC0C8ACBB2F7D4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Company's Revenue and Expense Ownership Percentage</link:label>
    <link:label id="lab_pfe_CollaborativeArrangementCompanysRevenueandExpenseOwnershipPercentage_18F1FA3FE0EBCE764392C9B1C2C59F1F_documentation_en-US" xlink:label="lab_pfe_CollaborativeArrangementCompanysRevenueandExpenseOwnershipPercentage_2323A02A058E5BACB0EC0C8ACBB2F7D4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Company's Revenue and Expense Ownership Percentage</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_CollaborativeArrangementCompanysRevenueandExpenseOwnershipPercentage" xlink:label="loc_pfe_CollaborativeArrangementCompanysRevenueandExpenseOwnershipPercentage_2323A02A058E5BACB0EC0C8ACBB2F7D4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_CollaborativeArrangementCompanysRevenueandExpenseOwnershipPercentage_2323A02A058E5BACB0EC0C8ACBB2F7D4" xlink:to="lab_pfe_CollaborativeArrangementCompanysRevenueandExpenseOwnershipPercentage_2323A02A058E5BACB0EC0C8ACBB2F7D4" xlink:type="arc" />
    <link:label id="lab_pfe_OtherSegmentReconcilingItemsAxis_6C866FB4E2F69A665454837D95F7FA37_terseLabel_en-US" xlink:label="lab_pfe_OtherSegmentReconcilingItemsAxis_6C866FB4E2F69A665454837D95F7FA37" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Segment Reconciling Items [Axis]</link:label>
    <link:label id="lab_pfe_OtherSegmentReconcilingItemsAxis_6C866FB4E2F69A665454837D95F7FA37_label_en-US" xlink:label="lab_pfe_OtherSegmentReconcilingItemsAxis_6C866FB4E2F69A665454837D95F7FA37" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Segment Reconciling Items [Axis]</link:label>
    <link:label id="lab_pfe_OtherSegmentReconcilingItemsAxis_6C866FB4E2F69A665454837D95F7FA37_documentation_en-US" xlink:label="lab_pfe_OtherSegmentReconcilingItemsAxis_6C866FB4E2F69A665454837D95F7FA37" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Segment Reconciling Items [Axis]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_OtherSegmentReconcilingItemsAxis" xlink:label="loc_pfe_OtherSegmentReconcilingItemsAxis_6C866FB4E2F69A665454837D95F7FA37" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherSegmentReconcilingItemsAxis_6C866FB4E2F69A665454837D95F7FA37" xlink:to="lab_pfe_OtherSegmentReconcilingItemsAxis_6C866FB4E2F69A665454837D95F7FA37" xlink:type="arc" />
    <link:label id="lab_pfe_OtherSegmentReconcilingItemsDomain_245781E5DB152A52AB7B837D95F7728D_terseLabel_en-US" xlink:label="lab_pfe_OtherSegmentReconcilingItemsDomain_245781E5DB152A52AB7B837D95F7728D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Segment Reconciling Items [Domain]</link:label>
    <link:label id="lab_pfe_OtherSegmentReconcilingItemsDomain_245781E5DB152A52AB7B837D95F7728D_label_en-US" xlink:label="lab_pfe_OtherSegmentReconcilingItemsDomain_245781E5DB152A52AB7B837D95F7728D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Segment Reconciling Items [Domain]</link:label>
    <link:label id="lab_pfe_OtherSegmentReconcilingItemsDomain_245781E5DB152A52AB7B837D95F7728D_documentation_en-US" xlink:label="lab_pfe_OtherSegmentReconcilingItemsDomain_245781E5DB152A52AB7B837D95F7728D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Domain] for Other Segment Reconciling Items [Axis]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_OtherSegmentReconcilingItemsDomain" xlink:label="loc_pfe_OtherSegmentReconcilingItemsDomain_245781E5DB152A52AB7B837D95F7728D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherSegmentReconcilingItemsDomain_245781E5DB152A52AB7B837D95F7728D" xlink:to="lab_pfe_OtherSegmentReconcilingItemsDomain_245781E5DB152A52AB7B837D95F7728D" xlink:type="arc" />
    <link:label id="lab_pfe_PurchaseAccountingAdjustmentsMember_D47244C480BA4A0D3040837D95F71919_terseLabel_en-US" xlink:label="lab_pfe_PurchaseAccountingAdjustmentsMember_D47244C480BA4A0D3040837D95F71919" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase Accounting Adjustments [Member]</link:label>
    <link:label id="lab_pfe_PurchaseAccountingAdjustmentsMember_D47244C480BA4A0D3040837D95F71919_label_en-US" xlink:label="lab_pfe_PurchaseAccountingAdjustmentsMember_D47244C480BA4A0D3040837D95F71919" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase Accounting Adjustments [Member]</link:label>
    <link:label id="lab_pfe_PurchaseAccountingAdjustmentsMember_D47244C480BA4A0D3040837D95F71919_documentation_en-US" xlink:label="lab_pfe_PurchaseAccountingAdjustmentsMember_D47244C480BA4A0D3040837D95F71919" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Purchase Accounting Adjustments [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_PurchaseAccountingAdjustmentsMember" xlink:label="loc_pfe_PurchaseAccountingAdjustmentsMember_D47244C480BA4A0D3040837D95F71919" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_PurchaseAccountingAdjustmentsMember_D47244C480BA4A0D3040837D95F71919" xlink:to="lab_pfe_PurchaseAccountingAdjustmentsMember_D47244C480BA4A0D3040837D95F71919" xlink:type="arc" />
    <link:label id="lab_pfe_BusinessCombinationsAcquisitionRelatedCostsMember_F90D5E8B2CDBC159B5A4837D95F74CB2_terseLabel_en-US" xlink:label="lab_pfe_BusinessCombinationsAcquisitionRelatedCostsMember_F90D5E8B2CDBC159B5A4837D95F74CB2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisition-Related Costs [Member]</link:label>
    <link:label id="lab_pfe_BusinessCombinationsAcquisitionRelatedCostsMember_F90D5E8B2CDBC159B5A4837D95F74CB2_label_en-US" xlink:label="lab_pfe_BusinessCombinationsAcquisitionRelatedCostsMember_F90D5E8B2CDBC159B5A4837D95F74CB2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combinations, Acquisition Related Costs [Member]</link:label>
    <link:label id="lab_pfe_BusinessCombinationsAcquisitionRelatedCostsMember_F90D5E8B2CDBC159B5A4837D95F74CB2_documentation_en-US" xlink:label="lab_pfe_BusinessCombinationsAcquisitionRelatedCostsMember_F90D5E8B2CDBC159B5A4837D95F74CB2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combinations, Acquisition Related Costs [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_BusinessCombinationsAcquisitionRelatedCostsMember" xlink:label="loc_pfe_BusinessCombinationsAcquisitionRelatedCostsMember_F90D5E8B2CDBC159B5A4837D95F74CB2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_BusinessCombinationsAcquisitionRelatedCostsMember_F90D5E8B2CDBC159B5A4837D95F74CB2" xlink:to="lab_pfe_BusinessCombinationsAcquisitionRelatedCostsMember_F90D5E8B2CDBC159B5A4837D95F74CB2" xlink:type="arc" />
    <link:label id="lab_pfe_CertainSignificantItemsMember_223422F094598AFBD2F2837D95F71B0C_terseLabel_en-US" xlink:label="lab_pfe_CertainSignificantItemsMember_223422F094598AFBD2F2837D95F71B0C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Certain Significant Items [Member]</link:label>
    <link:label id="lab_pfe_CertainSignificantItemsMember_223422F094598AFBD2F2837D95F71B0C_label_en-US" xlink:label="lab_pfe_CertainSignificantItemsMember_223422F094598AFBD2F2837D95F71B0C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Certain Significant Items [Member]</link:label>
    <link:label id="lab_pfe_CertainSignificantItemsMember_223422F094598AFBD2F2837D95F71B0C_documentation_en-US" xlink:label="lab_pfe_CertainSignificantItemsMember_223422F094598AFBD2F2837D95F71B0C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Certain significant items [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_CertainSignificantItemsMember" xlink:label="loc_pfe_CertainSignificantItemsMember_223422F094598AFBD2F2837D95F71B0C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_CertainSignificantItemsMember_223422F094598AFBD2F2837D95F71B0C" xlink:to="lab_pfe_CertainSignificantItemsMember_223422F094598AFBD2F2837D95F71B0C" xlink:type="arc" />
    <link:label id="lab_pfe_OtherUnallocatedMember_A02E22599C4F7ACA4BD5837D95F7C9EF_terseLabel_en-US" xlink:label="lab_pfe_OtherUnallocatedMember_A02E22599C4F7ACA4BD5837D95F7C9EF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Unallocated [Member]</link:label>
    <link:label id="lab_pfe_OtherUnallocatedMember_A02E22599C4F7ACA4BD5837D95F7C9EF_label_en-US" xlink:label="lab_pfe_OtherUnallocatedMember_A02E22599C4F7ACA4BD5837D95F7C9EF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Unallocated [Member]</link:label>
    <link:label id="lab_pfe_OtherUnallocatedMember_A02E22599C4F7ACA4BD5837D95F7C9EF_documentation_en-US" xlink:label="lab_pfe_OtherUnallocatedMember_A02E22599C4F7ACA4BD5837D95F7C9EF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other unallocated [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_OtherUnallocatedMember" xlink:label="loc_pfe_OtherUnallocatedMember_A02E22599C4F7ACA4BD5837D95F7C9EF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherUnallocatedMember_A02E22599C4F7ACA4BD5837D95F7C9EF" xlink:to="lab_pfe_OtherUnallocatedMember_A02E22599C4F7ACA4BD5837D95F7C9EF" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_AC3251273AE8953EDCA0837D95F7F0F3_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_AC3251273AE8953EDCA0837D95F7F0F3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Earnings</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_AC3251273AE8953EDCA0837D95F7F0F3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_AC3251273AE8953EDCA0837D95F7F0F3" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_AC3251273AE8953EDCA0837D95F7F0F3" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_9628E205BB024DF77A8AC8491997C4A4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_9B5CC266CC2A58E69F599AAC6DE6381E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Information about Certain Financial Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_9628E205BB024DF77A8AC8491997C4A4_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_9B5CC266CC2A58E69F599AAC6DE6381E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_9B5CC266CC2A58E69F599AAC6DE6381E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_9B5CC266CC2A58E69F599AAC6DE6381E" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_9B5CC266CC2A58E69F599AAC6DE6381E" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_B6F48BB300C9280B5576C84919970E79_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_25458F0544675354AAD76C52E373D2FA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selected Financial Assets and Liabilities Presented in the Condensed Consolidated Balance Sheets</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_B6F48BB300C9280B5576C84919970E79_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_25458F0544675354AAD76C52E373D2FA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_25458F0544675354AAD76C52E373D2FA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_25458F0544675354AAD76C52E373D2FA" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_25458F0544675354AAD76C52E373D2FA" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_7F4A7DEEA71499E953B3C849199736B0_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_95B4921305AE5F4E8FF4FD08031D9031" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contractual Maturities of Available-for-sale and Held-to-maturity Debt Securities</link:label>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_7F4A7DEEA71499E953B3C849199736B0_label_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_95B4921305AE5F4E8FF4FD08031D9031" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_95B4921305AE5F4E8FF4FD08031D9031" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_95B4921305AE5F4E8FF4FD08031D9031" xlink:to="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_95B4921305AE5F4E8FF4FD08031D9031" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_4B2915190B163C2BC82FC84919975FBF_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_47822082D7215697A66554B07923EFF6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Principal Amounts and Components of Unsecured Long-term Debt Issued</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_4B2915190B163C2BC82FC84919975FBF_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_47822082D7215697A66554B07923EFF6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_47822082D7215697A66554B07923EFF6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_47822082D7215697A66554B07923EFF6" xlink:to="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_47822082D7215697A66554B07923EFF6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_83156BF8E1FA54ACF5AAC84919974489_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_7B7282980F415755B4F686946CC160B8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maturity Schedule of Long-term Debt Outstanding</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_83156BF8E1FA54ACF5AAC84919974489_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_7B7282980F415755B4F686946CC160B8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Maturities of Long-term Debt [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_7B7282980F415755B4F686946CC160B8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_7B7282980F415755B4F686946CC160B8" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_7B7282980F415755B4F686946CC160B8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_1D47DD01D2F94FB57AB7C8491997E422_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_EBF43EE72CF65ACCAEF67291A017A253" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Information about Gains/(Losses) Incurred to Hedge or Offset Operational Foreign Exchange or Interest Rate Risk</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_1D47DD01D2F94FB57AB7C8491997E422_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_EBF43EE72CF65ACCAEF67291A017A253" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_EBF43EE72CF65ACCAEF67291A017A253" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_EBF43EE72CF65ACCAEF67291A017A253" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_EBF43EE72CF65ACCAEF67291A017A253" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskTable_CBEB5574A214DC6EF8F278AA472EDEC9_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable_CBEB5574A214DC6EF8F278AA472EDEC9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_CBEB5574A214DC6EF8F278AA472EDEC9_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable_CBEB5574A214DC6EF8F278AA472EDEC9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaap_ConcentrationRiskTable_CBEB5574A214DC6EF8F278AA472EDEC9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTable_CBEB5574A214DC6EF8F278AA472EDEC9" xlink:to="lab_us-gaap_ConcentrationRiskTable_CBEB5574A214DC6EF8F278AA472EDEC9" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquitySecuritiesByIndustryAxis_9E9C5EA8E5642C4521A478AA47304E13_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesByIndustryAxis_9E9C5EA8E5642C4521A478AA47304E13" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Industry Sector [Axis]</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesByIndustryAxis_9E9C5EA8E5642C4521A478AA47304E13_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesByIndustryAxis_9E9C5EA8E5642C4521A478AA47304E13" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Industry Sector [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquitySecuritiesByIndustryAxis" xlink:label="loc_us-gaap_EquitySecuritiesByIndustryAxis_9E9C5EA8E5642C4521A478AA47304E13" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesByIndustryAxis_9E9C5EA8E5642C4521A478AA47304E13" xlink:to="lab_us-gaap_EquitySecuritiesByIndustryAxis_9E9C5EA8E5642C4521A478AA47304E13" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquitySecuritiesIndustryMember_CB3727F93C4DD7330C2C78AA473067E8_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesIndustryMember_CB3727F93C4DD7330C2C78AA473067E8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Industry Sector [Domain]</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesIndustryMember_CB3727F93C4DD7330C2C78AA473067E8_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesIndustryMember_CB3727F93C4DD7330C2C78AA473067E8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Industry Sector [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquitySecuritiesIndustryMember" xlink:label="loc_us-gaap_EquitySecuritiesIndustryMember_CB3727F93C4DD7330C2C78AA473067E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesIndustryMember_CB3727F93C4DD7330C2C78AA473067E8" xlink:to="lab_us-gaap_EquitySecuritiesIndustryMember_CB3727F93C4DD7330C2C78AA473067E8" xlink:type="arc" />
    <link:label id="lab_us-gaap_TechnologySectorMember_6D75CFCEC3D8C53C57B378AA4730164D_terseLabel_en-US" xlink:label="lab_us-gaap_TechnologySectorMember_6D75CFCEC3D8C53C57B378AA4730164D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Technology sector [Member]</link:label>
    <link:label id="lab_us-gaap_TechnologySectorMember_6D75CFCEC3D8C53C57B378AA4730164D_label_en-US" xlink:label="lab_us-gaap_TechnologySectorMember_6D75CFCEC3D8C53C57B378AA4730164D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Technology Sector [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TechnologySectorMember" xlink:label="loc_us-gaap_TechnologySectorMember_6D75CFCEC3D8C53C57B378AA4730164D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TechnologySectorMember_6D75CFCEC3D8C53C57B378AA4730164D" xlink:to="lab_us-gaap_TechnologySectorMember_6D75CFCEC3D8C53C57B378AA4730164D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_0757E12B39E0E3ABD64F78AA47308503_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems_0757E12B39E0E3ABD64F78AA47308503" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_0757E12B39E0E3ABD64F78AA47308503_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems_0757E12B39E0E3ABD64F78AA47308503" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_0757E12B39E0E3ABD64F78AA47308503" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_0757E12B39E0E3ABD64F78AA47308503" xlink:to="lab_us-gaap_ConcentrationRiskLineItems_0757E12B39E0E3ABD64F78AA47308503" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeNetLiabilityPositionAggregateFairValue_22115CBE1C94C4CAAE2278AA473001A4_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNetLiabilityPositionAggregateFairValue_22115CBE1C94C4CAAE2278AA473001A4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivatives in a net liability position</link:label>
    <link:label id="lab_us-gaap_DerivativeNetLiabilityPositionAggregateFairValue_22115CBE1C94C4CAAE2278AA473001A4_label_en-US" xlink:label="lab_us-gaap_DerivativeNetLiabilityPositionAggregateFairValue_22115CBE1C94C4CAAE2278AA473001A4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative, Net Liability Position, Aggregate Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeNetLiabilityPositionAggregateFairValue" xlink:label="loc_us-gaap_DerivativeNetLiabilityPositionAggregateFairValue_22115CBE1C94C4CAAE2278AA473001A4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeNetLiabilityPositionAggregateFairValue_22115CBE1C94C4CAAE2278AA473001A4" xlink:to="lab_us-gaap_DerivativeNetLiabilityPositionAggregateFairValue_22115CBE1C94C4CAAE2278AA473001A4" xlink:type="arc" />
    <link:label id="lab_us-gaap_CollateralAlreadyPostedAggregateFairValue_B341494865806406B56278AA47300A3B_terseLabel_en-US" xlink:label="lab_us-gaap_CollateralAlreadyPostedAggregateFairValue_B341494865806406B56278AA47300A3B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collateral posted</link:label>
    <link:label id="lab_us-gaap_CollateralAlreadyPostedAggregateFairValue_B341494865806406B56278AA47300A3B_label_en-US" xlink:label="lab_us-gaap_CollateralAlreadyPostedAggregateFairValue_B341494865806406B56278AA47300A3B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collateral Already Posted, Aggregate Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollateralAlreadyPostedAggregateFairValue" xlink:label="loc_us-gaap_CollateralAlreadyPostedAggregateFairValue_B341494865806406B56278AA47300A3B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollateralAlreadyPostedAggregateFairValue_B341494865806406B56278AA47300A3B" xlink:to="lab_us-gaap_CollateralAlreadyPostedAggregateFairValue_B341494865806406B56278AA47300A3B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure_5BE33E2303446C911DD878AA47303821_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure_5BE33E2303446C911DD878AA47303821" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum exposure, amount</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure_5BE33E2303446C911DD878AA47303821_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure_5BE33E2303446C911DD878AA47303821" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Credit Risk, Financial Instrument, Maximum Exposure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure" xlink:label="loc_us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure_5BE33E2303446C911DD878AA47303821" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure_5BE33E2303446C911DD878AA47303821" xlink:to="lab_us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure_5BE33E2303446C911DD878AA47303821" xlink:type="arc" />
    <link:label id="lab_us-gaap_SecuritiesReceivedAsCollateral_4F30184BA1AF218D8E6F78AA4731F219_terseLabel_en-US" xlink:label="lab_us-gaap_SecuritiesReceivedAsCollateral_4F30184BA1AF218D8E6F78AA4731F219" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash collateral received</link:label>
    <link:label id="lab_us-gaap_SecuritiesReceivedAsCollateral_4F30184BA1AF218D8E6F78AA4731F219_label_en-US" xlink:label="lab_us-gaap_SecuritiesReceivedAsCollateral_4F30184BA1AF218D8E6F78AA4731F219" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Securities Received as Collateral</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SecuritiesReceivedAsCollateral" xlink:label="loc_us-gaap_SecuritiesReceivedAsCollateral_4F30184BA1AF218D8E6F78AA4731F219" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuritiesReceivedAsCollateral_4F30184BA1AF218D8E6F78AA4731F219" xlink:to="lab_us-gaap_SecuritiesReceivedAsCollateral_4F30184BA1AF218D8E6F78AA4731F219" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_A854E324248364658DDD7DDD5C44C907_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_A854E324248364658DDD7DDD5C44C907" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency translation adjustments, net</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_A854E324248364658DDD7DDD5C44C907_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_A854E324248364658DDD7DDD5C44C907" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_A854E324248364658DDD7DDD5C44C907" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_A854E324248364658DDD7DDD5C44C907" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_A854E324248364658DDD7DDD5C44C907" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax_4EA8DE98E1D8600A8F5A7DDD5C4433EB_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax_4EA8DE98E1D8600A8F5A7DDD5C4433EB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized holding losses on derivative financial instruments, net</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax_4EA8DE98E1D8600A8F5A7DDD5C4433EB_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax_4EA8DE98E1D8600A8F5A7DDD5C4433EB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax_4EA8DE98E1D8600A8F5A7DDD5C4433EB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax_4EA8DE98E1D8600A8F5A7DDD5C4433EB" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax_4EA8DE98E1D8600A8F5A7DDD5C4433EB" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesTax_E13C6BB90A7BC8A440797DDD5C44B728_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesTax_E13C6BB90A7BC8A440797DDD5C44B728" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Reclassification adjustments for realized (gains)/losses</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesTax_E13C6BB90A7BC8A440797DDD5C44B728_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesTax_E13C6BB90A7BC8A440797DDD5C44B728" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesTax_E13C6BB90A7BC8A440797DDD5C44B728" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesTax_E13C6BB90A7BC8A440797DDD5C44B728" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesTax_E13C6BB90A7BC8A440797DDD5C44B728" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesTax_27FB885AA2F6D4D56DE17DDD5C44F220_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesTax_27FB885AA2F6D4D56DE17DDD5C44F220" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Derivatives qualifying as hedges, tax, total</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesTax_27FB885AA2F6D4D56DE17DDD5C44F220_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesTax_27FB885AA2F6D4D56DE17DDD5C44F220" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesTax_27FB885AA2F6D4D56DE17DDD5C44F220" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesTax_27FB885AA2F6D4D56DE17DDD5C44F220" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesTax_27FB885AA2F6D4D56DE17DDD5C44F220" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_ACE1DA0322FF6A4750A97DDD5C44DC5E_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_ACE1DA0322FF6A4750A97DDD5C44DC5E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized holding gains on available-for-sale securities, net</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_ACE1DA0322FF6A4750A97DDD5C44DC5E_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_ACE1DA0322FF6A4750A97DDD5C44DC5E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_ACE1DA0322FF6A4750A97DDD5C44DC5E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_ACE1DA0322FF6A4750A97DDD5C44DC5E" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_ACE1DA0322FF6A4750A97DDD5C44DC5E" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax_F1F0368CF9088906319D7DDD5C452751_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax_F1F0368CF9088906319D7DDD5C452751" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Reclassification adjustments for realized gains</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax_F1F0368CF9088906319D7DDD5C452751_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax_F1F0368CF9088906319D7DDD5C452751" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax_F1F0368CF9088906319D7DDD5C452751" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax_F1F0368CF9088906319D7DDD5C452751" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax_F1F0368CF9088906319D7DDD5C452751" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_7C943BCFD2E55C73E33B7DDD5C45106E_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_7C943BCFD2E55C73E33B7DDD5C45106E" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Available-for-sale securities, tax, total</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_7C943BCFD2E55C73E33B7DDD5C45106E_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_7C943BCFD2E55C73E33B7DDD5C45106E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Available-for-sale Securities, Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_7C943BCFD2E55C73E33B7DDD5C45106E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_7C943BCFD2E55C73E33B7DDD5C45106E" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_7C943BCFD2E55C73E33B7DDD5C45106E" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodTax_565A1488A31CCC4CE0777DDD5C451782_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodTax_565A1488A31CCC4CE0777DDD5C451782" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Benefit plans: actuarial losses, net</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodTax_565A1488A31CCC4CE0777DDD5C451782_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodTax_565A1488A31CCC4CE0777DDD5C451782" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodTax_565A1488A31CCC4CE0777DDD5C451782" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodTax_565A1488A31CCC4CE0777DDD5C451782" xlink:to="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodTax_565A1488A31CCC4CE0777DDD5C451782" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossTax_CD3414D4BE86F0BD58B87DDD5C454941_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossTax_CD3414D4BE86F0BD58B87DDD5C454941" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Reclassification adjustments related to amortization</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossTax_CD3414D4BE86F0BD58B87DDD5C454941_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossTax_CD3414D4BE86F0BD58B87DDD5C454941" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), Reclassification Adjustment from AOCI, Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossTax_CD3414D4BE86F0BD58B87DDD5C454941" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossTax_CD3414D4BE86F0BD58B87DDD5C454941" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossTax_CD3414D4BE86F0BD58B87DDD5C454941" xlink:type="arc" />
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossTax_FFD5E62B4AA636B6B99F7DDD5C458BF4_negatedTerseLabel_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossTax_FFD5E62B4AA636B6B99F7DDD5C458BF4" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Reclassification adjustments related to settlements, net</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossTax_FFD5E62B4AA636B6B99F7DDD5C458BF4_label_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossTax_FFD5E62B4AA636B6B99F7DDD5C458BF4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Settlement Adjustment From AOCI, Pension And Other Postretirement Benefit Plans, for Net Gain (Loss), Tax</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossTax_FFD5E62B4AA636B6B99F7DDD5C458BF4_documentation_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossTax_FFD5E62B4AA636B6B99F7DDD5C458BF4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Settlement Adjustment From AOCI, Pension And Other Postretirement Benefit Plans, for Net Gain (Loss), Tax</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossTax" xlink:label="loc_pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossTax_FFD5E62B4AA636B6B99F7DDD5C458BF4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossTax_FFD5E62B4AA636B6B99F7DDD5C458BF4" xlink:to="lab_pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossTax_FFD5E62B4AA636B6B99F7DDD5C458BF4" xlink:type="arc" />
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodTax_02DC41CB8DB17CA7A9657DDD5C456D72_negatedTerseLabel_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodTax_02DC41CB8DB17CA7A9657DDD5C456D72" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodTax_02DC41CB8DB17CA7A9657DDD5C456D72_label_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodTax_02DC41CB8DB17CA7A9657DDD5C456D72" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Other Net Unamortized Gain (Loss) Arising During Period, Tax</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodTax_02DC41CB8DB17CA7A9657DDD5C456D72_documentation_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodTax_02DC41CB8DB17CA7A9657DDD5C456D72" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Other Net Unamortized Gain (Loss) Arising During Period, Tax</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodTax" xlink:label="loc_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodTax_02DC41CB8DB17CA7A9657DDD5C456D72" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodTax_02DC41CB8DB17CA7A9657DDD5C456D72" xlink:to="lab_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodTax_02DC41CB8DB17CA7A9657DDD5C456D72" xlink:type="arc" />
    <link:label id="lab_pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetActuarialGainLossTax_5766CF3C22992AF1B8AF7DDD5C45776C_totalLabel_en-US" xlink:label="lab_pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetActuarialGainLossTax_5766CF3C22992AF1B8AF7DDD5C45776C" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Defined benefit plans, actuarial gain (loss), tax, total</link:label>
    <link:label id="lab_pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetActuarialGainLossTax_5766CF3C22992AF1B8AF7DDD5C45776C_label_en-US" xlink:label="lab_pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetActuarialGainLossTax_5766CF3C22992AF1B8AF7DDD5C45776C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss), Net Actuarial Gain (Loss), Tax</link:label>
    <link:label id="lab_pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetActuarialGainLossTax_5766CF3C22992AF1B8AF7DDD5C45776C_documentation_en-US" xlink:label="lab_pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetActuarialGainLossTax_5766CF3C22992AF1B8AF7DDD5C45776C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss), Net Actuarial Gain (Loss), Tax</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetActuarialGainLossTax" xlink:label="loc_pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetActuarialGainLossTax_5766CF3C22992AF1B8AF7DDD5C45776C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetActuarialGainLossTax_5766CF3C22992AF1B8AF7DDD5C45776C" xlink:to="lab_pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetActuarialGainLossTax_5766CF3C22992AF1B8AF7DDD5C45776C" xlink:type="arc" />
    <link:label id="lab_pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetPriorServiceCostCreditAndOtherTax_6D34DF2C7D5F836BED457DDD5C46809B_negatedTerseLabel_en-US" xlink:label="lab_pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetPriorServiceCostCreditAndOtherTax_6D34DF2C7D5F836BED457DDD5C46809B" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Benefit plans: prior service (costs)/credits and other, net</link:label>
    <link:label id="lab_pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetPriorServiceCostCreditAndOtherTax_6D34DF2C7D5F836BED457DDD5C46809B_label_en-US" xlink:label="lab_pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetPriorServiceCostCreditAndOtherTax_6D34DF2C7D5F836BED457DDD5C46809B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss), Net Prior Service Cost (Credit) And Other, Tax</link:label>
    <link:label id="lab_pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetPriorServiceCostCreditAndOtherTax_6D34DF2C7D5F836BED457DDD5C46809B_documentation_en-US" xlink:label="lab_pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetPriorServiceCostCreditAndOtherTax_6D34DF2C7D5F836BED457DDD5C46809B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss), Net Prior Service Cost (Credit) And Other, Tax</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetPriorServiceCostCreditAndOtherTax" xlink:label="loc_pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetPriorServiceCostCreditAndOtherTax_6D34DF2C7D5F836BED457DDD5C46809B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetPriorServiceCostCreditAndOtherTax_6D34DF2C7D5F836BED457DDD5C46809B" xlink:to="lab_pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetPriorServiceCostCreditAndOtherTax_6D34DF2C7D5F836BED457DDD5C46809B" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax_92DA4C7B6A7295A63D707DDD5C46A4A1_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax_92DA4C7B6A7295A63D707DDD5C46A4A1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification adjustments related to amortization</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax_92DA4C7B6A7295A63D707DDD5C46A4A1_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax_92DA4C7B6A7295A63D707DDD5C46A4A1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Reclassification Adjustment from AOCI, Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax_92DA4C7B6A7295A63D707DDD5C46A4A1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax_92DA4C7B6A7295A63D707DDD5C46A4A1" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax_92DA4C7B6A7295A63D707DDD5C46A4A1" xlink:type="arc" />
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditTax_84394B4C3CF29F955EBC7DDD5C462A08_terseLabel_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditTax_84394B4C3CF29F955EBC7DDD5C462A08" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification adjustments related to curtailments, net</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditTax_84394B4C3CF29F955EBC7DDD5C462A08_label_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditTax_84394B4C3CF29F955EBC7DDD5C462A08" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive (Income) Loss, Curtailment Adjustment from AOCI, Pension and Other Postretirement Benefit Plans, for Net Prior Service Cost (Credit), Tax</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditTax_84394B4C3CF29F955EBC7DDD5C462A08_documentation_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditTax_84394B4C3CF29F955EBC7DDD5C462A08" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Comprehensive (Income) Loss, Curtailment Adjustment from AOCI, Pension and Other Postretirement Benefit Plans, for Net Prior Service Cost (Credit), Tax</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditTax" xlink:label="loc_pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditTax_84394B4C3CF29F955EBC7DDD5C462A08" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditTax_84394B4C3CF29F955EBC7DDD5C462A08" xlink:to="lab_pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditTax_84394B4C3CF29F955EBC7DDD5C462A08" xlink:type="arc" />
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax_7740AFE764DEC3E309627DDD5C466F3D_negatedLabel_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax_7740AFE764DEC3E309627DDD5C466F3D" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax_7740AFE764DEC3E309627DDD5C466F3D_label_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax_7740AFE764DEC3E309627DDD5C466F3D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Other Net Prior Service Cost (Credit) Arising During Period, Tax</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax_7740AFE764DEC3E309627DDD5C466F3D_documentation_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax_7740AFE764DEC3E309627DDD5C466F3D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Other Net Prior Service Cost (Credit) Arising During Period, Tax</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax" xlink:label="loc_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax_7740AFE764DEC3E309627DDD5C466F3D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax_7740AFE764DEC3E309627DDD5C466F3D" xlink:to="lab_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax_7740AFE764DEC3E309627DDD5C466F3D" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect_16F4DE6F02706B7799177DDD5C4699F0_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect_16F4DE6F02706B7799177DDD5C4699F0" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Pension and other postretirement benefit plans, net prior service cost (credit), tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect_16F4DE6F02706B7799177DDD5C4699F0_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect_16F4DE6F02706B7799177DDD5C4699F0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect_16F4DE6F02706B7799177DDD5C4699F0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect_16F4DE6F02706B7799177DDD5C4699F0" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect_16F4DE6F02706B7799177DDD5C4699F0" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTax_19B7099B45899EDBD5DE7DDD5C466355_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTax_19B7099B45899EDBD5DE7DDD5C466355" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Tax provision/(benefit) on other comprehensive income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTax_19B7099B45899EDBD5DE7DDD5C466355_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTax_19B7099B45899EDBD5DE7DDD5C466355" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTax_19B7099B45899EDBD5DE7DDD5C466355" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTax_19B7099B45899EDBD5DE7DDD5C466355" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossTax_19B7099B45899EDBD5DE7DDD5C466355" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_7C769AE3CC6F86D28583AE9F927128BA_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock_8DB4A92A688A5248B73AE34B52D79404" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_7C769AE3CC6F86D28583AE9F927128BA_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock_8DB4A92A688A5248B73AE34B52D79404" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_8DB4A92A688A5248B73AE34B52D79404" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock_8DB4A92A688A5248B73AE34B52D79404" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock_8DB4A92A688A5248B73AE34B52D79404" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShortTermDebtMember_6FE6A352A8A6BEDE8914CCD9F68F84D4_verboseLabel_en-US" xlink:label="lab_us-gaap_ShortTermDebtMember_95668803968B553A85AE557232D1CFAA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Short-term Debt [Member]</link:label>
    <link:label id="lab_us-gaap_ShortTermDebtMember_6FE6A352A8A6BEDE8914CCD9F68F84D4_label_en-US" xlink:label="lab_us-gaap_ShortTermDebtMember_95668803968B553A85AE557232D1CFAA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-term Debt [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtMember" xlink:label="loc_us-gaap_ShortTermDebtMember_95668803968B553A85AE557232D1CFAA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtMember_95668803968B553A85AE557232D1CFAA" xlink:to="lab_us-gaap_ShortTermDebtMember_95668803968B553A85AE557232D1CFAA" xlink:type="arc" />
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_A92E6E55C737EF73F486CCD9F690C498_terseLabel_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_771B641CCC625D02B5DC0D164D99D72D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reported Value Measurement [Member]</link:label>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_A92E6E55C737EF73F486CCD9F690C498_label_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_771B641CCC625D02B5DC0D164D99D72D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reported Value Measurement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_771B641CCC625D02B5DC0D164D99D72D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_771B641CCC625D02B5DC0D164D99D72D" xlink:to="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_771B641CCC625D02B5DC0D164D99D72D" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_1616AB28AFF4B79CDD78CCD9F6905CA9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis_6D53D367502959E693ADBA258307970F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_1616AB28AFF4B79CDD78CCD9F6905CA9_label_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis_6D53D367502959E693ADBA258307970F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_6D53D367502959E693ADBA258307970F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_6D53D367502959E693ADBA258307970F" xlink:to="lab_us-gaap_FairValueByAssetClassAxis_6D53D367502959E693ADBA258307970F" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_BF920E20AD12BF75ED1ACCD9F690BB9D_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_B4CB6A5E8A765731A8877EE68CB5615A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_BF920E20AD12BF75ED1ACCD9F690BB9D_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_B4CB6A5E8A765731A8877EE68CB5615A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_B4CB6A5E8A765731A8877EE68CB5615A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_B4CB6A5E8A765731A8877EE68CB5615A" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_B4CB6A5E8A765731A8877EE68CB5615A" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtSecuritiesMember_CC2F5D8C3CDEC80E1FF3CCD9F6907870_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesMember_1FCBA41C77C45892BAC20E318CE16DE1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Available-for-sale Debt Securities [Member]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesMember_CC2F5D8C3CDEC80E1FF3CCD9F6907870_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesMember_1FCBA41C77C45892BAC20E318CE16DE1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtSecuritiesMember" xlink:label="loc_us-gaap_DebtSecuritiesMember_1FCBA41C77C45892BAC20E318CE16DE1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesMember_1FCBA41C77C45892BAC20E318CE16DE1" xlink:to="lab_us-gaap_DebtSecuritiesMember_1FCBA41C77C45892BAC20E318CE16DE1" xlink:type="arc" />
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_B734A008A3FE457831ADCCD9F6906E10_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember_C802839F21555A069DC0A2D071158A14" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_B734A008A3FE457831ADCCD9F6906E10_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember_C802839F21555A069DC0A2D071158A14" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_C802839F21555A069DC0A2D071158A14" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember_C802839F21555A069DC0A2D071158A14" xlink:to="lab_us-gaap_MoneyMarketFundsMember_C802839F21555A069DC0A2D071158A14" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquitySecuritiesMember_9464CE00B1C392E10737CCD9F6903E28_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember_EEAC019B38EB5DA9AB6D94DC640FDB13" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Securities [Member]</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_9464CE00B1C392E10737CCD9F6903E28_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember_EEAC019B38EB5DA9AB6D94DC640FDB13" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquitySecuritiesMember" xlink:label="loc_us-gaap_EquitySecuritiesMember_EEAC019B38EB5DA9AB6D94DC640FDB13" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesMember_EEAC019B38EB5DA9AB6D94DC640FDB13" xlink:to="lab_us-gaap_EquitySecuritiesMember_EEAC019B38EB5DA9AB6D94DC640FDB13" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestRateSwapMember_3EC1C08972592766FB09CCD9F690B12A_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember_B6D8AE62BBDC578FB79A8A571A519D3D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest Rate Swaps [Member]</link:label>
    <link:label id="lab_us-gaap_InterestRateSwapMember_3EC1C08972592766FB09CCD9F690B12A_label_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember_B6D8AE62BBDC578FB79A8A571A519D3D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Rate Swap [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestRateSwapMember" xlink:label="loc_us-gaap_InterestRateSwapMember_B6D8AE62BBDC578FB79A8A571A519D3D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateSwapMember_B6D8AE62BBDC578FB79A8A571A519D3D" xlink:to="lab_us-gaap_InterestRateSwapMember_B6D8AE62BBDC578FB79A8A571A519D3D" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_E0D8115E006F8C16A038CCD9F690789E_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract_3A0DEE1C00B359B897C49F0910C8325E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_E0D8115E006F8C16A038CCD9F690789E_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract_3A0DEE1C00B359B897C49F0910C8325E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_3A0DEE1C00B359B897C49F0910C8325E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_3A0DEE1C00B359B897C49F0910C8325E" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract_3A0DEE1C00B359B897C49F0910C8325E" xlink:type="arc" />
    <link:label id="lab_us-gaap_TradingSecurities_CA9D10F8A0D6AB07B731CCD9F6900813_terseLabel_en-US" xlink:label="lab_us-gaap_TradingSecurities_2602A84370AF587B9C0DFDE8C39550AF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading funds and securities</link:label>
    <link:label id="lab_us-gaap_TradingSecurities_CA9D10F8A0D6AB07B731CCD9F6900813_label_en-US" xlink:label="lab_us-gaap_TradingSecurities_2602A84370AF587B9C0DFDE8C39550AF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TradingSecurities" xlink:label="loc_us-gaap_TradingSecurities_2602A84370AF587B9C0DFDE8C39550AF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradingSecurities_2602A84370AF587B9C0DFDE8C39550AF" xlink:to="lab_us-gaap_TradingSecurities_2602A84370AF587B9C0DFDE8C39550AF" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecurities_EBF9142E2E1C0D874C57CCD9F691982E_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecurities_365DD3AE4179535AA5E19545912E64A4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecurities_EBF9142E2E1C0D874C57CCD9F691982E_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecurities_365DD3AE4179535AA5E19545912E64A4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_365DD3AE4179535AA5E19545912E64A4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecurities_365DD3AE4179535AA5E19545912E64A4" xlink:to="lab_us-gaap_AvailableForSaleSecurities_365DD3AE4179535AA5E19545912E64A4" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeAssets_766E926BFB59A957E7D9CCD9F69152E8_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssets_0E984B72214D53D480A114C7B1535ECF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative financial instruments in a receivable position</link:label>
    <link:label id="lab_us-gaap_DerivativeAssets_766E926BFB59A957E7D9CCD9F69152E8_label_en-US" xlink:label="lab_us-gaap_DerivativeAssets_0E984B72214D53D480A114C7B1535ECF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Asset</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeAssets" xlink:label="loc_us-gaap_DerivativeAssets_0E984B72214D53D480A114C7B1535ECF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssets_0E984B72214D53D480A114C7B1535ECF" xlink:to="lab_us-gaap_DerivativeAssets_0E984B72214D53D480A114C7B1535ECF" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_D39E3AEA0A9A8B97FCC2CCD9F691C617_totalLabel_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure_3C54C80A45BC5A3D9FECB354356F334C" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Selected financial assets measured at fair value on a recurring basis</link:label>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_D39E3AEA0A9A8B97FCC2CCD9F691C617_label_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure_3C54C80A45BC5A3D9FECB354356F334C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_3C54C80A45BC5A3D9FECB354356F334C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsFairValueDisclosure_3C54C80A45BC5A3D9FECB354356F334C" xlink:to="lab_us-gaap_InvestmentsFairValueDisclosure_3C54C80A45BC5A3D9FECB354356F334C" xlink:type="arc" />
    <link:label id="lab_pfe_OtherSelectedFinancialAssetsAbstract_074C84CF577CE1D06629CCD9F69101ED_terseLabel_en-US" xlink:label="lab_pfe_OtherSelectedFinancialAssetsAbstract_F1112C10A70E5067893D9ED2271C9085" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other selected financial assets</link:label>
    <link:label id="lab_pfe_OtherSelectedFinancialAssetsAbstract_074C84CF577CE1D06629CCD9F69101ED_label_en-US" xlink:label="lab_pfe_OtherSelectedFinancialAssetsAbstract_F1112C10A70E5067893D9ED2271C9085" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Selected Financial Assets [Abstract]</link:label>
    <link:label id="lab_pfe_OtherSelectedFinancialAssetsAbstract_074C84CF577CE1D06629CCD9F69101ED_documentation_en-US" xlink:label="lab_pfe_OtherSelectedFinancialAssetsAbstract_F1112C10A70E5067893D9ED2271C9085" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other selected financial assets [Abstract]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_OtherSelectedFinancialAssetsAbstract" xlink:label="loc_pfe_OtherSelectedFinancialAssetsAbstract_F1112C10A70E5067893D9ED2271C9085" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherSelectedFinancialAssetsAbstract_F1112C10A70E5067893D9ED2271C9085" xlink:to="lab_pfe_OtherSelectedFinancialAssetsAbstract_F1112C10A70E5067893D9ED2271C9085" xlink:type="arc" />
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesAmortizedCostBeforeOtherThanTemporaryImpairment_6021D1E8B2E4DF429215CCD9F691E4EB_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesAmortizedCostBeforeOtherThanTemporaryImpairment_AA79B274BB565339A6C2C5761961CFC6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Held-to-maturity debt securities, carried at amortized cost</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesAmortizedCostBeforeOtherThanTemporaryImpairment_6021D1E8B2E4DF429215CCD9F691E4EB_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesAmortizedCostBeforeOtherThanTemporaryImpairment_AA79B274BB565339A6C2C5761961CFC6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Held-to-maturity Securities, Amortized Cost before Other than Temporary Impairment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HeldToMaturitySecuritiesAmortizedCostBeforeOtherThanTemporaryImpairment" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesAmortizedCostBeforeOtherThanTemporaryImpairment_AA79B274BB565339A6C2C5761961CFC6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesAmortizedCostBeforeOtherThanTemporaryImpairment_AA79B274BB565339A6C2C5761961CFC6" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesAmortizedCostBeforeOtherThanTemporaryImpairment_AA79B274BB565339A6C2C5761961CFC6" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_F7605B81D693E092C912CCD9F6910923_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_6B61AE09F9AA5EE2A21E466AE1C0E52A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted stock and private equity securities, carried at cost or at equity-method</link:label>
    <link:label id="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_F7605B81D693E092C912CCD9F6910923_label_en-US" xlink:label="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_6B61AE09F9AA5EE2A21E466AE1C0E52A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_6B61AE09F9AA5EE2A21E466AE1C0E52A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_6B61AE09F9AA5EE2A21E466AE1C0E52A" xlink:to="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_6B61AE09F9AA5EE2A21E466AE1C0E52A" xlink:type="arc" />
    <link:label id="lab_pfe_OtherSelectedFinancialAssets_DA72736292907AD0D8ADCCD9F6912335_totalLabel_en-US" xlink:label="lab_pfe_OtherSelectedFinancialAssets_C99451FEF3805145BE686459062E56B6" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_pfe_OtherSelectedFinancialAssets_DA72736292907AD0D8ADCCD9F6912335_label_en-US" xlink:label="lab_pfe_OtherSelectedFinancialAssets_C99451FEF3805145BE686459062E56B6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Selected Financial Assets</link:label>
    <link:label id="lab_pfe_OtherSelectedFinancialAssets_DA72736292907AD0D8ADCCD9F6912335_documentation_en-US" xlink:label="lab_pfe_OtherSelectedFinancialAssets_C99451FEF3805145BE686459062E56B6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The total amount of other selected financial assets presented in the balance sheet caption at the balance sheet date.</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_OtherSelectedFinancialAssets" xlink:label="loc_pfe_OtherSelectedFinancialAssets_C99451FEF3805145BE686459062E56B6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherSelectedFinancialAssets_C99451FEF3805145BE686459062E56B6" xlink:to="lab_pfe_OtherSelectedFinancialAssets_C99451FEF3805145BE686459062E56B6" xlink:type="arc" />
    <link:label id="lab_pfe_SelectedFinancialAssets_137D0E99981F8B85A20BCCD9F6917CFE_totalLabel_en-US" xlink:label="lab_pfe_SelectedFinancialAssets_5D2522FA4C2A5707B70C468084D3E203" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total selected financial assets</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_SelectedFinancialAssets" xlink:label="loc_pfe_SelectedFinancialAssets_5D2522FA4C2A5707B70C468084D3E203" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SelectedFinancialAssets_5D2522FA4C2A5707B70C468084D3E203" xlink:to="lab_pfe_SelectedFinancialAssets_5D2522FA4C2A5707B70C468084D3E203" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_C5B0708CC77C294492F9CCD9F691C0F6_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_A5B06994B824579E8F8506B1CB505171" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_C5B0708CC77C294492F9CCD9F691C0F6_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_A5B06994B824579E8F8506B1CB505171" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_A5B06994B824579E8F8506B1CB505171" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_A5B06994B824579E8F8506B1CB505171" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_A5B06994B824579E8F8506B1CB505171" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_13AE8E3076353253C429CCD9F691E2F5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_DF914707FD7952A0A8CD4E65ACC29C72" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selected financial liabilities measured at fair value on a recurring basis</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_13AE8E3076353253C429CCD9F691E2F5_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_DF914707FD7952A0A8CD4E65ACC29C72" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets, Liabilities and Stockholders' Equity Measured on Recurring Basis [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_DF914707FD7952A0A8CD4E65ACC29C72" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_DF914707FD7952A0A8CD4E65ACC29C72" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_DF914707FD7952A0A8CD4E65ACC29C72" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeLiabilities_E32364FD9829A22880ADCCD9F6918100_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities_08980192D7CA53DA8A1F3A4352A79649" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative financial instruments in a liability position</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilities_E32364FD9829A22880ADCCD9F6918100_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities_08980192D7CA53DA8A1F3A4352A79649" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities_08980192D7CA53DA8A1F3A4352A79649" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilities_08980192D7CA53DA8A1F3A4352A79649" xlink:to="lab_us-gaap_DerivativeLiabilities_08980192D7CA53DA8A1F3A4352A79649" xlink:type="arc" />
    <link:label id="lab_pfe_OtherSelectedFinancialLiabilitiesAbstract_DE12343FCBF94C2353DDCCD9F691F05E_terseLabel_en-US" xlink:label="lab_pfe_OtherSelectedFinancialLiabilitiesAbstract_983B0751E3D15BDA88A08E34B8934C8E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other selected financial liabilities</link:label>
    <link:label id="lab_pfe_OtherSelectedFinancialLiabilitiesAbstract_DE12343FCBF94C2353DDCCD9F691F05E_label_en-US" xlink:label="lab_pfe_OtherSelectedFinancialLiabilitiesAbstract_983B0751E3D15BDA88A08E34B8934C8E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Selected Financial Liabilities [Abstract]</link:label>
    <link:label id="lab_pfe_OtherSelectedFinancialLiabilitiesAbstract_DE12343FCBF94C2353DDCCD9F691F05E_documentation_en-US" xlink:label="lab_pfe_OtherSelectedFinancialLiabilitiesAbstract_983B0751E3D15BDA88A08E34B8934C8E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Selected Financial Liabilities [Abstract]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_OtherSelectedFinancialLiabilitiesAbstract" xlink:label="loc_pfe_OtherSelectedFinancialLiabilitiesAbstract_983B0751E3D15BDA88A08E34B8934C8E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherSelectedFinancialLiabilitiesAbstract_983B0751E3D15BDA88A08E34B8934C8E" xlink:to="lab_pfe_OtherSelectedFinancialLiabilitiesAbstract_983B0751E3D15BDA88A08E34B8934C8E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShortTermBorrowingsAbstract_00FABD6B42957CA698E4CCD9F691C792_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermBorrowingsAbstract_5A3658C5658D5B2AB754D9F4A22E8A82" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term borrowings:</link:label>
    <link:label id="lab_us-gaap_ShortTermBorrowingsAbstract_00FABD6B42957CA698E4CCD9F691C792_label_en-US" xlink:label="lab_us-gaap_ShortTermBorrowingsAbstract_5A3658C5658D5B2AB754D9F4A22E8A82" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-term Debt [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermBorrowingsAbstract" xlink:label="loc_us-gaap_ShortTermBorrowingsAbstract_5A3658C5658D5B2AB754D9F4A22E8A82" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermBorrowingsAbstract_5A3658C5658D5B2AB754D9F4A22E8A82" xlink:to="lab_us-gaap_ShortTermBorrowingsAbstract_5A3658C5658D5B2AB754D9F4A22E8A82" xlink:type="arc" />
    <link:label id="lab_pfe_ShorttermDebtGross_93380C67561BB1117811CCD9F691830D_terseLabel_en-US" xlink:label="lab_pfe_ShorttermDebtGross_4007320707415A9BBB0601DC8F4118A4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Principal amount</link:label>
    <link:label id="lab_pfe_ShorttermDebtGross_93380C67561BB1117811CCD9F691830D_label_en-US" xlink:label="lab_pfe_ShorttermDebtGross_4007320707415A9BBB0601DC8F4118A4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-term Debt, Gross</link:label>
    <link:label id="lab_pfe_ShorttermDebtGross_93380C67561BB1117811CCD9F691830D_documentation_en-US" xlink:label="lab_pfe_ShorttermDebtGross_4007320707415A9BBB0601DC8F4118A4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Short-term Debt, Gross</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_ShorttermDebtGross" xlink:label="loc_pfe_ShorttermDebtGross_4007320707415A9BBB0601DC8F4118A4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ShorttermDebtGross_4007320707415A9BBB0601DC8F4118A4" xlink:to="lab_pfe_ShorttermDebtGross_4007320707415A9BBB0601DC8F4118A4" xlink:type="arc" />
    <link:label id="lab_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting_CCEDC1B1BC56049EA7B4CCD9F6910FC0_terseLabel_en-US" xlink:label="lab_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting_A021C0E9ADB65466A7B60BA335A32C56" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net fair value adjustments related to hedging and purchase accounting</link:label>
    <link:label id="lab_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting_CCEDC1B1BC56049EA7B4CCD9F6910FC0_label_en-US" xlink:label="lab_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting_A021C0E9ADB65466A7B60BA335A32C56" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Fair Value Adjustments, Hedging and Purchase Accounting</link:label>
    <link:label id="lab_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting_CCEDC1B1BC56049EA7B4CCD9F6910FC0_documentation_en-US" xlink:label="lab_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting_A021C0E9ADB65466A7B60BA335A32C56" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Fair Value Adjustments, Hedging and Purchase Accounting</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting" xlink:label="loc_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting_A021C0E9ADB65466A7B60BA335A32C56" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting_A021C0E9ADB65466A7B60BA335A32C56" xlink:to="lab_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting_A021C0E9ADB65466A7B60BA335A32C56" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_A723EE7F782A3BE686DDCCD9F6925D10_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_653AAE9BD3DD571DB32C5142465DEC19" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Net unamortized discounts, premiums and debt issuance costs</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_A723EE7F782A3BE686DDCCD9F6925D10_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_653AAE9BD3DD571DB32C5142465DEC19" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_653AAE9BD3DD571DB32C5142465DEC19" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_653AAE9BD3DD571DB32C5142465DEC19" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_653AAE9BD3DD571DB32C5142465DEC19" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtCurrent_4738BAC52B327C5654ECCCD9F692A57D_totalLabel_en-US" xlink:label="lab_us-gaap_DebtCurrent_06FC4301F4415B64AEADF3A063C4913B" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total short-term borrowings, carried at historical proceeds, as adjusted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtCurrent" xlink:label="loc_us-gaap_DebtCurrent_06FC4301F4415B64AEADF3A063C4913B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtCurrent_06FC4301F4415B64AEADF3A063C4913B" xlink:to="lab_us-gaap_DebtCurrent_06FC4301F4415B64AEADF3A063C4913B" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtNoncurrentAbstract_D76CF07514BDE34AA330CCD9F692CE34_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrentAbstract_416F19A4639A530E96694ABA89DAFD7D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term debt:</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrentAbstract_D76CF07514BDE34AA330CCD9F692CE34_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrentAbstract_416F19A4639A530E96694ABA89DAFD7D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Excluding Current Maturities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtNoncurrentAbstract" xlink:label="loc_us-gaap_LongTermDebtNoncurrentAbstract_416F19A4639A530E96694ABA89DAFD7D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrentAbstract_416F19A4639A530E96694ABA89DAFD7D" xlink:to="lab_us-gaap_LongTermDebtNoncurrentAbstract_416F19A4639A530E96694ABA89DAFD7D" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_1A76E4E2CC5C91B2A7F4CCD9F692E96C_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount_D068782291165E76816DF7D94AA64026" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Principal amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_1A76E4E2CC5C91B2A7F4CCD9F692E96C_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount_D068782291165E76816DF7D94AA64026" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_D068782291165E76816DF7D94AA64026" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_D068782291165E76816DF7D94AA64026" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount_D068782291165E76816DF7D94AA64026" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_50D004F998FC8512236FCCD9F6929A21_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent_F868B271D2835272B876A4AE168AF71C" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total long-term debt, carried at historical proceeds, as adjusted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_F868B271D2835272B876A4AE168AF71C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent_F868B271D2835272B876A4AE168AF71C" xlink:to="lab_us-gaap_LongTermDebtNoncurrent_F868B271D2835272B876A4AE168AF71C" xlink:type="arc" />
    <link:label id="lab_pfe_OtherFinancialLiabilities_D0E4BFA54D2631703812CCD9F6922803_totalLabel_en-US" xlink:label="lab_pfe_OtherFinancialLiabilities_36E1F154592E58059EEA3103D2D7FCD4" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_pfe_OtherFinancialLiabilities_D0E4BFA54D2631703812CCD9F6922803_label_en-US" xlink:label="lab_pfe_OtherFinancialLiabilities_36E1F154592E58059EEA3103D2D7FCD4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Financial Liabilities</link:label>
    <link:label id="lab_pfe_OtherFinancialLiabilities_D0E4BFA54D2631703812CCD9F6922803_documentation_en-US" xlink:label="lab_pfe_OtherFinancialLiabilities_36E1F154592E58059EEA3103D2D7FCD4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Total other financial liabilities</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_OtherFinancialLiabilities" xlink:label="loc_pfe_OtherFinancialLiabilities_36E1F154592E58059EEA3103D2D7FCD4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherFinancialLiabilities_36E1F154592E58059EEA3103D2D7FCD4" xlink:to="lab_pfe_OtherFinancialLiabilities_36E1F154592E58059EEA3103D2D7FCD4" xlink:type="arc" />
    <link:label id="lab_pfe_SelectedFinancialLiabilities_152DFAC81533C6349E6FCCD9F6920217_totalLabel_en-US" xlink:label="lab_pfe_SelectedFinancialLiabilities_A028B2177B545D258BEAF0423003B1C1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total selected financial liabilities</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_SelectedFinancialLiabilities" xlink:label="loc_pfe_SelectedFinancialLiabilities_A028B2177B545D258BEAF0423003B1C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SelectedFinancialLiabilities_A028B2177B545D258BEAF0423003B1C1" xlink:to="lab_pfe_SelectedFinancialLiabilities_A028B2177B545D258BEAF0423003B1C1" xlink:type="arc" />
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_36823B41D5A566B800D4AE9F9328612A_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_A6212DBB9DBE5ECC8B158D3CF16D20AD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_36823B41D5A566B800D4AE9F9328612A_label_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_A6212DBB9DBE5ECC8B158D3CF16D20AD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_A6212DBB9DBE5ECC8B158D3CF16D20AD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_A6212DBB9DBE5ECC8B158D3CF16D20AD" xlink:to="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_A6212DBB9DBE5ECC8B158D3CF16D20AD" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_17B207D001E1B3905E029C88C9DABB83_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest_17B207D001E1B3905E029C88C9DABB83" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_17B207D001E1B3905E029C88C9DABB83_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest_17B207D001E1B3905E029C88C9DABB83" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_17B207D001E1B3905E029C88C9DABB83" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest_17B207D001E1B3905E029C88C9DABB83" xlink:to="lab_us-gaap_InvestmentIncomeInterest_17B207D001E1B3905E029C88C9DABB83" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestExpense_8749240F19234477FC029C88C9DAFA34_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense_8749240F19234477FC029C88C9DAFA34" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_8749240F19234477FC029C88C9DAFA34_label_en-US" xlink:label="lab_us-gaap_InterestExpense_8749240F19234477FC029C88C9DAFA34" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_8749240F19234477FC029C88C9DAFA34" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense_8749240F19234477FC029C88C9DAFA34" xlink:to="lab_us-gaap_InterestExpense_8749240F19234477FC029C88C9DAFA34" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestRevenueExpenseNet_0F06722ECD70EF6643E99C88C9DA103D_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_InterestRevenueExpenseNet_0F06722ECD70EF6643E99C88C9DA103D" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Net interest expense</link:label>
    <link:label id="lab_us-gaap_InterestRevenueExpenseNet_0F06722ECD70EF6643E99C88C9DA103D_label_en-US" xlink:label="lab_us-gaap_InterestRevenueExpenseNet_0F06722ECD70EF6643E99C88C9DA103D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Revenue (Expense), Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestRevenueExpenseNet" xlink:label="loc_us-gaap_InterestRevenueExpenseNet_0F06722ECD70EF6643E99C88C9DA103D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRevenueExpenseNet_0F06722ECD70EF6643E99C88C9DA103D" xlink:to="lab_us-gaap_InterestRevenueExpenseNet_0F06722ECD70EF6643E99C88C9DA103D" xlink:type="arc" />
    <link:label id="lab_us-gaap_RoyaltyRevenue_9B17FB6A7900C3C1B84C9C88C9DA9FDF_negatedLabel_en-US" xlink:label="lab_us-gaap_RoyaltyRevenue_9B17FB6A7900C3C1B84C9C88C9DA9FDF" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Royalty-related income</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:label="loc_us-gaap_RoyaltyRevenue_9B17FB6A7900C3C1B84C9C88C9DA9FDF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyRevenue_9B17FB6A7900C3C1B84C9C88C9DA9FDF" xlink:to="lab_us-gaap_RoyaltyRevenue_9B17FB6A7900C3C1B84C9C88C9DA9FDF" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainLossRelatedToLitigationSettlement_5062F316E14C1F56C54E9C88C9DB86BC_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossRelatedToLitigationSettlement_5062F316E14C1F56C54E9C88C9DB86BC" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Certain legal matters, net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_5062F316E14C1F56C54E9C88C9DB86BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossRelatedToLitigationSettlement_5062F316E14C1F56C54E9C88C9DB86BC" xlink:to="lab_us-gaap_GainLossRelatedToLitigationSettlement_5062F316E14C1F56C54E9C88C9DB86BC" xlink:type="arc" />
    <link:label id="lab_pfe_GainLossOnDispositionOfAssetsAndEquitySecurities_D487E82262204209FED29C88C9DB0D6F_negatedTerseLabel_en-US" xlink:label="lab_pfe_GainLossOnDispositionOfAssetsAndEquitySecurities_D487E82262204209FED29C88C9DB0D6F" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Net gains on asset disposals</link:label>
    <link:label id="lab_pfe_GainLossOnDispositionOfAssetsAndEquitySecurities_D487E82262204209FED29C88C9DB0D6F_label_en-US" xlink:label="lab_pfe_GainLossOnDispositionOfAssetsAndEquitySecurities_D487E82262204209FED29C88C9DB0D6F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) On Disposition Of Assets And Equity Securities</link:label>
    <link:label id="lab_pfe_GainLossOnDispositionOfAssetsAndEquitySecurities_D487E82262204209FED29C88C9DB0D6F_documentation_en-US" xlink:label="lab_pfe_GainLossOnDispositionOfAssetsAndEquitySecurities_D487E82262204209FED29C88C9DB0D6F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Disposition of Assets and Equity Securities</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_GainLossOnDispositionOfAssetsAndEquitySecurities" xlink:label="loc_pfe_GainLossOnDispositionOfAssetsAndEquitySecurities_D487E82262204209FED29C88C9DB0D6F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_GainLossOnDispositionOfAssetsAndEquitySecurities_D487E82262204209FED29C88C9DB0D6F" xlink:to="lab_pfe_GainLossOnDispositionOfAssetsAndEquitySecurities_D487E82262204209FED29C88C9DB0D6F" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_F40F29C3E7939906B1219C88C9DB3158_negatedLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_F40F29C3E7939906B1219C88C9DB3158" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Loss on sale and impairment on remeasurement of HIS net assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_F40F29C3E7939906B1219C88C9DB3158" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_F40F29C3E7939906B1219C88C9DB3158" xlink:to="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_F40F29C3E7939906B1219C88C9DB3158" xlink:type="arc" />
    <link:label id="lab_pfe_OtherNonoperatingIncomeExpenseNet_85642F210CC56EDCF1219C88C9DC25F5_negatedTerseLabel_en-US" xlink:label="lab_pfe_OtherNonoperatingIncomeExpenseNet_85642F210CC56EDCF1219C88C9DC25F5" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_pfe_OtherNonoperatingIncomeExpenseNet_85642F210CC56EDCF1219C88C9DC25F5_label_en-US" xlink:label="lab_pfe_OtherNonoperatingIncomeExpenseNet_85642F210CC56EDCF1219C88C9DC25F5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense), Net</link:label>
    <link:label id="lab_pfe_OtherNonoperatingIncomeExpenseNet_85642F210CC56EDCF1219C88C9DC25F5_documentation_en-US" xlink:label="lab_pfe_OtherNonoperatingIncomeExpenseNet_85642F210CC56EDCF1219C88C9DC25F5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense), Net</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_OtherNonoperatingIncomeExpenseNet" xlink:label="loc_pfe_OtherNonoperatingIncomeExpenseNet_85642F210CC56EDCF1219C88C9DC25F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherNonoperatingIncomeExpenseNet_85642F210CC56EDCF1219C88C9DC25F5" xlink:to="lab_pfe_OtherNonoperatingIncomeExpenseNet_85642F210CC56EDCF1219C88C9DC25F5" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_ADD39E504A89D63D22879C88C9DCB101_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_ADD39E504A89D63D22879C88C9DCB101" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Other (income)/deductions&#8211;&#8211;net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_ADD39E504A89D63D22879C88C9DCB101" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_ADD39E504A89D63D22879C88C9DCB101" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense_ADD39E504A89D63D22879C88C9DCB101" xlink:type="arc" />
    <link:label id="lab_us-gaap_DamagesFromProductDefectsMember_53446B40B4E52C01C4739C2641394A09_terseLabel_en-US" xlink:label="lab_us-gaap_DamagesFromProductDefectsMember_53446B40B4E52C01C4739C2641394A09" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Damages from Product Defects [Member]</link:label>
    <link:label id="lab_us-gaap_DamagesFromProductDefectsMember_53446B40B4E52C01C4739C2641394A09_label_en-US" xlink:label="lab_us-gaap_DamagesFromProductDefectsMember_53446B40B4E52C01C4739C2641394A09" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Damages from Product Defects [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DamagesFromProductDefectsMember" xlink:label="loc_us-gaap_DamagesFromProductDefectsMember_53446B40B4E52C01C4739C2641394A09" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DamagesFromProductDefectsMember_53446B40B4E52C01C4739C2641394A09" xlink:to="lab_us-gaap_DamagesFromProductDefectsMember_53446B40B4E52C01C4739C2641394A09" xlink:type="arc" />
    <link:label id="lab_pfe_AverageWholesalePriceMember_ACBF6A5C7D1CDB486CF29C264139034D_terseLabel_en-US" xlink:label="lab_pfe_AverageWholesalePriceMember_ACBF6A5C7D1CDB486CF29C264139034D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Average Wholesale Price [Member]</link:label>
    <link:label id="lab_pfe_AverageWholesalePriceMember_ACBF6A5C7D1CDB486CF29C264139034D_label_en-US" xlink:label="lab_pfe_AverageWholesalePriceMember_ACBF6A5C7D1CDB486CF29C264139034D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Average Wholesale Price [Member]</link:label>
    <link:label id="lab_pfe_AverageWholesalePriceMember_ACBF6A5C7D1CDB486CF29C264139034D_documentation_en-US" xlink:label="lab_pfe_AverageWholesalePriceMember_ACBF6A5C7D1CDB486CF29C264139034D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Average Wholesale Price [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_AverageWholesalePriceMember" xlink:label="loc_pfe_AverageWholesalePriceMember_ACBF6A5C7D1CDB486CF29C264139034D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_AverageWholesalePriceMember_ACBF6A5C7D1CDB486CF29C264139034D" xlink:to="lab_pfe_AverageWholesalePriceMember_ACBF6A5C7D1CDB486CF29C264139034D" xlink:type="arc" />
    <link:label id="lab_pfe_EnvironmentalRemediationLitigationMember_E720F0C45D11A386F7669C2641391C70_terseLabel_en-US" xlink:label="lab_pfe_EnvironmentalRemediationLitigationMember_E720F0C45D11A386F7669C2641391C70" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Environmental Remediation Litigation [Member]</link:label>
    <link:label id="lab_pfe_EnvironmentalRemediationLitigationMember_E720F0C45D11A386F7669C2641391C70_label_en-US" xlink:label="lab_pfe_EnvironmentalRemediationLitigationMember_E720F0C45D11A386F7669C2641391C70" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Environmental Remediation Litigation [Member]</link:label>
    <link:label id="lab_pfe_EnvironmentalRemediationLitigationMember_E720F0C45D11A386F7669C2641391C70_documentation_en-US" xlink:label="lab_pfe_EnvironmentalRemediationLitigationMember_E720F0C45D11A386F7669C2641391C70" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Environmental Remediation Litigation [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_EnvironmentalRemediationLitigationMember" xlink:label="loc_pfe_EnvironmentalRemediationLitigationMember_E720F0C45D11A386F7669C2641391C70" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_EnvironmentalRemediationLitigationMember_E720F0C45D11A386F7669C2641391C70" xlink:to="lab_pfe_EnvironmentalRemediationLitigationMember_E720F0C45D11A386F7669C2641391C70" xlink:type="arc" />
    <link:label id="lab_pfe_ViolationofAntitrustLawsMember_E4C61D560B4C2A67D33E9C264139C7AE_terseLabel_en-US" xlink:label="lab_pfe_ViolationofAntitrustLawsMember_E4C61D560B4C2A67D33E9C264139C7AE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Violation of Antitrust Laws [Member]</link:label>
    <link:label id="lab_pfe_ViolationofAntitrustLawsMember_E4C61D560B4C2A67D33E9C264139C7AE_label_en-US" xlink:label="lab_pfe_ViolationofAntitrustLawsMember_E4C61D560B4C2A67D33E9C264139C7AE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Violation of Antitrust Laws [Member]</link:label>
    <link:label id="lab_pfe_ViolationofAntitrustLawsMember_E4C61D560B4C2A67D33E9C264139C7AE_documentation_en-US" xlink:label="lab_pfe_ViolationofAntitrustLawsMember_E4C61D560B4C2A67D33E9C264139C7AE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Violation of Antitrust Laws [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_ViolationofAntitrustLawsMember" xlink:label="loc_pfe_ViolationofAntitrustLawsMember_E4C61D560B4C2A67D33E9C264139C7AE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ViolationofAntitrustLawsMember_E4C61D560B4C2A67D33E9C264139C7AE" xlink:to="lab_pfe_ViolationofAntitrustLawsMember_E4C61D560B4C2A67D33E9C264139C7AE" xlink:type="arc" />
    <link:label id="lab_pfe_InflectraMember_E7B862046E7E38AFCC889C2641399C79_terseLabel_en-US" xlink:label="lab_pfe_InflectraMember_E7B862046E7E38AFCC889C2641399C79" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inflectra [Member]</link:label>
    <link:label id="lab_pfe_InflectraMember_E7B862046E7E38AFCC889C2641399C79_label_en-US" xlink:label="lab_pfe_InflectraMember_E7B862046E7E38AFCC889C2641399C79" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inflectra [Member]</link:label>
    <link:label id="lab_pfe_InflectraMember_E7B862046E7E38AFCC889C2641399C79_documentation_en-US" xlink:label="lab_pfe_InflectraMember_E7B862046E7E38AFCC889C2641399C79" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Inflectra [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_InflectraMember" xlink:label="loc_pfe_InflectraMember_E7B862046E7E38AFCC889C2641399C79" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_InflectraMember_E7B862046E7E38AFCC889C2641399C79" xlink:to="lab_pfe_InflectraMember_E7B862046E7E38AFCC889C2641399C79" xlink:type="arc" />
    <link:label id="lab_pfe_PhenytoinSodiumCapsulesMember_26F0F18F2C0E74D1AFCA9C2641396BA1_terseLabel_en-US" xlink:label="lab_pfe_PhenytoinSodiumCapsulesMember_26F0F18F2C0E74D1AFCA9C2641396BA1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Phenytoin Sodium Capsules [Member]</link:label>
    <link:label id="lab_pfe_PhenytoinSodiumCapsulesMember_26F0F18F2C0E74D1AFCA9C2641396BA1_label_en-US" xlink:label="lab_pfe_PhenytoinSodiumCapsulesMember_26F0F18F2C0E74D1AFCA9C2641396BA1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Phenytoin Sodium Capsules [Member]</link:label>
    <link:label id="lab_pfe_PhenytoinSodiumCapsulesMember_26F0F18F2C0E74D1AFCA9C2641396BA1_documentation_en-US" xlink:label="lab_pfe_PhenytoinSodiumCapsulesMember_26F0F18F2C0E74D1AFCA9C2641396BA1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Phenytoin Sodium Capsules [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_PhenytoinSodiumCapsulesMember" xlink:label="loc_pfe_PhenytoinSodiumCapsulesMember_26F0F18F2C0E74D1AFCA9C2641396BA1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_PhenytoinSodiumCapsulesMember_26F0F18F2C0E74D1AFCA9C2641396BA1" xlink:to="lab_pfe_PhenytoinSodiumCapsulesMember_26F0F18F2C0E74D1AFCA9C2641396BA1" xlink:type="arc" />
    <link:label id="lab_pfe_JanssenandNewYorkUniversityVersusHospiraCelltrionHealthcareandCelltrionInc.Member_F43CE92616C5364FDD379C264139F984_terseLabel_en-US" xlink:label="lab_pfe_JanssenandNewYorkUniversityVersusHospiraCelltrionHealthcareandCelltrionInc.Member_F43CE92616C5364FDD379C264139F984" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Janssen and New York University Versus Hospira, Celltrion Healthcare and Celltrion Inc. [Member]</link:label>
    <link:label id="lab_pfe_JanssenandNewYorkUniversityVersusHospiraCelltrionHealthcareandCelltrionInc.Member_F43CE92616C5364FDD379C264139F984_label_en-US" xlink:label="lab_pfe_JanssenandNewYorkUniversityVersusHospiraCelltrionHealthcareandCelltrionInc.Member_F43CE92616C5364FDD379C264139F984" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Janssen and New York University Versus Hospira, Celltrion Healthcare and Celltrion Inc. [Member]</link:label>
    <link:label id="lab_pfe_JanssenandNewYorkUniversityVersusHospiraCelltrionHealthcareandCelltrionInc.Member_F43CE92616C5364FDD379C264139F984_documentation_en-US" xlink:label="lab_pfe_JanssenandNewYorkUniversityVersusHospiraCelltrionHealthcareandCelltrionInc.Member_F43CE92616C5364FDD379C264139F984" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Janssen and New York University Versus Hospira, Celltrion Healthcare and Celltrion Inc. [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_JanssenandNewYorkUniversityVersusHospiraCelltrionHealthcareandCelltrionInc.Member" xlink:label="loc_pfe_JanssenandNewYorkUniversityVersusHospiraCelltrionHealthcareandCelltrionInc.Member_F43CE92616C5364FDD379C264139F984" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_JanssenandNewYorkUniversityVersusHospiraCelltrionHealthcareandCelltrionInc.Member_F43CE92616C5364FDD379C264139F984" xlink:to="lab_pfe_JanssenandNewYorkUniversityVersusHospiraCelltrionHealthcareandCelltrionInc.Member_F43CE92616C5364FDD379C264139F984" xlink:type="arc" />
    <link:label id="lab_pfe_ClassActionVersusAmericanOpticalCorporationAndVariousOtherDefendantsMember_26B8E4869F899706A8259C2641393BDD_terseLabel_en-US" xlink:label="lab_pfe_ClassActionVersusAmericanOpticalCorporationAndVariousOtherDefendantsMember_26B8E4869F899706A8259C2641393BDD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class Action Versus American Optical Corporation And Various Other Defendants [Member]</link:label>
    <link:label id="lab_pfe_ClassActionVersusAmericanOpticalCorporationAndVariousOtherDefendantsMember_26B8E4869F899706A8259C2641393BDD_label_en-US" xlink:label="lab_pfe_ClassActionVersusAmericanOpticalCorporationAndVariousOtherDefendantsMember_26B8E4869F899706A8259C2641393BDD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class Action Versus American Optical Corporation And Various Other Defendants [Member]</link:label>
    <link:label id="lab_pfe_ClassActionVersusAmericanOpticalCorporationAndVariousOtherDefendantsMember_26B8E4869F899706A8259C2641393BDD_documentation_en-US" xlink:label="lab_pfe_ClassActionVersusAmericanOpticalCorporationAndVariousOtherDefendantsMember_26B8E4869F899706A8259C2641393BDD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class Action Versus American Optical Corporation And Various Other Defendants [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_ClassActionVersusAmericanOpticalCorporationAndVariousOtherDefendantsMember" xlink:label="loc_pfe_ClassActionVersusAmericanOpticalCorporationAndVariousOtherDefendantsMember_26B8E4869F899706A8259C2641393BDD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ClassActionVersusAmericanOpticalCorporationAndVariousOtherDefendantsMember_26B8E4869F899706A8259C2641393BDD" xlink:to="lab_pfe_ClassActionVersusAmericanOpticalCorporationAndVariousOtherDefendantsMember_26B8E4869F899706A8259C2641393BDD" xlink:type="arc" />
    <link:label id="lab_pfe_StateofIllinoisVersusPfizerMember_3131A2B719E7D7FA1E339C26413A7D3C_terseLabel_en-US" xlink:label="lab_pfe_StateofIllinoisVersusPfizerMember_3131A2B719E7D7FA1E339C26413A7D3C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State of Illinois Versus Pfizer [Member]</link:label>
    <link:label id="lab_pfe_StateofIllinoisVersusPfizerMember_3131A2B719E7D7FA1E339C26413A7D3C_label_en-US" xlink:label="lab_pfe_StateofIllinoisVersusPfizerMember_3131A2B719E7D7FA1E339C26413A7D3C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">State of Illinois Versus Pfizer [Member]</link:label>
    <link:label id="lab_pfe_StateofIllinoisVersusPfizerMember_3131A2B719E7D7FA1E339C26413A7D3C_documentation_en-US" xlink:label="lab_pfe_StateofIllinoisVersusPfizerMember_3131A2B719E7D7FA1E339C26413A7D3C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">State of Illinois Versus Pfizer [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_StateofIllinoisVersusPfizerMember" xlink:label="loc_pfe_StateofIllinoisVersusPfizerMember_3131A2B719E7D7FA1E339C26413A7D3C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_StateofIllinoisVersusPfizerMember_3131A2B719E7D7FA1E339C26413A7D3C" xlink:to="lab_pfe_StateofIllinoisVersusPfizerMember_3131A2B719E7D7FA1E339C26413A7D3C" xlink:type="arc" />
    <link:label id="lab_pfe_RegentsVersusMedivationMember_8D83BD4A67936EA98D019C26413A8C7D_terseLabel_en-US" xlink:label="lab_pfe_RegentsVersusMedivationMember_8D83BD4A67936EA98D019C26413A8C7D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Regents Versus Medivation [Member]</link:label>
    <link:label id="lab_pfe_RegentsVersusMedivationMember_8D83BD4A67936EA98D019C26413A8C7D_label_en-US" xlink:label="lab_pfe_RegentsVersusMedivationMember_8D83BD4A67936EA98D019C26413A8C7D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Regents Versus Medivation [Member]</link:label>
    <link:label id="lab_pfe_RegentsVersusMedivationMember_8D83BD4A67936EA98D019C26413A8C7D_documentation_en-US" xlink:label="lab_pfe_RegentsVersusMedivationMember_8D83BD4A67936EA98D019C26413A8C7D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Regents Versus Medivation [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_RegentsVersusMedivationMember" xlink:label="loc_pfe_RegentsVersusMedivationMember_8D83BD4A67936EA98D019C26413A8C7D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_RegentsVersusMedivationMember_8D83BD4A67936EA98D019C26413A8C7D" xlink:to="lab_pfe_RegentsVersusMedivationMember_8D83BD4A67936EA98D019C26413A8C7D" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingencyClaimsDismissedNumber_538F102A97B7626498C49C26413A577A_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyClaimsDismissedNumber_538F102A97B7626498C49C26413A577A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Claims dismissed</link:label>
    <link:label id="lab_us-gaap_LossContingencyClaimsDismissedNumber_538F102A97B7626498C49C26413A577A_label_en-US" xlink:label="lab_us-gaap_LossContingencyClaimsDismissedNumber_538F102A97B7626498C49C26413A577A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Claims Dismissed, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LossContingencyClaimsDismissedNumber" xlink:label="loc_us-gaap_LossContingencyClaimsDismissedNumber_538F102A97B7626498C49C26413A577A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyClaimsDismissedNumber_538F102A97B7626498C49C26413A577A" xlink:to="lab_us-gaap_LossContingencyClaimsDismissedNumber_538F102A97B7626498C49C26413A577A" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingencyPendingClaimsNumber_F368F6717B9D7719D8139C26413A3421_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyPendingClaimsNumber_F368F6717B9D7719D8139C26413A3421" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of pending claims</link:label>
    <link:label id="lab_us-gaap_LossContingencyPendingClaimsNumber_F368F6717B9D7719D8139C26413A3421_label_en-US" xlink:label="lab_us-gaap_LossContingencyPendingClaimsNumber_F368F6717B9D7719D8139C26413A3421" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Pending Claims, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LossContingencyPendingClaimsNumber" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber_F368F6717B9D7719D8139C26413A3421" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyPendingClaimsNumber_F368F6717B9D7719D8139C26413A3421" xlink:to="lab_us-gaap_LossContingencyPendingClaimsNumber_F368F6717B9D7719D8139C26413A3421" xlink:type="arc" />
    <link:label id="lab_pfe_FeasibilityStudyNumberOfLagoons_A87C24D0E15B0353317F9C26413A262B_terseLabel_en-US" xlink:label="lab_pfe_FeasibilityStudyNumberOfLagoons_A87C24D0E15B0353317F9C26413A262B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of lagoons</link:label>
    <link:label id="lab_pfe_FeasibilityStudyNumberOfLagoons_A87C24D0E15B0353317F9C26413A262B_label_en-US" xlink:label="lab_pfe_FeasibilityStudyNumberOfLagoons_A87C24D0E15B0353317F9C26413A262B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Feasibility Study, Number Of Lagoons</link:label>
    <link:label id="lab_pfe_FeasibilityStudyNumberOfLagoons_A87C24D0E15B0353317F9C26413A262B_documentation_en-US" xlink:label="lab_pfe_FeasibilityStudyNumberOfLagoons_A87C24D0E15B0353317F9C26413A262B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Feasibility Study, Number Of Lagoons</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_FeasibilityStudyNumberOfLagoons" xlink:label="loc_pfe_FeasibilityStudyNumberOfLagoons_A87C24D0E15B0353317F9C26413A262B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_FeasibilityStudyNumberOfLagoons_A87C24D0E15B0353317F9C26413A262B" xlink:to="lab_pfe_FeasibilityStudyNumberOfLagoons_A87C24D0E15B0353317F9C26413A262B" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_55CE6AD169D633CBF8C29C3641629B07_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_55CE6AD169D633CBF8C29C3641629B07" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Imposed fine</link:label>
    <link:label id="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_55CE6AD169D633CBF8C29C3641629B07_label_en-US" xlink:label="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_55CE6AD169D633CBF8C29C3641629B07" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Estimate of Possible Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_55CE6AD169D633CBF8C29C3641629B07" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_55CE6AD169D633CBF8C29C3641629B07" xlink:to="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_55CE6AD169D633CBF8C29C3641629B07" xlink:type="arc" />
    <link:label id="lab_pfe_LossContingencyCollaborationArrangementPercentageofPaymentsSoughtbyPlaintiff_25ECCDBE199B0490CE469C26413A1295_terseLabel_en-US" xlink:label="lab_pfe_LossContingencyCollaborationArrangementPercentageofPaymentsSoughtbyPlaintiff_25ECCDBE199B0490CE469C26413A1295" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of payments Medivation received sought by Regents</link:label>
    <link:label id="lab_pfe_LossContingencyCollaborationArrangementPercentageofPaymentsSoughtbyPlaintiff_25ECCDBE199B0490CE469C26413A1295_label_en-US" xlink:label="lab_pfe_LossContingencyCollaborationArrangementPercentageofPaymentsSoughtbyPlaintiff_25ECCDBE199B0490CE469C26413A1295" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Collaboration Arrangement, Percentage of Payments Sought by Plaintiff</link:label>
    <link:label id="lab_pfe_LossContingencyCollaborationArrangementPercentageofPaymentsSoughtbyPlaintiff_25ECCDBE199B0490CE469C26413A1295_documentation_en-US" xlink:label="lab_pfe_LossContingencyCollaborationArrangementPercentageofPaymentsSoughtbyPlaintiff_25ECCDBE199B0490CE469C26413A1295" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Loss Contingency, Collaboration Arrangement, Percentage of Payments Sought by Plaintiff</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_LossContingencyCollaborationArrangementPercentageofPaymentsSoughtbyPlaintiff" xlink:label="loc_pfe_LossContingencyCollaborationArrangementPercentageofPaymentsSoughtbyPlaintiff_25ECCDBE199B0490CE469C26413A1295" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_LossContingencyCollaborationArrangementPercentageofPaymentsSoughtbyPlaintiff_25ECCDBE199B0490CE469C26413A1295" xlink:to="lab_pfe_LossContingencyCollaborationArrangementPercentageofPaymentsSoughtbyPlaintiff_25ECCDBE199B0490CE469C26413A1295" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_C2C9DDDE270A0FF3563BAE9F92C3FDF1_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_B502A69B7F0E560FB5418E76B552B378" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective tax rate for income from continuing operations</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_C2C9DDDE270A0FF3563BAE9F92C3FDF1_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_B502A69B7F0E560FB5418E76B552B378" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_B502A69B7F0E560FB5418E76B552B378" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_B502A69B7F0E560FB5418E76B552B378" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_B502A69B7F0E560FB5418E76B552B378" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_5D41416BD5722C52B76F5A1C673209FB_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_5D41416BD5722C52B76F5A1C673209FB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Other (Income)/Deductions - Net</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_5D41416BD5722C52B76F5A1C673209FB_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_5D41416BD5722C52B76F5A1C673209FB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Other Nonoperating Income (Expense) [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_5D41416BD5722C52B76F5A1C673209FB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_5D41416BD5722C52B76F5A1C673209FB" xlink:to="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_5D41416BD5722C52B76F5A1C673209FB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfImpairedIntangibleAssetsTextBlock_DEBA8626BDCFE39043045A1C775E7E8D_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfImpairedIntangibleAssetsTextBlock_DEBA8626BDCFE39043045A1C775E7E8D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Impaired Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfImpairedIntangibleAssetsTextBlock_DEBA8626BDCFE39043045A1C775E7E8D_label_en-US" xlink:label="lab_us-gaap_ScheduleOfImpairedIntangibleAssetsTextBlock_DEBA8626BDCFE39043045A1C775E7E8D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Impaired Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfImpairedIntangibleAssetsTextBlock" xlink:label="loc_us-gaap_ScheduleOfImpairedIntangibleAssetsTextBlock_DEBA8626BDCFE39043045A1C775E7E8D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfImpairedIntangibleAssetsTextBlock_DEBA8626BDCFE39043045A1C775E7E8D" xlink:to="lab_us-gaap_ScheduleOfImpairedIntangibleAssetsTextBlock_DEBA8626BDCFE39043045A1C775E7E8D" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentTable_49A1C79334F503CD65EEC8264919FE2C_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable_51E56C85CE6A5ED89D2E0F3C6EA52B30" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_49A1C79334F503CD65EEC8264919FE2C_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable_51E56C85CE6A5ED89D2E0F3C6EA52B30" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_51E56C85CE6A5ED89D2E0F3C6EA52B30" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable_51E56C85CE6A5ED89D2E0F3C6EA52B30" xlink:to="lab_us-gaap_DebtInstrumentTable_51E56C85CE6A5ED89D2E0F3C6EA52B30" xlink:type="arc" />
    <link:label id="lab_us-gaap_RangeAxis_B5A8919850283AFF0243C8264919120C_terseLabel_en-US" xlink:label="lab_us-gaap_RangeAxis_CEF67C86DB7A53D29722F4B974084B7E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [Axis]</link:label>
    <link:label id="lab_us-gaap_RangeAxis_B5A8919850283AFF0243C8264919120C_label_en-US" xlink:label="lab_us-gaap_RangeAxis_CEF67C86DB7A53D29722F4B974084B7E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_CEF67C86DB7A53D29722F4B974084B7E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RangeAxis_CEF67C86DB7A53D29722F4B974084B7E" xlink:to="lab_us-gaap_RangeAxis_CEF67C86DB7A53D29722F4B974084B7E" xlink:type="arc" />
    <link:label id="lab_us-gaap_RangeMember_912B8DF6D3D2B165C51EC82649197DDD_terseLabel_en-US" xlink:label="lab_us-gaap_RangeMember_1101F102B98457D1BB25D3E98AA75AB1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_us-gaap_RangeMember_912B8DF6D3D2B165C51EC82649197DDD_label_en-US" xlink:label="lab_us-gaap_RangeMember_1101F102B98457D1BB25D3E98AA75AB1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_1101F102B98457D1BB25D3E98AA75AB1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RangeMember_1101F102B98457D1BB25D3E98AA75AB1" xlink:to="lab_us-gaap_RangeMember_1101F102B98457D1BB25D3E98AA75AB1" xlink:type="arc" />
    <link:label id="lab_us-gaap_MaximumMember_7D454DB08F7C4BBC71EFC826491949B2_terseLabel_en-US" xlink:label="lab_us-gaap_MaximumMember_377AD433D2E252BB917DA3960A7A9F7A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:label id="lab_us-gaap_MaximumMember_7D454DB08F7C4BBC71EFC826491949B2_label_en-US" xlink:label="lab_us-gaap_MaximumMember_377AD433D2E252BB917DA3960A7A9F7A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_377AD433D2E252BB917DA3960A7A9F7A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MaximumMember_377AD433D2E252BB917DA3960A7A9F7A" xlink:to="lab_us-gaap_MaximumMember_377AD433D2E252BB917DA3960A7A9F7A" xlink:type="arc" />
    <link:label id="lab_pfe_EURIBORMember_0B5300FDD287D22C1190C8264919354F_terseLabel_en-US" xlink:label="lab_pfe_EURIBORMember_5854D078EE9C53919750C41FDCCE1904" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">EURIBOR [Member]</link:label>
    <link:label id="lab_pfe_EURIBORMember_0B5300FDD287D22C1190C8264919354F_label_en-US" xlink:label="lab_pfe_EURIBORMember_5854D078EE9C53919750C41FDCCE1904" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">EURIBOR [Member]</link:label>
    <link:label id="lab_pfe_EURIBORMember_0B5300FDD287D22C1190C8264919354F_documentation_en-US" xlink:label="lab_pfe_EURIBORMember_5854D078EE9C53919750C41FDCCE1904" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">EURIBOR [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_EURIBORMember" xlink:label="loc_pfe_EURIBORMember_5854D078EE9C53919750C41FDCCE1904" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_EURIBORMember_5854D078EE9C53919750C41FDCCE1904" xlink:to="lab_pfe_EURIBORMember_5854D078EE9C53919750C41FDCCE1904" xlink:type="arc" />
    <link:label id="lab_pfe_GermanGovernmentBondRateMember_B239DFCAB27E23A2276BC8264919A59D_terseLabel_en-US" xlink:label="lab_pfe_GermanGovernmentBondRateMember_BD811ADB34CE560A873B6BA0F0151B30" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">German Government Bond Rate [Member]</link:label>
    <link:label id="lab_pfe_GermanGovernmentBondRateMember_B239DFCAB27E23A2276BC8264919A59D_label_en-US" xlink:label="lab_pfe_GermanGovernmentBondRateMember_BD811ADB34CE560A873B6BA0F0151B30" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">German Government Bond Rate [Member]</link:label>
    <link:label id="lab_pfe_GermanGovernmentBondRateMember_B239DFCAB27E23A2276BC8264919A59D_documentation_en-US" xlink:label="lab_pfe_GermanGovernmentBondRateMember_BD811ADB34CE560A873B6BA0F0151B30" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">German Government Bond Rate [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_GermanGovernmentBondRateMember" xlink:label="loc_pfe_GermanGovernmentBondRateMember_BD811ADB34CE560A873B6BA0F0151B30" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_GermanGovernmentBondRateMember_BD811ADB34CE560A873B6BA0F0151B30" xlink:to="lab_pfe_GermanGovernmentBondRateMember_BD811ADB34CE560A873B6BA0F0151B30" xlink:type="arc" />
    <link:label id="lab_us-gaap_SeniorNotesMember_9CE403D1E6FEF2328E08C826491A18DC_terseLabel_en-US" xlink:label="lab_us-gaap_SeniorNotesMember_F3CDF6FC53045E819F699426907CBB73" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Senior Notes [Member]</link:label>
    <link:label id="lab_us-gaap_SeniorNotesMember_9CE403D1E6FEF2328E08C826491A18DC_label_en-US" xlink:label="lab_us-gaap_SeniorNotesMember_F3CDF6FC53045E819F699426907CBB73" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeniorNotesMember" xlink:label="loc_us-gaap_SeniorNotesMember_F3CDF6FC53045E819F699426907CBB73" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorNotesMember_F3CDF6FC53045E819F699426907CBB73" xlink:to="lab_us-gaap_SeniorNotesMember_F3CDF6FC53045E819F699426907CBB73" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentAxis_B71AB27401211734E8F8C826491AD136_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis_B50E534C25C75D0883963661B805C526" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_B71AB27401211734E8F8C826491AD136_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis_B50E534C25C75D0883963661B805C526" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_B50E534C25C75D0883963661B805C526" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis_B50E534C25C75D0883963661B805C526" xlink:to="lab_us-gaap_DebtInstrumentAxis_B50E534C25C75D0883963661B805C526" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_FC6690859C6432494789C826491AB5DE_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain_B64CA27D9B5457B2A34CDBCC063EF114" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_FC6690859C6432494789C826491AB5DE_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain_B64CA27D9B5457B2A34CDBCC063EF114" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_B64CA27D9B5457B2A34CDBCC063EF114" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_B64CA27D9B5457B2A34CDBCC063EF114" xlink:to="lab_us-gaap_DebtInstrumentNameDomain_B64CA27D9B5457B2A34CDBCC063EF114" xlink:type="arc" />
    <link:label id="lab_pfe_SeniorUnsecuredEuroDebtThreemonthEURIBORPlus0.20FloatingRateNotesMember_6AA169C0BA6B62D3B9CFC826491AFF4B_terseLabel_en-US" xlink:label="lab_pfe_SeniorUnsecuredEuroDebtThreemonthEURIBORPlus0.20FloatingRateNotesMember_F4149BA6D6C15943AADBE6CA9F846679" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Three-month EURIBOR Plus 0.20% floating rate notes (2019 Notes) [Member]</link:label>
    <link:label id="lab_pfe_SeniorUnsecuredEuroDebtThreemonthEURIBORPlus0.20FloatingRateNotesMember_6AA169C0BA6B62D3B9CFC826491AFF4B_label_en-US" xlink:label="lab_pfe_SeniorUnsecuredEuroDebtThreemonthEURIBORPlus0.20FloatingRateNotesMember_F4149BA6D6C15943AADBE6CA9F846679" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Unsecured Euro Debt, Three-month EURIBOR Plus 0.20% Floating Rate Notes [Member]</link:label>
    <link:label id="lab_pfe_SeniorUnsecuredEuroDebtThreemonthEURIBORPlus0.20FloatingRateNotesMember_6AA169C0BA6B62D3B9CFC826491AFF4B_documentation_en-US" xlink:label="lab_pfe_SeniorUnsecuredEuroDebtThreemonthEURIBORPlus0.20FloatingRateNotesMember_F4149BA6D6C15943AADBE6CA9F846679" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Unsecured Euro Debt, Three-month EURIBOR Plus 0.20% Floating Rate Notes</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_SeniorUnsecuredEuroDebtThreemonthEURIBORPlus0.20FloatingRateNotesMember" xlink:label="loc_pfe_SeniorUnsecuredEuroDebtThreemonthEURIBORPlus0.20FloatingRateNotesMember_F4149BA6D6C15943AADBE6CA9F846679" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SeniorUnsecuredEuroDebtThreemonthEURIBORPlus0.20FloatingRateNotesMember_F4149BA6D6C15943AADBE6CA9F846679" xlink:to="lab_pfe_SeniorUnsecuredEuroDebtThreemonthEURIBORPlus0.20FloatingRateNotesMember_F4149BA6D6C15943AADBE6CA9F846679" xlink:type="arc" />
    <link:label id="lab_pfe_SeniorUnsecuredEuroDebtZeroPercentDue2020Member_8A0783F1846A40A80183C826491ABFF1_terseLabel_en-US" xlink:label="lab_pfe_SeniorUnsecuredEuroDebtZeroPercentDue2020Member_2E9473B14C455B688AE3AC9FEB73C6EA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">0.00% euro Notes (2020 Notes) [Member]</link:label>
    <link:label id="lab_pfe_SeniorUnsecuredEuroDebtZeroPercentDue2020Member_8A0783F1846A40A80183C826491ABFF1_label_en-US" xlink:label="lab_pfe_SeniorUnsecuredEuroDebtZeroPercentDue2020Member_2E9473B14C455B688AE3AC9FEB73C6EA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Unsecured Euro Debt, Zero Percent, Due 2020 [Member]</link:label>
    <link:label id="lab_pfe_SeniorUnsecuredEuroDebtZeroPercentDue2020Member_8A0783F1846A40A80183C826491ABFF1_documentation_en-US" xlink:label="lab_pfe_SeniorUnsecuredEuroDebtZeroPercentDue2020Member_2E9473B14C455B688AE3AC9FEB73C6EA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Unsecured Euro Debt, Zero Percent, Due 2020 [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_SeniorUnsecuredEuroDebtZeroPercentDue2020Member" xlink:label="loc_pfe_SeniorUnsecuredEuroDebtZeroPercentDue2020Member_2E9473B14C455B688AE3AC9FEB73C6EA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SeniorUnsecuredEuroDebtZeroPercentDue2020Member_2E9473B14C455B688AE3AC9FEB73C6EA" xlink:to="lab_pfe_SeniorUnsecuredEuroDebtZeroPercentDue2020Member_2E9473B14C455B688AE3AC9FEB73C6EA" xlink:type="arc" />
    <link:label id="lab_pfe_SeniorUnsecuredEuroDebtPointTwofivePercentDue2022Member_AD610360A49EB4E0F4B0C826491A141D_terseLabel_en-US" xlink:label="lab_pfe_SeniorUnsecuredEuroDebtPointTwofivePercentDue2022Member_ECEDA866B0755EDD93216096CF4FC691" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">0.25% euro Notes (2022 Notes) [Member]</link:label>
    <link:label id="lab_pfe_SeniorUnsecuredEuroDebtPointTwofivePercentDue2022Member_AD610360A49EB4E0F4B0C826491A141D_label_en-US" xlink:label="lab_pfe_SeniorUnsecuredEuroDebtPointTwofivePercentDue2022Member_ECEDA866B0755EDD93216096CF4FC691" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Unsecured Euro Debt, Point Two-five Percent, Due 2022 [Member]</link:label>
    <link:label id="lab_pfe_SeniorUnsecuredEuroDebtPointTwofivePercentDue2022Member_AD610360A49EB4E0F4B0C826491A141D_documentation_en-US" xlink:label="lab_pfe_SeniorUnsecuredEuroDebtPointTwofivePercentDue2022Member_ECEDA866B0755EDD93216096CF4FC691" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Unsecured Euro Debt, Point Two-five Percent, Due 2022 [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_SeniorUnsecuredEuroDebtPointTwofivePercentDue2022Member" xlink:label="loc_pfe_SeniorUnsecuredEuroDebtPointTwofivePercentDue2022Member_ECEDA866B0755EDD93216096CF4FC691" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SeniorUnsecuredEuroDebtPointTwofivePercentDue2022Member_ECEDA866B0755EDD93216096CF4FC691" xlink:to="lab_pfe_SeniorUnsecuredEuroDebtPointTwofivePercentDue2022Member_ECEDA866B0755EDD93216096CF4FC691" xlink:type="arc" />
    <link:label id="lab_pfe_SeniorUnsecuredEuroDebtOnePointZeroPercentDue2027Member_B6D6ECC7DEE49EE1A9E8C826491A6DFC_terseLabel_en-US" xlink:label="lab_pfe_SeniorUnsecuredEuroDebtOnePointZeroPercentDue2027Member_FF8440BBD346526FA5C94784631E22D4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">1.00% euro Notes (2027 Notes) [Member]</link:label>
    <link:label id="lab_pfe_SeniorUnsecuredEuroDebtOnePointZeroPercentDue2027Member_B6D6ECC7DEE49EE1A9E8C826491A6DFC_label_en-US" xlink:label="lab_pfe_SeniorUnsecuredEuroDebtOnePointZeroPercentDue2027Member_FF8440BBD346526FA5C94784631E22D4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Unsecured Euro Debt, One Point Zero Percent, Due 2027 [Member]</link:label>
    <link:label id="lab_pfe_SeniorUnsecuredEuroDebtOnePointZeroPercentDue2027Member_B6D6ECC7DEE49EE1A9E8C826491A6DFC_documentation_en-US" xlink:label="lab_pfe_SeniorUnsecuredEuroDebtOnePointZeroPercentDue2027Member_FF8440BBD346526FA5C94784631E22D4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Unsecured Euro Debt, One Point Zero Percent, Due 2027 [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_SeniorUnsecuredEuroDebtOnePointZeroPercentDue2027Member" xlink:label="loc_pfe_SeniorUnsecuredEuroDebtOnePointZeroPercentDue2027Member_FF8440BBD346526FA5C94784631E22D4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SeniorUnsecuredEuroDebtOnePointZeroPercentDue2027Member_FF8440BBD346526FA5C94784631E22D4" xlink:to="lab_pfe_SeniorUnsecuredEuroDebtOnePointZeroPercentDue2027Member_FF8440BBD346526FA5C94784631E22D4" xlink:type="arc" />
    <link:label id="lab_pfe_EuroLongtermDebtMember_83C1131981F1760786C4C826491A56C8_terseLabel_en-US" xlink:label="lab_pfe_EuroLongtermDebtMember_AED48123C30353279CCE218F7D0385D2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Euro Long-term Debt [Member]</link:label>
    <link:label id="lab_pfe_EuroLongtermDebtMember_83C1131981F1760786C4C826491A56C8_label_en-US" xlink:label="lab_pfe_EuroLongtermDebtMember_AED48123C30353279CCE218F7D0385D2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Euro Long-term Debt [Member]</link:label>
    <link:label id="lab_pfe_EuroLongtermDebtMember_83C1131981F1760786C4C826491A56C8_documentation_en-US" xlink:label="lab_pfe_EuroLongtermDebtMember_AED48123C30353279CCE218F7D0385D2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Euro Long-term Debt [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_EuroLongtermDebtMember" xlink:label="loc_pfe_EuroLongtermDebtMember_AED48123C30353279CCE218F7D0385D2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_EuroLongtermDebtMember_AED48123C30353279CCE218F7D0385D2" xlink:to="lab_pfe_EuroLongtermDebtMember_AED48123C30353279CCE218F7D0385D2" xlink:type="arc" />
    <link:label id="lab_pfe_SeniorUnsecuredDebtFourPointTwoPercentDue2047Member_C2E5ED6433EF73B81975C826491A1DEE_terseLabel_en-US" xlink:label="lab_pfe_SeniorUnsecuredDebtFourPointTwoPercentDue2047Member_496301FF359753DEAB925646D12549D9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">4.20% Notes (2047 Notes) [Member]</link:label>
    <link:label id="lab_pfe_SeniorUnsecuredDebtFourPointTwoPercentDue2047Member_C2E5ED6433EF73B81975C826491A1DEE_label_en-US" xlink:label="lab_pfe_SeniorUnsecuredDebtFourPointTwoPercentDue2047Member_496301FF359753DEAB925646D12549D9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Unsecured Debt, Four Point Two Percent, Due 2047 [Member]</link:label>
    <link:label id="lab_pfe_SeniorUnsecuredDebtFourPointTwoPercentDue2047Member_C2E5ED6433EF73B81975C826491A1DEE_documentation_en-US" xlink:label="lab_pfe_SeniorUnsecuredDebtFourPointTwoPercentDue2047Member_496301FF359753DEAB925646D12549D9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Unsecured Debt, Four Point Two Percent, Due 2047 [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_SeniorUnsecuredDebtFourPointTwoPercentDue2047Member" xlink:label="loc_pfe_SeniorUnsecuredDebtFourPointTwoPercentDue2047Member_496301FF359753DEAB925646D12549D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SeniorUnsecuredDebtFourPointTwoPercentDue2047Member_496301FF359753DEAB925646D12549D9" xlink:to="lab_pfe_SeniorUnsecuredDebtFourPointTwoPercentDue2047Member_496301FF359753DEAB925646D12549D9" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_DC4F68D21B0A3396D9A4C826491A503F_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems_EA31DB6B63CF54EAA7D8BD4798333EE2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_DC4F68D21B0A3396D9A4C826491A503F_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems_EA31DB6B63CF54EAA7D8BD4798333EE2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_EA31DB6B63CF54EAA7D8BD4798333EE2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems_EA31DB6B63CF54EAA7D8BD4798333EE2" xlink:to="lab_us-gaap_DebtInstrumentLineItems_EA31DB6B63CF54EAA7D8BD4798333EE2" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebt_1A1CD055C3B47F3AAE19C8264E1F154C_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt_314DB1A4337159798BCCFAADEB6D89E4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_314DB1A4337159798BCCFAADEB6D89E4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt_314DB1A4337159798BCCFAADEB6D89E4" xlink:to="lab_us-gaap_LongTermDebt_314DB1A4337159798BCCFAADEB6D89E4" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_6A0CEB139F8BFAF0BBCAC826491A7898_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_6F981CF6220250F9887BDFB936055FF5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_6A0CEB139F8BFAF0BBCAC826491A7898_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_6F981CF6220250F9887BDFB936055FF5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_6F981CF6220250F9887BDFB936055FF5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_6F981CF6220250F9887BDFB936055FF5" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_6F981CF6220250F9887BDFB936055FF5" xlink:type="arc" />
    <link:label id="lab_pfe_DebtInstrumentFloorInterestRate_E14089273A3E11F5050BC826491AAB49_terseLabel_en-US" xlink:label="lab_pfe_DebtInstrumentFloorInterestRate_164AC0EA45DC5FFBA8681FF0FC7C3420" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Floor interest rate</link:label>
    <link:label id="lab_pfe_DebtInstrumentFloorInterestRate_E14089273A3E11F5050BC826491AAB49_label_en-US" xlink:label="lab_pfe_DebtInstrumentFloorInterestRate_164AC0EA45DC5FFBA8681FF0FC7C3420" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Floor Interest Rate</link:label>
    <link:label id="lab_pfe_DebtInstrumentFloorInterestRate_E14089273A3E11F5050BC826491AAB49_documentation_en-US" xlink:label="lab_pfe_DebtInstrumentFloorInterestRate_164AC0EA45DC5FFBA8681FF0FC7C3420" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Floor Interest Rate</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_DebtInstrumentFloorInterestRate" xlink:label="loc_pfe_DebtInstrumentFloorInterestRate_164AC0EA45DC5FFBA8681FF0FC7C3420" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DebtInstrumentFloorInterestRate_164AC0EA45DC5FFBA8681FF0FC7C3420" xlink:to="lab_pfe_DebtInstrumentFloorInterestRate_164AC0EA45DC5FFBA8681FF0FC7C3420" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_5B7A1D077F396261A21AC826491A544B_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_38ED33A0BC6656999757EE2BAD65366A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stated interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_5B7A1D077F396261A21AC826491A544B_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_38ED33A0BC6656999757EE2BAD65366A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_38ED33A0BC6656999757EE2BAD65366A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_38ED33A0BC6656999757EE2BAD65366A" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_38ED33A0BC6656999757EE2BAD65366A" xlink:type="arc" />
    <link:label id="lab_pfe_DebtInstrumentRedemptionRuleRedemptionPricePercentageBasisSpread_D347818B7BDA313A3385C826491A9BB8_terseLabel_en-US" xlink:label="lab_pfe_DebtInstrumentRedemptionRuleRedemptionPricePercentageBasisSpread_F900FB0968FC5B9EBE02F79057C91D68" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Redemption basis spread</link:label>
    <link:label id="lab_pfe_DebtInstrumentRedemptionRuleRedemptionPricePercentageBasisSpread_D347818B7BDA313A3385C826491A9BB8_label_en-US" xlink:label="lab_pfe_DebtInstrumentRedemptionRuleRedemptionPricePercentageBasisSpread_F900FB0968FC5B9EBE02F79057C91D68" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption Rule, Redemption Price, Percentage, Basis Spread</link:label>
    <link:label id="lab_pfe_DebtInstrumentRedemptionRuleRedemptionPricePercentageBasisSpread_D347818B7BDA313A3385C826491A9BB8_documentation_en-US" xlink:label="lab_pfe_DebtInstrumentRedemptionRuleRedemptionPricePercentageBasisSpread_F900FB0968FC5B9EBE02F79057C91D68" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption Rule, Redemption Price, Percentage, Basis Spread</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_DebtInstrumentRedemptionRuleRedemptionPricePercentageBasisSpread" xlink:label="loc_pfe_DebtInstrumentRedemptionRuleRedemptionPricePercentageBasisSpread_F900FB0968FC5B9EBE02F79057C91D68" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DebtInstrumentRedemptionRuleRedemptionPricePercentageBasisSpread_F900FB0968FC5B9EBE02F79057C91D68" xlink:to="lab_pfe_DebtInstrumentRedemptionRuleRedemptionPricePercentageBasisSpread_F900FB0968FC5B9EBE02F79057C91D68" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtWeightedAverageInterestRate_5BA8E20EAB1CA9335C0FC826491A0FB3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtWeightedAverageInterestRate_AFD67E26F98A50AA837B5E1276BEAB98" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average effective interest rate</link:label>
    <link:label id="lab_us-gaap_DebtWeightedAverageInterestRate_5BA8E20EAB1CA9335C0FC826491A0FB3_label_en-US" xlink:label="lab_us-gaap_DebtWeightedAverageInterestRate_AFD67E26F98A50AA837B5E1276BEAB98" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt, Weighted Average Interest Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtWeightedAverageInterestRate" xlink:label="loc_us-gaap_DebtWeightedAverageInterestRate_AFD67E26F98A50AA837B5E1276BEAB98" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtWeightedAverageInterestRate_AFD67E26F98A50AA837B5E1276BEAB98" xlink:to="lab_us-gaap_DebtWeightedAverageInterestRate_AFD67E26F98A50AA837B5E1276BEAB98" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_D92FA193761AA4612FF2C83B6165DF50_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount_22D7B7FE951A5A8C84C2185B11E3BE78" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt issued</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_D92FA193761AA4612FF2C83B6165DF50_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount_22D7B7FE951A5A8C84C2185B11E3BE78" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_22D7B7FE951A5A8C84C2185B11E3BE78" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount_22D7B7FE951A5A8C84C2185B11E3BE78" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount_22D7B7FE951A5A8C84C2185B11E3BE78" xlink:type="arc" />
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_982210581F7C44B36B8DAE9F93263F85_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_9FA2919A779750A78E042E1074126D5C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_982210581F7C44B36B8DAE9F93263F85_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_9FA2919A779750A78E042E1074126D5C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_9FA2919A779750A78E042E1074126D5C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_9FA2919A779750A78E042E1074126D5C" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_9FA2919A779750A78E042E1074126D5C" xlink:type="arc" />
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_93ABA9A1BA288F07C7ABAE9F9326D26D_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_C516D03CF32F5E81B164102728F04D5A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adoption of New Accounting Standards</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_93ABA9A1BA288F07C7ABAE9F9326D26D_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_C516D03CF32F5E81B164102728F04D5A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_C516D03CF32F5E81B164102728F04D5A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_C516D03CF32F5E81B164102728F04D5A" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_C516D03CF32F5E81B164102728F04D5A" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_CA84F521E45EB1D9AC8FAE9F933DACE7_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_A0F560C44C255D9B99A2BEC08A682854" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Allowance for doubtful accounts</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_CA84F521E45EB1D9AC8FAE9F933DACE7_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_A0F560C44C255D9B99A2BEC08A682854" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Allowance for Doubtful Accounts Receivable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_A0F560C44C255D9B99A2BEC08A682854" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_A0F560C44C255D9B99A2BEC08A682854" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_A0F560C44C255D9B99A2BEC08A682854" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_86F5ED10AA19166AF325AE9F933D2786_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_85D595022B7A545A990F0BEE9743CC3A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment, accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_86F5ED10AA19166AF325AE9F933D2786_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_85D595022B7A545A990F0BEE9743CC3A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_85D595022B7A545A990F0BEE9743CC3A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_85D595022B7A545A990F0BEE9743CC3A" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_85D595022B7A545A990F0BEE9743CC3A" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtCurrent_AC5989FBF29C0A9B0EC5AE9F933D49CA_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent_A1383EAC48705685ACA7FAF87EE227F7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current portion of long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_AC5989FBF29C0A9B0EC5AE9F933D49CA_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent_A1383EAC48705685ACA7FAF87EE227F7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Current Maturities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_A1383EAC48705685ACA7FAF87EE227F7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent_A1383EAC48705685ACA7FAF87EE227F7" xlink:to="lab_us-gaap_LongTermDebtCurrent_A1383EAC48705685ACA7FAF87EE227F7" xlink:type="arc" />
    <link:label id="lab_pfe_DevelopedRestOfWorldMember_D3AEC74BFE02BBEE1BB87E0DD69942F4_terseLabel_en-US" xlink:label="lab_pfe_DevelopedRestOfWorldMember_D3AEC74BFE02BBEE1BB87E0DD69942F4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Developed Rest Of World [Member]</link:label>
    <link:label id="lab_pfe_DevelopedRestOfWorldMember_D3AEC74BFE02BBEE1BB87E0DD69942F4_label_en-US" xlink:label="lab_pfe_DevelopedRestOfWorldMember_D3AEC74BFE02BBEE1BB87E0DD69942F4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Developed Rest Of World [Member]</link:label>
    <link:label id="lab_pfe_DevelopedRestOfWorldMember_D3AEC74BFE02BBEE1BB87E0DD69942F4_documentation_en-US" xlink:label="lab_pfe_DevelopedRestOfWorldMember_D3AEC74BFE02BBEE1BB87E0DD69942F4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Developed Rest Of World [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_DevelopedRestOfWorldMember" xlink:label="loc_pfe_DevelopedRestOfWorldMember_D3AEC74BFE02BBEE1BB87E0DD69942F4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DevelopedRestOfWorldMember_D3AEC74BFE02BBEE1BB87E0DD69942F4" xlink:to="lab_pfe_DevelopedRestOfWorldMember_D3AEC74BFE02BBEE1BB87E0DD69942F4" xlink:type="arc" />
    <link:label id="lab_pfe_EmergingMarketsMember_BFEC4AFDB9DD7DD602B27E0DD6994010_terseLabel_en-US" xlink:label="lab_pfe_EmergingMarketsMember_BFEC4AFDB9DD7DD602B27E0DD6994010" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Emerging Markets [Member]</link:label>
    <link:label id="lab_pfe_EmergingMarketsMember_BFEC4AFDB9DD7DD602B27E0DD6994010_label_en-US" xlink:label="lab_pfe_EmergingMarketsMember_BFEC4AFDB9DD7DD602B27E0DD6994010" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Emerging Markets [Member]</link:label>
    <link:label id="lab_pfe_EmergingMarketsMember_BFEC4AFDB9DD7DD602B27E0DD6994010_documentation_en-US" xlink:label="lab_pfe_EmergingMarketsMember_BFEC4AFDB9DD7DD602B27E0DD6994010" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Emerging Markets [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_EmergingMarketsMember" xlink:label="loc_pfe_EmergingMarketsMember_BFEC4AFDB9DD7DD602B27E0DD6994010" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_EmergingMarketsMember_BFEC4AFDB9DD7DD602B27E0DD6994010" xlink:to="lab_pfe_EmergingMarketsMember_BFEC4AFDB9DD7DD602B27E0DD6994010" xlink:type="arc" />
    <link:label id="lab_pfe_PercentageChangeInRevenue_BBBEFD3949BB55481CA37E0DD6999C0D_terseLabel_en-US" xlink:label="lab_pfe_PercentageChangeInRevenue_BBBEFD3949BB55481CA37E0DD6999C0D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage Change In Revenue</link:label>
    <link:label id="lab_pfe_PercentageChangeInRevenue_BBBEFD3949BB55481CA37E0DD6999C0D_label_en-US" xlink:label="lab_pfe_PercentageChangeInRevenue_BBBEFD3949BB55481CA37E0DD6999C0D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Change In Revenue</link:label>
    <link:label id="lab_pfe_PercentageChangeInRevenue_BBBEFD3949BB55481CA37E0DD6999C0D_documentation_en-US" xlink:label="lab_pfe_PercentageChangeInRevenue_BBBEFD3949BB55481CA37E0DD6999C0D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The percentage change in revenue.</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_PercentageChangeInRevenue" xlink:label="loc_pfe_PercentageChangeInRevenue_BBBEFD3949BB55481CA37E0DD6999C0D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_PercentageChangeInRevenue_BBBEFD3949BB55481CA37E0DD6999C0D" xlink:to="lab_pfe_PercentageChangeInRevenue_BBBEFD3949BB55481CA37E0DD6999C0D" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_CC5D64EB666B8B8ECD1B4A426E1D70DA_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember_CC5D64EB666B8B8ECD1B4A426E1D70DA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Employee Termination Costs [Member]</link:label>
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_CC5D64EB666B8B8ECD1B4A426E1D70DA_label_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember_CC5D64EB666B8B8ECD1B4A426E1D70DA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Severance [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeSeveranceMember" xlink:label="loc_us-gaap_EmployeeSeveranceMember_CC5D64EB666B8B8ECD1B4A426E1D70DA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeSeveranceMember_CC5D64EB666B8B8ECD1B4A426E1D70DA" xlink:to="lab_us-gaap_EmployeeSeveranceMember_CC5D64EB666B8B8ECD1B4A426E1D70DA" xlink:type="arc" />
    <link:label id="lab_pfe_AssetImpairmentsMember_4746D4CFC20870F6680F4A426E1D96E1_terseLabel_en-US" xlink:label="lab_pfe_AssetImpairmentsMember_4746D4CFC20870F6680F4A426E1D96E1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset Impairment Charges [Member]</link:label>
    <link:label id="lab_pfe_AssetImpairmentsMember_4746D4CFC20870F6680F4A426E1D96E1_label_en-US" xlink:label="lab_pfe_AssetImpairmentsMember_4746D4CFC20870F6680F4A426E1D96E1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Impairments [Member]</link:label>
    <link:label id="lab_pfe_AssetImpairmentsMember_4746D4CFC20870F6680F4A426E1D96E1_documentation_en-US" xlink:label="lab_pfe_AssetImpairmentsMember_4746D4CFC20870F6680F4A426E1D96E1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Asset impairments [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_AssetImpairmentsMember" xlink:label="loc_pfe_AssetImpairmentsMember_4746D4CFC20870F6680F4A426E1D96E1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_AssetImpairmentsMember_4746D4CFC20870F6680F4A426E1D96E1" xlink:to="lab_pfe_AssetImpairmentsMember_4746D4CFC20870F6680F4A426E1D96E1" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherRestructuringMember_7118E1EA81FC2AAE30A44A426E1D2633_terseLabel_en-US" xlink:label="lab_us-gaap_OtherRestructuringMember_7118E1EA81FC2AAE30A44A426E1D2633" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exit Costs [Member]</link:label>
    <link:label id="lab_us-gaap_OtherRestructuringMember_7118E1EA81FC2AAE30A44A426E1D2633_label_en-US" xlink:label="lab_us-gaap_OtherRestructuringMember_7118E1EA81FC2AAE30A44A426E1D2633" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Restructuring [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherRestructuringMember" xlink:label="loc_us-gaap_OtherRestructuringMember_7118E1EA81FC2AAE30A44A426E1D2633" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherRestructuringMember_7118E1EA81FC2AAE30A44A426E1D2633" xlink:to="lab_us-gaap_OtherRestructuringMember_7118E1EA81FC2AAE30A44A426E1D2633" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_898A147C082D5F653B734A426E1EB103_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward_898A147C082D5F653B734A426E1EB103" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Reserve [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_898A147C082D5F653B734A426E1EB103_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward_898A147C082D5F653B734A426E1EB103" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Reserve [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringReserveRollForward" xlink:label="loc_us-gaap_RestructuringReserveRollForward_898A147C082D5F653B734A426E1EB103" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveRollForward_898A147C082D5F653B734A426E1EB103" xlink:to="lab_us-gaap_RestructuringReserveRollForward_898A147C082D5F653B734A426E1EB103" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringReserve_E68FA26099F7BAB5A4D34A426E1E457A_periodStartLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve_E68FA26099F7BAB5A4D34A426E1E457A" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance, December 31, 2016</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringReserve" xlink:label="loc_us-gaap_RestructuringReserve_E68FA26099F7BAB5A4D34A426E1E457A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserve_E68FA26099F7BAB5A4D34A426E1E457A" xlink:to="lab_us-gaap_RestructuringReserve_E68FA26099F7BAB5A4D34A426E1E457A" xlink:type="arc" />
    <link:label id="lab_pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment_97C105F1B08E1E964AEB4A426E1FBF98_negatedTerseLabel_en-US" xlink:label="lab_pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment_97C105F1B08E1E964AEB4A426E1FBF98" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Utilization and other</link:label>
    <link:label id="lab_pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment_97C105F1B08E1E964AEB4A426E1FBF98_label_en-US" xlink:label="lab_pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment_97C105F1B08E1E964AEB4A426E1FBF98" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Restructuring, Other Restructuring And Restructuring Translation Adjustment</link:label>
    <link:label id="lab_pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment_97C105F1B08E1E964AEB4A426E1FBF98_documentation_en-US" xlink:label="lab_pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment_97C105F1B08E1E964AEB4A426E1FBF98" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments for Restructuring, Other Restructuring And Restructuring Translation Adjustment</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment" xlink:label="loc_pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment_97C105F1B08E1E964AEB4A426E1FBF98" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment_97C105F1B08E1E964AEB4A426E1FBF98" xlink:to="lab_pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment_97C105F1B08E1E964AEB4A426E1FBF98" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringReserve_E529674473B61C080C174A426E1F2049_periodEndLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve_E529674473B61C080C174A426E1F2049" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance, October 1, 2017</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringReserve" xlink:label="loc_us-gaap_RestructuringReserve_E529674473B61C080C174A426E1F2049" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserve_E529674473B61C080C174A426E1F2049" xlink:to="lab_us-gaap_RestructuringReserve_E529674473B61C080C174A426E1F2049" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_E3CAF492BC8954F1C75EAE9F926E7CD8_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_7DA682F713985F08B06120D913CC7D4E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_E3CAF492BC8954F1C75EAE9F926E7CD8_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_7DA682F713985F08B06120D913CC7D4E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_7DA682F713985F08B06120D913CC7D4E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_7DA682F713985F08B06120D913CC7D4E" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_7DA682F713985F08B06120D913CC7D4E" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_44670B60A086BA16B7A5AE9F926EADB6_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves_5F75A5D991FA577DAE6C5858892BEDB6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Work-in-process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_44670B60A086BA16B7A5AE9F926EADB6_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves_5F75A5D991FA577DAE6C5858892BEDB6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_5F75A5D991FA577DAE6C5858892BEDB6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves_5F75A5D991FA577DAE6C5858892BEDB6" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves_5F75A5D991FA577DAE6C5858892BEDB6" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_CA327252469EB73C9D75AE9F926E86AC_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_05EE4BAC4938567CA05002B7313A0754" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Raw materials and supplies</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_CA327252469EB73C9D75AE9F926E86AC_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_05EE4BAC4938567CA05002B7313A0754" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Raw Materials and Supplies, Net of Reserves</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" xlink:label="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_05EE4BAC4938567CA05002B7313A0754" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_05EE4BAC4938567CA05002B7313A0754" xlink:to="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_05EE4BAC4938567CA05002B7313A0754" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryNet_1FF49A8C1672544C5165AE9F926E1CA2_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet_8DD9CC8B2D9C56E59ADE771891F1C5DB" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_8DD9CC8B2D9C56E59ADE771891F1C5DB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet_8DD9CC8B2D9C56E59ADE771891F1C5DB" xlink:to="lab_us-gaap_InventoryNet_8DD9CC8B2D9C56E59ADE771891F1C5DB" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryNoncurrent_CDFF043BC83F6C5238DDAE9F926E3242_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent_95E45CA9347854DC933E716F9BA79889" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncurrent inventories not included above</link:label>
    <link:label id="lab_us-gaap_InventoryNoncurrent_CDFF043BC83F6C5238DDAE9F926E3242_label_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent_95E45CA9347854DC933E716F9BA79889" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryNoncurrent" xlink:label="loc_us-gaap_InventoryNoncurrent_95E45CA9347854DC933E716F9BA79889" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNoncurrent_95E45CA9347854DC933E716F9BA79889" xlink:to="lab_us-gaap_InventoryNoncurrent_95E45CA9347854DC933E716F9BA79889" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_B77969D8CC7738F4267E91BE7BED05C0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_B77969D8CC7738F4267E91BE7BED05C0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 1 [Member]</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_B77969D8CC7738F4267E91BE7BED05C0_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_B77969D8CC7738F4267E91BE7BED05C0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_B77969D8CC7738F4267E91BE7BED05C0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member_B77969D8CC7738F4267E91BE7BED05C0" xlink:to="lab_us-gaap_FairValueInputsLevel1Member_B77969D8CC7738F4267E91BE7BED05C0" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_E49B3D40A47CED32C7A491BE7BEEB7C8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member_E49B3D40A47CED32C7A491BE7BEEB7C8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 3 [Member]</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_E49B3D40A47CED32C7A491BE7BEEB7C8_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member_E49B3D40A47CED32C7A491BE7BEEB7C8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_E49B3D40A47CED32C7A491BE7BEEB7C8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member_E49B3D40A47CED32C7A491BE7BEEB7C8" xlink:to="lab_us-gaap_FairValueInputsLevel3Member_E49B3D40A47CED32C7A491BE7BEEB7C8" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure_F1E9C2521982018511B291BE7BEECF7E_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure_F1E9C2521982018511B291BE7BEECF7E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-lived intangible assets, fair value disclosure</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure_F1E9C2521982018511B291BE7BEECF7E_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure_F1E9C2521982018511B291BE7BEECF7E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-lived Intangible Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure_F1E9C2521982018511B291BE7BEECF7E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure_F1E9C2521982018511B291BE7BEECF7E" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure_F1E9C2521982018511B291BE7BEECF7E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_A4E1817BB7886893854791BE7BEE1500_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_A4E1817BB7886893854791BE7BEE1500" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of finite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_A4E1817BB7886893854791BE7BEE1500_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_A4E1817BB7886893854791BE7BEE1500" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment of Intangible Assets, Finite-lived</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_A4E1817BB7886893854791BE7BEE1500" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_A4E1817BB7886893854791BE7BEE1500" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_A4E1817BB7886893854791BE7BEE1500" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_738F4D51980BB8F0C047AE9F92497227_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_0CE4BBAEEE0D5775A844C20D47A4524F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Net Periodic Benefit Costs</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_738F4D51980BB8F0C047AE9F92497227_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_0CE4BBAEEE0D5775A844C20D47A4524F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Net Benefit Costs [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_0CE4BBAEEE0D5775A844C20D47A4524F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_0CE4BBAEEE0D5775A844C20D47A4524F" xlink:to="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_0CE4BBAEEE0D5775A844C20D47A4524F" xlink:type="arc" />
    <link:label id="lab_pfe_ScheduleofEmployerContributionstoPensionandPostretirementPlansTableTextBlock_6B1296AFC2F853C71B43AE9F924993DE_terseLabel_en-US" xlink:label="lab_pfe_ScheduleofEmployerContributionstoPensionandPostretirementPlansTableTextBlock_29071CC0406757328CC10C7CFE424720" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Employer Contributions to Pension and Postretirement Plans</link:label>
    <link:label id="lab_pfe_ScheduleofEmployerContributionstoPensionandPostretirementPlansTableTextBlock_6B1296AFC2F853C71B43AE9F924993DE_label_en-US" xlink:label="lab_pfe_ScheduleofEmployerContributionstoPensionandPostretirementPlansTableTextBlock_29071CC0406757328CC10C7CFE424720" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Employer Contributions to Pension and Postretirement Plans [Table Text Block]</link:label>
    <link:label id="lab_pfe_ScheduleofEmployerContributionstoPensionandPostretirementPlansTableTextBlock_6B1296AFC2F853C71B43AE9F924993DE_documentation_en-US" xlink:label="lab_pfe_ScheduleofEmployerContributionstoPensionandPostretirementPlansTableTextBlock_29071CC0406757328CC10C7CFE424720" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule of Employer Contributions to Pension and Postretirement Plans [Table Text Block]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_ScheduleofEmployerContributionstoPensionandPostretirementPlansTableTextBlock" xlink:label="loc_pfe_ScheduleofEmployerContributionstoPensionandPostretirementPlansTableTextBlock_29071CC0406757328CC10C7CFE424720" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ScheduleofEmployerContributionstoPensionandPostretirementPlansTableTextBlock_29071CC0406757328CC10C7CFE424720" xlink:to="lab_pfe_ScheduleofEmployerContributionstoPensionandPostretirementPlansTableTextBlock_29071CC0406757328CC10C7CFE424720" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_592CD31D09785B96B30450828D6A104B_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_592CD31D09785B96B30450828D6A104B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_592CD31D09785B96B30450828D6A104B_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_592CD31D09785B96B30450828D6A104B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_592CD31D09785B96B30450828D6A104B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_592CD31D09785B96B30450828D6A104B" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_592CD31D09785B96B30450828D6A104B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_D7C47CB5089866E156A450828D6B08BF_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_D7C47CB5089866E156A450828D6B08BF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_D7C47CB5089866E156A450828D6B08BF_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_D7C47CB5089866E156A450828D6B08BF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_D7C47CB5089866E156A450828D6B08BF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_D7C47CB5089866E156A450828D6B08BF" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_D7C47CB5089866E156A450828D6B08BF" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityMethodInvestments_BC1259064AA82F921CE850828D6C694F_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments_BC1259064AA82F921CE850828D6C694F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity method investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_BC1259064AA82F921CE850828D6C694F_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments_BC1259064AA82F921CE850828D6C694F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:label="loc_us-gaap_EquityMethodInvestments_BC1259064AA82F921CE850828D6C694F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestments_BC1259064AA82F921CE850828D6C694F" xlink:to="lab_us-gaap_EquityMethodInvestments_BC1259064AA82F921CE850828D6C694F" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_C10E097C3B9A0D0E7D917DDD5E400129_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_C10E097C3B9A0D0E7D917DDD5E400129" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency translation adjustments, net</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_C10E097C3B9A0D0E7D917DDD5E400129_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_C10E097C3B9A0D0E7D917DDD5E400129" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss), before Reclassification and Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_C10E097C3B9A0D0E7D917DDD5E400129" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_C10E097C3B9A0D0E7D917DDD5E400129" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_C10E097C3B9A0D0E7D917DDD5E400129" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax_971106EC2B226DE0DBF57DDD5E407D48_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax_971106EC2B226DE0DBF57DDD5E407D48" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Reclassification adjustments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax_971106EC2B226DE0DBF57DDD5E407D48_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax_971106EC2B226DE0DBF57DDD5E407D48" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Reclassification Adjustment from AOCI, Realized upon Sale or Liquidation, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax_971106EC2B226DE0DBF57DDD5E407D48" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax_971106EC2B226DE0DBF57DDD5E407D48" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax_971106EC2B226DE0DBF57DDD5E407D48" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_49A977EA11A3DC5C90AD7DDD5E407D03_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_49A977EA11A3DC5C90AD7DDD5E407D03" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss), foreign currency transaction and translation adjustment, before tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_49A977EA11A3DC5C90AD7DDD5E407D03_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_49A977EA11A3DC5C90AD7DDD5E407D03" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_49A977EA11A3DC5C90AD7DDD5E407D03" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_49A977EA11A3DC5C90AD7DDD5E407D03" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_49A977EA11A3DC5C90AD7DDD5E407D03" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax_D77DBDAE35A7E3AD0C5E7DDD5E401BB6_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax_D77DBDAE35A7E3AD0C5E7DDD5E401BB6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized holding losses on derivative financial instruments, net</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax_D77DBDAE35A7E3AD0C5E7DDD5E401BB6_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax_D77DBDAE35A7E3AD0C5E7DDD5E401BB6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax_D77DBDAE35A7E3AD0C5E7DDD5E401BB6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax_D77DBDAE35A7E3AD0C5E7DDD5E401BB6" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax_D77DBDAE35A7E3AD0C5E7DDD5E401BB6" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesBeforeTax_10CDB03AD12A03642B027DDD5E416006_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesBeforeTax_10CDB03AD12A03642B027DDD5E416006" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Reclassification adjustments for realized (gains)/losses</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesBeforeTax_10CDB03AD12A03642B027DDD5E416006_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesBeforeTax_10CDB03AD12A03642B027DDD5E416006" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesBeforeTax_10CDB03AD12A03642B027DDD5E416006" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesBeforeTax_10CDB03AD12A03642B027DDD5E416006" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesBeforeTax_10CDB03AD12A03642B027DDD5E416006" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesBeforeTax_44C32B6CD265DCB1DD1B7DDD5E41B961_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesBeforeTax_44C32B6CD265DCB1DD1B7DDD5E41B961" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss), derivatives qualifying as hedges, before tax, total</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesBeforeTax_44C32B6CD265DCB1DD1B7DDD5E41B961_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesBeforeTax_44C32B6CD265DCB1DD1B7DDD5E41B961" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesBeforeTax_44C32B6CD265DCB1DD1B7DDD5E41B961" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesBeforeTax_44C32B6CD265DCB1DD1B7DDD5E41B961" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesBeforeTax_44C32B6CD265DCB1DD1B7DDD5E41B961" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_9AE9229DE582A8724A727DDD5E4160CE_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_9AE9229DE582A8724A727DDD5E4160CE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized holding gains on available-for-sale securities, net</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_9AE9229DE582A8724A727DDD5E4160CE_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_9AE9229DE582A8724A727DDD5E4160CE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_9AE9229DE582A8724A727DDD5E4160CE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_9AE9229DE582A8724A727DDD5E4160CE" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_9AE9229DE582A8724A727DDD5E4160CE" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax_729016E481C7BCA36D7C7DDD5E419178_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax_729016E481C7BCA36D7C7DDD5E419178" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Reclassification adjustments for realized gains</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax_729016E481C7BCA36D7C7DDD5E419178_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax_729016E481C7BCA36D7C7DDD5E419178" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax_729016E481C7BCA36D7C7DDD5E419178" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax_729016E481C7BCA36D7C7DDD5E419178" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax_729016E481C7BCA36D7C7DDD5E419178" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax_CBB9E401A5722B47596B7DDD5E418557_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax_CBB9E401A5722B47596B7DDD5E418557" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss), available-for-sale securities adjustment, before tax, total</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax_CBB9E401A5722B47596B7DDD5E418557_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax_CBB9E401A5722B47596B7DDD5E418557" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax_CBB9E401A5722B47596B7DDD5E418557" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax_CBB9E401A5722B47596B7DDD5E418557" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax_CBB9E401A5722B47596B7DDD5E418557" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_81A968E2528205117DA17DDD5E4154B0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_81A968E2528205117DA17DDD5E4154B0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Benefit plans: actuarial losses, net</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_81A968E2528205117DA17DDD5E4154B0_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_81A968E2528205117DA17DDD5E4154B0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_81A968E2528205117DA17DDD5E4154B0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_81A968E2528205117DA17DDD5E4154B0" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_81A968E2528205117DA17DDD5E4154B0" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax_4B4BA80B533F88E197B57DDD5E41CF93_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax_4B4BA80B533F88E197B57DDD5E41CF93" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Reclassification adjustments related to amortization</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax_4B4BA80B533F88E197B57DDD5E41CF93_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax_4B4BA80B533F88E197B57DDD5E41CF93" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), Reclassification Adjustment from AOCI, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax_4B4BA80B533F88E197B57DDD5E41CF93" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax_4B4BA80B533F88E197B57DDD5E41CF93" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax_4B4BA80B533F88E197B57DDD5E41CF93" xlink:type="arc" />
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax_873A23E01ADB9D86CCC27DDD5E419276_negatedTerseLabel_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax_873A23E01ADB9D86CCC27DDD5E419276" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Reclassification adjustments related to settlements, net</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax_873A23E01ADB9D86CCC27DDD5E419276_label_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax_873A23E01ADB9D86CCC27DDD5E419276" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Settlement Adjustment From AOCI, Pension And Other Postretirement Benefit Plans, for Net Gain (Loss), Before Tax</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax_873A23E01ADB9D86CCC27DDD5E419276_documentation_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax_873A23E01ADB9D86CCC27DDD5E419276" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sum of pre tax adjustment to other comprehensive income for curtailments and settlements, net, related to defined benefit plans.</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax" xlink:label="loc_pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax_873A23E01ADB9D86CCC27DDD5E419276" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax_873A23E01ADB9D86CCC27DDD5E419276" xlink:to="lab_pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax_873A23E01ADB9D86CCC27DDD5E419276" xlink:type="arc" />
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax_9C5883272A876A5DB9AF7DDD5E41EE38_negatedLabel_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax_9C5883272A876A5DB9AF7DDD5E41EE38" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax_9C5883272A876A5DB9AF7DDD5E41EE38_label_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax_9C5883272A876A5DB9AF7DDD5E41EE38" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Other Net Unamortized Gain (Loss) Arising During Period, before Tax</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax_9C5883272A876A5DB9AF7DDD5E41EE38_documentation_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax_9C5883272A876A5DB9AF7DDD5E41EE38" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pre tax adjustment to other comprehensive income for other adjustments related to defined benefit plans actuarial gains /losses.</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax" xlink:label="loc_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax_9C5883272A876A5DB9AF7DDD5E41EE38" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax_9C5883272A876A5DB9AF7DDD5E41EE38" xlink:to="lab_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax_9C5883272A876A5DB9AF7DDD5E41EE38" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax_3BC203736843A0F19FE27DDD5E4145B9_totalLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax_3BC203736843A0F19FE27DDD5E4145B9" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Defined benefit plan, amounts recognized in other comprehensive income (loss), net gain (loss), before tax, total</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax_3BC203736843A0F19FE27DDD5E4145B9_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax_3BC203736843A0F19FE27DDD5E4145B9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), after Reclassification Adjustment, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax_3BC203736843A0F19FE27DDD5E4145B9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax_3BC203736843A0F19FE27DDD5E4145B9" xlink:to="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax_3BC203736843A0F19FE27DDD5E4145B9" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax_CEF8E836DF4F064090BF7DDD5E4134A8_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax_CEF8E836DF4F064090BF7DDD5E4134A8" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Benefit plans: prior service (costs)/credits and other, net</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax_CEF8E836DF4F064090BF7DDD5E4134A8_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax_CEF8E836DF4F064090BF7DDD5E4134A8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax_CEF8E836DF4F064090BF7DDD5E4134A8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax_CEF8E836DF4F064090BF7DDD5E4134A8" xlink:to="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax_CEF8E836DF4F064090BF7DDD5E4134A8" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_A824A122E29C6D7D873E7DDD5E422296_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_A824A122E29C6D7D873E7DDD5E422296" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Reclassification adjustments related to amortization</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_A824A122E29C6D7D873E7DDD5E422296_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_A824A122E29C6D7D873E7DDD5E422296" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Reclassification Adjustment from AOCI, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_A824A122E29C6D7D873E7DDD5E422296" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_A824A122E29C6D7D873E7DDD5E422296" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_A824A122E29C6D7D873E7DDD5E422296" xlink:type="arc" />
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax_6231051424BD228A3CCE7DDD5E4240C6_terseLabel_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax_6231051424BD228A3CCE7DDD5E4240C6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification adjustments related to curtailments, net</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax_6231051424BD228A3CCE7DDD5E4240C6_label_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax_6231051424BD228A3CCE7DDD5E4240C6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive (Income) Loss, Curtailment Adjustment from AOCI, Pension and Other Postretirement Benefit Plans, for Net Prior Service Cost (Credit), before Tax</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax_6231051424BD228A3CCE7DDD5E4240C6_documentation_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax_6231051424BD228A3CCE7DDD5E4240C6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pre tax adjustment to other comprehensive income for curtailments and settlements, net, related to defined benefit plans prior service (costs)/credits.</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax" xlink:label="loc_pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax_6231051424BD228A3CCE7DDD5E4240C6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax_6231051424BD228A3CCE7DDD5E4240C6" xlink:to="lab_pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax_6231051424BD228A3CCE7DDD5E4240C6" xlink:type="arc" />
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax_E20C6785AE0A2AD6EC2F7DDD5E426598_negatedLabel_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax_E20C6785AE0A2AD6EC2F7DDD5E426598" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax_E20C6785AE0A2AD6EC2F7DDD5E426598_label_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax_E20C6785AE0A2AD6EC2F7DDD5E426598" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Other Net Prior Service Cost (Credit) Arising During Period, before Tax</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax_E20C6785AE0A2AD6EC2F7DDD5E426598_documentation_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax_E20C6785AE0A2AD6EC2F7DDD5E426598" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pre tax adjustment to other comprehensive income for other adjustments related to defined benefit plans prior service (costs)/credits.</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax" xlink:label="loc_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax_E20C6785AE0A2AD6EC2F7DDD5E426598" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax_E20C6785AE0A2AD6EC2F7DDD5E426598" xlink:to="lab_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax_E20C6785AE0A2AD6EC2F7DDD5E426598" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_F18F437C558B4D1733257DDD5E42F8EA_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_F18F437C558B4D1733257DDD5E42F8EA" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Defined benefit plan, amounts recognized in other comprehensive income (loss), net prior service cost, before tax</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_F18F437C558B4D1733257DDD5E42F8EA_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_F18F437C558B4D1733257DDD5E42F8EA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), after Reclassification Adjustment, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_F18F437C558B4D1733257DDD5E42F8EA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_F18F437C558B4D1733257DDD5E42F8EA" xlink:to="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_F18F437C558B4D1733257DDD5E42F8EA" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTax_C45F724FBBEE5873DA057DDD5E424622_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTax_C45F724FBBEE5873DA057DDD5E424622" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income, before tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTax_C45F724FBBEE5873DA057DDD5E424622_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTax_C45F724FBBEE5873DA057DDD5E424622" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax_C45F724FBBEE5873DA057DDD5E424622" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax_C45F724FBBEE5873DA057DDD5E424622" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTax_C45F724FBBEE5873DA057DDD5E424622" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTax_D24A5EEE64BCB2F5A2997DDD5E42108D_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTax_D24A5EEE64BCB2F5A2997DDD5E42108D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax provision/(benefit) on other comprehensive income</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTax_D24A5EEE64BCB2F5A2997DDD5E42108D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTax_D24A5EEE64BCB2F5A2997DDD5E42108D" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossTax_D24A5EEE64BCB2F5A2997DDD5E42108D" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_4B395EA91143DA09CCF97DDD5E4270FE_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_4B395EA91143DA09CCF97DDD5E4270FE" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income before allocation to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_4B395EA91143DA09CCF97DDD5E4270FE_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_4B395EA91143DA09CCF97DDD5E4270FE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_4B395EA91143DA09CCF97DDD5E4270FE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_4B395EA91143DA09CCF97DDD5E4270FE" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_4B395EA91143DA09CCF97DDD5E4270FE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_25475843EE4B26C9E7587DDD5E42BAAC_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_25475843EE4B26C9E7587DDD5E42BAAC" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive income before allocation to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_25475843EE4B26C9E7587DDD5E42BAAC_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_25475843EE4B26C9E7587DDD5E42BAAC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_25475843EE4B26C9E7587DDD5E42BAAC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_25475843EE4B26C9E7587DDD5E42BAAC" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_25475843EE4B26C9E7587DDD5E42BAAC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_37DAC2A40BB9A31D27857DDD5E427D0F_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_37DAC2A40BB9A31D27857DDD5E427D0F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Less: Comprehensive income attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_37DAC2A40BB9A31D27857DDD5E427D0F_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_37DAC2A40BB9A31D27857DDD5E427D0F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_37DAC2A40BB9A31D27857DDD5E427D0F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_37DAC2A40BB9A31D27857DDD5E427D0F" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_37DAC2A40BB9A31D27857DDD5E427D0F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_12362FEEDF2E83DCCC437DDD5E42EEF2_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_12362FEEDF2E83DCCC437DDD5E42EEF2" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive income attributable to Pfizer Inc.</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_12362FEEDF2E83DCCC437DDD5E42EEF2_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_12362FEEDF2E83DCCC437DDD5E42EEF2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_12362FEEDF2E83DCCC437DDD5E42EEF2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_12362FEEDF2E83DCCC437DDD5E42EEF2" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax_12362FEEDF2E83DCCC437DDD5E42EEF2" xlink:type="arc" />
    <link:label id="lab_us-gaap_MinimumMember_FFE6EAA4C9A94E283E659C26438DAC25_terseLabel_en-US" xlink:label="lab_us-gaap_MinimumMember_FFE6EAA4C9A94E283E659C26438DAC25" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:label id="lab_us-gaap_MinimumMember_FFE6EAA4C9A94E283E659C26438DAC25_label_en-US" xlink:label="lab_us-gaap_MinimumMember_FFE6EAA4C9A94E283E659C26438DAC25" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_FFE6EAA4C9A94E283E659C26438DAC25" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinimumMember_FFE6EAA4C9A94E283E659C26438DAC25" xlink:to="lab_us-gaap_MinimumMember_FFE6EAA4C9A94E283E659C26438DAC25" xlink:type="arc" />
    <link:label id="lab_pfe_AstraZenecaMember_18C9839497F71223222B9C26438D2C8F_terseLabel_en-US" xlink:label="lab_pfe_AstraZenecaMember_18C9839497F71223222B9C26438D2C8F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AstraZeneca [Member]</link:label>
    <link:label id="lab_pfe_AstraZenecaMember_18C9839497F71223222B9C26438D2C8F_label_en-US" xlink:label="lab_pfe_AstraZenecaMember_18C9839497F71223222B9C26438D2C8F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AstraZeneca [Member]</link:label>
    <link:label id="lab_pfe_AstraZenecaMember_18C9839497F71223222B9C26438D2C8F_documentation_en-US" xlink:label="lab_pfe_AstraZenecaMember_18C9839497F71223222B9C26438D2C8F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">AstraZeneca [Member]</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_AstraZenecaMember" xlink:label="loc_pfe_AstraZenecaMember_18C9839497F71223222B9C26438D2C8F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_AstraZenecaMember_18C9839497F71223222B9C26438D2C8F" xlink:to="lab_pfe_AstraZenecaMember_18C9839497F71223222B9C26438D2C8F" xlink:type="arc" />
    <link:label id="lab_pfe_PaymentstoAcquireBusinessesGrossInitialPayment_31C15AA6EC50462279CC9C26438E796F_terseLabel_en-US" xlink:label="lab_pfe_PaymentstoAcquireBusinessesGrossInitialPayment_31C15AA6EC50462279CC9C26438E796F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Initial payment</link:label>
    <link:label id="lab_pfe_PaymentstoAcquireBusinessesGrossInitialPayment_31C15AA6EC50462279CC9C26438E796F_label_en-US" xlink:label="lab_pfe_PaymentstoAcquireBusinessesGrossInitialPayment_31C15AA6EC50462279CC9C26438E796F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Businesses, Gross, Initial Payment</link:label>
    <link:label id="lab_pfe_PaymentstoAcquireBusinessesGrossInitialPayment_31C15AA6EC50462279CC9C26438E796F_documentation_en-US" xlink:label="lab_pfe_PaymentstoAcquireBusinessesGrossInitialPayment_31C15AA6EC50462279CC9C26438E796F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments to Acquire Businesses, Gross, Initial Payment</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_PaymentstoAcquireBusinessesGrossInitialPayment" xlink:label="loc_pfe_PaymentstoAcquireBusinessesGrossInitialPayment_31C15AA6EC50462279CC9C26438E796F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_PaymentstoAcquireBusinessesGrossInitialPayment_31C15AA6EC50462279CC9C26438E796F" xlink:to="lab_pfe_PaymentstoAcquireBusinessesGrossInitialPayment_31C15AA6EC50462279CC9C26438E796F" xlink:type="arc" />
    <link:label id="lab_pfe_PaymentstoAcquireBusinessesGrossPurchasePriceAdjustment_8FD878AEBAEE909C72C19C26438E1AC9_terseLabel_en-US" xlink:label="lab_pfe_PaymentstoAcquireBusinessesGrossPurchasePriceAdjustment_8FD878AEBAEE909C72C19C26438E1AC9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional payment made for a purchase price adjustment</link:label>
    <link:label id="lab_pfe_PaymentstoAcquireBusinessesGrossPurchasePriceAdjustment_8FD878AEBAEE909C72C19C26438E1AC9_label_en-US" xlink:label="lab_pfe_PaymentstoAcquireBusinessesGrossPurchasePriceAdjustment_8FD878AEBAEE909C72C19C26438E1AC9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Businesses, Gross, Purchase Price Adjustment</link:label>
    <link:label id="lab_pfe_PaymentstoAcquireBusinessesGrossPurchasePriceAdjustment_8FD878AEBAEE909C72C19C26438E1AC9_documentation_en-US" xlink:label="lab_pfe_PaymentstoAcquireBusinessesGrossPurchasePriceAdjustment_8FD878AEBAEE909C72C19C26438E1AC9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments to Acquire Businesses, Gross, Purchase Price Adjustment</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_PaymentstoAcquireBusinessesGrossPurchasePriceAdjustment" xlink:label="loc_pfe_PaymentstoAcquireBusinessesGrossPurchasePriceAdjustment_8FD878AEBAEE909C72C19C26438E1AC9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_PaymentstoAcquireBusinessesGrossPurchasePriceAdjustment_8FD878AEBAEE909C72C19C26438E1AC9" xlink:to="lab_pfe_PaymentstoAcquireBusinessesGrossPurchasePriceAdjustment_8FD878AEBAEE909C72C19C26438E1AC9" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities_854B8F1CED12D0FAF8719C26438ECDA9_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities_854B8F1CED12D0FAF8719C26438ECDA9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone payment</link:label>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities_854B8F1CED12D0FAF8719C26438ECDA9_label_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities_854B8F1CED12D0FAF8719C26438ECDA9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment for Contingent Consideration Liability, Investing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities_854B8F1CED12D0FAF8719C26438ECDA9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities_854B8F1CED12D0FAF8719C26438ECDA9" xlink:to="lab_us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities_854B8F1CED12D0FAF8719C26438ECDA9" xlink:type="arc" />
    <link:label id="lab_pfe_BusinessCombinationConsiderationTransferredDeferredPayment_302719788EFA43C18D8D9C26438E5745_terseLabel_en-US" xlink:label="lab_pfe_BusinessCombinationConsiderationTransferredDeferredPayment_302719788EFA43C18D8D9C26438E5745" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred payment</link:label>
    <link:label id="lab_pfe_BusinessCombinationConsiderationTransferredDeferredPayment_302719788EFA43C18D8D9C26438E5745_label_en-US" xlink:label="lab_pfe_BusinessCombinationConsiderationTransferredDeferredPayment_302719788EFA43C18D8D9C26438E5745" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Consideration Transferred, Deferred Payment</link:label>
    <link:label id="lab_pfe_BusinessCombinationConsiderationTransferredDeferredPayment_302719788EFA43C18D8D9C26438E5745_documentation_en-US" xlink:label="lab_pfe_BusinessCombinationConsiderationTransferredDeferredPayment_302719788EFA43C18D8D9C26438E5745" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Consideration Transferred, Deferred Payment</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_BusinessCombinationConsiderationTransferredDeferredPayment" xlink:label="loc_pfe_BusinessCombinationConsiderationTransferredDeferredPayment_302719788EFA43C18D8D9C26438E5745" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_BusinessCombinationConsiderationTransferredDeferredPayment_302719788EFA43C18D8D9C26438E5745" xlink:to="lab_pfe_BusinessCombinationConsiderationTransferredDeferredPayment_302719788EFA43C18D8D9C26438E5745" xlink:type="arc" />
    <link:label id="lab_pfe_BusinessCombinationConsiderationTransferredSalesrelatedPaymentsMaximum_4F00A539CF613684EB529C26438EA50D_terseLabel_en-US" xlink:label="lab_pfe_BusinessCombinationConsiderationTransferredSalesrelatedPaymentsMaximum_4F00A539CF613684EB529C26438EA50D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum amount of potential sales-related payments</link:label>
    <link:label id="lab_pfe_BusinessCombinationConsiderationTransferredSalesrelatedPaymentsMaximum_4F00A539CF613684EB529C26438EA50D_label_en-US" xlink:label="lab_pfe_BusinessCombinationConsiderationTransferredSalesrelatedPaymentsMaximum_4F00A539CF613684EB529C26438EA50D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Consideration Transferred, Sales-related Payments, Maximum</link:label>
    <link:label id="lab_pfe_BusinessCombinationConsiderationTransferredSalesrelatedPaymentsMaximum_4F00A539CF613684EB529C26438EA50D_documentation_en-US" xlink:label="lab_pfe_BusinessCombinationConsiderationTransferredSalesrelatedPaymentsMaximum_4F00A539CF613684EB529C26438EA50D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Consideration Transferred, Sales-related Payments, Maximum</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_BusinessCombinationConsiderationTransferredSalesrelatedPaymentsMaximum" xlink:label="loc_pfe_BusinessCombinationConsiderationTransferredSalesrelatedPaymentsMaximum_4F00A539CF613684EB529C26438EA50D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_BusinessCombinationConsiderationTransferredSalesrelatedPaymentsMaximum_4F00A539CF613684EB529C26438EA50D" xlink:to="lab_pfe_BusinessCombinationConsiderationTransferredSalesrelatedPaymentsMaximum_4F00A539CF613684EB529C26438EA50D" xlink:type="arc" />
    <link:label id="lab_pfe_BusinessCombinationConsiderationTransferredUndiscountedRoyaltyPaymentsTerm_1010B88A0E62C1A4F0FF9C26438E9C0D_terseLabel_en-US" xlink:label="lab_pfe_BusinessCombinationConsiderationTransferredUndiscountedRoyaltyPaymentsTerm_1010B88A0E62C1A4F0FF9C26438E9C0D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term of royalty payments</link:label>
    <link:label id="lab_pfe_BusinessCombinationConsiderationTransferredUndiscountedRoyaltyPaymentsTerm_1010B88A0E62C1A4F0FF9C26438E9C0D_label_en-US" xlink:label="lab_pfe_BusinessCombinationConsiderationTransferredUndiscountedRoyaltyPaymentsTerm_1010B88A0E62C1A4F0FF9C26438E9C0D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Consideration Transferred, Undiscounted Royalty Payments, Term</link:label>
    <link:label id="lab_pfe_BusinessCombinationConsiderationTransferredUndiscountedRoyaltyPaymentsTerm_1010B88A0E62C1A4F0FF9C26438E9C0D_documentation_en-US" xlink:label="lab_pfe_BusinessCombinationConsiderationTransferredUndiscountedRoyaltyPaymentsTerm_1010B88A0E62C1A4F0FF9C26438E9C0D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Consideration Transferred, Undiscounted Royalty Payments, Term</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_BusinessCombinationConsiderationTransferredUndiscountedRoyaltyPaymentsTerm" xlink:label="loc_pfe_BusinessCombinationConsiderationTransferredUndiscountedRoyaltyPaymentsTerm_1010B88A0E62C1A4F0FF9C26438E9C0D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_BusinessCombinationConsiderationTransferredUndiscountedRoyaltyPaymentsTerm_1010B88A0E62C1A4F0FF9C26438E9C0D" xlink:to="lab_pfe_BusinessCombinationConsiderationTransferredUndiscountedRoyaltyPaymentsTerm_1010B88A0E62C1A4F0FF9C26438E9C0D" xlink:type="arc" />
    <link:label id="lab_pfe_BusinessCombinationConsiderationTransferredUndiscountedRoyaltyPayments_2C907DDC618C4151095F9C26438E178F_terseLabel_en-US" xlink:label="lab_pfe_BusinessCombinationConsiderationTransferredUndiscountedRoyaltyPayments_2C907DDC618C4151095F9C26438E178F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Undiscounted royalty payments</link:label>
    <link:label id="lab_pfe_BusinessCombinationConsiderationTransferredUndiscountedRoyaltyPayments_2C907DDC618C4151095F9C26438E178F_label_en-US" xlink:label="lab_pfe_BusinessCombinationConsiderationTransferredUndiscountedRoyaltyPayments_2C907DDC618C4151095F9C26438E178F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Consideration Transferred, Undiscounted Royalty Payments</link:label>
    <link:label id="lab_pfe_BusinessCombinationConsiderationTransferredUndiscountedRoyaltyPayments_2C907DDC618C4151095F9C26438E178F_documentation_en-US" xlink:label="lab_pfe_BusinessCombinationConsiderationTransferredUndiscountedRoyaltyPayments_2C907DDC618C4151095F9C26438E178F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Consideration Transferred, Undiscounted Royalty Payments</link:label>
    <link:loc xlink:href="pfe-20171001.xsd#pfe_BusinessCombinationConsiderationTransferredUndiscountedRoyaltyPayments" xlink:label="loc_pfe_BusinessCombinationConsiderationTransferredUndiscountedRoyaltyPayments_2C907DDC618C4151095F9C26438E178F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_BusinessCombinationConsiderationTransferredUndiscountedRoyaltyPayments_2C907DDC618C4151095F9C26438E178F" xlink:to="lab_pfe_BusinessCombinationConsiderationTransferredUndiscountedRoyaltyPayments_2C907DDC618C4151095F9C26438E178F" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_989E8D34C59E3D90DFF39C26438EAF30_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_989E8D34C59E3D90DFF39C26438EAF30" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_989E8D34C59E3D90DFF39C26438EAF30_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_989E8D34C59E3D90DFF39C26438EAF30" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_989E8D34C59E3D90DFF39C26438EAF30" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_989E8D34C59E3D90DFF39C26438EAF30" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_989E8D34C59E3D90DFF39C26438EAF30" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_5681FFCE901C4B309EF2AE9F922CAE14_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_36C29CC848C450F6854E55400E483B91" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_5681FFCE901C4B309EF2AE9F922CAE14_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_36C29CC848C450F6854E55400E483B91" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_36C29CC848C450F6854E55400E483B91" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_36C29CC848C450F6854E55400E483B91" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_36C29CC848C450F6854E55400E483B91" xlink:type="arc" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>14
<FILENAME>pfe-20171001_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterests" xlink:href="pfe-20171001.xsd#AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterests" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetail" xlink:href="pfe-20171001.xsd#AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsTables" xlink:href="pfe-20171001.xsd#AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestments" xlink:href="pfe-20171001.xsd#AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsAnacorPharmaceuticalsIncDetails" xlink:href="pfe-20171001.xsd#AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsAnacorPharmaceuticalsIncDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsAstrazenecaDetails" xlink:href="pfe-20171001.xsd#AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsAstrazenecaDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsBambooTherapeuticsDetails" xlink:href="pfe-20171001.xsd#AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsBambooTherapeuticsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsCollaborationArrangementDetails" xlink:href="pfe-20171001.xsd#AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsCollaborationArrangementDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsEquityMethodInvestmentsDetails" xlink:href="pfe-20171001.xsd#AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsEquityMethodInvestmentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsMedivationDetails" xlink:href="pfe-20171001.xsd#AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsMedivationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsSaleOfHospiraInfusionSystemsNetAssetsToIcuMedicalIncEhDetails" xlink:href="pfe-20171001.xsd#AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsSaleOfHospiraInfusionSystemsNetAssetsToIcuMedicalIncEhDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPolicies" xlink:href="pfe-20171001.xsd#BasisOfPresentationAndSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetails" xlink:href="pfe-20171001.xsd#BasisOfPresentationAndSignificantAccountingPoliciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies" xlink:href="pfe-20171001.xsd#BasisOfPresentationAndSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/CommitmentsAndContingencies" xlink:href="pfe-20171001.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/CommitmentsAndContingenciesActionsInWhichWeAreDefendantDetail" xlink:href="pfe-20171001.xsd#CommitmentsAndContingenciesActionsInWhichWeAreDefendantDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/CommitmentsAndContingenciesActionsInWhichWeArePlaintiffDetails" xlink:href="pfe-20171001.xsd#CommitmentsAndContingenciesActionsInWhichWeArePlaintiffDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/CommitmentsAndContingenciesDetails" xlink:href="pfe-20171001.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets" xlink:href="pfe-20171001.xsd#CondensedConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:href="pfe-20171001.xsd#CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:href="pfe-20171001.xsd#CondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlowsParenthetical" xlink:href="pfe-20171001.xsd#CondensedConsolidatedStatementsOfCashFlowsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome" xlink:href="pfe-20171001.xsd#CondensedConsolidatedStatementsOfComprehensiveIncome" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeParenthetical" xlink:href="pfe-20171001.xsd#CondensedConsolidatedStatementsOfComprehensiveIncomeParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/CondensedConsolidatedStatementsOfIncome" xlink:href="pfe-20171001.xsd#CondensedConsolidatedStatementsOfIncome" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/DocumentAndEntityInformation" xlink:href="pfe-20171001.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/EarningsPerCommonShareAttributableToCommonShareholders" xlink:href="pfe-20171001.xsd#EarningsPerCommonShareAttributableToCommonShareholders" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/EarningsPerCommonShareAttributableToCommonShareholdersDetails" xlink:href="pfe-20171001.xsd#EarningsPerCommonShareAttributableToCommonShareholdersDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/EarningsPerCommonShareAttributableToCommonShareholdersTables" xlink:href="pfe-20171001.xsd#EarningsPerCommonShareAttributableToCommonShareholdersTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstruments" xlink:href="pfe-20171001.xsd#FinancialInstruments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail" xlink:href="pfe-20171001.xsd#FinancialInstrumentsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsAssetsAndLiabilitiesMeasuredOnRecurringBasisFootnotesDetail" xlink:href="pfe-20171001.xsd#FinancialInstrumentsAssetsAndLiabilitiesMeasuredOnRecurringBasisFootnotesDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsBalanceSheetGroupingDetail" xlink:href="pfe-20171001.xsd#FinancialInstrumentsBalanceSheetGroupingDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsBalanceSheetGroupingFootnotesDetail" xlink:href="pfe-20171001.xsd#FinancialInstrumentsBalanceSheetGroupingFootnotesDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetail" xlink:href="pfe-20171001.xsd#FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsInvestmentsInDebtSecuritiesDetail" xlink:href="pfe-20171001.xsd#FinancialInstrumentsInvestmentsInDebtSecuritiesDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails" xlink:href="pfe-20171001.xsd#FinancialInstrumentsLongTermDebtDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtMaturitiesDetails" xlink:href="pfe-20171001.xsd#FinancialInstrumentsLongTermDebtMaturitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsNarrativeDetail" xlink:href="pfe-20171001.xsd#FinancialInstrumentsNarrativeDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsOtherNoncurrentLiabilitiesDetail" xlink:href="pfe-20171001.xsd#FinancialInstrumentsOtherNoncurrentLiabilitiesDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails" xlink:href="pfe-20171001.xsd#FinancialInstrumentsShortTermBorrowingsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsTables" xlink:href="pfe-20171001.xsd#FinancialInstrumentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwill" xlink:href="pfe-20171001.xsd#IdentifiableIntangibleAssetsAndGoodwill" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsDetail" xlink:href="pfe-20171001.xsd#IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsFootnotesDetails" xlink:href="pfe-20171001.xsd#IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsFootnotesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedIntangibleAssetsPercentageOfTotalIntangiblesDetails" xlink:href="pfe-20171001.xsd#IdentifiableIntangibleAssetsAndGoodwillFiniteLivedIntangibleAssetsPercentageOfTotalIntangiblesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillGoodwillDetail" xlink:href="pfe-20171001.xsd#IdentifiableIntangibleAssetsAndGoodwillGoodwillDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillIndefiniteLivedIntangibleAssetsPercentageOfTotalIntangiblesDetails" xlink:href="pfe-20171001.xsd#IdentifiableIntangibleAssetsAndGoodwillIndefiniteLivedIntangibleAssetsPercentageOfTotalIntangiblesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillNarrativeDetail" xlink:href="pfe-20171001.xsd#IdentifiableIntangibleAssetsAndGoodwillNarrativeDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillTables" xlink:href="pfe-20171001.xsd#IdentifiableIntangibleAssetsAndGoodwillTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/Inventories" xlink:href="pfe-20171001.xsd#Inventories" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/InventoriesDetail" xlink:href="pfe-20171001.xsd#InventoriesDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/InventoriesTables" xlink:href="pfe-20171001.xsd#InventoriesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/OtherIncomeDeductionsNet" xlink:href="pfe-20171001.xsd#OtherIncomeDeductionsNet" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/OtherIncomeDeductionsNetDetail" xlink:href="pfe-20171001.xsd#OtherIncomeDeductionsNetDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail" xlink:href="pfe-20171001.xsd#OtherIncomeDeductionsNetFootnotesDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/OtherIncomeDeductionsNetImpairedIntangibleAssetsDetail" xlink:href="pfe-20171001.xsd#OtherIncomeDeductionsNetImpairedIntangibleAssetsDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/OtherIncomeDeductionsNetTables" xlink:href="pfe-20171001.xsd#OtherIncomeDeductionsNetTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlans" xlink:href="pfe-20171001.xsd#PensionAndPostretirementBenefitPlans" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansDetail" xlink:href="pfe-20171001.xsd#PensionAndPostretirementBenefitPlansDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansNetPeriodicBenefitCostDetail" xlink:href="pfe-20171001.xsd#PensionAndPostretirementBenefitPlansNetPeriodicBenefitCostDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansNetPeriodicBenefitCostFootnotesDetails" xlink:href="pfe-20171001.xsd#PensionAndPostretirementBenefitPlansNetPeriodicBenefitCostFootnotesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansTables" xlink:href="pfe-20171001.xsd#PensionAndPostretirementBenefitPlansTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiatives" xlink:href="pfe-20171001.xsd#RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiatives" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesDetail" xlink:href="pfe-20171001.xsd#RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesFootnotesDetails" xlink:href="pfe-20171001.xsd#RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesFootnotesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesRestructuringAccrualsDetail" xlink:href="pfe-20171001.xsd#RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesRestructuringAccrualsDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesRestructuringAccrualsFootnotesDetail" xlink:href="pfe-20171001.xsd#RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesRestructuringAccrualsFootnotesDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesTables" xlink:href="pfe-20171001.xsd#RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformation" xlink:href="pfe-20171001.xsd#SegmentGeographicAndOtherRevenueInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationDetail" xlink:href="pfe-20171001.xsd#SegmentGeographicAndOtherRevenueInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationFootnotesDetail" xlink:href="pfe-20171001.xsd#SegmentGeographicAndOtherRevenueInformationFootnotesDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationNarrativeDetail" xlink:href="pfe-20171001.xsd#SegmentGeographicAndOtherRevenueInformationNarrativeDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByGeographicAreaDetail" xlink:href="pfe-20171001.xsd#SegmentGeographicAndOtherRevenueInformationRevenuesByGeographicAreaDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByGeographicAreaFootnotesDetail" xlink:href="pfe-20171001.xsd#SegmentGeographicAndOtherRevenueInformationRevenuesByGeographicAreaFootnotesDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail" xlink:href="pfe-20171001.xsd#SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationTables" xlink:href="pfe-20171001.xsd#SegmentGeographicAndOtherRevenueInformationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/TaxMatters" xlink:href="pfe-20171001.xsd#TaxMatters" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/TaxMattersDetail" xlink:href="pfe-20171001.xsd#TaxMattersDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/TaxMattersNarrativeDetail" xlink:href="pfe-20171001.xsd#TaxMattersNarrativeDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/TaxMattersTables" xlink:href="pfe-20171001.xsd#TaxMattersTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:presentationLink xlink:role="http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterests" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_255CE2A4DF9F58F88E4E5771CB165BA0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_11FF3BE2048E5C799A05FA7760FA3807" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_255CE2A4DF9F58F88E4E5771CB165BA0" xlink:to="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_11FF3BE2048E5C799A05FA7760FA3807" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_DF4B4B8599DFF0F52F037446A1919801" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_D98A3BC99F189331103B7446A1940881" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_DF4B4B8599DFF0F52F037446A1919801" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_D98A3BC99F189331103B7446A1940881" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_15D38E7BD92704AE7C437446A19536D1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_D98A3BC99F189331103B7446A1940881" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_15D38E7BD92704AE7C437446A19536D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_B30B78A65E407728C5897446A195B4C5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_15D38E7BD92704AE7C437446A19536D1" xlink:to="loc_us-gaap_EquityComponentDomain_B30B78A65E407728C5897446A195B4C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_244C01AC044E0C65C6417446A1964989" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_B30B78A65E407728C5897446A195B4C5" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_244C01AC044E0C65C6417446A1964989" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_68298F86A77E69BA3A157446A196F407" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_244C01AC044E0C65C6417446A1964989" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_68298F86A77E69BA3A157446A196F407" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" xlink:label="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_9A40968A55C8B973A7CD7446A19614BD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_244C01AC044E0C65C6417446A1964989" xlink:to="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_9A40968A55C8B973A7CD7446A19614BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_32BF5C20461D335F5D387446A196D3F1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_244C01AC044E0C65C6417446A1964989" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_32BF5C20461D335F5D387446A196D3F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember_46183F99B4CE69FF3C7C7446A1966499" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_244C01AC044E0C65C6417446A1964989" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember_46183F99B4CE69FF3C7C7446A1966499" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember_8F3AD7B28F179F726DEA7446A196DED9" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_244C01AC044E0C65C6417446A1964989" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember_8F3AD7B28F179F726DEA7446A196DED9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_61F6C75527919523A7F47446A197C3CA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_D98A3BC99F189331103B7446A1940881" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_61F6C75527919523A7F47446A197C3CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:label="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_2D5308AC1E300A59F7A77446A1979E15" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_61F6C75527919523A7F47446A197C3CA" xlink:to="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_2D5308AC1E300A59F7A77446A1979E15" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_8C616BCBB3D4FF09F1497446A1973693" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_2D5308AC1E300A59F7A77446A1979E15" xlink:to="loc_us-gaap_StockholdersEquity_8C616BCBB3D4FF09F1497446A1973693" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_1A4BF9F0FFC5C577DB6A7446A1977450" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_2D5308AC1E300A59F7A77446A1979E15" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_1A4BF9F0FFC5C577DB6A7446A1977450" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_BEBB901AAEC7E178B0D27446A19747EA" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_2D5308AC1E300A59F7A77446A1979E15" xlink:to="loc_us-gaap_StockholdersEquity_BEBB901AAEC7E178B0D27446A19747EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToNoncontrollingInterest_D91DB8C069C4B1865E367446A1972A4C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_61F6C75527919523A7F47446A197C3CA" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToNoncontrollingInterest_D91DB8C069C4B1865E367446A1972A4C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths" xlink:label="loc_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths_74EDC3A7DF1D9815AD147446A1979B07" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_61F6C75527919523A7F47446A197C3CA" xlink:to="loc_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths_74EDC3A7DF1D9815AD147446A1979B07" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_ADD7FBB2A0195C59A6D8AE40E05047EA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_DF44E3A1D73F52039D1E12FC094C257F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_ADD7FBB2A0195C59A6D8AE40E05047EA" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_DF44E3A1D73F52039D1E12FC094C257F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestments" xlink:type="extended">
    <link:loc xlink:href="pfe-20171001.xsd#pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract" xlink:label="loc_pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract_DD074B2B7C4651FAA72AD008803D16D6" xlink:type="locator" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsCollaborativeArrangementsEquityandCostMethodInvestmentsDisclosureTextBlock" xlink:label="loc_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsCollaborativeArrangementsEquityandCostMethodInvestmentsDisclosureTextBlock_5BA7420DC8D15D10BECC32BC82E2E943" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract_DD074B2B7C4651FAA72AD008803D16D6" xlink:to="loc_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsCollaborativeArrangementsEquityandCostMethodInvestmentsDisclosureTextBlock_5BA7420DC8D15D10BECC32BC82E2E943" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsAnacorPharmaceuticalsIncDetails" xlink:type="extended">
    <link:loc xlink:href="pfe-20171001.xsd#pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract" xlink:label="loc_pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract_EE6FACA4E7E3526385DF6D0623F4284B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_F3D34B5FD15C513A8DA749041A49D470" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract_EE6FACA4E7E3526385DF6D0623F4284B" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_F3D34B5FD15C513A8DA749041A49D470" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_12B0D8D151C55A838BF715A6254A0C7A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_F3D34B5FD15C513A8DA749041A49D470" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_12B0D8D151C55A838BF715A6254A0C7A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_537E7C2E29EE5023B93E63CEDBD01877" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_12B0D8D151C55A838BF715A6254A0C7A" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_537E7C2E29EE5023B93E63CEDBD01877" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_AnacorMember" xlink:label="loc_pfe_AnacorMember_31ED3D13BB6C530386BB6CEA31CC95CB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_537E7C2E29EE5023B93E63CEDBD01877" xlink:to="loc_pfe_AnacorMember_31ED3D13BB6C530386BB6CEA31CC95CB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_52D01AB8EBAF579E92CBB030216C21A9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_F3D34B5FD15C513A8DA749041A49D470" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_52D01AB8EBAF579E92CBB030216C21A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_578AE2F0084957D29EFF355DBF2BA981" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_52D01AB8EBAF579E92CBB030216C21A9" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_578AE2F0084957D29EFF355DBF2BA981" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_9AEB86AF48FC56E6AC99C2D23C4F19F9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_578AE2F0084957D29EFF355DBF2BA981" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_9AEB86AF48FC56E6AC99C2D23C4F19F9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_1F98119F340F50028EB96C87310341C4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_F3D34B5FD15C513A8DA749041A49D470" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_1F98119F340F50028EB96C87310341C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_7D0718E45EE15B60A55649A6EC0131F9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1F98119F340F50028EB96C87310341C4" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_7D0718E45EE15B60A55649A6EC0131F9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_530CF42E5251557BBEB51D0F59601D95" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1F98119F340F50028EB96C87310341C4" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_530CF42E5251557BBEB51D0F59601D95" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_67275C04C8CF595BBFDAF9C71B077DDC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1F98119F340F50028EB96C87310341C4" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_67275C04C8CF595BBFDAF9C71B077DDC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_503CB5B33AEF5300914E6A2669BA891F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1F98119F340F50028EB96C87310341C4" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_503CB5B33AEF5300914E6A2669BA891F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_C3AA5110EEA45F82A408215AEB065640" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1F98119F340F50028EB96C87310341C4" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_C3AA5110EEA45F82A408215AEB065640" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_E8386BEFA9FA553AB8044BE4E66FD881" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1F98119F340F50028EB96C87310341C4" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_E8386BEFA9FA553AB8044BE4E66FD881" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_812B52E212BC5EC79F5C6B5BD4050E5E" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1F98119F340F50028EB96C87310341C4" xlink:to="loc_us-gaap_Goodwill_812B52E212BC5EC79F5C6B5BD4050E5E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_1067EF6A4A4B58E4A71623EC5EFBF08F" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1F98119F340F50028EB96C87310341C4" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_1067EF6A4A4B58E4A71623EC5EFBF08F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsAstrazenecaDetails" xlink:type="extended">
    <link:loc xlink:href="pfe-20171001.xsd#pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract" xlink:label="loc_pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract_B8D7881211453D3D9D9F9C26438C1861" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0F047C68B12BD1879CA79C26438C31C7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract_B8D7881211453D3D9D9F9C26438C1861" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0F047C68B12BD1879CA79C26438C31C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_D837182BDAE52C1633EE9C26438CF9EA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0F047C68B12BD1879CA79C26438C31C7" xlink:to="loc_us-gaap_StatementScenarioAxis_D837182BDAE52C1633EE9C26438CF9EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_391F33FA0B28885AA9439C26438DEB35" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementScenarioAxis_D837182BDAE52C1633EE9C26438CF9EA" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_391F33FA0B28885AA9439C26438DEB35" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioForecastMember" xlink:label="loc_us-gaap_ScenarioForecastMember_9A0C8FB1E272A7BF7E019C26438D6335" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_391F33FA0B28885AA9439C26438DEB35" xlink:to="loc_us-gaap_ScenarioForecastMember_9A0C8FB1E272A7BF7E019C26438D6335" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_778C197B2D2C3F2BBA2C9C26438D34F1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0F047C68B12BD1879CA79C26438C31C7" xlink:to="loc_us-gaap_RangeAxis_778C197B2D2C3F2BBA2C9C26438D34F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_9C6FE024805EC22A90A89C26438DDBE3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_778C197B2D2C3F2BBA2C9C26438D34F1" xlink:to="loc_us-gaap_RangeMember_9C6FE024805EC22A90A89C26438DDBE3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_FFE6EAA4C9A94E283E659C26438DAC25" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_9C6FE024805EC22A90A89C26438DDBE3" xlink:to="loc_us-gaap_MinimumMember_FFE6EAA4C9A94E283E659C26438DAC25" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_1519684DFD1B6D7A664A9C26438D793B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_9C6FE024805EC22A90A89C26438DDBE3" xlink:to="loc_us-gaap_MaximumMember_1519684DFD1B6D7A664A9C26438D793B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6E3AA90739EB1F172E419C26438D48E4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0F047C68B12BD1879CA79C26438C31C7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6E3AA90739EB1F172E419C26438D48E4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_62B60025539B43A4698A9C26438DDCAA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6E3AA90739EB1F172E419C26438D48E4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_62B60025539B43A4698A9C26438DDCAA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_720D8DE4795A03A9269B9C26438D5B1C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_62B60025539B43A4698A9C26438DDCAA" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_720D8DE4795A03A9269B9C26438D5B1C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_CD056FE46311189717289C26438DD314" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0F047C68B12BD1879CA79C26438C31C7" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_CD056FE46311189717289C26438DD314" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_6EC2EC19F57021A4D0B69C26438DE24D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_CD056FE46311189717289C26438DD314" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_6EC2EC19F57021A4D0B69C26438DE24D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_7E80A0C5AA7B1F9B9CAA9C26438DD5A6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_6EC2EC19F57021A4D0B69C26438DE24D" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_7E80A0C5AA7B1F9B9CAA9C26438DD5A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_75D9F0FDF04DB4C8FA069C26438D0D44" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0F047C68B12BD1879CA79C26438C31C7" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_75D9F0FDF04DB4C8FA069C26438D0D44" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7910038FD8FF3B1760D99C26438D5F3C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_75D9F0FDF04DB4C8FA069C26438D0D44" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7910038FD8FF3B1760D99C26438D5F3C" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_AstraZenecaMember" xlink:label="loc_pfe_AstraZenecaMember_18C9839497F71223222B9C26438D2C8F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7910038FD8FF3B1760D99C26438D5F3C" xlink:to="loc_pfe_AstraZenecaMember_18C9839497F71223222B9C26438D2C8F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_7163E1E0A807AA91B9E59C26438DEE2B" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0F047C68B12BD1879CA79C26438C31C7" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_7163E1E0A807AA91B9E59C26438DEE2B" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_PaymentstoAcquireBusinessesGrossInitialPayment" xlink:label="loc_pfe_PaymentstoAcquireBusinessesGrossInitialPayment_31C15AA6EC50462279CC9C26438E796F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7163E1E0A807AA91B9E59C26438DEE2B" xlink:to="loc_pfe_PaymentstoAcquireBusinessesGrossInitialPayment_31C15AA6EC50462279CC9C26438E796F" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_PaymentstoAcquireBusinessesGrossPurchasePriceAdjustment" xlink:label="loc_pfe_PaymentstoAcquireBusinessesGrossPurchasePriceAdjustment_8FD878AEBAEE909C72C19C26438E1AC9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7163E1E0A807AA91B9E59C26438DEE2B" xlink:to="loc_pfe_PaymentstoAcquireBusinessesGrossPurchasePriceAdjustment_8FD878AEBAEE909C72C19C26438E1AC9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities_854B8F1CED12D0FAF8719C26438ECDA9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7163E1E0A807AA91B9E59C26438DEE2B" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities_854B8F1CED12D0FAF8719C26438ECDA9" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_BusinessCombinationConsiderationTransferredDeferredPayment" xlink:label="loc_pfe_BusinessCombinationConsiderationTransferredDeferredPayment_302719788EFA43C18D8D9C26438E5745" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7163E1E0A807AA91B9E59C26438DEE2B" xlink:to="loc_pfe_BusinessCombinationConsiderationTransferredDeferredPayment_302719788EFA43C18D8D9C26438E5745" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_BusinessCombinationConsiderationTransferredMilestonePaymentsMaximum" xlink:label="loc_pfe_BusinessCombinationConsiderationTransferredMilestonePaymentsMaximum_98799FF8F157810099439C26438E622F" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7163E1E0A807AA91B9E59C26438DEE2B" xlink:to="loc_pfe_BusinessCombinationConsiderationTransferredMilestonePaymentsMaximum_98799FF8F157810099439C26438E622F" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_BusinessCombinationConsiderationTransferredSalesrelatedPaymentsMaximum" xlink:label="loc_pfe_BusinessCombinationConsiderationTransferredSalesrelatedPaymentsMaximum_4F00A539CF613684EB529C26438EA50D" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7163E1E0A807AA91B9E59C26438DEE2B" xlink:to="loc_pfe_BusinessCombinationConsiderationTransferredSalesrelatedPaymentsMaximum_4F00A539CF613684EB529C26438EA50D" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_BusinessCombinationConsiderationTransferredUndiscountedRoyaltyPaymentsTerm" xlink:label="loc_pfe_BusinessCombinationConsiderationTransferredUndiscountedRoyaltyPaymentsTerm_1010B88A0E62C1A4F0FF9C26438E9C0D" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7163E1E0A807AA91B9E59C26438DEE2B" xlink:to="loc_pfe_BusinessCombinationConsiderationTransferredUndiscountedRoyaltyPaymentsTerm_1010B88A0E62C1A4F0FF9C26438E9C0D" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_BusinessCombinationConsiderationTransferredUndiscountedRoyaltyPayments" xlink:label="loc_pfe_BusinessCombinationConsiderationTransferredUndiscountedRoyaltyPayments_2C907DDC618C4151095F9C26438E178F" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7163E1E0A807AA91B9E59C26438DEE2B" xlink:to="loc_pfe_BusinessCombinationConsiderationTransferredUndiscountedRoyaltyPayments_2C907DDC618C4151095F9C26438E178F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_854ED5294AE38DC5D9389C26438E3009" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7163E1E0A807AA91B9E59C26438DEE2B" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_854ED5294AE38DC5D9389C26438E3009" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_0EDC9679A0BFC6EFA90B9C26438ED136" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7163E1E0A807AA91B9E59C26438DEE2B" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_0EDC9679A0BFC6EFA90B9C26438ED136" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_6BA14089CB685427E1879C26438E9D8B" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7163E1E0A807AA91B9E59C26438DEE2B" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_6BA14089CB685427E1879C26438E9D8B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_DA5F83D33317A66259D99C26438E7E37" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7163E1E0A807AA91B9E59C26438DEE2B" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_DA5F83D33317A66259D99C26438E7E37" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_989E8D34C59E3D90DFF39C26438EAF30" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7163E1E0A807AA91B9E59C26438DEE2B" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_989E8D34C59E3D90DFF39C26438EAF30" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_F2536360DE835DB18D349C26438EED82" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7163E1E0A807AA91B9E59C26438DEE2B" xlink:to="loc_us-gaap_Goodwill_F2536360DE835DB18D349C26438EED82" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_F338CA99301B7198479E9C26438E3D99" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7163E1E0A807AA91B9E59C26438DEE2B" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_F338CA99301B7198479E9C26438E3D99" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsBambooTherapeuticsDetails" xlink:type="extended">
    <link:loc xlink:href="pfe-20171001.xsd#pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract" xlink:label="loc_pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract_1E313A5BEE629C8E11AB5A4F9EC35F27" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0916E06DFE4E727C23A85A4F9EC379BA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract_1E313A5BEE629C8E11AB5A4F9EC35F27" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0916E06DFE4E727C23A85A4F9EC379BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_8774CB76A362549C82795A4F9EC3E078" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0916E06DFE4E727C23A85A4F9EC379BA" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_8774CB76A362549C82795A4F9EC3E078" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_4DF437891E5D59D482DB5A4F9EC3F440" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_8774CB76A362549C82795A4F9EC3E078" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_4DF437891E5D59D482DB5A4F9EC3F440" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_9E84B8A4DDEE201F16DC5A4F9EC3CF03" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_4DF437891E5D59D482DB5A4F9EC3F440" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_9E84B8A4DDEE201F16DC5A4F9EC3CF03" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_3EA5C04CC58AEA01A5845A4F9EC30C9A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0916E06DFE4E727C23A85A4F9EC379BA" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_3EA5C04CC58AEA01A5845A4F9EC30C9A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_4B3FA1EB632BEAD704B15A4F9EC389B4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_3EA5C04CC58AEA01A5845A4F9EC30C9A" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_4B3FA1EB632BEAD704B15A4F9EC389B4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_6E76FDC5D44182494AC25A4F9EC3B1CB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_4B3FA1EB632BEAD704B15A4F9EC389B4" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_6E76FDC5D44182494AC25A4F9EC3B1CB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_A8113B07B6D11911BCF15A4F9EC3CE93" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0916E06DFE4E727C23A85A4F9EC379BA" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_A8113B07B6D11911BCF15A4F9EC3CE93" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_C108FB0D01672E725D725A4F9EC320A2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_A8113B07B6D11911BCF15A4F9EC3CE93" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_C108FB0D01672E725D725A4F9EC320A2" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_BambooTherapeuticsMember" xlink:label="loc_pfe_BambooTherapeuticsMember_86FF1FE02743DD78F6255A4F9EC3D861" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_C108FB0D01672E725D725A4F9EC320A2" xlink:to="loc_pfe_BambooTherapeuticsMember_86FF1FE02743DD78F6255A4F9EC3D861" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_836BF1F01B7F112700755A4F9EC3F7C0" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0916E06DFE4E727C23A85A4F9EC379BA" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_836BF1F01B7F112700755A4F9EC3F7C0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_40A6071BDE7D9D991DC85A4F9EC430BC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_836BF1F01B7F112700755A4F9EC3F7C0" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_40A6071BDE7D9D991DC85A4F9EC430BC" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_BusinessCombinationConsiderationTransferredMilestonePaymentsMaximum" xlink:label="loc_pfe_BusinessCombinationConsiderationTransferredMilestonePaymentsMaximum_DA5F81EFDCF50B9331BF5A4F9EC4EE03" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_836BF1F01B7F112700755A4F9EC3F7C0" xlink:to="loc_pfe_BusinessCombinationConsiderationTransferredMilestonePaymentsMaximum_DA5F81EFDCF50B9331BF5A4F9EC4EE03" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1_901FE66BCF82197792D75A4F9EC43936" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_836BF1F01B7F112700755A4F9EC3F7C0" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1_901FE66BCF82197792D75A4F9EC43936" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_C8249169E4D4BABE7A6F5A4F9EC4EE70" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_836BF1F01B7F112700755A4F9EC3F7C0" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_C8249169E4D4BABE7A6F5A4F9EC4EE70" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_2C448FE2FB6ABBB5D9665A4F9EC4F04C" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_836BF1F01B7F112700755A4F9EC3F7C0" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_2C448FE2FB6ABBB5D9665A4F9EC4F04C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_7E9A807808AE9DEF0DDB5A4F9EC4E913" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_836BF1F01B7F112700755A4F9EC3F7C0" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_7E9A807808AE9DEF0DDB5A4F9EC4E913" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_2D521555D25F2E09BFA05A4F9EC42AE4" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_836BF1F01B7F112700755A4F9EC3F7C0" xlink:to="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_2D521555D25F2E09BFA05A4F9EC42AE4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain_EC32B307C5744C3295805A4F9EC47108" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_836BF1F01B7F112700755A4F9EC3F7C0" xlink:to="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain_EC32B307C5744C3295805A4F9EC47108" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_9906617BB94929A4C1EE5A4F9EC42451" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_836BF1F01B7F112700755A4F9EC3F7C0" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_9906617BB94929A4C1EE5A4F9EC42451" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_B766946BF592CD04F37E5A4F9EC4B099" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_836BF1F01B7F112700755A4F9EC3F7C0" xlink:to="loc_us-gaap_Goodwill_B766946BF592CD04F37E5A4F9EC4B099" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_38D1EE8E07E7AE32FD1D5A4F9EC47F16" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_836BF1F01B7F112700755A4F9EC3F7C0" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_38D1EE8E07E7AE32FD1D5A4F9EC47F16" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsCollaborationArrangementDetails" xlink:type="extended">
    <link:loc xlink:href="pfe-20171001.xsd#pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract" xlink:label="loc_pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract_E7E85BF647AE5A4C997406C7794B46BB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_EC89331E05695A38973ED4022AB2196A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract_E7E85BF647AE5A4C997406C7794B46BB" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_EC89331E05695A38973ED4022AB2196A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_B0A69C44D49D5AB4B42211CD22C75E44" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_EC89331E05695A38973ED4022AB2196A" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_B0A69C44D49D5AB4B42211CD22C75E44" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_883E9CBCAD6C51968B046D153B80E3B8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_B0A69C44D49D5AB4B42211CD22C75E44" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_883E9CBCAD6C51968B046D153B80E3B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_7810ADBEECFC5A8C936DE51C87F68A6F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_883E9CBCAD6C51968B046D153B80E3B8" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_7810ADBEECFC5A8C936DE51C87F68A6F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="loc_us-gaap_CounterpartyNameAxis_E55C9EAE15B45F32A99049FF3CB3645E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_EC89331E05695A38973ED4022AB2196A" xlink:to="loc_us-gaap_CounterpartyNameAxis_E55C9EAE15B45F32A99049FF3CB3645E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_87E445B19A5C5A938FCF7D2FDAD4CAFF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CounterpartyNameAxis_E55C9EAE15B45F32A99049FF3CB3645E" xlink:to="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_87E445B19A5C5A938FCF7D2FDAD4CAFF" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_MerckKGaAMember" xlink:label="loc_pfe_MerckKGaAMember_E51F38A986FA5F51BCA366F221D83905" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_87E445B19A5C5A938FCF7D2FDAD4CAFF" xlink:to="loc_pfe_MerckKGaAMember_E51F38A986FA5F51BCA366F221D83905" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_A002382DF0945C958DF2EF3AA6BF1041" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_EC89331E05695A38973ED4022AB2196A" xlink:to="loc_us-gaap_TypeOfArrangementAxis_A002382DF0945C958DF2EF3AA6BF1041" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6362259A964D5829BDD1004C6A05C81D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_A002382DF0945C958DF2EF3AA6BF1041" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6362259A964D5829BDD1004C6A05C81D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="loc_us-gaap_CollaborativeArrangementMember_4AEA76069BEE562EB977746F9C1E22DB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6362259A964D5829BDD1004C6A05C81D" xlink:to="loc_us-gaap_CollaborativeArrangementMember_4AEA76069BEE562EB977746F9C1E22DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_10B877F410CE54A19F50694268EBEE36" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_EC89331E05695A38973ED4022AB2196A" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_10B877F410CE54A19F50694268EBEE36" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromCollaborators" xlink:label="loc_us-gaap_ProceedsFromCollaborators_C0B071DD1B8B5DF584A61B4CA682BEF1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_10B877F410CE54A19F50694268EBEE36" xlink:to="loc_us-gaap_ProceedsFromCollaborators_C0B071DD1B8B5DF584A61B4CA682BEF1" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_CollaborativeArrangementCollaboratorsRevenueandExpenseOwnershipPercentage" xlink:label="loc_pfe_CollaborativeArrangementCollaboratorsRevenueandExpenseOwnershipPercentage_AD6C963FD5DC5C179BF61145AFC1C305" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_10B877F410CE54A19F50694268EBEE36" xlink:to="loc_pfe_CollaborativeArrangementCollaboratorsRevenueandExpenseOwnershipPercentage_AD6C963FD5DC5C179BF61145AFC1C305" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_CollaborativeArrangementCompanysRevenueandExpenseOwnershipPercentage" xlink:label="loc_pfe_CollaborativeArrangementCompanysRevenueandExpenseOwnershipPercentage_2323A02A058E5BACB0EC0C8ACBB2F7D4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_10B877F410CE54A19F50694268EBEE36" xlink:to="loc_pfe_CollaborativeArrangementCompanysRevenueandExpenseOwnershipPercentage_2323A02A058E5BACB0EC0C8ACBB2F7D4" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsEquityMethodInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:href="pfe-20171001.xsd#pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract" xlink:label="loc_pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract_00EF738D542EDF4DC8AC50828D6A973C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_592CD31D09785B96B30450828D6A104B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract_00EF738D542EDF4DC8AC50828D6A973C" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_592CD31D09785B96B30450828D6A104B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_C7CDF88D8045CD6AA76950828D6AFFE1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_592CD31D09785B96B30450828D6A104B" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_C7CDF88D8045CD6AA76950828D6AFFE1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvesteeNameDomain" xlink:label="loc_us-gaap_EquityMethodInvesteeNameDomain_A0E07FB95D458FE2D72E50828D6AC26E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_C7CDF88D8045CD6AA76950828D6AFFE1" xlink:to="loc_us-gaap_EquityMethodInvesteeNameDomain_A0E07FB95D458FE2D72E50828D6AC26E" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_HisunPfizerPharmaceuticalsCoLtdMember" xlink:label="loc_pfe_HisunPfizerPharmaceuticalsCoLtdMember_FD66367D1E1AF8FC8E5650828D6A5825" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvesteeNameDomain_A0E07FB95D458FE2D72E50828D6AC26E" xlink:to="loc_pfe_HisunPfizerPharmaceuticalsCoLtdMember_FD66367D1E1AF8FC8E5650828D6A5825" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_LaboratorioTeutoBrasileroMember" xlink:label="loc_pfe_LaboratorioTeutoBrasileroMember_CEF44FE47CD3EA662A6150828D6BBDD0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvesteeNameDomain_A0E07FB95D458FE2D72E50828D6AC26E" xlink:to="loc_pfe_LaboratorioTeutoBrasileroMember_CEF44FE47CD3EA662A6150828D6BBDD0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_BEB99CB0A0549BEFC9EE50828D6B6ECF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_592CD31D09785B96B30450828D6A104B" xlink:to="loc_dei_LegalEntityAxis_BEB99CB0A0549BEFC9EE50828D6B6ECF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_29D0FA5E31B3100960E650828D6B84B0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_BEB99CB0A0549BEFC9EE50828D6B6ECF" xlink:to="loc_dei_EntityDomain_29D0FA5E31B3100960E650828D6B84B0" xlink:type="arc" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_29D0FA5E31B3100960E650828D6B84B0" xlink:to="loc_pfe_LaboratorioTeutoBrasileroMember_CEF44FE47CD3EA662A6150828D6BBDD0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_7D4D0695C7AE526E491A50828D6B8718" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_592CD31D09785B96B30450828D6A104B" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_7D4D0695C7AE526E491A50828D6B8718" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_A665EAE9A1079FBA2BDE50828D6B75F3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_7D4D0695C7AE526E491A50828D6B8718" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_A665EAE9A1079FBA2BDE50828D6B75F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_E012D118276871E039B550828D6BDA0F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_A665EAE9A1079FBA2BDE50828D6B75F3" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_E012D118276871E039B550828D6BDA0F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_D7C47CB5089866E156A450828D6B08BF" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_592CD31D09785B96B30450828D6A104B" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_D7C47CB5089866E156A450828D6B08BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_DE5BB3EB45BFBCA3EFED50828D6B800F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_D7C47CB5089866E156A450828D6B08BF" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_DE5BB3EB45BFBCA3EFED50828D6B800F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment" xlink:label="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_C924361E59A4E4218F6350828D6CC5C4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_D7C47CB5089866E156A450828D6B08BF" xlink:to="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_C924361E59A4E4218F6350828D6CC5C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:label="loc_us-gaap_EquityMethodInvestments_BC1259064AA82F921CE850828D6C694F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_D7C47CB5089866E156A450828D6B08BF" xlink:to="loc_us-gaap_EquityMethodInvestments_BC1259064AA82F921CE850828D6C694F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_C54AE19C698E666403AB50828D6C83A0" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_D7C47CB5089866E156A450828D6B08BF" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_C54AE19C698E666403AB50828D6C83A0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal" xlink:label="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_346FE7B391A5044F414950828D6C0207" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_D7C47CB5089866E156A450828D6B08BF" xlink:to="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_346FE7B391A5044F414950828D6C0207" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsMedivationDetails" xlink:type="extended">
    <link:loc xlink:href="pfe-20171001.xsd#pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract" xlink:label="loc_pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract_D26209BBEA80FBE4411791EBE155F018" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_237D460DAD574C1EECFD91EBE155C1A9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract_D26209BBEA80FBE4411791EBE155F018" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_237D460DAD574C1EECFD91EBE155C1A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_04052F71CF663ADC607091EBE155CFB2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_237D460DAD574C1EECFD91EBE155C1A9" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_04052F71CF663ADC607091EBE155CFB2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_A55D274BC0F8DD79E70E91EBE1556401" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_04052F71CF663ADC607091EBE155CFB2" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_A55D274BC0F8DD79E70E91EBE1556401" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_MedivationMember" xlink:label="loc_pfe_MedivationMember_9C3E86480097C6D9EFB791EBE156AAE6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_A55D274BC0F8DD79E70E91EBE1556401" xlink:to="loc_pfe_MedivationMember_9C3E86480097C6D9EFB791EBE156AAE6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_084A605F3340A0EF534291EBE156DE44" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_237D460DAD574C1EECFD91EBE155C1A9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_084A605F3340A0EF534291EBE156DE44" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_13C9D543E3EF79D8D15E91EBE156BC41" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_084A605F3340A0EF534291EBE156DE44" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_13C9D543E3EF79D8D15E91EBE156BC41" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_BD1FB8B55C172387B01A91EBE156DE7F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_13C9D543E3EF79D8D15E91EBE156BC41" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_BD1FB8B55C172387B01A91EBE156DE7F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_85B6EEF5A1C1691A286391EBE156C3A6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_237D460DAD574C1EECFD91EBE155C1A9" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_85B6EEF5A1C1691A286391EBE156C3A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_0A8E9DFFC379C4E7B48F91EBE1575359" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_85B6EEF5A1C1691A286391EBE156C3A6" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_0A8E9DFFC379C4E7B48F91EBE1575359" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_159F313A568C6BB1AC1391EBE157BF69" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_0A8E9DFFC379C4E7B48F91EBE1575359" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_159F313A568C6BB1AC1391EBE157BF69" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_D31B05A8BBB414F4A55D91EBE157106D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_237D460DAD574C1EECFD91EBE155C1A9" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_D31B05A8BBB414F4A55D91EBE157106D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_3FE543426C5156B53CD291EBE1578F40" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_D31B05A8BBB414F4A55D91EBE157106D" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_3FE543426C5156B53CD291EBE1578F40" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_B4CEF0692237DD8CAC8F91EBE1577894" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_D31B05A8BBB414F4A55D91EBE157106D" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_B4CEF0692237DD8CAC8F91EBE1577894" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_BusinessCombinationConsiderationTransferredNetofCashAcquired" xlink:label="loc_pfe_BusinessCombinationConsiderationTransferredNetofCashAcquired_9059B1BB75588548758E91EBE158E326" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_D31B05A8BBB414F4A55D91EBE157106D" xlink:to="loc_pfe_BusinessCombinationConsiderationTransferredNetofCashAcquired_9059B1BB75588548758E91EBE158E326" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_BusinessCombinationConsiderationTransferredAmountPayable" xlink:label="loc_pfe_BusinessCombinationConsiderationTransferredAmountPayable_160FB04D50237C5B28F791EBE158C168" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_D31B05A8BBB414F4A55D91EBE157106D" xlink:to="loc_pfe_BusinessCombinationConsiderationTransferredAmountPayable_160FB04D50237C5B28F791EBE158C168" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_B705294105545A8BB7C791EBE1584757" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_D31B05A8BBB414F4A55D91EBE157106D" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_B705294105545A8BB7C791EBE1584757" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_20D8491483ADAE1CD65291EBE158E989" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_D31B05A8BBB414F4A55D91EBE157106D" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_20D8491483ADAE1CD65291EBE158E989" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_E15390B7E7F614B4BA8A91EBE158F034" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_D31B05A8BBB414F4A55D91EBE157106D" xlink:to="loc_us-gaap_Goodwill_E15390B7E7F614B4BA8A91EBE158F034" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_17555EFBCB4BB15CB14991EBE158C8FE" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_D31B05A8BBB414F4A55D91EBE157106D" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_17555EFBCB4BB15CB14991EBE158C8FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_9846125E47FEA7AFF61291EBE158DCB9" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_D31B05A8BBB414F4A55D91EBE157106D" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_9846125E47FEA7AFF61291EBE158DCB9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles" xlink:label="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles_313884EB97AC930DA83091EBE1591060" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_D31B05A8BBB414F4A55D91EBE157106D" xlink:to="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles_313884EB97AC930DA83091EBE1591060" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIncreaseDecreaseinAmortizationofIntangibleAssets" xlink:label="loc_pfe_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIncreaseDecreaseinAmortizationofIntangibleAssets_E3EDB9081DDD762CC33D91EBE15962B9" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_D31B05A8BBB414F4A55D91EBE157106D" xlink:to="loc_pfe_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIncreaseDecreaseinAmortizationofIntangibleAssets_E3EDB9081DDD762CC33D91EBE15962B9" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsSaleOfHospiraInfusionSystemsNetAssetsToIcuMedicalIncEhDetails" xlink:type="extended">
    <link:loc xlink:href="pfe-20171001.xsd#pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract" xlink:label="loc_pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract_738C0C1420D1D3E23C899C89048A6AC4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5A8E4144DD81D17333969C89048BF582" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract_738C0C1420D1D3E23C899C89048A6AC4" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5A8E4144DD81D17333969C89048BF582" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaap_VariableRateAxis_63203E0DF31EEE0A25BC9C89048BBA75" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5A8E4144DD81D17333969C89048BF582" xlink:to="loc_us-gaap_VariableRateAxis_63203E0DF31EEE0A25BC9C89048BBA75" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_1927AB3144C1477F92119C89048B0235" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_63203E0DF31EEE0A25BC9C89048BBA75" xlink:to="loc_us-gaap_VariableRateDomain_1927AB3144C1477F92119C89048B0235" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_4377669E37C05573A56C9C89048BDDC5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_1927AB3144C1477F92119C89048B0235" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_4377669E37C05573A56C9C89048BDDC5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_D98266D382CE60CC9E899C89048B3D8A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5A8E4144DD81D17333969C89048BF582" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_D98266D382CE60CC9E899C89048B3D8A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_78712D984847674C928F9C89048BEEFE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_D98266D382CE60CC9E899C89048B3D8A" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_78712D984847674C928F9C89048BEEFE" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_HISMember" xlink:label="loc_pfe_HISMember_30293864854FE82E9ED59C89048C0869" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_78712D984847674C928F9C89048BEEFE" xlink:to="loc_pfe_HISMember_30293864854FE82E9ED59C89048C0869" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupClassificationAxis" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_63A5825036C27A4B5C799C89048C9158" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5A8E4144DD81D17333969C89048BF582" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_63A5825036C27A4B5C799C89048C9158" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_0124E2B1DB01A121B1D69C89048C9EBC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_63A5825036C27A4B5C799C89048C9158" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_0124E2B1DB01A121B1D69C89048C9EBC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_33082C7AE080085A39679C89048CE7B0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_0124E2B1DB01A121B1D69C89048C9EBC" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_33082C7AE080085A39679C89048CE7B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="loc_us-gaap_CounterpartyNameAxis_C8C480856DC659AEA4B49C89048C77F3" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5A8E4144DD81D17333969C89048BF582" xlink:to="loc_us-gaap_CounterpartyNameAxis_C8C480856DC659AEA4B49C89048C77F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_81D1DABD1DF6F5798BCE9C89048CDCC8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CounterpartyNameAxis_C8C480856DC659AEA4B49C89048C77F3" xlink:to="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_81D1DABD1DF6F5798BCE9C89048CDCC8" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_ICUMedicalMember" xlink:label="loc_pfe_ICUMedicalMember_83C66512139F3A5207539C89048C2457" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_81D1DABD1DF6F5798BCE9C89048CDCC8" xlink:to="loc_pfe_ICUMedicalMember_83C66512139F3A5207539C89048C2457" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_A5D63ACA983B2026A7459C89048D58E8" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5A8E4144DD81D17333969C89048BF582" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_A5D63ACA983B2026A7459C89048D58E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_4543AF01DA18FC5C60599C89048DA29A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_A5D63ACA983B2026A7459C89048D58E8" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_4543AF01DA18FC5C60599C89048DA29A" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationTransferredEquityInterestsShares" xlink:label="loc_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationTransferredEquityInterestsShares_58DF15E051EE10570EC59C89048D52A8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_A5D63ACA983B2026A7459C89048D58E8" xlink:to="loc_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationTransferredEquityInterestsShares_58DF15E051EE10570EC59C89048D52A8" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationTransferredEquityInterests" xlink:label="loc_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationTransferredEquityInterests_5F4463E417C690CD78609C89048D7A74" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_A5D63ACA983B2026A7459C89048D58E8" xlink:to="loc_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationTransferredEquityInterests_5F4463E417C690CD78609C89048D7A74" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivable" xlink:label="loc_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivable_D5DB28561CBA5B20EB979C89048D72D1" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_A5D63ACA983B2026A7459C89048D58E8" xlink:to="loc_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivable_D5DB28561CBA5B20EB979C89048D72D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_547579B034460F5B020B9C89048DC29E" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_A5D63ACA983B2026A7459C89048D58E8" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_547579B034460F5B020B9C89048DC29E" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_DisposalGroupIncludingDiscontinuedOperationContingentConsideration" xlink:label="loc_pfe_DisposalGroupIncludingDiscontinuedOperationContingentConsideration_7BBADF9184B0B2EAA8E59C89048E799C" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_A5D63ACA983B2026A7459C89048D58E8" xlink:to="loc_pfe_DisposalGroupIncludingDiscontinuedOperationContingentConsideration_7BBADF9184B0B2EAA8E59C89048E799C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_A8F969C39F5B237D2E189C89048E0927" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_A5D63ACA983B2026A7459C89048D58E8" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_A8F969C39F5B237D2E189C89048E0927" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_DisposalGroupIncludingDiscontinuedOperationShareTransferRestrictionTermMinimum" xlink:label="loc_pfe_DisposalGroupIncludingDiscontinuedOperationShareTransferRestrictionTermMinimum_4CC56E67984B173790829C89048E341A" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_A5D63ACA983B2026A7459C89048D58E8" xlink:to="loc_pfe_DisposalGroupIncludingDiscontinuedOperationShareTransferRestrictionTermMinimum_4CC56E67984B173790829C89048E341A" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivableTerm" xlink:label="loc_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivableTerm_F8B51D72DDE2111E041F9C89048F30A7" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_A5D63ACA983B2026A7459C89048D58E8" xlink:to="loc_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivableTerm_F8B51D72DDE2111E041F9C89048F30A7" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivableInterestRate" xlink:label="loc_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivableInterestRate_BE00E016104D79B7F63B9C89048FEA99" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_A5D63ACA983B2026A7459C89048D58E8" xlink:to="loc_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivableInterestRate_BE00E016104D79B7F63B9C89048FEA99" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivableInterestRateYearTwo" xlink:label="loc_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivableInterestRateYearTwo_FC67E5E2885156B124969C89048F3EC9" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_A5D63ACA983B2026A7459C89048D58E8" xlink:to="loc_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivableInterestRateYearTwo_FC67E5E2885156B124969C89048F3EC9" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivableInterestRateYearThree" xlink:label="loc_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivableInterestRateYearThree_56BD7F650FAE5DAF269F9C89048F2495" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_A5D63ACA983B2026A7459C89048D58E8" xlink:to="loc_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivableInterestRateYearThree_56BD7F650FAE5DAF269F9C89048F2495" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_B64DBAC9E0FCA3A725D39C89048F52CD" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_A5D63ACA983B2026A7459C89048D58E8" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_B64DBAC9E0FCA3A725D39C89048F52CD" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_AdministrativeServicePeriod" xlink:label="loc_pfe_AdministrativeServicePeriod_DEFE91415D66C1C85B869C89048FF8A3" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_A5D63ACA983B2026A7459C89048D58E8" xlink:to="loc_pfe_AdministrativeServicePeriod_DEFE91415D66C1C85B869C89048FF8A3" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_MaximumManufacturingServicePeriod" xlink:label="loc_pfe_MaximumManufacturingServicePeriod_09C4A207E2869BF7574E9C89049074BE" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_A5D63ACA983B2026A7459C89048D58E8" xlink:to="loc_pfe_MaximumManufacturingServicePeriod_09C4A207E2869BF7574E9C89049074BE" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7AA951FA5097527CA082718720E6F5D6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_A6212DBB9DBE5ECC8B158D3CF16D20AD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7AA951FA5097527CA082718720E6F5D6" xlink:to="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_A6212DBB9DBE5ECC8B158D3CF16D20AD" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_26A4BCB00EB8562680A61958ED3B7CB3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments_A944252DBC3E53A0B7ED40BB43AF2742" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_26A4BCB00EB8562680A61958ED3B7CB3" xlink:to="loc_us-gaap_NumberOfOperatingSegments_A944252DBC3E53A0B7ED40BB43AF2742" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_27391B8E11945EDC9D3D36DC96F5777A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_26A4BCB00EB8562680A61958ED3B7CB3" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_27391B8E11945EDC9D3D36DC96F5777A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_B8BB46B7F4E35266BA3DAE32F071AB36" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_27391B8E11945EDC9D3D36DC96F5777A" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_B8BB46B7F4E35266BA3DAE32F071AB36" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_D71E9079E36C545C9025B802638E4D82" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_B8BB46B7F4E35266BA3DAE32F071AB36" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_D71E9079E36C545C9025B802638E4D82" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_MedivationMember" xlink:label="loc_pfe_MedivationMember_5067282CB4485FF9999DD12D22A5C969" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_D71E9079E36C545C9025B802638E4D82" xlink:to="loc_pfe_MedivationMember_5067282CB4485FF9999DD12D22A5C969" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_AnacorMember" xlink:label="loc_pfe_AnacorMember_0B0566CF4E1F5D1DB17502E864058AE4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_D71E9079E36C545C9025B802638E4D82" xlink:to="loc_pfe_AnacorMember_0B0566CF4E1F5D1DB17502E864058AE4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_40CBB00E5D1C59BB97925CFE5747E432" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_27391B8E11945EDC9D3D36DC96F5777A" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_40CBB00E5D1C59BB97925CFE5747E432" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_0C0DD4007AE45F2C84E64CFCC1CAE1E8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_40CBB00E5D1C59BB97925CFE5747E432" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_0C0DD4007AE45F2C84E64CFCC1CAE1E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_BCD95F8D804750DF92D232BE0755A18F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_26A4BCB00EB8562680A61958ED3B7CB3" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_BCD95F8D804750DF92D232BE0755A18F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_F7106A59F68C56DBAB850ACFDF669E0E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_BCD95F8D804750DF92D232BE0755A18F" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_F7106A59F68C56DBAB850ACFDF669E0E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_A0D84E4FD93A54969239964A215A9845" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_F7106A59F68C56DBAB850ACFDF669E0E" xlink:to="loc_us-gaap_TypeOfAdoptionMember_A0D84E4FD93A54969239964A215A9845" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_AccountingStandardsUpdate201609StatutoryTaxWithholdingComponentMember" xlink:label="loc_pfe_AccountingStandardsUpdate201609StatutoryTaxWithholdingComponentMember_10626B4C8FDC57C6895DD7093B45EC2A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_A0D84E4FD93A54969239964A215A9845" xlink:to="loc_pfe_AccountingStandardsUpdate201609StatutoryTaxWithholdingComponentMember_10626B4C8FDC57C6895DD7093B45EC2A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_0D161D2EA75B5BDBAC387C1C2A50BD7E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_BCD95F8D804750DF92D232BE0755A18F" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_0D161D2EA75B5BDBAC387C1C2A50BD7E" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTaxBenefitAmount" xlink:label="loc_pfe_EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTaxBenefitAmount_928CEB226603580D91B813C675370772" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_0D161D2EA75B5BDBAC387C1C2A50BD7E" xlink:to="loc_pfe_EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTaxBenefitAmount_928CEB226603580D91B813C675370772" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_885850DC1E2A5C6982B1B611039834AF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_0D161D2EA75B5BDBAC387C1C2A50BD7E" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_885850DC1E2A5C6982B1B611039834AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_CC6E2694C04D53F0B28BBF293E6E5E59" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_0D161D2EA75B5BDBAC387C1C2A50BD7E" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_CC6E2694C04D53F0B28BBF293E6E5E59" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_D18588BA93D556839ECEFEAFA0972176" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_9FA2919A779750A78E042E1074126D5C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_D18588BA93D556839ECEFEAFA0972176" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_9FA2919A779750A78E042E1074126D5C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_C516D03CF32F5E81B164102728F04D5A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_D18588BA93D556839ECEFEAFA0972176" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_C516D03CF32F5E81B164102728F04D5A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/CommitmentsAndContingencies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_82423C80878856ABA50EE91754603085" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_36C29CC848C450F6854E55400E483B91" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_82423C80878856ABA50EE91754603085" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_36C29CC848C450F6854E55400E483B91" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/CommitmentsAndContingenciesActionsInWhichWeAreDefendantDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_C50317CADFEAA1B6655D9C26413858B1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaap_LossContingenciesTable_25832DF0933F602C66939C264138C0B6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_C50317CADFEAA1B6655D9C26413858B1" xlink:to="loc_us-gaap_LossContingenciesTable_25832DF0933F602C66939C264138C0B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_FE34E1FA3DFD842BDFBE9C2641382B63" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_25832DF0933F602C66939C264138C0B6" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_FE34E1FA3DFD842BDFBE9C2641382B63" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_6B8FD34ECD54E1EA85769C2641380155" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_FE34E1FA3DFD842BDFBE9C2641382B63" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_6B8FD34ECD54E1EA85769C2641380155" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_BF17C980A9DC259519489C2641380109" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_6B8FD34ECD54E1EA85769C2641380155" xlink:to="loc_us-gaap_SubsequentEventMember_BF17C980A9DC259519489C2641380109" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_DFB3AAB8BA03A997287B9C2641398ECF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_25832DF0933F602C66939C264138C0B6" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_DFB3AAB8BA03A997287B9C2641398ECF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="loc_us-gaap_LossContingencyNatureDomain_7A8252A5818F167A28E79C264139B539" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_DFB3AAB8BA03A997287B9C2641398ECF" xlink:to="loc_us-gaap_LossContingencyNatureDomain_7A8252A5818F167A28E79C264139B539" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DamagesFromProductDefectsMember" xlink:label="loc_us-gaap_DamagesFromProductDefectsMember_53446B40B4E52C01C4739C2641394A09" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_7A8252A5818F167A28E79C264139B539" xlink:to="loc_us-gaap_DamagesFromProductDefectsMember_53446B40B4E52C01C4739C2641394A09" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_AverageWholesalePriceMember" xlink:label="loc_pfe_AverageWholesalePriceMember_ACBF6A5C7D1CDB486CF29C264139034D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_7A8252A5818F167A28E79C264139B539" xlink:to="loc_pfe_AverageWholesalePriceMember_ACBF6A5C7D1CDB486CF29C264139034D" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_EnvironmentalRemediationLitigationMember" xlink:label="loc_pfe_EnvironmentalRemediationLitigationMember_E720F0C45D11A386F7669C2641391C70" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_7A8252A5818F167A28E79C264139B539" xlink:to="loc_pfe_EnvironmentalRemediationLitigationMember_E720F0C45D11A386F7669C2641391C70" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_ViolationofAntitrustLawsMember" xlink:label="loc_pfe_ViolationofAntitrustLawsMember_E4C61D560B4C2A67D33E9C264139C7AE" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_7A8252A5818F167A28E79C264139B539" xlink:to="loc_pfe_ViolationofAntitrustLawsMember_E4C61D560B4C2A67D33E9C264139C7AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_8B033566066B67E1113C9C2641390E3A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_25832DF0933F602C66939C264138C0B6" xlink:to="loc_us-gaap_ProductOrServiceAxis_8B033566066B67E1113C9C2641390E3A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_615F4976089CE192DE3F9C2641396E06" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductOrServiceAxis_8B033566066B67E1113C9C2641390E3A" xlink:to="loc_us-gaap_ProductsAndServicesDomain_615F4976089CE192DE3F9C2641396E06" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_InflectraMember" xlink:label="loc_pfe_InflectraMember_E7B862046E7E38AFCC889C2641399C79" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_615F4976089CE192DE3F9C2641396E06" xlink:to="loc_pfe_InflectraMember_E7B862046E7E38AFCC889C2641399C79" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_CelebrexMember" xlink:label="loc_pfe_CelebrexMember_FAF313B87916A7BA3F6D9C264139A114" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_615F4976089CE192DE3F9C2641396E06" xlink:to="loc_pfe_CelebrexMember_FAF313B87916A7BA3F6D9C264139A114" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_PhenytoinSodiumCapsulesMember" xlink:label="loc_pfe_PhenytoinSodiumCapsulesMember_26F0F18F2C0E74D1AFCA9C2641396BA1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_615F4976089CE192DE3F9C2641396E06" xlink:to="loc_pfe_PhenytoinSodiumCapsulesMember_26F0F18F2C0E74D1AFCA9C2641396BA1" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_XtandiMember" xlink:label="loc_pfe_XtandiMember_6A04313798EF26EEA4419C2641396204" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_615F4976089CE192DE3F9C2641396E06" xlink:to="loc_pfe_XtandiMember_6A04313798EF26EEA4419C2641396204" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationCaseAxis" xlink:label="loc_us-gaap_LitigationCaseAxis_4BD10A0FD6BD580FB45F9C264139CD48" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_25832DF0933F602C66939C264138C0B6" xlink:to="loc_us-gaap_LitigationCaseAxis_4BD10A0FD6BD580FB45F9C264139CD48" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationCaseTypeDomain" xlink:label="loc_us-gaap_LitigationCaseTypeDomain_9C8D5E1FE20637C34F4E9C2641397ED3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationCaseAxis_4BD10A0FD6BD580FB45F9C264139CD48" xlink:to="loc_us-gaap_LitigationCaseTypeDomain_9C8D5E1FE20637C34F4E9C2641397ED3" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_JanssenandNewYorkUniversityVersusHospiraCelltrionHealthcareandCelltrionInc.Member" xlink:label="loc_pfe_JanssenandNewYorkUniversityVersusHospiraCelltrionHealthcareandCelltrionInc.Member_F43CE92616C5364FDD379C264139F984" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationCaseTypeDomain_9C8D5E1FE20637C34F4E9C2641397ED3" xlink:to="loc_pfe_JanssenandNewYorkUniversityVersusHospiraCelltrionHealthcareandCelltrionInc.Member_F43CE92616C5364FDD379C264139F984" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_ClassActionVersusAmericanOpticalCorporationAndVariousOtherDefendantsMember" xlink:label="loc_pfe_ClassActionVersusAmericanOpticalCorporationAndVariousOtherDefendantsMember_26B8E4869F899706A8259C2641393BDD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationCaseTypeDomain_9C8D5E1FE20637C34F4E9C2641397ED3" xlink:to="loc_pfe_ClassActionVersusAmericanOpticalCorporationAndVariousOtherDefendantsMember_26B8E4869F899706A8259C2641393BDD" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_StateofIllinoisVersusPfizerMember" xlink:label="loc_pfe_StateofIllinoisVersusPfizerMember_3131A2B719E7D7FA1E339C26413A7D3C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationCaseTypeDomain_9C8D5E1FE20637C34F4E9C2641397ED3" xlink:to="loc_pfe_StateofIllinoisVersusPfizerMember_3131A2B719E7D7FA1E339C26413A7D3C" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_RegentsVersusMedivationMember" xlink:label="loc_pfe_RegentsVersusMedivationMember_8D83BD4A67936EA98D019C26413A8C7D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationCaseTypeDomain_9C8D5E1FE20637C34F4E9C2641397ED3" xlink:to="loc_pfe_RegentsVersusMedivationMember_8D83BD4A67936EA98D019C26413A8C7D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationStatusAxis" xlink:label="loc_us-gaap_LitigationStatusAxis_2357D2B8E4DFF4457B739C26413A4BEE" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_25832DF0933F602C66939C264138C0B6" xlink:to="loc_us-gaap_LitigationStatusAxis_2357D2B8E4DFF4457B739C26413A4BEE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationStatusDomain" xlink:label="loc_us-gaap_LitigationStatusDomain_74008D3A99DEA864E3CF9C26413AB77F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusAxis_2357D2B8E4DFF4457B739C26413A4BEE" xlink:to="loc_us-gaap_LitigationStatusDomain_74008D3A99DEA864E3CF9C26413AB77F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SettledLitigationMember" xlink:label="loc_us-gaap_SettledLitigationMember_5162DAD41C31B3FF6D409C26413A91B9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_74008D3A99DEA864E3CF9C26413AB77F" xlink:to="loc_us-gaap_SettledLitigationMember_5162DAD41C31B3FF6D409C26413A91B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PendingLitigationMember" xlink:label="loc_us-gaap_PendingLitigationMember_006736D35DFF4FF6A3E59C26413A8E1D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_74008D3A99DEA864E3CF9C26413AB77F" xlink:to="loc_us-gaap_PendingLitigationMember_006736D35DFF4FF6A3E59C26413A8E1D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaap_LossContingenciesLineItems_708B596EA28799D6E6699C26413A7FEB" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_25832DF0933F602C66939C264138C0B6" xlink:to="loc_us-gaap_LossContingenciesLineItems_708B596EA28799D6E6699C26413A7FEB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LossContingencyPatentsAllegedlyInfringedNumber" xlink:label="loc_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber_EB72EE4C83D07664297C9C26413AEDB4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_708B596EA28799D6E6699C26413A7FEB" xlink:to="loc_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber_EB72EE4C83D07664297C9C26413AEDB4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LossContingencyClaimsDismissedNumber" xlink:label="loc_us-gaap_LossContingencyClaimsDismissedNumber_538F102A97B7626498C49C26413A577A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_708B596EA28799D6E6699C26413A7FEB" xlink:to="loc_us-gaap_LossContingencyClaimsDismissedNumber_538F102A97B7626498C49C26413A577A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LossContingencyPendingClaimsNumber" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber_F368F6717B9D7719D8139C26413A3421" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_708B596EA28799D6E6699C26413A7FEB" xlink:to="loc_us-gaap_LossContingencyPendingClaimsNumber_F368F6717B9D7719D8139C26413A3421" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_FeasibilityStudyNumberOfLagoons" xlink:label="loc_pfe_FeasibilityStudyNumberOfLagoons_A87C24D0E15B0353317F9C26413A262B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_708B596EA28799D6E6699C26413A7FEB" xlink:to="loc_pfe_FeasibilityStudyNumberOfLagoons_A87C24D0E15B0353317F9C26413A262B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_55CE6AD169D633CBF8C29C3641629B07" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_708B596EA28799D6E6699C26413A7FEB" xlink:to="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_55CE6AD169D633CBF8C29C3641629B07" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_08D01608ABC38FD7BC789C26413A135A" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_708B596EA28799D6E6699C26413A7FEB" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_08D01608ABC38FD7BC789C26413A135A" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_LossContingencyCollaborationArrangementPercentageofPaymentsSoughtbyPlaintiff" xlink:label="loc_pfe_LossContingencyCollaborationArrangementPercentageofPaymentsSoughtbyPlaintiff_25ECCDBE199B0490CE469C26413A1295" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_708B596EA28799D6E6699C26413A7FEB" xlink:to="loc_pfe_LossContingencyCollaborationArrangementPercentageofPaymentsSoughtbyPlaintiff_25ECCDBE199B0490CE469C26413A1295" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/CommitmentsAndContingenciesActionsInWhichWeArePlaintiffDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_B1FE438AD8254A5599989D7882868F73" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainContingenciesTable" xlink:label="loc_us-gaap_GainContingenciesTable_0B11AB7C32B1849BD2579D7882865CBA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_B1FE438AD8254A5599989D7882868F73" xlink:to="loc_us-gaap_GainContingenciesTable_0B11AB7C32B1849BD2579D7882865CBA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_3C433EBADDE6B2A3CB7E9D788287016D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GainContingenciesTable_0B11AB7C32B1849BD2579D7882865CBA" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_3C433EBADDE6B2A3CB7E9D788287016D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_8B733AA18E370FDB09C99D7882870AD8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_3C433EBADDE6B2A3CB7E9D788287016D" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_8B733AA18E370FDB09C99D7882870AD8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_F33D8693CD0E95DB0DA89D78828782E6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_8B733AA18E370FDB09C99D7882870AD8" xlink:to="loc_us-gaap_SubsequentEventMember_F33D8693CD0E95DB0DA89D78828782E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_1EF6C649BAF87D989D869D7882873E22" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GainContingenciesTable_0B11AB7C32B1849BD2579D7882865CBA" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_1EF6C649BAF87D989D869D7882873E22" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="loc_us-gaap_LossContingencyNatureDomain_BD93AE6C2922F62D1C629D7882874DBB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_1EF6C649BAF87D989D869D7882873E22" xlink:to="loc_us-gaap_LossContingencyNatureDomain_BD93AE6C2922F62D1C629D7882874DBB" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_PatentInfringementMember" xlink:label="loc_pfe_PatentInfringementMember_141380A0570DA2E87F0A9D78828709B8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_BD93AE6C2922F62D1C629D7882874DBB" xlink:to="loc_pfe_PatentInfringementMember_141380A0570DA2E87F0A9D78828709B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainContingenciesByNatureAxis" xlink:label="loc_us-gaap_GainContingenciesByNatureAxis_C2E41C793FD8069315969D788287DCD7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GainContingenciesTable_0B11AB7C32B1849BD2579D7882865CBA" xlink:to="loc_us-gaap_GainContingenciesByNatureAxis_C2E41C793FD8069315969D788287DCD7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainContingencyNatureDomain" xlink:label="loc_us-gaap_GainContingencyNatureDomain_8D4C6E6F34B51A60A23D9D7882873A40" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GainContingenciesByNatureAxis_C2E41C793FD8069315969D788287DCD7" xlink:to="loc_us-gaap_GainContingencyNatureDomain_8D4C6E6F34B51A60A23D9D7882873A40" xlink:type="arc" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GainContingencyNatureDomain_8D4C6E6F34B51A60A23D9D7882873A40" xlink:to="loc_pfe_PatentInfringementMember_141380A0570DA2E87F0A9D78828709B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_94E2BD6873957AE8B0769D788288CAAB" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GainContingenciesTable_0B11AB7C32B1849BD2579D7882865CBA" xlink:to="loc_us-gaap_ProductOrServiceAxis_94E2BD6873957AE8B0769D788288CAAB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_F8D1D166D44B7E3A24659D7882888B49" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductOrServiceAxis_94E2BD6873957AE8B0769D788288CAAB" xlink:to="loc_us-gaap_ProductsAndServicesDomain_F8D1D166D44B7E3A24659D7882888B49" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_BosulifMember" xlink:label="loc_pfe_BosulifMember_8BA8420A02DB0ED147339D79B77F1B3B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_F8D1D166D44B7E3A24659D7882888B49" xlink:to="loc_pfe_BosulifMember_8BA8420A02DB0ED147339D79B77F1B3B" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_PrecedexPremixMember" xlink:label="loc_pfe_PrecedexPremixMember_511397B87A39C4C509AF9D78828DC65E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_F8D1D166D44B7E3A24659D7882888B49" xlink:to="loc_pfe_PrecedexPremixMember_511397B87A39C4C509AF9D78828DC65E" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_ToviazMember" xlink:label="loc_pfe_ToviazMember_5D10F9B4CB554C4BCBD79D78828DEC07" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_F8D1D166D44B7E3A24659D7882888B49" xlink:to="loc_pfe_ToviazMember_5D10F9B4CB554C4BCBD79D78828DEC07" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_ToviazCompositionofmatterPatentsMember" xlink:label="loc_pfe_ToviazCompositionofmatterPatentsMember_EE1049E1D16984A8EC009D78828D0D4E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_F8D1D166D44B7E3A24659D7882888B49" xlink:to="loc_pfe_ToviazCompositionofmatterPatentsMember_EE1049E1D16984A8EC009D78828D0D4E" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_XeljanzMember" xlink:label="loc_pfe_XeljanzMember_B119D7CB340A9EE832B29D78828D5B1C" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_F8D1D166D44B7E3A24659D7882888B49" xlink:to="loc_pfe_XeljanzMember_B119D7CB340A9EE832B29D78828D5B1C" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_EliquisMember" xlink:label="loc_pfe_EliquisMember_3C0CA17E8912055C50219D78828D4F18" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_F8D1D166D44B7E3A24659D7882888B49" xlink:to="loc_pfe_EliquisMember_3C0CA17E8912055C50219D78828D4F18" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_BavencioMember" xlink:label="loc_pfe_BavencioMember_5D8AB799F79AF5BEC1C69D78828D60E1" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_F8D1D166D44B7E3A24659D7882888B49" xlink:to="loc_pfe_BavencioMember_5D8AB799F79AF5BEC1C69D78828D60E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationCaseAxis" xlink:label="loc_us-gaap_LitigationCaseAxis_2100543976034476FBB69D78828D81C4" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GainContingenciesTable_0B11AB7C32B1849BD2579D7882865CBA" xlink:to="loc_us-gaap_LitigationCaseAxis_2100543976034476FBB69D78828D81C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationCaseTypeDomain" xlink:label="loc_us-gaap_LitigationCaseTypeDomain_395BA0AFF7ADC24D8E8B9D78828E436E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationCaseAxis_2100543976034476FBB69D78828D81C4" xlink:to="loc_us-gaap_LitigationCaseTypeDomain_395BA0AFF7ADC24D8E8B9D78828E436E" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_WyethVersusSunMember" xlink:label="loc_pfe_WyethVersusSunMember_E0D63AE17834610086739D7A3D6C16A0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationCaseTypeDomain_395BA0AFF7ADC24D8E8B9D78828E436E" xlink:to="loc_pfe_WyethVersusSunMember_E0D63AE17834610086739D7A3D6C16A0" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_HospiraVersusAmnealPharmaceuticalsLLCMember" xlink:label="loc_pfe_HospiraVersusAmnealPharmaceuticalsLLCMember_6DB834501C30D34EBCFE9D78828E9C47" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationCaseTypeDomain_395BA0AFF7ADC24D8E8B9D78828E436E" xlink:to="loc_pfe_HospiraVersusAmnealPharmaceuticalsLLCMember_6DB834501C30D34EBCFE9D78828E9C47" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_HospiraVersusFreseniusMember" xlink:label="loc_pfe_HospiraVersusFreseniusMember_47F5FE036AFCEAC745779D78828ECDFF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationCaseTypeDomain_395BA0AFF7ADC24D8E8B9D78828E436E" xlink:to="loc_pfe_HospiraVersusFreseniusMember_47F5FE036AFCEAC745779D78828ECDFF" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_HospiraVersusParMember" xlink:label="loc_pfe_HospiraVersusParMember_C59735FFE9A96304A7F79D78828EC83E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationCaseTypeDomain_395BA0AFF7ADC24D8E8B9D78828E436E" xlink:to="loc_pfe_HospiraVersusParMember_C59735FFE9A96304A7F79D78828EC83E" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_PfizerVersusMylanLaboratoriesandAccordHealthcareInc.Member" xlink:label="loc_pfe_PfizerVersusMylanLaboratoriesandAccordHealthcareInc.Member_72FBBF92812A13652E769D78828E7787" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationCaseTypeDomain_395BA0AFF7ADC24D8E8B9D78828E436E" xlink:to="loc_pfe_PfizerVersusMylanLaboratoriesandAccordHealthcareInc.Member_72FBBF92812A13652E769D78828E7787" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_PfizerVersusSeveralGenericManufacturersMember" xlink:label="loc_pfe_PfizerVersusSeveralGenericManufacturersMember_7CFA7D7E0CF6BAC8D2A49D78828EDB34" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationCaseTypeDomain_395BA0AFF7ADC24D8E8B9D78828E436E" xlink:to="loc_pfe_PfizerVersusSeveralGenericManufacturersMember_7CFA7D7E0CF6BAC8D2A49D78828EDB34" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_PfizerVersusMicroLabsMember" xlink:label="loc_pfe_PfizerVersusMicroLabsMember_CA8C0CF09D69846AEB419D78828E5710" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationCaseTypeDomain_395BA0AFF7ADC24D8E8B9D78828E436E" xlink:to="loc_pfe_PfizerVersusMicroLabsMember_CA8C0CF09D69846AEB419D78828E5710" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_PfizerVersusZydusMember" xlink:label="loc_pfe_PfizerVersusZydusMember_C0C413A44D85F5F2B49C9D78828ED067" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationCaseTypeDomain_395BA0AFF7ADC24D8E8B9D78828E436E" xlink:to="loc_pfe_PfizerVersusZydusMember_C0C413A44D85F5F2B49C9D78828ED067" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_PfizerVersusPrinstonandBreckenridgeMember" xlink:label="loc_pfe_PfizerVersusPrinstonandBreckenridgeMember_22EC7458E71D2C03D6209D78828EC414" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationCaseTypeDomain_395BA0AFF7ADC24D8E8B9D78828E436E" xlink:to="loc_pfe_PfizerVersusPrinstonandBreckenridgeMember_22EC7458E71D2C03D6209D78828EC414" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_PfizerVersusBreckenridgeMember" xlink:label="loc_pfe_PfizerVersusBreckenridgeMember_1D870EC79D91DCF699E09D78828E634C" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationCaseTypeDomain_395BA0AFF7ADC24D8E8B9D78828E436E" xlink:to="loc_pfe_PfizerVersusBreckenridgeMember_1D870EC79D91DCF699E09D78828E634C" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_PfizerandBMSVersusSeveralGenericManufacturersMember" xlink:label="loc_pfe_PfizerandBMSVersusSeveralGenericManufacturersMember_8E95607C6FDACAA666269D7882939D26" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationCaseTypeDomain_395BA0AFF7ADC24D8E8B9D78828E436E" xlink:to="loc_pfe_PfizerandBMSVersusSeveralGenericManufacturersMember_8E95607C6FDACAA666269D7882939D26" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_PfizerVersusBMSE.R.SquibbSonsOnoPharmaceuticalandTasukuHonjoMember" xlink:label="loc_pfe_PfizerVersusBMSE.R.SquibbSonsOnoPharmaceuticalandTasukuHonjoMember_924DA4E88E0762E397349D788293AD70" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationCaseTypeDomain_395BA0AFF7ADC24D8E8B9D78828E436E" xlink:to="loc_pfe_PfizerVersusBMSE.R.SquibbSonsOnoPharmaceuticalandTasukuHonjoMember_924DA4E88E0762E397349D788293AD70" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationStatusAxis" xlink:label="loc_us-gaap_LitigationStatusAxis_1CC9C75D8510465085939D7882946028" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GainContingenciesTable_0B11AB7C32B1849BD2579D7882865CBA" xlink:to="loc_us-gaap_LitigationStatusAxis_1CC9C75D8510465085939D7882946028" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationStatusDomain" xlink:label="loc_us-gaap_LitigationStatusDomain_23B1B5937CC5CC78B53F9D7882947AE1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusAxis_1CC9C75D8510465085939D7882946028" xlink:to="loc_us-gaap_LitigationStatusDomain_23B1B5937CC5CC78B53F9D7882947AE1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PendingLitigationMember" xlink:label="loc_us-gaap_PendingLitigationMember_E3F73B40EBF48DC7DFA59D7882949983" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_23B1B5937CC5CC78B53F9D7882947AE1" xlink:to="loc_us-gaap_PendingLitigationMember_E3F73B40EBF48DC7DFA59D7882949983" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SettledLitigationMember" xlink:label="loc_us-gaap_SettledLitigationMember_7A9CE589765D726A004A9D788294EF64" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_23B1B5937CC5CC78B53F9D7882947AE1" xlink:to="loc_us-gaap_SettledLitigationMember_7A9CE589765D726A004A9D788294EF64" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_JudicialRulingMember" xlink:label="loc_us-gaap_JudicialRulingMember_BF337A6F5F424A04C8369D788294EB44" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_23B1B5937CC5CC78B53F9D7882947AE1" xlink:to="loc_us-gaap_JudicialRulingMember_BF337A6F5F424A04C8369D788294EB44" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainContingenciesLineItems" xlink:label="loc_us-gaap_GainContingenciesLineItems_6660F8B8F6DEE34F584E9D7882941EE9" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GainContingenciesTable_0B11AB7C32B1849BD2579D7882865CBA" xlink:to="loc_us-gaap_GainContingenciesLineItems_6660F8B8F6DEE34F584E9D7882941EE9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber" xlink:label="loc_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_4612A4966F3380997A9E9D788294532C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GainContingenciesLineItems_6660F8B8F6DEE34F584E9D7882941EE9" xlink:to="loc_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_4612A4966F3380997A9E9D788294532C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainContingencyPatentsFoundNotInfringedUponNumber" xlink:label="loc_us-gaap_GainContingencyPatentsFoundNotInfringedUponNumber_EB8437E073F4D3AA05F49D7882946457" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GainContingenciesLineItems_6660F8B8F6DEE34F584E9D7882941EE9" xlink:to="loc_us-gaap_GainContingencyPatentsFoundNotInfringedUponNumber_EB8437E073F4D3AA05F49D7882946457" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainContingencyPatentsFoundInfringedUponNumber" xlink:label="loc_us-gaap_GainContingencyPatentsFoundInfringedUponNumber_7DFC846B9209D81E69EC9D78829465BE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GainContingenciesLineItems_6660F8B8F6DEE34F584E9D7882941EE9" xlink:to="loc_us-gaap_GainContingencyPatentsFoundInfringedUponNumber_7DFC846B9209D81E69EC9D78829465BE" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_GainContingencyNumberofDefendants" xlink:label="loc_pfe_GainContingencyNumberofDefendants_6D38BB06D773D68CADD69D788294A402" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GainContingenciesLineItems_6660F8B8F6DEE34F584E9D7882941EE9" xlink:to="loc_pfe_GainContingencyNumberofDefendants_6D38BB06D773D68CADD69D788294A402" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_GainContingencyPatentsAllegedlyInfringeduponNumberDuetoExpireinDecember2020" xlink:label="loc_pfe_GainContingencyPatentsAllegedlyInfringeduponNumberDuetoExpireinDecember2020_3F1C698956071047B90B9D78829406A6" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GainContingenciesLineItems_6660F8B8F6DEE34F584E9D7882941EE9" xlink:to="loc_pfe_GainContingencyPatentsAllegedlyInfringeduponNumberDuetoExpireinDecember2020_3F1C698956071047B90B9D78829406A6" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_GainContingencyPatentsAllegedlyInfringeduponNumberDuetoExpireinDecember2025" xlink:label="loc_pfe_GainContingencyPatentsAllegedlyInfringeduponNumberDuetoExpireinDecember2025_0B96A89B6ACEAB111FEF9D7882957B89" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GainContingenciesLineItems_6660F8B8F6DEE34F584E9D7882941EE9" xlink:to="loc_pfe_GainContingencyPatentsAllegedlyInfringeduponNumberDuetoExpireinDecember2025_0B96A89B6ACEAB111FEF9D7882957B89" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LossContingencyPatentsAllegedlyInfringedNumber" xlink:label="loc_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber_9FE15AC4E49F9D100D8E9D78829564EE" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GainContingenciesLineItems_6660F8B8F6DEE34F584E9D7882941EE9" xlink:to="loc_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber_9FE15AC4E49F9D100D8E9D78829564EE" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/CommitmentsAndContingenciesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_E0F3A69E2D0F5BDFBDED921D09D78545" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AcceleratedShareRepurchasesTable" xlink:label="loc_us-gaap_AcceleratedShareRepurchasesTable_3056D4ED28B8EA6C6A9B921D09D7F143" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_E0F3A69E2D0F5BDFBDED921D09D78545" xlink:to="loc_us-gaap_AcceleratedShareRepurchasesTable_3056D4ED28B8EA6C6A9B921D09D7F143" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_A228E606A0CE55574D25921D09D78BDB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesTable_3056D4ED28B8EA6C6A9B921D09D7F143" xlink:to="loc_us-gaap_StatementScenarioAxis_A228E606A0CE55574D25921D09D78BDB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_2ABC3B181E139BA20DE2921D09D725BF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementScenarioAxis_A228E606A0CE55574D25921D09D78BDB" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_2ABC3B181E139BA20DE2921D09D725BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProFormaMember" xlink:label="loc_us-gaap_ProFormaMember_DAFA70A739700CFC1679921D09D89319" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_2ABC3B181E139BA20DE2921D09D725BF" xlink:to="loc_us-gaap_ProFormaMember_DAFA70A739700CFC1679921D09D89319" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_09E6EB5D26C0B6510422921D09D8D62F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesTable_3056D4ED28B8EA6C6A9B921D09D7F143" xlink:to="loc_us-gaap_ProductOrServiceAxis_09E6EB5D26C0B6510422921D09D8D62F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_4E1F224DFFD62259162D921D09D8A903" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductOrServiceAxis_09E6EB5D26C0B6510422921D09D8D62F" xlink:to="loc_us-gaap_ProductsAndServicesDomain_4E1F224DFFD62259162D921D09D8A903" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_MylotargMember" xlink:label="loc_pfe_MylotargMember_8C172B1B8BE8902987BE921D09D864EB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_4E1F224DFFD62259162D921D09D8A903" xlink:to="loc_pfe_MylotargMember_8C172B1B8BE8902987BE921D09D864EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_83A3DB50A991F330FA64921D09D81AE3" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesTable_3056D4ED28B8EA6C6A9B921D09D7F143" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_83A3DB50A991F330FA64921D09D81AE3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_9027777ED142B7A23E04921D09D892BD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_83A3DB50A991F330FA64921D09D81AE3" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_9027777ED142B7A23E04921D09D892BD" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_ShareRepurchaseAgreementwithCitibankMember" xlink:label="loc_pfe_ShareRepurchaseAgreementwithCitibankMember_C2A8F71CFCA543DA86E3921D09D9940A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_9027777ED142B7A23E04921D09D892BD" xlink:to="loc_pfe_ShareRepurchaseAgreementwithCitibankMember_C2A8F71CFCA543DA86E3921D09D9940A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AcceleratedShareRepurchasesLineItems" xlink:label="loc_us-gaap_AcceleratedShareRepurchasesLineItems_C95954F5BFA0E3906192921D09D9D7C0" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesTable_3056D4ED28B8EA6C6A9B921D09D7F143" xlink:to="loc_us-gaap_AcceleratedShareRepurchasesLineItems_C95954F5BFA0E3906192921D09D9D7C0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_A685F6BD24A207A158D1921D09D9D31F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesLineItems_C95954F5BFA0E3906192921D09D9D7C0" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_A685F6BD24A207A158D1921D09D9D31F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt" xlink:label="loc_us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt_59992A404830AAEFBA76921D09D98A8A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesLineItems_C95954F5BFA0E3906192921D09D9D7C0" xlink:to="loc_us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt_59992A404830AAEFBA76921D09D98A8A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_F1230CAE177EE8066457921D09D91C51" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesLineItems_C95954F5BFA0E3906192921D09D9D7C0" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_F1230CAE177EE8066457921D09D91C51" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AcceleratedShareRepurchasesInitialPricePaidPerShare" xlink:label="loc_us-gaap_AcceleratedShareRepurchasesInitialPricePaidPerShare_FDB2AE370B97627EBE57921D09D950A6" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesLineItems_C95954F5BFA0E3906192921D09D9D7C0" xlink:to="loc_us-gaap_AcceleratedShareRepurchasesInitialPricePaidPerShare_FDB2AE370B97627EBE57921D09D950A6" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_AcceleratedShareRepurchasesSharesRepurchasedDuringPeriodPercentageofAgreementAmount" xlink:label="loc_pfe_AcceleratedShareRepurchasesSharesRepurchasedDuringPeriodPercentageofAgreementAmount_BAD406876B61F5808BFB921D09DA9E7E" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesLineItems_C95954F5BFA0E3906192921D09D9D7C0" xlink:to="loc_pfe_AcceleratedShareRepurchasesSharesRepurchasedDuringPeriodPercentageofAgreementAmount_BAD406876B61F5808BFB921D09DA9E7E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_7B16CC35C5484DE1E5B3921D09DA5008" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesLineItems_C95954F5BFA0E3906192921D09D9D7C0" xlink:to="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_7B16CC35C5484DE1E5B3921D09DA5008" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_74FF5D80B90DAA88CA40921D09DA107A" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesLineItems_C95954F5BFA0E3906192921D09D9D7C0" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_74FF5D80B90DAA88CA40921D09DA107A" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_ResearchandDevelopmentArrangementAggregatePaymentObligation" xlink:label="loc_pfe_ResearchandDevelopmentArrangementAggregatePaymentObligation_174C301B5B439354EB35921D09DAA635" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesLineItems_C95954F5BFA0E3906192921D09D9D7C0" xlink:to="loc_pfe_ResearchandDevelopmentArrangementAggregatePaymentObligation_174C301B5B439354EB35921D09DAA635" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_ResearchandDevelopmentArrangementAggregatePaymentObligationTerm" xlink:label="loc_pfe_ResearchandDevelopmentArrangementAggregatePaymentObligationTerm_13B172CEFAD1A71DE87E921D1B122958" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesLineItems_C95954F5BFA0E3906192921D09D9D7C0" xlink:to="loc_pfe_ResearchandDevelopmentArrangementAggregatePaymentObligationTerm_13B172CEFAD1A71DE87E921D1B122958" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_F94C2249B5D7BD6A5A59922806190712" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_74F3F16ECEB7275F4BB8922806211876" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_F94C2249B5D7BD6A5A59922806190712" xlink:to="loc_us-gaap_AssetsAbstract_74F3F16ECEB7275F4BB8922806211876" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1711DF4DF5E61D767ACB92280624F1DB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_74F3F16ECEB7275F4BB8922806211876" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1711DF4DF5E61D767ACB92280624F1DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaap_ShortTermInvestments_A686AA9DA2F1D4186F6A9228062B4990" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_74F3F16ECEB7275F4BB8922806211876" xlink:to="loc_us-gaap_ShortTermInvestments_A686AA9DA2F1D4186F6A9228062B4990" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_C13FD68362E825C322059228062B005D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_74F3F16ECEB7275F4BB8922806211876" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_C13FD68362E825C322059228062B005D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_5A761FB27869C6AEBC149228062B55D2" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_74F3F16ECEB7275F4BB8922806211876" xlink:to="loc_us-gaap_InventoryNet_5A761FB27869C6AEBC149228062B55D2" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_OtherTaxAssetsCurrent" xlink:label="loc_pfe_OtherTaxAssetsCurrent_0C80B6B41F2551E8EBB59228062CF695" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_74F3F16ECEB7275F4BB8922806211876" xlink:to="loc_pfe_OtherTaxAssetsCurrent_0C80B6B41F2551E8EBB59228062CF695" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_AC7CC689A43B2FF3916D9228062C6F3A" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_74F3F16ECEB7275F4BB8922806211876" xlink:to="loc_us-gaap_OtherAssetsCurrent_AC7CC689A43B2FF3916D9228062C6F3A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_F560940D16CF0D868CAC9228062C5BE3" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_74F3F16ECEB7275F4BB8922806211876" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_F560940D16CF0D868CAC9228062C5BE3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_4D0BA2E7EE60A497C2329228062D249C" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_74F3F16ECEB7275F4BB8922806211876" xlink:to="loc_us-gaap_AssetsCurrent_4D0BA2E7EE60A497C2329228062D249C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermInvestments" xlink:label="loc_us-gaap_LongTermInvestments_9CE3E7907D81D933B7889228062DA806" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_74F3F16ECEB7275F4BB8922806211876" xlink:to="loc_us-gaap_LongTermInvestments_9CE3E7907D81D933B7889228062DA806" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_D63E215E68A5617D4B2E9228062D5DCD" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_74F3F16ECEB7275F4BB8922806211876" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_D63E215E68A5617D4B2E9228062D5DCD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_A23CE82BC5FDAD1B7B079228062D56E1" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_74F3F16ECEB7275F4BB8922806211876" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_A23CE82BC5FDAD1B7B079228062D56E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_BD1B928176E001F17F829228062D54D8" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_74F3F16ECEB7275F4BB8922806211876" xlink:to="loc_us-gaap_Goodwill_BD1B928176E001F17F829228062D54D8" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent" xlink:label="loc_pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent_66A882FEB1C8D75108FD9228062E4A19" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_74F3F16ECEB7275F4BB8922806211876" xlink:to="loc_pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent_66A882FEB1C8D75108FD9228062E4A19" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_33C432905F731DAA1DAE9228062E22FB" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_74F3F16ECEB7275F4BB8922806211876" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_33C432905F731DAA1DAE9228062E22FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_F950CCDC3D300C67B55C9228062FF610" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_74F3F16ECEB7275F4BB8922806211876" xlink:to="loc_us-gaap_Assets_F950CCDC3D300C67B55C9228062FF610" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1B68E913F0337C850ADD9228062F34A3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_F94C2249B5D7BD6A5A59922806190712" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1B68E913F0337C850ADD9228062F34A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtCurrent" xlink:label="loc_us-gaap_DebtCurrent_E9840FCCE81C534FD0E59228062FE7A0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1B68E913F0337C850ADD9228062F34A3" xlink:to="loc_us-gaap_DebtCurrent_E9840FCCE81C534FD0E59228062FE7A0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_BE6CD6D4F2557C01C83E9228062F557D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1B68E913F0337C850ADD9228062F34A3" xlink:to="loc_us-gaap_AccountsPayableCurrent_BE6CD6D4F2557C01C83E9228062F557D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DividendsPayableCurrent" xlink:label="loc_us-gaap_DividendsPayableCurrent_A8E8A4EEFAE5E71B1704922806301DD7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1B68E913F0337C850ADD9228062F34A3" xlink:to="loc_us-gaap_DividendsPayableCurrent_A8E8A4EEFAE5E71B1704922806301DD7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TaxesPayableCurrent" xlink:label="loc_us-gaap_TaxesPayableCurrent_1E226FD90490FB45AEB1922806308EC7" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1B68E913F0337C850ADD9228062F34A3" xlink:to="loc_us-gaap_TaxesPayableCurrent_1E226FD90490FB45AEB1922806308EC7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_87B80030823CEFBFDBB8922806306845" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1B68E913F0337C850ADD9228062F34A3" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_87B80030823CEFBFDBB8922806306845" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_3C18E15CD39F76307AAC92280631C985" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1B68E913F0337C850ADD9228062F34A3" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_3C18E15CD39F76307AAC92280631C985" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_89D755F03D23B3C3F81D922806328E57" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1B68E913F0337C850ADD9228062F34A3" xlink:to="loc_us-gaap_LiabilitiesCurrent_89D755F03D23B3C3F81D922806328E57" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_66CBA391C6CEFF78646B92280632D38E" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1B68E913F0337C850ADD9228062F34A3" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_66CBA391C6CEFF78646B92280632D38E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent_276A31E2379B3A5A5152922806327BEC" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1B68E913F0337C850ADD9228062F34A3" xlink:to="loc_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent_276A31E2379B3A5A5152922806327BEC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent_CD2322A05C7C36C01B97922806327D6F" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1B68E913F0337C850ADD9228062F34A3" xlink:to="loc_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent_CD2322A05C7C36C01B97922806327D6F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_6381CDCC9AD3038DF6B0922806328AF6" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1B68E913F0337C850ADD9228062F34A3" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_6381CDCC9AD3038DF6B0922806328AF6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilityForUncertainTaxPositionsNoncurrent" xlink:label="loc_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent_E97D6FC393A4F580AAFC922806333917" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1B68E913F0337C850ADD9228062F34A3" xlink:to="loc_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent_E97D6FC393A4F580AAFC922806333917" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_73C358FBFD46733E147192280633A622" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1B68E913F0337C850ADD9228062F34A3" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_73C358FBFD46733E147192280633A622" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_860238CB62F6138103AB9228063366CB" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1B68E913F0337C850ADD9228062F34A3" xlink:to="loc_us-gaap_Liabilities_860238CB62F6138103AB9228063366CB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_6037E0D678ADA81283F392280633EB69" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1B68E913F0337C850ADD9228062F34A3" xlink:to="loc_us-gaap_CommitmentsAndContingencies_6037E0D678ADA81283F392280633EB69" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_4771A160FB2D31AFFBB5922806349857" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1B68E913F0337C850ADD9228062F34A3" xlink:to="loc_us-gaap_PreferredStockValue_4771A160FB2D31AFFBB5922806349857" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_BCDC5AD6017902A36D719228063455B6" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1B68E913F0337C850ADD9228062F34A3" xlink:to="loc_us-gaap_CommonStockValue_BCDC5AD6017902A36D719228063455B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_B62178FE23A58553DAE792280635CCC7" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1B68E913F0337C850ADD9228062F34A3" xlink:to="loc_us-gaap_AdditionalPaidInCapital_B62178FE23A58553DAE792280635CCC7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue_90B1A31FAD11873FCCD2922806350871" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1B68E913F0337C850ADD9228062F34A3" xlink:to="loc_us-gaap_TreasuryStockValue_90B1A31FAD11873FCCD2922806350871" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_76373F2281C6AC95284C9228063609B8" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1B68E913F0337C850ADD9228062F34A3" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_76373F2281C6AC95284C9228063609B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_B404E3979C4E498ABFF392280637E30E" xlink:type="locator" />
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1B68E913F0337C850ADD9228062F34A3" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_B404E3979C4E498ABFF392280637E30E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_EB3D9A07B11B65DE54E792280637748D" xlink:type="locator" />
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1B68E913F0337C850ADD9228062F34A3" xlink:to="loc_us-gaap_StockholdersEquity_EB3D9A07B11B65DE54E792280637748D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_D58A9B88052434E2BAC5922806379A68" xlink:type="locator" />
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1B68E913F0337C850ADD9228062F34A3" xlink:to="loc_us-gaap_MinorityInterest_D58A9B88052434E2BAC5922806379A68" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_FADEB8BB9689C117DB22922806374193" xlink:type="locator" />
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1B68E913F0337C850ADD9228062F34A3" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_FADEB8BB9689C117DB22922806374193" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_18A77A5777F4BE6C9ABA922806375EBE" xlink:type="locator" />
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1B68E913F0337C850ADD9228062F34A3" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_18A77A5777F4BE6C9ABA922806375EBE" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_FAA48A75C6205B528D73EDF2208F0D1F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_A0F560C44C255D9B99A2BEC08A682854" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_FAA48A75C6205B528D73EDF2208F0D1F" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_A0F560C44C255D9B99A2BEC08A682854" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_85D595022B7A545A990F0BEE9743CC3A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_FAA48A75C6205B528D73EDF2208F0D1F" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_85D595022B7A545A990F0BEE9743CC3A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_A1383EAC48705685ACA7FAF87EE227F7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_FAA48A75C6205B528D73EDF2208F0D1F" xlink:to="loc_us-gaap_LongTermDebtCurrent_A1383EAC48705685ACA7FAF87EE227F7" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_0162D4217BF08A128E3F7DDD5E1518AD" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2670F50E1159B58C55577DDD5E151C1D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0162D4217BF08A128E3F7DDD5E1518AD" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2670F50E1159B58C55577DDD5E151C1D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_CB3C0B8B4EC1914A73D07DDD5E15DEF3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2670F50E1159B58C55577DDD5E151C1D" xlink:to="loc_us-gaap_ProfitLoss_CB3C0B8B4EC1914A73D07DDD5E15DEF3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1B9B9E5EDF4ACD7AF6DB7DDD5E16F963" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2670F50E1159B58C55577DDD5E151C1D" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1B9B9E5EDF4ACD7AF6DB7DDD5E16F963" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization" xlink:label="loc_pfe_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization_6CFED759CF1B051C0C2E7DDD5E163591" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1B9B9E5EDF4ACD7AF6DB7DDD5E16F963" xlink:to="loc_pfe_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization_6CFED759CF1B051C0C2E7DDD5E163591" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_AssetWriteOffsAndAssetImpairmentCharges" xlink:label="loc_pfe_AssetWriteOffsAndAssetImpairmentCharges_3FFA79E484BF33A2C4307DDD5E164406" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1B9B9E5EDF4ACD7AF6DB7DDD5E16F963" xlink:to="loc_pfe_AssetWriteOffsAndAssetImpairmentCharges_3FFA79E484BF33A2C4307DDD5E164406" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_0D52202D3EFD165A689A7DDD5E16304F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1B9B9E5EDF4ACD7AF6DB7DDD5E16F963" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_0D52202D3EFD165A689A7DDD5E16304F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_20AAA73AA3465C2620CD7DDD5E1617C5" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1B9B9E5EDF4ACD7AF6DB7DDD5E16F963" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_20AAA73AA3465C2620CD7DDD5E1617C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_7F512FB452EF02DB1FBE7DDD5E163CA2" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1B9B9E5EDF4ACD7AF6DB7DDD5E16F963" xlink:to="loc_us-gaap_ShareBasedCompensation_7F512FB452EF02DB1FBE7DDD5E163CA2" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense" xlink:label="loc_pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense_FCABA2092F24933911837DDD5E177732" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1B9B9E5EDF4ACD7AF6DB7DDD5E16F963" xlink:to="loc_pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense_FCABA2092F24933911837DDD5E177732" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_EED424E935CD5157E7797DDD5E176D04" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1B9B9E5EDF4ACD7AF6DB7DDD5E16F963" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_EED424E935CD5157E7797DDD5E176D04" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapital" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapital_1CBBC0D3E250F4E427BC7DDD5E171720" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1B9B9E5EDF4ACD7AF6DB7DDD5E16F963" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapital_1CBBC0D3E250F4E427BC7DDD5E171720" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_F0581A12C5A6BD7E2F057DDD5E172D04" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2670F50E1159B58C55577DDD5E151C1D" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_F0581A12C5A6BD7E2F057DDD5E172D04" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5A0BFDA0D914E176B5317DDD5E17E518" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0162D4217BF08A128E3F7DDD5E1518AD" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5A0BFDA0D914E176B5317DDD5E17E518" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_36858490CC357470760D7DDD5E17324C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5A0BFDA0D914E176B5317DDD5E17E518" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_36858490CC357470760D7DDD5E17324C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments_9FBB402B7A4B1A446CE77DDD5E17A31D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5A0BFDA0D914E176B5317DDD5E17E518" xlink:to="loc_us-gaap_PaymentsToAcquireShortTermInvestments_9FBB402B7A4B1A446CE77DDD5E17A31D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_3BE04FFD29F4D0A6C2F77DDD5E17EB1F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5A0BFDA0D914E176B5317DDD5E17E518" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_3BE04FFD29F4D0A6C2F77DDD5E17EB1F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsForProceedsFromShortTermInvestments" xlink:label="loc_us-gaap_PaymentsForProceedsFromShortTermInvestments_9100CEA09C9000175DD37DDD5E1724AA" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5A0BFDA0D914E176B5317DDD5E17E518" xlink:to="loc_us-gaap_PaymentsForProceedsFromShortTermInvestments_9100CEA09C9000175DD37DDD5E1724AA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_027B7A058CA5EA39D0037DDD5E186595" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5A0BFDA0D914E176B5317DDD5E17E518" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_027B7A058CA5EA39D0037DDD5E186595" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments_1EE02F5084341C96E6697DDD5E1805BB" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5A0BFDA0D914E176B5317DDD5E17E518" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments_1EE02F5084341C96E6697DDD5E1805BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_F8353380BF664162B9887DDD5E18241A" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5A0BFDA0D914E176B5317DDD5E17E518" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_F8353380BF664162B9887DDD5E18241A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_0795380BB8548B3F3D517DDD5E18E76C" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5A0BFDA0D914E176B5317DDD5E17E518" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_0795380BB8548B3F3D517DDD5E18E76C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_C531859D4FDEB5B6D29D7DDD5E180413" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5A0BFDA0D914E176B5317DDD5E17E518" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_C531859D4FDEB5B6D29D7DDD5E180413" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_A1A36DE8210E39F72FC47DDD5E18A348" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5A0BFDA0D914E176B5317DDD5E17E518" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_A1A36DE8210E39F72FC47DDD5E18A348" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_943AD77F36B9090FDC007DDD5E193DF4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0162D4217BF08A128E3F7DDD5E1518AD" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_943AD77F36B9090FDC007DDD5E193DF4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromShortTermDebt" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt_E97D1818499D585082AD7DDD5E19494B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_943AD77F36B9090FDC007DDD5E193DF4" xlink:to="loc_us-gaap_ProceedsFromShortTermDebt_E97D1818499D585082AD7DDD5E19494B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepaymentsOfShortTermDebt" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt_BC86C1AA5C07B5FCEB167DDD5E19197F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_943AD77F36B9090FDC007DDD5E193DF4" xlink:to="loc_us-gaap_RepaymentsOfShortTermDebt_BC86C1AA5C07B5FCEB167DDD5E19197F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess_83A9948B09E6334E16897DDD5E198C3C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_943AD77F36B9090FDC007DDD5E193DF4" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess_83A9948B09E6334E16897DDD5E198C3C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_8EF598E46AD53F54036B7DDD5E1910A9" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_943AD77F36B9090FDC007DDD5E193DF4" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_8EF598E46AD53F54036B7DDD5E1910A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_4696ACE5F34A30D7DFB17DDD5E19F667" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_943AD77F36B9090FDC007DDD5E193DF4" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_4696ACE5F34A30D7DFB17DDD5E19F667" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_24AC6F1CC2D4DD9356DA7DDD5E190147" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_943AD77F36B9090FDC007DDD5E193DF4" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_24AC6F1CC2D4DD9356DA7DDD5E190147" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfOrdinaryDividends" xlink:label="loc_us-gaap_PaymentsOfOrdinaryDividends_F7D5921BF65E342244657DDD5E19E6F4" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_943AD77F36B9090FDC007DDD5E193DF4" xlink:to="loc_us-gaap_PaymentsOfOrdinaryDividends_F7D5921BF65E342244657DDD5E19E6F4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_0408F9110B05C32A251C7DDD5E19BB47" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_943AD77F36B9090FDC007DDD5E193DF4" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_0408F9110B05C32A251C7DDD5E19BB47" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_E678D8FD62605E1FAFA27DDD5E1976E9" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_943AD77F36B9090FDC007DDD5E193DF4" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_E678D8FD62605E1FAFA27DDD5E1976E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_74E7BB756C5099E598E47DDD5E190797" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_943AD77F36B9090FDC007DDD5E193DF4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_74E7BB756C5099E598E47DDD5E190797" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_EC893957C534375371077DDD5E192BB3" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0162D4217BF08A128E3F7DDD5E1518AD" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_EC893957C534375371077DDD5E192BB3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_56226AFBB2D407A71A3C7DDD5E19E14D" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0162D4217BF08A128E3F7DDD5E1518AD" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_56226AFBB2D407A71A3C7DDD5E19E14D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_C396345B492E39A7BB157DDD5E19F407" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0162D4217BF08A128E3F7DDD5E1518AD" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_C396345B492E39A7BB157DDD5E19F407" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_CD2F1FFBC8BC252963567DDD5E1A028A" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0162D4217BF08A128E3F7DDD5E1518AD" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_CD2F1FFBC8BC252963567DDD5E1A028A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_562CE419A7C40AF4F30A7DDD5E1AFA84" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0162D4217BF08A128E3F7DDD5E1518AD" xlink:to="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_562CE419A7C40AF4F30A7DDD5E1AFA84" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_81002851DA16F70A91887DDD5E1A20C9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_562CE419A7C40AF4F30A7DDD5E1AFA84" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_81002851DA16F70A91887DDD5E1A20C9" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_NoncashorPartNoncashDivestitureAmountofConsiderationReceivedCommonStock" xlink:label="loc_pfe_NoncashorPartNoncashDivestitureAmountofConsiderationReceivedCommonStock_564CDE91A176459F69867DDD5E1AEAAB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_81002851DA16F70A91887DDD5E1A20C9" xlink:to="loc_pfe_NoncashorPartNoncashDivestitureAmountofConsiderationReceivedCommonStock_564CDE91A176459F69867DDD5E1AEAAB" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_NoncashorPartNoncashDivestitureAmountofConsiderationReceivedNoteReceivable" xlink:label="loc_pfe_NoncashorPartNoncashDivestitureAmountofConsiderationReceivedNoteReceivable_511AF19B0F591B3D7F367DDD5E1A8FA6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_81002851DA16F70A91887DDD5E1A20C9" xlink:to="loc_pfe_NoncashorPartNoncashDivestitureAmountofConsiderationReceivedNoteReceivable_511AF19B0F591B3D7F367DDD5E1A8FA6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_647E67767F5BC570B80F7DDD5E1A2BB3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_562CE419A7C40AF4F30A7DDD5E1AFA84" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_647E67767F5BC570B80F7DDD5E1A2BB3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_920E3FCE80D618EC68697DDD5E1AE196" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_647E67767F5BC570B80F7DDD5E1A2BB3" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_920E3FCE80D618EC68697DDD5E1AE196" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet_A902F2169FF65DB6091D7DDD5E1A7A96" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_647E67767F5BC570B80F7DDD5E1A2BB3" xlink:to="loc_us-gaap_InterestPaidNet_A902F2169FF65DB6091D7DDD5E1A7A96" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_InterestPaidInterestRateHedges" xlink:label="loc_pfe_InterestPaidInterestRateHedges_782A6BA5F83067D5E4F67DDD5E1BB221" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_647E67767F5BC570B80F7DDD5E1A2BB3" xlink:to="loc_pfe_InterestPaidInterestRateHedges_782A6BA5F83067D5E4F67DDD5E1BB221" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlowsParenthetical" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_68FABB79E9B65259882A2F54A79C07F0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_9DAA17AEDC18518F93417AC216A15639" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_68FABB79E9B65259882A2F54A79C07F0" xlink:to="loc_us-gaap_StatementTable_9DAA17AEDC18518F93417AC216A15639" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_B602757FAD72594FAF04FDDBAD349E7C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_9DAA17AEDC18518F93417AC216A15639" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_B602757FAD72594FAF04FDDBAD349E7C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_50FFE29006525594AEA95079A199BE30" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_B602757FAD72594FAF04FDDBAD349E7C" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_50FFE29006525594AEA95079A199BE30" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_HISMember" xlink:label="loc_pfe_HISMember_51E2FA4E6F655681AB28225BE9453C8D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_50FFE29006525594AEA95079A199BE30" xlink:to="loc_pfe_HISMember_51E2FA4E6F655681AB28225BE9453C8D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupClassificationAxis" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_769627F58DC55CF489F3172C3F275FF1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_9DAA17AEDC18518F93417AC216A15639" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_769627F58DC55CF489F3172C3F275FF1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_52B39804D5D054BEB732B84338005E73" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_769627F58DC55CF489F3172C3F275FF1" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_52B39804D5D054BEB732B84338005E73" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_9443657AD3535CB580C3CD157A57631E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_52B39804D5D054BEB732B84338005E73" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_9443657AD3535CB580C3CD157A57631E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="loc_us-gaap_CounterpartyNameAxis_C6B1741913875E608A4A63D764520BD5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_9DAA17AEDC18518F93417AC216A15639" xlink:to="loc_us-gaap_CounterpartyNameAxis_C6B1741913875E608A4A63D764520BD5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_6B7A2EE67C42592AAFE0270BDE988DE1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CounterpartyNameAxis_C6B1741913875E608A4A63D764520BD5" xlink:to="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_6B7A2EE67C42592AAFE0270BDE988DE1" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_ICUMedicalMember" xlink:label="loc_pfe_ICUMedicalMember_B3650B3A5BF1558A908A1FA489EC7306" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_6B7A2EE67C42592AAFE0270BDE988DE1" xlink:to="loc_pfe_ICUMedicalMember_B3650B3A5BF1558A908A1FA489EC7306" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_6060E590E46B57269153434F0B52CF4B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_9DAA17AEDC18518F93417AC216A15639" xlink:to="loc_us-gaap_StatementLineItems_6060E590E46B57269153434F0B52CF4B" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationTransferredEquityInterestsShares" xlink:label="loc_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationTransferredEquityInterestsShares_B66755258E6953EFA9A8877E1083750C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6060E590E46B57269153434F0B52CF4B" xlink:to="loc_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationTransferredEquityInterestsShares_B66755258E6953EFA9A8877E1083750C" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationTransferredEquityInterests" xlink:label="loc_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationTransferredEquityInterests_1B160950912C5BA2BC740FD614313460" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6060E590E46B57269153434F0B52CF4B" xlink:to="loc_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationTransferredEquityInterests_1B160950912C5BA2BC740FD614313460" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivable" xlink:label="loc_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivable_75D9027D2C805ED4AE39641C1F40447E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6060E590E46B57269153434F0B52CF4B" xlink:to="loc_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivable_75D9027D2C805ED4AE39641C1F40447E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_9BFDE97D5E9FF36B9EF77DDD5E40DEE9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_D031D84B45066CC5B6B37DDD5E409A1A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_9BFDE97D5E9FF36B9EF77DDD5E40DEE9" xlink:to="loc_us-gaap_ProfitLoss_D031D84B45066CC5B6B37DDD5E409A1A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_C10E097C3B9A0D0E7D917DDD5E400129" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_9BFDE97D5E9FF36B9EF77DDD5E40DEE9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_C10E097C3B9A0D0E7D917DDD5E400129" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax_971106EC2B226DE0DBF57DDD5E407D48" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_9BFDE97D5E9FF36B9EF77DDD5E40DEE9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax_971106EC2B226DE0DBF57DDD5E407D48" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_49A977EA11A3DC5C90AD7DDD5E407D03" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_9BFDE97D5E9FF36B9EF77DDD5E40DEE9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_49A977EA11A3DC5C90AD7DDD5E407D03" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax_D77DBDAE35A7E3AD0C5E7DDD5E401BB6" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_9BFDE97D5E9FF36B9EF77DDD5E40DEE9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax_D77DBDAE35A7E3AD0C5E7DDD5E401BB6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesBeforeTax_10CDB03AD12A03642B027DDD5E416006" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_9BFDE97D5E9FF36B9EF77DDD5E40DEE9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesBeforeTax_10CDB03AD12A03642B027DDD5E416006" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesBeforeTax_44C32B6CD265DCB1DD1B7DDD5E41B961" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_9BFDE97D5E9FF36B9EF77DDD5E40DEE9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesBeforeTax_44C32B6CD265DCB1DD1B7DDD5E41B961" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_9AE9229DE582A8724A727DDD5E4160CE" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_9BFDE97D5E9FF36B9EF77DDD5E40DEE9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_9AE9229DE582A8724A727DDD5E4160CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax_729016E481C7BCA36D7C7DDD5E419178" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_9BFDE97D5E9FF36B9EF77DDD5E40DEE9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax_729016E481C7BCA36D7C7DDD5E419178" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax_CBB9E401A5722B47596B7DDD5E418557" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_9BFDE97D5E9FF36B9EF77DDD5E40DEE9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax_CBB9E401A5722B47596B7DDD5E418557" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_81A968E2528205117DA17DDD5E4154B0" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_9BFDE97D5E9FF36B9EF77DDD5E40DEE9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_81A968E2528205117DA17DDD5E4154B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax_4B4BA80B533F88E197B57DDD5E41CF93" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_9BFDE97D5E9FF36B9EF77DDD5E40DEE9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax_4B4BA80B533F88E197B57DDD5E41CF93" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax" xlink:label="loc_pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax_873A23E01ADB9D86CCC27DDD5E419276" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_9BFDE97D5E9FF36B9EF77DDD5E40DEE9" xlink:to="loc_pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax_873A23E01ADB9D86CCC27DDD5E419276" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax" xlink:label="loc_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax_9C5883272A876A5DB9AF7DDD5E41EE38" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_9BFDE97D5E9FF36B9EF77DDD5E40DEE9" xlink:to="loc_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax_9C5883272A876A5DB9AF7DDD5E41EE38" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax_3BC203736843A0F19FE27DDD5E4145B9" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_9BFDE97D5E9FF36B9EF77DDD5E40DEE9" xlink:to="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax_3BC203736843A0F19FE27DDD5E4145B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax_CEF8E836DF4F064090BF7DDD5E4134A8" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_9BFDE97D5E9FF36B9EF77DDD5E40DEE9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax_CEF8E836DF4F064090BF7DDD5E4134A8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_A824A122E29C6D7D873E7DDD5E422296" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_9BFDE97D5E9FF36B9EF77DDD5E40DEE9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_A824A122E29C6D7D873E7DDD5E422296" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax" xlink:label="loc_pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax_6231051424BD228A3CCE7DDD5E4240C6" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_9BFDE97D5E9FF36B9EF77DDD5E40DEE9" xlink:to="loc_pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax_6231051424BD228A3CCE7DDD5E4240C6" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax" xlink:label="loc_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax_E20C6785AE0A2AD6EC2F7DDD5E426598" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_9BFDE97D5E9FF36B9EF77DDD5E40DEE9" xlink:to="loc_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax_E20C6785AE0A2AD6EC2F7DDD5E426598" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_F18F437C558B4D1733257DDD5E42F8EA" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_9BFDE97D5E9FF36B9EF77DDD5E40DEE9" xlink:to="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_F18F437C558B4D1733257DDD5E42F8EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax_C45F724FBBEE5873DA057DDD5E424622" xlink:type="locator" />
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_9BFDE97D5E9FF36B9EF77DDD5E40DEE9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax_C45F724FBBEE5873DA057DDD5E424622" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTax_D24A5EEE64BCB2F5A2997DDD5E42108D" xlink:type="locator" />
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_9BFDE97D5E9FF36B9EF77DDD5E40DEE9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTax_D24A5EEE64BCB2F5A2997DDD5E42108D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_4B395EA91143DA09CCF97DDD5E4270FE" xlink:type="locator" />
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_9BFDE97D5E9FF36B9EF77DDD5E40DEE9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_4B395EA91143DA09CCF97DDD5E4270FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_25475843EE4B26C9E7587DDD5E42BAAC" xlink:type="locator" />
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_9BFDE97D5E9FF36B9EF77DDD5E40DEE9" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_25475843EE4B26C9E7587DDD5E42BAAC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_37DAC2A40BB9A31D27857DDD5E427D0F" xlink:type="locator" />
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_9BFDE97D5E9FF36B9EF77DDD5E40DEE9" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_37DAC2A40BB9A31D27857DDD5E427D0F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_12362FEEDF2E83DCCC437DDD5E42EEF2" xlink:type="locator" />
    <link:presentationArc order="26" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_9BFDE97D5E9FF36B9EF77DDD5E40DEE9" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_12362FEEDF2E83DCCC437DDD5E42EEF2" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeParenthetical" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_CA915345884B557CBED467AA541C40D0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_9115A4395B1F54869ADF1E0FB0F96F05" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_CA915345884B557CBED467AA541C40D0" xlink:to="loc_us-gaap_StatementTable_9115A4395B1F54869ADF1E0FB0F96F05" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_7562AF4A91A05C3DB25A6B1D01EAB64A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_9115A4395B1F54869ADF1E0FB0F96F05" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_7562AF4A91A05C3DB25A6B1D01EAB64A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvesteeNameDomain" xlink:label="loc_us-gaap_EquityMethodInvesteeNameDomain_7D123A8C8C675C38B52B7D17C8E42E30" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_7562AF4A91A05C3DB25A6B1D01EAB64A" xlink:to="loc_us-gaap_EquityMethodInvesteeNameDomain_7D123A8C8C675C38B52B7D17C8E42E30" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_LaboratorioTeutoBrasileroMember" xlink:label="loc_pfe_LaboratorioTeutoBrasileroMember_915688D5ED455C7E947109498C2DE751" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvesteeNameDomain_7D123A8C8C675C38B52B7D17C8E42E30" xlink:to="loc_pfe_LaboratorioTeutoBrasileroMember_915688D5ED455C7E947109498C2DE751" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_827A234471C250428B9E4F46165140FE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_9115A4395B1F54869ADF1E0FB0F96F05" xlink:to="loc_us-gaap_StatementLineItems_827A234471C250428B9E4F46165140FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_171F9C09396358B9B4BC48B1025A3AB2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_827A234471C250428B9E4F46165140FE" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_171F9C09396358B9B4BC48B1025A3AB2" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/CondensedConsolidatedStatementsOfIncome" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_64685388D78491E2F65A7EA6FEE4D4AA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_885264EF87A3FF5B63C57EA6FEE41893" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_64685388D78491E2F65A7EA6FEE4D4AA" xlink:to="loc_us-gaap_SalesRevenueGoodsNet_885264EF87A3FF5B63C57EA6FEE41893" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_273F730C1F44F27684027EA6FEE5E533" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_64685388D78491E2F65A7EA6FEE4D4AA" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_273F730C1F44F27684027EA6FEE5E533" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="loc_us-gaap_CostOfGoodsSold_A2D72BFF1DC38A805E947EA6FEE5F36B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_273F730C1F44F27684027EA6FEE5E533" xlink:to="loc_us-gaap_CostOfGoodsSold_A2D72BFF1DC38A805E947EA6FEE5F36B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_576359943B3F25CFB0807EA6FEE5242F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_273F730C1F44F27684027EA6FEE5E533" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_576359943B3F25CFB0807EA6FEE5242F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_2540AC7243661946F52A7EA6FEE507E1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_273F730C1F44F27684027EA6FEE5E533" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_2540AC7243661946F52A7EA6FEE507E1" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction" xlink:label="loc_pfe_AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction_22E9F8BB6DA3E845A7737EA6FEE5A01F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_273F730C1F44F27684027EA6FEE5E533" xlink:to="loc_pfe_AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction_22E9F8BB6DA3E845A7737EA6FEE5A01F" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_RestructuringChargesAndAcquisitionRelatedCosts" xlink:label="loc_pfe_RestructuringChargesAndAcquisitionRelatedCosts_A5166CE0FAB9F492BF0F7EA6FEE592DD" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_273F730C1F44F27684027EA6FEE5E533" xlink:to="loc_pfe_RestructuringChargesAndAcquisitionRelatedCosts_A5166CE0FAB9F492BF0F7EA6FEE592DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_DAAC7B846FED6527811D7EA6FEE5900B" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_273F730C1F44F27684027EA6FEE5E533" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_DAAC7B846FED6527811D7EA6FEE5900B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1335AEBA2296382B8EEE7EA6FEE58734" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_64685388D78491E2F65A7EA6FEE4D4AA" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1335AEBA2296382B8EEE7EA6FEE58734" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_4E478D07E0472B967CAB7EA6FEE5DC0A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_64685388D78491E2F65A7EA6FEE4D4AA" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_4E478D07E0472B967CAB7EA6FEE5DC0A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_9E0296CF45D128E2DE907EA6FEE5931F" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_64685388D78491E2F65A7EA6FEE4D4AA" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_9E0296CF45D128E2DE907EA6FEE5931F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_01E03CA8AE2486BA08B37EA6FEE598F4" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_64685388D78491E2F65A7EA6FEE4D4AA" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_01E03CA8AE2486BA08B37EA6FEE598F4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_C0BCF592ADDB4A91DA5F7EA6FEE583DE" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_64685388D78491E2F65A7EA6FEE4D4AA" xlink:to="loc_us-gaap_ProfitLoss_C0BCF592ADDB4A91DA5F7EA6FEE583DE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_617CD10DE1F4DAE60DB27EA6FEE573D0" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_64685388D78491E2F65A7EA6FEE4D4AA" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_617CD10DE1F4DAE60DB27EA6FEE573D0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_071F67558CE4E1386E747EA6FEE5A8D6" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_64685388D78491E2F65A7EA6FEE4D4AA" xlink:to="loc_us-gaap_NetIncomeLoss_071F67558CE4E1386E747EA6FEE5A8D6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_11D201C9CCD19F67E3267EA6FEE584E2" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_64685388D78491E2F65A7EA6FEE4D4AA" xlink:to="loc_us-gaap_EarningsPerShareBasicAbstract_11D201C9CCD19F67E3267EA6FEE584E2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_B87B48F51839C7139F5C7EA6FEE52FEC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_11D201C9CCD19F67E3267EA6FEE584E2" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_B87B48F51839C7139F5C7EA6FEE52FEC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_579D580453E97E052ABE7EA6FEE6ACA0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_11D201C9CCD19F67E3267EA6FEE584E2" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_579D580453E97E052ABE7EA6FEE6ACA0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_0048B25B9B539096D6E27EA6FEE66857" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_11D201C9CCD19F67E3267EA6FEE584E2" xlink:to="loc_us-gaap_EarningsPerShareBasic_0048B25B9B539096D6E27EA6FEE66857" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareDilutedAbstract" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract_246EA5AF43EB7DA3B0157EA6FEE68796" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_64685388D78491E2F65A7EA6FEE4D4AA" xlink:to="loc_us-gaap_EarningsPerShareDilutedAbstract_246EA5AF43EB7DA3B0157EA6FEE68796" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_E106F9E8241B4FBA95A37EA6FEE6D0E3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_246EA5AF43EB7DA3B0157EA6FEE68796" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_E106F9E8241B4FBA95A37EA6FEE6D0E3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_E1D17E8DB3820F172EC97EA6FEE60544" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_246EA5AF43EB7DA3B0157EA6FEE68796" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_E1D17E8DB3820F172EC97EA6FEE60544" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_2036C56CF2FED965FB8B7EA6FEE6DA9D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_246EA5AF43EB7DA3B0157EA6FEE68796" xlink:to="loc_us-gaap_EarningsPerShareDiluted_2036C56CF2FED965FB8B7EA6FEE6DA9D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_071324D69DDB53E348D37EA6FEE68F9C" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_64685388D78491E2F65A7EA6FEE4D4AA" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_071324D69DDB53E348D37EA6FEE68F9C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_846440AEE28A9EEA93497EA6FEE60350" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_64685388D78491E2F65A7EA6FEE4D4AA" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_846440AEE28A9EEA93497EA6FEE60350" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockDividendsPerShareCashPaid" xlink:label="loc_us-gaap_CommonStockDividendsPerShareCashPaid_4118EEF8CE9F6D7365D67EA6FEE690EE" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_64685388D78491E2F65A7EA6FEE4D4AA" xlink:to="loc_us-gaap_CommonStockDividendsPerShareCashPaid_4118EEF8CE9F6D7365D67EA6FEE690EE" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/DocumentAndEntityInformation" xlink:type="extended">
    <link:loc xlink:href="pfe-20171001.xsd#pfe_DocumentandEntityInformationAbstract" xlink:label="loc_pfe_DocumentandEntityInformationAbstract_42D3E5D6634DB04FF870983AF789FA65" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_A2CD80B2C6B27A8BD21C983AF793AB52" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_DocumentandEntityInformationAbstract_42D3E5D6634DB04FF870983AF789FA65" xlink:to="loc_dei_EntityRegistrantName_A2CD80B2C6B27A8BD21C983AF793AB52" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_4B28099BAB4ED65CE40B983AF794AE41" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_DocumentandEntityInformationAbstract_42D3E5D6634DB04FF870983AF789FA65" xlink:to="loc_dei_EntityCentralIndexKey_4B28099BAB4ED65CE40B983AF794AE41" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_6059370256CC9525769A983AF795F298" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_DocumentandEntityInformationAbstract_42D3E5D6634DB04FF870983AF789FA65" xlink:to="loc_dei_CurrentFiscalYearEndDate_6059370256CC9525769A983AF795F298" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_B8F4E202020BAD4AE042983AF7956E5B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_DocumentandEntityInformationAbstract_42D3E5D6634DB04FF870983AF789FA65" xlink:to="loc_dei_EntityFilerCategory_B8F4E202020BAD4AE042983AF7956E5B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_90DDD565A7E3B54845D6983AF795614D" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_DocumentandEntityInformationAbstract_42D3E5D6634DB04FF870983AF789FA65" xlink:to="loc_dei_DocumentType_90DDD565A7E3B54845D6983AF795614D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_6FAD49566DBB549309E8983AF795E884" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_DocumentandEntityInformationAbstract_42D3E5D6634DB04FF870983AF789FA65" xlink:to="loc_dei_DocumentPeriodEndDate_6FAD49566DBB549309E8983AF795E884" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_F76C9D1658BDFCD8FAB4983AF795A32A" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_DocumentandEntityInformationAbstract_42D3E5D6634DB04FF870983AF789FA65" xlink:to="loc_dei_DocumentFiscalYearFocus_F76C9D1658BDFCD8FAB4983AF795A32A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_A5128C513A7D59418918983AF7951A67" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_DocumentandEntityInformationAbstract_42D3E5D6634DB04FF870983AF789FA65" xlink:to="loc_dei_DocumentFiscalPeriodFocus_A5128C513A7D59418918983AF7951A67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_5863FF50D1ABF837F8A2983AF795DE4A" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_DocumentandEntityInformationAbstract_42D3E5D6634DB04FF870983AF789FA65" xlink:to="loc_dei_AmendmentFlag_5863FF50D1ABF837F8A2983AF795DE4A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_F66B89D653C9A717BA12983AF7958104" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_DocumentandEntityInformationAbstract_42D3E5D6634DB04FF870983AF789FA65" xlink:to="loc_dei_TradingSymbol_F66B89D653C9A717BA12983AF7958104" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_A0D5D1A02BDC6BAEBA4D983AF7967C4D" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_DocumentandEntityInformationAbstract_42D3E5D6634DB04FF870983AF789FA65" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_A0D5D1A02BDC6BAEBA4D983AF7967C4D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/EarningsPerCommonShareAttributableToCommonShareholders" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_6B8DC63659A65C418F9F03E25F43F55B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_4212A0810BDA57F9B7FF27C52C0BED30" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_6B8DC63659A65C418F9F03E25F43F55B" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_4212A0810BDA57F9B7FF27C52C0BED30" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/EarningsPerCommonShareAttributableToCommonShareholdersDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_10B327E73E831EE5D3A702A6B8601A61" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_22D9C89968C0D9CEF77602A6B8617B05" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_10B327E73E831EE5D3A702A6B8601A61" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_22D9C89968C0D9CEF77602A6B8617B05" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_489AE300F49771E002EB02A6B8617D16" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_22D9C89968C0D9CEF77602A6B8617B05" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_489AE300F49771E002EB02A6B8617D16" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_588EB517129D3C1A670102A6B861C1AB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_489AE300F49771E002EB02A6B8617D16" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_588EB517129D3C1A670102A6B861C1AB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaap_StockOptionMember_503125AB61B0643FC01702A6B861CE06" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_588EB517129D3C1A670102A6B861C1AB" xlink:to="loc_us-gaap_StockOptionMember_503125AB61B0643FC01702A6B861CE06" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1F7F5F50CDD9366C0DF002A6B8620604" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_22D9C89968C0D9CEF77602A6B8617B05" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1F7F5F50CDD9366C0DF002A6B8620604" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_A2BA5982DD04E5AE83D902A6B8620C3C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1F7F5F50CDD9366C0DF002A6B8620604" xlink:to="loc_us-gaap_EarningsPerShareBasicAbstract_A2BA5982DD04E5AE83D902A6B8620C3C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_D08D65B5B9BB717A138202A6B8624F8B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_A2BA5982DD04E5AE83D902A6B8620C3C" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_D08D65B5B9BB717A138202A6B8624F8B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_9588C5AA962822119D8102A6B8637D72" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_A2BA5982DD04E5AE83D902A6B8620C3C" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_9588C5AA962822119D8102A6B8637D72" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_4D55C0F333B0632BE31602A6B8631385" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_A2BA5982DD04E5AE83D902A6B8620C3C" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_4D55C0F333B0632BE31602A6B8631385" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:label="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_4C813C19B36FD90C4E0D02A6B863978E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_A2BA5982DD04E5AE83D902A6B8620C3C" xlink:to="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_4C813C19B36FD90C4E0D02A6B863978E" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic" xlink:label="loc_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic_DBB6E306430A25B2719402A6B863F524" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_A2BA5982DD04E5AE83D902A6B8620C3C" xlink:to="loc_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic_DBB6E306430A25B2719402A6B863F524" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_7E615AD050103C1F0AE602A6B864C758" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_A2BA5982DD04E5AE83D902A6B8620C3C" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_7E615AD050103C1F0AE602A6B864C758" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_EB930E4E68C35C69D2A802A6B8645574" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_A2BA5982DD04E5AE83D902A6B8620C3C" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_EB930E4E68C35C69D2A802A6B8645574" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DilutiveSecuritiesAbstract" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract_00C94EC5F5F0AC140FDA02A6B864236C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1F7F5F50CDD9366C0DF002A6B8620604" xlink:to="loc_us-gaap_DilutiveSecuritiesAbstract_00C94EC5F5F0AC140FDA02A6B864236C" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted" xlink:label="loc_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted_94530A6877C815A229F702A6B8646F92" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_00C94EC5F5F0AC140FDA02A6B864236C" xlink:to="loc_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted_94530A6877C815A229F702A6B8646F92" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_EFBB950EA99D751BFD3602A6B864CDE7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_00C94EC5F5F0AC140FDA02A6B864236C" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_EFBB950EA99D751BFD3602A6B864CDE7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_6BC97F5EACD1031E7B9402A6B865E16D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_00C94EC5F5F0AC140FDA02A6B864236C" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_6BC97F5EACD1031E7B9402A6B865E16D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_C443601E108786ABDAE202A6B865F980" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1F7F5F50CDD9366C0DF002A6B8620604" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_C443601E108786ABDAE202A6B865F980" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_D744C8BD7F635C8662C702A6B865ABA2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_C443601E108786ABDAE202A6B865F980" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_D744C8BD7F635C8662C702A6B865ABA2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_4DEB466CE0B924CF77BB02A6B86625BA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_C443601E108786ABDAE202A6B865F980" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_4DEB466CE0B924CF77BB02A6B86625BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_6D44E51893C215ADD81E02A6B86690EA" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_C443601E108786ABDAE202A6B865F980" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_6D44E51893C215ADD81E02A6B86690EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_DD3A1E3A2D538683DA2802A6B866006C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_C443601E108786ABDAE202A6B865F980" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_DD3A1E3A2D538683DA2802A6B866006C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/EarningsPerCommonShareAttributableToCommonShareholdersTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_6D5CE1DD4ABA5E61B364DDDFA989DFD0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_A1A573287B32581E85DF75A5794F3179" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_6D5CE1DD4ABA5E61B364DDDFA989DFD0" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_A1A573287B32581E85DF75A5794F3179" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/FinancialInstruments" xlink:type="extended">
    <link:loc xlink:href="pfe-20171001.xsd#pfe_FinancialInstrumentsAbstract" xlink:label="loc_pfe_FinancialInstrumentsAbstract_2FAD3E61E39E5BCB8C9057814C4AE4EE" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:label="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_27355AD1DEC2579D9EBB5D4850F90931" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_2FAD3E61E39E5BCB8C9057814C4AE4EE" xlink:to="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_27355AD1DEC2579D9EBB5D4850F90931" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail" xlink:type="extended">
    <link:loc xlink:href="pfe-20171001.xsd#pfe_FinancialInstrumentsAbstract" xlink:label="loc_pfe_FinancialInstrumentsAbstract_808DAB4DDE6E516B9ADE9E0B90B89120" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_82A5AE74CCCA55A0AE1D2595FF718979" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_808DAB4DDE6E516B9ADE9E0B90B89120" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_82A5AE74CCCA55A0AE1D2595FF718979" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_A315B5958242507ABDC1D6244F3ED121" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_82A5AE74CCCA55A0AE1D2595FF718979" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_A315B5958242507ABDC1D6244F3ED121" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_A3E6D8E48C8D5F7F9168903EBC833057" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_A315B5958242507ABDC1D6244F3ED121" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_A3E6D8E48C8D5F7F9168903EBC833057" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_92D8F6AA069E5FBF8FCD17ABF99AA752" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_A3E6D8E48C8D5F7F9168903EBC833057" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_92D8F6AA069E5FBF8FCD17ABF99AA752" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_815E5B9027BE5DD3BD981C571DF3210D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_82A5AE74CCCA55A0AE1D2595FF718979" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_815E5B9027BE5DD3BD981C571DF3210D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_D73ADD1F369F5A60AF4CC6118B273877" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_815E5B9027BE5DD3BD981C571DF3210D" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_D73ADD1F369F5A60AF4CC6118B273877" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtMember" xlink:label="loc_us-gaap_ShortTermDebtMember_95668803968B553A85AE557232D1CFAA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_D73ADD1F369F5A60AF4CC6118B273877" xlink:to="loc_us-gaap_ShortTermDebtMember_95668803968B553A85AE557232D1CFAA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_AA5DEF9F20F55DDCAE11A3371FCA525F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_82A5AE74CCCA55A0AE1D2595FF718979" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_AA5DEF9F20F55DDCAE11A3371FCA525F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_CE1C50779225516C80668B556C2F65BF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_AA5DEF9F20F55DDCAE11A3371FCA525F" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_CE1C50779225516C80668B556C2F65BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtMember" xlink:label="loc_us-gaap_LongTermDebtMember_CB213CE7B27A585FBFA574AD5361BB97" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_CE1C50779225516C80668B556C2F65BF" xlink:to="loc_us-gaap_LongTermDebtMember_CB213CE7B27A585FBFA574AD5361BB97" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_67056AA7DFAC52F2AFF902D45531EF38" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_82A5AE74CCCA55A0AE1D2595FF718979" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_67056AA7DFAC52F2AFF902D45531EF38" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_E6F7BDCB0B915802A089BB544237852A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_67056AA7DFAC52F2AFF902D45531EF38" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_E6F7BDCB0B915802A089BB544237852A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_B121D11620F05480923621A2BB5CB9DF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_E6F7BDCB0B915802A089BB544237852A" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_B121D11620F05480923621A2BB5CB9DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_771B641CCC625D02B5DC0D164D99D72D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_E6F7BDCB0B915802A089BB544237852A" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_771B641CCC625D02B5DC0D164D99D72D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_6D53D367502959E693ADBA258307970F" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_82A5AE74CCCA55A0AE1D2595FF718979" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_6D53D367502959E693ADBA258307970F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_B4CB6A5E8A765731A8877EE68CB5615A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_6D53D367502959E693ADBA258307970F" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_B4CB6A5E8A765731A8877EE68CB5615A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtSecuritiesMember" xlink:label="loc_us-gaap_DebtSecuritiesMember_1FCBA41C77C45892BAC20E318CE16DE1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_B4CB6A5E8A765731A8877EE68CB5615A" xlink:to="loc_us-gaap_DebtSecuritiesMember_1FCBA41C77C45892BAC20E318CE16DE1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_C802839F21555A069DC0A2D071158A14" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_B4CB6A5E8A765731A8877EE68CB5615A" xlink:to="loc_us-gaap_MoneyMarketFundsMember_C802839F21555A069DC0A2D071158A14" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquitySecuritiesMember" xlink:label="loc_us-gaap_EquitySecuritiesMember_EEAC019B38EB5DA9AB6D94DC640FDB13" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_B4CB6A5E8A765731A8877EE68CB5615A" xlink:to="loc_us-gaap_EquitySecuritiesMember_EEAC019B38EB5DA9AB6D94DC640FDB13" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_AC834DA6A7445646971E2713E6F7A27F" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_82A5AE74CCCA55A0AE1D2595FF718979" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_AC834DA6A7445646971E2713E6F7A27F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_16A4394594335F6F8B75CD13EB49ACCB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_AC834DA6A7445646971E2713E6F7A27F" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_16A4394594335F6F8B75CD13EB49ACCB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestRateSwapMember" xlink:label="loc_us-gaap_InterestRateSwapMember_B6D8AE62BBDC578FB79A8A571A519D3D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_16A4394594335F6F8B75CD13EB49ACCB" xlink:to="loc_us-gaap_InterestRateSwapMember_B6D8AE62BBDC578FB79A8A571A519D3D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CurrencySwapMember" xlink:label="loc_us-gaap_CurrencySwapMember_2054C324BF7D571FBAEFE4BFA3D75BB0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_16A4394594335F6F8B75CD13EB49ACCB" xlink:to="loc_us-gaap_CurrencySwapMember_2054C324BF7D571FBAEFE4BFA3D75BB0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ForeignExchangeForwardMember" xlink:label="loc_us-gaap_ForeignExchangeForwardMember_5A3FECD316B2595F963A61C5C8C3A570" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_16A4394594335F6F8B75CD13EB49ACCB" xlink:to="loc_us-gaap_ForeignExchangeForwardMember_5A3FECD316B2595F963A61C5C8C3A570" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_D09A33EFC8BA5D7C89FC6DC5981EF384" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_82A5AE74CCCA55A0AE1D2595FF718979" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_D09A33EFC8BA5D7C89FC6DC5981EF384" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_3A0DEE1C00B359B897C49F0910C8325E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_D09A33EFC8BA5D7C89FC6DC5981EF384" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_3A0DEE1C00B359B897C49F0910C8325E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TradingSecurities" xlink:label="loc_us-gaap_TradingSecurities_2602A84370AF587B9C0DFDE8C39550AF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_3A0DEE1C00B359B897C49F0910C8325E" xlink:to="loc_us-gaap_TradingSecurities_2602A84370AF587B9C0DFDE8C39550AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_365DD3AE4179535AA5E19545912E64A4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_3A0DEE1C00B359B897C49F0910C8325E" xlink:to="loc_us-gaap_AvailableForSaleSecurities_365DD3AE4179535AA5E19545912E64A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeAssets" xlink:label="loc_us-gaap_DerivativeAssets_0E984B72214D53D480A114C7B1535ECF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_3A0DEE1C00B359B897C49F0910C8325E" xlink:to="loc_us-gaap_DerivativeAssets_0E984B72214D53D480A114C7B1535ECF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_3C54C80A45BC5A3D9FECB354356F334C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_3A0DEE1C00B359B897C49F0910C8325E" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_3C54C80A45BC5A3D9FECB354356F334C" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_OtherSelectedFinancialAssetsAbstract" xlink:label="loc_pfe_OtherSelectedFinancialAssetsAbstract_F1112C10A70E5067893D9ED2271C9085" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_3A0DEE1C00B359B897C49F0910C8325E" xlink:to="loc_pfe_OtherSelectedFinancialAssetsAbstract_F1112C10A70E5067893D9ED2271C9085" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HeldToMaturitySecuritiesAmortizedCostBeforeOtherThanTemporaryImpairment" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesAmortizedCostBeforeOtherThanTemporaryImpairment_AA79B274BB565339A6C2C5761961CFC6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_OtherSelectedFinancialAssetsAbstract_F1112C10A70E5067893D9ED2271C9085" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesAmortizedCostBeforeOtherThanTemporaryImpairment_AA79B274BB565339A6C2C5761961CFC6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_6B61AE09F9AA5EE2A21E466AE1C0E52A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_OtherSelectedFinancialAssetsAbstract_F1112C10A70E5067893D9ED2271C9085" xlink:to="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_6B61AE09F9AA5EE2A21E466AE1C0E52A" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_OtherSelectedFinancialAssets" xlink:label="loc_pfe_OtherSelectedFinancialAssets_C99451FEF3805145BE686459062E56B6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_OtherSelectedFinancialAssetsAbstract_F1112C10A70E5067893D9ED2271C9085" xlink:to="loc_pfe_OtherSelectedFinancialAssets_C99451FEF3805145BE686459062E56B6" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_SelectedFinancialAssets" xlink:label="loc_pfe_SelectedFinancialAssets_5D2522FA4C2A5707B70C468084D3E203" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_3A0DEE1C00B359B897C49F0910C8325E" xlink:to="loc_pfe_SelectedFinancialAssets_5D2522FA4C2A5707B70C468084D3E203" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_A5B06994B824579E8F8506B1CB505171" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_D09A33EFC8BA5D7C89FC6DC5981EF384" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_A5B06994B824579E8F8506B1CB505171" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_DF914707FD7952A0A8CD4E65ACC29C72" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_A5B06994B824579E8F8506B1CB505171" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_DF914707FD7952A0A8CD4E65ACC29C72" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities_08980192D7CA53DA8A1F3A4352A79649" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_DF914707FD7952A0A8CD4E65ACC29C72" xlink:to="loc_us-gaap_DerivativeLiabilities_08980192D7CA53DA8A1F3A4352A79649" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_OtherSelectedFinancialLiabilitiesAbstract" xlink:label="loc_pfe_OtherSelectedFinancialLiabilitiesAbstract_983B0751E3D15BDA88A08E34B8934C8E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_A5B06994B824579E8F8506B1CB505171" xlink:to="loc_pfe_OtherSelectedFinancialLiabilitiesAbstract_983B0751E3D15BDA88A08E34B8934C8E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermBorrowingsAbstract" xlink:label="loc_us-gaap_ShortTermBorrowingsAbstract_5A3658C5658D5B2AB754D9F4A22E8A82" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_OtherSelectedFinancialLiabilitiesAbstract_983B0751E3D15BDA88A08E34B8934C8E" xlink:to="loc_us-gaap_ShortTermBorrowingsAbstract_5A3658C5658D5B2AB754D9F4A22E8A82" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_ShorttermDebtGross" xlink:label="loc_pfe_ShorttermDebtGross_4007320707415A9BBB0601DC8F4118A4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermBorrowingsAbstract_5A3658C5658D5B2AB754D9F4A22E8A82" xlink:to="loc_pfe_ShorttermDebtGross_4007320707415A9BBB0601DC8F4118A4" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting" xlink:label="loc_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting_A021C0E9ADB65466A7B60BA335A32C56" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermBorrowingsAbstract_5A3658C5658D5B2AB754D9F4A22E8A82" xlink:to="loc_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting_A021C0E9ADB65466A7B60BA335A32C56" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_653AAE9BD3DD571DB32C5142465DEC19" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermBorrowingsAbstract_5A3658C5658D5B2AB754D9F4A22E8A82" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_653AAE9BD3DD571DB32C5142465DEC19" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtCurrent" xlink:label="loc_us-gaap_DebtCurrent_06FC4301F4415B64AEADF3A063C4913B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermBorrowingsAbstract_5A3658C5658D5B2AB754D9F4A22E8A82" xlink:to="loc_us-gaap_DebtCurrent_06FC4301F4415B64AEADF3A063C4913B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtNoncurrentAbstract" xlink:label="loc_us-gaap_LongTermDebtNoncurrentAbstract_416F19A4639A530E96694ABA89DAFD7D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_OtherSelectedFinancialLiabilitiesAbstract_983B0751E3D15BDA88A08E34B8934C8E" xlink:to="loc_us-gaap_LongTermDebtNoncurrentAbstract_416F19A4639A530E96694ABA89DAFD7D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_D068782291165E76816DF7D94AA64026" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtNoncurrentAbstract_416F19A4639A530E96694ABA89DAFD7D" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_D068782291165E76816DF7D94AA64026" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_F868B271D2835272B876A4AE168AF71C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtNoncurrentAbstract_416F19A4639A530E96694ABA89DAFD7D" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_F868B271D2835272B876A4AE168AF71C" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_OtherFinancialLiabilities" xlink:label="loc_pfe_OtherFinancialLiabilities_36E1F154592E58059EEA3103D2D7FCD4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtNoncurrentAbstract_416F19A4639A530E96694ABA89DAFD7D" xlink:to="loc_pfe_OtherFinancialLiabilities_36E1F154592E58059EEA3103D2D7FCD4" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_SelectedFinancialLiabilities" xlink:label="loc_pfe_SelectedFinancialLiabilities_A028B2177B545D258BEAF0423003B1C1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_A5B06994B824579E8F8506B1CB505171" xlink:to="loc_pfe_SelectedFinancialLiabilities_A028B2177B545D258BEAF0423003B1C1" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsAssetsAndLiabilitiesMeasuredOnRecurringBasisFootnotesDetail" xlink:type="extended">
    <link:loc xlink:href="pfe-20171001.xsd#pfe_FinancialInstrumentsAbstract" xlink:label="loc_pfe_FinancialInstrumentsAbstract_33E70FB7323E67C7B68983C06F8E4EF5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_A4AE6D7FC6AEC33A451483C06F8FDCA8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_33E70FB7323E67C7B68983C06F8E4EF5" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_A4AE6D7FC6AEC33A451483C06F8FDCA8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_1F245BE68FF4A0B47C2383C06F8F26AB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_A4AE6D7FC6AEC33A451483C06F8FDCA8" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_1F245BE68FF4A0B47C2383C06F8F26AB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_244D52B2E81BF623D4E783C06F8F983D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1F245BE68FF4A0B47C2383C06F8F26AB" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_244D52B2E81BF623D4E783C06F8F983D" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_ForeignCurrencyLongTermDebtMember" xlink:label="loc_pfe_ForeignCurrencyLongTermDebtMember_4A41975D81F9C955C72A83C06F8F2E5D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_244D52B2E81BF623D4E783C06F8F983D" xlink:to="loc_pfe_ForeignCurrencyLongTermDebtMember_4A41975D81F9C955C72A83C06F8F2E5D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1FEA307C61087941203583C06F8FED0A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_A4AE6D7FC6AEC33A451483C06F8FDCA8" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1FEA307C61087941203583C06F8FED0A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_AAAB1E8F0CECBC2F4EA683C06F8F9BC4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1FEA307C61087941203583C06F8FED0A" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_AAAB1E8F0CECBC2F4EA683C06F8F9BC4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_C93D7B408724595C813583C06F94CCD6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_AAAB1E8F0CECBC2F4EA683C06F8F9BC4" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_C93D7B408724595C813583C06F94CCD6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="loc_us-gaap_HedgingDesignationAxis_4B0343557998B88C478283C06F95148F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_A4AE6D7FC6AEC33A451483C06F8FDCA8" xlink:to="loc_us-gaap_HedgingDesignationAxis_4B0343557998B88C478283C06F95148F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_7CC8A40ED56D8592BFF483C06F95413E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_4B0343557998B88C478283C06F95148F" xlink:to="loc_us-gaap_HedgingDesignationDomain_7CC8A40ED56D8592BFF483C06F95413E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="loc_us-gaap_NondesignatedMember_4E4929FA563EEB33FE7383C06F9565E0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_7CC8A40ED56D8592BFF483C06F95413E" xlink:to="loc_us-gaap_NondesignatedMember_4E4929FA563EEB33FE7383C06F9565E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_CEB3296B166509527C6283C06F9515CB" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_A4AE6D7FC6AEC33A451483C06F8FDCA8" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_CEB3296B166509527C6283C06F9515CB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_C8FF6EDA2FE92089BFA583C06F95AA9C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_CEB3296B166509527C6283C06F9515CB" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_C8FF6EDA2FE92089BFA583C06F95AA9C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ForeignExchangeForwardMember" xlink:label="loc_us-gaap_ForeignExchangeForwardMember_328FFD76C3BE75228D4B83C06F958EE1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_C8FF6EDA2FE92089BFA583C06F95AA9C" xlink:to="loc_us-gaap_ForeignExchangeForwardMember_328FFD76C3BE75228D4B83C06F958EE1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CurrencySwapMember" xlink:label="loc_us-gaap_CurrencySwapMember_88F285A0671EE32E943E83C06F9588B5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_C8FF6EDA2FE92089BFA583C06F95AA9C" xlink:to="loc_us-gaap_CurrencySwapMember_88F285A0671EE32E943E83C06F9588B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_4D72FB2E33761506BAAE83C06F9568FF" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_A4AE6D7FC6AEC33A451483C06F8FDCA8" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_4D72FB2E33761506BAAE83C06F9568FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_3E8E008349FD4001FE8483C06F956A9C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_4D72FB2E33761506BAAE83C06F9568FF" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_3E8E008349FD4001FE8483C06F956A9C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_E2A9923B9CA59CC7CCF383C06F95AEC8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_3E8E008349FD4001FE8483C06F956A9C" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_E2A9923B9CA59CC7CCF383C06F95AEC8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_16D79AF9254B2BA65ED383C06F9591C2" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_A4AE6D7FC6AEC33A451483C06F8FDCA8" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_16D79AF9254B2BA65ED383C06F9591C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_26361C6280493481B9F383C06F95ACB3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_16D79AF9254B2BA65ED383C06F9591C2" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_26361C6280493481B9F383C06F95ACB3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_CED491933FFCD21929B283C06F9583AE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_26361C6280493481B9F383C06F95ACB3" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_CED491933FFCD21929B283C06F9583AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_2F465C3BD268775757BB83C06F957AA5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_26361C6280493481B9F383C06F95ACB3" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_2F465C3BD268775757BB83C06F957AA5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1CD67510301DF2EAD6AD83C06F95E921" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_A4AE6D7FC6AEC33A451483C06F8FDCA8" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1CD67510301DF2EAD6AD83C06F95E921" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_FootnotesToSelectedFinancialAssetsAndLiabilitiesAbstract" xlink:label="loc_pfe_FootnotesToSelectedFinancialAssetsAndLiabilitiesAbstract_47737018BB84937F2CB083C06F969081" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1CD67510301DF2EAD6AD83C06F95E921" xlink:to="loc_pfe_FootnotesToSelectedFinancialAssetsAndLiabilitiesAbstract_47737018BB84937F2CB083C06F969081" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_FinancialAssetsAndLiabilitiesMeasuredAtFairValuePercentage" xlink:label="loc_pfe_FinancialAssetsAndLiabilitiesMeasuredAtFairValuePercentage_FAFE5F2A581C842C8DDB83C06F965418" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FootnotesToSelectedFinancialAssetsAndLiabilitiesAbstract_47737018BB84937F2CB083C06F969081" xlink:to="loc_pfe_FinancialAssetsAndLiabilitiesMeasuredAtFairValuePercentage_FAFE5F2A581C842C8DDB83C06F965418" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TradingSecuritiesEquity" xlink:label="loc_us-gaap_TradingSecuritiesEquity_17550727984FD2E15D9B83C06F96B03A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FootnotesToSelectedFinancialAssetsAndLiabilitiesAbstract_47737018BB84937F2CB083C06F969081" xlink:to="loc_us-gaap_TradingSecuritiesEquity_17550727984FD2E15D9B83C06F96B03A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TradingSecuritiesDebt" xlink:label="loc_us-gaap_TradingSecuritiesDebt_C1D3E3C5DD0B2D28137483C06F96161D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FootnotesToSelectedFinancialAssetsAndLiabilitiesAbstract_47737018BB84937F2CB083C06F969081" xlink:to="loc_us-gaap_TradingSecuritiesDebt_C1D3E3C5DD0B2D28137483C06F96161D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TradingSecuritiesRestricted" xlink:label="loc_us-gaap_TradingSecuritiesRestricted_F273278ECB9D2A003ED983C06F9BCD03" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FootnotesToSelectedFinancialAssetsAndLiabilitiesAbstract_47737018BB84937F2CB083C06F969081" xlink:to="loc_us-gaap_TradingSecuritiesRestricted_F273278ECB9D2A003ED983C06F9BCD03" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleEquitySecuritiesGrossUnrealizedGain" xlink:label="loc_us-gaap_AvailableForSaleEquitySecuritiesGrossUnrealizedGain_018B8867E1C6BEDC056583C06F9B518A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FootnotesToSelectedFinancialAssetsAndLiabilitiesAbstract_47737018BB84937F2CB083C06F969081" xlink:to="loc_us-gaap_AvailableForSaleEquitySecuritiesGrossUnrealizedGain_018B8867E1C6BEDC056583C06F9B518A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleEquitySecuritiesGrossUnrealizedLoss" xlink:label="loc_us-gaap_AvailableForSaleEquitySecuritiesGrossUnrealizedLoss_292E722B66CBD96B1C8B83C06F9BF32D" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FootnotesToSelectedFinancialAssetsAndLiabilitiesAbstract_47737018BB84937F2CB083C06F969081" xlink:to="loc_us-gaap_AvailableForSaleEquitySecuritiesGrossUnrealizedLoss_292E722B66CBD96B1C8B83C06F9BF32D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_8B4684F6A889AD23A6B183C06F9B105D" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FootnotesToSelectedFinancialAssetsAndLiabilitiesAbstract_47737018BB84937F2CB083C06F969081" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_8B4684F6A889AD23A6B183C06F9B105D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_BEA2FACC412603EC2E9C83C06F9CDE02" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FootnotesToSelectedFinancialAssetsAndLiabilitiesAbstract_47737018BB84937F2CB083C06F969081" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_BEA2FACC412603EC2E9C83C06F9CDE02" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtFairValue" xlink:label="loc_us-gaap_LongTermDebtFairValue_682A819E7E6ECBFB4D5783C06F9C4D9F" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FootnotesToSelectedFinancialAssetsAndLiabilitiesAbstract_47737018BB84937F2CB083C06F969081" xlink:to="loc_us-gaap_LongTermDebtFairValue_682A819E7E6ECBFB4D5783C06F9C4D9F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsBalanceSheetGroupingDetail" xlink:type="extended">
    <link:loc xlink:href="pfe-20171001.xsd#pfe_FinancialInstrumentsAbstract" xlink:label="loc_pfe_FinancialInstrumentsAbstract_A4824A40C0415119B2B4D0EFB209F2AA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_C3257AD4017C59A68CB4B966050AB1C2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_A4824A40C0415119B2B4D0EFB209F2AA" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_C3257AD4017C59A68CB4B966050AB1C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_6A3523DDB03557DE9D273D3755032668" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_C3257AD4017C59A68CB4B966050AB1C2" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_6A3523DDB03557DE9D273D3755032668" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_4BDF5E046AB95466A095F3ADAE5C803C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_6A3523DDB03557DE9D273D3755032668" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_4BDF5E046AB95466A095F3ADAE5C803C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsMember" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember_540B2769F98F562BA5A4CBA5C6E64BD1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_4BDF5E046AB95466A095F3ADAE5C803C" xlink:to="loc_us-gaap_CashAndCashEquivalentsMember_540B2769F98F562BA5A4CBA5C6E64BD1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermInvestmentsMember" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_DB0DDEC60A6D54DF88CBB2F83C60C9C3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_4BDF5E046AB95466A095F3ADAE5C803C" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_DB0DDEC60A6D54DF88CBB2F83C60C9C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherCurrentAssetsMember" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_9953FA6D110A533EBF4B7F78FDF39C63" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_4BDF5E046AB95466A095F3ADAE5C803C" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_9953FA6D110A533EBF4B7F78FDF39C63" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_LongtermInvestmentsMember" xlink:label="loc_pfe_LongtermInvestmentsMember_02A50238EE485DF7908769971C65B6FD" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_4BDF5E046AB95466A095F3ADAE5C803C" xlink:to="loc_pfe_LongtermInvestmentsMember_02A50238EE485DF7908769971C65B6FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_2474887ED15958C68C50F7EC35A4F24C" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_4BDF5E046AB95466A095F3ADAE5C803C" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_2474887ED15958C68C50F7EC35A4F24C" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_ShortTermDebtAndCurrentPortionofLongTermDebtMember" xlink:label="loc_pfe_ShortTermDebtAndCurrentPortionofLongTermDebtMember_B3DE2C6533265F19BB471811F695A7C1" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_4BDF5E046AB95466A095F3ADAE5C803C" xlink:to="loc_pfe_ShortTermDebtAndCurrentPortionofLongTermDebtMember_B3DE2C6533265F19BB471811F695A7C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_1C5D57B745B75C3785CA83CA3FFD90B5" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_4BDF5E046AB95466A095F3ADAE5C803C" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_1C5D57B745B75C3785CA83CA3FFD90B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtMember" xlink:label="loc_us-gaap_LongTermDebtMember_85E6279587DC5AA4B63517E2E8C434EA" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_4BDF5E046AB95466A095F3ADAE5C803C" xlink:to="loc_us-gaap_LongTermDebtMember_85E6279587DC5AA4B63517E2E8C434EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_9F799E46A82E534BB634EC1D8986FCD6" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_4BDF5E046AB95466A095F3ADAE5C803C" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_9F799E46A82E534BB634EC1D8986FCD6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_54E53BF25E635777A26D9863423332BE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_C3257AD4017C59A68CB4B966050AB1C2" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_54E53BF25E635777A26D9863423332BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_DFF744CF05D955CB905DC112328A5256" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_54E53BF25E635777A26D9863423332BE" xlink:to="loc_us-gaap_AssetsAbstract_DFF744CF05D955CB905DC112328A5256" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_SelectedFinancialAssets" xlink:label="loc_pfe_SelectedFinancialAssets_6D8A63016BA9577DA31990E75282FBD7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_DFF744CF05D955CB905DC112328A5256" xlink:to="loc_pfe_SelectedFinancialAssets_6D8A63016BA9577DA31990E75282FBD7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAbstract" xlink:label="loc_us-gaap_LiabilitiesAbstract_BD52E99619F559A28785225F8CDE01A6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_54E53BF25E635777A26D9863423332BE" xlink:to="loc_us-gaap_LiabilitiesAbstract_BD52E99619F559A28785225F8CDE01A6" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_SelectedFinancialLiabilities" xlink:label="loc_pfe_SelectedFinancialLiabilities_C1B2775507145CF084B6B3F239A46DAA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_BD52E99619F559A28785225F8CDE01A6" xlink:to="loc_pfe_SelectedFinancialLiabilities_C1B2775507145CF084B6B3F239A46DAA" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsBalanceSheetGroupingFootnotesDetail" xlink:type="extended">
    <link:loc xlink:href="pfe-20171001.xsd#pfe_FinancialInstrumentsAbstract" xlink:label="loc_pfe_FinancialInstrumentsAbstract_B40A8513D92012BB03B15A4F9E5E6FC6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_3F32F9245C50F47D8E7F5A4F9E5E0D30" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_B40A8513D92012BB03B15A4F9E5E6FC6" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_3F32F9245C50F47D8E7F5A4F9E5E0D30" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_18FB3598D46AA930EBC15A4F9E5E8FAE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_3F32F9245C50F47D8E7F5A4F9E5E0D30" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_18FB3598D46AA930EBC15A4F9E5E8FAE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_9A281FBF209F172DE3B25A4F9E5ED590" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_18FB3598D46AA930EBC15A4F9E5E8FAE" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_9A281FBF209F172DE3B25A4F9E5ED590" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherCurrentAssetsMember" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_5E3318AAC5C1471BD4C55A4F9E5EE154" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_9A281FBF209F172DE3B25A4F9E5ED590" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_5E3318AAC5C1471BD4C55A4F9E5EE154" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_9C4FC3F5220E9A520C165A4F9E5E6886" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_9A281FBF209F172DE3B25A4F9E5ED590" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_9C4FC3F5220E9A520C165A4F9E5E6886" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_D74EB8AE6C4EDDB1ED415A4F9E5E041A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_9A281FBF209F172DE3B25A4F9E5ED590" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_D74EB8AE6C4EDDB1ED415A4F9E5E041A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_C4C6FDA73863633169CB5A4F9E5E3820" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_9A281FBF209F172DE3B25A4F9E5ED590" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_C4C6FDA73863633169CB5A4F9E5E3820" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_8A5AC61C8E3FC92DCA525A4F9E5E92CC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_3F32F9245C50F47D8E7F5A4F9E5E0D30" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_8A5AC61C8E3FC92DCA525A4F9E5E92CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_9E06B97A4BC0B87408445A4F9E5EF6E6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_8A5AC61C8E3FC92DCA525A4F9E5E92CC" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_9E06B97A4BC0B87408445A4F9E5EF6E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestRateSwapMember" xlink:label="loc_us-gaap_InterestRateSwapMember_466BD5A865D714EB4AC25A4F9E5E945D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_9E06B97A4BC0B87408445A4F9E5EF6E6" xlink:to="loc_us-gaap_InterestRateSwapMember_466BD5A865D714EB4AC25A4F9E5E945D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CurrencySwapMember" xlink:label="loc_us-gaap_CurrencySwapMember_3F620A0F27C328909AB05A4F9E5E65C2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_9E06B97A4BC0B87408445A4F9E5EF6E6" xlink:to="loc_us-gaap_CurrencySwapMember_3F620A0F27C328909AB05A4F9E5E65C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ForeignExchangeForwardMember" xlink:label="loc_us-gaap_ForeignExchangeForwardMember_DD98A5D86855814D6E8B5A4F9E5EC550" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_9E06B97A4BC0B87408445A4F9E5EF6E6" xlink:to="loc_us-gaap_ForeignExchangeForwardMember_DD98A5D86855814D6E8B5A4F9E5EC550" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_47D3223EC1E7FE607A0C5A4F9E5E389F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_3F32F9245C50F47D8E7F5A4F9E5E0D30" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_47D3223EC1E7FE607A0C5A4F9E5E389F" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_SelectedFinancialAssets" xlink:label="loc_pfe_SelectedFinancialAssets_A414F4973077E27BDF6F5A4F9E5E2D66" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_47D3223EC1E7FE607A0C5A4F9E5E389F" xlink:to="loc_pfe_SelectedFinancialAssets_A414F4973077E27BDF6F5A4F9E5E2D66" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_SelectedFinancialLiabilities" xlink:label="loc_pfe_SelectedFinancialLiabilities_5D91E24654C3B7C739095A4F9E5E0D7E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_47D3223EC1E7FE607A0C5A4F9E5E389F" xlink:to="loc_pfe_SelectedFinancialLiabilities_5D91E24654C3B7C739095A4F9E5E0D7E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetail" xlink:type="extended">
    <link:loc xlink:href="pfe-20171001.xsd#pfe_FinancialInstrumentsAbstract" xlink:label="loc_pfe_FinancialInstrumentsAbstract_A2A35CF9268F8393BBA778AA4E1B1DF9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_CF27A3AAD79239BF848878AA4E1C48CD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_A2A35CF9268F8393BBA778AA4E1B1DF9" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_CF27A3AAD79239BF848878AA4E1C48CD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_48ED47ACDE4C298930AB78AA4E1C5915" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_CF27A3AAD79239BF848878AA4E1C48CD" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_48ED47ACDE4C298930AB78AA4E1C5915" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_75F9AB8FDFC21345FC8F78AA4E1C2245" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_48ED47ACDE4C298930AB78AA4E1C5915" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_75F9AB8FDFC21345FC8F78AA4E1C2245" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnsecuredDebtMember" xlink:label="loc_us-gaap_UnsecuredDebtMember_6266BD9FDC1A16C982D478AA4E1CE17C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_75F9AB8FDFC21345FC8F78AA4E1C2245" xlink:to="loc_us-gaap_UnsecuredDebtMember_6266BD9FDC1A16C982D478AA4E1CE17C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_5EF685C7B1E308E6555278AA4E1D71FA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_CF27A3AAD79239BF848878AA4E1C48CD" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_5EF685C7B1E308E6555278AA4E1D71FA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_4DA99CE97749FD2391A778AA4E1D742B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_5EF685C7B1E308E6555278AA4E1D71FA" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_4DA99CE97749FD2391A778AA4E1D742B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestRateContractMember" xlink:label="loc_us-gaap_InterestRateContractMember_DBA1E6354F5DE5B35CBF78AA4E1D4AE0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_4DA99CE97749FD2391A778AA4E1D742B" xlink:to="loc_us-gaap_InterestRateContractMember_DBA1E6354F5DE5B35CBF78AA4E1D4AE0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CurrencySwapMember" xlink:label="loc_us-gaap_CurrencySwapMember_82F87E83423B484497A378AA4E1DF576" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_4DA99CE97749FD2391A778AA4E1D742B" xlink:to="loc_us-gaap_CurrencySwapMember_82F87E83423B484497A378AA4E1DF576" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ForeignExchangeForwardMember" xlink:label="loc_us-gaap_ForeignExchangeForwardMember_4644AD243DB3EB919CA178AA4E1D98D4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_4DA99CE97749FD2391A778AA4E1D742B" xlink:to="loc_us-gaap_ForeignExchangeForwardMember_4644AD243DB3EB919CA178AA4E1D98D4" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_ForeignCurrencyShortTermBorrowingsMember" xlink:label="loc_pfe_ForeignCurrencyShortTermBorrowingsMember_BB6F2AD2ED115650B75978AA4E1E2B9A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_4DA99CE97749FD2391A778AA4E1D742B" xlink:to="loc_pfe_ForeignCurrencyShortTermBorrowingsMember_BB6F2AD2ED115650B75978AA4E1E2B9A" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_ForeignCurrencyLongTermDebtMember" xlink:label="loc_pfe_ForeignCurrencyLongTermDebtMember_499472B953FCD72A002878AA4E1E64D9" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_4DA99CE97749FD2391A778AA4E1D742B" xlink:to="loc_pfe_ForeignCurrencyLongTermDebtMember_499472B953FCD72A002878AA4E1E64D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="loc_us-gaap_HedgingDesignationAxis_45000618DCD62BD2202878AA4E1E7570" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_CF27A3AAD79239BF848878AA4E1C48CD" xlink:to="loc_us-gaap_HedgingDesignationAxis_45000618DCD62BD2202878AA4E1E7570" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_B1BE836C2F0D66D9036D78AA4E1EA68B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_45000618DCD62BD2202878AA4E1E7570" xlink:to="loc_us-gaap_HedgingDesignationDomain_B1BE836C2F0D66D9036D78AA4E1EA68B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_87EC418DEA5503470C9078AA4E1EF79A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_B1BE836C2F0D66D9036D78AA4E1EA68B" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_87EC418DEA5503470C9078AA4E1EF79A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="loc_us-gaap_NondesignatedMember_FF324CEEE2823836B39178AA4E1E519B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_B1BE836C2F0D66D9036D78AA4E1EA68B" xlink:to="loc_us-gaap_NondesignatedMember_FF324CEEE2823836B39178AA4E1E519B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_6FDD586F015E8F73B85878AA4E1E073B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_CF27A3AAD79239BF848878AA4E1C48CD" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_6FDD586F015E8F73B85878AA4E1E073B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HedgingRelationshipDomain" xlink:label="loc_us-gaap_HedgingRelationshipDomain_255FF6B0A7AD4429902578AA4E1E7418" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_6FDD586F015E8F73B85878AA4E1E073B" xlink:to="loc_us-gaap_HedgingRelationshipDomain_255FF6B0A7AD4429902578AA4E1E7418" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashFlowHedgingMember" xlink:label="loc_us-gaap_CashFlowHedgingMember_F281A920718EFF75ED8778AA4E1E2383" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_255FF6B0A7AD4429902578AA4E1E7418" xlink:to="loc_us-gaap_CashFlowHedgingMember_F281A920718EFF75ED8778AA4E1E2383" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetInvestmentHedgingMember" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_B613AD93F10553CAB19B78AA4E1E3F41" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_255FF6B0A7AD4429902578AA4E1E7418" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_B613AD93F10553CAB19B78AA4E1E3F41" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_NetInvestmentHedgingNonderivativeInstrumentsMember" xlink:label="loc_pfe_NetInvestmentHedgingNonderivativeInstrumentsMember_147B9FA1FEC67868DF0078AA4E1FCC8B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_255FF6B0A7AD4429902578AA4E1E7418" xlink:to="loc_pfe_NetInvestmentHedgingNonderivativeInstrumentsMember_147B9FA1FEC67868DF0078AA4E1FCC8B" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_OtherDerivativeInstrumentsMember" xlink:label="loc_pfe_OtherDerivativeInstrumentsMember_18FE7887BD8CF7C341E378AA4E1F933B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_255FF6B0A7AD4429902578AA4E1E7418" xlink:to="loc_pfe_OtherDerivativeInstrumentsMember_18FE7887BD8CF7C341E378AA4E1F933B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_9C71DF60AC5223DB5CC178AA4E1F0ABF" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_CF27A3AAD79239BF848878AA4E1C48CD" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_9C71DF60AC5223DB5CC178AA4E1F0ABF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_A44E817CE9C065926F2C78AA4E1F6FFB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_9C71DF60AC5223DB5CC178AA4E1F0ABF" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_A44E817CE9C065926F2C78AA4E1F6FFB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_696E486E8C8B4961607D78AA4E1F275F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_A44E817CE9C065926F2C78AA4E1F6FFB" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_696E486E8C8B4961607D78AA4E1F275F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_B3C007565DFD9CF164A978AA4E1F4320" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_CF27A3AAD79239BF848878AA4E1C48CD" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_B3C007565DFD9CF164A978AA4E1F4320" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_77FECC347A2998D162B978AA4E1FEEDB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_B3C007565DFD9CF164A978AA4E1F4320" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_77FECC347A2998D162B978AA4E1FEEDB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_61AB97485D607DA6180578AA4E20C1E5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_77FECC347A2998D162B978AA4E1FEEDB" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_61AB97485D607DA6180578AA4E20C1E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLocationAxis" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLocationAxis_D25A26AF52D62E47EEFA78AA4E203AF9" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_CF27A3AAD79239BF848878AA4E1C48CD" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLocationAxis_D25A26AF52D62E47EEFA78AA4E203AF9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLocationDomain" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLocationDomain_9F753970A4E05FA5ED0B78AA4E207D75" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLocationAxis_D25A26AF52D62E47EEFA78AA4E203AF9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLocationDomain_9F753970A4E05FA5ED0B78AA4E207D75" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_OtherComprehensiveIncomeMember_E374EA4569F6FC572E8D78AA4E20E5D6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLocationDomain_9F753970A4E05FA5ED0B78AA4E207D75" xlink:to="loc_us-gaap_OtherComprehensiveIncomeMember_E374EA4569F6FC572E8D78AA4E20E5D6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_20882AED6FCB469992E978AA4E209725" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_CF27A3AAD79239BF848878AA4E1C48CD" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_20882AED6FCB469992E978AA4E209725" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeAssetNotionalAmount" xlink:label="loc_us-gaap_DerivativeAssetNotionalAmount_A9DB330FD322608D665778AA4E20BD2C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_20882AED6FCB469992E978AA4E209725" xlink:to="loc_us-gaap_DerivativeAssetNotionalAmount_A9DB330FD322608D665778AA4E20BD2C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_31FC9AA89B9F1381E10A78AA4E204CB8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_20882AED6FCB469992E978AA4E209725" xlink:to="loc_us-gaap_LongTermDebt_31FC9AA89B9F1381E10A78AA4E204CB8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_DerivativeNotionalAmount" xlink:label="loc_invest_DerivativeNotionalAmount_E07148EA7884960A7D4178AA4E219F5A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_20882AED6FCB469992E978AA4E209725" xlink:to="loc_invest_DerivativeNotionalAmount_E07148EA7884960A7D4178AA4E219F5A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrealizedLossOnForeignCurrencyDerivativesBeforeTax" xlink:label="loc_us-gaap_UnrealizedLossOnForeignCurrencyDerivativesBeforeTax_A15B0D932880BD01634878AA4E211F6B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_20882AED6FCB469992E978AA4E209725" xlink:to="loc_us-gaap_UnrealizedLossOnForeignCurrencyDerivativesBeforeTax_A15B0D932880BD01634878AA4E211F6B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months" xlink:label="loc_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months_D44E3E36195FDE0E15DC78AA4E21307B" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_20882AED6FCB469992E978AA4E209725" xlink:to="loc_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months_D44E3E36195FDE0E15DC78AA4E21307B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ForeignCurrencyCashFlowHedgeGainLossReclassifiedToEarningsNet" xlink:label="loc_us-gaap_ForeignCurrencyCashFlowHedgeGainLossReclassifiedToEarningsNet_A9DFDC02E420F85C5EDC78AA4E21C144" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_20882AED6FCB469992E978AA4E209725" xlink:to="loc_us-gaap_ForeignCurrencyCashFlowHedgeGainLossReclassifiedToEarningsNet_A9DFDC02E420F85C5EDC78AA4E21C144" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_3B083D80AD6CAE23B85D78AA4E21FBAF" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_20882AED6FCB469992E978AA4E209725" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_3B083D80AD6CAE23B85D78AA4E21FBAF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet_14F201A640AEF7BB85DB78AA4E2111C9" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_20882AED6FCB469992E978AA4E209725" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet_14F201A640AEF7BB85DB78AA4E2111C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_5ACCD336FC896737348278AA4E21C2BB" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_20882AED6FCB469992E978AA4E209725" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_5ACCD336FC896737348278AA4E21C2BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossOnCashFlowHedgeIneffectivenessNet" xlink:label="loc_us-gaap_GainLossOnCashFlowHedgeIneffectivenessNet_FF4E452EE8E099C6002C78AA4E218395" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_20882AED6FCB469992E978AA4E209725" xlink:to="loc_us-gaap_GainLossOnCashFlowHedgeIneffectivenessNet_FF4E452EE8E099C6002C78AA4E218395" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsInvestmentsInDebtSecuritiesDetail" xlink:type="extended">
    <link:loc xlink:href="pfe-20171001.xsd#pfe_FinancialInstrumentsAbstract" xlink:label="loc_pfe_FinancialInstrumentsAbstract_9F4F8991A65299B6734778AA92B4CF12" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfInvestmentsTable" xlink:label="loc_us-gaap_ScheduleOfInvestmentsTable_1B122C04A037CB87665A78AA92B62F4B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_9F4F8991A65299B6734778AA92B4CF12" xlink:to="loc_us-gaap_ScheduleOfInvestmentsTable_1B122C04A037CB87665A78AA92B62F4B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_49AA14A49822CBB003FD78AA92B6ECE2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_1B122C04A037CB87665A78AA92B62F4B" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_49AA14A49822CBB003FD78AA92B6ECE2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_05F10A8052398DBB54ED78AA92B6B489" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_49AA14A49822CBB003FD78AA92B6ECE2" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_05F10A8052398DBB54ED78AA92B6B489" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_8D8EB9EE3F06820F3E5D78AA92B67537" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_05F10A8052398DBB54ED78AA92B6B489" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_8D8EB9EE3F06820F3E5D78AA92B67537" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_WesternEuropeanAsianandOtherGovernmentDebtMember" xlink:label="loc_pfe_WesternEuropeanAsianandOtherGovernmentDebtMember_EA72CD8D8A6F7FFE3EF278AA92B6C281" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_05F10A8052398DBB54ED78AA92B6B489" xlink:to="loc_pfe_WesternEuropeanAsianandOtherGovernmentDebtMember_EA72CD8D8A6F7FFE3EF278AA92B6C281" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_WesternEuropeanScandinaviaAndOtherGovernmentAgencyDebtMember" xlink:label="loc_pfe_WesternEuropeanScandinaviaAndOtherGovernmentAgencyDebtMember_CB30E57D4BF3F4C8799878AA92B6A970" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_05F10A8052398DBB54ED78AA92B6B489" xlink:to="loc_pfe_WesternEuropeanScandinaviaAndOtherGovernmentAgencyDebtMember_CB30E57D4BF3F4C8799878AA92B6A970" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_SupranationalDebtMember" xlink:label="loc_pfe_SupranationalDebtMember_1AD4FDACD3130EB6815178AA92B6F261" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_05F10A8052398DBB54ED78AA92B6B489" xlink:to="loc_pfe_SupranationalDebtMember_1AD4FDACD3130EB6815178AA92B6F261" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GovernmentNationalMortgageAssociationCertificatesAndObligationsGNMAMember" xlink:label="loc_us-gaap_GovernmentNationalMortgageAssociationCertificatesAndObligationsGNMAMember_89EF659F315C9297769378AA92B6FE38" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_05F10A8052398DBB54ED78AA92B6B489" xlink:to="loc_us-gaap_GovernmentNationalMortgageAssociationCertificatesAndObligationsGNMAMember_89EF659F315C9297769378AA92B6FE38" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_A4DA7F9D7B2D4F3B043778AA92B65309" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_05F10A8052398DBB54ED78AA92B6B489" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_A4DA7F9D7B2D4F3B043778AA92B65309" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_USGovernmentDebtSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentDebtSecuritiesMember_3DBEE0FBEA65A8E0E64778AA92B61D9A" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_05F10A8052398DBB54ED78AA92B6B489" xlink:to="loc_us-gaap_USGovernmentDebtSecuritiesMember_3DBEE0FBEA65A8E0E64778AA92B61D9A" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_TimeDepositsCorporateDebtAndOtherMember" xlink:label="loc_pfe_TimeDepositsCorporateDebtAndOtherMember_4E27277A92FBD0C3817D78AA92B7E012" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_05F10A8052398DBB54ED78AA92B6B489" xlink:to="loc_pfe_TimeDepositsCorporateDebtAndOtherMember_4E27277A92FBD0C3817D78AA92B7E012" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_WesternEuropeanandOtherGovernmentDebtMember" xlink:label="loc_pfe_WesternEuropeanandOtherGovernmentDebtMember_DC371F58241A67D2293C78AA92B7DF8A" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_05F10A8052398DBB54ED78AA92B6B489" xlink:to="loc_pfe_WesternEuropeanandOtherGovernmentDebtMember_DC371F58241A67D2293C78AA92B7DF8A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfInvestmentsLineItems" xlink:label="loc_us-gaap_ScheduleOfInvestmentsLineItems_A64830A5E08CAF95AC4678AA92B7E9C1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_1B122C04A037CB87665A78AA92B62F4B" xlink:to="loc_us-gaap_ScheduleOfInvestmentsLineItems_A64830A5E08CAF95AC4678AA92B7E9C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue_7F3DAEF96C226F9CCA9B78AA92B7DCD8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_A64830A5E08CAF95AC4678AA92B7E9C1" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue_7F3DAEF96C226F9CCA9B78AA92B7DCD8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue_C9752945532AD01CEBD678AA92B7E208" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_A64830A5E08CAF95AC4678AA92B7E9C1" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue_C9752945532AD01CEBD678AA92B7E208" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearSixThroughTenFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearSixThroughTenFairValue_670BA5D746D5AE0E305C78AA92B76099" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_A64830A5E08CAF95AC4678AA92B7E9C1" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearSixThroughTenFairValue_670BA5D746D5AE0E305C78AA92B76099" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingAfterYearTenFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingAfterYearTenFairValue_B83630CFB8696D07E88578AA92B7DE4B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_A64830A5E08CAF95AC4678AA92B7E9C1" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingAfterYearTenFairValue_B83630CFB8696D07E88578AA92B7DE4B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_C4367B456D1BDD012F1A78AA92B86676" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_A64830A5E08CAF95AC4678AA92B7E9C1" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_C4367B456D1BDD012F1A78AA92B86676" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue_9A9BBB1EA0953898D71978AA92B8BDAC" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_A64830A5E08CAF95AC4678AA92B7E9C1" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue_9A9BBB1EA0953898D71978AA92B8BDAC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue_A21CAE365F9B6009B17878AA92B86B69" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_A64830A5E08CAF95AC4678AA92B7E9C1" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue_A21CAE365F9B6009B17878AA92B86B69" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesRollingYearSixThroughTenFairValue" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesRollingYearSixThroughTenFairValue_D1831CABE6685FFFB00A78AA92B8F1C8" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_A64830A5E08CAF95AC4678AA92B7E9C1" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesRollingYearSixThroughTenFairValue_D1831CABE6685FFFB00A78AA92B8F1C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesRollingAfterTenYearsFairValue" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesRollingAfterTenYearsFairValue_7AF9BDB355A73F8DE7B078AA92B8AA34" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_A64830A5E08CAF95AC4678AA92B7E9C1" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesRollingAfterTenYearsFairValue_7AF9BDB355A73F8DE7B078AA92B8AA34" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HeldToMaturitySecurities" xlink:label="loc_us-gaap_HeldToMaturitySecurities_9A0F3DF4B3089CB57A8F78AA92B8A7D9" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_A64830A5E08CAF95AC4678AA92B7E9C1" xlink:to="loc_us-gaap_HeldToMaturitySecurities_9A0F3DF4B3089CB57A8F78AA92B8A7D9" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_DebtSecuritiesMaturitiesWithinOneYear" xlink:label="loc_pfe_DebtSecuritiesMaturitiesWithinOneYear_22A320D28C9E0CB0554A78AA92B8D19C" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_A64830A5E08CAF95AC4678AA92B7E9C1" xlink:to="loc_pfe_DebtSecuritiesMaturitiesWithinOneYear_22A320D28C9E0CB0554A78AA92B8D19C" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_DebtSecuritiesMaturitiesOverOneToFiveYears" xlink:label="loc_pfe_DebtSecuritiesMaturitiesOverOneToFiveYears_D8703D4D586E410647AC78AA92B9700D" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_A64830A5E08CAF95AC4678AA92B7E9C1" xlink:to="loc_pfe_DebtSecuritiesMaturitiesOverOneToFiveYears_D8703D4D586E410647AC78AA92B9700D" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_DebtSecuritiesMaturitiesOverFiveToTenYears" xlink:label="loc_pfe_DebtSecuritiesMaturitiesOverFiveToTenYears_DF1DBDFC358B17AF3EB478AA92B9CCEA" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_A64830A5E08CAF95AC4678AA92B7E9C1" xlink:to="loc_pfe_DebtSecuritiesMaturitiesOverFiveToTenYears_DF1DBDFC358B17AF3EB478AA92B9CCEA" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_DebtSecuritiesMaturitiesAfterTenYears" xlink:label="loc_pfe_DebtSecuritiesMaturitiesAfterTenYears_D62A663ECCA81C74435078AA92B9D1B3" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_A64830A5E08CAF95AC4678AA92B7E9C1" xlink:to="loc_pfe_DebtSecuritiesMaturitiesAfterTenYears_D62A663ECCA81C74435078AA92B9D1B3" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_DebtSecurities" xlink:label="loc_pfe_DebtSecurities_07220525955D29F6F70E78AA92B90D05" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_A64830A5E08CAF95AC4678AA92B7E9C1" xlink:to="loc_pfe_DebtSecurities_07220525955D29F6F70E78AA92B90D05" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:href="pfe-20171001.xsd#pfe_FinancialInstrumentsAbstract" xlink:label="loc_pfe_FinancialInstrumentsAbstract_F80DD5C04A495F50BE1B87A1771253E5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_51E56C85CE6A5ED89D2E0F3C6EA52B30" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_F80DD5C04A495F50BE1B87A1771253E5" xlink:to="loc_us-gaap_DebtInstrumentTable_51E56C85CE6A5ED89D2E0F3C6EA52B30" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_CEF67C86DB7A53D29722F4B974084B7E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_51E56C85CE6A5ED89D2E0F3C6EA52B30" xlink:to="loc_us-gaap_RangeAxis_CEF67C86DB7A53D29722F4B974084B7E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_1101F102B98457D1BB25D3E98AA75AB1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_CEF67C86DB7A53D29722F4B974084B7E" xlink:to="loc_us-gaap_RangeMember_1101F102B98457D1BB25D3E98AA75AB1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_377AD433D2E252BB917DA3960A7A9F7A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_1101F102B98457D1BB25D3E98AA75AB1" xlink:to="loc_us-gaap_MaximumMember_377AD433D2E252BB917DA3960A7A9F7A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaap_VariableRateAxis_EFB6E8A6A0EF5EE883EFD8800C086C92" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_51E56C85CE6A5ED89D2E0F3C6EA52B30" xlink:to="loc_us-gaap_VariableRateAxis_EFB6E8A6A0EF5EE883EFD8800C086C92" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_667EED42CD205DB381E9B8E5B9E25E43" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_EFB6E8A6A0EF5EE883EFD8800C086C92" xlink:to="loc_us-gaap_VariableRateDomain_667EED42CD205DB381E9B8E5B9E25E43" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_EURIBORMember" xlink:label="loc_pfe_EURIBORMember_5854D078EE9C53919750C41FDCCE1904" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_667EED42CD205DB381E9B8E5B9E25E43" xlink:to="loc_pfe_EURIBORMember_5854D078EE9C53919750C41FDCCE1904" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_GermanGovernmentBondRateMember" xlink:label="loc_pfe_GermanGovernmentBondRateMember_BD811ADB34CE560A873B6BA0F0151B30" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_667EED42CD205DB381E9B8E5B9E25E43" xlink:to="loc_pfe_GermanGovernmentBondRateMember_BD811ADB34CE560A873B6BA0F0151B30" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_503290E72B645D9095F581B9EA510429" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_51E56C85CE6A5ED89D2E0F3C6EA52B30" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_503290E72B645D9095F581B9EA510429" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_79F4ACBA125C563CBA786742CCD4750B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_503290E72B645D9095F581B9EA510429" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_79F4ACBA125C563CBA786742CCD4750B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeniorNotesMember" xlink:label="loc_us-gaap_SeniorNotesMember_F3CDF6FC53045E819F699426907CBB73" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_79F4ACBA125C563CBA786742CCD4750B" xlink:to="loc_us-gaap_SeniorNotesMember_F3CDF6FC53045E819F699426907CBB73" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_B50E534C25C75D0883963661B805C526" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_51E56C85CE6A5ED89D2E0F3C6EA52B30" xlink:to="loc_us-gaap_DebtInstrumentAxis_B50E534C25C75D0883963661B805C526" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_B64CA27D9B5457B2A34CDBCC063EF114" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_B50E534C25C75D0883963661B805C526" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_B64CA27D9B5457B2A34CDBCC063EF114" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_SeniorUnsecuredEuroDebtThreemonthEURIBORPlus0.20FloatingRateNotesMember" xlink:label="loc_pfe_SeniorUnsecuredEuroDebtThreemonthEURIBORPlus0.20FloatingRateNotesMember_F4149BA6D6C15943AADBE6CA9F846679" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_B64CA27D9B5457B2A34CDBCC063EF114" xlink:to="loc_pfe_SeniorUnsecuredEuroDebtThreemonthEURIBORPlus0.20FloatingRateNotesMember_F4149BA6D6C15943AADBE6CA9F846679" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_SeniorUnsecuredEuroDebtZeroPercentDue2020Member" xlink:label="loc_pfe_SeniorUnsecuredEuroDebtZeroPercentDue2020Member_2E9473B14C455B688AE3AC9FEB73C6EA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_B64CA27D9B5457B2A34CDBCC063EF114" xlink:to="loc_pfe_SeniorUnsecuredEuroDebtZeroPercentDue2020Member_2E9473B14C455B688AE3AC9FEB73C6EA" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_SeniorUnsecuredEuroDebtPointTwofivePercentDue2022Member" xlink:label="loc_pfe_SeniorUnsecuredEuroDebtPointTwofivePercentDue2022Member_ECEDA866B0755EDD93216096CF4FC691" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_B64CA27D9B5457B2A34CDBCC063EF114" xlink:to="loc_pfe_SeniorUnsecuredEuroDebtPointTwofivePercentDue2022Member_ECEDA866B0755EDD93216096CF4FC691" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_SeniorUnsecuredEuroDebtOnePointZeroPercentDue2027Member" xlink:label="loc_pfe_SeniorUnsecuredEuroDebtOnePointZeroPercentDue2027Member_FF8440BBD346526FA5C94784631E22D4" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_B64CA27D9B5457B2A34CDBCC063EF114" xlink:to="loc_pfe_SeniorUnsecuredEuroDebtOnePointZeroPercentDue2027Member_FF8440BBD346526FA5C94784631E22D4" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_EuroLongtermDebtMember" xlink:label="loc_pfe_EuroLongtermDebtMember_AED48123C30353279CCE218F7D0385D2" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_B64CA27D9B5457B2A34CDBCC063EF114" xlink:to="loc_pfe_EuroLongtermDebtMember_AED48123C30353279CCE218F7D0385D2" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_SeniorUnsecuredDebtFourPointTwoPercentDue2047Member" xlink:label="loc_pfe_SeniorUnsecuredDebtFourPointTwoPercentDue2047Member_496301FF359753DEAB925646D12549D9" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_B64CA27D9B5457B2A34CDBCC063EF114" xlink:to="loc_pfe_SeniorUnsecuredDebtFourPointTwoPercentDue2047Member_496301FF359753DEAB925646D12549D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_EA31DB6B63CF54EAA7D8BD4798333EE2" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_51E56C85CE6A5ED89D2E0F3C6EA52B30" xlink:to="loc_us-gaap_DebtInstrumentLineItems_EA31DB6B63CF54EAA7D8BD4798333EE2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_314DB1A4337159798BCCFAADEB6D89E4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_EA31DB6B63CF54EAA7D8BD4798333EE2" xlink:to="loc_us-gaap_LongTermDebt_314DB1A4337159798BCCFAADEB6D89E4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_6F981CF6220250F9887BDFB936055FF5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_EA31DB6B63CF54EAA7D8BD4798333EE2" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_6F981CF6220250F9887BDFB936055FF5" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_DebtInstrumentFloorInterestRate" xlink:label="loc_pfe_DebtInstrumentFloorInterestRate_164AC0EA45DC5FFBA8681FF0FC7C3420" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_EA31DB6B63CF54EAA7D8BD4798333EE2" xlink:to="loc_pfe_DebtInstrumentFloorInterestRate_164AC0EA45DC5FFBA8681FF0FC7C3420" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_38ED33A0BC6656999757EE2BAD65366A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_EA31DB6B63CF54EAA7D8BD4798333EE2" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_38ED33A0BC6656999757EE2BAD65366A" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_DebtInstrumentRedemptionRuleRedemptionPricePercentageBasisSpread" xlink:label="loc_pfe_DebtInstrumentRedemptionRuleRedemptionPricePercentageBasisSpread_F900FB0968FC5B9EBE02F79057C91D68" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_EA31DB6B63CF54EAA7D8BD4798333EE2" xlink:to="loc_pfe_DebtInstrumentRedemptionRuleRedemptionPricePercentageBasisSpread_F900FB0968FC5B9EBE02F79057C91D68" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtWeightedAverageInterestRate" xlink:label="loc_us-gaap_DebtWeightedAverageInterestRate_AFD67E26F98A50AA837B5E1276BEAB98" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_EA31DB6B63CF54EAA7D8BD4798333EE2" xlink:to="loc_us-gaap_DebtWeightedAverageInterestRate_AFD67E26F98A50AA837B5E1276BEAB98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_22D7B7FE951A5A8C84C2185B11E3BE78" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_EA31DB6B63CF54EAA7D8BD4798333EE2" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_22D7B7FE951A5A8C84C2185B11E3BE78" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:href="pfe-20171001.xsd#pfe_FinancialInstrumentsAbstract" xlink:label="loc_pfe_FinancialInstrumentsAbstract_1C0E4ADF1D3F5B64AB2ACB814E1647DA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_66B485098B1F55F98C4CF427C00262A7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_1C0E4ADF1D3F5B64AB2ACB814E1647DA" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_66B485098B1F55F98C4CF427C00262A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_EBDD7A410767558EA65B40FDFF9173E2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_1C0E4ADF1D3F5B64AB2ACB814E1647DA" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_EBDD7A410767558EA65B40FDFF9173E2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_C5FAE6EB88385F5BAF10CE2B740982B3" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_1C0E4ADF1D3F5B64AB2ACB814E1647DA" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_C5FAE6EB88385F5BAF10CE2B740982B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_F5ABF413955D54ACAF80E019FF6678E0" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_1C0E4ADF1D3F5B64AB2ACB814E1647DA" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_F5ABF413955D54ACAF80E019FF6678E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_28E0AB16E9BA51FF94800FA138FABCD8" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_1C0E4ADF1D3F5B64AB2ACB814E1647DA" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_28E0AB16E9BA51FF94800FA138FABCD8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_81FE1D1A8AD45D21AC3C067857E67765" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_1C0E4ADF1D3F5B64AB2ACB814E1647DA" xlink:to="loc_us-gaap_LongTermDebt_81FE1D1A8AD45D21AC3C067857E67765" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsNarrativeDetail" xlink:type="extended">
    <link:loc xlink:href="pfe-20171001.xsd#pfe_FinancialInstrumentsAbstract" xlink:label="loc_pfe_FinancialInstrumentsAbstract_B5308699332576A1565478AA472B0B61" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaap_ConcentrationRiskTable_CBEB5574A214DC6EF8F278AA472EDEC9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_B5308699332576A1565478AA472B0B61" xlink:to="loc_us-gaap_ConcentrationRiskTable_CBEB5574A214DC6EF8F278AA472EDEC9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_F11B5C9D792B53A1A30E78AA472F71C7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_CBEB5574A214DC6EF8F278AA472EDEC9" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_F11B5C9D792B53A1A30E78AA472F71C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_20D16A5BA7EA8F7D077B78AA472F7167" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_F11B5C9D792B53A1A30E78AA472F71C7" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_20D16A5BA7EA8F7D077B78AA472F7167" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsMember" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember_4569343500F1CC89B04C78AA472F52E4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_20D16A5BA7EA8F7D077B78AA472F7167" xlink:to="loc_us-gaap_CashAndCashEquivalentsMember_4569343500F1CC89B04C78AA472F52E4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquitySecuritiesByIndustryAxis" xlink:label="loc_us-gaap_EquitySecuritiesByIndustryAxis_9E9C5EA8E5642C4521A478AA47304E13" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_CBEB5574A214DC6EF8F278AA472EDEC9" xlink:to="loc_us-gaap_EquitySecuritiesByIndustryAxis_9E9C5EA8E5642C4521A478AA47304E13" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquitySecuritiesIndustryMember" xlink:label="loc_us-gaap_EquitySecuritiesIndustryMember_CB3727F93C4DD7330C2C78AA473067E8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquitySecuritiesByIndustryAxis_9E9C5EA8E5642C4521A478AA47304E13" xlink:to="loc_us-gaap_EquitySecuritiesIndustryMember_CB3727F93C4DD7330C2C78AA473067E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TechnologySectorMember" xlink:label="loc_us-gaap_TechnologySectorMember_6D75CFCEC3D8C53C57B378AA4730164D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquitySecuritiesIndustryMember_CB3727F93C4DD7330C2C78AA473067E8" xlink:to="loc_us-gaap_TechnologySectorMember_6D75CFCEC3D8C53C57B378AA4730164D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_0757E12B39E0E3ABD64F78AA47308503" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_CBEB5574A214DC6EF8F278AA472EDEC9" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_0757E12B39E0E3ABD64F78AA47308503" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeNetLiabilityPositionAggregateFairValue" xlink:label="loc_us-gaap_DerivativeNetLiabilityPositionAggregateFairValue_22115CBE1C94C4CAAE2278AA473001A4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_0757E12B39E0E3ABD64F78AA47308503" xlink:to="loc_us-gaap_DerivativeNetLiabilityPositionAggregateFairValue_22115CBE1C94C4CAAE2278AA473001A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollateralAlreadyPostedAggregateFairValue" xlink:label="loc_us-gaap_CollateralAlreadyPostedAggregateFairValue_B341494865806406B56278AA47300A3B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_0757E12B39E0E3ABD64F78AA47308503" xlink:to="loc_us-gaap_CollateralAlreadyPostedAggregateFairValue_B341494865806406B56278AA47300A3B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure" xlink:label="loc_us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure_5BE33E2303446C911DD878AA47303821" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_0757E12B39E0E3ABD64F78AA47308503" xlink:to="loc_us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure_5BE33E2303446C911DD878AA47303821" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SecuritiesReceivedAsCollateral" xlink:label="loc_us-gaap_SecuritiesReceivedAsCollateral_4F30184BA1AF218D8E6F78AA4731F219" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_0757E12B39E0E3ABD64F78AA47308503" xlink:to="loc_us-gaap_SecuritiesReceivedAsCollateral_4F30184BA1AF218D8E6F78AA4731F219" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsOtherNoncurrentLiabilitiesDetail" xlink:type="extended">
    <link:loc xlink:href="pfe-20171001.xsd#pfe_FinancialInstrumentsAbstract" xlink:label="loc_pfe_FinancialInstrumentsAbstract_C04E9A6D645B52AF5B339C8902F727D0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_C24D65E3CCC9F29D2F7E9C8902F7D722" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_C04E9A6D645B52AF5B339C8902F727D0" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_C24D65E3CCC9F29D2F7E9C8902F7D722" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis_88149657AECBEF1122D89C8902F76B22" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_C24D65E3CCC9F29D2F7E9C8902F7D722" xlink:to="loc_us-gaap_StatementGeographicalAxis_88149657AECBEF1122D89C8902F76B22" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_1AB33F44F76B1BA64A619C8902F70365" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementGeographicalAxis_88149657AECBEF1122D89C8902F76B22" xlink:to="loc_us-gaap_SegmentGeographicalDomain_1AB33F44F76B1BA64A619C8902F70365" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_FC27A23B3FA223BBA5979C8902F8BECB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentGeographicalDomain_1AB33F44F76B1BA64A619C8902F70365" xlink:to="loc_country_US_FC27A23B3FA223BBA5979C8902F8BECB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EuropeanUnionMember" xlink:label="loc_us-gaap_EuropeanUnionMember_67E5005DF02F0F96D6A29C8902F81649" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentGeographicalDomain_1AB33F44F76B1BA64A619C8902F70365" xlink:to="loc_us-gaap_EuropeanUnionMember_67E5005DF02F0F96D6A29C8902F81649" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_BCAF785B94CE881D37F99C8902F87707" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_C24D65E3CCC9F29D2F7E9C8902F7D722" xlink:to="loc_us-gaap_ProductOrServiceAxis_BCAF785B94CE881D37F99C8902F87707" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_D7BFC1AC761F2CE959BB9C8902F8947A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductOrServiceAxis_BCAF785B94CE881D37F99C8902F87707" xlink:to="loc_us-gaap_ProductsAndServicesDomain_D7BFC1AC761F2CE959BB9C8902F8947A" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_BesponsaMember" xlink:label="loc_pfe_BesponsaMember_A841B484277CADCB2EF89C8902F824FB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_D7BFC1AC761F2CE959BB9C8902F8947A" xlink:to="loc_pfe_BesponsaMember_A841B484277CADCB2EF89C8902F824FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_E1EAAB124FE6F314CAE89C8902F8F9BA" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_C24D65E3CCC9F29D2F7E9C8902F7D722" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_E1EAAB124FE6F314CAE89C8902F8F9BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_66DAD47E4DEB57A1FACE9C8902F91EE8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_E1EAAB124FE6F314CAE89C8902F8F9BA" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_66DAD47E4DEB57A1FACE9C8902F91EE8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_EB7C3E124740139AD72E9C8902F9B41E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_66DAD47E4DEB57A1FACE9C8902F91EE8" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_EB7C3E124740139AD72E9C8902F9B41E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_1F22C08B844E03AB5C479C8902F95016" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_C24D65E3CCC9F29D2F7E9C8902F7D722" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_1F22C08B844E03AB5C479C8902F95016" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_7134D53BAEC64641E6929C8902F9B790" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_1F22C08B844E03AB5C479C8902F95016" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_7134D53BAEC64641E6929C8902F9B790" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_386C2752E3CB56B176539C8902F9EF17" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_7134D53BAEC64641E6929C8902F9B790" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_386C2752E3CB56B176539C8902F9EF17" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_0BD3177B09D091CD1BA09C8902F97D68" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_7134D53BAEC64641E6929C8902F9B790" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_0BD3177B09D091CD1BA09C8902F97D68" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6189A6256DB10ECD8A9B9C8902FA10F2" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_C24D65E3CCC9F29D2F7E9C8902F7D722" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6189A6256DB10ECD8A9B9C8902FA10F2" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_ResearchandDevelopmentArrangementAggregatePaymentObligationTerm" xlink:label="loc_pfe_ResearchandDevelopmentArrangementAggregatePaymentObligationTerm_FA2281E8EDA4527C632C9C8902FA7A6A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6189A6256DB10ECD8A9B9C8902FA10F2" xlink:to="loc_pfe_ResearchandDevelopmentArrangementAggregatePaymentObligationTerm_FA2281E8EDA4527C632C9C8902FA7A6A" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_ResearchandDevelopmentArrangementAggregatePaymentObligation" xlink:label="loc_pfe_ResearchandDevelopmentArrangementAggregatePaymentObligation_4A3C3814B325E0AD89129C8902FAFE86" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6189A6256DB10ECD8A9B9C8902FA10F2" xlink:to="loc_pfe_ResearchandDevelopmentArrangementAggregatePaymentObligation_4A3C3814B325E0AD89129C8902FAFE86" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_6E92C8BE9CE5CC09D30C9C8902FA9FD6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6189A6256DB10ECD8A9B9C8902FA10F2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_6E92C8BE9CE5CC09D30C9C8902FA9FD6" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails" xlink:type="extended">
    <link:loc xlink:href="pfe-20171001.xsd#pfe_FinancialInstrumentsAbstract" xlink:label="loc_pfe_FinancialInstrumentsAbstract_905125034F495B7DBBB5578A5B45DD3D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTable_8F50BC16DCE6553EB1C336B431638DD5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_905125034F495B7DBBB5578A5B45DD3D" xlink:to="loc_us-gaap_ScheduleOfShortTermDebtTable_8F50BC16DCE6553EB1C336B431638DD5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_0D94F7C67CFD5E0F9D2C98FDCF278A90" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_8F50BC16DCE6553EB1C336B431638DD5" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_0D94F7C67CFD5E0F9D2C98FDCF278A90" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_13D069D1897C5677B6EC78BF0EC9B981" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_0D94F7C67CFD5E0F9D2C98FDCF278A90" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_13D069D1897C5677B6EC78BF0EC9B981" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_53F349890F1D5FC28196F318FBF0BD4A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_13D069D1897C5677B6EC78BF0EC9B981" xlink:to="loc_us-gaap_CommercialPaperMember_53F349890F1D5FC28196F318FBF0BD4A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaap_ShortTermDebtLineItems_CD77D0CF1291589FA9B487EF6A62990B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_8F50BC16DCE6553EB1C336B431638DD5" xlink:to="loc_us-gaap_ShortTermDebtLineItems_CD77D0CF1291589FA9B487EF6A62990B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommercialPaper" xlink:label="loc_us-gaap_CommercialPaper_A5E16A737045501E963CFD73CCBFE3EB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_CD77D0CF1291589FA9B487EF6A62990B" xlink:to="loc_us-gaap_CommercialPaper_A5E16A737045501E963CFD73CCBFE3EB" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsTables" xlink:type="extended">
    <link:loc xlink:href="pfe-20171001.xsd#pfe_FinancialInstrumentsAbstract" xlink:label="loc_pfe_FinancialInstrumentsAbstract_5260756CBA675EB9946C5584B65FE328" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_9B5CC266CC2A58E69F599AAC6DE6381E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_5260756CBA675EB9946C5584B65FE328" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_9B5CC266CC2A58E69F599AAC6DE6381E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_25458F0544675354AAD76C52E373D2FA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_5260756CBA675EB9946C5584B65FE328" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_25458F0544675354AAD76C52E373D2FA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_95B4921305AE5F4E8FF4FD08031D9031" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_5260756CBA675EB9946C5584B65FE328" xlink:to="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_95B4921305AE5F4E8FF4FD08031D9031" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_47822082D7215697A66554B07923EFF6" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_5260756CBA675EB9946C5584B65FE328" xlink:to="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_47822082D7215697A66554B07923EFF6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_7B7282980F415755B4F686946CC160B8" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_5260756CBA675EB9946C5584B65FE328" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_7B7282980F415755B4F686946CC160B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_EBF43EE72CF65ACCAEF67291A017A253" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_5260756CBA675EB9946C5584B65FE328" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_EBF43EE72CF65ACCAEF67291A017A253" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwill" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_D22D602201A850188680FCCBA32DE848" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_D43AFB0B2FA653B48D3396133C0817F6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_D22D602201A850188680FCCBA32DE848" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_D43AFB0B2FA653B48D3396133C0817F6" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_14F07F5FCF47B285F754831F4DF7261C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_90566B8A7E9CCB789766831F4DF748BC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_14F07F5FCF47B285F754831F4DF7261C" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_90566B8A7E9CCB789766831F4DF748BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_A42CB56934C171E3E6CF831F4DF7D133" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_90566B8A7E9CCB789766831F4DF748BC" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_A42CB56934C171E3E6CF831F4DF7D133" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_1784978FCF4D701C507B831F4DF79C5C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_A42CB56934C171E3E6CF831F4DF7D133" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_1784978FCF4D701C507B831F4DF79C5C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TradeNamesMember" xlink:label="loc_us-gaap_TradeNamesMember_B54943A4A64DDA9E5740831F4DF782D3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_1784978FCF4D701C507B831F4DF79C5C" xlink:to="loc_us-gaap_TradeNamesMember_B54943A4A64DDA9E5740831F4DF782D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_75F198E5BA07142C6B7A831F4DF75B2A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_1784978FCF4D701C507B831F4DF79C5C" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_75F198E5BA07142C6B7A831F4DF75B2A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_ECA9B8E0411B3B738C73831F4DF72137" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_90566B8A7E9CCB789766831F4DF748BC" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_ECA9B8E0411B3B738C73831F4DF72137" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_A5A06B69F2A0E8885368831F4DF761FC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_ECA9B8E0411B3B738C73831F4DF72137" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_A5A06B69F2A0E8885368831F4DF761FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_54376F526D9101D1C755831F4DF74845" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_14F07F5FCF47B285F754831F4DF7261C" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_54376F526D9101D1C755831F4DF74845" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_4FCEFE7A9998B6B42ED2831F4DF70CDB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_54376F526D9101D1C755831F4DF74845" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_4FCEFE7A9998B6B42ED2831F4DF70CDB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9446760460D29BC869C4831F4DF7F300" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_4FCEFE7A9998B6B42ED2831F4DF70CDB" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9446760460D29BC869C4831F4DF7F300" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_D3BEBC2A564CF777AF48831F4DF80008" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9446760460D29BC869C4831F4DF7F300" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_D3BEBC2A564CF777AF48831F4DF80008" xlink:type="arc" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9446760460D29BC869C4831F4DF7F300" xlink:to="loc_us-gaap_TradeNamesMember_B54943A4A64DDA9E5740831F4DF782D3" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_LicensingAgreementsAndOtherMember" xlink:label="loc_pfe_LicensingAgreementsAndOtherMember_51D7B1A8D94C158BAC3D831F4DF807AF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9446760460D29BC869C4831F4DF7F300" xlink:to="loc_pfe_LicensingAgreementsAndOtherMember_51D7B1A8D94C158BAC3D831F4DF807AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_3187CD8EAA6A3B2DC4A5831F4DF8074E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_54376F526D9101D1C755831F4DF74845" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_3187CD8EAA6A3B2DC4A5831F4DF8074E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_F59D3CC10B6649DFBE8B831F4DF86F54" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_3187CD8EAA6A3B2DC4A5831F4DF8074E" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_F59D3CC10B6649DFBE8B831F4DF86F54" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_6735039BE1644746F4B8831F4DF81CA5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_3187CD8EAA6A3B2DC4A5831F4DF8074E" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_6735039BE1644746F4B8831F4DF81CA5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_78E190F8687D3D6AE7CC831F4DF8A84E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_3187CD8EAA6A3B2DC4A5831F4DF8074E" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_78E190F8687D3D6AE7CC831F4DF8A84E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_F416B6ABCA68D67F0991831F4DF88328" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_14F07F5FCF47B285F754831F4DF7261C" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_F416B6ABCA68D67F0991831F4DF88328" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_4C729B36282CAFE0DA6F833BDF8A3B35" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_14F07F5FCF47B285F754831F4DF7261C" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_4C729B36282CAFE0DA6F833BDF8A3B35" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_4066F0C09C0A8669D359831F4DF8F372" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_14F07F5FCF47B285F754831F4DF7261C" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_4066F0C09C0A8669D359831F4DF8F372" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsFootnotesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_95B16B2D587717299FFC831F4DF21063" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_E6EECFFADB9C046D0704831F4DF23591" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_95B16B2D587717299FFC831F4DF21063" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_E6EECFFADB9C046D0704831F4DF23591" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_445EED84B0015F7064FE831F4DF27AE3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_E6EECFFADB9C046D0704831F4DF23591" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_445EED84B0015F7064FE831F4DF27AE3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_97546729E982B1580CC1831F4DF28263" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_445EED84B0015F7064FE831F4DF27AE3" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_97546729E982B1580CC1831F4DF28263" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_B61E3B4BF959AAE96FC7831F4DF2F9D8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_97546729E982B1580CC1831F4DF28263" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_B61E3B4BF959AAE96FC7831F4DF2F9D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_10B54043915404AD185B831F4DF218C6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_E6EECFFADB9C046D0704831F4DF23591" xlink:to="loc_us-gaap_ProductOrServiceAxis_10B54043915404AD185B831F4DF218C6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_3603130DA02E32A9EE8E831F4DF262B0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductOrServiceAxis_10B54043915404AD185B831F4DF218C6" xlink:to="loc_us-gaap_ProductsAndServicesDomain_3603130DA02E32A9EE8E831F4DF262B0" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_EucrisaMember" xlink:label="loc_pfe_EucrisaMember_26914EE32CE5AFDF51F9831F4DF2E794" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_3603130DA02E32A9EE8E831F4DF262B0" xlink:to="loc_pfe_EucrisaMember_26914EE32CE5AFDF51F9831F4DF2E794" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_BesponsaMember" xlink:label="loc_pfe_BesponsaMember_6D60C35F87FABAB6D1EA831F4DF3DDC4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_3603130DA02E32A9EE8E831F4DF262B0" xlink:to="loc_pfe_BesponsaMember_6D60C35F87FABAB6D1EA831F4DF3DDC4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_8C226E01BCD4C5756B13831F4DF3AE75" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_E6EECFFADB9C046D0704831F4DF23591" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_8C226E01BCD4C5756B13831F4DF3AE75" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_946798C5470F86DC4EDC831F4DF3E93D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_8C226E01BCD4C5756B13831F4DF3AE75" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_946798C5470F86DC4EDC831F4DF3E93D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_81D95332F077A1C3CD4C831F4DF39F3C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_946798C5470F86DC4EDC831F4DF3E93D" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_81D95332F077A1C3CD4C831F4DF39F3C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_F6696849D7519334CC62831F4DF31B96" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_E6EECFFADB9C046D0704831F4DF23591" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_F6696849D7519334CC62831F4DF31B96" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_IntangibleAssetsTransfersDuringPeriod" xlink:label="loc_pfe_IntangibleAssetsTransfersDuringPeriod_988F44A098D76E58DBD6831F4DF37EBC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_F6696849D7519334CC62831F4DF31B96" xlink:to="loc_pfe_IntangibleAssetsTransfersDuringPeriod_988F44A098D76E58DBD6831F4DF37EBC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_349DD2C7AB98C46186EE831F4DF39D1C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_F6696849D7519334CC62831F4DF31B96" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_349DD2C7AB98C46186EE831F4DF39D1C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedIntangibleAssetsPercentageOfTotalIntangiblesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_3EE23ECA8C465A509B816F6AA6F86E65" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_0E162BE702945F148E96B135BE75CCA3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_3EE23ECA8C465A509B816F6AA6F86E65" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_0E162BE702945F148E96B135BE75CCA3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsegmentsAxis" xlink:label="loc_us-gaap_SubsegmentsAxis_A38AEA57FE4650199E95DEA89A81D3D6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_0E162BE702945F148E96B135BE75CCA3" xlink:to="loc_us-gaap_SubsegmentsAxis_A38AEA57FE4650199E95DEA89A81D3D6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsegmentsDomain" xlink:label="loc_us-gaap_SubsegmentsDomain_21157A2CC7055DD3865AAA552EFF13A3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsAxis_A38AEA57FE4650199E95DEA89A81D3D6" xlink:to="loc_us-gaap_SubsegmentsDomain_21157A2CC7055DD3865AAA552EFF13A3" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_PfizersWorldwideResearchandDevelopmentMember" xlink:label="loc_pfe_PfizersWorldwideResearchandDevelopmentMember_D981B410F9845E55A31B6C49D5E5BD46" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_21157A2CC7055DD3865AAA552EFF13A3" xlink:to="loc_pfe_PfizersWorldwideResearchandDevelopmentMember_D981B410F9845E55A31B6C49D5E5BD46" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidationItemsAxis" xlink:label="loc_us-gaap_ConsolidationItemsAxis_218E4D00F9AE5E7388F05949EC7BC6B1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_0E162BE702945F148E96B135BE75CCA3" xlink:to="loc_us-gaap_ConsolidationItemsAxis_218E4D00F9AE5E7388F05949EC7BC6B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidationItemsDomain" xlink:label="loc_us-gaap_ConsolidationItemsDomain_2B22A735E8ED50F59811B0DD9CAED414" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidationItemsAxis_218E4D00F9AE5E7388F05949EC7BC6B1" xlink:to="loc_us-gaap_ConsolidationItemsDomain_2B22A735E8ED50F59811B0DD9CAED414" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingSegmentsMember" xlink:label="loc_us-gaap_OperatingSegmentsMember_589FC7283A575183A10440790726B9A5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidationItemsDomain_2B22A735E8ED50F59811B0DD9CAED414" xlink:to="loc_us-gaap_OperatingSegmentsMember_589FC7283A575183A10440790726B9A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaterialReconcilingItemsMember" xlink:label="loc_us-gaap_MaterialReconcilingItemsMember_144BA6D222BF5522AD0DD379CAC1B07A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidationItemsDomain_2B22A735E8ED50F59811B0DD9CAED414" xlink:to="loc_us-gaap_MaterialReconcilingItemsMember_144BA6D222BF5522AD0DD379CAC1B07A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_DDC77182EE7F5B16B8AFC995D063E6C7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_0E162BE702945F148E96B135BE75CCA3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_DDC77182EE7F5B16B8AFC995D063E6C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_F210AF62B1BF5E23ADF77D46891C1104" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_DDC77182EE7F5B16B8AFC995D063E6C7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_F210AF62B1BF5E23ADF77D46891C1104" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_B64EE51D62BA54A5A0E6FAE4B98D8B4C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_F210AF62B1BF5E23ADF77D46891C1104" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_B64EE51D62BA54A5A0E6FAE4B98D8B4C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TradeNamesMember" xlink:label="loc_us-gaap_TradeNamesMember_C0CA494F691C5DDDA3F5AFD2DA581205" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_F210AF62B1BF5E23ADF77D46891C1104" xlink:to="loc_us-gaap_TradeNamesMember_C0CA494F691C5DDDA3F5AFD2DA581205" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_05FAE0B8FC7F5FE6B5F19F11BED2F5F5" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_0E162BE702945F148E96B135BE75CCA3" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_05FAE0B8FC7F5FE6B5F19F11BED2F5F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_809E24EC080A5788A78531773EFD4438" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_05FAE0B8FC7F5FE6B5F19F11BED2F5F5" xlink:to="loc_us-gaap_SegmentDomain_809E24EC080A5788A78531773EFD4438" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_InnovativeHealthSegmentMember" xlink:label="loc_pfe_InnovativeHealthSegmentMember_EAAA02CB13AA5FECB279956095A36DB2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_809E24EC080A5788A78531773EFD4438" xlink:to="loc_pfe_InnovativeHealthSegmentMember_EAAA02CB13AA5FECB279956095A36DB2" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_EssentialHealthSegmentMember" xlink:label="loc_pfe_EssentialHealthSegmentMember_E5C2A7C425ED5EA1A69D30EBD7D3BD2F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_809E24EC080A5788A78531773EFD4438" xlink:to="loc_pfe_EssentialHealthSegmentMember_E5C2A7C425ED5EA1A69D30EBD7D3BD2F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_5B7C62FC74B45E6BBBE0D1B4F0EB089C" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_0E162BE702945F148E96B135BE75CCA3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_5B7C62FC74B45E6BBBE0D1B4F0EB089C" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet" xlink:label="loc_pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet_3C22A21358D9547291B7EEA98FDEAE93" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_5B7C62FC74B45E6BBBE0D1B4F0EB089C" xlink:to="loc_pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet_3C22A21358D9547291B7EEA98FDEAE93" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillGoodwillDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_AFB1480DBA2D3DD0604274487D3ABC1E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfGoodwillTable" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_04EA4343A0C97033104374487D3A60B8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_AFB1480DBA2D3DD0604274487D3ABC1E" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_04EA4343A0C97033104374487D3A60B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_2FC73F76BE892ABEE49E74487D3B9AA0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_04EA4343A0C97033104374487D3A60B8" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_2FC73F76BE892ABEE49E74487D3B9AA0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_8202DB036C4A2E1E58B574487D3BE9BA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_2FC73F76BE892ABEE49E74487D3B9AA0" xlink:to="loc_us-gaap_SegmentDomain_8202DB036C4A2E1E58B574487D3BE9BA" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_InnovativeHealthSegmentMember" xlink:label="loc_pfe_InnovativeHealthSegmentMember_B171016C9E0B2313ED3774487D3BE85C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_8202DB036C4A2E1E58B574487D3BE9BA" xlink:to="loc_pfe_InnovativeHealthSegmentMember_B171016C9E0B2313ED3774487D3BE85C" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_EssentialHealthSegmentMember" xlink:label="loc_pfe_EssentialHealthSegmentMember_D94B32983C35F9D8BF6A74487D3BA1B9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_8202DB036C4A2E1E58B574487D3BE9BA" xlink:to="loc_pfe_EssentialHealthSegmentMember_D94B32983C35F9D8BF6A74487D3BA1B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillLineItems" xlink:label="loc_us-gaap_GoodwillLineItems_7A07D8AF3A49752DF80B74487D3B596F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_04EA4343A0C97033104374487D3A60B8" xlink:to="loc_us-gaap_GoodwillLineItems_7A07D8AF3A49752DF80B74487D3B596F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillRollForward" xlink:label="loc_us-gaap_GoodwillRollForward_BE5204FF1CB245D3299574487D3B5DF8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_7A07D8AF3A49752DF80B74487D3B596F" xlink:to="loc_us-gaap_GoodwillRollForward_BE5204FF1CB245D3299574487D3B5DF8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_332FDC0453C655F3B75174487D3BD214" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_BE5204FF1CB245D3299574487D3B5DF8" xlink:to="loc_us-gaap_Goodwill_332FDC0453C655F3B75174487D3BD214" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_6C0FBE01AFE058A8873F74487D3B4955" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_BE5204FF1CB245D3299574487D3B5DF8" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_6C0FBE01AFE058A8873F74487D3B4955" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillOtherIncreaseDecrease" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease_E072660759D500C413B174487D3BA5F0" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_BE5204FF1CB245D3299574487D3B5DF8" xlink:to="loc_us-gaap_GoodwillOtherIncreaseDecrease_E072660759D500C413B174487D3BA5F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_C135527467B2A6C6E32474487D3B5419" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_BE5204FF1CB245D3299574487D3B5DF8" xlink:to="loc_us-gaap_Goodwill_C135527467B2A6C6E32474487D3B5419" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillIndefiniteLivedIntangibleAssetsPercentageOfTotalIntangiblesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_3D6D0F72EB295B69B021CC8360E7D5A1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_5BC3655DF7285E38BBEAA26FA3B61CFF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_3D6D0F72EB295B69B021CC8360E7D5A1" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_5BC3655DF7285E38BBEAA26FA3B61CFF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsegmentsAxis" xlink:label="loc_us-gaap_SubsegmentsAxis_F81489EAEDE45A4DBEA2F56039DBB42F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_5BC3655DF7285E38BBEAA26FA3B61CFF" xlink:to="loc_us-gaap_SubsegmentsAxis_F81489EAEDE45A4DBEA2F56039DBB42F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsegmentsDomain" xlink:label="loc_us-gaap_SubsegmentsDomain_7B8FD2B625D351818026A06A747D5E27" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsAxis_F81489EAEDE45A4DBEA2F56039DBB42F" xlink:to="loc_us-gaap_SubsegmentsDomain_7B8FD2B625D351818026A06A747D5E27" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_PfizersWorldwideResearchandDevelopmentMember" xlink:label="loc_pfe_PfizersWorldwideResearchandDevelopmentMember_FE77081B14DE5E099708308981CBAFA6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_7B8FD2B625D351818026A06A747D5E27" xlink:to="loc_pfe_PfizersWorldwideResearchandDevelopmentMember_FE77081B14DE5E099708308981CBAFA6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_5306EAE2932E517DA6A801AFEE2B9FCF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_5BC3655DF7285E38BBEAA26FA3B61CFF" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_5306EAE2932E517DA6A801AFEE2B9FCF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_358AEFC5DB945FCCBEE4B0519B57AA8D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_5306EAE2932E517DA6A801AFEE2B9FCF" xlink:to="loc_us-gaap_SegmentDomain_358AEFC5DB945FCCBEE4B0519B57AA8D" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_InnovativeHealthSegmentMember" xlink:label="loc_pfe_InnovativeHealthSegmentMember_644D9046537B5D059685547DDC316445" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_358AEFC5DB945FCCBEE4B0519B57AA8D" xlink:to="loc_pfe_InnovativeHealthSegmentMember_644D9046537B5D059685547DDC316445" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_EssentialHealthSegmentMember" xlink:label="loc_pfe_EssentialHealthSegmentMember_8BB667DE477D5A5D8C735D1C78856A04" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_358AEFC5DB945FCCBEE4B0519B57AA8D" xlink:to="loc_pfe_EssentialHealthSegmentMember_8BB667DE477D5A5D8C735D1C78856A04" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidationItemsAxis" xlink:label="loc_us-gaap_ConsolidationItemsAxis_DC642E6E5004572EB99FB7B133A2334D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_5BC3655DF7285E38BBEAA26FA3B61CFF" xlink:to="loc_us-gaap_ConsolidationItemsAxis_DC642E6E5004572EB99FB7B133A2334D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidationItemsDomain" xlink:label="loc_us-gaap_ConsolidationItemsDomain_9AC0563D3DA452B7978ED66F5F4C2E05" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidationItemsAxis_DC642E6E5004572EB99FB7B133A2334D" xlink:to="loc_us-gaap_ConsolidationItemsDomain_9AC0563D3DA452B7978ED66F5F4C2E05" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingSegmentsMember" xlink:label="loc_us-gaap_OperatingSegmentsMember_257CBC9F7D715EC1A759B8EBC09FA4FD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidationItemsDomain_9AC0563D3DA452B7978ED66F5F4C2E05" xlink:to="loc_us-gaap_OperatingSegmentsMember_257CBC9F7D715EC1A759B8EBC09FA4FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaterialReconcilingItemsMember" xlink:label="loc_us-gaap_MaterialReconcilingItemsMember_3CA2DFB7300B582BA36D774BF032908E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidationItemsDomain_9AC0563D3DA452B7978ED66F5F4C2E05" xlink:to="loc_us-gaap_MaterialReconcilingItemsMember_3CA2DFB7300B582BA36D774BF032908E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_194BFC11DBF75C56A37EB07F81DCDFD4" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_5BC3655DF7285E38BBEAA26FA3B61CFF" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_194BFC11DBF75C56A37EB07F81DCDFD4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_370DD81339515994AA53F5E702341EAF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_194BFC11DBF75C56A37EB07F81DCDFD4" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_370DD81339515994AA53F5E702341EAF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TradeNamesMember" xlink:label="loc_us-gaap_TradeNamesMember_ADB979B4DA1A5DFE8F0F7BE353795C94" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_370DD81339515994AA53F5E702341EAF" xlink:to="loc_us-gaap_TradeNamesMember_ADB979B4DA1A5DFE8F0F7BE353795C94" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_38A6F73BE13F55D2BD12D9F1E98FB113" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_370DD81339515994AA53F5E702341EAF" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_38A6F73BE13F55D2BD12D9F1E98FB113" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_2686E928DA335271AE0436BED1028B1D" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_5BC3655DF7285E38BBEAA26FA3B61CFF" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_2686E928DA335271AE0436BED1028B1D" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet" xlink:label="loc_pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet_9DE84574D1FD5FBCB9219FEB6426C264" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_2686E928DA335271AE0436BED1028B1D" xlink:to="loc_pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet_9DE84574D1FD5FBCB9219FEB6426C264" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillNarrativeDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4BE441AE92B45694BF4D8C51CECE6796" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_A75EF4138E575029A1E5E742823A1A8D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4BE441AE92B45694BF4D8C51CECE6796" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_A75EF4138E575029A1E5E742823A1A8D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9DDB03CEED8C5FE697A64B213BDDA920" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_A75EF4138E575029A1E5E742823A1A8D" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9DDB03CEED8C5FE697A64B213BDDA920" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_399D077872C45D3FBDFCDEE25C699D96" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9DDB03CEED8C5FE697A64B213BDDA920" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_399D077872C45D3FBDFCDEE25C699D96" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMember" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMember_70D5586D519056C2970E8B0081F42002" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_399D077872C45D3FBDFCDEE25C699D96" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMember_70D5586D519056C2970E8B0081F42002" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_5673DBE52289573C8E30136427C582D3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_A75EF4138E575029A1E5E742823A1A8D" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_5673DBE52289573C8E30136427C582D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_9D81C837E0B85203B907F1D08F8CE081" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_5673DBE52289573C8E30136427C582D3" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_9D81C837E0B85203B907F1D08F8CE081" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_D810F32FDB5D583EBACC333907CBB5BB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_522E886DF18E5E16A38D1CF845FE4787" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_D810F32FDB5D583EBACC333907CBB5BB" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_522E886DF18E5E16A38D1CF845FE4787" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_B42A9C82AA485E578A6AACC2F2559319" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_D810F32FDB5D583EBACC333907CBB5BB" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_B42A9C82AA485E578A6AACC2F2559319" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_IdentifiableintangibleassetsasapercentageoftotalidentifiableintangibleassetslessaccumulatedamortizationbysegmentTableTextBlock" xlink:label="loc_pfe_IdentifiableintangibleassetsasapercentageoftotalidentifiableintangibleassetslessaccumulatedamortizationbysegmentTableTextBlock_746080F1E22D50C7971746ED83D08F67" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_D810F32FDB5D583EBACC333907CBB5BB" xlink:to="loc_pfe_IdentifiableintangibleassetsasapercentageoftotalidentifiableintangibleassetslessaccumulatedamortizationbysegmentTableTextBlock_746080F1E22D50C7971746ED83D08F67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_188DF3902572562B82D58C26C37138D6" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_D810F32FDB5D583EBACC333907CBB5BB" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_188DF3902572562B82D58C26C37138D6" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/Inventories" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_DCABB19F351C5DED924AF5AC28DC6A39" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_8DB4A92A688A5248B73AE34B52D79404" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_DCABB19F351C5DED924AF5AC28DC6A39" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_8DB4A92A688A5248B73AE34B52D79404" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/InventoriesDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_78B52DD5F87F53A7925C9645A3DAA6CA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_7DA682F713985F08B06120D913CC7D4E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_78B52DD5F87F53A7925C9645A3DAA6CA" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_7DA682F713985F08B06120D913CC7D4E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_5F75A5D991FA577DAE6C5858892BEDB6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_78B52DD5F87F53A7925C9645A3DAA6CA" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_5F75A5D991FA577DAE6C5858892BEDB6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" xlink:label="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_05EE4BAC4938567CA05002B7313A0754" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_78B52DD5F87F53A7925C9645A3DAA6CA" xlink:to="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_05EE4BAC4938567CA05002B7313A0754" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_8DD9CC8B2D9C56E59ADE771891F1C5DB" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_78B52DD5F87F53A7925C9645A3DAA6CA" xlink:to="loc_us-gaap_InventoryNet_8DD9CC8B2D9C56E59ADE771891F1C5DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryNoncurrent" xlink:label="loc_us-gaap_InventoryNoncurrent_95E45CA9347854DC933E716F9BA79889" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_78B52DD5F87F53A7925C9645A3DAA6CA" xlink:to="loc_us-gaap_InventoryNoncurrent_95E45CA9347854DC933E716F9BA79889" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/InventoriesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_6DF70F13C35354498FE36682D0518DE2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_13A6807F77195E68BAE7BBB8258EBA98" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_6DF70F13C35354498FE36682D0518DE2" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_13A6807F77195E68BAE7BBB8258EBA98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock_BFF30696A3835837BCDC17A11823C319" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_6DF70F13C35354498FE36682D0518DE2" xlink:to="loc_us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock_BFF30696A3835837BCDC17A11823C319" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/OtherIncomeDeductionsNet" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_C227D7A3E4D5597EBAFFDE1EA714B641" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:label="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_E6816120C90B5C099513BE2277E0A478" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_C227D7A3E4D5597EBAFFDE1EA714B641" xlink:to="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_E6816120C90B5C099513BE2277E0A478" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/OtherIncomeDeductionsNetDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_5C39E5426A11165F4CD59C88C9D336EE" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_17B207D001E1B3905E029C88C9DABB83" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_5C39E5426A11165F4CD59C88C9D336EE" xlink:to="loc_us-gaap_InvestmentIncomeInterest_17B207D001E1B3905E029C88C9DABB83" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_8749240F19234477FC029C88C9DAFA34" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_5C39E5426A11165F4CD59C88C9D336EE" xlink:to="loc_us-gaap_InterestExpense_8749240F19234477FC029C88C9DAFA34" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestRevenueExpenseNet" xlink:label="loc_us-gaap_InterestRevenueExpenseNet_0F06722ECD70EF6643E99C88C9DA103D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_5C39E5426A11165F4CD59C88C9D336EE" xlink:to="loc_us-gaap_InterestRevenueExpenseNet_0F06722ECD70EF6643E99C88C9DA103D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:label="loc_us-gaap_RoyaltyRevenue_9B17FB6A7900C3C1B84C9C88C9DA9FDF" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_5C39E5426A11165F4CD59C88C9D336EE" xlink:to="loc_us-gaap_RoyaltyRevenue_9B17FB6A7900C3C1B84C9C88C9DA9FDF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_5062F316E14C1F56C54E9C88C9DB86BC" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_5C39E5426A11165F4CD59C88C9D336EE" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_5062F316E14C1F56C54E9C88C9DB86BC" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_GainLossOnDispositionOfAssetsAndEquitySecurities" xlink:label="loc_pfe_GainLossOnDispositionOfAssetsAndEquitySecurities_D487E82262204209FED29C88C9DB0D6F" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_5C39E5426A11165F4CD59C88C9D336EE" xlink:to="loc_pfe_GainLossOnDispositionOfAssetsAndEquitySecurities_D487E82262204209FED29C88C9DB0D6F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_F40F29C3E7939906B1219C88C9DB3158" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_5C39E5426A11165F4CD59C88C9D336EE" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_F40F29C3E7939906B1219C88C9DB3158" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges_7258662FE251A58D43349C88C9DBEB6C" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_5C39E5426A11165F4CD59C88C9D336EE" xlink:to="loc_us-gaap_AssetImpairmentCharges_7258662FE251A58D43349C88C9DBEB6C" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_BusinessInfrastructureAlignmentCosts" xlink:label="loc_pfe_BusinessInfrastructureAlignmentCosts_A9B5F5C0B7D0E2DE1AD89C88C9DCD938" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_5C39E5426A11165F4CD59C88C9D336EE" xlink:to="loc_pfe_BusinessInfrastructureAlignmentCosts_A9B5F5C0B7D0E2DE1AD89C88C9DCD938" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_OtherNonoperatingIncomeExpenseNet" xlink:label="loc_pfe_OtherNonoperatingIncomeExpenseNet_85642F210CC56EDCF1219C88C9DC25F5" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_5C39E5426A11165F4CD59C88C9D336EE" xlink:to="loc_pfe_OtherNonoperatingIncomeExpenseNet_85642F210CC56EDCF1219C88C9DC25F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_ADD39E504A89D63D22879C88C9DCB101" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_5C39E5426A11165F4CD59C88C9D336EE" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_ADD39E504A89D63D22879C88C9DCB101" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_10629A2EC6C648D870B79C47165009B6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaap_LossContingenciesTable_95A1ADCBE302F1B121559C471651BBAD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_10629A2EC6C648D870B79C47165009B6" xlink:to="loc_us-gaap_LossContingenciesTable_95A1ADCBE302F1B121559C471651BBAD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_709F9B95DC810227F9AD9C471651E6FC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_95A1ADCBE302F1B121559C471651BBAD" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_709F9B95DC810227F9AD9C471651E6FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="loc_us-gaap_LossContingencyNatureDomain_1A1C148E0BD54D4F878D9C4716512890" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_709F9B95DC810227F9AD9C471651E6FC" xlink:to="loc_us-gaap_LossContingencyNatureDomain_1A1C148E0BD54D4F878D9C4716512890" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_PatentMatterMember" xlink:label="loc_pfe_PatentMatterMember_854AC88B33C3596A32F39C471652D425" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_1A1C148E0BD54D4F878D9C4716512890" xlink:to="loc_pfe_PatentMatterMember_854AC88B33C3596A32F39C471652D425" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_95B7C524AFAE525B86779C4716524935" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_95A1ADCBE302F1B121559C471651BBAD" xlink:to="loc_dei_LegalEntityAxis_95B7C524AFAE525B86779C4716524935" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_4248376941AB31BDA5449C471652D4FF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_95B7C524AFAE525B86779C4716524935" xlink:to="loc_dei_EntityDomain_4248376941AB31BDA5449C471652D4FF" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_LaboratorioTeutoBrasileroMember" xlink:label="loc_pfe_LaboratorioTeutoBrasileroMember_7AEEED5A12921B85F5379C4716525A4C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_4248376941AB31BDA5449C471652D4FF" xlink:to="loc_pfe_LaboratorioTeutoBrasileroMember_7AEEED5A12921B85F5379C4716525A4C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidationItemsAxis" xlink:label="loc_us-gaap_ConsolidationItemsAxis_F9D03C181D949B79955B9C4716528D7C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_95A1ADCBE302F1B121559C471651BBAD" xlink:to="loc_us-gaap_ConsolidationItemsAxis_F9D03C181D949B79955B9C4716528D7C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidationItemsDomain" xlink:label="loc_us-gaap_ConsolidationItemsDomain_0B704730A752E5308FB69C4716523C80" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidationItemsAxis_F9D03C181D949B79955B9C4716528D7C" xlink:to="loc_us-gaap_ConsolidationItemsDomain_0B704730A752E5308FB69C4716523C80" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingSegmentsMember" xlink:label="loc_us-gaap_OperatingSegmentsMember_C3DE14DD4931B85510DC9C471652F135" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidationItemsDomain_0B704730A752E5308FB69C4716523C80" xlink:to="loc_us-gaap_OperatingSegmentsMember_C3DE14DD4931B85510DC9C471652F135" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_91E2A4E09B7B7FD76DE99C4716525571" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_95A1ADCBE302F1B121559C471651BBAD" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_91E2A4E09B7B7FD76DE99C4716525571" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_15DB0057F151FA9854A29C471653466D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_91E2A4E09B7B7FD76DE99C4716525571" xlink:to="loc_us-gaap_SegmentDomain_15DB0057F151FA9854A29C471653466D" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_EssentialHealthSegmentMember" xlink:label="loc_pfe_EssentialHealthSegmentMember_D95D2E295FD4390ADADA9C471653CC12" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_15DB0057F151FA9854A29C471653466D" xlink:to="loc_pfe_EssentialHealthSegmentMember_D95D2E295FD4390ADADA9C471653CC12" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_InnovativeHealthSegmentMember" xlink:label="loc_pfe_InnovativeHealthSegmentMember_F24057BAC55EFE88EC629C4716534727" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_15DB0057F151FA9854A29C471653466D" xlink:to="loc_pfe_InnovativeHealthSegmentMember_F24057BAC55EFE88EC629C4716534727" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_674BB4A1E66C60867F5B9C471653E3A8" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_95A1ADCBE302F1B121559C471651BBAD" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_674BB4A1E66C60867F5B9C471653E3A8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4655C8DBD7B143FD17EB9C471653D803" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_674BB4A1E66C60867F5B9C471653E3A8" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4655C8DBD7B143FD17EB9C471653D803" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_HospiraMember" xlink:label="loc_pfe_HospiraMember_00BEBE1779DE28A3200B9C471653AC08" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4655C8DBD7B143FD17EB9C471653D803" xlink:to="loc_pfe_HospiraMember_00BEBE1779DE28A3200B9C471653AC08" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_InnoPharmaMember" xlink:label="loc_pfe_InnoPharmaMember_F52F1246B3DDCBC7493B9C471653B739" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4655C8DBD7B143FD17EB9C471653D803" xlink:to="loc_pfe_InnoPharmaMember_F52F1246B3DDCBC7493B9C471653B739" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_KingMember" xlink:label="loc_pfe_KingMember_C8543860A5CCFF0B525B9C4716540F94" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4655C8DBD7B143FD17EB9C471653D803" xlink:to="loc_pfe_KingMember_C8543860A5CCFF0B525B9C4716540F94" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_DAE4D35468B8FE97F2E39C471654220B" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_95A1ADCBE302F1B121559C471651BBAD" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_DAE4D35468B8FE97F2E39C471654220B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_DA1E1A15D3E802A4DB0A9C471654F385" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_DAE4D35468B8FE97F2E39C471654220B" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_DA1E1A15D3E802A4DB0A9C471654F385" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_48A1C58AE61CE0275E7B9C47165431A2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_DA1E1A15D3E802A4DB0A9C471654F385" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_48A1C58AE61CE0275E7B9C47165431A2" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_OtherInProcessResearchandDevelopmentMember" xlink:label="loc_pfe_OtherInProcessResearchandDevelopmentMember_E43E5CA632F39E1D719A9C47165466C3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_DA1E1A15D3E802A4DB0A9C471654F385" xlink:to="loc_pfe_OtherInProcessResearchandDevelopmentMember_E43E5CA632F39E1D719A9C47165466C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationStatusAxis" xlink:label="loc_us-gaap_LitigationStatusAxis_2DCBF3D5007F128FC6779C471654ECDB" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_95A1ADCBE302F1B121559C471651BBAD" xlink:to="loc_us-gaap_LitigationStatusAxis_2DCBF3D5007F128FC6779C471654ECDB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationStatusDomain" xlink:label="loc_us-gaap_LitigationStatusDomain_686497904DD6AF2454AD9C471654BE2E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusAxis_2DCBF3D5007F128FC6779C471654ECDB" xlink:to="loc_us-gaap_LitigationStatusDomain_686497904DD6AF2454AD9C471654BE2E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PendingLitigationMember" xlink:label="loc_us-gaap_PendingLitigationMember_927004CA1DF7839C21079C471654EF7A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_686497904DD6AF2454AD9C471654BE2E" xlink:to="loc_us-gaap_PendingLitigationMember_927004CA1DF7839C21079C471654EF7A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_3CCA51C50DD9DAF0904C9C471655B0EB" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_95A1ADCBE302F1B121559C471651BBAD" xlink:to="loc_us-gaap_TypeOfArrangementAxis_3CCA51C50DD9DAF0904C9C471655B0EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_B81D011929653F84FB989C471655FEEB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_3CCA51C50DD9DAF0904C9C471655B0EB" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_B81D011929653F84FB989C471655FEEB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementCopromotionMember" xlink:label="loc_us-gaap_CollaborativeArrangementCopromotionMember_E9DA8B9E4D9D0E0776E09C471655BFD1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_B81D011929653F84FB989C471655FEEB" xlink:to="loc_us-gaap_CollaborativeArrangementCopromotionMember_E9DA8B9E4D9D0E0776E09C471655BFD1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_B467D00D2AC96D1223749C471655DF31" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_95A1ADCBE302F1B121559C471651BBAD" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_B467D00D2AC96D1223749C471655DF31" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0D3CA108D2EEF9C26C3A9C4716556636" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_B467D00D2AC96D1223749C471655DF31" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0D3CA108D2EEF9C26C3A9C4716556636" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DistributionRightsMember" xlink:label="loc_us-gaap_DistributionRightsMember_D8BB07B591FAF7725E1B9C4716551DE6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0D3CA108D2EEF9C26C3A9C4716556636" xlink:to="loc_us-gaap_DistributionRightsMember_D8BB07B591FAF7725E1B9C4716551DE6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_AAF10B0BE3DA18360C439C471655A98A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0D3CA108D2EEF9C26C3A9C4716556636" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_AAF10B0BE3DA18360C439C471655A98A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_24AA36B064BAF3A02C869C471656EBD8" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_95A1ADCBE302F1B121559C471651BBAD" xlink:to="loc_us-gaap_ProductOrServiceAxis_24AA36B064BAF3A02C869C471656EBD8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_274168A1D41E4248631B9C47165624B2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductOrServiceAxis_24AA36B064BAF3A02C869C471656EBD8" xlink:to="loc_us-gaap_ProductsAndServicesDomain_274168A1D41E4248631B9C47165624B2" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_EnbrelMember" xlink:label="loc_pfe_EnbrelMember_BA9498AB00CCC38840E39C471656E6A4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_274168A1D41E4248631B9C47165624B2" xlink:to="loc_pfe_EnbrelMember_BA9498AB00CCC38840E39C471656E6A4" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_XtandiMember" xlink:label="loc_pfe_XtandiMember_005A5310349C9D29CCAA9C471656FB57" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_274168A1D41E4248631B9C47165624B2" xlink:to="loc_pfe_XtandiMember_005A5310349C9D29CCAA9C471656FB57" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_CelebrexMember" xlink:label="loc_pfe_CelebrexMember_00CDD5B3C06D78AC5E139C4716563B98" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_274168A1D41E4248631B9C47165624B2" xlink:to="loc_pfe_CelebrexMember_00CDD5B3C06D78AC5E139C4716563B98" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_CelebrexandBextraMember" xlink:label="loc_pfe_CelebrexandBextraMember_5F13FF9444B2387028A29C471656CFA3" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_274168A1D41E4248631B9C47165624B2" xlink:to="loc_pfe_CelebrexandBextraMember_5F13FF9444B2387028A29C471656CFA3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ADCF77D77E653BCA2B369C4716573F4F" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_95A1ADCBE302F1B121559C471651BBAD" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ADCF77D77E653BCA2B369C4716573F4F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvesteeNameDomain" xlink:label="loc_us-gaap_EquityMethodInvesteeNameDomain_D51FB0AB68E0EA95AD4F9C471657753C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ADCF77D77E653BCA2B369C4716573F4F" xlink:to="loc_us-gaap_EquityMethodInvesteeNameDomain_D51FB0AB68E0EA95AD4F9C471657753C" xlink:type="arc" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvesteeNameDomain_D51FB0AB68E0EA95AD4F9C471657753C" xlink:to="loc_pfe_LaboratorioTeutoBrasileroMember_7AEEED5A12921B85F5379C4716525A4C" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_HisunPfizerPharmaceuticalsCoLtdMember" xlink:label="loc_pfe_HisunPfizerPharmaceuticalsCoLtdMember_17436B9DD03E74EC83369C4716574415" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvesteeNameDomain_D51FB0AB68E0EA95AD4F9C471657753C" xlink:to="loc_pfe_HisunPfizerPharmaceuticalsCoLtdMember_17436B9DD03E74EC83369C4716574415" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_ViivHealthcareLimitedMember" xlink:label="loc_pfe_ViivHealthcareLimitedMember_AD7335B3FA93CC96B4B29C471658E596" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvesteeNameDomain_D51FB0AB68E0EA95AD4F9C471657753C" xlink:to="loc_pfe_ViivHealthcareLimitedMember_AD7335B3FA93CC96B4B29C471658E596" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaap_LossContingenciesLineItems_190165E2439EFA6C88F09C471658495A" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_95A1ADCBE302F1B121559C471651BBAD" xlink:to="loc_us-gaap_LossContingenciesLineItems_190165E2439EFA6C88F09C471658495A" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_DecreaseinRoyaltyRevenue" xlink:label="loc_pfe_DecreaseinRoyaltyRevenue_DAC0D36C09A2A04546649C471658C5B4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_190165E2439EFA6C88F09C471658495A" xlink:to="loc_pfe_DecreaseinRoyaltyRevenue_DAC0D36C09A2A04546649C471658C5B4" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_RoyaltyRevenueTerm" xlink:label="loc_pfe_RoyaltyRevenueTerm_997316D9F18789639AD09C471658DE0A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_190165E2439EFA6C88F09C471658495A" xlink:to="loc_pfe_RoyaltyRevenueTerm_997316D9F18789639AD09C471658DE0A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:label="loc_us-gaap_RoyaltyRevenue_5875B80643E2F7FD923D9C4716583F48" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_190165E2439EFA6C88F09C471658495A" xlink:to="loc_us-gaap_RoyaltyRevenue_5875B80643E2F7FD923D9C4716583F48" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationSettlementExpense" xlink:label="loc_us-gaap_LitigationSettlementExpense_0D0A20883E0F6A98B2409C471658693A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_190165E2439EFA6C88F09C471658495A" xlink:to="loc_us-gaap_LitigationSettlementExpense_0D0A20883E0F6A98B2409C471658693A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_EEFC245F4CCA145AEF219C4716592E00" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_190165E2439EFA6C88F09C471658495A" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_EEFC245F4CCA145AEF219C4716592E00" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossOnDispositionOfIntangibleAssets" xlink:label="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_C4249E220EF8BB211A0F9C471659FC43" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_190165E2439EFA6C88F09C471658495A" xlink:to="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_C4249E220EF8BB211A0F9C471659FC43" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainOnSaleOfInvestments" xlink:label="loc_us-gaap_GainOnSaleOfInvestments_97BE826112523B53E56D9C4716592D6C" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_190165E2439EFA6C88F09C471658495A" xlink:to="loc_us-gaap_GainOnSaleOfInvestments_97BE826112523B53E56D9C4716592D6C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_4C699B9A4944A9D597A89C47165AD4BF" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_190165E2439EFA6C88F09C471658495A" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_4C699B9A4944A9D597A89C47165AD4BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_C0757627A7CC8D088D939C47165A4117" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_190165E2439EFA6C88F09C471658495A" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_C0757627A7CC8D088D939C47165A4117" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_B0D8DE3E83A9F7CCC40E9C47165A1990" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_190165E2439EFA6C88F09C471658495A" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_B0D8DE3E83A9F7CCC40E9C47165A1990" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal" xlink:label="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_AC3B6A2758DF4355B9C69C47165A45C8" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_190165E2439EFA6C88F09C471658495A" xlink:to="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_AC3B6A2758DF4355B9C69C47165A45C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_B8ADDD70296F19B54FB69C47165A97AF" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_190165E2439EFA6C88F09C471658495A" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_B8ADDD70296F19B54FB69C47165A97AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment" xlink:label="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_24F2E5BB9C009165AEF19C47165A2884" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_190165E2439EFA6C88F09C471658495A" xlink:to="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_24F2E5BB9C009165AEF19C47165A2884" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentIncomeDividend" xlink:label="loc_us-gaap_InvestmentIncomeDividend_793E89681EAA70594FD09C47165A2BB4" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_190165E2439EFA6C88F09C471658495A" xlink:to="loc_us-gaap_InvestmentIncomeDividend_793E89681EAA70594FD09C47165A2BB4" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_OtherNonoperatingIncomeMiscellaneous" xlink:label="loc_pfe_OtherNonoperatingIncomeMiscellaneous_2249A417ED8EC98A8CE29C47165A986A" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_190165E2439EFA6C88F09C471658495A" xlink:to="loc_pfe_OtherNonoperatingIncomeMiscellaneous_2249A417ED8EC98A8CE29C47165A986A" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_PaymentsforMergerTerminationCosts" xlink:label="loc_pfe_PaymentsforMergerTerminationCosts_7D8CFD62A7144EA1679F9C47165AB0AD" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_190165E2439EFA6C88F09C471658495A" xlink:to="loc_pfe_PaymentsforMergerTerminationCosts_7D8CFD62A7144EA1679F9C47165AB0AD" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/OtherIncomeDeductionsNetImpairedIntangibleAssetsDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_EEA04344958B1415A83391BE7BEC00DB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_098A9308C34D5D9FAD6291BE7BEC4169" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_EEA04344958B1415A83391BE7BEC00DB" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_098A9308C34D5D9FAD6291BE7BEC4169" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_18F268A3766C0679E3A491BE7BEDC241" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_098A9308C34D5D9FAD6291BE7BEC4169" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_18F268A3766C0679E3A491BE7BEDC241" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5C3B9269350C0958113A91BE7BEDB95E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_18F268A3766C0679E3A491BE7BEDC241" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5C3B9269350C0958113A91BE7BEDB95E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_4A0A986E30EEF78A537C91BE7BED15EE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5C3B9269350C0958113A91BE7BEDB95E" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_4A0A986E30EEF78A537C91BE7BED15EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_BFDF8AEA48384BFF16C291BE7BED3045" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_098A9308C34D5D9FAD6291BE7BEC4169" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_BFDF8AEA48384BFF16C291BE7BED3045" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_EA7160890314A6422B0F91BE7BED1149" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_BFDF8AEA48384BFF16C291BE7BED3045" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_EA7160890314A6422B0F91BE7BED1149" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_B77969D8CC7738F4267E91BE7BED05C0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_EA7160890314A6422B0F91BE7BED1149" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_B77969D8CC7738F4267E91BE7BED05C0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_DC2843CE2407EBEB7AF291BE7BEEB3E9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_EA7160890314A6422B0F91BE7BED1149" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_DC2843CE2407EBEB7AF291BE7BEEB3E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_E49B3D40A47CED32C7A491BE7BEEB7C8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_EA7160890314A6422B0F91BE7BED1149" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_E49B3D40A47CED32C7A491BE7BEEB7C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_5B2E9FD338207E47C1A891BE7BEE2344" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_098A9308C34D5D9FAD6291BE7BEC4169" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_5B2E9FD338207E47C1A891BE7BEE2344" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure_F1E9C2521982018511B291BE7BEECF7E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_5B2E9FD338207E47C1A891BE7BEE2344" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure_F1E9C2521982018511B291BE7BEECF7E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_A4E1817BB7886893854791BE7BEE1500" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_5B2E9FD338207E47C1A891BE7BEE2344" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_A4E1817BB7886893854791BE7BEE1500" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/OtherIncomeDeductionsNetTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_BDAE63C01518BEBC8F2E5A1C67328813" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_5D41416BD5722C52B76F5A1C673209FB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_BDAE63C01518BEBC8F2E5A1C67328813" xlink:to="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_5D41416BD5722C52B76F5A1C673209FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfImpairedIntangibleAssetsTextBlock" xlink:label="loc_us-gaap_ScheduleOfImpairedIntangibleAssetsTextBlock_DEBA8626BDCFE39043045A1C775E7E8D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_BDAE63C01518BEBC8F2E5A1C67328813" xlink:to="loc_us-gaap_ScheduleOfImpairedIntangibleAssetsTextBlock_DEBA8626BDCFE39043045A1C775E7E8D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlans" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_6B55419DC5235A0091FFD1B9C1B11783" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_5ED0B1634B0F5BAD901D0C8CE8AEB8FE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_6B55419DC5235A0091FFD1B9C1B11783" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_5ED0B1634B0F5BAD901D0C8CE8AEB8FE" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_C679AE7E0076F7FC34969C2600344F03" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_58F943B65501197DC9DB9C260035C20A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_C679AE7E0076F7FC34969C2600344F03" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_58F943B65501197DC9DB9C260035C20A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_9DDE60E9AF724D3EBC0A9C2600350B6C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_58F943B65501197DC9DB9C260035C20A" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_9DDE60E9AF724D3EBC0A9C2600350B6C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_06107B8D81988B97DFEB9C260035C7DE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_9DDE60E9AF724D3EBC0A9C2600350B6C" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_06107B8D81988B97DFEB9C260035C7DE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_248C21407034A7E0BA549C260035688F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_06107B8D81988B97DFEB9C260035C7DE" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_248C21407034A7E0BA549C260035688F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" xlink:label="loc_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember_1B64F4669BA2AE0B576A9C260035C031" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_06107B8D81988B97DFEB9C260035C7DE" xlink:to="loc_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember_1B64F4669BA2AE0B576A9C260035C031" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_1307BA41747480D8F2539C260035CC50" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_06107B8D81988B97DFEB9C260035C7DE" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_1307BA41747480D8F2539C260035CC50" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_1565ED786730FA4615959C2600358A98" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_58F943B65501197DC9DB9C260035C20A" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_1565ED786730FA4615959C2600358A98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_57C8C8363D5ADF3AA5FB9C260035B747" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_1565ED786730FA4615959C2600358A98" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_57C8C8363D5ADF3AA5FB9C260035B747" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DomesticPlanMember" xlink:label="loc_us-gaap_DomesticPlanMember_F5447EB850F5B34DE8C29C26003AB905" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_57C8C8363D5ADF3AA5FB9C260035B747" xlink:to="loc_us-gaap_DomesticPlanMember_F5447EB850F5B34DE8C29C26003AB905" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_0B0CCE0A7C5D9058C7D39C26003ABCF6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DomesticPlanMember_F5447EB850F5B34DE8C29C26003AB905" xlink:to="loc_country_US_0B0CCE0A7C5D9058C7D39C26003ABCF6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ForeignPlanMember" xlink:label="loc_us-gaap_ForeignPlanMember_3393F3E6D6A820AB4B129C26003A09D8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_57C8C8363D5ADF3AA5FB9C260035B747" xlink:to="loc_us-gaap_ForeignPlanMember_3393F3E6D6A820AB4B129C26003A09D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetirementPlanTaxStatusAxis" xlink:label="loc_us-gaap_RetirementPlanTaxStatusAxis_EE9B36554A064C65D1C49C26003B609C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_58F943B65501197DC9DB9C260035C20A" xlink:to="loc_us-gaap_RetirementPlanTaxStatusAxis_EE9B36554A064C65D1C49C26003B609C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetirementPlanTaxStatusDomain" xlink:label="loc_us-gaap_RetirementPlanTaxStatusDomain_323362365401814229A49C26003BD62B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTaxStatusAxis_EE9B36554A064C65D1C49C26003B609C" xlink:to="loc_us-gaap_RetirementPlanTaxStatusDomain_323362365401814229A49C26003BD62B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_QualifiedPlanMember" xlink:label="loc_us-gaap_QualifiedPlanMember_ADC75BD412157F4427729C26003BFEAD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTaxStatusDomain_323362365401814229A49C26003BD62B" xlink:to="loc_us-gaap_QualifiedPlanMember_ADC75BD412157F4427729C26003BFEAD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonqualifiedPlanMember" xlink:label="loc_us-gaap_NonqualifiedPlanMember_F7873889745A1D4F86169C26003B2B66" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTaxStatusDomain_323362365401814229A49C26003BD62B" xlink:to="loc_us-gaap_NonqualifiedPlanMember_F7873889745A1D4F86169C26003B2B66" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_0655BCA3A48F386F7BB69C26003B0E64" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_58F943B65501197DC9DB9C260035C20A" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_0655BCA3A48F386F7BB69C26003B0E64" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:label="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_83C75D167FE2921611F99C26003B923B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_0655BCA3A48F386F7BB69C26003B0E64" xlink:to="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_83C75D167FE2921611F99C26003B923B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsRemainderOfFiscalYear" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsRemainderOfFiscalYear_8B1881E5D9A67DFC93959C26003B464D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_0655BCA3A48F386F7BB69C26003B0E64" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsRemainderOfFiscalYear_8B1881E5D9A67DFC93959C26003B464D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansNetPeriodicBenefitCostDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_F95CD020A5D3B89F9C5A58E0C4A11CCF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_B1E6D9DEB85CD33D790258E0C4A11A00" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_F95CD020A5D3B89F9C5A58E0C4A11CCF" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_B1E6D9DEB85CD33D790258E0C4A11A00" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_8C1D741929AEB2306A9758E0C4A12E54" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_B1E6D9DEB85CD33D790258E0C4A11A00" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_8C1D741929AEB2306A9758E0C4A12E54" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_E1DD6B6C6E060F2986AA58E0C4A1BDAC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_8C1D741929AEB2306A9758E0C4A12E54" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_E1DD6B6C6E060F2986AA58E0C4A1BDAC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_CA24403FE5E80C8FDE5A58E0C4A1ED31" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_E1DD6B6C6E060F2986AA58E0C4A1BDAC" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_CA24403FE5E80C8FDE5A58E0C4A1ED31" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" xlink:label="loc_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember_22F13CC34B8F768DBF1058E0C4A13981" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_E1DD6B6C6E060F2986AA58E0C4A1BDAC" xlink:to="loc_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember_22F13CC34B8F768DBF1058E0C4A13981" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_8589B5192333D3A2674158E0C4A11B46" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_E1DD6B6C6E060F2986AA58E0C4A1BDAC" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_8589B5192333D3A2674158E0C4A11B46" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_68A521F7AD3147B74C7158E0C4A147CE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_B1E6D9DEB85CD33D790258E0C4A11A00" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_68A521F7AD3147B74C7158E0C4A147CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_A92C468E784C95F59A8A58E0C4A1C07D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_68A521F7AD3147B74C7158E0C4A147CE" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_A92C468E784C95F59A8A58E0C4A1C07D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DomesticPlanMember" xlink:label="loc_us-gaap_DomesticPlanMember_3F87AF0DF8AE9391A31D58E0C4A25178" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_A92C468E784C95F59A8A58E0C4A1C07D" xlink:to="loc_us-gaap_DomesticPlanMember_3F87AF0DF8AE9391A31D58E0C4A25178" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_764039C20B1AD4AF6E7B58E0C4A2B6E5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DomesticPlanMember_3F87AF0DF8AE9391A31D58E0C4A25178" xlink:to="loc_country_US_764039C20B1AD4AF6E7B58E0C4A2B6E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ForeignPlanMember" xlink:label="loc_us-gaap_ForeignPlanMember_9E5EFD1E7A6C75A973F958E0C4A29670" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_A92C468E784C95F59A8A58E0C4A1C07D" xlink:to="loc_us-gaap_ForeignPlanMember_9E5EFD1E7A6C75A973F958E0C4A29670" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetirementPlanTaxStatusAxis" xlink:label="loc_us-gaap_RetirementPlanTaxStatusAxis_B3CC59DA1369AACDA88458E0C4A28212" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_B1E6D9DEB85CD33D790258E0C4A11A00" xlink:to="loc_us-gaap_RetirementPlanTaxStatusAxis_B3CC59DA1369AACDA88458E0C4A28212" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetirementPlanTaxStatusDomain" xlink:label="loc_us-gaap_RetirementPlanTaxStatusDomain_38CD8A3CF34EF52A2E4C58E0C4A2F80D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTaxStatusAxis_B3CC59DA1369AACDA88458E0C4A28212" xlink:to="loc_us-gaap_RetirementPlanTaxStatusDomain_38CD8A3CF34EF52A2E4C58E0C4A2F80D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_QualifiedPlanMember" xlink:label="loc_us-gaap_QualifiedPlanMember_1EBEB72E59C504F19D9258E0C4A2EC55" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTaxStatusDomain_38CD8A3CF34EF52A2E4C58E0C4A2F80D" xlink:to="loc_us-gaap_QualifiedPlanMember_1EBEB72E59C504F19D9258E0C4A2EC55" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonqualifiedPlanMember" xlink:label="loc_us-gaap_NonqualifiedPlanMember_63B6E5D47646B0658AC658E0C4A225E4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTaxStatusDomain_38CD8A3CF34EF52A2E4C58E0C4A2F80D" xlink:to="loc_us-gaap_NonqualifiedPlanMember_63B6E5D47646B0658AC658E0C4A225E4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_CDBB8AF2C084C26F167E58E0C4A24AAC" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_B1E6D9DEB85CD33D790258E0C4A11A00" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_CDBB8AF2C084C26F167E58E0C4A24AAC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedBenefitPlanServiceCost" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_148CAA7E3A877C3E6F5A58E0C4A25CA4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_CDBB8AF2C084C26F167E58E0C4A24AAC" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_148CAA7E3A877C3E6F5A58E0C4A25CA4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedBenefitPlanInterestCost" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_C63935ADD22A0933A76658E0C4A26A28" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_CDBB8AF2C084C26F167E58E0C4A24AAC" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_C63935ADD22A0933A76658E0C4A26A28" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_A82F4BFA8169C436411858E0C4A204BE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_CDBB8AF2C084C26F167E58E0C4A24AAC" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_A82F4BFA8169C436411858E0C4A204BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_3CEC019DC12674A85AF558E0C4A2B5F6" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_CDBB8AF2C084C26F167E58E0C4A24AAC" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_3CEC019DC12674A85AF558E0C4A2B5F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_5CEE52BAFEE1A45F164658E0C4A257B2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_3CEC019DC12674A85AF558E0C4A2B5F6" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_5CEE52BAFEE1A45F164658E0C4A257B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_EB003D082E3D8B77235658E0C4A242EF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_3CEC019DC12674A85AF558E0C4A2B5F6" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_EB003D082E3D8B77235658E0C4A242EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments_00B33F4458EA06BCFC7A58E0C4A351CC" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_CDBB8AF2C084C26F167E58E0C4A24AAC" xlink:to="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments_00B33F4458EA06BCFC7A58E0C4A351CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_5A948B9C366415A04F5F58E0C4A3CB04" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_CDBB8AF2C084C26F167E58E0C4A24AAC" xlink:to="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_5A948B9C366415A04F5F58E0C4A3CB04" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_ACEDA0A695614709E61158E0C4A3EF28" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_CDBB8AF2C084C26F167E58E0C4A24AAC" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_ACEDA0A695614709E61158E0C4A3EF28" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansNetPeriodicBenefitCostFootnotesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_7CB388BA915C57AD9C772A20FDE84735" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_D0E4EA682CE85E7583739D01C7DA6D04" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_7CB388BA915C57AD9C772A20FDE84735" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_D0E4EA682CE85E7583739D01C7DA6D04" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_9A816E6E2C8E5FBDB0D00CB0AE558AAB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_D0E4EA682CE85E7583739D01C7DA6D04" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_9A816E6E2C8E5FBDB0D00CB0AE558AAB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_104C7B3624B45E08B38ABF7EBFBAD857" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_9A816E6E2C8E5FBDB0D00CB0AE558AAB" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_104C7B3624B45E08B38ABF7EBFBAD857" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_HospiraMember" xlink:label="loc_pfe_HospiraMember_31E812AD04A3597285CC63EF569B521A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_104C7B3624B45E08B38ABF7EBFBAD857" xlink:to="loc_pfe_HospiraMember_31E812AD04A3597285CC63EF569B521A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_82071F938F835596819F4BCCE1D982B8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_D0E4EA682CE85E7583739D01C7DA6D04" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_82071F938F835596819F4BCCE1D982B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_F2B8AB55FA2555C180C83366EA91D6CD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_82071F938F835596819F4BCCE1D982B8" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_F2B8AB55FA2555C180C83366EA91D6CD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_CDB8E7311EB25DA7ADE0506EB11388DE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_F2B8AB55FA2555C180C83366EA91D6CD" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_CDB8E7311EB25DA7ADE0506EB11388DE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_55484D933A7C5E3CAB8AE4A168A66F9F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_D0E4EA682CE85E7583739D01C7DA6D04" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_55484D933A7C5E3CAB8AE4A168A66F9F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_A0992C1AAC355AF4959E3215F4541E92" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_55484D933A7C5E3CAB8AE4A168A66F9F" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_A0992C1AAC355AF4959E3215F4541E92" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DomesticPlanMember" xlink:label="loc_us-gaap_DomesticPlanMember_168396ECD88153AF9930F95EA7B6BBA1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_A0992C1AAC355AF4959E3215F4541E92" xlink:to="loc_us-gaap_DomesticPlanMember_168396ECD88153AF9930F95EA7B6BBA1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_70C652CD6AC059EEBD955CE6ADDB5D7A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DomesticPlanMember_168396ECD88153AF9930F95EA7B6BBA1" xlink:to="loc_country_US_70C652CD6AC059EEBD955CE6ADDB5D7A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetirementPlanTaxStatusAxis" xlink:label="loc_us-gaap_RetirementPlanTaxStatusAxis_60FABF4A4FAD5627A7081CC65D5235AC" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_D0E4EA682CE85E7583739D01C7DA6D04" xlink:to="loc_us-gaap_RetirementPlanTaxStatusAxis_60FABF4A4FAD5627A7081CC65D5235AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetirementPlanTaxStatusDomain" xlink:label="loc_us-gaap_RetirementPlanTaxStatusDomain_1262126FE93B5006B7BDE401A606DA4F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTaxStatusAxis_60FABF4A4FAD5627A7081CC65D5235AC" xlink:to="loc_us-gaap_RetirementPlanTaxStatusDomain_1262126FE93B5006B7BDE401A606DA4F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_QualifiedPlanMember" xlink:label="loc_us-gaap_QualifiedPlanMember_2617FF9D9494576B8FA119416318DCB9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTaxStatusDomain_1262126FE93B5006B7BDE401A606DA4F" xlink:to="loc_us-gaap_QualifiedPlanMember_2617FF9D9494576B8FA119416318DCB9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_C94B763BAB585F6D9D2646362354FD13" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_D0E4EA682CE85E7583739D01C7DA6D04" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_C94B763BAB585F6D9D2646362354FD13" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedBenefitPlanSettlementsBenefitObligation" xlink:label="loc_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation_01D2742C605E58C79DD00E8D81F54B5A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_C94B763BAB585F6D9D2646362354FD13" xlink:to="loc_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation_01D2742C605E58C79DD00E8D81F54B5A" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_DefinedBenefitPlanNetPeriodicBenefitCostCreditGainLossDuetoSettlementPretax" xlink:label="loc_pfe_DefinedBenefitPlanNetPeriodicBenefitCostCreditGainLossDuetoSettlementPretax_759A631484EC5D9E81525B53E0BA088A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_C94B763BAB585F6D9D2646362354FD13" xlink:to="loc_pfe_DefinedBenefitPlanNetPeriodicBenefitCostCreditGainLossDuetoSettlementPretax_759A631484EC5D9E81525B53E0BA088A" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_DefinedBenefitPlanActuarialLossandPriorServiceCostsImmediateRecognitionasComponentinNetPeriodicBenefitCost" xlink:label="loc_pfe_DefinedBenefitPlanActuarialLossandPriorServiceCostsImmediateRecognitionasComponentinNetPeriodicBenefitCost_29CEBA4F376F53C48547A40435E9CCAF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_C94B763BAB585F6D9D2646362354FD13" xlink:to="loc_pfe_DefinedBenefitPlanActuarialLossandPriorServiceCostsImmediateRecognitionasComponentinNetPeriodicBenefitCost_29CEBA4F376F53C48547A40435E9CCAF" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_9C168C4209C653168FD9F1E1787C41A8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_0CE4BBAEEE0D5775A844C20D47A4524F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_9C168C4209C653168FD9F1E1787C41A8" xlink:to="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_0CE4BBAEEE0D5775A844C20D47A4524F" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_ScheduleofEmployerContributionstoPensionandPostretirementPlansTableTextBlock" xlink:label="loc_pfe_ScheduleofEmployerContributionstoPensionandPostretirementPlansTableTextBlock_29071CC0406757328CC10C7CFE424720" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_9C168C4209C653168FD9F1E1787C41A8" xlink:to="loc_pfe_ScheduleofEmployerContributionstoPensionandPostretirementPlansTableTextBlock_29071CC0406757328CC10C7CFE424720" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiatives" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_BF836A74013A577F9CA0357F94CB4D06" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_0A5B3CE2DFDA5A80B36CF5FA7761D854" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_BF836A74013A577F9CA0357F94CB4D06" xlink:to="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_0A5B3CE2DFDA5A80B36CF5FA7761D854" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_18DC2927954F1ABA2E299C2643177037" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_497351AF5A683035FED29C2643172B4F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_18DC2927954F1ABA2E299C2643177037" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_497351AF5A683035FED29C2643172B4F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_E027C3E6826D643AAFD99C2643171D8D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_497351AF5A683035FED29C2643172B4F" xlink:to="loc_us-gaap_StatementScenarioAxis_E027C3E6826D643AAFD99C2643171D8D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_A9CB31473C7744EA3C8D9C2643174C96" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementScenarioAxis_E027C3E6826D643AAFD99C2643171D8D" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_A9CB31473C7744EA3C8D9C2643174C96" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioForecastMember" xlink:label="loc_us-gaap_ScenarioForecastMember_99A0014D84F70574C4A19C264317A5BC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_A9CB31473C7744EA3C8D9C2643174C96" xlink:to="loc_us-gaap_ScenarioForecastMember_99A0014D84F70574C4A19C264317A5BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_471964441D0F0D8F67619C264317ACEA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_497351AF5A683035FED29C2643172B4F" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_471964441D0F0D8F67619C264317ACEA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9DF3FBD198B5098963419C264317B346" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_471964441D0F0D8F67619C264317ACEA" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9DF3FBD198B5098963419C264317B346" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_HospiraMember" xlink:label="loc_pfe_HospiraMember_CDFFBE04AF0AB75D94979C26431790C7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9DF3FBD198B5098963419C264317B346" xlink:to="loc_pfe_HospiraMember_CDFFBE04AF0AB75D94979C26431790C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_61533D8AB24ABEB493D49C264317E67C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_497351AF5A683035FED29C2643172B4F" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_61533D8AB24ABEB493D49C264317E67C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_1F166A59D29A3789F4489C2643174E41" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_61533D8AB24ABEB493D49C264317E67C" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_1F166A59D29A3789F4489C2643174E41" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_ReturnofAcquiredRightsMember" xlink:label="loc_pfe_ReturnofAcquiredRightsMember_E9C90B5409D9135B8FAA9C264318609A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_1F166A59D29A3789F4489C2643174E41" xlink:to="loc_pfe_ReturnofAcquiredRightsMember_E9C90B5409D9135B8FAA9C264318609A" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_ManufacturingPlantNetworkOptimizationMember" xlink:label="loc_pfe_ManufacturingPlantNetworkOptimizationMember_3B6ED7C95EE5E79B83899C26431846EF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_1F166A59D29A3789F4489C2643174E41" xlink:to="loc_pfe_ManufacturingPlantNetworkOptimizationMember_3B6ED7C95EE5E79B83899C26431846EF" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_CentralizationofCorporateandPlatformFunctionsMember" xlink:label="loc_pfe_CentralizationofCorporateandPlatformFunctionsMember_D99C8B77D06D90D7393E9C26431878E1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_1F166A59D29A3789F4489C2643174E41" xlink:to="loc_pfe_CentralizationofCorporateandPlatformFunctionsMember_D99C8B77D06D90D7393E9C26431878E1" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_BusinessIntegrationCostsMember" xlink:label="loc_pfe_BusinessIntegrationCostsMember_BA7DCFDB755847A59BFD9C264318BE89" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_1F166A59D29A3789F4489C2643174E41" xlink:to="loc_pfe_BusinessIntegrationCostsMember_BA7DCFDB755847A59BFD9C264318BE89" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringPlanAxis" xlink:label="loc_us-gaap_RestructuringPlanAxis_AC4C67B9CBC15C5E701A9C2643185AAF" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_497351AF5A683035FED29C2643172B4F" xlink:to="loc_us-gaap_RestructuringPlanAxis_AC4C67B9CBC15C5E701A9C2643185AAF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringPlanDomain" xlink:label="loc_us-gaap_RestructuringPlanDomain_644CBB9D270F40ACE5F59C264318D79A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanAxis_AC4C67B9CBC15C5E701A9C2643185AAF" xlink:to="loc_us-gaap_RestructuringPlanDomain_644CBB9D270F40ACE5F59C264318D79A" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_EnterprisewideCostReductionProductivityPlanMember" xlink:label="loc_pfe_EnterprisewideCostReductionProductivityPlanMember_49CAB6C335E6D2D669239C264318A44C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_644CBB9D270F40ACE5F59C264318D79A" xlink:to="loc_pfe_EnterprisewideCostReductionProductivityPlanMember_49CAB6C335E6D2D669239C264318A44C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_5A226EFB35573897CA7D9C2643185847" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_497351AF5A683035FED29C2643172B4F" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_5A226EFB35573897CA7D9C2643185847" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_9690C7DEDF5E0FBDA7CA9C2643180956" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_5A226EFB35573897CA7D9C2643185847" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_9690C7DEDF5E0FBDA7CA9C2643180956" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostOfSalesMember" xlink:label="loc_us-gaap_CostOfSalesMember_1299E222993D193C2A299C26431808F3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9690C7DEDF5E0FBDA7CA9C2643180956" xlink:to="loc_us-gaap_CostOfSalesMember_1299E222993D193C2A299C26431808F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_D5FD1FF344784AC23F7F9C26431852B8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9690C7DEDF5E0FBDA7CA9C2643180956" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_D5FD1FF344784AC23F7F9C26431852B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_F73112636689AE0FBFF99C26431879D4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9690C7DEDF5E0FBDA7CA9C2643180956" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_F73112636689AE0FBFF99C26431879D4" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_OtherIncomeExpenseMember" xlink:label="loc_pfe_OtherIncomeExpenseMember_5900C7FA344D739757019C264318BD38" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9690C7DEDF5E0FBDA7CA9C2643180956" xlink:to="loc_pfe_OtherIncomeExpenseMember_5900C7FA344D739757019C264318BD38" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_4CF542CCAD53A25C870A9C26431D90E8" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_497351AF5A683035FED29C2643172B4F" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_4CF542CCAD53A25C870A9C26431D90E8" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_BusinessCombinationExpectedIntegrationRelatedCostsPeriod" xlink:label="loc_pfe_BusinessCombinationExpectedIntegrationRelatedCostsPeriod_8437AE6B72C69EF70B0C9C26431D54C6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_4CF542CCAD53A25C870A9C26431D90E8" xlink:to="loc_pfe_BusinessCombinationExpectedIntegrationRelatedCostsPeriod_8437AE6B72C69EF70B0C9C26431D54C6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationIntegrationRelatedCosts" xlink:label="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_47A79B3D765841FBA50C9C26431ECA01" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_4CF542CCAD53A25C870A9C26431D90E8" xlink:to="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_47A79B3D765841FBA50C9C26431ECA01" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:label="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_6D52639CE0ADD899E0509C26431E2D77" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_4CF542CCAD53A25C870A9C26431D90E8" xlink:to="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_6D52639CE0ADD899E0509C26431E2D77" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_14778AEDD61BA7FFA4889C26431EAF83" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_4CF542CCAD53A25C870A9C26431D90E8" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_14778AEDD61BA7FFA4889C26431EAF83" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_RestructuringandRelatedCostNoncashChargesPercentage" xlink:label="loc_pfe_RestructuringandRelatedCostNoncashChargesPercentage_752ABE2FF7427400E15B9C30B8575657" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_4CF542CCAD53A25C870A9C26431D90E8" xlink:to="loc_pfe_RestructuringandRelatedCostNoncashChargesPercentage_752ABE2FF7427400E15B9C30B8575657" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:label="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_ED29960F846FAF1B7BAB9C26431E0F7E" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_4CF542CCAD53A25C870A9C26431D90E8" xlink:to="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_ED29960F846FAF1B7BAB9C26431E0F7E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringChargesAbstract" xlink:label="loc_us-gaap_RestructuringChargesAbstract_DEE58F2CAEA7EC41E4439C26431E515F" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_4CF542CCAD53A25C870A9C26431D90E8" xlink:to="loc_us-gaap_RestructuringChargesAbstract_DEE58F2CAEA7EC41E4439C26431E515F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeveranceCosts1" xlink:label="loc_us-gaap_SeveranceCosts1_259673FFB6E4DD36956C9C26431EB9E2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringChargesAbstract_DEE58F2CAEA7EC41E4439C26431E515F" xlink:to="loc_us-gaap_SeveranceCosts1_259673FFB6E4DD36956C9C26431EB9E2" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_RestructuringAssetImpairmentCharges" xlink:label="loc_pfe_RestructuringAssetImpairmentCharges_EA945165FB56660778959C26431E820B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/netLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringChargesAbstract_DEE58F2CAEA7EC41E4439C26431E515F" xlink:to="loc_pfe_RestructuringAssetImpairmentCharges_EA945165FB56660778959C26431E820B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessExitCosts1" xlink:label="loc_us-gaap_BusinessExitCosts1_A7F92F68BE4AA42A04839C26431E57B5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringChargesAbstract_DEE58F2CAEA7EC41E4439C26431E515F" xlink:to="loc_us-gaap_BusinessExitCosts1_A7F92F68BE4AA42A04839C26431E57B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_75F0F00A91F7F2B7A5519C26431EE306" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringChargesAbstract_DEE58F2CAEA7EC41E4439C26431E515F" xlink:to="loc_us-gaap_RestructuringCharges_75F0F00A91F7F2B7A5519C26431EE306" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts" xlink:label="loc_pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts_D2189C6236BE7605CB839C26431ED851" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_4CF542CCAD53A25C870A9C26431D90E8" xlink:to="loc_pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts_D2189C6236BE7605CB839C26431ED851" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationIntegrationRelatedCosts" xlink:label="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_2B6031F007B8ECB2ECB29C26431E1F01" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_4CF542CCAD53A25C870A9C26431D90E8" xlink:to="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_2B6031F007B8ECB2ECB29C26431E1F01" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_RestructuringChargesAndAcquisitionRelatedCosts" xlink:label="loc_pfe_RestructuringChargesAndAcquisitionRelatedCosts_BFB0FF6A296F75005B149C26431E157B" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_4CF542CCAD53A25C870A9C26431D90E8" xlink:to="loc_pfe_RestructuringChargesAndAcquisitionRelatedCosts_BFB0FF6A296F75005B149C26431E157B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringReserveAcceleratedDepreciation" xlink:label="loc_us-gaap_RestructuringReserveAcceleratedDepreciation_9F7C0E2FA20C7A8CA3069C26431EF616" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_4CF542CCAD53A25C870A9C26431D90E8" xlink:to="loc_us-gaap_RestructuringReserveAcceleratedDepreciation_9F7C0E2FA20C7A8CA3069C26431EF616" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_ImplementationCostAbstract" xlink:label="loc_pfe_ImplementationCostAbstract_2D129AC7E2F938D05CC99C26431EF49E" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_4CF542CCAD53A25C870A9C26431D90E8" xlink:to="loc_pfe_ImplementationCostAbstract_2D129AC7E2F938D05CC99C26431EF49E" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_ImplementationCosts" xlink:label="loc_pfe_ImplementationCosts_448A4FBE347219FC098C9C26431ECBDC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ImplementationCostAbstract_2D129AC7E2F938D05CC99C26431EF49E" xlink:to="loc_pfe_ImplementationCosts_448A4FBE347219FC098C9C26431ECBDC" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts" xlink:label="loc_pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts_2AF4FC65BD5170C491E09C26431FE1B1" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_4CF542CCAD53A25C870A9C26431D90E8" xlink:to="loc_pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts_2AF4FC65BD5170C491E09C26431FE1B1" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesFootnotesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_F24ADB107A4A0A95F3D97DDD5D041DA4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_9631D0D57299A46AF5D47DDD5D04A73E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_F24ADB107A4A0A95F3D97DDD5D041DA4" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_9631D0D57299A46AF5D47DDD5D04A73E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_06D5DEBC654A9FAE092F7DDD5D0510C9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_9631D0D57299A46AF5D47DDD5D04A73E" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_06D5DEBC654A9FAE092F7DDD5D0510C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_A28D86BB9346D92416B47DDD5D059AC1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_06D5DEBC654A9FAE092F7DDD5D0510C9" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_A28D86BB9346D92416B47DDD5D059AC1" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_HospiraMember" xlink:label="loc_pfe_HospiraMember_D9AEF4CFF6E47B2BB7C07DDD5D05B94A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_A28D86BB9346D92416B47DDD5D059AC1" xlink:to="loc_pfe_HospiraMember_D9AEF4CFF6E47B2BB7C07DDD5D05B94A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_4F5A2A0ABF10D1E6DFD07DDD5D059F24" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_9631D0D57299A46AF5D47DDD5D04A73E" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_4F5A2A0ABF10D1E6DFD07DDD5D059F24" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_C1EB874C58B1D6B659307DDD5D05BDEA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_4F5A2A0ABF10D1E6DFD07DDD5D059F24" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_C1EB874C58B1D6B659307DDD5D05BDEA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_07D73B34FB02B04768747DDD5D0542CE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_C1EB874C58B1D6B659307DDD5D05BDEA" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_07D73B34FB02B04768747DDD5D0542CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_C9F1E53DD8D65803DCF87DDD5D05EDC2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_9631D0D57299A46AF5D47DDD5D04A73E" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_C9F1E53DD8D65803DCF87DDD5D05EDC2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_D80A5143471C4330EFA07DDD5D06DD67" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_C9F1E53DD8D65803DCF87DDD5D05EDC2" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_D80A5143471C4330EFA07DDD5D06DD67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_749F3CC186D1C03051D47DDD5D06294D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_D80A5143471C4330EFA07DDD5D06DD67" xlink:to="loc_country_US_749F3CC186D1C03051D47DDD5D06294D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetirementPlanTaxStatusAxis" xlink:label="loc_us-gaap_RetirementPlanTaxStatusAxis_464CF2868CBC8C2BBED87DDD5D062191" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_9631D0D57299A46AF5D47DDD5D04A73E" xlink:to="loc_us-gaap_RetirementPlanTaxStatusAxis_464CF2868CBC8C2BBED87DDD5D062191" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetirementPlanTaxStatusDomain" xlink:label="loc_us-gaap_RetirementPlanTaxStatusDomain_49CFC114BC3DDED41A487DDD5D06D4CE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTaxStatusAxis_464CF2868CBC8C2BBED87DDD5D062191" xlink:to="loc_us-gaap_RetirementPlanTaxStatusDomain_49CFC114BC3DDED41A487DDD5D06D4CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_QualifiedPlanMember" xlink:label="loc_us-gaap_QualifiedPlanMember_FDA0A7D67149851DB6CB7DDD5D06B3A7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTaxStatusDomain_49CFC114BC3DDED41A487DDD5D06D4CE" xlink:to="loc_us-gaap_QualifiedPlanMember_FDA0A7D67149851DB6CB7DDD5D06B3A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsegmentsAxis" xlink:label="loc_us-gaap_SubsegmentsAxis_FB9E55F6F3449132336E7DDD5D0689CA" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_9631D0D57299A46AF5D47DDD5D04A73E" xlink:to="loc_us-gaap_SubsegmentsAxis_FB9E55F6F3449132336E7DDD5D0689CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsegmentsDomain" xlink:label="loc_us-gaap_SubsegmentsDomain_DDD398F1D891F48B15A27DDD5D06C2A7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsAxis_FB9E55F6F3449132336E7DDD5D0689CA" xlink:to="loc_us-gaap_SubsegmentsDomain_DDD398F1D891F48B15A27DDD5D06C2A7" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_WorldwideResearchandDevelopmentandGlobalProductDevelopmentMember" xlink:label="loc_pfe_WorldwideResearchandDevelopmentandGlobalProductDevelopmentMember_E5DD8003D74855C6FB1F7DDD5D0757E7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_DDD398F1D891F48B15A27DDD5D06C2A7" xlink:to="loc_pfe_WorldwideResearchandDevelopmentandGlobalProductDevelopmentMember_E5DD8003D74855C6FB1F7DDD5D0757E7" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_ManufacturingOperationsMember" xlink:label="loc_pfe_ManufacturingOperationsMember_DF0BEAD0C01492941C0D7DDD5D07014E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_DDD398F1D891F48B15A27DDD5D06C2A7" xlink:to="loc_pfe_ManufacturingOperationsMember_DF0BEAD0C01492941C0D7DDD5D07014E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_AD28D44D9FC7E7F50AAA7DDD5D07B259" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_9631D0D57299A46AF5D47DDD5D04A73E" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_AD28D44D9FC7E7F50AAA7DDD5D07B259" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_897520F535ECD42276957DDD5D0797EE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_AD28D44D9FC7E7F50AAA7DDD5D07B259" xlink:to="loc_us-gaap_SegmentDomain_897520F535ECD42276957DDD5D0797EE" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_InnovativeHealthSegmentMember" xlink:label="loc_pfe_InnovativeHealthSegmentMember_53A8158B44B09E6874737DDD5D075FD6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_897520F535ECD42276957DDD5D0797EE" xlink:to="loc_pfe_InnovativeHealthSegmentMember_53A8158B44B09E6874737DDD5D075FD6" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_EssentialHealthSegmentMember" xlink:label="loc_pfe_EssentialHealthSegmentMember_91E48AAB9A7C4DBBFA847DDD5D0708A3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_897520F535ECD42276957DDD5D0797EE" xlink:to="loc_pfe_EssentialHealthSegmentMember_91E48AAB9A7C4DBBFA847DDD5D0708A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidationItemsAxis" xlink:label="loc_us-gaap_ConsolidationItemsAxis_5AF6EC0A09A04FB26A217DDD5D07EC87" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_9631D0D57299A46AF5D47DDD5D04A73E" xlink:to="loc_us-gaap_ConsolidationItemsAxis_5AF6EC0A09A04FB26A217DDD5D07EC87" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidationItemsDomain" xlink:label="loc_us-gaap_ConsolidationItemsDomain_E36FDA73467B4909EA377DDD5D08ECB8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidationItemsAxis_5AF6EC0A09A04FB26A217DDD5D07EC87" xlink:to="loc_us-gaap_ConsolidationItemsDomain_E36FDA73467B4909EA377DDD5D08ECB8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingSegmentsMember" xlink:label="loc_us-gaap_OperatingSegmentsMember_646F29094B0140E8AA267DDD5D084D3C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidationItemsDomain_E36FDA73467B4909EA377DDD5D08ECB8" xlink:to="loc_us-gaap_OperatingSegmentsMember_646F29094B0140E8AA267DDD5D084D3C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaterialReconcilingItemsMember" xlink:label="loc_us-gaap_MaterialReconcilingItemsMember_5859EB1FE839235DD5B17DDD5D0841EB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidationItemsDomain_E36FDA73467B4909EA377DDD5D08ECB8" xlink:to="loc_us-gaap_MaterialReconcilingItemsMember_5859EB1FE839235DD5B17DDD5D0841EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CorporateNonSegmentMember" xlink:label="loc_us-gaap_CorporateNonSegmentMember_22E904595CD76FBE96F67DDD5D083A2B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidationItemsDomain_E36FDA73467B4909EA377DDD5D08ECB8" xlink:to="loc_us-gaap_CorporateNonSegmentMember_22E904595CD76FBE96F67DDD5D083A2B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_29D2347E7D0BC5E811C47DDD5D08AB9B" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_9631D0D57299A46AF5D47DDD5D04A73E" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_29D2347E7D0BC5E811C47DDD5D08AB9B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_AAABDCC8BBF7FDB61BBF7DDD5D0833EB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_29D2347E7D0BC5E811C47DDD5D08AB9B" xlink:to="loc_us-gaap_RestructuringCharges_AAABDCC8BBF7FDB61BBF7DDD5D0833EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_D148E70718E29B8A361F7DDD5D0D484F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_29D2347E7D0BC5E811C47DDD5D08AB9B" xlink:to="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_D148E70718E29B8A361F7DDD5D0D484F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesRestructuringAccrualsDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_9E59416157C1617AB12E4A426E1BF0FD" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_6173B35D92A51E8ED0E64A426E1BAB28" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_9E59416157C1617AB12E4A426E1BF0FD" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_6173B35D92A51E8ED0E64A426E1BAB28" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_37CFB68F5D37CD88C20F4A426E1B8FF5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_6173B35D92A51E8ED0E64A426E1BAB28" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_37CFB68F5D37CD88C20F4A426E1B8FF5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_F73A814D2C04B260E1844A426E1C15EF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_37CFB68F5D37CD88C20F4A426E1B8FF5" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_F73A814D2C04B260E1844A426E1C15EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeSeveranceMember" xlink:label="loc_us-gaap_EmployeeSeveranceMember_CC5D64EB666B8B8ECD1B4A426E1D70DA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_F73A814D2C04B260E1844A426E1C15EF" xlink:to="loc_us-gaap_EmployeeSeveranceMember_CC5D64EB666B8B8ECD1B4A426E1D70DA" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_AssetImpairmentsMember" xlink:label="loc_pfe_AssetImpairmentsMember_4746D4CFC20870F6680F4A426E1D96E1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_F73A814D2C04B260E1844A426E1C15EF" xlink:to="loc_pfe_AssetImpairmentsMember_4746D4CFC20870F6680F4A426E1D96E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherRestructuringMember" xlink:label="loc_us-gaap_OtherRestructuringMember_7118E1EA81FC2AAE30A44A426E1D2633" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_F73A814D2C04B260E1844A426E1C15EF" xlink:to="loc_us-gaap_OtherRestructuringMember_7118E1EA81FC2AAE30A44A426E1D2633" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_EAAC2EE9C6A02C55A0194A426E1E3ECC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_6173B35D92A51E8ED0E64A426E1BAB28" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_EAAC2EE9C6A02C55A0194A426E1E3ECC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringReserveRollForward" xlink:label="loc_us-gaap_RestructuringReserveRollForward_898A147C082D5F653B734A426E1EB103" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_EAAC2EE9C6A02C55A0194A426E1E3ECC" xlink:to="loc_us-gaap_RestructuringReserveRollForward_898A147C082D5F653B734A426E1EB103" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringReserve" xlink:label="loc_us-gaap_RestructuringReserve_E68FA26099F7BAB5A4D34A426E1E457A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_898A147C082D5F653B734A426E1EB103" xlink:to="loc_us-gaap_RestructuringReserve_E68FA26099F7BAB5A4D34A426E1E457A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_3E36A5FC78680B9C5E874A426E1E2886" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_898A147C082D5F653B734A426E1EB103" xlink:to="loc_us-gaap_RestructuringCharges_3E36A5FC78680B9C5E874A426E1E2886" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment" xlink:label="loc_pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment_97C105F1B08E1E964AEB4A426E1FBF98" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_898A147C082D5F653B734A426E1EB103" xlink:to="loc_pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment_97C105F1B08E1E964AEB4A426E1FBF98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringReserve" xlink:label="loc_us-gaap_RestructuringReserve_E529674473B61C080C174A426E1F2049" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_898A147C082D5F653B734A426E1EB103" xlink:to="loc_us-gaap_RestructuringReserve_E529674473B61C080C174A426E1F2049" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesRestructuringAccrualsFootnotesDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_12174B1AE144541F96EABE3DD5F7E5B9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_D46A5BADDBD85DF59713C3158C7F47C4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_12174B1AE144541F96EABE3DD5F7E5B9" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_D46A5BADDBD85DF59713C3158C7F47C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_21BBB950A1875DC6A16C489D1109346B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_D46A5BADDBD85DF59713C3158C7F47C4" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_21BBB950A1875DC6A16C489D1109346B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_C02975828E5B59F89DA02A2D8BA8D641" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_21BBB950A1875DC6A16C489D1109346B" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_C02975828E5B59F89DA02A2D8BA8D641" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_5C99509F109D5675AD0F1CE11172838F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_C02975828E5B59F89DA02A2D8BA8D641" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_5C99509F109D5675AD0F1CE11172838F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_DB9A9F85B2AD5CEE908FF0D336AD1C75" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_C02975828E5B59F89DA02A2D8BA8D641" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_DB9A9F85B2AD5CEE908FF0D336AD1C75" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_679FD60BC0485791AEA222D56A33AEB6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_D46A5BADDBD85DF59713C3158C7F47C4" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_679FD60BC0485791AEA222D56A33AEB6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringReserve" xlink:label="loc_us-gaap_RestructuringReserve_605DA31464FA56E0ABE89E8904FE141A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_679FD60BC0485791AEA222D56A33AEB6" xlink:to="loc_us-gaap_RestructuringReserve_605DA31464FA56E0ABE89E8904FE141A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_935FC0E4E40558CE93F17B3F8EBB73DC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_5D822B869F105875B8EC689244D06C94" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_935FC0E4E40558CE93F17B3F8EBB73DC" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_5D822B869F105875B8EC689244D06C94" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_5EF30186E3725633AE2330071E7D96EB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_935FC0E4E40558CE93F17B3F8EBB73DC" xlink:to="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_5EF30186E3725633AE2330071E7D96EB" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformation" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_3A7A650E9A5058F99DCE0852B5C74642" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_A9E5D049048859F4824D19EA600EA061" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_3A7A650E9A5058F99DCE0852B5C74642" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_A9E5D049048859F4824D19EA600EA061" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_449FFC2CA2BD9D62F7DE837D95F52349" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_4550F6E1C8A918855DDE837D95F523C0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_449FFC2CA2BD9D62F7DE837D95F52349" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_4550F6E1C8A918855DDE837D95F523C0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_886D4B59B55BCC45D756837D95F68E61" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_4550F6E1C8A918855DDE837D95F523C0" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_886D4B59B55BCC45D756837D95F68E61" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_62C6471C4A5759B51990837D95F67BA8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_886D4B59B55BCC45D756837D95F68E61" xlink:to="loc_us-gaap_SegmentDomain_62C6471C4A5759B51990837D95F67BA8" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_InnovativeHealthSegmentMember" xlink:label="loc_pfe_InnovativeHealthSegmentMember_C42732A02B36568BC558837D95F6A34A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_62C6471C4A5759B51990837D95F67BA8" xlink:to="loc_pfe_InnovativeHealthSegmentMember_C42732A02B36568BC558837D95F6A34A" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_EssentialHealthSegmentMember" xlink:label="loc_pfe_EssentialHealthSegmentMember_ED9A7CDFCD7C9D6F7B05837D95F613D2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_62C6471C4A5759B51990837D95F67BA8" xlink:to="loc_pfe_EssentialHealthSegmentMember_ED9A7CDFCD7C9D6F7B05837D95F613D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidationItemsAxis" xlink:label="loc_us-gaap_ConsolidationItemsAxis_612C7C13611324BEE095837D95F6133E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_4550F6E1C8A918855DDE837D95F523C0" xlink:to="loc_us-gaap_ConsolidationItemsAxis_612C7C13611324BEE095837D95F6133E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidationItemsDomain" xlink:label="loc_us-gaap_ConsolidationItemsDomain_12E75D91DB4CCEADC82F837D95F6E816" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidationItemsAxis_612C7C13611324BEE095837D95F6133E" xlink:to="loc_us-gaap_ConsolidationItemsDomain_12E75D91DB4CCEADC82F837D95F6E816" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingSegmentsMember" xlink:label="loc_us-gaap_OperatingSegmentsMember_6A139F9D81CB1435078D837D95F6EC82" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidationItemsDomain_12E75D91DB4CCEADC82F837D95F6E816" xlink:to="loc_us-gaap_OperatingSegmentsMember_6A139F9D81CB1435078D837D95F6EC82" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaterialReconcilingItemsMember" xlink:label="loc_us-gaap_MaterialReconcilingItemsMember_2680F3EFCF884E206E70837D95F6E505" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidationItemsDomain_12E75D91DB4CCEADC82F837D95F6E816" xlink:to="loc_us-gaap_MaterialReconcilingItemsMember_2680F3EFCF884E206E70837D95F6E505" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CorporateNonSegmentMember" xlink:label="loc_us-gaap_CorporateNonSegmentMember_A3ECBA604D59C5B1FE3E837D95F7F373" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidationItemsDomain_12E75D91DB4CCEADC82F837D95F6E816" xlink:to="loc_us-gaap_CorporateNonSegmentMember_A3ECBA604D59C5B1FE3E837D95F7F373" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_OtherSegmentReconcilingItemsAxis" xlink:label="loc_pfe_OtherSegmentReconcilingItemsAxis_6C866FB4E2F69A665454837D95F7FA37" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_4550F6E1C8A918855DDE837D95F523C0" xlink:to="loc_pfe_OtherSegmentReconcilingItemsAxis_6C866FB4E2F69A665454837D95F7FA37" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_OtherSegmentReconcilingItemsDomain" xlink:label="loc_pfe_OtherSegmentReconcilingItemsDomain_245781E5DB152A52AB7B837D95F7728D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_OtherSegmentReconcilingItemsAxis_6C866FB4E2F69A665454837D95F7FA37" xlink:to="loc_pfe_OtherSegmentReconcilingItemsDomain_245781E5DB152A52AB7B837D95F7728D" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_PurchaseAccountingAdjustmentsMember" xlink:label="loc_pfe_PurchaseAccountingAdjustmentsMember_D47244C480BA4A0D3040837D95F71919" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_OtherSegmentReconcilingItemsDomain_245781E5DB152A52AB7B837D95F7728D" xlink:to="loc_pfe_PurchaseAccountingAdjustmentsMember_D47244C480BA4A0D3040837D95F71919" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_BusinessCombinationsAcquisitionRelatedCostsMember" xlink:label="loc_pfe_BusinessCombinationsAcquisitionRelatedCostsMember_F90D5E8B2CDBC159B5A4837D95F74CB2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_OtherSegmentReconcilingItemsDomain_245781E5DB152A52AB7B837D95F7728D" xlink:to="loc_pfe_BusinessCombinationsAcquisitionRelatedCostsMember_F90D5E8B2CDBC159B5A4837D95F74CB2" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_CertainSignificantItemsMember" xlink:label="loc_pfe_CertainSignificantItemsMember_223422F094598AFBD2F2837D95F71B0C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_OtherSegmentReconcilingItemsDomain_245781E5DB152A52AB7B837D95F7728D" xlink:to="loc_pfe_CertainSignificantItemsMember_223422F094598AFBD2F2837D95F71B0C" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_OtherUnallocatedMember" xlink:label="loc_pfe_OtherUnallocatedMember_A02E22599C4F7ACA4BD5837D95F7C9EF" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_OtherSegmentReconcilingItemsDomain_245781E5DB152A52AB7B837D95F7728D" xlink:to="loc_pfe_OtherUnallocatedMember_A02E22599C4F7ACA4BD5837D95F7C9EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_5A3ECCB2C41EEF923E9C837D95F7CB13" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_4550F6E1C8A918855DDE837D95F523C0" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_5A3ECCB2C41EEF923E9C837D95F7CB13" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_AB51C9E3A6FE440106EF837D95F7B820" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_5A3ECCB2C41EEF923E9C837D95F7CB13" xlink:to="loc_us-gaap_SalesRevenueGoodsNet_AB51C9E3A6FE440106EF837D95F7B820" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_AC3251273AE8953EDCA0837D95F7F0F3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_5A3ECCB2C41EEF923E9C837D95F7CB13" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_AC3251273AE8953EDCA0837D95F7F0F3" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationFootnotesDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_02C3CF89784121E77FFA91EBDD9E9B84" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_F6982A4AE60A4DDED4C591EBDD9E3B81" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_02C3CF89784121E77FFA91EBDD9E9B84" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_F6982A4AE60A4DDED4C591EBDD9E3B81" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsegmentsAxis" xlink:label="loc_us-gaap_SubsegmentsAxis_D06344289680A49104F591EBDD9E3610" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_F6982A4AE60A4DDED4C591EBDD9E3B81" xlink:to="loc_us-gaap_SubsegmentsAxis_D06344289680A49104F591EBDD9E3610" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsegmentsDomain" xlink:label="loc_us-gaap_SubsegmentsDomain_C7D9F5C70F3534A7F33D91EBDD9EB1BE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsAxis_D06344289680A49104F591EBDD9E3610" xlink:to="loc_us-gaap_SubsegmentsDomain_C7D9F5C70F3534A7F33D91EBDD9EB1BE" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_PfizersWorldwideResearchandDevelopmentandPfizersGlobalProductDevelopmentMember" xlink:label="loc_pfe_PfizersWorldwideResearchandDevelopmentandPfizersGlobalProductDevelopmentMember_C595D4B4BC0C1691148591EBDD9EEF58" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_C7D9F5C70F3534A7F33D91EBDD9EB1BE" xlink:to="loc_pfe_PfizersWorldwideResearchandDevelopmentandPfizersGlobalProductDevelopmentMember_C595D4B4BC0C1691148591EBDD9EEF58" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_5455568EDB91E9961B6B91EBDD9F4714" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_F6982A4AE60A4DDED4C591EBDD9E3B81" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_5455568EDB91E9961B6B91EBDD9F4714" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvesteeNameDomain" xlink:label="loc_us-gaap_EquityMethodInvesteeNameDomain_C1AFB2B7F868416D5EBB91EBDD9FF18C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_5455568EDB91E9961B6B91EBDD9F4714" xlink:to="loc_us-gaap_EquityMethodInvesteeNameDomain_C1AFB2B7F868416D5EBB91EBDD9FF18C" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_ViivHealthcareLimitedMember" xlink:label="loc_pfe_ViivHealthcareLimitedMember_E37E02CE0382405082AC91EBDD9FE67D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvesteeNameDomain_C1AFB2B7F868416D5EBB91EBDD9FF18C" xlink:to="loc_pfe_ViivHealthcareLimitedMember_E37E02CE0382405082AC91EBDD9FE67D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_28B101B8259E953AECA091EBDD9FAB7D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_F6982A4AE60A4DDED4C591EBDD9E3B81" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_28B101B8259E953AECA091EBDD9FAB7D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_B55B978517F83577CEA791EBDDA04985" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_28B101B8259E953AECA091EBDD9FAB7D" xlink:to="loc_us-gaap_SegmentDomain_B55B978517F83577CEA791EBDDA04985" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_InnovativeHealthSegmentMember" xlink:label="loc_pfe_InnovativeHealthSegmentMember_06927BE4F9C7AE1E9DE091EBDDA07CC7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_B55B978517F83577CEA791EBDDA04985" xlink:to="loc_pfe_InnovativeHealthSegmentMember_06927BE4F9C7AE1E9DE091EBDDA07CC7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_1B3F3634C9A44B9A323091EBDDA12723" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_F6982A4AE60A4DDED4C591EBDD9E3B81" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_1B3F3634C9A44B9A323091EBDDA12723" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_CECA39F4B7252C4CEE6891EBDDA1005B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_1B3F3634C9A44B9A323091EBDDA12723" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_CECA39F4B7252C4CEE6891EBDDA1005B" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_HISMember" xlink:label="loc_pfe_HISMember_B97836FCABDF92599D8891EBDDA107C5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_CECA39F4B7252C4CEE6891EBDDA1005B" xlink:to="loc_pfe_HISMember_B97836FCABDF92599D8891EBDDA107C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_D5B7DEC46D51FF71DB5891EBDDA15C23" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_F6982A4AE60A4DDED4C591EBDD9E3B81" xlink:to="loc_us-gaap_StatementScenarioAxis_D5B7DEC46D51FF71DB5891EBDDA15C23" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_019378D76254E2B8B72C91EBDDA10BDF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementScenarioAxis_D5B7DEC46D51FF71DB5891EBDDA15C23" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_019378D76254E2B8B72C91EBDDA10BDF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioAdjustmentMember" xlink:label="loc_us-gaap_ScenarioAdjustmentMember_6ABA85151FAF9BDCCEA091EBDDA223D8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_019378D76254E2B8B72C91EBDDA10BDF" xlink:to="loc_us-gaap_ScenarioAdjustmentMember_6ABA85151FAF9BDCCEA091EBDDA223D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidationItemsAxis" xlink:label="loc_us-gaap_ConsolidationItemsAxis_240CDD347BA5F62A33C591EBDDA2B0A7" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_F6982A4AE60A4DDED4C591EBDD9E3B81" xlink:to="loc_us-gaap_ConsolidationItemsAxis_240CDD347BA5F62A33C591EBDDA2B0A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidationItemsDomain" xlink:label="loc_us-gaap_ConsolidationItemsDomain_832455364EDCED859E9291EBDDA27C02" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidationItemsAxis_240CDD347BA5F62A33C591EBDDA2B0A7" xlink:to="loc_us-gaap_ConsolidationItemsDomain_832455364EDCED859E9291EBDDA27C02" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingSegmentsMember" xlink:label="loc_us-gaap_OperatingSegmentsMember_044FCB88726B484EB45491EBDDA20CA5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidationItemsDomain_832455364EDCED859E9291EBDDA27C02" xlink:to="loc_us-gaap_OperatingSegmentsMember_044FCB88726B484EB45491EBDDA20CA5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CorporateNonSegmentMember" xlink:label="loc_us-gaap_CorporateNonSegmentMember_F7C7A79B33BAC7C5763A91EBDDA256DB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidationItemsDomain_832455364EDCED859E9291EBDDA27C02" xlink:to="loc_us-gaap_CorporateNonSegmentMember_F7C7A79B33BAC7C5763A91EBDDA256DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaterialReconcilingItemsMember" xlink:label="loc_us-gaap_MaterialReconcilingItemsMember_AD847E0385208CB7739D91EBDDA34D41" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidationItemsDomain_832455364EDCED859E9291EBDDA27C02" xlink:to="loc_us-gaap_MaterialReconcilingItemsMember_AD847E0385208CB7739D91EBDDA34D41" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_5039E8C561C92273647791EBDDA35D1B" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_F6982A4AE60A4DDED4C591EBDD9E3B81" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_5039E8C561C92273647791EBDDA35D1B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentIncomeDividend" xlink:label="loc_us-gaap_InvestmentIncomeDividend_9FFFCC883FE3F097D6CE91EBDDA318D9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_5039E8C561C92273647791EBDDA35D1B" xlink:to="loc_us-gaap_InvestmentIncomeDividend_9FFFCC883FE3F097D6CE91EBDDA318D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses_1E348DABEC76A044BEBB91EBDDA35AAC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_5039E8C561C92273647791EBDDA35D1B" xlink:to="loc_us-gaap_CostsAndExpenses_1E348DABEC76A044BEBB91EBDDA35AAC" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_RestructuringChargesandImplementationCosts" xlink:label="loc_pfe_RestructuringChargesandImplementationCosts_CC3D003862CD9B3F1BCE91EBDDA33A69" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_5039E8C561C92273647791EBDDA35D1B" xlink:to="loc_pfe_RestructuringChargesandImplementationCosts_CC3D003862CD9B3F1BCE91EBDDA33A69" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_668FBA7D1C8EAC04002991EBDDA34616" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_5039E8C561C92273647791EBDDA35D1B" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_668FBA7D1C8EAC04002991EBDDA34616" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_BusinessInfrastructureAlignmentCosts" xlink:label="loc_pfe_BusinessInfrastructureAlignmentCosts_0F9B5246D7B3D5A0F4B091EBDDA4D1A9" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_5039E8C561C92273647791EBDDA35D1B" xlink:to="loc_pfe_BusinessInfrastructureAlignmentCosts_0F9B5246D7B3D5A0F4B091EBDDA4D1A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_E4C2B282ACC4A9D1217491EBDDA445A1" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_5039E8C561C92273647791EBDDA35D1B" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_E4C2B282ACC4A9D1217491EBDDA445A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_BF1C5CD6553202146F4A91EBDDA49EB6" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_5039E8C561C92273647791EBDDA35D1B" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_BF1C5CD6553202146F4A91EBDDA49EB6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges_836B26AEF0B0CCA6EF1191EBDDA43345" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_5039E8C561C92273647791EBDDA35D1B" xlink:to="loc_us-gaap_AssetImpairmentCharges_836B26AEF0B0CCA6EF1191EBDDA43345" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationNarrativeDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_B0E67583CF790CFD4C3A91BE77D9B12D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments_B7189941FFD0F4966B2791BE77DE5A69" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_B0E67583CF790CFD4C3A91BE77D9B12D" xlink:to="loc_us-gaap_NumberOfOperatingSegments_B7189941FFD0F4966B2791BE77DE5A69" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_2117ECD6AFEF6230AC4E91BE77DEFDB3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_B0E67583CF790CFD4C3A91BE77D9B12D" xlink:to="loc_us-gaap_Assets_2117ECD6AFEF6230AC4E91BE77DEFDB3" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByGeographicAreaDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_28E2BB7757BC0CC65FF87E0DD6985D10" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_F04B81BB400E0D16DE967E0DD6982159" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_28E2BB7757BC0CC65FF87E0DD6985D10" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_F04B81BB400E0D16DE967E0DD6982159" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis_633581BD1BE27FC896037E0DD698F80C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_F04B81BB400E0D16DE967E0DD6982159" xlink:to="loc_us-gaap_StatementGeographicalAxis_633581BD1BE27FC896037E0DD698F80C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_781204E11D09B517B79F7E0DD699C22A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementGeographicalAxis_633581BD1BE27FC896037E0DD698F80C" xlink:to="loc_us-gaap_SegmentGeographicalDomain_781204E11D09B517B79F7E0DD699C22A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_D2D57405C9D8C1D0201B7E0DD6992523" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentGeographicalDomain_781204E11D09B517B79F7E0DD699C22A" xlink:to="loc_country_US_D2D57405C9D8C1D0201B7E0DD6992523" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_DevelopedEuropeMember" xlink:label="loc_pfe_DevelopedEuropeMember_2CFA9C32F71E493EE6807E0DD6990842" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentGeographicalDomain_781204E11D09B517B79F7E0DD699C22A" xlink:to="loc_pfe_DevelopedEuropeMember_2CFA9C32F71E493EE6807E0DD6990842" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_DevelopedRestOfWorldMember" xlink:label="loc_pfe_DevelopedRestOfWorldMember_D3AEC74BFE02BBEE1BB87E0DD69942F4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentGeographicalDomain_781204E11D09B517B79F7E0DD699C22A" xlink:to="loc_pfe_DevelopedRestOfWorldMember_D3AEC74BFE02BBEE1BB87E0DD69942F4" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_EmergingMarketsMember" xlink:label="loc_pfe_EmergingMarketsMember_BFEC4AFDB9DD7DD602B27E0DD6994010" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentGeographicalDomain_781204E11D09B517B79F7E0DD699C22A" xlink:to="loc_pfe_EmergingMarketsMember_BFEC4AFDB9DD7DD602B27E0DD6994010" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_4F7730562B05905E74767E0DD699C891" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_F04B81BB400E0D16DE967E0DD6982159" xlink:to="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_4F7730562B05905E74767E0DD699C891" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_9B9B5BD7E9DF0C5B81697E0DD6999DFF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_4F7730562B05905E74767E0DD699C891" xlink:to="loc_us-gaap_SalesRevenueGoodsNet_9B9B5BD7E9DF0C5B81697E0DD6999DFF" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_PercentageChangeInRevenue" xlink:label="loc_pfe_PercentageChangeInRevenue_BBBEFD3949BB55481CA37E0DD6999C0D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_4F7730562B05905E74767E0DD699C891" xlink:to="loc_pfe_PercentageChangeInRevenue_BBBEFD3949BB55481CA37E0DD6999C0D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByGeographicAreaFootnotesDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_8A175570E1A337941BB1837D970D02E8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_CF00AF0396992AAEADBE837D970D72EE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_8A175570E1A337941BB1837D970D02E8" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_CF00AF0396992AAEADBE837D970D72EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CurrencyAxis" xlink:label="loc_us-gaap_CurrencyAxis_59DFEB074CB136288389837D970D8D06" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_CF00AF0396992AAEADBE837D970D72EE" xlink:to="loc_us-gaap_CurrencyAxis_59DFEB074CB136288389837D970D8D06" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_687EBC63D5D8A6D0D262837D970D2E56" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrencyAxis_59DFEB074CB136288389837D970D8D06" xlink:to="loc_currency_AllCurrenciesDomain_687EBC63D5D8A6D0D262837D970D2E56" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_EUR" xlink:label="loc_currency_EUR_E0794DE1546099E7E15D837D970DC3A8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_687EBC63D5D8A6D0D262837D970D2E56" xlink:to="loc_currency_EUR_E0794DE1546099E7E15D837D970DC3A8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis_D9C8D74E23DCF9CF0A3D837D970E48D8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_CF00AF0396992AAEADBE837D970D72EE" xlink:to="loc_us-gaap_StatementGeographicalAxis_D9C8D74E23DCF9CF0A3D837D970E48D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_CB7F983773C111D2736D837D970E0F4E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementGeographicalAxis_D9C8D74E23DCF9CF0A3D837D970E48D8" xlink:to="loc_us-gaap_SegmentGeographicalDomain_CB7F983773C111D2736D837D970E0F4E" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_DevelopedEuropeMember" xlink:label="loc_pfe_DevelopedEuropeMember_6D0D472F6ABB78C450D9837D970E5D18" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentGeographicalDomain_CB7F983773C111D2736D837D970E0F4E" xlink:to="loc_pfe_DevelopedEuropeMember_6D0D472F6ABB78C450D9837D970E5D18" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_579FFA2F08D0C4CD4E86837D970E6205" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_CF00AF0396992AAEADBE837D970D72EE" xlink:to="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_579FFA2F08D0C4CD4E86837D970E6205" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_898997B91FC9F949B200837D970E8E87" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_579FFA2F08D0C4CD4E86837D970E6205" xlink:to="loc_us-gaap_SalesRevenueGoodsNet_898997B91FC9F949B200837D970E8E87" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_472C63DA96B1700E001B837D979D3894" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_E3EE6BE707967467633D837D979D4D7E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_472C63DA96B1700E001B837D979D3894" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_E3EE6BE707967467633D837D979D4D7E" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_InnovativeProductsCategoryAxis" xlink:label="loc_pfe_InnovativeProductsCategoryAxis_52FA49BA4DE59A8C4A57837D979D10F5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_E3EE6BE707967467633D837D979D4D7E" xlink:to="loc_pfe_InnovativeProductsCategoryAxis_52FA49BA4DE59A8C4A57837D979D10F5" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_InnovativeProductsCategoryDomain" xlink:label="loc_pfe_InnovativeProductsCategoryDomain_D0D0115D946D04174F3D837D979DA855" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_InnovativeProductsCategoryAxis_52FA49BA4DE59A8C4A57837D979D10F5" xlink:to="loc_pfe_InnovativeProductsCategoryDomain_D0D0115D946D04174F3D837D979DA855" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_InternalMedicineMember" xlink:label="loc_pfe_InternalMedicineMember_D6FB61B88B0F74866E5A837D979ED4CB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_InnovativeProductsCategoryDomain_D0D0115D946D04174F3D837D979DA855" xlink:to="loc_pfe_InternalMedicineMember_D6FB61B88B0F74866E5A837D979ED4CB" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_VaccinesMember" xlink:label="loc_pfe_VaccinesMember_34FDFBF768EF05945F11837D979EEB5E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_InnovativeProductsCategoryDomain_D0D0115D946D04174F3D837D979DA855" xlink:to="loc_pfe_VaccinesMember_34FDFBF768EF05945F11837D979EEB5E" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_OncologyMember" xlink:label="loc_pfe_OncologyMember_93FAF31B2880AAD022A5837D979E42D7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_InnovativeProductsCategoryDomain_D0D0115D946D04174F3D837D979DA855" xlink:to="loc_pfe_OncologyMember_93FAF31B2880AAD022A5837D979E42D7" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_InflammationandImmunologyMember" xlink:label="loc_pfe_InflammationandImmunologyMember_9722DB42B891AC4D3D0D837D979EDA1D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_InnovativeProductsCategoryDomain_D0D0115D946D04174F3D837D979DA855" xlink:to="loc_pfe_InflammationandImmunologyMember_9722DB42B891AC4D3D0D837D979EDA1D" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_RareDiseaseMember" xlink:label="loc_pfe_RareDiseaseMember_EA92F4BD3F3C4967A97F837D979E4462" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_InnovativeProductsCategoryDomain_D0D0115D946D04174F3D837D979DA855" xlink:to="loc_pfe_RareDiseaseMember_EA92F4BD3F3C4967A97F837D979E4462" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_ConsumerHealthcareMember" xlink:label="loc_pfe_ConsumerHealthcareMember_8CF5C28F6D005CD18348837D979EC785" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_InnovativeProductsCategoryDomain_D0D0115D946D04174F3D837D979DA855" xlink:to="loc_pfe_ConsumerHealthcareMember_8CF5C28F6D005CD18348837D979EC785" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_EssentialHealthProductCategoryAxis" xlink:label="loc_pfe_EssentialHealthProductCategoryAxis_99AAE0FF10784A8F437D837D979EF396" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_E3EE6BE707967467633D837D979D4D7E" xlink:to="loc_pfe_EssentialHealthProductCategoryAxis_99AAE0FF10784A8F437D837D979EF396" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_EssentialHealthProductCategoryDomain" xlink:label="loc_pfe_EssentialHealthProductCategoryDomain_5DCDEFF8A9AF1727C906837D979E0765" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_EssentialHealthProductCategoryAxis_99AAE0FF10784A8F437D837D979EF396" xlink:to="loc_pfe_EssentialHealthProductCategoryDomain_5DCDEFF8A9AF1727C906837D979E0765" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_LegacyEstablishedProductsMember" xlink:label="loc_pfe_LegacyEstablishedProductsMember_1400758F8D6D372C6365837D979E5E20" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_EssentialHealthProductCategoryDomain_5DCDEFF8A9AF1727C906837D979E0765" xlink:to="loc_pfe_LegacyEstablishedProductsMember_1400758F8D6D372C6365837D979E5E20" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_SterileInjectablePharmaceuticalsMember" xlink:label="loc_pfe_SterileInjectablePharmaceuticalsMember_636802574FC93027119D837D979E4E91" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_EssentialHealthProductCategoryDomain_5DCDEFF8A9AF1727C906837D979E0765" xlink:to="loc_pfe_SterileInjectablePharmaceuticalsMember_636802574FC93027119D837D979E4E91" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_PeriLOEProductsMember" xlink:label="loc_pfe_PeriLOEProductsMember_3428E82FEB4C7931EA2E837D979E8954" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_EssentialHealthProductCategoryDomain_5DCDEFF8A9AF1727C906837D979E0765" xlink:to="loc_pfe_PeriLOEProductsMember_3428E82FEB4C7931EA2E837D979E8954" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_BiosimilarsMember" xlink:label="loc_pfe_BiosimilarsMember_678FD5D22799BD321F49837D979E1588" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_EssentialHealthProductCategoryDomain_5DCDEFF8A9AF1727C906837D979E0765" xlink:to="loc_pfe_BiosimilarsMember_678FD5D22799BD321F49837D979E1588" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_CentreOneMember" xlink:label="loc_pfe_CentreOneMember_9E3014BDCE242D46ED94837D979E250C" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_EssentialHealthProductCategoryDomain_5DCDEFF8A9AF1727C906837D979E0765" xlink:to="loc_pfe_CentreOneMember_9E3014BDCE242D46ED94837D979E250C" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_HospiraInfusionSystemsMember" xlink:label="loc_pfe_HospiraInfusionSystemsMember_A94B6464CE6C8A440DD7837D979EF1D8" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_EssentialHealthProductCategoryDomain_5DCDEFF8A9AF1727C906837D979E0765" xlink:to="loc_pfe_HospiraInfusionSystemsMember_A94B6464CE6C8A440DD7837D979EF1D8" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_DistinctBusinessAxis" xlink:label="loc_pfe_DistinctBusinessAxis_830BC2ACF2D8F49898E6837D979E7D04" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_E3EE6BE707967467633D837D979D4D7E" xlink:to="loc_pfe_DistinctBusinessAxis_830BC2ACF2D8F49898E6837D979E7D04" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_DistinctBusinessDomain" xlink:label="loc_pfe_DistinctBusinessDomain_3DCBFF55E5B51536689B837D979EC700" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_DistinctBusinessAxis_830BC2ACF2D8F49898E6837D979E7D04" xlink:to="loc_pfe_DistinctBusinessDomain_3DCBFF55E5B51536689B837D979EC700" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_InnovativeHealthBusinessMember" xlink:label="loc_pfe_InnovativeHealthBusinessMember_AE5C91574ACFF5123399837D979E8268" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_DistinctBusinessDomain_3DCBFF55E5B51536689B837D979EC700" xlink:to="loc_pfe_InnovativeHealthBusinessMember_AE5C91574ACFF5123399837D979E8268" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_EssentialHealthBusinessMember" xlink:label="loc_pfe_EssentialHealthBusinessMember_D2EDB3E9B57286ECF857837D979EDD1B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_DistinctBusinessDomain_3DCBFF55E5B51536689B837D979EC700" xlink:to="loc_pfe_EssentialHealthBusinessMember_D2EDB3E9B57286ECF857837D979EDD1B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_87433A8CDAD0CFD3DE7B837D979E2C9D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_E3EE6BE707967467633D837D979D4D7E" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_87433A8CDAD0CFD3DE7B837D979E2C9D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_F49C6E1162911A0B5024837D979F4B0D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_87433A8CDAD0CFD3DE7B837D979E2C9D" xlink:to="loc_us-gaap_SegmentDomain_F49C6E1162911A0B5024837D979F4B0D" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_InnovativeHealthSegmentMember" xlink:label="loc_pfe_InnovativeHealthSegmentMember_4F844E53BFC21A3FBFA3837D979F5869" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_F49C6E1162911A0B5024837D979F4B0D" xlink:to="loc_pfe_InnovativeHealthSegmentMember_4F844E53BFC21A3FBFA3837D979F5869" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_EssentialHealthSegmentMember" xlink:label="loc_pfe_EssentialHealthSegmentMember_0FB0CFA49DA3789688F2837D979F84B0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_F49C6E1162911A0B5024837D979F4B0D" xlink:to="loc_pfe_EssentialHealthSegmentMember_0FB0CFA49DA3789688F2837D979F84B0" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_InnovativeHealthandEssentialHealthMember" xlink:label="loc_pfe_InnovativeHealthandEssentialHealthMember_4625026C6F2577C06CB4837D979FB6C1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_F49C6E1162911A0B5024837D979F4B0D" xlink:to="loc_pfe_InnovativeHealthandEssentialHealthMember_4625026C6F2577C06CB4837D979FB6C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_97AEAE1B21383D1AFD19837D979F9753" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_E3EE6BE707967467633D837D979D4D7E" xlink:to="loc_us-gaap_ProductOrServiceAxis_97AEAE1B21383D1AFD19837D979F9753" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_945515D087BA9E03A59B837D979FEC85" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductOrServiceAxis_97AEAE1B21383D1AFD19837D979F9753" xlink:to="loc_us-gaap_ProductsAndServicesDomain_945515D087BA9E03A59B837D979FEC85" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_LyricaMember" xlink:label="loc_pfe_LyricaMember_3F80DA0DEEB015126090837D979F96FD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_945515D087BA9E03A59B837D979FEC85" xlink:to="loc_pfe_LyricaMember_3F80DA0DEEB015126090837D979F96FD" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_EliquisMember" xlink:label="loc_pfe_EliquisMember_C2D2CDB8DFE95A7C7EE0837D979F26E5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_945515D087BA9E03A59B837D979FEC85" xlink:to="loc_pfe_EliquisMember_C2D2CDB8DFE95A7C7EE0837D979F26E5" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_ChantixChampixMember" xlink:label="loc_pfe_ChantixChampixMember_76314B1F59C73D27CC7A837D979FEF43" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_945515D087BA9E03A59B837D979FEC85" xlink:to="loc_pfe_ChantixChampixMember_76314B1F59C73D27CC7A837D979FEF43" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_ViagraMember" xlink:label="loc_pfe_ViagraMember_80E53BBAC83FE9EFF2BB837D979F22A8" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_945515D087BA9E03A59B837D979FEC85" xlink:to="loc_pfe_ViagraMember_80E53BBAC83FE9EFF2BB837D979F22A8" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_BMP2Member" xlink:label="loc_pfe_BMP2Member_5C217DA55C12A1F0659E837D979FAA91" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_945515D087BA9E03A59B837D979FEC85" xlink:to="loc_pfe_BMP2Member_5C217DA55C12A1F0659E837D979FAA91" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_ToviazMember" xlink:label="loc_pfe_ToviazMember_94181AA5AA9B4F568C89837D979F2E7C" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_945515D087BA9E03A59B837D979FEC85" xlink:to="loc_pfe_ToviazMember_94181AA5AA9B4F568C89837D979F2E7C" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_AllOtherInternalMedicineMember" xlink:label="loc_pfe_AllOtherInternalMedicineMember_95ED1FE94C32163CB3FA837D979FB284" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_945515D087BA9E03A59B837D979FEC85" xlink:to="loc_pfe_AllOtherInternalMedicineMember_95ED1FE94C32163CB3FA837D979FB284" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_PrevnarPrevenarFamilyMember" xlink:label="loc_pfe_PrevnarPrevenarFamilyMember_A8707CF8A10065A53BBA837D979F3540" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_945515D087BA9E03A59B837D979FEC85" xlink:to="loc_pfe_PrevnarPrevenarFamilyMember_A8707CF8A10065A53BBA837D979F3540" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_FSMEIMMUNTicoVacMember" xlink:label="loc_pfe_FSMEIMMUNTicoVacMember_CCE4686B46E6F4D8433F837D979F96C8" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_945515D087BA9E03A59B837D979FEC85" xlink:to="loc_pfe_FSMEIMMUNTicoVacMember_CCE4686B46E6F4D8433F837D979F96C8" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_OtherVaccinesProductsMember" xlink:label="loc_pfe_OtherVaccinesProductsMember_365902889FCB939503D1837D979FFA35" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_945515D087BA9E03A59B837D979FEC85" xlink:to="loc_pfe_OtherVaccinesProductsMember_365902889FCB939503D1837D979FFA35" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_IbranceMember" xlink:label="loc_pfe_IbranceMember_D15486EA1C1C081FA981837D979FFE36" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_945515D087BA9E03A59B837D979FEC85" xlink:to="loc_pfe_IbranceMember_D15486EA1C1C081FA981837D979FFE36" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_SutentMember" xlink:label="loc_pfe_SutentMember_5A74E63E49E4A1937E86837D979F1679" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_945515D087BA9E03A59B837D979FEC85" xlink:to="loc_pfe_SutentMember_5A74E63E49E4A1937E86837D979F1679" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_XalkoriMember" xlink:label="loc_pfe_XalkoriMember_837266581BACED4AE126837D979F058B" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_945515D087BA9E03A59B837D979FEC85" xlink:to="loc_pfe_XalkoriMember_837266581BACED4AE126837D979F058B" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_XtandiAllianceMember" xlink:label="loc_pfe_XtandiAllianceMember_9A86FE90CC1B6E14008C837D979F6125" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_945515D087BA9E03A59B837D979FEC85" xlink:to="loc_pfe_XtandiAllianceMember_9A86FE90CC1B6E14008C837D979F6125" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_InlytaMember" xlink:label="loc_pfe_InlytaMember_54B81A946661C3B03897837D97A0045A" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_945515D087BA9E03A59B837D979FEC85" xlink:to="loc_pfe_InlytaMember_54B81A946661C3B03897837D97A0045A" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_BosulifMember" xlink:label="loc_pfe_BosulifMember_F7CFDA2A9F669B0C8426837D97A0AB36" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_945515D087BA9E03A59B837D979FEC85" xlink:to="loc_pfe_BosulifMember_F7CFDA2A9F669B0C8426837D97A0AB36" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_OtherOncologyProductsMember" xlink:label="loc_pfe_OtherOncologyProductsMember_C1AA8C32D33C1E4B220D837D97A0D8D0" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_945515D087BA9E03A59B837D979FEC85" xlink:to="loc_pfe_OtherOncologyProductsMember_C1AA8C32D33C1E4B220D837D97A0D8D0" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_EnbrelMember" xlink:label="loc_pfe_EnbrelMember_BCEEA70944AB1CAE1374837D97A0B06A" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_945515D087BA9E03A59B837D979FEC85" xlink:to="loc_pfe_EnbrelMember_BCEEA70944AB1CAE1374837D97A0B06A" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_XeljanzMember" xlink:label="loc_pfe_XeljanzMember_874B10609F58DB3CDFCF837D97A0E399" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_945515D087BA9E03A59B837D979FEC85" xlink:to="loc_pfe_XeljanzMember_874B10609F58DB3CDFCF837D97A0E399" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_EucrisaMember" xlink:label="loc_pfe_EucrisaMember_EE95A03D351953062449837D97A05B28" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_945515D087BA9E03A59B837D979FEC85" xlink:to="loc_pfe_EucrisaMember_EE95A03D351953062449837D97A05B28" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_AllOtherInflammationandImmunologyProductsMember" xlink:label="loc_pfe_AllOtherInflammationandImmunologyProductsMember_6A672BB7C274B8EF6913837D97A06AB2" xlink:type="locator" />
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_945515D087BA9E03A59B837D979FEC85" xlink:to="loc_pfe_AllOtherInflammationandImmunologyProductsMember_6A672BB7C274B8EF6913837D97A06AB2" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_BeneFIXMember" xlink:label="loc_pfe_BeneFIXMember_E1B4E04FBF37C003B41A837D97A02E88" xlink:type="locator" />
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_945515D087BA9E03A59B837D979FEC85" xlink:to="loc_pfe_BeneFIXMember_E1B4E04FBF37C003B41A837D97A02E88" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_ReFactoAfXynthaMember" xlink:label="loc_pfe_ReFactoAfXynthaMember_244A3A71BCF63ED47516837D97A0A8F1" xlink:type="locator" />
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_945515D087BA9E03A59B837D979FEC85" xlink:to="loc_pfe_ReFactoAfXynthaMember_244A3A71BCF63ED47516837D97A0A8F1" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_GenotropinMember" xlink:label="loc_pfe_GenotropinMember_D94E0CCBA5F81F6A8F61837D97A07451" xlink:type="locator" />
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_945515D087BA9E03A59B837D979FEC85" xlink:to="loc_pfe_GenotropinMember_D94E0CCBA5F81F6A8F61837D97A07451" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_SomavertMember" xlink:label="loc_pfe_SomavertMember_E951959359591F94F838837D97A03160" xlink:type="locator" />
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_945515D087BA9E03A59B837D979FEC85" xlink:to="loc_pfe_SomavertMember_E951959359591F94F838837D97A03160" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_AllOtherRareDiseaseProductsMember" xlink:label="loc_pfe_AllOtherRareDiseaseProductsMember_E7A878EBE7353C6E9618837D97A0BB57" xlink:type="locator" />
    <link:presentationArc order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_945515D087BA9E03A59B837D979FEC85" xlink:to="loc_pfe_AllOtherRareDiseaseProductsMember_E7A878EBE7353C6E9618837D97A0BB57" xlink:type="arc" />
    <link:presentationArc order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_945515D087BA9E03A59B837D979FEC85" xlink:to="loc_pfe_ConsumerHealthcareMember_8CF5C28F6D005CD18348837D979EC785" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_LipitorMember" xlink:label="loc_pfe_LipitorMember_D8EE59AFB7A555241C09837D97A0B15B" xlink:type="locator" />
    <link:presentationArc order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_945515D087BA9E03A59B837D979FEC85" xlink:to="loc_pfe_LipitorMember_D8EE59AFB7A555241C09837D97A0B15B" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_PremarinFamilyMember" xlink:label="loc_pfe_PremarinFamilyMember_40EDC1EE16377D9FFFF5837D97A061C5" xlink:type="locator" />
    <link:presentationArc order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_945515D087BA9E03A59B837D979FEC85" xlink:to="loc_pfe_PremarinFamilyMember_40EDC1EE16377D9FFFF5837D97A061C5" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_NorvascMember" xlink:label="loc_pfe_NorvascMember_48FF3A77E5B788749795837D97A00113" xlink:type="locator" />
    <link:presentationArc order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_945515D087BA9E03A59B837D979FEC85" xlink:to="loc_pfe_NorvascMember_48FF3A77E5B788749795837D97A00113" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_EpiPenMember" xlink:label="loc_pfe_EpiPenMember_F5484E79173EB98F61A6837D97A0D5AB" xlink:type="locator" />
    <link:presentationArc order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_945515D087BA9E03A59B837D979FEC85" xlink:to="loc_pfe_EpiPenMember_F5484E79173EB98F61A6837D97A0D5AB" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_XalatanXalacomMember" xlink:label="loc_pfe_XalatanXalacomMember_9FAEFBA906BF2C1ED9EA837D97A08EC3" xlink:type="locator" />
    <link:presentationArc order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_945515D087BA9E03A59B837D979FEC85" xlink:to="loc_pfe_XalatanXalacomMember_9FAEFBA906BF2C1ED9EA837D97A08EC3" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_EffexorMember" xlink:label="loc_pfe_EffexorMember_7F98611C4B69CDCD93CF837D97A03FD4" xlink:type="locator" />
    <link:presentationArc order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_945515D087BA9E03A59B837D979FEC85" xlink:to="loc_pfe_EffexorMember_7F98611C4B69CDCD93CF837D97A03FD4" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_ZoloftMember" xlink:label="loc_pfe_ZoloftMember_C12E2871AAE7F73591F8837D97A0C951" xlink:type="locator" />
    <link:presentationArc order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_945515D087BA9E03A59B837D979FEC85" xlink:to="loc_pfe_ZoloftMember_C12E2871AAE7F73591F8837D97A0C951" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_ZithromaxZmaxMember" xlink:label="loc_pfe_ZithromaxZmaxMember_DA58EE86AC212CACCBA8837D97A151CC" xlink:type="locator" />
    <link:presentationArc order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_945515D087BA9E03A59B837D979FEC85" xlink:to="loc_pfe_ZithromaxZmaxMember_DA58EE86AC212CACCBA8837D97A151CC" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_RelpaxMember" xlink:label="loc_pfe_RelpaxMember_A6F54A09A1103ADEB812837D97A1B798" xlink:type="locator" />
    <link:presentationArc order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_945515D087BA9E03A59B837D979FEC85" xlink:to="loc_pfe_RelpaxMember_A6F54A09A1103ADEB812837D97A1B798" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_XanaxXanaxXRMember" xlink:label="loc_pfe_XanaxXanaxXRMember_9E84C1A6482C6DF9244B837D97A16BDC" xlink:type="locator" />
    <link:presentationArc order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_945515D087BA9E03A59B837D979FEC85" xlink:to="loc_pfe_XanaxXanaxXRMember_9E84C1A6482C6DF9244B837D97A16BDC" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_OtherLegacyEstablishedProductsMember" xlink:label="loc_pfe_OtherLegacyEstablishedProductsMember_9AAF444891F90574244F837D97A1C02D" xlink:type="locator" />
    <link:presentationArc order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_945515D087BA9E03A59B837D979FEC85" xlink:to="loc_pfe_OtherLegacyEstablishedProductsMember_9AAF444891F90574244F837D97A1C02D" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_MedrolMember" xlink:label="loc_pfe_MedrolMember_5FFBA03F600BCC2B01EF837D97A196A7" xlink:type="locator" />
    <link:presentationArc order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_945515D087BA9E03A59B837D979FEC85" xlink:to="loc_pfe_MedrolMember_5FFBA03F600BCC2B01EF837D97A196A7" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_SulperazonMember" xlink:label="loc_pfe_SulperazonMember_927E5CD5F2990CB86D18837D97A1289B" xlink:type="locator" />
    <link:presentationArc order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_945515D087BA9E03A59B837D979FEC85" xlink:to="loc_pfe_SulperazonMember_927E5CD5F2990CB86D18837D97A1289B" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_FragminMember" xlink:label="loc_pfe_FragminMember_CB9632849D1DDFFB016C837D97A1F6D3" xlink:type="locator" />
    <link:presentationArc order="41" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_945515D087BA9E03A59B837D979FEC85" xlink:to="loc_pfe_FragminMember_CB9632849D1DDFFB016C837D97A1F6D3" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_TygacilMember" xlink:label="loc_pfe_TygacilMember_D0F5315005B6A9E10B12837D97A1AECC" xlink:type="locator" />
    <link:presentationArc order="42" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_945515D087BA9E03A59B837D979FEC85" xlink:to="loc_pfe_TygacilMember_D0F5315005B6A9E10B12837D97A1AECC" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_PrecedexMember" xlink:label="loc_pfe_PrecedexMember_AA105921ECAAE35E1F4D837D97A11113" xlink:type="locator" />
    <link:presentationArc order="43" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_945515D087BA9E03A59B837D979FEC85" xlink:to="loc_pfe_PrecedexMember_AA105921ECAAE35E1F4D837D97A11113" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_AllOtherSterileInjectablePharmaceuticalsMember" xlink:label="loc_pfe_AllOtherSterileInjectablePharmaceuticalsMember_C406531A02D06DC0ABBC837D97A10C4F" xlink:type="locator" />
    <link:presentationArc order="44" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_945515D087BA9E03A59B837D979FEC85" xlink:to="loc_pfe_AllOtherSterileInjectablePharmaceuticalsMember_C406531A02D06DC0ABBC837D97A10C4F" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_CelebrexMember" xlink:label="loc_pfe_CelebrexMember_C8F332A299C4CB789935837D97A16599" xlink:type="locator" />
    <link:presentationArc order="45" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_945515D087BA9E03A59B837D979FEC85" xlink:to="loc_pfe_CelebrexMember_C8F332A299C4CB789935837D97A16599" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_VfendMember" xlink:label="loc_pfe_VfendMember_C5F8951550C576722852837D97A1696A" xlink:type="locator" />
    <link:presentationArc order="46" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_945515D087BA9E03A59B837D979FEC85" xlink:to="loc_pfe_VfendMember_C5F8951550C576722852837D97A1696A" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_PristiqMember" xlink:label="loc_pfe_PristiqMember_F57EC818FA6316CFBA45837D97A1165F" xlink:type="locator" />
    <link:presentationArc order="47" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_945515D087BA9E03A59B837D979FEC85" xlink:to="loc_pfe_PristiqMember_F57EC818FA6316CFBA45837D97A1165F" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_ZyvoxMember" xlink:label="loc_pfe_ZyvoxMember_749DC17FB837B8D3C345837D97A149E4" xlink:type="locator" />
    <link:presentationArc order="48" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_945515D087BA9E03A59B837D979FEC85" xlink:to="loc_pfe_ZyvoxMember_749DC17FB837B8D3C345837D97A149E4" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_RevatioMember" xlink:label="loc_pfe_RevatioMember_524240D949B70F8352BB837D97A1E575" xlink:type="locator" />
    <link:presentationArc order="49" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_945515D087BA9E03A59B837D979FEC85" xlink:to="loc_pfe_RevatioMember_524240D949B70F8352BB837D97A1E575" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_AllOtherPeriLOEProductsMember" xlink:label="loc_pfe_AllOtherPeriLOEProductsMember_96D370902ACD5EA1C0DB837D97A1D5E0" xlink:type="locator" />
    <link:presentationArc order="50" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_945515D087BA9E03A59B837D979FEC85" xlink:to="loc_pfe_AllOtherPeriLOEProductsMember_96D370902ACD5EA1C0DB837D97A1D5E0" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_InflectraRemsimaMember" xlink:label="loc_pfe_InflectraRemsimaMember_2558284452DA5EF8F5F9837D97A12801" xlink:type="locator" />
    <link:presentationArc order="51" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_945515D087BA9E03A59B837D979FEC85" xlink:to="loc_pfe_InflectraRemsimaMember_2558284452DA5EF8F5F9837D97A12801" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_AllOtherBiosimilarsMember" xlink:label="loc_pfe_AllOtherBiosimilarsMember_71B9936599D0A87A381D837D97A1883B" xlink:type="locator" />
    <link:presentationArc order="52" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_945515D087BA9E03A59B837D979FEC85" xlink:to="loc_pfe_AllOtherBiosimilarsMember_71B9936599D0A87A381D837D97A1883B" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_AllianceBiopharmaceuticalsMember" xlink:label="loc_pfe_AllianceBiopharmaceuticalsMember_0E998CAF50744740BDAF837D97A1F40F" xlink:type="locator" />
    <link:presentationArc order="53" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_945515D087BA9E03A59B837D979FEC85" xlink:to="loc_pfe_AllianceBiopharmaceuticalsMember_0E998CAF50744740BDAF837D97A1F40F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_0F3D0AD13C53A00665E9837D97A16C10" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_E3EE6BE707967467633D837D979D4D7E" xlink:to="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_0F3D0AD13C53A00665E9837D97A16C10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_1A20D25CAA640CEC8E1D837D97A292CB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_0F3D0AD13C53A00665E9837D97A16C10" xlink:to="loc_us-gaap_SalesRevenueGoodsNet_1A20D25CAA640CEC8E1D837D97A292CB" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_2E99240A067F57AEBB51FEF66F460D4E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock" xlink:label="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock_F167DC7757355C9483DB431852D9E57B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_2E99240A067F57AEBB51FEF66F460D4E" xlink:to="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock_F167DC7757355C9483DB431852D9E57B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_04CEC220EF6A580B84830CED0072ADBE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_2E99240A067F57AEBB51FEF66F460D4E" xlink:to="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_04CEC220EF6A580B84830CED0072ADBE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_A9676030138C50C4A508E00BA4C8187C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_2E99240A067F57AEBB51FEF66F460D4E" xlink:to="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_A9676030138C50C4A508E00BA4C8187C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_DDE87AB6A4BE53E5B612C1BB7921796D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_2E99240A067F57AEBB51FEF66F460D4E" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_DDE87AB6A4BE53E5B612C1BB7921796D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/TaxMatters" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_AAF17983A6EF5A5C951DFBC67CE8739D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_E228CB304B6D5D63BBDB4D00DEF868BE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_AAF17983A6EF5A5C951DFBC67CE8739D" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_E228CB304B6D5D63BBDB4D00DEF868BE" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/TaxMattersDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_9EF7279FCE469F8701EC7DDD5C43C00D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_A854E324248364658DDD7DDD5C44C907" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_9EF7279FCE469F8701EC7DDD5C43C00D" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_A854E324248364658DDD7DDD5C44C907" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax_4EA8DE98E1D8600A8F5A7DDD5C4433EB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_9EF7279FCE469F8701EC7DDD5C43C00D" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax_4EA8DE98E1D8600A8F5A7DDD5C4433EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesTax_E13C6BB90A7BC8A440797DDD5C44B728" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_9EF7279FCE469F8701EC7DDD5C43C00D" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesTax_E13C6BB90A7BC8A440797DDD5C44B728" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesTax_27FB885AA2F6D4D56DE17DDD5C44F220" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_9EF7279FCE469F8701EC7DDD5C43C00D" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesTax_27FB885AA2F6D4D56DE17DDD5C44F220" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_ACE1DA0322FF6A4750A97DDD5C44DC5E" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_9EF7279FCE469F8701EC7DDD5C43C00D" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_ACE1DA0322FF6A4750A97DDD5C44DC5E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax_F1F0368CF9088906319D7DDD5C452751" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_9EF7279FCE469F8701EC7DDD5C43C00D" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax_F1F0368CF9088906319D7DDD5C452751" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_7C943BCFD2E55C73E33B7DDD5C45106E" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_9EF7279FCE469F8701EC7DDD5C43C00D" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_7C943BCFD2E55C73E33B7DDD5C45106E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodTax_565A1488A31CCC4CE0777DDD5C451782" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_9EF7279FCE469F8701EC7DDD5C43C00D" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodTax_565A1488A31CCC4CE0777DDD5C451782" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossTax_CD3414D4BE86F0BD58B87DDD5C454941" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_9EF7279FCE469F8701EC7DDD5C43C00D" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossTax_CD3414D4BE86F0BD58B87DDD5C454941" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossTax" xlink:label="loc_pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossTax_FFD5E62B4AA636B6B99F7DDD5C458BF4" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_9EF7279FCE469F8701EC7DDD5C43C00D" xlink:to="loc_pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossTax_FFD5E62B4AA636B6B99F7DDD5C458BF4" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodTax" xlink:label="loc_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodTax_02DC41CB8DB17CA7A9657DDD5C456D72" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_9EF7279FCE469F8701EC7DDD5C43C00D" xlink:to="loc_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodTax_02DC41CB8DB17CA7A9657DDD5C456D72" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetActuarialGainLossTax" xlink:label="loc_pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetActuarialGainLossTax_5766CF3C22992AF1B8AF7DDD5C45776C" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_9EF7279FCE469F8701EC7DDD5C43C00D" xlink:to="loc_pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetActuarialGainLossTax_5766CF3C22992AF1B8AF7DDD5C45776C" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetPriorServiceCostCreditAndOtherTax" xlink:label="loc_pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetPriorServiceCostCreditAndOtherTax_6D34DF2C7D5F836BED457DDD5C46809B" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_9EF7279FCE469F8701EC7DDD5C43C00D" xlink:to="loc_pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetPriorServiceCostCreditAndOtherTax_6D34DF2C7D5F836BED457DDD5C46809B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax_92DA4C7B6A7295A63D707DDD5C46A4A1" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_9EF7279FCE469F8701EC7DDD5C43C00D" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax_92DA4C7B6A7295A63D707DDD5C46A4A1" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditTax" xlink:label="loc_pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditTax_84394B4C3CF29F955EBC7DDD5C462A08" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_9EF7279FCE469F8701EC7DDD5C43C00D" xlink:to="loc_pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditTax_84394B4C3CF29F955EBC7DDD5C462A08" xlink:type="arc" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax" xlink:label="loc_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax_7740AFE764DEC3E309627DDD5C466F3D" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_9EF7279FCE469F8701EC7DDD5C43C00D" xlink:to="loc_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax_7740AFE764DEC3E309627DDD5C466F3D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect_16F4DE6F02706B7799177DDD5C4699F0" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_9EF7279FCE469F8701EC7DDD5C43C00D" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect_16F4DE6F02706B7799177DDD5C4699F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTax_19B7099B45899EDBD5DE7DDD5C466355" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_9EF7279FCE469F8701EC7DDD5C43C00D" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTax_19B7099B45899EDBD5DE7DDD5C466355" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/TaxMattersNarrativeDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_D2CF50EB15D95A02BC20BACDE63AD74E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_B502A69B7F0E560FB5418E76B552B378" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_D2CF50EB15D95A02BC20BACDE63AD74E" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_B502A69B7F0E560FB5418E76B552B378" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/TaxMattersTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_1E708AFEB2FB54B1B3270AB8F40A6FEC" xlink:type="locator" />
    <link:loc xlink:href="pfe-20171001.xsd#pfe_ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_pfe_ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock_3AF7A07E8DF552AF823AFAB3AD53B176" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1E708AFEB2FB54B1B3270AB8F40A6FEC" xlink:to="loc_pfe_ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock_3AF7A07E8DF552AF823AFAB3AD53B176" xlink:type="arc" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>pfe-3q17qtdrevbygeo.jpg
<TEXT>
begin 644 pfe-3q17qtdrevbygeo.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $V 54# 2(  A$! Q$!_\0
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MM-LK_7_&/B3QEXZO(/"WA'P9H::5%)%::YKWB#Q/H=GI^GVFN<Y^SQ_P4O\
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M** $  X'^/YD\G\:6BB@ HZ]:** $  _^N23^9R<>W2EHHH 0 #)YYYY)/Y
MD@?08%+110  8X_S_GWHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MH6-E?Q*Z17UI;WD:2!1(L=S"DR*X5F4.JN P5F7<#AB,$VZQ/#/_ "+GA_\
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M:%*E:56=&I&3IPC*E*$6JD(2C)J-&<I2<:<8*=O9\]:?(U+]%?#/_(N>'_\
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M\O6&7L*E;VJQ7MO@E3CR\GU:EOSWOS:6M9WT]AHI,CU'YBC(]1^8KXFS[/\
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M^5+2-T/T/\J^ICNO5?F?*'W]X9_Y%SP__P!@32O_ $@MZVZQ/#/_ "+GA_\
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M:G\.VVH:]KM_;-X,\=NUM?ZUJE[;,Z:?9%':WN[N:$NA)*.4+*22I!KP>/?
MC&9)P5Q5G$^)</B(Y9D&:8Z5".55*4JRPV$J57351YA44'/E<5)PFHMWY6EK
M]#X?>/F#S[CCA/)8<,8G#3S7B#*L!'$2S:E5C0>)QE"DJKIK+Z;J*#FVX*<'
M)*W,KW/VN^/J.Z>%0B.^)-8SL1FQ\FG==H.,]L]><=#7SGY,W_/&;_OU)_\
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MS_3'*JZQ65Y;B5%P6(R_!UU!OF<%6P].HHN5E=QYK7LKVO9!1117">@%%%%
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M /:U^&-M?:]KM[;26OCGS+:\UK5;NVDV>!?$#H9+>YO)89"C@.F]&V. RX8
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M'8/#_BCPC;2V]MX>U*PT#Q1<^,]+EU.U\52Z9/X<L];CTJGX%_9D\&?#O1?
M7A'P_KWBB7P%\'_[-NO@GX'UB+PCJ&D_";6]*\%>(/ UKK_A[4H?"MCXCUB\
M33?%?B6^AL/%.KZOHMA?ZY?VVF:?9>'DTK0M*[=?A4-0\2:!XC\9>-?$OCM?
M"&MZ/XN\&:%KVE^"+#1O"7C?3? VI^ ;WQ9HS^&_"NCZV]YK.FZ_XGOY=.U7
M6=3TK2M2\2ZJNC6]II:Z7INF?=TZ>9^S2G.HJCQ5&JGST91C1BJ2Q%";23=*
M;C6=.T>>TX7:LTOSV<LOY[QC%TUA:\&K5HRG7DZKH58Q;DH3IQE152$JCIMT
MYJ,YW4G]O_ '_7^*?^N6C_\ H>I5R'QM:5?&LK0D"=-%T]X"Q(43JUXT)8J"
MP42A"Q4%@H)4$X%=?\ ?]=XH_P"N6C_^AZE7)?&O_D>'_P"P/IW_ *'=U\OA
M=?$',D^N7POU_P"83 =]_FCZ_%?\F\RS_L85?_4O''XU_L\? ;XV? O6OC=I
MOACP-K/A3X"?$[Q?JUSIGP(\'?&'PYX>O/A+XH\93Z9+XW^(_P"SWX]*6NH>
M#/AW=6:W*MX,37;6];Q4EAXG^'GA;P+'HVH:-KGO+?!WXW-^SOX2^!^F_%9]
M$\9^!_ GAK2-2^+>M>"/!7Q!T_XGSVF@>*M'G\,ZIX4GU3P>;&ZLY4\*76N^
M,Y+#1X-<U.*'5['29ENM?T^S^P:*^IHY-AZ,90C5K\LH5*=E/E2A4DYRBDM%
M%3M*,4N6%FHJTF?&U<RKU9JHX4%-3I5>;V;FW4I0]G&<O:RFIR<;J;FI.HWS
M3<IQA*/@/[#GPP\>?!/]FC]E'X._$_5M-UOX@?"WX3?!SX?^++[1[2RM-+35
M_"7A[0=#GTVP.GW5Y::C:Z(MDFBQ:]%,I\2+IX\0RVUE-J<EG!^RU?GWH?\
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MQ]>O1E.$JBE"3I5(N4)6<7>+U3M^'%?;7_!.W_D[OX7?]>OCO_U _$-?=O\
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M@QN;9IC*&69,Z&*S#&8BBY9]E\9.E6Q,ZE-RBZEXMPFFXO5/1[.WX<5]]_\
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M.\O[O]6]+_D[^B5XS-.V59+=K_HH,NZV_P"GGG_6MOTQ^!__ "1?X1?]DP\
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M/@_'_P %X/#UXNG)I=RGC2&%/^"ROCW4IKS4KZ;53X4%M'X7D@U.64:0D?\
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M)?$=]:C_ ()9^#M.L;?038ZGIT%O?IK(CTK2+?6+"\N;?QPMW;31_P!JQM:
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M]GYGVNRMKZTGN[;RI!#+]HMHIGG@\N5EBD\V--DA"-AB!6E7XJ_\$_DU>/\
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MIVIP6%U96>J61@B:ROM.DNK2T_M'2Y[5X7T[4K19M/N[8H]E<2P@,/R*\2_
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M7GZ\TM% !@<<#CI[?2BBB@!K(CXW(K8Z;E!Q],@TN!P<#(& <#@>@]![4M%
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M QSUR<9Y[^M.HH 3:N"NT8.<C P<]<CH<]Z,#C@<=.!QVX]...*6B@ HHHH
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MCJREB,5@:.'IJ.'PU::=2I%2<5"-YR43[YHHHK\:/VH**\>UWX]_"OPU\9O
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MTLLTCK''$ID=E0%JG5T8 JP8, RLO*L"-P((X.5^8 ')'(XYH =129'^0?\
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M **** "BBB@ KY5_;?('[)_QT).!_P (/=<G_K_L*^JJR->T#0_%.CZAX?\
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MI JCHJCG/  Y]?K[TM !1110 4444 %%%% $4_\ J)O^N4G_ * U?G97Z+D
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
%10!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>pfe-3q17ytdrevbygeo.jpg
<TEXT>
begin 644 pfe-3q17ytdrevbygeo.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $V 58# 2(  A$! Q$!_\0
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M\% O@7\%OC5X)^"_[+W[?OA+P/\ %'5/@OI?AS7[O2_@+^VIX+\5>#/%6O\
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M-5DTZR\!)X=N-=O=-DTRZG\6;XM @O?#OVE]?LOE'X)?\$[?"7PX_:4_8+\
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M7W!77> /^1W\+?\ 88@_] EKD:Z[P!_R._A7_L,0?^@2U6:?\BW,?^P'%_\
MJ/4)RIO^T\MU_P"8_!_^I%+_ "7W'O?QW_Y%G2?^P['_ .F^_KY6KZI^._\
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MX<_Z][O_ -.-Y7H%>??"HY^'_ALXQFUN3CTSJ%YQV_D*]!K\*SG_ )'&:_\
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M7GC<<FS:46XRCEN.<9)M--8:JTTUJFGJFM4SY*_X23Q'_P!#!KG_ (-]0_\
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MKOXE?M!?'SX+3^&=)\*VOP:MO#D^DC7[SXB:'\4/&ECK%Y=Z7<^.;?P#XO\
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MHH **** "BBB@ HHHH **** "BBB@ HHH/ )]* /A[XD_P#(]^)O^O\ C_\
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M?W:SA)*5&5^6;6REJM&5?^%P>/O^@K:?^"JQ_P#C5'_"X/'W_05M/_!58_\
MQJO"-/\ '?@C5K;P]>:9XR\)ZA:^+KN?3_"LUIXCT:=?$NHVNGW&K7>FZ"J7
MIDU?5++2[.[U&_TNP2?4=/L;2[NK^UMH;2Y>+;M=5TN^N;^RLM2T^[O=+D6'
M5+.UO;6XNM-F??LBU"VAE>:SE?RY J7*1L6BE3'F12*GZ3')>'Y6Y<LRJ7,[
M*V$PKN^52LK0U?*U*V_*T]F?F+SW/X[YIFBLKN^+Q2LE)1N[U-%S1Y?\5UN>
MO+\8/'Q= =4M,%T!_P")58]"P!Z1@]"?I7V0.0/H*_+G1/B)\/\ Q#XP\4>
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MFGMU/N3CWP>:3(XY'/3W^GK7^S?,^[^]G^)UO+^OZ2^X;L3_ )YQ_P#?M/\
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MO(ZH@:3PSX:BC4NY"AI)72*,$YDED2- SNJGY:*.,Y1QA_+.588D')C.1PX
M)*'Y@!TIG_!8_3-3OOV@/'VH:!X@72/$?AKXY>!?$&C:/KEKJ-U\//&LB#X<
MZ/=>%/B =-AFNK/3YXM9CU30]5LTN=7TK5]-:^TG2M<FCFTJX^%I;?7?%_Q/
M\/Z'I\WB?X,R>*/V!_%&F6T%Y=3:AJOPM\6:[\0?"4FGV]Y/+<06UYXE\):>
M]W(KRW%EJL^FZ==3H^FD2-:?ZW\(<8UL!POPAE,,HEBJE#@W@-8>5/&P@\7_
M &CD>#II)RH/#X6I1K0]FZ.,Q-"<X3AB(<V'YYP_QVXTX1I8_BOB_-I9I]6I
MXGC?CR&(4L#4J1P?]G9[C)RF^6O'$XNC4H2=3VV"PN(ITJL)X2HXXE4X5?NL
M@C&>XR/<9*G'T92I]&!!Y!%?1_[(:LG[47P'#JRG_A8^BG# J<&VOR#@@'!'
M(/>OSQ\ W>M:9J_Q/USQ'J(\->%?$-_X;LO -C%;WL<:WW@SX;,GQ$\8>&-/
MU*VN-0AT76=5L+C4=#MK_3DGU.V\)S>(9;"[36X[C5?HO_@EKX!_X5M\<_A1
MX=L[K0M;\/W?Q\@\3^&_&ND^&]+\*:GX\T_Q1H5IJUYXC\8Z5H5O9:%=>+TU
MF;4=)U+Q)HVF:+I_BBUT^PU8:'I=X]Y'+ZO$W$U7,>$L]HQRR=*GC^%.-_;5
M7BJ4IX1X'+<9'!5)8916)GALUPREB\-BI4J6'A3GAXRJ2J8K#QJ>7PGPW3P'
M&/#U:68J=3 \6\!RH4?JE6,,9]?S/+ZF.I+%\\L)3Q>3XF<<#BL'&K6Q52O3
MQDH4HT<#BZE+]Z_^"L?_ "0WX>?]E8L?_4-\6U^ <4T-P)3;S0SB"XFLYS!+
M',+>\MFVW-I.8V80W5LWRW%M+LG@8@2HA(K]]/\ @K<ZQ_ +P/(T=Q*D?Q-C
MD:*T,HNY5C\"^,7:*T,#+/\ :Y%4QVOD,LWVAH_)99-C#^+2[\.>*]#_ &8/
MVP/ ECH^K>+K+3_ WC_0_AO\25TK5K;Q]XNCOO%.OP67P]\9Z##8QR:Q\1O#
MDMO;ZF=?T.T274[3Q!&FO:;HWB07HU/\6^C[Q15X>\)L@IPR[Z]#$U^-\8Y1
MKSIRA6RG_;:.'=.EAL345/&0C7@\6X>PPTJ<(U7SUZ$*G[?](OA>EQ#XO9[4
MGF+P4\/A^ <"H_58UHRHYSR8"MBO:U,3AJ7/@93H36#4WB,7&K.=%*EAL35I
M?JWD9 R,LK.HSRR*55G ZE%9E5F VJSHI(+*"JD*R%B%!D1 6(4%V/R("2 7
M?!V(#N;!V@X-?-OBKPEXJO?B#97OA/Q#J&I0^)OBW\*?B#=Z@]K/%;?#OP/X
M#\.1:?XO\.6^JR2?8[S1_B7I]K#8Z7X;@MTU-]:\9>)M6OTGTFT;4-.K/J?Q
M!F^*EYXET[18O$_AZ]UOX(:)X&AN8-0CL+;X6^)]+U.?XM>-M,GN%M8-(\4Z
M#XE:WO\ 56U*UN+^]\/:'X=\/+!:#6[*<?T+5XPJX>I5IXC)L5"V<O+*52C4
M^M0J8>,<36GCK4*<ZDXK#T</)4:$:S^LYC@\#4J4\5]8IT/YOI<*4ZU.E5HY
MOAW?)H9K5IUJ,\-4IXB=3!T(X!^VG&-.7UG$8F+KXB5"/U++,?FD83P"P]:O
M_9#^P+_R:%\%/^P)KO\ ZF/B.OL&OCW]@3G]D'X*9X/]AZYD?]SCXCK["K_)
M3Q+_ .3C^('_ &6W%?\ ZO<>?["^&'_)M/#S_LAN$O\ U09>%%%%?$GW(444
M4 %%%% !7Q-_P41!/[(GQ3 &29O!  S@DGQ]X8  //)/ X/TK[9KXF_X*(\?
MLB?%,CKYO@G_ -3[PS7WWA5_R<[P[_[+CA7_ -7F!/@/%?\ Y-=XC?\ 9#<5
M_P#JBQW8_C"\ ^.O&-C\<?BSX(\:>)M7US^TCXG\5_"OQ%X>N;:[\":MX4L/
M#<>H-X/U?10LESX0\;?#J'5-)A%W:0MH7B\VEY?RZ]>>(Y]1\/V$7A3Q?XSU
MO]F7]F;XHWOB3X@ZMXPN_ _P#\3^,SX3USPY!?:Q;^,!X3A\7>(_$?@_5K>*
M#QW8WHU"^M[G0K)[6_CAO+[5?":+K^E6<,OUM!X5\,VESKEW:^']&M[CQ(J1
M^()8=.M4.LQQ0M;K'J"K&([B-H699D9-MTS--=":<F4Q:=X/\(Z0^DRZ3X4\
M,:7+H.FMHVA2Z=X?TBQET31VE$[:1H\EK9Q/I>E&<"8:;8M;V2R@2+ K<U_J
MG3X/SF.'Q&&GG+E"L\T5&H\1BWB,+]=S# XS!UG5:MBZ^7O"U_8U*D*-:4*T
M*53$3Q$*F8UO\D:O%N3SQ&'Q,<F@I45DSK4OJ^$CA\7_ &=@,?A,;1C2AR_4
M\/F3Q.'56E3E6P\98>=6.%C@ZE+*,/Y#^T'X3U'Q/IOARST#XD_%3P#XEO\
MQ-:^$?#*?#/QS)X4L[_4]<NXI]3U7Q/%;:7>S^(-/\(^%]%\0^(4M9+BVMHX
M;"ZB<"34/,']2_\ P2G"C]G#Q($W[!\7_%(3S&+2;!X<\&!?,8_>DV@>8_\
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MK_YI?\2E>,O_ $*\E_\ $@R[R_Z>>?X>MOPXK^A?_@E/_P FX>)/^RO^*O\
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MZ2[.JZ9;-I.HQ-'$X-U/JUE<VNJ>7.O[]_\ #I#PG_T6'7__  F;#_Y94?\
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M:<,9E^583"8F,*L&X5(1K49J-2+<9Q2E%V:"BBBOF3Z@**** "BBB@ HHHH
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M8QCB@!U0W%Q!:0375U-%;6UO&\T]Q/(D,$,,:EY)999&6..-%!9W=E15!9B
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M^&WQ\\1?"#X<^!O 7Q TP#6;2SEN/!R^'?BGX$BUFVN=3TZPE^)UCJ^II<^
M9_%-[; '[H6\L<UO!-$LB12PQ2Q)-;S6LJ1R(K(LMK<1PW%M(JD![>>**:%@
M8Y8T=6435Y5\"K+XI:;\%/A#IWQQU;3=>^,]A\,? =G\6M;T>WM+32=7^)5M
MX6TJ'QQJ>FVVGQP:?#97WB5-3N;=+"VM;$1R V5I:VIAMXO5: "BBB@ HHHH
M **** "BBB@!H1%)8(H8YR0H!.>N2!GGO2E5(VE05_ND#'KTZ=>:6B@ P..!
MQT]OI1110 UD1\;E5L=-R@X^F0:7 X.!D# .!P/0>@]J6B@! J@DA0"WWB
M3]?7\:4  8   Z < ?A110 4444 %%%% !32B%@Q12PQABH+#'3!QGCMZ4ZB
M@!,#DX&3U..O;GUXXYH"J!@* .N  !G.<XZ=>?K2T4 %(55AA@&'H0"/R/%+
M10 T(@&T*H&<X"@#/KC&,^]+@9#8&X# .!D ]0#UP:6B@!  ,X &>3@=3ZGU
MI:** "BBB@ HHHH 0@$$$ @\$$9!'H0>M($0 J$4*>H"@ _4 8-.HH 0JI()
M )7D$@$@^H/;\*7 ZXY/4^N.E%% !3=B;MVQ=W][:-W' YQGIQUIU% "8'/
MYZ\#GMSZ\<<T;5P%VC Z# P,=,#H,4M% !1110 4444 %%%% !1110 4444
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MN6]Q=63Z%KSP#2==\N&WS?+I5W=MI[3V:W@A:\MA)O9'^0?7'/I@]?3G.,4
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M()8FV2.FUV]9V)R=BY/7Y1SQCGCTX^G'2G=.E !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
K %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>pfe-10012017x10q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2017-01-31"
  xmlns:currency="http://xbrl.sec.gov/currency/2017-01-31"
  xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31"
  xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:pfe="http://www.pfizer.com/20171001"
  xmlns:us-gaap="http://fasb.org/us-gaap/2017-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="pfe-20171001.xsd" xlink:type="simple"/>
    <context id="FD2017Q3YTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FI2015Q4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
        </entity>
        <period>
            <instant>2015-12-31</instant>
        </period>
    </context>
    <context id="FD2016Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-04</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2017Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-03</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2016Q3YTD_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2017Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-03</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2016Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-04</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2016Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-04</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2016Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2016Q3QTD_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-04</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2016Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FI2016Q3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
        </entity>
        <period>
            <instant>2016-10-02</instant>
        </period>
    </context>
    <context id="FD2017Q3QTD_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-03</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="D2015Q3Sept3_us-gaap_BusinessAcquisitionAxis_pfe_HospiraMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:HospiraMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-09-03</startDate>
            <endDate>2015-09-03</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FI2017Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-01</instant>
        </period>
    </context>
    <context id="FI2017Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-01</instant>
        </period>
    </context>
    <context id="FI2017Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-01</instant>
        </period>
    </context>
    <context id="FI2017Q3_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-01</instant>
        </period>
    </context>
    <context id="FI2016Q3_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_LaboratorioTeutoBrasileroMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:LaboratorioTeutoBrasileroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-10-02</instant>
        </period>
    </context>
    <context id="FD2016Q3QTD_us-gaap_BusinessAcquisitionAxis_pfe_KingMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_pfe_OtherInProcessResearchandDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:KingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">pfe:OtherInProcessResearchandDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-04</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_us-gaap_BusinessAcquisitionAxis_pfe_HospiraMember_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:HospiraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="I2016Q2AnacorAcquisition_us-gaap_BusinessAcquisitionAxis_pfe_AnacorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:AnacorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-06-24</instant>
        </period>
    </context>
    <context id="FD2017Q3QTD_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViivHealthcareLimitedMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:ViivHealthcareLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-03</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2016Q3YTD_us-gaap_BusinessAcquisitionAxis_pfe_InnoPharmaMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:InnoPharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2016Q3YTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2016Q3QTD_us-gaap_BusinessAcquisitionAxis_pfe_InnoPharmaMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:InnoPharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-04</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2017Q3QTD_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_LossContingenciesByNatureOfContingencyAxis_pfe_PatentMatterMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">pfe:PatentMatterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-03</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DistributionRightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DistributionRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2017Q3QTD_us-gaap_ProductOrServiceAxis_pfe_XtandiMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:XtandiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-03</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2016Q3YTD_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_LaboratorioTeutoBrasileroMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:LaboratorioTeutoBrasileroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2016Q3YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2016Q3YTD_us-gaap_BusinessAcquisitionAxis_pfe_HospiraMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_pfe_OtherInProcessResearchandDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:HospiraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">pfe:OtherInProcessResearchandDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2016Q3YTD_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_pfe_AccountingStandardsUpdate201609StatutoryTaxWithholdingComponentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">pfe:AccountingStandardsUpdate201609StatutoryTaxWithholdingComponentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_us-gaap_ProductOrServiceAxis_pfe_XtandiMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:XtandiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2016Q3YTD_us-gaap_BusinessAcquisitionAxis_pfe_KingMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_pfe_OtherInProcessResearchandDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:KingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">pfe:OtherInProcessResearchandDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2017Q3QTD_us-gaap_ProductOrServiceAxis_pfe_EnbrelMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementCopromotionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:EnbrelMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementCopromotionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-03</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViivHealthcareLimitedMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:ViivHealthcareLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2017Q3QTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DistributionRightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DistributionRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-03</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2016Q3YTD_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_ProductOrServiceAxis_pfe_CelebrexandBextraMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:CelebrexandBextraMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2017Q3QTD_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_ProductOrServiceAxis_pfe_CelebrexMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:CelebrexMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-03</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_us-gaap_ProductOrServiceAxis_pfe_EnbrelMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementCopromotionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:EnbrelMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementCopromotionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2016Q3YTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_pfe_OtherInProcessResearchandDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">pfe:OtherInProcessResearchandDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2016Q3YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DistributionRightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DistributionRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="I2016Q3Sep28_us-gaap_BusinessAcquisitionAxis_pfe_MedivationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:MedivationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-09-28</instant>
        </period>
    </context>
    <context id="FD2017Q3YTD_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_ProductOrServiceAxis_pfe_CelebrexMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:CelebrexMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_LossContingenciesByNatureOfContingencyAxis_pfe_PatentMatterMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">pfe:PatentMatterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2017Q3QTD_us-gaap_BusinessAcquisitionAxis_pfe_HospiraMember_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:HospiraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-03</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="FI2017Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-01</instant>
        </period>
    </context>
    <context id="FI2017Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-01</instant>
        </period>
    </context>
    <context id="FI2017Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-01</instant>
        </period>
    </context>
    <context id="FD2017Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="D2016Q2Jun24-Jun24_us-gaap_BusinessAcquisitionAxis_pfe_AnacorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:AnacorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-06-24</startDate>
            <endDate>2016-06-24</endDate>
        </period>
    </context>
    <context id="FI2017Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-01</instant>
        </period>
    </context>
    <context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="FD2017Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FI2017Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-01</instant>
        </period>
    </context>
    <context id="FI2017Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-01</instant>
        </period>
    </context>
    <context id="FD2017Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="D2016Q3Aug01-Aug01_us-gaap_BusinessAcquisitionAxis_pfe_BambooTherapeuticsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:BambooTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-08-01</startDate>
            <endDate>2016-08-01</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-01</instant>
        </period>
    </context>
    <context id="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_USGovernmentDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-01</instant>
        </period>
    </context>
    <context id="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_pfe_WesternEuropeanandOtherGovernmentDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">pfe:WesternEuropeanandOtherGovernmentDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-01</instant>
        </period>
    </context>
    <context id="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_pfe_WesternEuropeanAsianandOtherGovernmentDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">pfe:WesternEuropeanAsianandOtherGovernmentDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-01</instant>
        </period>
    </context>
    <context id="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_pfe_TimeDepositsCorporateDebtAndOtherMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">pfe:TimeDepositsCorporateDebtAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-01</instant>
        </period>
    </context>
    <context id="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_pfe_SupranationalDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">pfe:SupranationalDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-01</instant>
        </period>
    </context>
    <context id="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_GovernmentNationalMortgageAssociationCertificatesAndObligationsGNMAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:GovernmentNationalMortgageAssociationCertificatesAndObligationsGNMAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-01</instant>
        </period>
    </context>
    <context id="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_pfe_WesternEuropeanScandinaviaAndOtherGovernmentAgencyDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">pfe:WesternEuropeanScandinaviaAndOtherGovernmentAgencyDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-01</instant>
        </period>
    </context>
    <context id="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_AssetBackedSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-01</instant>
        </period>
    </context>
    <context id="FD2017Q3QTD_us-gaap_BusinessAcquisitionAxis_pfe_MedivationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:MedivationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-03</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2016Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-04</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2016Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyShortTermBorrowingsMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_pfe_NetInvestmentHedgingNonderivativeInstrumentsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyShortTermBorrowingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">pfe:NetInvestmentHedgingNonderivativeInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2016Q3YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_pfe_OtherDerivativeInstrumentsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">pfe:OtherDerivativeInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2016Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyShortTermBorrowingsMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_pfe_NetInvestmentHedgingNonderivativeInstrumentsMember_us-gaap_OtherComprehensiveIncomeLocationAxis_us-gaap_OtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyShortTermBorrowingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">pfe:NetInvestmentHedgingNonderivativeInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherComprehensiveIncomeLocationAxis">us-gaap:OtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2016Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-04</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_pfe_OtherDerivativeInstrumentsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">pfe:OtherDerivativeInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2016Q3QTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_pfe_OtherDerivativeInstrumentsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">pfe:OtherDerivativeInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-04</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2017Q3QTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_pfe_OtherDerivativeInstrumentsMember_us-gaap_OtherComprehensiveIncomeLocationAxis_us-gaap_OtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">pfe:OtherDerivativeInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherComprehensiveIncomeLocationAxis">us-gaap:OtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-03</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="I2016Q3Aug01-Aug01_us-gaap_BusinessAcquisitionAxis_pfe_BambooTherapeuticsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:BambooTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-08-01</instant>
        </period>
    </context>
    <context id="FD2016Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyLongTermDebtMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_pfe_NetInvestmentHedgingNonderivativeInstrumentsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyLongTermDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">pfe:NetInvestmentHedgingNonderivativeInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2017Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyLongTermDebtMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_pfe_NetInvestmentHedgingNonderivativeInstrumentsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyLongTermDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">pfe:NetInvestmentHedgingNonderivativeInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-03</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2017Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-03</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2016Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-04</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyShortTermBorrowingsMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_pfe_NetInvestmentHedgingNonderivativeInstrumentsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyShortTermBorrowingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">pfe:NetInvestmentHedgingNonderivativeInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2016Q3YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_pfe_OtherDerivativeInstrumentsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">pfe:OtherDerivativeInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2016Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2017Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-03</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="I2017Q1Jan05_us-gaap_CounterpartyNameAxis_pfe_ICUMedicalMember_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_HISMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">pfe:ICUMedicalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pfe:HISMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-01-05</instant>
        </period>
    </context>
    <context id="FD2017Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-03</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2017Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember_us-gaap_OtherComprehensiveIncomeLocationAxis_us-gaap_OtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherComprehensiveIncomeLocationAxis">us-gaap:OtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-03</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2016Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2017Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyLongTermDebtMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_pfe_NetInvestmentHedgingNonderivativeInstrumentsMember_us-gaap_OtherComprehensiveIncomeLocationAxis_us-gaap_OtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyLongTermDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">pfe:NetInvestmentHedgingNonderivativeInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherComprehensiveIncomeLocationAxis">us-gaap:OtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-03</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2017Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-03</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2016Q3QTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_pfe_OtherDerivativeInstrumentsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">pfe:OtherDerivativeInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-04</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2017Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-03</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2016Q3YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_pfe_OtherDerivativeInstrumentsMember_us-gaap_OtherComprehensiveIncomeLocationAxis_us-gaap_OtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">pfe:OtherDerivativeInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherComprehensiveIncomeLocationAxis">us-gaap:OtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2017Q3QTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_pfe_OtherDerivativeInstrumentsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">pfe:OtherDerivativeInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-03</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="I2017Q4Nov06">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
        </entity>
        <period>
            <instant>2017-11-06</instant>
        </period>
    </context>
    <context id="FD2017Q2QTD_us-gaap_BusinessAcquisitionAxis_pfe_AstraZenecaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:AstraZenecaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-04-03</startDate>
            <endDate>2017-07-02</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2016Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_OtherComprehensiveIncomeLocationAxis_us-gaap_OtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherComprehensiveIncomeLocationAxis">us-gaap:OtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2016Q3QTD_us-gaap_OtherComprehensiveIncomeLocationAxis_us-gaap_OtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherComprehensiveIncomeLocationAxis">us-gaap:OtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-04</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2016Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2016Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2016Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_OtherComprehensiveIncomeLocationAxis_us-gaap_OtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherComprehensiveIncomeLocationAxis">us-gaap:OtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-04</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2016Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-04</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_pfe_OtherDerivativeInstrumentsMember_us-gaap_OtherComprehensiveIncomeLocationAxis_us-gaap_OtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">pfe:OtherDerivativeInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherComprehensiveIncomeLocationAxis">us-gaap:OtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2016Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_OtherComprehensiveIncomeLocationAxis_us-gaap_OtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherComprehensiveIncomeLocationAxis">us-gaap:OtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="D2016Q3Sep28-Sep28_us-gaap_BusinessAcquisitionAxis_pfe_MedivationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:MedivationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-09-28</startDate>
            <endDate>2016-09-28</endDate>
        </period>
    </context>
    <context id="FD2017Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-03</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2017Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_OtherComprehensiveIncomeLocationAxis_us-gaap_OtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherComprehensiveIncomeLocationAxis">us-gaap:OtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-03</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2016Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-04</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2017Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-03</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2016Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_OtherComprehensiveIncomeLocationAxis_us-gaap_OtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherComprehensiveIncomeLocationAxis">us-gaap:OtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_OtherComprehensiveIncomeLocationAxis_us-gaap_OtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherComprehensiveIncomeLocationAxis">us-gaap:OtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2016Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-04</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember_us-gaap_OtherComprehensiveIncomeLocationAxis_us-gaap_OtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherComprehensiveIncomeLocationAxis">us-gaap:OtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyShortTermBorrowingsMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_pfe_NetInvestmentHedgingNonderivativeInstrumentsMember_us-gaap_OtherComprehensiveIncomeLocationAxis_us-gaap_OtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyShortTermBorrowingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">pfe:NetInvestmentHedgingNonderivativeInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherComprehensiveIncomeLocationAxis">us-gaap:OtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="D2016Q4Dec22-Dec22_us-gaap_BusinessAcquisitionAxis_pfe_AstraZenecaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:AstraZenecaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-12-22</startDate>
            <endDate>2016-12-22</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_OtherComprehensiveIncomeLocationAxis_us-gaap_OtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherComprehensiveIncomeLocationAxis">us-gaap:OtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2017Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-03</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2016Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_OtherComprehensiveIncomeLocationAxis_us-gaap_OtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherComprehensiveIncomeLocationAxis">us-gaap:OtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-04</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2017Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_OtherComprehensiveIncomeLocationAxis_us-gaap_OtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherComprehensiveIncomeLocationAxis">us-gaap:OtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-03</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2016Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2017Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember_us-gaap_OtherComprehensiveIncomeLocationAxis_us-gaap_OtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherComprehensiveIncomeLocationAxis">us-gaap:OtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-03</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2016Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember_us-gaap_OtherComprehensiveIncomeLocationAxis_us-gaap_OtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherComprehensiveIncomeLocationAxis">us-gaap:OtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-04</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2016Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2016Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyLongTermDebtMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_pfe_NetInvestmentHedgingNonderivativeInstrumentsMember_us-gaap_OtherComprehensiveIncomeLocationAxis_us-gaap_OtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyLongTermDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">pfe:NetInvestmentHedgingNonderivativeInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherComprehensiveIncomeLocationAxis">us-gaap:OtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-04</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="I2016Q4Dec22_us-gaap_BusinessAcquisitionAxis_pfe_AstraZenecaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:AstraZenecaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-22</instant>
        </period>
    </context>
    <context id="FD2017Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-03</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2016Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyLongTermDebtMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_pfe_NetInvestmentHedgingNonderivativeInstrumentsMember_us-gaap_OtherComprehensiveIncomeLocationAxis_us-gaap_OtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyLongTermDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">pfe:NetInvestmentHedgingNonderivativeInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherComprehensiveIncomeLocationAxis">us-gaap:OtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2016Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2017Q3QTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_pfe_OtherDerivativeInstrumentsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">pfe:OtherDerivativeInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-03</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2016Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-04</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2016Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-04</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2017Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-03</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2016Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember_us-gaap_OtherComprehensiveIncomeLocationAxis_us-gaap_OtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherComprehensiveIncomeLocationAxis">us-gaap:OtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2016Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyShortTermBorrowingsMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_pfe_NetInvestmentHedgingNonderivativeInstrumentsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyShortTermBorrowingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">pfe:NetInvestmentHedgingNonderivativeInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2016Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_OtherComprehensiveIncomeLocationAxis_us-gaap_OtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherComprehensiveIncomeLocationAxis">us-gaap:OtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-04</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="I2017Q2Jun30_dei_LegalEntityAxis_pfe_LaboratorioTeutoBrasileroMember_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_LaboratorioTeutoBrasileroMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:LaboratorioTeutoBrasileroMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pfe:LaboratorioTeutoBrasileroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-06-30</instant>
        </period>
    </context>
    <context id="FD2016Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyShortTermBorrowingsMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_pfe_NetInvestmentHedgingNonderivativeInstrumentsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyShortTermBorrowingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">pfe:NetInvestmentHedgingNonderivativeInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_OtherComprehensiveIncomeLocationAxis_us-gaap_OtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherComprehensiveIncomeLocationAxis">us-gaap:OtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2016Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-04</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2016Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2016Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyLongTermDebtMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_pfe_NetInvestmentHedgingNonderivativeInstrumentsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyLongTermDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">pfe:NetInvestmentHedgingNonderivativeInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2016Q3QTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_pfe_OtherDerivativeInstrumentsMember_us-gaap_OtherComprehensiveIncomeLocationAxis_us-gaap_OtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">pfe:OtherDerivativeInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherComprehensiveIncomeLocationAxis">us-gaap:OtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-04</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_pfe_OtherDerivativeInstrumentsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">pfe:OtherDerivativeInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2016Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-04</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2016Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyLongTermDebtMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_pfe_NetInvestmentHedgingNonderivativeInstrumentsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyLongTermDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">pfe:NetInvestmentHedgingNonderivativeInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_us-gaap_CounterpartyNameAxis_pfe_MerckKGaAMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">pfe:MerckKGaAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2016Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2016Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-04</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2017Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-03</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2017Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-03</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2016Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyLongTermDebtMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_pfe_NetInvestmentHedgingNonderivativeInstrumentsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyLongTermDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">pfe:NetInvestmentHedgingNonderivativeInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-04</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember_us-gaap_OtherComprehensiveIncomeLocationAxis_us-gaap_OtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherComprehensiveIncomeLocationAxis">us-gaap:OtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2016Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember_us-gaap_OtherComprehensiveIncomeLocationAxis_us-gaap_OtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherComprehensiveIncomeLocationAxis">us-gaap:OtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2016Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="I2016Q4Oct06_us-gaap_CounterpartyNameAxis_pfe_ICUMedicalMember_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_HISMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">pfe:ICUMedicalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pfe:HISMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-10-06</instant>
        </period>
    </context>
    <context id="FD2016Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyLongTermDebtMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_pfe_NetInvestmentHedgingNonderivativeInstrumentsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyLongTermDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">pfe:NetInvestmentHedgingNonderivativeInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-04</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2016Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember_us-gaap_OtherComprehensiveIncomeLocationAxis_us-gaap_OtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherComprehensiveIncomeLocationAxis">us-gaap:OtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-04</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyLongTermDebtMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_pfe_NetInvestmentHedgingNonderivativeInstrumentsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyLongTermDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">pfe:NetInvestmentHedgingNonderivativeInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2017Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_OtherComprehensiveIncomeLocationAxis_us-gaap_OtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherComprehensiveIncomeLocationAxis">us-gaap:OtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-03</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2016Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-04</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_us-gaap_OtherComprehensiveIncomeLocationAxis_us-gaap_OtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherComprehensiveIncomeLocationAxis">us-gaap:OtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyLongTermDebtMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_pfe_NetInvestmentHedgingNonderivativeInstrumentsMember_us-gaap_OtherComprehensiveIncomeLocationAxis_us-gaap_OtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyLongTermDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">pfe:NetInvestmentHedgingNonderivativeInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherComprehensiveIncomeLocationAxis">us-gaap:OtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2017Q3QTD_us-gaap_OtherComprehensiveIncomeLocationAxis_us-gaap_OtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherComprehensiveIncomeLocationAxis">us-gaap:OtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-03</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="I2016Q3Sep28_us-gaap_BusinessAcquisitionAxis_pfe_MedivationMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:MedivationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-09-28</instant>
        </period>
    </context>
    <context id="FD2016Q3YTD_us-gaap_OtherComprehensiveIncomeLocationAxis_us-gaap_OtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherComprehensiveIncomeLocationAxis">us-gaap:OtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2017Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyLongTermDebtMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_pfe_NetInvestmentHedgingNonderivativeInstrumentsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyLongTermDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">pfe:NetInvestmentHedgingNonderivativeInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-03</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FI2017Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-01</instant>
        </period>
    </context>
    <context id="FI2017Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-01</instant>
        </period>
    </context>
    <context id="FI2017Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_ProductOrServiceAxis_pfe_BesponsaMember_us-gaap_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:BesponsaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-01</instant>
        </period>
    </context>
    <context id="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="FI2017Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_CashAndCashEquivalentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-01</instant>
        </period>
    </context>
    <context id="FI2017Q3_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-01</instant>
        </period>
    </context>
    <context id="FI2017Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-01</instant>
        </period>
    </context>
    <context id="FI2017Q3_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-01</instant>
        </period>
    </context>
    <context id="FD2016Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_LaboratorioTeutoBrasileroMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:LaboratorioTeutoBrasileroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FI2017Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-01</instant>
        </period>
    </context>
    <context id="FI2016Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="FI2017Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_ProductOrServiceAxis_pfe_BesponsaMember_us-gaap_StatementGeographicalAxis_us-gaap_EuropeanUnionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:BesponsaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">us-gaap:EuropeanUnionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-01</instant>
        </period>
    </context>
    <context id="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="FI2017Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-01</instant>
        </period>
    </context>
    <context id="FI2017Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-01</instant>
        </period>
    </context>
    <context id="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="FI2017Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-01</instant>
        </period>
    </context>
    <context id="FI2016Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="FI2017Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-01</instant>
        </period>
    </context>
    <context id="FD2017Q3YTD_us-gaap_CounterpartyNameAxis_pfe_ICUMedicalMember_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_HISMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">pfe:ICUMedicalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pfe:HISMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="FI2017Q1_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-04-02</instant>
        </period>
    </context>
    <context id="FI2017Q3_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_ProductOrServiceAxis_pfe_BesponsaMember_us-gaap_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:BesponsaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-01</instant>
        </period>
    </context>
    <context id="FI2017Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_LongtermDebtTypeAxis_pfe_ForeignCurrencyLongTermDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">pfe:ForeignCurrencyLongTermDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-01</instant>
        </period>
    </context>
    <context id="FI2017Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-01</instant>
        </period>
    </context>
    <context id="FI2017Q3_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_ProductOrServiceAxis_pfe_BesponsaMember_us-gaap_StatementGeographicalAxis_us-gaap_EuropeanUnionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:BesponsaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">us-gaap:EuropeanUnionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-01</instant>
        </period>
    </context>
    <context id="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="FI2016Q4_us-gaap_ShortTermDebtTypeAxis_us-gaap_CommercialPaperMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="FI2017Q3_us-gaap_DebtInstrumentAxis_pfe_EuroLongtermDebtMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:EuroLongtermDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-01</instant>
        </period>
    </context>
    <context id="FD2017Q3QTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
        </entity>
        <period>
            <startDate>2017-07-03</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="D2017Q1Feb03-Feb03_us-gaap_CounterpartyNameAxis_pfe_ICUMedicalMember_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_HISMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">pfe:ICUMedicalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pfe:HISMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-02-03</startDate>
            <endDate>2017-02-03</endDate>
        </period>
    </context>
    <context id="FI2017Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_ProductOrServiceAxis_pfe_BesponsaMember_us-gaap_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:BesponsaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-01</instant>
        </period>
    </context>
    <context id="FI2016Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="FI2017Q3_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-01</instant>
        </period>
    </context>
    <context id="FI2017Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-01</instant>
        </period>
    </context>
    <context id="FD2017Q3YTD_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_VariableRateAxis_pfe_GermanGovernmentBondRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">pfe:GermanGovernmentBondRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="FI2017Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-01</instant>
        </period>
    </context>
    <context id="FI2017Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_ProductOrServiceAxis_pfe_BesponsaMember_us-gaap_StatementGeographicalAxis_us-gaap_EuropeanUnionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:BesponsaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">us-gaap:EuropeanUnionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-01</instant>
        </period>
    </context>
    <context id="FI2017Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-01</instant>
        </period>
    </context>
    <context id="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="FD2017Q1QTD_us-gaap_CounterpartyNameAxis_pfe_MerckKGaAMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">pfe:MerckKGaAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-04-02</endDate>
        </period>
    </context>
    <context id="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="FD2017Q3YTD_us-gaap_EquitySecuritiesByIndustryAxis_us-gaap_TechnologySectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquitySecuritiesByIndustryAxis">us-gaap:TechnologySectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FI2017Q3_us-gaap_ShortTermDebtTypeAxis_us-gaap_CommercialPaperMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-01</instant>
        </period>
    </context>
    <context id="FI2017Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-01</instant>
        </period>
    </context>
    <context id="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="FI2017Q3_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-01</instant>
        </period>
    </context>
    <context id="I2017Q3Aug31_us-gaap_ProductOrServiceAxis_pfe_BesponsaMember_us-gaap_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:BesponsaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-08-31</instant>
        </period>
    </context>
    <context id="I2017Q2Jun30_us-gaap_ProductOrServiceAxis_pfe_BesponsaMember_us-gaap_StatementGeographicalAxis_us-gaap_EuropeanUnionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:BesponsaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">us-gaap:EuropeanUnionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-06-30</instant>
        </period>
    </context>
    <context id="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="FI2017Q3_us-gaap_CounterpartyNameAxis_pfe_ICUMedicalMember_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_HISMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">pfe:ICUMedicalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pfe:HISMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-01</instant>
        </period>
    </context>
    <context id="FI2017Q3_us-gaap_ShortTermDebtTypeAxis_us-gaap_ShortTermDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ShortTermDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-01</instant>
        </period>
    </context>
    <context id="FI2017Q3_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-01</instant>
        </period>
    </context>
    <context id="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_DebtSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="FI2016Q4_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="FI2016Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="FI2016Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_LongTermDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="FI2016Q4_us-gaap_ShortTermDebtTypeAxis_us-gaap_ShortTermDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ShortTermDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="FI2017Q3_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-01</instant>
        </period>
    </context>
    <context id="FI2016Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="FI2017Q3_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-01</instant>
        </period>
    </context>
    <context id="FD2017Q3QTD_us-gaap_CounterpartyNameAxis_pfe_ICUMedicalMember_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_HISMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">pfe:ICUMedicalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pfe:HISMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-03</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FI2017Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-01</instant>
        </period>
    </context>
    <context id="FI2017Q3_us-gaap_LongtermDebtTypeAxis_us-gaap_LongTermDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-01</instant>
        </period>
    </context>
    <context id="FI2017Q3_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-01</instant>
        </period>
    </context>
    <context id="FI2017Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_EquitySecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-01</instant>
        </period>
    </context>
    <context id="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="FI2017Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_DebtSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-01</instant>
        </period>
    </context>
    <context id="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_EquitySecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="FI2016Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="FI2017Q3_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredEuroDebtZeroPercentDue2020Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredEuroDebtZeroPercentDue2020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-01</instant>
        </period>
    </context>
    <context id="FI2017Q3_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredEuroDebtOnePointZeroPercentDue2027Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredEuroDebtOnePointZeroPercentDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-01</instant>
        </period>
    </context>
    <context id="FD2016Q3QTD_us-gaap_BusinessAcquisitionAxis_pfe_BambooTherapeuticsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:BambooTherapeuticsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-04</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FI2017Q3_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtFourPointTwoPercentDue2047Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtFourPointTwoPercentDue2047Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-01</instant>
        </period>
    </context>
    <context id="FI2017Q3_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredEuroDebtThreemonthEURIBORPlus0.20FloatingRateNotesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredEuroDebtThreemonthEURIBORPlus0.20FloatingRateNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-01</instant>
        </period>
    </context>
    <context id="FI2017Q3_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-01</instant>
        </period>
    </context>
    <context id="FI2017Q3_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredEuroDebtPointTwofivePercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredEuroDebtPointTwofivePercentDue2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-01</instant>
        </period>
    </context>
    <context id="FI2017Q3_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-01</instant>
        </period>
    </context>
    <context id="FI2017Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-01</instant>
        </period>
    </context>
    <context id="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="FI2017Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-01</instant>
        </period>
    </context>
    <context id="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_LongTermDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="FI2016Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="D2017Q3Sep29-Oct01_us-gaap_BusinessAcquisitionAxis_pfe_MedivationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:MedivationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-09-29</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FI2017Q3_us-gaap_BalanceSheetLocationAxis_pfe_ShortTermDebtAndCurrentPortionofLongTermDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:ShortTermDebtAndCurrentPortionofLongTermDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-01</instant>
        </period>
    </context>
    <context id="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="FI2016Q4_us-gaap_BalanceSheetLocationAxis_pfe_ShortTermDebtAndCurrentPortionofLongTermDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:ShortTermDebtAndCurrentPortionofLongTermDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="FI2017Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_LongTermDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-01</instant>
        </period>
    </context>
    <context id="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_CashAndCashEquivalentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="FI2017Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-01</instant>
        </period>
    </context>
    <context id="D2017Q2Jun01-Jun30_us-gaap_ProductOrServiceAxis_pfe_BesponsaMember_us-gaap_StatementGeographicalAxis_us-gaap_EuropeanUnionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:BesponsaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">us-gaap:EuropeanUnionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-06-01</startDate>
            <endDate>2017-06-30</endDate>
        </period>
    </context>
    <context id="D2017Q3Aug01-Aug31_us-gaap_ProductOrServiceAxis_pfe_BesponsaMember_us-gaap_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:BesponsaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-08-01</startDate>
            <endDate>2017-08-31</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredEuroDebtThreemonthEURIBORPlus0.20FloatingRateNotesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember_us-gaap_VariableRateAxis_pfe_EURIBORMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredEuroDebtThreemonthEURIBORPlus0.20FloatingRateNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">pfe:EURIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_LaboratorioTeutoBrasileroMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:LaboratorioTeutoBrasileroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2017Q3QTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_FiniteLivedIntangibleAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:FiniteLivedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-03</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2016Q3QTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_FiniteLivedIntangibleAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:FiniteLivedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-04</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_FiniteLivedIntangibleAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:FiniteLivedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FI2017Q3_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_ProductOrServiceAxis_pfe_BesponsaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:BesponsaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-01</instant>
        </period>
    </context>
    <context id="FD2016Q3YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_FiniteLivedIntangibleAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:FiniteLivedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FI2017Q3_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember_us-gaap_ProductOrServiceAxis_pfe_EucrisaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:EucrisaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-01</instant>
        </period>
    </context>
    <context id="FI2016Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="FI2016Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="FI2016Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsAndOtherMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">pfe:LicensingAgreementsAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="FI2016Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="I2016Q3Aug01-Aug01_us-gaap_BusinessAcquisitionAxis_pfe_BambooTherapeuticsMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:BambooTherapeuticsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-08-01</instant>
        </period>
    </context>
    <context id="FI2017Q3_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-01</instant>
        </period>
    </context>
    <context id="FI2017Q3_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-01</instant>
        </period>
    </context>
    <context id="FI2016Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="FI2017Q3_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsAndOtherMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">pfe:LicensingAgreementsAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-01</instant>
        </period>
    </context>
    <context id="FI2017Q3_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-01</instant>
        </period>
    </context>
    <context id="FD2017Q3YTD_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FI2017Q3_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-01</instant>
        </period>
    </context>
    <context id="FI2016Q4_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="FI2016Q4_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="D2017Q1Feb03-Feb03_us-gaap_CounterpartyNameAxis_pfe_ICUMedicalMember_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_HISMember_us-gaap_VariableRateAxis_us-gaap_LondonInterbankOfferedRateLIBORMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">pfe:ICUMedicalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pfe:HISMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-02-03</startDate>
            <endDate>2017-02-03</endDate>
        </period>
    </context>
    <context id="FI2017Q3_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-01</instant>
        </period>
    </context>
    <context id="FI2017Q3_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-01</instant>
        </period>
    </context>
    <context id="FI2017Q3_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-01</instant>
        </period>
    </context>
    <context id="FI2017Q3_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_SubsegmentsAxis_pfe_PfizersWorldwideResearchandDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">pfe:PfizersWorldwideResearchandDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-01</instant>
        </period>
    </context>
    <context id="FI2017Q3_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember_us-gaap_SubsegmentsAxis_pfe_PfizersWorldwideResearchandDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">pfe:PfizersWorldwideResearchandDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-01</instant>
        </period>
    </context>
    <context id="FI2017Q3_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-01</instant>
        </period>
    </context>
    <context id="FI2017Q3_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-01</instant>
        </period>
    </context>
    <context id="FI2017Q3_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-01</instant>
        </period>
    </context>
    <context id="FI2017Q3_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-01</instant>
        </period>
    </context>
    <context id="FI2017Q3_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-01</instant>
        </period>
    </context>
    <context id="I2016Q4Dec22_us-gaap_BusinessAcquisitionAxis_pfe_AstraZenecaMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-22</instant>
        </period>
    </context>
    <context id="FI2017Q3_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-01</instant>
        </period>
    </context>
    <context id="FI2017Q3_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember_us-gaap_SubsegmentsAxis_pfe_PfizersWorldwideResearchandDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">pfe:PfizersWorldwideResearchandDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-01</instant>
        </period>
    </context>
    <context id="FI2017Q3_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember_us-gaap_SubsegmentsAxis_pfe_PfizersWorldwideResearchandDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">pfe:PfizersWorldwideResearchandDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-01</instant>
        </period>
    </context>
    <context id="FI2017Q3_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_ProductOrServiceAxis_pfe_EucrisaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:EucrisaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-01</instant>
        </period>
    </context>
    <context id="FD2016Q3QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:NonqualifiedPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:SupplementalEmployeeRetirementPlanDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-04</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2016Q3YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2016Q3YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2016Q3QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-04</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2016Q3QTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-04</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2016Q3YTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="I2016Q4Dec22_us-gaap_BusinessAcquisitionAxis_pfe_AstraZenecaMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-22</instant>
        </period>
    </context>
    <context id="FD2017Q3QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:NonqualifiedPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:SupplementalEmployeeRetirementPlanDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-03</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2017Q3QTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-03</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2016Q3QTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-04</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2016Q3YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2017Q3QTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-03</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2017Q3QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-03</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:NonqualifiedPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:SupplementalEmployeeRetirementPlanDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2016Q3YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:NonqualifiedPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:SupplementalEmployeeRetirementPlanDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FI2017Q3_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_HisunPfizerPharmaceuticalsCoLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:HisunPfizerPharmaceuticalsCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-01</instant>
        </period>
    </context>
    <context id="FI2017Q3_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-01</instant>
        </period>
    </context>
    <context id="FI2017Q3_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-01</instant>
        </period>
    </context>
    <context id="FI2017Q3_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-01</instant>
        </period>
    </context>
    <context id="FI2017Q3_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:NonqualifiedPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:SupplementalEmployeeRetirementPlanDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-01</instant>
        </period>
    </context>
    <context id="D2017Q1Jan01-Jan31_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-01-31</endDate>
        </period>
    </context>
    <context id="D2017Q2Apr01-Apr30_us-gaap_BusinessAcquisitionAxis_pfe_HospiraMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:HospiraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-04-01</startDate>
            <endDate>2017-04-30</endDate>
        </period>
    </context>
    <context id="FD2016Q3QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-04</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2017Q3QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-03</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2016Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2018Q1QTD_us-gaap_BusinessAcquisitionAxis_pfe_AstraZenecaMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioForecastMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-04-01</endDate>
        </period>
    </context>
    <context id="D2017Q1Mar01-Mar31_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationCaseAxis_pfe_PfizerVersusZydusMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_ProductOrServiceAxis_pfe_XeljanzMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GainContingenciesByNatureAxis">pfe:PatentInfringementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">pfe:PfizerVersusZydusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:XeljanzMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-03-01</startDate>
            <endDate>2017-03-31</endDate>
        </period>
    </context>
    <context id="FI2016Q4_us-gaap_LossContingenciesByNatureOfContingencyAxis_pfe_ViolationofAntitrustLawsMember_us-gaap_ProductOrServiceAxis_pfe_PhenytoinSodiumCapsulesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">pfe:ViolationofAntitrustLawsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:PhenytoinSodiumCapsulesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="D2017Q1Mar01-Mar31_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationCaseAxis_pfe_PfizerVersusPrinstonandBreckenridgeMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_ProductOrServiceAxis_pfe_XeljanzMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GainContingenciesByNatureAxis">pfe:PatentInfringementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">pfe:PfizerVersusPrinstonandBreckenridgeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:XeljanzMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-03-01</startDate>
            <endDate>2017-03-31</endDate>
        </period>
    </context>
    <context id="D2017Q1Feb01-Feb28_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationCaseAxis_pfe_PfizerVersusMicroLabsMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_ProductOrServiceAxis_pfe_XeljanzMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GainContingenciesByNatureAxis">pfe:PatentInfringementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">pfe:PfizerVersusMicroLabsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:XeljanzMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-02-01</startDate>
            <endDate>2017-02-28</endDate>
        </period>
    </context>
    <context id="D2017Q2Feb01-Apr30_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationCaseAxis_pfe_PfizerandBMSVersusSeveralGenericManufacturersMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_ProductOrServiceAxis_pfe_EliquisMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GainContingenciesByNatureAxis">pfe:PatentInfringementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">pfe:PfizerandBMSVersusSeveralGenericManufacturersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:EliquisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-02-01</startDate>
            <endDate>2017-04-30</endDate>
        </period>
    </context>
    <context id="I2017Q1Feb02_us-gaap_ShareRepurchaseProgramAxis_pfe_ShareRepurchaseAgreementwithCitibankMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">pfe:ShareRepurchaseAgreementwithCitibankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-02-02</instant>
        </period>
    </context>
    <context id="FI2017Q3_us-gaap_ShareRepurchaseProgramAxis_pfe_ShareRepurchaseAgreementwithCitibankMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">pfe:ShareRepurchaseAgreementwithCitibankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-01</instant>
        </period>
    </context>
    <context id="D2017Q1Jan01-Jan31_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationCaseAxis_pfe_PfizerVersusMylanLaboratoriesandAccordHealthcareInc.Member_us-gaap_LitigationStatusAxis_us-gaap_JudicialRulingMember_us-gaap_ProductOrServiceAxis_pfe_ToviazMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GainContingenciesByNatureAxis">pfe:PatentInfringementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">pfe:PfizerVersusMylanLaboratoriesandAccordHealthcareInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:ToviazMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-01-31</endDate>
        </period>
    </context>
    <context id="D2017Q3Jul01-Jul31_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationCaseAxis_pfe_PfizerVersusMylanLaboratoriesandAccordHealthcareInc.Member_us-gaap_LitigationStatusAxis_us-gaap_JudicialRulingMember_us-gaap_ProductOrServiceAxis_pfe_ToviazMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GainContingenciesByNatureAxis">pfe:PatentInfringementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">pfe:PfizerVersusMylanLaboratoriesandAccordHealthcareInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:ToviazMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-01</startDate>
            <endDate>2017-07-31</endDate>
        </period>
    </context>
    <context id="FI2017Q3_us-gaap_LitigationCaseAxis_pfe_StateofIllinoisVersusPfizerMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_LossContingenciesByNatureOfContingencyAxis_pfe_AverageWholesalePriceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">pfe:StateofIllinoisVersusPfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">pfe:AverageWholesalePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-01</instant>
        </period>
    </context>
    <context id="FI2016Q3_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_HisunPfizerPharmaceuticalsCoLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:HisunPfizerPharmaceuticalsCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-10-02</instant>
        </period>
    </context>
    <context id="D2015Q1March2015_us-gaap_LitigationCaseAxis_pfe_JanssenandNewYorkUniversityVersusHospiraCelltrionHealthcareandCelltrionInc.Member_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_ProductOrServiceAxis_pfe_InflectraMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">pfe:JanssenandNewYorkUniversityVersusHospiraCelltrionHealthcareandCelltrionInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:InflectraMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-03-01</startDate>
            <endDate>2015-03-31</endDate>
        </period>
    </context>
    <context id="D2015Q1MonthOfJanuary_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationCaseAxis_pfe_PfizerVersusMylanLaboratoriesandAccordHealthcareInc.Member_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_ProductOrServiceAxis_pfe_ToviazMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GainContingenciesByNatureAxis">pfe:PatentInfringementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">pfe:PfizerVersusMylanLaboratoriesandAccordHealthcareInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:ToviazMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-01-01</startDate>
            <endDate>2015-01-31</endDate>
        </period>
    </context>
    <context id="D2015Q1SD_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationCaseAxis_pfe_PfizerVersusSeveralGenericManufacturersMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_us-gaap_ProductOrServiceAxis_pfe_ToviazMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GainContingenciesByNatureAxis">pfe:PatentInfringementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">pfe:PfizerVersusSeveralGenericManufacturersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:ToviazMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-06-01</startDate>
            <endDate>2015-07-31</endDate>
        </period>
    </context>
    <context id="D2016Q3Aug01-Aug31_us-gaap_LitigationCaseAxis_pfe_HospiraVersusParMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_ProductOrServiceAxis_pfe_PrecedexPremixMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">pfe:HospiraVersusParMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:PrecedexPremixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-08-01</startDate>
            <endDate>2016-08-31</endDate>
        </period>
    </context>
    <context id="D2017Q4Oct02-Oct31_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationCaseAxis_pfe_PfizerVersusBreckenridgeMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_ProductOrServiceAxis_pfe_XeljanzMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GainContingenciesByNatureAxis">pfe:PatentInfringementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">pfe:PfizerVersusBreckenridgeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:XeljanzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-02</startDate>
            <endDate>2017-10-31</endDate>
        </period>
    </context>
    <context id="D2017Q1Feb06-Feb06_us-gaap_ShareRepurchaseProgramAxis_pfe_ShareRepurchaseAgreementwithCitibankMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">pfe:ShareRepurchaseAgreementwithCitibankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-02-06</startDate>
            <endDate>2017-02-06</endDate>
        </period>
    </context>
    <context id="D2017Q2Feb06-May19_us-gaap_ShareRepurchaseProgramAxis_pfe_ShareRepurchaseAgreementwithCitibankMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">pfe:ShareRepurchaseAgreementwithCitibankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-02-06</startDate>
            <endDate>2017-05-19</endDate>
        </period>
    </context>
    <context id="D2017Q1Feb02-Feb02_us-gaap_ShareRepurchaseProgramAxis_pfe_ShareRepurchaseAgreementwithCitibankMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">pfe:ShareRepurchaseAgreementwithCitibankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-02-02</startDate>
            <endDate>2017-02-02</endDate>
        </period>
    </context>
    <context id="D2017Q2Apr01-Apr30_us-gaap_LitigationCaseAxis_pfe_RegentsVersusMedivationMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_us-gaap_ProductOrServiceAxis_pfe_XtandiMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">pfe:RegentsVersusMedivationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:XtandiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-04-01</startDate>
            <endDate>2017-04-30</endDate>
        </period>
    </context>
    <context id="D2015Q1March2015_us-gaap_LitigationCaseAxis_pfe_JanssenandNewYorkUniversityVersusHospiraCelltrionHealthcareandCelltrionInc.Member_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_us-gaap_ProductOrServiceAxis_pfe_InflectraMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">pfe:JanssenandNewYorkUniversityVersusHospiraCelltrionHealthcareandCelltrionInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:InflectraMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-03-01</startDate>
            <endDate>2015-03-31</endDate>
        </period>
    </context>
    <context id="D2016Q4Dec22-Dec22_us-gaap_BusinessAcquisitionAxis_pfe_AstraZenecaMember_us-gaap_RangeAxis_us-gaap_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-12-22</startDate>
            <endDate>2016-12-22</endDate>
        </period>
    </context>
    <context id="D2017Q3Sep01-Sep30_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationCaseAxis_pfe_WyethVersusSunMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_ProductOrServiceAxis_pfe_BosulifMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GainContingenciesByNatureAxis">pfe:PatentInfringementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">pfe:WyethVersusSunMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:BosulifMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-09-01</startDate>
            <endDate>2017-09-30</endDate>
        </period>
    </context>
    <context id="D2016Q3Jul01-Jul31_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationCaseAxis_pfe_PfizerVersusMylanLaboratoriesandAccordHealthcareInc.Member_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_ProductOrServiceAxis_pfe_ToviazMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GainContingenciesByNatureAxis">pfe:PatentInfringementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">pfe:PfizerVersusMylanLaboratoriesandAccordHealthcareInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:ToviazMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-01</startDate>
            <endDate>2016-07-31</endDate>
        </period>
    </context>
    <context id="D2015Q2June2015_us-gaap_LitigationCaseAxis_pfe_HospiraVersusAmnealPharmaceuticalsLLCMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_ProductOrServiceAxis_pfe_PrecedexPremixMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">pfe:HospiraVersusAmnealPharmaceuticalsLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:PrecedexPremixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-06-01</startDate>
            <endDate>2015-06-30</endDate>
        </period>
    </context>
    <context id="D2015Q3July2015_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationCaseAxis_pfe_PfizerVersusSeveralGenericManufacturersMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_ProductOrServiceAxis_pfe_ToviazMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GainContingenciesByNatureAxis">pfe:PatentInfringementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">pfe:PfizerVersusSeveralGenericManufacturersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:ToviazMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-07-01</startDate>
            <endDate>2015-07-31</endDate>
        </period>
    </context>
    <context id="D2015Q4_us-gaap_LitigationCaseAxis_pfe_HospiraVersusFreseniusMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_ProductOrServiceAxis_pfe_PrecedexPremixMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">pfe:HospiraVersusFreseniusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:PrecedexPremixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-12-01</startDate>
            <endDate>2015-12-31</endDate>
        </period>
    </context>
    <context id="D2017Q1Feb01-Feb28_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationCaseAxis_pfe_PfizerVersusMylanLaboratoriesandAccordHealthcareInc.Member_us-gaap_LitigationStatusAxis_us-gaap_JudicialRulingMember_us-gaap_ProductOrServiceAxis_pfe_ToviazMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GainContingenciesByNatureAxis">pfe:PatentInfringementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">pfe:PfizerVersusMylanLaboratoriesandAccordHealthcareInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:ToviazMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-02-01</startDate>
            <endDate>2017-02-28</endDate>
        </period>
    </context>
    <context id="D2016Q1Jan2016_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationCaseAxis_pfe_PfizerVersusMylanLaboratoriesandAccordHealthcareInc.Member_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_ProductOrServiceAxis_pfe_ToviazCompositionofmatterPatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GainContingenciesByNatureAxis">pfe:PatentInfringementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">pfe:PfizerVersusMylanLaboratoriesandAccordHealthcareInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:ToviazCompositionofmatterPatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-01-31</endDate>
        </period>
    </context>
    <context id="FI2017Q3_us-gaap_ProductOrServiceAxis_pfe_MylotargMember_us-gaap_StatementScenarioAxis_us-gaap_ProFormaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:MylotargMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ProFormaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-01</instant>
        </period>
    </context>
    <context id="D2013Q1MonthOfMarch_us-gaap_LossContingenciesByNatureOfContingencyAxis_pfe_EnvironmentalRemediationLitigationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">pfe:EnvironmentalRemediationLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-03-01</startDate>
            <endDate>2013-03-31</endDate>
        </period>
    </context>
    <context id="D2016Q1Jan2016_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationCaseAxis_pfe_PfizerVersusMylanLaboratoriesandAccordHealthcareInc.Member_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_ProductOrServiceAxis_pfe_ToviazMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GainContingenciesByNatureAxis">pfe:PatentInfringementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">pfe:PfizerVersusMylanLaboratoriesandAccordHealthcareInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:ToviazMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-01-31</endDate>
        </period>
    </context>
    <context id="FD2016Q1QTD_us-gaap_BusinessAcquisitionAxis_pfe_BambooTherapeuticsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:BambooTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-04-03</endDate>
        </period>
    </context>
    <context id="D2017Q4Oct02-Oct31_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_ProductOrServiceAxis_pfe_CelebrexMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:CelebrexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-02</startDate>
            <endDate>2017-10-31</endDate>
        </period>
    </context>
    <context id="D2015Q1Jan1-31_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationCaseAxis_pfe_PfizerVersusMylanLaboratoriesandAccordHealthcareInc.Member_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_ProductOrServiceAxis_pfe_ToviazCompositionofmatterPatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GainContingenciesByNatureAxis">pfe:PatentInfringementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">pfe:PfizerVersusMylanLaboratoriesandAccordHealthcareInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:ToviazCompositionofmatterPatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-01-01</startDate>
            <endDate>2015-01-31</endDate>
        </period>
    </context>
    <context id="D2015Q1March2015_us-gaap_LitigationCaseAxis_pfe_JanssenandNewYorkUniversityVersusHospiraCelltrionHealthcareandCelltrionInc.Member_us-gaap_ProductOrServiceAxis_pfe_InflectraMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">pfe:JanssenandNewYorkUniversityVersusHospiraCelltrionHealthcareandCelltrionInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:InflectraMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-03-01</startDate>
            <endDate>2015-03-31</endDate>
        </period>
    </context>
    <context id="D2013Q2MonthofJune_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationCaseAxis_pfe_PfizerVersusMylanLaboratoriesandAccordHealthcareInc.Member_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_ProductOrServiceAxis_pfe_ToviazMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GainContingenciesByNatureAxis">pfe:PatentInfringementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">pfe:PfizerVersusMylanLaboratoriesandAccordHealthcareInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:ToviazMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-06-01</startDate>
            <endDate>2013-06-30</endDate>
        </period>
    </context>
    <context id="D2017Q3Aug01-Aug10_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationCaseAxis_pfe_PfizerVersusMylanLaboratoriesandAccordHealthcareInc.Member_us-gaap_LitigationStatusAxis_us-gaap_JudicialRulingMember_us-gaap_ProductOrServiceAxis_pfe_ToviazMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GainContingenciesByNatureAxis">pfe:PatentInfringementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">pfe:PfizerVersusMylanLaboratoriesandAccordHealthcareInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:ToviazMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-08-01</startDate>
            <endDate>2017-08-10</endDate>
        </period>
    </context>
    <context id="I2017Q1Feb06_us-gaap_ShareRepurchaseProgramAxis_pfe_ShareRepurchaseAgreementwithCitibankMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">pfe:ShareRepurchaseAgreementwithCitibankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-02-06</instant>
        </period>
    </context>
    <context id="D2017Q3Jul01-Jul31_us-gaap_LitigationCaseAxis_pfe_PfizerVersusBMSE.R.SquibbSonsOnoPharmaceuticalandTasukuHonjoMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_LossContingenciesByNatureOfContingencyAxis_pfe_PatentInfringementMember_us-gaap_ProductOrServiceAxis_pfe_BavencioMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">pfe:PfizerVersusBMSE.R.SquibbSonsOnoPharmaceuticalandTasukuHonjoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">pfe:PatentInfringementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:BavencioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-01</startDate>
            <endDate>2017-07-31</endDate>
        </period>
    </context>
    <context id="D2013Q2MonthofJune_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationCaseAxis_pfe_PfizerVersusSeveralGenericManufacturersMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_ProductOrServiceAxis_pfe_ToviazCompositionofmatterPatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GainContingenciesByNatureAxis">pfe:PatentInfringementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">pfe:PfizerVersusSeveralGenericManufacturersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:ToviazCompositionofmatterPatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-06-01</startDate>
            <endDate>2013-06-30</endDate>
        </period>
    </context>
    <context id="FI2017Q3_us-gaap_LitigationCaseAxis_pfe_ClassActionVersusAmericanOpticalCorporationAndVariousOtherDefendantsMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_LossContingenciesByNatureOfContingencyAxis_us-gaap_DamagesFromProductDefectsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">pfe:ClassActionVersusAmericanOpticalCorporationAndVariousOtherDefendantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:DamagesFromProductDefectsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-01</instant>
        </period>
    </context>
    <context id="D2017Q2May19-May19_us-gaap_ShareRepurchaseProgramAxis_pfe_ShareRepurchaseAgreementwithCitibankMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">pfe:ShareRepurchaseAgreementwithCitibankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-05-19</startDate>
            <endDate>2017-05-19</endDate>
        </period>
    </context>
    <context id="FD2016Q3YTD_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_HisunPfizerPharmaceuticalsCoLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:HisunPfizerPharmaceuticalsCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_us-gaap_ProductOrServiceAxis_pfe_MylotargMember_us-gaap_StatementScenarioAxis_us-gaap_ProFormaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:MylotargMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ProFormaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2016Q3QTD_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-04</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2016Q3YTD_us-gaap_CurrencyAxis_currency_EUR_us-gaap_StatementGeographicalAxis_pfe_DevelopedEuropeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">pfe:DevelopedEuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2016Q3QTD_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_HISMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pfe:HISMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-04</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2017Q3QTD_us-gaap_CurrencyAxis_currency_EUR_us-gaap_StatementGeographicalAxis_pfe_DevelopedEuropeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">pfe:DevelopedEuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-03</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2017Q3QTD_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-03</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2017Q3QTD_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_HISMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pfe:HISMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-03</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2016Q3YTD_us-gaap_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2016Q3YTD_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="I2016Q3Sep28_us-gaap_BusinessAcquisitionAxis_pfe_MedivationMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:MedivationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-09-28</instant>
        </period>
    </context>
    <context id="FD2016Q3YTD_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_HISMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pfe:HISMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_HISMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pfe:HISMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2016Q3QTD_us-gaap_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-04</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_us-gaap_CurrencyAxis_currency_EUR_us-gaap_StatementGeographicalAxis_pfe_DevelopedEuropeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">pfe:DevelopedEuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2017Q3QTD_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-03</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2016Q3YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_CertainSignificantItemsMember_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:OtherSegmentReconcilingItemsAxis">pfe:CertainSignificantItemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2016Q3YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_OtherUnallocatedMember_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:OtherSegmentReconcilingItemsAxis">pfe:OtherUnallocatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2017Q3QTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_OtherUnallocatedMember_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:OtherSegmentReconcilingItemsAxis">pfe:OtherUnallocatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-03</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_PurchaseAccountingAdjustmentsMember_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:OtherSegmentReconcilingItemsAxis">pfe:PurchaseAccountingAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2016Q3YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_PurchaseAccountingAdjustmentsMember_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:OtherSegmentReconcilingItemsAxis">pfe:PurchaseAccountingAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="D2016Q4Dec22-Dec22_us-gaap_BusinessAcquisitionAxis_pfe_AstraZenecaMember_us-gaap_RangeAxis_us-gaap_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-12-22</startDate>
            <endDate>2016-12-22</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_CertainSignificantItemsMember_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:OtherSegmentReconcilingItemsAxis">pfe:CertainSignificantItemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2016Q3QTD_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-04</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2017Q3QTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_PurchaseAccountingAdjustmentsMember_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:OtherSegmentReconcilingItemsAxis">pfe:PurchaseAccountingAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-03</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2017Q3QTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_BusinessCombinationsAcquisitionRelatedCostsMember_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:OtherSegmentReconcilingItemsAxis">pfe:BusinessCombinationsAcquisitionRelatedCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-03</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2016Q3YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_BusinessCombinationsAcquisitionRelatedCostsMember_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:OtherSegmentReconcilingItemsAxis">pfe:BusinessCombinationsAcquisitionRelatedCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2016Q3YTD_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2016Q3QTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_PurchaseAccountingAdjustmentsMember_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:OtherSegmentReconcilingItemsAxis">pfe:PurchaseAccountingAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-04</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_OtherUnallocatedMember_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:OtherSegmentReconcilingItemsAxis">pfe:OtherUnallocatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_BusinessCombinationsAcquisitionRelatedCostsMember_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:OtherSegmentReconcilingItemsAxis">pfe:BusinessCombinationsAcquisitionRelatedCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FI2016Q4_us-gaap_BusinessAcquisitionAxis_pfe_MedivationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:MedivationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="FD2017Q3QTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_CertainSignificantItemsMember_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:OtherSegmentReconcilingItemsAxis">pfe:CertainSignificantItemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-03</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2016Q3QTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_BusinessCombinationsAcquisitionRelatedCostsMember_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:OtherSegmentReconcilingItemsAxis">pfe:BusinessCombinationsAcquisitionRelatedCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-04</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2016Q3QTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_CertainSignificantItemsMember_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:OtherSegmentReconcilingItemsAxis">pfe:CertainSignificantItemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-04</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2016Q3QTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_OtherUnallocatedMember_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:OtherSegmentReconcilingItemsAxis">pfe:OtherUnallocatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-04</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_PremarinFamilyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:PremarinFamilyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:LegacyEstablishedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_BiosimilarsMember_us-gaap_ProductOrServiceAxis_pfe_InflectraRemsimaMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:InflectraRemsimaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:BiosimilarsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_RareDiseaseMember_us-gaap_ProductOrServiceAxis_pfe_AllOtherRareDiseaseProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:AllOtherRareDiseaseProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-03</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2016Q3YTD_us-gaap_ProductOrServiceAxis_pfe_AllianceBiopharmaceuticalsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthandEssentialHealthMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:AllianceBiopharmaceuticalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthandEssentialHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_CentreOneMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:CentreOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-04</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_OncologyMember_us-gaap_ProductOrServiceAxis_pfe_BosulifMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:BosulifMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2016Q3QTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
        </entity>
        <period>
            <startDate>2016-07-04</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="I2016Q2AnacorAcquisition_us-gaap_BusinessAcquisitionAxis_pfe_AnacorMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:AnacorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-06-24</instant>
        </period>
    </context>
    <context id="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InternalMedicineMember_us-gaap_ProductOrServiceAxis_pfe_ToviazMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:ToviazMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-04</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_SterileInjectablePharmaceuticalsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:SterileInjectablePharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InternalMedicineMember_us-gaap_ProductOrServiceAxis_pfe_ChantixChampixMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:ChantixChampixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:VaccinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InflammationandImmunologyMember_us-gaap_ProductOrServiceAxis_pfe_XeljanzMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:XeljanzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_SterileInjectablePharmaceuticalsMember_us-gaap_ProductOrServiceAxis_pfe_SulperazonMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:SulperazonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:SterileInjectablePharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-04</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_ProductOrServiceAxis_pfe_VfendMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:VfendMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:PeriLOEProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_ProductOrServiceAxis_pfe_CelebrexMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:CelebrexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:PeriLOEProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-03</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_PremarinFamilyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:PremarinFamilyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:LegacyEstablishedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-04</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2017Q3QTD_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthandEssentialHealthMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthandEssentialHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-03</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_us-gaap_BusinessAcquisitionAxis_pfe_MedivationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:MedivationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_SterileInjectablePharmaceuticalsMember_us-gaap_ProductOrServiceAxis_pfe_AllOtherSterileInjectablePharmaceuticalsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:AllOtherSterileInjectablePharmaceuticalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:SterileInjectablePharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-03</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2016Q3QTD_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthandEssentialHealthMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthandEssentialHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-04</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:VaccinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-03</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InflammationandImmunologyMember_us-gaap_ProductOrServiceAxis_pfe_EnbrelMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:EnbrelMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-03</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-04</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_HospiraInfusionSystemsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:HospiraInfusionSystemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_RareDiseaseMember_us-gaap_ProductOrServiceAxis_pfe_SomavertMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:SomavertMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_SterileInjectablePharmaceuticalsMember_us-gaap_ProductOrServiceAxis_pfe_TygacilMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:TygacilMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:SterileInjectablePharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-03</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_ProductOrServiceAxis_pfe_AllOtherPeriLOEProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:AllOtherPeriLOEProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:PeriLOEProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="D2016Q3Sep28-Sep28_us-gaap_BusinessAcquisitionAxis_pfe_MedivationMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:MedivationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-09-28</startDate>
            <endDate>2016-09-28</endDate>
        </period>
    </context>
    <context id="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:LegacyEstablishedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_SterileInjectablePharmaceuticalsMember_us-gaap_ProductOrServiceAxis_pfe_SulperazonMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:SulperazonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:SterileInjectablePharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_RareDiseaseMember_us-gaap_ProductOrServiceAxis_pfe_BeneFIXMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:BeneFIXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-03</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_CentreOneMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:CentreOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_OncologyMember_us-gaap_ProductOrServiceAxis_pfe_XtandiAllianceMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:XtandiAllianceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-03</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InternalMedicineMember_us-gaap_ProductOrServiceAxis_pfe_ViagraMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:ViagraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-03</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_VaccinesMember_us-gaap_ProductOrServiceAxis_pfe_FSMEIMMUNTicoVacMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:FSMEIMMUNTicoVacMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:VaccinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InflammationandImmunologyMember_us-gaap_ProductOrServiceAxis_pfe_XeljanzMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:XeljanzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-04</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_EffexorMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:EffexorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:LegacyEstablishedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_ConsumerHealthcareMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:ConsumerHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-04</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InternalMedicineMember_us-gaap_ProductOrServiceAxis_pfe_ChantixChampixMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:ChantixChampixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_SterileInjectablePharmaceuticalsMember_us-gaap_ProductOrServiceAxis_pfe_PrecedexMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:PrecedexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:SterileInjectablePharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-04</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_OncologyMember_us-gaap_ProductOrServiceAxis_pfe_OtherOncologyProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:OtherOncologyProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:LegacyEstablishedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-03</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-04</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-04</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_LipitorMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:LipitorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:LegacyEstablishedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-04</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_LipitorMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:LipitorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:LegacyEstablishedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-03</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:PeriLOEProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_us-gaap_RestructuringCostAndReserveAxis_pfe_AssetImpairmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pfe:AssetImpairmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_OtherLegacyEstablishedProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:OtherLegacyEstablishedProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:LegacyEstablishedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_EffexorMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:EffexorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:LegacyEstablishedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-03</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_ProductOrServiceAxis_pfe_VfendMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:VfendMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:PeriLOEProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-03</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_SterileInjectablePharmaceuticalsMember_us-gaap_ProductOrServiceAxis_pfe_AllOtherSterileInjectablePharmaceuticalsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:AllOtherSterileInjectablePharmaceuticalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:SterileInjectablePharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_VaccinesMember_us-gaap_ProductOrServiceAxis_pfe_PrevnarPrevenarFamilyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:PrevnarPrevenarFamilyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:VaccinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_OncologyMember_us-gaap_ProductOrServiceAxis_pfe_IbranceMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:IbranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-03</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_ZoloftMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:ZoloftMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:LegacyEstablishedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-04</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_VaccinesMember_us-gaap_ProductOrServiceAxis_pfe_OtherVaccinesProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:OtherVaccinesProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:VaccinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-03</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_ProductOrServiceAxis_pfe_ViagraMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:ViagraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:PeriLOEProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-03</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_HospiraInfusionSystemsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:HospiraInfusionSystemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-03</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OtherRestructuringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_OncologyMember_us-gaap_ProductOrServiceAxis_pfe_OtherOncologyProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:OtherOncologyProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-04</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InflammationandImmunologyMember_us-gaap_ProductOrServiceAxis_pfe_AllOtherInflammationandImmunologyProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:AllOtherInflammationandImmunologyProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_SterileInjectablePharmaceuticalsMember_us-gaap_ProductOrServiceAxis_pfe_PrecedexMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:PrecedexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:SterileInjectablePharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-03</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_SterileInjectablePharmaceuticalsMember_us-gaap_ProductOrServiceAxis_pfe_TygacilMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:TygacilMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:SterileInjectablePharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-04</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_BiosimilarsMember_us-gaap_ProductOrServiceAxis_pfe_InflectraRemsimaMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:InflectraRemsimaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:BiosimilarsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-04</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_EpiPenMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:EpiPenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:LegacyEstablishedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_ProductOrServiceAxis_pfe_PristiqMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:PristiqMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:PeriLOEProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-04</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_ZoloftMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:ZoloftMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:LegacyEstablishedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InternalMedicineMember_us-gaap_ProductOrServiceAxis_pfe_LyricaMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:LyricaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-03</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FI2017Q3_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-01</instant>
        </period>
    </context>
    <context id="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_XanaxXanaxXRMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:XanaxXanaxXRMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:LegacyEstablishedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-04</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:PeriLOEProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_SterileInjectablePharmaceuticalsMember_us-gaap_ProductOrServiceAxis_pfe_PrecedexMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:PrecedexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:SterileInjectablePharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_PremarinFamilyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:PremarinFamilyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:LegacyEstablishedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-03</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_XanaxXanaxXRMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:XanaxXanaxXRMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:LegacyEstablishedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-03</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_SterileInjectablePharmaceuticalsMember_us-gaap_ProductOrServiceAxis_pfe_AllOtherSterileInjectablePharmaceuticalsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:AllOtherSterileInjectablePharmaceuticalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:SterileInjectablePharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InternalMedicineMember_us-gaap_ProductOrServiceAxis_pfe_BMP2Member_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:BMP2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-04</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InternalMedicineMember_us-gaap_ProductOrServiceAxis_pfe_AllOtherInternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:AllOtherInternalMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InternalMedicineMember_us-gaap_ProductOrServiceAxis_pfe_ViagraMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:ViagraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FI2017Q3_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OtherRestructuringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-01</instant>
        </period>
    </context>
    <context id="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_BiosimilarsMember_us-gaap_ProductOrServiceAxis_pfe_InflectraRemsimaMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:InflectraRemsimaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:BiosimilarsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-03</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_VaccinesMember_us-gaap_ProductOrServiceAxis_pfe_FSMEIMMUNTicoVacMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:FSMEIMMUNTicoVacMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:VaccinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-04</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_OncologyMember_us-gaap_ProductOrServiceAxis_pfe_OtherOncologyProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:OtherOncologyProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-04</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_EpiPenMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:EpiPenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:LegacyEstablishedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-04</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2016Q3YTD_us-gaap_ProductOrServiceAxis_pfe_ViagraMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthandEssentialHealthMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:ViagraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthandEssentialHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_OncologyMember_us-gaap_ProductOrServiceAxis_pfe_BosulifMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:BosulifMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-04</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_EpiPenMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:EpiPenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:LegacyEstablishedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_ProductOrServiceAxis_pfe_AllOtherPeriLOEProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:AllOtherPeriLOEProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:PeriLOEProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-03</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_SterileInjectablePharmaceuticalsMember_us-gaap_ProductOrServiceAxis_pfe_FragminMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:FragminMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:SterileInjectablePharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-03</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FI2016Q4_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-03</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InternalMedicineMember_us-gaap_ProductOrServiceAxis_pfe_EliquisMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:EliquisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-03</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_ConsumerHealthcareMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:ConsumerHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-03</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_ProductOrServiceAxis_pfe_CelebrexMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:CelebrexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:PeriLOEProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_OncologyMember_us-gaap_ProductOrServiceAxis_pfe_XtandiAllianceMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:XtandiAllianceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InflammationandImmunologyMember_us-gaap_ProductOrServiceAxis_pfe_EucrisaMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:EucrisaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InternalMedicineMember_us-gaap_ProductOrServiceAxis_pfe_EliquisMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:EliquisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-04</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InflammationandImmunologyMember_us-gaap_ProductOrServiceAxis_pfe_XeljanzMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:XeljanzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2017Q3QTD_us-gaap_ProductOrServiceAxis_pfe_LyricaMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthandEssentialHealthMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:LyricaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthandEssentialHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-03</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InflammationandImmunologyMember_us-gaap_ProductOrServiceAxis_pfe_EnbrelMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:EnbrelMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FI2016Q4_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OtherRestructuringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InternalMedicineMember_us-gaap_ProductOrServiceAxis_pfe_ToviazMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:ToviazMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InternalMedicineMember_us-gaap_ProductOrServiceAxis_pfe_LyricaMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:LyricaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-04</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_ProductOrServiceAxis_pfe_ViagraMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:ViagraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:PeriLOEProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_LipitorMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:LipitorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:LegacyEstablishedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_RareDiseaseMember_us-gaap_ProductOrServiceAxis_pfe_AllOtherRareDiseaseProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:AllOtherRareDiseaseProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-04</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_ZithromaxZmaxMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:ZithromaxZmaxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:LegacyEstablishedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-03</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InflammationandImmunologyMember_us-gaap_ProductOrServiceAxis_pfe_AllOtherInflammationandImmunologyProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:AllOtherInflammationandImmunologyProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-03</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_SterileInjectablePharmaceuticalsMember_us-gaap_ProductOrServiceAxis_pfe_AllOtherSterileInjectablePharmaceuticalsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:AllOtherSterileInjectablePharmaceuticalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:SterileInjectablePharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-04</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_ProductOrServiceAxis_pfe_ZyvoxMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:ZyvoxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:PeriLOEProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="I2017Q2Jun30_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_LaboratorioTeutoBrasileroMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:LaboratorioTeutoBrasileroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-06-30</instant>
        </period>
    </context>
    <context id="FI2016Q4_us-gaap_RestructuringCostAndReserveAxis_pfe_AssetImpairmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pfe:AssetImpairmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_OtherLegacyEstablishedProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:OtherLegacyEstablishedProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:LegacyEstablishedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-04</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_OncologyMember_us-gaap_ProductOrServiceAxis_pfe_OtherOncologyProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:OtherOncologyProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-03</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_BiosimilarsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:BiosimilarsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_BiosimilarsMember_us-gaap_ProductOrServiceAxis_pfe_AllOtherBiosimilarsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:AllOtherBiosimilarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:BiosimilarsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_OncologyMember_us-gaap_ProductOrServiceAxis_pfe_XtandiAllianceMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:XtandiAllianceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_RareDiseaseMember_us-gaap_ProductOrServiceAxis_pfe_AllOtherRareDiseaseProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:AllOtherRareDiseaseProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_BiosimilarsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:BiosimilarsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-04</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_NorvascMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:NorvascMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:LegacyEstablishedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-03</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_BiosimilarsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:BiosimilarsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FI2017Q3_us-gaap_RestructuringCostAndReserveAxis_pfe_AssetImpairmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pfe:AssetImpairmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-01</instant>
        </period>
    </context>
    <context id="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InternalMedicineMember_us-gaap_ProductOrServiceAxis_pfe_BMP2Member_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:BMP2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_HospiraInfusionSystemsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:HospiraInfusionSystemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_ProductOrServiceAxis_pfe_ZyvoxMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:ZyvoxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:PeriLOEProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-03</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_RareDiseaseMember_us-gaap_ProductOrServiceAxis_pfe_GenotropinMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:GenotropinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-03</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_ProductOrServiceAxis_pfe_AllOtherPeriLOEProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:AllOtherPeriLOEProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:PeriLOEProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-04</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_OtherLegacyEstablishedProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:OtherLegacyEstablishedProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:LegacyEstablishedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-03</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_SterileInjectablePharmaceuticalsMember_us-gaap_ProductOrServiceAxis_pfe_MedrolMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:MedrolMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:SterileInjectablePharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-03</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_OncologyMember_us-gaap_ProductOrServiceAxis_pfe_BosulifMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:BosulifMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-03</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-04</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_OncologyMember_us-gaap_ProductOrServiceAxis_pfe_InlytaMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:InlytaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FI2017Q3_us-gaap_RestructuringCostAndReserveAxis_pfe_ManufacturingPlantNetworkOptimizationMember_us-gaap_RestructuringPlanAxis_pfe_EnterprisewideCostReductionProductivityPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pfe:ManufacturingPlantNetworkOptimizationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pfe:EnterprisewideCostReductionProductivityPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-01</instant>
        </period>
    </context>
    <context id="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_ProductOrServiceAxis_pfe_VfendMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:VfendMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:PeriLOEProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InternalMedicineMember_us-gaap_ProductOrServiceAxis_pfe_ToviazMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:ToviazMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_SterileInjectablePharmaceuticalsMember_us-gaap_ProductOrServiceAxis_pfe_MedrolMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:MedrolMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:SterileInjectablePharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-04</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_NorvascMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:NorvascMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:LegacyEstablishedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_OncologyMember_us-gaap_ProductOrServiceAxis_pfe_SutentMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:SutentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_us-gaap_ProductOrServiceAxis_pfe_LyricaMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthandEssentialHealthMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:LyricaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthandEssentialHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_OncologyMember_us-gaap_ProductOrServiceAxis_pfe_IbranceMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:IbranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-04</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_SterileInjectablePharmaceuticalsMember_us-gaap_ProductOrServiceAxis_pfe_FragminMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:FragminMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:SterileInjectablePharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_CentreOneMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:CentreOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_VaccinesMember_us-gaap_ProductOrServiceAxis_pfe_FSMEIMMUNTicoVacMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:FSMEIMMUNTicoVacMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:VaccinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2016Q3YTD_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_us-gaap_SubsegmentsAxis_pfe_ManufacturingOperationsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">pfe:ManufacturingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-03</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_NorvascMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:NorvascMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:LegacyEstablishedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_RareDiseaseMember_us-gaap_ProductOrServiceAxis_pfe_ReFactoAfXynthaMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:ReFactoAfXynthaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2016Q3QTD_us-gaap_ProductOrServiceAxis_pfe_ViagraMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthandEssentialHealthMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:ViagraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthandEssentialHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-04</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_ProductOrServiceAxis_pfe_ViagraMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:ViagraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:PeriLOEProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-04</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_RareDiseaseMember_us-gaap_ProductOrServiceAxis_pfe_BeneFIXMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:BeneFIXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InflammationandImmunologyMember_us-gaap_ProductOrServiceAxis_pfe_EnbrelMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:EnbrelMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-04</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_ProductOrServiceAxis_pfe_ZyvoxMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:ZyvoxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:PeriLOEProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_BiosimilarsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:BiosimilarsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-03</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_us-gaap_RestructuringPlanAxis_pfe_EnterprisewideCostReductionProductivityPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pfe:EnterprisewideCostReductionProductivityPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_ConsumerHealthcareMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:ConsumerHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2016Q3QTD_us-gaap_ProductOrServiceAxis_pfe_LyricaMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthandEssentialHealthMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:LyricaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthandEssentialHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-04</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InternalMedicineMember_us-gaap_ProductOrServiceAxis_pfe_AllOtherInternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:AllOtherInternalMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-04</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InternalMedicineMember_us-gaap_ProductOrServiceAxis_pfe_ViagraMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:ViagraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:VaccinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2017Q3QTD_us-gaap_ProductOrServiceAxis_pfe_AllianceBiopharmaceuticalsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthandEssentialHealthMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:AllianceBiopharmaceuticalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthandEssentialHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-03</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_ProductOrServiceAxis_pfe_PristiqMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:PristiqMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:PeriLOEProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:PeriLOEProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-04</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_RareDiseaseMember_us-gaap_ProductOrServiceAxis_pfe_GenotropinMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:GenotropinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InflammationandImmunologyMember_us-gaap_ProductOrServiceAxis_pfe_EucrisaMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:EucrisaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-03</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_OncologyMember_us-gaap_ProductOrServiceAxis_pfe_SutentMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:SutentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_XanaxXanaxXRMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:XanaxXanaxXRMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:LegacyEstablishedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_ProductOrServiceAxis_pfe_LyricaMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:LyricaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:PeriLOEProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-03</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_ProductOrServiceAxis_pfe_AllOtherPeriLOEProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:AllOtherPeriLOEProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:PeriLOEProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_SterileInjectablePharmaceuticalsMember_us-gaap_ProductOrServiceAxis_pfe_PrecedexMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:PrecedexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:SterileInjectablePharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthandEssentialHealthMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthandEssentialHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InternalMedicineMember_us-gaap_ProductOrServiceAxis_pfe_LyricaMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:LyricaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InternalMedicineMember_us-gaap_ProductOrServiceAxis_pfe_ToviazMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:ToviazMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-03</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_VaccinesMember_us-gaap_ProductOrServiceAxis_pfe_OtherVaccinesProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:OtherVaccinesProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:VaccinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2016Q3QTD_us-gaap_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-04</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_ProductOrServiceAxis_pfe_RevatioMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:RevatioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:PeriLOEProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_RareDiseaseMember_us-gaap_ProductOrServiceAxis_pfe_GenotropinMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:GenotropinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_OncologyMember_us-gaap_ProductOrServiceAxis_pfe_XalkoriMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:XalkoriMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_XalatanXalacomMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:XalatanXalacomMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:LegacyEstablishedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-04</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_ZoloftMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:ZoloftMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:LegacyEstablishedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_SterileInjectablePharmaceuticalsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:SterileInjectablePharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-03</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_BiosimilarsMember_us-gaap_ProductOrServiceAxis_pfe_AllOtherBiosimilarsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:AllOtherBiosimilarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:BiosimilarsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-03</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_EpiPenMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:EpiPenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:LegacyEstablishedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-03</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_SterileInjectablePharmaceuticalsMember_us-gaap_ProductOrServiceAxis_pfe_FragminMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:FragminMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:SterileInjectablePharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-04</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_RelpaxMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:RelpaxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:LegacyEstablishedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2017Q3QTD_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-03</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InflammationandImmunologyMember_us-gaap_ProductOrServiceAxis_pfe_AllOtherInflammationandImmunologyProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:AllOtherInflammationandImmunologyProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-04</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InternalMedicineMember_us-gaap_ProductOrServiceAxis_pfe_EliquisMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:EliquisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_ProductOrServiceAxis_pfe_VfendMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:VfendMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:PeriLOEProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-04</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_RelpaxMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:RelpaxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:LegacyEstablishedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-04</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_RareDiseaseMember_us-gaap_ProductOrServiceAxis_pfe_ReFactoAfXynthaMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:ReFactoAfXynthaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-04</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_RareDiseaseMember_us-gaap_ProductOrServiceAxis_pfe_ReFactoAfXynthaMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:ReFactoAfXynthaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_OncologyMember_us-gaap_ProductOrServiceAxis_pfe_XtandiAllianceMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:XtandiAllianceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-04</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_OncologyMember_us-gaap_ProductOrServiceAxis_pfe_SutentMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:SutentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-03</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_ProductOrServiceAxis_pfe_RevatioMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:RevatioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:PeriLOEProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_OncologyMember_us-gaap_ProductOrServiceAxis_pfe_SutentMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:SutentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-04</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FI2017Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-01</instant>
        </period>
    </context>
    <context id="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InflammationandImmunologyMember_us-gaap_ProductOrServiceAxis_pfe_AllOtherInflammationandImmunologyProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:AllOtherInflammationandImmunologyProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InflammationandImmunologyMember_us-gaap_ProductOrServiceAxis_pfe_EucrisaMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:EucrisaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-04</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_OncologyMember_us-gaap_ProductOrServiceAxis_pfe_XalkoriMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:XalkoriMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-04</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-03</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_PremarinFamilyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:PremarinFamilyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:LegacyEstablishedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InflammationandImmunologyMember_us-gaap_ProductOrServiceAxis_pfe_EnbrelMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:EnbrelMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_us-gaap_ProductOrServiceAxis_pfe_AllianceBiopharmaceuticalsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthandEssentialHealthMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:AllianceBiopharmaceuticalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthandEssentialHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_VaccinesMember_us-gaap_ProductOrServiceAxis_pfe_OtherVaccinesProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:OtherVaccinesProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:VaccinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-04</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_SterileInjectablePharmaceuticalsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:SterileInjectablePharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-04</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_SterileInjectablePharmaceuticalsMember_us-gaap_ProductOrServiceAxis_pfe_FragminMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:FragminMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:SterileInjectablePharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2016Q3YTD_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_us-gaap_SubsegmentsAxis_pfe_WorldwideResearchandDevelopmentandGlobalProductDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">pfe:WorldwideResearchandDevelopmentandGlobalProductDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_HospiraInfusionSystemsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:HospiraInfusionSystemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-04</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_ZithromaxZmaxMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:ZithromaxZmaxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:LegacyEstablishedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-04</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_SterileInjectablePharmaceuticalsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:SterileInjectablePharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_BiosimilarsMember_us-gaap_ProductOrServiceAxis_pfe_AllOtherBiosimilarsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:AllOtherBiosimilarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:BiosimilarsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InflammationandImmunologyMember_us-gaap_ProductOrServiceAxis_pfe_XeljanzMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:XeljanzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-03</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_RareDiseaseMember_us-gaap_ProductOrServiceAxis_pfe_BeneFIXMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:BeneFIXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-04</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_ProductOrServiceAxis_pfe_LyricaMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:LyricaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:PeriLOEProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-04</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InternalMedicineMember_us-gaap_ProductOrServiceAxis_pfe_ChantixChampixMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:ChantixChampixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-03</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_RelpaxMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:RelpaxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:LegacyEstablishedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FI2016Q4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="FD2017Q3YTD_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_us-gaap_SubsegmentsAxis_pfe_ManufacturingOperationsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">pfe:ManufacturingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_BiosimilarsMember_us-gaap_ProductOrServiceAxis_pfe_AllOtherBiosimilarsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:AllOtherBiosimilarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:BiosimilarsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-04</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_OncologyMember_us-gaap_ProductOrServiceAxis_pfe_BosulifMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:BosulifMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_VaccinesMember_us-gaap_ProductOrServiceAxis_pfe_OtherVaccinesProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:OtherVaccinesProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:VaccinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:PeriLOEProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-03</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_VaccinesMember_us-gaap_ProductOrServiceAxis_pfe_PrevnarPrevenarFamilyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:PrevnarPrevenarFamilyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:VaccinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-04</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:LegacyEstablishedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_RareDiseaseMember_us-gaap_ProductOrServiceAxis_pfe_SomavertMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:SomavertMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_ProductOrServiceAxis_pfe_LyricaMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:LyricaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:PeriLOEProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-03</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2016Q3YTD_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthandEssentialHealthMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthandEssentialHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_us-gaap_SubsegmentsAxis_pfe_WorldwideResearchandDevelopmentandGlobalProductDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">pfe:WorldwideResearchandDevelopmentandGlobalProductDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2016Q3QTD_us-gaap_ProductOrServiceAxis_pfe_AllianceBiopharmaceuticalsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthandEssentialHealthMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:AllianceBiopharmaceuticalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthandEssentialHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-04</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_ZithromaxZmaxMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:ZithromaxZmaxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:LegacyEstablishedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_OncologyMember_us-gaap_ProductOrServiceAxis_pfe_IbranceMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:IbranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_XalatanXalacomMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:XalatanXalacomMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:LegacyEstablishedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-03</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_SterileInjectablePharmaceuticalsMember_us-gaap_ProductOrServiceAxis_pfe_SulperazonMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:SulperazonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:SterileInjectablePharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_ZoloftMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:ZoloftMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:LegacyEstablishedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-03</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_OncologyMember_us-gaap_ProductOrServiceAxis_pfe_IbranceMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:IbranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InternalMedicineMember_us-gaap_ProductOrServiceAxis_pfe_AllOtherInternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:AllOtherInternalMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_EffexorMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:EffexorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:LegacyEstablishedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2017Q3QTD_us-gaap_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-03</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_OncologyMember_us-gaap_ProductOrServiceAxis_pfe_XalkoriMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:XalkoriMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_ProductOrServiceAxis_pfe_RevatioMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:RevatioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:PeriLOEProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-04</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_SterileInjectablePharmaceuticalsMember_us-gaap_ProductOrServiceAxis_pfe_MedrolMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:MedrolMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:SterileInjectablePharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_RareDiseaseMember_us-gaap_ProductOrServiceAxis_pfe_SomavertMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:SomavertMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-04</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_ProductOrServiceAxis_pfe_CelebrexMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:CelebrexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:PeriLOEProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-04</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InternalMedicineMember_us-gaap_ProductOrServiceAxis_pfe_ViagraMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:ViagraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-04</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_OncologyMember_us-gaap_ProductOrServiceAxis_pfe_InlytaMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:InlytaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_SterileInjectablePharmaceuticalsMember_us-gaap_ProductOrServiceAxis_pfe_MedrolMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:MedrolMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:SterileInjectablePharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_RareDiseaseMember_us-gaap_ProductOrServiceAxis_pfe_GenotropinMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:GenotropinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-04</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-03</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_us-gaap_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_OncologyMember_us-gaap_ProductOrServiceAxis_pfe_InlytaMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:InlytaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-03</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InternalMedicineMember_us-gaap_ProductOrServiceAxis_pfe_AllOtherInternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:AllOtherInternalMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-03</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_XalatanXalacomMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:XalatanXalacomMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:LegacyEstablishedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_OncologyMember_us-gaap_ProductOrServiceAxis_pfe_InlytaMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:InlytaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-04</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InternalMedicineMember_us-gaap_ProductOrServiceAxis_pfe_BMP2Member_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:BMP2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_ProductOrServiceAxis_pfe_PristiqMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:PristiqMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:PeriLOEProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-03</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_BiosimilarsMember_us-gaap_ProductOrServiceAxis_pfe_InflectraRemsimaMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:InflectraRemsimaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:BiosimilarsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_us-gaap_ProductOrServiceAxis_pfe_ViagraMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthandEssentialHealthMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:ViagraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthandEssentialHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_ProductOrServiceAxis_pfe_CelebrexMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:CelebrexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:PeriLOEProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_VaccinesMember_us-gaap_ProductOrServiceAxis_pfe_PrevnarPrevenarFamilyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:PrevnarPrevenarFamilyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:VaccinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-03</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_ProductOrServiceAxis_pfe_ZyvoxMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:ZyvoxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:PeriLOEProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-04</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InflammationandImmunologyMember_us-gaap_ProductOrServiceAxis_pfe_EucrisaMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:EucrisaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_NorvascMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:NorvascMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:LegacyEstablishedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-04</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_OncologyMember_us-gaap_ProductOrServiceAxis_pfe_XalkoriMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:XalkoriMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-03</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_SterileInjectablePharmaceuticalsMember_us-gaap_ProductOrServiceAxis_pfe_SulperazonMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:SulperazonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:SterileInjectablePharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-03</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_VaccinesMember_us-gaap_ProductOrServiceAxis_pfe_FSMEIMMUNTicoVacMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:FSMEIMMUNTicoVacMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:VaccinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-03</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_ConsumerHealthcareMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:ConsumerHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_RareDiseaseMember_us-gaap_ProductOrServiceAxis_pfe_SomavertMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:SomavertMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-03</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InternalMedicineMember_us-gaap_ProductOrServiceAxis_pfe_BMP2Member_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:BMP2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-03</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FI2017Q3_us-gaap_RestructuringCostAndReserveAxis_pfe_CentralizationofCorporateandPlatformFunctionsMember_us-gaap_RestructuringPlanAxis_pfe_EnterprisewideCostReductionProductivityPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pfe:CentralizationofCorporateandPlatformFunctionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pfe:EnterprisewideCostReductionProductivityPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-01</instant>
        </period>
    </context>
    <context id="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_RareDiseaseMember_us-gaap_ProductOrServiceAxis_pfe_AllOtherRareDiseaseProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:AllOtherRareDiseaseProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_VaccinesMember_us-gaap_ProductOrServiceAxis_pfe_PrevnarPrevenarFamilyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:PrevnarPrevenarFamilyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:VaccinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_ProductOrServiceAxis_pfe_ViagraMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:ViagraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:PeriLOEProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_ProductOrServiceAxis_pfe_PristiqMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:PristiqMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:PeriLOEProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_RelpaxMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:RelpaxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:LegacyEstablishedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-03</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_ProductOrServiceAxis_pfe_RevatioMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:RevatioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:PeriLOEProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-03</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_SterileInjectablePharmaceuticalsMember_us-gaap_ProductOrServiceAxis_pfe_TygacilMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:TygacilMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:SterileInjectablePharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:LegacyEstablishedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-04</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2016Q3YTD_us-gaap_ProductOrServiceAxis_pfe_LyricaMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthandEssentialHealthMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:LyricaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthandEssentialHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FI2017Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-01</instant>
        </period>
    </context>
    <context id="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InternalMedicineMember_us-gaap_ProductOrServiceAxis_pfe_LyricaMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:LyricaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InternalMedicineMember_us-gaap_ProductOrServiceAxis_pfe_EliquisMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:EliquisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_CentreOneMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:CentreOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-03</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InternalMedicineMember_us-gaap_ProductOrServiceAxis_pfe_ChantixChampixMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:ChantixChampixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-04</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_OtherLegacyEstablishedProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:OtherLegacyEstablishedProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:LegacyEstablishedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_XanaxXanaxXRMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:XanaxXanaxXRMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:LegacyEstablishedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2017Q3QTD_us-gaap_ProductOrServiceAxis_pfe_ViagraMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthandEssentialHealthMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:ViagraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthandEssentialHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-03</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-03</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:VaccinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-04</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_XalatanXalacomMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:XalatanXalacomMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:LegacyEstablishedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2017Q3QTD_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-03</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_RareDiseaseMember_us-gaap_ProductOrServiceAxis_pfe_BeneFIXMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:BeneFIXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_ZithromaxZmaxMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:ZithromaxZmaxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:LegacyEstablishedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-04</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_RareDiseaseMember_us-gaap_ProductOrServiceAxis_pfe_ReFactoAfXynthaMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:ReFactoAfXynthaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:InnovativeHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:InnovativeProductsCategoryAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-03</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_ProductOrServiceAxis_pfe_LyricaMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:LyricaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:PeriLOEProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_SterileInjectablePharmaceuticalsMember_us-gaap_ProductOrServiceAxis_pfe_TygacilMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:TygacilMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:SterileInjectablePharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_LipitorMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:LipitorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:LegacyEstablishedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_EffexorMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">pfe:EffexorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:DistinctBusinessAxis">pfe:EssentialHealthBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:EssentialHealthProductCategoryAxis">pfe:LegacyEstablishedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-04</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_us-gaap_StatementGeographicalAxis_pfe_DevelopedEuropeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">pfe:DevelopedEuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_us-gaap_StatementGeographicalAxis_pfe_EmergingMarketsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">pfe:EmergingMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_us-gaap_BusinessAcquisitionAxis_pfe_HospiraMember_us-gaap_RestructuringCostAndReserveAxis_pfe_BusinessIntegrationCostsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:HospiraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pfe:BusinessIntegrationCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2017Q3QTD_us-gaap_StatementGeographicalAxis_pfe_DevelopedEuropeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">pfe:DevelopedEuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-03</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2017Q3QTD_us-gaap_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-03</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_us-gaap_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2017Q3QTD_us-gaap_StatementGeographicalAxis_pfe_EmergingMarketsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">pfe:EmergingMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-03</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2016Q3QTD_us-gaap_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-04</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2016Q3YTD_us-gaap_StatementGeographicalAxis_pfe_DevelopedRestOfWorldMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">pfe:DevelopedRestOfWorldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2017Q3QTD_us-gaap_StatementGeographicalAxis_pfe_DevelopedRestOfWorldMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">pfe:DevelopedRestOfWorldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-03</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2016Q3YTD_us-gaap_StatementGeographicalAxis_pfe_DevelopedEuropeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">pfe:DevelopedEuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_us-gaap_StatementGeographicalAxis_pfe_DevelopedRestOfWorldMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">pfe:DevelopedRestOfWorldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2016Q3QTD_us-gaap_StatementGeographicalAxis_pfe_DevelopedEuropeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">pfe:DevelopedEuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-04</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="FD2016Q3QTD_us-gaap_StatementGeographicalAxis_pfe_EmergingMarketsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">pfe:EmergingMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-04</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2016Q3YTD_us-gaap_StatementGeographicalAxis_pfe_EmergingMarketsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">pfe:EmergingMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2016Q3QTD_us-gaap_StatementGeographicalAxis_pfe_DevelopedRestOfWorldMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">pfe:DevelopedRestOfWorldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-04</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2016Q3YTD_us-gaap_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2016Q3QTD_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioAdjustmentMember_us-gaap_SubsegmentsAxis_pfe_PfizersWorldwideResearchandDevelopmentandPfizersGlobalProductDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">pfe:PfizersWorldwideResearchandDevelopmentandPfizersGlobalProductDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-04</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2016Q3QTD_us-gaap_CurrencyAxis_currency_EUR_us-gaap_StatementGeographicalAxis_pfe_DevelopedEuropeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">pfe:DevelopedEuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-04</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2016Q3YTD_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioAdjustmentMember_us-gaap_SubsegmentsAxis_pfe_PfizersWorldwideResearchandDevelopmentandPfizersGlobalProductDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">pfe:PfizersWorldwideResearchandDevelopmentandPfizersGlobalProductDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FI2017Q3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
        </entity>
        <period>
            <instant>2017-10-01</instant>
        </period>
    </context>
    <context id="FD2016Q3YTD_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FI2017Q3_us-gaap_RestructuringPlanAxis_pfe_EnterprisewideCostReductionProductivityPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pfe:EnterprisewideCostReductionProductivityPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-01</instant>
        </period>
    </context>
    <context id="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="FD2016Q3QTD_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_us-gaap_SubsegmentsAxis_pfe_WorldwideResearchandDevelopmentandGlobalProductDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">pfe:WorldwideResearchandDevelopmentandGlobalProductDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-04</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2017Q3QTD_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_us-gaap_SubsegmentsAxis_pfe_WorldwideResearchandDevelopmentandGlobalProductDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">pfe:WorldwideResearchandDevelopmentandGlobalProductDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-03</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_us-gaap_RestructuringCostAndReserveAxis_pfe_BusinessIntegrationCostsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pfe:BusinessIntegrationCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2016Q3QTD_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-04</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2016Q3YTD_us-gaap_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2016Q3QTD_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_us-gaap_SubsegmentsAxis_pfe_ManufacturingOperationsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">pfe:ManufacturingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-04</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2016Q3YTD_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:InnovativeHealthSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="I2017Q1Feb03_us-gaap_CounterpartyNameAxis_pfe_ICUMedicalMember_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_HISMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">pfe:ICUMedicalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pfe:HISMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-02-03</instant>
        </period>
    </context>
    <context id="FD2017Q3QTD_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_us-gaap_SubsegmentsAxis_pfe_ManufacturingOperationsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">pfe:ManufacturingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-03</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="D2018Q3Sept20152018_us-gaap_BusinessAcquisitionAxis_pfe_HospiraMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioForecastMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:HospiraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-09-03</startDate>
            <endDate>2018-09-03</endDate>
        </period>
    </context>
    <context id="FD2015Q4YTD_us-gaap_BusinessAcquisitionAxis_pfe_HospiraMember_us-gaap_RestructuringCostAndReserveAxis_pfe_ReturnofAcquiredRightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:HospiraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pfe:ReturnofAcquiredRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-01-01</startDate>
            <endDate>2015-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_us-gaap_BusinessAcquisitionAxis_pfe_HospiraMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:HospiraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2016Q3QTD_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:EssentialHealthSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-04</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2017Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-03</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2016Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-10-02</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="Operating_Segment">
        <measure>pfe:Operating_Segment</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="gbp">
        <measure>iso4217:GBP</measure>
    </unit>
    <unit id="Claim">
        <measure>pfe:Claim</measure>
    </unit>
    <unit id="lagoon">
        <measure>pfe:lagoon</measure>
    </unit>
    <unit id="Patent">
        <measure>pfe:Patents</measure>
    </unit>
    <unit id="Defendant">
        <measure>pfe:Defendant</measure>
    </unit>
    <unit id="iso4217_EUR">
        <measure>iso4217:EUR</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="FD2017Q3YTD"
      id="Fact-83D2860B497A5064A93AF07613474681-wk-Fact-83D2860B497A5064A93AF07613474681">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate
      contextRef="FD2017Q3YTD"
      id="Fact-091B6CEC43AC5F9B80D6BC4FEA2FAE5A-wk-Fact-091B6CEC43AC5F9B80D6BC4FEA2FAE5A">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalPeriodFocus
      contextRef="FD2017Q3YTD"
      id="Fact-F86CC2693C62557FBB4A21129802B162-wk-Fact-F86CC2693C62557FBB4A21129802B162">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus
      contextRef="FD2017Q3YTD"
      id="Fact-51AC809EDC6C5251A846176ECEF9E7E0-wk-Fact-51AC809EDC6C5251A846176ECEF9E7E0">2017</dei:DocumentFiscalYearFocus>
    <dei:DocumentPeriodEndDate
      contextRef="FD2017Q3YTD"
      id="Fact-E2444EC6498C5C90B4F6554272005CF7-wk-Fact-E2444EC6498C5C90B4F6554272005CF7">2017-10-01</dei:DocumentPeriodEndDate>
    <dei:EntityCentralIndexKey
      contextRef="FD2017Q3YTD"
      id="Fact-E26EE28CF2DB5C69AE66219664B5B8C7-wk-Fact-E26EE28CF2DB5C69AE66219664B5B8C7">0000078003</dei:EntityCentralIndexKey>
    <dei:EntityFilerCategory
      contextRef="FD2017Q3YTD"
      id="Fact-C4AF45A25BBA52C59CEA3C4FAEF95682-wk-Fact-C4AF45A25BBA52C59CEA3C4FAEF95682">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:TradingSymbol
      contextRef="FD2017Q3YTD"
      id="Fact-0D91055AAE495497A9207FE0E0A52D11-wk-Fact-0D91055AAE495497A9207FE0E0A52D11">PFE</dei:TradingSymbol>
    <pfe:AdministrativeServicePeriod
      contextRef="D2017Q1Feb03-Feb03_us-gaap_CounterpartyNameAxis_pfe_ICUMedicalMember_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_HISMember"
      id="Fact-95BD962ED6C754738A80F9397E3EBC26-wk-Fact-95BD962ED6C754738A80F9397E3EBC26">P24M</pfe:AdministrativeServicePeriod>
    <pfe:BusinessCombinationConsiderationTransferredUndiscountedRoyaltyPaymentsTerm
      contextRef="D2016Q4Dec22-Dec22_us-gaap_BusinessAcquisitionAxis_pfe_AstraZenecaMember"
      id="Fact-FFDCE598E8D55CB289ADEDDF07649B0C-wk-Fact-FFDCE598E8D55CB289ADEDDF07649B0C">P10Y</pfe:BusinessCombinationConsiderationTransferredUndiscountedRoyaltyPaymentsTerm>
    <pfe:BusinessCombinationExpectedIntegrationRelatedCostsPeriod
      contextRef="D2015Q3Sept3_us-gaap_BusinessAcquisitionAxis_pfe_HospiraMember"
      id="Fact-678327A4807F5E5B81DC971F6764C18E-wk-Fact-678327A4807F5E5B81DC971F6764C18E">P3Y</pfe:BusinessCombinationExpectedIntegrationRelatedCostsPeriod>
    <pfe:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIncreaseDecreaseinAmortizationofIntangibleAssets
      contextRef="FD2017Q3YTD_us-gaap_BusinessAcquisitionAxis_pfe_MedivationMember"
      decimals="-6"
      id="Fact-108ACE1BE67CD8CA124091F7C5BD2275-wk-Fact-108ACE1BE67CD8CA124091F7C5BD2275"
      unitRef="usd">-38000000</pfe:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIncreaseDecreaseinAmortizationofIntangibleAssets>
    <pfe:DebtInstrumentFloorInterestRate
      contextRef="FD2017Q3YTD_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredEuroDebtThreemonthEURIBORPlus0.20FloatingRateNotesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember_us-gaap_VariableRateAxis_pfe_EURIBORMember"
      decimals="INF"
      id="Fact-3CE8DD804B5255D8AD16D7F8D587D468-wk-Fact-3CE8DD804B5255D8AD16D7F8D587D468"
      unitRef="number">0</pfe:DebtInstrumentFloorInterestRate>
    <pfe:DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivableInterestRateYearThree
      contextRef="D2017Q1Feb03-Feb03_us-gaap_CounterpartyNameAxis_pfe_ICUMedicalMember_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_HISMember_us-gaap_VariableRateAxis_us-gaap_LondonInterbankOfferedRateLIBORMember"
      decimals="INF"
      id="Fact-B9BA37C4F97E50B4801E35D36C0350DA-wk-Fact-B9BA37C4F97E50B4801E35D36C0350DA"
      unitRef="number">0.025</pfe:DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivableInterestRateYearThree>
    <pfe:DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivableTerm
      contextRef="D2017Q1Feb03-Feb03_us-gaap_CounterpartyNameAxis_pfe_ICUMedicalMember_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_HISMember"
      id="Fact-9AA5438967D25A2FB18E43A9C6412819-wk-Fact-9AA5438967D25A2FB18E43A9C6412819">P3Y</pfe:DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivableTerm>
    <pfe:DisposalGroupIncludingDiscontinuedOperationShareTransferRestrictionTermMinimum
      contextRef="D2017Q1Feb03-Feb03_us-gaap_CounterpartyNameAxis_pfe_ICUMedicalMember_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_HISMember"
      id="Fact-83730CB88A1A580482A4329996C1C777-wk-Fact-83730CB88A1A580482A4329996C1C777">P18M</pfe:DisposalGroupIncludingDiscontinuedOperationShareTransferRestrictionTermMinimum>
    <pfe:IntangibleAssetsTransfersDuringPeriod
      contextRef="FI2017Q3_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_ProductOrServiceAxis_pfe_EucrisaMember"
      decimals="-8"
      id="Fact-1886FA38E19059AEB70E4C4D4D1E7C55-wk-Fact-1886FA38E19059AEB70E4C4D4D1E7C55"
      unitRef="usd">4800000000</pfe:IntangibleAssetsTransfersDuringPeriod>
    <pfe:MaximumManufacturingServicePeriod
      contextRef="D2017Q1Feb03-Feb03_us-gaap_CounterpartyNameAxis_pfe_ICUMedicalMember_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_HISMember"
      id="Fact-4488229945EF520D93DACCB283FA6143-wk-Fact-4488229945EF520D93DACCB283FA6143">P5Y</pfe:MaximumManufacturingServicePeriod>
    <pfe:OtherNonoperatingIncomeMiscellaneous
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="Fact-2DCBC353F98C1E49878F91FA7CB70CBC-wk-Fact-2DCBC353F98C1E49878F91FA7CB70CBC"
      unitRef="usd">62000000</pfe:OtherNonoperatingIncomeMiscellaneous>
    <pfe:ResearchandDevelopmentArrangementAggregatePaymentObligationTerm
      contextRef="D2017Q2Jun01-Jun30_us-gaap_ProductOrServiceAxis_pfe_BesponsaMember_us-gaap_StatementGeographicalAxis_us-gaap_EuropeanUnionMember"
      id="Fact-5AEB656A82955D31BB52F6AA233ABF00-wk-Fact-5AEB656A82955D31BB52F6AA233ABF00">P9Y</pfe:ResearchandDevelopmentArrangementAggregatePaymentObligationTerm>
    <pfe:ResearchandDevelopmentArrangementAggregatePaymentObligationTerm
      contextRef="D2017Q3Aug01-Aug31_us-gaap_ProductOrServiceAxis_pfe_BesponsaMember_us-gaap_StatementGeographicalAxis_country_US"
      id="Fact-CBCCCCDA49BA0FF2BD5578ECBDA59B31-wk-Fact-CBCCCCDA49BA0FF2BD5578ECBDA59B31">P9Y</pfe:ResearchandDevelopmentArrangementAggregatePaymentObligationTerm>
    <pfe:ResearchandDevelopmentArrangementAggregatePaymentObligationTerm
      contextRef="FD2017Q3YTD_us-gaap_ProductOrServiceAxis_pfe_MylotargMember_us-gaap_StatementScenarioAxis_us-gaap_ProFormaMember"
      id="Fact-157F827A2F6F6FB739A7921C1F74E307-wk-Fact-157F827A2F6F6FB739A7921C1F74E307">P10Y</pfe:ResearchandDevelopmentArrangementAggregatePaymentObligationTerm>
    <pfe:RoyaltyRevenueTerm
      contextRef="FD2017Q3YTD_us-gaap_ProductOrServiceAxis_pfe_EnbrelMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementCopromotionMember"
      id="Fact-26CAFC13D0405FFA992D15D4B236379C-wk-Fact-26CAFC13D0405FFA992D15D4B236379C">P36M</pfe:RoyaltyRevenueTerm>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="FI2016Q4"
      decimals="-6"
      id="Fact-E880E7106AA35CF2A064350EE9638A88-wk-Fact-E880E7106AA35CF2A064350EE9638A88"
      unitRef="usd">14807000000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="FI2017Q3"
      decimals="-6"
      id="Fact-F26558A44B7C5E24A9D0B3C320ABC3AC-wk-Fact-F26558A44B7C5E24A9D0B3C320ABC3AC"
      unitRef="usd">15906000000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="D2016Q3Sep28-Sep28_us-gaap_BusinessAcquisitionAxis_pfe_MedivationMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember"
      id="Fact-985CE3B601BD5CEB82036E285D8B99EA-wk-Fact-985CE3B601BD5CEB82036E285D8B99EA">P12Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="FI2016Q4"
      decimals="-6"
      id="Fact-88DE6FFC0A6C582BA8AE3854966F0852-wk-Fact-88DE6FFC0A6C582BA8AE3854966F0852"
      unitRef="usd">609000000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="FI2017Q3"
      decimals="-6"
      id="Fact-B85FE09635045F46B656606350B6714A-wk-Fact-B85FE09635045F46B656606350B6714A"
      unitRef="usd">590000000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:Assets
      contextRef="FI2016Q4"
      decimals="-9"
      id="Fact-4CB7130CEF915377BE0293C8FB86F1C5-wk-Fact-4CB7130CEF915377BE0293C8FB86F1C5"
      unitRef="usd">172000000000</us-gaap:Assets>
    <us-gaap:CostsAndExpenses
      contextRef="FD2016Q3QTD_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioAdjustmentMember_us-gaap_SubsegmentsAxis_pfe_PfizersWorldwideResearchandDevelopmentandPfizersGlobalProductDevelopmentMember"
      decimals="-6"
      id="Fact-69DA9C8DB01F29E760CF0D1D589D302E-wk-Fact-69DA9C8DB01F29E760CF0D1D589D302E"
      unitRef="usd">-33000000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="FD2016Q3YTD_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioAdjustmentMember_us-gaap_SubsegmentsAxis_pfe_PfizersWorldwideResearchandDevelopmentandPfizersGlobalProductDevelopmentMember"
      decimals="-6"
      id="Fact-17FB254DDBD7EBF0A4640D1CF0DFDF3C-wk-Fact-17FB254DDBD7EBF0A4640D1CF0DFDF3C"
      unitRef="usd">-94000000</us-gaap:CostsAndExpenses>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="FD2017Q3YTD_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredEuroDebtThreemonthEURIBORPlus0.20FloatingRateNotesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember_us-gaap_VariableRateAxis_pfe_EURIBORMember"
      decimals="INF"
      id="Fact-01BF741FB2755E73A886A5BE68BB5FC7-wk-Fact-01BF741FB2755E73A886A5BE68BB5FC7"
      unitRef="number">0.002</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="FI2017Q3_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtFourPointTwoPercentDue2047Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember"
      decimals="INF"
      id="Fact-6E82CA370AD05B74A8C040983981E3A5-wk-Fact-6E82CA370AD05B74A8C040983981E3A5"
      unitRef="number">0.042</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="FI2017Q3_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredEuroDebtOnePointZeroPercentDue2027Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember"
      decimals="INF"
      id="Fact-4451245F3A7F55148F3A9CF8EE4B2EA3-wk-Fact-4451245F3A7F55148F3A9CF8EE4B2EA3"
      unitRef="number">0.01</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="FI2017Q3_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredEuroDebtPointTwofivePercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember"
      decimals="INF"
      id="Fact-F07F689C9F345FB594015AD41DD952BD-wk-Fact-F07F689C9F345FB594015AD41DD952BD"
      unitRef="number">0.0025</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="FI2017Q3_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredEuroDebtZeroPercentDue2020Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember"
      decimals="INF"
      id="Fact-F8DC0CB6636E5AF6A5F71C82B82ABD2C-wk-Fact-F8DC0CB6636E5AF6A5F71C82B82ABD2C"
      unitRef="number">0</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:GainLossOnCashFlowHedgeIneffectivenessNet
      contextRef="FD2016Q3QTD"
      decimals="-6"
      id="Fact-C7C39FB31383575CB4CACADB51F1154E-wk-Fact-C7C39FB31383575CB4CACADB51F1154E"
      unitRef="usd">0</us-gaap:GainLossOnCashFlowHedgeIneffectivenessNet>
    <us-gaap:GainLossOnCashFlowHedgeIneffectivenessNet
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="Fact-6DC28BDC30C1507C83C9B34C55EA3419-wk-Fact-6DC28BDC30C1507C83C9B34C55EA3419"
      unitRef="usd">0</us-gaap:GainLossOnCashFlowHedgeIneffectivenessNet>
    <us-gaap:GainLossOnCashFlowHedgeIneffectivenessNet
      contextRef="FD2017Q3QTD"
      decimals="-6"
      id="Fact-9851E4D7078E5D07BA0939E6014D8042-wk-Fact-9851E4D7078E5D07BA0939E6014D8042"
      unitRef="usd">0</us-gaap:GainLossOnCashFlowHedgeIneffectivenessNet>
    <us-gaap:GainLossOnCashFlowHedgeIneffectivenessNet
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="Fact-6021DC299F0A510793175260F54CDDC3-wk-Fact-6021DC299F0A510793175260F54CDDC3"
      unitRef="usd">0</us-gaap:GainLossOnCashFlowHedgeIneffectivenessNet>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="FD2017Q3QTD_us-gaap_BusinessAcquisitionAxis_pfe_HospiraMember_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="Fact-4E5DABE54DEE36D9155191CB96BF29E6-wk-Fact-4E5DABE54DEE36D9155191CB96BF29E6"
      unitRef="usd">127000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:LitigationSettlementExpense
      contextRef="FD2017Q3YTD_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_LossContingenciesByNatureOfContingencyAxis_pfe_PatentMatterMember"
      decimals="-6"
      id="Fact-036EF4E92BD4F27B29AF91FD15932060-wk-Fact-036EF4E92BD4F27B29AF91FD15932060"
      unitRef="usd">79000000</us-gaap:LitigationSettlementExpense>
    <us-gaap:LitigationSettlementExpense
      contextRef="FD2017Q3YTD_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_ProductOrServiceAxis_pfe_CelebrexMember"
      decimals="-6"
      id="Fact-F4277608FF9F588BA3D091FCB8132DA4-wk-Fact-F4277608FF9F588BA3D091FCB8132DA4"
      unitRef="usd">94000000</us-gaap:LitigationSettlementExpense>
    <us-gaap:LongTermDebtCurrent
      contextRef="FI2016Q4"
      decimals="-6"
      id="Fact-4C5952B687735A68B4F8FF2FF8E28F5B-wk-Fact-4C5952B687735A68B4F8FF2FF8E28F5B"
      unitRef="usd">4225000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="FI2017Q3"
      decimals="-6"
      id="Fact-438EE85774DF543BA158096F9559C174-wk-Fact-438EE85774DF543BA158096F9559C174"
      unitRef="usd">3072000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="FD2016Q3YTD_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_pfe_AccountingStandardsUpdate201609StatutoryTaxWithholdingComponentMember"
      decimals="-6"
      id="Fact-01726B7A2C705A62882A466A815D605B-wk-Fact-01726B7A2C705A62882A466A815D605B"
      unitRef="usd">-87000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3QTD_us-gaap_CurrencyAxis_currency_EUR_us-gaap_StatementGeographicalAxis_pfe_DevelopedEuropeMember"
      decimals="-8"
      id="Fact-62FD8B6CE5625EEAA34044C5ED64A925-wk-Fact-62FD8B6CE5625EEAA34044C5ED64A925"
      unitRef="usd">1700000000</us-gaap:SalesRevenueGoodsNet>
    <dei:DocumentType
      contextRef="FD2017Q3YTD"
      id="d43681101e634-wk-Fact-6A04E86595C5527C8B9067516347E6DE">10-Q</dei:DocumentType>
    <dei:EntityRegistrantName
      contextRef="FD2017Q3YTD"
      id="d43681101e690-wk-Fact-539A3BE729915709A0D0D8552C5387E9">PFIZER INC</dei:EntityRegistrantName>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="I2017Q4Nov06"
      decimals="INF"
      id="d43681101e861-wk-Fact-F8AEF1028ECC5329874FFD2B3F3B9399"
      unitRef="shares">5960707317</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3QTD"
      decimals="-6"
      id="d43687704e843-wk-Fact-739EC43DD13B5516B11DE41A93EEDF71"
      unitRef="usd">13168000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3QTD"
      decimals="-6"
      id="d43687704e862-wk-Fact-08F7B1DEB2E25ACA94468FF7CE567177"
      unitRef="usd">13045000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43687704e882-wk-Fact-D1ABF3DF10655F18B16D5BEDE8158D66"
      unitRef="usd">38843000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43687704e901-wk-Fact-769863A67705599FBF10A0F9C982956F"
      unitRef="usd">39196000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:CostOfGoodsSold
      contextRef="FD2017Q3QTD"
      decimals="-6"
      id="d43687704e1010-wk-Fact-28E7163DD278532183F033BDA283F0A1"
      unitRef="usd">2847000000</us-gaap:CostOfGoodsSold>
    <us-gaap:CostOfGoodsSold
      contextRef="FD2016Q3QTD"
      decimals="-6"
      id="d43687704e1029-wk-Fact-570366E89FCD5DA8ACCEEA8270C0E4C3"
      unitRef="usd">3085000000</us-gaap:CostOfGoodsSold>
    <us-gaap:CostOfGoodsSold
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43687704e1048-wk-Fact-D3650EE23D875F2485C04773B26C6EBF"
      unitRef="usd">7980000000</us-gaap:CostOfGoodsSold>
    <us-gaap:CostOfGoodsSold
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43687704e1068-wk-Fact-0FC4340BB89A562D9A6DFA4186E041AB"
      unitRef="usd">9111000000</us-gaap:CostOfGoodsSold>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="FD2017Q3QTD"
      decimals="-6"
      id="d43687704e1095-wk-Fact-97AEC38197D45AB8B6B38E3761427F3A"
      unitRef="usd">3500000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="FD2016Q3QTD"
      decimals="-6"
      id="d43687704e1114-wk-Fact-D23657D890AE5F088F89E76D78FD1EB7"
      unitRef="usd">3559000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43687704e1133-wk-Fact-191AFA552BEF51A38ED7B886728FB89F"
      unitRef="usd">10233000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43687704e1153-wk-Fact-7E1F234CCFDF5CD5B6D2068DEF0EA230"
      unitRef="usd">10414000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="FD2017Q3QTD"
      decimals="-6"
      id="d43687704e1180-wk-Fact-225BF3E60210511691B41C170582C821"
      unitRef="usd">1859000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="FD2016Q3QTD"
      decimals="-6"
      id="d43687704e1199-wk-Fact-822E670EBB815BFB8925AC8ECADDC3AB"
      unitRef="usd">1881000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43687704e1218-wk-Fact-1577AD25D0BD5FE9BC590CD0FFB82AC1"
      unitRef="usd">5346000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43687704e1238-wk-Fact-B14EB26D36A55E6D996F420A2D075893"
      unitRef="usd">5360000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <pfe:AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction
      contextRef="FD2017Q3QTD"
      decimals="-6"
      id="d43687704e1263-wk-Fact-1A88D36F44FC57EEB2947A0516F8E2FB"
      unitRef="usd">1177000000</pfe:AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction>
    <pfe:AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction
      contextRef="FD2016Q3QTD"
      decimals="-6"
      id="d43687704e1282-wk-Fact-AD0FEF5202405A048EC52168262886B2"
      unitRef="usd">968000000</pfe:AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction>
    <pfe:AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43687704e1301-wk-Fact-C0E90259FF035CD683F5D973FC82FD05"
      unitRef="usd">3571000000</pfe:AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction>
    <pfe:AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43687704e1321-wk-Fact-2955D213201255B6B4C71E112F5F3621"
      unitRef="usd">2934000000</pfe:AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction>
    <pfe:RestructuringChargesAndAcquisitionRelatedCosts
      contextRef="FD2017Q3QTD"
      decimals="-6"
      id="d43687704e1346-wk-Fact-B73545D07B565820AFF53EEAE1860800"
      unitRef="usd">149000000</pfe:RestructuringChargesAndAcquisitionRelatedCosts>
    <pfe:RestructuringChargesAndAcquisitionRelatedCosts
      contextRef="FD2016Q3QTD"
      decimals="-6"
      id="d43687704e1365-wk-Fact-110B8A55AF7C5BFEAC9F11433EB9280B"
      unitRef="usd">531000000</pfe:RestructuringChargesAndAcquisitionRelatedCosts>
    <pfe:RestructuringChargesAndAcquisitionRelatedCosts
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43687704e1384-wk-Fact-F3D7E2873AD65FA18989892A60F6626A"
      unitRef="usd">377000000</pfe:RestructuringChargesAndAcquisitionRelatedCosts>
    <pfe:RestructuringChargesAndAcquisitionRelatedCosts
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43687704e1404-wk-Fact-5FBAE33C336F53F48E8FF7CDE77BBB26"
      unitRef="usd">988000000</pfe:RestructuringChargesAndAcquisitionRelatedCosts>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="FD2017Q3QTD"
      decimals="-6"
      id="d43687704e1429-wk-Fact-EEFC92F1B5E55E77955910BC4C0F4CE1"
      unitRef="usd">-51000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="FD2016Q3QTD"
      decimals="-6"
      id="d43687704e1448-wk-Fact-916495EF6D70560FBFED7475E53E1BEA"
      unitRef="usd">-1417000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43687704e1467-wk-Fact-EE9718ED59B15329A11D4FE12F405FEA"
      unitRef="usd">16000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43687704e1488-wk-Fact-901AC284652F5C9B93B4B3D55F3C6EAE"
      unitRef="usd">-2815000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2017Q3QTD"
      decimals="-6"
      id="d43687704e1513-wk-Fact-C6627323E3A7545BB805B65F89BE7911"
      unitRef="usd">3585000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2016Q3QTD"
      decimals="-6"
      id="d43687704e1532-wk-Fact-8EACD6F676A95BF0AB83AE15D642DBEA"
      unitRef="usd">1604000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43687704e1551-wk-Fact-6C225350ED6F51898E27B37470C6135A"
      unitRef="usd">11351000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43687704e1571-wk-Fact-6056A2295D7857F1915F488C04BDB11A"
      unitRef="usd">7575000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2017Q3QTD"
      decimals="-6"
      id="d43687704e1599-wk-Fact-4F4FAE747047530784054ED85551DFDC"
      unitRef="usd">727000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2016Q3QTD"
      decimals="-6"
      id="d43687704e1618-wk-Fact-2D8CDE5E04555F14B8B630B25163E15F"
      unitRef="usd">249000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43687704e1637-wk-Fact-741D17F5FCAB522EB406F004C9FDBAA3"
      unitRef="usd">2287000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43687704e1657-wk-Fact-626C408AD0435F32862D27637DFEBF9C"
      unitRef="usd">1109000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FD2017Q3QTD"
      decimals="-6"
      id="d43687704e1684-wk-Fact-10A93FAA5CBC5B458A708E3EEBF01F13"
      unitRef="usd">2858000000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FD2016Q3QTD"
      decimals="-6"
      id="d43687704e1703-wk-Fact-8F2AF78FFD8356E9921CBFEFF7E852B8"
      unitRef="usd">1355000000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43687704e1722-wk-Fact-1011397EB1385A98BE195F68F7FE92A7"
      unitRef="usd">9064000000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43687704e1742-wk-Fact-9CDAD2B93E775B8EA25F98BBA2F83485"
      unitRef="usd">6465000000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="FD2017Q3QTD"
      decimals="-6"
      id="d43687704e1767-wk-Fact-F8A88E3727775446BECFB5D7B19FFE9A"
      unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="FD2016Q3QTD"
      decimals="-6"
      id="d43687704e1786-wk-Fact-0A252F10C1E25CFA8D6B9B5104061718"
      unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43687704e1805-wk-Fact-60867BC7B4C25795A91A0C8BA6B7BDAB"
      unitRef="usd">1000000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43687704e1825-wk-Fact-D5E632B5D4A85473B7FDB1B2EC3EF703"
      unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:ProfitLoss
      contextRef="FD2017Q3QTD"
      decimals="-6"
      id="d43687704e1852-wk-Fact-C6BAFD428E8D5DBBB9FC324DE0B23F01"
      unitRef="usd">2858000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="FD2016Q3QTD"
      decimals="-6"
      id="d43687704e1871-wk-Fact-F91674DC2E49576AB1FD6B5399D570DE"
      unitRef="usd">1355000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43687704e1890-wk-Fact-769C4E4C0C905BDA89016FEC60CCEAB2"
      unitRef="usd">9066000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43687704e1910-wk-Fact-1F598F7CC0A659DC8B78C122AEB4F4CE"
      unitRef="usd">6465000000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="FD2017Q3QTD"
      decimals="-6"
      id="d43687704e1935-wk-Fact-09351BE188EA5C05843D243B15A603F5"
      unitRef="usd">18000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="FD2016Q3QTD"
      decimals="-6"
      id="d43687704e1954-wk-Fact-12644093904C5936B08DC2FFA86C8E1C"
      unitRef="usd">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43687704e1973-wk-Fact-110FAC29CE4C53DFB4DD30D11B664569"
      unitRef="usd">32000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43687704e1993-wk-Fact-288376604CC25FCA9066DC7223130DD2"
      unitRef="usd">25000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="FD2017Q3QTD"
      decimals="-6"
      id="d43687704e2025-wk-Fact-40459F40D11A5E0AA41A1F4213969546"
      unitRef="usd">2840000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2016Q3QTD"
      decimals="-6"
      id="d43687704e2044-wk-Fact-EBA23CAAE8065687AE88E6554D498B60"
      unitRef="usd">1355000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43687704e2064-wk-Fact-2F837D3EBB765EBCB1249DE75E4FF1D1"
      unitRef="usd">9034000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43687704e2083-wk-Fact-143D73146425519EBA3BAC0B389543EF"
      unitRef="usd">6440000000</us-gaap:NetIncomeLoss>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="FD2017Q3QTD"
      decimals="2"
      id="d43687704e2282-wk-Fact-E36AD239D16459E1808D418ACCF15849"
      unitRef="usdPerShare">0.48</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="FD2016Q3QTD"
      decimals="2"
      id="d43687704e2301-wk-Fact-E6450DE123AB5BECA240B4DA5F938164"
      unitRef="usdPerShare">0.22</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="FD2017Q3YTD"
      decimals="2"
      id="d43687704e2321-wk-Fact-57FC3ED392B859D78861D64EC5C88CB0"
      unitRef="usdPerShare">1.51</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="FD2016Q3YTD"
      decimals="2"
      id="d43687704e2340-wk-Fact-9652D747D2CD5DF5B4AE1CACCD0A7222"
      unitRef="usdPerShare">1.06</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="FD2017Q3QTD"
      decimals="2"
      id="d43687704e2360-wk-Fact-AF9D3709DF59553C9EBCFCBC41F64F99"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="FD2016Q3QTD"
      decimals="2"
      id="d43687704e2379-wk-Fact-B4B59AB6237151588AD0DCDB47024876"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="FD2017Q3YTD"
      decimals="2"
      id="d43687704e2398-wk-Fact-3F5327605CC159E0884F58369042FADA"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="FD2016Q3YTD"
      decimals="2"
      id="d43687704e2418-wk-Fact-4FA35F91DEE258C694579DEDDD33A6CF"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:EarningsPerShareBasic
      contextRef="FD2017Q3QTD"
      decimals="2"
      id="d43687704e2448-wk-Fact-8810BC1FB19F5CCBB75143FDC43F7193"
      unitRef="usdPerShare">0.48</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="FD2016Q3QTD"
      decimals="2"
      id="d43687704e2467-wk-Fact-F337EEA9B15A530CA79C01F287A6870F"
      unitRef="usdPerShare">0.22</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="FD2017Q3YTD"
      decimals="2"
      id="d43687704e2487-wk-Fact-8AF2BFF4A0B050A8AEDFE6EBFEC9B378"
      unitRef="usdPerShare">1.51</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="FD2016Q3YTD"
      decimals="2"
      id="d43687704e2506-wk-Fact-02AE17DCB8665481BC805EA0E0D7CB38"
      unitRef="usdPerShare">1.06</us-gaap:EarningsPerShareBasic>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="FD2017Q3QTD"
      decimals="2"
      id="d43687704e2706-wk-Fact-2BD65B1FAD49532F94B23261F5066D15"
      unitRef="usdPerShare">0.47</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="FD2016Q3QTD"
      decimals="2"
      id="d43687704e2725-wk-Fact-DB504CC293605BAF9CADCD1A8D93F11A"
      unitRef="usdPerShare">0.22</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="FD2017Q3YTD"
      decimals="2"
      id="d43687704e2745-wk-Fact-0EF2FD50430259DC8181FE20C0F40B34"
      unitRef="usdPerShare">1.49</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="FD2016Q3YTD"
      decimals="2"
      id="d43687704e2764-wk-Fact-F53A90EB6B0F5931A598FD416D03851F"
      unitRef="usdPerShare">1.04</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="FD2017Q3QTD"
      decimals="2"
      id="d43687704e2784-wk-Fact-485CB0863B5C5B9D8B2C74086517AD5B"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="FD2016Q3QTD"
      decimals="2"
      id="d43687704e2803-wk-Fact-669021DA4A3E525F9913592D2FD04D72"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="FD2017Q3YTD"
      decimals="2"
      id="d43687704e2822-wk-Fact-473E2E1DAAB95751BEEBC640CAD75D52"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="FD2016Q3YTD"
      decimals="2"
      id="d43687704e2842-wk-Fact-C799B208E12551D9925550E1584374F0"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:EarningsPerShareDiluted
      contextRef="FD2017Q3QTD"
      decimals="2"
      id="d43687704e2872-wk-Fact-9731AEDCAB005D1FBDC36BDD20F9FFF8"
      unitRef="usdPerShare">0.47</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="FD2016Q3QTD"
      decimals="2"
      id="d43687704e2891-wk-Fact-98E7EC7835B052E592B533FDD3656AFB"
      unitRef="usdPerShare">0.22</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="FD2017Q3YTD"
      decimals="2"
      id="d43687704e2911-wk-Fact-4B8F1DBA2929519A88C07E8910A30454"
      unitRef="usdPerShare">1.49</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="FD2016Q3YTD"
      decimals="2"
      id="d43687704e2930-wk-Fact-B227984E1B50586585A129EB332CFD86"
      unitRef="usdPerShare">1.04</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="FD2017Q3QTD"
      decimals="-6"
      id="d43687704e3037-wk-Fact-69E50427EE6E533896BB8B1907041230"
      unitRef="shares">5951000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="FD2016Q3QTD"
      decimals="-6"
      id="d43687704e3056-wk-Fact-63E834283E2059E3A8C189B4778885B0"
      unitRef="shares">6066000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43687704e3075-wk-Fact-89167C4150EA5B6CB2833B441C176EB5"
      unitRef="shares">5972000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43687704e3095-wk-Fact-044058D73AF55D17962CBA73D63800BD"
      unitRef="shares">6095000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="FD2017Q3QTD"
      decimals="-6"
      id="d43687704e3122-wk-Fact-4F013E58EAE3506D989984D20AC7A60B"
      unitRef="shares">6041000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="FD2016Q3QTD"
      decimals="-6"
      id="d43687704e3141-wk-Fact-1E5089DBEBB75DB7864724ADB41A8830"
      unitRef="shares">6150000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43687704e3160-wk-Fact-C0D5F9589E725D14B3DE492AFAAAEA7D"
      unitRef="shares">6057000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43687704e3180-wk-Fact-413D25685F8F583AB53236F9F57575B9"
      unitRef="shares">6175000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="FD2017Q3QTD"
      decimals="INF"
      id="d43687704e3210-wk-Fact-8BCC41FCBE495D779B180688D6602014"
      unitRef="usdPerShare">0.32</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="FD2016Q3QTD"
      decimals="INF"
      id="d43687704e3229-wk-Fact-6CE7E4C1FB715EB9A50793367CE85508"
      unitRef="usdPerShare">0.30</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="FD2017Q3YTD"
      decimals="INF"
      id="d43687704e3249-wk-Fact-ABA682EB80515D309B605AA81450C85B"
      unitRef="usdPerShare">0.96</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="FD2016Q3YTD"
      decimals="INF"
      id="d43687704e3268-wk-Fact-1F15569F17C85A6FB44008E62E8E62E3"
      unitRef="usdPerShare">0.90</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:ProfitLoss
      contextRef="FD2017Q3QTD"
      decimals="-6"
      id="d43687849e846-wk-Fact-C6BAFD428E8D5DBBB9FC324DE0B23F01"
      unitRef="usd">2858000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="FD2016Q3QTD"
      decimals="-6"
      id="d43687849e865-wk-Fact-F91674DC2E49576AB1FD6B5399D570DE"
      unitRef="usd">1355000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43687849e885-wk-Fact-769C4E4C0C905BDA89016FEC60CCEAB2"
      unitRef="usd">9066000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43687849e904-wk-Fact-1F598F7CC0A659DC8B78C122AEB4F4CE"
      unitRef="usd">6465000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax
      contextRef="FD2017Q3QTD"
      decimals="-6"
      id="d43687849e1009-wk-Fact-F703FF2FF1295F3C9A1F766CB8844DF9"
      unitRef="usd">878000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax
      contextRef="FD2016Q3QTD"
      decimals="-6"
      id="d43687849e1028-wk-Fact-72F6CFB7B5D35966938C0A78B6424FE7"
      unitRef="usd">417000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43687849e1047-wk-Fact-C15E30483A415EE0AF567E4AAFB1965C"
      unitRef="usd">1352000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43687849e1067-wk-Fact-3DD9D4B9BF27581180EA172B8CC2DC14"
      unitRef="usd">998000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax
      contextRef="FD2017Q3QTD"
      decimals="-6"
      id="d43687849e1094-wk-Fact-1745891B013F59B28C550000447D41B6"
      unitRef="usd">3000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax
      contextRef="FD2016Q3QTD"
      decimals="-6"
      id="d43687849e1114-wk-Fact-D6817414FA765B068A1698A96A9159E8"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43687849e1133-wk-Fact-34A31155E9EC5355982021CA6EBEFB38"
      unitRef="usd">-110000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43687849e1153-wk-Fact-8EF4AF6384775AC783C5F87F272BBA35"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax
      contextRef="FD2017Q3QTD"
      decimals="-6"
      id="d43687849e1178-wk-Fact-33A901EBBAEB5B7B8CD51B4273CBCE61"
      unitRef="usd">875000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax
      contextRef="FD2016Q3QTD"
      decimals="-6"
      id="d43687849e1197-wk-Fact-579A851CE2B25899921158748034540F"
      unitRef="usd">417000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43687849e1216-wk-Fact-524E646459CB5301AEC5027EA98F9741"
      unitRef="usd">1461000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43687849e1236-wk-Fact-3C8E3740EBD853D5A2217E87A8E69C70"
      unitRef="usd">998000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax
      contextRef="FD2017Q3QTD"
      decimals="-6"
      id="d43687849e1261-wk-Fact-C2DBD9F4462053918846BC5A4E78FE6B"
      unitRef="usd">-50000000</us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax
      contextRef="FD2016Q3QTD"
      decimals="-6"
      id="d43687849e1281-wk-Fact-FDB2255DA9ED588F82220AD2BD357172"
      unitRef="usd">-126000000</us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43687849e1301-wk-Fact-4C6BD95E3D2E5FB8B5E794AE6EE85755"
      unitRef="usd">-149000000</us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43687849e1322-wk-Fact-9DF54FB1EA595037ACB26A2654176B64"
      unitRef="usd">-970000000</us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesBeforeTax
      contextRef="FD2017Q3QTD"
      decimals="-6"
      id="d43687849e1350-wk-Fact-130257F4983E52BEA926FB24D7677099"
      unitRef="usd">-56000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesBeforeTax
      contextRef="FD2016Q3QTD"
      decimals="-6"
      id="d43687849e1369-wk-Fact-6968FECDFB645F1C88CC9A36C37CAA90"
      unitRef="usd">-150000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesBeforeTax
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43687849e1388-wk-Fact-DC0B04CD35255AAE8DB2F2B96794D8DC"
      unitRef="usd">393000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesBeforeTax
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43687849e1409-wk-Fact-2CCCE52F43F055888FBA5D0EB59CC576"
      unitRef="usd">-280000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesBeforeTax
      contextRef="FD2017Q3QTD"
      decimals="-6"
      id="d43687849e1434-wk-Fact-61418F4200B850038486B4BEDFA4FA9E"
      unitRef="usd">6000000</us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesBeforeTax
      contextRef="FD2016Q3QTD"
      decimals="-6"
      id="d43687849e1453-wk-Fact-FF71A5EF104C5E84BB31EB85E1C2233A"
      unitRef="usd">24000000</us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesBeforeTax
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43687849e1472-wk-Fact-8D699BC64D745ABCB0D7483468DED443"
      unitRef="usd">-542000000</us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesBeforeTax
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43687849e1493-wk-Fact-AF1D710099FA5129924DD7852F2F28B0"
      unitRef="usd">-690000000</us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesBeforeTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
      contextRef="FD2017Q3QTD"
      decimals="-6"
      id="d43687849e1519-wk-Fact-CF85F87F0E845EA3BF827845F15B8168"
      unitRef="usd">384000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
      contextRef="FD2016Q3QTD"
      decimals="-6"
      id="d43687849e1538-wk-Fact-6246160B22DB5F86A702C0FDC31AEA8A"
      unitRef="usd">261000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43687849e1557-wk-Fact-BBA831FA48DE546FAD427528571D0824"
      unitRef="usd">698000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43687849e1577-wk-Fact-C66A904313F45C85A833A23046CD2774"
      unitRef="usd">740000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax
      contextRef="FD2017Q3QTD"
      decimals="-6"
      id="d43687849e1605-wk-Fact-2EABA378D8055B138BD1C9439BF5DF77"
      unitRef="usd">278000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax
      contextRef="FD2016Q3QTD"
      decimals="-6"
      id="d43687849e1625-wk-Fact-9A9E5B540C0052C7BE5FB833D0FCA0E3"
      unitRef="usd">112000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43687849e1645-wk-Fact-F567CC4505EC55EF951CC1C3D6B62769"
      unitRef="usd">181000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43687849e1666-wk-Fact-51BE1E50E018595FBB09E1CA22E07612"
      unitRef="usd">129000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
      contextRef="FD2017Q3QTD"
      decimals="-6"
      id="d43687849e1692-wk-Fact-05DE724F3E9F5A43ABA68FEBEAE4BBAF"
      unitRef="usd">106000000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
      contextRef="FD2016Q3QTD"
      decimals="-6"
      id="d43687849e1711-wk-Fact-F6B16FF2F2E15556BF6FA7B44550EBC3"
      unitRef="usd">149000000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43687849e1730-wk-Fact-D4592919CCA35BD2BDC493D03993CB8A"
      unitRef="usd">518000000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43687849e1750-wk-Fact-7299B19500C65AA4886E0CA9F295C4DC"
      unitRef="usd">611000000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax
      contextRef="FD2017Q3QTD"
      decimals="-6"
      id="d43687849e1775-wk-Fact-627842F5F2E15231B3D26A535F4705CA"
      unitRef="usd">-103000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax
      contextRef="FD2016Q3QTD"
      decimals="-6"
      id="d43687849e1795-wk-Fact-F368335D74285386B4B988BC23C52314"
      unitRef="usd">-82000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43687849e1815-wk-Fact-1F4BA95B10925AE8A489F10EF8546E3C"
      unitRef="usd">-41000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43687849e1836-wk-Fact-80B5437E8AF253159081F26E14A232D2"
      unitRef="usd">-101000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax
      contextRef="FD2017Q3QTD"
      decimals="-6"
      id="d43687849e1864-wk-Fact-0BC6042F31745BE3B397485995AF247B"
      unitRef="usd">-140000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax
      contextRef="FD2016Q3QTD"
      decimals="-6"
      id="d43687849e1883-wk-Fact-DC5034ABC2EA5C18880A9E00522D29F5"
      unitRef="usd">-140000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43687849e1902-wk-Fact-526D1E8FCDB9599FBA3FC176B4CBDF40"
      unitRef="usd">-448000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43687849e1922-wk-Fact-76C4477D67B058D0ADA197C508A6BFA0"
      unitRef="usd">-418000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax>
    <pfe:OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax
      contextRef="FD2017Q3QTD"
      decimals="-6"
      id="d43687849e1949-wk-Fact-2B43072B673F54B48A3077572AC7B122"
      unitRef="usd">-38000000</pfe:OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax>
    <pfe:OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax
      contextRef="FD2016Q3QTD"
      decimals="-6"
      id="d43687849e1968-wk-Fact-472E8E6F6DB25346B046668C52D5902F"
      unitRef="usd">-28000000</pfe:OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax>
    <pfe:OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43687849e1987-wk-Fact-439917D3DAAF58E1AD6CD991FC80DC42"
      unitRef="usd">-89000000</pfe:OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax>
    <pfe:OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43687849e2007-wk-Fact-C6D0FE3E8F7154EE8F40BBCDB7B4F991"
      unitRef="usd">-76000000</pfe:OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax>
    <pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax
      contextRef="FD2017Q3QTD"
      decimals="-6"
      id="d43687849e2032-wk-Fact-13B324D73BAB58EC8AE8E3B51B6EC46D"
      unitRef="usd">76000000</pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax>
    <pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax
      contextRef="FD2016Q3QTD"
      decimals="-6"
      id="d43687849e2052-wk-Fact-A4006F8721A75370B615CE7A639018C5"
      unitRef="usd">-69000000</pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax>
    <pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43687849e2071-wk-Fact-3584E6A95DE851E29AE8ED49EB250F3F"
      unitRef="usd">111000000</pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax>
    <pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43687849e2092-wk-Fact-B02BB9D940C0596C9C0D21CC1C19783E"
      unitRef="usd">-51000000</pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax
      contextRef="FD2017Q3QTD"
      decimals="-6"
      id="d43687849e2117-wk-Fact-322107AB58155A3EA1AD6413AB9D9A99"
      unitRef="usd">-1000000</us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax
      contextRef="FD2016Q3QTD"
      decimals="-6"
      id="d43687849e2137-wk-Fact-E9A491CA05515608A24040D57754A17D"
      unitRef="usd">155000000</us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43687849e2156-wk-Fact-C6B1A7221C9D543BAFE59A9C9ECA2DF2"
      unitRef="usd">384000000</us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43687849e2176-wk-Fact-1C3BC6367D20581BA4D58D85D2EF3508"
      unitRef="usd">444000000</us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax
      contextRef="FD2017Q3QTD"
      decimals="-6"
      id="d43687849e2201-wk-Fact-9172F69C54DD547D933CB7C875628316"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax
      contextRef="FD2016Q3QTD"
      decimals="-6"
      id="d43687849e2220-wk-Fact-75134F72E4DA517BA3893A36B2D82E24"
      unitRef="usd">-95000000</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43687849e2239-wk-Fact-7A7785CEBF4755FBBB7EAA2A69D0EF09"
      unitRef="usd">2000000</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43687849e2260-wk-Fact-E969B5F6A0FD5E7199F96415161E24EE"
      unitRef="usd">-182000000</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax
      contextRef="FD2017Q3QTD"
      decimals="-6"
      id="d43687849e2287-wk-Fact-9768F9056D7E593CA8B86BE96384F1DB"
      unitRef="usd">-46000000</us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax
      contextRef="FD2016Q3QTD"
      decimals="-6"
      id="d43687849e2307-wk-Fact-6866C3FD323B5B328644E3617D27748F"
      unitRef="usd">-45000000</us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43687849e2327-wk-Fact-51ECCBCA921E59759451F63108AF904D"
      unitRef="usd">-138000000</us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43687849e2348-wk-Fact-ED18C0861D3E5C15B3C0A349152628B0"
      unitRef="usd">-127000000</us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax>
    <pfe:OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax
      contextRef="FD2017Q3QTD"
      decimals="-6"
      id="d43687849e2376-wk-Fact-065F9DBED67053D59EE0A60E93DFDD22"
      unitRef="usd">-3000000</pfe:OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax>
    <pfe:OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax
      contextRef="FD2016Q3QTD"
      decimals="-6"
      id="d43687849e2396-wk-Fact-719A3A5AFE7E590BA2BBA17A3393549C"
      unitRef="usd">-8000000</pfe:OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax>
    <pfe:OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43687849e2416-wk-Fact-5BC61B13CAF15E29B03835EA44B618DD"
      unitRef="usd">-14000000</pfe:OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax>
    <pfe:OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43687849e2437-wk-Fact-713AA3AA57EE5FBCBD96967A8F7E9885"
      unitRef="usd">-14000000</pfe:OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax>
    <pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax
      contextRef="FD2017Q3QTD"
      decimals="-6"
      id="d43687849e2463-wk-Fact-E42F286486CD5834BD8EB16236B31FEA"
      unitRef="usd">-1000000</pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax>
    <pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax
      contextRef="FD2016Q3QTD"
      decimals="-6"
      id="d43687849e2482-wk-Fact-A6BAD49A94C058098F01D059FDF7D0BF"
      unitRef="usd">-6000000</pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax>
    <pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43687849e2501-wk-Fact-075959EB0B9D5963B37F54F55082FEA0"
      unitRef="usd">-2000000</pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax>
    <pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43687849e2521-wk-Fact-72DABC7CCBA75E3598D920B948A182DB"
      unitRef="usd">-12000000</pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax
      contextRef="FD2017Q3QTD"
      decimals="-6"
      id="d43687849e2547-wk-Fact-84477EEDA0FB53F1A2DF30BC45CFD227"
      unitRef="usd">48000000</us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax
      contextRef="FD2016Q3QTD"
      decimals="-6"
      id="d43687849e2567-wk-Fact-A0788365B82455288EB3A6C6558EC05A"
      unitRef="usd">-48000000</us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43687849e2586-wk-Fact-B8A367981AE35AEF8C0BF4154D63FC01"
      unitRef="usd">151000000</us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43687849e2607-wk-Fact-9F76A95D96735FEB9B3AA6495B54B6C9"
      unitRef="usd">-54000000</us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTax
      contextRef="FD2017Q3QTD"
      decimals="-6"
      id="d43687849e2632-wk-Fact-FDE8C1D4A9445B5EB201CF6786FF4FCA"
      unitRef="usd">938000000</us-gaap:OtherComprehensiveIncomeLossBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTax
      contextRef="FD2016Q3QTD"
      decimals="-6"
      id="d43687849e2651-wk-Fact-AE655F3ED75A586981476B9D274B0149"
      unitRef="usd">793000000</us-gaap:OtherComprehensiveIncomeLossBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTax
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43687849e2670-wk-Fact-D8BF89A982EE5516AF5D38868D45AC49"
      unitRef="usd">1669000000</us-gaap:OtherComprehensiveIncomeLossBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTax
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43687849e2690-wk-Fact-672E389254015A85B0E497DA6B98ED65"
      unitRef="usd">1417000000</us-gaap:OtherComprehensiveIncomeLossBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="FD2017Q3QTD"
      decimals="-6"
      id="d43687849e2717-wk-Fact-5950DF108F195FB594A31172740C60B3"
      unitRef="usd">-80000000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="FD2016Q3QTD"
      decimals="-6"
      id="d43687849e2737-wk-Fact-31B8668E1E1956DF8878873FF4C52DA7"
      unitRef="usd">116000000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43687849e2756-wk-Fact-0A65F347C9FD5314AD71D7212990864D"
      unitRef="usd">-218000000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43687849e2777-wk-Fact-24F5F5FD900B538BB0C1F5C1D6714D02"
      unitRef="usd">111000000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2017Q3QTD"
      decimals="-6"
      id="d43687849e2807-wk-Fact-5FA838CDA13D589CA9003C05768C2A3F"
      unitRef="usd">1018000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2016Q3QTD"
      decimals="-6"
      id="d43687849e2826-wk-Fact-69A896461F495ACBB885D53F5353F71F"
      unitRef="usd">677000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43687849e2846-wk-Fact-CE6465895C815C29B1431FBD3ED3B46B"
      unitRef="usd">1888000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43687849e2865-wk-Fact-990F7FE47CEA5D99BCE375CA7BAC5739"
      unitRef="usd">1306000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FD2017Q3QTD"
      decimals="-6"
      id="d43687849e2977-wk-Fact-D64522201D7F5BB5BA48471538CE6CB8"
      unitRef="usd">3876000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FD2016Q3QTD"
      decimals="-6"
      id="d43687849e2996-wk-Fact-503B87CD9CE65FEDBBDC99370F10DF6B"
      unitRef="usd">2031000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43687849e3016-wk-Fact-3AB6460969F05E5CB5282AE2FB7FB81F"
      unitRef="usd">10953000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43687849e3035-wk-Fact-5FD229EF81AC578B949A3DF35BCE1FF6"
      unitRef="usd">7771000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="FD2017Q3QTD"
      decimals="-6"
      id="d43687849e3055-wk-Fact-3831F5857C7B5144886C985E77E751EE"
      unitRef="usd">19000000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="FD2016Q3QTD"
      decimals="-6"
      id="d43687849e3074-wk-Fact-32954ABF73B65A8C9307A33BA47D9ABB"
      unitRef="usd">0</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43687849e3093-wk-Fact-C761BA8C214D5A2D83B627623D2F876D"
      unitRef="usd">48000000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43687849e3113-wk-Fact-46E6ECDFD5B35112ACFA85A4DD680D69"
      unitRef="usd">24000000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="FD2017Q3QTD"
      decimals="-6"
      id="d43687849e3143-wk-Fact-A98E6DC1451C5074AFA6C1769B31F168"
      unitRef="usd">3857000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="FD2016Q3QTD"
      decimals="-6"
      id="d43687849e3162-wk-Fact-D87820179CF453388B904F407941F962"
      unitRef="usd">2032000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43687849e3182-wk-Fact-5CD3245395AF57768A6DF8D7BDF6B0BB"
      unitRef="usd">10906000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43687849e3201-wk-Fact-965936205F21501FABEFE22DBAD6AD70"
      unitRef="usd">7747000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="I2017Q2Jun30_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_LaboratorioTeutoBrasileroMember"
      decimals="2"
      id="d43687849e3224-wk-Fact-7A20B5BEC3C75D16BFE5A86C05D26ABA"
      unitRef="number">0.40</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2017Q3"
      decimals="-6"
      id="d43674379e798-wk-Fact-7EFAF7B942C85E77BB9972B343FAB410"
      unitRef="usd">2779000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2016Q4"
      decimals="-6"
      id="d43674379e817-wk-Fact-D156C275113454EF9843F3D3060B56DB"
      unitRef="usd">2595000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="FI2017Q3"
      decimals="-6"
      id="d43674379e837-wk-Fact-AE85FABD864252F78E2399FA5C6D7DCA"
      unitRef="usd">14146000000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="FI2016Q4"
      decimals="-6"
      id="d43674379e856-wk-Fact-030CEB52DE005078B1752AD07DFF2B1C"
      unitRef="usd">15255000000</us-gaap:ShortTermInvestments>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="FI2017Q3"
      decimals="-6"
      id="d43674379e881-wk-Fact-93CA7130473D54F2A4475CBF05C3A3EF"
      unitRef="usd">10002000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="FI2016Q4"
      decimals="-6"
      id="d43674379e900-wk-Fact-EA1D3C7D16595854B5CD606B1A735B28"
      unitRef="usd">8225000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="FI2017Q3"
      decimals="-6"
      id="d43674379e925-wk-Fact-2C8D97E870025A9E9218D1538714EA7C"
      unitRef="usd">7925000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="FI2016Q4"
      decimals="-6"
      id="d43674379e944-wk-Fact-B57DF7F90CE856C48797E9E94456B6CD"
      unitRef="usd">6783000000</us-gaap:InventoryNet>
    <pfe:OtherTaxAssetsCurrent
      contextRef="FI2017Q3"
      decimals="-6"
      id="d43674379e969-wk-Fact-C9379BA9136D5BBB8F3432FB4D96CBD5"
      unitRef="usd">3263000000</pfe:OtherTaxAssetsCurrent>
    <pfe:OtherTaxAssetsCurrent
      contextRef="FI2016Q4"
      decimals="-6"
      id="d43674379e988-wk-Fact-D05030AC7D8B5906A350262C6079BD92"
      unitRef="usd">3041000000</pfe:OtherTaxAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="FI2017Q3"
      decimals="-6"
      id="d43674379e1013-wk-Fact-09FA50EC8B6A5544A580831FEECF0695"
      unitRef="usd">2158000000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="FI2016Q4"
      decimals="-6"
      id="d43674379e1032-wk-Fact-686063BE60325E2A839CE026F903431A"
      unitRef="usd">2249000000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="FI2017Q3"
      decimals="-6"
      id="d43674379e1057-wk-Fact-AF72E85346065C12B27811C0B8AD4C52"
      unitRef="usd">16000000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="FI2016Q4"
      decimals="-6"
      id="d43674379e1076-wk-Fact-047944C84B99570199B5350DAC450B3B"
      unitRef="usd">801000000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:AssetsCurrent
      contextRef="FI2017Q3"
      decimals="-6"
      id="d43674379e1101-wk-Fact-B684218F9F965A0685489FB9D98355FE"
      unitRef="usd">40291000000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="FI2016Q4"
      decimals="-6"
      id="d43674379e1120-wk-Fact-5329671706335212AE3F5E2B75B7A4AB"
      unitRef="usd">38949000000</us-gaap:AssetsCurrent>
    <us-gaap:LongTermInvestments
      contextRef="FI2017Q3"
      decimals="-6"
      id="d43674379e1146-wk-Fact-F5595E1E6E5C5AB79FC9578F6E9622FC"
      unitRef="usd">7311000000</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="FI2016Q4"
      decimals="-6"
      id="d43674379e1165-wk-Fact-A14EC3C3E45252D8988217A4980EB580"
      unitRef="usd">7116000000</us-gaap:LongTermInvestments>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="FI2017Q3"
      decimals="-6"
      id="d43674379e1190-wk-Fact-F52CA4E0D2C151988CD5EF5FA00DEAFE"
      unitRef="usd">13505000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="FI2016Q4"
      decimals="-6"
      id="d43674379e1209-wk-Fact-E8F1DC92BC58566FACDD0804C8857081"
      unitRef="usd">13318000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="FI2017Q3"
      decimals="-6"
      id="d43674379e1234-wk-Fact-A41E764041225C8DBE154ADB89FBF66C"
      unitRef="usd">49721000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="FI2016Q4"
      decimals="-6"
      id="d43674379e1253-wk-Fact-4014B8D306BF54FC8CDF5431816FAA50"
      unitRef="usd">52648000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="FI2017Q3"
      decimals="-6"
      id="d43674379e1278-wk-Fact-691B87100C6755EB85765E65D5C328BA"
      unitRef="usd">56078000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="FI2016Q4"
      decimals="-6"
      id="d43674379e1297-wk-Fact-F8F5DF7C12C25020B65DFF915C2D461A"
      unitRef="usd">54449000000</us-gaap:Goodwill>
    <pfe:DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent
      contextRef="FI2017Q3"
      decimals="-6"
      id="d43674379e1322-wk-Fact-CD12C4F0CCE4505FAD338F25A39BF391"
      unitRef="usd">1858000000</pfe:DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent>
    <pfe:DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent
      contextRef="FI2016Q4"
      decimals="-6"
      id="d43674379e1341-wk-Fact-B7825C6743265E60AFD787E20D13F87D"
      unitRef="usd">1812000000</pfe:DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="FI2017Q3"
      decimals="-6"
      id="d43674379e1366-wk-Fact-6F2B43838191546AA755245948E565C5"
      unitRef="usd">3388000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="FI2016Q4"
      decimals="-6"
      id="d43674379e1385-wk-Fact-74A94C963B005FB79E90256BEDC19745"
      unitRef="usd">3323000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="FI2017Q3"
      decimals="-6"
      id="d43674379e1415-wk-Fact-70B456CF1E475D979F768DB28C19676E"
      unitRef="usd">172151000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="FI2016Q4"
      decimals="-6"
      id="d43674379e1434-wk-Fact-AB8C3651E3FA5E0381978C95D5308515"
      unitRef="usd">171615000000</us-gaap:Assets>
    <us-gaap:DebtCurrent
      contextRef="FI2017Q3"
      decimals="-6"
      id="d43674379e1549-wk-Fact-CDA40E6949B85E61B9C8AF985182E3E5"
      unitRef="usd">9448000000</us-gaap:DebtCurrent>
    <us-gaap:DebtCurrent
      contextRef="FI2016Q4"
      decimals="-6"
      id="d43674379e1568-wk-Fact-3A3BB372357A5CD2BCD070742B0C6955"
      unitRef="usd">10688000000</us-gaap:DebtCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="FI2017Q3"
      decimals="-6"
      id="d43674379e1588-wk-Fact-708405E59C1952EAA954BB6C9B186068"
      unitRef="usd">3480000000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="FI2016Q4"
      decimals="-6"
      id="d43674379e1607-wk-Fact-30C18A2BCA9E5DB3B71D6CCCF9EC18D9"
      unitRef="usd">4536000000</us-gaap:AccountsPayableCurrent>
    <us-gaap:DividendsPayableCurrent
      contextRef="FI2017Q3"
      decimals="-6"
      id="d43674379e1633-wk-Fact-93644FE962325258B137234D02EB03E6"
      unitRef="usd">1909000000</us-gaap:DividendsPayableCurrent>
    <us-gaap:DividendsPayableCurrent
      contextRef="FI2016Q4"
      decimals="-6"
      id="d43674379e1652-wk-Fact-C14BB34AB5A85079B41CF0775AFE681D"
      unitRef="usd">1944000000</us-gaap:DividendsPayableCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="FI2017Q3"
      decimals="-6"
      id="d43674379e1677-wk-Fact-0A0DAFD467625E0D8018223CBF2CB456"
      unitRef="usd">1003000000</us-gaap:TaxesPayableCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="FI2016Q4"
      decimals="-6"
      id="d43674379e1696-wk-Fact-90502764073B5E8B974A1DC7FD2018F9"
      unitRef="usd">437000000</us-gaap:TaxesPayableCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="FI2017Q3"
      decimals="-6"
      id="d43674379e1721-wk-Fact-41E568B8775D59BFBCD7C2E611178392"
      unitRef="usd">1932000000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="FI2016Q4"
      decimals="-6"
      id="d43674379e1740-wk-Fact-8C84C3AC99B45AE2BA8FC636F5622DE6"
      unitRef="usd">2487000000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="FI2017Q3"
      decimals="-6"
      id="d43674379e1765-wk-Fact-6C83895D828D8E3BC5AC922878C0762E"
      unitRef="usd">10446000000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="FI2016Q4"
      decimals="-6"
      id="d43674379e1784-wk-Fact-4A5801DF38F08BD8CEC3922878CFA84A"
      unitRef="usd">11023000000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="FI2017Q3"
      decimals="-6"
      id="d43674379e1809-wk-Fact-0CD797C3DDB8580E8F7A4492293BE3C1"
      unitRef="usd">28217000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="FI2016Q4"
      decimals="-6"
      id="d43674379e1828-wk-Fact-5A2D57F680925DEC8A9CCA1553046941"
      unitRef="usd">31115000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="FI2017Q3"
      decimals="-6"
      id="d43674379e1899-wk-Fact-A38618717132561C9E1931D14EDF6B51"
      unitRef="usd">34503000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="FI2016Q4"
      decimals="-6"
      id="d43674379e1918-wk-Fact-F0B612439D18585FBB73EEB374B11207"
      unitRef="usd">31398000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DefinedBenefitPensionPlanLiabilitiesNoncurrent
      contextRef="FI2017Q3"
      decimals="-6"
      id="d43674379e1943-wk-Fact-06E6B320DD2E5DEAAE0840FF5C32D34D"
      unitRef="usd">5531000000</us-gaap:DefinedBenefitPensionPlanLiabilitiesNoncurrent>
    <us-gaap:DefinedBenefitPensionPlanLiabilitiesNoncurrent
      contextRef="FI2016Q4"
      decimals="-6"
      id="d43674379e1962-wk-Fact-A538FCC6CCC752E695D754993DC8690B"
      unitRef="usd">6406000000</us-gaap:DefinedBenefitPensionPlanLiabilitiesNoncurrent>
    <us-gaap:OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent
      contextRef="FI2017Q3"
      decimals="-6"
      id="d43674379e1987-wk-Fact-22AAFEBAB3755B18A95911F7BF8494E3"
      unitRef="usd">1687000000</us-gaap:OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent>
    <us-gaap:OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent
      contextRef="FI2016Q4"
      decimals="-6"
      id="d43674379e2006-wk-Fact-0A96E5EFE1F05A0EAA09A948F325D5CB"
      unitRef="usd">1766000000</us-gaap:OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="FI2017Q3"
      decimals="-6"
      id="d43674379e2031-wk-Fact-45A307B4BFCC56B2A721109AA18533BB"
      unitRef="usd">30411000000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="FI2016Q4"
      decimals="-6"
      id="d43674379e2050-wk-Fact-EECAD1E5742D526A902588518CB825FF"
      unitRef="usd">30753000000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:LiabilityForUncertainTaxPositionsNoncurrent
      contextRef="FI2017Q3"
      decimals="-6"
      id="d43674379e2075-wk-Fact-808C96510A955E8CBDF7099B1662C942"
      unitRef="usd">4304000000</us-gaap:LiabilityForUncertainTaxPositionsNoncurrent>
    <us-gaap:LiabilityForUncertainTaxPositionsNoncurrent
      contextRef="FI2016Q4"
      decimals="-6"
      id="d43674379e2094-wk-Fact-4207CB01CC1150BFA16DC1CBD3FDE8A0"
      unitRef="usd">4000000000</us-gaap:LiabilityForUncertainTaxPositionsNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="FI2017Q3"
      decimals="-6"
      id="d43674379e2120-wk-Fact-7E0D6DBF276A520C83B6B208692E17BE"
      unitRef="usd">6388000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="FI2016Q4"
      decimals="-6"
      id="d43674379e2139-wk-Fact-5A59BE776E6E5E20B8346BDFE1D63D1D"
      unitRef="usd">6337000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="FI2017Q3"
      decimals="-6"
      id="d43674379e2164-wk-Fact-7EDA7F85A58A5A1F95B13001B9DBA028"
      unitRef="usd">111041000000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="FI2016Q4"
      decimals="-6"
      id="d43674379e2183-wk-Fact-50ADB7EB4847506EA08C0BF6C7E30E84"
      unitRef="usd">111776000000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="FI2017Q3"
      id="d43674379e2254-wk-Fact-949EBE5A327851FCB9BF19AA6ACC7A3A"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="FI2016Q4"
      id="d43674379e2272-wk-Fact-63822E0DBF7E5CA2BB97325B6C3209EA"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="FI2017Q3"
      decimals="-6"
      id="d43674379e2342-wk-Fact-E3E870C4333E5DBA8986F6E17DA1CE7C"
      unitRef="usd">22000000</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="FI2016Q4"
      decimals="-6"
      id="d43674379e2361-wk-Fact-279845FB1E2F5BE68F8072CC3AE0313B"
      unitRef="usd">24000000</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockValue
      contextRef="FI2017Q3"
      decimals="-6"
      id="d43674379e2386-wk-Fact-22383CE0D78B56089748D1342C097ED3"
      unitRef="usd">463000000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="FI2016Q4"
      decimals="-6"
      id="d43674379e2405-wk-Fact-42825AA4D3815C349BD40B420827B233"
      unitRef="usd">461000000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="FI2017Q3"
      decimals="-6"
      id="d43674379e2430-wk-Fact-95915EECEB845388928ED9B038AC306C"
      unitRef="usd">83827000000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="FI2016Q4"
      decimals="-6"
      id="d43674379e2449-wk-Fact-F986BFF5DEDA51E58393FB9819F5F489"
      unitRef="usd">82685000000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:TreasuryStockValue
      contextRef="FI2017Q3"
      decimals="-6"
      id="d43674379e2474-wk-Fact-BBB0550BDE1259DD997B8244242E79AE"
      unitRef="usd">89421000000</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue
      contextRef="FI2016Q4"
      decimals="-6"
      id="d43674379e2494-wk-Fact-CCCD07BEDF4C5FF9AF3BA300510C89D4"
      unitRef="usd">84364000000</us-gaap:TreasuryStockValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="FI2017Q3"
      decimals="-6"
      id="d43674379e2520-wk-Fact-7EDE13D2B0D259CBB94F5F415001BFCC"
      unitRef="usd">75043000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="FI2016Q4"
      decimals="-6"
      id="d43674379e2539-wk-Fact-B9792AE277D55415BD4430CE375AB579"
      unitRef="usd">71774000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2017Q3"
      decimals="-6"
      id="d43674379e2564-wk-Fact-A0D16119E38D5A9FAB554486905A9CCC"
      unitRef="usd">-9164000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2016Q4"
      decimals="-6"
      id="d43674379e2584-wk-Fact-3E322F23F0E95E659A8A7D474667DE0D"
      unitRef="usd">-11036000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="FI2017Q3"
      decimals="-6"
      id="d43674379e2611-wk-Fact-82E53639BF6557F091EE46784D53AC8F"
      unitRef="usd">60770000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2016Q4"
      decimals="-6"
      id="d43674379e2630-wk-Fact-1B54ADB976A25833A5F7A46C177A2A45"
      unitRef="usd">59544000000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="FI2017Q3"
      decimals="-6"
      id="d43674379e2655-wk-Fact-394FE75EF25C5117BE8B89037EFA6718"
      unitRef="usd">340000000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="FI2016Q4"
      decimals="-6"
      id="d43674379e2674-wk-Fact-2D9C52897DAC5AD0A4FC1108BB490212"
      unitRef="usd">296000000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2017Q3"
      decimals="-6"
      id="d43674379e2699-wk-Fact-0E8B49C6C7365DEB9EDE52E9D965698D"
      unitRef="usd">61110000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2016Q4"
      decimals="-6"
      id="d43674379e2718-wk-Fact-871F7D1326F153D0A78F67C95DCE6D47"
      unitRef="usd">59840000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="FI2017Q3"
      decimals="-6"
      id="d43674379e2748-wk-Fact-A7FCAA4C427E5D3F9EA836ACF3C4D395"
      unitRef="usd">172151000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="FI2016Q4"
      decimals="-6"
      id="d43674379e2767-wk-Fact-A00F92664332571D9A768489A67E66E0"
      unitRef="usd">171615000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43681613e802-wk-Fact-769C4E4C0C905BDA89016FEC60CCEAB2"
      unitRef="usd">9066000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43681613e821-wk-Fact-1F598F7CC0A659DC8B78C122AEB4F4CE"
      unitRef="usd">6465000000</us-gaap:ProfitLoss>
    <pfe:DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43681613e885-wk-Fact-ACB630B60395539B8BEB3946C0CF2A75"
      unitRef="usd">4695000000</pfe:DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization>
    <pfe:DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43681613e904-wk-Fact-4D5D0B01BEBB5DEFB2827E50144E0489"
      unitRef="usd">4208000000</pfe:DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization>
    <pfe:AssetWriteOffsAndAssetImpairmentCharges
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43681613e929-wk-Fact-E753F2020B8F56CEBAE560B3B8BB9086"
      unitRef="usd">326000000</pfe:AssetWriteOffsAndAssetImpairmentCharges>
    <pfe:AssetWriteOffsAndAssetImpairmentCharges
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43681613e948-wk-Fact-B7F6677B323F523BBF06F63407F96342"
      unitRef="usd">1146000000</pfe:AssetWriteOffsAndAssetImpairmentCharges>
    <us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43681613e973-wk-Fact-4CD7C8E134F3568695AECCF94C6AF4FD"
      unitRef="usd">-52000000</us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal>
    <us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43681613e992-wk-Fact-E944F13BD8105FBDB6ACB7D264796FD0"
      unitRef="usd">-1422000000</us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43681613e1017-wk-Fact-B740A96BCFB152CEB2E4602B18EBD8F1"
      unitRef="usd">241000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43681613e1036-wk-Fact-22BDA5BA109D56B8A234197E3982FF14"
      unitRef="usd">-1335000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:ShareBasedCompensation
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43681613e1062-wk-Fact-BA0D6BC1C45C599C91DF29089DAC818D"
      unitRef="usd">595000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43681613e1081-wk-Fact-B3E1F1C6FF4D55E59E6FE1D02902C8D3"
      unitRef="usd">532000000</us-gaap:ShareBasedCompensation>
    <pfe:PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43681613e1106-wk-Fact-0F638C219E595606B659714F53B6D14B"
      unitRef="usd">1042000000</pfe:PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense>
    <pfe:PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43681613e1126-wk-Fact-378721671BB456518AD2AD4867C237B9"
      unitRef="usd">775000000</pfe:PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43681613e1153-wk-Fact-C84FD7E0084E53B295E4FBE883879711"
      unitRef="usd">561000000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43681613e1173-wk-Fact-6944308547D65750B49346E97B2688A0"
      unitRef="usd">-68000000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInOperatingCapital
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43681613e1200-wk-Fact-1B9FEF203B3C5505BC6C4EC5902F0BCF"
      unitRef="usd">3644000000</us-gaap:IncreaseDecreaseInOperatingCapital>
    <us-gaap:IncreaseDecreaseInOperatingCapital
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43681613e1220-wk-Fact-DED2BD217A165276A7FC6775BFD357E2"
      unitRef="usd">1582000000</us-gaap:IncreaseDecreaseInOperatingCapital>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43681613e1248-wk-Fact-4205D6E535945DAFBDC33902ED523920"
      unitRef="usd">9728000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43681613e1267-wk-Fact-7D8048FC05695215AF1AB565B8040E8E"
      unitRef="usd">10151000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43681613e1382-wk-Fact-42968803AD055EFEB0C3ED702C15D6AC"
      unitRef="usd">1256000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43681613e1402-wk-Fact-4638ED2A9682598F89E8D0DE8B195AA8"
      unitRef="usd">1134000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43681613e1428-wk-Fact-71772D6AB77F595C866B3F8F2284E23A"
      unitRef="usd">6469000000</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43681613e1448-wk-Fact-C5C375E41B7D5A61A86D9015B4AC1F9C"
      unitRef="usd">15170000000</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43681613e1474-wk-Fact-8C91183376945DA18E85A8BAB3F22AAF"
      unitRef="usd">5783000000</us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43681613e1493-wk-Fact-A1C1CAB3E9EF556989E8998B597D9BF9"
      unitRef="usd">20685000000</us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments>
    <us-gaap:PaymentsForProceedsFromShortTermInvestments
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43681613e1518-wk-Fact-EA51BB96305D596BBCDA3AF91C4A5606"
      unitRef="usd">-2758000000</us-gaap:PaymentsForProceedsFromShortTermInvestments>
    <us-gaap:PaymentsForProceedsFromShortTermInvestments
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43681613e1537-wk-Fact-7715092F4977526AA9E3733E3C9831C4"
      unitRef="usd">-6485000000</us-gaap:PaymentsForProceedsFromShortTermInvestments>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43681613e1562-wk-Fact-751B2E1EB7FE550C886A2AD44ED6CFCB"
      unitRef="usd">2526000000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43681613e1582-wk-Fact-0BA196038F9B5E96BAFED82F9B4D0A80"
      unitRef="usd">4771000000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43681613e1608-wk-Fact-7366AB7164FB57C0B8A92433A2836E49"
      unitRef="usd">2417000000</us-gaap:ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43681613e1627-wk-Fact-7EE55D894B2E598CB81A5AD553F1A033"
      unitRef="usd">6915000000</us-gaap:ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43681613e1653-wk-Fact-5AFE9DE44AC65078B297BF4B6B39C511"
      unitRef="usd">1000000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43681613e1673-wk-Fact-A0FAAC12696C59849AE70392155E65FF"
      unitRef="usd">17679000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43681613e1699-wk-Fact-A6186BEADB90579F8CFC02466DEAFB87"
      unitRef="usd">188000000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43681613e1719-wk-Fact-050DF5AA83565B919248F2CDC8C1441E"
      unitRef="usd">96000000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43681613e1745-wk-Fact-33114474B11F56B7AE997B42206DB57C"
      unitRef="usd">-519000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43681613e1764-wk-Fact-F59987278FE651D99A4A03B22559E7CB"
      unitRef="usd">-60000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43681613e1789-wk-Fact-FB31F2DD4E78576D86B0CBE5A30FD593"
      unitRef="usd">38000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43681613e1808-wk-Fact-8788492837FF523EB753AAF056BFAF4A"
      unitRef="usd">-4704000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromShortTermDebt
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43681613e1924-wk-Fact-D165564A6DBB5ECA8030FB998D5E7FE7"
      unitRef="usd">7003000000</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:ProceedsFromShortTermDebt
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43681613e1943-wk-Fact-79F0FD4AFB255B0196EDFCDD331CEFF0"
      unitRef="usd">6397000000</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:RepaymentsOfShortTermDebt
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43681613e1968-wk-Fact-B6676B9BE7E95127A4888156B2CAD1CD"
      unitRef="usd">7691000000</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:RepaymentsOfShortTermDebt
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43681613e1988-wk-Fact-C220C3FE427351839AD8B1F16EE921CE"
      unitRef="usd">3321000000</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43681613e2014-wk-Fact-AA4DB1C4ACF95301B1C9DD8DFCDA37CF"
      unitRef="usd">555000000</us-gaap:ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess>
    <us-gaap:ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43681613e2033-wk-Fact-A9D9504EBEC15503A956269CA3DEC025"
      unitRef="usd">-963000000</us-gaap:ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43681613e2059-wk-Fact-450DDE9FBB965039B395036FE74CBBB0"
      unitRef="usd">5273000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43681613e2078-wk-Fact-4D68DAE5FD3059969FCBB65614BE4D06"
      unitRef="usd">5031000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43681613e2103-wk-Fact-EF326C0BF8D95F73A75E0D09B3DC12A4"
      unitRef="usd">4474000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43681613e2123-wk-Fact-0998A9FB896651C8813749DB0BBD1634"
      unitRef="usd">4317000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43681613e2150-wk-Fact-5D13F9FBBDEE52528006AA947B5F7E3A"
      unitRef="usd">5000000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43681613e2170-wk-Fact-81C7C1D62B7555CEB86C474159F55AB9"
      unitRef="usd">5000000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsOfOrdinaryDividends
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43681613e2196-wk-Fact-202F98BA511E52368E7B8599E950975E"
      unitRef="usd">5750000000</us-gaap:PaymentsOfOrdinaryDividends>
    <us-gaap:PaymentsOfOrdinaryDividends
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43681613e2216-wk-Fact-2BEDC5A7D4A059F58F71D107B4C1CAFF"
      unitRef="usd">5496000000</us-gaap:PaymentsOfOrdinaryDividends>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43681613e2242-wk-Fact-DA0EC5A432335C1691A8266D92801437"
      unitRef="usd">656000000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43681613e2261-wk-Fact-74EE204494395BACA3BF106440743D87"
      unitRef="usd">946000000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43681613e2288-wk-Fact-2F51CAACA19456CCB50C8D86205439BE"
      unitRef="usd">-223000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43681613e2308-wk-Fact-8AB5E43C2479535A8B0B89EA014F6940"
      unitRef="usd">-192000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43681613e2336-wk-Fact-94268C3E6B575791AF135AE3FFBDED27"
      unitRef="usd">-9650000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43681613e2356-wk-Fact-DB025A970D1451AEACFC8A982A850506"
      unitRef="usd">-6915000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43681613e2382-wk-Fact-E5CA2563496958358157EDDBD9180C21"
      unitRef="usd">67000000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43681613e2401-wk-Fact-910C3C95984A581EB892DD60EDC26455"
      unitRef="usd">-79000000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43681613e2427-wk-Fact-8446B584F9B25BB79D2E77028163C2CB"
      unitRef="usd">184000000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43681613e2446-wk-Fact-9C5F9B5D363652D592CA2481C87B9506"
      unitRef="usd">-1547000000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2016Q4"
      decimals="-6"
      id="d43681613e2472-wk-Fact-D156C275113454EF9843F3D3060B56DB"
      unitRef="usd">2595000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2015Q4"
      decimals="-6"
      id="d43681613e2491-wk-Fact-8CCB92621D2F5FA2970B7C2EB7A111BE"
      unitRef="usd">3641000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2017Q3"
      decimals="-6"
      id="d43681613e2521-wk-Fact-7EFAF7B942C85E77BB9972B343FAB410"
      unitRef="usd">2779000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2016Q3"
      decimals="-6"
      id="d43681613e2540-wk-Fact-98FDF1C40AF759C4B5005A20CA031801"
      unitRef="usd">2094000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <pfe:NoncashorPartNoncashDivestitureAmountofConsiderationReceivedCommonStock
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43681613e2704-wk-Fact-8690986C383F54748BB0095D0303FF1E"
      unitRef="usd">428000000</pfe:NoncashorPartNoncashDivestitureAmountofConsiderationReceivedCommonStock>
    <pfe:NoncashorPartNoncashDivestitureAmountofConsiderationReceivedCommonStock
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43681613e2723-wk-Fact-BC18C3B80FE15D95A67ED86E9A5C11B9"
      unitRef="usd">0</pfe:NoncashorPartNoncashDivestitureAmountofConsiderationReceivedCommonStock>
    <pfe:NoncashorPartNoncashDivestitureAmountofConsiderationReceivedNoteReceivable
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43681613e2745-wk-Fact-DEFAF9D423795479839BFC83C7E9408A"
      unitRef="usd">75000000</pfe:NoncashorPartNoncashDivestitureAmountofConsiderationReceivedNoteReceivable>
    <pfe:NoncashorPartNoncashDivestitureAmountofConsiderationReceivedNoteReceivable
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43681613e2764-wk-Fact-0C14F39B228253AAB03AA6A6439EFA78"
      unitRef="usd">0</pfe:NoncashorPartNoncashDivestitureAmountofConsiderationReceivedNoteReceivable>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43681613e2838-wk-Fact-0E16C50451235A15BAA9EA1F20FC4F80"
      unitRef="usd">1424000000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43681613e2857-wk-Fact-9641A5BEA98B590492283AE6831A946D"
      unitRef="usd">1430000000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43681613e2877-wk-Fact-F79EE7D9A58D5B3AA60618D470617657"
      unitRef="usd">1101000000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43681613e2896-wk-Fact-2876808E5D6E5BCEA80558572E768C26"
      unitRef="usd">1177000000</us-gaap:InterestPaidNet>
    <pfe:InterestPaidInterestRateHedges
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43681613e2921-wk-Fact-B7E0E2374E7052E886F3C5A3DD803575"
      unitRef="usd">-183000000</pfe:InterestPaidInterestRateHedges>
    <pfe:InterestPaidInterestRateHedges
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43681613e2941-wk-Fact-88DA733F540B50B5B2437B8FAA7A8EDF"
      unitRef="usd">-356000000</pfe:InterestPaidInterestRateHedges>
    <pfe:DisposalGroupIncludingDiscontinuedOperationConsiderationTransferredEquityInterestsShares
      contextRef="I2017Q1Feb03_us-gaap_CounterpartyNameAxis_pfe_ICUMedicalMember_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_HISMember"
      decimals="-5"
      id="d43681613e3005-wk-Fact-911EB761D3C6590EA6CD704F46034785"
      unitRef="shares">3200000</pfe:DisposalGroupIncludingDiscontinuedOperationConsiderationTransferredEquityInterestsShares>
    <pfe:DisposalGroupIncludingDiscontinuedOperationConsiderationTransferredEquityInterests
      contextRef="I2017Q1Feb03_us-gaap_CounterpartyNameAxis_pfe_ICUMedicalMember_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_HISMember"
      decimals="-6"
      id="d43681613e3009-wk-Fact-88E2E31CC1495183A0F02B04F4BB0670"
      unitRef="usd">428000000</pfe:DisposalGroupIncludingDiscontinuedOperationConsiderationTransferredEquityInterests>
    <pfe:DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivable
      contextRef="I2017Q1Feb03_us-gaap_CounterpartyNameAxis_pfe_ICUMedicalMember_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_HISMember"
      decimals="-6"
      id="d43681613e3013-wk-Fact-C837741F7E265EA590514DA12CED34D8"
      unitRef="usd">75000000</pfe:DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivable>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock
      contextRef="FD2017Q3YTD"
      id="TextSelection-169F7BFE968C5905A80BDF1DF1E87FD4-0-wk-Fact-37D24C33276B5176885EF5BD72149E0D">&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;Basis of Presentation and Significant Accounting Policies&lt;/span&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;A. Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;See the Glossary of Defined Terms at the beginning of this Quarterly Report on Form 10-Q for terms used throughout the condensed consolidated financial statements and related notes of this Quarterly Report on Form 10-Q.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We prepared the condensed consolidated financial statements following the requirements of the SEC for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP can be condensed or omitted.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The financial information included in our condensed consolidated financial statements for subsidiaries operating outside the U.S. is as of and for the three and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;nine months&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;August&#160;27, 2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;August&#160;28, 2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. The financial information included in our condensed consolidated financial statements for U.S. subsidiaries is as of and for the three and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;nine months&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;text-align:center;"&gt;October&#160;1, 2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;text-align:center;"&gt;October&#160;2, 2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Revenues, expenses, assets and liabilities can vary during each quarter of the year. Therefore, the results and trends in these interim financial statements may not be representative of those for the full year.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We are responsible for the unaudited financial statements included in this Quarterly Report on Form 10-Q. The interim financial statements include all normal and recurring adjustments that are considered necessary for the fair statement of our condensed consolidated balance sheets and condensed consolidated statements of income. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the consolidated financial statements and accompanying notes included in our &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;text-align:center;"&gt;2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; Form 10-K. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We manage our commercial operations through &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;two&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; distinct business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). For additional information, see &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Note 13&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and Notes to Consolidated Financial Statements&#x2013;&#x2013;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Note 18. Segment, Geographic and Other Revenue Information &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;in Pfizer&#x2019;s &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;text-align:center;"&gt;2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; Financial Report.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Certain amounts in the condensed consolidated financial statements and associated notes may not add due to rounding. All percentages have been calculated using unrounded amounts.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Our recent significant business development activities include:&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:24px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;On February 3, 2017, we completed the sale of our global infusion therapy net assets, HIS, to ICU Medical. The operating results of HIS are included in our condensed consolidated statement of income and EH&#x2019;s operating results through February 2, 2017 and, therefore, our financial results, and EH&#x2019;s operating results, for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;third quarter&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;text-align:center;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; do not reflect any contribution from HIS global operations, while our financial results, and EH&#x2019;s operating results, for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;third quarter&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;text-align:center;"&gt;2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; reflect three months of HIS global operations. Our financial results, and EH&#x2019;s operating results, for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;first nine months of&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;text-align:center;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; reflect approximately one month of HIS domestic operations and approximately two months of HIS international operations, while our financial results, and EH&#x2019;s operating results, for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;first nine months of&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;text-align:left;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;text-align:center;"&gt;2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; reflect nine months of HIS global operations. Assets and liabilities associated with HIS are presented as held for sale in the condensed consolidated balance sheet as of December 31, 2016. The HIS assets held for sale are reported in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Assets held for sale &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;and HIS liabilities held for sale are reported in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Other current liabilities.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:24px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;On December 22, 2016, which falls in the first fiscal quarter of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;text-align:center;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for our international operations, we acquired the development and commercialization rights to AstraZeneca&#x2019;s small molecule anti-infectives business, primarily outside the U.S. Commencing from the acquisition date, our financial statements reflect the assets, liabilities, operating results and cash flows of this business, and, in accordance with our international reporting period, our financial results, EH&#x2019;s operating results, and cash flows for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;third quarter&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;first nine months of&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;text-align:center;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; reflect approximately three months and eight months, respectively, of the small molecule anti-infectives business acquired from AstraZeneca.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:24px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;On September 28, 2016, we acquired Medivation for &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$81.50&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; per share. Commencing from the acquisition date, our financial statements reflect the assets, liabilities, operating results and cash flows of Medivation. Therefore, Medivation operations are reflected in our financial results, IH&#x2019;s operating results, and cash flows for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;third quarter&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;first nine months of&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;text-align:center;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. In accordance with our domestic and international reporting periods, our consolidated financial statements for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;third quarter&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;first nine months of&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;text-align:center;"&gt;2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; reflect three business days of Medivation operations, which were immaterial.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:24px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;On June 24, 2016, we acquired Anacor for &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$99.25&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; per share. Commencing from the acquisition date, our financial statements reflect the assets, liabilities, operating results and cash flows of Anacor. Therefore, Anacor operations are reflected in our financial results, IH&#x2019;s operating results, and cash flows for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;third quarter&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;first nine months of&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;text-align:center;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. In accordance with our domestic and international reporting periods, our consolidated financial statements for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;third quarter&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;first nine months of&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;text-align:center;"&gt;2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; reflect approximately three months of Anacor operations.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:4px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;For additional information, see &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Note 2&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and Notes to Consolidated Financial Statements&#x2013;&#x2013;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Note 2. &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Acquisitions, Sale of Hospira Infusion Systems Net Assets, Collaborative Arrangement and Equity-Method Investments&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;in&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Pfizer&#x2019;s &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;text-align:center;"&gt;2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; Financial Report.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;B. Adoption of New Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In the fourth quarter of 2016, we adopted a new accounting standard for certain elements of the accounting for share-based payments as of January 1, 2016. Specifically, the new standard requires excess tax benefits or deficiencies (including tax benefits of dividend equivalents) of share-based compensation to be recognized as a component of the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Provision for taxes on income&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, whereas excess tax benefits or deficiencies previously were recognized in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Additional paid-in capital&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. The net tax benefit for the Company was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$35 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;third quarter&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;text-align:center;"&gt;2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$85 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;first nine months of&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;text-align:center;"&gt;2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. Also, in the diluted net earnings per share calculation, when applying the treasury stock method for shares that could be repurchased, the assumed proceeds no longer include the amount of excess tax benefit.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Another element of the new accounting standard requires that we now present excess tax benefits as operating activities in our consolidated statement of cash flows. We elected to adopt this presentation on a prospective basis as of January 1, 2016. Additionally, cash paid by us when directly withholding shares for tax-withholding purposes is now a cash outflow from financing activities. This reclassification was required to be adopted retrospectively. As a result, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$87 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of cash outflows for the first nine months of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;text-align:center;"&gt;2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; was reclassified from operating activities to financing activities in the condensed consolidated statement of cash flows. For additional information, see Notes to Consolidated Financial Statements&#x2013;&#x2013;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Note 1B. &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Basis of Presentation and Significant Accounting Policies&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;:&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Adoption of New Accounting Standards&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; included in our &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;text-align:center;"&gt;2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; Financial Report.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We adopted a new standard as of January 1, 2017 that amended guidance on the assessment of whether an entity is the primary beneficiary of a variable interest entity. Under this new guidance, when evaluating whether an entity is the primary beneficiary, a single decision maker must consider its indirect interest held through related parties under common control proportionately. There was no material impact to our condensed consolidated financial statements from adopting this standard.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;We adopted a new standard as of January 1, 2017 related to inventory. The new guidance requires that inventory be measured at the lower of cost or net realizable value, which is defined as the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. There was no material impact to our condensed consolidated financial statements from adopting this standard.</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="FD2017Q3YTD"
      id="TextSelection-D30F8380EB1F5730961C36AF92547674-0-wk-Fact-ACB8EFA199AF54EC8B6A628FCE5B2652">Basis of Presentation&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;See the Glossary of Defined Terms at the beginning of this Quarterly Report on Form 10-Q for terms used throughout the condensed consolidated financial statements and related notes of this Quarterly Report on Form 10-Q.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We prepared the condensed consolidated financial statements following the requirements of the SEC for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP can be condensed or omitted.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The financial information included in our condensed consolidated financial statements for subsidiaries operating outside the U.S. is as of and for the three and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;nine months&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;August&#160;27, 2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;August&#160;28, 2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. The financial information included in our condensed consolidated financial statements for U.S. subsidiaries is as of and for the three and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;nine months&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;text-align:center;"&gt;October&#160;1, 2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;text-align:center;"&gt;October&#160;2, 2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Revenues, expenses, assets and liabilities can vary during each quarter of the year. Therefore, the results and trends in these interim financial statements may not be representative of those for the full year.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We are responsible for the unaudited financial statements included in this Quarterly Report on Form 10-Q. The interim financial statements include all normal and recurring adjustments that are considered necessary for the fair statement of our condensed consolidated balance sheets and condensed consolidated statements of income. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the consolidated financial statements and accompanying notes included in our &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;text-align:center;"&gt;2016&lt;/span&gt; Form 10-K.</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="FD2017Q3YTD"
      decimals="INF"
      id="d43675583e708-wk-Fact-7FDCD3767D7C5A07BAB773B71A23B8A3"
      unitRef="Operating_Segment">2</us-gaap:NumberOfOperatingSegments>
    <us-gaap:BusinessAcquisitionSharePrice
      contextRef="I2016Q3Sep28_us-gaap_BusinessAcquisitionAxis_pfe_MedivationMember"
      decimals="INF"
      id="d43675583e810-wk-Fact-BFC7B9276178582B99CC000090BE3B00"
      unitRef="usdPerShare">81.50</us-gaap:BusinessAcquisitionSharePrice>
    <us-gaap:BusinessAcquisitionSharePrice
      contextRef="I2016Q2AnacorAcquisition_us-gaap_BusinessAcquisitionAxis_pfe_AnacorMember"
      decimals="INF"
      id="d43675583e847-wk-Fact-A4CCFEF743375CD1801D535634B4A8AA"
      unitRef="usdPerShare">99.25</us-gaap:BusinessAcquisitionSharePrice>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="FD2017Q3YTD"
      id="TextSelection-3C50557390AC558DAE6FA5320BB98977-0-wk-Fact-57CAE0F791BB55BD9EC544EEB0C72C2E">Adoption of New Accounting Standards&lt;div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In the fourth quarter of 2016, we adopted a new accounting standard for certain elements of the accounting for share-based payments as of January 1, 2016. Specifically, the new standard requires excess tax benefits or deficiencies (including tax benefits of dividend equivalents) of share-based compensation to be recognized as a component of the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Provision for taxes on income&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, whereas excess tax benefits or deficiencies previously were recognized in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Additional paid-in capital&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. The net tax benefit for the Company was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$35 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;third quarter&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;text-align:center;"&gt;2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$85 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;first nine months of&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;text-align:center;"&gt;2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. Also, in the diluted net earnings per share calculation, when applying the treasury stock method for shares that could be repurchased, the assumed proceeds no longer include the amount of excess tax benefit.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Another element of the new accounting standard requires that we now present excess tax benefits as operating activities in our consolidated statement of cash flows. We elected to adopt this presentation on a prospective basis as of January 1, 2016. Additionally, cash paid by us when directly withholding shares for tax-withholding purposes is now a cash outflow from financing activities. This reclassification was required to be adopted retrospectively. As a result, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$87 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of cash outflows for the first nine months of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;text-align:center;"&gt;2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; was reclassified from operating activities to financing activities in the condensed consolidated statement of cash flows. For additional information, see Notes to Consolidated Financial Statements&#x2013;&#x2013;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Note 1B. &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Basis of Presentation and Significant Accounting Policies&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;:&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Adoption of New Accounting Standards&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; included in our &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;text-align:center;"&gt;2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; Financial Report.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We adopted a new standard as of January 1, 2017 that amended guidance on the assessment of whether an entity is the primary beneficiary of a variable interest entity. Under this new guidance, when evaluating whether an entity is the primary beneficiary, a single decision maker must consider its indirect interest held through related parties under common control proportionately. There was no material impact to our condensed consolidated financial statements from adopting this standard.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;We adopted a new standard as of January 1, 2017 related to inventory. The new guidance requires that inventory be measured at the lower of cost or net realizable value, which is defined as the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. There was no material impact to our condensed consolidated financial statements from adopting this standard.</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <pfe:EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTaxBenefitAmount
      contextRef="FD2016Q3QTD"
      decimals="-6"
      id="d43675583e924-wk-Fact-422175329FA65A29A0B38D483AE5E18B"
      unitRef="usd">35000000</pfe:EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTaxBenefitAmount>
    <pfe:EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTaxBenefitAmount
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43675583e937-wk-Fact-BD1046B7AB30529C847A0D7B4EE7F8B3"
      unitRef="usd">85000000</pfe:EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTaxBenefitAmount>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="FD2016Q3YTD_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_pfe_AccountingStandardsUpdate201609StatutoryTaxWithholdingComponentMember"
      decimals="-6"
      id="d43675583e952-wk-Fact-28CA698CD3A7539CA4CD81846D893B45"
      unitRef="usd">87000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <pfe:BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsCollaborativeArrangementsEquityandCostMethodInvestmentsDisclosureTextBlock
      contextRef="FD2017Q3YTD"
      id="TextSelection-D7B224EB00D154EB858CCD0ACC390AA6-0-wk-Fact-5E34F88968B15798B1D8F595279797A6">&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;Acquisitions, Sale of Hospira Infusion Systems Net Assets, Collaborative Arrangement and Equity-Method Investments&lt;/span&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;A. Acquisitions&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:10px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;text-decoration:underline;"&gt;AstraZeneca&#x2019;s Small Molecule Anti-Infectives Business (EH)&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;On December 22, 2016, which falls in the first fiscal quarter of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;text-align:center;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for our international operations, we acquired the development and commercialization rights to AstraZeneca&#x2019;s small molecule anti-infectives business, primarily outside the U.S., including the commercialization and development rights to the newly approved EU drug Zavicefta&#x2122; (ceftazidime-avibactam), the marketed agents Merrem&#x2122;/Meronem&#x2122; (meropenem) and Zinforo&#x2122;&#160;(ceftaroline fosamil), and the clinical development assets ATM-AVI and CXL (ceftaroline fosamil-AVI). Under the terms of the agreement, we made an upfront payment of approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$552 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; to AstraZeneca upon the close of the transaction and an additional &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; payment for a contractual purchase price adjustment in the second quarter of 2017. We also made a &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$50 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; milestone payment in the second quarter of 2017, we expect to make an additional milestone payment of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$125 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in our first fiscal quarter of 2018 and we will make a deferred payment of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$175 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; to AstraZeneca in January 2019. In addition, AstraZeneca may be eligible to receive an additional milestone payment of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$75 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; if the related milestone is achieved prior to December 31, 2021, and up to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$600 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; if sales of Zavicefta&#x2122; exceed certain thresholds prior to January 1, 2026, as well as tiered royalties on sales of Zavicefta&#x2122; and ATM-AVI in certain markets for a period ending on the later of ten years from first commercial sale or the loss of patent protection or loss of regulatory exclusivity. The total royalty payments are unlimited during the royalty term and the undiscounted payments are expected to be in the range of approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$250 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$425 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. The total fair value &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;of consideration transferred for AstraZeneca&#x2019;s small molecule anti-infectives business was approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1,045 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, which includes &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$555 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in cash, plus the fair value of contingent consideration of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$490 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; (which is composed of the deferred payment, the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$50 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; milestone payment made in the second quarter of 2017 and the future expected milestone and royalty payments). In connection with this acquisition, we provisionally recorded &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$879 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;background-color:#ffffff;"&gt;in&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;background-color:#ffffff;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;background-color:#ffffff;font-style:italic;"&gt;Identifiable intangible assets&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;background-color:#ffffff;"&gt;, primarily consisting&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$660 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt; Developed technology rights&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$219 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;IPR&amp;amp;D&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. We also recorded &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$92 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Other current assets&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; related to the economic value of inventory which was retained by AstraZeneca for sale on our behalf, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$92 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Goodwill&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$17 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of net deferred tax liabilities. The allocation of the consideration transferred to the assets and the&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;background-color:#ffffff;"&gt;liabilities assumed has not yet been finalized.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:10px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;text-decoration:underline;"&gt;Medivation, Inc. (IH)&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;On September 28, 2016, we acquired Medivation for &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$81.50&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; per share. The total fair value of consideration transferred for Medivation was approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$14.3 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in cash (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$13.9 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, net of cash acquired). Of this consideration, approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$365 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; was not paid as of December 31, 2016, and was recorded in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Other current liabilities. &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Substantially all of the remaining consideration was paid as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;text-align:center;"&gt;October&#160;1, 2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. Medivation is now a wholly-owned subsidiary of Pfizer. Medivation is a biopharmaceutical company focused on developing and commercializing small molecules for oncology. Medivation&#x2019;s portfolio includes Xtandi (enzalutamide), an androgen receptor inhibitor that blocks multiple steps in the androgen receptor signaling pathway within tumor cells. Xtandi is being developed and commercialized through a collaboration with Astellas. Astellas has exclusive commercialization rights for Xtandi outside the U.S. In addition, Medivation has a development-stage oncology asset in its pipeline, talazoparib, which is currently in a Phase 3 study for the treatment of BRCA-mutated breast cancer. In connection with this acquisition, we recorded &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$12.2 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Identifiable intangible assets&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, primarily consisting of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$8.1 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Developed technology rights&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; with an average useful life of approximately 12 years and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$4.1 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;IPR&amp;amp;D, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;and recorded &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$6.1 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt; Goodwill,&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$4.0 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of net income tax liabilities, and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$259 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of assumed contingent consideration. In 2017 and 2016, we recorded measurement period adjustments to the estimated fair values initially recorded in 2016, which resulted in a reduction in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Identifiable intangible assets&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1.0 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; with a corresponding change to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Goodwill&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and net income tax liabilities. The measurement period adjustments were recorded to better reflect market participant assumptions about facts and circumstances existing as of the acquisition date. The third quarter and first nine months of 2017 results include a decrease of approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$38 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Amortization of intangible assets&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; which reflects the cumulative pre-tax impact of the measurement period adjustments to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Identifiable intangible assets&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; that were amortized to the income statement since the acquisition date. The measurement period adjustments did not result from intervening events subsequent to the acquisition date. The final allocation of the consideration transferred to the assets acquired and the liabilities assumed has been completed.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:10px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;text-decoration:underline;"&gt;Bamboo Therapeutics, Inc. (IH)&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;On August 1, 2016, we acquired all the remaining equity in Bamboo, a privately-held biotechnology company focused on developing gene therapies for the potential treatment of patients with certain rare diseases relating to neuromuscular conditions and those affecting the central nervous system, for &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$150 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, plus potential milestone payments of up to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$495 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; contingent upon the progression of key assets through development, regulatory approval and commercialization. The total fair value of the consideration transferred for Bamboo was approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$343 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, including cash of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$130 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$101 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, net of cash acquired), contingent consideration of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$167 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, consisting of milestone payments, and the fair value of Pfizer&#x2019;s previously held equity interest in Bamboo of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$45 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. We previously purchased a minority stake in Bamboo in the first quarter of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;text-align:center;"&gt;2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for a payment of approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$43 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. Upon acquiring the remaining interest in Bamboo in the third quarter of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;text-align:center;"&gt;2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, we recognized a gain of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; on our existing investment in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Other (income)/deductions&#x2013;&#x2013;net&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; over the one- year allocation period&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;.&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; This acquisition provides us with several clinical and pre-clinical assets that complement our rare disease portfolio, an advanced recombinant AAV vector design and production technology, and a fully functional Phase I/II gene therapy manufacturing facility. Bamboo is now a wholly-owned subsidiary of Pfizer. In connection with this acquisition, we recorded &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$330 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Identifiable intangible assets, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;consisting entirely of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;IPR&amp;amp;D. &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We also recorded &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$142 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Goodwill &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$94 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of net deferred tax liabilities. The final allocation of the consideration transferred to the assets acquired and the liabilities assumed has been completed.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;text-decoration:underline;"&gt;Anacor Pharmaceuticals, Inc. (IH)&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;On June 24, 2016, we acquired Anacor for &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$99.25&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; per share. The total fair value of consideration transferred for Anacor was approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$4.9 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in cash (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$4.5 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; net of cash acquired), plus &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$698 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; debt assumed. Anacor is now a wholly-owned subsidiary of Pfizer. Anacor is a biopharmaceutical company focused on novel small-molecule therapeutics derived from its boron chemistry platform. Anacor&#x2019;s crisaborole, a non-steroidal topical PDE-4 inhibitor with anti-inflammatory properties, was approved by the FDA on December 14, 2016 under the trade name, Eucrisa. In connection with this acquisition, we recorded &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$698 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; as the fair value of notes payable in cash, and recorded &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$4.9 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Identifiable intangible assets&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;primarily consisting of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$4.8 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;IPR&amp;amp;D&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, and recorded &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$646 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Goodwill &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$346 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of net income tax liabilities. The final allocation of the consideration transferred to the assets acquired and the liabilities assumed has been completed.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;B. &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;Sale of Hospira Infusion Systems Net Assets to ICU Medical, Inc. (EH)&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;On October 6, 2016, we announced that we entered into a definitive agreement under which ICU Medical would acquire all of our global infusion therapy net assets, HIS, for approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in cash and ICU Medical common stock&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;.&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; HIS includes IV pumps, solutions, and devices.&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;As a result of the performance of HIS relative to ICU Medical&#x2019;s expectations, on January 5, 2017, we entered into a revised agreement with ICU Medical under which ICU Medical would acquire HIS for up to approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$900 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, composed of cash and contingent cash consideration, ICU Medical common stock and seller financing.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The revised transaction closed on February 3, 2017. At closing, under the terms of the revised agreement, we received &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; newly issued shares of ICU Medical common stock (as originally agreed), which we initially valued at approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$428 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; (based upon the closing price of ICU Medical common stock on the closing date less a discount for lack of marketability) and which are reported as available-for-sale equity securities at fair value in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Long-term investments&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; on the condensed consolidated balance sheet as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;October&#160;1, 2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, a promissory note in the amount of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$75 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, which is reported in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Other noncurrent assets&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; on the condensed consolidated balance sheet as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;October&#160;1, 2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, and net cash of approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$200 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; before customary adjustments for net working capital, which is reported in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Other investing activities, net&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; on the condensed consolidated statement of cash flows for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;nine&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;October&#160;1, 2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. In addition, we are entitled to receive a contingent amount of up to an additional &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$225 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in cash based on ICU Medical&#x2019;s achievement of certain cumulative performance targets for the combined company through December 31, 2019. After receipt of the ICU Medical shares, we own approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;16%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of ICU Medical. We have agreed to certain restrictions on transfer of our ICU Medical shares for 18 months after the closing date. The promissory note from ICU Medical has a term of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; years and bears interest at LIBOR plus &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2.25%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for the first year and LIBOR plus &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2.50%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for the second and third years. We recognized pre-tax income of approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$12 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;third&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; quarter of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;text-align:center;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and pre-tax losses of approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$52 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in the first &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;nine&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; months of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;text-align:center;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Other (income)/deductions&#x2013;&#x2013;net, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;representing adjustments to amounts previously recorded to write down the HIS net assets to fair value less costs to sell. For additional information, see &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Note 4&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and Notes to Consolidated Financial Statements&#x2013;&#x2013;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Note 2. &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Acquisitions, Sale of Hospira Infusion Systems Net Assets, Collaborative Arrangement and Equity-Method Investments&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;in&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Pfizer&#x2019;s &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;text-align:center;"&gt;2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; Financial Report.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;While we have received the full purchase price excluding the contingent amount as of the February 3, 2017 closing, the sale of the HIS net assets was not completed in certain non-U.S. jurisdictions due to temporary regulatory or operational constraints. In these jurisdictions, which represent a relatively small portion of the HIS net assets, we have continued to operate the net assets for the net economic benefit of ICU Medical, and we are indemnified by ICU Medical against risks associated with such operations during the interim period, subject to our obligations under the definitive transaction agreements. Sales of the HIS net assets have occurred in certain of these jurisdictions as of October 1, 2017 and we expect the sale of the HIS net assets in the remaining jurisdictions to be fully completed by the first quarter of 2018. As such, and as we have already received all of the non-contingent proceeds from the sale and ICU Medical is contractually obligated to complete the transaction, we have treated these jurisdictions as sold for accounting purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In connection with the sale transaction, we entered into certain transitional agreements designed to facilitate the orderly transition of the HIS net assets to ICU Medical. These agreements primarily relate to administrative services, which are generally to be provided for a period of up to 24 months after the closing date. We will also manufacture and supply certain HIS products for ICU Medical and ICU Medical will manufacture and supply certain retained Pfizer products for us after closing, generally for a term of five years. These agreements are not material to Pfizer and none confers upon us the ability to influence the operating and/or financial policies of ICU Medical subsequent to the sale.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;C. Collaboration Arrangement&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;text-decoration:underline;"&gt;Collaboration with Merck &amp;amp; Co., Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In 2013, we entered into a worldwide, except for Japan, collaboration agreement with Merck for the development and commercialization of ertugliflozin (PF-04971729), our oral sodium glucose cotransporter (SGLT2) inhibitor for the treatment of type 2 diabetes currently under regulatory review. Under the agreement, we are collaborating with Merck on the clinical development of ertugliflozin, and ertugliflozin-containing fixed-dose combinations with metformin and Januvia (sitagliptin) tablets.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:11pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In the first quarter of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;text-align:center;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:11pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;we received a &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$90 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; milestone payment from Merck upon the FDA&#x2019;s acceptance for review of the NDAs for ertugliflozin and two fixed-dose combinations (ertugliflozin plus Januvia (sitagliptin) and ertugliflozin plus metformin), which has been deferred and primarily reported in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Other noncurrent liabilities &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;and is being recognized in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Other (income)/deductions&#x2013;&#x2013;net&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; over a multi-year period. We are eligible for additional payments associated with the achievement of future clinical, regulatory and commercial milestones. We share potential revenues and certain costs with Merck on a &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;60%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;/&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;40%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; basis, with Pfizer having the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;40%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; share. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;D. Equity-Method Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;text-decoration:underline;"&gt;Investment in Hisun Pfizer Pharmaceuticals Company Limited&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:11pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;text-align:center;"&gt;2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;,&lt;/span&gt;&lt;span style="font-family:inherit;font-size:11pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;we determined that we had other-than-temporary declines in the value of Hisun Pfizer, our &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;49%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;-owned equity-method investment in China, and, therefore, we recognized a loss of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$211 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for the first &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;nine&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; months of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;text-align:center;"&gt;2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Other (income)/deductions&#x2013;&#x2013;net &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;(see &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Note 4&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;. &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The declines in value resulted from lower expectations as to the future cash flows to be generated by Hisun Pfizer, primarily as a result of an increase in risk due to the continued slowdown in the Chinese economy and changes in the expected timing and number of new product introductions by Hisun Pfizer. As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;text-align:center;"&gt;October&#160;1, 2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the carrying value of our investment in Hisun Pfizer is &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$270 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, which is included in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Long-term investments&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. We are continuing to evaluate strategic alternatives with Hisun. These strategic alternatives could impact the value of our investment in Hisun Pfizer in future periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:5pt;"&gt;&lt;span style="font-family:inherit;font-size:5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In valuing our investment in Hisun Pfizer, we used discounted cash flow techniques, reflecting our best estimate of the various risks inherent in the projected cash flows, and a nominal terminal year growth factor. Some of the more significant estimates and assumptions inherent in this approach include: the amount and timing of the projected net cash flows, which include the expected impact of competitive, legal, economic and/or regulatory forces on the products; the long-term growth rate, which seeks to project the sustainable growth rate over the long-term; and the discount rate, which seeks to reflect the various risks inherent in the projected cash flows, including country risk. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;text-decoration:underline;"&gt;Investment in Laborat&#xf3;rio Teuto Brasileiro S.A.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We entered into an agreement on June 30, 2017 to exit our investment in Teuto, a &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;40%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;-owned generics company in Brazil, and sell our &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;40%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; interest in Teuto to the majority shareholders. As part of the agreement, we have waived our option to acquire the remaining &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;60%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of Teuto, and Teuto&#x2019;s other shareholders have waived their option to sell their &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;60%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; stake in the company to us. As a result, in the second quarter of 2017, we recognized a net loss of approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$30 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Other (income)/deductions&#x2013;&#x2013;net &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;(see &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Note 4&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;), which included the impairment of our equity-method investment in Teuto, the reversal of a contingent liability associated with the majority shareholders&#x2019; option to sell their &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;60%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; stake in the company to us, and the recognition in earnings of the currency translation adjustment associated with the Teuto investment. The transaction closed on August 16, 2017. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:11pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;text-align:center;"&gt;2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:11pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;we determined that we had an other-than-temporary decline in the value of Teuto, and, therefore, we recognized a loss of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$50 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for the first &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;nine&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; months of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;text-align:center;"&gt;2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Other (income)/deductions&#x2013;&#x2013;net&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; (see &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Note 4&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;) related to our equity-method investment. The decline in value resulted from lower expectations as to the future cash flows to be generated by Teuto, primarily due to a slowdown in Brazilian economic conditions, which have been impacted by political risk, higher inflation, and the depreciation of the Brazilian real.&lt;/span&gt;&lt;/div&gt;In valuing our investment in Teuto, we used discounted cash flow techniques, reflecting our best estimate of the various risks inherent in the projected cash flows, and a nominal terminal year growth factor. Some of the more significant estimates and assumptions inherent in this approach include: the amount and timing of the projected net cash flows, which include the expected impact of competitive, legal, economic and/or regulatory forces on the products; the long-term growth rate, which seeks to project the sustainable growth rate over the long-term; and the discount rate, which seeks to reflect the various risks inherent in the projected cash flows, including country risk.</pfe:BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsCollaborativeArrangementsEquityandCostMethodInvestmentsDisclosureTextBlock>
    <pfe:PaymentstoAcquireBusinessesGrossInitialPayment
      contextRef="D2016Q4Dec22-Dec22_us-gaap_BusinessAcquisitionAxis_pfe_AstraZenecaMember"
      decimals="-6"
      id="d43687567e648-wk-Fact-657BE69A39C55387B9A8101A49B75190"
      unitRef="usd">552000000</pfe:PaymentstoAcquireBusinessesGrossInitialPayment>
    <pfe:PaymentstoAcquireBusinessesGrossPurchasePriceAdjustment
      contextRef="FD2017Q2QTD_us-gaap_BusinessAcquisitionAxis_pfe_AstraZenecaMember"
      decimals="-6"
      id="d43687567e652-wk-Fact-D9B9F1DEBE75560B8933A4AC4B9C5CBB"
      unitRef="usd">3000000</pfe:PaymentstoAcquireBusinessesGrossPurchasePriceAdjustment>
    <us-gaap:PaymentForContingentConsiderationLiabilityInvestingActivities
      contextRef="FD2017Q2QTD_us-gaap_BusinessAcquisitionAxis_pfe_AstraZenecaMember"
      decimals="-6"
      id="d43687567e656-wk-Fact-FD35C9C066AA554EA5D1807C52E5D2F8"
      unitRef="usd">50000000</us-gaap:PaymentForContingentConsiderationLiabilityInvestingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityInvestingActivities
      contextRef="FD2018Q1QTD_us-gaap_BusinessAcquisitionAxis_pfe_AstraZenecaMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioForecastMember"
      decimals="-6"
      id="d43687567e660-wk-Fact-7BE54186E055C9129E079229C2143B9E"
      unitRef="usd">125000000</us-gaap:PaymentForContingentConsiderationLiabilityInvestingActivities>
    <pfe:BusinessCombinationConsiderationTransferredDeferredPayment
      contextRef="D2016Q4Dec22-Dec22_us-gaap_BusinessAcquisitionAxis_pfe_AstraZenecaMember"
      decimals="-6"
      id="d43687567e665-wk-Fact-0D1D72A9F6215AEF9F76B0E41D313DD7"
      unitRef="usd">175000000</pfe:BusinessCombinationConsiderationTransferredDeferredPayment>
    <pfe:BusinessCombinationConsiderationTransferredMilestonePaymentsMaximum
      contextRef="D2016Q4Dec22-Dec22_us-gaap_BusinessAcquisitionAxis_pfe_AstraZenecaMember"
      decimals="-6"
      id="d43687567e669-wk-Fact-893E7328A6E2587F87C7C738D3872CF6"
      unitRef="usd">75000000</pfe:BusinessCombinationConsiderationTransferredMilestonePaymentsMaximum>
    <pfe:BusinessCombinationConsiderationTransferredSalesrelatedPaymentsMaximum
      contextRef="D2016Q4Dec22-Dec22_us-gaap_BusinessAcquisitionAxis_pfe_AstraZenecaMember"
      decimals="-6"
      id="d43687567e673-wk-Fact-2B31A81FDEC654199C1610C986A617BC"
      unitRef="usd">600000000</pfe:BusinessCombinationConsiderationTransferredSalesrelatedPaymentsMaximum>
    <pfe:BusinessCombinationConsiderationTransferredUndiscountedRoyaltyPayments
      contextRef="D2016Q4Dec22-Dec22_us-gaap_BusinessAcquisitionAxis_pfe_AstraZenecaMember_us-gaap_RangeAxis_us-gaap_MinimumMember"
      decimals="-6"
      id="d43687567e677-wk-Fact-F615B8561B78574CBB8752367FD1DA20"
      unitRef="usd">250000000</pfe:BusinessCombinationConsiderationTransferredUndiscountedRoyaltyPayments>
    <pfe:BusinessCombinationConsiderationTransferredUndiscountedRoyaltyPayments
      contextRef="D2016Q4Dec22-Dec22_us-gaap_BusinessAcquisitionAxis_pfe_AstraZenecaMember_us-gaap_RangeAxis_us-gaap_MaximumMember"
      decimals="-6"
      id="d43687567e681-wk-Fact-F63FF6A144A654A5B853607E09594E11"
      unitRef="usd">425000000</pfe:BusinessCombinationConsiderationTransferredUndiscountedRoyaltyPayments>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="D2016Q4Dec22-Dec22_us-gaap_BusinessAcquisitionAxis_pfe_AstraZenecaMember"
      decimals="-6"
      id="d43687567e688-wk-Fact-7EB40678643F5B9A8D29CAC721DDC2D1"
      unitRef="usd">1045000000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="D2016Q4Dec22-Dec22_us-gaap_BusinessAcquisitionAxis_pfe_AstraZenecaMember"
      decimals="-6"
      id="d43687567e692-wk-Fact-5F34E1E596905AD79AC3A31E592AD8AA"
      unitRef="usd">555000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="I2016Q4Dec22_us-gaap_BusinessAcquisitionAxis_pfe_AstraZenecaMember"
      decimals="-6"
      id="d43687567e696-wk-Fact-156CCDE95FE75A349CB4A7879A148ECE"
      unitRef="usd">490000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:PaymentForContingentConsiderationLiabilityInvestingActivities
      contextRef="FD2017Q2QTD_us-gaap_BusinessAcquisitionAxis_pfe_AstraZenecaMember"
      decimals="-6"
      id="d43687567e700-wk-Fact-FD35C9C066AA554EA5D1807C52E5D2F8"
      unitRef="usd">50000000</us-gaap:PaymentForContingentConsiderationLiabilityInvestingActivities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="I2016Q4Dec22_us-gaap_BusinessAcquisitionAxis_pfe_AstraZenecaMember"
      decimals="-6"
      id="d43687567e704-wk-Fact-69D18BDF56E3520398AFFB46BD54FB80"
      unitRef="usd">879000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="I2016Q4Dec22_us-gaap_BusinessAcquisitionAxis_pfe_AstraZenecaMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember"
      decimals="-6"
      id="d43687567e721-wk-Fact-E043D3E1364156A38BA50F1A95C5FDE6"
      unitRef="usd">660000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="I2016Q4Dec22_us-gaap_BusinessAcquisitionAxis_pfe_AstraZenecaMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember"
      decimals="-6"
      id="d43687567e729-wk-Fact-98DF5EAD37225F94AEF79B530F2A918E"
      unitRef="usd">219000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther
      contextRef="I2016Q4Dec22_us-gaap_BusinessAcquisitionAxis_pfe_AstraZenecaMember"
      decimals="-6"
      id="d43687567e738-wk-Fact-EFFCA6422CE7572E8AFA6946EA58D495"
      unitRef="usd">92000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther>
    <us-gaap:Goodwill
      contextRef="I2016Q4Dec22_us-gaap_BusinessAcquisitionAxis_pfe_AstraZenecaMember"
      decimals="-6"
      id="d43687567e746-wk-Fact-69E147FB5625509A914677905319EACB"
      unitRef="usd">92000000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities
      contextRef="I2016Q4Dec22_us-gaap_BusinessAcquisitionAxis_pfe_AstraZenecaMember"
      decimals="-6"
      id="d43687567e755-wk-Fact-BA47BF334B625B08B7BA3C98253886F4"
      unitRef="usd">17000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <us-gaap:BusinessAcquisitionSharePrice
      contextRef="I2016Q3Sep28_us-gaap_BusinessAcquisitionAxis_pfe_MedivationMember"
      decimals="INF"
      id="d43687567e769-wk-Fact-BFC7B9276178582B99CC000090BE3B00"
      unitRef="usdPerShare">81.50</us-gaap:BusinessAcquisitionSharePrice>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="D2016Q3Sep28-Sep28_us-gaap_BusinessAcquisitionAxis_pfe_MedivationMember"
      decimals="-8"
      id="d43687567e773-wk-Fact-E1AAD35F4B8F510FBE6343C41BBB3E35"
      unitRef="usd">14300000000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <pfe:BusinessCombinationConsiderationTransferredNetofCashAcquired
      contextRef="D2016Q3Sep28-Sep28_us-gaap_BusinessAcquisitionAxis_pfe_MedivationMember"
      decimals="-8"
      id="d43687567e777-wk-Fact-C75AE989F4BA5F97B616D203FD1E39E8"
      unitRef="usd">13900000000</pfe:BusinessCombinationConsiderationTransferredNetofCashAcquired>
    <pfe:BusinessCombinationConsiderationTransferredAmountPayable
      contextRef="FI2016Q4_us-gaap_BusinessAcquisitionAxis_pfe_MedivationMember"
      decimals="-6"
      id="d43687567e781-wk-Fact-17EF679F2F5A56B38C3FEBA1811ABAC3"
      unitRef="usd">365000000</pfe:BusinessCombinationConsiderationTransferredAmountPayable>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="I2016Q3Sep28_us-gaap_BusinessAcquisitionAxis_pfe_MedivationMember"
      decimals="-8"
      id="d43687567e794-wk-Fact-3492BBB2373A5647895A246D631BFA67"
      unitRef="usd">12200000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="I2016Q3Sep28_us-gaap_BusinessAcquisitionAxis_pfe_MedivationMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember"
      decimals="-8"
      id="d43687567e802-wk-Fact-8565C203A73153AA923606D5F1BC085C"
      unitRef="usd">8100000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="I2016Q3Sep28_us-gaap_BusinessAcquisitionAxis_pfe_MedivationMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember"
      decimals="-8"
      id="d43687567e810-wk-Fact-6F53AB2DFB3A5A6FAD6BC73529189371"
      unitRef="usd">4100000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:Goodwill
      contextRef="I2016Q3Sep28_us-gaap_BusinessAcquisitionAxis_pfe_MedivationMember"
      decimals="-8"
      id="d43687567e819-wk-Fact-6FEAC14518C35EF6BE23028F34113E5D"
      unitRef="usd">6100000000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities
      contextRef="I2016Q3Sep28_us-gaap_BusinessAcquisitionAxis_pfe_MedivationMember"
      decimals="-8"
      id="d43687567e827-wk-Fact-261798DC42D55FF282CBDF428112CF2B"
      unitRef="usd">4000000000.0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="I2016Q3Sep28_us-gaap_BusinessAcquisitionAxis_pfe_MedivationMember"
      decimals="-6"
      id="d43687567e831-wk-Fact-EE3442C5D0BD5184AE06BF9DD04A7205"
      unitRef="usd">259000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles
      contextRef="D2017Q3Sep29-Oct01_us-gaap_BusinessAcquisitionAxis_pfe_MedivationMember"
      decimals="-8"
      id="d43687567e840-wk-Fact-329FA1C56A20EBBA37677DED51F2DC7C"
      unitRef="usd">-1000000000.0</us-gaap:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles>
    <pfe:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIncreaseDecreaseinAmortizationofIntangibleAssets
      contextRef="FD2017Q3QTD_us-gaap_BusinessAcquisitionAxis_pfe_MedivationMember"
      decimals="-6"
      id="d43687567e848-wk-Fact-9D3A35DE9ECE7C4558687DF9A2AF61E6"
      unitRef="usd">-38000000</pfe:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIncreaseDecreaseinAmortizationofIntangibleAssets>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="D2016Q3Aug01-Aug01_us-gaap_BusinessAcquisitionAxis_pfe_BambooTherapeuticsMember"
      decimals="-6"
      id="d43687567e867-wk-Fact-F7D5BB52F6405772A445C2B27AC9F26D"
      unitRef="usd">150000000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <pfe:BusinessCombinationConsiderationTransferredMilestonePaymentsMaximum
      contextRef="D2016Q3Aug01-Aug01_us-gaap_BusinessAcquisitionAxis_pfe_BambooTherapeuticsMember"
      decimals="-6"
      id="d43687567e871-wk-Fact-D3A3EBBC5160517E94ADBCA595690003"
      unitRef="usd">495000000</pfe:BusinessCombinationConsiderationTransferredMilestonePaymentsMaximum>
    <us-gaap:BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1
      contextRef="D2016Q3Aug01-Aug01_us-gaap_BusinessAcquisitionAxis_pfe_BambooTherapeuticsMember"
      decimals="-6"
      id="d43687567e875-wk-Fact-1633E5F799E5581EBA3C932D6D8CE3A2"
      unitRef="usd">343000000</us-gaap:BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="D2016Q3Aug01-Aug01_us-gaap_BusinessAcquisitionAxis_pfe_BambooTherapeuticsMember"
      decimals="-6"
      id="d43687567e879-wk-Fact-EA29606A0E2B511E89A653AE9E0999B1"
      unitRef="usd">130000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="D2016Q3Aug01-Aug01_us-gaap_BusinessAcquisitionAxis_pfe_BambooTherapeuticsMember"
      decimals="-6"
      id="d43687567e883-wk-Fact-E0AC0361D7DA522494AE56B75ACFC3EA"
      unitRef="usd">101000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="I2016Q3Aug01-Aug01_us-gaap_BusinessAcquisitionAxis_pfe_BambooTherapeuticsMember"
      decimals="-6"
      id="d43687567e888-wk-Fact-45683FBF65C355B489C4D3A3D4143E54"
      unitRef="usd">167000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1
      contextRef="D2016Q3Aug01-Aug01_us-gaap_BusinessAcquisitionAxis_pfe_BambooTherapeuticsMember"
      decimals="-6"
      id="d43687567e892-wk-Fact-37CCCB24ADAA5E6D84A8C5A4C4A879E2"
      unitRef="usd">45000000</us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="FD2016Q1QTD_us-gaap_BusinessAcquisitionAxis_pfe_BambooTherapeuticsMember"
      decimals="-6"
      id="d43687567e900-wk-Fact-96260D53526D568284DF6AC40BF5FEA9"
      unitRef="usd">43000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain
      contextRef="FD2016Q3QTD_us-gaap_BusinessAcquisitionAxis_pfe_BambooTherapeuticsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember"
      decimals="-6"
      id="d43687567e908-wk-Fact-CAEE4F1B76BC58C4A8827053DF7A7864"
      unitRef="usd">2000000</us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="I2016Q3Aug01-Aug01_us-gaap_BusinessAcquisitionAxis_pfe_BambooTherapeuticsMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember"
      decimals="-6"
      id="d43687567e921-wk-Fact-468408BA9A31556A863846D8FA8DCE6A"
      unitRef="usd">330000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:Goodwill
      contextRef="I2016Q3Aug01-Aug01_us-gaap_BusinessAcquisitionAxis_pfe_BambooTherapeuticsMember"
      decimals="-6"
      id="d43687567e934-wk-Fact-11F70F11F63A531383B5426456C060D9"
      unitRef="usd">142000000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities
      contextRef="I2016Q3Aug01-Aug01_us-gaap_BusinessAcquisitionAxis_pfe_BambooTherapeuticsMember"
      decimals="-6"
      id="d43687567e942-wk-Fact-BB08A3DC05B553B9AC750857EF6E41A6"
      unitRef="usd">94000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <us-gaap:BusinessAcquisitionSharePrice
      contextRef="I2016Q2AnacorAcquisition_us-gaap_BusinessAcquisitionAxis_pfe_AnacorMember"
      decimals="INF"
      id="d43687567e955-wk-Fact-A4CCFEF743375CD1801D535634B4A8AA"
      unitRef="usdPerShare">99.25</us-gaap:BusinessAcquisitionSharePrice>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="D2016Q2Jun24-Jun24_us-gaap_BusinessAcquisitionAxis_pfe_AnacorMember"
      decimals="-8"
      id="d43687567e959-wk-Fact-95C29614540351DE9037594EC3C94315"
      unitRef="usd">4900000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="D2016Q2Jun24-Jun24_us-gaap_BusinessAcquisitionAxis_pfe_AnacorMember"
      decimals="-8"
      id="d43687567e963-wk-Fact-7F7DF1BB1F03504B8A8B5D2E9C815949"
      unitRef="usd">4500000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt
      contextRef="I2016Q2AnacorAcquisition_us-gaap_BusinessAcquisitionAxis_pfe_AnacorMember"
      decimals="-6"
      id="d43687567e967-wk-Fact-F1D518BE01C15066AFE97B15088EC11E"
      unitRef="usd">698000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt
      contextRef="I2016Q2AnacorAcquisition_us-gaap_BusinessAcquisitionAxis_pfe_AnacorMember"
      decimals="-6"
      id="d43687567e971-wk-Fact-F1D518BE01C15066AFE97B15088EC11E"
      unitRef="usd">698000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets
      contextRef="I2016Q2AnacorAcquisition_us-gaap_BusinessAcquisitionAxis_pfe_AnacorMember"
      decimals="-8"
      id="d43687567e976-wk-Fact-30109A63BBBB5D869A8C0F101C3C0957"
      unitRef="usd">4900000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="I2016Q2AnacorAcquisition_us-gaap_BusinessAcquisitionAxis_pfe_AnacorMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember"
      decimals="-8"
      id="d43687567e987-wk-Fact-68E476566B0850718997E601135758C9"
      unitRef="usd">4800000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:Goodwill
      contextRef="I2016Q2AnacorAcquisition_us-gaap_BusinessAcquisitionAxis_pfe_AnacorMember"
      decimals="-6"
      id="d43687567e995-wk-Fact-11AD8C3FBDFD5610B463B5D5299551B3"
      unitRef="usd">646000000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities
      contextRef="I2016Q2AnacorAcquisition_us-gaap_BusinessAcquisitionAxis_pfe_AnacorMember"
      decimals="-6"
      id="d43687567e1003-wk-Fact-654A611F62EB5266A240D2727045C86A"
      unitRef="usd">346000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration
      contextRef="I2016Q4Oct06_us-gaap_CounterpartyNameAxis_pfe_ICUMedicalMember_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_HISMember"
      decimals="-9"
      id="d43687567e1045-wk-Fact-BE2F6AB244E55D7A8640979329D166AC"
      unitRef="usd">1000000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration
      contextRef="I2017Q1Jan05_us-gaap_CounterpartyNameAxis_pfe_ICUMedicalMember_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_HISMember"
      decimals="-6"
      id="d43687567e1057-wk-Fact-422B7533CB3952A4836B385CAF9FF170"
      unitRef="usd">900000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration>
    <pfe:DisposalGroupIncludingDiscontinuedOperationConsiderationTransferredEquityInterestsShares
      contextRef="I2017Q1Feb03_us-gaap_CounterpartyNameAxis_pfe_ICUMedicalMember_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_HISMember"
      decimals="-5"
      id="d43687567e1064-wk-Fact-911EB761D3C6590EA6CD704F46034785"
      unitRef="shares">3200000</pfe:DisposalGroupIncludingDiscontinuedOperationConsiderationTransferredEquityInterestsShares>
    <pfe:DisposalGroupIncludingDiscontinuedOperationConsiderationTransferredEquityInterests
      contextRef="I2017Q1Feb03_us-gaap_CounterpartyNameAxis_pfe_ICUMedicalMember_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_HISMember"
      decimals="-6"
      id="d43687567e1068-wk-Fact-88E2E31CC1495183A0F02B04F4BB0670"
      unitRef="usd">428000000</pfe:DisposalGroupIncludingDiscontinuedOperationConsiderationTransferredEquityInterests>
    <pfe:DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivable
      contextRef="I2017Q1Feb03_us-gaap_CounterpartyNameAxis_pfe_ICUMedicalMember_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_HISMember"
      decimals="-6"
      id="d43687567e1080-wk-Fact-C837741F7E265EA590514DA12CED34D8"
      unitRef="usd">75000000</pfe:DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivable>
    <us-gaap:ProceedsFromDivestitureOfBusinesses
      contextRef="D2017Q1Feb03-Feb03_us-gaap_CounterpartyNameAxis_pfe_ICUMedicalMember_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_HISMember"
      decimals="-6"
      id="d43687567e1093-wk-Fact-DB17DE17C6F85F4CAB63402F954B36A7"
      unitRef="usd">200000000</us-gaap:ProceedsFromDivestitureOfBusinesses>
    <pfe:DisposalGroupIncludingDiscontinuedOperationContingentConsideration
      contextRef="I2017Q1Feb03_us-gaap_CounterpartyNameAxis_pfe_ICUMedicalMember_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_HISMember"
      decimals="-6"
      id="d43687567e1110-wk-Fact-CCE861B5954250CAA7F6496324EC1015"
      unitRef="usd">225000000</pfe:DisposalGroupIncludingDiscontinuedOperationContingentConsideration>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="FI2017Q3_us-gaap_CounterpartyNameAxis_pfe_ICUMedicalMember_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_HISMember"
      decimals="2"
      id="d43687567e1114-wk-Fact-89A1AEFA59C55B02AF326045F1AD9175"
      unitRef="number">0.16</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <pfe:DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivableInterestRate
      contextRef="D2017Q1Feb03-Feb03_us-gaap_CounterpartyNameAxis_pfe_ICUMedicalMember_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_HISMember_us-gaap_VariableRateAxis_us-gaap_LondonInterbankOfferedRateLIBORMember"
      decimals="4"
      id="d43687567e1122-wk-Fact-22A4660F38F150D2A1EE54C402FB0060"
      unitRef="number">0.0225</pfe:DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivableInterestRate>
    <pfe:DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivableInterestRateYearTwo
      contextRef="D2017Q1Feb03-Feb03_us-gaap_CounterpartyNameAxis_pfe_ICUMedicalMember_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_HISMember_us-gaap_VariableRateAxis_us-gaap_LondonInterbankOfferedRateLIBORMember"
      decimals="4"
      id="d43687567e1126-wk-Fact-058D7A80D5A055368745AF7482558CB0"
      unitRef="number">0.0250</pfe:DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivableInterestRateYearTwo>
    <us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
      contextRef="FD2017Q3QTD_us-gaap_CounterpartyNameAxis_pfe_ICUMedicalMember_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_HISMember"
      decimals="-6"
      id="d43687567e1131-wk-Fact-9D15F4421F756404E8579242D4ADE49A"
      unitRef="usd">12000000</us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal>
    <us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
      contextRef="FD2017Q3YTD_us-gaap_CounterpartyNameAxis_pfe_ICUMedicalMember_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_HISMember"
      decimals="-6"
      id="d43687567e1143-wk-Fact-E5CB1F203E7813A248DE9242F0D38585"
      unitRef="usd">-52000000</us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal>
    <us-gaap:ProceedsFromCollaborators
      contextRef="FD2017Q1QTD_us-gaap_CounterpartyNameAxis_pfe_MerckKGaAMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-6"
      id="d43687567e1238-wk-Fact-B002A9FE8D3757229766F6559419D0FF"
      unitRef="usd">90000000</us-gaap:ProceedsFromCollaborators>
    <pfe:CollaborativeArrangementCollaboratorsRevenueandExpenseOwnershipPercentage
      contextRef="FD2017Q3YTD_us-gaap_CounterpartyNameAxis_pfe_MerckKGaAMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="2"
      id="d43687567e1250-wk-Fact-8CFF4D7FC68454FCB7F23231E8D396E7"
      unitRef="number">0.60</pfe:CollaborativeArrangementCollaboratorsRevenueandExpenseOwnershipPercentage>
    <pfe:CollaborativeArrangementCompanysRevenueandExpenseOwnershipPercentage
      contextRef="FD2017Q3YTD_us-gaap_CounterpartyNameAxis_pfe_MerckKGaAMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="2"
      id="d43687567e1255-wk-Fact-0FA05C8A024E5017BC626808F9824970"
      unitRef="number">0.40</pfe:CollaborativeArrangementCompanysRevenueandExpenseOwnershipPercentage>
    <pfe:CollaborativeArrangementCompanysRevenueandExpenseOwnershipPercentage
      contextRef="FD2017Q3YTD_us-gaap_CounterpartyNameAxis_pfe_MerckKGaAMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="2"
      id="d43687567e1259-wk-Fact-0FA05C8A024E5017BC626808F9824970"
      unitRef="number">0.40</pfe:CollaborativeArrangementCompanysRevenueandExpenseOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="FI2016Q3_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_HisunPfizerPharmaceuticalsCoLtdMember"
      decimals="2"
      id="d43687567e1282-wk-Fact-E0E2AB1F4EEE53C6B6DCA69B4759EC8D"
      unitRef="number">0.49</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment
      contextRef="FD2016Q3YTD_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_HisunPfizerPharmaceuticalsCoLtdMember"
      decimals="-6"
      id="d43687567e1286-wk-Fact-B851DA622DEF69DCB2D83E8DBA5E58C7"
      unitRef="usd">211000000</us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment>
    <us-gaap:EquityMethodInvestments
      contextRef="FI2017Q3_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_HisunPfizerPharmaceuticalsCoLtdMember"
      decimals="-6"
      id="d43687567e1315-wk-Fact-EA898D13F5055FB9AF4A0540A1775D85"
      unitRef="usd">270000000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="I2017Q2Jun30_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_LaboratorioTeutoBrasileroMember"
      decimals="2"
      id="d43687567e1338-wk-Fact-7A20B5BEC3C75D16BFE5A86C05D26ABA"
      unitRef="number">0.40</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="I2017Q2Jun30_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_LaboratorioTeutoBrasileroMember"
      decimals="2"
      id="d43687567e1342-wk-Fact-7A20B5BEC3C75D16BFE5A86C05D26ABA"
      unitRef="number">0.40</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="I2017Q2Jun30_dei_LegalEntityAxis_pfe_LaboratorioTeutoBrasileroMember_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_LaboratorioTeutoBrasileroMember"
      decimals="2"
      id="d43687567e1346-wk-Fact-E514899ACB1955ECA8A28246180FA71D"
      unitRef="number">0.60</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="I2017Q2Jun30_dei_LegalEntityAxis_pfe_LaboratorioTeutoBrasileroMember_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_LaboratorioTeutoBrasileroMember"
      decimals="2"
      id="d43687567e1350-wk-Fact-E514899ACB1955ECA8A28246180FA71D"
      unitRef="number">0.60</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal
      contextRef="FD2017Q3YTD_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_LaboratorioTeutoBrasileroMember"
      decimals="-6"
      id="d43687567e1354-wk-Fact-3E108918AAAA5512B11A290783D5B15E"
      unitRef="usd">-30000000</us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="I2017Q2Jun30_dei_LegalEntityAxis_pfe_LaboratorioTeutoBrasileroMember_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_LaboratorioTeutoBrasileroMember"
      decimals="2"
      id="d43687567e1367-wk-Fact-E514899ACB1955ECA8A28246180FA71D"
      unitRef="number">0.60</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment
      contextRef="FD2016Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_LaboratorioTeutoBrasileroMember"
      decimals="-6"
      id="d43687567e1380-wk-Fact-6870F39A774D54ABA3E37823BC3AAA03"
      unitRef="usd">50000000</us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment>
    <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock
      contextRef="FD2017Q3YTD"
      id="TextSelection-618AF0F88D785702B89176A8C50F5054-0-wk-Fact-3E4D502FB086570FBDDEE5A68B121067">&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives&lt;/span&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We incur significant costs in connection with acquiring, integrating and restructuring businesses and in connection with our global cost-reduction/productivity initiatives. For example: &lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:18px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In connection with acquisition activity, we typically incur costs associated with executing the transactions, integrating the acquired operations (which may include expenditures for consulting and the integration of systems and processes), and restructuring the combined company (which may include charges related to employees, assets and activities that will not continue in the combined company); and&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:18px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In connection with our cost-reduction/productivity initiatives, we typically incur costs and charges associated with site closings and other facility rationalization actions, workforce reductions and the expansion of shared services, including the development of global systems.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;text-align:left;font-size:5pt;"&gt;&lt;span style="font-family:inherit;font-size:5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;All of our businesses and functions may be impacted by these actions, including sales and marketing, manufacturing and R&amp;amp;D, as well as groups such as information technology, shared services and corporate operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In connection with our acquisition of Hospira, we are focusing our efforts on achieving an appropriate cost structure for the combined company. For up to a three-year period post-acquisition, we expect to incur costs of approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;(not including costs of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$215 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for full-year 2015 associated with the return of acquired IPR&amp;amp;D rights as described in the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Current-Period Key Activities &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;section of Notes to Consolidated Financial Statements&#x2013;&#x2013;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Note 3&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;in our 2016 Financial Report) associated with the integration of Hospira.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In 2016, we substantially completed previously disclosed cost-reduction initiatives begun in 2014 associated with our global commercial structure reorganization, manufacturing plant network rationalization and optimization initiatives, and additional cost-reduction/productivity initiatives across the enterprise.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;As a result of the evaluation performed in connection with our decision in September 2016 to not pursue, at that time, splitting IH and EH into two separate publicly-traded companies, we identified new opportunities to potentially achieve greater optimization and efficiency to become more competitive in our business. Therefore, in early &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;text-align:center;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, we initiated new enterprise-wide cost reduction/productivity initiatives, which we expect to substantially complete by the end of 2019. These initiatives will encompass all areas of our cost base and will include:&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:18px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Optimization of our manufacturing plant network to support IH and EH products and pipelines. During 2017-2019, we expect to incur costs of approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$800 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; related to this initiative. Through &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;October&#160;1, 2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, we incurred approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$122 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; associated with this initiative.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:18px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Activities in non-manufacturing related areas, which include further centralization of our corporate and platform functions, as well as other activities where opportunities are identified. During 2017-2019, we expect to incur costs of approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$200 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; related to this initiative. Through &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;October&#160;1, 2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, we incurred approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$131 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; associated with this initiative. &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:4px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The costs expected to be incurred during 2017-2019, of approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1.0 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for the above-mentioned programs (but not including expected costs associated with the Hospira integration), include restructuring charges, implementation costs and additional depreciation&#x2013;&#x2013;asset restructuring. Of this amount, we expect that about &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;20%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of the total charges will be non-cash.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;text-decoration:underline;"&gt;Current-Period Key Activities&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:inherit;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;For the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;first nine months of&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;text-align:center;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, we incurred costs of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$253 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; associated with the 2017-2019 program, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$238 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; associated with the integration of Hospira and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$110 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; associated with all other acquisition-related initiatives.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:48%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="17" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table provides the components of costs associated with acquisitions and cost-reduction/productivity initiatives:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:Arial;font-size:9.5pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Three Months Ended&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Nine Months Ended&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;October&#160;1, &lt;br/&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;October&#160;2, &lt;br/&gt;2016&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;October&#160;1, &lt;br/&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;October&#160;2, &lt;br/&gt;2016&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Restructuring charges&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Arial;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Arial;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Employee terminations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(20&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;347&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;464&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Asset impairments&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;101&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;27&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;126&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;45&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Exit costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;29&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;16&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;64&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total restructuring charges&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;91&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;404&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;150&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;574&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Transaction costs&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(c)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(14&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;54&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;114&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Integration costs&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(d)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;73&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;74&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;224&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;300&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:36px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Restructuring charges and certain acquisition-related costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;149&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;531&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;377&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;988&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-left:6px;text-indent:-6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Additional depreciation&#x2013;&#x2013;asset restructuring&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&#160;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;recorded in our condensed consolidated statements of income as follows&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(e)&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Cost of sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;39&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;46&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;74&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;145&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Research and development expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total additional depreciation&#x2013;&#x2013;asset restructuring&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;39&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;47&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;74&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;151&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Implementation costs recorded in our condensed consolidated statements of income as follows&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(f)&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Cost of sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;26&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;46&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;77&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;127&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Selling, informational and administrative expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;22&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;23&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;46&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;56&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Research and development expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;26&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;17&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Other (income)/deductions&#x2013;&#x2013;net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total implementation costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;57&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;78&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;150&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;202&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total costs associated with acquisitions and cost-reduction/productivity initiatives&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;245&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;655&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;601&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,341&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;In the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;third quarter&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;first nine months of&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;text-align:center;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;, restructuring charges are primarily associated with our acquisitions of Hospira and Medivation, as well as cost-reduction and productivity initiatives not associated with acquisitions. In the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;third quarter&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;first nine months of&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;text-align:center;"&gt;2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;, restructuring charges are largely associated with cost-reduction and productivity initiatives not associated with acquisitions, as well as our acquisitions of Hospira and Medivation. In the third quarter and first &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;nine&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;October&#160;1, 2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;font-style:italic;"&gt;Employee terminations&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt; primarily include revisions of our estimates of severance benefits. Employee termination costs are generally recorded when the actions are probable and estimable and include accrued severance benefits, pension and postretirement benefits, many of which may be paid out during periods after termination.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:4px;padding-left:24px;text-indent:-12px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;The restructuring activities for &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;text-align:center;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt; are associated with the following:&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:24px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:12px;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;For the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;third quarter&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt; of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;text-align:center;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;, IH (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;$4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;); EH (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;$1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;); WRD/GPD (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;$15 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;); manufacturing operations (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;$47 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;); and Corporate (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;$25 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;).&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:24px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:12px;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;For the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;first nine months of&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;text-align:center;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;, IH (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;$10 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;); EH (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;$9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt; income); WRD/GPD (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;$29 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;); manufacturing operations (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;$70 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;); and Corporate (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;$51 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;).&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:4px;text-align:left;padding-left:24px;text-indent:-12px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;The restructuring activities for &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;text-align:center;"&gt;2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt; are associated with the following:&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:24px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:12px;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;For the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;third quarter&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt; of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;text-align:center;"&gt;2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;, IH (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;$148 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;); EH (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;$28 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;); WRD/GPD (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;$52 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;); manufacturing operations (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;$108 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;); and Corporate (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;$67 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;).&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:24px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:12px;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;For the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;first nine months of&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;text-align:center;"&gt;2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;, IH (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;$162 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;); EH (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;$19 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;); WRD/GPD (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;$104 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;); manufacturing operations (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;$181 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;); and Corporate (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;$107 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;).&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(b)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;The asset impairment charges for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;third&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt; quarter and the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;first nine months of&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;text-align:center;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt; are largely associated with our acquisitions of Hospira and Medivation.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(c)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Transaction costs represent external costs for banking, legal, accounting and other similar services, which in the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;third quarter&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt; of 2017 reflect the reversal of an accrual related to the acquisition of Medivation. Transaction costs for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;first nine months of&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;text-align:center;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt; are directly related to our acquisitions of Hospira, Anacor and Medivation. Transaction costs in the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;third quarter&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt; of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;text-align:center;"&gt;2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt; were mostly related to the Medivation acquisition, and in the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;first nine months of&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;text-align:center;"&gt;2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;, were mostly related to the Medivation and Anacor acquisitions, and our terminated transaction with Allergan.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(d)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Integration costs represent external, incremental costs directly related to integrating acquired businesses, and primarily include expenditures for consulting and the integration of systems and processes. In the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;third&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt; quarter and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;first nine months of&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;text-align:center;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;, integration costs primarily relate to our acquisitions of Hospira and Medivation. The &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;first nine months of&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;text-align:center;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt; also include a net gain of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;$12 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt; related to the settlement of the Hospira U.S. qualified defined benefit pension plan (see &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;font-style:italic;"&gt;Note 10&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;). In the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;third quarter&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt; of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;text-align:center;"&gt;2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;, integration &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-left:12px;text-align:left;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;costs were mostly related to our acquisition of Hospira, and in the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;first nine months of&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;text-align:center;"&gt;2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;, integration costs were mostly related to our acquisition of Hospira and our terminated transaction with Allergan.&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(e)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Additional depreciation&#x2013;&#x2013;asset restructuring represents the impact of changes in the estimated useful lives of assets involved in restructuring actions.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(f)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Implementation costs represent external, incremental costs directly related to implementing our non-acquisition-related cost-reduction/productivity initiatives.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.05068226120858%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:15%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="17" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table provides the components of and changes in our restructuring accruals:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Employee&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Termination Costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Asset&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Impairment Charges&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Exit Costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accrual&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Balance, December 31, 2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,547&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;36&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,583&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Provision&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;126&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;16&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;150&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Utilization and other&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(401&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(126&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(24&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(551&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Balance, October 1, 2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(c)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,154&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;28&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,182&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Included in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;font-style:italic;"&gt;Other current liabilities&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt; (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;$863 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;) and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;font-style:italic;"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt; (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;$720 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;).&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(b)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Includes adjustments for foreign currency translation.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(c)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Included in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;font-style:italic;"&gt;Other current liabilities &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;(&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;$533 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;) and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;font-style:italic;"&gt;Other noncurrent liabilities &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;(&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;$650 million&lt;/span&gt;&lt;/span&gt;).</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
    <us-gaap:BusinessCombinationIntegrationRelatedCosts
      contextRef="D2018Q3Sept20152018_us-gaap_BusinessAcquisitionAxis_pfe_HospiraMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioForecastMember"
      decimals="-9"
      id="d43712496e662-wk-Fact-0A980F0F2A3F5178AC7FC8E4FEA5946D"
      unitRef="usd">1000000000</us-gaap:BusinessCombinationIntegrationRelatedCosts>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="FD2015Q4YTD_us-gaap_BusinessAcquisitionAxis_pfe_HospiraMember_us-gaap_RestructuringCostAndReserveAxis_pfe_ReturnofAcquiredRightsMember"
      decimals="-6"
      id="d43712496e668-wk-Fact-630CDB7F3DE05425814E7E7D20334106"
      unitRef="usd">215000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostExpectedCost1
      contextRef="FI2017Q3_us-gaap_RestructuringCostAndReserveAxis_pfe_ManufacturingPlantNetworkOptimizationMember_us-gaap_RestructuringPlanAxis_pfe_EnterprisewideCostReductionProductivityPlanMember"
      decimals="-6"
      id="d43712496e703-wk-Fact-A6DA652414025530B36D028F2F20662D"
      unitRef="usd">800000000</us-gaap:RestructuringAndRelatedCostExpectedCost1>
    <us-gaap:RestructuringAndRelatedCostCostIncurredToDate1
      contextRef="FI2017Q3_us-gaap_RestructuringCostAndReserveAxis_pfe_ManufacturingPlantNetworkOptimizationMember_us-gaap_RestructuringPlanAxis_pfe_EnterprisewideCostReductionProductivityPlanMember"
      decimals="-6"
      id="d43712496e711-wk-Fact-A696CF153A785389AB4F20EB35681CCB"
      unitRef="usd">122000000</us-gaap:RestructuringAndRelatedCostCostIncurredToDate1>
    <us-gaap:RestructuringAndRelatedCostExpectedCost1
      contextRef="FI2017Q3_us-gaap_RestructuringCostAndReserveAxis_pfe_CentralizationofCorporateandPlatformFunctionsMember_us-gaap_RestructuringPlanAxis_pfe_EnterprisewideCostReductionProductivityPlanMember"
      decimals="-6"
      id="d43712496e722-wk-Fact-543739C1FDA4541AA1CFC40F4AFD1D54"
      unitRef="usd">200000000</us-gaap:RestructuringAndRelatedCostExpectedCost1>
    <us-gaap:RestructuringAndRelatedCostCostIncurredToDate1
      contextRef="FI2017Q3_us-gaap_RestructuringCostAndReserveAxis_pfe_CentralizationofCorporateandPlatformFunctionsMember_us-gaap_RestructuringPlanAxis_pfe_EnterprisewideCostReductionProductivityPlanMember"
      decimals="-6"
      id="d43712496e730-wk-Fact-B94BA700C26A571D85A5F6298779F4E4"
      unitRef="usd">131000000</us-gaap:RestructuringAndRelatedCostCostIncurredToDate1>
    <us-gaap:RestructuringAndRelatedCostExpectedCost1
      contextRef="FI2017Q3_us-gaap_RestructuringPlanAxis_pfe_EnterprisewideCostReductionProductivityPlanMember"
      decimals="-8"
      id="d43712496e737-wk-Fact-0655BCC984EC5E32A4901E8943054DB2"
      unitRef="usd">1000000000.0</us-gaap:RestructuringAndRelatedCostExpectedCost1>
    <pfe:RestructuringandRelatedCostNoncashChargesPercentage
      contextRef="FD2017Q3YTD_us-gaap_RestructuringPlanAxis_pfe_EnterprisewideCostReductionProductivityPlanMember"
      decimals="2"
      id="d43712496e741-wk-Fact-D1F0EB11DD424B38B635920E6B1F138B"
      unitRef="number">0.20</pfe:RestructuringandRelatedCostNoncashChargesPercentage>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="FD2017Q3YTD_us-gaap_RestructuringPlanAxis_pfe_EnterprisewideCostReductionProductivityPlanMember"
      decimals="-6"
      id="d43712496e761-wk-Fact-6DC8F760B64658B29976EADDD8399D10"
      unitRef="usd">253000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="FD2017Q3YTD_us-gaap_BusinessAcquisitionAxis_pfe_HospiraMember_us-gaap_RestructuringCostAndReserveAxis_pfe_BusinessIntegrationCostsMember"
      decimals="-6"
      id="d43712496e765-wk-Fact-8EA6CC21C47A56CEA78505DBDA24C339"
      unitRef="usd">238000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="FD2017Q3YTD_us-gaap_RestructuringCostAndReserveAxis_pfe_BusinessIntegrationCostsMember"
      decimals="-6"
      id="d43712496e769-wk-Fact-2E6527B47EEF5D9FAF41B981229A8F2A"
      unitRef="usd">110000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock
      contextRef="FD2017Q3YTD"
      id="TextSelection-257BED4D93EB563FAF639E7FF8921EF6-0-wk-Fact-E4BF1BE3099C5848BEFF399D6802A679">&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:48%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="17" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table provides the components of costs associated with acquisitions and cost-reduction/productivity initiatives:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:Arial;font-size:9.5pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Three Months Ended&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Nine Months Ended&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;October&#160;1, &lt;br/&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;October&#160;2, &lt;br/&gt;2016&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;October&#160;1, &lt;br/&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;October&#160;2, &lt;br/&gt;2016&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Restructuring charges&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Arial;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Arial;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Employee terminations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(20&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;347&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;464&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Asset impairments&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;101&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;27&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;126&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;45&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Exit costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;29&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;16&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;64&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total restructuring charges&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;91&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;404&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;150&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;574&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Transaction costs&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(c)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(14&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;54&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;114&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Integration costs&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(d)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;73&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;74&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;224&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;300&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:36px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Restructuring charges and certain acquisition-related costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;149&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;531&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;377&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;988&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-left:6px;text-indent:-6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Additional depreciation&#x2013;&#x2013;asset restructuring&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&#160;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;recorded in our condensed consolidated statements of income as follows&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(e)&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Cost of sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;39&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;46&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;74&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;145&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Research and development expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total additional depreciation&#x2013;&#x2013;asset restructuring&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;39&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;47&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;74&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;151&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Implementation costs recorded in our condensed consolidated statements of income as follows&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(f)&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Cost of sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;26&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;46&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;77&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;127&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Selling, informational and administrative expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;22&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;23&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;46&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;56&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Research and development expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;26&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;17&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Other (income)/deductions&#x2013;&#x2013;net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total implementation costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;57&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;78&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;150&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;202&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total costs associated with acquisitions and cost-reduction/productivity initiatives&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;245&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;655&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;601&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,341&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;In the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;third quarter&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;first nine months of&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;text-align:center;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;, restructuring charges are primarily associated with our acquisitions of Hospira and Medivation, as well as cost-reduction and productivity initiatives not associated with acquisitions. In the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;third quarter&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;first nine months of&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;text-align:center;"&gt;2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;, restructuring charges are largely associated with cost-reduction and productivity initiatives not associated with acquisitions, as well as our acquisitions of Hospira and Medivation. In the third quarter and first &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;nine&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;October&#160;1, 2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;font-style:italic;"&gt;Employee terminations&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt; primarily include revisions of our estimates of severance benefits. Employee termination costs are generally recorded when the actions are probable and estimable and include accrued severance benefits, pension and postretirement benefits, many of which may be paid out during periods after termination.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:4px;padding-left:24px;text-indent:-12px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;The restructuring activities for &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;text-align:center;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt; are associated with the following:&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:24px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:12px;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;For the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;third quarter&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt; of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;text-align:center;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;, IH (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;$4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;); EH (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;$1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;); WRD/GPD (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;$15 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;); manufacturing operations (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;$47 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;); and Corporate (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;$25 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;).&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:24px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:12px;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;For the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;first nine months of&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;text-align:center;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;, IH (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;$10 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;); EH (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;$9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt; income); WRD/GPD (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;$29 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;); manufacturing operations (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;$70 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;); and Corporate (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;$51 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;).&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:4px;text-align:left;padding-left:24px;text-indent:-12px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;The restructuring activities for &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;text-align:center;"&gt;2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt; are associated with the following:&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:24px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:12px;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;For the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;third quarter&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt; of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;text-align:center;"&gt;2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;, IH (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;$148 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;); EH (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;$28 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;); WRD/GPD (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;$52 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;); manufacturing operations (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;$108 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;); and Corporate (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;$67 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;).&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:24px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:12px;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;For the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;first nine months of&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;text-align:center;"&gt;2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;, IH (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;$162 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;); EH (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;$19 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;); WRD/GPD (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;$104 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;); manufacturing operations (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;$181 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;); and Corporate (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;$107 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;).&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(b)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;The asset impairment charges for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;third&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt; quarter and the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;first nine months of&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;text-align:center;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt; are largely associated with our acquisitions of Hospira and Medivation.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(c)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Transaction costs represent external costs for banking, legal, accounting and other similar services, which in the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;third quarter&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt; of 2017 reflect the reversal of an accrual related to the acquisition of Medivation. Transaction costs for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;first nine months of&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;text-align:center;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt; are directly related to our acquisitions of Hospira, Anacor and Medivation. Transaction costs in the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;third quarter&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt; of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;text-align:center;"&gt;2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt; were mostly related to the Medivation acquisition, and in the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;first nine months of&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;text-align:center;"&gt;2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;, were mostly related to the Medivation and Anacor acquisitions, and our terminated transaction with Allergan.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(d)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Integration costs represent external, incremental costs directly related to integrating acquired businesses, and primarily include expenditures for consulting and the integration of systems and processes. In the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;third&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt; quarter and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;first nine months of&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;text-align:center;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;, integration costs primarily relate to our acquisitions of Hospira and Medivation. The &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;first nine months of&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;text-align:center;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt; also include a net gain of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;$12 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt; related to the settlement of the Hospira U.S. qualified defined benefit pension plan (see &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;font-style:italic;"&gt;Note 10&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;). In the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;third quarter&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt; of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;text-align:center;"&gt;2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;, integration &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-left:12px;text-align:left;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;costs were mostly related to our acquisition of Hospira, and in the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;first nine months of&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;text-align:center;"&gt;2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;, integration costs were mostly related to our acquisition of Hospira and our terminated transaction with Allergan.&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(e)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Additional depreciation&#x2013;&#x2013;asset restructuring represents the impact of changes in the estimated useful lives of assets involved in restructuring actions.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(f)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;Implementation costs represent external, incremental costs directly related to implementing our non-acquisition-related cost-reduction/productivity initiatives.</us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock>
    <us-gaap:SeveranceCosts1
      contextRef="FD2017Q3QTD"
      decimals="-6"
      id="d43712496e1165-wk-Fact-F2A2071B8FC55425A60551104D415290"
      unitRef="usd">-20000000</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1
      contextRef="FD2016Q3QTD"
      decimals="-6"
      id="d43712496e1185-wk-Fact-5EB5BCA88A6D540EBCA8B56A37E73824"
      unitRef="usd">347000000</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43712496e1205-wk-Fact-6AEAE394B9B450FDAF7AF8A431A29CCE"
      unitRef="usd">9000000</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43712496e1224-wk-Fact-D042F83875705E98AC1B9D757B41F8B1"
      unitRef="usd">464000000</us-gaap:SeveranceCosts1>
    <pfe:RestructuringAssetImpairmentCharges
      contextRef="FD2017Q3QTD"
      decimals="-6"
      id="d43712496e1246-wk-Fact-BFEE13E8CEC95576907CDF47D40BBF3C"
      unitRef="usd">101000000</pfe:RestructuringAssetImpairmentCharges>
    <pfe:RestructuringAssetImpairmentCharges
      contextRef="FD2016Q3QTD"
      decimals="-6"
      id="d43712496e1265-wk-Fact-0ACADD6A2EFE53F1891A48EEF52A1F7C"
      unitRef="usd">27000000</pfe:RestructuringAssetImpairmentCharges>
    <pfe:RestructuringAssetImpairmentCharges
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43712496e1284-wk-Fact-632EFDC664F45A20BEB9A47C3FEE1B4D"
      unitRef="usd">126000000</pfe:RestructuringAssetImpairmentCharges>
    <pfe:RestructuringAssetImpairmentCharges
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43712496e1304-wk-Fact-7DF3605F8BAE533CAF6B416DD2F9F2C4"
      unitRef="usd">45000000</pfe:RestructuringAssetImpairmentCharges>
    <us-gaap:BusinessExitCosts1
      contextRef="FD2017Q3QTD"
      decimals="-6"
      id="d43712496e1329-wk-Fact-5D501002D38D5167AA036C63DF82035D"
      unitRef="usd">10000000</us-gaap:BusinessExitCosts1>
    <us-gaap:BusinessExitCosts1
      contextRef="FD2016Q3QTD"
      decimals="-6"
      id="d43712496e1348-wk-Fact-5183BF736F1E563FA304D5EEBF7843EF"
      unitRef="usd">29000000</us-gaap:BusinessExitCosts1>
    <us-gaap:BusinessExitCosts1
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43712496e1367-wk-Fact-FF8ADB2E22EA5E31A89D8C1DB543B9B8"
      unitRef="usd">16000000</us-gaap:BusinessExitCosts1>
    <us-gaap:BusinessExitCosts1
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43712496e1387-wk-Fact-C4C06BF1A8B6557EBFE62654491DA179"
      unitRef="usd">64000000</us-gaap:BusinessExitCosts1>
    <us-gaap:RestructuringCharges
      contextRef="FD2017Q3QTD"
      decimals="-6"
      id="d43712496e1412-wk-Fact-5902E7F7E3325E0295E9C62DFD622D3E"
      unitRef="usd">91000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="FD2016Q3QTD"
      decimals="-6"
      id="d43712496e1431-wk-Fact-058D1994C3365CD1AB976A08ED207000"
      unitRef="usd">404000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43712496e1450-wk-Fact-9947697CFC005CC4B553C619A29CF327"
      unitRef="usd">150000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43712496e1470-wk-Fact-33C51462AA72510092370BCC6B190DCD"
      unitRef="usd">574000000</us-gaap:RestructuringCharges>
    <pfe:BusinessCombinationAcquisitionRelatedCostsTransactionCosts
      contextRef="FD2017Q3QTD"
      decimals="-6"
      id="d43712496e1497-wk-Fact-88427B31421C553CAC12777E36570F80"
      unitRef="usd">-14000000</pfe:BusinessCombinationAcquisitionRelatedCostsTransactionCosts>
    <pfe:BusinessCombinationAcquisitionRelatedCostsTransactionCosts
      contextRef="FD2016Q3QTD"
      decimals="-6"
      id="d43712496e1517-wk-Fact-5EA5FA662B4B55B598D62154953933DD"
      unitRef="usd">54000000</pfe:BusinessCombinationAcquisitionRelatedCostsTransactionCosts>
    <pfe:BusinessCombinationAcquisitionRelatedCostsTransactionCosts
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43712496e1536-wk-Fact-ED45326FD065577BB318715037A629A6"
      unitRef="usd">4000000</pfe:BusinessCombinationAcquisitionRelatedCostsTransactionCosts>
    <pfe:BusinessCombinationAcquisitionRelatedCostsTransactionCosts
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43712496e1556-wk-Fact-C44B0511B35651E0887481BA20948E7C"
      unitRef="usd">114000000</pfe:BusinessCombinationAcquisitionRelatedCostsTransactionCosts>
    <us-gaap:BusinessCombinationIntegrationRelatedCosts
      contextRef="FD2017Q3QTD"
      decimals="-6"
      id="d43712496e1583-wk-Fact-3B1D1CAB9A6C50A0AFB2D0D10CB345EC"
      unitRef="usd">73000000</us-gaap:BusinessCombinationIntegrationRelatedCosts>
    <us-gaap:BusinessCombinationIntegrationRelatedCosts
      contextRef="FD2016Q3QTD"
      decimals="-6"
      id="d43712496e1602-wk-Fact-9DB7D15107575A4E87DEBC34B67A7866"
      unitRef="usd">74000000</us-gaap:BusinessCombinationIntegrationRelatedCosts>
    <us-gaap:BusinessCombinationIntegrationRelatedCosts
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43712496e1621-wk-Fact-309464A163D5551F8E0560FD895331BC"
      unitRef="usd">224000000</us-gaap:BusinessCombinationIntegrationRelatedCosts>
    <us-gaap:BusinessCombinationIntegrationRelatedCosts
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43712496e1641-wk-Fact-A94165CF2AD857B7B67158131637F55C"
      unitRef="usd">300000000</us-gaap:BusinessCombinationIntegrationRelatedCosts>
    <pfe:RestructuringChargesAndAcquisitionRelatedCosts
      contextRef="FD2017Q3QTD"
      decimals="-6"
      id="d43712496e1666-wk-Fact-B73545D07B565820AFF53EEAE1860800"
      unitRef="usd">149000000</pfe:RestructuringChargesAndAcquisitionRelatedCosts>
    <pfe:RestructuringChargesAndAcquisitionRelatedCosts
      contextRef="FD2016Q3QTD"
      decimals="-6"
      id="d43712496e1685-wk-Fact-110B8A55AF7C5BFEAC9F11433EB9280B"
      unitRef="usd">531000000</pfe:RestructuringChargesAndAcquisitionRelatedCosts>
    <pfe:RestructuringChargesAndAcquisitionRelatedCosts
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43712496e1704-wk-Fact-F3D7E2873AD65FA18989892A60F6626A"
      unitRef="usd">377000000</pfe:RestructuringChargesAndAcquisitionRelatedCosts>
    <pfe:RestructuringChargesAndAcquisitionRelatedCosts
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43712496e1724-wk-Fact-5FBAE33C336F53F48E8FF7CDE77BBB26"
      unitRef="usd">988000000</pfe:RestructuringChargesAndAcquisitionRelatedCosts>
    <us-gaap:RestructuringReserveAcceleratedDepreciation
      contextRef="FD2017Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember"
      decimals="-6"
      id="d43712496e1841-wk-Fact-4DC7F6E7ED055FD8910B97A13EEF264E"
      unitRef="usd">39000000</us-gaap:RestructuringReserveAcceleratedDepreciation>
    <us-gaap:RestructuringReserveAcceleratedDepreciation
      contextRef="FD2016Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember"
      decimals="-6"
      id="d43712496e1860-wk-Fact-FA60C203F66751A591C313394A513BBD"
      unitRef="usd">46000000</us-gaap:RestructuringReserveAcceleratedDepreciation>
    <us-gaap:RestructuringReserveAcceleratedDepreciation
      contextRef="FD2017Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember"
      decimals="-6"
      id="d43712496e1879-wk-Fact-90E6722B594454179E2707D4EF701095"
      unitRef="usd">74000000</us-gaap:RestructuringReserveAcceleratedDepreciation>
    <us-gaap:RestructuringReserveAcceleratedDepreciation
      contextRef="FD2016Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember"
      decimals="-6"
      id="d43712496e1899-wk-Fact-B97AEA2C854B5AABB4BE5CE4AE4372B1"
      unitRef="usd">145000000</us-gaap:RestructuringReserveAcceleratedDepreciation>
    <us-gaap:RestructuringReserveAcceleratedDepreciation
      contextRef="FD2017Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-6"
      id="d43712496e1924-wk-Fact-B30550C60EA75004A2CBFC5FF95F87DF"
      unitRef="usd">0</us-gaap:RestructuringReserveAcceleratedDepreciation>
    <us-gaap:RestructuringReserveAcceleratedDepreciation
      contextRef="FD2016Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-6"
      id="d43712496e1943-wk-Fact-2287BD2729395E10AA7149FD8CDD1C22"
      unitRef="usd">1000000</us-gaap:RestructuringReserveAcceleratedDepreciation>
    <us-gaap:RestructuringReserveAcceleratedDepreciation
      contextRef="FD2017Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-6"
      id="d43712496e1962-wk-Fact-A8F5B5BE613E55E4B3F2C69F2B5B38E3"
      unitRef="usd">0</us-gaap:RestructuringReserveAcceleratedDepreciation>
    <us-gaap:RestructuringReserveAcceleratedDepreciation
      contextRef="FD2016Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-6"
      id="d43712496e1982-wk-Fact-B4ED4EC770E85596B83EF4F1E598DF88"
      unitRef="usd">5000000</us-gaap:RestructuringReserveAcceleratedDepreciation>
    <us-gaap:RestructuringReserveAcceleratedDepreciation
      contextRef="FD2017Q3QTD"
      decimals="-6"
      id="d43712496e2007-wk-Fact-A453B8F62ABE5E21AF62323699CCC8B0"
      unitRef="usd">39000000</us-gaap:RestructuringReserveAcceleratedDepreciation>
    <us-gaap:RestructuringReserveAcceleratedDepreciation
      contextRef="FD2016Q3QTD"
      decimals="-6"
      id="d43712496e2026-wk-Fact-E6F32BC6EC2E5D5AB12A3A9ECA0A4CEF"
      unitRef="usd">47000000</us-gaap:RestructuringReserveAcceleratedDepreciation>
    <us-gaap:RestructuringReserveAcceleratedDepreciation
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43712496e2045-wk-Fact-CE9A93EF950C573BB8A81EBFDFFAF1D6"
      unitRef="usd">74000000</us-gaap:RestructuringReserveAcceleratedDepreciation>
    <us-gaap:RestructuringReserveAcceleratedDepreciation
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43712496e2065-wk-Fact-300D4D3DDB1355E8938FDCD261A66E64"
      unitRef="usd">151000000</us-gaap:RestructuringReserveAcceleratedDepreciation>
    <pfe:ImplementationCosts
      contextRef="FD2017Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember"
      decimals="-6"
      id="d43712496e2177-wk-Fact-93040E88DF5D56A99DAE7E4CE1BBE9F2"
      unitRef="usd">26000000</pfe:ImplementationCosts>
    <pfe:ImplementationCosts
      contextRef="FD2016Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember"
      decimals="-6"
      id="d43712496e2196-wk-Fact-C2FE704D6A285AB89F6177A77115F69D"
      unitRef="usd">46000000</pfe:ImplementationCosts>
    <pfe:ImplementationCosts
      contextRef="FD2017Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember"
      decimals="-6"
      id="d43712496e2215-wk-Fact-8A4AB1B8685C5997998FB7F7C5FFCE5D"
      unitRef="usd">77000000</pfe:ImplementationCosts>
    <pfe:ImplementationCosts
      contextRef="FD2016Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember"
      decimals="-6"
      id="d43712496e2235-wk-Fact-4DCE62D0C18E5CD6957CFB6E8F495684"
      unitRef="usd">127000000</pfe:ImplementationCosts>
    <pfe:ImplementationCosts
      contextRef="FD2017Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember"
      decimals="-6"
      id="d43712496e2260-wk-Fact-1D412AB78B1D52DEAA171F130190DA4E"
      unitRef="usd">22000000</pfe:ImplementationCosts>
    <pfe:ImplementationCosts
      contextRef="FD2016Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember"
      decimals="-6"
      id="d43712496e2279-wk-Fact-F1C2E56FFF6857968C5DF6D28AD574C9"
      unitRef="usd">23000000</pfe:ImplementationCosts>
    <pfe:ImplementationCosts
      contextRef="FD2017Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember"
      decimals="-6"
      id="d43712496e2298-wk-Fact-6B7573DC24D452F9A1161BC5959839D3"
      unitRef="usd">46000000</pfe:ImplementationCosts>
    <pfe:ImplementationCosts
      contextRef="FD2016Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember"
      decimals="-6"
      id="d43712496e2318-wk-Fact-91C0C255B43A5416B3C5C28C3BD45315"
      unitRef="usd">56000000</pfe:ImplementationCosts>
    <pfe:ImplementationCosts
      contextRef="FD2017Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-6"
      id="d43712496e2343-wk-Fact-E0337FF965B85F19893F5C95D32AAD5B"
      unitRef="usd">9000000</pfe:ImplementationCosts>
    <pfe:ImplementationCosts
      contextRef="FD2016Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-6"
      id="d43712496e2362-wk-Fact-5F3BEDE745975795948CDC9485283B89"
      unitRef="usd">8000000</pfe:ImplementationCosts>
    <pfe:ImplementationCosts
      contextRef="FD2017Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-6"
      id="d43712496e2381-wk-Fact-083D0D52D0F352EBA5B14A872E1DE0C8"
      unitRef="usd">26000000</pfe:ImplementationCosts>
    <pfe:ImplementationCosts
      contextRef="FD2016Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-6"
      id="d43712496e2401-wk-Fact-EADD6730C9975145BE6C22C98A531D3E"
      unitRef="usd">17000000</pfe:ImplementationCosts>
    <pfe:ImplementationCosts
      contextRef="FD2017Q3QTD_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeExpenseMember"
      decimals="-6"
      id="d43712496e2426-wk-Fact-73777733794C543CA62126B6042D00DB"
      unitRef="usd">0</pfe:ImplementationCosts>
    <pfe:ImplementationCosts
      contextRef="FD2016Q3QTD_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeExpenseMember"
      decimals="-6"
      id="d43712496e2445-wk-Fact-466AE7233A2D57E48E9D5268F9EEEBF0"
      unitRef="usd">1000000</pfe:ImplementationCosts>
    <pfe:ImplementationCosts
      contextRef="FD2017Q3YTD_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeExpenseMember"
      decimals="-6"
      id="d43712496e2464-wk-Fact-66E019D2BC3C5C3C98FDC370D9EE61F3"
      unitRef="usd">0</pfe:ImplementationCosts>
    <pfe:ImplementationCosts
      contextRef="FD2016Q3YTD_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeExpenseMember"
      decimals="-6"
      id="d43712496e2484-wk-Fact-5EA1B375EFA75241A699CD076C5A9E06"
      unitRef="usd">2000000</pfe:ImplementationCosts>
    <pfe:ImplementationCosts
      contextRef="FD2017Q3QTD"
      decimals="-6"
      id="d43712496e2509-wk-Fact-2F901B411CA0586B801E2011D88D1ACA"
      unitRef="usd">57000000</pfe:ImplementationCosts>
    <pfe:ImplementationCosts
      contextRef="FD2016Q3QTD"
      decimals="-6"
      id="d43712496e2528-wk-Fact-2E0D7E0341AF521EB10E77F7AB951A30"
      unitRef="usd">78000000</pfe:ImplementationCosts>
    <pfe:ImplementationCosts
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43712496e2547-wk-Fact-CE0D12184A835989A295DE71DFF72EF8"
      unitRef="usd">150000000</pfe:ImplementationCosts>
    <pfe:ImplementationCosts
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43712496e2567-wk-Fact-E6280093B5CF57199192AD6A1C984105"
      unitRef="usd">202000000</pfe:ImplementationCosts>
    <pfe:RestructuringChargesAcquisitionRelatedCostsandImplementationCosts
      contextRef="FD2017Q3QTD"
      decimals="-6"
      id="d43712496e2597-wk-Fact-92DAC8013B8C556790B4A17D538A564B"
      unitRef="usd">245000000</pfe:RestructuringChargesAcquisitionRelatedCostsandImplementationCosts>
    <pfe:RestructuringChargesAcquisitionRelatedCostsandImplementationCosts
      contextRef="FD2016Q3QTD"
      decimals="-6"
      id="d43712496e2616-wk-Fact-7CECCC8EC894510AB4D2C56B832BE7E6"
      unitRef="usd">655000000</pfe:RestructuringChargesAcquisitionRelatedCostsandImplementationCosts>
    <pfe:RestructuringChargesAcquisitionRelatedCostsandImplementationCosts
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43712496e2636-wk-Fact-8E185443D65254359F4DF6FCBC0332AD"
      unitRef="usd">601000000</pfe:RestructuringChargesAcquisitionRelatedCostsandImplementationCosts>
    <pfe:RestructuringChargesAcquisitionRelatedCostsandImplementationCosts
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43712496e2655-wk-Fact-FB4F3567F2715719817872203ABF0B67"
      unitRef="usd">1341000000</pfe:RestructuringChargesAcquisitionRelatedCostsandImplementationCosts>
    <us-gaap:RestructuringCharges
      contextRef="FD2017Q3QTD_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43712496e2737-wk-Fact-66B95E1A6D7B599799C4A84EB9110D19"
      unitRef="usd">4000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="FD2017Q3QTD_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43712496e2741-wk-Fact-5A0E5A3357A95DB4B2FD2A6FDF59334A"
      unitRef="usd">1000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="FD2017Q3QTD_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_us-gaap_SubsegmentsAxis_pfe_WorldwideResearchandDevelopmentandGlobalProductDevelopmentMember"
      decimals="-6"
      id="d43712496e2745-wk-Fact-B782EBE01C7659F081B7CA147E96F107"
      unitRef="usd">15000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="FD2017Q3QTD_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_us-gaap_SubsegmentsAxis_pfe_ManufacturingOperationsMember"
      decimals="-6"
      id="d43712496e2750-wk-Fact-6A98F19D2E4051A39A53CE6AAF3875FA"
      unitRef="usd">47000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="FD2017Q3QTD_us-gaap_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember"
      decimals="-6"
      id="d43712496e2754-wk-Fact-04706406A17B5F69814D3B93EE94C5D6"
      unitRef="usd">25000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="FD2017Q3YTD_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43712496e2773-wk-Fact-B291069689DF5433B74923044CD3EE55"
      unitRef="usd">10000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="FD2017Q3YTD_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43712496e2777-wk-Fact-EFE605EAE655557BA8F4271E31854382"
      unitRef="usd">-9000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="FD2017Q3YTD_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_us-gaap_SubsegmentsAxis_pfe_WorldwideResearchandDevelopmentandGlobalProductDevelopmentMember"
      decimals="-6"
      id="d43712496e2781-wk-Fact-B706C7115BAD564CA000F2546D6F7E7E"
      unitRef="usd">29000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="FD2017Q3YTD_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_us-gaap_SubsegmentsAxis_pfe_ManufacturingOperationsMember"
      decimals="-6"
      id="d43712496e2786-wk-Fact-7C9AE0C695D15F888B7BE9D8D97A7118"
      unitRef="usd">70000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="FD2017Q3YTD_us-gaap_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember"
      decimals="-6"
      id="d43712496e2790-wk-Fact-64F34CC93DDC542DA48141B016E34A41"
      unitRef="usd">51000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="FD2016Q3QTD_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43712496e2817-wk-Fact-1322E18998D05D589F0B8442817BA831"
      unitRef="usd">148000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="FD2016Q3QTD_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43712496e2821-wk-Fact-1239F4C8E82550F1B133AC9C07C7D4DE"
      unitRef="usd">28000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="FD2016Q3QTD_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_us-gaap_SubsegmentsAxis_pfe_WorldwideResearchandDevelopmentandGlobalProductDevelopmentMember"
      decimals="-6"
      id="d43712496e2825-wk-Fact-A51B360ED17555C7AB63195A3314FF36"
      unitRef="usd">52000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="FD2016Q3QTD_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_us-gaap_SubsegmentsAxis_pfe_ManufacturingOperationsMember"
      decimals="-6"
      id="d43712496e2830-wk-Fact-27E8D93198C95467A56674B994E4A8C3"
      unitRef="usd">108000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="FD2016Q3QTD_us-gaap_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember"
      decimals="-6"
      id="d43712496e2834-wk-Fact-47F671A9BF6B5E0381241BBFBE7146B2"
      unitRef="usd">67000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="FD2016Q3YTD_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43712496e2858-wk-Fact-CFCB464692345B42BEEB0DF525BA5F59"
      unitRef="usd">162000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="FD2016Q3YTD_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43712496e2862-wk-Fact-3CF994FD24A55EA68571449794C7E0C6"
      unitRef="usd">19000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="FD2016Q3YTD_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_us-gaap_SubsegmentsAxis_pfe_WorldwideResearchandDevelopmentandGlobalProductDevelopmentMember"
      decimals="-6"
      id="d43712496e2866-wk-Fact-A6F759F161E6564FB7A0CAD14447043E"
      unitRef="usd">104000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="FD2016Q3YTD_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_us-gaap_SubsegmentsAxis_pfe_ManufacturingOperationsMember"
      decimals="-6"
      id="d43712496e2871-wk-Fact-8F5857168E9254F7AD67D9E467C9964C"
      unitRef="usd">181000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="FD2016Q3YTD_us-gaap_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember"
      decimals="-6"
      id="d43712496e2875-wk-Fact-6112838DAC895E1FB980F1B2C5F1C930"
      unitRef="usd">107000000</us-gaap:RestructuringCharges>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="FD2017Q3YTD_us-gaap_BusinessAcquisitionAxis_pfe_HospiraMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d43712496e2982-wk-Fact-D2D1CF92DB215E23CC515B653B45E8EE"
      unitRef="usd">12000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock
      contextRef="FD2017Q3YTD"
      id="TextSelection-C02E54F660E853B6825EE03D4882D043-0-wk-Fact-1B0704622B8656D297CF2DFF4C48C616">&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.05068226120858%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:15%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="17" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table provides the components of and changes in our restructuring accruals:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Employee&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Termination Costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Asset&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Impairment Charges&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Exit Costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accrual&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Balance, December 31, 2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,547&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;36&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,583&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Provision&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;126&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;16&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;150&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Utilization and other&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(401&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(126&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(24&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(551&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Balance, October 1, 2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(c)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,154&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;28&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,182&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Included in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;font-style:italic;"&gt;Other current liabilities&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt; (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;$863 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;) and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;font-style:italic;"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt; (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;$720 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;).&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(b)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Includes adjustments for foreign currency translation.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(c)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Included in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;font-style:italic;"&gt;Other current liabilities &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;(&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;$533 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;) and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;font-style:italic;"&gt;Other noncurrent liabilities &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;(&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;$650 million&lt;/span&gt;&lt;/span&gt;).</us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock>
    <us-gaap:RestructuringReserve
      contextRef="FI2016Q4_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember"
      decimals="-6"
      id="d43712496e3283-wk-Fact-45F6314CE80C59AC9D1C31C3E15AFBD8"
      unitRef="usd">1547000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="FI2016Q4_us-gaap_RestructuringCostAndReserveAxis_pfe_AssetImpairmentsMember"
      decimals="-6"
      id="d43712496e3302-wk-Fact-CA0E038FD7FB54A5AFFBA924D7EA3A6D"
      unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="FI2016Q4_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OtherRestructuringMember"
      decimals="-6"
      id="d43712496e3322-wk-Fact-B933A905F21B5DBCAF9108FCBC88194E"
      unitRef="usd">36000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="FI2016Q4"
      decimals="-6"
      id="d43712496e3341-wk-Fact-5E7B2FD2D8475DEA875CCD41E3E715EF"
      unitRef="usd">1583000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringCharges
      contextRef="FD2017Q3YTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember"
      decimals="-6"
      id="d43712496e3361-wk-Fact-E2B8E755EC4E512694F08689178F25FB"
      unitRef="usd">9000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="FD2017Q3YTD_us-gaap_RestructuringCostAndReserveAxis_pfe_AssetImpairmentsMember"
      decimals="-6"
      id="d43712496e3380-wk-Fact-CFEA8FFE79D85111A3CD5895E62603FD"
      unitRef="usd">126000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="FD2017Q3YTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OtherRestructuringMember"
      decimals="-6"
      id="d43712496e3399-wk-Fact-C4388648F0E6529DA69A86993AA93AE7"
      unitRef="usd">16000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43712496e3419-wk-Fact-9947697CFC005CC4B553C619A29CF327"
      unitRef="usd">150000000</us-gaap:RestructuringCharges>
    <pfe:PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment
      contextRef="FD2017Q3YTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember"
      decimals="-6"
      id="d43712496e3446-wk-Fact-D319BAF88B8B545CA48395F0788E8501"
      unitRef="usd">401000000</pfe:PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment>
    <pfe:PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment
      contextRef="FD2017Q3YTD_us-gaap_RestructuringCostAndReserveAxis_pfe_AssetImpairmentsMember"
      decimals="-6"
      id="d43712496e3466-wk-Fact-8F95E4DDAC9B520C8A1E53E1D2C8CC7B"
      unitRef="usd">126000000</pfe:PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment>
    <pfe:PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment
      contextRef="FD2017Q3YTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OtherRestructuringMember"
      decimals="-6"
      id="d43712496e3486-wk-Fact-94001D1F99AF509E84946618AAA5FC87"
      unitRef="usd">24000000</pfe:PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment>
    <pfe:PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43712496e3507-wk-Fact-1AB7DD0AE8235344A53584C522F56843"
      unitRef="usd">551000000</pfe:PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment>
    <us-gaap:RestructuringReserve
      contextRef="FI2017Q3_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember"
      decimals="-6"
      id="d43712496e3540-wk-Fact-477878BBEDE5542C9F9E88C10D02CABE"
      unitRef="usd">1154000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="FI2017Q3_us-gaap_RestructuringCostAndReserveAxis_pfe_AssetImpairmentsMember"
      decimals="-6"
      id="d43712496e3559-wk-Fact-E88E61DCD79054CAB129EA8C07D5A4E5"
      unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="FI2017Q3_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OtherRestructuringMember"
      decimals="-6"
      id="d43712496e3579-wk-Fact-AA3098CB34F551A2922049EA2BBBF5A3"
      unitRef="usd">28000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="FI2017Q3"
      decimals="-6"
      id="d43712496e3598-wk-Fact-DFB58A1FD36B53C88918A31FB32F3CE9"
      unitRef="usd">1182000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember"
      decimals="-6"
      id="d43712496e3632-wk-Fact-390AAFCB20395D8BB52C559F36D58DEA"
      unitRef="usd">863000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember"
      decimals="-6"
      id="d43712496e3640-wk-Fact-8CD99659D08F5B5C8736AD83CC9D34B9"
      unitRef="usd">720000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="FI2017Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember"
      decimals="-6"
      id="d43712496e3696-wk-Fact-BC33EB2BDFDA5634AC2BD66608C560BF"
      unitRef="usd">533000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="FI2017Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember"
      decimals="-6"
      id="d43712496e3704-wk-Fact-EFB40B30DEDD59D39687610C2E350851"
      unitRef="usd">650000000</us-gaap:RestructuringReserve>
    <us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock
      contextRef="FD2017Q3YTD"
      id="TextSelection-C533AB02168D52D5BD955FB100D4D7A8-0-wk-Fact-8EE905C2CEF35A019008C9C7BCEB5544">&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;Other (Income)/Deductions&#x2014;Net&lt;/span&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:44%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="17" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table provides components of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Other (income)/deductions&#x2013;&#x2013;net&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Three Months Ended&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Nine Months Ended&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;October&#160;1, &lt;br/&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;October&#160;2, &lt;br/&gt;2016&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;October&#160;1, &lt;br/&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;October&#160;2, &lt;br/&gt;2016&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Interest income&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(99&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(123&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(275&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(357&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Interest expense&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;320&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;291&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;940&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;889&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net interest expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;220&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;168&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;666&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;532&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Royalty-related income&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(140&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(233&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(331&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(695&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Certain legal matters, net&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(c)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;183&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(40&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;194&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;494&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net gains on asset disposals&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(d)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(155&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(47&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(349&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(81&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-left:18px;text-indent:-18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Loss on sale and impairment on remeasurement of HIS net assets&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(e)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(12&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,422&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;52&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,422&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Certain asset impairments&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(f)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;130&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;133&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;143&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,080&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Business and legal entity alignment costs&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(g)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;16&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;69&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;54&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;180&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Other, net&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(h)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(191&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(55&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(445&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(117&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Other (income)/deductions&#x2013;&#x2013;net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;51&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,417&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(16&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,815&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8.5pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Interest income decreased in the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;third&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; quarter and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;first nine months of&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;text-align:center;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;, primarily driven by a lower investment balance. Interest expense increased in the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;third&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; quarter and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;first nine months of&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;text-align:center;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;, &lt;/span&gt;&lt;span style="font-size:8.5pt;"&gt;primarily as a result of higher short-term interest rates, offset, in part, by the retirement of high-coupon debt and the issuance of new low-coupon debt&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8.5pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(b)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Royalty-related income &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;decreased&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; in the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;third&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; quarter and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;first nine months of&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;text-align:center;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;, primarily due to lower royalty income for Enbrel of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;$139 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;$414 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;, respectively, resulting from the expiration on October 31, 2016 of the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;36&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;-month royalty period under the collaboration agreement for Enbrel in the U.S. and Canada (the collaboration period under the agreement expired on October 31, 2013), partially offset by the addition of Xtandi royalty-related income of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;$73 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;$160 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;, respectively. &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8.5pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(c)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;In the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;third quarter&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;first nine months of&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;text-align:center;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;, primarily includes a &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;$94 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; charge to resolve a class action lawsuit filed by direct purchasers relating to Celebrex, which is subject to the negotiation of a final settlement agreement and court approval, and a &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;$79 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; charge to reflect damages awarded by a jury in a patent matter. In the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;first nine months of&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;text-align:center;"&gt;2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;, primarily includes amounts to resolve a Multi-District Litigation relating to Celebrex and Bextra that was pending against the Company in New York federal court for &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;$486 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;, partially offset by the reversal of a legal accrual where a loss was no longer deemed probable. In addition, the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;first nine months of&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;text-align:center;"&gt;2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; includes a settlement related to a patent matter.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8.5pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(d)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;In the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;third&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; quarter of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;text-align:center;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;, primarily includes gains on sales/out-licensing of product and compound rights (approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;$71 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;) and gains on sales and redemptions of investments in equity and debt securities (approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;$66 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;). In the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;first nine months of&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;text-align:center;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;, primarily includes gains on sales and redemptions of investments in equity and debt securities (approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;$183 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;), gains on sales/out-licensing of product and compound rights (approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;$141 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;) and a gain on sale of property (approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;$52 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;), partially offset by a net loss related to the sale of our &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;40%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; ownership investment in Teuto, including the extinguishment of a put option for the remaining &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;60%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; ownership interest (approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;$30 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;). In the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;first nine months of&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;text-align:center;"&gt;2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;, includes gains on sales/out-licensing of product and compound rights (approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;$49 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;).&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8.5pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(e)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;In the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;third&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; quarter and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;first nine months of&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;text-align:center;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;, represents adjustments to amounts previously recorded to write down the HIS net assets to fair value less costs to sell related to the sale of HIS net assets to ICU Medical. In the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;third&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; quarter and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;first nine months of&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;text-align:center;"&gt;2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;, represents a charge related to the write-down of the HIS net assets to fair value less estimated costs to sell.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8.5pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(f)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;In the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;third quarter&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;first nine months of&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;text-align:center;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;, primarily includes an intangible asset impairment charge of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;$127 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; related to developed technology rights, acquired in connection with our acquisition of Hospira, for a generic sterile injectable product for the treatment of edema associated with certain conditions. The intangible asset impairment charge for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;third&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; quarter and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;first nine months of&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;text-align:center;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; is associated with EH and reflects, among other things, updated commercial forecasts and an increased competitive environment. In the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;third&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; quarter of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;text-align:center;"&gt;2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;, primarily includes intangible asset impairment charges of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;$126 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;, reflecting &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;$97 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; of sterile injectable IPR&amp;amp;D compounds acquired in connection with our acquisition of InnoPharma and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;$29 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; of other IPR&amp;amp;D assets acquired in connection with our acquisition of King in 2011. The intangible asset impairment charges for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;third quarter&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;text-align:center;"&gt;2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; are associated with the following: EH (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;$97 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;) and IH (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;$29 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;). In the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;first nine months of&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;text-align:center;"&gt;2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;, primarily includes intangible asset impairment charges of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;$767 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;, reflecting (i) &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;$331 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; related to developed technology rights for a generic injectable antibiotic product for the treatment of bacterial infections; and (ii) &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;$265 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; related to an IPR&amp;amp;D compound for the treatment of anemia, both acquired in connection with our acquisition of Hospira; (iii) &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;$97 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; of sterile injectable IPR&amp;amp;D compounds acquired in connection with our acquisition of InnoPharma; and (iv) &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;$74 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; of other IPR&amp;amp;D assets, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;$45 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; of which were acquired in connection with our acquisition of Hospira and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;$29 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; of which were acquired in connection with our acquisition of King in 2011. The intangible asset impairment charges for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;first nine months of&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;text-align:center;"&gt;2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; are associated with the following: EH (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;$738 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;) and IH (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;$29 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;). In addition, the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;first nine months of&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;text-align:center;"&gt;2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; includes an impairment loss of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;$211 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; related to Pfizer&#x2019;s &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;49%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;-owned equity-method investment with Hisun in China, Hisun Pfizer, and an impairment loss of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;$50 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; related to Pfizer&#x2019;s &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;40%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;-owned equity-method investment in Teuto. For additional information concerning Hisun Pfizer and Teuto, see &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;font-style:italic;"&gt;Note 2D. &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-bottom:1px;padding-top:1px;padding-left:12px;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;The intangible asset impairment charge for 2016 for the IPR&amp;amp;D compound for the treatment of anemia acquired in connection with our acquisition of Hospira reflects, among other things, the impact of regulatory delays, including delays resulting from a court ruling, which required a 180-day waiting period after approval before a biosimilar product can be launched. The intangible asset impairment charges for 2016 for the sterile injectable IPR&amp;amp;D compounds acquired in connection with our acquisition of InnoPharma reflect, among other things, the impact of portfolio prioritization decisions and decreased commercial profiles of certain compounds. The intangible asset impairment charges for 2016 for developed technology rights and other IPR&amp;amp;D assets acquired in connection with our acquisition of Hospira reflect, among other things, the impact of new scientific findings, updated commercial forecasts, changes in pricing, and an increased competitive environment. The intangible asset impairment charges for 2016 for other IPR&amp;amp;D assets acquired in connection with our acquisition of King reflect changes in the competitive environment.&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8.5pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(g)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;In the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;third&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; quarter and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;first nine months of&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;text-align:center;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;text-align:center;"&gt;2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;, represents expenses for changes to our infrastructure to align our commercial operations, including costs to internally separate our businesses into distinct legal entities, as well as to streamline our intercompany supply operations to better support each business. &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8.5pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(h)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;In the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;third quarter&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;first nine months of&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;text-align:center;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;, includes, among other things, dividend income of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;$54 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;$211 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;, respectively, from our investment in ViiV, and income of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;$62 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; from resolution of a contract disagreement. In the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;first nine months of&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;text-align:center;"&gt;2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;, includes, among other things, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;$150 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; paid to Allergan for reimbursement of Allergan&#x2019;s expenses associated with the terminated transaction and income of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;$116 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; from resolution of a contract disagreement.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-left:4px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="21"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:38%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:15%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table provides additional information about the intangible assets that were impaired during 2017 in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Other (income)/deductions&#x2013;&#x2013;net&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Fair Value&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Nine Months Ended&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;October 1, 2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Amount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Level 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Level 2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Level 3&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Impairment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Intangible assets&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;font-style:italic;"&gt;&#x2013;&#x2013;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Developed technology rights&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;50&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;50&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;127&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8.5pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;The fair value amount is presented as of the date of impairment, as these assets are not measured at fair value on a recurring basis.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;font-size:8.5pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(b)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Reflects intangible assets written down to fair value in the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;third quarter&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;text-align:center;"&gt;2017&lt;/span&gt;. Fair value was determined using the income approach, specifically the multi-period excess earnings method, also known as the discounted cash flow method. We started with a forecast of all the expected net cash flows associated with the asset and then applied an asset-specific discount rate to arrive at a net present value amount. Some of the more significant estimates and assumptions inherent in this approach include: the amount and timing of the projected net cash flows, which includes the expected impact of competitive, legal and/or regulatory forces on the product; the discount rate, which seeks to reflect the various risks inherent in the projected cash flows; and the tax rate, which seeks to incorporate the geographic diversity of the projected cash flows.</us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock>
    <us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock
      contextRef="FD2017Q3YTD"
      id="TextSelection-1D3ED85953925617BCBDD47BED8C2E25-0-wk-Fact-4C516EECB4E65E809D86019A1208131E">&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:44%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="17" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table provides components of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Other (income)/deductions&#x2013;&#x2013;net&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Three Months Ended&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Nine Months Ended&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;October&#160;1, &lt;br/&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;October&#160;2, &lt;br/&gt;2016&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;October&#160;1, &lt;br/&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;October&#160;2, &lt;br/&gt;2016&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Interest income&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(99&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(123&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(275&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(357&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Interest expense&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;320&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;291&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;940&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;889&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net interest expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;220&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;168&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;666&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;532&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Royalty-related income&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(140&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(233&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(331&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(695&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Certain legal matters, net&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(c)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;183&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(40&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;194&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;494&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net gains on asset disposals&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(d)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(155&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(47&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(349&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(81&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-left:18px;text-indent:-18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Loss on sale and impairment on remeasurement of HIS net assets&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(e)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(12&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,422&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;52&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,422&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Certain asset impairments&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(f)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;130&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;133&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;143&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,080&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Business and legal entity alignment costs&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(g)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;16&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;69&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;54&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;180&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Other, net&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(h)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(191&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(55&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(445&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(117&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Other (income)/deductions&#x2013;&#x2013;net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;51&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,417&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(16&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,815&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8.5pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Interest income decreased in the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;third&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; quarter and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;first nine months of&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;text-align:center;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;, primarily driven by a lower investment balance. Interest expense increased in the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;third&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; quarter and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;first nine months of&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;text-align:center;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;, &lt;/span&gt;&lt;span style="font-size:8.5pt;"&gt;primarily as a result of higher short-term interest rates, offset, in part, by the retirement of high-coupon debt and the issuance of new low-coupon debt&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8.5pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(b)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Royalty-related income &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;decreased&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; in the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;third&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; quarter and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;first nine months of&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;text-align:center;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;, primarily due to lower royalty income for Enbrel of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;$139 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;$414 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;, respectively, resulting from the expiration on October 31, 2016 of the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;36&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;-month royalty period under the collaboration agreement for Enbrel in the U.S. and Canada (the collaboration period under the agreement expired on October 31, 2013), partially offset by the addition of Xtandi royalty-related income of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;$73 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;$160 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;, respectively. &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8.5pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(c)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;In the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;third quarter&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;first nine months of&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;text-align:center;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;, primarily includes a &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;$94 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; charge to resolve a class action lawsuit filed by direct purchasers relating to Celebrex, which is subject to the negotiation of a final settlement agreement and court approval, and a &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;$79 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; charge to reflect damages awarded by a jury in a patent matter. In the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;first nine months of&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;text-align:center;"&gt;2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;, primarily includes amounts to resolve a Multi-District Litigation relating to Celebrex and Bextra that was pending against the Company in New York federal court for &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;$486 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;, partially offset by the reversal of a legal accrual where a loss was no longer deemed probable. In addition, the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;first nine months of&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;text-align:center;"&gt;2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; includes a settlement related to a patent matter.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8.5pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(d)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;In the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;third&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; quarter of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;text-align:center;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;, primarily includes gains on sales/out-licensing of product and compound rights (approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;$71 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;) and gains on sales and redemptions of investments in equity and debt securities (approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;$66 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;). In the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;first nine months of&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;text-align:center;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;, primarily includes gains on sales and redemptions of investments in equity and debt securities (approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;$183 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;), gains on sales/out-licensing of product and compound rights (approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;$141 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;) and a gain on sale of property (approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;$52 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;), partially offset by a net loss related to the sale of our &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;40%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; ownership investment in Teuto, including the extinguishment of a put option for the remaining &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;60%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; ownership interest (approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;$30 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;). In the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;first nine months of&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;text-align:center;"&gt;2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;, includes gains on sales/out-licensing of product and compound rights (approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;$49 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;).&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8.5pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(e)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;In the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;third&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; quarter and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;first nine months of&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;text-align:center;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;, represents adjustments to amounts previously recorded to write down the HIS net assets to fair value less costs to sell related to the sale of HIS net assets to ICU Medical. In the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;third&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; quarter and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;first nine months of&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;text-align:center;"&gt;2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;, represents a charge related to the write-down of the HIS net assets to fair value less estimated costs to sell.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8.5pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(f)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;In the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;third quarter&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;first nine months of&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;text-align:center;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;, primarily includes an intangible asset impairment charge of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;$127 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; related to developed technology rights, acquired in connection with our acquisition of Hospira, for a generic sterile injectable product for the treatment of edema associated with certain conditions. The intangible asset impairment charge for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;third&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; quarter and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;first nine months of&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;text-align:center;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; is associated with EH and reflects, among other things, updated commercial forecasts and an increased competitive environment. In the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;third&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; quarter of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;text-align:center;"&gt;2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;, primarily includes intangible asset impairment charges of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;$126 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;, reflecting &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;$97 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; of sterile injectable IPR&amp;amp;D compounds acquired in connection with our acquisition of InnoPharma and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;$29 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; of other IPR&amp;amp;D assets acquired in connection with our acquisition of King in 2011. The intangible asset impairment charges for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;third quarter&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;text-align:center;"&gt;2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; are associated with the following: EH (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;$97 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;) and IH (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;$29 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;). In the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;first nine months of&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;text-align:center;"&gt;2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;, primarily includes intangible asset impairment charges of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;$767 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;, reflecting (i) &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;$331 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; related to developed technology rights for a generic injectable antibiotic product for the treatment of bacterial infections; and (ii) &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;$265 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; related to an IPR&amp;amp;D compound for the treatment of anemia, both acquired in connection with our acquisition of Hospira; (iii) &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;$97 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; of sterile injectable IPR&amp;amp;D compounds acquired in connection with our acquisition of InnoPharma; and (iv) &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;$74 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; of other IPR&amp;amp;D assets, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;$45 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; of which were acquired in connection with our acquisition of Hospira and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;$29 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; of which were acquired in connection with our acquisition of King in 2011. The intangible asset impairment charges for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;first nine months of&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;text-align:center;"&gt;2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; are associated with the following: EH (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;$738 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;) and IH (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;$29 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;). In addition, the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;first nine months of&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;text-align:center;"&gt;2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; includes an impairment loss of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;$211 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; related to Pfizer&#x2019;s &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;49%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;-owned equity-method investment with Hisun in China, Hisun Pfizer, and an impairment loss of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;$50 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; related to Pfizer&#x2019;s &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;40%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;-owned equity-method investment in Teuto. For additional information concerning Hisun Pfizer and Teuto, see &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;font-style:italic;"&gt;Note 2D. &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-bottom:1px;padding-top:1px;padding-left:12px;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;The intangible asset impairment charge for 2016 for the IPR&amp;amp;D compound for the treatment of anemia acquired in connection with our acquisition of Hospira reflects, among other things, the impact of regulatory delays, including delays resulting from a court ruling, which required a 180-day waiting period after approval before a biosimilar product can be launched. The intangible asset impairment charges for 2016 for the sterile injectable IPR&amp;amp;D compounds acquired in connection with our acquisition of InnoPharma reflect, among other things, the impact of portfolio prioritization decisions and decreased commercial profiles of certain compounds. The intangible asset impairment charges for 2016 for developed technology rights and other IPR&amp;amp;D assets acquired in connection with our acquisition of Hospira reflect, among other things, the impact of new scientific findings, updated commercial forecasts, changes in pricing, and an increased competitive environment. The intangible asset impairment charges for 2016 for other IPR&amp;amp;D assets acquired in connection with our acquisition of King reflect changes in the competitive environment.&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8.5pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(g)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;In the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;third&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; quarter and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;first nine months of&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;text-align:center;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;text-align:center;"&gt;2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;, represents expenses for changes to our infrastructure to align our commercial operations, including costs to internally separate our businesses into distinct legal entities, as well as to streamline our intercompany supply operations to better support each business. &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;font-size:8.5pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(h)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;In the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;third quarter&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;first nine months of&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;text-align:center;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;, includes, among other things, dividend income of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;$54 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;$211 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;, respectively, from our investment in ViiV, and income of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;$62 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; from resolution of a contract disagreement. In the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;first nine months of&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;text-align:center;"&gt;2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;, includes, among other things, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;$150 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; paid to Allergan for reimbursement of Allergan&#x2019;s expenses associated with the terminated transaction and income of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;$116 million&lt;/span&gt;&lt;/span&gt; from resolution of a contract disagreement.</us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock>
    <us-gaap:InvestmentIncomeInterest
      contextRef="FD2017Q3QTD"
      decimals="-6"
      id="d43697224e944-wk-Fact-74E639AFF5BE5619A8D6D94B13D9C7F4"
      unitRef="usd">99000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="FD2016Q3QTD"
      decimals="-6"
      id="d43697224e964-wk-Fact-34F816D444055102A29F3BD0BBE0EC9E"
      unitRef="usd">123000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43697224e985-wk-Fact-D20C669A561D58BF9A9C9AC47CBBACC7"
      unitRef="usd">275000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43697224e1005-wk-Fact-A5329E1466235B2299472011E1D4E1D3"
      unitRef="usd">357000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="FD2017Q3QTD"
      decimals="-6"
      id="d43697224e1028-wk-Fact-143C071DEB4F5718B431ADB619B90A82"
      unitRef="usd">320000000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="FD2016Q3QTD"
      decimals="-6"
      id="d43697224e1047-wk-Fact-A15E72E726725EF2BD9FCCCC3A222E16"
      unitRef="usd">291000000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43697224e1066-wk-Fact-C68BCBB68BF9565C8536418482AA80FC"
      unitRef="usd">940000000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43697224e1086-wk-Fact-38D872801B2E5B2ABE4AE2E3D2CD2C57"
      unitRef="usd">889000000</us-gaap:InterestExpense>
    <us-gaap:InterestRevenueExpenseNet
      contextRef="FD2017Q3QTD"
      decimals="-6"
      id="d43697224e1111-wk-Fact-D14F3295B62D504D84DB0D76858E4471"
      unitRef="usd">-220000000</us-gaap:InterestRevenueExpenseNet>
    <us-gaap:InterestRevenueExpenseNet
      contextRef="FD2016Q3QTD"
      decimals="-6"
      id="d43697224e1130-wk-Fact-6E5ABDB000475A2E8AFE3E4F8D393B0C"
      unitRef="usd">-168000000</us-gaap:InterestRevenueExpenseNet>
    <us-gaap:InterestRevenueExpenseNet
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43697224e1149-wk-Fact-EBD7B6F7EC2A575BA2553AE5B835F7B7"
      unitRef="usd">-666000000</us-gaap:InterestRevenueExpenseNet>
    <us-gaap:InterestRevenueExpenseNet
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43697224e1169-wk-Fact-84432CAA802B54E295166E8D67B869DA"
      unitRef="usd">-532000000</us-gaap:InterestRevenueExpenseNet>
    <us-gaap:RoyaltyRevenue
      contextRef="FD2017Q3QTD"
      decimals="-6"
      id="d43697224e1196-wk-Fact-8C132ED2C80858EDAC92446BF10B1EF2"
      unitRef="usd">140000000</us-gaap:RoyaltyRevenue>
    <us-gaap:RoyaltyRevenue
      contextRef="FD2016Q3QTD"
      decimals="-6"
      id="d43697224e1216-wk-Fact-5EDED3CDB1965C449739DBF427B7E981"
      unitRef="usd">233000000</us-gaap:RoyaltyRevenue>
    <us-gaap:RoyaltyRevenue
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43697224e1236-wk-Fact-D7C62060D2E154C4AFD979CF86960190"
      unitRef="usd">331000000</us-gaap:RoyaltyRevenue>
    <us-gaap:RoyaltyRevenue
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43697224e1257-wk-Fact-994608FEC5B95CBF9C3D06616F806463"
      unitRef="usd">695000000</us-gaap:RoyaltyRevenue>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="FD2017Q3QTD"
      decimals="-6"
      id="d43697224e1285-wk-Fact-A648DF513A135C13B3F96F3C76C2A737"
      unitRef="usd">-183000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="FD2016Q3QTD"
      decimals="-6"
      id="d43697224e1304-wk-Fact-527425D761315660B95CBE4E0343A596"
      unitRef="usd">40000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43697224e1324-wk-Fact-66565D977AC4509C90AB6F21D06331BE"
      unitRef="usd">-194000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43697224e1344-wk-Fact-9B9CE720BFE65909A3F34FE77F5D328D"
      unitRef="usd">-494000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <pfe:GainLossOnDispositionOfAssetsAndEquitySecurities
      contextRef="FD2017Q3QTD"
      decimals="-6"
      id="d43697224e1371-wk-Fact-21036AB1E903531C8D597B8E28342703"
      unitRef="usd">155000000</pfe:GainLossOnDispositionOfAssetsAndEquitySecurities>
    <pfe:GainLossOnDispositionOfAssetsAndEquitySecurities
      contextRef="FD2016Q3QTD"
      decimals="-6"
      id="d43697224e1391-wk-Fact-2E6E4BDF4E235E37AD8DFBB014690780"
      unitRef="usd">47000000</pfe:GainLossOnDispositionOfAssetsAndEquitySecurities>
    <pfe:GainLossOnDispositionOfAssetsAndEquitySecurities
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43697224e1411-wk-Fact-E45333DA3C1351558E633F4210434F91"
      unitRef="usd">349000000</pfe:GainLossOnDispositionOfAssetsAndEquitySecurities>
    <pfe:GainLossOnDispositionOfAssetsAndEquitySecurities
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43697224e1432-wk-Fact-92A8B07CD3785791B6C291224D7DF376"
      unitRef="usd">81000000</pfe:GainLossOnDispositionOfAssetsAndEquitySecurities>
    <us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
      contextRef="FD2017Q3QTD"
      decimals="-6"
      id="d43697224e1460-wk-Fact-4927FC00863B524C890DD332985D1F82"
      unitRef="usd">12000000</us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal>
    <us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
      contextRef="FD2016Q3QTD"
      decimals="-6"
      id="d43697224e1480-wk-Fact-69F129F21E2851A6981AF851D0C9DC3E"
      unitRef="usd">-1422000000</us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal>
    <us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43697224e1499-wk-Fact-4CD7C8E134F3568695AECCF94C6AF4FD"
      unitRef="usd">-52000000</us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal>
    <us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43697224e1519-wk-Fact-E944F13BD8105FBDB6ACB7D264796FD0"
      unitRef="usd">-1422000000</us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal>
    <us-gaap:AssetImpairmentCharges
      contextRef="FD2017Q3QTD"
      decimals="-6"
      id="d43697224e1546-wk-Fact-5F0338CD4AAEEBC4E9D45A2FEA4E4512"
      unitRef="usd">130000000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="FD2016Q3QTD"
      decimals="-6"
      id="d43697224e1565-wk-Fact-872E272F8D3F541FBE9D985BACC8A6A2"
      unitRef="usd">133000000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43697224e1584-wk-Fact-53DF84C7A47DE18B0F1C5A2FEA57D70F"
      unitRef="usd">143000000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43697224e1604-wk-Fact-A203EA72411358678C6144B3CC9481A2"
      unitRef="usd">1080000000</us-gaap:AssetImpairmentCharges>
    <pfe:BusinessInfrastructureAlignmentCosts
      contextRef="FD2017Q3QTD"
      decimals="-6"
      id="d43697224e1632-wk-Fact-B77CD495CEF453F5A40BDFFD319AC5F2"
      unitRef="usd">16000000</pfe:BusinessInfrastructureAlignmentCosts>
    <pfe:BusinessInfrastructureAlignmentCosts
      contextRef="FD2016Q3QTD"
      decimals="-6"
      id="d43697224e1651-wk-Fact-84DD287398AF5474B3AA02B3F4BF9D06"
      unitRef="usd">69000000</pfe:BusinessInfrastructureAlignmentCosts>
    <pfe:BusinessInfrastructureAlignmentCosts
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43697224e1670-wk-Fact-E3EB811EAA2157F1B8A0AC676941AA20"
      unitRef="usd">54000000</pfe:BusinessInfrastructureAlignmentCosts>
    <pfe:BusinessInfrastructureAlignmentCosts
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43697224e1690-wk-Fact-A40CCA358E885B1BBACDE3FEAE88386D"
      unitRef="usd">180000000</pfe:BusinessInfrastructureAlignmentCosts>
    <pfe:OtherNonoperatingIncomeExpenseNet
      contextRef="FD2017Q3QTD"
      decimals="-6"
      id="d43697224e1717-wk-Fact-EE1FD7EDFFF655E3BCB6C13905C55C31"
      unitRef="usd">191000000</pfe:OtherNonoperatingIncomeExpenseNet>
    <pfe:OtherNonoperatingIncomeExpenseNet
      contextRef="FD2016Q3QTD"
      decimals="-6"
      id="d43697224e1737-wk-Fact-92DEAC51BE5052E8AC6E2521BB717C22"
      unitRef="usd">55000000</pfe:OtherNonoperatingIncomeExpenseNet>
    <pfe:OtherNonoperatingIncomeExpenseNet
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43697224e1757-wk-Fact-858DAA1BAEC456F597F882E9D0741E7F"
      unitRef="usd">445000000</pfe:OtherNonoperatingIncomeExpenseNet>
    <pfe:OtherNonoperatingIncomeExpenseNet
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43697224e1778-wk-Fact-264D8D2580555027A2EF57DE7B0E9E4A"
      unitRef="usd">117000000</pfe:OtherNonoperatingIncomeExpenseNet>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="FD2017Q3QTD"
      decimals="-6"
      id="d43697224e1809-wk-Fact-EEFC92F1B5E55E77955910BC4C0F4CE1"
      unitRef="usd">-51000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="FD2016Q3QTD"
      decimals="-6"
      id="d43697224e1828-wk-Fact-916495EF6D70560FBFED7475E53E1BEA"
      unitRef="usd">-1417000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43697224e1848-wk-Fact-EE9718ED59B15329A11D4FE12F405FEA"
      unitRef="usd">16000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43697224e1868-wk-Fact-901AC284652F5C9B93B4B3D55F3C6EAE"
      unitRef="usd">-2815000000</us-gaap:OtherNonoperatingIncomeExpense>
    <pfe:DecreaseinRoyaltyRevenue
      contextRef="FD2017Q3QTD_us-gaap_ProductOrServiceAxis_pfe_EnbrelMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementCopromotionMember"
      decimals="-6"
      id="d43697224e1960-wk-Fact-DDDA2865DA8E5B27856F2501BDE0E579"
      unitRef="usd">139000000</pfe:DecreaseinRoyaltyRevenue>
    <pfe:DecreaseinRoyaltyRevenue
      contextRef="FD2017Q3YTD_us-gaap_ProductOrServiceAxis_pfe_EnbrelMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementCopromotionMember"
      decimals="-6"
      id="d43697224e1965-wk-Fact-664B8E36A01C508E890ED26FD1160970"
      unitRef="usd">414000000</pfe:DecreaseinRoyaltyRevenue>
    <us-gaap:RoyaltyRevenue
      contextRef="FD2017Q3QTD_us-gaap_ProductOrServiceAxis_pfe_XtandiMember"
      decimals="-6"
      id="d43697224e1973-wk-Fact-3E9482897F2659E587019ECDD5CFA627"
      unitRef="usd">73000000</us-gaap:RoyaltyRevenue>
    <us-gaap:RoyaltyRevenue
      contextRef="FD2017Q3YTD_us-gaap_ProductOrServiceAxis_pfe_XtandiMember"
      decimals="-6"
      id="d43697224e1977-wk-Fact-3594D9BE74BB506C9B63A7F9083C250F"
      unitRef="usd">160000000</us-gaap:RoyaltyRevenue>
    <us-gaap:LitigationSettlementExpense
      contextRef="FD2017Q3QTD_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_ProductOrServiceAxis_pfe_CelebrexMember"
      decimals="-6"
      id="d43697224e2004-wk-Fact-CD48A7567A23874149CC5923C0F05394"
      unitRef="usd">94000000</us-gaap:LitigationSettlementExpense>
    <us-gaap:LitigationSettlementExpense
      contextRef="FD2017Q3QTD_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_LossContingenciesByNatureOfContingencyAxis_pfe_PatentMatterMember"
      decimals="-6"
      id="d43697224e2008-wk-Fact-3231336CCB0FB42B1C815926376CD5FE"
      unitRef="usd">79000000</us-gaap:LitigationSettlementExpense>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="FD2016Q3YTD_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_ProductOrServiceAxis_pfe_CelebrexandBextraMember"
      decimals="-6"
      id="d43697224e2021-wk-Fact-90148B681841572FA508B7090BDF2831"
      unitRef="usd">486000000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <us-gaap:GainLossOnDispositionOfIntangibleAssets
      contextRef="FD2017Q3QTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DistributionRightsMember"
      decimals="-6"
      id="d43697224e2066-wk-Fact-27FF63E43EB45961B411225F2EF045B3"
      unitRef="usd">71000000</us-gaap:GainLossOnDispositionOfIntangibleAssets>
    <us-gaap:GainOnSaleOfInvestments
      contextRef="FD2017Q3QTD"
      decimals="-6"
      id="d43697224e2070-wk-Fact-C4F53EFB305756E29F326D614DED4225"
      unitRef="usd">66000000</us-gaap:GainOnSaleOfInvestments>
    <us-gaap:GainOnSaleOfInvestments
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43697224e2087-wk-Fact-9AB5CF5D0B945844958CC736E8E4BBA4"
      unitRef="usd">183000000</us-gaap:GainOnSaleOfInvestments>
    <us-gaap:GainLossOnDispositionOfIntangibleAssets
      contextRef="FD2017Q3YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DistributionRightsMember"
      decimals="-6"
      id="d43697224e2091-wk-Fact-F7F8AF6D3AE054A8B25643416253F993"
      unitRef="usd">141000000</us-gaap:GainLossOnDispositionOfIntangibleAssets>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43697224e2095-wk-Fact-72BA63D2163F5848A6F0FD4B745778C3"
      unitRef="usd">52000000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="I2017Q2Jun30_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_LaboratorioTeutoBrasileroMember"
      decimals="2"
      id="d43697224e2099-wk-Fact-7A20B5BEC3C75D16BFE5A86C05D26ABA"
      unitRef="number">0.40</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="I2017Q2Jun30_dei_LegalEntityAxis_pfe_LaboratorioTeutoBrasileroMember_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_LaboratorioTeutoBrasileroMember"
      decimals="2"
      id="d43697224e2104-wk-Fact-E514899ACB1955ECA8A28246180FA71D"
      unitRef="number">0.60</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal
      contextRef="FD2017Q3YTD_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_LaboratorioTeutoBrasileroMember"
      decimals="-6"
      id="d43697224e2108-wk-Fact-3E108918AAAA5512B11A290783D5B15E"
      unitRef="usd">-30000000</us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal>
    <us-gaap:GainLossOnDispositionOfIntangibleAssets
      contextRef="FD2016Q3YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DistributionRightsMember"
      decimals="-6"
      id="d43697224e2123-wk-Fact-9B06F8DFF7275943B32FBE5BEF80BAD9"
      unitRef="usd">49000000</us-gaap:GainLossOnDispositionOfIntangibleAssets>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="FD2017Q3YTD_us-gaap_BusinessAcquisitionAxis_pfe_HospiraMember_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43697224e2190-wk-Fact-72EE4791596BA158F53D5A37348ABBAB"
      unitRef="usd">127000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="FD2016Q3QTD"
      decimals="-6"
      id="d43697224e2218-wk-Fact-1A9B5AD0645B5DC4A49B41F2929A74ED"
      unitRef="usd">126000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="FD2016Q3QTD_us-gaap_BusinessAcquisitionAxis_pfe_InnoPharmaMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember"
      decimals="-6"
      id="d43697224e2223-wk-Fact-DC8284A6DB6FB24085565A29C02C07A0"
      unitRef="usd">97000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="FD2016Q3QTD_us-gaap_BusinessAcquisitionAxis_pfe_KingMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_pfe_OtherInProcessResearchandDevelopmentMember"
      decimals="-6"
      id="d43697224e2227-wk-Fact-5968F9546C62F64E1D0C5A2A3BCBA564"
      unitRef="usd">29000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="FD2016Q3QTD_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43697224e2239-wk-Fact-D8C2AD7A7C3E87ED1F515A2AAF093A04"
      unitRef="usd">97000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="FD2016Q3QTD_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43697224e2243-wk-Fact-D2E5FB58422E0FB3AB815A2AEB5C5F61"
      unitRef="usd">29000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43697224e2256-wk-Fact-80C134FABADABFC450303B686A461AFA"
      unitRef="usd">767000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="FD2016Q3YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember"
      decimals="-6"
      id="d43697224e2260-wk-Fact-D58EC54B3CD75170A967113B6B0E9D54"
      unitRef="usd">331000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="FD2016Q3YTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember"
      decimals="-6"
      id="d43697224e2264-wk-Fact-BC61E6765AC157DC9B8F172FD69DC7DB"
      unitRef="usd">265000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="FD2016Q3YTD_us-gaap_BusinessAcquisitionAxis_pfe_InnoPharmaMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember"
      decimals="-6"
      id="d43697224e2269-wk-Fact-A5F6440492279866164E5A2B67C301AC"
      unitRef="usd">97000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="FD2016Q3YTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_pfe_OtherInProcessResearchandDevelopmentMember"
      decimals="-6"
      id="d43697224e2273-wk-Fact-EE3C7374F9AE43FFF5EA5A2BB1168494"
      unitRef="usd">74000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="FD2016Q3YTD_us-gaap_BusinessAcquisitionAxis_pfe_HospiraMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_pfe_OtherInProcessResearchandDevelopmentMember"
      decimals="-6"
      id="d43697224e2277-wk-Fact-2CDCE282EB5B536395E3B5210D3F57CB"
      unitRef="usd">45000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="FD2016Q3YTD_us-gaap_BusinessAcquisitionAxis_pfe_KingMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_pfe_OtherInProcessResearchandDevelopmentMember"
      decimals="-6"
      id="d43697224e2281-wk-Fact-A81F037EFFDE1ABBAF665A2C35DD472A"
      unitRef="usd">29000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="FD2016Q3YTD_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43697224e2294-wk-Fact-480BE219F98A3D26E5055A2C79EA0B25"
      unitRef="usd">738000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="FD2016Q3YTD_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43697224e2298-wk-Fact-ED3014D19D3478D49D105A2C9375E6EF"
      unitRef="usd">29000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment
      contextRef="FD2016Q3YTD_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_HisunPfizerPharmaceuticalsCoLtdMember"
      decimals="-6"
      id="d43697224e2310-wk-Fact-B851DA622DEF69DCB2D83E8DBA5E58C7"
      unitRef="usd">211000000</us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="FI2016Q3_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_HisunPfizerPharmaceuticalsCoLtdMember"
      decimals="2"
      id="d43697224e2315-wk-Fact-E0E2AB1F4EEE53C6B6DCA69B4759EC8D"
      unitRef="number">0.49</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment
      contextRef="FD2016Q3YTD_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_LaboratorioTeutoBrasileroMember"
      decimals="-6"
      id="d43697224e2319-wk-Fact-96654A18A70557C4A91408A50BAC15DE"
      unitRef="usd">50000000</us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="FI2016Q3_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_LaboratorioTeutoBrasileroMember"
      decimals="2"
      id="d43697224e2323-wk-Fact-31F8A4E3497D5CFFB700513EEC18625D"
      unitRef="number">0.40</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:InvestmentIncomeDividend
      contextRef="FD2017Q3QTD_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViivHealthcareLimitedMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43697224e2432-wk-Fact-4F0D695F67305B7684A19B343AB32C0C"
      unitRef="usd">54000000</us-gaap:InvestmentIncomeDividend>
    <us-gaap:InvestmentIncomeDividend
      contextRef="FD2017Q3YTD_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViivHealthcareLimitedMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43697224e2436-wk-Fact-A4D794D7B0F25073BE267F34843F9BB3"
      unitRef="usd">211000000</us-gaap:InvestmentIncomeDividend>
    <pfe:OtherNonoperatingIncomeMiscellaneous
      contextRef="FD2017Q3QTD"
      decimals="-6"
      id="d43697224e2441-wk-Fact-9562A60DEB5731FADACA592BE4044B46"
      unitRef="usd">62000000</pfe:OtherNonoperatingIncomeMiscellaneous>
    <pfe:PaymentsforMergerTerminationCosts
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43697224e2459-wk-Fact-EF1D4381DCB852C2BC671DE2544FB0BF"
      unitRef="usd">150000000</pfe:PaymentsforMergerTerminationCosts>
    <pfe:OtherNonoperatingIncomeMiscellaneous
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43697224e2471-wk-Fact-D1FAB14020F3553CBF8E62EB164D279F"
      unitRef="usd">116000000</pfe:OtherNonoperatingIncomeMiscellaneous>
    <us-gaap:ScheduleOfImpairedIntangibleAssetsTextBlock
      contextRef="FD2017Q3YTD"
      id="TextSelection-20B5D661C20C7C1C5B7F5A1C1412998A-0-wk-Fact-210637473B50FE09AFA05A1C328C470F">&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="21"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:38%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:15%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table provides additional information about the intangible assets that were impaired during 2017 in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Other (income)/deductions&#x2013;&#x2013;net&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Fair Value&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Nine Months Ended&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;October 1, 2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Amount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Level 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Level 2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Level 3&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Impairment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Intangible assets&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;font-style:italic;"&gt;&#x2013;&#x2013;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Developed technology rights&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;50&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;50&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;127&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8.5pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;The fair value amount is presented as of the date of impairment, as these assets are not measured at fair value on a recurring basis.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;font-size:8.5pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(b)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Reflects intangible assets written down to fair value in the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;third quarter&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;text-align:center;"&gt;2017&lt;/span&gt;. Fair value was determined using the income approach, specifically the multi-period excess earnings method, also known as the discounted cash flow method. We started with a forecast of all the expected net cash flows associated with the asset and then applied an asset-specific discount rate to arrive at a net present value amount. Some of the more significant estimates and assumptions inherent in this approach include: the amount and timing of the projected net cash flows, which includes the expected impact of competitive, legal and/or regulatory forces on the product; the discount rate, which seeks to reflect the various risks inherent in the projected cash flows; and the tax rate, which seeks to incorporate the geographic diversity of the projected cash flows.</us-gaap:ScheduleOfImpairedIntangibleAssetsTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsFairValueDisclosure
      contextRef="FI2017Q3_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember"
      decimals="-6"
      id="d43697224e2866-wk-Fact-53CD55B10DB9D18954E05A1EF2A58668"
      unitRef="usd">50000000</us-gaap:FiniteLivedIntangibleAssetsFairValueDisclosure>
    <us-gaap:FiniteLivedIntangibleAssetsFairValueDisclosure
      contextRef="FI2017Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember"
      decimals="-6"
      id="d43697224e2885-wk-Fact-0D2E2A926A3F9786A8C65A1EF5DC2AD4"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsFairValueDisclosure>
    <us-gaap:FiniteLivedIntangibleAssetsFairValueDisclosure
      contextRef="FI2017Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember"
      decimals="-6"
      id="d43697224e2905-wk-Fact-C12B4B795167254CFB615A1EFA195FC4"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsFairValueDisclosure>
    <us-gaap:FiniteLivedIntangibleAssetsFairValueDisclosure
      contextRef="FI2017Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember"
      decimals="-6"
      id="d43697224e2924-wk-Fact-49CB6967F08724E343E55A1EFDC1A551"
      unitRef="usd">50000000</us-gaap:FiniteLivedIntangibleAssetsFairValueDisclosure>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="FD2017Q3YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember"
      decimals="-6"
      id="d43697224e2943-wk-Fact-66BA540C016377984D0B5A1F012CEDE6"
      unitRef="usd">127000000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="FD2017Q3YTD"
      id="TextSelection-207F451CB634542BA031A4F17BD64BDC-0-wk-Fact-2ACE6A4FFC3A542DB9475C1606F2AD4D">&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;Tax Matters&lt;/span&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;A. Taxes on Income from Continuing Operations&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Our effective tax rate for continuing operations was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;20.3%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;third&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; quarter of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;text-align:center;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, compared to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;15.5%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;third&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; quarter of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;text-align:center;"&gt;2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;20.1%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;first nine months of&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;text-align:center;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, compared to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;14.6%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;first nine months of&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;text-align:center;"&gt;2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;higher&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; effective tax rate for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;third&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; quarter of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;text-align:center;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in comparison with the same period in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;text-align:center;"&gt;2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; was primarily due to: &lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:18px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;an unfavorable change in the jurisdictional mix of earnings as a result of operating fluctuations in the normal course of business,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;partially offset by:&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:18px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;the non-recurrence of the unfavorable tax effects of an impairment charge related to the write-down of the HIS net assets to fair value less estimated costs to sell, mainly related to goodwill, which is not deductible for tax purposes, and the jurisdictional mix of intangible assets.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;higher&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; effective tax rate for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;first nine months of&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;text-align:center;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in comparison with the same period in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;text-align:center;"&gt;2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; was primarily due to:&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:18px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;the non-recurrence of benefits related to the final resolution of an agreement in principle reached in February 2016 and finalized in April 2016 to resolve certain claims related to Protonix, which resulted in the receipt of information that raised our initial assessment in 2015 of the likelihood of prevailing on the technical merits of our tax position; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:18px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;the non-recurrence of benefits associated with our Venezuela operations; as well as &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:18px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;a decrease in benefits associated with the resolution of certain tax positions pertaining to prior years primarily with various foreign tax authorities, and the expiration of certain statutes of limitations,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;partially offset by:&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:18px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;the change in the jurisdictional mix of earnings as a result of operating fluctuations in the normal course of business; as well as&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:18px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;the non-recurrence of the unfavorable tax effects of an impairment charge related to the write-down of HIS net assets to fair value less estimated costs to sell, mainly related to goodwill, which is not deductible for tax purposes, and the jurisdictional mix of intangible assets.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;B. Tax Contingencies&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We are subject to income tax in many jurisdictions, and a certain degree of estimation is required in recording the assets and liabilities related to income taxes. All of our tax positions are subject to audit by the local taxing authorities in each tax jurisdiction. These tax audits can involve complex issues, interpretations and judgments and the resolution of matters may span multiple years, particularly if subject to negotiation or litigation. Our assessments are based on estimates and assumptions that have been deemed reasonable by management, but our estimates of unrecognized tax benefits and potential tax benefits may not be representative of actual outcomes, and variation from such estimates could materially affect our financial statements in the period of settlement or when the statutes of limitations expire, as we treat these events as discrete items in the period of resolution.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The U.S. is one of our major tax jurisdictions, and we are regularly audited by the IRS:&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:18px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;With respect to Pfizer, the IRS has issued a Revenue Agent&#x2019;s Report (RAR) for tax years 2009-2010. We are not in agreement with the RAR and are currently appealing certain disputed issues. Tax years 2011-2013 are currently under audit. Tax years 2014-2017 are open, but not under audit. All other tax years are closed.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:18px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;With respect to Hospira, the federal income tax audit for tax years 2012-2013 was effectively settled in the third quarter of 2017. The IRS is currently auditing tax year 2014 through short-year 2015. All other tax years are closed. The tax years under audit for Hospira are not considered material to Pfizer.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:18px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;With respect to Anacor and Medivation, the open tax years are not considered material to Pfizer.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In addition to the open audit years in the U.S., we have open audit years in other major tax jurisdictions, such as Canada (2010-2017), Japan (2015-2017), Europe (2011-2017, primarily reflecting Ireland, the United Kingdom, France, Italy, Spain and Germany), Latin America (1998-2017, primarily reflecting Brazil) and Puerto Rico (2010-2017).&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;C. Tax Provision/(Benefit) on Other Comprehensive Income&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90167158308752%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:56%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="17" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table provides the components of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Tax provision/(benefit) on&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;other comprehensive income:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Three Months Ended&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Nine Months Ended&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;October&#160;1, &lt;br/&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;October&#160;2, &lt;br/&gt;2016&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;October&#160;1, &lt;br/&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;October&#160;2, &lt;br/&gt;2016&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Foreign currency translation adjustments, net&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(62&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(192&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(15&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Unrealized holding losses on derivative financial instruments, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;28&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;30&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(192&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Reclassification adjustments for realized (gains)/losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(29&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;32&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(169&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;81&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;32&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(139&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(112&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Unrealized holding gains on available-for-sale securities, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;37&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;40&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;93&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;106&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Reclassification adjustments for realized gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(49&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(14&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(45&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(16&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(12&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;26&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;47&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;90&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Benefit plans: actuarial losses, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(37&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(31&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(15&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(39&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Reclassification adjustments related to amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;60&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;47&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;152&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;140&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Reclassification adjustments related to settlements, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;22&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;30&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;27&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(33&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;14&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(46&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;11&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;40&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;121&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;133&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Benefit plans: prior service (costs)/credits and other, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;35&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;66&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Reclassification adjustments related to amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(17&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(17&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(50&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(47&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Reclassification adjustments related to curtailments, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(17&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;18&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(55&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;15&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-style:italic;"&gt;Tax provision/(benefit) on other comprehensive income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(80&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;116&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(218&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;111&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;Taxes are not provided for foreign currency translation adjustments relating to investments in international subsidiaries that will be held indefinitely.</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="FD2017Q3QTD"
      decimals="3"
      id="d43691920e643-wk-Fact-B28AC12352F15ADEB0DE5D42E6FDA384"
      unitRef="number">0.203</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="FD2016Q3QTD"
      decimals="3"
      id="d43691920e655-wk-Fact-1695D7752478550AA5BC3FD108067073"
      unitRef="number">0.155</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="FD2017Q3YTD"
      decimals="3"
      id="d43691920e668-wk-Fact-4F62F6352743557B99817F09BD80BFD2"
      unitRef="number">0.201</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="FD2016Q3YTD"
      decimals="3"
      id="d43691920e680-wk-Fact-5A6FB2B5BFF655129456447A1D77D3A6"
      unitRef="number">0.146</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <pfe:ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock
      contextRef="FD2017Q3YTD"
      id="TextSelection-5FC0C4FA21D6594890557187529CE237-0-wk-Fact-80CB44040EA9534CAEFC9288DA01ED37">&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90167158308752%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:56%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="17" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table provides the components of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Tax provision/(benefit) on&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;other comprehensive income:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Three Months Ended&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Nine Months Ended&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;October&#160;1, &lt;br/&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;October&#160;2, &lt;br/&gt;2016&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;October&#160;1, &lt;br/&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;October&#160;2, &lt;br/&gt;2016&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Foreign currency translation adjustments, net&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(62&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(192&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(15&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Unrealized holding losses on derivative financial instruments, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;28&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;30&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(192&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Reclassification adjustments for realized (gains)/losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(29&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;32&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(169&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;81&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;32&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(139&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(112&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Unrealized holding gains on available-for-sale securities, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;37&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;40&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;93&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;106&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Reclassification adjustments for realized gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(49&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(14&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(45&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(16&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(12&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;26&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;47&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;90&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Benefit plans: actuarial losses, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(37&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(31&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(15&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(39&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Reclassification adjustments related to amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;60&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;47&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;152&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;140&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Reclassification adjustments related to settlements, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;22&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;30&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;27&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(33&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;14&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(46&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;11&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;40&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;121&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;133&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Benefit plans: prior service (costs)/credits and other, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;35&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;66&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Reclassification adjustments related to amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(17&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(17&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(50&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(47&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Reclassification adjustments related to curtailments, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(17&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;18&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(55&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;15&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-style:italic;"&gt;Tax provision/(benefit) on other comprehensive income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(80&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;116&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(218&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;111&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;Taxes are not provided for foreign currency translation adjustments relating to investments in international subsidiaries that will be held indefinitely.</pfe:ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="FD2017Q3QTD"
      decimals="-6"
      id="d43691920e1143-wk-Fact-20A5C02D91765E01AC1BECE67B1B1069"
      unitRef="usd">-62000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="FD2016Q3QTD"
      decimals="-6"
      id="d43691920e1163-wk-Fact-7E181FF37E2A50278584695E0D09574B"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43691920e1183-wk-Fact-9E3C8C139B5F5A29BA180FCB89C053CB"
      unitRef="usd">-192000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43691920e1203-wk-Fact-74D925B0A9935FB7A7B9371D66730DC0"
      unitRef="usd">-15000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax
      contextRef="FD2017Q3QTD"
      decimals="-6"
      id="d43691920e1224-wk-Fact-7D25F7010081517DA252227101C919B5"
      unitRef="usd">28000000</us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax
      contextRef="FD2016Q3QTD"
      decimals="-6"
      id="d43691920e1243-wk-Fact-0B09CD0C5C875357BE7DB79124A4E04C"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43691920e1262-wk-Fact-722BD08C0AD55CC19AEF3680CB2D5D3D"
      unitRef="usd">30000000</us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43691920e1282-wk-Fact-F256DC9852A85B949366691563740C3F"
      unitRef="usd">-192000000</us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesTax
      contextRef="FD2017Q3QTD"
      decimals="-6"
      id="d43691920e1308-wk-Fact-3001F1013C895E04954075538DBEE734"
      unitRef="usd">29000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesTax
      contextRef="FD2016Q3QTD"
      decimals="-6"
      id="d43691920e1328-wk-Fact-6BF3EA8F2B6E5F4A85E0DC70502C1FF0"
      unitRef="usd">-32000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesTax
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43691920e1347-wk-Fact-BF5C82D2F0C159A9A419B6DD8D19C3DD"
      unitRef="usd">169000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesTax
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43691920e1368-wk-Fact-3C0F36FE7BE25F00AA19BC7299034AA1"
      unitRef="usd">-81000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesTax
      contextRef="FD2017Q3QTD"
      decimals="-6"
      id="d43691920e1393-wk-Fact-AD1F5A27320B58F18350611619CB4C2D"
      unitRef="usd">-1000000</us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesTax
      contextRef="FD2016Q3QTD"
      decimals="-6"
      id="d43691920e1413-wk-Fact-1839ACB9C53D55CEBD85396C29D84D4B"
      unitRef="usd">32000000</us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesTax
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43691920e1432-wk-Fact-12958CC2E3FF51A3ADB14C7CA9457E07"
      unitRef="usd">-139000000</us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesTax
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43691920e1453-wk-Fact-17B8EE1FBF5052AC902A168CF6CC3D75"
      unitRef="usd">-112000000</us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
      contextRef="FD2017Q3QTD"
      decimals="-6"
      id="d43691920e1479-wk-Fact-B4261AE3D0AD53E7A8C763DE827437AD"
      unitRef="usd">37000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
      contextRef="FD2016Q3QTD"
      decimals="-6"
      id="d43691920e1498-wk-Fact-0254BA20C96B5206AB66C400FD6835C8"
      unitRef="usd">40000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43691920e1517-wk-Fact-28D2206529865A97837AAF55B33A5622"
      unitRef="usd">93000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43691920e1537-wk-Fact-A2AB1B08748952748A1F3C1E2F170710"
      unitRef="usd">106000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax
      contextRef="FD2017Q3QTD"
      decimals="-6"
      id="d43691920e1562-wk-Fact-030C80E057F5593F9D68A9372EB2A16A"
      unitRef="usd">49000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax
      contextRef="FD2016Q3QTD"
      decimals="-6"
      id="d43691920e1582-wk-Fact-D14F73654E0F5DF990DC7EC1EF852DF3"
      unitRef="usd">14000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43691920e1602-wk-Fact-22D264995729522A81CA77400001843C"
      unitRef="usd">45000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43691920e1623-wk-Fact-1947B284C39954C0AF1BB2E06C63F0ED"
      unitRef="usd">16000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax
      contextRef="FD2017Q3QTD"
      decimals="-6"
      id="d43691920e1649-wk-Fact-AFA051D845ED5A11AED1963B8C1115D7"
      unitRef="usd">-12000000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax
      contextRef="FD2016Q3QTD"
      decimals="-6"
      id="d43691920e1669-wk-Fact-36B9CCE20B0B58E3A6D7C635D646A4A9"
      unitRef="usd">26000000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43691920e1688-wk-Fact-7E914933941352F582E1401C1CA8F6F9"
      unitRef="usd">47000000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43691920e1708-wk-Fact-D44BF12F799052A8A971DB3069E83535"
      unitRef="usd">90000000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodTax
      contextRef="FD2017Q3QTD"
      decimals="-6"
      id="d43691920e1733-wk-Fact-C88E0803B3405BB08C35BC886D3586A7"
      unitRef="usd">-37000000</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodTax
      contextRef="FD2016Q3QTD"
      decimals="-6"
      id="d43691920e1753-wk-Fact-8EAA48BFD1E753AD9286C15FFA84D853"
      unitRef="usd">-31000000</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodTax
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43691920e1773-wk-Fact-A25C48C507965910871A9543E7003F58"
      unitRef="usd">-15000000</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodTax
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43691920e1794-wk-Fact-24AE98869F0F535BB9A91ABD483DF3F1"
      unitRef="usd">-39000000</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossTax
      contextRef="FD2017Q3QTD"
      decimals="-6"
      id="d43691920e1821-wk-Fact-0081DB29634057AD9D9EBDB3B979B8A3"
      unitRef="usd">-60000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossTax
      contextRef="FD2016Q3QTD"
      decimals="-6"
      id="d43691920e1840-wk-Fact-B416F2387D03519F9E13415DD2D9E08F"
      unitRef="usd">-47000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossTax
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43691920e1859-wk-Fact-87EAA8D878E75CC79AF824C14B894450"
      unitRef="usd">-152000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossTax
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43691920e1879-wk-Fact-B0A199C2320F541BB1BE527BA011F035"
      unitRef="usd">-140000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossTax>
    <pfe:OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossTax
      contextRef="FD2017Q3QTD"
      decimals="-6"
      id="d43691920e1904-wk-Fact-BF40EC18B19B5E49AFE8135277A519A5"
      unitRef="usd">-22000000</pfe:OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossTax>
    <pfe:OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossTax
      contextRef="FD2016Q3QTD"
      decimals="-6"
      id="d43691920e1923-wk-Fact-FCB00CA73E71550D82239494B41AFEDB"
      unitRef="usd">-10000000</pfe:OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossTax>
    <pfe:OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossTax
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43691920e1942-wk-Fact-FE1D94521C65567088D5F749B74F3A38"
      unitRef="usd">-30000000</pfe:OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossTax>
    <pfe:OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossTax
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43691920e1962-wk-Fact-27A911109D0B54CAB683C3341D54C568"
      unitRef="usd">-27000000</pfe:OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossTax>
    <pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodTax
      contextRef="FD2017Q3QTD"
      decimals="-6"
      id="d43691920e1987-wk-Fact-2D02134C06C45FB8B14D2201C3D7093F"
      unitRef="usd">33000000</pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodTax>
    <pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodTax
      contextRef="FD2016Q3QTD"
      decimals="-6"
      id="d43691920e2007-wk-Fact-994151A2479E5461AE616130A49BB496"
      unitRef="usd">-14000000</pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodTax>
    <pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodTax
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43691920e2026-wk-Fact-7ABB5D061EE55B3D89537240DDD85EB4"
      unitRef="usd">46000000</pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodTax>
    <pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodTax
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43691920e2047-wk-Fact-DCFF9A51C6D65F0AB9013F20E74CE188"
      unitRef="usd">-5000000</pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodTax>
    <pfe:DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetActuarialGainLossTax
      contextRef="FD2017Q3QTD"
      decimals="-6"
      id="d43691920e2072-wk-Fact-0EA8A7BD6AB55E229C923B6D7DBA89B3"
      unitRef="usd">11000000</pfe:DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetActuarialGainLossTax>
    <pfe:DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetActuarialGainLossTax
      contextRef="FD2016Q3QTD"
      decimals="-6"
      id="d43691920e2091-wk-Fact-0F7E9B3406F4555D90C0A9337371F4C1"
      unitRef="usd">40000000</pfe:DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetActuarialGainLossTax>
    <pfe:DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetActuarialGainLossTax
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43691920e2110-wk-Fact-2C7DDB814E8E5E38A07A56B0E4904F50"
      unitRef="usd">121000000</pfe:DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetActuarialGainLossTax>
    <pfe:DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetActuarialGainLossTax
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43691920e2130-wk-Fact-586CB94688A0590FAA31205761B7DECB"
      unitRef="usd">133000000</pfe:DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetActuarialGainLossTax>
    <pfe:DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetPriorServiceCostCreditAndOtherTax
      contextRef="FD2017Q3QTD"
      decimals="-6"
      id="d43691920e2155-wk-Fact-F15B315AAC995FCC90DC58635B7F0703"
      unitRef="usd">0</pfe:DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetPriorServiceCostCreditAndOtherTax>
    <pfe:DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetPriorServiceCostCreditAndOtherTax
      contextRef="FD2016Q3QTD"
      decimals="-6"
      id="d43691920e2174-wk-Fact-E3120D61B45B5500A79741CA03EE6AEA"
      unitRef="usd">-35000000</pfe:DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetPriorServiceCostCreditAndOtherTax>
    <pfe:DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetPriorServiceCostCreditAndOtherTax
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43691920e2193-wk-Fact-DF1241B013185B9CB0A7B8208F03EA3E"
      unitRef="usd">0</pfe:DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetPriorServiceCostCreditAndOtherTax>
    <pfe:DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetPriorServiceCostCreditAndOtherTax
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43691920e2213-wk-Fact-0C91880B29B654E2A2262315B815355C"
      unitRef="usd">-66000000</pfe:DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetPriorServiceCostCreditAndOtherTax>
    <us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax
      contextRef="FD2017Q3QTD"
      decimals="-6"
      id="d43691920e2238-wk-Fact-1D4D11ACEF6A550F9C379446440A583F"
      unitRef="usd">-17000000</us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax>
    <us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax
      contextRef="FD2016Q3QTD"
      decimals="-6"
      id="d43691920e2258-wk-Fact-A92831B4D5F55E66A0BB6737C4474926"
      unitRef="usd">-17000000</us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax>
    <us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43691920e2278-wk-Fact-9CEBD2DC02AF5056BDB9E0D45DD7DDCB"
      unitRef="usd">-50000000</us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax>
    <us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43691920e2299-wk-Fact-199FC1BC8DC55D4E9C754C068F72C6C5"
      unitRef="usd">-47000000</us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax>
    <pfe:OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditTax
      contextRef="FD2017Q3QTD"
      decimals="-6"
      id="d43691920e2325-wk-Fact-02B298FD4505502FAA9DBE3E2F9216CC"
      unitRef="usd">-1000000</pfe:OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditTax>
    <pfe:OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditTax
      contextRef="FD2016Q3QTD"
      decimals="-6"
      id="d43691920e2345-wk-Fact-B3F52E0194FF566A92AB7966FD65A1B8"
      unitRef="usd">-3000000</pfe:OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditTax>
    <pfe:OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditTax
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43691920e2365-wk-Fact-3107C1C590B45D1CA7422E04631E2C81"
      unitRef="usd">-5000000</pfe:OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditTax>
    <pfe:OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditTax
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43691920e2386-wk-Fact-3A8DE8AE66985B7A9FD65B5E72C64243"
      unitRef="usd">-5000000</pfe:OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditTax>
    <pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax
      contextRef="FD2017Q3QTD"
      decimals="-6"
      id="d43691920e2412-wk-Fact-0441EF2C04495634A674F15BDFDA7D0E"
      unitRef="usd">-1000000</pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax>
    <pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax
      contextRef="FD2016Q3QTD"
      decimals="-6"
      id="d43691920e2431-wk-Fact-6240EFE702B958268B507CF7BA87B7F2"
      unitRef="usd">-2000000</pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax>
    <pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43691920e2450-wk-Fact-DBA0FEB188FE5A5FADB65B9196841736"
      unitRef="usd">-1000000</pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax>
    <pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43691920e2470-wk-Fact-EB1E29CA46EA5B0A9E10C8FD860FDB64"
      unitRef="usd">-1000000</pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect
      contextRef="FD2017Q3QTD"
      decimals="-6"
      id="d43691920e2495-wk-Fact-7F10800AE77A5C41AA5BF5E4A13A33D8"
      unitRef="usd">17000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect
      contextRef="FD2016Q3QTD"
      decimals="-6"
      id="d43691920e2515-wk-Fact-ED107C23D8D75E359B0CB95276C3F32C"
      unitRef="usd">-18000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43691920e2534-wk-Fact-B86D23F2CD3E58FFACC67A9E65457798"
      unitRef="usd">55000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43691920e2555-wk-Fact-17AA06FDF341543CB908A3C9DE8AA4ED"
      unitRef="usd">-15000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="FD2017Q3QTD"
      decimals="-6"
      id="d43691920e2585-wk-Fact-5950DF108F195FB594A31172740C60B3"
      unitRef="usd">-80000000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="FD2016Q3QTD"
      decimals="-6"
      id="d43691920e2605-wk-Fact-31B8668E1E1956DF8878873FF4C52DA7"
      unitRef="usd">116000000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43691920e2625-wk-Fact-0A65F347C9FD5314AD71D7212990864D"
      unitRef="usd">-218000000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43691920e2645-wk-Fact-24F5F5FD900B538BB0C1F5C1D6714D02"
      unitRef="usd">111000000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:ComprehensiveIncomeNoteTextBlock
      contextRef="FD2017Q3YTD"
      id="TextSelection-2D11F2BB40C25512A3FC80946791DD6A-0-wk-Fact-724F5C5042095114BD75F8686409A36D">&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt; &lt;/span&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="25"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:23%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="25" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table provides the changes, net of tax, in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Accumulated other comprehensive loss&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net Unrealized Gains/(Losses)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Benefit Plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Foreign Currency Translation Adjustments &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Derivative Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Available-For-Sale Securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Actuarial Gains/(Losses)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Prior Service (Costs)/Credits and Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accumulated Other Comprehensive Income/(Loss)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Balance, December&#160;31, 2016&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(6,659&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;348&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(131&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(5,473&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;879&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(11,036&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Other comprehensive income/(loss)&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,638&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(403&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;470&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;263&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(96&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,872&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Balance, October&#160;1, 2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(5,021&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(55&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;339&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(5,210&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;783&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(9,164&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Amounts do not include foreign currency translation adjustments attributable to noncontrolling interests of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;$16 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt; income for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;first nine months of&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;text-align:center;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;October&#160;1, 2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, with respect to derivative financial instruments, the amount of unrealized pre-tax net losses on derivative financial instruments estimated to be reclassified into income within the next 12 months is approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$154 million&lt;/span&gt;&lt;/span&gt;, which is expected to be offset primarily by gains related to available-for-sale securities and gains resulting from reclassification adjustments related to foreign currency exchange-denominated forecasted intercompany inventory sales.</us-gaap:ComprehensiveIncomeNoteTextBlock>
    <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="FD2017Q3YTD"
      id="TextSelection-5DA93522D4A15C9A955CD584AA15E736-0-wk-Fact-EC3A117A8FF55DE3869BE8DD815E9ECC">&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="25"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:23%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="25" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table provides the changes, net of tax, in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Accumulated other comprehensive loss&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net Unrealized Gains/(Losses)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Benefit Plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Foreign Currency Translation Adjustments &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Derivative Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Available-For-Sale Securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Actuarial Gains/(Losses)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Prior Service (Costs)/Credits and Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accumulated Other Comprehensive Income/(Loss)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Balance, December&#160;31, 2016&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(6,659&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;348&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(131&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(5,473&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;879&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(11,036&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Other comprehensive income/(loss)&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,638&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(403&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;470&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;263&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(96&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,872&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Balance, October&#160;1, 2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(5,021&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(55&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;339&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(5,210&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;783&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(9,164&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Amounts do not include foreign currency translation adjustments attributable to noncontrolling interests of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;$16 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt; income for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;first nine months of&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;text-align:center;"&gt;2017&lt;/span&gt;.</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:StockholdersEquity
      contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember"
      decimals="-6"
      id="d43692105e1075-wk-Fact-A26834331A4E566C86D979822918457B"
      unitRef="usd">-6659000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember"
      decimals="-6"
      id="d43692105e1095-wk-Fact-221959FA9D815244845776458CA6E530"
      unitRef="usd">348000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"
      decimals="-6"
      id="d43692105e1115-wk-Fact-AD346E1FD4E35AD3868EB429B3A1BE5D"
      unitRef="usd">-131000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember"
      decimals="-6"
      id="d43692105e1135-wk-Fact-66FDB0064EDD5661A645D17405DAAE1E"
      unitRef="usd">-5473000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember"
      decimals="-6"
      id="d43692105e1155-wk-Fact-AE6E0103E5DC57999D8419D17047E55D"
      unitRef="usd">879000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-6"
      id="d43692105e1175-wk-Fact-1C5D2C0F26F45CC297A9902A74F9EEC2"
      unitRef="usd">-11036000000</us-gaap:StockholdersEquity>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2017Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember"
      decimals="-6"
      id="d43692105e1198-wk-Fact-53D122DE8506544FBB5C5E66B2ABDED8"
      unitRef="usd">1638000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2017Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember"
      decimals="-6"
      id="d43692105e1217-wk-Fact-985F88532E195B47BDB854CF286F26CD"
      unitRef="usd">-403000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2017Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"
      decimals="-6"
      id="d43692105e1237-wk-Fact-A34EE90663FB5081B9E32DEADBF0E652"
      unitRef="usd">470000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2017Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember"
      decimals="-6"
      id="d43692105e1257-wk-Fact-38D6CEB8D8AD5DDC81AC2FCD8FAE9F8C"
      unitRef="usd">263000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2017Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember"
      decimals="-6"
      id="d43692105e1276-wk-Fact-797701906D5A55A4A147956137258C89"
      unitRef="usd">-96000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2017Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-6"
      id="d43692105e1297-wk-Fact-FAF3334C03BB50B5921AB864A8788C26"
      unitRef="usd">1872000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockholdersEquity
      contextRef="FI2017Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember"
      decimals="-6"
      id="d43692105e1327-wk-Fact-9BD14851B5AF511ABBBC5C7674FAA3EF"
      unitRef="usd">-5021000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2017Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember"
      decimals="-6"
      id="d43692105e1347-wk-Fact-F15CE6FEF57E50C49CDB01BFBFF360E0"
      unitRef="usd">-55000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2017Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"
      decimals="-6"
      id="d43692105e1368-wk-Fact-24EDD802F3BA5DF78DE63E6A9EF3C0F4"
      unitRef="usd">339000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2017Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember"
      decimals="-6"
      id="d43692105e1387-wk-Fact-A7149C565C45560B9178A58A4E3356E5"
      unitRef="usd">-5210000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2017Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember"
      decimals="-6"
      id="d43692105e1407-wk-Fact-526D747181715C33A9D32427AAD93214"
      unitRef="usd">783000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2017Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-6"
      id="d43692105e1427-wk-Fact-7AA58A1D40FB550292F1257410C0514E"
      unitRef="usd">-9164000000</us-gaap:StockholdersEquity>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToNoncontrollingInterest
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43692105e1447-wk-Fact-85FFE2528F0255C4AF78F51D7D6CA92E"
      unitRef="usd">16000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToNoncontrollingInterest>
    <us-gaap:CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths
      contextRef="FD2017Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember"
      decimals="-6"
      id="d43692105e1481-wk-Fact-053DA37D6DF35D4488C445B5609AC8D8"
      unitRef="usd">-154000000</us-gaap:CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths>
    <us-gaap:FinancialInstrumentsDisclosureTextBlock
      contextRef="FD2017Q3YTD"
      id="TextSelection-1EE0D555564D5ACA882C4EC0D6E9B51D-0-wk-Fact-B3A5822AA2D35F53AB503C921439D025">&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;Financial Instruments&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt; &lt;/span&gt;&lt;div style="line-height:120%;font-size:6pt;"&gt;&lt;span style="font-family:inherit;font-size:6pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;A. Selected Financial Assets and Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:74%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table provides additional information about certain of our financial assets and liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;October&#160;1, &lt;br/&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;December&#160;31, &lt;br/&gt;2016&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:justify;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;text-decoration:underline;"&gt;Selected financial assets measured at fair value on a recurring basis&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:justify;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Trading funds and securities&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;347&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;325&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:justify;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Available-for-sale debt securities&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(c)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;16,598&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;18,632&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Money market funds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;1,824&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;1,445&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Available-for-sale equity securities&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(c)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;1,032&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;540&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:justify;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Derivative financial instruments in a receivable position&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(d)&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Interest rate swaps&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;630&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;625&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Foreign currency swaps&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;92&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;79&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Foreign currency forward-exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;110&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;551&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;20,631&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;22,198&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;text-decoration:underline;"&gt;Other selected financial assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Held-to-maturity debt securities, carried at amortized cost&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(c), (e)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;1,464&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;1,242&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Restricted stock and private equity securities, carried at cost or at equity-method&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(e)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;719&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;735&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;2,183&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;1,977&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Total selected financial assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;22,815&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;24,175&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:justify;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;text-decoration:underline;"&gt;Selected financial liabilities measured at fair value on a recurring basis&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:justify;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Derivative financial instruments in a liability position&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(f)&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Interest rate swaps&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;154&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;148&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Foreign currency swaps&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;710&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;1,374&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Foreign currency forward-exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;309&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;143&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;1,173&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;1,665&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;text-decoration:underline;"&gt;Other selected financial liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Short-term borrowings:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Principal amount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;9,460&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;10,674&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Net fair value adjustments related to hedging and purchase accounting&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;24&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Net unamortized discounts, premiums and debt issuance costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(15&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(11&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:30px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Total short-term borrowings, carried at historical proceeds, as adjusted&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(e)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;9,448&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;10,688&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Long-term debt:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Principal amount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;33,671&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;30,529&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Net fair value adjustments related to hedging and purchase accounting&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;981&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;998&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Net unamortized discounts, premiums and debt issuance costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(149&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(130&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:30px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Total long-term debt, carried at historical proceeds, as adjusted&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(g)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;34,503&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;31,398&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;43,951&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;42,085&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Total selected financial liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;45,124&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;43,750&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8.5pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;We use a market approach in valuing financial instruments on a recurring basis. All of our financial assets and liabilities measured at fair value on a recurring basis use Level 2 inputs in the calculation of fair value, except &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;5%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; that use Level 1 inputs.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8.5pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(b)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;October&#160;1, 2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;, trading funds and securities are composed of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;$274 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; of trading equity funds and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;$74 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; of trading debt funds. As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;text-align:center;"&gt;December&#160;31, 2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;, trading funds and securities are composed of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;$236 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; of trading equity funds and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;$89 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; of trading debt funds. As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;October&#160;1, 2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;text-align:center;"&gt;December&#160;31, 2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;, trading equity funds of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;$63 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;$71 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;, respectively, are held in trust for benefits attributable to the former Pharmacia Savings Plus Plan.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8.5pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(c)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Gross unrealized gains and losses are not significant, except as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;October&#160;1, 2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;, available-for-sale equity securities&#x2019; unrealized gains are &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;$406 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; and unrealized losses are &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;$119 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8.5pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(d)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Designated as hedging instruments, except for certain contracts used as offsets; namely, foreign currency forward-exchange contracts with fair values of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;$40 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;October&#160;1, 2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;; and foreign currency forward-exchange contracts with fair values of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;$162 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;text-align:center;"&gt;December&#160;31, 2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8.5pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(e)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;The differences between the estimated fair values and carrying values of held-to-maturity debt securities, restricted stock and private equity securities at cost, and short-term borrowings not measured at fair value on a recurring basis were not significant as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;October&#160;1, 2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; or &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;text-align:center;"&gt;December&#160;31, 2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;. The fair value measurements of our held-to-maturity debt securities and our short-term borrowings are based on Level 2 inputs, using a market approach. The fair value measurements of our &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;background-color:#ffffff;"&gt;priv&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;ate equity securities carried at cost are based on Level 3 inputs.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-left:4px;text-align:left;padding-left:12px;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8.5pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(f)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Designated as hedging instruments, except for certain contracts used as offsets; namely, foreign currency forward-exchange contracts with fair values of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;$60 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;October&#160;1, 2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;; and foreign currency swaps with fair values of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;$269 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; and foreign currency forward-exchange contracts with fair values of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;$113 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;text-align:center;"&gt;December&#160;31, 2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8.5pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(g)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;The fair value of our long-term debt (not including the current portion of long-term debt) was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;$39.0 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;October&#160;1, 2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;$34.9 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;text-align:center;"&gt;December&#160;31, 2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;. The fair value measurements for our long-term debt are based on Level 2 inputs, using a market approach. Long-term debt includes foreign currency long-term borrowings with fair values of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;$4.7 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;October&#160;1, 2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;, which are used as hedging instruments.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-left:4px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:72%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table provides the classification of these selected financial assets and liabilities in our condensed consolidated balance sheets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;October&#160;1, &lt;br/&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, &lt;br/&gt;2016&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;text-decoration:underline;"&gt;Assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;526&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;547&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Short-term investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;14,146&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;15,255&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Other current assets&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;288&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;567&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Long-term investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7,311&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7,116&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Other noncurrent assets&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;543&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;689&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;22,815&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;24,175&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;text-decoration:underline;"&gt;Liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Short-term borrowings, including current portion of long-term debt&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9,448&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10,688&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Other current liabilities&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(c)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;277&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;443&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Long-term debt&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;34,503&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;31,398&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(d)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;896&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,222&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;45,124&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;43,750&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;October&#160;1, 2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;, derivative instruments at fair value include interest rate swaps (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;$97 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;), foreign currency swaps (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;$86 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;) and foreign currency forward-exchange contracts (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;$105 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;) and, as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;text-align:center;"&gt;December&#160;31, 2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;, include interest rate swaps (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;$26 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;), foreign currency swaps (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;$43 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;) and foreign currency forward-exchange contracts (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;$497 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;).&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(b)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;October&#160;1, 2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;, derivative instruments at fair value include interest rate swaps (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;$532 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;), foreign currency swaps (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;$6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;) and foreign currency forward-exchange contracts (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;$5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;) and, as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;text-align:center;"&gt;December&#160;31, 2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;, include interest rate swaps (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;$599 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;), foreign currency swaps (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;$36 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;) and foreign currency forward-exchange contracts (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;$54 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;).&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(c)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;October&#160;1, 2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;, derivative instruments at fair value include foreign currency forward-exchange contracts (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;$276 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;) and interest rate swaps (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;$1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;) and, as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;text-align:center;"&gt;December&#160;31, 2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;, include interest rate swaps (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;$1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;), foreign currency swaps (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;$300 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;) and foreign currency forward-exchange contracts (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;$143 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;).&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(d)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;October&#160;1, 2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;, derivative instruments at fair value include interest rate swaps (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;$153 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;), foreign currency swaps (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;$710 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;) and foreign currency forward-exchange contracts (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;$33 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;) and, as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;text-align:center;"&gt;December&#160;31, 2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;, include interest rate swaps (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;$147 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;) and foreign currency swaps (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;$1.1 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;).&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-left:4px;text-align:left;font-size:5pt;"&gt;&lt;span style="font-family:inherit;font-size:5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;There were no significant impairments of financial assets recognized in any period presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;B. Investments in Debt Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.41520467836257%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="21"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:47%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table provides the contractual maturities, or as necessary, the estimated maturities, of the available-for-sale and held-to-maturity debt securities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;October&#160;1, &lt;br/&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:justify;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Within 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Over 1&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;to 5&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Over 5&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;to 10&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Over 10&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;text-decoration:underline;"&gt;Available-for-sale debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Corporate debt&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;2,741&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;2,591&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;1,525&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;17&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;6,874&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Western European, Asian, and other government debt&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;6,071&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;268&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;6,339&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Western European, Scandinavian and other government agency debt&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;1,955&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;42&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;1,998&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Supranational debt&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;387&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;195&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;582&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Government National Mortgage Association and other U.S. government guaranteed asset-backed securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;42&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;424&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;466&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Other asset-backed debt&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(c)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;161&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;61&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;226&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;U.S. government debt&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;112&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;112&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;text-decoration:underline;"&gt;Held-to-maturity debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Time deposits and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;1,133&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;1,137&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Western European government debt&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;326&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;326&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Total debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;12,818&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;3,694&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;1,532&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;18&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;18,061&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Issued by a diverse group of corporations, with a significant concentration in the technology sector, virtually all of which are investment-grade.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(b)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Issued by governments, government agencies or supranational entities, as applicable, all of which are high quality.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(c)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Includes receivable-backed, loan-backed, and mortgage-backed securities, all of which are high quality and in senior positions in the capital structure of the security. Receivable-backed securities are collateralized by credit cards receivables, loan-backed securities are collateralized by senior secured obligations of a diverse pool of companies or student loans, and mortgage-backed securities are collateralized by diversified pools of residential and commercial mortgages.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-left:4px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;C. Short-Term Borrowings&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Short-term borrowings include amounts for commercial paper of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$6.1 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;October&#160;1, 2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$5.8 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;text-align:center;"&gt;December&#160;31, 2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;D. Long-Term Debt&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="11"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:58%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table provides the amounts of senior unsecured long-term debt issued in the first quarter of 2017:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Principal&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;As of October&#160;1, 2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;(MILLIONS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Maturity Date&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Euro&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;U.S. Dollar&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;3-month EURIBOR + 0.20% floating rate notes (0% floor)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;March&#160;6, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#x20ac;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;1,250&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;1,479&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;0.00% euro notes&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;March&#160;6, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;1,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;1,183&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;0.25% euro notes&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;March&#160;6, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;1,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;1,183&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;1.00% euro notes&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;March&#160;6, 2027&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;750&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;887&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-left:12px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Total euro long-term debt issued in the first quarter of 2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#x20ac;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;4,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;4,732&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;4.20% notes&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(c)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;March 17, 2047&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;1,065&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Total long-term debt issued in the first quarter of 2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(d)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;5,797&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8.5pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Redeemable at any time, in whole, or in part, at our option prior to 30 to 90 days of maturity date at the comparable German government bond rate, plus &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;0.15%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;; plus, in each case, accrued and unpaid interest. The fixed rate euro notes are also redeemable at our option, in whole, or in part, within 30 to 90 days of maturity date.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8.5pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(b)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;The weighted-average effective interest rate for the euro notes at issuance was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;0.23%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8.5pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(c)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;The notes, issued in U.S. dollars in Taiwan, are redeemable, at our option, in whole but not in part, on each March 17 on or after March 17, 2020.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8.5pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(d)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;The aggregate amount at issuance date was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;$5,279 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;. The increase in the amount since the date of issuance is due to foreign currency exchange.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="25"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:28%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="25" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table provides the maturity schedule of our &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Long-term debt&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;outstanding as of October 1, 2017:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;After 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Maturities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;481&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,825&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,534&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,502&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;23,162&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;34,503&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;E. Other Noncurrent Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In August 2017, the U.S. approved Besponsa (inotuzumab ozogamicin) and in June 2017, the EU approved Besponsa as monotherapy for the treatment of adults with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia. In connection with the U.S. approval, we incurred an obligation to make guaranteed fixed annual payments over a nine-year period aggregating &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$296 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; related to a research and development arrangement. As a result, we have recorded the estimated net present value of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$248 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; as an intangible asset in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Developed technology rights&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, and we have recorded &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$233 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Other noncurrent liabilities &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$15 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Other current liabilities&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; as of October 1, 2017. In connection with the EU approval, we incurred an obligation to make guaranteed fixed annual payments over a nine-year period aggregating &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$148 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; related to a research and development arrangement. As a result, we recorded the estimated net present value of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$123 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; as an intangible asset in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Developed technology rights&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, and we have recorded &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$117 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Other noncurrent liabilities &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;and&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Other current liabilities&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; as of October 1, 2017.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;F. &lt;/span&gt;&lt;span style="font-weight:bold;text-decoration:underline;"&gt;Derivative Financial Instruments and Hedging Activities&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;text-decoration:underline;"&gt;Foreign Exchange Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;October&#160;1, 2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the aggregate notional amount of foreign exchange derivative financial instruments hedging or offsetting foreign currency exposures was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$31.5 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. The derivative financial instruments primarily hedge or offset exposures in the euro, Japanese yen and U.K. pound. The maximum length of time over which we are hedging future foreign exchange cash flow relates to our &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$2.0 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; U.K. pound debt maturing in 2038.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We designate foreign currency forward-exchange contracts as cash flow hedges of a portion of our forecasted euro, Japanese yen, U.K. pound, Canadian dollar, and Australian dollar-denominated intercompany inventory sales expected to occur no more than two years from the date of each hedge. As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;October&#160;1, 2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the notional amount of outstanding foreign currency forward-exchange contracts hedging our intercompany forecasted sales was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$3.9 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, with a pre-tax loss of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$97 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; deferred in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Accumulated other comprehensive loss. &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Based on quarter-end foreign exchange rates that are subject to change, we expect to reclassify a pre-tax loss of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$63 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; within the next 12 months into &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Cost of sales. &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We recognized a &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; loss in the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;third quarter&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;text-align:center;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and a &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$67 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; gain in the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;first nine months of&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;text-align:center;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; as an offset to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Cost of sales&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;text-decoration:underline;"&gt;Interest Rate Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;October&#160;1, 2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the aggregate notional amount of interest rate derivative financial instruments designated as fair value hedges was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$12.4 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. The derivative financial instruments primarily hedge U.S. dollar fixed-rate debt.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="25"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:28%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="25" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table provides information about the gains/(losses) incurred to hedge or offset operational foreign exchange or interest rate risk:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Three Months Ended&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Amount of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Gains/(Losses)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Recognized in OID&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(a), (b), (c)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Amount of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Gains/(Losses)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Recognized in OCI&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;(Effective Portion)&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(a), (d)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Amount of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Gains/(Losses)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Reclassified from&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;OCI into OID and COS&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;(Effective Portion)&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(a), (d)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:justify;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;October&#160;1, &lt;br/&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;October&#160;2, &lt;br/&gt;2016&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;October&#160;1, &lt;br/&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;October&#160;2, &lt;br/&gt;2016&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;October&#160;1, &lt;br/&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;October&#160;2, &lt;br/&gt;2016&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Derivative Financial Instruments in Cash Flow Hedge Relationships:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Foreign currency swaps&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;218&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;87&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;148&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(39&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Foreign currency forward-exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(269&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(212&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(204&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(111&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Derivative Financial Instruments in Net Investment Hedge Relationships:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Foreign currency forward-exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Derivative Financial Instruments Not Designated as Hedges:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Foreign currency forward-exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;33&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;20&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Foreign currency swaps&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Non-Derivative Financial Instruments in Net Investment Hedge Relationships:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Foreign currency long-term debt&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(166&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;All other net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;34&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;18&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(216&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(126&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(55&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(150&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Nine Months Ended&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Amount of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Gains/(Losses)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Recognized in OID&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(a), (b), (c)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Amount of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Gains/(Losses)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Recognized in OCI&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;(Effective Portion)&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(a), (d)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Amount of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Gains/(Losses)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Reclassified from&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;OCI into OID and COS&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;(Effective Portion)&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(a), (d)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:justify;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;October&#160;1, &lt;br/&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;October&#160;2, &lt;br/&gt;2016&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;October&#160;1, &lt;br/&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;October&#160;2, &lt;br/&gt;2016&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;October&#160;1, &lt;br/&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;October&#160;2, &lt;br/&gt;2016&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Derivative Financial Instruments in Cash Flow Hedge Relationships:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Foreign currency swaps&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;455&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(204&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;419&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(165&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Foreign currency forward-exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(604&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(770&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(26&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(118&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Derivative Financial Instruments in Net Investment Hedge Relationships:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Foreign currency forward-exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(15&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Derivative Financial Instruments Not Designated as Hedges:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Foreign currency forward-exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(111&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(49&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Foreign currency swaps&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Non-Derivative Financial Instruments in Net Investment Hedge Relationships:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Foreign currency short-term borrowings&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(26&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Foreign currency long-term debt&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(518&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;All other net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(117&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(56&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(666&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(1,014&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;394&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(283&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;OID = Other (income)/deductions&#x2014;net, included in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;font-style:italic;"&gt;Other (income)/deductions&#x2014;net&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt; in the condensed consolidated statements of income. COS = Cost of sales, included in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;font-style:italic;"&gt;Cost of sales&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt; in the condensed consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-left:12px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;OCI = Other comprehensive income/(loss), included in the&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;font-style:italic;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;condensed consolidated statements of comprehensive income&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;font-style:italic;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(b)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Includes gains and losses attributable to derivative instruments designated and qualifying as fair value hedges (primarily interest rate swaps), as well as the offsetting gains and losses attributable to the hedged items in such hedging relationships.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(c)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;There was no significant ineffectiveness for any period presented.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(d)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;For derivative financial instruments in cash flow hedge relationships, the effective portion is included in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;font-style:italic;"&gt;Other comprehensive income&#x2013;&#x2013;Unrealized holding losses on derivative financial instruments, net&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;. For derivative financial instruments in net investment hedge relationships and for foreign currency debt designated as hedging instruments, the effective portion is included in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;font-style:italic;"&gt;Other comprehensive income&#x2013;&#x2013;Foreign currency translation adjustments, net.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;text-align:left;font-size:5pt;"&gt;&lt;span style="font-family:inherit;font-size:5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;For information about the fair value of our derivative financial instruments, and the impact on our condensed consolidated balance sheets, see &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Note 7A&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; above&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;.&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; Certain of our derivative instruments are covered by associated credit-support agreements that have credit-risk-related contingent features designed to reduce our counterparties&#x2019; exposure to our risk of defaulting on amounts owed. As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;October&#160;1, 2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the aggregate fair value of these derivative instruments that are in a net liability position was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$491 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, for which we have posted collateral of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$505 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in the normal course of business. If there had been a ratings downgrade, we would not have been required to post any additional collateral to our counterparties&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:inherit;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;G. Credit Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:inherit;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;On an ongoing basis, we review the creditworthiness of counterparties to our foreign exchange and interest rate agreements and do not expect to incur a significant loss from failure of any counterparties to perform under the agreements. There are no significant concentrations of credit risk related to our financial instruments with any individual counterparty, except for certain significant customers. As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;October&#160;1, 2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, we had &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$946 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; due from a well-diversified, high quality group of technology companies around the world. For details about our investments, see &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Note 7B &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;above.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:inherit;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In general, there is no requirement for collateral from customers. However, derivative financial instruments are executed under credit-support agreements that provide for the ability to request collateral payments depending on levels of exposure, our credit rating and the credit rating of the counterparty. As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;October&#160;1, 2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, we received cash collateral of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$232 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; from various counterparties. The collateral primarily supports the approximate fair value of our derivative contracts. With respect to the collateral received, the obligations are reported in &lt;/span&gt;Short-term borrowings, including current portion of long-term debt.</us-gaap:FinancialInstrumentsDisclosureTextBlock>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock
      contextRef="FD2017Q3YTD"
      id="TextSelection-068F0051446755189ABCE40C311C2AE8-0-wk-Fact-250357A851405B8BA77916238965B5B8">&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:74%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table provides additional information about certain of our financial assets and liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;October&#160;1, &lt;br/&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;December&#160;31, &lt;br/&gt;2016&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:justify;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;text-decoration:underline;"&gt;Selected financial assets measured at fair value on a recurring basis&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:justify;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Trading funds and securities&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;347&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;325&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:justify;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Available-for-sale debt securities&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(c)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;16,598&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;18,632&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Money market funds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;1,824&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;1,445&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Available-for-sale equity securities&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(c)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;1,032&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;540&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:justify;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Derivative financial instruments in a receivable position&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(d)&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Interest rate swaps&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;630&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;625&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Foreign currency swaps&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;92&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;79&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Foreign currency forward-exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;110&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;551&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;20,631&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;22,198&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;text-decoration:underline;"&gt;Other selected financial assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Held-to-maturity debt securities, carried at amortized cost&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(c), (e)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;1,464&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;1,242&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Restricted stock and private equity securities, carried at cost or at equity-method&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(e)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;719&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;735&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;2,183&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;1,977&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Total selected financial assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;22,815&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;24,175&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:justify;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;text-decoration:underline;"&gt;Selected financial liabilities measured at fair value on a recurring basis&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:justify;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Derivative financial instruments in a liability position&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(f)&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Interest rate swaps&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;154&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;148&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Foreign currency swaps&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;710&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;1,374&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Foreign currency forward-exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;309&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;143&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;1,173&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;1,665&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;text-decoration:underline;"&gt;Other selected financial liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Short-term borrowings:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Principal amount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;9,460&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;10,674&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Net fair value adjustments related to hedging and purchase accounting&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;24&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Net unamortized discounts, premiums and debt issuance costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(15&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(11&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:30px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Total short-term borrowings, carried at historical proceeds, as adjusted&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(e)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;9,448&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;10,688&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Long-term debt:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Principal amount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;33,671&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;30,529&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Net fair value adjustments related to hedging and purchase accounting&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;981&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;998&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Net unamortized discounts, premiums and debt issuance costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(149&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(130&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:30px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Total long-term debt, carried at historical proceeds, as adjusted&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(g)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;34,503&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;31,398&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;43,951&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;42,085&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Total selected financial liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;45,124&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;43,750&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8.5pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;We use a market approach in valuing financial instruments on a recurring basis. All of our financial assets and liabilities measured at fair value on a recurring basis use Level 2 inputs in the calculation of fair value, except &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;5%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; that use Level 1 inputs.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8.5pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(b)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;October&#160;1, 2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;, trading funds and securities are composed of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;$274 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; of trading equity funds and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;$74 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; of trading debt funds. As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;text-align:center;"&gt;December&#160;31, 2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;, trading funds and securities are composed of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;$236 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; of trading equity funds and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;$89 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; of trading debt funds. As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;October&#160;1, 2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;text-align:center;"&gt;December&#160;31, 2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;, trading equity funds of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;$63 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;$71 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;, respectively, are held in trust for benefits attributable to the former Pharmacia Savings Plus Plan.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8.5pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(c)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Gross unrealized gains and losses are not significant, except as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;October&#160;1, 2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;, available-for-sale equity securities&#x2019; unrealized gains are &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;$406 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; and unrealized losses are &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;$119 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8.5pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(d)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Designated as hedging instruments, except for certain contracts used as offsets; namely, foreign currency forward-exchange contracts with fair values of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;$40 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;October&#160;1, 2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;; and foreign currency forward-exchange contracts with fair values of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;$162 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;text-align:center;"&gt;December&#160;31, 2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8.5pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(e)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;The differences between the estimated fair values and carrying values of held-to-maturity debt securities, restricted stock and private equity securities at cost, and short-term borrowings not measured at fair value on a recurring basis were not significant as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;October&#160;1, 2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; or &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;text-align:center;"&gt;December&#160;31, 2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;. The fair value measurements of our held-to-maturity debt securities and our short-term borrowings are based on Level 2 inputs, using a market approach. The fair value measurements of our &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;background-color:#ffffff;"&gt;priv&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;ate equity securities carried at cost are based on Level 3 inputs.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-left:4px;text-align:left;padding-left:12px;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8.5pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(f)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Designated as hedging instruments, except for certain contracts used as offsets; namely, foreign currency forward-exchange contracts with fair values of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;$60 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;October&#160;1, 2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;; and foreign currency swaps with fair values of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;$269 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; and foreign currency forward-exchange contracts with fair values of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;$113 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;text-align:center;"&gt;December&#160;31, 2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;font-size:8.5pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(g)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;The fair value of our long-term debt (not including the current portion of long-term debt) was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;$39.0 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;October&#160;1, 2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;$34.9 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;text-align:center;"&gt;December&#160;31, 2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;. The fair value measurements for our long-term debt are based on Level 2 inputs, using a market approach. Long-term debt includes foreign currency long-term borrowings with fair values of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;$4.7 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;October&#160;1, 2017&lt;/span&gt;, which are used as hedging instruments.</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:TradingSecurities
      contextRef="FI2017Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d43770747e822-wk-Fact-73ABA67055275455B7AA44864D34F006"
      unitRef="usd">347000000</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="FI2016Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d43770747e841-wk-Fact-2216EB0E4F0B50869B845DEBE01027C3"
      unitRef="usd">325000000</us-gaap:TradingSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="FI2017Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_DebtSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d43770747e863-wk-Fact-60F0DB778C3D556896B02410EB2C0B1B"
      unitRef="usd">16598000000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_DebtSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d43770747e882-wk-Fact-C249892FF0905C07897B0E4EF86B976C"
      unitRef="usd">18632000000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="FI2017Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d43770747e907-wk-Fact-6118811AB2DE5F6BA426EF1F188FBC53"
      unitRef="usd">1824000000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d43770747e926-wk-Fact-672E844C4F3953138ADA20A9FE757D32"
      unitRef="usd">1445000000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="FI2017Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_EquitySecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d43770747e953-wk-Fact-0041457EF706567A8463582BD5F7861D"
      unitRef="usd">1032000000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_EquitySecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d43770747e972-wk-Fact-D2E616C04C74565E87B5EFE91C979223"
      unitRef="usd">540000000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:DerivativeAssets
      contextRef="FI2017Q3_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d43770747e1045-wk-Fact-D53A0B9A3EDB5C82AE283FE0420CAB5D"
      unitRef="usd">630000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="FI2016Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d43770747e1064-wk-Fact-2A8F43C5F6985C19B50BEDA00C1E0EDB"
      unitRef="usd">625000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="FI2017Q3_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d43770747e1089-wk-Fact-24CD21A3984953BA839ABDB818130188"
      unitRef="usd">92000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="FI2016Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d43770747e1108-wk-Fact-7DAD092F708C5E7CAC2F33934FCB84C5"
      unitRef="usd">79000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="FI2017Q3_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d43770747e1133-wk-Fact-83B9658BE9A85FE39B70C11E0CE57D00"
      unitRef="usd">110000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="FI2016Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d43770747e1152-wk-Fact-7911451CA2425E27919489254BB944BC"
      unitRef="usd">551000000</us-gaap:DerivativeAssets>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="FI2017Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d43770747e1178-wk-Fact-F7F348B359C05BD59C8DCACAAC15C4ED"
      unitRef="usd">20631000000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="FI2016Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d43770747e1197-wk-Fact-757F830EC82D5CFD89824C319DD82983"
      unitRef="usd">22198000000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:HeldToMaturitySecuritiesAmortizedCostBeforeOtherThanTemporaryImpairment
      contextRef="FI2017Q3_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember"
      decimals="-6"
      id="d43770747e1268-wk-Fact-EF31EB7FE14056148C1A008C93495CEB"
      unitRef="usd">1464000000</us-gaap:HeldToMaturitySecuritiesAmortizedCostBeforeOtherThanTemporaryImpairment>
    <us-gaap:HeldToMaturitySecuritiesAmortizedCostBeforeOtherThanTemporaryImpairment
      contextRef="FI2016Q4_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember"
      decimals="-6"
      id="d43770747e1287-wk-Fact-016B619738A05C4C98C28A747752066A"
      unitRef="usd">1242000000</us-gaap:HeldToMaturitySecuritiesAmortizedCostBeforeOtherThanTemporaryImpairment>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
      contextRef="FI2017Q3_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember"
      decimals="-6"
      id="d43770747e1314-wk-Fact-A8F0564C8A745E648231F57D9FCE7C93"
      unitRef="usd">719000000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
      contextRef="FI2016Q4_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember"
      decimals="-6"
      id="d43770747e1333-wk-Fact-D91DA66DDA5D533D8090F62E9D24777E"
      unitRef="usd">735000000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <pfe:OtherSelectedFinancialAssets
      contextRef="FI2017Q3_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember"
      decimals="-6"
      id="d43770747e1358-wk-Fact-A0182ACA4F165CCB82F049A8ABDC4DBF"
      unitRef="usd">2183000000</pfe:OtherSelectedFinancialAssets>
    <pfe:OtherSelectedFinancialAssets
      contextRef="FI2016Q4_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember"
      decimals="-6"
      id="d43770747e1377-wk-Fact-CA4FA1C7373451C8A831BCB0B87C840F"
      unitRef="usd">1977000000</pfe:OtherSelectedFinancialAssets>
    <pfe:SelectedFinancialAssets
      contextRef="FI2017Q3"
      decimals="-6"
      id="d43770747e1407-wk-Fact-E6CB94780D3353F3BA7F2B694D175111"
      unitRef="usd">22815000000</pfe:SelectedFinancialAssets>
    <pfe:SelectedFinancialAssets
      contextRef="FI2016Q4"
      decimals="-6"
      id="d43770747e1426-wk-Fact-5C1AA03131755C62809F1FFA81347761"
      unitRef="usd">24175000000</pfe:SelectedFinancialAssets>
    <us-gaap:DerivativeLiabilities
      contextRef="FI2017Q3_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d43770747e1545-wk-Fact-86294AF06C6D55869B1ABEBE900AFFD4"
      unitRef="usd">154000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="FI2016Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d43770747e1564-wk-Fact-3ABBEBBC9C675BDDBFD1245A5C8DACAB"
      unitRef="usd">148000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="FI2017Q3_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d43770747e1584-wk-Fact-BC41639F074B5D2EB9452A1CA1147B95"
      unitRef="usd">710000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="FI2016Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d43770747e1603-wk-Fact-08EE5A3AD5B453F08A8BB6A7ACA9E8BF"
      unitRef="usd">1374000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="FI2017Q3_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d43770747e1628-wk-Fact-46A836D9C25B56FF9251C6C08C3CCB44"
      unitRef="usd">309000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="FI2016Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d43770747e1647-wk-Fact-8A158D27D5F55CB592CF35BFF232EA8E"
      unitRef="usd">143000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="FI2017Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d43770747e1673-wk-Fact-6AAB9598D7F95613809C632062D37B56"
      unitRef="usd">1173000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="FI2016Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d43770747e1692-wk-Fact-F94A368CB7E95851A8FE7949FC3E83F4"
      unitRef="usd">1665000000</us-gaap:DerivativeLiabilities>
    <pfe:ShorttermDebtGross
      contextRef="FI2017Q3_us-gaap_ShortTermDebtTypeAxis_us-gaap_ShortTermDebtMember"
      decimals="-6"
      id="d43770747e1807-wk-Fact-3F79F79E695F5CE4B962B63AAED2DE8F"
      unitRef="usd">9460000000</pfe:ShorttermDebtGross>
    <pfe:ShorttermDebtGross
      contextRef="FI2016Q4_us-gaap_ShortTermDebtTypeAxis_us-gaap_ShortTermDebtMember"
      decimals="-6"
      id="d43770747e1826-wk-Fact-027F10FE60DD52F486596E63C347B317"
      unitRef="usd">10674000000</pfe:ShorttermDebtGross>
    <pfe:DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting
      contextRef="FI2017Q3_us-gaap_ShortTermDebtTypeAxis_us-gaap_ShortTermDebtMember"
      decimals="-6"
      id="d43770747e1851-wk-Fact-E40F35B62CBF5523AF38617867D4C7F7"
      unitRef="usd">2000000</pfe:DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting>
    <pfe:DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting
      contextRef="FI2016Q4_us-gaap_ShortTermDebtTypeAxis_us-gaap_ShortTermDebtMember"
      decimals="-6"
      id="d43770747e1870-wk-Fact-D952476EAD965FD6B32296538DBBE2EC"
      unitRef="usd">24000000</pfe:DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="FI2017Q3_us-gaap_ShortTermDebtTypeAxis_us-gaap_ShortTermDebtMember"
      decimals="-6"
      id="d43770747e1895-wk-Fact-682AE28CCF9C5CFD92DE68FAEA990C8A"
      unitRef="usd">15000000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="FI2016Q4_us-gaap_ShortTermDebtTypeAxis_us-gaap_ShortTermDebtMember"
      decimals="-6"
      id="d43770747e1915-wk-Fact-FA96EB5CF9675E82B84293BDCF862686"
      unitRef="usd">11000000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtCurrent
      contextRef="FI2017Q3"
      decimals="-6"
      id="d43770747e1943-wk-Fact-CDA40E6949B85E61B9C8AF985182E3E5"
      unitRef="usd">9448000000</us-gaap:DebtCurrent>
    <us-gaap:DebtCurrent
      contextRef="FI2016Q4"
      decimals="-6"
      id="d43770747e1962-wk-Fact-3A3BB372357A5CD2BCD070742B0C6955"
      unitRef="usd">10688000000</us-gaap:DebtCurrent>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="FI2017Q3_us-gaap_LongtermDebtTypeAxis_us-gaap_LongTermDebtMember"
      decimals="-6"
      id="d43770747e2033-wk-Fact-62D4603F2920566D82D47397DAD177D8"
      unitRef="usd">33671000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="FI2016Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_LongTermDebtMember"
      decimals="-6"
      id="d43770747e2052-wk-Fact-60A8300F8F915FE4A2791C932D3F675C"
      unitRef="usd">30529000000</us-gaap:DebtInstrumentCarryingAmount>
    <pfe:DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting
      contextRef="FI2017Q3_us-gaap_LongtermDebtTypeAxis_us-gaap_LongTermDebtMember"
      decimals="-6"
      id="d43770747e2077-wk-Fact-7E1D2ADE8CC85A6A93BF9005DA5868E8"
      unitRef="usd">981000000</pfe:DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting>
    <pfe:DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting
      contextRef="FI2016Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_LongTermDebtMember"
      decimals="-6"
      id="d43770747e2096-wk-Fact-614F307EF6C9513B9C3CFB3B7890CA2B"
      unitRef="usd">998000000</pfe:DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="FI2017Q3_us-gaap_LongtermDebtTypeAxis_us-gaap_LongTermDebtMember"
      decimals="-6"
      id="d43770747e2121-wk-Fact-50C16A695EC55BD7BE645A931F2CD3FB"
      unitRef="usd">149000000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="FI2016Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_LongTermDebtMember"
      decimals="-6"
      id="d43770747e2141-wk-Fact-6D30546FE1C55A63A405488535B42F5C"
      unitRef="usd">130000000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="FI2017Q3"
      decimals="-6"
      id="d43770747e2170-wk-Fact-A38618717132561C9E1931D14EDF6B51"
      unitRef="usd">34503000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="FI2016Q4"
      decimals="-6"
      id="d43770747e2189-wk-Fact-F0B612439D18585FBB73EEB374B11207"
      unitRef="usd">31398000000</us-gaap:LongTermDebtNoncurrent>
    <pfe:OtherFinancialLiabilities
      contextRef="FI2017Q3"
      decimals="-6"
      id="d43770747e2214-wk-Fact-2C3C2A2FBC5A5C7782D4EC059C66B0D8"
      unitRef="usd">43951000000</pfe:OtherFinancialLiabilities>
    <pfe:OtherFinancialLiabilities
      contextRef="FI2016Q4"
      decimals="-6"
      id="d43770747e2233-wk-Fact-46F3B1E000295AB899BE7E92E41A5B2F"
      unitRef="usd">42085000000</pfe:OtherFinancialLiabilities>
    <pfe:SelectedFinancialLiabilities
      contextRef="FI2017Q3"
      decimals="-6"
      id="d43770747e2263-wk-Fact-8DCAFAA7B56457C6BEF555E12EFD7591"
      unitRef="usd">45124000000</pfe:SelectedFinancialLiabilities>
    <pfe:SelectedFinancialLiabilities
      contextRef="FI2016Q4"
      decimals="-6"
      id="d43770747e2282-wk-Fact-5E2BE4A63E3B578A867B078295A4C781"
      unitRef="usd">43750000000</pfe:SelectedFinancialLiabilities>
    <pfe:FinancialAssetsAndLiabilitiesMeasuredAtFairValuePercentage
      contextRef="FI2017Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="INF"
      id="d43770747e2301-wk-Fact-EB14449D25875188A6C1A2FB87CDCC9E"
      unitRef="number">0.05</pfe:FinancialAssetsAndLiabilitiesMeasuredAtFairValuePercentage>
    <us-gaap:TradingSecuritiesEquity
      contextRef="FI2017Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d43770747e2325-wk-Fact-F2BAAC1F8C0155D4BF7BAE62787DC4B4"
      unitRef="usd">274000000</us-gaap:TradingSecuritiesEquity>
    <us-gaap:TradingSecuritiesDebt
      contextRef="FI2017Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d43770747e2329-wk-Fact-6B300406E4D055CAA310A2CA99305580"
      unitRef="usd">74000000</us-gaap:TradingSecuritiesDebt>
    <us-gaap:TradingSecuritiesEquity
      contextRef="FI2016Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d43770747e2341-wk-Fact-B377D7EDA5A55915B767CED9AB9A0251"
      unitRef="usd">236000000</us-gaap:TradingSecuritiesEquity>
    <us-gaap:TradingSecuritiesDebt
      contextRef="FI2016Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d43770747e2346-wk-Fact-5673CD6101B3593E8580BF751D06B905"
      unitRef="usd">89000000</us-gaap:TradingSecuritiesDebt>
    <us-gaap:TradingSecuritiesRestricted
      contextRef="FI2017Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d43770747e2358-wk-Fact-3773CDF02A2C540293D7C2DE790FCA07"
      unitRef="usd">63000000</us-gaap:TradingSecuritiesRestricted>
    <us-gaap:TradingSecuritiesRestricted
      contextRef="FI2016Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d43770747e2362-wk-Fact-DFF536411EC059C38BB823809C4C34CE"
      unitRef="usd">71000000</us-gaap:TradingSecuritiesRestricted>
    <us-gaap:AvailableForSaleEquitySecuritiesGrossUnrealizedGain
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43770747e2386-wk-Fact-1FF87B2336F9B8E1315B831E8E8ED77B"
      unitRef="usd">406000000</us-gaap:AvailableForSaleEquitySecuritiesGrossUnrealizedGain>
    <us-gaap:AvailableForSaleEquitySecuritiesGrossUnrealizedLoss
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43770747e2390-wk-Fact-FFD37754D254246CC994831E8E9A1E3D"
      unitRef="usd">119000000</us-gaap:AvailableForSaleEquitySecuritiesGrossUnrealizedLoss>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="FI2017Q3_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember"
      decimals="-6"
      id="d43770747e2419-wk-Fact-FFB9B4A0936651119FB54BF7F4D85632"
      unitRef="usd">40000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="FI2016Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember"
      decimals="-6"
      id="d43770747e2427-wk-Fact-672D98C873A75FBD8A51318589146FD5"
      unitRef="usd">162000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="FI2017Q3_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember"
      decimals="-6"
      id="d43770747e2499-wk-Fact-3C97612091CC5A7080F96C66E1F8AF67"
      unitRef="usd">60000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="FI2016Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember"
      decimals="-6"
      id="d43770747e2507-wk-Fact-F650193C390E5EA5A151907EB06BF4AE"
      unitRef="usd">269000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="FI2016Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember"
      decimals="-6"
      id="d43770747e2516-wk-Fact-116969AF25A05CA8857AA9F6980B5573"
      unitRef="usd">113000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:LongTermDebtFairValue
      contextRef="FI2017Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember"
      decimals="-8"
      id="d43770747e2562-wk-Fact-45C5834678DB58BDAA717AECB3594675"
      unitRef="usd">39000000000.0</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember"
      decimals="-8"
      id="d43770747e2570-wk-Fact-0EA04BF7E19453C7A25ACCB13F4B457B"
      unitRef="usd">34900000000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="FI2017Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_LongtermDebtTypeAxis_pfe_ForeignCurrencyLongTermDebtMember"
      decimals="-8"
      id="d43770747e2582-wk-Fact-BC78E42FE17E5426A74B537FA7D7F232"
      unitRef="usd">4700000000</us-gaap:LongTermDebtFairValue>
    <us-gaap:FairValueByBalanceSheetGroupingTextBlock
      contextRef="FD2017Q3YTD"
      id="TextSelection-6E798238F9AC5935959E73C61E57387F-0-wk-Fact-B6875F7E94B654F18BD6C2CB1C5F7563">&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:72%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table provides the classification of these selected financial assets and liabilities in our condensed consolidated balance sheets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;October&#160;1, &lt;br/&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, &lt;br/&gt;2016&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;text-decoration:underline;"&gt;Assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;526&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;547&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Short-term investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;14,146&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;15,255&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Other current assets&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;288&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;567&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Long-term investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7,311&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7,116&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Other noncurrent assets&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;543&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;689&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;22,815&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;24,175&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;text-decoration:underline;"&gt;Liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Short-term borrowings, including current portion of long-term debt&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9,448&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10,688&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Other current liabilities&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(c)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;277&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;443&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Long-term debt&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;34,503&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;31,398&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(d)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;896&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,222&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;45,124&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;43,750&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;October&#160;1, 2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;, derivative instruments at fair value include interest rate swaps (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;$97 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;), foreign currency swaps (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;$86 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;) and foreign currency forward-exchange contracts (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;$105 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;) and, as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;text-align:center;"&gt;December&#160;31, 2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;, include interest rate swaps (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;$26 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;), foreign currency swaps (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;$43 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;) and foreign currency forward-exchange contracts (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;$497 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;).&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(b)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;October&#160;1, 2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;, derivative instruments at fair value include interest rate swaps (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;$532 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;), foreign currency swaps (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;$6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;) and foreign currency forward-exchange contracts (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;$5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;) and, as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;text-align:center;"&gt;December&#160;31, 2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;, include interest rate swaps (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;$599 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;), foreign currency swaps (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;$36 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;) and foreign currency forward-exchange contracts (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;$54 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;).&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(c)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;October&#160;1, 2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;, derivative instruments at fair value include foreign currency forward-exchange contracts (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;$276 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;) and interest rate swaps (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;$1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;) and, as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;text-align:center;"&gt;December&#160;31, 2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;, include interest rate swaps (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;$1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;), foreign currency swaps (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;$300 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;) and foreign currency forward-exchange contracts (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;$143 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;).&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(d)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;October&#160;1, 2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;, derivative instruments at fair value include interest rate swaps (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;$153 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;), foreign currency swaps (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;$710 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;) and foreign currency forward-exchange contracts (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;$33 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;) and, as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;text-align:center;"&gt;December&#160;31, 2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;, include interest rate swaps (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;$147 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;) and foreign currency swaps (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;$1.1 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;).&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;</us-gaap:FairValueByBalanceSheetGroupingTextBlock>
    <pfe:SelectedFinancialAssets
      contextRef="FI2017Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_CashAndCashEquivalentsMember"
      decimals="-6"
      id="d43770747e2786-wk-Fact-C14CB8A835A056749D89EDF60990A9AA"
      unitRef="usd">526000000</pfe:SelectedFinancialAssets>
    <pfe:SelectedFinancialAssets
      contextRef="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_CashAndCashEquivalentsMember"
      decimals="-6"
      id="d43770747e2805-wk-Fact-874EB63A337F5B4FA4242E746F192A96"
      unitRef="usd">547000000</pfe:SelectedFinancialAssets>
    <pfe:SelectedFinancialAssets
      contextRef="FI2017Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember"
      decimals="-6"
      id="d43770747e2825-wk-Fact-1581DCE37F87517D9ECBF9C086D87E06"
      unitRef="usd">14146000000</pfe:SelectedFinancialAssets>
    <pfe:SelectedFinancialAssets
      contextRef="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember"
      decimals="-6"
      id="d43770747e2844-wk-Fact-032D3B270315597495D82B755AC4482E"
      unitRef="usd">15255000000</pfe:SelectedFinancialAssets>
    <pfe:SelectedFinancialAssets
      contextRef="FI2017Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember"
      decimals="-6"
      id="d43770747e2871-wk-Fact-36F90A1B2B3150DD8B3EF42CE7A207C4"
      unitRef="usd">288000000</pfe:SelectedFinancialAssets>
    <pfe:SelectedFinancialAssets
      contextRef="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember"
      decimals="-6"
      id="d43770747e2890-wk-Fact-52A1B75A34225AB0850E4467B145EE4C"
      unitRef="usd">567000000</pfe:SelectedFinancialAssets>
    <pfe:SelectedFinancialAssets
      contextRef="FI2017Q3_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember"
      decimals="-6"
      id="d43770747e2915-wk-Fact-350A83F5C4215640814818A652039736"
      unitRef="usd">7311000000</pfe:SelectedFinancialAssets>
    <pfe:SelectedFinancialAssets
      contextRef="FI2016Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember"
      decimals="-6"
      id="d43770747e2934-wk-Fact-97A4038FB64E5728860321AE65BCAB42"
      unitRef="usd">7116000000</pfe:SelectedFinancialAssets>
    <pfe:SelectedFinancialAssets
      contextRef="FI2017Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember"
      decimals="-6"
      id="d43770747e2961-wk-Fact-70B840CF49ED50999728E55D1211F51E"
      unitRef="usd">543000000</pfe:SelectedFinancialAssets>
    <pfe:SelectedFinancialAssets
      contextRef="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember"
      decimals="-6"
      id="d43770747e2980-wk-Fact-5AA4AF01AEF35754AABE41FB942D2F87"
      unitRef="usd">689000000</pfe:SelectedFinancialAssets>
    <pfe:SelectedFinancialAssets
      contextRef="FI2017Q3"
      decimals="-6"
      id="d43770747e3010-wk-Fact-E6CB94780D3353F3BA7F2B694D175111"
      unitRef="usd">22815000000</pfe:SelectedFinancialAssets>
    <pfe:SelectedFinancialAssets
      contextRef="FI2016Q4"
      decimals="-6"
      id="d43770747e3029-wk-Fact-5C1AA03131755C62809F1FFA81347761"
      unitRef="usd">24175000000</pfe:SelectedFinancialAssets>
    <pfe:SelectedFinancialLiabilities
      contextRef="FI2017Q3_us-gaap_BalanceSheetLocationAxis_pfe_ShortTermDebtAndCurrentPortionofLongTermDebtMember"
      decimals="-6"
      id="d43770747e3098-wk-Fact-1D82794B618257F78F598CF9F73E8258"
      unitRef="usd">9448000000</pfe:SelectedFinancialLiabilities>
    <pfe:SelectedFinancialLiabilities
      contextRef="FI2016Q4_us-gaap_BalanceSheetLocationAxis_pfe_ShortTermDebtAndCurrentPortionofLongTermDebtMember"
      decimals="-6"
      id="d43770747e3117-wk-Fact-87FE279043415B0A8BAD4E7A3A89CFD4"
      unitRef="usd">10688000000</pfe:SelectedFinancialLiabilities>
    <pfe:SelectedFinancialLiabilities
      contextRef="FI2017Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember"
      decimals="-6"
      id="d43770747e3140-wk-Fact-C233B7CC79495307BFD442EFB72D3A1B"
      unitRef="usd">277000000</pfe:SelectedFinancialLiabilities>
    <pfe:SelectedFinancialLiabilities
      contextRef="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember"
      decimals="-6"
      id="d43770747e3159-wk-Fact-4F630A08F3EE5D04A766A973955E5DEE"
      unitRef="usd">443000000</pfe:SelectedFinancialLiabilities>
    <pfe:SelectedFinancialLiabilities
      contextRef="FI2017Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_LongTermDebtMember"
      decimals="-6"
      id="d43770747e3184-wk-Fact-591249F3A3B953A590882A39D1A9DD7A"
      unitRef="usd">34503000000</pfe:SelectedFinancialLiabilities>
    <pfe:SelectedFinancialLiabilities
      contextRef="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_LongTermDebtMember"
      decimals="-6"
      id="d43770747e3203-wk-Fact-5936AEBB2929595EAF13054CFE38FD5D"
      unitRef="usd">31398000000</pfe:SelectedFinancialLiabilities>
    <pfe:SelectedFinancialLiabilities
      contextRef="FI2017Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember"
      decimals="-6"
      id="d43770747e3230-wk-Fact-A940673F4FF9572DA53F97129770EE39"
      unitRef="usd">896000000</pfe:SelectedFinancialLiabilities>
    <pfe:SelectedFinancialLiabilities
      contextRef="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember"
      decimals="-6"
      id="d43770747e3249-wk-Fact-8AFCAB1E804757FEBFCB197A8AE4804C"
      unitRef="usd">1222000000</pfe:SelectedFinancialLiabilities>
    <pfe:SelectedFinancialLiabilities
      contextRef="FI2017Q3"
      decimals="-6"
      id="d43770747e3279-wk-Fact-8DCAFAA7B56457C6BEF555E12EFD7591"
      unitRef="usd">45124000000</pfe:SelectedFinancialLiabilities>
    <pfe:SelectedFinancialLiabilities
      contextRef="FI2016Q4"
      decimals="-6"
      id="d43770747e3298-wk-Fact-5E2BE4A63E3B578A867B078295A4C781"
      unitRef="usd">43750000000</pfe:SelectedFinancialLiabilities>
    <pfe:SelectedFinancialAssets
      contextRef="FI2017Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember"
      decimals="-6"
      id="d43770747e3321-wk-Fact-D9382D2EDCC659CA849F7D7BEE1A33C7"
      unitRef="usd">97000000</pfe:SelectedFinancialAssets>
    <pfe:SelectedFinancialAssets
      contextRef="FI2017Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember"
      decimals="-6"
      id="d43770747e3325-wk-Fact-5F43619CCE5E5C3C9F78C006EA857643"
      unitRef="usd">86000000</pfe:SelectedFinancialAssets>
    <pfe:SelectedFinancialAssets
      contextRef="FI2017Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember"
      decimals="-6"
      id="d43770747e3329-wk-Fact-5250A6954FA55E1C99886991BB3C2CF2"
      unitRef="usd">105000000</pfe:SelectedFinancialAssets>
    <pfe:SelectedFinancialAssets
      contextRef="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember"
      decimals="-6"
      id="d43770747e3338-wk-Fact-9A136F3603FE563FA0181F7FB96BD1CC"
      unitRef="usd">26000000</pfe:SelectedFinancialAssets>
    <pfe:SelectedFinancialAssets
      contextRef="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember"
      decimals="-6"
      id="d43770747e3342-wk-Fact-3F3E30F15064545B802AD046C9E17B4C"
      unitRef="usd">43000000</pfe:SelectedFinancialAssets>
    <pfe:SelectedFinancialAssets
      contextRef="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember"
      decimals="-6"
      id="d43770747e3355-wk-Fact-E01C9BFB927A5CA488365B65EC8BD6C8"
      unitRef="usd">497000000</pfe:SelectedFinancialAssets>
    <pfe:SelectedFinancialAssets
      contextRef="FI2017Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember"
      decimals="-6"
      id="d43770747e3374-wk-Fact-E6D90BEAB70E5F0E9E0D711DE2D3B265"
      unitRef="usd">532000000</pfe:SelectedFinancialAssets>
    <pfe:SelectedFinancialAssets
      contextRef="FI2017Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember"
      decimals="-6"
      id="d43770747e3378-wk-Fact-C04D58B8AC0D5303B3B2068EAD424F6A"
      unitRef="usd">6000000</pfe:SelectedFinancialAssets>
    <pfe:SelectedFinancialAssets
      contextRef="FI2017Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember"
      decimals="-6"
      id="d43770747e3382-wk-Fact-AF1808DC6D2A57B3B1C44677F5112896"
      unitRef="usd">5000000</pfe:SelectedFinancialAssets>
    <pfe:SelectedFinancialAssets
      contextRef="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember"
      decimals="-6"
      id="d43770747e3391-wk-Fact-EC83A458C6B35CFC979AC747D965A4D6"
      unitRef="usd">599000000</pfe:SelectedFinancialAssets>
    <pfe:SelectedFinancialAssets
      contextRef="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember"
      decimals="-6"
      id="d43770747e3395-wk-Fact-DC926B2EDC6654C18AE6604914AD72A0"
      unitRef="usd">36000000</pfe:SelectedFinancialAssets>
    <pfe:SelectedFinancialAssets
      contextRef="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember"
      decimals="-6"
      id="d43770747e3404-wk-Fact-93B2D486DC1755F597BE0363A34BF0D1"
      unitRef="usd">54000000</pfe:SelectedFinancialAssets>
    <pfe:SelectedFinancialLiabilities
      contextRef="FI2017Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember"
      decimals="-6"
      id="d43770747e3427-wk-Fact-D0C449F0E4795BCF86CF0547BDDD9858"
      unitRef="usd">276000000</pfe:SelectedFinancialLiabilities>
    <pfe:SelectedFinancialLiabilities
      contextRef="FI2017Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember"
      decimals="-6"
      id="d43770747e3431-wk-Fact-631131C929F031BC3E295A684B82600F"
      unitRef="usd">1000000</pfe:SelectedFinancialLiabilities>
    <pfe:SelectedFinancialLiabilities
      contextRef="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember"
      decimals="-6"
      id="d43770747e3439-wk-Fact-1A0D40EA51075595ABAC8E4790EF7080"
      unitRef="usd">1000000</pfe:SelectedFinancialLiabilities>
    <pfe:SelectedFinancialLiabilities
      contextRef="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember"
      decimals="-6"
      id="d43770747e3444-wk-Fact-08852AFF5F88570697995A5B34C82D12"
      unitRef="usd">300000000</pfe:SelectedFinancialLiabilities>
    <pfe:SelectedFinancialLiabilities
      contextRef="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember"
      decimals="-6"
      id="d43770747e3458-wk-Fact-A944C0B6E0975A6385CE0A94B72B97BA"
      unitRef="usd">143000000</pfe:SelectedFinancialLiabilities>
    <pfe:SelectedFinancialLiabilities
      contextRef="FI2017Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember"
      decimals="-6"
      id="d43770747e3478-wk-Fact-705FB2500D595ABA8C549B72A96B54CB"
      unitRef="usd">153000000</pfe:SelectedFinancialLiabilities>
    <pfe:SelectedFinancialLiabilities
      contextRef="FI2017Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember"
      decimals="-6"
      id="d43770747e3482-wk-Fact-D4436A20E8AA5B2E942797768A9AA765"
      unitRef="usd">710000000</pfe:SelectedFinancialLiabilities>
    <pfe:SelectedFinancialLiabilities
      contextRef="FI2017Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember"
      decimals="-6"
      id="d43770747e3486-wk-Fact-63C7D318AB085F0ABAA4D7A8C1586D44"
      unitRef="usd">33000000</pfe:SelectedFinancialLiabilities>
    <pfe:SelectedFinancialLiabilities
      contextRef="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember"
      decimals="-6"
      id="d43770747e3495-wk-Fact-1F8D622FE8D553B8ACC42D6FC66AB8F1"
      unitRef="usd">147000000</pfe:SelectedFinancialLiabilities>
    <pfe:SelectedFinancialLiabilities
      contextRef="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember"
      decimals="-8"
      id="d43770747e3499-wk-Fact-E6713FC610C95165BD885FB1D579C44E"
      unitRef="usd">1100000000</pfe:SelectedFinancialLiabilities>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock
      contextRef="FD2017Q3YTD"
      id="TextSelection-9688601E187958D5B11F4E2C12289E3E-0-wk-Fact-2EBB3A03ADF55C91AC6582A974E1EC8C">&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.41520467836257%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="21"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:47%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table provides the contractual maturities, or as necessary, the estimated maturities, of the available-for-sale and held-to-maturity debt securities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;October&#160;1, &lt;br/&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:justify;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Within 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Over 1&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;to 5&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Over 5&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;to 10&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Over 10&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;text-decoration:underline;"&gt;Available-for-sale debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Corporate debt&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;2,741&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;2,591&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;1,525&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;17&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;6,874&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Western European, Asian, and other government debt&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;6,071&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;268&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;6,339&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Western European, Scandinavian and other government agency debt&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;1,955&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;42&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;1,998&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Supranational debt&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;387&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;195&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;582&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Government National Mortgage Association and other U.S. government guaranteed asset-backed securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;42&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;424&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;466&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Other asset-backed debt&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(c)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;161&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;61&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;226&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;U.S. government debt&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;112&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;112&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;text-decoration:underline;"&gt;Held-to-maturity debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Time deposits and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;1,133&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;1,137&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Western European government debt&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;326&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;326&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Total debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;12,818&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;3,694&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;1,532&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;18&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;span&gt;18,061&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Issued by a diverse group of corporations, with a significant concentration in the technology sector, virtually all of which are investment-grade.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(b)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Issued by governments, government agencies or supranational entities, as applicable, all of which are high quality.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(c)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Includes receivable-backed, loan-backed, and mortgage-backed securities, all of which are high quality and in senior positions in the capital structure of the security. Receivable-backed securities are collateralized by credit cards receivables, loan-backed securities are collateralized by senior secured obligations of a diverse pool of companies or student loans, and mortgage-backed securities are collateralized by diversified pools of residential and commercial mortgages.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue
      contextRef="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-6"
      id="d43770747e4019-wk-Fact-C140E7BD63345101B2DD7451627EE662"
      unitRef="usd">2741000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue
      contextRef="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-6"
      id="d43770747e4038-wk-Fact-29ACCDED11BA511481ECE7E30ABD1FFA"
      unitRef="usd">2591000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearSixThroughTenFairValue
      contextRef="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-6"
      id="d43770747e4058-wk-Fact-47F85ABECEA3558FB193E486A6300E36"
      unitRef="usd">1525000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearSixThroughTenFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingAfterYearTenFairValue
      contextRef="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-6"
      id="d43770747e4077-wk-Fact-A7D161E015BF50168317EC6EF30D2E9C"
      unitRef="usd">17000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingAfterYearTenFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-6"
      id="d43770747e4096-wk-Fact-0C018797136D5DE49DB04A0BF65EC513"
      unitRef="usd">6874000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue
      contextRef="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_pfe_WesternEuropeanAsianandOtherGovernmentDebtMember"
      decimals="-6"
      id="d43770747e4118-wk-Fact-04349CF31E83539A9C576802A8424538"
      unitRef="usd">6071000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue
      contextRef="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_pfe_WesternEuropeanAsianandOtherGovernmentDebtMember"
      decimals="-6"
      id="d43770747e4137-wk-Fact-0A1FE70C55BA5D7C9D62C4839596BBE9"
      unitRef="usd">268000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearSixThroughTenFairValue
      contextRef="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_pfe_WesternEuropeanAsianandOtherGovernmentDebtMember"
      decimals="-6"
      id="d43770747e4156-wk-Fact-D3AD03E39A685B5F98D9E5A6DA5939DF"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearSixThroughTenFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingAfterYearTenFairValue
      contextRef="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_pfe_WesternEuropeanAsianandOtherGovernmentDebtMember"
      decimals="-6"
      id="d43770747e4176-wk-Fact-46FCF46F8CE857D6A45597A49A1788DE"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingAfterYearTenFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_pfe_WesternEuropeanAsianandOtherGovernmentDebtMember"
      decimals="-6"
      id="d43770747e4195-wk-Fact-30E328BC808A5B65A7A777945EE0CE96"
      unitRef="usd">6339000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue
      contextRef="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_pfe_WesternEuropeanScandinaviaAndOtherGovernmentAgencyDebtMember"
      decimals="-6"
      id="d43770747e4222-wk-Fact-626B15D2B1215E4FBC1B22217ABF166E"
      unitRef="usd">1955000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue
      contextRef="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_pfe_WesternEuropeanScandinaviaAndOtherGovernmentAgencyDebtMember"
      decimals="-6"
      id="d43770747e4241-wk-Fact-FF82CF35A3B95DE7946765F53E9FCC87"
      unitRef="usd">42000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearSixThroughTenFairValue
      contextRef="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_pfe_WesternEuropeanScandinaviaAndOtherGovernmentAgencyDebtMember"
      decimals="-6"
      id="d43770747e4260-wk-Fact-D1DB098BFAA05A5582E3C54C39A219DE"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearSixThroughTenFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingAfterYearTenFairValue
      contextRef="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_pfe_WesternEuropeanScandinaviaAndOtherGovernmentAgencyDebtMember"
      decimals="-6"
      id="d43770747e4280-wk-Fact-6CF1FB1C274D54BC8DA1DED40575D72D"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingAfterYearTenFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_pfe_WesternEuropeanScandinaviaAndOtherGovernmentAgencyDebtMember"
      decimals="-6"
      id="d43770747e4299-wk-Fact-0F8D6EEC302657CA8AE0B3CB897EB60C"
      unitRef="usd">1998000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue
      contextRef="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_pfe_SupranationalDebtMember"
      decimals="-6"
      id="d43770747e4326-wk-Fact-59CF56CBCF3D5BF18E0D45DDA6F642AA"
      unitRef="usd">387000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue
      contextRef="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_pfe_SupranationalDebtMember"
      decimals="-6"
      id="d43770747e4345-wk-Fact-3A9320AC96A65345AF2925F4F49F63EE"
      unitRef="usd">195000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearSixThroughTenFairValue
      contextRef="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_pfe_SupranationalDebtMember"
      decimals="-6"
      id="d43770747e4364-wk-Fact-0A66AB4BBDF556D9BBC2F78276184CD8"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearSixThroughTenFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingAfterYearTenFairValue
      contextRef="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_pfe_SupranationalDebtMember"
      decimals="-6"
      id="d43770747e4384-wk-Fact-1EB643CEE30E5AE0B145130CC6CEAC25"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingAfterYearTenFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_pfe_SupranationalDebtMember"
      decimals="-6"
      id="d43770747e4403-wk-Fact-44ACB44C1F6D5867A9AE1BCDA6662468"
      unitRef="usd">582000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue
      contextRef="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_GovernmentNationalMortgageAssociationCertificatesAndObligationsGNMAMember"
      decimals="-6"
      id="d43770747e4428-wk-Fact-739D85C3F5BC57A3959777FF1E874E02"
      unitRef="usd">42000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue
      contextRef="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_GovernmentNationalMortgageAssociationCertificatesAndObligationsGNMAMember"
      decimals="-6"
      id="d43770747e4447-wk-Fact-624B0C7232B950EF913C61FB2CEC9FD5"
      unitRef="usd">424000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearSixThroughTenFairValue
      contextRef="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_GovernmentNationalMortgageAssociationCertificatesAndObligationsGNMAMember"
      decimals="-6"
      id="d43770747e4466-wk-Fact-295DB833412051558996F47F668BDCCE"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearSixThroughTenFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingAfterYearTenFairValue
      contextRef="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_GovernmentNationalMortgageAssociationCertificatesAndObligationsGNMAMember"
      decimals="-6"
      id="d43770747e4486-wk-Fact-830495F390625246A197A34AEB1BE01A"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingAfterYearTenFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_GovernmentNationalMortgageAssociationCertificatesAndObligationsGNMAMember"
      decimals="-6"
      id="d43770747e4505-wk-Fact-A08E288683A85FB986B3A2F6B65016A4"
      unitRef="usd">466000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue
      contextRef="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_AssetBackedSecuritiesMember"
      decimals="-6"
      id="d43770747e4532-wk-Fact-7E56CAC1C19150F0843C9E5BCB9C0112"
      unitRef="usd">161000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue
      contextRef="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_AssetBackedSecuritiesMember"
      decimals="-6"
      id="d43770747e4551-wk-Fact-727F9AD82CCB5AC493868224E1DEDA9B"
      unitRef="usd">61000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearSixThroughTenFairValue
      contextRef="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_AssetBackedSecuritiesMember"
      decimals="-6"
      id="d43770747e4570-wk-Fact-823EA0B8A07A5702B678EABA58D52F52"
      unitRef="usd">3000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearSixThroughTenFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingAfterYearTenFairValue
      contextRef="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_AssetBackedSecuritiesMember"
      decimals="-6"
      id="d43770747e4590-wk-Fact-78AAF3709EB25116A215400F1CC559B2"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingAfterYearTenFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_AssetBackedSecuritiesMember"
      decimals="-6"
      id="d43770747e4609-wk-Fact-C34B3FEB300256D1ADBB0C35ECBFED0F"
      unitRef="usd">226000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue
      contextRef="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_USGovernmentDebtSecuritiesMember"
      decimals="-6"
      id="d43770747e4634-wk-Fact-052C6D67631B5167B39C1C450918ED2D"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue
      contextRef="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_USGovernmentDebtSecuritiesMember"
      decimals="-6"
      id="d43770747e4653-wk-Fact-84EFA802CC125F46BD1B6F80D744CBF8"
      unitRef="usd">112000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearSixThroughTenFairValue
      contextRef="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_USGovernmentDebtSecuritiesMember"
      decimals="-6"
      id="d43770747e4672-wk-Fact-81044F82060A5A71A3C4DC16A4BFA596"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearSixThroughTenFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingAfterYearTenFairValue
      contextRef="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_USGovernmentDebtSecuritiesMember"
      decimals="-6"
      id="d43770747e4692-wk-Fact-AA25A0077BA151A5B93F70D9F8C32C8B"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingAfterYearTenFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_USGovernmentDebtSecuritiesMember"
      decimals="-6"
      id="d43770747e4711-wk-Fact-781AE6F13E6558D6B180FCE59E8AA6FE"
      unitRef="usd">112000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:HeldToMaturitySecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue
      contextRef="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_pfe_TimeDepositsCorporateDebtAndOtherMember"
      decimals="-6"
      id="d43770747e4842-wk-Fact-9497D2B99E8F532ABA9BF8778499740F"
      unitRef="usd">1133000000</us-gaap:HeldToMaturitySecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue>
    <us-gaap:HeldToMaturitySecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue
      contextRef="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_pfe_TimeDepositsCorporateDebtAndOtherMember"
      decimals="-6"
      id="d43770747e4861-wk-Fact-C26A172AA2015DDC96937A8A949851FD"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue>
    <us-gaap:HeldToMaturitySecuritiesDebtMaturitiesRollingYearSixThroughTenFairValue
      contextRef="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_pfe_TimeDepositsCorporateDebtAndOtherMember"
      decimals="-6"
      id="d43770747e4880-wk-Fact-56B56E04C41758EEBF969C401CFB67CD"
      unitRef="usd">3000000</us-gaap:HeldToMaturitySecuritiesDebtMaturitiesRollingYearSixThroughTenFairValue>
    <us-gaap:HeldToMaturitySecuritiesDebtMaturitiesRollingAfterTenYearsFairValue
      contextRef="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_pfe_TimeDepositsCorporateDebtAndOtherMember"
      decimals="-6"
      id="d43770747e4900-wk-Fact-10F216CEA33854B1988BA3D20D83EF34"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesDebtMaturitiesRollingAfterTenYearsFairValue>
    <us-gaap:HeldToMaturitySecurities
      contextRef="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_pfe_TimeDepositsCorporateDebtAndOtherMember"
      decimals="-6"
      id="d43770747e4919-wk-Fact-05FAE8BC65185C4A8E628507C0468351"
      unitRef="usd">1137000000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue
      contextRef="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_pfe_WesternEuropeanandOtherGovernmentDebtMember"
      decimals="-6"
      id="d43770747e4946-wk-Fact-9897B650EC365D66BE5F4FE1539C840D"
      unitRef="usd">326000000</us-gaap:HeldToMaturitySecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue>
    <us-gaap:HeldToMaturitySecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue
      contextRef="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_pfe_WesternEuropeanandOtherGovernmentDebtMember"
      decimals="-6"
      id="d43770747e4965-wk-Fact-2C95CA02AB4558B9A40486FF0E1ECD3D"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue>
    <us-gaap:HeldToMaturitySecuritiesDebtMaturitiesRollingYearSixThroughTenFairValue
      contextRef="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_pfe_WesternEuropeanandOtherGovernmentDebtMember"
      decimals="-6"
      id="d43770747e4984-wk-Fact-A6A09D6704F35EF6866E3822B7B2DC81"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesDebtMaturitiesRollingYearSixThroughTenFairValue>
    <us-gaap:HeldToMaturitySecuritiesDebtMaturitiesRollingAfterTenYearsFairValue
      contextRef="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_pfe_WesternEuropeanandOtherGovernmentDebtMember"
      decimals="-6"
      id="d43770747e5004-wk-Fact-008DAD250F08510DA34610C6465700EC"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesDebtMaturitiesRollingAfterTenYearsFairValue>
    <us-gaap:HeldToMaturitySecurities
      contextRef="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_pfe_WesternEuropeanandOtherGovernmentDebtMember"
      decimals="-6"
      id="d43770747e5023-wk-Fact-119D2B7CC2895FCA84AA22FCC552D134"
      unitRef="usd">326000000</us-gaap:HeldToMaturitySecurities>
    <pfe:DebtSecuritiesMaturitiesWithinOneYear
      contextRef="FI2017Q3"
      decimals="-6"
      id="d43770747e5053-wk-Fact-C4BCB339A5495A399358BD6AA2AE0DE2"
      unitRef="usd">12818000000</pfe:DebtSecuritiesMaturitiesWithinOneYear>
    <pfe:DebtSecuritiesMaturitiesOverOneToFiveYears
      contextRef="FI2017Q3"
      decimals="-6"
      id="d43770747e5072-wk-Fact-4959CD52B8E35EA2BCB1FB75C3A00877"
      unitRef="usd">3694000000</pfe:DebtSecuritiesMaturitiesOverOneToFiveYears>
    <pfe:DebtSecuritiesMaturitiesOverFiveToTenYears
      contextRef="FI2017Q3"
      decimals="-6"
      id="d43770747e5092-wk-Fact-ACB94031FC6F50A4B5DB7E9A583E4985"
      unitRef="usd">1532000000</pfe:DebtSecuritiesMaturitiesOverFiveToTenYears>
    <pfe:DebtSecuritiesMaturitiesAfterTenYears
      contextRef="FI2017Q3"
      decimals="-6"
      id="d43770747e5111-wk-Fact-51B7B970C0FF534DBE86CE70940B8755"
      unitRef="usd">18000000</pfe:DebtSecuritiesMaturitiesAfterTenYears>
    <pfe:DebtSecurities
      contextRef="FI2017Q3"
      decimals="-6"
      id="d43770747e5130-wk-Fact-EEC42F263F2C58FC8D358F86963173E5"
      unitRef="usd">18061000000</pfe:DebtSecurities>
    <us-gaap:CommercialPaper
      contextRef="FI2017Q3_us-gaap_ShortTermDebtTypeAxis_us-gaap_CommercialPaperMember"
      decimals="-8"
      id="d43770747e5219-wk-Fact-12FEA2C55DBB5A1AB1A5BC0F06793EC2"
      unitRef="usd">6100000000</us-gaap:CommercialPaper>
    <us-gaap:CommercialPaper
      contextRef="FI2016Q4_us-gaap_ShortTermDebtTypeAxis_us-gaap_CommercialPaperMember"
      decimals="-8"
      id="d43770747e5243-wk-Fact-1CDCA4D062395A1E9FFCACCF22AEE7E3"
      unitRef="usd">5800000000</us-gaap:CommercialPaper>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock
      contextRef="FD2017Q3YTD"
      id="TextSelection-B4278B0788455C229D5F562E48108B1B-0-wk-Fact-DB729713D79F5291A2ADD6D80FCE7B7E">&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="11"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:58%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table provides the amounts of senior unsecured long-term debt issued in the first quarter of 2017:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Principal&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;As of October&#160;1, 2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;(MILLIONS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Maturity Date&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Euro&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;U.S. Dollar&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;3-month EURIBOR + 0.20% floating rate notes (0% floor)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;March&#160;6, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#x20ac;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;1,250&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;1,479&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;0.00% euro notes&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;March&#160;6, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;1,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;1,183&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;0.25% euro notes&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;March&#160;6, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;1,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;1,183&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;1.00% euro notes&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;March&#160;6, 2027&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;750&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;887&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-left:12px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Total euro long-term debt issued in the first quarter of 2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#x20ac;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;4,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;4,732&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;4.20% notes&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(c)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;March 17, 2047&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;1,065&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Total long-term debt issued in the first quarter of 2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(d)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;5,797&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8.5pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Redeemable at any time, in whole, or in part, at our option prior to 30 to 90 days of maturity date at the comparable German government bond rate, plus &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;0.15%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;; plus, in each case, accrued and unpaid interest. The fixed rate euro notes are also redeemable at our option, in whole, or in part, within 30 to 90 days of maturity date.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8.5pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(b)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;The weighted-average effective interest rate for the euro notes at issuance was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;0.23%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8.5pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(c)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;The notes, issued in U.S. dollars in Taiwan, are redeemable, at our option, in whole but not in part, on each March 17 on or after March 17, 2020.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;font-size:8.5pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(d)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;The aggregate amount at issuance date was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;$5,279 million&lt;/span&gt;&lt;/span&gt;. The increase in the amount since the date of issuance is due to foreign currency exchange.</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:LongTermDebt
      contextRef="FI2017Q3_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredEuroDebtThreemonthEURIBORPlus0.20FloatingRateNotesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember"
      decimals="-6"
      id="d43770747e5577-wk-Fact-6EDCC77F5B3B5A5898F08B197A517306"
      unitRef="iso4217_EUR">1250000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="FI2017Q3_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredEuroDebtThreemonthEURIBORPlus0.20FloatingRateNotesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember"
      decimals="-6"
      id="d43770747e5596-wk-Fact-70DFF9D31E2B55829E5F491E31F31C7A"
      unitRef="usd">1479000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="FI2017Q3_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredEuroDebtZeroPercentDue2020Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember"
      decimals="-6"
      id="d43770747e5628-wk-Fact-B09CC79A60405874AF13D1064AECD5EB"
      unitRef="iso4217_EUR">1000000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="FI2017Q3_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredEuroDebtZeroPercentDue2020Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember"
      decimals="-6"
      id="d43770747e5647-wk-Fact-57AB6949DEF75EA6A568EF9676344801"
      unitRef="usd">1183000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="FI2017Q3_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredEuroDebtPointTwofivePercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember"
      decimals="-6"
      id="d43770747e5684-wk-Fact-FD39AA4E611853FFB3347204D8FFAE7B"
      unitRef="iso4217_EUR">1000000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="FI2017Q3_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredEuroDebtPointTwofivePercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember"
      decimals="-6"
      id="d43770747e5703-wk-Fact-9BD0B9C42899598DB27286851288BA9C"
      unitRef="usd">1183000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="FI2017Q3_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredEuroDebtOnePointZeroPercentDue2027Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember"
      decimals="-6"
      id="d43770747e5740-wk-Fact-19A2A621AB2F5D67AFB144F44BDFF8C9"
      unitRef="iso4217_EUR">750000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="FI2017Q3_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredEuroDebtOnePointZeroPercentDue2027Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember"
      decimals="-6"
      id="d43770747e5759-wk-Fact-41F768EB6EEC5BBBA68D38AC1F01367F"
      unitRef="usd">887000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="FI2017Q3_us-gaap_DebtInstrumentAxis_pfe_EuroLongtermDebtMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember"
      decimals="-6"
      id="d43770747e5801-wk-Fact-A6F46F05463058AFAEAF923B7651C709"
      unitRef="iso4217_EUR">4000000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="FI2017Q3_us-gaap_DebtInstrumentAxis_pfe_EuroLongtermDebtMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember"
      decimals="-6"
      id="d43770747e5820-wk-Fact-FB5D18E9A92E5D758C68B08090472348"
      unitRef="usd">4732000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="FI2017Q3_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtFourPointTwoPercentDue2047Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember"
      decimals="-6"
      id="d43770747e5872-wk-Fact-ED395CB21D4254C59230DB3A66452C47"
      unitRef="usd">1065000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="FI2017Q3_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember"
      decimals="-6"
      id="d43770747e5934-wk-Fact-7F42A871CAE05783A75EB435EF78126F"
      unitRef="usd">5797000000</us-gaap:LongTermDebt>
    <pfe:DebtInstrumentRedemptionRuleRedemptionPricePercentageBasisSpread
      contextRef="FD2017Q3YTD_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_VariableRateAxis_pfe_GermanGovernmentBondRateMember"
      decimals="INF"
      id="d43770747e5949-wk-Fact-B55CD3A73A0154D1B36B441E7005C424"
      unitRef="number">0.0015</pfe:DebtInstrumentRedemptionRuleRedemptionPricePercentageBasisSpread>
    <us-gaap:DebtWeightedAverageInterestRate
      contextRef="FI2017Q3_us-gaap_DebtInstrumentAxis_pfe_EuroLongtermDebtMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember"
      decimals="4"
      id="d43770747e5965-wk-Fact-BC3DC25DC81C5DFB9A13CECE763F92E4"
      unitRef="number">0.0023</us-gaap:DebtWeightedAverageInterestRate>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="FI2017Q1_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember"
      decimals="-6"
      id="d43770747e5993-wk-Fact-49AA33C66F135204B829109228125B2B"
      unitRef="usd">5279000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="FD2017Q3YTD"
      id="TextSelection-3A1839DF39625590BB411A26F8418C46-0-wk-Fact-9BDDE0BC5BA952228898A0108A538356">&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="25"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:28%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="25" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table provides the maturity schedule of our &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Long-term debt&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;outstanding as of October 1, 2017:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;After 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Maturities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;481&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,825&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,534&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,502&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;23,162&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;34,503&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="FI2017Q3"
      decimals="-6"
      id="d43770747e6318-wk-Fact-AC7D38B45888587EA0DC514DE87C4C97"
      unitRef="usd">481000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="FI2017Q3"
      decimals="-6"
      id="d43770747e6337-wk-Fact-A9A80232BFEB5330A2ADCA7EE13D5D57"
      unitRef="usd">4825000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="FI2017Q3"
      decimals="-6"
      id="d43770747e6357-wk-Fact-36938B2094D55254A9001E639027E169"
      unitRef="usd">1534000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
      contextRef="FI2017Q3"
      decimals="-6"
      id="d43770747e6376-wk-Fact-CB25656B01C05BE88A63637C25270DD7"
      unitRef="usd">4502000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive
      contextRef="FI2017Q3"
      decimals="-6"
      id="d43770747e6395-wk-Fact-700581DDEEF45B26A99FBE4F4D6DEC2C"
      unitRef="usd">23162000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive>
    <us-gaap:LongTermDebt
      contextRef="FI2017Q3"
      decimals="-6"
      id="d43770747e6415-wk-Fact-5683EE7588BA524A9C12A9E4B64A122D"
      unitRef="usd">34503000000</us-gaap:LongTermDebt>
    <pfe:ResearchandDevelopmentArrangementAggregatePaymentObligation
      contextRef="I2017Q3Aug31_us-gaap_ProductOrServiceAxis_pfe_BesponsaMember_us-gaap_StatementGeographicalAxis_country_US"
      decimals="-6"
      id="d43770747e6437-wk-Fact-E3FE77994DEE098DC89774653986FAA8"
      unitRef="usd">296000000</pfe:ResearchandDevelopmentArrangementAggregatePaymentObligation>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="FI2017Q3_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_ProductOrServiceAxis_pfe_BesponsaMember_us-gaap_StatementGeographicalAxis_country_US"
      decimals="-6"
      id="d43770747e6441-wk-Fact-B0A1A71383936103AC777468C4C42FA8"
      unitRef="usd">248000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="FI2017Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_ProductOrServiceAxis_pfe_BesponsaMember_us-gaap_StatementGeographicalAxis_country_US"
      decimals="-6"
      id="d43770747e6449-wk-Fact-C1A1C96BF7D0B1F0211D7468F3C017EF"
      unitRef="usd">233000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="FI2017Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_ProductOrServiceAxis_pfe_BesponsaMember_us-gaap_StatementGeographicalAxis_country_US"
      decimals="-6"
      id="d43770747e6458-wk-Fact-9B810526969AEFFC8BD17469215CA157"
      unitRef="usd">15000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <pfe:ResearchandDevelopmentArrangementAggregatePaymentObligation
      contextRef="I2017Q2Jun30_us-gaap_ProductOrServiceAxis_pfe_BesponsaMember_us-gaap_StatementGeographicalAxis_us-gaap_EuropeanUnionMember"
      decimals="-6"
      id="d43770747e6468-wk-Fact-990703736CF35318A941AB8393055A5E"
      unitRef="usd">148000000</pfe:ResearchandDevelopmentArrangementAggregatePaymentObligation>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="FI2017Q3_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_ProductOrServiceAxis_pfe_BesponsaMember_us-gaap_StatementGeographicalAxis_us-gaap_EuropeanUnionMember"
      decimals="-6"
      id="d43770747e6472-wk-Fact-8D4BE048DA1152D883E89F25779C82AE"
      unitRef="usd">123000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="FI2017Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_ProductOrServiceAxis_pfe_BesponsaMember_us-gaap_StatementGeographicalAxis_us-gaap_EuropeanUnionMember"
      decimals="-6"
      id="d43770747e6481-wk-Fact-E05D9022639A54EF825FBE13B1CA8085"
      unitRef="usd">117000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="FI2017Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_ProductOrServiceAxis_pfe_BesponsaMember_us-gaap_StatementGeographicalAxis_us-gaap_EuropeanUnionMember"
      decimals="-6"
      id="d43770747e6491-wk-Fact-5A71AD33CDFC59868F473BBF286D1856"
      unitRef="usd">6000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:DerivativeAssetNotionalAmount
      contextRef="FI2017Q3_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember"
      decimals="-8"
      id="d43770747e6524-wk-Fact-AD2AC7E53C405A0FB0D82BBA282C9FE6"
      unitRef="usd">31500000000</us-gaap:DerivativeAssetNotionalAmount>
    <us-gaap:LongTermDebt
      contextRef="FI2017Q3_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember"
      decimals="-8"
      id="d43770747e6528-wk-Fact-E69F0F7513A15BC1875F9D0AEECF77B3"
      unitRef="usd">2000000000.0</us-gaap:LongTermDebt>
    <invest:DerivativeNotionalAmount
      contextRef="FI2017Q3_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember"
      decimals="-8"
      id="d43770747e6539-wk-Fact-C45BE8C73AE5550A968D05EA296EDAD6"
      unitRef="usd">3900000000</invest:DerivativeNotionalAmount>
    <us-gaap:UnrealizedLossOnForeignCurrencyDerivativesBeforeTax
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43770747e6543-wk-Fact-4575500D957C58BEB126E33983329C3A"
      unitRef="usd">97000000</us-gaap:UnrealizedLossOnForeignCurrencyDerivativesBeforeTax>
    <us-gaap:ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months
      contextRef="FI2017Q3"
      decimals="-6"
      id="d43770747e6551-wk-Fact-17E80A40DA32526383413D538658EA88"
      unitRef="usd">-63000000</us-gaap:ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months>
    <us-gaap:ForeignCurrencyCashFlowHedgeGainLossReclassifiedToEarningsNet
      contextRef="FD2017Q3QTD"
      decimals="-6"
      id="d43770747e6560-wk-Fact-0F9F8FB289DF58579790250AC327F0EA"
      unitRef="usd">-4000000</us-gaap:ForeignCurrencyCashFlowHedgeGainLossReclassifiedToEarningsNet>
    <us-gaap:ForeignCurrencyCashFlowHedgeGainLossReclassifiedToEarningsNet
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43770747e6572-wk-Fact-9EE7295EEEA651DCA19E75A1C6B523E6"
      unitRef="usd">67000000</us-gaap:ForeignCurrencyCashFlowHedgeGainLossReclassifiedToEarningsNet>
    <us-gaap:DerivativeAssetNotionalAmount
      contextRef="FI2017Q3_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember"
      decimals="-8"
      id="d43770747e6603-wk-Fact-022B25CABD9B5182A55A3669BB8FBECC"
      unitRef="usd">12400000000</us-gaap:DerivativeAssetNotionalAmount>
    <us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock
      contextRef="FD2017Q3YTD"
      id="TextSelection-45DB9A78706E5101A711A3F227E5B726-0-wk-Fact-6356769EA8525FE3B5A340D09DCB1D06">&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="25"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:28%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="25" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table provides information about the gains/(losses) incurred to hedge or offset operational foreign exchange or interest rate risk:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Three Months Ended&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Amount of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Gains/(Losses)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Recognized in OID&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(a), (b), (c)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Amount of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Gains/(Losses)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Recognized in OCI&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;(Effective Portion)&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(a), (d)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Amount of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Gains/(Losses)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Reclassified from&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;OCI into OID and COS&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;(Effective Portion)&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(a), (d)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:justify;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;October&#160;1, &lt;br/&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;October&#160;2, &lt;br/&gt;2016&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;October&#160;1, &lt;br/&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;October&#160;2, &lt;br/&gt;2016&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;October&#160;1, &lt;br/&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;October&#160;2, &lt;br/&gt;2016&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Derivative Financial Instruments in Cash Flow Hedge Relationships:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Foreign currency swaps&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;218&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;87&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;148&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(39&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Foreign currency forward-exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(269&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(212&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(204&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(111&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Derivative Financial Instruments in Net Investment Hedge Relationships:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Foreign currency forward-exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Derivative Financial Instruments Not Designated as Hedges:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Foreign currency forward-exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;33&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;20&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Foreign currency swaps&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Non-Derivative Financial Instruments in Net Investment Hedge Relationships:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Foreign currency long-term debt&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(166&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;All other net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;34&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;18&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(216&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(126&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(55&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(150&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Nine Months Ended&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Amount of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Gains/(Losses)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Recognized in OID&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(a), (b), (c)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Amount of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Gains/(Losses)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Recognized in OCI&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;(Effective Portion)&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(a), (d)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Amount of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Gains/(Losses)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Reclassified from&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;OCI into OID and COS&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;(Effective Portion)&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(a), (d)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:justify;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;October&#160;1, &lt;br/&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;October&#160;2, &lt;br/&gt;2016&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;October&#160;1, &lt;br/&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;October&#160;2, &lt;br/&gt;2016&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;October&#160;1, &lt;br/&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;October&#160;2, &lt;br/&gt;2016&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Derivative Financial Instruments in Cash Flow Hedge Relationships:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Foreign currency swaps&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;455&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(204&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;419&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(165&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Foreign currency forward-exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(604&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(770&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(26&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(118&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Derivative Financial Instruments in Net Investment Hedge Relationships:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Foreign currency forward-exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(15&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Derivative Financial Instruments Not Designated as Hedges:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Foreign currency forward-exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(111&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(49&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Foreign currency swaps&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Non-Derivative Financial Instruments in Net Investment Hedge Relationships:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Foreign currency short-term borrowings&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(26&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Foreign currency long-term debt&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(518&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;All other net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(117&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(56&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(666&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(1,014&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;394&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(283&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;OID = Other (income)/deductions&#x2014;net, included in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;font-style:italic;"&gt;Other (income)/deductions&#x2014;net&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt; in the condensed consolidated statements of income. COS = Cost of sales, included in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;font-style:italic;"&gt;Cost of sales&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt; in the condensed consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-left:12px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;OCI = Other comprehensive income/(loss), included in the&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;font-style:italic;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;condensed consolidated statements of comprehensive income&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;font-style:italic;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(b)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Includes gains and losses attributable to derivative instruments designated and qualifying as fair value hedges (primarily interest rate swaps), as well as the offsetting gains and losses attributable to the hedged items in such hedging relationships.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(c)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;There was no significant ineffectiveness for any period presented.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(d)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;For derivative financial instruments in cash flow hedge relationships, the effective portion is included in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;font-style:italic;"&gt;Other comprehensive income&#x2013;&#x2013;Unrealized holding losses on derivative financial instruments, net&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;. For derivative financial instruments in net investment hedge relationships and for foreign currency debt designated as hedging instruments, the effective portion is included in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;font-style:italic;"&gt;Other comprehensive income&#x2013;&#x2013;Foreign currency translation adjustments, net.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;</us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="FD2017Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember"
      decimals="-6"
      id="d43770747e7335-wk-Fact-4C647D3AD0F151A9BA9998C97C5B0A63"
      unitRef="usd">0</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="FD2016Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember"
      decimals="-6"
      id="d43770747e7354-wk-Fact-C2FB4FD03BD15A7097477EAB914C3310"
      unitRef="usd">0</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet
      contextRef="FD2017Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_OtherComprehensiveIncomeLocationAxis_us-gaap_OtherComprehensiveIncomeMember"
      decimals="-6"
      id="d43770747e7374-wk-Fact-2A83FB655E5C5030BB0751EC39ED3AD7"
      unitRef="usd">218000000</us-gaap:DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet>
    <us-gaap:DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet
      contextRef="FD2016Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_OtherComprehensiveIncomeLocationAxis_us-gaap_OtherComprehensiveIncomeMember"
      decimals="-6"
      id="d43770747e7393-wk-Fact-09DBCF3E9CE2515B8F9E9D356B588B2E"
      unitRef="usd">87000000</us-gaap:DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet>
    <us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet
      contextRef="FD2017Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"
      decimals="-6"
      id="d43770747e7412-wk-Fact-CADEEEB82C0B519FB5E1247FA7EE8C72"
      unitRef="usd">148000000</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
    <us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet
      contextRef="FD2016Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"
      decimals="-6"
      id="d43770747e7432-wk-Fact-090EF04B0EE45784B7F05495ED9053FC"
      unitRef="usd">-39000000</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="FD2017Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember"
      decimals="-6"
      id="d43770747e7453-wk-Fact-7FF9DC0A6C7D575C9FDD24720C8D14FC"
      unitRef="usd">1000000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="FD2016Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember"
      decimals="-6"
      id="d43770747e7472-wk-Fact-B8850FDF106C528A9CBED9CA08F2B4C9"
      unitRef="usd">2000000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet
      contextRef="FD2017Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_OtherComprehensiveIncomeLocationAxis_us-gaap_OtherComprehensiveIncomeMember"
      decimals="-6"
      id="d43770747e7491-wk-Fact-EFD127551F54519E94393635FCB3FC4A"
      unitRef="usd">-269000000</us-gaap:DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet>
    <us-gaap:DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet
      contextRef="FD2016Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_OtherComprehensiveIncomeLocationAxis_us-gaap_OtherComprehensiveIncomeMember"
      decimals="-6"
      id="d43770747e7512-wk-Fact-FDC488BF6B135DEAA89A53C4766192EC"
      unitRef="usd">-212000000</us-gaap:DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet>
    <us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet
      contextRef="FD2017Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"
      decimals="-6"
      id="d43770747e7532-wk-Fact-A9CF26AC98115AE2816DE97864E7E9E1"
      unitRef="usd">-204000000</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
    <us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet
      contextRef="FD2016Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"
      decimals="-6"
      id="d43770747e7553-wk-Fact-75B9ED2C492450B59C9FBE062087C17F"
      unitRef="usd">-111000000</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="FD2017Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember"
      decimals="-6"
      id="d43770747e7701-wk-Fact-581448B02BB95042932A4BD0D7479AFE"
      unitRef="usd">0</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="FD2016Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember"
      decimals="-6"
      id="d43770747e7720-wk-Fact-8727D6540E165428BFB9698977FED583"
      unitRef="usd">0</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet
      contextRef="FD2017Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_OtherComprehensiveIncomeLocationAxis_us-gaap_OtherComprehensiveIncomeMember"
      decimals="-6"
      id="d43770747e7739-wk-Fact-4918CC17DAC15E038DC184F1DA176587"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet>
    <us-gaap:DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet
      contextRef="FD2016Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_OtherComprehensiveIncomeLocationAxis_us-gaap_OtherComprehensiveIncomeMember"
      decimals="-6"
      id="d43770747e7759-wk-Fact-6E0D94B5020A54D8AA03215EBE1D7EF9"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet>
    <us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet
      contextRef="FD2017Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"
      decimals="-6"
      id="d43770747e7778-wk-Fact-8D17A1AAEAA359D5832C616000B8A948"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
    <us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet
      contextRef="FD2016Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"
      decimals="-6"
      id="d43770747e7798-wk-Fact-8F4FBA0654FF59F5B667567DEC33C73B"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="FD2017Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember"
      decimals="-6"
      id="d43770747e8074-wk-Fact-E84743BA7BEB5C538A4DCD2F234366E5"
      unitRef="usd">33000000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="FD2016Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember"
      decimals="-6"
      id="d43770747e8093-wk-Fact-9CA0877B96475CE6BFD987BA91892F67"
      unitRef="usd">20000000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet
      contextRef="FD2017Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember_us-gaap_OtherComprehensiveIncomeLocationAxis_us-gaap_OtherComprehensiveIncomeMember"
      decimals="-6"
      id="d43770747e8112-wk-Fact-620EDDBB2E7E58FE85B15DE61C5EDD21"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet>
    <us-gaap:DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet
      contextRef="FD2016Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember_us-gaap_OtherComprehensiveIncomeLocationAxis_us-gaap_OtherComprehensiveIncomeMember"
      decimals="-6"
      id="d43770747e8132-wk-Fact-ED0DC050AE3557C5AA59EE876A9CCB85"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet>
    <us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet
      contextRef="FD2017Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"
      decimals="-6"
      id="d43770747e8151-wk-Fact-5134E9EECF3F53FC8E0FBFCC64592278"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
    <us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet
      contextRef="FD2016Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"
      decimals="-6"
      id="d43770747e8171-wk-Fact-24B21791DB6C58DCB111630D09C1ACBF"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="FD2017Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember"
      decimals="-6"
      id="d43770747e8196-wk-Fact-324434DC15AC56F3976EFDF4A8E4050E"
      unitRef="usd">0</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="FD2016Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember"
      decimals="-6"
      id="d43770747e8215-wk-Fact-C2CABED6EA545FADA2D30E685CF99102"
      unitRef="usd">-4000000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet
      contextRef="FD2017Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember_us-gaap_OtherComprehensiveIncomeLocationAxis_us-gaap_OtherComprehensiveIncomeMember"
      decimals="-6"
      id="d43770747e8235-wk-Fact-6BED389587795F178A51DFB7B1F38F10"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet>
    <us-gaap:DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet
      contextRef="FD2016Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember_us-gaap_OtherComprehensiveIncomeLocationAxis_us-gaap_OtherComprehensiveIncomeMember"
      decimals="-6"
      id="d43770747e8255-wk-Fact-6D120F6B1B935942908A657A342EF520"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet>
    <us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet
      contextRef="FD2017Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"
      decimals="-6"
      id="d43770747e8274-wk-Fact-0A4EFE67B20358CA8861BC89A7FA3032"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
    <us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet
      contextRef="FD2016Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"
      decimals="-6"
      id="d43770747e8294-wk-Fact-B1F75F6B4A5C5BA399EFD6D1A9FEA6DE"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="FD2017Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyLongTermDebtMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_pfe_NetInvestmentHedgingNonderivativeInstrumentsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember"
      decimals="-6"
      id="d43770747e8569-wk-Fact-7245AD177ECF539AA450E00174CA6B5E"
      unitRef="usd">0</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="FD2016Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyLongTermDebtMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_pfe_NetInvestmentHedgingNonderivativeInstrumentsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember"
      decimals="-6"
      id="d43770747e8588-wk-Fact-FF816B32EE915991B09BB0A4C759A044"
      unitRef="usd">0</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet
      contextRef="FD2017Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyLongTermDebtMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_pfe_NetInvestmentHedgingNonderivativeInstrumentsMember_us-gaap_OtherComprehensiveIncomeLocationAxis_us-gaap_OtherComprehensiveIncomeMember"
      decimals="-6"
      id="d43770747e8607-wk-Fact-E989403B19655D56902F363195B8FB79"
      unitRef="usd">-166000000</us-gaap:DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet>
    <us-gaap:DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet
      contextRef="FD2016Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyLongTermDebtMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_pfe_NetInvestmentHedgingNonderivativeInstrumentsMember_us-gaap_OtherComprehensiveIncomeLocationAxis_us-gaap_OtherComprehensiveIncomeMember"
      decimals="-6"
      id="d43770747e8628-wk-Fact-838AFCED268F5D33AC4D66BBF1700DBF"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet>
    <us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet
      contextRef="FD2017Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyLongTermDebtMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_pfe_NetInvestmentHedgingNonderivativeInstrumentsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"
      decimals="-6"
      id="d43770747e8647-wk-Fact-1B18B8E0BFFA5FAB8CC46A153B1999C9"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
    <us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet
      contextRef="FD2016Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyLongTermDebtMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_pfe_NetInvestmentHedgingNonderivativeInstrumentsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"
      decimals="-6"
      id="d43770747e8667-wk-Fact-CFF329117B805CE791A8F04DB947E1BC"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="FD2017Q3QTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_pfe_OtherDerivativeInstrumentsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember"
      decimals="-6"
      id="d43770747e8692-wk-Fact-2EC8C97286795110842254B7AD03EA8C"
      unitRef="usd">0</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="FD2016Q3QTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_pfe_OtherDerivativeInstrumentsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember"
      decimals="-6"
      id="d43770747e8711-wk-Fact-C2B11447AB985916A925693B614D1F62"
      unitRef="usd">0</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet
      contextRef="FD2017Q3QTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_pfe_OtherDerivativeInstrumentsMember_us-gaap_OtherComprehensiveIncomeLocationAxis_us-gaap_OtherComprehensiveIncomeMember"
      decimals="-6"
      id="d43770747e8730-wk-Fact-FC17783C6AF95B6BA110F4B016C6E9A6"
      unitRef="usd">1000000</us-gaap:DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet>
    <us-gaap:DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet
      contextRef="FD2016Q3QTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_pfe_OtherDerivativeInstrumentsMember_us-gaap_OtherComprehensiveIncomeLocationAxis_us-gaap_OtherComprehensiveIncomeMember"
      decimals="-6"
      id="d43770747e8750-wk-Fact-3A60D355B3D65BBF94AB49C42ABD832B"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet>
    <us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet
      contextRef="FD2017Q3QTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_pfe_OtherDerivativeInstrumentsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"
      decimals="-6"
      id="d43770747e8769-wk-Fact-E158F0F72B4F5E699400B1D0DF2B49F9"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
    <us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet
      contextRef="FD2016Q3QTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_pfe_OtherDerivativeInstrumentsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"
      decimals="-6"
      id="d43770747e8789-wk-Fact-177D9D5D5C305B2CB2F2B8CFC0B8B38B"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="FD2017Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember"
      decimals="-6"
      id="d43770747e8819-wk-Fact-8F504B317F065E6AB4D6EA024526004B"
      unitRef="usd">34000000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="FD2016Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember"
      decimals="-6"
      id="d43770747e8838-wk-Fact-7E69FA8360D65E76BC4DD8B549DB440D"
      unitRef="usd">18000000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet
      contextRef="FD2017Q3QTD_us-gaap_OtherComprehensiveIncomeLocationAxis_us-gaap_OtherComprehensiveIncomeMember"
      decimals="-6"
      id="d43770747e8858-wk-Fact-288B765C343F5E4F98C92B3CC3D540BD"
      unitRef="usd">-216000000</us-gaap:DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet>
    <us-gaap:DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet
      contextRef="FD2016Q3QTD_us-gaap_OtherComprehensiveIncomeLocationAxis_us-gaap_OtherComprehensiveIncomeMember"
      decimals="-6"
      id="d43770747e8878-wk-Fact-8C7D1064A7B350C98174EAAD041CABE0"
      unitRef="usd">-126000000</us-gaap:DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet>
    <us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet
      contextRef="FD2017Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"
      decimals="-6"
      id="d43770747e8898-wk-Fact-42F9DF20DDCA5646904966177DFB6AA4"
      unitRef="usd">-55000000</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
    <us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet
      contextRef="FD2016Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"
      decimals="-6"
      id="d43770747e8919-wk-Fact-905FF1755B2D5F84A3DD31F07D5EFDAF"
      unitRef="usd">-150000000</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="FD2017Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember"
      decimals="-6"
      id="d43770747e9609-wk-Fact-8E3F5651762058A3BE3D1D3ABAC06BF2"
      unitRef="usd">0</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="FD2016Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember"
      decimals="-6"
      id="d43770747e9628-wk-Fact-7CF5E0D8BCEA5A01AC63CA0BE2F7F413"
      unitRef="usd">0</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet
      contextRef="FD2017Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_OtherComprehensiveIncomeLocationAxis_us-gaap_OtherComprehensiveIncomeMember"
      decimals="-6"
      id="d43770747e9648-wk-Fact-774518EA7FE3544C826E80CBE973BB7B"
      unitRef="usd">455000000</us-gaap:DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet>
    <us-gaap:DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet
      contextRef="FD2016Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_OtherComprehensiveIncomeLocationAxis_us-gaap_OtherComprehensiveIncomeMember"
      decimals="-6"
      id="d43770747e9667-wk-Fact-2F4C56B8E6C658B98917D6369850F69C"
      unitRef="usd">-204000000</us-gaap:DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet>
    <us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet
      contextRef="FD2017Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"
      decimals="-6"
      id="d43770747e9687-wk-Fact-B91047810A4357EFB8BEA4691EF47E86"
      unitRef="usd">419000000</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
    <us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet
      contextRef="FD2016Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"
      decimals="-6"
      id="d43770747e9707-wk-Fact-9086EDAB64E75CD192D2A7C873603ACA"
      unitRef="usd">-165000000</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="FD2017Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember"
      decimals="-6"
      id="d43770747e9728-wk-Fact-283251A1FA2159899190EA9CCFA53A25"
      unitRef="usd">-5000000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="FD2016Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember"
      decimals="-6"
      id="d43770747e9748-wk-Fact-019763780A0F5F0EB5ACCFF5ADADB2C7"
      unitRef="usd">1000000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet
      contextRef="FD2017Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_OtherComprehensiveIncomeLocationAxis_us-gaap_OtherComprehensiveIncomeMember"
      decimals="-6"
      id="d43770747e9767-wk-Fact-9AFC9FBE04FB5689977BCF73503C994B"
      unitRef="usd">-604000000</us-gaap:DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet>
    <us-gaap:DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet
      contextRef="FD2016Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_OtherComprehensiveIncomeLocationAxis_us-gaap_OtherComprehensiveIncomeMember"
      decimals="-6"
      id="d43770747e9788-wk-Fact-721EE01F467C5AA2AF5D9ABD57151BB3"
      unitRef="usd">-770000000</us-gaap:DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet>
    <us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet
      contextRef="FD2017Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"
      decimals="-6"
      id="d43770747e9808-wk-Fact-04C7C8ED03EF514FBDD27EE2DA62A7D5"
      unitRef="usd">-26000000</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
    <us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet
      contextRef="FD2016Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"
      decimals="-6"
      id="d43770747e9829-wk-Fact-ED75BB4B1C585EB9A02A2357479F8D29"
      unitRef="usd">-118000000</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="FD2017Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember"
      decimals="-6"
      id="d43770747e9977-wk-Fact-77E4DFB6EFD85BAB909056B138A7DECB"
      unitRef="usd">0</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="FD2016Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember"
      decimals="-6"
      id="d43770747e9996-wk-Fact-95C58C19C66A579CB912AE3B96A6747E"
      unitRef="usd">1000000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet
      contextRef="FD2017Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_OtherComprehensiveIncomeLocationAxis_us-gaap_OtherComprehensiveIncomeMember"
      decimals="-6"
      id="d43770747e10015-wk-Fact-481B3D6C84EF52CCBEBB11AB001F4356"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet>
    <us-gaap:DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet
      contextRef="FD2016Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_OtherComprehensiveIncomeLocationAxis_us-gaap_OtherComprehensiveIncomeMember"
      decimals="-6"
      id="d43770747e10035-wk-Fact-16809863F1405611BBE44B0DB80273DE"
      unitRef="usd">-15000000</us-gaap:DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet>
    <us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet
      contextRef="FD2017Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"
      decimals="-6"
      id="d43770747e10055-wk-Fact-EBE9947C4118517F84796F369756CEED"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
    <us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet
      contextRef="FD2016Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"
      decimals="-6"
      id="d43770747e10075-wk-Fact-3D22C73D416A54A79E8C5296818B091D"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="FD2017Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember"
      decimals="-6"
      id="d43770747e10350-wk-Fact-87C02FE05790562287F7FA992F915C2A"
      unitRef="usd">-111000000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="FD2016Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember"
      decimals="-6"
      id="d43770747e10370-wk-Fact-4ADCC13FDAC45B6BB3630C98712932FD"
      unitRef="usd">-49000000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet
      contextRef="FD2017Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember_us-gaap_OtherComprehensiveIncomeLocationAxis_us-gaap_OtherComprehensiveIncomeMember"
      decimals="-6"
      id="d43770747e10390-wk-Fact-238B98C4D02459528B018866A4D1E3C1"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet>
    <us-gaap:DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet
      contextRef="FD2016Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember_us-gaap_OtherComprehensiveIncomeLocationAxis_us-gaap_OtherComprehensiveIncomeMember"
      decimals="-6"
      id="d43770747e10410-wk-Fact-FD239FB115D9532BB0AC86A94B61DFC0"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet>
    <us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet
      contextRef="FD2017Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"
      decimals="-6"
      id="d43770747e10429-wk-Fact-1FF4C4C95159585A8AD2FEAE77CAC774"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
    <us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet
      contextRef="FD2016Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"
      decimals="-6"
      id="d43770747e10449-wk-Fact-D729388174C854FE8C4CEFABB9A6A065"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="FD2017Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember"
      decimals="-6"
      id="d43770747e10474-wk-Fact-DA9B023396AA59FCAFC767A3F15E2AAA"
      unitRef="usd">-1000000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="FD2016Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember"
      decimals="-6"
      id="d43770747e10494-wk-Fact-3DDF166872145F4BAF10CA9D1ED6DA8F"
      unitRef="usd">-9000000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet
      contextRef="FD2017Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember_us-gaap_OtherComprehensiveIncomeLocationAxis_us-gaap_OtherComprehensiveIncomeMember"
      decimals="-6"
      id="d43770747e10514-wk-Fact-BF8085F8D70957BA81DB64AF93C77FDE"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet>
    <us-gaap:DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet
      contextRef="FD2016Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember_us-gaap_OtherComprehensiveIncomeLocationAxis_us-gaap_OtherComprehensiveIncomeMember"
      decimals="-6"
      id="d43770747e10534-wk-Fact-92E17207D19C5E5A932D3D83BCD07078"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet>
    <us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet
      contextRef="FD2017Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"
      decimals="-6"
      id="d43770747e10553-wk-Fact-367407A06D845402883E3D448F892BA4"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
    <us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet
      contextRef="FD2016Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"
      decimals="-6"
      id="d43770747e10573-wk-Fact-F18080A5F5AD57518995089379096CF8"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="FD2017Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyShortTermBorrowingsMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_pfe_NetInvestmentHedgingNonderivativeInstrumentsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember"
      decimals="-6"
      id="d43770747e10849-wk-Fact-957B6D659FDB5023A7F0DBA1FC6C7332"
      unitRef="usd">0</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="FD2016Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyShortTermBorrowingsMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_pfe_NetInvestmentHedgingNonderivativeInstrumentsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember"
      decimals="-6"
      id="d43770747e10868-wk-Fact-52FA3ED749A551E69FCC2DB848C60415"
      unitRef="usd">0</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet
      contextRef="FD2017Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyShortTermBorrowingsMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_pfe_NetInvestmentHedgingNonderivativeInstrumentsMember_us-gaap_OtherComprehensiveIncomeLocationAxis_us-gaap_OtherComprehensiveIncomeMember"
      decimals="-6"
      id="d43770747e10887-wk-Fact-2B6D0F44C93359ADA6DC515DA57F73D4"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet>
    <us-gaap:DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet
      contextRef="FD2016Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyShortTermBorrowingsMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_pfe_NetInvestmentHedgingNonderivativeInstrumentsMember_us-gaap_OtherComprehensiveIncomeLocationAxis_us-gaap_OtherComprehensiveIncomeMember"
      decimals="-6"
      id="d43770747e10907-wk-Fact-F135E5CEAB8E5D4EB7575AEBFF4DF757"
      unitRef="usd">-26000000</us-gaap:DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet>
    <us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet
      contextRef="FD2017Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyShortTermBorrowingsMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_pfe_NetInvestmentHedgingNonderivativeInstrumentsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"
      decimals="-6"
      id="d43770747e10927-wk-Fact-5D5B1229DA1A57F080E4C581EAE83373"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
    <us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet
      contextRef="FD2016Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyShortTermBorrowingsMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_pfe_NetInvestmentHedgingNonderivativeInstrumentsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"
      decimals="-6"
      id="d43770747e10947-wk-Fact-CFFE4951A2DE534ABE61BA03B8048EA4"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="FD2017Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyLongTermDebtMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_pfe_NetInvestmentHedgingNonderivativeInstrumentsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember"
      decimals="-6"
      id="d43770747e10972-wk-Fact-67797DE457375667B2C84DC5692034E9"
      unitRef="usd">0</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="FD2016Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyLongTermDebtMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_pfe_NetInvestmentHedgingNonderivativeInstrumentsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember"
      decimals="-6"
      id="d43770747e10991-wk-Fact-3509C7CDE8445B7B95D3CD4AB8311EBD"
      unitRef="usd">0</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet
      contextRef="FD2017Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyLongTermDebtMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_pfe_NetInvestmentHedgingNonderivativeInstrumentsMember_us-gaap_OtherComprehensiveIncomeLocationAxis_us-gaap_OtherComprehensiveIncomeMember"
      decimals="-6"
      id="d43770747e11010-wk-Fact-1A851ADE80F15F3490D42C3F2F83E624"
      unitRef="usd">-518000000</us-gaap:DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet>
    <us-gaap:DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet
      contextRef="FD2016Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyLongTermDebtMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_pfe_NetInvestmentHedgingNonderivativeInstrumentsMember_us-gaap_OtherComprehensiveIncomeLocationAxis_us-gaap_OtherComprehensiveIncomeMember"
      decimals="-6"
      id="d43770747e11031-wk-Fact-EF8FCCDF207A5213AA733CAB56F33EB4"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet>
    <us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet
      contextRef="FD2017Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyLongTermDebtMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_pfe_NetInvestmentHedgingNonderivativeInstrumentsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"
      decimals="-6"
      id="d43770747e11050-wk-Fact-E5A70858CAFC5770B3F632E0F9C47F2B"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
    <us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet
      contextRef="FD2016Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyLongTermDebtMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_pfe_NetInvestmentHedgingNonderivativeInstrumentsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"
      decimals="-6"
      id="d43770747e11070-wk-Fact-604E73BB58B354A8BE73520A47D45028"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="FD2017Q3YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_pfe_OtherDerivativeInstrumentsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember"
      decimals="-6"
      id="d43770747e11095-wk-Fact-246EBF73EC0858A18FCF596C5A717E80"
      unitRef="usd">0</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="FD2016Q3YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_pfe_OtherDerivativeInstrumentsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember"
      decimals="-6"
      id="d43770747e11114-wk-Fact-09FE0334A6DB46CA6D5F5A6A83AF54B0"
      unitRef="usd">0</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet
      contextRef="FD2017Q3YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_pfe_OtherDerivativeInstrumentsMember_us-gaap_OtherComprehensiveIncomeLocationAxis_us-gaap_OtherComprehensiveIncomeMember"
      decimals="-6"
      id="d43770747e11133-wk-Fact-E9261ECFF1BF56E48D687B9EB690D501"
      unitRef="usd">1000000</us-gaap:DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet>
    <us-gaap:DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet
      contextRef="FD2016Q3YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_pfe_OtherDerivativeInstrumentsMember_us-gaap_OtherComprehensiveIncomeLocationAxis_us-gaap_OtherComprehensiveIncomeMember"
      decimals="-6"
      id="d43770747e11153-wk-Fact-909A7518DD255E87B44DE7EF018F16C1"
      unitRef="usd">1000000</us-gaap:DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet>
    <us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet
      contextRef="FD2017Q3YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_pfe_OtherDerivativeInstrumentsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"
      decimals="-6"
      id="d43770747e11172-wk-Fact-59D88BD8C3615E16ADCBC18168C4F03C"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
    <us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet
      contextRef="FD2016Q3YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_pfe_OtherDerivativeInstrumentsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"
      decimals="-6"
      id="d43770747e11192-wk-Fact-4E50B891ECDF54F8B82E01242152C091"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="FD2017Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember"
      decimals="-6"
      id="d43770747e11222-wk-Fact-9ABA0C515EA950C6981FD708D959A2E8"
      unitRef="usd">-117000000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="FD2016Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember"
      decimals="-6"
      id="d43770747e11242-wk-Fact-A6EB4F0FD63E5855AF650D3234A6748E"
      unitRef="usd">-56000000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet
      contextRef="FD2017Q3YTD_us-gaap_OtherComprehensiveIncomeLocationAxis_us-gaap_OtherComprehensiveIncomeMember"
      decimals="-6"
      id="d43770747e11263-wk-Fact-57780600A4525A59B0F30E20473A845F"
      unitRef="usd">-666000000</us-gaap:DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet>
    <us-gaap:DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet
      contextRef="FD2016Q3YTD_us-gaap_OtherComprehensiveIncomeLocationAxis_us-gaap_OtherComprehensiveIncomeMember"
      decimals="-6"
      id="d43770747e11283-wk-Fact-84FD9CC1745E5CF6B9EBD9E4EF9761DA"
      unitRef="usd">-1014000000</us-gaap:DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet>
    <us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet
      contextRef="FD2017Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"
      decimals="-6"
      id="d43770747e11303-wk-Fact-82FB012BDAB65A2A907B1CCC2DE535AD"
      unitRef="usd">394000000</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
    <us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet
      contextRef="FD2016Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"
      decimals="-6"
      id="d43770747e11323-wk-Fact-E257ACF9822153C0B4489B4BD0381028"
      unitRef="usd">-283000000</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
    <us-gaap:DerivativeNetLiabilityPositionAggregateFairValue
      contextRef="FI2017Q3"
      decimals="-6"
      id="d43770747e11462-wk-Fact-9AF94E1718055B36AF1473DD6FA8AC28"
      unitRef="usd">491000000</us-gaap:DerivativeNetLiabilityPositionAggregateFairValue>
    <us-gaap:CollateralAlreadyPostedAggregateFairValue
      contextRef="FI2017Q3"
      decimals="-6"
      id="d43770747e11466-wk-Fact-83676F6D04CF55E6BF4F2F7A93F749A2"
      unitRef="usd">505000000</us-gaap:CollateralAlreadyPostedAggregateFairValue>
    <us-gaap:ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure
      contextRef="FD2017Q3YTD_us-gaap_EquitySecuritiesByIndustryAxis_us-gaap_TechnologySectorMember"
      decimals="-6"
      id="d43770747e11487-wk-Fact-D427E787F5E953CC87B4E77E1029EE0B"
      unitRef="usd">946000000</us-gaap:ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure>
    <us-gaap:SecuritiesReceivedAsCollateral
      contextRef="FI2017Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_CashAndCashEquivalentsMember"
      decimals="-6"
      id="d43770747e11504-wk-Fact-36E81E11E9DD5BCF926972893DB780F4"
      unitRef="usd">232000000</us-gaap:SecuritiesReceivedAsCollateral>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="FD2017Q3YTD"
      id="TextSelection-4167516592215B518BC81B6C6A71159D-0-wk-Fact-45AE462D8C1754ABB1595A3DC2F1F0B0">&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;Inventories&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt; &lt;/span&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table provides the components of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Inventories&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;October&#160;1, &lt;br/&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, &lt;br/&gt;2016&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Finished goods&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,977&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,293&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Work-in-process&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,070&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,696&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Raw materials and supplies&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;879&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;793&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Inventories&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7,925&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,783&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Noncurrent inventories not included above&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;669&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;683&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;The change from &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;text-align:center;"&gt;December&#160;31, 2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt; reflects the build of inventory primarily for and in advance of new or potential product launches and increases to meet targeted levels for certain products in the normal course of business, including those related to demand.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(b)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Included in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;font-style:italic;"&gt;Other noncurrent assets&lt;/span&gt;. There are no recoverability issues associated with these amounts.</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryNoncurrentTableTextBlock
      contextRef="FD2017Q3YTD"
      id="TextSelection-73D671FE70D05EE080AADF16162F8780-0-wk-Fact-2869BD6C4F9556D5BA49E16C10F6DFB7">&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table provides the components of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Inventories&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;October&#160;1, &lt;br/&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, &lt;br/&gt;2016&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Finished goods&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,977&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,293&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Work-in-process&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,070&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,696&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Raw materials and supplies&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;879&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;793&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Inventories&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7,925&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,783&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Noncurrent inventories not included above&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;669&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;683&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;The change from &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;text-align:center;"&gt;December&#160;31, 2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt; reflects the build of inventory primarily for and in advance of new or potential product launches and increases to meet targeted levels for certain products in the normal course of business, including those related to demand.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(b)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Included in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;font-style:italic;"&gt;Other noncurrent assets&lt;/span&gt;. There are no recoverability issues associated with these amounts.</us-gaap:ScheduleOfInventoryNoncurrentTableTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="FD2017Q3YTD"
      id="TextSelection-BBF61FA9F0F75655BF81552E4FA32995-0-wk-Fact-95EC3C3E941157058D2F4623F88F3D8D">&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table provides the components of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Inventories&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;October&#160;1, &lt;br/&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, &lt;br/&gt;2016&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Finished goods&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,977&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,293&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Work-in-process&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,070&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,696&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Raw materials and supplies&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;879&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;793&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Inventories&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7,925&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,783&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Noncurrent inventories not included above&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;669&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;683&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;The change from &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;text-align:center;"&gt;December&#160;31, 2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt; reflects the build of inventory primarily for and in advance of new or potential product launches and increases to meet targeted levels for certain products in the normal course of business, including those related to demand.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(b)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Included in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;font-style:italic;"&gt;Other noncurrent assets&lt;/span&gt;. There are no recoverability issues associated with these amounts.</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="FI2017Q3"
      decimals="-6"
      id="d43678813e776-wk-Fact-1439518851A955238034978DD7259990"
      unitRef="usd">2977000000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="FI2016Q4"
      decimals="-6"
      id="d43678813e795-wk-Fact-12C6819137C35A228B5BD0A728DC7674"
      unitRef="usd">2293000000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="FI2017Q3"
      decimals="-6"
      id="d43678813e815-wk-Fact-F5CC53D4DCC551978E43CE6D859A7D31"
      unitRef="usd">4070000000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="FI2016Q4"
      decimals="-6"
      id="d43678813e834-wk-Fact-9AB42259ABDF5A918AF352862AB84CA0"
      unitRef="usd">3696000000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves
      contextRef="FI2017Q3"
      decimals="-6"
      id="d43678813e859-wk-Fact-8C25BE4FBE9C55FEBCD93C67D6DF1CD5"
      unitRef="usd">879000000</us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves>
    <us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves
      contextRef="FI2016Q4"
      decimals="-6"
      id="d43678813e878-wk-Fact-0DF17399CAC556DF9137FEB380FD9334"
      unitRef="usd">793000000</us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves>
    <us-gaap:InventoryNet
      contextRef="FI2017Q3"
      decimals="-6"
      id="d43678813e910-wk-Fact-2C8D97E870025A9E9218D1538714EA7C"
      unitRef="usd">7925000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="FI2016Q4"
      decimals="-6"
      id="d43678813e929-wk-Fact-B57DF7F90CE856C48797E9E94456B6CD"
      unitRef="usd">6783000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNoncurrent
      contextRef="FI2017Q3"
      decimals="-6"
      id="d43678813e956-wk-Fact-2164B7E786595ADF8A2FFDAB7982BEB2"
      unitRef="usd">669000000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="FI2016Q4"
      decimals="-6"
      id="d43678813e975-wk-Fact-9A5C2CB5B6525CAF82F961091ABF22D5"
      unitRef="usd">683000000</us-gaap:InventoryNoncurrent>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="FD2017Q3YTD"
      id="TextSelection-6062CC2978B259FEA1842F0E419EF5CF-0-wk-Fact-97F204FAA2BE518098817396FD8D037F">&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;Identifiable Intangible Assets and Goodwill&lt;/span&gt;&lt;div style="line-height:120%;text-align:left;font-size:5pt;"&gt;&lt;span style="font-family:inherit;font-size:5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;A. Identifiable Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:5pt;"&gt;&lt;span style="font-family:inherit;font-size:5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;text-decoration:underline;"&gt;Balance Sheet Information&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="25"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:28%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="25" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table provides the components of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Identifiable intangible assets&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;October&#160;1, 2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2016&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Carrying&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Amount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accumulated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Identifiable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Intangible&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Assets, less&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accumulated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Carrying&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Amount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accumulated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Identifiable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Intangible&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Assets, less&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accumulated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;text-decoration:underline;"&gt;Finite-lived intangible assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Developed technology rights&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;89,585&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(53,960&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;35,625&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;83,390&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(49,650&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;33,740&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Brands&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,135&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(1,127&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,008&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,092&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(1,032&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,060&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Licensing agreements and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,930&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(1,071&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;859&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,869&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(1,005&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;864&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;93,650&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(56,158&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;37,492&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;87,351&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(51,687&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;35,664&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;text-decoration:underline;"&gt;Indefinite-lived intangible assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Brands and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,937&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,937&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,883&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,883&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;IPR&amp;amp;D&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,292&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,292&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10,101&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10,101&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;12,229&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;12,229&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;16,984&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;16,984&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Identifiable intangible assets&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;105,879&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(56,158&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;49,721&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;104,335&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(51,687&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;52,648&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8.5pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;The changes in the gross carrying amount of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;font-style:italic;"&gt;Developed technology rights &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;font-style:italic;"&gt;IPR&amp;amp;D&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; primarily reflect (i) the transfer of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;$4.8 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; from &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;font-style:italic;"&gt;IPR&amp;amp;D&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;font-style:italic;"&gt;Developed technology rights&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; to reflect the approval of Eucrisa, (ii) the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;font-style:italic;"&gt;Developed technology rights&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;font-style:italic;"&gt;IPR&amp;amp;D&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; acquired as part of the acquisition of AstraZeneca&#x2019;s small molecule anti-infectives business (see &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;font-style:italic;"&gt;Note 2A&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;), (iii) the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;font-style:italic;"&gt;Developed technology rights&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;$371 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; recorded in connection with the EU and U.S. approvals of Besponsa (see &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;font-style:italic;"&gt;Note 7E&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;), partially offset by (iv) measurement period adjustments related to Medivation (see &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;font-style:italic;"&gt;Note 2A&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;) and (v) impairments of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;font-style:italic;"&gt;Developed technology rights&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; (see &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;font-style:italic;"&gt;Note 4)&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8.5pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(b)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;The decrease in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;font-style:italic;"&gt;I&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;font-style:italic;text-align:right;"&gt;dentifiable intangible assets, less accumulated amortization&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;text-align:right;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;is primarily due to amortization, measurement period adjustments related to Medivation (see &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;font-style:italic;"&gt;Note 2A&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;), as well as impairments of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;font-style:italic;"&gt;Developed technology rights&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; (see &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;font-style:italic;"&gt;Note 4)&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;, partially offset by assets acquired as part of the acquisition of AstraZeneca&#x2019;s small molecule anti-infectives business (see &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;font-style:italic;"&gt;Note 2A&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;) and the assets recorded in connection with the EU and U.S. approvals of Besponsa (see &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;font-style:italic;"&gt;Note 7E&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;).&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="10"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:55%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Our identifiable intangible assets are associated with the following, as a percentage of total identifiable intangible assets, less accumulated amortization:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;October&#160;1, 2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;IH&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;EH&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;WRD&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Developed technology rights&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;68&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;32&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Brands, finite-lived&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;75&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;25&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Brands, indefinite-lived&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;71&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;29&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;IPR&amp;amp;D &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;80&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;13&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:5pt;"&gt;&lt;span style="font-family:inherit;font-size:5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;text-decoration:underline;"&gt;Amortization&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:5pt;"&gt;&lt;span style="font-family:inherit;font-size:5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total amortization expense for finite-lived intangible assets was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1.2 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;third&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; quarter of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;text-align:center;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$988 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;third&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; quarter of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;text-align:center;"&gt;2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$3.6 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;first nine months of&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;text-align:center;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$3.0 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;first nine months of&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;text-align:center;"&gt;2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;B. Goodwill&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:55%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table provides the components of and changes in the carrying amount of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Goodwill&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;IH&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;EH&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Balance, December&#160;31, 2016&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;30,134&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;24,315&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;54,449&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Additions&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;572&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;92&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;664&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Other&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;491&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;475&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;966&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Balance, October&#160;1, 2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;31,197&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;24,882&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;56,078&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8.5pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;IH additions primarily represent measurement period adjustments related to our Medivation acquisition, and EH additions relate to our acquisition of AstraZeneca&#x2019;s small molecule anti-infectives business, which are subject to change until we complete the valuation of assets acquired and liabilities assumed (see &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;font-style:italic;"&gt;Note 2A&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;).&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;font-size:8.5pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(b)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;Primarily reflects the impact of foreign exchange and an adjustment of our estimate of goodwill associated with the HIS net assets sold.</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="FD2017Q3YTD"
      id="TextSelection-63DEC5623E5C5D73892FB2BAD239D760-0-wk-Fact-F090FF4A59965434BD425415F879FB2F">&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="25"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:28%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="25" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table provides the components of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Identifiable intangible assets&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;October&#160;1, 2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2016&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Carrying&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Amount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accumulated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Identifiable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Intangible&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Assets, less&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accumulated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Carrying&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Amount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accumulated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Identifiable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Intangible&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Assets, less&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accumulated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;text-decoration:underline;"&gt;Finite-lived intangible assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Developed technology rights&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;89,585&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(53,960&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;35,625&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;83,390&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(49,650&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;33,740&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Brands&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,135&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(1,127&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,008&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,092&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(1,032&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,060&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Licensing agreements and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,930&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(1,071&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;859&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,869&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(1,005&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;864&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;93,650&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(56,158&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;37,492&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;87,351&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(51,687&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;35,664&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;text-decoration:underline;"&gt;Indefinite-lived intangible assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Brands and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,937&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,937&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,883&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,883&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;IPR&amp;amp;D&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,292&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,292&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10,101&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10,101&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;12,229&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;12,229&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;16,984&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;16,984&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Identifiable intangible assets&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;105,879&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(56,158&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;49,721&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;104,335&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(51,687&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;52,648&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8.5pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;The changes in the gross carrying amount of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;font-style:italic;"&gt;Developed technology rights &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;font-style:italic;"&gt;IPR&amp;amp;D&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; primarily reflect (i) the transfer of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;$4.8 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; from &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;font-style:italic;"&gt;IPR&amp;amp;D&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;font-style:italic;"&gt;Developed technology rights&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; to reflect the approval of Eucrisa, (ii) the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;font-style:italic;"&gt;Developed technology rights&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;font-style:italic;"&gt;IPR&amp;amp;D&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; acquired as part of the acquisition of AstraZeneca&#x2019;s small molecule anti-infectives business (see &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;font-style:italic;"&gt;Note 2A&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;), (iii) the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;font-style:italic;"&gt;Developed technology rights&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;$371 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; recorded in connection with the EU and U.S. approvals of Besponsa (see &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;font-style:italic;"&gt;Note 7E&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;), partially offset by (iv) measurement period adjustments related to Medivation (see &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;font-style:italic;"&gt;Note 2A&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;) and (v) impairments of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;font-style:italic;"&gt;Developed technology rights&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; (see &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;font-style:italic;"&gt;Note 4)&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;font-size:8.5pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(b)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;The decrease in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;font-style:italic;"&gt;I&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;font-style:italic;text-align:right;"&gt;dentifiable intangible assets, less accumulated amortization&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;text-align:right;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;is primarily due to amortization, measurement period adjustments related to Medivation (see &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;font-style:italic;"&gt;Note 2A&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;), as well as impairments of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;font-style:italic;"&gt;Developed technology rights&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; (see &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;font-style:italic;"&gt;Note 4)&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;, partially offset by assets acquired as part of the acquisition of AstraZeneca&#x2019;s small molecule anti-infectives business (see &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;font-style:italic;"&gt;Note 2A&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;) and the assets recorded in connection with the EU and U.S. approvals of Besponsa (see &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;font-style:italic;"&gt;Note 7E&lt;/span&gt;).</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock
      contextRef="FD2017Q3YTD"
      id="TextSelection-6DFE3044CA0A5B71B9481DF8583265EB-0-wk-Fact-9F6AD4A71A38593CA1E839E2272D1DA6">&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="25"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:28%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="25" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table provides the components of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Identifiable intangible assets&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;October&#160;1, 2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2016&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Carrying&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Amount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accumulated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Identifiable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Intangible&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Assets, less&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accumulated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Carrying&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Amount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accumulated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Identifiable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Intangible&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Assets, less&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accumulated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;text-decoration:underline;"&gt;Finite-lived intangible assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Developed technology rights&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;89,585&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(53,960&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;35,625&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;83,390&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(49,650&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;33,740&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Brands&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,135&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(1,127&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,008&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,092&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(1,032&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,060&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Licensing agreements and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,930&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(1,071&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;859&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,869&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(1,005&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;864&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;93,650&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(56,158&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;37,492&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;87,351&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(51,687&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;35,664&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;text-decoration:underline;"&gt;Indefinite-lived intangible assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Brands and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,937&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,937&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,883&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,883&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;IPR&amp;amp;D&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,292&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,292&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10,101&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10,101&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;12,229&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;12,229&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;16,984&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;16,984&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Identifiable intangible assets&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;105,879&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(56,158&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;49,721&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;104,335&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(51,687&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;52,648&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8.5pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;The changes in the gross carrying amount of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;font-style:italic;"&gt;Developed technology rights &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;font-style:italic;"&gt;IPR&amp;amp;D&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; primarily reflect (i) the transfer of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;$4.8 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; from &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;font-style:italic;"&gt;IPR&amp;amp;D&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;font-style:italic;"&gt;Developed technology rights&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; to reflect the approval of Eucrisa, (ii) the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;font-style:italic;"&gt;Developed technology rights&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;font-style:italic;"&gt;IPR&amp;amp;D&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; acquired as part of the acquisition of AstraZeneca&#x2019;s small molecule anti-infectives business (see &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;font-style:italic;"&gt;Note 2A&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;), (iii) the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;font-style:italic;"&gt;Developed technology rights&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;$371 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; recorded in connection with the EU and U.S. approvals of Besponsa (see &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;font-style:italic;"&gt;Note 7E&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;), partially offset by (iv) measurement period adjustments related to Medivation (see &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;font-style:italic;"&gt;Note 2A&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;) and (v) impairments of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;font-style:italic;"&gt;Developed technology rights&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; (see &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;font-style:italic;"&gt;Note 4)&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;font-size:8.5pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(b)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;The decrease in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;font-style:italic;"&gt;I&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;font-style:italic;text-align:right;"&gt;dentifiable intangible assets, less accumulated amortization&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;text-align:right;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;is primarily due to amortization, measurement period adjustments related to Medivation (see &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;font-style:italic;"&gt;Note 2A&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;), as well as impairments of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;font-style:italic;"&gt;Developed technology rights&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; (see &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;font-style:italic;"&gt;Note 4)&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;, partially offset by assets acquired as part of the acquisition of AstraZeneca&#x2019;s small molecule anti-infectives business (see &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;font-style:italic;"&gt;Note 2A&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;) and the assets recorded in connection with the EU and U.S. approvals of Besponsa (see &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;font-style:italic;"&gt;Note 7E&lt;/span&gt;).</us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="FI2017Q3_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember"
      decimals="-6"
      id="d43697240e1285-wk-Fact-A1B9EBB00CA357B685505D97968F301E"
      unitRef="usd">89585000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="FI2017Q3_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember"
      decimals="-6"
      id="d43697240e1304-wk-Fact-A8BCB7724076572A894D8BDFC6785A6A"
      unitRef="usd">53960000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="FI2017Q3_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember"
      decimals="-6"
      id="d43697240e1325-wk-Fact-8222C49DFF25586385357680BA3E7A37"
      unitRef="usd">35625000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="FI2016Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember"
      decimals="-6"
      id="d43697240e1344-wk-Fact-DC886DFF855F55D5A5C4FBBBA585838D"
      unitRef="usd">83390000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="FI2016Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember"
      decimals="-6"
      id="d43697240e1363-wk-Fact-5609BB6BDB4E55C38CE62E60B3E67446"
      unitRef="usd">49650000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="FI2016Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember"
      decimals="-6"
      id="d43697240e1384-wk-Fact-81D16D7A3AE6589781565D5CDDE413F5"
      unitRef="usd">33740000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="FI2017Q3_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember"
      decimals="-6"
      id="d43697240e1404-wk-Fact-0673EBFC50BF5790974811704635181B"
      unitRef="usd">2135000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="FI2017Q3_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember"
      decimals="-6"
      id="d43697240e1423-wk-Fact-303BAFA42E765D29869BBFF7735E1676"
      unitRef="usd">1127000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="FI2017Q3_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember"
      decimals="-6"
      id="d43697240e1443-wk-Fact-4E7F9773EC505514835D19BCB42DBF5B"
      unitRef="usd">1008000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="FI2016Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember"
      decimals="-6"
      id="d43697240e1463-wk-Fact-6FCE50ADA4D65905979B13CF8B17B7F6"
      unitRef="usd">2092000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="FI2016Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember"
      decimals="-6"
      id="d43697240e1482-wk-Fact-2F7AA2C07FD35E5A832FBA6A253A51D2"
      unitRef="usd">1032000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="FI2016Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember"
      decimals="-6"
      id="d43697240e1503-wk-Fact-E2B9EAB1D5515A3EA298E93E09D3B133"
      unitRef="usd">1060000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="FI2017Q3_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsAndOtherMember"
      decimals="-6"
      id="d43697240e1528-wk-Fact-6E3E89D2AC2C5E169FB88F87EBFE2A6E"
      unitRef="usd">1930000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="FI2017Q3_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsAndOtherMember"
      decimals="-6"
      id="d43697240e1547-wk-Fact-78BB584B72D15F48A47507C651101086"
      unitRef="usd">1071000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="FI2017Q3_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsAndOtherMember"
      decimals="-6"
      id="d43697240e1567-wk-Fact-AFBAD8CE22005F63BAA4AEBF86677C90"
      unitRef="usd">859000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="FI2016Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsAndOtherMember"
      decimals="-6"
      id="d43697240e1587-wk-Fact-161ED29469D05B7E84E0C6CDEA89F9D1"
      unitRef="usd">1869000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="FI2016Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsAndOtherMember"
      decimals="-6"
      id="d43697240e1606-wk-Fact-FEFD4CD4E3FF538EB7329A3C9FF600DB"
      unitRef="usd">1005000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="FI2016Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsAndOtherMember"
      decimals="-6"
      id="d43697240e1627-wk-Fact-61A4C5F0781A594684642F5BB201E729"
      unitRef="usd">864000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="FI2017Q3"
      decimals="-6"
      id="d43697240e1652-wk-Fact-BF285486F7F35B8DB44772EFB8690A73"
      unitRef="usd">93650000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="FI2017Q3"
      decimals="-6"
      id="d43697240e1671-wk-Fact-CFD4991422BB5F588B49A4956375B606"
      unitRef="usd">56158000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="FI2017Q3"
      decimals="-6"
      id="d43697240e1691-wk-Fact-D3CF77A5EC1B5110ADD0AEEFD5A42263"
      unitRef="usd">37492000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="FI2016Q4"
      decimals="-6"
      id="d43697240e1711-wk-Fact-1CE3CA7DC39F5EA6AD800051DB3360BD"
      unitRef="usd">87351000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="FI2016Q4"
      decimals="-6"
      id="d43697240e1730-wk-Fact-305740AD59515768A45E4205357775C9"
      unitRef="usd">51687000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="FI2016Q4"
      decimals="-6"
      id="d43697240e1751-wk-Fact-F980A62CD1E6505DB9CEEDF97CA54153"
      unitRef="usd">35664000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="FI2017Q3_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember"
      decimals="-6"
      id="d43697240e1904-wk-Fact-3360B614FDB7584BB5E86371BB13C45A"
      unitRef="usd">6937000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="FI2017Q3_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember"
      decimals="-6"
      id="d43697240e1941-wk-Fact-3360B614FDB7584BB5E86371BB13C45A"
      unitRef="usd">6937000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="FI2016Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember"
      decimals="-6"
      id="d43697240e1961-wk-Fact-E25686C1008150CFA2AE2C8C99CD41BE"
      unitRef="usd">6883000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="FI2016Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember"
      decimals="-6"
      id="d43697240e1999-wk-Fact-E25686C1008150CFA2AE2C8C99CD41BE"
      unitRef="usd">6883000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="FI2017Q3_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember"
      decimals="-6"
      id="d43697240e2028-wk-Fact-6D6000856CC75C59855BFA6956D3EBE0"
      unitRef="usd">5292000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="FI2017Q3_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember"
      decimals="-6"
      id="d43697240e2065-wk-Fact-6D6000856CC75C59855BFA6956D3EBE0"
      unitRef="usd">5292000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="FI2016Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember"
      decimals="-6"
      id="d43697240e2085-wk-Fact-54A6BC26AA6157E19153460F2648274D"
      unitRef="usd">10101000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="FI2016Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember"
      decimals="-6"
      id="d43697240e2123-wk-Fact-54A6BC26AA6157E19153460F2648274D"
      unitRef="usd">10101000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="FI2017Q3"
      decimals="-6"
      id="d43697240e2149-wk-Fact-EFB5E853E99F51BDAD4EE953AE648F4E"
      unitRef="usd">12229000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="FI2017Q3"
      decimals="-6"
      id="d43697240e2186-wk-Fact-EFB5E853E99F51BDAD4EE953AE648F4E"
      unitRef="usd">12229000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="FI2016Q4"
      decimals="-6"
      id="d43697240e2206-wk-Fact-4A3790AC3D755608AA6E025EF63F2CE7"
      unitRef="usd">16984000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="FI2016Q4"
      decimals="-6"
      id="d43697240e2244-wk-Fact-4A3790AC3D755608AA6E025EF63F2CE7"
      unitRef="usd">16984000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="FI2017Q3"
      decimals="-6"
      id="d43697240e2276-wk-Fact-A5D936B4270856D1A914ABA7E1D66F0A"
      unitRef="usd">105879000000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="FI2017Q3"
      decimals="-6"
      id="d43697240e2295-wk-Fact-CFD4991422BB5F588B49A4956375B606"
      unitRef="usd">56158000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="FI2017Q3"
      decimals="-6"
      id="d43697240e2316-wk-Fact-A41E764041225C8DBE154ADB89FBF66C"
      unitRef="usd">49721000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="FI2016Q4"
      decimals="-6"
      id="d43697240e2335-wk-Fact-08713BCAEBE7560790D2B69F31D04450"
      unitRef="usd">104335000000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="FI2016Q4"
      decimals="-6"
      id="d43697240e2354-wk-Fact-305740AD59515768A45E4205357775C9"
      unitRef="usd">51687000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="FI2016Q4"
      decimals="-6"
      id="d43697240e2375-wk-Fact-4014B8D306BF54FC8CDF5431816FAA50"
      unitRef="usd">52648000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <pfe:IntangibleAssetsTransfersDuringPeriod
      contextRef="FI2017Q3_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember_us-gaap_ProductOrServiceAxis_pfe_EucrisaMember"
      decimals="-8"
      id="d43697240e2411-wk-Fact-35AD5C012C5D53ED891D36C19D6C896E"
      unitRef="usd">-4800000000</pfe:IntangibleAssetsTransfersDuringPeriod>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="FI2017Q3_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_ProductOrServiceAxis_pfe_BesponsaMember"
      decimals="-6"
      id="d43697240e2440-wk-Fact-406170E8DCB75316BF73021292411F88"
      unitRef="usd">371000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <pfe:IdentifiableintangibleassetsasapercentageoftotalidentifiableintangibleassetslessaccumulatedamortizationbysegmentTableTextBlock
      contextRef="FD2017Q3YTD"
      id="TextSelection-40578DE379BE5EACAEB3ED0AC4AEE674-0-wk-Fact-AD4E8626E6685A29AE7C19E7BCFF3A7A">&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="10"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:55%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Our identifiable intangible assets are associated with the following, as a percentage of total identifiable intangible assets, less accumulated amortization:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;October&#160;1, 2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;IH&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;EH&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;WRD&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Developed technology rights&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;68&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;32&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Brands, finite-lived&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;75&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;25&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Brands, indefinite-lived&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;71&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;29&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;IPR&amp;amp;D &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;80&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;13&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</pfe:IdentifiableintangibleassetsasapercentageoftotalidentifiableintangibleassetslessaccumulatedamortizationbysegmentTableTextBlock>
    <pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet
      contextRef="FI2017Q3_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="2"
      id="d43697240e2697-wk-Fact-311A195A53525918B720FC57C17CC107"
      unitRef="number">0.68</pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet>
    <pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet
      contextRef="FI2017Q3_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="2"
      id="d43697240e2712-wk-Fact-93D4315B06AC5101B88D1B4E2A1DCBCB"
      unitRef="number">0.32</pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet>
    <pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet
      contextRef="FI2017Q3_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_SubsegmentsAxis_pfe_PfizersWorldwideResearchandDevelopmentMember"
      decimals="2"
      id="d43697240e2727-wk-Fact-5C360B5BF9885FF7A6CB9E2EAFC8FE97"
      unitRef="number">0</pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet>
    <pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet
      contextRef="FI2017Q3_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="2"
      id="d43697240e2748-wk-Fact-E2E06C1C6FA1525C91AA7A739339ABBC"
      unitRef="number">0.75</pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet>
    <pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet
      contextRef="FI2017Q3_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="2"
      id="d43697240e2763-wk-Fact-4BFEDB0028C65FF4A59FA4C74032F0E6"
      unitRef="number">0.25</pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet>
    <pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet
      contextRef="FI2017Q3_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember_us-gaap_SubsegmentsAxis_pfe_PfizersWorldwideResearchandDevelopmentMember"
      decimals="2"
      id="d43697240e2778-wk-Fact-D6AD9D102B0C5CF4BBCA3D48DA9CFAA9"
      unitRef="number">0</pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet>
    <pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet
      contextRef="FI2017Q3_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="2"
      id="d43697240e2799-wk-Fact-E4AEE7EACC2E5C89B1CEE64FC524586A"
      unitRef="number">0.71</pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet>
    <pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet
      contextRef="FI2017Q3_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="2"
      id="d43697240e2814-wk-Fact-0EFE0CC1FA4651CE9B9C2A50ACFB7D9A"
      unitRef="number">0.29</pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet>
    <pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet
      contextRef="FI2017Q3_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember_us-gaap_SubsegmentsAxis_pfe_PfizersWorldwideResearchandDevelopmentMember"
      decimals="2"
      id="d43697240e2829-wk-Fact-28BA78A4F479559F980AF3252ED9CCB1"
      unitRef="number">0</pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet>
    <pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet
      contextRef="FI2017Q3_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="2"
      id="d43697240e2850-wk-Fact-5843645CD86D5318971467CD0235EF5F"
      unitRef="number">0.80</pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet>
    <pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet
      contextRef="FI2017Q3_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="2"
      id="d43697240e2865-wk-Fact-96A880B4097256C9BA83AAF51DE43150"
      unitRef="number">0.13</pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet>
    <pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet
      contextRef="FI2017Q3_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember_us-gaap_SubsegmentsAxis_pfe_PfizersWorldwideResearchandDevelopmentMember"
      decimals="2"
      id="d43697240e2880-wk-Fact-74D65A8327F95BD5B29F8FA42A695DBB"
      unitRef="number">0.07</pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="FD2017Q3QTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_FiniteLivedIntangibleAssetsMember"
      decimals="-8"
      id="d43697240e2907-wk-Fact-B26040C54F96504998E917E2A1EF109A"
      unitRef="usd">1200000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="FD2016Q3QTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_FiniteLivedIntangibleAssetsMember"
      decimals="-6"
      id="d43697240e2919-wk-Fact-698B176643E457EBA1FEFFCA8ECF5C73"
      unitRef="usd">988000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="FD2017Q3YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_FiniteLivedIntangibleAssetsMember"
      decimals="-8"
      id="d43697240e2932-wk-Fact-ACF2B879159B582D8139C91E8A10C009"
      unitRef="usd">3600000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="FD2016Q3YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_FiniteLivedIntangibleAssetsMember"
      decimals="-8"
      id="d43697240e2944-wk-Fact-C99DDFFBDCE059D4A7F2304F704FEFEE"
      unitRef="usd">3000000000.0</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ScheduleOfGoodwillTextBlock
      contextRef="FD2017Q3YTD"
      id="TextSelection-0F79EE6E5A2C58CB80DE00324DD8E137-0-wk-Fact-8D8A604DA01059F18645787F45FBA6DA">&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:55%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table provides the components of and changes in the carrying amount of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Goodwill&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;IH&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;EH&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Balance, December&#160;31, 2016&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;30,134&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;24,315&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;54,449&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Additions&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;572&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;92&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;664&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Other&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;491&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;475&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;966&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Balance, October&#160;1, 2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;31,197&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;24,882&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;56,078&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8.5pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;IH additions primarily represent measurement period adjustments related to our Medivation acquisition, and EH additions relate to our acquisition of AstraZeneca&#x2019;s small molecule anti-infectives business, which are subject to change until we complete the valuation of assets acquired and liabilities assumed (see &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;font-style:italic;"&gt;Note 2A&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;).&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;font-size:8.5pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(b)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;Primarily reflects the impact of foreign exchange and an adjustment of our estimate of goodwill associated with the HIS net assets sold.</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill
      contextRef="FI2016Q4_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43697240e3143-wk-Fact-8B858EB96E0B54168AAD76F7E31A02A1"
      unitRef="usd">30134000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="FI2016Q4_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43697240e3162-wk-Fact-ECD85C16469253E8ACB3C5F1B3BBE6EF"
      unitRef="usd">24315000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="FI2016Q4"
      decimals="-6"
      id="d43697240e3182-wk-Fact-F8F5DF7C12C25020B65DFF915C2D461A"
      unitRef="usd">54449000000</us-gaap:Goodwill>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="FD2017Q3YTD_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43697240e3204-wk-Fact-39F7ED9F3086578FAC1610BAD7C34831"
      unitRef="usd">572000000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="FD2017Q3YTD_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43697240e3223-wk-Fact-1B4BEA3CDC1756D68AA1A2E1DC80FA4D"
      unitRef="usd">92000000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43697240e3242-wk-Fact-32830C0722A659AF88B98C905235BC15"
      unitRef="usd">664000000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="FD2017Q3YTD_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43697240e3270-wk-Fact-5B921CA5279853B595C111072F4FBA7F"
      unitRef="usd">491000000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="FD2017Q3YTD_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43697240e3289-wk-Fact-6AC822CCA34E51E4AFF352F6B975BAEF"
      unitRef="usd">475000000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43697240e3308-wk-Fact-94EEFBE86EAF5F65881310E2436550F1"
      unitRef="usd">966000000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:Goodwill
      contextRef="FI2017Q3_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43697240e3339-wk-Fact-3B12F4B948D05D978CB909A2F4520D86"
      unitRef="usd">31197000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="FI2017Q3_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43697240e3358-wk-Fact-81A851BFCD2955758BC03DB834D3D37E"
      unitRef="usd">24882000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="FI2017Q3"
      decimals="-6"
      id="d43697240e3378-wk-Fact-691B87100C6755EB85765E65D5C328BA"
      unitRef="usd">56078000000</us-gaap:Goodwill>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="FD2017Q3YTD"
      id="TextSelection-108DD3F434485B42AD3B4CE4A038BDC6-0-wk-Fact-EFF2005AFB805E22A95DB5A897950074">&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;Pension and Postretirement Benefit Plans&lt;/span&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="33"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:27%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="33" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table provides the components of net periodic benefit cost/(income):&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="31" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Three Months Ended&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:Arial;font-size:9.5pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Pension Plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:Arial;font-size:9.5pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;U.S.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Qualified&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;U.S.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Supplemental&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;(Non-Qualified)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;International&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Postretirement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Oct&#160;1, 2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Oct&#160;2, 2016&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Oct&#160;1, 2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Oct&#160;2, 2016&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Oct&#160;1, 2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Oct&#160;2, 2016&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Oct&#160;1, 2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Oct&#160;2, 2016&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Net periodic benefit cost/(credit):&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Service cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;67&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;69&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;44&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;41&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;11&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Interest cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;157&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;218&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;13&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;18&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;52&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;58&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;23&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;33&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Expected return on plan assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(248&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(239&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(87&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(95&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Amortization of:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Actuarial losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;91&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;99&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;12&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;29&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;23&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Prior service costs (credits)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(45&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(45&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Curtailments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Settlements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;30&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;21&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;99&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;170&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;39&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;39&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;35&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;27&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(17&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="31" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Nine Months Ended&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:Arial;font-size:9.5pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Pension Plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:Arial;font-size:9.5pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;U.S.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Qualified&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;U.S.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Supplemental&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;(Non-Qualified)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;International&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Postretirement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Oct&#160;1, 2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Oct&#160;2, 2016&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Oct&#160;1, 2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Oct&#160;2, 2016&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Oct&#160;1, 2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Oct&#160;2, 2016&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Oct&#160;1, 2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Oct&#160;2, 2016&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Net periodic benefit cost/(credit):&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Service cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;202&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;193&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;18&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;14&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;127&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;126&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;32&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;31&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Interest cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;478&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;486&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;41&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;40&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;152&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;178&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;68&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;77&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Expected return on plan assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(759&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(721&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(256&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(291&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(27&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(25&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Amortization of:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Actuarial losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;302&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;297&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;37&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;27&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;86&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;70&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;23&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;23&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Prior service costs (credits)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(137&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(127&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Curtailments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(15&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(14&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:6px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Settlements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;54&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;52&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;32&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;23&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;292&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;316&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;127&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;105&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;106&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;81&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(57&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(36&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:6px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8.5pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;In April 2017, we settled the remaining obligation associated with the Hospira U.S. qualified defined benefit pension plan. We purchased a group annuity contract on behalf of the remaining plan participants with a third-party insurance provider. As a result, we were relieved of the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;$156 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; net pension benefit obligation and recorded a pretax settlement gain of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;$41 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;, partially offset by the recognition of actuarial losses and prior service costs upon plan settlement of approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;$30 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; in&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;font-style:italic;"&gt; Restructuring charges and certain acquisition-related costs&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; during the second quarter of 2017 (see &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;font-style:italic;"&gt;Note 3&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;).&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;As of and for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;nine months&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;October&#160;1, 2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, we contributed and expect to contribute in 2017 from our general assets as follows: &lt;/span&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.41520467836257%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:47%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Pension Plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;U.S. Qualified&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;U.S. Supplemental (Non-Qualified)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;International&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Postretirement Plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Contributions from our general assets for the nine months ended October 1, 2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;1,095&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;121&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;134&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;158&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-left:12px;text-indent:-12px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Expected contributions from our general assets during 2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;1,095&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;146&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;170&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;204&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8.5pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Contributions expected to be made for &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;text-align:center;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; are inclusive of amounts contributed during the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;nine months ended October 1, 2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;, including the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;$1.0 billion&lt;/span&gt;&lt;/span&gt; voluntary contribution that was made in January 2017 for the U.S. qualified plans, which was considered pre-funding for future anticipated mandatory contributions and is also expected to reduce Pension Benefit Guaranty Corporation variable rate premiums. The U.S. supplemental (non-qualified) pension plan, international pension plan and the postretirement plan contributions from our general assets include direct employer benefit payments.</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:ScheduleOfNetBenefitCostsTableTextBlock
      contextRef="FD2017Q3YTD"
      id="TextSelection-3F349BD1197C5BBA9A1BB21C88406E1E-0-wk-Fact-500E0CC9ACEE5A4690191FBC1A04F684">&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="33"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:27%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="33" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table provides the components of net periodic benefit cost/(income):&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="31" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Three Months Ended&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:Arial;font-size:9.5pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Pension Plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:Arial;font-size:9.5pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;U.S.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Qualified&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;U.S.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Supplemental&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;(Non-Qualified)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;International&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Postretirement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Oct&#160;1, 2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Oct&#160;2, 2016&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Oct&#160;1, 2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Oct&#160;2, 2016&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Oct&#160;1, 2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Oct&#160;2, 2016&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Oct&#160;1, 2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Oct&#160;2, 2016&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Net periodic benefit cost/(credit):&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Service cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;67&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;69&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;44&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;41&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;11&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Interest cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;157&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;218&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;13&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;18&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;52&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;58&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;23&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;33&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Expected return on plan assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(248&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(239&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(87&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(95&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Amortization of:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Actuarial losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;91&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;99&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;12&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;29&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;23&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Prior service costs (credits)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(45&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(45&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Curtailments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Settlements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;30&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;21&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;99&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;170&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;39&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;39&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;35&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;27&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(17&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="31" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Nine Months Ended&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:Arial;font-size:9.5pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Pension Plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;span style="font-family:Arial;font-size:9.5pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;U.S.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Qualified&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;U.S.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Supplemental&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;(Non-Qualified)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;International&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Postretirement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Oct&#160;1, 2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Oct&#160;2, 2016&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Oct&#160;1, 2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Oct&#160;2, 2016&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Oct&#160;1, 2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Oct&#160;2, 2016&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Oct&#160;1, 2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Oct&#160;2, 2016&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Net periodic benefit cost/(credit):&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Service cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;202&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;193&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;18&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;14&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;127&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;126&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;32&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;31&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Interest cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;478&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;486&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;41&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;40&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;152&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;178&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;68&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;77&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Expected return on plan assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(759&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(721&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(256&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(291&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(27&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(25&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Amortization of:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Actuarial losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;302&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;297&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;37&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;27&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;86&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;70&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;23&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;23&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Prior service costs (credits)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(137&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(127&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Curtailments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(15&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(14&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:6px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Settlements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;54&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;52&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;32&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;23&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;292&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;316&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;127&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;105&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;106&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;81&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(57&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;(36&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;div style="line-height:120%;font-size:8.5pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;In April 2017, we settled the remaining obligation associated with the Hospira U.S. qualified defined benefit pension plan. We purchased a group annuity contract on behalf of the remaining plan participants with a third-party insurance provider. As a result, we were relieved of the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;$156 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; net pension benefit obligation and recorded a pretax settlement gain of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;$41 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;, partially offset by the recognition of actuarial losses and prior service costs upon plan settlement of approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;$30 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; in&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;font-style:italic;"&gt; Restructuring charges and certain acquisition-related costs&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; during the second quarter of 2017 (see &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;font-style:italic;"&gt;Note 3&lt;/span&gt;).</us-gaap:ScheduleOfNetBenefitCostsTableTextBlock>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="FD2017Q3QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d43712510e1704-wk-Fact-9E9209F9A748579AAF874A87DF78C03D"
      unitRef="usd">67000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="FD2016Q3QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d43712510e1723-wk-Fact-8714D4A622405CD6AB9185ACD20BD070"
      unitRef="usd">69000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="FD2017Q3QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d43712510e1743-wk-Fact-1E3A1193A3EF5D5FA90C719E1E1C2A1D"
      unitRef="usd">6000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="FD2016Q3QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d43712510e1762-wk-Fact-0C863B6EEB905815B1F70A90BE67A0A2"
      unitRef="usd">5000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="FD2017Q3QTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d43712510e1781-wk-Fact-481449526D1057088ED9870C387494AE"
      unitRef="usd">44000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="FD2016Q3QTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d43712510e1801-wk-Fact-41EDF11A6AEB5CC0A903B82579EABF9A"
      unitRef="usd">41000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="FD2017Q3QTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d43712510e1820-wk-Fact-C814785A192A52CCAF640691C51A3304"
      unitRef="usd">10000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="FD2016Q3QTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d43712510e1839-wk-Fact-135852348E555F4AB8AB8330D1762860"
      unitRef="usd">11000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="FD2017Q3QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d43712510e1859-wk-Fact-8C938F85BB8A51A08B716303B9D043F4"
      unitRef="usd">157000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="FD2016Q3QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d43712510e1878-wk-Fact-D181F1F1F0F9549AB0AAD66667DA5D73"
      unitRef="usd">218000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="FD2017Q3QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d43712510e1897-wk-Fact-21AD6A14FD6E5AF1B3B95C4CB9BEB6F8"
      unitRef="usd">13000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="FD2016Q3QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d43712510e1917-wk-Fact-F0C627D912BB5038A7441B4C323F14CB"
      unitRef="usd">18000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="FD2017Q3QTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d43712510e1936-wk-Fact-2419217873095BD3AB73F321E36C47D2"
      unitRef="usd">52000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="FD2016Q3QTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d43712510e1956-wk-Fact-6EF224137E2A543BBAD79C942899C04D"
      unitRef="usd">58000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="FD2017Q3QTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d43712510e1975-wk-Fact-F16069631AEA55FFBFBAEA5F47EFA30B"
      unitRef="usd">23000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="FD2016Q3QTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d43712510e1994-wk-Fact-7EADE07DC1C65F9A8D9D917A78C49E82"
      unitRef="usd">33000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="FD2017Q3QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d43712510e2019-wk-Fact-9A7B6E07A41152D8AE4FAE1762D02940"
      unitRef="usd">248000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="FD2016Q3QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d43712510e2039-wk-Fact-918079B890DC59749E32C36C8E843601"
      unitRef="usd">239000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="FD2017Q3QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d43712510e2059-wk-Fact-6F2C0A4B5D0752368E32A74CDBD0FD9C"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="FD2016Q3QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d43712510e2079-wk-Fact-A936B10CF3A85F05AFE634207AC14544"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="FD2017Q3QTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d43712510e2098-wk-Fact-B594018F3E2657488F25A3772003918D"
      unitRef="usd">87000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="FD2016Q3QTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d43712510e2119-wk-Fact-BF0D1AA9D89854BFA0ED402AB6E63FBD"
      unitRef="usd">95000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="FD2017Q3QTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d43712510e2139-wk-Fact-22489E2609795BD3B1FDE0B8D17DDD91"
      unitRef="usd">9000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="FD2016Q3QTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d43712510e2159-wk-Fact-C59043F87A1658239E9BA9697B357B75"
      unitRef="usd">8000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="FD2017Q3QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d43712510e2346-wk-Fact-41E8CD7A36715DECB7404562BAE76D26"
      unitRef="usd">-91000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="FD2016Q3QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d43712510e2365-wk-Fact-88B688C938EB55DDB880C46047CEE537"
      unitRef="usd">-99000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="FD2017Q3QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d43712510e2384-wk-Fact-A879C840BBEB52A3AE989EEACE5274E6"
      unitRef="usd">-12000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="FD2016Q3QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d43712510e2404-wk-Fact-70B67E696D2C5B60BE542F2FB05F382E"
      unitRef="usd">-9000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="FD2017Q3QTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d43712510e2423-wk-Fact-36D28693F6A356BABCAE6F5DF3DA79F4"
      unitRef="usd">-29000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="FD2016Q3QTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d43712510e2443-wk-Fact-5FE299955AD05A708EF81988B211C3E7"
      unitRef="usd">-23000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="FD2017Q3QTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d43712510e2462-wk-Fact-C12C1826A6CA57A2B6B4C9FD4D3B59B1"
      unitRef="usd">-8000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="FD2016Q3QTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d43712510e2481-wk-Fact-0688D85081B75BDCA7C39E89C4BAD62C"
      unitRef="usd">-9000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="FD2017Q3QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d43712510e2507-wk-Fact-F63613D6C4635A1085DB928EB41688A4"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="FD2016Q3QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d43712510e2526-wk-Fact-6C3AED6081D956DB9A88358A6DBC4860"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="FD2017Q3QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d43712510e2545-wk-Fact-172B7D1439E957C5909E9CA529B344CD"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="FD2016Q3QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d43712510e2565-wk-Fact-64992226CD4A56A18E318C5D80777974"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="FD2017Q3QTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d43712510e2584-wk-Fact-A51AFD1ABFE35B3A9834A6482D23F893"
      unitRef="usd">-1000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="FD2016Q3QTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d43712510e2605-wk-Fact-3131B0A0FE0C54FABB189CDAB6310BFF"
      unitRef="usd">-1000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="FD2017Q3QTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d43712510e2625-wk-Fact-316E2928EA2D58D0AB005A0221B707BB"
      unitRef="usd">-45000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="FD2016Q3QTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d43712510e2645-wk-Fact-FE9EDE18655A5BDA9B23C201A401F1C4"
      unitRef="usd">-45000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments
      contextRef="FD2017Q3QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d43712510e2671-wk-Fact-3E4B2138956458C0A87D14CCDFFFE310"
      unitRef="usd">-1000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments
      contextRef="FD2016Q3QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d43712510e2690-wk-Fact-119B0C3F842254FBB549178DD2B0B03F"
      unitRef="usd">-2000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments
      contextRef="FD2017Q3QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d43712510e2709-wk-Fact-73AE6CA28F0956EEA08FFF8B0864B697"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments
      contextRef="FD2016Q3QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d43712510e2729-wk-Fact-94F622C3D10457ACA9281668326FF033"
      unitRef="usd">-1000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments
      contextRef="FD2017Q3QTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d43712510e2748-wk-Fact-D47337A92FE05C088F99D88647D3AAE0"
      unitRef="usd">2000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments
      contextRef="FD2016Q3QTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d43712510e2769-wk-Fact-5ACE4653B79D513195DB093FC19BC1FD"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments
      contextRef="FD2017Q3QTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d43712510e2788-wk-Fact-0AB1E7D5BDA3559BAF29906AD572874D"
      unitRef="usd">3000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments
      contextRef="FD2016Q3QTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d43712510e2808-wk-Fact-8F56DA0D0D69553292F1071E7183FC7E"
      unitRef="usd">8000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="FD2017Q3QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d43712510e2834-wk-Fact-E67F7356BDB85C86BFA985D27BB3661C"
      unitRef="usd">-30000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="FD2016Q3QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d43712510e2853-wk-Fact-790FED1A1448526D93D700D9E0FAFC88"
      unitRef="usd">-21000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="FD2017Q3QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d43712510e2872-wk-Fact-F88E8EB3200C59CC9B23BEBA7578EEDC"
      unitRef="usd">-7000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="FD2016Q3QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d43712510e2892-wk-Fact-4ED9BB0264BB502CAA444ECC25BDC794"
      unitRef="usd">-7000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="FD2017Q3QTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d43712510e2911-wk-Fact-2C23635A95855B45B523793ED15431B6"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="FD2016Q3QTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d43712510e2931-wk-Fact-A7CE8DD917725CFE8CC3ECDA78AEB77E"
      unitRef="usd">-1000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="FD2017Q3QTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d43712510e2950-wk-Fact-083C294BF26A544786E00C3E7C12EFAD"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="FD2016Q3QTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d43712510e2969-wk-Fact-95F4A2EA070D5BBDB6B1B498E2F481B5"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="FD2017Q3QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d43712510e2999-wk-Fact-0634C6E9A2985833989CFF0FED04324E"
      unitRef="usd">99000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="FD2016Q3QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d43712510e3018-wk-Fact-EB2CC601202B5F75A3AFB7E3C7411A43"
      unitRef="usd">170000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="FD2017Q3QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d43712510e3038-wk-Fact-88E8BFE6441E54D3BC4F7503E3CFA476"
      unitRef="usd">39000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="FD2016Q3QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d43712510e3057-wk-Fact-594C4C2B50DC5FBA9CDCFEABA069BD95"
      unitRef="usd">39000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="FD2017Q3QTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d43712510e3076-wk-Fact-E90EB1307D4C58DD8577753F88B5C776"
      unitRef="usd">35000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="FD2016Q3QTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d43712510e3096-wk-Fact-541D0ABF1C47588090B21F7F496B7A53"
      unitRef="usd">27000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="FD2017Q3QTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d43712510e3115-wk-Fact-E7BD283525F35A9A93A3A517FDA649FE"
      unitRef="usd">-17000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="FD2016Q3QTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d43712510e3135-wk-Fact-F82AC1F26D5556AEBEC85DA302886F9E"
      unitRef="usd">-9000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="FD2017Q3YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d43712510e4168-wk-Fact-88EBC3EBE111513F840C9F921A314BB9"
      unitRef="usd">202000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="FD2016Q3YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d43712510e4187-wk-Fact-1D5607877A1C54618597D694BA991812"
      unitRef="usd">193000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="FD2017Q3YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d43712510e4207-wk-Fact-1F98BD9FFCED5901924B791569BE79B4"
      unitRef="usd">18000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="FD2016Q3YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d43712510e4226-wk-Fact-20C79A8F2E045982B15335AA71808AF1"
      unitRef="usd">14000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="FD2017Q3YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d43712510e4245-wk-Fact-EE795E72CF0B586D8271826487C38254"
      unitRef="usd">127000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="FD2016Q3YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d43712510e4265-wk-Fact-F77ADF5E7EA55CCFA751E84649076560"
      unitRef="usd">126000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="FD2017Q3YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d43712510e4284-wk-Fact-18BEBD46DF265C0B8B7DABE4F2F2509A"
      unitRef="usd">32000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="FD2016Q3YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d43712510e4303-wk-Fact-8EE5C13B7DBD5E0BA3AC6121F7EA5D8E"
      unitRef="usd">31000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="FD2017Q3YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d43712510e4324-wk-Fact-1C567788B51552EC86AD93358A113C04"
      unitRef="usd">478000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="FD2016Q3YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d43712510e4343-wk-Fact-4C8B761BC8A857289F300FD346EDCFF2"
      unitRef="usd">486000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="FD2017Q3YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d43712510e4362-wk-Fact-E5565536FF3D5DE48C3815BCC3BC3B2E"
      unitRef="usd">41000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="FD2016Q3YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d43712510e4382-wk-Fact-F4590E0D775A5327AF25D5B8F905A8A3"
      unitRef="usd">40000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="FD2017Q3YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d43712510e4401-wk-Fact-6C5FEC04B2785666ACABA4F3B96A4636"
      unitRef="usd">152000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="FD2016Q3YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d43712510e4421-wk-Fact-21739BA9BEF15C0B855BD7CD56E00260"
      unitRef="usd">178000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="FD2017Q3YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d43712510e4440-wk-Fact-90D3C8712DB157458E1E52CF9BCEB9A1"
      unitRef="usd">68000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="FD2016Q3YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d43712510e4459-wk-Fact-4F487D83D43E56229435DA9286E5F40D"
      unitRef="usd">77000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="FD2017Q3YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d43712510e4484-wk-Fact-7A88DB0438DC5867A92DE1BB2A8BEC24"
      unitRef="usd">759000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="FD2016Q3YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d43712510e4504-wk-Fact-177183957B01565CA3DE15186DC0AA3E"
      unitRef="usd">721000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="FD2017Q3YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d43712510e4524-wk-Fact-C9BCC376A186520AB1BD957F9FBA6A2D"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="FD2016Q3YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d43712510e4544-wk-Fact-D5A99F0316C251ED852805136939B6CE"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="FD2017Q3YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d43712510e4563-wk-Fact-601051399A3C5E888AD42B1761966C5D"
      unitRef="usd">256000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="FD2016Q3YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d43712510e4584-wk-Fact-20AB6A6441BE569B81A0C2BF9DCCC1BE"
      unitRef="usd">291000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="FD2017Q3YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d43712510e4604-wk-Fact-7651EF7DB7CA52F4B5FE5AF758BEA23A"
      unitRef="usd">27000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="FD2016Q3YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d43712510e4624-wk-Fact-AE490A2A12DA5DD28FC1E4707DB5823B"
      unitRef="usd">25000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="FD2017Q3YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d43712510e4818-wk-Fact-4CE5EEDBEB0E56709AF5BDD28428C8A4"
      unitRef="usd">-302000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="FD2016Q3YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d43712510e4837-wk-Fact-13DD39AEEF96518F9A80C62D8E6A58EB"
      unitRef="usd">-297000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="FD2017Q3YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d43712510e4856-wk-Fact-AC375B6DCF765DE5837DCC465AE925C9"
      unitRef="usd">-37000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="FD2016Q3YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d43712510e4876-wk-Fact-8BA6DCC82B4D537780288614EE9E590B"
      unitRef="usd">-27000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="FD2017Q3YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d43712510e4895-wk-Fact-AF6BCFE35F745884842E47484E2EDC8F"
      unitRef="usd">-86000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="FD2016Q3YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d43712510e4915-wk-Fact-F76768D39E9F5FAF81B70BAE938B8DF9"
      unitRef="usd">-70000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="FD2017Q3YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d43712510e4934-wk-Fact-E316611573F4511EBAAEEDFD17698D80"
      unitRef="usd">-23000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="FD2016Q3YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d43712510e4953-wk-Fact-5D88572993275A159D7362B763962F8B"
      unitRef="usd">-23000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="FD2017Q3YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d43712510e4978-wk-Fact-680AB021A9D85E21AC0D650674666D7F"
      unitRef="usd">3000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="FD2016Q3YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d43712510e4997-wk-Fact-3AD287E437335513A247CED1511F52AE"
      unitRef="usd">4000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="FD2017Q3YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d43712510e5016-wk-Fact-FB7369F024D05E75AA6DF22182703DA6"
      unitRef="usd">-1000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="FD2016Q3YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d43712510e5037-wk-Fact-406C36C728985B18AAA8178B23CAEF0A"
      unitRef="usd">-1000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="FD2017Q3YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d43712510e5057-wk-Fact-B9E908A6A00C5A63B03CB653A7DEFA9B"
      unitRef="usd">-3000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="FD2016Q3YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d43712510e5078-wk-Fact-DEC9B7A087E352FF8CF2B700A565E84A"
      unitRef="usd">-2000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="FD2017Q3YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d43712510e5098-wk-Fact-4CB08463D31A5ECFA7D302165110B765"
      unitRef="usd">-137000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="FD2016Q3YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d43712510e5118-wk-Fact-EFF3ACA2894F5594939E61D017667DE7"
      unitRef="usd">-127000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments
      contextRef="FD2017Q3YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d43712510e5144-wk-Fact-7F7AD619600C57BDB92DA526BB9447DB"
      unitRef="usd">-10000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments
      contextRef="FD2016Q3YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d43712510e5163-wk-Fact-6D35DF163ED156B392B0ABBC405525F5"
      unitRef="usd">-5000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments
      contextRef="FD2017Q3YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d43712510e5182-wk-Fact-FBDDF40EF6005914A87FF3F8C1B40371"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments
      contextRef="FD2016Q3YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d43712510e5202-wk-Fact-CE2594AB59715893B8873903D64990F3"
      unitRef="usd">-1000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments
      contextRef="FD2017Q3YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d43712510e5221-wk-Fact-924C12340C895DA4AC7B5C27331978CF"
      unitRef="usd">2000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments
      contextRef="FD2016Q3YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d43712510e5242-wk-Fact-280C02B056E55C4E88BBC63F93B62E90"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments
      contextRef="FD2017Q3YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d43712510e5262-wk-Fact-5647AD9D2EB55C4682FEA8EADC4277DC"
      unitRef="usd">15000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments
      contextRef="FD2016Q3YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d43712510e5282-wk-Fact-2289F00C7F9B56E1934620C34080192A"
      unitRef="usd">14000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="FD2017Q3YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d43712510e5308-wk-Fact-F91DB48F665752F183FB6249B5C47098"
      unitRef="usd">-54000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="FD2016Q3YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d43712510e5327-wk-Fact-05422B8407F15A068C445BB5C57F5700"
      unitRef="usd">-52000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="FD2017Q3YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d43712510e5346-wk-Fact-99BCC57499EC5443A21A15A4EE3D4D19"
      unitRef="usd">-32000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="FD2016Q3YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d43712510e5366-wk-Fact-262F9FFDE5945D0895DA507FF57BEBFB"
      unitRef="usd">-23000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="FD2017Q3YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d43712510e5385-wk-Fact-6A451675830B5BCB88F49C7A376DD060"
      unitRef="usd">-3000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="FD2016Q3YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d43712510e5405-wk-Fact-50EB5D2681BA55DCA92E02E4FA9A5A65"
      unitRef="usd">-2000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="FD2017Q3YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d43712510e5424-wk-Fact-BB811267500F56E5A4A56D25EA764A32"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="FD2016Q3YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d43712510e5443-wk-Fact-0890865A19355663B5E6B53DEB1C67B3"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="FD2017Q3YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d43712510e5473-wk-Fact-CB88AB971B745EBB96F422CEAFCAA461"
      unitRef="usd">292000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="FD2016Q3YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d43712510e5492-wk-Fact-8A4811792A515F62A3DF96296C7FF609"
      unitRef="usd">316000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="FD2017Q3YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d43712510e5512-wk-Fact-1D9D70789485540EB39A4C803F82D501"
      unitRef="usd">127000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="FD2016Q3YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d43712510e5531-wk-Fact-CE0AE7E1EADD53ED9A9021F576D1E9F0"
      unitRef="usd">105000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="FD2017Q3YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d43712510e5550-wk-Fact-7490A5856338531D86C5ACC2B1999B22"
      unitRef="usd">106000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="FD2016Q3YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d43712510e5570-wk-Fact-B98CEE082A4B567DAE5062D3C0B469C1"
      unitRef="usd">81000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="FD2017Q3YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d43712510e5589-wk-Fact-D1A4B22C7EEF52E39B7E2BE8A00171F5"
      unitRef="usd">-57000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="FD2016Q3YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d43712510e5609-wk-Fact-3D45E9B89C2855B19D16F17D9B8411B1"
      unitRef="usd">-36000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanSettlementsBenefitObligation
      contextRef="D2017Q2Apr01-Apr30_us-gaap_BusinessAcquisitionAxis_pfe_HospiraMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d43712510e5669-wk-Fact-B14683B4545D5992A77B1DC1D5223C72"
      unitRef="usd">156000000</us-gaap:DefinedBenefitPlanSettlementsBenefitObligation>
    <pfe:DefinedBenefitPlanNetPeriodicBenefitCostCreditGainLossDuetoSettlementPretax
      contextRef="D2017Q2Apr01-Apr30_us-gaap_BusinessAcquisitionAxis_pfe_HospiraMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d43712510e5673-wk-Fact-9A6D679CCC3853AFBA200EBFC12C2334"
      unitRef="usd">41000000</pfe:DefinedBenefitPlanNetPeriodicBenefitCostCreditGainLossDuetoSettlementPretax>
    <pfe:DefinedBenefitPlanActuarialLossandPriorServiceCostsImmediateRecognitionasComponentinNetPeriodicBenefitCost
      contextRef="D2017Q2Apr01-Apr30_us-gaap_BusinessAcquisitionAxis_pfe_HospiraMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d43712510e5677-wk-Fact-CB6FAB81ED7E509598517EA9999DEB3C"
      unitRef="usd">30000000</pfe:DefinedBenefitPlanActuarialLossandPriorServiceCostsImmediateRecognitionasComponentinNetPeriodicBenefitCost>
    <pfe:ScheduleofEmployerContributionstoPensionandPostretirementPlansTableTextBlock
      contextRef="FD2017Q3YTD"
      id="TextSelection-D638BF741BE55958808C4743FE3F2B96-0-wk-Fact-A2DFD1479CC65E73A35055DEEBBA4D38">As of and for the &lt;span style="font-family:inherit;font-size:10pt;"&gt;nine months&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;October&#160;1, 2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, we contributed and expect to contribute in 2017 from our general assets as follows: &lt;/span&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.41520467836257%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:47%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Pension Plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;U.S. Qualified&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;U.S. Supplemental (Non-Qualified)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;International&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Postretirement Plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Contributions from our general assets for the nine months ended October 1, 2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;1,095&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;121&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;134&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;158&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-left:12px;text-indent:-12px;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;Expected contributions from our general assets during 2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;1,095&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;146&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;170&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;204&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8.5pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Contributions expected to be made for &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;text-align:center;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; are inclusive of amounts contributed during the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;nine months ended October 1, 2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;, including the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;$1.0 billion&lt;/span&gt;&lt;/span&gt; voluntary contribution that was made in January 2017 for the U.S. qualified plans, which was considered pre-funding for future anticipated mandatory contributions and is also expected to reduce Pension Benefit Guaranty Corporation variable rate premiums. The U.S. supplemental (non-qualified) pension plan, international pension plan and the postretirement plan contributions from our general assets include direct employer benefit payments.</pfe:ScheduleofEmployerContributionstoPensionandPostretirementPlansTableTextBlock>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="FD2017Q3YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d43712510e5926-wk-Fact-A5FB7ACA0EB850FFB76E01E8A4C4AB78"
      unitRef="usd">1095000000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="FD2017Q3YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d43712510e5945-wk-Fact-C675961749D85280943790477D62B603"
      unitRef="usd">121000000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="FD2017Q3YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d43712510e5965-wk-Fact-983F4374652F5EC897A4DFC34EA7D1C6"
      unitRef="usd">134000000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="FD2017Q3YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d43712510e5984-wk-Fact-D8D35E279DF7560C9A1471CA970C8FA7"
      unitRef="usd">158000000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsRemainderOfFiscalYear
      contextRef="FI2017Q3_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d43712510e6011-wk-Fact-AFBA8CD89F4951449553D70FD3AC0D6E"
      unitRef="usd">1095000000</us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsRemainderOfFiscalYear>
    <us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsRemainderOfFiscalYear
      contextRef="FI2017Q3_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d43712510e6030-wk-Fact-DACE24AFDEBA5A45B37C21CDA9314DB0"
      unitRef="usd">146000000</us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsRemainderOfFiscalYear>
    <us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsRemainderOfFiscalYear
      contextRef="FI2017Q3_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d43712510e6050-wk-Fact-29DAA58640B95FAD926B443F7C99CB05"
      unitRef="usd">170000000</us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsRemainderOfFiscalYear>
    <us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsRemainderOfFiscalYear
      contextRef="FI2017Q3_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d43712510e6069-wk-Fact-BF9FCFC1FC645049A852329D7379350D"
      unitRef="usd">204000000</us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsRemainderOfFiscalYear>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="D2017Q1Jan01-Jan31_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-8"
      id="d43712510e6099-wk-Fact-885470E609A55770B3A25C242F4D7451"
      unitRef="usd">1000000000.0</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="FD2017Q3YTD"
      id="TextSelection-BEB713F2A6E555C48CDD0BE6F45CF73D-0-wk-Fact-F19F42D3ED1153DA88341D380D30F862">&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;Earnings Per Common Share Attributable to Common Shareholders&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt; &lt;/span&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.22027290448344%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:52%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="17" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table provides the detailed calculation of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Earnings per common share (EPS)&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Three Months Ended&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Nine Months Ended&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;(IN MILLIONS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;October&#160;1, &lt;br/&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;October&#160;2, &lt;br/&gt;2016&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;October&#160;1, &lt;br/&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;October&#160;2, &lt;br/&gt;2016&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;text-decoration:underline;"&gt;EPS Numerator&#x2013;&#x2013;Basic&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-left:6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Income from continuing operations&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,858&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,355&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9,064&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,465&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Less: Net income attributable to noncontrolling interests&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;18&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;32&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;25&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-left:12px;text-indent:-6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Income from continuing operations attributable to Pfizer Inc.&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,840&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,355&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9,032&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,440&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Less: Preferred stock dividends&#x2013;&#x2013;net of tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-left:12px;text-indent:-6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Income from continuing operations attributable to Pfizer Inc. common shareholders&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,839&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,355&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9,032&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,439&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Discontinued operations&#x2013;&#x2013;net of tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-left:12px;text-indent:-6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net income attributable to Pfizer Inc. common shareholders&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,839&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,355&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9,033&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,439&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;text-decoration:underline;"&gt;EPS Numerator&#x2013;&#x2013;Diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-left:12px;text-indent:-6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Income from continuing operations attributable to Pfizer Inc. common shareholders and assumed conversions&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,840&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,355&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9,032&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,440&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Discontinued operations&#x2013;&#x2013;net of tax, attributable to Pfizer Inc. common shareholders and assumed conversions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-left:12px;text-indent:-6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net income attributable to Pfizer Inc. common shareholders and assumed conversions&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,840&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,355&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9,034&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,440&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;text-decoration:underline;"&gt;EPS Denominator&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Weighted-average number of common shares outstanding&#x2013;&#x2013;Basic&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,951&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,066&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,972&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,095&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-left:12px;text-indent:-6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Common-share equivalents: stock options, stock issuable under employee compensation plans, convertible preferred stock and accelerated share repurchase agreements&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;89&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;84&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;85&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;80&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-left:12px;text-indent:-6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Weighted-average number of common shares outstanding&#x2013;&#x2013;Diluted&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,041&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,150&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,057&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,175&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-left:12px;text-indent:-6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Stock options that had exercise prices greater than the average market price of our common stock issuable under employee compensation plans&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(a),&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;47&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;38&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;47&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;60&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8.5pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Amounts for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;third quarter&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; and first &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;nine months&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;October&#160;2, 2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; have been revised from previously reported amounts to reflect the adoption of a new accounting standard in the fourth quarter of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;text-align:center;"&gt;2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;, as of January 1, 2016, that requires, when applying the treasury stock method for shares that could be repurchased, that the assumed proceeds no longer include the amount of excess tax benefit (see &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;font-style:italic;"&gt;Note 1B&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;).&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;font-size:8.5pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(b)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;These common stock equivalents were outstanding for the periods presented, but were not included in the computation of diluted EPS for those periods because their inclusion would have had an anti-dilutive effect.</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="FD2017Q3YTD"
      id="TextSelection-68F99197870A50E0AF5421E0F000D153-0-wk-Fact-2CC1123C7E005A5A8A2A842C08052D73">&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.22027290448344%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:52%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="17" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table provides the detailed calculation of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Earnings per common share (EPS)&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Three Months Ended&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Nine Months Ended&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;(IN MILLIONS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;October&#160;1, &lt;br/&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;October&#160;2, &lt;br/&gt;2016&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;October&#160;1, &lt;br/&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;October&#160;2, &lt;br/&gt;2016&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;text-decoration:underline;"&gt;EPS Numerator&#x2013;&#x2013;Basic&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-left:6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Income from continuing operations&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,858&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,355&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9,064&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,465&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Less: Net income attributable to noncontrolling interests&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;18&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;32&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;25&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-left:12px;text-indent:-6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Income from continuing operations attributable to Pfizer Inc.&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,840&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,355&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9,032&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,440&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Less: Preferred stock dividends&#x2013;&#x2013;net of tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-left:12px;text-indent:-6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Income from continuing operations attributable to Pfizer Inc. common shareholders&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,839&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,355&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9,032&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,439&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Discontinued operations&#x2013;&#x2013;net of tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-left:12px;text-indent:-6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net income attributable to Pfizer Inc. common shareholders&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,839&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,355&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9,033&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,439&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;text-decoration:underline;"&gt;EPS Numerator&#x2013;&#x2013;Diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-left:12px;text-indent:-6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Income from continuing operations attributable to Pfizer Inc. common shareholders and assumed conversions&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,840&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,355&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9,032&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,440&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Discontinued operations&#x2013;&#x2013;net of tax, attributable to Pfizer Inc. common shareholders and assumed conversions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-left:12px;text-indent:-6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net income attributable to Pfizer Inc. common shareholders and assumed conversions&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,840&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,355&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9,034&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,440&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;text-decoration:underline;"&gt;EPS Denominator&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Weighted-average number of common shares outstanding&#x2013;&#x2013;Basic&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,951&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,066&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,972&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,095&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-left:12px;text-indent:-6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Common-share equivalents: stock options, stock issuable under employee compensation plans, convertible preferred stock and accelerated share repurchase agreements&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;89&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;84&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;85&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;80&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-left:12px;text-indent:-6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Weighted-average number of common shares outstanding&#x2013;&#x2013;Diluted&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,041&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,150&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,057&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,175&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-left:12px;text-indent:-6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Stock options that had exercise prices greater than the average market price of our common stock issuable under employee compensation plans&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(a),&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;47&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;38&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;47&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;60&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8.5pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Amounts for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;third quarter&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; and first &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;nine months&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;October&#160;2, 2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt; have been revised from previously reported amounts to reflect the adoption of a new accounting standard in the fourth quarter of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;text-align:center;"&gt;2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;, as of January 1, 2016, that requires, when applying the treasury stock method for shares that could be repurchased, that the assumed proceeds no longer include the amount of excess tax benefit (see &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;font-style:italic;"&gt;Note 1B&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;).&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;font-size:8.5pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(b)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;These common stock equivalents were outstanding for the periods presented, but were not included in the computation of diluted EPS for those periods because their inclusion would have had an anti-dilutive effect.</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FD2017Q3QTD"
      decimals="-6"
      id="d43690878e1033-wk-Fact-10A93FAA5CBC5B458A708E3EEBF01F13"
      unitRef="usd">2858000000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FD2016Q3QTD"
      decimals="-6"
      id="d43690878e1052-wk-Fact-8F2AF78FFD8356E9921CBFEFF7E852B8"
      unitRef="usd">1355000000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43690878e1072-wk-Fact-1011397EB1385A98BE195F68F7FE92A7"
      unitRef="usd">9064000000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43690878e1091-wk-Fact-9CDAD2B93E775B8EA25F98BBA2F83485"
      unitRef="usd">6465000000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity
      contextRef="FD2017Q3QTD"
      decimals="-6"
      id="d43690878e1111-wk-Fact-FEC1F9E3E96D52E58D0D70628A483E1B"
      unitRef="usd">18000000</us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity>
    <us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity
      contextRef="FD2016Q3QTD"
      decimals="-6"
      id="d43690878e1130-wk-Fact-9392927738705D6E92D72F8BB15FA833"
      unitRef="usd">0</us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity>
    <us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43690878e1149-wk-Fact-DC80DEB9EB6D52B8B5265B5AD1E69FF0"
      unitRef="usd">32000000</us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity>
    <us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43690878e1169-wk-Fact-62865A98C4E75066B568D0761F489763"
      unitRef="usd">25000000</us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="FD2017Q3QTD"
      decimals="-6"
      id="d43690878e1196-wk-Fact-0FA2545E29EF51FFAFF4BBCC15878817"
      unitRef="usd">2840000000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="FD2016Q3QTD"
      decimals="-6"
      id="d43690878e1215-wk-Fact-5CD97DE05A495D5EAFB1D7B5FE4550A4"
      unitRef="usd">1355000000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43690878e1234-wk-Fact-2AF1807BCF8A5ADC8187B51D6E464FFD"
      unitRef="usd">9032000000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43690878e1254-wk-Fact-232AC2542E565EDABA540B1D57A95D2D"
      unitRef="usd">6440000000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="FD2017Q3QTD"
      decimals="-6"
      id="d43690878e1279-wk-Fact-C8EBDE48436B51B9A53BB91E8B6C411C"
      unitRef="usd">0</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="FD2016Q3QTD"
      decimals="-6"
      id="d43690878e1298-wk-Fact-5EDA51D3C057538A9FF8CF7C050DFAD3"
      unitRef="usd">0</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43690878e1317-wk-Fact-CB617A7FF9EA50C6B252DA9FB0F9022D"
      unitRef="usd">1000000</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43690878e1337-wk-Fact-535C623BC356553C9A7C1964DD4187DA"
      unitRef="usd">1000000</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic
      contextRef="FD2017Q3QTD"
      decimals="-6"
      id="d43690878e1364-wk-Fact-9943CA1B5CD35B98836DDF43C586A63B"
      unitRef="usd">2839000000</pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic>
    <pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic
      contextRef="FD2016Q3QTD"
      decimals="-6"
      id="d43690878e1383-wk-Fact-8A7DCB81F28D538A87559BA9CEA85B1F"
      unitRef="usd">1355000000</pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic>
    <pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43690878e1402-wk-Fact-BB81900A80EC510B82BA9955D28FB794"
      unitRef="usd">9032000000</pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic>
    <pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43690878e1422-wk-Fact-18674C7559605F059F86A2A98B4C09F5"
      unitRef="usd">6439000000</pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="FD2017Q3QTD"
      decimals="-6"
      id="d43690878e1447-wk-Fact-F8A88E3727775446BECFB5D7B19FFE9A"
      unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="FD2016Q3QTD"
      decimals="-6"
      id="d43690878e1466-wk-Fact-0A252F10C1E25CFA8D6B9B5104061718"
      unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43690878e1485-wk-Fact-60867BC7B4C25795A91A0C8BA6B7BDAB"
      unitRef="usd">1000000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43690878e1505-wk-Fact-D5E632B5D4A85473B7FDB1B2EC3EF703"
      unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="FD2017Q3QTD"
      decimals="-6"
      id="d43690878e1537-wk-Fact-4791EB1764F851F9BFC3743AD13BD04D"
      unitRef="usd">2839000000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="FD2016Q3QTD"
      decimals="-6"
      id="d43690878e1556-wk-Fact-CB2E688471765831ADC0A8CA1A4F8DFD"
      unitRef="usd">1355000000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43690878e1576-wk-Fact-A97BF6B8A8BF52F4857350DD1D9E29F5"
      unitRef="usd">9033000000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43690878e1595-wk-Fact-EECF50AEC9F85FECBE21642BE05B9B94"
      unitRef="usd">6439000000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted
      contextRef="FD2017Q3QTD"
      decimals="-6"
      id="d43690878e1706-wk-Fact-01FC3E63A2EE59F6B2846C1357AAF742"
      unitRef="usd">2840000000</pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted>
    <pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted
      contextRef="FD2016Q3QTD"
      decimals="-6"
      id="d43690878e1725-wk-Fact-A1F4A6FC924452F79F29E27B44D8E522"
      unitRef="usd">1355000000</pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted>
    <pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43690878e1745-wk-Fact-D295627FDF4F561AB6C6612120051877"
      unitRef="usd">9032000000</pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted>
    <pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43690878e1764-wk-Fact-90C41519A36D526CAAA4ACCAE371F162"
      unitRef="usd">6440000000</pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="FD2017Q3QTD"
      decimals="-6"
      id="d43690878e1784-wk-Fact-4942B8D2D5425A1694B0B637E62DB5A3"
      unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="FD2016Q3QTD"
      decimals="-6"
      id="d43690878e1803-wk-Fact-BFBAA1FFB04554EE8A5DE945E2215A8B"
      unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43690878e1822-wk-Fact-C7BE3A035DD15D11B5F1395D4A05620F"
      unitRef="usd">1000000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43690878e1842-wk-Fact-46BFB691D89B5BA0A334C6AE54B4AB42"
      unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="FD2017Q3QTD"
      decimals="-6"
      id="d43690878e1874-wk-Fact-11F7A96D6D935A80A19BB49104FFB650"
      unitRef="usd">2840000000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="FD2016Q3QTD"
      decimals="-6"
      id="d43690878e1893-wk-Fact-AD762188EABB599D9776791285E37CB9"
      unitRef="usd">1355000000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43690878e1913-wk-Fact-FF15C80FFD7658F196DE22E2327F4EF5"
      unitRef="usd">9034000000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43690878e1932-wk-Fact-8F3C8079FB235F47AFEECF5DBF3A99E7"
      unitRef="usd">6440000000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="FD2017Q3QTD"
      decimals="-6"
      id="d43690878e2035-wk-Fact-69E50427EE6E533896BB8B1907041230"
      unitRef="shares">5951000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="FD2016Q3QTD"
      decimals="-6"
      id="d43690878e2054-wk-Fact-63E834283E2059E3A8C189B4778885B0"
      unitRef="shares">6066000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43690878e2073-wk-Fact-89167C4150EA5B6CB2833B441C176EB5"
      unitRef="shares">5972000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43690878e2093-wk-Fact-044058D73AF55D17962CBA73D63800BD"
      unitRef="shares">6095000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="FD2017Q3QTD"
      decimals="-6"
      id="d43690878e2120-wk-Fact-2D022CD3C3AD5211BB51112CC40FC473"
      unitRef="shares">89000000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="FD2016Q3QTD"
      decimals="-6"
      id="d43690878e2139-wk-Fact-712D745DC4AA5C53A5626F7D089F61CB"
      unitRef="shares">84000000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43690878e2158-wk-Fact-C43E96FF08B6534FA41614FCABAEB299"
      unitRef="shares">85000000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43690878e2178-wk-Fact-0C0E82D74BA85110A5BDBF458FE4D314"
      unitRef="shares">80000000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="FD2017Q3QTD"
      decimals="-6"
      id="d43690878e2205-wk-Fact-4F013E58EAE3506D989984D20AC7A60B"
      unitRef="shares">6041000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="FD2016Q3QTD"
      decimals="-6"
      id="d43690878e2224-wk-Fact-1E5089DBEBB75DB7864724ADB41A8830"
      unitRef="shares">6150000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43690878e2243-wk-Fact-C0D5F9589E725D14B3DE492AFAAAEA7D"
      unitRef="shares">6057000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43690878e2263-wk-Fact-413D25685F8F583AB53236F9F57575B9"
      unitRef="shares">6175000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2017Q3QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockOptionMember"
      decimals="-6"
      id="d43690878e2294-wk-Fact-B667DEF994C657D2B861FFE60640D001"
      unitRef="shares">47000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2016Q3QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockOptionMember"
      decimals="-6"
      id="d43690878e2313-wk-Fact-5342CFBA0356578DAD0043F0EADED8C5"
      unitRef="shares">38000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2017Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockOptionMember"
      decimals="-6"
      id="d43690878e2332-wk-Fact-B239C8DE6B03518BA7F0284DE06E3F57"
      unitRef="shares">47000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2016Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockOptionMember"
      decimals="-6"
      id="d43690878e2352-wk-Fact-D0EF06948F015270863207632A10DE91"
      unitRef="shares">60000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="FD2017Q3YTD"
      id="TextSelection-66B8C111E79C55E1A7A77357A28182A8-0-wk-Fact-27B9A092A14E5E03A0C1180A2C115DE3">&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;Commitments and Contingencies&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt; &lt;/span&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We and certain of our subsidiaries are subject to numerous contingencies arising in the ordinary course of business. For a discussion of our tax contingencies, see &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Note 5B.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accelerated share repurchase agreement&#x2013;&#x2013;On February 2, 2017, we entered into an accelerated share repurchase agreement with Citibank to repurchase &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$5 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of our common stock. Pursuant to the terms of the agreement, on February 6, 2017, we paid &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$5 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; to Citibank and received an initial delivery of approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;126 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; shares of our common stock from Citibank at a price of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$31.73&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; per share, which represented, based on the closing price of our common stock on the NYSE on February 2, 2017, approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;80%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of the notional amount of the accelerated share repurchase agreement. On May 16, 2017, the accelerated share repurchase agreement with Citibank was completed, which, per the terms of the agreement, resulted in Citibank owing us a certain number of shares of Pfizer common stock. Pursuant to the agreement&#x2019;s settlement terms, we received an additional &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;24 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; shares of our common stock from Citibank on May 19, 2017. The average price paid for all of the shares delivered under the accelerated share repurchase agreement was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$33.31&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; per share. The common stock received is included in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Treasury Stock&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. This agreement was entered into pursuant to our previously announced share repurchase authorization. At &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;October&#160;1, 2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, our remaining share-purchase authorization was approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$6.4 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Pending approval in the EU of Mylotarg&#x2013;&#x2013;Mylotarg was developed, in part, through a research arrangement with a third party. If Mylotarg is approved in the EU in 2018 for the treatment of acute myeloid leukemia, we will incur an obligation for additional fixed payments over a 10-year period aggregating &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$310 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;A. Legal Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Our non-tax contingencies include, but are not limited to, the following:&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:18px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Patent litigation, which typically involves challenges to the coverage and/or validity of patents on various products, processes or dosage forms. We are the plaintiff in the vast majority of these actions. An adverse outcome in actions in which we are the plaintiff could result in loss of patent protection for a drug, a significant loss of revenues from that drug or impairment of the value of associated assets.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:18px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Product liability and other product-related litigation, which can include personal injury, consumer, off-label promotion, securities, antitrust and breach of contract claims, among others, often involves highly complex issues relating to medical causation, label warnings and reliance on those warnings, scientific evidence and findings, actual, provable injury and other matters.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:18px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Commercial and other matters, which can include merger-related and product-pricing claims and environmental claims and proceedings, can involve complexities that will vary from matter to matter.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:18px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Government investigations, which often are related to the extensive regulation of pharmaceutical companies by national, state and local government agencies in the U.S. and in other countries.&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Certain of these contingencies could result in losses, including damages, fines and/or civil penalties, and/or criminal charges, which could be substantial.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We believe that our claims and defenses in these matters are substantial, but litigation is inherently unpredictable and excessive verdicts do occur. We do not believe that any of these matters will have a material adverse effect on our financial position. However, we could incur judgments, enter into settlements or revise our expectations regarding the outcome of certain matters, and such developments could have a material adverse effect on our results of operations in the period in which the amounts are accrued and/or our cash flows in the period in which the amounts are paid.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We have accrued for losses that are both probable and reasonably estimable. Substantially all of our contingencies are subject to significant uncertainties and, therefore, determining the likelihood of a loss and/or the measurement of any loss can be complex. Consequently, we are unable to estimate the range of reasonably possible loss in excess of amounts accrued. Our assessments are based on estimates and assumptions that have been deemed reasonable by management, but the assessment process relies heavily on estimates and assumptions that may prove to be incomplete or inaccurate, and unanticipated events and circumstances may occur that might cause us to change those estimates and assumptions.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Amounts recorded for legal and environmental contingencies can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The principal pending matters to which we are a party are discussed below. In determining whether a pending matter is a principal matter, we consider both quantitative and qualitative factors in order to assess materiality, such as, among other things, &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;the amount of damages and the nature of any other relief sought in the proceeding, if such damages and other relief are specified; our view of the merits of the claims and of the strength of our defenses; whether the action purports to be, or is, a class action and, if not certified, our view of the likelihood that a class will be certified by the court; the jurisdiction in which the proceeding is pending; any experience that we or, to our knowledge, other companies have had in similar proceedings; whether disclosure of the action would be important to a reader of our financial statements, including whether disclosure might change a reader&#x2019;s judgment about our financial statements in light of all of the information that is available to the reader; the potential impact of the proceeding on our reputation; and the extent of public interest in the matter. In addition, with respect to patent matters in which we are the plaintiff, we consider, among other things, the financial significance of the product protected by the patent. As a result of considering qualitative factors in our determination of principal matters, there are some matters discussed below with respect to which management believes that the likelihood of possible loss in excess of amounts accrued is remote.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;A1. Legal Proceedings&#x2013;&#x2013;Patent Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Like other pharmaceutical companies, we are involved in numerous suits relating to our patents, including but not limited to, those discussed below. Most of the suits involve claims by generic drug manufacturers that patents covering our products, processes or dosage forms are invalid and/or do not cover the product of the generic drug manufacturer. Also, counterclaims, as well as various independent actions, have been filed alleging that our assertions of, or attempts to enforce, patent rights with respect to certain products constitute unfair competition and/or violations of antitrust laws. In addition to the challenges to the U.S. patents on a number of our products that are discussed below, patent rights to certain of our products are being challenged in various other countries. We are also party to other patent damages suits in various jurisdictions pursuant to which generic drug manufacturers, payers, governments or other parties are seeking damages from us for alleged delay of generic entry. Additionally, our licensing and collaboration partners face challenges by generic drug manufacturers to patents covering several of their products that may impact our licenses or co-promotion rights to such products. We also are often involved in other proceedings, such as inter partes review, post-grant review, re-examination or opposition proceedings, before the U.S. Patent and Trademark Office, the European Patent Office, or other foreign counterparts relating to our intellectual property or the intellectual property rights of others. Also, if one of our patents is found to be invalid by such proceedings, generic or competitive products could be introduced into the market resulting in the erosion of sales of our existing products. For example, several of the patents in our pneumococcal vaccine portfolio have been challenged in inter partes review and post-grant review proceedings in the United States. The invalidation of these patents could potentially allow a competitor pneumococcal vaccine into the marketplace. We are also subject to patent litigation pursuant to which one or more third parties seeks damages and/or injunctive relief to compensate for alleged infringement of its patents by our commercial or other activities. For example, our subsidiary, Hospira, is involved in patent and patent-related disputes over its attempts to bring generic pharmaceutical and biosimilar products to market. If one of our marketed products is found to infringe valid patent rights of a third party, such third party may be awarded significant damages, or we may be prevented from further sales of that product. Such damages may be enhanced as much as three-fold in the event that we or one of our subsidiaries, like Hospira, is found to have willfully infringed valid patent rights of a third party.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Actions In Which We Are The Plaintiff&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Bosulif (bosutinib)&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In December 2016, Wyeth LLC, Wyeth Pharmaceuticals Inc., and PF Prism C.V. (collectively, Wyeth) brought a patent-infringement action against Alembic Pharmaceuticals, Ltd, Alembic Pharmaceuticals, Inc. (collectively, Alembic), Sun Pharmaceutical Industries, Inc., and Sun Pharmaceutical Industries Limited (collectively, Sun), in the U.S. District Court for the District of Delaware in connection with abbreviated new drug applications respectively filed with the FDA by Alembic and Sun, each seeking approval to market generic versions of bosutinib. Alembic is challenging patents, which expire in 2026, covering polymorphic forms of bosutinib and methods of treating chronic myelogenous leukemia. Sun is challenging the patent covering polymorphic forms of bosutinib that expires in 2026. In March 2017, Wyeth brought a patent-infringement action against MSN Laboratories Private Limited and MSN Pharmaceuticals, Inc. (collectively, MSN), in the U.S. District Court for the District of Delaware in connection with an abbreviated new drug application filed with the FDA by MSN, seeking approval to market a generic version of bosutinib, and challenging a patent expiring in 2026 covering polymorphic forms of bosutinib. In September 2017, the case against MSN was dismissed. Also, in September 2017, Wyeth brought an additional patent-infringement action against Sun in the U.S. District Court for the District of Delaware asserting the infringement and validity of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;two&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; other patents challenged by Sun, which expire in 2025 and 2026 respectively, covering compositions of bosutinib and methods of treating chronic myelogenous leukemia. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;EpiPen&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In July 2010, King, which we acquired in 2011 and is a wholly-owned subsidiary, brought a patent-infringement action against Sandoz in the U.S. District Court for the District of New Jersey in connection with Sandoz&#x2019;s abbreviated new drug application filed with the FDA seeking approval to market an epinephrine injectable product. Sandoz is challenging patents, which expire in 2025, covering the next-generation autoinjector for use with epinephrine that is sold under the EpiPen brand name.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Flector Patch (diclofenac)&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In October 2015, the owners (Teikoku Seiyaku Co., Ltd. and Altergon SA) of a patent covering Pfizer&#x2019;s Flector Patch product, along with the New Drug Application holder (IBSA Institut Biochemique SA), brought a patent-infringement action against Actavis Laboratories UT, Inc. in the U.S. District Court for the District of Delaware in connection with an abbreviated new drug application filed by Actavis Laboratories UT, Inc. with the FDA requesting approval to launch a generic version of Flector Patch prior to the 2019 expiration of the patent. In August 2016, Pfizer subsidiary Alpharma Pharmaceuticals LLC was added as a plaintiff to the lawsuit. In August 2017, this case was settled on terms not material to Pfizer. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Precedex Premix&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In June 2014,&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Ben Venue Laboratories, Inc. (Ben Venue)&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;notified our subsidiary, Hospira, that it had filed an abbreviated new drug application with the FDA seeking approval to market a generic version of Hospira&#x2019;s premix version of Precedex and containing allegations that a patent relating to the use of Precedex in an intensive care unit setting, which expires in March 2019, was invalid or not infringed. In August 2014, Hospira and Orion Corporation (co-owner of the patent that is the subject of the lawsuit) filed suit against Ben Venue, Hikma Pharmaceuticals PLC (Hikma), and West-Ward Pharmaceutical Corp. in the U.S. District Court for the District of Delaware asserting the validity and infringement of the patent that is the subject of the lawsuit. In October 2014, Eurohealth International Sarl was substituted for Ben Venue and Hikma. In June 2016, this case was settled on terms not material to Pfizer.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In June 2015, Amneal Pharmaceuticals LLC (Amneal) notified Hospira that it had filed an abbreviated new drug application with the FDA seeking approval to market a generic version of Hospira&#x2019;s premix version of Precedex and containing allegations that &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;four&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; patents relating to the Precedex premix formulations and their use, all of which expire in 2032, were invalid or not infringed. In August 2015, Hospira filed suit against Amneal in the U.S. District Court for the District of Delaware asserting the validity and infringement of the patents that are the subject of the lawsuit.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:5pt;"&gt;&lt;span style="font-family:inherit;font-size:5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In December 2015, Fresenius Kabi USA LLC (Fresenius) notified Hospira that it had filed an abbreviated new drug application with the FDA seeking approval to market a generic version of Hospira&#x2019;s premix version of Precedex and containing allegations that &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;four&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; patents relating to the Precedex premix formulations and their use, all of which expire in 2032, were invalid or not infringed. In January 2016, Hospira filed suit against Fresenius in the U.S. District Court for the Northern District of Illinois asserting the validity and infringement of the patents that are the subject of the lawsuit.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:5pt;"&gt;&lt;span style="font-family:inherit;font-size:5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In August 2016, Par Sterile Products, LLC (Par) notified Hospira that it had filed an abbreviated new drug application with the FDA seeking approval to market a generic version of Hospira&#x2019;s premix version of Precedex and containing allegations that &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;four&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; patents relating to the Precedex premix formulations and their use, all of which expire in 2032, were invalid or not infringed. In September 2016, Hospira filed suit against Par in the U.S. District Court for the District of Delaware asserting the validity and infringement of the patents that are the subject of the lawsuit. In December 2016, the case was stayed pending the outcome of Hospira&#x2019;s suit against Amneal (including all appeals).&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Toviaz (fesoterodine)&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We have an exclusive, worldwide license to market Toviaz from UCB Pharma GmbH (UCB), which owns the patents relating to Toviaz.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:5pt;"&gt;&lt;span style="font-family:inherit;font-size:5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Beginning in May 2013, several generic drug manufacturers notified us that they had filed abbreviated new drug applications with the FDA seeking approval to market generic versions of Toviaz and asserting the invalidity, unenforceability and/or non-infringement of all of our patents for Toviaz that are listed in the FDA&#x2019;s list of Approved Drug Products with Therapeutic Equivalence Evaluations, commonly referred to as the &#x201c;Orange Book&#x201d;. Beginning in June 2013, we filed actions against all of those generic drug manufacturers in the U.S. District Court for the District of Delaware, asserting the infringement of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;five&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of the patents for Toviaz: &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;three&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; composition-of-matter patents and a method-of-use patent that expire in 2019 and a patent covering salts of fesoterodine that expires in 2022. In June and July 2015, we settled with &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;four&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of the generic defendants. The trial relating to the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;four&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; remaining defendants occurred in July 2015. In April 2016, the District Court held that the patents that were the subject of the lawsuit were valid and infringed. The defendants&#x2019; deadline to appeal this decision expired in June 2016. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:5pt;"&gt;&lt;span style="font-family:inherit;font-size:5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In December 2014, Mylan Pharmaceuticals, Inc. (Mylan Pharmaceuticals) notified us that it had filed an&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;abbreviated new drug application with the FDA seeking approval to market a generic version of Toviaz and asserting the invalidity, unenforceability and/or non-infringement of all of our patents for Toviaz that are listed in the Orange Book. In January 2015, we filed an action against Mylan Pharmaceuticals in the U.S. District Court for the District of Delaware, asserting the infringement of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;five&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of the &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;patents for Toviaz: &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;three&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; composition-of-matter patents and a method-of-use patent that expire in 2019 and a patent covering salts of fesoterodine that expires in 2022. In January 2017, the District Court issued a verdict finding that the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;five&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; patents that are the subject of the lawsuit are valid and infringed. In August 2017, the District Court issued a written decision consistent with the verdict, finding the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;five&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; patents valid and infringed. In September 2017, Mylan Pharmaceuticals appealed the District Court&#x2019;s decision to the U.S. Court of Appeals for the Federal Circuit.&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:5pt;"&gt;&lt;span style="font-family:inherit;font-size:5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In December 2016, Torrent Pharmaceuticals, Ltd. (Torrent) notified us that it had filed an&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;abbreviated new drug application with the FDA seeking approval to market a generic version of Toviaz and asserting the invalidity, unenforceability and/or non-infringement of all of our patents for Toviaz that are listed in the Orange Book. In February 2017, we filed an action against Torrent in the U.S. District Court for the District of Delaware, asserting the infringement of the same &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;five&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; patents that are the subject of the action against Mylan Pharmaceuticals. In September 2017, this case was dismissed.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Xeljanz (tofacitinib)&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In February 2017, we brought a patent-infringement action against MicroLabs USA Inc. and MicroLabs Ltd. (collectively, MicroLabs) in the U.S. District Court for the District of Delaware asserting the infringement and validity of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;three&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; patents challenged by MicroLabs in its abbreviated new drug application seeking approval to market a generic version of tofacitinib 5 mg tablets. Of the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;three&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; patents that are the subject of the lawsuit, one covers the active ingredient and expires in December 2025, the second covers an enantiomer of tofacitinib and expires in 2022, and the third covers a polymorphic form of tofacitinib and expires in 2023. &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;Three&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; other patents for Xeljanz expiring in December 2020 have not been challenged by MicroLabs.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:5pt;"&gt;&lt;span style="font-family:inherit;font-size:5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Separately, also in February 2017, we brought a patent-infringement action against Sun Pharmaceutical Industries Ltd. in the U.S. District Court for the District of Delaware asserting the infringement and validity of our patent covering a polymorphic form of tofacitinib, expiring in 2023, that was challenged by Sun Pharmaceutical Industries Ltd. in its abbreviated new drug application seeking approval to market a generic version of tofacitinib 11 mg extended release tablets. In November 2017, we brought an additional patent-infringement action against Sun Pharmaceuticals Industries Ltd. in the U.S. District Court for the District of Delaware asserting the infringement and validity of another patent challenged by Sun Pharmaceuticals Industries Ltd, which covers the active ingredient and expires in December 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:5pt;"&gt;&lt;span style="font-family:inherit;font-size:5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In March 2017, we brought a patent-infringement action against Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Ltd. (collectively, Zydus) in the U.S. District Court for the District of Delaware asserting the infringement and validity of the same &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;three&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; patents that are the subject of the action against MicroLabs, which Zydus challenged in its abbreviated new drug application seeking approval to market a generic version of tofacitinib 5 mg tablets.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:5pt;"&gt;&lt;span style="font-family:inherit;font-size:5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Also in March 2017, we brought separate actions in the U.S. District Court for the District of Delaware against Prinston Pharmaceutical Inc., Zhejiang Huahai Pharmaceutical Co., Ltd., Huahai US Inc. and Solco Healthcare US, LLC (collectively Prinston) and against Breckenridge Pharmaceutical Inc., Pensa Pharma S.A. and Laboratorios Del Dr. Esteve, S.A. (collectively Breckenridge) on the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;two&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; patents expiring in 2022 and 2023, respectively, that were challenged by Prinston and Breckenridge in their respective abbreviated new drug applications seeking approval to market generic versions of tofacitinib 5 mg tablets. In October 2017, we brought an additional patent-infringement action against Breckenridge in the U.S. District Court for the District of Delaware asserting the infringement and validity of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;four&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; additional patents challenged by Breckenridge, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;three&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of which expire in December 2020 and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;one&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of which expires in December 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Xtandi (enzalutamide)&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In December 2016, Medivation and Medivation Prostate Therapeutics, Inc. (collectively, the Medivation Group); Astellas Pharma Inc., Astellas US LLC and Astellas Pharma US, Inc. (collectively, Astellas); and The Regents of the University of California filed patent-infringement suits in the U.S. District Court for the District of Delaware against Actavis Laboratories FL, Inc. and Actavis LLC (collectively, Actavis); Zydus; and Apotex Inc. and Apotex Corp. (collectively, Apotex) in connection with those companies&#x2019; respective abbreviated new drug applications filed with the FDA for approval to market generic versions of enzalutamide. The generic manufacturers are challenging patents, which expire as early as 2026, covering enzalutamide and treatments for prostate cancer. In May 2017, the Medivation Group filed a patent-infringement suit against Roxane Laboratories Inc. (Roxane) in the same court in connection with Roxane&#x2019;s abbreviated new drug application with the FDA for approval to market a generic version of enzalutamide. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Matters Involving Our Collaboration/Licensing Partners&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Nexium 24HR (esomeprazole)&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We have an exclusive license from AstraZeneca PLC (AstraZeneca) to market in the U.S. the OTC version of Nexium (Nexium 24HR). Between October 2014 and November 2016, Actavis Laboratories FL, Inc. (Actavis), Andrx Labs, LLC (Andrx), Perrigo Company plc (Perrigo), Lupin Limited, Dr. Reddy&#x2019;s Laboratories, Inc. &amp;amp; Ltd. (Dr. Reddy&#x2019;s), Hetero USA Inc. (Hetero), Aurobindo Pharma USA Inc. (Aurobindo) and Cipla Limited (Cipla) notified us that they had filed abbreviated new drug applications with the FDA seeking approval to market generic versions of Nexium 24HR prior to the expiration of one or more of AstraZeneca&#x2019;s patents listed in the Orange Book for Nexium 24HR. AstraZeneca filed actions against each of these companies in the U.S. District Court for the District of New Jersey asserting infringement of the challenged patents. In March 2017, the cases against Actavis and Andrx were settled on terms not material to Pfizer. In June 2017, the cases against Perrigo, Dr. Reddy&#x2019;s and Lupin Limited were settled on terms not material to Pfizer. In August 2017, the cases against Hetero and Aurobindo were settled on terms not material to Pfizer. In October 2017, AstraZeneca&#x2019;s action against Cipla was settled on terms not material to Pfizer. We were not a party to AstraZeneca&#x2019;s patent-infringement actions.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:5pt;"&gt;&lt;span style="font-family:inherit;font-size:5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Toviaz (fesoterodine)&#x2013;&#x2013;Inter-Partes Reviews&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In January 2016, Mylan Pharmaceuticals and Mylan Laboratories (collectively, Mylan) filed petitions with the U.S. Patent and Trademark Office requesting inter partes reviews of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;five&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of the patents covering fesoterodine, the active ingredient in Toviaz: &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;three&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; composition-of-matter patents and a method-of-use patent that expire in 2019 and a patent covering salts of fesoterodine that expires in 2022. The patents are owned by UCB, and we have an exclusive, worldwide license to market Toviaz from UCB. In July 2016, the Patent Trial and Appeal Board agreed to institute inter partes reviews of all &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;five&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; patents. Amerigen Pharmaceuticals Limited (Amerigen), Alembic Pharmaceuticals Limited and Torrent Pharmaceuticals Limited have joined the inter partes reviews. In July 2017, the U.S. Patent and Trademark Office issued decisions upholding all &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;five&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; patents. In September 2017, Mylan and Amerigen appealed the U.S. Patent and Trademark Office decisions to the U.S. Court of Appeals for the Federal Circuit&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:5pt;"&gt;&lt;span style="font-family:inherit;font-size:5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Eliquis&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In February, March, and April 2017, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;twenty-five&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; generic companies sent BMS Paragraph-IV certification letters informing BMS that they had filed abbreviated new drug applications seeking approval of generic versions of Eliquis, challenging the validity and infringement of one or more of the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;three&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; patents listed in the Orange Book for Eliquis. The patents currently are set to expire in 2019, 2026, and 2031. Eliquis has been jointly developed and is being commercialized by BMS and Pfizer. In April 2017, BMS and Pfizer filed patent-infringement actions against all generic filers in the U.S. District Court for the District of Delaware and the U.S. District Court for the District of West Virginia, asserting that each of the generic companies&#x2019; proposed products would infringe each of the patent(s) that each generic filer challenged. Some generic filers challenged only the 2031 patent, some challenged both the 2031 and 2026 patent, and one generic company challenged all &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;three&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; patents.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:5pt;"&gt;&lt;span style="font-family:inherit;font-size:5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Bavencio (avelumab)&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In July 2017, BMS, E.R. Squibb &amp;amp; Sons LLC, Ono Pharmaceutical Co. Ltd., and Tasuku Honjo brought a patent-infringement action in the U.S. District Court for the District of Delaware against Pfizer, Merck KGaA, and EMD Serono, alleging that Bavencio (avelumab) infringes &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;one&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; patent relating to methods for treating tumors with anti-PD-L1 antibodies, which expires in 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Actions In Which We Are The Defendant&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Inflectra (infliximab-dyyb)&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In March 2015, Janssen and New York University, together, brought a patent-infringement action in the U.S. District Court for the District of Massachusetts against Hospira, Celltrion Healthcare Co. Ltd. and Celltrion Inc. alleging that infliximab-dyyb, to be marketed by Hospira in the U.S. under the brand name Inflectra, would infringe &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;six&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; patents relating to infliximab, its manufacture and use. Claims with respect to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;four&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of the patents have since been dismissed by the plaintiffs, leaving &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;two&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; patents at issue in the ongoing action: the infliximab antibody patent and a patent relating to cell culture media. In August 2016, the U.S. District Court for the District of Massachusetts ruled that the antibody patent was invalid, and Janssen has appealed that ruling to the Court of Appeals for the Federal Circuit. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;A2. Legal Proceedings&#x2013;&#x2013;Product Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Like other pharmaceutical companies, we are defendants in numerous cases, including but not limited to those discussed below, related to our pharmaceutical and other products. Plaintiffs in these cases seek damages and other relief on various grounds for alleged personal injury and economic loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Asbestos&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Between 1967 and 1982, Warner-Lambert owned American Optical Corporation, which manufactured and sold respiratory protective devices and asbestos safety clothing. In connection with the sale of American Optical in 1982, Warner-Lambert agreed to indemnify the purchaser for certain liabilities, including certain asbestos-related and other claims. As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;October&#160;1, 2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;56,500&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; claims naming American Optical and numerous other defendants were pending in various federal and state courts seeking damages for alleged personal injury from exposure to asbestos and other allegedly hazardous materials. Warner-Lambert was acquired by Pfizer in 2000 and is a wholly-owned subsidiary of Pfizer. Warner-Lambert is actively engaged in the defense of, and will continue to explore various means of resolving, these claims.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:5pt;"&gt;&lt;span style="font-family:inherit;font-size:5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Numerous lawsuits are pending against Pfizer in various federal and state courts seeking damages for alleged personal injury from exposure to products allegedly containing asbestos and other allegedly hazardous materials sold by Pfizer and certain of its previously owned subsidiaries.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;There also are a small number of lawsuits pending in various federal and state courts seeking damages for alleged exposure to asbestos in facilities owned or formerly owned by Pfizer or its subsidiaries.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:5pt;"&gt;&lt;span style="font-family:inherit;font-size:5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Effexor&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:18px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Personal Injury Actions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:4px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;A number of individual lawsuits and multi-plaintiff lawsuits have been filed against us and/or our subsidiaries in various federal and state courts alleging personal injury as a result of the purported ingestion of Effexor. Among other types of actions, the Effexor personal injury litigation includes actions alleging a variety of birth defects as a result of the purported ingestion of Effexor by women during pregnancy. Plaintiffs in these birth-defect actions seek compensatory and punitive damages. In August 2013, the federal birth-defect cases were transferred for consolidated pre-trial proceedings to a Multi-District Litigation (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;In re Effexor&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Venlafaxine Hydrochloride) Products Liability Litigation MDL-2458&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;) in the U.S. District Court for the Eastern District of Pennsylvania. Almost all plaintiffs have voluntarily dismissed their actions. The Multi-District Litigation, as well as the coordinated state court proceedings in California, has been administratively stayed. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:5pt;"&gt;&lt;span style="font-family:inherit;font-size:5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:18px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Antitrust Actions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:4px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Beginning in May 2011, actions, including purported class actions, were filed in various federal courts against Wyeth and, in certain of the actions, affiliates of Wyeth and certain other defendants relating to Effexor XR, which is the extended-release formulation of Effexor. The plaintiffs in each of the class actions seek to represent a class consisting of all persons in the U.S. and its territories who directly purchased, indirectly purchased or reimbursed patients for the purchase of Effexor XR or generic Effexor XR from any of the defendants from June 14, 2008 until the time the defendants&#x2019; allegedly unlawful conduct ceased. The plaintiffs in all of the actions allege delay in the launch of generic Effexor XR in the U.S. and its territories, in violation of federal antitrust laws and, in certain of the actions, the antitrust, consumer protection and various other laws of certain states, as the result of Wyeth fraudulently obtaining and improperly listing certain patents for Effexor XR in the Orange Book, enforcing certain patents for Effexor XR and entering into a litigation settlement agreement with a generic drug manufacturer with respect to Effexor XR. Each of the plaintiffs seeks treble damages (for itself in the individual actions or on behalf of the putative class in the purported class actions) for alleged price overcharges for Effexor XR or generic Effexor XR in the U.S. and its territories since June 14, 2008. All of these actions have been consolidated in the U.S. District Court for the District of New Jersey. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In October 2014, the District Court dismissed the direct purchaser plaintiffs&#x2019; claims based on the litigation settlement agreement but declined to dismiss the other direct purchaser plaintiff claims. In January 2015, the District Court entered partial final judgments as to all settlement agreement claims, including those asserted by direct purchasers and end-payer plaintiffs, which plaintiffs appealed to the U.S. Court of Appeals for the Third Circuit. In August 2017, the U.S. Court of Appeals for the Third Circuit reversed the District Court&#x2019;s decisions and remanded the claims to the District Court. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Zoloft&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;A number of individual lawsuits and multi-plaintiff lawsuits have been filed against us and/or our subsidiaries in various federal and state courts alleging personal injury as a result of the purported ingestion of Zoloft. Among other types of actions, the Zoloft personal injury litigation includes actions alleging a variety of birth defects as a result of the purported ingestion of Zoloft by women during pregnancy. Plaintiffs in these birth-defect actions seek compensatory and punitive damages and the disgorgement of profits resulting from the sale of Zoloft. In April 2012, the federal birth-defect cases were transferred for consolidated pre-trial proceedings to a Multi-District Litigation (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;In re Zoloft Products Liability Litigation MDL-2342&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;) in the &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;U.S. District Court for the Eastern District of Pennsylvania. A number of plaintiffs have voluntarily dismissed their actions. In April 2016, the District Court granted our motion for summary judgment, dismissing the claims of almost all of the remaining plaintiffs. In May 2016, the plaintiffs appealed the District Court&#x2019;s decision to the U.S. Court of Appeals for the Third Circuit. In June 2017, the U.S. Court of Appeals for the Third Circuit affirmed the District Court&#x2019;s decision.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Lipitor&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:18px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Antitrust Actions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:4px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Beginning in November 2011, purported class actions relating to Lipitor were filed in various federal courts against, among others, Pfizer, certain affiliates of Pfizer, and, in most of the actions, Ranbaxy, Inc. (Ranbaxy) and certain affiliates of Ranbaxy. The plaintiffs in these various actions seek to represent nationwide, multi-state or statewide classes consisting of persons or entities who directly purchased, indirectly purchased or reimbursed patients for the purchase of Lipitor (or, in certain of the actions, generic Lipitor) from any of the defendants from March 2010 until the cessation of the defendants&#x2019; allegedly unlawful conduct (the Class Period). The plaintiffs allege delay in the launch of generic Lipitor, in violation of federal antitrust laws and/or state antitrust, consumer protection and various other laws, resulting from (i) the 2008 agreement pursuant to which Pfizer and Ranbaxy settled certain patent litigation involving Lipitor, and Pfizer granted Ranbaxy a license to sell a generic version of Lipitor in various markets beginning on varying dates, and (ii) in certain of the actions, the procurement and/or enforcement of certain patents for Lipitor. Each of the actions seeks, among other things, treble damages on behalf of the putative class for alleged price overcharges for Lipitor (or, in certain of the actions, generic Lipitor) during the Class Period. In addition, individual actions have been filed against Pfizer, Ranbaxy and certain of their affiliates, among others, that assert claims and seek relief for the plaintiffs that are substantially similar to the claims asserted and the relief sought in the purported class actions described above. These various actions have been consolidated for pre-trial proceedings in a Multi-District Litigation (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;In re Lipitor Antitrust Litigation MDL-2332&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;) in the U.S. District&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;color:#0000ff;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Court for the District of New Jersey. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:4px;font-size:5pt;"&gt;&lt;span style="font-family:inherit;font-size:5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In September 2013 and 2014, the District Court dismissed with prejudice the claims by direct purchasers. In October and November 2014, the District Court dismissed with prejudice the claims of all other Multi-District Litigation plaintiffs. All plaintiffs have appealed the District Court&#x2019;s orders dismissing their claims with prejudice to the U.S. Court of Appeals for the Third Circuit. In addition, the direct purchaser class plaintiffs appealed the order denying their motion to amend the judgment and for leave to amend their complaint to the U.S. Court of Appeals for the Third Circuit. In August 2017, the U.S. Court of Appeals for the Third Circuit reversed the District Court&#x2019;s decisions and remanded substantially all of the claims to the District Court.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:5pt;"&gt;&lt;span style="font-family:inherit;font-size:5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Also, in January 2013, the State of West Virginia filed an action in West Virginia state court against Pfizer and Ranbaxy, among others, that asserts claims and seeks relief on behalf of the State of West Virginia and residents of that state that are substantially similar to the claims asserted and the relief sought in the purported class actions described above.&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:18px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Personal Injury Actions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;A number of individual and multi-plaintiff lawsuits have been filed against us in various federal and state courts alleging that the plaintiffs developed type 2 diabetes as a result of the purported ingestion of Lipitor. Plaintiffs seek compensatory and punitive damages. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In February 2014, the federal actions were transferred for consolidated pre-trial proceedings to a Multi-District Litigation (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;In re Lipitor (Atorvastatin Calcium) Marketing, Sales Practices and Products Liability Litigation (No. II) MDL-2502&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;) in the U.S. District Court for the District of South Carolina. Since 2016, certain cases in the Multi-District Litigation were remanded to certain state courts. In January 2017, the District Court granted our motion for summary judgment, dismissing substantially all of the remaining cases pending in the Multi-District Litigation. In January 2017, the plaintiffs appealed the District Court&#x2019;s decision to the U.S. Court of Appeals for the Fourth Circuit.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Viagra&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;A number of individual and multi-plaintiff lawsuits have been filed against us in various federal and state courts alleging that the plaintiffs developed melanoma and/or the exacerbation of melanoma as a result of the purported ingestion of Viagra. Plaintiffs seek compensatory and punitive damages. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In April 2016, the federal actions were transferred for coordinated pre-trial proceedings to a Multi-District Litigation (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;In Re: Viagra (Sildenafil Citrate) Products Liability Litigation, MDL-2691&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;) in the U.S. District Court for the Northern District of California. In December 2016, federal actions filed against Lilly and filed against both us and Lilly, were transferred for coordinated pre-trial proceedings to the Multi-District Litigation (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;In re: Viagra (Sildenafil Citrate) and Cialis (Tadalafil) Products Liability Litigation, MDL-2691&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;).&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Celebrex&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Beginning in July 2014, purported class actions were filed in the U.S. District Court for the Eastern District of Virginia against Pfizer and certain subsidiaries of Pfizer relating to Celebrex. The plaintiffs seek to represent U.S. nationwide or multi-state classes consisting of persons or entities who directly purchased from the defendants, or indirectly purchased or reimbursed patients for some or all of the purchase price of, Celebrex or generic Celebrex from May 31, 2014 until the cessation of the defendants&#x2019; allegedly unlawful conduct. The plaintiffs allege delay in the launch of generic Celebrex in violation of federal antitrust laws or certain state antitrust, consumer protection and various other laws as a result of Pfizer fraudulently obtaining and improperly listing a patent on Celebrex, engaging in sham litigation and prolonging the impact of sham litigation through settlement activity that further delayed generic entry. Each of the actions seeks treble damages on behalf of the putative class for alleged price overcharges for Celebrex since May 31, 2014. In December 2014, the District Court granted the parties&#x2019; joint motions to consolidate the direct purchaser and end-payer cases, and all such cases were consolidated as of March 2015. In October 2014 and March 2015, we filed motions to dismiss the direct purchasers&#x2019; and end-payers&#x2019; amended complaints, respectively. In November 2015, the District Court denied in part and granted in part our motion to dismiss the direct purchasers&#x2019; amended complaint. In February 2016, the District Court denied in part and granted in part our motion to dismiss the end-payers&#x2019; amended complaint, and in August 2016, the District Court dismissed substantially all of the end-payer&#x2019;s remaining claims. In February 2017, the District Court dismissed with prejudice all of the end-payers&#x2019; claims. In March 2017, the end-payers appealed the District Court&#x2019;s order dismissing their claims with prejudice to the U.S. Court of Appeals for the Fourth Circuit. In August 2017, the District Court granted the direct purchasers&#x2019; motion for class certification. In October 2017, Pfizer and the direct purchasers entered into an agreement-in-principle, which is subject to the negotiation of a final settlement agreement and court approval, to resolve the direct purchasers&#x2019; class action for &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$94 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Intravenous Solutions&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Beginning in November 2016, purported class actions were filed in the U.S. District Court for the Northern District of Illinois against Hospira, Hospira Worldwide, Inc. and certain other defendants relating to intravenous saline solution. Plaintiffs seek to represent classes consisting of all persons and entities in the U.S. who directly purchased intravenous saline solution sold by any of the defendants from January 1, 2013 until the time the defendants&#x2019; allegedly unlawful conduct ceases. Plaintiffs allege that the defendants&#x2019; conduct restricts output and artificially fixes, raises, maintains and/or stabilizes the prices of intravenous saline solution sold throughout the U.S. in violation of federal antitrust laws. Plaintiffs seek treble damages (for themselves and on behalf of the putative classes) and an injunction against defendants for alleged price overcharges for intravenous saline solution in the U.S. since January 1, 2013. On February 3, 2017, we completed the sale of our global infusion therapy net assets, HIS, which includes intravenous saline solution, to ICU Medical. The litigation is the subject of cross-claims for indemnification by both Pfizer and ICU Medical under the purchase agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Separately, in April 2017, Pfizer, Hospira and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;two&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; employees of Pfizer received grand jury subpoenas issued by the United States District Court for the Eastern District of Pennsylvania, in connection with an investigation by the U.S. Department of Justice, Antitrust Division. The subpoenas seek documents related to the sale, manufacture, pricing and shortages of intravenous solutions, including saline, as well as communications among market participants regarding these issues. The Department of Justice investigation is also the subject of cross-claims for indemnification by both Pfizer and ICU Medical under the purchase agreement. In addition, in August 2015, the New York Attorney General issued a subpoena to Hospira for similar information. Hospira has produced records to the New York Attorney General and will coordinate with ICU Medical to produce records to the New York Attorney General as appropriate going forward, and Hospira and Pfizer will coordinate with ICU Medical to produce records to the Department of Justice.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Hormone Therapy Consumer Class Action&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;A certified consumer class action is pending against Wyeth in the U.S. District Court for the Southern District of California based on the alleged off-label marketing of its hormone therapy products. The case was originally filed in December 2003. The class consists of California consumers who purchased Wyeth&#x2019;s hormone-replacement products between January 1995 and January 2003 and who do not seek personal injury damages therefrom. The class seeks compensatory and punitive damages, including a full refund of the purchase price.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Eliquis&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;A number of individual and multi-plaintiff lawsuits have been filed against us and Bristol-Myers Squibb Company in various federal and state courts pursuant to which plaintiffs seek to recover for personal injuries, including wrongful death, due to bleeding as a result of the alleged ingestion of Eliquis. Plaintiffs seek compensatory and punitive damages.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In February 2017, the federal actions were transferred for coordinated pre-trial proceedings to a Multi-District Litigation (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;In Re: Eliquis (Apixaban) Products Liability Litigation MDL-2754&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;) in the U.S. District Court for the Southern District of New York. In July 2017, the District Court dismissed substantially all of the actions that were pending in the Multi-District Litigation. In &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;August 2017, certain plaintiffs appealed the District Court&#x2019;s dismissal to the U.S. Court of Appeals for the Second Circuit. Additional cases continue to be transferred to the Multi-District Litigation.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;EpiPen&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Beginning in February 2017, purported class actions were filed in various federal courts by indirect purchasers of EpiPen against Pfizer, and/or its affiliates King and Meridian, and/or various entities affiliated with Mylan N.V., and Mylan N.V. Chief Executive Officer, Heather Bresch. The plaintiffs in these actions seek to represent U.S. nationwide classes comprising persons or entities who paid for any portion of the end-user purchase price of an EpiPen between 2009 until the cessation of the defendants&#x2019; allegedly unlawful conduct. In August 2017, a similar lawsuit brought on behalf of a purported class of direct purchaser plaintiffs against Pfizer, King, Meridian and Mylan was voluntarily dismissed without prejudice. Against Pfizer and/or its affiliates, plaintiffs generally allege that Pfizer&#x2019;s and/or its affiliates&#x2019; settlement of patent litigation regarding EpiPen delayed market entry of generic EpiPen in violation of federal antitrust laws and various state antitrust or consumer protection laws. At least one lawsuit also alleges that Pfizer and/or Mylan N.V. violated the federal Racketeer Influenced and Corrupt Organizations Act. Plaintiffs also filed various consumer protection and unjust enrichment claims against, and relating to conduct attributable solely to, Mylan Pharmaceuticals regarding EpiPen. Plaintiffs seek treble damages for alleged overcharges for EpiPen since 2009. In August 2017, the actions were consolidated for coordinated pre-trial proceedings in a Multi-District Litigation (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;In re: EpiPen (Epinephrine Injection, USP) Marketing, Sales Practices and Antitrust Litigation&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, MDL-2785) in the U.S. District Court for the District of Kansas with other EpiPen-related actions against Mylan N.V. and/or its affiliates to which Pfizer, King and Meridian are not parties.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Nexium 24HR and Protonix&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;A number of individual and multi-plaintiff lawsuits have been filed against Pfizer, certain of its subsidiaries and/or other pharmaceutical manufacturers in various federal and state courts alleging that the plaintiffs developed kidney-related injuries as a result of the purported ingestion of certain proton pump inhibitors. The cases against us involve Nexium 24HR and/or Protonix and seek compensatory and punitive damages and, in some cases, treble damages, restitution or disgorgement. In August 2017, the federal actions were ordered transferred for coordinated pre-trial proceedings to a Multi-District Litigation (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;In re: Proton-Pump Inhibitor Products Liability Litigation&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; (No. II)) in the U.S. District Court for the District of New Jersey.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Docetaxel&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;A number of lawsuits have been filed against Hospira and Pfizer in various federal and state courts alleging that plaintiffs who were treated with Docetaxel developed permanent hair loss. The significant majority of the cases also name other defendants, including the manufacturer of the branded product, Taxotere. Plaintiffs seek compensatory and punitive damages.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In October 2016, the federal cases were transferred for coordinated pre-trial proceedings to a Multi-District Litigation (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;In re Taxotere (Docetaxel) Products Liability Litigation&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, MDL-2740) in the U.S. District Court for the Eastern District of Louisiana.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;A3. Legal Proceedings&#x2013;&#x2013;Commercial and Other Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Average Wholesale Price Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Pfizer, certain of its subsidiaries and other pharmaceutical manufacturers were sued in various state courts by a number of states alleging that the defendants provided average wholesale price (AWP) information for certain of their products that was higher than the actual average prices at which those products were sold. The AWP is used to determine reimbursement levels under Medicare Part B and Medicaid and in many private-sector insurance policies and medical plans. All but &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;one&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of those actions have been resolved through settlement, dismissal or final judgment. The plaintiff state, Illinois,&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;color:#ff0000;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;in the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;one&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; remaining action claims that the alleged spread between the AWPs at which purchasers were reimbursed and the actual sale prices was promoted by the defendants as an incentive to purchase certain of their products. The action&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;color:#ff0000;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;alleges, among other things, fraud&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;color:#ff0000;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;and violation of the state&#x2019;s unfair trade practices and&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;color:#ff0000;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;consumer protection statutes and seeks monetary and other relief, including civil penalties and treble damages.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Monsanto-Related Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In 1997, Monsanto Company (Former Monsanto) contributed certain chemical manufacturing operations and facilities to a newly formed corporation, Solutia Inc. (Solutia), and spun off the shares of Solutia. In 2000, Former Monsanto merged with Pharmacia &amp;amp; Upjohn Company to form Pharmacia. Pharmacia then transferred its agricultural operations to a newly created subsidiary, named Monsanto Company (New Monsanto), which it spun off in a two-stage process that was completed in 2002. Pharmacia was acquired by Pfizer in 2003 and is a wholly-owned subsidiary of Pfizer.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In connection with its spin-off that was completed in 2002, New Monsanto assumed, and agreed to indemnify Pharmacia for, any liabilities related to Pharmacia&#x2019;s former agricultural business. New Monsanto has defended and/or is defending Pharmacia in connection with various claims and litigation arising out of, or related to, the agricultural business, and has been indemnifying Pharmacia when liability has been imposed or settlement has been reached regarding such claims and litigation.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In connection with its spin-off in 1997, Solutia assumed, and agreed to indemnify Pharmacia for, liabilities related to Former Monsanto&#x2019;s chemical businesses. As the result of its reorganization under Chapter 11 of the U.S. Bankruptcy Code, Solutia&#x2019;s indemnification obligations relating to Former Monsanto&#x2019;s chemical businesses are primarily limited to sites that Solutia has owned or operated. In addition, in connection with its spinoff that was completed in 2002, New Monsanto assumed, and agreed to indemnify Pharmacia for, any liabilities primarily related to Former Monsanto&#x2019;s chemical businesses, including, but not limited to, any such liabilities that Solutia assumed. Solutia&#x2019;s and New Monsanto&#x2019;s assumption of, and agreement to, indemnify Pharmacia for these liabilities apply to pending actions and any future actions related to Former Monsanto&#x2019;s chemical businesses in which Pharmacia is named as a defendant, including, without limitation, actions asserting environmental claims, including alleged exposure to polychlorinated biphenyls. Solutia and/or New Monsanto are defending Pharmacia in connection with various claims and litigation arising out of, or related to, Former Monsanto&#x2019;s chemical businesses, and have been indemnifying Pharmacia when liability has been imposed or settlement has been reached regarding such claims and litigation.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Environmental Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In 2009, we submitted to the U.S. Environmental Protection Agency (EPA) a corrective measures study report with regard to Pharmacia&#x2019;s discontinued industrial chemical facility in North Haven, Connecticut and a revised site-wide feasibility study with regard to Wyeth Holdings Corporation&#x2019;s discontinued industrial chemical facility in Bound Brook, New Jersey. In September 2010, our corrective measures study report with regard to the North Haven facility was approved by the EPA, and we commenced construction of the site remedy in late 2011 under an Updated Administrative Order on Consent with the EPA. In July 2011, Wyeth Holdings Corporation finalized an Administrative Settlement Agreement and Order on Consent for Removal Action (the 2011 Administrative Settlement Agreement) with the EPA with regard to the Bound Brook facility. In May 2012, we completed construction of an interim remedy to address the discharge of impacted groundwater from that facility to the Raritan River. In September 2012, the EPA issued a final remediation plan for the Bound Brook facility&#x2019;s main plant area, which is generally in accordance with one of the remedies evaluated in our revised site-wide feasibility study. In March 2013, Wyeth Holdings Corporation (now Wyeth Holdings LLC) entered into an Administrative Settlement Agreement and Order on Consent with the EPA to allow us to undertake detailed engineering design of the remedy for the main plant area and to perform a focused feasibility study for &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;two&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; adjacent lagoons. In September 2015, the U.S., on behalf of the EPA, lodged a complaint and consent decree with the federal District Court for the District of New Jersey that will allow Wyeth Holdings LLC to complete the design and to implement the remedy for the main plant area. In December 2015, the consent decree (which supersedes the 2011 Administrative Settlement Agreement) was entered by the District Court. We have accrued for the estimated costs of the site remedy for the North Haven facility and the site remediation for the Bound Brook facility.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:5pt;"&gt;&lt;span style="font-family:inherit;font-size:5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We are a party to a number of other proceedings brought under the Comprehensive Environmental Response, Compensation, and Liability Act of 1980, as amended, and other state, local or foreign laws in which the primary relief sought is the cost of past and/or future remediation.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Contracts with Iraqi Ministry of Health&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In October 2017, a number of United States service members, civilians, and their families brought a complaint against a number of pharmaceutical and medical devices companies, including Pfizer and certain of its subsidiaries, alleging that the defendants violated the United States Anti-Terrorism Act. The complaint alleges that the defendants provided funding for terrorist organizations through their sales practices pursuant to pharmaceutical and medical device contracts with the Iraqi Ministry of Health.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;A4. Legal Proceedings&#x2013;&#x2013;Government Investigations&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Like other pharmaceutical companies, we are subject to investigations and extensive regulation by government agencies in the U.S., other developed markets and multiple emerging markets in which we operate. As a result, we have interactions with government agencies on an ongoing basis. Criminal charges, and substantial fines and/or civil penalties, as well as limitations on our ability to conduct business in applicable jurisdictions, could result from government investigations. Among the investigations by government agencies are the matters discussed below.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Phenytoin Sodium Capsules&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In 2012, Pfizer sold the U.K. Marketing Authorisation for phenytoin sodium capsules to a third party, but retained the right to supply the finished product to that third party. In May 2013, the U.K. Competition &amp;amp; Markets Authority (CMA) informed us that it had launched an investigation into the supply of phenytoin sodium capsules in the U.K. market. In August 2015, the CMA issued a Statement of Objections alleging that Pfizer and Pfizer Limited, a U.K. subsidiary, engaged in conduct that violates U.K. and EU antitrust laws. In December 2016, the CMA imposed a &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;color:#0b0c0c;"&gt;&#xa3;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;84.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; fine on Pfizer and Pfizer Limited. Pfizer appealed the CMA Decision to The Competition Appeal Tribunal in February 2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Civil Investigative Demand relating to Pharmacy Benefit Managers&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In March 2016, Pfizer received a Civil Investigative Demand from the U.S. Attorney&#x2019;s Office for the Southern District of New York related to Pfizer&#x2019;s contractual relationships with pharmacy benefit managers with respect to certain pharmaceutical products over the period from January 1, 2006 to the present. We have provided information to the government in response to this Civil Investigative Demand.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Subpoenas relating to Copayment Assistance Organizations&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In December 2015 and July 2016, Pfizer received subpoenas from the U.S. Attorney&#x2019;s Office for the District of Massachusetts requesting documents related to the Patient Access Network Foundation and other 501(c)(3) organizations that provide financial assistance to Medicare patients. We have been providing information to the government in response to these subpoenas.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;U.S. Department of Justice Investigation relating to Greenstone&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;As of July 2017, the U.S. Department of Justice&#x2019;s Antitrust Division is investigating our Greenstone generics business. We believe this is related to an ongoing antitrust investigation of the generic pharmaceutical industry. The government has been obtaining information from Greenstone.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Intravenous Solutions&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;See &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Note 12A2. Legal Proceedings&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2013;&#x2013;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Product Litigation&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2013;&#x2013;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Intravenous Solutions&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; above for information regarding government investigations related to sales of intravenous solution products.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;A5. Legal Proceedings&#x2013;&#x2013;Matters Resolved During the First &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;Nine Months&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt; of 2017&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;During 2017, certain matters, including the matter discussed below, were resolved or were the subject of definitive settlement agreements or settlement agreements-in-principle.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Xtandi&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In April 2014, the Regents of the University of California (the Regents) filed a complaint against the Medivation Group in California Superior Court in San Francisco. Medivation was acquired by Pfizer in September 2016 and is now a wholly-owned subsidiary of Pfizer. The Regents&#x2019; complaint sought a &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; share, under a license agreement between the Medivation Group and the Regents, of certain payments the Medivation Group receives with respect to Xtandi under the Medivation Group&#x2019;s sub-licensing and collaboration agreement with Astellas. Trial was scheduled to commence in May 2017. In July 2017, the parties resolved the matter through a settlement on terms not material to Pfizer, which was recorded in the second quarter of 2017 as a measurement period adjustment related to the Medivation acquisition.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;B. Guarantees and Indemnifications&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In the ordinary course of business and in connection with the sale of assets and businesses, we often indemnify our counterparties against certain liabilities that may arise in connection with the transaction or related to activities prior to the transaction. These indemnifications typically pertain to environmental, tax, employee and/or product-related matters and patent-infringement claims. If the indemnified party were to make a successful claim pursuant to the terms of the indemnification, we would be required to reimburse the loss. These indemnifications are generally subject to threshold amounts, specified claim periods and other restrictions and limitations. Historically, we have not paid significant amounts under these provisions and, as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;October&#160;1, 2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, recorded amounts for the estimated fair value of these indemnifications were not significant. &lt;/span&gt;&lt;/div&gt;Pfizer Inc. has also guaranteed the long-term debt of certain companies that it acquired and that now are subsidiaries of Pfizer.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="I2017Q1Feb02_us-gaap_ShareRepurchaseProgramAxis_pfe_ShareRepurchaseAgreementwithCitibankMember"
      decimals="INF"
      id="d43707686e645-wk-Fact-BE13D7C1D60C5FF79A853FF26CFA4638"
      unitRef="usd">5000000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:AcceleratedShareRepurchasesSettlementPaymentOrReceipt
      contextRef="I2017Q1Feb06_us-gaap_ShareRepurchaseProgramAxis_pfe_ShareRepurchaseAgreementwithCitibankMember"
      decimals="-9"
      id="d43707686e649-wk-Fact-A3F5302D1FAA5AB49D1B490F7BEB5AB9"
      unitRef="usd">-5000000000</us-gaap:AcceleratedShareRepurchasesSettlementPaymentOrReceipt>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="D2017Q1Feb06-Feb06_us-gaap_ShareRepurchaseProgramAxis_pfe_ShareRepurchaseAgreementwithCitibankMember"
      decimals="-6"
      id="d43707686e653-wk-Fact-8AD53DD45A3D5D6AA1B2FEA1E2C8CA7E"
      unitRef="shares">126000000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:AcceleratedShareRepurchasesInitialPricePaidPerShare
      contextRef="D2017Q1Feb06-Feb06_us-gaap_ShareRepurchaseProgramAxis_pfe_ShareRepurchaseAgreementwithCitibankMember"
      decimals="INF"
      id="d43707686e657-wk-Fact-21884CAAD38C5940A008A86452D48031"
      unitRef="usdPerShare">31.73</us-gaap:AcceleratedShareRepurchasesInitialPricePaidPerShare>
    <pfe:AcceleratedShareRepurchasesSharesRepurchasedDuringPeriodPercentageofAgreementAmount
      contextRef="D2017Q1Feb02-Feb02_us-gaap_ShareRepurchaseProgramAxis_pfe_ShareRepurchaseAgreementwithCitibankMember"
      decimals="2"
      id="d43707686e661-wk-Fact-E11E162A07C854CFBC7C05056862D8CC"
      unitRef="number">0.80</pfe:AcceleratedShareRepurchasesSharesRepurchasedDuringPeriodPercentageofAgreementAmount>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="D2017Q2May19-May19_us-gaap_ShareRepurchaseProgramAxis_pfe_ShareRepurchaseAgreementwithCitibankMember"
      decimals="-6"
      id="d43707686e666-wk-Fact-D750C4F2B63E590F8E54F970CFCFD791"
      unitRef="shares">24000000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="D2017Q2Feb06-May19_us-gaap_ShareRepurchaseProgramAxis_pfe_ShareRepurchaseAgreementwithCitibankMember"
      decimals="2"
      id="d43707686e670-wk-Fact-8E42571D5CEA5C2399EC72D3C489EEF3"
      unitRef="usdPerShare">33.31</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1
      contextRef="FI2017Q3_us-gaap_ShareRepurchaseProgramAxis_pfe_ShareRepurchaseAgreementwithCitibankMember"
      decimals="-8"
      id="d43707686e682-wk-Fact-A96737DE25D05E9E9E87B3E1D0D83CE0"
      unitRef="usd">6400000000</us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1>
    <pfe:ResearchandDevelopmentArrangementAggregatePaymentObligation
      contextRef="FI2017Q3_us-gaap_ProductOrServiceAxis_pfe_MylotargMember_us-gaap_StatementScenarioAxis_us-gaap_ProFormaMember"
      decimals="-6"
      id="d43707686e689-wk-Fact-8BBD252B838276FE62847E0EE6C2B52D"
      unitRef="usd">310000000</pfe:ResearchandDevelopmentArrangementAggregatePaymentObligation>
    <us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber
      contextRef="D2017Q3Sep01-Sep30_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationCaseAxis_pfe_WyethVersusSunMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_ProductOrServiceAxis_pfe_BosulifMember"
      decimals="INF"
      id="d43707686e782-wk-Fact-C8E2AFCA1B38D14844F19D7928EB1D5D"
      unitRef="Patent">2</us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber>
    <us-gaap:GainContingencyPatentsFoundNotInfringedUponNumber
      contextRef="D2015Q2June2015_us-gaap_LitigationCaseAxis_pfe_HospiraVersusAmnealPharmaceuticalsLLCMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_ProductOrServiceAxis_pfe_PrecedexPremixMember"
      decimals="INF"
      id="d43707686e816-wk-Fact-F836B59EF1E6523A93483B8C479F540F"
      unitRef="Patent">4</us-gaap:GainContingencyPatentsFoundNotInfringedUponNumber>
    <us-gaap:GainContingencyPatentsFoundNotInfringedUponNumber
      contextRef="D2015Q4_us-gaap_LitigationCaseAxis_pfe_HospiraVersusFreseniusMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_ProductOrServiceAxis_pfe_PrecedexPremixMember"
      decimals="INF"
      id="d43707686e825-wk-Fact-9B87954E679D58C79D73CE7D945E50CC"
      unitRef="Patent">4</us-gaap:GainContingencyPatentsFoundNotInfringedUponNumber>
    <us-gaap:GainContingencyPatentsFoundNotInfringedUponNumber
      contextRef="D2016Q3Aug01-Aug31_us-gaap_LitigationCaseAxis_pfe_HospiraVersusParMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_ProductOrServiceAxis_pfe_PrecedexPremixMember"
      decimals="INF"
      id="d43707686e834-wk-Fact-6510AC1D5754580B84274EACDF64E139"
      unitRef="Patent">4</us-gaap:GainContingencyPatentsFoundNotInfringedUponNumber>
    <us-gaap:GainContingencyPatentsFoundInfringedUponNumber
      contextRef="D2013Q2MonthofJune_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationCaseAxis_pfe_PfizerVersusMylanLaboratoriesandAccordHealthcareInc.Member_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_ProductOrServiceAxis_pfe_ToviazMember"
      decimals="INF"
      id="d43707686e850-wk-Fact-3E0BD8FE7B39597EA628675F2C76844D"
      unitRef="Patent">5</us-gaap:GainContingencyPatentsFoundInfringedUponNumber>
    <us-gaap:GainContingencyPatentsFoundInfringedUponNumber
      contextRef="D2013Q2MonthofJune_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationCaseAxis_pfe_PfizerVersusSeveralGenericManufacturersMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_ProductOrServiceAxis_pfe_ToviazCompositionofmatterPatentsMember"
      decimals="INF"
      id="d43707686e854-wk-Fact-3224E869B20A571898DF7DD0FB349424"
      unitRef="Patent">3</us-gaap:GainContingencyPatentsFoundInfringedUponNumber>
    <pfe:GainContingencyNumberofDefendants
      contextRef="D2015Q1SD_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationCaseAxis_pfe_PfizerVersusSeveralGenericManufacturersMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_us-gaap_ProductOrServiceAxis_pfe_ToviazMember"
      decimals="INF"
      id="d43707686e858-wk-Fact-E42DF851A7915AAC8FEEC578D4CA849C"
      unitRef="Defendant">4</pfe:GainContingencyNumberofDefendants>
    <pfe:GainContingencyNumberofDefendants
      contextRef="D2015Q3July2015_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationCaseAxis_pfe_PfizerVersusSeveralGenericManufacturersMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_ProductOrServiceAxis_pfe_ToviazMember"
      decimals="INF"
      id="d43707686e862-wk-Fact-47B6716DC5EE5CDE99EFE7EAD7231169"
      unitRef="Defendant">4</pfe:GainContingencyNumberofDefendants>
    <us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber
      contextRef="D2015Q1MonthOfJanuary_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationCaseAxis_pfe_PfizerVersusMylanLaboratoriesandAccordHealthcareInc.Member_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_ProductOrServiceAxis_pfe_ToviazMember"
      decimals="INF"
      id="d43707686e875-wk-Fact-CD087C72236253F0BE5CB2C866CC4CC9"
      unitRef="Patent">5</us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber>
    <us-gaap:GainContingencyPatentsFoundInfringedUponNumber
      contextRef="D2015Q1Jan1-31_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationCaseAxis_pfe_PfizerVersusMylanLaboratoriesandAccordHealthcareInc.Member_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_ProductOrServiceAxis_pfe_ToviazCompositionofmatterPatentsMember"
      decimals="INF"
      id="d43707686e882-wk-Fact-9B9FE860AB7B50C49B571A07FD7E0DDF"
      unitRef="Patent">3</us-gaap:GainContingencyPatentsFoundInfringedUponNumber>
    <us-gaap:GainContingencyPatentsFoundInfringedUponNumber
      contextRef="D2017Q1Jan01-Jan31_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationCaseAxis_pfe_PfizerVersusMylanLaboratoriesandAccordHealthcareInc.Member_us-gaap_LitigationStatusAxis_us-gaap_JudicialRulingMember_us-gaap_ProductOrServiceAxis_pfe_ToviazMember"
      decimals="INF"
      id="d43707686e886-wk-Fact-F05CEC43CAA05EBB93B0C39B4E9A2F6C"
      unitRef="Patent">5</us-gaap:GainContingencyPatentsFoundInfringedUponNumber>
    <us-gaap:GainContingencyPatentsFoundInfringedUponNumber
      contextRef="D2017Q3Aug01-Aug10_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationCaseAxis_pfe_PfizerVersusMylanLaboratoriesandAccordHealthcareInc.Member_us-gaap_LitigationStatusAxis_us-gaap_JudicialRulingMember_us-gaap_ProductOrServiceAxis_pfe_ToviazMember"
      decimals="INF"
      id="d43707686e890-wk-Fact-82C1AE73C31F5512A6DC0E04B6CBFDF0"
      unitRef="Patent">5</us-gaap:GainContingencyPatentsFoundInfringedUponNumber>
    <us-gaap:GainContingencyPatentsFoundInfringedUponNumber
      contextRef="D2017Q1Feb01-Feb28_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationCaseAxis_pfe_PfizerVersusMylanLaboratoriesandAccordHealthcareInc.Member_us-gaap_LitigationStatusAxis_us-gaap_JudicialRulingMember_us-gaap_ProductOrServiceAxis_pfe_ToviazMember"
      decimals="INF"
      id="d43707686e905-wk-Fact-DCE6E43BA9085B46AAF7CA7AEB3D8E0A"
      unitRef="Patent">5</us-gaap:GainContingencyPatentsFoundInfringedUponNumber>
    <us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber
      contextRef="D2017Q1Feb01-Feb28_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationCaseAxis_pfe_PfizerVersusMicroLabsMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_ProductOrServiceAxis_pfe_XeljanzMember"
      decimals="INF"
      id="d43707686e915-wk-Fact-3B7C7BE1ED075C00B0637749F3A5B24F"
      unitRef="Patent">3</us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber>
    <us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber
      contextRef="D2017Q1Feb01-Feb28_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationCaseAxis_pfe_PfizerVersusMicroLabsMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_ProductOrServiceAxis_pfe_XeljanzMember"
      decimals="INF"
      id="d43707686e919-wk-Fact-3B7C7BE1ED075C00B0637749F3A5B24F"
      unitRef="Patent">3</us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber>
    <us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber
      contextRef="D2017Q1Feb01-Feb28_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationCaseAxis_pfe_PfizerVersusMicroLabsMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_ProductOrServiceAxis_pfe_XeljanzMember"
      decimals="INF"
      id="d43707686e923-wk-Fact-3B7C7BE1ED075C00B0637749F3A5B24F"
      unitRef="Patent">3</us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber>
    <us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber
      contextRef="D2017Q1Mar01-Mar31_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationCaseAxis_pfe_PfizerVersusZydusMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_ProductOrServiceAxis_pfe_XeljanzMember"
      decimals="INF"
      id="d43707686e938-wk-Fact-CFDD2F198A3450C8A311ED1ADA364BFB"
      unitRef="Patent">3</us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber>
    <us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber
      contextRef="D2017Q1Mar01-Mar31_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationCaseAxis_pfe_PfizerVersusPrinstonandBreckenridgeMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_ProductOrServiceAxis_pfe_XeljanzMember"
      decimals="INF"
      id="d43707686e947-wk-Fact-0AB4EFF384BE569F8B6BB4992C90BFCB"
      unitRef="Patent">2</us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber>
    <us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber
      contextRef="D2017Q4Oct02-Oct31_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationCaseAxis_pfe_PfizerVersusBreckenridgeMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_ProductOrServiceAxis_pfe_XeljanzMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="d43707686e951-wk-Fact-A56B4A8FF13A028962D79CFB52106DA8"
      unitRef="Patent">4</us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber>
    <pfe:GainContingencyPatentsAllegedlyInfringeduponNumberDuetoExpireinDecember2020
      contextRef="D2017Q4Oct02-Oct31_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationCaseAxis_pfe_PfizerVersusBreckenridgeMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_ProductOrServiceAxis_pfe_XeljanzMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="d43707686e955-wk-Fact-2297A230035623E28B6C9D07DFC63B22"
      unitRef="Patent">3</pfe:GainContingencyPatentsAllegedlyInfringeduponNumberDuetoExpireinDecember2020>
    <pfe:GainContingencyPatentsAllegedlyInfringeduponNumberDuetoExpireinDecember2025
      contextRef="D2017Q4Oct02-Oct31_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationCaseAxis_pfe_PfizerVersusBreckenridgeMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_ProductOrServiceAxis_pfe_XeljanzMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="d43707686e959-wk-Fact-1FC6E796980ABAC596759D09C650A691"
      unitRef="Patent">1</pfe:GainContingencyPatentsAllegedlyInfringeduponNumberDuetoExpireinDecember2025>
    <us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber
      contextRef="D2016Q1Jan2016_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationCaseAxis_pfe_PfizerVersusMylanLaboratoriesandAccordHealthcareInc.Member_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_ProductOrServiceAxis_pfe_ToviazMember"
      decimals="INF"
      id="d43707686e989-wk-Fact-B827DE4CAA695625A887B42190536432"
      unitRef="Patent">5</us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber>
    <us-gaap:GainContingencyPatentsFoundInfringedUponNumber
      contextRef="D2016Q1Jan2016_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationCaseAxis_pfe_PfizerVersusMylanLaboratoriesandAccordHealthcareInc.Member_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_ProductOrServiceAxis_pfe_ToviazCompositionofmatterPatentsMember"
      decimals="INF"
      id="d43707686e993-wk-Fact-1CC84571D7CF59F08C207EDB52CE8144"
      unitRef="Patent">3</us-gaap:GainContingencyPatentsFoundInfringedUponNumber>
    <us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber
      contextRef="D2016Q3Jul01-Jul31_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationCaseAxis_pfe_PfizerVersusMylanLaboratoriesandAccordHealthcareInc.Member_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_ProductOrServiceAxis_pfe_ToviazMember"
      decimals="INF"
      id="d43707686e997-wk-Fact-C2AAE9F2BCE35DBCAADE3B01CFAF2055"
      unitRef="Patent">5</us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber>
    <us-gaap:GainContingencyPatentsFoundNotInfringedUponNumber
      contextRef="D2017Q3Jul01-Jul31_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationCaseAxis_pfe_PfizerVersusMylanLaboratoriesandAccordHealthcareInc.Member_us-gaap_LitigationStatusAxis_us-gaap_JudicialRulingMember_us-gaap_ProductOrServiceAxis_pfe_ToviazMember"
      decimals="INF"
      id="d43707686e1001-wk-Fact-ECE922F44A5155208854AB6F559ACD87"
      unitRef="Patent">5</us-gaap:GainContingencyPatentsFoundNotInfringedUponNumber>
    <pfe:GainContingencyNumberofDefendants
      contextRef="D2017Q2Feb01-Apr30_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationCaseAxis_pfe_PfizerandBMSVersusSeveralGenericManufacturersMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_ProductOrServiceAxis_pfe_EliquisMember"
      decimals="INF"
      id="d43707686e1015-wk-Fact-750640771EAF58C694292FC06FD2EE09"
      unitRef="Defendant">25</pfe:GainContingencyNumberofDefendants>
    <us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber
      contextRef="D2017Q2Feb01-Apr30_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationCaseAxis_pfe_PfizerandBMSVersusSeveralGenericManufacturersMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_ProductOrServiceAxis_pfe_EliquisMember"
      decimals="INF"
      id="d43707686e1019-wk-Fact-BC63078738B9511EA742B4F671C18334"
      unitRef="Patent">3</us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber>
    <us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber
      contextRef="D2017Q2Feb01-Apr30_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationCaseAxis_pfe_PfizerandBMSVersusSeveralGenericManufacturersMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_ProductOrServiceAxis_pfe_EliquisMember"
      decimals="INF"
      id="d43707686e1023-wk-Fact-BC63078738B9511EA742B4F671C18334"
      unitRef="Patent">3</us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber>
    <us-gaap:LossContingencyPatentsAllegedlyInfringedNumber
      contextRef="D2017Q3Jul01-Jul31_us-gaap_LitigationCaseAxis_pfe_PfizerVersusBMSE.R.SquibbSonsOnoPharmaceuticalandTasukuHonjoMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_LossContingenciesByNatureOfContingencyAxis_pfe_PatentInfringementMember_us-gaap_ProductOrServiceAxis_pfe_BavencioMember"
      decimals="INF"
      id="d43707686e1035-wk-Fact-41E085AAF2D45D2FA0940954E181FA2B"
      unitRef="Patent">1</us-gaap:LossContingencyPatentsAllegedlyInfringedNumber>
    <us-gaap:LossContingencyPatentsAllegedlyInfringedNumber
      contextRef="D2015Q1March2015_us-gaap_LitigationCaseAxis_pfe_JanssenandNewYorkUniversityVersusHospiraCelltrionHealthcareandCelltrionInc.Member_us-gaap_ProductOrServiceAxis_pfe_InflectraMember"
      decimals="INF"
      id="d43707686e1049-wk-Fact-83F6C3F97F875EAB83365A740872B386"
      unitRef="Patent">6</us-gaap:LossContingencyPatentsAllegedlyInfringedNumber>
    <us-gaap:LossContingencyClaimsDismissedNumber
      contextRef="D2015Q1March2015_us-gaap_LitigationCaseAxis_pfe_JanssenandNewYorkUniversityVersusHospiraCelltrionHealthcareandCelltrionInc.Member_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_us-gaap_ProductOrServiceAxis_pfe_InflectraMember"
      decimals="INF"
      id="d43707686e1053-wk-Fact-195837297ED85FA8AF050C77B7803645"
      unitRef="Patent">4</us-gaap:LossContingencyClaimsDismissedNumber>
    <us-gaap:LossContingencyPatentsAllegedlyInfringedNumber
      contextRef="D2015Q1March2015_us-gaap_LitigationCaseAxis_pfe_JanssenandNewYorkUniversityVersusHospiraCelltrionHealthcareandCelltrionInc.Member_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_ProductOrServiceAxis_pfe_InflectraMember"
      decimals="INF"
      id="d43707686e1057-wk-Fact-08744C5FDA975D9FAD7578D35D75C22D"
      unitRef="Patent">2</us-gaap:LossContingencyPatentsAllegedlyInfringedNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="FI2017Q3_us-gaap_LitigationCaseAxis_pfe_ClassActionVersusAmericanOpticalCorporationAndVariousOtherDefendantsMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_LossContingenciesByNatureOfContingencyAxis_us-gaap_DamagesFromProductDefectsMember"
      decimals="0"
      id="d43707686e1079-wk-Fact-37310CB06F485061B349B80A64A17695"
      unitRef="Claim">56500</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="D2017Q4Oct02-Oct31_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_ProductOrServiceAxis_pfe_CelebrexMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember"
      decimals="-6"
      id="d43707686e1216-wk-Fact-ECDDC95F6CDDCC54760F9203E934A283"
      unitRef="usd">94000000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="FI2017Q3_us-gaap_LitigationCaseAxis_pfe_StateofIllinoisVersusPfizerMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_LossContingenciesByNatureOfContingencyAxis_pfe_AverageWholesalePriceMember"
      decimals="INF"
      id="d43707686e1298-wk-Fact-D5208D6686935FF38064D253ECACA456"
      unitRef="Claim">1</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="FI2017Q3_us-gaap_LitigationCaseAxis_pfe_StateofIllinoisVersusPfizerMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_LossContingenciesByNatureOfContingencyAxis_pfe_AverageWholesalePriceMember"
      decimals="INF"
      id="d43707686e1306-wk-Fact-D5208D6686935FF38064D253ECACA456"
      unitRef="Claim">1</us-gaap:LossContingencyPendingClaimsNumber>
    <pfe:FeasibilityStudyNumberOfLagoons
      contextRef="D2013Q1MonthOfMarch_us-gaap_LossContingenciesByNatureOfContingencyAxis_pfe_EnvironmentalRemediationLitigationMember"
      decimals="INF"
      id="d43707686e1344-wk-Fact-36FD01124C8551AD9F189087D936C419"
      unitRef="lagoon">2</pfe:FeasibilityStudyNumberOfLagoons>
    <us-gaap:LossContingencyEstimateOfPossibleLoss
      contextRef="FI2016Q4_us-gaap_LossContingenciesByNatureOfContingencyAxis_pfe_ViolationofAntitrustLawsMember_us-gaap_ProductOrServiceAxis_pfe_PhenytoinSodiumCapsulesMember"
      decimals="-5"
      id="d43707686e1376-wk-Fact-8925E94D49E25FBFAFA3C8122B68CDD4"
      unitRef="gbp">84200000</us-gaap:LossContingencyEstimateOfPossibleLoss>
    <pfe:LossContingencyCollaborationArrangementPercentageofPaymentsSoughtbyPlaintiff
      contextRef="D2017Q2Apr01-Apr30_us-gaap_LitigationCaseAxis_pfe_RegentsVersusMedivationMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_us-gaap_ProductOrServiceAxis_pfe_XtandiMember"
      decimals="INF"
      id="d43707686e1435-wk-Fact-F5F570175048519D98A990604BA2E267"
      unitRef="number">0.10</pfe:LossContingencyCollaborationArrangementPercentageofPaymentsSoughtbyPlaintiff>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="FD2017Q3YTD"
      id="TextSelection-B389BD5A47A85F2CB2DBBB9DF9010D7E-0-wk-Fact-DD4ABF30826E58CF8AF9DE1186C26B83">&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;Segment, Geographic and Other Revenue Information&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt; &lt;/span&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;A. Segment Information&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We manage our commercial operations through &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;two&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; distinct business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH and EH segments are each led by a single manager. Each operating segment has responsibility for its commercial activities and for certain IPR&amp;amp;D projects for new investigational products and additional indications for in-line products that generally have achieved proof-of-concept. Each business has a geographic footprint across developed and emerging markets. Our chief operating decision maker uses the revenues and earnings of the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;two&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; operating segments, among other factors, for performance evaluation and resource allocation.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We regularly review our segments and the approach used by management for performance evaluation and resource allocation.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;As described in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Note 1A&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, acquisitions and divestitures have impacted our results of operations in 2017 and 2016.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;text-decoration:underline;"&gt;Operating Segments&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="3"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:50%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Some additional information about our business segments follows:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;font-style:italic;font-weight:bold;"&gt;IH Segment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;font-style:italic;font-weight:bold;"&gt;EH Segment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="padding-bottom:4px;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;IH focuses on developing and commercializing novel, value-creating medicines and vaccines that significantly improve patients&#x2019; lives, as well as products for consumer healthcare.&lt;br/&gt;Key therapeutic areas include internal medicine, vaccines, oncology, inflammation &amp;amp; immunology, rare diseases and consumer healthcare.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-left:5px;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;EH includes legacy brands that have lost or will soon lose market exclusivity in both developed and emerging markets, branded generics, generic sterile injectable products, biosimilars, select branded products including anti-infectives and, through February 2, 2017, HIS. EH also includes an R&amp;amp;D organization, as well as our contract manufacturing business.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #000000;"&gt;&lt;div style="font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:3pt;font-weight:bold;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9.5pt;font-weight:bold;"&gt;Leading brands include:&lt;br/&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;- &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9.5pt;font-style:italic;"&gt;Prevnar 13/Prevenar 13&lt;br/&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;- &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9.5pt;font-style:italic;"&gt;Xeljanz&lt;br/&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;- &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9.5pt;font-style:italic;"&gt;Eliquis&lt;br/&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;- &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9.5pt;font-style:italic;"&gt;Lyrica&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#160;(U.S., Japan and certain other markets)&lt;br/&gt;- &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9.5pt;font-style:italic;"&gt;Enbrel &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;(outside the U.S. and Canada)&lt;br/&gt;- &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9.5pt;font-style:italic;"&gt;Viagra&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#160;(U.S. and Canada)&lt;br/&gt;- &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9.5pt;font-style:italic;"&gt;Ibrance&lt;br/&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;- &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9.5pt;font-style:italic;"&gt;Xtandi&lt;br/&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;- Several OTC consumer healthcare products (e.g., &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9.5pt;font-style:italic;"&gt;Advil&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&#160;and&lt;br/&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9.5pt;font-style:italic;"&gt;&#160;&#160;Centrum&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #000000;"&gt;&lt;div style="font-size:3pt;"&gt;&lt;span style="font-family:inherit;font-size:3pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;font-weight:bold;"&gt;Leading brands include:&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;- &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9.5pt;font-style:italic;"&gt;Lipitor&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;font-style:italic;"&gt;- Premarin &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;family&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;font-style:italic;"&gt;- Norvasc&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:6px;text-indent:-6px;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;font-style:italic;"&gt;- Lyrica &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;(Europe, Russia, Turkey, Israel and Central Asia countries)&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;- &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9.5pt;font-style:italic;"&gt;Celebrex&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;- &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Inflectra/Remsima&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;font-style:italic;"&gt;- &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;Several sterile injectable products&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:5px;font-size:9.5pt;"&gt;&lt;span style="font-family:inherit;font-size:9.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;text-decoration:underline;"&gt;Other Costs and Business Activities&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:7pt;"&gt;&lt;span style="font-family:inherit;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Certain pre-tax costs are not allocated to our operating segment results, such as costs associated with the following:&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:18px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;WRD, which is generally responsible for research projects for our IH business until proof-of-concept is achieved and then for transitioning those projects to the IH segment via the GPD organization for possible clinical and commercial development. R&amp;amp;D spending may include upfront and milestone payments for intellectual property rights. The WRD organization also has responsibility for certain science-based and other platform-services organizations, which provide technical expertise and other services to the various R&amp;amp;D projects, including EH R&amp;amp;D projects. WRD is also responsible for facilitating all regulatory submissions and interactions with regulatory agencies, including all safety-event activities.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:18px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;GPD, which is generally responsible for the clinical development of assets that are in clinical trials for our WRD and Innovative portfolios. GPD also provides technical support and other services to Pfizer R&amp;amp;D projects.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:18px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Corporate, representing platform functions (such as worldwide technology, global real estate operations, legal, finance, human resources, worldwide public affairs, compliance and worldwide procurement) and certain compensation and other corporate costs, such as interest income and expense, and gains and losses on investments. Effective in the first quarter of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;text-align:center;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, Corporate also includes the costs associated with our Pfizer Medical organization (Medical), previously reported as part of Other Business Activities. Medical is responsible for the provision of medical information to healthcare providers, patients and other parties, transparency and disclosure activities, clinical trial results publication, grants for healthcare quality improvement and medical education, and partnerships with global public health and medical associations. &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:18px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Other unallocated costs, representing overhead expenses associated with our manufacturing and commercial operations that are not directly assessed to an operating segment, as business unit (segment) management does not manage these costs (which include manufacturing variances associated with production).&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:18px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Certain transactions and events such as (i) purchase accounting adjustments, where we incur expenses associated with the amortization of fair value adjustments to inventory, intangible assets and PP&amp;amp;E; (ii) acquisition-related costs, where we incur costs for executing the transaction, integrating the acquired operations and restructuring the combined company; and (iii) certain significant items, representing substantive and/or unusual, and in some cases recurring, items (such as restructuring or legal charges) that are evaluated on an individual basis by management and that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis. Such items can include, but are not limited to, non-acquisition-related restructuring costs, as well as costs incurred for legal settlements, asset impairments and disposals of assets or businesses, including, as applicable, any associated transition activities.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;text-decoration:underline;"&gt;Segment Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:inherit;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We manage our assets on a total company basis, not by operating segment, as many of our operating assets are shared (such as our plant network assets) or commingled (such as accounts receivable, as many of our customers are served by both operating segments). Therefore, our chief operating decision maker does not regularly review any asset information by operating segment and, accordingly, we do not report asset information by operating segment. Total assets were approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$172 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;October&#160;1, 2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;text-align:center;"&gt;December&#160;31, 2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;text-decoration:underline;"&gt;Selected Income Statement Information&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="17" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table provides selected income statement information by reportable segment:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Three Months Ended&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Earnings&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;October&#160;1, &lt;br/&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;October&#160;2, &lt;br/&gt;2016&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;October&#160;1, &lt;br/&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;October&#160;2, &lt;br/&gt;2016&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Reportable Segments:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;text-indent:6px;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;IH&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;8,118&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;7,332&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;4,875&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;4,187&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;text-indent:6px;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;EH&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;5,050&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;5,712&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;2,765&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;3,128&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Total reportable segments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;13,168&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;13,045&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;7,640&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;7,315&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-left:12px;text-indent:-12px;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Other business activities&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(b), (c)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(759&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(753&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Reconciling Items:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Corporate&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(c)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(1,382&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(1,537&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Purchase accounting adjustments&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(c)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(1,154&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(966&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Acquisition-related costs&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(c)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(155&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(280&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Certain significant items&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(d)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(449&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(1,969&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Other unallocated&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(156&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(206&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;13,168&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;13,045&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;3,585&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;1,604&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="17" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Nine Months Ended&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Earnings&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;October&#160;1, &lt;br/&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;October&#160;2, &lt;br/&gt;2016&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;October&#160;1, &lt;br/&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;October&#160;2, &lt;br/&gt;2016&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Reportable Segments:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;IH&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;23,204&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;21,471&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;14,190&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;12,470&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;EH&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;15,639&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;17,725&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;8,558&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;9,985&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Total reportable segments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;38,843&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;39,196&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;22,748&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;22,454&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Other business activities&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(b), (c)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(2,205&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(2,096&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Reconciling Items:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Corporate&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(c)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(3,948&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(4,217&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Purchase accounting adjustments&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(c)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(3,527&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(3,103&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Acquisition-related costs&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(c)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(347&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(598&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Certain significant items&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(d)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(797&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(4,112&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Other unallocated&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(573&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(753&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;38,843&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;39,196&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;11,351&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;7,575&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Income from continuing operations before provision for taxes on income. IH&#x2019;s earnings in the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;third quarter&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;first nine months of&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;text-align:center;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;text-align:center;"&gt; include d&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;ividend income of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$54 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$211 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;, respectively, from our investment in ViiV. For additional information, see &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;"&gt;Note 4.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Other business activities includes the costs managed by our WRD and GPD organizations. Effective in the first quarter of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;text-align:center;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;, Medical, previously reported as part of Other Business Activities, was reclassified to Corporate. We have reclassified approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$33 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$94 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; of costs from Other Business Activities to Corporate in the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;third quarter&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;first nine months of&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;text-align:center;"&gt;2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;, respectively, to conform to the current period presentation.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(c)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;For a description, see the &#x201c;Other Costs and Business Activities&#x201d; section above.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(d)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Certain significant items are substantive and/or unusual, and in some cases recurring, items (such as restructuring or legal charges) that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-bottom:1px;padding-top:1px;padding-left:12px;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;For Earnings in the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;third quarter&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;text-align:center;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;, certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$90 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;, (ii) charges for certain legal matters of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$183 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;, (iii) income of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$12 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;, representing an adjustment to amounts previously recorded to write down the HIS net assets to fair value less costs to sell, (iv) certain asset impairment charges of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$127 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;, (v) charges for business and legal entity alignment of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$16 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; and (vi) other charges of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$45 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;. For additional information, see &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;"&gt;Note 2B, Note 3&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;"&gt;Note 4.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:1px;text-align:left;padding-left:12px;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;For Earnings in the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;third quarter&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;text-align:center;"&gt;2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;, certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$375 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;, (ii) income for certain legal matters of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$40 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;, (iii) an impairment charge related to the write-down of the HIS net assets to fair value less estimated costs to sell of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$1.4 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;, (iv) certain asset impairment charges of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$126 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;, (v) charges for business and legal entity alignment of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$69 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; and (vi) other charges of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$17 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;. For additional information, see &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;"&gt;Note 3 &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;and&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;"&gt; Note 4&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:1px;text-align:left;padding-left:12px;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;For Earnings in the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;first nine months of&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;text-align:center;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;, certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$253 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;, (ii) charges for certain legal matters of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$191 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;, (iii) incremental charges to amounts previously recorded to write down the HIS net assets to fair value less costs to sell of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$52 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;, (iv) certain asset impairment charges of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$127 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;, (v) charges for business and legal entity alignment of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$54 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; and (vi) other charges of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$119 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;. For additional information, see &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;"&gt;Note 2B&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;"&gt;Note 3&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;"&gt;Note 4&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:4px;text-align:left;padding-left:12px;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;For Earnings in the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;first nine months of&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;text-align:center;"&gt;2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;, certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$743 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;, (ii) charges for certain legal matters of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$506 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;, (iii) an impairment charge related to the write-down of the HIS net assets to fair value less estimated costs to sell of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$1.4 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;, (iv) certain asset impairment charges of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$1.1 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;, (v) charges for business and legal entity alignment of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$180 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; and (vi) other charges of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$189 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;. For additional information, see &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;"&gt;Note 3&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;"&gt;Note 4&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Equity in the net income of investees accounted for by the equity method is not significant for any of our operating segments. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The operating segment information does not purport to represent the revenues, costs and income from continuing operations before provision for taxes on income that each of our operating segments would have recorded had each segment operated as a standalone company during the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:9px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;B. Geographic Information&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;As described in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Note 1A&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, acquisitions and divestitures have impacted our results of operations in 2017 and 2016.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.41520467836257%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="23"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:28%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table provides revenues by geographic area:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Three Months Ended&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Nine Months Ended&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;October&#160;1, &lt;br/&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;October&#160;2, &lt;br/&gt;2016&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Change&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;October&#160;1, &lt;br/&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;October&#160;2, &lt;br/&gt;2016&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Change&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,534&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,530&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;19,516&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;19,561&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Developed Europe&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,163&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,218&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,309&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,982&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Developed Rest of World&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,632&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,711&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,797&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,940&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Emerging Markets&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(c)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,839&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,586&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8,222&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7,714&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;13,168&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;13,045&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;38,843&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;39,196&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Developed Europe region includes the following markets: Western Europe, Scandinavian countries and Finland.&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; Revenues denominated in euros were &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$1.7 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; in both the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;third quarter&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;text-align:center;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;text-align:center;"&gt;2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;, and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$5.0 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$5.3 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; in the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;first nine months of&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;text-align:center;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;text-align:center;"&gt;2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;, respectively.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Developed Rest of World region includes the following markets: Japan, Canada, Australia, South Korea and New Zealand.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(c)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Emerging Markets region includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Africa, Eastern Europe, Central Europe, the Middle East and Turkey.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;C. Other Revenue Information&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:4px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;text-decoration:underline;"&gt;Significant Product Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;As described in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Note 1A&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, acquisitions and divestitures have impacted our results of operations in 2017 and 2016.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:48%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="17" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table provides detailed revenue information:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Three Months Ended&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Nine Months Ended&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:inherit;font-size:7pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;October&#160;1, &lt;br/&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;October&#160;2, &lt;br/&gt;2016&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;October&#160;1, &lt;br/&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;October&#160;2, &lt;br/&gt;2016&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;PFIZER INNOVATIVE HEALTH (IH)&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;8,118&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;7,332&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;23,204&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;21,471&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Internal Medicine&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;2,455&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;2,243&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;7,245&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;6,557&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Lyrica IH&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;1,150&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;1,049&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;3,382&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;3,107&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Eliquis alliance revenues and direct sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;644&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;449&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;1,813&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;1,225&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Chantix/Champix&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;240&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;198&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;727&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;631&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Viagra IH&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(c)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;206&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;297&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;711&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;897&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;BMP2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;79&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;63&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;198&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;175&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Toviaz&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;62&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;60&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;187&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;191&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;All other Internal Medicine&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;75&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;128&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;228&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;330&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Vaccines&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1,649&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1,641&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;4,385&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;4,576&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Prevnar 13/Prevenar 13&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;1,522&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;1,536&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;4,069&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;4,302&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;FSME/IMMUN-TicoVac&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;43&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;33&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;119&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;102&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;All other Vaccines&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;85&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;72&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;197&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;172&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Oncology&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1,616&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1,104&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;4,551&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;3,206&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Ibrance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;878&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;550&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;2,410&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;1,492&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Sutent&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;276&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;260&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;805&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;823&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Xalkori&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;146&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;140&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;442&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;415&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Xtandi alliance revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;150&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;422&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Inlyta&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;84&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;95&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;256&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;304&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Bosulif&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;57&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;43&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;163&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;121&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;All other Oncology&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;26&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;15&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;54&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;49&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Inflammation &amp;amp; Immunology (I&amp;amp;I)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;960&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;2,863&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;2,907&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Enbrel (Outside the U.S. and Canada)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;613&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;701&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;1,818&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;2,201&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Xeljanz&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;348&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;235&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;935&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;649&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Eucrisa&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;15&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;33&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;All other I&amp;amp;I&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;23&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;24&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;78&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;57&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Rare Disease&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;569&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;585&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1,637&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1,768&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;BeneFIX&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;151&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;176&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;453&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;543&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Refacto AF/Xyntha&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;140&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;140&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;409&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;408&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Genotropin&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;136&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;147&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;375&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;425&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Somavert&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;65&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;59&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;182&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;173&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;All other Rare Disease&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;77&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;64&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;218&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;219&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Consumer Healthcare&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;829&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;798&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;2,522&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;2,457&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;PFIZER ESSENTIAL HEALTH (EH)&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(d)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;5,050&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;5,712&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;15,639&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;17,725&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Legacy Established Products (LEP)&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(e)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;2,681&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;2,708&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;7,995&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;8,373&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Lipitor&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;491&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;422&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;1,341&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;1,294&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Premarin family&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;238&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;244&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;711&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;751&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Norvasc&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;226&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;238&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;684&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;714&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;EpiPen&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;82&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;110&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;253&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;300&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Xalatan/Xalacom&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;83&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;91&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;241&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;273&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Effexor&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;76&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;70&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;215&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;207&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Zoloft&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;78&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;72&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;215&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;228&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Zithromax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;61&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;56&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;202&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;203&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Relpax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;50&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;83&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;193&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;248&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Xanax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;58&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;55&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;164&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;163&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;All other LEP&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;1,237&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;1,268&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;3,776&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;3,992&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Sterile Injectable Pharmaceuticals (SIP)&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(f)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1,273&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1,461&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;4,270&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;4,481&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Medrol&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;109&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;102&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;352&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;330&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Sulperazon&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;114&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;102&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;345&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;304&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Fragmin&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;79&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;80&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;221&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;240&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Tygacil&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;60&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;69&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;192&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;203&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Precedex&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;51&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;64&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;182&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;199&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;All other SIP&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;860&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;1,044&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;2,977&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;3,206&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:48%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Three Months Ended&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Nine Months Ended&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:inherit;font-size:7pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;October&#160;1, &lt;br/&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;October&#160;2, &lt;br/&gt;2016&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;October&#160;1, &lt;br/&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;October&#160;2, &lt;br/&gt;2016&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Peri-LOE Products&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(g)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;794&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1,023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;2,398&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;3,224&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Celebrex&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;212&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;194&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;564&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;550&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Lyrica EH&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;134&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;191&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;428&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;623&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Vfend&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;97&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;140&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;305&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;459&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Viagra EH&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(c)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;102&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;89&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;285&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;286&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Pristiq&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;69&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;174&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;230&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;546&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Zyvox&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;68&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;94&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;220&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;334&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Revatio&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;58&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;73&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;189&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;213&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;All other Peri-LOE Products&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;55&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;68&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;176&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;214&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Biosimilars&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(h)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;141&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;83&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;367&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;228&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Inflectra/Remsima&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;112&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;49&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;284&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;130&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;All other Biosimilars&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;28&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;34&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;82&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;97&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Pfizer CentreOne&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(i)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;161&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;156&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;514&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;540&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Hospira Infusion Systems (HIS)&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(j)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;281&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;97&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;879&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;13,168&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;13,045&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;38,843&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;39,196&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Total Lyrica&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1,285&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1,240&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;3,810&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;3,730&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Total Viagra&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(c)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;308&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;387&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;996&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1,183&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Total Alliance revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;741&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;419&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;2,112&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1,155&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;The IH business encompasses Internal Medicine, Vaccines, Oncology, Inflammation &amp;amp; Immunology, Rare Disease and Consumer Healthcare. Through December 31, 2016, includes Duavive/Duavee and Viviant (recorded in All other Internal Medicine in 2016), which were transferred from Innovative Health to Essential Health effective January 1, 2017 (recorded in All other LEP (EH) beginning January 1, 2017), in order to align these products with our management of the women&#x2019;s health portfolio within EH. &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Lyrica revenues from all of Europe, Russia, Turkey, Israel and Central Asia countries are included in Lyrica EH. All other Lyrica revenues are included in Lyrica IH. Total Lyrica revenues represent the aggregate of worldwide revenues from Lyrica IH and Lyrica EH. &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(c)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Viagra revenues from the U.S. and Canada are included in Viagra IH. All other Viagra revenues are included in Viagra EH. Total Viagra revenues represent the aggregate of worldwide revenues from Viagra IH and Viagra EH. &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(d)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;The EH business encompasses Legacy Established Products, Sterile Injectable Pharmaceuticals, Peri-LOE Products, Biosimilars, Pfizer CentreOne and HIS (through February 2, 2017) and includes all legacy Hospira commercial operations.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(e)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Legacy Established Products primarily include products that have lost patent protection (excluding Sterile Injectable Pharmaceuticals and Peri-LOE Products). Effective January 1, 2017, All other LEP includes Duavive/Duavee and Viviant, which were transferred from Innovative Health (recorded in All other Internal Medicine (IH) in 2016), in order to align these products with our management of the women&#x2019;s health portfolio within EH.&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt; &lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;See note (a) above.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(f) &lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Sterile Injectable Pharmaceuticals include generic injectables and proprietary specialty injectables (excluding Peri-LOE Products). &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(g)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Peri-LOE Products include products that have recently lost or are anticipated to soon lose patent protection. These products include: Lyrica in Europe, Russia, Turkey, Israel and Central Asia; Viagra in all countries (excluding the U.S. and Canada); and worldwide revenues for Celebrex, Pristiq, Zyvox, Vfend, Revatio and Inspra. &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(h)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Biosimilars include Inflectra/Remsima (biosimilar infliximab) in the U.S. and certain international markets, Nivestim (biosimilar filgrastim) in certain European, Asian and Africa/Middle Eastern markets and Retacrit (biosimilar epoetin zeta) in certain European and Africa/Middle Eastern markets. &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(i)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Pfizer CentreOne includes revenues from our contract manufacturing and active pharmaceutical ingredient sales operation, including sterile injectables contract manufacturing, and revenues related to our manufacturing and supply agreements, including with Zoetis. &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(j)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;HIS (through February 2, 2017) includes Medication Management Systems products composed of infusion pumps and related software and services, as well as IV Infusion Products, including large volume IV solutions and their associated administration sets.</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="FD2017Q3YTD"
      decimals="INF"
      id="d43771853e654-wk-Fact-7FDCD3767D7C5A07BAB773B71A23B8A3"
      unitRef="Operating_Segment">2</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfOperatingSegments
      contextRef="FD2017Q3YTD"
      decimals="INF"
      id="d43771853e658-wk-Fact-7FDCD3767D7C5A07BAB773B71A23B8A3"
      unitRef="Operating_Segment">2</us-gaap:NumberOfOperatingSegments>
    <us-gaap:Assets
      contextRef="FI2017Q3"
      decimals="-9"
      id="d43771853e888-wk-Fact-D074F89DB2815EDFA2146FB266FB023F"
      unitRef="usd">172000000000</us-gaap:Assets>
    <us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock
      contextRef="FD2017Q3YTD"
      id="TextSelection-39C150A185E756079931FFB72A73329E-0-wk-Fact-969D3CD924E057A9B1F62A878378C5A0">&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="17" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table provides selected income statement information by reportable segment:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Three Months Ended&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Earnings&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;October&#160;1, &lt;br/&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;October&#160;2, &lt;br/&gt;2016&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;October&#160;1, &lt;br/&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;October&#160;2, &lt;br/&gt;2016&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Reportable Segments:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;text-indent:6px;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;IH&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;8,118&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;7,332&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;4,875&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;4,187&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;text-indent:6px;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;EH&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;5,050&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;5,712&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;2,765&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;3,128&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Total reportable segments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;13,168&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;13,045&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;7,640&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;7,315&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-left:12px;text-indent:-12px;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Other business activities&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(b), (c)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(759&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(753&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Reconciling Items:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Corporate&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(c)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(1,382&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(1,537&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Purchase accounting adjustments&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(c)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(1,154&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(966&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Acquisition-related costs&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(c)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(155&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(280&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Certain significant items&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(d)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(449&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(1,969&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Other unallocated&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(156&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(206&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;13,168&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;13,045&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;3,585&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;1,604&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="17" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Nine Months Ended&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Earnings&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;October&#160;1, &lt;br/&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;October&#160;2, &lt;br/&gt;2016&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;October&#160;1, &lt;br/&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;October&#160;2, &lt;br/&gt;2016&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Reportable Segments:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;IH&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;23,204&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;21,471&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;14,190&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;12,470&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;EH&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;15,639&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;17,725&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;8,558&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;9,985&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Total reportable segments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;38,843&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;39,196&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;22,748&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;22,454&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Other business activities&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(b), (c)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(2,205&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(2,096&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Reconciling Items:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Corporate&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(c)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(3,948&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(4,217&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Purchase accounting adjustments&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(c)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(3,527&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(3,103&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Acquisition-related costs&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(c)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(347&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(598&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Certain significant items&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(d)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(797&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(4,112&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Other unallocated&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(573&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(753&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;38,843&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;39,196&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;11,351&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;7,575&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Income from continuing operations before provision for taxes on income. IH&#x2019;s earnings in the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;third quarter&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;first nine months of&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;text-align:center;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;text-align:center;"&gt; include d&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;ividend income of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$54 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$211 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;, respectively, from our investment in ViiV. For additional information, see &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;"&gt;Note 4.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Other business activities includes the costs managed by our WRD and GPD organizations. Effective in the first quarter of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;text-align:center;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;, Medical, previously reported as part of Other Business Activities, was reclassified to Corporate. We have reclassified approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$33 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$94 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; of costs from Other Business Activities to Corporate in the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;third quarter&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;first nine months of&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;text-align:center;"&gt;2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;, respectively, to conform to the current period presentation.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(c)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;For a description, see the &#x201c;Other Costs and Business Activities&#x201d; section above.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(d)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Certain significant items are substantive and/or unusual, and in some cases recurring, items (such as restructuring or legal charges) that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-bottom:1px;padding-top:1px;padding-left:12px;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;For Earnings in the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;third quarter&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;text-align:center;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;, certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$90 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;, (ii) charges for certain legal matters of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$183 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;, (iii) income of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$12 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;, representing an adjustment to amounts previously recorded to write down the HIS net assets to fair value less costs to sell, (iv) certain asset impairment charges of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$127 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;, (v) charges for business and legal entity alignment of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$16 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; and (vi) other charges of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$45 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;. For additional information, see &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;"&gt;Note 2B, Note 3&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;"&gt;Note 4.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:1px;text-align:left;padding-left:12px;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;For Earnings in the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;third quarter&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;text-align:center;"&gt;2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;, certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$375 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;, (ii) income for certain legal matters of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$40 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;, (iii) an impairment charge related to the write-down of the HIS net assets to fair value less estimated costs to sell of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$1.4 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;, (iv) certain asset impairment charges of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$126 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;, (v) charges for business and legal entity alignment of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$69 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; and (vi) other charges of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$17 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;. For additional information, see &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;"&gt;Note 3 &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;and&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;"&gt; Note 4&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:1px;text-align:left;padding-left:12px;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;For Earnings in the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;first nine months of&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;text-align:center;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;, certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$253 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;, (ii) charges for certain legal matters of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$191 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;, (iii) incremental charges to amounts previously recorded to write down the HIS net assets to fair value less costs to sell of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$52 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;, (iv) certain asset impairment charges of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$127 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;, (v) charges for business and legal entity alignment of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$54 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; and (vi) other charges of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$119 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;. For additional information, see &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;"&gt;Note 2B&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;"&gt;Note 3&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;"&gt;Note 4&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;For Earnings in the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;first nine months of&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;text-align:center;"&gt;2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;, certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$743 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;, (ii) charges for certain legal matters of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$506 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;, (iii) an impairment charge related to the write-down of the HIS net assets to fair value less estimated costs to sell of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$1.4 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;, (iv) certain asset impairment charges of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$1.1 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;, (v) charges for business and legal entity alignment of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$180 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; and (vi) other charges of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$189 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;. For additional information, see &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;"&gt;Note 3&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;"&gt;Note 4&lt;/span&gt;.</us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock>
    <us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock
      contextRef="FD2017Q3YTD"
      id="TextSelection-3A70334D7C5D5252B1EF2B0781B55137-0-wk-Fact-2A0AF4F3CF765E09ADA3E806BBB2BCEB">&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="17" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table provides selected income statement information by reportable segment:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Three Months Ended&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Earnings&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;October&#160;1, &lt;br/&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;October&#160;2, &lt;br/&gt;2016&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;October&#160;1, &lt;br/&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;October&#160;2, &lt;br/&gt;2016&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Reportable Segments:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;text-indent:6px;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;IH&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;8,118&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;7,332&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;4,875&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;4,187&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;text-indent:6px;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;EH&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;5,050&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;5,712&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;2,765&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;3,128&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Total reportable segments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;13,168&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;13,045&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;7,640&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;7,315&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-left:12px;text-indent:-12px;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Other business activities&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(b), (c)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(759&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(753&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Reconciling Items:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Corporate&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(c)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(1,382&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(1,537&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Purchase accounting adjustments&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(c)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(1,154&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(966&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Acquisition-related costs&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(c)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(155&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(280&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Certain significant items&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(d)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(449&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(1,969&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Other unallocated&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(156&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(206&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;13,168&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;13,045&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;3,585&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;1,604&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="17" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Nine Months Ended&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Earnings&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;October&#160;1, &lt;br/&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;October&#160;2, &lt;br/&gt;2016&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;October&#160;1, &lt;br/&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;October&#160;2, &lt;br/&gt;2016&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Reportable Segments:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;IH&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;23,204&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;21,471&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;14,190&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;12,470&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;EH&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;15,639&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;17,725&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;8,558&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;9,985&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Total reportable segments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;38,843&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;39,196&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;22,748&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;22,454&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Other business activities&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(b), (c)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(2,205&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(2,096&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Reconciling Items:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Corporate&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(c)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(3,948&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(4,217&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Purchase accounting adjustments&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(c)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(3,527&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(3,103&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Acquisition-related costs&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(c)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(347&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(598&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Certain significant items&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(d)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(797&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(4,112&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;Other unallocated&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(573&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;(753&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;38,843&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;39,196&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;11,351&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8.5pt;"&gt;&lt;span style="font-family:inherit;font-size:8.5pt;"&gt;&lt;span&gt;7,575&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Income from continuing operations before provision for taxes on income. IH&#x2019;s earnings in the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;third quarter&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;first nine months of&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;text-align:center;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;text-align:center;"&gt; include d&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;ividend income of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$54 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$211 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;, respectively, from our investment in ViiV. For additional information, see &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;"&gt;Note 4.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Other business activities includes the costs managed by our WRD and GPD organizations. Effective in the first quarter of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;text-align:center;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;, Medical, previously reported as part of Other Business Activities, was reclassified to Corporate. We have reclassified approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$33 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$94 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; of costs from Other Business Activities to Corporate in the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;third quarter&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;first nine months of&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;text-align:center;"&gt;2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;, respectively, to conform to the current period presentation.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(c)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;For a description, see the &#x201c;Other Costs and Business Activities&#x201d; section above.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(d)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Certain significant items are substantive and/or unusual, and in some cases recurring, items (such as restructuring or legal charges) that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-bottom:1px;padding-top:1px;padding-left:12px;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;For Earnings in the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;third quarter&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;text-align:center;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;, certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$90 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;, (ii) charges for certain legal matters of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$183 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;, (iii) income of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$12 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;, representing an adjustment to amounts previously recorded to write down the HIS net assets to fair value less costs to sell, (iv) certain asset impairment charges of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$127 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;, (v) charges for business and legal entity alignment of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$16 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; and (vi) other charges of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$45 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;. For additional information, see &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;"&gt;Note 2B, Note 3&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;"&gt;Note 4.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:1px;text-align:left;padding-left:12px;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;For Earnings in the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;third quarter&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;text-align:center;"&gt;2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;, certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$375 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;, (ii) income for certain legal matters of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$40 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;, (iii) an impairment charge related to the write-down of the HIS net assets to fair value less estimated costs to sell of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$1.4 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;, (iv) certain asset impairment charges of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$126 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;, (v) charges for business and legal entity alignment of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$69 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; and (vi) other charges of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$17 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;. For additional information, see &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;"&gt;Note 3 &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;and&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;"&gt; Note 4&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:1px;text-align:left;padding-left:12px;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;For Earnings in the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;first nine months of&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;text-align:center;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;, certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$253 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;, (ii) charges for certain legal matters of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$191 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;, (iii) incremental charges to amounts previously recorded to write down the HIS net assets to fair value less costs to sell of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$52 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;, (iv) certain asset impairment charges of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$127 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;, (v) charges for business and legal entity alignment of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$54 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; and (vi) other charges of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$119 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;. For additional information, see &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;"&gt;Note 2B&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;"&gt;Note 3&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;"&gt;Note 4&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;For Earnings in the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;first nine months of&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;text-align:center;"&gt;2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;, certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$743 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;, (ii) charges for certain legal matters of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$506 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;, (iii) an impairment charge related to the write-down of the HIS net assets to fair value less estimated costs to sell of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$1.4 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;, (iv) certain asset impairment charges of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$1.1 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;, (v) charges for business and legal entity alignment of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$180 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; and (vi) other charges of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$189 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;. For additional information, see &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;"&gt;Note 3&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;"&gt;Note 4&lt;/span&gt;.</us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3QTD_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e1389-wk-Fact-32744FC079E6516B83654D2F854DDC81"
      unitRef="usd">8118000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3QTD_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e1408-wk-Fact-CD5A7DF5427B5D659DC40A0EF86911E6"
      unitRef="usd">7332000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2017Q3QTD_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e1428-wk-Fact-81F0756E8C76E147E68C5A6F0304AE04"
      unitRef="usd">4875000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2016Q3QTD_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e1447-wk-Fact-E7A96C031340595C8C21FFE23138776B"
      unitRef="usd">4187000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3QTD_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e1467-wk-Fact-1893B9D2D478593B987C2D75B2840206"
      unitRef="usd">5050000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3QTD_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e1486-wk-Fact-8E0B859C556B55518AC4A34726DE143E"
      unitRef="usd">5712000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2017Q3QTD_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e1505-wk-Fact-B11B8159E0957CFF66445A6F02FE77F4"
      unitRef="usd">2765000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2016Q3QTD_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e1525-wk-Fact-2C08174C90215980AF8C21393CA8C5DE"
      unitRef="usd">3128000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3QTD_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember"
      decimals="-6"
      id="d43771853e1550-wk-Fact-BF46CA4FE42754B5B32511A01C0C8DE0"
      unitRef="usd">13168000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3QTD_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember"
      decimals="-6"
      id="d43771853e1569-wk-Fact-DB74B53DC930574FB35809CDD61DBAF0"
      unitRef="usd">13045000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2017Q3QTD_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember"
      decimals="-6"
      id="d43771853e1588-wk-Fact-A18F9A2CB32656BA9AA6CDE701027F25"
      unitRef="usd">7640000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2016Q3QTD_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember"
      decimals="-6"
      id="d43771853e1608-wk-Fact-9F0EA4485B0153C7823866D0926BA03D"
      unitRef="usd">7315000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2017Q3QTD_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember"
      decimals="-6"
      id="d43771853e1673-wk-Fact-71E7D0DF9D86563A92C28ADB4DD1F792"
      unitRef="usd">-759000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2016Q3QTD_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember"
      decimals="-6"
      id="d43771853e1694-wk-Fact-57E8C529F5385E41A7B3E91CFC576F36"
      unitRef="usd">-753000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2017Q3QTD_us-gaap_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember"
      decimals="-6"
      id="d43771853e1845-wk-Fact-773AA58B1A2B57898FCAC12E9643C9F5"
      unitRef="usd">-1382000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2016Q3QTD_us-gaap_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember"
      decimals="-6"
      id="d43771853e1866-wk-Fact-8B6B8D08A6E0596D82BFAC1026B33906"
      unitRef="usd">-1537000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2017Q3QTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_PurchaseAccountingAdjustmentsMember_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember"
      decimals="-6"
      id="d43771853e1933-wk-Fact-FF681D2F4C60530BA4FA7ECF6068D66E"
      unitRef="usd">-1154000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2016Q3QTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_PurchaseAccountingAdjustmentsMember_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember"
      decimals="-6"
      id="d43771853e1954-wk-Fact-6C4D8296C83F57DC93CF1B41EF47EFF1"
      unitRef="usd">-966000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2017Q3QTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_BusinessCombinationsAcquisitionRelatedCostsMember_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember"
      decimals="-6"
      id="d43771853e2020-wk-Fact-701D108258D15E76898CF0E9F156AAB3"
      unitRef="usd">-155000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2016Q3QTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_BusinessCombinationsAcquisitionRelatedCostsMember_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember"
      decimals="-6"
      id="d43771853e2041-wk-Fact-2439FB836F6B538B8D7D394CD6614D2E"
      unitRef="usd">-280000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2017Q3QTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_CertainSignificantItemsMember_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember"
      decimals="-6"
      id="d43771853e2107-wk-Fact-5FBB1F07246D5AAFB10CAD5C2A396D68"
      unitRef="usd">-449000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2016Q3QTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_CertainSignificantItemsMember_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember"
      decimals="-6"
      id="d43771853e2128-wk-Fact-241DA9C0A5035519B185693E59F3571D"
      unitRef="usd">-1969000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2017Q3QTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_OtherUnallocatedMember_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember"
      decimals="-6"
      id="d43771853e2192-wk-Fact-4B3A8022310558FC9B763D89CFB05272"
      unitRef="usd">-156000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2016Q3QTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_OtherUnallocatedMember_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember"
      decimals="-6"
      id="d43771853e2213-wk-Fact-853524F647B75F4EA75709651DF1AA8F"
      unitRef="usd">-206000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3QTD"
      decimals="-6"
      id="d43771853e2244-wk-Fact-739EC43DD13B5516B11DE41A93EEDF71"
      unitRef="usd">13168000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3QTD"
      decimals="-6"
      id="d43771853e2263-wk-Fact-08F7B1DEB2E25ACA94468FF7CE567177"
      unitRef="usd">13045000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2017Q3QTD"
      decimals="-6"
      id="d43771853e2282-wk-Fact-C6627323E3A7545BB805B65F89BE7911"
      unitRef="usd">3585000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2016Q3QTD"
      decimals="-6"
      id="d43771853e2301-wk-Fact-8EACD6F676A95BF0AB83AE15D642DBEA"
      unitRef="usd">1604000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3YTD_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e2756-wk-Fact-ADD1149F121F5FEDB87B00FCFF919B53"
      unitRef="usd">23204000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3YTD_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e2775-wk-Fact-8161BA8BA7C8570786334FD60871F61F"
      unitRef="usd">21471000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2017Q3YTD_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e2795-wk-Fact-4978864FED0C5781909B06FB41801AC3"
      unitRef="usd">14190000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2016Q3YTD_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e2814-wk-Fact-A84CE5053CF85BC4965B4D4988840327"
      unitRef="usd">12470000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3YTD_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e2835-wk-Fact-A017B762D4F6541E8D5C4026A635906A"
      unitRef="usd">15639000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3YTD_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e2854-wk-Fact-4A86BFAF3887566093AD955E2EF858FC"
      unitRef="usd">17725000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2017Q3YTD_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e2873-wk-Fact-713D053AAB3F543EAA3B2BC05CA14525"
      unitRef="usd">8558000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2016Q3YTD_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e2893-wk-Fact-BAF1C761A7AF5C7CBFD0E58295157553"
      unitRef="usd">9985000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3YTD_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember"
      decimals="-6"
      id="d43771853e2918-wk-Fact-FBE7252DC35752CABDE9FD8E2DACE551"
      unitRef="usd">38843000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3YTD_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember"
      decimals="-6"
      id="d43771853e2937-wk-Fact-0F4B985F368C5B5DBE7D51634A6C7FAD"
      unitRef="usd">39196000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2017Q3YTD_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember"
      decimals="-6"
      id="d43771853e2956-wk-Fact-8CC7C9AC13B558B88EEA9469BCD245B1"
      unitRef="usd">22748000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2016Q3YTD_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember"
      decimals="-6"
      id="d43771853e2976-wk-Fact-0B8C5DECC76C5C9E999FC0C03F083D1F"
      unitRef="usd">22454000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2017Q3YTD_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember"
      decimals="-6"
      id="d43771853e3041-wk-Fact-8317B3014C2257C6BEBBD283124A965D"
      unitRef="usd">-2205000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2016Q3YTD_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember"
      decimals="-6"
      id="d43771853e3062-wk-Fact-D653E73218645753AB0757271374CCA1"
      unitRef="usd">-2096000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2017Q3YTD_us-gaap_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember"
      decimals="-6"
      id="d43771853e3215-wk-Fact-47A9B6BC4350580490BDDDA2982DE155"
      unitRef="usd">-3948000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2016Q3YTD_us-gaap_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember"
      decimals="-6"
      id="d43771853e3236-wk-Fact-E7E6EB83A98259609D63524CCF7C1687"
      unitRef="usd">-4217000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2017Q3YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_PurchaseAccountingAdjustmentsMember_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember"
      decimals="-6"
      id="d43771853e3302-wk-Fact-2E6085148E385843A6F6681DB2EA3E75"
      unitRef="usd">-3527000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2016Q3YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_PurchaseAccountingAdjustmentsMember_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember"
      decimals="-6"
      id="d43771853e3323-wk-Fact-16217BBC721C5351BFA615340C8310C9"
      unitRef="usd">-3103000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2017Q3YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_BusinessCombinationsAcquisitionRelatedCostsMember_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember"
      decimals="-6"
      id="d43771853e3389-wk-Fact-2E8BCB0198B9547BFA12E7848D133E48"
      unitRef="usd">-347000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2016Q3YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_BusinessCombinationsAcquisitionRelatedCostsMember_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember"
      decimals="-6"
      id="d43771853e3410-wk-Fact-8AA7427BBF485EA4842503B7D6B6F5B3"
      unitRef="usd">-598000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2017Q3YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_CertainSignificantItemsMember_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember"
      decimals="-6"
      id="d43771853e3476-wk-Fact-A872003B0DA95195BC5493ACF35066FF"
      unitRef="usd">-797000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2016Q3YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_CertainSignificantItemsMember_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember"
      decimals="-6"
      id="d43771853e3497-wk-Fact-F4E33C840C7351EB83A44DAB9FB01B6C"
      unitRef="usd">-4112000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2017Q3YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_OtherUnallocatedMember_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember"
      decimals="-6"
      id="d43771853e3561-wk-Fact-2131D133192A51CEA24287EC4D1DC30D"
      unitRef="usd">-573000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2016Q3YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_OtherUnallocatedMember_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember"
      decimals="-6"
      id="d43771853e3582-wk-Fact-D6C99180CE0A52CAAA4028B1B586C207"
      unitRef="usd">-753000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43771853e3613-wk-Fact-D1ABF3DF10655F18B16D5BEDE8158D66"
      unitRef="usd">38843000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43771853e3632-wk-Fact-769863A67705599FBF10A0F9C982956F"
      unitRef="usd">39196000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43771853e3652-wk-Fact-6C225350ED6F51898E27B37470C6135A"
      unitRef="usd">11351000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43771853e3671-wk-Fact-6056A2295D7857F1915F488C04BDB11A"
      unitRef="usd">7575000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:InvestmentIncomeDividend
      contextRef="FD2017Q3QTD_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViivHealthcareLimitedMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e3708-wk-Fact-4F0D695F67305B7684A19B343AB32C0C"
      unitRef="usd">54000000</us-gaap:InvestmentIncomeDividend>
    <us-gaap:InvestmentIncomeDividend
      contextRef="FD2017Q3YTD_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViivHealthcareLimitedMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e3713-wk-Fact-A4D794D7B0F25073BE267F34843F9BB3"
      unitRef="usd">211000000</us-gaap:InvestmentIncomeDividend>
    <us-gaap:CostsAndExpenses
      contextRef="FD2016Q3QTD_us-gaap_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioAdjustmentMember"
      decimals="-6"
      id="d43771853e3755-wk-Fact-5905DF29CEB855E3B862AF54314416A8"
      unitRef="usd">33000000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="FD2016Q3YTD_us-gaap_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioAdjustmentMember"
      decimals="-6"
      id="d43771853e3759-wk-Fact-B705E9A7D8C95A719E9D8EBCD91F3B0F"
      unitRef="usd">94000000</us-gaap:CostsAndExpenses>
    <pfe:RestructuringChargesandImplementationCosts
      contextRef="FD2017Q3QTD_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember"
      decimals="-6"
      id="d43771853e3827-wk-Fact-37BD8A19727152D698DBC1686715DAF3"
      unitRef="usd">90000000</pfe:RestructuringChargesandImplementationCosts>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="FD2017Q3QTD_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember"
      decimals="-6"
      id="d43771853e3831-wk-Fact-28221068F090B979068691C4E99F537C"
      unitRef="usd">-183000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
      contextRef="FD2017Q3QTD_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_HISMember"
      decimals="-6"
      id="d43771853e3835-wk-Fact-3611B2339C325915870B95AB1F744E4A"
      unitRef="usd">12000000</us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal>
    <us-gaap:AssetImpairmentCharges
      contextRef="FD2017Q3QTD_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember"
      decimals="-6"
      id="d43771853e3840-wk-Fact-6DDBD1867C46495FB2EB91F4D044DCDC"
      unitRef="usd">127000000</us-gaap:AssetImpairmentCharges>
    <pfe:BusinessInfrastructureAlignmentCosts
      contextRef="FD2017Q3QTD_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember"
      decimals="-6"
      id="d43771853e3844-wk-Fact-0B9DB54EC1E25EAA89596B22BF341CCB"
      unitRef="usd">16000000</pfe:BusinessInfrastructureAlignmentCosts>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="FD2017Q3QTD_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember"
      decimals="-6"
      id="d43771853e3848-wk-Fact-20AD4F5DADC053D79D3489491D0428DC"
      unitRef="usd">-45000000</us-gaap:OtherOperatingIncomeExpenseNet>
    <pfe:RestructuringChargesandImplementationCosts
      contextRef="FD2016Q3QTD_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember"
      decimals="-6"
      id="d43771853e3869-wk-Fact-872681DE787E5F8C88A4C6B4EFA47198"
      unitRef="usd">375000000</pfe:RestructuringChargesandImplementationCosts>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="FD2016Q3QTD_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember"
      decimals="-6"
      id="d43771853e3873-wk-Fact-1AFA07536C255929A6B61B3652BEC04C"
      unitRef="usd">40000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
      contextRef="FD2016Q3QTD_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_HISMember"
      decimals="-8"
      id="d43771853e3877-wk-Fact-A6569EB0674CCF1D6CFF06D996CFFC1E"
      unitRef="usd">-1400000000</us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal>
    <us-gaap:AssetImpairmentCharges
      contextRef="FD2016Q3QTD_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember"
      decimals="-6"
      id="d43771853e3882-wk-Fact-3C16F4BA6F45515DA360E5DB15216695"
      unitRef="usd">126000000</us-gaap:AssetImpairmentCharges>
    <pfe:BusinessInfrastructureAlignmentCosts
      contextRef="FD2016Q3QTD_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember"
      decimals="-6"
      id="d43771853e3886-wk-Fact-214FDB7F2FDD54F1A5930E33E66DEDA7"
      unitRef="usd">69000000</pfe:BusinessInfrastructureAlignmentCosts>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="FD2016Q3QTD_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember"
      decimals="-6"
      id="d43771853e3890-wk-Fact-A6DE9F337DBA5C059E43788A35061556"
      unitRef="usd">-17000000</us-gaap:OtherOperatingIncomeExpenseNet>
    <pfe:RestructuringChargesandImplementationCosts
      contextRef="FD2017Q3YTD_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember"
      decimals="-6"
      id="d43771853e3931-wk-Fact-566A8C7FB2E9567F8627369F2F7110E1"
      unitRef="usd">253000000</pfe:RestructuringChargesandImplementationCosts>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="FD2017Q3YTD_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember"
      decimals="-6"
      id="d43771853e3935-wk-Fact-1CAE3E85970E5125B600FBCDDDEB3CF3"
      unitRef="usd">-191000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
      contextRef="FD2017Q3YTD_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_HISMember"
      decimals="-6"
      id="d43771853e3939-wk-Fact-871B8C7C6D2657B0A7A3802199B06C67"
      unitRef="usd">-52000000</us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal>
    <us-gaap:AssetImpairmentCharges
      contextRef="FD2017Q3YTD_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember"
      decimals="-6"
      id="d43771853e3944-wk-Fact-0FF0873A3B7C8B24FE3C91C31F8FEECB"
      unitRef="usd">127000000</us-gaap:AssetImpairmentCharges>
    <pfe:BusinessInfrastructureAlignmentCosts
      contextRef="FD2017Q3YTD_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember"
      decimals="-6"
      id="d43771853e3948-wk-Fact-47D7D731E2AA51849CDAC797D0EC8C44"
      unitRef="usd">54000000</pfe:BusinessInfrastructureAlignmentCosts>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="FD2017Q3YTD_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember"
      decimals="-6"
      id="d43771853e3952-wk-Fact-7AB7F74380385861BC9DE7E304F1441B"
      unitRef="usd">-119000000</us-gaap:OtherOperatingIncomeExpenseNet>
    <pfe:RestructuringChargesandImplementationCosts
      contextRef="FD2016Q3YTD_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember"
      decimals="-6"
      id="d43771853e3980-wk-Fact-DA4CD3647EB85DAD999F46FDE8BCC875"
      unitRef="usd">743000000</pfe:RestructuringChargesandImplementationCosts>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="FD2016Q3YTD_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember"
      decimals="-6"
      id="d43771853e3984-wk-Fact-6E5F463B046E559FB6203DF71B997D6C"
      unitRef="usd">-506000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
      contextRef="FD2016Q3YTD_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_HISMember"
      decimals="-8"
      id="d43771853e3988-wk-Fact-2934EDB57FC9F122D58206DC8FEEF818"
      unitRef="usd">-1400000000</us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal>
    <us-gaap:AssetImpairmentCharges
      contextRef="FD2016Q3YTD_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember"
      decimals="-8"
      id="d43771853e3993-wk-Fact-2B16F76028F051AB9F14E509E904CEDE"
      unitRef="usd">1100000000</us-gaap:AssetImpairmentCharges>
    <pfe:BusinessInfrastructureAlignmentCosts
      contextRef="FD2016Q3YTD_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember"
      decimals="-6"
      id="d43771853e3997-wk-Fact-51707D511E915781B85A68A1F96A23C3"
      unitRef="usd">180000000</pfe:BusinessInfrastructureAlignmentCosts>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="FD2016Q3YTD_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember"
      decimals="-6"
      id="d43771853e4001-wk-Fact-A953722E279E5F628E0F1194A6AD4CD0"
      unitRef="usd">-189000000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock
      contextRef="FD2017Q3YTD"
      id="TextSelection-B3DC163610C85BDB8A33634D6C9634CD-0-wk-Fact-A284F798559C51C390060107A40A445E">&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.41520467836257%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="23"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:28%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table provides revenues by geographic area:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Three Months Ended&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Nine Months Ended&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;October&#160;1, &lt;br/&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;October&#160;2, &lt;br/&gt;2016&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Change&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;October&#160;1, &lt;br/&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;October&#160;2, &lt;br/&gt;2016&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Change&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,534&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,530&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;19,516&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;19,561&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Developed Europe&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,163&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,218&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,309&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,982&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Developed Rest of World&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,632&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,711&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,797&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,940&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Emerging Markets&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(c)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,839&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,586&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8,222&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7,714&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;13,168&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;13,045&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;38,843&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;39,196&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Developed Europe region includes the following markets: Western Europe, Scandinavian countries and Finland.&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; Revenues denominated in euros were &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$1.7 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; in both the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;third quarter&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;text-align:center;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;text-align:center;"&gt;2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;, and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$5.0 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$5.3 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; in the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;first nine months of&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;text-align:center;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;text-align:center;"&gt;2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;, respectively.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Developed Rest of World region includes the following markets: Japan, Canada, Australia, South Korea and New Zealand.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(c)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Emerging Markets region includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Africa, Eastern Europe, Central Europe, the Middle East and Turkey.&lt;/span&gt;</us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3QTD_us-gaap_StatementGeographicalAxis_country_US"
      decimals="-6"
      id="d43771853e4443-wk-Fact-0EA10CF754CD5C9DB01D72A4A1556529"
      unitRef="usd">6534000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3QTD_us-gaap_StatementGeographicalAxis_country_US"
      decimals="-6"
      id="d43771853e4462-wk-Fact-F97ABA1D718F526BA78D768C9F338C6C"
      unitRef="usd">6530000000</us-gaap:SalesRevenueGoodsNet>
    <pfe:PercentageChangeInRevenue
      contextRef="FD2017Q3QTD_us-gaap_StatementGeographicalAxis_country_US"
      decimals="2"
      id="d43771853e4476-wk-Fact-196BFDB75FA651D398D5C064BC502C40"
      unitRef="number">0</pfe:PercentageChangeInRevenue>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3YTD_us-gaap_StatementGeographicalAxis_country_US"
      decimals="-6"
      id="d43771853e4496-wk-Fact-17C8CEFC90255E2E8A36C1F2C89B8B7A"
      unitRef="usd">19516000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3YTD_us-gaap_StatementGeographicalAxis_country_US"
      decimals="-6"
      id="d43771853e4515-wk-Fact-9F3DFC9719AA53928C17946C2F27D2D5"
      unitRef="usd">19561000000</us-gaap:SalesRevenueGoodsNet>
    <pfe:PercentageChangeInRevenue
      contextRef="FD2017Q3YTD_us-gaap_StatementGeographicalAxis_country_US"
      decimals="2"
      id="d43771853e4529-wk-Fact-B6F9B0C09A965788BE5881BC84869216"
      unitRef="number">0</pfe:PercentageChangeInRevenue>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3QTD_us-gaap_StatementGeographicalAxis_pfe_DevelopedEuropeMember"
      decimals="-6"
      id="d43771853e4552-wk-Fact-5BB441E685D3543B8C59407802A0ACC5"
      unitRef="usd">2163000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3QTD_us-gaap_StatementGeographicalAxis_pfe_DevelopedEuropeMember"
      decimals="-6"
      id="d43771853e4571-wk-Fact-B972D2BE08BE594FA3E2081E6C7190CF"
      unitRef="usd">2218000000</us-gaap:SalesRevenueGoodsNet>
    <pfe:PercentageChangeInRevenue
      contextRef="FD2017Q3QTD_us-gaap_StatementGeographicalAxis_pfe_DevelopedEuropeMember"
      decimals="2"
      id="d43771853e4590-wk-Fact-379798FC1BCC5947B93DE423936B8B64"
      unitRef="number">-0.02</pfe:PercentageChangeInRevenue>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3YTD_us-gaap_StatementGeographicalAxis_pfe_DevelopedEuropeMember"
      decimals="-6"
      id="d43771853e4606-wk-Fact-465B9433DD0F5F3D8D3A8DC7524E082A"
      unitRef="usd">6309000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3YTD_us-gaap_StatementGeographicalAxis_pfe_DevelopedEuropeMember"
      decimals="-6"
      id="d43771853e4625-wk-Fact-F7E35E4375AD52538A3022CD6B0C19EC"
      unitRef="usd">6982000000</us-gaap:SalesRevenueGoodsNet>
    <pfe:PercentageChangeInRevenue
      contextRef="FD2017Q3YTD_us-gaap_StatementGeographicalAxis_pfe_DevelopedEuropeMember"
      decimals="2"
      id="d43771853e4644-wk-Fact-A8E12836BA70521E8E7886584342E2F2"
      unitRef="number">-0.10</pfe:PercentageChangeInRevenue>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3QTD_us-gaap_StatementGeographicalAxis_pfe_DevelopedRestOfWorldMember"
      decimals="-6"
      id="d43771853e4668-wk-Fact-4DBF4C8A615D5B5885A229550C249596"
      unitRef="usd">1632000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3QTD_us-gaap_StatementGeographicalAxis_pfe_DevelopedRestOfWorldMember"
      decimals="-6"
      id="d43771853e4687-wk-Fact-16BC8C896FAA55B4BECE452FC941C562"
      unitRef="usd">1711000000</us-gaap:SalesRevenueGoodsNet>
    <pfe:PercentageChangeInRevenue
      contextRef="FD2017Q3QTD_us-gaap_StatementGeographicalAxis_pfe_DevelopedRestOfWorldMember"
      decimals="2"
      id="d43771853e4706-wk-Fact-A9623F46D9315CFAA20B6FD10082039D"
      unitRef="number">-0.05</pfe:PercentageChangeInRevenue>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3YTD_us-gaap_StatementGeographicalAxis_pfe_DevelopedRestOfWorldMember"
      decimals="-6"
      id="d43771853e4722-wk-Fact-A244DBBB4D375344919B8BE000C88D5E"
      unitRef="usd">4797000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3YTD_us-gaap_StatementGeographicalAxis_pfe_DevelopedRestOfWorldMember"
      decimals="-6"
      id="d43771853e4741-wk-Fact-B1B730E391FC52EF8914EC8E437455FB"
      unitRef="usd">4940000000</us-gaap:SalesRevenueGoodsNet>
    <pfe:PercentageChangeInRevenue
      contextRef="FD2017Q3YTD_us-gaap_StatementGeographicalAxis_pfe_DevelopedRestOfWorldMember"
      decimals="2"
      id="d43771853e4760-wk-Fact-3C874C1F4C8853D68A9C0BEB283CEC51"
      unitRef="number">-0.03</pfe:PercentageChangeInRevenue>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3QTD_us-gaap_StatementGeographicalAxis_pfe_EmergingMarketsMember"
      decimals="-6"
      id="d43771853e4784-wk-Fact-B332B03EB88A57C19CFEC6C041626341"
      unitRef="usd">2839000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3QTD_us-gaap_StatementGeographicalAxis_pfe_EmergingMarketsMember"
      decimals="-6"
      id="d43771853e4803-wk-Fact-2DA3332AAA9A5E4A8EDAC00B3DB27FF9"
      unitRef="usd">2586000000</us-gaap:SalesRevenueGoodsNet>
    <pfe:PercentageChangeInRevenue
      contextRef="FD2017Q3QTD_us-gaap_StatementGeographicalAxis_pfe_EmergingMarketsMember"
      decimals="2"
      id="d43771853e4822-wk-Fact-4589B65A44FD5257A71D6C106B182464"
      unitRef="number">0.10</pfe:PercentageChangeInRevenue>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3YTD_us-gaap_StatementGeographicalAxis_pfe_EmergingMarketsMember"
      decimals="-6"
      id="d43771853e4837-wk-Fact-970AC97D21605174BC2DCA8AD22AECDF"
      unitRef="usd">8222000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3YTD_us-gaap_StatementGeographicalAxis_pfe_EmergingMarketsMember"
      decimals="-6"
      id="d43771853e4856-wk-Fact-8896D6C24D4F5AEEABD89DD662622B8D"
      unitRef="usd">7714000000</us-gaap:SalesRevenueGoodsNet>
    <pfe:PercentageChangeInRevenue
      contextRef="FD2017Q3YTD_us-gaap_StatementGeographicalAxis_pfe_EmergingMarketsMember"
      decimals="2"
      id="d43771853e4875-wk-Fact-E1E962311928538DB01EDDF50F83A4A9"
      unitRef="number">0.07</pfe:PercentageChangeInRevenue>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3QTD"
      decimals="-6"
      id="d43771853e4901-wk-Fact-739EC43DD13B5516B11DE41A93EEDF71"
      unitRef="usd">13168000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3QTD"
      decimals="-6"
      id="d43771853e4920-wk-Fact-08F7B1DEB2E25ACA94468FF7CE567177"
      unitRef="usd">13045000000</us-gaap:SalesRevenueGoodsNet>
    <pfe:PercentageChangeInRevenue
      contextRef="FD2017Q3QTD"
      decimals="2"
      id="d43771853e4934-wk-Fact-BD82079C9FF65D939C396D0EB390E35A"
      unitRef="number">0.01</pfe:PercentageChangeInRevenue>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3YTD"
      decimals="-6"
      id="d43771853e4954-wk-Fact-D1ABF3DF10655F18B16D5BEDE8158D66"
      unitRef="usd">38843000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3YTD"
      decimals="-6"
      id="d43771853e4973-wk-Fact-769863A67705599FBF10A0F9C982956F"
      unitRef="usd">39196000000</us-gaap:SalesRevenueGoodsNet>
    <pfe:PercentageChangeInRevenue
      contextRef="FD2017Q3YTD"
      decimals="2"
      id="d43771853e4987-wk-Fact-EA554CAB523557448216CC9E6AB99B0C"
      unitRef="number">-0.01</pfe:PercentageChangeInRevenue>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3QTD_us-gaap_CurrencyAxis_currency_EUR_us-gaap_StatementGeographicalAxis_pfe_DevelopedEuropeMember"
      decimals="-8"
      id="d43771853e5015-wk-Fact-8E8904BDAA9F5324B35C02BAA84B3364"
      unitRef="usd">1700000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3YTD_us-gaap_CurrencyAxis_currency_EUR_us-gaap_StatementGeographicalAxis_pfe_DevelopedEuropeMember"
      decimals="-8"
      id="d43771853e5037-wk-Fact-C846B4E888C353E9A2E2C25B78175769"
      unitRef="usd">5000000000.0</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3YTD_us-gaap_CurrencyAxis_currency_EUR_us-gaap_StatementGeographicalAxis_pfe_DevelopedEuropeMember"
      decimals="-8"
      id="d43771853e5041-wk-Fact-FCA4A3158A0758C4A9695F4278E7B491"
      unitRef="usd">5300000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
      contextRef="FD2017Q3YTD"
      id="TextSelection-49D25731B86F528799C83F48EBAD14A9-0-wk-Fact-F6E10F5E7CA055A1A83EB344BF04FB11">&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:48%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="17" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table provides detailed revenue information:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Three Months Ended&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Nine Months Ended&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:inherit;font-size:7pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;October&#160;1, &lt;br/&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;October&#160;2, &lt;br/&gt;2016&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;October&#160;1, &lt;br/&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;October&#160;2, &lt;br/&gt;2016&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;PFIZER INNOVATIVE HEALTH (IH)&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;8,118&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;7,332&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;23,204&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;21,471&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Internal Medicine&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;2,455&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;2,243&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;7,245&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;6,557&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Lyrica IH&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;1,150&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;1,049&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;3,382&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;3,107&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Eliquis alliance revenues and direct sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;644&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;449&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;1,813&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;1,225&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Chantix/Champix&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;240&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;198&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;727&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;631&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Viagra IH&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(c)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;206&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;297&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;711&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;897&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;BMP2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;79&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;63&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;198&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;175&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Toviaz&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;62&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;60&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;187&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;191&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;All other Internal Medicine&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;75&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;128&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;228&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;330&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Vaccines&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1,649&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1,641&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;4,385&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;4,576&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Prevnar 13/Prevenar 13&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;1,522&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;1,536&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;4,069&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;4,302&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;FSME/IMMUN-TicoVac&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;43&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;33&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;119&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;102&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;All other Vaccines&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;85&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;72&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;197&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;172&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Oncology&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1,616&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1,104&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;4,551&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;3,206&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Ibrance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;878&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;550&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;2,410&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;1,492&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Sutent&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;276&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;260&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;805&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;823&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Xalkori&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;146&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;140&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;442&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;415&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Xtandi alliance revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;150&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;422&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Inlyta&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;84&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;95&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;256&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;304&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Bosulif&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;57&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;43&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;163&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;121&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;All other Oncology&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;26&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;15&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;54&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;49&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Inflammation &amp;amp; Immunology (I&amp;amp;I)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;960&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;2,863&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;2,907&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Enbrel (Outside the U.S. and Canada)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;613&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;701&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;1,818&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;2,201&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Xeljanz&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;348&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;235&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;935&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;649&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Eucrisa&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;15&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;33&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;All other I&amp;amp;I&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;23&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;24&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;78&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;57&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Rare Disease&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;569&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;585&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1,637&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1,768&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;BeneFIX&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;151&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;176&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;453&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;543&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Refacto AF/Xyntha&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;140&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;140&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;409&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;408&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Genotropin&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;136&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;147&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;375&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;425&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Somavert&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;65&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;59&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;182&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;173&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;All other Rare Disease&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;77&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;64&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;218&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;219&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Consumer Healthcare&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;829&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;798&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;2,522&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;2,457&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;PFIZER ESSENTIAL HEALTH (EH)&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(d)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;5,050&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;5,712&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;15,639&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;17,725&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Legacy Established Products (LEP)&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(e)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;2,681&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;2,708&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;7,995&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;8,373&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Lipitor&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;491&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;422&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;1,341&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;1,294&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Premarin family&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;238&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;244&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;711&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;751&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Norvasc&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;226&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;238&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;684&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;714&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;EpiPen&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;82&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;110&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;253&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;300&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Xalatan/Xalacom&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;83&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;91&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;241&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;273&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Effexor&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;76&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;70&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;215&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;207&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Zoloft&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;78&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;72&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;215&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;228&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Zithromax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;61&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;56&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;202&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;203&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Relpax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;50&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;83&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;193&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;248&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Xanax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;58&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;55&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;164&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;163&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;All other LEP&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;1,237&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;1,268&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;3,776&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;3,992&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Sterile Injectable Pharmaceuticals (SIP)&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(f)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1,273&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1,461&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;4,270&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;4,481&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Medrol&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;109&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;102&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;352&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;330&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Sulperazon&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;114&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;102&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;345&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;304&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Fragmin&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;79&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;80&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;221&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;240&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Tygacil&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;60&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;69&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;192&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;203&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Precedex&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;51&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;64&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;182&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;199&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;All other SIP&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;860&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;1,044&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;2,977&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;3,206&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:48%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Three Months Ended&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Nine Months Ended&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:inherit;font-size:7pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;October&#160;1, &lt;br/&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;October&#160;2, &lt;br/&gt;2016&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;October&#160;1, &lt;br/&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;October&#160;2, &lt;br/&gt;2016&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Peri-LOE Products&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(g)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;794&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1,023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;2,398&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;3,224&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Celebrex&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;212&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;194&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;564&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;550&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Lyrica EH&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;134&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;191&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;428&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;623&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Vfend&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;97&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;140&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;305&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;459&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Viagra EH&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(c)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;102&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;89&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;285&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;286&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Pristiq&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;69&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;174&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;230&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;546&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Zyvox&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;68&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;94&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;220&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;334&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Revatio&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;58&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;73&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;189&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;213&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;All other Peri-LOE Products&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;55&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;68&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;176&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;214&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Biosimilars&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(h)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;141&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;83&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;367&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;228&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Inflectra/Remsima&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;112&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;49&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;284&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;130&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;All other Biosimilars&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;28&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;34&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;82&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;97&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Pfizer CentreOne&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(i)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;161&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;156&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;514&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;540&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Hospira Infusion Systems (HIS)&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(j)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;281&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;97&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;879&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;13,168&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;13,045&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;38,843&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;39,196&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Total Lyrica&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1,285&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1,240&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;3,810&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;3,730&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Total Viagra&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(c)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;308&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;387&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;996&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1,183&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Total Alliance revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;741&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;419&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;2,112&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1,155&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;The IH business encompasses Internal Medicine, Vaccines, Oncology, Inflammation &amp;amp; Immunology, Rare Disease and Consumer Healthcare. Through December 31, 2016, includes Duavive/Duavee and Viviant (recorded in All other Internal Medicine in 2016), which were transferred from Innovative Health to Essential Health effective January 1, 2017 (recorded in All other LEP (EH) beginning January 1, 2017), in order to align these products with our management of the women&#x2019;s health portfolio within EH. &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Lyrica revenues from all of Europe, Russia, Turkey, Israel and Central Asia countries are included in Lyrica EH. All other Lyrica revenues are included in Lyrica IH. Total Lyrica revenues represent the aggregate of worldwide revenues from Lyrica IH and Lyrica EH. &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(c)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Viagra revenues from the U.S. and Canada are included in Viagra IH. All other Viagra revenues are included in Viagra EH. Total Viagra revenues represent the aggregate of worldwide revenues from Viagra IH and Viagra EH. &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(d)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;The EH business encompasses Legacy Established Products, Sterile Injectable Pharmaceuticals, Peri-LOE Products, Biosimilars, Pfizer CentreOne and HIS (through February 2, 2017) and includes all legacy Hospira commercial operations.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(e)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Legacy Established Products primarily include products that have lost patent protection (excluding Sterile Injectable Pharmaceuticals and Peri-LOE Products). Effective January 1, 2017, All other LEP includes Duavive/Duavee and Viviant, which were transferred from Innovative Health (recorded in All other Internal Medicine (IH) in 2016), in order to align these products with our management of the women&#x2019;s health portfolio within EH.&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt; &lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;See note (a) above.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(f) &lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Sterile Injectable Pharmaceuticals include generic injectables and proprietary specialty injectables (excluding Peri-LOE Products). &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(g)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Peri-LOE Products include products that have recently lost or are anticipated to soon lose patent protection. These products include: Lyrica in Europe, Russia, Turkey, Israel and Central Asia; Viagra in all countries (excluding the U.S. and Canada); and worldwide revenues for Celebrex, Pristiq, Zyvox, Vfend, Revatio and Inspra. &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(h)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Biosimilars include Inflectra/Remsima (biosimilar infliximab) in the U.S. and certain international markets, Nivestim (biosimilar filgrastim) in certain European, Asian and Africa/Middle Eastern markets and Retacrit (biosimilar epoetin zeta) in certain European and Africa/Middle Eastern markets. &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(i)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Pfizer CentreOne includes revenues from our contract manufacturing and active pharmaceutical ingredient sales operation, including sterile injectables contract manufacturing, and revenues related to our manufacturing and supply agreements, including with Zoetis. &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(j)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;HIS (through February 2, 2017) includes Medication Management Systems products composed of infusion pumps and related software and services, as well as IV Infusion Products, including large volume IV solutions and their associated administration sets.&lt;/span&gt;</us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e5430-wk-Fact-C92E4F643F355942826164E220B2CDBA"
      unitRef="usd">8118000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e5449-wk-Fact-CB8A98F9684B5E90A54FF33CE216657C"
      unitRef="usd">7332000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e5469-wk-Fact-A95EC0EF20D05434AF953959C36E2AA3"
      unitRef="usd">23204000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e5488-wk-Fact-F89CB7AD3161526488B19688958B0E65"
      unitRef="usd">21471000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e5513-wk-Fact-CA16524707115418ACA6F55DC07EDB91"
      unitRef="usd">2455000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e5532-wk-Fact-3706400825245EE59A5F3CE23F7A4638"
      unitRef="usd">2243000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e5552-wk-Fact-41748AC25A5956969664BB602450202F"
      unitRef="usd">7245000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e5571-wk-Fact-A566B5CCA725505FBE0CCBD0E5B0D9C3"
      unitRef="usd">6557000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InternalMedicineMember_us-gaap_ProductOrServiceAxis_pfe_LyricaMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e5593-wk-Fact-92C4B36CCF2B53258C24D575B5A46D08"
      unitRef="usd">1150000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InternalMedicineMember_us-gaap_ProductOrServiceAxis_pfe_LyricaMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e5612-wk-Fact-91BE74609E00525280568DAA60F6DF3B"
      unitRef="usd">1049000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InternalMedicineMember_us-gaap_ProductOrServiceAxis_pfe_LyricaMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e5631-wk-Fact-9D09FA5E842755B1A0C73898B8865ED0"
      unitRef="usd">3382000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InternalMedicineMember_us-gaap_ProductOrServiceAxis_pfe_LyricaMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e5651-wk-Fact-B2EC756D8A9E5AF6969297EE142A38CF"
      unitRef="usd">3107000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InternalMedicineMember_us-gaap_ProductOrServiceAxis_pfe_EliquisMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e5676-wk-Fact-D171327093C15ED48BD61C1B80CD56A4"
      unitRef="usd">644000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InternalMedicineMember_us-gaap_ProductOrServiceAxis_pfe_EliquisMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e5695-wk-Fact-B53E687002905A7CB9CDCE789BE5C230"
      unitRef="usd">449000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InternalMedicineMember_us-gaap_ProductOrServiceAxis_pfe_EliquisMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e5714-wk-Fact-5A8BA30C5E2052EEBE7C6776D447D8DE"
      unitRef="usd">1813000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InternalMedicineMember_us-gaap_ProductOrServiceAxis_pfe_EliquisMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e5734-wk-Fact-036B59F8F72459729D84552CABD6D290"
      unitRef="usd">1225000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InternalMedicineMember_us-gaap_ProductOrServiceAxis_pfe_ChantixChampixMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e5759-wk-Fact-4657C468E2C65C92BD2ABB46F6BA77BA"
      unitRef="usd">240000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InternalMedicineMember_us-gaap_ProductOrServiceAxis_pfe_ChantixChampixMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e5778-wk-Fact-A1D511A04C5C55CBB466AD3F603D2DF6"
      unitRef="usd">198000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InternalMedicineMember_us-gaap_ProductOrServiceAxis_pfe_ChantixChampixMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e5797-wk-Fact-3F08840BF0F755898FB0502206E7BA27"
      unitRef="usd">727000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InternalMedicineMember_us-gaap_ProductOrServiceAxis_pfe_ChantixChampixMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e5817-wk-Fact-D2F37A473E40522EBE11CEC55D7345CF"
      unitRef="usd">631000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InternalMedicineMember_us-gaap_ProductOrServiceAxis_pfe_ViagraMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e5844-wk-Fact-C4B5621B0E4A59B3974A957DE7295490"
      unitRef="usd">206000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InternalMedicineMember_us-gaap_ProductOrServiceAxis_pfe_ViagraMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e5863-wk-Fact-1F06BFCD01CA55BFA37745ACCFA9290A"
      unitRef="usd">297000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InternalMedicineMember_us-gaap_ProductOrServiceAxis_pfe_ViagraMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e5882-wk-Fact-035E25AAED92520288A7CD55C86FFB01"
      unitRef="usd">711000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InternalMedicineMember_us-gaap_ProductOrServiceAxis_pfe_ViagraMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e5902-wk-Fact-96034CF0E4F8560C81E68935C2975A14"
      unitRef="usd">897000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InternalMedicineMember_us-gaap_ProductOrServiceAxis_pfe_BMP2Member_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e5927-wk-Fact-142E65278AE6532AA590EBBCD717A2B8"
      unitRef="usd">79000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InternalMedicineMember_us-gaap_ProductOrServiceAxis_pfe_BMP2Member_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e5946-wk-Fact-A61A879115A4506186E498490D97E0AF"
      unitRef="usd">63000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InternalMedicineMember_us-gaap_ProductOrServiceAxis_pfe_BMP2Member_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e5965-wk-Fact-4AB54F2A88CE587296961BC5EDD7B4F1"
      unitRef="usd">198000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InternalMedicineMember_us-gaap_ProductOrServiceAxis_pfe_BMP2Member_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e5985-wk-Fact-25A4B09EEA225883A45F9F720B0255C7"
      unitRef="usd">175000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InternalMedicineMember_us-gaap_ProductOrServiceAxis_pfe_ToviazMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e6010-wk-Fact-DFBC44A3B2F256D89E8352F65BCD80AA"
      unitRef="usd">62000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InternalMedicineMember_us-gaap_ProductOrServiceAxis_pfe_ToviazMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e6029-wk-Fact-ABE7D0EA841056008FD6062A7C39DCF7"
      unitRef="usd">60000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InternalMedicineMember_us-gaap_ProductOrServiceAxis_pfe_ToviazMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e6048-wk-Fact-4650451D4A7751FA869FFA12F7003E58"
      unitRef="usd">187000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InternalMedicineMember_us-gaap_ProductOrServiceAxis_pfe_ToviazMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e6068-wk-Fact-6C13C40E22545F58BD2C66B07FFBA38B"
      unitRef="usd">191000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InternalMedicineMember_us-gaap_ProductOrServiceAxis_pfe_AllOtherInternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e6094-wk-Fact-0C7EC998FC4E50E2B902BE677AA9DC99"
      unitRef="usd">75000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InternalMedicineMember_us-gaap_ProductOrServiceAxis_pfe_AllOtherInternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e6113-wk-Fact-015CDB41359B586F89ED430E8B803A71"
      unitRef="usd">128000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InternalMedicineMember_us-gaap_ProductOrServiceAxis_pfe_AllOtherInternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e6132-wk-Fact-694A0FD2AEB153E58CB6BF3309DCBAF7"
      unitRef="usd">228000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InternalMedicineMember_us-gaap_ProductOrServiceAxis_pfe_AllOtherInternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e6152-wk-Fact-F216298EC60A5A65B68CF963E1BE237E"
      unitRef="usd">330000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e6182-wk-Fact-F3FCBA95731F52C08EA41369F2E81D7F"
      unitRef="usd">1649000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e6201-wk-Fact-5BD3996759ED5CA9B9F1B5C5097FD0B6"
      unitRef="usd">1641000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e6221-wk-Fact-8975CADB3E155E6382572B4E39D69060"
      unitRef="usd">4385000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e6240-wk-Fact-E2D42F0B08935EDDBA04010AD3D25E86"
      unitRef="usd">4576000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_VaccinesMember_us-gaap_ProductOrServiceAxis_pfe_PrevnarPrevenarFamilyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e6260-wk-Fact-F1D03E298AFE5BB49EE38507362DFDFA"
      unitRef="usd">1522000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_VaccinesMember_us-gaap_ProductOrServiceAxis_pfe_PrevnarPrevenarFamilyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e6279-wk-Fact-AE220AEF612A5565B70C949960E90FD0"
      unitRef="usd">1536000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_VaccinesMember_us-gaap_ProductOrServiceAxis_pfe_PrevnarPrevenarFamilyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e6298-wk-Fact-B83EE0EEEF5650C9915D3EEEA2C9E44F"
      unitRef="usd">4069000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_VaccinesMember_us-gaap_ProductOrServiceAxis_pfe_PrevnarPrevenarFamilyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e6318-wk-Fact-8EE9C2E338FC5C3F94F62D1D10A9FABD"
      unitRef="usd">4302000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_VaccinesMember_us-gaap_ProductOrServiceAxis_pfe_FSMEIMMUNTicoVacMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e6343-wk-Fact-C1B77BB95D575829AE48D0BE96B7A983"
      unitRef="usd">43000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_VaccinesMember_us-gaap_ProductOrServiceAxis_pfe_FSMEIMMUNTicoVacMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e6362-wk-Fact-8D880736DA155DB5BC71B0FC575FA9C9"
      unitRef="usd">33000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_VaccinesMember_us-gaap_ProductOrServiceAxis_pfe_FSMEIMMUNTicoVacMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e6381-wk-Fact-6FFF21C6992C51A48DBA39AC95ABE556"
      unitRef="usd">119000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_VaccinesMember_us-gaap_ProductOrServiceAxis_pfe_FSMEIMMUNTicoVacMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e6401-wk-Fact-82EC0B3C97A65D948782FCC8492DC0CB"
      unitRef="usd">102000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_VaccinesMember_us-gaap_ProductOrServiceAxis_pfe_OtherVaccinesProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e6426-wk-Fact-6073CDC8548A501C818D6BA5BB71754B"
      unitRef="usd">85000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_VaccinesMember_us-gaap_ProductOrServiceAxis_pfe_OtherVaccinesProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e6445-wk-Fact-EA0282B4215E5EB59B0A858B7C943CFA"
      unitRef="usd">72000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_VaccinesMember_us-gaap_ProductOrServiceAxis_pfe_OtherVaccinesProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e6464-wk-Fact-92A1955541685690B9D2FD5CB311B9BA"
      unitRef="usd">197000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_VaccinesMember_us-gaap_ProductOrServiceAxis_pfe_OtherVaccinesProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e6484-wk-Fact-836A46AAB359562B9EA24D489A3362EA"
      unitRef="usd">172000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e6514-wk-Fact-08860EE288125986894C909F92BCF2A4"
      unitRef="usd">1616000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e6533-wk-Fact-DE27B499390D577195E3B6FF88C2FD46"
      unitRef="usd">1104000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e6553-wk-Fact-E911DF3381F35F38A1DF45AEDBD73FD9"
      unitRef="usd">4551000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e6572-wk-Fact-B94E4881267C5825B4EE800ADAA6D64A"
      unitRef="usd">3206000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_OncologyMember_us-gaap_ProductOrServiceAxis_pfe_IbranceMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e6592-wk-Fact-0DF89FAF74285087B3DBDCB2D3E032A8"
      unitRef="usd">878000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_OncologyMember_us-gaap_ProductOrServiceAxis_pfe_IbranceMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e6611-wk-Fact-C34E6A4C5B355A8BB64F366F84AF85A6"
      unitRef="usd">550000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_OncologyMember_us-gaap_ProductOrServiceAxis_pfe_IbranceMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e6630-wk-Fact-43AC460D5B15527C8C4DB286489E2C2F"
      unitRef="usd">2410000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_OncologyMember_us-gaap_ProductOrServiceAxis_pfe_IbranceMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e6650-wk-Fact-7EEC7835C987598BA91D539D1D33741E"
      unitRef="usd">1492000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_OncologyMember_us-gaap_ProductOrServiceAxis_pfe_SutentMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e6675-wk-Fact-AAD30F67E3565D6297813A2C98D4C6B5"
      unitRef="usd">276000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_OncologyMember_us-gaap_ProductOrServiceAxis_pfe_SutentMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e6694-wk-Fact-55173256EA9450E094C7CA17D252112E"
      unitRef="usd">260000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_OncologyMember_us-gaap_ProductOrServiceAxis_pfe_SutentMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e6713-wk-Fact-9087A7F6DD65523D888D34042DDFA88C"
      unitRef="usd">805000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_OncologyMember_us-gaap_ProductOrServiceAxis_pfe_SutentMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e6733-wk-Fact-92E0FA0AFEFD567C8DCA6935C8539F56"
      unitRef="usd">823000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_OncologyMember_us-gaap_ProductOrServiceAxis_pfe_XalkoriMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e6758-wk-Fact-A465E9D72ACB547BA03784F4DEABD170"
      unitRef="usd">146000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_OncologyMember_us-gaap_ProductOrServiceAxis_pfe_XalkoriMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e6777-wk-Fact-1EF2AA07098B51BCABA26C08A4E2EE29"
      unitRef="usd">140000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_OncologyMember_us-gaap_ProductOrServiceAxis_pfe_XalkoriMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e6796-wk-Fact-DA08E1D6E8AE59B9A96BDAA0DB9F50C2"
      unitRef="usd">442000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_OncologyMember_us-gaap_ProductOrServiceAxis_pfe_XalkoriMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e6816-wk-Fact-71C4FA44FB4D5F10B54E6BA126566708"
      unitRef="usd">415000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_OncologyMember_us-gaap_ProductOrServiceAxis_pfe_XtandiAllianceMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e6841-wk-Fact-C277EBD5B6E55350B5ABE43DCB81B2E3"
      unitRef="usd">150000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_OncologyMember_us-gaap_ProductOrServiceAxis_pfe_XtandiAllianceMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e6860-wk-Fact-633D0A720D6F0F6B11CA06EB48CFC067"
      unitRef="usd">2000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_OncologyMember_us-gaap_ProductOrServiceAxis_pfe_XtandiAllianceMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e6879-wk-Fact-10637337C98A5CF2AEA82F99FC8BF786"
      unitRef="usd">422000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_OncologyMember_us-gaap_ProductOrServiceAxis_pfe_XtandiAllianceMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e6899-wk-Fact-EA16560E96B45E27A58E57CB2F6D89A4"
      unitRef="usd">2000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_OncologyMember_us-gaap_ProductOrServiceAxis_pfe_InlytaMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e6924-wk-Fact-B5D93F1F50C05633A02F37D05FCD4FEB"
      unitRef="usd">84000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_OncologyMember_us-gaap_ProductOrServiceAxis_pfe_InlytaMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e6943-wk-Fact-D43C6DB9B5CF57AABD4144362BC80D42"
      unitRef="usd">95000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_OncologyMember_us-gaap_ProductOrServiceAxis_pfe_InlytaMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e6962-wk-Fact-2FCF41B5C7CA5DF9BA0C83AD4F9E3868"
      unitRef="usd">256000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_OncologyMember_us-gaap_ProductOrServiceAxis_pfe_InlytaMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e6982-wk-Fact-266FE0D041AD51B3BADFC22625A61E51"
      unitRef="usd">304000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_OncologyMember_us-gaap_ProductOrServiceAxis_pfe_BosulifMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e7008-wk-Fact-73EFEC7C5B0F5FB8AAB73A81AFA6625D"
      unitRef="usd">57000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_OncologyMember_us-gaap_ProductOrServiceAxis_pfe_BosulifMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e7027-wk-Fact-B8081C8455885B62AE392826639A12E7"
      unitRef="usd">43000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_OncologyMember_us-gaap_ProductOrServiceAxis_pfe_BosulifMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e7046-wk-Fact-10E6CE67EF6B54B3A47135CE5B66BF47"
      unitRef="usd">163000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_OncologyMember_us-gaap_ProductOrServiceAxis_pfe_BosulifMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e7066-wk-Fact-131F3EDDFD7D52FB952EED7E29955E92"
      unitRef="usd">121000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_OncologyMember_us-gaap_ProductOrServiceAxis_pfe_OtherOncologyProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e7091-wk-Fact-8FB7D77D7D87509EA2042D6B3FCB31C0"
      unitRef="usd">26000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_OncologyMember_us-gaap_ProductOrServiceAxis_pfe_OtherOncologyProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e7110-wk-Fact-A9C00ABE4C095675BFE21B9753F37E1B"
      unitRef="usd">15000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_OncologyMember_us-gaap_ProductOrServiceAxis_pfe_OtherOncologyProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e7129-wk-Fact-5427E2C43C7A5EA0940BC3C4BAFBE114"
      unitRef="usd">54000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_OncologyMember_us-gaap_ProductOrServiceAxis_pfe_OtherOncologyProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e7149-wk-Fact-EFDF08F413325FA994B39D089AB63398"
      unitRef="usd">49000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e7179-wk-Fact-219B87F1F5BD586DBB8F06C00D233740"
      unitRef="usd">1000000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e7198-wk-Fact-673C6E5A33FC51C68F9F0B9685E1C2F1"
      unitRef="usd">960000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e7218-wk-Fact-4A560A4F38C95E0BA9F9573B86D87D80"
      unitRef="usd">2863000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e7237-wk-Fact-B886B803C4265A719A50FB648A126929"
      unitRef="usd">2907000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InflammationandImmunologyMember_us-gaap_ProductOrServiceAxis_pfe_EnbrelMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e7257-wk-Fact-8B74C3380E3C501091B8DDE55E031995"
      unitRef="usd">613000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InflammationandImmunologyMember_us-gaap_ProductOrServiceAxis_pfe_EnbrelMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e7276-wk-Fact-BBBA91223D865B01A9D02A82ED5D5112"
      unitRef="usd">701000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InflammationandImmunologyMember_us-gaap_ProductOrServiceAxis_pfe_EnbrelMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e7295-wk-Fact-8E787801D82452BD87435D5EDD146AE4"
      unitRef="usd">1818000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InflammationandImmunologyMember_us-gaap_ProductOrServiceAxis_pfe_EnbrelMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e7315-wk-Fact-16957E3FC1865EC5818D304B896D3077"
      unitRef="usd">2201000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InflammationandImmunologyMember_us-gaap_ProductOrServiceAxis_pfe_XeljanzMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e7340-wk-Fact-1F22161872CA5538800B3F0F624588F0"
      unitRef="usd">348000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InflammationandImmunologyMember_us-gaap_ProductOrServiceAxis_pfe_XeljanzMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e7359-wk-Fact-D74A347EE03055F49E204091A2441955"
      unitRef="usd">235000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InflammationandImmunologyMember_us-gaap_ProductOrServiceAxis_pfe_XeljanzMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e7378-wk-Fact-C9F8A169F48D520FB7B2A38A107244B2"
      unitRef="usd">935000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InflammationandImmunologyMember_us-gaap_ProductOrServiceAxis_pfe_XeljanzMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e7398-wk-Fact-E2EB24E2CBDD5235A20D3C6FA6BA3A47"
      unitRef="usd">649000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InflammationandImmunologyMember_us-gaap_ProductOrServiceAxis_pfe_EucrisaMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e7422-wk-Fact-7953D783030F592BA8412FAEC83B50B7"
      unitRef="usd">15000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InflammationandImmunologyMember_us-gaap_ProductOrServiceAxis_pfe_EucrisaMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e7440-wk-Fact-95D977890609508D8D97487E681DD7A8"
      unitRef="usd">0</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InflammationandImmunologyMember_us-gaap_ProductOrServiceAxis_pfe_EucrisaMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e7458-wk-Fact-08EB232BAC905890B3444837B08BD4C3"
      unitRef="usd">33000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InflammationandImmunologyMember_us-gaap_ProductOrServiceAxis_pfe_EucrisaMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e7477-wk-Fact-D36D0948952453FF8454EDED26949131"
      unitRef="usd">0</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InflammationandImmunologyMember_us-gaap_ProductOrServiceAxis_pfe_AllOtherInflammationandImmunologyProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e7502-wk-Fact-675636511AB75FC68785AE8E8FA5510C"
      unitRef="usd">23000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InflammationandImmunologyMember_us-gaap_ProductOrServiceAxis_pfe_AllOtherInflammationandImmunologyProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e7521-wk-Fact-C3C364E503C85480A039A92DB5ECB885"
      unitRef="usd">24000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InflammationandImmunologyMember_us-gaap_ProductOrServiceAxis_pfe_AllOtherInflammationandImmunologyProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e7540-wk-Fact-58090A45EE23591F9421C0676B410E6F"
      unitRef="usd">78000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_InflammationandImmunologyMember_us-gaap_ProductOrServiceAxis_pfe_AllOtherInflammationandImmunologyProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e7560-wk-Fact-5F26EACB136F5EF28A856B0B174BF7DF"
      unitRef="usd">57000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e7590-wk-Fact-428E1568A6BF5B8E9B628219F6E50B5B"
      unitRef="usd">569000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e7609-wk-Fact-C67E33A41E0A5A08866F36100455BF9C"
      unitRef="usd">585000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e7629-wk-Fact-F92AA48F92C0526287A732ACF00839D0"
      unitRef="usd">1637000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e7648-wk-Fact-78634444335D5A7985E0115A4F94838B"
      unitRef="usd">1768000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_RareDiseaseMember_us-gaap_ProductOrServiceAxis_pfe_BeneFIXMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e7668-wk-Fact-3A4992B73D7D515A9630C09A8E8D7022"
      unitRef="usd">151000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_RareDiseaseMember_us-gaap_ProductOrServiceAxis_pfe_BeneFIXMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e7687-wk-Fact-0C7378A7F4CF53A4BA6A80E65A0D72DF"
      unitRef="usd">176000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_RareDiseaseMember_us-gaap_ProductOrServiceAxis_pfe_BeneFIXMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e7706-wk-Fact-9CD99F7F9EC85E0B9C70AB6E20622F25"
      unitRef="usd">453000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_RareDiseaseMember_us-gaap_ProductOrServiceAxis_pfe_BeneFIXMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e7726-wk-Fact-06B14C244D6F5C4CBA25CA4E62AC7B0A"
      unitRef="usd">543000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_RareDiseaseMember_us-gaap_ProductOrServiceAxis_pfe_ReFactoAfXynthaMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e7751-wk-Fact-1732BED87F0656A9B0353C1C87A48553"
      unitRef="usd">140000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_RareDiseaseMember_us-gaap_ProductOrServiceAxis_pfe_ReFactoAfXynthaMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e7770-wk-Fact-F71BABD18CD45261A41A611A3AECACAB"
      unitRef="usd">140000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_RareDiseaseMember_us-gaap_ProductOrServiceAxis_pfe_ReFactoAfXynthaMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e7789-wk-Fact-72A7D9EBF47B57CDA0B3DE510E431909"
      unitRef="usd">409000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_RareDiseaseMember_us-gaap_ProductOrServiceAxis_pfe_ReFactoAfXynthaMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e7809-wk-Fact-FACE6D4B059252CEA63781A89FB54BDA"
      unitRef="usd">408000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_RareDiseaseMember_us-gaap_ProductOrServiceAxis_pfe_GenotropinMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e7834-wk-Fact-B3E9FD5A43325ECFA22B3F96FF93DA60"
      unitRef="usd">136000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_RareDiseaseMember_us-gaap_ProductOrServiceAxis_pfe_GenotropinMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e7853-wk-Fact-56994BBD5BA05DACB90C9F5407ADC80A"
      unitRef="usd">147000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_RareDiseaseMember_us-gaap_ProductOrServiceAxis_pfe_GenotropinMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e7872-wk-Fact-80643250DAFE53DCA821C8AA917098E3"
      unitRef="usd">375000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_RareDiseaseMember_us-gaap_ProductOrServiceAxis_pfe_GenotropinMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e7892-wk-Fact-AF731B3F4A5555AABD62FFB6A2BF12F1"
      unitRef="usd">425000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_RareDiseaseMember_us-gaap_ProductOrServiceAxis_pfe_SomavertMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e7918-wk-Fact-72B961E07B085F2F93A837DE59686CF5"
      unitRef="usd">65000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_RareDiseaseMember_us-gaap_ProductOrServiceAxis_pfe_SomavertMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e7937-wk-Fact-94F261CAD03B54B283A6FFDC0C8B3267"
      unitRef="usd">59000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_RareDiseaseMember_us-gaap_ProductOrServiceAxis_pfe_SomavertMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e7956-wk-Fact-AA4E8389AB1457D5B2A64893F6FED20E"
      unitRef="usd">182000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_RareDiseaseMember_us-gaap_ProductOrServiceAxis_pfe_SomavertMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e7976-wk-Fact-4C3732254DAD546F823FD75D885F90F6"
      unitRef="usd">173000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_RareDiseaseMember_us-gaap_ProductOrServiceAxis_pfe_AllOtherRareDiseaseProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e8001-wk-Fact-7CCD756011875D60BF26983F931E3C30"
      unitRef="usd">77000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_RareDiseaseMember_us-gaap_ProductOrServiceAxis_pfe_AllOtherRareDiseaseProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e8020-wk-Fact-C8F59D52403859FDAE25CE4B2D75B61F"
      unitRef="usd">64000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_RareDiseaseMember_us-gaap_ProductOrServiceAxis_pfe_AllOtherRareDiseaseProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e8039-wk-Fact-32B6C9E3886F5235AEFB1DB4E626DEF5"
      unitRef="usd">218000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_RareDiseaseMember_us-gaap_ProductOrServiceAxis_pfe_AllOtherRareDiseaseProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e8059-wk-Fact-01C7C71AE4C65077B69A2A356736E709"
      unitRef="usd">219000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_ConsumerHealthcareMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e8089-wk-Fact-876FA36A390750B09C5C3A6768A26CAE"
      unitRef="usd">829000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_ConsumerHealthcareMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e8108-wk-Fact-2B7A9FB3F508549A8C434D1BC267C9DF"
      unitRef="usd">798000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_ConsumerHealthcareMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e8128-wk-Fact-800805A59D7956DD8B18DC38E202BCFA"
      unitRef="usd">2522000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_InnovativeHealthBusinessMember_pfe_InnovativeProductsCategoryAxis_pfe_ConsumerHealthcareMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember"
      decimals="-6"
      id="d43771853e8147-wk-Fact-E5DAD62FA91F5B43957002F62E3B847B"
      unitRef="usd">2457000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e8174-wk-Fact-091C801F849C5456B9FD0DC999483C5D"
      unitRef="usd">5050000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e8193-wk-Fact-CA9E5961B1D758D2820894BDF915B4EC"
      unitRef="usd">5712000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e8213-wk-Fact-2C55373A40E0521188DF042ECD16B096"
      unitRef="usd">15639000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e8232-wk-Fact-C8F31244A5485CAB8850FBA2D1B3FB16"
      unitRef="usd">17725000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e8259-wk-Fact-EE748539AE775F7AB4E662FB43CE60E4"
      unitRef="usd">2681000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e8278-wk-Fact-4207856257675CFDB3EB4159D299660D"
      unitRef="usd">2708000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e8298-wk-Fact-89988FDDF95F52A4910F81944C0989F3"
      unitRef="usd">7995000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e8317-wk-Fact-9577FDA2F67253B8A7F69BB91B1286ED"
      unitRef="usd">8373000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_LipitorMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e8337-wk-Fact-4F7D0A0BF0B3547696F65B90925A51C6"
      unitRef="usd">491000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_LipitorMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e8356-wk-Fact-C5E580417C255B5A9496B3FDC6855AA2"
      unitRef="usd">422000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_LipitorMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e8375-wk-Fact-C58A86525FE35C3081B70829D7BE6C7F"
      unitRef="usd">1341000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_LipitorMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e8395-wk-Fact-8D063B8E215F521BA88075E95FC81EF0"
      unitRef="usd">1294000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_PremarinFamilyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e8420-wk-Fact-14843DFEC83A5E1FA820F208F5B581A0"
      unitRef="usd">238000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_PremarinFamilyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e8439-wk-Fact-EF1D7C93406B59DAB08DBBCDA794B94C"
      unitRef="usd">244000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_PremarinFamilyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e8458-wk-Fact-9A540CD7E91C53D98C0A6FA10FC45B37"
      unitRef="usd">711000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_PremarinFamilyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e8478-wk-Fact-5B0A95DDA6D55C2B93F040732E862770"
      unitRef="usd">751000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_NorvascMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e8503-wk-Fact-0329EED4FEA551388AB212092162364A"
      unitRef="usd">226000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_NorvascMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e8522-wk-Fact-A7080FE1586B5C65A5EAF5CFE4E627BD"
      unitRef="usd">238000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_NorvascMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e8541-wk-Fact-47FF728D9FBA58A983AF4392C02B9ACA"
      unitRef="usd">684000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_NorvascMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e8561-wk-Fact-EFEBBDE9757A5676A83DAD10B3D86F3C"
      unitRef="usd">714000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_EpiPenMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e8586-wk-Fact-472F881EBECC59D28306B926958946F7"
      unitRef="usd">82000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_EpiPenMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e8605-wk-Fact-AF2DC9ED10685A39963CB757C976F5D5"
      unitRef="usd">110000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_EpiPenMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e8624-wk-Fact-2D58F17354D35378BFCD3AD0420F7078"
      unitRef="usd">253000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_EpiPenMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e8644-wk-Fact-1852BFDBB2515865AE0923F4F1AE42A1"
      unitRef="usd">300000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_XalatanXalacomMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e8669-wk-Fact-08437CD1F5145373A32D15ECA655D8F8"
      unitRef="usd">83000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_XalatanXalacomMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e8688-wk-Fact-7AC6C61132045FAB988619467004F635"
      unitRef="usd">91000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_XalatanXalacomMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e8707-wk-Fact-99C5FED6B8365B31B1D529DDF43CAD1A"
      unitRef="usd">241000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_XalatanXalacomMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e8727-wk-Fact-CDBECF1B07C6582DA036B977F1BEA0A8"
      unitRef="usd">273000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_EffexorMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e8752-wk-Fact-46F602264FBF5C009D3E0D19A2ADF39E"
      unitRef="usd">76000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_EffexorMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e8771-wk-Fact-B89A0271EA4B5EC2B44DC1EFA92C2A64"
      unitRef="usd">70000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_EffexorMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e8790-wk-Fact-F46C5E0C8CB7528B873CE42E32D3A924"
      unitRef="usd">215000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_EffexorMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e8810-wk-Fact-CDE83E5A2B5253EEBF9FE8AD4E19EFAE"
      unitRef="usd">207000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_ZoloftMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e8836-wk-Fact-51894A4611925F1481FB10D8D30710CD"
      unitRef="usd">78000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_ZoloftMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e8855-wk-Fact-1FB983165CB755E4BAA54DA34AA453E4"
      unitRef="usd">72000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_ZoloftMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e8874-wk-Fact-4E9DE66D1EB65A6DB7D6835507CA8456"
      unitRef="usd">215000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_ZoloftMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e8894-wk-Fact-B1FF7EE0D7EA5813A45C9F669E2AA9E9"
      unitRef="usd">228000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_ZithromaxZmaxMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e8919-wk-Fact-7C63A1EB803858EEB8F3D2778FF33364"
      unitRef="usd">61000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_ZithromaxZmaxMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e8938-wk-Fact-AF25C8D0B0ED5632AB6C04C50AA8AA34"
      unitRef="usd">56000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_ZithromaxZmaxMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e8957-wk-Fact-B483F4B999D95F64B9375C52EF0577E9"
      unitRef="usd">202000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_ZithromaxZmaxMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e8977-wk-Fact-DC5E960BEB09595E8E440E43508EB16C"
      unitRef="usd">203000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_RelpaxMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e9002-wk-Fact-83792D6D5C2E51E9A6E69BCF9587E366"
      unitRef="usd">50000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_RelpaxMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e9021-wk-Fact-6316D660281758D5AB86C9A110286AB6"
      unitRef="usd">83000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_RelpaxMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e9040-wk-Fact-1AE5F92DFF9551489544871F0B38FF8E"
      unitRef="usd">193000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_RelpaxMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e9060-wk-Fact-D50DD10668A95FA2969BB39F2080B0CD"
      unitRef="usd">248000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_XanaxXanaxXRMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e9085-wk-Fact-2EAD78360E6D57E599307914B8AF4D6B"
      unitRef="usd">58000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_XanaxXanaxXRMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e9104-wk-Fact-75B41DCF45805CAFAD944707054CC12E"
      unitRef="usd">55000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_XanaxXanaxXRMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e9123-wk-Fact-EF12303BC8E9530A8CF9F8DDCD1E93B7"
      unitRef="usd">164000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_XanaxXanaxXRMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e9143-wk-Fact-575289DA5DFE59458CF75A39F1D0183F"
      unitRef="usd">163000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_OtherLegacyEstablishedProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e9168-wk-Fact-067FA3EE0C9C5D5B8E26BE6B521AC0C8"
      unitRef="usd">1237000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_OtherLegacyEstablishedProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e9187-wk-Fact-C237E2DC723D59E1968237F06BF3B3F7"
      unitRef="usd">1268000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_OtherLegacyEstablishedProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e9206-wk-Fact-8964D9DAE58D5D5493AE61BE40FF32D1"
      unitRef="usd">3776000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_LegacyEstablishedProductsMember_us-gaap_ProductOrServiceAxis_pfe_OtherLegacyEstablishedProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e9226-wk-Fact-5A218722537F5902999ED660D7E8DC78"
      unitRef="usd">3992000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_SterileInjectablePharmaceuticalsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e9258-wk-Fact-CD1BFB65FFF5532B973C2FBCB7BE8C3E"
      unitRef="usd">1273000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_SterileInjectablePharmaceuticalsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e9277-wk-Fact-AD73F3732CE450B3B05C9A766AE2063A"
      unitRef="usd">1461000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_SterileInjectablePharmaceuticalsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e9297-wk-Fact-61AE31A35DC45F109F24557407C6BF9E"
      unitRef="usd">4270000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_SterileInjectablePharmaceuticalsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e9316-wk-Fact-BD8207C538F258AB9385CEC1E820D409"
      unitRef="usd">4481000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_SterileInjectablePharmaceuticalsMember_us-gaap_ProductOrServiceAxis_pfe_MedrolMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e9336-wk-Fact-BEB835E7E1605E8FADA0A2A97E3A6888"
      unitRef="usd">109000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_SterileInjectablePharmaceuticalsMember_us-gaap_ProductOrServiceAxis_pfe_MedrolMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e9355-wk-Fact-673B8C7C812E5410B44343DF17426FF6"
      unitRef="usd">102000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_SterileInjectablePharmaceuticalsMember_us-gaap_ProductOrServiceAxis_pfe_MedrolMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e9374-wk-Fact-954F0556430B59A3BD2C5F259E64EA5E"
      unitRef="usd">352000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_SterileInjectablePharmaceuticalsMember_us-gaap_ProductOrServiceAxis_pfe_MedrolMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e9394-wk-Fact-69D44FAD9EB45BA48306018AA309F457"
      unitRef="usd">330000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_SterileInjectablePharmaceuticalsMember_us-gaap_ProductOrServiceAxis_pfe_SulperazonMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e9419-wk-Fact-3408B775D7DC5296953F514B51FF23A8"
      unitRef="usd">114000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_SterileInjectablePharmaceuticalsMember_us-gaap_ProductOrServiceAxis_pfe_SulperazonMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e9438-wk-Fact-78DF62543AFC55BB97CA930C8853E5B5"
      unitRef="usd">102000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_SterileInjectablePharmaceuticalsMember_us-gaap_ProductOrServiceAxis_pfe_SulperazonMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e9457-wk-Fact-43E76B4E175C5BBCAE82C132443F1E2F"
      unitRef="usd">345000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_SterileInjectablePharmaceuticalsMember_us-gaap_ProductOrServiceAxis_pfe_SulperazonMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e9477-wk-Fact-1986CF96884B543DB3761C2BDAA8CFE5"
      unitRef="usd">304000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_SterileInjectablePharmaceuticalsMember_us-gaap_ProductOrServiceAxis_pfe_FragminMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e9502-wk-Fact-403E9BF3AE335295948677D8AA616270"
      unitRef="usd">79000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_SterileInjectablePharmaceuticalsMember_us-gaap_ProductOrServiceAxis_pfe_FragminMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e9521-wk-Fact-4E72A888DC875E13A10C3DCAD6E412A8"
      unitRef="usd">80000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_SterileInjectablePharmaceuticalsMember_us-gaap_ProductOrServiceAxis_pfe_FragminMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e9540-wk-Fact-74390EB852125F548009578A70D131E9"
      unitRef="usd">221000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_SterileInjectablePharmaceuticalsMember_us-gaap_ProductOrServiceAxis_pfe_FragminMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e9560-wk-Fact-622A4C714FC9589A8791D825723DCF5F"
      unitRef="usd">240000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_SterileInjectablePharmaceuticalsMember_us-gaap_ProductOrServiceAxis_pfe_TygacilMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e9585-wk-Fact-859AF1BEC09351F687B1AC1130ACF600"
      unitRef="usd">60000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_SterileInjectablePharmaceuticalsMember_us-gaap_ProductOrServiceAxis_pfe_TygacilMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e9604-wk-Fact-D75DA6B18B2450C5B56DFECFB5E6CC70"
      unitRef="usd">69000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_SterileInjectablePharmaceuticalsMember_us-gaap_ProductOrServiceAxis_pfe_TygacilMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e9623-wk-Fact-152A91A936FD53EB814D9C05B28228DF"
      unitRef="usd">192000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_SterileInjectablePharmaceuticalsMember_us-gaap_ProductOrServiceAxis_pfe_TygacilMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e9643-wk-Fact-8E39861200715A3B876182637BDF6124"
      unitRef="usd">203000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_SterileInjectablePharmaceuticalsMember_us-gaap_ProductOrServiceAxis_pfe_PrecedexMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e9668-wk-Fact-5C552D20D9EC501BA74A6B22B7F14C7F"
      unitRef="usd">51000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_SterileInjectablePharmaceuticalsMember_us-gaap_ProductOrServiceAxis_pfe_PrecedexMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e9687-wk-Fact-5FF89D5E27D551B98A5B9037DCB462D8"
      unitRef="usd">64000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_SterileInjectablePharmaceuticalsMember_us-gaap_ProductOrServiceAxis_pfe_PrecedexMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e9706-wk-Fact-9F35AC92683F55728D31E5B3DDD103DA"
      unitRef="usd">182000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_SterileInjectablePharmaceuticalsMember_us-gaap_ProductOrServiceAxis_pfe_PrecedexMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e9726-wk-Fact-125AA1D3DEF35DC883411C795FBF77FB"
      unitRef="usd">199000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_SterileInjectablePharmaceuticalsMember_us-gaap_ProductOrServiceAxis_pfe_AllOtherSterileInjectablePharmaceuticalsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e9752-wk-Fact-714ED3F1767956A495B34EBF44362035"
      unitRef="usd">860000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_SterileInjectablePharmaceuticalsMember_us-gaap_ProductOrServiceAxis_pfe_AllOtherSterileInjectablePharmaceuticalsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e9771-wk-Fact-15D8B9658D3D54ACA6557E0E44C871AF"
      unitRef="usd">1044000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_SterileInjectablePharmaceuticalsMember_us-gaap_ProductOrServiceAxis_pfe_AllOtherSterileInjectablePharmaceuticalsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e9790-wk-Fact-222AA9D4DB3258FE856F943CB208455D"
      unitRef="usd">2977000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_SterileInjectablePharmaceuticalsMember_us-gaap_ProductOrServiceAxis_pfe_AllOtherSterileInjectablePharmaceuticalsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e9810-wk-Fact-88105E4607635686BD1EA55E2ADC180D"
      unitRef="usd">3206000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e10035-wk-Fact-9E503F48EBD8524C93A07C83B1436882"
      unitRef="usd">794000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e10054-wk-Fact-0FBFE9A681A053E09C98AD1EEF2EAB26"
      unitRef="usd">1023000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e10074-wk-Fact-A9C11CFF51AD52A5B91FCAB3F6F3901C"
      unitRef="usd">2398000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e10093-wk-Fact-A3F1EC328F9650DFB210D8224644F83E"
      unitRef="usd">3224000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_ProductOrServiceAxis_pfe_CelebrexMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e10113-wk-Fact-128EA3181C745B7C8B9F3EC94CB87020"
      unitRef="usd">212000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_ProductOrServiceAxis_pfe_CelebrexMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e10132-wk-Fact-76A22FA87A9C500D8F6C27B6C096BCF0"
      unitRef="usd">194000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_ProductOrServiceAxis_pfe_CelebrexMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e10151-wk-Fact-BC3627280B1A54C895E1CCB4F8E7B930"
      unitRef="usd">564000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_ProductOrServiceAxis_pfe_CelebrexMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e10171-wk-Fact-CE2EF9820ED6573A94D07A737EFDBC56"
      unitRef="usd">550000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_ProductOrServiceAxis_pfe_LyricaMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e10198-wk-Fact-232A214804B055189EC1111DA289CA2D"
      unitRef="usd">134000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_ProductOrServiceAxis_pfe_LyricaMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e10217-wk-Fact-CD0D167B7BFA55D3B52DA395AB1BD7B8"
      unitRef="usd">191000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_ProductOrServiceAxis_pfe_LyricaMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e10236-wk-Fact-67696AFA82F051C9ADF09241496CA1F1"
      unitRef="usd">428000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_ProductOrServiceAxis_pfe_LyricaMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e10256-wk-Fact-65EF603C04E95A788234DDAF3AC7D0D3"
      unitRef="usd">623000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_ProductOrServiceAxis_pfe_VfendMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e10281-wk-Fact-6C9EAD1F0865512985D7C5705407E063"
      unitRef="usd">97000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_ProductOrServiceAxis_pfe_VfendMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e10300-wk-Fact-AEAD728E1868528B913D4433CA55D5AE"
      unitRef="usd">140000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_ProductOrServiceAxis_pfe_VfendMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e10319-wk-Fact-5A0A99EB245E547A975A8CBE45563188"
      unitRef="usd">305000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_ProductOrServiceAxis_pfe_VfendMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e10339-wk-Fact-0CF2265B71BC58559A7EB169A8902FD7"
      unitRef="usd">459000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_ProductOrServiceAxis_pfe_ViagraMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e10366-wk-Fact-C9F9F4BF1A82536D95AD4E1D85276729"
      unitRef="usd">102000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_ProductOrServiceAxis_pfe_ViagraMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e10385-wk-Fact-A18BC4FC7BA15BDA9B32041CAF276842"
      unitRef="usd">89000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_ProductOrServiceAxis_pfe_ViagraMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e10404-wk-Fact-2E5C7379161F5F76A0E97E4215BB339F"
      unitRef="usd">285000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_ProductOrServiceAxis_pfe_ViagraMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e10424-wk-Fact-9814D8F2526C58C48FBE9FC9B3F3314B"
      unitRef="usd">286000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_ProductOrServiceAxis_pfe_PristiqMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e10449-wk-Fact-CDC4B9988F0A5B9ABCDFB0E4C7C96002"
      unitRef="usd">69000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_ProductOrServiceAxis_pfe_PristiqMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e10468-wk-Fact-37776A41FA8E5495A56B3404B197B61E"
      unitRef="usd">174000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_ProductOrServiceAxis_pfe_PristiqMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e10487-wk-Fact-0AAF81ED405D54CB9351BC4158188A30"
      unitRef="usd">230000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_ProductOrServiceAxis_pfe_PristiqMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e10507-wk-Fact-697283B80FF25DA8A92A5D902E7974C8"
      unitRef="usd">546000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_ProductOrServiceAxis_pfe_ZyvoxMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e10532-wk-Fact-93B0D8808B855B85B6799ED23B3D6A0C"
      unitRef="usd">68000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_ProductOrServiceAxis_pfe_ZyvoxMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e10551-wk-Fact-97EFE3A796625669A1D8CCFBFD64954D"
      unitRef="usd">94000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_ProductOrServiceAxis_pfe_ZyvoxMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e10570-wk-Fact-3DFE2FB0892756F5AFED545B4B3F952D"
      unitRef="usd">220000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_ProductOrServiceAxis_pfe_ZyvoxMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e10590-wk-Fact-3C1421C03069507CA00F4331282370F7"
      unitRef="usd">334000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_ProductOrServiceAxis_pfe_RevatioMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e10615-wk-Fact-8007345A7AB456A7B0B97A5A65AB7E48"
      unitRef="usd">58000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_ProductOrServiceAxis_pfe_RevatioMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e10634-wk-Fact-E272C0172CA95773BCC48C38040FBE95"
      unitRef="usd">73000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_ProductOrServiceAxis_pfe_RevatioMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e10653-wk-Fact-C29FBDB6D43757AABB17FED9EE891C54"
      unitRef="usd">189000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_ProductOrServiceAxis_pfe_RevatioMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e10673-wk-Fact-FC0215B9880A51BFBED6DCD05771EFAD"
      unitRef="usd">213000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_ProductOrServiceAxis_pfe_AllOtherPeriLOEProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e10698-wk-Fact-A4F065E7CDE652B48F4562665548B6C6"
      unitRef="usd">55000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_ProductOrServiceAxis_pfe_AllOtherPeriLOEProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e10717-wk-Fact-7351A8567C2250DDBB54A13E3D7EEC46"
      unitRef="usd">68000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_ProductOrServiceAxis_pfe_AllOtherPeriLOEProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e10736-wk-Fact-B7F63A35B709523BAEB3AA24F46E256E"
      unitRef="usd">176000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_PeriLOEProductsMember_us-gaap_ProductOrServiceAxis_pfe_AllOtherPeriLOEProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e10756-wk-Fact-BCC18CBF49805065B56F06ED03FED531"
      unitRef="usd">214000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_BiosimilarsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e10789-wk-Fact-C004A733FEAB52B8AE0B44F23C300539"
      unitRef="usd">141000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_BiosimilarsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e10808-wk-Fact-F17AE8BADCC4517B9C333EAD88E5DA8B"
      unitRef="usd">83000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_BiosimilarsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e10828-wk-Fact-79FA16521B14520887AA9A50CD9012A4"
      unitRef="usd">367000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_BiosimilarsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e10847-wk-Fact-CDE473F11CA35CD29DE23110EB7E3FEF"
      unitRef="usd">228000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_BiosimilarsMember_us-gaap_ProductOrServiceAxis_pfe_InflectraRemsimaMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e10867-wk-Fact-269C5F3BDCF15ACE94261F539A3FF18E"
      unitRef="usd">112000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_BiosimilarsMember_us-gaap_ProductOrServiceAxis_pfe_InflectraRemsimaMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e10886-wk-Fact-A083D570556F5EF4A97874779BE8F39E"
      unitRef="usd">49000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_BiosimilarsMember_us-gaap_ProductOrServiceAxis_pfe_InflectraRemsimaMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e10905-wk-Fact-996D10C069CD5795A87BD6E87F80A5B8"
      unitRef="usd">284000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_BiosimilarsMember_us-gaap_ProductOrServiceAxis_pfe_InflectraRemsimaMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e10925-wk-Fact-55A6F1204F945EF892559AE70BC96F62"
      unitRef="usd">130000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_BiosimilarsMember_us-gaap_ProductOrServiceAxis_pfe_AllOtherBiosimilarsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e10950-wk-Fact-6CD3D18717EA5328937165998A7EF664"
      unitRef="usd">28000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_BiosimilarsMember_us-gaap_ProductOrServiceAxis_pfe_AllOtherBiosimilarsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e10969-wk-Fact-C37C5D32B0CF5A9EBB9E3E5724373EEA"
      unitRef="usd">34000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_BiosimilarsMember_us-gaap_ProductOrServiceAxis_pfe_AllOtherBiosimilarsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e10988-wk-Fact-2F825759B42459E4904B3140974BF299"
      unitRef="usd">82000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_BiosimilarsMember_us-gaap_ProductOrServiceAxis_pfe_AllOtherBiosimilarsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e11008-wk-Fact-22DE19FCF9B952DFA1EEF3D418C48472"
      unitRef="usd">97000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_CentreOneMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e11040-wk-Fact-3478C9FA86F457899DC079177D757215"
      unitRef="usd">161000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_CentreOneMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e11059-wk-Fact-E71ECFC84ED058A1982578968151CD88"
      unitRef="usd">156000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_CentreOneMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e11079-wk-Fact-3E9CA6EB4A915AFF8A6FCEB98114AB68"
      unitRef="usd">514000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_CentreOneMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e11098-wk-Fact-19D08708847D5BDEAC5A5C81A5DC8E05"
      unitRef="usd">540000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_HospiraInfusionSystemsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e11125-wk-Fact-E5DEE2763FF15719B07579F02111EFC3"
      unitRef="usd">0</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3QTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_HospiraInfusionSystemsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e11144-wk-Fact-473A8153DB95559E92CC6D9F938E0BCE"
      unitRef="usd">281000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_HospiraInfusionSystemsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e11164-wk-Fact-15783BA6644A5B24968CE32B5F022A68"
      unitRef="usd">97000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3YTD_pfe_DistinctBusinessAxis_pfe_EssentialHealthBusinessMember_pfe_EssentialHealthProductCategoryAxis_pfe_HospiraInfusionSystemsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_EssentialHealthSegmentMember"
      decimals="-6"
      id="d43771853e11183-wk-Fact-A931585378205E5DA65545918DAAB331"
      unitRef="usd">879000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3QTD_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthandEssentialHealthMember"
      decimals="-6"
      id="d43771853e11208-wk-Fact-9C752BB75A1455A0AF6ABEFA57EBB1AF"
      unitRef="usd">13168000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3QTD_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthandEssentialHealthMember"
      decimals="-6"
      id="d43771853e11227-wk-Fact-6B7BF854C7B35BE4A47B37F76C73D8AC"
      unitRef="usd">13045000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3YTD_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthandEssentialHealthMember"
      decimals="-6"
      id="d43771853e11247-wk-Fact-5F4B94C0B26E57A2859AEDD6C1C81FB5"
      unitRef="usd">38843000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3YTD_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthandEssentialHealthMember"
      decimals="-6"
      id="d43771853e11266-wk-Fact-DA5D9362F04050B1B725050577F60279"
      unitRef="usd">39196000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3QTD_us-gaap_ProductOrServiceAxis_pfe_LyricaMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthandEssentialHealthMember"
      decimals="-6"
      id="d43771853e11380-wk-Fact-442B1474BBCB5FE8A099D633CB680650"
      unitRef="usd">1285000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3QTD_us-gaap_ProductOrServiceAxis_pfe_LyricaMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthandEssentialHealthMember"
      decimals="-6"
      id="d43771853e11399-wk-Fact-B6E115CC3E7858DCA9A85E0C1738396B"
      unitRef="usd">1240000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3YTD_us-gaap_ProductOrServiceAxis_pfe_LyricaMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthandEssentialHealthMember"
      decimals="-6"
      id="d43771853e11419-wk-Fact-6313B867BAC65FC1A4718632BEF06E26"
      unitRef="usd">3810000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3YTD_us-gaap_ProductOrServiceAxis_pfe_LyricaMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthandEssentialHealthMember"
      decimals="-6"
      id="d43771853e11438-wk-Fact-000B2C159A9A57D09032E22544108F38"
      unitRef="usd">3730000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3QTD_us-gaap_ProductOrServiceAxis_pfe_ViagraMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthandEssentialHealthMember"
      decimals="-6"
      id="d43771853e11465-wk-Fact-A8CAE70BC2A35982B714238C0AC51A79"
      unitRef="usd">308000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3QTD_us-gaap_ProductOrServiceAxis_pfe_ViagraMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthandEssentialHealthMember"
      decimals="-6"
      id="d43771853e11484-wk-Fact-5F6DD21DF11E5B29871B857CC403739A"
      unitRef="usd">387000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3YTD_us-gaap_ProductOrServiceAxis_pfe_ViagraMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthandEssentialHealthMember"
      decimals="-6"
      id="d43771853e11504-wk-Fact-16FFF27FA1865523A99E7DB32984FAAA"
      unitRef="usd">996000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3YTD_us-gaap_ProductOrServiceAxis_pfe_ViagraMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthandEssentialHealthMember"
      decimals="-6"
      id="d43771853e11523-wk-Fact-A70792548E685ABAA23DB0FA57120893"
      unitRef="usd">1183000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3QTD_us-gaap_ProductOrServiceAxis_pfe_AllianceBiopharmaceuticalsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthandEssentialHealthMember"
      decimals="-6"
      id="d43771853e11548-wk-Fact-6D99D5C969795D1F87806F4E86EF0727"
      unitRef="usd">741000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3QTD_us-gaap_ProductOrServiceAxis_pfe_AllianceBiopharmaceuticalsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthandEssentialHealthMember"
      decimals="-6"
      id="d43771853e11567-wk-Fact-6BEE3DC90D785FB89CD0E73CF1AA35E3"
      unitRef="usd">419000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q3YTD_us-gaap_ProductOrServiceAxis_pfe_AllianceBiopharmaceuticalsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthandEssentialHealthMember"
      decimals="-6"
      id="d43771853e11587-wk-Fact-A5238AF29D395849A330587872DA06CE"
      unitRef="usd">2112000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q3YTD_us-gaap_ProductOrServiceAxis_pfe_AllianceBiopharmaceuticalsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthandEssentialHealthMember"
      decimals="-6"
      id="d43771853e11606-wk-Fact-8F4D63311073516AAC8FFE78BBAC2211"
      unitRef="usd">1155000000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="FD2017Q3QTD"
      decimals="2"
      id="d43712471e5775-wk-Fact-2BD65B1FAD49532F94B23261F5066D15"
      unitRef="usdPerShare">0.47</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="FD2016Q3QTD"
      decimals="2"
      id="d43712471e5794-wk-Fact-DB504CC293605BAF9CADCD1A8D93F11A"
      unitRef="usdPerShare">0.22</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#d43771853e11438-wk-Fact-000B2C159A9A57D09032E22544108F38"
          xlink:label="d43771853e11438-wk-Fact-000B2C159A9A57D09032E22544108F38"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-DE7EF4A6663E52BF8D3620854A57A945-0-wk-Footnote-DE7EF4A6663E52BF8D3620854A57A945_lbl" xlink:label="TextSelection-DE7EF4A6663E52BF8D3620854A57A945-0-wk-Footnote-DE7EF4A6663E52BF8D3620854A57A945_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Lyrica revenues from all of Europe, Russia, Turkey, Israel and Central Asia countries are included in Lyrica EH. All other Lyrica revenues are included in Lyrica IH. Total Lyrica revenues represent the aggregate of worldwide revenues from Lyrica IH and Lyrica EH. </link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e11438-wk-Fact-000B2C159A9A57D09032E22544108F38"
          xlink:to="TextSelection-DE7EF4A6663E52BF8D3620854A57A945-0-wk-Footnote-DE7EF4A6663E52BF8D3620854A57A945_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e953-wk-Fact-0041457EF706567A8463582BD5F7861D"
          xlink:label="d43770747e953-wk-Fact-0041457EF706567A8463582BD5F7861D"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-8D2A93033C2E56DE9E814F0AB36328EE-0-wk-Footnote-8D2A93033C2E56DE9E814F0AB36328EE_lbl" xlink:label="TextSelection-8D2A93033C2E56DE9E814F0AB36328EE-0-wk-Footnote-8D2A93033C2E56DE9E814F0AB36328EE_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">We use a market approach in valuing financial instruments on a recurring basis. All of our financial assets and liabilities measured at fair value on a recurring basis use Level 2 inputs in the calculation of fair value, except <xhtml:span style="font-family:inherit;font-size:8.5pt;"><xhtml:span>5%</xhtml:span></xhtml:span> that use Level 1 inputs.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e953-wk-Fact-0041457EF706567A8463582BD5F7861D"
          xlink:to="TextSelection-8D2A93033C2E56DE9E814F0AB36328EE-0-wk-Footnote-8D2A93033C2E56DE9E814F0AB36328EE_lbl"
          xlink:type="arc"/>
        <link:footnote id="TextSelection-E96B3A139CCA56EC98329BC3717B10E3-0-wk-Footnote-E96B3A139CCA56EC98329BC3717B10E3_lbl" xlink:label="TextSelection-E96B3A139CCA56EC98329BC3717B10E3-0-wk-Footnote-E96B3A139CCA56EC98329BC3717B10E3_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Gross unrealized gains and losses are not significant, except as of <xhtml:span style="font-family:inherit;font-size:8.5pt;">October&#160;1, 2017</xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;">, available-for-sale equity securities&#x2019; unrealized gains are </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"><xhtml:span>$406 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"> and unrealized losses are </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"><xhtml:span>$119 million</xhtml:span></xhtml:span>.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e953-wk-Fact-0041457EF706567A8463582BD5F7861D"
          xlink:to="TextSelection-E96B3A139CCA56EC98329BC3717B10E3-0-wk-Footnote-E96B3A139CCA56EC98329BC3717B10E3_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e5004-wk-Fact-008DAD250F08510DA34610C6465700EC"
          xlink:label="d43770747e5004-wk-Fact-008DAD250F08510DA34610C6465700EC"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-2BFD6C99096B50AD93705C5601B21F46-0-wk-Footnote-2BFD6C99096B50AD93705C5601B21F46_lbl" xlink:label="TextSelection-2BFD6C99096B50AD93705C5601B21F46-0-wk-Footnote-2BFD6C99096B50AD93705C5601B21F46_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Issued by governments, government agencies or supranational entities, as applicable, all of which are high quality.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e5004-wk-Fact-008DAD250F08510DA34610C6465700EC"
          xlink:to="TextSelection-2BFD6C99096B50AD93705C5601B21F46-0-wk-Footnote-2BFD6C99096B50AD93705C5601B21F46_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e1287-wk-Fact-016B619738A05C4C98C28A747752066A"
          xlink:label="d43770747e1287-wk-Fact-016B619738A05C4C98C28A747752066A"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-E90A054BCC035ECEB6B6F2B7C947C3CE-0-wk-Footnote-E90A054BCC035ECEB6B6F2B7C947C3CE_lbl" xlink:label="TextSelection-E90A054BCC035ECEB6B6F2B7C947C3CE-0-wk-Footnote-E90A054BCC035ECEB6B6F2B7C947C3CE_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The differences between the estimated fair values and carrying values of held-to-maturity debt securities, restricted stock and private equity securities at cost, and short-term borrowings not measured at fair value on a recurring basis were not significant as of <xhtml:span style="font-family:inherit;font-size:8.5pt;">October&#160;1, 2017</xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"> or </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;text-align:center;">December&#160;31, 2016</xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;">. The fair value measurements of our held-to-maturity debt securities and our short-term borrowings are based on Level 2 inputs, using a market approach. The fair value measurements of our </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;background-color:#ffffff;">priv</xhtml:span>ate equity securities carried at cost are based on Level 3 inputs.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e1287-wk-Fact-016B619738A05C4C98C28A747752066A"
          xlink:to="TextSelection-E90A054BCC035ECEB6B6F2B7C947C3CE-0-wk-Footnote-E90A054BCC035ECEB6B6F2B7C947C3CE_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e1287-wk-Fact-016B619738A05C4C98C28A747752066A"
          xlink:to="TextSelection-E96B3A139CCA56EC98329BC3717B10E3-0-wk-Footnote-E96B3A139CCA56EC98329BC3717B10E3_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e9748-wk-Fact-019763780A0F5F0EB5ACCFF5ADADB2C7"
          xlink:label="d43770747e9748-wk-Fact-019763780A0F5F0EB5ACCFF5ADADB2C7"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-39CF024D03225486829869F6CA02C00E-0-wk-Footnote-39CF024D03225486829869F6CA02C00E_lbl" xlink:label="TextSelection-39CF024D03225486829869F6CA02C00E-0-wk-Footnote-39CF024D03225486829869F6CA02C00E_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Includes gains and losses attributable to derivative instruments designated and qualifying as fair value hedges (primarily interest rate swaps), as well as the offsetting gains and losses attributable to the hedged items in such hedging relationships.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e9748-wk-Fact-019763780A0F5F0EB5ACCFF5ADADB2C7"
          xlink:to="TextSelection-39CF024D03225486829869F6CA02C00E-0-wk-Footnote-39CF024D03225486829869F6CA02C00E_lbl"
          xlink:type="arc"/>
        <link:footnote id="TextSelection-53BB8CAFCA475C0C9DB2195050D36025-0-wk-Footnote-53BB8CAFCA475C0C9DB2195050D36025_lbl" xlink:label="TextSelection-53BB8CAFCA475C0C9DB2195050D36025-0-wk-Footnote-53BB8CAFCA475C0C9DB2195050D36025_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">There was no significant ineffectiveness for any period presented.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e9748-wk-Fact-019763780A0F5F0EB5ACCFF5ADADB2C7"
          xlink:to="TextSelection-53BB8CAFCA475C0C9DB2195050D36025-0-wk-Footnote-53BB8CAFCA475C0C9DB2195050D36025_lbl"
          xlink:type="arc"/>
        <link:footnote id="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl" xlink:label="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">OID = Other (income)/deductions&#x2014;net, included in <xhtml:span style="font-family:inherit;font-size:9pt;font-style:italic;">Other (income)/deductions&#x2014;net</xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;"> in the condensed consolidated statements of income. COS = Cost of sales, included in </xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;font-style:italic;">Cost of sales</xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;"> in the condensed consolidated statements of income.</xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;">OCI = Other comprehensive income/(loss), included in the</xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;font-style:italic;"> </xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;">condensed consolidated statements of comprehensive income</xhtml:span>.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e9748-wk-Fact-019763780A0F5F0EB5ACCFF5ADADB2C7"
          xlink:to="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43690878e1706-wk-Fact-01FC3E63A2EE59F6B2846C1357AAF742"
          xlink:label="d43690878e1706-wk-Fact-01FC3E63A2EE59F6B2846C1357AAF742"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-792D3AB23D6354CFBB2776AE7F6407B4-0-wk-Footnote-792D3AB23D6354CFBB2776AE7F6407B4_lbl" xlink:label="TextSelection-792D3AB23D6354CFBB2776AE7F6407B4-0-wk-Footnote-792D3AB23D6354CFBB2776AE7F6407B4_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Amounts for the <xhtml:span style="font-family:inherit;font-size:8.5pt;">third quarter</xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"> and first </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;">nine months</xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"> ended </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;">October&#160;2, 2016</xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"> have been revised from previously reported amounts to reflect the adoption of a new accounting standard in the fourth quarter of </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;text-align:center;">2016</xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;">, as of January 1, 2016, that requires, when applying the treasury stock method for shares that could be repurchased, that the assumed proceeds no longer include the amount of excess tax benefit (see </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Note 1B</xhtml:span>).</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43690878e1706-wk-Fact-01FC3E63A2EE59F6B2846C1357AAF742"
          xlink:to="TextSelection-792D3AB23D6354CFBB2776AE7F6407B4-0-wk-Footnote-792D3AB23D6354CFBB2776AE7F6407B4_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687704e2506-wk-Fact-02AE17DCB8665481BC805EA0E0D7CB38"
          xlink:label="d43687704e2506-wk-Fact-02AE17DCB8665481BC805EA0E0D7CB38"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl" xlink:label="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Amounts may not add due to rounding.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e2506-wk-Fact-02AE17DCB8665481BC805EA0E0D7CB38"
          xlink:to="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"
          xlink:type="arc"/>
        <link:footnote id="TextSelection-9231AC55B8EC5775BC4995B0797F870F-0-wk-Footnote-9231AC55B8EC5775BC4995B0797F870F_lbl" xlink:label="TextSelection-9231AC55B8EC5775BC4995B0797F870F-0-wk-Footnote-9231AC55B8EC5775BC4995B0797F870F_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Amounts for the <xhtml:span style="font-family:inherit;font-size:9pt;">three and nine months ended October 2, 2016</xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;"> have been revised from previously reported amounts to reflect the adoption of a new accounting standard in the fourth quarter of 2016, as of January 1, 2016. For additional information, see </xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;font-style:italic;">Note 1B</xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;">. </xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;font-style:italic;">Basis of Presentation and Significant Accounting Policies&#x2013;&#x2013;Adoption of New Accounting Standards</xhtml:span>.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e2506-wk-Fact-02AE17DCB8665481BC805EA0E0D7CB38"
          xlink:to="TextSelection-9231AC55B8EC5775BC4995B0797F870F-0-wk-Footnote-9231AC55B8EC5775BC4995B0797F870F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43674379e856-wk-Fact-030CEB52DE005078B1752AD07DFF2B1C"
          xlink:label="d43674379e856-wk-Fact-030CEB52DE005078B1752AD07DFF2B1C"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl" xlink:label="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Amounts may not add due to rounding.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43674379e856-wk-Fact-030CEB52DE005078B1752AD07DFF2B1C"
          xlink:to="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43771853e5882-wk-Fact-035E25AAED92520288A7CD55C86FFB01"
          xlink:label="d43771853e5882-wk-Fact-035E25AAED92520288A7CD55C86FFB01"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-450A7304FB7E513FB479F6D9A06EF1D3-0-wk-Footnote-450A7304FB7E513FB479F6D9A06EF1D3_lbl" xlink:label="TextSelection-450A7304FB7E513FB479F6D9A06EF1D3-0-wk-Footnote-450A7304FB7E513FB479F6D9A06EF1D3_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Viagra revenues from the U.S. and Canada are included in Viagra IH. All other Viagra revenues are included in Viagra EH. Total Viagra revenues represent the aggregate of worldwide revenues from Viagra IH and Viagra EH. </link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e5882-wk-Fact-035E25AAED92520288A7CD55C86FFB01"
          xlink:to="TextSelection-450A7304FB7E513FB479F6D9A06EF1D3-0-wk-Footnote-450A7304FB7E513FB479F6D9A06EF1D3_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e4118-wk-Fact-04349CF31E83539A9C576802A8424538"
          xlink:label="d43770747e4118-wk-Fact-04349CF31E83539A9C576802A8424538"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e4118-wk-Fact-04349CF31E83539A9C576802A8424538"
          xlink:to="TextSelection-2BFD6C99096B50AD93705C5601B21F46-0-wk-Footnote-2BFD6C99096B50AD93705C5601B21F46_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687704e3095-wk-Fact-044058D73AF55D17962CBA73D63800BD"
          xlink:label="d43687704e3095-wk-Fact-044058D73AF55D17962CBA73D63800BD"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d43690878e2093-wk-Fact-044058D73AF55D17962CBA73D63800BD"
          xlink:label="d43690878e2093-wk-Fact-044058D73AF55D17962CBA73D63800BD"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e3095-wk-Fact-044058D73AF55D17962CBA73D63800BD"
          xlink:to="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43690878e2093-wk-Fact-044058D73AF55D17962CBA73D63800BD"
          xlink:to="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43674379e1076-wk-Fact-047944C84B99570199B5350DAC450B3B"
          xlink:label="d43674379e1076-wk-Fact-047944C84B99570199B5350DAC450B3B"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43674379e1076-wk-Fact-047944C84B99570199B5350DAC450B3B"
          xlink:to="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e9808-wk-Fact-04C7C8ED03EF514FBDD27EE2DA62A7D5"
          xlink:label="d43770747e9808-wk-Fact-04C7C8ED03EF514FBDD27EE2DA62A7D5"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e9808-wk-Fact-04C7C8ED03EF514FBDD27EE2DA62A7D5"
          xlink:to="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"
          xlink:type="arc"/>
        <link:footnote id="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl" xlink:label="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">For derivative financial instruments in cash flow hedge relationships, the effective portion is included in <xhtml:span style="font-family:inherit;font-size:9pt;font-style:italic;">Other comprehensive income&#x2013;&#x2013;Unrealized holding losses on derivative financial instruments, net</xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;">. For derivative financial instruments in net investment hedge relationships and for foreign currency debt designated as hedging instruments, the effective portion is included in </xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;font-style:italic;">Other comprehensive income&#x2013;&#x2013;Foreign currency translation adjustments, net.</xhtml:span><xhtml:br/></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e9808-wk-Fact-04C7C8ED03EF514FBDD27EE2DA62A7D5"
          xlink:to="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43681613e1719-wk-Fact-050DF5AA83565B919248F2CDC8C1441E"
          xlink:label="d43681613e1719-wk-Fact-050DF5AA83565B919248F2CDC8C1441E"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl" xlink:label="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Amounts may not add due to rounding.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43681613e1719-wk-Fact-050DF5AA83565B919248F2CDC8C1441E"
          xlink:to="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43712510e5327-wk-Fact-05422B8407F15A068C445BB5C57F5700"
          xlink:label="d43712510e5327-wk-Fact-05422B8407F15A068C445BB5C57F5700"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-621F9196966C550EA113DA57575C171E-0-wk-Footnote-621F9196966C550EA113DA57575C171E_lbl" xlink:label="TextSelection-621F9196966C550EA113DA57575C171E-0-wk-Footnote-621F9196966C550EA113DA57575C171E_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">In April 2017, we settled the remaining obligation associated with the Hospira U.S. qualified defined benefit pension plan. We purchased a group annuity contract on behalf of the remaining plan participants with a third-party insurance provider. As a result, we were relieved of the <xhtml:span style="font-family:inherit;font-size:8.5pt;"><xhtml:span>$156 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"> net pension benefit obligation and recorded a pretax settlement gain of </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"><xhtml:span>$41 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;">, partially offset by the recognition of actuarial losses and prior service costs upon plan settlement of approximately </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"><xhtml:span>$30 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"> in</xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;font-style:italic;"> Restructuring charges and certain acquisition-related costs</xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"> during the second quarter of 2017 (see </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Note 3</xhtml:span>).</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43712510e5327-wk-Fact-05422B8407F15A068C445BB5C57F5700"
          xlink:to="TextSelection-621F9196966C550EA113DA57575C171E-0-wk-Footnote-621F9196966C550EA113DA57575C171E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43712496e1431-wk-Fact-058D1994C3365CD1AB976A08ED207000"
          xlink:label="d43712496e1431-wk-Fact-058D1994C3365CD1AB976A08ED207000"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-B57619F44FCF544D96067CF4816A9082-0-wk-Footnote-B57619F44FCF544D96067CF4816A9082_lbl" xlink:label="TextSelection-B57619F44FCF544D96067CF4816A9082-0-wk-Footnote-B57619F44FCF544D96067CF4816A9082_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">In the <xhtml:span style="font-family:inherit;font-size:9pt;">third quarter</xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;"> and </xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;">first nine months of</xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;"> </xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;text-align:center;">2017</xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;">, restructuring charges are primarily associated with our acquisitions of Hospira and Medivation, as well as cost-reduction and productivity initiatives not associated with acquisitions. In the </xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;">third quarter</xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;"> and </xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;">first nine months of</xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;"> </xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;text-align:center;">2016</xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;">, restructuring charges are largely associated with cost-reduction and productivity initiatives not associated with acquisitions, as well as our acquisitions of Hospira and Medivation. In the third quarter and first </xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;">nine</xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;"> months ended </xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;">October&#160;1, 2017</xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;">, </xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;font-style:italic;">Employee terminations</xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;"> primarily include revisions of our estimates of severance benefits. Employee termination costs are generally recorded when the actions are probable and estimable and include accrued severance benefits, pension and postretirement benefits, many of which may be paid out during periods after termination.</xhtml:span><xhtml:div style="line-height:120%;padding-top:4px;padding-left:24px;text-indent:-12px;font-size:9pt;"><xhtml:span style="font-family:inherit;font-size:9pt;">The restructuring activities for </xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;text-align:center;">2017</xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;"> are associated with the following:</xhtml:span></xhtml:div><xhtml:table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><xhtml:tr><xhtml:td style="width:24px;"/><xhtml:td/></xhtml:tr><xhtml:tr><xhtml:td style="vertical-align:top"><xhtml:div style="line-height:120%;font-size:9pt;padding-left:12px;"><xhtml:span style="font-family:inherit;font-size:9pt;">&#x2022;</xhtml:span></xhtml:div></xhtml:td><xhtml:td style="vertical-align:top;"><xhtml:div style="line-height:120%;font-size:9pt;"><xhtml:span style="font-family:inherit;font-size:9pt;">For the </xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;">third quarter</xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;"> of </xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;text-align:center;">2017</xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;">, IH (</xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;"><xhtml:span>$4 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;">); EH (</xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;"><xhtml:span>$1 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;">); WRD/GPD (</xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;"><xhtml:span>$15 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;">); manufacturing operations (</xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;"><xhtml:span>$47 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;">); and Corporate (</xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;"><xhtml:span>$25 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;">).</xhtml:span></xhtml:div></xhtml:td></xhtml:tr></xhtml:table><xhtml:table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><xhtml:tr><xhtml:td style="width:24px;"/><xhtml:td/></xhtml:tr><xhtml:tr><xhtml:td style="vertical-align:top"><xhtml:div style="line-height:120%;font-size:9pt;padding-left:12px;"><xhtml:span style="font-family:inherit;font-size:9pt;">&#x2022;</xhtml:span></xhtml:div></xhtml:td><xhtml:td style="vertical-align:top;"><xhtml:div style="line-height:120%;text-align:left;font-size:9pt;"><xhtml:span style="font-family:inherit;font-size:9pt;">For the </xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;">first nine months of</xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;"> </xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;text-align:center;">2017</xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;">, IH (</xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;"><xhtml:span>$10 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;">); EH (</xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;"><xhtml:span>$9 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;"> income); WRD/GPD (</xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;"><xhtml:span>$29 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;">); manufacturing operations (</xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;"><xhtml:span>$70 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;">); and Corporate (</xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;"><xhtml:span>$51 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;">).</xhtml:span></xhtml:div></xhtml:td></xhtml:tr></xhtml:table><xhtml:div style="line-height:120%;padding-top:4px;text-align:left;padding-left:24px;text-indent:-12px;font-size:9pt;"><xhtml:span style="font-family:inherit;font-size:9pt;">The restructuring activities for </xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;text-align:center;">2016</xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;"> are associated with the following:</xhtml:span></xhtml:div><xhtml:table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><xhtml:tr><xhtml:td style="width:24px;"/><xhtml:td/></xhtml:tr><xhtml:tr><xhtml:td style="vertical-align:top"><xhtml:div style="line-height:120%;font-size:9pt;padding-left:12px;"><xhtml:span style="font-family:inherit;font-size:9pt;">&#x2022;</xhtml:span></xhtml:div></xhtml:td><xhtml:td style="vertical-align:top;"><xhtml:div style="line-height:120%;font-size:9pt;"><xhtml:span style="font-family:inherit;font-size:9pt;">For the </xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;">third quarter</xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;"> of </xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;text-align:center;">2016</xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;">, IH (</xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;"><xhtml:span>$148 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;">); EH (</xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;"><xhtml:span>$28 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;">); WRD/GPD (</xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;"><xhtml:span>$52 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;">); manufacturing operations (</xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;"><xhtml:span>$108 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;">); and Corporate (</xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;"><xhtml:span>$67 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;">).</xhtml:span></xhtml:div></xhtml:td></xhtml:tr></xhtml:table><xhtml:div style="line-height:120%;font-size:9pt;padding-left:12px;"><xhtml:span style="font-family:inherit;font-size:9pt;">&#x2022;</xhtml:span></xhtml:div><xhtml:span style="font-family:inherit;font-size:9pt;">For the </xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;">first nine months of</xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;"> </xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;text-align:center;">2016</xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;">, IH (</xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;"><xhtml:span>$162 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;">); EH (</xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;"><xhtml:span>$19 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;">); WRD/GPD (</xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;"><xhtml:span>$104 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;">); manufacturing operations (</xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;"><xhtml:span>$181 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;">); and Corporate (</xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;"><xhtml:span>$107 million</xhtml:span></xhtml:span>).</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43712496e1431-wk-Fact-058D1994C3365CD1AB976A08ED207000"
          xlink:to="TextSelection-B57619F44FCF544D96067CF4816A9082-0-wk-Footnote-B57619F44FCF544D96067CF4816A9082_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687849e1692-wk-Fact-05DE724F3E9F5A43ABA68FEBEAE4BBAF"
          xlink:label="d43687849e1692-wk-Fact-05DE724F3E9F5A43ABA68FEBEAE4BBAF"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl" xlink:label="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Amounts may not add due to rounding.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e1692-wk-Fact-05DE724F3E9F5A43ABA68FEBEAE4BBAF"
          xlink:to="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687849e2376-wk-Fact-065F9DBED67053D59EE0A60E93DFDD22"
          xlink:label="d43687849e2376-wk-Fact-065F9DBED67053D59EE0A60E93DFDD22"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-77536863BCE35B419E3A4119D41DB4BD-0-wk-Footnote-77536863BCE35B419E3A4119D41DB4BD_lbl" xlink:label="TextSelection-77536863BCE35B419E3A4119D41DB4BD-0-wk-Footnote-77536863BCE35B419E3A4119D41DB4BD_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Generally reclassified, as part of net periodic pension cost, into <xhtml:span style="font-family:inherit;font-size:9pt;font-style:italic;">Cost of sales, Selling, informational and administrative expenses,</xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;"> and/or </xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;font-style:italic;">Research and development expenses</xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;">, as appropriate, in the condensed consolidated statements of income. For additional information, see </xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;font-style:italic;">Note 10. </xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;font-style:italic;">Pension and Postretirement Benefit Plans</xhtml:span>.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e2376-wk-Fact-065F9DBED67053D59EE0A60E93DFDD22"
          xlink:to="TextSelection-77536863BCE35B419E3A4119D41DB4BD-0-wk-Footnote-77536863BCE35B419E3A4119D41DB4BD_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e2376-wk-Fact-065F9DBED67053D59EE0A60E93DFDD22"
          xlink:to="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43674379e1943-wk-Fact-06E6B320DD2E5DEAAE0840FF5C32D34D"
          xlink:label="d43674379e1943-wk-Fact-06E6B320DD2E5DEAAE0840FF5C32D34D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43674379e1943-wk-Fact-06E6B320DD2E5DEAAE0840FF5C32D34D"
          xlink:to="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687849e2501-wk-Fact-075959EB0B9D5963B37F54F55082FEA0"
          xlink:label="d43687849e2501-wk-Fact-075959EB0B9D5963B37F54F55082FEA0"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e2501-wk-Fact-075959EB0B9D5963B37F54F55082FEA0"
          xlink:to="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43712496e2381-wk-Fact-083D0D52D0F352EBA5B14A872E1DE0C8"
          xlink:label="d43712496e2381-wk-Fact-083D0D52D0F352EBA5B14A872E1DE0C8"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-C37CD88178CA35C475D25A62F2B54FED-0-wk-Footnote-C37CD88178CA35C475D25A62F2B54FED_lbl" xlink:label="TextSelection-C37CD88178CA35C475D25A62F2B54FED-0-wk-Footnote-C37CD88178CA35C475D25A62F2B54FED_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Implementation costs represent external, incremental costs directly related to implementing our non-acquisition-related cost-reduction/productivity initiatives.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43712496e2381-wk-Fact-083D0D52D0F352EBA5B14A872E1DE0C8"
          xlink:to="TextSelection-C37CD88178CA35C475D25A62F2B54FED-0-wk-Footnote-C37CD88178CA35C475D25A62F2B54FED_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43697240e2335-wk-Fact-08713BCAEBE7560790D2B69F31D04450"
          xlink:label="d43697240e2335-wk-Fact-08713BCAEBE7560790D2B69F31D04450"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-FF348CC7844F523299A112551B170BE6-0-wk-Footnote-FF348CC7844F523299A112551B170BE6_lbl" xlink:label="TextSelection-FF348CC7844F523299A112551B170BE6-0-wk-Footnote-FF348CC7844F523299A112551B170BE6_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The decrease in <xhtml:span style="font-family:inherit;font-size:8.5pt;font-style:italic;">I</xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;font-style:italic;text-align:right;">dentifiable intangible assets, less accumulated amortization</xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;text-align:right;">, </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;">is primarily due to amortization, measurement period adjustments related to Medivation (see </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Note 2A</xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;">), as well as impairments of </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Developed technology rights</xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"> (see </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Note 4)</xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;">, partially offset by assets acquired as part of the acquisition of AstraZeneca&#x2019;s small molecule anti-infectives business (see </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Note 2A</xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;">) and the assets recorded in connection with the EU and U.S. approvals of Besponsa (see </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Note 7E</xhtml:span>).</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43697240e2335-wk-Fact-08713BCAEBE7560790D2B69F31D04450"
          xlink:to="TextSelection-FF348CC7844F523299A112551B170BE6-0-wk-Footnote-FF348CC7844F523299A112551B170BE6_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e1603-wk-Fact-08EE5A3AD5B453F08A8BB6A7ACA9E8BF"
          xlink:label="d43770747e1603-wk-Fact-08EE5A3AD5B453F08A8BB6A7ACA9E8BF"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-58096FF6357955D6B6AA25D56767CB0A-0-wk-Footnote-58096FF6357955D6B6AA25D56767CB0A_lbl" xlink:label="TextSelection-58096FF6357955D6B6AA25D56767CB0A-0-wk-Footnote-58096FF6357955D6B6AA25D56767CB0A_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Designated as hedging instruments, except for certain contracts used as offsets; namely, foreign currency forward-exchange contracts with fair values of <xhtml:span style="font-family:inherit;font-size:8.5pt;"><xhtml:span>$60 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"> as of </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;">October&#160;1, 2017</xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;">; and foreign currency swaps with fair values of </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"><xhtml:span>$269 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"> and foreign currency forward-exchange contracts with fair values of </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"><xhtml:span>$113 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"> as of </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;text-align:center;">December&#160;31, 2016</xhtml:span>.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e1603-wk-Fact-08EE5A3AD5B453F08A8BB6A7ACA9E8BF"
          xlink:to="TextSelection-58096FF6357955D6B6AA25D56767CB0A-0-wk-Footnote-58096FF6357955D6B6AA25D56767CB0A_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e1603-wk-Fact-08EE5A3AD5B453F08A8BB6A7ACA9E8BF"
          xlink:to="TextSelection-8D2A93033C2E56DE9E814F0AB36328EE-0-wk-Footnote-8D2A93033C2E56DE9E814F0AB36328EE_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687704e862-wk-Fact-08F7B1DEB2E25ACA94468FF7CE567177"
          xlink:label="d43687704e862-wk-Fact-08F7B1DEB2E25ACA94468FF7CE567177"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d43771853e2263-wk-Fact-08F7B1DEB2E25ACA94468FF7CE567177"
          xlink:label="d43771853e2263-wk-Fact-08F7B1DEB2E25ACA94468FF7CE567177"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d43771853e4920-wk-Fact-08F7B1DEB2E25ACA94468FF7CE567177"
          xlink:label="d43771853e4920-wk-Fact-08F7B1DEB2E25ACA94468FF7CE567177"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e862-wk-Fact-08F7B1DEB2E25ACA94468FF7CE567177"
          xlink:to="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e2263-wk-Fact-08F7B1DEB2E25ACA94468FF7CE567177"
          xlink:to="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e4920-wk-Fact-08F7B1DEB2E25ACA94468FF7CE567177"
          xlink:to="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e7432-wk-Fact-090EF04B0EE45784B7F05495ED9053FC"
          xlink:label="d43770747e7432-wk-Fact-090EF04B0EE45784B7F05495ED9053FC"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e7432-wk-Fact-090EF04B0EE45784B7F05495ED9053FC"
          xlink:to="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e7432-wk-Fact-090EF04B0EE45784B7F05495ED9053FC"
          xlink:to="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43771853e8174-wk-Fact-091C801F849C5456B9FD0DC999483C5D"
          xlink:label="d43771853e8174-wk-Fact-091C801F849C5456B9FD0DC999483C5D"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-B88EBF1DF3CD5B06AADA1AA5E249F160-0-wk-Footnote-B88EBF1DF3CD5B06AADA1AA5E249F160_lbl" xlink:label="TextSelection-B88EBF1DF3CD5B06AADA1AA5E249F160-0-wk-Footnote-B88EBF1DF3CD5B06AADA1AA5E249F160_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The EH business encompasses Legacy Established Products, Sterile Injectable Pharmaceuticals, Peri-LOE Products, Biosimilars, Pfizer CentreOne and HIS (through February 2, 2017) and includes all legacy Hospira commercial operations.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e8174-wk-Fact-091C801F849C5456B9FD0DC999483C5D"
          xlink:to="TextSelection-B88EBF1DF3CD5B06AADA1AA5E249F160-0-wk-Footnote-B88EBF1DF3CD5B06AADA1AA5E249F160_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687704e1935-wk-Fact-09351BE188EA5C05843D243B15A603F5"
          xlink:label="d43687704e1935-wk-Fact-09351BE188EA5C05843D243B15A603F5"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e1935-wk-Fact-09351BE188EA5C05843D243B15A603F5"
          xlink:to="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43681613e2123-wk-Fact-0998A9FB896651C8813749DB0BBD1634"
          xlink:label="d43681613e2123-wk-Fact-0998A9FB896651C8813749DB0BBD1634"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43681613e2123-wk-Fact-0998A9FB896651C8813749DB0BBD1634"
          xlink:to="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e7393-wk-Fact-09DBCF3E9CE2515B8F9E9D356B588B2E"
          xlink:label="d43770747e7393-wk-Fact-09DBCF3E9CE2515B8F9E9D356B588B2E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e7393-wk-Fact-09DBCF3E9CE2515B8F9E9D356B588B2E"
          xlink:to="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e7393-wk-Fact-09DBCF3E9CE2515B8F9E9D356B588B2E"
          xlink:to="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43674379e1013-wk-Fact-09FA50EC8B6A5544A580831FEECF0695"
          xlink:label="d43674379e1013-wk-Fact-09FA50EC8B6A5544A580831FEECF0695"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43674379e1013-wk-Fact-09FA50EC8B6A5544A580831FEECF0695"
          xlink:to="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e11114-wk-Fact-09FE0334A6DB46CA6D5F5A6A83AF54B0"
          xlink:label="d43770747e11114-wk-Fact-09FE0334A6DB46CA6D5F5A6A83AF54B0"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e11114-wk-Fact-09FE0334A6DB46CA6D5F5A6A83AF54B0"
          xlink:to="TextSelection-39CF024D03225486829869F6CA02C00E-0-wk-Footnote-39CF024D03225486829869F6CA02C00E_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e11114-wk-Fact-09FE0334A6DB46CA6D5F5A6A83AF54B0"
          xlink:to="TextSelection-53BB8CAFCA475C0C9DB2195050D36025-0-wk-Footnote-53BB8CAFCA475C0C9DB2195050D36025_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e11114-wk-Fact-09FE0334A6DB46CA6D5F5A6A83AF54B0"
          xlink:to="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43674379e1677-wk-Fact-0A0DAFD467625E0D8018223CBF2CB456"
          xlink:label="d43674379e1677-wk-Fact-0A0DAFD467625E0D8018223CBF2CB456"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43674379e1677-wk-Fact-0A0DAFD467625E0D8018223CBF2CB456"
          xlink:to="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e4137-wk-Fact-0A1FE70C55BA5D7C9D62C4839596BBE9"
          xlink:label="d43770747e4137-wk-Fact-0A1FE70C55BA5D7C9D62C4839596BBE9"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e4137-wk-Fact-0A1FE70C55BA5D7C9D62C4839596BBE9"
          xlink:to="TextSelection-2BFD6C99096B50AD93705C5601B21F46-0-wk-Footnote-2BFD6C99096B50AD93705C5601B21F46_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687704e1786-wk-Fact-0A252F10C1E25CFA8D6B9B5104061718"
          xlink:label="d43687704e1786-wk-Fact-0A252F10C1E25CFA8D6B9B5104061718"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d43690878e1466-wk-Fact-0A252F10C1E25CFA8D6B9B5104061718"
          xlink:label="d43690878e1466-wk-Fact-0A252F10C1E25CFA8D6B9B5104061718"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43690878e1466-wk-Fact-0A252F10C1E25CFA8D6B9B5104061718"
          xlink:to="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e1786-wk-Fact-0A252F10C1E25CFA8D6B9B5104061718"
          xlink:to="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e8274-wk-Fact-0A4EFE67B20358CA8861BC89A7FA3032"
          xlink:label="d43770747e8274-wk-Fact-0A4EFE67B20358CA8861BC89A7FA3032"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e8274-wk-Fact-0A4EFE67B20358CA8861BC89A7FA3032"
          xlink:to="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e8274-wk-Fact-0A4EFE67B20358CA8861BC89A7FA3032"
          xlink:to="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687849e2756-wk-Fact-0A65F347C9FD5314AD71D7212990864D"
          xlink:label="d43687849e2756-wk-Fact-0A65F347C9FD5314AD71D7212990864D"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d43691920e2625-wk-Fact-0A65F347C9FD5314AD71D7212990864D"
          xlink:label="d43691920e2625-wk-Fact-0A65F347C9FD5314AD71D7212990864D"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-2A0DF68DD6E953419D1E9B1C848DB228-0-wk-Footnote-2A0DF68DD6E953419D1E9B1C848DB228_lbl" xlink:label="TextSelection-2A0DF68DD6E953419D1E9B1C848DB228-0-wk-Footnote-2A0DF68DD6E953419D1E9B1C848DB228_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">See Note 5C. Tax Matters: Tax Provision/(Benefit) on Other Comprehensive Income.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e2756-wk-Fact-0A65F347C9FD5314AD71D7212990864D"
          xlink:to="TextSelection-2A0DF68DD6E953419D1E9B1C848DB228-0-wk-Footnote-2A0DF68DD6E953419D1E9B1C848DB228_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43691920e2625-wk-Fact-0A65F347C9FD5314AD71D7212990864D"
          xlink:to="TextSelection-2A0DF68DD6E953419D1E9B1C848DB228-0-wk-Footnote-2A0DF68DD6E953419D1E9B1C848DB228_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e2756-wk-Fact-0A65F347C9FD5314AD71D7212990864D"
          xlink:to="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43691920e2625-wk-Fact-0A65F347C9FD5314AD71D7212990864D"
          xlink:to="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e4364-wk-Fact-0A66AB4BBDF556D9BBC2F78276184CD8"
          xlink:label="d43770747e4364-wk-Fact-0A66AB4BBDF556D9BBC2F78276184CD8"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e4364-wk-Fact-0A66AB4BBDF556D9BBC2F78276184CD8"
          xlink:to="TextSelection-2BFD6C99096B50AD93705C5601B21F46-0-wk-Footnote-2BFD6C99096B50AD93705C5601B21F46_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43674379e2006-wk-Fact-0A96E5EFE1F05A0EAA09A948F325D5CB"
          xlink:label="d43674379e2006-wk-Fact-0A96E5EFE1F05A0EAA09A948F325D5CB"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43674379e2006-wk-Fact-0A96E5EFE1F05A0EAA09A948F325D5CB"
          xlink:to="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43712496e1265-wk-Fact-0ACADD6A2EFE53F1891A48EEF52A1F7C"
          xlink:label="d43712496e1265-wk-Fact-0ACADD6A2EFE53F1891A48EEF52A1F7C"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-1B1FEAD5EA4E576891141CE7B2D9386E-0-wk-Footnote-1B1FEAD5EA4E576891141CE7B2D9386E_lbl" xlink:label="TextSelection-1B1FEAD5EA4E576891141CE7B2D9386E-0-wk-Footnote-1B1FEAD5EA4E576891141CE7B2D9386E_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The asset impairment charges for the <xhtml:span style="font-family:inherit;font-size:9pt;">third</xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;"> quarter and the </xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;">first nine months of</xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;"> </xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;text-align:center;">2017</xhtml:span> are largely associated with our acquisitions of Hospira and Medivation.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43712496e1265-wk-Fact-0ACADD6A2EFE53F1891A48EEF52A1F7C"
          xlink:to="TextSelection-1B1FEAD5EA4E576891141CE7B2D9386E-0-wk-Footnote-1B1FEAD5EA4E576891141CE7B2D9386E_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43712496e1265-wk-Fact-0ACADD6A2EFE53F1891A48EEF52A1F7C"
          xlink:to="TextSelection-B57619F44FCF544D96067CF4816A9082-0-wk-Footnote-B57619F44FCF544D96067CF4816A9082_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43771853e2976-wk-Fact-0B8C5DECC76C5C9E999FC0C03F083D1F"
          xlink:label="d43771853e2976-wk-Fact-0B8C5DECC76C5C9E999FC0C03F083D1F"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-78FC5AB8EFAB585E87BBCF93BE9FBF1D-0-wk-Footnote-78FC5AB8EFAB585E87BBCF93BE9FBF1D_lbl" xlink:label="TextSelection-78FC5AB8EFAB585E87BBCF93BE9FBF1D-0-wk-Footnote-78FC5AB8EFAB585E87BBCF93BE9FBF1D_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Income from continuing operations before provision for taxes on income. IH&#x2019;s earnings in the <xhtml:span style="font-family:inherit;font-size:8pt;">third quarter</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> and </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">first nine months of</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;text-align:center;">2017</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;text-align:center;"> include d</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">ividend income of </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"><xhtml:span>$54 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> and </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"><xhtml:span>$211 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">, respectively, from our investment in ViiV. For additional information, see </xhtml:span>Note 4.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e2976-wk-Fact-0B8C5DECC76C5C9E999FC0C03F083D1F"
          xlink:to="TextSelection-78FC5AB8EFAB585E87BBCF93BE9FBF1D-0-wk-Footnote-78FC5AB8EFAB585E87BBCF93BE9FBF1D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43681613e1582-wk-Fact-0BA196038F9B5E96BAFED82F9B4D0A80"
          xlink:label="d43681613e1582-wk-Fact-0BA196038F9B5E96BAFED82F9B4D0A80"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43681613e1582-wk-Fact-0BA196038F9B5E96BAFED82F9B4D0A80"
          xlink:to="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687849e1864-wk-Fact-0BC6042F31745BE3B397485995AF247B"
          xlink:label="d43687849e1864-wk-Fact-0BC6042F31745BE3B397485995AF247B"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e1864-wk-Fact-0BC6042F31745BE3B397485995AF247B"
          xlink:to="TextSelection-77536863BCE35B419E3A4119D41DB4BD-0-wk-Footnote-77536863BCE35B419E3A4119D41DB4BD_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e1864-wk-Fact-0BC6042F31745BE3B397485995AF247B"
          xlink:to="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e4096-wk-Fact-0C018797136D5DE49DB04A0BF65EC513"
          xlink:label="d43770747e4096-wk-Fact-0C018797136D5DE49DB04A0BF65EC513"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-7EC55EFE69505245B1A079B8132EFBB7-0-wk-Footnote-7EC55EFE69505245B1A079B8132EFBB7_lbl" xlink:label="TextSelection-7EC55EFE69505245B1A079B8132EFBB7-0-wk-Footnote-7EC55EFE69505245B1A079B8132EFBB7_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Issued by a diverse group of corporations, with a significant concentration in the technology sector, virtually all of which are investment-grade.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e4096-wk-Fact-0C018797136D5DE49DB04A0BF65EC513"
          xlink:to="TextSelection-7EC55EFE69505245B1A079B8132EFBB7-0-wk-Footnote-7EC55EFE69505245B1A079B8132EFBB7_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43690878e2178-wk-Fact-0C0E82D74BA85110A5BDBF458FE4D314"
          xlink:label="d43690878e2178-wk-Fact-0C0E82D74BA85110A5BDBF458FE4D314"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43690878e2178-wk-Fact-0C0E82D74BA85110A5BDBF458FE4D314"
          xlink:to="TextSelection-792D3AB23D6354CFBB2776AE7F6407B4-0-wk-Footnote-792D3AB23D6354CFBB2776AE7F6407B4_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43681613e2764-wk-Fact-0C14F39B228253AAB03AA6A6439EFA78"
          xlink:label="d43681613e2764-wk-Fact-0C14F39B228253AAB03AA6A6439EFA78"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43681613e2764-wk-Fact-0C14F39B228253AAB03AA6A6439EFA78"
          xlink:to="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"
          xlink:type="arc"/>
        <link:footnote id="TextSelection-EB5698F25D035A90984FA270E724B7BB-0-wk-Footnote-EB5698F25D035A90984FA270E724B7BB_lbl" xlink:label="TextSelection-EB5698F25D035A90984FA270E724B7BB-0-wk-Footnote-EB5698F25D035A90984FA270E724B7BB_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">In connection with the sale of HIS net assets to ICU Medical, on February 3, 2017, Pfizer received <xhtml:span style="font-family:inherit;font-size:7.5pt;"><xhtml:span>3.2 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:7.5pt;"> newly issued shares of ICU Medical common stock initially valued at </xhtml:span><xhtml:span style="font-family:inherit;font-size:7.5pt;"><xhtml:span>$428 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:7.5pt;"> and a promissory note in the amount of </xhtml:span><xhtml:span style="font-family:inherit;font-size:7.5pt;"><xhtml:span>$75 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:7.5pt;">. For additional information, see </xhtml:span><xhtml:span style="font-family:inherit;font-size:7.5pt;font-style:italic;">Note 2B</xhtml:span><xhtml:span style="font-family:inherit;font-size:7.5pt;">.</xhtml:span><xhtml:span style="font-family:inherit;font-size:7.5pt;font-style:italic;"> </xhtml:span><xhtml:span style="font-family:inherit;font-size:7.5pt;font-style:italic;">Acquisitions, Sale of Hospira Infusion Systems Net Assets, Collaborative Arrangement and Equity-Method Investments</xhtml:span>: Sale of Hospira Infusion Systems Net Assets.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43681613e2764-wk-Fact-0C14F39B228253AAB03AA6A6439EFA78"
          xlink:to="TextSelection-EB5698F25D035A90984FA270E724B7BB-0-wk-Footnote-EB5698F25D035A90984FA270E724B7BB_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43674379e1809-wk-Fact-0CD797C3DDB8580E8F7A4492293BE3C1"
          xlink:label="d43674379e1809-wk-Fact-0CD797C3DDB8580E8F7A4492293BE3C1"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43674379e1809-wk-Fact-0CD797C3DDB8580E8F7A4492293BE3C1"
          xlink:to="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43697224e2885-wk-Fact-0D2E2A926A3F9786A8C65A1EF5DC2AD4"
          xlink:label="d43697224e2885-wk-Fact-0D2E2A926A3F9786A8C65A1EF5DC2AD4"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-066A0A390204B79351965A22CE69E761-0-wk-Footnote-066A0A390204B79351965A22CE69E761_lbl" xlink:label="TextSelection-066A0A390204B79351965A22CE69E761-0-wk-Footnote-066A0A390204B79351965A22CE69E761_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Reflects intangible assets written down to fair value in the <xhtml:span style="font-family:inherit;font-size:8.5pt;">third quarter</xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"> of </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;text-align:center;">2017</xhtml:span>. Fair value was determined using the income approach, specifically the multi-period excess earnings method, also known as the discounted cash flow method. We started with a forecast of all the expected net cash flows associated with the asset and then applied an asset-specific discount rate to arrive at a net present value amount. Some of the more significant estimates and assumptions inherent in this approach include: the amount and timing of the projected net cash flows, which includes the expected impact of competitive, legal and/or regulatory forces on the product; the discount rate, which seeks to reflect the various risks inherent in the projected cash flows; and the tax rate, which seeks to incorporate the geographic diversity of the projected cash flows.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43697224e2885-wk-Fact-0D2E2A926A3F9786A8C65A1EF5DC2AD4"
          xlink:to="TextSelection-066A0A390204B79351965A22CE69E761-0-wk-Footnote-066A0A390204B79351965A22CE69E761_lbl"
          xlink:type="arc"/>
        <link:footnote id="TextSelection-4AF5AB391F1CD8054C065A2324C0D822-0-wk-Footnote-4AF5AB391F1CD8054C065A2324C0D822_lbl" xlink:label="TextSelection-4AF5AB391F1CD8054C065A2324C0D822-0-wk-Footnote-4AF5AB391F1CD8054C065A2324C0D822_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The fair value amount is presented as of the date of impairment, as these assets are not measured at fair value on a recurring basis.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43697224e2885-wk-Fact-0D2E2A926A3F9786A8C65A1EF5DC2AD4"
          xlink:to="TextSelection-4AF5AB391F1CD8054C065A2324C0D822-0-wk-Footnote-4AF5AB391F1CD8054C065A2324C0D822_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43681613e2838-wk-Fact-0E16C50451235A15BAA9EA1F20FC4F80"
          xlink:label="d43681613e2838-wk-Fact-0E16C50451235A15BAA9EA1F20FC4F80"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43681613e2838-wk-Fact-0E16C50451235A15BAA9EA1F20FC4F80"
          xlink:to="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43674379e2699-wk-Fact-0E8B49C6C7365DEB9EDE52E9D965698D"
          xlink:label="d43674379e2699-wk-Fact-0E8B49C6C7365DEB9EDE52E9D965698D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43674379e2699-wk-Fact-0E8B49C6C7365DEB9EDE52E9D965698D"
          xlink:to="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687704e2745-wk-Fact-0EF2FD50430259DC8181FE20C0F40B34"
          xlink:label="d43687704e2745-wk-Fact-0EF2FD50430259DC8181FE20C0F40B34"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e2745-wk-Fact-0EF2FD50430259DC8181FE20C0F40B34"
          xlink:to="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e2745-wk-Fact-0EF2FD50430259DC8181FE20C0F40B34"
          xlink:to="TextSelection-9231AC55B8EC5775BC4995B0797F870F-0-wk-Footnote-9231AC55B8EC5775BC4995B0797F870F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43681613e1106-wk-Fact-0F638C219E595606B659714F53B6D14B"
          xlink:label="d43681613e1106-wk-Fact-0F638C219E595606B659714F53B6D14B"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43681613e1106-wk-Fact-0F638C219E595606B659714F53B6D14B"
          xlink:to="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e4299-wk-Fact-0F8D6EEC302657CA8AE0B3CB897EB60C"
          xlink:label="d43770747e4299-wk-Fact-0F8D6EEC302657CA8AE0B3CB897EB60C"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e4299-wk-Fact-0F8D6EEC302657CA8AE0B3CB897EB60C"
          xlink:to="TextSelection-2BFD6C99096B50AD93705C5601B21F46-0-wk-Footnote-2BFD6C99096B50AD93705C5601B21F46_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43690878e1196-wk-Fact-0FA2545E29EF51FFAFF4BBCC15878817"
          xlink:label="d43690878e1196-wk-Fact-0FA2545E29EF51FFAFF4BBCC15878817"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43690878e1196-wk-Fact-0FA2545E29EF51FFAFF4BBCC15878817"
          xlink:to="TextSelection-792D3AB23D6354CFBB2776AE7F6407B4-0-wk-Footnote-792D3AB23D6354CFBB2776AE7F6407B4_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43771853e10054-wk-Fact-0FBFE9A681A053E09C98AD1EEF2EAB26"
          xlink:label="d43771853e10054-wk-Fact-0FBFE9A681A053E09C98AD1EEF2EAB26"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-3AE2F5A9070951C0ACDF4F146E825D8D-0-wk-Footnote-3AE2F5A9070951C0ACDF4F146E825D8D_lbl" xlink:label="TextSelection-3AE2F5A9070951C0ACDF4F146E825D8D-0-wk-Footnote-3AE2F5A9070951C0ACDF4F146E825D8D_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Peri-LOE Products include products that have recently lost or are anticipated to soon lose patent protection. These products include: Lyrica in Europe, Russia, Turkey, Israel and Central Asia; Viagra in all countries (excluding the U.S. and Canada); and worldwide revenues for Celebrex, Pristiq, Zyvox, Vfend, Revatio and Inspra. </link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e10054-wk-Fact-0FBFE9A681A053E09C98AD1EEF2EAB26"
          xlink:to="TextSelection-3AE2F5A9070951C0ACDF4F146E825D8D-0-wk-Footnote-3AE2F5A9070951C0ACDF4F146E825D8D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687704e1068-wk-Fact-0FC4340BB89A562D9A6DFA4186E041AB"
          xlink:label="d43687704e1068-wk-Fact-0FC4340BB89A562D9A6DFA4186E041AB"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e1068-wk-Fact-0FC4340BB89A562D9A6DFA4186E041AB"
          xlink:to="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"
          xlink:type="arc"/>
        <link:footnote id="TextSelection-AE19F19C6AE65BBDA7F551089E2E7EDF-0-wk-Footnote-AE19F19C6AE65BBDA7F551089E2E7EDF_lbl" xlink:label="TextSelection-AE19F19C6AE65BBDA7F551089E2E7EDF-0-wk-Footnote-AE19F19C6AE65BBDA7F551089E2E7EDF_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Excludes amortization of intangible assets, except as disclosed in Note 9A. Identifiable Intangible Assets and Goodwill: Identifiable Intangible Assets.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e1068-wk-Fact-0FC4340BB89A562D9A6DFA4186E041AB"
          xlink:to="TextSelection-AE19F19C6AE65BBDA7F551089E2E7EDF-0-wk-Footnote-AE19F19C6AE65BBDA7F551089E2E7EDF_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687704e1722-wk-Fact-1011397EB1385A98BE195F68F7FE92A7"
          xlink:label="d43687704e1722-wk-Fact-1011397EB1385A98BE195F68F7FE92A7"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d43690878e1072-wk-Fact-1011397EB1385A98BE195F68F7FE92A7"
          xlink:label="d43690878e1072-wk-Fact-1011397EB1385A98BE195F68F7FE92A7"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43690878e1072-wk-Fact-1011397EB1385A98BE195F68F7FE92A7"
          xlink:to="TextSelection-792D3AB23D6354CFBB2776AE7F6407B4-0-wk-Footnote-792D3AB23D6354CFBB2776AE7F6407B4_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e1722-wk-Fact-1011397EB1385A98BE195F68F7FE92A7"
          xlink:to="TextSelection-792D3AB23D6354CFBB2776AE7F6407B4-0-wk-Footnote-792D3AB23D6354CFBB2776AE7F6407B4_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43690878e1072-wk-Fact-1011397EB1385A98BE195F68F7FE92A7"
          xlink:to="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e1722-wk-Fact-1011397EB1385A98BE195F68F7FE92A7"
          xlink:to="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43690878e1072-wk-Fact-1011397EB1385A98BE195F68F7FE92A7"
          xlink:to="TextSelection-9231AC55B8EC5775BC4995B0797F870F-0-wk-Footnote-9231AC55B8EC5775BC4995B0797F870F_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e1722-wk-Fact-1011397EB1385A98BE195F68F7FE92A7"
          xlink:to="TextSelection-9231AC55B8EC5775BC4995B0797F870F-0-wk-Footnote-9231AC55B8EC5775BC4995B0797F870F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687704e1684-wk-Fact-10A93FAA5CBC5B458A708E3EEBF01F13"
          xlink:label="d43687704e1684-wk-Fact-10A93FAA5CBC5B458A708E3EEBF01F13"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d43690878e1033-wk-Fact-10A93FAA5CBC5B458A708E3EEBF01F13"
          xlink:label="d43690878e1033-wk-Fact-10A93FAA5CBC5B458A708E3EEBF01F13"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43690878e1033-wk-Fact-10A93FAA5CBC5B458A708E3EEBF01F13"
          xlink:to="TextSelection-792D3AB23D6354CFBB2776AE7F6407B4-0-wk-Footnote-792D3AB23D6354CFBB2776AE7F6407B4_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e1684-wk-Fact-10A93FAA5CBC5B458A708E3EEBF01F13"
          xlink:to="TextSelection-792D3AB23D6354CFBB2776AE7F6407B4-0-wk-Footnote-792D3AB23D6354CFBB2776AE7F6407B4_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43690878e1033-wk-Fact-10A93FAA5CBC5B458A708E3EEBF01F13"
          xlink:to="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e1684-wk-Fact-10A93FAA5CBC5B458A708E3EEBF01F13"
          xlink:to="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43690878e1033-wk-Fact-10A93FAA5CBC5B458A708E3EEBF01F13"
          xlink:to="TextSelection-9231AC55B8EC5775BC4995B0797F870F-0-wk-Footnote-9231AC55B8EC5775BC4995B0797F870F_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e1684-wk-Fact-10A93FAA5CBC5B458A708E3EEBF01F13"
          xlink:to="TextSelection-9231AC55B8EC5775BC4995B0797F870F-0-wk-Footnote-9231AC55B8EC5775BC4995B0797F870F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687704e1365-wk-Fact-110B8A55AF7C5BFEAC9F11433EB9280B"
          xlink:label="d43687704e1365-wk-Fact-110B8A55AF7C5BFEAC9F11433EB9280B"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d43712496e1685-wk-Fact-110B8A55AF7C5BFEAC9F11433EB9280B"
          xlink:label="d43712496e1685-wk-Fact-110B8A55AF7C5BFEAC9F11433EB9280B"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e1365-wk-Fact-110B8A55AF7C5BFEAC9F11433EB9280B"
          xlink:to="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43712496e1685-wk-Fact-110B8A55AF7C5BFEAC9F11433EB9280B"
          xlink:to="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687704e1973-wk-Fact-110FAC29CE4C53DFB4DD30D11B664569"
          xlink:label="d43687704e1973-wk-Fact-110FAC29CE4C53DFB4DD30D11B664569"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e1973-wk-Fact-110FAC29CE4C53DFB4DD30D11B664569"
          xlink:to="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e5023-wk-Fact-119D2B7CC2895FCA84AA22FCC552D134"
          xlink:label="d43770747e5023-wk-Fact-119D2B7CC2895FCA84AA22FCC552D134"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e5023-wk-Fact-119D2B7CC2895FCA84AA22FCC552D134"
          xlink:to="TextSelection-2BFD6C99096B50AD93705C5601B21F46-0-wk-Footnote-2BFD6C99096B50AD93705C5601B21F46_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43690878e1874-wk-Fact-11F7A96D6D935A80A19BB49104FFB650"
          xlink:label="d43690878e1874-wk-Fact-11F7A96D6D935A80A19BB49104FFB650"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43690878e1874-wk-Fact-11F7A96D6D935A80A19BB49104FFB650"
          xlink:to="TextSelection-792D3AB23D6354CFBB2776AE7F6407B4-0-wk-Footnote-792D3AB23D6354CFBB2776AE7F6407B4_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687704e1954-wk-Fact-12644093904C5936B08DC2FFA86C8E1C"
          xlink:label="d43687704e1954-wk-Fact-12644093904C5936B08DC2FFA86C8E1C"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e1954-wk-Fact-12644093904C5936B08DC2FFA86C8E1C"
          xlink:to="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687849e1350-wk-Fact-130257F4983E52BEA926FB24D7677099"
          xlink:label="d43687849e1350-wk-Fact-130257F4983E52BEA926FB24D7677099"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e1350-wk-Fact-130257F4983E52BEA926FB24D7677099"
          xlink:to="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"
          xlink:type="arc"/>
        <link:footnote id="TextSelection-F185CD45BC245C2EB8EDBFD55DB8A33F-0-wk-Footnote-F185CD45BC245C2EB8EDBFD55DB8A33F_lbl" xlink:label="TextSelection-F185CD45BC245C2EB8EDBFD55DB8A33F-0-wk-Footnote-F185CD45BC245C2EB8EDBFD55DB8A33F_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Reclassified into <xhtml:span style="font-family:inherit;font-size:9pt;font-style:italic;">Other (income)/deductions&#x2014;net </xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;">and </xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;font-style:italic;">Cost of sales</xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;"> in the condensed consolidated statements of income. For additional information on amounts reclassified into </xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;font-style:italic;">Cost of sales,</xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;"> see </xhtml:span>Note 7F. Financial Instruments: Derivative Financial Instruments and Hedging Activities.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e1350-wk-Fact-130257F4983E52BEA926FB24D7677099"
          xlink:to="TextSelection-F185CD45BC245C2EB8EDBFD55DB8A33F-0-wk-Footnote-F185CD45BC245C2EB8EDBFD55DB8A33F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687849e2032-wk-Fact-13B324D73BAB58EC8AE8E3B51B6EC46D"
          xlink:label="d43687849e2032-wk-Fact-13B324D73BAB58EC8AE8E3B51B6EC46D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e2032-wk-Fact-13B324D73BAB58EC8AE8E3B51B6EC46D"
          xlink:to="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43712510e4837-wk-Fact-13DD39AEEF96518F9A80C62D8E6A58EB"
          xlink:label="d43712510e4837-wk-Fact-13DD39AEEF96518F9A80C62D8E6A58EB"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43712510e4837-wk-Fact-13DD39AEEF96518F9A80C62D8E6A58EB"
          xlink:to="TextSelection-621F9196966C550EA113DA57575C171E-0-wk-Footnote-621F9196966C550EA113DA57575C171E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43697224e1028-wk-Fact-143C071DEB4F5718B431ADB619B90A82"
          xlink:label="d43697224e1028-wk-Fact-143C071DEB4F5718B431ADB619B90A82"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-FE5DD06AA8B65777900C47B8AC19C4C6-0-wk-Footnote-FE5DD06AA8B65777900C47B8AC19C4C6_lbl" xlink:label="TextSelection-FE5DD06AA8B65777900C47B8AC19C4C6-0-wk-Footnote-FE5DD06AA8B65777900C47B8AC19C4C6_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Interest income decreased in the <xhtml:span style="font-family:inherit;font-size:8.5pt;">third</xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"> quarter and </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;">first nine months of</xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"> </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;text-align:center;">2017</xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;">, primarily driven by a lower investment balance. Interest expense increased in the </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;">third</xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"> quarter and </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;">first nine months of</xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"> </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;text-align:center;">2017</xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;">, </xhtml:span><xhtml:span style="font-size:8.5pt;">primarily as a result of higher short-term interest rates, offset, in part, by the retirement of high-coupon debt and the issuance of new low-coupon debt</xhtml:span>.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43697224e1028-wk-Fact-143C071DEB4F5718B431ADB619B90A82"
          xlink:to="TextSelection-FE5DD06AA8B65777900C47B8AC19C4C6-0-wk-Footnote-FE5DD06AA8B65777900C47B8AC19C4C6_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687704e2083-wk-Fact-143D73146425519EBA3BAC0B389543EF"
          xlink:label="d43687704e2083-wk-Fact-143D73146425519EBA3BAC0B389543EF"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e2083-wk-Fact-143D73146425519EBA3BAC0B389543EF"
          xlink:to="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e2083-wk-Fact-143D73146425519EBA3BAC0B389543EF"
          xlink:to="TextSelection-9231AC55B8EC5775BC4995B0797F870F-0-wk-Footnote-9231AC55B8EC5775BC4995B0797F870F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687704e1218-wk-Fact-1577AD25D0BD5FE9BC590CD0FFB82AC1"
          xlink:label="d43687704e1218-wk-Fact-1577AD25D0BD5FE9BC590CD0FFB82AC1"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e1218-wk-Fact-1577AD25D0BD5FE9BC590CD0FFB82AC1"
          xlink:to="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e1218-wk-Fact-1577AD25D0BD5FE9BC590CD0FFB82AC1"
          xlink:to="TextSelection-AE19F19C6AE65BBDA7F551089E2E7EDF-0-wk-Footnote-AE19F19C6AE65BBDA7F551089E2E7EDF_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43771853e11164-wk-Fact-15783BA6644A5B24968CE32B5F022A68"
          xlink:label="d43771853e11164-wk-Fact-15783BA6644A5B24968CE32B5F022A68"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-ED6F6E1A7C41596DA6F5B1BDFBB72CB7-0-wk-Footnote-ED6F6E1A7C41596DA6F5B1BDFBB72CB7_lbl" xlink:label="TextSelection-ED6F6E1A7C41596DA6F5B1BDFBB72CB7-0-wk-Footnote-ED6F6E1A7C41596DA6F5B1BDFBB72CB7_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">HIS (through February 2, 2017) includes Medication Management Systems products composed of infusion pumps and related software and services, as well as IV Infusion Products, including large volume IV solutions and their associated administration sets.<xhtml:span style="font-family:inherit;font-size:8pt;"><xhtml:sup style="vertical-align:top;line-height:120%;font-size:5pt"> </xhtml:sup>&#160;</xhtml:span><xhtml:br/></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e11164-wk-Fact-15783BA6644A5B24968CE32B5F022A68"
          xlink:to="TextSelection-ED6F6E1A7C41596DA6F5B1BDFBB72CB7-0-wk-Footnote-ED6F6E1A7C41596DA6F5B1BDFBB72CB7_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43771853e3323-wk-Fact-16217BBC721C5351BFA615340C8310C9"
          xlink:label="d43771853e3323-wk-Fact-16217BBC721C5351BFA615340C8310C9"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-13C3E50268A15908A8AC9D1B6C938D2D-0-wk-Footnote-13C3E50268A15908A8AC9D1B6C938D2D_lbl" xlink:label="TextSelection-13C3E50268A15908A8AC9D1B6C938D2D-0-wk-Footnote-13C3E50268A15908A8AC9D1B6C938D2D_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">For a description, see the &#x201c;Other Costs and Business Activities&#x201d; section above.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e3323-wk-Fact-16217BBC721C5351BFA615340C8310C9"
          xlink:to="TextSelection-13C3E50268A15908A8AC9D1B6C938D2D-0-wk-Footnote-13C3E50268A15908A8AC9D1B6C938D2D_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e3323-wk-Fact-16217BBC721C5351BFA615340C8310C9"
          xlink:to="TextSelection-78FC5AB8EFAB585E87BBCF93BE9FBF1D-0-wk-Footnote-78FC5AB8EFAB585E87BBCF93BE9FBF1D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e10035-wk-Fact-16809863F1405611BBE44B0DB80273DE"
          xlink:label="d43770747e10035-wk-Fact-16809863F1405611BBE44B0DB80273DE"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e10035-wk-Fact-16809863F1405611BBE44B0DB80273DE"
          xlink:to="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e10035-wk-Fact-16809863F1405611BBE44B0DB80273DE"
          xlink:to="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43771853e4687-wk-Fact-16BC8C896FAA55B4BECE452FC941C562"
          xlink:label="d43771853e4687-wk-Fact-16BC8C896FAA55B4BECE452FC941C562"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-E9F14C2885BA59D8B6B4AD221FC38619-0-wk-Footnote-E9F14C2885BA59D8B6B4AD221FC38619_lbl" xlink:label="TextSelection-E9F14C2885BA59D8B6B4AD221FC38619-0-wk-Footnote-E9F14C2885BA59D8B6B4AD221FC38619_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-family:inherit;font-size:8pt;">Developed Rest of World region includes the following markets: Japan, Canada, Australia, South Korea and New Zealand.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e4687-wk-Fact-16BC8C896FAA55B4BECE452FC941C562"
          xlink:to="TextSelection-E9F14C2885BA59D8B6B4AD221FC38619-0-wk-Footnote-E9F14C2885BA59D8B6B4AD221FC38619_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43771853e11504-wk-Fact-16FFF27FA1865523A99E7DB32984FAAA"
          xlink:label="d43771853e11504-wk-Fact-16FFF27FA1865523A99E7DB32984FAAA"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e11504-wk-Fact-16FFF27FA1865523A99E7DB32984FAAA"
          xlink:to="TextSelection-450A7304FB7E513FB479F6D9A06EF1D3-0-wk-Footnote-450A7304FB7E513FB479F6D9A06EF1D3_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687849e1094-wk-Fact-1745891B013F59B28C550000447D41B6"
          xlink:label="d43687849e1094-wk-Fact-1745891B013F59B28C550000447D41B6"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-36C36413532355188985D26E3B171357-0-wk-Footnote-36C36413532355188985D26E3B171357_lbl" xlink:label="TextSelection-36C36413532355188985D26E3B171357-0-wk-Footnote-36C36413532355188985D26E3B171357_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The foreign currency translation adjustments reclassified into <xhtml:span style="font-family:inherit;font-size:9pt;font-style:italic;">Other (income)/deductions&#x2014;net </xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;">in the condensed consolidated statements of income primarily result from sale of our </xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;"><xhtml:span>40%</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;"> ownership investment in Teuto. See </xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;font-style:italic;">Note 2D. </xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;font-style:italic;">Acquisitions, Sale of Hospira Infusion Systems Net Assets, Collaborative Arrangement and Equity-Method Investments</xhtml:span>: Equity-Method Investments.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e1094-wk-Fact-1745891B013F59B28C550000447D41B6"
          xlink:to="TextSelection-36C36413532355188985D26E3B171357-0-wk-Footnote-36C36413532355188985D26E3B171357_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e1094-wk-Fact-1745891B013F59B28C550000447D41B6"
          xlink:to="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43712510e4504-wk-Fact-177183957B01565CA3DE15186DC0AA3E"
          xlink:label="d43712510e4504-wk-Fact-177183957B01565CA3DE15186DC0AA3E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43712510e4504-wk-Fact-177183957B01565CA3DE15186DC0AA3E"
          xlink:to="TextSelection-621F9196966C550EA113DA57575C171E-0-wk-Footnote-621F9196966C550EA113DA57575C171E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e8789-wk-Fact-177D9D5D5C305B2CB2F2B8CFC0B8B38B"
          xlink:label="d43770747e8789-wk-Fact-177D9D5D5C305B2CB2F2B8CFC0B8B38B"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e8789-wk-Fact-177D9D5D5C305B2CB2F2B8CFC0B8B38B"
          xlink:to="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e8789-wk-Fact-177D9D5D5C305B2CB2F2B8CFC0B8B38B"
          xlink:to="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43690878e1422-wk-Fact-18674C7559605F059F86A2A98B4C09F5"
          xlink:label="d43690878e1422-wk-Fact-18674C7559605F059F86A2A98B4C09F5"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43690878e1422-wk-Fact-18674C7559605F059F86A2A98B4C09F5"
          xlink:to="TextSelection-792D3AB23D6354CFBB2776AE7F6407B4-0-wk-Footnote-792D3AB23D6354CFBB2776AE7F6407B4_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687704e1133-wk-Fact-191AFA552BEF51A38ED7B886728FB89F"
          xlink:label="d43687704e1133-wk-Fact-191AFA552BEF51A38ED7B886728FB89F"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e1133-wk-Fact-191AFA552BEF51A38ED7B886728FB89F"
          xlink:to="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e1133-wk-Fact-191AFA552BEF51A38ED7B886728FB89F"
          xlink:to="TextSelection-AE19F19C6AE65BBDA7F551089E2E7EDF-0-wk-Footnote-AE19F19C6AE65BBDA7F551089E2E7EDF_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e5740-wk-Fact-19A2A621AB2F5D67AFB144F44BDFF8C9"
          xlink:label="d43770747e5740-wk-Fact-19A2A621AB2F5D67AFB144F44BDFF8C9"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-0BDE8CEE983B5F118E2EFACDF9CC6405-0-wk-Footnote-0BDE8CEE983B5F118E2EFACDF9CC6405_lbl" xlink:label="TextSelection-0BDE8CEE983B5F118E2EFACDF9CC6405-0-wk-Footnote-0BDE8CEE983B5F118E2EFACDF9CC6405_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Redeemable at any time, in whole, or in part, at our option prior to 30 to 90 days of maturity date at the comparable German government bond rate, plus <xhtml:span style="font-family:inherit;font-size:8.5pt;"><xhtml:span>0.15%</xhtml:span></xhtml:span>; plus, in each case, accrued and unpaid interest. The fixed rate euro notes are also redeemable at our option, in whole, or in part, within 30 to 90 days of maturity date.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e5740-wk-Fact-19A2A621AB2F5D67AFB144F44BDFF8C9"
          xlink:to="TextSelection-0BDE8CEE983B5F118E2EFACDF9CC6405-0-wk-Footnote-0BDE8CEE983B5F118E2EFACDF9CC6405_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43771853e11098-wk-Fact-19D08708847D5BDEAC5A5C81A5DC8E05"
          xlink:label="d43771853e11098-wk-Fact-19D08708847D5BDEAC5A5C81A5DC8E05"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-7266C8E6B8975A65A379AF3B415EA220-0-wk-Footnote-7266C8E6B8975A65A379AF3B415EA220_lbl" xlink:label="TextSelection-7266C8E6B8975A65A379AF3B415EA220-0-wk-Footnote-7266C8E6B8975A65A379AF3B415EA220_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Pfizer CentreOne includes revenues from our contract manufacturing and active pharmaceutical ingredient sales operation, including sterile injectables contract manufacturing, and revenues related to our manufacturing and supply agreements, including with Zoetis. </link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e11098-wk-Fact-19D08708847D5BDEAC5A5C81A5DC8E05"
          xlink:to="TextSelection-7266C8E6B8975A65A379AF3B415EA220-0-wk-Footnote-7266C8E6B8975A65A379AF3B415EA220_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e11010-wk-Fact-1A851ADE80F15F3490D42C3F2F83E624"
          xlink:label="d43770747e11010-wk-Fact-1A851ADE80F15F3490D42C3F2F83E624"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e11010-wk-Fact-1A851ADE80F15F3490D42C3F2F83E624"
          xlink:to="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e11010-wk-Fact-1A851ADE80F15F3490D42C3F2F83E624"
          xlink:to="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687704e1263-wk-Fact-1A88D36F44FC57EEB2947A0516F8E2FB"
          xlink:label="d43687704e1263-wk-Fact-1A88D36F44FC57EEB2947A0516F8E2FB"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e1263-wk-Fact-1A88D36F44FC57EEB2947A0516F8E2FB"
          xlink:to="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43712496e3507-wk-Fact-1AB7DD0AE8235344A53584C522F56843"
          xlink:label="d43712496e3507-wk-Fact-1AB7DD0AE8235344A53584C522F56843"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-04B3DB4115835E2FBB99EA13FC1FD64B-0-wk-Footnote-04B3DB4115835E2FBB99EA13FC1FD64B_lbl" xlink:label="TextSelection-04B3DB4115835E2FBB99EA13FC1FD64B-0-wk-Footnote-04B3DB4115835E2FBB99EA13FC1FD64B_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Includes adjustments for foreign currency translation.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43712496e3507-wk-Fact-1AB7DD0AE8235344A53584C522F56843"
          xlink:to="TextSelection-04B3DB4115835E2FBB99EA13FC1FD64B-0-wk-Footnote-04B3DB4115835E2FBB99EA13FC1FD64B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e8647-wk-Fact-1B18B8E0BFFA5FAB8CC46A153B1999C9"
          xlink:label="d43770747e8647-wk-Fact-1B18B8E0BFFA5FAB8CC46A153B1999C9"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e8647-wk-Fact-1B18B8E0BFFA5FAB8CC46A153B1999C9"
          xlink:to="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e8647-wk-Fact-1B18B8E0BFFA5FAB8CC46A153B1999C9"
          xlink:to="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43697240e3223-wk-Fact-1B4BEA3CDC1756D68AA1A2E1DC80FA4D"
          xlink:label="d43697240e3223-wk-Fact-1B4BEA3CDC1756D68AA1A2E1DC80FA4D"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-5368EA2EA2275823ADDE27DF2382EF3B-0-wk-Footnote-5368EA2EA2275823ADDE27DF2382EF3B_lbl" xlink:label="TextSelection-5368EA2EA2275823ADDE27DF2382EF3B-0-wk-Footnote-5368EA2EA2275823ADDE27DF2382EF3B_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">IH additions primarily represent measurement period adjustments related to our Medivation acquisition, and EH additions relate to our acquisition of AstraZeneca&#x2019;s small molecule anti-infectives business, which are subject to change until we complete the valuation of assets acquired and liabilities assumed (see <xhtml:span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Note 2A</xhtml:span>).</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43697240e3223-wk-Fact-1B4BEA3CDC1756D68AA1A2E1DC80FA4D"
          xlink:to="TextSelection-5368EA2EA2275823ADDE27DF2382EF3B-0-wk-Footnote-5368EA2EA2275823ADDE27DF2382EF3B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43674379e2630-wk-Fact-1B54ADB976A25833A5F7A46C177A2A45"
          xlink:label="d43674379e2630-wk-Fact-1B54ADB976A25833A5F7A46C177A2A45"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43674379e2630-wk-Fact-1B54ADB976A25833A5F7A46C177A2A45"
          xlink:to="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43681613e1200-wk-Fact-1B9FEF203B3C5505BC6C4EC5902F0BCF"
          xlink:label="d43681613e1200-wk-Fact-1B9FEF203B3C5505BC6C4EC5902F0BCF"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-3DD94144621C5A68BC21C5DB64345BB9-0-wk-Footnote-3DD94144621C5A68BC21C5DB64345BB9_lbl" xlink:label="TextSelection-3DD94144621C5A68BC21C5DB64345BB9-0-wk-Footnote-3DD94144621C5A68BC21C5DB64345BB9_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Amounts for the <xhtml:span style="font-family:inherit;font-size:7.5pt;">three and nine months ended October 2, 2016</xhtml:span><xhtml:span style="font-family:inherit;font-size:7.5pt;"> have been revised from previously reported amounts to reflect the adoption of a new accounting standard in the fourth quarter of 2016, as of January 1, 2016. For additional information, see </xhtml:span><xhtml:span style="font-family:inherit;font-size:7.5pt;font-style:italic;">Note 1B</xhtml:span><xhtml:span style="font-family:inherit;font-size:7.5pt;">. </xhtml:span><xhtml:span style="font-family:inherit;font-size:7.5pt;font-style:italic;">Basis of Presentation and Significant Accounting Policies</xhtml:span>: Adoption of New Accounting Standards.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43681613e1200-wk-Fact-1B9FEF203B3C5505BC6C4EC5902F0BCF"
          xlink:to="TextSelection-3DD94144621C5A68BC21C5DB64345BB9-0-wk-Footnote-3DD94144621C5A68BC21C5DB64345BB9_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43681613e1200-wk-Fact-1B9FEF203B3C5505BC6C4EC5902F0BCF"
          xlink:to="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687849e2176-wk-Fact-1C3BC6367D20581BA4D58D85D2EF3508"
          xlink:label="d43687849e2176-wk-Fact-1C3BC6367D20581BA4D58D85D2EF3508"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e2176-wk-Fact-1C3BC6367D20581BA4D58D85D2EF3508"
          xlink:to="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43712510e4324-wk-Fact-1C567788B51552EC86AD93358A113C04"
          xlink:label="d43712510e4324-wk-Fact-1C567788B51552EC86AD93358A113C04"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43712510e4324-wk-Fact-1C567788B51552EC86AD93358A113C04"
          xlink:to="TextSelection-621F9196966C550EA113DA57575C171E-0-wk-Footnote-621F9196966C550EA113DA57575C171E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43712496e2260-wk-Fact-1D412AB78B1D52DEAA171F130190DA4E"
          xlink:label="d43712496e2260-wk-Fact-1D412AB78B1D52DEAA171F130190DA4E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43712496e2260-wk-Fact-1D412AB78B1D52DEAA171F130190DA4E"
          xlink:to="TextSelection-C37CD88178CA35C475D25A62F2B54FED-0-wk-Footnote-C37CD88178CA35C475D25A62F2B54FED_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43712510e4187-wk-Fact-1D5607877A1C54618597D694BA991812"
          xlink:label="d43712510e4187-wk-Fact-1D5607877A1C54618597D694BA991812"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43712510e4187-wk-Fact-1D5607877A1C54618597D694BA991812"
          xlink:to="TextSelection-621F9196966C550EA113DA57575C171E-0-wk-Footnote-621F9196966C550EA113DA57575C171E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687704e3141-wk-Fact-1E5089DBEBB75DB7864724ADB41A8830"
          xlink:label="d43687704e3141-wk-Fact-1E5089DBEBB75DB7864724ADB41A8830"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d43690878e2224-wk-Fact-1E5089DBEBB75DB7864724ADB41A8830"
          xlink:label="d43690878e2224-wk-Fact-1E5089DBEBB75DB7864724ADB41A8830"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e3141-wk-Fact-1E5089DBEBB75DB7864724ADB41A8830"
          xlink:to="TextSelection-792D3AB23D6354CFBB2776AE7F6407B4-0-wk-Footnote-792D3AB23D6354CFBB2776AE7F6407B4_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43690878e2224-wk-Fact-1E5089DBEBB75DB7864724ADB41A8830"
          xlink:to="TextSelection-792D3AB23D6354CFBB2776AE7F6407B4-0-wk-Footnote-792D3AB23D6354CFBB2776AE7F6407B4_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e3141-wk-Fact-1E5089DBEBB75DB7864724ADB41A8830"
          xlink:to="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43690878e2224-wk-Fact-1E5089DBEBB75DB7864724ADB41A8830"
          xlink:to="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e3141-wk-Fact-1E5089DBEBB75DB7864724ADB41A8830"
          xlink:to="TextSelection-9231AC55B8EC5775BC4995B0797F870F-0-wk-Footnote-9231AC55B8EC5775BC4995B0797F870F_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43690878e2224-wk-Fact-1E5089DBEBB75DB7864724ADB41A8830"
          xlink:to="TextSelection-9231AC55B8EC5775BC4995B0797F870F-0-wk-Footnote-9231AC55B8EC5775BC4995B0797F870F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e4384-wk-Fact-1EB643CEE30E5AE0B145130CC6CEAC25"
          xlink:label="d43770747e4384-wk-Fact-1EB643CEE30E5AE0B145130CC6CEAC25"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e4384-wk-Fact-1EB643CEE30E5AE0B145130CC6CEAC25"
          xlink:to="TextSelection-2BFD6C99096B50AD93705C5601B21F46-0-wk-Footnote-2BFD6C99096B50AD93705C5601B21F46_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43771853e5863-wk-Fact-1F06BFCD01CA55BFA37745ACCFA9290A"
          xlink:label="d43771853e5863-wk-Fact-1F06BFCD01CA55BFA37745ACCFA9290A"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e5863-wk-Fact-1F06BFCD01CA55BFA37745ACCFA9290A"
          xlink:to="TextSelection-450A7304FB7E513FB479F6D9A06EF1D3-0-wk-Footnote-450A7304FB7E513FB479F6D9A06EF1D3_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687704e3268-wk-Fact-1F15569F17C85A6FB44008E62E8E62E3"
          xlink:label="d43687704e3268-wk-Fact-1F15569F17C85A6FB44008E62E8E62E3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e3268-wk-Fact-1F15569F17C85A6FB44008E62E8E62E3"
          xlink:to="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687849e1815-wk-Fact-1F4BA95B10925AE8A489F10EF8546E3C"
          xlink:label="d43687849e1815-wk-Fact-1F4BA95B10925AE8A489F10EF8546E3C"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e1815-wk-Fact-1F4BA95B10925AE8A489F10EF8546E3C"
          xlink:to="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687704e1910-wk-Fact-1F598F7CC0A659DC8B78C122AEB4F4CE"
          xlink:label="d43687704e1910-wk-Fact-1F598F7CC0A659DC8B78C122AEB4F4CE"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d43687849e904-wk-Fact-1F598F7CC0A659DC8B78C122AEB4F4CE"
          xlink:label="d43687849e904-wk-Fact-1F598F7CC0A659DC8B78C122AEB4F4CE"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d43681613e821-wk-Fact-1F598F7CC0A659DC8B78C122AEB4F4CE"
          xlink:label="d43681613e821-wk-Fact-1F598F7CC0A659DC8B78C122AEB4F4CE"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43681613e821-wk-Fact-1F598F7CC0A659DC8B78C122AEB4F4CE"
          xlink:to="TextSelection-3DD94144621C5A68BC21C5DB64345BB9-0-wk-Footnote-3DD94144621C5A68BC21C5DB64345BB9_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e1910-wk-Fact-1F598F7CC0A659DC8B78C122AEB4F4CE"
          xlink:to="TextSelection-3DD94144621C5A68BC21C5DB64345BB9-0-wk-Footnote-3DD94144621C5A68BC21C5DB64345BB9_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e904-wk-Fact-1F598F7CC0A659DC8B78C122AEB4F4CE"
          xlink:to="TextSelection-3DD94144621C5A68BC21C5DB64345BB9-0-wk-Footnote-3DD94144621C5A68BC21C5DB64345BB9_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43681613e821-wk-Fact-1F598F7CC0A659DC8B78C122AEB4F4CE"
          xlink:to="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e1910-wk-Fact-1F598F7CC0A659DC8B78C122AEB4F4CE"
          xlink:to="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e904-wk-Fact-1F598F7CC0A659DC8B78C122AEB4F4CE"
          xlink:to="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43681613e821-wk-Fact-1F598F7CC0A659DC8B78C122AEB4F4CE"
          xlink:to="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e1910-wk-Fact-1F598F7CC0A659DC8B78C122AEB4F4CE"
          xlink:to="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e904-wk-Fact-1F598F7CC0A659DC8B78C122AEB4F4CE"
          xlink:to="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43681613e821-wk-Fact-1F598F7CC0A659DC8B78C122AEB4F4CE"
          xlink:to="TextSelection-9231AC55B8EC5775BC4995B0797F870F-0-wk-Footnote-9231AC55B8EC5775BC4995B0797F870F_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e1910-wk-Fact-1F598F7CC0A659DC8B78C122AEB4F4CE"
          xlink:to="TextSelection-9231AC55B8EC5775BC4995B0797F870F-0-wk-Footnote-9231AC55B8EC5775BC4995B0797F870F_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e904-wk-Fact-1F598F7CC0A659DC8B78C122AEB4F4CE"
          xlink:to="TextSelection-9231AC55B8EC5775BC4995B0797F870F-0-wk-Footnote-9231AC55B8EC5775BC4995B0797F870F_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43681613e821-wk-Fact-1F598F7CC0A659DC8B78C122AEB4F4CE"
          xlink:to="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e1910-wk-Fact-1F598F7CC0A659DC8B78C122AEB4F4CE"
          xlink:to="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e904-wk-Fact-1F598F7CC0A659DC8B78C122AEB4F4CE"
          xlink:to="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e10429-wk-Fact-1FF4C4C95159585A8AD2FEAE77CAC774"
          xlink:label="d43770747e10429-wk-Fact-1FF4C4C95159585A8AD2FEAE77CAC774"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e10429-wk-Fact-1FF4C4C95159585A8AD2FEAE77CAC774"
          xlink:to="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e10429-wk-Fact-1FF4C4C95159585A8AD2FEAE77CAC774"
          xlink:to="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43681613e2196-wk-Fact-202F98BA511E52368E7B8599E950975E"
          xlink:label="d43681613e2196-wk-Fact-202F98BA511E52368E7B8599E950975E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43681613e2196-wk-Fact-202F98BA511E52368E7B8599E950975E"
          xlink:to="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43691920e1143-wk-Fact-20A5C02D91765E01AC1BECE67B1B1069"
          xlink:label="d43691920e1143-wk-Fact-20A5C02D91765E01AC1BECE67B1B1069"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-C94190737D79577A8993EFAC2CD3FC95-0-wk-Footnote-C94190737D79577A8993EFAC2CD3FC95_lbl" xlink:label="TextSelection-C94190737D79577A8993EFAC2CD3FC95-0-wk-Footnote-C94190737D79577A8993EFAC2CD3FC95_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Taxes are not provided for foreign currency translation adjustments relating to investments in international subsidiaries that will be held indefinitely.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43691920e1143-wk-Fact-20A5C02D91765E01AC1BECE67B1B1069"
          xlink:to="TextSelection-C94190737D79577A8993EFAC2CD3FC95-0-wk-Footnote-C94190737D79577A8993EFAC2CD3FC95_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43697224e1371-wk-Fact-21036AB1E903531C8D597B8E28342703"
          xlink:label="d43697224e1371-wk-Fact-21036AB1E903531C8D597B8E28342703"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-6E67095C033B51BB9FABBA85E8DC4DFA-0-wk-Footnote-6E67095C033B51BB9FABBA85E8DC4DFA_lbl" xlink:label="TextSelection-6E67095C033B51BB9FABBA85E8DC4DFA-0-wk-Footnote-6E67095C033B51BB9FABBA85E8DC4DFA_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">In the <xhtml:span style="font-family:inherit;font-size:8.5pt;">third</xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"> quarter of </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;text-align:center;">2017</xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;">, primarily includes gains on sales/out-licensing of product and compound rights (approximately </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"><xhtml:span>$71 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;">) and gains on sales and redemptions of investments in equity and debt securities (approximately </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"><xhtml:span>$66 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;">). In the </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;">first nine months of</xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"> </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;text-align:center;">2017</xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;">, primarily includes gains on sales and redemptions of investments in equity and debt securities (approximately </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"><xhtml:span>$183 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;">), gains on sales/out-licensing of product and compound rights (approximately </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"><xhtml:span>$141 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;">) and a gain on sale of property (approximately </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"><xhtml:span>$52 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;">), partially offset by a net loss related to the sale of our </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"><xhtml:span>40%</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"> ownership investment in Teuto, including the extinguishment of a put option for the remaining </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"><xhtml:span>60%</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"> ownership interest (approximately </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"><xhtml:span>$30 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;">). In the </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;">first nine months of</xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"> </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;text-align:center;">2016</xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;">, includes gains on sales/out-licensing of product and compound rights (approximately </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"><xhtml:span>$49 million</xhtml:span></xhtml:span>).</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43697224e1371-wk-Fact-21036AB1E903531C8D597B8E28342703"
          xlink:to="TextSelection-6E67095C033B51BB9FABBA85E8DC4DFA-0-wk-Footnote-6E67095C033B51BB9FABBA85E8DC4DFA_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43771853e3561-wk-Fact-2131D133192A51CEA24287EC4D1DC30D"
          xlink:label="d43771853e3561-wk-Fact-2131D133192A51CEA24287EC4D1DC30D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e3561-wk-Fact-2131D133192A51CEA24287EC4D1DC30D"
          xlink:to="TextSelection-78FC5AB8EFAB585E87BBCF93BE9FBF1D-0-wk-Footnote-78FC5AB8EFAB585E87BBCF93BE9FBF1D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43678813e956-wk-Fact-2164B7E786595ADF8A2FFDAB7982BEB2"
          xlink:label="d43678813e956-wk-Fact-2164B7E786595ADF8A2FFDAB7982BEB2"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-E16E3AA57ADF5C6FB93B6FC578ED7F95-0-wk-Footnote-E16E3AA57ADF5C6FB93B6FC578ED7F95_lbl" xlink:label="TextSelection-E16E3AA57ADF5C6FB93B6FC578ED7F95-0-wk-Footnote-E16E3AA57ADF5C6FB93B6FC578ED7F95_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Included in <xhtml:span style="font-family:inherit;font-size:9pt;font-style:italic;">Other noncurrent assets</xhtml:span>. There are no recoverability issues associated with these amounts.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43678813e956-wk-Fact-2164B7E786595ADF8A2FFDAB7982BEB2"
          xlink:to="TextSelection-E16E3AA57ADF5C6FB93B6FC578ED7F95-0-wk-Footnote-E16E3AA57ADF5C6FB93B6FC578ED7F95_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e841-wk-Fact-2216EB0E4F0B50869B845DEBE01027C3"
          xlink:label="d43770747e841-wk-Fact-2216EB0E4F0B50869B845DEBE01027C3"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-0A1952177FA453EC8B5651D58249A9BA-0-wk-Footnote-0A1952177FA453EC8B5651D58249A9BA_lbl" xlink:label="TextSelection-0A1952177FA453EC8B5651D58249A9BA-0-wk-Footnote-0A1952177FA453EC8B5651D58249A9BA_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">As of <xhtml:span style="font-family:inherit;font-size:8.5pt;">October&#160;1, 2017</xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;">, trading funds and securities are composed of </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"><xhtml:span>$274 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"> of trading equity funds and </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"><xhtml:span>$74 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"> of trading debt funds. As of </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;text-align:center;">December&#160;31, 2016</xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;">, trading funds and securities are composed of </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"><xhtml:span>$236 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"> of trading equity funds and </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"><xhtml:span>$89 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"> of trading debt funds. As of </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;">October&#160;1, 2017</xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"> and </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;text-align:center;">December&#160;31, 2016</xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;">, trading equity funds of </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"><xhtml:span>$63 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"> and </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"><xhtml:span>$71 million</xhtml:span></xhtml:span>, respectively, are held in trust for benefits attributable to the former Pharmacia Savings Plus Plan.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e841-wk-Fact-2216EB0E4F0B50869B845DEBE01027C3"
          xlink:to="TextSelection-0A1952177FA453EC8B5651D58249A9BA-0-wk-Footnote-0A1952177FA453EC8B5651D58249A9BA_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e841-wk-Fact-2216EB0E4F0B50869B845DEBE01027C3"
          xlink:to="TextSelection-8D2A93033C2E56DE9E814F0AB36328EE-0-wk-Footnote-8D2A93033C2E56DE9E814F0AB36328EE_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43674379e2386-wk-Fact-22383CE0D78B56089748D1342C097ED3"
          xlink:label="d43674379e2386-wk-Fact-22383CE0D78B56089748D1342C097ED3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43674379e2386-wk-Fact-22383CE0D78B56089748D1342C097ED3"
          xlink:to="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687704e1180-wk-Fact-225BF3E60210511691B41C170582C821"
          xlink:label="d43687704e1180-wk-Fact-225BF3E60210511691B41C170582C821"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e1180-wk-Fact-225BF3E60210511691B41C170582C821"
          xlink:to="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e1180-wk-Fact-225BF3E60210511691B41C170582C821"
          xlink:to="TextSelection-AE19F19C6AE65BBDA7F551089E2E7EDF-0-wk-Footnote-AE19F19C6AE65BBDA7F551089E2E7EDF_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43712496e1943-wk-Fact-2287BD2729395E10AA7149FD8CDD1C22"
          xlink:label="d43712496e1943-wk-Fact-2287BD2729395E10AA7149FD8CDD1C22"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-7160FF67E87550A19177FE255A41A2D7-0-wk-Footnote-7160FF67E87550A19177FE255A41A2D7_lbl" xlink:label="TextSelection-7160FF67E87550A19177FE255A41A2D7-0-wk-Footnote-7160FF67E87550A19177FE255A41A2D7_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Additional depreciation&#x2013;&#x2013;asset restructuring represents the impact of changes in the estimated useful lives of assets involved in restructuring actions.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43712496e1943-wk-Fact-2287BD2729395E10AA7149FD8CDD1C22"
          xlink:to="TextSelection-7160FF67E87550A19177FE255A41A2D7-0-wk-Footnote-7160FF67E87550A19177FE255A41A2D7_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43674379e1987-wk-Fact-22AAFEBAB3755B18A95911F7BF8494E3"
          xlink:label="d43674379e1987-wk-Fact-22AAFEBAB3755B18A95911F7BF8494E3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43674379e1987-wk-Fact-22AAFEBAB3755B18A95911F7BF8494E3"
          xlink:to="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43681613e1036-wk-Fact-22BDA5BA109D56B8A234197E3982FF14"
          xlink:label="d43681613e1036-wk-Fact-22BDA5BA109D56B8A234197E3982FF14"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43681613e1036-wk-Fact-22BDA5BA109D56B8A234197E3982FF14"
          xlink:to="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43771853e10198-wk-Fact-232A214804B055189EC1111DA289CA2D"
          xlink:label="d43771853e10198-wk-Fact-232A214804B055189EC1111DA289CA2D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e10198-wk-Fact-232A214804B055189EC1111DA289CA2D"
          xlink:to="TextSelection-DE7EF4A6663E52BF8D3620854A57A945-0-wk-Footnote-DE7EF4A6663E52BF8D3620854A57A945_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43690878e1254-wk-Fact-232AC2542E565EDABA540B1D57A95D2D"
          xlink:label="d43690878e1254-wk-Fact-232AC2542E565EDABA540B1D57A95D2D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43690878e1254-wk-Fact-232AC2542E565EDABA540B1D57A95D2D"
          xlink:to="TextSelection-792D3AB23D6354CFBB2776AE7F6407B4-0-wk-Footnote-792D3AB23D6354CFBB2776AE7F6407B4_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e10390-wk-Fact-238B98C4D02459528B018866A4D1E3C1"
          xlink:label="d43770747e10390-wk-Fact-238B98C4D02459528B018866A4D1E3C1"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e10390-wk-Fact-238B98C4D02459528B018866A4D1E3C1"
          xlink:to="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e10390-wk-Fact-238B98C4D02459528B018866A4D1E3C1"
          xlink:to="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43771853e2128-wk-Fact-241DA9C0A5035519B185693E59F3571D"
          xlink:label="d43771853e2128-wk-Fact-241DA9C0A5035519B185693E59F3571D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e2128-wk-Fact-241DA9C0A5035519B185693E59F3571D"
          xlink:to="TextSelection-78FC5AB8EFAB585E87BBCF93BE9FBF1D-0-wk-Footnote-78FC5AB8EFAB585E87BBCF93BE9FBF1D_lbl"
          xlink:type="arc"/>
        <link:footnote id="TextSelection-8540AADB45BE54D38C10451BF6A88AB4-0-wk-Footnote-8540AADB45BE54D38C10451BF6A88AB4_lbl" xlink:label="TextSelection-8540AADB45BE54D38C10451BF6A88AB4-0-wk-Footnote-8540AADB45BE54D38C10451BF6A88AB4_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Certain significant items are substantive and/or unusual, and in some cases recurring, items (such as restructuring or legal charges) that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis.<xhtml:div style="line-height:120%;padding-bottom:1px;padding-top:1px;padding-left:12px;font-size:8pt;"><xhtml:span style="font-family:inherit;font-size:8pt;">For Earnings in the </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">third quarter</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> of </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;text-align:center;">2017</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">, certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"><xhtml:span>$90 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">, (ii) charges for certain legal matters of </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"><xhtml:span>$183 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">, (iii) income of </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"><xhtml:span>$12 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">, representing an adjustment to amounts previously recorded to write down the HIS net assets to fair value less costs to sell, (iv) certain asset impairment charges of </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"><xhtml:span>$127 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">, (v) charges for business and legal entity alignment of </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"><xhtml:span>$16 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> and (vi) other charges of </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"><xhtml:span>$45 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">. For additional information, see </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;font-style:italic;">Note 2B, Note 3</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> and </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;font-style:italic;">Note 4.</xhtml:span></xhtml:div><xhtml:div style="line-height:120%;padding-bottom:1px;text-align:left;padding-left:12px;font-size:8pt;"><xhtml:span style="font-family:inherit;font-size:8pt;">For Earnings in the </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">third quarter</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> of </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;text-align:center;">2016</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">, certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"><xhtml:span>$375 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">, (ii) income for certain legal matters of </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"><xhtml:span>$40 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">, (iii) an impairment charge related to the write-down of the HIS net assets to fair value less estimated costs to sell of </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"><xhtml:span>$1.4 billion</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">, (iv) certain asset impairment charges of </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"><xhtml:span>$126 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">, (v) charges for business and legal entity alignment of </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"><xhtml:span>$69 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> and (vi) other charges of </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"><xhtml:span>$17 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">. For additional information, see </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;font-style:italic;">Note 3 </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">and</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;font-style:italic;"> Note 4</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">.</xhtml:span></xhtml:div><xhtml:div style="line-height:120%;padding-bottom:1px;text-align:left;padding-left:12px;font-size:8pt;"><xhtml:span style="font-family:inherit;font-size:8pt;">For Earnings in the </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">first nine months of</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;text-align:center;">2017</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">, certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"><xhtml:span>$253 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">, (ii) charges for certain legal matters of </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"><xhtml:span>$191 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">, (iii) incremental charges to amounts previously recorded to write down the HIS net assets to fair value less costs to sell of </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"><xhtml:span>$52 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">, (iv) certain asset impairment charges of </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"><xhtml:span>$127 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">, (v) charges for business and legal entity alignment of </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"><xhtml:span>$54 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> and (vi) other charges of </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"><xhtml:span>$119 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">. For additional information, see </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;font-style:italic;">Note 2B</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">, </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;font-style:italic;">Note 3</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> and </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;font-style:italic;">Note 4</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">.</xhtml:span></xhtml:div><xhtml:span style="font-family:inherit;font-size:8pt;">For Earnings in the </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">first nine months of</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;text-align:center;">2016</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">, certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"><xhtml:span>$743 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">, (ii) charges for certain legal matters of </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"><xhtml:span>$506 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">, (iii) an impairment charge related to the write-down of the HIS net assets to fair value less estimated costs to sell of </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"><xhtml:span>$1.4 billion</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">, (iv) certain asset impairment charges of </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"><xhtml:span>$1.1 billion</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">, (v) charges for business and legal entity alignment of </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"><xhtml:span>$180 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> and (vi) other charges of </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"><xhtml:span>$189 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">. For additional information, see </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;font-style:italic;">Note 3</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> and </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;font-style:italic;">Note 4</xhtml:span>.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e2128-wk-Fact-241DA9C0A5035519B185693E59F3571D"
          xlink:to="TextSelection-8540AADB45BE54D38C10451BF6A88AB4-0-wk-Footnote-8540AADB45BE54D38C10451BF6A88AB4_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43771853e2041-wk-Fact-2439FB836F6B538B8D7D394CD6614D2E"
          xlink:label="d43771853e2041-wk-Fact-2439FB836F6B538B8D7D394CD6614D2E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e2041-wk-Fact-2439FB836F6B538B8D7D394CD6614D2E"
          xlink:to="TextSelection-13C3E50268A15908A8AC9D1B6C938D2D-0-wk-Footnote-13C3E50268A15908A8AC9D1B6C938D2D_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e2041-wk-Fact-2439FB836F6B538B8D7D394CD6614D2E"
          xlink:to="TextSelection-78FC5AB8EFAB585E87BBCF93BE9FBF1D-0-wk-Footnote-78FC5AB8EFAB585E87BBCF93BE9FBF1D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e11095-wk-Fact-246EBF73EC0858A18FCF596C5A717E80"
          xlink:label="d43770747e11095-wk-Fact-246EBF73EC0858A18FCF596C5A717E80"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e11095-wk-Fact-246EBF73EC0858A18FCF596C5A717E80"
          xlink:to="TextSelection-39CF024D03225486829869F6CA02C00E-0-wk-Footnote-39CF024D03225486829869F6CA02C00E_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e11095-wk-Fact-246EBF73EC0858A18FCF596C5A717E80"
          xlink:to="TextSelection-53BB8CAFCA475C0C9DB2195050D36025-0-wk-Footnote-53BB8CAFCA475C0C9DB2195050D36025_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e11095-wk-Fact-246EBF73EC0858A18FCF596C5A717E80"
          xlink:to="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e8171-wk-Fact-24B21791DB6C58DCB111630D09C1ACBF"
          xlink:label="d43770747e8171-wk-Fact-24B21791DB6C58DCB111630D09C1ACBF"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e8171-wk-Fact-24B21791DB6C58DCB111630D09C1ACBF"
          xlink:to="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e8171-wk-Fact-24B21791DB6C58DCB111630D09C1ACBF"
          xlink:to="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e1089-wk-Fact-24CD21A3984953BA839ABDB818130188"
          xlink:label="d43770747e1089-wk-Fact-24CD21A3984953BA839ABDB818130188"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e1089-wk-Fact-24CD21A3984953BA839ABDB818130188"
          xlink:to="TextSelection-8D2A93033C2E56DE9E814F0AB36328EE-0-wk-Footnote-8D2A93033C2E56DE9E814F0AB36328EE_lbl"
          xlink:type="arc"/>
        <link:footnote id="TextSelection-91730671722A5F83BA05EF347193E4CF-0-wk-Footnote-91730671722A5F83BA05EF347193E4CF_lbl" xlink:label="TextSelection-91730671722A5F83BA05EF347193E4CF-0-wk-Footnote-91730671722A5F83BA05EF347193E4CF_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">&#160;<xhtml:span style="font-family:inherit;font-size:8.5pt;">Designated as hedging instruments, except for certain contracts used as offsets; namely, foreign currency forward-exchange contracts with fair values of </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"><xhtml:span>$40 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"> as of </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;">October&#160;1, 2017</xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;">; and foreign currency forward-exchange contracts with fair values of </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"><xhtml:span>$162 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"> as of </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;text-align:center;">December&#160;31, 2016</xhtml:span>.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e1089-wk-Fact-24CD21A3984953BA839ABDB818130188"
          xlink:to="TextSelection-91730671722A5F83BA05EF347193E4CF-0-wk-Footnote-91730671722A5F83BA05EF347193E4CF_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687849e2777-wk-Fact-24F5F5FD900B538BB0C1F5C1D6714D02"
          xlink:label="d43687849e2777-wk-Fact-24F5F5FD900B538BB0C1F5C1D6714D02"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d43691920e2645-wk-Fact-24F5F5FD900B538BB0C1F5C1D6714D02"
          xlink:label="d43691920e2645-wk-Fact-24F5F5FD900B538BB0C1F5C1D6714D02"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e2777-wk-Fact-24F5F5FD900B538BB0C1F5C1D6714D02"
          xlink:to="TextSelection-2A0DF68DD6E953419D1E9B1C848DB228-0-wk-Footnote-2A0DF68DD6E953419D1E9B1C848DB228_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43691920e2645-wk-Fact-24F5F5FD900B538BB0C1F5C1D6714D02"
          xlink:to="TextSelection-2A0DF68DD6E953419D1E9B1C848DB228-0-wk-Footnote-2A0DF68DD6E953419D1E9B1C848DB228_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e2777-wk-Fact-24F5F5FD900B538BB0C1F5C1D6714D02"
          xlink:to="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43691920e2645-wk-Fact-24F5F5FD900B538BB0C1F5C1D6714D02"
          xlink:to="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43697224e1778-wk-Fact-264D8D2580555027A2EF57DE7B0E9E4A"
          xlink:label="d43697224e1778-wk-Fact-264D8D2580555027A2EF57DE7B0E9E4A"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-ECF6A95A77365D79B2E9D472B81966D9-0-wk-Footnote-ECF6A95A77365D79B2E9D472B81966D9_lbl" xlink:label="TextSelection-ECF6A95A77365D79B2E9D472B81966D9-0-wk-Footnote-ECF6A95A77365D79B2E9D472B81966D9_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">In the <xhtml:span style="font-family:inherit;font-size:8.5pt;">third quarter</xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"> and </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;">first nine months of</xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"> </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;text-align:center;">2017</xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;">, includes, among other things, dividend income of </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"><xhtml:span>$54 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"> and </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"><xhtml:span>$211 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;">, respectively, from our investment in ViiV, and income of </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"><xhtml:span>$62 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"> from resolution of a contract disagreement. In the </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;">first nine months of</xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"> </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;text-align:center;">2016</xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;">, includes, among other things, </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"><xhtml:span>$150 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"> paid to Allergan for reimbursement of Allergan&#x2019;s expenses associated with the terminated transaction and income of </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"><xhtml:span>$116 million</xhtml:span></xhtml:span> from resolution of a contract disagreement.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43697224e1778-wk-Fact-264D8D2580555027A2EF57DE7B0E9E4A"
          xlink:to="TextSelection-ECF6A95A77365D79B2E9D472B81966D9-0-wk-Footnote-ECF6A95A77365D79B2E9D472B81966D9_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43674379e2361-wk-Fact-279845FB1E2F5BE68F8072CC3AE0313B"
          xlink:label="d43674379e2361-wk-Fact-279845FB1E2F5BE68F8072CC3AE0313B"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43674379e2361-wk-Fact-279845FB1E2F5BE68F8072CC3AE0313B"
          xlink:to="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e9728-wk-Fact-283251A1FA2159899190EA9CCFA53A25"
          xlink:label="d43770747e9728-wk-Fact-283251A1FA2159899190EA9CCFA53A25"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e9728-wk-Fact-283251A1FA2159899190EA9CCFA53A25"
          xlink:to="TextSelection-39CF024D03225486829869F6CA02C00E-0-wk-Footnote-39CF024D03225486829869F6CA02C00E_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e9728-wk-Fact-283251A1FA2159899190EA9CCFA53A25"
          xlink:to="TextSelection-53BB8CAFCA475C0C9DB2195050D36025-0-wk-Footnote-53BB8CAFCA475C0C9DB2195050D36025_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e9728-wk-Fact-283251A1FA2159899190EA9CCFA53A25"
          xlink:to="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43681613e2896-wk-Fact-2876808E5D6E5BCEA80558572E768C26"
          xlink:label="d43681613e2896-wk-Fact-2876808E5D6E5BCEA80558572E768C26"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43681613e2896-wk-Fact-2876808E5D6E5BCEA80558572E768C26"
          xlink:to="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687704e1993-wk-Fact-288376604CC25FCA9066DC7223130DD2"
          xlink:label="d43687704e1993-wk-Fact-288376604CC25FCA9066DC7223130DD2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e1993-wk-Fact-288376604CC25FCA9066DC7223130DD2"
          xlink:to="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e8858-wk-Fact-288B765C343F5E4F98C92B3CC3D540BD"
          xlink:label="d43770747e8858-wk-Fact-288B765C343F5E4F98C92B3CC3D540BD"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e8858-wk-Fact-288B765C343F5E4F98C92B3CC3D540BD"
          xlink:to="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e8858-wk-Fact-288B765C343F5E4F98C92B3CC3D540BD"
          xlink:to="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687704e1010-wk-Fact-28E7163DD278532183F033BDA283F0A1"
          xlink:label="d43687704e1010-wk-Fact-28E7163DD278532183F033BDA283F0A1"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e1010-wk-Fact-28E7163DD278532183F033BDA283F0A1"
          xlink:to="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e1010-wk-Fact-28E7163DD278532183F033BDA283F0A1"
          xlink:to="TextSelection-AE19F19C6AE65BBDA7F551089E2E7EDF-0-wk-Footnote-AE19F19C6AE65BBDA7F551089E2E7EDF_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687704e1321-wk-Fact-2955D213201255B6B4C71E112F5F3621"
          xlink:label="d43687704e1321-wk-Fact-2955D213201255B6B4C71E112F5F3621"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e1321-wk-Fact-2955D213201255B6B4C71E112F5F3621"
          xlink:to="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e4038-wk-Fact-29ACCDED11BA511481ECE7E30ABD1FFA"
          xlink:label="d43770747e4038-wk-Fact-29ACCDED11BA511481ECE7E30ABD1FFA"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e4038-wk-Fact-29ACCDED11BA511481ECE7E30ABD1FFA"
          xlink:to="TextSelection-7EC55EFE69505245B1A079B8132EFBB7-0-wk-Footnote-7EC55EFE69505245B1A079B8132EFBB7_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43712510e6050-wk-Fact-29DAA58640B95FAD926B443F7C99CB05"
          xlink:label="d43712510e6050-wk-Fact-29DAA58640B95FAD926B443F7C99CB05"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-6550A25092D55979B6A1D62BD4EDF090-0-wk-Footnote-6550A25092D55979B6A1D62BD4EDF090_lbl" xlink:label="TextSelection-6550A25092D55979B6A1D62BD4EDF090-0-wk-Footnote-6550A25092D55979B6A1D62BD4EDF090_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Contributions expected to be made for <xhtml:span style="font-family:inherit;font-size:8.5pt;text-align:center;">2017</xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"> are inclusive of amounts contributed during the </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;">nine months ended October 1, 2017</xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;">, including the </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"><xhtml:span>$1.0 billion</xhtml:span></xhtml:span> voluntary contribution that was made in January 2017 for the U.S. qualified plans, which was considered pre-funding for future anticipated mandatory contributions and is also expected to reduce Pension Benefit Guaranty Corporation variable rate premiums. The U.S. supplemental (non-qualified) pension plan, international pension plan and the postretirement plan contributions from our general assets include direct employer benefit payments.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43712510e6050-wk-Fact-29DAA58640B95FAD926B443F7C99CB05"
          xlink:to="TextSelection-6550A25092D55979B6A1D62BD4EDF090-0-wk-Footnote-6550A25092D55979B6A1D62BD4EDF090_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e7374-wk-Fact-2A83FB655E5C5030BB0751EC39ED3AD7"
          xlink:label="d43770747e7374-wk-Fact-2A83FB655E5C5030BB0751EC39ED3AD7"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e7374-wk-Fact-2A83FB655E5C5030BB0751EC39ED3AD7"
          xlink:to="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e7374-wk-Fact-2A83FB655E5C5030BB0751EC39ED3AD7"
          xlink:to="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e1064-wk-Fact-2A8F43C5F6985C19B50BEDA00C1E0EDB"
          xlink:label="d43770747e1064-wk-Fact-2A8F43C5F6985C19B50BEDA00C1E0EDB"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e1064-wk-Fact-2A8F43C5F6985C19B50BEDA00C1E0EDB"
          xlink:to="TextSelection-8D2A93033C2E56DE9E814F0AB36328EE-0-wk-Footnote-8D2A93033C2E56DE9E814F0AB36328EE_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e1064-wk-Fact-2A8F43C5F6985C19B50BEDA00C1E0EDB"
          xlink:to="TextSelection-91730671722A5F83BA05EF347193E4CF-0-wk-Footnote-91730671722A5F83BA05EF347193E4CF_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43690878e1234-wk-Fact-2AF1807BCF8A5ADC8187B51D6E464FFD"
          xlink:label="d43690878e1234-wk-Fact-2AF1807BCF8A5ADC8187B51D6E464FFD"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43690878e1234-wk-Fact-2AF1807BCF8A5ADC8187B51D6E464FFD"
          xlink:to="TextSelection-792D3AB23D6354CFBB2776AE7F6407B4-0-wk-Footnote-792D3AB23D6354CFBB2776AE7F6407B4_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687849e1949-wk-Fact-2B43072B673F54B48A3077572AC7B122"
          xlink:label="d43687849e1949-wk-Fact-2B43072B673F54B48A3077572AC7B122"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e1949-wk-Fact-2B43072B673F54B48A3077572AC7B122"
          xlink:to="TextSelection-77536863BCE35B419E3A4119D41DB4BD-0-wk-Footnote-77536863BCE35B419E3A4119D41DB4BD_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e1949-wk-Fact-2B43072B673F54B48A3077572AC7B122"
          xlink:to="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e10887-wk-Fact-2B6D0F44C93359ADA6DC515DA57F73D4"
          xlink:label="d43770747e10887-wk-Fact-2B6D0F44C93359ADA6DC515DA57F73D4"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e10887-wk-Fact-2B6D0F44C93359ADA6DC515DA57F73D4"
          xlink:to="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e10887-wk-Fact-2B6D0F44C93359ADA6DC515DA57F73D4"
          xlink:to="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687704e2706-wk-Fact-2BD65B1FAD49532F94B23261F5066D15"
          xlink:label="d43687704e2706-wk-Fact-2BD65B1FAD49532F94B23261F5066D15"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d43712471e5775-wk-Fact-2BD65B1FAD49532F94B23261F5066D15"
          xlink:label="d43712471e5775-wk-Fact-2BD65B1FAD49532F94B23261F5066D15"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43712471e5775-wk-Fact-2BD65B1FAD49532F94B23261F5066D15"
          xlink:to="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e2706-wk-Fact-2BD65B1FAD49532F94B23261F5066D15"
          xlink:to="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43712471e5775-wk-Fact-2BD65B1FAD49532F94B23261F5066D15"
          xlink:to="TextSelection-9231AC55B8EC5775BC4995B0797F870F-0-wk-Footnote-9231AC55B8EC5775BC4995B0797F870F_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e2706-wk-Fact-2BD65B1FAD49532F94B23261F5066D15"
          xlink:to="TextSelection-9231AC55B8EC5775BC4995B0797F870F-0-wk-Footnote-9231AC55B8EC5775BC4995B0797F870F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43681613e2216-wk-Fact-2BEDC5A7D4A059F58F71D107B4C1CAFF"
          xlink:label="d43681613e2216-wk-Fact-2BEDC5A7D4A059F58F71D107B4C1CAFF"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43681613e2216-wk-Fact-2BEDC5A7D4A059F58F71D107B4C1CAFF"
          xlink:to="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43771853e1525-wk-Fact-2C08174C90215980AF8C21393CA8C5DE"
          xlink:label="d43771853e1525-wk-Fact-2C08174C90215980AF8C21393CA8C5DE"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e1525-wk-Fact-2C08174C90215980AF8C21393CA8C5DE"
          xlink:to="TextSelection-78FC5AB8EFAB585E87BBCF93BE9FBF1D-0-wk-Footnote-78FC5AB8EFAB585E87BBCF93BE9FBF1D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43771853e8213-wk-Fact-2C55373A40E0521188DF042ECD16B096"
          xlink:label="d43771853e8213-wk-Fact-2C55373A40E0521188DF042ECD16B096"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e8213-wk-Fact-2C55373A40E0521188DF042ECD16B096"
          xlink:to="TextSelection-B88EBF1DF3CD5B06AADA1AA5E249F160-0-wk-Footnote-B88EBF1DF3CD5B06AADA1AA5E249F160_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43674379e925-wk-Fact-2C8D97E870025A9E9218D1538714EA7C"
          xlink:label="d43674379e925-wk-Fact-2C8D97E870025A9E9218D1538714EA7C"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d43678813e910-wk-Fact-2C8D97E870025A9E9218D1538714EA7C"
          xlink:label="d43678813e910-wk-Fact-2C8D97E870025A9E9218D1538714EA7C"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-431A3875E30657529B6519DFB33F40EB-0-wk-Footnote-431A3875E30657529B6519DFB33F40EB_lbl" xlink:label="TextSelection-431A3875E30657529B6519DFB33F40EB-0-wk-Footnote-431A3875E30657529B6519DFB33F40EB_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The change from <xhtml:span style="font-family:inherit;font-size:9pt;text-align:center;">December&#160;31, 2016</xhtml:span> reflects the build of inventory primarily for and in advance of new or potential product launches and increases to meet targeted levels for certain products in the normal course of business, including those related to demand.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43674379e925-wk-Fact-2C8D97E870025A9E9218D1538714EA7C"
          xlink:to="TextSelection-431A3875E30657529B6519DFB33F40EB-0-wk-Footnote-431A3875E30657529B6519DFB33F40EB_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43678813e910-wk-Fact-2C8D97E870025A9E9218D1538714EA7C"
          xlink:to="TextSelection-431A3875E30657529B6519DFB33F40EB-0-wk-Footnote-431A3875E30657529B6519DFB33F40EB_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43674379e925-wk-Fact-2C8D97E870025A9E9218D1538714EA7C"
          xlink:to="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43678813e910-wk-Fact-2C8D97E870025A9E9218D1538714EA7C"
          xlink:to="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e4965-wk-Fact-2C95CA02AB4558B9A40486FF0E1ECD3D"
          xlink:label="d43770747e4965-wk-Fact-2C95CA02AB4558B9A40486FF0E1ECD3D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e4965-wk-Fact-2C95CA02AB4558B9A40486FF0E1ECD3D"
          xlink:to="TextSelection-2BFD6C99096B50AD93705C5601B21F46-0-wk-Footnote-2BFD6C99096B50AD93705C5601B21F46_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687849e1409-wk-Fact-2CCCE52F43F055888FBA5D0EB59CC576"
          xlink:label="d43687849e1409-wk-Fact-2CCCE52F43F055888FBA5D0EB59CC576"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e1409-wk-Fact-2CCCE52F43F055888FBA5D0EB59CC576"
          xlink:to="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e1409-wk-Fact-2CCCE52F43F055888FBA5D0EB59CC576"
          xlink:to="TextSelection-F185CD45BC245C2EB8EDBFD55DB8A33F-0-wk-Footnote-F185CD45BC245C2EB8EDBFD55DB8A33F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43690878e2120-wk-Fact-2D022CD3C3AD5211BB51112CC40FC473"
          xlink:label="d43690878e2120-wk-Fact-2D022CD3C3AD5211BB51112CC40FC473"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43690878e2120-wk-Fact-2D022CD3C3AD5211BB51112CC40FC473"
          xlink:to="TextSelection-792D3AB23D6354CFBB2776AE7F6407B4-0-wk-Footnote-792D3AB23D6354CFBB2776AE7F6407B4_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687704e1618-wk-Fact-2D8CDE5E04555F14B8B630B25163E15F"
          xlink:label="d43687704e1618-wk-Fact-2D8CDE5E04555F14B8B630B25163E15F"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e1618-wk-Fact-2D8CDE5E04555F14B8B630B25163E15F"
          xlink:to="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e1618-wk-Fact-2D8CDE5E04555F14B8B630B25163E15F"
          xlink:to="TextSelection-9231AC55B8EC5775BC4995B0797F870F-0-wk-Footnote-9231AC55B8EC5775BC4995B0797F870F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43674379e2674-wk-Fact-2D9C52897DAC5AD0A4FC1108BB490212"
          xlink:label="d43674379e2674-wk-Fact-2D9C52897DAC5AD0A4FC1108BB490212"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43674379e2674-wk-Fact-2D9C52897DAC5AD0A4FC1108BB490212"
          xlink:to="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43771853e4803-wk-Fact-2DA3332AAA9A5E4A8EDAC00B3DB27FF9"
          xlink:label="d43771853e4803-wk-Fact-2DA3332AAA9A5E4A8EDAC00B3DB27FF9"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-DC6DDCB74FC9523D97BA51FBA6B1C05E-0-wk-Footnote-DC6DDCB74FC9523D97BA51FBA6B1C05E_lbl" xlink:label="TextSelection-DC6DDCB74FC9523D97BA51FBA6B1C05E-0-wk-Footnote-DC6DDCB74FC9523D97BA51FBA6B1C05E_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-family:inherit;font-size:8pt;">Emerging Markets region includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Africa, Eastern Europe, Central Europe, the Middle East and Turkey.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e4803-wk-Fact-2DA3332AAA9A5E4A8EDAC00B3DB27FF9"
          xlink:to="TextSelection-DC6DDCB74FC9523D97BA51FBA6B1C05E-0-wk-Footnote-DC6DDCB74FC9523D97BA51FBA6B1C05E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43712496e2528-wk-Fact-2E0D7E0341AF521EB10E77F7AB951A30"
          xlink:label="d43712496e2528-wk-Fact-2E0D7E0341AF521EB10E77F7AB951A30"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43712496e2528-wk-Fact-2E0D7E0341AF521EB10E77F7AB951A30"
          xlink:to="TextSelection-C37CD88178CA35C475D25A62F2B54FED-0-wk-Footnote-C37CD88178CA35C475D25A62F2B54FED_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43771853e10404-wk-Fact-2E5C7379161F5F76A0E97E4215BB339F"
          xlink:label="d43771853e10404-wk-Fact-2E5C7379161F5F76A0E97E4215BB339F"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e10404-wk-Fact-2E5C7379161F5F76A0E97E4215BB339F"
          xlink:to="TextSelection-450A7304FB7E513FB479F6D9A06EF1D3-0-wk-Footnote-450A7304FB7E513FB479F6D9A06EF1D3_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43771853e3302-wk-Fact-2E6085148E385843A6F6681DB2EA3E75"
          xlink:label="d43771853e3302-wk-Fact-2E6085148E385843A6F6681DB2EA3E75"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e3302-wk-Fact-2E6085148E385843A6F6681DB2EA3E75"
          xlink:to="TextSelection-13C3E50268A15908A8AC9D1B6C938D2D-0-wk-Footnote-13C3E50268A15908A8AC9D1B6C938D2D_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e3302-wk-Fact-2E6085148E385843A6F6681DB2EA3E75"
          xlink:to="TextSelection-78FC5AB8EFAB585E87BBCF93BE9FBF1D-0-wk-Footnote-78FC5AB8EFAB585E87BBCF93BE9FBF1D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43697224e1391-wk-Fact-2E6E4BDF4E235E37AD8DFBB014690780"
          xlink:label="d43697224e1391-wk-Fact-2E6E4BDF4E235E37AD8DFBB014690780"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43697224e1391-wk-Fact-2E6E4BDF4E235E37AD8DFBB014690780"
          xlink:to="TextSelection-6E67095C033B51BB9FABBA85E8DC4DFA-0-wk-Footnote-6E67095C033B51BB9FABBA85E8DC4DFA_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43771853e3389-wk-Fact-2E8BCB0198B9547BFA12E7848D133E48"
          xlink:label="d43771853e3389-wk-Fact-2E8BCB0198B9547BFA12E7848D133E48"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e3389-wk-Fact-2E8BCB0198B9547BFA12E7848D133E48"
          xlink:to="TextSelection-13C3E50268A15908A8AC9D1B6C938D2D-0-wk-Footnote-13C3E50268A15908A8AC9D1B6C938D2D_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e3389-wk-Fact-2E8BCB0198B9547BFA12E7848D133E48"
          xlink:to="TextSelection-78FC5AB8EFAB585E87BBCF93BE9FBF1D-0-wk-Footnote-78FC5AB8EFAB585E87BBCF93BE9FBF1D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687849e1605-wk-Fact-2EABA378D8055B138BD1C9439BF5DF77"
          xlink:label="d43687849e1605-wk-Fact-2EABA378D8055B138BD1C9439BF5DF77"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e1605-wk-Fact-2EABA378D8055B138BD1C9439BF5DF77"
          xlink:to="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e1605-wk-Fact-2EABA378D8055B138BD1C9439BF5DF77"
          xlink:to="TextSelection-F185CD45BC245C2EB8EDBFD55DB8A33F-0-wk-Footnote-F185CD45BC245C2EB8EDBFD55DB8A33F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e8692-wk-Fact-2EC8C97286795110842254B7AD03EA8C"
          xlink:label="d43770747e8692-wk-Fact-2EC8C97286795110842254B7AD03EA8C"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e8692-wk-Fact-2EC8C97286795110842254B7AD03EA8C"
          xlink:to="TextSelection-39CF024D03225486829869F6CA02C00E-0-wk-Footnote-39CF024D03225486829869F6CA02C00E_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e8692-wk-Fact-2EC8C97286795110842254B7AD03EA8C"
          xlink:to="TextSelection-53BB8CAFCA475C0C9DB2195050D36025-0-wk-Footnote-53BB8CAFCA475C0C9DB2195050D36025_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e8692-wk-Fact-2EC8C97286795110842254B7AD03EA8C"
          xlink:to="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e9667-wk-Fact-2F4C56B8E6C658B98917D6369850F69C"
          xlink:label="d43770747e9667-wk-Fact-2F4C56B8E6C658B98917D6369850F69C"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e9667-wk-Fact-2F4C56B8E6C658B98917D6369850F69C"
          xlink:to="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e9667-wk-Fact-2F4C56B8E6C658B98917D6369850F69C"
          xlink:to="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43681613e2288-wk-Fact-2F51CAACA19456CCB50C8D86205439BE"
          xlink:label="d43681613e2288-wk-Fact-2F51CAACA19456CCB50C8D86205439BE"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43681613e2288-wk-Fact-2F51CAACA19456CCB50C8D86205439BE"
          xlink:to="TextSelection-3DD94144621C5A68BC21C5DB64345BB9-0-wk-Footnote-3DD94144621C5A68BC21C5DB64345BB9_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43681613e2288-wk-Fact-2F51CAACA19456CCB50C8D86205439BE"
          xlink:to="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687704e2064-wk-Fact-2F837D3EBB765EBCB1249DE75E4FF1D1"
          xlink:label="d43687704e2064-wk-Fact-2F837D3EBB765EBCB1249DE75E4FF1D1"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e2064-wk-Fact-2F837D3EBB765EBCB1249DE75E4FF1D1"
          xlink:to="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e2064-wk-Fact-2F837D3EBB765EBCB1249DE75E4FF1D1"
          xlink:to="TextSelection-9231AC55B8EC5775BC4995B0797F870F-0-wk-Footnote-9231AC55B8EC5775BC4995B0797F870F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43712496e2509-wk-Fact-2F901B411CA0586B801E2011D88D1ACA"
          xlink:label="d43712496e2509-wk-Fact-2F901B411CA0586B801E2011D88D1ACA"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43712496e2509-wk-Fact-2F901B411CA0586B801E2011D88D1ACA"
          xlink:to="TextSelection-C37CD88178CA35C475D25A62F2B54FED-0-wk-Footnote-C37CD88178CA35C475D25A62F2B54FED_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43712496e2065-wk-Fact-300D4D3DDB1355E8938FDCD261A66E64"
          xlink:label="d43712496e2065-wk-Fact-300D4D3DDB1355E8938FDCD261A66E64"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43712496e2065-wk-Fact-300D4D3DDB1355E8938FDCD261A66E64"
          xlink:to="TextSelection-7160FF67E87550A19177FE255A41A2D7-0-wk-Footnote-7160FF67E87550A19177FE255A41A2D7_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43697240e1730-wk-Fact-305740AD59515768A45E4205357775C9"
          xlink:label="d43697240e1730-wk-Fact-305740AD59515768A45E4205357775C9"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d43697240e2354-wk-Fact-305740AD59515768A45E4205357775C9"
          xlink:label="d43697240e2354-wk-Fact-305740AD59515768A45E4205357775C9"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43697240e1730-wk-Fact-305740AD59515768A45E4205357775C9"
          xlink:to="TextSelection-FF348CC7844F523299A112551B170BE6-0-wk-Footnote-FF348CC7844F523299A112551B170BE6_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43697240e2354-wk-Fact-305740AD59515768A45E4205357775C9"
          xlink:to="TextSelection-FF348CC7844F523299A112551B170BE6-0-wk-Footnote-FF348CC7844F523299A112551B170BE6_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43712496e1621-wk-Fact-309464A163D5551F8E0560FD895331BC"
          xlink:label="d43712496e1621-wk-Fact-309464A163D5551F8E0560FD895331BC"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-C882D128F7C35640B8C0E15448983D9E-0-wk-Footnote-C882D128F7C35640B8C0E15448983D9E_lbl" xlink:label="TextSelection-C882D128F7C35640B8C0E15448983D9E-0-wk-Footnote-C882D128F7C35640B8C0E15448983D9E_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Integration costs represent external, incremental costs directly related to integrating acquired businesses, and primarily include expenditures for consulting and the integration of systems and processes. In the <xhtml:span style="font-family:inherit;font-size:9pt;">third</xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;"> quarter and </xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;">first nine months of</xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;"> </xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;text-align:center;">2017</xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;">, integration costs primarily relate to our acquisitions of Hospira and Medivation. The </xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;">first nine months of</xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;"> </xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;text-align:center;">2017</xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;"> also include a net gain of </xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;"><xhtml:span>$12 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;"> related to the settlement of the Hospira U.S. qualified defined benefit pension plan (see </xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;font-style:italic;">Note 10</xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;">). In the </xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;">third quarter</xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;"> of </xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;text-align:center;">2016</xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;">, integration </xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;">costs were mostly related to our acquisition of Hospira, and in the </xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;">first nine months of</xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;"> </xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;text-align:center;">2016</xhtml:span>, integration costs were mostly related to our acquisition of Hospira and our terminated transaction with Allergan.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43712496e1621-wk-Fact-309464A163D5551F8E0560FD895331BC"
          xlink:to="TextSelection-C882D128F7C35640B8C0E15448983D9E-0-wk-Footnote-C882D128F7C35640B8C0E15448983D9E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43674379e1607-wk-Fact-30C18A2BCA9E5DB3B71D6CCCF9EC18D9"
          xlink:label="d43674379e1607-wk-Fact-30C18A2BCA9E5DB3B71D6CCCF9EC18D9"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43674379e1607-wk-Fact-30C18A2BCA9E5DB3B71D6CCCF9EC18D9"
          xlink:to="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e4195-wk-Fact-30E328BC808A5B65A7A777945EE0CE96"
          xlink:label="d43770747e4195-wk-Fact-30E328BC808A5B65A7A777945EE0CE96"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e4195-wk-Fact-30E328BC808A5B65A7A777945EE0CE96"
          xlink:to="TextSelection-2BFD6C99096B50AD93705C5601B21F46-0-wk-Footnote-2BFD6C99096B50AD93705C5601B21F46_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687849e2737-wk-Fact-31B8668E1E1956DF8878873FF4C52DA7"
          xlink:label="d43687849e2737-wk-Fact-31B8668E1E1956DF8878873FF4C52DA7"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d43691920e2605-wk-Fact-31B8668E1E1956DF8878873FF4C52DA7"
          xlink:label="d43691920e2605-wk-Fact-31B8668E1E1956DF8878873FF4C52DA7"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43691920e2605-wk-Fact-31B8668E1E1956DF8878873FF4C52DA7"
          xlink:to="TextSelection-2A0DF68DD6E953419D1E9B1C848DB228-0-wk-Footnote-2A0DF68DD6E953419D1E9B1C848DB228_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e2737-wk-Fact-31B8668E1E1956DF8878873FF4C52DA7"
          xlink:to="TextSelection-2A0DF68DD6E953419D1E9B1C848DB228-0-wk-Footnote-2A0DF68DD6E953419D1E9B1C848DB228_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43691920e2605-wk-Fact-31B8668E1E1956DF8878873FF4C52DA7"
          xlink:to="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e2737-wk-Fact-31B8668E1E1956DF8878873FF4C52DA7"
          xlink:to="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687849e2117-wk-Fact-322107AB58155A3EA1AD6413AB9D9A99"
          xlink:label="d43687849e2117-wk-Fact-322107AB58155A3EA1AD6413AB9D9A99"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e2117-wk-Fact-322107AB58155A3EA1AD6413AB9D9A99"
          xlink:to="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e8196-wk-Fact-324434DC15AC56F3976EFDF4A8E4050E"
          xlink:label="d43770747e8196-wk-Fact-324434DC15AC56F3976EFDF4A8E4050E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e8196-wk-Fact-324434DC15AC56F3976EFDF4A8E4050E"
          xlink:to="TextSelection-39CF024D03225486829869F6CA02C00E-0-wk-Footnote-39CF024D03225486829869F6CA02C00E_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e8196-wk-Fact-324434DC15AC56F3976EFDF4A8E4050E"
          xlink:to="TextSelection-53BB8CAFCA475C0C9DB2195050D36025-0-wk-Footnote-53BB8CAFCA475C0C9DB2195050D36025_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e8196-wk-Fact-324434DC15AC56F3976EFDF4A8E4050E"
          xlink:to="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43697240e3242-wk-Fact-32830C0722A659AF88B98C905235BC15"
          xlink:label="d43697240e3242-wk-Fact-32830C0722A659AF88B98C905235BC15"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43697240e3242-wk-Fact-32830C0722A659AF88B98C905235BC15"
          xlink:to="TextSelection-5368EA2EA2275823ADDE27DF2382EF3B-0-wk-Footnote-5368EA2EA2275823ADDE27DF2382EF3B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687849e3074-wk-Fact-32954ABF73B65A8C9307A33BA47D9ABB"
          xlink:label="d43687849e3074-wk-Fact-32954ABF73B65A8C9307A33BA47D9ABB"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e3074-wk-Fact-32954ABF73B65A8C9307A33BA47D9ABB"
          xlink:to="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43681613e1745-wk-Fact-33114474B11F56B7AE997B42206DB57C"
          xlink:label="d43681613e1745-wk-Fact-33114474B11F56B7AE997B42206DB57C"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43681613e1745-wk-Fact-33114474B11F56B7AE997B42206DB57C"
          xlink:to="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687849e1178-wk-Fact-33A901EBBAEB5B7B8CD51B4273CBCE61"
          xlink:label="d43687849e1178-wk-Fact-33A901EBBAEB5B7B8CD51B4273CBCE61"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e1178-wk-Fact-33A901EBBAEB5B7B8CD51B4273CBCE61"
          xlink:to="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43712496e1470-wk-Fact-33C51462AA72510092370BCC6B190DCD"
          xlink:label="d43712496e1470-wk-Fact-33C51462AA72510092370BCC6B190DCD"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43712496e1470-wk-Fact-33C51462AA72510092370BCC6B190DCD"
          xlink:to="TextSelection-B57619F44FCF544D96067CF4816A9082-0-wk-Footnote-B57619F44FCF544D96067CF4816A9082_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43771853e11040-wk-Fact-3478C9FA86F457899DC079177D757215"
          xlink:label="d43771853e11040-wk-Fact-3478C9FA86F457899DC079177D757215"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e11040-wk-Fact-3478C9FA86F457899DC079177D757215"
          xlink:to="TextSelection-7266C8E6B8975A65A379AF3B415EA220-0-wk-Footnote-7266C8E6B8975A65A379AF3B415EA220_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687849e1133-wk-Fact-34A31155E9EC5355982021CA6EBEFB38"
          xlink:label="d43687849e1133-wk-Fact-34A31155E9EC5355982021CA6EBEFB38"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e1133-wk-Fact-34A31155E9EC5355982021CA6EBEFB38"
          xlink:to="TextSelection-36C36413532355188985D26E3B171357-0-wk-Footnote-36C36413532355188985D26E3B171357_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e1133-wk-Fact-34A31155E9EC5355982021CA6EBEFB38"
          xlink:to="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43697224e964-wk-Fact-34F816D444055102A29F3BD0BBE0EC9E"
          xlink:label="d43697224e964-wk-Fact-34F816D444055102A29F3BD0BBE0EC9E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43697224e964-wk-Fact-34F816D444055102A29F3BD0BBE0EC9E"
          xlink:to="TextSelection-FE5DD06AA8B65777900C47B8AC19C4C6-0-wk-Footnote-FE5DD06AA8B65777900C47B8AC19C4C6_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e10991-wk-Fact-3509C7CDE8445B7B95D3CD4AB8311EBD"
          xlink:label="d43770747e10991-wk-Fact-3509C7CDE8445B7B95D3CD4AB8311EBD"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e10991-wk-Fact-3509C7CDE8445B7B95D3CD4AB8311EBD"
          xlink:to="TextSelection-39CF024D03225486829869F6CA02C00E-0-wk-Footnote-39CF024D03225486829869F6CA02C00E_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e10991-wk-Fact-3509C7CDE8445B7B95D3CD4AB8311EBD"
          xlink:to="TextSelection-53BB8CAFCA475C0C9DB2195050D36025-0-wk-Footnote-53BB8CAFCA475C0C9DB2195050D36025_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e10991-wk-Fact-3509C7CDE8445B7B95D3CD4AB8311EBD"
          xlink:to="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687849e2071-wk-Fact-3584E6A95DE851E29AE8ED49EB250F3F"
          xlink:label="d43687849e2071-wk-Fact-3584E6A95DE851E29AE8ED49EB250F3F"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e2071-wk-Fact-3584E6A95DE851E29AE8ED49EB250F3F"
          xlink:to="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e10553-wk-Fact-367407A06D845402883E3D448F892BA4"
          xlink:label="d43770747e10553-wk-Fact-367407A06D845402883E3D448F892BA4"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e10553-wk-Fact-367407A06D845402883E3D448F892BA4"
          xlink:to="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e10553-wk-Fact-367407A06D845402883E3D448F892BA4"
          xlink:to="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e2871-wk-Fact-36F90A1B2B3150DD8B3EF42CE7A207C4"
          xlink:label="d43770747e2871-wk-Fact-36F90A1B2B3150DD8B3EF42CE7A207C4"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-A9B5859E968353E1AF0EF5AF16D3F7DE-0-wk-Footnote-A9B5859E968353E1AF0EF5AF16D3F7DE_lbl" xlink:label="TextSelection-A9B5859E968353E1AF0EF5AF16D3F7DE-0-wk-Footnote-A9B5859E968353E1AF0EF5AF16D3F7DE_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">As of <xhtml:span style="font-family:inherit;font-size:9pt;">October&#160;1, 2017</xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;">, derivative instruments at fair value include interest rate swaps (</xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;"><xhtml:span>$97 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;">), foreign currency swaps (</xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;"><xhtml:span>$86 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;">) and foreign currency forward-exchange contracts (</xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;"><xhtml:span>$105 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;">) and, as of </xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;text-align:center;">December&#160;31, 2016</xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;">, include interest rate swaps (</xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;"><xhtml:span>$26 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;">), foreign currency swaps (</xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;"><xhtml:span>$43 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;">) and foreign currency forward-exchange contracts (</xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;"><xhtml:span>$497 million</xhtml:span></xhtml:span>).</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e2871-wk-Fact-36F90A1B2B3150DD8B3EF42CE7A207C4"
          xlink:to="TextSelection-A9B5859E968353E1AF0EF5AF16D3F7DE-0-wk-Footnote-A9B5859E968353E1AF0EF5AF16D3F7DE_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43681613e1126-wk-Fact-378721671BB456518AD2AD4867C237B9"
          xlink:label="d43681613e1126-wk-Fact-378721671BB456518AD2AD4867C237B9"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43681613e1126-wk-Fact-378721671BB456518AD2AD4867C237B9"
          xlink:to="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43771853e4590-wk-Fact-379798FC1BCC5947B93DE423936B8B64"
          xlink:label="d43771853e4590-wk-Fact-379798FC1BCC5947B93DE423936B8B64"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-3802305E73EB52F28FAAF4EA5481D580-0-wk-Footnote-3802305E73EB52F28FAAF4EA5481D580_lbl" xlink:label="TextSelection-3802305E73EB52F28FAAF4EA5481D580-0-wk-Footnote-3802305E73EB52F28FAAF4EA5481D580_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-family:inherit;font-size:8pt;">Developed Europe region includes the following markets: Western Europe, Scandinavian countries and Finland.</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> Revenues denominated in euros were </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"><xhtml:span>$1.7 billion</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> in both the </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">third quarter</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> of </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;text-align:center;">2017</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> and </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;text-align:center;">2016</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">, and </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"><xhtml:span>$5.0 billion</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> and </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"><xhtml:span>$5.3 billion</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> in the </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">first nine months of</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;text-align:center;">2017</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> and </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;text-align:center;">2016</xhtml:span>, respectively.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e4590-wk-Fact-379798FC1BCC5947B93DE423936B8B64"
          xlink:to="TextSelection-3802305E73EB52F28FAAF4EA5481D580-0-wk-Footnote-3802305E73EB52F28FAAF4EA5481D580_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687849e3055-wk-Fact-3831F5857C7B5144886C985E77E751EE"
          xlink:label="d43687849e3055-wk-Fact-3831F5857C7B5144886C985E77E751EE"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e3055-wk-Fact-3831F5857C7B5144886C985E77E751EE"
          xlink:to="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43692105e1257-wk-Fact-38D6CEB8D8AD5DDC81AC2FCD8FAE9F8C"
          xlink:label="d43692105e1257-wk-Fact-38D6CEB8D8AD5DDC81AC2FCD8FAE9F8C"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-2A36E737FFF05E75B357CB41AFB5B6E2-0-wk-Footnote-2A36E737FFF05E75B357CB41AFB5B6E2_lbl" xlink:label="TextSelection-2A36E737FFF05E75B357CB41AFB5B6E2-0-wk-Footnote-2A36E737FFF05E75B357CB41AFB5B6E2_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Amounts do not include foreign currency translation adjustments attributable to noncontrolling interests of <xhtml:span style="font-family:inherit;font-size:9pt;"><xhtml:span>$16 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;"> income for the </xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;">first nine months of</xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;"> </xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;text-align:center;">2017</xhtml:span>.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43692105e1257-wk-Fact-38D6CEB8D8AD5DDC81AC2FCD8FAE9F8C"
          xlink:to="TextSelection-2A36E737FFF05E75B357CB41AFB5B6E2-0-wk-Footnote-2A36E737FFF05E75B357CB41AFB5B6E2_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43697224e1086-wk-Fact-38D872801B2E5B2ABE4AE2E3D2CD2C57"
          xlink:label="d43697224e1086-wk-Fact-38D872801B2E5B2ABE4AE2E3D2CD2C57"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43697224e1086-wk-Fact-38D872801B2E5B2ABE4AE2E3D2CD2C57"
          xlink:to="TextSelection-FE5DD06AA8B65777900C47B8AC19C4C6-0-wk-Footnote-FE5DD06AA8B65777900C47B8AC19C4C6_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43674379e2655-wk-Fact-394FE75EF25C5117BE8B89037EFA6718"
          xlink:label="d43674379e2655-wk-Fact-394FE75EF25C5117BE8B89037EFA6718"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43674379e2655-wk-Fact-394FE75EF25C5117BE8B89037EFA6718"
          xlink:to="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43697240e3204-wk-Fact-39F7ED9F3086578FAC1610BAD7C34831"
          xlink:label="d43697240e3204-wk-Fact-39F7ED9F3086578FAC1610BAD7C34831"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43697240e3204-wk-Fact-39F7ED9F3086578FAC1610BAD7C34831"
          xlink:to="TextSelection-5368EA2EA2275823ADDE27DF2382EF3B-0-wk-Footnote-5368EA2EA2275823ADDE27DF2382EF3B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43674379e1568-wk-Fact-3A3BB372357A5CD2BCD070742B0C6955"
          xlink:label="d43674379e1568-wk-Fact-3A3BB372357A5CD2BCD070742B0C6955"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d43770747e1962-wk-Fact-3A3BB372357A5CD2BCD070742B0C6955"
          xlink:label="d43770747e1962-wk-Fact-3A3BB372357A5CD2BCD070742B0C6955"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e1962-wk-Fact-3A3BB372357A5CD2BCD070742B0C6955"
          xlink:to="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43674379e1568-wk-Fact-3A3BB372357A5CD2BCD070742B0C6955"
          xlink:to="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e1962-wk-Fact-3A3BB372357A5CD2BCD070742B0C6955"
          xlink:to="TextSelection-E90A054BCC035ECEB6B6F2B7C947C3CE-0-wk-Footnote-E90A054BCC035ECEB6B6F2B7C947C3CE_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43674379e1568-wk-Fact-3A3BB372357A5CD2BCD070742B0C6955"
          xlink:to="TextSelection-E90A054BCC035ECEB6B6F2B7C947C3CE-0-wk-Footnote-E90A054BCC035ECEB6B6F2B7C947C3CE_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e8750-wk-Fact-3A60D355B3D65BBF94AB49C42ABD832B"
          xlink:label="d43770747e8750-wk-Fact-3A60D355B3D65BBF94AB49C42ABD832B"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e8750-wk-Fact-3A60D355B3D65BBF94AB49C42ABD832B"
          xlink:to="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e8750-wk-Fact-3A60D355B3D65BBF94AB49C42ABD832B"
          xlink:to="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e4345-wk-Fact-3A9320AC96A65345AF2925F4F49F63EE"
          xlink:label="d43770747e4345-wk-Fact-3A9320AC96A65345AF2925F4F49F63EE"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e4345-wk-Fact-3A9320AC96A65345AF2925F4F49F63EE"
          xlink:to="TextSelection-2BFD6C99096B50AD93705C5601B21F46-0-wk-Footnote-2BFD6C99096B50AD93705C5601B21F46_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687849e3016-wk-Fact-3AB6460969F05E5CB5282AE2FB7FB81F"
          xlink:label="d43687849e3016-wk-Fact-3AB6460969F05E5CB5282AE2FB7FB81F"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e3016-wk-Fact-3AB6460969F05E5CB5282AE2FB7FB81F"
          xlink:to="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e1564-wk-Fact-3ABBEBBC9C675BDDBFD1245A5C8DACAB"
          xlink:label="d43770747e1564-wk-Fact-3ABBEBBC9C675BDDBFD1245A5C8DACAB"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e1564-wk-Fact-3ABBEBBC9C675BDDBFD1245A5C8DACAB"
          xlink:to="TextSelection-58096FF6357955D6B6AA25D56767CB0A-0-wk-Footnote-58096FF6357955D6B6AA25D56767CB0A_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e1564-wk-Fact-3ABBEBBC9C675BDDBFD1245A5C8DACAB"
          xlink:to="TextSelection-8D2A93033C2E56DE9E814F0AB36328EE-0-wk-Footnote-8D2A93033C2E56DE9E814F0AB36328EE_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43712510e4997-wk-Fact-3AD287E437335513A247CED1511F52AE"
          xlink:label="d43712510e4997-wk-Fact-3AD287E437335513A247CED1511F52AE"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43712510e4997-wk-Fact-3AD287E437335513A247CED1511F52AE"
          xlink:to="TextSelection-621F9196966C550EA113DA57575C171E-0-wk-Footnote-621F9196966C550EA113DA57575C171E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43712496e1583-wk-Fact-3B1D1CAB9A6C50A0AFB2D0D10CB345EC"
          xlink:label="d43712496e1583-wk-Fact-3B1D1CAB9A6C50A0AFB2D0D10CB345EC"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43712496e1583-wk-Fact-3B1D1CAB9A6C50A0AFB2D0D10CB345EC"
          xlink:to="TextSelection-C882D128F7C35640B8C0E15448983D9E-0-wk-Footnote-C882D128F7C35640B8C0E15448983D9E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43771853e4760-wk-Fact-3C874C1F4C8853D68A9C0BEB283CEC51"
          xlink:label="d43771853e4760-wk-Fact-3C874C1F4C8853D68A9C0BEB283CEC51"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e4760-wk-Fact-3C874C1F4C8853D68A9C0BEB283CEC51"
          xlink:to="TextSelection-E9F14C2885BA59D8B6B4AD221FC38619-0-wk-Footnote-E9F14C2885BA59D8B6B4AD221FC38619_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687849e1236-wk-Fact-3C8E3740EBD853D5A2217E87A8E69C70"
          xlink:label="d43687849e1236-wk-Fact-3C8E3740EBD853D5A2217E87A8E69C70"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e1236-wk-Fact-3C8E3740EBD853D5A2217E87A8E69C70"
          xlink:to="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e10075-wk-Fact-3D22C73D416A54A79E8C5296818B091D"
          xlink:label="d43770747e10075-wk-Fact-3D22C73D416A54A79E8C5296818B091D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e10075-wk-Fact-3D22C73D416A54A79E8C5296818B091D"
          xlink:to="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e10075-wk-Fact-3D22C73D416A54A79E8C5296818B091D"
          xlink:to="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687849e1067-wk-Fact-3DD9D4B9BF27581180EA172B8CC2DC14"
          xlink:label="d43687849e1067-wk-Fact-3DD9D4B9BF27581180EA172B8CC2DC14"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e1067-wk-Fact-3DD9D4B9BF27581180EA172B8CC2DC14"
          xlink:to="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e10494-wk-Fact-3DDF166872145F4BAF10CA9D1ED6DA8F"
          xlink:label="d43770747e10494-wk-Fact-3DDF166872145F4BAF10CA9D1ED6DA8F"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e10494-wk-Fact-3DDF166872145F4BAF10CA9D1ED6DA8F"
          xlink:to="TextSelection-39CF024D03225486829869F6CA02C00E-0-wk-Footnote-39CF024D03225486829869F6CA02C00E_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e10494-wk-Fact-3DDF166872145F4BAF10CA9D1ED6DA8F"
          xlink:to="TextSelection-53BB8CAFCA475C0C9DB2195050D36025-0-wk-Footnote-53BB8CAFCA475C0C9DB2195050D36025_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e10494-wk-Fact-3DDF166872145F4BAF10CA9D1ED6DA8F"
          xlink:to="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43674379e2584-wk-Fact-3E322F23F0E95E659A8A7D474667DE0D"
          xlink:label="d43674379e2584-wk-Fact-3E322F23F0E95E659A8A7D474667DE0D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43674379e2584-wk-Fact-3E322F23F0E95E659A8A7D474667DE0D"
          xlink:to="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43771853e11079-wk-Fact-3E9CA6EB4A915AFF8A6FCEB98114AB68"
          xlink:label="d43771853e11079-wk-Fact-3E9CA6EB4A915AFF8A6FCEB98114AB68"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e11079-wk-Fact-3E9CA6EB4A915AFF8A6FCEB98114AB68"
          xlink:to="TextSelection-7266C8E6B8975A65A379AF3B415EA220-0-wk-Footnote-7266C8E6B8975A65A379AF3B415EA220_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687704e2398-wk-Fact-3F5327605CC159E0884F58369042FADA"
          xlink:label="d43687704e2398-wk-Fact-3F5327605CC159E0884F58369042FADA"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e2398-wk-Fact-3F5327605CC159E0884F58369042FADA"
          xlink:to="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e2398-wk-Fact-3F5327605CC159E0884F58369042FADA"
          xlink:to="TextSelection-9231AC55B8EC5775BC4995B0797F870F-0-wk-Footnote-9231AC55B8EC5775BC4995B0797F870F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43674379e1253-wk-Fact-4014B8D306BF54FC8CDF5431816FAA50"
          xlink:label="d43674379e1253-wk-Fact-4014B8D306BF54FC8CDF5431816FAA50"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d43697240e2375-wk-Fact-4014B8D306BF54FC8CDF5431816FAA50"
          xlink:label="d43697240e2375-wk-Fact-4014B8D306BF54FC8CDF5431816FAA50"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43674379e1253-wk-Fact-4014B8D306BF54FC8CDF5431816FAA50"
          xlink:to="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43697240e2375-wk-Fact-4014B8D306BF54FC8CDF5431816FAA50"
          xlink:to="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43674379e1253-wk-Fact-4014B8D306BF54FC8CDF5431816FAA50"
          xlink:to="TextSelection-FF348CC7844F523299A112551B170BE6-0-wk-Footnote-FF348CC7844F523299A112551B170BE6_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43697240e2375-wk-Fact-4014B8D306BF54FC8CDF5431816FAA50"
          xlink:to="TextSelection-FF348CC7844F523299A112551B170BE6-0-wk-Footnote-FF348CC7844F523299A112551B170BE6_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687704e2025-wk-Fact-40459F40D11A5E0AA41A1F4213969546"
          xlink:label="d43687704e2025-wk-Fact-40459F40D11A5E0AA41A1F4213969546"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e2025-wk-Fact-40459F40D11A5E0AA41A1F4213969546"
          xlink:to="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e2025-wk-Fact-40459F40D11A5E0AA41A1F4213969546"
          xlink:to="TextSelection-9231AC55B8EC5775BC4995B0797F870F-0-wk-Footnote-9231AC55B8EC5775BC4995B0797F870F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687704e3180-wk-Fact-413D25685F8F583AB53236F9F57575B9"
          xlink:label="d43687704e3180-wk-Fact-413D25685F8F583AB53236F9F57575B9"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d43690878e2263-wk-Fact-413D25685F8F583AB53236F9F57575B9"
          xlink:label="d43690878e2263-wk-Fact-413D25685F8F583AB53236F9F57575B9"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43690878e2263-wk-Fact-413D25685F8F583AB53236F9F57575B9"
          xlink:to="TextSelection-792D3AB23D6354CFBB2776AE7F6407B4-0-wk-Footnote-792D3AB23D6354CFBB2776AE7F6407B4_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e3180-wk-Fact-413D25685F8F583AB53236F9F57575B9"
          xlink:to="TextSelection-792D3AB23D6354CFBB2776AE7F6407B4-0-wk-Footnote-792D3AB23D6354CFBB2776AE7F6407B4_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43690878e2263-wk-Fact-413D25685F8F583AB53236F9F57575B9"
          xlink:to="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e3180-wk-Fact-413D25685F8F583AB53236F9F57575B9"
          xlink:to="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43690878e2263-wk-Fact-413D25685F8F583AB53236F9F57575B9"
          xlink:to="TextSelection-9231AC55B8EC5775BC4995B0797F870F-0-wk-Footnote-9231AC55B8EC5775BC4995B0797F870F_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e3180-wk-Fact-413D25685F8F583AB53236F9F57575B9"
          xlink:to="TextSelection-9231AC55B8EC5775BC4995B0797F870F-0-wk-Footnote-9231AC55B8EC5775BC4995B0797F870F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43674379e1721-wk-Fact-41E568B8775D59BFBCD7C2E611178392"
          xlink:label="d43674379e1721-wk-Fact-41E568B8775D59BFBCD7C2E611178392"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43674379e1721-wk-Fact-41E568B8775D59BFBCD7C2E611178392"
          xlink:to="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e5759-wk-Fact-41F768EB6EEC5BBBA68D38AC1F01367F"
          xlink:label="d43770747e5759-wk-Fact-41F768EB6EEC5BBBA68D38AC1F01367F"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e5759-wk-Fact-41F768EB6EEC5BBBA68D38AC1F01367F"
          xlink:to="TextSelection-0BDE8CEE983B5F118E2EFACDF9CC6405-0-wk-Footnote-0BDE8CEE983B5F118E2EFACDF9CC6405_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43681613e1248-wk-Fact-4205D6E535945DAFBDC33902ED523920"
          xlink:label="d43681613e1248-wk-Fact-4205D6E535945DAFBDC33902ED523920"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43681613e1248-wk-Fact-4205D6E535945DAFBDC33902ED523920"
          xlink:to="TextSelection-3DD94144621C5A68BC21C5DB64345BB9-0-wk-Footnote-3DD94144621C5A68BC21C5DB64345BB9_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43681613e1248-wk-Fact-4205D6E535945DAFBDC33902ED523920"
          xlink:to="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43771853e8278-wk-Fact-4207856257675CFDB3EB4159D299660D"
          xlink:label="d43771853e8278-wk-Fact-4207856257675CFDB3EB4159D299660D"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-C4FFB7FEB33B5D5EBA7924687B243323-0-wk-Footnote-C4FFB7FEB33B5D5EBA7924687B243323_lbl" xlink:label="TextSelection-C4FFB7FEB33B5D5EBA7924687B243323-0-wk-Footnote-C4FFB7FEB33B5D5EBA7924687B243323_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Legacy Established Products primarily include products that have lost patent protection (excluding Sterile Injectable Pharmaceuticals and Peri-LOE Products). Effective January 1, 2017, All other LEP includes Duavive/Duavee and Viviant, which were transferred from Innovative Health (recorded in All other Internal Medicine (IH) in 2016), in order to align these products with our management of the women&#x2019;s health portfolio within EH.<xhtml:span style="font-family:inherit;font-size:8pt;"><xhtml:sup style="vertical-align:top;line-height:120%;font-size:5pt"> </xhtml:sup></xhtml:span>See note (a) above.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e8278-wk-Fact-4207856257675CFDB3EB4159D299660D"
          xlink:to="TextSelection-C4FFB7FEB33B5D5EBA7924687B243323-0-wk-Footnote-C4FFB7FEB33B5D5EBA7924687B243323_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43674379e2094-wk-Fact-4207CB01CC1150BFA16DC1CBD3FDE8A0"
          xlink:label="d43674379e2094-wk-Fact-4207CB01CC1150BFA16DC1CBD3FDE8A0"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43674379e2094-wk-Fact-4207CB01CC1150BFA16DC1CBD3FDE8A0"
          xlink:to="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43674379e2405-wk-Fact-42825AA4D3815C349BD40B420827B233"
          xlink:label="d43674379e2405-wk-Fact-42825AA4D3815C349BD40B420827B233"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43674379e2405-wk-Fact-42825AA4D3815C349BD40B420827B233"
          xlink:to="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43681613e1382-wk-Fact-42968803AD055EFEB0C3ED702C15D6AC"
          xlink:label="d43681613e1382-wk-Fact-42968803AD055EFEB0C3ED702C15D6AC"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43681613e1382-wk-Fact-42968803AD055EFEB0C3ED702C15D6AC"
          xlink:to="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e8898-wk-Fact-42F9DF20DDCA5646904966177DFB6AA4"
          xlink:label="d43770747e8898-wk-Fact-42F9DF20DDCA5646904966177DFB6AA4"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e8898-wk-Fact-42F9DF20DDCA5646904966177DFB6AA4"
          xlink:to="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e8898-wk-Fact-42F9DF20DDCA5646904966177DFB6AA4"
          xlink:to="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact-438EE85774DF543BA158096F9559C174-wk-Fact-438EE85774DF543BA158096F9559C174"
          xlink:label="Fact-438EE85774DF543BA158096F9559C174-wk-Fact-438EE85774DF543BA158096F9559C174"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact-438EE85774DF543BA158096F9559C174-wk-Fact-438EE85774DF543BA158096F9559C174"
          xlink:to="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687849e1987-wk-Fact-439917D3DAAF58E1AD6CD991FC80DC42"
          xlink:label="d43687849e1987-wk-Fact-439917D3DAAF58E1AD6CD991FC80DC42"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e1987-wk-Fact-439917D3DAAF58E1AD6CD991FC80DC42"
          xlink:to="TextSelection-77536863BCE35B419E3A4119D41DB4BD-0-wk-Footnote-77536863BCE35B419E3A4119D41DB4BD_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e1987-wk-Fact-439917D3DAAF58E1AD6CD991FC80DC42"
          xlink:to="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43771853e11380-wk-Fact-442B1474BBCB5FE8A099D633CB680650"
          xlink:label="d43771853e11380-wk-Fact-442B1474BBCB5FE8A099D633CB680650"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e11380-wk-Fact-442B1474BBCB5FE8A099D633CB680650"
          xlink:to="TextSelection-DE7EF4A6663E52BF8D3620854A57A945-0-wk-Footnote-DE7EF4A6663E52BF8D3620854A57A945_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e4403-wk-Fact-44ACB44C1F6D5867A9AE1BCDA6662468"
          xlink:label="d43770747e4403-wk-Fact-44ACB44C1F6D5867A9AE1BCDA6662468"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e4403-wk-Fact-44ACB44C1F6D5867A9AE1BCDA6662468"
          xlink:to="TextSelection-2BFD6C99096B50AD93705C5601B21F46-0-wk-Footnote-2BFD6C99096B50AD93705C5601B21F46_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43681613e2059-wk-Fact-450DDE9FBB965039B395036FE74CBBB0"
          xlink:label="d43681613e2059-wk-Fact-450DDE9FBB965039B395036FE74CBBB0"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43681613e2059-wk-Fact-450DDE9FBB965039B395036FE74CBBB0"
          xlink:to="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43771853e4822-wk-Fact-4589B65A44FD5257A71D6C106B182464"
          xlink:label="d43771853e4822-wk-Fact-4589B65A44FD5257A71D6C106B182464"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e4822-wk-Fact-4589B65A44FD5257A71D6C106B182464"
          xlink:to="TextSelection-DC6DDCB74FC9523D97BA51FBA6B1C05E-0-wk-Footnote-DC6DDCB74FC9523D97BA51FBA6B1C05E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43674379e2031-wk-Fact-45A307B4BFCC56B2A721109AA18533BB"
          xlink:label="d43674379e2031-wk-Fact-45A307B4BFCC56B2A721109AA18533BB"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43674379e2031-wk-Fact-45A307B4BFCC56B2A721109AA18533BB"
          xlink:to="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43712496e3283-wk-Fact-45F6314CE80C59AC9D1C31C3E15AFBD8"
          xlink:label="d43712496e3283-wk-Fact-45F6314CE80C59AC9D1C31C3E15AFBD8"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-02609C62928C5D1CBFB6DD071D9D7B0E-0-wk-Footnote-02609C62928C5D1CBFB6DD071D9D7B0E_lbl" xlink:label="TextSelection-02609C62928C5D1CBFB6DD071D9D7B0E-0-wk-Footnote-02609C62928C5D1CBFB6DD071D9D7B0E_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Included in <xhtml:span style="font-family:inherit;font-size:9pt;font-style:italic;">Other current liabilities</xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;"> (</xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;"><xhtml:span>$863 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;">) and </xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;font-style:italic;">Other noncurrent liabilities</xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;"> (</xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;"><xhtml:span>$720 million</xhtml:span></xhtml:span>).</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43712496e3283-wk-Fact-45F6314CE80C59AC9D1C31C3E15AFBD8"
          xlink:to="TextSelection-02609C62928C5D1CBFB6DD071D9D7B0E-0-wk-Footnote-02609C62928C5D1CBFB6DD071D9D7B0E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43681613e1402-wk-Fact-4638ED2A9682598F89E8D0DE8B195AA8"
          xlink:label="d43681613e1402-wk-Fact-4638ED2A9682598F89E8D0DE8B195AA8"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43681613e1402-wk-Fact-4638ED2A9682598F89E8D0DE8B195AA8"
          xlink:to="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43771853e4606-wk-Fact-465B9433DD0F5F3D8D3A8DC7524E082A"
          xlink:label="d43771853e4606-wk-Fact-465B9433DD0F5F3D8D3A8DC7524E082A"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e4606-wk-Fact-465B9433DD0F5F3D8D3A8DC7524E082A"
          xlink:to="TextSelection-3802305E73EB52F28FAAF4EA5481D580-0-wk-Footnote-3802305E73EB52F28FAAF4EA5481D580_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43712496e2445-wk-Fact-466AE7233A2D57E48E9D5268F9EEEBF0"
          xlink:label="d43712496e2445-wk-Fact-466AE7233A2D57E48E9D5268F9EEEBF0"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43712496e2445-wk-Fact-466AE7233A2D57E48E9D5268F9EEEBF0"
          xlink:to="TextSelection-C37CD88178CA35C475D25A62F2B54FED-0-wk-Footnote-C37CD88178CA35C475D25A62F2B54FED_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e1628-wk-Fact-46A836D9C25B56FF9251C6C08C3CCB44"
          xlink:label="d43770747e1628-wk-Fact-46A836D9C25B56FF9251C6C08C3CCB44"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e1628-wk-Fact-46A836D9C25B56FF9251C6C08C3CCB44"
          xlink:to="TextSelection-58096FF6357955D6B6AA25D56767CB0A-0-wk-Footnote-58096FF6357955D6B6AA25D56767CB0A_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e1628-wk-Fact-46A836D9C25B56FF9251C6C08C3CCB44"
          xlink:to="TextSelection-8D2A93033C2E56DE9E814F0AB36328EE-0-wk-Footnote-8D2A93033C2E56DE9E814F0AB36328EE_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687849e3113-wk-Fact-46E6ECDFD5B35112ACFA85A4DD680D69"
          xlink:label="d43687849e3113-wk-Fact-46E6ECDFD5B35112ACFA85A4DD680D69"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e3113-wk-Fact-46E6ECDFD5B35112ACFA85A4DD680D69"
          xlink:to="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e4176-wk-Fact-46FCF46F8CE857D6A45597A49A1788DE"
          xlink:label="d43770747e4176-wk-Fact-46FCF46F8CE857D6A45597A49A1788DE"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e4176-wk-Fact-46FCF46F8CE857D6A45597A49A1788DE"
          xlink:to="TextSelection-2BFD6C99096B50AD93705C5601B21F46-0-wk-Footnote-2BFD6C99096B50AD93705C5601B21F46_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687849e1968-wk-Fact-472E8E6F6DB25346B046668C52D5902F"
          xlink:label="d43687849e1968-wk-Fact-472E8E6F6DB25346B046668C52D5902F"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e1968-wk-Fact-472E8E6F6DB25346B046668C52D5902F"
          xlink:to="TextSelection-77536863BCE35B419E3A4119D41DB4BD-0-wk-Footnote-77536863BCE35B419E3A4119D41DB4BD_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e1968-wk-Fact-472E8E6F6DB25346B046668C52D5902F"
          xlink:to="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43771853e11144-wk-Fact-473A8153DB95559E92CC6D9F938E0BCE"
          xlink:label="d43771853e11144-wk-Fact-473A8153DB95559E92CC6D9F938E0BCE"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e11144-wk-Fact-473A8153DB95559E92CC6D9F938E0BCE"
          xlink:to="TextSelection-ED6F6E1A7C41596DA6F5B1BDFBB72CB7-0-wk-Footnote-ED6F6E1A7C41596DA6F5B1BDFBB72CB7_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687704e2822-wk-Fact-473E2E1DAAB95751BEEBC640CAD75D52"
          xlink:label="d43687704e2822-wk-Fact-473E2E1DAAB95751BEEBC640CAD75D52"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e2822-wk-Fact-473E2E1DAAB95751BEEBC640CAD75D52"
          xlink:to="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e2822-wk-Fact-473E2E1DAAB95751BEEBC640CAD75D52"
          xlink:to="TextSelection-9231AC55B8EC5775BC4995B0797F870F-0-wk-Footnote-9231AC55B8EC5775BC4995B0797F870F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43712496e3540-wk-Fact-477878BBEDE5542C9F9E88C10D02CABE"
          xlink:label="d43712496e3540-wk-Fact-477878BBEDE5542C9F9E88C10D02CABE"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-3E9076747FF25E3B8D3B9AAF71548F16-0-wk-Footnote-3E9076747FF25E3B8D3B9AAF71548F16_lbl" xlink:label="TextSelection-3E9076747FF25E3B8D3B9AAF71548F16-0-wk-Footnote-3E9076747FF25E3B8D3B9AAF71548F16_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Included in <xhtml:span style="font-family:inherit;font-size:9pt;font-style:italic;">Other current liabilities </xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;">(</xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;"><xhtml:span>$533 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;">) and </xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;font-style:italic;">Other noncurrent liabilities </xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;">(</xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;"><xhtml:span>$650 million</xhtml:span></xhtml:span>).</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43712496e3540-wk-Fact-477878BBEDE5542C9F9E88C10D02CABE"
          xlink:to="TextSelection-3E9076747FF25E3B8D3B9AAF71548F16-0-wk-Footnote-3E9076747FF25E3B8D3B9AAF71548F16_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43690878e1537-wk-Fact-4791EB1764F851F9BFC3743AD13BD04D"
          xlink:label="d43690878e1537-wk-Fact-4791EB1764F851F9BFC3743AD13BD04D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43690878e1537-wk-Fact-4791EB1764F851F9BFC3743AD13BD04D"
          xlink:to="TextSelection-792D3AB23D6354CFBB2776AE7F6407B4-0-wk-Footnote-792D3AB23D6354CFBB2776AE7F6407B4_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43771853e3215-wk-Fact-47A9B6BC4350580490BDDDA2982DE155"
          xlink:label="d43771853e3215-wk-Fact-47A9B6BC4350580490BDDDA2982DE155"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e3215-wk-Fact-47A9B6BC4350580490BDDDA2982DE155"
          xlink:to="TextSelection-13C3E50268A15908A8AC9D1B6C938D2D-0-wk-Footnote-13C3E50268A15908A8AC9D1B6C938D2D_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e3215-wk-Fact-47A9B6BC4350580490BDDDA2982DE155"
          xlink:to="TextSelection-78FC5AB8EFAB585E87BBCF93BE9FBF1D-0-wk-Footnote-78FC5AB8EFAB585E87BBCF93BE9FBF1D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e4058-wk-Fact-47F85ABECEA3558FB193E486A6300E36"
          xlink:label="d43770747e4058-wk-Fact-47F85ABECEA3558FB193E486A6300E36"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e4058-wk-Fact-47F85ABECEA3558FB193E486A6300E36"
          xlink:to="TextSelection-7EC55EFE69505245B1A079B8132EFBB7-0-wk-Footnote-7EC55EFE69505245B1A079B8132EFBB7_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e10015-wk-Fact-481B3D6C84EF52CCBEBB11AB001F4356"
          xlink:label="d43770747e10015-wk-Fact-481B3D6C84EF52CCBEBB11AB001F4356"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e10015-wk-Fact-481B3D6C84EF52CCBEBB11AB001F4356"
          xlink:to="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e10015-wk-Fact-481B3D6C84EF52CCBEBB11AB001F4356"
          xlink:to="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687704e2784-wk-Fact-485CB0863B5C5B9D8B2C74086517AD5B"
          xlink:label="d43687704e2784-wk-Fact-485CB0863B5C5B9D8B2C74086517AD5B"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e2784-wk-Fact-485CB0863B5C5B9D8B2C74086517AD5B"
          xlink:to="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e2784-wk-Fact-485CB0863B5C5B9D8B2C74086517AD5B"
          xlink:to="TextSelection-9231AC55B8EC5775BC4995B0797F870F-0-wk-Footnote-9231AC55B8EC5775BC4995B0797F870F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e7739-wk-Fact-4918CC17DAC15E038DC184F1DA176587"
          xlink:label="d43770747e7739-wk-Fact-4918CC17DAC15E038DC184F1DA176587"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e7739-wk-Fact-4918CC17DAC15E038DC184F1DA176587"
          xlink:to="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e7739-wk-Fact-4918CC17DAC15E038DC184F1DA176587"
          xlink:to="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43697224e1460-wk-Fact-4927FC00863B524C890DD332985D1F82"
          xlink:label="d43697224e1460-wk-Fact-4927FC00863B524C890DD332985D1F82"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-FCAEF1B26EF652E4896D2456427B24D7-0-wk-Footnote-FCAEF1B26EF652E4896D2456427B24D7_lbl" xlink:label="TextSelection-FCAEF1B26EF652E4896D2456427B24D7-0-wk-Footnote-FCAEF1B26EF652E4896D2456427B24D7_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">In the <xhtml:span style="font-family:inherit;font-size:8.5pt;">third</xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"> quarter and </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;">first nine months of</xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"> </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;text-align:center;">2017</xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;">, represents adjustments to amounts previously recorded to write down the HIS net assets to fair value less costs to sell related to the sale of HIS net assets to ICU Medical. In the </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;">third</xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"> quarter and </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;">first nine months of</xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"> </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;text-align:center;">2016</xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;">, represents a charge related to the write-down of the HIS net assets to fair value less estimated costs to sell.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43697224e1460-wk-Fact-4927FC00863B524C890DD332985D1F82"
          xlink:to="TextSelection-FCAEF1B26EF652E4896D2456427B24D7-0-wk-Footnote-FCAEF1B26EF652E4896D2456427B24D7_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43771853e2795-wk-Fact-4978864FED0C5781909B06FB41801AC3"
          xlink:label="d43771853e2795-wk-Fact-4978864FED0C5781909B06FB41801AC3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e2795-wk-Fact-4978864FED0C5781909B06FB41801AC3"
          xlink:to="TextSelection-78FC5AB8EFAB585E87BBCF93BE9FBF1D-0-wk-Footnote-78FC5AB8EFAB585E87BBCF93BE9FBF1D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43697224e2924-wk-Fact-49CB6967F08724E343E55A1EFDC1A551"
          xlink:label="d43697224e2924-wk-Fact-49CB6967F08724E343E55A1EFDC1A551"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43697224e2924-wk-Fact-49CB6967F08724E343E55A1EFDC1A551"
          xlink:to="TextSelection-066A0A390204B79351965A22CE69E761-0-wk-Footnote-066A0A390204B79351965A22CE69E761_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43697224e2924-wk-Fact-49CB6967F08724E343E55A1EFDC1A551"
          xlink:to="TextSelection-4AF5AB391F1CD8054C065A2324C0D822-0-wk-Footnote-4AF5AB391F1CD8054C065A2324C0D822_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43674379e1784-wk-Fact-4A5801DF38F08BD8CEC3922878CFA84A"
          xlink:label="d43674379e1784-wk-Fact-4A5801DF38F08BD8CEC3922878CFA84A"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43674379e1784-wk-Fact-4A5801DF38F08BD8CEC3922878CFA84A"
          xlink:to="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e10370-wk-Fact-4ADCC13FDAC45B6BB3630C98712932FD"
          xlink:label="d43770747e10370-wk-Fact-4ADCC13FDAC45B6BB3630C98712932FD"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e10370-wk-Fact-4ADCC13FDAC45B6BB3630C98712932FD"
          xlink:to="TextSelection-39CF024D03225486829869F6CA02C00E-0-wk-Footnote-39CF024D03225486829869F6CA02C00E_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e10370-wk-Fact-4ADCC13FDAC45B6BB3630C98712932FD"
          xlink:to="TextSelection-53BB8CAFCA475C0C9DB2195050D36025-0-wk-Footnote-53BB8CAFCA475C0C9DB2195050D36025_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e10370-wk-Fact-4ADCC13FDAC45B6BB3630C98712932FD"
          xlink:to="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43771853e2192-wk-Fact-4B3A8022310558FC9B763D89CFB05272"
          xlink:label="d43771853e2192-wk-Fact-4B3A8022310558FC9B763D89CFB05272"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e2192-wk-Fact-4B3A8022310558FC9B763D89CFB05272"
          xlink:to="TextSelection-78FC5AB8EFAB585E87BBCF93BE9FBF1D-0-wk-Footnote-78FC5AB8EFAB585E87BBCF93BE9FBF1D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687704e2911-wk-Fact-4B8F1DBA2929519A88C07E8910A30454"
          xlink:label="d43687704e2911-wk-Fact-4B8F1DBA2929519A88C07E8910A30454"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e2911-wk-Fact-4B8F1DBA2929519A88C07E8910A30454"
          xlink:to="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e2911-wk-Fact-4B8F1DBA2929519A88C07E8910A30454"
          xlink:to="TextSelection-9231AC55B8EC5775BC4995B0797F870F-0-wk-Footnote-9231AC55B8EC5775BC4995B0797F870F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact-4C5952B687735A68B4F8FF2FF8E28F5B-wk-Fact-4C5952B687735A68B4F8FF2FF8E28F5B"
          xlink:label="Fact-4C5952B687735A68B4F8FF2FF8E28F5B-wk-Fact-4C5952B687735A68B4F8FF2FF8E28F5B"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact-4C5952B687735A68B4F8FF2FF8E28F5B-wk-Fact-4C5952B687735A68B4F8FF2FF8E28F5B"
          xlink:to="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e7335-wk-Fact-4C647D3AD0F151A9BA9998C97C5B0A63"
          xlink:label="d43770747e7335-wk-Fact-4C647D3AD0F151A9BA9998C97C5B0A63"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e7335-wk-Fact-4C647D3AD0F151A9BA9998C97C5B0A63"
          xlink:to="TextSelection-39CF024D03225486829869F6CA02C00E-0-wk-Footnote-39CF024D03225486829869F6CA02C00E_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e7335-wk-Fact-4C647D3AD0F151A9BA9998C97C5B0A63"
          xlink:to="TextSelection-53BB8CAFCA475C0C9DB2195050D36025-0-wk-Footnote-53BB8CAFCA475C0C9DB2195050D36025_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e7335-wk-Fact-4C647D3AD0F151A9BA9998C97C5B0A63"
          xlink:to="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687849e1301-wk-Fact-4C6BD95E3D2E5FB8B5E794AE6EE85755"
          xlink:label="d43687849e1301-wk-Fact-4C6BD95E3D2E5FB8B5E794AE6EE85755"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e1301-wk-Fact-4C6BD95E3D2E5FB8B5E794AE6EE85755"
          xlink:to="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43712510e4343-wk-Fact-4C8B761BC8A857289F300FD346EDCFF2"
          xlink:label="d43712510e4343-wk-Fact-4C8B761BC8A857289F300FD346EDCFF2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43712510e4343-wk-Fact-4C8B761BC8A857289F300FD346EDCFF2"
          xlink:to="TextSelection-621F9196966C550EA113DA57575C171E-0-wk-Footnote-621F9196966C550EA113DA57575C171E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact-4CB7130CEF915377BE0293C8FB86F1C5-wk-Fact-4CB7130CEF915377BE0293C8FB86F1C5"
          xlink:label="Fact-4CB7130CEF915377BE0293C8FB86F1C5-wk-Fact-4CB7130CEF915377BE0293C8FB86F1C5"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact-4CB7130CEF915377BE0293C8FB86F1C5-wk-Fact-4CB7130CEF915377BE0293C8FB86F1C5"
          xlink:to="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43681613e973-wk-Fact-4CD7C8E134F3568695AECCF94C6AF4FD"
          xlink:label="d43681613e973-wk-Fact-4CD7C8E134F3568695AECCF94C6AF4FD"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d43697224e1499-wk-Fact-4CD7C8E134F3568695AECCF94C6AF4FD"
          xlink:label="d43697224e1499-wk-Fact-4CD7C8E134F3568695AECCF94C6AF4FD"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43697224e1499-wk-Fact-4CD7C8E134F3568695AECCF94C6AF4FD"
          xlink:to="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43681613e973-wk-Fact-4CD7C8E134F3568695AECCF94C6AF4FD"
          xlink:to="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43697224e1499-wk-Fact-4CD7C8E134F3568695AECCF94C6AF4FD"
          xlink:to="TextSelection-FCAEF1B26EF652E4896D2456427B24D7-0-wk-Footnote-FCAEF1B26EF652E4896D2456427B24D7_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43681613e973-wk-Fact-4CD7C8E134F3568695AECCF94C6AF4FD"
          xlink:to="TextSelection-FCAEF1B26EF652E4896D2456427B24D7-0-wk-Footnote-FCAEF1B26EF652E4896D2456427B24D7_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43712510e4818-wk-Fact-4CE5EEDBEB0E56709AF5BDD28428C8A4"
          xlink:label="d43712510e4818-wk-Fact-4CE5EEDBEB0E56709AF5BDD28428C8A4"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43712510e4818-wk-Fact-4CE5EEDBEB0E56709AF5BDD28428C8A4"
          xlink:to="TextSelection-621F9196966C550EA113DA57575C171E-0-wk-Footnote-621F9196966C550EA113DA57575C171E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43681613e904-wk-Fact-4D5D0B01BEBB5DEFB2827E50144E0489"
          xlink:label="d43681613e904-wk-Fact-4D5D0B01BEBB5DEFB2827E50144E0489"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43681613e904-wk-Fact-4D5D0B01BEBB5DEFB2827E50144E0489"
          xlink:to="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43681613e2078-wk-Fact-4D68DAE5FD3059969FCBB65614BE4D06"
          xlink:label="d43681613e2078-wk-Fact-4D68DAE5FD3059969FCBB65614BE4D06"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43681613e2078-wk-Fact-4D68DAE5FD3059969FCBB65614BE4D06"
          xlink:to="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43771853e4668-wk-Fact-4DBF4C8A615D5B5885A229550C249596"
          xlink:label="d43771853e4668-wk-Fact-4DBF4C8A615D5B5885A229550C249596"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e4668-wk-Fact-4DBF4C8A615D5B5885A229550C249596"
          xlink:to="TextSelection-E9F14C2885BA59D8B6B4AD221FC38619-0-wk-Footnote-E9F14C2885BA59D8B6B4AD221FC38619_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43712496e1841-wk-Fact-4DC7F6E7ED055FD8910B97A13EEF264E"
          xlink:label="d43712496e1841-wk-Fact-4DC7F6E7ED055FD8910B97A13EEF264E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43712496e1841-wk-Fact-4DC7F6E7ED055FD8910B97A13EEF264E"
          xlink:to="TextSelection-7160FF67E87550A19177FE255A41A2D7-0-wk-Footnote-7160FF67E87550A19177FE255A41A2D7_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43712496e2235-wk-Fact-4DCE62D0C18E5CD6957CFB6E8F495684"
          xlink:label="d43712496e2235-wk-Fact-4DCE62D0C18E5CD6957CFB6E8F495684"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43712496e2235-wk-Fact-4DCE62D0C18E5CD6957CFB6E8F495684"
          xlink:to="TextSelection-C37CD88178CA35C475D25A62F2B54FED-0-wk-Footnote-C37CD88178CA35C475D25A62F2B54FED_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e11192-wk-Fact-4E50B891ECDF54F8B82E01242152C091"
          xlink:label="d43770747e11192-wk-Fact-4E50B891ECDF54F8B82E01242152C091"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e11192-wk-Fact-4E50B891ECDF54F8B82E01242152C091"
          xlink:to="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e11192-wk-Fact-4E50B891ECDF54F8B82E01242152C091"
          xlink:to="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687704e3122-wk-Fact-4F013E58EAE3506D989984D20AC7A60B"
          xlink:label="d43687704e3122-wk-Fact-4F013E58EAE3506D989984D20AC7A60B"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d43690878e2205-wk-Fact-4F013E58EAE3506D989984D20AC7A60B"
          xlink:label="d43690878e2205-wk-Fact-4F013E58EAE3506D989984D20AC7A60B"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e3122-wk-Fact-4F013E58EAE3506D989984D20AC7A60B"
          xlink:to="TextSelection-792D3AB23D6354CFBB2776AE7F6407B4-0-wk-Footnote-792D3AB23D6354CFBB2776AE7F6407B4_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43690878e2205-wk-Fact-4F013E58EAE3506D989984D20AC7A60B"
          xlink:to="TextSelection-792D3AB23D6354CFBB2776AE7F6407B4-0-wk-Footnote-792D3AB23D6354CFBB2776AE7F6407B4_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e3122-wk-Fact-4F013E58EAE3506D989984D20AC7A60B"
          xlink:to="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43690878e2205-wk-Fact-4F013E58EAE3506D989984D20AC7A60B"
          xlink:to="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e3122-wk-Fact-4F013E58EAE3506D989984D20AC7A60B"
          xlink:to="TextSelection-9231AC55B8EC5775BC4995B0797F870F-0-wk-Footnote-9231AC55B8EC5775BC4995B0797F870F_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43690878e2205-wk-Fact-4F013E58EAE3506D989984D20AC7A60B"
          xlink:to="TextSelection-9231AC55B8EC5775BC4995B0797F870F-0-wk-Footnote-9231AC55B8EC5775BC4995B0797F870F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687704e1599-wk-Fact-4F4FAE747047530784054ED85551DFDC"
          xlink:label="d43687704e1599-wk-Fact-4F4FAE747047530784054ED85551DFDC"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e1599-wk-Fact-4F4FAE747047530784054ED85551DFDC"
          xlink:to="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e1599-wk-Fact-4F4FAE747047530784054ED85551DFDC"
          xlink:to="TextSelection-9231AC55B8EC5775BC4995B0797F870F-0-wk-Footnote-9231AC55B8EC5775BC4995B0797F870F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e3159-wk-Fact-4F630A08F3EE5D04A766A973955E5DEE"
          xlink:label="d43770747e3159-wk-Fact-4F630A08F3EE5D04A766A973955E5DEE"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-DAFABE7CE058521690718900BE6137FA-0-wk-Footnote-DAFABE7CE058521690718900BE6137FA_lbl" xlink:label="TextSelection-DAFABE7CE058521690718900BE6137FA-0-wk-Footnote-DAFABE7CE058521690718900BE6137FA_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">As of <xhtml:span style="font-family:inherit;font-size:9pt;">October&#160;1, 2017</xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;">, derivative instruments at fair value include foreign currency forward-exchange contracts (</xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;"><xhtml:span>$276 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;">) and interest rate swaps (</xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;"><xhtml:span>$1 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;">) and, as of </xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;text-align:center;">December&#160;31, 2016</xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;">, include interest rate swaps (</xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;"><xhtml:span>$1 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;">), foreign currency swaps (</xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;"><xhtml:span>$300 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;">) and foreign currency forward-exchange contracts (</xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;"><xhtml:span>$143 million</xhtml:span></xhtml:span>).</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e3159-wk-Fact-4F630A08F3EE5D04A766A973955E5DEE"
          xlink:to="TextSelection-DAFABE7CE058521690718900BE6137FA-0-wk-Footnote-DAFABE7CE058521690718900BE6137FA_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687704e2418-wk-Fact-4FA35F91DEE258C694579DEDDD33A6CF"
          xlink:label="d43687704e2418-wk-Fact-4FA35F91DEE258C694579DEDDD33A6CF"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e2418-wk-Fact-4FA35F91DEE258C694579DEDDD33A6CF"
          xlink:to="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e2418-wk-Fact-4FA35F91DEE258C694579DEDDD33A6CF"
          xlink:to="TextSelection-9231AC55B8EC5775BC4995B0797F870F-0-wk-Footnote-9231AC55B8EC5775BC4995B0797F870F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687849e2996-wk-Fact-503B87CD9CE65FEDBBDC99370F10DF6B"
          xlink:label="d43687849e2996-wk-Fact-503B87CD9CE65FEDBBDC99370F10DF6B"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e2996-wk-Fact-503B87CD9CE65FEDBBDC99370F10DF6B"
          xlink:to="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43674379e2183-wk-Fact-50ADB7EB4847506EA08C0BF6C7E30E84"
          xlink:label="d43674379e2183-wk-Fact-50ADB7EB4847506EA08C0BF6C7E30E84"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43674379e2183-wk-Fact-50ADB7EB4847506EA08C0BF6C7E30E84"
          xlink:to="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e8151-wk-Fact-5134E9EECF3F53FC8E0FBFCC64592278"
          xlink:label="d43770747e8151-wk-Fact-5134E9EECF3F53FC8E0FBFCC64592278"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e8151-wk-Fact-5134E9EECF3F53FC8E0FBFCC64592278"
          xlink:to="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e8151-wk-Fact-5134E9EECF3F53FC8E0FBFCC64592278"
          xlink:to="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43712496e1348-wk-Fact-5183BF736F1E563FA304D5EEBF7843EF"
          xlink:label="d43712496e1348-wk-Fact-5183BF736F1E563FA304D5EEBF7843EF"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43712496e1348-wk-Fact-5183BF736F1E563FA304D5EEBF7843EF"
          xlink:to="TextSelection-B57619F44FCF544D96067CF4816A9082-0-wk-Footnote-B57619F44FCF544D96067CF4816A9082_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687849e1666-wk-Fact-51BE1E50E018595FBB09E1CA22E07612"
          xlink:label="d43687849e1666-wk-Fact-51BE1E50E018595FBB09E1CA22E07612"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e1666-wk-Fact-51BE1E50E018595FBB09E1CA22E07612"
          xlink:to="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e1666-wk-Fact-51BE1E50E018595FBB09E1CA22E07612"
          xlink:to="TextSelection-F185CD45BC245C2EB8EDBFD55DB8A33F-0-wk-Footnote-F185CD45BC245C2EB8EDBFD55DB8A33F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687849e2327-wk-Fact-51ECCBCA921E59759451F63108AF904D"
          xlink:label="d43687849e2327-wk-Fact-51ECCBCA921E59759451F63108AF904D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e2327-wk-Fact-51ECCBCA921E59759451F63108AF904D"
          xlink:to="TextSelection-77536863BCE35B419E3A4119D41DB4BD-0-wk-Footnote-77536863BCE35B419E3A4119D41DB4BD_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e2327-wk-Fact-51ECCBCA921E59759451F63108AF904D"
          xlink:to="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687849e1216-wk-Fact-524E646459CB5301AEC5027EA98F9741"
          xlink:label="d43687849e1216-wk-Fact-524E646459CB5301AEC5027EA98F9741"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e1216-wk-Fact-524E646459CB5301AEC5027EA98F9741"
          xlink:to="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687849e1902-wk-Fact-526D1E8FCDB9599FBA3FC176B4CBDF40"
          xlink:label="d43687849e1902-wk-Fact-526D1E8FCDB9599FBA3FC176B4CBDF40"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e1902-wk-Fact-526D1E8FCDB9599FBA3FC176B4CBDF40"
          xlink:to="TextSelection-77536863BCE35B419E3A4119D41DB4BD-0-wk-Footnote-77536863BCE35B419E3A4119D41DB4BD_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e1902-wk-Fact-526D1E8FCDB9599FBA3FC176B4CBDF40"
          xlink:to="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43697224e1304-wk-Fact-527425D761315660B95CBE4E0343A596"
          xlink:label="d43697224e1304-wk-Fact-527425D761315660B95CBE4E0343A596"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-7430C81CDF35536B95DB492D56AB6CFD-0-wk-Footnote-7430C81CDF35536B95DB492D56AB6CFD_lbl" xlink:label="TextSelection-7430C81CDF35536B95DB492D56AB6CFD-0-wk-Footnote-7430C81CDF35536B95DB492D56AB6CFD_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">In the <xhtml:span style="font-family:inherit;font-size:8.5pt;">third quarter</xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"> and </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;">first nine months of</xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"> </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;text-align:center;">2017</xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;">, primarily includes a </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"><xhtml:span>$94 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"> charge to resolve a class action lawsuit filed by direct purchasers relating to Celebrex, which is subject to the negotiation of a final settlement agreement and court approval, and a </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"><xhtml:span>$79 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"> charge to reflect damages awarded by a jury in a patent matter. In the </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;">first nine months of</xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"> </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;text-align:center;">2016</xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;">, primarily includes amounts to resolve a Multi-District Litigation relating to Celebrex and Bextra that was pending against the Company in New York federal court for </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"><xhtml:span>$486 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;">, partially offset by the reversal of a legal accrual where a loss was no longer deemed probable. In addition, the </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;">first nine months of</xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"> </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;text-align:center;">2016</xhtml:span> includes a settlement related to a patent matter.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43697224e1304-wk-Fact-527425D761315660B95CBE4E0343A596"
          xlink:to="TextSelection-7430C81CDF35536B95DB492D56AB6CFD-0-wk-Footnote-7430C81CDF35536B95DB492D56AB6CFD_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e2890-wk-Fact-52A1B75A34225AB0850E4467B145EE4C"
          xlink:label="d43770747e2890-wk-Fact-52A1B75A34225AB0850E4467B145EE4C"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e2890-wk-Fact-52A1B75A34225AB0850E4467B145EE4C"
          xlink:to="TextSelection-A9B5859E968353E1AF0EF5AF16D3F7DE-0-wk-Footnote-A9B5859E968353E1AF0EF5AF16D3F7DE_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e10868-wk-Fact-52FA3ED749A551E69FCC2DB848C60415"
          xlink:label="d43770747e10868-wk-Fact-52FA3ED749A551E69FCC2DB848C60415"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e10868-wk-Fact-52FA3ED749A551E69FCC2DB848C60415"
          xlink:to="TextSelection-39CF024D03225486829869F6CA02C00E-0-wk-Footnote-39CF024D03225486829869F6CA02C00E_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e10868-wk-Fact-52FA3ED749A551E69FCC2DB848C60415"
          xlink:to="TextSelection-53BB8CAFCA475C0C9DB2195050D36025-0-wk-Footnote-53BB8CAFCA475C0C9DB2195050D36025_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e10868-wk-Fact-52FA3ED749A551E69FCC2DB848C60415"
          xlink:to="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43674379e1120-wk-Fact-5329671706335212AE3F5E2B75B7A4AB"
          xlink:label="d43674379e1120-wk-Fact-5329671706335212AE3F5E2B75B7A4AB"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43674379e1120-wk-Fact-5329671706335212AE3F5E2B75B7A4AB"
          xlink:to="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43690878e2313-wk-Fact-5342CFBA0356578DAD0043F0EADED8C5"
          xlink:label="d43690878e2313-wk-Fact-5342CFBA0356578DAD0043F0EADED8C5"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-0333DDFA54555789BB4E2E73E3451A69-0-wk-Footnote-0333DDFA54555789BB4E2E73E3451A69_lbl" xlink:label="TextSelection-0333DDFA54555789BB4E2E73E3451A69-0-wk-Footnote-0333DDFA54555789BB4E2E73E3451A69_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">These common stock equivalents were outstanding for the periods presented, but were not included in the computation of diluted EPS for those periods because their inclusion would have had an anti-dilutive effect.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43690878e2313-wk-Fact-5342CFBA0356578DAD0043F0EADED8C5"
          xlink:to="TextSelection-0333DDFA54555789BB4E2E73E3451A69-0-wk-Footnote-0333DDFA54555789BB4E2E73E3451A69_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43690878e2313-wk-Fact-5342CFBA0356578DAD0043F0EADED8C5"
          xlink:to="TextSelection-792D3AB23D6354CFBB2776AE7F6407B4-0-wk-Footnote-792D3AB23D6354CFBB2776AE7F6407B4_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43697224e2866-wk-Fact-53CD55B10DB9D18954E05A1EF2A58668"
          xlink:label="d43697224e2866-wk-Fact-53CD55B10DB9D18954E05A1EF2A58668"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43697224e2866-wk-Fact-53CD55B10DB9D18954E05A1EF2A58668"
          xlink:to="TextSelection-066A0A390204B79351965A22CE69E761-0-wk-Footnote-066A0A390204B79351965A22CE69E761_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43697224e2866-wk-Fact-53CD55B10DB9D18954E05A1EF2A58668"
          xlink:to="TextSelection-4AF5AB391F1CD8054C065A2324C0D822-0-wk-Footnote-4AF5AB391F1CD8054C065A2324C0D822_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43692105e1198-wk-Fact-53D122DE8506544FBB5C5E66B2ABDED8"
          xlink:label="d43692105e1198-wk-Fact-53D122DE8506544FBB5C5E66B2ABDED8"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43692105e1198-wk-Fact-53D122DE8506544FBB5C5E66B2ABDED8"
          xlink:to="TextSelection-2A36E737FFF05E75B357CB41AFB5B6E2-0-wk-Footnote-2A36E737FFF05E75B357CB41AFB5B6E2_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43697224e1584-wk-Fact-53DF84C7A47DE18B0F1C5A2FEA57D70F"
          xlink:label="d43697224e1584-wk-Fact-53DF84C7A47DE18B0F1C5A2FEA57D70F"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-8C5E9E30C7EB5291A3E0EE605FC281E8-0-wk-Footnote-8C5E9E30C7EB5291A3E0EE605FC281E8_lbl" xlink:label="TextSelection-8C5E9E30C7EB5291A3E0EE605FC281E8-0-wk-Footnote-8C5E9E30C7EB5291A3E0EE605FC281E8_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">In the <xhtml:span style="font-family:inherit;font-size:8.5pt;">third quarter</xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"> and </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;">first nine months of</xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"> </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;text-align:center;">2017</xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;">, primarily includes an intangible asset impairment charge of </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"><xhtml:span>$127 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"> related to developed technology rights, acquired in connection with our acquisition of Hospira, for a generic sterile injectable product for the treatment of edema associated with certain conditions. The intangible asset impairment charge for the </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;">third</xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"> quarter and </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;">first nine months of</xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"> </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;text-align:center;">2017</xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"> is associated with EH and reflects, among other things, updated commercial forecasts and an increased competitive environment. In the </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;">third</xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"> quarter of </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;text-align:center;">2016</xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;">, primarily includes intangible asset impairment charges of </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"><xhtml:span>$126 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;">, reflecting </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"><xhtml:span>$97 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"> of sterile injectable IPR&amp;D compounds acquired in connection with our acquisition of InnoPharma and </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"><xhtml:span>$29 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"> of other IPR&amp;D assets acquired in connection with our acquisition of King in 2011. The intangible asset impairment charges for the </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;">third quarter</xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"> of </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;text-align:center;">2016</xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"> are associated with the following: EH (</xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"><xhtml:span>$97 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;">) and IH (</xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"><xhtml:span>$29 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;">). In the </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;">first nine months of</xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"> </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;text-align:center;">2016</xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;">, primarily includes intangible asset impairment charges of </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"><xhtml:span>$767 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;">, reflecting (i) </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"><xhtml:span>$331 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"> related to developed technology rights for a generic injectable antibiotic product for the treatment of bacterial infections; and (ii) </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"><xhtml:span>$265 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"> related to an IPR&amp;D compound for the treatment of anemia, both acquired in connection with our acquisition of Hospira; (iii) </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"><xhtml:span>$97 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"> of sterile injectable IPR&amp;D compounds acquired in connection with our acquisition of InnoPharma; and (iv) </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"><xhtml:span>$74 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"> of other IPR&amp;D assets, </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"><xhtml:span>$45 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"> of which were acquired in connection with our acquisition of Hospira and </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"><xhtml:span>$29 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"> of which were acquired in connection with our acquisition of King in 2011. The intangible asset impairment charges for the </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;">first nine months of</xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"> </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;text-align:center;">2016</xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"> are associated with the following: EH (</xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"><xhtml:span>$738 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;">) and IH (</xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"><xhtml:span>$29 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;">). In addition, the </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;">first nine months of</xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"> </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;text-align:center;">2016</xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"> includes an impairment loss of </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"><xhtml:span>$211 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"> related to Pfizer&#x2019;s </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"><xhtml:span>49%</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;">-owned equity-method investment with Hisun in China, Hisun Pfizer, and an impairment loss of </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"><xhtml:span>$50 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"> related to Pfizer&#x2019;s </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"><xhtml:span>40%</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;">-owned equity-method investment in Teuto. For additional information concerning Hisun Pfizer and Teuto, see </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Note 2D. </xhtml:span>The intangible asset impairment charge for 2016 for the IPR&amp;D compound for the treatment of anemia acquired in connection with our acquisition of Hospira reflects, among other things, the impact of regulatory delays, including delays resulting from a court ruling, which required a 180-day waiting period after approval before a biosimilar product can be launched. The intangible asset impairment charges for 2016 for the sterile injectable IPR&amp;D compounds acquired in connection with our acquisition of InnoPharma reflect, among other things, the impact of portfolio prioritization decisions and decreased commercial profiles of certain compounds. The intangible asset impairment charges for 2016 for developed technology rights and other IPR&amp;D assets acquired in connection with our acquisition of Hospira reflect, among other things, the impact of new scientific findings, updated commercial forecasts, changes in pricing, and an increased competitive environment. The intangible asset impairment charges for 2016 for other IPR&amp;D assets acquired in connection with our acquisition of King reflect changes in the competitive environment.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43697224e1584-wk-Fact-53DF84C7A47DE18B0F1C5A2FEA57D70F"
          xlink:to="TextSelection-8C5E9E30C7EB5291A3E0EE605FC281E8-0-wk-Footnote-8C5E9E30C7EB5291A3E0EE605FC281E8_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43697240e2085-wk-Fact-54A6BC26AA6157E19153460F2648274D"
          xlink:label="d43697240e2085-wk-Fact-54A6BC26AA6157E19153460F2648274D"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d43697240e2123-wk-Fact-54A6BC26AA6157E19153460F2648274D"
          xlink:label="d43697240e2123-wk-Fact-54A6BC26AA6157E19153460F2648274D"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-7432EEEACAB3598FA522C1D7E1584D05-0-wk-Footnote-7432EEEACAB3598FA522C1D7E1584D05_lbl" xlink:label="TextSelection-7432EEEACAB3598FA522C1D7E1584D05-0-wk-Footnote-7432EEEACAB3598FA522C1D7E1584D05_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The changes in the gross carrying amount of <xhtml:span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Developed technology rights </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;">and </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;font-style:italic;">IPR&amp;D</xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"> primarily reflect (i) the transfer of </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"><xhtml:span>$4.8 billion</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"> from </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;font-style:italic;">IPR&amp;D</xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"> to </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Developed technology rights</xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"> to reflect the approval of Eucrisa, (ii) the </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Developed technology rights</xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"> and </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;font-style:italic;">IPR&amp;D</xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"> acquired as part of the acquisition of AstraZeneca&#x2019;s small molecule anti-infectives business (see </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Note 2A</xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;">), (iii) the </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Developed technology rights</xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"> of </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"><xhtml:span>$371 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"> recorded in connection with the EU and U.S. approvals of Besponsa (see </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Note 7E</xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;">), partially offset by (iv) measurement period adjustments related to Medivation (see </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Note 2A</xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;">) and (v) impairments of </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Developed technology rights</xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"> (see </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Note 4)</xhtml:span>.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43697240e2085-wk-Fact-54A6BC26AA6157E19153460F2648274D"
          xlink:to="TextSelection-7432EEEACAB3598FA522C1D7E1584D05-0-wk-Footnote-7432EEEACAB3598FA522C1D7E1584D05_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43697240e2123-wk-Fact-54A6BC26AA6157E19153460F2648274D"
          xlink:to="TextSelection-7432EEEACAB3598FA522C1D7E1584D05-0-wk-Footnote-7432EEEACAB3598FA522C1D7E1584D05_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43697240e1363-wk-Fact-5609BB6BDB4E55C38CE62E60B3E67446"
          xlink:label="d43697240e1363-wk-Fact-5609BB6BDB4E55C38CE62E60B3E67446"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43697240e1363-wk-Fact-5609BB6BDB4E55C38CE62E60B3E67446"
          xlink:to="TextSelection-7432EEEACAB3598FA522C1D7E1584D05-0-wk-Footnote-7432EEEACAB3598FA522C1D7E1584D05_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687704e1029-wk-Fact-570366E89FCD5DA8ACCEEA8270C0E4C3"
          xlink:label="d43687704e1029-wk-Fact-570366E89FCD5DA8ACCEEA8270C0E4C3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e1029-wk-Fact-570366E89FCD5DA8ACCEEA8270C0E4C3"
          xlink:to="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e1029-wk-Fact-570366E89FCD5DA8ACCEEA8270C0E4C3"
          xlink:to="TextSelection-AE19F19C6AE65BBDA7F551089E2E7EDF-0-wk-Footnote-AE19F19C6AE65BBDA7F551089E2E7EDF_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e11263-wk-Fact-57780600A4525A59B0F30E20473A845F"
          xlink:label="d43770747e11263-wk-Fact-57780600A4525A59B0F30E20473A845F"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e11263-wk-Fact-57780600A4525A59B0F30E20473A845F"
          xlink:to="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e11263-wk-Fact-57780600A4525A59B0F30E20473A845F"
          xlink:to="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687849e1197-wk-Fact-579A851CE2B25899921158748034540F"
          xlink:label="d43687849e1197-wk-Fact-579A851CE2B25899921158748034540F"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e1197-wk-Fact-579A851CE2B25899921158748034540F"
          xlink:to="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e5647-wk-Fact-57AB6949DEF75EA6A568EF9676344801"
          xlink:label="d43770747e5647-wk-Fact-57AB6949DEF75EA6A568EF9676344801"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e5647-wk-Fact-57AB6949DEF75EA6A568EF9676344801"
          xlink:to="TextSelection-0BDE8CEE983B5F118E2EFACDF9CC6405-0-wk-Footnote-0BDE8CEE983B5F118E2EFACDF9CC6405_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43771853e1694-wk-Fact-57E8C529F5385E41A7B3E91CFC576F36"
          xlink:label="d43771853e1694-wk-Fact-57E8C529F5385E41A7B3E91CFC576F36"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e1694-wk-Fact-57E8C529F5385E41A7B3E91CFC576F36"
          xlink:to="TextSelection-13C3E50268A15908A8AC9D1B6C938D2D-0-wk-Footnote-13C3E50268A15908A8AC9D1B6C938D2D_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e1694-wk-Fact-57E8C529F5385E41A7B3E91CFC576F36"
          xlink:to="TextSelection-78FC5AB8EFAB585E87BBCF93BE9FBF1D-0-wk-Footnote-78FC5AB8EFAB585E87BBCF93BE9FBF1D_lbl"
          xlink:type="arc"/>
        <link:footnote id="TextSelection-C2AA3A20AB3F54349FC86854E44E1000-0-wk-Footnote-C2AA3A20AB3F54349FC86854E44E1000_lbl" xlink:label="TextSelection-C2AA3A20AB3F54349FC86854E44E1000-0-wk-Footnote-C2AA3A20AB3F54349FC86854E44E1000_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Other business activities includes the costs managed by our WRD and GPD organizations. Effective in the first quarter of <xhtml:span style="font-family:inherit;font-size:8pt;text-align:center;">2017</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">, Medical, previously reported as part of Other Business Activities, was reclassified to Corporate. We have reclassified approximately </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"><xhtml:span>$33 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> and </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"><xhtml:span>$94 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> of costs from Other Business Activities to Corporate in the </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">third quarter</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> and </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;">first nine months of</xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;"> </xhtml:span><xhtml:span style="font-family:inherit;font-size:8pt;text-align:center;">2016</xhtml:span>, respectively, to conform to the current period presentation.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e1694-wk-Fact-57E8C529F5385E41A7B3E91CFC576F36"
          xlink:to="TextSelection-C2AA3A20AB3F54349FC86854E44E1000-0-wk-Footnote-C2AA3A20AB3F54349FC86854E44E1000_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687704e2321-wk-Fact-57FC3ED392B859D78861D64EC5C88CB0"
          xlink:label="d43687704e2321-wk-Fact-57FC3ED392B859D78861D64EC5C88CB0"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e2321-wk-Fact-57FC3ED392B859D78861D64EC5C88CB0"
          xlink:to="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e2321-wk-Fact-57FC3ED392B859D78861D64EC5C88CB0"
          xlink:to="TextSelection-9231AC55B8EC5775BC4995B0797F870F-0-wk-Footnote-9231AC55B8EC5775BC4995B0797F870F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e7701-wk-Fact-581448B02BB95042932A4BD0D7479AFE"
          xlink:label="d43770747e7701-wk-Fact-581448B02BB95042932A4BD0D7479AFE"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e7701-wk-Fact-581448B02BB95042932A4BD0D7479AFE"
          xlink:to="TextSelection-39CF024D03225486829869F6CA02C00E-0-wk-Footnote-39CF024D03225486829869F6CA02C00E_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e7701-wk-Fact-581448B02BB95042932A4BD0D7479AFE"
          xlink:to="TextSelection-53BB8CAFCA475C0C9DB2195050D36025-0-wk-Footnote-53BB8CAFCA475C0C9DB2195050D36025_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e7701-wk-Fact-581448B02BB95042932A4BD0D7479AFE"
          xlink:to="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43712496e1412-wk-Fact-5902E7F7E3325E0295E9C62DFD622D3E"
          xlink:label="d43712496e1412-wk-Fact-5902E7F7E3325E0295E9C62DFD622D3E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43712496e1412-wk-Fact-5902E7F7E3325E0295E9C62DFD622D3E"
          xlink:to="TextSelection-B57619F44FCF544D96067CF4816A9082-0-wk-Footnote-B57619F44FCF544D96067CF4816A9082_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687849e2717-wk-Fact-5950DF108F195FB594A31172740C60B3"
          xlink:label="d43687849e2717-wk-Fact-5950DF108F195FB594A31172740C60B3"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d43691920e2585-wk-Fact-5950DF108F195FB594A31172740C60B3"
          xlink:label="d43691920e2585-wk-Fact-5950DF108F195FB594A31172740C60B3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43691920e2585-wk-Fact-5950DF108F195FB594A31172740C60B3"
          xlink:to="TextSelection-2A0DF68DD6E953419D1E9B1C848DB228-0-wk-Footnote-2A0DF68DD6E953419D1E9B1C848DB228_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e2717-wk-Fact-5950DF108F195FB594A31172740C60B3"
          xlink:to="TextSelection-2A0DF68DD6E953419D1E9B1C848DB228-0-wk-Footnote-2A0DF68DD6E953419D1E9B1C848DB228_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43691920e2585-wk-Fact-5950DF108F195FB594A31172740C60B3"
          xlink:to="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e2717-wk-Fact-5950DF108F195FB594A31172740C60B3"
          xlink:to="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e4326-wk-Fact-59CF56CBCF3D5BF18E0D45DDA6F642AA"
          xlink:label="d43770747e4326-wk-Fact-59CF56CBCF3D5BF18E0D45DDA6F642AA"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e4326-wk-Fact-59CF56CBCF3D5BF18E0D45DDA6F642AA"
          xlink:to="TextSelection-2BFD6C99096B50AD93705C5601B21F46-0-wk-Footnote-2BFD6C99096B50AD93705C5601B21F46_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e11172-wk-Fact-59D88BD8C3615E16ADCBC18168C4F03C"
          xlink:label="d43770747e11172-wk-Fact-59D88BD8C3615E16ADCBC18168C4F03C"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e11172-wk-Fact-59D88BD8C3615E16ADCBC18168C4F03C"
          xlink:to="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e11172-wk-Fact-59D88BD8C3615E16ADCBC18168C4F03C"
          xlink:to="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43674379e1828-wk-Fact-5A2D57F680925DEC8A9CCA1553046941"
          xlink:label="d43674379e1828-wk-Fact-5A2D57F680925DEC8A9CCA1553046941"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43674379e1828-wk-Fact-5A2D57F680925DEC8A9CCA1553046941"
          xlink:to="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43674379e2139-wk-Fact-5A59BE776E6E5E20B8346BDFE1D63D1D"
          xlink:label="d43674379e2139-wk-Fact-5A59BE776E6E5E20B8346BDFE1D63D1D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43674379e2139-wk-Fact-5A59BE776E6E5E20B8346BDFE1D63D1D"
          xlink:to="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e2980-wk-Fact-5AA4AF01AEF35754AABE41FB942D2F87"
          xlink:label="d43770747e2980-wk-Fact-5AA4AF01AEF35754AABE41FB942D2F87"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-D60DE89EECC65B759281157686B85E20-0-wk-Footnote-D60DE89EECC65B759281157686B85E20_lbl" xlink:label="TextSelection-D60DE89EECC65B759281157686B85E20-0-wk-Footnote-D60DE89EECC65B759281157686B85E20_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">As of <xhtml:span style="font-family:inherit;font-size:9pt;">October&#160;1, 2017</xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;">, derivative instruments at fair value include interest rate swaps (</xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;"><xhtml:span>$532 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;">), foreign currency swaps (</xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;"><xhtml:span>$6 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;">) and foreign currency forward-exchange contracts (</xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;"><xhtml:span>$5 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;">) and, as of </xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;text-align:center;">December&#160;31, 2016</xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;">, include interest rate swaps (</xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;"><xhtml:span>$599 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;">), foreign currency swaps (</xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;"><xhtml:span>$36 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;">) and foreign currency forward-exchange contracts (</xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;"><xhtml:span>$54 million</xhtml:span></xhtml:span>).</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e2980-wk-Fact-5AA4AF01AEF35754AABE41FB942D2F87"
          xlink:to="TextSelection-D60DE89EECC65B759281157686B85E20-0-wk-Footnote-D60DE89EECC65B759281157686B85E20_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43681613e1653-wk-Fact-5AFE9DE44AC65078B297BF4B6B39C511"
          xlink:label="d43681613e1653-wk-Fact-5AFE9DE44AC65078B297BF4B6B39C511"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43681613e1653-wk-Fact-5AFE9DE44AC65078B297BF4B6B39C511"
          xlink:to="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43697240e3270-wk-Fact-5B921CA5279853B595C111072F4FBA7F"
          xlink:label="d43697240e3270-wk-Fact-5B921CA5279853B595C111072F4FBA7F"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-73987C5EBB9C5D43BC69B77F006C18A6-0-wk-Footnote-73987C5EBB9C5D43BC69B77F006C18A6_lbl" xlink:label="TextSelection-73987C5EBB9C5D43BC69B77F006C18A6-0-wk-Footnote-73987C5EBB9C5D43BC69B77F006C18A6_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Primarily reflects the impact of foreign exchange and an adjustment of our estimate of goodwill associated with the HIS net assets sold.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43697240e3270-wk-Fact-5B921CA5279853B595C111072F4FBA7F"
          xlink:to="TextSelection-73987C5EBB9C5D43BC69B77F006C18A6-0-wk-Footnote-73987C5EBB9C5D43BC69B77F006C18A6_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43771853e4552-wk-Fact-5BB441E685D3543B8C59407802A0ACC5"
          xlink:label="d43771853e4552-wk-Fact-5BB441E685D3543B8C59407802A0ACC5"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e4552-wk-Fact-5BB441E685D3543B8C59407802A0ACC5"
          xlink:to="TextSelection-3802305E73EB52F28FAAF4EA5481D580-0-wk-Footnote-3802305E73EB52F28FAAF4EA5481D580_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687849e2416-wk-Fact-5BC61B13CAF15E29B03835EA44B618DD"
          xlink:label="d43687849e2416-wk-Fact-5BC61B13CAF15E29B03835EA44B618DD"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e2416-wk-Fact-5BC61B13CAF15E29B03835EA44B618DD"
          xlink:to="TextSelection-77536863BCE35B419E3A4119D41DB4BD-0-wk-Footnote-77536863BCE35B419E3A4119D41DB4BD_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e2416-wk-Fact-5BC61B13CAF15E29B03835EA44B618DD"
          xlink:to="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687849e3182-wk-Fact-5CD3245395AF57768A6DF8D7BDF6B0BB"
          xlink:label="d43687849e3182-wk-Fact-5CD3245395AF57768A6DF8D7BDF6B0BB"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e3182-wk-Fact-5CD3245395AF57768A6DF8D7BDF6B0BB"
          xlink:to="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43690878e1215-wk-Fact-5CD97DE05A495D5EAFB1D7B5FE4550A4"
          xlink:label="d43690878e1215-wk-Fact-5CD97DE05A495D5EAFB1D7B5FE4550A4"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43690878e1215-wk-Fact-5CD97DE05A495D5EAFB1D7B5FE4550A4"
          xlink:to="TextSelection-792D3AB23D6354CFBB2776AE7F6407B4-0-wk-Footnote-792D3AB23D6354CFBB2776AE7F6407B4_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43681613e2150-wk-Fact-5D13F9FBBDEE52528006AA947B5F7E3A"
          xlink:label="d43681613e2150-wk-Fact-5D13F9FBBDEE52528006AA947B5F7E3A"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43681613e2150-wk-Fact-5D13F9FBBDEE52528006AA947B5F7E3A"
          xlink:to="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43712496e1329-wk-Fact-5D501002D38D5167AA036C63DF82035D"
          xlink:label="d43712496e1329-wk-Fact-5D501002D38D5167AA036C63DF82035D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43712496e1329-wk-Fact-5D501002D38D5167AA036C63DF82035D"
          xlink:to="TextSelection-B57619F44FCF544D96067CF4816A9082-0-wk-Footnote-B57619F44FCF544D96067CF4816A9082_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e10927-wk-Fact-5D5B1229DA1A57F080E4C581EAE83373"
          xlink:label="d43770747e10927-wk-Fact-5D5B1229DA1A57F080E4C581EAE83373"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e10927-wk-Fact-5D5B1229DA1A57F080E4C581EAE83373"
          xlink:to="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e10927-wk-Fact-5D5B1229DA1A57F080E4C581EAE83373"
          xlink:to="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43712496e3341-wk-Fact-5E7B2FD2D8475DEA875CCD41E3E715EF"
          xlink:label="d43712496e3341-wk-Fact-5E7B2FD2D8475DEA875CCD41E3E715EF"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43712496e3341-wk-Fact-5E7B2FD2D8475DEA875CCD41E3E715EF"
          xlink:to="TextSelection-02609C62928C5D1CBFB6DD071D9D7B0E-0-wk-Footnote-02609C62928C5D1CBFB6DD071D9D7B0E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43712496e2484-wk-Fact-5EA1B375EFA75241A699CD076C5A9E06"
          xlink:label="d43712496e2484-wk-Fact-5EA1B375EFA75241A699CD076C5A9E06"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43712496e2484-wk-Fact-5EA1B375EFA75241A699CD076C5A9E06"
          xlink:to="TextSelection-C37CD88178CA35C475D25A62F2B54FED-0-wk-Footnote-C37CD88178CA35C475D25A62F2B54FED_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43712496e1517-wk-Fact-5EA5FA662B4B55B598D62154953933DD"
          xlink:label="d43712496e1517-wk-Fact-5EA5FA662B4B55B598D62154953933DD"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-6912797A078E5D59B618DFFBB81C1BB6-0-wk-Footnote-6912797A078E5D59B618DFFBB81C1BB6_lbl" xlink:label="TextSelection-6912797A078E5D59B618DFFBB81C1BB6-0-wk-Footnote-6912797A078E5D59B618DFFBB81C1BB6_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Transaction costs represent external costs for banking, legal, accounting and other similar services, which in the <xhtml:span style="font-family:inherit;font-size:9pt;">third quarter</xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;"> of 2017 reflect the reversal of an accrual related to the acquisition of Medivation. Transaction costs for the </xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;">first nine months of</xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;"> </xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;text-align:center;">2017</xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;"> are directly related to our acquisitions of Hospira, Anacor and Medivation. Transaction costs in the </xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;">third quarter</xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;"> of </xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;text-align:center;">2016</xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;"> were mostly related to the Medivation acquisition, and in the </xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;">first nine months of</xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;"> </xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;text-align:center;">2016</xhtml:span>, were mostly related to the Medivation and Anacor acquisitions, and our terminated transaction with Allergan.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43712496e1517-wk-Fact-5EA5FA662B4B55B598D62154953933DD"
          xlink:to="TextSelection-6912797A078E5D59B618DFFBB81C1BB6-0-wk-Footnote-6912797A078E5D59B618DFFBB81C1BB6_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43712496e1185-wk-Fact-5EB5BCA88A6D540EBCA8B56A37E73824"
          xlink:label="d43712496e1185-wk-Fact-5EB5BCA88A6D540EBCA8B56A37E73824"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43712496e1185-wk-Fact-5EB5BCA88A6D540EBCA8B56A37E73824"
          xlink:to="TextSelection-B57619F44FCF544D96067CF4816A9082-0-wk-Footnote-B57619F44FCF544D96067CF4816A9082_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43697224e1216-wk-Fact-5EDED3CDB1965C449739DBF427B7E981"
          xlink:label="d43697224e1216-wk-Fact-5EDED3CDB1965C449739DBF427B7E981"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-7679A63ACE625532ADFCC5B97C6C9FC6-0-wk-Footnote-7679A63ACE625532ADFCC5B97C6C9FC6_lbl" xlink:label="TextSelection-7679A63ACE625532ADFCC5B97C6C9FC6-0-wk-Footnote-7679A63ACE625532ADFCC5B97C6C9FC6_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Royalty-related income <xhtml:span style="font-family:inherit;font-size:8.5pt;">decreased</xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"> in the </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;">third</xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"> quarter and </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;">first nine months of</xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"> </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;text-align:center;">2017</xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;">, primarily due to lower royalty income for Enbrel of </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"><xhtml:span>$139 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"> and </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"><xhtml:span>$414 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;">, respectively, resulting from the expiration on October 31, 2016 of the </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;">36</xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;">-month royalty period under the collaboration agreement for Enbrel in the U.S. and Canada (the collaboration period under the agreement expired on October 31, 2013), partially offset by the addition of Xtandi royalty-related income of </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"><xhtml:span>$73 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"> and </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"><xhtml:span>$160 million</xhtml:span></xhtml:span>, respectively.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43697224e1216-wk-Fact-5EDED3CDB1965C449739DBF427B7E981"
          xlink:to="TextSelection-7679A63ACE625532ADFCC5B97C6C9FC6-0-wk-Footnote-7679A63ACE625532ADFCC5B97C6C9FC6_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43697224e1546-wk-Fact-5F0338CD4AAEEBC4E9D45A2FEA4E4512"
          xlink:label="d43697224e1546-wk-Fact-5F0338CD4AAEEBC4E9D45A2FEA4E4512"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43697224e1546-wk-Fact-5F0338CD4AAEEBC4E9D45A2FEA4E4512"
          xlink:to="TextSelection-8C5E9E30C7EB5291A3E0EE605FC281E8-0-wk-Footnote-8C5E9E30C7EB5291A3E0EE605FC281E8_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43712496e2362-wk-Fact-5F3BEDE745975795948CDC9485283B89"
          xlink:label="d43712496e2362-wk-Fact-5F3BEDE745975795948CDC9485283B89"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43712496e2362-wk-Fact-5F3BEDE745975795948CDC9485283B89"
          xlink:to="TextSelection-C37CD88178CA35C475D25A62F2B54FED-0-wk-Footnote-C37CD88178CA35C475D25A62F2B54FED_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43771853e11484-wk-Fact-5F6DD21DF11E5B29871B857CC403739A"
          xlink:label="d43771853e11484-wk-Fact-5F6DD21DF11E5B29871B857CC403739A"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e11484-wk-Fact-5F6DD21DF11E5B29871B857CC403739A"
          xlink:to="TextSelection-450A7304FB7E513FB479F6D9A06EF1D3-0-wk-Footnote-450A7304FB7E513FB479F6D9A06EF1D3_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687849e2807-wk-Fact-5FA838CDA13D589CA9003C05768C2A3F"
          xlink:label="d43687849e2807-wk-Fact-5FA838CDA13D589CA9003C05768C2A3F"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e2807-wk-Fact-5FA838CDA13D589CA9003C05768C2A3F"
          xlink:to="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687704e1404-wk-Fact-5FBAE33C336F53F48E8FF7CDE77BBB26"
          xlink:label="d43687704e1404-wk-Fact-5FBAE33C336F53F48E8FF7CDE77BBB26"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d43712496e1724-wk-Fact-5FBAE33C336F53F48E8FF7CDE77BBB26"
          xlink:label="d43712496e1724-wk-Fact-5FBAE33C336F53F48E8FF7CDE77BBB26"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e1404-wk-Fact-5FBAE33C336F53F48E8FF7CDE77BBB26"
          xlink:to="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43712496e1724-wk-Fact-5FBAE33C336F53F48E8FF7CDE77BBB26"
          xlink:to="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43771853e2107-wk-Fact-5FBB1F07246D5AAFB10CAD5C2A396D68"
          xlink:label="d43771853e2107-wk-Fact-5FBB1F07246D5AAFB10CAD5C2A396D68"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e2107-wk-Fact-5FBB1F07246D5AAFB10CAD5C2A396D68"
          xlink:to="TextSelection-78FC5AB8EFAB585E87BBCF93BE9FBF1D-0-wk-Footnote-78FC5AB8EFAB585E87BBCF93BE9FBF1D_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e2107-wk-Fact-5FBB1F07246D5AAFB10CAD5C2A396D68"
          xlink:to="TextSelection-8540AADB45BE54D38C10451BF6A88AB4-0-wk-Footnote-8540AADB45BE54D38C10451BF6A88AB4_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687849e3035-wk-Fact-5FD229EF81AC578B949A3DF35BCE1FF6"
          xlink:label="d43687849e3035-wk-Fact-5FD229EF81AC578B949A3DF35BCE1FF6"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e3035-wk-Fact-5FD229EF81AC578B949A3DF35BCE1FF6"
          xlink:to="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e11070-wk-Fact-604E73BB58B354A8BE73520A47D45028"
          xlink:label="d43770747e11070-wk-Fact-604E73BB58B354A8BE73520A47D45028"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e11070-wk-Fact-604E73BB58B354A8BE73520A47D45028"
          xlink:to="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e11070-wk-Fact-604E73BB58B354A8BE73520A47D45028"
          xlink:to="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687704e1571-wk-Fact-6056A2295D7857F1915F488C04BDB11A"
          xlink:label="d43687704e1571-wk-Fact-6056A2295D7857F1915F488C04BDB11A"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d43771853e3671-wk-Fact-6056A2295D7857F1915F488C04BDB11A"
          xlink:label="d43771853e3671-wk-Fact-6056A2295D7857F1915F488C04BDB11A"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e3671-wk-Fact-6056A2295D7857F1915F488C04BDB11A"
          xlink:to="TextSelection-78FC5AB8EFAB585E87BBCF93BE9FBF1D-0-wk-Footnote-78FC5AB8EFAB585E87BBCF93BE9FBF1D_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e1571-wk-Fact-6056A2295D7857F1915F488C04BDB11A"
          xlink:to="TextSelection-78FC5AB8EFAB585E87BBCF93BE9FBF1D-0-wk-Footnote-78FC5AB8EFAB585E87BBCF93BE9FBF1D_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e3671-wk-Fact-6056A2295D7857F1915F488C04BDB11A"
          xlink:to="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e1571-wk-Fact-6056A2295D7857F1915F488C04BDB11A"
          xlink:to="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687704e1805-wk-Fact-60867BC7B4C25795A91A0C8BA6B7BDAB"
          xlink:label="d43687704e1805-wk-Fact-60867BC7B4C25795A91A0C8BA6B7BDAB"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d43690878e1485-wk-Fact-60867BC7B4C25795A91A0C8BA6B7BDAB"
          xlink:label="d43690878e1485-wk-Fact-60867BC7B4C25795A91A0C8BA6B7BDAB"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43690878e1485-wk-Fact-60867BC7B4C25795A91A0C8BA6B7BDAB"
          xlink:to="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e1805-wk-Fact-60867BC7B4C25795A91A0C8BA6B7BDAB"
          xlink:to="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e863-wk-Fact-60F0DB778C3D556896B02410EB2C0B1B"
          xlink:label="d43770747e863-wk-Fact-60F0DB778C3D556896B02410EB2C0B1B"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e863-wk-Fact-60F0DB778C3D556896B02410EB2C0B1B"
          xlink:to="TextSelection-8D2A93033C2E56DE9E814F0AB36328EE-0-wk-Footnote-8D2A93033C2E56DE9E814F0AB36328EE_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e863-wk-Fact-60F0DB778C3D556896B02410EB2C0B1B"
          xlink:to="TextSelection-E96B3A139CCA56EC98329BC3717B10E3-0-wk-Footnote-E96B3A139CCA56EC98329BC3717B10E3_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e907-wk-Fact-6118811AB2DE5F6BA426EF1F188FBC53"
          xlink:label="d43770747e907-wk-Fact-6118811AB2DE5F6BA426EF1F188FBC53"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e907-wk-Fact-6118811AB2DE5F6BA426EF1F188FBC53"
          xlink:to="TextSelection-8D2A93033C2E56DE9E814F0AB36328EE-0-wk-Footnote-8D2A93033C2E56DE9E814F0AB36328EE_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687849e1434-wk-Fact-61418F4200B850038486B4BEDFA4FA9E"
          xlink:label="d43687849e1434-wk-Fact-61418F4200B850038486B4BEDFA4FA9E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e1434-wk-Fact-61418F4200B850038486B4BEDFA4FA9E"
          xlink:to="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43771853e9297-wk-Fact-61AE31A35DC45F109F24557407C6BF9E"
          xlink:label="d43771853e9297-wk-Fact-61AE31A35DC45F109F24557407C6BF9E"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-08466783230155A08D7C13267B950D39-0-wk-Footnote-08466783230155A08D7C13267B950D39_lbl" xlink:label="TextSelection-08466783230155A08D7C13267B950D39-0-wk-Footnote-08466783230155A08D7C13267B950D39_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Sterile Injectable Pharmaceuticals include generic injectables and proprietary specialty injectables (excluding Peri-LOE Products). </link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e9297-wk-Fact-61AE31A35DC45F109F24557407C6BF9E"
          xlink:to="TextSelection-08466783230155A08D7C13267B950D39-0-wk-Footnote-08466783230155A08D7C13267B950D39_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e8112-wk-Fact-620EDDBB2E7E58FE85B15DE61C5EDD21"
          xlink:label="d43770747e8112-wk-Fact-620EDDBB2E7E58FE85B15DE61C5EDD21"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e8112-wk-Fact-620EDDBB2E7E58FE85B15DE61C5EDD21"
          xlink:to="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e8112-wk-Fact-620EDDBB2E7E58FE85B15DE61C5EDD21"
          xlink:to="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687849e1538-wk-Fact-6246160B22DB5F86A702C0FDC31AEA8A"
          xlink:label="d43687849e1538-wk-Fact-6246160B22DB5F86A702C0FDC31AEA8A"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e1538-wk-Fact-6246160B22DB5F86A702C0FDC31AEA8A"
          xlink:to="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e4222-wk-Fact-626B15D2B1215E4FBC1B22217ABF166E"
          xlink:label="d43770747e4222-wk-Fact-626B15D2B1215E4FBC1B22217ABF166E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e4222-wk-Fact-626B15D2B1215E4FBC1B22217ABF166E"
          xlink:to="TextSelection-2BFD6C99096B50AD93705C5601B21F46-0-wk-Footnote-2BFD6C99096B50AD93705C5601B21F46_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687704e1657-wk-Fact-626C408AD0435F32862D27637DFEBF9C"
          xlink:label="d43687704e1657-wk-Fact-626C408AD0435F32862D27637DFEBF9C"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e1657-wk-Fact-626C408AD0435F32862D27637DFEBF9C"
          xlink:to="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e1657-wk-Fact-626C408AD0435F32862D27637DFEBF9C"
          xlink:to="TextSelection-9231AC55B8EC5775BC4995B0797F870F-0-wk-Footnote-9231AC55B8EC5775BC4995B0797F870F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687849e1775-wk-Fact-627842F5F2E15231B3D26A535F4705CA"
          xlink:label="d43687849e1775-wk-Fact-627842F5F2E15231B3D26A535F4705CA"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e1775-wk-Fact-627842F5F2E15231B3D26A535F4705CA"
          xlink:to="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43771853e11419-wk-Fact-6313B867BAC65FC1A4718632BEF06E26"
          xlink:label="d43771853e11419-wk-Fact-6313B867BAC65FC1A4718632BEF06E26"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e11419-wk-Fact-6313B867BAC65FC1A4718632BEF06E26"
          xlink:to="TextSelection-DE7EF4A6663E52BF8D3620854A57A945-0-wk-Footnote-DE7EF4A6663E52BF8D3620854A57A945_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43712496e1284-wk-Fact-632EFDC664F45A20BEB9A47C3FEE1B4D"
          xlink:label="d43712496e1284-wk-Fact-632EFDC664F45A20BEB9A47C3FEE1B4D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43712496e1284-wk-Fact-632EFDC664F45A20BEB9A47C3FEE1B4D"
          xlink:to="TextSelection-1B1FEAD5EA4E576891141CE7B2D9386E-0-wk-Footnote-1B1FEAD5EA4E576891141CE7B2D9386E_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43712496e1284-wk-Fact-632EFDC664F45A20BEB9A47C3FEE1B4D"
          xlink:to="TextSelection-B57619F44FCF544D96067CF4816A9082-0-wk-Footnote-B57619F44FCF544D96067CF4816A9082_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43674379e2272-wk-Fact-63822E0DBF7E5CA2BB97325B6C3209EA"
          xlink:label="d43674379e2272-wk-Fact-63822E0DBF7E5CA2BB97325B6C3209EA"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43674379e2272-wk-Fact-63822E0DBF7E5CA2BB97325B6C3209EA"
          xlink:to="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687704e3056-wk-Fact-63E834283E2059E3A8C189B4778885B0"
          xlink:label="d43687704e3056-wk-Fact-63E834283E2059E3A8C189B4778885B0"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d43690878e2054-wk-Fact-63E834283E2059E3A8C189B4778885B0"
          xlink:label="d43690878e2054-wk-Fact-63E834283E2059E3A8C189B4778885B0"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e3056-wk-Fact-63E834283E2059E3A8C189B4778885B0"
          xlink:to="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43690878e2054-wk-Fact-63E834283E2059E3A8C189B4778885B0"
          xlink:to="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43771853e10256-wk-Fact-65EF603C04E95A788234DDAF3AC7D0D3"
          xlink:label="d43771853e10256-wk-Fact-65EF603C04E95A788234DDAF3AC7D0D3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e10256-wk-Fact-65EF603C04E95A788234DDAF3AC7D0D3"
          xlink:to="TextSelection-DE7EF4A6663E52BF8D3620854A57A945-0-wk-Footnote-DE7EF4A6663E52BF8D3620854A57A945_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43697224e1324-wk-Fact-66565D977AC4509C90AB6F21D06331BE"
          xlink:label="d43697224e1324-wk-Fact-66565D977AC4509C90AB6F21D06331BE"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43697224e1324-wk-Fact-66565D977AC4509C90AB6F21D06331BE"
          xlink:to="TextSelection-7430C81CDF35536B95DB492D56AB6CFD-0-wk-Footnote-7430C81CDF35536B95DB492D56AB6CFD_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687704e2803-wk-Fact-669021DA4A3E525F9913592D2FD04D72"
          xlink:label="d43687704e2803-wk-Fact-669021DA4A3E525F9913592D2FD04D72"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e2803-wk-Fact-669021DA4A3E525F9913592D2FD04D72"
          xlink:to="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e2803-wk-Fact-669021DA4A3E525F9913592D2FD04D72"
          xlink:to="TextSelection-9231AC55B8EC5775BC4995B0797F870F-0-wk-Footnote-9231AC55B8EC5775BC4995B0797F870F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43697224e2943-wk-Fact-66BA540C016377984D0B5A1F012CEDE6"
          xlink:label="d43697224e2943-wk-Fact-66BA540C016377984D0B5A1F012CEDE6"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43697224e2943-wk-Fact-66BA540C016377984D0B5A1F012CEDE6"
          xlink:to="TextSelection-066A0A390204B79351965A22CE69E761-0-wk-Footnote-066A0A390204B79351965A22CE69E761_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43712496e2464-wk-Fact-66E019D2BC3C5C3C98FDC370D9EE61F3"
          xlink:label="d43712496e2464-wk-Fact-66E019D2BC3C5C3C98FDC370D9EE61F3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43712496e2464-wk-Fact-66E019D2BC3C5C3C98FDC370D9EE61F3"
          xlink:to="TextSelection-C37CD88178CA35C475D25A62F2B54FED-0-wk-Footnote-C37CD88178CA35C475D25A62F2B54FED_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687849e2690-wk-Fact-672E389254015A85B0E497DA6B98ED65"
          xlink:label="d43687849e2690-wk-Fact-672E389254015A85B0E497DA6B98ED65"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e2690-wk-Fact-672E389254015A85B0E497DA6B98ED65"
          xlink:to="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e926-wk-Fact-672E844C4F3953138ADA20A9FE757D32"
          xlink:label="d43770747e926-wk-Fact-672E844C4F3953138ADA20A9FE757D32"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e926-wk-Fact-672E844C4F3953138ADA20A9FE757D32"
          xlink:to="TextSelection-8D2A93033C2E56DE9E814F0AB36328EE-0-wk-Footnote-8D2A93033C2E56DE9E814F0AB36328EE_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43771853e10236-wk-Fact-67696AFA82F051C9ADF09241496CA1F1"
          xlink:label="d43771853e10236-wk-Fact-67696AFA82F051C9ADF09241496CA1F1"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e10236-wk-Fact-67696AFA82F051C9ADF09241496CA1F1"
          xlink:to="TextSelection-DE7EF4A6663E52BF8D3620854A57A945-0-wk-Footnote-DE7EF4A6663E52BF8D3620854A57A945_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e10972-wk-Fact-67797DE457375667B2C84DC5692034E9"
          xlink:label="d43770747e10972-wk-Fact-67797DE457375667B2C84DC5692034E9"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e10972-wk-Fact-67797DE457375667B2C84DC5692034E9"
          xlink:to="TextSelection-39CF024D03225486829869F6CA02C00E-0-wk-Footnote-39CF024D03225486829869F6CA02C00E_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e10972-wk-Fact-67797DE457375667B2C84DC5692034E9"
          xlink:to="TextSelection-53BB8CAFCA475C0C9DB2195050D36025-0-wk-Footnote-53BB8CAFCA475C0C9DB2195050D36025_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e10972-wk-Fact-67797DE457375667B2C84DC5692034E9"
          xlink:to="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43712510e4978-wk-Fact-680AB021A9D85E21AC0D650674666D7F"
          xlink:label="d43712510e4978-wk-Fact-680AB021A9D85E21AC0D650674666D7F"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43712510e4978-wk-Fact-680AB021A9D85E21AC0D650674666D7F"
          xlink:to="TextSelection-621F9196966C550EA113DA57575C171E-0-wk-Footnote-621F9196966C550EA113DA57575C171E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43674379e1032-wk-Fact-686063BE60325E2A839CE026F903431A"
          xlink:label="d43674379e1032-wk-Fact-686063BE60325E2A839CE026F903431A"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43674379e1032-wk-Fact-686063BE60325E2A839CE026F903431A"
          xlink:to="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687849e2307-wk-Fact-6866C3FD323B5B328644E3617D27748F"
          xlink:label="d43687849e2307-wk-Fact-6866C3FD323B5B328644E3617D27748F"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e2307-wk-Fact-6866C3FD323B5B328644E3617D27748F"
          xlink:to="TextSelection-77536863BCE35B419E3A4119D41DB4BD-0-wk-Footnote-77536863BCE35B419E3A4119D41DB4BD_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e2307-wk-Fact-6866C3FD323B5B328644E3617D27748F"
          xlink:to="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43674379e1278-wk-Fact-691B87100C6755EB85765E65D5C328BA"
          xlink:label="d43674379e1278-wk-Fact-691B87100C6755EB85765E65D5C328BA"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d43697240e3378-wk-Fact-691B87100C6755EB85765E65D5C328BA"
          xlink:label="d43697240e3378-wk-Fact-691B87100C6755EB85765E65D5C328BA"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43674379e1278-wk-Fact-691B87100C6755EB85765E65D5C328BA"
          xlink:to="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43697240e3378-wk-Fact-691B87100C6755EB85765E65D5C328BA"
          xlink:to="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43681613e1173-wk-Fact-6944308547D65750B49346E97B2688A0"
          xlink:label="d43681613e1173-wk-Fact-6944308547D65750B49346E97B2688A0"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43681613e1173-wk-Fact-6944308547D65750B49346E97B2688A0"
          xlink:to="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687849e1369-wk-Fact-6968FECDFB645F1C88CC9A36C37CAA90"
          xlink:label="d43687849e1369-wk-Fact-6968FECDFB645F1C88CC9A36C37CAA90"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e1369-wk-Fact-6968FECDFB645F1C88CC9A36C37CAA90"
          xlink:to="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e1369-wk-Fact-6968FECDFB645F1C88CC9A36C37CAA90"
          xlink:to="TextSelection-F185CD45BC245C2EB8EDBFD55DB8A33F-0-wk-Footnote-F185CD45BC245C2EB8EDBFD55DB8A33F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687849e2826-wk-Fact-69A896461F495ACBB885D53F5353F71F"
          xlink:label="d43687849e2826-wk-Fact-69A896461F495ACBB885D53F5353F71F"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e2826-wk-Fact-69A896461F495ACBB885D53F5353F71F"
          xlink:to="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687704e3037-wk-Fact-69E50427EE6E533896BB8B1907041230"
          xlink:label="d43687704e3037-wk-Fact-69E50427EE6E533896BB8B1907041230"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d43690878e2035-wk-Fact-69E50427EE6E533896BB8B1907041230"
          xlink:label="d43690878e2035-wk-Fact-69E50427EE6E533896BB8B1907041230"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e3037-wk-Fact-69E50427EE6E533896BB8B1907041230"
          xlink:to="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43690878e2035-wk-Fact-69E50427EE6E533896BB8B1907041230"
          xlink:to="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43697224e1480-wk-Fact-69F129F21E2851A6981AF851D0C9DC3E"
          xlink:label="d43697224e1480-wk-Fact-69F129F21E2851A6981AF851D0C9DC3E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43697224e1480-wk-Fact-69F129F21E2851A6981AF851D0C9DC3E"
          xlink:to="TextSelection-FCAEF1B26EF652E4896D2456427B24D7-0-wk-Footnote-FCAEF1B26EF652E4896D2456427B24D7_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e1673-wk-Fact-6AAB9598D7F95613809C632062D37B56"
          xlink:label="d43770747e1673-wk-Fact-6AAB9598D7F95613809C632062D37B56"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e1673-wk-Fact-6AAB9598D7F95613809C632062D37B56"
          xlink:to="TextSelection-58096FF6357955D6B6AA25D56767CB0A-0-wk-Footnote-58096FF6357955D6B6AA25D56767CB0A_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e1673-wk-Fact-6AAB9598D7F95613809C632062D37B56"
          xlink:to="TextSelection-8D2A93033C2E56DE9E814F0AB36328EE-0-wk-Footnote-8D2A93033C2E56DE9E814F0AB36328EE_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43697240e3289-wk-Fact-6AC822CCA34E51E4AFF352F6B975BAEF"
          xlink:label="d43697240e3289-wk-Fact-6AC822CCA34E51E4AFF352F6B975BAEF"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43697240e3289-wk-Fact-6AC822CCA34E51E4AFF352F6B975BAEF"
          xlink:to="TextSelection-73987C5EBB9C5D43BC69B77F006C18A6-0-wk-Footnote-73987C5EBB9C5D43BC69B77F006C18A6_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43712496e1205-wk-Fact-6AEAE394B9B450FDAF7AF8A431A29CCE"
          xlink:label="d43712496e1205-wk-Fact-6AEAE394B9B450FDAF7AF8A431A29CCE"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43712496e1205-wk-Fact-6AEAE394B9B450FDAF7AF8A431A29CCE"
          xlink:to="TextSelection-B57619F44FCF544D96067CF4816A9082-0-wk-Footnote-B57619F44FCF544D96067CF4816A9082_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43712496e2298-wk-Fact-6B7573DC24D452F9A1161BC5959839D3"
          xlink:label="d43712496e2298-wk-Fact-6B7573DC24D452F9A1161BC5959839D3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43712496e2298-wk-Fact-6B7573DC24D452F9A1161BC5959839D3"
          xlink:to="TextSelection-C37CD88178CA35C475D25A62F2B54FED-0-wk-Footnote-C37CD88178CA35C475D25A62F2B54FED_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e8235-wk-Fact-6BED389587795F178A51DFB7B1F38F10"
          xlink:label="d43770747e8235-wk-Fact-6BED389587795F178A51DFB7B1F38F10"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e8235-wk-Fact-6BED389587795F178A51DFB7B1F38F10"
          xlink:to="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e8235-wk-Fact-6BED389587795F178A51DFB7B1F38F10"
          xlink:to="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687704e1551-wk-Fact-6C225350ED6F51898E27B37470C6135A"
          xlink:label="d43687704e1551-wk-Fact-6C225350ED6F51898E27B37470C6135A"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d43771853e3652-wk-Fact-6C225350ED6F51898E27B37470C6135A"
          xlink:label="d43771853e3652-wk-Fact-6C225350ED6F51898E27B37470C6135A"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e3652-wk-Fact-6C225350ED6F51898E27B37470C6135A"
          xlink:to="TextSelection-78FC5AB8EFAB585E87BBCF93BE9FBF1D-0-wk-Footnote-78FC5AB8EFAB585E87BBCF93BE9FBF1D_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e1551-wk-Fact-6C225350ED6F51898E27B37470C6135A"
          xlink:to="TextSelection-78FC5AB8EFAB585E87BBCF93BE9FBF1D-0-wk-Footnote-78FC5AB8EFAB585E87BBCF93BE9FBF1D_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e3652-wk-Fact-6C225350ED6F51898E27B37470C6135A"
          xlink:to="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e1551-wk-Fact-6C225350ED6F51898E27B37470C6135A"
          xlink:to="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43771853e1954-wk-Fact-6C4D8296C83F57DC93CF1B41EF47EFF1"
          xlink:label="d43771853e1954-wk-Fact-6C4D8296C83F57DC93CF1B41EF47EFF1"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e1954-wk-Fact-6C4D8296C83F57DC93CF1B41EF47EFF1"
          xlink:to="TextSelection-13C3E50268A15908A8AC9D1B6C938D2D-0-wk-Footnote-13C3E50268A15908A8AC9D1B6C938D2D_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e1954-wk-Fact-6C4D8296C83F57DC93CF1B41EF47EFF1"
          xlink:to="TextSelection-78FC5AB8EFAB585E87BBCF93BE9FBF1D-0-wk-Footnote-78FC5AB8EFAB585E87BBCF93BE9FBF1D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43674379e1765-wk-Fact-6C83895D828D8E3BC5AC922878C0762E"
          xlink:label="d43674379e1765-wk-Fact-6C83895D828D8E3BC5AC922878C0762E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43674379e1765-wk-Fact-6C83895D828D8E3BC5AC922878C0762E"
          xlink:to="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687704e3229-wk-Fact-6CE7E4C1FB715EB9A50793367CE85508"
          xlink:label="d43687704e3229-wk-Fact-6CE7E4C1FB715EB9A50793367CE85508"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e3229-wk-Fact-6CE7E4C1FB715EB9A50793367CE85508"
          xlink:to="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e4280-wk-Fact-6CF1FB1C274D54BC8DA1DED40575D72D"
          xlink:label="d43770747e4280-wk-Fact-6CF1FB1C274D54BC8DA1DED40575D72D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e4280-wk-Fact-6CF1FB1C274D54BC8DA1DED40575D72D"
          xlink:to="TextSelection-2BFD6C99096B50AD93705C5601B21F46-0-wk-Footnote-2BFD6C99096B50AD93705C5601B21F46_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e8255-wk-Fact-6D120F6B1B935942908A657A342EF520"
          xlink:label="d43770747e8255-wk-Fact-6D120F6B1B935942908A657A342EF520"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e8255-wk-Fact-6D120F6B1B935942908A657A342EF520"
          xlink:to="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e8255-wk-Fact-6D120F6B1B935942908A657A342EF520"
          xlink:to="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43712510e5163-wk-Fact-6D35DF163ED156B392B0ABBC405525F5"
          xlink:label="d43712510e5163-wk-Fact-6D35DF163ED156B392B0ABBC405525F5"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43712510e5163-wk-Fact-6D35DF163ED156B392B0ABBC405525F5"
          xlink:to="TextSelection-621F9196966C550EA113DA57575C171E-0-wk-Footnote-621F9196966C550EA113DA57575C171E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43697240e2028-wk-Fact-6D6000856CC75C59855BFA6956D3EBE0"
          xlink:label="d43697240e2028-wk-Fact-6D6000856CC75C59855BFA6956D3EBE0"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d43697240e2065-wk-Fact-6D6000856CC75C59855BFA6956D3EBE0"
          xlink:label="d43697240e2065-wk-Fact-6D6000856CC75C59855BFA6956D3EBE0"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43697240e2028-wk-Fact-6D6000856CC75C59855BFA6956D3EBE0"
          xlink:to="TextSelection-7432EEEACAB3598FA522C1D7E1584D05-0-wk-Footnote-7432EEEACAB3598FA522C1D7E1584D05_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43697240e2065-wk-Fact-6D6000856CC75C59855BFA6956D3EBE0"
          xlink:to="TextSelection-7432EEEACAB3598FA522C1D7E1584D05-0-wk-Footnote-7432EEEACAB3598FA522C1D7E1584D05_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e7759-wk-Fact-6E0D94B5020A54D8AA03215EBE1D7EF9"
          xlink:label="d43770747e7759-wk-Fact-6E0D94B5020A54D8AA03215EBE1D7EF9"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e7759-wk-Fact-6E0D94B5020A54D8AA03215EBE1D7EF9"
          xlink:to="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e7759-wk-Fact-6E0D94B5020A54D8AA03215EBE1D7EF9"
          xlink:to="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43674379e1366-wk-Fact-6F2B43838191546AA755245948E565C5"
          xlink:label="d43674379e1366-wk-Fact-6F2B43838191546AA755245948E565C5"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43674379e1366-wk-Fact-6F2B43838191546AA755245948E565C5"
          xlink:to="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43771853e2020-wk-Fact-701D108258D15E76898CF0E9F156AAB3"
          xlink:label="d43771853e2020-wk-Fact-701D108258D15E76898CF0E9F156AAB3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e2020-wk-Fact-701D108258D15E76898CF0E9F156AAB3"
          xlink:to="TextSelection-13C3E50268A15908A8AC9D1B6C938D2D-0-wk-Footnote-13C3E50268A15908A8AC9D1B6C938D2D_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e2020-wk-Fact-701D108258D15E76898CF0E9F156AAB3"
          xlink:to="TextSelection-78FC5AB8EFAB585E87BBCF93BE9FBF1D-0-wk-Footnote-78FC5AB8EFAB585E87BBCF93BE9FBF1D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43674379e1588-wk-Fact-708405E59C1952EAA954BB6C9B186068"
          xlink:label="d43674379e1588-wk-Fact-708405E59C1952EAA954BB6C9B186068"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43674379e1588-wk-Fact-708405E59C1952EAA954BB6C9B186068"
          xlink:to="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43674379e1415-wk-Fact-70B456CF1E475D979F768DB28C19676E"
          xlink:label="d43674379e1415-wk-Fact-70B456CF1E475D979F768DB28C19676E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43674379e1415-wk-Fact-70B456CF1E475D979F768DB28C19676E"
          xlink:to="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e2961-wk-Fact-70B840CF49ED50999728E55D1211F51E"
          xlink:label="d43770747e2961-wk-Fact-70B840CF49ED50999728E55D1211F51E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e2961-wk-Fact-70B840CF49ED50999728E55D1211F51E"
          xlink:to="TextSelection-D60DE89EECC65B759281157686B85E20-0-wk-Footnote-D60DE89EECC65B759281157686B85E20_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43690878e2139-wk-Fact-712D745DC4AA5C53A5626F7D089F61CB"
          xlink:label="d43690878e2139-wk-Fact-712D745DC4AA5C53A5626F7D089F61CB"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43690878e2139-wk-Fact-712D745DC4AA5C53A5626F7D089F61CB"
          xlink:to="TextSelection-792D3AB23D6354CFBB2776AE7F6407B4-0-wk-Footnote-792D3AB23D6354CFBB2776AE7F6407B4_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687849e2437-wk-Fact-713AA3AA57EE5FBCBD96967A8F7E9885"
          xlink:label="d43687849e2437-wk-Fact-713AA3AA57EE5FBCBD96967A8F7E9885"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e2437-wk-Fact-713AA3AA57EE5FBCBD96967A8F7E9885"
          xlink:to="TextSelection-77536863BCE35B419E3A4119D41DB4BD-0-wk-Footnote-77536863BCE35B419E3A4119D41DB4BD_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e2437-wk-Fact-713AA3AA57EE5FBCBD96967A8F7E9885"
          xlink:to="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43771853e2873-wk-Fact-713D053AAB3F543EAA3B2BC05CA14525"
          xlink:label="d43771853e2873-wk-Fact-713D053AAB3F543EAA3B2BC05CA14525"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e2873-wk-Fact-713D053AAB3F543EAA3B2BC05CA14525"
          xlink:to="TextSelection-78FC5AB8EFAB585E87BBCF93BE9FBF1D-0-wk-Footnote-78FC5AB8EFAB585E87BBCF93BE9FBF1D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43681613e1428-wk-Fact-71772D6AB77F595C866B3F8F2284E23A"
          xlink:label="d43681613e1428-wk-Fact-71772D6AB77F595C866B3F8F2284E23A"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43681613e1428-wk-Fact-71772D6AB77F595C866B3F8F2284E23A"
          xlink:to="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687849e2396-wk-Fact-719A3A5AFE7E590BA2BBA17A3393549C"
          xlink:label="d43687849e2396-wk-Fact-719A3A5AFE7E590BA2BBA17A3393549C"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e2396-wk-Fact-719A3A5AFE7E590BA2BBA17A3393549C"
          xlink:to="TextSelection-77536863BCE35B419E3A4119D41DB4BD-0-wk-Footnote-77536863BCE35B419E3A4119D41DB4BD_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e2396-wk-Fact-719A3A5AFE7E590BA2BBA17A3393549C"
          xlink:to="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43771853e1673-wk-Fact-71E7D0DF9D86563A92C28ADB4DD1F792"
          xlink:label="d43771853e1673-wk-Fact-71E7D0DF9D86563A92C28ADB4DD1F792"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e1673-wk-Fact-71E7D0DF9D86563A92C28ADB4DD1F792"
          xlink:to="TextSelection-13C3E50268A15908A8AC9D1B6C938D2D-0-wk-Footnote-13C3E50268A15908A8AC9D1B6C938D2D_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e1673-wk-Fact-71E7D0DF9D86563A92C28ADB4DD1F792"
          xlink:to="TextSelection-78FC5AB8EFAB585E87BBCF93BE9FBF1D-0-wk-Footnote-78FC5AB8EFAB585E87BBCF93BE9FBF1D_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e1673-wk-Fact-71E7D0DF9D86563A92C28ADB4DD1F792"
          xlink:to="TextSelection-C2AA3A20AB3F54349FC86854E44E1000-0-wk-Footnote-C2AA3A20AB3F54349FC86854E44E1000_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e9788-wk-Fact-721EE01F467C5AA2AF5D9ABD57151BB3"
          xlink:label="d43770747e9788-wk-Fact-721EE01F467C5AA2AF5D9ABD57151BB3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e9788-wk-Fact-721EE01F467C5AA2AF5D9ABD57151BB3"
          xlink:to="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e9788-wk-Fact-721EE01F467C5AA2AF5D9ABD57151BB3"
          xlink:to="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e8569-wk-Fact-7245AD177ECF539AA450E00174CA6B5E"
          xlink:label="d43770747e8569-wk-Fact-7245AD177ECF539AA450E00174CA6B5E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e8569-wk-Fact-7245AD177ECF539AA450E00174CA6B5E"
          xlink:to="TextSelection-39CF024D03225486829869F6CA02C00E-0-wk-Footnote-39CF024D03225486829869F6CA02C00E_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e8569-wk-Fact-7245AD177ECF539AA450E00174CA6B5E"
          xlink:to="TextSelection-53BB8CAFCA475C0C9DB2195050D36025-0-wk-Footnote-53BB8CAFCA475C0C9DB2195050D36025_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e8569-wk-Fact-7245AD177ECF539AA450E00174CA6B5E"
          xlink:to="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e4551-wk-Fact-727F9AD82CCB5AC493868224E1DEDA9B"
          xlink:label="d43770747e4551-wk-Fact-727F9AD82CCB5AC493868224E1DEDA9B"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-5259D0A3B8885FEE951D5ABCA017CBFC-0-wk-Footnote-5259D0A3B8885FEE951D5ABCA017CBFC_lbl" xlink:label="TextSelection-5259D0A3B8885FEE951D5ABCA017CBFC-0-wk-Footnote-5259D0A3B8885FEE951D5ABCA017CBFC_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Includes receivable-backed, loan-backed, and mortgage-backed securities, all of which are high quality and in senior positions in the capital structure of the security. Receivable-backed securities are collateralized by credit cards receivables, loan-backed securities are collateralized by senior secured obligations of a diverse pool of companies or student loans, and mortgage-backed securities are collateralized by diversified pools of residential and commercial mortgages.<xhtml:br/></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e4551-wk-Fact-727F9AD82CCB5AC493868224E1DEDA9B"
          xlink:to="TextSelection-5259D0A3B8885FEE951D5ABCA017CBFC-0-wk-Footnote-5259D0A3B8885FEE951D5ABCA017CBFC_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687849e1750-wk-Fact-7299B19500C65AA4886E0CA9F295C4DC"
          xlink:label="d43687849e1750-wk-Fact-7299B19500C65AA4886E0CA9F295C4DC"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e1750-wk-Fact-7299B19500C65AA4886E0CA9F295C4DC"
          xlink:to="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687849e2521-wk-Fact-72DABC7CCBA75E3598D920B948A182DB"
          xlink:label="d43687849e2521-wk-Fact-72DABC7CCBA75E3598D920B948A182DB"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e2521-wk-Fact-72DABC7CCBA75E3598D920B948A182DB"
          xlink:to="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687849e1028-wk-Fact-72F6CFB7B5D35966938C0A78B6424FE7"
          xlink:label="d43687849e1028-wk-Fact-72F6CFB7B5D35966938C0A78B6424FE7"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e1028-wk-Fact-72F6CFB7B5D35966938C0A78B6424FE7"
          xlink:to="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43681613e1608-wk-Fact-7366AB7164FB57C0B8A92433A2836E49"
          xlink:label="d43681613e1608-wk-Fact-7366AB7164FB57C0B8A92433A2836E49"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43681613e1608-wk-Fact-7366AB7164FB57C0B8A92433A2836E49"
          xlink:to="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43712496e2426-wk-Fact-73777733794C543CA62126B6042D00DB"
          xlink:label="d43712496e2426-wk-Fact-73777733794C543CA62126B6042D00DB"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43712496e2426-wk-Fact-73777733794C543CA62126B6042D00DB"
          xlink:to="TextSelection-C37CD88178CA35C475D25A62F2B54FED-0-wk-Footnote-C37CD88178CA35C475D25A62F2B54FED_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687704e843-wk-Fact-739EC43DD13B5516B11DE41A93EEDF71"
          xlink:label="d43687704e843-wk-Fact-739EC43DD13B5516B11DE41A93EEDF71"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d43771853e2244-wk-Fact-739EC43DD13B5516B11DE41A93EEDF71"
          xlink:label="d43771853e2244-wk-Fact-739EC43DD13B5516B11DE41A93EEDF71"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d43771853e4901-wk-Fact-739EC43DD13B5516B11DE41A93EEDF71"
          xlink:label="d43771853e4901-wk-Fact-739EC43DD13B5516B11DE41A93EEDF71"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e2244-wk-Fact-739EC43DD13B5516B11DE41A93EEDF71"
          xlink:to="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e843-wk-Fact-739EC43DD13B5516B11DE41A93EEDF71"
          xlink:to="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e4901-wk-Fact-739EC43DD13B5516B11DE41A93EEDF71"
          xlink:to="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e822-wk-Fact-73ABA67055275455B7AA44864D34F006"
          xlink:label="d43770747e822-wk-Fact-73ABA67055275455B7AA44864D34F006"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e822-wk-Fact-73ABA67055275455B7AA44864D34F006"
          xlink:to="TextSelection-0A1952177FA453EC8B5651D58249A9BA-0-wk-Footnote-0A1952177FA453EC8B5651D58249A9BA_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e822-wk-Fact-73ABA67055275455B7AA44864D34F006"
          xlink:to="TextSelection-8D2A93033C2E56DE9E814F0AB36328EE-0-wk-Footnote-8D2A93033C2E56DE9E814F0AB36328EE_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687704e1637-wk-Fact-741D17F5FCAB522EB406F004C9FDBAA3"
          xlink:label="d43687704e1637-wk-Fact-741D17F5FCAB522EB406F004C9FDBAA3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e1637-wk-Fact-741D17F5FCAB522EB406F004C9FDBAA3"
          xlink:to="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e1637-wk-Fact-741D17F5FCAB522EB406F004C9FDBAA3"
          xlink:to="TextSelection-9231AC55B8EC5775BC4995B0797F870F-0-wk-Footnote-9231AC55B8EC5775BC4995B0797F870F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43674379e1385-wk-Fact-74A94C963B005FB79E90256BEDC19745"
          xlink:label="d43674379e1385-wk-Fact-74A94C963B005FB79E90256BEDC19745"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43674379e1385-wk-Fact-74A94C963B005FB79E90256BEDC19745"
          xlink:to="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43691920e1203-wk-Fact-74D925B0A9935FB7A7B9371D66730DC0"
          xlink:label="d43691920e1203-wk-Fact-74D925B0A9935FB7A7B9371D66730DC0"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43691920e1203-wk-Fact-74D925B0A9935FB7A7B9371D66730DC0"
          xlink:to="TextSelection-C94190737D79577A8993EFAC2CD3FC95-0-wk-Footnote-C94190737D79577A8993EFAC2CD3FC95_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43697224e944-wk-Fact-74E639AFF5BE5619A8D6D94B13D9C7F4"
          xlink:label="d43697224e944-wk-Fact-74E639AFF5BE5619A8D6D94B13D9C7F4"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43697224e944-wk-Fact-74E639AFF5BE5619A8D6D94B13D9C7F4"
          xlink:to="TextSelection-FE5DD06AA8B65777900C47B8AC19C4C6-0-wk-Footnote-FE5DD06AA8B65777900C47B8AC19C4C6_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43681613e2261-wk-Fact-74EE204494395BACA3BF106440743D87"
          xlink:label="d43681613e2261-wk-Fact-74EE204494395BACA3BF106440743D87"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43681613e2261-wk-Fact-74EE204494395BACA3BF106440743D87"
          xlink:to="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687849e2220-wk-Fact-75134F72E4DA517BA3893A36B2D82E24"
          xlink:label="d43687849e2220-wk-Fact-75134F72E4DA517BA3893A36B2D82E24"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e2220-wk-Fact-75134F72E4DA517BA3893A36B2D82E24"
          xlink:to="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43681613e1562-wk-Fact-751B2E1EB7FE550C886A2AD44ED6CFCB"
          xlink:label="d43681613e1562-wk-Fact-751B2E1EB7FE550C886A2AD44ED6CFCB"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43681613e1562-wk-Fact-751B2E1EB7FE550C886A2AD44ED6CFCB"
          xlink:to="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e1197-wk-Fact-757F830EC82D5CFD89824C319DD82983"
          xlink:label="d43770747e1197-wk-Fact-757F830EC82D5CFD89824C319DD82983"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e1197-wk-Fact-757F830EC82D5CFD89824C319DD82983"
          xlink:to="TextSelection-8D2A93033C2E56DE9E814F0AB36328EE-0-wk-Footnote-8D2A93033C2E56DE9E814F0AB36328EE_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e1197-wk-Fact-757F830EC82D5CFD89824C319DD82983"
          xlink:to="TextSelection-91730671722A5F83BA05EF347193E4CF-0-wk-Footnote-91730671722A5F83BA05EF347193E4CF_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e7553-wk-Fact-75B9ED2C492450B59C9FBE062087C17F"
          xlink:label="d43770747e7553-wk-Fact-75B9ED2C492450B59C9FBE062087C17F"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e7553-wk-Fact-75B9ED2C492450B59C9FBE062087C17F"
          xlink:to="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e7553-wk-Fact-75B9ED2C492450B59C9FBE062087C17F"
          xlink:to="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687704e901-wk-Fact-769863A67705599FBF10A0F9C982956F"
          xlink:label="d43687704e901-wk-Fact-769863A67705599FBF10A0F9C982956F"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d43771853e3632-wk-Fact-769863A67705599FBF10A0F9C982956F"
          xlink:label="d43771853e3632-wk-Fact-769863A67705599FBF10A0F9C982956F"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d43771853e4973-wk-Fact-769863A67705599FBF10A0F9C982956F"
          xlink:label="d43771853e4973-wk-Fact-769863A67705599FBF10A0F9C982956F"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e4973-wk-Fact-769863A67705599FBF10A0F9C982956F"
          xlink:to="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e901-wk-Fact-769863A67705599FBF10A0F9C982956F"
          xlink:to="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e3632-wk-Fact-769863A67705599FBF10A0F9C982956F"
          xlink:to="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687704e1890-wk-Fact-769C4E4C0C905BDA89016FEC60CCEAB2"
          xlink:label="d43687704e1890-wk-Fact-769C4E4C0C905BDA89016FEC60CCEAB2"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d43687849e885-wk-Fact-769C4E4C0C905BDA89016FEC60CCEAB2"
          xlink:label="d43687849e885-wk-Fact-769C4E4C0C905BDA89016FEC60CCEAB2"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d43681613e802-wk-Fact-769C4E4C0C905BDA89016FEC60CCEAB2"
          xlink:label="d43681613e802-wk-Fact-769C4E4C0C905BDA89016FEC60CCEAB2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43681613e802-wk-Fact-769C4E4C0C905BDA89016FEC60CCEAB2"
          xlink:to="TextSelection-3DD94144621C5A68BC21C5DB64345BB9-0-wk-Footnote-3DD94144621C5A68BC21C5DB64345BB9_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e885-wk-Fact-769C4E4C0C905BDA89016FEC60CCEAB2"
          xlink:to="TextSelection-3DD94144621C5A68BC21C5DB64345BB9-0-wk-Footnote-3DD94144621C5A68BC21C5DB64345BB9_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e1890-wk-Fact-769C4E4C0C905BDA89016FEC60CCEAB2"
          xlink:to="TextSelection-3DD94144621C5A68BC21C5DB64345BB9-0-wk-Footnote-3DD94144621C5A68BC21C5DB64345BB9_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43681613e802-wk-Fact-769C4E4C0C905BDA89016FEC60CCEAB2"
          xlink:to="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e885-wk-Fact-769C4E4C0C905BDA89016FEC60CCEAB2"
          xlink:to="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e1890-wk-Fact-769C4E4C0C905BDA89016FEC60CCEAB2"
          xlink:to="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43681613e802-wk-Fact-769C4E4C0C905BDA89016FEC60CCEAB2"
          xlink:to="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e885-wk-Fact-769C4E4C0C905BDA89016FEC60CCEAB2"
          xlink:to="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e1890-wk-Fact-769C4E4C0C905BDA89016FEC60CCEAB2"
          xlink:to="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43681613e802-wk-Fact-769C4E4C0C905BDA89016FEC60CCEAB2"
          xlink:to="TextSelection-9231AC55B8EC5775BC4995B0797F870F-0-wk-Footnote-9231AC55B8EC5775BC4995B0797F870F_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e885-wk-Fact-769C4E4C0C905BDA89016FEC60CCEAB2"
          xlink:to="TextSelection-9231AC55B8EC5775BC4995B0797F870F-0-wk-Footnote-9231AC55B8EC5775BC4995B0797F870F_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e1890-wk-Fact-769C4E4C0C905BDA89016FEC60CCEAB2"
          xlink:to="TextSelection-9231AC55B8EC5775BC4995B0797F870F-0-wk-Footnote-9231AC55B8EC5775BC4995B0797F870F_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43681613e802-wk-Fact-769C4E4C0C905BDA89016FEC60CCEAB2"
          xlink:to="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e885-wk-Fact-769C4E4C0C905BDA89016FEC60CCEAB2"
          xlink:to="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e1890-wk-Fact-769C4E4C0C905BDA89016FEC60CCEAB2"
          xlink:to="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687849e1922-wk-Fact-76C4477D67B058D0ADA197C508A6BFA0"
          xlink:label="d43687849e1922-wk-Fact-76C4477D67B058D0ADA197C508A6BFA0"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e1922-wk-Fact-76C4477D67B058D0ADA197C508A6BFA0"
          xlink:to="TextSelection-77536863BCE35B419E3A4119D41DB4BD-0-wk-Footnote-77536863BCE35B419E3A4119D41DB4BD_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e1922-wk-Fact-76C4477D67B058D0ADA197C508A6BFA0"
          xlink:to="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43681613e1537-wk-Fact-7715092F4977526AA9E3733E3C9831C4"
          xlink:label="d43681613e1537-wk-Fact-7715092F4977526AA9E3733E3C9831C4"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43681613e1537-wk-Fact-7715092F4977526AA9E3733E3C9831C4"
          xlink:to="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43771853e1845-wk-Fact-773AA58B1A2B57898FCAC12E9643C9F5"
          xlink:label="d43771853e1845-wk-Fact-773AA58B1A2B57898FCAC12E9643C9F5"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e1845-wk-Fact-773AA58B1A2B57898FCAC12E9643C9F5"
          xlink:to="TextSelection-13C3E50268A15908A8AC9D1B6C938D2D-0-wk-Footnote-13C3E50268A15908A8AC9D1B6C938D2D_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e1845-wk-Fact-773AA58B1A2B57898FCAC12E9643C9F5"
          xlink:to="TextSelection-78FC5AB8EFAB585E87BBCF93BE9FBF1D-0-wk-Footnote-78FC5AB8EFAB585E87BBCF93BE9FBF1D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e9648-wk-Fact-774518EA7FE3544C826E80CBE973BB7B"
          xlink:label="d43770747e9648-wk-Fact-774518EA7FE3544C826E80CBE973BB7B"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e9648-wk-Fact-774518EA7FE3544C826E80CBE973BB7B"
          xlink:to="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e9648-wk-Fact-774518EA7FE3544C826E80CBE973BB7B"
          xlink:to="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e9977-wk-Fact-77E4DFB6EFD85BAB909056B138A7DECB"
          xlink:label="d43770747e9977-wk-Fact-77E4DFB6EFD85BAB909056B138A7DECB"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e9977-wk-Fact-77E4DFB6EFD85BAB909056B138A7DECB"
          xlink:to="TextSelection-39CF024D03225486829869F6CA02C00E-0-wk-Footnote-39CF024D03225486829869F6CA02C00E_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e9977-wk-Fact-77E4DFB6EFD85BAB909056B138A7DECB"
          xlink:to="TextSelection-53BB8CAFCA475C0C9DB2195050D36025-0-wk-Footnote-53BB8CAFCA475C0C9DB2195050D36025_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e9977-wk-Fact-77E4DFB6EFD85BAB909056B138A7DECB"
          xlink:to="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e4590-wk-Fact-78AAF3709EB25116A215400F1CC559B2"
          xlink:label="d43770747e4590-wk-Fact-78AAF3709EB25116A215400F1CC559B2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e4590-wk-Fact-78AAF3709EB25116A215400F1CC559B2"
          xlink:to="TextSelection-5259D0A3B8885FEE951D5ABCA017CBFC-0-wk-Footnote-5259D0A3B8885FEE951D5ABCA017CBFC_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e1152-wk-Fact-7911451CA2425E27919489254BB944BC"
          xlink:label="d43770747e1152-wk-Fact-7911451CA2425E27919489254BB944BC"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e1152-wk-Fact-7911451CA2425E27919489254BB944BC"
          xlink:to="TextSelection-8D2A93033C2E56DE9E814F0AB36328EE-0-wk-Footnote-8D2A93033C2E56DE9E814F0AB36328EE_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e1152-wk-Fact-7911451CA2425E27919489254BB944BC"
          xlink:to="TextSelection-91730671722A5F83BA05EF347193E4CF-0-wk-Footnote-91730671722A5F83BA05EF347193E4CF_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43692105e1276-wk-Fact-797701906D5A55A4A147956137258C89"
          xlink:label="d43692105e1276-wk-Fact-797701906D5A55A4A147956137258C89"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43692105e1276-wk-Fact-797701906D5A55A4A147956137258C89"
          xlink:to="TextSelection-2A36E737FFF05E75B357CB41AFB5B6E2-0-wk-Footnote-2A36E737FFF05E75B357CB41AFB5B6E2_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43681613e1943-wk-Fact-79F0FD4AFB255B0196EDFCDD331CEFF0"
          xlink:label="d43681613e1943-wk-Fact-79F0FD4AFB255B0196EDFCDD331CEFF0"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43681613e1943-wk-Fact-79F0FD4AFB255B0196EDFCDD331CEFF0"
          xlink:to="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43771853e10828-wk-Fact-79FA16521B14520887AA9A50CD9012A4"
          xlink:label="d43771853e10828-wk-Fact-79FA16521B14520887AA9A50CD9012A4"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-A685A65E160C5D228F531BF7107B3DF7-0-wk-Footnote-A685A65E160C5D228F531BF7107B3DF7_lbl" xlink:label="TextSelection-A685A65E160C5D228F531BF7107B3DF7-0-wk-Footnote-A685A65E160C5D228F531BF7107B3DF7_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Biosimilars include Inflectra/Remsima (biosimilar infliximab) in the U.S. and certain international markets, Nivestim (biosimilar filgrastim) in certain European, Asian and Africa/Middle Eastern markets and Retacrit (biosimilar epoetin zeta) in certain European and Africa/Middle Eastern markets. </link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e10828-wk-Fact-79FA16521B14520887AA9A50CD9012A4"
          xlink:to="TextSelection-A685A65E160C5D228F531BF7107B3DF7-0-wk-Footnote-A685A65E160C5D228F531BF7107B3DF7_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687849e2239-wk-Fact-7A7785CEBF4755FBBB7EAA2A69D0EF09"
          xlink:label="d43687849e2239-wk-Fact-7A7785CEBF4755FBBB7EAA2A69D0EF09"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e2239-wk-Fact-7A7785CEBF4755FBBB7EAA2A69D0EF09"
          xlink:to="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43712510e4484-wk-Fact-7A88DB0438DC5867A92DE1BB2A8BEC24"
          xlink:label="d43712510e4484-wk-Fact-7A88DB0438DC5867A92DE1BB2A8BEC24"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43712510e4484-wk-Fact-7A88DB0438DC5867A92DE1BB2A8BEC24"
          xlink:to="TextSelection-621F9196966C550EA113DA57575C171E-0-wk-Footnote-621F9196966C550EA113DA57575C171E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e9628-wk-Fact-7CF5E0D8BCEA5A01AC63CA0BE2F7F413"
          xlink:label="d43770747e9628-wk-Fact-7CF5E0D8BCEA5A01AC63CA0BE2F7F413"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e9628-wk-Fact-7CF5E0D8BCEA5A01AC63CA0BE2F7F413"
          xlink:to="TextSelection-39CF024D03225486829869F6CA02C00E-0-wk-Footnote-39CF024D03225486829869F6CA02C00E_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e9628-wk-Fact-7CF5E0D8BCEA5A01AC63CA0BE2F7F413"
          xlink:to="TextSelection-53BB8CAFCA475C0C9DB2195050D36025-0-wk-Footnote-53BB8CAFCA475C0C9DB2195050D36025_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e9628-wk-Fact-7CF5E0D8BCEA5A01AC63CA0BE2F7F413"
          xlink:to="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43681613e1267-wk-Fact-7D8048FC05695215AF1AB565B8040E8E"
          xlink:label="d43681613e1267-wk-Fact-7D8048FC05695215AF1AB565B8040E8E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43681613e1267-wk-Fact-7D8048FC05695215AF1AB565B8040E8E"
          xlink:to="TextSelection-3DD94144621C5A68BC21C5DB64345BB9-0-wk-Footnote-3DD94144621C5A68BC21C5DB64345BB9_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43681613e1267-wk-Fact-7D8048FC05695215AF1AB565B8040E8E"
          xlink:to="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e1108-wk-Fact-7DAD092F708C5E7CAC2F33934FCB84C5"
          xlink:label="d43770747e1108-wk-Fact-7DAD092F708C5E7CAC2F33934FCB84C5"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e1108-wk-Fact-7DAD092F708C5E7CAC2F33934FCB84C5"
          xlink:to="TextSelection-8D2A93033C2E56DE9E814F0AB36328EE-0-wk-Footnote-8D2A93033C2E56DE9E814F0AB36328EE_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e1108-wk-Fact-7DAD092F708C5E7CAC2F33934FCB84C5"
          xlink:to="TextSelection-91730671722A5F83BA05EF347193E4CF-0-wk-Footnote-91730671722A5F83BA05EF347193E4CF_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43712496e1304-wk-Fact-7DF3605F8BAE533CAF6B416DD2F9F2C4"
          xlink:label="d43712496e1304-wk-Fact-7DF3605F8BAE533CAF6B416DD2F9F2C4"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43712496e1304-wk-Fact-7DF3605F8BAE533CAF6B416DD2F9F2C4"
          xlink:to="TextSelection-1B1FEAD5EA4E576891141CE7B2D9386E-0-wk-Footnote-1B1FEAD5EA4E576891141CE7B2D9386E_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43712496e1304-wk-Fact-7DF3605F8BAE533CAF6B416DD2F9F2C4"
          xlink:to="TextSelection-B57619F44FCF544D96067CF4816A9082-0-wk-Footnote-B57619F44FCF544D96067CF4816A9082_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43674379e2120-wk-Fact-7E0D6DBF276A520C83B6B208692E17BE"
          xlink:label="d43674379e2120-wk-Fact-7E0D6DBF276A520C83B6B208692E17BE"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43674379e2120-wk-Fact-7E0D6DBF276A520C83B6B208692E17BE"
          xlink:to="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43691920e1163-wk-Fact-7E181FF37E2A50278584695E0D09574B"
          xlink:label="d43691920e1163-wk-Fact-7E181FF37E2A50278584695E0D09574B"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43691920e1163-wk-Fact-7E181FF37E2A50278584695E0D09574B"
          xlink:to="TextSelection-C94190737D79577A8993EFAC2CD3FC95-0-wk-Footnote-C94190737D79577A8993EFAC2CD3FC95_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687704e1153-wk-Fact-7E1F234CCFDF5CD5B6D2068DEF0EA230"
          xlink:label="d43687704e1153-wk-Fact-7E1F234CCFDF5CD5B6D2068DEF0EA230"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e1153-wk-Fact-7E1F234CCFDF5CD5B6D2068DEF0EA230"
          xlink:to="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e1153-wk-Fact-7E1F234CCFDF5CD5B6D2068DEF0EA230"
          xlink:to="TextSelection-AE19F19C6AE65BBDA7F551089E2E7EDF-0-wk-Footnote-AE19F19C6AE65BBDA7F551089E2E7EDF_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e4532-wk-Fact-7E56CAC1C19150F0843C9E5BCB9C0112"
          xlink:label="d43770747e4532-wk-Fact-7E56CAC1C19150F0843C9E5BCB9C0112"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e4532-wk-Fact-7E56CAC1C19150F0843C9E5BCB9C0112"
          xlink:to="TextSelection-5259D0A3B8885FEE951D5ABCA017CBFC-0-wk-Footnote-5259D0A3B8885FEE951D5ABCA017CBFC_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e8838-wk-Fact-7E69FA8360D65E76BC4DD8B549DB440D"
          xlink:label="d43770747e8838-wk-Fact-7E69FA8360D65E76BC4DD8B549DB440D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e8838-wk-Fact-7E69FA8360D65E76BC4DD8B549DB440D"
          xlink:to="TextSelection-39CF024D03225486829869F6CA02C00E-0-wk-Footnote-39CF024D03225486829869F6CA02C00E_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e8838-wk-Fact-7E69FA8360D65E76BC4DD8B549DB440D"
          xlink:to="TextSelection-53BB8CAFCA475C0C9DB2195050D36025-0-wk-Footnote-53BB8CAFCA475C0C9DB2195050D36025_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e8838-wk-Fact-7E69FA8360D65E76BC4DD8B549DB440D"
          xlink:to="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43674379e2164-wk-Fact-7EDA7F85A58A5A1F95B13001B9DBA028"
          xlink:label="d43674379e2164-wk-Fact-7EDA7F85A58A5A1F95B13001B9DBA028"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43674379e2164-wk-Fact-7EDA7F85A58A5A1F95B13001B9DBA028"
          xlink:to="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43674379e2520-wk-Fact-7EDE13D2B0D259CBB94F5F415001BFCC"
          xlink:label="d43674379e2520-wk-Fact-7EDE13D2B0D259CBB94F5F415001BFCC"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43674379e2520-wk-Fact-7EDE13D2B0D259CBB94F5F415001BFCC"
          xlink:to="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43681613e1627-wk-Fact-7EE55D894B2E598CB81A5AD553F1A033"
          xlink:label="d43681613e1627-wk-Fact-7EE55D894B2E598CB81A5AD553F1A033"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43681613e1627-wk-Fact-7EE55D894B2E598CB81A5AD553F1A033"
          xlink:to="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43674379e798-wk-Fact-7EFAF7B942C85E77BB9972B343FAB410"
          xlink:label="d43674379e798-wk-Fact-7EFAF7B942C85E77BB9972B343FAB410"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d43681613e2521-wk-Fact-7EFAF7B942C85E77BB9972B343FAB410"
          xlink:label="d43681613e2521-wk-Fact-7EFAF7B942C85E77BB9972B343FAB410"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43681613e2521-wk-Fact-7EFAF7B942C85E77BB9972B343FAB410"
          xlink:to="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43674379e798-wk-Fact-7EFAF7B942C85E77BB9972B343FAB410"
          xlink:to="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43681613e2521-wk-Fact-7EFAF7B942C85E77BB9972B343FAB410"
          xlink:to="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43674379e798-wk-Fact-7EFAF7B942C85E77BB9972B343FAB410"
          xlink:to="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e5934-wk-Fact-7F42A871CAE05783A75EB435EF78126F"
          xlink:label="d43770747e5934-wk-Fact-7F42A871CAE05783A75EB435EF78126F"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-8921B51644785F769ECBA4D3CCF9CAD4-0-wk-Footnote-8921B51644785F769ECBA4D3CCF9CAD4_lbl" xlink:label="TextSelection-8921B51644785F769ECBA4D3CCF9CAD4-0-wk-Footnote-8921B51644785F769ECBA4D3CCF9CAD4_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The aggregate amount at issuance date was <xhtml:span style="font-family:inherit;font-size:8.5pt;"><xhtml:span>$5,279 million</xhtml:span></xhtml:span>. The increase in the amount since the date of issuance is due to foreign currency exchange.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e5934-wk-Fact-7F42A871CAE05783A75EB435EF78126F"
          xlink:to="TextSelection-8921B51644785F769ECBA4D3CCF9CAD4-0-wk-Footnote-8921B51644785F769ECBA4D3CCF9CAD4_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43712510e5144-wk-Fact-7F7AD619600C57BDB92DA526BB9447DB"
          xlink:label="d43712510e5144-wk-Fact-7F7AD619600C57BDB92DA526BB9447DB"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43712510e5144-wk-Fact-7F7AD619600C57BDB92DA526BB9447DB"
          xlink:to="TextSelection-621F9196966C550EA113DA57575C171E-0-wk-Footnote-621F9196966C550EA113DA57575C171E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e7453-wk-Fact-7FF9DC0A6C7D575C9FDD24720C8D14FC"
          xlink:label="d43770747e7453-wk-Fact-7FF9DC0A6C7D575C9FDD24720C8D14FC"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e7453-wk-Fact-7FF9DC0A6C7D575C9FDD24720C8D14FC"
          xlink:to="TextSelection-39CF024D03225486829869F6CA02C00E-0-wk-Footnote-39CF024D03225486829869F6CA02C00E_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e7453-wk-Fact-7FF9DC0A6C7D575C9FDD24720C8D14FC"
          xlink:to="TextSelection-53BB8CAFCA475C0C9DB2195050D36025-0-wk-Footnote-53BB8CAFCA475C0C9DB2195050D36025_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e7453-wk-Fact-7FF9DC0A6C7D575C9FDD24720C8D14FC"
          xlink:to="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43674379e2075-wk-Fact-808C96510A955E8CBDF7099B1662C942"
          xlink:label="d43674379e2075-wk-Fact-808C96510A955E8CBDF7099B1662C942"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43674379e2075-wk-Fact-808C96510A955E8CBDF7099B1662C942"
          xlink:to="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687849e1836-wk-Fact-80B5437E8AF253159081F26E14A232D2"
          xlink:label="d43687849e1836-wk-Fact-80B5437E8AF253159081F26E14A232D2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e1836-wk-Fact-80B5437E8AF253159081F26E14A232D2"
          xlink:to="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43681613e2170-wk-Fact-81C7C1D62B7555CEB86C474159F55AB9"
          xlink:label="d43681613e2170-wk-Fact-81C7C1D62B7555CEB86C474159F55AB9"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43681613e2170-wk-Fact-81C7C1D62B7555CEB86C474159F55AB9"
          xlink:to="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43697240e1384-wk-Fact-81D16D7A3AE6589781565D5CDDE413F5"
          xlink:label="d43697240e1384-wk-Fact-81D16D7A3AE6589781565D5CDDE413F5"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43697240e1384-wk-Fact-81D16D7A3AE6589781565D5CDDE413F5"
          xlink:to="TextSelection-7432EEEACAB3598FA522C1D7E1584D05-0-wk-Footnote-7432EEEACAB3598FA522C1D7E1584D05_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43771853e1428-wk-Fact-81F0756E8C76E147E68C5A6F0304AE04"
          xlink:label="d43771853e1428-wk-Fact-81F0756E8C76E147E68C5A6F0304AE04"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e1428-wk-Fact-81F0756E8C76E147E68C5A6F0304AE04"
          xlink:to="TextSelection-78FC5AB8EFAB585E87BBCF93BE9FBF1D-0-wk-Footnote-78FC5AB8EFAB585E87BBCF93BE9FBF1D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43697240e1325-wk-Fact-8222C49DFF25586385357680BA3E7A37"
          xlink:label="d43697240e1325-wk-Fact-8222C49DFF25586385357680BA3E7A37"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43697240e1325-wk-Fact-8222C49DFF25586385357680BA3E7A37"
          xlink:to="TextSelection-7432EEEACAB3598FA522C1D7E1584D05-0-wk-Footnote-7432EEEACAB3598FA522C1D7E1584D05_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687704e1199-wk-Fact-822E670EBB815BFB8925AC8ECADDC3AB"
          xlink:label="d43687704e1199-wk-Fact-822E670EBB815BFB8925AC8ECADDC3AB"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e1199-wk-Fact-822E670EBB815BFB8925AC8ECADDC3AB"
          xlink:to="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e1199-wk-Fact-822E670EBB815BFB8925AC8ECADDC3AB"
          xlink:to="TextSelection-AE19F19C6AE65BBDA7F551089E2E7EDF-0-wk-Footnote-AE19F19C6AE65BBDA7F551089E2E7EDF_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e4570-wk-Fact-823EA0B8A07A5702B678EABA58D52F52"
          xlink:label="d43770747e4570-wk-Fact-823EA0B8A07A5702B678EABA58D52F52"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e4570-wk-Fact-823EA0B8A07A5702B678EABA58D52F52"
          xlink:to="TextSelection-5259D0A3B8885FEE951D5ABCA017CBFC-0-wk-Footnote-5259D0A3B8885FEE951D5ABCA017CBFC_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43674379e2611-wk-Fact-82E53639BF6557F091EE46784D53AC8F"
          xlink:label="d43674379e2611-wk-Fact-82E53639BF6557F091EE46784D53AC8F"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43674379e2611-wk-Fact-82E53639BF6557F091EE46784D53AC8F"
          xlink:to="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e11303-wk-Fact-82FB012BDAB65A2A907B1CCC2DE535AD"
          xlink:label="d43770747e11303-wk-Fact-82FB012BDAB65A2A907B1CCC2DE535AD"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e11303-wk-Fact-82FB012BDAB65A2A907B1CCC2DE535AD"
          xlink:to="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e11303-wk-Fact-82FB012BDAB65A2A907B1CCC2DE535AD"
          xlink:to="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43771853e3041-wk-Fact-8317B3014C2257C6BEBBD283124A965D"
          xlink:label="d43771853e3041-wk-Fact-8317B3014C2257C6BEBBD283124A965D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e3041-wk-Fact-8317B3014C2257C6BEBBD283124A965D"
          xlink:to="TextSelection-13C3E50268A15908A8AC9D1B6C938D2D-0-wk-Footnote-13C3E50268A15908A8AC9D1B6C938D2D_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e3041-wk-Fact-8317B3014C2257C6BEBBD283124A965D"
          xlink:to="TextSelection-78FC5AB8EFAB585E87BBCF93BE9FBF1D-0-wk-Footnote-78FC5AB8EFAB585E87BBCF93BE9FBF1D_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e3041-wk-Fact-8317B3014C2257C6BEBBD283124A965D"
          xlink:to="TextSelection-C2AA3A20AB3F54349FC86854E44E1000-0-wk-Footnote-C2AA3A20AB3F54349FC86854E44E1000_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e8628-wk-Fact-838AFCED268F5D33AC4D66BBF1700DBF"
          xlink:label="d43770747e8628-wk-Fact-838AFCED268F5D33AC4D66BBF1700DBF"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e8628-wk-Fact-838AFCED268F5D33AC4D66BBF1700DBF"
          xlink:to="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e8628-wk-Fact-838AFCED268F5D33AC4D66BBF1700DBF"
          xlink:to="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e1133-wk-Fact-83B9658BE9A85FE39B70C11E0CE57D00"
          xlink:label="d43770747e1133-wk-Fact-83B9658BE9A85FE39B70C11E0CE57D00"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e1133-wk-Fact-83B9658BE9A85FE39B70C11E0CE57D00"
          xlink:to="TextSelection-8D2A93033C2E56DE9E814F0AB36328EE-0-wk-Footnote-8D2A93033C2E56DE9E814F0AB36328EE_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e1133-wk-Fact-83B9658BE9A85FE39B70C11E0CE57D00"
          xlink:to="TextSelection-91730671722A5F83BA05EF347193E4CF-0-wk-Footnote-91730671722A5F83BA05EF347193E4CF_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43681613e2427-wk-Fact-8446B584F9B25BB79D2E77028163C2CB"
          xlink:label="d43681613e2427-wk-Fact-8446B584F9B25BB79D2E77028163C2CB"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43681613e2427-wk-Fact-8446B584F9B25BB79D2E77028163C2CB"
          xlink:to="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687849e2547-wk-Fact-84477EEDA0FB53F1A2DF30BC45CFD227"
          xlink:label="d43687849e2547-wk-Fact-84477EEDA0FB53F1A2DF30BC45CFD227"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e2547-wk-Fact-84477EEDA0FB53F1A2DF30BC45CFD227"
          xlink:to="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43697224e1651-wk-Fact-84DD287398AF5474B3AA02B3F4BF9D06"
          xlink:label="d43697224e1651-wk-Fact-84DD287398AF5474B3AA02B3F4BF9D06"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-9C73CEBDEE585A83B2B18F3B38A6D8CD-0-wk-Footnote-9C73CEBDEE585A83B2B18F3B38A6D8CD_lbl" xlink:label="TextSelection-9C73CEBDEE585A83B2B18F3B38A6D8CD-0-wk-Footnote-9C73CEBDEE585A83B2B18F3B38A6D8CD_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">In the <xhtml:span style="font-family:inherit;font-size:8.5pt;">third</xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"> quarter and </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;">first nine months of</xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"> </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;text-align:center;">2017</xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"> and </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;text-align:center;">2016</xhtml:span>, represents expenses for changes to our infrastructure to align our commercial operations, including costs to internally separate our businesses into distinct legal entities, as well as to streamline our intercompany supply operations to better support each business. </link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43697224e1651-wk-Fact-84DD287398AF5474B3AA02B3F4BF9D06"
          xlink:to="TextSelection-9C73CEBDEE585A83B2B18F3B38A6D8CD-0-wk-Footnote-9C73CEBDEE585A83B2B18F3B38A6D8CD_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e11283-wk-Fact-84FD9CC1745E5CF6B9EBD9E4EF9761DA"
          xlink:label="d43770747e11283-wk-Fact-84FD9CC1745E5CF6B9EBD9E4EF9761DA"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e11283-wk-Fact-84FD9CC1745E5CF6B9EBD9E4EF9761DA"
          xlink:to="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e11283-wk-Fact-84FD9CC1745E5CF6B9EBD9E4EF9761DA"
          xlink:to="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43771853e2213-wk-Fact-853524F647B75F4EA75709651DF1AA8F"
          xlink:label="d43771853e2213-wk-Fact-853524F647B75F4EA75709651DF1AA8F"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e2213-wk-Fact-853524F647B75F4EA75709651DF1AA8F"
          xlink:to="TextSelection-78FC5AB8EFAB585E87BBCF93BE9FBF1D-0-wk-Footnote-78FC5AB8EFAB585E87BBCF93BE9FBF1D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43697224e1757-wk-Fact-858DAA1BAEC456F597F882E9D0741E7F"
          xlink:label="d43697224e1757-wk-Fact-858DAA1BAEC456F597F882E9D0741E7F"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43697224e1757-wk-Fact-858DAA1BAEC456F597F882E9D0741E7F"
          xlink:to="TextSelection-ECF6A95A77365D79B2E9D472B81966D9-0-wk-Footnote-ECF6A95A77365D79B2E9D472B81966D9_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e1545-wk-Fact-86294AF06C6D55869B1ABEBE900AFFD4"
          xlink:label="d43770747e1545-wk-Fact-86294AF06C6D55869B1ABEBE900AFFD4"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e1545-wk-Fact-86294AF06C6D55869B1ABEBE900AFFD4"
          xlink:to="TextSelection-58096FF6357955D6B6AA25D56767CB0A-0-wk-Footnote-58096FF6357955D6B6AA25D56767CB0A_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e1545-wk-Fact-86294AF06C6D55869B1ABEBE900AFFD4"
          xlink:to="TextSelection-8D2A93033C2E56DE9E814F0AB36328EE-0-wk-Footnote-8D2A93033C2E56DE9E814F0AB36328EE_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43681613e2704-wk-Fact-8690986C383F54748BB0095D0303FF1E"
          xlink:label="d43681613e2704-wk-Fact-8690986C383F54748BB0095D0303FF1E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43681613e2704-wk-Fact-8690986C383F54748BB0095D0303FF1E"
          xlink:to="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43681613e2704-wk-Fact-8690986C383F54748BB0095D0303FF1E"
          xlink:to="TextSelection-EB5698F25D035A90984FA270E724B7BB-0-wk-Footnote-EB5698F25D035A90984FA270E724B7BB_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43674379e2718-wk-Fact-871F7D1326F153D0A78F67C95DCE6D47"
          xlink:label="d43674379e2718-wk-Fact-871F7D1326F153D0A78F67C95DCE6D47"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43674379e2718-wk-Fact-871F7D1326F153D0A78F67C95DCE6D47"
          xlink:to="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e7720-wk-Fact-8727D6540E165428BFB9698977FED583"
          xlink:label="d43770747e7720-wk-Fact-8727D6540E165428BFB9698977FED583"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e7720-wk-Fact-8727D6540E165428BFB9698977FED583"
          xlink:to="TextSelection-39CF024D03225486829869F6CA02C00E-0-wk-Footnote-39CF024D03225486829869F6CA02C00E_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e7720-wk-Fact-8727D6540E165428BFB9698977FED583"
          xlink:to="TextSelection-53BB8CAFCA475C0C9DB2195050D36025-0-wk-Footnote-53BB8CAFCA475C0C9DB2195050D36025_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e7720-wk-Fact-8727D6540E165428BFB9698977FED583"
          xlink:to="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43697224e1565-wk-Fact-872E272F8D3F541FBE9D985BACC8A6A2"
          xlink:label="d43697224e1565-wk-Fact-872E272F8D3F541FBE9D985BACC8A6A2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43697224e1565-wk-Fact-872E272F8D3F541FBE9D985BACC8A6A2"
          xlink:to="TextSelection-8C5E9E30C7EB5291A3E0EE605FC281E8-0-wk-Footnote-8C5E9E30C7EB5291A3E0EE605FC281E8_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43681613e1808-wk-Fact-8788492837FF523EB753AAF056BFAF4A"
          xlink:label="d43681613e1808-wk-Fact-8788492837FF523EB753AAF056BFAF4A"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43681613e1808-wk-Fact-8788492837FF523EB753AAF056BFAF4A"
          xlink:to="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e10350-wk-Fact-87C02FE05790562287F7FA992F915C2A"
          xlink:label="d43770747e10350-wk-Fact-87C02FE05790562287F7FA992F915C2A"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e10350-wk-Fact-87C02FE05790562287F7FA992F915C2A"
          xlink:to="TextSelection-39CF024D03225486829869F6CA02C00E-0-wk-Footnote-39CF024D03225486829869F6CA02C00E_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e10350-wk-Fact-87C02FE05790562287F7FA992F915C2A"
          xlink:to="TextSelection-53BB8CAFCA475C0C9DB2195050D36025-0-wk-Footnote-53BB8CAFCA475C0C9DB2195050D36025_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e10350-wk-Fact-87C02FE05790562287F7FA992F915C2A"
          xlink:to="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687704e2448-wk-Fact-8810BC1FB19F5CCBB75143FDC43F7193"
          xlink:label="d43687704e2448-wk-Fact-8810BC1FB19F5CCBB75143FDC43F7193"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e2448-wk-Fact-8810BC1FB19F5CCBB75143FDC43F7193"
          xlink:to="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e2448-wk-Fact-8810BC1FB19F5CCBB75143FDC43F7193"
          xlink:to="TextSelection-9231AC55B8EC5775BC4995B0797F870F-0-wk-Footnote-9231AC55B8EC5775BC4995B0797F870F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43712496e1497-wk-Fact-88427B31421C553CAC12777E36570F80"
          xlink:label="d43712496e1497-wk-Fact-88427B31421C553CAC12777E36570F80"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43712496e1497-wk-Fact-88427B31421C553CAC12777E36570F80"
          xlink:to="TextSelection-6912797A078E5D59B618DFFBB81C1BB6-0-wk-Footnote-6912797A078E5D59B618DFFBB81C1BB6_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43771853e4856-wk-Fact-8896D6C24D4F5AEEABD89DD662622B8D"
          xlink:label="d43771853e4856-wk-Fact-8896D6C24D4F5AEEABD89DD662622B8D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e4856-wk-Fact-8896D6C24D4F5AEEABD89DD662622B8D"
          xlink:to="TextSelection-DC6DDCB74FC9523D97BA51FBA6B1C05E-0-wk-Footnote-DC6DDCB74FC9523D97BA51FBA6B1C05E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43681613e2941-wk-Fact-88DA733F540B50B5B2437B8FAA7A8EDF"
          xlink:label="d43681613e2941-wk-Fact-88DA733F540B50B5B2437B8FAA7A8EDF"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43681613e2941-wk-Fact-88DA733F540B50B5B2437B8FAA7A8EDF"
          xlink:to="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact-88DE6FFC0A6C582BA8AE3854966F0852-wk-Fact-88DE6FFC0A6C582BA8AE3854966F0852"
          xlink:label="Fact-88DE6FFC0A6C582BA8AE3854966F0852-wk-Fact-88DE6FFC0A6C582BA8AE3854966F0852"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact-88DE6FFC0A6C582BA8AE3854966F0852-wk-Fact-88DE6FFC0A6C582BA8AE3854966F0852"
          xlink:to="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43712510e4168-wk-Fact-88EBC3EBE111513F840C9F921A314BB9"
          xlink:label="d43712510e4168-wk-Fact-88EBC3EBE111513F840C9F921A314BB9"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43712510e4168-wk-Fact-88EBC3EBE111513F840C9F921A314BB9"
          xlink:to="TextSelection-621F9196966C550EA113DA57575C171E-0-wk-Footnote-621F9196966C550EA113DA57575C171E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687704e3075-wk-Fact-89167C4150EA5B6CB2833B441C176EB5"
          xlink:label="d43687704e3075-wk-Fact-89167C4150EA5B6CB2833B441C176EB5"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d43690878e2073-wk-Fact-89167C4150EA5B6CB2833B441C176EB5"
          xlink:label="d43690878e2073-wk-Fact-89167C4150EA5B6CB2833B441C176EB5"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43690878e2073-wk-Fact-89167C4150EA5B6CB2833B441C176EB5"
          xlink:to="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e3075-wk-Fact-89167C4150EA5B6CB2833B441C176EB5"
          xlink:to="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43771853e8298-wk-Fact-89988FDDF95F52A4910F81944C0989F3"
          xlink:label="d43771853e8298-wk-Fact-89988FDDF95F52A4910F81944C0989F3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e8298-wk-Fact-89988FDDF95F52A4910F81944C0989F3"
          xlink:to="TextSelection-C4FFB7FEB33B5D5EBA7924687B243323-0-wk-Footnote-C4FFB7FEB33B5D5EBA7924687B243323_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e1647-wk-Fact-8A158D27D5F55CB592CF35BFF232EA8E"
          xlink:label="d43770747e1647-wk-Fact-8A158D27D5F55CB592CF35BFF232EA8E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e1647-wk-Fact-8A158D27D5F55CB592CF35BFF232EA8E"
          xlink:to="TextSelection-58096FF6357955D6B6AA25D56767CB0A-0-wk-Footnote-58096FF6357955D6B6AA25D56767CB0A_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e1647-wk-Fact-8A158D27D5F55CB592CF35BFF232EA8E"
          xlink:to="TextSelection-8D2A93033C2E56DE9E814F0AB36328EE-0-wk-Footnote-8D2A93033C2E56DE9E814F0AB36328EE_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43712510e5492-wk-Fact-8A4811792A515F62A3DF96296C7FF609"
          xlink:label="d43712510e5492-wk-Fact-8A4811792A515F62A3DF96296C7FF609"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43712510e5492-wk-Fact-8A4811792A515F62A3DF96296C7FF609"
          xlink:to="TextSelection-621F9196966C550EA113DA57575C171E-0-wk-Footnote-621F9196966C550EA113DA57575C171E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43712496e2215-wk-Fact-8A4AB1B8685C5997998FB7F7C5FFCE5D"
          xlink:label="d43712496e2215-wk-Fact-8A4AB1B8685C5997998FB7F7C5FFCE5D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43712496e2215-wk-Fact-8A4AB1B8685C5997998FB7F7C5FFCE5D"
          xlink:to="TextSelection-C37CD88178CA35C475D25A62F2B54FED-0-wk-Footnote-C37CD88178CA35C475D25A62F2B54FED_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43690878e1383-wk-Fact-8A7DCB81F28D538A87559BA9CEA85B1F"
          xlink:label="d43690878e1383-wk-Fact-8A7DCB81F28D538A87559BA9CEA85B1F"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43690878e1383-wk-Fact-8A7DCB81F28D538A87559BA9CEA85B1F"
          xlink:to="TextSelection-792D3AB23D6354CFBB2776AE7F6407B4-0-wk-Footnote-792D3AB23D6354CFBB2776AE7F6407B4_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43771853e3410-wk-Fact-8AA7427BBF485EA4842503B7D6B6F5B3"
          xlink:label="d43771853e3410-wk-Fact-8AA7427BBF485EA4842503B7D6B6F5B3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e3410-wk-Fact-8AA7427BBF485EA4842503B7D6B6F5B3"
          xlink:to="TextSelection-13C3E50268A15908A8AC9D1B6C938D2D-0-wk-Footnote-13C3E50268A15908A8AC9D1B6C938D2D_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e3410-wk-Fact-8AA7427BBF485EA4842503B7D6B6F5B3"
          xlink:to="TextSelection-78FC5AB8EFAB585E87BBCF93BE9FBF1D-0-wk-Footnote-78FC5AB8EFAB585E87BBCF93BE9FBF1D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43681613e2308-wk-Fact-8AB5E43C2479535A8B0B89EA014F6940"
          xlink:label="d43681613e2308-wk-Fact-8AB5E43C2479535A8B0B89EA014F6940"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43681613e2308-wk-Fact-8AB5E43C2479535A8B0B89EA014F6940"
          xlink:to="TextSelection-3DD94144621C5A68BC21C5DB64345BB9-0-wk-Footnote-3DD94144621C5A68BC21C5DB64345BB9_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43681613e2308-wk-Fact-8AB5E43C2479535A8B0B89EA014F6940"
          xlink:to="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687704e2487-wk-Fact-8AF2BFF4A0B050A8AEDFE6EBFEC9B378"
          xlink:label="d43687704e2487-wk-Fact-8AF2BFF4A0B050A8AEDFE6EBFEC9B378"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e2487-wk-Fact-8AF2BFF4A0B050A8AEDFE6EBFEC9B378"
          xlink:to="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e2487-wk-Fact-8AF2BFF4A0B050A8AEDFE6EBFEC9B378"
          xlink:to="TextSelection-9231AC55B8EC5775BC4995B0797F870F-0-wk-Footnote-9231AC55B8EC5775BC4995B0797F870F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e3249-wk-Fact-8AFCAB1E804757FEBFCB197A8AE4804C"
          xlink:label="d43770747e3249-wk-Fact-8AFCAB1E804757FEBFCB197A8AE4804C"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-8C173666F61E55D5A1394009569043BA-0-wk-Footnote-8C173666F61E55D5A1394009569043BA_lbl" xlink:label="TextSelection-8C173666F61E55D5A1394009569043BA-0-wk-Footnote-8C173666F61E55D5A1394009569043BA_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">As of <xhtml:span style="font-family:inherit;font-size:9pt;">October&#160;1, 2017</xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;">, derivative instruments at fair value include interest rate swaps (</xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;"><xhtml:span>$153 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;">), foreign currency swaps (</xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;"><xhtml:span>$710 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;">) and foreign currency forward-exchange contracts (</xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;"><xhtml:span>$33 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;">) and, as of </xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;text-align:center;">December&#160;31, 2016</xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;">, include interest rate swaps (</xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;"><xhtml:span>$147 million</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;">) and foreign currency swaps (</xhtml:span><xhtml:span style="font-family:inherit;font-size:9pt;"><xhtml:span>$1.1 billion</xhtml:span></xhtml:span>).</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e3249-wk-Fact-8AFCAB1E804757FEBFCB197A8AE4804C"
          xlink:to="TextSelection-8C173666F61E55D5A1394009569043BA-0-wk-Footnote-8C173666F61E55D5A1394009569043BA_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43771853e1866-wk-Fact-8B6B8D08A6E0596D82BFAC1026B33906"
          xlink:label="d43771853e1866-wk-Fact-8B6B8D08A6E0596D82BFAC1026B33906"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e1866-wk-Fact-8B6B8D08A6E0596D82BFAC1026B33906"
          xlink:to="TextSelection-13C3E50268A15908A8AC9D1B6C938D2D-0-wk-Footnote-13C3E50268A15908A8AC9D1B6C938D2D_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e1866-wk-Fact-8B6B8D08A6E0596D82BFAC1026B33906"
          xlink:to="TextSelection-78FC5AB8EFAB585E87BBCF93BE9FBF1D-0-wk-Footnote-78FC5AB8EFAB585E87BBCF93BE9FBF1D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687704e3210-wk-Fact-8BCC41FCBE495D779B180688D6602014"
          xlink:label="d43687704e3210-wk-Fact-8BCC41FCBE495D779B180688D6602014"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e3210-wk-Fact-8BCC41FCBE495D779B180688D6602014"
          xlink:to="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43697224e1196-wk-Fact-8C132ED2C80858EDAC92446BF10B1EF2"
          xlink:label="d43697224e1196-wk-Fact-8C132ED2C80858EDAC92446BF10B1EF2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43697224e1196-wk-Fact-8C132ED2C80858EDAC92446BF10B1EF2"
          xlink:to="TextSelection-7679A63ACE625532ADFCC5B97C6C9FC6-0-wk-Footnote-7679A63ACE625532ADFCC5B97C6C9FC6_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e8878-wk-Fact-8C7D1064A7B350C98174EAAD041CABE0"
          xlink:label="d43770747e8878-wk-Fact-8C7D1064A7B350C98174EAAD041CABE0"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e8878-wk-Fact-8C7D1064A7B350C98174EAAD041CABE0"
          xlink:to="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e8878-wk-Fact-8C7D1064A7B350C98174EAAD041CABE0"
          xlink:to="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43674379e1740-wk-Fact-8C84C3AC99B45AE2BA8FC636F5622DE6"
          xlink:label="d43674379e1740-wk-Fact-8C84C3AC99B45AE2BA8FC636F5622DE6"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43674379e1740-wk-Fact-8C84C3AC99B45AE2BA8FC636F5622DE6"
          xlink:to="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43681613e1474-wk-Fact-8C91183376945DA18E85A8BAB3F22AAF"
          xlink:label="d43681613e1474-wk-Fact-8C91183376945DA18E85A8BAB3F22AAF"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43681613e1474-wk-Fact-8C91183376945DA18E85A8BAB3F22AAF"
          xlink:to="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43771853e2956-wk-Fact-8CC7C9AC13B558B88EEA9469BCD245B1"
          xlink:label="d43771853e2956-wk-Fact-8CC7C9AC13B558B88EEA9469BCD245B1"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e2956-wk-Fact-8CC7C9AC13B558B88EEA9469BCD245B1"
          xlink:to="TextSelection-78FC5AB8EFAB585E87BBCF93BE9FBF1D-0-wk-Footnote-78FC5AB8EFAB585E87BBCF93BE9FBF1D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43681613e2491-wk-Fact-8CCB92621D2F5FA2970B7C2EB7A111BE"
          xlink:label="d43681613e2491-wk-Fact-8CCB92621D2F5FA2970B7C2EB7A111BE"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43681613e2491-wk-Fact-8CCB92621D2F5FA2970B7C2EB7A111BE"
          xlink:to="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e7778-wk-Fact-8D17A1AAEAA359D5832C616000B8A948"
          xlink:label="d43770747e7778-wk-Fact-8D17A1AAEAA359D5832C616000B8A948"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e7778-wk-Fact-8D17A1AAEAA359D5832C616000B8A948"
          xlink:to="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e7778-wk-Fact-8D17A1AAEAA359D5832C616000B8A948"
          xlink:to="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687849e1472-wk-Fact-8D699BC64D745ABCB0D7483468DED443"
          xlink:label="d43687849e1472-wk-Fact-8D699BC64D745ABCB0D7483468DED443"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e1472-wk-Fact-8D699BC64D745ABCB0D7483468DED443"
          xlink:to="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e9609-wk-Fact-8E3F5651762058A3BE3D1D3ABAC06BF2"
          xlink:label="d43770747e9609-wk-Fact-8E3F5651762058A3BE3D1D3ABAC06BF2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e9609-wk-Fact-8E3F5651762058A3BE3D1D3ABAC06BF2"
          xlink:to="TextSelection-39CF024D03225486829869F6CA02C00E-0-wk-Footnote-39CF024D03225486829869F6CA02C00E_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e9609-wk-Fact-8E3F5651762058A3BE3D1D3ABAC06BF2"
          xlink:to="TextSelection-53BB8CAFCA475C0C9DB2195050D36025-0-wk-Footnote-53BB8CAFCA475C0C9DB2195050D36025_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e9609-wk-Fact-8E3F5651762058A3BE3D1D3ABAC06BF2"
          xlink:to="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687704e1532-wk-Fact-8EACD6F676A95BF0AB83AE15D642DBEA"
          xlink:label="d43687704e1532-wk-Fact-8EACD6F676A95BF0AB83AE15D642DBEA"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d43771853e2301-wk-Fact-8EACD6F676A95BF0AB83AE15D642DBEA"
          xlink:label="d43771853e2301-wk-Fact-8EACD6F676A95BF0AB83AE15D642DBEA"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e1532-wk-Fact-8EACD6F676A95BF0AB83AE15D642DBEA"
          xlink:to="TextSelection-78FC5AB8EFAB585E87BBCF93BE9FBF1D-0-wk-Footnote-78FC5AB8EFAB585E87BBCF93BE9FBF1D_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e2301-wk-Fact-8EACD6F676A95BF0AB83AE15D642DBEA"
          xlink:to="TextSelection-78FC5AB8EFAB585E87BBCF93BE9FBF1D-0-wk-Footnote-78FC5AB8EFAB585E87BBCF93BE9FBF1D_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e1532-wk-Fact-8EACD6F676A95BF0AB83AE15D642DBEA"
          xlink:to="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e2301-wk-Fact-8EACD6F676A95BF0AB83AE15D642DBEA"
          xlink:to="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687849e1153-wk-Fact-8EF4AF6384775AC783C5F87F272BBA35"
          xlink:label="d43687849e1153-wk-Fact-8EF4AF6384775AC783C5F87F272BBA35"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e1153-wk-Fact-8EF4AF6384775AC783C5F87F272BBA35"
          xlink:to="TextSelection-36C36413532355188985D26E3B171357-0-wk-Footnote-36C36413532355188985D26E3B171357_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e1153-wk-Fact-8EF4AF6384775AC783C5F87F272BBA35"
          xlink:to="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687704e1703-wk-Fact-8F2AF78FFD8356E9921CBFEFF7E852B8"
          xlink:label="d43687704e1703-wk-Fact-8F2AF78FFD8356E9921CBFEFF7E852B8"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d43690878e1052-wk-Fact-8F2AF78FFD8356E9921CBFEFF7E852B8"
          xlink:label="d43690878e1052-wk-Fact-8F2AF78FFD8356E9921CBFEFF7E852B8"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43690878e1052-wk-Fact-8F2AF78FFD8356E9921CBFEFF7E852B8"
          xlink:to="TextSelection-792D3AB23D6354CFBB2776AE7F6407B4-0-wk-Footnote-792D3AB23D6354CFBB2776AE7F6407B4_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e1703-wk-Fact-8F2AF78FFD8356E9921CBFEFF7E852B8"
          xlink:to="TextSelection-792D3AB23D6354CFBB2776AE7F6407B4-0-wk-Footnote-792D3AB23D6354CFBB2776AE7F6407B4_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43690878e1052-wk-Fact-8F2AF78FFD8356E9921CBFEFF7E852B8"
          xlink:to="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e1703-wk-Fact-8F2AF78FFD8356E9921CBFEFF7E852B8"
          xlink:to="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43690878e1052-wk-Fact-8F2AF78FFD8356E9921CBFEFF7E852B8"
          xlink:to="TextSelection-9231AC55B8EC5775BC4995B0797F870F-0-wk-Footnote-9231AC55B8EC5775BC4995B0797F870F_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e1703-wk-Fact-8F2AF78FFD8356E9921CBFEFF7E852B8"
          xlink:to="TextSelection-9231AC55B8EC5775BC4995B0797F870F-0-wk-Footnote-9231AC55B8EC5775BC4995B0797F870F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43690878e1932-wk-Fact-8F3C8079FB235F47AFEECF5DBF3A99E7"
          xlink:label="d43690878e1932-wk-Fact-8F3C8079FB235F47AFEECF5DBF3A99E7"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43690878e1932-wk-Fact-8F3C8079FB235F47AFEECF5DBF3A99E7"
          xlink:to="TextSelection-792D3AB23D6354CFBB2776AE7F6407B4-0-wk-Footnote-792D3AB23D6354CFBB2776AE7F6407B4_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e7798-wk-Fact-8F4FBA0654FF59F5B667567DEC33C73B"
          xlink:label="d43770747e7798-wk-Fact-8F4FBA0654FF59F5B667567DEC33C73B"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e7798-wk-Fact-8F4FBA0654FF59F5B667567DEC33C73B"
          xlink:to="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e7798-wk-Fact-8F4FBA0654FF59F5B667567DEC33C73B"
          xlink:to="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e8819-wk-Fact-8F504B317F065E6AB4D6EA024526004B"
          xlink:label="d43770747e8819-wk-Fact-8F504B317F065E6AB4D6EA024526004B"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e8819-wk-Fact-8F504B317F065E6AB4D6EA024526004B"
          xlink:to="TextSelection-39CF024D03225486829869F6CA02C00E-0-wk-Footnote-39CF024D03225486829869F6CA02C00E_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e8819-wk-Fact-8F504B317F065E6AB4D6EA024526004B"
          xlink:to="TextSelection-53BB8CAFCA475C0C9DB2195050D36025-0-wk-Footnote-53BB8CAFCA475C0C9DB2195050D36025_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e8819-wk-Fact-8F504B317F065E6AB4D6EA024526004B"
          xlink:to="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43712496e3466-wk-Fact-8F95E4DDAC9B520C8A1E53E1D2C8CC7B"
          xlink:label="d43712496e3466-wk-Fact-8F95E4DDAC9B520C8A1E53E1D2C8CC7B"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43712496e3466-wk-Fact-8F95E4DDAC9B520C8A1E53E1D2C8CC7B"
          xlink:to="TextSelection-04B3DB4115835E2FBB99EA13FC1FD64B-0-wk-Footnote-04B3DB4115835E2FBB99EA13FC1FD64B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687704e1488-wk-Fact-901AC284652F5C9B93B4B3D55F3C6EAE"
          xlink:label="d43687704e1488-wk-Fact-901AC284652F5C9B93B4B3D55F3C6EAE"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d43697224e1868-wk-Fact-901AC284652F5C9B93B4B3D55F3C6EAE"
          xlink:label="d43697224e1868-wk-Fact-901AC284652F5C9B93B4B3D55F3C6EAE"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43697224e1868-wk-Fact-901AC284652F5C9B93B4B3D55F3C6EAE"
          xlink:to="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e1488-wk-Fact-901AC284652F5C9B93B4B3D55F3C6EAE"
          xlink:to="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43674379e1696-wk-Fact-90502764073B5E8B974A1DC7FD2018F9"
          xlink:label="d43674379e1696-wk-Fact-90502764073B5E8B974A1DC7FD2018F9"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43674379e1696-wk-Fact-90502764073B5E8B974A1DC7FD2018F9"
          xlink:to="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e8919-wk-Fact-905FF1755B2D5F84A3DD31F07D5EFDAF"
          xlink:label="d43770747e8919-wk-Fact-905FF1755B2D5F84A3DD31F07D5EFDAF"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e8919-wk-Fact-905FF1755B2D5F84A3DD31F07D5EFDAF"
          xlink:to="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e8919-wk-Fact-905FF1755B2D5F84A3DD31F07D5EFDAF"
          xlink:to="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e9707-wk-Fact-9086EDAB64E75CD192D2A7C873603ACA"
          xlink:label="d43770747e9707-wk-Fact-9086EDAB64E75CD192D2A7C873603ACA"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e9707-wk-Fact-9086EDAB64E75CD192D2A7C873603ACA"
          xlink:to="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e9707-wk-Fact-9086EDAB64E75CD192D2A7C873603ACA"
          xlink:to="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e11153-wk-Fact-909A7518DD255E87B44DE7EF018F16C1"
          xlink:label="d43770747e11153-wk-Fact-909A7518DD255E87B44DE7EF018F16C1"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e11153-wk-Fact-909A7518DD255E87B44DE7EF018F16C1"
          xlink:to="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e11153-wk-Fact-909A7518DD255E87B44DE7EF018F16C1"
          xlink:to="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43690878e1764-wk-Fact-90C41519A36D526CAAA4ACCAE371F162"
          xlink:label="d43690878e1764-wk-Fact-90C41519A36D526CAAA4ACCAE371F162"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43690878e1764-wk-Fact-90C41519A36D526CAAA4ACCAE371F162"
          xlink:to="TextSelection-792D3AB23D6354CFBB2776AE7F6407B4-0-wk-Footnote-792D3AB23D6354CFBB2776AE7F6407B4_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43712496e1879-wk-Fact-90E6722B594454179E2707D4EF701095"
          xlink:label="d43712496e1879-wk-Fact-90E6722B594454179E2707D4EF701095"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43712496e1879-wk-Fact-90E6722B594454179E2707D4EF701095"
          xlink:to="TextSelection-7160FF67E87550A19177FE255A41A2D7-0-wk-Footnote-7160FF67E87550A19177FE255A41A2D7_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43681613e2401-wk-Fact-910C3C95984A581EB892DD60EDC26455"
          xlink:label="d43681613e2401-wk-Fact-910C3C95984A581EB892DD60EDC26455"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43681613e2401-wk-Fact-910C3C95984A581EB892DD60EDC26455"
          xlink:to="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687704e1448-wk-Fact-916495EF6D70560FBFED7475E53E1BEA"
          xlink:label="d43687704e1448-wk-Fact-916495EF6D70560FBFED7475E53E1BEA"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d43697224e1828-wk-Fact-916495EF6D70560FBFED7475E53E1BEA"
          xlink:label="d43697224e1828-wk-Fact-916495EF6D70560FBFED7475E53E1BEA"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43697224e1828-wk-Fact-916495EF6D70560FBFED7475E53E1BEA"
          xlink:to="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e1448-wk-Fact-916495EF6D70560FBFED7475E53E1BEA"
          xlink:to="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687849e2201-wk-Fact-9172F69C54DD547D933CB7C875628316"
          xlink:label="d43687849e2201-wk-Fact-9172F69C54DD547D933CB7C875628316"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e2201-wk-Fact-9172F69C54DD547D933CB7C875628316"
          xlink:to="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43771853e5612-wk-Fact-91BE74609E00525280568DAA60F6DF3B"
          xlink:label="d43771853e5612-wk-Fact-91BE74609E00525280568DAA60F6DF3B"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e5612-wk-Fact-91BE74609E00525280568DAA60F6DF3B"
          xlink:to="TextSelection-DE7EF4A6663E52BF8D3620854A57A945-0-wk-Footnote-DE7EF4A6663E52BF8D3620854A57A945_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43712496e2318-wk-Fact-91C0C255B43A5416B3C5C28C3BD45315"
          xlink:label="d43712496e2318-wk-Fact-91C0C255B43A5416B3C5C28C3BD45315"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43712496e2318-wk-Fact-91C0C255B43A5416B3C5C28C3BD45315"
          xlink:to="TextSelection-C37CD88178CA35C475D25A62F2B54FED-0-wk-Footnote-C37CD88178CA35C475D25A62F2B54FED_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43697224e1432-wk-Fact-92A8B07CD3785791B6C291224D7DF376"
          xlink:label="d43697224e1432-wk-Fact-92A8B07CD3785791B6C291224D7DF376"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43697224e1432-wk-Fact-92A8B07CD3785791B6C291224D7DF376"
          xlink:to="TextSelection-6E67095C033B51BB9FABBA85E8DC4DFA-0-wk-Footnote-6E67095C033B51BB9FABBA85E8DC4DFA_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43771853e5593-wk-Fact-92C4B36CCF2B53258C24D575B5A46D08"
          xlink:label="d43771853e5593-wk-Fact-92C4B36CCF2B53258C24D575B5A46D08"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e5593-wk-Fact-92C4B36CCF2B53258C24D575B5A46D08"
          xlink:to="TextSelection-DE7EF4A6663E52BF8D3620854A57A945-0-wk-Footnote-DE7EF4A6663E52BF8D3620854A57A945_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43697224e1737-wk-Fact-92DEAC51BE5052E8AC6E2521BB717C22"
          xlink:label="d43697224e1737-wk-Fact-92DEAC51BE5052E8AC6E2521BB717C22"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43697224e1737-wk-Fact-92DEAC51BE5052E8AC6E2521BB717C22"
          xlink:to="TextSelection-ECF6A95A77365D79B2E9D472B81966D9-0-wk-Footnote-ECF6A95A77365D79B2E9D472B81966D9_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e10534-wk-Fact-92E17207D19C5E5A932D3D83BCD07078"
          xlink:label="d43770747e10534-wk-Fact-92E17207D19C5E5A932D3D83BCD07078"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e10534-wk-Fact-92E17207D19C5E5A932D3D83BCD07078"
          xlink:to="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e10534-wk-Fact-92E17207D19C5E5A932D3D83BCD07078"
          xlink:to="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43712496e2177-wk-Fact-93040E88DF5D56A99DAE7E4CE1BBE9F2"
          xlink:label="d43712496e2177-wk-Fact-93040E88DF5D56A99DAE7E4CE1BBE9F2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43712496e2177-wk-Fact-93040E88DF5D56A99DAE7E4CE1BBE9F2"
          xlink:to="TextSelection-C37CD88178CA35C475D25A62F2B54FED-0-wk-Footnote-C37CD88178CA35C475D25A62F2B54FED_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43674379e1633-wk-Fact-93644FE962325258B137234D02EB03E6"
          xlink:label="d43674379e1633-wk-Fact-93644FE962325258B137234D02EB03E6"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43674379e1633-wk-Fact-93644FE962325258B137234D02EB03E6"
          xlink:to="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43674379e881-wk-Fact-93CA7130473D54F2A4475CBF05C3A3EF"
          xlink:label="d43674379e881-wk-Fact-93CA7130473D54F2A4475CBF05C3A3EF"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43674379e881-wk-Fact-93CA7130473D54F2A4475CBF05C3A3EF"
          xlink:to="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43712496e3486-wk-Fact-94001D1F99AF509E84946618AAA5FC87"
          xlink:label="d43712496e3486-wk-Fact-94001D1F99AF509E84946618AAA5FC87"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43712496e3486-wk-Fact-94001D1F99AF509E84946618AAA5FC87"
          xlink:to="TextSelection-04B3DB4115835E2FBB99EA13FC1FD64B-0-wk-Footnote-04B3DB4115835E2FBB99EA13FC1FD64B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43681613e2336-wk-Fact-94268C3E6B575791AF135AE3FFBDED27"
          xlink:label="d43681613e2336-wk-Fact-94268C3E6B575791AF135AE3FFBDED27"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43681613e2336-wk-Fact-94268C3E6B575791AF135AE3FFBDED27"
          xlink:to="TextSelection-3DD94144621C5A68BC21C5DB64345BB9-0-wk-Footnote-3DD94144621C5A68BC21C5DB64345BB9_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43681613e2336-wk-Fact-94268C3E6B575791AF135AE3FFBDED27"
          xlink:to="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43674379e2254-wk-Fact-949EBE5A327851FCB9BF19AA6ACC7A3A"
          xlink:label="d43674379e2254-wk-Fact-949EBE5A327851FCB9BF19AA6ACC7A3A"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43674379e2254-wk-Fact-949EBE5A327851FCB9BF19AA6ACC7A3A"
          xlink:to="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43697240e3308-wk-Fact-94EEFBE86EAF5F65881310E2436550F1"
          xlink:label="d43697240e3308-wk-Fact-94EEFBE86EAF5F65881310E2436550F1"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43697240e3308-wk-Fact-94EEFBE86EAF5F65881310E2436550F1"
          xlink:to="TextSelection-73987C5EBB9C5D43BC69B77F006C18A6-0-wk-Footnote-73987C5EBB9C5D43BC69B77F006C18A6_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43771853e8317-wk-Fact-9577FDA2F67253B8A7F69BB91B1286ED"
          xlink:label="d43771853e8317-wk-Fact-9577FDA2F67253B8A7F69BB91B1286ED"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e8317-wk-Fact-9577FDA2F67253B8A7F69BB91B1286ED"
          xlink:to="TextSelection-C4FFB7FEB33B5D5EBA7924687B243323-0-wk-Footnote-C4FFB7FEB33B5D5EBA7924687B243323_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e10849-wk-Fact-957B6D659FDB5023A7F0DBA1FC6C7332"
          xlink:label="d43770747e10849-wk-Fact-957B6D659FDB5023A7F0DBA1FC6C7332"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e10849-wk-Fact-957B6D659FDB5023A7F0DBA1FC6C7332"
          xlink:to="TextSelection-39CF024D03225486829869F6CA02C00E-0-wk-Footnote-39CF024D03225486829869F6CA02C00E_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e10849-wk-Fact-957B6D659FDB5023A7F0DBA1FC6C7332"
          xlink:to="TextSelection-53BB8CAFCA475C0C9DB2195050D36025-0-wk-Footnote-53BB8CAFCA475C0C9DB2195050D36025_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e10849-wk-Fact-957B6D659FDB5023A7F0DBA1FC6C7332"
          xlink:to="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43674379e2430-wk-Fact-95915EECEB845388928ED9B038AC306C"
          xlink:label="d43674379e2430-wk-Fact-95915EECEB845388928ED9B038AC306C"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43674379e2430-wk-Fact-95915EECEB845388928ED9B038AC306C"
          xlink:to="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e9996-wk-Fact-95C58C19C66A579CB912AE3B96A6747E"
          xlink:label="d43770747e9996-wk-Fact-95C58C19C66A579CB912AE3B96A6747E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e9996-wk-Fact-95C58C19C66A579CB912AE3B96A6747E"
          xlink:to="TextSelection-39CF024D03225486829869F6CA02C00E-0-wk-Footnote-39CF024D03225486829869F6CA02C00E_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e9996-wk-Fact-95C58C19C66A579CB912AE3B96A6747E"
          xlink:to="TextSelection-53BB8CAFCA475C0C9DB2195050D36025-0-wk-Footnote-53BB8CAFCA475C0C9DB2195050D36025_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e9996-wk-Fact-95C58C19C66A579CB912AE3B96A6747E"
          xlink:to="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43771853e5902-wk-Fact-96034CF0E4F8560C81E68935C2975A14"
          xlink:label="d43771853e5902-wk-Fact-96034CF0E4F8560C81E68935C2975A14"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e5902-wk-Fact-96034CF0E4F8560C81E68935C2975A14"
          xlink:to="TextSelection-450A7304FB7E513FB479F6D9A06EF1D3-0-wk-Footnote-450A7304FB7E513FB479F6D9A06EF1D3_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43681613e2857-wk-Fact-9641A5BEA98B590492283AE6831A946D"
          xlink:label="d43681613e2857-wk-Fact-9641A5BEA98B590492283AE6831A946D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43681613e2857-wk-Fact-9641A5BEA98B590492283AE6831A946D"
          xlink:to="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687704e2340-wk-Fact-9652D747D2CD5DF5B4AE1CACCD0A7222"
          xlink:label="d43687704e2340-wk-Fact-9652D747D2CD5DF5B4AE1CACCD0A7222"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e2340-wk-Fact-9652D747D2CD5DF5B4AE1CACCD0A7222"
          xlink:to="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e2340-wk-Fact-9652D747D2CD5DF5B4AE1CACCD0A7222"
          xlink:to="TextSelection-9231AC55B8EC5775BC4995B0797F870F-0-wk-Footnote-9231AC55B8EC5775BC4995B0797F870F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687849e3201-wk-Fact-965936205F21501FABEFE22DBAD6AD70"
          xlink:label="d43687849e3201-wk-Fact-965936205F21501FABEFE22DBAD6AD70"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e3201-wk-Fact-965936205F21501FABEFE22DBAD6AD70"
          xlink:to="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43771853e4837-wk-Fact-970AC97D21605174BC2DCA8AD22AECDF"
          xlink:label="d43771853e4837-wk-Fact-970AC97D21605174BC2DCA8AD22AECDF"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e4837-wk-Fact-970AC97D21605174BC2DCA8AD22AECDF"
          xlink:to="TextSelection-DC6DDCB74FC9523D97BA51FBA6B1C05E-0-wk-Footnote-DC6DDCB74FC9523D97BA51FBA6B1C05E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687704e2872-wk-Fact-9731AEDCAB005D1FBDC36BDD20F9FFF8"
          xlink:label="d43687704e2872-wk-Fact-9731AEDCAB005D1FBDC36BDD20F9FFF8"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e2872-wk-Fact-9731AEDCAB005D1FBDC36BDD20F9FFF8"
          xlink:to="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e2872-wk-Fact-9731AEDCAB005D1FBDC36BDD20F9FFF8"
          xlink:to="TextSelection-9231AC55B8EC5775BC4995B0797F870F-0-wk-Footnote-9231AC55B8EC5775BC4995B0797F870F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687849e2287-wk-Fact-9768F9056D7E593CA8B86BE96384F1DB"
          xlink:label="d43687849e2287-wk-Fact-9768F9056D7E593CA8B86BE96384F1DB"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e2287-wk-Fact-9768F9056D7E593CA8B86BE96384F1DB"
          xlink:to="TextSelection-77536863BCE35B419E3A4119D41DB4BD-0-wk-Footnote-77536863BCE35B419E3A4119D41DB4BD_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e2287-wk-Fact-9768F9056D7E593CA8B86BE96384F1DB"
          xlink:to="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687704e1095-wk-Fact-97AEC38197D45AB8B6B38E3761427F3A"
          xlink:label="d43687704e1095-wk-Fact-97AEC38197D45AB8B6B38E3761427F3A"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e1095-wk-Fact-97AEC38197D45AB8B6B38E3761427F3A"
          xlink:to="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e1095-wk-Fact-97AEC38197D45AB8B6B38E3761427F3A"
          xlink:to="TextSelection-AE19F19C6AE65BBDA7F551089E2E7EDF-0-wk-Footnote-AE19F19C6AE65BBDA7F551089E2E7EDF_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43771853e10424-wk-Fact-9814D8F2526C58C48FBE9FC9B3F3314B"
          xlink:label="d43771853e10424-wk-Fact-9814D8F2526C58C48FBE9FC9B3F3314B"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e10424-wk-Fact-9814D8F2526C58C48FBE9FC9B3F3314B"
          xlink:to="TextSelection-450A7304FB7E513FB479F6D9A06EF1D3-0-wk-Footnote-450A7304FB7E513FB479F6D9A06EF1D3_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43692105e1217-wk-Fact-985F88532E195B47BDB854CF286F26CD"
          xlink:label="d43692105e1217-wk-Fact-985F88532E195B47BDB854CF286F26CD"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43692105e1217-wk-Fact-985F88532E195B47BDB854CF286F26CD"
          xlink:to="TextSelection-2A36E737FFF05E75B357CB41AFB5B6E2-0-wk-Footnote-2A36E737FFF05E75B357CB41AFB5B6E2_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e4946-wk-Fact-9897B650EC365D66BE5F4FE1539C840D"
          xlink:label="d43770747e4946-wk-Fact-9897B650EC365D66BE5F4FE1539C840D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e4946-wk-Fact-9897B650EC365D66BE5F4FE1539C840D"
          xlink:to="TextSelection-2BFD6C99096B50AD93705C5601B21F46-0-wk-Footnote-2BFD6C99096B50AD93705C5601B21F46_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687704e2891-wk-Fact-98E7EC7835B052E592B533FDD3656AFB"
          xlink:label="d43687704e2891-wk-Fact-98E7EC7835B052E592B533FDD3656AFB"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e2891-wk-Fact-98E7EC7835B052E592B533FDD3656AFB"
          xlink:to="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e2891-wk-Fact-98E7EC7835B052E592B533FDD3656AFB"
          xlink:to="TextSelection-9231AC55B8EC5775BC4995B0797F870F-0-wk-Footnote-9231AC55B8EC5775BC4995B0797F870F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43681613e2540-wk-Fact-98FDF1C40AF759C4B5005A20CA031801"
          xlink:label="d43681613e2540-wk-Fact-98FDF1C40AF759C4B5005A20CA031801"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43681613e2540-wk-Fact-98FDF1C40AF759C4B5005A20CA031801"
          xlink:to="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687849e2865-wk-Fact-990F7FE47CEA5D99BCE375CA7BAC5739"
          xlink:label="d43687849e2865-wk-Fact-990F7FE47CEA5D99BCE375CA7BAC5739"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e2865-wk-Fact-990F7FE47CEA5D99BCE375CA7BAC5739"
          xlink:to="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43690878e1364-wk-Fact-9943CA1B5CD35B98836DDF43C586A63B"
          xlink:label="d43690878e1364-wk-Fact-9943CA1B5CD35B98836DDF43C586A63B"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43690878e1364-wk-Fact-9943CA1B5CD35B98836DDF43C586A63B"
          xlink:to="TextSelection-792D3AB23D6354CFBB2776AE7F6407B4-0-wk-Footnote-792D3AB23D6354CFBB2776AE7F6407B4_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43697224e1257-wk-Fact-994608FEC5B95CBF9C3D06616F806463"
          xlink:label="d43697224e1257-wk-Fact-994608FEC5B95CBF9C3D06616F806463"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43697224e1257-wk-Fact-994608FEC5B95CBF9C3D06616F806463"
          xlink:to="TextSelection-7679A63ACE625532ADFCC5B97C6C9FC6-0-wk-Footnote-7679A63ACE625532ADFCC5B97C6C9FC6_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43712496e1450-wk-Fact-9947697CFC005CC4B553C619A29CF327"
          xlink:label="d43712496e1450-wk-Fact-9947697CFC005CC4B553C619A29CF327"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d43712496e3419-wk-Fact-9947697CFC005CC4B553C619A29CF327"
          xlink:label="d43712496e3419-wk-Fact-9947697CFC005CC4B553C619A29CF327"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43712496e1450-wk-Fact-9947697CFC005CC4B553C619A29CF327"
          xlink:to="TextSelection-B57619F44FCF544D96067CF4816A9082-0-wk-Footnote-B57619F44FCF544D96067CF4816A9082_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43712496e3419-wk-Fact-9947697CFC005CC4B553C619A29CF327"
          xlink:to="TextSelection-B57619F44FCF544D96067CF4816A9082-0-wk-Footnote-B57619F44FCF544D96067CF4816A9082_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43678813e975-wk-Fact-9A5C2CB5B6525CAF82F961091ABF22D5"
          xlink:label="d43678813e975-wk-Fact-9A5C2CB5B6525CAF82F961091ABF22D5"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43678813e975-wk-Fact-9A5C2CB5B6525CAF82F961091ABF22D5"
          xlink:to="TextSelection-E16E3AA57ADF5C6FB93B6FC578ED7F95-0-wk-Footnote-E16E3AA57ADF5C6FB93B6FC578ED7F95_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687849e1625-wk-Fact-9A9E5B540C0052C7BE5FB833D0FCA0E3"
          xlink:label="d43687849e1625-wk-Fact-9A9E5B540C0052C7BE5FB833D0FCA0E3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e1625-wk-Fact-9A9E5B540C0052C7BE5FB833D0FCA0E3"
          xlink:to="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e1625-wk-Fact-9A9E5B540C0052C7BE5FB833D0FCA0E3"
          xlink:to="TextSelection-F185CD45BC245C2EB8EDBFD55DB8A33F-0-wk-Footnote-F185CD45BC245C2EB8EDBFD55DB8A33F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e11222-wk-Fact-9ABA0C515EA950C6981FD708D959A2E8"
          xlink:label="d43770747e11222-wk-Fact-9ABA0C515EA950C6981FD708D959A2E8"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e11222-wk-Fact-9ABA0C515EA950C6981FD708D959A2E8"
          xlink:to="TextSelection-39CF024D03225486829869F6CA02C00E-0-wk-Footnote-39CF024D03225486829869F6CA02C00E_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e11222-wk-Fact-9ABA0C515EA950C6981FD708D959A2E8"
          xlink:to="TextSelection-53BB8CAFCA475C0C9DB2195050D36025-0-wk-Footnote-53BB8CAFCA475C0C9DB2195050D36025_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e11222-wk-Fact-9ABA0C515EA950C6981FD708D959A2E8"
          xlink:to="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e9767-wk-Fact-9AFC9FBE04FB5689977BCF73503C994B"
          xlink:label="d43770747e9767-wk-Fact-9AFC9FBE04FB5689977BCF73503C994B"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e9767-wk-Fact-9AFC9FBE04FB5689977BCF73503C994B"
          xlink:to="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e9767-wk-Fact-9AFC9FBE04FB5689977BCF73503C994B"
          xlink:to="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43697224e1344-wk-Fact-9B9CE720BFE65909A3F34FE77F5D328D"
          xlink:label="d43697224e1344-wk-Fact-9B9CE720BFE65909A3F34FE77F5D328D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43697224e1344-wk-Fact-9B9CE720BFE65909A3F34FE77F5D328D"
          xlink:to="TextSelection-7430C81CDF35536B95DB492D56AB6CFD-0-wk-Footnote-7430C81CDF35536B95DB492D56AB6CFD_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e5703-wk-Fact-9BD0B9C42899598DB27286851288BA9C"
          xlink:label="d43770747e5703-wk-Fact-9BD0B9C42899598DB27286851288BA9C"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e5703-wk-Fact-9BD0B9C42899598DB27286851288BA9C"
          xlink:to="TextSelection-0BDE8CEE983B5F118E2EFACDF9CC6405-0-wk-Footnote-0BDE8CEE983B5F118E2EFACDF9CC6405_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43681613e2446-wk-Fact-9C5F9B5D363652D592CA2481C87B9506"
          xlink:label="d43681613e2446-wk-Fact-9C5F9B5D363652D592CA2481C87B9506"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43681613e2446-wk-Fact-9C5F9B5D363652D592CA2481C87B9506"
          xlink:to="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e8093-wk-Fact-9CA0877B96475CE6BFD987BA91892F67"
          xlink:label="d43770747e8093-wk-Fact-9CA0877B96475CE6BFD987BA91892F67"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e8093-wk-Fact-9CA0877B96475CE6BFD987BA91892F67"
          xlink:to="TextSelection-39CF024D03225486829869F6CA02C00E-0-wk-Footnote-39CF024D03225486829869F6CA02C00E_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e8093-wk-Fact-9CA0877B96475CE6BFD987BA91892F67"
          xlink:to="TextSelection-53BB8CAFCA475C0C9DB2195050D36025-0-wk-Footnote-53BB8CAFCA475C0C9DB2195050D36025_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e8093-wk-Fact-9CA0877B96475CE6BFD987BA91892F67"
          xlink:to="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687704e1742-wk-Fact-9CDAD2B93E775B8EA25F98BBA2F83485"
          xlink:label="d43687704e1742-wk-Fact-9CDAD2B93E775B8EA25F98BBA2F83485"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d43690878e1091-wk-Fact-9CDAD2B93E775B8EA25F98BBA2F83485"
          xlink:label="d43690878e1091-wk-Fact-9CDAD2B93E775B8EA25F98BBA2F83485"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e1742-wk-Fact-9CDAD2B93E775B8EA25F98BBA2F83485"
          xlink:to="TextSelection-792D3AB23D6354CFBB2776AE7F6407B4-0-wk-Footnote-792D3AB23D6354CFBB2776AE7F6407B4_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43690878e1091-wk-Fact-9CDAD2B93E775B8EA25F98BBA2F83485"
          xlink:to="TextSelection-792D3AB23D6354CFBB2776AE7F6407B4-0-wk-Footnote-792D3AB23D6354CFBB2776AE7F6407B4_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e1742-wk-Fact-9CDAD2B93E775B8EA25F98BBA2F83485"
          xlink:to="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43690878e1091-wk-Fact-9CDAD2B93E775B8EA25F98BBA2F83485"
          xlink:to="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e1742-wk-Fact-9CDAD2B93E775B8EA25F98BBA2F83485"
          xlink:to="TextSelection-9231AC55B8EC5775BC4995B0797F870F-0-wk-Footnote-9231AC55B8EC5775BC4995B0797F870F_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43690878e1091-wk-Fact-9CDAD2B93E775B8EA25F98BBA2F83485"
          xlink:to="TextSelection-9231AC55B8EC5775BC4995B0797F870F-0-wk-Footnote-9231AC55B8EC5775BC4995B0797F870F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43771853e5631-wk-Fact-9D09FA5E842755B1A0C73898B8865ED0"
          xlink:label="d43771853e5631-wk-Fact-9D09FA5E842755B1A0C73898B8865ED0"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e5631-wk-Fact-9D09FA5E842755B1A0C73898B8865ED0"
          xlink:to="TextSelection-DE7EF4A6663E52BF8D3620854A57A945-0-wk-Footnote-DE7EF4A6663E52BF8D3620854A57A945_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43712496e1602-wk-Fact-9DB7D15107575A4E87DEBC34B67A7866"
          xlink:label="d43712496e1602-wk-Fact-9DB7D15107575A4E87DEBC34B67A7866"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43712496e1602-wk-Fact-9DB7D15107575A4E87DEBC34B67A7866"
          xlink:to="TextSelection-C882D128F7C35640B8C0E15448983D9E-0-wk-Footnote-C882D128F7C35640B8C0E15448983D9E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687849e1322-wk-Fact-9DF54FB1EA595037ACB26A2654176B64"
          xlink:label="d43687849e1322-wk-Fact-9DF54FB1EA595037ACB26A2654176B64"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e1322-wk-Fact-9DF54FB1EA595037ACB26A2654176B64"
          xlink:to="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43691920e1183-wk-Fact-9E3C8C139B5F5A29BA180FCB89C053CB"
          xlink:label="d43691920e1183-wk-Fact-9E3C8C139B5F5A29BA180FCB89C053CB"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43691920e1183-wk-Fact-9E3C8C139B5F5A29BA180FCB89C053CB"
          xlink:to="TextSelection-C94190737D79577A8993EFAC2CD3FC95-0-wk-Footnote-C94190737D79577A8993EFAC2CD3FC95_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43771853e10035-wk-Fact-9E503F48EBD8524C93A07C83B1436882"
          xlink:label="d43771853e10035-wk-Fact-9E503F48EBD8524C93A07C83B1436882"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e10035-wk-Fact-9E503F48EBD8524C93A07C83B1436882"
          xlink:to="TextSelection-3AE2F5A9070951C0ACDF4F146E825D8D-0-wk-Footnote-3AE2F5A9070951C0ACDF4F146E825D8D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43771853e1608-wk-Fact-9F0EA4485B0153C7823866D0926BA03D"
          xlink:label="d43771853e1608-wk-Fact-9F0EA4485B0153C7823866D0926BA03D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e1608-wk-Fact-9F0EA4485B0153C7823866D0926BA03D"
          xlink:to="TextSelection-78FC5AB8EFAB585E87BBCF93BE9FBF1D-0-wk-Footnote-78FC5AB8EFAB585E87BBCF93BE9FBF1D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687849e2607-wk-Fact-9F76A95D96735FEB9B3AA6495B54B6C9"
          xlink:label="d43687849e2607-wk-Fact-9F76A95D96735FEB9B3AA6495B54B6C9"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e2607-wk-Fact-9F76A95D96735FEB9B3AA6495B54B6C9"
          xlink:to="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43674379e2767-wk-Fact-A00F92664332571D9A768489A67E66E0"
          xlink:label="d43674379e2767-wk-Fact-A00F92664332571D9A768489A67E66E0"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43674379e2767-wk-Fact-A00F92664332571D9A768489A67E66E0"
          xlink:to="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687849e2567-wk-Fact-A0788365B82455288EB3A6C6558EC05A"
          xlink:label="d43687849e2567-wk-Fact-A0788365B82455288EB3A6C6558EC05A"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e2567-wk-Fact-A0788365B82455288EB3A6C6558EC05A"
          xlink:to="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43674379e2564-wk-Fact-A0D16119E38D5A9FAB554486905A9CCC"
          xlink:label="d43674379e2564-wk-Fact-A0D16119E38D5A9FAB554486905A9CCC"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43674379e2564-wk-Fact-A0D16119E38D5A9FAB554486905A9CCC"
          xlink:to="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43681613e1673-wk-Fact-A0FAAC12696C59849AE70392155E65FF"
          xlink:label="d43681613e1673-wk-Fact-A0FAAC12696C59849AE70392155E65FF"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43681613e1673-wk-Fact-A0FAAC12696C59849AE70392155E65FF"
          xlink:to="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43674379e1165-wk-Fact-A14EC3C3E45252D8988217A4980EB580"
          xlink:label="d43674379e1165-wk-Fact-A14EC3C3E45252D8988217A4980EB580"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43674379e1165-wk-Fact-A14EC3C3E45252D8988217A4980EB580"
          xlink:to="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43697224e1047-wk-Fact-A15E72E726725EF2BD9FCCCC3A222E16"
          xlink:label="d43697224e1047-wk-Fact-A15E72E726725EF2BD9FCCCC3A222E16"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43697224e1047-wk-Fact-A15E72E726725EF2BD9FCCCC3A222E16"
          xlink:to="TextSelection-FE5DD06AA8B65777900C47B8AC19C4C6-0-wk-Footnote-FE5DD06AA8B65777900C47B8AC19C4C6_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43771853e10385-wk-Fact-A18BC4FC7BA15BDA9B32041CAF276842"
          xlink:label="d43771853e10385-wk-Fact-A18BC4FC7BA15BDA9B32041CAF276842"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e10385-wk-Fact-A18BC4FC7BA15BDA9B32041CAF276842"
          xlink:to="TextSelection-450A7304FB7E513FB479F6D9A06EF1D3-0-wk-Footnote-450A7304FB7E513FB479F6D9A06EF1D3_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43771853e1588-wk-Fact-A18F9A2CB32656BA9AA6CDE701027F25"
          xlink:label="d43771853e1588-wk-Fact-A18F9A2CB32656BA9AA6CDE701027F25"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e1588-wk-Fact-A18F9A2CB32656BA9AA6CDE701027F25"
          xlink:to="TextSelection-78FC5AB8EFAB585E87BBCF93BE9FBF1D-0-wk-Footnote-78FC5AB8EFAB585E87BBCF93BE9FBF1D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43697240e1285-wk-Fact-A1B9EBB00CA357B685505D97968F301E"
          xlink:label="d43697240e1285-wk-Fact-A1B9EBB00CA357B685505D97968F301E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43697240e1285-wk-Fact-A1B9EBB00CA357B685505D97968F301E"
          xlink:to="TextSelection-7432EEEACAB3598FA522C1D7E1584D05-0-wk-Footnote-7432EEEACAB3598FA522C1D7E1584D05_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43681613e1493-wk-Fact-A1C1CAB3E9EF556989E8998B597D9BF9"
          xlink:label="d43681613e1493-wk-Fact-A1C1CAB3E9EF556989E8998B597D9BF9"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43681613e1493-wk-Fact-A1C1CAB3E9EF556989E8998B597D9BF9"
          xlink:to="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43690878e1725-wk-Fact-A1F4A6FC924452F79F29E27B44D8E522"
          xlink:label="d43690878e1725-wk-Fact-A1F4A6FC924452F79F29E27B44D8E522"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43690878e1725-wk-Fact-A1F4A6FC924452F79F29E27B44D8E522"
          xlink:to="TextSelection-792D3AB23D6354CFBB2776AE7F6407B4-0-wk-Footnote-792D3AB23D6354CFBB2776AE7F6407B4_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43697224e1604-wk-Fact-A203EA72411358678C6144B3CC9481A2"
          xlink:label="d43697224e1604-wk-Fact-A203EA72411358678C6144B3CC9481A2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43697224e1604-wk-Fact-A203EA72411358678C6144B3CC9481A2"
          xlink:to="TextSelection-8C5E9E30C7EB5291A3E0EE605FC281E8-0-wk-Footnote-8C5E9E30C7EB5291A3E0EE605FC281E8_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43771853e4722-wk-Fact-A244DBBB4D375344919B8BE000C88D5E"
          xlink:label="d43771853e4722-wk-Fact-A244DBBB4D375344919B8BE000C88D5E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e4722-wk-Fact-A244DBBB4D375344919B8BE000C88D5E"
          xlink:to="TextSelection-E9F14C2885BA59D8B6B4AD221FC38619-0-wk-Footnote-E9F14C2885BA59D8B6B4AD221FC38619_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43692105e1237-wk-Fact-A34EE90663FB5081B9E32DEADBF0E652"
          xlink:label="d43692105e1237-wk-Fact-A34EE90663FB5081B9E32DEADBF0E652"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43692105e1237-wk-Fact-A34EE90663FB5081B9E32DEADBF0E652"
          xlink:to="TextSelection-2A36E737FFF05E75B357CB41AFB5B6E2-0-wk-Footnote-2A36E737FFF05E75B357CB41AFB5B6E2_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43674379e1899-wk-Fact-A38618717132561C9E1931D14EDF6B51"
          xlink:label="d43674379e1899-wk-Fact-A38618717132561C9E1931D14EDF6B51"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d43770747e2170-wk-Fact-A38618717132561C9E1931D14EDF6B51"
          xlink:label="d43770747e2170-wk-Fact-A38618717132561C9E1931D14EDF6B51"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43674379e1899-wk-Fact-A38618717132561C9E1931D14EDF6B51"
          xlink:to="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e2170-wk-Fact-A38618717132561C9E1931D14EDF6B51"
          xlink:to="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"
          xlink:type="arc"/>
        <link:footnote id="TextSelection-CBF70F977965537BB382CD083809AA0A-0-wk-Footnote-CBF70F977965537BB382CD083809AA0A_lbl" xlink:label="TextSelection-CBF70F977965537BB382CD083809AA0A-0-wk-Footnote-CBF70F977965537BB382CD083809AA0A_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The fair value of our long-term debt (not including the current portion of long-term debt) was <xhtml:span style="font-family:inherit;font-size:8.5pt;"><xhtml:span>$39.0 billion</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"> as of </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;">October&#160;1, 2017</xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"> and </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"><xhtml:span>$34.9 billion</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"> as of </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;text-align:center;">December&#160;31, 2016</xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;">. The fair value measurements for our long-term debt are based on Level 2 inputs, using a market approach. Long-term debt includes foreign currency long-term borrowings with fair values of </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"><xhtml:span>$4.7 billion</xhtml:span></xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;"> as of </xhtml:span><xhtml:span style="font-family:inherit;font-size:8.5pt;">October&#160;1, 2017</xhtml:span>, which are used as hedging instruments.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43674379e1899-wk-Fact-A38618717132561C9E1931D14EDF6B51"
          xlink:to="TextSelection-CBF70F977965537BB382CD083809AA0A-0-wk-Footnote-CBF70F977965537BB382CD083809AA0A_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e2170-wk-Fact-A38618717132561C9E1931D14EDF6B51"
          xlink:to="TextSelection-CBF70F977965537BB382CD083809AA0A-0-wk-Footnote-CBF70F977965537BB382CD083809AA0A_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43771853e10093-wk-Fact-A3F1EC328F9650DFB210D8224644F83E"
          xlink:label="d43771853e10093-wk-Fact-A3F1EC328F9650DFB210D8224644F83E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e10093-wk-Fact-A3F1EC328F9650DFB210D8224644F83E"
          xlink:to="TextSelection-3AE2F5A9070951C0ACDF4F146E825D8D-0-wk-Footnote-3AE2F5A9070951C0ACDF4F146E825D8D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687849e2052-wk-Fact-A4006F8721A75370B615CE7A639018C5"
          xlink:label="d43687849e2052-wk-Fact-A4006F8721A75370B615CE7A639018C5"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e2052-wk-Fact-A4006F8721A75370B615CE7A639018C5"
          xlink:to="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43697224e1690-wk-Fact-A40CCA358E885B1BBACDE3FEAE88386D"
          xlink:label="d43697224e1690-wk-Fact-A40CCA358E885B1BBACDE3FEAE88386D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43697224e1690-wk-Fact-A40CCA358E885B1BBACDE3FEAE88386D"
          xlink:to="TextSelection-9C73CEBDEE585A83B2B18F3B38A6D8CD-0-wk-Footnote-9C73CEBDEE585A83B2B18F3B38A6D8CD_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43674379e1234-wk-Fact-A41E764041225C8DBE154ADB89FBF66C"
          xlink:label="d43674379e1234-wk-Fact-A41E764041225C8DBE154ADB89FBF66C"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d43697240e2316-wk-Fact-A41E764041225C8DBE154ADB89FBF66C"
          xlink:label="d43697240e2316-wk-Fact-A41E764041225C8DBE154ADB89FBF66C"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43697240e2316-wk-Fact-A41E764041225C8DBE154ADB89FBF66C"
          xlink:to="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43674379e1234-wk-Fact-A41E764041225C8DBE154ADB89FBF66C"
          xlink:to="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43697240e2316-wk-Fact-A41E764041225C8DBE154ADB89FBF66C"
          xlink:to="TextSelection-FF348CC7844F523299A112551B170BE6-0-wk-Footnote-FF348CC7844F523299A112551B170BE6_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43674379e1234-wk-Fact-A41E764041225C8DBE154ADB89FBF66C"
          xlink:to="TextSelection-FF348CC7844F523299A112551B170BE6-0-wk-Footnote-FF348CC7844F523299A112551B170BE6_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43712496e2007-wk-Fact-A453B8F62ABE5E21AF62323699CCC8B0"
          xlink:label="d43712496e2007-wk-Fact-A453B8F62ABE5E21AF62323699CCC8B0"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43712496e2007-wk-Fact-A453B8F62ABE5E21AF62323699CCC8B0"
          xlink:to="TextSelection-7160FF67E87550A19177FE255A41A2D7-0-wk-Footnote-7160FF67E87550A19177FE255A41A2D7_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43697224e1005-wk-Fact-A5329E1466235B2299472011E1D4E1D3"
          xlink:label="d43697224e1005-wk-Fact-A5329E1466235B2299472011E1D4E1D3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43697224e1005-wk-Fact-A5329E1466235B2299472011E1D4E1D3"
          xlink:to="TextSelection-FE5DD06AA8B65777900C47B8AC19C4C6-0-wk-Footnote-FE5DD06AA8B65777900C47B8AC19C4C6_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43674379e1962-wk-Fact-A538FCC6CCC752E695D754993DC8690B"
          xlink:label="d43674379e1962-wk-Fact-A538FCC6CCC752E695D754993DC8690B"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43674379e1962-wk-Fact-A538FCC6CCC752E695D754993DC8690B"
          xlink:to="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43697240e2276-wk-Fact-A5D936B4270856D1A914ABA7E1D66F0A"
          xlink:label="d43697240e2276-wk-Fact-A5D936B4270856D1A914ABA7E1D66F0A"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43697240e2276-wk-Fact-A5D936B4270856D1A914ABA7E1D66F0A"
          xlink:to="TextSelection-FF348CC7844F523299A112551B170BE6-0-wk-Footnote-FF348CC7844F523299A112551B170BE6_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43681613e1699-wk-Fact-A6186BEADB90579F8CFC02466DEAFB87"
          xlink:label="d43681613e1699-wk-Fact-A6186BEADB90579F8CFC02466DEAFB87"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43681613e1699-wk-Fact-A6186BEADB90579F8CFC02466DEAFB87"
          xlink:to="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43697224e1285-wk-Fact-A648DF513A135C13B3F96F3C76C2A737"
          xlink:label="d43697224e1285-wk-Fact-A648DF513A135C13B3F96F3C76C2A737"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43697224e1285-wk-Fact-A648DF513A135C13B3F96F3C76C2A737"
          xlink:to="TextSelection-7430C81CDF35536B95DB492D56AB6CFD-0-wk-Footnote-7430C81CDF35536B95DB492D56AB6CFD_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e4984-wk-Fact-A6A09D6704F35EF6866E3822B7B2DC81"
          xlink:label="d43770747e4984-wk-Fact-A6A09D6704F35EF6866E3822B7B2DC81"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e4984-wk-Fact-A6A09D6704F35EF6866E3822B7B2DC81"
          xlink:to="TextSelection-2BFD6C99096B50AD93705C5601B21F46-0-wk-Footnote-2BFD6C99096B50AD93705C5601B21F46_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687849e2482-wk-Fact-A6BAD49A94C058098F01D059FDF7D0BF"
          xlink:label="d43687849e2482-wk-Fact-A6BAD49A94C058098F01D059FDF7D0BF"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e2482-wk-Fact-A6BAD49A94C058098F01D059FDF7D0BF"
          xlink:to="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e11242-wk-Fact-A6EB4F0FD63E5855AF650D3234A6748E"
          xlink:label="d43770747e11242-wk-Fact-A6EB4F0FD63E5855AF650D3234A6748E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e11242-wk-Fact-A6EB4F0FD63E5855AF650D3234A6748E"
          xlink:to="TextSelection-39CF024D03225486829869F6CA02C00E-0-wk-Footnote-39CF024D03225486829869F6CA02C00E_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e11242-wk-Fact-A6EB4F0FD63E5855AF650D3234A6748E"
          xlink:to="TextSelection-53BB8CAFCA475C0C9DB2195050D36025-0-wk-Footnote-53BB8CAFCA475C0C9DB2195050D36025_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e11242-wk-Fact-A6EB4F0FD63E5855AF650D3234A6748E"
          xlink:to="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e5801-wk-Fact-A6F46F05463058AFAEAF923B7651C709"
          xlink:label="d43770747e5801-wk-Fact-A6F46F05463058AFAEAF923B7651C709"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-A42108BE06A7587BABD0C4A820609CE4-0-wk-Footnote-A42108BE06A7587BABD0C4A820609CE4_lbl" xlink:label="TextSelection-A42108BE06A7587BABD0C4A820609CE4-0-wk-Footnote-A42108BE06A7587BABD0C4A820609CE4_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The weighted-average effective interest rate for the euro notes at issuance was <xhtml:span style="font-family:inherit;font-size:8.5pt;"><xhtml:span>0.23%</xhtml:span></xhtml:span>.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e5801-wk-Fact-A6F46F05463058AFAEAF923B7651C709"
          xlink:to="TextSelection-A42108BE06A7587BABD0C4A820609CE4-0-wk-Footnote-A42108BE06A7587BABD0C4A820609CE4_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43771853e11523-wk-Fact-A70792548E685ABAA23DB0FA57120893"
          xlink:label="d43771853e11523-wk-Fact-A70792548E685ABAA23DB0FA57120893"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e11523-wk-Fact-A70792548E685ABAA23DB0FA57120893"
          xlink:to="TextSelection-450A7304FB7E513FB479F6D9A06EF1D3-0-wk-Footnote-450A7304FB7E513FB479F6D9A06EF1D3_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e4077-wk-Fact-A7D161E015BF50168317EC6EF30D2E9C"
          xlink:label="d43770747e4077-wk-Fact-A7D161E015BF50168317EC6EF30D2E9C"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e4077-wk-Fact-A7D161E015BF50168317EC6EF30D2E9C"
          xlink:to="TextSelection-7EC55EFE69505245B1A079B8132EFBB7-0-wk-Footnote-7EC55EFE69505245B1A079B8132EFBB7_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43674379e2748-wk-Fact-A7FCAA4C427E5D3F9EA836ACF3C4D395"
          xlink:label="d43674379e2748-wk-Fact-A7FCAA4C427E5D3F9EA836ACF3C4D395"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43674379e2748-wk-Fact-A7FCAA4C427E5D3F9EA836ACF3C4D395"
          xlink:to="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43771853e2814-wk-Fact-A84CE5053CF85BC4965B4D4988840327"
          xlink:label="d43771853e2814-wk-Fact-A84CE5053CF85BC4965B4D4988840327"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e2814-wk-Fact-A84CE5053CF85BC4965B4D4988840327"
          xlink:to="TextSelection-78FC5AB8EFAB585E87BBCF93BE9FBF1D-0-wk-Footnote-78FC5AB8EFAB585E87BBCF93BE9FBF1D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43771853e3476-wk-Fact-A872003B0DA95195BC5493ACF35066FF"
          xlink:label="d43771853e3476-wk-Fact-A872003B0DA95195BC5493ACF35066FF"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e3476-wk-Fact-A872003B0DA95195BC5493ACF35066FF"
          xlink:to="TextSelection-78FC5AB8EFAB585E87BBCF93BE9FBF1D-0-wk-Footnote-78FC5AB8EFAB585E87BBCF93BE9FBF1D_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e3476-wk-Fact-A872003B0DA95195BC5493ACF35066FF"
          xlink:to="TextSelection-8540AADB45BE54D38C10451BF6A88AB4-0-wk-Footnote-8540AADB45BE54D38C10451BF6A88AB4_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43697240e1304-wk-Fact-A8BCB7724076572A894D8BDFC6785A6A"
          xlink:label="d43697240e1304-wk-Fact-A8BCB7724076572A894D8BDFC6785A6A"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43697240e1304-wk-Fact-A8BCB7724076572A894D8BDFC6785A6A"
          xlink:to="TextSelection-7432EEEACAB3598FA522C1D7E1584D05-0-wk-Footnote-7432EEEACAB3598FA522C1D7E1584D05_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43771853e11465-wk-Fact-A8CAE70BC2A35982B714238C0AC51A79"
          xlink:label="d43771853e11465-wk-Fact-A8CAE70BC2A35982B714238C0AC51A79"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e11465-wk-Fact-A8CAE70BC2A35982B714238C0AC51A79"
          xlink:to="TextSelection-450A7304FB7E513FB479F6D9A06EF1D3-0-wk-Footnote-450A7304FB7E513FB479F6D9A06EF1D3_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43771853e4644-wk-Fact-A8E12836BA70521E8E7886584342E2F2"
          xlink:label="d43771853e4644-wk-Fact-A8E12836BA70521E8E7886584342E2F2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e4644-wk-Fact-A8E12836BA70521E8E7886584342E2F2"
          xlink:to="TextSelection-3802305E73EB52F28FAAF4EA5481D580-0-wk-Footnote-3802305E73EB52F28FAAF4EA5481D580_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e1314-wk-Fact-A8F0564C8A745E648231F57D9FCE7C93"
          xlink:label="d43770747e1314-wk-Fact-A8F0564C8A745E648231F57D9FCE7C93"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e1314-wk-Fact-A8F0564C8A745E648231F57D9FCE7C93"
          xlink:to="TextSelection-E90A054BCC035ECEB6B6F2B7C947C3CE-0-wk-Footnote-E90A054BCC035ECEB6B6F2B7C947C3CE_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43712496e1962-wk-Fact-A8F5B5BE613E55E4B3F2C69F2B5B38E3"
          xlink:label="d43712496e1962-wk-Fact-A8F5B5BE613E55E4B3F2C69F2B5B38E3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43712496e1962-wk-Fact-A8F5B5BE613E55E4B3F2C69F2B5B38E3"
          xlink:to="TextSelection-7160FF67E87550A19177FE255A41A2D7-0-wk-Footnote-7160FF67E87550A19177FE255A41A2D7_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43771853e11183-wk-Fact-A931585378205E5DA65545918DAAB331"
          xlink:label="d43771853e11183-wk-Fact-A931585378205E5DA65545918DAAB331"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e11183-wk-Fact-A931585378205E5DA65545918DAAB331"
          xlink:to="TextSelection-ED6F6E1A7C41596DA6F5B1BDFBB72CB7-0-wk-Footnote-ED6F6E1A7C41596DA6F5B1BDFBB72CB7_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e3230-wk-Fact-A940673F4FF9572DA53F97129770EE39"
          xlink:label="d43770747e3230-wk-Fact-A940673F4FF9572DA53F97129770EE39"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e3230-wk-Fact-A940673F4FF9572DA53F97129770EE39"
          xlink:to="TextSelection-8C173666F61E55D5A1394009569043BA-0-wk-Footnote-8C173666F61E55D5A1394009569043BA_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43712496e1641-wk-Fact-A94165CF2AD857B7B67158131637F55C"
          xlink:label="d43712496e1641-wk-Fact-A94165CF2AD857B7B67158131637F55C"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43712496e1641-wk-Fact-A94165CF2AD857B7B67158131637F55C"
          xlink:to="TextSelection-C882D128F7C35640B8C0E15448983D9E-0-wk-Footnote-C882D128F7C35640B8C0E15448983D9E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43771853e5469-wk-Fact-A95EC0EF20D05434AF953959C36E2AA3"
          xlink:label="d43771853e5469-wk-Fact-A95EC0EF20D05434AF953959C36E2AA3"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-84795AFB20AD54C48C963C7C52B00178-0-wk-Footnote-84795AFB20AD54C48C963C7C52B00178_lbl" xlink:label="TextSelection-84795AFB20AD54C48C963C7C52B00178-0-wk-Footnote-84795AFB20AD54C48C963C7C52B00178_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The IH business encompasses Internal Medicine, Vaccines, Oncology, Inflammation &amp; Immunology, Rare Disease and Consumer Healthcare. Through December 31, 2016, includes Duavive/Duavee and Viviant (recorded in All other Internal Medicine in 2016), which were transferred from Innovative Health to Essential Health effective January 1, 2017 (recorded in All other LEP (EH) beginning January 1, 2017), in order to align these products with our management of the women&#x2019;s health portfolio within EH. </link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e5469-wk-Fact-A95EC0EF20D05434AF953959C36E2AA3"
          xlink:to="TextSelection-84795AFB20AD54C48C963C7C52B00178-0-wk-Footnote-84795AFB20AD54C48C963C7C52B00178_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43771853e4706-wk-Fact-A9623F46D9315CFAA20B6FD10082039D"
          xlink:label="d43771853e4706-wk-Fact-A9623F46D9315CFAA20B6FD10082039D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e4706-wk-Fact-A9623F46D9315CFAA20B6FD10082039D"
          xlink:to="TextSelection-E9F14C2885BA59D8B6B4AD221FC38619-0-wk-Footnote-E9F14C2885BA59D8B6B4AD221FC38619_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43690878e1576-wk-Fact-A97BF6B8A8BF52F4857350DD1D9E29F5"
          xlink:label="d43690878e1576-wk-Fact-A97BF6B8A8BF52F4857350DD1D9E29F5"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43690878e1576-wk-Fact-A97BF6B8A8BF52F4857350DD1D9E29F5"
          xlink:to="TextSelection-792D3AB23D6354CFBB2776AE7F6407B4-0-wk-Footnote-792D3AB23D6354CFBB2776AE7F6407B4_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687849e3143-wk-Fact-A98E6DC1451C5074AFA6C1769B31F168"
          xlink:label="d43687849e3143-wk-Fact-A98E6DC1451C5074AFA6C1769B31F168"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e3143-wk-Fact-A98E6DC1451C5074AFA6C1769B31F168"
          xlink:to="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43771853e10074-wk-Fact-A9C11CFF51AD52A5B91FCAB3F6F3901C"
          xlink:label="d43771853e10074-wk-Fact-A9C11CFF51AD52A5B91FCAB3F6F3901C"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e10074-wk-Fact-A9C11CFF51AD52A5B91FCAB3F6F3901C"
          xlink:to="TextSelection-3AE2F5A9070951C0ACDF4F146E825D8D-0-wk-Footnote-3AE2F5A9070951C0ACDF4F146E825D8D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e7532-wk-Fact-A9CF26AC98115AE2816DE97864E7E9E1"
          xlink:label="d43770747e7532-wk-Fact-A9CF26AC98115AE2816DE97864E7E9E1"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e7532-wk-Fact-A9CF26AC98115AE2816DE97864E7E9E1"
          xlink:to="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e7532-wk-Fact-A9CF26AC98115AE2816DE97864E7E9E1"
          xlink:to="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43681613e2033-wk-Fact-A9D9504EBEC15503A956269CA3DEC025"
          xlink:label="d43681613e2033-wk-Fact-A9D9504EBEC15503A956269CA3DEC025"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43681613e2033-wk-Fact-A9D9504EBEC15503A956269CA3DEC025"
          xlink:to="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43712496e3579-wk-Fact-AA3098CB34F551A2922049EA2BBBF5A3"
          xlink:label="d43712496e3579-wk-Fact-AA3098CB34F551A2922049EA2BBBF5A3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43712496e3579-wk-Fact-AA3098CB34F551A2922049EA2BBBF5A3"
          xlink:to="TextSelection-3E9076747FF25E3B8D3B9AAF71548F16-0-wk-Footnote-3E9076747FF25E3B8D3B9AAF71548F16_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43681613e2014-wk-Fact-AA4DB1C4ACF95301B1C9DD8DFCDA37CF"
          xlink:label="d43681613e2014-wk-Fact-AA4DB1C4ACF95301B1C9DD8DFCDA37CF"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43681613e2014-wk-Fact-AA4DB1C4ACF95301B1C9DD8DFCDA37CF"
          xlink:to="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43674379e1434-wk-Fact-AB8C3651E3FA5E0381978C95D5308515"
          xlink:label="d43674379e1434-wk-Fact-AB8C3651E3FA5E0381978C95D5308515"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43674379e1434-wk-Fact-AB8C3651E3FA5E0381978C95D5308515"
          xlink:to="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687704e3249-wk-Fact-ABA682EB80515D309B605AA81450C85B"
          xlink:label="d43687704e3249-wk-Fact-ABA682EB80515D309B605AA81450C85B"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e3249-wk-Fact-ABA682EB80515D309B605AA81450C85B"
          xlink:to="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43681613e885-wk-Fact-ACB630B60395539B8BEB3946C0CF2A75"
          xlink:label="d43681613e885-wk-Fact-ACB630B60395539B8BEB3946C0CF2A75"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43681613e885-wk-Fact-ACB630B60395539B8BEB3946C0CF2A75"
          xlink:to="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687704e1282-wk-Fact-AD0FEF5202405A048EC52168262886B2"
          xlink:label="d43687704e1282-wk-Fact-AD0FEF5202405A048EC52168262886B2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e1282-wk-Fact-AD0FEF5202405A048EC52168262886B2"
          xlink:to="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43771853e9277-wk-Fact-AD73F3732CE450B3B05C9A766AE2063A"
          xlink:label="d43771853e9277-wk-Fact-AD73F3732CE450B3B05C9A766AE2063A"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e9277-wk-Fact-AD73F3732CE450B3B05C9A766AE2063A"
          xlink:to="TextSelection-08466783230155A08D7C13267B950D39-0-wk-Footnote-08466783230155A08D7C13267B950D39_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43690878e1893-wk-Fact-AD762188EABB599D9776791285E37CB9"
          xlink:label="d43690878e1893-wk-Fact-AD762188EABB599D9776791285E37CB9"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43690878e1893-wk-Fact-AD762188EABB599D9776791285E37CB9"
          xlink:to="TextSelection-792D3AB23D6354CFBB2776AE7F6407B4-0-wk-Footnote-792D3AB23D6354CFBB2776AE7F6407B4_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687849e2651-wk-Fact-AE655F3ED75A586981476B9D274B0149"
          xlink:label="d43687849e2651-wk-Fact-AE655F3ED75A586981476B9D274B0149"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e2651-wk-Fact-AE655F3ED75A586981476B9D274B0149"
          xlink:to="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43674379e837-wk-Fact-AE85FABD864252F78E2399FA5C6D7DCA"
          xlink:label="d43674379e837-wk-Fact-AE85FABD864252F78E2399FA5C6D7DCA"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43674379e837-wk-Fact-AE85FABD864252F78E2399FA5C6D7DCA"
          xlink:to="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687849e1493-wk-Fact-AF1D710099FA5129924DD7852F2F28B0"
          xlink:label="d43687849e1493-wk-Fact-AF1D710099FA5129924DD7852F2F28B0"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e1493-wk-Fact-AF1D710099FA5129924DD7852F2F28B0"
          xlink:to="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43674379e1057-wk-Fact-AF72E85346065C12B27811C0B8AD4C52"
          xlink:label="d43674379e1057-wk-Fact-AF72E85346065C12B27811C0B8AD4C52"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43674379e1057-wk-Fact-AF72E85346065C12B27811C0B8AD4C52"
          xlink:to="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687704e2360-wk-Fact-AF9D3709DF59553C9EBCFCBC41F64F99"
          xlink:label="d43687704e2360-wk-Fact-AF9D3709DF59553C9EBCFCBC41F64F99"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e2360-wk-Fact-AF9D3709DF59553C9EBCFCBC41F64F99"
          xlink:to="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e2360-wk-Fact-AF9D3709DF59553C9EBCFCBC41F64F99"
          xlink:to="TextSelection-9231AC55B8EC5775BC4995B0797F870F-0-wk-Footnote-9231AC55B8EC5775BC4995B0797F870F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43712510e6011-wk-Fact-AFBA8CD89F4951449553D70FD3AC0D6E"
          xlink:label="d43712510e6011-wk-Fact-AFBA8CD89F4951449553D70FD3AC0D6E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43712510e6011-wk-Fact-AFBA8CD89F4951449553D70FD3AC0D6E"
          xlink:to="TextSelection-6550A25092D55979B6A1D62BD4EDF090-0-wk-Footnote-6550A25092D55979B6A1D62BD4EDF090_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687849e2092-wk-Fact-B02BB9D940C0596C9C0D21CC1C19783E"
          xlink:label="d43687849e2092-wk-Fact-B02BB9D940C0596C9C0D21CC1C19783E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e2092-wk-Fact-B02BB9D940C0596C9C0D21CC1C19783E"
          xlink:to="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e5628-wk-Fact-B09CC79A60405874AF13D1064AECD5EB"
          xlink:label="d43770747e5628-wk-Fact-B09CC79A60405874AF13D1064AECD5EB"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e5628-wk-Fact-B09CC79A60405874AF13D1064AECD5EB"
          xlink:to="TextSelection-0BDE8CEE983B5F118E2EFACDF9CC6405-0-wk-Footnote-0BDE8CEE983B5F118E2EFACDF9CC6405_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43771853e1505-wk-Fact-B11B8159E0957CFF66445A6F02FE77F4"
          xlink:label="d43771853e1505-wk-Fact-B11B8159E0957CFF66445A6F02FE77F4"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e1505-wk-Fact-B11B8159E0957CFF66445A6F02FE77F4"
          xlink:to="TextSelection-78FC5AB8EFAB585E87BBCF93BE9FBF1D-0-wk-Footnote-78FC5AB8EFAB585E87BBCF93BE9FBF1D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687704e1238-wk-Fact-B14EB26D36A55E6D996F420A2D075893"
          xlink:label="d43687704e1238-wk-Fact-B14EB26D36A55E6D996F420A2D075893"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e1238-wk-Fact-B14EB26D36A55E6D996F420A2D075893"
          xlink:to="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e1238-wk-Fact-B14EB26D36A55E6D996F420A2D075893"
          xlink:to="TextSelection-AE19F19C6AE65BBDA7F551089E2E7EDF-0-wk-Footnote-AE19F19C6AE65BBDA7F551089E2E7EDF_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43771853e4741-wk-Fact-B1B730E391FC52EF8914EC8E437455FB"
          xlink:label="d43771853e4741-wk-Fact-B1B730E391FC52EF8914EC8E437455FB"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e4741-wk-Fact-B1B730E391FC52EF8914EC8E437455FB"
          xlink:to="TextSelection-E9F14C2885BA59D8B6B4AD221FC38619-0-wk-Footnote-E9F14C2885BA59D8B6B4AD221FC38619_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e8294-wk-Fact-B1F75F6B4A5C5BA399EFD6D1A9FEA6DE"
          xlink:label="d43770747e8294-wk-Fact-B1F75F6B4A5C5BA399EFD6D1A9FEA6DE"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e8294-wk-Fact-B1F75F6B4A5C5BA399EFD6D1A9FEA6DE"
          xlink:to="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e8294-wk-Fact-B1F75F6B4A5C5BA399EFD6D1A9FEA6DE"
          xlink:to="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687704e2930-wk-Fact-B227984E1B50586585A129EB332CFD86"
          xlink:label="d43687704e2930-wk-Fact-B227984E1B50586585A129EB332CFD86"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e2930-wk-Fact-B227984E1B50586585A129EB332CFD86"
          xlink:to="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e2930-wk-Fact-B227984E1B50586585A129EB332CFD86"
          xlink:to="TextSelection-9231AC55B8EC5775BC4995B0797F870F-0-wk-Footnote-9231AC55B8EC5775BC4995B0797F870F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43690878e2332-wk-Fact-B239C8DE6B03518BA7F0284DE06E3F57"
          xlink:label="d43690878e2332-wk-Fact-B239C8DE6B03518BA7F0284DE06E3F57"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43690878e2332-wk-Fact-B239C8DE6B03518BA7F0284DE06E3F57"
          xlink:to="TextSelection-0333DDFA54555789BB4E2E73E3451A69-0-wk-Footnote-0333DDFA54555789BB4E2E73E3451A69_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43690878e2332-wk-Fact-B239C8DE6B03518BA7F0284DE06E3F57"
          xlink:to="TextSelection-792D3AB23D6354CFBB2776AE7F6407B4-0-wk-Footnote-792D3AB23D6354CFBB2776AE7F6407B4_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43771853e5651-wk-Fact-B2EC756D8A9E5AF6969297EE142A38CF"
          xlink:label="d43771853e5651-wk-Fact-B2EC756D8A9E5AF6969297EE142A38CF"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e5651-wk-Fact-B2EC756D8A9E5AF6969297EE142A38CF"
          xlink:to="TextSelection-DE7EF4A6663E52BF8D3620854A57A945-0-wk-Footnote-DE7EF4A6663E52BF8D3620854A57A945_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43712496e1924-wk-Fact-B30550C60EA75004A2CBFC5FF95F87DF"
          xlink:label="d43712496e1924-wk-Fact-B30550C60EA75004A2CBFC5FF95F87DF"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43712496e1924-wk-Fact-B30550C60EA75004A2CBFC5FF95F87DF"
          xlink:to="TextSelection-7160FF67E87550A19177FE255A41A2D7-0-wk-Footnote-7160FF67E87550A19177FE255A41A2D7_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43771853e4784-wk-Fact-B332B03EB88A57C19CFEC6C041626341"
          xlink:label="d43771853e4784-wk-Fact-B332B03EB88A57C19CFEC6C041626341"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e4784-wk-Fact-B332B03EB88A57C19CFEC6C041626341"
          xlink:to="TextSelection-DC6DDCB74FC9523D97BA51FBA6B1C05E-0-wk-Footnote-DC6DDCB74FC9523D97BA51FBA6B1C05E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43681613e1081-wk-Fact-B3E1F1C6FF4D55E59E6FE1D02902C8D3"
          xlink:label="d43681613e1081-wk-Fact-B3E1F1C6FF4D55E59E6FE1D02902C8D3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43681613e1081-wk-Fact-B3E1F1C6FF4D55E59E6FE1D02902C8D3"
          xlink:to="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687704e2379-wk-Fact-B4B59AB6237151588AD0DCDB47024876"
          xlink:label="d43687704e2379-wk-Fact-B4B59AB6237151588AD0DCDB47024876"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e2379-wk-Fact-B4B59AB6237151588AD0DCDB47024876"
          xlink:to="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e2379-wk-Fact-B4B59AB6237151588AD0DCDB47024876"
          xlink:to="TextSelection-9231AC55B8EC5775BC4995B0797F870F-0-wk-Footnote-9231AC55B8EC5775BC4995B0797F870F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43712496e1982-wk-Fact-B4ED4EC770E85596B83EF4F1E598DF88"
          xlink:label="d43712496e1982-wk-Fact-B4ED4EC770E85596B83EF4F1E598DF88"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43712496e1982-wk-Fact-B4ED4EC770E85596B83EF4F1E598DF88"
          xlink:to="TextSelection-7160FF67E87550A19177FE255A41A2D7-0-wk-Footnote-7160FF67E87550A19177FE255A41A2D7_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43674379e944-wk-Fact-B57DF7F90CE856C48797E9E94456B6CD"
          xlink:label="d43674379e944-wk-Fact-B57DF7F90CE856C48797E9E94456B6CD"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d43678813e929-wk-Fact-B57DF7F90CE856C48797E9E94456B6CD"
          xlink:label="d43678813e929-wk-Fact-B57DF7F90CE856C48797E9E94456B6CD"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43678813e929-wk-Fact-B57DF7F90CE856C48797E9E94456B6CD"
          xlink:to="TextSelection-431A3875E30657529B6519DFB33F40EB-0-wk-Footnote-431A3875E30657529B6519DFB33F40EB_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43674379e944-wk-Fact-B57DF7F90CE856C48797E9E94456B6CD"
          xlink:to="TextSelection-431A3875E30657529B6519DFB33F40EB-0-wk-Footnote-431A3875E30657529B6519DFB33F40EB_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43678813e929-wk-Fact-B57DF7F90CE856C48797E9E94456B6CD"
          xlink:to="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43674379e944-wk-Fact-B57DF7F90CE856C48797E9E94456B6CD"
          xlink:to="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43681613e1968-wk-Fact-B6676B9BE7E95127A4888156B2CAD1CD"
          xlink:label="d43681613e1968-wk-Fact-B6676B9BE7E95127A4888156B2CAD1CD"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43681613e1968-wk-Fact-B6676B9BE7E95127A4888156B2CAD1CD"
          xlink:to="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43690878e2294-wk-Fact-B667DEF994C657D2B861FFE60640D001"
          xlink:label="d43690878e2294-wk-Fact-B667DEF994C657D2B861FFE60640D001"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43690878e2294-wk-Fact-B667DEF994C657D2B861FFE60640D001"
          xlink:to="TextSelection-0333DDFA54555789BB4E2E73E3451A69-0-wk-Footnote-0333DDFA54555789BB4E2E73E3451A69_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43690878e2294-wk-Fact-B667DEF994C657D2B861FFE60640D001"
          xlink:to="TextSelection-792D3AB23D6354CFBB2776AE7F6407B4-0-wk-Footnote-792D3AB23D6354CFBB2776AE7F6407B4_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43674379e1101-wk-Fact-B684218F9F965A0685489FB9D98355FE"
          xlink:label="d43674379e1101-wk-Fact-B684218F9F965A0685489FB9D98355FE"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43674379e1101-wk-Fact-B684218F9F965A0685489FB9D98355FE"
          xlink:to="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43771853e11399-wk-Fact-B6E115CC3E7858DCA9A85E0C1738396B"
          xlink:label="d43771853e11399-wk-Fact-B6E115CC3E7858DCA9A85E0C1738396B"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e11399-wk-Fact-B6E115CC3E7858DCA9A85E0C1738396B"
          xlink:to="TextSelection-DE7EF4A6663E52BF8D3620854A57A945-0-wk-Footnote-DE7EF4A6663E52BF8D3620854A57A945_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687704e1346-wk-Fact-B73545D07B565820AFF53EEAE1860800"
          xlink:label="d43687704e1346-wk-Fact-B73545D07B565820AFF53EEAE1860800"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d43712496e1666-wk-Fact-B73545D07B565820AFF53EEAE1860800"
          xlink:label="d43712496e1666-wk-Fact-B73545D07B565820AFF53EEAE1860800"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43712496e1666-wk-Fact-B73545D07B565820AFF53EEAE1860800"
          xlink:to="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e1346-wk-Fact-B73545D07B565820AFF53EEAE1860800"
          xlink:to="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43681613e1017-wk-Fact-B740A96BCFB152CEB2E4602B18EBD8F1"
          xlink:label="d43681613e1017-wk-Fact-B740A96BCFB152CEB2E4602B18EBD8F1"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43681613e1017-wk-Fact-B740A96BCFB152CEB2E4602B18EBD8F1"
          xlink:to="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43697224e1632-wk-Fact-B77CD495CEF453F5A40BDFFD319AC5F2"
          xlink:label="d43697224e1632-wk-Fact-B77CD495CEF453F5A40BDFFD319AC5F2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43697224e1632-wk-Fact-B77CD495CEF453F5A40BDFFD319AC5F2"
          xlink:to="TextSelection-9C73CEBDEE585A83B2B18F3B38A6D8CD-0-wk-Footnote-9C73CEBDEE585A83B2B18F3B38A6D8CD_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43674379e1341-wk-Fact-B7825C6743265E60AFD787E20D13F87D"
          xlink:label="d43674379e1341-wk-Fact-B7825C6743265E60AFD787E20D13F87D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43674379e1341-wk-Fact-B7825C6743265E60AFD787E20D13F87D"
          xlink:to="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43681613e2921-wk-Fact-B7E0E2374E7052E886F3C5A3DD803575"
          xlink:label="d43681613e2921-wk-Fact-B7E0E2374E7052E886F3C5A3DD803575"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43681613e2921-wk-Fact-B7E0E2374E7052E886F3C5A3DD803575"
          xlink:to="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43681613e948-wk-Fact-B7F6677B323F523BBF06F63407F96342"
          xlink:label="d43681613e948-wk-Fact-B7F6677B323F523BBF06F63407F96342"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43681613e948-wk-Fact-B7F6677B323F523BBF06F63407F96342"
          xlink:to="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact-B85FE09635045F46B656606350B6714A-wk-Fact-B85FE09635045F46B656606350B6714A"
          xlink:label="Fact-B85FE09635045F46B656606350B6714A-wk-Fact-B85FE09635045F46B656606350B6714A"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact-B85FE09635045F46B656606350B6714A-wk-Fact-B85FE09635045F46B656606350B6714A"
          xlink:to="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e7472-wk-Fact-B8850FDF106C528A9CBED9CA08F2B4C9"
          xlink:label="d43770747e7472-wk-Fact-B8850FDF106C528A9CBED9CA08F2B4C9"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e7472-wk-Fact-B8850FDF106C528A9CBED9CA08F2B4C9"
          xlink:to="TextSelection-39CF024D03225486829869F6CA02C00E-0-wk-Footnote-39CF024D03225486829869F6CA02C00E_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e7472-wk-Fact-B8850FDF106C528A9CBED9CA08F2B4C9"
          xlink:to="TextSelection-53BB8CAFCA475C0C9DB2195050D36025-0-wk-Footnote-53BB8CAFCA475C0C9DB2195050D36025_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e7472-wk-Fact-B8850FDF106C528A9CBED9CA08F2B4C9"
          xlink:to="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687849e2586-wk-Fact-B8A367981AE35AEF8C0BF4154D63FC01"
          xlink:label="d43687849e2586-wk-Fact-B8A367981AE35AEF8C0BF4154D63FC01"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e2586-wk-Fact-B8A367981AE35AEF8C0BF4154D63FC01"
          xlink:to="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e9687-wk-Fact-B91047810A4357EFB8BEA4691EF47E86"
          xlink:label="d43770747e9687-wk-Fact-B91047810A4357EFB8BEA4691EF47E86"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e9687-wk-Fact-B91047810A4357EFB8BEA4691EF47E86"
          xlink:to="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e9687-wk-Fact-B91047810A4357EFB8BEA4691EF47E86"
          xlink:to="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43712496e3322-wk-Fact-B933A905F21B5DBCAF9108FCBC88194E"
          xlink:label="d43712496e3322-wk-Fact-B933A905F21B5DBCAF9108FCBC88194E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43712496e3322-wk-Fact-B933A905F21B5DBCAF9108FCBC88194E"
          xlink:to="TextSelection-02609C62928C5D1CBFB6DD071D9D7B0E-0-wk-Footnote-02609C62928C5D1CBFB6DD071D9D7B0E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43771853e4571-wk-Fact-B972D2BE08BE594FA3E2081E6C7190CF"
          xlink:label="d43771853e4571-wk-Fact-B972D2BE08BE594FA3E2081E6C7190CF"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e4571-wk-Fact-B972D2BE08BE594FA3E2081E6C7190CF"
          xlink:to="TextSelection-3802305E73EB52F28FAAF4EA5481D580-0-wk-Footnote-3802305E73EB52F28FAAF4EA5481D580_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43674379e2539-wk-Fact-B9792AE277D55415BD4430CE375AB579"
          xlink:label="d43674379e2539-wk-Fact-B9792AE277D55415BD4430CE375AB579"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43674379e2539-wk-Fact-B9792AE277D55415BD4430CE375AB579"
          xlink:to="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43712496e1899-wk-Fact-B97AEA2C854B5AABB4BE5CE4AE4372B1"
          xlink:label="d43712496e1899-wk-Fact-B97AEA2C854B5AABB4BE5CE4AE4372B1"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43712496e1899-wk-Fact-B97AEA2C854B5AABB4BE5CE4AE4372B1"
          xlink:to="TextSelection-7160FF67E87550A19177FE255A41A2D7-0-wk-Footnote-7160FF67E87550A19177FE255A41A2D7_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43681613e1062-wk-Fact-BA0D6BC1C45C599C91DF29089DAC818D"
          xlink:label="d43681613e1062-wk-Fact-BA0D6BC1C45C599C91DF29089DAC818D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43681613e1062-wk-Fact-BA0D6BC1C45C599C91DF29089DAC818D"
          xlink:to="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43771853e2893-wk-Fact-BAF1C761A7AF5C7CBFD0E58295157553"
          xlink:label="d43771853e2893-wk-Fact-BAF1C761A7AF5C7CBFD0E58295157553"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e2893-wk-Fact-BAF1C761A7AF5C7CBFD0E58295157553"
          xlink:to="TextSelection-78FC5AB8EFAB585E87BBCF93BE9FBF1D-0-wk-Footnote-78FC5AB8EFAB585E87BBCF93BE9FBF1D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43690878e1402-wk-Fact-BB81900A80EC510B82BA9955D28FB794"
          xlink:label="d43690878e1402-wk-Fact-BB81900A80EC510B82BA9955D28FB794"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43690878e1402-wk-Fact-BB81900A80EC510B82BA9955D28FB794"
          xlink:to="TextSelection-792D3AB23D6354CFBB2776AE7F6407B4-0-wk-Footnote-792D3AB23D6354CFBB2776AE7F6407B4_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687849e1557-wk-Fact-BBA831FA48DE546FAD427528571D0824"
          xlink:label="d43687849e1557-wk-Fact-BBA831FA48DE546FAD427528571D0824"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e1557-wk-Fact-BBA831FA48DE546FAD427528571D0824"
          xlink:to="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43674379e2474-wk-Fact-BBB0550BDE1259DD997B8244242E79AE"
          xlink:label="d43674379e2474-wk-Fact-BBB0550BDE1259DD997B8244242E79AE"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43674379e2474-wk-Fact-BBB0550BDE1259DD997B8244242E79AE"
          xlink:to="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43681613e2723-wk-Fact-BC18C3B80FE15D95A67ED86E9A5C11B9"
          xlink:label="d43681613e2723-wk-Fact-BC18C3B80FE15D95A67ED86E9A5C11B9"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43681613e2723-wk-Fact-BC18C3B80FE15D95A67ED86E9A5C11B9"
          xlink:to="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43681613e2723-wk-Fact-BC18C3B80FE15D95A67ED86E9A5C11B9"
          xlink:to="TextSelection-EB5698F25D035A90984FA270E724B7BB-0-wk-Footnote-EB5698F25D035A90984FA270E724B7BB_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e1584-wk-Fact-BC41639F074B5D2EB9452A1CA1147B95"
          xlink:label="d43770747e1584-wk-Fact-BC41639F074B5D2EB9452A1CA1147B95"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e1584-wk-Fact-BC41639F074B5D2EB9452A1CA1147B95"
          xlink:to="TextSelection-58096FF6357955D6B6AA25D56767CB0A-0-wk-Footnote-58096FF6357955D6B6AA25D56767CB0A_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e1584-wk-Fact-BC41639F074B5D2EB9452A1CA1147B95"
          xlink:to="TextSelection-8D2A93033C2E56DE9E814F0AB36328EE-0-wk-Footnote-8D2A93033C2E56DE9E814F0AB36328EE_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43771853e9316-wk-Fact-BD8207C538F258AB9385CEC1E820D409"
          xlink:label="d43771853e9316-wk-Fact-BD8207C538F258AB9385CEC1E820D409"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e9316-wk-Fact-BD8207C538F258AB9385CEC1E820D409"
          xlink:to="TextSelection-08466783230155A08D7C13267B950D39-0-wk-Footnote-08466783230155A08D7C13267B950D39_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e10514-wk-Fact-BF8085F8D70957BA81DB64AF93C77FDE"
          xlink:label="d43770747e10514-wk-Fact-BF8085F8D70957BA81DB64AF93C77FDE"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e10514-wk-Fact-BF8085F8D70957BA81DB64AF93C77FDE"
          xlink:to="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e10514-wk-Fact-BF8085F8D70957BA81DB64AF93C77FDE"
          xlink:to="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43712510e6069-wk-Fact-BF9FCFC1FC645049A852329D7379350D"
          xlink:label="d43712510e6069-wk-Fact-BF9FCFC1FC645049A852329D7379350D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43712510e6069-wk-Fact-BF9FCFC1FC645049A852329D7379350D"
          xlink:to="TextSelection-6550A25092D55979B6A1D62BD4EDF090-0-wk-Footnote-6550A25092D55979B6A1D62BD4EDF090_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43712496e1246-wk-Fact-BFEE13E8CEC95576907CDF47D40BBF3C"
          xlink:label="d43712496e1246-wk-Fact-BFEE13E8CEC95576907CDF47D40BBF3C"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43712496e1246-wk-Fact-BFEE13E8CEC95576907CDF47D40BBF3C"
          xlink:to="TextSelection-1B1FEAD5EA4E576891141CE7B2D9386E-0-wk-Footnote-1B1FEAD5EA4E576891141CE7B2D9386E_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43712496e1246-wk-Fact-BFEE13E8CEC95576907CDF47D40BBF3C"
          xlink:to="TextSelection-B57619F44FCF544D96067CF4816A9082-0-wk-Footnote-B57619F44FCF544D96067CF4816A9082_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43771853e10789-wk-Fact-C004A733FEAB52B8AE0B44F23C300539"
          xlink:label="d43771853e10789-wk-Fact-C004A733FEAB52B8AE0B44F23C300539"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e10789-wk-Fact-C004A733FEAB52B8AE0B44F23C300539"
          xlink:to="TextSelection-A685A65E160C5D228F531BF7107B3DF7-0-wk-Footnote-A685A65E160C5D228F531BF7107B3DF7_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687704e3160-wk-Fact-C0D5F9589E725D14B3DE492AFAAAEA7D"
          xlink:label="d43687704e3160-wk-Fact-C0D5F9589E725D14B3DE492AFAAAEA7D"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d43690878e2243-wk-Fact-C0D5F9589E725D14B3DE492AFAAAEA7D"
          xlink:label="d43690878e2243-wk-Fact-C0D5F9589E725D14B3DE492AFAAAEA7D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43690878e2243-wk-Fact-C0D5F9589E725D14B3DE492AFAAAEA7D"
          xlink:to="TextSelection-792D3AB23D6354CFBB2776AE7F6407B4-0-wk-Footnote-792D3AB23D6354CFBB2776AE7F6407B4_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e3160-wk-Fact-C0D5F9589E725D14B3DE492AFAAAEA7D"
          xlink:to="TextSelection-792D3AB23D6354CFBB2776AE7F6407B4-0-wk-Footnote-792D3AB23D6354CFBB2776AE7F6407B4_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43690878e2243-wk-Fact-C0D5F9589E725D14B3DE492AFAAAEA7D"
          xlink:to="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e3160-wk-Fact-C0D5F9589E725D14B3DE492AFAAAEA7D"
          xlink:to="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43690878e2243-wk-Fact-C0D5F9589E725D14B3DE492AFAAAEA7D"
          xlink:to="TextSelection-9231AC55B8EC5775BC4995B0797F870F-0-wk-Footnote-9231AC55B8EC5775BC4995B0797F870F_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e3160-wk-Fact-C0D5F9589E725D14B3DE492AFAAAEA7D"
          xlink:to="TextSelection-9231AC55B8EC5775BC4995B0797F870F-0-wk-Footnote-9231AC55B8EC5775BC4995B0797F870F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687704e1301-wk-Fact-C0E90259FF035CD683F5D973FC82FD05"
          xlink:label="d43687704e1301-wk-Fact-C0E90259FF035CD683F5D973FC82FD05"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e1301-wk-Fact-C0E90259FF035CD683F5D973FC82FD05"
          xlink:to="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43697224e2905-wk-Fact-C12B4B795167254CFB615A1EFA195FC4"
          xlink:label="d43697224e2905-wk-Fact-C12B4B795167254CFB615A1EFA195FC4"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43697224e2905-wk-Fact-C12B4B795167254CFB615A1EFA195FC4"
          xlink:to="TextSelection-066A0A390204B79351965A22CE69E761-0-wk-Footnote-066A0A390204B79351965A22CE69E761_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43697224e2905-wk-Fact-C12B4B795167254CFB615A1EFA195FC4"
          xlink:to="TextSelection-4AF5AB391F1CD8054C065A2324C0D822-0-wk-Footnote-4AF5AB391F1CD8054C065A2324C0D822_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e4019-wk-Fact-C140E7BD63345101B2DD7451627EE662"
          xlink:label="d43770747e4019-wk-Fact-C140E7BD63345101B2DD7451627EE662"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e4019-wk-Fact-C140E7BD63345101B2DD7451627EE662"
          xlink:to="TextSelection-7EC55EFE69505245B1A079B8132EFBB7-0-wk-Footnote-7EC55EFE69505245B1A079B8132EFBB7_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43674379e1652-wk-Fact-C14BB34AB5A85079B41CF0775AFE681D"
          xlink:label="d43674379e1652-wk-Fact-C14BB34AB5A85079B41CF0775AFE681D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43674379e1652-wk-Fact-C14BB34AB5A85079B41CF0775AFE681D"
          xlink:to="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687849e1047-wk-Fact-C15E30483A415EE0AF567E4AAFB1965C"
          xlink:label="d43687849e1047-wk-Fact-C15E30483A415EE0AF567E4AAFB1965C"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e1047-wk-Fact-C15E30483A415EE0AF567E4AAFB1965C"
          xlink:to="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43681613e1988-wk-Fact-C220C3FE427351839AD8B1F16EE921CE"
          xlink:label="d43681613e1988-wk-Fact-C220C3FE427351839AD8B1F16EE921CE"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43681613e1988-wk-Fact-C220C3FE427351839AD8B1F16EE921CE"
          xlink:to="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e3140-wk-Fact-C233B7CC79495307BFD442EFB72D3A1B"
          xlink:label="d43770747e3140-wk-Fact-C233B7CC79495307BFD442EFB72D3A1B"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e3140-wk-Fact-C233B7CC79495307BFD442EFB72D3A1B"
          xlink:to="TextSelection-DAFABE7CE058521690718900BE6137FA-0-wk-Footnote-DAFABE7CE058521690718900BE6137FA_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e882-wk-Fact-C249892FF0905C07897B0E4EF86B976C"
          xlink:label="d43770747e882-wk-Fact-C249892FF0905C07897B0E4EF86B976C"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e882-wk-Fact-C249892FF0905C07897B0E4EF86B976C"
          xlink:to="TextSelection-8D2A93033C2E56DE9E814F0AB36328EE-0-wk-Footnote-8D2A93033C2E56DE9E814F0AB36328EE_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e882-wk-Fact-C249892FF0905C07897B0E4EF86B976C"
          xlink:to="TextSelection-E96B3A139CCA56EC98329BC3717B10E3-0-wk-Footnote-E96B3A139CCA56EC98329BC3717B10E3_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e8711-wk-Fact-C2B11447AB985916A925693B614D1F62"
          xlink:label="d43770747e8711-wk-Fact-C2B11447AB985916A925693B614D1F62"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e8711-wk-Fact-C2B11447AB985916A925693B614D1F62"
          xlink:to="TextSelection-39CF024D03225486829869F6CA02C00E-0-wk-Footnote-39CF024D03225486829869F6CA02C00E_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e8711-wk-Fact-C2B11447AB985916A925693B614D1F62"
          xlink:to="TextSelection-53BB8CAFCA475C0C9DB2195050D36025-0-wk-Footnote-53BB8CAFCA475C0C9DB2195050D36025_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e8711-wk-Fact-C2B11447AB985916A925693B614D1F62"
          xlink:to="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e8215-wk-Fact-C2CABED6EA545FADA2D30E685CF99102"
          xlink:label="d43770747e8215-wk-Fact-C2CABED6EA545FADA2D30E685CF99102"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e8215-wk-Fact-C2CABED6EA545FADA2D30E685CF99102"
          xlink:to="TextSelection-39CF024D03225486829869F6CA02C00E-0-wk-Footnote-39CF024D03225486829869F6CA02C00E_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e8215-wk-Fact-C2CABED6EA545FADA2D30E685CF99102"
          xlink:to="TextSelection-53BB8CAFCA475C0C9DB2195050D36025-0-wk-Footnote-53BB8CAFCA475C0C9DB2195050D36025_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e8215-wk-Fact-C2CABED6EA545FADA2D30E685CF99102"
          xlink:to="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687849e1261-wk-Fact-C2DBD9F4462053918846BC5A4E78FE6B"
          xlink:label="d43687849e1261-wk-Fact-C2DBD9F4462053918846BC5A4E78FE6B"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e1261-wk-Fact-C2DBD9F4462053918846BC5A4E78FE6B"
          xlink:to="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e7354-wk-Fact-C2FB4FD03BD15A7097477EAB914C3310"
          xlink:label="d43770747e7354-wk-Fact-C2FB4FD03BD15A7097477EAB914C3310"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e7354-wk-Fact-C2FB4FD03BD15A7097477EAB914C3310"
          xlink:to="TextSelection-39CF024D03225486829869F6CA02C00E-0-wk-Footnote-39CF024D03225486829869F6CA02C00E_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e7354-wk-Fact-C2FB4FD03BD15A7097477EAB914C3310"
          xlink:to="TextSelection-53BB8CAFCA475C0C9DB2195050D36025-0-wk-Footnote-53BB8CAFCA475C0C9DB2195050D36025_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e7354-wk-Fact-C2FB4FD03BD15A7097477EAB914C3310"
          xlink:to="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43712496e2196-wk-Fact-C2FE704D6A285AB89F6177A77115F69D"
          xlink:label="d43712496e2196-wk-Fact-C2FE704D6A285AB89F6177A77115F69D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43712496e2196-wk-Fact-C2FE704D6A285AB89F6177A77115F69D"
          xlink:to="TextSelection-C37CD88178CA35C475D25A62F2B54FED-0-wk-Footnote-C37CD88178CA35C475D25A62F2B54FED_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e4609-wk-Fact-C34B3FEB300256D1ADBB0C35ECBFED0F"
          xlink:label="d43770747e4609-wk-Fact-C34B3FEB300256D1ADBB0C35ECBFED0F"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e4609-wk-Fact-C34B3FEB300256D1ADBB0C35ECBFED0F"
          xlink:to="TextSelection-5259D0A3B8885FEE951D5ABCA017CBFC-0-wk-Footnote-5259D0A3B8885FEE951D5ABCA017CBFC_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43690878e2158-wk-Fact-C43E96FF08B6534FA41614FCABAEB299"
          xlink:label="d43690878e2158-wk-Fact-C43E96FF08B6534FA41614FCABAEB299"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43690878e2158-wk-Fact-C43E96FF08B6534FA41614FCABAEB299"
          xlink:to="TextSelection-792D3AB23D6354CFBB2776AE7F6407B4-0-wk-Footnote-792D3AB23D6354CFBB2776AE7F6407B4_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43712496e1556-wk-Fact-C44B0511B35651E0887481BA20948E7C"
          xlink:label="d43712496e1556-wk-Fact-C44B0511B35651E0887481BA20948E7C"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43712496e1556-wk-Fact-C44B0511B35651E0887481BA20948E7C"
          xlink:to="TextSelection-6912797A078E5D59B618DFFBB81C1BB6-0-wk-Footnote-6912797A078E5D59B618DFFBB81C1BB6_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43771853e5844-wk-Fact-C4B5621B0E4A59B3974A957DE7295490"
          xlink:label="d43771853e5844-wk-Fact-C4B5621B0E4A59B3974A957DE7295490"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e5844-wk-Fact-C4B5621B0E4A59B3974A957DE7295490"
          xlink:to="TextSelection-450A7304FB7E513FB479F6D9A06EF1D3-0-wk-Footnote-450A7304FB7E513FB479F6D9A06EF1D3_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43712496e1387-wk-Fact-C4C06BF1A8B6557EBFE62654491DA179"
          xlink:label="d43712496e1387-wk-Fact-C4C06BF1A8B6557EBFE62654491DA179"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43712496e1387-wk-Fact-C4C06BF1A8B6557EBFE62654491DA179"
          xlink:to="TextSelection-B57619F44FCF544D96067CF4816A9082-0-wk-Footnote-B57619F44FCF544D96067CF4816A9082_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43681613e1448-wk-Fact-C5C375E41B7D5A61A86D9015B4AC1F9C"
          xlink:label="d43681613e1448-wk-Fact-C5C375E41B7D5A61A86D9015B4AC1F9C"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43681613e1448-wk-Fact-C5C375E41B7D5A61A86D9015B4AC1F9C"
          xlink:to="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687704e1513-wk-Fact-C6627323E3A7545BB805B65F89BE7911"
          xlink:label="d43687704e1513-wk-Fact-C6627323E3A7545BB805B65F89BE7911"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d43771853e2282-wk-Fact-C6627323E3A7545BB805B65F89BE7911"
          xlink:label="d43771853e2282-wk-Fact-C6627323E3A7545BB805B65F89BE7911"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e1513-wk-Fact-C6627323E3A7545BB805B65F89BE7911"
          xlink:to="TextSelection-78FC5AB8EFAB585E87BBCF93BE9FBF1D-0-wk-Footnote-78FC5AB8EFAB585E87BBCF93BE9FBF1D_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e2282-wk-Fact-C6627323E3A7545BB805B65F89BE7911"
          xlink:to="TextSelection-78FC5AB8EFAB585E87BBCF93BE9FBF1D-0-wk-Footnote-78FC5AB8EFAB585E87BBCF93BE9FBF1D_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e1513-wk-Fact-C6627323E3A7545BB805B65F89BE7911"
          xlink:to="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e2282-wk-Fact-C6627323E3A7545BB805B65F89BE7911"
          xlink:to="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687849e1577-wk-Fact-C66A904313F45C85A833A23046CD2774"
          xlink:label="d43687849e1577-wk-Fact-C66A904313F45C85A833A23046CD2774"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e1577-wk-Fact-C66A904313F45C85A833A23046CD2774"
          xlink:to="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43697224e1066-wk-Fact-C68BCBB68BF9565C8536418482AA80FC"
          xlink:label="d43697224e1066-wk-Fact-C68BCBB68BF9565C8536418482AA80FC"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43697224e1066-wk-Fact-C68BCBB68BF9565C8536418482AA80FC"
          xlink:to="TextSelection-FE5DD06AA8B65777900C47B8AC19C4C6-0-wk-Footnote-FE5DD06AA8B65777900C47B8AC19C4C6_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687849e2156-wk-Fact-C6B1A7221C9D543BAFE59A9C9ECA2DF2"
          xlink:label="d43687849e2156-wk-Fact-C6B1A7221C9D543BAFE59A9C9ECA2DF2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e2156-wk-Fact-C6B1A7221C9D543BAFE59A9C9ECA2DF2"
          xlink:to="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687704e1852-wk-Fact-C6BAFD428E8D5DBBB9FC324DE0B23F01"
          xlink:label="d43687704e1852-wk-Fact-C6BAFD428E8D5DBBB9FC324DE0B23F01"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d43687849e846-wk-Fact-C6BAFD428E8D5DBBB9FC324DE0B23F01"
          xlink:label="d43687849e846-wk-Fact-C6BAFD428E8D5DBBB9FC324DE0B23F01"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e1852-wk-Fact-C6BAFD428E8D5DBBB9FC324DE0B23F01"
          xlink:to="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e846-wk-Fact-C6BAFD428E8D5DBBB9FC324DE0B23F01"
          xlink:to="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e1852-wk-Fact-C6BAFD428E8D5DBBB9FC324DE0B23F01"
          xlink:to="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e846-wk-Fact-C6BAFD428E8D5DBBB9FC324DE0B23F01"
          xlink:to="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e1852-wk-Fact-C6BAFD428E8D5DBBB9FC324DE0B23F01"
          xlink:to="TextSelection-9231AC55B8EC5775BC4995B0797F870F-0-wk-Footnote-9231AC55B8EC5775BC4995B0797F870F_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e846-wk-Fact-C6BAFD428E8D5DBBB9FC324DE0B23F01"
          xlink:to="TextSelection-9231AC55B8EC5775BC4995B0797F870F-0-wk-Footnote-9231AC55B8EC5775BC4995B0797F870F_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e1852-wk-Fact-C6BAFD428E8D5DBBB9FC324DE0B23F01"
          xlink:to="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e846-wk-Fact-C6BAFD428E8D5DBBB9FC324DE0B23F01"
          xlink:to="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687849e2007-wk-Fact-C6D0FE3E8F7154EE8F40BBCDB7B4F991"
          xlink:label="d43687849e2007-wk-Fact-C6D0FE3E8F7154EE8F40BBCDB7B4F991"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e2007-wk-Fact-C6D0FE3E8F7154EE8F40BBCDB7B4F991"
          xlink:to="TextSelection-77536863BCE35B419E3A4119D41DB4BD-0-wk-Footnote-77536863BCE35B419E3A4119D41DB4BD_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e2007-wk-Fact-C6D0FE3E8F7154EE8F40BBCDB7B4F991"
          xlink:to="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687849e3093-wk-Fact-C761BA8C214D5A2D83B627623D2F876D"
          xlink:label="d43687849e3093-wk-Fact-C761BA8C214D5A2D83B627623D2F876D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e3093-wk-Fact-C761BA8C214D5A2D83B627623D2F876D"
          xlink:to="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687704e2842-wk-Fact-C799B208E12551D9925550E1584374F0"
          xlink:label="d43687704e2842-wk-Fact-C799B208E12551D9925550E1584374F0"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e2842-wk-Fact-C799B208E12551D9925550E1584374F0"
          xlink:to="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e2842-wk-Fact-C799B208E12551D9925550E1584374F0"
          xlink:to="TextSelection-9231AC55B8EC5775BC4995B0797F870F-0-wk-Footnote-9231AC55B8EC5775BC4995B0797F870F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43681613e1153-wk-Fact-C84FD7E0084E53B295E4FBE883879711"
          xlink:label="d43681613e1153-wk-Fact-C84FD7E0084E53B295E4FBE883879711"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43681613e1153-wk-Fact-C84FD7E0084E53B295E4FBE883879711"
          xlink:to="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43771853e8232-wk-Fact-C8F31244A5485CAB8850FBA2D1B3FB16"
          xlink:label="d43771853e8232-wk-Fact-C8F31244A5485CAB8850FBA2D1B3FB16"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e8232-wk-Fact-C8F31244A5485CAB8850FBA2D1B3FB16"
          xlink:to="TextSelection-B88EBF1DF3CD5B06AADA1AA5E249F160-0-wk-Footnote-B88EBF1DF3CD5B06AADA1AA5E249F160_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43771853e5430-wk-Fact-C92E4F643F355942826164E220B2CDBA"
          xlink:label="d43771853e5430-wk-Fact-C92E4F643F355942826164E220B2CDBA"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e5430-wk-Fact-C92E4F643F355942826164E220B2CDBA"
          xlink:to="TextSelection-84795AFB20AD54C48C963C7C52B00178-0-wk-Footnote-84795AFB20AD54C48C963C7C52B00178_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43674379e969-wk-Fact-C9379BA9136D5BBB8F3432FB4D96CBD5"
          xlink:label="d43674379e969-wk-Fact-C9379BA9136D5BBB8F3432FB4D96CBD5"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43674379e969-wk-Fact-C9379BA9136D5BBB8F3432FB4D96CBD5"
          xlink:to="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43771853e10366-wk-Fact-C9F9F4BF1A82536D95AD4E1D85276729"
          xlink:label="d43771853e10366-wk-Fact-C9F9F4BF1A82536D95AD4E1D85276729"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e10366-wk-Fact-C9F9F4BF1A82536D95AD4E1D85276729"
          xlink:to="TextSelection-450A7304FB7E513FB479F6D9A06EF1D3-0-wk-Footnote-450A7304FB7E513FB479F6D9A06EF1D3_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43712496e3302-wk-Fact-CA0E038FD7FB54A5AFFBA924D7EA3A6D"
          xlink:label="d43712496e3302-wk-Fact-CA0E038FD7FB54A5AFFBA924D7EA3A6D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43712496e3302-wk-Fact-CA0E038FD7FB54A5AFFBA924D7EA3A6D"
          xlink:to="TextSelection-02609C62928C5D1CBFB6DD071D9D7B0E-0-wk-Footnote-02609C62928C5D1CBFB6DD071D9D7B0E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43771853e8193-wk-Fact-CA9E5961B1D758D2820894BDF915B4EC"
          xlink:label="d43771853e8193-wk-Fact-CA9E5961B1D758D2820894BDF915B4EC"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e8193-wk-Fact-CA9E5961B1D758D2820894BDF915B4EC"
          xlink:to="TextSelection-B88EBF1DF3CD5B06AADA1AA5E249F160-0-wk-Footnote-B88EBF1DF3CD5B06AADA1AA5E249F160_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e7412-wk-Fact-CADEEEB82C0B519FB5E1247FA7EE8C72"
          xlink:label="d43770747e7412-wk-Fact-CADEEEB82C0B519FB5E1247FA7EE8C72"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e7412-wk-Fact-CADEEEB82C0B519FB5E1247FA7EE8C72"
          xlink:to="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e7412-wk-Fact-CADEEEB82C0B519FB5E1247FA7EE8C72"
          xlink:to="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43690878e1556-wk-Fact-CB2E688471765831ADC0A8CA1A4F8DFD"
          xlink:label="d43690878e1556-wk-Fact-CB2E688471765831ADC0A8CA1A4F8DFD"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43690878e1556-wk-Fact-CB2E688471765831ADC0A8CA1A4F8DFD"
          xlink:to="TextSelection-792D3AB23D6354CFBB2776AE7F6407B4-0-wk-Footnote-792D3AB23D6354CFBB2776AE7F6407B4_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43712510e5473-wk-Fact-CB88AB971B745EBB96F422CEAFCAA461"
          xlink:label="d43712510e5473-wk-Fact-CB88AB971B745EBB96F422CEAFCAA461"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43712510e5473-wk-Fact-CB88AB971B745EBB96F422CEAFCAA461"
          xlink:to="TextSelection-621F9196966C550EA113DA57575C171E-0-wk-Footnote-621F9196966C550EA113DA57575C171E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43771853e5449-wk-Fact-CB8A98F9684B5E90A54FF33CE216657C"
          xlink:label="d43771853e5449-wk-Fact-CB8A98F9684B5E90A54FF33CE216657C"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e5449-wk-Fact-CB8A98F9684B5E90A54FF33CE216657C"
          xlink:to="TextSelection-84795AFB20AD54C48C963C7C52B00178-0-wk-Footnote-84795AFB20AD54C48C963C7C52B00178_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43674379e2494-wk-Fact-CCCD07BEDF4C5FF9AF3BA300510C89D4"
          xlink:label="d43674379e2494-wk-Fact-CCCD07BEDF4C5FF9AF3BA300510C89D4"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43674379e2494-wk-Fact-CCCD07BEDF4C5FF9AF3BA300510C89D4"
          xlink:to="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43771853e10217-wk-Fact-CD0D167B7BFA55D3B52DA395AB1BD7B8"
          xlink:label="d43771853e10217-wk-Fact-CD0D167B7BFA55D3B52DA395AB1BD7B8"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e10217-wk-Fact-CD0D167B7BFA55D3B52DA395AB1BD7B8"
          xlink:to="TextSelection-DE7EF4A6663E52BF8D3620854A57A945-0-wk-Footnote-DE7EF4A6663E52BF8D3620854A57A945_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43674379e1322-wk-Fact-CD12C4F0CCE4505FAD338F25A39BF391"
          xlink:label="d43674379e1322-wk-Fact-CD12C4F0CCE4505FAD338F25A39BF391"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43674379e1322-wk-Fact-CD12C4F0CCE4505FAD338F25A39BF391"
          xlink:to="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43771853e9258-wk-Fact-CD1BFB65FFF5532B973C2FBCB7BE8C3E"
          xlink:label="d43771853e9258-wk-Fact-CD1BFB65FFF5532B973C2FBCB7BE8C3E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e9258-wk-Fact-CD1BFB65FFF5532B973C2FBCB7BE8C3E"
          xlink:to="TextSelection-08466783230155A08D7C13267B950D39-0-wk-Footnote-08466783230155A08D7C13267B950D39_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43674379e1549-wk-Fact-CDA40E6949B85E61B9C8AF985182E3E5"
          xlink:label="d43674379e1549-wk-Fact-CDA40E6949B85E61B9C8AF985182E3E5"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d43770747e1943-wk-Fact-CDA40E6949B85E61B9C8AF985182E3E5"
          xlink:label="d43770747e1943-wk-Fact-CDA40E6949B85E61B9C8AF985182E3E5"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e1943-wk-Fact-CDA40E6949B85E61B9C8AF985182E3E5"
          xlink:to="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43674379e1549-wk-Fact-CDA40E6949B85E61B9C8AF985182E3E5"
          xlink:to="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e1943-wk-Fact-CDA40E6949B85E61B9C8AF985182E3E5"
          xlink:to="TextSelection-E90A054BCC035ECEB6B6F2B7C947C3CE-0-wk-Footnote-E90A054BCC035ECEB6B6F2B7C947C3CE_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43674379e1549-wk-Fact-CDA40E6949B85E61B9C8AF985182E3E5"
          xlink:to="TextSelection-E90A054BCC035ECEB6B6F2B7C947C3CE-0-wk-Footnote-E90A054BCC035ECEB6B6F2B7C947C3CE_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43771853e10847-wk-Fact-CDE473F11CA35CD29DE23110EB7E3FEF"
          xlink:label="d43771853e10847-wk-Fact-CDE473F11CA35CD29DE23110EB7E3FEF"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e10847-wk-Fact-CDE473F11CA35CD29DE23110EB7E3FEF"
          xlink:to="TextSelection-A685A65E160C5D228F531BF7107B3DF7-0-wk-Footnote-A685A65E160C5D228F531BF7107B3DF7_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43712496e2547-wk-Fact-CE0D12184A835989A295DE71DFF72EF8"
          xlink:label="d43712496e2547-wk-Fact-CE0D12184A835989A295DE71DFF72EF8"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43712496e2547-wk-Fact-CE0D12184A835989A295DE71DFF72EF8"
          xlink:to="TextSelection-C37CD88178CA35C475D25A62F2B54FED-0-wk-Footnote-C37CD88178CA35C475D25A62F2B54FED_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687849e2846-wk-Fact-CE6465895C815C29B1431FBD3ED3B46B"
          xlink:label="d43687849e2846-wk-Fact-CE6465895C815C29B1431FBD3ED3B46B"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e2846-wk-Fact-CE6465895C815C29B1431FBD3ED3B46B"
          xlink:to="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43712496e2045-wk-Fact-CE9A93EF950C573BB8A81EBFDFFAF1D6"
          xlink:label="d43712496e2045-wk-Fact-CE9A93EF950C573BB8A81EBFDFFAF1D6"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43712496e2045-wk-Fact-CE9A93EF950C573BB8A81EBFDFFAF1D6"
          xlink:to="TextSelection-7160FF67E87550A19177FE255A41A2D7-0-wk-Footnote-7160FF67E87550A19177FE255A41A2D7_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687849e1519-wk-Fact-CF85F87F0E845EA3BF827845F15B8168"
          xlink:label="d43687849e1519-wk-Fact-CF85F87F0E845EA3BF827845F15B8168"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e1519-wk-Fact-CF85F87F0E845EA3BF827845F15B8168"
          xlink:to="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43697240e1671-wk-Fact-CFD4991422BB5F588B49A4956375B606"
          xlink:label="d43697240e1671-wk-Fact-CFD4991422BB5F588B49A4956375B606"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d43697240e2295-wk-Fact-CFD4991422BB5F588B49A4956375B606"
          xlink:label="d43697240e2295-wk-Fact-CFD4991422BB5F588B49A4956375B606"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43697240e1671-wk-Fact-CFD4991422BB5F588B49A4956375B606"
          xlink:to="TextSelection-FF348CC7844F523299A112551B170BE6-0-wk-Footnote-FF348CC7844F523299A112551B170BE6_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43697240e2295-wk-Fact-CFD4991422BB5F588B49A4956375B606"
          xlink:to="TextSelection-FF348CC7844F523299A112551B170BE6-0-wk-Footnote-FF348CC7844F523299A112551B170BE6_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e8667-wk-Fact-CFF329117B805CE791A8F04DB947E1BC"
          xlink:label="d43770747e8667-wk-Fact-CFF329117B805CE791A8F04DB947E1BC"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e8667-wk-Fact-CFF329117B805CE791A8F04DB947E1BC"
          xlink:to="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e8667-wk-Fact-CFF329117B805CE791A8F04DB947E1BC"
          xlink:to="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e10947-wk-Fact-CFFE4951A2DE534ABE61BA03B8048EA4"
          xlink:label="d43770747e10947-wk-Fact-CFFE4951A2DE534ABE61BA03B8048EA4"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e10947-wk-Fact-CFFE4951A2DE534ABE61BA03B8048EA4"
          xlink:to="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e10947-wk-Fact-CFFE4951A2DE534ABE61BA03B8048EA4"
          xlink:to="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43712496e1224-wk-Fact-D042F83875705E98AC1B9D757B41F8B1"
          xlink:label="d43712496e1224-wk-Fact-D042F83875705E98AC1B9D757B41F8B1"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43712496e1224-wk-Fact-D042F83875705E98AC1B9D757B41F8B1"
          xlink:to="TextSelection-B57619F44FCF544D96067CF4816A9082-0-wk-Footnote-B57619F44FCF544D96067CF4816A9082_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43674379e988-wk-Fact-D05030AC7D8B5906A350262C6079BD92"
          xlink:label="d43674379e988-wk-Fact-D05030AC7D8B5906A350262C6079BD92"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43674379e988-wk-Fact-D05030AC7D8B5906A350262C6079BD92"
          xlink:to="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43771853e888-wk-Fact-D074F89DB2815EDFA2146FB266FB023F"
          xlink:label="d43771853e888-wk-Fact-D074F89DB2815EDFA2146FB266FB023F"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e888-wk-Fact-D074F89DB2815EDFA2146FB266FB023F"
          xlink:to="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43690878e2352-wk-Fact-D0EF06948F015270863207632A10DE91"
          xlink:label="d43690878e2352-wk-Fact-D0EF06948F015270863207632A10DE91"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43690878e2352-wk-Fact-D0EF06948F015270863207632A10DE91"
          xlink:to="TextSelection-0333DDFA54555789BB4E2E73E3451A69-0-wk-Footnote-0333DDFA54555789BB4E2E73E3451A69_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43690878e2352-wk-Fact-D0EF06948F015270863207632A10DE91"
          xlink:to="TextSelection-792D3AB23D6354CFBB2776AE7F6407B4-0-wk-Footnote-792D3AB23D6354CFBB2776AE7F6407B4_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43674379e817-wk-Fact-D156C275113454EF9843F3D3060B56DB"
          xlink:label="d43674379e817-wk-Fact-D156C275113454EF9843F3D3060B56DB"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d43681613e2472-wk-Fact-D156C275113454EF9843F3D3060B56DB"
          xlink:label="d43681613e2472-wk-Fact-D156C275113454EF9843F3D3060B56DB"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43674379e817-wk-Fact-D156C275113454EF9843F3D3060B56DB"
          xlink:to="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43681613e2472-wk-Fact-D156C275113454EF9843F3D3060B56DB"
          xlink:to="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43674379e817-wk-Fact-D156C275113454EF9843F3D3060B56DB"
          xlink:to="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43681613e2472-wk-Fact-D156C275113454EF9843F3D3060B56DB"
          xlink:to="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43681613e1924-wk-Fact-D165564A6DBB5ECA8030FB998D5E7FE7"
          xlink:label="d43681613e1924-wk-Fact-D165564A6DBB5ECA8030FB998D5E7FE7"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43681613e1924-wk-Fact-D165564A6DBB5ECA8030FB998D5E7FE7"
          xlink:to="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687704e882-wk-Fact-D1ABF3DF10655F18B16D5BEDE8158D66"
          xlink:label="d43687704e882-wk-Fact-D1ABF3DF10655F18B16D5BEDE8158D66"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d43771853e3613-wk-Fact-D1ABF3DF10655F18B16D5BEDE8158D66"
          xlink:label="d43771853e3613-wk-Fact-D1ABF3DF10655F18B16D5BEDE8158D66"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d43771853e4954-wk-Fact-D1ABF3DF10655F18B16D5BEDE8158D66"
          xlink:label="d43771853e4954-wk-Fact-D1ABF3DF10655F18B16D5BEDE8158D66"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e4954-wk-Fact-D1ABF3DF10655F18B16D5BEDE8158D66"
          xlink:to="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e3613-wk-Fact-D1ABF3DF10655F18B16D5BEDE8158D66"
          xlink:to="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e882-wk-Fact-D1ABF3DF10655F18B16D5BEDE8158D66"
          xlink:to="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e4260-wk-Fact-D1DB098BFAA05A5582E3C54C39A219DE"
          xlink:label="d43770747e4260-wk-Fact-D1DB098BFAA05A5582E3C54C39A219DE"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e4260-wk-Fact-D1DB098BFAA05A5582E3C54C39A219DE"
          xlink:to="TextSelection-2BFD6C99096B50AD93705C5601B21F46-0-wk-Footnote-2BFD6C99096B50AD93705C5601B21F46_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43697224e985-wk-Fact-D20C669A561D58BF9A9C9AC47CBBACC7"
          xlink:label="d43697224e985-wk-Fact-D20C669A561D58BF9A9C9AC47CBBACC7"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43697224e985-wk-Fact-D20C669A561D58BF9A9C9AC47CBBACC7"
          xlink:to="TextSelection-FE5DD06AA8B65777900C47B8AC19C4C6-0-wk-Footnote-FE5DD06AA8B65777900C47B8AC19C4C6_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687704e1114-wk-Fact-D23657D890AE5F088F89E76D78FD1EB7"
          xlink:label="d43687704e1114-wk-Fact-D23657D890AE5F088F89E76D78FD1EB7"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e1114-wk-Fact-D23657D890AE5F088F89E76D78FD1EB7"
          xlink:to="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e1114-wk-Fact-D23657D890AE5F088F89E76D78FD1EB7"
          xlink:to="TextSelection-AE19F19C6AE65BBDA7F551089E2E7EDF-0-wk-Footnote-AE19F19C6AE65BBDA7F551089E2E7EDF_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43690878e1745-wk-Fact-D295627FDF4F561AB6C6612120051877"
          xlink:label="d43690878e1745-wk-Fact-D295627FDF4F561AB6C6612120051877"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43690878e1745-wk-Fact-D295627FDF4F561AB6C6612120051877"
          xlink:to="TextSelection-792D3AB23D6354CFBB2776AE7F6407B4-0-wk-Footnote-792D3AB23D6354CFBB2776AE7F6407B4_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e972-wk-Fact-D2E616C04C74565E87B5EFE91C979223"
          xlink:label="d43770747e972-wk-Fact-D2E616C04C74565E87B5EFE91C979223"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e972-wk-Fact-D2E616C04C74565E87B5EFE91C979223"
          xlink:to="TextSelection-8D2A93033C2E56DE9E814F0AB36328EE-0-wk-Footnote-8D2A93033C2E56DE9E814F0AB36328EE_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e972-wk-Fact-D2E616C04C74565E87B5EFE91C979223"
          xlink:to="TextSelection-E96B3A139CCA56EC98329BC3717B10E3-0-wk-Footnote-E96B3A139CCA56EC98329BC3717B10E3_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43712496e3446-wk-Fact-D319BAF88B8B545CA48395F0788E8501"
          xlink:label="d43712496e3446-wk-Fact-D319BAF88B8B545CA48395F0788E8501"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43712496e3446-wk-Fact-D319BAF88B8B545CA48395F0788E8501"
          xlink:to="TextSelection-04B3DB4115835E2FBB99EA13FC1FD64B-0-wk-Footnote-04B3DB4115835E2FBB99EA13FC1FD64B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687704e1048-wk-Fact-D3650EE23D875F2485C04773B26C6EBF"
          xlink:label="d43687704e1048-wk-Fact-D3650EE23D875F2485C04773B26C6EBF"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e1048-wk-Fact-D3650EE23D875F2485C04773B26C6EBF"
          xlink:to="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e1048-wk-Fact-D3650EE23D875F2485C04773B26C6EBF"
          xlink:to="TextSelection-AE19F19C6AE65BBDA7F551089E2E7EDF-0-wk-Footnote-AE19F19C6AE65BBDA7F551089E2E7EDF_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e4156-wk-Fact-D3AD03E39A685B5F98D9E5A6DA5939DF"
          xlink:label="d43770747e4156-wk-Fact-D3AD03E39A685B5F98D9E5A6DA5939DF"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e4156-wk-Fact-D3AD03E39A685B5F98D9E5A6DA5939DF"
          xlink:to="TextSelection-2BFD6C99096B50AD93705C5601B21F46-0-wk-Footnote-2BFD6C99096B50AD93705C5601B21F46_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687849e1730-wk-Fact-D4592919CCA35BD2BDC493D03993CB8A"
          xlink:label="d43687849e1730-wk-Fact-D4592919CCA35BD2BDC493D03993CB8A"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e1730-wk-Fact-D4592919CCA35BD2BDC493D03993CB8A"
          xlink:to="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e1045-wk-Fact-D53A0B9A3EDB5C82AE283FE0420CAB5D"
          xlink:label="d43770747e1045-wk-Fact-D53A0B9A3EDB5C82AE283FE0420CAB5D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e1045-wk-Fact-D53A0B9A3EDB5C82AE283FE0420CAB5D"
          xlink:to="TextSelection-8D2A93033C2E56DE9E814F0AB36328EE-0-wk-Footnote-8D2A93033C2E56DE9E814F0AB36328EE_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e1045-wk-Fact-D53A0B9A3EDB5C82AE283FE0420CAB5D"
          xlink:to="TextSelection-91730671722A5F83BA05EF347193E4CF-0-wk-Footnote-91730671722A5F83BA05EF347193E4CF_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687704e1825-wk-Fact-D5E632B5D4A85473B7FDB1B2EC3EF703"
          xlink:label="d43687704e1825-wk-Fact-D5E632B5D4A85473B7FDB1B2EC3EF703"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d43690878e1505-wk-Fact-D5E632B5D4A85473B7FDB1B2EC3EF703"
          xlink:label="d43690878e1505-wk-Fact-D5E632B5D4A85473B7FDB1B2EC3EF703"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43690878e1505-wk-Fact-D5E632B5D4A85473B7FDB1B2EC3EF703"
          xlink:to="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e1825-wk-Fact-D5E632B5D4A85473B7FDB1B2EC3EF703"
          xlink:to="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687849e2977-wk-Fact-D64522201D7F5BB5BA48471538CE6CB8"
          xlink:label="d43687849e2977-wk-Fact-D64522201D7F5BB5BA48471538CE6CB8"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e2977-wk-Fact-D64522201D7F5BB5BA48471538CE6CB8"
          xlink:to="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43771853e3062-wk-Fact-D653E73218645753AB0757271374CCA1"
          xlink:label="d43771853e3062-wk-Fact-D653E73218645753AB0757271374CCA1"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e3062-wk-Fact-D653E73218645753AB0757271374CCA1"
          xlink:to="TextSelection-13C3E50268A15908A8AC9D1B6C938D2D-0-wk-Footnote-13C3E50268A15908A8AC9D1B6C938D2D_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e3062-wk-Fact-D653E73218645753AB0757271374CCA1"
          xlink:to="TextSelection-78FC5AB8EFAB585E87BBCF93BE9FBF1D-0-wk-Footnote-78FC5AB8EFAB585E87BBCF93BE9FBF1D_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e3062-wk-Fact-D653E73218645753AB0757271374CCA1"
          xlink:to="TextSelection-C2AA3A20AB3F54349FC86854E44E1000-0-wk-Footnote-C2AA3A20AB3F54349FC86854E44E1000_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687849e1114-wk-Fact-D6817414FA765B068A1698A96A9159E8"
          xlink:label="d43687849e1114-wk-Fact-D6817414FA765B068A1698A96A9159E8"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e1114-wk-Fact-D6817414FA765B068A1698A96A9159E8"
          xlink:to="TextSelection-36C36413532355188985D26E3B171357-0-wk-Footnote-36C36413532355188985D26E3B171357_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e1114-wk-Fact-D6817414FA765B068A1698A96A9159E8"
          xlink:to="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43771853e3582-wk-Fact-D6C99180CE0A52CAAA4028B1B586C207"
          xlink:label="d43771853e3582-wk-Fact-D6C99180CE0A52CAAA4028B1B586C207"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e3582-wk-Fact-D6C99180CE0A52CAAA4028B1B586C207"
          xlink:to="TextSelection-78FC5AB8EFAB585E87BBCF93BE9FBF1D-0-wk-Footnote-78FC5AB8EFAB585E87BBCF93BE9FBF1D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e10449-wk-Fact-D729388174C854FE8C4CEFABB9A6A065"
          xlink:label="d43770747e10449-wk-Fact-D729388174C854FE8C4CEFABB9A6A065"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e10449-wk-Fact-D729388174C854FE8C4CEFABB9A6A065"
          xlink:to="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e10449-wk-Fact-D729388174C854FE8C4CEFABB9A6A065"
          xlink:to="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43697224e1236-wk-Fact-D7C62060D2E154C4AFD979CF86960190"
          xlink:label="d43697224e1236-wk-Fact-D7C62060D2E154C4AFD979CF86960190"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43697224e1236-wk-Fact-D7C62060D2E154C4AFD979CF86960190"
          xlink:to="TextSelection-7679A63ACE625532ADFCC5B97C6C9FC6-0-wk-Footnote-7679A63ACE625532ADFCC5B97C6C9FC6_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687849e3162-wk-Fact-D87820179CF453388B904F407941F962"
          xlink:label="d43687849e3162-wk-Fact-D87820179CF453388B904F407941F962"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e3162-wk-Fact-D87820179CF453388B904F407941F962"
          xlink:to="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687849e2670-wk-Fact-D8BF89A982EE5516AF5D38868D45AC49"
          xlink:label="d43687849e2670-wk-Fact-D8BF89A982EE5516AF5D38868D45AC49"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e2670-wk-Fact-D8BF89A982EE5516AF5D38868D45AC49"
          xlink:to="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e1333-wk-Fact-D91DA66DDA5D533D8090F62E9D24777E"
          xlink:label="d43770747e1333-wk-Fact-D91DA66DDA5D533D8090F62E9D24777E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e1333-wk-Fact-D91DA66DDA5D533D8090F62E9D24777E"
          xlink:to="TextSelection-E90A054BCC035ECEB6B6F2B7C947C3CE-0-wk-Footnote-E90A054BCC035ECEB6B6F2B7C947C3CE_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43681613e2242-wk-Fact-DA0EC5A432335C1691A8266D92801437"
          xlink:label="d43681613e2242-wk-Fact-DA0EC5A432335C1691A8266D92801437"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43681613e2242-wk-Fact-DA0EC5A432335C1691A8266D92801437"
          xlink:to="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e10474-wk-Fact-DA9B023396AA59FCAFC767A3F15E2AAA"
          xlink:label="d43770747e10474-wk-Fact-DA9B023396AA59FCAFC767A3F15E2AAA"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e10474-wk-Fact-DA9B023396AA59FCAFC767A3F15E2AAA"
          xlink:to="TextSelection-39CF024D03225486829869F6CA02C00E-0-wk-Footnote-39CF024D03225486829869F6CA02C00E_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e10474-wk-Fact-DA9B023396AA59FCAFC767A3F15E2AAA"
          xlink:to="TextSelection-53BB8CAFCA475C0C9DB2195050D36025-0-wk-Footnote-53BB8CAFCA475C0C9DB2195050D36025_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e10474-wk-Fact-DA9B023396AA59FCAFC767A3F15E2AAA"
          xlink:to="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43712510e6030-wk-Fact-DACE24AFDEBA5A45B37C21CDA9314DB0"
          xlink:label="d43712510e6030-wk-Fact-DACE24AFDEBA5A45B37C21CDA9314DB0"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43712510e6030-wk-Fact-DACE24AFDEBA5A45B37C21CDA9314DB0"
          xlink:to="TextSelection-6550A25092D55979B6A1D62BD4EDF090-0-wk-Footnote-6550A25092D55979B6A1D62BD4EDF090_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43681613e2356-wk-Fact-DB025A970D1451AEACFC8A982A850506"
          xlink:label="d43681613e2356-wk-Fact-DB025A970D1451AEACFC8A982A850506"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43681613e2356-wk-Fact-DB025A970D1451AEACFC8A982A850506"
          xlink:to="TextSelection-3DD94144621C5A68BC21C5DB64345BB9-0-wk-Footnote-3DD94144621C5A68BC21C5DB64345BB9_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43681613e2356-wk-Fact-DB025A970D1451AEACFC8A982A850506"
          xlink:to="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687704e2725-wk-Fact-DB504CC293605BAF9CADCD1A8D93F11A"
          xlink:label="d43687704e2725-wk-Fact-DB504CC293605BAF9CADCD1A8D93F11A"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d43712471e5794-wk-Fact-DB504CC293605BAF9CADCD1A8D93F11A"
          xlink:label="d43712471e5794-wk-Fact-DB504CC293605BAF9CADCD1A8D93F11A"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e2725-wk-Fact-DB504CC293605BAF9CADCD1A8D93F11A"
          xlink:to="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43712471e5794-wk-Fact-DB504CC293605BAF9CADCD1A8D93F11A"
          xlink:to="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e2725-wk-Fact-DB504CC293605BAF9CADCD1A8D93F11A"
          xlink:to="TextSelection-9231AC55B8EC5775BC4995B0797F870F-0-wk-Footnote-9231AC55B8EC5775BC4995B0797F870F_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43712471e5794-wk-Fact-DB504CC293605BAF9CADCD1A8D93F11A"
          xlink:to="TextSelection-9231AC55B8EC5775BC4995B0797F870F-0-wk-Footnote-9231AC55B8EC5775BC4995B0797F870F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687849e1388-wk-Fact-DC0B04CD35255AAE8DB2F2B96794D8DC"
          xlink:label="d43687849e1388-wk-Fact-DC0B04CD35255AAE8DB2F2B96794D8DC"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e1388-wk-Fact-DC0B04CD35255AAE8DB2F2B96794D8DC"
          xlink:to="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e1388-wk-Fact-DC0B04CD35255AAE8DB2F2B96794D8DC"
          xlink:to="TextSelection-F185CD45BC245C2EB8EDBFD55DB8A33F-0-wk-Footnote-F185CD45BC245C2EB8EDBFD55DB8A33F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687849e1883-wk-Fact-DC5034ABC2EA5C18880A9E00522D29F5"
          xlink:label="d43687849e1883-wk-Fact-DC5034ABC2EA5C18880A9E00522D29F5"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e1883-wk-Fact-DC5034ABC2EA5C18880A9E00522D29F5"
          xlink:to="TextSelection-77536863BCE35B419E3A4119D41DB4BD-0-wk-Footnote-77536863BCE35B419E3A4119D41DB4BD_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e1883-wk-Fact-DC5034ABC2EA5C18880A9E00522D29F5"
          xlink:to="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43697240e1344-wk-Fact-DC886DFF855F55D5A5C4FBBBA585838D"
          xlink:label="d43697240e1344-wk-Fact-DC886DFF855F55D5A5C4FBBBA585838D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43697240e1344-wk-Fact-DC886DFF855F55D5A5C4FBBBA585838D"
          xlink:to="TextSelection-7432EEEACAB3598FA522C1D7E1584D05-0-wk-Footnote-7432EEEACAB3598FA522C1D7E1584D05_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43681613e1220-wk-Fact-DED2BD217A165276A7FC6775BFD357E2"
          xlink:label="d43681613e1220-wk-Fact-DED2BD217A165276A7FC6775BFD357E2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43681613e1220-wk-Fact-DED2BD217A165276A7FC6775BFD357E2"
          xlink:to="TextSelection-3DD94144621C5A68BC21C5DB64345BB9-0-wk-Footnote-3DD94144621C5A68BC21C5DB64345BB9_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43681613e1220-wk-Fact-DED2BD217A165276A7FC6775BFD357E2"
          xlink:to="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43681613e2745-wk-Fact-DEFAF9D423795479839BFC83C7E9408A"
          xlink:label="d43681613e2745-wk-Fact-DEFAF9D423795479839BFC83C7E9408A"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43681613e2745-wk-Fact-DEFAF9D423795479839BFC83C7E9408A"
          xlink:to="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43681613e2745-wk-Fact-DEFAF9D423795479839BFC83C7E9408A"
          xlink:to="TextSelection-EB5698F25D035A90984FA270E724B7BB-0-wk-Footnote-EB5698F25D035A90984FA270E724B7BB_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43712496e3598-wk-Fact-DFB58A1FD36B53C88918A31FB32F3CE9"
          xlink:label="d43712496e3598-wk-Fact-DFB58A1FD36B53C88918A31FB32F3CE9"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43712496e3598-wk-Fact-DFB58A1FD36B53C88918A31FB32F3CE9"
          xlink:to="TextSelection-3E9076747FF25E3B8D3B9AAF71548F16-0-wk-Footnote-3E9076747FF25E3B8D3B9AAF71548F16_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43712496e2343-wk-Fact-E0337FF965B85F19893F5C95D32AAD5B"
          xlink:label="d43712496e2343-wk-Fact-E0337FF965B85F19893F5C95D32AAD5B"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43712496e2343-wk-Fact-E0337FF965B85F19893F5C95D32AAD5B"
          xlink:to="TextSelection-C37CD88178CA35C475D25A62F2B54FED-0-wk-Footnote-C37CD88178CA35C475D25A62F2B54FED_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e8769-wk-Fact-E158F0F72B4F5E699400B1D0DF2B49F9"
          xlink:label="d43770747e8769-wk-Fact-E158F0F72B4F5E699400B1D0DF2B49F9"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e8769-wk-Fact-E158F0F72B4F5E699400B1D0DF2B49F9"
          xlink:to="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e8769-wk-Fact-E158F0F72B4F5E699400B1D0DF2B49F9"
          xlink:to="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43771853e4875-wk-Fact-E1E962311928538DB01EDDF50F83A4A9"
          xlink:label="d43771853e4875-wk-Fact-E1E962311928538DB01EDDF50F83A4A9"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e4875-wk-Fact-E1E962311928538DB01EDDF50F83A4A9"
          xlink:to="TextSelection-DC6DDCB74FC9523D97BA51FBA6B1C05E-0-wk-Footnote-DC6DDCB74FC9523D97BA51FBA6B1C05E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e11323-wk-Fact-E257ACF9822153C0B4489B4BD0381028"
          xlink:label="d43770747e11323-wk-Fact-E257ACF9822153C0B4489B4BD0381028"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e11323-wk-Fact-E257ACF9822153C0B4489B4BD0381028"
          xlink:to="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e11323-wk-Fact-E257ACF9822153C0B4489B4BD0381028"
          xlink:to="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687704e2282-wk-Fact-E36AD239D16459E1808D418ACCF15849"
          xlink:label="d43687704e2282-wk-Fact-E36AD239D16459E1808D418ACCF15849"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e2282-wk-Fact-E36AD239D16459E1808D418ACCF15849"
          xlink:to="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e2282-wk-Fact-E36AD239D16459E1808D418ACCF15849"
          xlink:to="TextSelection-9231AC55B8EC5775BC4995B0797F870F-0-wk-Footnote-9231AC55B8EC5775BC4995B0797F870F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43674379e2342-wk-Fact-E3E870C4333E5DBA8986F6E17DA1CE7C"
          xlink:label="d43674379e2342-wk-Fact-E3E870C4333E5DBA8986F6E17DA1CE7C"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43674379e2342-wk-Fact-E3E870C4333E5DBA8986F6E17DA1CE7C"
          xlink:to="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43697224e1670-wk-Fact-E3EB811EAA2157F1B8A0AC676941AA20"
          xlink:label="d43697224e1670-wk-Fact-E3EB811EAA2157F1B8A0AC676941AA20"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43697224e1670-wk-Fact-E3EB811EAA2157F1B8A0AC676941AA20"
          xlink:to="TextSelection-9C73CEBDEE585A83B2B18F3B38A6D8CD-0-wk-Footnote-9C73CEBDEE585A83B2B18F3B38A6D8CD_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687849e2463-wk-Fact-E42F286486CD5834BD8EB16236B31FEA"
          xlink:label="d43687849e2463-wk-Fact-E42F286486CD5834BD8EB16236B31FEA"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e2463-wk-Fact-E42F286486CD5834BD8EB16236B31FEA"
          xlink:to="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43697224e1411-wk-Fact-E45333DA3C1351558E633F4210434F91"
          xlink:label="d43697224e1411-wk-Fact-E45333DA3C1351558E633F4210434F91"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43697224e1411-wk-Fact-E45333DA3C1351558E633F4210434F91"
          xlink:to="TextSelection-6E67095C033B51BB9FABBA85E8DC4DFA-0-wk-Footnote-6E67095C033B51BB9FABBA85E8DC4DFA_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e11050-wk-Fact-E5A70858CAFC5770B3F632E0F9C47F2B"
          xlink:label="d43770747e11050-wk-Fact-E5A70858CAFC5770B3F632E0F9C47F2B"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e11050-wk-Fact-E5A70858CAFC5770B3F632E0F9C47F2B"
          xlink:to="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e11050-wk-Fact-E5A70858CAFC5770B3F632E0F9C47F2B"
          xlink:to="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43681613e2382-wk-Fact-E5CA2563496958358157EDDBD9180C21"
          xlink:label="d43681613e2382-wk-Fact-E5CA2563496958358157EDDBD9180C21"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43681613e2382-wk-Fact-E5CA2563496958358157EDDBD9180C21"
          xlink:to="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43771853e11125-wk-Fact-E5DEE2763FF15719B07579F02111EFC3"
          xlink:label="d43771853e11125-wk-Fact-E5DEE2763FF15719B07579F02111EFC3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e11125-wk-Fact-E5DEE2763FF15719B07579F02111EFC3"
          xlink:to="TextSelection-ED6F6E1A7C41596DA6F5B1BDFBB72CB7-0-wk-Footnote-ED6F6E1A7C41596DA6F5B1BDFBB72CB7_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43712496e2567-wk-Fact-E6280093B5CF57199192AD6A1C984105"
          xlink:label="d43712496e2567-wk-Fact-E6280093B5CF57199192AD6A1C984105"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43712496e2567-wk-Fact-E6280093B5CF57199192AD6A1C984105"
          xlink:to="TextSelection-C37CD88178CA35C475D25A62F2B54FED-0-wk-Footnote-C37CD88178CA35C475D25A62F2B54FED_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687704e2301-wk-Fact-E6450DE123AB5BECA240B4DA5F938164"
          xlink:label="d43687704e2301-wk-Fact-E6450DE123AB5BECA240B4DA5F938164"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e2301-wk-Fact-E6450DE123AB5BECA240B4DA5F938164"
          xlink:to="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e2301-wk-Fact-E6450DE123AB5BECA240B4DA5F938164"
          xlink:to="TextSelection-9231AC55B8EC5775BC4995B0797F870F-0-wk-Footnote-9231AC55B8EC5775BC4995B0797F870F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43712496e2026-wk-Fact-E6F32BC6EC2E5D5AB12A3A9ECA0A4CEF"
          xlink:label="d43712496e2026-wk-Fact-E6F32BC6EC2E5D5AB12A3A9ECA0A4CEF"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43712496e2026-wk-Fact-E6F32BC6EC2E5D5AB12A3A9ECA0A4CEF"
          xlink:to="TextSelection-7160FF67E87550A19177FE255A41A2D7-0-wk-Footnote-7160FF67E87550A19177FE255A41A2D7_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43771853e11059-wk-Fact-E71ECFC84ED058A1982578968151CD88"
          xlink:label="d43771853e11059-wk-Fact-E71ECFC84ED058A1982578968151CD88"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e11059-wk-Fact-E71ECFC84ED058A1982578968151CD88"
          xlink:to="TextSelection-7266C8E6B8975A65A379AF3B415EA220-0-wk-Footnote-7266C8E6B8975A65A379AF3B415EA220_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43681613e929-wk-Fact-E753F2020B8F56CEBAE560B3B8BB9086"
          xlink:label="d43681613e929-wk-Fact-E753F2020B8F56CEBAE560B3B8BB9086"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43681613e929-wk-Fact-E753F2020B8F56CEBAE560B3B8BB9086"
          xlink:to="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43771853e1447-wk-Fact-E7A96C031340595C8C21FFE23138776B"
          xlink:label="d43771853e1447-wk-Fact-E7A96C031340595C8C21FFE23138776B"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e1447-wk-Fact-E7A96C031340595C8C21FFE23138776B"
          xlink:to="TextSelection-78FC5AB8EFAB585E87BBCF93BE9FBF1D-0-wk-Footnote-78FC5AB8EFAB585E87BBCF93BE9FBF1D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43771853e3236-wk-Fact-E7E6EB83A98259609D63524CCF7C1687"
          xlink:label="d43771853e3236-wk-Fact-E7E6EB83A98259609D63524CCF7C1687"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e3236-wk-Fact-E7E6EB83A98259609D63524CCF7C1687"
          xlink:to="TextSelection-13C3E50268A15908A8AC9D1B6C938D2D-0-wk-Footnote-13C3E50268A15908A8AC9D1B6C938D2D_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e3236-wk-Fact-E7E6EB83A98259609D63524CCF7C1687"
          xlink:to="TextSelection-78FC5AB8EFAB585E87BBCF93BE9FBF1D-0-wk-Footnote-78FC5AB8EFAB585E87BBCF93BE9FBF1D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e8074-wk-Fact-E84743BA7BEB5C538A4DCD2F234366E5"
          xlink:label="d43770747e8074-wk-Fact-E84743BA7BEB5C538A4DCD2F234366E5"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e8074-wk-Fact-E84743BA7BEB5C538A4DCD2F234366E5"
          xlink:to="TextSelection-39CF024D03225486829869F6CA02C00E-0-wk-Footnote-39CF024D03225486829869F6CA02C00E_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e8074-wk-Fact-E84743BA7BEB5C538A4DCD2F234366E5"
          xlink:to="TextSelection-53BB8CAFCA475C0C9DB2195050D36025-0-wk-Footnote-53BB8CAFCA475C0C9DB2195050D36025_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e8074-wk-Fact-E84743BA7BEB5C538A4DCD2F234366E5"
          xlink:to="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact-E880E7106AA35CF2A064350EE9638A88-wk-Fact-E880E7106AA35CF2A064350EE9638A88"
          xlink:label="Fact-E880E7106AA35CF2A064350EE9638A88-wk-Fact-E880E7106AA35CF2A064350EE9638A88"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact-E880E7106AA35CF2A064350EE9638A88-wk-Fact-E880E7106AA35CF2A064350EE9638A88"
          xlink:to="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43712496e3559-wk-Fact-E88E61DCD79054CAB129EA8C07D5A4E5"
          xlink:label="d43712496e3559-wk-Fact-E88E61DCD79054CAB129EA8C07D5A4E5"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43712496e3559-wk-Fact-E88E61DCD79054CAB129EA8C07D5A4E5"
          xlink:to="TextSelection-3E9076747FF25E3B8D3B9AAF71548F16-0-wk-Footnote-3E9076747FF25E3B8D3B9AAF71548F16_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43674379e1209-wk-Fact-E8F1DC92BC58566FACDD0804C8857081"
          xlink:label="d43674379e1209-wk-Fact-E8F1DC92BC58566FACDD0804C8857081"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43674379e1209-wk-Fact-E8F1DC92BC58566FACDD0804C8857081"
          xlink:to="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e11133-wk-Fact-E9261ECFF1BF56E48D687B9EB690D501"
          xlink:label="d43770747e11133-wk-Fact-E9261ECFF1BF56E48D687B9EB690D501"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e11133-wk-Fact-E9261ECFF1BF56E48D687B9EB690D501"
          xlink:to="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e11133-wk-Fact-E9261ECFF1BF56E48D687B9EB690D501"
          xlink:to="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43681613e992-wk-Fact-E944F13BD8105FBDB6ACB7D264796FD0"
          xlink:label="d43681613e992-wk-Fact-E944F13BD8105FBDB6ACB7D264796FD0"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d43697224e1519-wk-Fact-E944F13BD8105FBDB6ACB7D264796FD0"
          xlink:label="d43697224e1519-wk-Fact-E944F13BD8105FBDB6ACB7D264796FD0"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43697224e1519-wk-Fact-E944F13BD8105FBDB6ACB7D264796FD0"
          xlink:to="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43681613e992-wk-Fact-E944F13BD8105FBDB6ACB7D264796FD0"
          xlink:to="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43697224e1519-wk-Fact-E944F13BD8105FBDB6ACB7D264796FD0"
          xlink:to="TextSelection-FCAEF1B26EF652E4896D2456427B24D7-0-wk-Footnote-FCAEF1B26EF652E4896D2456427B24D7_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43681613e992-wk-Fact-E944F13BD8105FBDB6ACB7D264796FD0"
          xlink:to="TextSelection-FCAEF1B26EF652E4896D2456427B24D7-0-wk-Footnote-FCAEF1B26EF652E4896D2456427B24D7_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687849e2260-wk-Fact-E969B5F6A0FD5E7199F96415161E24EE"
          xlink:label="d43687849e2260-wk-Fact-E969B5F6A0FD5E7199F96415161E24EE"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e2260-wk-Fact-E969B5F6A0FD5E7199F96415161E24EE"
          xlink:to="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e8607-wk-Fact-E989403B19655D56902F363195B8FB79"
          xlink:label="d43770747e8607-wk-Fact-E989403B19655D56902F363195B8FB79"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e8607-wk-Fact-E989403B19655D56902F363195B8FB79"
          xlink:to="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e8607-wk-Fact-E989403B19655D56902F363195B8FB79"
          xlink:to="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687849e2137-wk-Fact-E9A491CA05515608A24040D57754A17D"
          xlink:label="d43687849e2137-wk-Fact-E9A491CA05515608A24040D57754A17D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e2137-wk-Fact-E9A491CA05515608A24040D57754A17D"
          xlink:to="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43674379e900-wk-Fact-EA1D3C7D16595854B5CD606B1A735B28"
          xlink:label="d43674379e900-wk-Fact-EA1D3C7D16595854B5CD606B1A735B28"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43674379e900-wk-Fact-EA1D3C7D16595854B5CD606B1A735B28"
          xlink:to="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43681613e1518-wk-Fact-EA51BB96305D596BBCDA3AF91C4A5606"
          xlink:label="d43681613e1518-wk-Fact-EA51BB96305D596BBCDA3AF91C4A5606"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43681613e1518-wk-Fact-EA51BB96305D596BBCDA3AF91C4A5606"
          xlink:to="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43712496e2401-wk-Fact-EADD6730C9975145BE6C22C98A531D3E"
          xlink:label="d43712496e2401-wk-Fact-EADD6730C9975145BE6C22C98A531D3E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43712496e2401-wk-Fact-EADD6730C9975145BE6C22C98A531D3E"
          xlink:to="TextSelection-C37CD88178CA35C475D25A62F2B54FED-0-wk-Footnote-C37CD88178CA35C475D25A62F2B54FED_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687704e2044-wk-Fact-EBA23CAAE8065687AE88E6554D498B60"
          xlink:label="d43687704e2044-wk-Fact-EBA23CAAE8065687AE88E6554D498B60"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e2044-wk-Fact-EBA23CAAE8065687AE88E6554D498B60"
          xlink:to="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e2044-wk-Fact-EBA23CAAE8065687AE88E6554D498B60"
          xlink:to="TextSelection-9231AC55B8EC5775BC4995B0797F870F-0-wk-Footnote-9231AC55B8EC5775BC4995B0797F870F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e10055-wk-Fact-EBE9947C4118517F84796F369756CEED"
          xlink:label="d43770747e10055-wk-Fact-EBE9947C4118517F84796F369756CEED"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e10055-wk-Fact-EBE9947C4118517F84796F369756CEED"
          xlink:to="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e10055-wk-Fact-EBE9947C4118517F84796F369756CEED"
          xlink:to="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e8132-wk-Fact-ED0DC050AE3557C5AA59EE876A9CCB85"
          xlink:label="d43770747e8132-wk-Fact-ED0DC050AE3557C5AA59EE876A9CCB85"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e8132-wk-Fact-ED0DC050AE3557C5AA59EE876A9CCB85"
          xlink:to="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e8132-wk-Fact-ED0DC050AE3557C5AA59EE876A9CCB85"
          xlink:to="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687849e2348-wk-Fact-ED18C0861D3E5C15B3C0A349152628B0"
          xlink:label="d43687849e2348-wk-Fact-ED18C0861D3E5C15B3C0A349152628B0"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e2348-wk-Fact-ED18C0861D3E5C15B3C0A349152628B0"
          xlink:to="TextSelection-77536863BCE35B419E3A4119D41DB4BD-0-wk-Footnote-77536863BCE35B419E3A4119D41DB4BD_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e2348-wk-Fact-ED18C0861D3E5C15B3C0A349152628B0"
          xlink:to="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e5872-wk-Fact-ED395CB21D4254C59230DB3A66452C47"
          xlink:label="d43770747e5872-wk-Fact-ED395CB21D4254C59230DB3A66452C47"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-10C1964C9B955D8AB1D255A5330FE0A9-0-wk-Footnote-10C1964C9B955D8AB1D255A5330FE0A9_lbl" xlink:label="TextSelection-10C1964C9B955D8AB1D255A5330FE0A9-0-wk-Footnote-10C1964C9B955D8AB1D255A5330FE0A9_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The notes, issued in U.S. dollars in Taiwan, are redeemable, at our option, in whole but not in part, on each March 17 on or after March 17, 2020.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e5872-wk-Fact-ED395CB21D4254C59230DB3A66452C47"
          xlink:to="TextSelection-10C1964C9B955D8AB1D255A5330FE0A9-0-wk-Footnote-10C1964C9B955D8AB1D255A5330FE0A9_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43712496e1536-wk-Fact-ED45326FD065577BB318715037A629A6"
          xlink:label="d43712496e1536-wk-Fact-ED45326FD065577BB318715037A629A6"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43712496e1536-wk-Fact-ED45326FD065577BB318715037A629A6"
          xlink:to="TextSelection-6912797A078E5D59B618DFFBB81C1BB6-0-wk-Footnote-6912797A078E5D59B618DFFBB81C1BB6_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e9829-wk-Fact-ED75BB4B1C585EB9A02A2357479F8D29"
          xlink:label="d43770747e9829-wk-Fact-ED75BB4B1C585EB9A02A2357479F8D29"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e9829-wk-Fact-ED75BB4B1C585EB9A02A2357479F8D29"
          xlink:to="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e9829-wk-Fact-ED75BB4B1C585EB9A02A2357479F8D29"
          xlink:to="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43697224e1717-wk-Fact-EE1FD7EDFFF655E3BCB6C13905C55C31"
          xlink:label="d43697224e1717-wk-Fact-EE1FD7EDFFF655E3BCB6C13905C55C31"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43697224e1717-wk-Fact-EE1FD7EDFFF655E3BCB6C13905C55C31"
          xlink:to="TextSelection-ECF6A95A77365D79B2E9D472B81966D9-0-wk-Footnote-ECF6A95A77365D79B2E9D472B81966D9_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43771853e8259-wk-Fact-EE748539AE775F7AB4E662FB43CE60E4"
          xlink:label="d43771853e8259-wk-Fact-EE748539AE775F7AB4E662FB43CE60E4"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e8259-wk-Fact-EE748539AE775F7AB4E662FB43CE60E4"
          xlink:to="TextSelection-C4FFB7FEB33B5D5EBA7924687B243323-0-wk-Footnote-C4FFB7FEB33B5D5EBA7924687B243323_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687704e1467-wk-Fact-EE9718ED59B15329A11D4FE12F405FEA"
          xlink:label="d43687704e1467-wk-Fact-EE9718ED59B15329A11D4FE12F405FEA"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d43697224e1848-wk-Fact-EE9718ED59B15329A11D4FE12F405FEA"
          xlink:label="d43697224e1848-wk-Fact-EE9718ED59B15329A11D4FE12F405FEA"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43697224e1848-wk-Fact-EE9718ED59B15329A11D4FE12F405FEA"
          xlink:to="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e1467-wk-Fact-EE9718ED59B15329A11D4FE12F405FEA"
          xlink:to="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43674379e2050-wk-Fact-EECAD1E5742D526A902588518CB825FF"
          xlink:label="d43674379e2050-wk-Fact-EECAD1E5742D526A902588518CB825FF"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43674379e2050-wk-Fact-EECAD1E5742D526A902588518CB825FF"
          xlink:to="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43690878e1595-wk-Fact-EECF50AEC9F85FECBE21642BE05B9B94"
          xlink:label="d43690878e1595-wk-Fact-EECF50AEC9F85FECBE21642BE05B9B94"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43690878e1595-wk-Fact-EECF50AEC9F85FECBE21642BE05B9B94"
          xlink:to="TextSelection-792D3AB23D6354CFBB2776AE7F6407B4-0-wk-Footnote-792D3AB23D6354CFBB2776AE7F6407B4_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687704e1429-wk-Fact-EEFC92F1B5E55E77955910BC4C0F4CE1"
          xlink:label="d43687704e1429-wk-Fact-EEFC92F1B5E55E77955910BC4C0F4CE1"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d43697224e1809-wk-Fact-EEFC92F1B5E55E77955910BC4C0F4CE1"
          xlink:label="d43697224e1809-wk-Fact-EEFC92F1B5E55E77955910BC4C0F4CE1"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e1429-wk-Fact-EEFC92F1B5E55E77955910BC4C0F4CE1"
          xlink:to="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43697224e1809-wk-Fact-EEFC92F1B5E55E77955910BC4C0F4CE1"
          xlink:to="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e1268-wk-Fact-EF31EB7FE14056148C1A008C93495CEB"
          xlink:label="d43770747e1268-wk-Fact-EF31EB7FE14056148C1A008C93495CEB"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e1268-wk-Fact-EF31EB7FE14056148C1A008C93495CEB"
          xlink:to="TextSelection-E90A054BCC035ECEB6B6F2B7C947C3CE-0-wk-Footnote-E90A054BCC035ECEB6B6F2B7C947C3CE_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e1268-wk-Fact-EF31EB7FE14056148C1A008C93495CEB"
          xlink:to="TextSelection-E96B3A139CCA56EC98329BC3717B10E3-0-wk-Footnote-E96B3A139CCA56EC98329BC3717B10E3_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43681613e2103-wk-Fact-EF326C0BF8D95F73A75E0D09B3DC12A4"
          xlink:label="d43681613e2103-wk-Fact-EF326C0BF8D95F73A75E0D09B3DC12A4"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43681613e2103-wk-Fact-EF326C0BF8D95F73A75E0D09B3DC12A4"
          xlink:to="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e11031-wk-Fact-EF8FCCDF207A5213AA733CAB56F33EB4"
          xlink:label="d43770747e11031-wk-Fact-EF8FCCDF207A5213AA733CAB56F33EB4"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e11031-wk-Fact-EF8FCCDF207A5213AA733CAB56F33EB4"
          xlink:to="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e11031-wk-Fact-EF8FCCDF207A5213AA733CAB56F33EB4"
          xlink:to="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e7491-wk-Fact-EFD127551F54519E94393635FCB3FC4A"
          xlink:label="d43770747e7491-wk-Fact-EFD127551F54519E94393635FCB3FC4A"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e7491-wk-Fact-EFD127551F54519E94393635FCB3FC4A"
          xlink:to="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e7491-wk-Fact-EFD127551F54519E94393635FCB3FC4A"
          xlink:to="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43674379e1918-wk-Fact-F0B612439D18585FBB73EEB374B11207"
          xlink:label="d43674379e1918-wk-Fact-F0B612439D18585FBB73EEB374B11207"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d43770747e2189-wk-Fact-F0B612439D18585FBB73EEB374B11207"
          xlink:label="d43770747e2189-wk-Fact-F0B612439D18585FBB73EEB374B11207"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e2189-wk-Fact-F0B612439D18585FBB73EEB374B11207"
          xlink:to="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43674379e1918-wk-Fact-F0B612439D18585FBB73EEB374B11207"
          xlink:to="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e2189-wk-Fact-F0B612439D18585FBB73EEB374B11207"
          xlink:to="TextSelection-CBF70F977965537BB382CD083809AA0A-0-wk-Footnote-CBF70F977965537BB382CD083809AA0A_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43674379e1918-wk-Fact-F0B612439D18585FBB73EEB374B11207"
          xlink:to="TextSelection-CBF70F977965537BB382CD083809AA0A-0-wk-Footnote-CBF70F977965537BB382CD083809AA0A_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e10907-wk-Fact-F135E5CEAB8E5D4EB7575AEBFF4DF757"
          xlink:label="d43770747e10907-wk-Fact-F135E5CEAB8E5D4EB7575AEBFF4DF757"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e10907-wk-Fact-F135E5CEAB8E5D4EB7575AEBFF4DF757"
          xlink:to="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e10907-wk-Fact-F135E5CEAB8E5D4EB7575AEBFF4DF757"
          xlink:to="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43771853e10808-wk-Fact-F17AE8BADCC4517B9C333EAD88E5DA8B"
          xlink:label="d43771853e10808-wk-Fact-F17AE8BADCC4517B9C333EAD88E5DA8B"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e10808-wk-Fact-F17AE8BADCC4517B9C333EAD88E5DA8B"
          xlink:to="TextSelection-A685A65E160C5D228F531BF7107B3DF7-0-wk-Footnote-A685A65E160C5D228F531BF7107B3DF7_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e10573-wk-Fact-F18080A5F5AD57518995089379096CF8"
          xlink:label="d43770747e10573-wk-Fact-F18080A5F5AD57518995089379096CF8"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e10573-wk-Fact-F18080A5F5AD57518995089379096CF8"
          xlink:to="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e10573-wk-Fact-F18080A5F5AD57518995089379096CF8"
          xlink:to="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43712496e2279-wk-Fact-F1C2E56FFF6857968C5DF6D28AD574C9"
          xlink:label="d43712496e2279-wk-Fact-F1C2E56FFF6857968C5DF6D28AD574C9"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43712496e2279-wk-Fact-F1C2E56FFF6857968C5DF6D28AD574C9"
          xlink:to="TextSelection-C37CD88178CA35C475D25A62F2B54FED-0-wk-Footnote-C37CD88178CA35C475D25A62F2B54FED_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact-F26558A44B7C5E24A9D0B3C320ABC3AC-wk-Fact-F26558A44B7C5E24A9D0B3C320ABC3AC"
          xlink:label="Fact-F26558A44B7C5E24A9D0B3C320ABC3AC-wk-Fact-F26558A44B7C5E24A9D0B3C320ABC3AC"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact-F26558A44B7C5E24A9D0B3C320ABC3AC-wk-Fact-F26558A44B7C5E24A9D0B3C320ABC3AC"
          xlink:to="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43712496e1165-wk-Fact-F2A2071B8FC55425A60551104D415290"
          xlink:label="d43712496e1165-wk-Fact-F2A2071B8FC55425A60551104D415290"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43712496e1165-wk-Fact-F2A2071B8FC55425A60551104D415290"
          xlink:to="TextSelection-B57619F44FCF544D96067CF4816A9082-0-wk-Footnote-B57619F44FCF544D96067CF4816A9082_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687704e2467-wk-Fact-F337EEA9B15A530CA79C01F287A6870F"
          xlink:label="d43687704e2467-wk-Fact-F337EEA9B15A530CA79C01F287A6870F"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e2467-wk-Fact-F337EEA9B15A530CA79C01F287A6870F"
          xlink:to="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e2467-wk-Fact-F337EEA9B15A530CA79C01F287A6870F"
          xlink:to="TextSelection-9231AC55B8EC5775BC4995B0797F870F-0-wk-Footnote-9231AC55B8EC5775BC4995B0797F870F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687849e1795-wk-Fact-F368335D74285386B4B988BC23C52314"
          xlink:label="d43687849e1795-wk-Fact-F368335D74285386B4B988BC23C52314"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e1795-wk-Fact-F368335D74285386B4B988BC23C52314"
          xlink:to="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687704e1384-wk-Fact-F3D7E2873AD65FA18989892A60F6626A"
          xlink:label="d43687704e1384-wk-Fact-F3D7E2873AD65FA18989892A60F6626A"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d43712496e1704-wk-Fact-F3D7E2873AD65FA18989892A60F6626A"
          xlink:label="d43712496e1704-wk-Fact-F3D7E2873AD65FA18989892A60F6626A"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e1384-wk-Fact-F3D7E2873AD65FA18989892A60F6626A"
          xlink:to="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43712496e1704-wk-Fact-F3D7E2873AD65FA18989892A60F6626A"
          xlink:to="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43771853e3497-wk-Fact-F4E33C840C7351EB83A44DAB9FB01B6C"
          xlink:label="d43771853e3497-wk-Fact-F4E33C840C7351EB83A44DAB9FB01B6C"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e3497-wk-Fact-F4E33C840C7351EB83A44DAB9FB01B6C"
          xlink:to="TextSelection-78FC5AB8EFAB585E87BBCF93BE9FBF1D-0-wk-Footnote-78FC5AB8EFAB585E87BBCF93BE9FBF1D_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e3497-wk-Fact-F4E33C840C7351EB83A44DAB9FB01B6C"
          xlink:to="TextSelection-8540AADB45BE54D38C10451BF6A88AB4-0-wk-Footnote-8540AADB45BE54D38C10451BF6A88AB4_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43674379e1190-wk-Fact-F52CA4E0D2C151988CD5EF5FA00DEAFE"
          xlink:label="d43674379e1190-wk-Fact-F52CA4E0D2C151988CD5EF5FA00DEAFE"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43674379e1190-wk-Fact-F52CA4E0D2C151988CD5EF5FA00DEAFE"
          xlink:to="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687704e2764-wk-Fact-F53A90EB6B0F5931A598FD416D03851F"
          xlink:label="d43687704e2764-wk-Fact-F53A90EB6B0F5931A598FD416D03851F"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e2764-wk-Fact-F53A90EB6B0F5931A598FD416D03851F"
          xlink:to="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e2764-wk-Fact-F53A90EB6B0F5931A598FD416D03851F"
          xlink:to="TextSelection-9231AC55B8EC5775BC4995B0797F870F-0-wk-Footnote-9231AC55B8EC5775BC4995B0797F870F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43674379e1146-wk-Fact-F5595E1E6E5C5AB79FC9578F6E9622FC"
          xlink:label="d43674379e1146-wk-Fact-F5595E1E6E5C5AB79FC9578F6E9622FC"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43674379e1146-wk-Fact-F5595E1E6E5C5AB79FC9578F6E9622FC"
          xlink:to="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687849e1645-wk-Fact-F567CC4505EC55EF951CC1C3D6B62769"
          xlink:label="d43687849e1645-wk-Fact-F567CC4505EC55EF951CC1C3D6B62769"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e1645-wk-Fact-F567CC4505EC55EF951CC1C3D6B62769"
          xlink:to="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e1645-wk-Fact-F567CC4505EC55EF951CC1C3D6B62769"
          xlink:to="TextSelection-F185CD45BC245C2EB8EDBFD55DB8A33F-0-wk-Footnote-F185CD45BC245C2EB8EDBFD55DB8A33F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43681613e1764-wk-Fact-F59987278FE651D99A4A03B22559E7CB"
          xlink:label="d43681613e1764-wk-Fact-F59987278FE651D99A4A03B22559E7CB"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43681613e1764-wk-Fact-F59987278FE651D99A4A03B22559E7CB"
          xlink:to="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687849e1711-wk-Fact-F6B16FF2F2E15556BF6FA7B44550EBC3"
          xlink:label="d43687849e1711-wk-Fact-F6B16FF2F2E15556BF6FA7B44550EBC3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e1711-wk-Fact-F6B16FF2F2E15556BF6FA7B44550EBC3"
          xlink:to="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687849e1009-wk-Fact-F703FF2FF1295F3C9A1F766CB8844DF9"
          xlink:label="d43687849e1009-wk-Fact-F703FF2FF1295F3C9A1F766CB8844DF9"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e1009-wk-Fact-F703FF2FF1295F3C9A1F766CB8844DF9"
          xlink:to="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43681613e2877-wk-Fact-F79EE7D9A58D5B3AA60618D470617657"
          xlink:label="d43681613e2877-wk-Fact-F79EE7D9A58D5B3AA60618D470617657"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43681613e2877-wk-Fact-F79EE7D9A58D5B3AA60618D470617657"
          xlink:to="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43771853e4625-wk-Fact-F7E35E4375AD52538A3022CD6B0C19EC"
          xlink:label="d43771853e4625-wk-Fact-F7E35E4375AD52538A3022CD6B0C19EC"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e4625-wk-Fact-F7E35E4375AD52538A3022CD6B0C19EC"
          xlink:to="TextSelection-3802305E73EB52F28FAAF4EA5481D580-0-wk-Footnote-3802305E73EB52F28FAAF4EA5481D580_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e1178-wk-Fact-F7F348B359C05BD59C8DCACAAC15C4ED"
          xlink:label="d43770747e1178-wk-Fact-F7F348B359C05BD59C8DCACAAC15C4ED"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e1178-wk-Fact-F7F348B359C05BD59C8DCACAAC15C4ED"
          xlink:to="TextSelection-8D2A93033C2E56DE9E814F0AB36328EE-0-wk-Footnote-8D2A93033C2E56DE9E814F0AB36328EE_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e1178-wk-Fact-F7F348B359C05BD59C8DCACAAC15C4ED"
          xlink:to="TextSelection-91730671722A5F83BA05EF347193E4CF-0-wk-Footnote-91730671722A5F83BA05EF347193E4CF_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43771853e5488-wk-Fact-F89CB7AD3161526488B19688958B0E65"
          xlink:label="d43771853e5488-wk-Fact-F89CB7AD3161526488B19688958B0E65"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e5488-wk-Fact-F89CB7AD3161526488B19688958B0E65"
          xlink:to="TextSelection-84795AFB20AD54C48C963C7C52B00178-0-wk-Footnote-84795AFB20AD54C48C963C7C52B00178_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687704e1767-wk-Fact-F8A88E3727775446BECFB5D7B19FFE9A"
          xlink:label="d43687704e1767-wk-Fact-F8A88E3727775446BECFB5D7B19FFE9A"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d43690878e1447-wk-Fact-F8A88E3727775446BECFB5D7B19FFE9A"
          xlink:label="d43690878e1447-wk-Fact-F8A88E3727775446BECFB5D7B19FFE9A"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e1767-wk-Fact-F8A88E3727775446BECFB5D7B19FFE9A"
          xlink:to="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43690878e1447-wk-Fact-F8A88E3727775446BECFB5D7B19FFE9A"
          xlink:to="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43674379e1297-wk-Fact-F8F5DF7C12C25020B65DFF915C2D461A"
          xlink:label="d43674379e1297-wk-Fact-F8F5DF7C12C25020B65DFF915C2D461A"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d43697240e3182-wk-Fact-F8F5DF7C12C25020B65DFF915C2D461A"
          xlink:label="d43697240e3182-wk-Fact-F8F5DF7C12C25020B65DFF915C2D461A"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43674379e1297-wk-Fact-F8F5DF7C12C25020B65DFF915C2D461A"
          xlink:to="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43697240e3182-wk-Fact-F8F5DF7C12C25020B65DFF915C2D461A"
          xlink:to="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687704e1871-wk-Fact-F91674DC2E49576AB1FD6B5399D570DE"
          xlink:label="d43687704e1871-wk-Fact-F91674DC2E49576AB1FD6B5399D570DE"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d43687849e865-wk-Fact-F91674DC2E49576AB1FD6B5399D570DE"
          xlink:label="d43687849e865-wk-Fact-F91674DC2E49576AB1FD6B5399D570DE"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e865-wk-Fact-F91674DC2E49576AB1FD6B5399D570DE"
          xlink:to="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e1871-wk-Fact-F91674DC2E49576AB1FD6B5399D570DE"
          xlink:to="TextSelection-9156E2712F625783BFF06058DEEDCC1B-0-wk-Footnote-9156E2712F625783BFF06058DEEDCC1B_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e865-wk-Fact-F91674DC2E49576AB1FD6B5399D570DE"
          xlink:to="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e1871-wk-Fact-F91674DC2E49576AB1FD6B5399D570DE"
          xlink:to="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e865-wk-Fact-F91674DC2E49576AB1FD6B5399D570DE"
          xlink:to="TextSelection-9231AC55B8EC5775BC4995B0797F870F-0-wk-Footnote-9231AC55B8EC5775BC4995B0797F870F_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e1871-wk-Fact-F91674DC2E49576AB1FD6B5399D570DE"
          xlink:to="TextSelection-9231AC55B8EC5775BC4995B0797F870F-0-wk-Footnote-9231AC55B8EC5775BC4995B0797F870F_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e865-wk-Fact-F91674DC2E49576AB1FD6B5399D570DE"
          xlink:to="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687704e1871-wk-Fact-F91674DC2E49576AB1FD6B5399D570DE"
          xlink:to="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43712510e5308-wk-Fact-F91DB48F665752F183FB6249B5C47098"
          xlink:label="d43712510e5308-wk-Fact-F91DB48F665752F183FB6249B5C47098"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43712510e5308-wk-Fact-F91DB48F665752F183FB6249B5C47098"
          xlink:to="TextSelection-621F9196966C550EA113DA57575C171E-0-wk-Footnote-621F9196966C550EA113DA57575C171E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e1692-wk-Fact-F94A368CB7E95851A8FE7949FC3E83F4"
          xlink:label="d43770747e1692-wk-Fact-F94A368CB7E95851A8FE7949FC3E83F4"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e1692-wk-Fact-F94A368CB7E95851A8FE7949FC3E83F4"
          xlink:to="TextSelection-58096FF6357955D6B6AA25D56767CB0A-0-wk-Footnote-58096FF6357955D6B6AA25D56767CB0A_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e1692-wk-Fact-F94A368CB7E95851A8FE7949FC3E83F4"
          xlink:to="TextSelection-8D2A93033C2E56DE9E814F0AB36328EE-0-wk-Footnote-8D2A93033C2E56DE9E814F0AB36328EE_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43674379e2449-wk-Fact-F986BFF5DEDA51E58393FB9819F5F489"
          xlink:label="d43674379e2449-wk-Fact-F986BFF5DEDA51E58393FB9819F5F489"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43674379e2449-wk-Fact-F986BFF5DEDA51E58393FB9819F5F489"
          xlink:to="TextSelection-9EED90EEC9EE5B06991B85C254C68B51-0-wk-Footnote-9EED90EEC9EE5B06991B85C254C68B51_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43712496e1860-wk-Fact-FA60C203F66751A591C313394A513BBD"
          xlink:label="d43712496e1860-wk-Fact-FA60C203F66751A591C313394A513BBD"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43712496e1860-wk-Fact-FA60C203F66751A591C313394A513BBD"
          xlink:to="TextSelection-7160FF67E87550A19177FE255A41A2D7-0-wk-Footnote-7160FF67E87550A19177FE255A41A2D7_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43692105e1297-wk-Fact-FAF3334C03BB50B5921AB864A8788C26"
          xlink:label="d43692105e1297-wk-Fact-FAF3334C03BB50B5921AB864A8788C26"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43692105e1297-wk-Fact-FAF3334C03BB50B5921AB864A8788C26"
          xlink:to="TextSelection-2A36E737FFF05E75B357CB41AFB5B6E2-0-wk-Footnote-2A36E737FFF05E75B357CB41AFB5B6E2_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43681613e1789-wk-Fact-FB31F2DD4E78576D86B0CBE5A30FD593"
          xlink:label="d43681613e1789-wk-Fact-FB31F2DD4E78576D86B0CBE5A30FD593"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43681613e1789-wk-Fact-FB31F2DD4E78576D86B0CBE5A30FD593"
          xlink:to="TextSelection-92148CDC50B759928C7B24CD314A0415-0-wk-Footnote-92148CDC50B759928C7B24CD314A0415_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e5820-wk-Fact-FB5D18E9A92E5D758C68B08090472348"
          xlink:label="d43770747e5820-wk-Fact-FB5D18E9A92E5D758C68B08090472348"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e5820-wk-Fact-FB5D18E9A92E5D758C68B08090472348"
          xlink:to="TextSelection-A42108BE06A7587BABD0C4A820609CE4-0-wk-Footnote-A42108BE06A7587BABD0C4A820609CE4_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e8730-wk-Fact-FC17783C6AF95B6BA110F4B016C6E9A6"
          xlink:label="d43770747e8730-wk-Fact-FC17783C6AF95B6BA110F4B016C6E9A6"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e8730-wk-Fact-FC17783C6AF95B6BA110F4B016C6E9A6"
          xlink:to="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e8730-wk-Fact-FC17783C6AF95B6BA110F4B016C6E9A6"
          xlink:to="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e10410-wk-Fact-FD239FB115D9532BB0AC86A94B61DFC0"
          xlink:label="d43770747e10410-wk-Fact-FD239FB115D9532BB0AC86A94B61DFC0"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e10410-wk-Fact-FD239FB115D9532BB0AC86A94B61DFC0"
          xlink:to="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e10410-wk-Fact-FD239FB115D9532BB0AC86A94B61DFC0"
          xlink:to="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e5684-wk-Fact-FD39AA4E611853FFB3347204D8FFAE7B"
          xlink:label="d43770747e5684-wk-Fact-FD39AA4E611853FFB3347204D8FFAE7B"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e5684-wk-Fact-FD39AA4E611853FFB3347204D8FFAE7B"
          xlink:to="TextSelection-0BDE8CEE983B5F118E2EFACDF9CC6405-0-wk-Footnote-0BDE8CEE983B5F118E2EFACDF9CC6405_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687849e1281-wk-Fact-FDB2255DA9ED588F82220AD2BD357172"
          xlink:label="d43687849e1281-wk-Fact-FDB2255DA9ED588F82220AD2BD357172"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e1281-wk-Fact-FDB2255DA9ED588F82220AD2BD357172"
          xlink:to="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e7512-wk-Fact-FDC488BF6B135DEAA89A53C4766192EC"
          xlink:label="d43770747e7512-wk-Fact-FDC488BF6B135DEAA89A53C4766192EC"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e7512-wk-Fact-FDC488BF6B135DEAA89A53C4766192EC"
          xlink:to="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e7512-wk-Fact-FDC488BF6B135DEAA89A53C4766192EC"
          xlink:to="TextSelection-C789897C877D591AA18C91398D33C66E-0-wk-Footnote-C789897C877D591AA18C91398D33C66E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687849e2632-wk-Fact-FDE8C1D4A9445B5EB201CF6786FF4FCA"
          xlink:label="d43687849e2632-wk-Fact-FDE8C1D4A9445B5EB201CF6786FF4FCA"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e2632-wk-Fact-FDE8C1D4A9445B5EB201CF6786FF4FCA"
          xlink:to="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43690878e1913-wk-Fact-FF15C80FFD7658F196DE22E2327F4EF5"
          xlink:label="d43690878e1913-wk-Fact-FF15C80FFD7658F196DE22E2327F4EF5"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43690878e1913-wk-Fact-FF15C80FFD7658F196DE22E2327F4EF5"
          xlink:to="TextSelection-792D3AB23D6354CFBB2776AE7F6407B4-0-wk-Footnote-792D3AB23D6354CFBB2776AE7F6407B4_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43771853e1933-wk-Fact-FF681D2F4C60530BA4FA7ECF6068D66E"
          xlink:label="d43771853e1933-wk-Fact-FF681D2F4C60530BA4FA7ECF6068D66E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e1933-wk-Fact-FF681D2F4C60530BA4FA7ECF6068D66E"
          xlink:to="TextSelection-13C3E50268A15908A8AC9D1B6C938D2D-0-wk-Footnote-13C3E50268A15908A8AC9D1B6C938D2D_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43771853e1933-wk-Fact-FF681D2F4C60530BA4FA7ECF6068D66E"
          xlink:to="TextSelection-78FC5AB8EFAB585E87BBCF93BE9FBF1D-0-wk-Footnote-78FC5AB8EFAB585E87BBCF93BE9FBF1D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43687849e1453-wk-Fact-FF71A5EF104C5E84BB31EB85E1C2233A"
          xlink:label="d43687849e1453-wk-Fact-FF71A5EF104C5E84BB31EB85E1C2233A"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43687849e1453-wk-Fact-FF71A5EF104C5E84BB31EB85E1C2233A"
          xlink:to="TextSelection-DE5CE11259855EDB90FE5430FB21A5CC-0-wk-Footnote-DE5CE11259855EDB90FE5430FB21A5CC_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e8588-wk-Fact-FF816B32EE915991B09BB0A4C759A044"
          xlink:label="d43770747e8588-wk-Fact-FF816B32EE915991B09BB0A4C759A044"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e8588-wk-Fact-FF816B32EE915991B09BB0A4C759A044"
          xlink:to="TextSelection-39CF024D03225486829869F6CA02C00E-0-wk-Footnote-39CF024D03225486829869F6CA02C00E_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e8588-wk-Fact-FF816B32EE915991B09BB0A4C759A044"
          xlink:to="TextSelection-53BB8CAFCA475C0C9DB2195050D36025-0-wk-Footnote-53BB8CAFCA475C0C9DB2195050D36025_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e8588-wk-Fact-FF816B32EE915991B09BB0A4C759A044"
          xlink:to="TextSelection-65D371B3E1255C359F57BC7540F815ED-0-wk-Footnote-65D371B3E1255C359F57BC7540F815ED_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43770747e4241-wk-Fact-FF82CF35A3B95DE7946765F53E9FCC87"
          xlink:label="d43770747e4241-wk-Fact-FF82CF35A3B95DE7946765F53E9FCC87"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43770747e4241-wk-Fact-FF82CF35A3B95DE7946765F53E9FCC87"
          xlink:to="TextSelection-2BFD6C99096B50AD93705C5601B21F46-0-wk-Footnote-2BFD6C99096B50AD93705C5601B21F46_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d43712496e1367-wk-Fact-FF8ADB2E22EA5E31A89D8C1DB543B9B8"
          xlink:label="d43712496e1367-wk-Fact-FF8ADB2E22EA5E31A89D8C1DB543B9B8"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d43712496e1367-wk-Fact-FF8ADB2E22EA5E31A89D8C1DB543B9B8"
          xlink:to="TextSelection-B57619F44FCF544D96067CF4816A9082-0-wk-Footnote-B57619F44FCF544D96067CF4816A9082_lbl"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6910536624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 01, 2017</div></th>
<th class="th"><div>Nov. 06, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DocumentandEntityInformationAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">PFIZER INC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000078003<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Oct.  01,  2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PFE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,960,707,317<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DocumentandEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Document and Entity Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DocumentandEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6929516192">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF INCOME - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="4">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 01, 2017</div></th>
<th class="th"><div>Oct. 02, 2016</div></th>
<th class="th" colspan="2"><div>Oct. 01, 2017</div></th>
<th class="th" colspan="2"><div>Oct. 02, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 13,168<span></span>
</td>
<td class="nump">$ 13,045<span></span>
</td>
<td class="nump">$ 38,843<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 39,196<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsSold', window );">Cost of sales</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="nump">2,847<span></span>
</td>
<td class="nump">3,085<span></span>
</td>
<td class="nump">7,980<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">9,111<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, informational and administrative expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="nump">3,500<span></span>
</td>
<td class="nump">3,559<span></span>
</td>
<td class="nump">10,233<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">10,414<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="nump">1,859<span></span>
</td>
<td class="nump">1,881<span></span>
</td>
<td class="nump">5,346<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">5,360<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction', window );">Amortization of intangible assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,177<span></span>
</td>
<td class="nump">968<span></span>
</td>
<td class="nump">3,571<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,934<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_RestructuringChargesAndAcquisitionRelatedCosts', window );">Restructuring charges and certain acquisition-related costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">149<span></span>
</td>
<td class="nump">531<span></span>
</td>
<td class="nump">377<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">988<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (income)/deductions&#8211;&#8211;net</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">51<span></span>
</td>
<td class="nump">1,417<span></span>
</td>
<td class="num">(16)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,815<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income from continuing operations before provision for taxes on income</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[3]</sup></td>
<td class="nump">3,585<span></span>
</td>
<td class="nump">1,604<span></span>
</td>
<td class="nump">11,351<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">7,575<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for taxes on income</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[4]</sup></td>
<td class="nump">727<span></span>
</td>
<td class="nump">249<span></span>
</td>
<td class="nump">2,287<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,109<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Income from continuing operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[4],[5]</sup></td>
<td class="nump">2,858<span></span>
</td>
<td class="nump">1,355<span></span>
</td>
<td class="nump">9,064<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">6,465<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Discontinued operations&#8211;&#8211;net of tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income before allocation to noncontrolling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[4],[6],[7]</sup></td>
<td class="nump">2,858<span></span>
</td>
<td class="nump">1,355<span></span>
</td>
<td class="nump">9,066<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[8]</sup></td>
<td class="nump">6,465<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[8]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Less: Net income attributable to noncontrolling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">18<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">32<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">25<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Pfizer Inc.</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[4]</sup></td>
<td class="nump">$ 2,840<span></span>
</td>
<td class="nump">$ 1,355<span></span>
</td>
<td class="nump">$ 9,034<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 6,440<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Earnings per common share&#8211;&#8211;basic:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[4]</sup></td>
<td class="nump">$ 0.48<span></span>
</td>
<td class="nump">$ 0.22<span></span>
</td>
<td class="nump">$ 1.51<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 1.06<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare', window );">Discontinued operations&#8211;&#8211;net of tax (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[4]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income attributable to Pfizer Inc. common shareholders (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[4]</sup></td>
<td class="nump">0.48<span></span>
</td>
<td class="nump">0.22<span></span>
</td>
<td class="nump">1.51<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1.06<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedAbstract', window );"><strong>Earnings per common share&#8211;&#8211;diluted:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare', window );">Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[4]</sup></td>
<td class="nump">0.47<span></span>
</td>
<td class="nump">0.22<span></span>
</td>
<td class="nump">1.49<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1.04<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare', window );">Discontinued operations&#8211;&#8211;net of tax (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[4]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income attributable to Pfizer Inc. common shareholders (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[4]</sup></td>
<td class="nump">$ 0.47<span></span>
</td>
<td class="nump">$ 0.22<span></span>
</td>
<td class="nump">$ 1.49<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 1.04<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares&#8211;&#8211;basic</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">5,951<span></span>
</td>
<td class="nump">6,066<span></span>
</td>
<td class="nump">5,972<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">6,095<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares&#8211;&#8211;diluted</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[4],[5]</sup></td>
<td class="nump">6,041<span></span>
</td>
<td class="nump">6,150<span></span>
</td>
<td class="nump">6,057<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">6,175<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareCashPaid', window );">Cash dividends paid per common share (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 0.32<span></span>
</td>
<td class="nump">$ 0.30<span></span>
</td>
<td class="nump">$ 0.96<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 0.90<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="8"></td></tr>
<tr><td colspan="8"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Amounts may not add due to rounding.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Excludes amortization of intangible assets, except as disclosed in Note 9A. Identifiable Intangible Assets and Goodwill: Identifiable Intangible Assets.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">Income from continuing operations before provision for taxes on income. IH&#8217;s earnings in the <span style="font-family:inherit;font-size:8pt;">third quarter</span><span style="font-family:inherit;font-size:8pt;"> and </span><span style="font-family:inherit;font-size:8pt;">first nine months of</span><span style="font-family:inherit;font-size:8pt;"> </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:8pt;text-align:center;"> include d</span><span style="font-family:inherit;font-size:8pt;">ividend income of </span><span style="font-family:inherit;font-size:8pt;"><span>$54 million</span></span><span style="font-family:inherit;font-size:8pt;"> and </span><span style="font-family:inherit;font-size:8pt;"><span>$211 million</span></span><span style="font-family:inherit;font-size:8pt;">, respectively, from our investment in ViiV. For additional information, see </span>Note 4.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top">Amounts for the <span style="font-family:inherit;font-size:9pt;">three and nine months ended October 2, 2016</span><span style="font-family:inherit;font-size:9pt;"> have been revised from previously reported amounts to reflect the adoption of a new accounting standard in the fourth quarter of 2016, as of January 1, 2016. For additional information, see </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Note 1B</span><span style="font-family:inherit;font-size:9pt;">. </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Basis of Presentation and Significant Accounting Policies&#8211;&#8211;Adoption of New Accounting Standards</span>.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[5]</td>
<td style="vertical-align: top;" valign="top">Amounts for the <span style="font-family:inherit;font-size:8.5pt;">third quarter</span><span style="font-family:inherit;font-size:8.5pt;"> and first </span><span style="font-family:inherit;font-size:8.5pt;">nine months</span><span style="font-family:inherit;font-size:8.5pt;"> ended </span><span style="font-family:inherit;font-size:8.5pt;">October&#160;2, 2016</span><span style="font-family:inherit;font-size:8.5pt;"> have been revised from previously reported amounts to reflect the adoption of a new accounting standard in the fourth quarter of </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:8.5pt;">, as of January 1, 2016, that requires, when applying the treasury stock method for shares that could be repurchased, that the assumed proceeds no longer include the amount of excess tax benefit (see </span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Note 1B</span>).</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[6]</td>
<td style="vertical-align: top;" valign="top">Amounts may not add due to rounding.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[7]</td>
<td style="vertical-align: top;" valign="top">Amounts may not add due to rounding.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[8]</td>
<td style="vertical-align: top;" valign="top">Amounts for the <span style="font-family:inherit;font-size:7.5pt;">three and nine months ended October 2, 2016</span><span style="font-family:inherit;font-size:7.5pt;"> have been revised from previously reported amounts to reflect the adoption of a new accounting standard in the fourth quarter of 2016, as of January 1, 2016. For additional information, see </span><span style="font-family:inherit;font-size:7.5pt;font-style:italic;">Note 1B</span><span style="font-family:inherit;font-size:7.5pt;">. </span><span style="font-family:inherit;font-size:7.5pt;font-style:italic;">Basis of Presentation and Significant Accounting Policies</span>: Adoption of New Accounting Standards.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of amortization that is not associated with a single function. Amounts associated in a single function are included in Cost of sales, Selling, information and administrative expenses and Research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_RestructuringChargesAndAcquisitionRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents (i) restructuring charges, which are amounts charged against earnings in the period for incurred and estimated costs associated with exit from or disposal of business activities or restructurings pursuant to a program that is planned and controlled by management, and materially changes either the scope of a business undertaken by an entity, or the manner in which that business is conducted; and (ii) acquisition-related costs, which are costs incurred to effect a business combination which costs have been expensed during the period. Such costs can include transaction costs such as banking, legal, accounting and other costs directly related to effect a business combination as well as external, incremental costs of integration planning that are directly related to a business combination, including costs associated with preparing for systems and other integration activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_RestructuringChargesAndAcquisitionRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareCashPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends paid during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareCashPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs related to goods produced and sold during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=96948231&amp;loc=d3e4984-109258<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1252-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=96868048&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1252-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20187-122688<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20187-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1252-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721675-107760<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e1012-107759<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721525-107759<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721523-107759<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e957-107759<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=d3e1361-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1278-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 5.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355146-122828<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1278-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591551-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161450&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=96868048&amp;loc=SL4569616-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161450&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591551-111686<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161450&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueGoodsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueGoodsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=68048583&amp;loc=d3e3636-108311<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1505-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6929953360">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="4">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 01, 2017</div></th>
<th class="th"><div>Oct. 02, 2016</div></th>
<th class="th" colspan="2"><div>Oct. 01, 2017</div></th>
<th class="th" colspan="2"><div>Oct. 02, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income before allocation to noncontrolling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2],[3],[4]</sup></td>
<td class="nump">$ 2,858<span></span>
</td>
<td class="nump">$ 1,355<span></span>
</td>
<td class="nump">$ 9,066<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="nump">$ 6,465<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[5]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax', window );">Foreign currency translation adjustments, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">878<span></span>
</td>
<td class="nump">417<span></span>
</td>
<td class="nump">1,352<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">998<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax', window );">Reclassification adjustments</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3],[6]</sup></td>
<td class="num">(3)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">110<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax', window );">Other comprehensive income (loss), foreign currency transaction and translation adjustment, before tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">875<span></span>
</td>
<td class="nump">417<span></span>
</td>
<td class="nump">1,461<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">998<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax', window );">Unrealized holding losses on derivative financial instruments, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="num">(50)<span></span>
</td>
<td class="num">(126)<span></span>
</td>
<td class="num">(149)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(970)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesBeforeTax', window );">Reclassification adjustments for realized (gains)/losses</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3],[7]</sup></td>
<td class="nump">56<span></span>
</td>
<td class="nump">150<span></span>
</td>
<td class="num">(393)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">280<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesBeforeTax', window );">Other comprehensive income (loss), derivatives qualifying as hedges, before tax, total</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">6<span></span>
</td>
<td class="nump">24<span></span>
</td>
<td class="num">(542)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(690)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax', window );">Unrealized holding gains on available-for-sale securities, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">384<span></span>
</td>
<td class="nump">261<span></span>
</td>
<td class="nump">698<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">740<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax', window );">Reclassification adjustments for realized gains</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3],[7]</sup></td>
<td class="num">(278)<span></span>
</td>
<td class="num">(112)<span></span>
</td>
<td class="num">(181)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(129)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax', window );">Other comprehensive income (loss), available-for-sale securities adjustment, before tax, total</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">106<span></span>
</td>
<td class="nump">149<span></span>
</td>
<td class="nump">518<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">611<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax', window );">Benefit plans: actuarial losses, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="num">(103)<span></span>
</td>
<td class="num">(82)<span></span>
</td>
<td class="num">(41)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(101)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax', window );">Reclassification adjustments related to amortization</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3],[8]</sup></td>
<td class="nump">140<span></span>
</td>
<td class="nump">140<span></span>
</td>
<td class="nump">448<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">418<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax', window );">Reclassification adjustments related to settlements, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3],[8]</sup></td>
<td class="nump">38<span></span>
</td>
<td class="nump">28<span></span>
</td>
<td class="nump">89<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">76<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax', window );">Other</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="num">(76)<span></span>
</td>
<td class="nump">69<span></span>
</td>
<td class="num">(111)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">51<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax', window );">Defined benefit plan, amounts recognized in other comprehensive income (loss), net gain (loss), before tax, total</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">155<span></span>
</td>
<td class="nump">384<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">444<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax', window );">Benefit plans: prior service (costs)/credits and other, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">95<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">182<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax', window );">Reclassification adjustments related to amortization</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3],[8]</sup></td>
<td class="num">(46)<span></span>
</td>
<td class="num">(45)<span></span>
</td>
<td class="num">(138)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(127)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax', window );">Reclassification adjustments related to curtailments, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3],[8]</sup></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
<td class="num">(14)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(14)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax', window );">Other</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">1<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">12<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax', window );">Defined benefit plan, amounts recognized in other comprehensive income (loss), net prior service cost, before tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="num">(48)<span></span>
</td>
<td class="nump">48<span></span>
</td>
<td class="num">(151)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">54<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeTax', window );">Other comprehensive income, before tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">938<span></span>
</td>
<td class="nump">793<span></span>
</td>
<td class="nump">1,669<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,417<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTax', window );">Tax provision/(benefit) on other comprehensive income</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3],[9]</sup></td>
<td class="num">(80)<span></span>
</td>
<td class="nump">116<span></span>
</td>
<td class="num">(218)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">111<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income before allocation to noncontrolling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">1,018<span></span>
</td>
<td class="nump">677<span></span>
</td>
<td class="nump">1,888<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,306<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive income before allocation to noncontrolling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">3,876<span></span>
</td>
<td class="nump">2,031<span></span>
</td>
<td class="nump">10,953<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">7,771<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest', window );">Less: Comprehensive income attributable to noncontrolling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">19<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">48<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">24<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income attributable to Pfizer Inc.</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">$ 3,857<span></span>
</td>
<td class="nump">$ 2,032<span></span>
</td>
<td class="nump">$ 10,906<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 7,747<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="8"></td></tr>
<tr><td colspan="8"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Amounts for the <span style="font-family:inherit;font-size:9pt;">three and nine months ended October 2, 2016</span><span style="font-family:inherit;font-size:9pt;"> have been revised from previously reported amounts to reflect the adoption of a new accounting standard in the fourth quarter of 2016, as of January 1, 2016. For additional information, see </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Note 1B</span><span style="font-family:inherit;font-size:9pt;">. </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Basis of Presentation and Significant Accounting Policies&#8211;&#8211;Adoption of New Accounting Standards</span>.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Amounts may not add due to rounding.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">Amounts may not add due to rounding.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top">Amounts may not add due to rounding.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[5]</td>
<td style="vertical-align: top;" valign="top">Amounts for the <span style="font-family:inherit;font-size:7.5pt;">three and nine months ended October 2, 2016</span><span style="font-family:inherit;font-size:7.5pt;"> have been revised from previously reported amounts to reflect the adoption of a new accounting standard in the fourth quarter of 2016, as of January 1, 2016. For additional information, see </span><span style="font-family:inherit;font-size:7.5pt;font-style:italic;">Note 1B</span><span style="font-family:inherit;font-size:7.5pt;">. </span><span style="font-family:inherit;font-size:7.5pt;font-style:italic;">Basis of Presentation and Significant Accounting Policies</span>: Adoption of New Accounting Standards.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[6]</td>
<td style="vertical-align: top;" valign="top">The foreign currency translation adjustments reclassified into <span style="font-family:inherit;font-size:9pt;font-style:italic;">Other (income)/deductions&#8212;net </span><span style="font-family:inherit;font-size:9pt;">in the condensed consolidated statements of income primarily result from sale of our </span><span style="font-family:inherit;font-size:9pt;"><span>40%</span></span><span style="font-family:inherit;font-size:9pt;"> ownership investment in Teuto. See </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Note 2D. </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Acquisitions, Sale of Hospira Infusion Systems Net Assets, Collaborative Arrangement and Equity-Method Investments</span>: Equity-Method Investments.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[7]</td>
<td style="vertical-align: top;" valign="top">Reclassified into <span style="font-family:inherit;font-size:9pt;font-style:italic;">Other (income)/deductions&#8212;net </span><span style="font-family:inherit;font-size:9pt;">and </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Cost of sales</span><span style="font-family:inherit;font-size:9pt;"> in the condensed consolidated statements of income. For additional information on amounts reclassified into </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Cost of sales,</span><span style="font-family:inherit;font-size:9pt;"> see </span>Note 7F. Financial Instruments: Derivative Financial Instruments and Hedging Activities.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[8]</td>
<td style="vertical-align: top;" valign="top">Generally reclassified, as part of net periodic pension cost, into <span style="font-family:inherit;font-size:9pt;font-style:italic;">Cost of sales, Selling, informational and administrative expenses,</span><span style="font-family:inherit;font-size:9pt;"> and/or </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Research and development expenses</span><span style="font-family:inherit;font-size:9pt;">, as appropriate, in the condensed consolidated statements of income. For additional information, see </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Note 10. </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Pension and Postretirement Benefit Plans</span>.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[9]</td>
<td style="vertical-align: top;" valign="top">See Note 5C. Tax Matters: Tax Provision/(Benefit) on Other Comprehensive Income.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Pre tax adjustment to other comprehensive income for curtailments and settlements, net, related to defined benefit plans prior service (costs)/credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Pre tax adjustment to other comprehensive income for other adjustments related to defined benefit plans prior service (costs)/credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Pre tax adjustment to other comprehensive income for other adjustments related to defined benefit plans actuarial gains /losses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of pre tax adjustment to other comprehensive income for curtailments and settlements, net, related to defined benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=d3e557-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=96868048&amp;loc=SL4613674-111683<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=96868048&amp;loc=SL4569643-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591552-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=96868048&amp;loc=SL4569616-111683<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591552-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, after reclassification adjustment, of increase (decrease) in accumulated other comprehensive income from gain (loss) of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=82843861&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=SL7669646-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, after reclassification adjustment, of (increase) decrease in accumulated other comprehensive income from prior service cost (credit) of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (j)<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=SL7669646-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=82843861&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of cost (credit) of benefit change attributable to participants' prior service from plan amendment or plan initiation of defined benefit plan, that has not been recognized in net periodic benefit cost (credit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (j)<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=82843861&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=64808268&amp;loc=d3e32022-110900<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=82918529&amp;loc=d3e30304-110892<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=SL7669646-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=64808268&amp;loc=d3e32211-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of reclassification adjustment from accumulated other comprehensive (income) loss for prior service cost (credit) of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=82843861&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=d3e689-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax, after reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities. Excludes amounts related to other than temporary impairment (OTTI) loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax, after reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=SL7669625-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=66022249&amp;loc=d3e33775-111570<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax, after reclassification adjustments, of increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax, after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=82918529&amp;loc=d3e30304-110892<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b,d)<br> -URI http://asc.fasb.org/extlink&amp;oid=64808268&amp;loc=d3e32211-110900<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of reclassification adjustment from accumulated other comprehensive income for translation gain (loss) realized upon the sale or liquidation of an investment in a foreign entity and foreign currency hedges that are designated and qualified as hedging instruments for hedges of the foreign currency exposure of a net investment in a foreign operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=d3e709-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=64808268&amp;loc=d3e32211-110900<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=d3e689-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=84158357&amp;loc=d3e1436-108581<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of gain (loss) for (increase) decrease in value of benefit obligation for change in actuarial assumptions and increase (decrease) in value of plan assets from experience different from that assumed of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=SL7669646-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=82843861&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=d3e689-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27357-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of reclassification adjustment from accumulated other comprehensive income of accumulated gain (loss) realized from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's deferred hedging gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph c<br> -URI http://asc.fasb.org/extlink&amp;oid=84234895&amp;loc=d3e41638-113959<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=d3e689-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of reclassification adjustment from accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=d3e689-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=82843861&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) allocated to other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=d3e640-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=79507043&amp;loc=d3e39076-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6441202&amp;loc=d3e80720-113993<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=SL7669646-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax and reclassification adjustments of unrealized holding gain (loss) on available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=96868048&amp;loc=SL4569616-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161450&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591551-111686<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161450&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6922079568">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (PARENTHETICAL)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Oct. 02, 2016</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_LaboratorioTeutoBrasileroMember', window );">Laboratorio Teuto Brasilero [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method investment, ownership percentage</a></td>
<td class="nump">40.00%<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66011266&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_LaboratorioTeutoBrasileroMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_LaboratorioTeutoBrasileroMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6929665264">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Oct. 01, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="nump">$ 2,779<span></span>
</td>
<td class="nump">$ 2,595<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">14,146<span></span>
</td>
<td class="nump">15,255<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Trade accounts receivable, less allowance for doubtful accounts: 2017&#8212;$590; 2016&#8212;$609</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">10,002<span></span>
</td>
<td class="nump">8,225<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2],[3]</sup></td>
<td class="nump">7,925<span></span>
</td>
<td class="nump">6,783<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_OtherTaxAssetsCurrent', window );">Current tax assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">3,263<span></span>
</td>
<td class="nump">3,041<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">2,158<span></span>
</td>
<td class="nump">2,249<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Assets held for sale</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">16<span></span>
</td>
<td class="nump">801<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">40,291<span></span>
</td>
<td class="nump">38,949<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long-term investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">7,311<span></span>
</td>
<td class="nump">7,116<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, less accumulated depreciation: 2017&#8212;$15,906; 2016&#8212;$14,807</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">13,505<span></span>
</td>
<td class="nump">13,318<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Identifiable intangible assets, less accumulated amortization</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2],[4]</sup></td>
<td class="nump">49,721<span></span>
</td>
<td class="nump">52,648<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">56,078<span></span>
</td>
<td class="nump">54,449<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent', window );">Noncurrent deferred tax assets and other noncurrent tax assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">1,858<span></span>
</td>
<td class="nump">1,812<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">3,388<span></span>
</td>
<td class="nump">3,323<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">172,151<span></span>
</td>
<td class="nump">171,615<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract', window );"><strong>Liabilities and Equity</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Short-term borrowings, including current portion of long-term debt: 2017&#8212;$3,072; 2016&#8212;$4,225</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2],[5]</sup></td>
<td class="nump">9,448<span></span>
</td>
<td class="nump">10,688<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Trade accounts payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">3,480<span></span>
</td>
<td class="nump">4,536<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPayableCurrent', window );">Dividends payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">1,909<span></span>
</td>
<td class="nump">1,944<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Income taxes payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">1,003<span></span>
</td>
<td class="nump">437<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation and related items</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">1,932<span></span>
</td>
<td class="nump">2,487<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">10,446<span></span>
</td>
<td class="nump">11,023<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">28,217<span></span>
</td>
<td class="nump">31,115<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2],[6]</sup></td>
<td class="nump">34,503<span></span>
</td>
<td class="nump">31,398<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent', window );">Pension benefit obligations, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">5,531<span></span>
</td>
<td class="nump">6,406<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent', window );">Postretirement benefit obligations, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">1,687<span></span>
</td>
<td class="nump">1,766<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Noncurrent deferred tax liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">30,411<span></span>
</td>
<td class="nump">30,753<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent', window );">Other taxes payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">4,304<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">6,388<span></span>
</td>
<td class="nump">6,337<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">111,041<span></span>
</td>
<td class="nump">111,776<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">22<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">463<span></span>
</td>
<td class="nump">461<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">83,827<span></span>
</td>
<td class="nump">82,685<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="num">(89,421)<span></span>
</td>
<td class="num">(84,364)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">75,043<span></span>
</td>
<td class="nump">71,774<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="num">(9,164)<span></span>
</td>
<td class="num">(11,036)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Pfizer Inc. shareholders&#8217; equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">60,770<span></span>
</td>
<td class="nump">59,544<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Equity attributable to noncontrolling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">340<span></span>
</td>
<td class="nump">296<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">61,110<span></span>
</td>
<td class="nump">59,840<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">$ 172,151<span></span>
</td>
<td class="nump">$ 171,615<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Amounts may not add due to rounding.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Amounts may not add due to rounding.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">The change from <span style="font-family:inherit;font-size:9pt;text-align:center;">December&#160;31, 2016</span> reflects the build of inventory primarily for and in advance of new or potential product launches and increases to meet targeted levels for certain products in the normal course of business, including those related to demand.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top">The decrease in <span style="font-family:inherit;font-size:8.5pt;font-style:italic;">I</span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;text-align:right;">dentifiable intangible assets, less accumulated amortization</span><span style="font-family:inherit;font-size:8.5pt;text-align:right;">, </span><span style="font-family:inherit;font-size:8.5pt;">is primarily due to amortization, measurement period adjustments related to Medivation (see </span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Note 2A</span><span style="font-family:inherit;font-size:8.5pt;">), as well as impairments of </span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Developed technology rights</span><span style="font-family:inherit;font-size:8.5pt;"> (see </span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Note 4)</span><span style="font-family:inherit;font-size:8.5pt;">, partially offset by assets acquired as part of the acquisition of AstraZeneca&#8217;s small molecule anti-infectives business (see </span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Note 2A</span><span style="font-family:inherit;font-size:8.5pt;">) and the assets recorded in connection with the EU and U.S. approvals of Besponsa (see </span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Note 7E</span>).</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[5]</td>
<td style="vertical-align: top;" valign="top">The differences between the estimated fair values and carrying values of held-to-maturity debt securities, restricted stock and private equity securities at cost, and short-term borrowings not measured at fair value on a recurring basis were not significant as of <span style="font-family:inherit;font-size:8.5pt;">October&#160;1, 2017</span><span style="font-family:inherit;font-size:8.5pt;"> or </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">December&#160;31, 2016</span><span style="font-family:inherit;font-size:8.5pt;">. The fair value measurements of our held-to-maturity debt securities and our short-term borrowings are based on Level 2 inputs, using a market approach. The fair value measurements of our </span><span style="font-family:inherit;font-size:8.5pt;background-color:#ffffff;">priv</span>ate equity securities carried at cost are based on Level 3 inputs.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[6]</td>
<td style="vertical-align: top;" valign="top">The fair value of our long-term debt (not including the current portion of long-term debt) was <span style="font-family:inherit;font-size:8.5pt;"><span>$39.0 billion</span></span><span style="font-family:inherit;font-size:8.5pt;"> as of </span><span style="font-family:inherit;font-size:8.5pt;">October&#160;1, 2017</span><span style="font-family:inherit;font-size:8.5pt;"> and </span><span style="font-family:inherit;font-size:8.5pt;"><span>$34.9 billion</span></span><span style="font-family:inherit;font-size:8.5pt;"> as of </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">December&#160;31, 2016</span><span style="font-family:inherit;font-size:8.5pt;">. The fair value measurements for our long-term debt are based on Level 2 inputs, using a market approach. Long-term debt includes foreign currency long-term borrowings with fair values of </span><span style="font-family:inherit;font-size:8.5pt;"><span>$4.7 billion</span></span><span style="font-family:inherit;font-size:8.5pt;"> as of </span><span style="font-family:inherit;font-size:8.5pt;">October&#160;1, 2017</span>, which are used as hedging instruments.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Net, And Other Tax Assets, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_OtherTaxAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Tax Assets, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_OtherTaxAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=d3e681-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6801-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e1107-107759<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721533-107759<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84176398&amp;loc=d3e2941-110230<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=68055307&amp;loc=d3e2473-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14326-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term debt and current maturity of long-term debt and capital lease obligations due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e31931-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability, recognized in statement of financial position, for defined benefit pension plan, classified as noncurrent. Excludes other postretirement benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=82843861&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64852052&amp;loc=d3e1703-114919<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64852052&amp;loc=d3e1731-114919<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388280&amp;loc=d3e13770-109266<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=d3e3927-108312<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for uncertainty in income taxes classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUncertainTaxPositionsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6904-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability, recognized in statement of financial position, for defined benefit other postretirement plan, classified as noncurrent. Excludes pension plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=82843861&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64852052&amp;loc=d3e1731-114919<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64852052&amp;loc=d3e1703-114919<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4590271-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=96868048&amp;loc=SL4568740-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=96868048&amp;loc=SL4568447-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6920213376">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (PARENTHETICAL) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Oct. 01, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Allowance for doubtful accounts</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 590<span></span>
</td>
<td class="nump">$ 609<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Property, plant and equipment, accumulated depreciation</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">15,906<span></span>
</td>
<td class="nump">14,807<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 3,072<span></span>
</td>
<td class="nump">$ 4,225<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Amounts may not add due to rounding.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A valuation allowance for trade and other receivables due to an Entity within one year (or the normal operating cycle, whichever is longer) that are expected to be uncollectible.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84173941&amp;loc=d3e5074-111524<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6930146336">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">9 Months Ended</th>
</tr>
<tr>
<th class="th" colspan="2"><div>Oct. 01, 2017</div></th>
<th class="th"><div>Oct. 02, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating Activities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income before allocation to noncontrolling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2],[3],[4],[5]</sup></td>
<td class="nump">$ 9,066<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 6,465<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income before allocation to noncontrolling interests to net cash provided by operating activities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization', window );">Depreciation and amortization</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="nump">4,695<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">4,208<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_AssetWriteOffsAndAssetImpairmentCharges', window );">Asset write-offs and impairments</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="nump">326<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,146<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal', window );">Loss on sale of HIS net assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5],[6]</sup></td>
<td class="nump">52<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,422<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred taxes from continuing operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="nump">241<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(1,335)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="nump">595<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">532<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense', window );">Benefit plan contributions in excess of expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="num">(1,042)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(775)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other adjustments, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="num">(561)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">68<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapital', window );">Other changes in assets and liabilities, net of acquisitions and divestitures</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[5]</sup></td>
<td class="num">(3,644)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(1,582)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[5]</sup></td>
<td class="nump">9,728<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">10,151<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing Activities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, plant and equipment</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="num">(1,256)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(1,134)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireShortTermInvestments', window );">Purchases of short-term investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="num">(6,469)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(15,170)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments', window );">Proceeds from redemptions/sales of short-term investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="nump">5,783<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">20,685<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromShortTermInvestments', window );">Net proceeds from redemptions/sales of short-term investments with original maturities of three months or less</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="nump">2,758<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">6,485<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of long-term investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="num">(2,526)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(4,771)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments', window );">Proceeds from redemptions/sales of long-term investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="nump">2,417<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">6,915<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Acquisitions of businesses, net of cash acquired</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="num">(1,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(17,679)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquisitions of intangible assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="num">(188)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(96)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Other investing activities, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="nump">519<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">60<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by/(used in) investing activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="nump">38<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(4,704)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing Activities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromShortTermDebt', window );">Proceeds from short-term borrowings</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="nump">7,003<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">6,397<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfShortTermDebt', window );">Principal payments on short-term borrowings</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="num">(7,691)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(3,321)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess', window );">Net proceeds from/(payments on) short-term borrowings with original maturities of three months or less</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="nump">555<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(963)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from issuance of long-term debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="nump">5,273<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">5,031<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Principal payments on long-term debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="num">(4,474)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(4,317)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchases of common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="num">(5,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(5,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfOrdinaryDividends', window );">Cash dividends paid</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="num">(5,750)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(5,496)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="nump">656<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">946<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other financing activities, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[5]</sup></td>
<td class="num">(223)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(192)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in financing activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[5]</sup></td>
<td class="num">(9,650)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(6,915)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents', window );">Effect of exchange-rate changes on cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="nump">67<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(79)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net increase/(decrease) in cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="nump">184<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(1,547)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, beginning</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="nump">2,595<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[7]</sup></td>
<td class="nump">3,641<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, end</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="nump">2,779<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[7]</sup></td>
<td class="nump">2,094<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Non-cash transactions:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_NoncashorPartNoncashDivestitureAmountofConsiderationReceivedCommonStock', window );">Receipt of ICU Medical common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5],[8]</sup></td>
<td class="nump">428<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_NoncashorPartNoncashDivestitureAmountofConsiderationReceivedNoteReceivable', window );">Promissory note from ICU Medical</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5],[8]</sup></td>
<td class="nump">75<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Cash paid (received) during the period for:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Income taxes</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="nump">1,424<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,430<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="nump">1,101<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,177<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_InterestPaidInterestRateHedges', window );">Interest rate hedges</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="num">$ (183)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (356)<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Amounts for the <span style="font-family:inherit;font-size:7.5pt;">three and nine months ended October 2, 2016</span><span style="font-family:inherit;font-size:7.5pt;"> have been revised from previously reported amounts to reflect the adoption of a new accounting standard in the fourth quarter of 2016, as of January 1, 2016. For additional information, see </span><span style="font-family:inherit;font-size:7.5pt;font-style:italic;">Note 1B</span><span style="font-family:inherit;font-size:7.5pt;">. </span><span style="font-family:inherit;font-size:7.5pt;font-style:italic;">Basis of Presentation and Significant Accounting Policies</span>: Adoption of New Accounting Standards.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Amounts for the <span style="font-family:inherit;font-size:9pt;">three and nine months ended October 2, 2016</span><span style="font-family:inherit;font-size:9pt;"> have been revised from previously reported amounts to reflect the adoption of a new accounting standard in the fourth quarter of 2016, as of January 1, 2016. For additional information, see </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Note 1B</span><span style="font-family:inherit;font-size:9pt;">. </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Basis of Presentation and Significant Accounting Policies&#8211;&#8211;Adoption of New Accounting Standards</span>.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">Amounts may not add due to rounding.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top">Amounts may not add due to rounding.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[5]</td>
<td style="vertical-align: top;" valign="top">Amounts may not add due to rounding.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[6]</td>
<td style="vertical-align: top;" valign="top">In the <span style="font-family:inherit;font-size:8.5pt;">third</span><span style="font-family:inherit;font-size:8.5pt;"> quarter and </span><span style="font-family:inherit;font-size:8.5pt;">first nine months of</span><span style="font-family:inherit;font-size:8.5pt;"> </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:8.5pt;">, represents adjustments to amounts previously recorded to write down the HIS net assets to fair value less costs to sell related to the sale of HIS net assets to ICU Medical. In the </span><span style="font-family:inherit;font-size:8.5pt;">third</span><span style="font-family:inherit;font-size:8.5pt;"> quarter and </span><span style="font-family:inherit;font-size:8.5pt;">first nine months of</span><span style="font-family:inherit;font-size:8.5pt;"> </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:8.5pt;">, represents a charge related to the write-down of the HIS net assets to fair value less estimated costs to sell.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[7]</td>
<td style="vertical-align: top;" valign="top">Amounts may not add due to rounding.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[8]</td>
<td style="vertical-align: top;" valign="top">In connection with the sale of HIS net assets to ICU Medical, on February 3, 2017, Pfizer received <span style="font-family:inherit;font-size:7.5pt;"><span>3.2 million</span></span><span style="font-family:inherit;font-size:7.5pt;"> newly issued shares of ICU Medical common stock initially valued at </span><span style="font-family:inherit;font-size:7.5pt;"><span>$428 million</span></span><span style="font-family:inherit;font-size:7.5pt;"> and a promissory note in the amount of </span><span style="font-family:inherit;font-size:7.5pt;"><span>$75 million</span></span><span style="font-family:inherit;font-size:7.5pt;">. For additional information, see </span><span style="font-family:inherit;font-size:7.5pt;font-style:italic;">Note 2B</span><span style="font-family:inherit;font-size:7.5pt;">.</span><span style="font-family:inherit;font-size:7.5pt;font-style:italic;"> </span><span style="font-family:inherit;font-size:7.5pt;font-style:italic;">Acquisitions, Sale of Hospira Infusion Systems Net Assets, Collaborative Arrangement and Equity-Method Investments</span>: Sale of Hospira Infusion Systems Net Assets.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_AssetWriteOffsAndAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset Write-Offs And Asset Impairment Charges</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_AssetWriteOffsAndAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets. Includes the amount of expense from discontinued operations, that reflects the allocation of the cost of tangible and intangible assets over the assets' useful lives.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_InterestPaidInterestRateHedges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest Paid, Interest Rate Hedges</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_InterestPaidInterestRateHedges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_NoncashorPartNoncashDivestitureAmountofConsiderationReceivedCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncash or Part Noncash Divestiture, Amount of Consideration Received, Common Stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_NoncashorPartNoncashDivestitureAmountofConsiderationReceivedCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_NoncashorPartNoncashDivestitureAmountofConsiderationReceivedNoteReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncash or Part Noncash Divestiture, Amount of Consideration Received, Note Receivable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_NoncashorPartNoncashDivestitureAmountofConsiderationReceivedNoteReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash or cash equivalents contributed during the reporting period by the entity to fund its pension plans and its non-pension postretirement benefit plans less the amount of pension and other postretirement benefit costs recognized during the period for defined benefit plans (periodic benefit costs include the following components: service cost, interest cost, expected return on plan assets, gain or loss on assets, prior service cost or credit, transition asset or obligation, and gain or loss due to settlements or curtailments).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68055307&amp;loc=d3e2443-110228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84176398&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period of all assets and liabilities used in operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid, after deduction of cash paid for capitalized interest, for interest. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3574-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3574-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3098-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3095-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount paid (received) by the reporting entity through acquisition or sale and maturities of short-term investments with an original maturity that is three months or less which qualify for treatment as an investing activity based on management's intention and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3098-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3095-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfOrdinaryDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash outflow in the form of ordinary dividends to common shareholders, preferred shareholders and noncontrolling interests, generally out of earnings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfOrdinaryDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash outflow for purchase of trading, available-for-sale securities and held-to-maturity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=82896770&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3095-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3098-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing net of the cash outflow from repayment of a borrowing having initial term of repayment within three months.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3095-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3291-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3098-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales, maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, beyond the current operating cycle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales, maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of stock options granted under share-based compensation arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=SL79508275-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=96868048&amp;loc=SL4569616-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161450&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591551-111686<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161450&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6923371472">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (PARENTHETICAL) - HIS [Member] - Disposed of by Sale [Member] - ICU Medical [Member]<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th">
<div>Feb. 03, 2017 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationTransferredEquityInterestsShares', window );">Number of shares received in disposition | shares</a></td>
<td class="nump">3.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationTransferredEquityInterests', window );">Value of shares received from disposition</a></td>
<td class="nump">$ 428<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivable', window );">Promissory note</a></td>
<td class="nump">$ 75<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Consideration, Note Receivable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationTransferredEquityInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Consideration Transferred, Equity Interests</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationTransferredEquityInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationTransferredEquityInterestsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Consideration Transferred, Equity Interests, Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationTransferredEquityInterestsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=pfe_HISMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=pfe_HISMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=pfe_ICUMedicalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=pfe_ICUMedicalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6919155360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 01, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Basis of Presentation and Significant Accounting Policies</a></td>
<td class="text"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Basis of Presentation and Significant Accounting Policies</span><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">A. Basis of Presentation</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">See the Glossary of Defined Terms at the beginning of this Quarterly Report on Form 10-Q for terms used throughout the condensed consolidated financial statements and related notes of this Quarterly Report on Form 10-Q.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We prepared the condensed consolidated financial statements following the requirements of the SEC for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP can be condensed or omitted.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The financial information included in our condensed consolidated financial statements for subsidiaries operating outside the U.S. is as of and for the three and </span><span style="font-family:inherit;font-size:10pt;">nine months</span><span style="font-family:inherit;font-size:10pt;"> ended </span><span style="font-family:inherit;font-size:10pt;">August&#160;27, 2017</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">August&#160;28, 2016</span><span style="font-family:inherit;font-size:10pt;">. The financial information included in our condensed consolidated financial statements for U.S. subsidiaries is as of and for the three and </span><span style="font-family:inherit;font-size:10pt;">nine months</span><span style="font-family:inherit;font-size:10pt;"> ended </span><span style="font-family:inherit;font-size:10pt;text-align:center;">October&#160;1, 2017</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;text-align:center;">October&#160;2, 2016</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenues, expenses, assets and liabilities can vary during each quarter of the year. Therefore, the results and trends in these interim financial statements may not be representative of those for the full year.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are responsible for the unaudited financial statements included in this Quarterly Report on Form 10-Q. The interim financial statements include all normal and recurring adjustments that are considered necessary for the fair statement of our condensed consolidated balance sheets and condensed consolidated statements of income. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the consolidated financial statements and accompanying notes included in our </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;"> Form 10-K. </span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We manage our commercial operations through </span><span style="font-family:inherit;font-size:10pt;"><span>two</span></span><span style="font-family:inherit;font-size:10pt;"> distinct business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). For additional information, see </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 13</span><span style="font-family:inherit;font-size:10pt;"> and Notes to Consolidated Financial Statements&#8211;&#8211;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 18. Segment, Geographic and Other Revenue Information </span><span style="font-family:inherit;font-size:10pt;">in Pfizer&#8217;s </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;"> Financial Report.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certain amounts in the condensed consolidated financial statements and associated notes may not add due to rounding. All percentages have been calculated using unrounded amounts.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our recent significant business development activities include:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On February 3, 2017, we completed the sale of our global infusion therapy net assets, HIS, to ICU Medical. The operating results of HIS are included in our condensed consolidated statement of income and EH&#8217;s operating results through February 2, 2017 and, therefore, our financial results, and EH&#8217;s operating results, for the </span><span style="font-family:inherit;font-size:10pt;">third quarter</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;"> do not reflect any contribution from HIS global operations, while our financial results, and EH&#8217;s operating results, for the </span><span style="font-family:inherit;font-size:10pt;">third quarter</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;"> reflect three months of HIS global operations. Our financial results, and EH&#8217;s operating results, for the </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;"> reflect approximately one month of HIS domestic operations and approximately two months of HIS international operations, while our financial results, and EH&#8217;s operating results, for the </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;text-align:left;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;"> reflect nine months of HIS global operations. Assets and liabilities associated with HIS are presented as held for sale in the condensed consolidated balance sheet as of December 31, 2016. The HIS assets held for sale are reported in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Assets held for sale </span><span style="font-family:inherit;font-size:10pt;">and HIS liabilities held for sale are reported in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other current liabilities.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On December 22, 2016, which falls in the first fiscal quarter of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;"> for our international operations, we acquired the development and commercialization rights to AstraZeneca&#8217;s small molecule anti-infectives business, primarily outside the U.S. Commencing from the acquisition date, our financial statements reflect the assets, liabilities, operating results and cash flows of this business, and, in accordance with our international reporting period, our financial results, EH&#8217;s operating results, and cash flows for the </span><span style="font-family:inherit;font-size:10pt;">third quarter</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;"> reflect approximately three months and eight months, respectively, of the small molecule anti-infectives business acquired from AstraZeneca.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On September 28, 2016, we acquired Medivation for </span><span style="font-family:inherit;font-size:10pt;"><span>$81.50</span></span><span style="font-family:inherit;font-size:10pt;"> per share. Commencing from the acquisition date, our financial statements reflect the assets, liabilities, operating results and cash flows of Medivation. Therefore, Medivation operations are reflected in our financial results, IH&#8217;s operating results, and cash flows for the </span><span style="font-family:inherit;font-size:10pt;">third quarter</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;">. In accordance with our domestic and international reporting periods, our consolidated financial statements for the </span><span style="font-family:inherit;font-size:10pt;">third quarter</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;"> reflect three business days of Medivation operations, which were immaterial.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On June 24, 2016, we acquired Anacor for </span><span style="font-family:inherit;font-size:10pt;"><span>$99.25</span></span><span style="font-family:inherit;font-size:10pt;"> per share. Commencing from the acquisition date, our financial statements reflect the assets, liabilities, operating results and cash flows of Anacor. Therefore, Anacor operations are reflected in our financial results, IH&#8217;s operating results, and cash flows for the </span><span style="font-family:inherit;font-size:10pt;">third quarter</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;">. In accordance with our domestic and international reporting periods, our consolidated financial statements for the </span><span style="font-family:inherit;font-size:10pt;">third quarter</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;"> reflect approximately three months of Anacor operations.</span></div></td></tr></table><div style="line-height:120%;padding-top:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For additional information, see </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 2</span><span style="font-family:inherit;font-size:10pt;"> and Notes to Consolidated Financial Statements&#8211;&#8211;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 2. </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Acquisitions, Sale of Hospira Infusion Systems Net Assets, Collaborative Arrangement and Equity-Method Investments</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span><span style="font-family:inherit;font-size:10pt;">in</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span><span style="font-family:inherit;font-size:10pt;">Pfizer&#8217;s </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;"> Financial Report.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">B. Adoption of New Accounting Standards</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the fourth quarter of 2016, we adopted a new accounting standard for certain elements of the accounting for share-based payments as of January 1, 2016. Specifically, the new standard requires excess tax benefits or deficiencies (including tax benefits of dividend equivalents) of share-based compensation to be recognized as a component of the </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Provision for taxes on income</span><span style="font-family:inherit;font-size:10pt;">, whereas excess tax benefits or deficiencies previously were recognized in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Additional paid-in capital</span><span style="font-family:inherit;font-size:10pt;">. The net tax benefit for the Company was </span><span style="font-family:inherit;font-size:10pt;"><span>$35 million</span></span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">third quarter</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$85 million</span></span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;">. Also, in the diluted net earnings per share calculation, when applying the treasury stock method for shares that could be repurchased, the assumed proceeds no longer include the amount of excess tax benefit.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Another element of the new accounting standard requires that we now present excess tax benefits as operating activities in our consolidated statement of cash flows. We elected to adopt this presentation on a prospective basis as of January 1, 2016. Additionally, cash paid by us when directly withholding shares for tax-withholding purposes is now a cash outflow from financing activities. This reclassification was required to be adopted retrospectively. As a result, </span><span style="font-family:inherit;font-size:10pt;"><span>$87 million</span></span><span style="font-family:inherit;font-size:10pt;"> of cash outflows for the first nine months of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;"> was reclassified from operating activities to financing activities in the condensed consolidated statement of cash flows. For additional information, see Notes to Consolidated Financial Statements&#8211;&#8211;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 1B. </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Basis of Presentation and Significant Accounting Policies</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">:</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Adoption of New Accounting Standards</span><span style="font-family:inherit;font-size:10pt;"> included in our </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;"> Financial Report.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We adopted a new standard as of January 1, 2017 that amended guidance on the assessment of whether an entity is the primary beneficiary of a variable interest entity. Under this new guidance, when evaluating whether an entity is the primary beneficiary, a single decision maker must consider its indirect interest held through related parties under common control proportionately. There was no material impact to our condensed consolidated financial statements from adopting this standard.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div>We adopted a new standard as of January 1, 2017 related to inventory. The new guidance requires that inventory be measured at the lower of cost or net realizable value, which is defined as the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. There was no material impact to our condensed consolidated financial statements from adopting this standard.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6917900048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions, Sale of Hospira Infusion Systems Net Assets, Collaborative Arrangement and Equity-Method Investments<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 01, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract', window );"><strong>Business Combinations, Discontinued Operations And Disposal Groups, Collaborative Arrangements And Equity Method Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsCollaborativeArrangementsEquityandCostMethodInvestmentsDisclosureTextBlock', window );">Acquisitions, Sale of Hospira Infusion Systems Net Assets, Collaborative Arrangement and Equity-Method Investments</a></td>
<td class="text"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Acquisitions, Sale of Hospira Infusion Systems Net Assets, Collaborative Arrangement and Equity-Method Investments</span><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">A. Acquisitions</span></div><div style="line-height:120%;padding-bottom:6px;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">AstraZeneca&#8217;s Small Molecule Anti-Infectives Business (EH)</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On December 22, 2016, which falls in the first fiscal quarter of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;"> for our international operations, we acquired the development and commercialization rights to AstraZeneca&#8217;s small molecule anti-infectives business, primarily outside the U.S., including the commercialization and development rights to the newly approved EU drug Zavicefta&#8482; (ceftazidime-avibactam), the marketed agents Merrem&#8482;/Meronem&#8482; (meropenem) and Zinforo&#8482;&#160;(ceftaroline fosamil), and the clinical development assets ATM-AVI and CXL (ceftaroline fosamil-AVI). Under the terms of the agreement, we made an upfront payment of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$552 million</span></span><span style="font-family:inherit;font-size:10pt;"> to AstraZeneca upon the close of the transaction and an additional </span><span style="font-family:inherit;font-size:10pt;"><span>$3 million</span></span><span style="font-family:inherit;font-size:10pt;"> payment for a contractual purchase price adjustment in the second quarter of 2017. We also made a </span><span style="font-family:inherit;font-size:10pt;"><span>$50 million</span></span><span style="font-family:inherit;font-size:10pt;"> milestone payment in the second quarter of 2017, we expect to make an additional milestone payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$125 million</span></span><span style="font-family:inherit;font-size:10pt;"> in our first fiscal quarter of 2018 and we will make a deferred payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$175 million</span></span><span style="font-family:inherit;font-size:10pt;"> to AstraZeneca in January 2019. In addition, AstraZeneca may be eligible to receive an additional milestone payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$75 million</span></span><span style="font-family:inherit;font-size:10pt;"> if the related milestone is achieved prior to December 31, 2021, and up to </span><span style="font-family:inherit;font-size:10pt;"><span>$600 million</span></span><span style="font-family:inherit;font-size:10pt;"> if sales of Zavicefta&#8482; exceed certain thresholds prior to January 1, 2026, as well as tiered royalties on sales of Zavicefta&#8482; and ATM-AVI in certain markets for a period ending on the later of ten years from first commercial sale or the loss of patent protection or loss of regulatory exclusivity. The total royalty payments are unlimited during the royalty term and the undiscounted payments are expected to be in the range of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$250 million</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>$425 million</span></span><span style="font-family:inherit;font-size:10pt;">. The total fair value </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">of consideration transferred for AstraZeneca&#8217;s small molecule anti-infectives business was approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$1,045 million</span></span><span style="font-family:inherit;font-size:10pt;">, which includes </span><span style="font-family:inherit;font-size:10pt;"><span>$555 million</span></span><span style="font-family:inherit;font-size:10pt;"> in cash, plus the fair value of contingent consideration of </span><span style="font-family:inherit;font-size:10pt;"><span>$490 million</span></span><span style="font-family:inherit;font-size:10pt;"> (which is composed of the deferred payment, the </span><span style="font-family:inherit;font-size:10pt;"><span>$50 million</span></span><span style="font-family:inherit;font-size:10pt;"> milestone payment made in the second quarter of 2017 and the future expected milestone and royalty payments). In connection with this acquisition, we provisionally recorded </span><span style="font-family:inherit;font-size:10pt;"><span>$879 million</span></span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;">in</span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;"> </span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;font-style:italic;">Identifiable intangible assets</span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;">, primarily consisting</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">of </span><span style="font-family:inherit;font-size:10pt;"><span>$660 million</span></span><span style="font-family:inherit;font-size:10pt;"> in</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> Developed technology rights</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$219 million</span></span><span style="font-family:inherit;font-size:10pt;"> in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">IPR&amp;D</span><span style="font-family:inherit;font-size:10pt;">. We also recorded </span><span style="font-family:inherit;font-size:10pt;"><span>$92 million</span></span><span style="font-family:inherit;font-size:10pt;"> in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other current assets</span><span style="font-family:inherit;font-size:10pt;"> related to the economic value of inventory which was retained by AstraZeneca for sale on our behalf, </span><span style="font-family:inherit;font-size:10pt;"><span>$92 million</span></span><span style="font-family:inherit;font-size:10pt;"> in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Goodwill</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$17 million</span></span><span style="font-family:inherit;font-size:10pt;"> of net deferred tax liabilities. The allocation of the consideration transferred to the assets and the</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;">liabilities assumed has not yet been finalized.</span></div><div style="line-height:120%;padding-bottom:6px;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Medivation, Inc. (IH)</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On September 28, 2016, we acquired Medivation for </span><span style="font-family:inherit;font-size:10pt;"><span>$81.50</span></span><span style="font-family:inherit;font-size:10pt;"> per share. The total fair value of consideration transferred for Medivation was approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$14.3 billion</span></span><span style="font-family:inherit;font-size:10pt;"> in cash (</span><span style="font-family:inherit;font-size:10pt;"><span>$13.9 billion</span></span><span style="font-family:inherit;font-size:10pt;">, net of cash acquired). Of this consideration, approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$365 million</span></span><span style="font-family:inherit;font-size:10pt;"> was not paid as of December 31, 2016, and was recorded in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other current liabilities. </span><span style="font-family:inherit;font-size:10pt;">Substantially all of the remaining consideration was paid as of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">October&#160;1, 2017</span><span style="font-family:inherit;font-size:10pt;">. Medivation is now a wholly-owned subsidiary of Pfizer. Medivation is a biopharmaceutical company focused on developing and commercializing small molecules for oncology. Medivation&#8217;s portfolio includes Xtandi (enzalutamide), an androgen receptor inhibitor that blocks multiple steps in the androgen receptor signaling pathway within tumor cells. Xtandi is being developed and commercialized through a collaboration with Astellas. Astellas has exclusive commercialization rights for Xtandi outside the U.S. In addition, Medivation has a development-stage oncology asset in its pipeline, talazoparib, which is currently in a Phase 3 study for the treatment of BRCA-mutated breast cancer. In connection with this acquisition, we recorded </span><span style="font-family:inherit;font-size:10pt;"><span>$12.2 billion</span></span><span style="font-family:inherit;font-size:10pt;"> in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Identifiable intangible assets</span><span style="font-family:inherit;font-size:10pt;">, primarily consisting of </span><span style="font-family:inherit;font-size:10pt;"><span>$8.1 billion</span></span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Developed technology rights</span><span style="font-family:inherit;font-size:10pt;"> with an average useful life of approximately 12 years and </span><span style="font-family:inherit;font-size:10pt;"><span>$4.1 billion</span></span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">IPR&amp;D, </span><span style="font-family:inherit;font-size:10pt;">and recorded </span><span style="font-family:inherit;font-size:10pt;"><span>$6.1 billion</span></span><span style="font-family:inherit;font-size:10pt;"> of</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> Goodwill,</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;"><span>$4.0 billion</span></span><span style="font-family:inherit;font-size:10pt;"> of net income tax liabilities, and </span><span style="font-family:inherit;font-size:10pt;"><span>$259 million</span></span><span style="font-family:inherit;font-size:10pt;"> of assumed contingent consideration. In 2017 and 2016, we recorded measurement period adjustments to the estimated fair values initially recorded in 2016, which resulted in a reduction in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Identifiable intangible assets</span><span style="font-family:inherit;font-size:10pt;"> of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$1.0 billion</span></span><span style="font-family:inherit;font-size:10pt;"> with a corresponding change to </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Goodwill</span><span style="font-family:inherit;font-size:10pt;"> and net income tax liabilities. The measurement period adjustments were recorded to better reflect market participant assumptions about facts and circumstances existing as of the acquisition date. The third quarter and first nine months of 2017 results include a decrease of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$38 million</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Amortization of intangible assets</span><span style="font-family:inherit;font-size:10pt;"> which reflects the cumulative pre-tax impact of the measurement period adjustments to </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Identifiable intangible assets</span><span style="font-family:inherit;font-size:10pt;"> that were amortized to the income statement since the acquisition date. The measurement period adjustments did not result from intervening events subsequent to the acquisition date. The final allocation of the consideration transferred to the assets acquired and the liabilities assumed has been completed.</span></div><div style="line-height:120%;padding-bottom:6px;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Bamboo Therapeutics, Inc. (IH)</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On August 1, 2016, we acquired all the remaining equity in Bamboo, a privately-held biotechnology company focused on developing gene therapies for the potential treatment of patients with certain rare diseases relating to neuromuscular conditions and those affecting the central nervous system, for </span><span style="font-family:inherit;font-size:10pt;"><span>$150 million</span></span><span style="font-family:inherit;font-size:10pt;">, plus potential milestone payments of up to </span><span style="font-family:inherit;font-size:10pt;"><span>$495 million</span></span><span style="font-family:inherit;font-size:10pt;"> contingent upon the progression of key assets through development, regulatory approval and commercialization. The total fair value of the consideration transferred for Bamboo was approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$343 million</span></span><span style="font-family:inherit;font-size:10pt;">, including cash of </span><span style="font-family:inherit;font-size:10pt;"><span>$130 million</span></span><span style="font-family:inherit;font-size:10pt;"> (</span><span style="font-family:inherit;font-size:10pt;"><span>$101 million</span></span><span style="font-family:inherit;font-size:10pt;">, net of cash acquired), contingent consideration of </span><span style="font-family:inherit;font-size:10pt;"><span>$167 million</span></span><span style="font-family:inherit;font-size:10pt;">, consisting of milestone payments, and the fair value of Pfizer&#8217;s previously held equity interest in Bamboo of </span><span style="font-family:inherit;font-size:10pt;"><span>$45 million</span></span><span style="font-family:inherit;font-size:10pt;">. We previously purchased a minority stake in Bamboo in the first quarter of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;"> for a payment of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$43 million</span></span><span style="font-family:inherit;font-size:10pt;">. Upon acquiring the remaining interest in Bamboo in the third quarter of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;">, we recognized a gain of </span><span style="font-family:inherit;font-size:10pt;"><span>$2 million</span></span><span style="font-family:inherit;font-size:10pt;"> on our existing investment in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net</span><span style="font-family:inherit;font-size:10pt;"> over the one- year allocation period</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">.</span><span style="font-family:inherit;font-size:10pt;"> This acquisition provides us with several clinical and pre-clinical assets that complement our rare disease portfolio, an advanced recombinant AAV vector design and production technology, and a fully functional Phase I/II gene therapy manufacturing facility. Bamboo is now a wholly-owned subsidiary of Pfizer. In connection with this acquisition, we recorded </span><span style="font-family:inherit;font-size:10pt;"><span>$330 million</span></span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Identifiable intangible assets, </span><span style="font-family:inherit;font-size:10pt;">consisting entirely of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">IPR&amp;D. </span><span style="font-family:inherit;font-size:10pt;">We also recorded </span><span style="font-family:inherit;font-size:10pt;"><span>$142 million</span></span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Goodwill </span><span style="font-family:inherit;font-size:10pt;">and </span><span style="font-family:inherit;font-size:10pt;"><span>$94 million</span></span><span style="font-family:inherit;font-size:10pt;"> of net deferred tax liabilities. The final allocation of the consideration transferred to the assets acquired and the liabilities assumed has been completed.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;padding-bottom:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Anacor Pharmaceuticals, Inc. (IH)</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On June 24, 2016, we acquired Anacor for </span><span style="font-family:inherit;font-size:10pt;"><span>$99.25</span></span><span style="font-family:inherit;font-size:10pt;"> per share. The total fair value of consideration transferred for Anacor was approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$4.9 billion</span></span><span style="font-family:inherit;font-size:10pt;"> in cash (</span><span style="font-family:inherit;font-size:10pt;"><span>$4.5 billion</span></span><span style="font-family:inherit;font-size:10pt;"> net of cash acquired), plus </span><span style="font-family:inherit;font-size:10pt;"><span>$698 million</span></span><span style="font-family:inherit;font-size:10pt;"> debt assumed. Anacor is now a wholly-owned subsidiary of Pfizer. Anacor is a biopharmaceutical company focused on novel small-molecule therapeutics derived from its boron chemistry platform. Anacor&#8217;s crisaborole, a non-steroidal topical PDE-4 inhibitor with anti-inflammatory properties, was approved by the FDA on December 14, 2016 under the trade name, Eucrisa. In connection with this acquisition, we recorded </span><span style="font-family:inherit;font-size:10pt;"><span>$698 million</span></span><span style="font-family:inherit;font-size:10pt;"> as the fair value of notes payable in cash, and recorded </span><span style="font-family:inherit;font-size:10pt;"><span>$4.9 billion</span></span><span style="font-family:inherit;font-size:10pt;"> in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Identifiable intangible assets</span><span style="font-family:inherit;font-size:10pt;">, </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">primarily consisting of </span><span style="font-family:inherit;font-size:10pt;"><span>$4.8 billion</span></span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">IPR&amp;D</span><span style="font-family:inherit;font-size:10pt;">, and recorded </span><span style="font-family:inherit;font-size:10pt;"><span>$646 million</span></span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Goodwill </span><span style="font-family:inherit;font-size:10pt;">and </span><span style="font-family:inherit;font-size:10pt;"><span>$346 million</span></span><span style="font-family:inherit;font-size:10pt;"> of net income tax liabilities. The final allocation of the consideration transferred to the assets acquired and the liabilities assumed has been completed.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">B. </span><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Sale of Hospira Infusion Systems Net Assets to ICU Medical, Inc. (EH)</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"> </span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On October 6, 2016, we announced that we entered into a definitive agreement under which ICU Medical would acquire all of our global infusion therapy net assets, HIS, for approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$1 billion</span></span><span style="font-family:inherit;font-size:10pt;"> in cash and ICU Medical common stock</span><span style="font-family:Arial;font-size:8pt;">.</span><span style="font-family:inherit;font-size:10pt;"> HIS includes IV pumps, solutions, and devices.</span><span style="font-family:Arial;font-size:8pt;"> </span><span style="font-family:inherit;font-size:10pt;">As a result of the performance of HIS relative to ICU Medical&#8217;s expectations, on January 5, 2017, we entered into a revised agreement with ICU Medical under which ICU Medical would acquire HIS for up to approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$900 million</span></span><span style="font-family:inherit;font-size:10pt;">, composed of cash and contingent cash consideration, ICU Medical common stock and seller financing.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The revised transaction closed on February 3, 2017. At closing, under the terms of the revised agreement, we received </span><span style="font-family:inherit;font-size:10pt;"><span>3.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> newly issued shares of ICU Medical common stock (as originally agreed), which we initially valued at approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$428 million</span></span><span style="font-family:inherit;font-size:10pt;"> (based upon the closing price of ICU Medical common stock on the closing date less a discount for lack of marketability) and which are reported as available-for-sale equity securities at fair value in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Long-term investments</span><span style="font-family:inherit;font-size:10pt;"> on the condensed consolidated balance sheet as of </span><span style="font-family:inherit;font-size:10pt;">October&#160;1, 2017</span><span style="font-family:inherit;font-size:10pt;">, a promissory note in the amount of </span><span style="font-family:inherit;font-size:10pt;"><span>$75 million</span></span><span style="font-family:inherit;font-size:10pt;">, which is reported in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other noncurrent assets</span><span style="font-family:inherit;font-size:10pt;"> on the condensed consolidated balance sheet as of </span><span style="font-family:inherit;font-size:10pt;">October&#160;1, 2017</span><span style="font-family:inherit;font-size:10pt;">, and net cash of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$200 million</span></span><span style="font-family:inherit;font-size:10pt;"> before customary adjustments for net working capital, which is reported in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other investing activities, net</span><span style="font-family:inherit;font-size:10pt;"> on the condensed consolidated statement of cash flows for the </span><span style="font-family:inherit;font-size:10pt;">nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">October&#160;1, 2017</span><span style="font-family:inherit;font-size:10pt;">. In addition, we are entitled to receive a contingent amount of up to an additional </span><span style="font-family:inherit;font-size:10pt;"><span>$225 million</span></span><span style="font-family:inherit;font-size:10pt;"> in cash based on ICU Medical&#8217;s achievement of certain cumulative performance targets for the combined company through December 31, 2019. After receipt of the ICU Medical shares, we own approximately </span><span style="font-family:inherit;font-size:10pt;"><span>16%</span></span><span style="font-family:inherit;font-size:10pt;"> of ICU Medical. We have agreed to certain restrictions on transfer of our ICU Medical shares for 18 months after the closing date. The promissory note from ICU Medical has a term of </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> years and bears interest at LIBOR plus </span><span style="font-family:inherit;font-size:10pt;"><span>2.25%</span></span><span style="font-family:inherit;font-size:10pt;"> for the first year and LIBOR plus </span><span style="font-family:inherit;font-size:10pt;"><span>2.50%</span></span><span style="font-family:inherit;font-size:10pt;"> for the second and third years. We recognized pre-tax income of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$12 million</span></span><span style="font-family:inherit;font-size:10pt;"> in the </span><span style="font-family:inherit;font-size:10pt;">third</span><span style="font-family:inherit;font-size:10pt;"> quarter of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;"> and pre-tax losses of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$52 million</span></span><span style="font-family:inherit;font-size:10pt;"> in the first </span><span style="font-family:inherit;font-size:10pt;">nine</span><span style="font-family:inherit;font-size:10pt;"> months of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;"> in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net, </span><span style="font-family:inherit;font-size:10pt;">representing adjustments to amounts previously recorded to write down the HIS net assets to fair value less costs to sell. For additional information, see </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 4</span><span style="font-family:inherit;font-size:10pt;"> and Notes to Consolidated Financial Statements&#8211;&#8211;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 2. </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Acquisitions, Sale of Hospira Infusion Systems Net Assets, Collaborative Arrangement and Equity-Method Investments</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span><span style="font-family:inherit;font-size:10pt;">in</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span><span style="font-family:inherit;font-size:10pt;">Pfizer&#8217;s </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;"> Financial Report.</span></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">While we have received the full purchase price excluding the contingent amount as of the February 3, 2017 closing, the sale of the HIS net assets was not completed in certain non-U.S. jurisdictions due to temporary regulatory or operational constraints. In these jurisdictions, which represent a relatively small portion of the HIS net assets, we have continued to operate the net assets for the net economic benefit of ICU Medical, and we are indemnified by ICU Medical against risks associated with such operations during the interim period, subject to our obligations under the definitive transaction agreements. Sales of the HIS net assets have occurred in certain of these jurisdictions as of October 1, 2017 and we expect the sale of the HIS net assets in the remaining jurisdictions to be fully completed by the first quarter of 2018. As such, and as we have already received all of the non-contingent proceeds from the sale and ICU Medical is contractually obligated to complete the transaction, we have treated these jurisdictions as sold for accounting purposes.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In connection with the sale transaction, we entered into certain transitional agreements designed to facilitate the orderly transition of the HIS net assets to ICU Medical. These agreements primarily relate to administrative services, which are generally to be provided for a period of up to 24 months after the closing date. We will also manufacture and supply certain HIS products for ICU Medical and ICU Medical will manufacture and supply certain retained Pfizer products for us after closing, generally for a term of five years. These agreements are not material to Pfizer and none confers upon us the ability to influence the operating and/or financial policies of ICU Medical subsequent to the sale.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">C. Collaboration Arrangement</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;padding-bottom:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Collaboration with Merck &amp; Co., Inc.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In 2013, we entered into a worldwide, except for Japan, collaboration agreement with Merck for the development and commercialization of ertugliflozin (PF-04971729), our oral sodium glucose cotransporter (SGLT2) inhibitor for the treatment of type 2 diabetes currently under regulatory review. Under the agreement, we are collaborating with Merck on the clinical development of ertugliflozin, and ertugliflozin-containing fixed-dose combinations with metformin and Januvia (sitagliptin) tablets.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:10pt;">In the first quarter of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:10pt;">we received a </span><span style="font-family:inherit;font-size:10pt;"><span>$90 million</span></span><span style="font-family:inherit;font-size:10pt;"> milestone payment from Merck upon the FDA&#8217;s acceptance for review of the NDAs for ertugliflozin and two fixed-dose combinations (ertugliflozin plus Januvia (sitagliptin) and ertugliflozin plus metformin), which has been deferred and primarily reported in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other noncurrent liabilities </span><span style="font-family:inherit;font-size:10pt;">and is being recognized in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net</span><span style="font-family:inherit;font-size:10pt;"> over a multi-year period. We are eligible for additional payments associated with the achievement of future clinical, regulatory and commercial milestones. We share potential revenues and certain costs with Merck on a </span><span style="font-family:inherit;font-size:10pt;"><span>60%</span></span><span style="font-family:inherit;font-size:10pt;">/</span><span style="font-family:inherit;font-size:10pt;"><span>40%</span></span><span style="font-family:inherit;font-size:10pt;"> basis, with Pfizer having the </span><span style="font-family:inherit;font-size:10pt;"><span>40%</span></span><span style="font-family:inherit;font-size:10pt;"> share. </span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">D. Equity-Method Investments</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;padding-bottom:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Investment in Hisun Pfizer Pharmaceuticals Company Limited</span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:10pt;">In </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;">,</span><span style="font-family:inherit;font-size:11pt;"> </span><span style="font-family:inherit;font-size:10pt;">we determined that we had other-than-temporary declines in the value of Hisun Pfizer, our </span><span style="font-family:inherit;font-size:10pt;"><span>49%</span></span><span style="font-family:inherit;font-size:10pt;">-owned equity-method investment in China, and, therefore, we recognized a loss of </span><span style="font-family:inherit;font-size:10pt;"><span>$211 million</span></span><span style="font-family:inherit;font-size:10pt;"> for the first </span><span style="font-family:inherit;font-size:10pt;">nine</span><span style="font-family:inherit;font-size:10pt;"> months of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;"> in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net </span><span style="font-family:inherit;font-size:10pt;">(see </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 4</span><span style="font-family:inherit;font-size:10pt;">)</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">. </span><span style="font-family:inherit;font-size:10pt;">The declines in value resulted from lower expectations as to the future cash flows to be generated by Hisun Pfizer, primarily as a result of an increase in risk due to the continued slowdown in the Chinese economy and changes in the expected timing and number of new product introductions by Hisun Pfizer. As of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">October&#160;1, 2017</span><span style="font-family:inherit;font-size:10pt;">, the carrying value of our investment in Hisun Pfizer is </span><span style="font-family:inherit;font-size:10pt;"><span>$270 million</span></span><span style="font-family:inherit;font-size:10pt;">, which is included in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Long-term investments</span><span style="font-family:inherit;font-size:10pt;">. We are continuing to evaluate strategic alternatives with Hisun. These strategic alternatives could impact the value of our investment in Hisun Pfizer in future periods.</span></div><div style="line-height:120%;text-align:left;font-size:5pt;"><span style="font-family:inherit;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In valuing our investment in Hisun Pfizer, we used discounted cash flow techniques, reflecting our best estimate of the various risks inherent in the projected cash flows, and a nominal terminal year growth factor. Some of the more significant estimates and assumptions inherent in this approach include: the amount and timing of the projected net cash flows, which include the expected impact of competitive, legal, economic and/or regulatory forces on the products; the long-term growth rate, which seeks to project the sustainable growth rate over the long-term; and the discount rate, which seeks to reflect the various risks inherent in the projected cash flows, including country risk. </span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;padding-bottom:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Investment in Laborat&#243;rio Teuto Brasileiro S.A.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We entered into an agreement on June 30, 2017 to exit our investment in Teuto, a </span><span style="font-family:inherit;font-size:10pt;"><span>40%</span></span><span style="font-family:inherit;font-size:10pt;">-owned generics company in Brazil, and sell our </span><span style="font-family:inherit;font-size:10pt;"><span>40%</span></span><span style="font-family:inherit;font-size:10pt;"> interest in Teuto to the majority shareholders. As part of the agreement, we have waived our option to acquire the remaining </span><span style="font-family:inherit;font-size:10pt;"><span>60%</span></span><span style="font-family:inherit;font-size:10pt;"> of Teuto, and Teuto&#8217;s other shareholders have waived their option to sell their </span><span style="font-family:inherit;font-size:10pt;"><span>60%</span></span><span style="font-family:inherit;font-size:10pt;"> stake in the company to us. As a result, in the second quarter of 2017, we recognized a net loss of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$30 million</span></span><span style="font-family:inherit;font-size:10pt;"> in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net </span><span style="font-family:inherit;font-size:10pt;">(see </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 4</span><span style="font-family:inherit;font-size:10pt;">), which included the impairment of our equity-method investment in Teuto, the reversal of a contingent liability associated with the majority shareholders&#8217; option to sell their </span><span style="font-family:inherit;font-size:10pt;"><span>60%</span></span><span style="font-family:inherit;font-size:10pt;"> stake in the company to us, and the recognition in earnings of the currency translation adjustment associated with the Teuto investment. The transaction closed on August 16, 2017. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:10pt;">In </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:10pt;">we determined that we had an other-than-temporary decline in the value of Teuto, and, therefore, we recognized a loss of </span><span style="font-family:inherit;font-size:10pt;"><span>$50 million</span></span><span style="font-family:inherit;font-size:10pt;"> for the first </span><span style="font-family:inherit;font-size:10pt;">nine</span><span style="font-family:inherit;font-size:10pt;"> months of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;"> in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net</span><span style="font-family:inherit;font-size:10pt;"> (see </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 4</span><span style="font-family:inherit;font-size:10pt;">) related to our equity-method investment. The decline in value resulted from lower expectations as to the future cash flows to be generated by Teuto, primarily due to a slowdown in Brazilian economic conditions, which have been impacted by political risk, higher inflation, and the depreciation of the Brazilian real.</span></div>In valuing our investment in Teuto, we used discounted cash flow techniques, reflecting our best estimate of the various risks inherent in the projected cash flows, and a nominal terminal year growth factor. Some of the more significant estimates and assumptions inherent in this approach include: the amount and timing of the projected net cash flows, which include the expected impact of competitive, legal, economic and/or regulatory forces on the products; the long-term growth rate, which seeks to project the sustainable growth rate over the long-term; and the discount rate, which seeks to reflect the various risks inherent in the projected cash flows, including country risk.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combinations, Discontinued Operations And Disposal Groups, Collaborative Arrangements And Equity Method Investments [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsCollaborativeArrangementsEquityandCostMethodInvestmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combinations, Disposal Groups, Including Discontinued Operations, Collaborative Arrangements, Equity and Cost Method Investments Disclosure [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsCollaborativeArrangementsEquityandCostMethodInvestmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6923678720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 01, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives</a></td>
<td class="text"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives</span><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We incur significant costs in connection with acquiring, integrating and restructuring businesses and in connection with our global cost-reduction/productivity initiatives. For example: </span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In connection with acquisition activity, we typically incur costs associated with executing the transactions, integrating the acquired operations (which may include expenditures for consulting and the integration of systems and processes), and restructuring the combined company (which may include charges related to employees, assets and activities that will not continue in the combined company); and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In connection with our cost-reduction/productivity initiatives, we typically incur costs and charges associated with site closings and other facility rationalization actions, workforce reductions and the expansion of shared services, including the development of global systems.</span></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:5pt;"><span style="font-family:inherit;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">All of our businesses and functions may be impacted by these actions, including sales and marketing, manufacturing and R&amp;D, as well as groups such as information technology, shared services and corporate operations. </span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In connection with our acquisition of Hospira, we are focusing our efforts on achieving an appropriate cost structure for the combined company. For up to a three-year period post-acquisition, we expect to incur costs of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$1 billion</span></span><span style="font-family:Arial;font-size:8pt;"> </span><span style="font-family:inherit;font-size:10pt;">(not including costs of </span><span style="font-family:inherit;font-size:10pt;"><span>$215 million</span></span><span style="font-family:inherit;font-size:10pt;"> for full-year 2015 associated with the return of acquired IPR&amp;D rights as described in the </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Current-Period Key Activities </span><span style="font-family:inherit;font-size:10pt;">section of Notes to Consolidated Financial Statements&#8211;&#8211;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 3</span><span style="font-family:inherit;font-size:10pt;">. </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives </span><span style="font-family:inherit;font-size:10pt;">in our 2016 Financial Report) associated with the integration of Hospira.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In 2016, we substantially completed previously disclosed cost-reduction initiatives begun in 2014 associated with our global commercial structure reorganization, manufacturing plant network rationalization and optimization initiatives, and additional cost-reduction/productivity initiatives across the enterprise.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As a result of the evaluation performed in connection with our decision in September 2016 to not pursue, at that time, splitting IH and EH into two separate publicly-traded companies, we identified new opportunities to potentially achieve greater optimization and efficiency to become more competitive in our business. Therefore, in early </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;">, we initiated new enterprise-wide cost reduction/productivity initiatives, which we expect to substantially complete by the end of 2019. These initiatives will encompass all areas of our cost base and will include:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Optimization of our manufacturing plant network to support IH and EH products and pipelines. During 2017-2019, we expect to incur costs of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$800 million</span></span><span style="font-family:inherit;font-size:10pt;"> related to this initiative. Through </span><span style="font-family:inherit;font-size:10pt;">October&#160;1, 2017</span><span style="font-family:inherit;font-size:10pt;">, we incurred approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$122 million</span></span><span style="font-family:inherit;font-size:10pt;"> associated with this initiative.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Activities in non-manufacturing related areas, which include further centralization of our corporate and platform functions, as well as other activities where opportunities are identified. During 2017-2019, we expect to incur costs of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$200 million</span></span><span style="font-family:inherit;font-size:10pt;"> related to this initiative. Through </span><span style="font-family:inherit;font-size:10pt;">October&#160;1, 2017</span><span style="font-family:inherit;font-size:10pt;">, we incurred approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$131 million</span></span><span style="font-family:inherit;font-size:10pt;"> associated with this initiative. </span></div></td></tr></table><div style="line-height:120%;padding-top:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The costs expected to be incurred during 2017-2019, of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$1.0 billion</span></span><span style="font-family:inherit;font-size:10pt;"> for the above-mentioned programs (but not including expected costs associated with the Hospira integration), include restructuring charges, implementation costs and additional depreciation&#8211;&#8211;asset restructuring. Of this amount, we expect that about </span><span style="font-family:inherit;font-size:10pt;"><span>20%</span></span><span style="font-family:inherit;font-size:10pt;"> of the total charges will be non-cash.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Current-Period Key Activities</span></div><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For the </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;">, we incurred costs of </span><span style="font-family:inherit;font-size:10pt;"><span>$253 million</span></span><span style="font-family:inherit;font-size:10pt;"> associated with the 2017-2019 program, </span><span style="font-family:inherit;font-size:10pt;"><span>$238 million</span></span><span style="font-family:inherit;font-size:10pt;"> associated with the integration of Hospira and </span><span style="font-family:inherit;font-size:10pt;"><span>$110 million</span></span><span style="font-family:inherit;font-size:10pt;"> associated with all other acquisition-related initiatives.</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:48%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td colspan="17" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides the components of costs associated with acquisitions and cost-reduction/productivity initiatives:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Arial;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nine Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">October&#160;1, <br/>2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">October&#160;2, <br/>2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">October&#160;1, <br/>2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">October&#160;2, <br/>2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Restructuring charges</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(a)</sup></span><span style="font-family:inherit;font-size:10pt;">:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Employee terminations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(20</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>347</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>464</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Asset impairments</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>101</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>126</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>45</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exit costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>29</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>64</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total restructuring charges</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>91</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>404</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>150</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>574</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Transaction costs</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(14</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>54</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>114</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Integration costs</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(d)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>73</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>74</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>224</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>300</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:36px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Restructuring charges and certain acquisition-related costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>149</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>531</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>377</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>988</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Additional depreciation&#8211;&#8211;asset restructuring</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#160;</sup></span><span style="font-family:inherit;font-size:10pt;">recorded in our condensed consolidated statements of income as follows</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(e)</sup></span><span style="font-family:inherit;font-size:10pt;">:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Cost of sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>39</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>46</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>74</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>145</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Research and development expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total additional depreciation&#8211;&#8211;asset restructuring</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>39</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>47</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>74</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>151</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Implementation costs recorded in our condensed consolidated statements of income as follows</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(f)</sup></span><span style="font-family:inherit;font-size:10pt;">:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Cost of sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>46</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>77</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>127</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Selling, informational and administrative expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>46</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>56</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Research and development expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total implementation costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>57</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>78</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>150</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>202</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total costs associated with acquisitions and cost-reduction/productivity initiatives</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>245</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>655</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>601</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,341</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">In the </span><span style="font-family:inherit;font-size:9pt;">third quarter</span><span style="font-family:inherit;font-size:9pt;"> and </span><span style="font-family:inherit;font-size:9pt;">first nine months of</span><span style="font-family:inherit;font-size:9pt;"> </span><span style="font-family:inherit;font-size:9pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:9pt;">, restructuring charges are primarily associated with our acquisitions of Hospira and Medivation, as well as cost-reduction and productivity initiatives not associated with acquisitions. In the </span><span style="font-family:inherit;font-size:9pt;">third quarter</span><span style="font-family:inherit;font-size:9pt;"> and </span><span style="font-family:inherit;font-size:9pt;">first nine months of</span><span style="font-family:inherit;font-size:9pt;"> </span><span style="font-family:inherit;font-size:9pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:9pt;">, restructuring charges are largely associated with cost-reduction and productivity initiatives not associated with acquisitions, as well as our acquisitions of Hospira and Medivation. In the third quarter and first </span><span style="font-family:inherit;font-size:9pt;">nine</span><span style="font-family:inherit;font-size:9pt;"> months ended </span><span style="font-family:inherit;font-size:9pt;">October&#160;1, 2017</span><span style="font-family:inherit;font-size:9pt;">, </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Employee terminations</span><span style="font-family:inherit;font-size:9pt;"> primarily include revisions of our estimates of severance benefits. Employee termination costs are generally recorded when the actions are probable and estimable and include accrued severance benefits, pension and postretirement benefits, many of which may be paid out during periods after termination.</span></div></td></tr></table><div style="line-height:120%;padding-top:4px;padding-left:24px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">The restructuring activities for </span><span style="font-family:inherit;font-size:9pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:9pt;"> are associated with the following:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:12px;"><span style="font-family:inherit;font-size:9pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">For the </span><span style="font-family:inherit;font-size:9pt;">third quarter</span><span style="font-family:inherit;font-size:9pt;"> of </span><span style="font-family:inherit;font-size:9pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:9pt;">, IH (</span><span style="font-family:inherit;font-size:9pt;"><span>$4 million</span></span><span style="font-family:inherit;font-size:9pt;">); EH (</span><span style="font-family:inherit;font-size:9pt;"><span>$1 million</span></span><span style="font-family:inherit;font-size:9pt;">); WRD/GPD (</span><span style="font-family:inherit;font-size:9pt;"><span>$15 million</span></span><span style="font-family:inherit;font-size:9pt;">); manufacturing operations (</span><span style="font-family:inherit;font-size:9pt;"><span>$47 million</span></span><span style="font-family:inherit;font-size:9pt;">); and Corporate (</span><span style="font-family:inherit;font-size:9pt;"><span>$25 million</span></span><span style="font-family:inherit;font-size:9pt;">).</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:12px;"><span style="font-family:inherit;font-size:9pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">For the </span><span style="font-family:inherit;font-size:9pt;">first nine months of</span><span style="font-family:inherit;font-size:9pt;"> </span><span style="font-family:inherit;font-size:9pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:9pt;">, IH (</span><span style="font-family:inherit;font-size:9pt;"><span>$10 million</span></span><span style="font-family:inherit;font-size:9pt;">); EH (</span><span style="font-family:inherit;font-size:9pt;"><span>$9 million</span></span><span style="font-family:inherit;font-size:9pt;"> income); WRD/GPD (</span><span style="font-family:inherit;font-size:9pt;"><span>$29 million</span></span><span style="font-family:inherit;font-size:9pt;">); manufacturing operations (</span><span style="font-family:inherit;font-size:9pt;"><span>$70 million</span></span><span style="font-family:inherit;font-size:9pt;">); and Corporate (</span><span style="font-family:inherit;font-size:9pt;"><span>$51 million</span></span><span style="font-family:inherit;font-size:9pt;">).</span></div></td></tr></table><div style="line-height:120%;padding-top:4px;text-align:left;padding-left:24px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">The restructuring activities for </span><span style="font-family:inherit;font-size:9pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:9pt;"> are associated with the following:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:12px;"><span style="font-family:inherit;font-size:9pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">For the </span><span style="font-family:inherit;font-size:9pt;">third quarter</span><span style="font-family:inherit;font-size:9pt;"> of </span><span style="font-family:inherit;font-size:9pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:9pt;">, IH (</span><span style="font-family:inherit;font-size:9pt;"><span>$148 million</span></span><span style="font-family:inherit;font-size:9pt;">); EH (</span><span style="font-family:inherit;font-size:9pt;"><span>$28 million</span></span><span style="font-family:inherit;font-size:9pt;">); WRD/GPD (</span><span style="font-family:inherit;font-size:9pt;"><span>$52 million</span></span><span style="font-family:inherit;font-size:9pt;">); manufacturing operations (</span><span style="font-family:inherit;font-size:9pt;"><span>$108 million</span></span><span style="font-family:inherit;font-size:9pt;">); and Corporate (</span><span style="font-family:inherit;font-size:9pt;"><span>$67 million</span></span><span style="font-family:inherit;font-size:9pt;">).</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:12px;"><span style="font-family:inherit;font-size:9pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">For the </span><span style="font-family:inherit;font-size:9pt;">first nine months of</span><span style="font-family:inherit;font-size:9pt;"> </span><span style="font-family:inherit;font-size:9pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:9pt;">, IH (</span><span style="font-family:inherit;font-size:9pt;"><span>$162 million</span></span><span style="font-family:inherit;font-size:9pt;">); EH (</span><span style="font-family:inherit;font-size:9pt;"><span>$19 million</span></span><span style="font-family:inherit;font-size:9pt;">); WRD/GPD (</span><span style="font-family:inherit;font-size:9pt;"><span>$104 million</span></span><span style="font-family:inherit;font-size:9pt;">); manufacturing operations (</span><span style="font-family:inherit;font-size:9pt;"><span>$181 million</span></span><span style="font-family:inherit;font-size:9pt;">); and Corporate (</span><span style="font-family:inherit;font-size:9pt;"><span>$107 million</span></span><span style="font-family:inherit;font-size:9pt;">).</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">The asset impairment charges for the </span><span style="font-family:inherit;font-size:9pt;">third</span><span style="font-family:inherit;font-size:9pt;"> quarter and the </span><span style="font-family:inherit;font-size:9pt;">first nine months of</span><span style="font-family:inherit;font-size:9pt;"> </span><span style="font-family:inherit;font-size:9pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:9pt;"> are largely associated with our acquisitions of Hospira and Medivation.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(c)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Transaction costs represent external costs for banking, legal, accounting and other similar services, which in the </span><span style="font-family:inherit;font-size:9pt;">third quarter</span><span style="font-family:inherit;font-size:9pt;"> of 2017 reflect the reversal of an accrual related to the acquisition of Medivation. Transaction costs for the </span><span style="font-family:inherit;font-size:9pt;">first nine months of</span><span style="font-family:inherit;font-size:9pt;"> </span><span style="font-family:inherit;font-size:9pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:9pt;"> are directly related to our acquisitions of Hospira, Anacor and Medivation. Transaction costs in the </span><span style="font-family:inherit;font-size:9pt;">third quarter</span><span style="font-family:inherit;font-size:9pt;"> of </span><span style="font-family:inherit;font-size:9pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:9pt;"> were mostly related to the Medivation acquisition, and in the </span><span style="font-family:inherit;font-size:9pt;">first nine months of</span><span style="font-family:inherit;font-size:9pt;"> </span><span style="font-family:inherit;font-size:9pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:9pt;">, were mostly related to the Medivation and Anacor acquisitions, and our terminated transaction with Allergan.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(d)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Integration costs represent external, incremental costs directly related to integrating acquired businesses, and primarily include expenditures for consulting and the integration of systems and processes. In the </span><span style="font-family:inherit;font-size:9pt;">third</span><span style="font-family:inherit;font-size:9pt;"> quarter and </span><span style="font-family:inherit;font-size:9pt;">first nine months of</span><span style="font-family:inherit;font-size:9pt;"> </span><span style="font-family:inherit;font-size:9pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:9pt;">, integration costs primarily relate to our acquisitions of Hospira and Medivation. The </span><span style="font-family:inherit;font-size:9pt;">first nine months of</span><span style="font-family:inherit;font-size:9pt;"> </span><span style="font-family:inherit;font-size:9pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:9pt;"> also include a net gain of </span><span style="font-family:inherit;font-size:9pt;"><span>$12 million</span></span><span style="font-family:inherit;font-size:9pt;"> related to the settlement of the Hospira U.S. qualified defined benefit pension plan (see </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Note 10</span><span style="font-family:inherit;font-size:9pt;">). In the </span><span style="font-family:inherit;font-size:9pt;">third quarter</span><span style="font-family:inherit;font-size:9pt;"> of </span><span style="font-family:inherit;font-size:9pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:9pt;">, integration </span></div></td></tr></table><div style="line-height:120%;padding-left:12px;text-align:left;"><span style="font-family:inherit;font-size:9pt;">costs were mostly related to our acquisition of Hospira, and in the </span><span style="font-family:inherit;font-size:9pt;">first nine months of</span><span style="font-family:inherit;font-size:9pt;"> </span><span style="font-family:inherit;font-size:9pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:9pt;">, integration costs were mostly related to our acquisition of Hospira and our terminated transaction with Allergan.</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(e)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Additional depreciation&#8211;&#8211;asset restructuring represents the impact of changes in the estimated useful lives of assets involved in restructuring actions.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(f)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Implementation costs represent external, incremental costs directly related to implementing our non-acquisition-related cost-reduction/productivity initiatives.</span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.05068226120858%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:41%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td colspan="17" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides the components of and changes in our restructuring accruals:</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Employee</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Termination Costs</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Asset</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Impairment Charges</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exit Costs</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrual</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance, December 31, 2016</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,547</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>36</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,583</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Provision</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>126</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>150</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Utilization and other</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(401</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(126</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(24</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(551</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance, October 1, 2017</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(c)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,154</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,182</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Included in </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Other current liabilities</span><span style="font-family:inherit;font-size:9pt;"> (</span><span style="font-family:inherit;font-size:9pt;"><span>$863 million</span></span><span style="font-family:inherit;font-size:9pt;">) and </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Other noncurrent liabilities</span><span style="font-family:inherit;font-size:9pt;"> (</span><span style="font-family:inherit;font-size:9pt;"><span>$720 million</span></span><span style="font-family:inherit;font-size:9pt;">).</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Includes adjustments for foreign currency translation.</span></div></td></tr></table><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(c)</sup>&#160;</span></div><span style="font-family:inherit;font-size:9pt;">Included in </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Other current liabilities </span><span style="font-family:inherit;font-size:9pt;">(</span><span style="font-family:inherit;font-size:9pt;"><span>$533 million</span></span><span style="font-family:inherit;font-size:9pt;">) and </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Other noncurrent liabilities </span><span style="font-family:inherit;font-size:9pt;">(</span><span style="font-family:inherit;font-size:9pt;"><span>$650 million</span></span>).<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -URI http://asc.fasb.org/topic&amp;trid=2175745<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6919158528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other (Income)/Deductions - Net<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 01, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock', window );">Other (Income)/Deductions - Net</a></td>
<td class="text"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Other (Income)/Deductions&#8212;Net</span><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:44%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td colspan="17" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides components of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net</span><span style="font-family:inherit;font-size:10pt;">:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nine Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">October&#160;1, <br/>2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">October&#160;2, <br/>2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">October&#160;1, <br/>2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">October&#160;2, <br/>2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest income</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(99</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(123</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(275</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(357</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest expense</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>320</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>291</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>940</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>889</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net interest expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>220</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>168</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>666</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>532</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Royalty-related income</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(140</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(233</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(331</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(695</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certain legal matters, net</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>183</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(40</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>194</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>494</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net gains on asset disposals</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(d)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(155</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(47</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(349</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(81</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:18px;text-indent:-18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Loss on sale and impairment on remeasurement of HIS net assets</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(e)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(12</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,422</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>52</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,422</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certain asset impairments</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(f)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>130</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>133</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>143</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,080</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Business and legal entity alignment costs</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(g)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>69</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>54</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>180</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other, net</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(h)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(191</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(55</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(445</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(117</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>51</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,417</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(16</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,815</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Interest income decreased in the </span><span style="font-family:inherit;font-size:8.5pt;">third</span><span style="font-family:inherit;font-size:8.5pt;"> quarter and </span><span style="font-family:inherit;font-size:8.5pt;">first nine months of</span><span style="font-family:inherit;font-size:8.5pt;"> </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:8.5pt;">, primarily driven by a lower investment balance. Interest expense increased in the </span><span style="font-family:inherit;font-size:8.5pt;">third</span><span style="font-family:inherit;font-size:8.5pt;"> quarter and </span><span style="font-family:inherit;font-size:8.5pt;">first nine months of</span><span style="font-family:inherit;font-size:8.5pt;"> </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:8.5pt;">, </span><span style="font-size:8.5pt;">primarily as a result of higher short-term interest rates, offset, in part, by the retirement of high-coupon debt and the issuance of new low-coupon debt</span><span style="font-family:inherit;font-size:8.5pt;">.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Royalty-related income </span><span style="font-family:inherit;font-size:8.5pt;">decreased</span><span style="font-family:inherit;font-size:8.5pt;"> in the </span><span style="font-family:inherit;font-size:8.5pt;">third</span><span style="font-family:inherit;font-size:8.5pt;"> quarter and </span><span style="font-family:inherit;font-size:8.5pt;">first nine months of</span><span style="font-family:inherit;font-size:8.5pt;"> </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:8.5pt;">, primarily due to lower royalty income for Enbrel of </span><span style="font-family:inherit;font-size:8.5pt;"><span>$139 million</span></span><span style="font-family:inherit;font-size:8.5pt;"> and </span><span style="font-family:inherit;font-size:8.5pt;"><span>$414 million</span></span><span style="font-family:inherit;font-size:8.5pt;">, respectively, resulting from the expiration on October 31, 2016 of the </span><span style="font-family:inherit;font-size:8.5pt;">36</span><span style="font-family:inherit;font-size:8.5pt;">-month royalty period under the collaboration agreement for Enbrel in the U.S. and Canada (the collaboration period under the agreement expired on October 31, 2013), partially offset by the addition of Xtandi royalty-related income of </span><span style="font-family:inherit;font-size:8.5pt;"><span>$73 million</span></span><span style="font-family:inherit;font-size:8.5pt;"> and </span><span style="font-family:inherit;font-size:8.5pt;"><span>$160 million</span></span><span style="font-family:inherit;font-size:8.5pt;">, respectively. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(c)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">In the </span><span style="font-family:inherit;font-size:8.5pt;">third quarter</span><span style="font-family:inherit;font-size:8.5pt;"> and </span><span style="font-family:inherit;font-size:8.5pt;">first nine months of</span><span style="font-family:inherit;font-size:8.5pt;"> </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:8.5pt;">, primarily includes a </span><span style="font-family:inherit;font-size:8.5pt;"><span>$94 million</span></span><span style="font-family:inherit;font-size:8.5pt;"> charge to resolve a class action lawsuit filed by direct purchasers relating to Celebrex, which is subject to the negotiation of a final settlement agreement and court approval, and a </span><span style="font-family:inherit;font-size:8.5pt;"><span>$79 million</span></span><span style="font-family:inherit;font-size:8.5pt;"> charge to reflect damages awarded by a jury in a patent matter. In the </span><span style="font-family:inherit;font-size:8.5pt;">first nine months of</span><span style="font-family:inherit;font-size:8.5pt;"> </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:8.5pt;">, primarily includes amounts to resolve a Multi-District Litigation relating to Celebrex and Bextra that was pending against the Company in New York federal court for </span><span style="font-family:inherit;font-size:8.5pt;"><span>$486 million</span></span><span style="font-family:inherit;font-size:8.5pt;">, partially offset by the reversal of a legal accrual where a loss was no longer deemed probable. In addition, the </span><span style="font-family:inherit;font-size:8.5pt;">first nine months of</span><span style="font-family:inherit;font-size:8.5pt;"> </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:8.5pt;"> includes a settlement related to a patent matter.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(d)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">In the </span><span style="font-family:inherit;font-size:8.5pt;">third</span><span style="font-family:inherit;font-size:8.5pt;"> quarter of </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:8.5pt;">, primarily includes gains on sales/out-licensing of product and compound rights (approximately </span><span style="font-family:inherit;font-size:8.5pt;"><span>$71 million</span></span><span style="font-family:inherit;font-size:8.5pt;">) and gains on sales and redemptions of investments in equity and debt securities (approximately </span><span style="font-family:inherit;font-size:8.5pt;"><span>$66 million</span></span><span style="font-family:inherit;font-size:8.5pt;">). In the </span><span style="font-family:inherit;font-size:8.5pt;">first nine months of</span><span style="font-family:inherit;font-size:8.5pt;"> </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:8.5pt;">, primarily includes gains on sales and redemptions of investments in equity and debt securities (approximately </span><span style="font-family:inherit;font-size:8.5pt;"><span>$183 million</span></span><span style="font-family:inherit;font-size:8.5pt;">), gains on sales/out-licensing of product and compound rights (approximately </span><span style="font-family:inherit;font-size:8.5pt;"><span>$141 million</span></span><span style="font-family:inherit;font-size:8.5pt;">) and a gain on sale of property (approximately </span><span style="font-family:inherit;font-size:8.5pt;"><span>$52 million</span></span><span style="font-family:inherit;font-size:8.5pt;">), partially offset by a net loss related to the sale of our </span><span style="font-family:inherit;font-size:8.5pt;"><span>40%</span></span><span style="font-family:inherit;font-size:8.5pt;"> ownership investment in Teuto, including the extinguishment of a put option for the remaining </span><span style="font-family:inherit;font-size:8.5pt;"><span>60%</span></span><span style="font-family:inherit;font-size:8.5pt;"> ownership interest (approximately </span><span style="font-family:inherit;font-size:8.5pt;"><span>$30 million</span></span><span style="font-family:inherit;font-size:8.5pt;">). In the </span><span style="font-family:inherit;font-size:8.5pt;">first nine months of</span><span style="font-family:inherit;font-size:8.5pt;"> </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:8.5pt;">, includes gains on sales/out-licensing of product and compound rights (approximately </span><span style="font-family:inherit;font-size:8.5pt;"><span>$49 million</span></span><span style="font-family:inherit;font-size:8.5pt;">).</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(e)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">In the </span><span style="font-family:inherit;font-size:8.5pt;">third</span><span style="font-family:inherit;font-size:8.5pt;"> quarter and </span><span style="font-family:inherit;font-size:8.5pt;">first nine months of</span><span style="font-family:inherit;font-size:8.5pt;"> </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:8.5pt;">, represents adjustments to amounts previously recorded to write down the HIS net assets to fair value less costs to sell related to the sale of HIS net assets to ICU Medical. In the </span><span style="font-family:inherit;font-size:8.5pt;">third</span><span style="font-family:inherit;font-size:8.5pt;"> quarter and </span><span style="font-family:inherit;font-size:8.5pt;">first nine months of</span><span style="font-family:inherit;font-size:8.5pt;"> </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:8.5pt;">, represents a charge related to the write-down of the HIS net assets to fair value less estimated costs to sell.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(f)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">In the </span><span style="font-family:inherit;font-size:8.5pt;">third quarter</span><span style="font-family:inherit;font-size:8.5pt;"> and </span><span style="font-family:inherit;font-size:8.5pt;">first nine months of</span><span style="font-family:inherit;font-size:8.5pt;"> </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:8.5pt;">, primarily includes an intangible asset impairment charge of </span><span style="font-family:inherit;font-size:8.5pt;"><span>$127 million</span></span><span style="font-family:inherit;font-size:8.5pt;"> related to developed technology rights, acquired in connection with our acquisition of Hospira, for a generic sterile injectable product for the treatment of edema associated with certain conditions. The intangible asset impairment charge for the </span><span style="font-family:inherit;font-size:8.5pt;">third</span><span style="font-family:inherit;font-size:8.5pt;"> quarter and </span><span style="font-family:inherit;font-size:8.5pt;">first nine months of</span><span style="font-family:inherit;font-size:8.5pt;"> </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:8.5pt;"> is associated with EH and reflects, among other things, updated commercial forecasts and an increased competitive environment. In the </span><span style="font-family:inherit;font-size:8.5pt;">third</span><span style="font-family:inherit;font-size:8.5pt;"> quarter of </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:8.5pt;">, primarily includes intangible asset impairment charges of </span><span style="font-family:inherit;font-size:8.5pt;"><span>$126 million</span></span><span style="font-family:inherit;font-size:8.5pt;">, reflecting </span><span style="font-family:inherit;font-size:8.5pt;"><span>$97 million</span></span><span style="font-family:inherit;font-size:8.5pt;"> of sterile injectable IPR&amp;D compounds acquired in connection with our acquisition of InnoPharma and </span><span style="font-family:inherit;font-size:8.5pt;"><span>$29 million</span></span><span style="font-family:inherit;font-size:8.5pt;"> of other IPR&amp;D assets acquired in connection with our acquisition of King in 2011. The intangible asset impairment charges for the </span><span style="font-family:inherit;font-size:8.5pt;">third quarter</span><span style="font-family:inherit;font-size:8.5pt;"> of </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:8.5pt;"> are associated with the following: EH (</span><span style="font-family:inherit;font-size:8.5pt;"><span>$97 million</span></span><span style="font-family:inherit;font-size:8.5pt;">) and IH (</span><span style="font-family:inherit;font-size:8.5pt;"><span>$29 million</span></span><span style="font-family:inherit;font-size:8.5pt;">). In the </span><span style="font-family:inherit;font-size:8.5pt;">first nine months of</span><span style="font-family:inherit;font-size:8.5pt;"> </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:8.5pt;">, primarily includes intangible asset impairment charges of </span><span style="font-family:inherit;font-size:8.5pt;"><span>$767 million</span></span><span style="font-family:inherit;font-size:8.5pt;">, reflecting (i) </span><span style="font-family:inherit;font-size:8.5pt;"><span>$331 million</span></span><span style="font-family:inherit;font-size:8.5pt;"> related to developed technology rights for a generic injectable antibiotic product for the treatment of bacterial infections; and (ii) </span><span style="font-family:inherit;font-size:8.5pt;"><span>$265 million</span></span><span style="font-family:inherit;font-size:8.5pt;"> related to an IPR&amp;D compound for the treatment of anemia, both acquired in connection with our acquisition of Hospira; (iii) </span><span style="font-family:inherit;font-size:8.5pt;"><span>$97 million</span></span><span style="font-family:inherit;font-size:8.5pt;"> of sterile injectable IPR&amp;D compounds acquired in connection with our acquisition of InnoPharma; and (iv) </span><span style="font-family:inherit;font-size:8.5pt;"><span>$74 million</span></span><span style="font-family:inherit;font-size:8.5pt;"> of other IPR&amp;D assets, </span><span style="font-family:inherit;font-size:8.5pt;"><span>$45 million</span></span><span style="font-family:inherit;font-size:8.5pt;"> of which were acquired in connection with our acquisition of Hospira and </span><span style="font-family:inherit;font-size:8.5pt;"><span>$29 million</span></span><span style="font-family:inherit;font-size:8.5pt;"> of which were acquired in connection with our acquisition of King in 2011. The intangible asset impairment charges for the </span><span style="font-family:inherit;font-size:8.5pt;">first nine months of</span><span style="font-family:inherit;font-size:8.5pt;"> </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:8.5pt;"> are associated with the following: EH (</span><span style="font-family:inherit;font-size:8.5pt;"><span>$738 million</span></span><span style="font-family:inherit;font-size:8.5pt;">) and IH (</span><span style="font-family:inherit;font-size:8.5pt;"><span>$29 million</span></span><span style="font-family:inherit;font-size:8.5pt;">). In addition, the </span><span style="font-family:inherit;font-size:8.5pt;">first nine months of</span><span style="font-family:inherit;font-size:8.5pt;"> </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:8.5pt;"> includes an impairment loss of </span><span style="font-family:inherit;font-size:8.5pt;"><span>$211 million</span></span><span style="font-family:inherit;font-size:8.5pt;"> related to Pfizer&#8217;s </span><span style="font-family:inherit;font-size:8.5pt;"><span>49%</span></span><span style="font-family:inherit;font-size:8.5pt;">-owned equity-method investment with Hisun in China, Hisun Pfizer, and an impairment loss of </span><span style="font-family:inherit;font-size:8.5pt;"><span>$50 million</span></span><span style="font-family:inherit;font-size:8.5pt;"> related to Pfizer&#8217;s </span><span style="font-family:inherit;font-size:8.5pt;"><span>40%</span></span><span style="font-family:inherit;font-size:8.5pt;">-owned equity-method investment in Teuto. For additional information concerning Hisun Pfizer and Teuto, see </span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Note 2D. </span></div></td></tr></table><div style="line-height:120%;padding-bottom:1px;padding-top:1px;padding-left:12px;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">The intangible asset impairment charge for 2016 for the IPR&amp;D compound for the treatment of anemia acquired in connection with our acquisition of Hospira reflects, among other things, the impact of regulatory delays, including delays resulting from a court ruling, which required a 180-day waiting period after approval before a biosimilar product can be launched. The intangible asset impairment charges for 2016 for the sterile injectable IPR&amp;D compounds acquired in connection with our acquisition of InnoPharma reflect, among other things, the impact of portfolio prioritization decisions and decreased commercial profiles of certain compounds. The intangible asset impairment charges for 2016 for developed technology rights and other IPR&amp;D assets acquired in connection with our acquisition of Hospira reflect, among other things, the impact of new scientific findings, updated commercial forecasts, changes in pricing, and an increased competitive environment. The intangible asset impairment charges for 2016 for other IPR&amp;D assets acquired in connection with our acquisition of King reflect changes in the competitive environment.</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(g)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">In the </span><span style="font-family:inherit;font-size:8.5pt;">third</span><span style="font-family:inherit;font-size:8.5pt;"> quarter and </span><span style="font-family:inherit;font-size:8.5pt;">first nine months of</span><span style="font-family:inherit;font-size:8.5pt;"> </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:8.5pt;"> and </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:8.5pt;">, represents expenses for changes to our infrastructure to align our commercial operations, including costs to internally separate our businesses into distinct legal entities, as well as to streamline our intercompany supply operations to better support each business. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(h)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">In the </span><span style="font-family:inherit;font-size:8.5pt;">third quarter</span><span style="font-family:inherit;font-size:8.5pt;"> and </span><span style="font-family:inherit;font-size:8.5pt;">first nine months of</span><span style="font-family:inherit;font-size:8.5pt;"> </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:8.5pt;">, includes, among other things, dividend income of </span><span style="font-family:inherit;font-size:8.5pt;"><span>$54 million</span></span><span style="font-family:inherit;font-size:8.5pt;"> and </span><span style="font-family:inherit;font-size:8.5pt;"><span>$211 million</span></span><span style="font-family:inherit;font-size:8.5pt;">, respectively, from our investment in ViiV, and income of </span><span style="font-family:inherit;font-size:8.5pt;"><span>$62 million</span></span><span style="font-family:inherit;font-size:8.5pt;"> from resolution of a contract disagreement. In the </span><span style="font-family:inherit;font-size:8.5pt;">first nine months of</span><span style="font-family:inherit;font-size:8.5pt;"> </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:8.5pt;">, includes, among other things, </span><span style="font-family:inherit;font-size:8.5pt;"><span>$150 million</span></span><span style="font-family:inherit;font-size:8.5pt;"> paid to Allergan for reimbursement of Allergan&#8217;s expenses associated with the terminated transaction and income of </span><span style="font-family:inherit;font-size:8.5pt;"><span>$116 million</span></span><span style="font-family:inherit;font-size:8.5pt;"> from resolution of a contract disagreement.</span></div></td></tr></table><div style="line-height:120%;padding-left:4px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="21"/></tr><tr><td style="width:38%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td colspan="21" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides additional information about the intangible assets that were impaired during 2017 in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net</span><span style="font-family:inherit;font-size:10pt;">:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Fair Value</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Nine Months Ended</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">October 1, 2017</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Level 3</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Impairment</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Intangible assets</span><span style="font-family:inherit;font-size:9pt;font-style:italic;">&#8211;&#8211;</span><span style="font-family:inherit;font-size:9pt;">Developed technology rights</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(b)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>50</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>50</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>127</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">The fair value amount is presented as of the date of impairment, as these assets are not measured at fair value on a recurring basis.</span></div></td></tr></table><div style="line-height:120%;font-size:8.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(b)</sup>&#160;</span></div><span style="font-family:inherit;font-size:8.5pt;">Reflects intangible assets written down to fair value in the </span><span style="font-family:inherit;font-size:8.5pt;">third quarter</span><span style="font-family:inherit;font-size:8.5pt;"> of </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">2017</span>. Fair value was determined using the income approach, specifically the multi-period excess earnings method, also known as the discounted cash flow method. We started with a forecast of all the expected net cash flows associated with the asset and then applied an asset-specific discount rate to arrive at a net present value amount. Some of the more significant estimates and assumptions inherent in this approach include: the amount and timing of the projected net cash flows, which includes the expected impact of competitive, legal and/or regulatory forces on the product; the discount rate, which seeks to reflect the various risks inherent in the projected cash flows; and the tax rate, which seeks to incorporate the geographic diversity of the projected cash flows.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -URI http://asc.fasb.org/topic&amp;trid=2122503<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 610<br> -URI http://asc.fasb.org/topic&amp;trid=49130413<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6929585168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Tax Matters<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 01, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Tax Matters</a></td>
<td class="text"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Tax Matters</span><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">A. Taxes on Income from Continuing Operations</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our effective tax rate for continuing operations was </span><span style="font-family:inherit;font-size:10pt;"><span>20.3%</span></span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">third</span><span style="font-family:inherit;font-size:10pt;"> quarter of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;">, compared to </span><span style="font-family:inherit;font-size:10pt;"><span>15.5%</span></span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">third</span><span style="font-family:inherit;font-size:10pt;"> quarter of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;"> and was </span><span style="font-family:inherit;font-size:10pt;"><span>20.1%</span></span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;">, compared to </span><span style="font-family:inherit;font-size:10pt;"><span>14.6%</span></span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The </span><span style="font-family:inherit;font-size:10pt;">higher</span><span style="font-family:inherit;font-size:10pt;"> effective tax rate for the </span><span style="font-family:inherit;font-size:10pt;">third</span><span style="font-family:inherit;font-size:10pt;"> quarter of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;"> in comparison with the same period in </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;"> was primarily due to: </span></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">an unfavorable change in the jurisdictional mix of earnings as a result of operating fluctuations in the normal course of business,</span></div></td></tr></table><div style="line-height:120%;padding-top:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">partially offset by:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the non-recurrence of the unfavorable tax effects of an impairment charge related to the write-down of the HIS net assets to fair value less estimated costs to sell, mainly related to goodwill, which is not deductible for tax purposes, and the jurisdictional mix of intangible assets.</span></div></td></tr></table><div style="line-height:120%;padding-top:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The </span><span style="font-family:inherit;font-size:10pt;">higher</span><span style="font-family:inherit;font-size:10pt;"> effective tax rate for the </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;"> in comparison with the same period in </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;"> was primarily due to:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the non-recurrence of benefits related to the final resolution of an agreement in principle reached in February 2016 and finalized in April 2016 to resolve certain claims related to Protonix, which resulted in the receipt of information that raised our initial assessment in 2015 of the likelihood of prevailing on the technical merits of our tax position; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the non-recurrence of benefits associated with our Venezuela operations; as well as </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">a decrease in benefits associated with the resolution of certain tax positions pertaining to prior years primarily with various foreign tax authorities, and the expiration of certain statutes of limitations,</span></div></td></tr></table><div style="line-height:120%;padding-top:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">partially offset by:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the change in the jurisdictional mix of earnings as a result of operating fluctuations in the normal course of business; as well as</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the non-recurrence of the unfavorable tax effects of an impairment charge related to the write-down of HIS net assets to fair value less estimated costs to sell, mainly related to goodwill, which is not deductible for tax purposes, and the jurisdictional mix of intangible assets.</span></div></td></tr></table><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">B. Tax Contingencies</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are subject to income tax in many jurisdictions, and a certain degree of estimation is required in recording the assets and liabilities related to income taxes. All of our tax positions are subject to audit by the local taxing authorities in each tax jurisdiction. These tax audits can involve complex issues, interpretations and judgments and the resolution of matters may span multiple years, particularly if subject to negotiation or litigation. Our assessments are based on estimates and assumptions that have been deemed reasonable by management, but our estimates of unrecognized tax benefits and potential tax benefits may not be representative of actual outcomes, and variation from such estimates could materially affect our financial statements in the period of settlement or when the statutes of limitations expire, as we treat these events as discrete items in the period of resolution.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The U.S. is one of our major tax jurisdictions, and we are regularly audited by the IRS:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">With respect to Pfizer, the IRS has issued a Revenue Agent&#8217;s Report (RAR) for tax years 2009-2010. We are not in agreement with the RAR and are currently appealing certain disputed issues. Tax years 2011-2013 are currently under audit. Tax years 2014-2017 are open, but not under audit. All other tax years are closed.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">With respect to Hospira, the federal income tax audit for tax years 2012-2013 was effectively settled in the third quarter of 2017. The IRS is currently auditing tax year 2014 through short-year 2015. All other tax years are closed. The tax years under audit for Hospira are not considered material to Pfizer.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">With respect to Anacor and Medivation, the open tax years are not considered material to Pfizer.</span></div></td></tr></table><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition to the open audit years in the U.S., we have open audit years in other major tax jurisdictions, such as Canada (2010-2017), Japan (2015-2017), Europe (2011-2017, primarily reflecting Ireland, the United Kingdom, France, Italy, Spain and Germany), Latin America (1998-2017, primarily reflecting Brazil) and Puerto Rico (2010-2017).</span></div><div style="line-height:120%;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">C. Tax Provision/(Benefit) on Other Comprehensive Income</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90167158308752%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:56%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td colspan="17" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides the components of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Tax provision/(benefit) on</span><span style="font-family:inherit;font-size:10pt;">&#160;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">other comprehensive income:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Nine Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">October&#160;1, <br/>2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">October&#160;2, <br/>2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">October&#160;1, <br/>2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">October&#160;2, <br/>2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Foreign currency translation adjustments, net</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(62</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(192</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(15</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Unrealized holding losses on derivative financial instruments, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>28</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>30</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(192</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Reclassification adjustments for realized (gains)/losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(29</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>32</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(169</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>81</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>32</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(139</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(112</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Unrealized holding gains on available-for-sale securities, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>37</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>40</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>93</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>106</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Reclassification adjustments for realized gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(49</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(14</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(45</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(16</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(12</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>26</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>47</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>90</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Benefit plans: actuarial losses, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(37</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(31</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(15</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(39</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Reclassification adjustments related to amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>60</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>47</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>152</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>140</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Reclassification adjustments related to settlements, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>22</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>30</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>27</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(33</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>14</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(46</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>40</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>121</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>133</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Benefit plans: prior service (costs)/credits and other, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>35</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>66</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Reclassification adjustments related to amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(17</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(17</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(50</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(47</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Reclassification adjustments related to curtailments, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(17</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>18</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(55</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>15</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">Tax provision/(benefit) on other comprehensive income</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(80</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>116</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(218</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>111</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup>&#160;</span></div>Taxes are not provided for foreign currency translation adjustments relating to investments in international subsidiaries that will be held indefinitely.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6919158528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 01, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNoteTextBlock', window );">Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests</a></td>
<td class="text"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"> </span><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"/></tr><tr><td style="width:23%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td colspan="25" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides the changes, net of tax, in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Accumulated other comprehensive loss</span><span style="font-family:inherit;font-size:10pt;">:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net Unrealized Gains/(Losses)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Benefit Plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign Currency Translation Adjustments </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Derivative Financial Instruments</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Available-For-Sale Securities</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Actuarial Gains/(Losses)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prior Service (Costs)/Credits and Other</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accumulated Other Comprehensive Income/(Loss)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance, December&#160;31, 2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6,659</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>348</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(131</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5,473</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>879</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(11,036</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other comprehensive income/(loss)</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,638</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(403</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>470</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>263</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(96</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,872</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance, October&#160;1, 2017</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5,021</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(55</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>339</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5,210</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>783</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(9,164</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Amounts do not include foreign currency translation adjustments attributable to noncontrolling interests of </span><span style="font-family:inherit;font-size:9pt;"><span>$16 million</span></span><span style="font-family:inherit;font-size:9pt;"> income for the </span><span style="font-family:inherit;font-size:9pt;">first nine months of</span><span style="font-family:inherit;font-size:9pt;"> </span><span style="font-family:inherit;font-size:9pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:9pt;">.</span></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">October&#160;1, 2017</span><span style="font-family:inherit;font-size:10pt;">, with respect to derivative financial instruments, the amount of unrealized pre-tax net losses on derivative financial instruments estimated to be reclassified into income within the next 12 months is approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$154 million</span></span>, which is expected to be offset primarily by gains related to available-for-sale securities and gains resulting from reclassification adjustments related to foreign currency exchange-denominated forecasted intercompany inventory sales.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNoteTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -URI http://asc.fasb.org/topic&amp;trid=2134417<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNoteTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6917242976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 01, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_FinancialInstrumentsAbstract', window );"><strong>Financial Instruments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsDisclosureTextBlock', window );">Financial Instruments</a></td>
<td class="text"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Financial Instruments</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"> </span><div style="line-height:120%;font-size:6pt;"><span style="font-family:inherit;font-size:6pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">A. Selected Financial Assets and Liabilities</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:74%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides additional information about certain of our financial assets and liabilities:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">October&#160;1, <br/>2017</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">December&#160;31, <br/>2016</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:justify;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;text-decoration:underline;">Selected financial assets measured at fair value on a recurring basis</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Trading funds and securities</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>347</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>325</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Available-for-sale debt securities</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>16,598</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>18,632</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Money market funds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1,824</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1,445</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Available-for-sale equity securities</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1,032</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>540</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Derivative financial instruments in a receivable position</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(d)</sup></span><span style="font-family:inherit;font-size:9pt;">:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Interest rate swaps</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>630</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>625</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Foreign currency swaps</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>92</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>79</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Foreign currency forward-exchange contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>110</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>551</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>20,631</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>22,198</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;text-decoration:underline;">Other selected financial assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Held-to-maturity debt securities, carried at amortized cost</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(c), (e)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1,464</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1,242</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Restricted stock and private equity securities, carried at cost or at equity-method</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(e)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>719</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>735</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2,183</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1,977</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total selected financial assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>22,815</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>24,175</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;text-decoration:underline;">Selected financial liabilities measured at fair value on a recurring basis</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Derivative financial instruments in a liability position</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(f)</sup></span><span style="font-family:inherit;font-size:9pt;">:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Interest rate swaps</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>154</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>148</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Foreign currency swaps</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>710</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1,374</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Foreign currency forward-exchange contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>309</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>143</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1,173</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1,665</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;text-decoration:underline;">Other selected financial liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Short-term borrowings:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Principal amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>9,460</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>10,674</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net fair value adjustments related to hedging and purchase accounting</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>24</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net unamortized discounts, premiums and debt issuance costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(15</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(11</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:30px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total short-term borrowings, carried at historical proceeds, as adjusted</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(e)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>9,448</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>10,688</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Long-term debt:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Principal amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>33,671</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>30,529</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net fair value adjustments related to hedging and purchase accounting</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>981</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>998</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net unamortized discounts, premiums and debt issuance costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(149</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(130</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:30px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total long-term debt, carried at historical proceeds, as adjusted</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(g)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>34,503</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>31,398</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>43,951</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>42,085</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total selected financial liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>45,124</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>43,750</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">We use a market approach in valuing financial instruments on a recurring basis. All of our financial assets and liabilities measured at fair value on a recurring basis use Level 2 inputs in the calculation of fair value, except </span><span style="font-family:inherit;font-size:8.5pt;"><span>5%</span></span><span style="font-family:inherit;font-size:8.5pt;"> that use Level 1 inputs.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">As of </span><span style="font-family:inherit;font-size:8.5pt;">October&#160;1, 2017</span><span style="font-family:inherit;font-size:8.5pt;">, trading funds and securities are composed of </span><span style="font-family:inherit;font-size:8.5pt;"><span>$274 million</span></span><span style="font-family:inherit;font-size:8.5pt;"> of trading equity funds and </span><span style="font-family:inherit;font-size:8.5pt;"><span>$74 million</span></span><span style="font-family:inherit;font-size:8.5pt;"> of trading debt funds. As of </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">December&#160;31, 2016</span><span style="font-family:inherit;font-size:8.5pt;">, trading funds and securities are composed of </span><span style="font-family:inherit;font-size:8.5pt;"><span>$236 million</span></span><span style="font-family:inherit;font-size:8.5pt;"> of trading equity funds and </span><span style="font-family:inherit;font-size:8.5pt;"><span>$89 million</span></span><span style="font-family:inherit;font-size:8.5pt;"> of trading debt funds. As of </span><span style="font-family:inherit;font-size:8.5pt;">October&#160;1, 2017</span><span style="font-family:inherit;font-size:8.5pt;"> and </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">December&#160;31, 2016</span><span style="font-family:inherit;font-size:8.5pt;">, trading equity funds of </span><span style="font-family:inherit;font-size:8.5pt;"><span>$63 million</span></span><span style="font-family:inherit;font-size:8.5pt;"> and </span><span style="font-family:inherit;font-size:8.5pt;"><span>$71 million</span></span><span style="font-family:inherit;font-size:8.5pt;">, respectively, are held in trust for benefits attributable to the former Pharmacia Savings Plus Plan.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(c)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Gross unrealized gains and losses are not significant, except as of </span><span style="font-family:inherit;font-size:8.5pt;">October&#160;1, 2017</span><span style="font-family:inherit;font-size:8.5pt;">, available-for-sale equity securities&#8217; unrealized gains are </span><span style="font-family:inherit;font-size:8.5pt;"><span>$406 million</span></span><span style="font-family:inherit;font-size:8.5pt;"> and unrealized losses are </span><span style="font-family:inherit;font-size:8.5pt;"><span>$119 million</span></span><span style="font-family:inherit;font-size:8.5pt;">.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(d)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Designated as hedging instruments, except for certain contracts used as offsets; namely, foreign currency forward-exchange contracts with fair values of </span><span style="font-family:inherit;font-size:8.5pt;"><span>$40 million</span></span><span style="font-family:inherit;font-size:8.5pt;"> as of </span><span style="font-family:inherit;font-size:8.5pt;">October&#160;1, 2017</span><span style="font-family:inherit;font-size:8.5pt;">; and foreign currency forward-exchange contracts with fair values of </span><span style="font-family:inherit;font-size:8.5pt;"><span>$162 million</span></span><span style="font-family:inherit;font-size:8.5pt;"> as of </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">December&#160;31, 2016</span><span style="font-family:inherit;font-size:8.5pt;">.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(e)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">The differences between the estimated fair values and carrying values of held-to-maturity debt securities, restricted stock and private equity securities at cost, and short-term borrowings not measured at fair value on a recurring basis were not significant as of </span><span style="font-family:inherit;font-size:8.5pt;">October&#160;1, 2017</span><span style="font-family:inherit;font-size:8.5pt;"> or </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">December&#160;31, 2016</span><span style="font-family:inherit;font-size:8.5pt;">. The fair value measurements of our held-to-maturity debt securities and our short-term borrowings are based on Level 2 inputs, using a market approach. The fair value measurements of our </span><span style="font-family:inherit;font-size:8.5pt;background-color:#ffffff;">priv</span><span style="font-family:inherit;font-size:8.5pt;">ate equity securities carried at cost are based on Level 3 inputs.</span></div></td></tr></table><div style="line-height:120%;padding-left:4px;text-align:left;padding-left:12px;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(f)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Designated as hedging instruments, except for certain contracts used as offsets; namely, foreign currency forward-exchange contracts with fair values of </span><span style="font-family:inherit;font-size:8.5pt;"><span>$60 million</span></span><span style="font-family:inherit;font-size:8.5pt;"> as of </span><span style="font-family:inherit;font-size:8.5pt;">October&#160;1, 2017</span><span style="font-family:inherit;font-size:8.5pt;">; and foreign currency swaps with fair values of </span><span style="font-family:inherit;font-size:8.5pt;"><span>$269 million</span></span><span style="font-family:inherit;font-size:8.5pt;"> and foreign currency forward-exchange contracts with fair values of </span><span style="font-family:inherit;font-size:8.5pt;"><span>$113 million</span></span><span style="font-family:inherit;font-size:8.5pt;"> as of </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">December&#160;31, 2016</span><span style="font-family:inherit;font-size:8.5pt;">.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(g)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">The fair value of our long-term debt (not including the current portion of long-term debt) was </span><span style="font-family:inherit;font-size:8.5pt;"><span>$39.0 billion</span></span><span style="font-family:inherit;font-size:8.5pt;"> as of </span><span style="font-family:inherit;font-size:8.5pt;">October&#160;1, 2017</span><span style="font-family:inherit;font-size:8.5pt;"> and </span><span style="font-family:inherit;font-size:8.5pt;"><span>$34.9 billion</span></span><span style="font-family:inherit;font-size:8.5pt;"> as of </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">December&#160;31, 2016</span><span style="font-family:inherit;font-size:8.5pt;">. The fair value measurements for our long-term debt are based on Level 2 inputs, using a market approach. Long-term debt includes foreign currency long-term borrowings with fair values of </span><span style="font-family:inherit;font-size:8.5pt;"><span>$4.7 billion</span></span><span style="font-family:inherit;font-size:8.5pt;"> as of </span><span style="font-family:inherit;font-size:8.5pt;">October&#160;1, 2017</span><span style="font-family:inherit;font-size:8.5pt;">, which are used as hedging instruments.</span></div></td></tr></table><div style="line-height:120%;padding-left:4px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:72%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides the classification of these selected financial assets and liabilities in our condensed consolidated balance sheets:</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">October&#160;1, <br/>2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December&#160;31, <br/>2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>526</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>547</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Short-term investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,146</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15,255</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other current assets</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>288</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>567</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Long-term investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,311</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,116</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other noncurrent assets</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>543</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>689</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22,815</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24,175</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Short-term borrowings, including current portion of long-term debt</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,448</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,688</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other current liabilities</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>277</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>443</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Long-term debt</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34,503</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>31,398</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other noncurrent liabilities</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(d)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>896</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,222</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>45,124</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>43,750</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">As of </span><span style="font-family:inherit;font-size:9pt;">October&#160;1, 2017</span><span style="font-family:inherit;font-size:9pt;">, derivative instruments at fair value include interest rate swaps (</span><span style="font-family:inherit;font-size:9pt;"><span>$97 million</span></span><span style="font-family:inherit;font-size:9pt;">), foreign currency swaps (</span><span style="font-family:inherit;font-size:9pt;"><span>$86 million</span></span><span style="font-family:inherit;font-size:9pt;">) and foreign currency forward-exchange contracts (</span><span style="font-family:inherit;font-size:9pt;"><span>$105 million</span></span><span style="font-family:inherit;font-size:9pt;">) and, as of </span><span style="font-family:inherit;font-size:9pt;text-align:center;">December&#160;31, 2016</span><span style="font-family:inherit;font-size:9pt;">, include interest rate swaps (</span><span style="font-family:inherit;font-size:9pt;"><span>$26 million</span></span><span style="font-family:inherit;font-size:9pt;">), foreign currency swaps (</span><span style="font-family:inherit;font-size:9pt;"><span>$43 million</span></span><span style="font-family:inherit;font-size:9pt;">) and foreign currency forward-exchange contracts (</span><span style="font-family:inherit;font-size:9pt;"><span>$497 million</span></span><span style="font-family:inherit;font-size:9pt;">).</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">As of </span><span style="font-family:inherit;font-size:9pt;">October&#160;1, 2017</span><span style="font-family:inherit;font-size:9pt;">, derivative instruments at fair value include interest rate swaps (</span><span style="font-family:inherit;font-size:9pt;"><span>$532 million</span></span><span style="font-family:inherit;font-size:9pt;">), foreign currency swaps (</span><span style="font-family:inherit;font-size:9pt;"><span>$6 million</span></span><span style="font-family:inherit;font-size:9pt;">) and foreign currency forward-exchange contracts (</span><span style="font-family:inherit;font-size:9pt;"><span>$5 million</span></span><span style="font-family:inherit;font-size:9pt;">) and, as of </span><span style="font-family:inherit;font-size:9pt;text-align:center;">December&#160;31, 2016</span><span style="font-family:inherit;font-size:9pt;">, include interest rate swaps (</span><span style="font-family:inherit;font-size:9pt;"><span>$599 million</span></span><span style="font-family:inherit;font-size:9pt;">), foreign currency swaps (</span><span style="font-family:inherit;font-size:9pt;"><span>$36 million</span></span><span style="font-family:inherit;font-size:9pt;">) and foreign currency forward-exchange contracts (</span><span style="font-family:inherit;font-size:9pt;"><span>$54 million</span></span><span style="font-family:inherit;font-size:9pt;">).</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(c)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">As of </span><span style="font-family:inherit;font-size:9pt;">October&#160;1, 2017</span><span style="font-family:inherit;font-size:9pt;">, derivative instruments at fair value include foreign currency forward-exchange contracts (</span><span style="font-family:inherit;font-size:9pt;"><span>$276 million</span></span><span style="font-family:inherit;font-size:9pt;">) and interest rate swaps (</span><span style="font-family:inherit;font-size:9pt;"><span>$1 million</span></span><span style="font-family:inherit;font-size:9pt;">) and, as of </span><span style="font-family:inherit;font-size:9pt;text-align:center;">December&#160;31, 2016</span><span style="font-family:inherit;font-size:9pt;">, include interest rate swaps (</span><span style="font-family:inherit;font-size:9pt;"><span>$1 million</span></span><span style="font-family:inherit;font-size:9pt;">), foreign currency swaps (</span><span style="font-family:inherit;font-size:9pt;"><span>$300 million</span></span><span style="font-family:inherit;font-size:9pt;">) and foreign currency forward-exchange contracts (</span><span style="font-family:inherit;font-size:9pt;"><span>$143 million</span></span><span style="font-family:inherit;font-size:9pt;">).</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(d)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">As of </span><span style="font-family:inherit;font-size:9pt;">October&#160;1, 2017</span><span style="font-family:inherit;font-size:9pt;">, derivative instruments at fair value include interest rate swaps (</span><span style="font-family:inherit;font-size:9pt;"><span>$153 million</span></span><span style="font-family:inherit;font-size:9pt;">), foreign currency swaps (</span><span style="font-family:inherit;font-size:9pt;"><span>$710 million</span></span><span style="font-family:inherit;font-size:9pt;">) and foreign currency forward-exchange contracts (</span><span style="font-family:inherit;font-size:9pt;"><span>$33 million</span></span><span style="font-family:inherit;font-size:9pt;">) and, as of </span><span style="font-family:inherit;font-size:9pt;text-align:center;">December&#160;31, 2016</span><span style="font-family:inherit;font-size:9pt;">, include interest rate swaps (</span><span style="font-family:inherit;font-size:9pt;"><span>$147 million</span></span><span style="font-family:inherit;font-size:9pt;">) and foreign currency swaps (</span><span style="font-family:inherit;font-size:9pt;"><span>$1.1 billion</span></span><span style="font-family:inherit;font-size:9pt;">).</span></div></td></tr></table><div style="line-height:120%;padding-left:4px;text-align:left;font-size:5pt;"><span style="font-family:inherit;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">There were no significant impairments of financial assets recognized in any period presented.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">B. Investments in Debt Securities</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.41520467836257%;border-collapse:collapse;text-align:left;"><tr><td colspan="21"/></tr><tr><td style="width:47%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td colspan="21" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides the contractual maturities, or as necessary, the estimated maturities, of the available-for-sale and held-to-maturity debt securities:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Years</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">October&#160;1, <br/>2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Within 1</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Over 1</span></div><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">to 5</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Over 5</span></div><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">to 10</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Over 10</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">Available-for-sale debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Corporate debt</span><span style="font-family:inherit;font-size:9.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>2,741</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>2,591</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>1,525</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>17</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>6,874</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Western European, Asian, and other government debt</span><span style="font-family:inherit;font-size:9.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>6,071</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>268</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>6,339</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Western European, Scandinavian and other government agency debt</span><span style="font-family:inherit;font-size:9.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>1,955</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>42</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>1,998</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Supranational debt</span><span style="font-family:inherit;font-size:9.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>387</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>195</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>582</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Government National Mortgage Association and other U.S. government guaranteed asset-backed securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>42</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>424</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>466</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Other asset-backed debt</span><span style="font-family:inherit;font-size:9.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>161</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>61</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>226</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">U.S. government debt</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>112</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>112</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">Held-to-maturity debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Time deposits and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>1,133</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>1,137</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Western European government debt</span><span style="font-family:inherit;font-size:9.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>326</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>326</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Total debt securities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>12,818</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>3,694</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>1,532</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>18</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>18,061</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Issued by a diverse group of corporations, with a significant concentration in the technology sector, virtually all of which are investment-grade.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Issued by governments, government agencies or supranational entities, as applicable, all of which are high quality.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(c)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Includes receivable-backed, loan-backed, and mortgage-backed securities, all of which are high quality and in senior positions in the capital structure of the security. Receivable-backed securities are collateralized by credit cards receivables, loan-backed securities are collateralized by senior secured obligations of a diverse pool of companies or student loans, and mortgage-backed securities are collateralized by diversified pools of residential and commercial mortgages.</span></div></td></tr></table><div style="line-height:120%;padding-left:4px;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">C. Short-Term Borrowings</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Short-term borrowings include amounts for commercial paper of </span><span style="font-family:inherit;font-size:10pt;"><span>$6.1 billion</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">October&#160;1, 2017</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$5.8 billion</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">December&#160;31, 2016</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">D. Long-Term Debt</span></div><div style="line-height:120%;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"/></tr><tr><td style="width:58%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides the amounts of senior unsecured long-term debt issued in the first quarter of 2017:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Principal</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">As of October&#160;1, 2017</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Maturity Date</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Euro</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">U.S. Dollar</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">3-month EURIBOR + 0.20% floating rate notes (0% floor)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">March&#160;6, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8364;</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1,250</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1,479</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">0.00% euro notes</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">March&#160;6, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1,183</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">0.25% euro notes</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">March&#160;6, 2022</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1,183</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1.00% euro notes</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">March&#160;6, 2027</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>750</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>887</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total euro long-term debt issued in the first quarter of 2017</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8364;</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>4,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>4,732</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">4.20% notes</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">March 17, 2047</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1,065</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total long-term debt issued in the first quarter of 2017</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(d)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>5,797</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Redeemable at any time, in whole, or in part, at our option prior to 30 to 90 days of maturity date at the comparable German government bond rate, plus </span><span style="font-family:inherit;font-size:8.5pt;"><span>0.15%</span></span><span style="font-family:inherit;font-size:8.5pt;">; plus, in each case, accrued and unpaid interest. The fixed rate euro notes are also redeemable at our option, in whole, or in part, within 30 to 90 days of maturity date.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">The weighted-average effective interest rate for the euro notes at issuance was </span><span style="font-family:inherit;font-size:8.5pt;"><span>0.23%</span></span><span style="font-family:inherit;font-size:8.5pt;">.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(c)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">The notes, issued in U.S. dollars in Taiwan, are redeemable, at our option, in whole but not in part, on each March 17 on or after March 17, 2020.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(d)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">The aggregate amount at issuance date was </span><span style="font-family:inherit;font-size:8.5pt;"><span>$5,279 million</span></span><span style="font-family:inherit;font-size:8.5pt;">. The increase in the amount since the date of issuance is due to foreign currency exchange.</span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"/></tr><tr><td style="width:28%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td colspan="25" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides the maturity schedule of our </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Long-term debt</span><span style="font-family:inherit;font-size:10pt;">&#160;outstanding as of October 1, 2017:</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">After 2021</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Maturities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>481</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,825</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,534</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,502</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23,162</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34,503</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">E. Other Noncurrent Liabilities</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In August 2017, the U.S. approved Besponsa (inotuzumab ozogamicin) and in June 2017, the EU approved Besponsa as monotherapy for the treatment of adults with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia. In connection with the U.S. approval, we incurred an obligation to make guaranteed fixed annual payments over a nine-year period aggregating </span><span style="font-family:inherit;font-size:10pt;"><span>$296 million</span></span><span style="font-family:inherit;font-size:10pt;"> related to a research and development arrangement. As a result, we have recorded the estimated net present value of </span><span style="font-family:inherit;font-size:10pt;"><span>$248 million</span></span><span style="font-family:inherit;font-size:10pt;"> as an intangible asset in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Developed technology rights</span><span style="font-family:inherit;font-size:10pt;">, and we have recorded </span><span style="font-family:inherit;font-size:10pt;"><span>$233 million</span></span><span style="font-family:inherit;font-size:10pt;"> in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other noncurrent liabilities </span><span style="font-family:inherit;font-size:10pt;">and </span><span style="font-family:inherit;font-size:10pt;"><span>$15 million</span></span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span><span style="font-family:inherit;font-size:10pt;">in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other current liabilities</span><span style="font-family:inherit;font-size:10pt;"> as of October 1, 2017. In connection with the EU approval, we incurred an obligation to make guaranteed fixed annual payments over a nine-year period aggregating </span><span style="font-family:inherit;font-size:10pt;"><span>$148 million</span></span><span style="font-family:inherit;font-size:10pt;"> related to a research and development arrangement. As a result, we recorded the estimated net present value of </span><span style="font-family:inherit;font-size:10pt;"><span>$123 million</span></span><span style="font-family:inherit;font-size:10pt;"> as an intangible asset in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Developed technology rights</span><span style="font-family:inherit;font-size:10pt;">, and we have recorded </span><span style="font-family:inherit;font-size:10pt;"><span>$117 million</span></span><span style="font-family:inherit;font-size:10pt;"> in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other noncurrent liabilities </span><span style="font-family:inherit;font-size:10pt;">and</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span><span style="font-family:inherit;font-size:10pt;"><span>$6 million</span></span><span style="font-family:inherit;font-size:10pt;"> in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other current liabilities</span><span style="font-family:inherit;font-size:10pt;"> as of October 1, 2017.&#160;</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">F. </span><span style="font-weight:bold;text-decoration:underline;">Derivative Financial Instruments and Hedging Activities</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"> </span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Foreign Exchange Risk</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">October&#160;1, 2017</span><span style="font-family:inherit;font-size:10pt;">, the aggregate notional amount of foreign exchange derivative financial instruments hedging or offsetting foreign currency exposures was </span><span style="font-family:inherit;font-size:10pt;"><span>$31.5 billion</span></span><span style="font-family:inherit;font-size:10pt;">. The derivative financial instruments primarily hedge or offset exposures in the euro, Japanese yen and U.K. pound. The maximum length of time over which we are hedging future foreign exchange cash flow relates to our </span><span style="font-family:inherit;font-size:10pt;"><span>$2.0 billion</span></span><span style="font-family:inherit;font-size:10pt;"> U.K. pound debt maturing in 2038.</span></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We designate foreign currency forward-exchange contracts as cash flow hedges of a portion of our forecasted euro, Japanese yen, U.K. pound, Canadian dollar, and Australian dollar-denominated intercompany inventory sales expected to occur no more than two years from the date of each hedge. As of </span><span style="font-family:inherit;font-size:10pt;">October&#160;1, 2017</span><span style="font-family:inherit;font-size:10pt;">, the notional amount of outstanding foreign currency forward-exchange contracts hedging our intercompany forecasted sales was </span><span style="font-family:inherit;font-size:10pt;"><span>$3.9 billion</span></span><span style="font-family:inherit;font-size:10pt;">, with a pre-tax loss of </span><span style="font-family:inherit;font-size:10pt;"><span>$97 million</span></span><span style="font-family:inherit;font-size:10pt;"> deferred in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Accumulated other comprehensive loss. </span><span style="font-family:inherit;font-size:10pt;">Based on quarter-end foreign exchange rates that are subject to change, we expect to reclassify a pre-tax loss of </span><span style="font-family:inherit;font-size:10pt;"><span>$63 million</span></span><span style="font-family:inherit;font-size:10pt;"> within the next 12 months into </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Cost of sales. </span><span style="font-family:inherit;font-size:10pt;">We recognized a </span><span style="font-family:inherit;font-size:10pt;"><span>$4 million</span></span><span style="font-family:inherit;font-size:10pt;"> loss in the </span><span style="font-family:inherit;font-size:10pt;">third quarter</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;"> and a </span><span style="font-family:inherit;font-size:10pt;"><span>$67 million</span></span><span style="font-family:inherit;font-size:10pt;"> gain in the </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;"> as an offset to </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Cost of sales</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Interest Rate Risk</span></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">October&#160;1, 2017</span><span style="font-family:inherit;font-size:10pt;">, the aggregate notional amount of interest rate derivative financial instruments designated as fair value hedges was </span><span style="font-family:inherit;font-size:10pt;"><span>$12.4 billion</span></span><span style="font-family:inherit;font-size:10pt;">. The derivative financial instruments primarily hedge U.S. dollar fixed-rate debt.</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"/></tr><tr><td style="width:28%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td colspan="25" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides information about the gains/(losses) incurred to hedge or offset operational foreign exchange or interest rate risk:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Three Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Amount of</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Gains/(Losses)</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Recognized in OID</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a), (b), (c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Amount of</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Gains/(Losses)</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Recognized in OCI</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(Effective Portion)</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a), (d)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Amount of</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Gains/(Losses)</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Reclassified from</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">OCI into OID and COS</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(Effective Portion)</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a), (d)</sup></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">October&#160;1, <br/>2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">October&#160;2, <br/>2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">October&#160;1, <br/>2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">October&#160;2, <br/>2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">October&#160;1, <br/>2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">October&#160;2, <br/>2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Derivative Financial Instruments in Cash Flow Hedge Relationships:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Foreign currency swaps</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>218</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>87</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>148</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(39</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Foreign currency forward-exchange contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(269</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(212</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(204</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(111</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Derivative Financial Instruments in Net Investment Hedge Relationships:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Foreign currency forward-exchange contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Derivative Financial Instruments Not Designated as Hedges:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Foreign currency forward-exchange contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>33</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>20</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Foreign currency swaps</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Non-Derivative Financial Instruments in Net Investment Hedge Relationships:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Foreign currency long-term debt</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(166</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">All other net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>34</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>18</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(216</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(126</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(55</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(150</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Nine Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Amount of</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Gains/(Losses)</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Recognized in OID</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a), (b), (c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Amount of</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Gains/(Losses)</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Recognized in OCI</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(Effective Portion)</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a), (d)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Amount of</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Gains/(Losses)</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Reclassified from</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">OCI into OID and COS</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(Effective Portion)</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a), (d)</sup></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">October&#160;1, <br/>2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">October&#160;2, <br/>2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">October&#160;1, <br/>2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">October&#160;2, <br/>2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">October&#160;1, <br/>2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">October&#160;2, <br/>2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Derivative Financial Instruments in Cash Flow Hedge Relationships:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Foreign currency swaps</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>455</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(204</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>419</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(165</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Foreign currency forward-exchange contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(604</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(770</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(26</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(118</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Derivative Financial Instruments in Net Investment Hedge Relationships:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Foreign currency forward-exchange contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(15</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Derivative Financial Instruments Not Designated as Hedges:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Foreign currency forward-exchange contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(111</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(49</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Foreign currency swaps</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Non-Derivative Financial Instruments in Net Investment Hedge Relationships:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Foreign currency short-term borrowings</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(26</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Foreign currency long-term debt</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(518</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">All other net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(117</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(56</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(666</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(1,014</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>394</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(283</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">OID = Other (income)/deductions&#8212;net, included in </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Other (income)/deductions&#8212;net</span><span style="font-family:inherit;font-size:9pt;"> in the condensed consolidated statements of income. COS = Cost of sales, included in </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Cost of sales</span><span style="font-family:inherit;font-size:9pt;"> in the condensed consolidated statements of income.</span></div></td></tr></table><div style="line-height:120%;padding-left:12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">OCI = Other comprehensive income/(loss), included in the</span><span style="font-family:inherit;font-size:9pt;font-style:italic;"> </span><span style="font-family:inherit;font-size:9pt;">condensed consolidated statements of comprehensive income</span><span style="font-family:inherit;font-size:9pt;font-style:italic;">.</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Includes gains and losses attributable to derivative instruments designated and qualifying as fair value hedges (primarily interest rate swaps), as well as the offsetting gains and losses attributable to the hedged items in such hedging relationships.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(c)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">There was no significant ineffectiveness for any period presented.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(d)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">For derivative financial instruments in cash flow hedge relationships, the effective portion is included in </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Other comprehensive income&#8211;&#8211;Unrealized holding losses on derivative financial instruments, net</span><span style="font-family:inherit;font-size:9pt;">. For derivative financial instruments in net investment hedge relationships and for foreign currency debt designated as hedging instruments, the effective portion is included in </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Other comprehensive income&#8211;&#8211;Foreign currency translation adjustments, net.</span></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:5pt;"><span style="font-family:inherit;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For information about the fair value of our derivative financial instruments, and the impact on our condensed consolidated balance sheets, see </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 7A</span><span style="font-family:inherit;font-size:10pt;"> above</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">.</span><span style="font-family:inherit;font-size:10pt;"> Certain of our derivative instruments are covered by associated credit-support agreements that have credit-risk-related contingent features designed to reduce our counterparties&#8217; exposure to our risk of defaulting on amounts owed. As of </span><span style="font-family:inherit;font-size:10pt;">October&#160;1, 2017</span><span style="font-family:inherit;font-size:10pt;">, the aggregate fair value of these derivative instruments that are in a net liability position was </span><span style="font-family:inherit;font-size:10pt;"><span>$491 million</span></span><span style="font-family:inherit;font-size:10pt;">, for which we have posted collateral of </span><span style="font-family:inherit;font-size:10pt;"><span>$505 million</span></span><span style="font-family:inherit;font-size:10pt;"> in the normal course of business. If there had been a ratings downgrade, we would not have been required to post any additional collateral to our counterparties</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">.</span></div><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">G. Credit Risk</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On an ongoing basis, we review the creditworthiness of counterparties to our foreign exchange and interest rate agreements and do not expect to incur a significant loss from failure of any counterparties to perform under the agreements. There are no significant concentrations of credit risk related to our financial instruments with any individual counterparty, except for certain significant customers. As of </span><span style="font-family:inherit;font-size:10pt;">October&#160;1, 2017</span><span style="font-family:inherit;font-size:10pt;">, we had </span><span style="font-family:inherit;font-size:10pt;"><span>$946 million</span></span><span style="font-family:inherit;font-size:10pt;"> due from a well-diversified, high quality group of technology companies around the world. For details about our investments, see </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 7B </span><span style="font-family:inherit;font-size:10pt;">above.</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><br/></span></div><span style="font-family:inherit;font-size:10pt;">In general, there is no requirement for collateral from customers. However, derivative financial instruments are executed under credit-support agreements that provide for the ability to request collateral payments depending on levels of exposure, our credit rating and the credit rating of the counterparty. As of </span><span style="font-family:inherit;font-size:10pt;">October&#160;1, 2017</span><span style="font-family:inherit;font-size:10pt;">, we received cash collateral of </span><span style="font-family:inherit;font-size:10pt;"><span>$232 million</span></span><span style="font-family:inherit;font-size:10pt;"> from various counterparties. The collateral primarily supports the approximate fair value of our derivative contracts. With respect to the collateral received, the obligations are reported in </span>Short-term borrowings, including current portion of long-term debt.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_FinancialInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financial Instruments [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_FinancialInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6919166160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 01, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventories</a></td>
<td class="text"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Inventories</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"> </span><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides the components of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Inventories</span><span style="font-family:inherit;font-size:10pt;">:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">October&#160;1, <br/>2017</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December&#160;31, <br/>2016</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finished goods</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,977</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,293</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Work-in-process</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,070</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,696</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Raw materials and supplies</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>879</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>793</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Inventories</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,925</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,783</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Noncurrent inventories not included above</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(b)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>669</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>683</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">The change from </span><span style="font-family:inherit;font-size:9pt;text-align:center;">December&#160;31, 2016</span><span style="font-family:inherit;font-size:9pt;"> reflects the build of inventory primarily for and in advance of new or potential product launches and increases to meet targeted levels for certain products in the normal course of business, including those related to demand.</span></div></td></tr></table><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(b)</sup>&#160;</span></div><span style="font-family:inherit;font-size:9pt;">Included in </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Other noncurrent assets</span>. There are no recoverability issues associated with these amounts.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6923694432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Identifiable Intangible Assets and Goodwill<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 01, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Identifiable Intangible Assets and Goodwill</a></td>
<td class="text"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Identifiable Intangible Assets and Goodwill</span><div style="line-height:120%;text-align:left;font-size:5pt;"><span style="font-family:inherit;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">A. Identifiable Intangible Assets</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:inherit;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Balance Sheet Information</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"/></tr><tr><td style="width:28%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td colspan="25" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides the components of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Identifiable intangible assets</span><span style="font-family:inherit;font-size:10pt;">:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">October&#160;1, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Carrying</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amount</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accumulated</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Identifiable</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Intangible</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Assets, less</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accumulated</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Carrying</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amount</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accumulated</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Identifiable</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Intangible</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Assets, less</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accumulated</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Finite-lived intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Developed technology rights</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>89,585</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(53,960</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35,625</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>83,390</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(49,650</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>33,740</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Brands</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,135</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,127</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,008</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,092</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,032</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,060</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Licensing agreements and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,930</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,071</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>859</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,869</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,005</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>864</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>93,650</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(56,158</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>37,492</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>87,351</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(51,687</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35,664</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Indefinite-lived intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Brands and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,937</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,937</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,883</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,883</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">IPR&amp;D</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(a)</sup></span><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,292</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,292</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,101</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,101</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,229</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,229</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,984</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,984</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Identifiable intangible assets</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(b)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>105,879</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(56,158</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>49,721</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>104,335</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(51,687</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>52,648</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">The changes in the gross carrying amount of </span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Developed technology rights </span><span style="font-family:inherit;font-size:8.5pt;">and </span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">IPR&amp;D</span><span style="font-family:inherit;font-size:8.5pt;"> primarily reflect (i) the transfer of </span><span style="font-family:inherit;font-size:8.5pt;"><span>$4.8 billion</span></span><span style="font-family:inherit;font-size:8.5pt;"> from </span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">IPR&amp;D</span><span style="font-family:inherit;font-size:8.5pt;"> to </span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Developed technology rights</span><span style="font-family:inherit;font-size:8.5pt;"> to reflect the approval of Eucrisa, (ii) the </span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Developed technology rights</span><span style="font-family:inherit;font-size:8.5pt;"> and </span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">IPR&amp;D</span><span style="font-family:inherit;font-size:8.5pt;"> acquired as part of the acquisition of AstraZeneca&#8217;s small molecule anti-infectives business (see </span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Note 2A</span><span style="font-family:inherit;font-size:8.5pt;">), (iii) the </span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Developed technology rights</span><span style="font-family:inherit;font-size:8.5pt;"> of </span><span style="font-family:inherit;font-size:8.5pt;"><span>$371 million</span></span><span style="font-family:inherit;font-size:8.5pt;"> recorded in connection with the EU and U.S. approvals of Besponsa (see </span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Note 7E</span><span style="font-family:inherit;font-size:8.5pt;">), partially offset by (iv) measurement period adjustments related to Medivation (see </span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Note 2A</span><span style="font-family:inherit;font-size:8.5pt;">) and (v) impairments of </span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Developed technology rights</span><span style="font-family:inherit;font-size:8.5pt;"> (see </span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Note 4)</span><span style="font-family:inherit;font-size:8.5pt;">.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">The decrease in </span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">I</span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;text-align:right;">dentifiable intangible assets, less accumulated amortization</span><span style="font-family:inherit;font-size:8.5pt;text-align:right;">, </span><span style="font-family:inherit;font-size:8.5pt;">is primarily due to amortization, measurement period adjustments related to Medivation (see </span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Note 2A</span><span style="font-family:inherit;font-size:8.5pt;">), as well as impairments of </span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Developed technology rights</span><span style="font-family:inherit;font-size:8.5pt;"> (see </span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Note 4)</span><span style="font-family:inherit;font-size:8.5pt;">, partially offset by assets acquired as part of the acquisition of AstraZeneca&#8217;s small molecule anti-infectives business (see </span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Note 2A</span><span style="font-family:inherit;font-size:8.5pt;">) and the assets recorded in connection with the EU and U.S. approvals of Besponsa (see </span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Note 7E</span><span style="font-family:inherit;font-size:8.5pt;">).</span></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"/></tr><tr><td style="width:55%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our identifiable intangible assets are associated with the following, as a percentage of total identifiable intangible assets, less accumulated amortization:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">October&#160;1, 2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">IH</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">EH</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">WRD</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Developed technology rights</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>68</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>32</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Brands, finite-lived</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>75</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Brands, indefinite-lived</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>71</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>29</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">IPR&amp;D </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>80</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:5pt;"><span style="font-family:inherit;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Amortization</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:inherit;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total amortization expense for finite-lived intangible assets was </span><span style="font-family:inherit;font-size:10pt;"><span>$1.2 billion</span></span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">third</span><span style="font-family:inherit;font-size:10pt;"> quarter of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$988 million</span></span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">third</span><span style="font-family:inherit;font-size:10pt;"> quarter of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;"><span>$3.6 billion</span></span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$3.0 billion</span></span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">B. Goodwill</span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:55%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides the components of and changes in the carrying amount of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Goodwill</span><span style="font-family:inherit;font-size:10pt;">:</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">IH</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">EH</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance, December&#160;31, 2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30,134</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24,315</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>54,449</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Additions</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>572</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>92</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>664</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>491</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>475</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>966</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance, October&#160;1, 2017</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>31,197</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24,882</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>56,078</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">IH additions primarily represent measurement period adjustments related to our Medivation acquisition, and EH additions relate to our acquisition of AstraZeneca&#8217;s small molecule anti-infectives business, which are subject to change until we complete the valuation of assets acquired and liabilities assumed (see </span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Note 2A</span><span style="font-family:inherit;font-size:8.5pt;">).</span></div></td></tr></table><div style="line-height:120%;font-size:8.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(b)</sup>&#160;</span></div>Primarily reflects the impact of foreign exchange and an adjustment of our estimate of goodwill associated with the HIS net assets sold.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final.  May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6923805824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pension and Postretirement Benefit Plans<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 01, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Pension and Postretirement Benefit Plans</a></td>
<td class="text"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Pension and Postretirement Benefit Plans</span><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="33"/></tr><tr><td style="width:27%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/></tr><tr><td colspan="33" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides the components of net periodic benefit cost/(income):</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="31" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Three Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Arial;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Pension Plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Arial;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">U.S.</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Qualified</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">U.S.</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Supplemental</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(Non-Qualified)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">International</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Postretirement</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Plans</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Oct&#160;1, 2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Oct&#160;2, 2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Oct&#160;1, 2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Oct&#160;2, 2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Oct&#160;1, 2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Oct&#160;2, 2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Oct&#160;1, 2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Oct&#160;2, 2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net periodic benefit cost/(credit):</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Service cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>67</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>69</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>44</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>41</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Interest cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>157</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>218</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>18</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>52</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>58</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>23</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>33</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Expected return on plan assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(248</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(239</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(87</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(95</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Amortization of:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Actuarial losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>91</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>99</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>29</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>23</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Prior service costs (credits)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(45</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(45</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Curtailments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Settlements</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>30</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>21</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>99</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>170</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>39</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>39</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>35</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>27</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(17</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="31" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Nine Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Arial;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Pension Plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Arial;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">U.S.</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Qualified</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">U.S.</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Supplemental</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(Non-Qualified)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">International</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Postretirement</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Plans</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Oct&#160;1, 2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Oct&#160;2, 2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Oct&#160;1, 2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Oct&#160;2, 2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Oct&#160;1, 2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Oct&#160;2, 2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Oct&#160;1, 2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Oct&#160;2, 2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net periodic benefit cost/(credit):</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Service cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>202</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>193</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>18</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>14</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>127</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>126</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>32</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>31</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Interest cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>478</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>486</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>41</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>40</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>152</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>178</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>68</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>77</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Expected return on plan assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(759</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(721</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(256</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(291</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(27</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(25</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Amortization of:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Actuarial losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>302</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>297</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>37</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>27</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>86</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>70</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>23</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>23</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Prior service costs (credits)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(137</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(127</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Curtailments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(15</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(14</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Settlements</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>54</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>52</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>32</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>23</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>292</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>316</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>127</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>105</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>106</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>81</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(57</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(36</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">In April 2017, we settled the remaining obligation associated with the Hospira U.S. qualified defined benefit pension plan. We purchased a group annuity contract on behalf of the remaining plan participants with a third-party insurance provider. As a result, we were relieved of the </span><span style="font-family:inherit;font-size:8.5pt;"><span>$156 million</span></span><span style="font-family:inherit;font-size:8.5pt;"> net pension benefit obligation and recorded a pretax settlement gain of </span><span style="font-family:inherit;font-size:8.5pt;"><span>$41 million</span></span><span style="font-family:inherit;font-size:8.5pt;">, partially offset by the recognition of actuarial losses and prior service costs upon plan settlement of approximately </span><span style="font-family:inherit;font-size:8.5pt;"><span>$30 million</span></span><span style="font-family:inherit;font-size:8.5pt;"> in</span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;"> Restructuring charges and certain acquisition-related costs</span><span style="font-family:inherit;font-size:8.5pt;"> during the second quarter of 2017 (see </span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Note 3</span><span style="font-family:inherit;font-size:8.5pt;">).</span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of and for the </span><span style="font-family:inherit;font-size:10pt;">nine months</span><span style="font-family:inherit;font-size:10pt;"> ended </span><span style="font-family:inherit;font-size:10pt;">October&#160;1, 2017</span><span style="font-family:inherit;font-size:10pt;">, we contributed and expect to contribute in 2017 from our general assets as follows: </span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.41520467836257%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:47%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Pension Plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">U.S. Qualified</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">U.S. Supplemental (Non-Qualified)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">International</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Postretirement Plans</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Contributions from our general assets for the nine months ended October 1, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1,095</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>121</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>134</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>158</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Expected contributions from our general assets during 2017</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1,095</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>146</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>170</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>204</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:8.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup>&#160;</span></div><span style="font-family:inherit;font-size:8.5pt;">Contributions expected to be made for </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:8.5pt;"> are inclusive of amounts contributed during the </span><span style="font-family:inherit;font-size:8.5pt;">nine months ended October 1, 2017</span><span style="font-family:inherit;font-size:8.5pt;">, including the </span><span style="font-family:inherit;font-size:8.5pt;"><span>$1.0 billion</span></span> voluntary contribution that was made in January 2017 for the U.S. qualified plans, which was considered pre-funding for future anticipated mandatory contributions and is also expected to reduce Pension Benefit Guaranty Corporation variable rate premiums. The U.S. supplemental (non-qualified) pension plan, international pension plan and the postretirement plan contributions from our general assets include direct employer benefit payments.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for pension and other postretirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6917880032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Common Share Attributable to Common Shareholders<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 01, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings Per Common Share Attributable to Common Shareholders</a></td>
<td class="text"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Earnings Per Common Share Attributable to Common Shareholders</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"> </span><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.22027290448344%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:52%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td colspan="17" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides the detailed calculation of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Earnings per common share (EPS)</span><span style="font-family:inherit;font-size:10pt;">:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nine Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(IN MILLIONS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">October&#160;1, <br/>2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">October&#160;2, <br/>2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">October&#160;1, <br/>2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">October&#160;2, <br/>2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">EPS Numerator&#8211;&#8211;Basic</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income from continuing operations</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,858</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,355</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,064</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,465</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: Net income attributable to noncontrolling interests</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>32</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income from continuing operations attributable to Pfizer Inc.</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,840</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,355</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,032</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,440</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: Preferred stock dividends&#8211;&#8211;net of tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income from continuing operations attributable to Pfizer Inc. common shareholders</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,839</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,355</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,032</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,439</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Discontinued operations&#8211;&#8211;net of tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income attributable to Pfizer Inc. common shareholders</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,839</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,355</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,033</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,439</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">EPS Numerator&#8211;&#8211;Diluted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income from continuing operations attributable to Pfizer Inc. common shareholders and assumed conversions</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,840</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,355</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,032</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,440</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Discontinued operations&#8211;&#8211;net of tax, attributable to Pfizer Inc. common shareholders and assumed conversions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income attributable to Pfizer Inc. common shareholders and assumed conversions</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,840</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,355</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,034</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,440</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">EPS Denominator</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted-average number of common shares outstanding&#8211;&#8211;Basic</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,951</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,066</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,972</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,095</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Common-share equivalents: stock options, stock issuable under employee compensation plans, convertible preferred stock and accelerated share repurchase agreements</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>89</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>84</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>85</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>80</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted-average number of common shares outstanding&#8211;&#8211;Diluted</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,041</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,150</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,057</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,175</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock options that had exercise prices greater than the average market price of our common stock issuable under employee compensation plans</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a),</sup></span><span style="font-family:inherit;font-size:9pt;">&#160;</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(b)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>47</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>38</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>47</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>60</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Amounts for the </span><span style="font-family:inherit;font-size:8.5pt;">third quarter</span><span style="font-family:inherit;font-size:8.5pt;"> and first </span><span style="font-family:inherit;font-size:8.5pt;">nine months</span><span style="font-family:inherit;font-size:8.5pt;"> ended </span><span style="font-family:inherit;font-size:8.5pt;">October&#160;2, 2016</span><span style="font-family:inherit;font-size:8.5pt;"> have been revised from previously reported amounts to reflect the adoption of a new accounting standard in the fourth quarter of </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:8.5pt;">, as of January 1, 2016, that requires, when applying the treasury stock method for shares that could be repurchased, that the assumed proceeds no longer include the amount of excess tax benefit (see </span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Note 1B</span><span style="font-family:inherit;font-size:8.5pt;">).</span></div></td></tr></table><div style="line-height:120%;font-size:8.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(b)</sup>&#160;</span></div>These common stock equivalents were outstanding for the periods presented, but were not included in the computation of diluted EPS for those periods because their inclusion would have had an anti-dilutive effect.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6919165008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 01, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Commitments and Contingencies</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"> </span><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We and certain of our subsidiaries are subject to numerous contingencies arising in the ordinary course of business. For a discussion of our tax contingencies, see </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 5B.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accelerated share repurchase agreement&#8211;&#8211;On February 2, 2017, we entered into an accelerated share repurchase agreement with Citibank to repurchase </span><span style="font-family:inherit;font-size:10pt;"><span>$5 billion</span></span><span style="font-family:inherit;font-size:10pt;"> of our common stock. Pursuant to the terms of the agreement, on February 6, 2017, we paid </span><span style="font-family:inherit;font-size:10pt;"><span>$5 billion</span></span><span style="font-family:inherit;font-size:10pt;"> to Citibank and received an initial delivery of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>126 million</span></span><span style="font-family:inherit;font-size:10pt;"> shares of our common stock from Citibank at a price of </span><span style="font-family:inherit;font-size:10pt;"><span>$31.73</span></span><span style="font-family:inherit;font-size:10pt;"> per share, which represented, based on the closing price of our common stock on the NYSE on February 2, 2017, approximately </span><span style="font-family:inherit;font-size:10pt;"><span>80%</span></span><span style="font-family:inherit;font-size:10pt;"> of the notional amount of the accelerated share repurchase agreement. On May 16, 2017, the accelerated share repurchase agreement with Citibank was completed, which, per the terms of the agreement, resulted in Citibank owing us a certain number of shares of Pfizer common stock. Pursuant to the agreement&#8217;s settlement terms, we received an additional </span><span style="font-family:inherit;font-size:10pt;"><span>24 million</span></span><span style="font-family:inherit;font-size:10pt;"> shares of our common stock from Citibank on May 19, 2017. The average price paid for all of the shares delivered under the accelerated share repurchase agreement was </span><span style="font-family:inherit;font-size:10pt;"><span>$33.31</span></span><span style="font-family:inherit;font-size:10pt;"> per share. The common stock received is included in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Treasury Stock</span><span style="font-family:inherit;font-size:10pt;">. This agreement was entered into pursuant to our previously announced share repurchase authorization. At </span><span style="font-family:inherit;font-size:10pt;">October&#160;1, 2017</span><span style="font-family:inherit;font-size:10pt;">, our remaining share-purchase authorization was approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$6.4 billion</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pending approval in the EU of Mylotarg&#8211;&#8211;Mylotarg was developed, in part, through a research arrangement with a third party. If Mylotarg is approved in the EU in 2018 for the treatment of acute myeloid leukemia, we will incur an obligation for additional fixed payments over a 10-year period aggregating </span><span style="font-family:inherit;font-size:10pt;"><span>$310 million</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">A. Legal Proceedings</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our non-tax contingencies include, but are not limited to, the following:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Patent litigation, which typically involves challenges to the coverage and/or validity of patents on various products, processes or dosage forms. We are the plaintiff in the vast majority of these actions. An adverse outcome in actions in which we are the plaintiff could result in loss of patent protection for a drug, a significant loss of revenues from that drug or impairment of the value of associated assets.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Product liability and other product-related litigation, which can include personal injury, consumer, off-label promotion, securities, antitrust and breach of contract claims, among others, often involves highly complex issues relating to medical causation, label warnings and reliance on those warnings, scientific evidence and findings, actual, provable injury and other matters.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Commercial and other matters, which can include merger-related and product-pricing claims and environmental claims and proceedings, can involve complexities that will vary from matter to matter.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Government investigations, which often are related to the extensive regulation of pharmaceutical companies by national, state and local government agencies in the U.S. and in other countries.&#160;</span></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certain of these contingencies could result in losses, including damages, fines and/or civil penalties, and/or criminal charges, which could be substantial.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We believe that our claims and defenses in these matters are substantial, but litigation is inherently unpredictable and excessive verdicts do occur. We do not believe that any of these matters will have a material adverse effect on our financial position. However, we could incur judgments, enter into settlements or revise our expectations regarding the outcome of certain matters, and such developments could have a material adverse effect on our results of operations in the period in which the amounts are accrued and/or our cash flows in the period in which the amounts are paid.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have accrued for losses that are both probable and reasonably estimable. Substantially all of our contingencies are subject to significant uncertainties and, therefore, determining the likelihood of a loss and/or the measurement of any loss can be complex. Consequently, we are unable to estimate the range of reasonably possible loss in excess of amounts accrued. Our assessments are based on estimates and assumptions that have been deemed reasonable by management, but the assessment process relies heavily on estimates and assumptions that may prove to be incomplete or inaccurate, and unanticipated events and circumstances may occur that might cause us to change those estimates and assumptions.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amounts recorded for legal and environmental contingencies can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The principal pending matters to which we are a party are discussed below. In determining whether a pending matter is a principal matter, we consider both quantitative and qualitative factors in order to assess materiality, such as, among other things, </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the amount of damages and the nature of any other relief sought in the proceeding, if such damages and other relief are specified; our view of the merits of the claims and of the strength of our defenses; whether the action purports to be, or is, a class action and, if not certified, our view of the likelihood that a class will be certified by the court; the jurisdiction in which the proceeding is pending; any experience that we or, to our knowledge, other companies have had in similar proceedings; whether disclosure of the action would be important to a reader of our financial statements, including whether disclosure might change a reader&#8217;s judgment about our financial statements in light of all of the information that is available to the reader; the potential impact of the proceeding on our reputation; and the extent of public interest in the matter. In addition, with respect to patent matters in which we are the plaintiff, we consider, among other things, the financial significance of the product protected by the patent. As a result of considering qualitative factors in our determination of principal matters, there are some matters discussed below with respect to which management believes that the likelihood of possible loss in excess of amounts accrued is remote.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">A1. Legal Proceedings&#8211;&#8211;Patent Litigation</span></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Like other pharmaceutical companies, we are involved in numerous suits relating to our patents, including but not limited to, those discussed below. Most of the suits involve claims by generic drug manufacturers that patents covering our products, processes or dosage forms are invalid and/or do not cover the product of the generic drug manufacturer. Also, counterclaims, as well as various independent actions, have been filed alleging that our assertions of, or attempts to enforce, patent rights with respect to certain products constitute unfair competition and/or violations of antitrust laws. In addition to the challenges to the U.S. patents on a number of our products that are discussed below, patent rights to certain of our products are being challenged in various other countries. We are also party to other patent damages suits in various jurisdictions pursuant to which generic drug manufacturers, payers, governments or other parties are seeking damages from us for alleged delay of generic entry. Additionally, our licensing and collaboration partners face challenges by generic drug manufacturers to patents covering several of their products that may impact our licenses or co-promotion rights to such products. We also are often involved in other proceedings, such as inter partes review, post-grant review, re-examination or opposition proceedings, before the U.S. Patent and Trademark Office, the European Patent Office, or other foreign counterparts relating to our intellectual property or the intellectual property rights of others. Also, if one of our patents is found to be invalid by such proceedings, generic or competitive products could be introduced into the market resulting in the erosion of sales of our existing products. For example, several of the patents in our pneumococcal vaccine portfolio have been challenged in inter partes review and post-grant review proceedings in the United States. The invalidation of these patents could potentially allow a competitor pneumococcal vaccine into the marketplace. We are also subject to patent litigation pursuant to which one or more third parties seeks damages and/or injunctive relief to compensate for alleged infringement of its patents by our commercial or other activities. For example, our subsidiary, Hospira, is involved in patent and patent-related disputes over its attempts to bring generic pharmaceutical and biosimilar products to market. If one of our marketed products is found to infringe valid patent rights of a third party, such third party may be awarded significant damages, or we may be prevented from further sales of that product. Such damages may be enhanced as much as three-fold in the event that we or one of our subsidiaries, like Hospira, is found to have willfully infringed valid patent rights of a third party.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Actions In Which We Are The Plaintiff</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Bosulif (bosutinib)</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In December 2016, Wyeth LLC, Wyeth Pharmaceuticals Inc., and PF Prism C.V. (collectively, Wyeth) brought a patent-infringement action against Alembic Pharmaceuticals, Ltd, Alembic Pharmaceuticals, Inc. (collectively, Alembic), Sun Pharmaceutical Industries, Inc., and Sun Pharmaceutical Industries Limited (collectively, Sun), in the U.S. District Court for the District of Delaware in connection with abbreviated new drug applications respectively filed with the FDA by Alembic and Sun, each seeking approval to market generic versions of bosutinib. Alembic is challenging patents, which expire in 2026, covering polymorphic forms of bosutinib and methods of treating chronic myelogenous leukemia. Sun is challenging the patent covering polymorphic forms of bosutinib that expires in 2026. In March 2017, Wyeth brought a patent-infringement action against MSN Laboratories Private Limited and MSN Pharmaceuticals, Inc. (collectively, MSN), in the U.S. District Court for the District of Delaware in connection with an abbreviated new drug application filed with the FDA by MSN, seeking approval to market a generic version of bosutinib, and challenging a patent expiring in 2026 covering polymorphic forms of bosutinib. In September 2017, the case against MSN was dismissed. Also, in September 2017, Wyeth brought an additional patent-infringement action against Sun in the U.S. District Court for the District of Delaware asserting the infringement and validity of </span><span style="font-family:inherit;font-size:10pt;"><span>two</span></span><span style="font-family:inherit;font-size:10pt;"> other patents challenged by Sun, which expire in 2025 and 2026 respectively, covering compositions of bosutinib and methods of treating chronic myelogenous leukemia. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">EpiPen</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In July 2010, King, which we acquired in 2011 and is a wholly-owned subsidiary, brought a patent-infringement action against Sandoz in the U.S. District Court for the District of New Jersey in connection with Sandoz&#8217;s abbreviated new drug application filed with the FDA seeking approval to market an epinephrine injectable product. Sandoz is challenging patents, which expire in 2025, covering the next-generation autoinjector for use with epinephrine that is sold under the EpiPen brand name.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Flector Patch (diclofenac)</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In October 2015, the owners (Teikoku Seiyaku Co., Ltd. and Altergon SA) of a patent covering Pfizer&#8217;s Flector Patch product, along with the New Drug Application holder (IBSA Institut Biochemique SA), brought a patent-infringement action against Actavis Laboratories UT, Inc. in the U.S. District Court for the District of Delaware in connection with an abbreviated new drug application filed by Actavis Laboratories UT, Inc. with the FDA requesting approval to launch a generic version of Flector Patch prior to the 2019 expiration of the patent. In August 2016, Pfizer subsidiary Alpharma Pharmaceuticals LLC was added as a plaintiff to the lawsuit. In August 2017, this case was settled on terms not material to Pfizer. </span></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Precedex Premix</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In June 2014,</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span><span style="font-family:inherit;font-size:10pt;">Ben Venue Laboratories, Inc. (Ben Venue)</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span><span style="font-family:inherit;font-size:10pt;">notified our subsidiary, Hospira, that it had filed an abbreviated new drug application with the FDA seeking approval to market a generic version of Hospira&#8217;s premix version of Precedex and containing allegations that a patent relating to the use of Precedex in an intensive care unit setting, which expires in March 2019, was invalid or not infringed. In August 2014, Hospira and Orion Corporation (co-owner of the patent that is the subject of the lawsuit) filed suit against Ben Venue, Hikma Pharmaceuticals PLC (Hikma), and West-Ward Pharmaceutical Corp. in the U.S. District Court for the District of Delaware asserting the validity and infringement of the patent that is the subject of the lawsuit. In October 2014, Eurohealth International Sarl was substituted for Ben Venue and Hikma. In June 2016, this case was settled on terms not material to Pfizer.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In June 2015, Amneal Pharmaceuticals LLC (Amneal) notified Hospira that it had filed an abbreviated new drug application with the FDA seeking approval to market a generic version of Hospira&#8217;s premix version of Precedex and containing allegations that </span><span style="font-family:inherit;font-size:10pt;"><span>four</span></span><span style="font-family:inherit;font-size:10pt;"> patents relating to the Precedex premix formulations and their use, all of which expire in 2032, were invalid or not infringed. In August 2015, Hospira filed suit against Amneal in the U.S. District Court for the District of Delaware asserting the validity and infringement of the patents that are the subject of the lawsuit.</span></div><div style="line-height:120%;text-align:left;font-size:5pt;"><span style="font-family:inherit;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In December 2015, Fresenius Kabi USA LLC (Fresenius) notified Hospira that it had filed an abbreviated new drug application with the FDA seeking approval to market a generic version of Hospira&#8217;s premix version of Precedex and containing allegations that </span><span style="font-family:inherit;font-size:10pt;"><span>four</span></span><span style="font-family:inherit;font-size:10pt;"> patents relating to the Precedex premix formulations and their use, all of which expire in 2032, were invalid or not infringed. In January 2016, Hospira filed suit against Fresenius in the U.S. District Court for the Northern District of Illinois asserting the validity and infringement of the patents that are the subject of the lawsuit.</span></div><div style="line-height:120%;text-align:justify;font-size:5pt;"><span style="font-family:inherit;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In August 2016, Par Sterile Products, LLC (Par) notified Hospira that it had filed an abbreviated new drug application with the FDA seeking approval to market a generic version of Hospira&#8217;s premix version of Precedex and containing allegations that </span><span style="font-family:inherit;font-size:10pt;"><span>four</span></span><span style="font-family:inherit;font-size:10pt;"> patents relating to the Precedex premix formulations and their use, all of which expire in 2032, were invalid or not infringed. In September 2016, Hospira filed suit against Par in the U.S. District Court for the District of Delaware asserting the validity and infringement of the patents that are the subject of the lawsuit. In December 2016, the case was stayed pending the outcome of Hospira&#8217;s suit against Amneal (including all appeals).</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Toviaz (fesoterodine)</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have an exclusive, worldwide license to market Toviaz from UCB Pharma GmbH (UCB), which owns the patents relating to Toviaz.</span></div><div style="line-height:120%;text-align:left;font-size:5pt;"><span style="font-family:inherit;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Beginning in May 2013, several generic drug manufacturers notified us that they had filed abbreviated new drug applications with the FDA seeking approval to market generic versions of Toviaz and asserting the invalidity, unenforceability and/or non-infringement of all of our patents for Toviaz that are listed in the FDA&#8217;s list of Approved Drug Products with Therapeutic Equivalence Evaluations, commonly referred to as the &#8220;Orange Book&#8221;. Beginning in June 2013, we filed actions against all of those generic drug manufacturers in the U.S. District Court for the District of Delaware, asserting the infringement of </span><span style="font-family:inherit;font-size:10pt;"><span>five</span></span><span style="font-family:inherit;font-size:10pt;"> of the patents for Toviaz: </span><span style="font-family:inherit;font-size:10pt;"><span>three</span></span><span style="font-family:inherit;font-size:10pt;"> composition-of-matter patents and a method-of-use patent that expire in 2019 and a patent covering salts of fesoterodine that expires in 2022. In June and July 2015, we settled with </span><span style="font-family:inherit;font-size:10pt;"><span>four</span></span><span style="font-family:inherit;font-size:10pt;"> of the generic defendants. The trial relating to the </span><span style="font-family:inherit;font-size:10pt;"><span>four</span></span><span style="font-family:inherit;font-size:10pt;"> remaining defendants occurred in July 2015. In April 2016, the District Court held that the patents that were the subject of the lawsuit were valid and infringed. The defendants&#8217; deadline to appeal this decision expired in June 2016. </span></div><div style="line-height:120%;text-align:left;font-size:5pt;"><span style="font-family:inherit;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In December 2014, Mylan Pharmaceuticals, Inc. (Mylan Pharmaceuticals) notified us that it had filed an</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span><span style="font-family:inherit;font-size:10pt;">abbreviated new drug application with the FDA seeking approval to market a generic version of Toviaz and asserting the invalidity, unenforceability and/or non-infringement of all of our patents for Toviaz that are listed in the Orange Book. In January 2015, we filed an action against Mylan Pharmaceuticals in the U.S. District Court for the District of Delaware, asserting the infringement of </span><span style="font-family:inherit;font-size:10pt;"><span>five</span></span><span style="font-family:inherit;font-size:10pt;"> of the </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">patents for Toviaz: </span><span style="font-family:inherit;font-size:10pt;"><span>three</span></span><span style="font-family:inherit;font-size:10pt;"> composition-of-matter patents and a method-of-use patent that expire in 2019 and a patent covering salts of fesoterodine that expires in 2022. In January 2017, the District Court issued a verdict finding that the </span><span style="font-family:inherit;font-size:10pt;"><span>five</span></span><span style="font-family:inherit;font-size:10pt;"> patents that are the subject of the lawsuit are valid and infringed. In August 2017, the District Court issued a written decision consistent with the verdict, finding the </span><span style="font-family:inherit;font-size:10pt;"><span>five</span></span><span style="font-family:inherit;font-size:10pt;"> patents valid and infringed. In September 2017, Mylan Pharmaceuticals appealed the District Court&#8217;s decision to the U.S. Court of Appeals for the Federal Circuit.</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span></div><div style="line-height:120%;text-align:left;font-size:5pt;"><span style="font-family:inherit;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In December 2016, Torrent Pharmaceuticals, Ltd. (Torrent) notified us that it had filed an</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span><span style="font-family:inherit;font-size:10pt;">abbreviated new drug application with the FDA seeking approval to market a generic version of Toviaz and asserting the invalidity, unenforceability and/or non-infringement of all of our patents for Toviaz that are listed in the Orange Book. In February 2017, we filed an action against Torrent in the U.S. District Court for the District of Delaware, asserting the infringement of the same </span><span style="font-family:inherit;font-size:10pt;"><span>five</span></span><span style="font-family:inherit;font-size:10pt;"> patents that are the subject of the action against Mylan Pharmaceuticals. In September 2017, this case was dismissed.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Xeljanz (tofacitinib)</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2017, we brought a patent-infringement action against MicroLabs USA Inc. and MicroLabs Ltd. (collectively, MicroLabs) in the U.S. District Court for the District of Delaware asserting the infringement and validity of </span><span style="font-family:inherit;font-size:10pt;"><span>three</span></span><span style="font-family:inherit;font-size:10pt;"> patents challenged by MicroLabs in its abbreviated new drug application seeking approval to market a generic version of tofacitinib 5 mg tablets. Of the </span><span style="font-family:inherit;font-size:10pt;"><span>three</span></span><span style="font-family:inherit;font-size:10pt;"> patents that are the subject of the lawsuit, one covers the active ingredient and expires in December 2025, the second covers an enantiomer of tofacitinib and expires in 2022, and the third covers a polymorphic form of tofacitinib and expires in 2023. </span><span style="font-family:inherit;font-size:10pt;"><span>Three</span></span><span style="font-family:inherit;font-size:10pt;"> other patents for Xeljanz expiring in December 2020 have not been challenged by MicroLabs.</span></div><div style="line-height:120%;text-align:left;font-size:5pt;"><span style="font-family:inherit;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Separately, also in February 2017, we brought a patent-infringement action against Sun Pharmaceutical Industries Ltd. in the U.S. District Court for the District of Delaware asserting the infringement and validity of our patent covering a polymorphic form of tofacitinib, expiring in 2023, that was challenged by Sun Pharmaceutical Industries Ltd. in its abbreviated new drug application seeking approval to market a generic version of tofacitinib 11 mg extended release tablets. In November 2017, we brought an additional patent-infringement action against Sun Pharmaceuticals Industries Ltd. in the U.S. District Court for the District of Delaware asserting the infringement and validity of another patent challenged by Sun Pharmaceuticals Industries Ltd, which covers the active ingredient and expires in December 2025.</span></div><div style="line-height:120%;text-align:left;font-size:5pt;"><span style="font-family:inherit;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In March 2017, we brought a patent-infringement action against Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Ltd. (collectively, Zydus) in the U.S. District Court for the District of Delaware asserting the infringement and validity of the same </span><span style="font-family:inherit;font-size:10pt;"><span>three</span></span><span style="font-family:inherit;font-size:10pt;"> patents that are the subject of the action against MicroLabs, which Zydus challenged in its abbreviated new drug application seeking approval to market a generic version of tofacitinib 5 mg tablets.</span></div><div style="line-height:120%;text-align:left;font-size:5pt;"><span style="font-family:inherit;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Also in March 2017, we brought separate actions in the U.S. District Court for the District of Delaware against Prinston Pharmaceutical Inc., Zhejiang Huahai Pharmaceutical Co., Ltd., Huahai US Inc. and Solco Healthcare US, LLC (collectively Prinston) and against Breckenridge Pharmaceutical Inc., Pensa Pharma S.A. and Laboratorios Del Dr. Esteve, S.A. (collectively Breckenridge) on the </span><span style="font-family:inherit;font-size:10pt;"><span>two</span></span><span style="font-family:inherit;font-size:10pt;"> patents expiring in 2022 and 2023, respectively, that were challenged by Prinston and Breckenridge in their respective abbreviated new drug applications seeking approval to market generic versions of tofacitinib 5 mg tablets. In October 2017, we brought an additional patent-infringement action against Breckenridge in the U.S. District Court for the District of Delaware asserting the infringement and validity of </span><span style="font-family:inherit;font-size:10pt;"><span>four</span></span><span style="font-family:inherit;font-size:10pt;"> additional patents challenged by Breckenridge, </span><span style="font-family:inherit;font-size:10pt;"><span>three</span></span><span style="font-family:inherit;font-size:10pt;"> of which expire in December 2020 and </span><span style="font-family:inherit;font-size:10pt;"><span>one</span></span><span style="font-family:inherit;font-size:10pt;"> of which expires in December 2025.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Xtandi (enzalutamide)</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In December 2016, Medivation and Medivation Prostate Therapeutics, Inc. (collectively, the Medivation Group); Astellas Pharma Inc., Astellas US LLC and Astellas Pharma US, Inc. (collectively, Astellas); and The Regents of the University of California filed patent-infringement suits in the U.S. District Court for the District of Delaware against Actavis Laboratories FL, Inc. and Actavis LLC (collectively, Actavis); Zydus; and Apotex Inc. and Apotex Corp. (collectively, Apotex) in connection with those companies&#8217; respective abbreviated new drug applications filed with the FDA for approval to market generic versions of enzalutamide. The generic manufacturers are challenging patents, which expire as early as 2026, covering enzalutamide and treatments for prostate cancer. In May 2017, the Medivation Group filed a patent-infringement suit against Roxane Laboratories Inc. (Roxane) in the same court in connection with Roxane&#8217;s abbreviated new drug application with the FDA for approval to market a generic version of enzalutamide. </span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Matters Involving Our Collaboration/Licensing Partners</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Nexium 24HR (esomeprazole)</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have an exclusive license from AstraZeneca PLC (AstraZeneca) to market in the U.S. the OTC version of Nexium (Nexium 24HR). Between October 2014 and November 2016, Actavis Laboratories FL, Inc. (Actavis), Andrx Labs, LLC (Andrx), Perrigo Company plc (Perrigo), Lupin Limited, Dr. Reddy&#8217;s Laboratories, Inc. &amp; Ltd. (Dr. Reddy&#8217;s), Hetero USA Inc. (Hetero), Aurobindo Pharma USA Inc. (Aurobindo) and Cipla Limited (Cipla) notified us that they had filed abbreviated new drug applications with the FDA seeking approval to market generic versions of Nexium 24HR prior to the expiration of one or more of AstraZeneca&#8217;s patents listed in the Orange Book for Nexium 24HR. AstraZeneca filed actions against each of these companies in the U.S. District Court for the District of New Jersey asserting infringement of the challenged patents. In March 2017, the cases against Actavis and Andrx were settled on terms not material to Pfizer. In June 2017, the cases against Perrigo, Dr. Reddy&#8217;s and Lupin Limited were settled on terms not material to Pfizer. In August 2017, the cases against Hetero and Aurobindo were settled on terms not material to Pfizer. In October 2017, AstraZeneca&#8217;s action against Cipla was settled on terms not material to Pfizer. We were not a party to AstraZeneca&#8217;s patent-infringement actions.</span></div><div style="line-height:120%;text-align:left;font-size:5pt;"><span style="font-family:inherit;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Toviaz (fesoterodine)&#8211;&#8211;Inter-Partes Reviews</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In January 2016, Mylan Pharmaceuticals and Mylan Laboratories (collectively, Mylan) filed petitions with the U.S. Patent and Trademark Office requesting inter partes reviews of </span><span style="font-family:inherit;font-size:10pt;"><span>five</span></span><span style="font-family:inherit;font-size:10pt;"> of the patents covering fesoterodine, the active ingredient in Toviaz: </span><span style="font-family:inherit;font-size:10pt;"><span>three</span></span><span style="font-family:inherit;font-size:10pt;"> composition-of-matter patents and a method-of-use patent that expire in 2019 and a patent covering salts of fesoterodine that expires in 2022. The patents are owned by UCB, and we have an exclusive, worldwide license to market Toviaz from UCB. In July 2016, the Patent Trial and Appeal Board agreed to institute inter partes reviews of all </span><span style="font-family:inherit;font-size:10pt;"><span>five</span></span><span style="font-family:inherit;font-size:10pt;"> patents. Amerigen Pharmaceuticals Limited (Amerigen), Alembic Pharmaceuticals Limited and Torrent Pharmaceuticals Limited have joined the inter partes reviews. In July 2017, the U.S. Patent and Trademark Office issued decisions upholding all </span><span style="font-family:inherit;font-size:10pt;"><span>five</span></span><span style="font-family:inherit;font-size:10pt;"> patents. In September 2017, Mylan and Amerigen appealed the U.S. Patent and Trademark Office decisions to the U.S. Court of Appeals for the Federal Circuit</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">.</span></div><div style="line-height:120%;text-align:left;font-size:5pt;"><span style="font-family:inherit;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Eliquis</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February, March, and April 2017, </span><span style="font-family:inherit;font-size:10pt;"><span>twenty-five</span></span><span style="font-family:inherit;font-size:10pt;"> generic companies sent BMS Paragraph-IV certification letters informing BMS that they had filed abbreviated new drug applications seeking approval of generic versions of Eliquis, challenging the validity and infringement of one or more of the </span><span style="font-family:inherit;font-size:10pt;"><span>three</span></span><span style="font-family:inherit;font-size:10pt;"> patents listed in the Orange Book for Eliquis. The patents currently are set to expire in 2019, 2026, and 2031. Eliquis has been jointly developed and is being commercialized by BMS and Pfizer. In April 2017, BMS and Pfizer filed patent-infringement actions against all generic filers in the U.S. District Court for the District of Delaware and the U.S. District Court for the District of West Virginia, asserting that each of the generic companies&#8217; proposed products would infringe each of the patent(s) that each generic filer challenged. Some generic filers challenged only the 2031 patent, some challenged both the 2031 and 2026 patent, and one generic company challenged all </span><span style="font-family:inherit;font-size:10pt;"><span>three</span></span><span style="font-family:inherit;font-size:10pt;"> patents.</span></div><div style="line-height:120%;text-align:left;font-size:5pt;"><span style="font-family:inherit;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Bavencio (avelumab)</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In July 2017, BMS, E.R. Squibb &amp; Sons LLC, Ono Pharmaceutical Co. Ltd., and Tasuku Honjo brought a patent-infringement action in the U.S. District Court for the District of Delaware against Pfizer, Merck KGaA, and EMD Serono, alleging that Bavencio (avelumab) infringes </span><span style="font-family:inherit;font-size:10pt;"><span>one</span></span><span style="font-family:inherit;font-size:10pt;"> patent relating to methods for treating tumors with anti-PD-L1 antibodies, which expires in 2023.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Actions In Which We Are The Defendant</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Inflectra (infliximab-dyyb)</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In March 2015, Janssen and New York University, together, brought a patent-infringement action in the U.S. District Court for the District of Massachusetts against Hospira, Celltrion Healthcare Co. Ltd. and Celltrion Inc. alleging that infliximab-dyyb, to be marketed by Hospira in the U.S. under the brand name Inflectra, would infringe </span><span style="font-family:inherit;font-size:10pt;"><span>six</span></span><span style="font-family:inherit;font-size:10pt;"> patents relating to infliximab, its manufacture and use. Claims with respect to </span><span style="font-family:inherit;font-size:10pt;"><span>four</span></span><span style="font-family:inherit;font-size:10pt;"> of the patents have since been dismissed by the plaintiffs, leaving </span><span style="font-family:inherit;font-size:10pt;"><span>two</span></span><span style="font-family:inherit;font-size:10pt;"> patents at issue in the ongoing action: the infliximab antibody patent and a patent relating to cell culture media. In August 2016, the U.S. District Court for the District of Massachusetts ruled that the antibody patent was invalid, and Janssen has appealed that ruling to the Court of Appeals for the Federal Circuit. </span></div><div style="line-height:120%;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">A2. Legal Proceedings&#8211;&#8211;Product Litigation</span></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Like other pharmaceutical companies, we are defendants in numerous cases, including but not limited to those discussed below, related to our pharmaceutical and other products. Plaintiffs in these cases seek damages and other relief on various grounds for alleged personal injury and economic loss.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Asbestos</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Between 1967 and 1982, Warner-Lambert owned American Optical Corporation, which manufactured and sold respiratory protective devices and asbestos safety clothing. In connection with the sale of American Optical in 1982, Warner-Lambert agreed to indemnify the purchaser for certain liabilities, including certain asbestos-related and other claims. As of </span><span style="font-family:inherit;font-size:10pt;">October&#160;1, 2017</span><span style="font-family:inherit;font-size:10pt;">, approximately </span><span style="font-family:inherit;font-size:10pt;"><span>56,500</span></span><span style="font-family:inherit;font-size:10pt;"> claims naming American Optical and numerous other defendants were pending in various federal and state courts seeking damages for alleged personal injury from exposure to asbestos and other allegedly hazardous materials. Warner-Lambert was acquired by Pfizer in 2000 and is a wholly-owned subsidiary of Pfizer. Warner-Lambert is actively engaged in the defense of, and will continue to explore various means of resolving, these claims.</span></div><div style="line-height:120%;text-align:left;font-size:5pt;"><span style="font-family:inherit;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Numerous lawsuits are pending against Pfizer in various federal and state courts seeking damages for alleged personal injury from exposure to products allegedly containing asbestos and other allegedly hazardous materials sold by Pfizer and certain of its previously owned subsidiaries.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">There also are a small number of lawsuits pending in various federal and state courts seeking damages for alleged exposure to asbestos in facilities owned or formerly owned by Pfizer or its subsidiaries.</span></div><div style="line-height:120%;text-align:left;font-size:5pt;"><span style="font-family:inherit;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Effexor</span></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Personal Injury Actions</span></div></td></tr></table><div style="line-height:120%;padding-top:4px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A number of individual lawsuits and multi-plaintiff lawsuits have been filed against us and/or our subsidiaries in various federal and state courts alleging personal injury as a result of the purported ingestion of Effexor. Among other types of actions, the Effexor personal injury litigation includes actions alleging a variety of birth defects as a result of the purported ingestion of Effexor by women during pregnancy. Plaintiffs in these birth-defect actions seek compensatory and punitive damages. In August 2013, the federal birth-defect cases were transferred for consolidated pre-trial proceedings to a Multi-District Litigation (</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">In re Effexor</span><span style="font-family:inherit;font-size:10pt;"> (</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Venlafaxine Hydrochloride) Products Liability Litigation MDL-2458</span><span style="font-family:inherit;font-size:10pt;">) in the U.S. District Court for the Eastern District of Pennsylvania. Almost all plaintiffs have voluntarily dismissed their actions. The Multi-District Litigation, as well as the coordinated state court proceedings in California, has been administratively stayed. </span></div><div style="line-height:120%;text-align:left;font-size:5pt;"><span style="font-family:inherit;font-size:5pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Antitrust Actions</span></div></td></tr></table><div style="line-height:120%;padding-top:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Beginning in May 2011, actions, including purported class actions, were filed in various federal courts against Wyeth and, in certain of the actions, affiliates of Wyeth and certain other defendants relating to Effexor XR, which is the extended-release formulation of Effexor. The plaintiffs in each of the class actions seek to represent a class consisting of all persons in the U.S. and its territories who directly purchased, indirectly purchased or reimbursed patients for the purchase of Effexor XR or generic Effexor XR from any of the defendants from June 14, 2008 until the time the defendants&#8217; allegedly unlawful conduct ceased. The plaintiffs in all of the actions allege delay in the launch of generic Effexor XR in the U.S. and its territories, in violation of federal antitrust laws and, in certain of the actions, the antitrust, consumer protection and various other laws of certain states, as the result of Wyeth fraudulently obtaining and improperly listing certain patents for Effexor XR in the Orange Book, enforcing certain patents for Effexor XR and entering into a litigation settlement agreement with a generic drug manufacturer with respect to Effexor XR. Each of the plaintiffs seeks treble damages (for itself in the individual actions or on behalf of the putative class in the purported class actions) for alleged price overcharges for Effexor XR or generic Effexor XR in the U.S. and its territories since June 14, 2008. All of these actions have been consolidated in the U.S. District Court for the District of New Jersey. </span></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In October 2014, the District Court dismissed the direct purchaser plaintiffs&#8217; claims based on the litigation settlement agreement but declined to dismiss the other direct purchaser plaintiff claims. In January 2015, the District Court entered partial final judgments as to all settlement agreement claims, including those asserted by direct purchasers and end-payer plaintiffs, which plaintiffs appealed to the U.S. Court of Appeals for the Third Circuit. In August 2017, the U.S. Court of Appeals for the Third Circuit reversed the District Court&#8217;s decisions and remanded the claims to the District Court. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Zoloft</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A number of individual lawsuits and multi-plaintiff lawsuits have been filed against us and/or our subsidiaries in various federal and state courts alleging personal injury as a result of the purported ingestion of Zoloft. Among other types of actions, the Zoloft personal injury litigation includes actions alleging a variety of birth defects as a result of the purported ingestion of Zoloft by women during pregnancy. Plaintiffs in these birth-defect actions seek compensatory and punitive damages and the disgorgement of profits resulting from the sale of Zoloft. In April 2012, the federal birth-defect cases were transferred for consolidated pre-trial proceedings to a Multi-District Litigation (</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">In re Zoloft Products Liability Litigation MDL-2342</span><span style="font-family:inherit;font-size:10pt;">) in the </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. District Court for the Eastern District of Pennsylvania. A number of plaintiffs have voluntarily dismissed their actions. In April 2016, the District Court granted our motion for summary judgment, dismissing the claims of almost all of the remaining plaintiffs. In May 2016, the plaintiffs appealed the District Court&#8217;s decision to the U.S. Court of Appeals for the Third Circuit. In June 2017, the U.S. Court of Appeals for the Third Circuit affirmed the District Court&#8217;s decision.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Lipitor</span></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Antitrust Actions</span></div></td></tr></table><div style="line-height:120%;padding-top:4px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Beginning in November 2011, purported class actions relating to Lipitor were filed in various federal courts against, among others, Pfizer, certain affiliates of Pfizer, and, in most of the actions, Ranbaxy, Inc. (Ranbaxy) and certain affiliates of Ranbaxy. The plaintiffs in these various actions seek to represent nationwide, multi-state or statewide classes consisting of persons or entities who directly purchased, indirectly purchased or reimbursed patients for the purchase of Lipitor (or, in certain of the actions, generic Lipitor) from any of the defendants from March 2010 until the cessation of the defendants&#8217; allegedly unlawful conduct (the Class Period). The plaintiffs allege delay in the launch of generic Lipitor, in violation of federal antitrust laws and/or state antitrust, consumer protection and various other laws, resulting from (i) the 2008 agreement pursuant to which Pfizer and Ranbaxy settled certain patent litigation involving Lipitor, and Pfizer granted Ranbaxy a license to sell a generic version of Lipitor in various markets beginning on varying dates, and (ii) in certain of the actions, the procurement and/or enforcement of certain patents for Lipitor. Each of the actions seeks, among other things, treble damages on behalf of the putative class for alleged price overcharges for Lipitor (or, in certain of the actions, generic Lipitor) during the Class Period. In addition, individual actions have been filed against Pfizer, Ranbaxy and certain of their affiliates, among others, that assert claims and seek relief for the plaintiffs that are substantially similar to the claims asserted and the relief sought in the purported class actions described above. These various actions have been consolidated for pre-trial proceedings in a Multi-District Litigation (</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">In re Lipitor Antitrust Litigation MDL-2332</span><span style="font-family:inherit;font-size:10pt;">) in the U.S. District</span><span style="font-family:inherit;font-size:10pt;color:#0000ff;"> </span><span style="font-family:inherit;font-size:10pt;">Court for the District of New Jersey. </span></div><div style="line-height:120%;padding-top:4px;font-size:5pt;"><span style="font-family:inherit;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In September 2013 and 2014, the District Court dismissed with prejudice the claims by direct purchasers. In October and November 2014, the District Court dismissed with prejudice the claims of all other Multi-District Litigation plaintiffs. All plaintiffs have appealed the District Court&#8217;s orders dismissing their claims with prejudice to the U.S. Court of Appeals for the Third Circuit. In addition, the direct purchaser class plaintiffs appealed the order denying their motion to amend the judgment and for leave to amend their complaint to the U.S. Court of Appeals for the Third Circuit. In August 2017, the U.S. Court of Appeals for the Third Circuit reversed the District Court&#8217;s decisions and remanded substantially all of the claims to the District Court.</span></div><div style="line-height:120%;text-align:left;font-size:5pt;"><span style="font-family:inherit;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Also, in January 2013, the State of West Virginia filed an action in West Virginia state court against Pfizer and Ranbaxy, among others, that asserts claims and seeks relief on behalf of the State of West Virginia and residents of that state that are substantially similar to the claims asserted and the relief sought in the purported class actions described above.</span></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Personal Injury Actions</span></div></td></tr></table><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A number of individual and multi-plaintiff lawsuits have been filed against us in various federal and state courts alleging that the plaintiffs developed type 2 diabetes as a result of the purported ingestion of Lipitor. Plaintiffs seek compensatory and punitive damages. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2014, the federal actions were transferred for consolidated pre-trial proceedings to a Multi-District Litigation (</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">In re Lipitor (Atorvastatin Calcium) Marketing, Sales Practices and Products Liability Litigation (No. II) MDL-2502</span><span style="font-family:inherit;font-size:10pt;">) in the U.S. District Court for the District of South Carolina. Since 2016, certain cases in the Multi-District Litigation were remanded to certain state courts. In January 2017, the District Court granted our motion for summary judgment, dismissing substantially all of the remaining cases pending in the Multi-District Litigation. In January 2017, the plaintiffs appealed the District Court&#8217;s decision to the U.S. Court of Appeals for the Fourth Circuit.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Viagra</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A number of individual and multi-plaintiff lawsuits have been filed against us in various federal and state courts alleging that the plaintiffs developed melanoma and/or the exacerbation of melanoma as a result of the purported ingestion of Viagra. Plaintiffs seek compensatory and punitive damages. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In April 2016, the federal actions were transferred for coordinated pre-trial proceedings to a Multi-District Litigation (</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">In Re: Viagra (Sildenafil Citrate) Products Liability Litigation, MDL-2691</span><span style="font-family:inherit;font-size:10pt;">) in the U.S. District Court for the Northern District of California. In December 2016, federal actions filed against Lilly and filed against both us and Lilly, were transferred for coordinated pre-trial proceedings to the Multi-District Litigation (</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">In re: Viagra (Sildenafil Citrate) and Cialis (Tadalafil) Products Liability Litigation, MDL-2691</span><span style="font-family:inherit;font-size:10pt;">).</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Celebrex</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Beginning in July 2014, purported class actions were filed in the U.S. District Court for the Eastern District of Virginia against Pfizer and certain subsidiaries of Pfizer relating to Celebrex. The plaintiffs seek to represent U.S. nationwide or multi-state classes consisting of persons or entities who directly purchased from the defendants, or indirectly purchased or reimbursed patients for some or all of the purchase price of, Celebrex or generic Celebrex from May 31, 2014 until the cessation of the defendants&#8217; allegedly unlawful conduct. The plaintiffs allege delay in the launch of generic Celebrex in violation of federal antitrust laws or certain state antitrust, consumer protection and various other laws as a result of Pfizer fraudulently obtaining and improperly listing a patent on Celebrex, engaging in sham litigation and prolonging the impact of sham litigation through settlement activity that further delayed generic entry. Each of the actions seeks treble damages on behalf of the putative class for alleged price overcharges for Celebrex since May 31, 2014. In December 2014, the District Court granted the parties&#8217; joint motions to consolidate the direct purchaser and end-payer cases, and all such cases were consolidated as of March 2015. In October 2014 and March 2015, we filed motions to dismiss the direct purchasers&#8217; and end-payers&#8217; amended complaints, respectively. In November 2015, the District Court denied in part and granted in part our motion to dismiss the direct purchasers&#8217; amended complaint. In February 2016, the District Court denied in part and granted in part our motion to dismiss the end-payers&#8217; amended complaint, and in August 2016, the District Court dismissed substantially all of the end-payer&#8217;s remaining claims. In February 2017, the District Court dismissed with prejudice all of the end-payers&#8217; claims. In March 2017, the end-payers appealed the District Court&#8217;s order dismissing their claims with prejudice to the U.S. Court of Appeals for the Fourth Circuit. In August 2017, the District Court granted the direct purchasers&#8217; motion for class certification. In October 2017, Pfizer and the direct purchasers entered into an agreement-in-principle, which is subject to the negotiation of a final settlement agreement and court approval, to resolve the direct purchasers&#8217; class action for </span><span style="font-family:inherit;font-size:10pt;"><span>$94 million</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Intravenous Solutions</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Beginning in November 2016, purported class actions were filed in the U.S. District Court for the Northern District of Illinois against Hospira, Hospira Worldwide, Inc. and certain other defendants relating to intravenous saline solution. Plaintiffs seek to represent classes consisting of all persons and entities in the U.S. who directly purchased intravenous saline solution sold by any of the defendants from January 1, 2013 until the time the defendants&#8217; allegedly unlawful conduct ceases. Plaintiffs allege that the defendants&#8217; conduct restricts output and artificially fixes, raises, maintains and/or stabilizes the prices of intravenous saline solution sold throughout the U.S. in violation of federal antitrust laws. Plaintiffs seek treble damages (for themselves and on behalf of the putative classes) and an injunction against defendants for alleged price overcharges for intravenous saline solution in the U.S. since January 1, 2013. On February 3, 2017, we completed the sale of our global infusion therapy net assets, HIS, which includes intravenous saline solution, to ICU Medical. The litigation is the subject of cross-claims for indemnification by both Pfizer and ICU Medical under the purchase agreement.</span></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Separately, in April 2017, Pfizer, Hospira and </span><span style="font-family:inherit;font-size:10pt;">two</span><span style="font-family:inherit;font-size:10pt;"> employees of Pfizer received grand jury subpoenas issued by the United States District Court for the Eastern District of Pennsylvania, in connection with an investigation by the U.S. Department of Justice, Antitrust Division. The subpoenas seek documents related to the sale, manufacture, pricing and shortages of intravenous solutions, including saline, as well as communications among market participants regarding these issues. The Department of Justice investigation is also the subject of cross-claims for indemnification by both Pfizer and ICU Medical under the purchase agreement. In addition, in August 2015, the New York Attorney General issued a subpoena to Hospira for similar information. Hospira has produced records to the New York Attorney General and will coordinate with ICU Medical to produce records to the New York Attorney General as appropriate going forward, and Hospira and Pfizer will coordinate with ICU Medical to produce records to the Department of Justice.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Hormone Therapy Consumer Class Action</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A certified consumer class action is pending against Wyeth in the U.S. District Court for the Southern District of California based on the alleged off-label marketing of its hormone therapy products. The case was originally filed in December 2003. The class consists of California consumers who purchased Wyeth&#8217;s hormone-replacement products between January 1995 and January 2003 and who do not seek personal injury damages therefrom. The class seeks compensatory and punitive damages, including a full refund of the purchase price.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Eliquis</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A number of individual and multi-plaintiff lawsuits have been filed against us and Bristol-Myers Squibb Company in various federal and state courts pursuant to which plaintiffs seek to recover for personal injuries, including wrongful death, due to bleeding as a result of the alleged ingestion of Eliquis. Plaintiffs seek compensatory and punitive damages.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2017, the federal actions were transferred for coordinated pre-trial proceedings to a Multi-District Litigation (</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">In Re: Eliquis (Apixaban) Products Liability Litigation MDL-2754</span><span style="font-family:inherit;font-size:10pt;">) in the U.S. District Court for the Southern District of New York. In July 2017, the District Court dismissed substantially all of the actions that were pending in the Multi-District Litigation. In </span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">August 2017, certain plaintiffs appealed the District Court&#8217;s dismissal to the U.S. Court of Appeals for the Second Circuit. Additional cases continue to be transferred to the Multi-District Litigation.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">EpiPen</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Beginning in February 2017, purported class actions were filed in various federal courts by indirect purchasers of EpiPen against Pfizer, and/or its affiliates King and Meridian, and/or various entities affiliated with Mylan N.V., and Mylan N.V. Chief Executive Officer, Heather Bresch. The plaintiffs in these actions seek to represent U.S. nationwide classes comprising persons or entities who paid for any portion of the end-user purchase price of an EpiPen between 2009 until the cessation of the defendants&#8217; allegedly unlawful conduct. In August 2017, a similar lawsuit brought on behalf of a purported class of direct purchaser plaintiffs against Pfizer, King, Meridian and Mylan was voluntarily dismissed without prejudice. Against Pfizer and/or its affiliates, plaintiffs generally allege that Pfizer&#8217;s and/or its affiliates&#8217; settlement of patent litigation regarding EpiPen delayed market entry of generic EpiPen in violation of federal antitrust laws and various state antitrust or consumer protection laws. At least one lawsuit also alleges that Pfizer and/or Mylan N.V. violated the federal Racketeer Influenced and Corrupt Organizations Act. Plaintiffs also filed various consumer protection and unjust enrichment claims against, and relating to conduct attributable solely to, Mylan Pharmaceuticals regarding EpiPen. Plaintiffs seek treble damages for alleged overcharges for EpiPen since 2009. In August 2017, the actions were consolidated for coordinated pre-trial proceedings in a Multi-District Litigation (</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">In re: EpiPen (Epinephrine Injection, USP) Marketing, Sales Practices and Antitrust Litigation</span><span style="font-family:inherit;font-size:10pt;">, MDL-2785) in the U.S. District Court for the District of Kansas with other EpiPen-related actions against Mylan N.V. and/or its affiliates to which Pfizer, King and Meridian are not parties.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Nexium 24HR and Protonix</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A number of individual and multi-plaintiff lawsuits have been filed against Pfizer, certain of its subsidiaries and/or other pharmaceutical manufacturers in various federal and state courts alleging that the plaintiffs developed kidney-related injuries as a result of the purported ingestion of certain proton pump inhibitors. The cases against us involve Nexium 24HR and/or Protonix and seek compensatory and punitive damages and, in some cases, treble damages, restitution or disgorgement. In August 2017, the federal actions were ordered transferred for coordinated pre-trial proceedings to a Multi-District Litigation (</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">In re: Proton-Pump Inhibitor Products Liability Litigation</span><span style="font-family:inherit;font-size:10pt;"> (No. II)) in the U.S. District Court for the District of New Jersey.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Docetaxel&#160;</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A number of lawsuits have been filed against Hospira and Pfizer in various federal and state courts alleging that plaintiffs who were treated with Docetaxel developed permanent hair loss. The significant majority of the cases also name other defendants, including the manufacturer of the branded product, Taxotere. Plaintiffs seek compensatory and punitive damages.</span></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In October 2016, the federal cases were transferred for coordinated pre-trial proceedings to a Multi-District Litigation (</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">In re Taxotere (Docetaxel) Products Liability Litigation</span><span style="font-family:inherit;font-size:10pt;">, MDL-2740) in the U.S. District Court for the Eastern District of Louisiana.</span></div><div style="line-height:120%;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">A3. Legal Proceedings&#8211;&#8211;Commercial and Other Matters</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Average Wholesale Price Litigation</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pfizer, certain of its subsidiaries and other pharmaceutical manufacturers were sued in various state courts by a number of states alleging that the defendants provided average wholesale price (AWP) information for certain of their products that was higher than the actual average prices at which those products were sold. The AWP is used to determine reimbursement levels under Medicare Part B and Medicaid and in many private-sector insurance policies and medical plans. All but </span><span style="font-family:inherit;font-size:10pt;"><span>one</span></span><span style="font-family:inherit;font-size:10pt;"> of those actions have been resolved through settlement, dismissal or final judgment. The plaintiff state, Illinois,</span><span style="font-family:inherit;font-size:10pt;color:#ff0000;"> </span><span style="font-family:inherit;font-size:10pt;">in the </span><span style="font-family:inherit;font-size:10pt;"><span>one</span></span><span style="font-family:inherit;font-size:10pt;"> remaining action claims that the alleged spread between the AWPs at which purchasers were reimbursed and the actual sale prices was promoted by the defendants as an incentive to purchase certain of their products. The action</span><span style="font-family:inherit;font-size:10pt;color:#ff0000;"> </span><span style="font-family:inherit;font-size:10pt;">alleges, among other things, fraud</span><span style="font-family:inherit;font-size:10pt;color:#ff0000;"> </span><span style="font-family:inherit;font-size:10pt;">and violation of the state&#8217;s unfair trade practices and</span><span style="font-family:inherit;font-size:10pt;color:#ff0000;"> </span><span style="font-family:inherit;font-size:10pt;">consumer protection statutes and seeks monetary and other relief, including civil penalties and treble damages.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Monsanto-Related Matters</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In 1997, Monsanto Company (Former Monsanto) contributed certain chemical manufacturing operations and facilities to a newly formed corporation, Solutia Inc. (Solutia), and spun off the shares of Solutia. In 2000, Former Monsanto merged with Pharmacia &amp; Upjohn Company to form Pharmacia. Pharmacia then transferred its agricultural operations to a newly created subsidiary, named Monsanto Company (New Monsanto), which it spun off in a two-stage process that was completed in 2002. Pharmacia was acquired by Pfizer in 2003 and is a wholly-owned subsidiary of Pfizer.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In connection with its spin-off that was completed in 2002, New Monsanto assumed, and agreed to indemnify Pharmacia for, any liabilities related to Pharmacia&#8217;s former agricultural business. New Monsanto has defended and/or is defending Pharmacia in connection with various claims and litigation arising out of, or related to, the agricultural business, and has been indemnifying Pharmacia when liability has been imposed or settlement has been reached regarding such claims and litigation.</span></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In connection with its spin-off in 1997, Solutia assumed, and agreed to indemnify Pharmacia for, liabilities related to Former Monsanto&#8217;s chemical businesses. As the result of its reorganization under Chapter 11 of the U.S. Bankruptcy Code, Solutia&#8217;s indemnification obligations relating to Former Monsanto&#8217;s chemical businesses are primarily limited to sites that Solutia has owned or operated. In addition, in connection with its spinoff that was completed in 2002, New Monsanto assumed, and agreed to indemnify Pharmacia for, any liabilities primarily related to Former Monsanto&#8217;s chemical businesses, including, but not limited to, any such liabilities that Solutia assumed. Solutia&#8217;s and New Monsanto&#8217;s assumption of, and agreement to, indemnify Pharmacia for these liabilities apply to pending actions and any future actions related to Former Monsanto&#8217;s chemical businesses in which Pharmacia is named as a defendant, including, without limitation, actions asserting environmental claims, including alleged exposure to polychlorinated biphenyls. Solutia and/or New Monsanto are defending Pharmacia in connection with various claims and litigation arising out of, or related to, Former Monsanto&#8217;s chemical businesses, and have been indemnifying Pharmacia when liability has been imposed or settlement has been reached regarding such claims and litigation.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Environmental Matters</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In 2009, we submitted to the U.S. Environmental Protection Agency (EPA) a corrective measures study report with regard to Pharmacia&#8217;s discontinued industrial chemical facility in North Haven, Connecticut and a revised site-wide feasibility study with regard to Wyeth Holdings Corporation&#8217;s discontinued industrial chemical facility in Bound Brook, New Jersey. In September 2010, our corrective measures study report with regard to the North Haven facility was approved by the EPA, and we commenced construction of the site remedy in late 2011 under an Updated Administrative Order on Consent with the EPA. In July 2011, Wyeth Holdings Corporation finalized an Administrative Settlement Agreement and Order on Consent for Removal Action (the 2011 Administrative Settlement Agreement) with the EPA with regard to the Bound Brook facility. In May 2012, we completed construction of an interim remedy to address the discharge of impacted groundwater from that facility to the Raritan River. In September 2012, the EPA issued a final remediation plan for the Bound Brook facility&#8217;s main plant area, which is generally in accordance with one of the remedies evaluated in our revised site-wide feasibility study. In March 2013, Wyeth Holdings Corporation (now Wyeth Holdings LLC) entered into an Administrative Settlement Agreement and Order on Consent with the EPA to allow us to undertake detailed engineering design of the remedy for the main plant area and to perform a focused feasibility study for </span><span style="font-family:inherit;font-size:10pt;"><span>two</span></span><span style="font-family:inherit;font-size:10pt;"> adjacent lagoons. In September 2015, the U.S., on behalf of the EPA, lodged a complaint and consent decree with the federal District Court for the District of New Jersey that will allow Wyeth Holdings LLC to complete the design and to implement the remedy for the main plant area. In December 2015, the consent decree (which supersedes the 2011 Administrative Settlement Agreement) was entered by the District Court. We have accrued for the estimated costs of the site remedy for the North Haven facility and the site remediation for the Bound Brook facility.</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:inherit;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are a party to a number of other proceedings brought under the Comprehensive Environmental Response, Compensation, and Liability Act of 1980, as amended, and other state, local or foreign laws in which the primary relief sought is the cost of past and/or future remediation.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Contracts with Iraqi Ministry of Health</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In October 2017, a number of United States service members, civilians, and their families brought a complaint against a number of pharmaceutical and medical devices companies, including Pfizer and certain of its subsidiaries, alleging that the defendants violated the United States Anti-Terrorism Act. The complaint alleges that the defendants provided funding for terrorist organizations through their sales practices pursuant to pharmaceutical and medical device contracts with the Iraqi Ministry of Health.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">A4. Legal Proceedings&#8211;&#8211;Government Investigations</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Like other pharmaceutical companies, we are subject to investigations and extensive regulation by government agencies in the U.S., other developed markets and multiple emerging markets in which we operate. As a result, we have interactions with government agencies on an ongoing basis. Criminal charges, and substantial fines and/or civil penalties, as well as limitations on our ability to conduct business in applicable jurisdictions, could result from government investigations. Among the investigations by government agencies are the matters discussed below.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Phenytoin Sodium Capsules</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In 2012, Pfizer sold the U.K. Marketing Authorisation for phenytoin sodium capsules to a third party, but retained the right to supply the finished product to that third party. In May 2013, the U.K. Competition &amp; Markets Authority (CMA) informed us that it had launched an investigation into the supply of phenytoin sodium capsules in the U.K. market. In August 2015, the CMA issued a Statement of Objections alleging that Pfizer and Pfizer Limited, a U.K. subsidiary, engaged in conduct that violates U.K. and EU antitrust laws. In December 2016, the CMA imposed a </span><span style="font-family:inherit;font-size:10pt;color:#0b0c0c;">&#163;</span><span style="font-family:inherit;font-size:10pt;"><span>84.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> fine on Pfizer and Pfizer Limited. Pfizer appealed the CMA Decision to The Competition Appeal Tribunal in February 2017</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Civil Investigative Demand relating to Pharmacy Benefit Managers</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In March 2016, Pfizer received a Civil Investigative Demand from the U.S. Attorney&#8217;s Office for the Southern District of New York related to Pfizer&#8217;s contractual relationships with pharmacy benefit managers with respect to certain pharmaceutical products over the period from January 1, 2006 to the present. We have provided information to the government in response to this Civil Investigative Demand.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Subpoenas relating to Copayment Assistance Organizations</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In December 2015 and July 2016, Pfizer received subpoenas from the U.S. Attorney&#8217;s Office for the District of Massachusetts requesting documents related to the Patient Access Network Foundation and other 501(c)(3) organizations that provide financial assistance to Medicare patients. We have been providing information to the government in response to these subpoenas.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">U.S. Department of Justice Investigation relating to Greenstone</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of July 2017, the U.S. Department of Justice&#8217;s Antitrust Division is investigating our Greenstone generics business. We believe this is related to an ongoing antitrust investigation of the generic pharmaceutical industry. The government has been obtaining information from Greenstone.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Intravenous Solutions</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">See </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 12A2. Legal Proceedings</span><span style="font-family:inherit;font-size:10pt;">&#8211;&#8211;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Product Litigation</span><span style="font-family:inherit;font-size:10pt;">&#8211;&#8211;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Intravenous Solutions</span><span style="font-family:inherit;font-size:10pt;"> above for information regarding government investigations related to sales of intravenous solution products.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">A5. Legal Proceedings&#8211;&#8211;Matters Resolved During the First </span><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Nine Months</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"> of 2017</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During 2017, certain matters, including the matter discussed below, were resolved or were the subject of definitive settlement agreements or settlement agreements-in-principle.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Xtandi</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In April 2014, the Regents of the University of California (the Regents) filed a complaint against the Medivation Group in California Superior Court in San Francisco. Medivation was acquired by Pfizer in September 2016 and is now a wholly-owned subsidiary of Pfizer. The Regents&#8217; complaint sought a </span><span style="font-family:inherit;font-size:10pt;"><span>10%</span></span><span style="font-family:inherit;font-size:10pt;"> share, under a license agreement between the Medivation Group and the Regents, of certain payments the Medivation Group receives with respect to Xtandi under the Medivation Group&#8217;s sub-licensing and collaboration agreement with Astellas. Trial was scheduled to commence in May 2017. In July 2017, the parties resolved the matter through a settlement on terms not material to Pfizer, which was recorded in the second quarter of 2017 as a measurement period adjustment related to the Medivation acquisition.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">B. Guarantees and Indemnifications</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the ordinary course of business and in connection with the sale of assets and businesses, we often indemnify our counterparties against certain liabilities that may arise in connection with the transaction or related to activities prior to the transaction. These indemnifications typically pertain to environmental, tax, employee and/or product-related matters and patent-infringement claims. If the indemnified party were to make a successful claim pursuant to the terms of the indemnification, we would be required to reimburse the loss. These indemnifications are generally subject to threshold amounts, specified claim periods and other restrictions and limitations. Historically, we have not paid significant amounts under these provisions and, as of </span><span style="font-family:inherit;font-size:10pt;">October&#160;1, 2017</span><span style="font-family:inherit;font-size:10pt;">, recorded amounts for the estimated fair value of these indemnifications were not significant. </span></div>Pfizer Inc. has also guaranteed the long-term debt of certain companies that it acquired and that now are subsidiaries of Pfizer.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6917880032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment, Geographic and Other Revenue Information<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 01, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment, Geographic and Other Revenue Information</a></td>
<td class="text"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Segment, Geographic and Other Revenue Information</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">A. Segment Information</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We manage our commercial operations through </span><span style="font-family:inherit;font-size:10pt;"><span>two</span></span><span style="font-family:inherit;font-size:10pt;"> distinct business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH and EH segments are each led by a single manager. Each operating segment has responsibility for its commercial activities and for certain IPR&amp;D projects for new investigational products and additional indications for in-line products that generally have achieved proof-of-concept. Each business has a geographic footprint across developed and emerging markets. Our chief operating decision maker uses the revenues and earnings of the </span><span style="font-family:inherit;font-size:10pt;"><span>two</span></span><span style="font-family:inherit;font-size:10pt;"> operating segments, among other factors, for performance evaluation and resource allocation.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We regularly review our segments and the approach used by management for performance evaluation and resource allocation.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As described in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 1A</span><span style="font-family:inherit;font-size:10pt;">, acquisitions and divestitures have impacted our results of operations in 2017 and 2016.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Operating Segments</span></div><div style="line-height:120%;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:50%;"/></tr><tr><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Some additional information about our business segments follows:</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-style:italic;font-weight:bold;">IH Segment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-style:italic;font-weight:bold;">EH Segment</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:4px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">IH focuses on developing and commercializing novel, value-creating medicines and vaccines that significantly improve patients&#8217; lives, as well as products for consumer healthcare.<br/>Key therapeutic areas include internal medicine, vaccines, oncology, inflammation &amp; immunology, rare diseases and consumer healthcare.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:5px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">EH includes legacy brands that have lost or will soon lose market exclusivity in both developed and emerging markets, branded generics, generic sterile injectable products, biosimilars, select branded products including anti-infectives and, through February 2, 2017, HIS. EH also includes an R&amp;D organization, as well as our contract manufacturing business.</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #000000;"><div style="font-size:9.5pt;"><span style="font-family:inherit;font-size:3pt;font-weight:bold;"><br/></span><span style="font-family:inherit;font-size:9.5pt;font-weight:bold;">Leading brands include:<br/></span><span style="font-family:inherit;font-size:9.5pt;">- </span><span style="font-family:inherit;font-size:9.5pt;font-style:italic;">Prevnar 13/Prevenar 13<br/></span><span style="font-family:inherit;font-size:9.5pt;">- </span><span style="font-family:inherit;font-size:9.5pt;font-style:italic;">Xeljanz<br/></span><span style="font-family:inherit;font-size:9.5pt;">- </span><span style="font-family:inherit;font-size:9.5pt;font-style:italic;">Eliquis<br/></span><span style="font-family:inherit;font-size:9.5pt;">- </span><span style="font-family:inherit;font-size:9.5pt;font-style:italic;">Lyrica</span><span style="font-family:inherit;font-size:9.5pt;">&#160;(U.S., Japan and certain other markets)<br/>- </span><span style="font-family:inherit;font-size:9.5pt;font-style:italic;">Enbrel </span><span style="font-family:inherit;font-size:9.5pt;">(outside the U.S. and Canada)<br/>- </span><span style="font-family:inherit;font-size:9.5pt;font-style:italic;">Viagra</span><span style="font-family:inherit;font-size:9.5pt;">&#160;(U.S. and Canada)<br/>- </span><span style="font-family:inherit;font-size:9.5pt;font-style:italic;">Ibrance<br/></span><span style="font-family:inherit;font-size:9.5pt;">- </span><span style="font-family:inherit;font-size:9.5pt;font-style:italic;">Xtandi<br/></span><span style="font-family:inherit;font-size:9.5pt;">- Several OTC consumer healthcare products (e.g., </span><span style="font-family:inherit;font-size:9.5pt;font-style:italic;">Advil</span><span style="font-family:inherit;font-size:9.5pt;">&#160;and<br/></span><span style="font-family:inherit;font-size:9.5pt;font-style:italic;">&#160;&#160;Centrum</span><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #000000;"><div style="font-size:3pt;"><span style="font-family:inherit;font-size:3pt;"><br/></span></div><div style="font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-weight:bold;">Leading brands include:</span></div><div style="font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">- </span><span style="font-family:inherit;font-size:9.5pt;font-style:italic;">Lipitor</span></div><div style="font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-style:italic;">- Premarin </span><span style="font-family:inherit;font-size:9.5pt;">family</span></div><div style="font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-style:italic;">- Norvasc</span></div><div style="padding-left:6px;text-indent:-6px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-style:italic;">- Lyrica </span><span style="font-family:inherit;font-size:9.5pt;">(Europe, Russia, Turkey, Israel and Central Asia countries)</span></div><div style="font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">- </span><span style="font-family:inherit;font-size:9.5pt;font-style:italic;">Celebrex</span></div><div style="font-size:10pt;"><span style="font-family:inherit;font-size:9.5pt;">- </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Inflectra/Remsima</span></div><div style="font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-style:italic;">- </span><span style="font-family:inherit;font-size:9.5pt;">Several sterile injectable products</span></div><div style="padding-left:5px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Other Costs and Business Activities</span></div><div style="line-height:120%;text-align:justify;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certain pre-tax costs are not allocated to our operating segment results, such as costs associated with the following:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">WRD, which is generally responsible for research projects for our IH business until proof-of-concept is achieved and then for transitioning those projects to the IH segment via the GPD organization for possible clinical and commercial development. R&amp;D spending may include upfront and milestone payments for intellectual property rights. The WRD organization also has responsibility for certain science-based and other platform-services organizations, which provide technical expertise and other services to the various R&amp;D projects, including EH R&amp;D projects. WRD is also responsible for facilitating all regulatory submissions and interactions with regulatory agencies, including all safety-event activities.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">GPD, which is generally responsible for the clinical development of assets that are in clinical trials for our WRD and Innovative portfolios. GPD also provides technical support and other services to Pfizer R&amp;D projects.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate, representing platform functions (such as worldwide technology, global real estate operations, legal, finance, human resources, worldwide public affairs, compliance and worldwide procurement) and certain compensation and other corporate costs, such as interest income and expense, and gains and losses on investments. Effective in the first quarter of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:10pt;">, Corporate also includes the costs associated with our Pfizer Medical organization (Medical), previously reported as part of Other Business Activities. Medical is responsible for the provision of medical information to healthcare providers, patients and other parties, transparency and disclosure activities, clinical trial results publication, grants for healthcare quality improvement and medical education, and partnerships with global public health and medical associations. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other unallocated costs, representing overhead expenses associated with our manufacturing and commercial operations that are not directly assessed to an operating segment, as business unit (segment) management does not manage these costs (which include manufacturing variances associated with production).</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certain transactions and events such as (i) purchase accounting adjustments, where we incur expenses associated with the amortization of fair value adjustments to inventory, intangible assets and PP&amp;E; (ii) acquisition-related costs, where we incur costs for executing the transaction, integrating the acquired operations and restructuring the combined company; and (iii) certain significant items, representing substantive and/or unusual, and in some cases recurring, items (such as restructuring or legal charges) that are evaluated on an individual basis by management and that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis. Such items can include, but are not limited to, non-acquisition-related restructuring costs, as well as costs incurred for legal settlements, asset impairments and disposals of assets or businesses, including, as applicable, any associated transition activities.</span></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Segment Assets</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We manage our assets on a total company basis, not by operating segment, as many of our operating assets are shared (such as our plant network assets) or commingled (such as accounts receivable, as many of our customers are served by both operating segments). Therefore, our chief operating decision maker does not regularly review any asset information by operating segment and, accordingly, we do not report asset information by operating segment. Total assets were approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$172 billion</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">October&#160;1, 2017</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;text-align:center;">December&#160;31, 2016</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Selected Income Statement Information</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td colspan="17" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides selected income statement information by reportable segment:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Three Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Earnings</span><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">October&#160;1, <br/>2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">October&#160;2, <br/>2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">October&#160;1, <br/>2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">October&#160;2, <br/>2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Reportable Segments:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:6px;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">IH</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>8,118</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>7,332</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>4,875</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>4,187</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:6px;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">EH</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>5,050</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>5,712</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>2,765</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>3,128</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Total reportable segments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>13,168</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>13,045</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>7,640</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>7,315</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-12px;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Other business activities</span><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(b), (c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(759</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(753</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Reconciling Items:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Corporate</span><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(1,382</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(1,537</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Purchase accounting adjustments</span><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(1,154</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(966</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Acquisition-related costs</span><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(155</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(280</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Certain significant items</span><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(d)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(449</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(1,969</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Other unallocated</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(156</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(206</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>13,168</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>13,045</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>3,585</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>1,604</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="17" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Nine Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Earnings</span><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">October&#160;1, <br/>2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">October&#160;2, <br/>2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">October&#160;1, <br/>2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">October&#160;2, <br/>2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Reportable Segments:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">IH</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>23,204</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>21,471</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>14,190</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>12,470</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">EH</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>15,639</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>17,725</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>8,558</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>9,985</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Total reportable segments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>38,843</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>39,196</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>22,748</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>22,454</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Other business activities</span><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(b), (c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(2,205</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(2,096</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Reconciling Items:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Corporate</span><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(3,948</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(4,217</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Purchase accounting adjustments</span><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(3,527</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(3,103</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Acquisition-related costs</span><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(347</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(598</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Certain significant items</span><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(d)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(797</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(4,112</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Other unallocated</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(573</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(753</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>38,843</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>39,196</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>11,351</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>7,575</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Income from continuing operations before provision for taxes on income. IH&#8217;s earnings in the </span><span style="font-family:inherit;font-size:8pt;">third quarter</span><span style="font-family:inherit;font-size:8pt;"> and </span><span style="font-family:inherit;font-size:8pt;">first nine months of</span><span style="font-family:inherit;font-size:8pt;"> </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:8pt;text-align:center;"> include d</span><span style="font-family:inherit;font-size:8pt;">ividend income of </span><span style="font-family:inherit;font-size:8pt;"><span>$54 million</span></span><span style="font-family:inherit;font-size:8pt;"> and </span><span style="font-family:inherit;font-size:8pt;"><span>$211 million</span></span><span style="font-family:inherit;font-size:8pt;">, respectively, from our investment in ViiV. For additional information, see </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Note 4.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Other business activities includes the costs managed by our WRD and GPD organizations. Effective in the first quarter of </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:8pt;">, Medical, previously reported as part of Other Business Activities, was reclassified to Corporate. We have reclassified approximately </span><span style="font-family:inherit;font-size:8pt;"><span>$33 million</span></span><span style="font-family:inherit;font-size:8pt;"> and </span><span style="font-family:inherit;font-size:8pt;"><span>$94 million</span></span><span style="font-family:inherit;font-size:8pt;"> of costs from Other Business Activities to Corporate in the </span><span style="font-family:inherit;font-size:8pt;">third quarter</span><span style="font-family:inherit;font-size:8pt;"> and </span><span style="font-family:inherit;font-size:8pt;">first nine months of</span><span style="font-family:inherit;font-size:8pt;"> </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:8pt;">, respectively, to conform to the current period presentation.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">For a description, see the &#8220;Other Costs and Business Activities&#8221; section above.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(d)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Certain significant items are substantive and/or unusual, and in some cases recurring, items (such as restructuring or legal charges) that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:1px;padding-top:1px;padding-left:12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">For Earnings in the </span><span style="font-family:inherit;font-size:8pt;">third quarter</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:8pt;">, certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of </span><span style="font-family:inherit;font-size:8pt;"><span>$90 million</span></span><span style="font-family:inherit;font-size:8pt;">, (ii) charges for certain legal matters of </span><span style="font-family:inherit;font-size:8pt;"><span>$183 million</span></span><span style="font-family:inherit;font-size:8pt;">, (iii) income of </span><span style="font-family:inherit;font-size:8pt;"><span>$12 million</span></span><span style="font-family:inherit;font-size:8pt;">, representing an adjustment to amounts previously recorded to write down the HIS net assets to fair value less costs to sell, (iv) certain asset impairment charges of </span><span style="font-family:inherit;font-size:8pt;"><span>$127 million</span></span><span style="font-family:inherit;font-size:8pt;">, (v) charges for business and legal entity alignment of </span><span style="font-family:inherit;font-size:8pt;"><span>$16 million</span></span><span style="font-family:inherit;font-size:8pt;"> and (vi) other charges of </span><span style="font-family:inherit;font-size:8pt;"><span>$45 million</span></span><span style="font-family:inherit;font-size:8pt;">. For additional information, see </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Note 2B, Note 3</span><span style="font-family:inherit;font-size:8pt;"> and </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Note 4.</span></div><div style="line-height:120%;padding-bottom:1px;text-align:left;padding-left:12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">For Earnings in the </span><span style="font-family:inherit;font-size:8pt;">third quarter</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:8pt;">, certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of </span><span style="font-family:inherit;font-size:8pt;"><span>$375 million</span></span><span style="font-family:inherit;font-size:8pt;">, (ii) income for certain legal matters of </span><span style="font-family:inherit;font-size:8pt;"><span>$40 million</span></span><span style="font-family:inherit;font-size:8pt;">, (iii) an impairment charge related to the write-down of the HIS net assets to fair value less estimated costs to sell of </span><span style="font-family:inherit;font-size:8pt;"><span>$1.4 billion</span></span><span style="font-family:inherit;font-size:8pt;">, (iv) certain asset impairment charges of </span><span style="font-family:inherit;font-size:8pt;"><span>$126 million</span></span><span style="font-family:inherit;font-size:8pt;">, (v) charges for business and legal entity alignment of </span><span style="font-family:inherit;font-size:8pt;"><span>$69 million</span></span><span style="font-family:inherit;font-size:8pt;"> and (vi) other charges of </span><span style="font-family:inherit;font-size:8pt;"><span>$17 million</span></span><span style="font-family:inherit;font-size:8pt;">. For additional information, see </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Note 3 </span><span style="font-family:inherit;font-size:8pt;">and</span><span style="font-family:inherit;font-size:8pt;font-style:italic;"> Note 4</span><span style="font-family:inherit;font-size:8pt;">.</span></div><div style="line-height:120%;padding-bottom:1px;text-align:left;padding-left:12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">For Earnings in the </span><span style="font-family:inherit;font-size:8pt;">first nine months of</span><span style="font-family:inherit;font-size:8pt;"> </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:8pt;">, certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of </span><span style="font-family:inherit;font-size:8pt;"><span>$253 million</span></span><span style="font-family:inherit;font-size:8pt;">, (ii) charges for certain legal matters of </span><span style="font-family:inherit;font-size:8pt;"><span>$191 million</span></span><span style="font-family:inherit;font-size:8pt;">, (iii) incremental charges to amounts previously recorded to write down the HIS net assets to fair value less costs to sell of </span><span style="font-family:inherit;font-size:8pt;"><span>$52 million</span></span><span style="font-family:inherit;font-size:8pt;">, (iv) certain asset impairment charges of </span><span style="font-family:inherit;font-size:8pt;"><span>$127 million</span></span><span style="font-family:inherit;font-size:8pt;">, (v) charges for business and legal entity alignment of </span><span style="font-family:inherit;font-size:8pt;"><span>$54 million</span></span><span style="font-family:inherit;font-size:8pt;"> and (vi) other charges of </span><span style="font-family:inherit;font-size:8pt;"><span>$119 million</span></span><span style="font-family:inherit;font-size:8pt;">. For additional information, see </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Note 2B</span><span style="font-family:inherit;font-size:8pt;">, </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Note 3</span><span style="font-family:inherit;font-size:8pt;"> and </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Note 4</span><span style="font-family:inherit;font-size:8pt;">.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;padding-left:12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">For Earnings in the </span><span style="font-family:inherit;font-size:8pt;">first nine months of</span><span style="font-family:inherit;font-size:8pt;"> </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:8pt;">, certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of </span><span style="font-family:inherit;font-size:8pt;"><span>$743 million</span></span><span style="font-family:inherit;font-size:8pt;">, (ii) charges for certain legal matters of </span><span style="font-family:inherit;font-size:8pt;"><span>$506 million</span></span><span style="font-family:inherit;font-size:8pt;">, (iii) an impairment charge related to the write-down of the HIS net assets to fair value less estimated costs to sell of </span><span style="font-family:inherit;font-size:8pt;"><span>$1.4 billion</span></span><span style="font-family:inherit;font-size:8pt;">, (iv) certain asset impairment charges of </span><span style="font-family:inherit;font-size:8pt;"><span>$1.1 billion</span></span><span style="font-family:inherit;font-size:8pt;">, (v) charges for business and legal entity alignment of </span><span style="font-family:inherit;font-size:8pt;"><span>$180 million</span></span><span style="font-family:inherit;font-size:8pt;"> and (vi) other charges of </span><span style="font-family:inherit;font-size:8pt;"><span>$189 million</span></span><span style="font-family:inherit;font-size:8pt;">. For additional information, see </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Note 3</span><span style="font-family:inherit;font-size:8pt;"> and </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Note 4</span><span style="font-family:inherit;font-size:8pt;">.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Equity in the net income of investees accounted for by the equity method is not significant for any of our operating segments. </span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The operating segment information does not purport to represent the revenues, costs and income from continuing operations before provision for taxes on income that each of our operating segments would have recorded had each segment operated as a standalone company during the periods presented.</span></div><div style="line-height:120%;padding-top:9px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">B. Geographic Information</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As described in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 1A</span><span style="font-family:inherit;font-size:10pt;">, acquisitions and divestitures have impacted our results of operations in 2017 and 2016.</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.41520467836257%;border-collapse:collapse;text-align:left;"><tr><td colspan="23"/></tr><tr><td style="width:28%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/></tr><tr><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides revenues by geographic area:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nine Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">October&#160;1, <br/>2017</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">October&#160;2, <br/>2016</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Change</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">October&#160;1, <br/>2017</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">October&#160;2, <br/>2016</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Change</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,534</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,530</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19,516</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19,561</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Developed Europe</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,163</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,218</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,309</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,982</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(10</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Developed Rest of World</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,632</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,711</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,797</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,940</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Emerging Markets</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,839</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,586</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,222</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,714</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,168</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,045</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>38,843</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>39,196</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Developed Europe region includes the following markets: Western Europe, Scandinavian countries and Finland.</span><span style="font-family:inherit;font-size:8pt;"> Revenues denominated in euros were </span><span style="font-family:inherit;font-size:8pt;"><span>$1.7 billion</span></span><span style="font-family:inherit;font-size:8pt;"> in both the </span><span style="font-family:inherit;font-size:8pt;">third quarter</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:8pt;"> and </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:8pt;">, and </span><span style="font-family:inherit;font-size:8pt;"><span>$5.0 billion</span></span><span style="font-family:inherit;font-size:8pt;"> and </span><span style="font-family:inherit;font-size:8pt;"><span>$5.3 billion</span></span><span style="font-family:inherit;font-size:8pt;"> in the </span><span style="font-family:inherit;font-size:8pt;">first nine months of</span><span style="font-family:inherit;font-size:8pt;"> </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:8pt;"> and </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:8pt;">, respectively.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Developed Rest of World region includes the following markets: Japan, Canada, Australia, South Korea and New Zealand.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Emerging Markets region includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Africa, Eastern Europe, Central Europe, the Middle East and Turkey.</span></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">C. Other Revenue Information</span></div><div style="line-height:120%;padding-top:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Significant Product Revenues</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As described in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 1A</span><span style="font-family:inherit;font-size:10pt;">, acquisitions and divestitures have impacted our results of operations in 2017 and 2016.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:48%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td colspan="17" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides detailed revenue information:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Nine Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">October&#160;1, <br/>2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">October&#160;2, <br/>2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">October&#160;1, <br/>2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">October&#160;2, <br/>2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">PFIZER INNOVATIVE HEALTH (IH)</span><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>8,118</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>7,332</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>23,204</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>21,471</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Internal Medicine</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>2,455</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>2,243</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>7,245</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>6,557</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Lyrica IH</span><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>1,150</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>1,049</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>3,382</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>3,107</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Eliquis alliance revenues and direct sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>644</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>449</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>1,813</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>1,225</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Chantix/Champix</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>240</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>198</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>727</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>631</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Viagra IH</span><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>206</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>297</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>711</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>897</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">BMP2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>79</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>63</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>198</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>175</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Toviaz</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>62</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>60</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>187</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>191</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">All other Internal Medicine</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>75</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>128</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>228</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>330</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Vaccines</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>1,649</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>1,641</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>4,385</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>4,576</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Prevnar 13/Prevenar 13</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>1,522</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>1,536</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>4,069</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>4,302</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">FSME/IMMUN-TicoVac</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>43</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>33</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>119</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>102</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">All other Vaccines</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>85</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>72</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>197</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>172</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Oncology</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>1,616</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>1,104</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>4,551</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>3,206</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Ibrance</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>878</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>550</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>2,410</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>1,492</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Sutent</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>276</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>260</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>805</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>823</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Xalkori</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>146</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>140</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>442</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>415</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Xtandi alliance revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>150</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>422</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Inlyta</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>84</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>95</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>256</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>304</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Bosulif</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>57</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>43</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>163</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>121</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">All other Oncology</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>26</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>15</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>54</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>49</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Inflammation &amp; Immunology (I&amp;I)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>1,000</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>960</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>2,863</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>2,907</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Enbrel (Outside the U.S. and Canada)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>613</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>701</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>1,818</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>2,201</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Xeljanz</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>348</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>235</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>935</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>649</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Eucrisa</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>15</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>33</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">All other I&amp;I</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>23</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>24</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>78</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>57</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Rare Disease</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>569</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>585</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>1,637</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>1,768</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">BeneFIX</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>151</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>176</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>453</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>543</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Refacto AF/Xyntha</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>140</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>140</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>409</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>408</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Genotropin</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>136</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>147</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>375</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>425</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Somavert</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>65</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>59</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>182</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>173</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">All other Rare Disease</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>77</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>64</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>218</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>219</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Consumer Healthcare</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>829</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>798</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>2,522</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>2,457</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">PFIZER ESSENTIAL HEALTH (EH)</span><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(d)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>5,050</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>5,712</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>15,639</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>17,725</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Legacy Established Products (LEP)</span><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(e)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>2,681</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>2,708</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>7,995</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>8,373</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Lipitor</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>491</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>422</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>1,341</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>1,294</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Premarin family</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>238</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>244</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>711</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>751</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Norvasc</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>226</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>238</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>684</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>714</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">EpiPen</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>82</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>110</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>253</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>300</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Xalatan/Xalacom</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>83</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>91</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>241</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>273</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Effexor</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>76</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>70</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>215</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>207</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Zoloft</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>78</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>72</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>215</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>228</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Zithromax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>61</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>56</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>202</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>203</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Relpax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>50</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>83</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>193</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>248</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Xanax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>58</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>55</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>164</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>163</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">All other LEP</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>1,237</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>1,268</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>3,776</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>3,992</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Sterile Injectable Pharmaceuticals (SIP)</span><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(f)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>1,273</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>1,461</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>4,270</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>4,481</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Medrol</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>109</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>102</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>352</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>330</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Sulperazon</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>114</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>102</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>345</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>304</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Fragmin</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>79</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>80</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>221</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>240</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Tygacil</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>60</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>69</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>192</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>203</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Precedex</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>51</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>64</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>182</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>199</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">All other SIP</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>860</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>1,044</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>2,977</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>3,206</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:48%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Nine Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">October&#160;1, <br/>2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">October&#160;2, <br/>2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">October&#160;1, <br/>2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">October&#160;2, <br/>2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Peri-LOE Products</span><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(g)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>794</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>1,023</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>2,398</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>3,224</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Celebrex</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>212</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>194</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>564</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>550</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Lyrica EH</span><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>134</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>191</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>428</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>623</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Vfend</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>97</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>140</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>305</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>459</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Viagra EH</span><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>102</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>89</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>285</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>286</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Pristiq</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>69</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>174</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>230</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>546</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Zyvox</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>68</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>94</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>220</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>334</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Revatio</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>58</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>73</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>189</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>213</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">All other Peri-LOE Products</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>55</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>68</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>176</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>214</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Biosimilars</span><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(h)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>141</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>83</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>367</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>228</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Inflectra/Remsima</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>112</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>49</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>284</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>130</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">All other Biosimilars</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>28</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>34</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>82</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>97</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Pfizer CentreOne</span><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(i)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>161</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>156</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>514</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>540</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Hospira Infusion Systems (HIS)</span><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(j)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>281</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>97</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>879</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>13,168</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>13,045</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>38,843</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>39,196</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total Lyrica</span><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>1,285</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>1,240</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>3,810</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>3,730</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total Viagra</span><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>308</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>387</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>996</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>1,183</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total Alliance revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>741</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>419</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>2,112</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>1,155</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">The IH business encompasses Internal Medicine, Vaccines, Oncology, Inflammation &amp; Immunology, Rare Disease and Consumer Healthcare. Through December 31, 2016, includes Duavive/Duavee and Viviant (recorded in All other Internal Medicine in 2016), which were transferred from Innovative Health to Essential Health effective January 1, 2017 (recorded in All other LEP (EH) beginning January 1, 2017), in order to align these products with our management of the women&#8217;s health portfolio within EH. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Lyrica revenues from all of Europe, Russia, Turkey, Israel and Central Asia countries are included in Lyrica EH. All other Lyrica revenues are included in Lyrica IH. Total Lyrica revenues represent the aggregate of worldwide revenues from Lyrica IH and Lyrica EH. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Viagra revenues from the U.S. and Canada are included in Viagra IH. All other Viagra revenues are included in Viagra EH. Total Viagra revenues represent the aggregate of worldwide revenues from Viagra IH and Viagra EH. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(d)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">The EH business encompasses Legacy Established Products, Sterile Injectable Pharmaceuticals, Peri-LOE Products, Biosimilars, Pfizer CentreOne and HIS (through February 2, 2017) and includes all legacy Hospira commercial operations.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(e)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Legacy Established Products primarily include products that have lost patent protection (excluding Sterile Injectable Pharmaceuticals and Peri-LOE Products). Effective January 1, 2017, All other LEP includes Duavive/Duavee and Viviant, which were transferred from Innovative Health (recorded in All other Internal Medicine (IH) in 2016), in order to align these products with our management of the women&#8217;s health portfolio within EH.</span><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt"> </sup></span><span style="font-family:inherit;font-size:8pt;">See note (a) above.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(f) </sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Sterile Injectable Pharmaceuticals include generic injectables and proprietary specialty injectables (excluding Peri-LOE Products). </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(g)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Peri-LOE Products include products that have recently lost or are anticipated to soon lose patent protection. These products include: Lyrica in Europe, Russia, Turkey, Israel and Central Asia; Viagra in all countries (excluding the U.S. and Canada); and worldwide revenues for Celebrex, Pristiq, Zyvox, Vfend, Revatio and Inspra. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(h)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Biosimilars include Inflectra/Remsima (biosimilar infliximab) in the U.S. and certain international markets, Nivestim (biosimilar filgrastim) in certain European, Asian and Africa/Middle Eastern markets and Retacrit (biosimilar epoetin zeta) in certain European and Africa/Middle Eastern markets. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(i)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Pfizer CentreOne includes revenues from our contract manufacturing and active pharmaceutical ingredient sales operation, including sterile injectables contract manufacturing, and revenues related to our manufacturing and supply agreements, including with Zoetis. </span></div></td></tr></table><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(j)</sup>&#160;</span></div>HIS (through February 2, 2017) includes Medication Management Systems products composed of infusion pumps and related software and services, as well as IV Infusion Products, including large volume IV solutions and their associated administration sets.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI http://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6913370032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 01, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text">Basis of Presentation<div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">See the Glossary of Defined Terms at the beginning of this Quarterly Report on Form 10-Q for terms used throughout the condensed consolidated financial statements and related notes of this Quarterly Report on Form 10-Q.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We prepared the condensed consolidated financial statements following the requirements of the SEC for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP can be condensed or omitted.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The financial information included in our condensed consolidated financial statements for subsidiaries operating outside the U.S. is as of and for the three and </span><span style="font-family:inherit;font-size:10pt;">nine months</span><span style="font-family:inherit;font-size:10pt;"> ended </span><span style="font-family:inherit;font-size:10pt;">August&#160;27, 2017</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">August&#160;28, 2016</span><span style="font-family:inherit;font-size:10pt;">. The financial information included in our condensed consolidated financial statements for U.S. subsidiaries is as of and for the three and </span><span style="font-family:inherit;font-size:10pt;">nine months</span><span style="font-family:inherit;font-size:10pt;"> ended </span><span style="font-family:inherit;font-size:10pt;text-align:center;">October&#160;1, 2017</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;text-align:center;">October&#160;2, 2016</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenues, expenses, assets and liabilities can vary during each quarter of the year. Therefore, the results and trends in these interim financial statements may not be representative of those for the full year.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><span style="font-family:inherit;font-size:10pt;">We are responsible for the unaudited financial statements included in this Quarterly Report on Form 10-Q. The interim financial statements include all normal and recurring adjustments that are considered necessary for the fair statement of our condensed consolidated balance sheets and condensed consolidated statements of income. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the consolidated financial statements and accompanying notes included in our </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span> Form 10-K.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Adoption of New Accounting Standards</a></td>
<td class="text">Adoption of New Accounting Standards<div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the fourth quarter of 2016, we adopted a new accounting standard for certain elements of the accounting for share-based payments as of January 1, 2016. Specifically, the new standard requires excess tax benefits or deficiencies (including tax benefits of dividend equivalents) of share-based compensation to be recognized as a component of the </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Provision for taxes on income</span><span style="font-family:inherit;font-size:10pt;">, whereas excess tax benefits or deficiencies previously were recognized in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Additional paid-in capital</span><span style="font-family:inherit;font-size:10pt;">. The net tax benefit for the Company was </span><span style="font-family:inherit;font-size:10pt;"><span>$35 million</span></span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">third quarter</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$85 million</span></span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;">. Also, in the diluted net earnings per share calculation, when applying the treasury stock method for shares that could be repurchased, the assumed proceeds no longer include the amount of excess tax benefit.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Another element of the new accounting standard requires that we now present excess tax benefits as operating activities in our consolidated statement of cash flows. We elected to adopt this presentation on a prospective basis as of January 1, 2016. Additionally, cash paid by us when directly withholding shares for tax-withholding purposes is now a cash outflow from financing activities. This reclassification was required to be adopted retrospectively. As a result, </span><span style="font-family:inherit;font-size:10pt;"><span>$87 million</span></span><span style="font-family:inherit;font-size:10pt;"> of cash outflows for the first nine months of </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;"> was reclassified from operating activities to financing activities in the condensed consolidated statement of cash flows. For additional information, see Notes to Consolidated Financial Statements&#8211;&#8211;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 1B. </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Basis of Presentation and Significant Accounting Policies</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">:</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Adoption of New Accounting Standards</span><span style="font-family:inherit;font-size:10pt;"> included in our </span><span style="font-family:inherit;font-size:10pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:10pt;"> Financial Report.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We adopted a new standard as of January 1, 2017 that amended guidance on the assessment of whether an entity is the primary beneficiary of a variable interest entity. Under this new guidance, when evaluating whether an entity is the primary beneficiary, a single decision maker must consider its indirect interest held through related parties under common control proportionately. There was no material impact to our condensed consolidated financial statements from adopting this standard.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div>We adopted a new standard as of January 1, 2017 related to inventory. The new guidance requires that inventory be measured at the lower of cost or net realizable value, which is defined as the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. There was no material impact to our condensed consolidated financial statements from adopting this standard.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6916588128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 01, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock', window );">Schedule of Components of Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives</a></td>
<td class="text"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:48%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td colspan="17" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides the components of costs associated with acquisitions and cost-reduction/productivity initiatives:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Arial;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nine Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">October&#160;1, <br/>2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">October&#160;2, <br/>2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">October&#160;1, <br/>2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">October&#160;2, <br/>2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Restructuring charges</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(a)</sup></span><span style="font-family:inherit;font-size:10pt;">:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Employee terminations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(20</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>347</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>464</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Asset impairments</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>101</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>126</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>45</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exit costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>29</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>64</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total restructuring charges</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>91</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>404</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>150</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>574</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Transaction costs</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(14</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>54</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>114</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Integration costs</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(d)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>73</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>74</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>224</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>300</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:36px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Restructuring charges and certain acquisition-related costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>149</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>531</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>377</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>988</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Additional depreciation&#8211;&#8211;asset restructuring</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#160;</sup></span><span style="font-family:inherit;font-size:10pt;">recorded in our condensed consolidated statements of income as follows</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(e)</sup></span><span style="font-family:inherit;font-size:10pt;">:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Cost of sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>39</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>46</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>74</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>145</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Research and development expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total additional depreciation&#8211;&#8211;asset restructuring</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>39</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>47</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>74</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>151</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Implementation costs recorded in our condensed consolidated statements of income as follows</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(f)</sup></span><span style="font-family:inherit;font-size:10pt;">:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Cost of sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>46</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>77</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>127</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Selling, informational and administrative expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>46</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>56</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Research and development expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total implementation costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>57</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>78</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>150</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>202</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total costs associated with acquisitions and cost-reduction/productivity initiatives</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>245</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>655</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>601</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,341</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">In the </span><span style="font-family:inherit;font-size:9pt;">third quarter</span><span style="font-family:inherit;font-size:9pt;"> and </span><span style="font-family:inherit;font-size:9pt;">first nine months of</span><span style="font-family:inherit;font-size:9pt;"> </span><span style="font-family:inherit;font-size:9pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:9pt;">, restructuring charges are primarily associated with our acquisitions of Hospira and Medivation, as well as cost-reduction and productivity initiatives not associated with acquisitions. In the </span><span style="font-family:inherit;font-size:9pt;">third quarter</span><span style="font-family:inherit;font-size:9pt;"> and </span><span style="font-family:inherit;font-size:9pt;">first nine months of</span><span style="font-family:inherit;font-size:9pt;"> </span><span style="font-family:inherit;font-size:9pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:9pt;">, restructuring charges are largely associated with cost-reduction and productivity initiatives not associated with acquisitions, as well as our acquisitions of Hospira and Medivation. In the third quarter and first </span><span style="font-family:inherit;font-size:9pt;">nine</span><span style="font-family:inherit;font-size:9pt;"> months ended </span><span style="font-family:inherit;font-size:9pt;">October&#160;1, 2017</span><span style="font-family:inherit;font-size:9pt;">, </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Employee terminations</span><span style="font-family:inherit;font-size:9pt;"> primarily include revisions of our estimates of severance benefits. Employee termination costs are generally recorded when the actions are probable and estimable and include accrued severance benefits, pension and postretirement benefits, many of which may be paid out during periods after termination.</span></div></td></tr></table><div style="line-height:120%;padding-top:4px;padding-left:24px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">The restructuring activities for </span><span style="font-family:inherit;font-size:9pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:9pt;"> are associated with the following:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:12px;"><span style="font-family:inherit;font-size:9pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">For the </span><span style="font-family:inherit;font-size:9pt;">third quarter</span><span style="font-family:inherit;font-size:9pt;"> of </span><span style="font-family:inherit;font-size:9pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:9pt;">, IH (</span><span style="font-family:inherit;font-size:9pt;"><span>$4 million</span></span><span style="font-family:inherit;font-size:9pt;">); EH (</span><span style="font-family:inherit;font-size:9pt;"><span>$1 million</span></span><span style="font-family:inherit;font-size:9pt;">); WRD/GPD (</span><span style="font-family:inherit;font-size:9pt;"><span>$15 million</span></span><span style="font-family:inherit;font-size:9pt;">); manufacturing operations (</span><span style="font-family:inherit;font-size:9pt;"><span>$47 million</span></span><span style="font-family:inherit;font-size:9pt;">); and Corporate (</span><span style="font-family:inherit;font-size:9pt;"><span>$25 million</span></span><span style="font-family:inherit;font-size:9pt;">).</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:12px;"><span style="font-family:inherit;font-size:9pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">For the </span><span style="font-family:inherit;font-size:9pt;">first nine months of</span><span style="font-family:inherit;font-size:9pt;"> </span><span style="font-family:inherit;font-size:9pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:9pt;">, IH (</span><span style="font-family:inherit;font-size:9pt;"><span>$10 million</span></span><span style="font-family:inherit;font-size:9pt;">); EH (</span><span style="font-family:inherit;font-size:9pt;"><span>$9 million</span></span><span style="font-family:inherit;font-size:9pt;"> income); WRD/GPD (</span><span style="font-family:inherit;font-size:9pt;"><span>$29 million</span></span><span style="font-family:inherit;font-size:9pt;">); manufacturing operations (</span><span style="font-family:inherit;font-size:9pt;"><span>$70 million</span></span><span style="font-family:inherit;font-size:9pt;">); and Corporate (</span><span style="font-family:inherit;font-size:9pt;"><span>$51 million</span></span><span style="font-family:inherit;font-size:9pt;">).</span></div></td></tr></table><div style="line-height:120%;padding-top:4px;text-align:left;padding-left:24px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">The restructuring activities for </span><span style="font-family:inherit;font-size:9pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:9pt;"> are associated with the following:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:12px;"><span style="font-family:inherit;font-size:9pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">For the </span><span style="font-family:inherit;font-size:9pt;">third quarter</span><span style="font-family:inherit;font-size:9pt;"> of </span><span style="font-family:inherit;font-size:9pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:9pt;">, IH (</span><span style="font-family:inherit;font-size:9pt;"><span>$148 million</span></span><span style="font-family:inherit;font-size:9pt;">); EH (</span><span style="font-family:inherit;font-size:9pt;"><span>$28 million</span></span><span style="font-family:inherit;font-size:9pt;">); WRD/GPD (</span><span style="font-family:inherit;font-size:9pt;"><span>$52 million</span></span><span style="font-family:inherit;font-size:9pt;">); manufacturing operations (</span><span style="font-family:inherit;font-size:9pt;"><span>$108 million</span></span><span style="font-family:inherit;font-size:9pt;">); and Corporate (</span><span style="font-family:inherit;font-size:9pt;"><span>$67 million</span></span><span style="font-family:inherit;font-size:9pt;">).</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:12px;"><span style="font-family:inherit;font-size:9pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">For the </span><span style="font-family:inherit;font-size:9pt;">first nine months of</span><span style="font-family:inherit;font-size:9pt;"> </span><span style="font-family:inherit;font-size:9pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:9pt;">, IH (</span><span style="font-family:inherit;font-size:9pt;"><span>$162 million</span></span><span style="font-family:inherit;font-size:9pt;">); EH (</span><span style="font-family:inherit;font-size:9pt;"><span>$19 million</span></span><span style="font-family:inherit;font-size:9pt;">); WRD/GPD (</span><span style="font-family:inherit;font-size:9pt;"><span>$104 million</span></span><span style="font-family:inherit;font-size:9pt;">); manufacturing operations (</span><span style="font-family:inherit;font-size:9pt;"><span>$181 million</span></span><span style="font-family:inherit;font-size:9pt;">); and Corporate (</span><span style="font-family:inherit;font-size:9pt;"><span>$107 million</span></span><span style="font-family:inherit;font-size:9pt;">).</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">The asset impairment charges for the </span><span style="font-family:inherit;font-size:9pt;">third</span><span style="font-family:inherit;font-size:9pt;"> quarter and the </span><span style="font-family:inherit;font-size:9pt;">first nine months of</span><span style="font-family:inherit;font-size:9pt;"> </span><span style="font-family:inherit;font-size:9pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:9pt;"> are largely associated with our acquisitions of Hospira and Medivation.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(c)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Transaction costs represent external costs for banking, legal, accounting and other similar services, which in the </span><span style="font-family:inherit;font-size:9pt;">third quarter</span><span style="font-family:inherit;font-size:9pt;"> of 2017 reflect the reversal of an accrual related to the acquisition of Medivation. Transaction costs for the </span><span style="font-family:inherit;font-size:9pt;">first nine months of</span><span style="font-family:inherit;font-size:9pt;"> </span><span style="font-family:inherit;font-size:9pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:9pt;"> are directly related to our acquisitions of Hospira, Anacor and Medivation. Transaction costs in the </span><span style="font-family:inherit;font-size:9pt;">third quarter</span><span style="font-family:inherit;font-size:9pt;"> of </span><span style="font-family:inherit;font-size:9pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:9pt;"> were mostly related to the Medivation acquisition, and in the </span><span style="font-family:inherit;font-size:9pt;">first nine months of</span><span style="font-family:inherit;font-size:9pt;"> </span><span style="font-family:inherit;font-size:9pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:9pt;">, were mostly related to the Medivation and Anacor acquisitions, and our terminated transaction with Allergan.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(d)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Integration costs represent external, incremental costs directly related to integrating acquired businesses, and primarily include expenditures for consulting and the integration of systems and processes. In the </span><span style="font-family:inherit;font-size:9pt;">third</span><span style="font-family:inherit;font-size:9pt;"> quarter and </span><span style="font-family:inherit;font-size:9pt;">first nine months of</span><span style="font-family:inherit;font-size:9pt;"> </span><span style="font-family:inherit;font-size:9pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:9pt;">, integration costs primarily relate to our acquisitions of Hospira and Medivation. The </span><span style="font-family:inherit;font-size:9pt;">first nine months of</span><span style="font-family:inherit;font-size:9pt;"> </span><span style="font-family:inherit;font-size:9pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:9pt;"> also include a net gain of </span><span style="font-family:inherit;font-size:9pt;"><span>$12 million</span></span><span style="font-family:inherit;font-size:9pt;"> related to the settlement of the Hospira U.S. qualified defined benefit pension plan (see </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Note 10</span><span style="font-family:inherit;font-size:9pt;">). In the </span><span style="font-family:inherit;font-size:9pt;">third quarter</span><span style="font-family:inherit;font-size:9pt;"> of </span><span style="font-family:inherit;font-size:9pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:9pt;">, integration </span></div></td></tr></table><div style="line-height:120%;padding-left:12px;text-align:left;"><span style="font-family:inherit;font-size:9pt;">costs were mostly related to our acquisition of Hospira, and in the </span><span style="font-family:inherit;font-size:9pt;">first nine months of</span><span style="font-family:inherit;font-size:9pt;"> </span><span style="font-family:inherit;font-size:9pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:9pt;">, integration costs were mostly related to our acquisition of Hospira and our terminated transaction with Allergan.</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(e)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Additional depreciation&#8211;&#8211;asset restructuring represents the impact of changes in the estimated useful lives of assets involved in restructuring actions.</span></div></td></tr></table><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(f)</sup>&#160;</span></div>Implementation costs represent external, incremental costs directly related to implementing our non-acquisition-related cost-reduction/productivity initiatives.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock', window );">Schedule of Components of and Changes in Restructuring Accruals</a></td>
<td class="text"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.05068226120858%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:41%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td colspan="17" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides the components of and changes in our restructuring accruals:</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Employee</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Termination Costs</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Asset</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Impairment Charges</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exit Costs</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrual</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance, December 31, 2016</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,547</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>36</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,583</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Provision</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>126</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>150</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Utilization and other</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(401</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(126</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(24</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(551</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance, October 1, 2017</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(c)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,154</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,182</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Included in </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Other current liabilities</span><span style="font-family:inherit;font-size:9pt;"> (</span><span style="font-family:inherit;font-size:9pt;"><span>$863 million</span></span><span style="font-family:inherit;font-size:9pt;">) and </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Other noncurrent liabilities</span><span style="font-family:inherit;font-size:9pt;"> (</span><span style="font-family:inherit;font-size:9pt;"><span>$720 million</span></span><span style="font-family:inherit;font-size:9pt;">).</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Includes adjustments for foreign currency translation.</span></div></td></tr></table><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(c)</sup>&#160;</span></div><span style="font-family:inherit;font-size:9pt;">Included in </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Other current liabilities </span><span style="font-family:inherit;font-size:9pt;">(</span><span style="font-family:inherit;font-size:9pt;"><span>$533 million</span></span><span style="font-family:inherit;font-size:9pt;">) and </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Other noncurrent liabilities </span><span style="font-family:inherit;font-size:9pt;">(</span><span style="font-family:inherit;font-size:9pt;"><span>$650 million</span></span>).<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140904-122747<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140864-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6916588128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other (Income)/Deductions - Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 01, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock', window );">Schedule of Other (Income)/Deductions - Net</a></td>
<td class="text"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:44%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td colspan="17" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides components of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net</span><span style="font-family:inherit;font-size:10pt;">:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nine Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">October&#160;1, <br/>2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">October&#160;2, <br/>2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">October&#160;1, <br/>2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">October&#160;2, <br/>2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest income</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(99</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(123</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(275</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(357</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest expense</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>320</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>291</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>940</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>889</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net interest expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>220</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>168</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>666</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>532</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Royalty-related income</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(140</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(233</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(331</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(695</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certain legal matters, net</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>183</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(40</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>194</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>494</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net gains on asset disposals</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(d)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(155</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(47</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(349</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(81</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:18px;text-indent:-18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Loss on sale and impairment on remeasurement of HIS net assets</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(e)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(12</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,422</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>52</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,422</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certain asset impairments</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(f)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>130</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>133</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>143</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,080</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Business and legal entity alignment costs</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(g)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>69</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>54</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>180</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other, net</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(h)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(191</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(55</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(445</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(117</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>51</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,417</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(16</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,815</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Interest income decreased in the </span><span style="font-family:inherit;font-size:8.5pt;">third</span><span style="font-family:inherit;font-size:8.5pt;"> quarter and </span><span style="font-family:inherit;font-size:8.5pt;">first nine months of</span><span style="font-family:inherit;font-size:8.5pt;"> </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:8.5pt;">, primarily driven by a lower investment balance. Interest expense increased in the </span><span style="font-family:inherit;font-size:8.5pt;">third</span><span style="font-family:inherit;font-size:8.5pt;"> quarter and </span><span style="font-family:inherit;font-size:8.5pt;">first nine months of</span><span style="font-family:inherit;font-size:8.5pt;"> </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:8.5pt;">, </span><span style="font-size:8.5pt;">primarily as a result of higher short-term interest rates, offset, in part, by the retirement of high-coupon debt and the issuance of new low-coupon debt</span><span style="font-family:inherit;font-size:8.5pt;">.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Royalty-related income </span><span style="font-family:inherit;font-size:8.5pt;">decreased</span><span style="font-family:inherit;font-size:8.5pt;"> in the </span><span style="font-family:inherit;font-size:8.5pt;">third</span><span style="font-family:inherit;font-size:8.5pt;"> quarter and </span><span style="font-family:inherit;font-size:8.5pt;">first nine months of</span><span style="font-family:inherit;font-size:8.5pt;"> </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:8.5pt;">, primarily due to lower royalty income for Enbrel of </span><span style="font-family:inherit;font-size:8.5pt;"><span>$139 million</span></span><span style="font-family:inherit;font-size:8.5pt;"> and </span><span style="font-family:inherit;font-size:8.5pt;"><span>$414 million</span></span><span style="font-family:inherit;font-size:8.5pt;">, respectively, resulting from the expiration on October 31, 2016 of the </span><span style="font-family:inherit;font-size:8.5pt;">36</span><span style="font-family:inherit;font-size:8.5pt;">-month royalty period under the collaboration agreement for Enbrel in the U.S. and Canada (the collaboration period under the agreement expired on October 31, 2013), partially offset by the addition of Xtandi royalty-related income of </span><span style="font-family:inherit;font-size:8.5pt;"><span>$73 million</span></span><span style="font-family:inherit;font-size:8.5pt;"> and </span><span style="font-family:inherit;font-size:8.5pt;"><span>$160 million</span></span><span style="font-family:inherit;font-size:8.5pt;">, respectively. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(c)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">In the </span><span style="font-family:inherit;font-size:8.5pt;">third quarter</span><span style="font-family:inherit;font-size:8.5pt;"> and </span><span style="font-family:inherit;font-size:8.5pt;">first nine months of</span><span style="font-family:inherit;font-size:8.5pt;"> </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:8.5pt;">, primarily includes a </span><span style="font-family:inherit;font-size:8.5pt;"><span>$94 million</span></span><span style="font-family:inherit;font-size:8.5pt;"> charge to resolve a class action lawsuit filed by direct purchasers relating to Celebrex, which is subject to the negotiation of a final settlement agreement and court approval, and a </span><span style="font-family:inherit;font-size:8.5pt;"><span>$79 million</span></span><span style="font-family:inherit;font-size:8.5pt;"> charge to reflect damages awarded by a jury in a patent matter. In the </span><span style="font-family:inherit;font-size:8.5pt;">first nine months of</span><span style="font-family:inherit;font-size:8.5pt;"> </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:8.5pt;">, primarily includes amounts to resolve a Multi-District Litigation relating to Celebrex and Bextra that was pending against the Company in New York federal court for </span><span style="font-family:inherit;font-size:8.5pt;"><span>$486 million</span></span><span style="font-family:inherit;font-size:8.5pt;">, partially offset by the reversal of a legal accrual where a loss was no longer deemed probable. In addition, the </span><span style="font-family:inherit;font-size:8.5pt;">first nine months of</span><span style="font-family:inherit;font-size:8.5pt;"> </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:8.5pt;"> includes a settlement related to a patent matter.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(d)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">In the </span><span style="font-family:inherit;font-size:8.5pt;">third</span><span style="font-family:inherit;font-size:8.5pt;"> quarter of </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:8.5pt;">, primarily includes gains on sales/out-licensing of product and compound rights (approximately </span><span style="font-family:inherit;font-size:8.5pt;"><span>$71 million</span></span><span style="font-family:inherit;font-size:8.5pt;">) and gains on sales and redemptions of investments in equity and debt securities (approximately </span><span style="font-family:inherit;font-size:8.5pt;"><span>$66 million</span></span><span style="font-family:inherit;font-size:8.5pt;">). In the </span><span style="font-family:inherit;font-size:8.5pt;">first nine months of</span><span style="font-family:inherit;font-size:8.5pt;"> </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:8.5pt;">, primarily includes gains on sales and redemptions of investments in equity and debt securities (approximately </span><span style="font-family:inherit;font-size:8.5pt;"><span>$183 million</span></span><span style="font-family:inherit;font-size:8.5pt;">), gains on sales/out-licensing of product and compound rights (approximately </span><span style="font-family:inherit;font-size:8.5pt;"><span>$141 million</span></span><span style="font-family:inherit;font-size:8.5pt;">) and a gain on sale of property (approximately </span><span style="font-family:inherit;font-size:8.5pt;"><span>$52 million</span></span><span style="font-family:inherit;font-size:8.5pt;">), partially offset by a net loss related to the sale of our </span><span style="font-family:inherit;font-size:8.5pt;"><span>40%</span></span><span style="font-family:inherit;font-size:8.5pt;"> ownership investment in Teuto, including the extinguishment of a put option for the remaining </span><span style="font-family:inherit;font-size:8.5pt;"><span>60%</span></span><span style="font-family:inherit;font-size:8.5pt;"> ownership interest (approximately </span><span style="font-family:inherit;font-size:8.5pt;"><span>$30 million</span></span><span style="font-family:inherit;font-size:8.5pt;">). In the </span><span style="font-family:inherit;font-size:8.5pt;">first nine months of</span><span style="font-family:inherit;font-size:8.5pt;"> </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:8.5pt;">, includes gains on sales/out-licensing of product and compound rights (approximately </span><span style="font-family:inherit;font-size:8.5pt;"><span>$49 million</span></span><span style="font-family:inherit;font-size:8.5pt;">).</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(e)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">In the </span><span style="font-family:inherit;font-size:8.5pt;">third</span><span style="font-family:inherit;font-size:8.5pt;"> quarter and </span><span style="font-family:inherit;font-size:8.5pt;">first nine months of</span><span style="font-family:inherit;font-size:8.5pt;"> </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:8.5pt;">, represents adjustments to amounts previously recorded to write down the HIS net assets to fair value less costs to sell related to the sale of HIS net assets to ICU Medical. In the </span><span style="font-family:inherit;font-size:8.5pt;">third</span><span style="font-family:inherit;font-size:8.5pt;"> quarter and </span><span style="font-family:inherit;font-size:8.5pt;">first nine months of</span><span style="font-family:inherit;font-size:8.5pt;"> </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:8.5pt;">, represents a charge related to the write-down of the HIS net assets to fair value less estimated costs to sell.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(f)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">In the </span><span style="font-family:inherit;font-size:8.5pt;">third quarter</span><span style="font-family:inherit;font-size:8.5pt;"> and </span><span style="font-family:inherit;font-size:8.5pt;">first nine months of</span><span style="font-family:inherit;font-size:8.5pt;"> </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:8.5pt;">, primarily includes an intangible asset impairment charge of </span><span style="font-family:inherit;font-size:8.5pt;"><span>$127 million</span></span><span style="font-family:inherit;font-size:8.5pt;"> related to developed technology rights, acquired in connection with our acquisition of Hospira, for a generic sterile injectable product for the treatment of edema associated with certain conditions. The intangible asset impairment charge for the </span><span style="font-family:inherit;font-size:8.5pt;">third</span><span style="font-family:inherit;font-size:8.5pt;"> quarter and </span><span style="font-family:inherit;font-size:8.5pt;">first nine months of</span><span style="font-family:inherit;font-size:8.5pt;"> </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:8.5pt;"> is associated with EH and reflects, among other things, updated commercial forecasts and an increased competitive environment. In the </span><span style="font-family:inherit;font-size:8.5pt;">third</span><span style="font-family:inherit;font-size:8.5pt;"> quarter of </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:8.5pt;">, primarily includes intangible asset impairment charges of </span><span style="font-family:inherit;font-size:8.5pt;"><span>$126 million</span></span><span style="font-family:inherit;font-size:8.5pt;">, reflecting </span><span style="font-family:inherit;font-size:8.5pt;"><span>$97 million</span></span><span style="font-family:inherit;font-size:8.5pt;"> of sterile injectable IPR&amp;D compounds acquired in connection with our acquisition of InnoPharma and </span><span style="font-family:inherit;font-size:8.5pt;"><span>$29 million</span></span><span style="font-family:inherit;font-size:8.5pt;"> of other IPR&amp;D assets acquired in connection with our acquisition of King in 2011. The intangible asset impairment charges for the </span><span style="font-family:inherit;font-size:8.5pt;">third quarter</span><span style="font-family:inherit;font-size:8.5pt;"> of </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:8.5pt;"> are associated with the following: EH (</span><span style="font-family:inherit;font-size:8.5pt;"><span>$97 million</span></span><span style="font-family:inherit;font-size:8.5pt;">) and IH (</span><span style="font-family:inherit;font-size:8.5pt;"><span>$29 million</span></span><span style="font-family:inherit;font-size:8.5pt;">). In the </span><span style="font-family:inherit;font-size:8.5pt;">first nine months of</span><span style="font-family:inherit;font-size:8.5pt;"> </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:8.5pt;">, primarily includes intangible asset impairment charges of </span><span style="font-family:inherit;font-size:8.5pt;"><span>$767 million</span></span><span style="font-family:inherit;font-size:8.5pt;">, reflecting (i) </span><span style="font-family:inherit;font-size:8.5pt;"><span>$331 million</span></span><span style="font-family:inherit;font-size:8.5pt;"> related to developed technology rights for a generic injectable antibiotic product for the treatment of bacterial infections; and (ii) </span><span style="font-family:inherit;font-size:8.5pt;"><span>$265 million</span></span><span style="font-family:inherit;font-size:8.5pt;"> related to an IPR&amp;D compound for the treatment of anemia, both acquired in connection with our acquisition of Hospira; (iii) </span><span style="font-family:inherit;font-size:8.5pt;"><span>$97 million</span></span><span style="font-family:inherit;font-size:8.5pt;"> of sterile injectable IPR&amp;D compounds acquired in connection with our acquisition of InnoPharma; and (iv) </span><span style="font-family:inherit;font-size:8.5pt;"><span>$74 million</span></span><span style="font-family:inherit;font-size:8.5pt;"> of other IPR&amp;D assets, </span><span style="font-family:inherit;font-size:8.5pt;"><span>$45 million</span></span><span style="font-family:inherit;font-size:8.5pt;"> of which were acquired in connection with our acquisition of Hospira and </span><span style="font-family:inherit;font-size:8.5pt;"><span>$29 million</span></span><span style="font-family:inherit;font-size:8.5pt;"> of which were acquired in connection with our acquisition of King in 2011. The intangible asset impairment charges for the </span><span style="font-family:inherit;font-size:8.5pt;">first nine months of</span><span style="font-family:inherit;font-size:8.5pt;"> </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:8.5pt;"> are associated with the following: EH (</span><span style="font-family:inherit;font-size:8.5pt;"><span>$738 million</span></span><span style="font-family:inherit;font-size:8.5pt;">) and IH (</span><span style="font-family:inherit;font-size:8.5pt;"><span>$29 million</span></span><span style="font-family:inherit;font-size:8.5pt;">). In addition, the </span><span style="font-family:inherit;font-size:8.5pt;">first nine months of</span><span style="font-family:inherit;font-size:8.5pt;"> </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:8.5pt;"> includes an impairment loss of </span><span style="font-family:inherit;font-size:8.5pt;"><span>$211 million</span></span><span style="font-family:inherit;font-size:8.5pt;"> related to Pfizer&#8217;s </span><span style="font-family:inherit;font-size:8.5pt;"><span>49%</span></span><span style="font-family:inherit;font-size:8.5pt;">-owned equity-method investment with Hisun in China, Hisun Pfizer, and an impairment loss of </span><span style="font-family:inherit;font-size:8.5pt;"><span>$50 million</span></span><span style="font-family:inherit;font-size:8.5pt;"> related to Pfizer&#8217;s </span><span style="font-family:inherit;font-size:8.5pt;"><span>40%</span></span><span style="font-family:inherit;font-size:8.5pt;">-owned equity-method investment in Teuto. For additional information concerning Hisun Pfizer and Teuto, see </span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Note 2D. </span></div></td></tr></table><div style="line-height:120%;padding-bottom:1px;padding-top:1px;padding-left:12px;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">The intangible asset impairment charge for 2016 for the IPR&amp;D compound for the treatment of anemia acquired in connection with our acquisition of Hospira reflects, among other things, the impact of regulatory delays, including delays resulting from a court ruling, which required a 180-day waiting period after approval before a biosimilar product can be launched. The intangible asset impairment charges for 2016 for the sterile injectable IPR&amp;D compounds acquired in connection with our acquisition of InnoPharma reflect, among other things, the impact of portfolio prioritization decisions and decreased commercial profiles of certain compounds. The intangible asset impairment charges for 2016 for developed technology rights and other IPR&amp;D assets acquired in connection with our acquisition of Hospira reflect, among other things, the impact of new scientific findings, updated commercial forecasts, changes in pricing, and an increased competitive environment. The intangible asset impairment charges for 2016 for other IPR&amp;D assets acquired in connection with our acquisition of King reflect changes in the competitive environment.</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(g)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">In the </span><span style="font-family:inherit;font-size:8.5pt;">third</span><span style="font-family:inherit;font-size:8.5pt;"> quarter and </span><span style="font-family:inherit;font-size:8.5pt;">first nine months of</span><span style="font-family:inherit;font-size:8.5pt;"> </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:8.5pt;"> and </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:8.5pt;">, represents expenses for changes to our infrastructure to align our commercial operations, including costs to internally separate our businesses into distinct legal entities, as well as to streamline our intercompany supply operations to better support each business. </span></div></td></tr></table><div style="line-height:120%;font-size:8.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(h)</sup>&#160;</span></div><span style="font-family:inherit;font-size:8.5pt;">In the </span><span style="font-family:inherit;font-size:8.5pt;">third quarter</span><span style="font-family:inherit;font-size:8.5pt;"> and </span><span style="font-family:inherit;font-size:8.5pt;">first nine months of</span><span style="font-family:inherit;font-size:8.5pt;"> </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:8.5pt;">, includes, among other things, dividend income of </span><span style="font-family:inherit;font-size:8.5pt;"><span>$54 million</span></span><span style="font-family:inherit;font-size:8.5pt;"> and </span><span style="font-family:inherit;font-size:8.5pt;"><span>$211 million</span></span><span style="font-family:inherit;font-size:8.5pt;">, respectively, from our investment in ViiV, and income of </span><span style="font-family:inherit;font-size:8.5pt;"><span>$62 million</span></span><span style="font-family:inherit;font-size:8.5pt;"> from resolution of a contract disagreement. In the </span><span style="font-family:inherit;font-size:8.5pt;">first nine months of</span><span style="font-family:inherit;font-size:8.5pt;"> </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:8.5pt;">, includes, among other things, </span><span style="font-family:inherit;font-size:8.5pt;"><span>$150 million</span></span><span style="font-family:inherit;font-size:8.5pt;"> paid to Allergan for reimbursement of Allergan&#8217;s expenses associated with the terminated transaction and income of </span><span style="font-family:inherit;font-size:8.5pt;"><span>$116 million</span></span> from resolution of a contract disagreement.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfImpairedIntangibleAssetsTextBlock', window );">Schedule of Impaired Intangible Assets</a></td>
<td class="text"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="21"/></tr><tr><td style="width:38%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td colspan="21" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides additional information about the intangible assets that were impaired during 2017 in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net</span><span style="font-family:inherit;font-size:10pt;">:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Fair Value</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Nine Months Ended</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">October 1, 2017</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Level 3</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Impairment</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Intangible assets</span><span style="font-family:inherit;font-size:9pt;font-style:italic;">&#8211;&#8211;</span><span style="font-family:inherit;font-size:9pt;">Developed technology rights</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(b)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>50</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>50</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>127</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">The fair value amount is presented as of the date of impairment, as these assets are not measured at fair value on a recurring basis.</span></div></td></tr></table><div style="line-height:120%;font-size:8.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(b)</sup>&#160;</span></div><span style="font-family:inherit;font-size:8.5pt;">Reflects intangible assets written down to fair value in the </span><span style="font-family:inherit;font-size:8.5pt;">third quarter</span><span style="font-family:inherit;font-size:8.5pt;"> of </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">2017</span>. Fair value was determined using the income approach, specifically the multi-period excess earnings method, also known as the discounted cash flow method. We started with a forecast of all the expected net cash flows associated with the asset and then applied an asset-specific discount rate to arrive at a net present value amount. Some of the more significant estimates and assumptions inherent in this approach include: the amount and timing of the projected net cash flows, which includes the expected impact of competitive, legal and/or regulatory forces on the product; the discount rate, which seeks to reflect the various risks inherent in the projected cash flows; and the tax rate, which seeks to incorporate the geographic diversity of the projected cash flows.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfImpairedIntangibleAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of impaired intangible assets excluding goodwill. This may include a description of the facts and circumstances leading to the recording of impairment charges of intangible assets in the period, the amount of the impairment charges, the methods of determining fair value of the associated assets, the caption in the income statement in which the impairment losses are aggregated, and the segment in which the impaired intangible assets are reported.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfImpairedIntangibleAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6919182288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Tax Matters (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 01, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Tax Provision (Benefit) on Other Comprehensive Income/(Loss)</a></td>
<td class="text"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90167158308752%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:56%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td colspan="17" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides the components of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Tax provision/(benefit) on</span><span style="font-family:inherit;font-size:10pt;">&#160;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">other comprehensive income:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Nine Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">October&#160;1, <br/>2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">October&#160;2, <br/>2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">October&#160;1, <br/>2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">October&#160;2, <br/>2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Foreign currency translation adjustments, net</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(62</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(192</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(15</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Unrealized holding losses on derivative financial instruments, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>28</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>30</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(192</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Reclassification adjustments for realized (gains)/losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(29</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>32</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(169</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>81</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>32</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(139</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(112</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Unrealized holding gains on available-for-sale securities, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>37</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>40</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>93</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>106</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Reclassification adjustments for realized gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(49</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(14</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(45</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(16</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(12</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>26</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>47</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>90</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Benefit plans: actuarial losses, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(37</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(31</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(15</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(39</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Reclassification adjustments related to amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>60</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>47</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>152</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>140</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Reclassification adjustments related to settlements, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>22</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>30</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>27</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(33</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>14</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(46</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>40</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>121</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>133</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Benefit plans: prior service (costs)/credits and other, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>35</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>66</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Reclassification adjustments related to amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(17</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(17</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(50</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(47</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Reclassification adjustments related to curtailments, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(17</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>18</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(55</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>15</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">Tax provision/(benefit) on other comprehensive income</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(80</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>116</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(218</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>111</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup>&#160;</span></div>Taxes are not provided for foreign currency translation adjustments relating to investments in international subsidiaries that will be held indefinitely.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Other Comprehensive Income (Loss), Components of Income Tax Expense (Benefit) [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6920940704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 01, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Schedule of Changes in Accumulated Other Comprehensive Loss, Net of Tax</a></td>
<td class="text"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"/></tr><tr><td style="width:23%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td colspan="25" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides the changes, net of tax, in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Accumulated other comprehensive loss</span><span style="font-family:inherit;font-size:10pt;">:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net Unrealized Gains/(Losses)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Benefit Plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign Currency Translation Adjustments </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Derivative Financial Instruments</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Available-For-Sale Securities</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Actuarial Gains/(Losses)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prior Service (Costs)/Credits and Other</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accumulated Other Comprehensive Income/(Loss)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance, December&#160;31, 2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6,659</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>348</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(131</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5,473</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>879</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(11,036</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other comprehensive income/(loss)</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,638</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(403</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>470</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>263</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(96</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,872</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance, October&#160;1, 2017</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5,021</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(55</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>339</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5,210</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>783</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(9,164</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup>&#160;</span></div><span style="font-family:inherit;font-size:9pt;">Amounts do not include foreign currency translation adjustments attributable to noncontrolling interests of </span><span style="font-family:inherit;font-size:9pt;"><span>$16 million</span></span><span style="font-family:inherit;font-size:9pt;"> income for the </span><span style="font-family:inherit;font-size:9pt;">first nine months of</span><span style="font-family:inherit;font-size:9pt;"> </span><span style="font-family:inherit;font-size:9pt;text-align:center;">2017</span>.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6921620384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 01, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_FinancialInstrumentsAbstract', window );"><strong>Financial Instruments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Information about Certain Financial Assets and Liabilities</a></td>
<td class="text"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:74%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides additional information about certain of our financial assets and liabilities:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">October&#160;1, <br/>2017</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">December&#160;31, <br/>2016</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:justify;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;text-decoration:underline;">Selected financial assets measured at fair value on a recurring basis</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Trading funds and securities</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>347</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>325</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Available-for-sale debt securities</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>16,598</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>18,632</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Money market funds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1,824</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1,445</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Available-for-sale equity securities</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1,032</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>540</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Derivative financial instruments in a receivable position</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(d)</sup></span><span style="font-family:inherit;font-size:9pt;">:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Interest rate swaps</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>630</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>625</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Foreign currency swaps</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>92</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>79</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Foreign currency forward-exchange contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>110</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>551</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>20,631</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>22,198</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;text-decoration:underline;">Other selected financial assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Held-to-maturity debt securities, carried at amortized cost</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(c), (e)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1,464</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1,242</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Restricted stock and private equity securities, carried at cost or at equity-method</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(e)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>719</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>735</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2,183</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1,977</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total selected financial assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>22,815</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>24,175</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;text-decoration:underline;">Selected financial liabilities measured at fair value on a recurring basis</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Derivative financial instruments in a liability position</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(f)</sup></span><span style="font-family:inherit;font-size:9pt;">:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Interest rate swaps</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>154</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>148</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Foreign currency swaps</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>710</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1,374</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Foreign currency forward-exchange contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>309</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>143</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1,173</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1,665</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;text-decoration:underline;">Other selected financial liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Short-term borrowings:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Principal amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>9,460</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>10,674</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net fair value adjustments related to hedging and purchase accounting</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>24</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net unamortized discounts, premiums and debt issuance costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(15</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(11</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:30px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total short-term borrowings, carried at historical proceeds, as adjusted</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(e)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>9,448</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>10,688</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Long-term debt:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Principal amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>33,671</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>30,529</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net fair value adjustments related to hedging and purchase accounting</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>981</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>998</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net unamortized discounts, premiums and debt issuance costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(149</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(130</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:30px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total long-term debt, carried at historical proceeds, as adjusted</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(g)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>34,503</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>31,398</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>43,951</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>42,085</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total selected financial liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>45,124</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>43,750</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">We use a market approach in valuing financial instruments on a recurring basis. All of our financial assets and liabilities measured at fair value on a recurring basis use Level 2 inputs in the calculation of fair value, except </span><span style="font-family:inherit;font-size:8.5pt;"><span>5%</span></span><span style="font-family:inherit;font-size:8.5pt;"> that use Level 1 inputs.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">As of </span><span style="font-family:inherit;font-size:8.5pt;">October&#160;1, 2017</span><span style="font-family:inherit;font-size:8.5pt;">, trading funds and securities are composed of </span><span style="font-family:inherit;font-size:8.5pt;"><span>$274 million</span></span><span style="font-family:inherit;font-size:8.5pt;"> of trading equity funds and </span><span style="font-family:inherit;font-size:8.5pt;"><span>$74 million</span></span><span style="font-family:inherit;font-size:8.5pt;"> of trading debt funds. As of </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">December&#160;31, 2016</span><span style="font-family:inherit;font-size:8.5pt;">, trading funds and securities are composed of </span><span style="font-family:inherit;font-size:8.5pt;"><span>$236 million</span></span><span style="font-family:inherit;font-size:8.5pt;"> of trading equity funds and </span><span style="font-family:inherit;font-size:8.5pt;"><span>$89 million</span></span><span style="font-family:inherit;font-size:8.5pt;"> of trading debt funds. As of </span><span style="font-family:inherit;font-size:8.5pt;">October&#160;1, 2017</span><span style="font-family:inherit;font-size:8.5pt;"> and </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">December&#160;31, 2016</span><span style="font-family:inherit;font-size:8.5pt;">, trading equity funds of </span><span style="font-family:inherit;font-size:8.5pt;"><span>$63 million</span></span><span style="font-family:inherit;font-size:8.5pt;"> and </span><span style="font-family:inherit;font-size:8.5pt;"><span>$71 million</span></span><span style="font-family:inherit;font-size:8.5pt;">, respectively, are held in trust for benefits attributable to the former Pharmacia Savings Plus Plan.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(c)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Gross unrealized gains and losses are not significant, except as of </span><span style="font-family:inherit;font-size:8.5pt;">October&#160;1, 2017</span><span style="font-family:inherit;font-size:8.5pt;">, available-for-sale equity securities&#8217; unrealized gains are </span><span style="font-family:inherit;font-size:8.5pt;"><span>$406 million</span></span><span style="font-family:inherit;font-size:8.5pt;"> and unrealized losses are </span><span style="font-family:inherit;font-size:8.5pt;"><span>$119 million</span></span><span style="font-family:inherit;font-size:8.5pt;">.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(d)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Designated as hedging instruments, except for certain contracts used as offsets; namely, foreign currency forward-exchange contracts with fair values of </span><span style="font-family:inherit;font-size:8.5pt;"><span>$40 million</span></span><span style="font-family:inherit;font-size:8.5pt;"> as of </span><span style="font-family:inherit;font-size:8.5pt;">October&#160;1, 2017</span><span style="font-family:inherit;font-size:8.5pt;">; and foreign currency forward-exchange contracts with fair values of </span><span style="font-family:inherit;font-size:8.5pt;"><span>$162 million</span></span><span style="font-family:inherit;font-size:8.5pt;"> as of </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">December&#160;31, 2016</span><span style="font-family:inherit;font-size:8.5pt;">.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(e)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">The differences between the estimated fair values and carrying values of held-to-maturity debt securities, restricted stock and private equity securities at cost, and short-term borrowings not measured at fair value on a recurring basis were not significant as of </span><span style="font-family:inherit;font-size:8.5pt;">October&#160;1, 2017</span><span style="font-family:inherit;font-size:8.5pt;"> or </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">December&#160;31, 2016</span><span style="font-family:inherit;font-size:8.5pt;">. The fair value measurements of our held-to-maturity debt securities and our short-term borrowings are based on Level 2 inputs, using a market approach. The fair value measurements of our </span><span style="font-family:inherit;font-size:8.5pt;background-color:#ffffff;">priv</span><span style="font-family:inherit;font-size:8.5pt;">ate equity securities carried at cost are based on Level 3 inputs.</span></div></td></tr></table><div style="line-height:120%;padding-left:4px;text-align:left;padding-left:12px;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(f)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Designated as hedging instruments, except for certain contracts used as offsets; namely, foreign currency forward-exchange contracts with fair values of </span><span style="font-family:inherit;font-size:8.5pt;"><span>$60 million</span></span><span style="font-family:inherit;font-size:8.5pt;"> as of </span><span style="font-family:inherit;font-size:8.5pt;">October&#160;1, 2017</span><span style="font-family:inherit;font-size:8.5pt;">; and foreign currency swaps with fair values of </span><span style="font-family:inherit;font-size:8.5pt;"><span>$269 million</span></span><span style="font-family:inherit;font-size:8.5pt;"> and foreign currency forward-exchange contracts with fair values of </span><span style="font-family:inherit;font-size:8.5pt;"><span>$113 million</span></span><span style="font-family:inherit;font-size:8.5pt;"> as of </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">December&#160;31, 2016</span><span style="font-family:inherit;font-size:8.5pt;">.</span></div></td></tr></table><div style="line-height:120%;font-size:8.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(g)</sup>&#160;</span></div><span style="font-family:inherit;font-size:8.5pt;">The fair value of our long-term debt (not including the current portion of long-term debt) was </span><span style="font-family:inherit;font-size:8.5pt;"><span>$39.0 billion</span></span><span style="font-family:inherit;font-size:8.5pt;"> as of </span><span style="font-family:inherit;font-size:8.5pt;">October&#160;1, 2017</span><span style="font-family:inherit;font-size:8.5pt;"> and </span><span style="font-family:inherit;font-size:8.5pt;"><span>$34.9 billion</span></span><span style="font-family:inherit;font-size:8.5pt;"> as of </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">December&#160;31, 2016</span><span style="font-family:inherit;font-size:8.5pt;">. The fair value measurements for our long-term debt are based on Level 2 inputs, using a market approach. Long-term debt includes foreign currency long-term borrowings with fair values of </span><span style="font-family:inherit;font-size:8.5pt;"><span>$4.7 billion</span></span><span style="font-family:inherit;font-size:8.5pt;"> as of </span><span style="font-family:inherit;font-size:8.5pt;">October&#160;1, 2017</span>, which are used as hedging instruments.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock', window );">Selected Financial Assets and Liabilities Presented in the Condensed Consolidated Balance Sheets</a></td>
<td class="text"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:72%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides the classification of these selected financial assets and liabilities in our condensed consolidated balance sheets:</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">October&#160;1, <br/>2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December&#160;31, <br/>2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>526</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>547</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Short-term investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,146</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15,255</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other current assets</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>288</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>567</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Long-term investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,311</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,116</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other noncurrent assets</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>543</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>689</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22,815</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24,175</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Short-term borrowings, including current portion of long-term debt</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,448</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,688</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other current liabilities</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>277</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>443</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Long-term debt</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34,503</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>31,398</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other noncurrent liabilities</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(d)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>896</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,222</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>45,124</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>43,750</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">As of </span><span style="font-family:inherit;font-size:9pt;">October&#160;1, 2017</span><span style="font-family:inherit;font-size:9pt;">, derivative instruments at fair value include interest rate swaps (</span><span style="font-family:inherit;font-size:9pt;"><span>$97 million</span></span><span style="font-family:inherit;font-size:9pt;">), foreign currency swaps (</span><span style="font-family:inherit;font-size:9pt;"><span>$86 million</span></span><span style="font-family:inherit;font-size:9pt;">) and foreign currency forward-exchange contracts (</span><span style="font-family:inherit;font-size:9pt;"><span>$105 million</span></span><span style="font-family:inherit;font-size:9pt;">) and, as of </span><span style="font-family:inherit;font-size:9pt;text-align:center;">December&#160;31, 2016</span><span style="font-family:inherit;font-size:9pt;">, include interest rate swaps (</span><span style="font-family:inherit;font-size:9pt;"><span>$26 million</span></span><span style="font-family:inherit;font-size:9pt;">), foreign currency swaps (</span><span style="font-family:inherit;font-size:9pt;"><span>$43 million</span></span><span style="font-family:inherit;font-size:9pt;">) and foreign currency forward-exchange contracts (</span><span style="font-family:inherit;font-size:9pt;"><span>$497 million</span></span><span style="font-family:inherit;font-size:9pt;">).</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">As of </span><span style="font-family:inherit;font-size:9pt;">October&#160;1, 2017</span><span style="font-family:inherit;font-size:9pt;">, derivative instruments at fair value include interest rate swaps (</span><span style="font-family:inherit;font-size:9pt;"><span>$532 million</span></span><span style="font-family:inherit;font-size:9pt;">), foreign currency swaps (</span><span style="font-family:inherit;font-size:9pt;"><span>$6 million</span></span><span style="font-family:inherit;font-size:9pt;">) and foreign currency forward-exchange contracts (</span><span style="font-family:inherit;font-size:9pt;"><span>$5 million</span></span><span style="font-family:inherit;font-size:9pt;">) and, as of </span><span style="font-family:inherit;font-size:9pt;text-align:center;">December&#160;31, 2016</span><span style="font-family:inherit;font-size:9pt;">, include interest rate swaps (</span><span style="font-family:inherit;font-size:9pt;"><span>$599 million</span></span><span style="font-family:inherit;font-size:9pt;">), foreign currency swaps (</span><span style="font-family:inherit;font-size:9pt;"><span>$36 million</span></span><span style="font-family:inherit;font-size:9pt;">) and foreign currency forward-exchange contracts (</span><span style="font-family:inherit;font-size:9pt;"><span>$54 million</span></span><span style="font-family:inherit;font-size:9pt;">).</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(c)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">As of </span><span style="font-family:inherit;font-size:9pt;">October&#160;1, 2017</span><span style="font-family:inherit;font-size:9pt;">, derivative instruments at fair value include foreign currency forward-exchange contracts (</span><span style="font-family:inherit;font-size:9pt;"><span>$276 million</span></span><span style="font-family:inherit;font-size:9pt;">) and interest rate swaps (</span><span style="font-family:inherit;font-size:9pt;"><span>$1 million</span></span><span style="font-family:inherit;font-size:9pt;">) and, as of </span><span style="font-family:inherit;font-size:9pt;text-align:center;">December&#160;31, 2016</span><span style="font-family:inherit;font-size:9pt;">, include interest rate swaps (</span><span style="font-family:inherit;font-size:9pt;"><span>$1 million</span></span><span style="font-family:inherit;font-size:9pt;">), foreign currency swaps (</span><span style="font-family:inherit;font-size:9pt;"><span>$300 million</span></span><span style="font-family:inherit;font-size:9pt;">) and foreign currency forward-exchange contracts (</span><span style="font-family:inherit;font-size:9pt;"><span>$143 million</span></span><span style="font-family:inherit;font-size:9pt;">).</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(d)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">As of </span><span style="font-family:inherit;font-size:9pt;">October&#160;1, 2017</span><span style="font-family:inherit;font-size:9pt;">, derivative instruments at fair value include interest rate swaps (</span><span style="font-family:inherit;font-size:9pt;"><span>$153 million</span></span><span style="font-family:inherit;font-size:9pt;">), foreign currency swaps (</span><span style="font-family:inherit;font-size:9pt;"><span>$710 million</span></span><span style="font-family:inherit;font-size:9pt;">) and foreign currency forward-exchange contracts (</span><span style="font-family:inherit;font-size:9pt;"><span>$33 million</span></span><span style="font-family:inherit;font-size:9pt;">) and, as of </span><span style="font-family:inherit;font-size:9pt;text-align:center;">December&#160;31, 2016</span><span style="font-family:inherit;font-size:9pt;">, include interest rate swaps (</span><span style="font-family:inherit;font-size:9pt;"><span>$147 million</span></span><span style="font-family:inherit;font-size:9pt;">) and foreign currency swaps (</span><span style="font-family:inherit;font-size:9pt;"><span>$1.1 billion</span></span><span style="font-family:inherit;font-size:9pt;">).</span></div></td></tr></table><br/><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Contractual Maturities of Available-for-sale and Held-to-maturity Debt Securities</a></td>
<td class="text"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.41520467836257%;border-collapse:collapse;text-align:left;"><tr><td colspan="21"/></tr><tr><td style="width:47%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td colspan="21" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides the contractual maturities, or as necessary, the estimated maturities, of the available-for-sale and held-to-maturity debt securities:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Years</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">October&#160;1, <br/>2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Within 1</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Over 1</span></div><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">to 5</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Over 5</span></div><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">to 10</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Over 10</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">Available-for-sale debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Corporate debt</span><span style="font-family:inherit;font-size:9.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>2,741</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>2,591</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>1,525</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>17</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>6,874</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Western European, Asian, and other government debt</span><span style="font-family:inherit;font-size:9.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>6,071</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>268</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>6,339</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Western European, Scandinavian and other government agency debt</span><span style="font-family:inherit;font-size:9.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>1,955</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>42</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>1,998</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Supranational debt</span><span style="font-family:inherit;font-size:9.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>387</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>195</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>582</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Government National Mortgage Association and other U.S. government guaranteed asset-backed securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>42</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>424</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>466</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Other asset-backed debt</span><span style="font-family:inherit;font-size:9.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>161</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>61</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>226</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">U.S. government debt</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>112</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>112</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">Held-to-maturity debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Time deposits and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>1,133</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>1,137</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Western European government debt</span><span style="font-family:inherit;font-size:9.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>326</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>326</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Total debt securities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>12,818</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>3,694</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>1,532</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>18</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>18,061</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Issued by a diverse group of corporations, with a significant concentration in the technology sector, virtually all of which are investment-grade.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Issued by governments, government agencies or supranational entities, as applicable, all of which are high quality.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(c)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Includes receivable-backed, loan-backed, and mortgage-backed securities, all of which are high quality and in senior positions in the capital structure of the security. Receivable-backed securities are collateralized by credit cards receivables, loan-backed securities are collateralized by senior secured obligations of a diverse pool of companies or student loans, and mortgage-backed securities are collateralized by diversified pools of residential and commercial mortgages.</span></div></td></tr></table><br/><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Schedule of Principal Amounts and Components of Unsecured Long-term Debt Issued</a></td>
<td class="text"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"/></tr><tr><td style="width:58%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides the amounts of senior unsecured long-term debt issued in the first quarter of 2017:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Principal</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">As of October&#160;1, 2017</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Maturity Date</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Euro</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">U.S. Dollar</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">3-month EURIBOR + 0.20% floating rate notes (0% floor)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">March&#160;6, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8364;</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1,250</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1,479</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">0.00% euro notes</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">March&#160;6, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1,183</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">0.25% euro notes</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">March&#160;6, 2022</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1,183</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1.00% euro notes</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">March&#160;6, 2027</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>750</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>887</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total euro long-term debt issued in the first quarter of 2017</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8364;</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>4,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>4,732</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">4.20% notes</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">March 17, 2047</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1,065</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total long-term debt issued in the first quarter of 2017</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(d)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>5,797</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Redeemable at any time, in whole, or in part, at our option prior to 30 to 90 days of maturity date at the comparable German government bond rate, plus </span><span style="font-family:inherit;font-size:8.5pt;"><span>0.15%</span></span><span style="font-family:inherit;font-size:8.5pt;">; plus, in each case, accrued and unpaid interest. The fixed rate euro notes are also redeemable at our option, in whole, or in part, within 30 to 90 days of maturity date.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">The weighted-average effective interest rate for the euro notes at issuance was </span><span style="font-family:inherit;font-size:8.5pt;"><span>0.23%</span></span><span style="font-family:inherit;font-size:8.5pt;">.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(c)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">The notes, issued in U.S. dollars in Taiwan, are redeemable, at our option, in whole but not in part, on each March 17 on or after March 17, 2020.</span></div></td></tr></table><div style="line-height:120%;font-size:8.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(d)</sup>&#160;</span></div><span style="font-family:inherit;font-size:8.5pt;">The aggregate amount at issuance date was </span><span style="font-family:inherit;font-size:8.5pt;"><span>$5,279 million</span></span>. The increase in the amount since the date of issuance is due to foreign currency exchange.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Maturity Schedule of Long-term Debt Outstanding</a></td>
<td class="text"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"/></tr><tr><td style="width:28%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td colspan="25" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides the maturity schedule of our </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Long-term debt</span><span style="font-family:inherit;font-size:10pt;">&#160;outstanding as of October 1, 2017:</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">After 2021</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Maturities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>481</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,825</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,534</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,502</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23,162</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34,503</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock', window );">Information about Gains/(Losses) Incurred to Hedge or Offset Operational Foreign Exchange or Interest Rate Risk</a></td>
<td class="text"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"/></tr><tr><td style="width:28%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td colspan="25" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides information about the gains/(losses) incurred to hedge or offset operational foreign exchange or interest rate risk:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Three Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Amount of</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Gains/(Losses)</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Recognized in OID</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a), (b), (c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Amount of</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Gains/(Losses)</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Recognized in OCI</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(Effective Portion)</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a), (d)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Amount of</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Gains/(Losses)</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Reclassified from</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">OCI into OID and COS</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(Effective Portion)</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a), (d)</sup></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">October&#160;1, <br/>2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">October&#160;2, <br/>2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">October&#160;1, <br/>2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">October&#160;2, <br/>2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">October&#160;1, <br/>2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">October&#160;2, <br/>2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Derivative Financial Instruments in Cash Flow Hedge Relationships:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Foreign currency swaps</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>218</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>87</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>148</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(39</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Foreign currency forward-exchange contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(269</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(212</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(204</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(111</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Derivative Financial Instruments in Net Investment Hedge Relationships:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Foreign currency forward-exchange contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Derivative Financial Instruments Not Designated as Hedges:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Foreign currency forward-exchange contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>33</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>20</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Foreign currency swaps</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Non-Derivative Financial Instruments in Net Investment Hedge Relationships:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Foreign currency long-term debt</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(166</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">All other net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>34</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>18</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(216</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(126</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(55</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(150</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Nine Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Amount of</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Gains/(Losses)</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Recognized in OID</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a), (b), (c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Amount of</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Gains/(Losses)</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Recognized in OCI</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(Effective Portion)</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a), (d)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Amount of</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Gains/(Losses)</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Reclassified from</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">OCI into OID and COS</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(Effective Portion)</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a), (d)</sup></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">October&#160;1, <br/>2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">October&#160;2, <br/>2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">October&#160;1, <br/>2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">October&#160;2, <br/>2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">October&#160;1, <br/>2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">October&#160;2, <br/>2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Derivative Financial Instruments in Cash Flow Hedge Relationships:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Foreign currency swaps</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>455</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(204</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>419</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(165</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Foreign currency forward-exchange contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(604</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(770</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(26</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(118</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Derivative Financial Instruments in Net Investment Hedge Relationships:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Foreign currency forward-exchange contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(15</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Derivative Financial Instruments Not Designated as Hedges:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Foreign currency forward-exchange contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(111</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(49</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Foreign currency swaps</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Non-Derivative Financial Instruments in Net Investment Hedge Relationships:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Foreign currency short-term borrowings</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(26</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Foreign currency long-term debt</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(518</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">All other net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(117</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(56</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(666</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(1,014</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>394</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(283</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr></table></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">OID = Other (income)/deductions&#8212;net, included in </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Other (income)/deductions&#8212;net</span><span style="font-family:inherit;font-size:9pt;"> in the condensed consolidated statements of income. COS = Cost of sales, included in </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Cost of sales</span><span style="font-family:inherit;font-size:9pt;"> in the condensed consolidated statements of income.</span></div></td></tr></table><div style="line-height:120%;padding-left:12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">OCI = Other comprehensive income/(loss), included in the</span><span style="font-family:inherit;font-size:9pt;font-style:italic;"> </span><span style="font-family:inherit;font-size:9pt;">condensed consolidated statements of comprehensive income</span><span style="font-family:inherit;font-size:9pt;font-style:italic;">.</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Includes gains and losses attributable to derivative instruments designated and qualifying as fair value hedges (primarily interest rate swaps), as well as the offsetting gains and losses attributable to the hedged items in such hedging relationships.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(c)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">There was no significant ineffectiveness for any period presented.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(d)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">For derivative financial instruments in cash flow hedge relationships, the effective portion is included in </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Other comprehensive income&#8211;&#8211;Unrealized holding losses on derivative financial instruments, net</span><span style="font-family:inherit;font-size:9pt;">. For derivative financial instruments in net investment hedge relationships and for foreign currency debt designated as hedging instruments, the effective portion is included in </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Other comprehensive income&#8211;&#8211;Foreign currency translation adjustments, net.</span></div></td></tr></table><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_FinancialInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financial Instruments [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_FinancialInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19279-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2C<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=SL7498348-110258<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19190-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13476-108611<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13467-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=75026489&amp;loc=d3e13220-108610<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14172-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13433-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByBalanceSheetGroupingTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21475-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=75038535&amp;loc=d3e64711-112823<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(e),(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=64930739&amp;loc=d3e28878-108400<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21538-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21506-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28541-108399<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28551-108399<br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21521-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -URI http://asc.fasb.org/extlink&amp;oid=84234895&amp;loc=SL5624171-113959<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84234895&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the combined aggregate amount of maturities and sinking fund requirements for all long-term borrowings for each of the five years following the date of the latest balance sheet date presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6917317616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 01, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Components of Inventories, Current</a></td>
<td class="text"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides the components of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Inventories</span><span style="font-family:inherit;font-size:10pt;">:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">October&#160;1, <br/>2017</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December&#160;31, <br/>2016</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finished goods</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,977</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,293</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Work-in-process</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,070</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,696</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Raw materials and supplies</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>879</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>793</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Inventories</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,925</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,783</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Noncurrent inventories not included above</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(b)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>669</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>683</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">The change from </span><span style="font-family:inherit;font-size:9pt;text-align:center;">December&#160;31, 2016</span><span style="font-family:inherit;font-size:9pt;"> reflects the build of inventory primarily for and in advance of new or potential product launches and increases to meet targeted levels for certain products in the normal course of business, including those related to demand.</span></div></td></tr></table><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(b)</sup>&#160;</span></div><span style="font-family:inherit;font-size:9pt;">Included in </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Other noncurrent assets</span>. There are no recoverability issues associated with these amounts.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock', window );">Schedule of Components of Inventories, Noncurrent</a></td>
<td class="text"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides the components of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Inventories</span><span style="font-family:inherit;font-size:10pt;">:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">October&#160;1, <br/>2017</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December&#160;31, <br/>2016</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finished goods</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,977</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,293</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Work-in-process</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,070</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,696</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Raw materials and supplies</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>879</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>793</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Inventories</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,925</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,783</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Noncurrent inventories not included above</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(b)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>669</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>683</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">The change from </span><span style="font-family:inherit;font-size:9pt;text-align:center;">December&#160;31, 2016</span><span style="font-family:inherit;font-size:9pt;"> reflects the build of inventory primarily for and in advance of new or potential product launches and increases to meet targeted levels for certain products in the normal course of business, including those related to demand.</span></div></td></tr></table><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(b)</sup>&#160;</span></div><span style="font-family:inherit;font-size:9pt;">Included in </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Other noncurrent assets</span>. There are no recoverability issues associated with these amounts.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle including inventoried costs relating to long-term contracts or programs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6749751168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Identifiable Intangible Assets and Goodwill (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 01, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Finite-Lived Intangible Assets</a></td>
<td class="text"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"/></tr><tr><td style="width:28%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td colspan="25" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides the components of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Identifiable intangible assets</span><span style="font-family:inherit;font-size:10pt;">:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">October&#160;1, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Carrying</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amount</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accumulated</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Identifiable</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Intangible</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Assets, less</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accumulated</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Carrying</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amount</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accumulated</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Identifiable</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Intangible</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Assets, less</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accumulated</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Finite-lived intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Developed technology rights</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>89,585</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(53,960</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35,625</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>83,390</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(49,650</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>33,740</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Brands</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,135</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,127</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,008</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,092</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,032</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,060</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Licensing agreements and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,930</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,071</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>859</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,869</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,005</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>864</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>93,650</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(56,158</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>37,492</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>87,351</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(51,687</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35,664</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Indefinite-lived intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Brands and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,937</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,937</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,883</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,883</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">IPR&amp;D</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(a)</sup></span><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,292</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,292</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,101</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,101</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,229</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,229</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,984</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,984</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Identifiable intangible assets</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(b)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>105,879</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(56,158</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>49,721</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>104,335</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(51,687</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>52,648</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">The changes in the gross carrying amount of </span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Developed technology rights </span><span style="font-family:inherit;font-size:8.5pt;">and </span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">IPR&amp;D</span><span style="font-family:inherit;font-size:8.5pt;"> primarily reflect (i) the transfer of </span><span style="font-family:inherit;font-size:8.5pt;"><span>$4.8 billion</span></span><span style="font-family:inherit;font-size:8.5pt;"> from </span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">IPR&amp;D</span><span style="font-family:inherit;font-size:8.5pt;"> to </span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Developed technology rights</span><span style="font-family:inherit;font-size:8.5pt;"> to reflect the approval of Eucrisa, (ii) the </span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Developed technology rights</span><span style="font-family:inherit;font-size:8.5pt;"> and </span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">IPR&amp;D</span><span style="font-family:inherit;font-size:8.5pt;"> acquired as part of the acquisition of AstraZeneca&#8217;s small molecule anti-infectives business (see </span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Note 2A</span><span style="font-family:inherit;font-size:8.5pt;">), (iii) the </span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Developed technology rights</span><span style="font-family:inherit;font-size:8.5pt;"> of </span><span style="font-family:inherit;font-size:8.5pt;"><span>$371 million</span></span><span style="font-family:inherit;font-size:8.5pt;"> recorded in connection with the EU and U.S. approvals of Besponsa (see </span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Note 7E</span><span style="font-family:inherit;font-size:8.5pt;">), partially offset by (iv) measurement period adjustments related to Medivation (see </span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Note 2A</span><span style="font-family:inherit;font-size:8.5pt;">) and (v) impairments of </span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Developed technology rights</span><span style="font-family:inherit;font-size:8.5pt;"> (see </span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Note 4)</span><span style="font-family:inherit;font-size:8.5pt;">.</span></div></td></tr></table><div style="line-height:120%;font-size:8.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(b)</sup>&#160;</span></div><span style="font-family:inherit;font-size:8.5pt;">The decrease in </span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">I</span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;text-align:right;">dentifiable intangible assets, less accumulated amortization</span><span style="font-family:inherit;font-size:8.5pt;text-align:right;">, </span><span style="font-family:inherit;font-size:8.5pt;">is primarily due to amortization, measurement period adjustments related to Medivation (see </span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Note 2A</span><span style="font-family:inherit;font-size:8.5pt;">), as well as impairments of </span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Developed technology rights</span><span style="font-family:inherit;font-size:8.5pt;"> (see </span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Note 4)</span><span style="font-family:inherit;font-size:8.5pt;">, partially offset by assets acquired as part of the acquisition of AstraZeneca&#8217;s small molecule anti-infectives business (see </span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Note 2A</span><span style="font-family:inherit;font-size:8.5pt;">) and the assets recorded in connection with the EU and U.S. approvals of Besponsa (see </span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Note 7E</span>).<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Indefinite Lived Intangible Assets</a></td>
<td class="text"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"/></tr><tr><td style="width:28%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td colspan="25" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides the components of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Identifiable intangible assets</span><span style="font-family:inherit;font-size:10pt;">:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">October&#160;1, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Carrying</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amount</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accumulated</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Identifiable</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Intangible</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Assets, less</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accumulated</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Carrying</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amount</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accumulated</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Identifiable</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Intangible</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Assets, less</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accumulated</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Finite-lived intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Developed technology rights</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>89,585</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(53,960</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35,625</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>83,390</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(49,650</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>33,740</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Brands</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,135</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,127</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,008</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,092</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,032</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,060</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Licensing agreements and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,930</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,071</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>859</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,869</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,005</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>864</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>93,650</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(56,158</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>37,492</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>87,351</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(51,687</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35,664</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Indefinite-lived intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Brands and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,937</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,937</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,883</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,883</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">IPR&amp;D</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(a)</sup></span><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,292</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,292</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,101</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,101</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,229</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,229</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,984</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,984</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Identifiable intangible assets</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(b)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>105,879</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(56,158</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>49,721</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>104,335</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(51,687</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>52,648</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">The changes in the gross carrying amount of </span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Developed technology rights </span><span style="font-family:inherit;font-size:8.5pt;">and </span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">IPR&amp;D</span><span style="font-family:inherit;font-size:8.5pt;"> primarily reflect (i) the transfer of </span><span style="font-family:inherit;font-size:8.5pt;"><span>$4.8 billion</span></span><span style="font-family:inherit;font-size:8.5pt;"> from </span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">IPR&amp;D</span><span style="font-family:inherit;font-size:8.5pt;"> to </span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Developed technology rights</span><span style="font-family:inherit;font-size:8.5pt;"> to reflect the approval of Eucrisa, (ii) the </span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Developed technology rights</span><span style="font-family:inherit;font-size:8.5pt;"> and </span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">IPR&amp;D</span><span style="font-family:inherit;font-size:8.5pt;"> acquired as part of the acquisition of AstraZeneca&#8217;s small molecule anti-infectives business (see </span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Note 2A</span><span style="font-family:inherit;font-size:8.5pt;">), (iii) the </span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Developed technology rights</span><span style="font-family:inherit;font-size:8.5pt;"> of </span><span style="font-family:inherit;font-size:8.5pt;"><span>$371 million</span></span><span style="font-family:inherit;font-size:8.5pt;"> recorded in connection with the EU and U.S. approvals of Besponsa (see </span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Note 7E</span><span style="font-family:inherit;font-size:8.5pt;">), partially offset by (iv) measurement period adjustments related to Medivation (see </span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Note 2A</span><span style="font-family:inherit;font-size:8.5pt;">) and (v) impairments of </span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Developed technology rights</span><span style="font-family:inherit;font-size:8.5pt;"> (see </span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Note 4)</span><span style="font-family:inherit;font-size:8.5pt;">.</span></div></td></tr></table><div style="line-height:120%;font-size:8.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(b)</sup>&#160;</span></div><span style="font-family:inherit;font-size:8.5pt;">The decrease in </span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">I</span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;text-align:right;">dentifiable intangible assets, less accumulated amortization</span><span style="font-family:inherit;font-size:8.5pt;text-align:right;">, </span><span style="font-family:inherit;font-size:8.5pt;">is primarily due to amortization, measurement period adjustments related to Medivation (see </span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Note 2A</span><span style="font-family:inherit;font-size:8.5pt;">), as well as impairments of </span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Developed technology rights</span><span style="font-family:inherit;font-size:8.5pt;"> (see </span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Note 4)</span><span style="font-family:inherit;font-size:8.5pt;">, partially offset by assets acquired as part of the acquisition of AstraZeneca&#8217;s small molecule anti-infectives business (see </span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Note 2A</span><span style="font-family:inherit;font-size:8.5pt;">) and the assets recorded in connection with the EU and U.S. approvals of Besponsa (see </span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Note 7E</span>).<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_IdentifiableintangibleassetsasapercentageoftotalidentifiableintangibleassetslessaccumulatedamortizationbysegmentTableTextBlock', window );">Identifiable Intangible Assets as a Percentage of Total Identifiable Intangible Assets Less Accumulated Amortization, By Segment</a></td>
<td class="text"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"/></tr><tr><td style="width:55%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our identifiable intangible assets are associated with the following, as a percentage of total identifiable intangible assets, less accumulated amortization:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">October&#160;1, 2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">IH</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">EH</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">WRD</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Developed technology rights</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>68</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>32</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Brands, finite-lived</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>75</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Brands, indefinite-lived</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>71</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>29</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">IPR&amp;D </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>80</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Schedule of Goodwill</a></td>
<td class="text"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:55%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides the components of and changes in the carrying amount of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Goodwill</span><span style="font-family:inherit;font-size:10pt;">:</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">IH</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">EH</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance, December&#160;31, 2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30,134</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24,315</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>54,449</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Additions</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>572</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>92</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>664</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>491</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>475</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>966</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance, October&#160;1, 2017</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>31,197</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24,882</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>56,078</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">IH additions primarily represent measurement period adjustments related to our Medivation acquisition, and EH additions relate to our acquisition of AstraZeneca&#8217;s small molecule anti-infectives business, which are subject to change until we complete the valuation of assets acquired and liabilities assumed (see </span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Note 2A</span><span style="font-family:inherit;font-size:8.5pt;">).</span></div></td></tr></table><div style="line-height:120%;font-size:8.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(b)</sup>&#160;</span></div>Primarily reflects the impact of foreign exchange and an adjustment of our estimate of goodwill associated with the HIS net assets sold.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_IdentifiableintangibleassetsasapercentageoftotalidentifiableintangibleassetslessaccumulatedamortizationbysegmentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>[Table Text Block] for Identifiable intangible assets as a percentage of total identifiable intangible assets less accumulated amortization, by segment [Table]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_IdentifiableintangibleassetsasapercentageoftotalidentifiableintangibleassetslessaccumulatedamortizationbysegmentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13854-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b),(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6917883056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pension and Postretirement Benefit Plans (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 01, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock', window );">Schedule of Net Periodic Benefit Costs</a></td>
<td class="text"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="33"/></tr><tr><td style="width:27%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/></tr><tr><td colspan="33" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides the components of net periodic benefit cost/(income):</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="31" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Three Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Arial;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Pension Plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Arial;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">U.S.</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Qualified</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">U.S.</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Supplemental</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(Non-Qualified)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">International</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Postretirement</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Plans</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Oct&#160;1, 2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Oct&#160;2, 2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Oct&#160;1, 2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Oct&#160;2, 2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Oct&#160;1, 2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Oct&#160;2, 2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Oct&#160;1, 2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Oct&#160;2, 2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net periodic benefit cost/(credit):</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Service cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>67</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>69</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>44</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>41</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Interest cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>157</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>218</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>18</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>52</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>58</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>23</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>33</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Expected return on plan assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(248</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(239</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(87</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(95</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Amortization of:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Actuarial losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>91</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>99</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>29</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>23</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Prior service costs (credits)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(45</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(45</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Curtailments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Settlements</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>30</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>21</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>99</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>170</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>39</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>39</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>35</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>27</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(17</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="31" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Nine Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Arial;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Pension Plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Arial;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">U.S.</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Qualified</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">U.S.</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Supplemental</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(Non-Qualified)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">International</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Postretirement</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Plans</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Oct&#160;1, 2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Oct&#160;2, 2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Oct&#160;1, 2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Oct&#160;2, 2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Oct&#160;1, 2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Oct&#160;2, 2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Oct&#160;1, 2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Oct&#160;2, 2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net periodic benefit cost/(credit):</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Service cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>202</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>193</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>18</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>14</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>127</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>126</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>32</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>31</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Interest cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>478</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>486</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>41</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>40</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>152</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>178</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>68</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>77</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Expected return on plan assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(759</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(721</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(256</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(291</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(27</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(25</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Amortization of:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Actuarial losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>302</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>297</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>37</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>27</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>86</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>70</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>23</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>23</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Prior service costs (credits)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(137</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(127</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Curtailments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(15</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(14</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Settlements</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>54</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>52</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>32</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>23</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>292</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>316</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>127</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>105</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>106</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>81</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(57</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(36</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span><div style="line-height:120%;font-size:8.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup>&#160;</span></div><span style="font-family:inherit;font-size:8.5pt;">In April 2017, we settled the remaining obligation associated with the Hospira U.S. qualified defined benefit pension plan. We purchased a group annuity contract on behalf of the remaining plan participants with a third-party insurance provider. As a result, we were relieved of the </span><span style="font-family:inherit;font-size:8.5pt;"><span>$156 million</span></span><span style="font-family:inherit;font-size:8.5pt;"> net pension benefit obligation and recorded a pretax settlement gain of </span><span style="font-family:inherit;font-size:8.5pt;"><span>$41 million</span></span><span style="font-family:inherit;font-size:8.5pt;">, partially offset by the recognition of actuarial losses and prior service costs upon plan settlement of approximately </span><span style="font-family:inherit;font-size:8.5pt;"><span>$30 million</span></span><span style="font-family:inherit;font-size:8.5pt;"> in</span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;"> Restructuring charges and certain acquisition-related costs</span><span style="font-family:inherit;font-size:8.5pt;"> during the second quarter of 2017 (see </span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Note 3</span>).<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ScheduleofEmployerContributionstoPensionandPostretirementPlansTableTextBlock', window );">Schedule of Employer Contributions to Pension and Postretirement Plans</a></td>
<td class="text">As of and for the <span style="font-family:inherit;font-size:10pt;">nine months</span><span style="font-family:inherit;font-size:10pt;"> ended </span><span style="font-family:inherit;font-size:10pt;">October&#160;1, 2017</span><span style="font-family:inherit;font-size:10pt;">, we contributed and expect to contribute in 2017 from our general assets as follows: </span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.41520467836257%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:47%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Pension Plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">U.S. Qualified</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">U.S. Supplemental (Non-Qualified)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">International</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Postretirement Plans</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Contributions from our general assets for the nine months ended October 1, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1,095</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>121</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>134</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>158</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Expected contributions from our general assets during 2017</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1,095</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>146</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>170</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>204</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><div style="line-height:120%;font-size:8.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup>&#160;</span></div><span style="font-family:inherit;font-size:8.5pt;">Contributions expected to be made for </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:8.5pt;"> are inclusive of amounts contributed during the </span><span style="font-family:inherit;font-size:8.5pt;">nine months ended October 1, 2017</span><span style="font-family:inherit;font-size:8.5pt;">, including the </span><span style="font-family:inherit;font-size:8.5pt;"><span>$1.0 billion</span></span> voluntary contribution that was made in January 2017 for the U.S. qualified plans, which was considered pre-funding for future anticipated mandatory contributions and is also expected to reduce Pension Benefit Guaranty Corporation variable rate premiums. The U.S. supplemental (non-qualified) pension plan, international pension plan and the postretirement plan contributions from our general assets include direct employer benefit payments.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_ScheduleofEmployerContributionstoPensionandPostretirementPlansTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Employer Contributions to Pension and Postretirement Plans [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_ScheduleofEmployerContributionstoPensionandPostretirementPlansTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=82843861&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNetBenefitCostsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6923752032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Common Share Attributable to Common Shareholders (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 01, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Basic and Diluted Earning Per Share</a></td>
<td class="text"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.22027290448344%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:52%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td colspan="17" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides the detailed calculation of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Earnings per common share (EPS)</span><span style="font-family:inherit;font-size:10pt;">:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nine Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(IN MILLIONS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">October&#160;1, <br/>2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">October&#160;2, <br/>2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">October&#160;1, <br/>2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">October&#160;2, <br/>2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">EPS Numerator&#8211;&#8211;Basic</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income from continuing operations</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,858</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,355</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,064</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,465</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: Net income attributable to noncontrolling interests</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>32</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income from continuing operations attributable to Pfizer Inc.</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,840</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,355</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,032</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,440</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: Preferred stock dividends&#8211;&#8211;net of tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income from continuing operations attributable to Pfizer Inc. common shareholders</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,839</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,355</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,032</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,439</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Discontinued operations&#8211;&#8211;net of tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income attributable to Pfizer Inc. common shareholders</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,839</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,355</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,033</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,439</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">EPS Numerator&#8211;&#8211;Diluted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income from continuing operations attributable to Pfizer Inc. common shareholders and assumed conversions</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,840</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,355</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,032</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,440</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Discontinued operations&#8211;&#8211;net of tax, attributable to Pfizer Inc. common shareholders and assumed conversions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income attributable to Pfizer Inc. common shareholders and assumed conversions</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,840</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,355</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,034</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,440</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">EPS Denominator</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted-average number of common shares outstanding&#8211;&#8211;Basic</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,951</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,066</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,972</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,095</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Common-share equivalents: stock options, stock issuable under employee compensation plans, convertible preferred stock and accelerated share repurchase agreements</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>89</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>84</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>85</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>80</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted-average number of common shares outstanding&#8211;&#8211;Diluted</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,041</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,150</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,057</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,175</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock options that had exercise prices greater than the average market price of our common stock issuable under employee compensation plans</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a),</sup></span><span style="font-family:inherit;font-size:9pt;">&#160;</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(b)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>47</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>38</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>47</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>60</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Amounts for the </span><span style="font-family:inherit;font-size:8.5pt;">third quarter</span><span style="font-family:inherit;font-size:8.5pt;"> and first </span><span style="font-family:inherit;font-size:8.5pt;">nine months</span><span style="font-family:inherit;font-size:8.5pt;"> ended </span><span style="font-family:inherit;font-size:8.5pt;">October&#160;2, 2016</span><span style="font-family:inherit;font-size:8.5pt;"> have been revised from previously reported amounts to reflect the adoption of a new accounting standard in the fourth quarter of </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:8.5pt;">, as of January 1, 2016, that requires, when applying the treasury stock method for shares that could be repurchased, that the assumed proceeds no longer include the amount of excess tax benefit (see </span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Note 1B</span><span style="font-family:inherit;font-size:8.5pt;">).</span></div></td></tr></table><div style="line-height:120%;font-size:8.5pt;padding-left:0px;"><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(b)</sup>&#160;</span></div>These common stock equivalents were outstanding for the periods presented, but were not included in the computation of diluted EPS for those periods because their inclusion would have had an anti-dilutive effect.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6758745584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment, Geographic and Other Revenue Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 01, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock', window );">Reconciliation of Revenue from Segments to Consolidated</a></td>
<td class="text"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td colspan="17" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides selected income statement information by reportable segment:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Three Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Earnings</span><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">October&#160;1, <br/>2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">October&#160;2, <br/>2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">October&#160;1, <br/>2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">October&#160;2, <br/>2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Reportable Segments:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:6px;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">IH</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>8,118</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>7,332</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>4,875</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>4,187</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:6px;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">EH</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>5,050</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>5,712</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>2,765</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>3,128</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Total reportable segments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>13,168</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>13,045</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>7,640</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>7,315</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-12px;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Other business activities</span><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(b), (c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(759</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(753</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Reconciling Items:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Corporate</span><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(1,382</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(1,537</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Purchase accounting adjustments</span><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(1,154</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(966</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Acquisition-related costs</span><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(155</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(280</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Certain significant items</span><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(d)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(449</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(1,969</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Other unallocated</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(156</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(206</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>13,168</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>13,045</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>3,585</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>1,604</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="17" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Nine Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Earnings</span><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">October&#160;1, <br/>2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">October&#160;2, <br/>2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">October&#160;1, <br/>2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">October&#160;2, <br/>2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Reportable Segments:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">IH</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>23,204</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>21,471</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>14,190</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>12,470</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">EH</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>15,639</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>17,725</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>8,558</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>9,985</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Total reportable segments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>38,843</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>39,196</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>22,748</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>22,454</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Other business activities</span><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(b), (c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(2,205</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(2,096</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Reconciling Items:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Corporate</span><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(3,948</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(4,217</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Purchase accounting adjustments</span><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(3,527</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(3,103</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Acquisition-related costs</span><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(347</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(598</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Certain significant items</span><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(d)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(797</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(4,112</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Other unallocated</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(573</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(753</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>38,843</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>39,196</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>11,351</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>7,575</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Income from continuing operations before provision for taxes on income. IH&#8217;s earnings in the </span><span style="font-family:inherit;font-size:8pt;">third quarter</span><span style="font-family:inherit;font-size:8pt;"> and </span><span style="font-family:inherit;font-size:8pt;">first nine months of</span><span style="font-family:inherit;font-size:8pt;"> </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:8pt;text-align:center;"> include d</span><span style="font-family:inherit;font-size:8pt;">ividend income of </span><span style="font-family:inherit;font-size:8pt;"><span>$54 million</span></span><span style="font-family:inherit;font-size:8pt;"> and </span><span style="font-family:inherit;font-size:8pt;"><span>$211 million</span></span><span style="font-family:inherit;font-size:8pt;">, respectively, from our investment in ViiV. For additional information, see </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Note 4.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Other business activities includes the costs managed by our WRD and GPD organizations. Effective in the first quarter of </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:8pt;">, Medical, previously reported as part of Other Business Activities, was reclassified to Corporate. We have reclassified approximately </span><span style="font-family:inherit;font-size:8pt;"><span>$33 million</span></span><span style="font-family:inherit;font-size:8pt;"> and </span><span style="font-family:inherit;font-size:8pt;"><span>$94 million</span></span><span style="font-family:inherit;font-size:8pt;"> of costs from Other Business Activities to Corporate in the </span><span style="font-family:inherit;font-size:8pt;">third quarter</span><span style="font-family:inherit;font-size:8pt;"> and </span><span style="font-family:inherit;font-size:8pt;">first nine months of</span><span style="font-family:inherit;font-size:8pt;"> </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:8pt;">, respectively, to conform to the current period presentation.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">For a description, see the &#8220;Other Costs and Business Activities&#8221; section above.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(d)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Certain significant items are substantive and/or unusual, and in some cases recurring, items (such as restructuring or legal charges) that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:1px;padding-top:1px;padding-left:12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">For Earnings in the </span><span style="font-family:inherit;font-size:8pt;">third quarter</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:8pt;">, certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of </span><span style="font-family:inherit;font-size:8pt;"><span>$90 million</span></span><span style="font-family:inherit;font-size:8pt;">, (ii) charges for certain legal matters of </span><span style="font-family:inherit;font-size:8pt;"><span>$183 million</span></span><span style="font-family:inherit;font-size:8pt;">, (iii) income of </span><span style="font-family:inherit;font-size:8pt;"><span>$12 million</span></span><span style="font-family:inherit;font-size:8pt;">, representing an adjustment to amounts previously recorded to write down the HIS net assets to fair value less costs to sell, (iv) certain asset impairment charges of </span><span style="font-family:inherit;font-size:8pt;"><span>$127 million</span></span><span style="font-family:inherit;font-size:8pt;">, (v) charges for business and legal entity alignment of </span><span style="font-family:inherit;font-size:8pt;"><span>$16 million</span></span><span style="font-family:inherit;font-size:8pt;"> and (vi) other charges of </span><span style="font-family:inherit;font-size:8pt;"><span>$45 million</span></span><span style="font-family:inherit;font-size:8pt;">. For additional information, see </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Note 2B, Note 3</span><span style="font-family:inherit;font-size:8pt;"> and </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Note 4.</span></div><div style="line-height:120%;padding-bottom:1px;text-align:left;padding-left:12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">For Earnings in the </span><span style="font-family:inherit;font-size:8pt;">third quarter</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:8pt;">, certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of </span><span style="font-family:inherit;font-size:8pt;"><span>$375 million</span></span><span style="font-family:inherit;font-size:8pt;">, (ii) income for certain legal matters of </span><span style="font-family:inherit;font-size:8pt;"><span>$40 million</span></span><span style="font-family:inherit;font-size:8pt;">, (iii) an impairment charge related to the write-down of the HIS net assets to fair value less estimated costs to sell of </span><span style="font-family:inherit;font-size:8pt;"><span>$1.4 billion</span></span><span style="font-family:inherit;font-size:8pt;">, (iv) certain asset impairment charges of </span><span style="font-family:inherit;font-size:8pt;"><span>$126 million</span></span><span style="font-family:inherit;font-size:8pt;">, (v) charges for business and legal entity alignment of </span><span style="font-family:inherit;font-size:8pt;"><span>$69 million</span></span><span style="font-family:inherit;font-size:8pt;"> and (vi) other charges of </span><span style="font-family:inherit;font-size:8pt;"><span>$17 million</span></span><span style="font-family:inherit;font-size:8pt;">. For additional information, see </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Note 3 </span><span style="font-family:inherit;font-size:8pt;">and</span><span style="font-family:inherit;font-size:8pt;font-style:italic;"> Note 4</span><span style="font-family:inherit;font-size:8pt;">.</span></div><div style="line-height:120%;padding-bottom:1px;text-align:left;padding-left:12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">For Earnings in the </span><span style="font-family:inherit;font-size:8pt;">first nine months of</span><span style="font-family:inherit;font-size:8pt;"> </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:8pt;">, certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of </span><span style="font-family:inherit;font-size:8pt;"><span>$253 million</span></span><span style="font-family:inherit;font-size:8pt;">, (ii) charges for certain legal matters of </span><span style="font-family:inherit;font-size:8pt;"><span>$191 million</span></span><span style="font-family:inherit;font-size:8pt;">, (iii) incremental charges to amounts previously recorded to write down the HIS net assets to fair value less costs to sell of </span><span style="font-family:inherit;font-size:8pt;"><span>$52 million</span></span><span style="font-family:inherit;font-size:8pt;">, (iv) certain asset impairment charges of </span><span style="font-family:inherit;font-size:8pt;"><span>$127 million</span></span><span style="font-family:inherit;font-size:8pt;">, (v) charges for business and legal entity alignment of </span><span style="font-family:inherit;font-size:8pt;"><span>$54 million</span></span><span style="font-family:inherit;font-size:8pt;"> and (vi) other charges of </span><span style="font-family:inherit;font-size:8pt;"><span>$119 million</span></span><span style="font-family:inherit;font-size:8pt;">. For additional information, see </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Note 2B</span><span style="font-family:inherit;font-size:8pt;">, </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Note 3</span><span style="font-family:inherit;font-size:8pt;"> and </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Note 4</span><span style="font-family:inherit;font-size:8pt;">.</span></div><span style="font-family:inherit;font-size:8pt;">For Earnings in the </span><span style="font-family:inherit;font-size:8pt;">first nine months of</span><span style="font-family:inherit;font-size:8pt;"> </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:8pt;">, certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of </span><span style="font-family:inherit;font-size:8pt;"><span>$743 million</span></span><span style="font-family:inherit;font-size:8pt;">, (ii) charges for certain legal matters of </span><span style="font-family:inherit;font-size:8pt;"><span>$506 million</span></span><span style="font-family:inherit;font-size:8pt;">, (iii) an impairment charge related to the write-down of the HIS net assets to fair value less estimated costs to sell of </span><span style="font-family:inherit;font-size:8pt;"><span>$1.4 billion</span></span><span style="font-family:inherit;font-size:8pt;">, (iv) certain asset impairment charges of </span><span style="font-family:inherit;font-size:8pt;"><span>$1.1 billion</span></span><span style="font-family:inherit;font-size:8pt;">, (v) charges for business and legal entity alignment of </span><span style="font-family:inherit;font-size:8pt;"><span>$180 million</span></span><span style="font-family:inherit;font-size:8pt;"> and (vi) other charges of </span><span style="font-family:inherit;font-size:8pt;"><span>$189 million</span></span><span style="font-family:inherit;font-size:8pt;">. For additional information, see </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Note 3</span><span style="font-family:inherit;font-size:8pt;"> and </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Note 4</span>.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock', window );">Reconciliation of Operating Profit (Loss) from Segments to Consolidated</a></td>
<td class="text"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td colspan="17" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides selected income statement information by reportable segment:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Three Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Earnings</span><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">October&#160;1, <br/>2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">October&#160;2, <br/>2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">October&#160;1, <br/>2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">October&#160;2, <br/>2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Reportable Segments:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:6px;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">IH</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>8,118</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>7,332</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>4,875</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>4,187</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:6px;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">EH</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>5,050</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>5,712</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>2,765</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>3,128</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Total reportable segments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>13,168</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>13,045</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>7,640</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>7,315</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-12px;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Other business activities</span><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(b), (c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(759</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(753</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Reconciling Items:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Corporate</span><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(1,382</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(1,537</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Purchase accounting adjustments</span><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(1,154</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(966</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Acquisition-related costs</span><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(155</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(280</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Certain significant items</span><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(d)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(449</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(1,969</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Other unallocated</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(156</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(206</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>13,168</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>13,045</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>3,585</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>1,604</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="17" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Nine Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Earnings</span><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">October&#160;1, <br/>2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">October&#160;2, <br/>2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">October&#160;1, <br/>2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">October&#160;2, <br/>2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Reportable Segments:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">IH</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>23,204</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>21,471</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>14,190</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>12,470</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">EH</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>15,639</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>17,725</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>8,558</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>9,985</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Total reportable segments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>38,843</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>39,196</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>22,748</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>22,454</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Other business activities</span><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(b), (c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(2,205</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(2,096</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Reconciling Items:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Corporate</span><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(3,948</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(4,217</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Purchase accounting adjustments</span><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(3,527</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(3,103</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Acquisition-related costs</span><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(347</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(598</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Certain significant items</span><span style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(d)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(797</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(4,112</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Other unallocated</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(573</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>(753</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>38,843</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>39,196</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>11,351</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;"><span>7,575</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Income from continuing operations before provision for taxes on income. IH&#8217;s earnings in the </span><span style="font-family:inherit;font-size:8pt;">third quarter</span><span style="font-family:inherit;font-size:8pt;"> and </span><span style="font-family:inherit;font-size:8pt;">first nine months of</span><span style="font-family:inherit;font-size:8pt;"> </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:8pt;text-align:center;"> include d</span><span style="font-family:inherit;font-size:8pt;">ividend income of </span><span style="font-family:inherit;font-size:8pt;"><span>$54 million</span></span><span style="font-family:inherit;font-size:8pt;"> and </span><span style="font-family:inherit;font-size:8pt;"><span>$211 million</span></span><span style="font-family:inherit;font-size:8pt;">, respectively, from our investment in ViiV. For additional information, see </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Note 4.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Other business activities includes the costs managed by our WRD and GPD organizations. Effective in the first quarter of </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:8pt;">, Medical, previously reported as part of Other Business Activities, was reclassified to Corporate. We have reclassified approximately </span><span style="font-family:inherit;font-size:8pt;"><span>$33 million</span></span><span style="font-family:inherit;font-size:8pt;"> and </span><span style="font-family:inherit;font-size:8pt;"><span>$94 million</span></span><span style="font-family:inherit;font-size:8pt;"> of costs from Other Business Activities to Corporate in the </span><span style="font-family:inherit;font-size:8pt;">third quarter</span><span style="font-family:inherit;font-size:8pt;"> and </span><span style="font-family:inherit;font-size:8pt;">first nine months of</span><span style="font-family:inherit;font-size:8pt;"> </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:8pt;">, respectively, to conform to the current period presentation.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">For a description, see the &#8220;Other Costs and Business Activities&#8221; section above.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(d)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Certain significant items are substantive and/or unusual, and in some cases recurring, items (such as restructuring or legal charges) that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:1px;padding-top:1px;padding-left:12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">For Earnings in the </span><span style="font-family:inherit;font-size:8pt;">third quarter</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:8pt;">, certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of </span><span style="font-family:inherit;font-size:8pt;"><span>$90 million</span></span><span style="font-family:inherit;font-size:8pt;">, (ii) charges for certain legal matters of </span><span style="font-family:inherit;font-size:8pt;"><span>$183 million</span></span><span style="font-family:inherit;font-size:8pt;">, (iii) income of </span><span style="font-family:inherit;font-size:8pt;"><span>$12 million</span></span><span style="font-family:inherit;font-size:8pt;">, representing an adjustment to amounts previously recorded to write down the HIS net assets to fair value less costs to sell, (iv) certain asset impairment charges of </span><span style="font-family:inherit;font-size:8pt;"><span>$127 million</span></span><span style="font-family:inherit;font-size:8pt;">, (v) charges for business and legal entity alignment of </span><span style="font-family:inherit;font-size:8pt;"><span>$16 million</span></span><span style="font-family:inherit;font-size:8pt;"> and (vi) other charges of </span><span style="font-family:inherit;font-size:8pt;"><span>$45 million</span></span><span style="font-family:inherit;font-size:8pt;">. For additional information, see </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Note 2B, Note 3</span><span style="font-family:inherit;font-size:8pt;"> and </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Note 4.</span></div><div style="line-height:120%;padding-bottom:1px;text-align:left;padding-left:12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">For Earnings in the </span><span style="font-family:inherit;font-size:8pt;">third quarter</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:8pt;">, certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of </span><span style="font-family:inherit;font-size:8pt;"><span>$375 million</span></span><span style="font-family:inherit;font-size:8pt;">, (ii) income for certain legal matters of </span><span style="font-family:inherit;font-size:8pt;"><span>$40 million</span></span><span style="font-family:inherit;font-size:8pt;">, (iii) an impairment charge related to the write-down of the HIS net assets to fair value less estimated costs to sell of </span><span style="font-family:inherit;font-size:8pt;"><span>$1.4 billion</span></span><span style="font-family:inherit;font-size:8pt;">, (iv) certain asset impairment charges of </span><span style="font-family:inherit;font-size:8pt;"><span>$126 million</span></span><span style="font-family:inherit;font-size:8pt;">, (v) charges for business and legal entity alignment of </span><span style="font-family:inherit;font-size:8pt;"><span>$69 million</span></span><span style="font-family:inherit;font-size:8pt;"> and (vi) other charges of </span><span style="font-family:inherit;font-size:8pt;"><span>$17 million</span></span><span style="font-family:inherit;font-size:8pt;">. For additional information, see </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Note 3 </span><span style="font-family:inherit;font-size:8pt;">and</span><span style="font-family:inherit;font-size:8pt;font-style:italic;"> Note 4</span><span style="font-family:inherit;font-size:8pt;">.</span></div><div style="line-height:120%;padding-bottom:1px;text-align:left;padding-left:12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">For Earnings in the </span><span style="font-family:inherit;font-size:8pt;">first nine months of</span><span style="font-family:inherit;font-size:8pt;"> </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:8pt;">, certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of </span><span style="font-family:inherit;font-size:8pt;"><span>$253 million</span></span><span style="font-family:inherit;font-size:8pt;">, (ii) charges for certain legal matters of </span><span style="font-family:inherit;font-size:8pt;"><span>$191 million</span></span><span style="font-family:inherit;font-size:8pt;">, (iii) incremental charges to amounts previously recorded to write down the HIS net assets to fair value less costs to sell of </span><span style="font-family:inherit;font-size:8pt;"><span>$52 million</span></span><span style="font-family:inherit;font-size:8pt;">, (iv) certain asset impairment charges of </span><span style="font-family:inherit;font-size:8pt;"><span>$127 million</span></span><span style="font-family:inherit;font-size:8pt;">, (v) charges for business and legal entity alignment of </span><span style="font-family:inherit;font-size:8pt;"><span>$54 million</span></span><span style="font-family:inherit;font-size:8pt;"> and (vi) other charges of </span><span style="font-family:inherit;font-size:8pt;"><span>$119 million</span></span><span style="font-family:inherit;font-size:8pt;">. For additional information, see </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Note 2B</span><span style="font-family:inherit;font-size:8pt;">, </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Note 3</span><span style="font-family:inherit;font-size:8pt;"> and </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Note 4</span><span style="font-family:inherit;font-size:8pt;">.</span></div><span style="font-family:inherit;font-size:8pt;">For Earnings in the </span><span style="font-family:inherit;font-size:8pt;">first nine months of</span><span style="font-family:inherit;font-size:8pt;"> </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:8pt;">, certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of </span><span style="font-family:inherit;font-size:8pt;"><span>$743 million</span></span><span style="font-family:inherit;font-size:8pt;">, (ii) charges for certain legal matters of </span><span style="font-family:inherit;font-size:8pt;"><span>$506 million</span></span><span style="font-family:inherit;font-size:8pt;">, (iii) an impairment charge related to the write-down of the HIS net assets to fair value less estimated costs to sell of </span><span style="font-family:inherit;font-size:8pt;"><span>$1.4 billion</span></span><span style="font-family:inherit;font-size:8pt;">, (iv) certain asset impairment charges of </span><span style="font-family:inherit;font-size:8pt;"><span>$1.1 billion</span></span><span style="font-family:inherit;font-size:8pt;">, (v) charges for business and legal entity alignment of </span><span style="font-family:inherit;font-size:8pt;"><span>$180 million</span></span><span style="font-family:inherit;font-size:8pt;"> and (vi) other charges of </span><span style="font-family:inherit;font-size:8pt;"><span>$189 million</span></span><span style="font-family:inherit;font-size:8pt;">. For additional information, see </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Note 3</span><span style="font-family:inherit;font-size:8pt;"> and </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Note 4</span>.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock', window );">Schedule of Revenues by Geographic Region</a></td>
<td class="text"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.41520467836257%;border-collapse:collapse;text-align:left;"><tr><td colspan="23"/></tr><tr><td style="width:28%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/></tr><tr><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides revenues by geographic area:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nine Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">October&#160;1, <br/>2017</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">October&#160;2, <br/>2016</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Change</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">October&#160;1, <br/>2017</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">October&#160;2, <br/>2016</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Change</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,534</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,530</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19,516</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19,561</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Developed Europe</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,163</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,218</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,309</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,982</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(10</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Developed Rest of World</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,632</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,711</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,797</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,940</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Emerging Markets</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,839</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,586</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,222</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,714</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,168</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,045</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>38,843</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>39,196</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Developed Europe region includes the following markets: Western Europe, Scandinavian countries and Finland.</span><span style="font-family:inherit;font-size:8pt;"> Revenues denominated in euros were </span><span style="font-family:inherit;font-size:8pt;"><span>$1.7 billion</span></span><span style="font-family:inherit;font-size:8pt;"> in both the </span><span style="font-family:inherit;font-size:8pt;">third quarter</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:8pt;"> and </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:8pt;">, and </span><span style="font-family:inherit;font-size:8pt;"><span>$5.0 billion</span></span><span style="font-family:inherit;font-size:8pt;"> and </span><span style="font-family:inherit;font-size:8pt;"><span>$5.3 billion</span></span><span style="font-family:inherit;font-size:8pt;"> in the </span><span style="font-family:inherit;font-size:8pt;">first nine months of</span><span style="font-family:inherit;font-size:8pt;"> </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:8pt;"> and </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:8pt;">, respectively.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Developed Rest of World region includes the following markets: Japan, Canada, Australia, South Korea and New Zealand.</span></div></td></tr></table><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup>&#160;</span></div><span style="font-family:inherit;font-size:8pt;">Emerging Markets region includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Africa, Eastern Europe, Central Europe, the Middle East and Turkey.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock', window );">Schedule of Significant Product Revenues</a></td>
<td class="text"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:48%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td colspan="17" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides detailed revenue information:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Nine Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">October&#160;1, <br/>2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">October&#160;2, <br/>2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">October&#160;1, <br/>2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">October&#160;2, <br/>2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">PFIZER INNOVATIVE HEALTH (IH)</span><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>8,118</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>7,332</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>23,204</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>21,471</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Internal Medicine</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>2,455</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>2,243</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>7,245</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>6,557</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Lyrica IH</span><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>1,150</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>1,049</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>3,382</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>3,107</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Eliquis alliance revenues and direct sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>644</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>449</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>1,813</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>1,225</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Chantix/Champix</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>240</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>198</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>727</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>631</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Viagra IH</span><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>206</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>297</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>711</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>897</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">BMP2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>79</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>63</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>198</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>175</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Toviaz</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>62</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>60</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>187</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>191</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">All other Internal Medicine</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>75</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>128</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>228</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>330</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Vaccines</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>1,649</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>1,641</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>4,385</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>4,576</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Prevnar 13/Prevenar 13</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>1,522</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>1,536</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>4,069</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>4,302</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">FSME/IMMUN-TicoVac</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>43</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>33</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>119</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>102</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">All other Vaccines</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>85</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>72</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>197</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>172</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Oncology</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>1,616</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>1,104</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>4,551</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>3,206</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Ibrance</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>878</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>550</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>2,410</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>1,492</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Sutent</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>276</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>260</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>805</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>823</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Xalkori</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>146</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>140</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>442</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>415</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Xtandi alliance revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>150</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>422</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Inlyta</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>84</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>95</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>256</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>304</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Bosulif</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>57</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>43</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>163</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>121</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">All other Oncology</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>26</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>15</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>54</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>49</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Inflammation &amp; Immunology (I&amp;I)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>1,000</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>960</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>2,863</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>2,907</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Enbrel (Outside the U.S. and Canada)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>613</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>701</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>1,818</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>2,201</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Xeljanz</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>348</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>235</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>935</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>649</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Eucrisa</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>15</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>33</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">All other I&amp;I</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>23</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>24</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>78</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>57</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Rare Disease</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>569</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>585</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>1,637</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>1,768</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">BeneFIX</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>151</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>176</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>453</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>543</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Refacto AF/Xyntha</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>140</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>140</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>409</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>408</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Genotropin</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>136</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>147</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>375</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>425</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Somavert</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>65</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>59</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>182</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>173</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">All other Rare Disease</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>77</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>64</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>218</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>219</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Consumer Healthcare</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>829</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>798</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>2,522</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>2,457</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">PFIZER ESSENTIAL HEALTH (EH)</span><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(d)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>5,050</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>5,712</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>15,639</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>17,725</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Legacy Established Products (LEP)</span><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(e)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>2,681</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>2,708</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>7,995</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>8,373</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Lipitor</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>491</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>422</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>1,341</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>1,294</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Premarin family</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>238</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>244</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>711</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>751</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Norvasc</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>226</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>238</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>684</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>714</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">EpiPen</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>82</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>110</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>253</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>300</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Xalatan/Xalacom</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>83</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>91</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>241</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>273</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Effexor</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>76</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>70</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>215</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>207</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Zoloft</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>78</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>72</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>215</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>228</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Zithromax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>61</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>56</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>202</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>203</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Relpax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>50</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>83</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>193</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>248</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Xanax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>58</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>55</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>164</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>163</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">All other LEP</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>1,237</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>1,268</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>3,776</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>3,992</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Sterile Injectable Pharmaceuticals (SIP)</span><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(f)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>1,273</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>1,461</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>4,270</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>4,481</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Medrol</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>109</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>102</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>352</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>330</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Sulperazon</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>114</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>102</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>345</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>304</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Fragmin</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>79</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>80</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>221</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>240</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Tygacil</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>60</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>69</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>192</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>203</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Precedex</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>51</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>64</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>182</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>199</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">All other SIP</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>860</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>1,044</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>2,977</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>3,206</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:48%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Nine Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">October&#160;1, <br/>2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">October&#160;2, <br/>2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">October&#160;1, <br/>2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">October&#160;2, <br/>2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Peri-LOE Products</span><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(g)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>794</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>1,023</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>2,398</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>3,224</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Celebrex</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>212</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>194</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>564</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>550</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Lyrica EH</span><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>134</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>191</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>428</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>623</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Vfend</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>97</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>140</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>305</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>459</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Viagra EH</span><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>102</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>89</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>285</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>286</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Pristiq</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>69</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>174</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>230</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>546</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Zyvox</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>68</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>94</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>220</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>334</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Revatio</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>58</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>73</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>189</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>213</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">All other Peri-LOE Products</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>55</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>68</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>176</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>214</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Biosimilars</span><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(h)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>141</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>83</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>367</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>228</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Inflectra/Remsima</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>112</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>49</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>284</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>130</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">All other Biosimilars</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>28</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>34</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>82</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>97</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Pfizer CentreOne</span><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(i)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>161</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>156</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>514</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>540</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Hospira Infusion Systems (HIS)</span><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(j)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>281</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>97</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>879</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>13,168</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>13,045</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>38,843</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>39,196</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total Lyrica</span><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>1,285</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>1,240</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>3,810</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>3,730</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total Viagra</span><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>308</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>387</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>996</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>1,183</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total Alliance revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>741</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>419</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>2,112</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span>1,155</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">The IH business encompasses Internal Medicine, Vaccines, Oncology, Inflammation &amp; Immunology, Rare Disease and Consumer Healthcare. Through December 31, 2016, includes Duavive/Duavee and Viviant (recorded in All other Internal Medicine in 2016), which were transferred from Innovative Health to Essential Health effective January 1, 2017 (recorded in All other LEP (EH) beginning January 1, 2017), in order to align these products with our management of the women&#8217;s health portfolio within EH. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Lyrica revenues from all of Europe, Russia, Turkey, Israel and Central Asia countries are included in Lyrica EH. All other Lyrica revenues are included in Lyrica IH. Total Lyrica revenues represent the aggregate of worldwide revenues from Lyrica IH and Lyrica EH. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Viagra revenues from the U.S. and Canada are included in Viagra IH. All other Viagra revenues are included in Viagra EH. Total Viagra revenues represent the aggregate of worldwide revenues from Viagra IH and Viagra EH. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(d)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">The EH business encompasses Legacy Established Products, Sterile Injectable Pharmaceuticals, Peri-LOE Products, Biosimilars, Pfizer CentreOne and HIS (through February 2, 2017) and includes all legacy Hospira commercial operations.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(e)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Legacy Established Products primarily include products that have lost patent protection (excluding Sterile Injectable Pharmaceuticals and Peri-LOE Products). Effective January 1, 2017, All other LEP includes Duavive/Duavee and Viviant, which were transferred from Innovative Health (recorded in All other Internal Medicine (IH) in 2016), in order to align these products with our management of the women&#8217;s health portfolio within EH.</span><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt"> </sup></span><span style="font-family:inherit;font-size:8pt;">See note (a) above.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(f) </sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Sterile Injectable Pharmaceuticals include generic injectables and proprietary specialty injectables (excluding Peri-LOE Products). </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(g)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Peri-LOE Products include products that have recently lost or are anticipated to soon lose patent protection. These products include: Lyrica in Europe, Russia, Turkey, Israel and Central Asia; Viagra in all countries (excluding the U.S. and Canada); and worldwide revenues for Celebrex, Pristiq, Zyvox, Vfend, Revatio and Inspra. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(h)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Biosimilars include Inflectra/Remsima (biosimilar infliximab) in the U.S. and certain international markets, Nivestim (biosimilar filgrastim) in certain European, Asian and Africa/Middle Eastern markets and Retacrit (biosimilar epoetin zeta) in certain European and Africa/Middle Eastern markets. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(i)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Pfizer CentreOne includes revenues from our contract manufacturing and active pharmaceutical ingredient sales operation, including sterile injectables contract manufacturing, and revenues related to our manufacturing and supply agreements, including with Zoetis. </span></div></td></tr></table><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(j)</sup>&#160;</span></div><span style="font-family:inherit;font-size:8pt;">HIS (through February 2, 2017) includes Medication Management Systems products composed of infusion pumps and related software and services, as well as IV Infusion Products, including large volume IV solutions and their associated administration sets.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of all significant reconciling items in the reconciliation of total revenues from reportable segments to the entity's consolidated revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph a<br> -URI http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e9031-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6910488080">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Significant Accounting Policies (Details)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 02, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 01, 2017 </div>
<div>USD ($) </div>
<div>Operating_Segment</div>
</th>
<th class="th">
<div>Oct. 02, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 28, 2016 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jun. 24, 2016 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of business segments | Operating_Segment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTaxBenefitAmount', window );">Net tax benefit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Amount reclassified from operating activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (9,728)<span></span>
</td>
<td class="num">(10,151)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Amount reclassified to financing activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (9,650)<span></span>
</td>
<td class="num">(6,915)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pfe_MedivationMember', window );">Medivation [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionSharePrice', window );">Business acquisition, per share in cash (in dollars per share) | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 81.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pfe_AnacorMember', window );">Anacor [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionSharePrice', window );">Business acquisition, per share in cash (in dollars per share) | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 99.25<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=pfe_AccountingStandardsUpdate201609StatutoryTaxWithholdingComponentMember', window );">Accounting Standards Update 2016-09, Statutory Tax Withholding Component [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Amount reclassified from operating activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Amount reclassified to financing activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="7"></td></tr>
<tr><td colspan="7"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Amounts for the <span style="font-family:inherit;font-size:7.5pt;">three and nine months ended October 2, 2016</span><span style="font-family:inherit;font-size:7.5pt;"> have been revised from previously reported amounts to reflect the adoption of a new accounting standard in the fourth quarter of 2016, as of January 1, 2016. For additional information, see </span><span style="font-family:inherit;font-size:7.5pt;font-style:italic;">Note 1B</span><span style="font-family:inherit;font-size:7.5pt;">. </span><span style="font-family:inherit;font-size:7.5pt;font-style:italic;">Basis of Presentation and Significant Accounting Policies</span>: Adoption of New Accounting Standards.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Amounts may not add due to rounding.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTaxBenefitAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Share-based Compensation, Excess Tax Benefit, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTaxBenefitAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3574-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=pfe_MedivationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=pfe_MedivationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=pfe_AnacorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=pfe_AnacorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=pfe_AccountingStandardsUpdate201609StatutoryTaxWithholdingComponentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=pfe_AccountingStandardsUpdate201609StatutoryTaxWithholdingComponentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6905345696">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Acquisitions, Sale of Hospira Infusion Systems Net Assets, Collaborative Arrangement and Equity-Method Investments - AstraZeneca (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 22, 2016</div></th>
<th class="th"><div>Apr. 01, 2018</div></th>
<th class="th"><div>Jul. 02, 2017</div></th>
<th class="th"><div>Oct. 01, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56,078<span></span>
</td>
<td class="nump">$ 54,449<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pfe_AstraZenecaMember', window );">AstraZeneca [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_PaymentstoAcquireBusinessesGrossInitialPayment', window );">Initial payment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 552<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_PaymentstoAcquireBusinessesGrossPurchasePriceAdjustment', window );">Additional payment made for a purchase price adjustment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities', window );">Milestone payment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_BusinessCombinationConsiderationTransferredDeferredPayment', window );">Deferred payment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_BusinessCombinationConsiderationTransferredMilestonePaymentsMaximum', window );">Maximum amount of potential milestone payments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_BusinessCombinationConsiderationTransferredSalesrelatedPaymentsMaximum', window );">Maximum amount of potential sales-related payments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_BusinessCombinationConsiderationTransferredUndiscountedRoyaltyPaymentsTerm', window );">Term of royalty payments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Consideration transferred in business acquisition</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,045<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payments for acquisitions, cash portion</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration assumed</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">490<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Identifiable intangible assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">879<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther', window );">Other current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred tax liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">In Process Research and Development [Member] | AstraZeneca [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Identifiable intangible assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">219<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed Technology Rights [Member] | AstraZeneca [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Identifiable intangible assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum [Member] | AstraZeneca [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_BusinessCombinationConsiderationTransferredUndiscountedRoyaltyPayments', window );">Undiscounted royalty payments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum [Member] | AstraZeneca [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_BusinessCombinationConsiderationTransferredUndiscountedRoyaltyPayments', window );">Undiscounted royalty payments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember', window );">Forecast [Member] | AstraZeneca [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities', window );">Milestone payment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Amounts may not add due to rounding.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_BusinessCombinationConsiderationTransferredDeferredPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Consideration Transferred, Deferred Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_BusinessCombinationConsiderationTransferredDeferredPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_BusinessCombinationConsiderationTransferredMilestonePaymentsMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Consideration Transferred, Milestone Payments, Maximum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_BusinessCombinationConsiderationTransferredMilestonePaymentsMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_BusinessCombinationConsiderationTransferredSalesrelatedPaymentsMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Consideration Transferred, Sales-related Payments, Maximum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_BusinessCombinationConsiderationTransferredSalesrelatedPaymentsMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_BusinessCombinationConsiderationTransferredUndiscountedRoyaltyPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Consideration Transferred, Undiscounted Royalty Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_BusinessCombinationConsiderationTransferredUndiscountedRoyaltyPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_BusinessCombinationConsiderationTransferredUndiscountedRoyaltyPaymentsTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Consideration Transferred, Undiscounted Royalty Payments, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_BusinessCombinationConsiderationTransferredUndiscountedRoyaltyPaymentsTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_PaymentstoAcquireBusinessesGrossInitialPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments to Acquire Businesses, Gross, Initial Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_PaymentstoAcquireBusinessesGrossInitialPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_PaymentstoAcquireBusinessesGrossPurchasePriceAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments to Acquire Businesses, Gross, Purchase Price Adjustment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_PaymentstoAcquireBusinessesGrossPurchasePriceAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=6911251&amp;loc=d3e6578-128477<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6911251&amp;loc=d3e6613-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6911338&amp;loc=d3e6819-128478<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other assets expected to be realized or consumed before one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e31917-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388280&amp;loc=d3e13770-109266<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow, made soon after acquisition date of business combination, to settle contingent consideration liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=pfe_AstraZenecaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=pfe_AstraZenecaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6905413664">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Acquisitions, Sale of Hospira Infusion Systems Net Assets, Collaborative Arrangement and Equity-Method Investments - Medivation (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 28, 2016</div></th>
<th class="th"><div>Oct. 01, 2017</div></th>
<th class="th"><div>Oct. 01, 2017</div></th>
<th class="th"><div>Oct. 01, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56,078<span></span>
</td>
<td class="nump">$ 56,078<span></span>
</td>
<td class="nump">$ 56,078<span></span>
</td>
<td class="nump">$ 54,449<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pfe_MedivationMember', window );">Medivation [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionSharePrice', window );">Business acquisition, per share in cash (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 81.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Consideration transferred in business acquisition</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 14,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_BusinessCombinationConsiderationTransferredNetofCashAcquired', window );">Consideration transferred in business acquisition, net of cash acquired</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">13,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_BusinessCombinationConsiderationTransferredAmountPayable', window );">Amount payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 365<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Identifiable intangible assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">12,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred tax liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration assumed</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">259<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles', window );">Reduction in intangible assets due to measurement period adjustments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIncreaseDecreaseinAmortizationofIntangibleAssets', window );">Decrease in amortization of intangible assets due to measurement period adjustments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38<span></span>
</td>
<td class="nump">$ 38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pfe_MedivationMember', window );">Medivation [Member] | In Process Research and Development [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Identifiable intangible assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pfe_MedivationMember', window );">Medivation [Member] | Developed Technology Rights [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Identifiable intangible assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 8,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Acquired intangible assets, average useful life</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Amounts may not add due to rounding.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_BusinessCombinationConsiderationTransferredAmountPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Consideration Transferred, Amount Payable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_BusinessCombinationConsiderationTransferredAmountPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_BusinessCombinationConsiderationTransferredNetofCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Consideration Transferred, Net of Cash Acquired</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_BusinessCombinationConsiderationTransferredNetofCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIncreaseDecreaseinAmortizationofIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Increase (Decrease) in Amortization of Intangible Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIncreaseDecreaseinAmortizationofIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=6911251&amp;loc=d3e6578-128477<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6911251&amp;loc=d3e6613-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6911338&amp;loc=d3e6819-128478<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to intangibles acquired in connection with a business combination for which the initial accounting was incomplete.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=SL65897772-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e31917-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388280&amp;loc=d3e13770-109266<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=pfe_MedivationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=pfe_MedivationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6929802544">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Acquisitions, Sale of Hospira Infusion Systems Net Assets, Collaborative Arrangement and Equity-Method Investments - Bamboo Therapeutics (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 01, 2016</div></th>
<th class="th"><div>Oct. 02, 2016</div></th>
<th class="th"><div>Apr. 03, 2016</div></th>
<th class="th"><div>Oct. 01, 2017</div></th>
<th class="th"><div>Oct. 02, 2016</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Cash payments for acquisition, net of cash acquired</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 17,679<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56,078<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54,449<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pfe_BambooTherapeuticsMember', window );">Bamboo Therapeutics [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Payment to acquire the remaining equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_BusinessCombinationConsiderationTransferredMilestonePaymentsMaximum', window );">Maximum amount of potential milestone payments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1', window );">Total fair value of consideration transferred</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">343<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payments for acquisitions, cash portion</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Cash payments for acquisition, net of cash acquired</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration incurred</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1', window );">Fair value of previously held equity interest</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred tax liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember', window );">Other (Income)/Deductions, Net [Member] | Bamboo Therapeutics [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain', window );">Gain recognized upon acquisition of remaining interest in acquiree</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">In Process Research and Development [Member] | Bamboo Therapeutics [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Identifiable intangible assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="8"></td></tr>
<tr><td colspan="8"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Amounts may not add due to rounding.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Amounts may not add due to rounding.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_BusinessCombinationConsiderationTransferredMilestonePaymentsMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Consideration Transferred, Milestone Payments, Maximum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_BusinessCombinationConsiderationTransferredMilestonePaymentsMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=6911251&amp;loc=d3e6578-128477<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6911251&amp;loc=d3e6613-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value at acquisition-date of the assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interests issued by the acquirer, including but not limited to,  instruments or interests issued or issuable in consideration for the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6911338&amp;loc=d3e6819-128478<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e31917-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value at acquisition-date of the equity interest in the acquiree held by the acquirer, immediately before the acquisition date for businesses combined in stages.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>In a business combination achieved in stages, this element represents the amount of gain recognized by the entity as a result of remeasuring to fair value the equity interest in the acquiree it held before the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388280&amp;loc=d3e13770-109266<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=pfe_BambooTherapeuticsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=pfe_BambooTherapeuticsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6919205056">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Acquisitions, Sale of Hospira Infusion Systems Net Assets, Collaborative Arrangement and Equity-Method Investments - Anacor Pharmaceuticals, Inc. (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 24, 2016</div></th>
<th class="th"><div>Oct. 01, 2017</div></th>
<th class="th"><div>Oct. 02, 2016</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Cash payments for acquisition, net of cash acquired</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 17,679<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56,078<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54,449<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pfe_AnacorMember', window );">Anacor [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionSharePrice', window );">Business acquisition, per share in cash (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 99.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payments for acquisitions, cash portion</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 4,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Cash payments for acquisition, net of cash acquired</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt', window );">Debt assumed</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">698<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">IPR&amp;D</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">646<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred tax liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">346<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pfe_AnacorMember', window );">Anacor [Member] | In Process Research and Development [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Identifiable intangible assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 4,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Amounts may not add due to rounding.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Amounts may not add due to rounding.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e31917-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388280&amp;loc=d3e13770-109266<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=pfe_AnacorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=pfe_AnacorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6930296080">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Acquisitions, Sale of Hospira Infusion Systems Net Assets, Collaborative Arrangement and Equity-Method Investments - Sale of Hospira Infusion Systems Net Assets to ICU Medical, Inc. (EH) (Details) - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="4">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 03, 2017</div></th>
<th class="th"><div>Oct. 01, 2017</div></th>
<th class="th"><div>Oct. 02, 2016</div></th>
<th class="th" colspan="2"><div>Oct. 01, 2017</div></th>
<th class="th"><div>Oct. 02, 2016</div></th>
<th class="th"><sup>[2]</sup></th>
<th class="th"><div>Jan. 05, 2017</div></th>
<th class="th"><div>Oct. 06, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal', window );">Gain (loss) on sale of HIS net assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
<td class="num">$ (1,422)<span></span>
</td>
<td class="num">$ (52)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td colspan="2" class="num">$ (1,422)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=pfe_HISMember', window );">HIS [Member] | Disposed of by Sale [Member] | ICU Medical [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration', window );">Consideration transferred</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationTransferredEquityInterestsShares', window );">Number of shares received in disposition</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationTransferredEquityInterests', window );">Value of shares received from disposition</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 428<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivable', window );">Promissory note</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfBusinesses', window );">Cash received from disposition</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DisposalGroupIncludingDiscontinuedOperationContingentConsideration', window );">Contingent consideration</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Ownership percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DisposalGroupIncludingDiscontinuedOperationShareTransferRestrictionTermMinimum', window );">Minimum share transfer restriction term</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivableTerm', window );">Term of promissory note</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal', window );">Gain (loss) on sale of HIS net assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (52)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_AdministrativeServicePeriod', window );">Administrative service period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_MaximumManufacturingServicePeriod', window );">Maximum manufacturing service period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember', window );">London Interbank Offered Rate (LIBOR) [Member] | HIS [Member] | Disposed of by Sale [Member] | ICU Medical [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivableInterestRate', window );">Interest rate of promissory note in year one</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivableInterestRateYearTwo', window );">Interest rate of promissory note in year two</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivableInterestRateYearThree', window );">Interest rate of promissory note in year three</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="10"></td></tr>
<tr><td colspan="10"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">In the <span style="font-family:inherit;font-size:8.5pt;">third</span><span style="font-family:inherit;font-size:8.5pt;"> quarter and </span><span style="font-family:inherit;font-size:8.5pt;">first nine months of</span><span style="font-family:inherit;font-size:8.5pt;"> </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:8.5pt;">, represents adjustments to amounts previously recorded to write down the HIS net assets to fair value less costs to sell related to the sale of HIS net assets to ICU Medical. In the </span><span style="font-family:inherit;font-size:8.5pt;">third</span><span style="font-family:inherit;font-size:8.5pt;"> quarter and </span><span style="font-family:inherit;font-size:8.5pt;">first nine months of</span><span style="font-family:inherit;font-size:8.5pt;"> </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:8.5pt;">, represents a charge related to the write-down of the HIS net assets to fair value less estimated costs to sell.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Amounts may not add due to rounding.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_AdministrativeServicePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Administrative Service Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_AdministrativeServicePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Consideration, Note Receivable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivableInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Consideration, Note Receivable, Interest Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivableInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivableInterestRateYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Consideration, Note Receivable, Interest Rate, Year Three</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivableInterestRateYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivableInterestRateYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Consideration, Note Receivable, Interest Rate, Year Two</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivableInterestRateYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivableTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Consideration, Note Receivable, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivableTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationTransferredEquityInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Consideration Transferred, Equity Interests</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationTransferredEquityInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationTransferredEquityInterestsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Consideration Transferred, Equity Interests, Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationTransferredEquityInterestsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DisposalGroupIncludingDiscontinuedOperationContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Contingent Consideration</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DisposalGroupIncludingDiscontinuedOperationContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DisposalGroupIncludingDiscontinuedOperationShareTransferRestrictionTermMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Share Transfer Restriction Term, Minimum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DisposalGroupIncludingDiscontinuedOperationShareTransferRestrictionTermMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_MaximumManufacturingServicePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum manufacturing service period provided as a transition services to disposal group.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_MaximumManufacturingServicePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68055307&amp;loc=d3e2443-110228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84176398&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDivestitureOfBusinesses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDivestitureOfBusinesses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=pfe_HISMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=pfe_HISMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=pfe_ICUMedicalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=pfe_ICUMedicalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6758703696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions, Sale of Hospira Infusion Systems Net Assets, Collaborative Arrangement and Equity-Method Investments - Collaboration Arrangement (Details) - Other (Income)/Deductions, Net [Member] - Merck KGaA [Member] - Collaborative Arrangement [Member] - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 02, 2017</div></th>
<th class="th"><div>Oct. 01, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Upfront payments received</a></td>
<td class="nump">$ 90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_CollaborativeArrangementCollaboratorsRevenueandExpenseOwnershipPercentage', window );">Collaborator's revenue and expense ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_CollaborativeArrangementCompanysRevenueandExpenseOwnershipPercentage', window );">Company's revenue and expense ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_CollaborativeArrangementCollaboratorsRevenueandExpenseOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Collaborator's Revenue and Expense Ownership Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_CollaborativeArrangementCollaboratorsRevenueandExpenseOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_CollaborativeArrangementCompanysRevenueandExpenseOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Company's Revenue and Expense Ownership Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_CollaborativeArrangementCompanysRevenueandExpenseOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromCollaborators">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received from collaborators during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromCollaborators</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=pfe_MerckKGaAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=pfe_MerckKGaAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6917255184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions, Sale of Hospira Infusion Systems Net Assets, Collaborative Arrangement and Equity-Method Investments - Equity-Method Investments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 01, 2017</div></th>
<th class="th"><div>Oct. 02, 2016</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_HisunPfizerPharmaceuticalsCoLtdMember', window );">Hisun Pfizer Pharmaceuticals Co. Ltd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method investment, ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment', window );">Equity method investment, impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity method investments</a></td>
<td class="nump">$ 270<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_LaboratorioTeutoBrasileroMember', window );">Laboratorio Teuto Brasilero [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method investment, ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment', window );">Equity method investment, impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal', window );">Loss on disposal of equity method investment</a></td>
<td class="nump">$ 30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_LaboratorioTeutoBrasileroMember', window );">Laboratorio Teuto Brasilero [Member] | Other (Income)/Deductions, Net [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment', window );">Equity method investment, impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_LaboratorioTeutoBrasileroMember', window );">Laboratorio Teuto Brasilero [Member] | Laboratorio Teuto Brasilero [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents an other than temporary decline in value that has been recognized against an investment accounted for under the equity method of accounting. The excess of the carrying amount over the fair value of the investment represents the amount of the write down which is or was reflected in earnings. The written down value is a new cost basis with the adjusted value of the investment becoming its new carrying value subject to the equity accounting method. Evidence of a loss in value might include, but would not necessarily be limited to, absence of an ability to recover the carrying amount of the investment or inability of the investee to sustain an earnings capacity which would justify the carrying amount of the investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 35<br> -Paragraph 32<br> -URI http://asc.fasb.org/extlink&amp;oid=99375318&amp;loc=d3e32787-111569<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66011266&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of an equity method investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66022249&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_HisunPfizerPharmaceuticalsCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_HisunPfizerPharmaceuticalsCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_LaboratorioTeutoBrasileroMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_LaboratorioTeutoBrasileroMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=pfe_LaboratorioTeutoBrasileroMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=pfe_LaboratorioTeutoBrasileroMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6932278896">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1">36 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 03, 2015</div></th>
<th class="th"><div>Oct. 01, 2017</div></th>
<th class="th"><div>Oct. 02, 2016</div></th>
<th class="th"><div>Oct. 01, 2017</div></th>
<th class="th"><div>Oct. 02, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Sep. 03, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationIntegrationRelatedCosts', window );">Integration costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 73<span></span>
</td>
<td class="nump">$ 74<span></span>
</td>
<td class="nump">$ 224<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringChargesAbstract', window );"><strong>Restructuring charges:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Employee terminations</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(20)<span></span>
</td>
<td class="nump">347<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">464<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_RestructuringAssetImpairmentCharges', window );">Asset impairments</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2],[3]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101<span></span>
</td>
<td class="nump">27<span></span>
</td>
<td class="nump">126<span></span>
</td>
<td class="nump">45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessExitCosts1', window );">Exit costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="nump">29<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="nump">64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Total restructuring charges</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91<span></span>
</td>
<td class="nump">404<span></span>
</td>
<td class="nump">150<span></span>
</td>
<td class="nump">574<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts', window );">Transaction costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14)<span></span>
</td>
<td class="nump">54<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">114<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationIntegrationRelatedCosts', window );">Integration costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73<span></span>
</td>
<td class="nump">74<span></span>
</td>
<td class="nump">224<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_RestructuringChargesAndAcquisitionRelatedCosts', window );">Restructuring charges and certain acquisition-related costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">149<span></span>
</td>
<td class="nump">531<span></span>
</td>
<td class="nump">377<span></span>
</td>
<td class="nump">988<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveAcceleratedDepreciation', window );">Total additional depreciation&#8211;&#8211;asset restructuring</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[6]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39<span></span>
</td>
<td class="nump">47<span></span>
</td>
<td class="nump">74<span></span>
</td>
<td class="nump">151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ImplementationCostAbstract', window );"><strong>Implementation costs recorded in our condensed consolidated statements of income as follows:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ImplementationCosts', window );">Total implementation costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[7]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57<span></span>
</td>
<td class="nump">78<span></span>
</td>
<td class="nump">150<span></span>
</td>
<td class="nump">202<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts', window );">Total costs associated with acquisitions and cost-reduction/productivity initiatives</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">245<span></span>
</td>
<td class="nump">655<span></span>
</td>
<td class="nump">601<span></span>
</td>
<td class="nump">1,341<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of Sales [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringChargesAbstract', window );"><strong>Restructuring charges:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveAcceleratedDepreciation', window );">Total additional depreciation&#8211;&#8211;asset restructuring</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[6]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39<span></span>
</td>
<td class="nump">46<span></span>
</td>
<td class="nump">74<span></span>
</td>
<td class="nump">145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ImplementationCostAbstract', window );"><strong>Implementation costs recorded in our condensed consolidated statements of income as follows:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ImplementationCosts', window );">Total implementation costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[7]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="nump">46<span></span>
</td>
<td class="nump">77<span></span>
</td>
<td class="nump">127<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, Informational and Administrative Expenses [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ImplementationCostAbstract', window );"><strong>Implementation costs recorded in our condensed consolidated statements of income as follows:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ImplementationCosts', window );">Total implementation costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[7]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="nump">46<span></span>
</td>
<td class="nump">56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringChargesAbstract', window );"><strong>Restructuring charges:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveAcceleratedDepreciation', window );">Total additional depreciation&#8211;&#8211;asset restructuring</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[6]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ImplementationCostAbstract', window );"><strong>Implementation costs recorded in our condensed consolidated statements of income as follows:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ImplementationCosts', window );">Total implementation costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[7]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=pfe_OtherIncomeExpenseMember', window );">Other (Income)/Deductions - Net [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ImplementationCostAbstract', window );"><strong>Implementation costs recorded in our condensed consolidated statements of income as follows:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ImplementationCosts', window );">Total implementation costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[7]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=pfe_EnterprisewideCostReductionProductivityPlanMember', window );">Enterprise-wide Cost Reduction/Productivity Plan [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Restructuring cost incurred associated with the return of acquired in-process research and development rights</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">253<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCost1', window );">Expected restructuring cost</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_RestructuringandRelatedCostNoncashChargesPercentage', window );">Percentage of expected costs to be non-cash</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=pfe_ManufacturingPlantNetworkOptimizationMember', window );">Manufacturing Plant Network Optimization [Member] | Enterprise-wide Cost Reduction/Productivity Plan [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCost1', window );">Expected restructuring cost</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1', window );">Restructuring costs incurred</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">122<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">122<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=pfe_CentralizationofCorporateandPlatformFunctionsMember', window );">Centralization of Corporate and Platform Functions [Member] | Enterprise-wide Cost Reduction/Productivity Plan [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCost1', window );">Expected restructuring cost</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1', window );">Restructuring costs incurred</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=pfe_BusinessIntegrationCostsMember', window );">Business Integration Costs [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Restructuring cost incurred associated with the return of acquired in-process research and development rights</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pfe_HospiraMember', window );">Hospira [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_BusinessCombinationExpectedIntegrationRelatedCostsPeriod', window );">Expected integration related costs, period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pfe_HospiraMember', window );">Hospira [Member] | Return of Acquired Rights [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Restructuring cost incurred associated with the return of acquired in-process research and development rights</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pfe_HospiraMember', window );">Hospira [Member] | Business Integration Costs [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Restructuring cost incurred associated with the return of acquired in-process research and development rights</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 238<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember', window );">Forecast [Member] | Hospira [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationIntegrationRelatedCosts', window );">Integration costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringChargesAbstract', window );"><strong>Restructuring charges:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationIntegrationRelatedCosts', window );">Integration costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
</tr>
<tr><td colspan="9"></td></tr>
<tr><td colspan="9"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Integration costs represent external, incremental costs directly related to integrating acquired businesses, and primarily include expenditures for consulting and the integration of systems and processes. In the <span style="font-family:inherit;font-size:9pt;">third</span><span style="font-family:inherit;font-size:9pt;"> quarter and </span><span style="font-family:inherit;font-size:9pt;">first nine months of</span><span style="font-family:inherit;font-size:9pt;"> </span><span style="font-family:inherit;font-size:9pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:9pt;">, integration costs primarily relate to our acquisitions of Hospira and Medivation. The </span><span style="font-family:inherit;font-size:9pt;">first nine months of</span><span style="font-family:inherit;font-size:9pt;"> </span><span style="font-family:inherit;font-size:9pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:9pt;"> also include a net gain of </span><span style="font-family:inherit;font-size:9pt;"><span>$12 million</span></span><span style="font-family:inherit;font-size:9pt;"> related to the settlement of the Hospira U.S. qualified defined benefit pension plan (see </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Note 10</span><span style="font-family:inherit;font-size:9pt;">). In the </span><span style="font-family:inherit;font-size:9pt;">third quarter</span><span style="font-family:inherit;font-size:9pt;"> of </span><span style="font-family:inherit;font-size:9pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:9pt;">, integration </span><span style="font-family:inherit;font-size:9pt;">costs were mostly related to our acquisition of Hospira, and in the </span><span style="font-family:inherit;font-size:9pt;">first nine months of</span><span style="font-family:inherit;font-size:9pt;"> </span><span style="font-family:inherit;font-size:9pt;text-align:center;">2016</span>, integration costs were mostly related to our acquisition of Hospira and our terminated transaction with Allergan.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">In the <span style="font-family:inherit;font-size:9pt;">third quarter</span><span style="font-family:inherit;font-size:9pt;"> and </span><span style="font-family:inherit;font-size:9pt;">first nine months of</span><span style="font-family:inherit;font-size:9pt;"> </span><span style="font-family:inherit;font-size:9pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:9pt;">, restructuring charges are primarily associated with our acquisitions of Hospira and Medivation, as well as cost-reduction and productivity initiatives not associated with acquisitions. In the </span><span style="font-family:inherit;font-size:9pt;">third quarter</span><span style="font-family:inherit;font-size:9pt;"> and </span><span style="font-family:inherit;font-size:9pt;">first nine months of</span><span style="font-family:inherit;font-size:9pt;"> </span><span style="font-family:inherit;font-size:9pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:9pt;">, restructuring charges are largely associated with cost-reduction and productivity initiatives not associated with acquisitions, as well as our acquisitions of Hospira and Medivation. In the third quarter and first </span><span style="font-family:inherit;font-size:9pt;">nine</span><span style="font-family:inherit;font-size:9pt;"> months ended </span><span style="font-family:inherit;font-size:9pt;">October&#160;1, 2017</span><span style="font-family:inherit;font-size:9pt;">, </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Employee terminations</span><span style="font-family:inherit;font-size:9pt;"> primarily include revisions of our estimates of severance benefits. Employee termination costs are generally recorded when the actions are probable and estimable and include accrued severance benefits, pension and postretirement benefits, many of which may be paid out during periods after termination.</span><div style="line-height:120%;padding-top:4px;padding-left:24px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">The restructuring activities for </span><span style="font-family:inherit;font-size:9pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:9pt;"> are associated with the following:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:12px;"><span style="font-family:inherit;font-size:9pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">For the </span><span style="font-family:inherit;font-size:9pt;">third quarter</span><span style="font-family:inherit;font-size:9pt;"> of </span><span style="font-family:inherit;font-size:9pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:9pt;">, IH (</span><span style="font-family:inherit;font-size:9pt;"><span>$4 million</span></span><span style="font-family:inherit;font-size:9pt;">); EH (</span><span style="font-family:inherit;font-size:9pt;"><span>$1 million</span></span><span style="font-family:inherit;font-size:9pt;">); WRD/GPD (</span><span style="font-family:inherit;font-size:9pt;"><span>$15 million</span></span><span style="font-family:inherit;font-size:9pt;">); manufacturing operations (</span><span style="font-family:inherit;font-size:9pt;"><span>$47 million</span></span><span style="font-family:inherit;font-size:9pt;">); and Corporate (</span><span style="font-family:inherit;font-size:9pt;"><span>$25 million</span></span><span style="font-family:inherit;font-size:9pt;">).</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:12px;"><span style="font-family:inherit;font-size:9pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">For the </span><span style="font-family:inherit;font-size:9pt;">first nine months of</span><span style="font-family:inherit;font-size:9pt;"> </span><span style="font-family:inherit;font-size:9pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:9pt;">, IH (</span><span style="font-family:inherit;font-size:9pt;"><span>$10 million</span></span><span style="font-family:inherit;font-size:9pt;">); EH (</span><span style="font-family:inherit;font-size:9pt;"><span>$9 million</span></span><span style="font-family:inherit;font-size:9pt;"> income); WRD/GPD (</span><span style="font-family:inherit;font-size:9pt;"><span>$29 million</span></span><span style="font-family:inherit;font-size:9pt;">); manufacturing operations (</span><span style="font-family:inherit;font-size:9pt;"><span>$70 million</span></span><span style="font-family:inherit;font-size:9pt;">); and Corporate (</span><span style="font-family:inherit;font-size:9pt;"><span>$51 million</span></span><span style="font-family:inherit;font-size:9pt;">).</span></div></td></tr></table><div style="line-height:120%;padding-top:4px;text-align:left;padding-left:24px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">The restructuring activities for </span><span style="font-family:inherit;font-size:9pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:9pt;"> are associated with the following:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:12px;"><span style="font-family:inherit;font-size:9pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">For the </span><span style="font-family:inherit;font-size:9pt;">third quarter</span><span style="font-family:inherit;font-size:9pt;"> of </span><span style="font-family:inherit;font-size:9pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:9pt;">, IH (</span><span style="font-family:inherit;font-size:9pt;"><span>$148 million</span></span><span style="font-family:inherit;font-size:9pt;">); EH (</span><span style="font-family:inherit;font-size:9pt;"><span>$28 million</span></span><span style="font-family:inherit;font-size:9pt;">); WRD/GPD (</span><span style="font-family:inherit;font-size:9pt;"><span>$52 million</span></span><span style="font-family:inherit;font-size:9pt;">); manufacturing operations (</span><span style="font-family:inherit;font-size:9pt;"><span>$108 million</span></span><span style="font-family:inherit;font-size:9pt;">); and Corporate (</span><span style="font-family:inherit;font-size:9pt;"><span>$67 million</span></span><span style="font-family:inherit;font-size:9pt;">).</span></div></td></tr></table><div style="line-height:120%;font-size:9pt;padding-left:12px;"><span style="font-family:inherit;font-size:9pt;">&#8226;</span></div><span style="font-family:inherit;font-size:9pt;">For the </span><span style="font-family:inherit;font-size:9pt;">first nine months of</span><span style="font-family:inherit;font-size:9pt;"> </span><span style="font-family:inherit;font-size:9pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:9pt;">, IH (</span><span style="font-family:inherit;font-size:9pt;"><span>$162 million</span></span><span style="font-family:inherit;font-size:9pt;">); EH (</span><span style="font-family:inherit;font-size:9pt;"><span>$19 million</span></span><span style="font-family:inherit;font-size:9pt;">); WRD/GPD (</span><span style="font-family:inherit;font-size:9pt;"><span>$104 million</span></span><span style="font-family:inherit;font-size:9pt;">); manufacturing operations (</span><span style="font-family:inherit;font-size:9pt;"><span>$181 million</span></span><span style="font-family:inherit;font-size:9pt;">); and Corporate (</span><span style="font-family:inherit;font-size:9pt;"><span>$107 million</span></span>).</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">The asset impairment charges for the <span style="font-family:inherit;font-size:9pt;">third</span><span style="font-family:inherit;font-size:9pt;"> quarter and the </span><span style="font-family:inherit;font-size:9pt;">first nine months of</span><span style="font-family:inherit;font-size:9pt;"> </span><span style="font-family:inherit;font-size:9pt;text-align:center;">2017</span> are largely associated with our acquisitions of Hospira and Medivation.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top">Transaction costs represent external costs for banking, legal, accounting and other similar services, which in the <span style="font-family:inherit;font-size:9pt;">third quarter</span><span style="font-family:inherit;font-size:9pt;"> of 2017 reflect the reversal of an accrual related to the acquisition of Medivation. Transaction costs for the </span><span style="font-family:inherit;font-size:9pt;">first nine months of</span><span style="font-family:inherit;font-size:9pt;"> </span><span style="font-family:inherit;font-size:9pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:9pt;"> are directly related to our acquisitions of Hospira, Anacor and Medivation. Transaction costs in the </span><span style="font-family:inherit;font-size:9pt;">third quarter</span><span style="font-family:inherit;font-size:9pt;"> of </span><span style="font-family:inherit;font-size:9pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:9pt;"> were mostly related to the Medivation acquisition, and in the </span><span style="font-family:inherit;font-size:9pt;">first nine months of</span><span style="font-family:inherit;font-size:9pt;"> </span><span style="font-family:inherit;font-size:9pt;text-align:center;">2016</span>, were mostly related to the Medivation and Anacor acquisitions, and our terminated transaction with Allergan.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[5]</td>
<td style="vertical-align: top;" valign="top">Amounts may not add due to rounding.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[6]</td>
<td style="vertical-align: top;" valign="top">Additional depreciation&#8211;&#8211;asset restructuring represents the impact of changes in the estimated useful lives of assets involved in restructuring actions.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[7]</td>
<td style="vertical-align: top;" valign="top">Implementation costs represent external, incremental costs directly related to implementing our non-acquisition-related cost-reduction/productivity initiatives.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents external costs directly related to effecting a business combination which costs have been expensed during the period. Such costs include advisory, legal, accounting, valuation, and other similar services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_BusinessCombinationExpectedIntegrationRelatedCostsPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Expected Integration Related Costs, Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_BusinessCombinationExpectedIntegrationRelatedCostsPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_ImplementationCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Implementation Cost [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_ImplementationCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_ImplementationCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Implementation costs represent external, incremental costs directly related to Implementing cost-reduction initiatives, and primarily include expenditures related to system and process standardization and the expansion of shared services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_ImplementationCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_RestructuringAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restructuring, Asset Impairment Charges</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_RestructuringAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restructuring Charges, Acquisition Related Costs and Implementation Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_RestructuringChargesAndAcquisitionRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents (i) restructuring charges, which are amounts charged against earnings in the period for incurred and estimated costs associated with exit from or disposal of business activities or restructurings pursuant to a program that is planned and controlled by management, and materially changes either the scope of a business undertaken by an entity, or the manner in which that business is conducted; and (ii) acquisition-related costs, which are costs incurred to effect a business combination which costs have been expensed during the period. Such costs can include transaction costs such as banking, legal, accounting and other costs directly related to effect a business combination as well as external, incremental costs of integration planning that are directly related to a business combination, including costs associated with preparing for systems and other integration activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_RestructuringChargesAndAcquisitionRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_RestructuringandRelatedCostNoncashChargesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restructuring and Related Cost, Noncash Charges, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_RestructuringandRelatedCostNoncashChargesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationIntegrationRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Costs incurred to effect a business combination which have been expensed during the period. Such costs could include business integration costs, systems integration and conversion costs, and severance and other employee-related costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationIntegrationRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessExitCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Includes, but is not limited to, one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, and relocating employees, and termination benefits associated with an ongoing benefit arrangement. Excludes expenses associated with special or contractual termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140864-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140904-122747<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessExitCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of costs incurred to date for the specified restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostCostIncurredToDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostExpectedCost1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount expected to be recognized in earnings for the specified restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostExpectedCost1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostIncurredCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discloses the amount charged against the accrued restructuring reserves, or earnings if not previously accrued, during the period for the specified type of restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostIncurredCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140864-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringChargesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringChargesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveAcceleratedDepreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accelerated depreciation charged against earnings associated with exit from or disposal of business activities or restructuring plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveAcceleratedDepreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140904-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140864-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=pfe_OtherIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=pfe_OtherIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=pfe_EnterprisewideCostReductionProductivityPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=pfe_EnterprisewideCostReductionProductivityPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=pfe_ManufacturingPlantNetworkOptimizationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=pfe_ManufacturingPlantNetworkOptimizationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=pfe_CentralizationofCorporateandPlatformFunctionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=pfe_CentralizationofCorporateandPlatformFunctionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=pfe_BusinessIntegrationCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=pfe_BusinessIntegrationCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=pfe_HospiraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=pfe_HospiraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=pfe_ReturnofAcquiredRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=pfe_ReturnofAcquiredRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6916351536">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Footnotes (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="4">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 01, 2017</div></th>
<th class="th"><div>Oct. 02, 2016</div></th>
<th class="th" colspan="2"><div>Oct. 01, 2017</div></th>
<th class="th" colspan="2"><div>Oct. 02, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Provision</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 91<span></span>
</td>
<td class="nump">$ 404<span></span>
</td>
<td class="nump">$ 150<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 574<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Corporate [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Provision</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">25<span></span>
</td>
<td class="nump">67<span></span>
</td>
<td class="nump">51<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">107<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=pfe_InnovativeHealthSegmentMember', window );">IH [Member] | Operating Segments [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Provision</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4<span></span>
</td>
<td class="nump">148<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">162<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=pfe_EssentialHealthSegmentMember', window );">EH [Member] | Operating Segments [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Provision</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1<span></span>
</td>
<td class="nump">28<span></span>
</td>
<td class="num">(9)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">19<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsegmentsAxis=pfe_WorldwideResearchandDevelopmentandGlobalProductDevelopmentMember', window );">WRD &amp; GPD [Member] | Segment Reconciling Items [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Provision</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">15<span></span>
</td>
<td class="nump">52<span></span>
</td>
<td class="nump">29<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">104<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsegmentsAxis=pfe_ManufacturingOperationsMember', window );">Manufacturing operations [Member] | Segment Reconciling Items [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Provision</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">47<span></span>
</td>
<td class="nump">108<span></span>
</td>
<td class="nump">70<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">181<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Plan [Member] | U.S. [Member] | Qualified [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1', window );">Net gain related to the settlement</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (30)<span></span>
</td>
<td class="num">$ (21)<span></span>
</td>
<td class="num">(54)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="num">$ (52)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pfe_HospiraMember', window );">Hospira [Member] | Pension Plan [Member] | U.S. [Member] | Qualified [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1', window );">Net gain related to the settlement</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="7"></td></tr>
<tr><td colspan="7"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">In the <span style="font-family:inherit;font-size:9pt;">third quarter</span><span style="font-family:inherit;font-size:9pt;"> and </span><span style="font-family:inherit;font-size:9pt;">first nine months of</span><span style="font-family:inherit;font-size:9pt;"> </span><span style="font-family:inherit;font-size:9pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:9pt;">, restructuring charges are primarily associated with our acquisitions of Hospira and Medivation, as well as cost-reduction and productivity initiatives not associated with acquisitions. In the </span><span style="font-family:inherit;font-size:9pt;">third quarter</span><span style="font-family:inherit;font-size:9pt;"> and </span><span style="font-family:inherit;font-size:9pt;">first nine months of</span><span style="font-family:inherit;font-size:9pt;"> </span><span style="font-family:inherit;font-size:9pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:9pt;">, restructuring charges are largely associated with cost-reduction and productivity initiatives not associated with acquisitions, as well as our acquisitions of Hospira and Medivation. In the third quarter and first </span><span style="font-family:inherit;font-size:9pt;">nine</span><span style="font-family:inherit;font-size:9pt;"> months ended </span><span style="font-family:inherit;font-size:9pt;">October&#160;1, 2017</span><span style="font-family:inherit;font-size:9pt;">, </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Employee terminations</span><span style="font-family:inherit;font-size:9pt;"> primarily include revisions of our estimates of severance benefits. Employee termination costs are generally recorded when the actions are probable and estimable and include accrued severance benefits, pension and postretirement benefits, many of which may be paid out during periods after termination.</span><div style="line-height:120%;padding-top:4px;padding-left:24px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">The restructuring activities for </span><span style="font-family:inherit;font-size:9pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:9pt;"> are associated with the following:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:12px;"><span style="font-family:inherit;font-size:9pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">For the </span><span style="font-family:inherit;font-size:9pt;">third quarter</span><span style="font-family:inherit;font-size:9pt;"> of </span><span style="font-family:inherit;font-size:9pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:9pt;">, IH (</span><span style="font-family:inherit;font-size:9pt;"><span>$4 million</span></span><span style="font-family:inherit;font-size:9pt;">); EH (</span><span style="font-family:inherit;font-size:9pt;"><span>$1 million</span></span><span style="font-family:inherit;font-size:9pt;">); WRD/GPD (</span><span style="font-family:inherit;font-size:9pt;"><span>$15 million</span></span><span style="font-family:inherit;font-size:9pt;">); manufacturing operations (</span><span style="font-family:inherit;font-size:9pt;"><span>$47 million</span></span><span style="font-family:inherit;font-size:9pt;">); and Corporate (</span><span style="font-family:inherit;font-size:9pt;"><span>$25 million</span></span><span style="font-family:inherit;font-size:9pt;">).</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:12px;"><span style="font-family:inherit;font-size:9pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">For the </span><span style="font-family:inherit;font-size:9pt;">first nine months of</span><span style="font-family:inherit;font-size:9pt;"> </span><span style="font-family:inherit;font-size:9pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:9pt;">, IH (</span><span style="font-family:inherit;font-size:9pt;"><span>$10 million</span></span><span style="font-family:inherit;font-size:9pt;">); EH (</span><span style="font-family:inherit;font-size:9pt;"><span>$9 million</span></span><span style="font-family:inherit;font-size:9pt;"> income); WRD/GPD (</span><span style="font-family:inherit;font-size:9pt;"><span>$29 million</span></span><span style="font-family:inherit;font-size:9pt;">); manufacturing operations (</span><span style="font-family:inherit;font-size:9pt;"><span>$70 million</span></span><span style="font-family:inherit;font-size:9pt;">); and Corporate (</span><span style="font-family:inherit;font-size:9pt;"><span>$51 million</span></span><span style="font-family:inherit;font-size:9pt;">).</span></div></td></tr></table><div style="line-height:120%;padding-top:4px;text-align:left;padding-left:24px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">The restructuring activities for </span><span style="font-family:inherit;font-size:9pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:9pt;"> are associated with the following:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:12px;"><span style="font-family:inherit;font-size:9pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">For the </span><span style="font-family:inherit;font-size:9pt;">third quarter</span><span style="font-family:inherit;font-size:9pt;"> of </span><span style="font-family:inherit;font-size:9pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:9pt;">, IH (</span><span style="font-family:inherit;font-size:9pt;"><span>$148 million</span></span><span style="font-family:inherit;font-size:9pt;">); EH (</span><span style="font-family:inherit;font-size:9pt;"><span>$28 million</span></span><span style="font-family:inherit;font-size:9pt;">); WRD/GPD (</span><span style="font-family:inherit;font-size:9pt;"><span>$52 million</span></span><span style="font-family:inherit;font-size:9pt;">); manufacturing operations (</span><span style="font-family:inherit;font-size:9pt;"><span>$108 million</span></span><span style="font-family:inherit;font-size:9pt;">); and Corporate (</span><span style="font-family:inherit;font-size:9pt;"><span>$67 million</span></span><span style="font-family:inherit;font-size:9pt;">).</span></div></td></tr></table><div style="line-height:120%;font-size:9pt;padding-left:12px;"><span style="font-family:inherit;font-size:9pt;">&#8226;</span></div><span style="font-family:inherit;font-size:9pt;">For the </span><span style="font-family:inherit;font-size:9pt;">first nine months of</span><span style="font-family:inherit;font-size:9pt;"> </span><span style="font-family:inherit;font-size:9pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:9pt;">, IH (</span><span style="font-family:inherit;font-size:9pt;"><span>$162 million</span></span><span style="font-family:inherit;font-size:9pt;">); EH (</span><span style="font-family:inherit;font-size:9pt;"><span>$19 million</span></span><span style="font-family:inherit;font-size:9pt;">); WRD/GPD (</span><span style="font-family:inherit;font-size:9pt;"><span>$104 million</span></span><span style="font-family:inherit;font-size:9pt;">); manufacturing operations (</span><span style="font-family:inherit;font-size:9pt;"><span>$181 million</span></span><span style="font-family:inherit;font-size:9pt;">); and Corporate (</span><span style="font-family:inherit;font-size:9pt;"><span>$107 million</span></span>).</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">In April 2017, we settled the remaining obligation associated with the Hospira U.S. qualified defined benefit pension plan. We purchased a group annuity contract on behalf of the remaining plan participants with a third-party insurance provider. As a result, we were relieved of the <span style="font-family:inherit;font-size:8.5pt;"><span>$156 million</span></span><span style="font-family:inherit;font-size:8.5pt;"> net pension benefit obligation and recorded a pretax settlement gain of </span><span style="font-family:inherit;font-size:8.5pt;"><span>$41 million</span></span><span style="font-family:inherit;font-size:8.5pt;">, partially offset by the recognition of actuarial losses and prior service costs upon plan settlement of approximately </span><span style="font-family:inherit;font-size:8.5pt;"><span>$30 million</span></span><span style="font-family:inherit;font-size:8.5pt;"> in</span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;"> Restructuring charges and certain acquisition-related costs</span><span style="font-family:inherit;font-size:8.5pt;"> during the second quarter of 2017 (see </span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Note 3</span>).</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in net periodic benefit (cost) credit from irrevocable action relieving primary responsibility for benefit obligation and eliminating risk related to obligation and assets used to effect settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(7)<br> -URI http://asc.fasb.org/extlink&amp;oid=82843861&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140864-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=pfe_InnovativeHealthSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=pfe_InnovativeHealthSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=pfe_EssentialHealthSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=pfe_EssentialHealthSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=pfe_WorldwideResearchandDevelopmentandGlobalProductDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=pfe_WorldwideResearchandDevelopmentandGlobalProductDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=pfe_ManufacturingOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=pfe_ManufacturingOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTaxStatusAxis=us-gaap_QualifiedPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTaxStatusAxis=us-gaap_QualifiedPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=pfe_HospiraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=pfe_HospiraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6915375168">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Restructuring Accruals (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 01, 2017</div></th>
<th class="th"><div>Oct. 02, 2016</div></th>
<th class="th"><div>Oct. 01, 2017</div></th>
<th class="th"><div>Oct. 02, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Balance, December 31, 2016</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,583<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Provision</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">$ 91<span></span>
</td>
<td class="nump">$ 404<span></span>
</td>
<td class="nump">150<span></span>
</td>
<td class="nump">$ 574<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment', window );">Utilization and other</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(551)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Balance, October 1, 2017</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">1,182<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,182<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember', window );">Employee Termination Costs [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Balance, December 31, 2016</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,547<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Provision</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment', window );">Utilization and other</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(401)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Balance, October 1, 2017</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">1,154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=pfe_AssetImpairmentsMember', window );">Asset Impairment Charges [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Balance, December 31, 2016</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Provision</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment', window );">Utilization and other</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(126)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Balance, October 1, 2017</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember', window );">Exit Costs [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Balance, December 31, 2016</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Provision</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment', window );">Utilization and other</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(24)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Balance, October 1, 2017</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">$ 28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Included in <span style="font-family:inherit;font-size:9pt;font-style:italic;">Other current liabilities</span><span style="font-family:inherit;font-size:9pt;"> (</span><span style="font-family:inherit;font-size:9pt;"><span>$863 million</span></span><span style="font-family:inherit;font-size:9pt;">) and </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Other noncurrent liabilities</span><span style="font-family:inherit;font-size:9pt;"> (</span><span style="font-family:inherit;font-size:9pt;"><span>$720 million</span></span>).</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">In the <span style="font-family:inherit;font-size:9pt;">third quarter</span><span style="font-family:inherit;font-size:9pt;"> and </span><span style="font-family:inherit;font-size:9pt;">first nine months of</span><span style="font-family:inherit;font-size:9pt;"> </span><span style="font-family:inherit;font-size:9pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:9pt;">, restructuring charges are primarily associated with our acquisitions of Hospira and Medivation, as well as cost-reduction and productivity initiatives not associated with acquisitions. In the </span><span style="font-family:inherit;font-size:9pt;">third quarter</span><span style="font-family:inherit;font-size:9pt;"> and </span><span style="font-family:inherit;font-size:9pt;">first nine months of</span><span style="font-family:inherit;font-size:9pt;"> </span><span style="font-family:inherit;font-size:9pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:9pt;">, restructuring charges are largely associated with cost-reduction and productivity initiatives not associated with acquisitions, as well as our acquisitions of Hospira and Medivation. In the third quarter and first </span><span style="font-family:inherit;font-size:9pt;">nine</span><span style="font-family:inherit;font-size:9pt;"> months ended </span><span style="font-family:inherit;font-size:9pt;">October&#160;1, 2017</span><span style="font-family:inherit;font-size:9pt;">, </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Employee terminations</span><span style="font-family:inherit;font-size:9pt;"> primarily include revisions of our estimates of severance benefits. Employee termination costs are generally recorded when the actions are probable and estimable and include accrued severance benefits, pension and postretirement benefits, many of which may be paid out during periods after termination.</span><div style="line-height:120%;padding-top:4px;padding-left:24px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">The restructuring activities for </span><span style="font-family:inherit;font-size:9pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:9pt;"> are associated with the following:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:12px;"><span style="font-family:inherit;font-size:9pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">For the </span><span style="font-family:inherit;font-size:9pt;">third quarter</span><span style="font-family:inherit;font-size:9pt;"> of </span><span style="font-family:inherit;font-size:9pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:9pt;">, IH (</span><span style="font-family:inherit;font-size:9pt;"><span>$4 million</span></span><span style="font-family:inherit;font-size:9pt;">); EH (</span><span style="font-family:inherit;font-size:9pt;"><span>$1 million</span></span><span style="font-family:inherit;font-size:9pt;">); WRD/GPD (</span><span style="font-family:inherit;font-size:9pt;"><span>$15 million</span></span><span style="font-family:inherit;font-size:9pt;">); manufacturing operations (</span><span style="font-family:inherit;font-size:9pt;"><span>$47 million</span></span><span style="font-family:inherit;font-size:9pt;">); and Corporate (</span><span style="font-family:inherit;font-size:9pt;"><span>$25 million</span></span><span style="font-family:inherit;font-size:9pt;">).</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:12px;"><span style="font-family:inherit;font-size:9pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">For the </span><span style="font-family:inherit;font-size:9pt;">first nine months of</span><span style="font-family:inherit;font-size:9pt;"> </span><span style="font-family:inherit;font-size:9pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:9pt;">, IH (</span><span style="font-family:inherit;font-size:9pt;"><span>$10 million</span></span><span style="font-family:inherit;font-size:9pt;">); EH (</span><span style="font-family:inherit;font-size:9pt;"><span>$9 million</span></span><span style="font-family:inherit;font-size:9pt;"> income); WRD/GPD (</span><span style="font-family:inherit;font-size:9pt;"><span>$29 million</span></span><span style="font-family:inherit;font-size:9pt;">); manufacturing operations (</span><span style="font-family:inherit;font-size:9pt;"><span>$70 million</span></span><span style="font-family:inherit;font-size:9pt;">); and Corporate (</span><span style="font-family:inherit;font-size:9pt;"><span>$51 million</span></span><span style="font-family:inherit;font-size:9pt;">).</span></div></td></tr></table><div style="line-height:120%;padding-top:4px;text-align:left;padding-left:24px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">The restructuring activities for </span><span style="font-family:inherit;font-size:9pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:9pt;"> are associated with the following:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:12px;"><span style="font-family:inherit;font-size:9pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">For the </span><span style="font-family:inherit;font-size:9pt;">third quarter</span><span style="font-family:inherit;font-size:9pt;"> of </span><span style="font-family:inherit;font-size:9pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:9pt;">, IH (</span><span style="font-family:inherit;font-size:9pt;"><span>$148 million</span></span><span style="font-family:inherit;font-size:9pt;">); EH (</span><span style="font-family:inherit;font-size:9pt;"><span>$28 million</span></span><span style="font-family:inherit;font-size:9pt;">); WRD/GPD (</span><span style="font-family:inherit;font-size:9pt;"><span>$52 million</span></span><span style="font-family:inherit;font-size:9pt;">); manufacturing operations (</span><span style="font-family:inherit;font-size:9pt;"><span>$108 million</span></span><span style="font-family:inherit;font-size:9pt;">); and Corporate (</span><span style="font-family:inherit;font-size:9pt;"><span>$67 million</span></span><span style="font-family:inherit;font-size:9pt;">).</span></div></td></tr></table><div style="line-height:120%;font-size:9pt;padding-left:12px;"><span style="font-family:inherit;font-size:9pt;">&#8226;</span></div><span style="font-family:inherit;font-size:9pt;">For the </span><span style="font-family:inherit;font-size:9pt;">first nine months of</span><span style="font-family:inherit;font-size:9pt;"> </span><span style="font-family:inherit;font-size:9pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:9pt;">, IH (</span><span style="font-family:inherit;font-size:9pt;"><span>$162 million</span></span><span style="font-family:inherit;font-size:9pt;">); EH (</span><span style="font-family:inherit;font-size:9pt;"><span>$19 million</span></span><span style="font-family:inherit;font-size:9pt;">); WRD/GPD (</span><span style="font-family:inherit;font-size:9pt;"><span>$104 million</span></span><span style="font-family:inherit;font-size:9pt;">); manufacturing operations (</span><span style="font-family:inherit;font-size:9pt;"><span>$181 million</span></span><span style="font-family:inherit;font-size:9pt;">); and Corporate (</span><span style="font-family:inherit;font-size:9pt;"><span>$107 million</span></span>).</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">Includes adjustments for foreign currency translation.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top">Included in <span style="font-family:inherit;font-size:9pt;font-style:italic;">Other current liabilities </span><span style="font-family:inherit;font-size:9pt;">(</span><span style="font-family:inherit;font-size:9pt;"><span>$533 million</span></span><span style="font-family:inherit;font-size:9pt;">) and </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Other noncurrent liabilities </span><span style="font-family:inherit;font-size:9pt;">(</span><span style="font-family:inherit;font-size:9pt;"><span>$650 million</span></span>).</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments for Restructuring, Other Restructuring And Restructuring Translation Adjustment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140864-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140904-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=pfe_AssetImpairmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=pfe_AssetImpairmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6921718400">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Restructuring Accruals - Footnotes (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2"><div>Oct. 01, 2017</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring reserve</a></td>
<td class="nump">$ 1,182<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 1,583<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember', window );">Other Current Liabilities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring reserve</a></td>
<td class="nump">533<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">863<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember', window );">Other Noncurrent Liabilities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring reserve</a></td>
<td class="nump">$ 650<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 720<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Included in <span style="font-family:inherit;font-size:9pt;font-style:italic;">Other current liabilities </span><span style="font-family:inherit;font-size:9pt;">(</span><span style="font-family:inherit;font-size:9pt;"><span>$533 million</span></span><span style="font-family:inherit;font-size:9pt;">) and </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Other noncurrent liabilities </span><span style="font-family:inherit;font-size:9pt;">(</span><span style="font-family:inherit;font-size:9pt;"><span>$650 million</span></span>).</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Included in <span style="font-family:inherit;font-size:9pt;font-style:italic;">Other current liabilities</span><span style="font-family:inherit;font-size:9pt;"> (</span><span style="font-family:inherit;font-size:9pt;"><span>$863 million</span></span><span style="font-family:inherit;font-size:9pt;">) and </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Other noncurrent liabilities</span><span style="font-family:inherit;font-size:9pt;"> (</span><span style="font-family:inherit;font-size:9pt;"><span>$720 million</span></span>).</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140904-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6919940192">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Other (Income)/Deductions - Net (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="4">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 01, 2017</div></th>
<th class="th"><div>Oct. 02, 2016</div></th>
<th class="th" colspan="2"><div>Oct. 01, 2017</div></th>
<th class="th" colspan="2"><div>Oct. 02, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">$ (99)<span></span>
</td>
<td class="num">$ (123)<span></span>
</td>
<td class="num">$ (275)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (357)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">320<span></span>
</td>
<td class="nump">291<span></span>
</td>
<td class="nump">940<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">889<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestRevenueExpenseNet', window );">Net interest expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">220<span></span>
</td>
<td class="nump">168<span></span>
</td>
<td class="nump">666<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">532<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyRevenue', window );">Royalty-related income</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="num">(140)<span></span>
</td>
<td class="num">(233)<span></span>
</td>
<td class="num">(331)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(695)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossRelatedToLitigationSettlement', window );">Certain legal matters, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">183<span></span>
</td>
<td class="num">(40)<span></span>
</td>
<td class="nump">194<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">494<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_GainLossOnDispositionOfAssetsAndEquitySecurities', window );">Net gains on asset disposals</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="num">(155)<span></span>
</td>
<td class="num">(47)<span></span>
</td>
<td class="num">(349)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(81)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal', window );">Loss on sale and impairment on remeasurement of HIS net assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="num">(12)<span></span>
</td>
<td class="nump">1,422<span></span>
</td>
<td class="nump">52<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[6]</sup></td>
<td class="nump">1,422<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[6]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Certain asset impairments</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[7]</sup></td>
<td class="nump">130<span></span>
</td>
<td class="nump">133<span></span>
</td>
<td class="nump">143<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,080<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_BusinessInfrastructureAlignmentCosts', window );">Business and legal entity alignment costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[8]</sup></td>
<td class="nump">16<span></span>
</td>
<td class="nump">69<span></span>
</td>
<td class="nump">54<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">180<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_OtherNonoperatingIncomeExpenseNet', window );">Other, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[9]</sup></td>
<td class="num">(191)<span></span>
</td>
<td class="num">(55)<span></span>
</td>
<td class="num">(445)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(117)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (income)/deductions&#8211;&#8211;net</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[10]</sup></td>
<td class="nump">$ 51<span></span>
</td>
<td class="nump">$ 1,417<span></span>
</td>
<td class="num">$ (16)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 2,815<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="8"></td></tr>
<tr><td colspan="8"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Interest income decreased in the <span style="font-family:inherit;font-size:8.5pt;">third</span><span style="font-family:inherit;font-size:8.5pt;"> quarter and </span><span style="font-family:inherit;font-size:8.5pt;">first nine months of</span><span style="font-family:inherit;font-size:8.5pt;"> </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:8.5pt;">, primarily driven by a lower investment balance. Interest expense increased in the </span><span style="font-family:inherit;font-size:8.5pt;">third</span><span style="font-family:inherit;font-size:8.5pt;"> quarter and </span><span style="font-family:inherit;font-size:8.5pt;">first nine months of</span><span style="font-family:inherit;font-size:8.5pt;"> </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:8.5pt;">, </span><span style="font-size:8.5pt;">primarily as a result of higher short-term interest rates, offset, in part, by the retirement of high-coupon debt and the issuance of new low-coupon debt</span>.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Royalty-related income <span style="font-family:inherit;font-size:8.5pt;">decreased</span><span style="font-family:inherit;font-size:8.5pt;"> in the </span><span style="font-family:inherit;font-size:8.5pt;">third</span><span style="font-family:inherit;font-size:8.5pt;"> quarter and </span><span style="font-family:inherit;font-size:8.5pt;">first nine months of</span><span style="font-family:inherit;font-size:8.5pt;"> </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:8.5pt;">, primarily due to lower royalty income for Enbrel of </span><span style="font-family:inherit;font-size:8.5pt;"><span>$139 million</span></span><span style="font-family:inherit;font-size:8.5pt;"> and </span><span style="font-family:inherit;font-size:8.5pt;"><span>$414 million</span></span><span style="font-family:inherit;font-size:8.5pt;">, respectively, resulting from the expiration on October 31, 2016 of the </span><span style="font-family:inherit;font-size:8.5pt;">36</span><span style="font-family:inherit;font-size:8.5pt;">-month royalty period under the collaboration agreement for Enbrel in the U.S. and Canada (the collaboration period under the agreement expired on October 31, 2013), partially offset by the addition of Xtandi royalty-related income of </span><span style="font-family:inherit;font-size:8.5pt;"><span>$73 million</span></span><span style="font-family:inherit;font-size:8.5pt;"> and </span><span style="font-family:inherit;font-size:8.5pt;"><span>$160 million</span></span>, respectively.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">In the <span style="font-family:inherit;font-size:8.5pt;">third quarter</span><span style="font-family:inherit;font-size:8.5pt;"> and </span><span style="font-family:inherit;font-size:8.5pt;">first nine months of</span><span style="font-family:inherit;font-size:8.5pt;"> </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:8.5pt;">, primarily includes a </span><span style="font-family:inherit;font-size:8.5pt;"><span>$94 million</span></span><span style="font-family:inherit;font-size:8.5pt;"> charge to resolve a class action lawsuit filed by direct purchasers relating to Celebrex, which is subject to the negotiation of a final settlement agreement and court approval, and a </span><span style="font-family:inherit;font-size:8.5pt;"><span>$79 million</span></span><span style="font-family:inherit;font-size:8.5pt;"> charge to reflect damages awarded by a jury in a patent matter. In the </span><span style="font-family:inherit;font-size:8.5pt;">first nine months of</span><span style="font-family:inherit;font-size:8.5pt;"> </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:8.5pt;">, primarily includes amounts to resolve a Multi-District Litigation relating to Celebrex and Bextra that was pending against the Company in New York federal court for </span><span style="font-family:inherit;font-size:8.5pt;"><span>$486 million</span></span><span style="font-family:inherit;font-size:8.5pt;">, partially offset by the reversal of a legal accrual where a loss was no longer deemed probable. In addition, the </span><span style="font-family:inherit;font-size:8.5pt;">first nine months of</span><span style="font-family:inherit;font-size:8.5pt;"> </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">2016</span> includes a settlement related to a patent matter.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top">In the <span style="font-family:inherit;font-size:8.5pt;">third</span><span style="font-family:inherit;font-size:8.5pt;"> quarter of </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:8.5pt;">, primarily includes gains on sales/out-licensing of product and compound rights (approximately </span><span style="font-family:inherit;font-size:8.5pt;"><span>$71 million</span></span><span style="font-family:inherit;font-size:8.5pt;">) and gains on sales and redemptions of investments in equity and debt securities (approximately </span><span style="font-family:inherit;font-size:8.5pt;"><span>$66 million</span></span><span style="font-family:inherit;font-size:8.5pt;">). In the </span><span style="font-family:inherit;font-size:8.5pt;">first nine months of</span><span style="font-family:inherit;font-size:8.5pt;"> </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:8.5pt;">, primarily includes gains on sales and redemptions of investments in equity and debt securities (approximately </span><span style="font-family:inherit;font-size:8.5pt;"><span>$183 million</span></span><span style="font-family:inherit;font-size:8.5pt;">), gains on sales/out-licensing of product and compound rights (approximately </span><span style="font-family:inherit;font-size:8.5pt;"><span>$141 million</span></span><span style="font-family:inherit;font-size:8.5pt;">) and a gain on sale of property (approximately </span><span style="font-family:inherit;font-size:8.5pt;"><span>$52 million</span></span><span style="font-family:inherit;font-size:8.5pt;">), partially offset by a net loss related to the sale of our </span><span style="font-family:inherit;font-size:8.5pt;"><span>40%</span></span><span style="font-family:inherit;font-size:8.5pt;"> ownership investment in Teuto, including the extinguishment of a put option for the remaining </span><span style="font-family:inherit;font-size:8.5pt;"><span>60%</span></span><span style="font-family:inherit;font-size:8.5pt;"> ownership interest (approximately </span><span style="font-family:inherit;font-size:8.5pt;"><span>$30 million</span></span><span style="font-family:inherit;font-size:8.5pt;">). In the </span><span style="font-family:inherit;font-size:8.5pt;">first nine months of</span><span style="font-family:inherit;font-size:8.5pt;"> </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:8.5pt;">, includes gains on sales/out-licensing of product and compound rights (approximately </span><span style="font-family:inherit;font-size:8.5pt;"><span>$49 million</span></span>).</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[5]</td>
<td style="vertical-align: top;" valign="top">In the <span style="font-family:inherit;font-size:8.5pt;">third</span><span style="font-family:inherit;font-size:8.5pt;"> quarter and </span><span style="font-family:inherit;font-size:8.5pt;">first nine months of</span><span style="font-family:inherit;font-size:8.5pt;"> </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:8.5pt;">, represents adjustments to amounts previously recorded to write down the HIS net assets to fair value less costs to sell related to the sale of HIS net assets to ICU Medical. In the </span><span style="font-family:inherit;font-size:8.5pt;">third</span><span style="font-family:inherit;font-size:8.5pt;"> quarter and </span><span style="font-family:inherit;font-size:8.5pt;">first nine months of</span><span style="font-family:inherit;font-size:8.5pt;"> </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:8.5pt;">, represents a charge related to the write-down of the HIS net assets to fair value less estimated costs to sell.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[6]</td>
<td style="vertical-align: top;" valign="top">Amounts may not add due to rounding.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[7]</td>
<td style="vertical-align: top;" valign="top">In the <span style="font-family:inherit;font-size:8.5pt;">third quarter</span><span style="font-family:inherit;font-size:8.5pt;"> and </span><span style="font-family:inherit;font-size:8.5pt;">first nine months of</span><span style="font-family:inherit;font-size:8.5pt;"> </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:8.5pt;">, primarily includes an intangible asset impairment charge of </span><span style="font-family:inherit;font-size:8.5pt;"><span>$127 million</span></span><span style="font-family:inherit;font-size:8.5pt;"> related to developed technology rights, acquired in connection with our acquisition of Hospira, for a generic sterile injectable product for the treatment of edema associated with certain conditions. The intangible asset impairment charge for the </span><span style="font-family:inherit;font-size:8.5pt;">third</span><span style="font-family:inherit;font-size:8.5pt;"> quarter and </span><span style="font-family:inherit;font-size:8.5pt;">first nine months of</span><span style="font-family:inherit;font-size:8.5pt;"> </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:8.5pt;"> is associated with EH and reflects, among other things, updated commercial forecasts and an increased competitive environment. In the </span><span style="font-family:inherit;font-size:8.5pt;">third</span><span style="font-family:inherit;font-size:8.5pt;"> quarter of </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:8.5pt;">, primarily includes intangible asset impairment charges of </span><span style="font-family:inherit;font-size:8.5pt;"><span>$126 million</span></span><span style="font-family:inherit;font-size:8.5pt;">, reflecting </span><span style="font-family:inherit;font-size:8.5pt;"><span>$97 million</span></span><span style="font-family:inherit;font-size:8.5pt;"> of sterile injectable IPR&amp;D compounds acquired in connection with our acquisition of InnoPharma and </span><span style="font-family:inherit;font-size:8.5pt;"><span>$29 million</span></span><span style="font-family:inherit;font-size:8.5pt;"> of other IPR&amp;D assets acquired in connection with our acquisition of King in 2011. The intangible asset impairment charges for the </span><span style="font-family:inherit;font-size:8.5pt;">third quarter</span><span style="font-family:inherit;font-size:8.5pt;"> of </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:8.5pt;"> are associated with the following: EH (</span><span style="font-family:inherit;font-size:8.5pt;"><span>$97 million</span></span><span style="font-family:inherit;font-size:8.5pt;">) and IH (</span><span style="font-family:inherit;font-size:8.5pt;"><span>$29 million</span></span><span style="font-family:inherit;font-size:8.5pt;">). In the </span><span style="font-family:inherit;font-size:8.5pt;">first nine months of</span><span style="font-family:inherit;font-size:8.5pt;"> </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:8.5pt;">, primarily includes intangible asset impairment charges of </span><span style="font-family:inherit;font-size:8.5pt;"><span>$767 million</span></span><span style="font-family:inherit;font-size:8.5pt;">, reflecting (i) </span><span style="font-family:inherit;font-size:8.5pt;"><span>$331 million</span></span><span style="font-family:inherit;font-size:8.5pt;"> related to developed technology rights for a generic injectable antibiotic product for the treatment of bacterial infections; and (ii) </span><span style="font-family:inherit;font-size:8.5pt;"><span>$265 million</span></span><span style="font-family:inherit;font-size:8.5pt;"> related to an IPR&amp;D compound for the treatment of anemia, both acquired in connection with our acquisition of Hospira; (iii) </span><span style="font-family:inherit;font-size:8.5pt;"><span>$97 million</span></span><span style="font-family:inherit;font-size:8.5pt;"> of sterile injectable IPR&amp;D compounds acquired in connection with our acquisition of InnoPharma; and (iv) </span><span style="font-family:inherit;font-size:8.5pt;"><span>$74 million</span></span><span style="font-family:inherit;font-size:8.5pt;"> of other IPR&amp;D assets, </span><span style="font-family:inherit;font-size:8.5pt;"><span>$45 million</span></span><span style="font-family:inherit;font-size:8.5pt;"> of which were acquired in connection with our acquisition of Hospira and </span><span style="font-family:inherit;font-size:8.5pt;"><span>$29 million</span></span><span style="font-family:inherit;font-size:8.5pt;"> of which were acquired in connection with our acquisition of King in 2011. The intangible asset impairment charges for the </span><span style="font-family:inherit;font-size:8.5pt;">first nine months of</span><span style="font-family:inherit;font-size:8.5pt;"> </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:8.5pt;"> are associated with the following: EH (</span><span style="font-family:inherit;font-size:8.5pt;"><span>$738 million</span></span><span style="font-family:inherit;font-size:8.5pt;">) and IH (</span><span style="font-family:inherit;font-size:8.5pt;"><span>$29 million</span></span><span style="font-family:inherit;font-size:8.5pt;">). In addition, the </span><span style="font-family:inherit;font-size:8.5pt;">first nine months of</span><span style="font-family:inherit;font-size:8.5pt;"> </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:8.5pt;"> includes an impairment loss of </span><span style="font-family:inherit;font-size:8.5pt;"><span>$211 million</span></span><span style="font-family:inherit;font-size:8.5pt;"> related to Pfizer&#8217;s </span><span style="font-family:inherit;font-size:8.5pt;"><span>49%</span></span><span style="font-family:inherit;font-size:8.5pt;">-owned equity-method investment with Hisun in China, Hisun Pfizer, and an impairment loss of </span><span style="font-family:inherit;font-size:8.5pt;"><span>$50 million</span></span><span style="font-family:inherit;font-size:8.5pt;"> related to Pfizer&#8217;s </span><span style="font-family:inherit;font-size:8.5pt;"><span>40%</span></span><span style="font-family:inherit;font-size:8.5pt;">-owned equity-method investment in Teuto. For additional information concerning Hisun Pfizer and Teuto, see </span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Note 2D. </span>The intangible asset impairment charge for 2016 for the IPR&amp;D compound for the treatment of anemia acquired in connection with our acquisition of Hospira reflects, among other things, the impact of regulatory delays, including delays resulting from a court ruling, which required a 180-day waiting period after approval before a biosimilar product can be launched. The intangible asset impairment charges for 2016 for the sterile injectable IPR&amp;D compounds acquired in connection with our acquisition of InnoPharma reflect, among other things, the impact of portfolio prioritization decisions and decreased commercial profiles of certain compounds. The intangible asset impairment charges for 2016 for developed technology rights and other IPR&amp;D assets acquired in connection with our acquisition of Hospira reflect, among other things, the impact of new scientific findings, updated commercial forecasts, changes in pricing, and an increased competitive environment. The intangible asset impairment charges for 2016 for other IPR&amp;D assets acquired in connection with our acquisition of King reflect changes in the competitive environment.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[8]</td>
<td style="vertical-align: top;" valign="top">In the <span style="font-family:inherit;font-size:8.5pt;">third</span><span style="font-family:inherit;font-size:8.5pt;"> quarter and </span><span style="font-family:inherit;font-size:8.5pt;">first nine months of</span><span style="font-family:inherit;font-size:8.5pt;"> </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:8.5pt;"> and </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">2016</span>, represents expenses for changes to our infrastructure to align our commercial operations, including costs to internally separate our businesses into distinct legal entities, as well as to streamline our intercompany supply operations to better support each business.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[9]</td>
<td style="vertical-align: top;" valign="top">In the <span style="font-family:inherit;font-size:8.5pt;">third quarter</span><span style="font-family:inherit;font-size:8.5pt;"> and </span><span style="font-family:inherit;font-size:8.5pt;">first nine months of</span><span style="font-family:inherit;font-size:8.5pt;"> </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:8.5pt;">, includes, among other things, dividend income of </span><span style="font-family:inherit;font-size:8.5pt;"><span>$54 million</span></span><span style="font-family:inherit;font-size:8.5pt;"> and </span><span style="font-family:inherit;font-size:8.5pt;"><span>$211 million</span></span><span style="font-family:inherit;font-size:8.5pt;">, respectively, from our investment in ViiV, and income of </span><span style="font-family:inherit;font-size:8.5pt;"><span>$62 million</span></span><span style="font-family:inherit;font-size:8.5pt;"> from resolution of a contract disagreement. In the </span><span style="font-family:inherit;font-size:8.5pt;">first nine months of</span><span style="font-family:inherit;font-size:8.5pt;"> </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:8.5pt;">, includes, among other things, </span><span style="font-family:inherit;font-size:8.5pt;"><span>$150 million</span></span><span style="font-family:inherit;font-size:8.5pt;"> paid to Allergan for reimbursement of Allergan&#8217;s expenses associated with the terminated transaction and income of </span><span style="font-family:inherit;font-size:8.5pt;"><span>$116 million</span></span> from resolution of a contract disagreement.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[10]</td>
<td style="vertical-align: top;" valign="top">Amounts may not add due to rounding.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_BusinessInfrastructureAlignmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Infrastructure Alignment Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_BusinessInfrastructureAlignmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_GainLossOnDispositionOfAssetsAndEquitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) on Disposition of Assets and Equity Securities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_GainLossOnDispositionOfAssetsAndEquitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_OtherNonoperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Nonoperating Income (Expense), Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_OtherNonoperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=68055307&amp;loc=d3e2420-110228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68055307&amp;loc=d3e2443-110228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84176398&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossRelatedToLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossRelatedToLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestRevenueExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest revenue (income derived from investments in debt securities and on cash and cash equivalents) net of interest expense (cost of borrowed funds accounted for as interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestRevenueExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue earned during the period from the leasing or otherwise lending to a third party the entity's rights or title to certain property. Royalty revenue is derived from a percentage or stated amount of sales proceeds or revenue generated by the third party using the entity's property. Examples of property from which royalties may be derived include patents and oil and mineral rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6930908352">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Other (Income)/Deductions - Net (Footnotes) (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 01, 2017</div></th>
<th class="th"><div>Oct. 02, 2016</div></th>
<th class="th"><div>Oct. 01, 2017</div></th>
<th class="th"><div>Oct. 02, 2016</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyRevenue', window );">Royalty revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 140<span></span>
</td>
<td class="nump">$ 233<span></span>
</td>
<td class="nump">$ 331<span></span>
</td>
<td class="nump">$ 695<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainOnSaleOfInvestments', window );">Gain on sale of investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Gain on sale of property</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Intangible asset impairment charges</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">767<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_OtherNonoperatingIncomeMiscellaneous', window );">Income from contract resolution</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62<span></span>
</td>
<td class="nump">116<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_PaymentsforMergerTerminationCosts', window );">Payments for merger termination costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_LaboratorioTeutoBrasileroMember', window );">Laboratorio Teuto Brasilero [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method investment, ownership percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal', window );">Loss on disposal of equity method investment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment', window );">Equity method investment, impairment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_HisunPfizerPharmaceuticalsCoLtdMember', window );">Hisun Pfizer Pharmaceuticals Co. Ltd [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method investment, ownership percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment', window );">Equity method investment, impairment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=pfe_XtandiMember', window );">Xtandi [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyRevenue', window );">Royalty revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DistributionRightsMember', window );">Distribution Rights [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfIntangibleAssets', window );">Gain on disposition of intangible assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">141<span></span>
</td>
<td class="nump">49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed Technology Rights [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Intangible asset impairment charges</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">331<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementCopromotionMember', window );">Collaborative Arrangement, Co-promotion [Member] | Enbrel [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DecreaseinRoyaltyRevenue', window );">Decrease in royalty revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 414<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_RoyaltyRevenueTerm', window );">Royalty period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember', window );">Pending Litigation [Member] | Celebrex [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Litigation settlement expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember', window );">Pending Litigation [Member] | Celebrex and Bextra [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Amount awarded to other party</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">486<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">In Process Research and Development [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Intangible asset impairment charges</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">265<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=pfe_OtherInProcessResearchandDevelopmentMember', window );">Other In Process Research and Development [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Intangible asset impairment charges</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pfe_HospiraMember', window );">Hospira [Member] | Other In Process Research and Development [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Intangible asset impairment charges</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pfe_InnoPharmaMember', window );">InnoPharma [Member] | In Process Research and Development [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Intangible asset impairment charges</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pfe_KingMember', window );">King [Member] | Other In Process Research and Development [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Intangible asset impairment charges</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments [Member] | EH [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Intangible asset impairment charges</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">738<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments [Member] | EH [Member] | Hospira [Member] | Developed Technology Rights [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Intangible asset impairment charges</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">127<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">127<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments [Member] | IH [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Intangible asset impairment charges</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments [Member] | IH [Member] | ViiV Healthcare Limited [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeDividend', window );">Dividend income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=pfe_LaboratorioTeutoBrasileroMember', window );">Laboratorio Teuto Brasilero [Member] | Laboratorio Teuto Brasilero [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Ownership percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=pfe_PatentMatterMember', window );">Patent Matter [Member] | Pending Litigation [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Litigation settlement expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Royalty-related income <span style="font-family:inherit;font-size:8.5pt;">decreased</span><span style="font-family:inherit;font-size:8.5pt;"> in the </span><span style="font-family:inherit;font-size:8.5pt;">third</span><span style="font-family:inherit;font-size:8.5pt;"> quarter and </span><span style="font-family:inherit;font-size:8.5pt;">first nine months of</span><span style="font-family:inherit;font-size:8.5pt;"> </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:8.5pt;">, primarily due to lower royalty income for Enbrel of </span><span style="font-family:inherit;font-size:8.5pt;"><span>$139 million</span></span><span style="font-family:inherit;font-size:8.5pt;"> and </span><span style="font-family:inherit;font-size:8.5pt;"><span>$414 million</span></span><span style="font-family:inherit;font-size:8.5pt;">, respectively, resulting from the expiration on October 31, 2016 of the </span><span style="font-family:inherit;font-size:8.5pt;">36</span><span style="font-family:inherit;font-size:8.5pt;">-month royalty period under the collaboration agreement for Enbrel in the U.S. and Canada (the collaboration period under the agreement expired on October 31, 2013), partially offset by the addition of Xtandi royalty-related income of </span><span style="font-family:inherit;font-size:8.5pt;"><span>$73 million</span></span><span style="font-family:inherit;font-size:8.5pt;"> and </span><span style="font-family:inherit;font-size:8.5pt;"><span>$160 million</span></span>, respectively.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DecreaseinRoyaltyRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Decrease in Royalty Revenue</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DecreaseinRoyaltyRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_OtherNonoperatingIncomeMiscellaneous">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Nonoperating Income, Miscellaneous</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_OtherNonoperatingIncomeMiscellaneous</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_PaymentsforMergerTerminationCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments for Merger Termination Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_PaymentsforMergerTerminationCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_RoyaltyRevenueTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty Revenue, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_RoyaltyRevenueTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents an other than temporary decline in value that has been recognized against an investment accounted for under the equity method of accounting. The excess of the carrying amount over the fair value of the investment represents the amount of the write down which is or was reflected in earnings. The written down value is a new cost basis with the adjusted value of the investment becoming its new carrying value subject to the equity accounting method. Evidence of a loss in value might include, but would not necessarily be limited to, absence of an ability to recover the carrying amount of the investment or inability of the investee to sustain an earnings capacity which would justify the carrying amount of the investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 35<br> -Paragraph 32<br> -URI http://asc.fasb.org/extlink&amp;oid=99375318&amp;loc=d3e32787-111569<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66011266&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of an equity method investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7,9)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainOnSaleOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the carrying value and the sale price of an investment.  A gain would be recognized when the sale price of the investment is greater than the carrying value of the investment.  This element refers to the Gain included in earnings and not to the cash proceeds of the sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainOnSaleOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount awarded to other party in judgment or settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmountAwardedToOtherParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue earned during the period from the leasing or otherwise lending to a third party the entity's rights or title to certain property. Royalty revenue is derived from a percentage or stated amount of sales proceeds or revenue generated by the third party using the entity's property. Examples of property from which royalties may be derived include patents and oil and mineral rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_LaboratorioTeutoBrasileroMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_LaboratorioTeutoBrasileroMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_HisunPfizerPharmaceuticalsCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_HisunPfizerPharmaceuticalsCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=pfe_XtandiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=pfe_XtandiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DistributionRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DistributionRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementCopromotionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementCopromotionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=pfe_EnbrelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=pfe_EnbrelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=pfe_CelebrexMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=pfe_CelebrexMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=pfe_CelebrexandBextraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=pfe_CelebrexandBextraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=pfe_OtherInProcessResearchandDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=pfe_OtherInProcessResearchandDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=pfe_HospiraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=pfe_HospiraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=pfe_InnoPharmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=pfe_InnoPharmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=pfe_KingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=pfe_KingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=pfe_EssentialHealthSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=pfe_EssentialHealthSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=pfe_InnovativeHealthSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=pfe_InnovativeHealthSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_ViivHealthcareLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_ViivHealthcareLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=pfe_LaboratorioTeutoBrasileroMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=pfe_LaboratorioTeutoBrasileroMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=pfe_PatentMatterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=pfe_PatentMatterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6923230464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other (Income)/Deductions - Net - Impaired Intangible Assets (Detail) - Developed Technology Rights [Member]<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Oct. 01, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th"><sup>[1]</sup></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure', window );">Finite-lived intangible assets, fair value disclosure</a></td>
<td class="nump">$ 50<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of finite-lived intangible assets</a></td>
<td class="nump">127<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure', window );">Finite-lived intangible assets, fair value disclosure</a></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure', window );">Finite-lived intangible assets, fair value disclosure</a></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure', window );">Finite-lived intangible assets, fair value disclosure</a></td>
<td class="nump">$ 50<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Reflects intangible assets written down to fair value in the <span style="font-family:inherit;font-size:8.5pt;">third quarter</span><span style="font-family:inherit;font-size:8.5pt;"> of </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">2017</span>. Fair value was determined using the income approach, specifically the multi-period excess earnings method, also known as the discounted cash flow method. We started with a forecast of all the expected net cash flows associated with the asset and then applied an asset-specific discount rate to arrive at a net present value amount. Some of the more significant estimates and assumptions inherent in this approach include: the amount and timing of the projected net cash flows, which includes the expected impact of competitive, legal and/or regulatory forces on the product; the discount rate, which seeks to reflect the various risks inherent in the projected cash flows; and the tax rate, which seeks to incorporate the geographic diversity of the projected cash flows.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">The fair value amount is presented as of the date of impairment, as these assets are not measured at fair value on a recurring basis.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of assets, excluding financial assets, that lack physical substance, having a limited useful life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19190-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6917258592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Tax Matters - Narrative (Detail)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 01, 2017</div></th>
<th class="th"><div>Oct. 02, 2016</div></th>
<th class="th"><div>Oct. 01, 2017</div></th>
<th class="th"><div>Oct. 02, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate for income from continuing operations</a></td>
<td class="nump">20.30%<span></span>
</td>
<td class="nump">15.50%<span></span>
</td>
<td class="nump">20.10%<span></span>
</td>
<td class="nump">14.60%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6913143696">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Tax Matters (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 01, 2017</div></th>
<th class="th"><div>Oct. 02, 2016</div></th>
<th class="th"><div>Oct. 01, 2017</div></th>
<th class="th"><div>Oct. 02, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax', window );">Foreign currency translation adjustments, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">$ (62)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (192)<span></span>
</td>
<td class="num">$ (15)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax', window );">Unrealized holding losses on derivative financial instruments, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">28<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="num">(192)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesTax', window );">Reclassification adjustments for realized (gains)/losses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(29)<span></span>
</td>
<td class="nump">32<span></span>
</td>
<td class="num">(169)<span></span>
</td>
<td class="nump">81<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesTax', window );">Derivatives qualifying as hedges, tax, total</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">32<span></span>
</td>
<td class="num">(139)<span></span>
</td>
<td class="num">(112)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax', window );">Unrealized holding gains on available-for-sale securities, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">37<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="nump">93<span></span>
</td>
<td class="nump">106<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax', window );">Reclassification adjustments for realized gains</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(49)<span></span>
</td>
<td class="num">(14)<span></span>
</td>
<td class="num">(45)<span></span>
</td>
<td class="num">(16)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax', window );">Available-for-sale securities, tax, total</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(12)<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="nump">47<span></span>
</td>
<td class="nump">90<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodTax', window );">Benefit plans: actuarial losses, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(37)<span></span>
</td>
<td class="num">(31)<span></span>
</td>
<td class="num">(15)<span></span>
</td>
<td class="num">(39)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossTax', window );">Reclassification adjustments related to amortization</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">60<span></span>
</td>
<td class="nump">47<span></span>
</td>
<td class="nump">152<span></span>
</td>
<td class="nump">140<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossTax', window );">Reclassification adjustments related to settlements, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">22<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodTax', window );">Other</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(33)<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="num">(46)<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetActuarialGainLossTax', window );">Defined benefit plans, actuarial gain (loss), tax, total</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">11<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="nump">121<span></span>
</td>
<td class="nump">133<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetPriorServiceCostCreditAndOtherTax', window );">Benefit plans: prior service (costs)/credits and other, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">35<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">66<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax', window );">Reclassification adjustments related to amortization</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(17)<span></span>
</td>
<td class="num">(17)<span></span>
</td>
<td class="num">(50)<span></span>
</td>
<td class="num">(47)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditTax', window );">Reclassification adjustments related to curtailments, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax', window );">Other</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect', window );">Pension and other postretirement benefit plans, net prior service cost (credit), tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(17)<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="num">(55)<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTax', window );">Tax provision/(benefit) on other comprehensive income</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2],[3]</sup></td>
<td class="num">$ (80)<span></span>
</td>
<td class="nump">$ 116<span></span>
</td>
<td class="num">$ (218)<span></span>
</td>
<td class="nump">$ 111<span></span>
</td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Taxes are not provided for foreign currency translation adjustments relating to investments in international subsidiaries that will be held indefinitely.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Amounts may not add due to rounding.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">See Note 5C. Tax Matters: Tax Provision/(Benefit) on Other Comprehensive Income.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetActuarialGainLossTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss), Net Actuarial Gain (Loss), Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetActuarialGainLossTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetPriorServiceCostCreditAndOtherTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss), Net Prior Service Cost (Credit) And Other, Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetPriorServiceCostCreditAndOtherTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Comprehensive (Income) Loss, Curtailment Adjustment from AOCI, Pension and Other Postretirement Benefit Plans, for Net Prior Service Cost (Credit), Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Other Net Prior Service Cost (Credit) Arising During Period, Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Other Net Unamortized Gain (Loss) Arising During Period, Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Comprehensive Income (Loss), Settlement Adjustment From AOCI, Pension And Other Postretirement Benefit Plans, for Net Gain (Loss), Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) for (increase) decrease in value of benefit obligation for change in actuarial assumptions and increase (decrease) in value of plan assets from experience different from that assumed of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=d3e640-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax (expense) benefit of reclassification adjustment from accumulated other comprehensive (income) loss for prior service cost (credit) of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=d3e640-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit), after reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities. Excludes amounts related to other than temporary impairment (OTTI) loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=d3e640-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit), after reclassification adjustments, of increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=d3e640-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=d3e640-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax (expense) benefit for cost (credit) of benefit change attributable to participants' prior service from plan amendment or plan initiation of defined benefit plan, that has not been recognized in net periodic benefit cost (credit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=d3e640-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=96868048&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27357-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=d3e640-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) of reclassification adjustment from accumulated other comprehensive income of accumulated gain (loss) realized from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's deferred hedging gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=d3e640-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph c<br> -URI http://asc.fasb.org/extlink&amp;oid=84234895&amp;loc=d3e41638-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) of reclassification adjustment from accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=d3e640-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) allocated to other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=d3e640-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=79507043&amp;loc=d3e39076-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit), before reclassification adjustments, related to increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=d3e640-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) before reclassification adjustments of unrealized holding gain (loss) on available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=d3e640-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e,f)<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6914564944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests (Detail)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr><th class="th" colspan="2">
<div>Oct. 01, 2017 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, December 31, 2016</a></td>
<td class="nump">$ 59,544<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, October 1, 2017</a></td>
<td class="nump">60,770<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToNoncontrollingInterest', window );">Foreign currency translation adjustments attributable to noncontrolling interests</a></td>
<td class="nump">16<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember', window );">Accumulated Other Comprehensive Income (Loss) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, December 31, 2016</a></td>
<td class="num">(11,036)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income/(loss)</a></td>
<td class="nump">1,872<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, October 1, 2017</a></td>
<td class="num">(9,164)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember', window );">Foreign Currency Translation Adjustment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, December 31, 2016</a></td>
<td class="num">(6,659)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income/(loss)</a></td>
<td class="nump">1,638<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, October 1, 2017</a></td>
<td class="num">(5,021)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember', window );">Derivative Financial Instruments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, December 31, 2016</a></td>
<td class="nump">348<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income/(loss)</a></td>
<td class="num">(403)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, October 1, 2017</a></td>
<td class="num">(55)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths', window );">Cash flow hedge loss to be reclassified within twelve months</a></td>
<td class="nump">154<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember', window );">Available-For-Sale Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, December 31, 2016</a></td>
<td class="num">(131)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income/(loss)</a></td>
<td class="nump">470<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, October 1, 2017</a></td>
<td class="nump">339<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember', window );">Actuarial Gains/(Losses) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, December 31, 2016</a></td>
<td class="num">(5,473)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income/(loss)</a></td>
<td class="nump">263<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, October 1, 2017</a></td>
<td class="num">(5,210)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember', window );">Prior Service (Costs)/Credits and Other [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, December 31, 2016</a></td>
<td class="nump">879<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income/(loss)</a></td>
<td class="num">(96)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, October 1, 2017</a></td>
<td class="nump">$ 783<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Amounts may not add due to rounding.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Amounts do not include foreign currency translation adjustments attributable to noncontrolling interests of <span style="font-family:inherit;font-size:9pt;"><span>$16 million</span></span><span style="font-family:inherit;font-size:9pt;"> income for the </span><span style="font-family:inherit;font-size:9pt;">first nine months of</span><span style="font-family:inherit;font-size:9pt;"> </span><span style="font-family:inherit;font-size:9pt;text-align:center;">2017</span>.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AOCIAttributableToParentNetOfTaxRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated net amount of existing gains or losses on cash flow hedges at the reporting date expected to be reclassified to earnings within the next 12 months.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=35736893&amp;loc=d3e80748-113994<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax, after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to noncontrolling interests.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=96868048&amp;loc=SL4569616-111683<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161450&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=96868048&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161450&amp;loc=SL4573702-111684<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=96868048&amp;loc=SL4569616-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=96868048&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6905517360">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Assets and Liabilities Measured on Recurring Basis (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Oct. 01, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_OtherSelectedFinancialAssetsAbstract', window );"><strong>Other selected financial assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_SelectedFinancialAssets', window );">Total selected financial assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 22,815<span></span>
</td>
<td class="nump">$ 24,175<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermBorrowingsAbstract', window );"><strong>Short-term borrowings:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Total short-term borrowings, carried at historical proceeds, as adjusted</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="nump">9,448<span></span>
</td>
<td class="nump">10,688<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Long-term debt:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Total long-term debt, carried at historical proceeds, as adjusted</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[3]</sup></td>
<td class="nump">34,503<span></span>
</td>
<td class="nump">31,398<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_OtherFinancialLiabilities', window );">Total</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">43,951<span></span>
</td>
<td class="nump">42,085<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_SelectedFinancialLiabilities', window );">Total selected financial liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">45,124<span></span>
</td>
<td class="nump">43,750<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Reported Value Measurement [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_OtherSelectedFinancialAssetsAbstract', window );"><strong>Other selected financial assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAmortizedCostBeforeOtherThanTemporaryImpairment', window );">Held-to-maturity debt securities, carried at amortized cost</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2],[4]</sup></td>
<td class="nump">1,464<span></span>
</td>
<td class="nump">1,242<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures', window );">Restricted stock and private equity securities, carried at cost or at equity-method</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">719<span></span>
</td>
<td class="nump">735<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_OtherSelectedFinancialAssets', window );">Total</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,183<span></span>
</td>
<td class="nump">1,977<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LongTermDebtMember', window );">Long-term debt [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermBorrowingsAbstract', window );"><strong>Short-term borrowings:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting', window );">Net fair value adjustments related to hedging and purchase accounting</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">981<span></span>
</td>
<td class="nump">998<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Net unamortized discounts, premiums and debt issuance costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(149)<span></span>
</td>
<td class="num">(130)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Long-term debt:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">33,671<span></span>
</td>
<td class="nump">30,529<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ShortTermDebtMember', window );">Short-term Debt [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermBorrowingsAbstract', window );"><strong>Short-term borrowings:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ShorttermDebtGross', window );">Principal amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">9,460<span></span>
</td>
<td class="nump">10,674<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting', window );">Net fair value adjustments related to hedging and purchase accounting</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Net unamortized discounts, premiums and debt issuance costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(15)<span></span>
</td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets, Fair Value Disclosure [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Trading funds and securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5],[6]</sup></td>
<td class="nump">347<span></span>
</td>
<td class="nump">325<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Selected financial assets measured at fair value on a recurring basis</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[6],[7]</sup></td>
<td class="nump">20,631<span></span>
</td>
<td class="nump">22,198<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract', window );"><strong>Selected financial liabilities measured at fair value on a recurring basis</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative financial instruments in a liability position</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[6],[8]</sup></td>
<td class="nump">1,173<span></span>
</td>
<td class="nump">1,665<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring [Member] | Interest Rate Swaps [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets, Fair Value Disclosure [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative financial instruments in a receivable position</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[6],[7]</sup></td>
<td class="nump">630<span></span>
</td>
<td class="nump">625<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract', window );"><strong>Selected financial liabilities measured at fair value on a recurring basis</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative financial instruments in a liability position</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[6],[8]</sup></td>
<td class="nump">154<span></span>
</td>
<td class="nump">148<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring [Member] | Foreign Currency Swap [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets, Fair Value Disclosure [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative financial instruments in a receivable position</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[6],[7]</sup></td>
<td class="nump">92<span></span>
</td>
<td class="nump">79<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract', window );"><strong>Selected financial liabilities measured at fair value on a recurring basis</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative financial instruments in a liability position</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[6],[8]</sup></td>
<td class="nump">710<span></span>
</td>
<td class="nump">1,374<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring [Member] | Foreign Currency Forward-Exchange Contracts [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets, Fair Value Disclosure [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative financial instruments in a receivable position</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[6],[7]</sup></td>
<td class="nump">110<span></span>
</td>
<td class="nump">551<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract', window );"><strong>Selected financial liabilities measured at fair value on a recurring basis</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative financial instruments in a liability position</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[6],[8]</sup></td>
<td class="nump">309<span></span>
</td>
<td class="nump">143<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring [Member] | Available-for-sale Debt Securities [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets, Fair Value Disclosure [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Available-for-sale securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4],[6]</sup></td>
<td class="nump">16,598<span></span>
</td>
<td class="nump">18,632<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring [Member] | Money Market Funds [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets, Fair Value Disclosure [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Available-for-sale securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[6]</sup></td>
<td class="nump">1,824<span></span>
</td>
<td class="nump">1,445<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring [Member] | Equity Securities [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets, Fair Value Disclosure [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Available-for-sale securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4],[6]</sup></td>
<td class="nump">$ 1,032<span></span>
</td>
<td class="nump">$ 540<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Amounts may not add due to rounding.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">The differences between the estimated fair values and carrying values of held-to-maturity debt securities, restricted stock and private equity securities at cost, and short-term borrowings not measured at fair value on a recurring basis were not significant as of <span style="font-family:inherit;font-size:8.5pt;">October&#160;1, 2017</span><span style="font-family:inherit;font-size:8.5pt;"> or </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">December&#160;31, 2016</span><span style="font-family:inherit;font-size:8.5pt;">. The fair value measurements of our held-to-maturity debt securities and our short-term borrowings are based on Level 2 inputs, using a market approach. The fair value measurements of our </span><span style="font-family:inherit;font-size:8.5pt;background-color:#ffffff;">priv</span>ate equity securities carried at cost are based on Level 3 inputs.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">The fair value of our long-term debt (not including the current portion of long-term debt) was <span style="font-family:inherit;font-size:8.5pt;"><span>$39.0 billion</span></span><span style="font-family:inherit;font-size:8.5pt;"> as of </span><span style="font-family:inherit;font-size:8.5pt;">October&#160;1, 2017</span><span style="font-family:inherit;font-size:8.5pt;"> and </span><span style="font-family:inherit;font-size:8.5pt;"><span>$34.9 billion</span></span><span style="font-family:inherit;font-size:8.5pt;"> as of </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">December&#160;31, 2016</span><span style="font-family:inherit;font-size:8.5pt;">. The fair value measurements for our long-term debt are based on Level 2 inputs, using a market approach. Long-term debt includes foreign currency long-term borrowings with fair values of </span><span style="font-family:inherit;font-size:8.5pt;"><span>$4.7 billion</span></span><span style="font-family:inherit;font-size:8.5pt;"> as of </span><span style="font-family:inherit;font-size:8.5pt;">October&#160;1, 2017</span>, which are used as hedging instruments.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top">Gross unrealized gains and losses are not significant, except as of <span style="font-family:inherit;font-size:8.5pt;">October&#160;1, 2017</span><span style="font-family:inherit;font-size:8.5pt;">, available-for-sale equity securities&#8217; unrealized gains are </span><span style="font-family:inherit;font-size:8.5pt;"><span>$406 million</span></span><span style="font-family:inherit;font-size:8.5pt;"> and unrealized losses are </span><span style="font-family:inherit;font-size:8.5pt;"><span>$119 million</span></span>.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[5]</td>
<td style="vertical-align: top;" valign="top">As of <span style="font-family:inherit;font-size:8.5pt;">October&#160;1, 2017</span><span style="font-family:inherit;font-size:8.5pt;">, trading funds and securities are composed of </span><span style="font-family:inherit;font-size:8.5pt;"><span>$274 million</span></span><span style="font-family:inherit;font-size:8.5pt;"> of trading equity funds and </span><span style="font-family:inherit;font-size:8.5pt;"><span>$74 million</span></span><span style="font-family:inherit;font-size:8.5pt;"> of trading debt funds. As of </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">December&#160;31, 2016</span><span style="font-family:inherit;font-size:8.5pt;">, trading funds and securities are composed of </span><span style="font-family:inherit;font-size:8.5pt;"><span>$236 million</span></span><span style="font-family:inherit;font-size:8.5pt;"> of trading equity funds and </span><span style="font-family:inherit;font-size:8.5pt;"><span>$89 million</span></span><span style="font-family:inherit;font-size:8.5pt;"> of trading debt funds. As of </span><span style="font-family:inherit;font-size:8.5pt;">October&#160;1, 2017</span><span style="font-family:inherit;font-size:8.5pt;"> and </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">December&#160;31, 2016</span><span style="font-family:inherit;font-size:8.5pt;">, trading equity funds of </span><span style="font-family:inherit;font-size:8.5pt;"><span>$63 million</span></span><span style="font-family:inherit;font-size:8.5pt;"> and </span><span style="font-family:inherit;font-size:8.5pt;"><span>$71 million</span></span>, respectively, are held in trust for benefits attributable to the former Pharmacia Savings Plus Plan.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[6]</td>
<td style="vertical-align: top;" valign="top">We use a market approach in valuing financial instruments on a recurring basis. All of our financial assets and liabilities measured at fair value on a recurring basis use Level 2 inputs in the calculation of fair value, except <span style="font-family:inherit;font-size:8.5pt;"><span>5%</span></span> that use Level 1 inputs.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[7]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family:inherit;font-size:8.5pt;">Designated as hedging instruments, except for certain contracts used as offsets; namely, foreign currency forward-exchange contracts with fair values of </span><span style="font-family:inherit;font-size:8.5pt;"><span>$40 million</span></span><span style="font-family:inherit;font-size:8.5pt;"> as of </span><span style="font-family:inherit;font-size:8.5pt;">October&#160;1, 2017</span><span style="font-family:inherit;font-size:8.5pt;">; and foreign currency forward-exchange contracts with fair values of </span><span style="font-family:inherit;font-size:8.5pt;"><span>$162 million</span></span><span style="font-family:inherit;font-size:8.5pt;"> as of </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">December&#160;31, 2016</span>.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[8]</td>
<td style="vertical-align: top;" valign="top">Designated as hedging instruments, except for certain contracts used as offsets; namely, foreign currency forward-exchange contracts with fair values of <span style="font-family:inherit;font-size:8.5pt;"><span>$60 million</span></span><span style="font-family:inherit;font-size:8.5pt;"> as of </span><span style="font-family:inherit;font-size:8.5pt;">October&#160;1, 2017</span><span style="font-family:inherit;font-size:8.5pt;">; and foreign currency swaps with fair values of </span><span style="font-family:inherit;font-size:8.5pt;"><span>$269 million</span></span><span style="font-family:inherit;font-size:8.5pt;"> and foreign currency forward-exchange contracts with fair values of </span><span style="font-family:inherit;font-size:8.5pt;"><span>$113 million</span></span><span style="font-family:inherit;font-size:8.5pt;"> as of </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">December&#160;31, 2016</span>.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Fair Value Adjustments, Hedging and Purchase Accounting</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_OtherFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total other financial liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_OtherFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_OtherSelectedFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of other selected financial assets presented in the balance sheet caption at the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_OtherSelectedFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_OtherSelectedFinancialAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other selected financial assets [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_OtherSelectedFinancialAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_SelectedFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total selected financial assets at the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_SelectedFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_SelectedFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total selected financial liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_SelectedFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_ShorttermDebtGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Short-term Debt, Gross</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_ShorttermDebtGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 25<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=75030427&amp;loc=d3e22054-111558<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27232-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82896770&amp;loc=d3e26610-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term debt and current maturity of long-term debt and capital lease obligations due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41271-113958<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41228-113958<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13495-108611<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=82849420&amp;loc=SL20226008-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=82849420&amp;loc=SL20226008-175313<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13495-108611<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13433-108611<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41271-113958<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41228-113958<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesAmortizedCostBeforeOtherThanTemporaryImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before other than temporary impairment (OTTI) accretion, of investments in debt securities classified as held-to-maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesAmortizedCostBeforeOtherThanTemporaryImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 35<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82895926&amp;loc=d3e24584-111560<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=75030427&amp;loc=d3e22054-111558<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total investments in (A) an entity in which the entity has significant influence, but does not have control, (B) subsidiaries that are not required to be consolidated and are accounted for using the equity and or cost method, and (C) an entity in which the reporting entity shares control of the entity with another party or group. Includes long-term advances receivable from a party that is affiliated with the reporting entity by means of direct or indirect ownership.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowingsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowingsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradingSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments in debt and equity securities and other forms of securities that provide ownership interests classified as trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82896770&amp;loc=d3e26626-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82896770&amp;loc=d3e26610-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradingSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LongTermDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LongTermDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ShortTermDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_ShortTermDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeForwardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeForwardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_DebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_DebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6922980080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments - Assets and Liabilities Measured on Recurring Basis - Footnotes (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 01, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_FootnotesToSelectedFinancialAssetsAndLiabilitiesAbstract', window );"><strong>Footnotes to selected financial assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleEquitySecuritiesGrossUnrealizedGain', window );">Gross unrealized gain</a></td>
<td class="nump">$ 406<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleEquitySecuritiesGrossUnrealizedLoss', window );">Gross unrealized loss</a></td>
<td class="nump">$ 119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_FootnotesToSelectedFinancialAssetsAndLiabilitiesAbstract', window );"><strong>Footnotes to selected financial assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_FinancialAssetsAndLiabilitiesMeasuredAtFairValuePercentage', window );">Percentage of financial assets and liabilities measured at fair value inputs Level 1 and Level 3 inputs (less than)</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecuritiesEquity', window );">Trading equity funds</a></td>
<td class="nump">$ 274<span></span>
</td>
<td class="nump">$ 236<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecuritiesDebt', window );">Trading debt funds</a></td>
<td class="nump">74<span></span>
</td>
<td class="nump">89<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecuritiesRestricted', window );">Trading securities held in trust</a></td>
<td class="nump">63<span></span>
</td>
<td class="nump">71<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Not Designated as Hedging Instrument [Member] | Foreign Currency Forward-Exchange Contracts [Member] | Fair Value, Measurements, Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_FootnotesToSelectedFinancialAssetsAndLiabilitiesAbstract', window );"><strong>Footnotes to selected financial assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Instruments used as offsets (assets)</a></td>
<td class="nump">40<span></span>
</td>
<td class="nump">162<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Instruments used as offsets (liabilities)</a></td>
<td class="nump">60<span></span>
</td>
<td class="nump">113<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Not Designated as Hedging Instrument [Member] | Foreign Currency Swap [Member] | Fair Value, Measurements, Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_FootnotesToSelectedFinancialAssetsAndLiabilitiesAbstract', window );"><strong>Footnotes to selected financial assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Instruments used as offsets (liabilities)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">269<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member] | Estimate of Fair Value Measurement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_FootnotesToSelectedFinancialAssetsAndLiabilitiesAbstract', window );"><strong>Footnotes to selected financial assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Fair value of long-term debt</a></td>
<td class="nump">39,000<span></span>
</td>
<td class="nump">$ 34,900<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=pfe_ForeignCurrencyLongTermDebtMember', window );">Foreign Currency Long Term Debt [Member] | Level 2 [Member] | Estimate of Fair Value Measurement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_FootnotesToSelectedFinancialAssetsAndLiabilitiesAbstract', window );"><strong>Footnotes to selected financial assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Fair value of long-term debt</a></td>
<td class="nump">$ 4,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_FinancialAssetsAndLiabilitiesMeasuredAtFairValuePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financial Assets And Liabilities Measured At Fair Value, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_FinancialAssetsAndLiabilitiesMeasuredAtFairValuePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_FootnotesToSelectedFinancialAssetsAndLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Footnotes to selected financial assets and liabilities [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_FootnotesToSelectedFinancialAssetsAndLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleEquitySecuritiesGrossUnrealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain before deducting unrealized loss on investments in equity securities classified as available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleEquitySecuritiesGrossUnrealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleEquitySecuritiesGrossUnrealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized loss before deducting unrealized gain on investments in available-for-sale equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleEquitySecuritiesGrossUnrealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84234895&amp;loc=SL5624163-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=82849420&amp;loc=SL20226000-175313<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=82924980&amp;loc=SL51823488-111719<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=82924980&amp;loc=SL51823488-111719<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84234895&amp;loc=SL5624163-113959<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=82849420&amp;loc=SL20226000-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradingSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments in debt securities classified as trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82896770&amp;loc=d3e26626-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82896770&amp;loc=d3e26610-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradingSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradingSecuritiesEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investments in trading equity securities and other forms of trading securities that provide ownership interests.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82896770&amp;loc=d3e26626-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82896770&amp;loc=d3e26610-111562<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),1(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradingSecuritiesEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradingSecuritiesRestricted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all securities that are purchased with the intent to be sold in the short-term and that are pledged to one or more secured parties who have the right to buy, sell, or re-pledge the collateral.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82896770&amp;loc=d3e26610-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=6488002&amp;loc=d3e600178-122990<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82896770&amp;loc=d3e26626-111562<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12)<br> -URI http://asc.fasb.org/extlink&amp;oid=50485924&amp;loc=d3e611133-123010<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66007379&amp;loc=d3e113888-111728<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradingSecuritiesRestricted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeForwardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeForwardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=pfe_ForeignCurrencyLongTermDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=pfe_ForeignCurrencyLongTermDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6916446368">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Balance Sheet Grouping (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Oct. 01, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_SelectedFinancialAssets', window );">Selected financial assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 22,815<span></span>
</td>
<td class="nump">$ 24,175<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_SelectedFinancialLiabilities', window );">Selected financial liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">45,124<span></span>
</td>
<td class="nump">43,750<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_CashAndCashEquivalentsMember', window );">Cash and Cash Equivalents [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_SelectedFinancialAssets', window );">Selected financial assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">526<span></span>
</td>
<td class="nump">547<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term Investments [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_SelectedFinancialAssets', window );">Selected financial assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">14,146<span></span>
</td>
<td class="nump">15,255<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember', window );">Other Current Assets [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_SelectedFinancialAssets', window );">Selected financial assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">288<span></span>
</td>
<td class="nump">567<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=pfe_LongtermInvestmentsMember', window );">Long-term Investments [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_SelectedFinancialAssets', window );">Selected financial assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,311<span></span>
</td>
<td class="nump">7,116<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember', window );">Other Noncurrent Assets [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_SelectedFinancialAssets', window );">Selected financial assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">543<span></span>
</td>
<td class="nump">689<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=pfe_ShortTermDebtAndCurrentPortionofLongTermDebtMember', window );">Short-Term Borrowings, Including Current Portion of Long-Term Debt [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_SelectedFinancialLiabilities', window );">Selected financial liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">9,448<span></span>
</td>
<td class="nump">10,688<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember', window );">Other Current Liabilities [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_SelectedFinancialLiabilities', window );">Selected financial liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">277<span></span>
</td>
<td class="nump">443<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_LongTermDebtMember', window );">Long-term debt [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_SelectedFinancialLiabilities', window );">Selected financial liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">34,503<span></span>
</td>
<td class="nump">31,398<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember', window );">Other Noncurrent Liabilities [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_SelectedFinancialLiabilities', window );">Selected financial liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">$ 896<span></span>
</td>
<td class="nump">$ 1,222<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">As of <span style="font-family:inherit;font-size:9pt;">October&#160;1, 2017</span><span style="font-family:inherit;font-size:9pt;">, derivative instruments at fair value include interest rate swaps (</span><span style="font-family:inherit;font-size:9pt;"><span>$97 million</span></span><span style="font-family:inherit;font-size:9pt;">), foreign currency swaps (</span><span style="font-family:inherit;font-size:9pt;"><span>$86 million</span></span><span style="font-family:inherit;font-size:9pt;">) and foreign currency forward-exchange contracts (</span><span style="font-family:inherit;font-size:9pt;"><span>$105 million</span></span><span style="font-family:inherit;font-size:9pt;">) and, as of </span><span style="font-family:inherit;font-size:9pt;text-align:center;">December&#160;31, 2016</span><span style="font-family:inherit;font-size:9pt;">, include interest rate swaps (</span><span style="font-family:inherit;font-size:9pt;"><span>$26 million</span></span><span style="font-family:inherit;font-size:9pt;">), foreign currency swaps (</span><span style="font-family:inherit;font-size:9pt;"><span>$43 million</span></span><span style="font-family:inherit;font-size:9pt;">) and foreign currency forward-exchange contracts (</span><span style="font-family:inherit;font-size:9pt;"><span>$497 million</span></span>).</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">As of <span style="font-family:inherit;font-size:9pt;">October&#160;1, 2017</span><span style="font-family:inherit;font-size:9pt;">, derivative instruments at fair value include interest rate swaps (</span><span style="font-family:inherit;font-size:9pt;"><span>$532 million</span></span><span style="font-family:inherit;font-size:9pt;">), foreign currency swaps (</span><span style="font-family:inherit;font-size:9pt;"><span>$6 million</span></span><span style="font-family:inherit;font-size:9pt;">) and foreign currency forward-exchange contracts (</span><span style="font-family:inherit;font-size:9pt;"><span>$5 million</span></span><span style="font-family:inherit;font-size:9pt;">) and, as of </span><span style="font-family:inherit;font-size:9pt;text-align:center;">December&#160;31, 2016</span><span style="font-family:inherit;font-size:9pt;">, include interest rate swaps (</span><span style="font-family:inherit;font-size:9pt;"><span>$599 million</span></span><span style="font-family:inherit;font-size:9pt;">), foreign currency swaps (</span><span style="font-family:inherit;font-size:9pt;"><span>$36 million</span></span><span style="font-family:inherit;font-size:9pt;">) and foreign currency forward-exchange contracts (</span><span style="font-family:inherit;font-size:9pt;"><span>$54 million</span></span>).</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">As of <span style="font-family:inherit;font-size:9pt;">October&#160;1, 2017</span><span style="font-family:inherit;font-size:9pt;">, derivative instruments at fair value include foreign currency forward-exchange contracts (</span><span style="font-family:inherit;font-size:9pt;"><span>$276 million</span></span><span style="font-family:inherit;font-size:9pt;">) and interest rate swaps (</span><span style="font-family:inherit;font-size:9pt;"><span>$1 million</span></span><span style="font-family:inherit;font-size:9pt;">) and, as of </span><span style="font-family:inherit;font-size:9pt;text-align:center;">December&#160;31, 2016</span><span style="font-family:inherit;font-size:9pt;">, include interest rate swaps (</span><span style="font-family:inherit;font-size:9pt;"><span>$1 million</span></span><span style="font-family:inherit;font-size:9pt;">), foreign currency swaps (</span><span style="font-family:inherit;font-size:9pt;"><span>$300 million</span></span><span style="font-family:inherit;font-size:9pt;">) and foreign currency forward-exchange contracts (</span><span style="font-family:inherit;font-size:9pt;"><span>$143 million</span></span>).</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top">As of <span style="font-family:inherit;font-size:9pt;">October&#160;1, 2017</span><span style="font-family:inherit;font-size:9pt;">, derivative instruments at fair value include interest rate swaps (</span><span style="font-family:inherit;font-size:9pt;"><span>$153 million</span></span><span style="font-family:inherit;font-size:9pt;">), foreign currency swaps (</span><span style="font-family:inherit;font-size:9pt;"><span>$710 million</span></span><span style="font-family:inherit;font-size:9pt;">) and foreign currency forward-exchange contracts (</span><span style="font-family:inherit;font-size:9pt;"><span>$33 million</span></span><span style="font-family:inherit;font-size:9pt;">) and, as of </span><span style="font-family:inherit;font-size:9pt;text-align:center;">December&#160;31, 2016</span><span style="font-family:inherit;font-size:9pt;">, include interest rate swaps (</span><span style="font-family:inherit;font-size:9pt;"><span>$147 million</span></span><span style="font-family:inherit;font-size:9pt;">) and foreign currency swaps (</span><span style="font-family:inherit;font-size:9pt;"><span>$1.1 billion</span></span>).</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_SelectedFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total selected financial assets at the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_SelectedFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_SelectedFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total selected financial liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_SelectedFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_CashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_CashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_ShortTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_ShortTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=pfe_LongtermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=pfe_LongtermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=pfe_ShortTermDebtAndCurrentPortionofLongTermDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=pfe_ShortTermDebtAndCurrentPortionofLongTermDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_LongTermDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_LongTermDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6777763952">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Balance Sheet Grouping - Footnotes (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Oct. 01, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_SelectedFinancialAssets', window );">Selected financial assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 22,815<span></span>
</td>
<td class="nump">$ 24,175<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_SelectedFinancialLiabilities', window );">Selected financial liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">45,124<span></span>
</td>
<td class="nump">43,750<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember', window );">Other Current Assets [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_SelectedFinancialAssets', window );">Selected financial assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">288<span></span>
</td>
<td class="nump">567<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember', window );">Other Current Assets [Member] | Interest Rate Swaps [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_SelectedFinancialAssets', window );">Selected financial assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">97<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember', window );">Other Current Assets [Member] | Foreign Currency Swap [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_SelectedFinancialAssets', window );">Selected financial assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">86<span></span>
</td>
<td class="nump">43<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember', window );">Other Current Assets [Member] | Foreign Currency Forward-Exchange Contracts [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_SelectedFinancialAssets', window );">Selected financial assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">105<span></span>
</td>
<td class="nump">497<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember', window );">Other Noncurrent Assets [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_SelectedFinancialAssets', window );">Selected financial assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">543<span></span>
</td>
<td class="nump">689<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember', window );">Other Noncurrent Assets [Member] | Interest Rate Swaps [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_SelectedFinancialAssets', window );">Selected financial assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">532<span></span>
</td>
<td class="nump">599<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember', window );">Other Noncurrent Assets [Member] | Foreign Currency Swap [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_SelectedFinancialAssets', window );">Selected financial assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember', window );">Other Noncurrent Assets [Member] | Foreign Currency Forward-Exchange Contracts [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_SelectedFinancialAssets', window );">Selected financial assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5<span></span>
</td>
<td class="nump">54<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember', window );">Other Current Liabilities [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_SelectedFinancialLiabilities', window );">Selected financial liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">277<span></span>
</td>
<td class="nump">443<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember', window );">Other Current Liabilities [Member] | Interest Rate Swaps [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_SelectedFinancialLiabilities', window );">Selected financial liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember', window );">Other Current Liabilities [Member] | Foreign Currency Swap [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_SelectedFinancialLiabilities', window );">Selected financial liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember', window );">Other Current Liabilities [Member] | Foreign Currency Forward-Exchange Contracts [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_SelectedFinancialLiabilities', window );">Selected financial liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">276<span></span>
</td>
<td class="nump">143<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember', window );">Other Noncurrent Liabilities [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_SelectedFinancialLiabilities', window );">Selected financial liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">896<span></span>
</td>
<td class="nump">1,222<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember', window );">Other Noncurrent Liabilities [Member] | Interest Rate Swaps [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_SelectedFinancialLiabilities', window );">Selected financial liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">153<span></span>
</td>
<td class="nump">147<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember', window );">Other Noncurrent Liabilities [Member] | Foreign Currency Swap [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_SelectedFinancialLiabilities', window );">Selected financial liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">710<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember', window );">Other Noncurrent Liabilities [Member] | Foreign Currency Forward-Exchange Contracts [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_SelectedFinancialLiabilities', window );">Selected financial liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">As of <span style="font-family:inherit;font-size:9pt;">October&#160;1, 2017</span><span style="font-family:inherit;font-size:9pt;">, derivative instruments at fair value include interest rate swaps (</span><span style="font-family:inherit;font-size:9pt;"><span>$97 million</span></span><span style="font-family:inherit;font-size:9pt;">), foreign currency swaps (</span><span style="font-family:inherit;font-size:9pt;"><span>$86 million</span></span><span style="font-family:inherit;font-size:9pt;">) and foreign currency forward-exchange contracts (</span><span style="font-family:inherit;font-size:9pt;"><span>$105 million</span></span><span style="font-family:inherit;font-size:9pt;">) and, as of </span><span style="font-family:inherit;font-size:9pt;text-align:center;">December&#160;31, 2016</span><span style="font-family:inherit;font-size:9pt;">, include interest rate swaps (</span><span style="font-family:inherit;font-size:9pt;"><span>$26 million</span></span><span style="font-family:inherit;font-size:9pt;">), foreign currency swaps (</span><span style="font-family:inherit;font-size:9pt;"><span>$43 million</span></span><span style="font-family:inherit;font-size:9pt;">) and foreign currency forward-exchange contracts (</span><span style="font-family:inherit;font-size:9pt;"><span>$497 million</span></span>).</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">As of <span style="font-family:inherit;font-size:9pt;">October&#160;1, 2017</span><span style="font-family:inherit;font-size:9pt;">, derivative instruments at fair value include interest rate swaps (</span><span style="font-family:inherit;font-size:9pt;"><span>$532 million</span></span><span style="font-family:inherit;font-size:9pt;">), foreign currency swaps (</span><span style="font-family:inherit;font-size:9pt;"><span>$6 million</span></span><span style="font-family:inherit;font-size:9pt;">) and foreign currency forward-exchange contracts (</span><span style="font-family:inherit;font-size:9pt;"><span>$5 million</span></span><span style="font-family:inherit;font-size:9pt;">) and, as of </span><span style="font-family:inherit;font-size:9pt;text-align:center;">December&#160;31, 2016</span><span style="font-family:inherit;font-size:9pt;">, include interest rate swaps (</span><span style="font-family:inherit;font-size:9pt;"><span>$599 million</span></span><span style="font-family:inherit;font-size:9pt;">), foreign currency swaps (</span><span style="font-family:inherit;font-size:9pt;"><span>$36 million</span></span><span style="font-family:inherit;font-size:9pt;">) and foreign currency forward-exchange contracts (</span><span style="font-family:inherit;font-size:9pt;"><span>$54 million</span></span>).</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">As of <span style="font-family:inherit;font-size:9pt;">October&#160;1, 2017</span><span style="font-family:inherit;font-size:9pt;">, derivative instruments at fair value include foreign currency forward-exchange contracts (</span><span style="font-family:inherit;font-size:9pt;"><span>$276 million</span></span><span style="font-family:inherit;font-size:9pt;">) and interest rate swaps (</span><span style="font-family:inherit;font-size:9pt;"><span>$1 million</span></span><span style="font-family:inherit;font-size:9pt;">) and, as of </span><span style="font-family:inherit;font-size:9pt;text-align:center;">December&#160;31, 2016</span><span style="font-family:inherit;font-size:9pt;">, include interest rate swaps (</span><span style="font-family:inherit;font-size:9pt;"><span>$1 million</span></span><span style="font-family:inherit;font-size:9pt;">), foreign currency swaps (</span><span style="font-family:inherit;font-size:9pt;"><span>$300 million</span></span><span style="font-family:inherit;font-size:9pt;">) and foreign currency forward-exchange contracts (</span><span style="font-family:inherit;font-size:9pt;"><span>$143 million</span></span>).</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top">As of <span style="font-family:inherit;font-size:9pt;">October&#160;1, 2017</span><span style="font-family:inherit;font-size:9pt;">, derivative instruments at fair value include interest rate swaps (</span><span style="font-family:inherit;font-size:9pt;"><span>$153 million</span></span><span style="font-family:inherit;font-size:9pt;">), foreign currency swaps (</span><span style="font-family:inherit;font-size:9pt;"><span>$710 million</span></span><span style="font-family:inherit;font-size:9pt;">) and foreign currency forward-exchange contracts (</span><span style="font-family:inherit;font-size:9pt;"><span>$33 million</span></span><span style="font-family:inherit;font-size:9pt;">) and, as of </span><span style="font-family:inherit;font-size:9pt;text-align:center;">December&#160;31, 2016</span><span style="font-family:inherit;font-size:9pt;">, include interest rate swaps (</span><span style="font-family:inherit;font-size:9pt;"><span>$147 million</span></span><span style="font-family:inherit;font-size:9pt;">) and foreign currency swaps (</span><span style="font-family:inherit;font-size:9pt;"><span>$1.1 billion</span></span>).</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_SelectedFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total selected financial assets at the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_SelectedFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_SelectedFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total selected financial liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_SelectedFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeForwardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeForwardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6919460048">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Investments in Debt Securities (Detail)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">
<div>Oct. 01, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Total Debt Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DebtSecuritiesMaturitiesWithinOneYear', window );">Debt securities maturities within one year</a></td>
<td class="nump">$ 12,818<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DebtSecuritiesMaturitiesOverOneToFiveYears', window );">Debt securities maturities over 1 to 5 years</a></td>
<td class="nump">3,694<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DebtSecuritiesMaturitiesOverFiveToTenYears', window );">Debt securities maturities over 5 to 10 years</a></td>
<td class="nump">1,532<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DebtSecuritiesMaturitiesAfterTenYears', window );">Debt securities maturities over 10 years</a></td>
<td class="nump">18<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DebtSecurities', window );">Total debt securities</a></td>
<td class="nump">18,061<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Total Debt Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue', window );">Available-for-sale debt securities maturities within 1 year</a></td>
<td class="nump">2,741<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue', window );">Available-for-sale debt securities maturities over 1 to 5 years</a></td>
<td class="nump">2,591<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearSixThroughTenFairValue', window );">Available-for-sale debt securities maturities over 5 to 10 years</a></td>
<td class="nump">1,525<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingAfterYearTenFairValue', window );">Available-for-sale debt securities maturities over 10 years</a></td>
<td class="nump">17<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities maturities total</a></td>
<td class="nump">6,874<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=pfe_WesternEuropeanAsianandOtherGovernmentDebtMember', window );">Western European, Asian and other government debt [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Total Debt Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue', window );">Available-for-sale debt securities maturities within 1 year</a></td>
<td class="nump">6,071<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue', window );">Available-for-sale debt securities maturities over 1 to 5 years</a></td>
<td class="nump">268<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearSixThroughTenFairValue', window );">Available-for-sale debt securities maturities over 5 to 10 years</a></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingAfterYearTenFairValue', window );">Available-for-sale debt securities maturities over 10 years</a></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities maturities total</a></td>
<td class="nump">6,339<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=pfe_WesternEuropeanScandinaviaAndOtherGovernmentAgencyDebtMember', window );">Western European, Scandinavia and other government agency debt [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Total Debt Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue', window );">Available-for-sale debt securities maturities within 1 year</a></td>
<td class="nump">1,955<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue', window );">Available-for-sale debt securities maturities over 1 to 5 years</a></td>
<td class="nump">42<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearSixThroughTenFairValue', window );">Available-for-sale debt securities maturities over 5 to 10 years</a></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingAfterYearTenFairValue', window );">Available-for-sale debt securities maturities over 10 years</a></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities maturities total</a></td>
<td class="nump">1,998<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=pfe_SupranationalDebtMember', window );">Supranational debt [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Total Debt Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue', window );">Available-for-sale debt securities maturities within 1 year</a></td>
<td class="nump">387<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue', window );">Available-for-sale debt securities maturities over 1 to 5 years</a></td>
<td class="nump">195<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearSixThroughTenFairValue', window );">Available-for-sale debt securities maturities over 5 to 10 years</a></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingAfterYearTenFairValue', window );">Available-for-sale debt securities maturities over 10 years</a></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities maturities total</a></td>
<td class="nump">582<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_GovernmentNationalMortgageAssociationCertificatesAndObligationsGNMAMember', window );">Government National Mortgage Association and other U.S. government guaranteed asset-back securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Total Debt Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue', window );">Available-for-sale debt securities maturities within 1 year</a></td>
<td class="nump">42<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue', window );">Available-for-sale debt securities maturities over 1 to 5 years</a></td>
<td class="nump">424<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearSixThroughTenFairValue', window );">Available-for-sale debt securities maturities over 5 to 10 years</a></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingAfterYearTenFairValue', window );">Available-for-sale debt securities maturities over 10 years</a></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities maturities total</a></td>
<td class="nump">466<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_AssetBackedSecuritiesMember', window );">Other asset-backed debt [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Total Debt Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue', window );">Available-for-sale debt securities maturities within 1 year</a></td>
<td class="nump">161<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue', window );">Available-for-sale debt securities maturities over 1 to 5 years</a></td>
<td class="nump">61<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearSixThroughTenFairValue', window );">Available-for-sale debt securities maturities over 5 to 10 years</a></td>
<td class="nump">3<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingAfterYearTenFairValue', window );">Available-for-sale debt securities maturities over 10 years</a></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities maturities total</a></td>
<td class="nump">226<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_USGovernmentDebtSecuritiesMember', window );">U.S. government debt [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Total Debt Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue', window );">Available-for-sale debt securities maturities within 1 year</a></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue', window );">Available-for-sale debt securities maturities over 1 to 5 years</a></td>
<td class="nump">112<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearSixThroughTenFairValue', window );">Available-for-sale debt securities maturities over 5 to 10 years</a></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingAfterYearTenFairValue', window );">Available-for-sale debt securities maturities over 10 years</a></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities maturities total</a></td>
<td class="nump">112<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=pfe_TimeDepositsCorporateDebtAndOtherMember', window );">Time deposits and other [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Total Debt Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue', window );">Held-to-maturity debt securities maturities within 1 year</a></td>
<td class="nump">1,133<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue', window );">Held-to-maturity debt securities with maturities over 1 to 5 years</a></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesRollingYearSixThroughTenFairValue', window );">Held-to-maturity debt securities maturities over 5 to 10 years</a></td>
<td class="nump">3<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesRollingAfterTenYearsFairValue', window );">Held-to-maturity debt securities maturities over 10 years</a></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Held-to-maturity debt securities maturities total</a></td>
<td class="nump">1,137<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=pfe_WesternEuropeanandOtherGovernmentDebtMember', window );">Western European government debt [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Total Debt Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue', window );">Held-to-maturity debt securities maturities within 1 year</a></td>
<td class="nump">326<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue', window );">Held-to-maturity debt securities with maturities over 1 to 5 years</a></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesRollingYearSixThroughTenFairValue', window );">Held-to-maturity debt securities maturities over 5 to 10 years</a></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesRollingAfterTenYearsFairValue', window );">Held-to-maturity debt securities maturities over 10 years</a></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Held-to-maturity debt securities maturities total</a></td>
<td class="nump">$ 326<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Issued by a diverse group of corporations, with a significant concentration in the technology sector, virtually all of which are investment-grade.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Issued by governments, government agencies or supranational entities, as applicable, all of which are high quality.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">Includes receivable-backed, loan-backed, and mortgage-backed securities, all of which are high quality and in senior positions in the capital structure of the security. Receivable-backed securities are collateralized by credit cards receivables, loan-backed securities are collateralized by senior secured obligations of a diverse pool of companies or student loans, and mortgage-backed securities are collateralized by diversified pools of residential and commercial mortgages.<br/></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the total of all debt securities grouped by maturity dates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DebtSecuritiesMaturitiesAfterTenYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities Maturities After Ten Years</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DebtSecuritiesMaturitiesAfterTenYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DebtSecuritiesMaturitiesOverFiveToTenYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents debt securities which are expected to mature after five and through ten years from the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DebtSecuritiesMaturitiesOverFiveToTenYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DebtSecuritiesMaturitiesOverOneToFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents debt securities which are expected to mature after one year and through five years from the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DebtSecuritiesMaturitiesOverOneToFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DebtSecuritiesMaturitiesWithinOneYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents debt securities which are expected to mature within one year of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DebtSecuritiesMaturitiesWithinOneYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of available-for-sale debt securities maturing in the next rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingAfterYearTenFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of available-for-sale debt securities maturing after the tenth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingAfterYearTenFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearSixThroughTenFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of available-for-sale debt securities maturing in the sixth through tenth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearSixThroughTenFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of available-for-sale debt securities maturing in the second through fifth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of debt securities categorized neither as held-to-maturity nor trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 25<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=75030427&amp;loc=d3e22054-111558<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82896770&amp;loc=d3e26610-111562<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)-(g)<br> -URI http://asc.fasb.org/extlink&amp;oid=75019621&amp;loc=d3e62557-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after other than temporary impairment (OTTI) accretion, of investments in debt securities classified as held-to-maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27232-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 25<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=75030427&amp;loc=d3e22054-111558<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27232-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.6)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of held-to-maturity debt securities maturing in the next rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesRollingAfterTenYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of held-to-maturity debt securities maturing after the tenth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesDebtMaturitiesRollingAfterTenYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesRollingYearSixThroughTenFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of held-to-maturity debt securities maturing in the sixth through tenth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesDebtMaturitiesRollingYearSixThroughTenFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of held-to-maturity debt securities maturing in the second through fifth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=pfe_WesternEuropeanAsianandOtherGovernmentDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=pfe_WesternEuropeanAsianandOtherGovernmentDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=pfe_WesternEuropeanScandinaviaAndOtherGovernmentAgencyDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=pfe_WesternEuropeanScandinaviaAndOtherGovernmentAgencyDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=pfe_SupranationalDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=pfe_SupranationalDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_GovernmentNationalMortgageAssociationCertificatesAndObligationsGNMAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_GovernmentNationalMortgageAssociationCertificatesAndObligationsGNMAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_USGovernmentDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_USGovernmentDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=pfe_TimeDepositsCorporateDebtAndOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=pfe_TimeDepositsCorporateDebtAndOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=pfe_WesternEuropeanandOtherGovernmentDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=pfe_WesternEuropeanandOtherGovernmentDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6917244864">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Short-Term Borrowings (Details) - USD ($)<br> $ in Billions</strong></div></th>
<th class="th"><div>Oct. 01, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommercialPaper', window );">Commercial paper</a></td>
<td class="nump">$ 6.1<span></span>
</td>
<td class="nump">$ 5.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommercialPaper">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of short-term borrowings using unsecured obligations issued by banks, corporations and other borrowers to investors. The maturities of these money market securities generally do not exceed 270 days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommercialPaper</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6919314336">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments - Long-Term Debt (Details)<br> &#8364; in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 01, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 01, 2017 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Apr. 02, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Debt issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 34,503<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Debt issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">5,797<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,279<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes [Member] | Three-month EURIBOR Plus 0.20% floating rate notes (2019 Notes) [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Debt issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,479<span></span>
</td>
<td class="nump">&#8364; 1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes [Member] | 0.00% euro Notes (2020 Notes) [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Debt issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">$ 1,183<span></span>
</td>
<td class="nump">&#8364; 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes [Member] | 0.25% euro Notes (2022 Notes) [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Debt issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">$ 1,183<span></span>
</td>
<td class="nump">&#8364; 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.25%<span></span>
</td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes [Member] | 1.00% euro Notes (2027 Notes) [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Debt issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">$ 887<span></span>
</td>
<td class="nump">&#8364; 750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes [Member] | Euro Long-term Debt [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Debt issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">$ 4,732<span></span>
</td>
<td class="nump">&#8364; 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtWeightedAverageInterestRate', window );">Weighted average effective interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.23%<span></span>
</td>
<td class="nump">0.23%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes [Member] | 4.20% Notes (2047 Notes) [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Debt issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">$ 1,065<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4.20%<span></span>
</td>
<td class="nump">4.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableRateAxis=pfe_EURIBORMember', window );">EURIBOR [Member] | Senior Notes [Member] | Three-month EURIBOR Plus 0.20% floating rate notes (2019 Notes) [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DebtInstrumentFloorInterestRate', window );">Floor interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum [Member] | German Government Bond Rate [Member] | Senior Notes [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DebtInstrumentRedemptionRuleRedemptionPricePercentageBasisSpread', window );">Redemption basis spread</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The aggregate amount at issuance date was <span style="font-family:inherit;font-size:8.5pt;"><span>$5,279 million</span></span>. The increase in the amount since the date of issuance is due to foreign currency exchange.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Redeemable at any time, in whole, or in part, at our option prior to 30 to 90 days of maturity date at the comparable German government bond rate, plus <span style="font-family:inherit;font-size:8.5pt;"><span>0.15%</span></span>; plus, in each case, accrued and unpaid interest. The fixed rate euro notes are also redeemable at our option, in whole, or in part, within 30 to 90 days of maturity date.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">The weighted-average effective interest rate for the euro notes at issuance was <span style="font-family:inherit;font-size:8.5pt;"><span>0.23%</span></span>.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top">The notes, issued in U.S. dollars in Taiwan, are redeemable, at our option, in whole but not in part, on each March 17 on or after March 17, 2020.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DebtInstrumentFloorInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Floor Interest Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DebtInstrumentFloorInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DebtInstrumentRedemptionRuleRedemptionPricePercentageBasisSpread">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Redemption Rule, Redemption Price, Percentage, Basis Spread</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DebtInstrumentRedemptionRuleRedemptionPricePercentageBasisSpread</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=64930739&amp;loc=d3e28878-108400<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28551-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtWeightedAverageInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average interest rate of debt outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtWeightedAverageInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pfe_SeniorUnsecuredEuroDebtThreemonthEURIBORPlus0.20FloatingRateNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pfe_SeniorUnsecuredEuroDebtThreemonthEURIBORPlus0.20FloatingRateNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pfe_SeniorUnsecuredEuroDebtZeroPercentDue2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pfe_SeniorUnsecuredEuroDebtZeroPercentDue2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pfe_SeniorUnsecuredEuroDebtPointTwofivePercentDue2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pfe_SeniorUnsecuredEuroDebtPointTwofivePercentDue2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pfe_SeniorUnsecuredEuroDebtOnePointZeroPercentDue2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pfe_SeniorUnsecuredEuroDebtOnePointZeroPercentDue2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pfe_EuroLongtermDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pfe_EuroLongtermDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pfe_SeniorUnsecuredDebtFourPointTwoPercentDue2047Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pfe_SeniorUnsecuredDebtFourPointTwoPercentDue2047Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=pfe_EURIBORMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=pfe_EURIBORMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=pfe_GermanGovernmentBondRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=pfe_GermanGovernmentBondRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6918214464">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Long-Term Debt - Maturities (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Oct. 01, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_FinancialInstrumentsAbstract', window );"><strong>Financial Instruments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2018</a></td>
<td class="nump">$ 481<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2019</a></td>
<td class="nump">4,825<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2020</a></td>
<td class="nump">1,534<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive', window );">2021</a></td>
<td class="nump">4,502<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive', window );">After 2021</a></td>
<td class="nump">23,162<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">$ 34,503<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_FinancialInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financial Instruments [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_FinancialInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6918809440">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments - Other Noncurrent Liabilities (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 31, 2017</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Oct. 01, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-lived intangible assets, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37,492<span></span>
</td>
<td class="nump">$ 35,664<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed Technology Rights [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-lived intangible assets, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,625<span></span>
</td>
<td class="nump">$ 33,740<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=pfe_BesponsaMember', window );">Besponsa [Member] | Developed Technology Rights [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-lived intangible assets, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">371<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementGeographicalAxis=country_US', window );">U.S. [Member] | Besponsa [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ResearchandDevelopmentArrangementAggregatePaymentObligationTerm', window );">Term over which fixed annual payments are to be made</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">9 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ResearchandDevelopmentArrangementAggregatePaymentObligation', window );">Aggregate amount of guaranteed fixed annual payments to be made in connection with research and development arrangement</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 296<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementGeographicalAxis=country_US', window );">U.S. [Member] | Besponsa [Member] | Developed Technology Rights [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-lived intangible assets, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">248<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementGeographicalAxis=country_US', window );">U.S. [Member] | Besponsa [Member] | Developed Technology Rights [Member] | Other Noncurrent Liabilities [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-lived intangible assets, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">233<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementGeographicalAxis=country_US', window );">U.S. [Member] | Besponsa [Member] | Developed Technology Rights [Member] | Other Current Liabilities [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-lived intangible assets, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementGeographicalAxis=us-gaap_EuropeanUnionMember', window );">EU [Member] | Besponsa [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ResearchandDevelopmentArrangementAggregatePaymentObligationTerm', window );">Term over which fixed annual payments are to be made</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ResearchandDevelopmentArrangementAggregatePaymentObligation', window );">Aggregate amount of guaranteed fixed annual payments to be made in connection with research and development arrangement</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 148<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementGeographicalAxis=us-gaap_EuropeanUnionMember', window );">EU [Member] | Besponsa [Member] | Developed Technology Rights [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-lived intangible assets, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementGeographicalAxis=us-gaap_EuropeanUnionMember', window );">EU [Member] | Besponsa [Member] | Developed Technology Rights [Member] | Other Noncurrent Liabilities [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-lived intangible assets, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">117<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementGeographicalAxis=us-gaap_EuropeanUnionMember', window );">EU [Member] | Besponsa [Member] | Developed Technology Rights [Member] | Other Current Liabilities [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-lived intangible assets, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The changes in the gross carrying amount of <span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Developed technology rights </span><span style="font-family:inherit;font-size:8.5pt;">and </span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">IPR&amp;D</span><span style="font-family:inherit;font-size:8.5pt;"> primarily reflect (i) the transfer of </span><span style="font-family:inherit;font-size:8.5pt;"><span>$4.8 billion</span></span><span style="font-family:inherit;font-size:8.5pt;"> from </span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">IPR&amp;D</span><span style="font-family:inherit;font-size:8.5pt;"> to </span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Developed technology rights</span><span style="font-family:inherit;font-size:8.5pt;"> to reflect the approval of Eucrisa, (ii) the </span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Developed technology rights</span><span style="font-family:inherit;font-size:8.5pt;"> and </span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">IPR&amp;D</span><span style="font-family:inherit;font-size:8.5pt;"> acquired as part of the acquisition of AstraZeneca&#8217;s small molecule anti-infectives business (see </span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Note 2A</span><span style="font-family:inherit;font-size:8.5pt;">), (iii) the </span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Developed technology rights</span><span style="font-family:inherit;font-size:8.5pt;"> of </span><span style="font-family:inherit;font-size:8.5pt;"><span>$371 million</span></span><span style="font-family:inherit;font-size:8.5pt;"> recorded in connection with the EU and U.S. approvals of Besponsa (see </span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Note 7E</span><span style="font-family:inherit;font-size:8.5pt;">), partially offset by (iv) measurement period adjustments related to Medivation (see </span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Note 2A</span><span style="font-family:inherit;font-size:8.5pt;">) and (v) impairments of </span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Developed technology rights</span><span style="font-family:inherit;font-size:8.5pt;"> (see </span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Note 4)</span>.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_ResearchandDevelopmentArrangementAggregatePaymentObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and Development Arrangement, Aggregate Payment Obligation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_ResearchandDevelopmentArrangementAggregatePaymentObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_ResearchandDevelopmentArrangementAggregatePaymentObligationTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and Development Arrangement, Aggregate Payment Obligation, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_ResearchandDevelopmentArrangementAggregatePaymentObligationTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=pfe_BesponsaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=pfe_BesponsaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=us-gaap_EuropeanUnionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=us-gaap_EuropeanUnionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6905120944">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments - Derivative Financial Instruments and Hedging Activities (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 01, 2017</div></th>
<th class="th"><div>Oct. 02, 2016</div></th>
<th class="th"><div>Oct. 01, 2017</div></th>
<th class="th"><div>Oct. 02, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 34,503<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,503<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedLossOnForeignCurrencyDerivativesBeforeTax', window );">Pre-tax loss on foreign currency forward exchange contracts</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months', window );">Pre-tax loss to be reclassified</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyCashFlowHedgeGainLossReclassifiedToEarningsNet', window );">Gain (loss) recognized as an offset</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnCashFlowHedgeIneffectivenessNet', window );">Gain (loss) on cash flow hedge ineffectiveness</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLocationAxis=us-gaap_OtherComprehensiveIncomeMember', window );">Other Comprehensive Income (Loss) [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet', window );">Amount of Gains/(Losses) Recognized in OCI (Effective Portion)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="num">(216)<span></span>
</td>
<td class="num">(126)<span></span>
</td>
<td class="num">(666)<span></span>
</td>
<td class="num">(1,014)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember', window );">Other (Income)/Deductions, Net [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Amount of Gains/(Losses) Recognized in OID</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2],[3],[4]</sup></td>
<td class="nump">34<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="num">(117)<span></span>
</td>
<td class="num">(56)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember', window );">Reclassification out of Accumulated Other Comprehensive Income [Member] | Other (Income)/Deductions, Net [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet', window );">Amount of Gains/(Losses) Reclassified from OCI into OID and COS (Effective Portion)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="num">(55)<span></span>
</td>
<td class="num">(150)<span></span>
</td>
<td class="nump">394<span></span>
</td>
<td class="num">(283)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=pfe_OtherDerivativeInstrumentsMember', window );">Other Derivative Instruments [Member] | Other Comprehensive Income (Loss) [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet', window );">Amount of Gains/(Losses) Recognized in OCI (Effective Portion)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=pfe_OtherDerivativeInstrumentsMember', window );">Other Derivative Instruments [Member] | Other (Income)/Deductions, Net [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Amount of Gains/(Losses) Recognized in OID</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2],[3],[4]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=pfe_OtherDerivativeInstrumentsMember', window );">Other Derivative Instruments [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member] | Other (Income)/Deductions, Net [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet', window );">Amount of Gains/(Losses) Reclassified from OCI into OID and COS (Effective Portion)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember', window );">Interest Rate Contract [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetNotionalAmount', window );">Derivative asset, notional amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">12,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember', window );">Foreign Currency Swap [Member] | Designated as Hedging Instrument [Member] | Cash Flow Hedging [Member] | Other Comprehensive Income (Loss) [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet', window );">Amount of Gains/(Losses) Recognized in OCI (Effective Portion)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="nump">218<span></span>
</td>
<td class="nump">87<span></span>
</td>
<td class="nump">455<span></span>
</td>
<td class="num">(204)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember', window );">Foreign Currency Swap [Member] | Designated as Hedging Instrument [Member] | Cash Flow Hedging [Member] | Other (Income)/Deductions, Net [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Amount of Gains/(Losses) Recognized in OID</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2],[3],[4]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember', window );">Foreign Currency Swap [Member] | Designated as Hedging Instrument [Member] | Cash Flow Hedging [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member] | Other (Income)/Deductions, Net [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet', window );">Amount of Gains/(Losses) Reclassified from OCI into OID and COS (Effective Portion)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="nump">148<span></span>
</td>
<td class="num">(39)<span></span>
</td>
<td class="nump">419<span></span>
</td>
<td class="num">(165)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember', window );">Foreign Currency Swap [Member] | Not Designated as Hedging Instrument [Member] | Other Comprehensive Income (Loss) [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet', window );">Amount of Gains/(Losses) Recognized in OCI (Effective Portion)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember', window );">Foreign Currency Swap [Member] | Not Designated as Hedging Instrument [Member] | Other (Income)/Deductions, Net [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Amount of Gains/(Losses) Recognized in OID</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2],[3],[4]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember', window );">Foreign Currency Swap [Member] | Not Designated as Hedging Instrument [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member] | Other (Income)/Deductions, Net [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet', window );">Amount of Gains/(Losses) Reclassified from OCI into OID and COS (Effective Portion)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeForwardMember', window );">Foreign Currency Forward-Exchange Contracts [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetNotionalAmount', window );">Derivative asset, notional amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">31,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_DerivativeNotionalAmount', window );">Notional amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeForwardMember', window );">Foreign Currency Forward-Exchange Contracts [Member] | Designated as Hedging Instrument [Member] | Cash Flow Hedging [Member] | Other Comprehensive Income (Loss) [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet', window );">Amount of Gains/(Losses) Recognized in OCI (Effective Portion)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="num">(269)<span></span>
</td>
<td class="num">(212)<span></span>
</td>
<td class="num">(604)<span></span>
</td>
<td class="num">(770)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeForwardMember', window );">Foreign Currency Forward-Exchange Contracts [Member] | Designated as Hedging Instrument [Member] | Cash Flow Hedging [Member] | Other (Income)/Deductions, Net [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Amount of Gains/(Losses) Recognized in OID</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2],[3],[4]</sup></td>
<td class="nump">1<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeForwardMember', window );">Foreign Currency Forward-Exchange Contracts [Member] | Designated as Hedging Instrument [Member] | Cash Flow Hedging [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member] | Other (Income)/Deductions, Net [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet', window );">Amount of Gains/(Losses) Reclassified from OCI into OID and COS (Effective Portion)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="num">(204)<span></span>
</td>
<td class="num">(111)<span></span>
</td>
<td class="num">(26)<span></span>
</td>
<td class="num">(118)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeForwardMember', window );">Foreign Currency Forward-Exchange Contracts [Member] | Designated as Hedging Instrument [Member] | Net Investment Hedging [Member] | Other Comprehensive Income (Loss) [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet', window );">Amount of Gains/(Losses) Recognized in OCI (Effective Portion)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(15)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeForwardMember', window );">Foreign Currency Forward-Exchange Contracts [Member] | Designated as Hedging Instrument [Member] | Net Investment Hedging [Member] | Other (Income)/Deductions, Net [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Amount of Gains/(Losses) Recognized in OID</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2],[3],[4]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeForwardMember', window );">Foreign Currency Forward-Exchange Contracts [Member] | Designated as Hedging Instrument [Member] | Net Investment Hedging [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member] | Other (Income)/Deductions, Net [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet', window );">Amount of Gains/(Losses) Reclassified from OCI into OID and COS (Effective Portion)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeForwardMember', window );">Foreign Currency Forward-Exchange Contracts [Member] | Not Designated as Hedging Instrument [Member] | Other Comprehensive Income (Loss) [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet', window );">Amount of Gains/(Losses) Recognized in OCI (Effective Portion)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeForwardMember', window );">Foreign Currency Forward-Exchange Contracts [Member] | Not Designated as Hedging Instrument [Member] | Other (Income)/Deductions, Net [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Amount of Gains/(Losses) Recognized in OID</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2],[3],[4]</sup></td>
<td class="nump">33<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="num">(111)<span></span>
</td>
<td class="num">(49)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeForwardMember', window );">Foreign Currency Forward-Exchange Contracts [Member] | Not Designated as Hedging Instrument [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member] | Other (Income)/Deductions, Net [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet', window );">Amount of Gains/(Losses) Reclassified from OCI into OID and COS (Effective Portion)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=pfe_ForeignCurrencyShortTermBorrowingsMember', window );">Foreign Currency Short Term Borrowings [Member] | Net Investment Hedging, Nonderivative Instruments [Member] | Other Comprehensive Income (Loss) [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet', window );">Amount of Gains/(Losses) Recognized in OCI (Effective Portion)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(26)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=pfe_ForeignCurrencyShortTermBorrowingsMember', window );">Foreign Currency Short Term Borrowings [Member] | Net Investment Hedging, Nonderivative Instruments [Member] | Other (Income)/Deductions, Net [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Amount of Gains/(Losses) Recognized in OID</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2],[3],[4]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=pfe_ForeignCurrencyShortTermBorrowingsMember', window );">Foreign Currency Short Term Borrowings [Member] | Net Investment Hedging, Nonderivative Instruments [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member] | Other (Income)/Deductions, Net [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet', window );">Amount of Gains/(Losses) Reclassified from OCI into OID and COS (Effective Portion)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=pfe_ForeignCurrencyLongTermDebtMember', window );">Foreign Currency Long Term Debt [Member] | Net Investment Hedging, Nonderivative Instruments [Member] | Other Comprehensive Income (Loss) [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet', window );">Amount of Gains/(Losses) Recognized in OCI (Effective Portion)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="num">(166)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(518)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=pfe_ForeignCurrencyLongTermDebtMember', window );">Foreign Currency Long Term Debt [Member] | Net Investment Hedging, Nonderivative Instruments [Member] | Other (Income)/Deductions, Net [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Amount of Gains/(Losses) Recognized in OID</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2],[3],[4]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=pfe_ForeignCurrencyLongTermDebtMember', window );">Foreign Currency Long Term Debt [Member] | Net Investment Hedging, Nonderivative Instruments [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member] | Other (Income)/Deductions, Net [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet', window );">Amount of Gains/(Losses) Reclassified from OCI into OID and COS (Effective Portion)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">For derivative financial instruments in cash flow hedge relationships, the effective portion is included in <span style="font-family:inherit;font-size:9pt;font-style:italic;">Other comprehensive income&#8211;&#8211;Unrealized holding losses on derivative financial instruments, net</span><span style="font-family:inherit;font-size:9pt;">. For derivative financial instruments in net investment hedge relationships and for foreign currency debt designated as hedging instruments, the effective portion is included in </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Other comprehensive income&#8211;&#8211;Foreign currency translation adjustments, net.</span><br/></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">OID = Other (income)/deductions&#8212;net, included in <span style="font-family:inherit;font-size:9pt;font-style:italic;">Other (income)/deductions&#8212;net</span><span style="font-family:inherit;font-size:9pt;"> in the condensed consolidated statements of income. COS = Cost of sales, included in </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Cost of sales</span><span style="font-family:inherit;font-size:9pt;"> in the condensed consolidated statements of income.</span><span style="font-family:inherit;font-size:9pt;">OCI = Other comprehensive income/(loss), included in the</span><span style="font-family:inherit;font-size:9pt;font-style:italic;"> </span><span style="font-family:inherit;font-size:9pt;">condensed consolidated statements of comprehensive income</span>.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">Includes gains and losses attributable to derivative instruments designated and qualifying as fair value hedges (primarily interest rate swaps), as well as the offsetting gains and losses attributable to the hedged items in such hedging relationships.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top">There was no significant ineffectiveness for any period presented.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_invest_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate notional amount specified by the derivative(s). Expressed as an absolute value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Article 12<br> -Section 13<br> -Sentence Column B<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">invest_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>invest_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payments on the derivative asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=84234895&amp;loc=SL5579245-113959<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=84234895&amp;loc=SL5580258-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84234895&amp;loc=SL5618551-113959<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (a),(c),(d),(e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84234895&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The effective portion of net gain (loss) reclassified from accumulated other comprehensive income into income on derivative instruments designated and qualifying as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84234895&amp;loc=SL5624171-113959<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84234895&amp;loc=SL5624177-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The effective portion of gains and losses (net) on derivative instruments designated and qualifying as hedging instruments that was recognized in other comprehensive income during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84234895&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyCashFlowHedgeGainLossReclassifiedToEarningsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net gains or losses on foreign currency cash flow hedges reclassified during the period to earnings from accumulated other comprehensive income upon the hedged transaction affecting earnings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84234895&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyCashFlowHedgeGainLossReclassifiedToEarningsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated net amount of unrealized gains or losses on foreign currency cash flow hedges at the reporting date expected to be reclassified to earnings within the next 12 months.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=35736893&amp;loc=d3e80748-113994<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnCashFlowHedgeIneffectivenessNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net gain (loss) recognized in earnings during the reporting period representing the amount of the cash flow hedges' ineffectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=84234895&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnCashFlowHedgeIneffectivenessNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedLossOnForeignCurrencyDerivativesBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized loss recorded in accumulated other comprehensive income pertaining to the decrease in fair value of foreign currency exchange rate derivatives designated as cash flow hedging instruments to the extent that a cash flow hedge is determined to be effective.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84234895&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedLossOnForeignCurrencyDerivativesBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLocationAxis=us-gaap_OtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLocationAxis=us-gaap_OtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=pfe_OtherDerivativeInstrumentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=pfe_OtherDerivativeInstrumentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeForwardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeForwardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=pfe_ForeignCurrencyShortTermBorrowingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=pfe_ForeignCurrencyShortTermBorrowingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=pfe_NetInvestmentHedgingNonderivativeInstrumentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=pfe_NetInvestmentHedgingNonderivativeInstrumentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=pfe_ForeignCurrencyLongTermDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=pfe_ForeignCurrencyLongTermDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6922993760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments - Narrative (Detail)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Oct. 01, 2017 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNetLiabilityPositionAggregateFairValue', window );">Derivatives in a net liability position</a></td>
<td class="nump">$ 491<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollateralAlreadyPostedAggregateFairValue', window );">Collateral posted</a></td>
<td class="nump">505<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesByIndustryAxis=us-gaap_TechnologySectorMember', window );">Technology sector [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure', window );">Maximum exposure, amount</a></td>
<td class="nump">946<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_CashAndCashEquivalentsMember', window );">Cash and Cash Equivalents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecuritiesReceivedAsCollateral', window );">Cash collateral received</a></td>
<td class="nump">$ 232<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollateralAlreadyPostedAggregateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate fair value of assets that are already posted, at the end of the reporting period, as collateral for derivative instruments with credit-risk-related contingent features.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4H<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=84234895&amp;loc=SL5624258-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollateralAlreadyPostedAggregateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum amount of loss due to credit risk that, based on the gross fair value of the financial instrument, the entity would incur if parties to the financial instruments that make up the concentration failed completely to perform according to the terms of the contracts and the collateral or other security, if any, for the amount due proved to be of no value to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13537-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNetLiabilityPositionAggregateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate fair value amounts of derivative instruments that contain credit-risk-related contingent features that are in a net liability position at the end of the reporting period. For nonderivative instruments that are designated and qualify as hedging instruments, the fair value amounts are the carrying value of the nonderivative hedging instrument, including the adjustment for the foreign currency transaction gain (loss) on that instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4H<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84234895&amp;loc=SL5624258-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNetLiabilityPositionAggregateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecuritiesReceivedAsCollateral">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the assets received as collateral against securities loaned to other broker-dealers. Borrowers of securities generally are required to provide collateral to the lenders of securities, commonly cash but sometimes other securities or standby letters of credit, with a value slightly higher than that of the securities borrowed. In instances where the entity is permitted to sell or re-pledge these securities, the entity reports the fair value of the collateral received and the related obligation to return the collateral as a liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 10<br> -Section 05<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=64836671&amp;loc=d3e93645-111703<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=64858031&amp;loc=SL6224234-111729<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecuritiesReceivedAsCollateral</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesByIndustryAxis=us-gaap_TechnologySectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesByIndustryAxis=us-gaap_TechnologySectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_CashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_CashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6923734288">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Inventories (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Oct. 01, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 2,977<span></span>
</td>
<td class="nump">$ 2,293<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work-in-process</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,070<span></span>
</td>
<td class="nump">3,696<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves', window );">Raw materials and supplies</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">879<span></span>
</td>
<td class="nump">793<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="nump">7,925<span></span>
</td>
<td class="nump">6,783<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Noncurrent inventories not included above</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">$ 669<span></span>
</td>
<td class="nump">$ 683<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Amounts may not add due to rounding.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">The change from <span style="font-family:inherit;font-size:9pt;text-align:center;">December&#160;31, 2016</span> reflects the build of inventory primarily for and in advance of new or potential product launches and increases to meet targeted levels for certain products in the normal course of business, including those related to demand.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">Included in <span style="font-family:inherit;font-size:9pt;font-style:italic;">Other noncurrent assets</span>. There are no recoverability issues associated with these amounts.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=d3e3927-108312<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregated amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed. This amount is net of valuation reserves and adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6914375984">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Identifiable Intangible Assets and Goodwill - Finite-lived and Indefinite-lived Intangible Assets (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Oct. 01, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Indefinite-lived intangible assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 12,229<span></span>
</td>
<td class="nump">$ 16,984<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-lived intangible assets, gross carrying amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">93,650<span></span>
</td>
<td class="nump">87,351<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Finite-lived intangible assets, accumulated amortization</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(56,158)<span></span>
</td>
<td class="num">(51,687)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-lived Intangible Assets, less Accumulated Amortization</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">37,492<span></span>
</td>
<td class="nump">35,664<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Intangible assets, gross carrying amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">105,879<span></span>
</td>
<td class="nump">104,335<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Finite-lived intangible assets, accumulated amortization</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(56,158)<span></span>
</td>
<td class="num">(51,687)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Identifiable Intangible Assets, less Accumulated Amortization</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="nump">49,721<span></span>
</td>
<td class="nump">52,648<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember', window );">Brands [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Indefinite-lived intangible assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,937<span></span>
</td>
<td class="nump">6,883<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">In Process Research and Development [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Indefinite-lived intangible assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">5,292<span></span>
</td>
<td class="nump">10,101<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed Technology Rights [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-lived intangible assets, gross carrying amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">89,585<span></span>
</td>
<td class="nump">83,390<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Finite-lived intangible assets, accumulated amortization</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="num">(53,960)<span></span>
</td>
<td class="num">(49,650)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-lived Intangible Assets, less Accumulated Amortization</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">35,625<span></span>
</td>
<td class="nump">33,740<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Finite-lived intangible assets, accumulated amortization</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="num">(53,960)<span></span>
</td>
<td class="num">(49,650)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember', window );">Brands [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-lived intangible assets, gross carrying amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,135<span></span>
</td>
<td class="nump">2,092<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Finite-lived intangible assets, accumulated amortization</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,127)<span></span>
</td>
<td class="num">(1,032)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-lived Intangible Assets, less Accumulated Amortization</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,008<span></span>
</td>
<td class="nump">1,060<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Finite-lived intangible assets, accumulated amortization</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,127)<span></span>
</td>
<td class="num">(1,032)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=pfe_LicensingAgreementsAndOtherMember', window );">License Agreements and Other [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-lived intangible assets, gross carrying amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,930<span></span>
</td>
<td class="nump">1,869<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Finite-lived intangible assets, accumulated amortization</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,071)<span></span>
</td>
<td class="num">(1,005)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-lived Intangible Assets, less Accumulated Amortization</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">859<span></span>
</td>
<td class="nump">864<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Finite-lived intangible assets, accumulated amortization</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (1,071)<span></span>
</td>
<td class="num">$ (1,005)<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The decrease in <span style="font-family:inherit;font-size:8.5pt;font-style:italic;">I</span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;text-align:right;">dentifiable intangible assets, less accumulated amortization</span><span style="font-family:inherit;font-size:8.5pt;text-align:right;">, </span><span style="font-family:inherit;font-size:8.5pt;">is primarily due to amortization, measurement period adjustments related to Medivation (see </span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Note 2A</span><span style="font-family:inherit;font-size:8.5pt;">), as well as impairments of </span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Developed technology rights</span><span style="font-family:inherit;font-size:8.5pt;"> (see </span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Note 4)</span><span style="font-family:inherit;font-size:8.5pt;">, partially offset by assets acquired as part of the acquisition of AstraZeneca&#8217;s small molecule anti-infectives business (see </span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Note 2A</span><span style="font-family:inherit;font-size:8.5pt;">) and the assets recorded in connection with the EU and U.S. approvals of Besponsa (see </span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Note 7E</span>).</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Amounts may not add due to rounding.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">The changes in the gross carrying amount of <span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Developed technology rights </span><span style="font-family:inherit;font-size:8.5pt;">and </span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">IPR&amp;D</span><span style="font-family:inherit;font-size:8.5pt;"> primarily reflect (i) the transfer of </span><span style="font-family:inherit;font-size:8.5pt;"><span>$4.8 billion</span></span><span style="font-family:inherit;font-size:8.5pt;"> from </span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">IPR&amp;D</span><span style="font-family:inherit;font-size:8.5pt;"> to </span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Developed technology rights</span><span style="font-family:inherit;font-size:8.5pt;"> to reflect the approval of Eucrisa, (ii) the </span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Developed technology rights</span><span style="font-family:inherit;font-size:8.5pt;"> and </span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">IPR&amp;D</span><span style="font-family:inherit;font-size:8.5pt;"> acquired as part of the acquisition of AstraZeneca&#8217;s small molecule anti-infectives business (see </span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Note 2A</span><span style="font-family:inherit;font-size:8.5pt;">), (iii) the </span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Developed technology rights</span><span style="font-family:inherit;font-size:8.5pt;"> of </span><span style="font-family:inherit;font-size:8.5pt;"><span>$371 million</span></span><span style="font-family:inherit;font-size:8.5pt;"> recorded in connection with the EU and U.S. approvals of Besponsa (see </span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Note 7E</span><span style="font-family:inherit;font-size:8.5pt;">), partially offset by (iv) measurement period adjustments related to Medivation (see </span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Note 2A</span><span style="font-family:inherit;font-size:8.5pt;">) and (v) impairments of </span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Developed technology rights</span><span style="font-family:inherit;font-size:8.5pt;"> (see </span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Note 4)</span>.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=pfe_LicensingAgreementsAndOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=pfe_LicensingAgreementsAndOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6923776432">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Identifiable Intangible Assets and Goodwill - Finite-lived and Indefinite-lived Intangible Assets - Footnotes (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Oct. 01, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Increase in finite-lived intangible assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 37,492<span></span>
</td>
<td class="nump">$ 35,664<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed Technology Rights [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Increase in finite-lived intangible assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">35,625<span></span>
</td>
<td class="nump">$ 33,740<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=pfe_EucrisaMember', window );">Eucrisa [Member] | Developed Technology Rights [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_IntangibleAssetsTransfersDuringPeriod', window );">Transfer of intangible assets during period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=pfe_BesponsaMember', window );">Besponsa [Member] | Developed Technology Rights [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Increase in finite-lived intangible assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">371<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">In Process Research and Development [Member] | Eucrisa [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_IntangibleAssetsTransfersDuringPeriod', window );">Transfer of intangible assets during period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (4,800)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The changes in the gross carrying amount of <span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Developed technology rights </span><span style="font-family:inherit;font-size:8.5pt;">and </span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">IPR&amp;D</span><span style="font-family:inherit;font-size:8.5pt;"> primarily reflect (i) the transfer of </span><span style="font-family:inherit;font-size:8.5pt;"><span>$4.8 billion</span></span><span style="font-family:inherit;font-size:8.5pt;"> from </span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">IPR&amp;D</span><span style="font-family:inherit;font-size:8.5pt;"> to </span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Developed technology rights</span><span style="font-family:inherit;font-size:8.5pt;"> to reflect the approval of Eucrisa, (ii) the </span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Developed technology rights</span><span style="font-family:inherit;font-size:8.5pt;"> and </span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">IPR&amp;D</span><span style="font-family:inherit;font-size:8.5pt;"> acquired as part of the acquisition of AstraZeneca&#8217;s small molecule anti-infectives business (see </span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Note 2A</span><span style="font-family:inherit;font-size:8.5pt;">), (iii) the </span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Developed technology rights</span><span style="font-family:inherit;font-size:8.5pt;"> of </span><span style="font-family:inherit;font-size:8.5pt;"><span>$371 million</span></span><span style="font-family:inherit;font-size:8.5pt;"> recorded in connection with the EU and U.S. approvals of Besponsa (see </span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Note 7E</span><span style="font-family:inherit;font-size:8.5pt;">), partially offset by (iv) measurement period adjustments related to Medivation (see </span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Note 2A</span><span style="font-family:inherit;font-size:8.5pt;">) and (v) impairments of </span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Developed technology rights</span><span style="font-family:inherit;font-size:8.5pt;"> (see </span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Note 4)</span>.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_IntangibleAssetsTransfersDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intangible Assets, Transfers During Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_IntangibleAssetsTransfersDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=pfe_EucrisaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=pfe_EucrisaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=pfe_BesponsaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=pfe_BesponsaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6923271104">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Identifiable Intangible Assets and Goodwill - Finite-lived Intangible Assets Percentage of Total Intangibles (Details)<br></strong></div></th>
<th class="th"><div>Oct. 01, 2017</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments [Member] | Developed Technology Rights [Member] | IH [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet', window );">Percentage of total identifiable intangible assets, less accumulated amortization</a></td>
<td class="nump">68.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments [Member] | Developed Technology Rights [Member] | EH [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet', window );">Percentage of total identifiable intangible assets, less accumulated amortization</a></td>
<td class="nump">32.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments [Member] | Brands [Member] | IH [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet', window );">Percentage of total identifiable intangible assets, less accumulated amortization</a></td>
<td class="nump">75.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments [Member] | Brands [Member] | EH [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet', window );">Percentage of total identifiable intangible assets, less accumulated amortization</a></td>
<td class="nump">25.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsegmentsAxis=pfe_PfizersWorldwideResearchandDevelopmentMember', window );">Pfizer's Worldwide Research and Development [Member] | Segment Reconciling Items [Member] | Developed Technology Rights [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet', window );">Percentage of total identifiable intangible assets, less accumulated amortization</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsegmentsAxis=pfe_PfizersWorldwideResearchandDevelopmentMember', window );">Pfizer's Worldwide Research and Development [Member] | Segment Reconciling Items [Member] | Brands [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet', window );">Percentage of total identifiable intangible assets, less accumulated amortization</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intangible Assets, Net, Percentage of Intangible Assets, Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=pfe_InnovativeHealthSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=pfe_InnovativeHealthSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=pfe_EssentialHealthSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=pfe_EssentialHealthSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=pfe_PfizersWorldwideResearchandDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=pfe_PfizersWorldwideResearchandDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6919470304">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Identifiable Intangible Assets and Goodwill - Indefinite-lived Intangible Assets Percentage of Total Intangibles (Details)<br></strong></div></th>
<th class="th"><div>Oct. 01, 2017</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=pfe_InnovativeHealthSegmentMember', window );">IH [Member] | Operating Segments [Member] | Brands [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet', window );">Percentage of total identifiable intangible assets, less accumulated amortization</a></td>
<td class="nump">71.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=pfe_InnovativeHealthSegmentMember', window );">IH [Member] | Operating Segments [Member] | In Process Research and Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet', window );">Percentage of total identifiable intangible assets, less accumulated amortization</a></td>
<td class="nump">80.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=pfe_EssentialHealthSegmentMember', window );">EH [Member] | Operating Segments [Member] | Brands [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet', window );">Percentage of total identifiable intangible assets, less accumulated amortization</a></td>
<td class="nump">29.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=pfe_EssentialHealthSegmentMember', window );">EH [Member] | Operating Segments [Member] | In Process Research and Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet', window );">Percentage of total identifiable intangible assets, less accumulated amortization</a></td>
<td class="nump">13.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsegmentsAxis=pfe_PfizersWorldwideResearchandDevelopmentMember', window );">Pfizer's Worldwide Research and Development [Member] | Segment Reconciling Items [Member] | Brands [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet', window );">Percentage of total identifiable intangible assets, less accumulated amortization</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsegmentsAxis=pfe_PfizersWorldwideResearchandDevelopmentMember', window );">Pfizer's Worldwide Research and Development [Member] | Segment Reconciling Items [Member] | In Process Research and Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet', window );">Percentage of total identifiable intangible assets, less accumulated amortization</a></td>
<td class="nump">7.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intangible Assets, Net, Percentage of Intangible Assets, Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=pfe_InnovativeHealthSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=pfe_InnovativeHealthSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=pfe_EssentialHealthSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=pfe_EssentialHealthSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=pfe_PfizersWorldwideResearchandDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=pfe_PfizersWorldwideResearchandDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6921747312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Identifiable Intangible Assets and Goodwill - Narrative (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 01, 2017</div></th>
<th class="th"><div>Oct. 02, 2016</div></th>
<th class="th"><div>Oct. 01, 2017</div></th>
<th class="th"><div>Oct. 02, 2016</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_FiniteLivedIntangibleAssetsMember', window );">Finite-Lived Intangible Assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense for finite-lived intangible assets</a></td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="nump">$ 988<span></span>
</td>
<td class="nump">$ 3,600<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_FiniteLivedIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_FiniteLivedIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6917332576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Identifiable Intangible Assets and Goodwill - Goodwill (Detail)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr><th class="th" colspan="2">
<div>Oct. 01, 2017 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance, December 31, 2016</a></td>
<td class="nump">$ 54,449<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Additions</a></td>
<td class="nump">664<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Other</a></td>
<td class="nump">966<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance, October 1, 2017</a></td>
<td class="nump">56,078<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=pfe_InnovativeHealthSegmentMember', window );">IH [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance, December 31, 2016</a></td>
<td class="nump">30,134<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Additions</a></td>
<td class="nump">572<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Other</a></td>
<td class="nump">491<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance, October 1, 2017</a></td>
<td class="nump">31,197<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=pfe_EssentialHealthSegmentMember', window );">EH [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance, December 31, 2016</a></td>
<td class="nump">24,315<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Additions</a></td>
<td class="nump">92<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Other</a></td>
<td class="nump">475<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance, October 1, 2017</a></td>
<td class="nump">$ 24,882<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Amounts may not add due to rounding.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">IH additions primarily represent measurement period adjustments related to our Medivation acquisition, and EH additions relate to our acquisition of AstraZeneca&#8217;s small molecule anti-infectives business, which are subject to change until we complete the valuation of assets acquired and liabilities assumed (see <span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Note 2A</span>).</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">Primarily reflects the impact of foreign exchange and an adjustment of our estimate of goodwill associated with the HIS net assets sold.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388280&amp;loc=d3e13770-109266<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillOtherIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease), classified as other, of an asset representing the future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillOtherIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=pfe_InnovativeHealthSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=pfe_InnovativeHealthSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=pfe_EssentialHealthSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=pfe_EssentialHealthSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6915191712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pension and Postretirement Benefit Plans - Net Periodic Benefit Cost (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="4">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 01, 2017</div></th>
<th class="th"><div>Oct. 02, 2016</div></th>
<th class="th" colspan="2"><div>Oct. 01, 2017</div></th>
<th class="th" colspan="2"><div>Oct. 02, 2016</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Plan [Member] | U.S. [Member] | Qualified [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">$ 67<span></span>
</td>
<td class="nump">$ 69<span></span>
</td>
<td class="nump">$ 202<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 193<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">157<span></span>
</td>
<td class="nump">218<span></span>
</td>
<td class="nump">478<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">486<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets', window );">Expected return on plan assets</a></td>
<td class="num">(248)<span></span>
</td>
<td class="num">(239)<span></span>
</td>
<td class="num">(759)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(721)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract', window );"><strong>Amortization of:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses', window );">Actuarial losses</a></td>
<td class="nump">91<span></span>
</td>
<td class="nump">99<span></span>
</td>
<td class="nump">302<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">297<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit', window );">Prior service costs (credits)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">4<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments', window );">Curtailments</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">5<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1', window );">Settlements</a></td>
<td class="nump">30<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="nump">54<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">52<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Defined benefit plan, net periodic benefit cost</a></td>
<td class="nump">99<span></span>
</td>
<td class="nump">170<span></span>
</td>
<td class="nump">292<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">316<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Plan [Member] | International [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">44<span></span>
</td>
<td class="nump">41<span></span>
</td>
<td class="nump">127<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">126<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">52<span></span>
</td>
<td class="nump">58<span></span>
</td>
<td class="nump">152<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">178<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets', window );">Expected return on plan assets</a></td>
<td class="num">(87)<span></span>
</td>
<td class="num">(95)<span></span>
</td>
<td class="num">(256)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(291)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract', window );"><strong>Amortization of:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses', window );">Actuarial losses</a></td>
<td class="nump">29<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="nump">86<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">70<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit', window );">Prior service costs (credits)</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(2)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments', window );">Curtailments</a></td>
<td class="num">(2)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(1)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1', window );">Settlements</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Defined benefit plan, net periodic benefit cost</a></td>
<td class="nump">35<span></span>
</td>
<td class="nump">27<span></span>
</td>
<td class="nump">106<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">81<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember', window );">Supplemental Employee Retirement Plan [Member] | U.S. [Member] | Non-Qualified [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">14<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="nump">41<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">40<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets', window );">Expected return on plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract', window );"><strong>Amortization of:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses', window );">Actuarial losses</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">37<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">27<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit', window );">Prior service costs (credits)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(1)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments', window );">Curtailments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1', window );">Settlements</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">32<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">23<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Defined benefit plan, net periodic benefit cost</a></td>
<td class="nump">39<span></span>
</td>
<td class="nump">39<span></span>
</td>
<td class="nump">127<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">105<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Postretirement Plans [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="nump">32<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">31<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">23<span></span>
</td>
<td class="nump">33<span></span>
</td>
<td class="nump">68<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">77<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets', window );">Expected return on plan assets</a></td>
<td class="num">(9)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
<td class="num">(27)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(25)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract', window );"><strong>Amortization of:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses', window );">Actuarial losses</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">23<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit', window );">Prior service costs (credits)</a></td>
<td class="num">(45)<span></span>
</td>
<td class="num">(45)<span></span>
</td>
<td class="num">(137)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(127)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments', window );">Curtailments</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
<td class="num">(15)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(14)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1', window );">Settlements</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Defined benefit plan, net periodic benefit cost</a></td>
<td class="num">$ (17)<span></span>
</td>
<td class="num">$ (9)<span></span>
</td>
<td class="num">$ (57)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (36)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="7"></td></tr>
<tr><td colspan="7"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">In April 2017, we settled the remaining obligation associated with the Hospira U.S. qualified defined benefit pension plan. We purchased a group annuity contract on behalf of the remaining plan participants with a third-party insurance provider. As a result, we were relieved of the <span style="font-family:inherit;font-size:8.5pt;"><span>$156 million</span></span><span style="font-family:inherit;font-size:8.5pt;"> net pension benefit obligation and recorded a pretax settlement gain of </span><span style="font-family:inherit;font-size:8.5pt;"><span>$41 million</span></span><span style="font-family:inherit;font-size:8.5pt;">, partially offset by the recognition of actuarial losses and prior service costs upon plan settlement of approximately </span><span style="font-family:inherit;font-size:8.5pt;"><span>$30 million</span></span><span style="font-family:inherit;font-size:8.5pt;"> in</span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;"> Restructuring charges and certain acquisition-related costs</span><span style="font-family:inherit;font-size:8.5pt;"> during the second quarter of 2017 (see </span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Note 3</span>).</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=82843861&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(5)<br> -URI http://asc.fasb.org/extlink&amp;oid=82843861&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82843861&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanInterestCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost recognized for passage of time related to defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=82843861&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=82843861&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanInterestCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of net periodic benefit cost (credit) for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=82843861&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in net periodic benefit (cost) credit from event reducing expected years of future service of present employees or eliminating accrual of defined benefits for some or all future services of present employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(7)<br> -URI http://asc.fasb.org/extlink&amp;oid=82843861&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in net periodic benefit (cost) credit from irrevocable action relieving primary responsibility for benefit obligation and eliminating risk related to obligation and assets used to effect settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(7)<br> -URI http://asc.fasb.org/extlink&amp;oid=82843861&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanServiceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=82843861&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=82843861&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanServiceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTaxStatusAxis=us-gaap_QualifiedPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTaxStatusAxis=us-gaap_QualifiedPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTaxStatusAxis=us-gaap_NonqualifiedPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTaxStatusAxis=us-gaap_NonqualifiedPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6921720064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pension and Postretirement Benefit Plans - Net Periodic Benefit Cost - Footnotes (Details) - Hospira [Member] - Pension Plan [Member] - U.S. [Member] - Qualified [Member]<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr><th class="th">
<div>Apr. 30, 2017 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation', window );">Decrease in pension benefit obligation in connection with Hospira pension plan</a></td>
<td class="nump">$ 156<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DefinedBenefitPlanNetPeriodicBenefitCostCreditGainLossDuetoSettlementPretax', window );">Pretax settlement gain</a></td>
<td class="nump">41<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DefinedBenefitPlanActuarialLossandPriorServiceCostsImmediateRecognitionasComponentinNetPeriodicBenefitCost', window );">Actuarial losses and prior service costs recognized upon plan settlement</a></td>
<td class="nump">$ 30<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DefinedBenefitPlanActuarialLossandPriorServiceCostsImmediateRecognitionasComponentinNetPeriodicBenefitCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Defined Benefit Plan, Actuarial Loss and Prior Service Costs, Immediate Recognition as Component in Net Periodic Benefit Cost</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DefinedBenefitPlanActuarialLossandPriorServiceCostsImmediateRecognitionasComponentinNetPeriodicBenefitCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DefinedBenefitPlanNetPeriodicBenefitCostCreditGainLossDuetoSettlementPretax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement, Pretax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DefinedBenefitPlanNetPeriodicBenefitCostCreditGainLossDuetoSettlementPretax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of (increase) decrease to benefit obligation of defined benefit plan from irrevocable action relieving primary responsibility for benefit obligation and eliminating risk for obligation and assets used to effect settlement. Includes, but is not limited to, lump-sum cash payment to participant in exchange for right to receive specified benefits, purchase of nonparticipating annuity contract and change from remeasurement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(10)<br> -URI http://asc.fasb.org/extlink&amp;oid=82843861&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanSettlementsBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=pfe_HospiraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=pfe_HospiraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTaxStatusAxis=us-gaap_QualifiedPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTaxStatusAxis=us-gaap_QualifiedPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6913107040">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Pension and Postretirement Benefit Plans (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2017</div></th>
<th class="th"><div>Oct. 01, 2017</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Plan [Member] | U.S. [Member] | Qualified [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanContributionsByEmployer', window );">Contributions from our general assets for the nine months ended October 1, 2017</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 1,095<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsRemainderOfFiscalYear', window );">Expected contributions from our general assets during 2017</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,095<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Plan [Member] | International [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanContributionsByEmployer', window );">Contributions from our general assets for the nine months ended October 1, 2017</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">134<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsRemainderOfFiscalYear', window );">Expected contributions from our general assets during 2017</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">170<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember', window );">Supplemental Employee Retirement Plan [Member] | U.S. [Member] | Non-Qualified [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanContributionsByEmployer', window );">Contributions from our general assets for the nine months ended October 1, 2017</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">121<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsRemainderOfFiscalYear', window );">Expected contributions from our general assets during 2017</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">146<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Postretirement Plans [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanContributionsByEmployer', window );">Contributions from our general assets for the nine months ended October 1, 2017</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">158<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsRemainderOfFiscalYear', window );">Expected contributions from our general assets during 2017</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 204<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Contributions expected to be made for <span style="font-family:inherit;font-size:8.5pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:8.5pt;"> are inclusive of amounts contributed during the </span><span style="font-family:inherit;font-size:8.5pt;">nine months ended October 1, 2017</span><span style="font-family:inherit;font-size:8.5pt;">, including the </span><span style="font-family:inherit;font-size:8.5pt;"><span>$1.0 billion</span></span> voluntary contribution that was made in January 2017 for the U.S. qualified plans, which was considered pre-funding for future anticipated mandatory contributions and is also expected to reduce Pension Benefit Guaranty Corporation variable rate premiums. The U.S. supplemental (non-qualified) pension plan, international pension plan and the postretirement plan contributions from our general assets include direct employer benefit payments.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanContributionsByEmployer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contribution received by defined benefit plan from employer which increases plan assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(5)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=82843861&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82843861&amp;loc=d3e2709-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82843861&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(5)(iv)(01)<br> -URI http://asc.fasb.org/extlink&amp;oid=82843861&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanContributionsByEmployer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contributions expected to be received by defined benefit plan from employer in fiscal year. Excludes contributions paid by employer in current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82843861&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTaxStatusAxis=us-gaap_QualifiedPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTaxStatusAxis=us-gaap_QualifiedPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTaxStatusAxis=us-gaap_NonqualifiedPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTaxStatusAxis=us-gaap_NonqualifiedPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6916991904">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Common Share Attributable to Common Shareholders (Details) - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 01, 2017</div></th>
<th class="th"><div>Oct. 02, 2016</div></th>
<th class="th"><div>Oct. 01, 2017</div></th>
<th class="th"><div>Oct. 02, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>EPS Numerator&#8211;&#8211;Basic</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Income from continuing operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2],[3]</sup></td>
<td class="nump">$ 2,858<span></span>
</td>
<td class="nump">$ 1,355<span></span>
</td>
<td class="nump">$ 9,064<span></span>
</td>
<td class="nump">$ 6,465<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity', window );">Less: Net income attributable to noncontrolling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">18<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">32<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperations', window );">Income from continuing operations attributable to Pfizer Inc.</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">2,840<span></span>
</td>
<td class="nump">1,355<span></span>
</td>
<td class="nump">9,032<span></span>
</td>
<td class="nump">6,440<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsIncomeStatementImpact', window );">Less: Preferred stock dividends&#8211;&#8211;net of tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic', window );">Income from continuing operations attributable to Pfizer Inc. common shareholders</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">2,839<span></span>
</td>
<td class="nump">1,355<span></span>
</td>
<td class="nump">9,032<span></span>
</td>
<td class="nump">6,439<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Discontinued operations&#8211;&#8211;net of tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net income attributable to Pfizer Inc. common shareholders</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">2,839<span></span>
</td>
<td class="nump">1,355<span></span>
</td>
<td class="nump">9,033<span></span>
</td>
<td class="nump">6,439<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>EPS Numerator&#8211;&#8211;Diluted</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted', window );">Income from continuing operations attributable to Pfizer Inc. common shareholders and assumed conversions</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">2,840<span></span>
</td>
<td class="nump">1,355<span></span>
</td>
<td class="nump">9,032<span></span>
</td>
<td class="nump">6,440<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity', window );">Discontinued operations&#8211;&#8211;net of tax, attributable to Pfizer Inc. common shareholders and assumed conversions</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net income attributable to Pfizer Inc. common shareholders and assumed conversions</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 2,840<span></span>
</td>
<td class="nump">$ 1,355<span></span>
</td>
<td class="nump">$ 9,034<span></span>
</td>
<td class="nump">$ 6,440<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>EPS Denominator</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average number of common shares outstanding&#8211;&#8211;Basic</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">5,951<span></span>
</td>
<td class="nump">6,066<span></span>
</td>
<td class="nump">5,972<span></span>
</td>
<td class="nump">6,095<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Common-share equivalents: stock options, stock issuable under employee compensation plans, convertible preferred stock and accelerated share repurchase agreements (shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">89<span></span>
</td>
<td class="nump">84<span></span>
</td>
<td class="nump">85<span></span>
</td>
<td class="nump">80<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average number of common shares outstanding&#8211;&#8211;Diluted</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2],[3]</sup></td>
<td class="nump">6,041<span></span>
</td>
<td class="nump">6,150<span></span>
</td>
<td class="nump">6,057<span></span>
</td>
<td class="nump">6,175<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember', window );">Equity Option [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>EPS Denominator</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Stock options that had exercise prices greater than the average market price of our common stock issuable under employee compensation plans (shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[4]</sup></td>
<td class="nump">47<span></span>
</td>
<td class="nump">38<span></span>
</td>
<td class="nump">47<span></span>
</td>
<td class="nump">60<span></span>
</td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Amounts for the <span style="font-family:inherit;font-size:8.5pt;">third quarter</span><span style="font-family:inherit;font-size:8.5pt;"> and first </span><span style="font-family:inherit;font-size:8.5pt;">nine months</span><span style="font-family:inherit;font-size:8.5pt;"> ended </span><span style="font-family:inherit;font-size:8.5pt;">October&#160;2, 2016</span><span style="font-family:inherit;font-size:8.5pt;"> have been revised from previously reported amounts to reflect the adoption of a new accounting standard in the fourth quarter of </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:8.5pt;">, as of January 1, 2016, that requires, when applying the treasury stock method for shares that could be repurchased, that the assumed proceeds no longer include the amount of excess tax benefit (see </span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Note 1B</span>).</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Amounts for the <span style="font-family:inherit;font-size:9pt;">three and nine months ended October 2, 2016</span><span style="font-family:inherit;font-size:9pt;"> have been revised from previously reported amounts to reflect the adoption of a new accounting standard in the fourth quarter of 2016, as of January 1, 2016. For additional information, see </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Note 1B</span><span style="font-family:inherit;font-size:9pt;">. </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Basis of Presentation and Significant Accounting Policies&#8211;&#8211;Adoption of New Accounting Standards</span>.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">Amounts may not add due to rounding.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top">These common stock equivalents were outstanding for the periods presented, but were not included in the computation of diluted EPS for those periods because their inclusion would have had an anti-dilutive effect.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the income or loss from continuing operations available to common stockholders which may also be defined as revenue less expenses and taxes from ongoing operations before extraordinary items and cumulative effects of changes in accounting principles, but after deduction of those portions of income or loss from continuing operations that are allocable to noncontrolling interests and preferred stock dividends declared or paid in the period, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the income or loss from continuing operations available to common stockholders which may also be defined as revenue less expenses and taxes from ongoing operations before extraordinary items and cumulative effects of changes in accounting principles, but after deduction of those portions of income or loss from continuing operations that are allocable to noncontrolling interests and preferred stock dividends declared or paid in the period, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DilutiveSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DilutiveSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=96868048&amp;loc=SL4613673-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=96868048&amp;loc=SL4569616-111683<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=96868048&amp;loc=SL4568447-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=96868048&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721675-107760<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e1012-107759<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721525-107759<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721523-107759<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e957-107759<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=d3e1361-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721675-107760<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721525-107759<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721523-107759<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e957-107759<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e1012-107759<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=d3e1361-107760<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=96868048&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1505-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsIncomeStatementImpact">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendsIncomeStatementImpact</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1505-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6923123616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details) - USD ($)<br> $ / shares in Units, shares in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 19, 2017</div></th>
<th class="th"><div>Feb. 06, 2017</div></th>
<th class="th"><div>Feb. 02, 2017</div></th>
<th class="th"><div>May 19, 2017</div></th>
<th class="th"><div>Oct. 01, 2017</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=pfe_ShareRepurchaseAgreementwithCitibankMember', window );">Share Repurchase Agreement with Citibank [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcceleratedShareRepurchasesLineItems', window );"><strong>Accelerated Share Repurchases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Share repurchase agreement, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt', window );">Accelerated share repurchases, cash paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Shares repurchased</a></td>
<td class="nump">24<span></span>
</td>
<td class="nump">126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcceleratedShareRepurchasesInitialPricePaidPerShare', window );">Shares repurchased, price per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_AcceleratedShareRepurchasesSharesRepurchasedDuringPeriodPercentageofAgreementAmount', window );">Shares received in initial delivery, percentage of agreement amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare', window );">Average price paid for shares delivered under agreement (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33.31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1', window );">Remaining authorized repurchase amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,400,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementScenarioAxis=us-gaap_ProFormaMember', window );">Pro Forma [Member] | Mylotarg [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcceleratedShareRepurchasesLineItems', window );"><strong>Accelerated Share Repurchases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ResearchandDevelopmentArrangementAggregatePaymentObligation', window );">Research arrangement, fixed payment obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 310,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ResearchandDevelopmentArrangementAggregatePaymentObligationTerm', window );">Term over which additional fixed payments are to be made</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_AcceleratedShareRepurchasesSharesRepurchasedDuringPeriodPercentageofAgreementAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accelerated Share Repurchases, Shares Repurchased During Period, Percentage of Agreement Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_AcceleratedShareRepurchasesSharesRepurchasedDuringPeriodPercentageofAgreementAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_ResearchandDevelopmentArrangementAggregatePaymentObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and Development Arrangement, Aggregate Payment Obligation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_ResearchandDevelopmentArrangementAggregatePaymentObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_ResearchandDevelopmentArrangementAggregatePaymentObligationTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and Development Arrangement, Aggregate Payment Obligation, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_ResearchandDevelopmentArrangementAggregatePaymentObligationTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcceleratedShareRepurchasesInitialPricePaidPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price paid per share to immediately purchase the targeted number of shares on the date of executing the accelerated share repurchase agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 25<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6405686&amp;loc=d3e22802-112653<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcceleratedShareRepurchasesInitialPricePaidPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcceleratedShareRepurchasesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcceleratedShareRepurchasesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash receipt from (payment to) bank; or stock received from (issuance to) bank in the settlement of the accelerated share repurchase agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 25<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6405686&amp;loc=d3e22802-112653<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount remaining of a stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total cost of shares repurchased divided by the total number of shares repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockAcquiredAverageCostPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=pfe_ShareRepurchaseAgreementwithCitibankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=pfe_ShareRepurchaseAgreementwithCitibankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=us-gaap_ProFormaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=us-gaap_ProFormaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=pfe_MylotargMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=pfe_MylotargMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6931721168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Actions In Which We Are The Plaintiff) (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="14">1 Months Ended</th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Aug. 10, 2017 </div>
<div>Patents</div>
</th>
<th class="th">
<div>Oct. 31, 2017 </div>
<div>Patents</div>
</th>
<th class="th">
<div>Sep. 30, 2017 </div>
<div>Patents</div>
</th>
<th class="th">
<div>Jul. 31, 2017 </div>
<div>Patents</div>
</th>
<th class="th">
<div>Mar. 31, 2017 </div>
<div>Patents</div>
</th>
<th class="th">
<div>Feb. 28, 2017 </div>
<div>Patents</div>
</th>
<th class="th">
<div>Jan. 31, 2017 </div>
<div>Patents</div>
</th>
<th class="th">
<div>Aug. 31, 2016 </div>
<div>Patents</div>
</th>
<th class="th">
<div>Jul. 31, 2016 </div>
<div>Patents</div>
</th>
<th class="th">
<div>Jan. 31, 2016 </div>
<div>Patents</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>Patents</div>
</th>
<th class="th">
<div>Jul. 31, 2015 </div>
<div>Defendant</div>
</th>
<th class="th">
<div>Jun. 30, 2015 </div>
<div>Patents</div>
</th>
<th class="th">
<div>Jan. 31, 2015 </div>
<div>Patents</div>
</th>
<th class="th">
<div>Jun. 30, 2013 </div>
<div>Patents</div>
</th>
<th class="th">
<div>Jul. 31, 2015 </div>
<div>Defendant</div>
</th>
<th class="th">
<div>Apr. 30, 2017 </div>
<div>Patents </div>
<div>Defendant</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=pfe_PrecedexPremixMember', window );">Precedex Premix [Member] | Hospira Versus Amneal Pharmaceuticals LLC [Member] | Pending Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainContingenciesLineItems', window );"><strong>Gain Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainContingencyPatentsFoundNotInfringedUponNumber', window );">Number of patents not infringed upon</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=pfe_PrecedexPremixMember', window );">Precedex Premix [Member] | Hospira Versus Fresenius [Member] | Pending Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainContingenciesLineItems', window );"><strong>Gain Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainContingencyPatentsFoundNotInfringedUponNumber', window );">Number of patents not infringed upon</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=pfe_PrecedexPremixMember', window );">Precedex Premix [Member] | Hospira Versus Par [Member] | Pending Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainContingenciesLineItems', window );"><strong>Gain Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainContingencyPatentsFoundNotInfringedUponNumber', window );">Number of patents not infringed upon</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainContingenciesByNatureAxis=pfe_PatentInfringementMember', window );">Patent Infringement [Member] | Bosulif [Member] | Wyeth Versus Sun [Member] | Pending Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainContingenciesLineItems', window );"><strong>Gain Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber', window );">Number of patents allegedly infringed upon</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainContingenciesByNatureAxis=pfe_PatentInfringementMember', window );">Patent Infringement [Member] | Toviaz [Member] | Pfizer Versus Mylan Laboratories Limited [Member] | Pending Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainContingenciesLineItems', window );"><strong>Gain Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber', window );">Number of patents allegedly infringed upon</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainContingencyPatentsFoundInfringedUponNumber', window );">Number of patents infringed upon</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainContingenciesByNatureAxis=pfe_PatentInfringementMember', window );">Patent Infringement [Member] | Toviaz [Member] | Pfizer Versus Mylan Laboratories Limited [Member] | Judicial Ruling [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainContingenciesLineItems', window );"><strong>Gain Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainContingencyPatentsFoundNotInfringedUponNumber', window );">Number of patents not infringed upon</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainContingencyPatentsFoundInfringedUponNumber', window );">Number of patents infringed upon</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainContingenciesByNatureAxis=pfe_PatentInfringementMember', window );">Patent Infringement [Member] | Toviaz [Member] | Pfizer Versus Several Generic Manufacturers [Member] | Pending Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainContingenciesLineItems', window );"><strong>Gain Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_GainContingencyNumberofDefendants', window );">Number of defendants | Defendant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainContingenciesByNatureAxis=pfe_PatentInfringementMember', window );">Patent Infringement [Member] | Toviaz [Member] | Pfizer Versus Several Generic Manufacturers [Member] | Settled Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainContingenciesLineItems', window );"><strong>Gain Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_GainContingencyNumberofDefendants', window );">Number of defendants | Defendant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainContingenciesByNatureAxis=pfe_PatentInfringementMember', window );">Patent Infringement [Member] | Toviaz Composition-of-matter Patents [Member] | Pfizer Versus Mylan Laboratories Limited [Member] | Pending Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainContingenciesLineItems', window );"><strong>Gain Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainContingencyPatentsFoundInfringedUponNumber', window );">Number of patents infringed upon</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainContingenciesByNatureAxis=pfe_PatentInfringementMember', window );">Patent Infringement [Member] | Toviaz Composition-of-matter Patents [Member] | Pfizer Versus Several Generic Manufacturers [Member] | Pending Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainContingenciesLineItems', window );"><strong>Gain Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainContingencyPatentsFoundInfringedUponNumber', window );">Number of patents infringed upon</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainContingenciesByNatureAxis=pfe_PatentInfringementMember', window );">Patent Infringement [Member] | Xeljanz [Member] | Pfizer Versus MicroLabs [Member] | Pending Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainContingenciesLineItems', window );"><strong>Gain Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber', window );">Number of patents allegedly infringed upon</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainContingenciesByNatureAxis=pfe_PatentInfringementMember', window );">Patent Infringement [Member] | Xeljanz [Member] | Pfizer Versus Zydus [Member] | Pending Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainContingenciesLineItems', window );"><strong>Gain Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber', window );">Number of patents allegedly infringed upon</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainContingenciesByNatureAxis=pfe_PatentInfringementMember', window );">Patent Infringement [Member] | Xeljanz [Member] | Pfizer Versus Prinston and Breckenridge [Member] | Pending Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainContingenciesLineItems', window );"><strong>Gain Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber', window );">Number of patents allegedly infringed upon</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainContingenciesByNatureAxis=pfe_PatentInfringementMember', window );">Patent Infringement [Member] | Eliquis [Member] | Pfizer and BMS Versus Several Generic Manufacturers [Member] | Pending Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainContingenciesLineItems', window );"><strong>Gain Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber', window );">Number of patents allegedly infringed upon</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_GainContingencyNumberofDefendants', window );">Number of defendants | Defendant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=pfe_PatentInfringementMember', window );">Patent Infringement [Member] | Bavencio [Member] | Pfizer Versus BMS, E.R. Squibb &amp; Sons, Ono Pharmaceutical and Tasuku Honjo [Member] | Pending Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainContingenciesLineItems', window );"><strong>Gain Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber', window );">Number of patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Patent Infringement [Member] | Xeljanz [Member] | Pfizer Versus Breckenridge [Member] | Pending Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainContingenciesLineItems', window );"><strong>Gain Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber', window );">Number of patents allegedly infringed upon</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_GainContingencyPatentsAllegedlyInfringeduponNumberDuetoExpireinDecember2020', window );">Number of patents due to expire in December 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_GainContingencyPatentsAllegedlyInfringeduponNumberDuetoExpireinDecember2025', window );">Number or patents due to expire in December 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_GainContingencyNumberofDefendants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain Contingency, Number of Defendants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_GainContingencyNumberofDefendants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_GainContingencyPatentsAllegedlyInfringeduponNumberDuetoExpireinDecember2020">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain Contingency, Patents Allegedly Infringed upon, Number Due to Expire in December 2020</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_GainContingencyPatentsAllegedlyInfringeduponNumberDuetoExpireinDecember2020</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_GainContingencyPatentsAllegedlyInfringeduponNumberDuetoExpireinDecember2025">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain Contingency, Patents Allegedly Infringed upon, Number Due to Expire in December 2025</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_GainContingencyPatentsAllegedlyInfringeduponNumberDuetoExpireinDecember2025</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of entity's patents that another entity has allegedly infringed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainContingencyPatentsFoundInfringedUponNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of entity's patents that another entity was found to have infringed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainContingencyPatentsFoundInfringedUponNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainContingencyPatentsFoundNotInfringedUponNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of entity's patents that another entity was found not to have infringed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainContingencyPatentsFoundNotInfringedUponNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of another entity's patents that the entity has allegedly infringed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyPatentsAllegedlyInfringedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=pfe_PrecedexPremixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=pfe_PrecedexPremixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationCaseAxis=pfe_HospiraVersusAmnealPharmaceuticalsLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationCaseAxis=pfe_HospiraVersusAmnealPharmaceuticalsLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationCaseAxis=pfe_HospiraVersusFreseniusMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationCaseAxis=pfe_HospiraVersusFreseniusMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationCaseAxis=pfe_HospiraVersusParMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationCaseAxis=pfe_HospiraVersusParMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainContingenciesByNatureAxis=pfe_PatentInfringementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainContingenciesByNatureAxis=pfe_PatentInfringementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=pfe_BosulifMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=pfe_BosulifMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationCaseAxis=pfe_WyethVersusSunMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationCaseAxis=pfe_WyethVersusSunMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=pfe_ToviazMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=pfe_ToviazMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationCaseAxis=pfe_PfizerVersusMylanLaboratoriesandAccordHealthcareInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationCaseAxis=pfe_PfizerVersusMylanLaboratoriesandAccordHealthcareInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_JudicialRulingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_JudicialRulingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationCaseAxis=pfe_PfizerVersusSeveralGenericManufacturersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationCaseAxis=pfe_PfizerVersusSeveralGenericManufacturersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=pfe_ToviazCompositionofmatterPatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=pfe_ToviazCompositionofmatterPatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=pfe_XeljanzMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=pfe_XeljanzMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationCaseAxis=pfe_PfizerVersusMicroLabsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationCaseAxis=pfe_PfizerVersusMicroLabsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationCaseAxis=pfe_PfizerVersusZydusMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationCaseAxis=pfe_PfizerVersusZydusMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationCaseAxis=pfe_PfizerVersusPrinstonandBreckenridgeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationCaseAxis=pfe_PfizerVersusPrinstonandBreckenridgeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=pfe_EliquisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=pfe_EliquisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationCaseAxis=pfe_PfizerandBMSVersusSeveralGenericManufacturersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationCaseAxis=pfe_PfizerandBMSVersusSeveralGenericManufacturersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=pfe_PatentInfringementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=pfe_PatentInfringementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=pfe_BavencioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=pfe_BavencioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationCaseAxis=pfe_PfizerVersusBMSE.R.SquibbSonsOnoPharmaceuticalandTasukuHonjoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationCaseAxis=pfe_PfizerVersusBMSE.R.SquibbSonsOnoPharmaceuticalandTasukuHonjoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationCaseAxis=pfe_PfizerVersusBreckenridgeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationCaseAxis=pfe_PfizerVersusBreckenridgeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6913961024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Actions In Which We Are The Defendant) (Detail)<br> &#163; in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Apr. 30, 2017</div></th>
<th class="th">
<div>Mar. 31, 2015 </div>
<div>Patents</div>
</th>
<th class="th">
<div>Mar. 31, 2013 </div>
<div>lagoon</div>
</th>
<th class="th">
<div>Oct. 01, 2017 </div>
<div>Claim</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>GBP (&#163;)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=pfe_InflectraMember', window );">Inflectra [Member] | Janssen and New York University Versus Hospira, Celltrion Healthcare and Celltrion Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber', window );">Number of patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=pfe_InflectraMember', window );">Inflectra [Member] | Janssen and New York University Versus Hospira, Celltrion Healthcare and Celltrion Inc. [Member] | Settled Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyClaimsDismissedNumber', window );">Claims dismissed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=pfe_InflectraMember', window );">Inflectra [Member] | Janssen and New York University Versus Hospira, Celltrion Healthcare and Celltrion Inc. [Member] | Pending Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber', window );">Number of patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=pfe_XtandiMember', window );">Xtandi [Member] | Regents Versus Medivation [Member] | Settled Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_LossContingencyCollaborationArrangementPercentageofPaymentsSoughtbyPlaintiff', window );">Percentage of payments Medivation received sought by Regents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_DamagesFromProductDefectsMember', window );">Damages from Product Defects [Member] | Class Action Versus American Optical Corporation And Various Other Defendants [Member] | Pending Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of pending claims | Claim</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=pfe_AverageWholesalePriceMember', window );">Average Wholesale Price [Member] | State of Illinois Versus Pfizer [Member] | Pending Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of pending claims | Claim</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=pfe_EnvironmentalRemediationLitigationMember', window );">Environmental Remediation Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_FeasibilityStudyNumberOfLagoons', window );">Number of lagoons | lagoon</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=pfe_ViolationofAntitrustLawsMember', window );">Violation of Antitrust Laws [Member] | Phenytoin Sodium Capsules [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyEstimateOfPossibleLoss', window );">Imposed fine | &#163;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 84.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Celebrex [Member] | Pending Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Amount awarded to other party | $</a></td>
<td class="nump">$ 94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_FeasibilityStudyNumberOfLagoons">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Feasibility Study, Number Of Lagoons</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_FeasibilityStudyNumberOfLagoons</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_LossContingencyCollaborationArrangementPercentageofPaymentsSoughtbyPlaintiff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Collaboration Arrangement, Percentage of Payments Sought by Plaintiff</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_LossContingencyCollaborationArrangementPercentageofPaymentsSoughtbyPlaintiff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount awarded to other party in judgment or settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmountAwardedToOtherParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyClaimsDismissedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of claims dismissed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyClaimsDismissedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyEstimateOfPossibleLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14557-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyEstimateOfPossibleLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of another entity's patents that the entity has allegedly infringed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyPatentsAllegedlyInfringedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyPendingClaimsNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of pending claims pertaining to a loss contingency.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14435-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyPendingClaimsNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=pfe_InflectraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=pfe_InflectraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationCaseAxis=pfe_JanssenandNewYorkUniversityVersusHospiraCelltrionHealthcareandCelltrionInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationCaseAxis=pfe_JanssenandNewYorkUniversityVersusHospiraCelltrionHealthcareandCelltrionInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=pfe_XtandiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=pfe_XtandiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationCaseAxis=pfe_RegentsVersusMedivationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationCaseAxis=pfe_RegentsVersusMedivationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_DamagesFromProductDefectsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_DamagesFromProductDefectsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationCaseAxis=pfe_ClassActionVersusAmericanOpticalCorporationAndVariousOtherDefendantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationCaseAxis=pfe_ClassActionVersusAmericanOpticalCorporationAndVariousOtherDefendantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=pfe_AverageWholesalePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=pfe_AverageWholesalePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationCaseAxis=pfe_StateofIllinoisVersusPfizerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationCaseAxis=pfe_StateofIllinoisVersusPfizerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=pfe_EnvironmentalRemediationLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=pfe_EnvironmentalRemediationLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=pfe_ViolationofAntitrustLawsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=pfe_ViolationofAntitrustLawsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=pfe_PhenytoinSodiumCapsulesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=pfe_PhenytoinSodiumCapsulesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=pfe_CelebrexMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=pfe_CelebrexMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6923658400">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Segment, Geographic and Other Revenue Information - Narrative (Detail)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 01, 2017 </div>
<div>USD ($) </div>
<div>Operating_Segment</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of business segments | Operating_Segment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Assets | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 172,151<span></span>
</td>
<td class="nump">$ 171,615<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Amounts may not add due to rounding.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6930976528">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Segment, Geographic and Other Revenue Information (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 01, 2017</div></th>
<th class="th"><div>Oct. 02, 2016</div></th>
<th class="th"><div>Oct. 01, 2017</div></th>
<th class="th"><div>Oct. 02, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 13,168<span></span>
</td>
<td class="nump">$ 13,045<span></span>
</td>
<td class="nump">$ 38,843<span></span>
</td>
<td class="nump">$ 39,196<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Earnings</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="nump">3,585<span></span>
</td>
<td class="nump">1,604<span></span>
</td>
<td class="nump">11,351<span></span>
</td>
<td class="nump">7,575<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">13,168<span></span>
</td>
<td class="nump">13,045<span></span>
</td>
<td class="nump">38,843<span></span>
</td>
<td class="nump">39,196<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Earnings</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">7,640<span></span>
</td>
<td class="nump">7,315<span></span>
</td>
<td class="nump">22,748<span></span>
</td>
<td class="nump">22,454<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember', window );">Segment Reconciling Items [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Earnings</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2],[3],[4]</sup></td>
<td class="num">(759)<span></span>
</td>
<td class="num">(753)<span></span>
</td>
<td class="num">(2,205)<span></span>
</td>
<td class="num">(2,096)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember', window );">Segment Reconciling Items [Member] | Purchase Accounting Adjustments [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Earnings</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2],[3]</sup></td>
<td class="num">(1,154)<span></span>
</td>
<td class="num">(966)<span></span>
</td>
<td class="num">(3,527)<span></span>
</td>
<td class="num">(3,103)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember', window );">Segment Reconciling Items [Member] | Acquisition-Related Costs [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Earnings</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2],[3]</sup></td>
<td class="num">(155)<span></span>
</td>
<td class="num">(280)<span></span>
</td>
<td class="num">(347)<span></span>
</td>
<td class="num">(598)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember', window );">Segment Reconciling Items [Member] | Certain Significant Items [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Earnings</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2],[5]</sup></td>
<td class="num">(449)<span></span>
</td>
<td class="num">(1,969)<span></span>
</td>
<td class="num">(797)<span></span>
</td>
<td class="num">(4,112)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember', window );">Segment Reconciling Items [Member] | Other Unallocated [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Earnings</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="num">(156)<span></span>
</td>
<td class="num">(206)<span></span>
</td>
<td class="num">(573)<span></span>
</td>
<td class="num">(753)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Corporate [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Earnings</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2],[3]</sup></td>
<td class="num">(1,382)<span></span>
</td>
<td class="num">(1,537)<span></span>
</td>
<td class="num">(3,948)<span></span>
</td>
<td class="num">(4,217)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=pfe_InnovativeHealthSegmentMember', window );">IH [Member] | Operating Segments [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">8,118<span></span>
</td>
<td class="nump">7,332<span></span>
</td>
<td class="nump">23,204<span></span>
</td>
<td class="nump">21,471<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Earnings</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">4,875<span></span>
</td>
<td class="nump">4,187<span></span>
</td>
<td class="nump">14,190<span></span>
</td>
<td class="nump">12,470<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=pfe_EssentialHealthSegmentMember', window );">EH [Member] | Operating Segments [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,050<span></span>
</td>
<td class="nump">5,712<span></span>
</td>
<td class="nump">15,639<span></span>
</td>
<td class="nump">17,725<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Earnings</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">$ 2,765<span></span>
</td>
<td class="nump">$ 3,128<span></span>
</td>
<td class="nump">$ 8,558<span></span>
</td>
<td class="nump">$ 9,985<span></span>
</td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Amounts may not add due to rounding.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Income from continuing operations before provision for taxes on income. IH&#8217;s earnings in the <span style="font-family:inherit;font-size:8pt;">third quarter</span><span style="font-family:inherit;font-size:8pt;"> and </span><span style="font-family:inherit;font-size:8pt;">first nine months of</span><span style="font-family:inherit;font-size:8pt;"> </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:8pt;text-align:center;"> include d</span><span style="font-family:inherit;font-size:8pt;">ividend income of </span><span style="font-family:inherit;font-size:8pt;"><span>$54 million</span></span><span style="font-family:inherit;font-size:8pt;"> and </span><span style="font-family:inherit;font-size:8pt;"><span>$211 million</span></span><span style="font-family:inherit;font-size:8pt;">, respectively, from our investment in ViiV. For additional information, see </span>Note 4.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">For a description, see the &#8220;Other Costs and Business Activities&#8221; section above.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top">Other business activities includes the costs managed by our WRD and GPD organizations. Effective in the first quarter of <span style="font-family:inherit;font-size:8pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:8pt;">, Medical, previously reported as part of Other Business Activities, was reclassified to Corporate. We have reclassified approximately </span><span style="font-family:inherit;font-size:8pt;"><span>$33 million</span></span><span style="font-family:inherit;font-size:8pt;"> and </span><span style="font-family:inherit;font-size:8pt;"><span>$94 million</span></span><span style="font-family:inherit;font-size:8pt;"> of costs from Other Business Activities to Corporate in the </span><span style="font-family:inherit;font-size:8pt;">third quarter</span><span style="font-family:inherit;font-size:8pt;"> and </span><span style="font-family:inherit;font-size:8pt;">first nine months of</span><span style="font-family:inherit;font-size:8pt;"> </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2016</span>, respectively, to conform to the current period presentation.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[5]</td>
<td style="vertical-align: top;" valign="top">Certain significant items are substantive and/or unusual, and in some cases recurring, items (such as restructuring or legal charges) that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis.<div style="line-height:120%;padding-bottom:1px;padding-top:1px;padding-left:12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">For Earnings in the </span><span style="font-family:inherit;font-size:8pt;">third quarter</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:8pt;">, certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of </span><span style="font-family:inherit;font-size:8pt;"><span>$90 million</span></span><span style="font-family:inherit;font-size:8pt;">, (ii) charges for certain legal matters of </span><span style="font-family:inherit;font-size:8pt;"><span>$183 million</span></span><span style="font-family:inherit;font-size:8pt;">, (iii) income of </span><span style="font-family:inherit;font-size:8pt;"><span>$12 million</span></span><span style="font-family:inherit;font-size:8pt;">, representing an adjustment to amounts previously recorded to write down the HIS net assets to fair value less costs to sell, (iv) certain asset impairment charges of </span><span style="font-family:inherit;font-size:8pt;"><span>$127 million</span></span><span style="font-family:inherit;font-size:8pt;">, (v) charges for business and legal entity alignment of </span><span style="font-family:inherit;font-size:8pt;"><span>$16 million</span></span><span style="font-family:inherit;font-size:8pt;"> and (vi) other charges of </span><span style="font-family:inherit;font-size:8pt;"><span>$45 million</span></span><span style="font-family:inherit;font-size:8pt;">. For additional information, see </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Note 2B, Note 3</span><span style="font-family:inherit;font-size:8pt;"> and </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Note 4.</span></div><div style="line-height:120%;padding-bottom:1px;text-align:left;padding-left:12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">For Earnings in the </span><span style="font-family:inherit;font-size:8pt;">third quarter</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:8pt;">, certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of </span><span style="font-family:inherit;font-size:8pt;"><span>$375 million</span></span><span style="font-family:inherit;font-size:8pt;">, (ii) income for certain legal matters of </span><span style="font-family:inherit;font-size:8pt;"><span>$40 million</span></span><span style="font-family:inherit;font-size:8pt;">, (iii) an impairment charge related to the write-down of the HIS net assets to fair value less estimated costs to sell of </span><span style="font-family:inherit;font-size:8pt;"><span>$1.4 billion</span></span><span style="font-family:inherit;font-size:8pt;">, (iv) certain asset impairment charges of </span><span style="font-family:inherit;font-size:8pt;"><span>$126 million</span></span><span style="font-family:inherit;font-size:8pt;">, (v) charges for business and legal entity alignment of </span><span style="font-family:inherit;font-size:8pt;"><span>$69 million</span></span><span style="font-family:inherit;font-size:8pt;"> and (vi) other charges of </span><span style="font-family:inherit;font-size:8pt;"><span>$17 million</span></span><span style="font-family:inherit;font-size:8pt;">. For additional information, see </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Note 3 </span><span style="font-family:inherit;font-size:8pt;">and</span><span style="font-family:inherit;font-size:8pt;font-style:italic;"> Note 4</span><span style="font-family:inherit;font-size:8pt;">.</span></div><div style="line-height:120%;padding-bottom:1px;text-align:left;padding-left:12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">For Earnings in the </span><span style="font-family:inherit;font-size:8pt;">first nine months of</span><span style="font-family:inherit;font-size:8pt;"> </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:8pt;">, certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of </span><span style="font-family:inherit;font-size:8pt;"><span>$253 million</span></span><span style="font-family:inherit;font-size:8pt;">, (ii) charges for certain legal matters of </span><span style="font-family:inherit;font-size:8pt;"><span>$191 million</span></span><span style="font-family:inherit;font-size:8pt;">, (iii) incremental charges to amounts previously recorded to write down the HIS net assets to fair value less costs to sell of </span><span style="font-family:inherit;font-size:8pt;"><span>$52 million</span></span><span style="font-family:inherit;font-size:8pt;">, (iv) certain asset impairment charges of </span><span style="font-family:inherit;font-size:8pt;"><span>$127 million</span></span><span style="font-family:inherit;font-size:8pt;">, (v) charges for business and legal entity alignment of </span><span style="font-family:inherit;font-size:8pt;"><span>$54 million</span></span><span style="font-family:inherit;font-size:8pt;"> and (vi) other charges of </span><span style="font-family:inherit;font-size:8pt;"><span>$119 million</span></span><span style="font-family:inherit;font-size:8pt;">. For additional information, see </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Note 2B</span><span style="font-family:inherit;font-size:8pt;">, </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Note 3</span><span style="font-family:inherit;font-size:8pt;"> and </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Note 4</span><span style="font-family:inherit;font-size:8pt;">.</span></div><span style="font-family:inherit;font-size:8pt;">For Earnings in the </span><span style="font-family:inherit;font-size:8pt;">first nine months of</span><span style="font-family:inherit;font-size:8pt;"> </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:8pt;">, certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of </span><span style="font-family:inherit;font-size:8pt;"><span>$743 million</span></span><span style="font-family:inherit;font-size:8pt;">, (ii) charges for certain legal matters of </span><span style="font-family:inherit;font-size:8pt;"><span>$506 million</span></span><span style="font-family:inherit;font-size:8pt;">, (iii) an impairment charge related to the write-down of the HIS net assets to fair value less estimated costs to sell of </span><span style="font-family:inherit;font-size:8pt;"><span>$1.4 billion</span></span><span style="font-family:inherit;font-size:8pt;">, (iv) certain asset impairment charges of </span><span style="font-family:inherit;font-size:8pt;"><span>$1.1 billion</span></span><span style="font-family:inherit;font-size:8pt;">, (v) charges for business and legal entity alignment of </span><span style="font-family:inherit;font-size:8pt;"><span>$180 million</span></span><span style="font-family:inherit;font-size:8pt;"> and (vi) other charges of </span><span style="font-family:inherit;font-size:8pt;"><span>$189 million</span></span><span style="font-family:inherit;font-size:8pt;">. For additional information, see </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Note 3</span><span style="font-family:inherit;font-size:8pt;"> and </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Note 4</span>.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueGoodsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueGoodsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_OtherSegmentReconcilingItemsAxis=pfe_PurchaseAccountingAdjustmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_OtherSegmentReconcilingItemsAxis=pfe_PurchaseAccountingAdjustmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_OtherSegmentReconcilingItemsAxis=pfe_BusinessCombinationsAcquisitionRelatedCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_OtherSegmentReconcilingItemsAxis=pfe_BusinessCombinationsAcquisitionRelatedCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_OtherSegmentReconcilingItemsAxis=pfe_CertainSignificantItemsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_OtherSegmentReconcilingItemsAxis=pfe_CertainSignificantItemsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_OtherSegmentReconcilingItemsAxis=pfe_OtherUnallocatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_OtherSegmentReconcilingItemsAxis=pfe_OtherUnallocatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=pfe_InnovativeHealthSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=pfe_InnovativeHealthSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=pfe_EssentialHealthSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=pfe_EssentialHealthSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6905481856">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Segment, Geographic and Other Revenue Information - Footnotes (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="4">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 01, 2017</div></th>
<th class="th"><div>Oct. 02, 2016</div></th>
<th class="th" colspan="2"><div>Oct. 01, 2017</div></th>
<th class="th" colspan="2"><div>Oct. 02, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal', window );">Gain (loss) on sale of HIS net assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 12<span></span>
</td>
<td class="num">$ (1,422)<span></span>
</td>
<td class="num">$ (52)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="num">$ (1,422)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_BusinessInfrastructureAlignmentCosts', window );">Business and legal entity alignment costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">16<span></span>
</td>
<td class="nump">69<span></span>
</td>
<td class="nump">54<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">180<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossRelatedToLitigationSettlement', window );">Income (charges) for certain legal matters</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="num">(183)<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="num">(194)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(494)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Certain asset impairments</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="nump">130<span></span>
</td>
<td class="nump">133<span></span>
</td>
<td class="nump">143<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,080<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember', window );">Segment Reconciling Items [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_RestructuringChargesandImplementationCosts', window );">Cost reduction and productivity initiatives excluding acquisition related costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">90<span></span>
</td>
<td class="nump">375<span></span>
</td>
<td class="nump">253<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">743<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_BusinessInfrastructureAlignmentCosts', window );">Business and legal entity alignment costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">16<span></span>
</td>
<td class="nump">69<span></span>
</td>
<td class="nump">54<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">180<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other charges</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">45<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="nump">119<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">189<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossRelatedToLitigationSettlement', window );">Income (charges) for certain legal matters</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(183)<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="num">(191)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(506)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Certain asset impairments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">127<span></span>
</td>
<td class="nump">126<span></span>
</td>
<td class="nump">127<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,100<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementScenarioAxis=us-gaap_ScenarioAdjustmentMember', window );">Adjustment [Member] | Corporate [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Costs and expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">94<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=pfe_HISMember', window );">HIS [Member] | Segment Reconciling Items [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal', window );">Gain (loss) on sale of HIS net assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">12<span></span>
</td>
<td class="num">(1,400)<span></span>
</td>
<td class="num">(52)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(1,400)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_ViivHealthcareLimitedMember', window );">ViiV Healthcare Limited [Member] | Innovative Health Segment [Member] | Operating Segments [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeDividend', window );">Dividend income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 211<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsegmentsAxis=pfe_PfizersWorldwideResearchandDevelopmentandPfizersGlobalProductDevelopmentMember', window );">Pfizer's Worldwide Research and Development and Pfizer's Global Product Development [Member] | Adjustment [Member] | Segment Reconciling Items [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Costs and expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (33)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (94)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="8"></td></tr>
<tr><td colspan="8"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">In the <span style="font-family:inherit;font-size:8.5pt;">third</span><span style="font-family:inherit;font-size:8.5pt;"> quarter and </span><span style="font-family:inherit;font-size:8.5pt;">first nine months of</span><span style="font-family:inherit;font-size:8.5pt;"> </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:8.5pt;">, represents adjustments to amounts previously recorded to write down the HIS net assets to fair value less costs to sell related to the sale of HIS net assets to ICU Medical. In the </span><span style="font-family:inherit;font-size:8.5pt;">third</span><span style="font-family:inherit;font-size:8.5pt;"> quarter and </span><span style="font-family:inherit;font-size:8.5pt;">first nine months of</span><span style="font-family:inherit;font-size:8.5pt;"> </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:8.5pt;">, represents a charge related to the write-down of the HIS net assets to fair value less estimated costs to sell.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Amounts may not add due to rounding.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">In the <span style="font-family:inherit;font-size:8.5pt;">third</span><span style="font-family:inherit;font-size:8.5pt;"> quarter and </span><span style="font-family:inherit;font-size:8.5pt;">first nine months of</span><span style="font-family:inherit;font-size:8.5pt;"> </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:8.5pt;"> and </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">2016</span>, represents expenses for changes to our infrastructure to align our commercial operations, including costs to internally separate our businesses into distinct legal entities, as well as to streamline our intercompany supply operations to better support each business.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top">In the <span style="font-family:inherit;font-size:8.5pt;">third quarter</span><span style="font-family:inherit;font-size:8.5pt;"> and </span><span style="font-family:inherit;font-size:8.5pt;">first nine months of</span><span style="font-family:inherit;font-size:8.5pt;"> </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:8.5pt;">, primarily includes a </span><span style="font-family:inherit;font-size:8.5pt;"><span>$94 million</span></span><span style="font-family:inherit;font-size:8.5pt;"> charge to resolve a class action lawsuit filed by direct purchasers relating to Celebrex, which is subject to the negotiation of a final settlement agreement and court approval, and a </span><span style="font-family:inherit;font-size:8.5pt;"><span>$79 million</span></span><span style="font-family:inherit;font-size:8.5pt;"> charge to reflect damages awarded by a jury in a patent matter. In the </span><span style="font-family:inherit;font-size:8.5pt;">first nine months of</span><span style="font-family:inherit;font-size:8.5pt;"> </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:8.5pt;">, primarily includes amounts to resolve a Multi-District Litigation relating to Celebrex and Bextra that was pending against the Company in New York federal court for </span><span style="font-family:inherit;font-size:8.5pt;"><span>$486 million</span></span><span style="font-family:inherit;font-size:8.5pt;">, partially offset by the reversal of a legal accrual where a loss was no longer deemed probable. In addition, the </span><span style="font-family:inherit;font-size:8.5pt;">first nine months of</span><span style="font-family:inherit;font-size:8.5pt;"> </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">2016</span> includes a settlement related to a patent matter.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[5]</td>
<td style="vertical-align: top;" valign="top">In the <span style="font-family:inherit;font-size:8.5pt;">third quarter</span><span style="font-family:inherit;font-size:8.5pt;"> and </span><span style="font-family:inherit;font-size:8.5pt;">first nine months of</span><span style="font-family:inherit;font-size:8.5pt;"> </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:8.5pt;">, primarily includes an intangible asset impairment charge of </span><span style="font-family:inherit;font-size:8.5pt;"><span>$127 million</span></span><span style="font-family:inherit;font-size:8.5pt;"> related to developed technology rights, acquired in connection with our acquisition of Hospira, for a generic sterile injectable product for the treatment of edema associated with certain conditions. The intangible asset impairment charge for the </span><span style="font-family:inherit;font-size:8.5pt;">third</span><span style="font-family:inherit;font-size:8.5pt;"> quarter and </span><span style="font-family:inherit;font-size:8.5pt;">first nine months of</span><span style="font-family:inherit;font-size:8.5pt;"> </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:8.5pt;"> is associated with EH and reflects, among other things, updated commercial forecasts and an increased competitive environment. In the </span><span style="font-family:inherit;font-size:8.5pt;">third</span><span style="font-family:inherit;font-size:8.5pt;"> quarter of </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:8.5pt;">, primarily includes intangible asset impairment charges of </span><span style="font-family:inherit;font-size:8.5pt;"><span>$126 million</span></span><span style="font-family:inherit;font-size:8.5pt;">, reflecting </span><span style="font-family:inherit;font-size:8.5pt;"><span>$97 million</span></span><span style="font-family:inherit;font-size:8.5pt;"> of sterile injectable IPR&amp;D compounds acquired in connection with our acquisition of InnoPharma and </span><span style="font-family:inherit;font-size:8.5pt;"><span>$29 million</span></span><span style="font-family:inherit;font-size:8.5pt;"> of other IPR&amp;D assets acquired in connection with our acquisition of King in 2011. The intangible asset impairment charges for the </span><span style="font-family:inherit;font-size:8.5pt;">third quarter</span><span style="font-family:inherit;font-size:8.5pt;"> of </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:8.5pt;"> are associated with the following: EH (</span><span style="font-family:inherit;font-size:8.5pt;"><span>$97 million</span></span><span style="font-family:inherit;font-size:8.5pt;">) and IH (</span><span style="font-family:inherit;font-size:8.5pt;"><span>$29 million</span></span><span style="font-family:inherit;font-size:8.5pt;">). In the </span><span style="font-family:inherit;font-size:8.5pt;">first nine months of</span><span style="font-family:inherit;font-size:8.5pt;"> </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:8.5pt;">, primarily includes intangible asset impairment charges of </span><span style="font-family:inherit;font-size:8.5pt;"><span>$767 million</span></span><span style="font-family:inherit;font-size:8.5pt;">, reflecting (i) </span><span style="font-family:inherit;font-size:8.5pt;"><span>$331 million</span></span><span style="font-family:inherit;font-size:8.5pt;"> related to developed technology rights for a generic injectable antibiotic product for the treatment of bacterial infections; and (ii) </span><span style="font-family:inherit;font-size:8.5pt;"><span>$265 million</span></span><span style="font-family:inherit;font-size:8.5pt;"> related to an IPR&amp;D compound for the treatment of anemia, both acquired in connection with our acquisition of Hospira; (iii) </span><span style="font-family:inherit;font-size:8.5pt;"><span>$97 million</span></span><span style="font-family:inherit;font-size:8.5pt;"> of sterile injectable IPR&amp;D compounds acquired in connection with our acquisition of InnoPharma; and (iv) </span><span style="font-family:inherit;font-size:8.5pt;"><span>$74 million</span></span><span style="font-family:inherit;font-size:8.5pt;"> of other IPR&amp;D assets, </span><span style="font-family:inherit;font-size:8.5pt;"><span>$45 million</span></span><span style="font-family:inherit;font-size:8.5pt;"> of which were acquired in connection with our acquisition of Hospira and </span><span style="font-family:inherit;font-size:8.5pt;"><span>$29 million</span></span><span style="font-family:inherit;font-size:8.5pt;"> of which were acquired in connection with our acquisition of King in 2011. The intangible asset impairment charges for the </span><span style="font-family:inherit;font-size:8.5pt;">first nine months of</span><span style="font-family:inherit;font-size:8.5pt;"> </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:8.5pt;"> are associated with the following: EH (</span><span style="font-family:inherit;font-size:8.5pt;"><span>$738 million</span></span><span style="font-family:inherit;font-size:8.5pt;">) and IH (</span><span style="font-family:inherit;font-size:8.5pt;"><span>$29 million</span></span><span style="font-family:inherit;font-size:8.5pt;">). In addition, the </span><span style="font-family:inherit;font-size:8.5pt;">first nine months of</span><span style="font-family:inherit;font-size:8.5pt;"> </span><span style="font-family:inherit;font-size:8.5pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:8.5pt;"> includes an impairment loss of </span><span style="font-family:inherit;font-size:8.5pt;"><span>$211 million</span></span><span style="font-family:inherit;font-size:8.5pt;"> related to Pfizer&#8217;s </span><span style="font-family:inherit;font-size:8.5pt;"><span>49%</span></span><span style="font-family:inherit;font-size:8.5pt;">-owned equity-method investment with Hisun in China, Hisun Pfizer, and an impairment loss of </span><span style="font-family:inherit;font-size:8.5pt;"><span>$50 million</span></span><span style="font-family:inherit;font-size:8.5pt;"> related to Pfizer&#8217;s </span><span style="font-family:inherit;font-size:8.5pt;"><span>40%</span></span><span style="font-family:inherit;font-size:8.5pt;">-owned equity-method investment in Teuto. For additional information concerning Hisun Pfizer and Teuto, see </span><span style="font-family:inherit;font-size:8.5pt;font-style:italic;">Note 2D. </span>The intangible asset impairment charge for 2016 for the IPR&amp;D compound for the treatment of anemia acquired in connection with our acquisition of Hospira reflects, among other things, the impact of regulatory delays, including delays resulting from a court ruling, which required a 180-day waiting period after approval before a biosimilar product can be launched. The intangible asset impairment charges for 2016 for the sterile injectable IPR&amp;D compounds acquired in connection with our acquisition of InnoPharma reflect, among other things, the impact of portfolio prioritization decisions and decreased commercial profiles of certain compounds. The intangible asset impairment charges for 2016 for developed technology rights and other IPR&amp;D assets acquired in connection with our acquisition of Hospira reflect, among other things, the impact of new scientific findings, updated commercial forecasts, changes in pricing, and an increased competitive environment. The intangible asset impairment charges for 2016 for other IPR&amp;D assets acquired in connection with our acquisition of King reflect changes in the competitive environment.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_BusinessInfrastructureAlignmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Infrastructure Alignment Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_BusinessInfrastructureAlignmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_RestructuringChargesandImplementationCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restructuring Charges and Implementation Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_RestructuringChargesandImplementationCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=68055307&amp;loc=d3e2420-110228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68055307&amp;loc=d3e2443-110228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84176398&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossRelatedToLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossRelatedToLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=us-gaap_ScenarioAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=us-gaap_ScenarioAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=pfe_HISMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=pfe_HISMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_ViivHealthcareLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_ViivHealthcareLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=pfe_InnovativeHealthSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=pfe_InnovativeHealthSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=pfe_PfizersWorldwideResearchandDevelopmentandPfizersGlobalProductDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=pfe_PfizersWorldwideResearchandDevelopmentandPfizersGlobalProductDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6914987104">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Segment, Geographic and Other Revenue Information - Revenues By Geographic Area (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 01, 2017</div></th>
<th class="th"><div>Oct. 02, 2016</div></th>
<th class="th"><div>Oct. 01, 2017</div></th>
<th class="th"><div>Oct. 02, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 13,168<span></span>
</td>
<td class="nump">$ 13,045<span></span>
</td>
<td class="nump">$ 38,843<span></span>
</td>
<td class="nump">$ 39,196<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_PercentageChangeInRevenue', window );">Percentage Change In Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementGeographicalAxis=country_US', window );">U.S. [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 6,534<span></span>
</td>
<td class="nump">6,530<span></span>
</td>
<td class="nump">$ 19,516<span></span>
</td>
<td class="nump">19,561<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_PercentageChangeInRevenue', window );">Percentage Change In Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementGeographicalAxis=pfe_DevelopedEuropeMember', window );">Developed Europe [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">$ 2,163<span></span>
</td>
<td class="nump">2,218<span></span>
</td>
<td class="nump">$ 6,309<span></span>
</td>
<td class="nump">6,982<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_PercentageChangeInRevenue', window );">Percentage Change In Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="num">(2.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementGeographicalAxis=pfe_DevelopedRestOfWorldMember', window );">Developed Rest Of World [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">$ 1,632<span></span>
</td>
<td class="nump">1,711<span></span>
</td>
<td class="nump">$ 4,797<span></span>
</td>
<td class="nump">4,940<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_PercentageChangeInRevenue', window );">Percentage Change In Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="num">(5.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementGeographicalAxis=pfe_EmergingMarketsMember', window );">Emerging Markets [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">$ 2,839<span></span>
</td>
<td class="nump">$ 2,586<span></span>
</td>
<td class="nump">$ 8,222<span></span>
</td>
<td class="nump">$ 7,714<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_PercentageChangeInRevenue', window );">Percentage Change In Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Amounts may not add due to rounding.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family:inherit;font-size:8pt;">Developed Europe region includes the following markets: Western Europe, Scandinavian countries and Finland.</span><span style="font-family:inherit;font-size:8pt;"> Revenues denominated in euros were </span><span style="font-family:inherit;font-size:8pt;"><span>$1.7 billion</span></span><span style="font-family:inherit;font-size:8pt;"> in both the </span><span style="font-family:inherit;font-size:8pt;">third quarter</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:8pt;"> and </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:8pt;">, and </span><span style="font-family:inherit;font-size:8pt;"><span>$5.0 billion</span></span><span style="font-family:inherit;font-size:8pt;"> and </span><span style="font-family:inherit;font-size:8pt;"><span>$5.3 billion</span></span><span style="font-family:inherit;font-size:8pt;"> in the </span><span style="font-family:inherit;font-size:8pt;">first nine months of</span><span style="font-family:inherit;font-size:8pt;"> </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:8pt;"> and </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2016</span>, respectively.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family:inherit;font-size:8pt;">Developed Rest of World region includes the following markets: Japan, Canada, Australia, South Korea and New Zealand.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family:inherit;font-size:8pt;">Emerging Markets region includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Africa, Eastern Europe, Central Europe, the Middle East and Turkey.</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_PercentageChangeInRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage change in revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_PercentageChangeInRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueGoodsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueGoodsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=pfe_DevelopedEuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=pfe_DevelopedEuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=pfe_DevelopedRestOfWorldMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=pfe_DevelopedRestOfWorldMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=pfe_EmergingMarketsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=pfe_EmergingMarketsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6915104112">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Segment, Geographic and Other Revenue Information - Revenues By Geographic Area - Footnotes (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 01, 2017</div></th>
<th class="th"><div>Oct. 02, 2016</div></th>
<th class="th"><div>Oct. 01, 2017</div></th>
<th class="th"><div>Oct. 02, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 13,168<span></span>
</td>
<td class="nump">$ 13,045<span></span>
</td>
<td class="nump">$ 38,843<span></span>
</td>
<td class="nump">$ 39,196<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementGeographicalAxis=pfe_DevelopedEuropeMember', window );">Developed Europe [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">2,163<span></span>
</td>
<td class="nump">2,218<span></span>
</td>
<td class="nump">6,309<span></span>
</td>
<td class="nump">6,982<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrencyAxis=currency_EUR', window );">Euro Member Countries, Euro [Member] | Developed Europe [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,700<span></span>
</td>
<td class="nump">$ 1,700<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="nump">$ 5,300<span></span>
</td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Amounts may not add due to rounding.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family:inherit;font-size:8pt;">Developed Europe region includes the following markets: Western Europe, Scandinavian countries and Finland.</span><span style="font-family:inherit;font-size:8pt;"> Revenues denominated in euros were </span><span style="font-family:inherit;font-size:8pt;"><span>$1.7 billion</span></span><span style="font-family:inherit;font-size:8pt;"> in both the </span><span style="font-family:inherit;font-size:8pt;">third quarter</span><span style="font-family:inherit;font-size:8pt;"> of </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:8pt;"> and </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2016</span><span style="font-family:inherit;font-size:8pt;">, and </span><span style="font-family:inherit;font-size:8pt;"><span>$5.0 billion</span></span><span style="font-family:inherit;font-size:8pt;"> and </span><span style="font-family:inherit;font-size:8pt;"><span>$5.3 billion</span></span><span style="font-family:inherit;font-size:8pt;"> in the </span><span style="font-family:inherit;font-size:8pt;">first nine months of</span><span style="font-family:inherit;font-size:8pt;"> </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2017</span><span style="font-family:inherit;font-size:8pt;"> and </span><span style="font-family:inherit;font-size:8pt;text-align:center;">2016</span>, respectively.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueGoodsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueGoodsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=pfe_DevelopedEuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=pfe_DevelopedEuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrencyAxis=currency_EUR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrencyAxis=currency_EUR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6935549456">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Segment, Geographic and Other Revenue Information - Revenues By Products (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 01, 2017</div></th>
<th class="th"><div>Oct. 02, 2016</div></th>
<th class="th"><div>Oct. 01, 2017</div></th>
<th class="th"><div>Oct. 02, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 13,168<span></span>
</td>
<td class="nump">$ 13,045<span></span>
</td>
<td class="nump">$ 38,843<span></span>
</td>
<td class="nump">$ 39,196<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=pfe_InnovativeHealthandEssentialHealthMember', window );">Innovative Health and Essential Health [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">13,168<span></span>
</td>
<td class="nump">13,045<span></span>
</td>
<td class="nump">38,843<span></span>
</td>
<td class="nump">39,196<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=pfe_InnovativeHealthandEssentialHealthMember', window );">Innovative Health and Essential Health [Member] | Lyrica [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">1,285<span></span>
</td>
<td class="nump">1,240<span></span>
</td>
<td class="nump">3,810<span></span>
</td>
<td class="nump">3,730<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=pfe_InnovativeHealthandEssentialHealthMember', window );">Innovative Health and Essential Health [Member] | Viagra [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">308<span></span>
</td>
<td class="nump">387<span></span>
</td>
<td class="nump">996<span></span>
</td>
<td class="nump">1,183<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=pfe_InnovativeHealthandEssentialHealthMember', window );">Innovative Health and Essential Health [Member] | Alliance revenues [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">741<span></span>
</td>
<td class="nump">419<span></span>
</td>
<td class="nump">2,112<span></span>
</td>
<td class="nump">1,155<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DistinctBusinessAxis=pfe_InnovativeHealthBusinessMember', window );">Innovative Health Business [Member] | IH [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">8,118<span></span>
</td>
<td class="nump">7,332<span></span>
</td>
<td class="nump">23,204<span></span>
</td>
<td class="nump">21,471<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DistinctBusinessAxis=pfe_EssentialHealthBusinessMember', window );">Essential Health Business [Member] | EH [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="nump">5,050<span></span>
</td>
<td class="nump">5,712<span></span>
</td>
<td class="nump">15,639<span></span>
</td>
<td class="nump">17,725<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_EssentialHealthProductCategoryAxis=pfe_LegacyEstablishedProductsMember', window );">Legacy Established Products (LEP) [Member] | Essential Health Business [Member] | EH [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[6]</sup></td>
<td class="nump">2,681<span></span>
</td>
<td class="nump">2,708<span></span>
</td>
<td class="nump">7,995<span></span>
</td>
<td class="nump">8,373<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_EssentialHealthProductCategoryAxis=pfe_LegacyEstablishedProductsMember', window );">Legacy Established Products (LEP) [Member] | Essential Health Business [Member] | EH [Member] | Lipitor [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">491<span></span>
</td>
<td class="nump">422<span></span>
</td>
<td class="nump">1,341<span></span>
</td>
<td class="nump">1,294<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_EssentialHealthProductCategoryAxis=pfe_LegacyEstablishedProductsMember', window );">Legacy Established Products (LEP) [Member] | Essential Health Business [Member] | EH [Member] | Premarin family [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">238<span></span>
</td>
<td class="nump">244<span></span>
</td>
<td class="nump">711<span></span>
</td>
<td class="nump">751<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_EssentialHealthProductCategoryAxis=pfe_LegacyEstablishedProductsMember', window );">Legacy Established Products (LEP) [Member] | Essential Health Business [Member] | EH [Member] | Norvasc [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">226<span></span>
</td>
<td class="nump">238<span></span>
</td>
<td class="nump">684<span></span>
</td>
<td class="nump">714<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_EssentialHealthProductCategoryAxis=pfe_LegacyEstablishedProductsMember', window );">Legacy Established Products (LEP) [Member] | Essential Health Business [Member] | EH [Member] | EpiPen [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">82<span></span>
</td>
<td class="nump">110<span></span>
</td>
<td class="nump">253<span></span>
</td>
<td class="nump">300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_EssentialHealthProductCategoryAxis=pfe_LegacyEstablishedProductsMember', window );">Legacy Established Products (LEP) [Member] | Essential Health Business [Member] | EH [Member] | Xalatan/Xalacom [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">83<span></span>
</td>
<td class="nump">91<span></span>
</td>
<td class="nump">241<span></span>
</td>
<td class="nump">273<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_EssentialHealthProductCategoryAxis=pfe_LegacyEstablishedProductsMember', window );">Legacy Established Products (LEP) [Member] | Essential Health Business [Member] | EH [Member] | Effexor [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">76<span></span>
</td>
<td class="nump">70<span></span>
</td>
<td class="nump">215<span></span>
</td>
<td class="nump">207<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_EssentialHealthProductCategoryAxis=pfe_LegacyEstablishedProductsMember', window );">Legacy Established Products (LEP) [Member] | Essential Health Business [Member] | EH [Member] | Zoloft [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">78<span></span>
</td>
<td class="nump">72<span></span>
</td>
<td class="nump">215<span></span>
</td>
<td class="nump">228<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_EssentialHealthProductCategoryAxis=pfe_LegacyEstablishedProductsMember', window );">Legacy Established Products (LEP) [Member] | Essential Health Business [Member] | EH [Member] | Zithromax [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">61<span></span>
</td>
<td class="nump">56<span></span>
</td>
<td class="nump">202<span></span>
</td>
<td class="nump">203<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_EssentialHealthProductCategoryAxis=pfe_LegacyEstablishedProductsMember', window );">Legacy Established Products (LEP) [Member] | Essential Health Business [Member] | EH [Member] | Relpax [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">50<span></span>
</td>
<td class="nump">83<span></span>
</td>
<td class="nump">193<span></span>
</td>
<td class="nump">248<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_EssentialHealthProductCategoryAxis=pfe_LegacyEstablishedProductsMember', window );">Legacy Established Products (LEP) [Member] | Essential Health Business [Member] | EH [Member] | Xanax [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">58<span></span>
</td>
<td class="nump">55<span></span>
</td>
<td class="nump">164<span></span>
</td>
<td class="nump">163<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_EssentialHealthProductCategoryAxis=pfe_LegacyEstablishedProductsMember', window );">Legacy Established Products (LEP) [Member] | Essential Health Business [Member] | EH [Member] | Other Legacy Established Products [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,237<span></span>
</td>
<td class="nump">1,268<span></span>
</td>
<td class="nump">3,776<span></span>
</td>
<td class="nump">3,992<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_EssentialHealthProductCategoryAxis=pfe_SterileInjectablePharmaceuticalsMember', window );">Sterile Injectable Pharmaceuticals [Member] | Essential Health Business [Member] | EH [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[7]</sup></td>
<td class="nump">1,273<span></span>
</td>
<td class="nump">1,461<span></span>
</td>
<td class="nump">4,270<span></span>
</td>
<td class="nump">4,481<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_EssentialHealthProductCategoryAxis=pfe_SterileInjectablePharmaceuticalsMember', window );">Sterile Injectable Pharmaceuticals [Member] | Essential Health Business [Member] | EH [Member] | Medrol [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">109<span></span>
</td>
<td class="nump">102<span></span>
</td>
<td class="nump">352<span></span>
</td>
<td class="nump">330<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_EssentialHealthProductCategoryAxis=pfe_SterileInjectablePharmaceuticalsMember', window );">Sterile Injectable Pharmaceuticals [Member] | Essential Health Business [Member] | EH [Member] | Sulperazon [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">114<span></span>
</td>
<td class="nump">102<span></span>
</td>
<td class="nump">345<span></span>
</td>
<td class="nump">304<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_EssentialHealthProductCategoryAxis=pfe_SterileInjectablePharmaceuticalsMember', window );">Sterile Injectable Pharmaceuticals [Member] | Essential Health Business [Member] | EH [Member] | Fragmin [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">79<span></span>
</td>
<td class="nump">80<span></span>
</td>
<td class="nump">221<span></span>
</td>
<td class="nump">240<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_EssentialHealthProductCategoryAxis=pfe_SterileInjectablePharmaceuticalsMember', window );">Sterile Injectable Pharmaceuticals [Member] | Essential Health Business [Member] | EH [Member] | Tygacil [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">60<span></span>
</td>
<td class="nump">69<span></span>
</td>
<td class="nump">192<span></span>
</td>
<td class="nump">203<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_EssentialHealthProductCategoryAxis=pfe_SterileInjectablePharmaceuticalsMember', window );">Sterile Injectable Pharmaceuticals [Member] | Essential Health Business [Member] | EH [Member] | Precedex [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">51<span></span>
</td>
<td class="nump">64<span></span>
</td>
<td class="nump">182<span></span>
</td>
<td class="nump">199<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_EssentialHealthProductCategoryAxis=pfe_SterileInjectablePharmaceuticalsMember', window );">Sterile Injectable Pharmaceuticals [Member] | Essential Health Business [Member] | EH [Member] | All Other Sterile Injectable Pharmaceuticals [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">860<span></span>
</td>
<td class="nump">1,044<span></span>
</td>
<td class="nump">2,977<span></span>
</td>
<td class="nump">3,206<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_EssentialHealthProductCategoryAxis=pfe_PeriLOEProductsMember', window );">Peri-LOE Products [Member] | Essential Health Business [Member] | EH [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[8]</sup></td>
<td class="nump">794<span></span>
</td>
<td class="nump">1,023<span></span>
</td>
<td class="nump">2,398<span></span>
</td>
<td class="nump">3,224<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_EssentialHealthProductCategoryAxis=pfe_PeriLOEProductsMember', window );">Peri-LOE Products [Member] | Essential Health Business [Member] | EH [Member] | Lyrica [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">134<span></span>
</td>
<td class="nump">191<span></span>
</td>
<td class="nump">428<span></span>
</td>
<td class="nump">623<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_EssentialHealthProductCategoryAxis=pfe_PeriLOEProductsMember', window );">Peri-LOE Products [Member] | Essential Health Business [Member] | EH [Member] | Viagra [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">102<span></span>
</td>
<td class="nump">89<span></span>
</td>
<td class="nump">285<span></span>
</td>
<td class="nump">286<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_EssentialHealthProductCategoryAxis=pfe_PeriLOEProductsMember', window );">Peri-LOE Products [Member] | Essential Health Business [Member] | EH [Member] | Celebrex [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">212<span></span>
</td>
<td class="nump">194<span></span>
</td>
<td class="nump">564<span></span>
</td>
<td class="nump">550<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_EssentialHealthProductCategoryAxis=pfe_PeriLOEProductsMember', window );">Peri-LOE Products [Member] | Essential Health Business [Member] | EH [Member] | Vfend [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">97<span></span>
</td>
<td class="nump">140<span></span>
</td>
<td class="nump">305<span></span>
</td>
<td class="nump">459<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_EssentialHealthProductCategoryAxis=pfe_PeriLOEProductsMember', window );">Peri-LOE Products [Member] | Essential Health Business [Member] | EH [Member] | Pristiq [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">69<span></span>
</td>
<td class="nump">174<span></span>
</td>
<td class="nump">230<span></span>
</td>
<td class="nump">546<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_EssentialHealthProductCategoryAxis=pfe_PeriLOEProductsMember', window );">Peri-LOE Products [Member] | Essential Health Business [Member] | EH [Member] | Zyvox [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">68<span></span>
</td>
<td class="nump">94<span></span>
</td>
<td class="nump">220<span></span>
</td>
<td class="nump">334<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_EssentialHealthProductCategoryAxis=pfe_PeriLOEProductsMember', window );">Peri-LOE Products [Member] | Essential Health Business [Member] | EH [Member] | Revatio [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">58<span></span>
</td>
<td class="nump">73<span></span>
</td>
<td class="nump">189<span></span>
</td>
<td class="nump">213<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_EssentialHealthProductCategoryAxis=pfe_PeriLOEProductsMember', window );">Peri-LOE Products [Member] | Essential Health Business [Member] | EH [Member] | All Other Peri-LOE Products [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">55<span></span>
</td>
<td class="nump">68<span></span>
</td>
<td class="nump">176<span></span>
</td>
<td class="nump">214<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_EssentialHealthProductCategoryAxis=pfe_BiosimilarsMember', window );">Biosimilars [Member] | Essential Health Business [Member] | EH [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[9]</sup></td>
<td class="nump">141<span></span>
</td>
<td class="nump">83<span></span>
</td>
<td class="nump">367<span></span>
</td>
<td class="nump">228<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_EssentialHealthProductCategoryAxis=pfe_BiosimilarsMember', window );">Biosimilars [Member] | Essential Health Business [Member] | EH [Member] | Inflectra/Remsima [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">112<span></span>
</td>
<td class="nump">49<span></span>
</td>
<td class="nump">284<span></span>
</td>
<td class="nump">130<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_EssentialHealthProductCategoryAxis=pfe_BiosimilarsMember', window );">Biosimilars [Member] | Essential Health Business [Member] | EH [Member] | All Other Biosimilars [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">28<span></span>
</td>
<td class="nump">34<span></span>
</td>
<td class="nump">82<span></span>
</td>
<td class="nump">97<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_EssentialHealthProductCategoryAxis=pfe_CentreOneMember', window );">CentreOne [Member] | Essential Health Business [Member] | EH [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[10]</sup></td>
<td class="nump">161<span></span>
</td>
<td class="nump">156<span></span>
</td>
<td class="nump">514<span></span>
</td>
<td class="nump">540<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_EssentialHealthProductCategoryAxis=pfe_HospiraInfusionSystemsMember', window );">Hospira Infusion Systems (HIS) [Member] | Essential Health Business [Member] | EH [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[11]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">281<span></span>
</td>
<td class="nump">97<span></span>
</td>
<td class="nump">879<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_InnovativeProductsCategoryAxis=pfe_InternalMedicineMember', window );">Internal Medicine [Member] | Innovative Health Business [Member] | IH [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,455<span></span>
</td>
<td class="nump">2,243<span></span>
</td>
<td class="nump">7,245<span></span>
</td>
<td class="nump">6,557<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_InnovativeProductsCategoryAxis=pfe_InternalMedicineMember', window );">Internal Medicine [Member] | Innovative Health Business [Member] | IH [Member] | Lyrica [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">1,150<span></span>
</td>
<td class="nump">1,049<span></span>
</td>
<td class="nump">3,382<span></span>
</td>
<td class="nump">3,107<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_InnovativeProductsCategoryAxis=pfe_InternalMedicineMember', window );">Internal Medicine [Member] | Innovative Health Business [Member] | IH [Member] | Eliquis [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">644<span></span>
</td>
<td class="nump">449<span></span>
</td>
<td class="nump">1,813<span></span>
</td>
<td class="nump">1,225<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_InnovativeProductsCategoryAxis=pfe_InternalMedicineMember', window );">Internal Medicine [Member] | Innovative Health Business [Member] | IH [Member] | Chantix / Champix [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">240<span></span>
</td>
<td class="nump">198<span></span>
</td>
<td class="nump">727<span></span>
</td>
<td class="nump">631<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_InnovativeProductsCategoryAxis=pfe_InternalMedicineMember', window );">Internal Medicine [Member] | Innovative Health Business [Member] | IH [Member] | Viagra [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">206<span></span>
</td>
<td class="nump">297<span></span>
</td>
<td class="nump">711<span></span>
</td>
<td class="nump">897<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_InnovativeProductsCategoryAxis=pfe_InternalMedicineMember', window );">Internal Medicine [Member] | Innovative Health Business [Member] | IH [Member] | B M P 2 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">79<span></span>
</td>
<td class="nump">63<span></span>
</td>
<td class="nump">198<span></span>
</td>
<td class="nump">175<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_InnovativeProductsCategoryAxis=pfe_InternalMedicineMember', window );">Internal Medicine [Member] | Innovative Health Business [Member] | IH [Member] | Toviaz [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">62<span></span>
</td>
<td class="nump">60<span></span>
</td>
<td class="nump">187<span></span>
</td>
<td class="nump">191<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_InnovativeProductsCategoryAxis=pfe_InternalMedicineMember', window );">Internal Medicine [Member] | Innovative Health Business [Member] | IH [Member] | All Other Internal Medicine [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">75<span></span>
</td>
<td class="nump">128<span></span>
</td>
<td class="nump">228<span></span>
</td>
<td class="nump">330<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_InnovativeProductsCategoryAxis=pfe_VaccinesMember', window );">Vaccines [Member] | Innovative Health Business [Member] | IH [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,649<span></span>
</td>
<td class="nump">1,641<span></span>
</td>
<td class="nump">4,385<span></span>
</td>
<td class="nump">4,576<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_InnovativeProductsCategoryAxis=pfe_VaccinesMember', window );">Vaccines [Member] | Innovative Health Business [Member] | IH [Member] | Prevnar 13/Prevenar 13 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,522<span></span>
</td>
<td class="nump">1,536<span></span>
</td>
<td class="nump">4,069<span></span>
</td>
<td class="nump">4,302<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_InnovativeProductsCategoryAxis=pfe_VaccinesMember', window );">Vaccines [Member] | Innovative Health Business [Member] | IH [Member] | FSME-IMMUN/TicoVac [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">43<span></span>
</td>
<td class="nump">33<span></span>
</td>
<td class="nump">119<span></span>
</td>
<td class="nump">102<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_InnovativeProductsCategoryAxis=pfe_VaccinesMember', window );">Vaccines [Member] | Innovative Health Business [Member] | IH [Member] | All other Vaccines [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">85<span></span>
</td>
<td class="nump">72<span></span>
</td>
<td class="nump">197<span></span>
</td>
<td class="nump">172<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_InnovativeProductsCategoryAxis=pfe_OncologyMember', window );">Oncology [Member] | Innovative Health Business [Member] | IH [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,616<span></span>
</td>
<td class="nump">1,104<span></span>
</td>
<td class="nump">4,551<span></span>
</td>
<td class="nump">3,206<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_InnovativeProductsCategoryAxis=pfe_OncologyMember', window );">Oncology [Member] | Innovative Health Business [Member] | IH [Member] | Ibrance [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">878<span></span>
</td>
<td class="nump">550<span></span>
</td>
<td class="nump">2,410<span></span>
</td>
<td class="nump">1,492<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_InnovativeProductsCategoryAxis=pfe_OncologyMember', window );">Oncology [Member] | Innovative Health Business [Member] | IH [Member] | Sutent [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">276<span></span>
</td>
<td class="nump">260<span></span>
</td>
<td class="nump">805<span></span>
</td>
<td class="nump">823<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_InnovativeProductsCategoryAxis=pfe_OncologyMember', window );">Oncology [Member] | Innovative Health Business [Member] | IH [Member] | Xalkori [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">146<span></span>
</td>
<td class="nump">140<span></span>
</td>
<td class="nump">442<span></span>
</td>
<td class="nump">415<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_InnovativeProductsCategoryAxis=pfe_OncologyMember', window );">Oncology [Member] | Innovative Health Business [Member] | IH [Member] | Xtandi Alliance [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">150<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">422<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_InnovativeProductsCategoryAxis=pfe_OncologyMember', window );">Oncology [Member] | Innovative Health Business [Member] | IH [Member] | Inlyta [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">84<span></span>
</td>
<td class="nump">95<span></span>
</td>
<td class="nump">256<span></span>
</td>
<td class="nump">304<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_InnovativeProductsCategoryAxis=pfe_OncologyMember', window );">Oncology [Member] | Innovative Health Business [Member] | IH [Member] | Bosulif [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">57<span></span>
</td>
<td class="nump">43<span></span>
</td>
<td class="nump">163<span></span>
</td>
<td class="nump">121<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_InnovativeProductsCategoryAxis=pfe_OncologyMember', window );">Oncology [Member] | Innovative Health Business [Member] | IH [Member] | All other Oncology [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">26<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="nump">54<span></span>
</td>
<td class="nump">49<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_InnovativeProductsCategoryAxis=pfe_InflammationandImmunologyMember', window );">Inflammation and Immunology (I&amp;I) [Member] | Innovative Health Business [Member] | IH [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">960<span></span>
</td>
<td class="nump">2,863<span></span>
</td>
<td class="nump">2,907<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_InnovativeProductsCategoryAxis=pfe_InflammationandImmunologyMember', window );">Inflammation and Immunology (I&amp;I) [Member] | Innovative Health Business [Member] | IH [Member] | Enbrel (Outside the U.S. and Canada) [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">613<span></span>
</td>
<td class="nump">701<span></span>
</td>
<td class="nump">1,818<span></span>
</td>
<td class="nump">2,201<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_InnovativeProductsCategoryAxis=pfe_InflammationandImmunologyMember', window );">Inflammation and Immunology (I&amp;I) [Member] | Innovative Health Business [Member] | IH [Member] | Xeljanz [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">348<span></span>
</td>
<td class="nump">235<span></span>
</td>
<td class="nump">935<span></span>
</td>
<td class="nump">649<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_InnovativeProductsCategoryAxis=pfe_InflammationandImmunologyMember', window );">Inflammation and Immunology (I&amp;I) [Member] | Innovative Health Business [Member] | IH [Member] | Eucrisa [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">15<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">33<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_InnovativeProductsCategoryAxis=pfe_InflammationandImmunologyMember', window );">Inflammation and Immunology (I&amp;I) [Member] | Innovative Health Business [Member] | IH [Member] | All Other Inflammation and Immunology Products [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">23<span></span>
</td>
<td class="nump">24<span></span>
</td>
<td class="nump">78<span></span>
</td>
<td class="nump">57<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_InnovativeProductsCategoryAxis=pfe_RareDiseaseMember', window );">Rare Disease [Member] | Innovative Health Business [Member] | IH [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">569<span></span>
</td>
<td class="nump">585<span></span>
</td>
<td class="nump">1,637<span></span>
</td>
<td class="nump">1,768<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_InnovativeProductsCategoryAxis=pfe_RareDiseaseMember', window );">Rare Disease [Member] | Innovative Health Business [Member] | IH [Member] | BeneFIX [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">151<span></span>
</td>
<td class="nump">176<span></span>
</td>
<td class="nump">453<span></span>
</td>
<td class="nump">543<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_InnovativeProductsCategoryAxis=pfe_RareDiseaseMember', window );">Rare Disease [Member] | Innovative Health Business [Member] | IH [Member] | ReFacto AF/ Xyntha [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">140<span></span>
</td>
<td class="nump">140<span></span>
</td>
<td class="nump">409<span></span>
</td>
<td class="nump">408<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_InnovativeProductsCategoryAxis=pfe_RareDiseaseMember', window );">Rare Disease [Member] | Innovative Health Business [Member] | IH [Member] | Genotropin [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">136<span></span>
</td>
<td class="nump">147<span></span>
</td>
<td class="nump">375<span></span>
</td>
<td class="nump">425<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_InnovativeProductsCategoryAxis=pfe_RareDiseaseMember', window );">Rare Disease [Member] | Innovative Health Business [Member] | IH [Member] | Somavert [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">65<span></span>
</td>
<td class="nump">59<span></span>
</td>
<td class="nump">182<span></span>
</td>
<td class="nump">173<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_InnovativeProductsCategoryAxis=pfe_RareDiseaseMember', window );">Rare Disease [Member] | Innovative Health Business [Member] | IH [Member] | All Other Rare Disease [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">77<span></span>
</td>
<td class="nump">64<span></span>
</td>
<td class="nump">218<span></span>
</td>
<td class="nump">219<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_InnovativeProductsCategoryAxis=pfe_ConsumerHealthcareMember', window );">Consumer Healthcare [Member] | Innovative Health Business [Member] | IH [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 829<span></span>
</td>
<td class="nump">$ 798<span></span>
</td>
<td class="nump">$ 2,522<span></span>
</td>
<td class="nump">$ 2,457<span></span>
</td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Amounts may not add due to rounding.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Lyrica revenues from all of Europe, Russia, Turkey, Israel and Central Asia countries are included in Lyrica EH. All other Lyrica revenues are included in Lyrica IH. Total Lyrica revenues represent the aggregate of worldwide revenues from Lyrica IH and Lyrica EH.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">Viagra revenues from the U.S. and Canada are included in Viagra IH. All other Viagra revenues are included in Viagra EH. Total Viagra revenues represent the aggregate of worldwide revenues from Viagra IH and Viagra EH.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top">The IH business encompasses Internal Medicine, Vaccines, Oncology, Inflammation &amp; Immunology, Rare Disease and Consumer Healthcare. Through December 31, 2016, includes Duavive/Duavee and Viviant (recorded in All other Internal Medicine in 2016), which were transferred from Innovative Health to Essential Health effective January 1, 2017 (recorded in All other LEP (EH) beginning January 1, 2017), in order to align these products with our management of the women&#8217;s health portfolio within EH.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[5]</td>
<td style="vertical-align: top;" valign="top">The EH business encompasses Legacy Established Products, Sterile Injectable Pharmaceuticals, Peri-LOE Products, Biosimilars, Pfizer CentreOne and HIS (through February 2, 2017) and includes all legacy Hospira commercial operations.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[6]</td>
<td style="vertical-align: top;" valign="top">Legacy Established Products primarily include products that have lost patent protection (excluding Sterile Injectable Pharmaceuticals and Peri-LOE Products). Effective January 1, 2017, All other LEP includes Duavive/Duavee and Viviant, which were transferred from Innovative Health (recorded in All other Internal Medicine (IH) in 2016), in order to align these products with our management of the women&#8217;s health portfolio within EH.<span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt"> </sup></span>See note (a) above.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[7]</td>
<td style="vertical-align: top;" valign="top">Sterile Injectable Pharmaceuticals include generic injectables and proprietary specialty injectables (excluding Peri-LOE Products).</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[8]</td>
<td style="vertical-align: top;" valign="top">Peri-LOE Products include products that have recently lost or are anticipated to soon lose patent protection. These products include: Lyrica in Europe, Russia, Turkey, Israel and Central Asia; Viagra in all countries (excluding the U.S. and Canada); and worldwide revenues for Celebrex, Pristiq, Zyvox, Vfend, Revatio and Inspra.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[9]</td>
<td style="vertical-align: top;" valign="top">Biosimilars include Inflectra/Remsima (biosimilar infliximab) in the U.S. and certain international markets, Nivestim (biosimilar filgrastim) in certain European, Asian and Africa/Middle Eastern markets and Retacrit (biosimilar epoetin zeta) in certain European and Africa/Middle Eastern markets.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[10]</td>
<td style="vertical-align: top;" valign="top">Pfizer CentreOne includes revenues from our contract manufacturing and active pharmaceutical ingredient sales operation, including sterile injectables contract manufacturing, and revenues related to our manufacturing and supply agreements, including with Zoetis.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[11]</td>
<td style="vertical-align: top;" valign="top">HIS (through February 2, 2017) includes Medication Management Systems products composed of infusion pumps and related software and services, as well as IV Infusion Products, including large volume IV solutions and their associated administration sets.<span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt"> </sup>&#160;</span><br/></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueGoodsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueGoodsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=pfe_InnovativeHealthandEssentialHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=pfe_InnovativeHealthandEssentialHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=pfe_LyricaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=pfe_LyricaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=pfe_ViagraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=pfe_ViagraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=pfe_AllianceBiopharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=pfe_AllianceBiopharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DistinctBusinessAxis=pfe_InnovativeHealthBusinessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DistinctBusinessAxis=pfe_InnovativeHealthBusinessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=pfe_InnovativeHealthSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=pfe_InnovativeHealthSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DistinctBusinessAxis=pfe_EssentialHealthBusinessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DistinctBusinessAxis=pfe_EssentialHealthBusinessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=pfe_EssentialHealthSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=pfe_EssentialHealthSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_EssentialHealthProductCategoryAxis=pfe_LegacyEstablishedProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_EssentialHealthProductCategoryAxis=pfe_LegacyEstablishedProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=pfe_LipitorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=pfe_LipitorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=pfe_PremarinFamilyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=pfe_PremarinFamilyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=pfe_NorvascMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=pfe_NorvascMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=pfe_EpiPenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=pfe_EpiPenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=pfe_XalatanXalacomMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=pfe_XalatanXalacomMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=pfe_EffexorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=pfe_EffexorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=pfe_ZoloftMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=pfe_ZoloftMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=pfe_ZithromaxZmaxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=pfe_ZithromaxZmaxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=pfe_RelpaxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=pfe_RelpaxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=pfe_XanaxXanaxXRMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=pfe_XanaxXanaxXRMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=pfe_OtherLegacyEstablishedProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=pfe_OtherLegacyEstablishedProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_EssentialHealthProductCategoryAxis=pfe_SterileInjectablePharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_EssentialHealthProductCategoryAxis=pfe_SterileInjectablePharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=pfe_MedrolMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=pfe_MedrolMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=pfe_SulperazonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=pfe_SulperazonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=pfe_FragminMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=pfe_FragminMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=pfe_TygacilMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=pfe_TygacilMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=pfe_PrecedexMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=pfe_PrecedexMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=pfe_AllOtherSterileInjectablePharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=pfe_AllOtherSterileInjectablePharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_EssentialHealthProductCategoryAxis=pfe_PeriLOEProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_EssentialHealthProductCategoryAxis=pfe_PeriLOEProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=pfe_CelebrexMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=pfe_CelebrexMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=pfe_VfendMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=pfe_VfendMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=pfe_PristiqMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=pfe_PristiqMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=pfe_ZyvoxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=pfe_ZyvoxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=pfe_RevatioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=pfe_RevatioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=pfe_AllOtherPeriLOEProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=pfe_AllOtherPeriLOEProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_EssentialHealthProductCategoryAxis=pfe_BiosimilarsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_EssentialHealthProductCategoryAxis=pfe_BiosimilarsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=pfe_InflectraRemsimaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=pfe_InflectraRemsimaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=pfe_AllOtherBiosimilarsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=pfe_AllOtherBiosimilarsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_EssentialHealthProductCategoryAxis=pfe_CentreOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_EssentialHealthProductCategoryAxis=pfe_CentreOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_EssentialHealthProductCategoryAxis=pfe_HospiraInfusionSystemsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_EssentialHealthProductCategoryAxis=pfe_HospiraInfusionSystemsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_InnovativeProductsCategoryAxis=pfe_InternalMedicineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_InnovativeProductsCategoryAxis=pfe_InternalMedicineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=pfe_EliquisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=pfe_EliquisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=pfe_ChantixChampixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=pfe_ChantixChampixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=pfe_BMP2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=pfe_BMP2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=pfe_ToviazMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=pfe_ToviazMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=pfe_AllOtherInternalMedicineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=pfe_AllOtherInternalMedicineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_InnovativeProductsCategoryAxis=pfe_VaccinesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_InnovativeProductsCategoryAxis=pfe_VaccinesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=pfe_PrevnarPrevenarFamilyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=pfe_PrevnarPrevenarFamilyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=pfe_FSMEIMMUNTicoVacMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=pfe_FSMEIMMUNTicoVacMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=pfe_OtherVaccinesProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=pfe_OtherVaccinesProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_InnovativeProductsCategoryAxis=pfe_OncologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_InnovativeProductsCategoryAxis=pfe_OncologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=pfe_IbranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=pfe_IbranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=pfe_SutentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=pfe_SutentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=pfe_XalkoriMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=pfe_XalkoriMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=pfe_XtandiAllianceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=pfe_XtandiAllianceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=pfe_InlytaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=pfe_InlytaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=pfe_BosulifMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=pfe_BosulifMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=pfe_OtherOncologyProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=pfe_OtherOncologyProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_InnovativeProductsCategoryAxis=pfe_InflammationandImmunologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_InnovativeProductsCategoryAxis=pfe_InflammationandImmunologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=pfe_EnbrelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=pfe_EnbrelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=pfe_XeljanzMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=pfe_XeljanzMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=pfe_EucrisaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=pfe_EucrisaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=pfe_AllOtherInflammationandImmunologyProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=pfe_AllOtherInflammationandImmunologyProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_InnovativeProductsCategoryAxis=pfe_RareDiseaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_InnovativeProductsCategoryAxis=pfe_RareDiseaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=pfe_BeneFIXMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=pfe_BeneFIXMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=pfe_ReFactoAfXynthaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=pfe_ReFactoAfXynthaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=pfe_GenotropinMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=pfe_GenotropinMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=pfe_SomavertMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=pfe_SomavertMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=pfe_AllOtherRareDiseaseProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=pfe_AllOtherRareDiseaseProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_InnovativeProductsCategoryAxis=pfe_ConsumerHealthcareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_InnovativeProductsCategoryAxis=pfe_ConsumerHealthcareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>99
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M_O"["OO>NIW[Q\870=7 K[M07U!+ P04    " #5@&E+F5R<(Q &  "<)P
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M5\X5U2'!)QU,I7OTM&#TJLPTTW,Q-*IAH7@W-F$P_1,H_@!02P,$%     @
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M/77]Q]1_;O8O]/=?NGHW_E@A.OQBXO9_4$L#!!0    ( -6 :4NF$.?</@8
M +LC   8    >&PO=V]R:W-H965T<R]S:&5E=#,N>&ULC9I;3^M&%(7_2I1W
MCCT7WR) PDDPE5H)G:KMLP$#T4GBU#9P^N\[=DQ.LM<:X 42SS>7-7LN:R8^
M?ZN;'^US5763GYOUMKV8/G?=;A8$[?USM2G;;_6NVKJ4Q[K9E)W[VCP%[:ZI
MRH<ATV8=Z#",@TVYVDXOSX=GM\WE>?W2K5?;ZK:9M"^;3=G\EU?K^NUBJJ;O
M#[ZOGIZ[_D%P>;XKGZH_J^ZOW6WCO@6'4AY6FVK;KNKMI*D>+Z97:G9CLC[#
M0/R]JM[:H\^37LI=7?_HO_SV<#$-^Q95Z^J^ZXLHW;_7:EZMUWU)KAW_CH5.
M#W7V&8\_OY=^/8AW8N[*MIK7ZW]6#]WSQ32=3AZJQ_)EW7VOWVZJ45 TG8SJ
M?Z]>J[7#^Y:X.N[K=3O\G=R_M%V]&4MQ3=F4/_?_5]OA_]M8_GLVGD&/&?17
M,Y@Q@SED<(W]*(,=,]A?&>R'&:(Q0_35&N(Q0WS(\'$%R<@G7VU1.F9(3RL(
M]L$8HKLHN_+RO*G?)LU^@.[*?AZH6>K&SWW_<!@N0YH+<.N>OEXFX7GPVI<S
M(O,]HH\0'9TB2T34@0A<_8=&:-:(N<8:3BM8$"(6;?BTD.+#0DZ::6A?F2&_
M.>XKCTQ+\]LAOSW*;T5'YH@D0L5\CR0#LMVK2*-4]!="RD0R:@AE82RZ]1I;
M%(MR"BPGMA*Z^;"<D\Z+:.=%V#-&=!XBL1*=MT>BHZ:FB>P[9*Q*1-<AX_I7
MCC>$LBSEFF.J.4;-5F@FB.CY>0S-.!,]MT!$+ )+))023/%1*2=J$ZHV02EB
M,.:(0(03$F'1(PMD,,+(*"LK*Q#R1CBEFE/4+!J2(P*:4XQP)(*S((R"-91!
M-A.B"90EGDAG5'6&JL4DS DBVC'/H!V1T+- 1,F.62)S9C(Q00J$=.J1K$*^
MT8:@*!5-R0D#L1Z9XZ9(U0318MU8$N8LLG(%8U2<^81['(9"X4H*1P:%*VB+
M2:V4CI"6)2T)%&>IE(Y08GW*J:VY4AJ5:ZD<&1CH(W,2!0W;%J.4TE([HV0\
M"DKIS*.>NR5E4+W<L0F#<3<XB4,8\@22"]>20)&"N",4*X_-4]SG*?0Z<J#F
MA$'EED0AE'LWH^0P6S+(0M1I?3[MW*8I-&&I-+F,B:5VXK"LW-.^ BT)9"U$
MG9D^STZNN%E3:,52N9<S!I2CC3(PUY'1J=2-3"JW<L(DGB.1XJ9-H25+Y5Y.
M&!SK:*7.I/U;$"B&24X*4@J&.E*1;Z!SYZ;0E\GNS0F#PIGGDKJ147":(Q#L
MCP6!K+4>X=R\*;1F&1@99% X>BJ8WXAD()OX-[ QQ <>+9&G-Q3<OFEBW^2Z
MQA@YNS5Q5%:.<PI)X0Q2<J4H**43CW;NX#2ZLTPZ.,*@=K14<!)EC%S9&*/D
M2/\$.M7-_9LF_DVN;82!D:[13<D93A"XWT($+KA(1;YASDV;1D.62<M*&)2,
M+NI,;KH+ DEFR0I2D5S."17Y8LT]FT8_)@^!.6%0.'JH#+9O B6RMB6!5"RW
MNX)1QY<9I]JY9]/HQS+I5QDC+YHTFJ@S><9=$$@I&.ND) U6G1;ENWCFIDVC
M(<ODI1-A,.SD?BR4#5X0*I;W/4M65"K7G8)1)O1X-\V]FT9?EDG'2A@4CV;*
MI&#>"*5#(\_FA%)A%LG[&((EB>\V7G,'I]&=R5N G# HG[BS3(I'1IY3" +'
M%,)HWSK'W9LF[DW:5L*@Z#V3G,0\2J1LI%S,Y>&44"[F\HQ?$"Q)K&>I,]+&
MG:9RHV/0Q&C9.82)/2$PW%88M P1U$(8SW'4>'ZL^GR7S@GCK85OFX9LB7+;
M)(RW%KY!&?++CC3?C/%<6!F^%QBRSLOED# J]-P*&K[J&K*BRF6',-Z+&,-7
M-X,KEP4UR*C08Q@-7T\,KA5P19532$Z:X.@GZTW5/ TO-+23^_IEVPW734>/
M#V]-Y+K_S5L\GZO90I'G2S6[H<_U[)J54^C9#7M^9<)984*2XE8'E\+J<#/:
MI;#2W"QT*8:F6)=B:4KD4B*:$KN4F*8D+B6A*:E+26E*YE*&%U."7S'9O];R
M1]D\K;;MY*[NNGHSO$/P6-==Y0(>?G.3\;DJ'PY?UM5CUW],W.=F_SK)_DM7
M[\9798+#^SJ7_P-02P,$%     @ U8!I2THN'U:G 0  T@,  !@   !X;"]W
M;W)K<VAE971S+W-H965T-"YX;6Q]4^UNVR 4?17$ Q1_M$T7V9;63%,G;5+4
M:>UO8E_'J&!<(''W]KM@ZB:9U3^&>SGG< Z&8M3FQ78 CKPIV=N2=LX-:\9L
MW8'B]DH/T.-*JXWB#DNS9W8PP)M 4I)E27++%!<]K8K0VYJJT <G10];0^Q!
M*6[^WH/48TE3^MYX%/O.^0:KBH'OX3>X/\/68,5FE48HZ*W0/3'0EO1KNM[D
M'A\ 3P)&>S(G/LE.ZQ=?_&A*FGA#(*%V7H'C<(0-2.F%T,9KU*3SEIYX.G]7
M_QZR8Y8=M[#1\EDTKBOI'24-M/P@W:,>'R#FN:$DAO\)1Y (]TYPCUI+&[ZD
M/EBG551!*XJ_3:/HPSA.*ZOK2%LF9)&0S83T<T(>"?D%@4W.0M1OW/&J,'HD
M9OI9 _=W(EWG>)BU;X:S"VN8UF+W6*7)3<&.7BAB[B=,=H:Y/<=L_L=D'Q"&
M%F8?V:*/+/"OS_98+0ODBP+Y@L#=19 ES)>+()]C)B/LY'3];?_%S5[TENRT
MPQ\5CK/5V@'J)5=XA3I\8',AH75^NL*YF:[95#@]Q!?$YF=<_0-02P,$%
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M3Z7VPB< B_4PM:XB+$$"$G3<* "2OU](O7F5YWPM"#!7NM3*BK &"6C0<:<
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MHE$8>>O'NK%CU^_@U9#F3HB&A&A,B/&'"?&0$(\)8?)A0C(D)+,$U)=B[^9
M%"ERP3M/]/]N2\Q#%&X2??NE"=K+MGOZ>J2.WHLPBW-T-T:#9M]KHHDF>E0<
MEHHP#$<-T@0C1N3$B*Q!_("1N UBIT%L#9('@_21<K?41.M9J;T$6TEC)>DZ
MF!6[U&3!VLV:.%D3!VLV8UUJ%JR]))UPA!IV9G1PJ))5@-V\J9,W=?#B&>]2
ML^!-%_<6!WC^)"U%212E;MIL1ONPB9VEX/]B[I:2=#4['TW>+@;B:CN7]$I^
M:Y1Y0"?1L3GN;"^;Q[/-/G/$=WBSM_T"_;/O._%W(JYU([T35[HGV#?WPKD"
M31X\Z<NK=/,?%Q0NRDRQGHN^!?8+Q=NANZ/Q$U/\!5!+ P04    " #5@&E+
M9QOISWD&  !4)0  &    'AL+W=O<FMS:&5E=',O<VAE970W+GAM;(V:W6[C
M-A"%7\7PO5?D\$>2X02(8Q<MT *++=I>*PZ3&&M;KJ3$V[<O)3M>>^9P-S>)
M)1X.#REJ/E+2[% W7]N7$+K1M^UFU]Z,7[IN/\VR=O42ME7[J=Z'72QYJIMM
MU<7#YCEK]TVH'H=*VTU&2OEL6ZUWX]O9<.YS<SNK7[O->A<^-Z/V=;NMFO_F
M85,?;L9Z_'[BR_KYI>M/9+>S??4<_@S=7_O/33S*SE$>U]NP:]?U;M2$IYOQ
MG9XNG>\K#(J_U^'07OP>]5UYJ.NO_<%OCS=CU3L*F[#J^A!5_/<6[L-FTT>*
M/OX]!1V?V^PK7OY^C_[+T/G8F8>J#??UYI_U8_=R,R[&H\?P5+UNNB_UX==P
MZI ;CTZ]_SV\A4V4]TYB&ZMZTPY_1ZO7MJNWIRC1RK;Z=OR_W@W_#Z?X[]5P
M!3I5H(]6,*<*YEPAFOU1!7NJ8,\5[ _U[J1WWQL8*F3'K@]CN:BZZG;6U(=1
M<YP.^ZJ?=7KJXM5:]2>'BS.4Q>%LX]FW6^V+6?;6!SII[H\:NM2<%5F,?FZ"
M4!/W)*K3=0-+H/"X!0,[88;ZYJH3)0Y@80 [!+ 7 :R[]CB7$ITK-E!'33YH
M=H.F5-ZSSDJ1M]YAMPZZ=;*[>>**>!C @[ZP:S*7&L^&Y/XH<1<]L;YDHB40
MD2JPVQRZS8%;P]Q*C7";"R.&^+61&JUM8BH6T&P!S%IF%FFXVT(X<?RND1)M
MB;#9$IHM@1$V)'.I$2-;"B-D-3,K-1-M3&+::X5SE0)^<^87B(3AD^9J=,7$
M12*3&%Z=2*X:&"ZX82F2AC48/F7YC$"R/$\-,LS6=YJ YY)[EB+IF:09Y_F\
M "J?R X:)W]MI.%"<<-(I+EC(QT;;RVW#&3:%:FI@8FC 4\*GH.A2+BVPDZ9
M4\%-2Y56VB6PH3%X-"!/81(A,'HT8$_!$R00R>DEP3+1Y'A&AS)M;,(T)I &
M""KX @&(I&D)F$FD?\E- UF\5A?KC6O7&$4:<*;@Z1V(I&L H[PPW+14D?)%
M*OM@(FF I$*D^ \P20,HY4[<%5+E;<HR82H1H%+!DSP0"<LD@3,A)]8H2&;S
MU *0,)D(D*G@61Z(I&F)G C_G'N6*E_JU#AC,!$ 4\GS/!!)RP!,6BG%/2-9
M[O/$QH(PG0B I]3<M11)UX@Z?)XMD:I,+& )DXD =$I.)B"2CB5RG.:I#HA\
M(LT1AA(YX)?O#X!(^G5RAR#&5VKBS:<2."',0/(2HV4J!"82 2+Q%>P<B&2G
M)6IRI7AN!RIORCQA&>.( (Y*CB,@DI8E:":YYS?5$LF,H52>Q#PBP*.2\PB(
MI&E)&N?XE@.(XMV;6& 9C",#<%1R' &1<&S _H?XQGN)5,HD!ME@&!D HY+#
M"(BD9;#_L9;OOY=09G1B.AN,(R-)0YPA<R"2IM$^2>+HI[)KTXD'91(TI#B-
M@$B:!IQQN1.FD<RF@&0PD(QD#2D.)""2I@%KQ(8!B,K4(R"#B60D;(BGU#D0
MR;V= ;@A$O<@4%TB^]HS9I*16RY2?%\&1, SV'&57DX-($NO"0W&H)&$(\4Q
M"$1R:@# \44LT$Q2JT&#&6@DWN(>B?O]  ,->/C'M]%+((K;2)O*<YB 1L*-
M%"<@$$G+8$<FGKHM4"2^" .1C+<)YEB,22L)>/E8^M@M(!+=LA* E/,'9@L4
MB7<+15*I=:'%*+5:+"UCC$0(##8+P*8YV*"(9P(KD67%@RD@2C#-8J99P#3-
M\0!%PJ^D%7\NOP2:E-W$JR8KKY!.+/$LYHL%?-$\5P.1G+L2'-H23R-095*]
MQGBQ "^:)VH@DI8E-K3F2Y@E5.6)Q&<Q6RQ@B^:Y&HBDY:,FOTK#XO$94AF7
M6'A8CI?K4IS)+<CD?)4--*DWJ0XG5B<SG>.M (U/Y#F'\YP#NP&^C@4:EWBU
MX' J=&#YSM=Q0)-L!2<P]_/U]AQHDJW@O./  IEC'&@HM2URB7?3(.UPK )-
MLC,XG3B9*:SH#$HYO)GLXCN);6B>AV]6VM&J?MUUPRNRB]/G#V/FU']HP<[?
MZ^E2H_,T72#]G2VFBW@?RY)X$\:2$I4X-5TX!4MT+$'MQPD:2Y"#.*EBB8$E
M-I986.)BB8,E/I8,7PQEWT?R^+W1'U7SO-ZUHX>ZZ^KM\+G)4UUW(5XF]2E.
MAI=0/9X/-N&IZW_F\7=S_,[G>-#5^],W3-GY0ZK;_P%02P,$%     @ U8!I
M2ZW,S@*S 0  XP,  !@   !X;"]W;W)K<VAE971S+W-H965T."YX;6QMD]V.
MFS 0A5_%\@/$X+";;01(S5:K5FJE:*NVUPX,P5H;4]L)V[?OV!!$4VZPQYPY
MWXQ_\L'8-]<">/*N5><*VGK?[QES50M:N(WIH<,_C;%:> SMF;G>@JACDE:,
M)\DCTT)VM,SCVM&6N;EX)3LX6N(N6@O[YP#*# 5-Z6WA59Y;'Q98F??B#-_!
M_^B/%B,VN]120^>DZ8B%IJ ?T_TA"_HH^"EA<(LY"9V<C'D+P9>ZH$DH"!14
M/C@('*[P#$H%(RSC]^1)9V1(7,YO[B^Q=^SE)!P\&_5+UKXMZ!,E-33BHORK
M&3[#U,\#)5/S7^$*"N6A$F141KGX)=7%>:,G%RQ%B_=QE%T<A\G_EK:>P*<$
M/B?P7>QE!,7*/PDORMR:@=AQ[WL1CCC=<]R;*BS&K8C_L'B'J]>2IQ]R=@U&
MD^8P:OA2PY-9P]!_AO!5"(\&V3\&Z1UDU*1)%'51M-WP=<IVE;)=H? [RJC9
M+2 9?UJ'9*N0; 6RO8-D_T%V#W<,MCB?</V_"7N6G2,GX_&HXX$TQGA NV2#
M=ZK%%S<'"AH?ICN<V_'>C8$W_?2DV/RNR[]02P,$%     @ U8!I2YX 2/ZQ
M 0  T@,  !@   !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q]4]MNVS ,_15!
M'U EBML5@6V@Z5!TP 8$';8^*S9]075Q)3EN_WZ4[+A>9^S%(FF>PT.*2@=C
M7UP#X,F;DMIEM/&^VS/FB@:4<%>F XU_*F.5\.C:FKG.@B@C2$G&-YL;ID2K
M:9[&V-'FJ>F];#4<+7&]4L*^'T":(:-;>@D\M77C0X#E:2=J^ G^5W>TZ+&9
MI6P5:-<:32Q4&;W;[@])R(\)OUL8W,(FH9.3,2_!^59F=!,$@83"!P:!QQGN
M0<I A#)>)TXZEPS I7UA?XB]8R\GX>#>R.>V]$U&;RDIH1*]]$]F>(2IGVM*
MIN:_PQDDI@<E6*,PTL4O*7KGC9I84(H2;^/9ZG@.$_\%M@[@$X!_ K"Q4%3^
M57B1I]8,Q(ZS[T2XXNV>XVR*$(RCB/]0O,/H.><\2=DY$$TYAS&'+W*V<P9#
M]KD$7RMQX/_ ^3I\MZIP%^&[OQ1>KQ,DJP1))$C^V^):SLVG(FPQ4P6VCMOD
M2&%Z'3=Y$9T7]H['._E('[?]A[!UJQTY&8\W&^=?&>,!I6RN<(4:?&"S(Z'R
MP?R"MAW7;'2\Z:87Q.9GG/\!4$L#!!0    ( -6 :4MC;QARL0$  -(#   9
M    >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;'U3VV[;, S]%4$?4"5*NG:!
M;:!I,6S !@0=MCTK-FT+U<63Y+C[^U&RXWF=L1>+I'D.#RDJ&ZQ[\2U (*]:
M&9_3-H3NP)@O6]#"W]@.#/ZIK=,BH.L:YCL'HDH@K1C?;-XQ+:2A199B)U=D
MM@]*&C@YXGNMA?MU!&6'G&[I-? LFS;$ "NR3C3P%<*W[N308S-+)348+ZTA
M#NJ</FP/QWW,3PG?)0Q^89/8R=G:E^A\JG*ZB8) 01DB@\#C H^@5"1"&3\G
M3CJ7C,"E?67_D'K'7L["PZ-5/V05VIS>4U)!+7H5GNWP$:9^;BF9FO\,%U"8
M'I5@C=(JG[ZD['VP>F)!*5J\CJ<TZ1PF_BML'< G '\#8&.AI/Q)!%%DS@[$
MC;/O1+SB[8'C;,H83*-(_U"\Q^BEX/PN8Y=(-.4<QQR^R-G.&0S9YQ)\K<21
M_P/GZ_#=JL)=@N_^4GB_3K!?)=@G@OU_6US+>?^F"%O,5(-KTC9Y4MK>I$U>
M1.>%?>#I3OZDC]O^1;A&&D_.-N#-IOG7U@9 *9L;7*$6']CL**A#-._0=N.:
MC4ZPW?2"V/R,B]]02P,$%     @ U8!I2RS&[I"O 0  T@,  !D   !X;"]W
M;W)K<VAE971S+W-H965T,3$N>&UL?5/;CM0P#/V5*!^PZ62&BT9MI9U%""20
M1HN YTSKMM'F4I)TNOP]3MHI92F\-+;K<WSL./EHW9/O  )YULKX@G8A]$?&
M?-6!%O[.]F#P3V.=%@%=US+?.Q!U FG%>):]9EI(0\L\Q<ZNS.T0E#1P=L0/
M6@OW\P3*C@7=T5O@4;9=B %6YKUHX0N$K_W9H<<6EEIJ,%Y:0QPT!;W?'4^'
MF)\2ODD8_<HFL9.+M4_1^5@7-(N"0$$5(H/ XPH/H%0D0AD_9DZZE(S M7UC
M?Y]ZQUXNPL.#5=]E';J"OJ6DAD8,*CS:\0/,_;RB9&[^$UQ!87I4@C4JJWSZ
MDFKPP>J9!:5H\3R=TJ1SG/EOL&T GP'\!8!-A9+R=R*(,G=V)&Z:?2_B%>^.
M'&=3Q6 :1?J'XCU&KR7?9SF[1J(YYS3E\%7.;LE@R+Z4X%LE3OPO.-^&[S<5
M[A-\_X?"?]0_;!(<$L'AORUNY;Q4R58SU>#:M$V>5'8P:9-7T65A[WFZD]_I
MT[9_%JZ5QI.+#7BS:?Z-M0%02G:'*]3A UL<!4V(YANTW;1FDQ-L/[\@MCSC
M\A=02P,$%     @ U8!I2ZWE%<2U 0  T@,  !D   !X;"]W;W)K<VAE971S
M+W-H965T,3(N>&UL?5/;;MP@$/T5Q >$7>Q<M+(M95-5K=1*JT1MGEE[?%&X
M.(#7Z=]GP([KME9?@!GFG#DS#-EH[(MK 3QY4U*[G+;>]P?&7-F"$N[*]*#Q
MIC96"8^F;9CK+8@J@I1D?+>[84ITFA99])ULD9G!RT[#R1(W*"7LKR-(,^9T
M3S\<CUW3^N!@1=:+!I[ _^A/%BVVL%2= NTZHXF%.J?W^\,Q#?$QX&<'HUN=
M2:CD;,Q+,+Y6.=T%02"A](%!X':!!Y R$*&,UYF3+BD#<'W^8/\<:\=:SL+!
M@Y'/7>7;G-Y14D$M!ND?S?@%YGJN*9F+_P87D!@>E&".TD@75U(.SALULZ 4
M)=ZFO=-Q'Z>;Y':&;0/X#. +X"[F85.BJ/R3\*+(K!F)G7K?B_#$^P/'WI3!
M&5L1[U"\0^^EX$F2L4L@FF..4PQ?Q>R7"(;L2PJ^E>+(_X'S;7BRJ3")\.0/
MA>DV0;I)D$:"]+\E;L5<_Y6$K7JJP#9QFAPIS:#C)*^\R\#>\_@FO\.G:?\N
M;--I1\[&X\O&_M?&>$ INRL<H18_V&)(J'TXWN+93F,V&=[T\P]BRS<NW@%0
M2P,$%     @ U8!I2TYG/SFU 0  T@,  !D   !X;"]W;W)K<VAE971S+W-H
M965T,3,N>&UL?5/;;MP@$/T5Q >$7;Q-5BO;4C91E4JMM$K5YIFUQQ<%& ?P
M.OW[ G8<)[7Z LPPY\R984@'-,^V 7#D54EM,]HXUQT8LT4#2M@K[$#[FPJ-
M$LZ;IF:V,R#*"%*2\<WFFBG1:IJGT7<R>8J]DZV&DR&V5TJ8/T>0.&1T2]\<
MCVW=N.!@>=J)&GZ"^]6=C+?8S%*V"K1M41,#549OMX?C+L3'@-\M#'9Q)J&2
M,^)S,+Z5&=T$02"A<(%!^.T"=R!E(/(R7B9..J<,P.7YC?UKK-W7<A86[E ^
MM:5K,KJGI(1*]-(]XO  4SU?*)F*_PX7D#X\*/$Y"I0VKJ3HK4,UL7@I2KR.
M>ZOC/HPW23+!U@%\ O 9L(]YV)@H*K\73N2IP8&8L?>="$^\/7#?FR(X8ROB
MG1=OO?>2\^0Z99= -,4<QQB^B-G.$<RSSRGX6HHC_P?.U^')JL(DPI,/"F_6
M"7:K!+M(L/MOB6LQ^T])V**G"DP=I\F2 GL=)WGAG0?VEL<W>0\?I_V','6K
M+3FC\R\;^U\A.O!2-E=^A!K_P69#0N7"\<:?S3AFH^&PFWX0F[]Q_A=02P,$
M%     @ U8!I2WX^*=^T 0  T@,  !D   !X;"]W;W)K<VAE971S+W-H965T
M,30N>&UL?5/;;IPP$/T5RQ\0LX8VZ0J0LJFJ5FJE5:JVSUX8P(K-4-LLZ=_7
M-H2B!N7%]HS/.7/Q.)_0/-D.P)%GK7I;T,ZYX<B8K3K0PM[@ +V_:=!HX;QI
M6F8' Z*.)*T83Y+W3 O9TS*/OK,I<QR=DCV<#;&CUL+\.8'"J: '^N)XE&WG
M@H.5^2!:^ [NQW VWF*K2BTU]%9B3PPT!;T_'$]9P$? 3PF3W9Q)J.2"^!2,
M+W5!DY 0**A<4!!^N\(#*!6$?!J_%TVZA@S$[?E%_5.LW==R$18>4/V2M>L*
M>D=)#8T8E7O$Z3,L];RC9"G^*UQ!>7C(Q,>H4-FXDFJT#O6BXE/1XGG>91_W
M:;ZY31?:/H$O!+X2[F(<-@>*F7\43I2YP8F8N?>#"$]\.'+?FRHX8ROBG4_>
M>N^UY.F'G%V#T((YS1B^P1Q6!//J:PB^%^+$7]'Y/CW=S3"-]'1+SY)]@6Q7
M((L"V9LE[F"R_XMDFYYJ,&V<)DLJ'/LXR1OO.K#W/+[)/_@\[=^$:65OR06=
M?]G8_P;1@4\EN?$CU/D/MAH*&A>.M_YLYC&;#8?#\H/8^HW+OU!+ P04
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MQGA *;LK'*$6/]AB**A].'["LYW&;#*\Z><?Q)9O7/P!4$L#!!0    ( -6
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M&TSU7%,R%?\ %U 8'I1@CL(H%U=2],X;/;&@%"U>QEVV<1_&F^O=!%L'\ G
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M<N%XX\]F'+/1<-A-/XC-WSC_#5!+ P04    " #5@&E+@NL/N+8!  #2 P
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M>/!G,X[9:#CLIA_$YF^<OP-02P,$%     @ U8!I2W40GO^U 0  T@,  !D
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MZ[=W;J_'MSP:5G73F)+Y7Y'_!U!+ P04    " #5@&E+^NO6K-P!   !!0
M&0   'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6QU5&UOVR 0_BN('U <XB1M
M9%MJ.E6;M$E1IW6?B7U^4<&X@./NWP^PXUD>_1*X\_-R1SB20:HW70,8]"%X
MJU-<&],="=%Y#8+I.]E!:[^44@EF;*@JHCL%K/ DP0F-HCT1K&EQEOC<666)
M[ UO6C@KI'LAF/IS BZ'%&_P+?'25+5Q"9(E':O@)YA?W5G9B,PJ12.@U8UL
MD8(RQ8^;X^G@\![PVL"@%WOD.KE(^>:";T6*(U<0<,B-4V!VN<(3<.Z$;!GO
MDR:>+1UQN;^I/_O>;2\7IN%)\M]-8>H4WV-40,EZ;E[D\!6F?G883<U_ARMP
M"W>56(]<<NU_4=YK(\6D8DL1[&-<F]:OPZ1_HX4)="+0%8&,1K[R+\RP+%%R
M0&H\^XZYOWASI/9L<I?T1^&_V>*US5XS^O"0D*L3FC"G$4,7F,V,(%9]MJ A
MBQ/]CT[#]&VPPJVG;Y?T^#XL$ <%8B\0+P2V4;1J,83YI,E=T&07$* KDQ#F
M$Y-]T&0?$-BN3$*8.&QR")H< @*[E4D(LU^9D,45%* J/WP:Y;)O_> OLO-\
M/U)_A?_!Q\?A!U-5TVITD<8.@K^NI90&;"G1G3W5VKY'<\"A-&Y[L'LU3N48
M&-E-#PZ97[WL+U!+ P04    " #5@&E+VS4SH<4!   W!   &0   'AL+W=O
M<FMS:&5E=',O<VAE970S,"YX;6QU5.MNVR 4?A7$ Q2;Q$L6V9::5E,GK5+4
M:=MO8A]?5# NX+A]^P%V/2^E?PP<OLLYP'$Z2O6L&P"#7@7O=(8;8_H#(;IH
M0#!](WOH[$XEE6#&+E5-=*^ E9XD.*%1](4(UG8X3WWLI/)4#H:W'9P4TH,0
M3+T=@<LQPS%^#SRU=6-<@.1ISVKX">97?U)V11:5LA70Z59V2$&5X=OX<$P<
MW@-^MS#JU1RY2LY2/KO%]S+#D4L(.!3&*3 [7. ..'="-HV761,OEHZXGK^K
M?_.UVUK.3,.=Y'_:TC09WF-40L4&;I[D^ !S/0E&<_$_X +<PETFUJ.07/LO
M*@9MI)A5;"J"O4YCV_EQG'9V\4P+$^A,H MA[WW(9.0SOV>&Y:F2(U+3V??,
M77%\H/9L"A?T1^'W;/+:1B_Y)MJEY.*$9LQQPM 5)EX0Q*HO%C1D<:0?Z#1,
MWP0SW'CZ9DU//O'?!@6V7F#[7XG[JQ)#F*]ADR1HDGP4B*,KDQ#FNA*RNC@!
MJO9/5J-"#IUOEU5TZ8I;ZB_^'WQJJ4>FZK;3Z"R-?3[^DBLI#=A4HAN;2V.[
M>%EPJ(R;[NQ<36]Y6AC9SVU*EG]%_A=02P,$%     @ U8!I2R[R:NFU 0
MT@,  !D   !X;"]W;W)K<VAE971S+W-H965T,S$N>&UL;5/;;IPP$/T5RQ\0
M+X8TT0J0LJFJ5FJE5:JVSUX8+HHOU#9+^O<=&T)HRHOM&9]SYN)Q/AG[[#H
M3UZ4U*Z@G??#D3%7=:"$NS$#:+QIC%7"HVE;Y@8+HHXD)1D_'#XP)7I-RSSZ
MSK;,S>AEK^%LB1N5$O;/":29"IK05\=3WW8^.%B9#Z*%[^!_#&>+%EM5ZEZ!
M=KW1Q$)3T(?D>,H"/@)^]C"YS9F$2B[&/ ?C2UW00T@()%0^* C<KO (4@8A
M3./WHDG7D(&X/;^J?XJU8RT7X>#1R%]][;N"WE-20R-&Z9_,]!F6>FXI68K_
M"E>0" ^98(S*2!=74HW.&[6H8"I*O,Q[K^,^S3=WR4+;)_"%P%?"?8S#YD Q
M\X_"BS*W9B)V[OT@PA,G1XZ]J8(SMB+>8?(.O=<R37C.KD%HP9QF#-]@DA7!
M4'T-P?="G/A_=+Y/3W<S3",]W=)OLWV!;%<@BP+9/R6F[TK<P[P/PC8]56#;
M.$V.5&;4<9(WWG5@'WA\DS?X/.W?A&U[[<C%>'S9V/_&& ^8RN$&1ZC##[8:
M$AH?CG=XMO.8S88WP_*#V/J-R[]02P,$%     @ U8!I2S]*N%C@ 0   04
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MFC7Q8FF)Z_F[^B?7N^GE2A4\"O:S+763X2-&)51T8/I9C)]A[B?&:&[^*]R
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MY70KIT"+?GYPR/+JY7\ 4$L#!!0    ( -6 :4NEI(XL$0,  "4,   9
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MG1"2J_#C.U67 \^V_4/!=[*]3=5]W9VZNP<ICN8?A:C_6V/Q'U!+ P04
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MR"K]Z^TNE12Y\:)"R9.WYC\M]/_-^+^;P0;8&.#6@,3O&A!C0%H#1-\UH,:
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M]PUJ(:YENVILKR<DNU6IV=J99V++-C6 O(#CV;]?<0EKI%;"2PRMTY?34I\
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MPNQ X@0(N@)R!>4,DC2@K$'2!I0W2.* ,@=)'5#N(,D#RAXD?4#Y@VP H!T
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M;O5>C/=T#!3OIR<(S>]@_@=02P,$%     @ U8!I2WM?WF.& @  5PD  !D
M  !X;"]W;W)K<VAE971S+W-H965T-# N>&ULE5;MCILP$'P5Q ,<V$!((H*4
M#U6MU$K15;W^=H@3T &FMA.N;U_;$([ <LW]";8S.[.[9K"CFO%7D5(JK;<B
M+\7*3J6LEHXCDI061#RQBI;JGQ/C!9%JRL^.J#@E1Q-4Y YVW9E3D*RTX\BL
M[7D<L8O,LY+NN24N14'XWPW-6;VRD7U;>,[.J=0+3AQ5Y$Q_4OFKVG,U<SJ6
M8U;04F2LM#@]K>PU6N[07 <8Q$M&:]$;6[J4 V.O>O+MN+)=G1'-:2(U!5&/
M*]W2/-=,*H\_+:G=:>K _OC&_L44KXHY$$&W+/^='66ZLN>V=:0G<LGE,ZN_
MTK:@P+;:ZK_3*\T57&>B-!*6"_-K)1<A6=&RJ%0*\M8\L](\ZY;_%@8'X#8
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M3E+ AD2?<"2"+8D@OXUZ&CS>4]B4"'"E-^$X!%L.A9\H%C84&CO*=]WABPJ
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MB<O^)92/^R^K\-1V'[/XN=Z];K7[TE;;X56R9/\^V^P_4$L#!!0    ( -6
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M0]$_FW*P:I=J3FQP(4;/,S> B74NB21F46.@A0&O"UGI$-(@+)% DP5@62Q
M7Z&[P!)!^$H.7Y*LKY)TTG10L9PJWFF+Y?00N"B!6Q&X';6=;I)S'0,C94-J
M2%!!L@HR(HI>.L2U744P'4,\6Y%,QWB!BY?LH25[2,D]!#Y*X \7/4 )@J]%
M7]08KU6FVN)+'>('BJ ZQ%/V9:U#B!W@U81H-2%2C8<3C%""T7 ]B8U[ACU
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M2-[7_9>(_D'P@_K*X@R?>N;_ %!+ P04    " #5@&E+GDW,;FX"   ="
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M(,P+2HD,8?RIWK:/(XW'<.) P< 8NG0,=8@6M:AG1@G;M%! B!8*!#DV'1\
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MZC0*:_JO(S!2"B E [NRPK2H 2=!A6E1J/CS ^)$/;#]@^!E3=\43)T"U,G
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MQ$"<[;N6J.1=HTPQ)M9Q=#S$IA5G]DVTVD8>^TZ/FF$RO,L/<^H[$>>ZD>C
ME7X MDU/G"O0H8=WNO$K/1K' X63,MNEWHMA0 P'Q5LW^_ X@(N_4$L#!!0
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M8L<S9B!(#D6(',Z+A^5P$$S$)V0%A410B 8;AW2P:#UN*.+CU4:1"+W'"47
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MN'SA8T%9'(W5?^-G7AMXGXG1V(I:V<]H>U):-".+2:5A+\.U:NWU,O)?P^
M,@:0*<!H_R^ C@'T-<!V,QDRLZ5^8IJMEU)<(CF\K8[U/PI\2TTSM_VA[9W]
MSE2KS.EYG1.\3,X]T8BY'S!DAGE%)(9]DB"0Q#WQPLE;@8V/P#@@0<$JJ"6@
M;ZH@,$$*$J26('U#0)TV#)C"8EJ+25$.BV2@2 :(I(Y(YHE@7,(B.2B2>R)9
M&2 H0(+B_;U<@ 0+H,S,*1/"!'I9@B(E0% X(J772U(X_=X &!I(!"/800A(
M9>%:: !E,QTO%0"S"+PY'# S!E(IW52P)Y-3-Q4?4P0,B4'3WV'BIT)1@ (V
M-?Z JS%L:PSXFGKC+?6*39';$!^#\U NL/LQ8']*W%PR_^5XN?@8C&D@%WA(
M8']*Y#1$ 8\)_($Y@>%!@8$IX'9D,X+FU9(\9 MX5F!@6- 4IB"PR0EZ?[4$
M-B<!S$G=N4A\X]$2(?<G,,+F8XNF)0KXB\ 6)9!% [./P!8E'[ H@2U*((MZ
M;0'^>PNOW&2V]#1<'NQ^J**M.+5V.9V=3COH';%+TRM\6&"_,WFH6A4]"6U6
M+[L@[870W"2#;LS;.9J=>7JH^5[WMX6YE\/B.#QHT8U+<3)MYNM_4$L#!!0
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MRUW3/B;ZN;I>@EU?&G7J+_B"VRWCXC]02P,$%     @ U8!I2XVSNR7U 0
M8 4  !D   !X;"]W;W)K<VAE971S+W-H965T-3@N>&UL?93;;IPP$(9?!?$
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M277/S&UH&).@'(,'E7.KGKME0*&1NINI/K>7W@XD&^?W#"V/:OD74$L#!!0
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M&=L)=1K+\[(>=>L+P8_-&.^U_R7,_P-02P,$%     @ U8!I2P4>Y57+!P
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MAH8#QU!* )2<)X=),"B2&;E?@D&13#D; 45T4Y"$D[^P) U+LE')<,R8; F
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MDD3DJ$C+U*]571DGW1Q%H'3H;7HVO7J.TTX0SFYF!V]V\!8''W[HX,\._N(
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M<P2$<,  H6"0X1IEN(K &Q$$@6,F\(P$GB+P[_(()WGTF$AA&H7Q(C^9YF)
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MR-"I\(G+9B3:M+^&^PXGK7YB@.&=D_T!4$L#!!0    ( -6 :4MJO.(,*@(
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M<R]S:&5E=#8V+GAM;)66W8Z;,!"%7P7Q &O,3T(B@M1LM6JE5HJV:GOM)).
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M-Y]UU?^1O6?;6MYD4I_C,=^6[<_9XUM9Y;LN2IW*+OUY_+W9M[\_NOB?P_@
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M=)?:7FHY5Z S"9]TH;U^+%:#0JO,-M=[X4;&&8I/RVN UR>I^@M02P,$%
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M4ICS_,"8I$K0G:E"RM6MH^^4]"!U,U)MWGYZVXYD37>M</J[3?874$L#!!0
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M$5V.(OQ2B%_KCN>1.C<ZBB!.@5;'0\0#09R.:'84(8]"Y%GI_J#._8XBY%&
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MHV0;J5^I>F^[PWS7D+RQ%Y6@ORW-_P-02P,$%     @ U8!I2Z733& ; @
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MVCHCRM;94B'8A88 )72A(:*,X#F 6F=F"TGP7E*3+231>TES;&%"Z\Z8$2=
MF7LA8,SR'^/;>U+G1101/ ]0:TQ;BBA/:C*%)((O:8XI3&#"T0R? D@O.S,@
MR.E)M1%1]+D:(0\&"'@RH%:9W4E)%%]2DR<D87Q)<SQA I.$.@.((#L] R#1
M@TTCI.BB;>01 0'/"-0JL_J0/+[D)C=($OF2Y[C!#&82C2P#2#^T/R HFIE?
M +$@GY"G! 0\ E!KS%P@B=M+;G*!)' O>8X+S,B5=4:4 59L)P-0+MNK&6&%
M3FV19P$$!/UKJ6F#$>G)35:0).LES[&"&61;]6S4"E&I,\-(@*K7KQFQ YAS
M'1,.DOD7$.B7+C,[2 +TDIOL((G02YEC!PMP9L%8%$ Y;Z0#4$53(Z)Z*AXD
MVB\@VU_KS%J+1.FE-%E!$J:7,L<*%N#+S. &@(QP $8/,XUO[TB=%9%$D.^O
M%6:=0I*GE])D 4FB7LH<"UB N3.2@2 SJ $@[=I'!-$,"$GY"XCYUQHS^T=B
M]5+:UD!EBZ#.L7\%K5]CQO<1I4?R!D35[IP9I4-88H/%CB3^'4C\UTJSE0M)
MNMYU3:N<DG2]ZV88P"-TJA=F:4=$Z6&/ 5'!K."&J,B>'G4D\^] YK_6F:V>
M2?+UKFLQ@8[DZUTWPP0>H3>'*E:SJ %10><T1TS1ZYDL4@I2_[7.Q 8ZDK!W
M7=,ZI21A[[HY*Y5V:(%1[5 @I9\+'A#E]73NB*A UW$EN7\'(_V958B$YYVT
M&$%'PO,.+ EOZRS6F>D%DE<(TE&^ 4%V70!(T15W2:#?@4!_K3+[3I#LO),6
M*^A(=MZ!5=]!E4%25 ]J(,@LOH @9\P)IDB?V9$\OP-Y_EIENA>B/-+B AU)
MSSNP]CNH\AYZ_3,A6?]XR0I1R<3N$.7,=/D(L<#Z=<ZD^M5F(BIHP7EU6@L$
ML22V8PN[@Y7=]?=\@2#I"K$+CJW_#E+Q.KJW0%#]*+9:/5TF'JP![\U'(4EA
M\V".K<@.EF37:KI 4/THIH%LX7:0=]>/<BT05#^*=6/9^NYH\7:[T#Y2B\+N
MGVPQ=;":NKZ?+Q!4/XIU9MB:ZR"?;IZ^6V"*A3D=6YL=9,7-$SD+1-7/HE]B
MHA9PP70]A+[ F%FBY^K5+WG=;1Z_//\.V]/%Q^VW^]V43[A\]?++K[TMW/13
M8.KUI;Q;"7A]D'<C>KW*7GXW3))IMTUJ-VTK<)OKZC;7X6TR;4.?-TG M T=
M^_2=G;9YO"U,VP+>%J=M$6_KIVT]WI:F;0EOF^KB<%W<5)?];^U=_=5>^Y_J
M^^?Z\<O-_=/%[]O=;GMW/?WLVN?M=K>IET/W4_WV?MVL/[W\<;OYO)O^=YJ$
M>MS_0M[^C]WVX7K_\W]7+[]!^.'_4$L#!!0    ( -6 :4NDV\IGR_X  !%0
M!  4    >&PO<VAA<F5D4W1R:6YG<RYX;6SLO6ESVUB6*/CYS:] U%-V4#$0
MS7VQNSI"EN2TJKRH+3NSNSKF T2"$M(@P,(B61GSX^=L=\/"1;*SNN=51*8E
MD<!=SCWW[,N_YGGAE4GT]S(\2\ND^/.?^OU>[T_>MW6<Y'_^TUU1;%Z^>)$O
M[L)UD'?339C -ZLT6P<%_)G=OL@W61@L\[LP+-;QBT&O-WFQ#J+D3__VKWGT
M;_]:_-MYNBC785)X0;+T+I(B*AZ]RX1'B-+$._'RNR +\W]]4?S;O[[ =_B]
MN?<^38J['-Y9ALOJMQ\71=?K]7UOT.M/JU]^2._ARTGSE[O6\U^G-WF1!8OB
M_ZF^*0]_"F\C? *&^!"LP^I35V\N_W;QR;O\<-;R_AE,G@4Q3+H,OWE_#1^K
MSYV5688+?!/E"WCN/\,@0R!XYT%1F^WDI#\X&?9;IGH3Q6'FG<%[MVE6F^==
MD-V&WNEB$<)3\,R2GV\%V.?'36W^?N_DWUM?N JS*%VVKIW.L.__7__K?VT]
M)QL,;^##&J94GY1I&Y_]]V'UDU-X=<FOQ\%M]=M5$.>UA7_.@F64W'K7C^N;
M-*XCP$7;R:?K-6#8=9$NOOK>-:&]][$L\@)P$0:L(<+'#^<7'ZXOSCWX[?KC
MN\OST\_PQ_5G^/'^XL/G:^_C&T2TC^\OX!I]N3[W.D?'<IV\*/'>1W$,*)W[
MWI']9W6:X1XW;4"7:5+]\C)9I.L0=@3'2S!LOSV?POLP*>OW_+_ZM4?/TKS(
MZ7Z&WX#@Y&'^LND1+UUY>1 W#NG_UZ V['4(^T]N?8"%ONZ +CA/L%Q'"=WJ
M(KH/];3U/>2 A8L[>F<)&XK3#6V[[873=9H5T>],66"Y40)'?1O=Q*$7Y'E8
M-,U09.6B*#-$L,4=7E$&Q2+,"J"K7K#X>QGE$8YXDH4QW=L% JQV<,4=7/Y.
M1$=T_ *.%L;%\_^7_ST;]/NOY$<2%BVGNLK2-0P-N)N4N!H@_AGM)/=N0H!@
MZ&VR]![6 GN#/[TB^ 9KA3]XRL93&=9.Y>K@,4:U,78NN&4<_[_&M;'.@8CP
M$ !8,T(-:'B<L-H:[X%O>.T*2$$<IPO&@"+UDC3!X;.4<!$1(H3;6C\]O<()
M_#^MK?*_9K6/WH5Y_M*SY@^*(HMNRB) =#M@ZBU#7*VBWP&I -[=&HT+L@2&
MS3T &1P"43HB12[D;H(\6M2N\VZ,V[(29[:[-%Z&68YX[RUAIT'&*Z(OCY]Y
MV'N.NA\ G['L/6&]C.(2R$,-VK^&T>T=?'$2W,..009@EM%P4$]Z4Z:MD>P@
MO_.6T7VT!(8+2P^B96W]>^X?R"J(JKFW#AX!JT&46P(Y+@G &7R#O+2&GPT,
MX>+;(BZ72%]WD6D?*/PBW,!,.6PA7\1I#@@#:_V0%J$W/^UZE["K(EI%=-"7
MYOU3>I\H^,]INGP 'OQRQ\/UI=>H)HKG+_--L C__">0O_,PNP__])WH-NSE
M+9WD]%7NA0K38*_ 3^#_*%MZ?R^##(@'[6H59<"*X:'06[,8 0!$@0Z'0_!Z
M "@^='4IX(&C\<A;LSQ"HQP!XN@/? ^VM D7R(OC1Y\WE)89O'\/!(LX+JSG
MERCZI0MB7H;G'PDWMWB[[^5AZ-6 66<?"IT(&+3)#%[$9=G;"E$Z\D <2F]@
MZR(0>7=P$P"L80)K!IC"$[3:#?Z5EGG\")]O +O@BT"F02P-5S'LCV8+ENE&
M(5[@)>$#L/@%/HEG1Z)AD"T5_%< AN).'P"#&C2=@,#^ER"!+QX]UHLFNX%#
MZ-M_[76]UW#=:8PK1"= R4(=S75TFP"N+E#A.34KNTKC:!%5[_ZIM9D/L!7K
MA6O92IW5U9EP_41VH]U_X_/Q6@[(AW>" F8#D0[ [GL/=[#08+.)'W%PVCEH
MUWD)K^2H-7CKL+@#W0;A(G(^C0#KB9>P3=Q,"0)J !N5P6D+>0X:TA+O_2(,
M@?@FJ1>GR6V8Z4M*CQ$ <)U([?*<6-Y-F(2KJ/ Z%K[43G!2%U#J,LL_K]DS
MKMF3=$/0#*\^7;R%YRY_N:AKBENU0J/3P6I!<P50 W+FJ!X)GVG7]40!0W&_
M25P'<($<D7@+,G0L'CVTIN2QP&+Y6\DT'NY#@W+R*5S$@,\$JNH+#8S3;\!-
MUHP6SIZ$-76 L^?'/N)HPQ*#A3ZNYB7[BL,V: 9?$KC*,8A_2P^E/3Q<G(Q9
M+PA_T3TKGZLH"9)%1'B$RN#30$&W3$_8N075,3]^P1,V@JE^7_< DUEVCI<E
MCE9$N.":W(7+6Z1H!AY C](BJ)E+&L!"BT6H!/=!%*.0= *#G*"N#]<)C@0N
M6OA<D- D3]CRUC6UH$++UE\+:=W$@$LO@1X50%;PX/F8#M^@L@< Z;-%VL;S
MKBN0^PX-,FH1A^UH24"L:5JPTR1<:G:">_8UK<["10KD[W<6JM/=IX Z&9Z@
M_N!08&^R"'DH",[1 H8E"\KQBT46 A5G<9U6\:PS *PH %G:(?4#@.+N"[>U
MC2:UX_NVMSZ#6*!5B!<=6?TQWMCV538BX?P0HO,L>\K9=Q^1[2V-XS[5\K+7
M8%ML,)])=-F/N2)Z"183@L'(VRV& S*$B( $VUFBQ1-MCTD.,LJ2D#Y70D/.
M:C1M %!R#72-9+2\C L6W8ARPD.HUXUZ/WGI0Q)F^5VTJ6AYG\.R2+O>M1*C
M!N==D(^T#10NUK6,]#;--U$6H#>G).7V^C&'U>1D$SL5/?X,C0LWJ1AZ3S,
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MZ%E5U9>&8BMD?UW";XN(,P(HA52%?#K/K;3OWO8<'VNG1%.T%: ,V5YT>GE
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MGF'Y?/V,PDO>R_T84;/1N<;7?JTR)'W%FO!U*M;_-?MN;LN(Y9TTT=)>GBN
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MMR@'EXZW^&V4ETI;J#K4=#+_.TF#8*(G7NIEB*R .(FRA=\%TD3P!#Y)3HQ
MO@P19B8;6?M"[.F97HWF/WGBPF*#VTFMYS".<G8'R.W7ZMQ5O><J ^0(\.2
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MU.2I E^?>A1&?+XB%XD)&('D4UX+ ':"X!V,!EQ@-%IP <MT\545Q+G'K=<
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M=<VC:DW, ]<\FM>*GO_(H\":C7OMZYE'\?T.8CR?[[?BX7.7/'(.8O&=#N+
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M6HN\+0.8M0A)L ;L/KD)%E]#QZ0'*QZ!^%-=P&BBY$/G15XX>>[Z'OPW-+W
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MC_=WC3[U4!F?S52P #UZ.+")W*D-CF@!H.G[4Z#6(X*4S+Y0LV-P^J"'<;-
MQ,>-KM7]YEU2<0)_.N<"!)]"3&SBVF\%B97<MQX&>;A+D7ZFF:=+J@><-"3U
M5#F"%F2M80__G?>\)59*XDPN89IXSIS](QG -!6'XMN$_2;%0HSPM.]MT&?5
MZ_;AW%[1'[Y.2EL$>>CK!H/L*:)J&TI25XV$OH4\FGV45&\,&PEESI[-AMIV
M+9%CVW=I>J$]A%@'(ER>!-C_$(0BDS+M*A0J\,Y>H^521[,MH._P)T_:F-W)
ME?&MDZ9;MZ1;1XSD<Q ]D.1)N4]JGW[;1CW3NELVFPJH%=IYG%#'=:ML7!ST
M6#W$906WMUEX2V?- 0KV/@@'R 8]]@=3VX/W^<XT#%!H*P/D$;[J5+U0XT6Y
M*I-?4[N4ZK>'858?7HY)WZ6I.EPQX:5ED5/9>#1/-Y'%-ILK?#=C0D9$:8"1
MH:<$1?J5;_![K3?A_9_UB0K,6+\ V8WL?_ZXAS+<8.BCK^](&14ONB()?S &
M1=L(>IEXI^4MNH\YM44E]$CQL1"+G.<;8. !EF%)B_+W$G#%2W]/;X,U%HY2
ME@WO+V426H-<?&D8 D #))\DX&#SV%+0#<"L'"48F+(A7P F+JQ0Y<3R:V?G
M@\$)2T9P75Z?+#![>4/.O9PZMY6 #/'C>G,'$DB08YW*."R_8J$XRFRJUIFJ
M;!I+U=O=U8$&&4D&,6H=? UM]80I29 D)7'^1]'/4;$,*%26\\54<3>Y!E1\
M=3 W1B*GJ'K6U@<YR#)$7B[)<VI2P$T*EBG'[&C?&#*KNEII]]'18&0W?V\N
M+)QLK62C,RG=R8\&EC%%U_)IL6MS&X5Q_?G&AYLN6.O!:D3\(X_5[ACZ'8[U
MH!/%5D$_YD2Q,<U!)SIYUH&^Z>[.1L!IWHK/[=3T@E4ABA?*RO<IRK^V1S(Y
MS GH$RN+)@!=L1!M--P9<*[\@.CD))\V%V:HLZ(-53'*Q?W:[XZU%L#L:>=,
M)AD1YPS-C-;@JF4>B!"24HG>Q<>0S2]?NG_M>E0>D:=<!]^B=;D&FIG<8L6.
M%4E[C/BJ0*S$'_$F5R4IHC4HD:,0I/8'N0.Z3M[1P'(SF^F9ES+/5=5DAS/*
MAUZJ (.#++K8J%RO@< CBJCETJ-8/*F,"$A>AY%OK=#G)%4TK+$XQ5?EM,20
M_=A\? +Z9JI*L3D5]]"FD1 7XUX/6,]MH1HP+A;4,!#54A1K8+CB(94\6MV2
M1XDZ)(#1IMHS+[B.1PV?;7'E$'AJK*[6$;0 R-MB=+:"!+2-2&5PZ/JUEMML
M&:["3,I=[),:U?5>JU !46%.0LO0KG>0,?)AE&.EW 4_0$263X)K]8A#_K%I
MO5:0WI9L$<PI.:/0\A6#A-#8LL\'=B]P&GQ;LKK4"[%;0E.G#4>-:RQB21Q
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MSN_U^5(,R07>&<R&DF>/5.+/.RI/#[#DM(X LOIM;WU!NW";@W2MTFHD2^-
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MU!_$+(17[T^6VSBB.@&&0R5^^X]E-:="]%J.,Q?Z:->$>1J@E0$UPQ]I _'
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M)VP;. @X*D6BY1NWV]T*#,&I1<8.4VPYR]5R  3WQ75R[21_A3,. $;)VCC
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MDT^' 6AE+N?N3*0P+A-<L89_\971P&K-(A?GI@D5Y'+;1&EF,FM^6:?V4M$
M/Y#V=I,'IVSY.3?FU%-C2NTDAR1QG;U_?_;IXT7PZ6WPYM/[]R?G%X?^-*V+
M/FSX]-QU?V%M\Z2M'@3C,(K&]'L4]GHQ_>Z'X]& ?T?C$52I0=@==.GG*(JI
MI=%P$/3"*![KQE3GE0<1/3 <XU>W/Z"&A_TNFH\&*J98/N:9V3N7)$YVIH=\
M+T?QC_9W9S28!(?XU:-?YT@ @+)&6W$&9O?2$W!K7X_"WA@>-OICT!O1'Y_;
M+_&F5J)!'ZU,AD/Z==)TPS:\/1C@W7C<I5^OFRZ^H#.K>;??G\CH)T/\417T
M:GH;<F]=_#HPNW%@]N. ]F\PQN\H'';[P4>X'O[.1!CWPIB&0G]$87\486Q$
M?Y,N_HCIDRX(,1J$P]XDB$;A*!X0W0X&XV 23F@JS:38&X?C?B_H3:BU81 3
M_?;'^-6GW7P,,<8T3MG+L#L9/HH@>^&DCX#43C^,HT<3).UAC)?ICZC;VY\D
M>WU^>S 9[T^2H\E(QA]%\6XD.1CUW!D^,+MR8/:%=IF.Z2!B-C0@]@-Z4Z;,
M_GY-<&#)S0F=EWRK>;HB:X_)-Z,NX_UC(C#K$[;^*=69!=+5Z,SLZ6,M>H$C
M<2M'PFC21MD@5@_6O[ LGQXX(&JZ-5<0?7,0 \=3/RCCW/&$<!$[?1[C^27+
M?I&RZO4>'2YF*WZF_C$HM(5^:Y1\D8)FIKR[,0"5K9/[6!94A7^\%4!JWI&L
M@X@Z ?19+]WQ.;;H3(5'2M=_KU=<^HG;"@15BH*#)6\<1J'3_4EC6-EA)#8N
M>>>,U5)3\>%FS)8<6@+U1GV).)^\[^I2O'/;C7=-+9'M]GFM,0+$8^,#O*=5
MQ!EN/N$L1?Z).M;?6T_"2I^V\@%'X8TZJCUA+]DN4-*9-/930W)%)Q)!L-G@
MAF^(;ZM]@MJG'4W$U5>PLY3?98AWR_F9&=&UZ7@/&P3\:%2;&,A;<ZN(:G@O
M&O>*+V:'/H\C7N^S-$]%9[!+<U^QW>=6U)@"8X R('N'*@=0![[*ZK\[NX""
M9.W72]\4,D]SHW/2%R1NSS&T^T,O@[&H:=K)RIA'_I3NBTOA6"?LK+P>F!$@
M.N:TX\:N?D!'W&<QG7M:&#7P>GV1:&6>VI&/QZ]"^:,G2?3*VW>ET.$_+(7V
M1H,RB2JAM5-HOULA4)@ZRGOOIS!C\9C>CIC>-#!E.\DA9./6$Z*4^(0>COM6
MX]R/&H?/0(VD!NQ C=%H7VKTB3"HI\)FZ>@?E1+C0>^1S'(2U3%+<0ZY.^^[
M<T,1/^/"6/Y<[EB2?9OH,9KLSQZ#&OZX)VG^XS+)4?^1I#GH#O^QV>1QY+_W
MV$M[W-V)+L=[TV6)&E$@<&WST!;IVA.:1,5+4VO:58NYPJZD\JH@_< 5"M+P
MJ923B^JLSL; (>$;50.L;WVT%EV-]B^F*/I!G*&A;*?=/E']#@H(6?5S4"'?
M:'K"& '-QJ^9&<E[HEDFL+,N9LE<RL.("7_F_$ZB9N5&ST)BX:MC/RRZ$ 3]
MIX=RMEJ4;4 MT8@7Q$N,(ZFU&%?-=_L8ZGX(7M]P[M^6KSF:[B 8AH->7W]W
MK7GG((@FX2 :ZA_#R'[SQL9.2G@;&W;B,!KVZ&<<C8,.#$C#L->=T,_). XZ
M$6RD[KWS5,IU_HH@##9[1.&P%]//410%'=CB^B$,4OUP0N)A!P:F4Q.C^4$B
M!UG#CL-Q;T(_!^-A0'V,PSB.@Q&UT@]&SN)9-9=&-?:J3@1K5G)8G1\IFX7\
MG$(DFXED?,F <LCE,$%_%U-$)"Z2^RQ9N,@^)IFWV6).OX_=&&<I(' 6)K,O
MI3;4,T*L<V19IXE?;59P#44&HN4?#(Z[SI,B'_3\YMI%0*\UWQPBMJJF#=UQ
MO3@T--103N!'(P5BCC#)B^6&YO@78D2)L.7T:_!;FLB28=\KQ%#J4CRDRGM]
M!VG#4#CXLL.!PAS>Y:)6O:$ 41M,SB#@T)"OY+?)XC$[;V(ZS;_1ZX=L-IM+
MP@\W+*&@Q\'KXY9<C@OOVC"84I9D_IOQN%E*4L"<G<TR$>^Z^@Y,KO[3SV_/
M?CL]#\X^?OSTR\F7LU].@W>G)^^_O)/,%)SNJG.L[*=@4&-("A\TX!U?A?W!
M@'_'S#-&]'L@/',P,N&^9^^4ET6#+OWL]B=!CQU5,.>/;(AT,M<XM$*:A::/
M(@$N#X;]?@ ?412.HQ[]C.,!,^UU]NT%_;Z]R[X%,7'&:#(.1B3P#WN1B9'&
M(, 925Z,B8."H8[I]ZL/GXDS$D/N\4O1:& 0?(=Q,*26QJ, Z@]G(#,]5I>!
MWH&/,*;_>W13_&(R -CI1*.5WQ'[&7MC\3<.1L.F\/$H',3@^8/>D![LD@I,
MKW7CX.W%A],79Q\^_/SQZ$LV75(W ;P]] *I&Q$]X,9HAT"]C:@MFB@\QY](
M3$$\H8Q([C#:@KZ,B%T2V/.A#1\?C\;!@#:-MCG"UO4G<7"Q84"YF"80TP*-
MNX-@'/>"OR;S/Y:K+(CZ=.70%O3[<="/!B;^O+JY( 9ZA*8:TYK.']9),.X'
MDT$0#X9!CP;U:DFG+[L*B)!HGKA&H]C?"#N;F'H<!*2:T5HC(CRY538A^)IG
MM[<;B:,D:N>/SMA5& *XZB"8#+M,P.-ACW]/0)(:?/^I+?A^2'LUZD9,C&.<
M /K;!/[WX'GK#8()_0\2.-T0/\H3C-.("[1QYD^/N&1\]"[1<8#5I_L:>M2;
M+&?HCH-@, 1%6:=F;\2_1W2-OTH7Z=NSOU(G-"C:GC[I^P-:NO.4\XZ"D[<O
M_OI ;"7A#>)-(E&DWQV3M$@7P@J)+T2 V+]1 +-5GX[7Q?*6^"()TD-:8J(S
M.K;1J.<-N3"\$9VY?@!A)R:B?&W2##Q82N(S,28PFHQYN4'KPD=&ADN=7ER<
M?OQR=O+>,JE3,*D9=DT<] ?JHC\P?M(#XRE]+ZDPISFX<);?$/>T>:F=]Z>?
MJ9WTD#L<CB/^/>H*TYM,!LP$>S0[D\W0IY/?Y\/8ZV.CXTF_DM\0]VBRQ)?
M44:T\B;;(2:RQ'?#,;[K!Z=WV>=T$6#]Z"S!%M,C^J-CD] )>8'?)-P'XUY
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MZDUQ;*V(75M_G"?']^722U*P!:GRS>7OJ7BI)4[G>KG.K%*7:(WTVGKHXK-
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M*.9(DFX_[/5DT\QT$6 ;#OOC$L>U[.N:J=*F=B36,-!&(@S=:2?MU_83U#?
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M,(Y[P5^3^1_+5<8A;Q%M01_(X]$@^"M[WVLV%\0 </*8?IXMY@_K!.[]R2!
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M@=(^2VF>$8B2*7<R\>9)XPS&0[F2^HH@(_SOS[J5:2V/WG\Z]4CTFM%FM.A
M-Q:6U)M(,8*8>,+K=)X2<Z)[+L)\^K37?>;1>MF>ZF5+6D7$U$L42,W\<@5?
M'NX!6J\>\>P^'6:]&D_E:L0ZDYH8$V>)Q[B=,M)Z_XM7=$3+0QLS(-[^V\/]
M\ALR6JCK.*:VJ".2B\!P05 HA(U&(I^@JO,DND/H!.X0VN%7V3(G.9%!G#LW
M3#=\78Y90^ $,Y X>#L1W2IY<9[>T@L)%YCH8\@T61J?Z]%O$==R'^>.9J]A
M>RPCII]H1V$0.>!R%^ EG,'&J3XH4F^R/ZC?#3M>+QYR\02].Z.=[OR.5[U$
M%68HG&L*L(H6#:BJ_XAK7[=002_"6'E\S+&"/;IFY/>H9VJQZ 9B]Y!,RU3"
M0+*3B5[NM(1:MJ5R 1.=B5#" (\QN[GYG<' HF:0U&0M$>F"(<PY4Z,B!(56
MY@CMQ1RVW\9A\>J0@@&5"P.0YJOEYOJFFD <.BWGS88TO?OT!7ZGTM8O&72_
M==#Q$_?;Q#C)@1@>FB1:5@ -E,?*1,.=+19+11:30<*H<9KGBK2DGSG,KV(8
MVZAI.."Y?,U=DC*U6(@>5'B3D?0"O,J@\VP&TJ*'%IO)&NC$#VZL1&SV6M*_
M;(C C0P37FQ27.CH*LC[Z3O1+I42+:WPU+4JAU&LSC=Y#H51E"G:['R5I%(_
MPNA@K-IYVO?*%J[BZ5N6=>RO1*GKAI?.Z*7"J;$ON.SM=0&;G8;^%2KR5TAT
MQ9DY187+6;IAX63I(2N^42,15D9J-0]_>N76&EXZM=,KO_"(Z3D52 Z&[<$
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MRE&B8XBYYRCEI#)JJ;/AT#?$;Z&TG2;_O./SJQ415WO.=8[ZY85.5*EWB21
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M9:?';O$]XLFN.$Q:V-:;4N*Y.J?QIT:;H)XYZH_M\>;R'E<DK#\-A>&VO3O
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M/ FSE$[0KC"!S6^0<=R]'0ZEAQGEHIRM5N'DX!3]T@S1;A&;**W#$QW$3-5
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M+>00WR<R(";TCU"\;3:XE8J?FSHF:#75Z>0%.O5 Z((K@A7%BF0570FT73O
MQ 3$KO8+G><BL6^"].>"D$F%.$U(=E34<2$.W[D,NR60YQ(\SF+LMW7E%@%?
M_L.4<!-=BRV&[NTJW)>'*)N4<:N+$#MTF432( K26T2DB6,3C^5;G/S<":*=
M*:NG8+A4O'L,PJ(*9APJ+,-(<S,727/-!QJW&EXN3)!^;):>[QI+6:2:*@>_
MZ%+8\RA@)<D,Q'UD\QUTEI"M=YQ<K _YI27(-?^QLHA S4+T"YNLTECC\X7
M_8L"F$J##9HVXFD'(@YPZI7"0%;VW'4(:4@_79U6-%8L_E.W,]5*T9"),]BW
M*_ 1+ZE6*K0M:E+509%>O]:6Y)N;H?MV%59%?9KI(H\,6356Z+,6PF*6BQAF
M!$547D>H24$8"I_.,]SB2)EOY_&\6%ZG>DL;*.,X6%G$I6;D4D61F#QCE'GE
M!'K/2U8$FD1UEX7CEV4Q[:UTJZ).S^%!<ZJ%Z5XMMY-2>+2F!"IZ<%!*@!49
M_._4@2T[!-T;^K5TG7-#@15P%F.5&.ATN.)T72<_"Y;?9O.SQL*Y]!S-EU)J
MI .&6I5F@#0AL$I9K)>E632=]KIW\&I5 JMT;__PL:?4*MR>E&I"(Z4ON6(U
MN"]4E;.R\*R?ID2E/6:9:726:-9+^==Z]TCY>G7)F%->]M5DSKYF5RSG\)4H
M))OF(GCYQ;E!)"CFA&C1H%KX+$LL[>BDV'?BL_9";5TMQ3?-^G]1L'#,HYT=
M+)(0.O<L32?TD8%;GVP@$L2X6-N\"&D*S[,)_*X'NYKQF85(:&8NP4#8 :N#
MQDUQ,M23EP]6DA5(SKZ&!CD6&E)6U/5]MT>F!,Y_&H>FR4,O&'6=+Q5UQDM%
M76.I*%[)[IJ&.QC(AV13:QXWRZI=Z11R51LJKIX]K4Z5-02N[&'G8<I@)J&+
M64+53+$(EF5>YY:'>&3@YZJ:/LRX53+>A:):J:BJ9>[*YQFB,X<T?<S^BGJ@
M5C'J-;UX22\Q3.)1F4#$T)/T<SN!7H#+MDKTT*Y"?,%+'9@Z\=S'[4BJ3['9
M8G+)QSC:^5^R/F*0J?74EM=)IHOV&T(+RFR[E!HU,G><<@GN%+JZXYC=7%!)
M#'.R#Y\OR,E6U]\IYT.,MDKX+\L+$!T17Z':E(238S2Y5HRV#!^Z. E$I1Q#
M\[40\VPJ)IYJ?.EQ;+KP?/ B>XX=!07P>LBI*@L^!HJ)PK,6Z95Z62L?\_F*
M\(76]6=0BPZW'RQFU!?M:GENR"2K59!P?$1R*>!>QDN#2280G(:1JM4K"5TH
MOG@&UP ;_&#'HZKS=%]!WR0T[/1ND:=BF3S](?KIM,*-.8M0BB^D#8 0.M<]
MYR/LSG"XC).\\PNQV =&N/[^?UP>LE]B<*JN;FDX.-AY'?VPQKY["0>3UW#B
M]D=^DOBBTI2H99_F.8U8\<"26HPK\40('%AR6I.Z828G9QP16;&EBI%X&X19
MB?^B]<ZQ,Q4_K4&+!%)2=C[!DEA$#]%3)#G;H+CKXF-YX=>E@(/RUH]B*B0?
M&T@EWXI)YU&&VQ=W5DJB*48DI%1M/AK7F&1LMN_0MX3/SR&\7_-IP-+(86JS
M?U+N.O8[PV )QQ>'#3RQPT[!-CI>T)3U=49WL&EA=I%,!@,_Q '%7V]9&KLJ
MFJ;,XUNL8\:VN[I$+,K.:Q)]FE96FN[I\F'U4&\]S ]#O!E$]$E@TTT=Z <Z
MP:A: DM<Y-SRNC+TFKA/"+X;RMHJHL]4G3C7JC;&<-5"L"0E';FCLD.K5@C9
M)?@ >C_GEI,^]<D4)H2XI0V97!U4:=9DG*I&^W!QQ*HU\&&0B"T13T1Q%@Y!
MAK [HB )[0ZND=08;IG,DVPLWZC!@:B6B=E0M%P(Z*MR7\:>MGM]B0(T3YO;
MF>F9G3O[KRR@ 'Y_UWE^7/7PH/PAVX1OE.9+QQ [(I[#Q;;O13_MUA-M&A4;
MJW8=]JR3SN9T/JV8LE1^,;UUIEY@P@TQX:J7:[SA\JF!4%",UE8020 ,^:NA
M\[(EY@]WJ(YQ0%!70Q]-2<G<Q<\UJZWLMZW;?,IRAJ"#I-9<97BK>*"FB:I:
MJ\?PC3^! SUY)S.8*0F=S?51*>7I.HG1"C7)^<ZNYF$\\Q)[V0UE3U20"BX'
M:^ H#=J5Q8QBR,-)"(,1B#;7Q")(B053]I3%(*$=]!O1^0:S AK$Q'BX; 1H
MY1MMVRWK!-^QS^]LUZ"L)1=V0N42UP_+.SU_JNY^EG<^9.'"=JZ\9.$[M$8<
MO*RFI5^9+._HT"7'-7BVOJ/1LKT#]U[YSE$-6D=OX1 0#3U3F3]DD92TM26-
M(SLUU<ZA34+ZC9Z_8V7L&I>1H?^ UX-)\*#/-7%W_PKGN2QU3B>1C]!U,,4G
MWL"'+6N <2^7E^?Z1W"=IHWV$N8--PO8IBHE>>=G1M5B_E$>?J:L3WRC'N&%
MDE_VE^_=!1T$@BQ=LC/U*5U[R;(TJ-^P:K N%UTO9W&:A<%(_^G;W(<=EA/N
M9=&2A$W1>V'H@] I4J]R *I9_AS?!=ZO'%?LKL%9AN4>3DF77C^FFQRJR&4
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M'LZ". W@(N$EK<[REIHELSB/SMZ[\2?0IGWNM4=3";*L33,$*IHE_J?(;U.
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M(] [\O6.0._(USL"O2-?[PCTCBN<%42'!?EZ1Z!WY.L=@=Z1KW<-]*[Y>M=
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M;W!S+V%P<"YX;6Q02P$"% ,4    " #5@&E+4RN>C>X    K @  $0
M        @ &9 0  9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    " #5@&E+
MF5R<(Q &  "<)P  $P              @ &V @  >&PO=&AE;64O=&AE;64Q
M+GAM;%!+ 0(4 Q0    ( -6 :4NAE0=#8P(  !4(   8              "
M ?<(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4    " #5@&E+
MN4_Z2.8%   ](0  &               @ &0"P  >&PO=V]R:W-H965T<R]S
M:&5E=#(N>&UL4$L! A0#%     @ U8!I2Z80Y]P^!@  NR,  !@
M     ( !K!$  'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    (
M -6 :4M*+A]6IP$  -(#   8              "  2 8  !X;"]W;W)K<VAE
M971S+W-H965T-"YX;6Q02P$"% ,4    " #5@&E+B-RNSB0&   N(P  &
M            @ ']&0  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#
M%     @ U8!I2[E=%,8S @  ;@8  !@              ( !5R   'AL+W=O
M<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( -6 :4MG&^G/>08  %0E
M   8              "  < B  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q0
M2P$"% ,4    " #5@&E+K<S. K,!  #C P  &               @ %O*0
M>&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ U8!I2YX 2/ZQ
M 0  T@,  !@              ( !6"L  'AL+W=O<FMS:&5E=',O<VAE970Y
M+GAM;%!+ 0(4 Q0    ( -6 :4MC;QARL0$  -(#   9              "
M 3\M  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ U8!I
M2RS&[I"O 0  T@,  !D              ( !)R\  'AL+W=O<FMS:&5E=',O
M<VAE970Q,2YX;6Q02P$"% ,4    " #5@&E+K>45Q+4!  #2 P  &0
M        @ $-,0  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0
M   ( -6 :4M.9S\YM0$  -(#   9              "  ?DR  !X;"]W;W)K
M<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @ U8!I2WX^*=^T 0  T@,
M !D              ( !Y30  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q0
M2P$"% ,4    " #5@&E+YV7!%;0!  #2 P  &0              @ '0-@
M>&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( -6 :4NG^6FB
MM0$  -(#   9              "  ;LX  !X;"]W;W)K<VAE971S+W-H965T
M,38N>&UL4$L! A0#%     @ U8!I2R!"?T"U 0  T@,  !D
M ( !ISH  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4    " #5
M@&E+/L?EV[,!  #2 P  &0              @ &3/   >&PO=V]R:W-H965T
M<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( -6 :4OAD%JHM0$  -(#   9
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M970R,RYX;6Q02P$"% ,4    " #5@&E+2(T4X,,!   W!   &0
M    @ $R2   >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    (
M -6 :4O'OEF%MP$  -(#   9              "  2Q*  !X;"]W;W)K<VAE
M971S+W-H965T,C4N>&UL4$L! A0#%     @ U8!I2VD/=K>R 0  T@,  !D
M             ( !&DP  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"
M% ,4    " #5@&E+$KQOX/4!  #+!0  &0              @ $#3@  >&PO
M=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( -6 :4LG]7Z7Q $
M #<$   9              "  2]0  !X;"]W;W)K<VAE971S+W-H965T,C@N
M>&UL4$L! A0#%     @ U8!I2_KKUJS< 0   04  !D              ( !
M*E(  'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4    " #5@&E+
MVS4SH<4!   W!   &0              @ $]5   >&PO=V]R:W-H965T<R]S
M:&5E=#,P+GAM;%!+ 0(4 Q0    ( -6 :4LN\FKIM0$  -(#   9
M      "  3E6  !X;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%
M  @ U8!I2S]*N%C@ 0   04  !D              ( !)5@  'AL+W=O<FMS
M:&5E=',O<VAE970S,BYX;6Q02P$"% ,4    " #5@&E+I:2.+!$#   E#
M&0              @ $\6@  >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+
M 0(4 Q0    ( -6 :4LV(L&JGP,  .(0   9              "  81=  !X
M;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @ U8!I2QY M3$I
M P  70T  !D              ( !6F$  'AL+W=O<FMS:&5E=',O<VAE970S
M-2YX;6Q02P$"% ,4    " #5@&E+%584U3X#  "[#0  &0
M@ &Z9   >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( -6
M:4ML]^3 [0(  #H+   9              "  2]H  !X;"]W;W)K<VAE971S
M+W-H965T,S<N>&UL4$L! A0#%     @ U8!I2U4TMASP P  ^A$  !D
M         ( !4VL  'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"% ,4
M    " #5@&E+$,+R?.X!   3!0  &0              @ %Z;P  >&PO=V]R
M:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    ( -6 :4M[7]YCA@(  %<)
M   9              "  9]Q  !X;"]W;W)K<VAE971S+W-H965T-# N>&UL
M4$L! A0#%     @ U8!I2^=H>&UM!@  VR8  !D              ( !7'0
M 'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q02P$"% ,4    " #5@&E+PY5W
M\:4#  #O$   &0              @ $ >P  >&PO=V]R:W-H965T<R]S:&5E
M=#0R+GAM;%!+ 0(4 Q0    ( -6 :4LG)RFXR ,  /81   9
M  "  =Q^  !X;"]W;W)K<VAE971S+W-H965T-#,N>&UL4$L! A0#%     @
MU8!I2YY-S&YN @  '0@  !D              ( !VX(  'AL+W=O<FMS:&5E
M=',O<VAE970T-"YX;6Q02P$"% ,4    " #5@&E+\==#G7D$  "1%0  &0
M            @ & A0  >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4
M Q0    ( -6 :4M-[[1G7@4  -8>   9              "  3"*  !X;"]W
M;W)K<VAE971S+W-H965T-#8N>&UL4$L! A0#%     @ U8!I2Z%H'FE[ @
M* D  !D              ( !Q8\  'AL+W=O<FMS:&5E=',O<VAE970T-RYX
M;6Q02P$"% ,4    " #5@&E+=Y#U* ("  ",!0  &0              @ %W
MD@  >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4 Q0    ( -6 :4LX
M7>(M4@0  +(5   9              "  ;"4  !X;"]W;W)K<VAE971S+W-H
M965T-#DN>&UL4$L! A0#%     @ U8!I2RS2G7:Y P  /Q(  !D
M     ( !.9D  'AL+W=O<FMS:&5E=',O<VAE970U,"YX;6Q02P$"% ,4
M" #5@&E+=UNR$* %  "S'P  &0              @ $IG0  >&PO=V]R:W-H
M965T<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0    ( -6 :4M(K RIX (  *4+   9
M              "  0"C  !X;"]W;W)K<VAE971S+W-H965T-3(N>&UL4$L!
M A0#%     @ U8!I2T!&,CNY P  BQ$  !D              ( !%Z8  'AL
M+W=O<FMS:&5E=',O<VAE970U,RYX;6Q02P$"% ,4    " #5@&E+&MN#_'H$
M  !G&   &0              @ $'J@  >&PO=V]R:W-H965T<R]S:&5E=#4T
M+GAM;%!+ 0(4 Q0    ( -6 :4ML7#:4H04  "PB   9              "
M ;BN  !X;"]W;W)K<VAE971S+W-H965T-34N>&UL4$L! A0#%     @ U8!I
M2Z9]/K.] 0  % 0  !D              ( !D+0  'AL+W=O<FMS:&5E=',O
M<VAE970U-BYX;6Q02P$"% ,4    " #5@&E+RNA65@H$  !Q%   &0
M        @ &$M@  >&PO=V]R:W-H965T<R]S:&5E=#4W+GAM;%!+ 0(4 Q0
M   ( -6 :4N-L[LE]0$  & %   9              "  <6Z  !X;"]W;W)K
M<VAE971S+W-H965T-3@N>&UL4$L! A0#%     @ U8!I2TTI;H!J P  5Q
M !D              ( !\;P  'AL+W=O<FMS:&5E=',O<VAE970U.2YX;6Q0
M2P$"% ,4    " #5@&E+!1[E5<L'   N-0  &0              @ &2P
M>&PO=V]R:W-H965T<R]S:&5E=#8P+GAM;%!+ 0(4 Q0    ( -6 :4N3;+A^
M%0(   T&   9              "  93(  !X;"]W;W)K<VAE971S+W-H965T
M-C$N>&UL4$L! A0#%     @ U8!I2Z(:KMZ% @  8 @  !D
M ( !X,H  'AL+W=O<FMS:&5E=',O<VAE970V,BYX;6Q02P$"% ,4    " #5
M@&E+Y28^BSL$  !9%0  &0              @ &<S0  >&PO=V]R:W-H965T
M<R]S:&5E=#8S+GAM;%!+ 0(4 Q0    ( -6 :4M02D/QA0(  /,(   9
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M970V."YX;6Q02P$"% ,4    " #5@&E+L?5BGB\&  !N)0  &0
M    @ $JWP  >&PO=V]R:W-H965T<R]S:&5E=#8Y+GAM;%!+ 0(4 Q0    (
M -6 :4N3@NBXX $  )X$   9              "  9#E  !X;"]W;W)K<VAE
M971S+W-H965T-S N>&UL4$L! A0#%     @ U8!I2VK<A!JV @  C0H  !D
M             ( !I^<  'AL+W=O<FMS:&5E=',O<VAE970W,2YX;6Q02P$"
M% ,4    " #5@&E+4:&0<C@$  !2%0  &0              @ &4Z@  >&PO
M=V]R:W-H965T<R]S:&5E=#<R+GAM;%!+ 0(4 Q0    ( -6 :4LYC* L<P(
M .<(   9              "  0/O  !X;"]W;W)K<VAE971S+W-H965T-S,N
M>&UL4$L! A0#%     @ U8!I2ST),WA8!   J1D  !D              ( !
MK?$  'AL+W=O<FMS:&5E=',O<VAE970W-"YX;6Q02P$"% ,4    " #5@&E+
MO(< JQ,#   Y#0  &0              @ $\]@  >&PO=V]R:W-H965T<R]S
M:&5E=#<U+GAM;%!+ 0(4 Q0    ( -6 :4NETTQ@&P(  +H%   9
M      "  8;Y  !X;"]W;W)K<VAE971S+W-H965T-S8N>&UL4$L! A0#%
M  @ U8!I2_ZZ0A'S!   XAD  !D              ( !V/L  'AL+W=O<FMS
M:&5E=',O<VAE970W-RYX;6Q02P$"% ,4    " #5@&E+[*VRXF($  ";%0
M&0              @ $" 0$ >&PO=V]R:W-H965T<R]S:&5E=#<X+GAM;%!+
M 0(4 Q0    ( -6 :4L%L6L-Q0,  $(1   9              "  9L% 0!X
M;"]W;W)K<VAE971S+W-H965T-SDN>&UL4$L! A0#%     @ U8!I2VFS%U^\
M @  _0D  !D              ( !EPD! 'AL+W=O<FMS:&5E=',O<VAE970X
M,"YX;6Q02P$"% ,4    " #5@&E+M^NK<Y$/  "/<   &0
M@ &*# $ >&PO=V]R:W-H965T<R]S:&5E=#@Q+GAM;%!+ 0(4 Q0    ( -6
M:4NDV\IGR_X  !%0!  4              "  5(< 0!X;"]S:&%R9613=')I
M;F=S+GAM;%!+ 0(4 Q0    ( -6 :4O\7\MMD (  /T.   -
M  "  4\; @!X;"]S='EL97,N>&UL4$L! A0#%     @ U8!I2ZGC)@1(!0
M2#4   \              ( !"AX" 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0
M   ( -6 :4M<Y9VVAP(  &@P   :              "  7\C @!X;"]?<F5L
M<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( -6 :4MG_9"@)P(  !\O
M   3              "  3XF @!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@
0  !: %H J!@  )8H @    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='UTF-8'?>
<FilingSummary>
  <Version>3.8.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>796</ContextCount>
  <ElementCount>412</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>238</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>11</UnitCount>
  <MyReports>
    <Report instance="pfe-10012017x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="pfe-10012017x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF INCOME</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/CondensedConsolidatedStatementsOfIncome</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF INCOME</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="pfe-10012017x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="pfe-10012017x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1002501 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (PARENTHETICAL)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (PARENTHETICAL)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="pfe-10012017x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1003000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="pfe-10012017x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1003001 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (PARENTHETICAL)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (PARENTHETICAL)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="pfe-10012017x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1004000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="pfe-10012017x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1004501 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (PARENTHETICAL)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlowsParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (PARENTHETICAL)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="pfe-10012017x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2101100 - Disclosure - Basis of Presentation and Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPolicies</Role>
      <ShortName>Basis of Presentation and Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="pfe-10012017x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2103100 - Disclosure - Acquisitions, Sale of Hospira Infusion Systems Net Assets, Collaborative Arrangement and Equity-Method Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestments</Role>
      <ShortName>Acquisitions, Sale of Hospira Infusion Systems Net Assets, Collaborative Arrangement and Equity-Method Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="pfe-10012017x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2104100 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiatives</Role>
      <ShortName>Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="pfe-10012017x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2107100 - Disclosure - Other (Income)/Deductions - Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/OtherIncomeDeductionsNet</Role>
      <ShortName>Other (Income)/Deductions - Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="pfe-10012017x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2108100 - Disclosure - Tax Matters</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/TaxMatters</Role>
      <ShortName>Tax Matters</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="pfe-10012017x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2109100 - Disclosure - Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterests</Role>
      <ShortName>Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="pfe-10012017x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2110100 - Disclosure - Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/FinancialInstruments</Role>
      <ShortName>Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="pfe-10012017x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2111100 - Disclosure - Inventories</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/Inventories</Role>
      <ShortName>Inventories</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="pfe-10012017x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2112100 - Disclosure - Identifiable Intangible Assets and Goodwill</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwill</Role>
      <ShortName>Identifiable Intangible Assets and Goodwill</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="pfe-10012017x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2113100 - Disclosure - Pension and Postretirement Benefit Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/PensionAndPostretirementBenefitPlans</Role>
      <ShortName>Pension and Postretirement Benefit Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="pfe-10012017x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2114100 - Disclosure - Earnings Per Common Share Attributable to Common Shareholders</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/EarningsPerCommonShareAttributableToCommonShareholders</Role>
      <ShortName>Earnings Per Common Share Attributable to Common Shareholders</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="pfe-10012017x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2115100 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="pfe-10012017x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2116100 - Disclosure - Segment, Geographic and Other Revenue Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformation</Role>
      <ShortName>Segment, Geographic and Other Revenue Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="pfe-10012017x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2201201 - Disclosure - Basis of Presentation and Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Basis of Presentation and Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="pfe-10012017x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2304301 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesTables</Role>
      <ShortName>Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiatives</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="pfe-10012017x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2307301 - Disclosure - Other (Income)/Deductions - Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/OtherIncomeDeductionsNetTables</Role>
      <ShortName>Other (Income)/Deductions - Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/OtherIncomeDeductionsNet</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="pfe-10012017x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2308301 - Disclosure - Tax Matters (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/TaxMattersTables</Role>
      <ShortName>Tax Matters (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/TaxMatters</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="pfe-10012017x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2309301 - Disclosure - Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsTables</Role>
      <ShortName>Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterests</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="pfe-10012017x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2310301 - Disclosure - Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/FinancialInstrumentsTables</Role>
      <ShortName>Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/FinancialInstruments</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="pfe-10012017x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2311301 - Disclosure - Inventories (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/InventoriesTables</Role>
      <ShortName>Inventories (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/Inventories</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="pfe-10012017x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2312301 - Disclosure - Identifiable Intangible Assets and Goodwill (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillTables</Role>
      <ShortName>Identifiable Intangible Assets and Goodwill (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwill</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="pfe-10012017x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2313301 - Disclosure - Pension and Postretirement Benefit Plans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansTables</Role>
      <ShortName>Pension and Postretirement Benefit Plans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/PensionAndPostretirementBenefitPlans</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="pfe-10012017x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2314301 - Disclosure - Earnings Per Common Share Attributable to Common Shareholders (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/EarningsPerCommonShareAttributableToCommonShareholdersTables</Role>
      <ShortName>Earnings Per Common Share Attributable to Common Shareholders (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/EarningsPerCommonShareAttributableToCommonShareholders</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="pfe-10012017x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2316301 - Disclosure - Segment, Geographic and Other Revenue Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationTables</Role>
      <ShortName>Segment, Geographic and Other Revenue Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformation</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="pfe-10012017x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2401402 - Disclosure - Basis of Presentation and Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetails</Role>
      <ShortName>Basis of Presentation and Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="pfe-10012017x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2403401 - Disclosure - Acquisitions, Sale of Hospira Infusion Systems Net Assets, Collaborative Arrangement and Equity-Method Investments - AstraZeneca (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsAstrazenecaDetails</Role>
      <ShortName>Acquisitions, Sale of Hospira Infusion Systems Net Assets, Collaborative Arrangement and Equity-Method Investments - AstraZeneca (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestments</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="pfe-10012017x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2403402 - Disclosure - Acquisitions, Sale of Hospira Infusion Systems Net Assets, Collaborative Arrangement and Equity-Method Investments - Medivation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsMedivationDetails</Role>
      <ShortName>Acquisitions, Sale of Hospira Infusion Systems Net Assets, Collaborative Arrangement and Equity-Method Investments - Medivation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestments</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="pfe-10012017x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2403403 - Disclosure - Acquisitions, Sale of Hospira Infusion Systems Net Assets, Collaborative Arrangement and Equity-Method Investments - Bamboo Therapeutics (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsBambooTherapeuticsDetails</Role>
      <ShortName>Acquisitions, Sale of Hospira Infusion Systems Net Assets, Collaborative Arrangement and Equity-Method Investments - Bamboo Therapeutics (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestments</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="pfe-10012017x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2403404 - Disclosure - Acquisitions, Sale of Hospira Infusion Systems Net Assets, Collaborative Arrangement and Equity-Method Investments - Anacor Pharmaceuticals, Inc. (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsAnacorPharmaceuticalsIncDetails</Role>
      <ShortName>Acquisitions, Sale of Hospira Infusion Systems Net Assets, Collaborative Arrangement and Equity-Method Investments - Anacor Pharmaceuticals, Inc. (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="pfe-10012017x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2403405 - Disclosure - Acquisitions, Sale of Hospira Infusion Systems Net Assets, Collaborative Arrangement and Equity-Method Investments - Sale of Hospira Infusion Systems Net Assets to ICU Medical, Inc. (EH) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsSaleOfHospiraInfusionSystemsNetAssetsToIcuMedicalIncEhDetails</Role>
      <ShortName>Acquisitions, Sale of Hospira Infusion Systems Net Assets, Collaborative Arrangement and Equity-Method Investments - Sale of Hospira Infusion Systems Net Assets to ICU Medical, Inc. (EH) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="pfe-10012017x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2403406 - Disclosure - Acquisitions, Sale of Hospira Infusion Systems Net Assets, Collaborative Arrangement and Equity-Method Investments - Collaboration Arrangement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsCollaborationArrangementDetails</Role>
      <ShortName>Acquisitions, Sale of Hospira Infusion Systems Net Assets, Collaborative Arrangement and Equity-Method Investments - Collaboration Arrangement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestments</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="pfe-10012017x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2403407 - Disclosure - Acquisitions, Sale of Hospira Infusion Systems Net Assets, Collaborative Arrangement and Equity-Method Investments - Equity-Method Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsEquityMethodInvestmentsDetails</Role>
      <ShortName>Acquisitions, Sale of Hospira Infusion Systems Net Assets, Collaborative Arrangement and Equity-Method Investments - Equity-Method Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestments</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="pfe-10012017x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2404402 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesDetail</Role>
      <ShortName>Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="pfe-10012017x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2404403 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Footnotes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesFootnotesDetails</Role>
      <ShortName>Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Footnotes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="pfe-10012017x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2404404 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Restructuring Accruals (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesRestructuringAccrualsDetail</Role>
      <ShortName>Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Restructuring Accruals (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="pfe-10012017x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2404405 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Restructuring Accruals - Footnotes (Detail)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesRestructuringAccrualsFootnotesDetail</Role>
      <ShortName>Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Restructuring Accruals - Footnotes (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="pfe-10012017x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2407402 - Disclosure - Other (Income)/Deductions - Net (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/OtherIncomeDeductionsNetDetail</Role>
      <ShortName>Other (Income)/Deductions - Net (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/OtherIncomeDeductionsNetTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="pfe-10012017x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Other (Income)/Deductions - Net (Footnotes) (Detail)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail</Role>
      <ShortName>Other (Income)/Deductions - Net (Footnotes) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/OtherIncomeDeductionsNetTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="pfe-10012017x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2407404 - Disclosure - Other (Income)/Deductions - Net - Impaired Intangible Assets (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/OtherIncomeDeductionsNetImpairedIntangibleAssetsDetail</Role>
      <ShortName>Other (Income)/Deductions - Net - Impaired Intangible Assets (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/OtherIncomeDeductionsNetTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="pfe-10012017x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2408402 - Disclosure - Tax Matters - Narrative (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/TaxMattersNarrativeDetail</Role>
      <ShortName>Tax Matters - Narrative (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="pfe-10012017x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2408403 - Disclosure - Tax Matters (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/TaxMattersDetail</Role>
      <ShortName>Tax Matters (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/TaxMattersTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="pfe-10012017x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2409402 - Disclosure - Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetail</Role>
      <ShortName>Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="pfe-10012017x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2410402 - Disclosure - Financial Instruments - Assets and Liabilities Measured on Recurring Basis (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/FinancialInstrumentsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail</Role>
      <ShortName>Financial Instruments - Assets and Liabilities Measured on Recurring Basis (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="pfe-10012017x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2410403 - Disclosure - Financial Instruments - Assets and Liabilities Measured on Recurring Basis - Footnotes (Detail)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.pfizer.com/role/FinancialInstrumentsAssetsAndLiabilitiesMeasuredOnRecurringBasisFootnotesDetail</Role>
      <ShortName>Financial Instruments - Assets and Liabilities Measured on Recurring Basis - Footnotes (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="pfe-10012017x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2410404 - Disclosure - Financial Instruments - Balance Sheet Grouping (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/FinancialInstrumentsBalanceSheetGroupingDetail</Role>
      <ShortName>Financial Instruments - Balance Sheet Grouping (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="pfe-10012017x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2410405 - Disclosure - Financial Instruments - Balance Sheet Grouping - Footnotes (Detail)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.pfizer.com/role/FinancialInstrumentsBalanceSheetGroupingFootnotesDetail</Role>
      <ShortName>Financial Instruments - Balance Sheet Grouping - Footnotes (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="pfe-10012017x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2410406 - Disclosure - Financial Instruments - Investments in Debt Securities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/FinancialInstrumentsInvestmentsInDebtSecuritiesDetail</Role>
      <ShortName>Financial Instruments - Investments in Debt Securities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="pfe-10012017x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2410407 - Disclosure - Financial Instruments - Short-Term Borrowings (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails</Role>
      <ShortName>Financial Instruments - Short-Term Borrowings (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="pfe-10012017x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2410408 - Disclosure - Financial Instruments - Long-Term Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails</Role>
      <ShortName>Financial Instruments - Long-Term Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="pfe-10012017x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2410409 - Disclosure - Financial Instruments - Long-Term Debt - Maturities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtMaturitiesDetails</Role>
      <ShortName>Financial Instruments - Long-Term Debt - Maturities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="pfe-10012017x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2410410 - Disclosure - Financial Instruments - Other Noncurrent Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/FinancialInstrumentsOtherNoncurrentLiabilitiesDetail</Role>
      <ShortName>Financial Instruments - Other Noncurrent Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="pfe-10012017x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2410411 - Disclosure - Financial Instruments - Derivative Financial Instruments and Hedging Activities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetail</Role>
      <ShortName>Financial Instruments - Derivative Financial Instruments and Hedging Activities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="pfe-10012017x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2410412 - Disclosure - Financial Instruments - Narrative (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/FinancialInstrumentsNarrativeDetail</Role>
      <ShortName>Financial Instruments - Narrative (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="pfe-10012017x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2411402 - Disclosure - Inventories (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/InventoriesDetail</Role>
      <ShortName>Inventories (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/InventoriesTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="pfe-10012017x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2412402 - Disclosure - Identifiable Intangible Assets and Goodwill - Finite-lived and Indefinite-lived Intangible Assets (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsDetail</Role>
      <ShortName>Identifiable Intangible Assets and Goodwill - Finite-lived and Indefinite-lived Intangible Assets (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="pfe-10012017x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>2412403 - Disclosure - Identifiable Intangible Assets and Goodwill - Finite-lived and Indefinite-lived Intangible Assets - Footnotes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsFootnotesDetails</Role>
      <ShortName>Identifiable Intangible Assets and Goodwill - Finite-lived and Indefinite-lived Intangible Assets - Footnotes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="pfe-10012017x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>2412404 - Disclosure - Identifiable Intangible Assets and Goodwill - Finite-lived Intangible Assets Percentage of Total Intangibles (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedIntangibleAssetsPercentageOfTotalIntangiblesDetails</Role>
      <ShortName>Identifiable Intangible Assets and Goodwill - Finite-lived Intangible Assets Percentage of Total Intangibles (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="pfe-10012017x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>2412405 - Disclosure - Identifiable Intangible Assets and Goodwill - Indefinite-lived Intangible Assets Percentage of Total Intangibles (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillIndefiniteLivedIntangibleAssetsPercentageOfTotalIntangiblesDetails</Role>
      <ShortName>Identifiable Intangible Assets and Goodwill - Indefinite-lived Intangible Assets Percentage of Total Intangibles (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="pfe-10012017x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>2412406 - Disclosure - Identifiable Intangible Assets and Goodwill - Narrative (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillNarrativeDetail</Role>
      <ShortName>Identifiable Intangible Assets and Goodwill - Narrative (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="pfe-10012017x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>2412407 - Disclosure - Identifiable Intangible Assets and Goodwill - Goodwill (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillGoodwillDetail</Role>
      <ShortName>Identifiable Intangible Assets and Goodwill - Goodwill (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="pfe-10012017x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>2413402 - Disclosure - Pension and Postretirement Benefit Plans - Net Periodic Benefit Cost (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansNetPeriodicBenefitCostDetail</Role>
      <ShortName>Pension and Postretirement Benefit Plans - Net Periodic Benefit Cost (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="pfe-10012017x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>2413403 - Disclosure - Pension and Postretirement Benefit Plans - Net Periodic Benefit Cost - Footnotes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansNetPeriodicBenefitCostFootnotesDetails</Role>
      <ShortName>Pension and Postretirement Benefit Plans - Net Periodic Benefit Cost - Footnotes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="pfe-10012017x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>2413404 - Disclosure - Pension and Postretirement Benefit Plans (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansDetail</Role>
      <ShortName>Pension and Postretirement Benefit Plans (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansTables</ParentRole>
      <Position>71</Position>
    </Report>
    <Report instance="pfe-10012017x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>2414402 - Disclosure - Earnings Per Common Share Attributable to Common Shareholders (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/EarningsPerCommonShareAttributableToCommonShareholdersDetails</Role>
      <ShortName>Earnings Per Common Share Attributable to Common Shareholders (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/EarningsPerCommonShareAttributableToCommonShareholdersTables</ParentRole>
      <Position>72</Position>
    </Report>
    <Report instance="pfe-10012017x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>2415401 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/CommitmentsAndContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>73</Position>
    </Report>
    <Report instance="pfe-10012017x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>2415402 - Disclosure - Commitments and Contingencies (Actions In Which We Are The Plaintiff) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/CommitmentsAndContingenciesActionsInWhichWeArePlaintiffDetails</Role>
      <ShortName>Commitments and Contingencies (Actions In Which We Are The Plaintiff) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>74</Position>
    </Report>
    <Report instance="pfe-10012017x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>2415403 - Disclosure - Commitments and Contingencies (Actions In Which We Are The Defendant) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/CommitmentsAndContingenciesActionsInWhichWeAreDefendantDetail</Role>
      <ShortName>Commitments and Contingencies (Actions In Which We Are The Defendant) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>75</Position>
    </Report>
    <Report instance="pfe-10012017x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>2416402 - Disclosure - Segment, Geographic and Other Revenue Information - Narrative (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationNarrativeDetail</Role>
      <ShortName>Segment, Geographic and Other Revenue Information - Narrative (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationTables</ParentRole>
      <Position>76</Position>
    </Report>
    <Report instance="pfe-10012017x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>2416403 - Disclosure - Segment, Geographic and Other Revenue Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationDetail</Role>
      <ShortName>Segment, Geographic and Other Revenue Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationTables</ParentRole>
      <Position>77</Position>
    </Report>
    <Report instance="pfe-10012017x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>2416404 - Disclosure - Segment, Geographic and Other Revenue Information - Footnotes (Detail)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationFootnotesDetail</Role>
      <ShortName>Segment, Geographic and Other Revenue Information - Footnotes (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationTables</ParentRole>
      <Position>78</Position>
    </Report>
    <Report instance="pfe-10012017x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>2416405 - Disclosure - Segment, Geographic and Other Revenue Information - Revenues By Geographic Area (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByGeographicAreaDetail</Role>
      <ShortName>Segment, Geographic and Other Revenue Information - Revenues By Geographic Area (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="pfe-10012017x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>2416406 - Disclosure - Segment, Geographic and Other Revenue Information - Revenues By Geographic Area - Footnotes (Detail)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByGeographicAreaFootnotesDetail</Role>
      <ShortName>Segment, Geographic and Other Revenue Information - Revenues By Geographic Area - Footnotes (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="pfe-10012017x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>2416407 - Disclosure - Segment, Geographic and Other Revenue Information - Revenues By Products (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail</Role>
      <ShortName>Segment, Geographic and Other Revenue Information - Revenues By Products (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="pfe-10012017x10q.htm">pfe-10012017x10q.htm</File>
    <File>pfe-10012017x10qexhibit101.htm</File>
    <File>pfe-10012017x10qexhibit102.htm</File>
    <File>pfe-10012017x10qexhibit12.htm</File>
    <File>pfe-10012017x10qexhibit15.htm</File>
    <File>pfe-10012017x10qexhibit311.htm</File>
    <File>pfe-10012017x10qexhibit312.htm</File>
    <File>pfe-10012017x10qexhibit321.htm</File>
    <File>pfe-10012017x10qexhibit322.htm</File>
    <File>pfe-20171001.xsd</File>
    <File>pfe-20171001_cal.xml</File>
    <File>pfe-20171001_def.xml</File>
    <File>pfe-20171001_lab.xml</File>
    <File>pfe-20171001_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2014-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/currency/2017-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2017-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/invest/2013-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2017-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>105
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "pfe-10012017x10q.htm": {
   "axisCustom": 4,
   "axisStandard": 48,
   "contextCount": 796,
   "dts": {
    "calculationLink": {
     "local": [
      "pfe-20171001_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "pfe-20171001_def.xml"
     ]
    },
    "inline": {
     "local": [
      "pfe-10012017x10q.htm"
     ]
    },
    "labelLink": {
     "local": [
      "pfe-20171001_lab.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-doc-2017-01-31.xml",
      "http://xbrl.sec.gov/dei/2014/dei-doc-2014-01-31.xml",
      "http://xbrl.sec.gov/invest/2013/invest-doc-2013-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "pfe-20171001_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-ref-2017-01-31.xml",
      "http://xbrl.sec.gov/dei/2014/dei-ref-2014-01-31.xml",
      "http://xbrl.sec.gov/invest/2013/invest-ref-2013-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "pfe-20171001.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2017/elts/us-parts-codification-2017-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2017/elts/us-roles-2017-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2017/elts/us-types-2017-01-31.xsd",
      "http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd",
      "http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd",
      "http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd",
      "http://xbrl.sec.gov/exch/2017/exch-2017-01-31.xsd",
      "http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd",
      "http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd",
      "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd",
      "http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd"
     ]
    }
   },
   "elementCount": 847,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2017-01-31": 24,
    "http://www.pfizer.com/20171001": 15,
    "http://xbrl.sec.gov/dei/2014-01-31": 8,
    "total": 47
   },
   "keyCustom": 92,
   "keyStandard": 320,
   "memberCustom": 153,
   "memberStandard": 79,
   "nsprefix": "pfe",
   "nsuri": "http://www.pfizer.com/20171001",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001000 - Document - Document and Entity Information",
     "role": "http://www.pfizer.com/role/DocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pfe:BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsCollaborativeArrangementsEquityandCostMethodInvestmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103100 - Disclosure - Acquisitions, Sale of Hospira Infusion Systems Net Assets, Collaborative Arrangement and Equity-Method Investments",
     "role": "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestments",
     "shortName": "Acquisitions, Sale of Hospira Infusion Systems Net Assets, Collaborative Arrangement and Equity-Method Investments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pfe:BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsCollaborativeArrangementsEquityandCostMethodInvestmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2104100 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives",
     "role": "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiatives",
     "shortName": "Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2107100 - Disclosure - Other (Income)/Deductions - Net",
     "role": "http://www.pfizer.com/role/OtherIncomeDeductionsNet",
     "shortName": "Other (Income)/Deductions - Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2108100 - Disclosure - Tax Matters",
     "role": "http://www.pfizer.com/role/TaxMatters",
     "shortName": "Tax Matters",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2109100 - Disclosure - Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests",
     "role": "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterests",
     "shortName": "Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2110100 - Disclosure - Financial Instruments",
     "role": "http://www.pfizer.com/role/FinancialInstruments",
     "shortName": "Financial Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2111100 - Disclosure - Inventories",
     "role": "http://www.pfizer.com/role/Inventories",
     "shortName": "Inventories",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2112100 - Disclosure - Identifiable Intangible Assets and Goodwill",
     "role": "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwill",
     "shortName": "Identifiable Intangible Assets and Goodwill",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2113100 - Disclosure - Pension and Postretirement Benefit Plans",
     "role": "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlans",
     "shortName": "Pension and Postretirement Benefit Plans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2114100 - Disclosure - Earnings Per Common Share Attributable to Common Shareholders",
     "role": "http://www.pfizer.com/role/EarningsPerCommonShareAttributableToCommonShareholders",
     "shortName": "Earnings Per Common Share Attributable to Common Shareholders",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
       "us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q3QTD",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:SalesRevenueGoodsNet",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF INCOME",
     "role": "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfIncome",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF INCOME",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q3QTD",
      "decimals": "-6",
      "lang": null,
      "name": "us-gaap:CostOfGoodsSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2115100 - Disclosure - Commitments and Contingencies",
     "role": "http://www.pfizer.com/role/CommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2116100 - Disclosure - Segment, Geographic and Other Revenue Information",
     "role": "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformation",
     "shortName": "Segment, Geographic and Other Revenue Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2201201 - Disclosure - Basis of Presentation and Significant Accounting Policies (Policies)",
     "role": "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies",
     "shortName": "Basis of Presentation and Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2304301 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives (Tables)",
     "role": "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesTables",
     "shortName": "Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2307301 - Disclosure - Other (Income)/Deductions - Net (Tables)",
     "role": "http://www.pfizer.com/role/OtherIncomeDeductionsNetTables",
     "shortName": "Other (Income)/Deductions - Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pfe:ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2308301 - Disclosure - Tax Matters (Tables)",
     "role": "http://www.pfizer.com/role/TaxMattersTables",
     "shortName": "Tax Matters (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pfe:ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2309301 - Disclosure - Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests (Tables)",
     "role": "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsTables",
     "shortName": "Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2310301 - Disclosure - Financial Instruments (Tables)",
     "role": "http://www.pfizer.com/role/FinancialInstrumentsTables",
     "shortName": "Financial Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ScheduleOfInventoryNoncurrentTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2311301 - Disclosure - Inventories (Tables)",
     "role": "http://www.pfizer.com/role/InventoriesTables",
     "shortName": "Inventories (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ScheduleOfInventoryNoncurrentTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2312301 - Disclosure - Identifiable Intangible Assets and Goodwill (Tables)",
     "role": "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillTables",
     "shortName": "Identifiable Intangible Assets and Goodwill (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q3QTD",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME",
     "role": "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q3QTD",
      "decimals": "-6",
      "lang": null,
      "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2313301 - Disclosure - Pension and Postretirement Benefit Plans (Tables)",
     "role": "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansTables",
     "shortName": "Pension and Postretirement Benefit Plans (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2314301 - Disclosure - Earnings Per Common Share Attributable to Common Shareholders (Tables)",
     "role": "http://www.pfizer.com/role/EarningsPerCommonShareAttributableToCommonShareholdersTables",
     "shortName": "Earnings Per Common Share Attributable to Common Shareholders (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2316301 - Disclosure - Segment, Geographic and Other Revenue Information (Tables)",
     "role": "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationTables",
     "shortName": "Segment, Geographic and Other Revenue Information (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q3YTD",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unitRef": "Operating_Segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2401402 - Disclosure - Basis of Presentation and Significant Accounting Policies (Details)",
     "role": "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetails",
     "shortName": "Basis of Presentation and Significant Accounting Policies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2016Q3QTD",
      "decimals": "-6",
      "lang": null,
      "name": "pfe:EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTaxBenefitAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "contextRef": "FI2017Q3",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403401 - Disclosure - Acquisitions, Sale of Hospira Infusion Systems Net Assets, Collaborative Arrangement and Equity-Method Investments - AstraZeneca (Details)",
     "role": "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsAstrazenecaDetails",
     "shortName": "Acquisitions, Sale of Hospira Infusion Systems Net Assets, Collaborative Arrangement and Equity-Method Investments - AstraZeneca (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "D2016Q4Dec22-Dec22_us-gaap_BusinessAcquisitionAxis_pfe_AstraZenecaMember",
      "decimals": "-6",
      "lang": null,
      "name": "pfe:PaymentstoAcquireBusinessesGrossInitialPayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "contextRef": "FI2017Q3",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403402 - Disclosure - Acquisitions, Sale of Hospira Infusion Systems Net Assets, Collaborative Arrangement and Equity-Method Investments - Medivation (Details)",
     "role": "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsMedivationDetails",
     "shortName": "Acquisitions, Sale of Hospira Infusion Systems Net Assets, Collaborative Arrangement and Equity-Method Investments - Medivation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "D2016Q3Sep28-Sep28_us-gaap_BusinessAcquisitionAxis_pfe_MedivationMember",
      "decimals": "-8",
      "lang": null,
      "name": "us-gaap:BusinessCombinationConsiderationTransferred1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q3YTD",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403403 - Disclosure - Acquisitions, Sale of Hospira Infusion Systems Net Assets, Collaborative Arrangement and Equity-Method Investments - Bamboo Therapeutics (Details)",
     "role": "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsBambooTherapeuticsDetails",
     "shortName": "Acquisitions, Sale of Hospira Infusion Systems Net Assets, Collaborative Arrangement and Equity-Method Investments - Bamboo Therapeutics (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "D2016Q3Aug01-Aug01_us-gaap_BusinessAcquisitionAxis_pfe_BambooTherapeuticsMember",
      "decimals": "-6",
      "lang": null,
      "name": "us-gaap:BusinessCombinationConsiderationTransferred1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q3YTD",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403404 - Disclosure - Acquisitions, Sale of Hospira Infusion Systems Net Assets, Collaborative Arrangement and Equity-Method Investments - Anacor Pharmaceuticals, Inc. (Details)",
     "role": "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsAnacorPharmaceuticalsIncDetails",
     "shortName": "Acquisitions, Sale of Hospira Infusion Systems Net Assets, Collaborative Arrangement and Equity-Method Investments - Anacor Pharmaceuticals, Inc. (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "D2016Q2Jun24-Jun24_us-gaap_BusinessAcquisitionAxis_pfe_AnacorMember",
      "decimals": "-8",
      "lang": null,
      "name": "us-gaap:PaymentsToAcquireBusinessesGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q3QTD",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403405 - Disclosure - Acquisitions, Sale of Hospira Infusion Systems Net Assets, Collaborative Arrangement and Equity-Method Investments - Sale of Hospira Infusion Systems Net Assets to ICU Medical, Inc. (EH) (Details)",
     "role": "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsSaleOfHospiraInfusionSystemsNetAssetsToIcuMedicalIncEhDetails",
     "shortName": "Acquisitions, Sale of Hospira Infusion Systems Net Assets, Collaborative Arrangement and Equity-Method Investments - Sale of Hospira Infusion Systems Net Assets to ICU Medical, Inc. (EH) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "I2017Q1Jan05_us-gaap_CounterpartyNameAxis_pfe_ICUMedicalMember_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_HISMember",
      "decimals": "-6",
      "lang": null,
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q1QTD_us-gaap_CounterpartyNameAxis_pfe_MerckKGaAMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromCollaborators",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403406 - Disclosure - Acquisitions, Sale of Hospira Infusion Systems Net Assets, Collaborative Arrangement and Equity-Method Investments - Collaboration Arrangement (Details)",
     "role": "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsCollaborationArrangementDetails",
     "shortName": "Acquisitions, Sale of Hospira Infusion Systems Net Assets, Collaborative Arrangement and Equity-Method Investments - Collaboration Arrangement (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q1QTD_us-gaap_CounterpartyNameAxis_pfe_MerckKGaAMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromCollaborators",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "I2017Q2Jun30_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_LaboratorioTeutoBrasileroMember",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002501 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (PARENTHETICAL)",
     "role": "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeParenthetical",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (PARENTHETICAL)",
     "subGroupType": "",
     "uniqueAnchor": null
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "ix:continuation",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FI2016Q3_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_HisunPfizerPharmaceuticalsCoLtdMember",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403407 - Disclosure - Acquisitions, Sale of Hospira Infusion Systems Net Assets, Collaborative Arrangement and Equity-Method Investments - Equity-Method Investments (Details)",
     "role": "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsEquityMethodInvestmentsDetails",
     "shortName": "Acquisitions, Sale of Hospira Infusion Systems Net Assets, Collaborative Arrangement and Equity-Method Investments - Equity-Method Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FI2017Q3_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_HisunPfizerPharmaceuticalsCoLtdMember",
      "decimals": "-6",
      "lang": null,
      "name": "us-gaap:EquityMethodInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q3QTD",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:BusinessCombinationIntegrationRelatedCosts",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2404402 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives (Detail)",
     "role": "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesDetail",
     "shortName": "Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q3QTD",
      "decimals": "-6",
      "lang": null,
      "name": "us-gaap:SeveranceCosts1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q3QTD",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:RestructuringCharges",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2404403 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Footnotes (Details)",
     "role": "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesFootnotesDetails",
     "shortName": "Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Footnotes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q3QTD_us-gaap_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember",
      "decimals": "-6",
      "lang": null,
      "name": "us-gaap:RestructuringCharges",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FI2016Q4",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:RestructuringReserve",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2404404 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Restructuring Accruals (Detail)",
     "role": "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesRestructuringAccrualsDetail",
     "shortName": "Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Restructuring Accruals (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q3YTD",
      "decimals": "-6",
      "lang": null,
      "name": "pfe:PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FI2017Q3",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:RestructuringReserve",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2404405 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Restructuring Accruals - Footnotes (Detail)",
     "role": "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesRestructuringAccrualsFootnotesDetail",
     "shortName": "Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Restructuring Accruals - Footnotes (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "contextRef": "FI2017Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember",
      "decimals": "-6",
      "lang": null,
      "name": "us-gaap:RestructuringReserve",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q3QTD",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:InvestmentIncomeInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407402 - Disclosure - Other (Income)/Deductions - Net (Detail)",
     "role": "http://www.pfizer.com/role/OtherIncomeDeductionsNetDetail",
     "shortName": "Other (Income)/Deductions - Net (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q3QTD",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:InvestmentIncomeInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q3QTD",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:RoyaltyRevenue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407403 - Disclosure - Other (Income)/Deductions - Net (Footnotes) (Detail)",
     "role": "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail",
     "shortName": "Other (Income)/Deductions - Net (Footnotes) (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "ix:continuation",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q3QTD",
      "decimals": "-6",
      "lang": null,
      "name": "us-gaap:GainOnSaleOfInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfImpairedIntangibleAssetsTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FI2017Q3_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407404 - Disclosure - Other (Income)/Deductions - Net - Impaired Intangible Assets (Detail)",
     "role": "http://www.pfizer.com/role/OtherIncomeDeductionsNetImpairedIntangibleAssetsDetail",
     "shortName": "Other (Income)/Deductions - Net - Impaired Intangible Assets (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfImpairedIntangibleAssetsTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FI2017Q3_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q3QTD",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408402 - Disclosure - Tax Matters - Narrative (Detail)",
     "role": "http://www.pfizer.com/role/TaxMattersNarrativeDetail",
     "shortName": "Tax Matters - Narrative (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q3QTD",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "pfe:ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q3QTD",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408403 - Disclosure - Tax Matters (Detail)",
     "role": "http://www.pfizer.com/role/TaxMattersDetail",
     "shortName": "Tax Matters (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "pfe:ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q3QTD",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "contextRef": "FI2017Q3",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS",
     "role": "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "contextRef": "FI2017Q3",
      "decimals": "-6",
      "lang": null,
      "name": "us-gaap:ShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "contextRef": "FI2016Q4",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409402 - Disclosure - Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests (Detail)",
     "role": "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetail",
     "shortName": "Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "ix:continuation",
       "ix:continuation",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q3YTD",
      "decimals": "-6",
      "lang": null,
      "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FI2017Q3",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "pfe:SelectedFinancialAssets",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410402 - Disclosure - Financial Instruments - Assets and Liabilities Measured on Recurring Basis (Detail)",
     "role": "http://www.pfizer.com/role/FinancialInstrumentsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail",
     "shortName": "Financial Instruments - Assets and Liabilities Measured on Recurring Basis (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FI2017Q3",
      "decimals": "-6",
      "lang": null,
      "name": "pfe:OtherFinancialLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "ix:continuation",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q3YTD",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleEquitySecuritiesGrossUnrealizedGain",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410403 - Disclosure - Financial Instruments - Assets and Liabilities Measured on Recurring Basis - Footnotes (Detail)",
     "role": "http://www.pfizer.com/role/FinancialInstrumentsAssetsAndLiabilitiesMeasuredOnRecurringBasisFootnotesDetail",
     "shortName": "Financial Instruments - Assets and Liabilities Measured on Recurring Basis - Footnotes (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "ix:continuation",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q3YTD",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleEquitySecuritiesGrossUnrealizedGain",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FI2017Q3",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "pfe:SelectedFinancialAssets",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410404 - Disclosure - Financial Instruments - Balance Sheet Grouping (Detail)",
     "role": "http://www.pfizer.com/role/FinancialInstrumentsBalanceSheetGroupingDetail",
     "shortName": "Financial Instruments - Balance Sheet Grouping (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FI2017Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_CashAndCashEquivalentsMember",
      "decimals": "-6",
      "lang": null,
      "name": "pfe:SelectedFinancialAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FI2017Q3",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "pfe:SelectedFinancialAssets",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410405 - Disclosure - Financial Instruments - Balance Sheet Grouping - Footnotes (Detail)",
     "role": "http://www.pfizer.com/role/FinancialInstrumentsBalanceSheetGroupingFootnotesDetail",
     "shortName": "Financial Instruments - Balance Sheet Grouping - Footnotes (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "ix:continuation",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FI2017Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember",
      "decimals": "-6",
      "lang": null,
      "name": "pfe:SelectedFinancialAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FI2017Q3",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "pfe:DebtSecuritiesMaturitiesWithinOneYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410406 - Disclosure - Financial Instruments - Investments in Debt Securities (Detail)",
     "role": "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsInDebtSecuritiesDetail",
     "shortName": "Financial Instruments - Investments in Debt Securities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FI2017Q3",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "pfe:DebtSecuritiesMaturitiesWithinOneYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FI2017Q3_us-gaap_ShortTermDebtTypeAxis_us-gaap_CommercialPaperMember",
      "decimals": "-8",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommercialPaper",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410407 - Disclosure - Financial Instruments - Short-Term Borrowings (Details)",
     "role": "http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails",
     "shortName": "Financial Instruments - Short-Term Borrowings (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FI2017Q3_us-gaap_ShortTermDebtTypeAxis_us-gaap_CommercialPaperMember",
      "decimals": "-8",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommercialPaper",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FI2017Q3",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410408 - Disclosure - Financial Instruments - Long-Term Debt (Details)",
     "role": "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails",
     "shortName": "Financial Instruments - Long-Term Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FI2017Q3_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember",
      "decimals": "-6",
      "lang": null,
      "name": "us-gaap:LongTermDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FI2017Q3",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410409 - Disclosure - Financial Instruments - Long-Term Debt - Maturities (Details)",
     "role": "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtMaturitiesDetails",
     "shortName": "Financial Instruments - Long-Term Debt - Maturities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FI2017Q3",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FI2017Q3",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsNet",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410410 - Disclosure - Financial Instruments - Other Noncurrent Liabilities (Detail)",
     "role": "http://www.pfizer.com/role/FinancialInstrumentsOtherNoncurrentLiabilitiesDetail",
     "shortName": "Financial Instruments - Other Noncurrent Liabilities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "I2017Q3Aug31_us-gaap_ProductOrServiceAxis_pfe_BesponsaMember_us-gaap_StatementGeographicalAxis_country_US",
      "decimals": "-6",
      "lang": null,
      "name": "pfe:ResearchandDevelopmentArrangementAggregatePaymentObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": null,
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003001 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (PARENTHETICAL)",
     "role": "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (PARENTHETICAL)",
     "subGroupType": "",
     "uniqueAnchor": null
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FI2017Q3",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410411 - Disclosure - Financial Instruments - Derivative Financial Instruments and Hedging Activities (Detail)",
     "role": "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetail",
     "shortName": "Financial Instruments - Derivative Financial Instruments and Hedging Activities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q3YTD",
      "decimals": "-6",
      "lang": null,
      "name": "us-gaap:UnrealizedLossOnForeignCurrencyDerivativesBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FI2017Q3",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:DerivativeNetLiabilityPositionAggregateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410412 - Disclosure - Financial Instruments - Narrative (Detail)",
     "role": "http://www.pfizer.com/role/FinancialInstrumentsNarrativeDetail",
     "shortName": "Financial Instruments - Narrative (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FI2017Q3",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:DerivativeNetLiabilityPositionAggregateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:ScheduleOfInventoryNoncurrentTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FI2017Q3",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryFinishedGoodsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411402 - Disclosure - Inventories (Detail)",
     "role": "http://www.pfizer.com/role/InventoriesDetail",
     "shortName": "Inventories (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:ScheduleOfInventoryNoncurrentTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FI2017Q3",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryFinishedGoodsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FI2017Q3",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412402 - Disclosure - Identifiable Intangible Assets and Goodwill - Finite-lived and Indefinite-lived Intangible Assets (Detail)",
     "role": "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsDetail",
     "shortName": "Identifiable Intangible Assets and Goodwill - Finite-lived and Indefinite-lived Intangible Assets (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FI2017Q3",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FI2017Q3",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsNet",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412403 - Disclosure - Identifiable Intangible Assets and Goodwill - Finite-lived and Indefinite-lived Intangible Assets - Footnotes (Details)",
     "role": "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsFootnotesDetails",
     "shortName": "Identifiable Intangible Assets and Goodwill - Finite-lived and Indefinite-lived Intangible Assets - Footnotes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "ix:continuation",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FI2017Q3_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember_us-gaap_ProductOrServiceAxis_pfe_EucrisaMember",
      "decimals": "-8",
      "lang": null,
      "name": "pfe:IntangibleAssetsTransfersDuringPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "pfe:IdentifiableintangibleassetsasapercentageoftotalidentifiableintangibleassetslessaccumulatedamortizationbysegmentTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FI2017Q3_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412404 - Disclosure - Identifiable Intangible Assets and Goodwill - Finite-lived Intangible Assets Percentage of Total Intangibles (Details)",
     "role": "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedIntangibleAssetsPercentageOfTotalIntangiblesDetails",
     "shortName": "Identifiable Intangible Assets and Goodwill - Finite-lived Intangible Assets Percentage of Total Intangibles (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "pfe:IdentifiableintangibleassetsasapercentageoftotalidentifiableintangibleassetslessaccumulatedamortizationbysegmentTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FI2017Q3_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "pfe:IdentifiableintangibleassetsasapercentageoftotalidentifiableintangibleassetslessaccumulatedamortizationbysegmentTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FI2017Q3_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412405 - Disclosure - Identifiable Intangible Assets and Goodwill - Indefinite-lived Intangible Assets Percentage of Total Intangibles (Details)",
     "role": "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillIndefiniteLivedIntangibleAssetsPercentageOfTotalIntangiblesDetails",
     "shortName": "Identifiable Intangible Assets and Goodwill - Indefinite-lived Intangible Assets Percentage of Total Intangibles (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "pfe:IdentifiableintangibleassetsasapercentageoftotalidentifiableintangibleassetslessaccumulatedamortizationbysegmentTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FI2017Q3_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthSegmentMember",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q3QTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_FiniteLivedIntangibleAssetsMember",
      "decimals": "-8",
      "first": true,
      "lang": null,
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412406 - Disclosure - Identifiable Intangible Assets and Goodwill - Narrative (Detail)",
     "role": "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillNarrativeDetail",
     "shortName": "Identifiable Intangible Assets and Goodwill - Narrative (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q3QTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_FiniteLivedIntangibleAssetsMember",
      "decimals": "-8",
      "first": true,
      "lang": null,
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "contextRef": "FI2016Q4",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412407 - Disclosure - Identifiable Intangible Assets and Goodwill - Goodwill (Detail)",
     "role": "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillGoodwillDetail",
     "shortName": "Identifiable Intangible Assets and Goodwill - Goodwill (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q3YTD",
      "decimals": "-6",
      "lang": null,
      "name": "us-gaap:GoodwillAcquiredDuringPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q3QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedBenefitPlanServiceCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413402 - Disclosure - Pension and Postretirement Benefit Plans - Net Periodic Benefit Cost (Detail)",
     "role": "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansNetPeriodicBenefitCostDetail",
     "shortName": "Pension and Postretirement Benefit Plans - Net Periodic Benefit Cost (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q3QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedBenefitPlanServiceCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q3YTD",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "role": "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlows",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q3YTD",
      "decimals": "-6",
      "lang": null,
      "name": "pfe:DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "ix:continuation",
       "ix:continuation",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "D2017Q2Apr01-Apr30_us-gaap_BusinessAcquisitionAxis_pfe_HospiraMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedBenefitPlanSettlementsBenefitObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413403 - Disclosure - Pension and Postretirement Benefit Plans - Net Periodic Benefit Cost - Footnotes (Details)",
     "role": "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansNetPeriodicBenefitCostFootnotesDetails",
     "shortName": "Pension and Postretirement Benefit Plans - Net Periodic Benefit Cost - Footnotes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "ix:continuation",
       "ix:continuation",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "D2017Q2Apr01-Apr30_us-gaap_BusinessAcquisitionAxis_pfe_HospiraMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedBenefitPlanSettlementsBenefitObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "contextRef": "D2017Q1Jan01-Jan31_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember",
      "decimals": "-8",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedBenefitPlanContributionsByEmployer",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413404 - Disclosure - Pension and Postretirement Benefit Plans (Detail)",
     "role": "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansDetail",
     "shortName": "Pension and Postretirement Benefit Plans (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "contextRef": "D2017Q1Jan01-Jan31_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember",
      "decimals": "-8",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedBenefitPlanContributionsByEmployer",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q3QTD",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414402 - Disclosure - Earnings Per Common Share Attributable to Common Shareholders (Details)",
     "role": "http://www.pfizer.com/role/EarningsPerCommonShareAttributableToCommonShareholdersDetails",
     "shortName": "Earnings Per Common Share Attributable to Common Shareholders (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q3QTD",
      "decimals": "-6",
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "I2017Q1Feb02_us-gaap_ShareRepurchaseProgramAxis_pfe_ShareRepurchaseAgreementwithCitibankMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415401 - Disclosure - Commitments and Contingencies (Details)",
     "role": "http://www.pfizer.com/role/CommitmentsAndContingenciesDetails",
     "shortName": "Commitments and Contingencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "I2017Q1Feb02_us-gaap_ShareRepurchaseProgramAxis_pfe_ShareRepurchaseAgreementwithCitibankMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "D2015Q2June2015_us-gaap_LitigationCaseAxis_pfe_HospiraVersusAmnealPharmaceuticalsLLCMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_ProductOrServiceAxis_pfe_PrecedexPremixMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:GainContingencyPatentsFoundNotInfringedUponNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Patent",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415402 - Disclosure - Commitments and Contingencies (Actions In Which We Are The Plaintiff) (Details)",
     "role": "http://www.pfizer.com/role/CommitmentsAndContingenciesActionsInWhichWeArePlaintiffDetails",
     "shortName": "Commitments and Contingencies (Actions In Which We Are The Plaintiff) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "D2015Q2June2015_us-gaap_LitigationCaseAxis_pfe_HospiraVersusAmnealPharmaceuticalsLLCMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_ProductOrServiceAxis_pfe_PrecedexPremixMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:GainContingencyPatentsFoundNotInfringedUponNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Patent",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "D2015Q1March2015_us-gaap_LitigationCaseAxis_pfe_JanssenandNewYorkUniversityVersusHospiraCelltrionHealthcareandCelltrionInc.Member_us-gaap_ProductOrServiceAxis_pfe_InflectraMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:LossContingencyPatentsAllegedlyInfringedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Patent",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415403 - Disclosure - Commitments and Contingencies (Actions In Which We Are The Defendant) (Detail)",
     "role": "http://www.pfizer.com/role/CommitmentsAndContingenciesActionsInWhichWeAreDefendantDetail",
     "shortName": "Commitments and Contingencies (Actions In Which We Are The Defendant) (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "D2015Q1March2015_us-gaap_LitigationCaseAxis_pfe_JanssenandNewYorkUniversityVersusHospiraCelltrionHealthcareandCelltrionInc.Member_us-gaap_ProductOrServiceAxis_pfe_InflectraMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:LossContingencyPatentsAllegedlyInfringedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Patent",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q3YTD",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unitRef": "Operating_Segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416402 - Disclosure - Segment, Geographic and Other Revenue Information - Narrative (Detail)",
     "role": "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationNarrativeDetail",
     "shortName": "Segment, Geographic and Other Revenue Information - Narrative (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
       "us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q3QTD",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:SalesRevenueGoodsNet",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416403 - Disclosure - Segment, Geographic and Other Revenue Information (Detail)",
     "role": "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationDetail",
     "shortName": "Segment, Geographic and Other Revenue Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
       "us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q3QTD_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember",
      "decimals": "-6",
      "lang": null,
      "name": "us-gaap:SalesRevenueGoodsNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q3QTD",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416404 - Disclosure - Segment, Geographic and Other Revenue Information - Footnotes (Detail)",
     "role": "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationFootnotesDetail",
     "shortName": "Segment, Geographic and Other Revenue Information - Footnotes (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q3QTD_us-gaap_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember",
      "decimals": "-6",
      "lang": null,
      "name": "pfe:RestructuringChargesandImplementationCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R79": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
       "us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q3QTD",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:SalesRevenueGoodsNet",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416405 - Disclosure - Segment, Geographic and Other Revenue Information - Revenues By Geographic Area (Detail)",
     "role": "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByGeographicAreaDetail",
     "shortName": "Segment, Geographic and Other Revenue Information - Revenues By Geographic Area (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q3QTD",
      "decimals": "2",
      "lang": null,
      "name": "pfe:PercentageChangeInRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "ix:continuation",
       "div",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "contextRef": "I2017Q1Feb03_us-gaap_CounterpartyNameAxis_pfe_ICUMedicalMember_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_HISMember",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "pfe:DisposalGroupIncludingDiscontinuedOperationConsiderationTransferredEquityInterestsShares",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004501 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (PARENTHETICAL)",
     "role": "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlowsParenthetical",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (PARENTHETICAL)",
     "subGroupType": "",
     "uniqueAnchor": null
    },
    "R80": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
       "us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q3QTD",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:SalesRevenueGoodsNet",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416406 - Disclosure - Segment, Geographic and Other Revenue Information - Revenues By Geographic Area - Footnotes (Detail)",
     "role": "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByGeographicAreaFootnotesDetail",
     "shortName": "Segment, Geographic and Other Revenue Information - Revenues By Geographic Area - Footnotes (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "link:footnote",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q3QTD_us-gaap_CurrencyAxis_currency_EUR_us-gaap_StatementGeographicalAxis_pfe_DevelopedEuropeMember",
      "decimals": "-8",
      "lang": "en-US",
      "name": "us-gaap:SalesRevenueGoodsNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R81": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
       "us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q3QTD",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:SalesRevenueGoodsNet",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416407 - Disclosure - Segment, Geographic and Other Revenue Information - Revenues By Products (Detail)",
     "role": "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail",
     "shortName": "Segment, Geographic and Other Revenue Information - Revenues By Products (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q3QTD_us-gaap_StatementBusinessSegmentsAxis_pfe_InnovativeHealthandEssentialHealthMember",
      "decimals": "-6",
      "lang": null,
      "name": "us-gaap:SalesRevenueGoodsNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101100 - Disclosure - Basis of Presentation and Significant Accounting Policies",
     "role": "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPolicies",
     "shortName": "Basis of Presentation and Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 238,
   "tag": {
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "U.S. [Member]"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsOtherNoncurrentLiabilitiesDetail",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansDetail",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansNetPeriodicBenefitCostDetail",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansNetPeriodicBenefitCostFootnotesDetails",
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesFootnotesDetails",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByGeographicAreaDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_AllCurrenciesDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "All Currencies [Domain]",
        "terseLabel": "All Currencies [Domain]"
       }
      }
     },
     "localname": "AllCurrenciesDomain",
     "nsuri": "http://xbrl.sec.gov/currency/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByGeographicAreaFootnotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_EUR": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Euro Member Countries, Euro",
        "terseLabel": "Euro Member Countries, Euro [Member]"
       }
      }
     },
     "localname": "EUR",
     "nsuri": "http://xbrl.sec.gov/currency/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByGeographicAreaFootnotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "If the value is true, then the document is an amendment to previously-filed/accepted document.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2014-01-31",
     "presentation": [
      "http://www.pfizer.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2014-01-31",
     "presentation": [
      "http://www.pfizer.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2014-01-31",
     "presentation": [
      "http://www.pfizer.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2014-01-31",
     "presentation": [
      "http://www.pfizer.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2014-01-31",
     "presentation": [
      "http://www.pfizer.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word \"Other\".",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2014-01-31",
     "presentation": [
      "http://www.pfizer.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r454"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2014-01-31",
     "presentation": [
      "http://www.pfizer.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2014-01-31",
     "presentation": [
      "http://www.pfizer.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2014-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsEquityMethodInvestmentsDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2014-01-31",
     "presentation": [
      "http://www.pfizer.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r454"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2014-01-31",
     "presentation": [
      "http://www.pfizer.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2014-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsEquityMethodInvestmentsDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2014-01-31",
     "presentation": [
      "http://www.pfizer.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "invest_DerivativeNotionalAmount": {
     "auth_ref": [
      "r455"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate notional amount specified by the derivative(s). Expressed as an absolute value.",
        "label": "Derivative, Notional Amount",
        "terseLabel": "Notional amount"
       }
      }
     },
     "localname": "DerivativeNotionalAmount",
     "nsuri": "http://xbrl.sec.gov/invest/2013-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_AcceleratedShareRepurchasesSharesRepurchasedDuringPeriodPercentageofAgreementAmount": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accelerated Share Repurchases, Shares Repurchased During Period, Percentage of Agreement Amount",
        "label": "Accelerated Share Repurchases, Shares Repurchased During Period, Percentage of Agreement Amount",
        "terseLabel": "Shares received in initial delivery, percentage of agreement amount"
       }
      }
     },
     "localname": "AcceleratedShareRepurchasesSharesRepurchasedDuringPeriodPercentageofAgreementAmount",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pfe_AccountingStandardsUpdate201609StatutoryTaxWithholdingComponentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accounting Standards Update 2016-09, Statutory Tax Withholding Component [Member]",
        "label": "Accounting Standards Update 2016-09, Statutory Tax Withholding Component [Member]",
        "terseLabel": "Accounting Standards Update 2016-09, Statutory Tax Withholding Component [Member]"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201609StatutoryTaxWithholdingComponentMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_AdministrativeServicePeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Administrative Service Period",
        "label": "Administrative Service Period",
        "terseLabel": "Administrative service period"
       }
      }
     },
     "localname": "AdministrativeServicePeriod",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsSaleOfHospiraInfusionSystemsNetAssetsToIcuMedicalIncEhDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "pfe_AllOtherBiosimilarsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "All Other Biosimilars [Member]",
        "label": "All Other Biosimilars [Member]",
        "terseLabel": "All Other Biosimilars [Member]"
       }
      }
     },
     "localname": "AllOtherBiosimilarsMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_AllOtherInflammationandImmunologyProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "All Other Inflammation and Immunology Products [Member]",
        "label": "All Other Inflammation and Immunology Products [Member]",
        "terseLabel": "All Other Inflammation and Immunology Products [Member]"
       }
      }
     },
     "localname": "AllOtherInflammationandImmunologyProductsMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_AllOtherInternalMedicineMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "All Other Internal Medicine [Member]",
        "label": "All Other Internal Medicine [Member]",
        "terseLabel": "All Other Internal Medicine [Member]"
       }
      }
     },
     "localname": "AllOtherInternalMedicineMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_AllOtherPeriLOEProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "All Other Peri-LOE Products [Member]",
        "label": "All Other Peri-LOE Products [Member]",
        "terseLabel": "All Other Peri-LOE Products [Member]"
       }
      }
     },
     "localname": "AllOtherPeriLOEProductsMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_AllOtherRareDiseaseProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "All Other Rare Disease Products [Member]",
        "label": "All Other Rare Disease Products [Member]",
        "terseLabel": "All Other Rare Disease [Member]"
       }
      }
     },
     "localname": "AllOtherRareDiseaseProductsMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_AllOtherSterileInjectablePharmaceuticalsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "All Other Sterile Injectable Pharmaceuticals [Member]",
        "label": "All Other Sterile Injectable Pharmaceuticals [Member]",
        "terseLabel": "All Other Sterile Injectable Pharmaceuticals [Member]"
       }
      }
     },
     "localname": "AllOtherSterileInjectablePharmaceuticalsMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_AllianceBiopharmaceuticalsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Alliance Biopharmaceuticals [Member]",
        "label": "Alliance Biopharmaceuticals [Member]",
        "terseLabel": "Alliance revenues [Member]"
       }
      }
     },
     "localname": "AllianceBiopharmaceuticalsMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfIncome": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of amortization that is not associated with a single function. Amounts associated in a single function are included in Cost of sales, Selling, information and administrative expenses and Research and development expenses.",
        "label": "Amortization Of Intangible Assets Not Associated With Single Function",
        "terseLabel": "Amortization of intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_AnacorMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Anacor [Member]",
        "label": "Anacor [Member]",
        "terseLabel": "Anacor [Member]"
       }
      }
     },
     "localname": "AnacorMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsAnacorPharmaceuticalsIncDetails",
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_AssetImpairmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Asset impairments [Member]",
        "label": "Asset Impairments [Member]",
        "terseLabel": "Asset Impairment Charges [Member]"
       }
      }
     },
     "localname": "AssetImpairmentsMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesRestructuringAccrualsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_AssetWriteOffsAndAssetImpairmentCharges": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Asset Write-Offs And Asset Impairment Charges",
        "label": "Asset Write-Offs And Asset Impairment Charges",
        "verboseLabel": "Asset write-offs and impairments"
       }
      }
     },
     "localname": "AssetWriteOffsAndAssetImpairmentCharges",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_AstraZenecaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "AstraZeneca [Member]",
        "label": "AstraZeneca [Member]",
        "terseLabel": "AstraZeneca [Member]"
       }
      }
     },
     "localname": "AstraZenecaMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsAstrazenecaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_AverageWholesalePriceMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Average Wholesale Price [Member]",
        "label": "Average Wholesale Price [Member]",
        "terseLabel": "Average Wholesale Price [Member]"
       }
      }
     },
     "localname": "AverageWholesalePriceMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/CommitmentsAndContingenciesActionsInWhichWeAreDefendantDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_BMP2Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "B M P 2 [Member]",
        "label": "B M P 2 [Member]",
        "terseLabel": "B M P 2 [Member]"
       }
      }
     },
     "localname": "BMP2Member",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_BambooTherapeuticsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Bamboo Therapeutics [Member]",
        "label": "Bamboo Therapeutics [Member]",
        "terseLabel": "Bamboo Therapeutics [Member]"
       }
      }
     },
     "localname": "BambooTherapeuticsMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsBambooTherapeuticsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_BavencioMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Bavencio [Member]",
        "label": "Bavencio [Member]",
        "terseLabel": "Bavencio [Member]"
       }
      }
     },
     "localname": "BavencioMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/CommitmentsAndContingenciesActionsInWhichWeArePlaintiffDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_BeneFIXMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Bene F I X [Member]",
        "label": "Bene F I X [Member]",
        "terseLabel": "BeneFIX [Member]"
       }
      }
     },
     "localname": "BeneFIXMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_BesponsaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Besponsa [Member]",
        "label": "Besponsa [Member]",
        "terseLabel": "Besponsa [Member]"
       }
      }
     },
     "localname": "BesponsaMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsOtherNoncurrentLiabilitiesDetail",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsFootnotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_BiosimilarsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Biosimilars [Member]",
        "label": "Biosimilars [Member]",
        "terseLabel": "Biosimilars [Member]"
       }
      }
     },
     "localname": "BiosimilarsMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_BosulifMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Bosulif [Member]",
        "label": "Bosulif [Member]",
        "terseLabel": "Bosulif [Member]"
       }
      }
     },
     "localname": "BosulifMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/CommitmentsAndContingenciesActionsInWhichWeArePlaintiffDetails",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesDetail": {
       "order": 2.0,
       "parentTag": "pfe_RestructuringChargesAndAcquisitionRelatedCosts",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This element represents external costs directly related to effecting a business combination which costs have been expensed during the period. Such costs include advisory, legal, accounting, valuation, and other similar services.",
        "label": "Business Combination, Acquisition Related Costs, Transaction Costs",
        "terseLabel": "Transaction costs"
       }
      }
     },
     "localname": "BusinessCombinationAcquisitionRelatedCostsTransactionCosts",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_BusinessCombinationConsiderationTransferredAmountPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business Combination, Consideration Transferred, Amount Payable",
        "label": "Business Combination, Consideration Transferred, Amount Payable",
        "terseLabel": "Amount payable"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredAmountPayable",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsMedivationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_BusinessCombinationConsiderationTransferredDeferredPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business Combination, Consideration Transferred, Deferred Payment",
        "label": "Business Combination, Consideration Transferred, Deferred Payment",
        "terseLabel": "Deferred payment"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredDeferredPayment",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsAstrazenecaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_BusinessCombinationConsiderationTransferredMilestonePaymentsMaximum": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business Combination, Consideration Transferred, Milestone Payments, Maximum",
        "label": "Business Combination, Consideration Transferred, Milestone Payments, Maximum",
        "terseLabel": "Maximum amount of potential milestone payments"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredMilestonePaymentsMaximum",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsAstrazenecaDetails",
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsBambooTherapeuticsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_BusinessCombinationConsiderationTransferredNetofCashAcquired": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business Combination, Consideration Transferred, Net of Cash Acquired",
        "label": "Business Combination, Consideration Transferred, Net of Cash Acquired",
        "terseLabel": "Consideration transferred in business acquisition, net of cash acquired"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredNetofCashAcquired",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsMedivationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_BusinessCombinationConsiderationTransferredSalesrelatedPaymentsMaximum": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business Combination, Consideration Transferred, Sales-related Payments, Maximum",
        "label": "Business Combination, Consideration Transferred, Sales-related Payments, Maximum",
        "terseLabel": "Maximum amount of potential sales-related payments"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredSalesrelatedPaymentsMaximum",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsAstrazenecaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_BusinessCombinationConsiderationTransferredUndiscountedRoyaltyPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business Combination, Consideration Transferred, Undiscounted Royalty Payments",
        "label": "Business Combination, Consideration Transferred, Undiscounted Royalty Payments",
        "terseLabel": "Undiscounted royalty payments"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredUndiscountedRoyaltyPayments",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsAstrazenecaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_BusinessCombinationConsiderationTransferredUndiscountedRoyaltyPaymentsTerm": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business Combination, Consideration Transferred, Undiscounted Royalty Payments, Term",
        "label": "Business Combination, Consideration Transferred, Undiscounted Royalty Payments, Term",
        "terseLabel": "Term of royalty payments"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredUndiscountedRoyaltyPaymentsTerm",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsAstrazenecaDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "pfe_BusinessCombinationExpectedIntegrationRelatedCostsPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business Combination, Expected Integration Related Costs, Period",
        "label": "Business Combination, Expected Integration Related Costs, Period",
        "terseLabel": "Expected integration related costs, period"
       }
      }
     },
     "localname": "BusinessCombinationExpectedIntegrationRelatedCostsPeriod",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "pfe_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIncreaseDecreaseinAmortizationofIntangibleAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Increase (Decrease) in Amortization of Intangible Assets",
        "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Increase (Decrease) in Amortization of Intangible Assets",
        "negatedTerseLabel": "Decrease in amortization of intangible assets due to measurement period adjustments"
       }
      }
     },
     "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIncreaseDecreaseinAmortizationofIntangibleAssets",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsMedivationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_BusinessCombinationsAcquisitionRelatedCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business Combinations, Acquisition Related Costs [Member]",
        "label": "Business Combinations, Acquisition Related Costs [Member]",
        "terseLabel": "Acquisition-Related Costs [Member]"
       }
      }
     },
     "localname": "BusinessCombinationsAcquisitionRelatedCostsMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business Combinations, Discontinued Operations And Disposal Groups, Collaborative Arrangements And Equity Method Investments [Abstract]",
        "label": "Business Combinations, Discontinued Operations And Disposal Groups, Collaborative Arrangements And Equity Method Investments [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract",
     "nsuri": "http://www.pfizer.com/20171001",
     "xbrltype": "stringItemType"
    },
    "pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsCollaborativeArrangementsEquityandCostMethodInvestmentsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business Combinations, Disposal Groups, Including Discontinued Operations, Collaborative Arrangements, Equity and Cost Method Investments Disclosure [Text Block]",
        "label": "Business Combinations, Disposal Groups, Including Discontinued Operations, Collaborative Arrangements, Equity and Cost Method Investments Disclosure [Text Block]",
        "terseLabel": "Acquisitions, Sale of Hospira Infusion Systems Net Assets, Collaborative Arrangement and Equity-Method Investments"
       }
      }
     },
     "localname": "BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsCollaborativeArrangementsEquityandCostMethodInvestmentsDisclosureTextBlock",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "pfe_BusinessInfrastructureAlignmentCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetDetail": {
       "order": 7.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business Infrastructure Alignment Costs",
        "label": "Business Infrastructure Alignment Costs",
        "terseLabel": "Business and legal entity alignment costs"
       }
      }
     },
     "localname": "BusinessInfrastructureAlignmentCosts",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetDetail",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationFootnotesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_BusinessIntegrationCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business Integration Costs [Member]",
        "label": "Business Integration Costs [Member]",
        "terseLabel": "Business Integration Costs [Member]"
       }
      }
     },
     "localname": "BusinessIntegrationCostsMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_CelebrexMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Celebrex [Member]",
        "label": "Celebrex [Member]",
        "terseLabel": "Celebrex [Member]"
       }
      }
     },
     "localname": "CelebrexMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/CommitmentsAndContingenciesActionsInWhichWeAreDefendantDetail",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_CelebrexandBextraMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Celebrex and Bextra [Member]",
        "label": "Celebrex and Bextra [Member]",
        "terseLabel": "Celebrex and Bextra [Member]"
       }
      }
     },
     "localname": "CelebrexandBextraMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_CentralizationofCorporateandPlatformFunctionsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Centralization of Corporate and Platform Functions [Member]",
        "label": "Centralization of Corporate and Platform Functions [Member]",
        "terseLabel": "Centralization of Corporate and Platform Functions [Member]"
       }
      }
     },
     "localname": "CentralizationofCorporateandPlatformFunctionsMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_CentreOneMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "CentreOne [Member]",
        "label": "CentreOne [Member]",
        "terseLabel": "CentreOne [Member]"
       }
      }
     },
     "localname": "CentreOneMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_CertainSignificantItemsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Certain significant items [Member]",
        "label": "Certain Significant Items [Member]",
        "terseLabel": "Certain Significant Items [Member]"
       }
      }
     },
     "localname": "CertainSignificantItemsMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_ChantixChampixMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Chantix / Champix [Member]",
        "label": "Chantix Champix [Member]",
        "terseLabel": "Chantix / Champix [Member]"
       }
      }
     },
     "localname": "ChantixChampixMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_ClassActionVersusAmericanOpticalCorporationAndVariousOtherDefendantsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Class Action Versus American Optical Corporation And Various Other Defendants [Member]",
        "label": "Class Action Versus American Optical Corporation And Various Other Defendants [Member]",
        "terseLabel": "Class Action Versus American Optical Corporation And Various Other Defendants [Member]"
       }
      }
     },
     "localname": "ClassActionVersusAmericanOpticalCorporationAndVariousOtherDefendantsMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/CommitmentsAndContingenciesActionsInWhichWeAreDefendantDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_CollaborativeArrangementCollaboratorsRevenueandExpenseOwnershipPercentage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Arrangement, Collaborator's Revenue and Expense Ownership Percentage",
        "label": "Collaborative Arrangement, Collaborator's Revenue and Expense Ownership Percentage",
        "terseLabel": "Collaborator's revenue and expense ownership percentage"
       }
      }
     },
     "localname": "CollaborativeArrangementCollaboratorsRevenueandExpenseOwnershipPercentage",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsCollaborationArrangementDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pfe_CollaborativeArrangementCompanysRevenueandExpenseOwnershipPercentage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Arrangement, Company's Revenue and Expense Ownership Percentage",
        "label": "Collaborative Arrangement, Company's Revenue and Expense Ownership Percentage",
        "terseLabel": "Company's revenue and expense ownership percentage"
       }
      }
     },
     "localname": "CollaborativeArrangementCompanysRevenueandExpenseOwnershipPercentage",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsCollaborationArrangementDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pfe_ConsumerHealthcareMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Consumer Healthcare [Member]",
        "label": "Consumer Healthcare [Member]",
        "terseLabel": "Consumer Healthcare [Member]"
       }
      }
     },
     "localname": "ConsumerHealthcareMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebtNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, Fair Value Adjustments, Hedging and Purchase Accounting",
        "label": "Debt Instrument, Fair Value Adjustments, Hedging and Purchase Accounting",
        "terseLabel": "Net fair value adjustments related to hedging and purchase accounting"
       }
      }
     },
     "localname": "DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_DebtInstrumentFloorInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, Floor Interest Rate",
        "label": "Debt Instrument, Floor Interest Rate",
        "terseLabel": "Floor interest rate"
       }
      }
     },
     "localname": "DebtInstrumentFloorInterestRate",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pfe_DebtInstrumentRedemptionRuleRedemptionPricePercentageBasisSpread": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, Redemption Rule, Redemption Price, Percentage, Basis Spread",
        "label": "Debt Instrument, Redemption Rule, Redemption Price, Percentage, Basis Spread",
        "terseLabel": "Redemption basis spread"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionRuleRedemptionPricePercentageBasisSpread",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pfe_DebtSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsInDebtSecuritiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsInDebtSecuritiesDetailCalc2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This item represents the total of all debt securities grouped by maturity dates.",
        "label": "Debt Securities",
        "totalLabel": "Total debt securities"
       }
      }
     },
     "localname": "DebtSecurities",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsInDebtSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_DebtSecuritiesMaturitiesAfterTenYears": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsInDebtSecuritiesDetail": {
       "order": 4.0,
       "parentTag": "pfe_DebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Securities Maturities After Ten Years",
        "label": "Debt Securities Maturities After Ten Years",
        "totalLabel": "Debt securities maturities over 10 years"
       }
      }
     },
     "localname": "DebtSecuritiesMaturitiesAfterTenYears",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsInDebtSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_DebtSecuritiesMaturitiesOverFiveToTenYears": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsInDebtSecuritiesDetail": {
       "order": 3.0,
       "parentTag": "pfe_DebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This item represents debt securities which are expected to mature after five and through ten years from the balance sheet date.",
        "label": "Debt Securities Maturities Over Five To Ten Years",
        "totalLabel": "Debt securities maturities over 5 to 10 years"
       }
      }
     },
     "localname": "DebtSecuritiesMaturitiesOverFiveToTenYears",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsInDebtSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_DebtSecuritiesMaturitiesOverOneToFiveYears": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsInDebtSecuritiesDetail": {
       "order": 2.0,
       "parentTag": "pfe_DebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This item represents debt securities which are expected to mature after one year and through five years from the balance sheet date.",
        "label": "Debt Securities Maturities Over One To Five Years",
        "totalLabel": "Debt securities maturities over 1 to 5 years"
       }
      }
     },
     "localname": "DebtSecuritiesMaturitiesOverOneToFiveYears",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsInDebtSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_DebtSecuritiesMaturitiesWithinOneYear": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsInDebtSecuritiesDetail": {
       "order": 1.0,
       "parentTag": "pfe_DebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This item represents debt securities which are expected to mature within one year of the balance sheet date.",
        "label": "Debt Securities Maturities Within One Year",
        "totalLabel": "Debt securities maturities within one year"
       }
      }
     },
     "localname": "DebtSecuritiesMaturitiesWithinOneYear",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsInDebtSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_DecreaseinRoyaltyRevenue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Decrease in Royalty Revenue",
        "label": "Decrease in Royalty Revenue",
        "terseLabel": "Decrease in royalty revenue"
       }
      }
     },
     "localname": "DecreaseinRoyaltyRevenue",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Deferred Tax Assets, Net, And Other Tax Assets, Noncurrent",
        "label": "Deferred Tax Assets, Net, And Other Tax Assets, Noncurrent",
        "terseLabel": "Noncurrent deferred tax assets and other noncurrent tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_DefinedBenefitPlanActuarialLossandPriorServiceCostsImmediateRecognitionasComponentinNetPeriodicBenefitCost": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Defined Benefit Plan, Actuarial Loss and Prior Service Costs, Immediate Recognition as Component in Net Periodic Benefit Cost",
        "label": "Defined Benefit Plan, Actuarial Loss and Prior Service Costs, Immediate Recognition as Component in Net Periodic Benefit Cost",
        "terseLabel": "Actuarial losses and prior service costs recognized upon plan settlement"
       }
      }
     },
     "localname": "DefinedBenefitPlanActuarialLossandPriorServiceCostsImmediateRecognitionasComponentinNetPeriodicBenefitCost",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansNetPeriodicBenefitCostFootnotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetActuarialGainLossTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss), Net Actuarial Gain (Loss), Tax",
        "label": "Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss), Net Actuarial Gain (Loss), Tax",
        "totalLabel": "Defined benefit plans, actuarial gain (loss), tax, total"
       }
      }
     },
     "localname": "DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetActuarialGainLossTax",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetPriorServiceCostCreditAndOtherTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss), Net Prior Service Cost (Credit) And Other, Tax",
        "label": "Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss), Net Prior Service Cost (Credit) And Other, Tax",
        "negatedTerseLabel": "Benefit plans: prior service (costs)/credits and other, net"
       }
      }
     },
     "localname": "DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetPriorServiceCostCreditAndOtherTax",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_DefinedBenefitPlanNetPeriodicBenefitCostCreditGainLossDuetoSettlementPretax": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement, Pretax",
        "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement, Pretax",
        "terseLabel": "Pretax settlement gain"
       }
      }
     },
     "localname": "DefinedBenefitPlanNetPeriodicBenefitCostCreditGainLossDuetoSettlementPretax",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansNetPeriodicBenefitCostFootnotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets. Includes the amount of expense from discontinued operations, that reflects the allocation of the cost of tangible and intangible assets over the assets' useful lives.",
        "label": "Depreciation, Depletion And Amortization, Including Discontinued Operation, Depreciation and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_DevelopedEuropeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Developed Europe [Member]",
        "label": "Developed Europe [Member]",
        "terseLabel": "Developed Europe [Member]"
       }
      }
     },
     "localname": "DevelopedEuropeMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByGeographicAreaDetail",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByGeographicAreaFootnotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_DevelopedRestOfWorldMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Developed Rest Of World [Member]",
        "label": "Developed Rest Of World [Member]",
        "terseLabel": "Developed Rest Of World [Member]"
       }
      }
     },
     "localname": "DevelopedRestOfWorldMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByGeographicAreaDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disposal Group, Including Discontinued Operation, Consideration, Note Receivable",
        "label": "Disposal Group, Including Discontinued Operation, Consideration, Note Receivable",
        "terseLabel": "Promissory note"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivable",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsSaleOfHospiraInfusionSystemsNetAssetsToIcuMedicalIncEhDetails",
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlowsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivableInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disposal Group, Including Discontinued Operation, Consideration, Note Receivable, Interest Rate",
        "label": "Disposal Group, Including Discontinued Operation, Consideration, Note Receivable, Interest Rate",
        "terseLabel": "Interest rate of promissory note in year one"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivableInterestRate",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsSaleOfHospiraInfusionSystemsNetAssetsToIcuMedicalIncEhDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivableInterestRateYearThree": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disposal Group, Including Discontinued Operation, Consideration, Note Receivable, Interest Rate, Year Three",
        "label": "Disposal Group, Including Discontinued Operation, Consideration, Note Receivable, Interest Rate, Year Three",
        "terseLabel": "Interest rate of promissory note in year three"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivableInterestRateYearThree",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsSaleOfHospiraInfusionSystemsNetAssetsToIcuMedicalIncEhDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivableInterestRateYearTwo": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disposal Group, Including Discontinued Operation, Consideration, Note Receivable, Interest Rate, Year Two",
        "label": "Disposal Group, Including Discontinued Operation, Consideration, Note Receivable, Interest Rate, Year Two",
        "terseLabel": "Interest rate of promissory note in year two"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivableInterestRateYearTwo",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsSaleOfHospiraInfusionSystemsNetAssetsToIcuMedicalIncEhDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivableTerm": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disposal Group, Including Discontinued Operation, Consideration, Note Receivable, Term",
        "label": "Disposal Group, Including Discontinued Operation, Consideration, Note Receivable, Term",
        "terseLabel": "Term of promissory note"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivableTerm",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsSaleOfHospiraInfusionSystemsNetAssetsToIcuMedicalIncEhDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationTransferredEquityInterests": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disposal Group, Including Discontinued Operation, Consideration Transferred, Equity Interests",
        "label": "Disposal Group, Including Discontinued Operation, Consideration Transferred, Equity Interests",
        "terseLabel": "Value of shares received from disposition"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationConsiderationTransferredEquityInterests",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsSaleOfHospiraInfusionSystemsNetAssetsToIcuMedicalIncEhDetails",
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlowsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationTransferredEquityInterestsShares": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disposal Group, Including Discontinued Operation, Consideration Transferred, Equity Interests, Shares",
        "label": "Disposal Group, Including Discontinued Operation, Consideration Transferred, Equity Interests, Shares",
        "terseLabel": "Number of shares received in disposition"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationConsiderationTransferredEquityInterestsShares",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsSaleOfHospiraInfusionSystemsNetAssetsToIcuMedicalIncEhDetails",
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlowsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "pfe_DisposalGroupIncludingDiscontinuedOperationContingentConsideration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disposal Group, Including Discontinued Operation, Contingent Consideration",
        "label": "Disposal Group, Including Discontinued Operation, Contingent Consideration",
        "terseLabel": "Contingent consideration"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationContingentConsideration",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsSaleOfHospiraInfusionSystemsNetAssetsToIcuMedicalIncEhDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_DisposalGroupIncludingDiscontinuedOperationShareTransferRestrictionTermMinimum": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disposal Group, Including Discontinued Operation, Share Transfer Restriction Term, Minimum",
        "label": "Disposal Group, Including Discontinued Operation, Share Transfer Restriction Term, Minimum",
        "terseLabel": "Minimum share transfer restriction term"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationShareTransferRestrictionTermMinimum",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsSaleOfHospiraInfusionSystemsNetAssetsToIcuMedicalIncEhDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "pfe_DistinctBusinessAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Distinct Business [Axis]",
        "label": "Distinct Business [Axis]",
        "terseLabel": "Distinct Business [Axis]"
       }
      }
     },
     "localname": "DistinctBusinessAxis",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "pfe_DistinctBusinessDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "[Domain] for Distinct Business [Axis]",
        "label": "Distinct Business [Domain]",
        "terseLabel": "Distinct Business [Domain]"
       }
      }
     },
     "localname": "DistinctBusinessDomain",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_DocumentandEntityInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Document and Entity Information [Abstract]",
        "label": "Document and Entity Information [Abstract]"
       }
      }
     },
     "localname": "DocumentandEntityInformationAbstract",
     "nsuri": "http://www.pfizer.com/20171001",
     "xbrltype": "stringItemType"
    },
    "pfe_EURIBORMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "EURIBOR [Member]",
        "label": "EURIBOR [Member]",
        "terseLabel": "EURIBOR [Member]"
       }
      }
     },
     "localname": "EURIBORMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTaxBenefitAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Share-based Compensation, Excess Tax Benefit, Amount",
        "label": "Effective Income Tax Rate Reconciliation, Share-based Compensation, Excess Tax Benefit, Amount",
        "terseLabel": "Net tax benefit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTaxBenefitAmount",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_EffexorMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Effexor [Member]",
        "label": "Effexor [Member]",
        "terseLabel": "Effexor [Member]"
       }
      }
     },
     "localname": "EffexorMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_EliquisMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Eliquis [Member]",
        "label": "Eliquis [Member]",
        "terseLabel": "Eliquis [Member]"
       }
      }
     },
     "localname": "EliquisMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/CommitmentsAndContingenciesActionsInWhichWeArePlaintiffDetails",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_EmergingMarketsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Emerging Markets [Member]",
        "label": "Emerging Markets [Member]",
        "terseLabel": "Emerging Markets [Member]"
       }
      }
     },
     "localname": "EmergingMarketsMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByGeographicAreaDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_EnbrelMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Enbrel [Member]",
        "label": "Enbrel [Member]",
        "terseLabel": "Enbrel [Member]",
        "verboseLabel": "Enbrel (Outside the U.S. and Canada) [Member]"
       }
      }
     },
     "localname": "EnbrelMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_EnterprisewideCostReductionProductivityPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Enterprise-wide Cost Reduction/Productivity Plan [Member]",
        "label": "Enterprise-wide Cost Reduction/Productivity Plan [Member]",
        "terseLabel": "Enterprise-wide Cost Reduction/Productivity Plan [Member]"
       }
      }
     },
     "localname": "EnterprisewideCostReductionProductivityPlanMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_EnvironmentalRemediationLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Environmental Remediation Litigation [Member]",
        "label": "Environmental Remediation Litigation [Member]",
        "terseLabel": "Environmental Remediation Litigation [Member]"
       }
      }
     },
     "localname": "EnvironmentalRemediationLitigationMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/CommitmentsAndContingenciesActionsInWhichWeAreDefendantDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_EpiPenMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "EpiPen [Member]",
        "label": "Epi Pen [Member]",
        "terseLabel": "EpiPen [Member]"
       }
      }
     },
     "localname": "EpiPenMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_EssentialHealthBusinessMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Essential Health Business [Member]",
        "label": "Essential Health Business [Member]",
        "terseLabel": "Essential Health Business [Member]"
       }
      }
     },
     "localname": "EssentialHealthBusinessMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_EssentialHealthProductCategoryAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Essential Health Product Category [Axis]",
        "label": "Essential Health Product Category [Axis]",
        "terseLabel": "Essential Health Product Category [Axis]"
       }
      }
     },
     "localname": "EssentialHealthProductCategoryAxis",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "pfe_EssentialHealthProductCategoryDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "[Domain] for Essential Health Product Category [Axis]",
        "label": "Essential Health Product Category [Domain]",
        "terseLabel": "Essential Health Product Category [Domain]"
       }
      }
     },
     "localname": "EssentialHealthProductCategoryDomain",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_EssentialHealthSegmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Essential Health Segment [Member]",
        "label": "Essential Health Segment [Member]",
        "verboseLabel": "EH [Member]"
       }
      }
     },
     "localname": "EssentialHealthSegmentMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedIntangibleAssetsPercentageOfTotalIntangiblesDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillGoodwillDetail",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillIndefiniteLivedIntangibleAssetsPercentageOfTotalIntangiblesDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail",
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesFootnotesDetails",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationDetail",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_EucrisaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Eucrisa [Member]",
        "label": "Eucrisa [Member]",
        "terseLabel": "Eucrisa [Member]"
       }
      }
     },
     "localname": "EucrisaMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsFootnotesDetails",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_EuroLongtermDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Euro Long-term Debt [Member]",
        "label": "Euro Long-term Debt [Member]",
        "terseLabel": "Euro Long-term Debt [Member]"
       }
      }
     },
     "localname": "EuroLongtermDebtMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_FSMEIMMUNTicoVacMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "FSME-IMMUN/TicoVac [Member]",
        "label": "FSME-IMMUN/TicoVac [Member]",
        "terseLabel": "FSME-IMMUN/TicoVac [Member]"
       }
      }
     },
     "localname": "FSMEIMMUNTicoVacMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_FeasibilityStudyNumberOfLagoons": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Feasibility Study, Number Of Lagoons",
        "label": "Feasibility Study, Number Of Lagoons",
        "terseLabel": "Number of lagoons"
       }
      }
     },
     "localname": "FeasibilityStudyNumberOfLagoons",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/CommitmentsAndContingenciesActionsInWhichWeAreDefendantDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "pfe_FinancialAssetsAndLiabilitiesMeasuredAtFairValuePercentage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Financial Assets And Liabilities Measured At Fair Value, Percentage",
        "label": "Financial Assets And Liabilities Measured At Fair Value, Percentage",
        "terseLabel": "Percentage of financial assets and liabilities measured at fair value inputs Level 1 and Level 3 inputs (less than)"
       }
      }
     },
     "localname": "FinancialAssetsAndLiabilitiesMeasuredAtFairValuePercentage",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsAssetsAndLiabilitiesMeasuredOnRecurringBasisFootnotesDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "pfe_FinancialInstrumentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Financial Instruments [Abstract]",
        "label": "Financial Instruments [Abstract]"
       }
      }
     },
     "localname": "FinancialInstrumentsAbstract",
     "nsuri": "http://www.pfizer.com/20171001",
     "xbrltype": "stringItemType"
    },
    "pfe_FootnotesToSelectedFinancialAssetsAndLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Footnotes to selected financial assets and liabilities [Abstract]",
        "label": "Footnotes To Selected Financial Assets And Liabilities [Abstract]",
        "terseLabel": "Footnotes to selected financial assets and liabilities:"
       }
      }
     },
     "localname": "FootnotesToSelectedFinancialAssetsAndLiabilitiesAbstract",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsAssetsAndLiabilitiesMeasuredOnRecurringBasisFootnotesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "pfe_ForeignCurrencyLongTermDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Foreign currency long - term debt [Member]",
        "label": "Foreign Currency Long Term Debt [Member]",
        "terseLabel": "Foreign Currency Long Term Debt [Member]"
       }
      }
     },
     "localname": "ForeignCurrencyLongTermDebtMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsAssetsAndLiabilitiesMeasuredOnRecurringBasisFootnotesDetail",
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_ForeignCurrencyShortTermBorrowingsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Foreign currency short - term borrowings [Member]",
        "label": "Foreign Currency Short Term Borrowings [Member]",
        "terseLabel": "Foreign Currency Short Term Borrowings [Member]"
       }
      }
     },
     "localname": "ForeignCurrencyShortTermBorrowingsMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_FragminMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fragmin [Member]",
        "label": "Fragmin [Member]",
        "terseLabel": "Fragmin [Member]"
       }
      }
     },
     "localname": "FragminMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_GainContingencyNumberofDefendants": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gain Contingency, Number of Defendants",
        "label": "Gain Contingency, Number of Defendants",
        "terseLabel": "Number of defendants"
       }
      }
     },
     "localname": "GainContingencyNumberofDefendants",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/CommitmentsAndContingenciesActionsInWhichWeArePlaintiffDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "pfe_GainContingencyPatentsAllegedlyInfringeduponNumberDuetoExpireinDecember2020": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gain Contingency, Patents Allegedly Infringed upon, Number Due to Expire in December 2020",
        "label": "Gain Contingency, Patents Allegedly Infringed upon, Number Due to Expire in December 2020",
        "terseLabel": "Number of patents due to expire in December 2020"
       }
      }
     },
     "localname": "GainContingencyPatentsAllegedlyInfringeduponNumberDuetoExpireinDecember2020",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/CommitmentsAndContingenciesActionsInWhichWeArePlaintiffDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "pfe_GainContingencyPatentsAllegedlyInfringeduponNumberDuetoExpireinDecember2025": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gain Contingency, Patents Allegedly Infringed upon, Number Due to Expire in December 2025",
        "label": "Gain Contingency, Patents Allegedly Infringed upon, Number Due to Expire in December 2025",
        "terseLabel": "Number or patents due to expire in December 2025"
       }
      }
     },
     "localname": "GainContingencyPatentsAllegedlyInfringeduponNumberDuetoExpireinDecember2025",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/CommitmentsAndContingenciesActionsInWhichWeArePlaintiffDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "pfe_GainLossOnDispositionOfAssetsAndEquitySecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gain (Loss) on Disposition of Assets and Equity Securities",
        "label": "Gain (Loss) On Disposition Of Assets And Equity Securities",
        "negatedTerseLabel": "Net gains on asset disposals"
       }
      }
     },
     "localname": "GainLossOnDispositionOfAssetsAndEquitySecurities",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_GenotropinMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Genotropin [Member]",
        "label": "Genotropin [Member]",
        "terseLabel": "Genotropin [Member]"
       }
      }
     },
     "localname": "GenotropinMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_GermanGovernmentBondRateMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "German Government Bond Rate [Member]",
        "label": "German Government Bond Rate [Member]",
        "terseLabel": "German Government Bond Rate [Member]"
       }
      }
     },
     "localname": "GermanGovernmentBondRateMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_HISMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "HIS [Member]",
        "label": "HIS [Member]",
        "terseLabel": "HIS [Member]"
       }
      }
     },
     "localname": "HISMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsSaleOfHospiraInfusionSystemsNetAssetsToIcuMedicalIncEhDetails",
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlowsParenthetical",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationFootnotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_HisunPfizerPharmaceuticalsCoLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Hisun Pfizer Pharmaceuticals Co. Ltd [Member]",
        "label": "Hisun Pfizer Pharmaceuticals Co. Ltd [Member]",
        "terseLabel": "Hisun Pfizer Pharmaceuticals Co. Ltd [Member]"
       }
      }
     },
     "localname": "HisunPfizerPharmaceuticalsCoLtdMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsEquityMethodInvestmentsDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_HospiraInfusionSystemsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Hospira Infusion Systems [Member]",
        "label": "Hospira Infusion Systems [Member]",
        "terseLabel": "Hospira Infusion Systems (HIS) [Member]"
       }
      }
     },
     "localname": "HospiraInfusionSystemsMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_HospiraMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Hospira [Member]",
        "label": "Hospira [Member]",
        "terseLabel": "Hospira [Member]"
       }
      }
     },
     "localname": "HospiraMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansNetPeriodicBenefitCostFootnotesDetails",
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesDetail",
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesFootnotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_HospiraVersusAmnealPharmaceuticalsLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Hospira Versus Amneal Pharmaceuticals LLC [Member]",
        "label": "Hospira Versus Amneal Pharmaceuticals LLC [Member]",
        "terseLabel": "Hospira Versus Amneal Pharmaceuticals LLC [Member]"
       }
      }
     },
     "localname": "HospiraVersusAmnealPharmaceuticalsLLCMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/CommitmentsAndContingenciesActionsInWhichWeArePlaintiffDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_HospiraVersusFreseniusMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Hospira Versus Fresenius [Member]",
        "label": "Hospira Versus Fresenius [Member]",
        "terseLabel": "Hospira Versus Fresenius [Member]"
       }
      }
     },
     "localname": "HospiraVersusFreseniusMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/CommitmentsAndContingenciesActionsInWhichWeArePlaintiffDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_HospiraVersusParMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Hospira Versus Par [Member]",
        "label": "Hospira Versus Par [Member]",
        "terseLabel": "Hospira Versus Par [Member]"
       }
      }
     },
     "localname": "HospiraVersusParMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/CommitmentsAndContingenciesActionsInWhichWeArePlaintiffDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_ICUMedicalMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "ICU Medical [Member]",
        "label": "ICU Medical [Member]",
        "terseLabel": "ICU Medical [Member]"
       }
      }
     },
     "localname": "ICUMedicalMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsSaleOfHospiraInfusionSystemsNetAssetsToIcuMedicalIncEhDetails",
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlowsParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_IbranceMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Ibrance [Member]",
        "label": "Ibrance [Member]",
        "terseLabel": "Ibrance [Member]"
       }
      }
     },
     "localname": "IbranceMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_IdentifiableintangibleassetsasapercentageoftotalidentifiableintangibleassetslessaccumulatedamortizationbysegmentTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "[Table Text Block] for Identifiable intangible assets as a percentage of total identifiable intangible assets less accumulated amortization, by segment [Table]",
        "label": "Identifiable intangible assets as a percentage of total identifiable intangible assets less accumulated amortization, by segment [Table Text Block]",
        "terseLabel": "Identifiable Intangible Assets as a Percentage of Total Identifiable Intangible Assets Less Accumulated Amortization, By Segment"
       }
      }
     },
     "localname": "IdentifiableintangibleassetsasapercentageoftotalidentifiableintangibleassetslessaccumulatedamortizationbysegmentTableTextBlock",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "pfe_ImplementationCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Implementation Cost [Abstract]",
        "label": "Implementation Cost [Abstract]",
        "terseLabel": "Implementation costs recorded in our condensed consolidated statements of income as follows:"
       }
      }
     },
     "localname": "ImplementationCostAbstract",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "pfe_ImplementationCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesDetail": {
       "order": 3.0,
       "parentTag": "pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Implementation costs represent external, incremental costs directly related to Implementing cost-reduction initiatives, and primarily include expenditures related to system and process standardization and the expansion of shared services.",
        "label": "Implementation Costs",
        "terseLabel": "Total implementation costs"
       }
      }
     },
     "localname": "ImplementationCosts",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributableToCommonShareholdersDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This element represents the income or loss from continuing operations available to common stockholders which may also be defined as revenue less expenses and taxes from ongoing operations before extraordinary items and cumulative effects of changes in accounting principles, but after deduction of those portions of income or loss from continuing operations that are allocable to noncontrolling interests and preferred stock dividends declared or paid in the period, if any.",
        "label": "Income Loss From Continuing Operations Available To Common Stockholders Basic",
        "totalLabel": "Income from continuing operations attributable to Pfizer Inc. common shareholders"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributableToCommonShareholdersDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributableToCommonShareholdersDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This element represents the income or loss from continuing operations available to common stockholders which may also be defined as revenue less expenses and taxes from ongoing operations before extraordinary items and cumulative effects of changes in accounting principles, but after deduction of those portions of income or loss from continuing operations that are allocable to noncontrolling interests and preferred stock dividends declared or paid in the period, if any.",
        "label": "Income Loss From Continuing Operations Available To Common Stockholders diluted",
        "terseLabel": "Income from continuing operations attributable to Pfizer Inc. common shareholders and assumed conversions"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributableToCommonShareholdersDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_InflammationandImmunologyMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inflammation and Immunology [Member]",
        "label": "Inflammation and Immunology [Member]",
        "terseLabel": "Inflammation and Immunology (I&amp;I) [Member]"
       }
      }
     },
     "localname": "InflammationandImmunologyMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_InflectraMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inflectra [Member]",
        "label": "Inflectra [Member]",
        "terseLabel": "Inflectra [Member]"
       }
      }
     },
     "localname": "InflectraMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/CommitmentsAndContingenciesActionsInWhichWeAreDefendantDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_InflectraRemsimaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inflectra/Remsima [Member]",
        "label": "Inflectra/Remsima [Member]",
        "terseLabel": "Inflectra/Remsima [Member]"
       }
      }
     },
     "localname": "InflectraRemsimaMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_InlytaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inlyta [Member]",
        "label": "Inlyta [Member]",
        "terseLabel": "Inlyta [Member]"
       }
      }
     },
     "localname": "InlytaMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_InnoPharmaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "InnoPharma [Member]",
        "label": "InnoPharma [Member]",
        "terseLabel": "InnoPharma [Member]"
       }
      }
     },
     "localname": "InnoPharmaMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_InnovativeHealthBusinessMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Innovative Health Business [Member]",
        "label": "Innovative Health Business [Member]",
        "terseLabel": "Innovative Health Business [Member]"
       }
      }
     },
     "localname": "InnovativeHealthBusinessMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_InnovativeHealthSegmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Innovative Health Segment [Member]",
        "label": "Innovative Health Segment [Member]",
        "terseLabel": "Innovative Health Segment [Member]",
        "verboseLabel": "IH [Member]"
       }
      }
     },
     "localname": "InnovativeHealthSegmentMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedIntangibleAssetsPercentageOfTotalIntangiblesDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillGoodwillDetail",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillIndefiniteLivedIntangibleAssetsPercentageOfTotalIntangiblesDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail",
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesFootnotesDetails",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationDetail",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationFootnotesDetail",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_InnovativeHealthandEssentialHealthMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Innovative Health and Essential Health [Member]",
        "label": "Innovative Health and Essential Health [Member]",
        "terseLabel": "Innovative Health and Essential Health [Member]"
       }
      }
     },
     "localname": "InnovativeHealthandEssentialHealthMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_InnovativeProductsCategoryAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Innovative Products Category [Axis]",
        "label": "Innovative Products Category [Axis]",
        "terseLabel": "Innovative Products Category [Axis]"
       }
      }
     },
     "localname": "InnovativeProductsCategoryAxis",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "pfe_InnovativeProductsCategoryDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "[Domain] for Innovative Products Category [Axis]",
        "label": "Innovative Products Category [Domain]",
        "terseLabel": "Innovative Products Category [Domain]"
       }
      }
     },
     "localname": "InnovativeProductsCategoryDomain",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Intangible Assets, Net, Percentage of Intangible Assets, Net",
        "label": "Intangible Assets, Net, Percentage of Intangible Assets, Net",
        "terseLabel": "Percentage of total identifiable intangible assets, less accumulated amortization"
       }
      }
     },
     "localname": "IntangibleAssetsNetPercentageofIntangibleAssetsNet",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedIntangibleAssetsPercentageOfTotalIntangiblesDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillIndefiniteLivedIntangibleAssetsPercentageOfTotalIntangiblesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pfe_IntangibleAssetsTransfersDuringPeriod": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Intangible Assets, Transfers During Period",
        "label": "Intangible Assets, Transfers During Period",
        "terseLabel": "Transfer of intangible assets during period"
       }
      }
     },
     "localname": "IntangibleAssetsTransfersDuringPeriod",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsFootnotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_InterestPaidInterestRateHedges": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Interest Paid, Interest Rate Hedges",
        "label": "Interest Paid, Interest Rate Hedges",
        "terseLabel": "Interest rate hedges"
       }
      }
     },
     "localname": "InterestPaidInterestRateHedges",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_InternalMedicineMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Internal Medicine [Member]",
        "label": "Internal Medicine [Member]",
        "terseLabel": "Internal Medicine [Member]"
       }
      }
     },
     "localname": "InternalMedicineMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_JanssenandNewYorkUniversityVersusHospiraCelltrionHealthcareandCelltrionInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Janssen and New York University Versus Hospira, Celltrion Healthcare and Celltrion Inc. [Member]",
        "label": "Janssen and New York University Versus Hospira, Celltrion Healthcare and Celltrion Inc. [Member]",
        "terseLabel": "Janssen and New York University Versus Hospira, Celltrion Healthcare and Celltrion Inc. [Member]"
       }
      }
     },
     "localname": "JanssenandNewYorkUniversityVersusHospiraCelltrionHealthcareandCelltrionInc.Member",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/CommitmentsAndContingenciesActionsInWhichWeAreDefendantDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_KingMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "King [Member]",
        "label": "King [Member]",
        "terseLabel": "King [Member]"
       }
      }
     },
     "localname": "KingMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_LaboratorioTeutoBrasileroMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Laboratorio Teuto Brasilero [Member]",
        "label": "Laboratorio Teuto Brasilero [Member]",
        "terseLabel": "Laboratorio Teuto Brasilero [Member]"
       }
      }
     },
     "localname": "LaboratorioTeutoBrasileroMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsEquityMethodInvestmentsDetails",
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeParenthetical",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_LegacyEstablishedProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Legacy Established Products",
        "label": "Legacy Established Products [Member]",
        "terseLabel": "Legacy Established Products (LEP) [Member]"
       }
      }
     },
     "localname": "LegacyEstablishedProductsMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_LicensingAgreementsAndOtherMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Licensing Agreements And Other [Member]",
        "label": "Licensing Agreements And Other [Member]",
        "terseLabel": "License Agreements and Other [Member]"
       }
      }
     },
     "localname": "LicensingAgreementsAndOtherMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_LipitorMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lipitor [Member]",
        "label": "Lipitor [Member]",
        "terseLabel": "Lipitor [Member]"
       }
      }
     },
     "localname": "LipitorMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_LongtermInvestmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Long-term Investments [Member]",
        "label": "Long-term Investments [Member]",
        "terseLabel": "Long-term Investments [Member]"
       }
      }
     },
     "localname": "LongtermInvestmentsMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsBalanceSheetGroupingDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_LossContingencyCollaborationArrangementPercentageofPaymentsSoughtbyPlaintiff": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Loss Contingency, Collaboration Arrangement, Percentage of Payments Sought by Plaintiff",
        "label": "Loss Contingency, Collaboration Arrangement, Percentage of Payments Sought by Plaintiff",
        "terseLabel": "Percentage of payments Medivation received sought by Regents"
       }
      }
     },
     "localname": "LossContingencyCollaborationArrangementPercentageofPaymentsSoughtbyPlaintiff",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/CommitmentsAndContingenciesActionsInWhichWeAreDefendantDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "pfe_LyricaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lyrica [Member]",
        "label": "Lyrica [Member]",
        "terseLabel": "Lyrica [Member]"
       }
      }
     },
     "localname": "LyricaMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_ManufacturingOperationsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Manufacturing Operations [Member]",
        "label": "Manufacturing Operations [Member]",
        "terseLabel": "Manufacturing operations [Member]"
       }
      }
     },
     "localname": "ManufacturingOperationsMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesFootnotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_ManufacturingPlantNetworkOptimizationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Manufacturing Plant Network Optimization [Member]",
        "label": "Manufacturing Plant Network Optimization [Member]",
        "terseLabel": "Manufacturing Plant Network Optimization [Member]"
       }
      }
     },
     "localname": "ManufacturingPlantNetworkOptimizationMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_MaximumManufacturingServicePeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Maximum manufacturing service period provided as a transition services to disposal group.",
        "label": "Maximum Manufacturing Service Period",
        "terseLabel": "Maximum manufacturing service period"
       }
      }
     },
     "localname": "MaximumManufacturingServicePeriod",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsSaleOfHospiraInfusionSystemsNetAssetsToIcuMedicalIncEhDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "pfe_MedivationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Medivation [Member]",
        "label": "Medivation [Member]",
        "terseLabel": "Medivation [Member]"
       }
      }
     },
     "localname": "MedivationMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsMedivationDetails",
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_MedrolMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Medrol [Member]",
        "label": "Medrol [Member]",
        "terseLabel": "Medrol [Member]"
       }
      }
     },
     "localname": "MedrolMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_MerckKGaAMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Merck KGaA [Member]",
        "label": "Merck KGaA [Member]",
        "terseLabel": "Merck KGaA [Member]"
       }
      }
     },
     "localname": "MerckKGaAMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsCollaborationArrangementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_MylotargMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Mylotarg [Member]",
        "label": "Mylotarg [Member]",
        "terseLabel": "Mylotarg [Member]"
       }
      }
     },
     "localname": "MylotargMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_NetInvestmentHedgingNonderivativeInstrumentsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Net Investment Hedging, Nonderivative Instruments [Member]",
        "label": "Net Investment Hedging, Nonderivative Instruments [Member]",
        "terseLabel": "Net Investment Hedging, Nonderivative Instruments [Member]"
       }
      }
     },
     "localname": "NetInvestmentHedgingNonderivativeInstrumentsMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_NoncashorPartNoncashDivestitureAmountofConsiderationReceivedCommonStock": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Noncash or Part Noncash Divestiture, Amount of Consideration Received, Common Stock",
        "label": "Noncash or Part Noncash Divestiture, Amount of Consideration Received, Common Stock",
        "terseLabel": "Receipt of ICU Medical common stock"
       }
      }
     },
     "localname": "NoncashorPartNoncashDivestitureAmountofConsiderationReceivedCommonStock",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_NoncashorPartNoncashDivestitureAmountofConsiderationReceivedNoteReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Noncash or Part Noncash Divestiture, Amount of Consideration Received, Note Receivable",
        "label": "Noncash or Part Noncash Divestiture, Amount of Consideration Received, Note Receivable",
        "terseLabel": "Promissory note from ICU Medical"
       }
      }
     },
     "localname": "NoncashorPartNoncashDivestitureAmountofConsiderationReceivedNoteReceivable",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_NorvascMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Norvasc [Member]",
        "label": "Norvasc [Member]",
        "terseLabel": "Norvasc [Member]"
       }
      }
     },
     "localname": "NorvascMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_OncologyMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Oncology [Member]",
        "label": "Oncology [Member]",
        "terseLabel": "Oncology [Member]"
       }
      }
     },
     "localname": "OncologyMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other Comprehensive (Income) Loss, Curtailment Adjustment from AOCI, Pension and Other Postretirement Benefit Plans, for Net Prior Service Cost (Credit), Tax",
        "label": "Other Comprehensive (Income) Loss, Curtailment Adjustment from AOCI, Pension and Other Postretirement Benefit Plans, for Net Prior Service Cost (Credit), Tax",
        "terseLabel": "Reclassification adjustments related to curtailments, net"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditTax",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome": {
       "order": 3.0,
       "parentTag": "us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Pre tax adjustment to other comprehensive income for curtailments and settlements, net, related to defined benefit plans prior service (costs)/credits.",
        "label": "Other Comprehensive (Income) Loss, Curtailment Adjustment from AOCI, Pension and Other Postretirement Benefit Plans, for Net Prior Service Cost (Credit), before Tax",
        "terseLabel": "Reclassification adjustments related to curtailments, net"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Other Net Prior Service Cost (Credit) Arising During Period, Tax",
        "label": "Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Other Net Prior Service Cost (Credit) Arising During Period, Tax",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome": {
       "order": 4.0,
       "parentTag": "us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Pre tax adjustment to other comprehensive income for other adjustments related to defined benefit plans prior service (costs)/credits.",
        "label": "Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Other Net Prior Service Cost (Credit) Arising During Period, before Tax",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersDetail": {
       "order": 4.0,
       "parentTag": "pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetActuarialGainLossTax",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Other Net Unamortized Gain (Loss) Arising During Period, Tax",
        "label": "Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Other Net Unamortized Gain (Loss) Arising During Period, Tax",
        "negatedTerseLabel": "Other"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodTax",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome": {
       "order": 4.0,
       "parentTag": "us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Pre tax adjustment to other comprehensive income for other adjustments related to defined benefit plans actuarial gains /losses.",
        "label": "Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Other Net Unamortized Gain (Loss) Arising During Period, before Tax",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome": {
       "order": 3.0,
       "parentTag": "us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of pre tax adjustment to other comprehensive income for curtailments and settlements, net, related to defined benefit plans.",
        "label": "Other Comprehensive Income (Loss), Settlement Adjustment From AOCI, Pension And Other Postretirement Benefit Plans, for Net Gain (Loss), Before Tax",
        "negatedTerseLabel": "Reclassification adjustments related to settlements, net"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersDetail": {
       "order": 3.0,
       "parentTag": "pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetActuarialGainLossTax",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other Comprehensive Income (Loss), Settlement Adjustment From AOCI, Pension And Other Postretirement Benefit Plans, for Net Gain (Loss), Tax",
        "label": "Other Comprehensive Income (Loss), Settlement Adjustment From AOCI, Pension And Other Postretirement Benefit Plans, for Net Gain (Loss), Tax",
        "negatedTerseLabel": "Reclassification adjustments related to settlements, net"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossTax",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_OtherDerivativeInstrumentsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other Derivative Instruments [Member]",
        "label": "Other Derivative Instruments [Member]",
        "terseLabel": "Other Derivative Instruments [Member]"
       }
      }
     },
     "localname": "OtherDerivativeInstrumentsMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_OtherFinancialLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail": {
       "order": 2.0,
       "parentTag": "pfe_SelectedFinancialLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total other financial liabilities",
        "label": "Other Financial Liabilities",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "OtherFinancialLiabilities",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_OtherInProcessResearchandDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other In Process Research and Development [Member]",
        "label": "Other In Process Research and Development [Member]",
        "terseLabel": "Other In Process Research and Development [Member]"
       }
      }
     },
     "localname": "OtherInProcessResearchandDevelopmentMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_OtherIncomeExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other Income (Expense) [Member]",
        "label": "Other Income (Expense) [Member]",
        "terseLabel": "Other (Income)/Deductions - Net [Member]"
       }
      }
     },
     "localname": "OtherIncomeExpenseMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_OtherLegacyEstablishedProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other Legacy Established Products [Member]",
        "label": "Other Legacy Established Products [Member]",
        "terseLabel": "Other Legacy Established Products [Member]"
       }
      }
     },
     "localname": "OtherLegacyEstablishedProductsMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_OtherNonoperatingIncomeExpenseNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetDetail": {
       "order": 8.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other Nonoperating Income (Expense), Net",
        "label": "Other Nonoperating Income (Expense), Net",
        "negatedTerseLabel": "Other, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpenseNet",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_OtherNonoperatingIncomeMiscellaneous": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other Nonoperating Income, Miscellaneous",
        "label": "Other Nonoperating Income, Miscellaneous",
        "terseLabel": "Income from contract resolution"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeMiscellaneous",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_OtherOncologyProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other Oncology Products [Member]",
        "label": "Other Oncology Products [Member]",
        "terseLabel": "All other Oncology [Member]"
       }
      }
     },
     "localname": "OtherOncologyProductsMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_OtherSegmentReconcilingItemsAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other Segment Reconciling Items [Axis]",
        "label": "Other Segment Reconciling Items [Axis]",
        "terseLabel": "Other Segment Reconciling Items [Axis]"
       }
      }
     },
     "localname": "OtherSegmentReconcilingItemsAxis",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "pfe_OtherSegmentReconcilingItemsDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "[Domain] for Other Segment Reconciling Items [Axis]",
        "label": "Other Segment Reconciling Items [Domain]",
        "terseLabel": "Other Segment Reconciling Items [Domain]"
       }
      }
     },
     "localname": "OtherSegmentReconcilingItemsDomain",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_OtherSelectedFinancialAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail": {
       "order": 2.0,
       "parentTag": "pfe_SelectedFinancialAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The total amount of other selected financial assets presented in the balance sheet caption at the balance sheet date.",
        "label": "Other Selected Financial Assets",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "OtherSelectedFinancialAssets",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_OtherSelectedFinancialAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other selected financial assets [Abstract]",
        "label": "Other Selected Financial Assets [Abstract]",
        "terseLabel": "Other selected financial assets"
       }
      }
     },
     "localname": "OtherSelectedFinancialAssetsAbstract",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "pfe_OtherSelectedFinancialLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other Selected Financial Liabilities [Abstract]",
        "label": "Other Selected Financial Liabilities [Abstract]",
        "terseLabel": "Other selected financial liabilities"
       }
      }
     },
     "localname": "OtherSelectedFinancialLiabilitiesAbstract",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "pfe_OtherTaxAssetsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other Tax Assets, Current",
        "label": "Other Tax Assets, Current",
        "terseLabel": "Current tax assets"
       }
      }
     },
     "localname": "OtherTaxAssetsCurrent",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_OtherUnallocatedMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other unallocated [Member]",
        "label": "Other Unallocated [Member]",
        "terseLabel": "Other Unallocated [Member]"
       }
      }
     },
     "localname": "OtherUnallocatedMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_OtherVaccinesProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other Vaccines Products [Member]",
        "label": "Other Vaccines Products [Member]",
        "terseLabel": "All other Vaccines [Member]"
       }
      }
     },
     "localname": "OtherVaccinesProductsMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_PatentInfringementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Patent Infringement [Member]",
        "label": "Patent Infringement [Member]",
        "terseLabel": "Patent Infringement [Member]"
       }
      }
     },
     "localname": "PatentInfringementMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/CommitmentsAndContingenciesActionsInWhichWeArePlaintiffDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_PatentMatterMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Patent Matter [Member]",
        "label": "Patent Matter [Member]",
        "terseLabel": "Patent Matter [Member]"
       }
      }
     },
     "localname": "PatentMatterMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_PaymentsforMergerTerminationCosts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Payments for Merger Termination Costs",
        "label": "Payments for Merger Termination Costs",
        "terseLabel": "Payments for merger termination costs"
       }
      }
     },
     "localname": "PaymentsforMergerTerminationCosts",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Payments for Restructuring, Other Restructuring And Restructuring Translation Adjustment",
        "label": "Payments for Restructuring, Other Restructuring And Restructuring Translation Adjustment",
        "negatedTerseLabel": "Utilization and other"
       }
      }
     },
     "localname": "PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesRestructuringAccrualsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_PaymentstoAcquireBusinessesGrossInitialPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Payments to Acquire Businesses, Gross, Initial Payment",
        "label": "Payments to Acquire Businesses, Gross, Initial Payment",
        "terseLabel": "Initial payment"
       }
      }
     },
     "localname": "PaymentstoAcquireBusinessesGrossInitialPayment",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsAstrazenecaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_PaymentstoAcquireBusinessesGrossPurchasePriceAdjustment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Payments to Acquire Businesses, Gross, Purchase Price Adjustment",
        "label": "Payments to Acquire Businesses, Gross, Purchase Price Adjustment",
        "terseLabel": "Additional payment made for a purchase price adjustment"
       }
      }
     },
     "localname": "PaymentstoAcquireBusinessesGrossPurchasePriceAdjustment",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsAstrazenecaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of cash or cash equivalents contributed during the reporting period by the entity to fund its pension plans and its non-pension postretirement benefit plans less the amount of pension and other postretirement benefit costs recognized during the period for defined benefit plans (periodic benefit costs include the following components: service cost, interest cost, expected return on plan assets, gain or loss on assets, prior service cost or credit, transition asset or obligation, and gain or loss due to settlements or curtailments).",
        "label": "Pension And Other Postretirement Benefit Contributions, Net Of Pension And Other Postretirement Benefit (Expense)",
        "negatedTerseLabel": "Benefit plan contributions in excess of expense"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_PercentageChangeInRevenue": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The percentage change in revenue.",
        "label": "Percentage Change In Revenue",
        "terseLabel": "Percentage Change In Revenue"
       }
      }
     },
     "localname": "PercentageChangeInRevenue",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByGeographicAreaDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "pfe_PeriLOEProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Peri-LOE Products",
        "label": "Peri-LOE Products [Member]",
        "terseLabel": "Peri-LOE Products [Member]"
       }
      }
     },
     "localname": "PeriLOEProductsMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_PfizerVersusBMSE.R.SquibbSonsOnoPharmaceuticalandTasukuHonjoMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Pfizer Versus BMS, E.R. Squibb &amp; Sons, Ono Pharmaceutical and Tasuku Honjo [Member]",
        "label": "Pfizer Versus BMS, E.R. Squibb &amp; Sons, Ono Pharmaceutical and Tasuku Honjo [Member]",
        "terseLabel": "Pfizer Versus BMS, E.R. Squibb &amp; Sons, Ono Pharmaceutical and Tasuku Honjo [Member]"
       }
      }
     },
     "localname": "PfizerVersusBMSE.R.SquibbSonsOnoPharmaceuticalandTasukuHonjoMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/CommitmentsAndContingenciesActionsInWhichWeArePlaintiffDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_PfizerVersusBreckenridgeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Pfizer Versus Breckenridge [Member]",
        "label": "Pfizer Versus Breckenridge [Member]",
        "terseLabel": "Pfizer Versus Breckenridge [Member]"
       }
      }
     },
     "localname": "PfizerVersusBreckenridgeMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/CommitmentsAndContingenciesActionsInWhichWeArePlaintiffDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_PfizerVersusMicroLabsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Pfizer Versus MicroLabs [Member]",
        "label": "Pfizer Versus MicroLabs [Member]",
        "terseLabel": "Pfizer Versus MicroLabs [Member]"
       }
      }
     },
     "localname": "PfizerVersusMicroLabsMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/CommitmentsAndContingenciesActionsInWhichWeArePlaintiffDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_PfizerVersusMylanLaboratoriesandAccordHealthcareInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Pfizer Versus Mylan Laboratories and Accord Healthcare Inc. [Member]",
        "label": "Pfizer Versus Mylan Laboratories and Accord Healthcare Inc. [Member]",
        "terseLabel": "Pfizer Versus Mylan Laboratories Limited [Member]"
       }
      }
     },
     "localname": "PfizerVersusMylanLaboratoriesandAccordHealthcareInc.Member",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/CommitmentsAndContingenciesActionsInWhichWeArePlaintiffDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_PfizerVersusPrinstonandBreckenridgeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Pfizer Versus Prinston and Breckenridge [Member]",
        "label": "Pfizer Versus Prinston and Breckenridge [Member]",
        "terseLabel": "Pfizer Versus Prinston and Breckenridge [Member]"
       }
      }
     },
     "localname": "PfizerVersusPrinstonandBreckenridgeMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/CommitmentsAndContingenciesActionsInWhichWeArePlaintiffDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_PfizerVersusSeveralGenericManufacturersMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Pfizer Versus Several Generic Manufacturers [Member]",
        "label": "Pfizer Versus Several Generic Manufacturers [Member]",
        "terseLabel": "Pfizer Versus Several Generic Manufacturers [Member]"
       }
      }
     },
     "localname": "PfizerVersusSeveralGenericManufacturersMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/CommitmentsAndContingenciesActionsInWhichWeArePlaintiffDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_PfizerVersusZydusMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Pfizer Versus Zydus [Member]",
        "label": "Pfizer Versus Zydus [Member]",
        "terseLabel": "Pfizer Versus Zydus [Member]"
       }
      }
     },
     "localname": "PfizerVersusZydusMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/CommitmentsAndContingenciesActionsInWhichWeArePlaintiffDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_PfizerandBMSVersusSeveralGenericManufacturersMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Pfizer and BMS Versus Several Generic Manufacturers [Member]",
        "label": "Pfizer and BMS Versus Several Generic Manufacturers [Member]",
        "terseLabel": "Pfizer and BMS Versus Several Generic Manufacturers [Member]"
       }
      }
     },
     "localname": "PfizerandBMSVersusSeveralGenericManufacturersMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/CommitmentsAndContingenciesActionsInWhichWeArePlaintiffDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_PfizersWorldwideResearchandDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Pfizer's Worldwide Research and Development [Member]",
        "label": "Pfizer's Worldwide Research and Development [Member]",
        "terseLabel": "Pfizer's Worldwide Research and Development [Member]"
       }
      }
     },
     "localname": "PfizersWorldwideResearchandDevelopmentMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedIntangibleAssetsPercentageOfTotalIntangiblesDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillIndefiniteLivedIntangibleAssetsPercentageOfTotalIntangiblesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_PfizersWorldwideResearchandDevelopmentandPfizersGlobalProductDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Pfizer's Worldwide Research and Development and Pfizer's Global Product Development [Member]",
        "label": "Pfizer's Worldwide Research and Development and Pfizer's Global Product Development [Member]",
        "terseLabel": "Pfizer's Worldwide Research and Development and Pfizer's Global Product Development [Member]"
       }
      }
     },
     "localname": "PfizersWorldwideResearchandDevelopmentandPfizersGlobalProductDevelopmentMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationFootnotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_PhenytoinSodiumCapsulesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Phenytoin Sodium Capsules [Member]",
        "label": "Phenytoin Sodium Capsules [Member]",
        "terseLabel": "Phenytoin Sodium Capsules [Member]"
       }
      }
     },
     "localname": "PhenytoinSodiumCapsulesMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/CommitmentsAndContingenciesActionsInWhichWeAreDefendantDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_PrecedexMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Precedex [Member]",
        "label": "Precedex [Member]",
        "terseLabel": "Precedex [Member]"
       }
      }
     },
     "localname": "PrecedexMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_PrecedexPremixMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Precedex Premix [Member]",
        "label": "Precedex Premix [Member]",
        "terseLabel": "Precedex Premix [Member]"
       }
      }
     },
     "localname": "PrecedexPremixMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/CommitmentsAndContingenciesActionsInWhichWeArePlaintiffDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_PremarinFamilyMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Premarin family [Member]",
        "label": "Premarin Family [Member]",
        "terseLabel": "Premarin family [Member]"
       }
      }
     },
     "localname": "PremarinFamilyMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_PrevnarPrevenarFamilyMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Prevnar/Prevenar Family 13 [Member]",
        "label": "Prevnar Prevenar Family [Member]",
        "terseLabel": "Prevnar 13/Prevenar 13 [Member]"
       }
      }
     },
     "localname": "PrevnarPrevenarFamilyMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_PristiqMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Pristiq [Member]",
        "label": "Pristiq [Member]",
        "terseLabel": "Pristiq [Member]"
       }
      }
     },
     "localname": "PristiqMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_PurchaseAccountingAdjustmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Purchase Accounting Adjustments [Member]",
        "label": "Purchase Accounting Adjustments [Member]",
        "terseLabel": "Purchase Accounting Adjustments [Member]"
       }
      }
     },
     "localname": "PurchaseAccountingAdjustmentsMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_RareDiseaseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Rare Disease [Member]",
        "label": "Rare Disease [Member]",
        "terseLabel": "Rare Disease [Member]"
       }
      }
     },
     "localname": "RareDiseaseMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_ReFactoAfXynthaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Re Facto AF Xyntha [Member]",
        "label": "Re Facto AF Xyntha [Member]",
        "terseLabel": "ReFacto AF/ Xyntha [Member]"
       }
      }
     },
     "localname": "ReFactoAfXynthaMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_RegentsVersusMedivationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Regents Versus Medivation [Member]",
        "label": "Regents Versus Medivation [Member]",
        "terseLabel": "Regents Versus Medivation [Member]"
       }
      }
     },
     "localname": "RegentsVersusMedivationMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/CommitmentsAndContingenciesActionsInWhichWeAreDefendantDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_RelpaxMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Relpax [Member]",
        "label": "Relpax [Member]",
        "terseLabel": "Relpax [Member]"
       }
      }
     },
     "localname": "RelpaxMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_ResearchandDevelopmentArrangementAggregatePaymentObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Research and Development Arrangement, Aggregate Payment Obligation",
        "label": "Research and Development Arrangement, Aggregate Payment Obligation",
        "terseLabel": "Aggregate amount of guaranteed fixed annual payments to be made in connection with research and development arrangement",
        "verboseLabel": "Research arrangement, fixed payment obligation"
       }
      }
     },
     "localname": "ResearchandDevelopmentArrangementAggregatePaymentObligation",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/CommitmentsAndContingenciesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsOtherNoncurrentLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_ResearchandDevelopmentArrangementAggregatePaymentObligationTerm": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Research and Development Arrangement, Aggregate Payment Obligation, Term",
        "label": "Research and Development Arrangement, Aggregate Payment Obligation, Term",
        "terseLabel": "Term over which fixed annual payments are to be made",
        "verboseLabel": "Term over which additional fixed payments are to be made"
       }
      }
     },
     "localname": "ResearchandDevelopmentArrangementAggregatePaymentObligationTerm",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/CommitmentsAndContingenciesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsOtherNoncurrentLiabilitiesDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "pfe_RestructuringAssetImpairmentCharges": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_RestructuringCharges",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Restructuring, Asset Impairment Charges",
        "label": "Restructuring, Asset Impairment Charges",
        "netLabel": "Asset impairments"
       }
      }
     },
     "localname": "RestructuringAssetImpairmentCharges",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Restructuring Charges, Acquisition Related Costs and Implementation Costs",
        "label": "Restructuring Charges, Acquisition Related Costs and Implementation Costs",
        "totalLabel": "Total costs associated with acquisitions and cost-reduction/productivity initiatives"
       }
      }
     },
     "localname": "RestructuringChargesAcquisitionRelatedCostsandImplementationCosts",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_RestructuringChargesAndAcquisitionRelatedCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfIncome": {
       "order": 6.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      },
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesDetail": {
       "order": 1.0,
       "parentTag": "pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This element represents (i) restructuring charges, which are amounts charged against earnings in the period for incurred and estimated costs associated with exit from or disposal of business activities or restructurings pursuant to a program that is planned and controlled by management, and materially changes either the scope of a business undertaken by an entity, or the manner in which that business is conducted; and (ii) acquisition-related costs, which are costs incurred to effect a business combination which costs have been expensed during the period. Such costs can include transaction costs such as banking, legal, accounting and other costs directly related to effect a business combination as well as external, incremental costs of integration planning that are directly related to a business combination, including costs associated with preparing for systems and other integration activities.",
        "label": "Restructuring Charges And Acquisition Related Costs",
        "terseLabel": "Restructuring charges and certain acquisition-related costs",
        "totalLabel": "Restructuring charges and certain acquisition-related costs"
       }
      }
     },
     "localname": "RestructuringChargesAndAcquisitionRelatedCosts",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfIncome",
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_RestructuringChargesandImplementationCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Restructuring Charges and Implementation Costs",
        "label": "Restructuring Charges and Implementation Costs",
        "terseLabel": "Cost reduction and productivity initiatives excluding acquisition related costs"
       }
      }
     },
     "localname": "RestructuringChargesandImplementationCosts",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationFootnotesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_RestructuringandRelatedCostNoncashChargesPercentage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Restructuring and Related Cost, Noncash Charges, Percentage",
        "label": "Restructuring and Related Cost, Noncash Charges, Percentage",
        "terseLabel": "Percentage of expected costs to be non-cash"
       }
      }
     },
     "localname": "RestructuringandRelatedCostNoncashChargesPercentage",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "pfe_ReturnofAcquiredRightsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Return of Acquired Rights [Member]",
        "label": "Return of Acquired Rights [Member]",
        "terseLabel": "Return of Acquired Rights [Member]"
       }
      }
     },
     "localname": "ReturnofAcquiredRightsMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_RevatioMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revatio [Member]",
        "label": "Revatio [Member]",
        "terseLabel": "Revatio [Member]"
       }
      }
     },
     "localname": "RevatioMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_RoyaltyRevenueTerm": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Royalty Revenue, Term",
        "label": "Royalty Revenue, Term",
        "terseLabel": "Royalty period"
       }
      }
     },
     "localname": "RoyaltyRevenueTerm",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "pfe_ScheduleofEmployerContributionstoPensionandPostretirementPlansTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of Employer Contributions to Pension and Postretirement Plans [Table Text Block]",
        "label": "Schedule of Employer Contributions to Pension and Postretirement Plans [Table Text Block]",
        "terseLabel": "Schedule of Employer Contributions to Pension and Postretirement Plans"
       }
      }
     },
     "localname": "ScheduleofEmployerContributionstoPensionandPostretirementPlansTableTextBlock",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "pfe_ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of Other Comprehensive Income (Loss), Components of Income Tax Expense (Benefit) [Table Text Block]",
        "label": "Schedule of Other Comprehensive Income (Loss), Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Schedule of Tax Provision (Benefit) on Other Comprehensive Income/(Loss)"
       }
      }
     },
     "localname": "ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "pfe_SelectedFinancialAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total selected financial assets at the balance sheet date.",
        "label": "Selected Financial Assets",
        "totalLabel": "Total selected financial assets",
        "verboseLabel": "Selected financial assets"
       }
      }
     },
     "localname": "SelectedFinancialAssets",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail",
      "http://www.pfizer.com/role/FinancialInstrumentsBalanceSheetGroupingDetail",
      "http://www.pfizer.com/role/FinancialInstrumentsBalanceSheetGroupingFootnotesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_SelectedFinancialLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total selected financial liabilities.",
        "label": "Selected Financial Liabilities",
        "terseLabel": "Selected financial liabilities",
        "totalLabel": "Total selected financial liabilities"
       }
      }
     },
     "localname": "SelectedFinancialLiabilities",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail",
      "http://www.pfizer.com/role/FinancialInstrumentsBalanceSheetGroupingDetail",
      "http://www.pfizer.com/role/FinancialInstrumentsBalanceSheetGroupingFootnotesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_SeniorUnsecuredDebtFourPointTwoPercentDue2047Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Senior Unsecured Debt, Four Point Two Percent, Due 2047 [Member]",
        "label": "Senior Unsecured Debt, Four Point Two Percent, Due 2047 [Member]",
        "terseLabel": "4.20% Notes (2047 Notes) [Member]"
       }
      }
     },
     "localname": "SeniorUnsecuredDebtFourPointTwoPercentDue2047Member",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_SeniorUnsecuredEuroDebtOnePointZeroPercentDue2027Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Senior Unsecured Euro Debt, One Point Zero Percent, Due 2027 [Member]",
        "label": "Senior Unsecured Euro Debt, One Point Zero Percent, Due 2027 [Member]",
        "terseLabel": "1.00% euro Notes (2027 Notes) [Member]"
       }
      }
     },
     "localname": "SeniorUnsecuredEuroDebtOnePointZeroPercentDue2027Member",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_SeniorUnsecuredEuroDebtPointTwofivePercentDue2022Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Senior Unsecured Euro Debt, Point Two-five Percent, Due 2022 [Member]",
        "label": "Senior Unsecured Euro Debt, Point Two-five Percent, Due 2022 [Member]",
        "terseLabel": "0.25% euro Notes (2022 Notes) [Member]"
       }
      }
     },
     "localname": "SeniorUnsecuredEuroDebtPointTwofivePercentDue2022Member",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_SeniorUnsecuredEuroDebtThreemonthEURIBORPlus0.20FloatingRateNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Senior Unsecured Euro Debt, Three-month EURIBOR Plus 0.20% Floating Rate Notes",
        "label": "Senior Unsecured Euro Debt, Three-month EURIBOR Plus 0.20% Floating Rate Notes [Member]",
        "terseLabel": "Three-month EURIBOR Plus 0.20% floating rate notes (2019 Notes) [Member]"
       }
      }
     },
     "localname": "SeniorUnsecuredEuroDebtThreemonthEURIBORPlus0.20FloatingRateNotesMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_SeniorUnsecuredEuroDebtZeroPercentDue2020Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Senior Unsecured Euro Debt, Zero Percent, Due 2020 [Member]",
        "label": "Senior Unsecured Euro Debt, Zero Percent, Due 2020 [Member]",
        "terseLabel": "0.00% euro Notes (2020 Notes) [Member]"
       }
      }
     },
     "localname": "SeniorUnsecuredEuroDebtZeroPercentDue2020Member",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_ShareRepurchaseAgreementwithCitibankMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share Repurchase Agreement with Citibank [Member]",
        "label": "Share Repurchase Agreement with Citibank [Member]",
        "terseLabel": "Share Repurchase Agreement with Citibank [Member]"
       }
      }
     },
     "localname": "ShareRepurchaseAgreementwithCitibankMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_ShortTermDebtAndCurrentPortionofLongTermDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Short-Term Debt And Current Portion of Long-Term Debt [Member]",
        "label": "Short-Term Debt And Current Portion of Long-Term Debt [Member]",
        "terseLabel": "Short-Term Borrowings, Including Current Portion of Long-Term Debt [Member]"
       }
      }
     },
     "localname": "ShortTermDebtAndCurrentPortionofLongTermDebtMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsBalanceSheetGroupingDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_ShorttermDebtGross": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Short-term Debt, Gross",
        "label": "Short-term Debt, Gross",
        "terseLabel": "Principal amount"
       }
      }
     },
     "localname": "ShorttermDebtGross",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_SomavertMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Somavert [Member]",
        "label": "Somavert [Member]",
        "terseLabel": "Somavert [Member]"
       }
      }
     },
     "localname": "SomavertMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_StateofIllinoisVersusPfizerMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "State of Illinois Versus Pfizer [Member]",
        "label": "State of Illinois Versus Pfizer [Member]",
        "terseLabel": "State of Illinois Versus Pfizer [Member]"
       }
      }
     },
     "localname": "StateofIllinoisVersusPfizerMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/CommitmentsAndContingenciesActionsInWhichWeAreDefendantDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_SterileInjectablePharmaceuticalsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sterile Injectable Pharmaceuticals [Member]",
        "label": "Sterile Injectable Pharmaceuticals [Member]",
        "terseLabel": "Sterile Injectable Pharmaceuticals [Member]"
       }
      }
     },
     "localname": "SterileInjectablePharmaceuticalsMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_SulperazonMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sulperazon [Member]",
        "label": "Sulperazon [Member]",
        "terseLabel": "Sulperazon [Member]"
       }
      }
     },
     "localname": "SulperazonMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_SupranationalDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the debt of international organizations such as the World Bank, the International Monetary Fund, regional multilateral development banks, multilateral financial institutions, and other similar organizations.",
        "label": "Supranational Debt [Member]",
        "terseLabel": "Supranational debt [Member]"
       }
      }
     },
     "localname": "SupranationalDebtMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsInDebtSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_SutentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sutent [Member]",
        "label": "Sutent [Member]",
        "terseLabel": "Sutent [Member]"
       }
      }
     },
     "localname": "SutentMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_TimeDepositsCorporateDebtAndOtherMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Time Deposits, Corporate Debt And Other [Member]",
        "label": "Time Deposits, Corporate Debt And Other [Member]",
        "terseLabel": "Time deposits and other [Member]"
       }
      }
     },
     "localname": "TimeDepositsCorporateDebtAndOtherMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsInDebtSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_ToviazCompositionofmatterPatentsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Toviaz Composition-of-matter Patents [Member]",
        "label": "Toviaz Composition-of-matter Patents [Member]",
        "terseLabel": "Toviaz Composition-of-matter Patents [Member]"
       }
      }
     },
     "localname": "ToviazCompositionofmatterPatentsMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/CommitmentsAndContingenciesActionsInWhichWeArePlaintiffDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_ToviazMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Toviaz [Member]",
        "label": "Toviaz [Member]",
        "terseLabel": "Toviaz [Member]"
       }
      }
     },
     "localname": "ToviazMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/CommitmentsAndContingenciesActionsInWhichWeArePlaintiffDetails",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_TygacilMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tygacil [Member]",
        "label": "Tygacil [Member]",
        "terseLabel": "Tygacil [Member]"
       }
      }
     },
     "localname": "TygacilMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_VaccinesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Vaccines [Member]",
        "label": "Vaccines [Member]",
        "terseLabel": "Vaccines [Member]"
       }
      }
     },
     "localname": "VaccinesMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_VfendMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Vfend [Member]",
        "label": "Vfend [Member]",
        "terseLabel": "Vfend [Member]"
       }
      }
     },
     "localname": "VfendMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_ViagraMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Viagra [Member]",
        "label": "Viagra [Member]",
        "terseLabel": "Viagra [Member]"
       }
      }
     },
     "localname": "ViagraMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_ViivHealthcareLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "ViiV Healthcare Limited [Member]",
        "label": "ViiV Healthcare Limited [Member]",
        "terseLabel": "ViiV Healthcare Limited [Member]"
       }
      }
     },
     "localname": "ViivHealthcareLimitedMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationFootnotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_ViolationofAntitrustLawsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Violation of Antitrust Laws [Member]",
        "label": "Violation of Antitrust Laws [Member]",
        "terseLabel": "Violation of Antitrust Laws [Member]"
       }
      }
     },
     "localname": "ViolationofAntitrustLawsMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/CommitmentsAndContingenciesActionsInWhichWeAreDefendantDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_WesternEuropeanAsianandOtherGovernmentDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Western European, Asian and Other Government Debt [Member]",
        "label": "Western European, Asian and Other Government Debt [Member]",
        "terseLabel": "Western European, Asian and other government debt [Member]"
       }
      }
     },
     "localname": "WesternEuropeanAsianandOtherGovernmentDebtMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsInDebtSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_WesternEuropeanScandinaviaAndOtherGovernmentAgencyDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Western European, Scandinavia And Other Government Agency Debt [Member]",
        "label": "Western European, Scandinavia And Other Government Agency Debt [Member]",
        "terseLabel": "Western European, Scandinavia and other government agency debt [Member]"
       }
      }
     },
     "localname": "WesternEuropeanScandinaviaAndOtherGovernmentAgencyDebtMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsInDebtSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_WesternEuropeanandOtherGovernmentDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Western European and Other Government Debt [Member]",
        "label": "Western European and Other Government Debt [Member]",
        "terseLabel": "Western European government debt [Member]"
       }
      }
     },
     "localname": "WesternEuropeanandOtherGovernmentDebtMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsInDebtSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_WorldwideResearchandDevelopmentandGlobalProductDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Worldwide Research and Development and Global Product Development [Member]",
        "label": "Worldwide Research and Development and Global Product Development [Member]",
        "terseLabel": "WRD &amp; GPD [Member]"
       }
      }
     },
     "localname": "WorldwideResearchandDevelopmentandGlobalProductDevelopmentMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesFootnotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_WyethVersusSunMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Wyeth Versus Sun [Member]",
        "label": "Wyeth Versus Sun [Member]",
        "terseLabel": "Wyeth Versus Sun [Member]"
       }
      }
     },
     "localname": "WyethVersusSunMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/CommitmentsAndContingenciesActionsInWhichWeArePlaintiffDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_XalatanXalacomMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Xalatan / Xalacom [Member]",
        "label": "Xalatan Xalacom [Member]",
        "terseLabel": "Xalatan/Xalacom [Member]"
       }
      }
     },
     "localname": "XalatanXalacomMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_XalkoriMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Xalkori [Member]",
        "label": "Xalkori [Member]",
        "terseLabel": "Xalkori [Member]"
       }
      }
     },
     "localname": "XalkoriMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_XanaxXanaxXRMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Xanax/Xanax XR [Member]",
        "label": "Xanax/Xanax XR [Member]",
        "terseLabel": "Xanax [Member]"
       }
      }
     },
     "localname": "XanaxXanaxXRMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_XeljanzMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Xeljanz [Member]",
        "label": "Xeljanz [Member]",
        "terseLabel": "Xeljanz [Member]"
       }
      }
     },
     "localname": "XeljanzMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/CommitmentsAndContingenciesActionsInWhichWeArePlaintiffDetails",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_XtandiAllianceMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Xtandi Alliance [Member]",
        "label": "Xtandi Alliance [Member]",
        "terseLabel": "Xtandi Alliance [Member]"
       }
      }
     },
     "localname": "XtandiAllianceMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_XtandiMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Xtandi [Member]",
        "label": "Xtandi [Member]",
        "terseLabel": "Xtandi [Member]"
       }
      }
     },
     "localname": "XtandiMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/CommitmentsAndContingenciesActionsInWhichWeAreDefendantDetail",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_ZithromaxZmaxMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Zithromax / Zmax [Member]",
        "label": "Zithromax Zmax [Member]",
        "terseLabel": "Zithromax [Member]"
       }
      }
     },
     "localname": "ZithromaxZmaxMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_ZoloftMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Zoloft [Member]",
        "label": "Zoloft [Member]",
        "terseLabel": "Zoloft [Member]"
       }
      }
     },
     "localname": "ZoloftMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_ZyvoxMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Zyvox [Member]",
        "label": "Zyvox [Member]",
        "terseLabel": "Zyvox [Member]"
       }
      }
     },
     "localname": "ZyvoxMember",
     "nsuri": "http://www.pfizer.com/20171001",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AOCIAttributableToParentNetOfTaxRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "AOCI Attributable to Parent, Net of Tax [Roll Forward]",
        "terseLabel": "AOCI Attributable to Parent, Net of Tax [Roll Forward]"
       }
      }
     },
     "localname": "AOCIAttributableToParentNetOfTaxRollForward",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AcceleratedShareRepurchasesInitialPricePaidPerShare": {
     "auth_ref": [
      "r263"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The price paid per share to immediately purchase the targeted number of shares on the date of executing the accelerated share repurchase agreement.",
        "label": "Accelerated Share Repurchases, Initial Price Paid Per Share",
        "terseLabel": "Shares repurchased, price per share (in dollars per share)"
       }
      }
     },
     "localname": "AcceleratedShareRepurchasesInitialPricePaidPerShare",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_AcceleratedShareRepurchasesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accelerated Share Repurchases [Line Items]",
        "terseLabel": "Accelerated Share Repurchases [Line Items]"
       }
      }
     },
     "localname": "AcceleratedShareRepurchasesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt": {
     "auth_ref": [
      "r263"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash receipt from (payment to) bank; or stock received from (issuance to) bank in the settlement of the accelerated share repurchase agreement.",
        "label": "Accelerated Share Repurchases, Settlement (Payment) or Receipt",
        "negatedTerseLabel": "Accelerated share repurchases, cash paid"
       }
      }
     },
     "localname": "AcceleratedShareRepurchasesSettlementPaymentOrReceipt",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AcceleratedShareRepurchasesTable": {
     "auth_ref": [
      "r263"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A table reflecting activity in an accelerated share repurchase (ASR) program.",
        "label": "Accelerated Share Repurchases [Table]",
        "terseLabel": "Accelerated Share Repurchases [Table]"
       }
      }
     },
     "localname": "AcceleratedShareRepurchasesTable",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Trade accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r30",
      "r36"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.",
        "label": "Accounts Receivable, Net, Current",
        "terseLabel": "Trade accounts receivable, less allowance for doubtful accounts: 2017\u2014$590; 2016\u2014$609"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember": {
     "auth_ref": [
      "r79",
      "r84",
      "r289",
      "r336"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated other comprehensive (income) loss related to prior service cost (credit) component of defined benefit plans attributable to the parent.",
        "label": "Accumulated Defined Benefit Plans Adjustment, Net Prior Service Attributable to Parent [Member]",
        "terseLabel": "Prior Service (Costs)/Credits and Other [Member]"
       }
      }
     },
     "localname": "AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember": {
     "auth_ref": [
      "r78",
      "r84",
      "r289",
      "r336"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) related to gain (loss) component of defined benefit plans attributable to the parent.",
        "label": "Accumulated Defined Benefit Plans Adjustment, Net Gain (Loss) Attributable to Parent [Member]",
        "terseLabel": "Actuarial Gains/(Losses) [Member]"
       }
      }
     },
     "localname": "AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r47",
      "r223"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "terseLabel": "Property, plant and equipment, accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember": {
     "auth_ref": [
      "r74",
      "r84",
      "r336"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) resulting from gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges, attributable to the parent.",
        "label": "Accumulated Net Gain (Loss) from Cash Flow Hedges Attributable to Parent [Member]",
        "terseLabel": "Derivative Financial Instruments [Member]"
       }
      }
     },
     "localname": "AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": {
     "auth_ref": [
      "r76",
      "r84",
      "r336"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) resulting from the appreciation (depreciation) in value of securities attributable to the parent.",
        "label": "Accumulated Net Investment Gain (Loss) Attributable to Parent [Member]",
        "terseLabel": "Available-For-Sale Securities [Member]"
       }
      }
     },
     "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r81",
      "r83",
      "r84"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).",
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r80",
      "r84",
      "r336"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Member]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedTranslationAdjustmentMember": {
     "auth_ref": [
      "r73",
      "r84",
      "r336"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.",
        "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]",
        "terseLabel": "Foreign Currency Translation Adjustment [Member]"
       }
      }
     },
     "localname": "AccumulatedTranslationAdjustmentMember",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": {
     "auth_ref": [
      "r209"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Acquired Finite-lived Intangible Assets, Weighted Average Useful Life",
        "terseLabel": "Acquired intangible assets, average useful life"
       }
      }
     },
     "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsMedivationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Additional Cash Flow Elements and Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental Cash Flow Information"
       }
      }
     },
     "localname": "AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by new accounting pronouncement.",
        "label": "Adjustments for New Accounting Pronouncements [Axis]",
        "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net income before allocation to noncontrolling interests to net cash provided by operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "auth_ref": [
      "r63",
      "r172"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A valuation allowance for trade and other receivables due to an Entity within one year (or the normal operating cycle, whichever is longer) that are expected to be uncollectible.",
        "label": "Allowance for Doubtful Accounts Receivable, Current",
        "terseLabel": "Allowance for doubtful accounts"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r126",
      "r207",
      "r214"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "verboseLabel": "Amortization expense for finite-lived intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillNarrativeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r151"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Stock options that had exercise prices greater than the average market price of our common stock issuable under employee compensation plans (shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributableToCommonShareholdersDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r151"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributableToCommonShareholdersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributableToCommonShareholdersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r151"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributableToCommonShareholdersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This item is to be populated with the collective of (i) types (categories) of arrangements of the entity applicable to its revenue-generating activities or operations and non-arrangement transactions, including but not limited to, for instance, sales of product manufactured by the entity, if such comparison of arrangements as a component of all transactions is provided by the entity.",
        "label": "Arrangements and Non-arrangement Transactions [Domain]",
        "terseLabel": "Arrangements and Non-arrangement Transactions [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsCollaborationArrangementDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetBackedSecuritiesMember": {
     "auth_ref": [
      "r187"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans.",
        "label": "Asset-backed Securities [Member]",
        "terseLabel": "Other asset-backed debt [Member]"
       }
      }
     },
     "localname": "AssetBackedSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsInDebtSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetImpairmentCharges": {
     "auth_ref": [
      "r126",
      "r220"
     ],
     "calculation": {
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetDetail": {
       "order": 6.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.",
        "label": "Asset Impairment Charges",
        "terseLabel": "Certain asset impairments"
       }
      }
     },
     "localname": "AssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetDetail",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationFootnotesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r406",
      "r433"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "terseLabel": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationNarrativeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.pfizer.com/role/FinancialInstrumentsBalanceSheetGroupingDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r13",
      "r14",
      "r67"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets, Fair Value Disclosure [Abstract]"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent": {
     "auth_ref": [
      "r1",
      "r2",
      "r9",
      "r222",
      "r226"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Assets, Current",
        "terseLabel": "Assets held for sale"
       }
      }
     },
     "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleEquitySecuritiesGrossUnrealizedGain": {
     "auth_ref": [
      "r182"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of unrealized gain before deducting unrealized loss on investments in equity securities classified as available-for-sale securities.",
        "label": "Available-for-sale Equity Securities, Gross Unrealized Gain",
        "terseLabel": "Gross unrealized gain"
       }
      }
     },
     "localname": "AvailableForSaleEquitySecuritiesGrossUnrealizedGain",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsAssetsAndLiabilitiesMeasuredOnRecurringBasisFootnotesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleEquitySecuritiesGrossUnrealizedLoss": {
     "auth_ref": [
      "r183"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of unrealized loss before deducting unrealized gain on investments in available-for-sale equity securities.",
        "label": "Available-for-sale Equity Securities, Gross Unrealized Loss",
        "terseLabel": "Gross unrealized loss"
       }
      }
     },
     "localname": "AvailableForSaleEquitySecuritiesGrossUnrealizedLoss",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsAssetsAndLiabilitiesMeasuredOnRecurringBasisFootnotesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecurities": {
     "auth_ref": [
      "r174",
      "r178",
      "r185"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_InvestmentsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.",
        "label": "Available-for-sale Securities",
        "terseLabel": "Available-for-sale securities"
       }
      }
     },
     "localname": "AvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsInDebtSecuritiesDetail": {
       "order": 1.0,
       "parentTag": "pfe_DebtSecuritiesMaturitiesWithinOneYear",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of available-for-sale debt securities maturing in the next rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Available-for-sale Securities, Debt Maturities, Next Rolling Twelve Months, Fair Value",
        "terseLabel": "Available-for-sale debt securities maturities within 1 year"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsInDebtSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingAfterYearTenFairValue": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsInDebtSecuritiesDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of available-for-sale debt securities maturing after the tenth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Available-for-sale Securities, Debt Maturities, Rolling after Year Ten, Fair Value",
        "terseLabel": "Available-for-sale debt securities maturities over 10 years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesRollingAfterYearTenFairValue",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsInDebtSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearSixThroughTenFairValue": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsInDebtSecuritiesDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of available-for-sale debt securities maturing in the sixth through tenth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Available-for-sale Securities, Debt Maturities, Rolling Year Six Through Ten, Fair Value",
        "terseLabel": "Available-for-sale debt securities maturities over 5 to 10 years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesRollingYearSixThroughTenFairValue",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsInDebtSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsInDebtSecuritiesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of available-for-sale debt securities maturing in the second through fifth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Available-for-sale Securities, Debt Maturities, Rolling Year Two Through Five, Fair Value",
        "terseLabel": "Available-for-sale debt securities maturities over 1 to 5 years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsInDebtSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r174",
      "r178",
      "r181",
      "r426"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsInDebtSecuritiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsInDebtSecuritiesDetailCalc2": {
       "order": 1.0,
       "parentTag": "pfe_DebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of debt securities categorized neither as held-to-maturity nor trading.",
        "label": "Available-for-sale Securities, Debt Securities",
        "totalLabel": "Available-for-sale debt securities maturities total"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsInDebtSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsBalanceSheetGroupingDetail",
      "http://www.pfizer.com/role/FinancialInstrumentsBalanceSheetGroupingFootnotesDetail",
      "http://www.pfizer.com/role/FinancialInstrumentsNarrativeDetail",
      "http://www.pfizer.com/role/FinancialInstrumentsOtherNoncurrentLiabilitiesDetail",
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesRestructuringAccrualsFootnotesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r349",
      "r353"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsBalanceSheetGroupingDetail",
      "http://www.pfizer.com/role/FinancialInstrumentsBalanceSheetGroupingFootnotesDetail",
      "http://www.pfizer.com/role/FinancialInstrumentsNarrativeDetail",
      "http://www.pfizer.com/role/FinancialInstrumentsOtherNoncurrentLiabilitiesDetail",
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesRestructuringAccrualsFootnotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r141"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.",
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "terseLabel": "Basis of Presentation and Significant Accounting Policies"
       }
      }
     },
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsAnacorPharmaceuticalsIncDetails",
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsAstrazenecaDetails",
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsBambooTherapeuticsDetails",
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsMedivationDetails",
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansNetPeriodicBenefitCostFootnotesDetails",
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesDetail",
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesFootnotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r314",
      "r315"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsAnacorPharmaceuticalsIncDetails",
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsAstrazenecaDetails",
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsBambooTherapeuticsDetails",
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsMedivationDetails",
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansNetPeriodicBenefitCostFootnotesDetails",
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesDetail",
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesFootnotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsAnacorPharmaceuticalsIncDetails",
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsAstrazenecaDetails",
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsBambooTherapeuticsDetails",
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsMedivationDetails",
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsSaleOfHospiraInfusionSystemsNetAssetsToIcuMedicalIncEhDetails",
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionSharePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.",
        "label": "Business Acquisition, Share Price",
        "terseLabel": "Business acquisition, per share in cash (in dollars per share)"
       }
      }
     },
     "localname": "BusinessAcquisitionSharePrice",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsAnacorPharmaceuticalsIncDetails",
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsMedivationDetails",
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "auth_ref": [
      "r321",
      "r322",
      "r324"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.",
        "label": "Business Combination, Consideration Transferred",
        "terseLabel": "Payment to acquire the remaining equity",
        "verboseLabel": "Consideration transferred in business acquisition"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferred1",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsAstrazenecaDetails",
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsBambooTherapeuticsDetails",
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsMedivationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1": {
     "auth_ref": [
      "r311",
      "r324"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value at acquisition-date of the assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interests issued by the acquirer, including but not limited to,  instruments or interests issued or issuable in consideration for the business combination.",
        "label": "Business Combination, Consideration Transferred, Including Equity Interest in Acquiree Held Prior to Combination",
        "terseLabel": "Total fair value of consideration transferred"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsBambooTherapeuticsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r320",
      "r323",
      "r325"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "terseLabel": "Contingent consideration assumed",
        "verboseLabel": "Contingent consideration incurred"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsAstrazenecaDetails",
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsBambooTherapeuticsDetails",
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsMedivationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationIntegrationRelatedCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesDetail": {
       "order": 3.0,
       "parentTag": "pfe_RestructuringChargesAndAcquisitionRelatedCosts",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Costs incurred to effect a business combination which have been expensed during the period. Such costs could include business integration costs, systems integration and conversion costs, and severance and other employee-related costs.",
        "label": "Business Combination, Integration Related Costs",
        "terseLabel": "Integration costs",
        "verboseLabel": "Integration costs"
       }
      }
     },
     "localname": "BusinessCombinationIntegrationRelatedCosts",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles": {
     "auth_ref": [
      "r317"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to intangibles acquired in connection with a business combination for which the initial accounting was incomplete.",
        "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Intangibles",
        "negatedTerseLabel": "Reduction in intangible assets due to measurement period adjustments"
       }
      }
     },
     "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsMedivationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther": {
     "auth_ref": [
      "r316"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of other assets expected to be realized or consumed before one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsAstrazenecaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt": {
     "auth_ref": [
      "r316"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of long-term debt due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-term Debt",
        "verboseLabel": "Debt assumed"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsAnacorPharmaceuticalsIncDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": {
     "auth_ref": [
      "r301",
      "r316"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities",
        "terseLabel": "Deferred tax liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsAnacorPharmaceuticalsIncDetails",
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsAstrazenecaDetails",
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsBambooTherapeuticsDetails",
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsMedivationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets": {
     "auth_ref": [
      "r316"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets",
        "terseLabel": "IPR&amp;D"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsAnacorPharmaceuticalsIncDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": {
     "auth_ref": [
      "r316"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill",
        "verboseLabel": "Identifiable intangible assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsAnacorPharmaceuticalsIncDetails",
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsAstrazenecaDetails",
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsBambooTherapeuticsDetails",
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsMedivationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1": {
     "auth_ref": [
      "r312"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value at acquisition-date of the equity interest in the acquiree held by the acquirer, immediately before the acquisition date for businesses combined in stages.",
        "label": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value",
        "terseLabel": "Fair value of previously held equity interest"
       }
      }
     },
     "localname": "BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsBambooTherapeuticsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain": {
     "auth_ref": [
      "r313"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "In a business combination achieved in stages, this element represents the amount of gain recognized by the entity as a result of remeasuring to fair value the equity interest in the acquiree it held before the business combination.",
        "label": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain",
        "terseLabel": "Gain recognized upon acquisition of remaining interest in acquiree"
       }
      }
     },
     "localname": "BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsBambooTherapeuticsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessExitCosts1": {
     "auth_ref": [
      "r126",
      "r228",
      "r232",
      "r236"
     ],
     "calculation": {
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_RestructuringCharges",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Includes, but is not limited to, one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, and relocating employees, and termination benefits associated with an ongoing benefit arrangement. Excludes expenses associated with special or contractual termination benefits, a discontinued operation or an asset retirement obligation.",
        "label": "Business Exit Costs",
        "terseLabel": "Exit costs"
       }
      }
     },
     "localname": "BusinessExitCosts1",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CarryingReportedAmountFairValueDisclosureMember": {
     "auth_ref": [
      "r382",
      "r383"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measured as reported on the statement of financial position (balance sheet).",
        "label": "Reported Value Measurement [Member]",
        "terseLabel": "Reported Value Measurement [Member]"
       }
      }
     },
     "localname": "CarryingReportedAmountFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r11",
      "r45",
      "r128"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "periodEndLabel": "Cash and cash equivalents, end",
        "periodStartLabel": "Cash and cash equivalents, beginning",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Member]",
        "terseLabel": "Cash and Cash Equivalents [Member]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsBalanceSheetGroupingDetail",
      "http://www.pfizer.com/role/FinancialInstrumentsNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease": {
     "auth_ref": [
      "r121",
      "r390"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.",
        "label": "Cash and Cash Equivalents, Period Increase (Decrease)",
        "totalLabel": "Net increase/(decrease) in cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths": {
     "auth_ref": [
      "r367"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated net amount of existing gains or losses on cash flow hedges at the reporting date expected to be reclassified to earnings within the next 12 months.",
        "label": "Cash Flow Hedge Gain (Loss) to be Reclassified within Twelve Months",
        "negatedLabel": "Cash flow hedge loss to be reclassified within twelve months"
       }
      }
     },
     "localname": "CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowHedgingMember": {
     "auth_ref": [
      "r345"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk.",
        "label": "Cash Flow Hedging [Member]",
        "terseLabel": "Cash Flow Hedging [Member]"
       }
      }
     },
     "localname": "CashFlowHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Non-cash transactions:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementCopromotionMember": {
     "auth_ref": [
      "r326"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contractual arrangement involving the promotion of products jointly developed, manufactured, marketed, or otherwise in which both the entity and its partner: (i) actively participate in the joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.",
        "label": "Collaborative Arrangement, Co-promotion [Member]",
        "terseLabel": "Collaborative Arrangement, Co-promotion [Member]"
       }
      }
     },
     "localname": "CollaborativeArrangementCopromotionMember",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementMember": {
     "auth_ref": [
      "r326"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.",
        "label": "Collaborative Arrangement [Member]",
        "terseLabel": "Collaborative Arrangement [Member]"
       }
      }
     },
     "localname": "CollaborativeArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsCollaborationArrangementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]",
        "terseLabel": "Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsCollaborationArrangementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollateralAlreadyPostedAggregateFairValue": {
     "auth_ref": [
      "r363"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate fair value of assets that are already posted, at the end of the reporting period, as collateral for derivative instruments with credit-risk-related contingent features.",
        "label": "Collateral Already Posted, Aggregate Fair Value",
        "terseLabel": "Collateral posted"
       }
      }
     },
     "localname": "CollateralAlreadyPostedAggregateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsNarrativeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommercialPaper": {
     "auth_ref": [
      "r22",
      "r407",
      "r434"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of short-term borrowings using unsecured obligations issued by banks, corporations and other borrowers to investors. The maturities of these money market securities generally do not exceed 270 days.",
        "label": "Commercial Paper",
        "terseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaper",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r254"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial Paper [Member]"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r59",
      "r239",
      "r415",
      "r441"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r238",
      "r251"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockDividendsPerShareCashPaid": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate dividends paid during the period for each share of common stock outstanding.",
        "label": "Common Stock, Dividends, Per Share, Cash Paid",
        "terseLabel": "Cash dividends paid per common share (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockDividendsPerShareCashPaid",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive income attributable to Pfizer Inc."
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r331",
      "r332",
      "r339"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest",
        "terseLabel": "Less: Comprehensive income attributable to noncontrolling interests"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r330",
      "r339"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Comprehensive income before allocation to noncontrolling interests"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNoteTextBlock": {
     "auth_ref": [
      "r91"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.",
        "label": "Comprehensive Income (Loss) Note [Text Block]",
        "terseLabel": "Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests"
       }
      }
     },
     "localname": "ComprehensiveIncomeNoteTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterests"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure": {
     "auth_ref": [
      "r386"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Maximum amount of loss due to credit risk that, based on the gross fair value of the financial instrument, the entity would incur if parties to the financial instruments that make up the concentration failed completely to perform according to the terms of the contracts and the collateral or other security, if any, for the amount due proved to be of no value to the entity.",
        "label": "Concentration Risk, Credit Risk, Financial Instrument, Maximum Exposure",
        "terseLabel": "Maximum exposure, amount"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsNarrativeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Concentration Risk [Line Items]",
        "terseLabel": "Concentration Risk [Line Items]"
       }
      }
     },
     "localname": "ConcentrationRiskLineItems",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsNarrativeDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskTable": {
     "auth_ref": [
      "r155",
      "r156",
      "r157",
      "r158",
      "r385",
      "r387"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Concentration Risk [Table]",
        "terseLabel": "Concentration Risk [Table]"
       }
      }
     },
     "localname": "ConcentrationRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsNarrativeDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConsolidationItemsAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by components, eliminations, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments.",
        "label": "Consolidation Items [Axis]",
        "terseLabel": "Consolidation Items [Axis]"
       }
      }
     },
     "localname": "ConsolidationItemsAxis",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedIntangibleAssetsPercentageOfTotalIntangiblesDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillIndefiniteLivedIntangibleAssetsPercentageOfTotalIntangiblesDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail",
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesFootnotesDetails",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationDetail",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationFootnotesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConsolidationItemsDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components, elimination, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments.",
        "label": "Consolidation Items [Domain]",
        "terseLabel": "Consolidation Items [Domain]"
       }
      }
     },
     "localname": "ConsolidationItemsDomain",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedIntangibleAssetsPercentageOfTotalIntangiblesDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillIndefiniteLivedIntangibleAssetsPercentageOfTotalIntangiblesDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail",
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesFootnotesDetails",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationDetail",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationFootnotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate debt [Member]"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsInDebtSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CorporateNonSegmentMember": {
     "auth_ref": [
      "r167"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment.",
        "label": "Corporate, Non-Segment [Member]",
        "terseLabel": "Corporate [Member]"
       }
      }
     },
     "localname": "CorporateNonSegmentMember",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesFootnotesDetails",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationDetail",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationFootnotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsSold": {
     "auth_ref": [
      "r103"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total costs related to goods produced and sold during the reporting period.",
        "label": "Cost of Goods Sold",
        "terseLabel": "Cost of sales"
       }
      }
     },
     "localname": "CostOfGoodsSold",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing cost of sales.",
        "label": "Cost of Sales [Member]",
        "terseLabel": "Cost of Sales [Member]"
       }
      }
     },
     "localname": "CostOfSalesMember",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r99"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "terseLabel": "Costs and expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationFootnotesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "terseLabel": "Costs and expenses:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CounterpartyNameAxis": {
     "auth_ref": [
      "r138"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by name of counterparty. A counterparty is the other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution.",
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsCollaborationArrangementDetails",
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsSaleOfHospiraInfusionSystemsNetAssetsToIcuMedicalIncEhDetails",
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlowsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrencyAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by currency.",
        "label": "Currency [Axis]",
        "terseLabel": "Currency [Axis]"
       }
      }
     },
     "localname": "CurrencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByGeographicAreaFootnotesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrencySwapMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Swap involving the exchange of principal and interest in one currency for another currency.",
        "label": "Currency Swap [Member]",
        "verboseLabel": "Foreign Currency Swap [Member]"
       }
      }
     },
     "localname": "CurrencySwapMember",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail",
      "http://www.pfizer.com/role/FinancialInstrumentsAssetsAndLiabilitiesMeasuredOnRecurringBasisFootnotesDetail",
      "http://www.pfizer.com/role/FinancialInstrumentsBalanceSheetGroupingFootnotesDetail",
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DamagesFromProductDefectsMember": {
     "auth_ref": [
      "r249"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The risk of loss arises with respect to product defects and recalls, or improperly performed services which actually or allegedly resulted in damages suffered by the injured party, excluding major product liability matters.",
        "label": "Damages from Product Defects [Member]",
        "terseLabel": "Damages from Product Defects [Member]"
       }
      }
     },
     "localname": "DamagesFromProductDefectsMember",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CommitmentsAndContingenciesActionsInWhichWeAreDefendantDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtCurrent": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.pfizer.com/role/FinancialInstrumentsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail": {
       "order": 1.0,
       "parentTag": "pfe_OtherFinancialLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of short-term debt and current maturity of long-term debt and capital lease obligations due within one year or the normal operating cycle, if longer.",
        "label": "Debt, Current",
        "totalLabel": "Total short-term borrowings, carried at historical proceeds, as adjusted",
        "verboseLabel": "Short-term borrowings, including current portion of long-term debt: 2017\u2014$3,072; 2016\u2014$4,225"
       }
      }
     },
     "localname": "DebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.pfizer.com/role/FinancialInstrumentsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r23",
      "r25",
      "r26",
      "r408",
      "r409",
      "r429"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Interest rate"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r26",
      "r409",
      "r429"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebtNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-term Debt, Gross",
        "terseLabel": "Principal amount"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r397",
      "r399"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Debt issued"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r56"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Stated interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r57"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r57",
      "r135",
      "r258",
      "r259",
      "r260",
      "r261",
      "r396",
      "r397",
      "r399",
      "r428"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "auth_ref": [
      "r398"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_LongTermDebtNoncurrent",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.",
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "negatedTerseLabel": "Net unamortized discounts, premiums and debt issuance costs"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesMember": {
     "auth_ref": [
      "r189"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt instrument issued by corporations, governments and governmental agencies, municipalities, and other institutions.",
        "label": "Debt Securities [Member]",
        "terseLabel": "Available-for-sale Debt Securities [Member]"
       }
      }
     },
     "localname": "DebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtWeightedAverageInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average interest rate of debt outstanding.",
        "label": "Debt, Weighted Average Interest Rate",
        "terseLabel": "Weighted average effective interest rate"
       }
      }
     },
     "localname": "DebtWeightedAverageInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r126",
      "r134",
      "r307",
      "r308"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "verboseLabel": "Deferred taxes from continuing operations"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r302",
      "r305"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Noncurrent deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent": {
     "auth_ref": [
      "r27",
      "r272",
      "r273",
      "r278"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension plan, classified as noncurrent. Excludes other postretirement benefit plan.",
        "label": "Liability, Defined Benefit Pension Plan, Noncurrent",
        "terseLabel": "Pension benefit obligations, net"
       }
      }
     },
     "localname": "DefinedBenefitPensionPlanLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses": {
     "auth_ref": [
      "r285"
     ],
     "calculation": {
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansNetPeriodicBenefitCostDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan.",
        "label": "Defined Benefit Plan, Amortization of Gain (Loss)",
        "negatedTerseLabel": "Actuarial losses"
       }
      }
     },
     "localname": "DefinedBenefitPlanAmortizationOfGainsLosses",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansNetPeriodicBenefitCostDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit": {
     "auth_ref": [
      "r286"
     ],
     "calculation": {
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansNetPeriodicBenefitCostDetail": {
       "order": 5.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan.",
        "label": "Defined Benefit Plan, Amortization of Prior Service Cost (Credit)",
        "terseLabel": "Prior service costs (credits)"
       }
      }
     },
     "localname": "DefinedBenefitPlanAmortizationOfPriorServiceCostCredit",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansNetPeriodicBenefitCostDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax": {
     "auth_ref": [
      "r78",
      "r81",
      "r288"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, after reclassification adjustment, of increase (decrease) in accumulated other comprehensive income from gain (loss) of defined benefit plan.",
        "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), after Reclassification Adjustment, before Tax",
        "totalLabel": "Defined benefit plan, amounts recognized in other comprehensive income (loss), net gain (loss), before tax, total"
       }
      }
     },
     "localname": "DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax": {
     "auth_ref": [
      "r79",
      "r81",
      "r288"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossBeforeTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, after reclassification adjustment, of (increase) decrease in accumulated other comprehensive income from prior service cost (credit) of defined benefit plan.",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), after Reclassification Adjustment, before Tax",
        "negatedTotalLabel": "Defined benefit plan, amounts recognized in other comprehensive income (loss), net prior service cost, before tax"
       }
      }
     },
     "localname": "DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanContributionsByEmployer": {
     "auth_ref": [
      "r277",
      "r279",
      "r280",
      "r294"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of contribution received by defined benefit plan from employer which increases plan assets.",
        "label": "Defined Benefit Plan, Plan Assets, Contributions by Employer",
        "terseLabel": "Contributions from our general assets for the nine months ended October 1, 2017"
       }
      }
     },
     "localname": "DefinedBenefitPlanContributionsByEmployer",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Defined Benefit Plan Disclosure [Line Items]",
        "terseLabel": "Defined Benefit Plan Disclosure [Line Items]"
       }
      }
     },
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansDetail",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansNetPeriodicBenefitCostDetail",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansNetPeriodicBenefitCostFootnotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsRemainderOfFiscalYear": {
     "auth_ref": [
      "r294"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of contributions expected to be received by defined benefit plan from employer in fiscal year. Excludes contributions paid by employer in current fiscal year.",
        "label": "Defined Benefit Plan, Expected Future Employer Contributions, Remainder of Fiscal Year",
        "terseLabel": "Expected contributions from our general assets during 2017"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureEmployerContributionsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets": {
     "auth_ref": [
      "r284"
     ],
     "calculation": {
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansNetPeriodicBenefitCostDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.",
        "label": "Defined Benefit Plan, Expected Return (Loss) on Plan Assets",
        "negatedTerseLabel": "Expected return on plan assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedReturnOnPlanAssets",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansNetPeriodicBenefitCostDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanInterestCost": {
     "auth_ref": [
      "r276",
      "r283"
     ],
     "calculation": {
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansNetPeriodicBenefitCostDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cost recognized for passage of time related to defined benefit plan.",
        "label": "Defined Benefit Plan, Interest Cost",
        "terseLabel": "Interest cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanInterestCost",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansNetPeriodicBenefitCostDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost": {
     "auth_ref": [
      "r281"
     ],
     "calculation": {
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansNetPeriodicBenefitCostDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of net periodic benefit cost (credit) for defined benefit plan.",
        "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit)",
        "totalLabel": "Defined benefit plan, net periodic benefit cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanNetPeriodicBenefitCost",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansNetPeriodicBenefitCostDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit) [Abstract]",
        "terseLabel": "Amortization of:"
       }
      }
     },
     "localname": "DefinedBenefitPlanNetPeriodicBenefitCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansNetPeriodicBenefitCostDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments": {
     "auth_ref": [
      "r287"
     ],
     "calculation": {
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansNetPeriodicBenefitCostDetail": {
       "order": 6.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit from event reducing expected years of future service of present employees or eliminating accrual of defined benefits for some or all future services of present employees.",
        "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Curtailment",
        "negatedTerseLabel": "Curtailments"
       }
      }
     },
     "localname": "DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansNetPeriodicBenefitCostDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1": {
     "auth_ref": [
      "r287"
     ],
     "calculation": {
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansNetPeriodicBenefitCostDetail": {
       "order": 7.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit from irrevocable action relieving primary responsibility for benefit obligation and eliminating risk related to obligation and assets used to effect settlement.",
        "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement",
        "negatedTerseLabel": "Settlements",
        "terseLabel": "Net gain related to the settlement"
       }
      }
     },
     "localname": "DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansNetPeriodicBenefitCostDetail",
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesFootnotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanServiceCost": {
     "auth_ref": [
      "r274",
      "r282"
     ],
     "calculation": {
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansNetPeriodicBenefitCostDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.",
        "label": "Defined Benefit Plan, Service Cost",
        "terseLabel": "Service cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanServiceCost",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansNetPeriodicBenefitCostDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanSettlementsBenefitObligation": {
     "auth_ref": [
      "r275"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of (increase) decrease to benefit obligation of defined benefit plan from irrevocable action relieving primary responsibility for benefit obligation and eliminating risk for obligation and assets used to effect settlement. Includes, but is not limited to, lump-sum cash payment to participant in exchange for right to receive specified benefits, purchase of nonparticipating annuity contract and change from remeasurement.",
        "label": "Defined Benefit Plan, Benefit Obligation, (Increase) Decrease for Settlement",
        "terseLabel": "Decrease in pension benefit obligation in connection with Hospira pension plan"
       }
      }
     },
     "localname": "DefinedBenefitPlanSettlementsBenefitObligation",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansNetPeriodicBenefitCostFootnotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssetNotionalAmount": {
     "auth_ref": [
      "r343",
      "r344"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payments on the derivative asset.",
        "label": "Derivative Asset, Notional Amount",
        "terseLabel": "Derivative asset, notional amount"
       }
      }
     },
     "localname": "DerivativeAssetNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssets": {
     "auth_ref": [
      "r69",
      "r70",
      "r341",
      "r342",
      "r381",
      "r384"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_InvestmentsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Asset",
        "terseLabel": "Derivative financial instruments in a receivable position"
       }
      }
     },
     "localname": "DerivativeAssets",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [
      "r360"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]",
        "terseLabel": "Derivative Contract Type [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail",
      "http://www.pfizer.com/role/FinancialInstrumentsAssetsAndLiabilitiesMeasuredOnRecurringBasisFootnotesDetail",
      "http://www.pfizer.com/role/FinancialInstrumentsBalanceSheetGroupingFootnotesDetail",
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeFairValueOfDerivativeAsset": {
     "auth_ref": [
      "r68",
      "r71",
      "r351",
      "r402"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.",
        "label": "Derivative Asset, Fair Value, Gross Asset",
        "terseLabel": "Instruments used as offsets (assets)"
       }
      }
     },
     "localname": "DerivativeFairValueOfDerivativeAsset",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsAssetsAndLiabilitiesMeasuredOnRecurringBasisFootnotesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeFairValueOfDerivativeLiability": {
     "auth_ref": [
      "r68",
      "r71",
      "r351",
      "r402"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.",
        "label": "Derivative Liability, Fair Value, Gross Liability",
        "terseLabel": "Instruments used as offsets (liabilities)"
       }
      }
     },
     "localname": "DerivativeFairValueOfDerivativeLiability",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsAssetsAndLiabilitiesMeasuredOnRecurringBasisFootnotesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeGainLossOnDerivativeNet": {
     "auth_ref": [
      "r350",
      "r354"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.",
        "label": "Derivative, Gain (Loss) on Derivative, Net",
        "terseLabel": "Amount of Gains/(Losses) Recognized in OID"
       }
      }
     },
     "localname": "DerivativeGainLossOnDerivativeNet",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r350",
      "r352",
      "r358",
      "r360"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]",
        "terseLabel": "Derivative Instrument Risk [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail",
      "http://www.pfizer.com/role/FinancialInstrumentsAssetsAndLiabilitiesMeasuredOnRecurringBasisFootnotesDetail",
      "http://www.pfizer.com/role/FinancialInstrumentsBalanceSheetGroupingFootnotesDetail",
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": {
     "auth_ref": [
      "r347",
      "r350",
      "r358"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of hedging relationship.",
        "label": "Hedging Relationship [Axis]",
        "terseLabel": "Hedging Relationship [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable": {
     "auth_ref": [
      "r347",
      "r350",
      "r358",
      "r360",
      "r361",
      "r364",
      "r365"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.",
        "label": "Derivative Instruments, Gain (Loss) [Table]",
        "terseLabel": "Derivative Instruments, Gain (Loss) [Table]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivative Instruments, Gain (Loss) [Line Items]",
        "terseLabel": "Derivative Instruments, Gain (Loss) [Line Items]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet": {
     "auth_ref": [
      "r356",
      "r359"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The effective portion of net gain (loss) reclassified from accumulated other comprehensive income into income on derivative instruments designated and qualifying as hedging instruments.",
        "label": "Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net",
        "terseLabel": "Amount of Gains/(Losses) Reclassified from OCI into OID and COS (Effective Portion)"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet": {
     "auth_ref": [
      "r355"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The effective portion of gains and losses (net) on derivative instruments designated and qualifying as hedging instruments that was recognized in other comprehensive income during the current period.",
        "label": "Derivative Instruments, Gain (Loss) Recognized in Other Comprehensive Income (Loss), Effective Portion, Net",
        "terseLabel": "Amount of Gains/(Losses) Recognized in OCI (Effective Portion)"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilities": {
     "auth_ref": [
      "r69",
      "r70",
      "r341",
      "r342",
      "r381",
      "r384"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail": {
       "order": 1.0,
       "parentTag": "pfe_SelectedFinancialLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability",
        "terseLabel": "Derivative financial instruments in a liability position"
       }
      }
     },
     "localname": "DerivativeLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeNetLiabilityPositionAggregateFairValue": {
     "auth_ref": [
      "r362"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate fair value amounts of derivative instruments that contain credit-risk-related contingent features that are in a net liability position at the end of the reporting period. For nonderivative instruments that are designated and qualify as hedging instruments, the fair value amounts are the carrying value of the nonderivative hedging instrument, including the adjustment for the foreign currency transaction gain (loss) on that instrument.",
        "label": "Derivative, Net Liability Position, Aggregate Fair Value",
        "terseLabel": "Derivatives in a net liability position"
       }
      }
     },
     "localname": "DerivativeNetLiabilityPositionAggregateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsNarrativeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DesignatedAsHedgingInstrumentMember": {
     "auth_ref": [
      "r347"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Designated as Hedging Instrument [Member]",
        "terseLabel": "Designated as Hedging Instrument [Member]"
       }
      }
     },
     "localname": "DesignatedAsHedgingInstrumentMember",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DevelopedTechnologyRightsMember": {
     "auth_ref": [
      "r319"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.",
        "label": "Developed Technology Rights [Member]",
        "terseLabel": "Developed Technology Rights [Member]"
       }
      }
     },
     "localname": "DevelopedTechnologyRightsMember",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsAstrazenecaDetails",
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsMedivationDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsOtherNoncurrentLiabilitiesDetail",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsDetail",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsFootnotesDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedIntangibleAssetsPercentageOfTotalIntangiblesDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetImpairedIntangibleAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DilutiveSecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]",
        "terseLabel": "EPS Numerator\u2013\u2013Diluted"
       }
      }
     },
     "localname": "DilutiveSecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributableToCommonShareholdersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisposalGroupClassificationAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by disposal group classification.",
        "label": "Disposal Group Classification [Axis]",
        "terseLabel": "Disposal Group Classification [Axis]"
       }
      }
     },
     "localname": "DisposalGroupClassificationAxis",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsSaleOfHospiraInfusionSystemsNetAssetsToIcuMedicalIncEhDetails",
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlowsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisposalGroupClassificationDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations.",
        "label": "Disposal Group Classification [Domain]",
        "terseLabel": "Disposal Group Classification [Domain]"
       }
      }
     },
     "localname": "DisposalGroupClassificationDomain",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsSaleOfHospiraInfusionSystemsNetAssetsToIcuMedicalIncEhDetails",
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlowsParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember": {
     "auth_ref": [
      "r221",
      "r227"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disposal group that has been sold. Excludes disposals classified as discontinued operations.",
        "label": "Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]",
        "terseLabel": "Disposed of by Sale [Member]"
       }
      }
     },
     "localname": "DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsSaleOfHospiraInfusionSystemsNetAssetsToIcuMedicalIncEhDetails",
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlowsParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Consideration",
        "terseLabel": "Consideration transferred"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationConsideration",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsSaleOfHospiraInfusionSystemsNetAssetsToIcuMedicalIncEhDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal": {
     "auth_ref": [
      "r221",
      "r225"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetDetail": {
       "order": 5.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations.",
        "label": "Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal",
        "negatedLabel": "Loss on sale and impairment on remeasurement of HIS net assets",
        "negatedTerseLabel": "Loss on sale of HIS net assets",
        "terseLabel": "Gain (loss) on sale of HIS net assets"
       }
      }
     },
     "localname": "DisposalGroupNotDiscontinuedOperationGainLossOnDisposal",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsSaleOfHospiraInfusionSystemsNetAssetsToIcuMedicalIncEhDetails",
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetDetail",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationFootnotesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of disposal group.",
        "label": "Disposal Group Name [Domain]",
        "terseLabel": "Disposal Group Name [Domain]"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsSaleOfHospiraInfusionSystemsNetAssetsToIcuMedicalIncEhDetails",
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlowsParenthetical",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationFootnotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DistributionRightsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Legal rights, generally of a limited duration, to distribute a product or products, often within specific geographic areas or supply channels.",
        "label": "Distribution Rights [Member]",
        "terseLabel": "Distribution Rights [Member]"
       }
      }
     },
     "localname": "DistributionRightsMember",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DividendsPayableCurrent": {
     "auth_ref": [
      "r17",
      "r54"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Dividends Payable, Current",
        "terseLabel": "Dividends payable"
       }
      }
     },
     "localname": "DividendsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DomesticPlanMember": {
     "auth_ref": [
      "r291"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location of employer sponsoring plan, designed to provide retirement benefits, determined as principal place of business. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Domestic Plan [Member]",
        "terseLabel": "Domestic Plan [Member]"
       }
      }
     },
     "localname": "DomesticPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansDetail",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansNetPeriodicBenefitCostDetail",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansNetPeriodicBenefitCostFootnotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r98",
      "r148",
      "r152",
      "r153",
      "r424",
      "r446"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "totalLabel": "Net income attributable to Pfizer Inc. common shareholders (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Earnings Per Share, Basic [Abstract]",
        "terseLabel": "Earnings per common share\u2013\u2013basic:",
        "verboseLabel": "EPS Numerator\u2013\u2013Basic"
       }
      }
     },
     "localname": "EarningsPerShareBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfIncome",
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributableToCommonShareholdersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r98",
      "r148",
      "r424",
      "r446"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "totalLabel": "Net income attributable to Pfizer Inc. common shareholders (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Earnings Per Share, Diluted [Abstract]",
        "terseLabel": "Earnings per common share\u2013\u2013diluted:"
       }
      }
     },
     "localname": "EarningsPerShareDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r154"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Earnings Per Common Share Attributable to Common Shareholders"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributableToCommonShareholders"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents": {
     "auth_ref": [
      "r390"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.",
        "label": "Effect of Exchange Rate on Cash and Cash Equivalents",
        "terseLabel": "Effect of exchange-rate changes on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r136",
      "r303",
      "r304"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "terseLabel": "Effective tax rate for income from continuing operations"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersNarrativeDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r54"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued compensation and related items"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeSeveranceMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan.",
        "label": "Employee Severance [Member]",
        "verboseLabel": "Employee Termination Costs [Member]"
       }
      }
     },
     "localname": "EmployeeSeveranceMember",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesRestructuringAccrualsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue from External Customer [Line Items]",
        "terseLabel": "Revenue from External Customer [Line Items]"
       }
      }
     },
     "localname": "EntityWideInformationRevenueFromExternalCustomerLineItems",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r257"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvesteeNameDomain": {
     "auth_ref": [
      "r193"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of investment, including named security. Excludes consolidated entity.",
        "label": "Investment, Name [Domain]",
        "terseLabel": "Investment, Name [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvesteeNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsEquityMethodInvestmentsDetails",
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeParenthetical",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationFootnotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment": {
     "auth_ref": [
      "r190"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This item represents an other than temporary decline in value that has been recognized against an investment accounted for under the equity method of accounting. The excess of the carrying amount over the fair value of the investment represents the amount of the write down which is or was reflected in earnings. The written down value is a new cost basis with the adjusted value of the investment becoming its new carrying value subject to the equity accounting method. Evidence of a loss in value might include, but would not necessarily be limited to, absence of an ability to recover the carrying amount of the investment or inability of the investee to sustain an earnings capacity which would justify the carrying amount of the investment.",
        "label": "Equity Method Investment, Other than Temporary Impairment",
        "terseLabel": "Equity method investment, impairment"
       }
      }
     },
     "localname": "EquityMethodInvestmentOtherThanTemporaryImpairment",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsEquityMethodInvestmentsDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "auth_ref": [
      "r193"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.",
        "label": "Equity Method Investment, Ownership Percentage",
        "terseLabel": "Equity method investment, ownership percentage"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsEquityMethodInvestmentsDetails",
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeParenthetical",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of an equity method investment.",
        "label": "Equity Method Investment, Realized Gain (Loss) on Disposal",
        "negatedTerseLabel": "Loss on disposal of equity method investment"
       }
      }
     },
     "localname": "EquityMethodInvestmentRealizedGainLossOnDisposal",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsEquityMethodInvestmentsDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestments": {
     "auth_ref": [
      "r46",
      "r191"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.",
        "label": "Equity Method Investments",
        "terseLabel": "Equity method investments"
       }
      }
     },
     "localname": "EquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesByIndustryAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by industry sector, examples include but are not limited to, commercial, industrial, agricultural, financial services, technology, healthcare and real estate.",
        "label": "Industry Sector [Axis]",
        "terseLabel": "Industry Sector [Axis]"
       }
      }
     },
     "localname": "EquitySecuritiesByIndustryAxis",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsNarrativeDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquitySecuritiesIndustryMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Industry sector consisting of government, private and corporate entities engaged in business activities, including but not limited to, commercial, industrial, agricultural, financial services, technology, healthcare and real estate.",
        "label": "Industry Sector [Domain]",
        "terseLabel": "Industry Sector [Domain]"
       }
      }
     },
     "localname": "EquitySecuritiesIndustryMember",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquitySecuritiesMember": {
     "auth_ref": [
      "r19",
      "r24",
      "r189",
      "r414",
      "r430",
      "r452"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants.",
        "label": "Equity Securities [Member]",
        "terseLabel": "Equity Securities [Member]"
       }
      }
     },
     "localname": "EquitySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EstimateOfFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r371",
      "r381"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measured as an estimate of fair value.",
        "label": "Estimate of Fair Value Measurement [Member]",
        "terseLabel": "Estimate of Fair Value Measurement [Member]"
       }
      }
     },
     "localname": "EstimateOfFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsAssetsAndLiabilitiesMeasuredOnRecurringBasisFootnotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EuropeanUnionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Economic and political union of member states, located primarily in Europe.",
        "label": "European Union [Member]",
        "terseLabel": "EU [Member]"
       }
      }
     },
     "localname": "EuropeanUnionMember",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsOtherNoncurrentLiabilitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail",
      "http://www.pfizer.com/role/FinancialInstrumentsAssetsAndLiabilitiesMeasuredOnRecurringBasisFootnotesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r370",
      "r371",
      "r372",
      "r373",
      "r376",
      "r377"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.",
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail",
      "http://www.pfizer.com/role/FinancialInstrumentsAssetsAndLiabilitiesMeasuredOnRecurringBasisFootnotesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "auth_ref": [
      "r370",
      "r371",
      "r372",
      "r373",
      "r376",
      "r377"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.",
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]",
        "terseLabel": "Information about Certain Financial Assets and Liabilities"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Fair Value, Assets, Liabilities and Stockholders' Equity Measured on Recurring Basis [Abstract]",
        "terseLabel": "Selected financial liabilities measured at fair value on a recurring basis"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r374",
      "r377"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Asset Class [Domain]",
        "terseLabel": "Asset Class [Domain]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]"
       }
      }
     },
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsBalanceSheetGroupingDetail",
      "http://www.pfizer.com/role/FinancialInstrumentsBalanceSheetGroupingFootnotesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r371",
      "r377"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Asset Class [Axis]",
        "terseLabel": "Asset Class [Axis]"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "auth_ref": [
      "r371",
      "r380",
      "r381",
      "r382",
      "r383",
      "r388"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table]",
        "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTable",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsBalanceSheetGroupingDetail",
      "http://www.pfizer.com/role/FinancialInstrumentsBalanceSheetGroupingFootnotesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTextBlock": {
     "auth_ref": [
      "r371",
      "r380",
      "r381",
      "r382",
      "r383",
      "r388"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table Text Block]",
        "terseLabel": "Selected Financial Assets and Liabilities Presented in the Condensed Consolidated Balance Sheets"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r372"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by level within the fair value hierarchy.",
        "label": "Fair Value, Hierarchy [Axis]",
        "terseLabel": "Fair Value, Hierarchy [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsAssetsAndLiabilitiesMeasuredOnRecurringBasisFootnotesDetail",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetImpairedIntangibleAssetsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementBasisAxis": {
     "auth_ref": [
      "r371",
      "r378"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by measurement basis.",
        "label": "Measurement Basis [Axis]",
        "terseLabel": "Measurement Basis [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementBasisAxis",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail",
      "http://www.pfizer.com/role/FinancialInstrumentsAssetsAndLiabilitiesMeasuredOnRecurringBasisFootnotesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r370"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail",
      "http://www.pfizer.com/role/FinancialInstrumentsAssetsAndLiabilitiesMeasuredOnRecurringBasisFootnotesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosureItemAmountsDomain": {
     "auth_ref": [
      "r371",
      "r380",
      "r381",
      "r382",
      "r383",
      "r388"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.",
        "label": "Fair Value Measurement [Domain]",
        "terseLabel": "Fair Value Measurement [Domain]"
       }
      }
     },
     "localname": "FairValueDisclosureItemAmountsDomain",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail",
      "http://www.pfizer.com/role/FinancialInstrumentsAssetsAndLiabilitiesMeasuredOnRecurringBasisFootnotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r372"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetImpairedIntangibleAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r368",
      "r372"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsAssetsAndLiabilitiesMeasuredOnRecurringBasisFootnotesDetail",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetImpairedIntangibleAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r372"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetImpairedIntangibleAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [
      "r370",
      "r375"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Provides the general categories used to describe the frequency with which financial assets and liabilities (as defined) are measured at fair value (on a recurring or nonrecurring basis).",
        "label": "Fair Value, Measurement Frequency [Domain]",
        "terseLabel": "Fair Value, Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail",
      "http://www.pfizer.com/role/FinancialInstrumentsAssetsAndLiabilitiesMeasuredOnRecurringBasisFootnotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy [Domain]",
        "terseLabel": "Fair Value Hierarchy [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsAssetsAndLiabilitiesMeasuredOnRecurringBasisFootnotesDetail",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetImpairedIntangibleAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r370",
      "r375"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This item represents a description of the frequency with which certain items are measured at fair value. Items measured at fair value on a recurring basis generally include those items for which measurement inputs are readily available and which are measured at fair value at successive reporting periods.",
        "label": "Fair Value, Measurements, Recurring [Member]",
        "terseLabel": "Fair Value, Measurements, Recurring [Member]"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail",
      "http://www.pfizer.com/role/FinancialInstrumentsAssetsAndLiabilitiesMeasuredOnRecurringBasisFootnotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.",
        "label": "Financial Instruments Disclosure [Text Block]",
        "terseLabel": "Financial Instruments"
       }
      }
     },
     "localname": "FinancialInstrumentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r213"
     ],
     "calculation": {
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedLabel": "Finite-lived intangible assets, accumulated amortization",
        "negatedTerseLabel": "Finite-lived intangible assets, accumulated amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r208",
      "r212"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsAstrazenecaDetails",
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsMedivationDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsOtherNoncurrentLiabilitiesDetail",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsDetail",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsFootnotesDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedIntangibleAssetsPercentageOfTotalIntangiblesDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillNarrativeDetail",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetImpairedIntangibleAssetsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure": {
     "auth_ref": [
      "r369"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of assets, excluding financial assets, that lack physical substance, having a limited useful life.",
        "label": "Finite-lived Intangible Assets, Fair Value Disclosure",
        "terseLabel": "Finite-lived intangible assets, fair value disclosure"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetImpairedIntangibleAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r213"
     ],
     "calculation": {
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_IntangibleAssetsGrossExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Finite-lived intangible assets, gross carrying amount"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsOtherNoncurrentLiabilitiesDetail",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsDetail",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsFootnotesDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedIntangibleAssetsPercentageOfTotalIntangiblesDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillNarrativeDetail",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetImpairedIntangibleAssetsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r208",
      "r212"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsAstrazenecaDetails",
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsMedivationDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsOtherNoncurrentLiabilitiesDetail",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsDetail",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsFootnotesDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedIntangibleAssetsPercentageOfTotalIntangiblesDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillNarrativeDetail",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetImpairedIntangibleAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Assets, excluding financial assets, that lack physical substance, having a limited useful life.",
        "label": "Finite-Lived Intangible Assets [Member]",
        "terseLabel": "Finite-Lived Intangible Assets [Member]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r213"
     ],
     "calculation": {
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "terseLabel": "Finite-lived intangible assets, net",
        "totalLabel": "Finite-lived Intangible Assets, less Accumulated Amortization",
        "verboseLabel": "Increase in finite-lived intangible assets"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsOtherNoncurrentLiabilitiesDetail",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsDetail",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsFootnotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyCashFlowHedgeGainLossReclassifiedToEarningsNet": {
     "auth_ref": [
      "r356"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net gains or losses on foreign currency cash flow hedges reclassified during the period to earnings from accumulated other comprehensive income upon the hedged transaction affecting earnings.",
        "label": "Foreign Currency Cash Flow Hedge Gain (Loss) Reclassified to Earnings, Net",
        "terseLabel": "Gain (loss) recognized as an offset"
       }
      }
     },
     "localname": "ForeignCurrencyCashFlowHedgeGainLossReclassifiedToEarningsNet",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months": {
     "auth_ref": [
      "r367"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated net amount of unrealized gains or losses on foreign currency cash flow hedges at the reporting date expected to be reclassified to earnings within the next 12 months.",
        "label": "Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months",
        "negatedTerseLabel": "Pre-tax loss to be reclassified"
       }
      }
     },
     "localname": "ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignExchangeForwardMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Foreign exchange forward traded on an exchange (examples include but are not limited to the International Securities Exchange, Philadelphia Stock Exchange, or the Chicago Mercantile Exchange) for options or future contracts to buy or sell a certain currency, at a specified date, at a fixed exercise exchange rate.",
        "label": "Foreign Exchange Forward [Member]",
        "terseLabel": "Foreign Currency Forward-Exchange Contracts [Member]"
       }
      }
     },
     "localname": "ForeignExchangeForwardMember",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail",
      "http://www.pfizer.com/role/FinancialInstrumentsAssetsAndLiabilitiesMeasuredOnRecurringBasisFootnotesDetail",
      "http://www.pfizer.com/role/FinancialInstrumentsBalanceSheetGroupingFootnotesDetail",
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignPlanMember": {
     "auth_ref": [
      "r291"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location of employer sponsoring plan, designed to provide retirement benefits, not determined as principal place of business. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Foreign Plan [Member]",
        "terseLabel": "International [Member]"
       }
      }
     },
     "localname": "ForeignPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansDetail",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansNetPeriodicBenefitCostDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainContingenciesByNatureAxis": {
     "auth_ref": [
      "r250"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by nature of gain contingency.",
        "label": "Gain Contingencies, Nature [Axis]",
        "terseLabel": "Gain Contingencies, Nature [Axis]"
       }
      }
     },
     "localname": "GainContingenciesByNatureAxis",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CommitmentsAndContingenciesActionsInWhichWeArePlaintiffDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GainContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Gain Contingencies [Line Items]",
        "terseLabel": "Gain Contingencies [Line Items]"
       }
      }
     },
     "localname": "GainContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CommitmentsAndContingenciesActionsInWhichWeArePlaintiffDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GainContingenciesTable": {
     "auth_ref": [
      "r250"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sets forth the existing conditions, situations, or sets of circumstances involving uncertainties as of the balance sheet date (or before issuance of the financial statements) that might result in a gain, typically reflecting care to avoid misleading implications as to the likelihood of realization, and previously disclosed contingent gains that were recognized as income in the period.",
        "label": "Gain Contingencies [Table]",
        "terseLabel": "Gain Contingencies [Table]"
       }
      }
     },
     "localname": "GainContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CommitmentsAndContingenciesActionsInWhichWeArePlaintiffDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GainContingencyNatureDomain": {
     "auth_ref": [
      "r250"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Describes any existing condition, situation, or set of circumstances involving uncertainty as of the balance sheet date (or before issuance of the financial statements) that might result in a gain, typically reflecting care to avoid misleading implications as to the likelihood of realization.",
        "label": "Gain Contingency, Nature [Domain]",
        "terseLabel": "Gain Contingency, Nature [Domain]"
       }
      }
     },
     "localname": "GainContingencyNatureDomain",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CommitmentsAndContingenciesActionsInWhichWeArePlaintiffDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of entity's patents that another entity has allegedly infringed.",
        "label": "Gain Contingency, Patents Allegedly Infringed upon, Number",
        "terseLabel": "Number of patents allegedly infringed upon"
       }
      }
     },
     "localname": "GainContingencyPatentsAllegedlyInfringedUponNumber",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CommitmentsAndContingenciesActionsInWhichWeArePlaintiffDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_GainContingencyPatentsFoundInfringedUponNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of entity's patents that another entity was found to have infringed.",
        "label": "Gain Contingency, Patents Found Infringed upon, Number",
        "terseLabel": "Number of patents infringed upon"
       }
      }
     },
     "localname": "GainContingencyPatentsFoundInfringedUponNumber",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CommitmentsAndContingenciesActionsInWhichWeArePlaintiffDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_GainContingencyPatentsFoundNotInfringedUponNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of entity's patents that another entity was found not to have infringed.",
        "label": "Gain Contingency, Patents Found Not Infringed upon, Number",
        "terseLabel": "Number of patents not infringed upon"
       }
      }
     },
     "localname": "GainContingencyPatentsFoundNotInfringedUponNumber",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CommitmentsAndContingenciesActionsInWhichWeArePlaintiffDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_GainLossOnCashFlowHedgeIneffectivenessNet": {
     "auth_ref": [
      "r357"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net gain (loss) recognized in earnings during the reporting period representing the amount of the cash flow hedges' ineffectiveness.",
        "label": "Gain (Loss) on Cash Flow Hedge Ineffectiveness, Net",
        "terseLabel": "Gain (loss) on cash flow hedge ineffectiveness"
       }
      }
     },
     "localname": "GainLossOnCashFlowHedgeIneffectivenessNet",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnDispositionOfIntangibleAssets": {
     "auth_ref": [
      "r107",
      "r127"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of intangible assets.",
        "label": "Gain (Loss) on Disposition of Intangible Assets",
        "verboseLabel": "Gain on disposition of intangible assets"
       }
      }
     },
     "localname": "GainLossOnDispositionOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "auth_ref": [
      "r126"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "terseLabel": "Gain on sale of property"
       }
      }
     },
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossRelatedToLitigationSettlement": {
     "auth_ref": [
      "r239"
     ],
     "calculation": {
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.",
        "label": "Gain (Loss) Related to Litigation Settlement",
        "negatedTerseLabel": "Certain legal matters, net",
        "terseLabel": "Income (charges) for certain legal matters"
       }
      }
     },
     "localname": "GainLossRelatedToLitigationSettlement",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetDetail",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationFootnotesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainOnSaleOfInvestments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The difference between the carrying value and the sale price of an investment.  A gain would be recognized when the sale price of the investment is greater than the carrying value of the investment.  This element refers to the Gain included in earnings and not to the cash proceeds of the sale.",
        "label": "Gain on Sale of Investments",
        "terseLabel": "Gain on sale of investments"
       }
      }
     },
     "localname": "GainOnSaleOfInvestments",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r199",
      "r200",
      "r201"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "periodEndLabel": "Balance, October 1, 2017",
        "periodStartLabel": "Balance, December 31, 2016",
        "terseLabel": "Goodwill",
        "verboseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsAnacorPharmaceuticalsIncDetails",
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsAstrazenecaDetails",
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsBambooTherapeuticsDetails",
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsMedivationDetails",
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillGoodwillDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAcquiredDuringPeriod": {
     "auth_ref": [
      "r202"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.",
        "label": "Goodwill, Acquired During Period",
        "terseLabel": "Additions"
       }
      }
     },
     "localname": "GoodwillAcquiredDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillGoodwillDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r219"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final.  May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Identifiable Intangible Assets and Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwill"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Goodwill [Line Items]",
        "terseLabel": "Goodwill [Line Items]"
       }
      }
     },
     "localname": "GoodwillLineItems",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillGoodwillDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillOtherIncreaseDecrease": {
     "auth_ref": [
      "r203"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease), classified as other, of an asset representing the future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Other Increase (Decrease)",
        "verboseLabel": "Other"
       }
      }
     },
     "localname": "GoodwillOtherIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillGoodwillDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Goodwill [Roll Forward]",
        "terseLabel": "Goodwill [Roll Forward]"
       }
      }
     },
     "localname": "GoodwillRollForward",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillGoodwillDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GovernmentNationalMortgageAssociationCertificatesAndObligationsGNMAMember": {
     "auth_ref": [
      "r419"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Investments in debentures, bonds and other debt securities issued by the Government National Mortgage Association (GNMA or Ginnie Mae).",
        "label": "Government National Mortgage Association Certificates and Obligations (GNMA) [Member]",
        "terseLabel": "Government National Mortgage Association and other U.S. government guaranteed asset-back securities [Member]"
       }
      }
     },
     "localname": "GovernmentNationalMortgageAssociationCertificatesAndObligationsGNMAMember",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsInDebtSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HedgingDesignationAxis": {
     "auth_ref": [
      "r347"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Axis]",
        "terseLabel": "Hedging Designation [Axis]"
       }
      }
     },
     "localname": "HedgingDesignationAxis",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsAssetsAndLiabilitiesMeasuredOnRecurringBasisFootnotesDetail",
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationDomain": {
     "auth_ref": [
      "r347"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Domain]",
        "terseLabel": "Hedging Designation [Domain]"
       }
      }
     },
     "localname": "HedgingDesignationDomain",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsAssetsAndLiabilitiesMeasuredOnRecurringBasisFootnotesDetail",
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HedgingRelationshipDomain": {
     "auth_ref": [
      "r347"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Nature or intent of a hedge.",
        "label": "Hedging Relationship [Domain]",
        "terseLabel": "Hedging Relationship [Domain]"
       }
      }
     },
     "localname": "HedgingRelationshipDomain",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HeldToMaturitySecurities": {
     "auth_ref": [
      "r175",
      "r184",
      "r186",
      "r418",
      "r442"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsInDebtSecuritiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsInDebtSecuritiesDetailCalc2": {
       "order": 2.0,
       "parentTag": "pfe_DebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after other than temporary impairment (OTTI) accretion, of investments in debt securities classified as held-to-maturity.",
        "label": "Held-to-maturity Securities",
        "totalLabel": "Held-to-maturity debt securities maturities total"
       }
      }
     },
     "localname": "HeldToMaturitySecurities",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsInDebtSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesAmortizedCostBeforeOtherThanTemporaryImpairment": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail": {
       "order": 2.0,
       "parentTag": "pfe_OtherSelectedFinancialAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before other than temporary impairment (OTTI) accretion, of investments in debt securities classified as held-to-maturity.",
        "label": "Held-to-maturity Securities, Amortized Cost before Other than Temporary Impairment",
        "terseLabel": "Held-to-maturity debt securities, carried at amortized cost"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesAmortizedCostBeforeOtherThanTemporaryImpairment",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsInDebtSecuritiesDetail": {
       "order": 2.0,
       "parentTag": "pfe_DebtSecuritiesMaturitiesWithinOneYear",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of held-to-maturity debt securities maturing in the next rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Held-to-maturity Securities, Debt Maturities, Next Rolling Twelve Months, Fair Value",
        "terseLabel": "Held-to-maturity debt securities maturities within 1 year"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsInDebtSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesDebtMaturitiesRollingAfterTenYearsFairValue": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsInDebtSecuritiesDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_HeldToMaturitySecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of held-to-maturity debt securities maturing after the tenth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Held-to-maturity Securities, Debt Maturities, Rolling after Ten Years, Fair Value",
        "terseLabel": "Held-to-maturity debt securities maturities over 10 years"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesDebtMaturitiesRollingAfterTenYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsInDebtSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesDebtMaturitiesRollingYearSixThroughTenFairValue": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsInDebtSecuritiesDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_HeldToMaturitySecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of held-to-maturity debt securities maturing in the sixth through tenth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Held-to-maturity Securities, Debt Maturities, Rolling Year Six Through Ten, Fair Value",
        "terseLabel": "Held-to-maturity debt securities maturities over 5 to 10 years"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesDebtMaturitiesRollingYearSixThroughTenFairValue",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsInDebtSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsInDebtSecuritiesDetail": {
       "order": 2.0,
       "parentTag": "pfe_DebtSecuritiesMaturitiesOverOneToFiveYears",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of held-to-maturity debt securities maturing in the second through fifth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Held-to-maturity Securities, Debt Maturities, Rolling Year Two Through Five, Fair Value",
        "terseLabel": "Held-to-maturity debt securities with maturities over 1 to 5 years"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsInDebtSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r126",
      "r216"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.",
        "label": "Impairment of Intangible Assets (Excluding Goodwill)",
        "terseLabel": "Intangible asset impairment charges"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": {
     "auth_ref": [
      "r216"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.",
        "label": "Impairment of Intangible Assets, Finite-lived",
        "terseLabel": "Impairment of finite-lived intangible assets"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsFinitelived",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetImpairedIntangibleAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InProcessResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.",
        "label": "In Process Research and Development [Member]",
        "terseLabel": "In Process Research and Development [Member]"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentMember",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsAnacorPharmaceuticalsIncDetails",
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsAstrazenecaDetails",
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsBambooTherapeuticsDetails",
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsMedivationDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsDetail",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsFootnotesDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillIndefiniteLivedIntangibleAssetsPercentageOfTotalIntangiblesDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperations": {
     "auth_ref": [
      "r102",
      "r127",
      "r150",
      "r329"
     ],
     "calculation": {
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributableToCommonShareholdersDetails": {
       "order": 1.0,
       "parentTag": "pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of income (loss) from continuing operations attributable to the parent.",
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent",
        "totalLabel": "Income from continuing operations attributable to Pfizer Inc."
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributableToCommonShareholdersDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity": {
     "auth_ref": [
      "r327",
      "r330"
     ],
     "calculation": {
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributableToCommonShareholdersDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of income (loss) from continuing operations attributable to the noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest",
        "terseLabel": "Less: Net income attributable to noncontrolling interests"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributableToCommonShareholdersDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r95",
      "r405",
      "r421",
      "r447"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Income from continuing operations before provision for taxes on income",
        "verboseLabel": "Earnings"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfIncome",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r330"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      },
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributableToCommonShareholdersDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Income from continuing operations",
        "totalLabel": "Income from continuing operations"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfIncome",
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributableToCommonShareholdersDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": {
     "auth_ref": [
      "r93",
      "r98",
      "r148",
      "r420",
      "r422",
      "r424",
      "r443"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_EarningsPerShareBasic",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.",
        "label": "Income (Loss) from Continuing Operations, Per Basic Share",
        "terseLabel": "Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share)"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerBasicShare",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": {
     "auth_ref": [
      "r93",
      "r98",
      "r148",
      "r150",
      "r424",
      "r443",
      "r446"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_EarningsPerShareDiluted",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Income (Loss) from Continuing Operations, Per Diluted Share",
        "terseLabel": "Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share)"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerDilutedShare",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax": {
     "auth_ref": [
      "r3",
      "r4",
      "r5",
      "r6",
      "r7",
      "r10",
      "r98",
      "r444"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      },
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributableToCommonShareholdersDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.",
        "label": "Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Discontinued operations\u2013\u2013net of tax",
        "verboseLabel": "Discontinued operations\u2013\u2013net of tax"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfIncome",
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributableToCommonShareholdersDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity": {
     "auth_ref": [
      "r3",
      "r4",
      "r5",
      "r6",
      "r7",
      "r8",
      "r10",
      "r330"
     ],
     "calculation": {
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributableToCommonShareholdersDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.",
        "label": "Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent",
        "verboseLabel": "Discontinued operations\u2013\u2013net of tax, attributable to Pfizer Inc. common shareholders and assumed conversions"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributableToCommonShareholdersDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare": {
     "auth_ref": [
      "r96",
      "r98",
      "r149",
      "r424",
      "r444",
      "r446"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_EarningsPerShareBasic",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.",
        "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share",
        "terseLabel": "Discontinued operations\u2013\u2013net of tax (in dollars per share)"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare": {
     "auth_ref": [
      "r149",
      "r340"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_EarningsPerShareDiluted",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.",
        "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share",
        "terseLabel": "Discontinued operations\u2013\u2013net of tax (in dollars per share)"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by name of disposal group.",
        "label": "Disposal Group Name [Axis]",
        "terseLabel": "Disposal Group Name [Axis]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsSaleOfHospiraInfusionSystemsNetAssetsToIcuMedicalIncEhDetails",
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlowsParenthetical",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationFootnotesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsBambooTherapeuticsDetails",
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsCollaborationArrangementDetails",
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsEquityMethodInvestmentsDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetail",
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsBambooTherapeuticsDetails",
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsCollaborationArrangementDetails",
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsEquityMethodInvestmentsDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetail",
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r310"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Tax Matters"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMatters"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r137",
      "r306"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Provision for taxes on income"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r133"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income Taxes Paid, Net",
        "terseLabel": "Income taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapital": {
     "auth_ref": [
      "r125"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period of all assets and liabilities used in operating activities.",
        "label": "Increase (Decrease) in Operating Capital",
        "negatedLabel": "Other changes in assets and liabilities, net of acquisitions and divestitures"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapital",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets [Axis]",
        "terseLabel": "Indefinite-lived Intangible Assets [Axis]",
        "verboseLabel": "Indefinite-lived Intangible Assets [Axis]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsAnacorPharmaceuticalsIncDetails",
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsAstrazenecaDetails",
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsBambooTherapeuticsDetails",
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsMedivationDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsDetail",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsFootnotesDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillIndefiniteLivedIntangibleAssetsPercentageOfTotalIntangiblesDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Indefinite-lived Intangible Assets [Line Items]",
        "terseLabel": "Indefinite-lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassLineItems",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsDetail",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillIndefiniteLivedIntangibleAssetsPercentageOfTotalIntangiblesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r215"
     ],
     "calculation": {
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_IntangibleAssetsGrossExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)",
        "terseLabel": "Indefinite-lived intangible assets"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r210",
      "r215"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.",
        "label": "Indefinite-lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsAnacorPharmaceuticalsIncDetails",
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsAstrazenecaDetails",
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsBambooTherapeuticsDetails",
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsMedivationDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsDetail",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsFootnotesDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillIndefiniteLivedIntangibleAssetsPercentageOfTotalIntangiblesDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IntangibleAssetsGrossExcludingGoodwill": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.",
        "label": "Intangible Assets, Gross (Excluding Goodwill)",
        "totalLabel": "Intangible assets, gross carrying amount"
       }
      }
     },
     "localname": "IntangibleAssetsGrossExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r206",
      "r211"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "totalLabel": "Identifiable Intangible Assets, less Accumulated Amortization",
        "verboseLabel": "Identifiable intangible assets, less accumulated amortization"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r395",
      "r398",
      "r425"
     ],
     "calculation": {
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_InterestRevenueExpenseNet",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r133"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash paid, after deduction of cash paid for capitalized interest, for interest. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Net",
        "terseLabel": "Interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestRateContractMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Derivative instrument whose primary underlying risk is tied to the right to receive or pay a sum of money at a given interest rate.",
        "label": "Interest Rate Contract [Member]",
        "terseLabel": "Interest Rate Contract [Member]"
       }
      }
     },
     "localname": "InterestRateContractMember",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InterestRateSwapMember": {
     "auth_ref": [
      "r360"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period.",
        "label": "Interest Rate Swap [Member]",
        "terseLabel": "Interest Rate Swaps [Member]"
       }
      }
     },
     "localname": "InterestRateSwapMember",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail",
      "http://www.pfizer.com/role/FinancialInstrumentsBalanceSheetGroupingFootnotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InterestRevenueExpenseNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of interest revenue (income derived from investments in debt securities and on cash and cash equivalents) net of interest expense (cost of borrowed funds accounted for as interest).",
        "label": "Interest Revenue (Expense), Net",
        "negatedTotalLabel": "Net interest expense"
       }
      }
     },
     "localname": "InterestRevenueExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r198"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/Inventories"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r37",
      "r197"
     ],
     "calculation": {
      "http://www.pfizer.com/role/InventoriesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/InventoriesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r12",
      "r64",
      "r196"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.pfizer.com/role/InventoriesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventories",
        "totalLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.pfizer.com/role/InventoriesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNoncurrent": {
     "auth_ref": [
      "r65"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.",
        "label": "Inventory, Noncurrent",
        "terseLabel": "Noncurrent inventories not included above"
       }
      }
     },
     "localname": "InventoryNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/InventoriesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves": {
     "auth_ref": [
      "r39",
      "r40",
      "r197"
     ],
     "calculation": {
      "http://www.pfizer.com/role/InventoriesDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregated amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed. This amount is net of valuation reserves and adjustments.",
        "label": "Inventory, Raw Materials and Supplies, Net of Reserves",
        "terseLabel": "Raw materials and supplies"
       }
      }
     },
     "localname": "InventoryRawMaterialsAndSuppliesNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/InventoriesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "auth_ref": [
      "r38",
      "r197"
     ],
     "calculation": {
      "http://www.pfizer.com/role/InventoriesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
        "label": "Inventory, Work in Process, Net of Reserves",
        "terseLabel": "Work-in-process"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/InventoriesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeDividend": {
     "auth_ref": [
      "r105"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of dividend income on nonoperating securities.",
        "label": "Investment Income, Dividend",
        "terseLabel": "Dividend income"
       }
      }
     },
     "localname": "InvestmentIncomeDividend",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationFootnotesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r106"
     ],
     "calculation": {
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_InterestRevenueExpenseNet",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "negatedTerseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.",
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "terseLabel": "Contractual Maturities of Available-for-sale and Held-to-maturity Debt Securities"
       }
      }
     },
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "auth_ref": [
      "r19",
      "r24",
      "r176",
      "r177",
      "r413",
      "r414",
      "r432"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail": {
       "order": 1.0,
       "parentTag": "pfe_SelectedFinancialAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.",
        "label": "Investments, Fair Value Disclosure",
        "totalLabel": "Selected financial assets measured at fair value on a recurring basis"
       }
      }
     },
     "localname": "InvestmentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail": {
       "order": 1.0,
       "parentTag": "pfe_OtherSelectedFinancialAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total investments in (A) an entity in which the entity has significant influence, but does not have control, (B) subsidiaries that are not required to be consolidated and are accounted for using the equity and or cost method, and (C) an entity in which the reporting entity shares control of the entity with another party or group. Includes long-term advances receivable from a party that is affiliated with the reporting entity by means of direct or indirect ownership.",
        "label": "Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures",
        "terseLabel": "Restricted stock and private equity securities, carried at cost or at equity-method"
       }
      }
     },
     "localname": "InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_JudicialRulingMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Litigation outcome that occurs as a result of judicial intervention, supervision, or approval.",
        "label": "Judicial Ruling [Member]",
        "terseLabel": "Judicial Ruling [Member]"
       }
      }
     },
     "localname": "JudicialRulingMember",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CommitmentsAndContingenciesActionsInWhichWeArePlaintiffDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities [Abstract]",
        "terseLabel": "Liabilities"
       }
      }
     },
     "localname": "LiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsBalanceSheetGroupingDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r35",
      "r411",
      "r437"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure [Abstract]",
        "terseLabel": "Liabilities, Fair Value Disclosure [Abstract]"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilityForUncertainTaxPositionsNoncurrent": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount recognized for uncertainty in income taxes classified as noncurrent.",
        "label": "Liability for Uncertainty in Income Taxes, Noncurrent",
        "terseLabel": "Other taxes payable"
       }
      }
     },
     "localname": "LiabilityForUncertainTaxPositionsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of judicial proceeding, alternative dispute resolution or claim.",
        "label": "Litigation Case [Axis]",
        "terseLabel": "Litigation Case [Axis]"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CommitmentsAndContingenciesActionsInWhichWeAreDefendantDetail",
      "http://www.pfizer.com/role/CommitmentsAndContingenciesActionsInWhichWeArePlaintiffDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LitigationCaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Judicial proceeding, alternative dispute resolution or claim. For example, but not limited to, name of case, category of litigation, or other differentiating information.",
        "label": "Litigation Case [Domain]",
        "terseLabel": "Litigation Case [Domain]"
       }
      }
     },
     "localname": "LitigationCaseTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CommitmentsAndContingenciesActionsInWhichWeAreDefendantDetail",
      "http://www.pfizer.com/role/CommitmentsAndContingenciesActionsInWhichWeArePlaintiffDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LitigationSettlementAmountAwardedToOtherParty": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount awarded to other party in judgment or settlement of litigation.",
        "label": "Litigation Settlement, Amount Awarded to Other Party",
        "verboseLabel": "Amount awarded to other party"
       }
      }
     },
     "localname": "LitigationSettlementAmountAwardedToOtherParty",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CommitmentsAndContingenciesActionsInWhichWeAreDefendantDetail",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationSettlementExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.",
        "label": "Litigation Settlement, Expense",
        "terseLabel": "Litigation settlement expense"
       }
      }
     },
     "localname": "LitigationSettlementExpense",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationStatusAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by status of pending, threatened, or settled litigation.",
        "label": "Litigation Status [Axis]",
        "terseLabel": "Litigation Status [Axis]"
       }
      }
     },
     "localname": "LitigationStatusAxis",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CommitmentsAndContingenciesActionsInWhichWeAreDefendantDetail",
      "http://www.pfizer.com/role/CommitmentsAndContingenciesActionsInWhichWeArePlaintiffDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LitigationStatusDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Status of pending, threatened, or settled litigation.",
        "label": "Litigation Status [Domain]",
        "terseLabel": "Litigation Status [Domain]"
       }
      }
     },
     "localname": "LitigationStatusDomain",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CommitmentsAndContingenciesActionsInWhichWeAreDefendantDetail",
      "http://www.pfizer.com/role/CommitmentsAndContingenciesActionsInWhichWeArePlaintiffDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LondonInterbankOfferedRateLIBORMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.",
        "label": "London Interbank Offered Rate (LIBOR) [Member]",
        "terseLabel": "London Interbank Offered Rate (LIBOR) [Member]"
       }
      }
     },
     "localname": "LondonInterbankOfferedRateLIBORMember",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsSaleOfHospiraInfusionSystemsNetAssetsToIcuMedicalIncEhDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r26",
      "r409",
      "r434"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtMaturitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "terseLabel": "Debt issued",
        "totalLabel": "Total",
        "verboseLabel": "Long-term debt"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetail",
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r51"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Current Maturities",
        "terseLabel": "Current portion of long-term debt"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.",
        "label": "Long-term Debt, Fair Value",
        "terseLabel": "Fair value of long-term debt"
       }
      }
     },
     "localname": "LongTermDebtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsAssetsAndLiabilitiesMeasuredOnRecurringBasisFootnotesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive": {
     "auth_ref": [
      "r140",
      "r255"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtMaturitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Long-term Debt, Maturities, Repayments of Principal after Year Five",
        "terseLabel": "After 2021"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": {
     "auth_ref": [
      "r140",
      "r255"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtMaturitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Long-term Debt, Maturities, Repayments of Principal in Year Five",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "auth_ref": [
      "r140",
      "r255"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtMaturitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Long-term Debt, Maturities, Repayments of Principal in Year Four",
        "terseLabel": "2020"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "auth_ref": [
      "r140",
      "r255"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtMaturitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Long-term Debt, Maturities, Repayments of Principal in Year Three",
        "terseLabel": "2019"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "auth_ref": [
      "r140",
      "r255"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtMaturitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Long-term Debt, Maturities, Repayments of Principal in Year Two",
        "terseLabel": "2018"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt arrangement having an initial term longer than one year or beyond the normal operating cycle, if longer.",
        "label": "Long-term Debt [Member]",
        "terseLabel": "Long-term debt [Member]"
       }
      }
     },
     "localname": "LongTermDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail",
      "http://www.pfizer.com/role/FinancialInstrumentsBalanceSheetGroupingDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.pfizer.com/role/FinancialInstrumentsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail": {
       "order": 2.0,
       "parentTag": "pfe_OtherFinancialLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Excluding Current Maturities",
        "terseLabel": "Long-term debt",
        "totalLabel": "Total long-term debt, carried at historical proceeds, as adjusted"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.pfizer.com/role/FinancialInstrumentsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Long-term Debt, Excluding Current Maturities [Abstract]",
        "terseLabel": "Long-term debt:"
       }
      }
     },
     "localname": "LongTermDebtNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermInvestments": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).",
        "label": "Long-term Investments",
        "terseLabel": "Long-term investments"
       }
      }
     },
     "localname": "LongTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r57"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail",
      "http://www.pfizer.com/role/FinancialInstrumentsAssetsAndLiabilitiesMeasuredOnRecurringBasisFootnotesDetail",
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetail",
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r57",
      "r256"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail",
      "http://www.pfizer.com/role/FinancialInstrumentsAssetsAndLiabilitiesMeasuredOnRecurringBasisFootnotesDetail",
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetail",
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingenciesByNatureOfContingencyAxis": {
     "auth_ref": [
      "r239",
      "r240",
      "r241",
      "r244",
      "r245",
      "r246",
      "r248",
      "r252",
      "r253"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur.",
        "label": "Loss Contingency Nature [Axis]",
        "terseLabel": "Loss Contingency Nature [Axis]"
       }
      }
     },
     "localname": "LossContingenciesByNatureOfContingencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CommitmentsAndContingenciesActionsInWhichWeAreDefendantDetail",
      "http://www.pfizer.com/role/CommitmentsAndContingenciesActionsInWhichWeArePlaintiffDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CommitmentsAndContingenciesActionsInWhichWeAreDefendantDetail",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r239",
      "r240",
      "r241",
      "r244",
      "r245",
      "r246",
      "r248",
      "r252",
      "r253"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CommitmentsAndContingenciesActionsInWhichWeAreDefendantDetail",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyClaimsDismissedNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of claims dismissed.",
        "label": "Loss Contingency, Claims Dismissed, Number",
        "terseLabel": "Claims dismissed"
       }
      }
     },
     "localname": "LossContingencyClaimsDismissedNumber",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CommitmentsAndContingenciesActionsInWhichWeAreDefendantDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_LossContingencyEstimateOfPossibleLoss": {
     "auth_ref": [
      "r243",
      "r247"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.",
        "label": "Loss Contingency, Estimate of Possible Loss",
        "terseLabel": "Imposed fine"
       }
      }
     },
     "localname": "LossContingencyEstimateOfPossibleLoss",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CommitmentsAndContingenciesActionsInWhichWeAreDefendantDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyNatureDomain": {
     "auth_ref": [
      "r239",
      "r240",
      "r241",
      "r244",
      "r245",
      "r246",
      "r248",
      "r252",
      "r253"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability.",
        "label": "Loss Contingency, Nature [Domain]",
        "terseLabel": "Loss Contingency, Nature [Domain]"
       }
      }
     },
     "localname": "LossContingencyNatureDomain",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CommitmentsAndContingenciesActionsInWhichWeAreDefendantDetail",
      "http://www.pfizer.com/role/CommitmentsAndContingenciesActionsInWhichWeArePlaintiffDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingencyPatentsAllegedlyInfringedNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of another entity's patents that the entity has allegedly infringed.",
        "label": "Loss Contingency, Patents Allegedly Infringed, Number",
        "terseLabel": "Number of patents"
       }
      }
     },
     "localname": "LossContingencyPatentsAllegedlyInfringedNumber",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CommitmentsAndContingenciesActionsInWhichWeAreDefendantDetail",
      "http://www.pfizer.com/role/CommitmentsAndContingenciesActionsInWhichWeArePlaintiffDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_LossContingencyPendingClaimsNumber": {
     "auth_ref": [
      "r242"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of pending claims pertaining to a loss contingency.",
        "label": "Loss Contingency, Pending Claims, Number",
        "terseLabel": "Number of pending claims"
       }
      }
     },
     "localname": "LossContingencyPendingClaimsNumber",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CommitmentsAndContingenciesActionsInWhichWeAreDefendantDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by major type of debt and equity security.",
        "label": "Major Types of Debt and Equity Securities [Axis]",
        "terseLabel": "Major Types of Debt and Equity Securities [Axis]"
       }
      }
     },
     "localname": "MajorTypesOfDebtAndEquitySecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsInDebtSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain": {
     "auth_ref": [
      "r189",
      "r427"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt instrument issued by corporations, governments and governmental agencies, municipalities, and other institutions. Equity securities are ownership interests or the right to acquire or dispose of ownership interests in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock.",
        "label": "Major Types of Debt and Equity Securities [Domain]",
        "terseLabel": "Major Types of Debt and Equity Securities [Domain]"
       }
      }
     },
     "localname": "MajorTypesOfDebtAndEquitySecuritiesDomain",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsInDebtSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MaterialReconcilingItemsMember": {
     "auth_ref": [
      "r165",
      "r166"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Items used in reconciling reportable segments' amounts to consolidated amount. Excludes corporate-level activity.",
        "label": "Segment Reconciling Items [Member]",
        "terseLabel": "Segment Reconciling Items [Member]"
       }
      }
     },
     "localname": "MaterialReconcilingItemsMember",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedIntangibleAssetsPercentageOfTotalIntangiblesDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillIndefiniteLivedIntangibleAssetsPercentageOfTotalIntangiblesDetails",
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesFootnotesDetails",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationDetail",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationFootnotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MaximumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Upper limit of the provided range.",
        "label": "Maximum [Member]",
        "terseLabel": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsAstrazenecaDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MinimumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lower limit of the provided range.",
        "label": "Minimum [Member]",
        "terseLabel": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsAstrazenecaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r62",
      "r410",
      "r436"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "terseLabel": "Equity attributable to noncontrolling interests"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestOwnershipPercentageByParent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage.",
        "label": "Noncontrolling Interest, Ownership Percentage by Parent",
        "terseLabel": "Ownership percentage"
       }
      }
     },
     "localname": "MinorityInterestOwnershipPercentageByParent",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsEquityMethodInvestmentsDetails",
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsSaleOfHospiraInfusionSystemsNetAssetsToIcuMedicalIncEhDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r450"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money Market Funds [Member]"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r121",
      "r124"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "terseLabel": "Amount reclassified to financing activities",
        "totalLabel": "Net cash used in financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetails",
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Financing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r121",
      "r124"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by/(used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Investing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r121",
      "r123",
      "r127"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "negatedTerseLabel": "Amount reclassified from operating activities",
        "totalLabel": "Net cash provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetails",
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Operating Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r97",
      "r127",
      "r152",
      "r423",
      "r445"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "totalLabel": "Net income attributable to Pfizer Inc."
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r333",
      "r338"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "terseLabel": "Less: Net income attributable to noncontrolling interests"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r146"
     ],
     "calculation": {
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributableToCommonShareholdersDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "totalLabel": "Net income attributable to Pfizer Inc. common shareholders"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributableToCommonShareholdersDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "auth_ref": [
      "r146",
      "r147"
     ],
     "calculation": {
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributableToCommonShareholdersDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted",
        "totalLabel": "Net income attributable to Pfizer Inc. common shareholders and assumed conversions"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributableToCommonShareholdersDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetInvestmentHedgingMember": {
     "auth_ref": [
      "r346"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Hedges of a net investment in a foreign operation.",
        "label": "Net Investment Hedging [Member]",
        "terseLabel": "Net Investment Hedging [Member]"
       }
      }
     },
     "localname": "NetInvestmentHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]",
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": {
     "auth_ref": [
      "r142",
      "r143",
      "r144"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.",
        "label": "New Accounting Pronouncements or Change in Accounting Principle [Table]",
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Table]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Adoption of New Accounting Standards"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NondesignatedMember": {
     "auth_ref": [
      "r347"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Not Designated as Hedging Instrument [Member]",
        "terseLabel": "Not Designated as Hedging Instrument [Member]"
       }
      }
     },
     "localname": "NondesignatedMember",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsAssetsAndLiabilitiesMeasuredOnRecurringBasisFootnotesDetail",
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonqualifiedPlanMember": {
     "auth_ref": [
      "r291"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Plan without tax-exempt status in accordance with applicable tax provision of designated taxing authority. Taxing authority includes, but is not limited to, U.S. Internal Revenue Service (IRS). Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Nonqualified Plan [Member]",
        "terseLabel": "Non-Qualified [Member]"
       }
      }
     },
     "localname": "NonqualifiedPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansDetail",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansNetPeriodicBenefitCostDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "verboseLabel": "Number of business segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetails",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationNarrativeDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingSegmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Operating Segments [Member]",
        "terseLabel": "Operating Segments [Member]"
       }
      }
     },
     "localname": "OperatingSegmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedIntangibleAssetsPercentageOfTotalIntangiblesDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillIndefiniteLivedIntangibleAssetsPercentageOfTotalIntangiblesDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail",
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesFootnotesDetails",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationDetail",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationFootnotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "verboseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "verboseLabel": "Other noncurrent assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax": {
     "auth_ref": [
      "r79",
      "r81",
      "r288"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of cost (credit) of benefit change attributable to participants' prior service from plan amendment or plan initiation of defined benefit plan, that has not been recognized in net periodic benefit cost (credit).",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), before Tax",
        "negatedLabel": "Benefit plans: prior service (costs)/credits and other, net"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodTax": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersDetail": {
       "order": 1.0,
       "parentTag": "pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetActuarialGainLossTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of tax expense (benefit) for (increase) decrease in value of benefit obligation for change in actuarial assumptions and increase (decrease) in value of plan assets from experience different from that assumed of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit.",
        "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, Tax",
        "terseLabel": "Benefit plans: actuarial losses, net"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodTax",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r330",
      "r331",
      "r335"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before tax, after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to noncontrolling interests.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, before Tax, Portion Attributable to Noncontrolling Interest",
        "verboseLabel": "Foreign currency translation adjustments attributable to noncontrolling interests"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax": {
     "auth_ref": [
      "r72",
      "r81",
      "r389",
      "r391",
      "r392"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss), before Reclassification and Tax",
        "terseLabel": "Foreign currency translation adjustments, net"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by location in other comprehensive income.",
        "label": "Other Comprehensive Income Location [Axis]",
        "terseLabel": "Other Comprehensive Income Location [Axis]"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location in other comprehensive income.",
        "label": "Other Comprehensive Income Location [Domain]",
        "terseLabel": "Other Comprehensive Income Location [Domain]"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax": {
     "auth_ref": [
      "r81",
      "r85",
      "r288"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of reclassification adjustment from accumulated other comprehensive (income) loss for prior service cost (credit) of defined benefit plan.",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Reclassification Adjustment from AOCI, before Tax",
        "verboseLabel": "Reclassification adjustments related to amortization"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of tax (expense) benefit of reclassification adjustment from accumulated other comprehensive (income) loss for prior service cost (credit) of defined benefit plan.",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Reclassification Adjustment from AOCI, Tax",
        "terseLabel": "Reclassification adjustments related to amortization"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax": {
     "auth_ref": [
      "r75",
      "r188"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before tax, after reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities. Excludes amounts related to other than temporary impairment (OTTI) loss.",
        "label": "Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, before Tax",
        "totalLabel": "Other comprehensive income (loss), available-for-sale securities adjustment, before tax, total"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax": {
     "auth_ref": [
      "r75",
      "r82"
     ],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of tax expense (benefit), after reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities. Excludes amounts related to other than temporary impairment (OTTI) loss.",
        "label": "Other Comprehensive Income (Loss), Available-for-sale Securities, Tax",
        "totalLabel": "Available-for-sale securities, tax, total"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossBeforeTax": {
     "auth_ref": [
      "r87",
      "r88",
      "r192"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before tax, after reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), before Tax",
        "totalLabel": "Other comprehensive income, before tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesBeforeTax": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before tax, after reclassification adjustments, of increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss).",
        "label": "Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, before Tax",
        "totalLabel": "Other comprehensive income (loss), derivatives qualifying as hedges, before tax, total"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesTax": {
     "auth_ref": [
      "r74",
      "r82"
     ],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of tax expense (benefit), after reclassification adjustments, of increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss).",
        "label": "Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Tax",
        "totalLabel": "Derivatives qualifying as hedges, tax, total"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesTax",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax": {
     "auth_ref": [
      "r72",
      "r81",
      "r389",
      "r393"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome": {
       "order": 5.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before tax, after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, before Tax",
        "totalLabel": "Other comprehensive income (loss), foreign currency transaction and translation adjustment, before tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax": {
     "auth_ref": [
      "r81",
      "r85",
      "r86",
      "r394"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before tax of reclassification adjustment from accumulated other comprehensive income for translation gain (loss) realized upon the sale or liquidation of an investment in a foreign entity and foreign currency hedges that are designated and qualified as hedging instruments for hedges of the foreign currency exposure of a net investment in a foreign operation.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Reclassification Adjustment from AOCI, Realized upon Sale or Liquidation, before Tax",
        "negatedTerseLabel": "Reclassification adjustments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax": {
     "auth_ref": [
      "r72",
      "r82"
     ],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax",
        "terseLabel": "Foreign currency translation adjustments, net"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r87",
      "r88",
      "r90",
      "r257"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "totalLabel": "Other comprehensive income before allocation to noncontrolling interests"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r330",
      "r331",
      "r335"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Other comprehensive income/(loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect": {
     "auth_ref": [
      "r82",
      "r330"
     ],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersDetail": {
       "order": 5.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossTax",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of tax (expense) benefit for cost (credit) of benefit change attributable to participants' prior service from plan amendment or plan initiation of defined benefit plan, that has not been recognized in net periodic benefit cost (credit).",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Tax",
        "negatedTotalLabel": "Pension and other postretirement benefit plans, net prior service cost (credit), tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax": {
     "auth_ref": [
      "r78",
      "r81",
      "r288"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of gain (loss) for (increase) decrease in value of benefit obligation for change in actuarial assumptions and increase (decrease) in value of plan assets from experience different from that assumed of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit.",
        "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, before Tax",
        "terseLabel": "Benefit plans: actuarial losses, net"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax": {
     "auth_ref": [
      "r81",
      "r85",
      "r188"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.",
        "label": "Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, before Tax",
        "negatedTerseLabel": "Reclassification adjustments for realized gains"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax": {
     "auth_ref": [
      "r82",
      "r188"
     ],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of tax expense (benefit) of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.",
        "label": "Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Tax",
        "negatedTerseLabel": "Reclassification adjustments for realized gains"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesBeforeTax": {
     "auth_ref": [
      "r81",
      "r85",
      "r348"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesBeforeTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before tax of reclassification adjustment from accumulated other comprehensive income of accumulated gain (loss) realized from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's deferred hedging gain (loss).",
        "label": "Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, before Tax",
        "negatedTerseLabel": "Reclassification adjustments for realized (gains)/losses"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesTax": {
     "auth_ref": [
      "r82",
      "r348"
     ],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesTax",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of tax expense (benefit) of reclassification adjustment from accumulated other comprehensive income of accumulated gain (loss) realized from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's deferred hedging gain (loss).",
        "label": "Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, Tax",
        "negatedTerseLabel": "Reclassification adjustments for realized (gains)/losses"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesTax",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax": {
     "auth_ref": [
      "r81",
      "r85",
      "r288"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of reclassification adjustment from accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan.",
        "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), Reclassification Adjustment from AOCI, before Tax",
        "negatedTerseLabel": "Reclassification adjustments related to amortization"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossTax": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersDetail": {
       "order": 2.0,
       "parentTag": "pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetActuarialGainLossTax",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of tax expense (benefit) of reclassification adjustment from accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan.",
        "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), Reclassification Adjustment from AOCI, Tax",
        "negatedTerseLabel": "Reclassification adjustments related to amortization"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossTax",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossTax": {
     "auth_ref": [
      "r82",
      "r309"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": -1.0
      },
      "http://www.pfizer.com/role/TaxMattersDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Tax",
        "terseLabel": "Tax provision/(benefit) on other comprehensive income",
        "totalLabel": "Tax provision/(benefit) on other comprehensive income"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossTax",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome",
      "http://www.pfizer.com/role/TaxMattersDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r359"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption in which reported facts about other comprehensive income have been included.",
        "label": "Other Comprehensive Income (Loss) [Member]",
        "terseLabel": "Other Comprehensive Income (Loss) [Member]"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax": {
     "auth_ref": [
      "r74",
      "r81",
      "r366"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before tax of increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss).",
        "label": "Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, before Tax",
        "terseLabel": "Unrealized holding losses on derivative financial instruments, net"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax": {
     "auth_ref": [
      "r74",
      "r82"
     ],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of tax expense (benefit), before reclassification adjustments, related to increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss).",
        "label": "Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Tax",
        "terseLabel": "Unrealized holding losses on derivative financial instruments, net"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax": {
     "auth_ref": [
      "r75",
      "r81"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before tax and reclassification adjustments of unrealized holding gain (loss) on available-for-sale securities.",
        "label": "Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, before Tax",
        "terseLabel": "Unrealized holding gains on available-for-sale securities, net"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax": {
     "auth_ref": [
      "r77",
      "r82"
     ],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of tax expense (benefit) before reclassification adjustments of unrealized holding gain (loss) on available-for-sale securities.",
        "label": "Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Tax",
        "terseLabel": "Unrealized holding gains on available-for-sale securities, net"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCurrentAssetsMember": {
     "auth_ref": [
      "r349",
      "r364"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other current assets.",
        "label": "Other Current Assets [Member]",
        "terseLabel": "Other Current Assets [Member]"
       }
      }
     },
     "localname": "OtherCurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsBalanceSheetGroupingDetail",
      "http://www.pfizer.com/role/FinancialInstrumentsBalanceSheetGroupingFootnotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherCurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other current liabilities.",
        "label": "Other Current Liabilities [Member]",
        "terseLabel": "Other Current Liabilities [Member]"
       }
      }
     },
     "localname": "OtherCurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsBalanceSheetGroupingDetail",
      "http://www.pfizer.com/role/FinancialInstrumentsBalanceSheetGroupingFootnotesDetail",
      "http://www.pfizer.com/role/FinancialInstrumentsOtherNoncurrentLiabilitiesDetail",
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesRestructuringAccrualsFootnotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherIncomeAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Other Income and Expenses [Abstract]"
       }
      }
     },
     "localname": "OtherIncomeAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock": {
     "auth_ref": [
      "r269",
      "r299"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions.",
        "label": "Other Income and Other Expense Disclosure [Text Block]",
        "terseLabel": "Other (Income)/Deductions - Net"
       }
      }
     },
     "localname": "OtherIncomeAndOtherExpenseDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r15",
      "r16",
      "r54"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "verboseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other noncurrent liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r127"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedLabel": "Other adjustments, net"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncurrentAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent assets.",
        "label": "Other Noncurrent Assets [Member]",
        "terseLabel": "Other Noncurrent Assets [Member]"
       }
      }
     },
     "localname": "OtherNoncurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsBalanceSheetGroupingDetail",
      "http://www.pfizer.com/role/FinancialInstrumentsBalanceSheetGroupingFootnotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNoncurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.",
        "label": "Other Noncurrent Liabilities [Member]",
        "terseLabel": "Other Noncurrent Liabilities [Member]"
       }
      }
     },
     "localname": "OtherNoncurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsBalanceSheetGroupingDetail",
      "http://www.pfizer.com/role/FinancialInstrumentsBalanceSheetGroupingFootnotesDetail",
      "http://www.pfizer.com/role/FinancialInstrumentsOtherNoncurrentLiabilitiesDetail",
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesRestructuringAccrualsFootnotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r108"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfIncome": {
       "order": 7.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "negatedLabel": "Other (income)/deductions\u2013\u2013net",
        "negatedTotalLabel": "Other (income)/deductions\u2013\u2013net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfIncome",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other nonoperating income (expense).",
        "label": "Other Nonoperating Income (Expense) [Member]",
        "terseLabel": "Other (Income)/Deductions, Net [Member]"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsBambooTherapeuticsDetails",
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsCollaborationArrangementDetails",
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsEquityMethodInvestmentsDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherOperatingIncomeExpenseNet": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.",
        "label": "Other Operating Income (Expense), Net",
        "negatedLabel": "Other charges"
       }
      }
     },
     "localname": "OtherOperatingIncomeExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationFootnotesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember": {
     "auth_ref": [
      "r271",
      "r290",
      "r291",
      "r296"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Plan designed to provide other postretirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes pension benefits.",
        "label": "Other Postretirement Benefits Plan [Member]",
        "terseLabel": "Postretirement Plans [Member]"
       }
      }
     },
     "localname": "OtherPostretirementBenefitPlansDefinedBenefitMember",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansDetail",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansNetPeriodicBenefitCostDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent": {
     "auth_ref": [
      "r27",
      "r272",
      "r273",
      "r278"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit other postretirement plan, classified as noncurrent. Excludes pension plan.",
        "label": "Liability, Other Postretirement Defined Benefit Plan, Noncurrent",
        "terseLabel": "Postretirement benefit obligations, net"
       }
      }
     },
     "localname": "OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherRestructuringMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Restructuring and related activities classified as other.",
        "label": "Other Restructuring [Member]",
        "terseLabel": "Exit Costs [Member]"
       }
      }
     },
     "localname": "OtherRestructuringMember",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesRestructuringAccrualsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities": {
     "auth_ref": [
      "r115"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow, made soon after acquisition date of business combination, to settle contingent consideration liability.",
        "label": "Payment for Contingent Consideration Liability, Investing Activities",
        "terseLabel": "Milestone payment"
       }
      }
     },
     "localname": "PaymentForContingentConsiderationLiabilityInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsAstrazenecaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": {
     "auth_ref": [
      "r129",
      "r132"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.",
        "label": "Payments for (Proceeds from) Other Investing Activities",
        "negatedLabel": "Other investing activities, net"
       }
      }
     },
     "localname": "PaymentsForProceedsFromOtherInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForProceedsFromShortTermInvestments": {
     "auth_ref": [
      "r129",
      "r130"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net amount paid (received) by the reporting entity through acquisition or sale and maturities of short-term investments with an original maturity that is three months or less which qualify for treatment as an investing activity based on management's intention and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.",
        "label": "Payments for (Proceeds from) Short-term Investments",
        "negatedLabel": "Net proceeds from redemptions/sales of short-term investments with original maturities of three months or less"
       }
      }
     },
     "localname": "PaymentsForProceedsFromShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r119"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedLabel": "Purchases of common stock"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfOrdinaryDividends": {
     "auth_ref": [
      "r119"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash outflow in the form of ordinary dividends to common shareholders, preferred shareholders and noncontrolling interests, generally out of earnings.",
        "label": "Payments of Ordinary Dividends",
        "negatedLabel": "Cash dividends paid"
       }
      }
     },
     "localname": "PaymentsOfOrdinaryDividends",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "auth_ref": [
      "r113"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.",
        "label": "Payments to Acquire Businesses, Gross",
        "verboseLabel": "Payments for acquisitions, cash portion"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGross",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsAnacorPharmaceuticalsIncDetails",
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsAstrazenecaDetails",
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsBambooTherapeuticsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "auth_ref": [
      "r113"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "negatedTerseLabel": "Acquisitions of businesses, net of cash acquired",
        "terseLabel": "Cash payments for acquisition, net of cash acquired"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsAnacorPharmaceuticalsIncDetails",
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsBambooTherapeuticsDetails",
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "auth_ref": [
      "r114"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.",
        "label": "Payments to Acquire Intangible Assets",
        "negatedTerseLabel": "Acquisitions of intangible assets"
       }
      }
     },
     "localname": "PaymentsToAcquireIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r112",
      "r179"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash outflow for purchase of trading, available-for-sale securities and held-to-maturity securities.",
        "label": "Payments to Acquire Marketable Securities",
        "negatedLabel": "Purchases of long-term investments"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r114"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property, plant and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireShortTermInvestments": {
     "auth_ref": [
      "r116"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.",
        "label": "Payments to Acquire Short-term Investments",
        "negatedLabel": "Purchases of short-term investments"
       }
      }
     },
     "localname": "PaymentsToAcquireShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PendingLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Risk of loss associated with the outcome of pending litigation against the entity, for example, but not limited to, litigation in arbitration or within the trial process.",
        "label": "Pending Litigation [Member]",
        "terseLabel": "Pending Litigation [Member]"
       }
      }
     },
     "localname": "PendingLitigationMember",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CommitmentsAndContingenciesActionsInWhichWeAreDefendantDetail",
      "http://www.pfizer.com/role/CommitmentsAndContingenciesActionsInWhichWeArePlaintiffDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r297"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for pension and other postretirement benefits.",
        "label": "Pension and Other Postretirement Benefits Disclosure [Text Block]",
        "terseLabel": "Pension and Postretirement Benefit Plans"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PensionPlansDefinedBenefitMember": {
     "auth_ref": [
      "r270",
      "r290",
      "r291",
      "r296"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Plan designed to provide participant with pension benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes other postretirement benefits.",
        "label": "Pension Plan [Member]",
        "terseLabel": "Pension Plan [Member]"
       }
      }
     },
     "localname": "PensionPlansDefinedBenefitMember",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansDetail",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansNetPeriodicBenefitCostDetail",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansNetPeriodicBenefitCostFootnotesDetails",
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesFootnotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PortionAtFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r379",
      "r380"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measured at fair value for financial reporting purposes.",
        "label": "Portion at Fair Value Measurement [Member]",
        "terseLabel": "Portion at Fair Value Measurement [Member]"
       }
      }
     },
     "localname": "PortionAtFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail",
      "http://www.pfizer.com/role/FinancialInstrumentsAssetsAndLiabilitiesMeasuredOnRecurringBasisFootnotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockDividendsIncomeStatementImpact": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributableToCommonShareholdersDetails": {
       "order": 2.0,
       "parentTag": "pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders.",
        "label": "Preferred Stock Dividends, Income Statement Impact",
        "terseLabel": "Less: Preferred stock dividends\u2013\u2013net of tax"
       }
      }
     },
     "localname": "PreferredStockDividendsIncomeStatementImpact",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributableToCommonShareholdersDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProFormaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Financial information that is based on fully or partially assumed figures or facts. For example, but not limited to, pro forma disclosure of a change in accounting principle of what earnings would have been if the new principle had been applied. Excludes forecasts.",
        "label": "Pro Forma [Member]",
        "terseLabel": "Pro Forma [Member]"
       }
      }
     },
     "localname": "ProFormaMember",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromCollaborators": {
     "auth_ref": [
      "r122"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash received from collaborators during the current period.",
        "label": "Proceeds from Collaborators",
        "terseLabel": "Upfront payments received"
       }
      }
     },
     "localname": "ProceedsFromCollaborators",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsCollaborationArrangementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromDivestitureOfBusinesses": {
     "auth_ref": [
      "r110"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.",
        "label": "Proceeds from Divestiture of Businesses",
        "terseLabel": "Cash received from disposition"
       }
      }
     },
     "localname": "ProceedsFromDivestitureOfBusinesses",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsSaleOfHospiraInfusionSystemsNetAssetsToIcuMedicalIncEhDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r118"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Proceeds from Issuance of Long-term Debt",
        "terseLabel": "Proceeds from issuance of long-term debt"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": {
     "auth_ref": [
      "r129",
      "r132"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.",
        "label": "Proceeds from (Payments for) Other Financing Activities",
        "terseLabel": "Other financing activities, net"
       }
      }
     },
     "localname": "ProceedsFromPaymentsForOtherFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess": {
     "auth_ref": [
      "r118",
      "r120",
      "r129",
      "r131"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from a borrowing net of the cash outflow from repayment of a borrowing having initial term of repayment within three months.",
        "label": "Proceeds from (Repayments of) Short-term Debt, Maturing in Three Months or Less",
        "terseLabel": "Net proceeds from/(payments on) short-term borrowings with original maturities of three months or less"
       }
      }
     },
     "localname": "ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from sales, maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, beyond the current operating cycle.",
        "label": "Proceeds from Sale, Maturity and Collection of Long-term Investments",
        "terseLabel": "Proceeds from redemptions/sales of long-term investments"
       }
      }
     },
     "localname": "ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments": {
     "auth_ref": [
      "r111"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from sales, maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.",
        "label": "Proceeds from Sale, Maturity and Collection of Short-term Investments",
        "terseLabel": "Proceeds from redemptions/sales of short-term investments"
       }
      }
     },
     "localname": "ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromShortTermDebt": {
     "auth_ref": [
      "r118"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.",
        "label": "Proceeds from Short-term Debt",
        "terseLabel": "Proceeds from short-term borrowings"
       }
      }
     },
     "localname": "ProceedsFromShortTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r117",
      "r298"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of stock options granted under share-based compensation arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductOrServiceAxis": {
     "auth_ref": [
      "r168",
      "r266",
      "r267"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by products and services or groups of similar products and services.",
        "label": "Products and Services [Axis]",
        "terseLabel": "Products and Services [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CommitmentsAndContingenciesActionsInWhichWeAreDefendantDetail",
      "http://www.pfizer.com/role/CommitmentsAndContingenciesActionsInWhichWeArePlaintiffDetails",
      "http://www.pfizer.com/role/CommitmentsAndContingenciesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsOtherNoncurrentLiabilitiesDetail",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsFootnotesDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ProductsAndServicesDomain": {
     "auth_ref": [
      "r168"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Product or service, or a group of similar products or similar services.",
        "label": "Products and Services [Domain]",
        "terseLabel": "Products and Services [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CommitmentsAndContingenciesActionsInWhichWeAreDefendantDetail",
      "http://www.pfizer.com/role/CommitmentsAndContingenciesActionsInWhichWeArePlaintiffDetails",
      "http://www.pfizer.com/role/CommitmentsAndContingenciesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsOtherNoncurrentLiabilitiesDetail",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsFootnotesDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r330",
      "r333",
      "r334",
      "r338",
      "r339"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net income before allocation to noncontrolling interests",
        "totalLabel": "Net income before allocation to noncontrolling interests"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome",
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r20",
      "r21",
      "r224",
      "r438"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property, plant and equipment, less accumulated depreciation: 2017\u2014$15,906; 2016\u2014$14,807"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_QualifiedPlanMember": {
     "auth_ref": [
      "r291"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Plan with tax-exempt status designed and operated in accordance with applicable tax provision of designated taxing authority. Taxing authority includes, but is not limited to, U.S. Internal Revenue Service (IRS). Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Qualified Plan [Member]",
        "terseLabel": "Qualified [Member]"
       }
      }
     },
     "localname": "QualifiedPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansDetail",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansNetPeriodicBenefitCostDetail",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansNetPeriodicBenefitCostFootnotesDetails",
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesFootnotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RangeAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by range, including, but not limited to, upper and lower bounds.",
        "label": "Range [Axis]",
        "terseLabel": "Range [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsAstrazenecaDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RangeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Extent of variation, for example, but not limited to, upper and lower bounds.",
        "label": "Range [Domain]",
        "terseLabel": "Range [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsAstrazenecaDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by item reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Axis]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Axis]"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Item reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Domain]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Domain]"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identifies item reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Member]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Member]"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": {
     "auth_ref": [
      "r164",
      "r166"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.",
        "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]",
        "terseLabel": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated"
       }
      }
     },
     "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock": {
     "auth_ref": [
      "r163",
      "r166"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of all significant reconciling items in the reconciliation of total revenues from reportable segments to the entity's consolidated revenues.",
        "label": "Reconciliation of Revenue from Segments to Consolidated [Table Text Block]",
        "terseLabel": "Reconciliation of Revenue from Segments to Consolidated"
       }
      }
     },
     "localname": "ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r120"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-term Debt",
        "negatedLabel": "Principal payments on long-term debt"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfShortTermDebt": {
     "auth_ref": [
      "r120"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.",
        "label": "Repayments of Short-term Debt",
        "negatedLabel": "Principal payments on short-term borrowings"
       }
      }
     },
     "localname": "RepaymentsOfShortTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r138"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Named other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution.",
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsCollaborationArrangementDetails",
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsSaleOfHospiraInfusionSystemsNetAssetsToIcuMedicalIncEhDetails",
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlowsParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "auth_ref": [
      "r300"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfIncome": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.",
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "verboseLabel": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and Development Expense [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Restructuring and Related Activities [Abstract]"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r237"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.",
        "label": "Restructuring and Related Activities Disclosure [Text Block]",
        "terseLabel": "Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiatives"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestructuringAndRelatedCostCostIncurredToDate1": {
     "auth_ref": [
      "r228",
      "r236"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of costs incurred to date for the specified restructuring cost.",
        "label": "Restructuring and Related Cost, Cost Incurred to Date",
        "terseLabel": "Restructuring costs incurred"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostCostIncurredToDate1",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringAndRelatedCostExpectedCost1": {
     "auth_ref": [
      "r228",
      "r236"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount expected to be recognized in earnings for the specified restructuring cost.",
        "label": "Restructuring and Related Cost, Expected Cost",
        "terseLabel": "Expected restructuring cost"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostExpectedCost1",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringAndRelatedCostIncurredCost": {
     "auth_ref": [
      "r228",
      "r236"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Discloses the amount charged against the accrued restructuring reserves, or earnings if not previously accrued, during the period for the specified type of restructuring cost.",
        "label": "Restructuring and Related Cost, Incurred Cost",
        "terseLabel": "Restructuring cost incurred associated with the return of acquired in-process research and development rights"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostIncurredCost",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringCharges": {
     "auth_ref": [
      "r126",
      "r228",
      "r232",
      "r236"
     ],
     "calculation": {
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesDetail": {
       "order": 1.0,
       "parentTag": "pfe_RestructuringChargesAndAcquisitionRelatedCosts",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.",
        "label": "Restructuring Charges",
        "terseLabel": "Provision",
        "totalLabel": "Total restructuring charges"
       }
      }
     },
     "localname": "RestructuringCharges",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesDetail",
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesFootnotesDetails",
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesRestructuringAccrualsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringChargesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Restructuring Charges [Abstract]",
        "terseLabel": "Restructuring charges:"
       }
      }
     },
     "localname": "RestructuringChargesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of restructuring cost.",
        "label": "Restructuring Type [Axis]",
        "terseLabel": "Restructuring Type [Axis]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveAxis",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesDetail",
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesRestructuringAccrualsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Restructuring Cost and Reserve [Line Items]",
        "terseLabel": "Restructuring Cost and Reserve [Line Items]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveLineItems",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesDetail",
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesFootnotesDetails",
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesRestructuringAccrualsDetail",
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesRestructuringAccrualsFootnotesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringPlanAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by individual restructuring plan.",
        "label": "Restructuring Plan [Axis]",
        "terseLabel": "Restructuring Plan [Axis]"
       }
      }
     },
     "localname": "RestructuringPlanAxis",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringPlanDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identification of the individual restructuring plans.",
        "label": "Restructuring Plan [Domain]",
        "terseLabel": "Restructuring Plan [Domain]"
       }
      }
     },
     "localname": "RestructuringPlanDomain",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringReserve": {
     "auth_ref": [
      "r229",
      "r233"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.",
        "label": "Restructuring Reserve",
        "periodEndLabel": "Balance, October 1, 2017",
        "periodStartLabel": "Balance, December 31, 2016",
        "terseLabel": "Restructuring reserve"
       }
      }
     },
     "localname": "RestructuringReserve",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesRestructuringAccrualsDetail",
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesRestructuringAccrualsFootnotesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringReserveAcceleratedDepreciation": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesDetail": {
       "order": 2.0,
       "parentTag": "pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accelerated depreciation charged against earnings associated with exit from or disposal of business activities or restructuring plan.",
        "label": "Restructuring and Related Cost, Accelerated Depreciation",
        "terseLabel": "Total additional depreciation\u2013\u2013asset restructuring"
       }
      }
     },
     "localname": "RestructuringReserveAcceleratedDepreciation",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringReserveRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Restructuring Reserve [Roll Forward]",
        "terseLabel": "Restructuring Reserve [Roll Forward]"
       }
      }
     },
     "localname": "RestructuringReserveRollForward",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesRestructuringAccrualsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r32",
      "r262",
      "r435"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetirementPlanSponsorLocationAxis": {
     "auth_ref": [
      "r291",
      "r293"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Retirement Plan Sponsor Location [Axis]",
        "terseLabel": "Retirement Plan Sponsor Location [Axis]"
       }
      }
     },
     "localname": "RetirementPlanSponsorLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansDetail",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansNetPeriodicBenefitCostDetail",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansNetPeriodicBenefitCostFootnotesDetails",
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesFootnotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetirementPlanSponsorLocationDomain": {
     "auth_ref": [
      "r291",
      "r293"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Retirement Plan Sponsor Location [Domain]",
        "terseLabel": "Retirement Plan Sponsor Location [Domain]"
       }
      }
     },
     "localname": "RetirementPlanSponsorLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansDetail",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansNetPeriodicBenefitCostDetail",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansNetPeriodicBenefitCostFootnotesDetails",
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesFootnotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetirementPlanTaxStatusAxis": {
     "auth_ref": [
      "r291"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by tax status of plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Retirement Plan Tax Status [Axis]",
        "terseLabel": "Retirement Plan Tax Status [Axis]"
       }
      }
     },
     "localname": "RetirementPlanTaxStatusAxis",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansDetail",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansNetPeriodicBenefitCostDetail",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansNetPeriodicBenefitCostFootnotesDetails",
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesFootnotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetirementPlanTaxStatusDomain": {
     "auth_ref": [
      "r291"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tax status of plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Retirement Plan Tax Status [Domain]",
        "terseLabel": "Retirement Plan Tax Status [Domain]"
       }
      }
     },
     "localname": "RetirementPlanTaxStatusDomain",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansDetail",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansNetPeriodicBenefitCostDetail",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansNetPeriodicBenefitCostFootnotesDetails",
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesFootnotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetirementPlanTypeAxis": {
     "auth_ref": [
      "r270",
      "r271",
      "r290",
      "r291",
      "r296"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.",
        "label": "Retirement Plan Type [Axis]",
        "terseLabel": "Retirement Plan Type [Axis]"
       }
      }
     },
     "localname": "RetirementPlanTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansDetail",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansNetPeriodicBenefitCostDetail",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansNetPeriodicBenefitCostFootnotesDetails",
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesFootnotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetirementPlanTypeDomain": {
     "auth_ref": [
      "r270",
      "r271",
      "r290",
      "r291",
      "r296"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.",
        "label": "Retirement Plan Type [Domain]",
        "terseLabel": "Retirement Plan Type [Domain]"
       }
      }
     },
     "localname": "RetirementPlanTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansDetail",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansNetPeriodicBenefitCostDetail",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansNetPeriodicBenefitCostFootnotesDetails",
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesFootnotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": {
     "auth_ref": [
      "r169"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.",
        "label": "Revenue from External Customers by Geographic Areas [Table Text Block]",
        "terseLabel": "Schedule of Revenues by Geographic Region"
       }
      }
     },
     "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenues from External Customers and Long-Lived Assets [Line Items]",
        "terseLabel": "Revenues from External Customers and Long-Lived Assets [Line Items]"
       }
      }
     },
     "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByGeographicAreaDetail",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByGeographicAreaFootnotesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RoyaltyRevenue": {
     "auth_ref": [
      "r101"
     ],
     "calculation": {
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue earned during the period from the leasing or otherwise lending to a third party the entity's rights or title to certain property. Royalty revenue is derived from a percentage or stated amount of sales proceeds or revenue generated by the third party using the entity's property. Examples of property from which royalties may be derived include patents and oil and mineral rights.",
        "label": "Royalty Revenue",
        "negatedLabel": "Royalty-related income",
        "terseLabel": "Royalty revenue"
       }
      }
     },
     "localname": "RoyaltyRevenue",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetDetail",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SalesRevenueGoodsNet": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.",
        "label": "Sales Revenue, Goods, Net",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "SalesRevenueGoodsNet",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfIncome",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationDetail",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByGeographicAreaDetail",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByGeographicAreaFootnotesDetail",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ScenarioAdjustmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Domain member used to indicate figures that are adjustments during a period or as of a point in time. This domain member would never be expected to appear in a relationship group without the \"Scenario, Previously Reported\" Member with the same parent.",
        "label": "Scenario, Adjustment [Member]",
        "terseLabel": "Adjustment [Member]"
       }
      }
     },
     "localname": "ScenarioAdjustmentMember",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationFootnotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScenarioForecastMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The reporting scenario used to indicate financial results forecast for a future period.",
        "label": "Scenario, Forecast [Member]",
        "terseLabel": "Forecast [Member]"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsAstrazenecaDetails",
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScenarioUnspecifiedDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Any scenario, that is, the particular reporting scenario is left unspecified. Scenarios distinguish among different kinds of business reporting facts, as for example actual versus budgeted figures.",
        "label": "Scenario, Unspecified [Domain]",
        "terseLabel": "Scenario, Unspecified [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsAstrazenecaDetails",
      "http://www.pfizer.com/role/CommitmentsAndContingenciesDetails",
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesDetail",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationFootnotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r84"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).",
        "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Schedule of Changes in Accumulated Other Comprehensive Loss, Net of Tax"
       }
      }
     },
     "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r151"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributableToCommonShareholdersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r314",
      "r315"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsAnacorPharmaceuticalsIncDetails",
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsAstrazenecaDetails",
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsBambooTherapeuticsDetails",
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsMedivationDetails",
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsSaleOfHospiraInfusionSystemsNetAssetsToIcuMedicalIncEhDetails",
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r326"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of contractual arrangements that involve two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity. Additionally, the element may include all other transactions of the entity categorized collectively, if such comparison of collaborative arrangements as a component of all transactions of the entity is desired.",
        "label": "Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]",
        "terseLabel": "Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsCollaborationArrangementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "auth_ref": [
      "r57",
      "r135",
      "r258",
      "r259",
      "r260",
      "r261",
      "r396",
      "r397",
      "r399",
      "r428"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table Text Block]",
        "terseLabel": "Schedule of Principal Amounts and Components of Unsecured Long-term Debt Issued"
       }
      }
     },
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "auth_ref": [
      "r290",
      "r291",
      "r292",
      "r293",
      "r295"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans.  Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Defined Benefit Plans Disclosures [Table]",
        "terseLabel": "Schedule of Defined Benefit Plans Disclosures [Table]"
       }
      }
     },
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansDetail",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansNetPeriodicBenefitCostDetail",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansNetPeriodicBenefitCostFootnotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": {
     "auth_ref": [
      "r350",
      "r358"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.",
        "label": "Derivative Instruments, Gain (Loss) [Table Text Block]",
        "terseLabel": "Information about Gains/(Losses) Incurred to Hedge or Offset Operational Foreign Exchange or Interest Rate Risk"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r152"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Basic and Diluted Earning Per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributableToCommonShareholdersTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable": {
     "auth_ref": [
      "r168"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular presentation of the description and amount of revenues from a product or service, or a group of similar products or similar services, reported from external customers during the period, if the information is not provided as part of the reportable operating segment information.",
        "label": "Revenue from External Customers by Products and Services [Table]",
        "terseLabel": "Revenue from External Customers by Products and Services [Table]"
       }
      }
     },
     "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock": {
     "auth_ref": [
      "r168"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.",
        "label": "Revenue from External Customers by Products and Services [Table Text Block]",
        "terseLabel": "Schedule of Significant Product Revenues"
       }
      }
     },
     "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "auth_ref": [
      "r193"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by name of investment, including named security. Excludes consolidated entity.",
        "label": "Investment, Name [Axis]",
        "terseLabel": "Investment, Name [Axis]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsEquityMethodInvestmentsDetails",
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeParenthetical",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationFootnotesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Schedule of Equity Method Investments [Line Items]",
        "terseLabel": "Schedule of Equity Method Investments [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsTable": {
     "auth_ref": [
      "r194"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Summarization of information required and determined to be disclosed concerning equity method investments in common stock. The summarized information includes: (a) the name of each investee or group of investees for which combined disclosure is appropriate, (2) the percentage ownership of common stock, (3) the difference, if any, between the carrying amount of an investment and the value of the underlying equity in the net assets and the accounting treatment of difference, if any, and (4) the aggregate value of each identified investment based on its quoted market price, if available.",
        "label": "Schedule of Equity Method Investments [Table]",
        "terseLabel": "Schedule of Equity Method Investments [Table]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r208",
      "r212"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsOtherNoncurrentLiabilitiesDetail",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsDetail",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsFootnotesDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedIntangibleAssetsPercentageOfTotalIntangiblesDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillNarrativeDetail",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetImpairedIntangibleAssetsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r208",
      "r212"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfGoodwillTable": {
     "auth_ref": [
      "r204",
      "r205"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.",
        "label": "Schedule of Goodwill [Table]",
        "terseLabel": "Schedule of Goodwill [Table]"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTable",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillGoodwillDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "auth_ref": [
      "r204",
      "r205"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.",
        "label": "Schedule of Goodwill [Table Text Block]",
        "terseLabel": "Schedule of Goodwill"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfImpairedIntangibleAssetsTextBlock": {
     "auth_ref": [
      "r218"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of impaired intangible assets excluding goodwill. This may include a description of the facts and circumstances leading to the recording of impairment charges of intangible assets in the period, the amount of the impairment charges, the methods of determining fair value of the associated assets, the caption in the income statement in which the impairment losses are aggregated, and the segment in which the impaired intangible assets are reported.",
        "label": "Schedule of Impaired Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of Impaired Intangible Assets"
       }
      }
     },
     "localname": "ScheduleOfImpairedIntangibleAssetsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r215",
      "r217"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity.",
        "label": "Schedule of Indefinite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Indefinite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsDetail",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillIndefiniteLivedIntangibleAssetsPercentageOfTotalIntangiblesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r215",
      "r217"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.",
        "label": "Schedule of Indefinite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of Indefinite Lived Intangible Assets"
       }
      }
     },
     "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r18",
      "r41",
      "r42",
      "r43"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of Components of Inventories, Current"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/InventoriesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock": {
     "auth_ref": [
      "r18",
      "r41",
      "r42",
      "r43",
      "r44"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle including inventoried costs relating to long-term contracts or programs.",
        "label": "Schedule of Inventory, Noncurrent [Table Text Block]",
        "terseLabel": "Schedule of Components of Inventories, Noncurrent"
       }
      }
     },
     "localname": "ScheduleOfInventoryNoncurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/InventoriesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInvestmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Schedule of Investments [Line Items]",
        "terseLabel": "Total Debt Securities [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfInvestmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsInDebtSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfInvestmentsTable": {
     "auth_ref": [
      "r451"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A container table for all schedule of investment items. It ties in the \"Legal Entity [Axis]\" to all of its contained line items.",
        "label": "Schedule of Investments [Table]",
        "terseLabel": "Schedule of Investments [Table]"
       }
      }
     },
     "localname": "ScheduleOfInvestmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsInDebtSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r255"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the combined aggregate amount of maturities and sinking fund requirements for all long-term borrowings for each of the five years following the date of the latest balance sheet date presented.",
        "label": "Schedule of Maturities of Long-term Debt [Table Text Block]",
        "terseLabel": "Maturity Schedule of Long-term Debt Outstanding"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNetBenefitCostsTableTextBlock": {
     "auth_ref": [
      "r281"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments.",
        "label": "Schedule of Net Benefit Costs [Table Text Block]",
        "terseLabel": "Schedule of Net Periodic Benefit Costs"
       }
      }
     },
     "localname": "ScheduleOfNetBenefitCostsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.",
        "label": "Schedule of Other Nonoperating Income (Expense) [Table Text Block]",
        "terseLabel": "Schedule of Other (Income)/Deductions - Net"
       }
      }
     },
     "localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "auth_ref": [
      "r230",
      "r231",
      "r234"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.",
        "label": "Schedule of Restructuring and Related Costs [Table]",
        "terseLabel": "Schedule of Restructuring and Related Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesDetail",
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesFootnotesDetails",
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesRestructuringAccrualsDetail",
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesRestructuringAccrualsFootnotesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": {
     "auth_ref": [
      "r230",
      "r231",
      "r234"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.",
        "label": "Restructuring and Related Costs [Table Text Block]",
        "terseLabel": "Schedule of Components of Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": {
     "auth_ref": [
      "r229",
      "r235"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.",
        "label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]",
        "terseLabel": "Schedule of Components of and Changes in Restructuring Accruals"
       }
      }
     },
     "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": {
     "auth_ref": [
      "r92",
      "r94",
      "r170"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material.  An entity may also provide subtotals of geographic information about groups of countries.",
        "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]",
        "terseLabel": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByGeographicAreaDetail",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByGeographicAreaFootnotesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "auth_ref": [
      "r160",
      "r161",
      "r162",
      "r165",
      "r204"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationDetail",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationFootnotesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShortTermDebtTable": {
     "auth_ref": [
      "r50"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.",
        "label": "Schedule of Short-term Debt [Table]",
        "terseLabel": "Schedule of Short-term Debt [Table]"
       }
      }
     },
     "localname": "ScheduleOfShortTermDebtTable",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SecuritiesReceivedAsCollateral": {
     "auth_ref": [
      "r401",
      "r404"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The carrying value as of the balance sheet date of the assets received as collateral against securities loaned to other broker-dealers. Borrowers of securities generally are required to provide collateral to the lenders of securities, commonly cash but sometimes other securities or standby letters of credit, with a value slightly higher than that of the securities borrowed. In instances where the entity is permitted to sell or re-pledge these securities, the entity reports the fair value of the collateral received and the related obligation to return the collateral as a liability.",
        "label": "Securities Received as Collateral",
        "terseLabel": "Cash collateral received"
       }
      }
     },
     "localname": "SecuritiesReceivedAsCollateral",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsNarrativeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SegmentDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Segments [Domain]",
        "terseLabel": "Segments [Domain]"
       }
      }
     },
     "localname": "SegmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedIntangibleAssetsPercentageOfTotalIntangiblesDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillGoodwillDetail",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillIndefiniteLivedIntangibleAssetsPercentageOfTotalIntangiblesDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail",
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesFootnotesDetails",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationDetail",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationFootnotesDetail",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentGeographicalDomain": {
     "auth_ref": [
      "r0",
      "r170",
      "r453"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Geographical area.",
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsOtherNoncurrentLiabilitiesDetail",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByGeographicAreaDetail",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByGeographicAreaFootnotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r171"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "Segment, Geographic and Other Revenue Information"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting Information [Line Items]",
        "terseLabel": "Segment Reporting Information [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationDetail",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationFootnotesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r104",
      "r195"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfIncome": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, informational and administrative expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [
      "r109"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "terseLabel": "Selling, Informational and Administrative Expenses [Member]"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeniorNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors.",
        "label": "Senior Notes [Member]",
        "terseLabel": "Senior Notes [Member]"
       }
      }
     },
     "localname": "SeniorNotesMember",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SettledLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Agreement reached between parties in a litigation that occurs without judicial intervention, supervision or approval.",
        "label": "Settled Litigation [Member]",
        "terseLabel": "Settled Litigation [Member]"
       }
      }
     },
     "localname": "SettledLitigationMember",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CommitmentsAndContingenciesActionsInWhichWeAreDefendantDetail",
      "http://www.pfizer.com/role/CommitmentsAndContingenciesActionsInWhichWeArePlaintiffDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeveranceCosts1": {
     "auth_ref": [
      "r126",
      "r228",
      "r232",
      "r236"
     ],
     "calculation": {
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_RestructuringCharges",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.",
        "label": "Severance Costs",
        "terseLabel": "Employee terminations"
       }
      }
     },
     "localname": "SeveranceCosts1",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r125"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.",
        "label": "Share-based Compensation",
        "terseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareRepurchaseProgramAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by share repurchase program.",
        "label": "Share Repurchase Program [Axis]",
        "terseLabel": "Share Repurchase Program [Axis]"
       }
      }
     },
     "localname": "ShareRepurchaseProgramAxis",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareRepurchaseProgramDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the share repurchase program.",
        "label": "Share Repurchase Program [Domain]",
        "terseLabel": "Share Repurchase Program [Domain]"
       }
      }
     },
     "localname": "ShareRepurchaseProgramDomain",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShortTermBorrowingsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Short-term Debt [Abstract]",
        "terseLabel": "Short-term borrowings:"
       }
      }
     },
     "localname": "ShortTermBorrowingsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermDebtLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Short-term Debt [Line Items]",
        "terseLabel": "Short-term Debt [Line Items]"
       }
      }
     },
     "localname": "ShortTermDebtLineItems",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt arrangement having an initial term within one year or the normal operating cycle, if longer.",
        "label": "Short-term Debt [Member]",
        "verboseLabel": "Short-term Debt [Member]"
       }
      }
     },
     "localname": "ShortTermDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShortTermDebtTypeAxis": {
     "auth_ref": [
      "r50"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of short-term debt arrangement.",
        "label": "Short-term Debt, Type [Axis]",
        "terseLabel": "Short-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "ShortTermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail",
      "http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermDebtTypeDomain": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing.",
        "label": "Short-term Debt, Type [Domain]",
        "terseLabel": "Short-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "ShortTermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail",
      "http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShortTermInvestments": {
     "auth_ref": [
      "r24",
      "r412",
      "r413",
      "r414",
      "r431"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.",
        "label": "Short-term Investments",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "ShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShortTermInvestmentsMember": {
     "auth_ref": [
      "r412",
      "r413",
      "r431",
      "r448"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet.",
        "label": "Short-term Investments [Member]",
        "terseLabel": "Short-term Investments [Member]"
       }
      }
     },
     "localname": "ShortTermInvestmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsBalanceSheetGroupingDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "auth_ref": [
      "r159"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by business segments.",
        "label": "Segments [Axis]",
        "terseLabel": "Segments [Axis]"
       }
      }
     },
     "localname": "StatementBusinessSegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedIntangibleAssetsPercentageOfTotalIntangiblesDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillGoodwillDetail",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillIndefiniteLivedIntangibleAssetsPercentageOfTotalIntangiblesDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail",
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesFootnotesDetails",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationDetail",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationFootnotesDetail",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r61",
      "r257"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementGeographicalAxis": {
     "auth_ref": [
      "r0",
      "r170",
      "r266",
      "r268",
      "r453"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by geographical components.",
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsOtherNoncurrentLiabilitiesDetail",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByGeographicAreaDetail",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByGeographicAreaFootnotesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlowsParenthetical",
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementScenarioAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by scenario to be reported. Scenarios distinguish among different kinds of business reporting facts, as for example actual versus budgeted figures.",
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsAstrazenecaDetails",
      "http://www.pfizer.com/role/CommitmentsAndContingenciesDetails",
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesDetail",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationFootnotesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlowsParenthetical",
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).",
        "label": "Equity Option [Member]",
        "terseLabel": "Equity Option [Member]"
       }
      }
     },
     "localname": "StockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributableToCommonShareholdersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockRepurchaseProgramAuthorizedAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Authorized Amount",
        "terseLabel": "Share repurchase agreement, amount"
       }
      }
     },
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount remaining of a stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount",
        "terseLabel": "Remaining authorized repurchase amount"
       }
      }
     },
     "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r29",
      "r33",
      "r34",
      "r173"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance, October 1, 2017",
        "periodStartLabel": "Balance, December 31, 2016",
        "totalLabel": "Total Pfizer Inc. shareholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetail",
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r327",
      "r328",
      "r337"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Total equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsegmentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by business subsegments.",
        "label": "Subsegments [Axis]",
        "terseLabel": "Subsegments [Axis]"
       }
      }
     },
     "localname": "SubsegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedIntangibleAssetsPercentageOfTotalIntangiblesDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillIndefiniteLivedIntangibleAssetsPercentageOfTotalIntangiblesDetails",
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesFootnotesDetails",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationFootnotesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsegmentsDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Divisions of a component of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Subsegments [Domain]",
        "terseLabel": "Subsegments [Domain]"
       }
      }
     },
     "localname": "SubsegmentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedIntangibleAssetsPercentageOfTotalIntangiblesDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillIndefiniteLivedIntangibleAssetsPercentageOfTotalIntangiblesDetails",
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesFootnotesDetails",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationFootnotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event [Member]"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CommitmentsAndContingenciesActionsInWhichWeAreDefendantDetail",
      "http://www.pfizer.com/role/CommitmentsAndContingenciesActionsInWhichWeArePlaintiffDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r400"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CommitmentsAndContingenciesActionsInWhichWeAreDefendantDetail",
      "http://www.pfizer.com/role/CommitmentsAndContingenciesActionsInWhichWeArePlaintiffDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r400"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CommitmentsAndContingenciesActionsInWhichWeAreDefendantDetail",
      "http://www.pfizer.com/role/CommitmentsAndContingenciesActionsInWhichWeArePlaintiffDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Cash paid (received) during the period for:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Plan designed to provide limited group of employees with supplemental retirement benefits, in addition to other pension benefits. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Supplemental Employee Retirement Plan [Member]",
        "terseLabel": "Supplemental Employee Retirement Plan [Member]"
       }
      }
     },
     "localname": "SupplementalEmployeeRetirementPlanDefinedBenefitMember",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansDetail",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansNetPeriodicBenefitCostDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TaxesPayableCurrent": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Taxes Payable, Current",
        "terseLabel": "Income taxes payable"
       }
      }
     },
     "localname": "TaxesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TechnologySectorMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sector of the economy consisting of companies engaged in technology-related business activities.",
        "label": "Technology Sector [Member]",
        "terseLabel": "Technology sector [Member]"
       }
      }
     },
     "localname": "TechnologySectorMember",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TradeNamesMember": {
     "auth_ref": [
      "r318"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof.",
        "label": "Trade Names [Member]",
        "verboseLabel": "Brands [Member]"
       }
      }
     },
     "localname": "TradeNamesMember",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsDetail",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedIntangibleAssetsPercentageOfTotalIntangiblesDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillIndefiniteLivedIntangibleAssetsPercentageOfTotalIntangiblesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TradingSecurities": {
     "auth_ref": [
      "r178",
      "r180",
      "r416"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_InvestmentsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investments in debt and equity securities and other forms of securities that provide ownership interests classified as trading.",
        "label": "Trading Securities",
        "terseLabel": "Trading funds and securities"
       }
      }
     },
     "localname": "TradingSecurities",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TradingSecuritiesDebt": {
     "auth_ref": [
      "r178",
      "r180",
      "r416",
      "r440"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investments in debt securities classified as trading.",
        "label": "Trading Securities, Debt",
        "verboseLabel": "Trading debt funds"
       }
      }
     },
     "localname": "TradingSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsAssetsAndLiabilitiesMeasuredOnRecurringBasisFootnotesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TradingSecuritiesEquity": {
     "auth_ref": [
      "r53",
      "r178",
      "r180",
      "r416",
      "r439"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of investments in trading equity securities and other forms of trading securities that provide ownership interests.",
        "label": "Trading Securities, Equity",
        "verboseLabel": "Trading equity funds"
       }
      }
     },
     "localname": "TradingSecuritiesEquity",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsAssetsAndLiabilitiesMeasuredOnRecurringBasisFootnotesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TradingSecuritiesRestricted": {
     "auth_ref": [
      "r139",
      "r178",
      "r180",
      "r403",
      "r412",
      "r432",
      "r449",
      "r451"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all securities that are purchased with the intent to be sold in the short-term and that are pledged to one or more secured parties who have the right to buy, sell, or re-pledge the collateral.",
        "label": "Trading Securities, Restricted",
        "terseLabel": "Trading securities held in trust"
       }
      }
     },
     "localname": "TradingSecuritiesRestricted",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsAssetsAndLiabilitiesMeasuredOnRecurringBasisFootnotesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockAcquiredAverageCostPerShare": {
     "auth_ref": [
      "r264"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total cost of shares repurchased divided by the total number of shares repurchased.",
        "label": "Treasury Stock Acquired, Average Cost Per Share",
        "terseLabel": "Average price paid for shares delivered under agreement (in dollars per share)"
       }
      }
     },
     "localname": "TreasuryStockAcquiredAverageCostPerShare",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_TreasuryStockSharesAcquired": {
     "auth_ref": [
      "r29",
      "r257",
      "r262"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.",
        "label": "Treasury Stock, Shares, Acquired",
        "terseLabel": "Shares repurchased"
       }
      }
     },
     "localname": "TreasuryStockSharesAcquired",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockValue": {
     "auth_ref": [
      "r60",
      "r264",
      "r265"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.",
        "label": "Treasury Stock, Value",
        "negatedLabel": "Treasury stock"
       }
      }
     },
     "localname": "TreasuryStockValue",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Adoption and early adoption of sources of change to generally accepted accounting principles (GAAP) in the United States. The FASB released the FASB Accounting Standards Codification as the authoritative source of literature effective for interim and annual periods ending after September 15, 2009. As part of the Codification process, the FASB issues Accounting Standards Updates to amend the Codification but otherwise the Accounting Standards Updates are not authoritative in their own right. All previous accounting standards (such as FASB Statements of Financial Accounting Standards, FASB Interpretations, FASB Staff Positions, Emerging Issues Task Force Consensuses, other pronouncements of the FASB or other designated bodies, or other forms of GAAP are considered accounting pronouncements) were superseded upon the adoption of the Codification. For an interim period, references to the superseded standards are included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.",
        "label": "Type of Adoption [Domain]",
        "terseLabel": "Type of Adoption [Domain]"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r326"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by category of arrangement, including but not limited to collaborative arrangements and non-collaborative arrangements.",
        "label": "Type of Arrangement and Non-arrangement Transactions [Axis]",
        "terseLabel": "Type of Arrangement and Non-arrangement Transactions [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsCollaborationArrangementDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identification of the types of restructuring costs.",
        "label": "Type of Restructuring [Domain]",
        "terseLabel": "Type of Restructuring [Domain]"
       }
      }
     },
     "localname": "TypeOfRestructuringDomain",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesDetail",
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesRestructuringAccrualsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USGovernmentDebtSecuritiesMember": {
     "auth_ref": [
      "r417"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt securities issued by the United States government.",
        "label": "US Government Debt Securities [Member]",
        "terseLabel": "U.S. government debt [Member]"
       }
      }
     },
     "localname": "USGovernmentDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsInDebtSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrealizedLossOnForeignCurrencyDerivativesBeforeTax": {
     "auth_ref": [
      "r355"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of unrealized loss recorded in accumulated other comprehensive income pertaining to the decrease in fair value of foreign currency exchange rate derivatives designated as cash flow hedging instruments to the extent that a cash flow hedge is determined to be effective.",
        "label": "Unrealized Loss on Foreign Currency Derivatives, before Tax",
        "terseLabel": "Pre-tax loss on foreign currency forward exchange contracts"
       }
      }
     },
     "localname": "UnrealizedLossOnForeignCurrencyDerivativesBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnsecuredDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt obligation not collateralized by pledge of, mortgage of or other lien on the entity's assets.",
        "label": "Unsecured Debt [Member]",
        "terseLabel": "Unsecured Debt [Member]"
       }
      }
     },
     "localname": "UnsecuredDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsSaleOfHospiraInfusionSystemsNetAssetsToIcuMedicalIncEhDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsSaleOfHospiraInfusionSystemsNetAssetsCollaborativeArrangementAndEquityMethodInvestmentsSaleOfHospiraInfusionSystemsNetAssetsToIcuMedicalIncEhDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "auth_ref": [
      "r150"
     ],
     "calculation": {
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributableToCommonShareholdersDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.",
        "label": "Weighted Average Number Diluted Shares Outstanding Adjustment",
        "terseLabel": "Common-share equivalents: stock options, stock issuable under employee compensation plans, convertible preferred stock and accelerated share repurchase agreements (shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributableToCommonShareholdersDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r147",
      "r150"
     ],
     "calculation": {
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributableToCommonShareholdersDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average shares\u2013\u2013diluted",
        "totalLabel": "Weighted-average number of common shares outstanding\u2013\u2013Diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfIncome",
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributableToCommonShareholdersDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "EPS Denominator"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributableToCommonShareholdersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r145",
      "r150"
     ],
     "calculation": {
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributableToCommonShareholdersDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average number of common shares outstanding\u2013\u2013Basic",
        "verboseLabel": "Weighted-average shares\u2013\u2013basic"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CondensedConsolidatedStatementsOfIncome",
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributableToCommonShareholdersDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 11
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-04.(c) Schedule III)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=27047687&loc=d3e5864-122674"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=65878427&loc=d3e1107-107759"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=64827811&loc=SL51721675-107760"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1(a))",
   "Topic": "225",
   "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1(e))",
   "Topic": "225",
   "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.13)",
   "Topic": "225",
   "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a))",
   "Topic": "225",
   "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "225",
   "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(a))",
   "Topic": "225",
   "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "225",
   "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7,9)",
   "Topic": "225",
   "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "225",
   "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "225",
   "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98514028&loc=d3e3179-108585"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98514028&loc=d3e3179-108585"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a),(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98514028&loc=d3e3213-108585"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98514028&loc=d3e3213-108585"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98514028&loc=d3e3213-108585"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98514028&loc=d3e3213-108585"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98514028&loc=d3e3213-108585"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98514028&loc=d3e3255-108585"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98514028&loc=d3e3255-108585"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98514028&loc=d3e3291-108585"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98514028&loc=d3e3291-108585"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98514028&loc=d3e3521-108585"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98514028&loc=d3e3536-108585"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98514028&loc=d3e3536-108585"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98514028&loc=d3e3574-108585"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98514028&loc=d3e3602-108585"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98514028&loc=d3e3602-108585"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98514028&loc=d3e3602-108585"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98514028&loc=d3e3044-108585"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98514028&loc=d3e3095-108585"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98514028&loc=d3e3098-108585"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98514028&loc=d3e3098-108585"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98514028&loc=d3e3098-108585"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4297-108586"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(e),(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(m)(1)(i)(B)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6801-107765"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04.(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=64853466&loc=d3e22499-107794"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=64853466&loc=d3e22580-107794"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=64853466&loc=d3e22583-107794"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=96947427&loc=d3e1448-109256"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=96947427&loc=d3e1377-109256"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=96947427&loc=d3e1505-109256"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=96947427&loc=d3e1252-109256"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=96947427&loc=d3e1278-109256"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6904-107765"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=96948231&loc=d3e4984-109258"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=84177426&loc=d3e6327-108592"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=84177426&loc=d3e6351-108592"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=84177426&loc=d3e6404-108592"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=84177426&loc=d3e6442-108592"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=68060357&loc=d3e8538-108599"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6911-107765"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=68060357&loc=d3e8721-108599"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=68060357&loc=d3e8736-108599"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=68060357&loc=d3e8813-108599"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=68060357&loc=d3e8906-108599"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=68060357&loc=d3e8906-108599"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=68060357&loc=d3e8906-108599"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=68060357&loc=d3e8924-108599"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=68060357&loc=d3e8475-108599"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=68060357&loc=d3e9031-108599"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "a",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=68060357&loc=d3e9038-108599"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6935-107765"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=68060357&loc=d3e9038-108599"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "http://asc.fasb.org/topic&trid=2134510"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84173941&loc=d3e5074-111524"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=75030427&loc=d3e22054-111558"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=75030427&loc=d3e22054-111558"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=75030427&loc=d3e22054-111558"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=82895926&loc=d3e24584-111560"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=82896770&loc=d3e26610-111562"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=82896770&loc=d3e26853-111562"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=82896770&loc=d3e26626-111562"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27232-111563"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27232-111563"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27232-111563"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27232-111563"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27357-111563"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=99375318&loc=d3e32787-111569"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=66022249&loc=d3e33749-111570"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=66022249&loc=d3e33775-111570"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=66011266&loc=d3e33918-111571"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(b)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=66011266&loc=d3e33918-111571"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=68048583&loc=d3e3636-108311"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=68049868&loc=d3e3927-108312"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388280&loc=d3e13770-109266"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=65878427&loc=SL51721533-107759"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=77989000&loc=SL49117168-202975"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=35741047&loc=d3e13854-109267"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b),(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=68055307&loc=d3e2420-110228"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=68055307&loc=d3e2443-110228"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=68055307&loc=d3e2473-110228"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=84176398&loc=d3e2941-110230"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=84176398&loc=d3e2941-110230"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=84176398&loc=d3e2941-110230"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.3)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=27011515&loc=d3e140864-122747"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=27011515&loc=d3e140864-122747"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4(b))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=27011515&loc=d3e140904-122747"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=27011515&loc=d3e140904-122747"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=27011515&loc=d3e140904-122747"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=27011515&loc=d3e140904-122747"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "420",
   "URI": "http://asc.fasb.org/topic&trid=2175745"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=82911808&loc=d3e14326-108349"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=82911808&loc=d3e14615-108349"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=82911808&loc=d3e14394-108349"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=82911808&loc=d3e14435-108349"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=82911808&loc=d3e14435-108349"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=82911808&loc=d3e14435-108349"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=82911808&loc=d3e14453-108349"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=82911808&loc=d3e14472-108349"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=82911808&loc=d3e14557-108349"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=82911808&loc=d3e14557-108349"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=6396582&loc=d3e14981-108350"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=6397426&loc=d3e17499-108355"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=82913245&loc=d3e12021-110248"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=82913245&loc=d3e12053-110248"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=84159872&loc=d3e21463-112644"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=84159872&loc=d3e21475-112644"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=84159872&loc=d3e21506-112644"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=84159872&loc=d3e21521-112644"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=84159872&loc=d3e21538-112644"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405686&loc=d3e22802-112653"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=82913847&loc=SL49130545-203045"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=96862333&loc=SL49130690-203046-203046"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=96862333&loc=SL49130690-203046-203046"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "610",
   "URI": "http://asc.fasb.org/topic&trid=49130413"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "712",
   "URI": "http://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "712",
   "URI": "http://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=64852052&loc=d3e1703-114919"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=64852052&loc=d3e1731-114919"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=82843861&loc=d3e1928-114920"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(10)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=82843861&loc=d3e1928-114920"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=82843861&loc=d3e1928-114920"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=82843861&loc=d3e1928-114920"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=82843861&loc=d3e1928-114920"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(5)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=82843861&loc=d3e1928-114920"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(5)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=82843861&loc=d3e1928-114920"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=82843861&loc=d3e1928-114920"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=82843861&loc=d3e1928-114920"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=82843861&loc=d3e1928-114920"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=82843861&loc=d3e1928-114920"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=82843861&loc=d3e1928-114920"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=82843861&loc=d3e1928-114920"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=82843861&loc=d3e1928-114920"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=82843861&loc=d3e1928-114920"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i),(j)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=82843861&loc=d3e1928-114920"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=82843861&loc=d3e1928-114920"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=82843861&loc=d3e2410-114920"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=82843861&loc=d3e2417-114920"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=82843861&loc=d3e2439-114920"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=82843861&loc=d3e2709-114920"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=77993564&loc=d3e4179-114921"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "http://asc.fasb.org/topic&trid=2235017"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=96867065&loc=SL79508275-113901"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "720",
   "URI": "http://asc.fasb.org/topic&trid=2122503"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=65878427&loc=d3e957-107759"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84176650&loc=d3e31917-109318"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84176650&loc=d3e31931-109318"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=79507043&loc=d3e39076-109324"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=84161108&loc=d3e4845-128472"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=84161108&loc=SL65897772-128472"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5263-128473"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5504-128473"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911251&loc=d3e6578-128477"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911251&loc=d3e6613-128477"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911338&loc=d3e6819-128478"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=96868048&loc=SL4568447-111683"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=96868048&loc=SL4568740-111683"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=96868048&loc=SL4613673-111683"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=96868048&loc=SL4569616-111683"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=96868048&loc=SL4569643-111683"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=96868048&loc=SL4613674-111683"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=84161450&loc=SL4573702-111684"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=84161450&loc=SL4573702-111684"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=84161450&loc=SL4573702-111684"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=84161450&loc=SL4573702-111684"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=84234705&loc=SL4590271-111686"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=84234705&loc=SL4591551-111686"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=84234705&loc=SL4591552-111686"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.E)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=27015204&loc=d3e355146-122828"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=6945355&loc=d3e41228-113958"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=6945355&loc=d3e41271-113958"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=84234895&loc=SL5579245-113959"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=84234895&loc=SL5580258-113959"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(ii)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=84234895&loc=d3e41620-113959"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(iii)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=84234895&loc=d3e41620-113959"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=84234895&loc=d3e41620-113959"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "c",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=84234895&loc=d3e41638-113959"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=84234895&loc=SL5618551-113959"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=84234895&loc=SL5618551-113959"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=84234895&loc=SL5624163-113959"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=84234895&loc=SL5624163-113959"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=84234895&loc=SL5624163-113959"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(c),(d),(e)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=84234895&loc=SL5624171-113959"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=84234895&loc=SL5624171-113959"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=84234895&loc=SL5624171-113959"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=84234895&loc=SL5624171-113959"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=84234895&loc=SL5624171-113959"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=84234895&loc=SL5624177-113959"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=84234895&loc=SL5624177-113959"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=84234895&loc=SL5624181-113959"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=84234895&loc=SL5624258-113959"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=84234895&loc=SL5624258-113959"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "182",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=95459573&loc=SL5629052-113961"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=6886632&loc=d3e76258-113986"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=6441202&loc=d3e80720-113993"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=35736893&loc=d3e80748-113994"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "48",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=65894324&loc=d3e18349-110257"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=66048111&loc=d3e19190-110258"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=66048111&loc=d3e19190-110258"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=66048111&loc=d3e19207-110258"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=66048111&loc=d3e19207-110258"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=66048111&loc=d3e19207-110258"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=66048111&loc=d3e19207-110258"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=66048111&loc=d3e19207-110258"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=66048111&loc=SL7498348-110258"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=66048111&loc=d3e19279-110258"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=66048111&loc=SL6742756-110258"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75026489&loc=d3e13217-108610"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75026489&loc=d3e13220-108610"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=77997519&loc=d3e13433-108611"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=77997519&loc=d3e13467-108611"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=77997519&loc=d3e13476-108611"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=77997519&loc=d3e13495-108611"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=77997519&loc=d3e13531-108611"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=77997519&loc=d3e13537-108611"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=77997519&loc=d3e13537-108611"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14172-108612"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=82918529&loc=d3e30304-110892"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=64808268&loc=d3e32022-110900"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=64808268&loc=d3e32211-110900"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b,d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=64808268&loc=d3e32211-110900"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=64808268&loc=d3e32211-110900"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=64930785&loc=d3e28541-108399"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=64930785&loc=d3e28551-108399"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=64930785&loc=d3e28555-108399"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=64930739&loc=d3e28878-108400"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=65878427&loc=SL51721523-107759"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(5))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=64836671&loc=d3e93645-111703"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=82924980&loc=SL51823488-111719"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=64858031&loc=SL6224234-111729"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(4))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.4)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.6(a)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.6)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.7(a)(3))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "225",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "225",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "225",
   "Subparagraph": "(SX 210.9-04(20))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "225",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "225",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "225",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)-(g)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62557-112803"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62557-112803"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(b))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),1(b))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(d))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "225",
   "Subparagraph": "(SX 210.7-04(11))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "225",
   "Subparagraph": "(SX 210.7-04(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "225",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "225",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "225",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6484115&loc=d3e19393-158473"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(f))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=6488002&loc=d3e600178-122990"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S35",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=6488548&loc=SL6090579-123006"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12)",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611133-123010"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15)",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611379-123010"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28)",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=6590653&loc=d3e638233-123024"
  },
  "r454": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12b",
   "Subsection": "1"
  },
  "r455": {
   "Article": "12",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "13",
   "Sentence": "Column B"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=65878427&loc=SL51721525-107759"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.2)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=65878427&loc=d3e1012-107759"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(d))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=64827811&loc=d3e1361-107760"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82849420&loc=SL20226008-175313"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82849420&loc=SL20226000-175313"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=84228862&loc=SL7669646-108580"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a),(b),(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=84228862&loc=SL7669646-108580"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=84228862&loc=SL7669646-108580"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=84228862&loc=SL7669646-108580"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e),(f),(h)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=84228862&loc=SL7669646-108580"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e,f)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=84228862&loc=SL7669646-108580"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=84228862&loc=SL7669646-108580"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=84228862&loc=SL7669646-108580"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=64827811&loc=SL51721673-107760"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=84228862&loc=SL7669646-108580"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=84228862&loc=d3e637-108580"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=84228862&loc=d3e640-108580"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=84228862&loc=d3e681-108580"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=84228862&loc=SL7669686-108580"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=84228862&loc=d3e689-108580"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=84228862&loc=d3e709-108580"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=84228862&loc=SL7669619-108580"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=84228862&loc=SL7669625-108580"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=84228862&loc=d3e557-108580"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=64827811&loc=SL51721673-107760"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=84158357&loc=d3e1436-108581"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "220",
   "URI": "http://asc.fasb.org/topic&trid=2134417"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-03(e))",
   "Topic": "225",
   "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20187-122688"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(13))",
   "Topic": "225",
   "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20187-122688"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "225",
   "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "225",
   "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(14))",
   "Topic": "225",
   "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "225",
   "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "225",
   "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "225",
   "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688"
  }
 },
 "version": "2.0"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>106
<FILENAME>0000078003-17-000049-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000078003-17-000049-xbrl.zip
M4$L#!!0    ( -: :4N:]*WZR^L% +3O8  4    <&9E+3$P,#$R,#$W>#$P
M<2YH=&WLO5M[VT:R+GR]]Z_PY^M/,<Z'[(SW@Z.C69:M2'8FDYL\$-F2D(
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M0KK*$EI! (%CX)03A_L'SN0NLR3VI:K? ^7?$+O2O=A#R0P-R_;L4 69NCK
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M.XC#!KPQ_)4&O' GJ[V<DGS4O+O1Z"[+OCP")QZ3Z20>%#W2@:J7:T\?K%J
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MJMYR*\=:]9H8M!X(6O^3@7@H6U[6:$8;-9KPKP])=A<E"_[,;=$LNW'M:V=
MU- 7$SF<*CP+B9SNHY;6M!D1OFN%YP3AF; )C.39B>2[/WF@'DBB0HB $*WF
ML3&U(TQJAZ-2:*J9'KQB'B6+JH'L?H4-0">NDVARG^6C<)H.=K6Y%GW5L*I
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MQDB9V@2$1P5!UX=OQ]3/YAL+JH-LFD[RYS^^WE9<]"7Z3H%FNLE8?IE&"57
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MO*RS$%*/=>/(=Q=-)6ZGXQR,A.;9HZ3G\%#QKB)-^7+\&@T_+>1Q!6':0_1
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M?SC,MC&Q_(<(APB'"(<(U]- ZY3U!+8#+4SL8]#'5M"'*7(A4N2OP#YD6.)
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M:\[-?>]["K&$>))Z!& W\)91TF_MV/>:0BC'MN- S>A4,]J+%M!#=.PA6CP
M&6V:$9L^<Q"(-LV.39\YP/.RM,B2>#C;OG8)XMB,XS[#S6=%[TO1;-4XM%-)
M(0;P[)Z*TG;"W7/14.D$%_4=/& SVP9[SKI/--/SFRG#Q:AHG(>,\PH$E,/;
MWQ"XRR!.0$EF@]JTT>E=L6V5U_?Q/R0O_I.!^+^!K2R!/.)X;?>0E>Z?"@&,
M=5,/YN991Q'07)M<)$?[Y,8^ZZSTH$$*1&Y[D1-!=HO)(M:21=7.$@-.=O-"
MY_*3&&7R9X;H&D6T0_2'S=-5-$+N^"D:(!H@DE$1[0^)*!?% ^@8L7H /6:=
M)8_F0TA<]FAOV8.Y4!*7/KHVS)HN%:V5 VMMU;6B"7?44Y'+9F(,K_/UN(78
MCL[$-V02YS-.?)U$Z2UM&9GE&\>UK,\XJ+CH2_2=$NOIIEY_RM*_IU%"%69(
M1VVI\]8M7K2EGX['R>SC* E&XR1[)F3S$I]B(AFZ)(6_<.96#@K]V-,13O[.
MC3E;6]CN23O/$[QL<7_2G)_/#AGK [W5"O6  <W:$%QGQ21?C5N(C0XO^F,]
M+_7HA%=O3XDZ;()Z4(D:1/]?3H?^Z_E\]TQ-&0+Y'7/3$L(?FEJ1S+ 5$H9F
MB&;(LAEV3ZFJS1 I%2>4BJWS60YC^2I;E.4D?D@1FO= \RI?M"TKL:"2B;Y/
MF#9BWUXP;<16VJC[D^AJ&RZZ)W1//&HY)D?Y9O+=<YS:61F$2H1*[N+5VDL
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M=G!U=G^9P%QD<;'(L,\4J,F<1<WE2X?&V0_D/X]9 AJ; .N$R>0+'JJ,\Z#
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M"'/K(MTLB6[H@U K,=W[28:V*"  ]!L N#')[O/6[.X#^$#2;))GXQ.:XF'
MV;>M -O*@$%N)T$N%[L!I@-@>9B;9@TT.M\.4-8+L?"#CV0!GDZ!:+%Z"#R=
M0AANP5</L-^B-/H^_^,&TPK,I16Z;@3V4CU$RVET'ZDPORQQ8ETKH@?/24G6
MJG@90(ONJV?:S&M@Y2W3$0>6OO*2*.C:?2^+I7&1$?WYOF)Z7.(4+!QHZC"P
MZYP,R)!@*P?V$(61T\ V-40H3&$B:"@?IRM>O2Z7Y;)L*$WWD>:Y=UOWR.GT
M/RYE+2G%2!#</5:PD96JQ(HOV5,<_8-8@5A!O[:L#<)A!0<)LVX.Q9SE0)87
MG9PD0\C@</-H-53L40JQD$.PU-B)J?8;0N<IPT08<XFP;E+K&_J ::^>9C!P
MMU"?& ;N%D*D8*7:_[<H^2O+8\0(QC"BY7+_#35 =.BD^VL[<4<#]?Y)-(E2
M^F.0C3 082X0Z;[B_Z6""!69=-_'H-5,QJL1Y7?P=/<31!)$DNT#6TJ*(12"
M=,])6CVQI6:9($)#]]#0:MD?-T;;_=DN+!RS='"? )[0Q+)IG^N$IL/[ _!L
M*('PX]5A0S".KTG]U0T$D+Z'#67%0 3I;RJSJ=U%81X]C$Y8)T4DZ56440TH
M&PHB%*)TG\KDJQG2#4G&$6Y39 ])NN8D9<40#4&Z;Z?&2ZO6]:ES%3?"JG%&
MZS6Z;N9:4W/$*O'@@\5TNX$M2.*_IS$""WO TLD.M@UU$ XM.& L76]$^?4>
MWA0#'>8"G6ZVH92T0;3HIGMFP=&:#>9'&(4-S(\@@K"XC>V&A-%@DCGWOSVG
MDT=LQL-:>-+^7K:=&B%<A,)!@3EB!F(&8@8KF-%]27E[/*/V)MA)E [CY='J
MB!>,X47;>V%W:(-86,$$OV 4*_!X/,0(D8_'8Z+&%-MT<8<2K"0ZL4T7KJ8B
MEV 5)9!+B,0ENH\SVJS+PMI00?$$:T/9QB!A^,FK,2B8#O*XP!451)BM:M&R
M7@B'']US&$;C&VPNRB9<8'-1<=#A]3T],'MYWNPE7_F\[O/_?#6WO,[)*,KC
M-(Q&<;+M.=&DNE\0Z+KR>9>"B(8HW5<F\9(%#-*[G"3(J!ECU)T'X"6U$(YA
MLW%LV#$)_%E%F1MGXU?VM^W;^=E[<]=[A=:=L@M_@'=[>2<\:+.//A,/VA0U
M)\5RET@,R;L/R;&Y/)M&VU[:#5N[HHVWP@J$;NW*0>%+8XCR<U:,XSRZ3.^G
M=+9NGPN8(W3^[ '#OHD2S4"[=_D<]1;Z/9X\YMDH^O[["%L,,6C872^T[= /
MQ!,,(1 AF$$(C/L99.FMEMO@H7(]-6T\5$[4XIKV6GF\NKCF-Y+\&:7_X$HA
M8RN%75?7;.B%6(N%W9?[ME><5[&]!>V_:_L_RWX53@RP^P" Z?[ +DE)>/D;
MFBQC)MM^C\\-31 .([K/[#%_8LG'YSP>U-^[CKF!<^<&NFG)558'H5("W:-%
MFRF!TTY#\QXCD.IW^#$:Q_47$Y%=G#LAT,FA:+NT0BRFT7TZ@*_=OWC>$:.<
MH^MB!&'/.^I^0:+56 47-'L*(+B@*6KTTOF"1'4R-"NF27R/X0ICX4K+_;8V
MU$"L^*3[U9+V3D;#7=%]Q K<%2UJ7/+Z3GV-K:%@@-%]@''.51$^J#X?R<8#
MSAP]Z[D]*SH:9@MZZE+4ZYP\I5%.?Q#X>6+/3#2D7E'4/4HA%G)TG_IB<O$-
MR6KW9+6=Y31N:&OWD61+.:@3*G9OLU'T1/()NG7&W'K[);N;JB"6,V<")5C)
M-V'-+F\.'VMV!4N%&9M=KL7K4<U?B^CN%T,7F29LC7ZZVF%K=,R38.,TH;E6
MU[7*HC=.8R)4:^V HKT;IC!+TW66YJQ;GS!WPGT-\.5=3DDAVBUC=MMR#?"&
M&HB%#MV'O:UF5E]-_W^+DF@2I?3'(!LA_T?^__+\[A<*(EH P$;VM1U$:>KP
ME=MI B\:_9/A^2OL@0HCYZ]LZXA0N(),I6:B$ACT??W"$023OC.4LF((A2#=
M,Y/V4I.8"<%,"&9",$_:;*>W95<-7/A@'#8ZZOFV7S_$PA,FXA6."BN"^WOR
M/<LQ8,& 90M5-C1#M(A%&$Y2-V+Y+4K^RO(8J0=CU*/EB&5##9!A8"?[EUUE
MZ3QER"N8XQ7=;(O9T >AV$3WI=Y<KLQ"$)MG">('<_C!R*IL63]$PQ,.^ ?N
MW6<(.IB(4'#OOG"L@_DHQ2,)N<L)[BACCV9T$Z9L*H1HO((#Q.AV)?;7.'K(
MZ_?Z0&K1RW77LC8@NV!OE;6CFJXT>9X@1K"&$6V7=)6T0"QLZ'[UM-4*#,QW
M]CP0P7PG5F,PG._\0-)LDF?CN/X.-J0<?<MX;BN#6,R#B:CDM4B!YGMN\^5,
MJYG8/]62_\-8FVG+P5@;L:$S;,#=4SU'#=P]A7C"V>XI[$O%>/*NZTU4V)=*
MH.P=1B^]X"$8O0B3KV._]X-[=:T@0C"&$!U%*FM=$ XGNN_IP'PM\W5.G^QO
M#$*8"T*Z*67>T ?18@Z1>N&Z<5;$HSB)\J.QXC*]3\A@DD<W9 37XNF%[('&
MBUEM(1#9I11"(0<33.._QQQ'U]!.A/X>/<=&<7['Q\QUGWUK-9^/NP#[Y@5Q
M%Z!P^?KV*@I^C08T>U,CPB9/:933'P1^AA'0L^UD/R;GND[.;<YJ"V%VI5*(
ME:5C(NIF/DOW^_-3AD0#B<;B4(BU-@C%,L1:^;M/HM&(=K]+(1R\'(VF::TR
M@6 ZR.,"ZP18(QH')O;LX+&A%V)QC>[S=*URC5?7*7[*\J>H&"#O8(YW=%V@
MN*$9R$&8JRK +N^,  83E .[O(N3S6BUY@C/TQ6 :S#2R43H\W3YP)5NUE?"
MVZO@\NKJZZ<O\2"#BY%^,$8_6EY:V:T/R$/8JV5L98\$VG_7]H];I!E)/;9D
MD%Z6%M,1R>?W&$0YFB1K)EDU16B4?<WEX9DH_;%>/!-%+"[-?K<DW&_,($S@
M?F/!<*(]BG\"FU@VS"I=6E&/@,C1-7*T3S .:H=86,)$9-(2EN!^BCY"".ZG
M$'4G5JM=#$[<3W'B/F@L-NCGAHIN=GTS4%? !\_H&BVP1Q+"!?9(8H-=M%K?
M^.H=%#<D&4>X<9,]X.AZ T59,41#$ Y64[IF'#>$QI$9 @=SP-$-X]C0!\2+
M_N8SFMI1\>49_%N,!\.R!R",;*?84!"A$*7[G =[721PO:3K]9)VVD)PLHC!
MA(FREV9 ]]V]^VXG<<"-)V6C']-!.OSQ.0=R]6JGU]^^QV4!=>=K.NY[S(3;
M86/7W+DMJ4>>B1'ZV$FM+QNP(29%;:]"[U2L")+X[VF,Y;T(%G/&6E8'L=!"
ML'5S#P;EY/,)>_$Q@#UW +LU-T(%K$PL)C&^E<^#*&P2?X<?HW%<OW0%?7<O
M??<NK1#+A3.3[&(K)UV)([/M7)C9YH<8=%T2=XS"",56^$@QL(,XOT5I]'W^
MQPWB"^++B[;$V^HA%)HPDX+ 0TKYW*[&V&)=][%\YXWX,1KO.AH_2V=]3@+B
M[@VPO61:18\*-,"N#? L;28X,4#,2-6-#Y-H$J7TQR ;882($>++@VM>*(A0
M,2(?&:?.6MBY)"7AY6]( A@C >VWJ]O0!+%81_=Y)+Y8Q^_QY#'/1M'WWT?8
M"0))Q\O#O%_J!W(.YO9ZX5$U0C )/*J&A;0"TZ=BW) P&DPRY_ZWYW3RB#MA
M6#/A]H.!G1HA%F8PL1; ?!_)$_?.80QP[AB@FZ9.W6R>0\K?=F$;]G3J.WY@
M3R<L;N,J*?DQ'L>3+$<H80Y*NDY';F@&8@AS]4SL8$AP?T^^(X8@AKS<Z%_6
M#*$PA(G<:;DCUDIL'TCVD$?C1\I'5Z;HDR>29&,R#*8Y_.##!E]HQ/:KS;5A
MY[L)XTIJJ4$P(OE#G#Y<1?E?9(D2/5&#G>\FDAK\@FC0/1JPL5/EL!H,LFDZ
MR9__^'K;@WE?O,R/7V]%FNCC8!\G6B!@1__>5WLW$-C%".N,D\*Z&U),/M__
M)P,1]<KHJU]0I!7,$Y@]*D2?70$F?KH.]9C !7043.$"&XM*B L=XT+W!!(#
MQJX#1B;4 -<%&% #-K8\(4M@@R5PA N82.J5Y7M96F1)/)R=.W@)<IK7Z2P_
MOHIH96N4W!"XT2!. #!G@ZJ*?FX')(W@B39NLOKE\,]I,5G79*P'3.^*[2JA
MZ_OX'Y(7,UO\!OH IDFB?$"[SBW,E8Z'?RT&?DBRNRA9U*241O %5+NGX^W[
MY>?[YV.?$I]B,.797#]#U70V]>V;RK#8H-&H-HB$ZAO&/LUSD@[F-8"#Q3_^
M"+[>B! =EE\>D'_QKQ_A[9LV&PP_#_(+=#MLV0:ZG5ZYG78YYC2-YY9>/$8Y
M*<I*/R)1,<W)^\6CS#Y?WF7YV?J^]$8O;OH9OA[T,GWX8U'0N^O^=+)>#*SY
M1>ETVV0WGWX,?ZUYRVDQW'6_N,@T138A[/#KW_":Y+=4CN4;#^,GT,[R!-,K
M/DU'5")9V1:.?(C_M?$8FS<J?8-/TFP4IY7?L7_:-[]DZU[+CU:OME<N#W?C
M?8+^X%[7%+271/&H2M-F']:\81(]9%E:=<?YIS5O>0UV6FT.\T_K6IM/[@$!
MHNK;K@;4O/%B*BC;W#=3*SI6?>/X^X\Y26:NJGB,QV\ D/,LV72>=/P/6?[P
M3@&7^6XQXMU]-)A<W&?9),TFY.T;<&-_W>R_<G89'??V398/2?ZOM_+;-_=Y
M-KHA]\6_W@XUU31E2U>)+&NJ=?'MKPO:"N("G+6K>+)N.[:CF[YD2ZH2*(JN
M:;)DA:KU]LTDF]_A"^#H+4G(@+[.A1^80:@YAF&H@:ZXH>6KAB)9N@9W<6Q-
MOY!F7[%X@X/#_TCNDK?ONI:8\D)BDJF9Q-;5DKPT6=/A94S)T W3L31#U2W%
M]?70M S9KY*7Y2N.K4JJZBF!;OB!'5BR%DJ.JQJJ8@7!EKP.#6=#7B\UK#%Y
M!;;AJHZLVI[GZ$;@V9:JV*ZGFK+IRE*@;LGKT'"FY:6#D$H"LWS'5W0I!/.0
M)=]1-4.6/$,S=%.2 J]*8&!4ON'9M@22T"7'MU53TCW=D&17D4/-V!+8H>%,
M"TQ6+',M,-EP#=DV5<N!-]!@ZCW%<F"8J2N283C5&B;!!9KK>9*J!U[@PFU"
MQ34]6S,]U=NVR$/#V1!8!8(U)#!Q3-(VM9*/!&$9*L2TCA3JH12XNN-Y8:@[
M8*C@/,TJ@<&KAY*B^>!2P:%:AJ78EF&'AN=(B@>VO"6P0\/9$)AZ1H'IJNM:
MGA-ZCF;JGN39,%JV=4F7@"Y(RC:I.#2<#8%5D8HF!&;H/MB3JP:RHNN>JMNA
M;KJ>J6M2:,EZX&\)[-!P-@2V;9*&+5FF161@$"6!A9X:&*JC! &\AN$J0"P\
M604VZ82FIE0)S+057W5<1?6!AFA>Z+J*:1I.8(:&)IFNMB6P0\/9$-BVAAD6
MZ)A&@$.4!*8X@6SZGFL9!H"+['J6I >.%$B^Z;G5/-^6 ;L54U9"0]%-2W7#
M4#(DW?*#P/<\V=T2V*'A; CLA88U*3!%E1U/UUTK\'1PJ:ZGV;;N2J9MAI8I
MA=L".S"<48&9@&,VL?22O%0)2)&N^($$ &Q:K@QTPO$ETP^!)LF5O-4&S;"E
M /@!6+(K&;8MNY;N@0?T#,O5Y6UY'1C.IKP6H;=N64I)8'J@Z(X#[Z, \5(L
MX&">#[AL&6'H2G*5P#2@ZZ8J::%K!KJLAJYF @#ZMB,902C[VS3LT'!6!39S
MDIHLEYRDIFI D50YL%1=M1T;#,:PP$XM3='T:HL4(C):0)@JV7I)8!J%7E-U
M0EWW9=,V%,\%90!G9DF2Z[]9.U=%LM6CKQ/;5\RA3Y;,$O:!36F:9VDN8+<)
M9,YV=158J..!];FJ*SCVS?FN)95-V3,]*X!0)PAU&;#)]Q4S"!3?,13']'6A
M^&Y5@-"$P#S3LBT;+C5AD"T[CFQY-L3DEJ^JGF%LAZ"'AK,AL)?8)QNR"@&"
M;*\%!N8'\9,#KL+075NV%<T*%<_W+$_6-#FHIF^R9L$PL%M3MVW%\DQ7T3Q?
ME35'TN3M$/30<#8%!IBKRQ+15:64%=(U17$M"&M"60=R8'F:IKLN>#XSI)G'
M2I,$IPCB-6S# !HK!8XLJ[ZCF_ _#V9D6\,.#6=68)IM$%E3Y9+ +!^07O-4
MU= ]7W9<B.$="8Q4D4!>E0)S@;7(=JAIH1?JFN;;AF287@@AAN& ,U:V!'9H
M.)L" SIB:> E#;M$>'4_,!4M5 / 84>#N-HQK#!P R?07-<)JY>:="^0065M
M2P?0=FTI#'1-E4+@8X[N>2^6FO8/9UI@BEJF%88>VKX;^ 8P4!4 .0@DQY "
M6_5#P/_J)(>IP_T,U?4"57<UV0Y4!YBT[6NR[VKNMI<\-)P-@>U(<C0F,#$T
M;$%<;:W$](W <%5% N$$8)T0C$K@ <(0R)+BJUHUTQ>!N"XU3)=*H ]>'M3*
ME5P;U ML1@7OJ$&8!$@<!DXEZ NA80LOJ:A626"6ZDN^KOA2J.I*X#JZ"]3(
M,I5 ]@/)JPS:/=7T?,N23<MS5-W33-U7=""[H>*"O%\P_4/#V12888,_E$!@
M:BEHMTP9H-@!OVCJAF3:DJ^XAAVJL@]QN5ZI86&H A,% @],05=4Q;8=JD"Z
M[,JFY ;;68Y#P]D4V'(YTY!*&&8!J#BJXX/OTM50LAS+=0W'=#S'#BRWDE;H
MEF0;86BHNFGKNF_ -8ZB^[IA K]R)6=[L>G <#8$5K7^VX3 A"AA6>31+*/$
M6ZW0= &M7(7F:T%(F@:\-30]>"U3-LTWZP2OHACJ*==IMB(=?9U0Z;<*A08N
M4YH@X!:AI+G ,#1X$\TU0XAF;9V2#E#PRJ6'7F:3*B"S$8$)D4U:F"1PB5)1
MEBU[EB2'P <]7=,-UPZ!U7@VA/^6ZNF5/-FUK, -93]4/9\27\?Q'9"#'@!1
M"@&4MV/] \/9%-@",F6[S&+@'[(;R/!"P%<!53355S35E8&426I8F:_L)895
MY"L562DY"]NV'#MT+=LP=% V2U9-#6)9R75]V5 UL?.5"PQ3RXM4(!R/YI(\
M\)*R[EJA'=B^"K:I6Q:X3J% O\I+-B$P(4!_M:HGEP46.KH4>!:08UW7- ="
M $N5PR#P &7L:@P3(3FR#"S@O[*;# ,@_)IC^*YF>/!##P'P'8NN) /=$*I0
MLBH4:T1BO:R4K"@M;49BO<3]*A@SS-+"GB/Y3NAKA@D<*9!\X+&6HJB>&RJ>
M"UP688S6&:EE@0'&FQ(MRG-TWP1C,10/>+ZMVX;K!C;6&0'9-ZW2LHNCZ$HH
M2YX,S,(+'<N'  FF7-(D0X9HJE1G)&O&\=<)%214N M+*8>ACA:$@0&475)U
MP'/+,FA=JNV8H:."-Q0:^YH4F!B<=[&^99:K>!U##U4-0"_T=1H4^J;LFQ"I
M DY9AK8H&91M12(*6-/1UU5B)CBGT+!\WPAL7=5DVY<#VX7X5[. HBC6-F8>
M&,Z&H*N6JKL4M!@+D MOKAIE"# ,Q]5<UP]UW?!MU_64T 24,&1+\WS!JX;G
M?!%&ES73-@(=8%,.)=V1 L>1;,?6K%"ERUV>X,6LBT(PQ2B;I.< (CD*R$Q7
M0]D"#Z!901#J"C!)LS*;+KO ,QU?#\!)T4IV&\(<V0O 68'V6"^<S*'A; CL
M!8UI4&!"5,XM5Q+M<ET3!.^Z'WB>:7@Z&(QMVR%$\1)=O%5]N7+%UK1"3W=<
M*P@=5[?TP#(!_4);A2 FI.L,VX5@!X:S*;!E]:]>WEOC.C),MVJ%$$_0C<A.
M&/B6 O_2?,FQ*I,$0F33E[695ME+NIXA:4JHRJ:FNX'JJG1_*KR3[H2*9E:"
MODBEAHT(3"@>!F1H+3!/DBW3-F75\ '+9FM;8"5N:.B!I\MJI8;!IY2-&#1=
MJ8"L94<R;=>257 ?KFMN:]B!X6P*;+D+2S:MLL "2_%-S74L798E1W=]-]1T
M*PPTBC!";7&N6D(URR;IR5JHVC0.5'35<5P)_C <0U-M\&CFGAV[/03]EQC6
MG, "5S=L*X1P0%)UH%*VI86.8DJTNM\%SK#=".3 <#8$5I5*MZ32IB+/!P3S
M5-^'4,4"\PQ-1]-L1:$<2?4JM^SV,C1ZH6&VJ2@:42RKQ/1])5 <6S$<-;1-
MRW LS] =&9B^[RF.7XEAM V-Y*BVI$B@(K26Q(;K%,4#7 ^ U6\)[-!P-@2V
MJ_JW*8%I3@C,7;7E4/9\2P)-D:@$5  F"8CO=FAT:#BC EM@F%7N7Q?($!-)
MFBXK "ZR[CJ.'4 4J4BAIX6B,_U%>@<0I"0PR]5LS_!,U0 >YMH!<$PEL"$\
MIC MUI:/JLXIP.E+ @N5T <54R6@X;YGR98<!@K0LU"3W#V567U<I:KJG-*(
MP(3HG++(5LCEC&MHJ):G0#2LV[HA&:ZA0YRDA;KJ&KZL56=<1<"P92RIE#$L
MM'P#L 44S-!-S[&< !3+<RW;#%Q#$KM'XG*E72X'WT"X=4T/%)NV#PA#)PPU
MUP58T6&H)5=N*1 BEESVQ96 !Y4DYH:![8"Y.I*N!I+MV9;CRP%@6P!O6%DU
MHSJ!$M(HQY1L7?8DQ_-#+90U V)YW;>V$V*'AK,IL641B&24B!CP+17P'8S0
MT0W%!]GYH:/)EA$ N#C5(-9'-UG!*QH1F!/(=B@#@W,"0W==WS%#79<ERPZ4
MP S\;3=Y:#C; H,(:24P69)EE2*\K%I@,I8+;Z:'!@3A8*F*8Y;+C"3S^.N$
M K_M&DL6!-U+"*@LG.M2T'UDV%7085A:26".K8:.HWNN1W>]6HXI68$:!&XH
MR:&L;@A:58^^#J&C8T$+!1V="KJ/T%$E:+54K *1NFLYNNZ$)@@L#!P/Z)2L
MJ6K@0@@MN6]*12Z&=?QUJ-%TRZBIE@46.IYB>X'FZ:H?NIKOJY(ORZYA:+I1
M678OA,!6)T4H98'9/CV P%,L\/Z>8VF.HRBA!V:G^')UGDVH+(A5J@:7Y=!T
M;,,WX!UTQY(<V79=S98E+0Q=H[JU2B^]>:5)EI(@LF)HFF2KM@0F::N&*UF^
MIX2A8QF>%>SIZ=Q'DZRJ"E+U=>L.F::\S5"SK=DQ1P%=R0M=1?-- Z1K5V*8
M$%5!30HLE"W=\S7@%8JF>TH /,,'G-)U'YRNJF[3D4/#F1:8(I5:=\BJJU+Q
MJ"ZMT0P\RPF OKDZ>,G TPS!Z__G?4TUJ[2;3U:!1MA.$(2VH<M6: /P>X;B
M6X'A@  K>9@0?4T7)0BRI*SSDL!1/<FD_8>T4#=ER]6 ROOTQ"#0 L>JW#,%
M"N+[M&>)!;[4-$U;DCS-!/OR9-O3O!<-R X,9T-@50O$DJ66!0;V*&N&1ONG
MV8'K@'%ZDJL"+=/4H+(ZNY=>LFJ!N!&!B12#*J63#V1X?'HFG"_1<_,"&T)W
M6_)\"6BKI3A[ZL[ZJ&%5^;XF!-;+M97*<T#E4BVH/)MP!T)MS=%=FLZPO$!5
M7#V4%,4QJFM!?2,T MDQ/4W6(;9RC%!W9=>GM=:*]Z(\^]!PIB6FJN7H&SP^
MW1]C*K*GTV97H6/(NJI)GJ7*DE?)7&75 ZHK*8;E@ 1H\T7'LWV@;YZM6KZR
MO4!\:#@; GNY>;TY@0FQB6G9Z@1&EU*(AB79EJ&&LB;IABR[;J!IK@0QBZ28
MJH\MKAJ3F!#[_9>]1HW26:"RX7J69]D&71+07<T-O$#3E="S-;!2HY+L@S')
MFD=+EUU'MWW@\*X&#E>AQ_)9$"J\. MT_W"F!2;+>NE\7MD(PU Q0YAS0]<5
MU;'MP/0A*)]M:W J3T_MY;%=53DQR2X)S-1TRY9="=Y"MUW%HO$Q_*=IIJ^!
M(ZNLI#(\U=!D50<G JS* I/3?<4(5!?B:57?9A:'AK,AL*J<6!,"$RK%LV&2
MU%!5&[R6!!&,[CF ]#*H@.%[DN.HU7ZRCRF>JCY"X++* O-MGW9S4"4@^YY+
M^^1;7@@QN 51>'5.K(_$HJJ/4!,"$X)7K%I[E2N;+,/48*HAQI,@A(2IMPQ'
MH:5*FB?9U?U_A5IJD\MU&3#=(5 PQ:45VHYJ!;[I6B!%Q:)-@<5*(E:E>)H0
MF" IGGFY@*F5EMIL,$#P86 NH>X;IA.ZLJ:%$!_Y86A5Q]^2ZP?_C[UOS9+C
MQI7>BI? %T#B)_C 3KS_+7S![JH653U4:>Z7YZBFJ&M?CR4S=3HC22 "Q*.T
M,02[A<S[@C>WF:<NK>&4/5:9/%O^JH#=J#[DXX)8AV5SI8!X$5Y+&X$8%;"C
MWLIP>R,6>-Z/\ZQ'(672F$4MU@2GIR$\=GU_MOQ5$;LU9W5^V6.S58%B SCS
MLTV9N)Y"BQ:LQ,%AFY+REL1BVP#X"L3.8!;WT/XR506 X8?FC[9.E,>H05)6
M1]#E,#5V=E[=+1$QDEM"/%IS[TY'@3".,[P?J:1& 6Z 2]IF?+I48X<1\E3F
MI')P*YF5U=&:M\[I$;!GRU\#L)TZXK0 5GVIL._XY$JFX/DML7J*U8O(WE&^
MI1';J:,K #O#AGW.>(MAO0J9@5:-K3>?B3L7O(O.B7@-;D#W33QG\RQ0@LD*
M,N$X:^^P4=U"+"!9\?%(/EO^HH#=FQ;$Q4M62MH_!NP&V)>(;98U,>#+(+7I
M[%$,]Y)R+%\ $QL67*QQQJJH-FYIS%OP8*ZVK3J*O4N"+.!Y2:=XZ3;_I5=.
M<4Z#?HSK/UO^&H!M>B%= M@1-?CW1$2_]*3T+0(CG-8>0(M\A=D".YHQ=Y@6
M<MN$@:.BU#$L4>I&G'.9=H0HC%9XYM*#B\TX<G-[;?2.4>K=Z-C RY'LR0>0
MUU+]'" [X"3S+%%R'B))T_XR]X31L?<=YM?+W#X'QH(>*?9:8E](<F=)5>'(
MBM^/!WC'';:)(<+0_AA.[ <,U1P87F&-.W8:6&V81"--E1G=4D07PGJ4GSQW
M5'1[4Q;Z1X$^0NR_!- GI.1^C158ZV_')+EMC.@&S?9#/A%<4P-M' K%<'3Q
MW2V:3F6-V^%(56O=^38SC4RQ*I&V9BI!W%EY,[NC');^,* Z1"SF<RO@(WB3
MY%P9',;'/XXOB?]LR>V7Y#^;3(>J=P("-XJF O3<L (R-.*V6O$M%<FN68.L
M=P^&=[#<VAPJ,QOUP>XW'X+.TI_4QC\_@)8UW>:W'ON0V"7XWW[LJ) $O<WG
M.<7<_*]^GG>,3^WR0_X7/\\;\N?T-I_G+:G!MO8DA27CT8!+:D*>A, _B_9@
M0T?.31N8^U&7H-O:DRL0.^,6]-:Z?6U*&UPP*57)^T%AWE7F.B?H#"$GF<YR
M:=^OC3]F/\Z.40M@,"(N=/&9:3AX C_K=3A7#]&S[Y TBWG$Y9A[EED86T3B
MS,D+ ,&P81]WV)/EKPK89RL#F),?@'D76:L?XB)%WPI.#/;8""6FD-U60C,P
M=0*LXT=GC2JF=4[A&:6WU$T?C=B3Y:\)V+U&DW@%+/KN8\3>P[%L0T,*)0^\
MA>\MNFUBPA$UFCQ;9<=_99GB&CRGFD<N8!6DW8H&LZXU2PEUU'WYG.<152GC
M&6IL%>_.,Y]M9C';MQ/Y;/EKX+7+K5K"TP& C>I&,E?)%99:TAQ" 6/F0F[[
M7#3U0L'G;)HH#O W8O*=2DBB4A\/Y+/EKX'7+K7J KQ*#RH1]JB%0=R'C.+Q
M9VB-'$,9CYSBV?+7Q.N>*!274?0!OXIMN)[G-W=E#N6;O?!" Z48?1\T/2-1
MZ%9&4=P"&%6+@QU\)8@8:$=-OOGL<%@:)-1189]MW<D%@)U1=W)KA"HK:P6#
MJ#WD(%%H>*>:?1+KX.3=M[#UD=FS,^,,=D T+?JTYP,R49/7T+\-?GRR_#4!
MNT^9DR6-(P15&Q76%V]2?5&!SO.6JY4DZ1<7/V?8L,_</1#[!3"<#ZKJG73B
M"A(6H6#R@"@&'=M/RCQ"2'Y--_%+95.(0>?;N%3=+):7T3S^KVLHTG!:]O&P
M/"PI,W^T:[19B1%<H32YJ:1'Q)XM?TW$[O6L8>F$.@&;1V/R(QI@^$K)S;PT
MO ?U/6!OF?&S#2!&6?QD+%4*E*,+">(HE.I\*<P*+?FK69EG!1"O0.R( .+-
MC 6_=*H,"19+FE-RL^6'P%<2"TR-6*3LSXI6;%IP70(8+#9H6Z]STCFE'DOS
M<^)F-=92])L5>[;\-0#;[3"WZN\4\8U+9.-*.)ZEYQX%/I_9IQZV(>J3FKQ=
M MA;'LE]R;30@AB/:CF.!F*$[X\W,Q+&ZV4/,;/-O(S2#(ZBNPA%F@J7((7%
MN*D+S;E'J_]L^6L@]IBU="EB%&LM3:UIRM0<3E@-7LB1 RUUX9&\/EO^&HCM
MB\PO0.PD+E;\>G&4\*VS^ X33*6W.INE1M>=-*^M;JO!WA*P79SZ"L .X:XW
MMK]TE)J!@^ 5/WH26!HM4;3V.F<EQTG[CXKL;^71!8")S]%QGG/WE&SV.'8T
M+*;L07PAL;\%JG^]_#4 VQ5HYKR$$9,1_NKBW <5JZYYH^8[WFYJS']^9!D$
M3O3;SVTK&]1UX]([#WR@Y$%@!Q1&*ZG <T*%/%0V/%G^&D!O&ES^4:"/2$J[
MIW/DO,A73AT&C8HC@EK*&@8<9A^Y.ABVM"TA&0W*4T!V<H3'S5+#D)YR@/$0
MYOZM6>V3Y2\*V/TV=$WGR+"69-7/(=-U<+'B<F@MZG#1QWVOG!-N$FY.!OML
MV6$E!O+J30.$>,&+X+U49I$21=U7=9TDQBX!["0M=@E@1RB+>Y9H6;-$2^;B
MRB 0!:IMZ+3^A7(8^/T6MMV0C[C<^\JLE^6^O928F5UJL, X,>+@M!J\*2R^
MZWU+*X[(Z+AKUT+KD2PU,TY)BD8CF4!3AAKA)ON\Y-M&Q8\XDE<"=H38OQ_)
MM<DCE';V'''X<J$8?(DV<X7G=3O^3?\F65T%V!%)5E]3JI<"IR!$/>"WW+0N
M<[Q&RWZJ/@C,R(>E\>WZ-[BXV##1UOJ8XZ5G 4HJ?C1\\^BT=F^VU9)Y-*AH
M&SS99TA4O3I(Q +HQQQB]7A1]63YBP+VV5P(7W8YDM)5J3 ,O)!IEX!-!@>0
MFTBK^V;(/+/Q CD)G4CP[JR^<Z@]X8 Y>6R&_&SYBP+VN<-R7*9-!X6MJGB?
M06"5T=7J,F&711D]:L]'T8H-#[L$L"-HQ5=(G'\"S%)L9"R%FI<*\3*Z.M?\
M<*-OPSMGW2%< -@9=PCWM,>X F:^.-@3*TK:6_$E5X)!'HF3V=EIC_<>-)*6
M6ZJ:HLNA<H8T2C45Q2\SY: M5_^+9/<\F_5RK&U$JLG+B)J\EYY\KZE^RW]Y
MLOPU -M-![L"L",N07[<@Z[E 96[LY3:;!XJVI5[(T^S Z/EV/]6YE^&V%L2
MB]U$\^R6F&OMT,,>+'_>M0>3!-L<V!O-6**G?VZE/MG_.[N0_/9S1ZO0EP#Z
M'=O-[&X1@E^!QM8@S3WI'$9&Q;+O?G*+YIO:V>V][R5"%)8=UESQ&2;3?=Q3
M.;72 HQ9;%H:[2?I'I+(^P%8 2 +8$0Q@X:YX2AX7THWE\)HW7-ULKVGJJ6,
M^:866Y^7YPK_!-]!(R0QSX_QD6?+7P.P;T[F,SE!?MI@I<NLUG0ND,K T2FP
M7+%DGX;F]L_2<6&-##]Y;-M&-,X9<9D&E!EE"E*9P)>MQFCX9(\NYMGRUX!Y
MDP/R!V$^*7,D":\X"\WT#:V)J%2!'4B%04R&APF(6Z7\EOV =\(ON47XM=8&
M!4O1YH5^*5:5.HX620/9.'O*\96 &7Q5ZPGD+20<K0%GV[&+B'J%V(Z/G._9
M\A<%[-;3W(?%AG479L^J%K5/CUQA4+ 36H.$;2EOZ^C?,GBUNW5EO]R)S9X,
M@X:#"2/SJ9;*T=5 GN/P=-8,VMVMZR6 '2'#[G.\UBN>+HU"D=SG+-7N-%GS
MWI5:TQ0:^]RD,VC%AZI(Q2VJHL/FQJ"J HZ?%,98FW-SU&+(9MN6?[UQ[ZWF
M-!OVP31)GM?<\!A<?7/T&+IZMOQ% ;L-#:(UOW+V?AHN)J\&HS^J=R-GRUIE
M3HG>EKJ=,33HW@LD+2UU QA2QDGU,WQD\%QN@/DGR/X*M;,?I'W$8(9[D\3H
MP@(8NT(^E1$+E125C;EXG,BA<>1M\.VDHO!+ #LBEO35MU3\"MB88]G3")%&
MS-I+!Z]T/H'GYE_4ZY[4MS2NQ8&CU%9GBR.8^92KJ0\CEX_>?W&D;7'@64?R
M L#>\DCNPA40)0M@6C7FTF?Y0?6QU.Z;I"C5J%O>)B<=%:ZX K CPA5?4[1E
M]9*MM%DKQ!E4%:(HS>*P"N/OXM"R#;F^9>W9=D[[!8"]9>W9IECO$L#>,G-D
M5P[*O"2.6&JSH>3@QC.H7\3GSG%F#SIC.0NP777C%8"]9:;--B^A+.$*(]]4
MFWI)Q*U5<@TNDX.CZ2K/&HJVF=-^"6!OF<BQR^7Z*>?92LP]SL&N3 .D?P;-
M.E3W2 8&?G9ET*6 G1#4_PJYKA>3)FXV0<>YQ >']7=^!.=]+U"3.*EGAUQO
M@+DE5R ZUU.'388L@LHK$HOUU@-[A?/B;3[J&1W105"3^W>64"R 44Y.X>O)
M4^:B"8<1%C_BX("3RS\_G@MQZ=K\[+FM!K4(ZP^6D9)1B$%$IR8G7WUV=3PF
M93Q;_II WWOU\U)&&ITD3CI+;PD_OY7A")NH%Z$8?=WSMU)"]V&.V(LT2P1+
M<\-32N!IL<LW_O9D^6L"=N_5SRXO@#5?--2F,L"G8LV^@Y4TFQW52]_NL$,N
M-#_SI+RLMF_$ /Y97%&J3)H59Q%<;@S7QCY-\BWSI+9MW.*RP_"EF<OP S!R
MMX(U)<<Y;)!"U_Q3=[$E_O;LN;]MW/XPT"=%AH/W"] A>)?GA8 '%XE#O79.
M/FJ5+BK[G(83 /MJKKJT0(HA0:?WY@F"@2U*YF'=9C9(<N3V08*3(L-7 '94
M9/@*P-XRT+E1), H+( 54#\W*[R91&'TY^@.<:#_4/+[ JQ9MCLTX.^0J82H
MO8^0NX58PK#X&%5YMOQ% ?LT^M$MF7]0191T-B&?I ]0X;]JC!5'!T:_;DOO
MCS#Z]Z%6>>D."[WE4\JI>F_$->L0R36%X+A7^D4%QCL&.G<7SG[I#ANCBO.C
M5AV5:H9E[E#@"1ROU39X&[<[8H?=Q7[*2U0E-O*)@VJ>[7Z<!(BDVAI7+ZZW
M;<D*=A][L93F%(&4NK#CW"QA$^,+E/!8L?9D^8L"=DN5G+F2/Q!+&9;+M+ E
MRD6DPP7,L%J?'0OV5C\'YE8&UR*9X# T9OB,6'&^IFE_K/%[MOPU$-MES?@8
M%\ 49@SG1$:C2#@SP07?E$<=5N,VS2ARBU,24 QS4%$I.&P]\(C59_SN8Z3S
MV?+7 &QKQ"X [ @C=DN5E.6R)B8P1^XII3G'T 4-@H/27:W#S6C9-L([J/=9
M/5M 1V8 RKF6X#.T>6FI?8OP/EG^FGA]-<.0);<TDI.66Q\EI>DF!9R\=5"S
M@HTW]LT[WU),[N8-78+86ZK);<.5*Q [0T[>0F(NKX"5-.;0 4!&?@31449/
M,FH@9W%;@W&$V?_:8D2+H^2<H" AADK"!Y]-KT>$'RA6)$!5'K7%MH?R"L2.
MR,VZ(1;*>BC9Q*FOH48/(]P+MH&ET$96'-ZV!4QEYKK+$"Y@I,.KN6&D!IX2
M+?='P)XM?TW [B$+'Y8H8BY008SS4A,Q>+CVH!W./S=(R[J_##TA9'&O[J1E
MXB]T799BS4-UDX!02NPCA2B19RGQ=H?%XD)T-'(<E8*%8JJ6AH)H^4[E44\^
M6_Z:@'U%$6D)BH% V)S^T&8;2MBNP@V^;.0\9JO8+=T_PD\R#H:C.;=\N6LK
MG=NHI>,L0L*TXK4%:QU;8(CM4[Z#1L9^R68V-PY5J.A69U%MI<KC,<;S;/FK
M O99>N<*KX#!B)69)S"H!JTCZ0APE*'A;]J7K9P@*+]*^M<C*<EF<J0%:N1]
MKJ/4(B[F80I7L)_+=T(&S-?5T5)O'<4RWL4BMAUE',0&3^JJ]MQB@GT[^^KH
MEF-%O 3V%<HXY@"; N/;0VW=3;H6JFLL]-DD\<9XA<-O/W?4SMQT9/NC0 _0
M:T<)Y,=%&G!37-E"S0U4J,7V2)2?+7\-H'<)'7F9I1"578\$-SG;>%:3I#7!
M[L/=]!+#]C+T)/%Z"6 G:==9RK, )G ZVH25"?]!+4@@2Y;$..Z)\DEIEM$M
M#6*C0F\QWD,F@Z4&H50"F)_5;+7XOQ&X:?1IO7G16D>M31J#[_=9=.T#-AJU
MTK7I]DA";PH;-B'E.;,(-EPU4"?.#,G@'GM4/%O^&H#M G!7 /:6TSHV$X>2
MR*)=M8>2!_YCG+>Z40/\_.B>9D8,SN;62\+T" B*,#<B-]3[.'N]XZ_FLW\$
M[-GREP7L(Z&#RA+AK;Y[["11O FX$M1WZ*Y[URI<P#B[>N,>?\N\T IX^M3@
MJ/!*!&I15)K#(0T%=!)J=D]<S:<6\%!5DE[FO#5L5FRD%@O[;P.EGRQ_3<#N
MZ0DA\@K8B'DV0.X3,(*X]+.^3,M@:7G;F.@MO>3VUL4MG?HCOG.;0R8\*R7-
M,,>-@G#QI3KQ9U^%7HK8$5S_?BC=TG1A%O?W5*7:C/1X7Z8/F^/J6PN]^>TM
MPEL>RNT62Y)6Q,PSS]NJ!%%4U> C=98N=>Y:MF3_K!R8*Q [*P?F"L2.,/SW
MBP0J"V #Q\1"-#>$QJRJ*'->2T[,N0^WM?MO&:[=IR-G61"3C\S0I.))S8JR
MM5$%/B!IY7T3OT/2D3]:>\"C_P#,* 8( '@K3S)<*<D@H%A<"J9]VZGBJ%XH
MEP!V0B^4^Q5*6)*LDIM=X'MT7(V2M=(Z_C?ZXME4R?W4J6(AO<^>.\KX[>ZJ
M_B30;]D29-L_*JR )9"*Y+H'RQ].9_,8;VG. F.AM&W8<)3-O 2P=[29FQV&
M\_8C"I<\)#]Q(2O3N6B=93QLD\GBKWKK[O,YWR5P_.WGCIKO\JCB7@'HDTS
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M1;BZD+P;-317_1:OTH,*B$%L81#W(:/X9+-"BV,HX]'4/EO^&GCMVH-?@-?
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MT)[2Z-QLGUIUQ [[&O:]C&_,!+<>'9AWZ-2L%P'U;M%+GZ6>Y:P!H=OIZ!<
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MS2FWW.=/+]9[2'F&E;I/MO7))^F*2P [25=< MA1NL+E'W44Q94F#-.F0C3
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M EP>^&XM$<?9X%_'V2W8KP3,(&<;='YM(=$<.X&M A% !$6FX'\/@#U;_IJ
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MO]!Q4F?EDI:#)Y11(P=X"0<RI5-B*RSAP@KGFX:34BF<,C+TO=]6+$L%.:.
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MZ1!%D'30@)5BPCIN6) *8LD[>@.T(#!:%D51SC+ HF41;(OUF!N)-*R0 5P
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M=>?3>7.:->]KE606IF=_5:"3!T><6>=02O\.5E@1B95.,^G J]^H#KY[^6X
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M[+^]!*P4BFT#L&"YT*FYID<40CFD%8N&2!3 3%II5R.$=<MW [!2CCQ8W6O
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M(:*+Q"#!:.JIIP5 E24,KUO8ZMW^J\R>G,XJ()D89$UJ!%>? @ =C')(0C3
M[C!M;<CL60YI)2@'#%R7TQ T@4\3(AKG/5*(.:6X1*KM\Y876[$X*ZD.FH@4
M,T5L(0((3'G@&%8'*S3R=S18W4O;5MR\W@9B;=J\AA@OPXNQB*GU"D+U:+T5
MQEGIB6!2B^A1E1U$Y2,TU[VO5;%I(7'V:^(,Q"Z #A 1HN $]$ +3Q@7C"0
M;^PRK5N^&SB7CI3S.1= 5[3E41@4TZ@6K'74 B0%GD@@+!2[4+3B2/EJ@B;*
M-DW D#%$+=8B%:6 G221"@K!@%71RG:ECQ9GM&X!L):XF+E*8IH#9IC&$(IS
MCKE *ATM,/#&$IZ^P;)8]]0*E5R.@T29"3/84R?3""H-3)E!6.L%$A8;2;DM
MIT*V@B<ORYXXSD)7TR2I"(I '[6PUGE#30298X;?,69Z+\E(Z>R*Y8=]QGLA
M*7):2XX9MT$X0IQ6AE.0O:*3;-5Q,LI*-X,UA+I41HT$AP6F"?XY9YYI9469
M[K;I.'DK@+7B.'G9=P@\8H98T*F%&<-8<0R7WS#\%!2DL[]0]))MXF';0:P5
M1&S)7#'-@E"/O$,<F4 YEXZG!E<A*"F,=@Y\?R=B6P*L%1*VI/HTF]<3/%PZ
M4B*1".XPM]0A0X']<R*(*O<":U,3C:T UHK8:*&27,E<):GF#B[;LQ2I<&
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MI='!O(YP-!B,/B64+^8HOZC,I-^KGM:_IG>G%QJ"V?##C%!^=U"][$W[P\K
M4P+@@7B^G_\=>E_RT[3=F=H/+'].W_JJ?W8VJ)NES0>_G<%W=[JQ@6Z\Z4Y]
M-E2'NC<>PJU,JLMZ7$W.>^,NS6<#>>O2RQ[* 'X>/O0D9ZM=IKXM:3L^M*^/
M.Y';7.2JPW2XV.RPOW[_OJDR..XR&C<2OE]/SWO##W6AG+>3P#LD,)NJE\.8
M6DAA35E>7=U)Y+TE,IH3VTGB0YL*W9KG;4?P5R>"]Q=!WVT!/237)Z:CPQ3A
M^O'L0V7.+OK#?CJ?Z;)[-A*_'XWI>D5L*'\_UL/4]G'P.5G ^C)M^F2F\,VX
M#^;Q<M"=8&\BAH<G;SLQW$P,/_3 WHWZ$)5,0/# 'Z<?+^#OZ>QB-.ZD;P/I
M>^,[X=O0!@Y&[T#4WLQK[ZM%!DHJU>_D[MYR]]=P3)YUDK>9Y)W/+N -]64?
MKB!9NP_CT:?I>94RR$;C:EPGCPS_(,^&]0=@@Q^['9H-!/*P._S84!S_.II<
M]L>]-#5L-DGU?B>?)]/ZHNO7N(G8]2>S]A:8/E#P_G5>_V^_!P%'@]YJDY'*
MC9X?5"^G9UW%WX9RN)@$T(GCAG8PP^X686Q* *N7\QR)3B3O+Y)S]]))XX.\
M<E?SO*FX'?_?3M0VC$=&XXO1L+Z*/)Y=CB;]+N[82.P.W<_S?,[>H!._#7,1
MKZ'KK-VF8M?E^F^<^3H<?6QV5;ID_XVE#;";$^-.ZC:7NCERG8G;5.C>'/^Q
M=W'Y?7? L:',]8>IP?!I&G@XKB=U;YS&] W/EFV%NY..S<3PN-M8?DB62Y-S
M.FPF5C4-LJN3>ORQ?]K%%AN(7C> :F/3-QWW0-Q&78OT#>3LOWO#5 C;"=MF
MPK: K;+]-$'JO.-WFTG=W^#2.Y';3.029OO6E'_Q8K%OT^\NF"_]R[V3RZ\*
M\I,?!J-/$'X,)_WIYVK0OQQ=IJ%[_6*V\Y^:J=M7OS];S Y?#I)?_GS+Y2Y&
MAW]Y.W?,LW_P1'FZ<NW-G^?CY6=<]C[4S]Z-Z]XOSWKOX8I>] :?>I\G\$U_
M.A_?>3,/&8Q^X_EDGW=C<3<(_;(;A/Z[V-&P<7[^.C.U\W;VD>WHR_I#[_1S
M%29)&_N3\_ILF<?:Q3L;"&972/P T1L-S])<T:Z4^#<*7W\PN*VK22=\=U6Q
M#_I5 US5' ETC=DW%[O7H1.Z38.6R215J3==CR;]CQ"\= )W;X%[Y5YW K>9
MP+WJ#2%L/)M/E7^=AMDN!GAW8G=_L?.-A^@JTQ\D>^EL^(]_4 3+[R=I#L7I
M;-)4AJ3C8S/L#3Y/^HU)O.ZDX( 6]J?+-<?U9#:8-DM>7];SDO8N,ME >FOX
MOI+*=_)[E_Q>(?>M[X=_!:$;GW8S*S:6-P#M*AKIAM,^0.CZ9_U>9^<VE[L&
MMV7F=/6V/CT?C@:C#TWG_DX*-Y/"T>CL\Y+P=**XH2CFX('D?:PGTU$:GM<E
M>FTHAD==)ZU-A6]8?ZK.4O^LWN4E@-B%R1M*W.AC[Z<9*&PG=YO)W15PP/J>
MS6U>"IJK.(/P]^\'U<OG;SH'O($<GKB7W<3036W?:/AL<M$;#)KTBVHP&WZH
M3GO#TUM+_SO)*TC>/T^Z$Y%-C1\XW7^.QK]4)],11+_+=KZ=U-U;ZEZ_^5MW
M++*AU"7,%C6;78"[J;R][;SKAN(V^IB^^;Q^UO1%[7SJ!M+VQK[JI&TS:5LD
M\W^N;#VLW_>GU?P@KI.Z#:1N#F&_*TY_F.SU>Q#+CB]'70?R307O37/^TX41
MF\I=FH(TGGX^J"X'O>%T<8I6_WO6[XK3-Y/ GV:],5"4P>?JN 8%GE:C815'
MXXL*HV<_=6*YF5C>"6;U?C1NQA3^^VH5R'!_=%8UDVNJUZ?3T;MZ7.&#BB L
M.QF^MPP?NRY$V5!2QW5JK-!L_IWVQJ?]X>C6SCR=Q!4DKNLK\S"IZYK)_%;)
M>W/82=UF4@>0+=)-Z^KM>';KB64G;K>+VPEHZN@_G<1M.+"P06V^U7Q0]2KX
MKGZ3!3UZ7Z7C7P!L4ID?.SG<1 X_]"Y&G2!N+(@)MNHMO-R[;/I]="E^&\M>
MZ,*+A_1OR\:V)KYW-;K5C2XN^DU52">$]Q?"^-^=$&YH_.)_WQC&\.-X-+OL
MQ.[^8G?8=>#8MEA.X=>#&KSP_]:G\YXX*U+:R>?]Y;/9B.FFN&XL@_.1U8UC
M?C,:C>^H8.A$[W;1>POJV@4DF_: Z;U+I\1__ -A]/MQ'R*3A&)EQ[T)V,3^
M>%2=/#==<')_*?SY^=]N@ZL3PKNBDV$:Q%6E5IAGHXM.V#80MI-.V!XF;.!Q
MI]U4] UD[>_]?M>\?$-92Y@M\IQ/4P>8;N3@IE+WC^/N4'=#H?O':#PX^]0_
MJU/OENOCW6U,1?]R*X'"G9V-9BE@OG4OH14"^J]1/>UO7&B^&9 M%.(YK'>>
MC!1:2B^_Y:ZNRRO7^."6T8N&S_GUG>U64VOVVYM:]ZK^V5^>3&*4*CBM'&..
M8X2L("%RSREC6@K+TGMZ]T#A\9]+\^.G^3>\&PW.4GZJ.7Y;'?[Q#UB@[Y]5
M\?#('+E#\[(Z/(JOCU^9MX>OCVYYC(L[=TY$+STRTC)NB3?,&1TM$C(8BP-9
MO?/BG:ZH++[JW?W(=W\XK2\J_#SK\=6PW^0*)N7;9@8Q++DF@A).L#:(6D<I
M"]Y(%+6_]VW?E/LM"/:;>/BO< P/T#VOS)&O3GZV)X?^T!S_LW*O7[TQ1X?A
MY,:]_;Z7Z%X?^7!T$CQ<T=')ZY>'WKR%'T[>PE^OPM';D^IU3#?P^E7XRE?Z
M].<C\[,_A*O[[OY7<O-[L]5?^*\=[%$_[_D.9NRWM9S'\DF90,V_(W6U?W*#
M$RR^_V$O/?!MW9<]Y,O6,^.Y.=\N]_UMI$MM:@?F;YC[QTVX[->Z]531^7XP
M^O3BO'\&)F4;-O"NF[_2=_ED^T \[(EOS_B_/1_7=?4*?GT^J4(J?>@DX.$2
ML-%I^S<B(4?@J]<)R+W-Y&, =%.2'ME2/GUU^/(E! TG!U7X'Q?>O*W> !D%
M)O?J]5%U\E=S'"H@>^:[KZ9)NZ$LY)M1E@:Y;>"RJ!J;PX,/JB8*+M2/_595
MV0I7V.;F1R?@+1-P<BW@HA/P3L"W(N#[9:0[,>W$]!LPM5]-3'_G_95'O\_C
M^F,]G-V:6M("C=SZ_3WZ\_H_O^%&OJIU^//\LON_OAB.AG'<.VUFMJ2CFS-&
MA9(2L5HQ^NS3+\\BO/A,4AT<H]YC:CG'PF+L \-&TQ!\E/A)->Q=P)?/)L\^
M]'J7+TYZ@WJRD.8?1Z.SR5$]?0(F=YANYKA^_Y<GT2>?^1/]Z:U_4LV&_?EO
M9Y.S)]59?=J_Z TF?WGR3(!M!@3AD^%?[]-6__0O3_J_3E\,9Q=GH^EBY9,?
M,#W 0OWY3U_>T+7)V/@I=9ZWT_.VZ+D@5WJ.5)065-N20+AQ1C,F5(S2!2XD
MEO*!>BZVJ.>(\4[/.SWO]'QC/5?7>NZQL9'ZB)'@/&)EL?#<!A\4YLH+\7!_
M_L^MZ#E5!T _.CWO]+S3\TWU7"-\S=N%5H(: 2]PKG6TH/$&1>VT(IJ+^'!_
MOB4]UP=8BWW0\WW;BG"CR73>ZZ'^];(>3NK)BW9:MZM]0OH(^1L[=J_[?G_=
ML]R?^^N>Y?[<7VN>Y0-9 MIIFI ZX4T2<5S>\*8%.W^>S"X+<*2"ISNRQ\7E
M],D/3WLI5VIVV=+PZ]X'F;MY4'F?D 8CC*YB&J*"Q()Z3Z3BE&!%(Z+4>D/2
MO\R-LX@DHJ_?-]',R6AP]IC'$.1 ,;D/T4RG-ONA-D1?J0V7B H1E([.<V^4
M<2X$HXA$#@7FZ.9JL[5=?7J 5+>IWZG-SJ@-4]<[Y51P% *A7DD>"5/<(28E
MM40X$>R-';1[>9OM;)[) ZU0IS:=VNR*VHAKM4'1,<J0M4H;+HC71OAH&%8B
M((:-?9"WV8[:Z .,\3ZHS=X%DR?U &*]#P=5?SA_?O!@>H-F$[IW=M$?]B?3
M-)7L8WVU)]U%G)TQ>R1CIOF5,=/2!$<5UM(S;JRRPE(5J!28$1FIN7&*-I?C
M'^MA/>X-S/#,?"&]82Z\CQF(T@...FK0:=.N:!/&[)I1$Z#4TBN-3. 1*165
M#E)XJ:+'P=[,,7NH-FTQ/N5<=]K4:=.N:!.]SLS&&IMH."<V1(X-^"4OK5)"
M$A6!?-_,\/@-OFD[_!NC T*[W*Y.G79&G7A6Z!!P))0Y%WWDSG,K0/:%\B&B
M8 A%VW1.6U,GAMD^J-/>Q;/'A1&)7?C:V;3'MFDJ.S EW$8:!"(8<8R%QI9A
MAR7BBCA%;AR8+L46K%G6^'5ARL*OIX-9NFES^N]9?UR?'0[?C$>G]622MO >
MM<;K0'4LO%.QW5$Q?7VXJ@@)0J)@K<*@;$"\4_F4"LYX[^C-[>[MJMCVRJL.
ME-J+K?%.Q?9"Q0B^/E'"7$KC"??(>AZ#MHYKY#R*H&W$N,?W8MNAZ_R LKTH
M>.A4;#]4C%ZKF,4L6"(\%8;S(+S6(C*"#/%(<J5OI AMW8MM3<7$7AQ^[%U
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M"!"L-D"(-PSQ@!"S*CBC]5(/G;4T3UN%B40FW9/@TQGX0 T?3KAE2&J'&(5
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M;327Q!N) (.C2!F.0&N)&2 KE[M%;FX'K522M X'J?T8_9TX*'%0#SF(R_I
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M2,ZEQSZBE[L@XS52T!"8!>+T4K[.^NAM;\PC3OGV>P;"+H/L41W9&-6(-(=
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MT0?,]$N]ZM/3Z751PN3RJAC/JARG*I=I6BR:+@[GQ>6>UL+TGSH$J>OE&?;
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M \)U.6E-ECU%K9$$0G@ZA%H*=Z.!@%X<%/5+$R^*6E('AWV@#5&7JT@DK>*
MHXD/X"-9N""04@9S3JQB2P6EMRSQ+4RFOX]/XX/)A^/('M':'U81EQTXRFQ
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M">O<RK)V2NFLIG0M@M6:64:$!T>#\EI2KFV@ECFJEB*QC4[@>GRVP],,+,@
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M/^,J_UR\/ID6^3]?Y^?QCM[EHR_YMUGY?"ZF-XO)JT<\DS3( !8Y87%\F-2
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M&LY;2!C\67K_@+<Z+7PCXZ2M)H?)>$GXW0R_I,:O\XX81[#0F ,1O)PPQ84
M$QP%X9>:/FV$WQ:+"D ^>QBRH_C=T&:2';:9#E=M Y/LH=[RZ9:'L6[;DR2-
M"BY&$#CN@8)BX'0PSE(:#27O@%!%ECS)*/XV2O_1C?";;[_/RKRR.\*M._!N
MMP&?(&TZE2]S[&I"<T)S1'-C,)YP$C$9+ *N@&#0 6L#'$Q\&WFYU$WO26AN
MSX)"VYG+^<+@_*R]^A[B^L:^@*NOVX;X'BWU69MZIQU..[R597>JQV@+>O=G
MHR8.QE7 .XV:Z,BAVZXG2R1;/TE43R2J;[3]ZB]'U]/3BWQ65&G/5],R*#?_
M-J@2I.?5<67QK^OA59FBE #V@O,D'CM*H)(TPEN*2XFH=@C !V^0I=X)1"P&
MQ[5=:B^??ZM2V#Y-='G6/2V.;L3HJ!0B/3[SMR*TW<QF FWV*4KY2@F'N\<A
M:\QQ89Q*[XB.:"3EP >IO'3(>6FP JUEJSALLU\8??:C^9=U=/=2S(/9Q60Z
M?STOII?9L/+I4@/0WO,1J8^]!!:"1 / "!% @96<&QID($0R3ZA^E(^.2_GY
M%,7GH):>;9H$Y40:M:=4E"#8&P@V3IXM6"K ,VR$ \VQEMPIA,$P;7%0CYOF
M*T*P/6L !EB@/<5@#\V!Z>2T*,YN^I)-B[/B\JK*;'Y;MB!-1D(_&>HQ@A+U
MN )I%<:24L&KU!@LO00MC8Z& B%:+Z41WPI4B/)T'$7HMWQ^'6_E6_16[&0T
M*JHO_'!>T=9\=Y8##(2D?2C 2"#K"\A47<FDL<4V0LHK'P"X*@,#2DD#2CAE
M@MHNR%JS#0@:<-F+/D.=4O3WOF.;$R/+K-ZK30V"[,MP?I%-XJ*&XWR472Y$
M<KCXD_G%M"BRR_B-%_'U-(N?E"R('I,;X-K%\1JP,8I3! X4-\8Z3750V#)=
MMF;YD8L3)M-[/+>-6,,JA9MD(* 7M9L)77U!%VTDNPH,2)' E!! N-;*4T&I
MIU9)&B'6+KJV4!8]8,EDZ&ALH'E4,)J4=YB" /TAF<?"E-!H<"JB"B<>>R."
M!T!62J[+IDS,.VZ#-8^&*7_+I_\LYOG)J#@N3F\,PZUV+A] JP/#7E*4,D&P
M-Q!L)/$@H['BB,J@#/AH1^O@G23Q%7-(RZ4:M4TAV.(,T&B;["D$>V@,/!X7
M2"9"W_CI$7KBJ)%+0'F92( Y"P:$149J11BEFDC*/=LTA/D^RM0.CPG(@&'1
M!V\D8:PO&",-7]]'X]M)Q:(M#DI:([$&[0!HP!K1I4;IK6*L-;N #Q1.'G\G
ME;QNMC:+&OWD>C8<%[-9H_M9U?4C7UB49XEX7C#Q/.9\\$9[4XC.AG*>,6TY
M("$-4<($9KBARL)R>],EY\/<25+5@;FLM[_YS=F6NZ.C?4U62DCL#1(;34\U
M"EI;3+CB-MH 3&DO$%4$ W@.83D?YVE(;"]O4 RXV-?<W?Y;"L/Q/!]_'IZ,
MBC2K? \(2:F:D#B6W'CMC$(@5) V6$08Y\[K8*1XE) .[D1'5Y*S57M MGF2
M_Y(H*(&O+^ 3N 8? N1"63I(R_Y6"BO"9"#666DQ8WBIU=4FX&O-!%#[>B#7
M/_6_Z)D^O.L#4S?\3&-/^M[$^#%Z8E"/<J(XTI!@!N, W CME1*&$8*X*T\)
M5DQ.JJ3MKNE0B\TU5TE0 MRFU]+9OGL)G_N"3UX7]P102@HB9/ <L%-*,XVH
M(01 >?'CM)[-\;F%!,(VXWN=A>>>]!!_^\MU.4M]./[S=XV+Q%O;XJW_G[TW
M;V[<1O/'WXHJ>U2GRNX0-Y#\=JH 'A/O)MT]W9V9[^X_4[1$MS6118V.[GA>
M_>\!P$N';5FB9-EF9C>Q98HD@.<^/L\SA_\5LO:)$D-0@J.(QD(RP2/)31":
MF&D2)!%3:UG2.^!_#V%OW#< I4/R[ECY5;#R0_$-V:@JDD)*JK D(DD8)K$1
MC&B=!.!,)#JA:P@E>_%R^[8)/1/!DT,G'448O*2(28<1W6%$=R?<G7"' GXO
M"G@R'*?C_K!# 7_^B:?GA]O<455'52<393M9\;W:MM- [@##?YI_@_?I9/;S
MY*ZMXF(*U\'^"''&.-4\,H;%H98!"1*CE(Q8+))XO5!G$SQ E%T>%/1;G 5!
MA]/5L= )L1"MBV^%2H(DHCHQF#$3(,7C* FCB! 4QDFRWH/["!9JL;^&J!?1
MP_82M?$0/*9).NI-BDQJ#PBNT\HO3:0\%.)6O YQ&\X%-\K$(E8,8:&IE!(Q
M;G"H(Q1&JS+E8U;23@'P=QRUS-5K[>7OV.[%L)UL &]C'(0DB2D6A"%)E(ZD
M00GB<:PP:/-]V*XU54[."'ZM;'=2VG_I&4>%X/SA3<-4^'ZSK=!!;[XF*7>_
MD /Q4[O\6M/(6)S-,%&,! A^5E$DK<^BB0CO!>^^4^!Y%('QEXOQ9TM:OSK*
M>C_]!>CJH C>[$6 !G1\]ESX[ %K @>DT96K(L4"&ILX1(P%1"O&,5>A)E$<
M!I@=@=':KUY1O,U(7&=[G$X>8#B;+=)Q/UM&[1H S742ZQE+K(<$%JN+9"D+
MHBA6B07F!GFE# 'Y17@2"QH:8^Z-9%X4U..1@XX1?F!GX*5UVK_CI=/A)5&'
M$FC$9:1CED0$6$QQE0 +<<81-3&--@#<[\)+K<44V%E VHPI=.F! Z<'.@7]
M8H3*0RX%"FJ7(DX(YF%@$@FN12*(%BP.H@ T=10BK-> _9MNQ+'T,CVCXLGK
MV[NT0,=U^W$=KKDN4$IJ,(NEXIRA4$I$!%61"8R)$"?[<%V+P-JD59#:Y\1U
M+U#I-Z=L]/.;&UL1,,_[OW<RYR7+'!;4X)H1(HEUQ:,X9IAA&01VC@\5!O1^
M?/<8[B2?@O@IR.?]5>AHYY,EG</ZXAVD9L=_SY[_1,U_$H4B1!''1C#&PMA(
M'H)=BYA*&--F';I^%_YKTW]_M?SW\K2_[5;NP4.&P-J#&?C]PPY4^T7+'<4K
MN8,#G"AI-$,(]#Y<$@LCF5*Q8H$";_\NN?/^ZOT45IA.;Z.2< X\.IN]5H'3
M,=Y+83R,&HQGXBAD6D14!U;)RT2@" 7"4#N&^VX,[>T8KT5-3SO(S!>CZ9<S
M\-D?V;0_G+D,O//V>[D?I]4)H6<LA!Z20;0>YQ?I( 891 DFA(6(*Z0EYCQ2
MX/XC2N[OQK,$\][32UP0TD'':'#6IASJLN\=(^W)2!S5/7DTCG% J:)$,:-#
M34R" DYI("B)-N#/[\!([4%@TQ?!2"]/.WM ZZL*TN0.0.M=Z'DQN6./8 ]^
MLE@JYP4X#<+!?S3N,)E_]Z<WJ36.%I-.FCUG:?:@;]+H2\() Q\$Q!A2E/$P
M-';:=B0Y#A@(.+,>%&B(LT9@TM%SA=!S9,ALC%]KX7#'DR^%)TD3A5(;%E,2
M8BH4(TQ+$QBI8@V&>L(5O;=8=C>>;+^8'RG\2GGR)4-G%VC9&PV7SF9Y>?+Q
M94#\8D+J8*RBF,N0Q-PPP81".D$@8F.2)":*([SFO]T!\?M4MHXZXT^?'7F.
M$+^=*.A$@14%K!8%D0DPTTH$$:(,Z5B'22BUDEA+%K#U1HJ]1,$!)I&T/-C\
MU8B"EQ=.BJ^NLKZ;EY[]T;].QU^R\VDZSWK^9]?6X0>ICP?^A^R?B^%7(+9Q
M-SGU]<K*AT2EK--',0LU9IQ0Q163A$G$1!Q%)E)(!B%>&\CN"?+]55R0XT>@
MQO=C-_QY/+#_B6L"/&@FJ<W"]6[,2<?,)\O,#QD^-*AS6 H%(0F5G>>N@95C
M(Q6.(A[$48@Y96OP$7MR<_NFS]-/=G]%=L^I1Z:&X_XT2V?9#V^ /MQ/=II;
M9_"<BHP\&8.&8E''V"GEADF:*(.9,4)%.!8BP' I"?'Z*,K-PNX#O$X.+J G
MNZ@@O\-.E&^S 7:W<^LLEHX;V[!(:",J&S+@1!813CC#$5,8_ TJ42B%41M"
M,7NRXP'R76>,/GF3;"OLW!D=6S71;+(LSGJ7V9?A> QOU(FU0XFU$_"U'A)L
MHE%WBQ@/L6 ($<IHG(#+11(2D8 'AO%H2SM#S\-T.KV%#?EK.EJL2K0+)]%H
M"]8%/F.JS9!R%Q3I>/&)>5'580\9AD9ACE&$$Y9HK$1@1(AC(S1":+W6;5=>
M9*WP(CGCM$W@K)/EQ==E(63C5]IQ^Y2!60)_'^2+RU%V3'/XW_?8B..O^]B2
MF>%&4T6<Z 0\/8I#R6(AC%%*8$/ 5M*&HK6*QUTEL_@+:<5*$JT&H(]#R)T-
MU<FL3F;M*;-H#>.B9!(E**0!2"ZF0FI8$#"-@U '!,E@+26^NV?7CLP*U-$B
MQZ<KLYZT].>Y"Z\36]^)=(8\6N#L=W"=NN\HZH50U$NKPW2W!(V;3U.K77]<
MC$$+VNX5N-FGQ60RRFQK5CKJN?!  G3=NQA[G0V7OW*6(P=@N1-;ZTM?WZLY
MRY<FN+[[T[M\?.YBE?-I.IYY[V#V8T?&+WVM+WU]K^8L=Q1)03LK7;KI(>>5
M?LSZV7#B.ETNPM]ZOV8#N\*-..:[A(#VZD.^?-5]R,?SETX^V'DRX4H1U+-9
M)5>!DCPDDB2,"BJ-"0+%HH $)$E0E?R>7&4_@C5@C8%\^B&=SHM?HN'7;#8?
MSA?33-_DB_$\OPK!1AB"B^/<%\>97[/!D6#A*98O =FJ$PR=8'@*P= 806-"
M)$-B9)#$B$6*:2[B2/)8:18B5,/1'U8P[ YY]Z]LF@_@/2P52HSP3R]!+KP2
M<^[#-+\9SF;Y]+8WSN>9QZIM&':=+?>:X^"'%H*4U66ZM@!%1103H< Z4I(H
MDX22A")6-)"Z+2'X#JC<_YQ>C@[:*"2Z\?4=LYT0L_':%0E"1!-@,(PE9D1K
M$\"_N.:4*&!#(8_&;)W1\<+#VB[19H?<]-Y,"Z+XOC=83.%%>O/KK#=Q#6/V
M9%][K/NY"I_GE_7NJ*JCJI.1W2TYC <1WA?C?GZ3]>;I']DKQ6SH0F>G9\A*
M4@,U!S'B(0LH0Y@PC9C16L4:)3A(0IK(M;8%3]&?+4%_ */D77;0:>GHC.(V
M2WX[C=EQ^JOB=%;#Q2A.D68FUDH:I@*JP'<E.N:2(*THCW;B]-;&O "GDS9!
M@3LKIDTK9IY-L]G\=<JU9^\);"<I1"TI$J'B6$1*,QDQ8P-; 4<RH@+^(SA;
MPQ<OZ>,H!@$*VNPH[PR"CG'V9)SF>&(IN QDS"(>,Q/&6@:,@0[&,7P>XC4(
MJ(<9IT7]BD2;X$ZO1K^>0D=K22<]AXA]G0V^/&$XX9$;\I*$S@EU^3Z$3*<:
MT 1&Q$&,B:"Q"!B.I>0)"9DF420#P@1K)JN:(JG\V6+E_NR([BCS09!\\EEH
MI\#T3S<!I./P9\'AM $+)2,MB*V*#0R#_S.8$F%DHK70,HZ2O3B\?:1)TNIP
MY!?%X<Z\^6%NL_WEYVV83NZ&O7XV&A5[\5_?!=^YW^&J?OG[AH=\'MYDL]Z[
M[%OO8WZ3CG_JK3]MV1C[-AS,KWW%W7?5 6YMN\&)+6_\/55NPFWC$I<'_JG;
M[YAH=W[;X^.C]NX/K/ANVA./I[WJ*\!^5WD^=S6+5K)\AJ=\RD:9X\9SL U
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MV7RI_SN_VGW9)\,.%1],)M/\#W# YMGHMI>7JRR/8@ 2#9RB?M-#=7;3TM?
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M#"-!@K5"<ANS^AE2_L78M20]FOHOQA\LS,5L]C&;9>FT?PWKBNHBUO;R#>B
MVK5=T*F+#Q__,[V9_!3M$0,O*^Z.9?>1.B 4)TFH.<4X!+=2X!C,/LT5Y>!R
MR(BJ-;2&-ND_]*,@&\1_@H:>.F#E[B'G:^YE(#GHW:IKTO4LPL'D-\-^'1:I
M.R2+>2(.KL$FO#,'F=*LY:G&B^:^/.PRNTY'5X=#)2GHG/*&?Q,C*A+#.&8L
M4"#;*1="!8P@%>O0K-+Y";L>SX<BRTT\:6. U76 1E-A$D*H 2HQ@33":!(J
MB1F1DB?TD,*P+!;\G/[1^.,)DA\Z+%*-;:6NPF\6-ZHY*-AEB]/1*.]7$=@"
MW^6.7$TAO=)ZF#3\>DJ.^<IL:P<E=NVZL>>]6]B*RRP;NT[KD:6I'9#"3J9-
ML!Y&==:[&/??]MY</'WOWXE,<RQ$4:.JM)OFN%];3#WE9&.!R8,)WL;!'SM?
M*QHUI#'2X)NRA!J9,!0D)N:$DI B8PR)R3;F^:/RM9XJSMNBC24%(RN24/<K
M&/IV0\/49;O9OMZ;0Q]B77 8"J9C)16<HF:)$H8C#MM-D@C%1,5RQYJS=]D\
MO[+0>:5=<;('2MYN<.=;.M S9S&4 &ZEX/[^;>]],5Q\B<_/CLO)C<)#).*$
M"Y7@A&G&#9$A26*CD41(&QV2'8G  ]Q^2&^MF;F2R2O,Q;:/?>NN1W[ I/VW
MPD9R )T>]V>E[-^J<M=IY&$$?6#ED![WDJ&Z\\H^+2XM8([M:K:=[:-1:>1.
MLQOPK6TI]K+FLNMK[$*+> 3O^_/\T@[IL#WM!9K2'E&NADJMT%"_7>>PS//\
MFPT:S&#IPT&)>>8GA*Q^+06YD4] L]^D_6SA!N6Y[+V%8;_*^PN7Q!^7G?4.
M#G(%V< AMBZ5:OG*_'S<=P'LYA.KVBZ+F'25 ^7693[_S\(:#7MOLO&_P*28
MP_('F6ORMT^<YE_ ;K?]2I-Y;C$9KH>7P[FKVT_!J+=8.;/>S6(T'TY&&>QC
M-JF )M:_/8-323U.5#J__I9Z]%E[^>+&35 8C8#BBO>!/;K,[+6#*CB_N@-9
M#<YF6X8KL)DR0PU>(]PRG;VM?G(N2=D^L FEH4!EL/M8O,<JTL-RHU?C4*_=
M$(0&% )P66H[!(KS\,Z;W1T+-C<93C+K&YR!;SA*_Y5/TNGPL@&U53 CL,[0
M8O]^<!W0!'9X,;BM<$\MYO.\[!0S'T-]?K.8NVB7+=*U#1<6$6RZ??K^6(%;
M52?L"548C$!,! %]0H543&/*(TZ02307)Y>X:,WAV,T&P6\WA,U:-"K;3"D<
M(N=]5VK[\%5L,J@K%B7C+ 335PN"&-%:8<(#'K$$F3"0+'Q)5/M$>>9M.4*^
M18=CB-V):A-#'"3/[*2YU=9?P9("?0.FP]5B!%;<U8;N-(2+KKS#!Z0EJNL
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MLUT23ZIHVYCR(4GT<-;GV]YOUEWRBJX"8Z^B0AL$5D&?R\F.$Z+/*DWLJR^
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M<[]^\T^XS$>#^[O7=ZY%>=1C/KGA7%>]G_/99#A->Q?CJX5KR?SD>K!GO7=
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MZLIF]>UECM2V$"UT6]&"-R$?["]<2@7K\5@]>A[PSA$YI>ZT"YBT14Y!Q'3
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M:H:(,?<#1CR:&_EI<"/M!D]TW'@RW"AJF'@5Q%Q@;)BBE%$D5(Q%("(:)R)
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M3KHE[]V&I1IVPZ N(RW7)O6VKL37%8&'388&- :TG<: 5^B.=5.:U$SITHE
M5D0#;*A??KW.%@ O+5&KE\7NNOF!"/F"+A=A,])MV0 XC'NAD>Z3+*C%E6_
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M %KHI52> ND$D0%$H%!*46\$/VB4V(,W RVW_VNAHH6*GP4J*.!5 0:EN;5
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M /1R*H:UR- BP[Z1@57(@(D7D%E""* 4 J20]%A;H+4#SLBE"E)/0 ;6%#)
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M*\]Z-Q>3?)3-SNMFO\Z/\^>>E/OB=L?3U8D'+WDZ&$TW8\\PQBL8LP&Z-"0
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M@-"#IYWO[U^0-LVDC=:I:<_Z]U8M;UU3?I2-Q_V"V-H8@6-&. E(K14/ <Y
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MQ>9'!K'J8\IZCJ->=6$*CMZ#3K%?33_7L!"3),'SQJ [R1$<I@CRJO0XJ1B
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M;13*1 %EVA#(L/3A&TTM<EH2BA0T"D+"M7RE<O":]:@]*Q]<E]>LV;DB[,Q
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M6960)E<&/P[2,)C)Y\-IG]W?AELUQI^&#^-JMSKWZ61_+\,XAQL4/CD&3'@
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M-VHVJ'.&/[YE_4&O%5WR^R>LV6R@]OJX9"M(5RHI:;VGF!$(AS%Q6&@M$!9
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MQ_K#AY5^5CK2;_6[!$'^S_"\)?.<$07K3P9:C2-JC?.=8]LR.82'@6JRZ![
M@?5>6@P=TI0*)&/W  D=AAY#P]4!H]KR51L(EP>/9CLU5%;F W "@KF1!=H:
M6A]+=&M9:T9@+2ZV;>!NR*I!H")3K:JOJ8J^I(6D(D-B(A4UD$'7EXH! JC@
M1'F(+02,*&<L=7IK4O%_LE[W:]:+1UCV/HOD5QV=/HBG0VAO5C/O(3 O*0QU
MRI5FDDCK/*=.,469<%XRSC A LQTOMA#YEVA)Z$XB(Z_^ZZ=(EIKI[M&Q4/4
M3E%%IEH+N'4+N%)K)V^Q5(HX!J&@V'N-,>$($"N\5XYO3SO]VFUU!I</W>O6
MSVQ*T*%:2ZVUU)J)GS(Q!T4*I]06:&D($E)2*:Q&' DF*$2QS[V<:<JTQTQ<
M:ZM[K:W"VI=: 70\1&WUN<#I=["5!QVWMY@@)$6>,I0**8:@TLA3R[CR&A+B
M"='6>V'DU@3A>2?+9>&,VX9719OEFXBBJ%Z,9 T![P$":%'[AD#/F7":.6>H
MUEHQ8;%0!GH ,>/^@"!@65U8"/X>6'^GFO+4/?-BCBNSPK Q8:X[OSTC?U>*
M]E6M:-?SJ^<W5USN08AU)42] $6+%,4\81Y0PC"@0GGEE)<(:\XH-!QL0-N/
MLKTLKJNBS)/:-?U^,:6.>]X%#J'"Z^ UM5 XJ21RU'(J#!,:"" !X0@3L3\X
MM*Q%08[X)IK/U6',:W2]DSR;<J=>]T9M#!R USV!/'K<R7OWN.,-'"U7;*Z'
M/K_:=2I*#;>=Q9(:C: EB!)#@RT%K,:*,4*1(7SCKM-XE>_>]\9A!&6W*=FY
MVQ0> 49KQ^F+,]A2R\LU^5'WQX7:7%YKJGN2U@MP^ NPL$;V'A:C7H"M+\"^
M.>#6T;RX^AXZB8LH=^X)4H)#HQR@7&#%J=,$4^>Y@(BM$A2P=364'G&YN?/[
M9ZBAPLZX];1*7J1!Q2K]+0ZU5;+(FXQ/(>:;.TB*2:/R997D779+%F_OS#[Y
MR>MM)(&V3ACGI,":>@B%0\XK8[TTAA% G[21G'?YMMI(SATV_/#'MZR99;<Y
M/Z2#).T\)H- XT?1]GJXZ<;&K=U>?',7K*^C>$GW/MA@=SGSWO5B:XI!-\$@
M_I4@:::/>2WEVW%-V68L$QA^E?>*C.T5>_FC_A8P.NQ1J:/L5;?3S(L*'B5W
M[?M^\GP#Q/GPL<"<5UHRM"1#+2(C21$XIP-XV2 9L0*0$@LU9IH0Z#@ U!!$
MQC+R[CK[-.W.B1MZF^_/M_MV5KS[&E!XG :2_LATVF_U+^YZ6=I\(E.+SD9+
MBM7)-]\"G4Y?^R7]U;J]OWURW7^GO58DBU@(:.*-&I+(WR84H@.!Q MF1'>0
MR/D'A?0^/?,3\1TV[#7Y#4[@K!?IMZ?R>Z91Y'((LRKI!MK[:\X=.7MF:>,F
M::3]V%NYT>A%ATEL5G??N4M;T7<2-BSK#TZ2O-M,ZU<V9*]2ND?>M#0L6#?I
M38% P>$OP4!LO1[>O,[V)_,:;+Z/OLX5DLL[:J"^.;FL"(I:G0,LV!"":Z4M
M,$0)!!B0QI$G<GG>Y=N2RW.'#8<]HH9M\K+F<1JV(V!VDEU?QUO\S";L/>3I
MV.4T2M@R;P^]J&FG$>Z3+B]/%QCK2E/=I#QEM)"G!EN#J#4"&FJ]E@IBXXSC
M#'L9K(.G-F>4='\?+;\:KO[I:,FC$*I6H,BL!"2+RS\TFXBY(_FW"*W40J5J
M0J5Q:$(% @,E(T9J2:D52D.+*%448^ =4/*)4)EW^3J%2BX5<GP_*IV1Y07U
MFWE!_=@ .[E,6P]IT-VB>E=H=D<OJ7;)U?T@WK10[[HCY7(<8!(_"!(FO8[G
M;^6H$P16;E2_7]RY!O<56LU]A?<1(YJO8<0LGF\!-=:PD7BUC22;P"XA$=04
M,D*XH)XSZ8Q6Q&)C@A&I[%.%>-[EVU*(YPY[I!"G/W[TLA^Y2RGOD#JEY>:N
MIE54W05&L=(D5E%UY_60E[(H0$*D4A@;QCS$% &B!9(02(0$1%2CF2I"T]IJ
MN$6F\M5]5LF%NSQK0<^49TYNG^TD_PRL;$>+78@,U@ _ 3^&OIU6I]'+TGXV
M#I<9L4:_%9DB?I S1O>ZX)16/VG>9]%W$U8[X&8G:=SW>EFG\9ADOQHWT6OW
MK)[]5LU[]@?YA<,SI.:3#NZS??T6EG1+'V?-5%7+_][TQC>Y"V;?\558W3^/
M<^7G4]I^2!_[47VXZ8UFLZ @FNE5"-\\YI=.X)8>P;++]M6?_H_[EIR>F9-$
MG=GDXKN^.+6GZML_$G/^Y:LZ.W47BP_QZ?GV1H9\=G[I+I++\S# ,^O.+IR-
MKR[./Y]:=1G>^-,S=69.U>?DXC)\\,6=759M"K]_/U/?[6D8[=,^2^/Q3;'6
M?(B!S@%+PW^,6*J,$@(9X@RPS,F 8#9 S&OR;N[/Z1O5M!E5-;^@U6F&)<S?
MSR[BU!GS2\<83^7=1>,F:]ZWL_/K4>O#5M8_ORY'&5Q&_(JSU>UNX\\/SZP=
M5E!@:3V6+%A[$FA-(%2(>4&@,(0=@W(],.N -E0K25&0PD(*!0**!QM18!ID
M7A;$WUV$P-Y]]DKB^G-+4E[43A2=[2EBA".-?VU6UI,M&-I44IX(0 $3"+&P
MLX+^-@Y3:$2K]*Z??1J_F-GTPDPKPK_IAY?-LN$3D?BM9,0]L?"6^DJN^X;U
ML][9L\K$6J;E[><R+!ZTO;0PR@\5 T]W'\*#DB&\W/6Z/UO- !=1Z9P<!?9'
M:!LUT.A^>GO@=O[(X=MX^:?6(*Q@(PSB\U34^)(W'L<O=N\'_4':B0N7I.6&
MT,FH%_2GZC>#7DMPV*J=HI-SG]CSSY_5M_?:-'JG26D;T3T#_8MZ+P]F+]]I
M \]#W,MWW[;HD/82UGMY&'NI\J/2>D</9T?S/-6E+(!X8+F35*\-Y'\4#K.J
MI'M5C/"WOP"[30C:[XRWY?.@%H@_9!@6?0>5X18+3:@0@@KN%+"&0F*=X(88
M^6HUAX+IOF5WZ6,\I.V?7W_MM3J-UEW:/NW\(TM[EP_=YX,2UU%02L ZQ:U&
MMQK=:G0KH1LN&C,JJ01 &&GO= Q\5$A9H[AS$%MJZ1K0+?80WQR^'0FTN5HR
M-<+5"%<CW#XB'"T0#C,9U#<$)+&4(DJ4!  ZAB5 W$'V:G7CA1 N5MK:&,#!
M(XI)#7 UP-4 5P-<"> XFP"<T8@RRC2 !E#MA% ,APL,HH@#:U=7X7SKYR8U
M. HV4/*X!K@:X&J VV. DT4&<*R<(:"USGE"-6)*2J\=\<0RZPQZM2WK'(#+
M3WLVCG$('T%6@UP-<C7(U2!7 CD""Y"C3&#G.(V=IBD*5JJ!2$E'-",*(C03
M"C^_M-X:@ M'[6R=[9[W%+@6*)*WCF<MF1F[7-3GVIZ_Y&KG;X=U4@)UM)O#
M)P32Z_;RM)=/]YU "7$<X>;N)#D?A-LD9]W.,.-MD'QNI5>M]C-'VN]J&3_\
M<=I)U/V/^_X@CW4^RF.X\\("Z5V,Z\Z:B<[Z=]U./TU^;W6Z@_M_W]^F5TGW
MW]T?X<Z-5N<O>?6I5B?Y/_>=K'03]_V96Z3]Y+8;[A(&D]X]3NK7#'I9.LC+
MP76OD[1YWQ[T\UI322_+LT>:L0Q!+[N.$-+M/2;&(G1\U^VW\IHX^C@FM"1W
MO5B_OA\+%C3N!UG2?KR]N^E>M=-^@)*DG=W_F=VVTI,DS#@ 7F>8T#-\S)-)
MI^VCY"%/L(S$$LMK)>$^K1_#A*I!-[E-_\R2'_=I+PW &2X8EME*.YW[-(QC
MI"@F43=(TJ03=_$Q:(G)7=B";G.2S1PCSI<.7E\H/9B1TF&-P]YQ+B4)JC"0
MPAHA.2>,8BF85TJ42\M]R_I9K/<0MM9F/[-V]RXO:-/KQ1S1_.4X(_OK<+;G
MD_69%B<C:1)(#!<9Q%][W>9]8W#>N\AZ/UN-HO;;F$Z>%,BY&(0'Q:?\+>O^
M"(1S$T5#_J-&3'GM/?XSYIFOKFA+MFB6\9NW*Z?D02"20#UI>#-<WIQUFL4"
M)VFQPB>)Z@\O#>R0T^--^C,6]FA$(=<<UGT*I'V;W[:3#2(#].-- OW>YVD7
MFR8N4G0!U$!!Q2$66&(& 5:&1^(2AAB"O)KION5;8;>RSX%]FZ>=09AS*TA'
MU>]G@_Y9-J_:[RL_UH]?TO_7[9G ]?VIQ/01&6?-RZQQT^FVNS\>OT5@?5J[
ML*JT2<3F:#.@<OA):[*4X8.PEA'3UYBT,]F 9##9@237F)?HA#4:^5'.0#.L
ML7&Z+^IU&JB@D4Q[;H&&'B (;:1[CTV@63=3TWHENM=I.^;Q7]QDV>!SMY'#
M[121YUI.H>24=)PG5/L>.0C/FB)KXZ#ULLI06>T4RFJ[V,CEB3NRRJ8Y@XI2
M^K. @"(FF53.>R.TA8$S)(+4*#@;&[(%SC U6\P>$<\&P*R'*YXC[.7I;Q,,
M]@QWK21#9U-'7S0V)L;1 9D:K,3[$G" .6;&8XJA4)) I:-N"&*)/+=!4P,%
M,Q2##7#=^(I8S/,N2SO?.V$$ZVMKMDG];@VV1Y7,CE*S/&&)=H#\_^R]:7,;
M1Y8V^E<J]':_(4=0=.Z+'>.(7'MXKTRY)?E.S'SI (FBB&X08 .@:<VOOYF%
MI4 "Q%H "D!Z>D02J"67<YZSY%F$51!29(7 3DB/:+!SC4#*G:'9L6,ZG5,V
M-MDA![)#1&E_.T"M! @Q+!4ES@M$O780:VB4 ((F.Z2^+ 5G&PF=FV%2"QUS
M1:Z3)==1Q:&R&!OK#94BF/V$8ZT]$LQ"$4L\)1NGCBRW0S_OD1HJ\X(.SNHD
M;*T#17_Y]B:O^@P;1O%'HSC "BP9.+L5#+JR'&N_4"G^,V]^B[:;BMT?MMGX
MM8:6K;X/1[_O"[=Y5"75C8JC9I];_7^=T=J\^T7UMS+H1B@S!)<1U&RA9 ]>
ME(+N=..&!:89%;X- QV7M1U7LPVR8<)D=Q,F:TTQV?V(P;JQP?1=$(*%JV1.
M>=S';O\I&+JC0M,[U3 H*GMF*HN4X8YB0P!5P&M@!=):(8&,]&Y&PRA1I1#I
MUZ,U6E#8>;I[R?C>J:YB@>)?".013XQ9(OSYW.@UETIF,9',<G',$+R<XY"\
MJ48X#^LF+Z6)QUX82R\\J:".O*2-*3(8U5R.C7<NLO^G$4:2]_/L>]XI8/OW
MR__W,GL,2]X<OO)AV/XL:^>=;X/[2*FQV=[0:_<<E)[[:#O&M@UC<KQ[&H37
MS-+S;:-_G\5XPY%/IQ]].EM4UUN=)$OGGF/2 \\IQ I2;:#@U$L+E'/&<Z[Q
MKMJX_M[IQP"/O%FVT*F X- EV!F]3='!L+_]L#ABV-] /@A@<;E9J6$VMR;N
MVL/[K\@+_4!?HU92+R'O;LC9'TK:"_?'%>I'%;(DQ()'"C'1"%/M%=0S*OD8
MGQDNC(["64:YF%J=B\PT.HUF*TQ@V,]DZ%!13X$I@T";?!P$=:?[T.H4OL>B
M%5;16[+S/?SQ1^#=&!O4#YO>CYR:WXY\GMW;,*D@+K*',)[ MN%Q@^=N%OWD
M_>RNUWUX42V]Z(!23*KP@M9,_,T1>M,%+-?9Q8GH>^J]7,NI;1LNYCYD'IXZ
M4R<Q$<EPK!RE%"C)A 74*229L\I.9%[<\_Y@2N0=G[2[G-/7H"+P&79KC$S9
MRS\,&G]F[6Y_.W)><2?)5$<*RL,& BLI-U1HIR%B#F,I,$;28/5:5/S>Z>6!
MW_\W;WX,@_W4&2V_&5%SN65]G4<J_=KX\\TFIA6X">9T^*[,3]#,[_+BQ*]:
MAX$*6/?P-#SNZ0Z=!X&K>_E]WNE'C2<2P0+C==FP=:,(QNQD_WYJ] )D?,@#
M3,]H*;VA9G(?&PL'Q.T_W?PS@'&$XN$%Q8G2$*'CAP%MHL>I=??] -1*2V\>
MY$X 18!5&%'$L, DUK' @E'AE)B-87M)G2:(1!\D8K39\[\U6IU(PU^[.O\\
MGE\KZ"Z%_+\.] K1KV'(]_WMPN^C^ Z?+?9V[?#(9M01MA!-80X91#' -TPK
MBI1NE91MNOU"W!4B:0L2_J_A <VW3H290'"[)C!6=@0 7GKA-1+2>BHHEUP"
M% 2<P8A[X&;@<!4"FR:NKUW7Z'4"?<WQ)H^ \>^K ^,JI#5;7* RRBH 8$1:
M&S\E$&>O.0:KS<>R.0[-ZVZSE1I8*,:[I]JI,W;I'$>2.N<4H] :!:7C5$'#
M-$5XU@6Q ZJM1IRS'8KS;V%B6U/K7:L7,"X&\8Q!M'NW^9#J0['%L?[(A;)#
MH;"Y7^B,?+J+_-WC3L=9;'6\IK-[:J#_#&9[4.:.?ZV.SO_]LCOX4D?GQ/O3
MC#QZUVCU1D%<(Y_.'NQ^!DIK$2"D$35*V]A'2B!%J<*,2:V#TN3,3*;^SGW=
MTYV_S<AO4IGM#]'E'.WIL)[NJ8["PT#3#R-"NAF\PLCZM_C#KP;<3"W^5EBV
MU.+O/%K\T>U:_+&U&7C+CGWS\+H_MB:N.I- HD]WDV"*W_)> ;^=V\4M_0BU
M6BHN.&".0A#3&*'"'B'NJ.9HNJ4?PY3%SJY*4$2]PSH(* (LD-9H: %;N*A+
MWP-31\#4$3"]Z_C?=3P= 7=@,BWL$-CJ##7B*+4:-]VG06'31.=)_\?WT>.7
M]W\HDZ$&W9D(C.YC/C1<@R8[<^[0[;VR@'I!H]^J?=^IEXPZ@?F5#+:LY\PN
M&.Q-=II1#N6Z<Y<C=NKE>38\*LI<$/?-1,\G/;\)/?-3)&<U]E6]:8'MX*5_
M&\J7CT/YLL\W?RY/&EN=[-.57=^C,W[ST^,;Y!#[3"TPP-CC(!B8C1\NLO<W
M\9_;N !/CYO47TO<E;BKQMQEKO;Y\O?N[BY:]G_DV6_#L,<?#LK<S<37B:]/
MAJ\GT0%%@.X^7QY@9!B[%*1U$6QA/KWM+CYO7%G9[#BP:Z.R ^G4ZWZ.V7T
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MI Z0VI= +&E4"8N.%8M(J5!!#846#FCO%?5*"V,(4Y!&%4M*L[9"=: $P6/
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MG%=:2\448(=LU55'E2FAVPFC6[W.#:L_$^P_-Q[3\=^QHOI23SWAI(1U)35
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MX-BVCJ!*JZSREC U86K"U#/#5%:><%'.!6  *$(1551JX#%P"!".E2#4U^-
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M1BQ51@F!#'$&6.:DIM!&"W(!^"^]G:^$/2O8+5N9/3B9/3LU>VZ.V>S!TGB
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M?LUO[SO==O=;O'30[566.2');%)S90*Q&530@KD:Q:G,AT"]@0B+R.F+[#Z
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M>CU*@*'X0K(J>YW.\F0="/U,XY\3(M5+O\&HU&\$0L@0:;U'E J&!0UJ#A-
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M  $I,%XAY9 11DIC"=0S]5\JX-+IE)%:<:D0.'%IXM*DGB62.CZ26@GXI4S
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MRV]3PO<N#GA8,JCU$'"G* 043(VP>;'.^TB:1=$4MJL4Q_&J*$[S_B \*ZQ
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M#"M0OW7_]\?\Q:VCE,@B1/KE]"JK9,VJ++6?CET23)T%3$WU/!8<$DL40X@
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M6RB@C_\'O*1$*@V4LBS\QZVBEN.MV3_%]T3V1[#*?O>)_1/[;\'^DD_8'\'
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M5(CQ%"$=N?8YSC,Y*R?]8M(0+![_2/KE_&Q8)/\&PO]> G_'!=CY M0/]7=
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M_^F#7*N7(@.RU0^%H(0#XZXI2CD'&KMM3Q%!EF2<T#7.!U@K6Z%*5H!_S4<
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MJ*Z%#3$WG0L_GJ^2M<ZG@YX:];/!T&N+]S<I9,)*"247'"@*#%"6$@0-L "
MS%%TA]11FD+HCQ<P %!%E5!("8)2( !%&;_;[KOW/==)_1"[TB$$$$<2.(W"
M:15;[TI'-][73>ZP=]OK?E=W4[M[_A W[&X:,FS =^L5MZKM9+ + QO69[Y,
M@PK6+V;YP)]MXV;<FP_SIK/_4\1*N+UM]KT0;V,GWGJ5!)L&\?;&?&K[/CUX
M;K_L>R>)CG'TN#Y9S]Q0\%FCB0O6? [.O'5?-]=\^LO%I"B2WRI?D/&^H+C/
M+W&?/WB7WSW;_,JZ_[W[D#0- %][ZR^T3T1_+;V@ZQ!>,\&@_LIJ$^X00WYD
MKZ+[UF!ODWXBH1X8H:*64%DDU$BH>TNH$5$CH1X$H;Y41-U3/\,CYWEG<.+3
M:1+<Y#[F^'_^32 (?ZW_"4[O5\[%N^E:O[]YW2]@?G$O7\[\XEZ^G/F]FKU\
M5F5BZ9G+W:T?/=-WHUYY653).W5LVH>?RG%1*1B//QSN\:G@_*GM6@Z=RK8Q
MOZWKWUMJ!K:V'?1XP^&N&BLF@>"B@ #C198'!$IBJQ1-=4HUH4)Q( PV1EL
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MC#MU0VM(K1+X$1[/1S'JX[T6_RHF93^?7OAM%PBB7R.C1D9]*8Q*VO8>62I
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M!K?7/0B'A+C+#I]\DIQZU7SHJ:BIY0B0ZSZ*8/L@L,5D ;:,0J!2F%%."15
M"X(X,2K-+",&XFM'"6X ;-E_8;>U !Z[GQ@^"'?=5D?$W5?$7<KON1MS/3?O
MH4Z;7,_37&0X!8_!++_RZ=EU^X[9<J^M5?:_29%_TU;%^=5VR.*N3M_NDX_A
M!O?DE])AYK^2-^?%M'087+H!%,\;.%HTQ JEM,.Y=_DY&BTGP_[W0;]HZH<Z
MB%W/(:2R_Y[JVF>2_/GR["_)&W?A[:+;X_?1=(ERNBQ5/>6 C)\MK+WVE8BC
M.H70'Y3E. 6W139WU(4MA/2\K92^ZDKH>Y-RUY7/-R7:UA10=SM:RO]K4.3(
M87Q=.MGI&_US69T'L HOG=YI#:UXY*K?LP"<H4.Q]A04-_ %0OA/_!-4<U)*
MB#PVZDTUV2]N%_)Q<.HDYI_S@1MJZ,!@?-/SID]I=:#4\,K1ZGDQF50=2O.*
MC$,?5O#KQZHGFB[+/\(5^.M)LK23C5L1AZK?>D/J4H &Q1:]#7SQ[AT;_4AL
M/[HK,7/;N9B"MD>C80-T)JSA&DLJN5$,"<:I1:F[E9 U<S&#5K262H3_"_WF
M+EV4YWX7=I"'6;FV*Z7JMZMA/NI&NAS)JY[O7?:7X(#WD10?^MJ)YE4QSX8U
M+B<<MI"MN:Q?M)S_R[;IM-7>,4+$""8U HIR**3(+,\R8#4FDB#RHNCTM!(P
M?ZY@Y[<NX.R0--,VG;8\KQJ&U,NXX0QC7R>W>:KM9 ,?E^?'=0>ZAHB#;*QS
M@OW'\^ER%*]K%$!9W[Z:=S/-Z_:P777QI@H0U,;G_).:C#D:!% 3G0M"<,L,
M)=K#C0G*K*!0<0FI4JF3 2:E7&0D58+(I<.-5YBIXIGR//,-H/JY6\Z;_(SP
M-#M,MCFM]F-CB+Y8IKTRHU?;>BSVLJK1GH70\*J-O5WJ9&V)".&:<<BRE!I#
MT\Q(:9R.8E3&$8:0R2=3)_8\N!1^/"@:W;36L9\TVAY(VI)GU:6W3BI> &D5
M:AQ/!L..-V-%'[\HAOV%,;;L+0DNG]O=)=7GBW8Y76^0YY5V<+6]XZ[D_6&0
M!67M^:@R,OS:!@]I)1[Z76N$/229[@4:VRL>*7*4!'7]MGK&&S]\>]WP7G&,
M[T,FVW9]\_MA_'>,\-4@%>V:W:-K=:XW[>MAFMF\C?2F&1 \Y0AAABBV0#NI
MIE$J&$M3DJ9K!A\>5O+H5+!@PGP\KQ<_6ML'9&T?6O$AC,6'L?@P%A_>6CWX
MI.)#NOL&U;OW]G4Z!$@MK1$,*,TU!2F1FG*H +<9-R#+'I*1NJZH=#(2'G>"
M]*]61D:WWZ;=?JWJRV\T3,,YI_Y%]7E=S5FDK;&Z9<;KI((#FIJ4X%0I0(W6
M$FN08JF)D0I9]I",Q#7;<GC& _#8_7P1S/?7N=O!03[\/'<@_?7E::</2#()
M']_H-+E>>W@[3WQWXYB%(Z9JUTEHBCX-'+FPDVO&.>IPSK:91K8Q5(%2J S'
M*8:64H@4RU)@ -$LU3:S8/-,TZ:5P5WTLHE,LQFFN8T95OM%W>P#J1R)1?\&
M=EGD62RXI-M]NN*H*OO")V$M7":VZ(=$EM0?A=9)O7V,<RS<_LM@YJ;8ZWK'
MHB\S^*._E!-_8.>-G0A/DC?UQ]%_N:_^2UN<33I:W!T.S&:GM^2R#/+6B9/M
MBC<)6M]EEAIF"-9* D$U84I9GCH3U6B<"0/4%G1"M]I.O+F?2$3Q=C#B[2Z=
M<!TO_RV-%[N5S&VWQ?W.(_[_B^$_\M&_DC>S\CSO#?:C,>]U#'M8!])!;U(Z
MUIB&&L 0A0L]1Q>7*U&VTFBT^?3MP;>PE+#%1*QYRK6!)@.<I@!HP##G1%JL
MJ$9D30?50UM8/B<N-ONX$T]4S3X'X7"ZN8MERQ7^ (79&HW$'JHG=9 EH<FE
MXP[?1\SG[WP\W[[]*Z&,S!"9X0GNH:-P^D%PJDX7*L(W#_!?)T5_T,![QZ/:
M,:E0W4'-3:L,!8;A*;Y&)ASW75[6'6DZ/++R,.^>/5H<*%B=D= \YEJ#Z/N?
MA4^VS&\(1WX[8'[[LAU^6VZD[-6H1O/L=C_O,@ZHRLE\4>/J43]=L?6Z"[^<
M$9([ S!HL.'@H,&3M>=[#H/PJO,.%.36"=*&L^Z%NZ/55OJX[K7F+;)KS;O7
MF.76]2$(O4(43HGUK1 GQ;#P%N1"0W+&T <W_8Z9V=W.Q_3GOWZHR<[W-A\M
MG=QWW\:LCK&I"GVT1'[=D+%RPL=#X>%_KMQ>7-NA-[_[GJ\+4SO-^X-AGK2>
MJ!M-[O"HG9C;._)%XK9J);59ABR40F%"0>K^@4X-@BI3F!%M]994'[>S3O5Q
M/W<>HPZ;>;AJSS.:&;=YKQJ<JSANY:3#G1KJKQHO5:U6W0*:TUH#6Q1F/QK.
MFD8<$_]/>8-ZXH_K^I^+XA^#W&WJ7^;Y13ZXWDRT;LA]U-SP^VD+RZ?EL%=V
M4?GWT[IA3Q>8%R-X6\6VFI:GDZ+W1S&:#/I?BYO']LD?']ET<3@]4=5+VQA%
M.?6S3;+)26*FL\*WAPAW+;^]^YZWH1/HUEU$A"]P&RA-C+58$&THDU9HIC61
M$J42:)N^/-QN-MMM57?E#QC)MW$.4(/C*_8%:H[ZP4<K9_VTU5K+ZNV"N_T7
MEUBJPHW!I/.@-;IO/+#AQNV^V.5VOT\T-&Z8V &'4RA<P(.B3!,EK(58 20D
M0QF7J=440< R);8##\3M#$#'[N?.X>%Y,:$M=9Z?3?WA!J.9\4?3?KD:%\NE
MT,N?'T)[L&L<M>JBZ"[]T;9)O(T8(B2Y0A@ 3!G"!CD)F,H,\,RF#&N$[JAH
MOI6\YPORSN;%K#3!,!^,&JO<>_LBW>\=W6_))KJAG]VRW]>C^Y;)O8T)0D?6
MADLFA5/]5$HEX]21NTP9!8I)N!URIY'<]X[<R]'VB?U)SLAGR0^:.6X<)&^*
MT;_RX7SFOMY_YCZ#UU-6?ROZ_H3A0:U5=_YTY#>=>>.\T[+MEH.&O8[9^>:?
MG>H[?OMKHIRA.ASFC<>SMG075YUU[>WG</K5RIW>MK[Q?.[Z/O=P_S7?E^&S
MPX]15:D3-.71(.CLE6Z;NN5S9#L:-&T[;]*_?9SZZ:Z'&X^:LN^/6@_"XHY5
MI\%1\Y&;5G!85;-3X]*10.?[U=_5F2>K#PB?O;WIP*RJNYVOF,I';DQ-]XH'
M64HWG'_G%V5-PZE+_U4SC>:NY39[><?B&]QZ')ZCDB*?#*_\+RLGAG=?5$7]
M_1FPEXNPZ;@AZ5X^ZOF#K=XM.C[RFZFX20"^E7 6^_^Y_)&/EH]8JDFX^F3A
MJP^^]%Y5_W)]MZJ;US^9<)T]N=%AN;PIFT E\5!0$K=Y*?>_$![%0OA8"!\+
MX6^M9']2(3S;=2'\#;K;;Z&DV$/XMW+XS0N7C_.)D[U.^SBKST7[^7WHRNP_
M^Y1/9OZ4S_W61S\4/P;SRP21OWQV2NFTO"S&D_Q?Y7 /FU\O.EZ'!M=.[9OD
M_^-D6"^O#H?K7'C;$71='2[4]WQ)NR*OGO^;SCJ\]5V#9]]]CE3WP+:@/'23
M1]C1/0K>FT:%<S>.^I,?216%K(XN\Q?>^AC/9#+X6B9IT,6NDO&PE[RI+[J/
MW\_';@+O!Y<#)^V/0JCG<]'O7RV4@1N.;_P_^>7XUSI!X-H7W#/_4OC2]3:7
M_TUUP8]R/BG/!J-^V>K<S3V+CZH@5CH8#_-F7,F;\.<--6P[;7[=)>6E@U>7
MSUSUR:?NL\MR$EK:=\BF/=6B]A_>6AD6M*K.^TZ6R/'FQM)%[CNO!XNDJWL_
MX1#KUJ%_4ZU8Q_E9SZ?6;=NP:]/Y?WK-8@FV1:#9$'-9^U38SME]-SZ_INR;
M*#G$-KOD_O!77ZLM7WYY3?AA;@M*?_!+EJ,Z-Y'/2O"FXI4'':[KX"^,RW_N
M[8R),UW=Q[?3ZDW1HU>=9W"#J+OQB(>PCO#7^I]P#N>QE]R.;#X[J"J^/T!^
M;^DLS*53GFZI$/=NFO#)DB1:+<GR=S3'KXZ+V6 %<P,$52Z_RI4RR?N%!]SD
MX_FYD[W=\[#]*;230)F%/SXBK-3V(X>B]3-K@7AF2*H4DY0AJH3@FB H <6,
M8+2-R"$+34O\+R^@./7U=-1;A ,;GU 7 8YN27AU<F@GW:^D;.L[8)H*0CG,
M>&JIM$"D"'"3:8I2(R#9>*_[2,^Q^]5VNE]]Z;"==^'ZH\)#$/[W5%?%5]^?
M>KQ1K6P.&\D8C@*KAOPEZ%.5?SST8-:E/R@\=\Q=G1OC];)PKO:M<LSWCM@R
MW[=)<BE2RDB+=&HPS;23:9G!&L#4*HL I=N19;X3NF_ -1^^B 9<KT">+>PX
M=>GN<!MT_5CTQB)O[O!6_=!-S=G*M]T;5+V;N]0L[@FL^H]R,*J[$-W$-DL,
M61M@]ZJ4=;NOIGW1-)F/+YRZ/JA/C]LJ"T( VDPTDQJ)D"5$44@I D)0HC2S
ME$J59H)OX91(_M)8\)7T.[FC=5>0.0US+O7MNI<36A9X3 NO#7;PBFZ#);>!
M&0[^.1\\NQN@J4(]JCQX1[5Z4Q]\P;><T A!IP<*IX 1P#DTRE*1,DF01#8%
MS&;(&/#4,UKX?Z&JXMS-#N^NRZ%/V/_M=#\.:ZEI;N.GM<R^NT6Y.MX..C8^
M^=:U/?5@YQ;5Q\*<\IV/+X[?_7?2\T[K\R9985A40;6!;^MVZ>6^_\+CH@?7
M @8.-V^*%-3+>[2467+O4;LK@8.ME]$XGNNXNU*& 1<<"RTI=)S'"=+$,@Y3
M*#!>TS7PT$3YR(BW,.(^N@#6BUK5,UHVT</!2J.93Z"JHB%>!UEV"AS5B555
M@0Z&)\V3'(=.JXX2WC[PS^B[31N6X]JT&/A//8/Y$UR+B=</W:BKC'S'Z?Z6
M;@BG(]&6/[XC6^^F,UP;OO??>OQQK8L^,>M^\6^%>_]_#R8.4@;Y<DO'?"D&
M>!TNFRP\AUWC<NJGNC@EMYP/6SQ:>DJU'&^F;SLO6)IZ)PYXDISZ<[Q75J83
M)PSGZ_JG^@VN'WV4^*2 I5**LHX7A+OJ@BVVN-U?\%"Y/+^K[A-V8-EUNN9$
MZ(S0N:9A%RV?KN6C\V^>2LODC?ME.+_,G[^39<>]Y C]*#$GGQVJ.3H[.ZOS
M7DZ]('C_/CU*/H[*&\JYZVKN8(+GT_D?\^0OY>@?Y7I-.YY<BQZXU&?83WI_
M)/_YYUQ5(S&_98GCGW)4^K9#P^+K0F+<L <+03#=-HCBUN8CT !!E;(H(S1#
M5@%)@*3$0 &M0M?JN-^7T^DZ(/I W]@ZI3>_G7JJJ(C"4X.C@V4R<"M>;7W8
M^4V"X?*L._C^\;RS&.N#_:W@VI#% 53LU&&D[HFR52"J]F7Y=/QP?>XLJSH;
MP;?R._Z4';^'X=>SLA_2VZY5_H3^>X]+L'3#VTV&I:J54X=>?POC_UN1J$DH
MH4D6]OQ^)XDZ"O5I)),\>>.P9SCXX4CK[+A_=?40@; 9 ;!(7Z-'/C/&J=>5
MT]6GQ?V]G/S1*?8Y<J3VM?"=L8ZV@NZ_.>7>J=MSG]7523(KIS[;\"A)B^'0
MW>N>VVD0T@B@*HER<4=5S[,$_"L+[2?C[*@Z%EJ93_6KEL8]'_6+:JAG7AL,
MJ)PL]N]HU938L@ AK0-#8,M2;"6W@E.CM-.\&76J.! <:2S8_V/OS9O;1I+T
MX:^"\,[\0HZ@9%P%%-SO=@3.;NW8LM=R3^_N/Q,0"4GHI@@V0$K6?/HWLPX<
M/,0+E$@)>[A%$D<=67GGDVT+$,) 0/JWC5;/2\2'("18+R CI***B+A,$2M=
M;EBUHW!/^>V"<,E2!EYN2;L<O$A_[,^Q4&?A%7GV&'A2K6J+T3:<BC/%'\;I
MG6#IHK8,[]TST9%:0HU#J&'KCAT&E$0N=2.5J+YM>S95#<N<"ZS/$!T??R"A
MYP^;U/;3VGY/=+K7UO:27EG0NDA'_83[I\H> L@\V86PO[#9U]>@6PR3F)5T
M[)LX:]!(U#9-GT2!Z]@D<"(WL(E- X/ ?WU=#UXG1]R/LV%/9+I7[*-8-#N3
M\CL;W60L>L'>\U&B] @V*Q7A1ZE0-Y*TZJRY#ZNO]*=#QHOODD$:SR3'6[T=
M])Q\RB/:HD'A[*@PS5WTZ^&FK532T$M<"XC#[3G+$I#1[K5[51U=@V2CJPOM
MZD*[NM"EA9T[U87:*P[P4R;_'\ /T^O'/9C,["4@<415Z$=FE>'8T!^@@PF8
MW !' VG63Q(<7M$L0Q%B3JGDX%:'<7Y^[97C/[/K]U/Z9R(Q[YLNW3)\QA#V
MT,8>E+DE*%E!G"=@_/-64G 1J(/#*<LOO)I.6('54.0X,D&$N!B@)_:G7$],
MAME#CTM7?@7#46^.@ 6\^-!$P.Y,^5IJED*Z%[(8#7,4E$%\%Z/_MKH57I$F
MF&.@W,>@.<%X;W+,)>1R,.9*GC(&W8LAG*6C/Z8Y3U/ 1AC97=I7AJ ?'CCZ
MC5M<)<4D>]ED*EG<JSF6S590<ZC>4WZ/\U&2GWZ*48&<B(QUELO7AQ=\&<L(
M0CX6IUKZ(VNF+X]X%S!99N^F++?R$>EB(G!5!@GJK2(C7ZR&4L37R>11Z0^!
M%F!+F+HV#]F","%#7K,Z.ZITM'@2]8SW07(W F[ #9\IV % CCFC+DS( 7*%
M@\";*J;-<R)_EL,]E<>AHMX^,Y2Q"G:G&C!16OG__D.SU)^T'@OT;/VP'D\#
M0N49^SGLV["S:VV1;$-3?4^U(I,2U=(\PW0\JKJ6Z6JVY:SR.@@CB#L?%AES
MT3D/D*PRXN )1<'=S]QHDW0CR*9&R^YH\$_.=[[@AE;I>2\4'9&W!)Q11GEV
M)X0B#JV_H"B'+5?=S%.7&'EHX VRB;CPW<_$ZA%5W4-%#G=^P5;C(9H[LLPY
M*V43/T4UP<6J?\=\/?%T2Z%P+8PAQF8X;!':357JFY0L3TD-5D&3_!AG!5J(
MP!Q*1E2=Z%BZ%<!P^W><#_#ELE(9#OH,GT&K+^[_-4US@<K+,W98A$9591I0
M# PS&PX?3SEO+:9710K6:<Y@N<K2Y^:3TT+4YL%(DM%-?%-E-K'E*I ABHJB
M%.U>H4N*!*9AQEJ1\\6[2V*>_P>\F0-X]*1HYOSK#8?_P7J1Q"C:=/'"+4F#
MS0CV_DFRS'VJ"!&W%@;!1K,AP7*17!$FWB;%&M #3G:,N:5P$SQ@ACR!41V2
M6H4MI9 [L/9$++E *>XPHVK$1 7.I]S!MCC(0F8!#T7P:ZXPB$7+F$8!A%0N
M8[7H\!N.:<MU?74G;E&IP?5U\B/+FX-BB.+,J2=(BPDT_ Q7]>7GTIG4I+[Z
M.+ZG=[!/&"C]EH'.^I,R/X5)#O\_D ][2 >3VX\:A>>@-VHRP!_%'Q_8I8W+
M[S'3$42;6"48PF;.-3EV7-Z/*G_IQF<#+6C=^FG&><&'OGR@>W<#+JJS^2IY
MX#GG@2)18,'0V6)_8(2P/O,QY?;OV*ZCQE? B$COT\$4QEP)"> C=]/A)#TM
MHRG5CRP"PV(O(H5?2)%I(?NVHSU=YPAKL:HR4CYG#Z.2 =(=QE,&@Z:HY/*$
MZ!L$K^ H0.*H82EE!@_B,F3R.$YX]2_?"NXG%Y?.O6Q8ZKG"6$J**A-9CC!F
MLTDX].A5FH,E-^ :[.:#15[ZD-UA)&O**K)!9MV,8M"9%SL<V.M.^>O*D3'_
M SI-L+D(LTYQ><>H1S/[E'/_F8B!P5=";DCCP=RMP13620X*UG62HQ;(#$MX
M839,!\Q:A,&>3EAA]KCR>S&!HGQF]%/&'"H#0CEIL:X-9I27N[F]7M_FD/Z9
MC(;Q=?P#"^E_?1S NMR"QHJ0P,I7J0!]$E;Y8WU=/@>?3G63T*VGL5:;L# N
M0($:-:)!8.2-BL?A?3S"N)([O,M$PGT53.7'_CX;3D%ARU.L""@CK[PEAP0H
M8DE02W<?T^>!L.#9,6]+U\^R',B&D5.-(30("J95(?SVJN*$> !V&+XC%M8$
M/. 1<^(/2P792-IWTOUPI;L+9V&23SFF6MMR?2]>49!7(V$L" !DK5=)PLH?
M6 FI/CJ8JDN8#.""?H$4E[);J "_/R8LT7/08Y#'E3%6M7"#1\;7\#PL^6-B
MN;RGNG[6<5(/A$NQ^3_?I*LV+00@(.\/>BK[@Z+-,AW&<\K!]T:2" ZT7GO3
MF#X7K/#6/ %)QRH?8W$%BL&4PV8)9!&N2C2KDIB3!%O;(42> /!ZN,V =^8@
M9H%A2:<M6['Y;]&^RI/T[FJ:%[Q.*BU!KNL^W[I"\3_?\"Y9J5/[EMGC6+4C
MIEI;8?83 _G33'31JE0!/I\.>3MMX$(S-\BRILI GX+0>[B>,F<-BW/U<1,&
MBY8;%ZM)$^(Y\((A$*E8P&$\'?%]63"7%8O,Z ],_VK[*[U3'F%4:%?2JDR'
M8+?TV*ZC2Z7T_@LX?7DN..FR)\.3Y$.96"MZ4N)5ZB&G_>L\G@ZF0UZKEUV5
M_A"<UAT6CC'+>RBH33ZTWB9Z?F%J%8(])<$RW/X:-[/0$X:=!1H<ZG$UC9A#
M'?+L6@Q"L+]X;G>Y1ZR MP[W/I<I6+WO#)216M5;121X[ K,(D>Y*7T7)]?<
MV9 ,K^4L:[:+I"0T/T:@'=S&<%FI@4^8@B".KKAY"<M[W_1IY0CC@&A)<,YR
MZ4)9>=16\0">P-8X<*AWR7-15">CLK8:BO?6 *.;Z$8+'0\[9WO7\7=[S9'R
M"3042\$J:]&MBDXD%Q)>^2O.,07W6$&V&"@>)/TA1[_)Y$MYTA870$M?7(;&
MFDB.9.%LV'EBO!M4&"#4ZQ3-S3^F@QO>KR#F]A+L_<)Q\E?5136/9_,B5.Z+
MFQUI(0[RX'0,ZG#>2(GD,K-VUJK\K7402K[?IOF@2MM:A,^ZP0,092C)Y4XW
M%ZX$0ZTP5'!6>0+,92#N$!LO1MZ\?Q="?PZ_X/]EP^QZ@QJ1?71M?9UN(+ZR
MZWB!^)4OZ 02 W@^'U!9^P[\[B;+*R ,T#.N4Z9KX[ 9H";JA/4,!;FN]8I^
M_?4XD<1>K.&C,4Q]=Q_-L66\FEW&:Y?QVF6\+DU9W2GCE3YW)Y1W/^_H(ZZI
M#ELYB>M"Q%JH.-^ S$#Q@&K$7<8V!L<']O<=*MQ2@^[)=TB\)Z$4,J],Z<@6
M8ABU1VY=5X.N=P<3(UFH'J_64+=5H6>Z*VRB0*,O+;];;WB'E/"P0"'^E([1
M/.X"Y9TK_0!"Y W7>;U#D-9;YCEJ^*D%-6_D/^\I<66R@(DBD47*9-V&XUS^
M*EV8C-?-^B^_Q:.K^,>C;%XD/KYO^-N;CQ67+'+<<NM#SF&YCWS$Q"@B?O>$
M_<A-/.3>^ ?# F=+E\PZTJ43'2Y-D$+VZ3"76W22Y4_Z@*5_3US_?J4CO<0S
M4&M>]'Y2%*4W>F-O^@DKIV/4]A4&DPW>SVW0>CYT,8E-'.0?Y+YMYPGOS=J4
M)^E[ 36FTIJG"[:FF,8CYB/F7JI:8I^@RK+;3M.1W;3892.W<JHUO#FI5,CG
MQ75,^H*%I1<UT92D4CO"'+0! ]&24? ZCT>>;\<=_O#BDS1]ORK"@';O-!>N
M/[[@W&=?FN>+'/=B4$TO>OU4%@V&HK Z!'QCTZ^^REV^VAV^]4$2[HY9VF9*
M$;)TGC"PP,N_S/DD>6*YO<V<4*&#EOQNEN&R$E;N695J)'-0(8<3Q3PE(ZD.
M'K\+,1:G5W!.1NCFQ5R$%"1,7#8LD\^3?EOIB!'/+3B6R=.Q"3C<13]/KQAP
M*NP"XP$+6/*2H %OC;O(V8)2X%F=+9)D*C5@SLEBM.!D:1@Y6SZNGPVS_.-_
MJ/ _U]>8++3UL/89GVFJ/<^3/MM./*@!NFX([,F5H2$6501B_@/AZ9/Z"5L4
M$&DT>9OM^;C]JT3DG[/7Y<>G;FNZ"[*JUK$QLWR @9VFK9O**JVY,6YGB%8\
M=V'DC?.B9<8Q&R%PJ-%C-3IAMZ,O%R09OTX:[FP?<"R(TI$TKL%Y97?\1<<6
MEVH*@9KOX<E@U6$EK.WYT+O#(F.*0BUX*K)1+[FA,(.Y*Z7\J(;JU;R@GCDX
M4]924Q^?D/?%K, O:N6[3?UHR1@Y%11@VXQX2R7V=#ZP%U01.G_*MOZ41=K+
M?CPL^W&O/6]IPI[JHI;$J+<-36\4@BX!<6HBK\)!QY"RHH.4C*\2])VL'_4M
M#;=:<'?=%/X#\N$V6IC4%*ER805'.IH(<&G'NO#O?8Q$P3//^^GT[CVZ=<#B
M9Q6FEZ#U@+7*ZHIEY?_3@>.3BPS4DO/WW+@A:MO&S1/)7Y?9%)1#/\YAO4?Q
MF7+)DL]XM$,:QSQ6+QZ\?,W95E8I.%DSQ5$<H-F\*+NU\,Y2W:J*Z_")U&HD
MGYS0DJ'N-?X3X0^WI:YZ0 =Z05#FGRGV>#G$+*4#D !WR3 >@?8C?783EH8>
MPYFX*MVJU35KBP>^YJ]".LR&>-<4#55%T"%(AF_)1[$GRLEE.@3]/@:J@@.,
M=4>KJKIZG.%;CK9?AG\!A'0[&[.OBJ88HPN2?NGT@ V9W8SF4?F4,AX[&LQ\
MSSJ%\"0_?DUOAUU\6MJT+N&?WD<&WXR=; KEY'L\B(?X\S-L[]FQI8*1+A6L
M2P7K4L&6YG+ME KF; !^^%Q:H _#AP/]XUF]A(T,#-DCQER>?=',M%@E+Q>E
MN%6NO'D/8FGHU!/:RRR,1NJ'7*VY"/U\I@0;894NP5H1UA(F=LV1J'*XJV2#
M'L-LV3!U@K4+XW'@FO+*,RE$3/BZ5TZ\7A15?B<R(QX5@X/ F6WE1FR9"%$.
M;,U$B!JFW@[)$+-F@&R#MU$)8(D0#:^1T^AQ)"UQ7(K;^*Z>%,&L!;#_LZHM
M)CPWYF0_>_'DEC76:-0C(5P7:C[,(+J>YKQ""E<82$4N*5R9/SZ1CM!^YD&Y
MB;R@KDY><QKOXC"?=$.PUV.)5M6SC[4^%+X)IJW6?%:+ V3-LBL!3LI0(;&\
M:PK+4JN):'C XH*C<LM&*(V )3LM^)AZHY0'R>QJ ZP7L<W%0,N35!]D]>T=
MJYZNXFX\;V><"* V-J!ZU'1QM1LHU2EGP+B8[%URA>5W-8?/VD.>'1P;3=WU
MN#B%>*?1K+%&/=%3=AZ'?6DP>:D+JWQ=Z5:J.;6J>L/ZI!<[UI8&KA>];*:&
M4N1""RH3SZ\N7C]2W6J@>L9CMC"Z^\2Q7DI6-;>C*.JO=S&>/8)VKZX/+'QP
M6>S):Z='57;;:3HZ!18VZJ?C85)#+@!R^$/41>,31\D-C*D41;&H%EU8&<JT
M$A[P%*V1>URY0!S$Q0RJOMNEYL3FOR.0ZM]6(*GJFE4BJ89^$/@.B2S\KT],
MVU(C1U>-T#%,T(*-.235"IZT7 ;W+@/MP7V(@=8&WS.&;_H5CO/CHJ9S)FRB
MJI_"OPN;SK79LD+*HYGK+^'0)W]-8>#A/?SS_7&<-#NY-'^?PT&=%H,Z"BKB
MJPL85.M)&%3'G(- 56 [AW7P\2WW?0>_]3XLE'-0/;!]'FI;E]EPNB"T^>R(
MU$L2R*VV3)B%+K]SV-U1EB[H728[B_V>Y<,!3\[F+<K6A5Y):VM<Q+B&",$Y
MY;QRUEG=,',6VS%UT!2!/,&-F?K<EQ@V3XREQ 5]"NI$A'RXKFBT W;2A(@7
M5D@909A_GKP9%HEM'XC.Z0148*XQ<DG$U83K] =JDGF<,HT2U0+<KGIV-GHF
M_YT4(IV8!259O&3%,@E='UY<+?EZ!M&"+5^ UP$/O2L2D$<"UO5IC3\IN!<V
M'K%2[)&PI 0EUS=QI67PU,SK]"60.)KT<*9\J6E:1D^(_X>$JWZ)U"QD930J
MD3?#[(J5D%]/>2P03E(\?@21SE.,4*'^]?RRE/VRL/R)@3)Y?N[_IGQ.!IA0
MPBW=>JX[WV^I1&">>)X5Q:G0M?@Z<(QXH=3@N6 >_)HJ4WM#K=5@:=^7&L=+
MLOQW/U\FH*\SU'>6.E;O*2^SOB6'PTEM+=A8>ZAM<003H([L,9EQ#?43H'!N
M>@P4EGL#.S;.DA'V5<)N467SLM]&K&L%RS KMJW.Y#GX,ZT&V)&ZQR#C34D(
ME8#!M9W(6H/_PA8C?1 /57)V -8_*R%D%%B-GC>^R/K3NZJ98 4E@L>C5P<#
MZK'#*CT;Q2T(,.X(F.%44H#784_XV6C !\)AO ,=B5-V(7+[>%T&M^5!VQ92
M[";.!7@*YLNS11=(A0OG/K-6*$X1F?DY#]ML#43-Y!&F=]D>U9U,LGR4/"JL
M+SPR(4Y4<;E3N"/R=#!_GD@\3$=<>V1;*R] >$4.U9U@1F,?&Z?)+5W^SAI:
MNPS\<<JKS[@$ 4\V>'#!#1P@'7PF[Z<&PT;EGQO@]7,OEGJ'D2PDB -/T_@5
M=C$;L?[#3.CXTB')RVIXJM\+9W$(XYKY3\3H&F9H6LP!TW-\M#5489;BM#SZ
MW82&DHI#=GU].HRODJ'@&4(M9?DC8CVE$*^: "'+0"<>:X^0Y>D-&NA,11-:
M>\WEJ!KB^CIB8#$S-+D8W(=?:;AL[J5310SH%'3J82S*PDHX_2O1_*;48AR'
MR#Y]PE>D\L(*IDUGK$,28]VSR#=2=\-Y)Z@IUR? ?;@KLU#J3!NXS10.(CQK
MBMK?HLC!@9^L<)C^-4U?UI1L.0,*[_-R(,5L>/J9N?4N88I75W"FL.W6XUHI
M4O/5F@L#77W4RWGA68/49MH1/>0@NM&@&B3QY+:G#'BS#S G$DY'\\E3\A0W
M0;7Y;FV3.W5 9#B76&L?>?:4V!;EQ!VG/^*K>+06%+9-S/WF3"V4&E(1$<@<
MP[4\[4N]^G*KF!M@M@'0ZM348\L,LKK,H"XSJ,L,6IK:LU-FD*:^=&H0J"+U
MN%L)2K!ANCQGF]P(6QW]N\1FF+7:3E<8Q0B?$@NO<MD>[*HI$%>EF!Z2U%^D
M?([3K\G+VFV-,,:,3K)>&&,)YLW58YF%5(^@HA+'9CV'Z2!\W0R8M$*L^8?T
M)GV&\0_2>%1>*-];AA7*NT1D_//C$!;CXNR?9]R-4'U6_%LLN Q_)/TI4Q*_
MP*U]YF)$_10T6@^4T?[M<I"<Y> XLRE?56SD#NRAHH(^G4_P&L<IU_%02<>5
MKV5,89!^RE"*9_.RT/4GEE0:BF /.NVE7\V&X^/2O22L$>4JYZ6K#?=_/$<_
M\.43:,]S!/$/5HHE][VVA6B:+P:APWW'6$>9@ #L9"[7;Y[*>O5AW'"_%-?S
MRA /O[WD<0L?(Q>S%L['=+XY")O*72GV329:"=\FR[-J ./SR]:']"D/QTPJ
MFR(J\V:3V7C QYU@K3Y>-4K*O>4MZ]A*%/6ED$M0.U5\<$(XR,%]B_LPIP1N
M.!]=#Z?)J"\JG_TLSZ?CB?(EOXE'Z;^%D]=%BFN$V>#UG-?(.2W+QIN.L'DV
MK!XLV6T-7+L&O\5*N*N(IXS0Q1,0'%=37CQ=9$-L-3/)>F)N7QNMHXNY[5L9
M*:M'L^:@YOG6%J)F3W46I[\T6.\<Z,MJF_"Y 6 ^RHF=P']'R?@VQ\#7^>@/
MOE\]Y;?+KRLK+A>!Q^S06I@;G91L7&#Y#U X8I':Q"/H?')54V4)'BUX3>U,
M+)9J,Q!8O7DQQ] $T(\GDA8/7).Y2'ZDTSM%-W_])HME)]DHW2"C_,#]:K-8
M?<*1W$@7E[CHDP4M[^LM,UHM4OPS'8R2QY(4I?=M@WK$4LUG>P97W8WA@MOT
M"HNE:R[QHEEF><_2T&8V'N<O][["UEH+MIP%P5@BNDBL;7)1EJX*_("'^+.\
M@7"^F&DN]*>Q]$6440?N5T,>RE?R]"ONR+G<D:==:SOTR!,5[!NSQQJXU6$S
MJ0#V<A+_2(:\6?W!\*:5S&=! '1S#E+C'FAL".=R4ME+Y?+4N N8*L"Y4)>Z
MC5-0^+-",(0"%H,%PC&%/OXCR]-)F8TEF 5J;ICJ.9=UUNQVDC3;"8EG7.4<
M@T $P7K*]_A'ALFWS^O[;\?77\LRGBF4?K*'PJ$QI'(/E).25E9X^G=6UTQU
MZZZ7G[(IV-OQ*-YR_S6UR9?0NDBO'_? FMA+!IBFP!;M(TL<P;$AHS#.E$]@
M<0QQH>76,TM3^TG\Q\_NP!S"7$)&_BQ;&G3K":S(!H'-E^#(+EA#<$*5WV_!
MZ&+9=E^95V.>@%Z$2:^I]*VC\;$CSK)V:IR[P:TQH[4F%'A3N05:8"U-$LL"
M4N22L5C'AW(=N7?HQ/W]Z_MZ%A#G++.(J66F 0]C@>IX"^O*<I?BD;0_F>HL
MWB,R4/%B9L;PGE7E8_AD88NYK(!!8/;'M!"MN!(@S#NT!\MR1&:M#U'J%")K
MBN?QP&,P[5_QA&V$WZ4#695SQ_QD>7H/*W5:@&7)4K2**3!2F/L83.2^W*$[
MD18$0G D4!JQ0]B.91&KJB(<6E9%!$17:6#!]XY!HLB@JF4&.C%"W_5=DUAS
M51$@:7WF^+Y)1OU'4;'@,X?&Q937#]1+(:)S5@MA+"B \$'&E!4,+/4PNY9I
MY/\$VIP6G,YGBAIVJJ!H#A]VP7N\B/$H?+FNS:H<E> #)1M@7&"N3(+-OEXH
M<7X1E942:J-2 LD!JR4>,/,K&;W[.1LE<[42N]9(\ .4+>SF)\ITR@SLFE.P
M5XN0 ,4V&\;-N)PY&^B5:?^]W4!NKZ\1YG8GD-N9]D;[.3F&:G4GYS6?G*KV
M41" 1$^54D[Z2PM0?>-!&=F8<'%2$SVUV)) +RM+W&4=GQ!>E5PLF(P#<767
M3:KD[)I@1><):PZ'\1D.7EO&799*3WYTX_X.>F][QU1X[!<CQ+-R])<?(L8I
MZO$,EGZ-IZP,LTQ'UVAV@FDTP*VK.8=??/2+HA X^.DDJ8/,8E;G)!:&*=\%
M#O=:-X+[Z7V*M5(@""928VEZOUH!$*:;JL%TQQ2:O=D-GV'QX:!FI]^$VW-C
M:V<_27V:X]A@N8K1E0F7)Q'P5U1JQ0_OF0!B(:=:KXO^;7(W8SFPE.5QDLL*
M"$3KBOMH9*>)L/]'R0.F)V>L2Q18D&-A1/9$G60L6L.(3^]Y%*P83_'(B3,'
MA@NOTA 7,7>J#B>DI\R,'!3I_$8ZC$1@#%[Q_^*[\4_*;^,_LMM1.6NX&H=5
M7796NP/>.VJX/%B$Y :X\W0($T?5J)IW;:)]X;$J;;#''I/_@P6KCH[)<LG+
MPJQ)-7D6%9L\9 C'<L/;="1%S0JJJL%2MAYZ?09X0=S_:YKF7(14CKDR'1OK
M2IA--GP\S1Y&C6%7%42'Y#5E5#Q;6\1LWG$Z.N4$LVQQ>DI]P;$H#OBC*.%@
M=2\#7F7*:V@>:TMYS;NX( (*=R$A==>*C<HK2\%PS<FR03!7TP+6"QV4C7%@
MN0L7[5PE8.$X^14>L&H<"^JJRJ!SA1Y>QUT1&1V8<X (.5E>&[:(W"X:(E\4
M'!DS%LHU:0[G <_(L/2J59??C3,!Z%-+-2A_AA,"K&10BU-S:))%,S@Z;#J[
MRT#M,E"[#-3E*:2[I:!J&Z:@/H/ 2:5:)?69307+$J$RH]F4HJ54PR2SQDI2
MEU=B5_%TWDL[J^4N"<>E?QN/@7X439,F#8M;>/'H3TQWZF/Q'F(SB-F4KYVM
M+<VNAH)'-U$:-A@VRR$!@_>.I\D-T[M4S+U()S*;2ZXJB@^NHV * ].]DOE.
M74NWZEE5@VI.V^UGS?;J,3\P)MI4R\-?R(1F_:V-Y1)3.)O;1]9]J#;9Z@>\
M8RQLW=K4F?">L(8I"Z<O,D[K(XG'8Y:A5A54]BL# <=^/46/4;-QY<:KA)LG
MLI0J#:D0VC9++RD])HT%E4F8;$&%+5(.D/4^P2$GH_LTST8X>XR#,N6D45HH
M'$#)#U!V<#(XW6SXV+\%"UZ$1:_2,:A(C\/BK-H7KN UR2U/GD7=VX@"N0(H
MW<4'HP$>6H0P;)#)QF9^._()\S(9/ B8;T#3-0@$QMN;8_Q:^8-<YJM53L*O
M[GL%2X'SG./M@1D=(U%C"' Z0#:&B5F<!/FF+39[!FE1BG>DF6G!LP)*"A/>
M@4<.2H2H:K\BZD(/*\89H?<E_@SVP$I9;1MPO5.6JGX-@TH%J?%QS0R(UVO_
M"CO#\@_\RMNPW0B];,IJ5;/LSUZC1]YLVSBUQS!8-EW $D6)KT+U[@<).G!?
MN7]AD_BIY# P=SQ3&=U\DWS:;_@H8<70@YT,V"R0 ;#.P4(# /KZ;<R3<]W!
M73K"E 0.@O.%0><AJB<\%4\L&Z]X>:,@4>L]L=@\9 0DRI!T9MY1@:@!^=6Q
MY.9>CK+E6W*'R'("08"WH6536>.I[QO#7[3VM?TMU[[>CEV?P=R976SF@X<#
MG][)Y49N/ACD28DH6?!D:J:2,<13!L2"[WV()PQYE2'D(JJIW'PQN&_ S2?P
MAF\POWR>Y/1>.;,2;H.'ZMA0TK+UWZA,0EDTW?)@W(E*JA%K%!;7, *K@@/T
M1_41K((%L'F^\2BI-4&!]P+))[!C4Y'MR<[%&D>YB?QH/$E>)Z/L8?;W3Y_\
M]W/PAUN37H-P)JR^ %XY99X^=H@F\9\HLR<QRX-+$-8V29@[=)!@ZEEC31[+
M'9A99.Y(1S4I9YY(U*?Z+ UAGM6U@)*X*JAIFF50T["B (Z9;OJ4$,T-G$BC
MCDKMP#$LW]0<&=0<7R<?HVJLESA4'L3\<OTIOLE@/><A$8W_UD 'F=Q^N68;
MOFUHL2'6OE5$/QNZK,49AVQ(6P8:&3)3VX'&>/!'W&?9)7RUY@\ZJ=I']N8!
MS)A4&&:#&\8 JJZ5')V34S/,%JB](FJ9W+=1[JRPGA#7AI^&^0/(2U8XLQ01
M2W86!)6G^ NW)E:>C#GT9+$*,U,ZX4RJF(Y9NTR!/[>!@(@KS%0A9F<:8RJ_
M)Z)):K^?3T7J(RMX*R9 0EPJ%++A8E/V-H 29T6\#/Y6-Z15!M12X;2-9OD\
M?3GWX.J'I4?3*&8U)H\BRE(FH(FDMEJ^J2SSJW"M,-22)V"D%$@#33WX6U*,
MD9IZ["J6H,M-0=981IHT+C\'FD-5AOTE,)A[M7BI2($99GV1,)/E"9(]*W8K
M;=3)K?1U/,XVU"P$:1>B'J\HN[ +.[E&'@=N#B&?1MXHJI'.\_BO5/G,#R(+
M*?V:Q,/)[4O'09NPRG6J:B+@%1Q?%[1Y_!VL8A8)3^.1,)!Y@@5[(2H^D@ ;
MC%CDR-=?,I.)64\ '"3W+(6@SX*$,S U"_I!+$CY[#V=E-FH@FQ.%PO:3K\G
M>9[E:7'':QU9=4TUFWJAY;)L3P1;$B!IRD0\#4L[ZW64,NV,KV#!JNNJ!(HZ
MNL_*Q>+!ZHKH<%C+"*^E5.L]G9\G\ZS-E7G6OV#Q)F-O(#UK^(&MI!T<:7+&
MNY\_I7\FBS.@:V?L(9'MD24<>@.!40 $_Y@(20)FY'188BS>5.L>"\VU7A/0
M*PM,RL9]K*ZTJ"K]0#%2$DQ=2$L$R9KH@,$)AS=S],NR.39JIILP([2L(L,S
ML&A(K P9_N4(AE>@M(.VZ8-(8E:C*/H5Z1<5GA :E57MX$PF4 ,.L_*GLG>A
MX2>E:*V66?H8F3$Y'@]A)S"/"*L""SC5 G>SGTV' QG.8#9R;4;-K8$U82ED
MN-PSF[9D;W"GN<[)O'7,2I^R^OPKV*"' Q>Q7]&E/($]5"ZS =8V^O$8EBEY
M\>0B[I00,DJ@.^,)^,=954BMN-/)+<J#2M<=E_,I^'SZ8CY<X9O<IOF :X \
M%I*CU3T2\BO'2;&(T93''-"\0:Y_6]5F<8<*DU?EH^I>'J-7#92I@A,63A))
M0Y_%:10#!V(^\3^[LF@!WC(5TC!%!_= =/I)!O.(M\PKP51^/E:F""R;>\D_
M8%"<(<S4D J#",92^7^8&)>X#E^N1#'[;)%&38L0?W[BH274A-@+Z\E+K*T/
M=^7((\R>(M2(@M^!#PM_FX/HGF_Z6(Y91 CB;9T:(E-2O5+[*N^,KEG&3WOV
MD-A5VC=U=!(Z9F ZH4XB+W(CU_"IINN>1?T@,%>D?8?"?/QR_15^2($%X@4+
M,K^M_S:W=9#\4R:O9M<E5,$GV)=UNTF4G(8S&LEGYKPJ-U?C1GL(LF9["&J>
MZ7MK$,'D%LJAI>1^5OY4!XU"X@QJ#96_"S-2<@4.#Z5\Q^Q(#B?9A"5JL:CQ
MZ)*?:)?\U"4_=<E/RY.7=DM^TE\:?V^1PX<9!#5S\QX1S.]FD8Q$J/A1\9)1
M<@VJTN=X!-S@Y3/BRY"3U9MKF! K3\RN;&W)0NP2-;X,IW'$MO6@7ANIQ$T<
M+^G:F+*X'I?FQ6TZEHW,Y+)>B66]$\LJHYVL@1XSOR2(2M,$+DMB&4XR\U'"
M4F6#!6UJ5$M&)@647.4;+ST_]4I><7'#;F,C0J<K_S4MGECA S?#+LLF%(W>
MJ]DX?N11A@+1UEF@M($@]M($WPBJ<)1V$=-?< *J3AN;D7N=RC_'11'W;Z>8
M"(2+]=<TX2V8EO;M^,I;ORINGY4[7"23!SPE$09$JGZBW*E"5.VD__[$>#_G
M7XPGDBY97'S$\0>J78&7E47<LMEL1=(L3XG?S\$G-R)L3(@KU^[ "7EY!Y:F
M%[%!Y[_DL#[%A-5>/F.NDUOPX350L9=/H"3/^4XR&'6IF><L:2ZO34MB&Q:U
MLHW?D2R&:<*Z&^+]#<JM^=8J,[CI 1 Q0@F;.,.+13;2(_>YU\BKS)NK.O,V
M(!/P:%8C/W!R.[Q.>9?)UN7BBZRVBVR2*)KNZ@O\]5M;LTU'?XNC%<9_&Y X
M>QOCDR2S1<K%%1PMT2^I.D55+NI23W/]M/.(U9+&457)]2&?Q2>C361EM$GD
MNF(<G2-)!+P>%#E<E.;%UN@E&PWT KT\+)MH6XK8Z'6XXW4OSP'LZ[N?Q<(W
M0=%%<&,>RPR_G@UY]"0V@=A*.!L<\ZO9<&R0H&^=Z>B+6@(7,_G>U0^-]L,'
M?2C>_?P_H!X.TI=6T\O^@J)M_+?DAJ_PM8S; Y,J!*A=K9W32>WB]Q*F;T$Z
M EZ&ZN\]YWZ_Y-D4437KC[J<,ELP%^EA&'"">42(7H1)U&?U^Y<7&S=RV2Q9
M=HP9G.N4'C-52$RGZELJ)U/(=(O]NOU-@Y1N_XA$Q(:#1E23$LT)'.HZCFJI
MIN?JH6[9]<3(&9>_#Y,%V<.YBIO#.G)PT*])CFXML-NSZZ_<>BPNV<RN'DLL
MP46-I74@$E4[A7\-=14ZC%A#C@I3;=PFR# \A6ZP>5=J?J+FP@8C 7:S.!GS
M5'\R=J"I<Y&#O^\<,F!  SV9)J^ ]I&,ZDT1&S O<Z='9O2)I>XUL&O%OBZ^
M4]C;\UX;OG*UA+;96TL+!T[/*1^O1&KNU\FM-@?V#K>8)/ S8L*P\@<\OP6&
M+:=#KM_("@,\PB).:B]J223@G^MX4J60D3D^<0-Q?H0Y07<%JVG#"!A[?^GY
MDGGG#\RQ@KGF2=F,NN"=./Z:PCMY(A6.@Y=ZB7H+WIB.N[#B 2(BLF]F' RU
M561,JT@//K7N*:7$.U-^@34!JS,1X"SGS6+-MYT =,ZIAZ.5@G1!/,."52V4
MN2@"L&^VVHX1G>BQS'LHLROK97*8FW,]J5?(B4J@*08JY.F04E>R@[FRS3LX
M8EB]ERP;!H,B$>*I4=;'2A?OR[I3=,!ELW<P,<J>W20+9?(X1M<#MC87(X.;
M&Y6/<,KC'[VRL;#, Q(&3@GK+5-I&+PM:R@!*M\UJJ5)K=,!,)!KD:<C!I*(
M? RA;F;PH#\3UCB6^?Y8GP^\M9$1R&;'>$@V\[B^R.&%77E@&417"?,XIJ(9
M3PF^Q6XKT8(7+0VZ!:O*EUIB&'"UI+C%]);X#G<9B #YM6@MR@?+&% =>U/V
M6"]SR6K)4F?*K]@,,><[465U<73]=-# ,A;OK$1"(=SOA7PTR\F"A=E:#(KD
M6 Y"S3N2;QO51IS<DHO+H<]GT#,0+2P:DK5$BS:$40CK'%HMQ]DZ'>I>TC1K
M)6ZH2Z17#I6$[D &7GTCF?Y D#/.!<X%:%17D[KV428ZEIE*I:[.E99XPC5R
MG@)9@<?6,8!FEU:98^H__W\QFU^A:2IU0H_2B-HD#%V74"\R0]NF)O%"U\>(
M?WR$.;@7S^%B8.Y#XZRM5]4PY+B^?(&H<&F_F6G$#0KC?[\'LWE+EPG#_?S&
M"EAA+P*P_8:LXAW)V!MF_3_?+:!JSZ".%Q#7M%U*(MWW],#S/">('%53 SL\
M52L S<!TO<A0J6Z%A/H1=2,G"#6-6KX.9\-X,FJ^\CW:.V T_7B,.3'Y--DS
MA8C5ZBF_)-E-'H]!EZUA7G]+[A-L%'=>^1WWL,T?&ON\?@+#.DNYRTZL2E\X
M>E5S,P_KF2*(91$Y;!)-.]+58O5=/%]!J,PE2GP=6D_8D'OR\-@:)49BD:KR
MU8X"/S!LRPYLG[BJ[;D>B&//UES=\*AKS/)'6>WZA8]Y="-V=3:7L\YA2Q=(
M>=._Q%V'5)HZ2#%.7T_9+\34/BJE/C+*[GG2!J^O44[.?WU?S[4,"TP5P4V5
M%X2_ON=NO?-?>=KPK^5SF0*"V"#*D+L1L97?Z&8HZ20_4T+\-9/+)N]D.I$(
MP<NRZ6O1UJI&5S53B:7PU+#FS[]^8_G> 6K3J.IS/764/#2#0/6<&893474#
MQ19.4EGET:53/$4SZ/6532'*2F\QH,R2U;/K4_@_H)I^,IZ(J99KS[0^N+L4
M*]=9-D&?.BIS.5@RM?H25JPR4TYRIGS!0\8:2U;K-Y"9KFAWY0B!+X&DF*02
M=2]Q/F(%EL+<VO-9I-U9G#N+<Q0_@YR,<*P91GM$JWLV0'3?"2P&F32#;KII
MWF?XU5E_EXK2_:CC3"CPZJJ<P6?=IW "43Q4/$*B9B,^"AX1!I@ S(+SB#L)
M'7+4J^#B<2[Z>7K%W9^MYR>X.UCT-9\IWXY!>L][GR'@#:](DU@G'/X#R[@8
M^ZA)=@:]ANY;> "&AHXNV]WILMV[;/>WFNV^AK6WD[%H;)#KOA\F_)3Q5NH*
MTH;;+L(B]E?.!<?]L9P+.D!'_//\7&HO6'EW?00CE(C#^=6#1_+NPOUD.!2_
M,DT'/\/,^O+S@O7[GMXE!4MF_Y:!N)T=+>B?-Z@*X_#BZ2237[#23?[-0SJ8
MW,+5L#I7K/_E*0M>CHODH_QC;G]QQ,!&)RS0B6O_G^^09CY,!OA/7OXJ!LQ?
M83I__TE>-/N;MOPGHE:_U9]=>[.\X1[A(T%/%$.]RB:3[$[.BG\"9OQ#80V2
ME?]0V?\T*0"9P"Q3D)_%$^I?\774^28NEHFM94IB]].&Q5/ES\57#'42Q/V<
MN0CJ&"(&%1]G6,^2K9I90EB"?:_/')]USC8&S>&WS"M<"SQU8/@*MK%@09:N
M@R"E?2P%)CQ>PPY]O$T'P#;:()5%+4S7FM\+'Y5G)H7P*5)XSK,AEIT)A+DU
M7RQPQ//,AH#:>KG8L>#P=PP^0G@SJFP6Z<5)_XW?C8!FAST>-#QE33>8KP,+
M.B1>!?S8YQ^8XZ46-D0HPSN&KEE6?LCDLB&:,@U8B])]PYN>BJXZM\R;A<4C
M9TQQ^@=#2 .M8,S2^1F(62%R+P5 !W),.<!>.3C$=,-:]IM'3-6\'L9W@J%R
M^('T[FXZ$C_G#"@X+1+>OU8@O,T-I^,I>Y<=C6>2M@X , -!,(4R3&Y871^V
M&18$S SK(4,)RSD07Y$!G0RQP1]W\BG)#[B]0!\G ^N$&=VN< OVRD[&LN"E
M5]:G8,O:=(C4BPY1IA[*PP"WI5F1PH1B]#H53+&?;8I<U'*/L20&4T(X/*Y(
M5)#._:J OB=2RWX]1]SB7WF<NUP41$,57MIZM5?CN/)0 J^:G.E45%;R;,UK
MF\+) $8YR*:X+NU*IQEF/,@8I/-B;KP3Y1F+0XD-/\%6<J_YO$])S(A 4+/8
MSX\[O>;=SZ=;>,66B68LA$GN1W&N:,:'K\S[S?X^J"'^3S+\(Q[]^Z#&% Y3
M= 8>U)@^/6(NU?:CX7+FA&-W_5>,]S<@]YC'7?#/]VSF+:_IZ"I/AEL_\MW/
M)V"*%5CX6I9'XOC]>!0/XGT,^)]I?).WL^!['NGY%6N^?%#D*@I.=AW297+/
M4'V_?/<7Z8654#Y)SFZ L-N<@CNX3X>[[C]VS=Q9\,P,C#^9_^N#GI]/[[8?
MYJSK='-S=F\:PX'JW@>M+QG;:$NK@BAM.0[64Z#V.(K6A7(Z3B=9OO>%FWGM
MJ?(5>SGG6\50Y4CX!<\_](LLOX^+_M(7-TY/F<$L7/^G5CMVZ>*A<1UK%QTE
MG.9@E?:4;].B2..>\GT*"M5C3SDO\CCA.+^,8V/W#[B EU1@5O+[8R)['RQC
MT.9^K#'FS7GS+D-^HMK^&HWY//[P+;D#$S]^?KK?GJJD$O2$ZV*]T]2:4V>!
MN*@<#A_8T.9BL2]7L?!DT)/9/3[K=H"GTY-Q'K=,J]LJ"HI5>NGU8VTH]J9C
MM[=);UC@Q]Y#S,R7%:!Y<CJ)?XAN$;&H91$)2+PZ"5U7\ZF-(GNFQWNDL>Z%
M[ E%D?53=FO5V(/%V>#F&<U@H]#N,O?^DFBO,K]&BR*O&N5:JM 9-_&Z;9;*
M,Q<.WT[;I;IN;:SNKACI/K+EO@4+.S65N;!#CG2"B&T,Z:Z1W8H$=_YK%; %
M 9L.YS)169MPF:8JLN]$FQ(L,63!8 XOD?%B-/X"4:AW7J;W*O>\K[KRR]>F
M_Y:GZPD87*4/ZU8B_=>2=X4?^XXASTDW<"$[3&(!I8RV3,?7>29ZX,#R)1S0
MJ2S!YKFY6/^<<&"],2HB6(3(+ I>$JC RC8'R5S12_*,I6NHZ*=8-'UZ%1=B
MK03P_#">8*C\5#24*)IH97(+)5[9).G?\C5(?N#(L"ZTUF]$/D.LL.P).9O
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M=((0^MNNE&NKAF$B=%1 =*)[6ACIGFI3S2-$,^S:2NFNZD9F9/B1;9%0==S
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MU;  JU9D[ED>#53J6J%*'"N@NA<!#U!URS,,9QYHXI ][,_$ HC1)I[.,;&
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MW?N8NLGTL@=X9J(,L@>N%,"<E5'"!% R82ZTZQC4O/MX.$V .8&.QH4;_%"
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MS.,Z>2WX9_3=_#/&T9W__E/G?YY1/P='V'4/C96,)?"M(/ ]VXQ\A^A&X-C
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M-@4I^AZWVH/[NYX)CS$1-@O7_DQ+POL^%US.B=EH-/AUL2P<DGP[K4/@P(;
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M5U.^.'E$C^0^FEE_=:R6V22R8K=BMV*WP6["8ML,RGJNM52@@P=GM-616G!
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M?##64[5%H^1"#:GEV"Z.A%143TL%1"& 4.H:$#1$9@Q11*,%:IVQADE'T(C
M0F#E%S+O#R"JJZ4"HA! Z+9PIC<$ _4RH F@K39:6I^(X6TRI(ACO7.UE H(
M(7JQ9ET!T0- (&T!H:@3T0@1K? 0*4EV1I#64"9!2D4VC9TOU]=2+"!H+YRQ
M?7.V7 [/3\>#X60RSL%0@]EBY->BY'U%HUC+&F!*!>O!R@# (:'1V""X=Q:I
M9:'\=G+W1F,SV,URK!='2%J3!RHG2N&$;".#)>>>&,6(EY%$:2EUALA@!;KH
MB%3]<\*4S8EJ:%5*%$()I5M7+9%<<:Z<1@.YYF$PR*+6T:&-"LMO)=<S2@A6
M.5$Y40@GM%YK/D(E2)*;5@L(3!G  ,I9%J5'O7&EU((=,F5SHA>4Z)E7YOA\
M\O%R6&G83QIJUJ826/":1YK7J@@D0\L0%KGR!*+S(H;R&[_=.^NR&=K%41!W
M64*U*DL5#UO@0:R531;<26^U3185*&.L%U0(+IEU2+S8='F[7-=+H7C0O5B[
MJGCH QYD6QB.11<%37!0SH"/VAKBD)ND.>C 46Y1&*Y06ZI0/#"HX;.5#X7P
M =?X(&4,Q!-!C0=JN34^.L8D R-I -H[7TNA?. [[=!0O2R[\;+8Z?QJ,GY3
M0=A+$"I"VD0CQ4,,24L"2R)$B\F24MP@-='(1$/?.S?+<FP71T+89=/9JBA5
M/FS!!];F&5DD2!T* $2PDIG -<.D/G%M* O]"W$IE0^B%QG9E0]]X(.0:\$M
M0;H@58C2@K#<"$4YN)!8(6T4F_*A7$=+J7R@L@*B J(00,@U0' :>? ^>N6!
M1:N!A>!58%H#!+W%0DT%Q/T P7;9[*U\5\O]NIZ5ZHHQD\E@>IE^&QQV _D[
M0_-!F]T]*%1UFZ"$T2JOTO][5$!T,"S7T).61V<Y=?TK#_,L3X'53JNC%H=8
M=A#MXBIM#H VE+9I3D8[0G(&I",:I (; Z-6*^"1JT W#<4KUP?4#=KL-&V\
ML[39QPRL-"J-1JQ-DP#!DO7H!'?*0#!$"V(==\*:: .EFZ9)E.MQZ@:-8)<+
M^9VE4:5-'V@CUI*RHH\$HZ"<,XA&:V&Y]@2UL9)SW;\J.=V@C="'0)L]^;K(
MIEQ:GB;OL_E3VFCF-I\^C)HK>3V=G#:I8&\FP[,T0/(,_I_AV<5/@^.SLZOS
M9N .OCUNOCK^[C A_N#@+FIH_/<>'\K.G\%.)-L7'L+=1-U:G0)&M4654^ZL
M!Y3>6HQ$)M/?L]SHL'RGXCH1AN>G+0V*$U_T* V)!Y1@.YF=59FN'*X<WA.'
M=1N2*Q5W,H#A/#J@3F+4D5@M$0)U+&Z1FU Y?#-[<:=]TBJ%*X5O<6/T"[1E
MLI31EJ7"@"1&1(Y.0R#6Z*A!<9O46U0>M]!I'\A]TQV6LB/<:0ABL5Z9"LP*
MS'X!DZ_G>Z"T2+@33())>JD!$JT4F O#ZVWZRE1@?@9,37:9]%4L,!\Z._;Q
M;.!O?@[GKV>CR>#;9U>7\_'I:'#Y;C3XV_<OOQ^DL3APP_/AZ?! 7=+]#WMG
MT'(4K1*.<R2!.R"4:&K1^P!)">54:^B-,_6K"XF+F5 <=26M>3(5&(4 0[5Y
M,M8FXY2RW!1=@B74:$^8018\>*"T_()F?06&(KW(FZG Z ,P-+0:1E"HD%"/
M3 "S'I7@"17!>RJD">7'0?85&/0(*59D5&04@0Q.6V10J4$%'AU-.D9PD,:I
MYT18U#+]5VU1S*,B8TM7$.N'EM&S0FA_'TW^.3S_3V5C3]DHVB0W&AFCDJ)B
MS@!P1$(LSUV]DG:%&/L3_?;U=AR+P5X<'+FHVE0E1B'$@#9>UBMAN% A$$X
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M\RLZ"D''6K^-$*E73G-!I 7MC27HK77>*"VL%H^7FES1<8T.T0LUJZ*C#^B
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M(!"'.7"/H47%71 L<.9YPL86[7([9(D5B@Q&=]E'K#*C,F-S9B E:]Z;@#R
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M0T7-%@'?E5T/US./B%TZN"J]*KT*II=NTU488\9H+[SE## &!!FUX,XR@@+
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M<$[/F2Q;][C344=A(S7(@$NOP7@1:"ZUI:1BNL_>H&:BE09E2FK65B5%*:3
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M6J$22FD;,'+=B1KL/22-V&4"605-!<VC@$:3MO*%UM)3XDC2;!)O-!A4ULN
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MNN8";I-E=YOWH\'*6;R>@]1DBK_^^/7:@57@UOR;/=SWYV]S5_DW%"(F'L9
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MG_;W#@XM[6\I[==%19: MI2 MIIY[I^X)P?[EO8M[6\A[9^ZW=,JOB)+^YM
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M6_:^RGN JXFS,%?TR:;".1+* 6H,8972'J;/^DBYK*V_87V%!5;Q/^ASU9,
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M/F$JAI 43ID4_:&%9Z8I043E0I:Q1%2F2NZ]Y]NWU?*@NL=UU&!9!8JT O&
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M:3>B/O&B]Z:R]%F?=Z,*2D]-P_:T?6:F\U"]8 6MIPK<ID[H\0I#[[I'>U4
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M*CED2>IQ)'74;15)M5\0[7R IXODY:NP9*F$8N2%SL3+,C'7R]F:*O9$/XK
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M;)[R4SCEM?NF'C6ARVB0@]R=[5Y-A1\, Q\5SC 4V(6PN9M>^YK=O409* S
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M'OLU05+XPPF]//+'O%-ZP>'O3UX"QQO1+1UGSKI;45 OL6&0NBH>=T.8PFN
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M-G+/SL^<&P]A\)Z?S1D-CQ"/OZ .Q87HY)XI%Q'NE2 6D"7 6C93-CY"U]Y
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MX[@?>BDV;PQ%_D-, N^6<D6E26/HY4;HT[?H>)E@:L@(U&OLPJ%%BA=%U(]
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MC/WH95<%\00)1 37=GWF1H0&(X!&$$G>B77035>* ?ER=4]ZONC 0\>R,&S
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M<*/^[</$F,QYC0!1,J+P+SS_.U-^G1F;Y*+U+,WDB$"U":CA\S9Q!! "Z'4
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M>UP,:=3G;O[G82@DU^VW\U_Z].^8I;^%^AOFP542+IO_C0;?1[X(88XD'(K
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MR-GG#W^.@JA?TU/X=C<;#2FU5PB=PP-4"(W"DWT8*MZS%7&$.,HK>576\6H
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M;3P*>BUFW\LA]]DP'#7(4(01X$ .&<R4!"R6U.]Q2FC@$8_3COYZ"(\9PD4
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M]*F*+U4&@E&R/),UV2?_ZBNW4&(DR/9J$31XF-BUU?YP94SOPP:I;P<QS&0
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MP6@AF;X[U &69R#A&NX')'EW&PI8U) /!B/6=C,81*YR5&\X:_R$C)U!QJV
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M!>]Q"3J8?G8'(-N5X8%.3O!\U96.T*<WX^0378=Y*LEA.AZY8)*#J4Z127#
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M#'7>O9YELL:V&N 9&"NSREJA&+\M?%43>X,%HWW376]=Z"_S1A5  >,3FT,
M'Q>!A<N[Q90%%6AY]@32:WZM_@]H=A4Z$)Z>]CZK']=/0#L^@3F='2]YVKOU
M_G'OH_G'O1OY?LIY6TE>=E;IT9=PJ39S.GVYN-'YPE9Y)NUQT^?,/S)U-/Z[
M8&A\Z4L;6& 1!LU;DT\Y4J/^3H6(\=#D]#3RK%1!)1]R@N)9*Z>W1C9?@\"Q
M"2 $D,P-=ZB[O8./#S/152S/-)!6''_?O[WY_OWF_NZ)W7]C5_??O[<?GQ;*
M^"F4:LI!&.^5UEG%QL_=9KTXRR/_W@I51_AF_HT:TXZZK.6ZP%Z_-_^/0C;W
M+L[P,A)(MPVDS1%(3PBDE0+IU@'SYX\TABGH769A+W6\@G!?*=SO#G,F#8)
M6GJ0D@9169!N'3!)@U@>]VMV;Z_4@VT^X=5?]#EH*Q.,"Z:#<43W.>>WXC#$
M3TM,8X/<J%D[.\JCMY'((^A7'/JM6OWLF*"_H] O"$3[9TM,9+3HFR?B'0WU
M$*]="YF<UL[/%BJ"2[R6H+\=T#^O-1H-@OZ.0K\H-:/1W&(](V>BS<IJ:(PO
MP=)3;N,!2$_XF+O$>R+?:8YYKJ)'K'L>Y?(2;60UJQ'C*&@Q5NZ]:1PN'\]X
M8ZYE8AP_$\)W$>$M0C@A?),(+]EB[/P";#F_JQ_F\4D3OR.$5P7AK<,\MBPA
MG!"^A8N1JW%W=H[OU9E9XNCX1Y)2%EZ)_-4$;&%A55N1_P'YWWWV<_X)QS6<
MEJLADO_U<?&1XFN(Y"]U4=,%*W+?WFAN<#?*7--BF1VQU,#CNCR;T@L4\(%
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MIWDT'9(!1 );0@+G)WDJ1A !5(@ -J/D-)LEF5[5MX_XUUM#;]6.3ZDD.Y'
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MX0DWR#](?.!GY1<XU"?86P!3#7:DJ_P!CX]7XL"Y/8"] \3IS5MZ[#6$$/<
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MU#2 ^AQ&%X_2-A/^(8'^A#/,@?9X2WXZ';TF]T-PO./3Z/LJZO7S#BNC!UK
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MV3BVPO&-;TEIF%\0Z2W,X")>'O-$3WH"Z2"H99U%/"4>O3MZV&::K[@W$[!
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MDNBS6\"^C%7[IXQJ?X.)8N6%=GELH#BC[G+>3QE)I_/:N/&)@;3X#"^(W"C
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MB+[2S!FKC5%@!%2!!@VB"=%TN.*I5 .YL+"OSE:86;YHUR)U-]]=-JE7BIH
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MRS;G6>IQ^V8!:;LKYE99RP#IMXT%*$2UUHR;)=M(;:."QV].O)I&$K(:67T
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M#V0+;44[=8*2T+$,I0J+P!([L8Z9WC\3ET4L''-?QECE+_^(0RY<[B3-N+W
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M/><UGEMOT_'W7L'5-G&B-&/@><&3LD,D=Q+;9":D?)4].)'&F<M>*+E*Z'T
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M8,)"E1\NR#T;!B$CDS!XY$)FC,-+$M&?3!!XH8,!!E H9:&KU)MO*PNP96O
MI!W?VO,L46.V+;MO(L_>G%ME52K2#^E7&?JU++.6,D@_I!_2KX#0O]4>F*1
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M_L'QUZOKZZN;;W?DYC/Y='-]?7%[APE8Q<_5C <%Q0^N?#]XU$W7OC#J16
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M*@;[/J(PL>G[ZK_J/SIPF[Y>,3"'^1$+%P;^2J==8Q;W%\O+J/^.PO0B$_K
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M,&4B#1M?*:E4QY)A[">ZZ%C$LI G**4@]-RGJ6H-O.#AV2(/7G!/I6:3BE:
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MR:4OC; ;)PKNP8JS+9(U#:I2VW/_B%$-[+>V4!>W3D+@H"<_14'OX 3@Y4)
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MCPZZG,I#KIFAG9$KF0_JIT&ZC$_SZD(,Z6,0JGP)*6;D*?HTSV=((I")\K3
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M*A\Z;:LA3W\GLDMD#YM<QD[(!;7F3H+K Z9GYE,MF1\O_G)I55?(?4^=T1&
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M$M92FR55GT5,3^IDC%D=P%R^1CHV0<<LW5&$M]2VYO%G=A_":)_U0&4@%#O
MUK )PW&SW\CQV.I?&7O_3(C#FFJE=&5EC,3Z-&UXS4A<;KRE._Z\/T[:%9Z@
M@;C?<ZT4TG=A(*:M/I5E]QV^<GI]<TF^3VN%S*KL)100NBLH%Q'_*YL@EI[*
M\V0Y,%W'5/Z*_516X"-7&7:S=+*YDWD6H8(\,<^3_UX_A[#<*M_L/T/FNY8N
M_3K7:'BQQ_"!L[*>AF#SL W!?18DDN9WX%ARCY$K_P_P)=6.]O<1#<?48;%:
M!T%D*>=AX/' 6NZ2FQQ'_Q((F>XZ+6 G1O ;^L!$5IH@_>M'?[MOLCN ]*\H
M_7_/-,O^)P\$AV_34" S:\?,CDDSV@KORNT9T; Y= Z^U;'5X#8ZA"%="^\-
MG;C'R,)Z:KWC;M,^:'MT_Z+6AS752H5H<5_"@+?83/I +;SCMHGJP6;2!< X
M]XPJE3RN&;1XV@HEQ6$TDS[N=K>1<&TD1\KL99O+_JUG\^E*22%L/KU=OP6;
M3^]#\^F.U>B8;( ?<//I]@*4^Y.M%&71S:@O,TUZYS).<O>B+K562J]=1%FJ
MFO:B;IVU*E0K)<<Z%%8K15*NU%(IW6V52EG=0W&IB,J:9']B(2/4$P'QV8/J
M*B<3T=1EX5NJ[:+Q/%JM@H#@OIK+ISOCF0\3!/(6AKEIIM#ZB4+Q9 )?6IDO
MM+ISICF&"ZKWDV0;+R51U*.K_5L<RM?4?BMZ72TT&[/P00KSW(H]=P? /(J]
MWRM9K^<@04ZU;I_UBE7KQE?I%2H(K)7M,\M6M7-22DK4:RV +X44W5R,@/)3
MG3.3VU+[F-M*>3H\OS;V350/5EQ;7=[L\F=Z1$">ZE1+JS/VU0E.82UJAB6!
M^Q"R)_.Q%V1&>\\E*ZC7#B9]U/W;@$*7"]T;JU+)5%:1TZ002;&VM,\DN0<[
MX"D5KQ:AXP">O>Y)&XU@9("0EWK-RO>7#_[.C'?X.)A6I4U/."?'BVF8G$&6
M84<U)-4#I7<N5OPF&H5!_##*W$S')^6:J^'!\('\UHJ?JGK)7Z8Q3V,PSIW(
MS@'I'&(@&Y'=_,X+A\=?."8._J*WZJGMS3*NJDN=K=:T^5C2%5WK$/V"%*M
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MOA7O<@VB5>MGQE?X5^^"]VRDCV.@];^,2.\78Z>8.\5O>HIZXAXLC"]VBL]
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M&Z&6;RI+\!N=O-:AAG4-)73V6IV]1:(&C9IKJ&H^5>VW=O8;S;%NFN-S55E
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M12;0D+V9@$'9TB8!$O 5V!#Y$ S@9:SV&XPXE-P#^9/*6="+![MA"EZQM;7
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MKR?_LYE0/^M\V,I>JV$'5)?!7/6TDH>>6#Z](C[=3 I[T2E!+TAMSTMLU77
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MQ%T,<\#![V]K4)3/0=J#WWZ#;6 !WI-#C85U%V\16($A3+B0YI*  I(4= B
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M*\*[J3SIX7L[N^3FXDOW]&+Y80:[K=V]_<4U7^4JV]Z9,W;!^CG*42SLPIU
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MDT(IS)+WKO+%3<&UJAP[+"YOA95C]<0G;&K(F:I.N\4CJ&*:A^4P^@Q!&;W
M<O8$)#5V$K&=9*Y:W-/=KZW1@+-(\-.X_X,1\IWQMPY8_BSD_7K,-N_L+%%2
M4^-B3JC!Q8XE.:$ C8+>72(4#;=25;+?HT0.J? 558L(.2%]!A8XV/@W18CO
M[^R*76$MB_1+1W"1ICG(JBLCWZINHZIQ:4@/CG*^N&AY%W"BW@[;D4'J_1<+
M/3#C&<@>4VE 0&.OL[WU7PO6("BA]"""]RRC.P]8=_SOL4B&0<3+ RT5ZP^X
MM9\^4?W%V]O+@8)W'D8%WSM:"*?[OJ\60_YN'K;0PRI!TCL-2CJ[7':P,^GH
MM$KM>5HA^Z:^@Z.X \_:@&STD6M$HQHQ>&'3$8^R!=*'4-3O/;&W#IKR!M[O
M16<4J'N2_IJYX5Q&K ]!^AM5S'V)J>+Z#)-L+T8$3]B*AD*>CT*^8DG^ P2R
M(,[?JA388EM63_CKW<WOW>NS&^_BJ_?EXO/GB\NO-RWO]/+SY^XU??A)??A^
MPX7M2Z#1+T87M>-R=5J/F1)0VV/=;$6->.&U,-G"+U41/UM;%/2&Q9Z=Q7:>
MG<7*?;:;RV(-"[T)%@(MA02P6*Z[7M#$AK4:[;5)K+=C6&^!@;7UXD9N#.L]
M"O[SM018;TS4M#IBVFCUVM_UA44')0EWEH"]7C-V;,BQ(<>&'!MRK(<<._O;
M#2DVI+@>I+CW9DCQ<3;S2\_5J*VXO%1=\%I&C*Q3N<!*-F#E)__K*M]TD1=;
M'SMM_ONMK8)LF+!APH8)&R9LF+!A0ON+_?82+F+#@ T#-@S8,& S9M'MWWG2
M;N(=>J+_ V=X13[VS<3)AW\;T/];()\Y]U;.ICW#9,;Y]+;0Q+Q[-NA:3A"N
M'1O95,^$[8]PH2(6[(%\N,EPT4SU2S0G'M?=FWB\<&OBO*74W)EX_-H;$Q^2
ML&]1JM+S7ZE87>G@T3K5^+/+U4)+>JPQ=X\85^]!.;LPZ]<AGS=>*K-<6_@,
M AZ/5N]TBH5KQ)Q#9(F[U/1<>_=7"Q_470+HKV:,*!Z_@Q/F0/:7T5<T1@KC
M:R(,2TV#8GX]:.\MC5'Q\C JST<S]PYT#K"A.?)3%/(G7(=W@W5XZ[L_)<>_
M4XW9\&2**(^7/V3ZKD#_@:T,14)0L;[:/KS@U^WV[@Z"R#$GM+R)F)*]%SNP
M0IV%I\#6/O:G18-<<:D(BZ<0LAGV3<-4]\.X!+P([V*P[CO;Z_,RL_S\C_\K
MO,#_CU_2[M[IV?G)V=Y1MW.\WSWO=$_W.T?=H[W#@_/NX<[N.=K'XFF$WND\
MF<@Z6EG?\1U[L.?W<N;7LS^\[LG)Y?>OWRZ^_N;=?.M^/>U>G]ZL+V,^J^"Z
MEGV>C-3UXPD:>]T^(="A)@)K+_*!;=<8-K4DQ%8$B'VSGKA*GVA 1I"RNTZ.
MBS!0V#<.;*8]T\5ACFI<_15L&D8V/C#1*:QN],JKB*\6?,-5<@[%1*H9IX5D
M8UAK*612Y:NJ2/>]$,CW6*<-TE-YM<^']+3_R_S $3]B=T&@I^.%?K;W$$31
M_KR*S''@^Z%<,X2BA8+L#^ 3":^7!'( IFK:3P(CJA+-^@&SOK"LGUK6UZ,4
M!;/_AR4B$ZZQ<T\:].&(I#JY%9_,#"#)0F=3\>9:L/[]U![(9I9-O\GCM8/K
M3A%XN3G9-W:RZ/:B/UQE*R,J]B6A8KN6ZQ>&UG_A'LY[*_(?TH+%S5[:0:+1
M]302<8]QE<^[-Y^,(AKS[)QA#EX)CL!P!B4\7?T<59^E&@K-LP1I1 \-C*(4
M<C]/81><$WOJZ_'X11P=9-XAP"% ?MXG?<Q#A0*@GDDHTZT>Y68&";SX79S\
M('1]O3Z,P0 EN<.!,!"3)[(--$9W1O#U%-,Z?6GW$J<EJOU,@Y]>]^8[CG;
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M-<T\4FY*(2:@*-Y$./'"$Y&.O'.P$RM/LS%<UXE(5U\L?2:2, !UI.H#B9I
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MIJ*7,N1C=/!.R,R W0IZ.7N&Y),HE! D;7QWB;X-/ #UJRFX'J*I($A-:/)
MK)KDA\S(!2(I3O%Q) CELL&B4[($9*@JAHL9@)DX?222!&/OA+=2X @Z.@P*
MJ,E.O$0]<0FK)<0/!#;CO4\S,]QK%-_I]U%*'%L'>TPM%)>?L"53A8S25/VN
MD:1O L(-&;R)@+%6)%7U;T%JL)MX] >U-9CH<H]P[POP*T5L%HI5%?*H]D5<
MU3V#SX1O3X:Q+54SMKE? D(!>5SBG98WD'=H*[O6@;:(9VR#JHPI& F^I+J_
M0*%-VN3H,(Y]NAFHQ)RB9E1<'*.4Y]-2)8/XTXNKZW\'C^?C*;T>6/OO/=?Z
M*)I7M TS)ZHK[P:V^FX6L0.74(7*X1GTC^)F,%VPTT5S48J^#M]OQJ-)9:%W
M97Y)WFO Z3AN<#H:G([-P>EXUG$!:]9]WT!U/ K7?"-IHT'K:,AB+EF\5<".
M%3LQ%Y%W+GO)/6',^S#R:PYEEF+O41R5V]J;-.>;I,(FHO(:R>#U1E!L*![I
MRT&KR$/"0Z'(-.:FL1LW3FP.LUHJM53,'<,(001O,@Q,]H  S#$M2GEN>@^3
M$VPI\%9>.>4K!.&V4'LP$CP#B(."2S#S:'*G5(Q>J"@WF-AZG$9?) G!<13R
M(;2DBGWP8\GY==/8EVU9Z& 74M2@!]N^1[JD"H#>0 O-1) 6"9WPJ\V+C3PB
M!#(G VL1=YI4[%I;D+59/%]$ G13;>X\6^L ]H9S!S+6I2"GJ6#>)$ZS1&:Z
M'E WSB!:U.)MU=]GN\E;M@2#([D3+-!).(&&7*0[=K!FAGE#-_/@VMUU(:,P
MRE@Z'SVL?)(%4EHAFMB-3&X)&0L7JEE<)4E--H]QKKC>T^)B8\#,"^ /E#58
MLLP!6@D**IY*2:H*3HZ) ^^?*F!U;LB97['S(GNQPQ(P-O /! =/D>V9 ]7[
M9#NI=.$JY:%IG]P^,J[1&BC :M3H69RA,DCM+1XN8+)B9R;*]RP[M-OV+B.%
M@Y^Z9&-VRVQ,7TQ(;O]%7?PC4,I._N7=H%! 15H$;T-[9Y2_'EFRA:54:3S(
M[FA^.^8ZX.GA8 M5?);D?2Z8^RE5GO_]X^EJ>6DYH,4HU#'##WBN><I.H!8*
MV2-IJX7I=E4!HBKTN!4 ##9\B#,\E"H[*I^/J 7$EZHN$!?34H,89J]A'I]A
M;^;IQZZ;6-O(#2JUZ)GQ+HU+LH&F1(/P]<HHH#:/M;818H7Q3U65K:61*6S!
M%053H>#455NIZ]'8-NL5@#$U(Y!J'8&TM1X05-SG/Y*!@_)3;(''4KE:L<E.
ME)F$D1>P*&]D"/I\B+820I/J6GDJ8?2QM#'-5$>_*MJ WRSZMGC3.GWY5)*;
MR1UEMA!6+[06B"P5W%*>*L9%$.D O_4#MG!H !IY9JI:'X0SUOLX]JOQ/M72
MS,"B8H.J"7J8R(R;81EX%PI'^6M)//U=([7=(Z; 1/ZULV_[/S5JWQ3V4,'U
MF0&NNZQN#[@-].AXYD</0OUY[U)PWKYJG-J3&)T(M&9/W!:5JDS2JH#B<"U>
M9[N]*$D4]?/RZ[ERXA%7Q7C$)S[:)6=EX5D-&*,1:\A%$*;O36B1!P-R=%=7
M=97'6B(*-I&==4") $RT,)5#6B\[XR1$G,"B4T/GS)+4XY9LEX\IL$-"Q:O'
M,AO%?AS&0S.P<P(DTP_D3')JE1TZ-A<^6U&G9G#U^TF.A6L62) ;:(I4KD_Z
M*H0%O,.]#1$D'J3P]_9-NS(8]%Y%2@>)E'\Y$YS5[?5/3,4XS8H4MQC0I-_K
M6!*U%;C#N=38,/>'*C2/=6\.D":]&YZ&6M937A*#(('&4^>E,#4A6<@P&)MZ
MO('>RJ*PTF(&7^4-!5HK[E=/K/51_3&Q!1)7;(G;7%NPM0"!R.@"(&C4.'0%
M2>2).TP3U-@YHY 6=8"U!#");0E4F@#T[@=F96+^VJH;9@KXCKII'%1^:?:#
M\Q24L2#'9D.U16<IC$7&GK*G*MR0*+R9,L.%PK+%9[N_7^!VWRJ;?WA?,&IV
MITJD3:17I',:AF+@G8!D$?]&]P6"T.EQH7355:EYEGVOE]K:G?JW5B."%0FU
M8HN%VA]WC^?_^/7O]6[]>UU@9I.65=JJ&H2,!.>=:K02SK04#!XS"A6&E TB
MF/--]18VD:NUT\[/4W(SG5MP4RQQX-1%,#:391OZV33ZJ;=VIP2FL+;-3U45
M).2@!@Y2D@ZZ6MP'>K;N?[WCV5SNO.0GF*=JVH/:?5@TI^>IA,;'7N3Y/_4(
MG1S-($23J*JD7"?7I?YV?;?0]<6@KT)$J*_!R>C>?+>=^6:E% &)LQ&-Z99<
M;H;_1 / ,@Y0B@R!FA\U1Z[8J"X\.B&D4<Q:,_(%=Y33FSE61J\P3@-7QN^N
M0:_\/#$FS) :R%5L,(XX\-=HE35@O!4;'L=-K>]FDL&S9E)+C04@QU 49=ZO
M.V:B$:ES&XFT0_3Z<0++F<0,RNP.TE.QZ,)0/!/#MF!4Q3BVZ3YVUH]Y#1_S
M%$I /G[RTQ#L&[YX#&R%$%)YPKN5I?!IG\+>.GSIEO$R_!3C<<!V.S ;\-1(
M]DUVKVS;*/,FDAH/'6%">//#N,?GQ^%TMK%D?Q11M!P34_ Z-JJK \#DOCKU
M/TYUM559E$7C4ALTF&!/Q(L//JECX,DS. +/CXMT7WUM$16)ZDX1Z%5&:;W=
M1&*,69^_6)VPF\K%Y0:Q/:2I6XSH[XS:&LG09^@<((QQD(]K# @[MI34MU?8
M/VJ]MJ]*DEK$VD.,Y:(0:!3ANC//\QA+BT9I0!/$!)/,<<)I(:7/=<N#4%*U
MJ<65[LEA$!&\E_I@ %(89#-EYHE_54EDJFHLW4?B(ISF%LT&VE]O;+L-)&EE
M'U5G]P<:K/DV2&VJ8-')F*\9]*2SO=V@GC2H)PWJR1I%SAO4DP;>HD$]:<AB
M?<CBK:*>//-,E/_,P\=6J:VJ0DW'):P=:ZLT5,JD/Q)8X@WW2^%4R#9VPY$8
M(N/2C]:24U4PG5-\S4>LKCX<F/@N\A)X.ACU4F!^-%V\OT3H>S#(<]7ZV8M-
ML&E#.;$X/N@'NB$8-<7 <*2IH?+W@8I'XR4)=FZ&*6=A&2D>-H@GVZL),@J?
M4LUV$0K-P82+R7WQ9]9@GC!G$1C-Q*^="J ML'Q_S+M>)>$*C^E)D.BU+*?<
MHKK9>FHMY6:3V&MH9".#/Z]V[JF=(_^0G3(6/VASL9.#!AR,<5>56;A<^V<I
MRU(T$T;2'P:%V;W+)4_BWI_*]]&D0&ATK'6YFXW?S*$ T^^#O]$+(LPZI*E1
M,$DYXX)FL(>7)H)3?68RC]-<)-2<FBEU?!U^3#TPOGY@LE4,U2A>.X@!(^[8
M'U*9J26C"@<_P,-36'6H1X&XTE&MN- 'T<P2>$8V?;8$CJY#7+C&=I6+KHKK
M-N3V&LCM&?4K2K269X:5PT\&U*;!13HM+G.=&I@ZRF=;PG]I[?SL 89(/G)>
M^<H"##CI+B-D079,*WWY6HL=BO-7>Y1@H=D\1":V)"L;@<H=X8S4 17EJ&$-
M!(*H9PIR/9A"(?BMV[W2'JQMR)UJ3YZRV*EJDL=.5/OJ]GZ-/GUIQEJMLMW9
M?M@#574.3DE#ZA0\\* -@SO0V=<=U@6T3U=':SP,HD/GK@VMO3E:>TY/UKLR
MK>\*:ZXHS&F:^E@*+(WT52L\BLB6]5^\H8QD0CTZ<11:M4Q-(N!4JCX<*GC5
M4"^V81-(FF]O7M25T?<5NBG,$1ZJ-VWQ.%D$#?#C/@<B\9%I/D%/C.Y1 %@@
MA?"O7-"O\>'WRW2Z7)LB,[I-SY=UL&0,X@,<3A8GC)YB[N;NAO$.970;)'&$
M=V2L K5)8 N%.2L[[(R $\?)0G%$6D^](/T;.X[Z@@;UF774A2.P"VS@QSD^
MYG4G9!X_6;-6(\E.C ).#A).#W #<XV6D4:94+91:?H[Z!*D"S!M1M,)EF@S
MJ,\D3_HCD>H8/&+Z*(V&I<_,_%[%^MM>$?O5*;ZMO)[>5VE)7 ?C*=.H6\/^
MQ;YYX<1<<C#IV#+#4(@!H>:<!T=!=%,0?1ZY3\8$UU :@ V5*(&GVQK"TAVU
MJ"TM0/[L2PGJF,(Q9JWP^!#G4@Y'-/"1!T#SI0S(0(BE%>/#U%[KVER1E9ZW
MT%2"9V+<-34 UD]LO;PUNHB5V%#1&Z>B/TRG;P:N1%;=8?UP1]03C,W?XSNP
M!A.*X/BQ@_-?<5>0APSA6P7_OP$UNIWE:W0%6,?_\4NZ=WZVO=W9.^GN[IWO
M=SX==[O[NYW33V=G.P?GYWN[5-LI%JFOG:EUG4^BG<Z3-Z)394?1$WP<HD!"
M[@-Y)+@PN/GYY?4?W>O3K<^7E_^\^/J;=_$5/OG2_79Q^=7K?CT%.^_DV^7U
MC??M]^XW[TOW?[SN^?G9R3?O_/NW[]=GWO79S??/WV[FQL+O.>;Z@N&/+&<N
M[^ZB9$9X96QQ.&U[=PDJ#1X;FA0CLV2B:)@!!O$,QCRW&_^+/7-4S!,GB NP
M%<8QI0M=(7"#?M'\"Q A+PZ+\ ^4&F.G*8]4P5!&L'A:AF5)H-#2<6@V9M_
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M"8>W4!6[A)X:BCN\3G7!)>#[S#;IJ8CCS=E)V_N?."=2$/XMW!5H<!3?P>/
MR6(L0EH:25<U-AVC^F',N)^DL7X0C6@#0XG,IU#&*Z2$2[ 4] .?^.,JZ;FS
MW3E8\':__,,[1WSPSO;6/T&3IW@&&B)"(?1B@QGH!!0?#B MC7<JZPJ<.DD
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M,:CAJ&R:M0QPF'FJ]%4,ZBY&5C(.<.>EQ=F95G)(T<WF(OU6"G"7(T+"5BV
M&6<(IU2H14='U8\W^WP^A!8;PKH$B($V1[1@*HXV$*#D.9@T0L:S]W/30WN>
M\4YO._YTQ(M/=JVN*?M/=M;;.>FD0^FD; RH7L4^QOZ"IS.2RJ_ UQ!3<S"
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M^7 E30,RH=-E0J[I"ER![,F3(O_)[RNR4I]&CT5DQ^>FI,CU-.>>F9G32/$
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M;8.W.7E97PF]7$2]"LB?L1-@24"*NI558=-)-9K:W@-)4D.*I>DU_L,')P2
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M0WTINYICFO8/<LF2)OB_,/\$:\8_2H-F#HB[>.B-K2ZKU, 3^(D\$O*^8B8
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M.%C4!#5M'$SPKQ<OX;N=Q,5_(O6K&!M_8;/YZSMY4?&W_?TIOU7_U-RM_NU
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M/(&GU3R9[1.8KW VJ]'L&0VX5 E^5S$MGRT/ 2<J7(]2!SO# L:LP)C"AG*
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MFY 7V[#^!F^+Y_\.CZX1K2;0?-OHVN94OK?9+?]=H/<?4$L#!!0    ( -:
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MS(EROFV,![8 LKB!=<U9$*W80A!0*B#?(R*:]R'KL@"X&4BP!_5L'72Q*B"
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MR&E";)C;/IRAK^[,_F6>IA2D6\C[C*/H(@?R"WJYTL\6(I$YUQ8CS3J>AR3
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M#L3<I'A^G;;%J)J&@Z=T6ND0HD#S!<$P"IYS 9EY5'HR"B^U%"%,_DA;AS[
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M.3"E*'F,T8&E(95*;B(EI;1QSS:WW[M =8#FR"[_9KOBN/SLD3U5,CGG;7+
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MN+W.&":NS_/KSVB>%Q?IO5NG\\7C2=X]LG9,-Y51S#JM<<F1\AQ3N4INK2%
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MK^XYNN<ZI6OW93,/Y_G=<H:3<UUF9Q<I-.2\:7=5CL18XSD8%U1YGEZ 2IX
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M!VITM--Y8JG5*&BBT&A%@T1B%LT6"&3K5P8>IF)'G_1JA&1?2MNF3%HV7?J
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M,VV ]W+),DH-8^0<&88;-KU-K[--Q;^+(I^N)ZOH-9JL*MS2<KAE0F.%0$V
M)HXB Z AO%R;)5%C5$5:D=ZW*>*MHE3W^/M35H11_'$3P%BF\X>(T<.'VOM;
M),IHSQ0UW$)C-1',>%0.&6!2/_N_L].<-@7;+CIUSZ$7GV9%OH@NJW3^/KO-
MI@]GDZ\#I-?'$R*J-D\<1\ #0ZB%4&'!?+PR^W$RT/#ZEREU=K;2MJ@[@JJF
MW/\^R^>;E^97*LQQ5:R7J]?IY_V+]?%&B2.&04M96((,4HQ;C$L#6\;KGVK+
MN+/"#FW+N%6 ^MJX'W>3=\5CB8(C-N*NQQ.A <:4,<"89MQ!"+'9KE4.UP\Z
MZOBVSY:MP1:PZ5GJ\?3O<;#+HXK\WC8)@]03R1D0TC@HD778EW-D#K!QVWS-
MQ+:; ZV!]#(),4J[;B0\:&6#?[6XF@?KH$@/WT;U]5-!]]""(4"8XPX+Y8T1
MI6]3ABUJA*96"S#G;>%14U0FFV<?B^S+04E]_5#BE<<0:\$E9(IK%?8I6PY,
M03C"5-9V!=4(CIIRNKC)%O>K?+:XS*>S]:U)[Y;K8+8=%-O!-@EB'OB@7P9[
MW7%B82"8VLY<J_KWC71F%;4KQ3;1J2G4_XZ1XK.#,GS^2,(4((%J7 KG$7-.
M$0*W@PHKQ?B,G'9%U@",WKS46XO:Q#L*CQQY??=P0K2%0 %OF;94 *\)W<)B
M+*F?)=[QK;YM'VTU1688>5<*>=C7))%&6.J@=P@PS TFGFQ-=.XL'K<ATT1D
M!Z7?&*&7R(51VC!CH$ K&_-_I8OE,EN$W>9M]OG_Y,6?OR]FG[)B.5O=_SW\
ML5[^EB_O9D4:-,'YJ@B#_"U+YZN;25IDH<WVIZ\6DY\/[NZMOR?Q!!LG$8/,
M4,R(MQ9O/8=>BOHJ0G?G58TEG8\'T+I6V#Q=/L:^/PQ3W69%3 EX=[>*MQ&;
MO+C+BS)CX.]I&.-Z^6YUDQ7;Z/C#ID![+PB:L1:."":]D)(#%EW5)2!8VS$>
MG+7)L,&0K$FMF'B:Y5>OYN'!?+9\&//%)B/C(&..MDN"\@T5TAQ*QRWW"CI<
MZG:*6US_"KGNCM7:)$+; -64[_LL7DOW^/J*I>0.MDF$%8%]1#$N,7-*"@M*
MPTH)P^M_X-T=I;4IUS;!Z5_SW.29'RM'L^OQ!&'*+8HKDO6>$,KU-H9#$>WZ
MO#UT')9G;6R&DOH)UL;S!@DG  @;0\2L4X(1ATVIHRO-N3\7N[..P(Y(OQ%"
M+XT'([<YAQ/_,&*_S%:K>3:M$"UUI$5"(4-660(-AAI[SRP!Y?PDU",\>6LJ
MJ&^3+5H!IK?3\F!&A-WN!,'O:9$ P#AF%M/XF83I*>SH5IMQ<-2V7"N";P>8
M@4+@+X(!$G/HY_.@LD[G]Z\65_&VEVSZ=GV$#Z=UE#C-D7/$"&P!9XP@R<LP
M!.6L'J-3J>N4[I8Q&XA!9I[.;I=VMKR=+9>G\V9G\X1BX2% 2H9=EX4)2V%(
M.7/:Y*:4GB*KNV!+&T@-M<H\+)$/,SAY9?F^<>(Q$YYQR+6TG$-I!=PJ9YB@
M$08>]+":-,:IIOO(9^ER]G$VGZWN+U?KZ?W#N]]=O4ZO\WRQRXE0H56B!#>(
M6. @U0!3C"'?;L>(H4JU38:,QFXDXO8!&NC+=\O5[#9L<^^N+L(O9A_G67R@
M^L>_NWU"J7%,6<@"EA@;[85!TN P=X:D!O5O7^_LDK[NO_]6H!K W["QFV):
MR4.E0/4Y#:*8?L@W!QX7:;&ZK^:&.-Y/ J*KE0&AM G;IN7:\#(<4D%,ZZL5
M[)QHTR%D-7>0;S6=?!Y$79Z %46L Q='>9$5DYA^=)WE5Q?I_:;ZUV6^OKY9
M?;R_"-M>Z.#J:L]VT^8K$D2=,58[*,,71"0PCK M**C!M=/\#'@T,)I/%.ND
MP-YIA>6VDQCZ$L]XM_+)E>7V-TH88\ +'91'ZQPFG@KB@@HI!)($.E?)G=?3
M3(]5EMO=( $:0J6YP4A#0:2VB/*'&0I&C1[-99QM""GO )'TKU%9#AN"L=/*
M6L<T4D&!XH\8"QXVQ@8WO'=[I-E4QA4KRYT&3V_'&JU6$1.:8ZP4% YSX*T&
MTLCM')45XS[;;"RYRN7$ZN'T,CDQRG/.\5!A%!2H65G.8VP%D]A8X"0-<[-*
ME',3R/6:&MJTLEQE.56J+'<:,L-XI+JO+ >=9X:%O55YP:T," 1,'E' #M6_
M8J+CRG(M:PR=(3:0)[.%8F$Z7@;CF$$2(<^0A8:A<I[$:CUN1:(+@9Y0-:P>
M>"^7+*/4,$;.D5:<E0^G]N59_>VQ6['V/9[ 3<%5!2@/^R1R@OM8DO5Q[Y5Z
MA)?YM@)]WCHT?7WCWVV0);F/Z X'VR4&.0(-E]A; 5B\]T]NOP-K;/VCK(Y+
M#[6L+K0)TC"$J+KH'VB5"$L,<\QCHBE4#"B$[7915 2,6T-H288'F=$&7B^7
M'Z-4"L9'BU'I =@Q2KR#L?:ZD-H("N'C8(7PN-=+"JKI :U 7T4/. V:WF*G
M6R@X*(E#VK* B:1<.:$!+UDOC%)]1C<-N>NW@$W/4F^IOIP7%EK(F"5$<X<5
M(HQNF:W)R(O,-Q-;Y4)S]4!ZF808Y<X^$AZTLIWK?+F>SZX.[N%?/9,(K01!
MP4Q%5@-G(>$8AV')F"P"->[50].TE%9EB/-VT*BK<Q79))MF7\*?M[/#!0=W
M/9H$_0%+K@576!IB*)#*/T[3&D;K)R@/4':PCLA: *6FY#[DGV;IOPY*[/DC
M";40>*F)T9020[31MM0HK#,-(GP'*"U81U(-P&@DH<UM\LO90Q'PVW2UBH&@
MFS2E"K([UCAQ09<GTD4TI"!*A,&#<B+ DA&66.]"JBW#5%/>_YW-_Y$N#G^2
M7SV3Z(WU930F0$GG1-#V2Q^OI1K6K];26=1]N])K@D9-(;GY[)_KV>%O[ZMG
M$FR 49 [(2$"E(;E')4VLR4>UC]6Z"S&O5TA-4&CKNJ8?HK&<'Y8=_SJH;"D
MBV P2^EYV&VI=@::4DNV#+CZ&6R=A9"WK#PV@:/_+)5ZE5A1H DE.):HQ81P
MYK7>SDI 4S_IN>-Z.&V'@C1%9AAY-ZN^&:Q?K8#RGBL;\_1$L(0?9^@(9F[<
M'IXF(JM:AK,>0B^1"Z-T[HR! JULSW_<9ZN;AUILE^O#5>UV/9HX8!E6#G*!
M"0L]"\:C9T-ARPQDJM=#MX;%["KCG;>*24W!/19:+6MD+K)T?G&3%K?I)%MO
M"F4N7[\V!^5Y0@\)LSI,A@)H,(BW+6OCRRAH)PVI[W'HORAI'3%W!U4;TO=%
MMLP6L_5A2^A0DX1P3[T#F"EOG#*<4%YJ+\Y87[\T6?^U1AO+MQDV;0CT(CU<
M.W;WPXFADF/J ]V49!@0Q?W30 4>H0.I.R'61:6N[WV3*?M8T_1^GBY>/Z3\
MYD4P$-+%5$TF <NG8MA'*Y?7[S#A**@>7B(!D8*84>2V9TR.<S'&^@]MTJ W
MY%J@RF46[XB=_YHM8HWK-^EB?95.8L!(<>3FH5/Z2+CQBEON@/%,*R,L4J2<
MEM6XOJ7=766'K@C1-EAM+!>S $W@:'6)?],B,4J8,%P@;?2(,^4T*?UXCH87
MC\]=UMT'WPB:%J3Y?^^G1_2P/4\G89R;\JEATC0H'$@3:;;$ ZS^LBW.3HKU
M86E!@A?%;+%<Y?&."UUDDS^S13&;7A^^"+UR^P0A%S7(L)] BPP()B$"6VV$
M-+C;3YZ=E-L$J@6YUQ+VCH%#*S@(8Y=60ALV$2G==N ,D_H'@4^KU=F(N#$\
MC>0:B?7FL@U-ZZ2>DF#G4P:X8=XJHQ1C##VJD1)+BQHD09^'4ZQ[S-KXW-]<
MNI_?_WSYS_7LX\?+?+%\M\B_]NF$"7Q(E^L_U[_EBW\</K]LWG$B [B*."$<
MX PY'(Q64@*@+&_@2#T/%UOO$/9_5E+_[A!HC#2<!A4( L(H$#1^%0_%C!A
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MC^'LKROD@7S_<,(  XY*X C3E",F(<4$$P\T1<:32C$0'<_L6(['UP\F<0>
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MB&K$H20E")ZB2B<T_5:K;Y<Y P$YS&ZUIUQ.MGIW]2']4GG?.MQ-PAV#5%E
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MF:\U;SSK6-P<F7(&8T6"!7R/H_#6J.%EM(MNS=N9/9.UYNV'^Z+DUKPI^L1
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MPBHLOETY!",*// 70:8),"R$/2U*I^RMKJ^HM%/(*V,(1"RH! 8Y:?8(&.O
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M+&>QMDM@9')$B^5D;Y,CT6^H+!0X(*@=8X)Z[S4 AQ/&0S/<$)[,4UP*(Y,
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M-2;LN1@<OA/I[7#23)8%,FE(<%*T9@CO?_^I66_C!JB;];KY8[FZ.5.%+4,
M83NE6!SN=8=0_N<'5,9R;H'QX6N$5,@ N":".\^"G*7LUOQRZN#][Z;>/5S_
MQV&5\!1H YDUCE&*G88&8Z8)A@P+:W,&2IX,T!\KK*,A^:,Q*3L(_[O5?3O;
M/_K9YRM@)?%!M^'&VW!6>6E1['1GS:X02%:7PT GY1@I/Z5. HBR!54_G>OY
MD.KG1U1,(T #8"BV)"#."@^\<M)+)"05#EQH#\F1PCQ'C6G NSSV0&P!DS8H
M2]Q0%HQNY@P7V@>5*>A+8G@.\*3A^%FXT0^:?*GDGS^'?38H?6\78<,]7Q_M
MN><KBCTF,JBM'EKJ33"49;Q8%CXL3UM2H)]AM)1^R/L>C\M,,N\N[4I1!YGB
MF ,2MCGH9*Q(;3DV1GL73M;"Y3Q>G1P'R SVVTX%FJYB]JOK\$N6'W<=:Y[:
MMVIU_4O37/^QO#V6!)[M]S^RPL-/7ZWVO^QYNWSFO/4SLWL<S-/%^!WRNLJ9
M\$$$?85 J+'F6)CP?PP]L9XCB#O=,TUM&I]96'=CN<N+*@DH8UJH&-%@- _'
M V,M(D1H4XKY/*VXCQK7$V!8M+G= ^8SAGC/-U6*H'BK*3$QD,-PQC#C6Q M
MQ#G-KX$F>EJN-#GAS*6AG5E%S_C7 6^K(!=$<N%-0((#:"C@NL5%&FK*#DJ:
MC 7]V)80V;^8U^)3I OAD@DW#]$^K!?7=9SE^0B8IX]6FA))L"**$6N5=)03
MT*Y(()O5!=G-#)U4;D^KJ(Z#*]].\W;=7-6;37NWKKZ[6S_+BD[C*TX]E,)1
MK0"'X:-CFJMV[52CX9ZIR6(8<E)E"@P+.:G<GU>W=]?+U<U3'T3_8^J'5U6*
M*L TDQXIX(00%#/1(L*@SWI&)6%56KMP8CP+")'IXGGI%%>"H>#&"J<44U@C
M:XBB^Y4+P$FGE*&I/2UY*@A2@CGS%#$K(8 6&D[I@\5'B@E02"O6X14$^^%5
MM#<E?XXZ\<9YQY644FBF"7(6M> !8W->9$R5C=69'R-RU/O!6,"^/7'FL"2$
M<08( Q9);023AK1X> P*3^6:1/(C4XB'(?H7TXKTDEPBP>8AUG0YZA9KIPU2
ME!'C.>?*$W'03 #(6MQ@FASUSA+MF:/>#[E+\*,%C<!AX*#3*%A=5@*'6[>!
MX%@.;R,S1X)'4BZ,A&I@^L_KY57<25<WZF9=[_3P&,2PRVX[69?K[+B*0LLU
M5&'BQ$ JM(J]E [VB/*#)3U'5D8224^!6P%JQR_K9C/02-H-K3R5%AL#@6:,
M2.NU$P>B!W.BP-92DQKDB?$J@"'JZNKN\UWL+W*M/C?K[?+?Q_('A[^L8AQ3
M@*5VD!'""?-$'\Y*:-1P9\Z\J8,3L"@-@@7P:E36(!<.2A"^&,$MMDPY;DR[
M6B6ZN4&+.9\FY4M_M":..ITB!-,WS7;5;.O9<PUS7 %XQB03X>S@%$J,B3&L
MM70QU+)3QNS+N )PS#GCO;):FJ#)6<!!J\,A3&7.[)'Q5P"=Q3K\"J ?7D5?
M <P74$D(=<X*HH,E1CT'C'C7@LB5NX" RG0\&1E,V0_*0@(%,H2T24Z#<8JD
MDP+I8$:"8"^TN C$<-G7 I.Q($%LVS!D_V)>BT^1UP273+B7'$NG&718$^TE
ME4HYR;SA[=J]M 5>'4PJX4&Q=/TPS,6?%'U^(-"4 ((EC/]2%@K:.L(0%"9G
MM:C2]*@$>&5F0J*V+I@!##&P"B"'D9+.B</.S) N/!YBG-@Z]W<9!M++)$21
M^D@A/$ARQ>CNKM;+,VU^OGNF0DQ"XL*,C*/*6T^AE^VT'!]Q23Q#EY_.$#=I
MT!@HI"'-F)AEP&#J!?=**\TL=&V0/K;6%'B7GU9,H^ HX/IDHD!781!B#D!M
M+#&4QW+(;0@_5HX/OX@KIQG34*UL.A@+H-/DX8>,2V$HX?$:*GQ/SK8W4-A)
M;,M6[":1_.@XQ"&(_L6T(C7&2R382PMT%=!*BC'R@',%#8[PMNN5'A>8HS>9
M1'L&NO9#;J".^\-9OEZL-A_K]<;>K9>KF[?U>ME<'U%].XVMI!">$ 6DL)PY
M*JRV;0D1S%W6DCTI8TKZWBM/!5@!1\^HD",<(+3(<*7#-T08%$&-/+#<PN'T
MF#=$;6C805*TB@LY>OI48/Q5>,?B)A@8'YIM+)G7/O!3Q!Q1S0,OO.%$$^J8
MUMH!"S7QP&D@9"?ROXR8(^ @0]IQ@"2A'A+A9-3 :/@1-4;EO"$='W/46:S#
M8X[ZX55TS-'[N]_WO^Z<Q^7)DY7"0CE%N7>$40"E=)):IX14L>/[B"87Y<0,
M=9;S4RJ-@BJ74O%HEN=K73]]MD+.ZMCV!T(NE84L?%KPOLPWU29\;I=:(WVH
MZ(Y38!K +H0E$%*ND#$<4&HM%HPJI2A%SGN(LYXL/6JA3\>!7G ,M"K?[C3%
MS3^;<+C\L;RNG^_;=/)>I<\K*BM%H"\$7HIPX%*J@H[-3-"5PU^T)3D/@JX%
ML8<+ILD"4JZ/VS2K37.[O-ZEV^S4IS-*P/,# GS"$0O"ZI2CCN-@1 ,JB72&
M:Q..S!<0]S)4%TB"V'Q\.+OG'QM281S.-XX)Q( SJY4PTK7G73C\T(4J"&/E
M>98>T\!WB0Q"&J$  8T-)RGP-&RA4 -KI5'.$I@UZJ*S\I"+'_W R27^-V'S
M#5-=W;S?GZ_G6_L^/Z**'2D,1P('Q8O"\"\(" %< HZ8EB.R9R?3*L:+ZFE+
MWR30Y!+]KXMMO5XN;M_55\WJ:AG>?[,#X2P#3@^L("%:,8L0TCXH9$C9 !WF
M ;Q@-0%>8/72Y$1(BE !=Q83Q?E8:SB' CG'/=4PEL[W1@9;#;!87'IX9_AR
MXGR&:J'3P5@ G2:.OH#:&*0)95A@*X RGHF])F8(DN)"%=E)*#$R/B,QU"^?
MFQY!H'S8$F#8^AW"RGK.+6%"0@.#6E"DBEPB\_H!>?F109H1YRBT8<6*DEA[
MVC&O'-%26*')906&C)-HS\B@?LCE8LJ8$G@&&$4D\2P@0ZVU"OL8UX^LH@(B
M<%F%BI)R8214V>YHML% B!:BOMLL5_5F\[[CE>ZI<16@@=;AP VVIJ?>,1U;
M(/A@L3B+P@^&TX)<O#J=$KAL)+F?XOE+O,?/5983R UR2"H.":522MUJ9#C\
M_$*5WT0"?$J+*:$KFR<"2(>(,R!H[90+H;B@&'*.G;>$X*QY\=TO>C.PH!\P
M@P.)5\W7Q39L='^O%[?;3_LIG+SC/3FF<DHI@$S8#)4*BS<:\:!U,R"IPLQJ
M5)Y^.!#V9AI$AJ:FAL-IM5TN;KO+\=20RE&#% ^V,W66.@45DQ8#IRVW6 <:
MEZ?:C1=C0D 2Q?7_5F\?@FV;C]U"N(>]J HG"U(HZ##"2DHXDC <,4Z%P\7&
M^\,"^\)-$M69!;TR0KS;?\_<L[N=QNL.\=D_/%MQ!;@5RN-@7G&*8FU0S0F)
MQ3TUE:S31C5U,'8[Z^Z1U]^-J !QBF""%3"2 XR#X8GW:U0L*!H9/\V38=8C
MI',TIGH,$F4'4$]B>\>=#GO.M!,2*>T<D:X%7 8])"-5!MK> P7>R]#NAU+A
M!A0"R&J F2$*.>BHT+1=BPN&8]G9Y(GD=-J2&H3094O] LWF/,(NU&S6\3=
M9J0#&F&(G<7\,&V1MW'W('NK*^R=S>9^B!1B-EM)-$92X%@^1UJA/5/MI!74
MLGBS>8 8$P*2:\]M=8QWS>VM;]9_+-;/9<N?>+K2CB) O(=&(T)M6*(\ $6#
MFEO>]YI..1^/1VXY=Q!N%6LV6 ,(Q891ZK'F%+8KL"AOT' _B0Z2PQ&9]H0A
MMR#5U;_NENOZ^DR=BR[#*F: UPY Y1V@0@D1M8_]2HFD!=Y>3R'P!-#D)L&N
MQ]BKU=6Z7FQJ6]__NP,+GAU7N1C]S "GTE( #(%8'PBOJ!]N,4_6/6<*&J3
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M>:D8PMIP$2M/4NRHQ9#+2ZW=.0DE1I8/3PSU3\!-*2W@7'!D8IZCU]8;ZUQ
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M32[13U-$3T*'%'$@?#.:>\N9=?*@\5 ^_-I^XMS7Q#I!2I"R$6)0$31(K0:
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M)B&*U#D+X4&2 "&W^GU=WYY.*W[T2*65).$,T@ 88[ 0!!PB[)ACJL".BPD
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MO>2YMQ+A-O-#!#6R0'_=!!TH1V$R0[9:O=W>M[%T?WX)ML;)=J/'1U7  H6
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MG #@(&VJM (M**<LHXK38+64!]-KAH=O FO+[NKX>VWCKQ-7F#T/"LU)A63
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MN21PT_$U'W+L3J6BQ90\O#3N"UXA#X0%AAA+G&"/U4DX< SUJPK]G^7A-1X
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M".F-EEA2@&V;!<-[A3/<(N RJ"P'3NHYRJ?5;'EU) _/;IM@(26".04--$!
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M61?BO\B!(]O1?R"Q8Z\M[<2G!*881UIS@Z(D"N>9A+B=&E,Z/0\CNA"OQ["
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MTN%"/"PY<*3'"=W.5O-EOP"A'YH& IPUT#G(,(]#\_%_=&NO0)/QDEV(PZ4
M*HG4?:A77V?K[E"@%VT"$=Y'Q9<[JKD0G,1Y;8<%(,P(([\0OTL.'*G>L;OY
MKU6W#;#;)'A*!'%<0HZ=EHVNJ[;&B:4J?1'$%^(QR4 C/09A=C];-E^NZMMC
MH0@_- W2*^?C! '3'L77WDJW]08(9S)>JPMQCA1 )?7M^ORY^G9$R7C1)C1%
MK1F$AF@FC356XF>7./8V(S?CA?A$<N!(9.E_ZT7]N=NTWFT2#$0."0Z5<MQ'
M4R-:DULSP\@,'PB^$!](!AJI%,WOO\1)S;[];_Q_-U,_M@Q6T:BL"J8,@LBH
MQEG3#A%2:-+O;> +\83D@Y+L)%[<'2%LMTE0+&ZI"D@%89R9=5I U Y*<YGN
MR,<7XN3(0"-9O5C.OCW]\]L1Y>)UPR"=(";J/$0@PZR7B!#=#I!IF_%B78@/
M(QN3G&B?M#HG?;H&J90GA(C&40HH)W$2[;X;[7R4?E$>7XBO8P"4$JG^N;J.
M,'12NMLD4!_5VJ@<,0"T,4@#Z+:#DDQEE/J\$)='!AK)@?R+NVHU^W?=;4B_
M;A8DBL:]L=0C*8'1@MFMOSHN]#+=F"87XO#(1"3UMMIJ=G-[Y.#S19M@M&08
M"2(MM#9*%(#,M,/RS*:;T.1"O!XY<"2R]/OWN/C.NQ>^%VV"!9YB2 &@FL69
M0:"?U27E,M1\<B&.CAPXTAWT5]5UU:WBOVP4E(* 2@2=B38CI@XV]QHW X,Y
M?EYR(3Z.+#PR#Z:S2J>=]I!@"&!1!%54A0"S!BBMM^L$,,2G$WTACI)!\4H]
MOZX6U:?5D3?V9:-@A,<8J;@I&V(T%U)BNK5I:$;<,KD0!TH6'HE$_?5SM;SN
M9&FG13#4"QGG18&AG'&$!-VN]DQFQ/^3"_&<I(.1O/4U51/^>63GVVD3/.5Q
M]%!XQ7!4F:)E0K9B$^4F8SV\$'=)#ARIGN/O7^LC'N/G%H%'G=9 [IN9:&&Q
MP<]#:BX:IS-T(7Z/=#"2/<1-4N+ZB(MXITV@B" "K"12<Q"->;I-VZ6@HSP]
MIH-<B(,C!XY,[?&4"JR=?8)LR@,#"9"*YGZ3: '8[;#C+]*C4^F%^#Y*PI/(
M:G/K(RJDJ]EOU>UZ?GOL&O:^Q@%1*I @A"*KJ//"4]^&@45S$V3DK+L0UT@1
M7#)?R[Y%=0^V#QSJJ,0VNJL%2G"%!=S:H$+@=%<DO1#?22EHTIE\S+T0/_[N
M-(.\LUL 3DIAE*> $\()T%9M_=^>@'25DUZ(KZ4P0L?I+51,:+:HUIO$_C_5
M]?7Z0W6_1P:ZF@>H$+"(&J48 28"Y+:"BR0R&:EHAJ+^U/(&[^?+ZEU3?C<
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M\1M"'+/L8$;S<35?;A<B@6\O)OFX$I%+0/VX*\S_:[%<?%V7U?JB.O@Z?X:
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MG9"Q_]LLB\(D)5&<4)]0,3$*N-_?.0^3)$UF&[FT:B,L:#2J)?T[?(ZDOVG
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MD>P[\+"444]X7LD1':G7Z9-"5X95SI5?KT#_1?:OS]5**)+L7ZOK=A=7ORI
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MW+PIH>9L3DG^!ECQHG0-9<5>OOVQ+WE]E6M=U0IO-NOR<KN1[\5>5*]H)&)
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M=RVTHI\6,\;2+$U@F'(0)0(28S#N-2",?*4G0(="()2F./)!VEP\($).3"+
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M5KUO#=*;3'\33:ZW<SFI7UWCU>);L<SE48*Y -Q,\W>W:G'1-.<$^J Y)!!
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MX00/$7Q'W%I1;55:1U1OI;O#K#$]91TU,4=)#(UY4JX+;:KY'U_NI,+V-SB
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M?^:UEKRK&_Q;R$?"R;C.G4:0&=EFNQ?W&S&NLD/_UV(AIM@'S]"@+&0PB2
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ML?UF(RUUD^=#DD\B"!B*.8X21@3B-(J'/L10J+76<]$(Q@@(Z4\4A00!P*F
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M@\V$AWIN4J1>N9&F/_Q]4^Z*]W=WVP9H\X/7#X^+<M,(U;"+!0A!4LQA!JD
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M)GB2 V1:&%RXD9E@Y"E4*[XM5=\^CK^.V#OPU4#C73&LOTH[('A?G<P42;N
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MTR!-3F>K0KI^O*Q#1LP8*M%PBQ< >99@P/*08R1MY608U:59S+4F)LTLC*U
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M8J=!Z%F)>]1!T_B" 7=P !Y\^1$,T-OKH@;PP3]:^+J'*:<)LIJ^SS^^>FG
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M,M?M\*2YR?0/Y T2XU>]/*.]PQB97FH'XJ]]]0US(655O:ONJW6Q/8IUCI6
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MR@Q&C>-3F:84&;V5>>K<&7UT(V!Z+73$70]M>JL2]/?%MMH\JZ.<Q5)P("5
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MUEZ Z=!%!WA.KX$,(?-Z*L5H/-J&27.AT.9]E9&H='UNQ9E2LP=8SGM_)@7
M"V'3'^?[<:/VW)',]?K78O-X6W2SPGO=9_:_E?L_ZNW?WCWLJ_NNMDM_J8,A
M*7).H)10YH3A%)/>>H:D<954GS8#J_DSJ%&+->K 1J=H'93)*_/7M7XJTNVD
M_Q^%;_.)82K>W>8)?_R;3!L6W)R914*P._VD$L2K.FR?-)]RN.Z5VV+=F:EO
M>;U]J+?%OBPV*PUFWU0M5(^;9?-?^XE/:)N8Y;F(D2"QR%.2RAY%CJ7Q8S0A
M; >>@IY#;D*X(^A#S;\.=G3$[2".0=KD^J0T=7/834[_N"UA/EU-W2)NTU:(
MEC&9P!S8.C.1A>1]^@DMJ'?U.+W7?()CC[MJ4^YV;S?[\LNVJXZY.R[B&,T%
M5X+E$.(LIY P)7J#3&)B.I<--!-XVNK112?PHA:?@R@.9?3Z3#0BF7:3SJQX
M-)]'1N33;<H8PJO)U'"9@#.S@"?6IA=\7X[4WGO4@"209J74'N!2GG&4,\(9
M!Y#K95$,CMMPD%*CC;!A%D9-^&A0#4_X,&?/(<TC"'%#DCM,. N?W-'38IK2
M84WC/(Y,!_IP*7W#D1%G?>D.9E&6<<:(2/)893'E$BK86Q.YV4GI4!L3:(Q3
MMH8SAXXZ$X"^X4HS29K&&6ILU,:2S)GJC:T7UQ3'B16CDALZ>-H^;*M=^4>U
M*IOXZ4/9O"ZN@ZGNG?'F)M'W!D,75V6$4X9XFD*)1")06_2QPT U/N.:&MXM
M!]:G)\!O&L3MVB Z8O[Y%'0W!JV78P%:X_I*=]J&L%.Z?\PVL"AN,6E;.%:O
M\-XF1H4I;)DZL\(.Q_CTB^Z OM5C]%F[T+FQ_.[V8[$N^RT D! BDT3_,Q6
MI#RAR?&H,L;*J RP^]=#'P,VPZR^C5I(CI>_'"@SBY'#LF5Y2F='5)# ^ <^
M+H3$[MS-(Q@>@+_VU8LL[XZ6:_U?O_REW)3;8DTW*[JZKS95\QQ94Q-'?FNJ
MW1PQ"*@$4"K-LAPW+Y.D*E?'A7_"K)X"\VLYL.)T8&^BDX<DBW5[GOH<=M3C
M=KV3ZK<]S"1KNJ:PD[-C*W1(A_$?YFZK#947E#!,D\Q#)0/Y]O*";$ &+;8T
M2_UG[[1U47XMU_5#L\;H3'>659X"D* 4(4RHC!53ZJCK.;&K\./#7OBMSA9B
M.W9/0/8#UU$WO3!MO DZ*LG6&Z(#^0VU/7J-M,M;I=XHGX<&>O7HQRU4SVR9
M;*>^V]^5VT/UD^>F((ECGBNJM;7)*,IA'O<E"3 3J5'0.,A 8$5K<44_'9#]
MZ6?1[P#LHC=-OKC#/IP[E=>W/$=AT4ZR#@1V]9%^ZE#]:53>S+<I1^'/;3?2
ME4>3/<=S;I_96AS,TO0[B,-=J#WV&ON,2U[??ZXV7:':AW*Y;^KD'=.%/I3K
MIK)JFS7TOMQ6]6J!LS2G$K$\X:AY8C1F,>^@-,]5(-M<3.\ 0A]R=2"CZB0+
M;GN &2T;G#?10XO4/LG0?V-<5_I9M(/=3'!,1#S!?!,=&^8T/;'#?4A3O(G>
MSZ9A[/-")VV@@1FCOAO*)IW4EK<KB:;!FF'ZN2R\BZ\DIP;FTW0/YA4X9V L
MLISFA*4B1Q!G0#$*CP DIW8/^'HT&WC>.QVL[31GM_/BDU^S#9B)J/4QE9T5
MQG%W8\P9O+ I$Z 9YK$W$\*Q.G@7'I!LV]9D.YK4RY3'[?;PZP42,$$IX3*F
M0F!"9 SCWGHB\MPY^7: S5&3<1M%U"N" [RHV.WJ9=4.VS^J_5VDEW5ZB=#7
MDRGZ>C+5YLW#MFY?I=F>[L>N3O9CMVTQDP'IO4-:S7BG>_0&L][M/FFKAN)3
M56WTMFNXYK<3)@2?)\\T0=@#_?-05^]>74H@]L::!UWM@^#FUV !LCS'5 J!
M *.Y4C3#?;DY216V2M#R9G2L'9;M#Q+K30<M61XLA.$(]JN$1^YGI83/V'.3
M0K<&F+T6.KIE+H9#>#.K?GEBNGAF^C?-3K&[XW?%]DO9K/Z7S0;4EW*1PX0R
MF2B59TF>Q;$$D!&>Q@S#'")H%&V&LAU8&Y^0-)%DV8_6=D'>O'WTN8PV]>9-
M@]VFXF. -KB^\SPU_7Z5LX,<=9C;+<P.]<0M85.2<]H6<:W4Z;]ES$IX6K-U
M9F\Y)._3;RL']:X>I_=Z"^]/%QB?:J%_#!92)(2@6.$,*:H RQEE_:P:JUQZ
M"O)=3(^^B;([[J)XB_6=*!\<\8=FV^_LU5X!.6Z#Z$"B 3R;^/\5+MU6 4,:
M9?9K@4'.F:\(AG/H]I[00;OIYR8U>[E?""DA5@FGDN:29T!F67]%3D( W2O*
MV!H:5R(/X/YYR#-"MD0Z2&%(#H<(7X<K^KU'-ND[0L]),E4T5VYGJ%_.KEQ\
M/F@0/^8WXKZ6VT*[W!Z_@44""<I3I1B2F1 I(A =S]\8D8G=G3>[;X?>C[U_
M6-??RS+2?_>^.X:T/)&R9LM,<T(292<S1R13G-._H.&"D+@2-@_M<$;_PYVO
M(2Q8[VK2W:[<O[U_**IML[G1Z=-"4I)!@*!B$"$4YSDF?:D:B9.8+3;EWG(/
MT]&2T; @AV'1@S(>&2VFJ#J",E0.;RQ:[D.&I'!X ',3'>A\ MB'-".SZKBG
M. *['O80'5BVWB]\G0F3_<&!',YL/W"H-^?V_[RP9)L\*K]5^VY.H;DBB6I>
MZ\XHS1(:9_@IZLP9=$D2M?A\\"/Z:C\D"]2&*+-0,#!'=II]S.IL>9HP<_.)
M#8,,30?JYA$7#G'@3,:E,Q=#]K86.52QBF-*@,I5PG(*87_-2\HT1HM]O2_6
M[GM:5PU8R<81B_&X^-3\E9=I/78S:[A]&,O]%V,NYS%&AKE@L-]BR8?C'<7V
MC;]=]3+]^9->SNV*Y;'"^4(D !..DA0QF:,8<O8T: 6&QJ\?!800>(H^P6,S
M4X?F_?IR;":4.\[XS^YQG.!^><'MM'DN!PBC-L^@:XE3-)/;<N_37;6+RG5Y
M2+$O'YKT^\U>_^B;'FE-R:[#4?2JVI;+_?K[\7[OOH[*VUO]L_84-?K<M_KR
MB83HC[MJ>==]X*[X6D:?RW+3IFIM=OH3J\.TUUP).%P3_G/T\?'X%ZK-<OVX
M*J-B];7:U=OO-]&Z_%*L;Z)BN:P?-_MV=?JU6#]V/:PYR:W;"_V[ZKY:%_K?
MY?9KM2QW?_9]>=*P=<\L84?H+M.O;,=P\O(5RC"<!KA$F3 4IT#'"SG#DK.D
M^5\/0/\8++Z6V\]U@&N4UPS;B,\I1F/M,;](^?_%I3Y3ON<1)H=PS/U2GQUW
MU@<3_4GI9G5&-A9,L5@I1!."5 [C&#*0'0'HQ:_)@C2 V<#+U%=3+MJI=EEN
M]T6U.5SA.P!_\ZSVA[\-XJLLF>P5^Z-Z^LDUE&/G=I!]<^>T,]04:=M^+>ER
MJ:/5YEG&E6BBU>9R:1.@$Y7S6":*)C'/*>94K[-[! H!HV(\(>R&7MNV^TC%
M:E5U%797)^#^S__""0#_TOVK:$]RGFTY#<B=&MH<9GO94[7$@(/)5U)*3Q!'
MIY GW.F[S*7I!J"G%IE'P!/$LTO;A5[9,PEYWMX_'!;ZQP<0CZEAB0 )H3S7
M]DB*A5X&<7(TEA&CQ/N!)@(KY7-DW2:#9KOI5TT!@DC_1?W3S>JP.:%_M:O7
MU:H=M#O]E]J_NVONFE6'@H'%+KJMU^OZ#],<U*%-<'W#<"3V[=3Q!?%M?KU!
MUJE7ZLPW\T:BT&VSSI%*DXC[O-]GHFL/1$T?2?MPHO;:>8:H^6Z199AFBLDT
MRQ- %(\)?JI]PX3Q@VLNWQXETJU>4?$A$F) F8OL^F5KL-Z&IFB(O/JERHNN
M]K%!=QAR/ NY::;^[>$/7CH8.7ZNO\KW9MO7N-9?T"NU]D&%W>',XF%;W1?;
M2G^A/_%H#TCT@NY1FS_][.[[3D<AW5\Z%$O2@<EF56Q7U=\/R)O_UIRGZ$\4
MFUWS$QVO[/3RO0EBO!R'O-* QA.$>5//<6:P0']Q2K!EP7DS\_6]&MU%7L.4
M4)4ICB 3$.0QSPB0?74?)0$#@_8WO2(9)3/G,+A?5B\[V>SL=D&?#>Z?'T[?
M+SP9Z8XIR6$:\OI\-J\V'+(7<RQT<#;_H&W&85/F"&WFF&0^>=OY*&,1H@V=
MSR!LF+0YE@C20M//HB/Z>NWP(B##)C.TZ$?"9B5U8+C_?O(PWG&1F"4BE5 @
ME&:"Q9E2.->Q04I5CHFBZ%H&N#<[X>2YA]<.V0/ TR<"G3:&_%!K+K&C4^RF
MHAZH-I%)$S;.**%7(J<7.[_NU($ZG)EDK<IJ<;#UH?S2O@&XV?]6W)<+FG"!
M8Y9PQ)*<8B82P ]F2$H9-+K=[?SQP%M,W2!Y A4UJ,R$R)VPRYH^"E=V&FY)
MTX7#S%VY_/.7^NO/VLGF'#-K?M$H3'9R?'F.@%<T93!7TVK(</BUISYCJQ%<
MB].V6+_=K,IO_U9^7V0LP3$AC+),"@2YS&+6V<FHS(SN'+A_?1R5Z%!%+:Q(
MX[+5"6O23(4B)%].2F%.E3>M>,'!1;%PY6LN:N&,_P>Y&,:$B5[PIEC69J^J
MW;)8_]^RV,K-JBF<M4 Q)&D>)Q!Q3F "<T1H9PJJA!@]>CG(0&#5Z'!%!V!1
M@TP'Y:O+U>4\TG==/$9ASDX_G$CSH"'GJ#@C(X.9FUY)AKM0>^Q)MO&'JM;E
MEFL+7^KM]P7#*I-)W/P_1H46JCA+>BM(0F87?=A]>YS8H\44]:!L P]+MDS#
MCG!$.04=AAQYBSB>N7\QWG C:GJ-&(3^AUAC" LFRM!OFGS2?V-!8B$$1)#F
M,F4PPQD4Z/AYD E32;#Z:& M..[O-6#,-<".E^N#/Q@ECAO+%]GP,-I/_3TS
MS)THF7Y\N\&N!W8%^Q%]>/WR&%,HK1?ZDT@P;8:D,9&XMR,QSFR'MMW7QQKC
M!U0.*P9'TLS'?3B^' 7 E"J/6O",@RNBX,;7?-3!$?\K,C&$"1N]>%J'*/V3
MW4+EB!,!$,1,*"ZPHBSK+=$TH;:*8?O]L33C=-7<(K-7#6OJS'4C)&N.RF%.
MF$?M>,'#%?5P96T^^N'LP2L*,HP->PTY*-;!%H4@P1R"E.8"D@Q@ HYZ!2@R
M>GIKF(61=:2;5P<IB16!MEH2BKMA:F)$FW<].>'"2%%<N)N;ICCY<%95W!DQ
MT16J#:U:8^OBRP)BE"H%8P$H4SC-%:;'W0\A,^.(Q.ZK@?7C""9JT)@KAB4U
MUU4B'"MVRF!(B <M>.;QF?'OQLKT8]X1=SVT/YB/[4_;8E5MOGS\?O^Y7B\4
M0@P3@6#*"<U!SB@X?A^#V'A_PNZK@<=V!R8ZH#$?VY;47!_;X5BQ&]N&A'@8
MV\\\/C.VW5B9?FP[XJZ']@?K?*?Z_K[>?-S7R[]];"[7[=X][MNK>-KT@L8"
M:C&)$R8X8E0RFHG.*,JY^5F#!U,C94*U$*,6XTUT0!F=P+1.C!K$KNEQY6C$
M.IU>.G/J+X/J C^7TZE\$#N]%OETYL=$*W\<F1;3>E^V%X+I9O6NJ9+ZOM[M
MM^6^.EQG9N6FO*WV.Z&7/NMZ][@M/Y7?]DQS\;=%KE(FH,J!_H>*::9$HD$1
M19*,T409I5,,!@&EB!E :<9B!1D5) 8BYIA+K/G!*G3QF YW>Y7B.>BH0QV]
MUW_!\@V(<$UR601GU1IV\GC:$"WH,\VQBYYP1[\WR*,6^LBO'+HR_(K CM9H
M\ZC&%=[->N3!8%'9I;GJ\Z7ZO"[;MWL.-8MOM6J)]D;C86=J03!6649C@D6.
M),2""813H#*ATEPR\UHO7JR%7W"VH [UMWK 45O3<-=7$C]4$;>H=>*'Y\MB
M.PW%=JKZA._PWE=?E;^!&!TP=OO8HY-K45IF=)(=B\T,)]NH4(L)':_,,_ZI
MG/YFIF=_ZE"=SBZB5TV%D?*7ZFNY>@GCMW*_2#,B1,)SR@CF&0(82=D;)0)P
MN[KR XW9#"O'6O++;5GLRJ:2XVV+]<VZ ?OC;#%N!'B9MPMQGB?"YQ'-^7*F
M#M(IS2.S][?5W_7@_H]ZNU[]4:W*IH2K_GMW>CDBRJ_ENGYHYH-?R_O/Y7:A
ME^H4,QT.II0F.=6\Y>"P2H-(K]B,7UZR,JIDGL<8,) )"65,B/Y=&F." 6=4
MT=#UJ ]8_VD7'=%&/=QVS78"./K] -FBTH-?^J_';9,Q;[DH_@<BW3R>FXQ\
MM[#.:R.8!'@V_)R)\X)0/'VX%\:M.G#7=-\?T'.=#C2739?]4M:WKTV%4L^%
MDD&1(*64CD9IFL3=N,QAGJ2NFP4&IHF0.(-Y)H 24#'.2%/T4#*4):@IJ11\
MZ[:'U^P=[ ]59%?Z)]5M5311X0\!8O/2V&[7O#/V>/]X*#-6W-?;?5=DTWT)
M[*.=[#<;1FZBP3L/&M!-]+S57O]3TS:$^\;$R WB;9=B>,.X[%M<9\MP$\,C
M[=-/<2&=N["]X9U#X[V.HMK^>[%^[ S1S>H7K=[5NMI7Y>Y7O?!_W):K=YL/
MY?)QVSYZOUG]5F^V_6]9L:MVGQJY7]",2B1RQ1&5/$UI!D&&4QXCA97@U*C0
MQ/BH D^2C2-1ZTG4P6X40X_F(_0VACT%'_W>(C=<2$S0CF9GH/-L0KM)-$3K
MA=D,\T7VI7VST1MT)EMLX_O]<C=N(N:MYQ#V_?C+?ZW*;;-R^_Y+LVZCWZK=
M BA)TSCG",0X)QE(XA3VQJ6(C9+Q/9L<3?UOHB.ZZ/<&FJN\#Z384KO'8]=5
MF"V(#:N\%ZDRD54_7,],,STY=4X0?7)FK7:G(<&/,$1]7U2;!:64 8E5S"5G
M/%&9I*C'0!@WNJ40QO)XD>_)"#U@<Q4_/XQ;:N#H9#O'J!8\A]5"$\I,)-$K
M]3-31K^^G1/(  Q:Z^3;S</C?M?*<M*?9I%4Y"S3LIQDD$".0:_,).-<6#TJ
M/,1.8 ULL42)Y=F@%P(M12XP=^[1W0'8361,95AE^Y$G$QT;P.[,5&N()^<T
M:C [#NO4$UU4V_)_'LO-\GL;,V8B3Q1+9)KF", 8,4IE9QDBK)3C(M797F"%
M.L$5'8$-7:&ZDVN]/!V%5SOU<J(T]-KT'$]F"]/!+,],Q7QX='Y)ZHFM(>O1
MH]TNPDLEEG&,TXPHD<6Q7ACC[&B9$J,K#3[MC;CO=F8X>EN(6E/MOOP,R;)[
MA.9(\&@KT!>L6:X[73F?F>+Y\,A@C3F,K4$[<,?3CRZ$E DE)$D9X102SG/.
M5=J;II*['4</,3B-YCT[K!RX#AU$]X!=MY!,>]$].Y+'VWM[09SMEILK[_/5
M/G>73#;8AO$U;!7;'O(>3CV0R EM\NDREC"*H!1'JP1PHX?D?-D:<?7:@O*X
M<K4@=,BJ-0R7[BM6(QI'7*T>^;%>J=HS.S/=&NJ-T0K5E25KM7JZX?]V7][3
M^_I1*V87)B8H18"C!,<923,,&#D12LZ,DNB]&IPD*W#HHG00PY8:-A:YSF>A
M5KR&U;,+7)F(F@^J9Z9L7EPZ)V_^^#*N -7<8:DW='_$\ J8_F1#BHP DJ9*
M<9$ DA"6] AP2J55T2>/=@,K7@<U*O;1N4'JM#;U2KV9!D[%NIT4>B \3.$F
M<_8NB&.(-IB'1@;Q[&5%IF#LF2JFW.VK^V)?OKLU@)"H#$&>,I$@G.?-+3'&
M>@@YI=!&,KT:#JR9/=;F/IA7T?3+OIEJ3D:\G6SZX#R(;MKP=T$X@S3#/)0S
MC&OU"-UX_!M[OU2;-CK6JWXN4 Y!G,9 J$12@:CH,4IB5DME&F0CGJ<<_&GO
M>IUXU*O"*M)QUH4;8=V66N-9U+HVP=4^BP:WW F875N[G^B,ULRSO0-X;!&3
MC8E16WX><\Q$O@>X#^C: B9E5%1=[S?UOMQ]JC^6ZW*Y+U>JVA2;956L7X-,
M/^_VVV*Y7V1YGN8QP'J:S$B:JX2SN(."2(R-"WL% Q!ZSNEQ1_LZVG7(FZI[
M!^A]5=9&>M9/Z/_9O%Y'N):Y/&O,IE$L)X=C>WRJHQYT=$3=3QCTQ83Q>P_=
MHAA8N)8QKZ<RBQ9RJZKB-G),6LJDM(HK<:_,LJ.TP_1E5L*[6(_8KRVFQDMV
M^ZG[9&/NJ2C,0E$EH4HHQ(#C+.%8B'XUB6 &C!+: D,(?8CPK$32U<%]W\?M
MQ3ZZ;<+\K^U>3M5>-^DN%(%#M-_^.NW_TT]MF;+]7;'YDX6 !VQ9@\EU'HUJ
M.;U>FTB/*R]Z>HIQ6BMK'NUC,<7.HYT<)]F [64TS3J3=VZB#=\:,YAJ1W"R
M'K6'V^V7]B_7-<O?%H3\G\=J_WT!<@CC/,D);I[YD0 *<K3&XI3:E7%WM6(S
M:IWJM_</*)8MGNCV<;.R?$W)F4"SG<0QF+.;EXYO3AXAW40'4./NZ)UAYL+>
MW% NY['+-MB+VF\/&Z@WHOR\7W @4IER*$3,$I%@D.;]31@$$! #U<;(QFA:
ML])HO"B-&76..N.=L^$JTT":6&,:"#8*8\7B3/7%SH=KZN+ B+.V?"AW^VW5
M[&@L5)*G28XE9T0D5-,BF\<M6XN,B]@JB7J(G<"; /VPV1VQ17?ENGF.)MIO
M'W>&Q:N]$.JH.X&X'*X^3\ FUJ G(#9*Y,#K3/7(Q9-KJN3,CJDVT:]%M6ZJ
MC*IZ^[%8EX<@ZPG 7[;U;O?7S;8LUM7?R]5?FGSL9F\58Y1+P!&3@L<0]75>
M& 38JB1H"/N!M:R%%#T>,45?-"@[ 0O"NIFP34VXG> =T;ZYK;=O=AIOMZ9[
M)H&'%GD"'?WE4HL$44,'6B^H9,A&FH=Z!O6P'J_+!U7;7_3O%@E)9)XD#"'.
MA%[B H[[]2Y3:2("JJV1_;'5=JU_'U1MS5@/HK;>"1]%;7^YU")S4-L&H#^U
MM6JD?TBUM?-PF-HZL&FJMJ+<5E^+??7U*=O[W>W3#]NCC@5F&<*90A1C0D62
M4FV]-PUB:"6O7@P&UM.W&[VB:(\1M:KNFG/V753?WK8G@S\=SN0-S\_]TFRF
MIZ,S;">@3T@.AZTWSPY4#\+9_H=QY=*$M0OZZ)7T>0BB7Y?J@)W4J^3UA[K?
M%TS21%'.,Y"@.)4\D81WYKF0L56]&6]&IY2^DQPDO_IGP;D7#0Q#M[,.'N&\
MIH7'_S@K/3RB<M=$^T;XA]!%![?LM-&5-U-]_*7>?/E4;N^;TYXC@ 7""<6
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M:775-R",P,%=5X2HO?W;[$<UMPPL-Y@"-H'A]M,\V+>3MQYLU**]B8YXHU/
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MJ]^=@T.#G[@4'7R*#D[=1.^?M?;30?V53=QYM+9Y_L3<6]TMT6*JUC=)RPC
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MCW@'+:$'\'1FJ3P&\],OB4?QLAZW/X\RQIO:>0N0,I G7"HJ ,V!D#AOBRH
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M]#)1%\)*3PS/(T3TY4P=I!?Z42Z+R/*7IPJZ-.<(8Y0I(?),T82+N!^.R/*
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M3QBC$Y .N?9>"+X^%XS-K=UD,%-:S6>#L>EUFPX&TVPR!QA0<682\$GB]+.
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M'T;5[^I!@^$;_S2+YY^3Y[R. V.%!"10  5IKI'2'!4-/9!"!>T/Q@S'.$*
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M/0DLG;'J:!$"L(L5Q['>,Q'BQ*?1N''AU,&I?@@J2!,#[@6=O2AH_>.H(A9
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M=SX/U,7J=1*$IT%@J91YYM1S,HR"K_=M%G71K.D=EQ[*3<#E&1SK@C"F+32
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M_TYT'N B>A<H*!'LTV"E5,H\[?M/B5&[;$\[1_?-S3E9[])<0\FHQ19I3;2
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MR):"<K6HUK]7V\-S(D);#'(#+2UL@7+$+>#[12(A-U$UZN\_O<BU*6CA?!'
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MR6>?#0!/=K]WIW?V=Q7T%QCV;;L6P>%DIM.T \3IP!08)$Y'X*@MR?V^PXF
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M$$M!^+P,U4CX^O!&!/<K)35U@*;9*8F6@OL)5]3NKCD_;$GN\+IUS0%%DD!
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M2<[BMT55_II/9J_+^?S=K'Z\Z5%\\QXSS8C5RD@'O%%8<41M'0GC*3(I]XC
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MD4!&$R*H]S+\S]K@6B"DPD@OK6Y2B\(J6P/UV'WH63XJJYW2?OI(!C2@C)G
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MYQ7W6D7XV$C4ST451O&/VX#%/)\^YJ[LCB_=WB)31GNFJ.$6&JN)8,:C>L@
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M$?Z8FK*Z+ZLZ)^$_\S#&Y?S=XK:H-M&QNRWD]EX0C#XM'!%,>B$E!RSN2]:
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MKSA0'$L.@/$&,B[7LQ$2PPNKB]J"5+\OCGH\G#V2([GL,I"..4TM8@9H%B/
M4 V0L RE*),!GIUTMAJU@&W/K&FI #-QT"-$K/=A1D$'0X9J$U H"2[,/$X3
M<^,"S(>!>N0NX9N':;G(J^T12M\_E D#.=)0"^V$!$@*KET]L."D7YCMVH*
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MMIK-7(W^M9P$B>Y@XHY6F8<( Q/KUW+G!& QRKB>)S0T)5'WO#S)=**U!_,
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M9D%*A$3S=,(>\WD&0=^VQ=(7]<(88[9288O'/Y^@LC\A<7_C#!JM#0BV.*+
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M):R#6I GK3A.,"*[1R7")%-*!H^YYLI!$,%1E,%16',C827>\(A.7?NV(YV
M>Z8IV2Z#>2\O^U3W'_)P=:3^U+KB\^DO2I;Z0&!&4 @9>,3:6B:QPC@*S8TL
MZG\RHL/0GHQ/[WA?PJ]YE@EZ@G/SP[B$'?=<6LFXE=Q1J;C+-; -C=%K5%3F
M9$3GFP-Y.*7P7N+@Z"A_=DP0Q8,@$HRM](X;PZR@',M @G*,LE"21#2B(\D>
M25.,Z85<H9/MSH&A28._IP-@ITC@E%F0F 6'O=)*Q++2RR,Z>!S.*2I%>/B"
M$#LVW;>G.Q] J=5]%\RO&:O3;@>>^>K$&0!E(X')2+F4TA#A 2S*" 5OP);<
MJA[A=E&O!R #ZV*PW,C[1('C39B?/YA\C)(Q%Q'WN=6(U? O#F-"B3*<\*D6
MFN]=^2^S&TM0/S<VW)U,LB\ W/UT$EX901$6UFB0V!N*M4:YHJ(BT7HY)$&&
M*#AXKJ8.];,\"\K!O.Y6EX0//)VLYR1H+;".'$PQ41!/$,*CRDEHV)38D%&O
M3@/;D'+HNS(DA8US';9$;J[M8<9A:BF(*BR-A.9^PKY=2M3K67.*U-:V2^YI
MD(XH>>^5=,.U#!G%,?4:?HI8FWL/YWU<'6 61]?*Q+W>+#X:*8F: +,XBDQZ
M%61LI$>>3J110W<D.">+[S2,7V,6'U;14JZ5A\C?:(J"=5OX5)QL:;!.E-XV
MB^\TC%]K%E]>,7$$%PKIB"7Q@5K22.FYGH@]ZD[9[;/X3D/V->;.\$ I5L8X
M[C"3V'KF>"-AP'QBS1N[4'7;W)G3D'V]61/:L>AH!(<=!6TX00Z+K1N@U,3"
MW;X8U FXK_N0VTL6K#)!.!:\MSAXMK7?B.&2./AUI?%U88I*X9W"T:5C3D1O
M)%6""C#&0CO;2$P5*?&+7E<Z8$>6J13AX>]]=]=?3QENG,!.!1J=)M[E[>X'
M235Q);F!(USE>HW6.L1Y>$9UUSI/!R2LEH99AZR2#"G&&DFC"!,[:NQ&Z:>T
MSCL-WZ&8]&8!6%>K]?O9NFK5]&SW@,2$L)X;);B7&!9V9MPC9*RHXLFHV5.B
MZ+H'9 >[N5?8*(]&09!!D4A'B=)(&XNV@00ONGD^JF*<O3*F&-?!DK=Z:-#I
MO08[[950G"O,O AJZ^LYSDN\Z1&&9[WPIT-\_YT&N$K@<U)":' 8/,\@D#3(
M/48?135Q1LC(7GWR@75QT10NPS"+3$N*I Q$6A_%%B/BQ:".]Q!+X7"Z;9'T
M=1KX(\G0X5[C0)C@S%$KG:2PSC_.*CG9?.-+\N5\_"^4SO.D3-VNK(G%]3^J
MZYO<!.,*GGFHL#WF'!]##.4.%A.AHJ*:6FND5,:P@"WV45\NQV?77L(J%^K-
M55#M]P><WU>W&[VN/L^_VN]O%J"\:DO:9H/4?M^W,7$L4VBXCT@.H@M#C?%2
M$ZIM5/DB[;TF'%-N(K%^=X1LL=\X"DT->9%P_7"/+4<Q1_;!=SV>F J>2>-\
M8(YHI2DRMI&,:UQR W5$'!PS979<3BS4TJ7X=W3??/> )'G4QN;B(XY@RGAT
M*C;2$8AYIL7!,@4?8<M9B [%ES\6JUSGO+IN=?-YQ]-)D+R)JZ-WV&#AM"*
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MT#EZX?!7W#DSL=/:GEAR?E;+:? /5BCF[L]5=7-_??)(O^?G3R9#E0F&RQ@
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MJ31"&&DQ9NZ"3<T+Q;'9%N?OC[-_MXJ?1/S)&6/ZV)  N4: 6P"@@QI+0!U
M^U6J:-^DY''7_[#E(\%6V6V1:?#;I;_OVI(_XA9V /)PD83'Z>W77\F>%T\&
MP8E$)%H_$F%"./?F:3U>X4&KP5Y<&[1G2PJH0Y/D<Q:-U8=L/]ES0<D38P+P
M@'&$G+$<.,\8P4Z6:X0 #U,9]M5NTWN@LF?^I*(\%),^YS]FR^V/_70KZ//R
MP2 UY%XSQ24 !ANH!3'E:J2W*97'ZD>U7W+F&NF2A.I0'/EEMEB]SXLJ0LO'
M;_/]8KNXW8GM2[;=+G<E^JNN4=09'RA@R&/('"0&>LH,)6Z_=BV8-@F,JA\
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M4JZ8"9%T'?P:>-14\,<-Y*[P'2RD\W!__UBO;[9T=_?+_$>6O<2F(<_:O3!
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M! .=%IP8*C2T3#,J\=.'8I/Z/XQPZTD5\UG6M$)U*-[L^Y'NVH^^;-=]MI#
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M&6'$.&:$(@18RP\&-$S*@Q]9&*,W'G2(;]M4Y<5FNUC-MV7+A8H QK%'@\!
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M+HK\/O!L1]R][YH9"&<%H@A3Y3ARS'"D D+6L+2'TNDM32-,3H_ UKZ@[RW
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M_?G$GY%-;Q+LTE?PA=6]*U:K^=U$.ZQKUD)9AIE(%J/G01#+C!%46&&UC@W
MRL8N9[1Q^Q.<IZPC)R&X(VC&9N[YJW._^[ICE#7<9#)$O&/86>4MELY(HP5O
M@!9>=@G </N-U7/6D-$(;T\M^3:0-!_K=;5*KK&^J=(TRVH; + D,UFM\T69
MSU_W$L<:+N-2"!>I(T1K8B*VRCR8%"E%EZ)8O/N&ZTGET2.2RX DO@2U6VR*
M'AUHL0-AEZO&NQV7T:^.G0F()7TD($<>%;C,X%EC"X1"G1K XA]CQW6LLAI#
M;FWN/=)A4J#O ]3A\6DOD\LT\88Y:8611'.(2[U$C=0,,UWR;3S"NO/>'\2.
M48I'R"S<>I'J6I^F3+.GRWP]6)SMK$FCF%>F&-7,,D==)#IJSH-MF".(05WJ
M@O"9[S^?H@#'D)F_X(\'2\YWF4\F)4,F!BF8#XX&BK0@#=PBTBYGG?"^^]=G
MHS%C$MT8HKS63O;1_V_A3O5ML:D03Z^VVWH^HH_A,RPB8"XB(A()*Z76N-F[
M$EK'+J5[N/V6^;-<Z*0R_A&+:PR*LG^ND@P#3FTPM;:,*ZV#MY[[\& 8*._2
M613OONM]=KS<'>)>C[7]E2\6=X6O9W>^S1,7.0H6<P^9%2+6$62- ]6FQLLA
MV^#<&YH'EL#TK\ FN[I:E=4:G/:F'T5=;>W5UOHFF>6(& $<C"AP@:+E#"N(
M!"SGQ%+9*<LYK22G-2>>MU@[%MB]ZOK /:X.K^(X2*0@J+4DP6RQI>"SC541
M0ET10ZM-E%898-.DH)YM37GAX[I*+6/JV<.TP^=/\+MB$W6\VG#EB*-EU$1I
MD S*1R"CB8K )\8"]3FU6(H?QPZT)DX]-JFT,!B;+]*?#_FR^.V7_P%02P$"
M% ,4    " #6@&E+FO2M^LOK!0"T[V  %               @ $     <&9E
M+3$P,#$R,#$W>#$P<2YH=&U02P$"% ,4    " #6@&E+*:H]V\X'  "%(P
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M+FAT;5!+ 0(4 Q0    ( -: :4MQZ'K$W0<  *(E   >              "
M 3-"!@!P9F4M,3 P,3(P,3=X,3!Q97AH:6)I=#,Q,2YH=&U02P$"% ,4
M" #6@&E+\LH9+>L'  #1)0  '@              @ %,2@8 <&9E+3$P,#$R
M,#$W>#$P<65X:&EB:70S,3(N:'1M4$L! A0#%     @ UH!I2^@*2V,,!0
M,AD  !X              ( !<U(& '!F92TQ,# Q,C Q-W@Q,'%E>&AI8FET
M,S(Q+FAT;5!+ 0(4 Q0    ( -: :4NG@_PB.@4  -49   >
M  "  ;M7!@!P9F4M,3 P,3(P,3=X,3!Q97AH:6)I=#,R,BYH=&U02P$"% ,4
M    " #6@&E+[!W5W+HA  "8J0$ $               @ $Q708 <&9E+3(P
M,3<Q,# Q+GAS9%!+ 0(4 Q0    ( -: :4O\  3*V#@  "Z6 @ 4
M      "  1E_!@!P9F4M,C Q-S$P,#%?8V%L+GAM;%!+ 0(4 Q0    ( -:
M:4M.-Y2?6LD  /X("@ 4              "  2.X!@!P9F4M,C Q-S$P,#%?
M9&5F+GAM;%!+ 0(4 Q0    ( -: :4NS?]S'QW$! /G.$@ 4
M  "  :^!!P!P9F4M,C Q-S$P,#%?;&%B+GAM;%!+ 0(4 Q0    ( -: :4N<
MB04=[OD  ,:?#  4              "  :CS" !P9F4M,C Q-S$P,#%?<')E
:+GAM;%!+!08     #@ . .8#  #([0D    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
